--
-- PostgreSQL database dump
--

-- Dumped from database version 13.5
-- Dumped by pg_dump version 13.1

SET statement_timeout = 0;
SET lock_timeout = 0;
SET idle_in_transaction_session_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SELECT pg_catalog.set_config('search_path', '', false);
SET check_function_bodies = false;
SET xmloption = content;
SET client_min_messages = warning;
SET row_security = off;

SET default_tablespace = '';

SET default_table_access_method = heap;

--
-- Name: area_na_link; Type: TABLE; Schema: public; Owner: borisbastian
--

CREATE TABLE public.area_na_link (
    id integer NOT NULL,
    input_vol double precision,
    input_amount double precision,
    area_id integer,
    nucacid_id integer,
    date timestamp with time zone,
    area_name text,
    nuc_name text
);


ALTER TABLE public.area_na_link OWNER TO borisbastian;

--
-- Name: area_na_link_id_seq; Type: SEQUENCE; Schema: public; Owner: borisbastian
--

CREATE SEQUENCE public.area_na_link_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.area_na_link_id_seq OWNER TO borisbastian;

--
-- Name: area_na_link_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: borisbastian
--

ALTER SEQUENCE public.area_na_link_id_seq OWNED BY public.area_na_link.id;


--
-- Name: areas; Type: TABLE; Schema: public; Owner: borisbastian
--

CREATE TABLE public.areas (
    ar_id integer NOT NULL,
    name character varying,
    area_type character varying,
    completion_date timestamp with time zone,
    image character varying,
    notes text,
    block integer,
    _blockname text
);


ALTER TABLE public.areas OWNER TO borisbastian;

--
-- Name: block_area_link; Type: TABLE; Schema: public; Owner: borisbastian
--

CREATE TABLE public.block_area_link (
    id integer NOT NULL,
    block integer,
    area integer
);


ALTER TABLE public.block_area_link OWNER TO borisbastian;

--
-- Name: block_area_link_id_seq; Type: SEQUENCE; Schema: public; Owner: borisbastian
--

CREATE SEQUENCE public.block_area_link_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.block_area_link_id_seq OWNER TO borisbastian;

--
-- Name: block_area_link_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: borisbastian
--

ALTER SEQUENCE public.block_area_link_id_seq OWNED BY public.block_area_link.id;


--
-- Name: blocks; Type: TABLE; Schema: public; Owner: borisbastian
--

CREATE TABLE public.blocks (
    bl_id integer NOT NULL,
    name character varying NOT NULL,
    age double precision,
    ulceration boolean,
    thickness double precision,
    mitoses integer,
    p_stage character varying,
    prim character varying,
    subtype character varying,
    slides integer,
    slides_left integer,
    fixation character varying,
    storage character varying,
    scan_number character varying,
    icd10 text,
    diagnosis text,
    notes text,
    micro text,
    gross text,
    clinical text,
    date_added timestamp with time zone,
    old_body_site character varying,
    collection character varying,
    path_note text,
    ip_dx text,
    body_site_id bigint,
    patient integer,
    project_id integer,
    department character varying,
    path_number character varying,
    specimen character varying,
    patient_id character varying,
    project character varying,
    patient_ip_id character varying,
    import_source character varying
);


ALTER TABLE public.blocks OWNER TO borisbastian;

--
-- Name: na_sl_link; Type: TABLE; Schema: public; Owner: borisbastian
--

CREATE TABLE public.na_sl_link (
    id bigint NOT NULL,
    input_vol double precision,
    input_amount double precision,
    nucacid_id integer,
    sample_lib_id bigint,
    date timestamp with time zone
);


ALTER TABLE public.na_sl_link OWNER TO borisbastian;

--
-- Name: na_sl_link_id_seq; Type: SEQUENCE; Schema: public; Owner: borisbastian
--

CREATE SEQUENCE public.na_sl_link_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.na_sl_link_id_seq OWNER TO borisbastian;

--
-- Name: na_sl_link_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: borisbastian
--

ALTER SEQUENCE public.na_sl_link_id_seq OWNED BY public.na_sl_link.id;


--
-- Name: nuc_acids; Type: TABLE; Schema: public; Owner: borisbastian
--

CREATE TABLE public.nuc_acids (
    nu_id integer NOT NULL,
    name character varying NOT NULL,
    date timestamp with time zone,
    na_type character varying,
    conc double precision,
    vol_init double precision,
    vol_remain double precision,
    notes text,
    method_id bigint
);


ALTER TABLE public.nuc_acids OWNER TO borisbastian;

--
-- Name: nuc_acids_nu_id_seq; Type: SEQUENCE; Schema: public; Owner: borisbastian
--

CREATE SEQUENCE public.nuc_acids_nu_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.nuc_acids_nu_id_seq OWNER TO borisbastian;

--
-- Name: nuc_acids_nu_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: borisbastian
--

ALTER SEQUENCE public.nuc_acids_nu_id_seq OWNED BY public.nuc_acids.nu_id;


--
-- Name: patients; Type: TABLE; Schema: public; Owner: borisbastian
--

CREATE TABLE public.patients (
    pat_id character varying(12),
    sex character varying(10),
    dob integer,
    race character varying(50),
    source character varying(20),
    blocks_temp text,
    notes text,
    pa_id integer NOT NULL,
    date_added timestamp with time zone,
    pat_ip_id character varying(12)
);


ALTER TABLE public.patients OWNER TO borisbastian;

--
-- Name: patients_pa_id_seq; Type: SEQUENCE; Schema: public; Owner: borisbastian
--

CREATE SEQUENCE public.patients_pa_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.patients_pa_id_seq OWNER TO borisbastian;

--
-- Name: patients_pa_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: borisbastian
--

ALTER SEQUENCE public.patients_pa_id_seq OWNED BY public.patients.pa_id;


--
-- Name: sample_lib; Type: TABLE; Schema: public; Owner: borisbastian
--

CREATE TABLE public.sample_lib (
    id bigint NOT NULL,
    name character varying(50) NOT NULL,
    date timestamp with time zone,
    qubit double precision,
    shear_volume double precision,
    qpcr_conc double precision,
    pcr_cycles double precision,
    amount_in double precision,
    amount_final double precision,
    vol_init double precision,
    vol_remain double precision,
    notes text,
    barcode_id text,
    method_id bigint,
    na_name character varying(255)
);


ALTER TABLE public.sample_lib OWNER TO borisbastian;

--
-- Name: sample_lib_id_seq; Type: SEQUENCE; Schema: public; Owner: borisbastian
--

CREATE SEQUENCE public.sample_lib_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.sample_lib_id_seq OWNER TO borisbastian;

--
-- Name: sample_lib_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: borisbastian
--

ALTER SEQUENCE public.sample_lib_id_seq OWNED BY public.sample_lib.id;


--
-- Name: area_na_link id; Type: DEFAULT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.area_na_link ALTER COLUMN id SET DEFAULT nextval('public.area_na_link_id_seq'::regclass);


--
-- Name: block_area_link id; Type: DEFAULT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.block_area_link ALTER COLUMN id SET DEFAULT nextval('public.block_area_link_id_seq'::regclass);


--
-- Name: na_sl_link id; Type: DEFAULT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.na_sl_link ALTER COLUMN id SET DEFAULT nextval('public.na_sl_link_id_seq'::regclass);


--
-- Name: nuc_acids nu_id; Type: DEFAULT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.nuc_acids ALTER COLUMN nu_id SET DEFAULT nextval('public.nuc_acids_nu_id_seq'::regclass);


--
-- Name: patients pa_id; Type: DEFAULT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.patients ALTER COLUMN pa_id SET DEFAULT nextval('public.patients_pa_id_seq'::regclass);


--
-- Name: sample_lib id; Type: DEFAULT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.sample_lib ALTER COLUMN id SET DEFAULT nextval('public.sample_lib_id_seq'::regclass);


--
-- Data for Name: area_na_link; Type: TABLE DATA; Schema: public; Owner: borisbastian
--

COPY public.area_na_link (id, input_vol, input_amount, area_id, nucacid_id, date, area_name, nuc_name) FROM stdin;
90320	\N	\N	2857	\N	\N	2857 Unknown	\N
90442	\N	\N	3451	\N	\N	3451 Not Processed	\N
90324	\N	\N	2715	4501	\N	2715 Tumor	KAM10-T
90325	\N	\N	2750	4500	\N	2750 Normal	KAM10-N-B7
90330	\N	\N	1098	2569	\N	1098 Mel	MDD-186
90332	\N	\N	936	2449	\N	936 Mel	MDD-66
90333	\N	\N	937	2450	\N	937 Mel	MDD-67
90334	\N	\N	1099	2570	\N	1099 Mel	MDD-187
90336	\N	\N	938	2451	\N	938 Mel	MDD-68
90337	\N	\N	1100	2571	\N	1100 Mel	MDD-188
90338	\N	\N	1027	2498	\N	1027 Mel	MDD-115
90339	\N	\N	632	2384	\N	632 Mel	MDD-01
90340	\N	\N	1033	2504	\N	1033 Mel	MDD-121
90515	\N	\N	3452	\N	\N	3452 Not Processed	\N
90546	\N	\N	2140	\N	\N	2140 Not Processed	\N
90547	\N	\N	2142	\N	\N	2142 Not Processed	\N
90548	\N	\N	2143	\N	\N	2143 Not Processed	\N
90549	\N	\N	2144	\N	\N	2144 Not Processed	\N
90550	\N	\N	2145	\N	\N	2145 Not Processed	\N
90448	\N	\N	1696	2710	\N	1696 Normal	MMD-92
90450	\N	\N	1698	2710	\N	1698 Normal	MMD-92
90451	\N	\N	555	3260	\N	555 Nodular Mel	NM D-05
90452	\N	\N	945	2458	\N	945 Mel	MDD-75
90453	\N	\N	1065	2536	\N	1065 Mel	MDD-153
90454	\N	\N	946	2459	\N	946 Mel	MDD-76
90455	\N	\N	639	2391	\N	639 Mel	MDD-08
90456	\N	\N	1078	2549	\N	1078 Mel	MDD-166
90457	\N	\N	1077	2548	\N	1077 Mel	MDD-165
90594	\N	\N	3455	\N	\N	3455 Not Processed	\N
90641	\N	\N	3526	\N	\N	3526 Not Processed	\N
90642	\N	\N	2885	\N	\N	2885 Tumor	\N
90660	\N	\N	2139	\N	\N	2139 Not Processed	\N
90661	\N	\N	2792	\N	\N	2792 Tumor	\N
90678	\N	\N	2146	\N	\N	2146 Not Processed	\N
90574	\N	\N	1659	2659	\N	1659 Normal	MMD-39
90577	\N	\N	1758	2781	\N	1758 Normal	MMD-166
90578	\N	\N	644	2396	\N	644 Mel	MDD-13
90579	\N	\N	1043	2514	\N	1043 Mel	MDD-131
90580	\N	\N	1045	2516	\N	1045 Mel	MDD-133
90581	\N	\N	915	2428	\N	915 Mel	MDD-45
90582	\N	\N	2752	4537	\N	2752 MVP	JBU10-MVP
90583	\N	\N	2751	4536	\N	2751 Normal	JBU10-Norm
90584	\N	\N	3226	1831	\N	3226 Tumor	DPN_16_Tumor_NA
90585	\N	\N	629	2422	\N	629 Mel	MDD-39
90587	\N	\N	1042	2513	\N	1042 Mel	MDD-130
90591	\N	\N	975	2488	\N	975 Mel	MDD-105
90596	\N	\N	979	2492	\N	979 Mel	MDD-109
90712	\N	\N	3681	\N	\N	3681 Unknown	\N
90718	\N	\N	3804	\N	\N	3804 Normal	\N
90719	\N	\N	3805	\N	\N	3805 Tumor	\N
90733	\N	\N	2767	\N	\N	2767 Tumor	\N
90760	\N	\N	2138	\N	\N	2138 Not Processed	\N
90782	\N	\N	2147	\N	\N	2147 Not Processed	\N
90789	\N	\N	2134	\N	\N	2134 Not Processed	\N
90806	\N	\N	2148	\N	\N	2148 Not Processed	\N
90816	\N	\N	2886	\N	\N	2886 Tumor	\N
90697	\N	\N	556	3261	\N	556 Nodular Mel	NM D-06
90698	\N	\N	3087	1207	\N	3087 Tumor	CNS_44_Tumor_NA
90700	\N	\N	1683	2695	\N	1683 Normal	MMD-77
90702	\N	\N	1685	2695	\N	1685 Normal	MMD-77
90703	\N	\N	3245	1859	\N	3245 Tumor	G5 DP08-4205A Tumor_NA
90704	\N	\N	3244	1858	\N	3244 Normal	G5 DP08-4205A Normal_NA
90705	\N	\N	3081	1201	\N	3081 Tumor	CNS_38_Tumor_NA
90829	\N	\N	3682	\N	\N	3682 Not Processed	\N
90830	\N	\N	3683	\N	\N	3683 Not Processed	\N
90842	\N	\N	3684	\N	\N	3684 Not Processed	\N
90871	\N	\N	2864	\N	\N	2864 Tumor	\N
90942	\N	\N	2152	\N	\N	2152 Unknown	\N
90828	\N	\N	956	2469	\N	956 Mel	MDD-86
90833	\N	\N	1738	2874	\N	1738 Normal	MMD-259
90834	\N	\N	2769	1823	\N	2769 Normal	DPN_8_Normal_NA
90835	\N	\N	2770	1824	\N	2770 Tumor	DPN_8_Tumor_NA
90838	\N	\N	3082	1202	\N	3082 Tumor	CNS_39_Tumor_NA
90952	\N	\N	3685	\N	\N	3685 Not Processed	\N
90982	\N	\N	2163	\N	\N	2163 	\N
91034	\N	\N	2149	\N	\N	2149 Not Processed	\N
91035	\N	\N	3857	\N	\N	3857 Not Processed	\N
91052	\N	\N	3686	\N	\N	3686 Not Processed	\N
91059	\N	\N	2458	\N	\N	2458 Normal 2	\N
90943	\N	\N	2962	877	\N	2962 Tumor	BB09_CGH11_125_NA
90944	\N	\N	3396	3240	\N	3396 Tumor	N3_14_NA
90945	\N	\N	1320	1849	\N	1320 Tumor	Fusion-02
90946	\N	\N	2963	878	\N	2963 Tumor	BB09_CGH11_194_NA
91115	\N	\N	2164	\N	\N	2164 Unknown	\N
91123	\N	\N	3842	\N	\N	3842 Tumor	\N
91151	\N	\N	3687	\N	\N	3687 Not Processed	\N
91152	\N	\N	3696	\N	\N	3696 Not Processed	\N
91159	\N	\N	3697	\N	\N	3697 Not Processed	\N
91174	\N	\N	2165	\N	\N	2165 Unknown	\N
91070	\N	\N	2400	1	\N	2400 Melanocytic Nevus	D1_NA
91071	\N	\N	2401	2	\N	2401 Melanocytic Nevus	D2_NA
91227	\N	\N	2883	\N	\N	2883 Tumor	\N
91230	\N	\N	2677	\N	\N	2677 MIS	\N
91231	\N	\N	2676	\N	\N	2676 Invasive	\N
91232	\N	\N	2679	\N	\N	2679  (+) Lymph Node	\N
91236	\N	\N	2884	\N	\N	2884 Tumor	\N
91258	\N	\N	3540	\N	\N	3540 Waiting Process	\N
91260	\N	\N	3541	\N	\N	3541 Waiting Process	\N
91262	\N	\N	3698	\N	\N	3698 Not Processed	\N
91268	\N	\N	3542	\N	\N	3542 Waiting Process	\N
91298	\N	\N	2151	\N	\N	2151 Unknown	\N
91307	\N	\N	3786	\N	\N	3786 Not Processed	\N
91310	\N	\N	2681	\N	\N	2681 MIS	\N
91311	\N	\N	2680	\N	\N	2680 Invasive	\N
91319	\N	\N	3543	\N	\N	3543 Waiting Process	\N
91200	\N	\N	3061	1009	\N	3061 Tumor	CGH13-011_NA
91201	\N	\N	1140	1982	\N	1140 Tumor	KIT-07
91203	\N	\N	1139	1981	\N	1139 Tumor	KIT-06
91204	\N	\N	1138	1980	\N	1138 Tumor	KIT-05
91205	\N	\N	1137	1979	\N	1137 Tumor	KIT-04
91206	\N	\N	1136	1978	\N	1136 Tumor	KIT-03
91207	\N	\N	1135	1977	\N	1135 Tumor	KIT-02
91208	\N	\N	2934	90	\N	2934 Tumor	AF13_212_NA
91209	\N	\N	2853	4563	\N	2853 Tumor	NGS 1-7_NA
91332	\N	\N	3787	\N	\N	3787 Not Processed	\N
91335	\N	\N	2171	\N	\N	2171 Unknown	\N
91347	\N	\N	2168	\N	\N	2168 Unknown	\N
91348	\N	\N	2172	\N	\N	2172 Unknown	\N
91349	\N	\N	2176	\N	\N	2176 Unknown	\N
91353	\N	\N	2177	\N	\N	2177 Unknown	\N
91354	\N	\N	2173	\N	\N	2173 Unknown	\N
91363	\N	\N	2174	\N	\N	2174 Unknown	\N
91426	\N	\N	3544	\N	\N	3544 Waiting Process	\N
91427	\N	\N	3545	\N	\N	3545 Waiting Process	\N
91429	\N	\N	3546	\N	\N	3546 Waiting Process	\N
91430	\N	\N	3547	\N	\N	3547 Waiting Process	\N
91431	\N	\N	3548	\N	\N	3548 Waiting Process	\N
91433	\N	\N	3549	\N	\N	3549 Waiting Process	\N
91435	\N	\N	3550	\N	\N	3550 Waiting Process	\N
91436	\N	\N	3551	\N	\N	3551 Waiting Process	\N
91440	\N	\N	3552	\N	\N	3552 Waiting Process	\N
91323	\N	\N	2078	1232	\N	2078 Normal	D-NA-557
91324	\N	\N	2079	1233	\N	2079 Nevus	D-NA-558
91325	\N	\N	2080	1234	\N	2080 Mel	D-NA-559
91331	\N	\N	452	3917	\N	452 Spitz mel	SMPR2
91333	\N	\N	1351	1023	\N	1351 Tumor	CGH14-119
91334	\N	\N	1001	1026	\N	1001 Tumor	CGH14-147
91336	\N	\N	1352	1024	\N	1352 Tumor	CGH14-144
91337	\N	\N	2081	1259	\N	2081 Normal	D-NA-645
91338	\N	\N	2083	1261	\N	2083 Mel	D-NA-647
91339	\N	\N	2082	1260	\N	2082 Nevus	D-NA-646
91340	\N	\N	492	1025	\N	492 nevus or nevus like	CGH14-145
91444	\N	\N	3699	\N	\N	3699 Not Processed	\N
91451	\N	\N	3700	\N	\N	3700 Not Processed	\N
91475	\N	\N	3553	\N	\N	3553 Waiting Process	\N
91476	\N	\N	3554	\N	\N	3554 Waiting Process	\N
91487	\N	\N	3555	\N	\N	3555 Waiting Process	\N
91488	\N	\N	3556	\N	\N	3556 Waiting Process	\N
91528	\N	\N	3527	\N	\N	3527 Waiting Process	\N
91532	\N	\N	3528	\N	\N	3528 Waiting Process	\N
91533	\N	\N	3529	\N	\N	3529 Waiting Process	\N
91534	\N	\N	3530	\N	\N	3530 Waiting Process	\N
91535	\N	\N	3531	\N	\N	3531 Waiting Process	\N
91536	\N	\N	3532	\N	\N	3532 Waiting Process	\N
91537	\N	\N	3533	\N	\N	3533 Waiting Process	\N
91538	\N	\N	3534	\N	\N	3534 Waiting Process	\N
91539	\N	\N	3535	\N	\N	3535 Waiting Process	\N
91540	\N	\N	3536	\N	\N	3536 Waiting Process	\N
91543	\N	\N	3537	\N	\N	3537 Waiting Process	\N
91551	\N	\N	3538	\N	\N	3538 Waiting Process	\N
91552	\N	\N	3539	\N	\N	3539 Waiting Process	\N
91441	\N	\N	2166	4657	\N	2166 Normal	CGP-1556_NA
91442	\N	\N	2280	4658	\N	2280 Nevus	CGP-1557_NA
91443	\N	\N	2279	4659	\N	2279 Mel	CGP-1558_NA
91445	\N	\N	436	3882	\N	436 common+ sclerotic dermal component 	SM D-13
91447	\N	\N	1358	1034	\N	1358 Tumor	CGH15-064
91456	\N	\N	424	3870	\N	424 Blue + spitz	SM D-01
91457	\N	\N	2162	4663	\N	2162 Normal	CGP-1575_NA
91458	\N	\N	2283	4665	\N	2283 Mel	CGP-1577_NA
91459	\N	\N	2284	4664	\N	2284 Nevus	CGP-1576_NA
91460	\N	\N	666	2418	\N	666 Mel	MDD-35
91574	\N	\N	3557	\N	\N	3557 Waiting Process	\N
91581	\N	\N	3558	\N	\N	3558 Waiting Process	\N
91592	\N	\N	3559	\N	\N	3559 Waiting Process	\N
91593	\N	\N	3560	\N	\N	3560 Waiting Process	\N
91559	\N	\N	1378	1056	\N	1378 Tumor	CGH16-038
91560	\N	\N	1386	1064	\N	1386 Tumor	CGH16-097
91561	\N	\N	1376	1054	\N	1376 Tumor	CGH16-032
91562	\N	\N	1377	1055	\N	1377 Tumor	CGH16-035
91564	\N	\N	1613	437	\N	1613 Normal	AM2 D-360
91565	\N	\N	1998	3387	\N	1998 Intramucosal Nevus	OM D-64
91566	\N	\N	1379	1057	\N	1379 Tumor	CGH16-053
91567	\N	\N	1381	1059	\N	1381 Tumor	CGH16-062
91711	\N	\N	3561	\N	\N	3561 Waiting Process	\N
91712	\N	\N	3562	\N	\N	3562 Waiting Process	\N
91713	\N	\N	3563	\N	\N	3563 Waiting Process	\N
91723	\N	\N	3564	\N	\N	3564 Waiting Process	\N
91732	\N	\N	3565	\N	\N	3565 Waiting Process	\N
91733	\N	\N	3788	\N	\N	3788 Not Processed	\N
91735	\N	\N	3566	\N	\N	3566 Waiting Process	\N
91736	\N	\N	3567	\N	\N	3567 Waiting Process	\N
91742	\N	\N	3568	\N	\N	3568 Waiting Process	\N
91745	\N	\N	3569	\N	\N	3569 Waiting Process	\N
91746	\N	\N	3570	\N	\N	3570 Waiting Process	\N
91747	\N	\N	3571	\N	\N	3571 Waiting Process	\N
91748	\N	\N	3572	\N	\N	3572 Waiting Process	\N
91779	\N	\N	3701	\N	\N	3701 Not Processed	\N
91808	\N	\N	3826	\N	\N	3826 Not Processed	\N
91809	\N	\N	3827	\N	\N	3827 Not Processed	\N
91685	\N	\N	208	4048	\N	208 DN	TPP 2_17
91686	\N	\N	130	4140	\N	130 DN	TPP_3-21
91687	\N	\N	209	4049	\N	209 DN	TPP 2_18
91688	\N	\N	166	4006	\N	166 DN	TPP 1_2
91830	\N	\N	2671	\N	\N	2671 MIS	\N
91831	\N	\N	2670	\N	\N	2670 Invasive	\N
91843	\N	\N	3702	\N	\N	3702 Not Processed	\N
91845	\N	\N	3828	\N	\N	3828 Not Processed	\N
91867	\N	\N	3573	\N	\N	3573 Waiting Process	\N
91875	\N	\N	2135	\N	\N	2135 Not Processed	\N
91885	\N	\N	3789	\N	\N	3789 Not Processed	\N
91890	\N	\N	3574	\N	\N	3574 Waiting Process	\N
91891	\N	\N	3575	\N	\N	3575 Waiting Process	\N
91936	\N	\N	2178	\N	\N	2178 Normal	\N
91937	\N	\N	2179	\N	\N	2179 Normal	\N
91829	\N	\N	2672	4458	\N	2672 Normal	MucM D-009
91832	\N	\N	146	4156	\N	146 DN	TPP_3-37
91833	\N	\N	240	4080	\N	240 DN	TPP 2_49
91834	\N	\N	147	4157	\N	147 DN	TPP_3-38
91835	\N	\N	241	4081	\N	241 DN	TPP 2_50
91836	\N	\N	148	4158	\N	148 DN	TPP_3-39
91983	\N	\N	3829	\N	\N	3829 Not Processed	\N
91994	\N	\N	2137	\N	\N	2137 Nevus	\N
92035	\N	\N	2636	\N	\N	2636 Invasive	\N
92036	\N	\N	2637	\N	\N	2637 MIS	\N
91966	\N	\N	725	3218	\N	725 DN	MR-048
91967	\N	\N	3522	3218	\N	3522 DN	MR-048
91968	\N	\N	721	3214	\N	721 DN	MR-044
91969	\N	\N	3518	3214	\N	3518 DN	MR-044
91970	\N	\N	720	3213	\N	720 DN	MR-043
91971	\N	\N	3517	3213	\N	3517 DN	MR-043
91972	\N	\N	431	3877	\N	431 common + blue	SM D-08
92094	\N	\N	3576	\N	\N	3576 Waiting Process	\N
92095	\N	\N	3577	\N	\N	3577 Waiting Process	\N
92096	\N	\N	3578	\N	\N	3578 Waiting Process	\N
92097	\N	\N	3579	\N	\N	3579 Waiting Process	\N
92098	\N	\N	3580	\N	\N	3580 Waiting Process	\N
92099	\N	\N	3581	\N	\N	3581 Waiting Process	\N
92100	\N	\N	3582	\N	\N	3582 Waiting Process	\N
92104	\N	\N	3703	\N	\N	3703 Not Processed	\N
92107	\N	\N	3704	\N	\N	3704 Not Processed	\N
92108	\N	\N	3705	\N	\N	3705 Not Processed	\N
92109	\N	\N	3706	\N	\N	3706 Not Processed	\N
92110	\N	\N	3707	\N	\N	3707 Not Processed	\N
92111	\N	\N	3708	\N	\N	3708 Not Processed	\N
92112	\N	\N	3709	\N	\N	3709 Not Processed	\N
92129	\N	\N	3583	\N	\N	3583 Waiting Process	\N
92135	\N	\N	3710	\N	\N	3710 Not Processed	\N
92143	\N	\N	2643	\N	\N	2643 MIS	\N
92144	\N	\N	2642	\N	\N	2642 Invasive	\N
92181	\N	\N	2136	\N	\N	2136 	\N
92182	\N	\N	3680	\N	\N	3680 Unknown	\N
92086	\N	\N	3507	3203	\N	3507 DN	MR-033
92087	\N	\N	447	3893	\N	447 balloon cell nevus	SM D-24
92092	\N	\N	624	1099	\N	624 Nevus?	CGH18-012-D
92224	\N	\N	2648	\N	\N	2648 Invasive	\N
92225	\N	\N	2649	\N	\N	2649 MIS	\N
92227	\N	\N	2690	\N	\N	2690 Invasive	\N
92230	\N	\N	3584	\N	\N	3584 Waiting Process	\N
92231	\N	\N	3585	\N	\N	3585 Waiting Process	\N
92236	\N	\N	3586	\N	\N	3586 Waiting Process	\N
92237	\N	\N	3587	\N	\N	3587 Waiting Process	\N
92238	\N	\N	3588	\N	\N	3588 Waiting Process	\N
92239	\N	\N	3589	\N	\N	3589 Waiting Process	\N
92240	\N	\N	3590	\N	\N	3590 Waiting Process	\N
92242	\N	\N	3591	\N	\N	3591 Waiting Process	\N
92243	\N	\N	3592	\N	\N	3592 Waiting Process	\N
92244	\N	\N	3593	\N	\N	3593 Waiting Process	\N
92245	\N	\N	3594	\N	\N	3594 Waiting Process	\N
92250	\N	\N	3711	\N	\N	3711 Not Processed	\N
92251	\N	\N	3712	\N	\N	3712 Not Processed	\N
92261	\N	\N	3595	\N	\N	3595 Waiting Process	\N
92262	\N	\N	3596	\N	\N	3596 Waiting Process	\N
92264	\N	\N	3597	\N	\N	3597 Waiting Process	\N
92266	\N	\N	3830	\N	\N	3830 Single Cell Gene Expression	\N
92270	\N	\N	3598	\N	\N	3598 Waiting Process	\N
92273	\N	\N	3713	\N	\N	3713 Not Processed	\N
92275	\N	\N	3714	\N	\N	3714 Not Processed	\N
92276	\N	\N	3599	\N	\N	3599 Waiting Process	\N
92282	\N	\N	3600	\N	\N	3600 Waiting Process	\N
92283	\N	\N	3715	\N	\N	3715 Not Processed	\N
92284	\N	\N	3716	\N	\N	3716 Not Processed	\N
92288	\N	\N	2238	\N	\N	2238 Mel	\N
92290	\N	\N	2239	\N	\N	2239 Nevus	\N
92300	\N	\N	3717	\N	\N	3717 Not Processed	\N
92310	\N	\N	3718	\N	\N	3718 Not Processed	\N
92313	\N	\N	3601	\N	\N	3601 Waiting Process	\N
92317	\N	\N	3719	\N	\N	3719 Not Processed	\N
92324	\N	\N	3720	\N	\N	3720 Not Processed	\N
92335	\N	\N	3790	\N	\N	3790 Not Processed	\N
92216	\N	\N	1258	1393	\N	1258 DN	DN-061
92217	\N	\N	1259	1394	\N	1259 DN	DN-062
92218	\N	\N	1262	1397	\N	1262 DN	DN-065
92219	\N	\N	1260	1395	\N	1260 DN	DN-063
92220	\N	\N	1261	1396	\N	1261 DN	DN-064
92226	\N	\N	2650	598	\N	2650 Normal	AM2 D-550
92228	\N	\N	889	1494	\N	889 Blue Nevus	DNA-91
92345	\N	\N	3791	\N	\N	3791 Not Processed	\N
92436	\N	\N	3602	\N	\N	3602 Waiting Process	\N
92437	\N	\N	3448	\N	\N	3448 Waiting Process	\N
92438	\N	\N	3603	\N	\N	3603 Waiting Process	\N
92439	\N	\N	3604	\N	\N	3604 Waiting Process	\N
92440	\N	\N	3605	\N	\N	3605 Waiting Process	\N
92441	\N	\N	3606	\N	\N	3606 Waiting Process	\N
92442	\N	\N	3607	\N	\N	3607 Waiting Process	\N
92443	\N	\N	3608	\N	\N	3608 Waiting Process	\N
92444	\N	\N	3609	\N	\N	3609 Waiting Process	\N
92445	\N	\N	3610	\N	\N	3610 Waiting Process	\N
92448	\N	\N	3611	\N	\N	3611 Waiting Process	\N
92449	\N	\N	3612	\N	\N	3612 Waiting Process	\N
92452	\N	\N	3613	\N	\N	3613 Waiting Process	\N
92454	\N	\N	2661	\N	\N	2661 Invasive	\N
92455	\N	\N	2662	\N	\N	2662 MIS	\N
92456	\N	\N	3614	\N	\N	3614 Waiting Process	\N
92458	\N	\N	2668	\N	\N	2668 MIS	\N
92460	\N	\N	2667	\N	\N	2667 Invasive	\N
92462	\N	\N	3721	\N	\N	3721 Not Processed	\N
92463	\N	\N	3722	\N	\N	3722 Not Processed	\N
92464	\N	\N	3615	\N	\N	3615 Waiting Process	\N
92469	\N	\N	2674	\N	\N	2674 MIS	\N
92470	\N	\N	2673	\N	\N	2673 Invasive	\N
92594	\N	\N	2645	\N	\N	2645 Invasive	\N
92348	\N	\N	3412	3440	\N	3412 Unknown	OM-12D
92349	\N	\N	1420	1810	\N	1420 NEVUS	DNPD-05
92351	\N	\N	806	1106	\N	806 MELANOMA	CMD-01
92477	\N	\N	3723	\N	\N	3723 Not Processed	\N
92479	\N	\N	3616	\N	\N	3616 Waiting Process	\N
92489	\N	\N	3831	\N	\N	3831 Single Cell Gene Expression	\N
92503	\N	\N	2655	\N	\N	2655 Invasive	\N
92504	\N	\N	2656	\N	\N	2656 MIS	\N
92514	\N	\N	3617	\N	\N	3617 Waiting Process	\N
92515	\N	\N	3618	\N	\N	3618 Waiting Process	\N
92516	\N	\N	3619	\N	\N	3619 Waiting Process	\N
92521	\N	\N	3620	\N	\N	3620 Waiting Process	\N
92522	\N	\N	3621	\N	\N	3621 Waiting Process	\N
92523	\N	\N	3622	\N	\N	3622 Waiting Process	\N
92526	\N	\N	3724	\N	\N	3724 Not Processed	\N
92548	\N	\N	2658	\N	\N	2658 Invasive	\N
92549	\N	\N	2659	\N	\N	2659 MIS1	\N
92550	\N	\N	2693	\N	\N	2693 MIS2	\N
92576	\N	\N	2651	\N	\N	2651 Invasive	\N
92577	\N	\N	2652	\N	\N	2652 MIS1	\N
92578	\N	\N	2691	\N	\N	2691 Invasive	\N
92579	\N	\N	2653	\N	\N	2653 MIS2	\N
92580	\N	\N	2692	\N	\N	2692 Invasive	\N
92584	\N	\N	3725	\N	\N	3725 Not Processed	\N
92590	\N	\N	3623	\N	\N	3623 Waiting Process	\N
92591	\N	\N	3792	\N	\N	3792 Not Processed	\N
92592	\N	\N	3624	\N	\N	3624 Waiting Process	\N
92593	\N	\N	2646	\N	\N	2646 MIS	\N
92483	\N	\N	1611	492	\N	1611 Normal	AM2 D-430
92484	\N	\N	1999	3388	\N	1999 blue nevus with ovoid melanocytes	OM D-65
92488	\N	\N	2155	4606	\N	2155 Capture Area B1	VS-02_NA
92491	\N	\N	2603	4296	\N	2603 Normal	DMS-037N
92496	\N	\N	2203	1740	\N	2203 Normal	DNA-358
92505	\N	\N	2657	600	\N	2657 Normal	AM2 D-557
92507	\N	\N	2206	1743	\N	2206 Normal	DNA-363
92520	\N	\N	2210	1747	\N	2210 Normal	DNA-367
92529	\N	\N	2051	3338	\N	2051 Mel	NM D-096
92530	\N	\N	2053	3340	\N	2053 Mel	NM D-098
92596	\N	\N	3625	\N	\N	3625 Waiting Process	\N
92597	\N	\N	3626	\N	\N	3626 Waiting Process	\N
92601	\N	\N	3627	\N	\N	3627 Waiting Process	\N
92602	\N	\N	3628	\N	\N	3628 Waiting Process	\N
92603	\N	\N	3629	\N	\N	3629 Waiting Process	\N
92604	\N	\N	3630	\N	\N	3630 Waiting Process	\N
92605	\N	\N	3631	\N	\N	3631 Waiting Process	\N
92606	\N	\N	3632	\N	\N	3632 Waiting Process	\N
92607	\N	\N	3633	\N	\N	3633 Waiting Process	\N
92608	\N	\N	3634	\N	\N	3634 Waiting Process	\N
92609	\N	\N	3635	\N	\N	3635 Waiting Process	\N
92610	\N	\N	3726	\N	\N	3726 Not Processed	\N
92611	\N	\N	3636	\N	\N	3636 Waiting Process	\N
92612	\N	\N	3637	\N	\N	3637 Waiting Process	\N
92613	\N	\N	3638	\N	\N	3638 Waiting Process	\N
92615	\N	\N	3639	\N	\N	3639 Waiting Process	\N
92616	\N	\N	3640	\N	\N	3640 Waiting Process	\N
92617	\N	\N	3641	\N	\N	3641 Waiting Process	\N
92618	\N	\N	3642	\N	\N	3642 Waiting Process	\N
92619	\N	\N	3643	\N	\N	3643 Waiting Process	\N
92620	\N	\N	3644	\N	\N	3644 Waiting Process	\N
92621	\N	\N	3645	\N	\N	3645 Waiting Process	\N
92624	\N	\N	2019	\N	\N	2019 Invasive Melanoma	\N
92625	\N	\N	2020	\N	\N	2020 Invasive Melanoma	\N
92629	\N	\N	2018	\N	\N	2018 Invasive Melanoma	\N
92640	\N	\N	2304	\N	\N	2304 Tumor	\N
92643	\N	\N	3727	\N	\N	3727 Not Processed	\N
92644	\N	\N	3646	\N	\N	3646 Waiting Process	\N
92645	\N	\N	3647	\N	\N	3647 Waiting Process	\N
92647	\N	\N	3648	\N	\N	3648 Waiting Process	\N
92688	\N	\N	3728	\N	\N	3728 Not Processed	\N
92689	\N	\N	3729	\N	\N	3729 Not Processed	\N
92690	\N	\N	3730	\N	\N	3730 Not Processed	\N
92691	\N	\N	2907	\N	\N	2907 NAN	\N
92692	\N	\N	3731	\N	\N	3731 Not Processed	\N
92693	\N	\N	3732	\N	\N	3732 Not Processed	\N
92694	\N	\N	3733	\N	\N	3733 Not Processed	\N
92695	\N	\N	2902	\N	\N	2902 Not Processed	\N
92696	\N	\N	3734	\N	\N	3734 Not Processed	\N
92697	\N	\N	3735	\N	\N	3735 Not Processed	\N
92626	\N	\N	3417	3450	\N	3417 Unknown	OM-18D3
92627	\N	\N	3416	3449	\N	3416 Unknown	OM-18D2
92628	\N	\N	3418	3451	\N	3418 Unknown	OM-18D4
92630	\N	\N	3414	3447	\N	3414 Unknown	OM-17D
92631	\N	\N	3415	3448	\N	3415 Unknown	OM-18D
92632	\N	\N	2013	3438	\N	2013 Intramucosal Melanocytic Nevus	OM-11D (P040_11C)
92633	\N	\N	3411	3439	\N	3411 Unknown	OM-11R (P040_07C)
92634	\N	\N	2015	3442	\N	2015 Intramucosal Nevus	OM-14D
92635	\N	\N	2014	3441	\N	2014 Intramucosal Nevus	OM-13D
92636	\N	\N	2016	3446	\N	2016 Blue Nevus	OM-16D
92638	\N	\N	3410	3437	\N	3410 Unknown	OM-10R (P040_07B)
92641	\N	\N	3413	3445	\N	3413 Unknown	OM-15R (P040_07D)
92667	\N	\N	2520	2051	\N	2520 Normal	LMM D-039
92678	\N	\N	2527	4373	\N	2527 Normal	KA D-01
92679	\N	\N	2529	4375	\N	2529 Normal	KA D-03
92728	\N	\N	3649	\N	\N	3649 Waiting Process	\N
92730	\N	\N	3650	\N	\N	3650 Waiting Process	\N
92731	\N	\N	3651	\N	\N	3651 Waiting Process	\N
92732	\N	\N	3652	\N	\N	3652 Waiting Process	\N
92733	\N	\N	3653	\N	\N	3653 Waiting Process	\N
92734	\N	\N	3654	\N	\N	3654 Waiting Process	\N
92735	\N	\N	3655	\N	\N	3655 Waiting Process	\N
92736	\N	\N	3656	\N	\N	3656 Waiting Process	\N
92737	\N	\N	3657	\N	\N	3657 Waiting Process	\N
92738	\N	\N	3658	\N	\N	3658 Waiting Process	\N
92742	\N	\N	3736	\N	\N	3736 Not Processed	\N
92743	\N	\N	3737	\N	\N	3737 Not Processed	\N
92748	\N	\N	3659	\N	\N	3659 Waiting Process	\N
92749	\N	\N	3660	\N	\N	3660 Waiting Process	\N
92750	\N	\N	3661	\N	\N	3661 Waiting Process	\N
92751	\N	\N	3662	\N	\N	3662 Waiting Process	\N
92752	\N	\N	3663	\N	\N	3663 Waiting Process	\N
92753	\N	\N	3664	\N	\N	3664 Waiting Process	\N
92754	\N	\N	3738	\N	\N	3738 Not Processed	\N
92755	\N	\N	3739	\N	\N	3739 Not Processed	\N
92756	\N	\N	3665	\N	\N	3665 Waiting Process	\N
92758	\N	\N	2665	\N	\N	2665 MIS	\N
92759	\N	\N	2664	\N	\N	2664 Invasive	\N
92760	\N	\N	2666	\N	\N	2666 Normal	\N
92761	\N	\N	3666	\N	\N	3666 Waiting Process	\N
92765	\N	\N	3667	\N	\N	3667 Waiting Process	\N
92766	\N	\N	3740	\N	\N	3740 Not Processed	\N
92767	\N	\N	3741	\N	\N	3741 Not Processed	\N
92793	\N	\N	3832	\N	\N	3832 Not Processed	\N
92800	\N	\N	3833	\N	\N	3833 Not Processed	\N
92815	\N	\N	3793	\N	\N	3793 Not Processed	\N
92719	\N	\N	2218	1755	\N	2218 Normal	DNA-382
92729	\N	\N	2589	4282	\N	2589 Blue Nevus	DMS-025
92741	\N	\N	2586	4279	\N	2586 Blue Nevus	DMS-022
92762	\N	\N	2569	4262	\N	2569 Spitz Nevus	DMS-005
92771	\N	\N	2038	3326	\N	2038 Mel	NM D-084
92772	\N	\N	2039	3327	\N	2039 Mel	NM D-085
92773	\N	\N	2040	3328	\N	2040 Mel	NM D-086
92774	\N	\N	2041	3329	\N	2041 Normal	NM D-087
92776	\N	\N	2535	4381	\N	2535 Normal	KA D-09
92779	\N	\N	2537	4383	\N	2537 Normal	KA D-11
92781	\N	\N	2574	4267	\N	2574 Spitz Nevus	DMS-010
92785	\N	\N	2687	4612	\N	2687 Capture Area D1	VS-08_NA
92827	\N	\N	2462	\N	\N	2462 Normal	\N
92838	\N	\N	3834	\N	\N	3834 Not Processed	\N
92842	\N	\N	3794	\N	\N	3794 Not Processed	\N
92852	\N	\N	3795	\N	\N	3795 Not Processed	\N
92853	\N	\N	3742	\N	\N	3742 Not Processed	\N
92856	\N	\N	3668	\N	\N	3668 Waiting Process	\N
92857	\N	\N	3669	\N	\N	3669 Waiting Process	\N
92858	\N	\N	3670	\N	\N	3670 Waiting Process	\N
92863	\N	\N	2639	\N	\N	2639 Invasive	\N
92864	\N	\N	2640	\N	\N	2640 MIS	\N
92867	\N	\N	3671	\N	\N	3671 Waiting Process	\N
92868	\N	\N	3672	\N	\N	3672 Waiting Process	\N
92872	\N	\N	3673	\N	\N	3673 Waiting Process	\N
92873	\N	\N	3674	\N	\N	3674 Waiting Process	\N
92876	\N	\N	3675	\N	\N	3675 Waiting Process	\N
92879	\N	\N	3676	\N	\N	3676 Waiting Process	\N
92880	\N	\N	3677	\N	\N	3677 Waiting Process	\N
92881	\N	\N	3743	\N	\N	3743 Not Processed	\N
92882	\N	\N	3744	\N	\N	3744 Not Processed	\N
92883	\N	\N	3745	\N	\N	3745 Not Processed	\N
92884	\N	\N	3678	\N	\N	3678 Waiting Process	\N
92889	\N	\N	3679	\N	\N	3679 Waiting Process	\N
92893	\N	\N	3835	\N	\N	3835 Not Processed	\N
92911	\N	\N	2689	\N	\N	2689 Invasive	\N
92914	\N	\N	2688	\N	\N	2688 Invasive	\N
92915	\N	\N	3796	\N	\N	3796 Not Processed	\N
92916	\N	\N	3797	\N	\N	3797 Not Processed	\N
92917	\N	\N	3798	\N	\N	3798 Not Processed	\N
92825	\N	\N	2236	1773	\N	2236 Normal	DNA-407
92828	\N	\N	2918	24	\N	2918 Unknown	22-104389A4-RNA
92829	\N	\N	2917	23	\N	2917 Unknown	22-104389A4-DNA
92834	\N	\N	2539	4385	\N	2539 Normal	KA D-13
92836	\N	\N	2541	4387	\N	2541 Normal	KA D-15
92982	\N	\N	3799	\N	\N	3799 Not Processed	\N
92983	\N	\N	3800	\N	\N	3800 Not Processed	\N
92949	\N	\N	1132	2603	\N	1132 Mel	MDD-220
92950	\N	\N	1111	2582	\N	1111 Mel	MDD-199
92951	\N	\N	920	2433	\N	920 Mel	MDD-50
92952	\N	\N	919	2432	\N	919 Mel	MDD-49
92953	\N	\N	1123	2594	\N	1123 Mel	MDD-211
92955	\N	\N	1730	2752	\N	1730 Normal	MMD-135
92956	\N	\N	1131	2602	\N	1131 Mel	MDD-219
92957	\N	\N	1129	2600	\N	1129 Mel	MDD-217
92958	\N	\N	2731	4520	\N	2731 Tumor	KAM26-T
92959	\N	\N	1128	2599	\N	1128 Mel	MDD-216
93076	\N	\N	3746	\N	\N	3746 Not Processed	\N
93077	\N	\N	3747	\N	\N	3747 Not Processed	\N
93083	\N	\N	3748	\N	\N	3748 Not Processed	\N
93088	\N	\N	3749	\N	\N	3749 Not Processed	\N
93097	\N	\N	3750	\N	\N	3750 Not Processed	\N
93098	\N	\N	3751	\N	\N	3751 Not Processed	\N
93117	\N	\N	3752	\N	\N	3752 Not Processed	\N
93118	\N	\N	3753	\N	\N	3753 Not Processed	\N
93119	\N	\N	3754	\N	\N	3754 Not Processed	\N
93120	\N	\N	3755	\N	\N	3755 Not Processed	\N
93121	\N	\N	3756	\N	\N	3756 Not Processed	\N
93140	\N	\N	3757	\N	\N	3757 Not Processed	\N
93145	\N	\N	3758	\N	\N	3758 Not Processed	\N
93146	\N	\N	3759	\N	\N	3759 Not Processed	\N
93149	\N	\N	3760	\N	\N	3760 Not Processed	\N
93151	\N	\N	3761	\N	\N	3761 Not Processed	\N
93159	\N	\N	3762	\N	\N	3762 Not Processed	\N
93162	\N	\N	3763	\N	\N	3763 Not Processed	\N
93163	\N	\N	3764	\N	\N	3764 Not Processed	\N
93167	\N	\N	3765	\N	\N	3765 Not Processed	\N
93168	\N	\N	3766	\N	\N	3766 Not Processed	\N
93170	\N	\N	3767	\N	\N	3767 Not Processed	\N
93173	\N	\N	3768	\N	\N	3768 Not Processed	\N
93174	\N	\N	3769	\N	\N	3769 Not Processed	\N
93175	\N	\N	3770	\N	\N	3770 Not Processed	\N
93176	\N	\N	3771	\N	\N	3771 Not Processed	\N
93177	\N	\N	3772	\N	\N	3772 Not Processed	\N
93184	\N	\N	3773	\N	\N	3773 Not Processed	\N
93185	\N	\N	3774	\N	\N	3774 Not Processed	\N
93186	\N	\N	3775	\N	\N	3775 Not Processed	\N
93188	\N	\N	3776	\N	\N	3776 Not Processed	\N
93192	\N	\N	3777	\N	\N	3777 Not Processed	\N
93205	\N	\N	3778	\N	\N	3778 Not Processed	\N
93216	\N	\N	3779	\N	\N	3779 Not Processed	\N
93217	\N	\N	3780	\N	\N	3780 Not Processed	\N
93218	\N	\N	3781	\N	\N	3781 Not Processed	\N
93225	\N	\N	3783	\N	\N	3783 Not Processed	\N
93228	\N	\N	3784	\N	\N	3784 Not Processed	\N
93236	\N	\N	3782	\N	\N	3782 Not Processed	\N
93329	\N	\N	2333	\N	\N	2333 Tumor	\N
93207	\N	\N	59	108	\N	59 MIS1	AM2 D-11
93208	\N	\N	60	109	\N	60 MIS2	AM2 D-12
93338	\N	\N	2330	\N	\N	2330 Tumor	\N
93339	\N	\N	2332	\N	\N	2332 Tumor	\N
93340	\N	\N	2331	\N	\N	2331 Tumor	\N
93341	\N	\N	2334	\N	\N	2334 Tumor	\N
93342	\N	\N	2335	\N	\N	2335 Tumor	\N
93480	\N	\N	3902	\N	\N	3902 Unknown	\N
93482	\N	\N	3785	\N	\N	3785 Not Processed	\N
93458	\N	\N	3856	4604	\N	3856 Tumor	DM93_Tumor_NA
93459	\N	\N	3149	1320	\N	3149 Normal	DM_94_Normal_NA
93460	\N	\N	3150	1321	\N	3150 Tumor	DM_94_Tumor_NA
93461	\N	\N	3151	1322	\N	3151 Tumor	DM_95_2_Tumor_NA
93462	\N	\N	3152	1323	\N	3152 Normal	DM_95_Normal_NA
93463	\N	\N	3153	1324	\N	3153 Tumor	DM_96_2_Tumor_NA
93617	\N	\N	3688	\N	\N	3688 Not Processed	\N
93635	\N	\N	3689	\N	\N	3689 Not Processed	\N
93644	\N	\N	3690	\N	\N	3690 Not Processed	\N
93645	\N	\N	3691	\N	\N	3691 Not Processed	\N
93655	\N	\N	3692	\N	\N	3692 Not Processed	\N
93657	\N	\N	3693	\N	\N	3693 Not Processed	\N
93661	\N	\N	3694	\N	\N	3694 Not Processed	\N
93662	\N	\N	3695	\N	\N	3695 Not Processed	\N
93578	\N	\N	78	127	\N	78 Normal	AM2 D-30
93581	\N	\N	83	132	\N	83 MIS1	AM2 D-35
93582	\N	\N	84	133	\N	84 Mel	AM2 D-36
93583	\N	\N	1152	281	\N	1152 Met1	AM2 D-183
93584	\N	\N	82	131	\N	82 Normal	AM2 D-34
93588	\N	\N	97	184	\N	97 Normal	AM2 D-87
93590	\N	\N	102	189	\N	102 Met2	AM2 D-92
93869	\N	\N	2824	\N	\N	2824 MM	\N
95320	\N	\N	1941	3690	\N	\N	RNA-184
90341	\N	\N	1097	2568	\N	1097 Mel	MDD-185
90343	\N	\N	1768	2791	\N	1768 Normal	MMD-176
90344	\N	\N	972	2485	\N	972 Mel	MDD-102
90345	\N	\N	633	2385	\N	633 Mel	MDD-02
90346	\N	\N	971	2484	\N	971 Mel	MDD-101
90347	\N	\N	1095	2566	\N	1095 Mel	MDD-183
90348	\N	\N	2730	4519	\N	2730 Tumor	KAM14-T
90351	\N	\N	634	2386	\N	634 Mel	MDD-03
90352	\N	\N	1076	2547	\N	1076 Mel	MDD-164
90357	\N	\N	1804	2839	\N	1804 Normal	MMD-224
90358	\N	\N	1053	2524	\N	1053 Mel	MDD-141
90361	\N	\N	1096	2567	\N	1096 Mel	MDD-184
90363	\N	\N	635	2387	\N	635 Mel	MDD-04
90364	\N	\N	1094	2565	\N	1094 Mel	MDD-182
90367	\N	\N	2732	4521	\N	2732 Tumor	KAM3-T-A
90368	\N	\N	974	2487	\N	974 Mel	MDD-104
90369	\N	\N	2254	2615	\N	2254 Tumor	MM-4
90370	\N	\N	2756	4541	\N	2756 MVP	JBU7-MVP
90371	\N	\N	2755	4540	\N	2755 Normal	JBU7-Norm
90373	\N	\N	636	2388	\N	636 Mel	MDD-05
90374	\N	\N	1023	2494	\N	1023 Mel	MDD-111
90378	\N	\N	2723	4512	\N	2723 Tumor	KAM123-T
90381	\N	\N	939	2452	\N	939 Mel	MDD-69
90382	\N	\N	2716	4502	\N	2716 Normal	KAM100-N
90383	\N	\N	942	2455	\N	942 Mel	MDD-72
90384	\N	\N	973	2486	\N	973 Mel	MDD-103
90385	\N	\N	1091	2562	\N	1091 Mel	MDD-179
90387	\N	\N	2717	4503	\N	2717 Tumor	KAM100-T-11
90388	\N	\N	1093	2564	\N	1093 Mel	MDD-181
90390	\N	\N	1725	2747	\N	1725 Normal	MMD-130
90392	\N	\N	3871	4624	\N	3871 Tumor	DPN61-Tumor_NA
90393	\N	\N	1090	2561	\N	1090 Mel	MDD-178
90394	\N	\N	941	2454	\N	941 Mel	MDD-71
90395	\N	\N	940	2453	\N	940 Mel	MDD-70
90396	\N	\N	3075	1195	\N	3075 Tumor	CNS_33_Tumor_NA
90397	\N	\N	1089	2560	\N	1089 Mel	MDD-177
90398	\N	\N	1092	2563	\N	1092 Mel	MDD-180
90400	\N	\N	3076	1196	\N	3076 Normal	CNS_34_Normal_NA
90401	\N	\N	3077	1197	\N	3077 Tumor	CNS_34_Tumor_NA
90402	\N	\N	2774	97	\N	2774 Tumor	AM_14_Tumor_NA
90404	\N	\N	2255	3475	\N	2255 Tumor	PM-1
90405	\N	\N	2754	4538	\N	2754 MVP	JBU11-MVP
90406	\N	\N	2753	4539	\N	2753 Normal	JBU11-Norm
90408	\N	\N	1773	2795	\N	1773 Normal	MMD-180
90411	\N	\N	943	2456	\N	943 Mel	MDD-73
90412	\N	\N	2741	4530	\N	2741 Tumor	KAM79-T
90413	\N	\N	1088	2559	\N	1088 Mel	MDD-176
90414	\N	\N	1085	2556	\N	1085 Mel	MDD-173
90415	\N	\N	944	2457	\N	944 Mel	MDD-74
90419	\N	\N	1086	2557	\N	1086 Mel	MDD-174
90420	\N	\N	1084	2555	\N	1084 Mel	MDD-172
90421	\N	\N	1022	2493	\N	1022 Mel	MDD-110
90422	\N	\N	1079	2550	\N	1079 Mel	MDD-167
90423	\N	\N	1083	2554	\N	1083 Mel	MDD-171
90424	\N	\N	1080	2551	\N	1080 Mel	MDD-168
90425	\N	\N	1081	2552	\N	1081 Mel	MDD-169
90426	\N	\N	1827	2858	\N	1827 Normal	MMD-243
90428	\N	\N	1087	2558	\N	1087 Mel	MDD-175
90429	\N	\N	637	2389	\N	637 Mel	MDD-06
90430	\N	\N	976	2489	\N	976 Mel	MDD-106
90436	\N	\N	2773	96	\N	2773 Tumor	AM_13_Tumor_NA
90322	\N	\N	1855	3160	\N	1855 Mel	MMR-344
90323	\N	\N	1857	3162	\N	1857 MIS	MMR-346
90326	\N	\N	1847	2951	\N	1847 Mel	MMD-336
90327	\N	\N	1848	2952	\N	1848 Normal	MMD-337
90328	\N	\N	1820	2855	\N	1820 Mel	MMD-240
90329	\N	\N	1821	2856	\N	1821 Normal	MMD-241
90331	\N	\N	1769	3087	\N	1769 Mel	MMR-177
90335	\N	\N	1645	2640	\N	1645 Mel	MMD-20
90342	\N	\N	1767	2790	\N	1767 Mel	MMD-175
90349	\N	\N	1765	2788	\N	1765 Mel	MMD-173
90350	\N	\N	1766	2789	\N	1766 Normal	MMD-174
90353	\N	\N	1947	1588	\N	1947 Melanocytoma	DNA-190
90354	\N	\N	1948	1589	\N	1948 Nevus	DNA-191
90355	\N	\N	1949	1590	\N	1949 Normal	DNA-192
90356	\N	\N	1803	2838	\N	1803 Mel	MMD-223
90359	\N	\N	1693	3038	\N	1693 Mel	MMR-89
90360	\N	\N	1694	3039	\N	1694 MIS	MMR-90
90362	\N	\N	1657	2657	\N	1657 Mel	MMD-37
90365	\N	\N	1851	2955	\N	1851 Mel	MMD-340
90366	\N	\N	1852	3157	\N	1852 Normal	MMR-341
90372	\N	\N	1652	2652	\N	1652 Mel	MMD-32
90375	\N	\N	1641	2992	\N	1641 Mel	MMR-16
90376	\N	\N	1642	2993	\N	1642 Nevus	MMR-17
90377	\N	\N	1956	1599	\N	1956 Normal	DNA-201
90379	\N	\N	1646	2641	\N	1646 Mel	MMD-21
90380	\N	\N	1647	2642	\N	1647 Mel	MMD-22
90386	\N	\N	1665	3017	\N	1665 Mel	MMR-44
90389	\N	\N	1724	2746	\N	1724 Mel	MMD-129
90391	\N	\N	1726	2748	\N	1726 MIS	MMD-131
90399	\N	\N	1666	2665	\N	1666 Mel	MMD-45
90403	\N	\N	1660	2660	\N	1660 Mel	MMD-40
90407	\N	\N	1770	2793	\N	1770 Mel	MMD-178
90409	\N	\N	1771	2793	\N	1771 Mel	MMD-178
90410	\N	\N	1772	2794	\N	1772 MIS	MMD-179
90416	\N	\N	1714	2739	\N	1714 Normal	MMD-122
90417	\N	\N	1715	2738	\N	1715 Mel	MMD-121
90418	\N	\N	1716	2740	\N	1716 MIS	MMD-123
90427	\N	\N	1826	2857	\N	1826 Mel	MMD-242
90431	\N	\N	1854	2958	\N	1854 Normal	MMD-343
90432	\N	\N	1853	3158	\N	1853 Mel	MMR-342
90433	\N	\N	1860	3165	\N	1860 MIS	MMR-349
90434	\N	\N	1858	3163	\N	1858 Mel	MMR-347
90435	\N	\N	1859	2963	\N	1859 Normal	MMD-348
90437	\N	\N	1721	2743	\N	1721 Mel	MMD-126
90438	\N	\N	1722	2744	\N	1722 Normal	MMD-127
90439	\N	\N	1723	2745	\N	1723 MIS	MMD-128
90440	\N	\N	1713	3055	\N	1713 Mel	MMR-120
90441	\N	\N	1707	2732	\N	1707 Mel	MMD-115
90443	\N	\N	1944	1585	\N	1944 Mel	DNA-187
90444	\N	\N	1946	1587	\N	1946 Normal	DNA-189
90445	\N	\N	1945	1586	\N	1945 Nevus	DNA-188
90458	\N	\N	1075	2546	\N	1075 Mel	MDD-163
90459	\N	\N	1073	2544	\N	1073 Mel	MDD-161
90460	\N	\N	2722	4511	\N	2722 Tumor	KAM122-T-A
90461	\N	\N	640	2392	\N	640 Mel	MDD-09
90462	\N	\N	1074	2545	\N	1074 Mel	MDD-162
90464	\N	\N	1702	2717	\N	1702 Normal	MMD-99
90466	\N	\N	1060	2531	\N	1060 Mel	MDD-148
90467	\N	\N	3869	4622	\N	3869 Tumor	DPN59-Tumor_NA
90468	\N	\N	1066	2537	\N	1066 Mel	MDD-154
90469	\N	\N	1850	2954	\N	1850 Normal	MMD-339
90471	\N	\N	1072	2543	\N	1072 Mel	MDD-160
90472	\N	\N	1071	2542	\N	1071 Mel	MDD-159
90473	\N	\N	1067	2538	\N	1067 Mel	MDD-155
90474	\N	\N	1064	2535	\N	1064 Mel	MDD-152
90478	\N	\N	1068	2539	\N	1068 Mel	MDD-156
90479	\N	\N	1070	2541	\N	1070 Mel	MDD-158
90480	\N	\N	1069	2540	\N	1069 Mel	MDD-157
90482	\N	\N	1063	2534	\N	1063 Mel	MDD-151
90483	\N	\N	977	2490	\N	977 Mel	MDD-107
90484	\N	\N	947	2460	\N	947 Mel	MDD-77
90485	\N	\N	1061	2532	\N	1061 Mel	MDD-149
90493	\N	\N	1670	2669	\N	1670 Normal	MMD-49
90497	\N	\N	2256	3476	\N	2256 Tumor	PM-2
90498	\N	\N	2260	3224	\N	2260 Normal	N-2
90499	\N	\N	3872	4625	\N	3872 Tumor	DPN62-Tumor_NA
90503	\N	\N	1818	2853	\N	1818 Mel	MMD-238
90504	\N	\N	1819	2854	\N	1819 Normal	MMD-239
90506	\N	\N	2251	2612	\N	2251 Tumor	MM-1
90507	\N	\N	2259	3223	\N	2259 Normal	N-1
90508	\N	\N	628	2421	\N	628 Mel	MDD-38
90509	\N	\N	948	2461	\N	948 Mel	MDD-78
90510	\N	\N	1058	2529	\N	1058 Mel	MDD-146
90511	\N	\N	1062	2533	\N	1062 Mel	MDD-150
90512	\N	\N	1797	2918	\N	1797 Normal	MMD-303
90516	\N	\N	2738	4527	\N	2738 Tumor	KAM65-T
90517	\N	\N	3078	1198	\N	3078 Tumor	CNS_35_Tumor_NA
90518	\N	\N	2745	4535	\N	2745 Tumor	KAM99-T
90519	\N	\N	912	2425	\N	912 Mel	MDD-42
90520	\N	\N	1055	2526	\N	1055 Mel	MDD-143
90521	\N	\N	978	2491	\N	978 Mel	MDD-108
90522	\N	\N	642	2394	\N	642 Mel	MDD-11
90523	\N	\N	1059	2530	\N	1059 Mel	MDD-147
90524	\N	\N	2746	4534	\N	2746 Normal	KAM99-N
90525	\N	\N	1056	2527	\N	1056 Mel	MDD-144
90527	\N	\N	1054	2525	\N	1054 Mel	MDD-142
90528	\N	\N	949	2462	\N	949 Mel	MDD-79
90529	\N	\N	641	2393	\N	641 Mel	MDD-10
90530	\N	\N	1057	2528	\N	1057 Mel	MDD-145
90531	\N	\N	1051	2522	\N	1051 Mel	MDD-139
90532	\N	\N	1049	2520	\N	1049 Mel	MDD-137
90533	\N	\N	1052	2523	\N	1052 Mel	MDD-140
90534	\N	\N	913	2426	\N	913 Mel	MDD-43
90541	\N	\N	1776	2798	\N	1776 Normal	MMD-183
90543	\N	\N	643	2395	\N	643 Mel	MDD-12
90544	\N	\N	1048	2519	\N	1048 Mel	MDD-136
90560	\N	\N	3079	1199	\N	3079 Tumor	CNS_36_Tumor_NA
90563	\N	\N	1756	2779	\N	1756 Normal	MMD-164
90565	\N	\N	1656	2656	\N	1656 Normal	MMD-36
90566	\N	\N	2252	2613	\N	2252 Tumor	MM-2
90567	\N	\N	3227	1832	\N	3227 Tumor	DPN_17_Tumor_NA
90568	\N	\N	645	2397	\N	645 Mel	MDD-14
90569	\N	\N	1025	2496	\N	1025 Mel	MDD-113
90570	\N	\N	1044	2515	\N	1044 Mel	MDD-132
90571	\N	\N	426	3872	\N	426 blue nevus+ cellular+  DF like	SM D-03
90572	\N	\N	914	2427	\N	914 Mel	MDD-44
90447	\N	\N	1695	2709	\N	1695 Mel	MMD-91
90449	\N	\N	1697	2709	\N	1697 Mel	MMD-91
90463	\N	\N	1701	3046	\N	1701 Mel	MMR-98
90465	\N	\N	1703	3047	\N	1703 MIS	MMR-100
90470	\N	\N	1849	2953	\N	1849 Mel	MMD-338
90475	\N	\N	1742	2765	\N	1742 Normal	MMD-150
90476	\N	\N	1741	2764	\N	1741 Mel	MMD-149
90477	\N	\N	1639	2990	\N	1639 Mel	MMR-14
90481	\N	\N	1632	2627	\N	1632 Mel	MMD-07
90486	\N	\N	1717	2741	\N	1717 Mel	MMD-124
90487	\N	\N	1718	2742	\N	1718 Normal	MMD-125
90488	\N	\N	1719	2741	\N	1719 Mel	MMD-124
90489	\N	\N	1720	2742	\N	1720 Normal	MMD-125
90490	\N	\N	1712	2736	\N	1712 Mel	MMD-119
90491	\N	\N	638	2390	\N	638 Mel	MDD-07
90492	\N	\N	1669	2668	\N	1669 Mel	MMD-48
90494	\N	\N	1671	2670	\N	1671 MIS	MMD-50
90495	\N	\N	1922	1563	\N	1922 Nevus	DNA-165
90496	\N	\N	1921	1562	\N	1921 Mel	DNA-164
90500	\N	\N	1637	2988	\N	1637 Mel	MMR-12
90501	\N	\N	1734	2756	\N	1734 Mel	MMD-141
90502	\N	\N	1735	2757	\N	1735 Normal	MMD-142
90505	\N	\N	1640	2991	\N	1640 Mel	MMR-15
90513	\N	\N	1798	2919	\N	1798 MIS	MMD-304
90514	\N	\N	1796	2917	\N	1796 Mel	MMD-302
90526	\N	\N	1643	2638	\N	1643 Mel	MMD-18
90535	\N	\N	1926	1567	\N	1926 Mel	DNA-169
90536	\N	\N	1927	1568	\N	1927 MIS	DNA-170
90537	\N	\N	1928	1569	\N	1928 Nevus	DNA-171
90538	\N	\N	1929	1570	\N	1929 Normal	DNA-172
90539	\N	\N	1774	2796	\N	1774 Mel	MMD-181
90540	\N	\N	1775	2797	\N	1775 Mel	MMD-182
90542	\N	\N	1629	2624	\N	1629 Mel	MMD-04
90545	\N	\N	1957	1657	\N	1957 Normal	DNA-261
90551	\N	\N	1930	1571	\N	1930 Normal	DNA-173
90552	\N	\N	1814	2849	\N	1814 Mel	MMD-234
90553	\N	\N	1815	2850	\N	1815 Normal	MMD-235
90554	\N	\N	1816	2851	\N	1816 MIS	MMD-236
90555	\N	\N	1817	2852	\N	1817 Nevus	MMD-237
90556	\N	\N	1931	1572	\N	1931 Mel	DNA-174
90557	\N	\N	1932	1573	\N	1932 MIS	DNA-175
90558	\N	\N	1933	1574	\N	1933 Nevus	DNA-176
90559	\N	\N	1934	1575	\N	1934 Normal	DNA-177
90561	\N	\N	1650	2650	\N	1650 Mel	MMD-30
90562	\N	\N	1755	2778	\N	1755 Mel	MMD-163
90564	\N	\N	1655	2655	\N	1655 Mel	MMD-35
90573	\N	\N	1658	2658	\N	1658 Mel	MMD-38
90598	\N	\N	630	2423	\N	630 Mel	MDD-40
90599	\N	\N	1041	2512	\N	1041 Mel	MDD-129
90600	\N	\N	916	2429	\N	916 Mel	MDD-46
90601	\N	\N	653	2405	\N	653 Mel	MDD-22
90602	\N	\N	1037	2508	\N	1037 Mel	MDD-125
90603	\N	\N	648	2400	\N	648 Mel	MDD-17
90604	\N	\N	1034	2505	\N	1034 Mel	MDD-122
90605	\N	\N	1039	2510	\N	1039 Mel	MDD-127
90607	\N	\N	1785	2814	\N	1785 Normal	MMD-199
90610	\N	\N	2739	4528	\N	2739 Tumor	KAM71-T
90611	\N	\N	1036	2507	\N	1036 Mel	MDD-124
90612	\N	\N	1035	2506	\N	1035 Mel	MDD-123
90614	\N	\N	1800	2921	\N	1800 Normal	MMD-306
90615	\N	\N	2771	1833	\N	2771 Normal	DPN_18_Normal_NA
90616	\N	\N	3228	1834	\N	3228 Tumor	DPN_18_Tumor_NA
90621	\N	\N	652	2404	\N	652 Mel	MDD-21
90622	\N	\N	1031	2502	\N	1031 Mel	MDD-119
90623	\N	\N	1032	2503	\N	1032 Mel	MDD-120
90624	\N	\N	649	2401	\N	649 Mel	MDD-18
90625	\N	\N	1024	2495	\N	1024 Mel	MDD-112
90629	\N	\N	3080	1200	\N	3080 Tumor	CNS_37_Tumor_NA
90630	\N	\N	3229	1835	\N	3229 Tumor	DPN_19_Tumor_NA
90632	\N	\N	2787	3903	\N	2787 Tumor	SM_6_Tumor_NA
90633	\N	\N	2788	3904	\N	2788 Normal	SM_7_Normal_NA
90639	\N	\N	1836	2867	\N	1836 Normal	MMD-252
90655	\N	\N	2790	3906	\N	2790 Normal	SM_8_Normal_NA
90656	\N	\N	2791	3907	\N	2791 Tumor	SM_8_Tumor_NA
90658	\N	\N	2813	1937	\N	2813 Normal	K2_4
90659	\N	\N	2744	4533	\N	2744 Tumor	KAM95-T-B1
90662	\N	\N	2793	3908	\N	2793 Normal	SM_9_Normal_NA
90663	\N	\N	2804	1949	\N	2804 Tumor	Kit_53_Acral_NRAS_NA
90664	\N	\N	654	2406	\N	654 Mel	MDD-23
90665	\N	\N	1050	2521	\N	1050 Mel	MDD-138
90669	\N	\N	1664	2881	\N	1664 Nevus	MMD-266
90682	\N	\N	1360	1036	\N	1360 Tumor	CGH15-082
90684	\N	\N	1687	2700	\N	1687 Normal	MMD-82
90687	\N	\N	3400	3417	\N	3400 Unknown	OM-1R (P040_05A)
90688	\N	\N	3399	3414	\N	3399 Unknown	OM-1D (P040_09A)
90689	\N	\N	2000	3389	\N	2000 Typical Melanotic Macule	OM D-66.1
90690	\N	\N	2001	3390	\N	2001 Typical Melanotic Macule	OM D-66.2
90691	\N	\N	2002	3391	\N	2002 Atypical Melanocytic Proliferation	OM D-66.3
90693	\N	\N	1806	2841	\N	1806 Normal	MMD-226
90576	\N	\N	1757	2780	\N	1757 Mel	MMD-165
90586	\N	\N	1633	2628	\N	1633 Mel	MMD-08
90588	\N	\N	1938	1579	\N	1938 MIS	DNA-181
90589	\N	\N	1939	1580	\N	1939 Nevus	DNA-182
90590	\N	\N	1940	1581	\N	1940 Normal	DNA-183
90592	\N	\N	1843	2947	\N	1843 Mel	MMD-332
90593	\N	\N	1844	2949	\N	1844 MIS	MMD-334
90595	\N	\N	1845	2948	\N	1845 Normal	MMD-333
90597	\N	\N	647	2399	\N	647 Mel	MDD-16
90606	\N	\N	1784	2813	\N	1784 Normal	MMD-198
90608	\N	\N	1783	2812	\N	1783 Mel	MMD-197
90609	\N	\N	1651	3007	\N	1651 Mel	MMR-31
90613	\N	\N	1799	3136	\N	1799 Mel	MMR-305
90617	\N	\N	1812	2847	\N	1812 Mel	MMD-232
90618	\N	\N	1813	2848	\N	1813 Normal	MMD-233
90619	\N	\N	1950	1591	\N	1950 Normal	DNA-193
90620	\N	\N	650	2402	\N	650 Mel	MDD-19
90626	\N	\N	651	2403	\N	651 Mel	MDD-20
90627	\N	\N	1630	2625	\N	1630 Mel	MMD-05
90628	\N	\N	2786	3903	\N	2786 Tumor	SM_6_Tumor_NA
90631	\N	\N	1638	2989	\N	1638 Mel	MMR-13
90634	\N	\N	1661	2661	\N	1661 Mel	MMD-41
90635	\N	\N	1700	3045	\N	1700 Mel	MMR-97
90636	\N	\N	1677	2685	\N	1677 Mel	MMD-67
90637	\N	\N	1627	2622	\N	1627 Mel	MMD-02
90638	\N	\N	1446	1546	\N	1446 Normal	DNA-148
90640	\N	\N	1835	2866	\N	1835 Mel	MMD-251
90643	\N	\N	2309	3503	\N	2309 Met9	PROG D-25
90644	\N	\N	2310	3504	\N	2310 Met10	PROG D-26
90645	\N	\N	1311	3479	\N	1311 Normal	PROG D-01
90646	\N	\N	1312	3480	\N	1312 Met1	PROG D-02
90647	\N	\N	1313	3481	\N	1313 Met2	PROG D-03
90648	\N	\N	2305	3499	\N	2305 Met5	PROG D-21
90649	\N	\N	2306	3500	\N	2306 Met6	PROG D-22
90650	\N	\N	2307	3501	\N	2307 Met7	PROG D-23
90651	\N	\N	2308	3502	\N	2308 Met8	PROG D-24
90652	\N	\N	1314	3482	\N	1314 Met3	PROG D-04
90653	\N	\N	1426	3483	\N	1426 Met4	PROG D-05
90654	\N	\N	2789	3907	\N	2789 Tumor	SM_8_Tumor_NA
90657	\N	\N	1786	3100	\N	1786 Mel	MMR-200
90666	\N	\N	2794	3910	\N	2794 Tumor	SM_10_Tumor_NA
90667	\N	\N	1662	2662	\N	1662 Mel	MMD-42
90668	\N	\N	1663	2663	\N	1663 Normal	MMD-43
90670	\N	\N	1923	1564	\N	1923 Mel	DNA-166
90671	\N	\N	1924	1565	\N	1924 Nevus	DNA-167
90672	\N	\N	1925	1566	\N	1925 Normal	DNA-168
90673	\N	\N	1747	2770	\N	1747 Mel	MMD-155
90674	\N	\N	1748	2771	\N	1748 Normal	MMD-156
90675	\N	\N	2042	1668	\N	2042 Nevus	DNA-272
90676	\N	\N	1782	2811	\N	1782 Mel	MMD-196
90677	\N	\N	2037	1656	\N	2037 Normal	DNA-260
90679	\N	\N	1750	2773	\N	1750 Mel	MMD-158
90680	\N	\N	1751	2774	\N	1751 MIS	MMD-159
90681	\N	\N	1764	3084	\N	1764 Mel	MMR-172
90683	\N	\N	1686	2699	\N	1686 Mel	MMD-81
90685	\N	\N	1688	2701	\N	1688 Mel	MMD-83
90686	\N	\N	2029	3415	\N	2029 Atypical Melanocytic Proliferation	OM-1D-2
90692	\N	\N	1805	2840	\N	1805 Mel	MMD-225
90706	\N	\N	2261	3225	\N	2261 Normal	N-3
90707	\N	\N	2257	3477	\N	2257 Tumor	PM-3
90713	\N	\N	2736	4525	\N	2736 Tumor	KAM48-T
90714	\N	\N	655	2407	\N	655 Mel	MDD-24
90715	\N	\N	950	2463	\N	950 Mel	MDD-80
90716	\N	\N	3243	1857	\N	3243 Tumor	G3 DP08-21965C Tumor_NA
90717	\N	\N	3242	1856	\N	3242 Normal	G3 DP08-21965C Normal_NA
90722	\N	\N	2779	3895	\N	2779 Tumor	SM_1_Tumor_NA
90723	\N	\N	2780	3896	\N	2780 Normal	SM_2_Normal_NA
90726	\N	\N	3270	1884	\N	3270 MELANOMA	Ivanka_5_1_NA
90727	\N	\N	3271	1885	\N	3271 MELANOMA	Ivanka_5_2_NA
90728	\N	\N	3272	1886	\N	3272 MELANOMA	Ivanka_5_3_NA
90729	\N	\N	3273	1887	\N	3273 MELANOMA	Ivanka_5_4_NA
90730	\N	\N	3274	1888	\N	3274 MELANOMA	Ivanka_5_5_NA
90734	\N	\N	2914	16	\N	2914 Mel	22_Melanoma_NA
90735	\N	\N	2915	17	\N	2915 Nevus	22_Nevus_NA
90736	\N	\N	2913	15	\N	2913 Tumor	22_IS_NA
90737	\N	\N	2916	18	\N	2916 Normal	22_Normal_NA
90738	\N	\N	3296	1915	\N	3296 Mel	Ivanka_22_2_NA
90739	\N	\N	3295	1914	\N	3295 Mel	Ivanka_22_1_NA
90740	\N	\N	3298	1917	\N	3298 Nevus	Ivanka_22_4_NA
90741	\N	\N	3297	1916	\N	3297 Nevus	Ivanka_22_3_NA
90742	\N	\N	3299	1918	\N	3299 Normal	Ivanka_22_5_NA
90747	\N	\N	3280	1894	\N	3280 MELANOMA	Ivanka_10_1_NA
90748	\N	\N	3281	1895	\N	3281 MELANOMA	Ivanka_10_2_NA
90749	\N	\N	3282	1896	\N	3282 MELANOMA	Ivanka_10_3_NA
90750	\N	\N	3283	1897	\N	3283 MELANOMA	Ivanka_10_4_NA
90751	\N	\N	3284	1898	\N	3284 MELANOMA	Ivanka_10_5_NA
90754	\N	\N	3285	1899	\N	3285 MELANOMA	Ivanka_12_1_NA
90755	\N	\N	3286	1900	\N	3286 MELANOMA	Ivanka_12_2_NA
90756	\N	\N	3288	1902	\N	3288 MELANOMA	Ivanka_12_4_NA
90757	\N	\N	3289	1903	\N	3289 MELANOMA	Ivanka_12_5_NA
90758	\N	\N	3287	1901	\N	3287 MELANOMA	Ivanka_12_3_NA
90761	\N	\N	2772	95	\N	2772 Tumor	AM_11_Tumor_NA
90762	\N	\N	561	3266	\N	561 Nodular Mel	NM D-11
90763	\N	\N	560	3265	\N	560 Nodular Mel	NM D-10
90764	\N	\N	3426	3855	\N	3426 Tumor	RPA_09_0209_NA
90765	\N	\N	3071	1191	\N	3071 Normal	CNS_29_Normal_NA
90766	\N	\N	3072	1192	\N	3072 Tumor	CNS_29_Tumor_NA
90767	\N	\N	2742	4531	\N	2742 Normal	KAM93-N-B10
90768	\N	\N	2743	4532	\N	2743 Tumor	KAM93-T
90769	\N	\N	3292	1906	\N	3292 Nevus	Ivanka_16_3_NA
90770	\N	\N	3291	1905	\N	3291 Mel	Ivanka_16_2_NA
90771	\N	\N	3290	1904	\N	3290 Mel	Ivanka_16_1_NA
90772	\N	\N	3293	1907	\N	3293 Nevus	Ivanka_16_4_NA
90773	\N	\N	3294	1908	\N	3294 Normal	Ivanka_16_5_NA
90774	\N	\N	2721	4510	\N	2721 Tumor	KAM12-T
90775	\N	\N	952	2465	\N	952 Mel	MDD-82
90776	\N	\N	953	2466	\N	953 Mel	MDD-83
90777	\N	\N	2815	1939	\N	2815 Normal	K2_6
90778	\N	\N	951	2464	\N	951 Mel	MDD-81
90780	\N	\N	656	2408	\N	656 Mel	MDD-25
90781	\N	\N	954	2467	\N	954 Mel	MDD-84
90786	\N	\N	1675	2720	\N	1675 Mel	MMD-102
90787	\N	\N	1676	2721	\N	1676 Normal	MMD-103
90788	\N	\N	1680	2690	\N	1680 Mel	MMD-72
90790	\N	\N	2800	3915	\N	2800 Tumor	SM_18_Tumor_NA
90792	\N	\N	3222	1827	\N	3222 Tumor	DPN_10_Tumor_NA
90793	\N	\N	2694	4545	\N	2694 Normal	UM38-Normal_NA
90794	\N	\N	2695	4546	\N	2695 Tumor	UM38-Tumor_NA
90795	\N	\N	3401	3418	\N	3401 Unknown	OM-3D (P040_09B)
90796	\N	\N	3402	3419	\N	3402 Unknown	OM-3R (P040_05B)
90798	\N	\N	3220	1825	\N	3220 Normal	DPN_9_Normal_NA
90799	\N	\N	3221	1826	\N	3221 Tumor	DPN_9_Tumor_NA
90800	\N	\N	3073	1193	\N	3073 Tumor	CNS_30_Tumor_NA
90801	\N	\N	2979	894	\N	2979 Tumor	bMV_10_0206_NA
90802	\N	\N	2821	1931	\N	2821 MM	K1_20
90803	\N	\N	2820	1930	\N	2820 Normal	K1_19
90804	\N	\N	2826	4585	\N	2826 Met	JBP-9Met_NA
90805	\N	\N	2822	1933	\N	2822 Normal	K1_22
90807	\N	\N	2733	4522	\N	2733 Tumor	KAM34-T
90808	\N	\N	3089	1209	\N	3089 Tumor	CNS_49_Tumor_NA
90809	\N	\N	2748	4506	\N	2748 Tumor	KAM111-T-A1
90810	\N	\N	2827	4584	\N	2827 MM	JBP-9MM_NA
90811	\N	\N	657	2409	\N	657 Mel	MDD-26
90812	\N	\N	955	2468	\N	955 Mel	MDD-85
90813	\N	\N	2829	4582	\N	2829 MM	JBP-6-MM_NA
90814	\N	\N	2830	4581	\N	2830 Met	JBP-6-Met_NA
90815	\N	\N	917	2430	\N	917 Mel	MDD-47
90695	\N	\N	1749	3074	\N	1749 Mel	MMR-157
90696	\N	\N	1955	1596	\N	1955 Normal	DNA-198
90699	\N	\N	1682	2694	\N	1682 Mel	MMD-76
90701	\N	\N	1684	2696	\N	1684 Mel	MMD-78
90708	\N	\N	1743	2766	\N	1743 Mel	MMD-151
90709	\N	\N	1744	2766	\N	1744 Mel	MMD-151
90710	\N	\N	1745	2767	\N	1745 Normal	MMD-152
90711	\N	\N	1746	3072	\N	1746 MIS	MMR-153
90720	\N	\N	1727	2834	\N	1727 Mel	MMD-219
90721	\N	\N	1728	2835	\N	1728 Normal	MMD-220
90724	\N	\N	1600	470	\N	1600 MIS1	AM2 D-403
90725	\N	\N	1601	471	\N	1601 Invasive Primary Mel	AM2 D-404
90731	\N	\N	1752	2775	\N	1752 Mel	MMD-160
90732	\N	\N	1753	2776	\N	1753 Normal	MMD-161
90743	\N	\N	1917	1558	\N	1917 Mel	DNA-160
90744	\N	\N	1918	1559	\N	1918 MIS	DNA-161
90745	\N	\N	1919	1560	\N	1919 Nevus	DNA-162
90746	\N	\N	1920	1561	\N	1920 Normal	DNA-163
90752	\N	\N	1653	2653	\N	1653 Mel	MMD-33
90753	\N	\N	1654	2654	\N	1654 Normal	MMD-34
90759	\N	\N	1958	1654	\N	1958 Normal	DNA-258
90779	\N	\N	1754	2777	\N	1754 Mel	MMD-162
90783	\N	\N	1672	2671	\N	1672 Mel	MMD-51
90784	\N	\N	1673	2672	\N	1673 Normal	MMD-52
90785	\N	\N	1674	2719	\N	1674 MIS	MMD-101
90791	\N	\N	1626	2621	\N	1626 Mel	MMD-01
90797	\N	\N	1644	2639	\N	1644 Mel	MMD-19
90839	\N	\N	958	2471	\N	958 Mel	MDD-88
90840	\N	\N	957	2470	\N	957 Mel	MDD-87
90841	\N	\N	3225	1830	\N	3225 Tumor	DPN_14_Tumor_NA
90845	\N	\N	2762	14	\N	2762 Normal	21-5_NA
90846	\N	\N	2909	10	\N	2909 Mel	D21-1_NA
90847	\N	\N	2910	11	\N	2910 Mel	21-2_NA
90848	\N	\N	2912	13	\N	2912 Nevus	21-4_NA
90849	\N	\N	2911	12	\N	2911 Nevus	21-3_NA
90850	\N	\N	2854	4564	\N	2854 Normal	NGS 1-8_NA
90852	\N	\N	3083	1203	\N	3083 Tumor	CNS_40_Tumor_NA
90853	\N	\N	3223	1828	\N	3223 Tumor	DPN_11_Tumor_NA
90854	\N	\N	2938	853	\N	2938 Tumor	BB008_CGH10-013_NA
90855	\N	\N	2995	922	\N	2995 Tumor	CGH10_17_NA
90856	\N	\N	911	1809	\N	911 DPN-mm	DNPD-04
90857	\N	\N	1235	1814	\N	1235 NEVUS	DNPD-09
90858	\N	\N	3275	1889	\N	3275 Mel	Ivanka_9_1_NA
90859	\N	\N	3276	1890	\N	3276 Mel	Ivanka_9_2_NA
90860	\N	\N	3277	1891	\N	3277 Nevus	Ivanka_9_3_NA
90861	\N	\N	3278	1892	\N	3278 Nevus	Ivanka_9_4_NA
90862	\N	\N	3279	1893	\N	3279 Normal	Ivanka_9_5_NA
90863	\N	\N	2994	921	\N	2994 Tumor	CGH10_16_NA
90864	\N	\N	3237	1843	\N	3237 Normal	DT10_63051C_NA
90865	\N	\N	2996	923	\N	2996 Tumor	CGH10_020_NA
90867	\N	\N	2999	926	\N	2999 Tumor	CGH10-028_NA
90868	\N	\N	1002	996	\N	1002 Tumor	CGH12-067
90869	\N	\N	3000	927	\N	3000 Tumor	CGH10-045_NA
90870	\N	\N	472	908	\N	472 cellular blue nevus	BND-010
90872	\N	\N	3219	1821	\N	3219 Tumor	DPN_6_Tumor_NA
90873	\N	\N	3224	1829	\N	3224 Tumor	DPN_12_Tumor_NA
90874	\N	\N	2997	924	\N	2997 Tumor	CGH10_049_NA
90875	\N	\N	1980	3368	\N	1980 Typical Melanotic Macule	OM D-48
90876	\N	\N	2959	874	\N	2959 Tumor	BB09_CGH11_029_NA
90877	\N	\N	3393	3237	\N	3393 Tumor	N3_11_NA
90878	\N	\N	3003	930	\N	3003 Tumor	CGH11_020_NA
90879	\N	\N	2998	925	\N	2998 Tumor	CGH10_058_NA
90880	\N	\N	3001	928	\N	3001 Tumor	CGH10-058_NA
90881	\N	\N	3002	929	\N	3002 Tumor	CGH10-062_NA
90882	\N	\N	562	3267	\N	562 Nodular Mel	NM D-12
90883	\N	\N	563	3268	\N	563 Nodular Mel	NM D-13
90884	\N	\N	559	3264	\N	559 Nodular Mel	NM D-09
90885	\N	\N	1330	1988	\N	1330 Tumor	KIT-13
90886	\N	\N	1331	1989	\N	1331 Tumor	KIT-14
90887	\N	\N	1332	1990	\N	1332 Tumor	KIT-15
90888	\N	\N	1333	1991	\N	1333 Tumor	KIT-16
90889	\N	\N	1334	1992	\N	1334 Tumor	KIT-17
90890	\N	\N	1335	1993	\N	1335 Tumor	KIT-18
90891	\N	\N	3020	948	\N	3020 Tumor	CGH11-011_NA
90892	\N	\N	459	3923	\N	459 Spitz mel	SMPR55
90899	\N	\N	658	2410	\N	658 Mel	MDD-27
90900	\N	\N	959	2472	\N	959 Mel	MDD-89
90901	\N	\N	3218	1820	\N	3218 Tumor	DPN_5_Tumor_NA
90902	\N	\N	1321	1850	\N	1321 Tumor	Fusion-05
90903	\N	\N	3004	931	\N	3004 Tumor	CGH11_035_NA
90904	\N	\N	3021	949	\N	3021 Tumor	CGH11-035_NA
90905	\N	\N	460	3924	\N	460 Spitz mel	SMPR56
90906	\N	\N	2939	854	\N	2939 Tumor	BB008_CGH11-036_NA
90907	\N	\N	1336	950	\N	1336 Tumor	CGH11-045_NA
90908	\N	\N	2960	875	\N	2960 Tumor	BB09_CGH11_045_NA
90909	\N	\N	3394	3238	\N	3394 Tumor	N3_12_NA
90910	\N	\N	3440	4549	\N	3440 Unknown	CGH11-051
90911	\N	\N	617	955	\N	617 Tumor	CGH11-098-D
90912	\N	\N	2154	4605	\N	2154 Capture Area A1	VS-01_NA
90913	\N	\N	3005	932	\N	3005 Tumor	CGH11_60_NA
90914	\N	\N	3022	951	\N	3022 Tumor	CGH11-072_NA
90915	\N	\N	473	909	\N	473 cellular blue nevus	BND-011
90916	\N	\N	2253	2614	\N	2253 Tumor	MM-3
90917	\N	\N	3024	953	\N	3024 Tumor	CGH11-089_NA
90918	\N	\N	3006	933	\N	3006 Tumor	CGH11_078_NA
90919	\N	\N	3023	952	\N	3023 Tumor	CGH11-087_NA
90920	\N	\N	3090	1210	\N	3090 Tumor	CNS_50_Tumor_NA
90921	\N	\N	2768	936	\N	2768 Tumor	CGH11_109_NA
90922	\N	\N	3008	935	\N	3008 Tumor	CGH11_091_NA
90923	\N	\N	3007	934	\N	3007 Tumor	CGH11_080_NA
90924	\N	\N	2919	31	\N	2919 Mel	24-1_NA
90925	\N	\N	2920	32	\N	2920 Mel	24-2_NA
90926	\N	\N	2921	33	\N	2921 Nevus	24-3_NA
90927	\N	\N	2922	34	\N	2922 Nevus	24-4_NA
90928	\N	\N	2150	35	\N	2150 Normal	24-5_NA
90929	\N	\N	2090	1211	\N	2090 Normal	D-NA-536
90930	\N	\N	2091	1212	\N	2091 Nevus	D-NA-537
90931	\N	\N	2092	1213	\N	2092 Mel	D-NA-538
90932	\N	\N	2763	35	\N	2763 Normal	24-5_NA
90933	\N	\N	1324	1853	\N	1324 Tumor	Fusion-09
90934	\N	\N	1337	954	\N	1337 Tumor	CGH11-092
90935	\N	\N	2961	876	\N	2961 Tumor	BB09_CGH11_092_NA
90936	\N	\N	3395	3239	\N	3395 Tumor	N3_13_NA
90937	\N	\N	3025	956	\N	3025 Tumor	CGH11-115_NA
90938	\N	\N	3216	1817	\N	3216 Tumor	DPN_3_Tumor_NA
90939	\N	\N	659	2411	\N	659 Mel	MDD-28
90940	\N	\N	961	2474	\N	961 Mel	MDD-91
90941	\N	\N	3217	1818	\N	3217 Tumor	DPN_4_Tumor_NA
90818	\N	\N	1511	377	\N	1511 Intestine Met 2	AM2 D-289
90819	\N	\N	1512	377	\N	1512 Met3	AM2 D-289
90820	\N	\N	1509	375	\N	1509 Met1	AM2 D-287
90821	\N	\N	1508	374	\N	1508 MIS1	AM2 D-286
90822	\N	\N	1502	369	\N	1502 Mel1	AM2 D-280
90823	\N	\N	1513	378	\N	1513 Brain Met 4	AM2 D-291
90824	\N	\N	1514	378	\N	1514 Met5	AM2 D-291
90825	\N	\N	1507	370	\N	1507 Normal	AM2 D-281
90826	\N	\N	1503	370	\N	1503 Normal	AM2 D-281
90827	\N	\N	1504	371	\N	1504 Met1	AM2 D-282
90831	\N	\N	1736	2758	\N	1736 Mel	MMD-143
90832	\N	\N	1737	2759	\N	1737 MIS	MMD-144
90836	\N	\N	1739	2760	\N	1739 Normal	MMD-145
90837	\N	\N	1740	2762	\N	1740 Normal	MMD-147
90843	\N	\N	1505	372	\N	1505 Met2	AM2 D-283
90844	\N	\N	1506	373	\N	1506 Met3	AM2 D-284
90851	\N	\N	1846	2950	\N	1846 Mel	MMD-335
90866	\N	\N	2766	1919	\N	2766 Tumor	Ivanka_23_1_NA
90893	\N	\N	2302	3498	\N	2302 Invasive 1	PROG D-20
90894	\N	\N	1428	3484	\N	1428 MIS1	PROG D-06
90895	\N	\N	1429	3485	\N	1429 Invasive 1	PROG D-07
90896	\N	\N	1435	3486	\N	1435 Invasive 2	PROG D-08
90897	\N	\N	1436	3487	\N	1436 Invasive 3	PROG D-09
90898	\N	\N	1437	3488	\N	1437 Invasive 4	PROG D-10
90947	\N	\N	3031	962	\N	3031 Tumor	CGH11-194_NA
90948	\N	\N	3397	3241	\N	3397 Tumor	N3_15_NA
90949	\N	\N	3086	1206	\N	3086 Tumor	CNS_43_Tumor_NA
90950	\N	\N	3027	958	\N	3027 Tumor	CGH11-158_NA
90951	\N	\N	2940	855	\N	2940 Tumor	BB008_CGH11-153_NA
90953	\N	\N	3026	957	\N	3026 Tumor	CGH11-147_NA
90963	\N	\N	2923	39	\N	2923 Mel	D28-1_NA
90964	\N	\N	2924	40	\N	2924 Mel	D28-2_NA
90965	\N	\N	2927	43	\N	2927 Normal	28-5_NA
90966	\N	\N	2926	42	\N	2926 Nevus	28-4_NA
90967	\N	\N	2925	41	\N	2925 Nevus	D28-3_NA
90968	\N	\N	2059	1248	\N	2059 Nevus	D-NA-621
90969	\N	\N	2058	1247	\N	2058 Normal	D-NA-620
90970	\N	\N	2060	1249	\N	2060 Mel1	D-NA-622
90971	\N	\N	2061	1250	\N	2061 Mel2	D-NA-623
90972	\N	\N	2777	1819	\N	2777 Normal	DPN_5_Normal_NA
90973	\N	\N	3028	959	\N	3028 Tumor	CGH11-166_NA
90974	\N	\N	3084	1204	\N	3084 Tumor	CNS_41_Tumor_NA
90975	\N	\N	3029	960	\N	3029 Tumor	CGH11-172_NA
90976	\N	\N	3030	961	\N	3030 Tumor	CGH11-184_NA
90977	\N	\N	474	910	\N	474 cellular blue nevus	BND-012
90978	\N	\N	2811	4190	\N	2811 Tumor	WTMM-23-Tumor_NA
90979	\N	\N	3398	3242	\N	3398 Tumor	N3_16_NA
90980	\N	\N	469	905	\N	469 cellular blue nevus	BND-007
90981	\N	\N	1959	3346	\N	1959 Typical Melanotic Macule	OM D-30
90983	\N	\N	3033	964	\N	3033 Tumor	CGH11-229_NA
90984	\N	\N	3032	963	\N	3032 Tumor	CGH11-224_NA
90985	\N	\N	3034	965	\N	3034 Tumor	CGH11-231_NA
90986	\N	\N	3035	966	\N	3035 Tumor	CGH11-232_NA
90987	\N	\N	425	3871	\N	425 Blue + spitz	SM D-02
90988	\N	\N	3036	967	\N	3036 Tumor	CGH11-237_NA
90989	\N	\N	3038	969	\N	3038 Tumor	CGH11-259_NA
90990	\N	\N	470	906	\N	470 cellular blue nevus	BND-008
90991	\N	\N	3009	937	\N	3009 Tumor	CGH11_252_NA
90992	\N	\N	3037	968	\N	3037 Tumor	CGH11-252_NA
90993	\N	\N	1323	1852	\N	1323 Tumor	Fusion-08
90994	\N	\N	3441	4550	\N	3441 Unknown	CGH11-275
90995	\N	\N	3011	939	\N	3011 Tumor	CGH11_283_NA
90996	\N	\N	1338	970	\N	1338 Tumor	CGH11-268
90997	\N	\N	3012	940	\N	3012 Tumor	CGH11_292_NA
90998	\N	\N	1339	971	\N	1339 Tumor	CGH11-282
90999	\N	\N	3014	942	\N	3014 Tumor	CGH11_310_NA
91000	\N	\N	3010	938	\N	3010 Tumor	CGH11_281_NA
91001	\N	\N	1340	972	\N	1340 Tumor	CGH11-294
91002	\N	\N	3039	973	\N	3039 Tumor	CGH11-315_NA
91003	\N	\N	3215	1816	\N	3215 Tumor	DPN_1_Tumor_NA
91004	\N	\N	3013	941	\N	3013 Tumor	CGH11_305_NA
91005	\N	\N	3231	1837	\N	3231 Tumor	DPN_CNN 30_NA
91006	\N	\N	3232	1838	\N	3232 Normal	DPN_CNN 32_NA
91007	\N	\N	3015	943	\N	3015 Tumor	CGH11_319_NA
91008	\N	\N	3017	945	\N	3017 Tumor	CGH11_348_NA
91009	\N	\N	3040	974	\N	3040 Tumor	CGH11-339_NA
91010	\N	\N	2988	915	\N	2988 Tumor	CGH_11_361_NA
91011	\N	\N	3016	944	\N	3016 Tumor	CGH11_343_NA
91014	\N	\N	2989	916	\N	2989 Tumor	CGH_11_366_NA
91015	\N	\N	3806	1909	\N	3806 Mel	Ivanka_20_1_NA
91016	\N	\N	3807	1910	\N	3807 Mel	Ivanka_20_2_NA
91017	\N	\N	3808	1911	\N	3808 Nevus	Ivanka_20_3_NA
91018	\N	\N	3810	1913	\N	3810 Normal	Ivanka_20_5_NA
91019	\N	\N	3809	1912	\N	3809 Nevus	Ivanka_20_4_NA
91020	\N	\N	2991	918	\N	2991 Tumor	CGH_11_388_NA
91021	\N	\N	1341	975	\N	1341 Tumor	CGH11-386_DNA
91022	\N	\N	2941	856	\N	2941 Tumor	BB008_CGH11-386_NA
91023	\N	\N	471	907	\N	471 cellular blue nevus	BND-009
91024	\N	\N	2990	917	\N	2990 Tumor	CGH_11_376_NA
91025	\N	\N	3018	946	\N	3018 Tumor	CGH11_410_NA
91026	\N	\N	2992	919	\N	2992 Tumor	CGH_11_422_NA
91027	\N	\N	1342	976	\N	1342 Tumor	CGH11-399
91028	\N	\N	3042	979	\N	3042 Tumor	CGH11-409_NA
91029	\N	\N	3442	4551	\N	3442 Tumor	CHG11-409_NA
91030	\N	\N	1343	977	\N	1343 Tumor	CGH11-402
91031	\N	\N	3069	1104	\N	3069 Tumor	CHG11-402_NA
91032	\N	\N	3041	978	\N	3041 Tumor	CGH11-404_NA
91036	\N	\N	3019	947	\N	3019 Tumor	CGH11_424_NA
91037	\N	\N	2062	1241	\N	2062 Normal	D-NA-585
91038	\N	\N	2063	1242	\N	2063 Nevus	D-NA-586
91039	\N	\N	2064	1243	\N	2064 Mel	D-NA-587
91040	\N	\N	2993	920	\N	2993 Tumor	CGH_12_016_NA
91041	\N	\N	2778	1822	\N	2778 Tumor	DPN_7_Tumor_NA
91042	\N	\N	3355	2012	\N	3355 Normal	L11_96096_A2_Norm_NA
91043	\N	\N	568	3273	\N	568 Nodular Mel	NM D-18
91044	\N	\N	567	3272	\N	567 Nodular Mel	NM D-17
91045	\N	\N	3427	3856	\N	3427 Tumor	S12_20321_A2_Tumor_NA
91046	\N	\N	1141	1983	\N	1141 Tumor	KIT-08
91047	\N	\N	1142	1984	\N	1142 Tumor	KIT-09
91048	\N	\N	1143	1985	\N	1143 Tumor	KIT-10
91049	\N	\N	1144	1986	\N	1144 Tumor	KIT-11
91050	\N	\N	1329	1987	\N	1329 Tumor	KIT-12
91051	\N	\N	2405	7	\N	2405 Unknown	D13_NA
91053	\N	\N	620	991	\N	620 Nevus?	CGH12-039-D
91054	\N	\N	2322	981	\N	2322 Tumor	CGH12_039_NA
91055	\N	\N	3043	980	\N	3043 Tumor	CGH12_026_NA
91060	\N	\N	1315	1848	\N	1315 Tumor	Fusion-01
91061	\N	\N	3045	982	\N	3045 Tumor	CGH12_040_NA
91062	\N	\N	2835	81	\N	2835 Normal	D76_NA
91063	\N	\N	2817	1925	\N	2817 Met1	K1_14
91064	\N	\N	2818	1926	\N	2818 Met2	K1_15
91065	\N	\N	2819	1924	\N	2819 Met2	K1_13
91066	\N	\N	2814	1938	\N	2814 Tumor	K2_5
91067	\N	\N	918	2431	\N	918 Mel	MDD-48
91068	\N	\N	660	2412	\N	660 Mel	MDD-29
91069	\N	\N	962	2475	\N	962 Mel	MDD-92
90954	\N	\N	1494	361	\N	1494 Mel1	AM2 D-272
90955	\N	\N	1495	362	\N	1495 Mel2	AM2 D-273
90956	\N	\N	1496	363	\N	1496 Mel3	AM2 D-274
90957	\N	\N	1497	364	\N	1497 Normal	AM2 D-275
90958	\N	\N	1498	365	\N	1498 MIS	AM2 D-276
90959	\N	\N	1500	367	\N	1500 Met2	AM2 D-278
90960	\N	\N	1499	366	\N	1499 LN Met 1	AM2 D-277
90961	\N	\N	1501	368	\N	1501 Met3	AM2 D-279
90962	\N	\N	1733	3066	\N	1733 Mel	MMR-140
91012	\N	\N	1731	2753	\N	1731 Mel	MMD-136
91013	\N	\N	1732	2754	\N	1732 Normal	MMD-137
91033	\N	\N	2036	1655	\N	2036 Normal	DNA-259
91056	\N	\N	1438	3489	\N	1438 Normal	PROG D-11
91057	\N	\N	1439	3490	\N	1439 Invasive 5	PROG D-12
91058	\N	\N	1440	3491	\N	1440 Invasive 6	PROG D-13
91072	\N	\N	3085	1205	\N	3085 Tumor	CNS_42_Tumor_NA
91073	\N	\N	466	902	\N	466 cellular blue nevus	BND-004
91074	\N	\N	2942	857	\N	2942 Tumor	BB008_CGH12-047_NA
91075	\N	\N	3088	1208	\N	3088 Tumor	CNS_48_Tumor_NA
91076	\N	\N	3054	992	\N	3054 Tumor	CGH12-043_NA
91077	\N	\N	3046	983	\N	3046 Tumor	CGH12_053_NA
91078	\N	\N	1344	993	\N	1344 Tumor	CGH12-055
91079	\N	\N	2834	1929	\N	2834 Met	K1_18
91080	\N	\N	2831	1927	\N	2831 Normal	K1_16
91081	\N	\N	2832	1928	\N	2832 MM	K1_17
91082	\N	\N	2833	1928	\N	2833 MM	K1_17
91083	\N	\N	619	994	\N	619 Nevus?	CGH12-056-D
91084	\N	\N	2321	984	\N	2321 Tumor	CGH12_056_NA
91085	\N	\N	997	995	\N	997 Tumor	CGH12-058
91086	\N	\N	1322	1851	\N	1322 Tumor	Fusion-06
91087	\N	\N	2250	1855	\N	2250 Tumor	Fusion-11
91088	\N	\N	2328	985	\N	2328 Tumor	CGH12_058_NA
91089	\N	\N	2776	94	\N	2776 Tumor	AM_9_Tumor_NA
91090	\N	\N	661	2413	\N	661 Mel	MDD-30
91091	\N	\N	2402	3	\N	2402 SCC	D6_NA
91092	\N	\N	2403	4	\N	2403 Melanocytic Nevus	D7_NA
91093	\N	\N	2404	5	\N	2404 BCC	D11_NA
91094	\N	\N	2407	9	\N	2407 Cellular Dermatofibroma 	D20_NA
91095	\N	\N	2406	8	\N	2406 Melanocytic Nevus	D15_NA
91096	\N	\N	2096	1220	\N	2096 Normal	D-NA-545
91097	\N	\N	2097	1221	\N	2097 Nevus	D-NA-546
91098	\N	\N	2098	1222	\N	2098 Mel	D-NA-547
91099	\N	\N	2411	38	\N	2411 SCC	28_NA
91100	\N	\N	2410	37	\N	2410 Melanocytic Nevus	27_NA
91101	\N	\N	2408	29	\N	2408 SCC	23_NA
91102	\N	\N	2421	55	\N	2421 SCC	D44_NA
91103	\N	\N	2422	56	\N	2422 SCC	D45_NA
91104	\N	\N	2423	57	\N	2423 SCC	D46_NA
91105	\N	\N	3307	1944	\N	3307 Tumor	K2_11_NA
91106	\N	\N	477	3243	\N	477 nevus or nevus like	NLD-013
91107	\N	\N	446	3892	\N	446 DPN+ pure	SM D-23
91108	\N	\N	2409	30	\N	2409 SCC+ in situ	24_NA
91109	\N	\N	2935	91	\N	2935 Tumor	Algazi_Tumor_NA
91110	\N	\N	2764	36	\N	2764 Tumor	26_NA
91111	\N	\N	2413	45	\N	2413 Dermatofibroma	D31_NA
91112	\N	\N	2412	44	\N	2412 SCC+ in situ	D29_NA
91113	\N	\N	467	903	\N	467 cellular blue nevus	BND-005
91114	\N	\N	2416	49	\N	2416 Dermatofibroma	38_NA
91116	\N	\N	2099	1223	\N	2099 Normal	D-NA-548
91117	\N	\N	2100	1224	\N	2100 Nevus	D-NA-549
91118	\N	\N	2101	1225	\N	2101 Mel	D-NA-550
91119	\N	\N	2414	47	\N	2414 Normal	D35_NA
91120	\N	\N	2415	48	\N	2415 SCC+ in situ	D36_NA
91121	\N	\N	2426	59	\N	2426 Melanocytic Nevus	D48_NA
91122	\N	\N	2427	61	\N	2427 Melanocytic Nevus	D49_NA
91124	\N	\N	2428	62	\N	2428 Melanocytic Nevus	D51_NA
91125	\N	\N	2429	63	\N	2429 Keratosis	D55_NA
91127	\N	\N	2431	65	\N	2431 Melanocytic Nevus	D58_NA
91128	\N	\N	2432	66	\N	2432 Melanocytic Nevus	D59_NA
91129	\N	\N	2433	67	\N	2433 Pilomatricoma+ cystic	D60_NA
91130	\N	\N	2434	68	\N	2434 BCC	D61_NA
91131	\N	\N	2435	69	\N	2435 Leiomyoma	D62_NA
91132	\N	\N	2424	54	\N	2424 SCC	D43_NA_SCC
91133	\N	\N	2419	52	\N	2419 Normal	D41_NA
91134	\N	\N	2425	58	\N	2425 Mel	D47_NA
91135	\N	\N	2436	70	\N	2436 Melanocytic Nevus	D64_NA
91136	\N	\N	2437	71	\N	2437 Melanocytic Nevus	D65_NA
91137	\N	\N	2438	72	\N	2438 Melanocytic Nevus	D66_NA
91138	\N	\N	2439	73	\N	2439 Melanocytic Nevus	D67_NA
91139	\N	\N	2440	74	\N	2440 Melanocytic Nevus	D68_NA
91140	\N	\N	2441	75	\N	2441 Melanocytic Nevus	D70_NA
91141	\N	\N	2442	76	\N	2442 SCC	D71_NA
91142	\N	\N	2418	51	\N	2418 Tumor	D40_NA
91143	\N	\N	2417	50	\N	2417 Normal	D39_NA
91144	\N	\N	3055	998	\N	3055 Tumor	CGH12-104_NA
91145	\N	\N	455	3919	\N	455 Spitz mel	SMPR11
91149	\N	\N	621	997	\N	621 Nevus?	CGH12-092-D
91153	\N	\N	490	999	\N	490 nevus or nevus like	CGH12-109
91154	\N	\N	3056	1000	\N	3056 Tumor	CGH12-124_NA
91155	\N	\N	3049	986	\N	3049 Tumor	CGH12_135_NA
91156	\N	\N	468	904	\N	468 cellular blue nevus	BND-006
91157	\N	\N	463	899	\N	463 cellular blue nevus	BND-001
91158	\N	\N	3050	987	\N	3050 Tumor	CGH12_161_NA
91160	\N	\N	1345	1001	\N	1345 Tumor	CGH12-191
91161	\N	\N	880	1813	\N	880 DPN-mm	DNPD-08
91162	\N	\N	881	1812	\N	881 MM	DNPD-07
91163	\N	\N	429	3875	\N	429 common + blue	SM D-06
91164	\N	\N	464	900	\N	464 cellular blue nevus	BND-002
91165	\N	\N	3091	1264	\N	3091 Normal	D12_54296_Norm_NA
91166	\N	\N	3092	1265	\N	3092 Tumor	D12_54296_Tumor_NA
91167	\N	\N	3093	1266	\N	3093 Normal	D12_54992_Norm_NA
91168	\N	\N	3094	1267	\N	3094 Tumor	D12_54992_Tumor_NA
91169	\N	\N	3051	988	\N	3051 Tumor	CGH12_224_NA
91170	\N	\N	2106	1252	\N	2106 Nevus	D-NA-625
91171	\N	\N	2107	1253	\N	2107 Mel1	D-NA-626
91172	\N	\N	2108	1254	\N	2108 Mel2	D-NA-627
91173	\N	\N	2105	1251	\N	2105 Normal	D-NA-624
91175	\N	\N	1346	1002	\N	1346 Tumor	CGH12-273
91176	\N	\N	491	1003	\N	491 nevus or nevus like	CGH12-280
91177	\N	\N	3095	1268	\N	3095 Normal	D12_67298_Norm_NA
91178	\N	\N	3096	1269	\N	3096 Tumor	D12_67298_Tumor_NA
91179	\N	\N	2093	1214	\N	2093 Normal	D-NA-539
91180	\N	\N	2094	1215	\N	2094 Nevus	D-NA-540
91181	\N	\N	2095	1216	\N	2095 Mel	D-NA-541
91182	\N	\N	998	1004	\N	998 Tumor	CGH12-301
91183	\N	\N	3052	989	\N	3052 Tumor	CGH12_317_NA
91184	\N	\N	2102	1217	\N	2102 Normal	D-NA-542
91185	\N	\N	2103	1218	\N	2103 Nevus	D-NA-543
91186	\N	\N	2104	1219	\N	2104 Mel	D-NA-544
91187	\N	\N	3070	1105	\N	3070 Tumor	CHG12-335_NA
91188	\N	\N	3053	990	\N	3053 Tumor	CGH12_343_NA
91189	\N	\N	3057	1005	\N	3057 Tumor	CGH12-345_NA
91190	\N	\N	3058	1006	\N	3058 Tumor	CGH12-347_NA
91192	\N	\N	457	3921	\N	457 Spitz mel	SMPR20
91193	\N	\N	2065	1244	\N	2065 Normal	D-NA-588
91194	\N	\N	2066	1245	\N	2066 Nevus	D-NA-589
91195	\N	\N	2067	1246	\N	2067 Mel	D-NA-590
91196	\N	\N	3059	1007	\N	3059 Tumor	CGH13-003_NA
91197	\N	\N	465	901	\N	465 cellular blue nevus	BND-003
91198	\N	\N	2812	4191	\N	2812 Tumor	WTMM-24-Tumor_NA
91199	\N	\N	3060	1008	\N	3060 Tumor	CGH13-009_NA
91146	\N	\N	1490	357	\N	1490 Normal	AM2 D-268
91147	\N	\N	1491	358	\N	1491 Mel1	AM2 D-269
91148	\N	\N	1492	359	\N	1492 Mel2	AM2 D-270
91150	\N	\N	1493	360	\N	1493 Lung Met 1	AM2 D-271
91191	\N	\N	1628	2623	\N	1628 Mel	MMD-03
91210	\N	\N	2068	1255	\N	2068 Normal	D-NA-628
91211	\N	\N	2069	1256	\N	2069 Nevus	D-NA-629
91212	\N	\N	2070	1257	\N	2070 AMB	D-NA-630
91213	\N	\N	2071	1258	\N	2071 Mel	D-NA-631
91214	\N	\N	3234	1840	\N	3234 Tumor	DPN_MM 20_NA
91215	\N	\N	3063	1011	\N	3063 Tumor	CGH13-034_NA
91216	\N	\N	3062	1010	\N	3062 Tumor	CGH13-033_NA
91217	\N	\N	3064	1012	\N	3064 Tumor	CGH13-041_NA
91218	\N	\N	3065	1013	\N	3065 Tumor	CGH13-044_NA
91219	\N	\N	3066	1014	\N	3066 Tumor	CGH13-046_NA
91220	\N	\N	2816	1940	\N	2816 Tumor	K2_7
91221	\N	\N	3067	1015	\N	3067 Tumor	CGH13-058_NA
91222	\N	\N	3382	3222	\N	3382 Tumor	MS_1_Tumor_NA
91223	\N	\N	2852	4562	\N	2852 Tumor	NGS 1-6_NA
91224	\N	\N	2810	4189	\N	2810 Tumor	WTMM-22-Tumor_NA
91225	\N	\N	2726	4515	\N	2726 Tumor	KAM128-T
91233	\N	\N	2678	4460	\N	2678 Normal	MucM D-015
91234	\N	\N	2725	4514	\N	2725 Tumor	KAM127-T
91235	\N	\N	2724	4513	\N	2724 Normal	KAM127-N
91242	\N	\N	662	2414	\N	662 Mel	MDD-31
91243	\N	\N	960	2473	\N	960 Mel	MDD-90
91244	\N	\N	631	2424	\N	631 Mel	MDD-41
91245	\N	\N	3377	2607	\N	3377 Nevus	MIN_2_NA
91246	\N	\N	3376	2606	\N	3376 Mel	MIN_1_NA
91247	\N	\N	3378	2608	\N	3378 Normal	MIN_3_NA
91248	\N	\N	663	2415	\N	663 Mel	MDD-32
91249	\N	\N	963	2476	\N	963 Mel	MDD-93
91253	\N	\N	1347	1016	\N	1347 Tumor	CGH13-159
91255	\N	\N	1690	2705	\N	1690 Normal	MMD-87
91259	\N	\N	2809	4188	\N	2809 Tumor	WTMM-21-Tumor_NA
91261	\N	\N	2805	4184	\N	2805 Tumor	WTMM-17-Tumor_NA
91263	\N	\N	3380	2610	\N	3380 Nevus	MIN_5_NA
91264	\N	\N	3379	2609	\N	3379 Mel	MIN_4_NA
91265	\N	\N	3381	2611	\N	3381 Normal	MIN_6_NA
91267	\N	\N	3235	1841	\N	3235 Tumor	DPN_MM 21_NA
91269	\N	\N	3236	1842	\N	3236 Tumor	DPN_MM 22_NA
91270	\N	\N	1963	3350	\N	1963 Typical Melanotic Macule	OM D-33A
91272	\N	\N	1981	3369	\N	1981 Typical Melanotic Macule	OM D-49
91273	\N	\N	3230	1836	\N	3230 Tumor	DPN_35_NA
91274	\N	\N	3233	1839	\N	3233 Tumor	DPN_Conv_35_NA
91278	\N	\N	3403	3420	\N	3403 Unknown	OM-4D (P040_09C)
91279	\N	\N	3404	3423	\N	3404 Unknown	OM-4R (P040_05C)
91281	\N	\N	1348	1017	\N	1348 Tumor	CGH13-321
91282	\N	\N	1349	1018	\N	1349 Tumor	CGH13-340
91284	\N	\N	2808	4187	\N	2808 Tumor	WTMM-20-Tumor_NA
91285	\N	\N	2072	1226	\N	2072 Normal	D-NA-551
91286	\N	\N	2073	1227	\N	2073 Nevus	D-NA-552
91287	\N	\N	2074	1228	\N	2074 Mel	D-NA-553
91288	\N	\N	2807	4186	\N	2807 Tumor	WTMM-19-Tumor_NA
91289	\N	\N	2806	4185	\N	2806 Tumor	WTMM-18-Tumor_NA
91290	\N	\N	456	3920	\N	456 Spitz mel	SMPR12
91292	\N	\N	3405	3424	\N	3405 Unknown	OM-5D (P040_09D)
91293	\N	\N	3406	3427	\N	3406 Unknown	OM-5R (P040_05D)
91294	\N	\N	566	3271	\N	566 Nodular Mel	NM D-16
91295	\N	\N	1328	1976	\N	1328 Tumor	KIT-01
91296	\N	\N	2727	4516	\N	2727 Tumor	KAM130-T
91297	\N	\N	2005	3392	\N	2005 Typical Melanotic Macule	OM D-67
91299	\N	\N	664	2416	\N	664 Mel	MDD-33
91301	\N	\N	964	2477	\N	964 Mel	MDD-94
91302	\N	\N	2006	3393	\N	2006 Typical Melanotic Macule	OM D-68.1
91303	\N	\N	2007	3394	\N	2007 Atypical Melanocytic Proliferation	OM D-68.2
91304	\N	\N	2008	3395	\N	2008 Atypical Melanocytic Proliferation	OM D-68.3
91305	\N	\N	2728	4517	\N	2728 Normal	KAM131-N
91306	\N	\N	2729	4518	\N	2729 Tumor	KAM131-T
91308	\N	\N	1350	1019	\N	1350 Tumor	CGH14-032
91309	\N	\N	2683	4462	\N	2683 Normal	MucM D-020
91312	\N	\N	2682	4461	\N	2682 Normal	MucM D-019
91315	\N	\N	999	1020	\N	999 Tumor	CGH14-050
91316	\N	\N	3068	1021	\N	3068 Tumor	CGH14-059_NA
91317	\N	\N	965	2478	\N	965 Mel	MDD-95
91318	\N	\N	622	1022	\N	622 Nevus?	CGH14-083-D
91226	\N	\N	1961	3348	\N	1961 Typical Melanotic Macule	OM D-32
91228	\N	\N	1678	2688	\N	1678 Mel	MMD-70
91229	\N	\N	1679	2689	\N	1679 Normal	MMD-71
91237	\N	\N	1529	389	\N	1529 Mel1	AM2 D-308
91238	\N	\N	1530	390	\N	1530 Mel2	AM2 D-309
91239	\N	\N	1532	392	\N	1532 Mel4	AM2 D-311
91240	\N	\N	1531	391	\N	1531 Mel3	AM2 D-310
91241	\N	\N	1533	393	\N	1533 MIS1	AM2 D-312
91250	\N	\N	1470	346	\N	1470 Normal	AM2 D-256
91251	\N	\N	1471	347	\N	1471 Mel1	AM2 D-257
91252	\N	\N	1472	348	\N	1472 MIS1	AM2 D-258
91254	\N	\N	1689	2704	\N	1689 Mel	MMD-86
91256	\N	\N	1691	2704	\N	1691 Mel	MMD-86
91257	\N	\N	1692	2706	\N	1692 MIS	MMD-88
91266	\N	\N	2712	4479	\N	2712 Tumor	AM-30-Tumor
91271	\N	\N	1962	3349	\N	1962 Typical Melanotic Macule	OM D-33
91275	\N	\N	2699	4466	\N	2699 Tumor	AM-17-Tumor
91276	\N	\N	2714	4481	\N	2714 Tumor	AM-32-Tumor
91277	\N	\N	2030	3421	\N	2030 Atypical Melanocytic Proliferation	OM-4D-2
91280	\N	\N	2713	4480	\N	2713 Tumor	AM-31-Tumor
91283	\N	\N	2708	4475	\N	2708 Tumor	AM-26-Tumor
91291	\N	\N	2031	3425	\N	2031 Atypical Melanocytic Proliferation	OM-5D-2
91300	\N	\N	2701	4468	\N	2701 Tumor	AM-19-Tumor
91313	\N	\N	2700	4467	\N	2700 Tumor	AM-18-Tumor
91314	\N	\N	1965	3352	\N	1965 Typical Melanotic Macule	OM D-35
91320	\N	\N	1473	349	\N	1473 Recurrence 1	AM2 D-259
91321	\N	\N	1624	526	\N	1624 Normal	AM2 D-467
91322	\N	\N	2702	4469	\N	2702 Tumor	AM-20-Tumor
91343	\N	\N	2126	1686	\N	2126 Normal	DNA-290
91350	\N	\N	1353	1027	\N	1353 Tumor	CGH14-181
91351	\N	\N	3858	4629	\N	3858 Mel	Rob-T001-Mel_NA
91352	\N	\N	3859	4630	\N	3859 Normal	Rob-T001-Normal_NA
91355	\N	\N	2867	4637	\N	2867 Nevus	Rob-T009-Nev_NA
91356	\N	\N	2868	4638	\N	2868 Normal	Rob-T009-Normal_NA
91357	\N	\N	2869	4639	\N	2869 Nevus	Rob-T010-Nev_NA
91358	\N	\N	2870	4640	\N	2870 Normal	Rob-T010-Normal_NA
91359	\N	\N	2861	4633	\N	2861 Nevus	Rob-T005-Nev_NA
91360	\N	\N	2862	4634	\N	2862 Normal	Rob-T005-Normal_NA
91361	\N	\N	454	3918	\N	454 Spitz mel	SMPR4
91362	\N	\N	3864	4617	\N	3864 Tumor	DPN54-Tumor_NA
91364	\N	\N	2825	4632	\N	2825 Normal	Rob-T003-Normal_NA
91365	\N	\N	2860	4631	\N	2860 Mel	Rob-T003-Mel_NA
91366	\N	\N	2865	4635	\N	2865 Nevus	Rob-T008-Nev_NA
91367	\N	\N	2866	4636	\N	2866 Normal	Rob-T008-Normal_NA
91368	\N	\N	3866	4619	\N	3866 Tumor	DPN56-Tumor_NA
91369	\N	\N	2075	1229	\N	2075 Normal	D-NA-554
91370	\N	\N	2076	1230	\N	2076 Nevus	D-NA-555
91371	\N	\N	2077	1231	\N	2077 Mel	D-NA-556
91374	\N	\N	2084	1235	\N	2084 Normal	D-NA-560
91375	\N	\N	2085	1236	\N	2085 Nevus	D-NA-561
91376	\N	\N	2086	1237	\N	2086 Mel	D-NA-562
91381	\N	\N	3862	4615	\N	3862 Tumor	DPN52-Tumor_NA
91385	\N	\N	3863	4616	\N	3863 Tumor	DPN53-Tumor_NA
91386	\N	\N	1355	1029	\N	1355 Tumor	CGH14-293
91388	\N	\N	1354	1028	\N	1354 Tumor	CGH14-286
91390	\N	\N	623	1031	\N	623 Nevus?	CGH14-341-D
91391	\N	\N	3861	4614	\N	3861 Tumor	DPN51-Tumor_NA
91392	\N	\N	1356	1030	\N	1356 Tumor	CGH14-328
91393	\N	\N	493	1032	\N	493 nevus or nevus like	CGH14-348
91394	\N	\N	3865	4618	\N	3865 Tumor	DPN55-Tumor_NA
91397	\N	\N	3860	4613	\N	3860 Tumor	DPN50-Tumor_NA
91398	\N	\N	3868	4621	\N	3868 Tumor	DPN58-Tumor_NA
91399	\N	\N	486	3252	\N	486 nevus or nevus like	NLD-022
91400	\N	\N	461	3925	\N	461 Spitz mel	SMPR58A
91401	\N	\N	462	3926	\N	462 Spitz mel	SMPR58B
91403	\N	\N	565	3270	\N	565 Nodular Mel	NM D-15
91404	\N	\N	558	3263	\N	558 Nodular Mel	NM D-08
91409	\N	\N	3409	3433	\N	3409 Unknown	OM-9D
91410	\N	\N	665	2417	\N	665 Mel	MDD-34
91417	\N	\N	1612	443	\N	1612 Normal	AM2 D-367
91428	\N	\N	3867	4620	\N	3867 Tumor	DPN57-Tumor_NA
91432	\N	\N	3870	4623	\N	3870 Tumor	DPN60-Tumor_NA
91434	\N	\N	1357	1033	\N	1357 Tumor	CGH15-043
91437	\N	\N	2160	4654	\N	2160 Normal	CGP-1553_NA
91438	\N	\N	2277	4656	\N	2277 Mel	CGP-1555_NA
91439	\N	\N	2278	4655	\N	2278 Nevus	CGP-1554_NA
91327	\N	\N	1534	394	\N	1534 Skin Met1	AM2 D-313
91328	\N	\N	1535	395	\N	1535 Normal	AM2 D-314
91329	\N	\N	1536	396	\N	1536 Skin Met2	AM2 D-316
91330	\N	\N	2703	4470	\N	2703 Tumor	AM-21-Tumor
91341	\N	\N	2125	1685	\N	2125 Nevus	DNA-289
91342	\N	\N	2124	1684	\N	2124 Mel	DNA-288
91344	\N	\N	1539	399	\N	1539 MIS1	AM2 D-319
91345	\N	\N	1540	400	\N	1540 MIS2	AM2 D-320
91346	\N	\N	1625	532	\N	1625 MIS2 In situ	AM2 D-474
91372	\N	\N	2704	4471	\N	2704 Tumor	AM-22-Tumor
91373	\N	\N	1964	3351	\N	1964 Typical Melanotic Macule	OM D-34
91377	\N	\N	2111	1671	\N	2111 Mel	DNA-275
91378	\N	\N	2112	1672	\N	2112 Nevus	DNA-276
91379	\N	\N	2113	1673	\N	2113 Normal	DNA-277
91380	\N	\N	2130	1709	\N	2130 Nevus	DNA-313
91382	\N	\N	2088	1239	\N	2088 Nevus	D-NA-564
91383	\N	\N	2087	1238	\N	2087 Normal	D-NA-563
91384	\N	\N	2089	1240	\N	2089 Mel	D-NA-565
91387	\N	\N	2705	4472	\N	2705 Tumor	AM-23-Tumor
91389	\N	\N	2710	4477	\N	2710 Tumor	AM-28-Tumor
91395	\N	\N	2706	4473	\N	2706 Tumor	AM-24-Tumor
91396	\N	\N	2697	4464	\N	2697 Tumor	AM-15-Tumor
91402	\N	\N	2709	4476	\N	2709 Tumor	AM-27-Tumor
91405	\N	\N	1544	404	\N	1544 LN Met 3	AM2 D-324
91406	\N	\N	1545	405	\N	1545 LN Met 4	AM2 D-325
91407	\N	\N	1546	406	\N	1546 LN Met5	AM2 D-326
91408	\N	\N	2032	3429	\N	2032 Atypical Melanocytic Proliferation	OM-6D-2
91411	\N	\N	2707	4474	\N	2707 Tumor	AM-25-Tumor
91412	\N	\N	1519	380	\N	1519 LN Met 1	AM2 D-294
91413	\N	\N	1515	379	\N	1515 Mel1	AM2 D-293
91414	\N	\N	1516	433	\N	1516 Mel2	AM2 D-355
91415	\N	\N	1517	434	\N	1517 Mel3	AM2 D-356
91416	\N	\N	1518	435	\N	1518 Mel4	AM2 D-357
91418	\N	\N	1521	382	\N	1521 Normal	AM2 D-296
91419	\N	\N	1522	383	\N	1522 Mel5	AM2 D-297
91420	\N	\N	1523	384	\N	1523 Normal	AM2 D-298
91421	\N	\N	1524	385	\N	1524 Mel1	AM2 D-299
91422	\N	\N	1525	386	\N	1525 MIS1	AM2 D-300
91423	\N	\N	1526	384	\N	1526 Normal	AM2 D-298
91424	\N	\N	1527	387	\N	1527 LN Met 1	AM2 D-303
91425	\N	\N	1528	388	\N	1528 LN Met 2	AM2 D-304
91461	\N	\N	2157	4608	\N	2157 Capture Area D1	VS-04_NA
91462	\N	\N	2158	4648	\N	2158 Normal	CGP-1544_NA
91463	\N	\N	2273	4650	\N	2273 Mel	CGP-1546_NA
91464	\N	\N	2274	4649	\N	2274 Nevus	CGP-1545_NA
91466	\N	\N	1359	1035	\N	1359 Tumor	CGH15-081
91473	\N	\N	618	2419	\N	618 Mel	MDD-36
91474	\N	\N	1361	1037	\N	1361 Tumor	CGH15-090
91477	\N	\N	1362	1039	\N	1362 Tumor	CGH15-115
91478	\N	\N	625	1038	\N	625 Nevus?	CGH15-109-D
91480	\N	\N	1983	3371	\N	1983 Typical Melanotic Macule	OM D-51
91482	\N	\N	2170	4645	\N	2170 Normal	CGP-1550_NA
91483	\N	\N	2271	4647	\N	2271 Mel	CGP-1552_NA
91484	\N	\N	2272	4646	\N	2272 Nevus	CGP-1551_NA
91489	\N	\N	2159	4651	\N	2159 Normal	CGP-1547_NA
91490	\N	\N	2275	4653	\N	2275 Mel	CGP-1549_NA
91491	\N	\N	2276	4652	\N	2276 Nevus	CGP-1548_NA
91492	\N	\N	1363	1040	\N	1363 Tumor	CGH15-139
91493	\N	\N	458	3922	\N	458 Spitz mel	SMPR48
91494	\N	\N	1364	1041	\N	1364 Tumor	CGH15-151
91495	\N	\N	1365	1042	\N	1365 Tumor	CGH15-163
91496	\N	\N	1366	1043	\N	1366 Tumor	CGH15-176
91497	\N	\N	430	3876	\N	430 common + blue	SM D-07
91498	\N	\N	1984	3372	\N	1984 Typical Melanotic Macule	OM D-52
91499	\N	\N	2161	4660	\N	2161 Normal	CGP-1559_NA
91500	\N	\N	2281	4662	\N	2281 Mel	CGP-1561_NA
91501	\N	\N	2282	4661	\N	2282 Nevus	CGP-1560_NA
91502	\N	\N	1982	3370	\N	1982 Typical Melanotic Macule	OM D-50
91503	\N	\N	1369	1046	\N	1369 Tumor	CGH15-211
91504	\N	\N	1367	1044	\N	1367 Tumor	CGH15-206
91505	\N	\N	1368	1045	\N	1368 Tumor	CGH15-210
91506	\N	\N	1985	3373	\N	1985 Typical Melanotic Macule	OM D-53
91507	\N	\N	2153	4642	\N	2153 Normal	CGP-1481_NA
91508	\N	\N	2285	4644	\N	2285 Mel	CGP-1483_NA
91509	\N	\N	2286	4643	\N	2286 Nevus	CGP-1482_NA
91511	\N	\N	1000	1048	\N	1000 Tumor	CGH15-249
91512	\N	\N	485	3251	\N	485 nevus or nevus like	NLD-021
91515	\N	\N	1370	1047	\N	1370 Tumor	CGH15-246
91516	\N	\N	1371	1049	\N	1371 Tumor	CGH15-253
91517	\N	\N	1372	1050	\N	1372 Tumor	CGH15-263
91518	\N	\N	437	3883	\N	437 common+ sclerotic dermal component 	SM D-14
91520	\N	\N	2009	3396	\N	2009 Typical Melanotic Macule	OM D-69
91521	\N	\N	1373	1051	\N	1373 Tumor	CGH16-002
91522	\N	\N	1552	412	\N	1552 Normal	AM2 D-332
91529	\N	\N	890	1495	\N	890 Blue Nevus	DNA-92
91530	\N	\N	1970	3357	\N	1970 Intramucosal Nevus	OM D-40.1
91531	\N	\N	2003	3358	\N	2003 Intramucosal Nevus	OM D-40.2
91541	\N	\N	1988	3376	\N	1988 Typical Melanotic Macule	OM D-56
91545	\N	\N	1569	427	\N	1569 Normal	AM2 D-349
91550	\N	\N	1375	1053	\N	1375 Tumor	CGH16-025
91553	\N	\N	165	4005	\N	165 DN	TPP 1_1
91554	\N	\N	1374	1052	\N	1374 Tumor	CGH16-023
91558	\N	\N	2183	1720	\N	2183 Normal	DNA-333
91448	\N	\N	1476	352	\N	1476 Mel2	AM2 D-262
91449	\N	\N	1475	351	\N	1475 Mel1	AM2 D-261
91450	\N	\N	1477	353	\N	1477 Mel3	AM2 D-263
91452	\N	\N	1478	354	\N	1478 Normal	AM2 D-264
91453	\N	\N	1479	355	\N	1479 LN Met 1	AM2 D-265
91454	\N	\N	1489	356	\N	1489 LN Met 2	AM2 D-266
91455	\N	\N	1520	381	\N	1520 Met2	AM2 D-295
91465	\N	\N	1610	486	\N	1610 Invasive Primary Mel	AM2 D-423
91467	\N	\N	1548	408	\N	1548 Mel1	AM2 D-328
91468	\N	\N	1547	407	\N	1547 Normal	AM2 D-327
91469	\N	\N	1549	409	\N	1549 Mel2	AM2 D-329
91470	\N	\N	1550	410	\N	1550 MIS1	AM2 D-330
91471	\N	\N	1474	350	\N	1474 Met1	AM2 D-260
91472	\N	\N	1966	3353	\N	1966 Typical Melanotic Macule	OM D-36
91479	\N	\N	1681	2691	\N	1681 Mel	MMD-73
91481	\N	\N	2698	4465	\N	2698 Tumor	AM-16-Tumor
91485	\N	\N	1541	401	\N	1541 Normal	AM2 D-321
91486	\N	\N	1542	402	\N	1542 Skin Met1	AM2 D-322
91510	\N	\N	1967	3354	\N	1967 Typical Melanotic Macule	OM D-37
91513	\N	\N	1968	3355	\N	1968 Typical Melanotic Macule	OM D-38
91514	\N	\N	1455	3931	\N	1455 Nevus	SND-05
91519	\N	\N	1969	3356	\N	1969 Typical Melanotic Macule	OM D-39
91523	\N	\N	1553	413	\N	1553 Mel1	AM2 D-333
91524	\N	\N	1554	414	\N	1554 Mel2	AM2 D-334
91525	\N	\N	1555	415	\N	1555 MIS1	AM2 D-335
91526	\N	\N	1556	416	\N	1556 MIS2	AM2 D-336
91527	\N	\N	1557	417	\N	1557 MIS3	AM2 D-337
91542	\N	\N	1537	397	\N	1537 Skin Met4	AM2 D-317
91544	\N	\N	1570	428	\N	1570 Mel1	AM2 D-350
91546	\N	\N	1571	429	\N	1571 Mel2	AM2 D-351
91547	\N	\N	1573	431	\N	1573 MIS2	AM2 D-353
91548	\N	\N	1572	430	\N	1572 MIS1	AM2 D-352
91549	\N	\N	1574	432	\N	1574 LN Met 1	AM2 D-354
91555	\N	\N	2180	1717	\N	2180 Mel1	DNA-330
91556	\N	\N	2181	1718	\N	2181 Mel2	DNA-331
91557	\N	\N	2182	1719	\N	2182 Nevus	DNA-332
91568	\N	\N	1385	1063	\N	1385 Tumor	CGH16-093
91569	\N	\N	1380	1058	\N	1380 Tumor	CGH16-054
91570	\N	\N	627	2420	\N	627 Mel	MDD-37
91571	\N	\N	1382	1060	\N	1382 Tumor	CGH16-071
91575	\N	\N	427	3873	\N	427 blue nevus+ cellular+  DF like	SM D-04
91576	\N	\N	1608	484	\N	1608 Normal	AM2 D-421
91580	\N	\N	2186	1723	\N	2186 Normal	DNA-336
91582	\N	\N	1989	3377	\N	1989 Mel	OM D-57
91583	\N	\N	1383	1061	\N	1383 Tumor	CGH16-087
91584	\N	\N	1387	1065	\N	1387 Tumor	CGH16-105
91585	\N	\N	1390	1068	\N	1390 Tumor	CGH16-130
91586	\N	\N	1384	1062	\N	1384 Tumor	CGH16-089
91587	\N	\N	1990	3378	\N	1990 Atypical Melanocytic Proliferation	OM D-58.1
91588	\N	\N	1991	3379	\N	1991 Atypical Melanocytic Proliferation	OM D-58.2
91589	\N	\N	2004	3380	\N	2004 Typical Melanotic Macule	OM D-58.3
91590	\N	\N	229	4069	\N	229 DN	TPP 2_38
91591	\N	\N	1986	3374	\N	1986 Typical Melanotic Macule	OM D-54
91594	\N	\N	1388	1066	\N	1388 Tumor	CGH16-117
91595	\N	\N	1987	3375	\N	1987 Typical Melanotic Macule	OM D-55
91596	\N	\N	1389	1067	\N	1389 Tumor	CGH16-123
91597	\N	\N	1391	1069	\N	1391 Tumor	CGH16-136
91600	\N	\N	1992	3381	\N	1992 Intramucosal Nevus	OM D-59
91601	\N	\N	1392	1070	\N	1392 Tumor	CGH16-172-2
91603	\N	\N	1393	1071	\N	1393 Tumor	CGH16-179
91604	\N	\N	494	1073	\N	494 nevus or nevus like	CGH16-200
91608	\N	\N	2010	3397	\N	2010 Typical Melanotic Macule	OM D-70
91611	\N	\N	804	1487	\N	804 Normal	DNA-83
91612	\N	\N	884	1488	\N	884 MIS	DNA-85
91613	\N	\N	1394	1072	\N	1394 Tumor	CGH16-198
91614	\N	\N	1395	1074	\N	1395 Tumor	CGH16-209
91615	\N	\N	1401	1080	\N	1401 Tumor	CGH17-003
91616	\N	\N	1396	1075	\N	1396 Tumor	CGH16-215
91617	\N	\N	1397	1076	\N	1397 Tumor	CGH16-222
91618	\N	\N	116	4126	\N	116 DN	TPP_3-07
91619	\N	\N	170	4010	\N	170 DN	TPP 1_6
91620	\N	\N	182	4022	\N	182 DN	TPP 1_18
91621	\N	\N	1399	1078	\N	1399 Tumor	CGH16-254
91622	\N	\N	131	4141	\N	131 DN	TPP_3-22
91623	\N	\N	210	4050	\N	210 DN	TPP 2_19
91624	\N	\N	204	4044	\N	204 DN	TPP 2_13
91625	\N	\N	128	4138	\N	128 DN	TPP_3-19
91626	\N	\N	205	4045	\N	205 DN	TPP 2_14
91627	\N	\N	117	4127	\N	117 DN	TPP_3-08
91628	\N	\N	197	4037	\N	197 DN	TPP 2_6
91629	\N	\N	227	4067	\N	227 DN	TPP 2_36
91630	\N	\N	133	4143	\N	133 DN	TPP_3-24
91631	\N	\N	214	4054	\N	214 DN	TPP 2_23
91632	\N	\N	203	4043	\N	203 DN	TPP 2_12
91633	\N	\N	202	4042	\N	202 DN	TPP 2_11
91634	\N	\N	139	4149	\N	139 DN	TPP_3-30
91635	\N	\N	230	4070	\N	230 DN	TPP 2_39
91648	\N	\N	2127	1698	\N	2127 Normal	DNA-302
91651	\N	\N	1398	1077	\N	1398 Tumor	CGH16-250
91659	\N	\N	1993	3382	\N	1993 Typical Melanotic Macule	OM D-60
91669	\N	\N	122	4132	\N	122 DN	TPP_3-13
91670	\N	\N	173	4013	\N	173 DN	TPP 1_9
91671	\N	\N	185	4025	\N	185 DN	TPP 1_21
91672	\N	\N	143	4153	\N	143 DN	TPP_3-34
91673	\N	\N	235	4075	\N	235 DN	TPP 2_44
91674	\N	\N	111	4121	\N	111 DN	TPP_3-02
91675	\N	\N	224	4064	\N	224 DN	TPP 2_33
91676	\N	\N	1994	3383	\N	1994 Typical Melanotic Macule	OM D-61
91677	\N	\N	174	4014	\N	174 DN	TPP 1_10
91678	\N	\N	186	4026	\N	186 DN	TPP 1_22
91679	\N	\N	120	4130	\N	120 DN	TPP_3-11
91680	\N	\N	178	4018	\N	178 DN	TPP 1_14
91681	\N	\N	190	4030	\N	190 DN	TPP 1_26
91682	\N	\N	220	4060	\N	220 DN	TPP 2_29
91683	\N	\N	110	4120	\N	110 DN	TPP_3-01
91684	\N	\N	207	4047	\N	207 DN	TPP 2_16
91572	\N	\N	1606	482	\N	1606 Invasive Primary Mel 1	AM2 D-419
91573	\N	\N	1607	483	\N	1607 Invasive Primary Mel 2	AM2 D-420
91577	\N	\N	1609	485	\N	1609 LN Met 1	AM2 D-422
91578	\N	\N	2184	1721	\N	2184 Mel	DNA-334
91579	\N	\N	2185	1722	\N	2185 Nevus	DNA-335
91598	\N	\N	2483	4435	\N	2483 Invasive	LMM D-052
91599	\N	\N	2484	4436	\N	2484 MIS	LMM D-053
91602	\N	\N	1971	3359	\N	1971 Typical Melanotic Macule	OM D-41
91605	\N	\N	283	3534	\N	283 Normal	RNA-04
91606	\N	\N	285	3536	\N	285 Mel	RNA-06
91607	\N	\N	284	3535	\N	284 Nevus	RNA-05
91609	\N	\N	298	3549	\N	298 Nevus	RNA-19
91610	\N	\N	299	3550	\N	299 Mel	RNA-20
91636	\N	\N	350	3564	\N	350 Nevus	RNA-34
91637	\N	\N	351	3565	\N	351 Mel	RNA-35
91638	\N	\N	2243	1778	\N	2243 MIS	DNA-421
91639	\N	\N	2244	1716	\N	2244 Nevus	DNA-320
91640	\N	\N	2245	1779	\N	2245 Normal	DNA-422
91641	\N	\N	355	3569	\N	355 MIS	RNA-39
91642	\N	\N	354	3568	\N	354 Normal	RNA-38
91643	\N	\N	356	3570	\N	356 Mel	RNA-40
91644	\N	\N	772	1452	\N	772 Mel	DNA-43
91645	\N	\N	773	1453	\N	773 Nevus	DNA-44
91646	\N	\N	349	3563	\N	349 Mel	RNA-33
91647	\N	\N	348	3562	\N	348 Nevus	RNA-32
91649	\N	\N	1449	1548	\N	1449 Normal	DNA-150
91650	\N	\N	1430	1501	\N	1430 Normal	DNA-98
91652	\N	\N	290	3541	\N	290 Nevus	RNA-11
91653	\N	\N	291	3542	\N	291 Mel	RNA-12
91654	\N	\N	289	3540	\N	289 Normal	RNA-10
91655	\N	\N	296	3547	\N	296 Nevus	RNA-17
91656	\N	\N	297	3548	\N	297 Mel	RNA-18
91657	\N	\N	304	3555	\N	304 Normal	RNA-25
91658	\N	\N	1448	1547	\N	1448 Normal	DNA-149
91660	\N	\N	2117	1677	\N	2117 Mel	DNA-281
91661	\N	\N	2119	1679	\N	2119 MIS	DNA-283
91662	\N	\N	2118	1678	\N	2118 Nevus	DNA-282
91663	\N	\N	2120	1680	\N	2120 Normal	DNA-284
91664	\N	\N	280	3531	\N	280 Normal	RNA-01
91665	\N	\N	282	3533	\N	282 Mel	RNA-03
91666	\N	\N	281	3532	\N	281 Nevus	RNA-02
91667	\N	\N	300	3551	\N	300 Nevus	RNA-21
91668	\N	\N	301	3552	\N	301 Mel	RNA-22
91689	\N	\N	192	4032	\N	192 DN	TPP 2_1
91690	\N	\N	114	4124	\N	114 DN	TPP_3-05
91691	\N	\N	168	4008	\N	168 DN	TPP 1_4
91692	\N	\N	180	4020	\N	180 DN	TPP 1_16
91693	\N	\N	171	4011	\N	171 DN	TPP 1_7
91694	\N	\N	183	4023	\N	183 DN	TPP 1_19
91695	\N	\N	126	4136	\N	126 DN	TPP_3-17
91696	\N	\N	200	4040	\N	200 DN	TPP 2_9
91697	\N	\N	138	4148	\N	138 DN	TPP_3-29
91698	\N	\N	228	4068	\N	228 DN	TPP 2_37
91699	\N	\N	199	4039	\N	199 DN	TPP 2_8
91700	\N	\N	1402	1081	\N	1402 Tumor	CGH17-008
91701	\N	\N	176	4016	\N	176 DN	TPP 1_12
91702	\N	\N	188	4028	\N	188 DN	TPP 1_24
91703	\N	\N	123	4133	\N	123 DN	TPP_3-14
91704	\N	\N	195	4035	\N	195 DN	TPP 2_4
91705	\N	\N	145	4155	\N	145 DN	TPP_3-36
91706	\N	\N	237	4077	\N	237 DN	TPP 2_46
91707	\N	\N	223	4063	\N	223 DN	TPP 2_32
91708	\N	\N	1400	1079	\N	1400 Tumor	CGH17-001
91709	\N	\N	564	3269	\N	564 Nodular Mel	NM D-14
91710	\N	\N	557	3262	\N	557 Nodular Mel	NM D-07
91714	\N	\N	601	3306	\N	601 Nodular Mel	NM D-064
91715	\N	\N	602	3307	\N	602 Nodular Mel	NM D-065
91716	\N	\N	1404	1083	\N	1404 Tumor	CGH17-017
91717	\N	\N	226	4066	\N	226 DN	TPP 2_35
91718	\N	\N	177	4017	\N	177 DN	TPP 1_13
91719	\N	\N	189	4029	\N	189 DN	TPP 1_25
91720	\N	\N	1403	1082	\N	1403 Tumor	CGH17-015
91721	\N	\N	1995	3384	\N	1995 Typical Melanotic Macule	OM D-62A
91722	\N	\N	1996	3385	\N	1996 Typical Melanotic Macule	OM D-62B
91724	\N	\N	135	4145	\N	135 DN	TPP_3-26
91725	\N	\N	219	4059	\N	219 DN	TPP 2_28
91726	\N	\N	163	4173	\N	163 DN	TPP_3-54
91727	\N	\N	211	4051	\N	211 DN	TPP 2_20
91728	\N	\N	129	4139	\N	129 DN	TPP_3-20
91729	\N	\N	206	4046	\N	206 DN	TPP 2_15
91730	\N	\N	1405	1084	\N	1405 Tumor	CGH17-021
91731	\N	\N	1406	1085	\N	1406 Tumor	CGH17-024
91734	\N	\N	1407	1086	\N	1407 Tumor	CGH17-026
91741	\N	\N	1408	1087	\N	1408 Tumor	CGH17-031
91743	\N	\N	1409	1088	\N	1409 Tumor	CGH17-033
91744	\N	\N	438	3884	\N	438 common+ sclerotic dermal component 	SM D-15
91751	\N	\N	1413	1092	\N	1413 Tumor	CGH17-076
91752	\N	\N	787	1451	\N	787 MIS	DNA-41
91754	\N	\N	1310	3571	\N	1310 Mel	RNA-41
91755	\N	\N	1564	412	\N	1564 Normal	AM2 D-332
91757	\N	\N	1566	412	\N	1566 Normal	AM2 D-332
91760	\N	\N	1410	1089	\N	1410 Tumor	CGH17-039
91761	\N	\N	142	4152	\N	142 DN	TPP_3-33
91762	\N	\N	234	4074	\N	234 DN	TPP 2_43
91763	\N	\N	144	4154	\N	144 DN	TPP_3-35
91764	\N	\N	236	4076	\N	236 DN	TPP 2_45
91765	\N	\N	140	4150	\N	140 DN	TPP_3-31
91766	\N	\N	231	4071	\N	231 DN	TPP 2_40
91767	\N	\N	225	4065	\N	225 DN	TPP 2_34
91768	\N	\N	193	4033	\N	193 DN	TPP 2_2
91769	\N	\N	112	4122	\N	112 DN	TPP_3-03
91770	\N	\N	217	4057	\N	217 DN	TPP 2_26
91771	\N	\N	137	4147	\N	137 DN	TPP_3-28
91772	\N	\N	222	4062	\N	222 DN	TPP 2_31
91773	\N	\N	125	4135	\N	125 DN	TPP_3-16
91774	\N	\N	198	4038	\N	198 DN	TPP 2_7
91775	\N	\N	167	4007	\N	167 DN	TPP 1_3
91776	\N	\N	194	4034	\N	194 DN	TPP 2_3
91777	\N	\N	124	4134	\N	124 DN	TPP_3-15
91778	\N	\N	196	4036	\N	196 DN	TPP 2_5
91780	\N	\N	439	3885	\N	439 common+ sclerotic dermal component 	SM D-16
91786	\N	\N	1411	1090	\N	1411 Tumor	CGH17-052
91787	\N	\N	164	4174	\N	164 DN	TPP_3-55
91788	\N	\N	213	4053	\N	213 DN	TPP 2_22
91789	\N	\N	169	4009	\N	169 DN	TPP 1_5
91790	\N	\N	181	4021	\N	181 DN	TPP 1_17
91791	\N	\N	215	4055	\N	215 DN	TPP 2_24
91792	\N	\N	134	4144	\N	134 DN	TPP_3-25
91793	\N	\N	216	4056	\N	216 DN	TPP 2_25
91794	\N	\N	132	4142	\N	132 DN	TPP_3-23
91795	\N	\N	212	4052	\N	212 DN	TPP 2_21
91796	\N	\N	175	4015	\N	175 DN	TPP 1_11
91797	\N	\N	187	4027	\N	187 DN	TPP 1_23
91801	\N	\N	218	4058	\N	218 DN	TPP 2_27
91802	\N	\N	136	4146	\N	136 DN	TPP_3-27
91803	\N	\N	221	4061	\N	221 DN	TPP 2_30
91805	\N	\N	141	4151	\N	141 DN	TPP_3-32
91806	\N	\N	233	4073	\N	233 DN	TPP 2_42
91807	\N	\N	232	4072	\N	232 DN	TPP 2_41
91810	\N	\N	119	4129	\N	119 DN	TPP_3-10
91811	\N	\N	172	4012	\N	172 DN	TPP 1_8
91812	\N	\N	184	4024	\N	184 DN	TPP 1_20
91813	\N	\N	127	4137	\N	127 DN	TPP_3-18
91814	\N	\N	201	4041	\N	201 DN	TPP 2_10
91815	\N	\N	121	4131	\N	121 DN	TPP_3-12
91816	\N	\N	179	4019	\N	179 DN	TPP 1_15
91817	\N	\N	191	4031	\N	191 DN	TPP 1_27
91818	\N	\N	1412	1091	\N	1412 Tumor	CGH17-058
91822	\N	\N	784	1471	\N	784 Mel	DNA-65
91738	\N	\N	1559	419	\N	1559 LN Met 2	AM2 D-339
91739	\N	\N	1560	420	\N	1560 LN Met 3	AM2 D-340
91740	\N	\N	1561	421	\N	1561 LN Met 4	AM2 D-341
91749	\N	\N	293	3544	\N	293 Mel	RNA-14
91750	\N	\N	292	3543	\N	292 Nevus	RNA-13
91753	\N	\N	788	1479	\N	788 Nevus	DNA-75
91756	\N	\N	1565	424	\N	1565 LN Met 9	AM2 D-345
91758	\N	\N	1567	425	\N	1567 LN Met 7	AM2 D-347
91759	\N	\N	1568	426	\N	1568 LN Met 8	AM2 D-348
91781	\N	\N	1543	403	\N	1543 Brain Met2	AM2 D-323
91782	\N	\N	2122	1682	\N	2122 MIS	DNA-286
91783	\N	\N	2121	1681	\N	2121 Nevus	DNA-285
91784	\N	\N	2123	1683	\N	2123 Normal	DNA-287
91785	\N	\N	1973	3361	\N	1973 Typical Melanotic Macule	OM D-43
91798	\N	\N	286	3537	\N	286 Normal	RNA-07
91799	\N	\N	288	3539	\N	288 Mel	RNA-09
91800	\N	\N	287	3538	\N	287 Nevus	RNA-08
91804	\N	\N	1432	1503	\N	1432 Normal	DNA-100
91819	\N	\N	789	1460	\N	789 Nevus	DNA-52
91820	\N	\N	790	1474	\N	790 Normal	DNA-70
91821	\N	\N	791	1480	\N	791 Mel	DNA-76
91823	\N	\N	785	1485	\N	785 Nevus	DNA-81
91824	\N	\N	786	1476	\N	786 Normal	DNA-72
91837	\N	\N	242	4082	\N	242 DN	TPP 2_51
91838	\N	\N	252	4092	\N	252 DN	TPP 2_61
91839	\N	\N	153	4163	\N	153 DN	TPP_3-44
91840	\N	\N	254	4094	\N	254 DN	TPP 2_63
91841	\N	\N	154	4164	\N	154 DN	TPP_3-45
91842	\N	\N	255	4095	\N	255 DN	TPP 2_64
91844	\N	\N	253	4093	\N	253 DN	TPP 2_62
91846	\N	\N	149	4159	\N	149 DN	TPP_3-40
91847	\N	\N	243	4083	\N	243 DN	TPP 2_52
91848	\N	\N	244	4084	\N	244 DN	TPP 2_53
91849	\N	\N	250	4090	\N	250 DN	TPP 2_59
91850	\N	\N	251	4091	\N	251 DN	TPP 2_60
91851	\N	\N	238	4078	\N	238 DN	TPP 2_47
91852	\N	\N	151	4161	\N	151 DN	TPP_3-42
91853	\N	\N	247	4087	\N	247 DN	TPP 2_56
91854	\N	\N	248	4088	\N	248 DN	TPP 2_57
91855	\N	\N	152	4162	\N	152 DN	TPP_3-43
91856	\N	\N	249	4089	\N	249 DN	TPP 2_58
91857	\N	\N	239	4079	\N	239 DN	TPP 2_48
91858	\N	\N	150	4160	\N	150 DN	TPP_3-41
91859	\N	\N	245	4085	\N	245 DN	TPP 2_54
91860	\N	\N	246	4086	\N	246 DN	TPP 2_55
91864	\N	\N	118	4128	\N	118 DN	TPP_3-09
91865	\N	\N	258	4098	\N	258 DN	TPP 2_67
91866	\N	\N	256	4096	\N	256 DN	TPP 2_65
91871	\N	\N	1414	1093	\N	1414 Tumor	CGH17-083
91878	\N	\N	1415	1094	\N	1415 Tumor	CGH17-095
91879	\N	\N	257	4097	\N	257 DN	TPP 2_66
91881	\N	\N	1416	1095	\N	1416 Tumor	CGH17-097
91882	\N	\N	724	3217	\N	724 DN	MR-047
91883	\N	\N	3521	3217	\N	3521 DN	MR-047
91884	\N	\N	1417	1096	\N	1417 Tumor	CGH17-104
91886	\N	\N	440	3886	\N	440 common+ sclerotic dermal component 	SM D-17
91894	\N	\N	495	1097	\N	495 nevus or nevus like	CGH17-135
91902	\N	\N	276	4116	\N	276 DN	TPP 2_85
91903	\N	\N	259	4099	\N	259 DN	TPP 2_68
91904	\N	\N	260	4100	\N	260 DN	TPP 2_69
91905	\N	\N	158	4168	\N	158 DN	TPP_3-49
91906	\N	\N	270	4110	\N	270 DN	TPP 2_79
91907	\N	\N	159	4169	\N	159 DN	TPP_3-50
91908	\N	\N	271	4111	\N	271 DN	TPP 2_80
91909	\N	\N	113	4123	\N	113 DN	TPP_3-04
91910	\N	\N	264	4104	\N	264 DN	TPP 2_73
91911	\N	\N	161	4171	\N	161 DN	TPP_3-52
91912	\N	\N	273	4113	\N	273 DN	TPP 2_82
91913	\N	\N	261	4101	\N	261 DN	TPP 2_70
91914	\N	\N	262	4102	\N	262 DN	TPP 2_71
91915	\N	\N	275	4115	\N	275 DN	TPP 2_84
91916	\N	\N	267	4107	\N	267 DN	TPP 2_76
91917	\N	\N	155	4165	\N	155 DN	TPP_3-46
91918	\N	\N	265	4105	\N	265 DN	TPP 2_74
91919	\N	\N	278	4118	\N	278 DN	TPP 2_87
91920	\N	\N	156	4166	\N	156 DN	TPP_3-47
91921	\N	\N	266	4106	\N	266 DN	TPP 2_75
91922	\N	\N	269	4109	\N	269 DN	TPP 2_78
91923	\N	\N	157	4167	\N	157 DN	TPP_3-48
91924	\N	\N	268	4108	\N	268 DN	TPP 2_77
91925	\N	\N	279	4119	\N	279 DN	TPP 2_88
91926	\N	\N	263	4103	\N	263 DN	TPP 2_72
91927	\N	\N	162	4172	\N	162 DN	TPP_3-53
91928	\N	\N	274	4114	\N	274 DN	TPP 2_83
91929	\N	\N	160	4170	\N	160 DN	TPP_3-51
91930	\N	\N	272	4112	\N	272 DN	TPP 2_81
91931	\N	\N	115	4125	\N	115 DN	TPP_3-06
91932	\N	\N	277	4117	\N	277 DN	TPP 2_86
91935	\N	\N	798	1478	\N	798 Nevus	DNA-74
91939	\N	\N	2110	1670	\N	2110 Normal	DNA-274
91943	\N	\N	693	3186	\N	693 DN	MR-008
91944	\N	\N	3490	3186	\N	3490 DN	MR-008
91945	\N	\N	702	3195	\N	702 DN	MR-024
91946	\N	\N	3500	3196	\N	3500 DN	MR-025
91947	\N	\N	701	3194	\N	701 DN	MR-021
91948	\N	\N	3499	3195	\N	3499 DN	MR-024
91949	\N	\N	689	3182	\N	689 DN	MR-003
91950	\N	\N	3486	3182	\N	3486 DN	MR-003
91951	\N	\N	688	3181	\N	688 DN	MR-002
91952	\N	\N	3485	3181	\N	3485 DN	MR-002
91953	\N	\N	690	3183	\N	690 DN	MR-004
91954	\N	\N	3487	3183	\N	3487 DN	MR-004
91955	\N	\N	705	3198	\N	705 DN	MR-027
91956	\N	\N	3503	3199	\N	3503 DN	MR-029
91957	\N	\N	708	3201	\N	708 DN	MR-031
91958	\N	\N	3506	3202	\N	3506 DN	MR-032
91959	\N	\N	706	3199	\N	706 DN	MR-029
91960	\N	\N	3504	3200	\N	3504 DN	MR-030
91961	\N	\N	707	3200	\N	707 DN	MR-030
91962	\N	\N	3505	3201	\N	3505 DN	MR-031
91826	\N	\N	305	3556	\N	305 Normal	RNA-26
91827	\N	\N	344	3558	\N	344 Mel	RNA-28
91828	\N	\N	343	3557	\N	343 MIS	RNA-27
91861	\N	\N	792	1475	\N	792 Normal	DNA-71
91862	\N	\N	794	1461	\N	794 Mel	DNA-53
91863	\N	\N	793	1463	\N	793 Nevus	DNA-54
91868	\N	\N	2114	1674	\N	2114 Mel	DNA-278
91869	\N	\N	2115	1675	\N	2115 Nevus	DNA-279
91870	\N	\N	2116	1676	\N	2116 Normal	DNA-280
91872	\N	\N	781	1469	\N	781 Mel	DNA-61
91873	\N	\N	782	1470	\N	782 Nevus	DNA-62
91874	\N	\N	783	1477	\N	783 Normal	DNA-73
91876	\N	\N	801	1483	\N	801 Nevus	DNA-79
91877	\N	\N	802	1484	\N	802 Mel	DNA-80
91880	\N	\N	2619	4312	\N	2619 Spitz Nevus	DMS-050
91887	\N	\N	1434	1500	\N	1434 Normal	DNA-97
91888	\N	\N	803	1486	\N	803 Nevus	DNA-82
91889	\N	\N	805	1467	\N	805 Mel	DNA-59
91892	\N	\N	779	1465	\N	779 Mel	DNA-55
91893	\N	\N	780	1466	\N	780 Nevus	DNA-56
91895	\N	\N	795	1456	\N	795 Mel	DNA-47
91896	\N	\N	796	1457	\N	796 Nevus	DNA-48
91897	\N	\N	797	1472	\N	797 Normal	DNA-68
91898	\N	\N	776	1458	\N	776 Mel	DNA-49
91899	\N	\N	777	1459	\N	777 Nevus	DNA-50
91900	\N	\N	778	1473	\N	778 Normal	DNA-69
91901	\N	\N	1433	1504	\N	1433 Normal	DNA-101
91933	\N	\N	302	3553	\N	302 Normal	RNA-23
91934	\N	\N	303	3554	\N	303 Mel	RNA-24
91938	\N	\N	2109	1669	\N	2109 Mel	DNA-273
91940	\N	\N	2128	1707	\N	2128 Nevus	DNA-311
91941	\N	\N	2129	1708	\N	2129 Mel	DNA-312
91942	\N	\N	1972	3360	\N	1972 Typical Melanotic Macule	OM D-42
91963	\N	\N	2620	4313	\N	2620 Spitz Nevus	DMS-051
91964	\N	\N	2471	2036	\N	2471 Normal	LMM D-024
91973	\N	\N	692	3185	\N	692 DN	MR-006
91974	\N	\N	3489	3185	\N	3489 DN	MR-006
91977	\N	\N	719	3212	\N	719 DN	MR-042
91978	\N	\N	3516	3212	\N	3516 DN	MR-042
91985	\N	\N	704	3197	\N	704 DN	MR-026
91986	\N	\N	3502	3198	\N	3502 DN	MR-027
91995	\N	\N	432	3878	\N	432 common + blue	SM D-09
91996	\N	\N	2011	3398	\N	2011 Typical Melanotic Macule	OM D-71
91999	\N	\N	695	3188	\N	695 DN	MR-010
92000	\N	\N	3492	3188	\N	3492 DN	MR-010
92001	\N	\N	703	3196	\N	703 DN	MR-025
92002	\N	\N	3501	3197	\N	3501 DN	MR-026
92003	\N	\N	716	3209	\N	716 DN	MR-039
92004	\N	\N	3514	3210	\N	3514 DN	MR-040
92005	\N	\N	728	3221	\N	728 DN	MR-051
92006	\N	\N	3525	3221	\N	3525 DN	MR-051
92007	\N	\N	691	3184	\N	691 DN	MR-005
92008	\N	\N	3488	3184	\N	3488 DN	MR-005
92009	\N	\N	710	3203	\N	710 DN	MR-033
92010	\N	\N	3508	3204	\N	3508 DN	MR-034
92013	\N	\N	1872	2112	\N	1872 Compound	LN D-17 (LN-17)
92019	\N	\N	433	3879	\N	433 common + blue	SM D-10
92020	\N	\N	434	3880	\N	434 common + blue	SM D-11
92021	\N	\N	676	2098	\N	676 Junctional	LN D-03 (LN-03)
92022	\N	\N	683	2109	\N	683 Compound	LN D-14 (LN-14)
92023	\N	\N	525	2140	\N	525 Congenital superficial	LN D-045 (LN-045)
92024	\N	\N	502	2117	\N	502 Junctional	LN D-022 (LN-022)
92025	\N	\N	526	2141	\N	526 Congenital superficial	LN D-046 (LN-046)
92026	\N	\N	517	2132	\N	517 Junctional	LN D-037 (LN-037)
92027	\N	\N	522	2137	\N	522 Congenital superficial	LN D-042 LN-042)
92028	\N	\N	510	2125	\N	510 Junctional	LN D-030 (LN-030)
92029	\N	\N	531	2146	\N	531 Compound	LN D-051 (LN-051)
92030	\N	\N	504	2119	\N	504 Junctional	LN D-024 (LN-024)
92031	\N	\N	508	2123	\N	508 Junctional	LN D-028 (LN-028)
92032	\N	\N	509	2124	\N	509 Junctional	LN D-029 (LN-029)
92033	\N	\N	534	2149	\N	534 Compound	LN D-054 (LN-054)
92034	\N	\N	535	2150	\N	535 Compound	LN D-055 (LN-055)
92037	\N	\N	713	3206	\N	713 DN	MR-036
92038	\N	\N	3511	3207	\N	3511 DN	MR-037
92039	\N	\N	520	2135	\N	520 Junctional	LN D-040 (LN-040)
92040	\N	\N	503	2118	\N	503 Junctional	LN D-023 (LN-023)
92041	\N	\N	497	1098	\N	497 nevus or nevus like	CGH17-240
92042	\N	\N	521	2136	\N	521 Junctional	LN D-041 (LN-041)
92043	\N	\N	726	3219	\N	726 DN	MR-049
92044	\N	\N	3523	3219	\N	3523 DN	MR-049
92045	\N	\N	513	2128	\N	513 Junctional	LN D-033 (LN-033)
92047	\N	\N	532	2147	\N	532 Compound	LN D-052 (LN-052)
92048	\N	\N	515	2130	\N	515 Junctional	LN D-035 (LN-035)
92049	\N	\N	529	2144	\N	529 Compound	LN D-049 (LN-049)
92050	\N	\N	435	3881	\N	435 common + blue	SM D-12
92051	\N	\N	516	2131	\N	516 Junctional	LN D-036 (LN-036)
92052	\N	\N	514	2129	\N	514 Junctional	LN D-034 (LN-034)
92053	\N	\N	518	2133	\N	518 Junctional	LN D-038 (LN-038)
92054	\N	\N	519	2134	\N	519 Junctional	LN D-039 (LN-039)
92055	\N	\N	505	2120	\N	505 Junctional	LN D-025 (LN-025)
92056	\N	\N	506	2121	\N	506 Junctional	LN D-026 (LN-026)
92057	\N	\N	507	2122	\N	507 Junctional	LN D-027 (LN-027)
92058	\N	\N	1974	3362	\N	1974 Superficial Melanoma	OM D-44.1
92059	\N	\N	1975	3363	\N	1975 Mel	OM D-44.2
92060	\N	\N	1976	3364	\N	1976 Invasive Mel 1	OM D-44.3
92061	\N	\N	722	3215	\N	722 DN	MR-045
92062	\N	\N	3519	3215	\N	3519 DN	MR-045
92063	\N	\N	723	3216	\N	723 DN	MR-046
92064	\N	\N	3520	3216	\N	3520 DN	MR-046
92065	\N	\N	675	2097	\N	675 Junctional	LN D-02 (LN-02)
92066	\N	\N	1870	2110	\N	1870 Compound	LN D-15 (LN-15)
92067	\N	\N	681	2103	\N	681 Junctional	LN D-08 (LN-08)
92068	\N	\N	678	2100	\N	678 Junctional	LN D-05 (LN-05)
92069	\N	\N	1871	2111	\N	1871 Compound	LN D-16 (LN-16)
92070	\N	\N	680	2102	\N	680 Junctional	LN D-07 (LN-07)
92071	\N	\N	679	2101	\N	679 Junctional	LN D-06 (LN-06)
92072	\N	\N	1866	2105	\N	1866 Junctional	LN D-10 (LN-10)
92073	\N	\N	1865	2096	\N	1865 Junctional	LN D-01 (LN-01)
92074	\N	\N	677	2099	\N	677 Junctional	LN D-04 (LN-04)
92075	\N	\N	1869	2108	\N	1869 Compound	LN D-13 (LN-13)
92076	\N	\N	1868	2107	\N	1868 Compound	LN D-12 (LN-12)
92077	\N	\N	441	3887	\N	441 common+ sclerotic dermal component 	SM D-18
92078	\N	\N	682	2104	\N	682 Junctional	LN D-09 (LN-09)
92079	\N	\N	1867	2106	\N	1867 Compound	LN D-11 (LN-11)
92080	\N	\N	428	3874	\N	428 blue nevus+ cellular+  DF like	SM D-05
92081	\N	\N	2638	4441	\N	2638 Normal	LMM D-060
92085	\N	\N	709	3202	\N	709 DN	MR-032
91975	\N	\N	774	1454	\N	774 Mel	DNA-45
91976	\N	\N	775	1455	\N	775 Nevus	DNA-46
91979	\N	\N	352	3566	\N	352 Nevus	RNA-36
91980	\N	\N	353	3567	\N	353 Mel	RNA-37
91981	\N	\N	1441	1522	\N	1441 MIS1	DNA-124
91982	\N	\N	1444	1523	\N	1444 MIS2	DNA-125
91984	\N	\N	1450	1549	\N	1450 Normal	DNA-151
91987	\N	\N	294	3545	\N	294 Nevus	RNA-15
91988	\N	\N	295	3546	\N	295 Mel	RNA-16
91989	\N	\N	895	1490	\N	895 Normal	DNA-87
91990	\N	\N	1442	1511	\N	1442 MIS1	DNA-113
91991	\N	\N	1443	1512	\N	1443 MIS2	DNA-114
91992	\N	\N	799	1481	\N	799 Mel	DNA-77
91993	\N	\N	800	1482	\N	800 Nevus	DNA-78
91997	\N	\N	2621	4314	\N	2621 Spitz Nevus	DMS-052 A
91998	\N	\N	2622	4315	\N	2622 Spitz Nevus	DMS-052 B
92011	\N	\N	2623	4316	\N	2623 Spitz Nevus	DMS-053
92012	\N	\N	1451	1545	\N	1451 Normal	DNA-147
92014	\N	\N	1447	1544	\N	1447 Normal	DNA-146
92015	\N	\N	2131	1710	\N	2131 Mel	DNA-314
92016	\N	\N	2133	1712	\N	2133 Normal	DNA-316
92017	\N	\N	2132	1711	\N	2132 Nevus	DNA-315
92018	\N	\N	2616	4309	\N	2616 Spitz Nevus	DMS-047
92046	\N	\N	2617	4310	\N	2617 Spitz Nevus	DMS-048
92082	\N	\N	892	1497	\N	892 Mel	DNA-94
92083	\N	\N	893	1498	\N	893 Nevus	DNA-95
92084	\N	\N	894	1499	\N	894 Normal	DNA-96
92103	\N	\N	2514	2045	\N	2514 Normal	LMM D-033
92105	\N	\N	1873	2114	\N	1873 Compound	LN D-19 (LN-19)
92106	\N	\N	684	2113	\N	684 Compound	LN D-18 (LN-18)
92113	\N	\N	1874	2116	\N	1874 Compound	LN D-21 (LN-21)
92114	\N	\N	685	2115	\N	685 Compound	LN D-20 (LN-20)
92115	\N	\N	533	2148	\N	533 Compound	LN D-053 (LN-053)
92116	\N	\N	512	2127	\N	512 Junctional	LN D-032 (LN-032)
92117	\N	\N	536	2151	\N	536 Compound	LN D-056 (LN-056)
92118	\N	\N	537	2152	\N	537 Compound	LN D-057 (LN-057)
92119	\N	\N	541	2156	\N	541 Compound	LN D-061 (LN-061)
92121	\N	\N	1581	445	\N	1581 Normal	AM2 D-369
92123	\N	\N	442	3888	\N	442 compound meloncytic nevus 	SM D-19
92124	\N	\N	530	2145	\N	530 Compound	LN D-050 (LN-050)
92125	\N	\N	523	2138	\N	523 Congenital superficial	LN D-043 (LN-043)
92126	\N	\N	730	1263	\N	730 Tumor	D-NA-8692
92128	\N	\N	1614	441	\N	1614 Normal	AM2 D-365
92130	\N	\N	882	1808	\N	882 DPN-mm	DNPD-03
92131	\N	\N	487	3253	\N	487 nevus or nevus like	NLD-023
92133	\N	\N	1584	453	\N	1584 Normal	AM2 D-378
92136	\N	\N	524	2139	\N	524 Congenital superficial	LN D-044 (LN-044)
92137	\N	\N	542	2157	\N	542 Compound	LN D-062 (LN-062)
92138	\N	\N	543	2158	\N	543 Compound	LN D-063 (LN-063)
92139	\N	\N	544	2159	\N	544 Compound	LN D-064 (LN-064)
92140	\N	\N	548	2163	\N	548 Congenital superficial	LN D-068 (LN-068)
92142	\N	\N	2644	596	\N	2644 Normal	AM2 D-544
92145	\N	\N	715	3208	\N	715 DN	MR-038
92146	\N	\N	3513	3209	\N	3513 DN	MR-039
92147	\N	\N	711	3204	\N	711 DN	MR-034
92148	\N	\N	3509	3205	\N	3509 DN	MR-035
92149	\N	\N	538	2153	\N	538 Compound	LN D-058 (LN-058)
92150	\N	\N	443	3889	\N	443 common+ sclerotic dermal component 	SM D-20
92151	\N	\N	511	2126	\N	511 Junctional	LN D-031 (LN-031)
92152	\N	\N	727	3220	\N	727 DN	MR-050
92153	\N	\N	3524	3220	\N	3524 DN	MR-050
92154	\N	\N	539	2154	\N	539 Compound	LN D-059 (LN-059)
92155	\N	\N	540	2155	\N	540 Compound	LN D-060 (LN-060)
92157	\N	\N	729	1262	\N	729 Normal	D-NA-8691
92158	\N	\N	545	2160	\N	545 Compound	LN D-065 (LN-065)
92159	\N	\N	546	2161	\N	546 Compound	LN D-066 (LN-066)
92162	\N	\N	2192	1729	\N	2192 Normal	DNA-342
92163	\N	\N	444	3890	\N	444 blue nevus+ cellular 	SM D-21
92164	\N	\N	547	2162	\N	547 Compound	LN D-067 (LN-067)
92165	\N	\N	527	2142	\N	527 Congenital superficial	LN D-047 (LN-047)
92168	\N	\N	448	3894	\N	448 common & balloon	SM D-25
92171	\N	\N	700	3193	\N	700 DN	MR-020
92172	\N	\N	3498	3194	\N	3498 DN	MR-021
92173	\N	\N	3408	3432	\N	3408 Unknown	OM-8R (P040_07A)
92174	\N	\N	3407	3431	\N	3407 Unknown	OM-8D (P040_11A)
92175	\N	\N	498	1100	\N	498 DPN-mm	CGH18-137
92176	\N	\N	496	1101	\N	496 nevus or nevus like	CGH18-139
92177	\N	\N	696	3189	\N	696 DN	MR-011
92178	\N	\N	3493	3189	\N	3493 DN	MR-011
92179	\N	\N	687	3180	\N	687 DN	MR-001
92180	\N	\N	3484	3180	\N	3484 DN	MR-001
92183	\N	\N	445	3891	\N	445 common+ sclerotic dermal component 	SM D-22
92184	\N	\N	694	3187	\N	694 DN	MR-009
92185	\N	\N	3491	3187	\N	3491 DN	MR-009
92186	\N	\N	698	3191	\N	698 DN	MR-015
92187	\N	\N	3496	3192	\N	3496 DN	MR-017
92188	\N	\N	717	3210	\N	717 DN	MR-040
92189	\N	\N	718	3211	\N	718 DN	MR-041
92190	\N	\N	3515	3211	\N	3515 DN	MR-041
92191	\N	\N	699	3192	\N	699 DN	MR-017
92192	\N	\N	3497	3193	\N	3497 DN	MR-020
92193	\N	\N	714	3207	\N	714 DN	MR-037
92194	\N	\N	3512	3208	\N	3512 DN	MR-038
92195	\N	\N	697	3190	\N	697 DN	MR-012
92196	\N	\N	3494	3190	\N	3494 DN	MR-012
92197	\N	\N	3495	3191	\N	3495 DN	MR-015
92198	\N	\N	712	3205	\N	712 DN	MR-035
92199	\N	\N	3510	3206	\N	3510 DN	MR-036
92200	\N	\N	481	3247	\N	481 nevus or nevus like	NLD-017
92201	\N	\N	482	3248	\N	482 nevus or nevus like	NLD-018
92202	\N	\N	483	3249	\N	483 nevus or nevus like	NLD-019
92203	\N	\N	484	3250	\N	484 nevus or nevus like	NLD-020
92204	\N	\N	488	3254	\N	488 nevus or nevus like	NLD-024
92205	\N	\N	489	3255	\N	489 nevus or nevus like	NLD-025
92206	\N	\N	478	3244	\N	478 nevus or nevus like	NLD-014
92207	\N	\N	1256	1391	\N	1256 DN	DN-059
92208	\N	\N	1251	1386	\N	1251 DN	DN-054
92209	\N	\N	1250	1385	\N	1250 DN	DN-053
92210	\N	\N	1249	1384	\N	1249 DN	DN-052
92211	\N	\N	1257	1392	\N	1257 DN	DN-060
92212	\N	\N	528	2143	\N	528 Compound	LN D-048 (LN-048)
92213	\N	\N	1253	1388	\N	1253 DN	DN-056
92214	\N	\N	1252	1387	\N	1252 DN	DN-055
92215	\N	\N	1254	1389	\N	1254 DN	DN-057
92089	\N	\N	346	3560	\N	346 Nevus	RNA-30
92090	\N	\N	347	3561	\N	347 Mel	RNA-31
92093	\N	\N	2021	3452	\N	2021 Lentiginous Juntional Melanocytic Nevus	OM-22D
92101	\N	\N	2512	2086	\N	2512 Invasive	LMM R-031
92102	\N	\N	2513	2087	\N	2513 MIS	LMM R-032
92120	\N	\N	1582	446	\N	1582 Invasive Mel 1	AM2 D-370
92122	\N	\N	1583	447	\N	1583 Invasive Mel 2	AM2 D-371
92127	\N	\N	1551	411	\N	1551 Salivary Met1	AM2 D-331
92132	\N	\N	1585	454	\N	1585 Invasive Mel 1	AM2 D-379
92134	\N	\N	1586	455	\N	1586 LN Met	AM2 D-380
92141	\N	\N	1977	3365	\N	1977 Mel	OM D-45
92156	\N	\N	2241	1775	\N	2241 Normal	DNA-418
92160	\N	\N	2190	1727	\N	2190 Mel	DNA-340
92161	\N	\N	2191	1728	\N	2191 Nevus	DNA-341
92166	\N	\N	2510	2085	\N	2510 MIS	LMM R-029
92167	\N	\N	2509	2084	\N	2509 Invasive	LMM R-028
92169	\N	\N	1978	3366	\N	1978 Mel	OM D-46
92170	\N	\N	1979	3367	\N	1979 Mel	OM D-47
92229	\N	\N	891	1496	\N	891 Blue Nevus	DNA-93
92232	\N	\N	479	3245	\N	479 nevus or nevus like	NLD-015
92233	\N	\N	888	1493	\N	888 Blue Nevus	DNA-90
92234	\N	\N	480	3246	\N	480 nevus or nevus like	NLD-016
92235	\N	\N	886	1491	\N	886 Blue Nevus	DNA-88
92241	\N	\N	887	1492	\N	887 Blue Nevus	DNA-89
92249	\N	\N	2199	1736	\N	2199 Normal	DNA-353
92252	\N	\N	1263	1398	\N	1263 DN	DN-066
92253	\N	\N	1264	1399	\N	1264 DN	DN-067
92254	\N	\N	1265	1400	\N	1265 DN	DN-068
92255	\N	\N	1266	1401	\N	1266 DN	DN-069
92256	\N	\N	1267	1402	\N	1267 DN	DN-070
92257	\N	\N	1268	1403	\N	1268 DN	DN-071
92258	\N	\N	1269	1404	\N	1269 DN	DN-072
92259	\N	\N	1270	1405	\N	1270 DN	DN-073
92260	\N	\N	1255	1390	\N	1255 DN	DN-058
92265	\N	\N	2156	4607	\N	2156 Capture Area C1	VS-03_NA
92267	\N	\N	1272	1407	\N	1272 DN	DN-075
92268	\N	\N	1278	1413	\N	1278 DN	DN-081
92269	\N	\N	1283	1418	\N	1283 DN	DN-086
92277	\N	\N	1421	1811	\N	1421 NEVUS	DNPD-06
92278	\N	\N	1274	1409	\N	1274 DN	DN-077
92279	\N	\N	1271	1406	\N	1271 DN	DN-074
92280	\N	\N	1275	1410	\N	1275 DN	DN-078
92281	\N	\N	1281	1416	\N	1281 DN	DN-084
92287	\N	\N	2195	1732	\N	2195 Normal	DNA-347
92289	\N	\N	2240	3791	\N	2240 Normal	RNA-347
92291	\N	\N	1280	1415	\N	1280 DN	DN-083
92292	\N	\N	1284	1419	\N	1284 DN	DN-087
92293	\N	\N	1276	1411	\N	1276 DN	DN-079
92294	\N	\N	1279	1414	\N	1279 DN	DN-082
92295	\N	\N	1273	1408	\N	1273 DN	DN-076
92296	\N	\N	1282	1417	\N	1282 DN	DN-085
92297	\N	\N	1277	1412	\N	1277 DN	DN-080
92308	\N	\N	1591	498	\N	1591 Normal	AM2 D-437
92311	\N	\N	1003	1102	\N	1003 Tumor	CGH19-097_1.00
92312	\N	\N	1134	1103	\N	1134 Nevus	CGH19-097_2
92320	\N	\N	1593	466	\N	1593 Normal	AM2 D-399
92329	\N	\N	2511	2042	\N	2511 Normal	LMM D-030
92333	\N	\N	878	1806	\N	878 DPN-mm	DNPD-01
92336	\N	\N	1997	3386	\N	1997 Lentiginous junctional melanocytic nevus	OM D-63
92341	\N	\N	879	1807	\N	879 DPN-mm	DNPD-02
92222	\N	\N	2188	1725	\N	2188 Nevus	DNA-338
92223	\N	\N	2189	1726	\N	2189 Normal	DNA-339
92246	\N	\N	2196	1733	\N	2196 Mel	DNA-348
92247	\N	\N	2197	1734	\N	2197 MIS	DNA-350
92248	\N	\N	2198	1735	\N	2198 Nevus	DNA-351
92263	\N	\N	1468	3944	\N	1468 Nevus	SND-18
92271	\N	\N	1562	422	\N	1562 Brain Met 5	AM2 D-342
92272	\N	\N	1563	423	\N	1563 Brain Met 6	AM2 D-343
92274	\N	\N	1467	3943	\N	1467 Nevus	SND-17
92285	\N	\N	2193	1730	\N	2193 Mel	DNA-344
92286	\N	\N	2194	1731	\N	2194 Nevus	DNA-346
92298	\N	\N	1822	456	\N	1822 Invasive Mel 1	AM2 D-381
92299	\N	\N	1823	457	\N	1823 Invasive Mel 2	AM2 D-382
92301	\N	\N	1824	493	\N	1824 Normal	AM2 D-431
92302	\N	\N	1460	3936	\N	1460 Nevus	SND-10
92303	\N	\N	1463	3939	\N	1463 Nevus	SND-13
92304	\N	\N	1588	495	\N	1588 MIS2	AM2 D-434
92305	\N	\N	1587	494	\N	1587 MIS1	AM2 D-433
92306	\N	\N	1589	496	\N	1589 Primary Mel 1	AM2 D-435
92307	\N	\N	1590	497	\N	1590 Primary Mel 2	AM2 D-436
92309	\N	\N	1592	499	\N	1592 In Transit Met	AM2 D-438
92314	\N	\N	1597	463	\N	1597 MIS1	AM2 D-393
92315	\N	\N	1599	465	\N	1599 Invasive Mel 2	AM2 D-395
92316	\N	\N	1598	464	\N	1598 Invasive Mel 1	AM2 D-394
92318	\N	\N	1602	472	\N	1602 Metastatic Mel 2	AM2 D-405
92319	\N	\N	1603	473	\N	1603 Normal 2	AM2 D-406
92321	\N	\N	1594	467	\N	1594 MIS1	AM2 D-400
92322	\N	\N	1596	469	\N	1596 Invasive Primary Mel 2	AM2 D-402
92323	\N	\N	1595	468	\N	1595 Invasive Primary Mel 1	AM2 D-401
92325	\N	\N	1445	3927	\N	1445 Nevus	SND-01
92326	\N	\N	1459	3935	\N	1459 Nevus	SND-09
92327	\N	\N	1452	3928	\N	1452 Nevus	SND-02
92328	\N	\N	2022	3454	\N	2022 Compound Nevus	OM-23D
92330	\N	\N	1464	3940	\N	1464 Nevus	SND-14
92331	\N	\N	1461	3937	\N	1461 Nevus	SND-11
92332	\N	\N	1462	3938	\N	1462 Nevus	SND-12
92334	\N	\N	1465	3941	\N	1465 Nevus	SND-15
92337	\N	\N	1458	3934	\N	1458 Nevus	SND-08
92338	\N	\N	1454	3930	\N	1454 Nevus	SND-04
92339	\N	\N	1453	3929	\N	1453 Nevus	SND-03
92340	\N	\N	1466	3942	\N	1466 Nevus	SND-16
92342	\N	\N	2597	4290	\N	2597 Spitz Nevus	DMS-033
92352	\N	\N	807	1107	\N	807 PAM	CMD-02
92353	\N	\N	808	1108	\N	808 MELANOMA	CM D-03
92354	\N	\N	809	1109	\N	809 MELANOMA	CM D-04
92355	\N	\N	810	1110	\N	810 NORMAL	CM D-05
92356	\N	\N	811	1111	\N	811 MELANOMA	CM D-06
92357	\N	\N	996	1190	\N	996 Normal	CM D-85
92358	\N	\N	812	1112	\N	812 MELANOMA	CM D-07
92359	\N	\N	980	1174	\N	980 Normal	CM D-69
92360	\N	\N	813	1113	\N	813 MELANOMA	CM D-08
92361	\N	\N	814	1114	\N	814 MELANOMA	CM D-09
92362	\N	\N	815	1115	\N	815 MELANOMA	CM D-10
92363	\N	\N	816	1116	\N	816 MELANOMA	CM D-11
92364	\N	\N	981	1175	\N	981 Normal	CM D-70
92365	\N	\N	883	1173	\N	883 Normal	CM D-68
92366	\N	\N	818	1118	\N	818 MELANOMA	CM D-13
92367	\N	\N	982	1176	\N	982 Normal	CM D-71
92368	\N	\N	819	1119	\N	819 MELANOMA	CM D-14
92369	\N	\N	820	1120	\N	820 NORMAL	CM D-15
92370	\N	\N	821	1121	\N	821 MELANOMA	CM D-16
92371	\N	\N	825	1124	\N	825 MELANOMA	CM D-19
92372	\N	\N	826	1125	\N	826 NORMAL	CM D-20
92373	\N	\N	827	1126	\N	827 MELANOMA	CM D-21
92374	\N	\N	983	1177	\N	983 Normal	CM D-72
92375	\N	\N	828	1127	\N	828 MELANOMA	CM D-22
92376	\N	\N	829	1128	\N	829 MELANOMA	CM D-23
92377	\N	\N	830	1129	\N	830 MELANOMA	CM D-24
92378	\N	\N	831	1130	\N	831 MELANOMA	CM D-25
92379	\N	\N	832	1131	\N	832 NORMAL	CM D-26
92380	\N	\N	833	1132	\N	833 MELANOMA	CM D-27
92381	\N	\N	834	1133	\N	834 NORMAL	CM D-28
92382	\N	\N	835	1134	\N	835 MELANOMA	CM D-29
92383	\N	\N	837	1135	\N	837 MELANOMA	CM D-30
92384	\N	\N	838	1136	\N	838 MELANOMA	CM D-31
92385	\N	\N	984	1178	\N	984 Normal	CM D-73
92386	\N	\N	839	1137	\N	839 MELANOMA	CM D-32
92387	\N	\N	840	1138	\N	840 PAM	CM D-33
92388	\N	\N	841	1139	\N	841 NORMAL	CM D-34
92389	\N	\N	842	1140	\N	842 MELANOMA	CM D-35
92390	\N	\N	985	1179	\N	985 Normal	CM D-74
92391	\N	\N	843	1141	\N	843 MELANOMA	CM D-36
92392	\N	\N	844	1142	\N	844 MELANOMA	CM D-37
92393	\N	\N	986	1180	\N	986 Normal	CM D-75
92394	\N	\N	845	1143	\N	845 MELANOMA	CM D-38
92395	\N	\N	987	1181	\N	987 Normal	CM D-76
92396	\N	\N	846	1144	\N	846 MELANOMA	CM D-39
92397	\N	\N	988	1182	\N	988 Normal	CM D-77
92398	\N	\N	847	1145	\N	847 MELANOMA	CM D-40
92399	\N	\N	848	1146	\N	848 NORMAL	CM D-41
92400	\N	\N	989	1183	\N	989 Normal	CM D-78
92401	\N	\N	850	1147	\N	850 NEVUS	CM D-42
92402	\N	\N	851	1148	\N	851 NEVUS	CM D-43
92403	\N	\N	852	1149	\N	852 NEVUS	CM D-44
92404	\N	\N	853	1150	\N	853 NEVUS	CM D-45
92405	\N	\N	854	1151	\N	854 NEVUS	CM D-46
92406	\N	\N	855	1152	\N	855 NEVUS	CM D-47
92407	\N	\N	856	1153	\N	856 NEVUS	CM D-48
92408	\N	\N	990	1184	\N	990 Normal	CM D-79
92409	\N	\N	857	1154	\N	857 NEVUS	CM D-49
92410	\N	\N	858	1155	\N	858 NEVUS	CM D-50
92411	\N	\N	859	1156	\N	859 NEVUS	CM D-51
92412	\N	\N	991	1185	\N	991 Normal	CM D-80
92413	\N	\N	860	1157	\N	860 NEVUS	CM D-52
92414	\N	\N	992	1186	\N	992 Normal	CM D-81
92415	\N	\N	861	1158	\N	861 NEVUS	CM D-53
92416	\N	\N	863	1159	\N	863 PAM	CM D-54
92417	\N	\N	864	1160	\N	864 NORMAL	CM D-55
92418	\N	\N	865	1161	\N	865 PAM	CM D-56
92419	\N	\N	866	1162	\N	866 NORMAL	CM D-57
92420	\N	\N	867	1163	\N	867 PAM	CM D-58
92421	\N	\N	868	1164	\N	868 PAM	CM D-59
92422	\N	\N	993	1187	\N	993 Normal	CM D-82
92423	\N	\N	869	1165	\N	869 PAM	CM D-60
92424	\N	\N	870	1166	\N	870 NORMAL	CM D-61
92425	\N	\N	994	1188	\N	994 Normal	CM D-83
92426	\N	\N	871	1167	\N	871 PAM	CM D-62
92427	\N	\N	817	1117	\N	817 PAM	CM D-12
92428	\N	\N	872	1168	\N	872 PAM	CM D-63
92429	\N	\N	995	1189	\N	995 Normal	CM D-84
92430	\N	\N	873	1169	\N	873 PAM	CM D-64
92431	\N	\N	874	1170	\N	874 PAM	CM D-65
92432	\N	\N	875	1171	\N	875 PAM	CM D-66
92433	\N	\N	877	1172	\N	877 PAM	CM D-67
92434	\N	\N	822	1122	\N	822 MELANOMA	CM D-17
92435	\N	\N	823	1123	\N	823 NORMAL	CM D-18
92453	\N	\N	2663	602	\N	2663 Normal	AM2 D-563
92459	\N	\N	2669	4457	\N	2669 Normal	MucM D-006
92461	\N	\N	2508	2039	\N	2508 Normal	LMM D-027
92466	\N	\N	2600	4293	\N	2600 Normal	DMS-035N
92468	\N	\N	2675	4459	\N	2675 Normal	MucM D-012
92473	\N	\N	2523	2054	\N	2523 Normal	LMM D-042
92474	\N	\N	2557	4403	\N	2557 Normal	KA D-31
92595	\N	\N	2647	597	\N	2647 Normal	AM2 D-547
92344	\N	\N	1483	3949	\N	1483 Nevus	SND-23
92346	\N	\N	1457	3933	\N	1457 Nevus	SND-07
92347	\N	\N	2023	3456	\N	2023 Intramucosal Nevus	OM-24D
92350	\N	\N	1431	1502	\N	1431 Normal	DNA-99
92446	\N	\N	2608	4301	\N	2608 Spitz Nevus	DMS-040
92447	\N	\N	2609	4302	\N	2609 Normal	DMS-040N
92450	\N	\N	2507	2083	\N	2507 MIS	LMM R-026
92451	\N	\N	2506	2082	\N	2506 Invasive	LMM R-025
92457	\N	\N	1579	478	\N	1579 Met1	AM2 D-412
92465	\N	\N	2599	4292	\N	2599 Spitz Nevus	DMS-035
92467	\N	\N	2024	3458	\N	2024 Intramucosal Nevus	OM-25D
92471	\N	\N	2522	2093	\N	2522 MIS	LMM R-041
92472	\N	\N	2521	2092	\N	2521 Invasive	LMM R-040
92475	\N	\N	2558	4404	\N	2558 Keratoacanthoma	KA D-32
92531	\N	\N	2052	3339	\N	2052 Mel	NM D-097
92532	\N	\N	2054	3341	\N	2054 Normal	NM D-099
92533	\N	\N	2611	4304	\N	2611 Spitz Nevus	DMS-042
92536	\N	\N	2214	1751	\N	2214 Normal	DNA-374
92541	\N	\N	2543	4389	\N	2543 Normal	KA D-17
92546	\N	\N	2548	4394	\N	2548 Normal	KA D-22
92551	\N	\N	2660	601	\N	2660 Normal	AM2 D-560
92552	\N	\N	2531	4377	\N	2531 Normal	KA D-05
92555	\N	\N	2533	4379	\N	2533 Normal	KA D-07
92556	\N	\N	2047	3334	\N	2047 Mel	NM D-092
92557	\N	\N	2048	3335	\N	2048 Mel	NM D-093
92558	\N	\N	2049	3336	\N	2049 Mel	NM D-094
92559	\N	\N	2050	3337	\N	2050 Normal	NM D-095
92561	\N	\N	2559	4405	\N	2559 Normal	KA D-33
92564	\N	\N	2562	4408	\N	2562 Normal	KA D-36
92569	\N	\N	2553	4399	\N	2553 Normal	KA D-27
92570	\N	\N	2555	4401	\N	2555 Normal	KA D-29
92572	\N	\N	2044	3331	\N	2044 Mel	NM D-089
92573	\N	\N	2043	3330	\N	2043 Mel	NM D-088
92574	\N	\N	2045	3332	\N	2045 Mel	NM D-090
92575	\N	\N	2046	3333	\N	2046 Normal	NM D-091
92581	\N	\N	2654	599	\N	2654 Normal	AM2 D-554
92589	\N	\N	2226	1763	\N	2226 Normal	DNA-393
92478	\N	\N	2601	4294	\N	2601 Spitz Nevus	DMS-036
92480	\N	\N	1469	3945	\N	1469 Nevus	SND-19
92481	\N	\N	1578	487	\N	1578 Local Recurrent-Met2	AM2 D-425
92482	\N	\N	1580	480	\N	1580 Local Recurrent-Met3	AM2 D-414
92485	\N	\N	2025	3460	\N	2025 Blue Nevus	OM-26D
92486	\N	\N	1604	474	\N	1604 Normal	AM2 D-407
92487	\N	\N	1605	475	\N	1605 Metastatic Mel 1	AM2 D-408
92490	\N	\N	2303	3857	\N	2303 Tumor	SCH D-01
92492	\N	\N	2602	4295	\N	2602 Spitz Nevus	DMS-037
92493	\N	\N	2200	1737	\N	2200 Mel	DNA-355
92494	\N	\N	2201	1738	\N	2201 MIS	DNA-356
92495	\N	\N	2202	1739	\N	2202 Nevus	DNA-357
92497	\N	\N	1577	458	\N	1577 Met1	AM2 D-383
92498	\N	\N	1488	3954	\N	1488 Nevus	SND-28
92499	\N	\N	2604	4297	\N	2604 Spitz Nevus	DMS-038
92500	\N	\N	2605	4298	\N	2605 Normal	DMS-038N
92501	\N	\N	1480	3946	\N	1480 Nevus	SND-20
92502	\N	\N	1484	3950	\N	1484 Nevus	SND-24
92506	\N	\N	2204	1741	\N	2204 Mel	DNA-359
92508	\N	\N	2205	1742	\N	2205 Nevus	DNA-361
92509	\N	\N	1482	3948	\N	1482 Nevus	SND-22
92510	\N	\N	2607	4300	\N	2607 Normal	DMS-039N
92511	\N	\N	2606	4299	\N	2606 Spitz Nevus	DMS-039
92512	\N	\N	1486	3952	\N	1486 Nevus	SND-26
92513	\N	\N	1485	3951	\N	1485 Nevus	SND-25
92517	\N	\N	2207	1744	\N	2207 MIS	DNA-364
92518	\N	\N	2208	1745	\N	2208 Nevus	DNA-365
92519	\N	\N	2209	1746	\N	2209 PRAME-positive Nevus	DNA-366
92524	\N	\N	1487	3953	\N	1487 Nevus	SND-27
92525	\N	\N	2610	4303	\N	2610 Spitz Nevus	DMS-041
92527	\N	\N	1877	2166	\N	1877 Lentigo Simplex	LN D-071
92528	\N	\N	1878	2167	\N	1878 Junctional Melanocytic Nevus	LN D-072
92534	\N	\N	2211	1748	\N	2211 Mel	DNA-369
92535	\N	\N	2212	1749	\N	2212 MIS	DNA-372
92537	\N	\N	2213	1750	\N	2213 Nevus	DNA-373
92538	\N	\N	2493	2015	\N	2493 Normal	LMM D-003
92539	\N	\N	2491	2013	\N	2491 Invasive	LMM D-001
92540	\N	\N	2492	2014	\N	2492 MIS	LMM D-002
92542	\N	\N	2544	4390	\N	2544 Keratoacanthoma	KA D-18
92543	\N	\N	2545	4391	\N	2545 Keratoacanthoma	KA D-19
92544	\N	\N	2546	4392	\N	2546 Keratoacanthoma	KA D-20
92545	\N	\N	2547	4393	\N	2547 Keratoacanthoma	KA D-21
92547	\N	\N	2549	4395	\N	2549 Keratoacanthoma	KA D-23
92553	\N	\N	2532	4378	\N	2532 Keratoacanthoma	KA D-06
92554	\N	\N	2534	4380	\N	2534 Keratoacanthoma	KA D-08
92560	\N	\N	1481	3947	\N	1481 Nevus	SND-21
92562	\N	\N	2560	4406	\N	2560 Keratoacanthoma	KA D-34
92563	\N	\N	2561	4407	\N	2561 Keratoacanthoma	KA D-35
92565	\N	\N	2470	2035	\N	2470 MIS	LMM D-023
92566	\N	\N	2469	2034	\N	2469 Invasive	LMM D-022
92567	\N	\N	2598	4291	\N	2598 Spitz Nevus	DMS-034
92568	\N	\N	2554	4400	\N	2554 Keratoacanthoma	KA D-28
92571	\N	\N	2556	4402	\N	2556 Keratoacanthoma	KA D-30
92582	\N	\N	2498	2020	\N	2498 MIS	LMM D-008
92583	\N	\N	2497	2019	\N	2497 Invasive	LMM D-007
92585	\N	\N	2233	1770	\N	2233 Normal	DNA-403
92586	\N	\N	2223	1760	\N	2223 Mel1	DNA-390
92587	\N	\N	2225	1762	\N	2225 Nevus	DNA-392
92588	\N	\N	2224	1761	\N	2224 Mel2	DNA-391
92682	\N	\N	2550	4396	\N	2550 Normal	KA D-24
92599	\N	\N	2494	2016	\N	2494 Invasive	LMM D-004
92600	\N	\N	2495	2017	\N	2495 MIS	LMM D-005
92614	\N	\N	2242	1776	\N	2242 Normal	DNA-419
92622	\N	\N	2501	2023	\N	2501 MIS	LMM D-011
92623	\N	\N	2500	2022	\N	2500 Invasive	LMM D-010
92637	\N	\N	2012	3434	\N	2012 Intramucosal Melanocytic Nevus	OM-10D (P040_11B)
92639	\N	\N	2017	3443	\N	2017 Invasive Melanoma	OM-15D (P040_11D)
92642	\N	\N	2499	2021	\N	2499 Normal	LMM D-009
92646	\N	\N	2502	2024	\N	2502 Normal	LMM D-012
92648	\N	\N	2227	1764	\N	2227 Mel	DNA-394
92649	\N	\N	2228	1765	\N	2228 Nevus	DNA-396
92650	\N	\N	2229	1766	\N	2229 Normal	DNA-397
92651	\N	\N	2231	1768	\N	2231 MIS	DNA-401
92652	\N	\N	2230	1767	\N	2230 Mel	DNA-399
92653	\N	\N	2232	1769	\N	2232 Nevus	DNA-402
92654	\N	\N	1875	2164	\N	1875 Compound Melanocytic Nevus	LN D-069
92655	\N	\N	1876	2165	\N	1876 Nevus	LN D-070
92656	\N	\N	2026	3462	\N	2026 Intramucosal Nevus	OM-27D
92657	\N	\N	2027	3464	\N	2027 Intramucosal Nevus	OM-28D
92658	\N	\N	1882	2171	\N	1882 Lentigo Simplex	LN D-076
92659	\N	\N	1883	2172	\N	1883 Nevus	LN D-077
92660	\N	\N	1884	2173	\N	1884 Mel	LN D-078
92661	\N	\N	1890	2178	\N	1890 Lentigo Simplex	LN D-084
92662	\N	\N	1891	2179	\N	1891 Seborrheic Keratosis	LN D-085
92663	\N	\N	1879	2168	\N	1879 Lentigo Simplex	LN D-073
92664	\N	\N	1880	2169	\N	1880 Junctional Melanocytic Nevus	LN D-074
92665	\N	\N	1909	2207	\N	1909 Compound Melanocytic Nevus	LN D-114
92666	\N	\N	1910	2208	\N	1910 Compound Melanocytic Nevus	LN D-115
92668	\N	\N	2518	2090	\N	2518 Invasive	LMM R-037
92669	\N	\N	2519	2091	\N	2519 MIS	LMM R-038
92670	\N	\N	1888	2176	\N	1888 Nevus	LN D-082
92671	\N	\N	1889	2177	\N	1889 Mel	LN D-083
92672	\N	\N	1881	2170	\N	1881 Nevus	LN D-075
92673	\N	\N	2525	2095	\N	2525 MIS	LMM R-044
92674	\N	\N	2524	2094	\N	2524 Invasive	LMM R-043
92675	\N	\N	2515	2088	\N	2515 Invasive	LMM R-034
92676	\N	\N	2516	2089	\N	2516 MIS	LMM R-035
92677	\N	\N	2528	4374	\N	2528 Keratoacanthoma	KA D-02
92680	\N	\N	2530	4376	\N	2530 Keratoacanthoma	KA D-04
92681	\N	\N	2028	3466	\N	2028 Intramucosal Nevus	OM-29D
92683	\N	\N	2551	4397	\N	2551 Keratoacanthoma	KA D-25
92684	\N	\N	2552	4398	\N	2552 Keratoacanthoma	KA D-26
92685	\N	\N	1892	2180	\N	1892 Lentigo Simplex	LN D-086
92686	\N	\N	1886	2175	\N	1886 Nevus	LN D-080
92687	\N	\N	1885	2174	\N	1885 Nevus	LN D-079
92698	\N	\N	1900	2187	\N	1900 Nevus	LN D-094
92699	\N	\N	1898	2185	\N	1898 Lentigo Simplex	LN D-092
92700	\N	\N	1899	2186	\N	1899 Nevus	LN D-093
92701	\N	\N	1895	2182	\N	1895 Lentigo Simplex	LN D-089
92702	\N	\N	1896	2183	\N	1896 Nevus	LN D-090
92703	\N	\N	1897	2184	\N	1897 Nevus	LN D-091
92704	\N	\N	1894	2181	\N	1894 Nevus	LN D-087
92705	\N	\N	1905	2198	\N	1905 Lentigo Simplex	LN D-105
92786	\N	\N	2684	4609	\N	2684 Capture Area A1	VS-05_NA
92787	\N	\N	2526	2057	\N	2526 Normal	LMM D-045
92794	\N	\N	2587	4280	\N	2587 Blue Nevus	DMS-023
92798	\N	\N	2588	4281	\N	2588 Blue Nevus	DMS-024
92799	\N	\N	2581	4274	\N	2581 Blue Nevus	DMS-017
92802	\N	\N	2590	4283	\N	2590 Blue Nevus	DMS-026
92804	\N	\N	2591	4284	\N	2591 Blue Nevus	DMS-027
92805	\N	\N	2592	4285	\N	2592 Blue Nevus	DMS-028
92806	\N	\N	2593	4286	\N	2593 Blue Nevus	DMS-029
92812	\N	\N	2594	4287	\N	2594 Blue Nevus	DMS-030
92813	\N	\N	2517	2048	\N	2517 Normal	LMM D-036
92816	\N	\N	2595	4288	\N	2595 Blue Nevus	DMS-031
92707	\N	\N	1901	2201	\N	1901 Lentigo Simplex	LN D-108
92708	\N	\N	1902	2202	\N	1902 Nevus	LN D-109
92709	\N	\N	1907	2203	\N	1907 Lentigo Simplex	LN D-110
92710	\N	\N	1908	2204	\N	1908 Junctional Nevus	LN D-111
92711	\N	\N	1911	2200	\N	1911 Nevus	LN D-107
92712	\N	\N	1912	2225	\N	1912 Nevus	LN D-132
92713	\N	\N	1913	2226	\N	1913 Lentigo Simplex	LN D-133
92714	\N	\N	1914	2227	\N	1914 Lentigo Simplex	LN D-134
92715	\N	\N	1903	2205	\N	1903 Lentigo Simplex	LN D-112
92716	\N	\N	1904	2206	\N	1904 Nevus	LN D-113
92717	\N	\N	2215	1752	\N	2215 Mel	DNA-377
92718	\N	\N	2216	1753	\N	2216 Nevus	DNA-379
92720	\N	\N	2217	1754	\N	2217 Regressed Area	DNA-381
92721	\N	\N	2237	1774	\N	2237 MIS	DNA-417
92722	\N	\N	2219	1756	\N	2219 Mel	DNA-383
92723	\N	\N	2221	1758	\N	2221 Nevus	DNA-387
92724	\N	\N	2220	1757	\N	2220 MIS	DNA-385
92725	\N	\N	2222	1759	\N	2222 Normal	DNA-388
92726	\N	\N	2455	2033	\N	2455 Invasive	LMM D-021
92727	\N	\N	2454	2032	\N	2454 MIS	LMM D-020
92739	\N	\N	2481	4433	\N	2481 MIS	LMM D-050
92740	\N	\N	2480	4432	\N	2480 Invasive	LMM D-049
92744	\N	\N	2482	4434	\N	2482 Normal	LMM D-051
92745	\N	\N	1951	1592	\N	1951 Mel	DNA-194
92746	\N	\N	1952	1593	\N	1952 Nevus	DNA-195
92747	\N	\N	1953	1594	\N	1953 Normal	DNA-196
92757	\N	\N	2453	2031	\N	2453 Normal	LMM D-019
92763	\N	\N	2486	4438	\N	2486 Invasive	LMM D-055
92764	\N	\N	2487	4439	\N	2487 MIS	LMM D-056
92768	\N	\N	2476	19	\N	2476 Mel	22-44183B-DNA
92769	\N	\N	2624	4317	\N	2624 Congenital Nevus	DMS-054
92770	\N	\N	2625	4318	\N	2625 Congenital Nevus	DMS-055
92775	\N	\N	2626	4319	\N	2626 Congenital Nevus	DMS-056
92777	\N	\N	2536	4382	\N	2536 Keratoacanthoma	KA D-10
92778	\N	\N	2538	4384	\N	2538 Keratoacanthoma	KA D-12
92780	\N	\N	2627	4320	\N	2627 Congenital Nevus	DMS-057
92782	\N	\N	2628	4321	\N	2628 Congenital Nevus	DMS-058
92783	\N	\N	2629	4322	\N	2629 Congenital Nevus	DMS-059A
92784	\N	\N	2630	4323	\N	2630 Congenital Nevus	DMS-059B
92788	\N	\N	2294	1788	\N	2294 Mel	DNA-431
92789	\N	\N	2295	1789	\N	2295 MIS	DNA-432
92790	\N	\N	2296	1790	\N	2296 Nevus	DNA-433
92791	\N	\N	2297	1791	\N	2297 Mel	DNA-434
92792	\N	\N	2298	1792	\N	2298 Normal	DNA-435
92795	\N	\N	2268	3342	\N	2268 Met1	NM D-100
92796	\N	\N	2269	3342	\N	2269 Met2	NM D-100
92797	\N	\N	2270	3343	\N	2270 Normal	NM D-101
92801	\N	\N	2631	4324	\N	2631 Congenital Nevus	DMS-060
92803	\N	\N	2632	4325	\N	2632 Congenital Nevus	DMS-061
92807	\N	\N	2504	2026	\N	2504 MIS	LMM D-014
92808	\N	\N	2503	2025	\N	2503 Invasive	LMM D-013
92809	\N	\N	2505	2027	\N	2505 Normal	LMM D-015
92810	\N	\N	2633	4326	\N	2633 Congenital Nevus	DMS-062
92811	\N	\N	2634	4327	\N	2634 Normal	DMS-062N
92814	\N	\N	2635	4328	\N	2635 Congenital Nevus	DMS-063
92817	\N	\N	2596	4289	\N	2596 Blue Nevus	DMS-032
92818	\N	\N	2287	1781	\N	2287 Mel	DNA-424
92819	\N	\N	2288	1782	\N	2288 Melanocytoma	DNA-425
92820	\N	\N	2477	4429	\N	2477 Invasive	LMM D-046
92821	\N	\N	2478	4430	\N	2478 MIS	LMM D-047
92822	\N	\N	2479	4431	\N	2479 Normal	LMM D-048
92840	\N	\N	2576	4269	\N	2576 Blue Nevus	DMS-012
92843	\N	\N	2573	4266	\N	2573 Blue Nevus	DMS-009
92844	\N	\N	2686	4611	\N	2686 Capture Area C1	VS-07_NA
92845	\N	\N	2572	4265	\N	2572 Blue Nevus	DMS-008
92846	\N	\N	2685	4610	\N	2685 Capture Area B1	VS-06_NA
92848	\N	\N	2577	4270	\N	2577 Blue Nevus	DMS-013
92849	\N	\N	2578	4271	\N	2578 Blue Nevus	DMS-014
92850	\N	\N	2579	4272	\N	2579 Blue Nevus	DMS-015
92851	\N	\N	2580	4273	\N	2580 Blue Nevus	DMS-016
92865	\N	\N	3438	4442	\N	3438 Unknown	LMM D-061
92866	\N	\N	3439	4443	\N	3439 Unknown	LMM D-062
92869	\N	\N	2566	4259	\N	2566 Congenital Nevus	DMS-002
92870	\N	\N	2567	4260	\N	2567 Congenital Nevus	DMS-003
92871	\N	\N	2571	4264	\N	2571 Congenital Nevus	DMS-007
92875	\N	\N	2570	4263	\N	2570 Congenital Nevus	DMS-006
92877	\N	\N	2575	4268	\N	2575 Blue Nevus	DMS-011
92878	\N	\N	2568	4261	\N	2568 Congenital Nevus	DMS-004
92891	\N	\N	2641	4444	\N	2641 Normal	LMM D-063
92918	\N	\N	2928	46	\N	2928 Tumor	35_M_NA
92919	\N	\N	2929	60	\N	2929 Tumor	49_M_NA
92920	\N	\N	1005	3309	\N	1005 Nodular Mel	NM D-067
92921	\N	\N	924	2437	\N	924 Mel	MDD-54
92922	\N	\N	1124	2595	\N	1124 Mel	MDD-212
92923	\N	\N	1118	2589	\N	1118 Mel	MDD-206
92924	\N	\N	1119	2590	\N	1119 Mel	MDD-207
92925	\N	\N	923	2436	\N	923 Mel	MDD-53
92926	\N	\N	1133	2604	\N	1133 Mel	MDD-221
92927	\N	\N	1127	2598	\N	1127 Mel	MDD-215
92928	\N	\N	1109	2580	\N	1109 Mel	MDD-197
92929	\N	\N	2718	4504	\N	2718 Tumor	KAM102-T-B
92930	\N	\N	1113	2584	\N	1113 Mel	MDD-201
92931	\N	\N	1126	2597	\N	1126 Mel	MDD-214
92932	\N	\N	928	2441	\N	928 Mel	MDD-58
92933	\N	\N	2720	4509	\N	2720 Tumor	KAM116-T
92936	\N	\N	2719	4508	\N	2719 Tumor	KAM113-T-H
92937	\N	\N	1112	2583	\N	1112 Mel	MDD-200
92940	\N	\N	1122	2593	\N	1122 Mel	MDD-210
92941	\N	\N	1120	2591	\N	1120 Mel	MDD-208
92942	\N	\N	1117	2588	\N	1117 Mel	MDD-205
92943	\N	\N	921	2434	\N	921 Mel	MDD-51
92944	\N	\N	1125	2596	\N	1125 Mel	MDD-213
92824	\N	\N	2234	1771	\N	2234 Mel	DNA-404
92826	\N	\N	2456	21	\N	2456 Tumor	22-104389A2-DNA
92830	\N	\N	2457	25	\N	2457 Tumor	22-104389C-DNA
92831	\N	\N	2299	1793	\N	2299 Mel	DNA-436
92832	\N	\N	2300	1794	\N	2300 Nevus	DNA-437
92833	\N	\N	2301	1795	\N	2301 Normal	DNA-438
92835	\N	\N	2540	4386	\N	2540 Keratoacanthoma	KA D-14
92837	\N	\N	2542	4388	\N	2542 Keratoacanthoma	KA D-16
92839	\N	\N	2289	1783	\N	2289 Normal	DNA-426
92841	\N	\N	2584	4277	\N	2584 Congenital Nevus	DMS-020
92847	\N	\N	2247	28	\N	2247 tum	22-125373-RNA
92854	\N	\N	2582	4275	\N	2582 Blue Nevus	DMS-018
92855	\N	\N	2488	4440	\N	2488 Normal	LMM D-057
92859	\N	\N	2291	1785	\N	2291 Nevus	DNA-428
92860	\N	\N	2290	1784	\N	2290 Mel	DNA-427
92861	\N	\N	2292	1786	\N	2292 Mel	DNA-429
92862	\N	\N	2585	4278	\N	2585 Congenital Nevus	DMS-021
92874	\N	\N	2583	4276	\N	2583 Congenital Nevus	DMS-019
92885	\N	\N	2563	4256	\N	2563 Congenital Nevus	DMS-001A
92886	\N	\N	2564	4257	\N	2564 Congenital Nevus	DMS-001B
92887	\N	\N	2565	4258	\N	2565 Congenital Nevus	DMS-001C
92888	\N	\N	2612	4305	\N	2612 Spitz Nevus	DMS-043
92890	\N	\N	2293	1787	\N	2293 Normal	DNA-430
92892	\N	\N	2613	4306	\N	2613 Spitz Nevus	DMS-044
92894	\N	\N	2447	1800	\N	2447 Mel	DNA-443
92895	\N	\N	2450	2028	\N	2450 Normal	LMM D-016
92896	\N	\N	2451	2029	\N	2451 MIS	LMM D-017
92897	\N	\N	2452	2030	\N	2452 Invasive	LMM D-018
92898	\N	\N	2614	4307	\N	2614 Spitz Nevus	DMS-045
92899	\N	\N	2615	4308	\N	2615 Spitz Nevus	DMS-046
92900	\N	\N	2449	1802	\N	2449 Normal	DNA-445
92901	\N	\N	2448	1801	\N	2448 Nevus	DNA-444
92902	\N	\N	2445	1798	\N	2445 Nevus	DNA-441
92903	\N	\N	2446	1799	\N	2446 Normal	DNA-442
92904	\N	\N	2443	1796	\N	2443 Mel	DNA-439
92905	\N	\N	2444	1797	\N	2444 MIS	DNA-440
92906	\N	\N	2460	1804	\N	2460 Nevus	DNA-447
92907	\N	\N	2459	1803	\N	2459 MIS	DNA-446
92908	\N	\N	2461	1805	\N	2461 Normal	DNA-448
92909	\N	\N	2475	595	\N	2475 Normal	AM2 D-541
92910	\N	\N	2473	593	\N	2473 MIS	AM2 D-539
92912	\N	\N	2474	594	\N	2474 MIS	AM2 D-540
92913	\N	\N	2472	592	\N	2472 Invasive	AM2 D-538
92934	\N	\N	1842	2946	\N	1842 Normal	MMD-331
92935	\N	\N	1841	2945	\N	1841 Mel	MMD-330
92938	\N	\N	1839	2943	\N	1839 Mel	MMD-328
92939	\N	\N	1840	2944	\N	1840 Normal	MMD-329
92945	\N	\N	1795	2824	\N	1795 Normal	MMD-209
92946	\N	\N	1792	2821	\N	1792 Mel	MMD-206
92947	\N	\N	1793	2822	\N	1793 Normal	MMD-207
92948	\N	\N	1794	2823	\N	1794 MIS	MMD-208
92960	\N	\N	1121	2592	\N	1121 Mel	MDD-209
92961	\N	\N	966	2479	\N	966 Mel	MDD-96
92962	\N	\N	1130	2601	\N	1130 Mel	MDD-218
92963	\N	\N	3074	1194	\N	3074 Tumor	CNS_31_Tumor_NA
92964	\N	\N	925	2438	\N	925 Mel	MDD-55
92965	\N	\N	1108	2579	\N	1108 Mel	MDD-196
92966	\N	\N	926	2439	\N	926 Mel	MDD-56
92969	\N	\N	922	2435	\N	922 Mel	MDD-52
92970	\N	\N	2734	4523	\N	2734 Tumor	KAM37-T
92971	\N	\N	1114	2585	\N	1114 Mel	MDD-202
92972	\N	\N	1026	2497	\N	1026 Mel	MDD-114
92973	\N	\N	1116	2587	\N	1116 Mel	MDD-204
92976	\N	\N	1789	2818	\N	1789 Normal	MMD-203
92977	\N	\N	1115	2586	\N	1115 Mel	MDD-203
92981	\N	\N	2262	3226	\N	2262 Normal	N-4
92984	\N	\N	2803	1965	\N	2803 Mel	Kit_227_Acral_WT_NA
92985	\N	\N	927	2440	\N	927 Mel	MDD-57
92986	\N	\N	967	2480	\N	967 Mel	MDD-97
92988	\N	\N	968	2481	\N	968 Mel	MDD-98
92989	\N	\N	2258	3478	\N	2258 Tumor	PM-4
92994	\N	\N	929	2442	\N	929 Mel	MDD-59
92995	\N	\N	1110	2581	\N	1110 Mel	MDD-198
92996	\N	\N	969	2482	\N	969 Mel	MDD-99
92997	\N	\N	1046	2517	\N	1046 Mel	MDD-134
92998	\N	\N	930	2443	\N	930 Mel	MDD-60
92999	\N	\N	1107	2578	\N	1107 Mel	MDD-195
93001	\N	\N	1834	2865	\N	1834 Normal	MMD-250
93004	\N	\N	2740	4529	\N	2740 Tumor	KAM75-T
93005	\N	\N	2757	4542	\N	2757 Normal	JBU8-Norm
93006	\N	\N	2758	4543	\N	2758 MVP	JBU8-MVP
93009	\N	\N	931	2444	\N	931 Mel	MDD-61
93010	\N	\N	932	2445	\N	932 Mel	MDD-62
93011	\N	\N	933	2446	\N	933 Mel	MDD-63
93014	\N	\N	1106	2577	\N	1106 Mel	MDD-194
93021	\N	\N	1829	2860	\N	1829 Normal	MMD-245
93029	\N	\N	2775	93	\N	2775 Tumor	AM_7_Tumor_NA
93030	\N	\N	2735	4524	\N	2735 Tumor	KAM43-T
93031	\N	\N	1105	2576	\N	1105 Mel	MDD-193
93034	\N	\N	970	2483	\N	970 Mel	MDD-100
93036	\N	\N	1763	2786	\N	1763 Normal	MMD-171
93037	\N	\N	1837	2878	\N	1837 Mel	MMD-263
93038	\N	\N	1838	2879	\N	1838 Normal	MMD-264
93040	\N	\N	1831	2862	\N	1831 Normal	MMD-247
93042	\N	\N	2737	4526	\N	2737 Tumor	KAM62-T
93043	\N	\N	1103	2574	\N	1103 Mel	MDD-191
93044	\N	\N	2747	4505	\N	2747 Normal	KAM111-N-A4
93045	\N	\N	2749	4507	\N	2749 Tumor	KAM111-T-A2
93046	\N	\N	1028	2499	\N	1028 Mel	MDD-116
93049	\N	\N	1101	2572	\N	1101 Mel	MDD-189
93050	\N	\N	934	2447	\N	934 Mel	MDD-64
93051	\N	\N	1104	2575	\N	1104 Mel	MDD-192
93055	\N	\N	1082	2553	\N	1082 Mel	MDD-170
93058	\N	\N	1102	2573	\N	1102 Mel	MDD-190
93059	\N	\N	935	2448	\N	935 Mel	MDD-65
93064	\N	\N	2463	82	\N	2463 Melanoma Cell Line	DNA-144 Imat B15
93065	\N	\N	2464	83	\N	2464 Melanoma Cell Line	144 Imat B15-2
93066	\N	\N	2465	84	\N	2465 Cell Line	144aI WT
93067	\N	\N	573	3278	\N	573 Nodular Mel	NM D-32
93068	\N	\N	1011	3315	\N	1011 Nodular Mel	NM D-073
93069	\N	\N	2466	85	\N	2466 Cell Line	230 WT
93070	\N	\N	593	3298	\N	593 Nodular Mel	NM D-053
93071	\N	\N	594	3299	\N	594 Nodular Mel	NM D-054
93072	\N	\N	31	152	\N	31 Normal	AM2 D-55
93073	\N	\N	32	153	\N	32 MIS	AM2 D-56
93074	\N	\N	33	154	\N	33 MIS	AM2 D-57
92967	\N	\N	1667	3019	\N	1667 Mel	MMR-46
92968	\N	\N	1668	2667	\N	1668 Normal	MMD-47
92974	\N	\N	1788	2817	\N	1788 Normal	MMD-202
92975	\N	\N	1787	2816	\N	1787 Mel	MMD-201
92978	\N	\N	1704	2729	\N	1704 Mel	MMD-112
92979	\N	\N	1705	2730	\N	1705 Normal	MMD-113
92980	\N	\N	1706	2731	\N	1706 MIS	MMD-114
92987	\N	\N	1699	2714	\N	1699 Mel	MMD-96
92990	\N	\N	1709	2909	\N	1709 Normal	MMD-294
92991	\N	\N	1710	2735	\N	1710 MIS	MMD-118
92992	\N	\N	1708	2733	\N	1708 Mel	MMD-116
92993	\N	\N	1711	2735	\N	1711 MIS	MMD-118
93000	\N	\N	1833	3123	\N	1833 Mel	MMR-249
93002	\N	\N	1861	3166	\N	1861 Mel	MMR-350
93003	\N	\N	1862	2966	\N	1862 Normal	MMD-351
93007	\N	\N	1808	2843	\N	1808 Mel	MMD-228
93008	\N	\N	1809	2844	\N	1809 Normal	MMD-229
93012	\N	\N	1801	2836	\N	1801 Mel	MMD-221
93013	\N	\N	1802	2837	\N	1802 Normal	MMD-222
93015	\N	\N	1777	3092	\N	1777 Mel	MMR-184
93016	\N	\N	1778	2800	\N	1778 Normal	MMD-185
93017	\N	\N	1779	3093	\N	1779 Nevus	MMR-186
93018	\N	\N	1942	1583	\N	1942 Nevus	DNA-185
93019	\N	\N	1941	1582	\N	1941 Mel	DNA-184
93020	\N	\N	1943	1584	\N	1943 Normal	DNA-186
93022	\N	\N	1828	3120	\N	1828 Mel	MMR-244
93023	\N	\N	1760	2783	\N	1760 Normal	MMD-168
93024	\N	\N	1759	2782	\N	1759 Mel	MMD-167
93025	\N	\N	1761	2784	\N	1761 MIS	MMD-169
93026	\N	\N	1790	2892	\N	1790 Mel	MMD-277
93027	\N	\N	1791	2893	\N	1791 Normal	MMD-278
93028	\N	\N	1631	2626	\N	1631 Mel	MMD-06
93032	\N	\N	1781	2803	\N	1781 Normal	MMD-188
93033	\N	\N	1780	3094	\N	1780 Mel	MMR-187
93035	\N	\N	1762	2785	\N	1762 Mel	MMD-170
93039	\N	\N	1830	2861	\N	1830 Mel	MMD-246
93041	\N	\N	1832	2863	\N	1832 MIS	MMD-248
93047	\N	\N	1648	2648	\N	1648 Mel	MMD-28
93048	\N	\N	1649	2649	\N	1649 Normal	MMD-29
93052	\N	\N	1635	2630	\N	1635 Mel	MMD-10
93053	\N	\N	1810	2845	\N	1810 Mel	MMD-230
93054	\N	\N	1811	2846	\N	1811 Normal	MMD-231
93056	\N	\N	1864	3169	\N	1864 Normal	MMR-353
93057	\N	\N	1863	3168	\N	1863 Mel	MMR-352
93060	\N	\N	1636	2987	\N	1636 Mel	MMR-11
93061	\N	\N	1936	1577	\N	1936 Nevus	DNA-179
93062	\N	\N	1935	1576	\N	1935 Mel	DNA-178
93063	\N	\N	1937	1578	\N	1937 Normal	DNA-180
93075	\N	\N	34	155	\N	34 Mel1	AM2 D-58
93078	\N	\N	42	163	\N	42 Normal	AM2 D-66
93079	\N	\N	43	164	\N	43 MIS1	AM2 D-67
93080	\N	\N	44	165	\N	44 MIS2	AM2 D-68
93081	\N	\N	45	166	\N	45 Mel1	AM2 D-69
93082	\N	\N	595	3300	\N	595 Nodular Mel	NM D-055
93084	\N	\N	18	140	\N	18 MIS1	AM2 D-43
93085	\N	\N	19	141	\N	19 MIS2	AM2 D-44
93086	\N	\N	20	142	\N	20 Normal	AM2 D-45
93087	\N	\N	21	143	\N	21 Mel1	AM2 D-46
93089	\N	\N	1006	3310	\N	1006 Nodular Mel	NM D-068
93090	\N	\N	1004	3308	\N	1004 Nodular Mel	NM D-066
93091	\N	\N	577	3282	\N	577 Nodular Mel	NM D-036
93092	\N	\N	3801	4626	\N	3801 Cell Line	1205lu-1_NA
93093	\N	\N	3802	4627	\N	3802 Cell Line	1205lu-2_NA
93094	\N	\N	3803	4628	\N	3803 Cell Line	1205LU-3_NA
93095	\N	\N	576	3281	\N	576 Nodular Mel	NM D-035
93096	\N	\N	552	3257	\N	552 Nodular Mel	NM D-02
93099	\N	\N	38	159	\N	38 Normal	AM2 D-62
93100	\N	\N	39	160	\N	39 MIS1	AM2 D-63
93101	\N	\N	40	161	\N	40 MIS2	AM2 D-64
93102	\N	\N	41	162	\N	41 Mel1	AM2 D-65
93103	\N	\N	578	3283	\N	578 Nodular Mel	NM D-037
93104	\N	\N	1020	3324	\N	1020 Nodular Mel	NM D-082
93105	\N	\N	1012	3316	\N	1012 Nodular Mel	NM D-074
93106	\N	\N	570	3275	\N	570 Nodular Mel	NM D-27
93107	\N	\N	572	3277	\N	572 Nodular Mel	NM D-31
93108	\N	\N	35	156	\N	35 Normal	AM2 D-59
93109	\N	\N	36	157	\N	36 MIS1	AM2 D-60
93110	\N	\N	37	158	\N	37 Mel1	AM2 D-61
93111	\N	\N	1291	300	\N	1291 Normal	AM2 D-205
93112	\N	\N	553	3258	\N	553 Nodular Mel	NM D-03
93113	\N	\N	598	3303	\N	598 Nodular Mel	NM D-060
93114	\N	\N	46	167	\N	46 Normal	AM2 D-70
93115	\N	\N	47	168	\N	47 MIS1	AM2 D-71
93116	\N	\N	48	170	\N	48 Mel1	AM2 D-73
93122	\N	\N	574	3279	\N	574 Nodular Mel	NM D-033
93123	\N	\N	575	3280	\N	575 Nodular Mel	NM D-034
93124	\N	\N	579	3284	\N	579 Nodular Mel	NM D-038
93125	\N	\N	554	3259	\N	554 Nodular Mel	NM D-04
93126	\N	\N	582	3287	\N	582 Nodular Mel	NM D-041
93127	\N	\N	551	3256	\N	551 Nodular Mel	NM D-01
93128	\N	\N	580	3285	\N	580 Nodular Mel	NM D-039
93129	\N	\N	1009	3313	\N	1009 Nodular Mel	NM D-071
93130	\N	\N	1018	3322	\N	1018 Nodular Mel	NM D-080
93131	\N	\N	1014	3318	\N	1014 Nodular Mel	NM D-076
93132	\N	\N	569	3274	\N	569 Nodular Mel	NM D-19
93133	\N	\N	581	3286	\N	581 Nodular Mel	NM D-040
93134	\N	\N	583	3288	\N	583 Nodular Mel	NM D-043
93135	\N	\N	1017	3321	\N	1017 Nodular Mel	NM D-079
93136	\N	\N	599	3304	\N	599 Nodular Mel	NM D-061
93137	\N	\N	1021	3325	\N	1021 Nodular Mel	NM D-083
93138	\N	\N	571	3276	\N	571 Nodular Mel	NM D-29
93139	\N	\N	584	3289	\N	584 Nodular Mel	NM D-044
93141	\N	\N	85	171	\N	85 Normal	AM2 D-74
93142	\N	\N	86	172	\N	86 MIS1	AM2 D-75
93143	\N	\N	87	173	\N	87 MIS2	AM2 D-76
93144	\N	\N	88	174	\N	88 Mel1	AM2 D-77
93147	\N	\N	90	176	\N	90 MIS1	AM2 D-79
93148	\N	\N	91	177	\N	91 Mel1	AM2 D-80
93150	\N	\N	89	175	\N	89 Normal	AM2 D-78
93152	\N	\N	1010	3314	\N	1010 Nodular Mel	NM D-072
93153	\N	\N	92	178	\N	92 Normal	AM2 D-81
93154	\N	\N	93	179	\N	93 MIS1	AM2 D-82
93155	\N	\N	94	180	\N	94 MIS2	AM2 D-83
93156	\N	\N	95	181	\N	95 Mel1	AM2 D-84
93157	\N	\N	96	182	\N	96 Mel2	AM2 D-85
93158	\N	\N	1285	294	\N	1285 Met1	AM2 D-196
93160	\N	\N	1008	3312	\N	1008 Nodular Mel	NM D-070
93161	\N	\N	2696	4463	\N	2696 Tumor	DPN 49
93164	\N	\N	15	137	\N	15 Normal	AM2 D-40
93165	\N	\N	16	138	\N	16 MIS1	AM2 D-41
93166	\N	\N	17	139	\N	17 Mel1	AM2 D-42
93169	\N	\N	28	149	\N	28 Normal	AM2 D-52
93171	\N	\N	29	150	\N	29 MIS1	AM2 D-53
93172	\N	\N	30	151	\N	30 Mel1	AM2 D-54
93178	\N	\N	26	147	\N	26 MIS1	AM2 D-50
93179	\N	\N	27	148	\N	27 Mel1	AM2 D-51
93180	\N	\N	25	146	\N	25 Normal	AM2 D-49
93181	\N	\N	12	134	\N	12 Normal	AM2 D-37
93182	\N	\N	13	135	\N	13 MIS1	AM2 D-38
93183	\N	\N	14	136	\N	14 Mel1	AM2 D-39
93187	\N	\N	23	145	\N	23 Mel1	AM2 D-48
93189	\N	\N	24	183	\N	24 MIS1	AM2 D-86
93190	\N	\N	1289	298	\N	1289 Mel2	AM2 D-202
93191	\N	\N	1290	299	\N	1290 LN Met	AM2 D-203
93193	\N	\N	22	144	\N	22 Normal	AM2 D-47
93194	\N	\N	1007	3311	\N	1007 Nodular Mel	NM D-069
93195	\N	\N	600	3305	\N	600 Nodular Mel	NM D-063
93196	\N	\N	62	111	\N	62 Normal	AM2 D-14
93197	\N	\N	63	112	\N	63 MIS1	AM2 D-15
93198	\N	\N	64	113	\N	64 Mel1	AM2 D-16
93199	\N	\N	49	98	\N	49 Normal	AM2 D-01
93200	\N	\N	50	99	\N	50 MIS1	AM2 D-02
93201	\N	\N	51	100	\N	51 Mel1	AM2 D-03
93202	\N	\N	1147	276	\N	1147 Normal	AM2 D-178
93203	\N	\N	1146	275	\N	1146 MIS	AM2 D-177
93204	\N	\N	1145	274	\N	1145 Mel1	AM2 D-176
93206	\N	\N	58	107	\N	58 Normal	AM2 D-10
93209	\N	\N	61	110	\N	61 Mel1	AM2 D-13
93210	\N	\N	52	101	\N	52 Normal	AM2 D-04
93211	\N	\N	53	102	\N	53 Nevus	AM2 D-05
93212	\N	\N	54	103	\N	54 MIS1	AM2 D-06
93213	\N	\N	55	104	\N	55 MIS2	AM2 D-07
93214	\N	\N	56	105	\N	56 MIS3	AM2 D-08
93215	\N	\N	57	106	\N	57 Mel1	AM2 D-09
93219	\N	\N	2937	169	\N	2937 Not Processed	AM2 D-72
93220	\N	\N	1296	305	\N	1296 MIS1	AM2 D-211
93221	\N	\N	1297	306	\N	1297 MIS2	AM2 D-212
93222	\N	\N	1298	307	\N	1298 Mel1	AM2 D-213
93223	\N	\N	1299	308	\N	1299 Mel2	AM2 D-214
93224	\N	\N	1294	303	\N	1294 LN Met	AM2 D-208
93226	\N	\N	1300	309	\N	1300 LN Met	AM2 D-215
93229	\N	\N	1148	277	\N	1148 LN Met 1	AM2 D-179
93231	\N	\N	1307	316	\N	1307 LN Met 1	AM2 D-222
93234	\N	\N	1616	502	\N	1616 Normal	AM2 D-441
93235	\N	\N	1308	317	\N	1308 Bladder Metastasis	AM2 D-223
93237	\N	\N	1615	500	\N	1615 Normal	AM2 D-439
93238	\N	\N	592	3297	\N	592 Nodular Mel	NM D-052
93239	\N	\N	588	3293	\N	588 Nodular Mel	NM D-048
93240	\N	\N	590	3295	\N	590 Nodular Mel	NM D-050
93241	\N	\N	591	3296	\N	591 Nodular Mel	NM D-051
93242	\N	\N	587	3292	\N	587 Nodular Mel	NM D-047
93243	\N	\N	589	3294	\N	589 Nodular Mel	NM D-049
93244	\N	\N	585	3290	\N	585 Nodular Mel	NM D-045
93245	\N	\N	586	3291	\N	586 Nodular Mel	NM D-046
93246	\N	\N	3813	886	\N	3813 Lung Cells	Bivona_L_1_NA
93247	\N	\N	3814	889	\N	3814 Lung Cells	Bivona_L2_NA
93248	\N	\N	3815	890	\N	3815 Lung Cells	Bivona_L3_NA
93249	\N	\N	3816	891	\N	3816 Lung Cells	Bivona_L4_NA
93250	\N	\N	3817	892	\N	3817 Lung Cells	Bivona_L5_NA
93251	\N	\N	3818	893	\N	3818 Lung Cells	Bivona_L6_NA
93252	\N	\N	3819	869	\N	3819 Lung Cell Line	BB09_Bivona_L7_NA
93253	\N	\N	3820	870	\N	3820 Lung Cell Line	BB09_Bivona_L8_NA
93254	\N	\N	3821	871	\N	3821 Lung Cell Line	BB09_Bivona_L9_NA
93255	\N	\N	3811	872	\N	3811 Lung Cell Line	BB09_Bivona_L10_NA
93256	\N	\N	3812	873	\N	3812 Lung Cell Line	BB09_Bivona_L11_NA
93257	\N	\N	3823	885	\N	3823 Lung Cell Line	Bivona_L_17_NA
93258	\N	\N	3824	887	\N	3824 Tumor	Bivona_L_18_NA
93259	\N	\N	3825	888	\N	3825 Tumor	Bivona_L_19_NA
93260	\N	\N	2980	895	\N	2980 Tumor	BN_M1_NA
93261	\N	\N	2981	896	\N	2981 Tumor	BN_M2_NA
93262	\N	\N	2982	897	\N	2982 Normal	BN_N1_NA
93263	\N	\N	2983	898	\N	2983 Normal	BN_N2_NA
93264	\N	\N	2420	53	\N	2420 Buffy Coat DNA	D43_NA_BC
93265	\N	\N	2336	4192	\N	2336 Cell Line	Xu-1
93266	\N	\N	2337	4193	\N	2337 Cell Line	Xu-2
93267	\N	\N	2338	4194	\N	2338 Cell Line	Xu-3
93268	\N	\N	2339	4195	\N	2339 Cell Line	Xu-4
93269	\N	\N	2340	4196	\N	2340 Cell Line	Xu-5
93270	\N	\N	2341	4197	\N	2341 Cell Line	Xu-6
93271	\N	\N	2342	4198	\N	2342 Cell Line	Xu-7
93272	\N	\N	2343	4199	\N	2343 Cell Line	Xu-8
93273	\N	\N	2344	4200	\N	2344 Cell Line	Xu-9
93274	\N	\N	2345	4201	\N	2345 Cell Line	Xu-10
93275	\N	\N	2346	4202	\N	2346 Cell Line	Xu-11
93276	\N	\N	2347	4203	\N	2347 Cell Line	Xu-12
93277	\N	\N	2348	4204	\N	2348 Cell Line	Xu-13
93278	\N	\N	2349	4205	\N	2349 Cell Line	Xu-14
93279	\N	\N	2350	4206	\N	2350 Cell Line	Xu-015
93280	\N	\N	2351	4207	\N	2351 Cell Line	Xu-016
93281	\N	\N	2352	4208	\N	2352 Cell Line	Xu-017
93282	\N	\N	2353	4209	\N	2353 Cell Line	Xu-018
93283	\N	\N	2354	4210	\N	2354 Cell Line	Xu-019
93284	\N	\N	2355	4211	\N	2355 Cell Line	Xu-020
93285	\N	\N	2356	4212	\N	2356 Cell Line	Xu-021
93286	\N	\N	2357	4213	\N	2357 Cell Line	Xu-022
93287	\N	\N	2358	4214	\N	2358 Cell Line	Xu-023
93288	\N	\N	2359	4215	\N	2359 Cell Line	Xu-024
93289	\N	\N	2360	4216	\N	2360 Cell Line	Xu-025
93290	\N	\N	2361	4217	\N	2361 Cell Line	Xu-026
93291	\N	\N	2362	4218	\N	2362 Cell Line	Xu-027
93292	\N	\N	2363	4219	\N	2363 Cell Line	Xu-028
93293	\N	\N	2364	4220	\N	2364 Cell Line	Xu-029
93294	\N	\N	2365	4221	\N	2365 Cell Line	Xu-030
93295	\N	\N	2366	4222	\N	2366 Cell Line	Xu-031
93296	\N	\N	2367	4223	\N	2367 Cell Line	Xu-032
93297	\N	\N	2368	4224	\N	2368 Cell Line	Xu-033
93298	\N	\N	2369	4225	\N	2369 Cell Line	Xu-034
93299	\N	\N	2370	4226	\N	2370 Cell Line	Xu-035
93300	\N	\N	2371	4227	\N	2371 Cell Line	Xu-036
93301	\N	\N	2372	4228	\N	2372 Cell Line	Xu-037
93302	\N	\N	2373	4229	\N	2373 Cell Line	Xu-038
93303	\N	\N	2374	4230	\N	2374 Cell Line	Xu-039
93304	\N	\N	2375	4231	\N	2375 Cell Line	Xu-040
93305	\N	\N	2376	4232	\N	2376 Cell Line	Xu-041
93306	\N	\N	2377	4233	\N	2377 Cell Line	Xu-042
93307	\N	\N	2378	4234	\N	2378 Cell Line	Xu-043
93308	\N	\N	2379	4235	\N	2379 Cell Line	Xu-044
93309	\N	\N	2380	4236	\N	2380 Cell Line	Xu-045
93310	\N	\N	2381	4237	\N	2381 Cell Line	Xu-046
93311	\N	\N	2382	4238	\N	2382 Cell Line	Xu-047
93312	\N	\N	2383	4239	\N	2383 Cell Line	Xu-048
93313	\N	\N	2384	4240	\N	2384 Cell Line	Xu-049
93314	\N	\N	2385	4241	\N	2385 Cell Line	Xu-050
93315	\N	\N	2386	4242	\N	2386 Cell Line	Xu-051
93316	\N	\N	2387	4243	\N	2387 Cell Line	Xu-052
93317	\N	\N	2388	4244	\N	2388 Cell Line	Xu-053
93318	\N	\N	2389	4245	\N	2389 Cell Line	Xu-054
93319	\N	\N	2390	4246	\N	2390 Cell Line	Xu-055
93320	\N	\N	2391	4247	\N	2391 Cell Line	Xu-056
93321	\N	\N	2392	4248	\N	2392 Cell Line	Xu-057
93322	\N	\N	2393	4249	\N	2393 Cell Line	Xu-058
93323	\N	\N	2394	4250	\N	2394 Cell Line	Xu-059
93324	\N	\N	2395	4251	\N	2395 Cell Line	Xu-060
93325	\N	\N	2396	4252	\N	2396 Cell Line	Xu-061
93326	\N	\N	2397	4253	\N	2397 Cell Line	Xu-062
93327	\N	\N	2398	4254	\N	2398 Cell Line	Xu-063
93328	\N	\N	2399	4255	\N	2399 Cell Line	Xu-064
93330	\N	\N	2848	4558	\N	2848 Tumor	NGS 1-1_NA
93331	\N	\N	3443	4565	\N	3443 Unknown	NGS 1-9_NA
93332	\N	\N	3444	4566	\N	3444 Unknown	NGS 1-10_NA
93333	\N	\N	2851	4561	\N	2851 Tumor	NGS 1-5_NA
93334	\N	\N	2850	4560	\N	2850 Tumor	NGS 1-4_NA
93335	\N	\N	3445	4567	\N	3445 Unknown	NGS 1-13_NA
93336	\N	\N	2849	4559	\N	2849 Normal	NGS 1-3_NA
93230	\N	\N	1422	319	\N	1422 Normal	AM2 D-225
93232	\N	\N	1425	343	\N	1425 Normal	AM2 D-253
93233	\N	\N	1423	337	\N	1423 LN Met 1	AM2 D-247
93337	\N	\N	3446	4568	\N	3446 Unknown	NGS 1-14_NA
93343	\N	\N	3852	4600	\N	3852 Normal	NA_CP1_Normal
93344	\N	\N	3847	4595	\N	3847 Tumor	NA_CP1-5_Tumor
93345	\N	\N	3848	4596	\N	3848 Tumor	NA_CP1-10_Tumor
93346	\N	\N	3849	4597	\N	3849 Tumor	NA_CP1-20_Tumor
93347	\N	\N	3850	4598	\N	3850 Tumor	NA_CP1-40_Tumor
93348	\N	\N	3851	4599	\N	3851 Tumor	NA_CP1-80_Tumor
93349	\N	\N	2888	4570	\N	2888 Cell Line - Control	ChIP1_2_NA
93350	\N	\N	2894	4576	\N	2894 Cell Line - Control	ChIP1_8_NA
93351	\N	\N	2889	4571	\N	2889 Cell Line - Control	ChIP1_3_NA
93352	\N	\N	2895	4577	\N	2895 Cell Line - Control	ChIP1_9_NA
93353	\N	\N	2887	4569	\N	2887 Cell Line - Control	ChIP1_1_NA
93354	\N	\N	2893	4575	\N	2893 Cell Line - Control	ChIP1_7_NA
93355	\N	\N	2908	6	\N	2908 Unknown	D12_M_NA
93356	\N	\N	3174	1344	\N	3174 Normal	DM1_Normal_NA
93357	\N	\N	3175	1345	\N	3175 Tumor	DM1_Tumor_NA
93358	\N	\N	3099	1272	\N	3099 Tumor	DM_2_NA
93359	\N	\N	3100	1273	\N	3100 Tumor	DM_2_Tumor_NA
93360	\N	\N	3176	1346	\N	3176 Normal	DM2_Normal_NA
93361	\N	\N	3177	1347	\N	3177 Tumor	DM2_Tumor_NA
93362	\N	\N	3101	1274	\N	3101 Normal	DM_4_Normal_NA
93363	\N	\N	3102	1275	\N	3102 Tumor	DM_4_Tumor_NA
93364	\N	\N	3178	1348	\N	3178 Tumor	DM5 _Tumor_NA
93365	\N	\N	3179	1349	\N	3179 Normal	DM5_Normal_NA
93366	\N	\N	3103	1276	\N	3103 Normal	DM_6_Normal_NA
93367	\N	\N	3104	1277	\N	3104 Tumor	DM_6_Tumor_NA
93368	\N	\N	3180	1350	\N	3180 Normal	DM7_Normal_NA
93369	\N	\N	3181	1351	\N	3181 Tumor	DM7_Tumor_NA
93370	\N	\N	3105	1278	\N	3105 Tumor	DM_8_Tumor_NA
93371	\N	\N	3901	4641	\N	3901 Tumor	DM8TumorCrest_NA
93372	\N	\N	3106	1279	\N	3106 Normal	DM_10_Normal_NA
93373	\N	\N	3107	1280	\N	3107 Tumor	DM_10_Tumor_NA
93374	\N	\N	3182	1352	\N	3182 Normal	DM11_Normal_NA
93375	\N	\N	3183	1353	\N	3183 Tumor	DM11_Tumor_NA
93376	\N	\N	3184	1354	\N	3184 Normal	DM12_Normal_NA
93377	\N	\N	3185	1355	\N	3185 Tumor	DM12_Tumor_NA
93378	\N	\N	3109	1282	\N	3109 Tumor	DM_13_Tumor_NA
93379	\N	\N	3110	1283	\N	3110 Tumor	DM_13_2_Tumor_NA
93380	\N	\N	3187	1357	\N	3187 Tumor	DM13_Tumor_NA
93381	\N	\N	3186	1356	\N	3186 Normal	DM13_Normal_NA
93382	\N	\N	3111	1284	\N	3111 Tumor	DM_14_Tumor_NA
93383	\N	\N	3188	1358	\N	3188 Normal	DM14_Normal_NA
93384	\N	\N	3189	1359	\N	3189 Tumor	DM14_Tumor_NA
93385	\N	\N	3190	1360	\N	3190 Normal	DM16_Normal_NA
93386	\N	\N	3191	1361	\N	3191 Tumor	DM16_Tumor_NA
93387	\N	\N	3112	1285	\N	3112 Normal	DM_17_Normal_NA
93388	\N	\N	3113	1286	\N	3113 Tumor	DM_17_Tumor_NA
93389	\N	\N	3114	1287	\N	3114 Normal	DM_18_Normal_NA
93390	\N	\N	3115	1288	\N	3115 Tumor	DM_18_Tumor_NA
93391	\N	\N	3116	1288	\N	3116 Tumor	DM_18_Tumor_NA
93392	\N	\N	3192	1362	\N	3192 Normal	DM21_Normal_NA
93393	\N	\N	3193	1363	\N	3193 Tumor	DM21_Tumor_NA
93394	\N	\N	3117	1289	\N	3117 Normal	DM_22_Normal_NA
93395	\N	\N	3118	1290	\N	3118 Tumor	DM_22_Tumor_NA
93396	\N	\N	3119	1291	\N	3119 Normal	DM_23_Normal_NA
93397	\N	\N	3120	1292	\N	3120 Tumor	DM_23_Tumor_NA
93398	\N	\N	3121	1293	\N	3121 Normal	DM_25_Normal_NA
93399	\N	\N	3122	1294	\N	3122 Tumor	DM_25_Tumor_NA
93400	\N	\N	3194	1364	\N	3194 Normal	DM26_Normal_NA
93401	\N	\N	3195	1365	\N	3195 Tumor	DM26_Tumor_NA
93402	\N	\N	3196	1366	\N	3196 Normal	DM28_Normal_NA
93403	\N	\N	3197	1367	\N	3197 Tumor	DM28_Tumor_NA
93404	\N	\N	3198	1368	\N	3198 Tumor	DM29_2_Tumor_NA
93405	\N	\N	3199	1369	\N	3199 Normal	DM29_Normal_NA
93406	\N	\N	3123	1295	\N	3123 Tumor	DM_31_2_Tumor_NA
93407	\N	\N	3124	1296	\N	3124 Normal	DM_31_Normal_NA
93408	\N	\N	3200	1370	\N	3200 Normal	DM34_Normal_NA
93409	\N	\N	3201	1371	\N	3201 Tumor	DM34_Tumor_NA
93410	\N	\N	3126	1298	\N	3126 Normal	DM_36_Normal_NA
93411	\N	\N	3125	1297	\N	3125 Tumor	DM_36_2_Tumor_NA
93412	\N	\N	3127	1299	\N	3127 Tumor	DM_37_Tumor_NA
93413	\N	\N	3202	1372	\N	3202 Normal	DM37_1_Normal_NA
93414	\N	\N	3128	1300	\N	3128 Normal	DM_42_Normal_NA
93415	\N	\N	3129	1301	\N	3129 Tumor	DM_42_Tumor_NA
93416	\N	\N	3130	1302	\N	3130 Normal	DM_43_Normal_NA
93417	\N	\N	3131	1303	\N	3131 Tumor	DM_43_Tumor_NA
93418	\N	\N	3203	1373	\N	3203 Tumor	DM45_2_Tumor_NA
93419	\N	\N	3204	1374	\N	3204 Normal	DM45_Normal_NA
93420	\N	\N	3853	4601	\N	3853 Tumor	DM45_Tumor_NA
93421	\N	\N	3132	1304	\N	3132 Tumor	DM_48_Tumor_NA
93422	\N	\N	3133	1305	\N	3133 Tumor	DM_49_2_Tumor_NA
93423	\N	\N	3134	1306	\N	3134 Normal	DM_49_Normal_NA
93424	\N	\N	3135	1307	\N	3135 Tumor	DM_51_Tumor_NA
93425	\N	\N	3205	1375	\N	3205 Normal	DM55 Normal_NA
93426	\N	\N	3206	1376	\N	3206 Tumor	DM55_Tumor_NA
93427	\N	\N	3136	1308	\N	3136 Normal	DM_58_Normal_NA
93428	\N	\N	3137	1309	\N	3137 Tumor	DM_58_Tumor_NA
93429	\N	\N	3138	1310	\N	3138 Tumor	DM_59_Tumor_NA
93430	\N	\N	3165	1335	\N	3165 Tumor	DM-60-Tumor_NA
93431	\N	\N	3166	1336	\N	3166 Tumor	DM-61-Tumor_NA
93432	\N	\N	3167	1337	\N	3167 Tumor	DM-62-Tumor_NA
93433	\N	\N	3168	1338	\N	3168 Tumor	DM-63-Tumor_NA
93434	\N	\N	3140	1312	\N	3140 Tumor	DM_64_Tumor_NA
93435	\N	\N	3139	1311	\N	3139 Normal	DM_64_1_Normal_NA
93436	\N	\N	3141	1313	\N	3141 Tumor	DM_65_2_Tumor_NA
93437	\N	\N	3169	1339	\N	3169 Tumor	DM-66-Tumor_NA
93438	\N	\N	3170	1340	\N	3170 Tumor	DM-67-Tumor_NA
93439	\N	\N	3142	1314	\N	3142 Tumor	DM_68_Tumor_NA
93440	\N	\N	3171	1341	\N	3171 Tumor	DM-69-Tumor_NA
93441	\N	\N	3172	1342	\N	3172 Tumor	DM-70-Tumor_NA
93442	\N	\N	3144	1316	\N	3144 Tumor	DM_74_2_Tumor_NA
93443	\N	\N	3143	1315	\N	3143 Tumor	DM_74_1_Tumor_NA
93444	\N	\N	3145	1316	\N	3145 Tumor	DM_74_2_Tumor_NA
93445	\N	\N	3207	1377	\N	3207 Tumor	DM77_2_Tumor_NA
93446	\N	\N	3208	1378	\N	3208 Normal	DM77_Normal_NA
93447	\N	\N	3209	1379	\N	3209 Tumor	DM79_2_Tumor_NA
93448	\N	\N	3210	1380	\N	3210 Normal	DM79_Normal_NA
93449	\N	\N	3854	4602	\N	3854 Tumor	DM79_Tumor_NA
93450	\N	\N	3173	1343	\N	3173 Tumor	DM-81-Tumor_NA
93451	\N	\N	3146	1317	\N	3146 Tumor	DM_93_3_Tumor_NA
93452	\N	\N	3148	1319	\N	3148 Normal	DM_93_Normal_NA
93453	\N	\N	3147	1318	\N	3147 Tumor	DM_93_cgn_NA
93454	\N	\N	3211	1381	\N	3211 Tumor	DM93_2_Tumor_NA
93455	\N	\N	3213	1383	\N	3213 Normal	DM93_Normal_NA
93456	\N	\N	3212	1382	\N	3212 Tumor	DM93_CGN_NA
93457	\N	\N	3855	4603	\N	3855 Tumor	DM93_NFKBIE_NA
93464	\N	\N	3154	1325	\N	3154 Normal	DM_96_Normal_NA
93465	\N	\N	3155	1326	\N	3155 Normal	DM_98_2_Normal_NA
93466	\N	\N	3156	1327	\N	3156 Tumor	DM_98_Tumor_NA
93467	\N	\N	3157	1328	\N	3157 Normal	DM_99_Normal_NA
93468	\N	\N	3158	1329	\N	3158 Tumor	DM_99_Tumor_NA
93469	\N	\N	3159	1329	\N	3159 Tumor	DM_99_Tumor_NA
93470	\N	\N	3160	1330	\N	3160 Tumor	DM_100_Tumor_Pool_NA
93471	\N	\N	3162	1332	\N	3162 Normal	DM_101_Normal_NA
93472	\N	\N	3161	1331	\N	3161 Unknown	DM_101_IS_NA
93473	\N	\N	3163	1333	\N	3163 Tumor	DM_101_Tumor_NA
93474	\N	\N	3164	1334	\N	3164 Tumor	DM_102_Tumor_NA
93475	\N	\N	3383	3227	\N	3383 Tumor	N3_1_NA
93476	\N	\N	3384	3228	\N	3384 Tumor	N3_2_NA
93477	\N	\N	3385	3229	\N	3385 Tumor	N3_3_NA
93478	\N	\N	3386	3230	\N	3386 Tumor	N3_4_NA
93479	\N	\N	3214	1815	\N	3214 Tumor	DP12_200_NA
93483	\N	\N	2	198	\N	2 Mel1	AM2 D-101
93484	\N	\N	1	197	\N	1 Normal	AM2 D-100
93485	\N	\N	1149	278	\N	1149 Mel3	AM2 D-180
93486	\N	\N	1302	311	\N	1302 Normal	AM2 D-217
93487	\N	\N	1303	312	\N	1303 Mel1	AM2 D-218
93488	\N	\N	1309	318	\N	1309 Mel1	AM2 D-224
93489	\N	\N	3	199	\N	3 Met1	AM2 D-102
93490	\N	\N	1150	279	\N	1150 Normal3	AM2 D-181
93491	\N	\N	1151	280	\N	1151 Met2	AM2 D-182
93493	\N	\N	1293	302	\N	1293 Mel1	AM2 D-207
93494	\N	\N	1295	304	\N	1295 Normal	AM2 D-210
93495	\N	\N	1301	310	\N	1301 Cutaneous Metastasis	AM2 D-216
93498	\N	\N	1304	313	\N	1304 Subcutaneous Metastasis	AM2 D-219
93508	\N	\N	1617	503	\N	1617 Normal	AM2 D-443
93509	\N	\N	1287	296	\N	1287 Met2	AM2 D-200
93519	\N	\N	72	121	\N	72 Normal	AM2 D-24
93520	\N	\N	73	122	\N	73 MIS1	AM2 D-25
93521	\N	\N	1305	314	\N	1305 Normal	AM2 D-220
93522	\N	\N	1306	315	\N	1306 Mel1	AM2 D-221
93524	\N	\N	8	205	\N	8 Met1	AM2 D-107
93525	\N	\N	3249	1863	\N	3249 Normal	HW_A1_Cntl_NA
93526	\N	\N	3250	1864	\N	3250 Tumor	HW_A1_Tumor_NA
93527	\N	\N	3251	1865	\N	3251 Normal	HW_A2_Cntl_NA
93528	\N	\N	3252	1866	\N	3252 Tumor	HW_A2_Tumor_NA
93529	\N	\N	3253	1867	\N	3253 Normal	HW_A3_Cntl_NA
93530	\N	\N	3254	1868	\N	3254 Tumor	HW_A3_Tumor_NA
93531	\N	\N	3255	1869	\N	3255 Normal	HW_A4_Cntl_NA
93532	\N	\N	3256	1870	\N	3256 Tumor	HW_A4_Tumor_NA
93533	\N	\N	3257	1871	\N	3257 Normal	HW_A5_Cntl_NA
93534	\N	\N	3258	1872	\N	3258 Tumor	HW_A5_Tumor_NA
93535	\N	\N	3259	1873	\N	3259 Normal	HW_A6_Cntl_NA
93536	\N	\N	3260	1874	\N	3260 Tumor	HW_A6_Tumor_NA
93537	\N	\N	3261	1875	\N	3261 Normal	HW_A7 Cntl_NA
93538	\N	\N	3262	1876	\N	3262 Tumor	HW_A7_Tumor_NA
93539	\N	\N	3263	1877	\N	3263 Normal	HW_A8_Cntl_NA
93540	\N	\N	3264	1878	\N	3264 Tumor	HW_A8_Tumor_NA
93541	\N	\N	3269	1883	\N	3269 Tumor	HW_Acral_#8_Tumor_NA
93542	\N	\N	3265	1879	\N	3265 Normal	HW_A9_Cntl_NA
93543	\N	\N	3266	1880	\N	3266 Tumor	HW_A9_Tumor_NA
93544	\N	\N	3267	1881	\N	3267 Normal	HW_A10_Cntl_NA
93545	\N	\N	3268	1882	\N	3268 Tumor	HW_A10_Tumor_NA
93546	\N	\N	2943	858	\N	2943 Normal	BB008_HW2NC_NA
93547	\N	\N	2944	859	\N	2944 Tumor	BB008_HW2TC_NA
93548	\N	\N	3246	1860	\N	3246 Tumor	HW_2_Tumor Dissect_NA
93549	\N	\N	2964	879	\N	2964 Normal	BB09_HW3_N_NA
93550	\N	\N	3388	3232	\N	3388 Normal	N3_6_NA
93551	\N	\N	2965	880	\N	2965 Tumor	BB09_HW3_T_NA
93552	\N	\N	3247	1861	\N	3247 Tumor	HW_3_Tumor_NA
93553	\N	\N	3387	3231	\N	3387 Tumor	N3_5_NA
93554	\N	\N	2966	881	\N	2966 Normal	BB09_HW4_N_NA
93555	\N	\N	3390	3234	\N	3390 Normal	N3_8_NA
93556	\N	\N	2967	882	\N	2967 Tumor	BB09_HW4_T_NA
93557	\N	\N	3389	3233	\N	3389 Tumor	N3_7_NA
93558	\N	\N	2968	883	\N	2968 Normal	BB09_HW6_ND_NA
93559	\N	\N	3392	3236	\N	3392 Normal	N3_10_NA
93560	\N	\N	2969	884	\N	2969 Tumor	BB09_HW6_TD_NA
93561	\N	\N	3391	3235	\N	3391 Tumor	N3_9_NA
93562	\N	\N	2945	860	\N	2945 Normal	BB008_HW8NC_NA
93563	\N	\N	2946	861	\N	2946 Tumor	BB008_HW8TC_NA
93564	\N	\N	3248	1862	\N	3248 Tumor	HW_8_Mucosal_Tumor_NA
93565	\N	\N	2947	862	\N	2947 Normal	BB008_HW9-NB_NA
93566	\N	\N	2948	863	\N	2948 Tumor	BB008_HW9TC_NA
93567	\N	\N	3304	1941	\N	3304 Normal	K2_8
93568	\N	\N	3306	1943	\N	3306 Tumor	K2_10
93569	\N	\N	3305	1942	\N	3305 Tumor	K2_9
93570	\N	\N	3300	1932	\N	3300 Tumor	K1_21
93571	\N	\N	79	128	\N	79 MIS1	AM2 D-31
93572	\N	\N	80	129	\N	80 MIS2	AM2 D-32
93575	\N	\N	81	130	\N	81 Mel1	AM2 D-33
93576	\N	\N	1153	282	\N	1153 LN Met 2	AM2 D-184
93577	\N	\N	1154	283	\N	1154 LN Met 1	AM2 D-185
93492	\N	\N	1292	301	\N	1292 Normal	AM2 D-206
93496	\N	\N	6	203	\N	6 Normal	AM2 D-105
93497	\N	\N	7	204	\N	7 MIS1	AM2 D-106
93499	\N	\N	4	200	\N	4 Mel1	AM2 D-103
93500	\N	\N	1286	295	\N	1286 Mel2	AM2 D-199
93501	\N	\N	9	206	\N	9 Normal	AM2 D-108
93502	\N	\N	10	207	\N	10 Mel1	AM2 D-109
93503	\N	\N	65	114	\N	65 Normal	AM2 D-17
93504	\N	\N	66	115	\N	66 MIS1	AM2 D-18
93505	\N	\N	67	116	\N	67 Mel1	AM2 D-19
93506	\N	\N	11	208	\N	11 Met1	AM2 D-110
93507	\N	\N	5	201	\N	5 Met1	AM2 D-104
93510	\N	\N	1288	297	\N	1288 Normal	AM2 D-201
93511	\N	\N	68	117	\N	68 Normal	AM2 D-20
93512	\N	\N	69	118	\N	69 MIS1	AM2 D-21
93513	\N	\N	70	119	\N	70 MIS2	AM2 D-22
93514	\N	\N	71	120	\N	71 Mel1	AM2 D-23
93515	\N	\N	74	123	\N	74 MIS2	AM2 D-26
93516	\N	\N	75	124	\N	75 MIS3	AM2 D-27
93517	\N	\N	76	125	\N	76 Mel1	AM2 D-28
93518	\N	\N	77	126	\N	77 Mel2	AM2 D-29
93523	\N	\N	1623	513	\N	1623 Invasive Mel 1	AM2 D-454
93573	\N	\N	1620	768	\N	1620 MIS3	AM2 R-445
93574	\N	\N	1621	506	\N	1621 MIS4	AM2 D-446
93591	\N	\N	98	185	\N	98 Normal2	AM2 D-88
93592	\N	\N	105	192	\N	105 MIS2	AM2 D-95
93593	\N	\N	104	191	\N	104 MIS1	AM2 D-94
93594	\N	\N	106	193	\N	106 Mel1	AM2 D-96
93595	\N	\N	107	194	\N	107 Mel2	AM2 D-97
93596	\N	\N	108	195	\N	108 Met1	AM2 D-98
93597	\N	\N	109	196	\N	109 Met2	AM2 D-99
93598	\N	\N	1236	284	\N	1236 LN Met 4	AM2 D-186
93599	\N	\N	1237	285	\N	1237 LN Met 3	AM2 D-187
93600	\N	\N	103	190	\N	103 Normal	AM2 D-93
93601	\N	\N	359	209	\N	359 Normal 1	AM2 D-111
93602	\N	\N	363	213	\N	363 Mel1	AM2 D-115
93603	\N	\N	361	211	\N	361 MIS1	AM2 D-113
93604	\N	\N	362	212	\N	362 MIS2	AM2 D-114
93605	\N	\N	360	210	\N	360 Normal 2	AM2 D-112
93606	\N	\N	364	243	\N	364 Normal 1	AM2 D-145
93607	\N	\N	365	214	\N	365 MIS1	AM2 D-116
93608	\N	\N	366	215	\N	366 MIS2	AM2 D-117
93609	\N	\N	368	217	\N	368 Mel2	AM2 D-119
93610	\N	\N	367	216	\N	367 Mel1	AM2 D-118
93611	\N	\N	1240	288	\N	1240 MIS2	AM2 D-190
93612	\N	\N	371	220	\N	371 Mel1	AM2 D-122
93613	\N	\N	369	218	\N	369 Normal1	AM2 D-120
93614	\N	\N	370	219	\N	370 MIS1	AM2 D-121
93615	\N	\N	1238	286	\N	1238 MIS4	AM2 D-188
93616	\N	\N	1239	287	\N	1239 MIS3	AM2 D-189
93618	\N	\N	374	223	\N	374 MIS2	AM2 D-125
93619	\N	\N	372	221	\N	372 Normal1	AM2 D-123
93624	\N	\N	378	227	\N	378 Mel1	AM2 D-129
93625	\N	\N	377	226	\N	377 MIS1	AM2 D-128
93626	\N	\N	379	228	\N	379 LN Met 1	AM2 D-130
93627	\N	\N	376	225	\N	376 Normal1	AM2 D-127
93628	\N	\N	380	229	\N	380 Normal 1	AM2 D-131
93629	\N	\N	383	232	\N	383 MIS2	AM2 D-134
93630	\N	\N	382	231	\N	382 MIS1	AM2 D-133
93631	\N	\N	384	233	\N	384 Mel1	AM2 D-135
93633	\N	\N	381	230	\N	381 Normal 2	AM2 D-132
93634	\N	\N	2033	560	\N	2033 Met2	AM2 D-503
93636	\N	\N	388	237	\N	388 MIS3	AM2 D-139
93637	\N	\N	387	236	\N	387 MIS2	AM2 D-138
93638	\N	\N	386	235	\N	386 MIS1	AM2 D-137
93639	\N	\N	389	238	\N	389 Mel1	AM2 D-140
93640	\N	\N	390	242	\N	390 Normal 1	AM2 D-144
93641	\N	\N	392	240	\N	392 MIS1	AM2 D-142
93642	\N	\N	393	241	\N	393 Mel1	AM2 D-143
93643	\N	\N	391	239	\N	391 Normal 1	AM2 D-141
93646	\N	\N	394	244	\N	394 Normal 1	AM2 D-146
93647	\N	\N	396	246	\N	396 MIS1	AM2 D-148
93648	\N	\N	397	247	\N	397 Mel 1	AM2 D-149
93649	\N	\N	395	245	\N	395 Normal 1	AM2 D-147
93651	\N	\N	400	250	\N	400 MIS2	AM2 D-152
93654	\N	\N	398	248	\N	398 Normal 1	AM2 D-150
93656	\N	\N	403	253	\N	403 Normal 1	AM2 D-155
93658	\N	\N	405	255	\N	405 MIS1	AM2 D-157
93659	\N	\N	406	256	\N	406 Mel1	AM2 D-158
93660	\N	\N	404	254	\N	404 Normal 1	AM2 D-156
93663	\N	\N	408	258	\N	408 MIS1	AM2 D-160
93664	\N	\N	410	260	\N	410 Mel1	AM2 D-162
93665	\N	\N	409	259	\N	409 MIS2	AM2 D-161
93666	\N	\N	407	257	\N	407 Normal 1	AM2 D-159
93668	\N	\N	411	261	\N	411 Normal 1	AM2 D-163
93670	\N	\N	412	262	\N	412 MIS1	AM2 D-164
93671	\N	\N	417	267	\N	417 MIS2	AM2 D-169
93672	\N	\N	415	265	\N	415 Normal 1	AM2 D-167
93673	\N	\N	416	266	\N	416 MIS1	AM2 D-168
93674	\N	\N	418	268	\N	418 Mel1	AM2 D-170
93675	\N	\N	1241	289	\N	1241 MIS3	AM2 D-191
93676	\N	\N	1242	290	\N	1242 Normal2	AM2 D-192
93677	\N	\N	422	272	\N	422 Mel1	AM2 D-174
93680	\N	\N	419	269	\N	419 Normal 1	AM2 D-171
93683	\N	\N	1243	291	\N	1243 Normal	AM2 D-193
93686	\N	\N	423	273	\N	423 Mel1	AM2 D-175
93687	\N	\N	1013	3317	\N	1013 Nodular Mel	NM D-075
93688	\N	\N	3309	1946	\N	3309 Tumor	Kit_8_NA
93689	\N	\N	3310	1947	\N	3310 Tumor	Kit_21_NA
93690	\N	\N	3311	1948	\N	3311 Tumor	Kit_37_Acral_NRAS_NA
93691	\N	\N	3312	1950	\N	3312 Tumor	Kit_55_NA
93692	\N	\N	3313	1951	\N	3313 Tumor	Kit_62__Acral_NRAS_NA
93693	\N	\N	3314	1952	\N	3314 Tumor	Kit_76_NA
93694	\N	\N	3315	1953	\N	3315 Tumor	Kit_118_Muc_NRAS_NA
93695	\N	\N	3316	1954	\N	3316 Tumor	KIT_134_NA
93697	\N	\N	3319	1957	\N	3319 Tumor	KIT_191_NA
93698	\N	\N	3320	1958	\N	3320 Tumor	Kit_192_NA
93699	\N	\N	3321	1959	\N	3321 Tumor	Kit_203_NA
93700	\N	\N	3322	1960	\N	3322 Tumor	KIT_205_NA
93701	\N	\N	3323	1961	\N	3323 Tumor	KIT_206_NA
93702	\N	\N	3324	1962	\N	3324 Tumor	KIT_210_NA
93703	\N	\N	3325	1963	\N	3325 Tumor	KIT_217_NA
93704	\N	\N	3326	1964	\N	3326 Tumor	KIT_225_NA
93579	\N	\N	2034	556	\N	2034 MIS2	AM2 D-498
93580	\N	\N	2035	557	\N	2035 MIS3	AM2 D-499
93585	\N	\N	99	186	\N	99 MIS1	AM2 D-89
93586	\N	\N	100	187	\N	100 Mel1	AM2 D-90
93587	\N	\N	2246	833	\N	2246 Mel2	AM2 R-517
93589	\N	\N	101	188	\N	101 Met1	AM2 D-91
93620	\N	\N	373	222	\N	373 MIS1	AM2 D-124
93621	\N	\N	375	224	\N	375 Mel1	AM2 D-126
93622	\N	\N	1575	436	\N	1575 	AM2 D-358
93623	\N	\N	1622	512	\N	1622 Mel2	AM2 D-453
93632	\N	\N	385	234	\N	385 LN Met 1	AM2 D-136
93650	\N	\N	399	249	\N	399 MIS1	AM2 D-151
93652	\N	\N	401	251	\N	401 Mel1	AM2 D-153
93653	\N	\N	402	252	\N	402 Mel2	AM2 D-154
93667	\N	\N	414	264	\N	414 Mel1	AM2 D-166
93669	\N	\N	413	263	\N	413 MIS2	AM2 D-165
93678	\N	\N	421	271	\N	421 MIS2	AM2 D-173
93679	\N	\N	420	270	\N	420 MIS1	AM2 D-172
93681	\N	\N	1244	292	\N	1244 MIS1	AM2 D-194
93682	\N	\N	1245	293	\N	1245 MIS2	AM2 D-195
93684	\N	\N	1618	510	\N	1618 MIS3	AM2 D-451
93685	\N	\N	1619	511	\N	1619 MIS4	AM2 D-452
93696	\N	\N	3318	1956	\N	3318 Tumor	Kit_181_Muc_BRAF_NA
93705	\N	\N	2949	864	\N	2949 Tumor	BB008_Kit 227 Acral WT_NA
93706	\N	\N	3327	1966	\N	3327 Tumor	KIT_230_NA
93707	\N	\N	3328	1967	\N	3328 Tumor	KIT_244_NA
93708	\N	\N	3329	1968	\N	3329 Tumor	KIT_260_NA
93709	\N	\N	3308	1945	\N	3308 Tumor	Kit 262_NA
93710	\N	\N	3330	1969	\N	3330 Tumor	KIT_273_NA
93711	\N	\N	3331	1970	\N	3331 Tumor	Kit_275_Muc_BRAF_NA
93712	\N	\N	3332	1971	\N	3332 Tumor	KIT_295_NA
93713	\N	\N	3333	1972	\N	3333 Tumor	KIT_297_NA
93714	\N	\N	3334	1973	\N	3334 Tumor	KIT_302_NA
93715	\N	\N	3335	1974	\N	3335 Tumor	Kit_313_Mucosal_NA
93716	\N	\N	3336	1975	\N	3336 Tumor	KIT_316_NA
93717	\N	\N	3337	1994	\N	3337 Tumor	KR_8_NA
93718	\N	\N	3338	1995	\N	3338 Tumor	KR_150_NA
93719	\N	\N	3339	1996	\N	3339 Tumor	KR_166_NA
93720	\N	\N	3340	1997	\N	3340 Tumor	KR_177_NA
93721	\N	\N	3341	1998	\N	3341 Tumor	KR_203_NA
93722	\N	\N	3342	1999	\N	3342 Tumor	KR_229_NA
93723	\N	\N	3343	2000	\N	3343 Tumor	KR_2030_NA
93724	\N	\N	3344	2001	\N	3344 Tumor	KR_2064_NA
93725	\N	\N	3345	2002	\N	3345 Tumor	KR_5233_NA
93726	\N	\N	3346	2003	\N	3346 Tumor	KR_RMK0091B_NA
93727	\N	\N	3347	2004	\N	3347 Tumor	KR_RMK0137C_NA
93728	\N	\N	3348	2005	\N	3348 Tumor	KR_RMK0162C_NA
93729	\N	\N	3349	2006	\N	3349 Tumor	KR_RMK0168C_NA
93730	\N	\N	3350	2007	\N	3350 Tumor	KR_RMK0194C_NA
93731	\N	\N	2951	866	\N	2951 Cell Line	BB008_LAL-L2_NA
93732	\N	\N	2950	865	\N	2950 Cell Line	BB008_LAL-L1_NA
93733	\N	\N	3351	2008	\N	3351 Intermediate	L2-HGD_NA
93734	\N	\N	3352	2009	\N	3352 Normal	L2-Normal_NA
93735	\N	\N	3354	2011	\N	3354 Normal	L3-Normal_NA
93736	\N	\N	3353	2010	\N	3353 Intermediate	L3-HGD_NA
93737	\N	\N	1325	1854	\N	1325 Tumor	Fusion-10
93738	\N	\N	3447	2352	\N	3447 Tumor	Luping_ROS 1_NA
93739	\N	\N	2467	2353	\N	2467 Melanoma Cell Line	M230 Imat A2
93995	\N	\N	1671	3021	\N	\N	MMR-50
93740	\N	\N	2468	2354	\N	2468 Melanoma Cell Line	M230 Imat A3
93741	\N	\N	1016	3320	\N	1016 Nodular Mel	NM D-078
93742	\N	\N	1019	3323	\N	1019 Nodular Mel	NM D-081
93743	\N	\N	1015	3319	\N	1015 Nodular Mel	NM D-077
93744	\N	\N	610	2355	\N	610 Acral Melanoma Cells	M040204 (AMC-07)
93745	\N	\N	1248	2356	\N	1248 Acral Melanoma Cells	M040204 Dec2019 (AMC-07)
93746	\N	\N	611	2357	\N	611 Acral Melanoma Cells	M040415 (AMC-08)
93747	\N	\N	612	2358	\N	612 Acral Melanoma Cells	M040416 (AMC-08)
93748	\N	\N	613	2359	\N	613 Acral Melanoma Cells	M040418 (AMC-08)
93749	\N	\N	614	2360	\N	614 Acral Melanoma Cells	M040419A (AMC-08)
93750	\N	\N	605	2361	\N	605 Acral Melanoma Cells	M100118 (AMC-02)
93751	\N	\N	616	2362	\N	616 Acral Melanoma Cells	M180322 (AMC-13)
93752	\N	\N	604	2363	\N	604 Acral Melanoma Cells	MaMel  152aI (AMC-01)
93753	\N	\N	3356	2364	\N	3356 Normal	MB_161_Normal_NA
93754	\N	\N	3357	2365	\N	3357 Tumor	MB_161_Tumor_NA
93755	\N	\N	3358	2366	\N	3358 Tumor	MB_327_Tumor_NA
93756	\N	\N	3359	2367	\N	3359 Tumor	MB_760_Tumor_NA
93757	\N	\N	3360	2368	\N	3360 Normal	MB_1028_Normal_NA
93758	\N	\N	3361	2369	\N	3361 Tumor	MB_1029_Tumor_NA
93759	\N	\N	3362	2370	\N	3362 Normal	MB_1036_Normal_NA
93760	\N	\N	3363	2371	\N	3363 Tumor	MB_1046_Tumor_NA
93761	\N	\N	3364	2372	\N	3364 Normal	MB_1418_Normal_NA
93762	\N	\N	3365	2373	\N	3365 Normal	MB_1454_Normal_NA
93763	\N	\N	3367	2375	\N	3367 Normal	MB1241_Norm_NA
93764	\N	\N	3368	2376	\N	3368 Tumor	MB1242_Tumor_NA
93765	\N	\N	3369	2377	\N	3369 Normal	MB1421_Norm_NA
93766	\N	\N	3371	2379	\N	3371 Tumor	MB1423_Tumor_NA
93767	\N	\N	3370	2378	\N	3370 Normal	MB1423_Norm_NA
93768	\N	\N	3372	2380	\N	3372 Tumor	MB1424 _Tumor_NA
93769	\N	\N	3373	2381	\N	3373 Normal	MB1428_Norm_NA
93770	\N	\N	3374	2382	\N	3374 Tumor	MB1429_Tumor_NA
93771	\N	\N	3366	2374	\N	3366 Normal	MB_1609_Normal_NA
93772	\N	\N	3375	2383	\N	3375 Tumor	MB1617_Tumor_NA
93773	\N	\N	896	3607	\N	896 Mel	RNA-101 (Mel_1)
93774	\N	\N	897	3608	\N	897 Mel	RNA-102 (Mel_2)
93775	\N	\N	898	3609	\N	898 Mel	RNA-103 (Mel_3)
93776	\N	\N	899	3610	\N	899 Mel	RNA-104 (Mel_4)
93777	\N	\N	901	3612	\N	901 Mel	RNA-106 (Mel_6)
93778	\N	\N	900	3611	\N	900 Mel	RNA-105 (Mel_5)
93779	\N	\N	1319	2605	\N	1319 Acral Melanoma Cells	Mel290
93780	\N	\N	606	2616	\N	606 Acral Melanoma Cells	MM100511 (AMC-03)
93781	\N	\N	607	2617	\N	607 Acral Melanoma Cells	MM100512 (AMC-03)
93782	\N	\N	608	2618	\N	608 Acral Melanoma Cells	MM100513 (AMC-03)
93783	\N	\N	609	2619	\N	609 Acral Melanoma Cells	MM100916 (AMC-03)
93784	\N	\N	615	2620	\N	615 Acral Melanoma Cells	MM160113 (AMC-12)
93785	\N	\N	673	3178	\N	673 Uveal Mel	MP41-D
93786	\N	\N	674	3179	\N	674 Uveal Mel	MP41-YM-R1-D
93787	\N	\N	597	3302	\N	597 Nodular Mel	NM D-059
93788	\N	\N	596	3301	\N	596 Nodular Mel	NM D-058
93789	\N	\N	2952	867	\N	2952 Cell Line	BB008_NB2107_NA
93790	\N	\N	3423	3472	\N	3423 Normal	P57-Normal_NA
93791	\N	\N	3424	3472	\N	3424 Normal	P57-Normal_NA
93792	\N	\N	3419	3468	\N	3419 Cadaver Skin	P57-A-1.0mm_NA
93793	\N	\N	3420	3469	\N	3420 Cadaver Skin	P57-A-2.0mm_NA
93794	\N	\N	3421	3470	\N	3421 Cadaver Skin	P57-B-1.0mm_NA
93795	\N	\N	3422	3471	\N	3422 Cadaver Skin	P57-B-2.0mm_NA
93796	\N	\N	3425	3474	\N	3425 Unknown	PG_8_NA
93797	\N	\N	3845	4666	\N	3845 Tumor	PG8_NA
93798	\N	\N	3303	1936	\N	3303 Unknown	K2_3_NA
93799	\N	\N	3428	3859	\N	3428 Tumor	Seider_Roe_NA
93800	\N	\N	3429	3860	\N	3429 Tumor	Seider_Uveal Melanoma_NA
93801	\N	\N	2891	4573	\N	2891 Cell Line - Knockdown	ChIP1_5_NA
93802	\N	\N	2897	4579	\N	2897 Cell Line - Knockdown	ChIP1_11_NA
93803	\N	\N	2892	4574	\N	2892 Cell Line - Knockdown	ChIP1_6_NA
93804	\N	\N	2898	4580	\N	2898 Cell Line - Knockdown	ChIP1_12_NA
93805	\N	\N	2890	4572	\N	2890 Cell Line - Knockdown	ChIP1_4_NA
93806	\N	\N	2896	4578	\N	2896 Cell Line - Knockdown	ChIP1_10_NA
93807	\N	\N	1316	3865	\N	1316 Acral Melanoma Cells	SKMEL 1023A
93808	\N	\N	1317	3866	\N	1317 Acral Melanoma Cells	SKMEL 1107B
93809	\N	\N	1246	3867	\N	1246 Acral Melanoma Cells	SKMel 1107B Dec2019 (MC-02)
93810	\N	\N	1318	3868	\N	1318 Acral Melanoma Cells	SKMEL 1121B
93811	\N	\N	1247	3869	\N	1247 Acral Melanoma Cells	SKMel 1121B Dec2019 (MC-03)
93812	\N	\N	2845	4555	\N	2845 Cell Line	SKMEL5-1_NA
93813	\N	\N	2846	4556	\N	2846 Cell Line	SKMEL5-2_NA
93814	\N	\N	2847	4557	\N	2847 Cell Line	SKMEL5-3_NA
93815	\N	\N	2842	4552	\N	2842 Cell Line	SKMEL28-1_NA
93816	\N	\N	2843	4553	\N	2843 Cell Line	SKMEL28-2_NA
93817	\N	\N	2844	4554	\N	2844 Cell Line	SKMEL28-3_NA
93818	\N	\N	2781	3897	\N	2781 Tumor	SM_2_Tumor_NA
93819	\N	\N	2782	3898	\N	2782 Tumor	SM_3_Tumor_NA
93820	\N	\N	2783	3899	\N	2783 Normal	SM_4_Normal_NA
93821	\N	\N	2784	3900	\N	2784 Tumor	SM_4_Tumor_NA
93822	\N	\N	2785	3901	\N	2785 Normal	SM_5_Normal_NA
93823	\N	\N	2795	3910	\N	2795 Tumor	SM_10_Tumor_NA
93824	\N	\N	2796	3911	\N	2796 Tumor	SM_11_Tumor_NA
93825	\N	\N	2797	3912	\N	2797 Tumor	SM_12_Tumor_NA
93826	\N	\N	2799	3914	\N	2799 Tumor	SM_16_Tumor_NA
93827	\N	\N	2798	3913	\N	2798 Normal	SM_16_Normal_NA
93828	\N	\N	2802	3916	\N	2802 Tumor	SM7_Tumor_NA
93829	\N	\N	3836	4589	\N	3836 Tumor	TCR-Beta-1_NA
93830	\N	\N	3837	4590	\N	3837 Tumor	TCR-Beta-2_NA
93831	\N	\N	3434	4004	\N	3434 Cell Line	Thomas_SK_MEL_23_NA
93832	\N	\N	2759	4544	\N	2759 Cell Line	Thomas_SK_Mel23
93833	\N	\N	2936	92	\N	2936 Normal	ALK_Cntl_NA
93834	\N	\N	2930	86	\N	2930 Human Cadaver Skin - Acral	ACL01
93835	\N	\N	2931	87	\N	2931 Human Cadaver Skin - Acral	ACL03
93836	\N	\N	2932	88	\N	2932 Human Cadaver Skin - Acral	ACL05
93837	\N	\N	2933	89	\N	2933 Human Cadaver Skin - Acral	ACL06
93838	\N	\N	2984	911	\N	2984 Human Cadaver Skin - Buttocks	BTK01
93839	\N	\N	2985	912	\N	2985 Human Cadaver Skin - Buttocks	BTK03
93840	\N	\N	2986	913	\N	2986 Human Cadaver Skin - Buttocks	BTK05
93841	\N	\N	2987	914	\N	2987 Human Cadaver Skin - Buttocks	BTK06
93842	\N	\N	3238	1844	\N	3238 Human Cadaver Skin - Face	FAC01
93843	\N	\N	3239	1845	\N	3239 Human Cadaver Skin - Face	FAC03
93844	\N	\N	3240	1846	\N	3240 Human Cadaver Skin - Face	FAC05
93845	\N	\N	3241	1847	\N	3241 Human Cadaver Skin - Face	FAC06
93846	\N	\N	3431	3862	\N	3431 Human Cadaver Skin - Shoulder	SHR03
93847	\N	\N	3430	3861	\N	3430 Human Cadaver Skin - Shoulder	SHR01
93848	\N	\N	3433	3864	\N	3433 Human Cadaver Skin - Shoulder	SHR06
93849	\N	\N	3432	3863	\N	3432 Human Cadaver Skin - Shoulder	SHR05
93850	\N	\N	2760	4547	\N	2760 Uveal Mel	UM1_NA
93851	\N	\N	2761	4548	\N	2761 Uveal Mel	UM2_NA
93852	\N	\N	3838	4591	\N	3838 Uveal Mel	UM23_NA
93853	\N	\N	3839	4592	\N	3839 Uveal Mel	UM24_NA
93854	\N	\N	3840	4593	\N	3840 Uveal Mel	UM25_NA
93855	\N	\N	3841	4594	\N	3841 Uveal Mel	UM26_NA
93856	\N	\N	2836	4175	\N	2836 Acral Melanoma Cells	WM8_NA
93857	\N	\N	2837	4176	\N	2837 Acral Melanoma Cells	WM51_NA
93858	\N	\N	2838	4177	\N	2838 Acral Melanoma Cells	WM1963_NA
93859	\N	\N	2953	868	\N	2953 Cell Line	BB008_WM3211_NA
93860	\N	\N	2839	4178	\N	2839 Acral Melanoma Cells	WM3622_NA
93861	\N	\N	2840	4179	\N	2840 Acral Melanoma Cells	WM3912_NA
93862	\N	\N	2841	4180	\N	2841 Acral Melanoma Cells	WM3918_NA
93863	\N	\N	3435	4181	\N	3435 Tumor	WP_11_NA
93864	\N	\N	3436	4182	\N	3436 Tumor	WP_23_NA
93865	\N	\N	3437	4183	\N	3437 Tumor	WP_29_NA
93866	\N	\N	3301	1934	\N	3301 Tumor	K2_1_NA
93867	\N	\N	3302	1935	\N	3302 Tumor	K2_2_NA
93868	\N	\N	2900	4587	\N	2900 MM	JBP-11MM
93870	\N	\N	2899	4586	\N	2899 Met	JBP-11Met
93871	\N	\N	2901	4588	\N	2901 Normal	JBP-11Norm
93872	\N	\N	2828	4583	\N	2828 Normal	JBP-6-Norm_NA
93873	\N	\N	1856	2960	\N	\N	MMD-345
90321	\N	\N	1856	3161	\N	1856 Normal	MMR-345
93874	\N	\N	1855	2959	\N	\N	MMD-344
93875	\N	\N	1857	2961	\N	\N	MMD-346
93876	\N	\N	1847	3153	\N	\N	MMR-336
93877	\N	\N	1848	3154	\N	\N	MMR-337
93878	\N	\N	1820	2904	\N	\N	MMD-289
93879	\N	\N	1820	3118	\N	\N	MMR-240
93880	\N	\N	1821	2905	\N	\N	MMD-290
93881	\N	\N	1769	2792	\N	\N	MMD-177
93882	\N	\N	1645	2996	\N	\N	MMR-20
93883	\N	\N	1767	3086	\N	\N	MMR-175
93884	\N	\N	1765	3085	\N	\N	MMR-173
93885	\N	\N	1765	2930	\N	\N	MMD-315
93886	\N	\N	1766	2931	\N	\N	MMD-316
93887	\N	\N	1947	3696	\N	\N	RNA-190
93888	\N	\N	1947	1632	\N	\N	DNA-234
93889	\N	\N	1947	1645	\N	\N	DNA-247
93890	\N	\N	1947	3728	\N	\N	RNA-234
93891	\N	\N	1947	3737	\N	\N	RNA-247
93892	\N	\N	1948	3697	\N	\N	RNA-191
93893	\N	\N	1948	1633	\N	\N	DNA-235
93894	\N	\N	1948	3729	\N	\N	RNA-235
93895	\N	\N	1949	3698	\N	\N	RNA-192
93896	\N	\N	1949	1634	\N	\N	DNA-236
93897	\N	\N	1803	3109	\N	\N	MMR-223
93898	\N	\N	1693	2707	\N	\N	MMD-89
93899	\N	\N	1694	2708	\N	\N	MMD-90
93900	\N	\N	1657	3012	\N	\N	MMR-37
93901	\N	\N	1851	3156	\N	\N	MMR-340
93902	\N	\N	1852	2956	\N	\N	MMD-341
93903	\N	\N	1652	3008	\N	\N	MMR-32
93904	\N	\N	1652	2679	\N	\N	MMD-61
93905	\N	\N	1641	2636	\N	\N	MMD-16
93906	\N	\N	1641	2644	\N	\N	MMD-24
93907	\N	\N	1641	3000	\N	\N	MMR-24
93908	\N	\N	1641	1597	\N	\N	DNA-199
93909	\N	\N	1641	1640	\N	\N	DNA-242
93910	\N	\N	1641	3732	\N	\N	RNA-242
93911	\N	\N	1641	3704	\N	\N	RNA-199
93912	\N	\N	1642	2637	\N	\N	MMD-17
93913	\N	\N	1642	1598	\N	\N	DNA-200
93914	\N	\N	1642	1641	\N	\N	DNA-243
93915	\N	\N	1642	3733	\N	\N	RNA-243
93916	\N	\N	1642	3705	\N	\N	RNA-200
93917	\N	\N	1642	1650	\N	\N	DNA-254
93918	\N	\N	1642	3741	\N	\N	RNA-254
93919	\N	\N	1956	1642	\N	\N	DNA-244
93920	\N	\N	1956	3734	\N	\N	RNA-244
93921	\N	\N	1956	1651	\N	\N	DNA-255
93922	\N	\N	1646	2646	\N	\N	MMD-26
93923	\N	\N	1646	2997	\N	\N	MMR-21
93924	\N	\N	1646	3002	\N	\N	MMR-26
93925	\N	\N	1647	2647	\N	\N	MMD-27
93926	\N	\N	1647	2998	\N	\N	MMR-22
93927	\N	\N	1647	3003	\N	\N	MMR-27
93928	\N	\N	1665	2681	\N	\N	MMD-63
93929	\N	\N	1665	2664	\N	\N	MMD-44
93930	\N	\N	1724	3061	\N	\N	MMR-129
93931	\N	\N	1724	2832	\N	\N	MMD-217
93932	\N	\N	1726	3062	\N	\N	MMR-131
93933	\N	\N	1726	2833	\N	\N	MMD-218
93934	\N	\N	1666	3018	\N	\N	MMR-45
93935	\N	\N	1660	2676	\N	\N	MMD-56
93936	\N	\N	1660	3026	\N	\N	MMR-56
93937	\N	\N	1660	3014	\N	\N	MMR-40
93938	\N	\N	1770	3088	\N	\N	MMR-178
93939	\N	\N	1771	3088	\N	\N	MMR-178
93940	\N	\N	1772	3089	\N	\N	MMR-179
93941	\N	\N	1714	2911	\N	\N	MMD-296
93942	\N	\N	1715	3056	\N	\N	MMR-121
93943	\N	\N	1716	3057	\N	\N	MMR-123
93944	\N	\N	1716	2912	\N	\N	MMD-297
93945	\N	\N	1826	3119	\N	\N	MMR-242
93946	\N	\N	1854	3159	\N	\N	MMR-343
93947	\N	\N	1853	2957	\N	\N	MMD-342
93948	\N	\N	1860	2964	\N	\N	MMD-349
93949	\N	\N	1858	2962	\N	\N	MMD-347
93950	\N	\N	1859	3164	\N	\N	MMR-348
93951	\N	\N	1721	3059	\N	\N	MMR-126
93952	\N	\N	1722	2830	\N	\N	MMD-215
93953	\N	\N	1722	2915	\N	\N	MMD-300
93954	\N	\N	1723	3060	\N	\N	MMR-128
93955	\N	\N	1723	2831	\N	\N	MMD-216
93956	\N	\N	1723	3107	\N	\N	MMR-216
93957	\N	\N	1723	2916	\N	\N	MMD-301
93958	\N	\N	1723	3133	\N	\N	MMR-301
93959	\N	\N	1713	2737	\N	\N	MMD-120
93960	\N	\N	1707	3051	\N	\N	MMR-115
93961	\N	\N	1944	3693	\N	\N	RNA-187
93962	\N	\N	1944	1628	\N	\N	DNA-230
93963	\N	\N	1944	3725	\N	\N	RNA-230
93964	\N	\N	1946	3695	\N	\N	RNA-189
93965	\N	\N	1946	1630	\N	\N	DNA-232
93966	\N	\N	1945	3694	\N	\N	RNA-188
93967	\N	\N	1945	1629	\N	\N	DNA-231
93968	\N	\N	1945	3726	\N	\N	RNA-231
93969	\N	\N	1954	1595	\N	\N	DNA-197
93970	\N	\N	1954	1631	\N	\N	DNA-233
93971	\N	\N	1954	3727	\N	\N	RNA-233
90446	\N	\N	1954	3703	\N	1954 MIS	RNA-197
93972	\N	\N	1695	3040	\N	\N	MMR-91
93973	\N	\N	1697	3040	\N	\N	MMR-91
93974	\N	\N	1701	2716	\N	\N	MMD-98
93975	\N	\N	1703	2718	\N	\N	MMD-100
93976	\N	\N	1849	3155	\N	\N	MMR-338
93977	\N	\N	1742	2927	\N	\N	MMD-312
93978	\N	\N	1741	3070	\N	\N	MMR-149
93979	\N	\N	1741	2926	\N	\N	MMD-311
93980	\N	\N	1639	2634	\N	\N	MMD-14
93981	\N	\N	1639	2643	\N	\N	MMD-23
93982	\N	\N	1639	2999	\N	\N	MMR-23
93983	\N	\N	1632	2983	\N	\N	MMR-07
93984	\N	\N	1717	3058	\N	\N	MMR-124
93985	\N	\N	1717	2913	\N	\N	MMD-298
93986	\N	\N	1718	2914	\N	\N	MMD-299
93987	\N	\N	1719	3058	\N	\N	MMR-124
93988	\N	\N	1719	2913	\N	\N	MMD-298
93989	\N	\N	1720	2914	\N	\N	MMD-299
93990	\N	\N	1712	3054	\N	\N	MMR-119
93991	\N	\N	638	2518	\N	\N	MDD-135
93992	\N	\N	1669	2683	\N	\N	MMD-65
93993	\N	\N	1669	3020	\N	\N	MMR-48
93994	\N	\N	1671	2684	\N	\N	MMD-66
93996	\N	\N	1922	3671	\N	\N	RNA-165
93997	\N	\N	1922	1606	\N	\N	DNA-208
93998	\N	\N	1922	3710	\N	\N	RNA-208
93999	\N	\N	1921	3670	\N	\N	RNA-164
94000	\N	\N	1921	1605	\N	\N	DNA-207
94001	\N	\N	1921	1643	\N	\N	DNA-245
94002	\N	\N	1921	3709	\N	\N	RNA-207
94003	\N	\N	1921	3735	\N	\N	RNA-245
94004	\N	\N	1637	2632	\N	\N	MMD-12
94005	\N	\N	1734	3067	\N	\N	MMR-141
94006	\N	\N	1734	2871	\N	\N	MMD-256
94007	\N	\N	1735	2872	\N	\N	MMD-257
94008	\N	\N	1640	2635	\N	\N	MMD-15
94009	\N	\N	1798	3135	\N	\N	MMR-304
94010	\N	\N	1796	3134	\N	\N	MMR-302
94011	\N	\N	1643	2994	\N	\N	MMR-18
94012	\N	\N	1926	3675	\N	\N	RNA-169
94013	\N	\N	1926	1610	\N	\N	DNA-212
94014	\N	\N	1926	3713	\N	\N	RNA-212
94015	\N	\N	1927	3676	\N	\N	RNA-170
94016	\N	\N	1927	1611	\N	\N	DNA-213
94017	\N	\N	1927	3714	\N	\N	RNA-213
94018	\N	\N	1928	3677	\N	\N	RNA-171
94019	\N	\N	1928	1612	\N	\N	DNA-214
94020	\N	\N	1928	3715	\N	\N	RNA-214
94021	\N	\N	1929	3678	\N	\N	RNA-172
94022	\N	\N	1929	1613	\N	\N	DNA-215
94023	\N	\N	1774	3090	\N	\N	MMR-181
94024	\N	\N	1775	3091	\N	\N	MMR-182
94025	\N	\N	1629	2980	\N	\N	MMR-04
94026	\N	\N	1957	1658	\N	\N	DNA-262
94027	\N	\N	1930	3679	\N	\N	RNA-173
94028	\N	\N	1930	1614	\N	\N	DNA-216
94029	\N	\N	1814	2900	\N	\N	MMD-285
94030	\N	\N	1814	3115	\N	\N	MMR-234
94031	\N	\N	1815	2901	\N	\N	MMD-286
94032	\N	\N	1816	2902	\N	\N	MMD-287
94033	\N	\N	1816	3116	\N	\N	MMR-236
94034	\N	\N	1817	2903	\N	\N	MMD-288
94035	\N	\N	1817	3117	\N	\N	MMR-237
94036	\N	\N	1817	3131	\N	\N	MMR-288
94037	\N	\N	1931	3680	\N	\N	RNA-174
94038	\N	\N	1931	1615	\N	\N	DNA-217
94039	\N	\N	1931	3716	\N	\N	RNA-217
94040	\N	\N	1932	3681	\N	\N	RNA-175
94041	\N	\N	1932	1616	\N	\N	DNA-218
94042	\N	\N	1932	3717	\N	\N	RNA-218
94043	\N	\N	1933	3682	\N	\N	RNA-176
94044	\N	\N	1933	1617	\N	\N	DNA-219
94045	\N	\N	1933	3718	\N	\N	RNA-219
94046	\N	\N	1933	1648	\N	\N	DNA-252
94047	\N	\N	1933	3739	\N	\N	RNA-252
94048	\N	\N	1934	3683	\N	\N	RNA-177
94049	\N	\N	1934	1618	\N	\N	DNA-220
94050	\N	\N	1650	3006	\N	\N	MMR-30
94051	\N	\N	1755	3079	\N	\N	MMR-163
94052	\N	\N	1655	3011	\N	\N	MMR-35
94053	\N	\N	1658	3013	\N	\N	MMR-38
94054	\N	\N	646	2511	\N	\N	MDD-128
90575	\N	\N	646	2398	\N	646 Mel	MDD-15
94055	\N	\N	1757	3080	\N	\N	MMR-165
94056	\N	\N	1633	2984	\N	\N	MMR-08
94057	\N	\N	1938	3687	\N	\N	RNA-181
94058	\N	\N	1938	1622	\N	\N	DNA-224
94059	\N	\N	1938	3721	\N	\N	RNA-224
94060	\N	\N	1939	3688	\N	\N	RNA-182
94061	\N	\N	1939	1623	\N	\N	DNA-225
94062	\N	\N	1939	3722	\N	\N	RNA-225
94063	\N	\N	1939	1649	\N	\N	DNA-253
94064	\N	\N	1939	3740	\N	\N	RNA-253
94065	\N	\N	1940	3689	\N	\N	RNA-183
94066	\N	\N	1940	1624	\N	\N	DNA-226
94067	\N	\N	1843	3149	\N	\N	MMR-332
94068	\N	\N	1844	3151	\N	\N	MMR-334
94069	\N	\N	1845	3150	\N	\N	MMR-333
94070	\N	\N	647	2509	\N	\N	MDD-126
94071	\N	\N	1784	2933	\N	\N	MMD-318
94072	\N	\N	1783	2932	\N	\N	MMD-317
94073	\N	\N	1783	3099	\N	\N	MMR-197
94074	\N	\N	1651	2651	\N	\N	MMD-31
94075	\N	\N	1651	2678	\N	\N	MMD-60
94076	\N	\N	1799	2920	\N	\N	MMD-305
94077	\N	\N	1812	2941	\N	\N	MMD-326
94078	\N	\N	1812	3114	\N	\N	MMR-232
94079	\N	\N	1812	3143	\N	\N	MMR-326
94080	\N	\N	1813	2942	\N	\N	MMD-327
94081	\N	\N	1813	3144	\N	\N	MMR-327
94082	\N	\N	1950	3699	\N	\N	RNA-193
94083	\N	\N	1950	1600	\N	\N	DNA-202
94084	\N	\N	1950	1635	\N	\N	DNA-237
94085	\N	\N	1950	1646	\N	\N	DNA-248
94086	\N	\N	650	2500	\N	\N	MDD-117
94087	\N	\N	651	2501	\N	\N	MDD-118
94088	\N	\N	1630	2981	\N	\N	MMR-05
94089	\N	\N	1630	2674	\N	\N	MMD-54
94090	\N	\N	1630	3024	\N	\N	MMR-54
94091	\N	\N	1630	2686	\N	\N	MMD-68
94092	\N	\N	2786	3902	\N	\N	SM_5_Tumor_NA
94093	\N	\N	1638	2633	\N	\N	MMD-13
94094	\N	\N	1661	3015	\N	\N	MMR-41
94095	\N	\N	1700	2715	\N	\N	MMD-97
94096	\N	\N	1677	2673	\N	\N	MMD-53
94097	\N	\N	1677	3023	\N	\N	MMR-53
94098	\N	\N	1627	2978	\N	\N	MMR-02
94099	\N	\N	1446	3654	\N	\N	RNA-148
94100	\N	\N	1446	1551	\N	\N	DNA-153
94101	\N	\N	1446	3659	\N	\N	RNA-153
94102	\N	\N	1835	3124	\N	\N	MMR-251
94103	\N	\N	2309	3529	\N	\N	PROG R-25
94104	\N	\N	2310	3530	\N	\N	PROG R-26
94105	\N	\N	1311	3505	\N	\N	PROG R-01
94106	\N	\N	1311	3493	\N	\N	PROG D-15
94107	\N	\N	1311	3519	\N	\N	PROG R-15
94108	\N	\N	1312	3506	\N	\N	PROG R-02
94109	\N	\N	1312	3494	\N	\N	PROG D-16
94110	\N	\N	1312	3520	\N	\N	PROG R-16
94111	\N	\N	1313	3507	\N	\N	PROG R-03
94112	\N	\N	1313	3494	\N	\N	PROG D-16
94113	\N	\N	1313	3520	\N	\N	PROG R-16
94114	\N	\N	2305	3525	\N	\N	PROG R-21
94115	\N	\N	2306	3526	\N	\N	PROG R-22
94116	\N	\N	2307	3527	\N	\N	PROG R-23
94117	\N	\N	2308	3528	\N	\N	PROG R-24
94118	\N	\N	1314	3508	\N	\N	PROG R-04
94119	\N	\N	1314	3495	\N	\N	PROG D-17
94120	\N	\N	1314	3521	\N	\N	PROG R-17
94121	\N	\N	1426	3509	\N	\N	PROG R-05
94122	\N	\N	2789	3905	\N	\N	SM_7_Tumor_NA
94123	\N	\N	1786	2815	\N	\N	MMD-200
94124	\N	\N	2794	3909	\N	\N	SM_9_Tumor_NA
94125	\N	\N	1662	3016	\N	\N	MMR-42
94126	\N	\N	1662	2726	\N	\N	MMD-108
94127	\N	\N	1662	2809	\N	\N	MMD-194
94128	\N	\N	1663	2727	\N	\N	MMD-109
94129	\N	\N	1663	2810	\N	\N	MMD-195
94130	\N	\N	1663	3097	\N	\N	MMR-195
94131	\N	\N	1663	2882	\N	\N	MMD-267
94132	\N	\N	1663	3128	\N	\N	MMR-267
94133	\N	\N	1923	3672	\N	\N	RNA-166
94134	\N	\N	1923	1607	\N	\N	DNA-209
94135	\N	\N	1923	1644	\N	\N	DNA-246
94136	\N	\N	1923	3711	\N	\N	RNA-209
94137	\N	\N	1923	3736	\N	\N	RNA-246
94138	\N	\N	1924	3673	\N	\N	RNA-167
94139	\N	\N	1924	1608	\N	\N	DNA-210
94140	\N	\N	1924	3712	\N	\N	RNA-210
94141	\N	\N	1924	1647	\N	\N	DNA-251
94142	\N	\N	1924	3738	\N	\N	RNA-251
94143	\N	\N	1925	3674	\N	\N	RNA-168
94144	\N	\N	1925	1609	\N	\N	DNA-211
94145	\N	\N	1747	2928	\N	\N	MMD-313
94146	\N	\N	1747	3073	\N	\N	MMR-155
94147	\N	\N	1747	3138	\N	\N	MMR-313
94148	\N	\N	1748	2929	\N	\N	MMD-314
94149	\N	\N	2042	3745	\N	\N	RNA-272
94150	\N	\N	1782	3098	\N	\N	MMR-196
94151	\N	\N	1782	2891	\N	\N	MMD-276
94152	\N	\N	2037	1661	\N	\N	DNA-265
94153	\N	\N	1750	3075	\N	\N	MMR-158
94154	\N	\N	1751	3076	\N	\N	MMR-159
94155	\N	\N	1751	3129	\N	\N	MMR-275
94156	\N	\N	1751	2890	\N	\N	MMD-275
94157	\N	\N	1764	2787	\N	\N	MMD-172
94158	\N	\N	1686	3033	\N	\N	MMR-81
94159	\N	\N	1688	2702	\N	\N	MMD-84
94160	\N	\N	1688	2703	\N	\N	MMD-85
94161	\N	\N	1688	2713	\N	\N	MMD-95
94162	\N	\N	1688	3034	\N	\N	MMR-83
94163	\N	\N	1688	3035	\N	\N	MMR-84
94164	\N	\N	1688	3043	\N	\N	MMR-95
94165	\N	\N	2029	3416	\N	\N	OM-1D-3
94166	\N	\N	1805	3110	\N	\N	MMR-225
94167	\N	\N	1805	2896	\N	\N	MMD-281
94168	\N	\N	1807	3111	\N	\N	MMR-227
94169	\N	\N	1807	2897	\N	\N	MMD-282
90694	\N	\N	1807	2842	\N	1807 MIS	MMD-227
94170	\N	\N	1749	2772	\N	\N	MMD-157
94171	\N	\N	1955	1639	\N	\N	DNA-241
94172	\N	\N	1955	1652	\N	\N	DNA-256
94173	\N	\N	1955	1653	\N	\N	DNA-257
94174	\N	\N	1682	3030	\N	\N	MMR-76
94175	\N	\N	1684	2697	\N	\N	MMD-79
94176	\N	\N	1684	2698	\N	\N	MMD-80
94177	\N	\N	1684	3031	\N	\N	MMR-78
94178	\N	\N	1684	3032	\N	\N	MMR-79
94179	\N	\N	1684	2712	\N	\N	MMD-94
94180	\N	\N	1684	3042	\N	\N	MMR-94
94181	\N	\N	1743	3071	\N	\N	MMR-151
94182	\N	\N	1744	3071	\N	\N	MMR-151
94183	\N	\N	1744	2875	\N	\N	MMD-260
94184	\N	\N	1745	2769	\N	\N	MMD-154
94185	\N	\N	1745	2876	\N	\N	MMD-261
94186	\N	\N	1745	2975	\N	\N	MMD-360
94187	\N	\N	1745	3176	\N	\N	MMR-360
94188	\N	\N	1746	2768	\N	\N	MMD-153
94189	\N	\N	1746	2877	\N	\N	MMD-262
94190	\N	\N	1746	3127	\N	\N	MMR-262
94191	\N	\N	1746	2976	\N	\N	MMD-361 (P041_03A)
94192	\N	\N	1746	3177	\N	\N	MMR-361
94193	\N	\N	1727	2749	\N	\N	MMD-132
94194	\N	\N	1727	3063	\N	\N	MMR-132
94195	\N	\N	1728	2750	\N	\N	MMD-133
94196	\N	\N	1600	743	\N	\N	AM2 R-403
94197	\N	\N	1600	537	\N	\N	AM2 D-479
94198	\N	\N	1600	800	\N	\N	AM2 R-479
94199	\N	\N	1601	744	\N	\N	AM2 R-404
94200	\N	\N	1601	538	\N	\N	AM2 D-480
94201	\N	\N	1601	801	\N	\N	AM2 R-480
94202	\N	\N	1752	3077	\N	\N	MMR-160
94203	\N	\N	1753	2880	\N	\N	MMD-265
94204	\N	\N	1917	3666	\N	\N	RNA-160
94205	\N	\N	1917	1601	\N	\N	DNA-203
94206	\N	\N	1917	3706	\N	\N	RNA-203
94207	\N	\N	1918	3667	\N	\N	RNA-161
94208	\N	\N	1918	1602	\N	\N	DNA-204
94209	\N	\N	1918	3707	\N	\N	RNA-204
94210	\N	\N	1919	3668	\N	\N	RNA-162
94211	\N	\N	1919	1603	\N	\N	DNA-205
94212	\N	\N	1919	3708	\N	\N	RNA-205
94213	\N	\N	1920	3669	\N	\N	RNA-163
94214	\N	\N	1920	1604	\N	\N	DNA-206
94215	\N	\N	1653	3009	\N	\N	MMR-33
94216	\N	\N	1653	2680	\N	\N	MMD-62
94217	\N	\N	1653	2724	\N	\N	MMD-106
94218	\N	\N	1654	3010	\N	\N	MMR-34
94219	\N	\N	1654	2725	\N	\N	MMD-107
94220	\N	\N	1654	2808	\N	\N	MMD-193
94221	\N	\N	1958	1659	\N	\N	DNA-263
94222	\N	\N	1754	3078	\N	\N	MMR-162
94223	\N	\N	1672	3022	\N	\N	MMR-51
94224	\N	\N	1672	2720	\N	\N	MMD-102
94225	\N	\N	1673	2721	\N	\N	MMD-103
94226	\N	\N	1674	3048	\N	\N	MMR-101
94227	\N	\N	1626	2977	\N	\N	MMR-01
94228	\N	\N	1644	2995	\N	\N	MMR-19
94229	\N	\N	1644	2645	\N	\N	MMD-25
94230	\N	\N	1644	3001	\N	\N	MMR-25
94231	\N	\N	1510	660	\N	\N	AM2 R-288
94232	\N	\N	1510	575	\N	\N	AM2 D-519
94233	\N	\N	1510	835	\N	\N	AM2 R-519
90817	\N	\N	1510	376	\N	1510 Normal	AM2 D-288
94234	\N	\N	1511	661	\N	\N	AM2 R-289
94235	\N	\N	1511	578	\N	\N	AM2 D-522
94236	\N	\N	1511	838	\N	\N	AM2 R-522
94237	\N	\N	1512	661	\N	\N	AM2 R-289
94238	\N	\N	1512	578	\N	\N	AM2 D-522
94239	\N	\N	1512	838	\N	\N	AM2 R-522
94240	\N	\N	1509	659	\N	\N	AM2 R-287
94241	\N	\N	1509	577	\N	\N	AM2 D-521
94242	\N	\N	1509	837	\N	\N	AM2 R-521
94243	\N	\N	1508	658	\N	\N	AM2 R-286
94244	\N	\N	1508	576	\N	\N	AM2 D-520
94245	\N	\N	1508	836	\N	\N	AM2 R-520
94246	\N	\N	1502	653	\N	\N	AM2 R-280
94247	\N	\N	1513	662	\N	\N	AM2 R-291
94248	\N	\N	1514	662	\N	\N	AM2 R-291
94249	\N	\N	1507	654	\N	\N	AM2 R-281
94250	\N	\N	1503	654	\N	\N	AM2 R-281
94251	\N	\N	1504	655	\N	\N	AM2 R-282
94252	\N	\N	1736	3068	\N	\N	MMR-143
94253	\N	\N	1736	2873	\N	\N	MMD-258
94254	\N	\N	1736	2973	\N	\N	MMD-358
94255	\N	\N	1736	3174	\N	\N	MMR-358
94256	\N	\N	1737	3069	\N	\N	MMR-144
94257	\N	\N	1737	2974	\N	\N	MMD-359 (P041_01D)
94258	\N	\N	1737	3175	\N	\N	MMR-359
94259	\N	\N	1739	2761	\N	\N	MMD-146
94260	\N	\N	1740	2763	\N	\N	MMD-148
94261	\N	\N	1505	656	\N	\N	AM2 R-283
94262	\N	\N	1506	657	\N	\N	AM2 R-284
94263	\N	\N	1846	3152	\N	\N	MMR-335
94264	\N	\N	2766	1920	\N	\N	Ivanka_23_2_NA
94265	\N	\N	2766	1921	\N	\N	Ivanka_23_3_NA
94266	\N	\N	2766	1922	\N	\N	Ivanka_23_4_NA
94267	\N	\N	2766	1923	\N	\N	Ivanka_23_5_NA
94268	\N	\N	2302	3524	\N	\N	PROG R-20
94269	\N	\N	1428	3510	\N	\N	PROG R-06
94270	\N	\N	1429	3511	\N	\N	PROG R-07
94271	\N	\N	1435	3512	\N	\N	PROG R-08
94272	\N	\N	1436	3513	\N	\N	PROG R-09
94273	\N	\N	1437	3514	\N	\N	PROG R-10
94274	\N	\N	1494	645	\N	\N	AM2 R-272
94275	\N	\N	1494	587	\N	\N	AM2 D-533
94276	\N	\N	1495	646	\N	\N	AM2 R-273
94277	\N	\N	1495	588	\N	\N	AM2 D-534
94278	\N	\N	1496	647	\N	\N	AM2 R-274
94279	\N	\N	1496	589	\N	\N	AM2 D-535
94280	\N	\N	1497	648	\N	\N	AM2 R-275
94281	\N	\N	1498	649	\N	\N	AM2 R-276
94282	\N	\N	1500	651	\N	\N	AM2 R-278
94283	\N	\N	1499	650	\N	\N	AM2 R-277
94284	\N	\N	1501	652	\N	\N	AM2 R-279
94285	\N	\N	1733	2755	\N	\N	MMD-140
94286	\N	\N	1733	3126	\N	\N	MMR-255
94287	\N	\N	1733	2870	\N	\N	MMD-255
94288	\N	\N	1731	3065	\N	\N	MMR-136
94289	\N	\N	1731	2868	\N	\N	MMD-253
94290	\N	\N	1731	3125	\N	\N	MMR-253
94291	\N	\N	1731	2971	\N	\N	MMD-356 (P041_01B)
94292	\N	\N	1731	3172	\N	\N	MMR-356
94293	\N	\N	1732	2869	\N	\N	MMD-254
94294	\N	\N	1732	2972	\N	\N	MMD-357 (P041_01C)
94295	\N	\N	1732	3173	\N	\N	MMR-357
94296	\N	\N	2036	1660	\N	\N	DNA-264
94297	\N	\N	1438	3515	\N	\N	PROG R-11
94298	\N	\N	1438	3492	\N	\N	PROG D-14
94299	\N	\N	1438	3518	\N	\N	PROG R-14
94300	\N	\N	1438	3497	\N	\N	PROG D-19
94301	\N	\N	1438	3523	\N	\N	PROG R-19
94302	\N	\N	1439	3516	\N	\N	PROG R-12
94303	\N	\N	1439	3496	\N	\N	PROG D-18
94304	\N	\N	1439	3522	\N	\N	PROG R-18
94305	\N	\N	1440	3517	\N	\N	PROG R-13
94306	\N	\N	2430	77	\N	\N	D72_NA
94307	\N	\N	2430	78	\N	\N	D73_NA
94308	\N	\N	2430	79	\N	\N	D74_NA
94309	\N	\N	2430	80	\N	\N	D75_NA
91126	\N	\N	2430	64	\N	2430 BCC	D56_NA
94310	\N	\N	1490	641	\N	\N	AM2 R-268
94311	\N	\N	1490	444	\N	\N	AM2 D-368
94312	\N	\N	1491	642	\N	\N	AM2 R-269
94313	\N	\N	1491	570	\N	\N	AM2 D-513
94314	\N	\N	1491	830	\N	\N	AM2 R-513
94315	\N	\N	1492	643	\N	\N	AM2 R-270
94316	\N	\N	1492	571	\N	\N	AM2 D-514
94317	\N	\N	1492	831	\N	\N	AM2 R-514
94318	\N	\N	1493	644	\N	\N	AM2 R-271
94319	\N	\N	1628	2979	\N	\N	MMR-03
94320	\N	\N	1960	3399	\N	\N	OM R-31
91202	\N	\N	1960	3347	\N	1960 Typical Melanotic Macule	OM D-31
94321	\N	\N	1961	3400	\N	\N	OM R-32
94322	\N	\N	1678	3027	\N	\N	MMR-70
94323	\N	\N	1678	2804	\N	\N	MMD-189
94324	\N	\N	1678	2888	\N	\N	MMD-273
94325	\N	\N	1678	2969	\N	\N	MMD-354
94326	\N	\N	1678	3170	\N	\N	MMR-354
94327	\N	\N	1679	2805	\N	\N	MMD-190
94328	\N	\N	1679	2889	\N	\N	MMD-274
94329	\N	\N	1679	2970	\N	\N	MMD-355 (P041_01A)
94330	\N	\N	1679	3171	\N	\N	MMR-355
94331	\N	\N	1529	673	\N	\N	AM2 R-308
94332	\N	\N	1529	516	\N	\N	AM2 D-457
94333	\N	\N	1529	779	\N	\N	AM2 R-457
94334	\N	\N	1530	674	\N	\N	AM2 R-309
94335	\N	\N	1532	676	\N	\N	AM2 R-311
94336	\N	\N	1532	517	\N	\N	AM2 D-458
94337	\N	\N	1532	780	\N	\N	AM2 R-458
94338	\N	\N	1531	675	\N	\N	AM2 R-310
94339	\N	\N	1531	585	\N	\N	AM2 D-531
94340	\N	\N	1531	845	\N	\N	AM2 R-531
94341	\N	\N	1533	677	\N	\N	AM2 R-312
94342	\N	\N	1470	630	\N	\N	AM2 R-256
94343	\N	\N	1470	526	\N	\N	AM2 D-467
94344	\N	\N	1470	789	\N	\N	AM2 R-467
94345	\N	\N	1471	631	\N	\N	AM2 R-257
94346	\N	\N	1471	528	\N	\N	AM2 D-470
94347	\N	\N	1471	791	\N	\N	AM2 R-470
94348	\N	\N	1472	632	\N	\N	AM2 R-258
94349	\N	\N	1472	539	\N	\N	AM2 D-481 (P041_03B)
94350	\N	\N	1689	3036	\N	\N	MMR-86
94351	\N	\N	1691	3036	\N	\N	MMR-86
94352	\N	\N	1691	3095	\N	\N	MMR-191
94353	\N	\N	1691	2806	\N	\N	MMD-191
94354	\N	\N	1692	3037	\N	\N	MMR-88
94355	\N	\N	1692	2807	\N	\N	MMD-192
94356	\N	\N	1692	3096	\N	\N	MMR-192
94357	\N	\N	1692	2887	\N	\N	MMD-272
94358	\N	\N	2712	4479	\N	\N	AM-30-Tumor
94359	\N	\N	1962	3401	\N	\N	OM R-33
94360	\N	\N	2699	4466	\N	\N	AM-17-Tumor
94361	\N	\N	2714	4481	\N	\N	AM-32-Tumor
94362	\N	\N	2030	3422	\N	\N	OM-4D-3
94363	\N	\N	2713	4480	\N	\N	AM-31-Tumor
94364	\N	\N	2708	4475	\N	\N	AM-26-Tumor
94365	\N	\N	2031	3426	\N	\N	OM-5D-3
94366	\N	\N	2701	4468	\N	\N	AM-19-Tumor
94367	\N	\N	2700	4467	\N	\N	AM-18-Tumor
94368	\N	\N	1965	3403	\N	\N	OM R-35
94369	\N	\N	1473	633	\N	\N	AM2 R-259
94370	\N	\N	1473	527	\N	\N	AM2 D-468
94371	\N	\N	1473	790	\N	\N	AM2 R-468
94372	\N	\N	1624	789	\N	\N	AM2 R-467
94373	\N	\N	2702	4469	\N	\N	AM-20-Tumor
94374	\N	\N	1634	2985	\N	\N	MMR-09
94375	\N	\N	1634	2675	\N	\N	MMD-55
94376	\N	\N	1634	3025	\N	\N	MMR-55
94377	\N	\N	1634	2687	\N	\N	MMD-69
91326	\N	\N	1634	2629	\N	1634 Mel	MMD-09
94378	\N	\N	1534	678	\N	\N	AM2 R-313
94379	\N	\N	1534	518	\N	\N	AM2 D-459
94380	\N	\N	1534	781	\N	\N	AM2 R-459
94381	\N	\N	1535	679	\N	\N	AM2 R-314
94382	\N	\N	1535	476	\N	\N	AM2 D-410
94383	\N	\N	1535	477	\N	\N	AM2 D-411
94384	\N	\N	1535	747	\N	\N	AM2 R-410
94385	\N	\N	1535	748	\N	\N	AM2 R-411
94386	\N	\N	1536	680	\N	\N	AM2 R-316
94387	\N	\N	2703	4470	\N	\N	AM-21-Tumor
94388	\N	\N	2125	3758	\N	\N	RNA-289
94389	\N	\N	2124	3757	\N	\N	RNA-288
94390	\N	\N	1539	683	\N	\N	AM2 R-319
94391	\N	\N	1539	531	\N	\N	AM2 D-473
94392	\N	\N	1539	794	\N	\N	AM2 R-473
94393	\N	\N	1540	684	\N	\N	AM2 R-320
94394	\N	\N	1540	438	\N	\N	AM2 D-361
94395	\N	\N	1540	719	\N	\N	AM2 R-361
94396	\N	\N	1540	532	\N	\N	AM2 D-474
94397	\N	\N	1540	795	\N	\N	AM2 R-474
94398	\N	\N	1540	824	\N	\N	AM2 R-507
94399	\N	\N	1540	564	\N	\N	AM2 D-507
94400	\N	\N	1625	795	\N	\N	AM2 R-474
94401	\N	\N	2704	4471	\N	\N	AM-22-Tumor
94402	\N	\N	1964	3402	\N	\N	OM R-34
94403	\N	\N	2111	3747	\N	\N	RNA-275
94404	\N	\N	2112	3748	\N	\N	RNA-276
94405	\N	\N	2113	1687	\N	\N	DNA-291
94406	\N	\N	2130	3774	\N	\N	RNA-313
94407	\N	\N	2088	1691	\N	\N	DNA-295
94408	\N	\N	2088	3760	\N	\N	RNA-295
94409	\N	\N	2087	1692	\N	\N	DNA-296
94410	\N	\N	2089	1690	\N	\N	DNA-294
94411	\N	\N	2089	3759	\N	\N	RNA-294
94412	\N	\N	2705	4472	\N	\N	AM-23-Tumor
94413	\N	\N	2710	4477	\N	\N	AM-28-Tumor
94414	\N	\N	2706	4473	\N	\N	AM-24-Tumor
94415	\N	\N	2697	4464	\N	\N	AM-15-Tumor
94416	\N	\N	2709	4476	\N	\N	AM-27-Tumor
94417	\N	\N	1544	688	\N	\N	AM2 R-324
94418	\N	\N	1545	689	\N	\N	AM2 R-325
94419	\N	\N	1546	690	\N	\N	AM2 R-326
94420	\N	\N	2032	3430	\N	\N	OM-6D-3
94421	\N	\N	2707	4474	\N	\N	AM-25-Tumor
94422	\N	\N	1519	664	\N	\N	AM2 R-294
94423	\N	\N	1519	839	\N	\N	AM2 R-523
94424	\N	\N	1519	579	\N	\N	AM2 D-523
94425	\N	\N	1515	663	\N	\N	AM2 R-293
94426	\N	\N	1515	514	\N	\N	AM2 D-455
94427	\N	\N	1515	777	\N	\N	AM2 R-455
94428	\N	\N	1516	715	\N	\N	AM2 R-355
94429	\N	\N	1516	541	\N	\N	AM2 D-483 (P041_03D)
94430	\N	\N	1517	716	\N	\N	AM2 R-356
94431	\N	\N	1517	823	\N	\N	AM2 R-506
94432	\N	\N	1517	563	\N	\N	AM2 D-506
94433	\N	\N	1518	717	\N	\N	AM2 R-357
94434	\N	\N	1518	515	\N	\N	AM2 D-456
94435	\N	\N	1518	778	\N	\N	AM2 R-456
94436	\N	\N	1521	666	\N	\N	AM2 R-296
94437	\N	\N	1521	442	\N	\N	AM2 D-366
94438	\N	\N	1522	667	\N	\N	AM2 R-297
94439	\N	\N	1523	668	\N	\N	AM2 R-298
94440	\N	\N	1524	669	\N	\N	AM2 R-299
94441	\N	\N	1524	841	\N	\N	AM2 R-525
94442	\N	\N	1524	581	\N	\N	AM2 D-525
94443	\N	\N	1525	670	\N	\N	AM2 R-300
94444	\N	\N	1525	842	\N	\N	AM2 R-526
94445	\N	\N	1525	582	\N	\N	AM2 D-526
94446	\N	\N	1526	668	\N	\N	AM2 R-298
94447	\N	\N	1526	584	\N	\N	AM2 D-528
94448	\N	\N	1526	844	\N	\N	AM2 R-528
94449	\N	\N	1527	671	\N	\N	AM2 R-303
94450	\N	\N	1528	672	\N	\N	AM2 R-304
94451	\N	\N	1528	843	\N	\N	AM2 R-527
94452	\N	\N	1528	583	\N	\N	AM2 D-527
94453	\N	\N	2711	4478	\N	\N	AM-29-Tumor
91446	\N	\N	2711	4478	\N	2711 Tumor	AM-29-Tumor
94454	\N	\N	1476	636	\N	\N	AM2 R-262
94455	\N	\N	1476	540	\N	\N	AM2 D-482 (P041_03C)
94456	\N	\N	1475	635	\N	\N	AM2 R-261
94457	\N	\N	1475	440	\N	\N	AM2 D-363
94458	\N	\N	1475	720	\N	\N	AM2 R-363
94459	\N	\N	1475	543	\N	\N	AM2 D-485
94460	\N	\N	1475	803	\N	\N	AM2 R-485
94461	\N	\N	1477	637	\N	\N	AM2 R-263
94462	\N	\N	1478	638	\N	\N	AM2 R-264
94463	\N	\N	1478	547	\N	\N	AM2 D-488
94464	\N	\N	1478	548	\N	\N	AM2 D-489
94465	\N	\N	1478	807	\N	\N	AM2 R-488
94466	\N	\N	1478	808	\N	\N	AM2 R-489
94467	\N	\N	1479	639	\N	\N	AM2 R-265
94468	\N	\N	1479	544	\N	\N	AM2 D-486-1
94469	\N	\N	1479	804	\N	\N	AM2 R-486-1
94470	\N	\N	1489	640	\N	\N	AM2 R-266
94471	\N	\N	1489	545	\N	\N	AM2 D-486-2
94472	\N	\N	1489	805	\N	\N	AM2 R-486-2
94473	\N	\N	1520	665	\N	\N	AM2 R-295
94474	\N	\N	1520	840	\N	\N	AM2 R-524
94475	\N	\N	1520	580	\N	\N	AM2 D-524
94476	\N	\N	1610	756	\N	\N	AM2 R-423
94477	\N	\N	1548	692	\N	\N	AM2 R-328
94478	\N	\N	1548	519	\N	\N	AM2 D-460
94479	\N	\N	1548	782	\N	\N	AM2 R-460
94480	\N	\N	1547	691	\N	\N	AM2 R-327
94481	\N	\N	1549	693	\N	\N	AM2 R-329
94482	\N	\N	1549	520	\N	\N	AM2 D-461
94483	\N	\N	1549	783	\N	\N	AM2 R-461
94484	\N	\N	1550	694	\N	\N	AM2 R-330
94485	\N	\N	1474	634	\N	\N	AM2 R-260
94486	\N	\N	1966	3404	\N	\N	OM R-36
94487	\N	\N	1681	2692	\N	\N	MMD-74
94488	\N	\N	1681	2693	\N	\N	MMD-75
94489	\N	\N	1681	2711	\N	\N	MMD-93
94490	\N	\N	1681	3028	\N	\N	MMR-73
94491	\N	\N	1681	3029	\N	\N	MMR-74
94492	\N	\N	1681	3041	\N	\N	MMR-93
94493	\N	\N	2698	4465	\N	\N	AM-16-Tumor
94494	\N	\N	1541	685	\N	\N	AM2 R-321
94495	\N	\N	1541	439	\N	\N	AM2 D-362
94496	\N	\N	1541	529	\N	\N	AM2 D-471
94497	\N	\N	1541	792	\N	\N	AM2 R-471
94498	\N	\N	1542	686	\N	\N	AM2 R-322
94499	\N	\N	1542	530	\N	\N	AM2 D-472
94500	\N	\N	1542	793	\N	\N	AM2 R-472
94501	\N	\N	1542	555	\N	\N	AM2 D-496
94502	\N	\N	1542	815	\N	\N	AM2 R-496
94503	\N	\N	1967	3405	\N	\N	OM R-37
94504	\N	\N	1968	3406	\N	\N	OM R-38
94505	\N	\N	1455	3974	\N	\N	SNR-05
94506	\N	\N	1455	3966	\N	\N	SND-40
94507	\N	\N	1969	3407	\N	\N	OM R-39
94508	\N	\N	1553	696	\N	\N	AM2 R-333
94509	\N	\N	1553	523	\N	\N	AM2 D-464
94510	\N	\N	1553	786	\N	\N	AM2 R-464
94511	\N	\N	1554	697	\N	\N	AM2 R-334
94512	\N	\N	1554	524	\N	\N	AM2 D-465
94513	\N	\N	1554	787	\N	\N	AM2 R-465
94514	\N	\N	1555	698	\N	\N	AM2 R-335
94515	\N	\N	1556	699	\N	\N	AM2 R-336
94516	\N	\N	1557	700	\N	\N	AM2 R-337
94517	\N	\N	1557	525	\N	\N	AM2 D-466
94518	\N	\N	1557	788	\N	\N	AM2 R-466
94519	\N	\N	1557	825	\N	\N	AM2 R-508
94520	\N	\N	1557	565	\N	\N	AM2 D-508
94521	\N	\N	1537	681	\N	\N	AM2 R-317
94522	\N	\N	1570	710	\N	\N	AM2 R-350
94523	\N	\N	1571	711	\N	\N	AM2 R-351
94524	\N	\N	1573	713	\N	\N	AM2 R-353
94525	\N	\N	1572	712	\N	\N	AM2 R-352
94526	\N	\N	1574	714	\N	\N	AM2 R-354
94527	\N	\N	2180	3779	\N	\N	RNA-330
94528	\N	\N	2181	3780	\N	\N	RNA-331
94529	\N	\N	2182	3781	\N	\N	RNA-332
94530	\N	\N	1538	682	\N	\N	AM2 R-318
91563	\N	\N	1538	398	\N	1538 Skin Met3	AM2 D-318
94531	\N	\N	1606	753	\N	\N	AM2 R-419
94532	\N	\N	1606	827	\N	\N	AM2 R-510
94533	\N	\N	1606	567	\N	\N	AM2 D-510
94534	\N	\N	1607	754	\N	\N	AM2 R-420
94535	\N	\N	1607	828	\N	\N	AM2 R-511
94536	\N	\N	1607	568	\N	\N	AM2 D-511
94537	\N	\N	1609	755	\N	\N	AM2 R-422
94538	\N	\N	2184	3782	\N	\N	RNA-334
94539	\N	\N	2185	3783	\N	\N	RNA-335
94540	\N	\N	2483	4451	\N	\N	LMM R-052
94541	\N	\N	2484	4452	\N	\N	LMM R-053
94542	\N	\N	1971	3408	\N	\N	OM R-41
94543	\N	\N	283	1424	\N	\N	DNA-04
94544	\N	\N	285	1426	\N	\N	DNA-06
94545	\N	\N	284	1425	\N	\N	DNA-05
94546	\N	\N	298	1437	\N	\N	DNA-19
94547	\N	\N	299	1438	\N	\N	DNA-20
94548	\N	\N	350	1519	\N	\N	DNA-121
94549	\N	\N	350	3627	\N	\N	RNA-121
94550	\N	\N	351	1518	\N	\N	DNA-120
94551	\N	\N	351	3626	\N	\N	RNA-120
94552	\N	\N	2243	3827	\N	\N	RNA-421
94553	\N	\N	2244	3778	\N	\N	RNA-320
94554	\N	\N	2245	3828	\N	\N	RNA-422
94555	\N	\N	355	1525	\N	\N	DNA-127
94556	\N	\N	355	3633	\N	\N	RNA-127
94557	\N	\N	355	1538	\N	\N	DNA-140
94558	\N	\N	354	1450	\N	\N	DNA-38
94559	\N	\N	354	1524	\N	\N	DNA-126
94560	\N	\N	354	3632	\N	\N	RNA-126
94561	\N	\N	354	3645	\N	\N	RNA-139
94562	\N	\N	354	1537	\N	\N	DNA-139
94563	\N	\N	356	3646	\N	\N	RNA-140
94564	\N	\N	772	3573	\N	\N	RNA-43
94565	\N	\N	772	1699	\N	\N	DNA-303
94566	\N	\N	772	3765	\N	\N	RNA-303
94567	\N	\N	773	3574	\N	\N	RNA-44
94568	\N	\N	773	1700	\N	\N	DNA-304
94569	\N	\N	773	3766	\N	\N	RNA-304
94570	\N	\N	349	1516	\N	\N	DNA-118
94571	\N	\N	349	3624	\N	\N	RNA-118
94572	\N	\N	349	1697	\N	\N	DNA-301
94573	\N	\N	349	3764	\N	\N	RNA-301
94574	\N	\N	348	1517	\N	\N	DNA-119
94575	\N	\N	348	3625	\N	\N	RNA-119
94576	\N	\N	348	3642	\N	\N	RNA-136
94577	\N	\N	348	1534	\N	\N	DNA-136
94578	\N	\N	348	1696	\N	\N	DNA-300
94579	\N	\N	348	3763	\N	\N	RNA-300
94580	\N	\N	1449	3656	\N	\N	RNA-150
94581	\N	\N	1449	1553	\N	\N	DNA-155
94582	\N	\N	1449	3661	\N	\N	RNA-155
94583	\N	\N	1430	3603	\N	\N	RNA-98
94584	\N	\N	290	1431	\N	\N	DNA-11
94585	\N	\N	291	1432	\N	\N	DNA-12
94586	\N	\N	289	1430	\N	\N	DNA-10
94587	\N	\N	289	1505	\N	\N	DNA-107
94588	\N	\N	289	3613	\N	\N	RNA-107
94589	\N	\N	296	1435	\N	\N	DNA-17
94590	\N	\N	297	1436	\N	\N	DNA-18
94591	\N	\N	304	1443	\N	\N	DNA-25
94592	\N	\N	1448	3655	\N	\N	RNA-149
94593	\N	\N	1448	1552	\N	\N	DNA-154
94594	\N	\N	1448	3660	\N	\N	RNA-154
94595	\N	\N	1448	1556	\N	\N	DNA-158
94596	\N	\N	1448	3664	\N	\N	RNA-158
94597	\N	\N	2117	3751	\N	\N	RNA-281
94598	\N	\N	2119	3753	\N	\N	RNA-283
94599	\N	\N	2118	3752	\N	\N	RNA-282
94600	\N	\N	2120	3754	\N	\N	RNA-284
94601	\N	\N	2120	1689	\N	\N	DNA-293
94602	\N	\N	280	1420	\N	\N	DNA-01
94603	\N	\N	280	1421	\N	\N	DNA-01_REPEAT
94604	\N	\N	280	1693	\N	\N	DNA-297
94605	\N	\N	280	1704	\N	\N	DNA-308
94606	\N	\N	282	1423	\N	\N	DNA-03
94607	\N	\N	282	1695	\N	\N	DNA-299
94608	\N	\N	282	3762	\N	\N	RNA-299
94609	\N	\N	282	1706	\N	\N	DNA-310
94610	\N	\N	282	3771	\N	\N	RNA-310
94611	\N	\N	281	1422	\N	\N	DNA-02
94612	\N	\N	281	1694	\N	\N	DNA-298
94613	\N	\N	281	3761	\N	\N	RNA-298
94614	\N	\N	281	1705	\N	\N	DNA-309
94615	\N	\N	281	3770	\N	\N	RNA-309
94616	\N	\N	300	1439	\N	\N	DNA-21
94617	\N	\N	301	1440	\N	\N	DNA-22
94618	\N	\N	1558	701	\N	\N	AM2 R-338
91737	\N	\N	1558	418	\N	1558 LN Met 1	AM2 D-338
94619	\N	\N	1559	702	\N	\N	AM2 R-339
94620	\N	\N	1560	703	\N	\N	AM2 R-340
94621	\N	\N	1561	704	\N	\N	AM2 R-341
94622	\N	\N	293	1506	\N	\N	DNA-108
94623	\N	\N	293	3614	\N	\N	RNA-108
94624	\N	\N	292	1507	\N	\N	DNA-109
94625	\N	\N	292	3615	\N	\N	RNA-109
94626	\N	\N	788	3572	\N	\N	RNA-42
94627	\N	\N	1565	707	\N	\N	AM2 R-345
94628	\N	\N	1567	708	\N	\N	AM2 R-347
94629	\N	\N	1568	709	\N	\N	AM2 R-348
94630	\N	\N	1543	687	\N	\N	AM2 R-323
94631	\N	\N	1543	586	\N	\N	AM2 D-532
94632	\N	\N	1543	846	\N	\N	AM2 R-532
94633	\N	\N	2122	3756	\N	\N	RNA-286
94634	\N	\N	2121	3755	\N	\N	RNA-285
94635	\N	\N	2121	1714	\N	\N	DNA-318
94636	\N	\N	2121	3777	\N	\N	RNA-318
94637	\N	\N	2123	1715	\N	\N	DNA-319
94638	\N	\N	1973	3410	\N	\N	OM R-43
94639	\N	\N	286	1427	\N	\N	DNA-07
94640	\N	\N	288	1429	\N	\N	DNA-09
94641	\N	\N	287	1428	\N	\N	DNA-08
94642	\N	\N	1432	3605	\N	\N	RNA-100
94643	\N	\N	1432	3647	\N	\N	RNA-141
94644	\N	\N	1432	1539	\N	\N	DNA-141
94645	\N	\N	789	3582	\N	\N	RNA-52
94646	\N	\N	790	3600	\N	\N	RNA-75
94647	\N	\N	791	3581	\N	\N	RNA-51
94648	\N	\N	785	3596	\N	\N	RNA-66
94649	\N	\N	786	1527	\N	\N	DNA-129
94650	\N	\N	786	3635	\N	\N	RNA-129
94651	\N	\N	885	3595	\N	\N	RNA-65
94652	\N	\N	885	1528	\N	\N	DNA-130
94653	\N	\N	885	3636	\N	\N	RNA-130
91825	\N	\N	885	1489	\N	885 MIS	DNA-86
94654	\N	\N	305	1444	\N	\N	DNA-26
94655	\N	\N	344	1446	\N	\N	DNA-28
94656	\N	\N	343	1445	\N	\N	DNA-27
94657	\N	\N	792	3599	\N	\N	RNA-74
94658	\N	\N	794	3583	\N	\N	RNA-53
94659	\N	\N	794	1462	\N	\N	DNA-53_REPEAT
94660	\N	\N	793	3584	\N	\N	RNA-54
94661	\N	\N	793	1464	\N	\N	DNA-54_REPEAT
94662	\N	\N	2114	3749	\N	\N	RNA-278
94663	\N	\N	2115	3750	\N	\N	RNA-279
94664	\N	\N	2116	1688	\N	\N	DNA-292
94665	\N	\N	781	3591	\N	\N	RNA-61
94666	\N	\N	781	1702	\N	\N	DNA-306
94667	\N	\N	781	3768	\N	\N	RNA-306
94668	\N	\N	782	3592	\N	\N	RNA-62
94669	\N	\N	782	1703	\N	\N	DNA-307
94670	\N	\N	782	3769	\N	\N	RNA-307
94671	\N	\N	783	3598	\N	\N	RNA-73
94672	\N	\N	783	1526	\N	\N	DNA-128
94673	\N	\N	783	3634	\N	\N	RNA-128
94674	\N	\N	801	3594	\N	\N	RNA-64
94675	\N	\N	802	3593	\N	\N	RNA-63
94676	\N	\N	2619	4356	\N	\N	RMS-050
94677	\N	\N	1434	3602	\N	\N	RNA-97
94678	\N	\N	1434	3641	\N	\N	RNA-135
94679	\N	\N	1434	1533	\N	\N	DNA-135
94680	\N	\N	803	3590	\N	\N	RNA-60
94681	\N	\N	803	1515	\N	\N	DNA-117
94682	\N	\N	803	3623	\N	\N	RNA-117
94683	\N	\N	805	3589	\N	\N	RNA-59
94684	\N	\N	805	1468	\N	\N	DNA-59_REPEAT
94685	\N	\N	779	3585	\N	\N	RNA-55
94686	\N	\N	780	3586	\N	\N	RNA-56
94687	\N	\N	795	3577	\N	\N	RNA-47
94688	\N	\N	796	3578	\N	\N	RNA-48
94689	\N	\N	797	3601	\N	\N	RNA-76
94690	\N	\N	776	3579	\N	\N	RNA-49
94691	\N	\N	776	1701	\N	\N	DNA-305
94692	\N	\N	776	3767	\N	\N	RNA-305
94693	\N	\N	777	3580	\N	\N	RNA-50
94694	\N	\N	778	3597	\N	\N	RNA-72
94695	\N	\N	1433	3606	\N	\N	RNA-101
94696	\N	\N	302	1441	\N	\N	DNA-23
94697	\N	\N	302	1513	\N	\N	DNA-115
94698	\N	\N	302	3621	\N	\N	RNA-115
94699	\N	\N	302	1543	\N	\N	DNA-145
94700	\N	\N	302	3651	\N	\N	RNA-145
94701	\N	\N	303	1442	\N	\N	DNA-24
94702	\N	\N	303	1514	\N	\N	DNA-116
94703	\N	\N	303	3622	\N	\N	RNA-116
94704	\N	\N	2109	3746	\N	\N	RNA-273
94705	\N	\N	2128	3772	\N	\N	RNA-311
94706	\N	\N	2129	3773	\N	\N	RNA-312
94707	\N	\N	1972	3409	\N	\N	OM R-42
94708	\N	\N	2620	4357	\N	\N	RMS-051
94709	\N	\N	2471	2081	\N	\N	LMM R-024
94710	\N	\N	2485	4453	\N	\N	LMM R-054
91965	\N	\N	2485	4437	\N	2485 Normal	LMM D-054
94711	\N	\N	774	3575	\N	\N	RNA-45
94712	\N	\N	775	3576	\N	\N	RNA-46
94713	\N	\N	352	1521	\N	\N	DNA-123
94714	\N	\N	352	3629	\N	\N	RNA-123
94715	\N	\N	352	3643	\N	\N	RNA-137
94716	\N	\N	352	1535	\N	\N	DNA-137
94717	\N	\N	353	1520	\N	\N	DNA-122
94718	\N	\N	353	3628	\N	\N	RNA-122
94719	\N	\N	1441	3630	\N	\N	RNA-124
94720	\N	\N	1441	3644	\N	\N	RNA-138
94721	\N	\N	1441	1536	\N	\N	DNA-138
94722	\N	\N	1444	3631	\N	\N	RNA-125
94723	\N	\N	1444	1542	\N	\N	DNA-144
94724	\N	\N	1444	3650	\N	\N	RNA-144
94725	\N	\N	1450	3657	\N	\N	RNA-151
94726	\N	\N	1450	1554	\N	\N	DNA-156
94727	\N	\N	1450	3662	\N	\N	RNA-156
94728	\N	\N	1450	1557	\N	\N	DNA-159
94729	\N	\N	1450	3665	\N	\N	RNA-159
94730	\N	\N	294	1433	\N	\N	DNA-15
94731	\N	\N	294	1510	\N	\N	DNA-112
94732	\N	\N	294	3618	\N	\N	RNA-112
94733	\N	\N	295	1434	\N	\N	DNA-16
94734	\N	\N	295	1509	\N	\N	DNA-111
94735	\N	\N	295	3617	\N	\N	RNA-111
94736	\N	\N	895	1508	\N	\N	DNA-110
94737	\N	\N	895	3616	\N	\N	RNA-110
94738	\N	\N	895	3640	\N	\N	RNA-134
94739	\N	\N	895	1532	\N	\N	DNA-134
94740	\N	\N	1442	3619	\N	\N	RNA-113
94741	\N	\N	1442	1540	\N	\N	DNA-142
94742	\N	\N	1442	3648	\N	\N	RNA-142
94743	\N	\N	1443	3620	\N	\N	RNA-114
94744	\N	\N	1443	1541	\N	\N	DNA-143
94745	\N	\N	1443	3649	\N	\N	RNA-143
94746	\N	\N	799	3587	\N	\N	RNA-57
94747	\N	\N	800	3588	\N	\N	RNA-58
94748	\N	\N	2621	4358	\N	\N	RMS-052A
94749	\N	\N	2622	4359	\N	\N	RMS-052B
94750	\N	\N	2623	4360	\N	\N	RMS-053
94751	\N	\N	1451	3653	\N	\N	RNA-147
94752	\N	\N	1451	1550	\N	\N	DNA-152
94753	\N	\N	1451	3658	\N	\N	RNA-152
94754	\N	\N	1451	1555	\N	\N	DNA-157
94755	\N	\N	1451	3663	\N	\N	RNA-157
94756	\N	\N	1447	3652	\N	\N	RNA-146
94757	\N	\N	2131	3775	\N	\N	RNA-314
94758	\N	\N	2133	1713	\N	\N	DNA-317
94759	\N	\N	2132	3776	\N	\N	RNA-315
94760	\N	\N	2616	4353	\N	\N	RMS-047
94761	\N	\N	2617	4354	\N	\N	RMS-048
94762	\N	\N	892	1530	\N	\N	DNA-132
94763	\N	\N	892	3638	\N	\N	RNA-132
94764	\N	\N	892	1662	\N	\N	DNA-266
94765	\N	\N	892	3742	\N	\N	RNA-266
94766	\N	\N	893	1531	\N	\N	DNA-133
94767	\N	\N	893	3639	\N	\N	RNA-133
94768	\N	\N	894	1529	\N	\N	DNA-131
94769	\N	\N	894	3637	\N	\N	RNA-131
94770	\N	\N	894	1663	\N	\N	DNA-267
94771	\N	\N	894	1666	\N	\N	DNA-270
94772	\N	\N	894	1667	\N	\N	DNA-271
94773	\N	\N	345	1447	\N	\N	DNA-29
92088	\N	\N	345	3559	\N	345 Normal	RNA-29
94774	\N	\N	346	1448	\N	\N	DNA-30
94775	\N	\N	347	1449	\N	\N	DNA-31
94776	\N	\N	2618	4355	\N	\N	RMS-049
92091	\N	\N	2618	4311	\N	2618 Spitz Nevus	DMS-049
94777	\N	\N	2021	3453	\N	\N	OM-22D-2
94778	\N	\N	2512	2043	\N	\N	LMM D-031
94779	\N	\N	2513	2044	\N	\N	LMM D-032
94780	\N	\N	1582	721	\N	\N	AM2 R-370
94781	\N	\N	1583	722	\N	\N	AM2 R-371
94782	\N	\N	1551	695	\N	\N	AM2 R-331
94783	\N	\N	1585	728	\N	\N	AM2 R-379
94784	\N	\N	1586	729	\N	\N	AM2 R-380
94785	\N	\N	1977	3411	\N	\N	OM R-45
94786	\N	\N	2241	3824	\N	\N	RNA-418
94787	\N	\N	2190	3787	\N	\N	RNA-340
94788	\N	\N	2191	3788	\N	\N	RNA-341
94789	\N	\N	2510	2041	\N	\N	LMM D-029
94790	\N	\N	2509	2040	\N	\N	LMM D-028
94791	\N	\N	1978	3412	\N	\N	OM R-46
94792	\N	\N	1979	3413	\N	\N	OM R-47
94793	\N	\N	2187	3784	\N	\N	RNA-337
92221	\N	\N	2187	1724	\N	2187 Mel	DNA-337
94794	\N	\N	2188	3785	\N	\N	RNA-338
94795	\N	\N	2189	3786	\N	\N	RNA-339
94796	\N	\N	2196	3792	\N	\N	RNA-348
94797	\N	\N	2197	3793	\N	\N	RNA-350
94798	\N	\N	2198	3794	\N	\N	RNA-351
94799	\N	\N	1468	3987	\N	\N	SNR-18
94800	\N	\N	1468	3960	\N	\N	SND-34
94801	\N	\N	1468	4003	\N	\N	SNR-34
94802	\N	\N	1468	3963	\N	\N	SND-37
94803	\N	\N	1562	705	\N	\N	AM2 R-342
94804	\N	\N	1562	521	\N	\N	AM2 D-462
94805	\N	\N	1562	784	\N	\N	AM2 R-462
94806	\N	\N	1563	706	\N	\N	AM2 R-343
94807	\N	\N	1563	522	\N	\N	AM2 D-463
94808	\N	\N	1563	785	\N	\N	AM2 R-463
94809	\N	\N	1467	3986	\N	\N	SNR-17
94810	\N	\N	2193	3789	\N	\N	RNA-344
94811	\N	\N	2194	3790	\N	\N	RNA-346
94812	\N	\N	1822	730	\N	\N	AM2 R-381
94813	\N	\N	1823	731	\N	\N	AM2 R-382
94814	\N	\N	1824	762	\N	\N	AM2 R-431
94815	\N	\N	1460	3979	\N	\N	SNR-10
94816	\N	\N	1463	3982	\N	\N	SNR-13
94817	\N	\N	1588	764	\N	\N	AM2 R-434
94818	\N	\N	1588	533	\N	\N	AM2 D-475
94819	\N	\N	1588	796	\N	\N	AM2 R-475
94820	\N	\N	1587	763	\N	\N	AM2 R-433
94821	\N	\N	1589	765	\N	\N	AM2 R-435
94822	\N	\N	1589	826	\N	\N	AM2 R-509
94823	\N	\N	1589	566	\N	\N	AM2 D-509
94824	\N	\N	1590	766	\N	\N	AM2 R-436
94825	\N	\N	1592	767	\N	\N	AM2 R-438
94826	\N	\N	1597	737	\N	\N	AM2 R-393
94827	\N	\N	1599	739	\N	\N	AM2 R-395
94828	\N	\N	1598	738	\N	\N	AM2 R-394
94829	\N	\N	1602	745	\N	\N	AM2 R-405
94830	\N	\N	1602	536	\N	\N	AM2 D-478
94831	\N	\N	1602	799	\N	\N	AM2 R-478
94832	\N	\N	1603	534	\N	\N	AM2 D-476
94833	\N	\N	1603	797	\N	\N	AM2 R-476
94834	\N	\N	1594	740	\N	\N	AM2 R-400
94835	\N	\N	1596	742	\N	\N	AM2 R-402
94836	\N	\N	1595	741	\N	\N	AM2 R-401
94837	\N	\N	1445	3970	\N	\N	SNR-01
94838	\N	\N	1459	3978	\N	\N	SNR-09
94839	\N	\N	1452	3971	\N	\N	SNR-02
94840	\N	\N	2022	3455	\N	\N	OM-23D-2
94841	\N	\N	1464	3983	\N	\N	SNR-14
94842	\N	\N	1461	3980	\N	\N	SNR-11
94843	\N	\N	1461	3957	\N	\N	SND-31
94844	\N	\N	1461	4000	\N	\N	SNR-31
94845	\N	\N	1461	3969	\N	\N	SND-43
94846	\N	\N	1462	3981	\N	\N	SNR-12
94847	\N	\N	1462	3958	\N	\N	SND-32
94848	\N	\N	1462	4001	\N	\N	SNR-32
94849	\N	\N	1462	3968	\N	\N	SND-42
94850	\N	\N	1465	3984	\N	\N	SNR-15
94851	\N	\N	1458	3977	\N	\N	SNR-08
94852	\N	\N	1458	3956	\N	\N	SND-30
94853	\N	\N	1458	3999	\N	\N	SNR-30
94854	\N	\N	1458	3962	\N	\N	SND-36
94855	\N	\N	1454	3973	\N	\N	SNR-04
94856	\N	\N	1454	3965	\N	\N	SND-39
94857	\N	\N	1453	3972	\N	\N	SNR-03
94858	\N	\N	1453	3955	\N	\N	SND-29
94859	\N	\N	1453	3998	\N	\N	SNR-29
94860	\N	\N	1453	3961	\N	\N	SND-35
94861	\N	\N	1466	3985	\N	\N	SNR-16
94862	\N	\N	1466	3959	\N	\N	SND-33
94863	\N	\N	1466	4002	\N	\N	SNR-33
94864	\N	\N	2597	4337	\N	\N	RMS-033
94865	\N	\N	1456	3975	\N	\N	SNR-06
94866	\N	\N	1456	3967	\N	\N	SND-41
92343	\N	\N	1456	3932	\N	1456 Nevus	SND-06
94867	\N	\N	1483	3992	\N	\N	SNR-23
94868	\N	\N	1457	3976	\N	\N	SNR-07
94869	\N	\N	2023	3457	\N	\N	OM-24D-2
94870	\N	\N	1431	3604	\N	\N	RNA-99
94871	\N	\N	2608	4346	\N	\N	RMS-040
94872	\N	\N	2609	4347	\N	\N	RMS-040N
94873	\N	\N	2507	2038	\N	\N	LMM D-026
94874	\N	\N	2506	2037	\N	\N	LMM D-025
94875	\N	\N	1579	479	\N	\N	AM2 D-413
94876	\N	\N	1579	749	\N	\N	AM2 R-412
94877	\N	\N	1579	750	\N	\N	AM2 R-413
94878	\N	\N	2599	4339	\N	\N	RMS-035
94879	\N	\N	2024	3459	\N	\N	OM-25D-2
94880	\N	\N	2522	2053	\N	\N	LMM D-041
94881	\N	\N	2521	2052	\N	\N	LMM D-040
94882	\N	\N	2558	4426	\N	\N	KA R-32
94883	\N	\N	1576	450	\N	\N	AM2 D-374
94884	\N	\N	1576	449	\N	\N	AM2 D-373
94885	\N	\N	1576	451	\N	\N	AM2 D-375
94886	\N	\N	1576	452	\N	\N	AM2 D-376
94887	\N	\N	1576	723	\N	\N	AM2 R-372
94888	\N	\N	1576	724	\N	\N	AM2 R-373
94889	\N	\N	1576	725	\N	\N	AM2 R-374
94890	\N	\N	1576	726	\N	\N	AM2 R-375
94891	\N	\N	1576	727	\N	\N	AM2 R-376
92476	\N	\N	1576	448	\N	1576 Subcutaneous Met 2	AM2 D-372
94892	\N	\N	2601	4340	\N	\N	RMS-036
94893	\N	\N	1469	3988	\N	\N	SNR-19
94894	\N	\N	1578	488	\N	\N	AM2 D-426
94895	\N	\N	1578	489	\N	\N	AM2 D-427
94896	\N	\N	1578	490	\N	\N	AM2 D-428
94897	\N	\N	1578	491	\N	\N	AM2 D-429
94898	\N	\N	1578	757	\N	\N	AM2 R-425
94899	\N	\N	1578	758	\N	\N	AM2 R-426
94900	\N	\N	1578	759	\N	\N	AM2 R-427
94901	\N	\N	1578	760	\N	\N	AM2 R-428
94902	\N	\N	1578	761	\N	\N	AM2 R-429
94903	\N	\N	1580	481	\N	\N	AM2 D-415
94904	\N	\N	1580	751	\N	\N	AM2 R-414
94905	\N	\N	1580	752	\N	\N	AM2 R-415
94906	\N	\N	2025	3461	\N	\N	OM-26D-2
94907	\N	\N	1604	534	\N	\N	AM2 D-476
94908	\N	\N	1604	797	\N	\N	AM2 R-476
94909	\N	\N	1605	746	\N	\N	AM2 R-408
94910	\N	\N	1605	535	\N	\N	AM2 D-477
94911	\N	\N	1605	798	\N	\N	AM2 R-477
94912	\N	\N	2303	3858	\N	\N	SCH R-01
94913	\N	\N	2602	4341	\N	\N	RMS-037
94914	\N	\N	2200	3795	\N	\N	RNA-355
94915	\N	\N	2201	3796	\N	\N	RNA-356
94916	\N	\N	2202	3797	\N	\N	RNA-357
94917	\N	\N	1577	459	\N	\N	AM2 D-384
94918	\N	\N	1577	460	\N	\N	AM2 D-385
94919	\N	\N	1577	461	\N	\N	AM2 D-386
94920	\N	\N	1577	732	\N	\N	AM2 R-383
94921	\N	\N	1577	733	\N	\N	AM2 R-384
94922	\N	\N	1577	734	\N	\N	AM2 R-385
94923	\N	\N	1577	735	\N	\N	AM2 R-386
94924	\N	\N	1577	736	\N	\N	AM2 R-387
94925	\N	\N	1577	462	\N	\N	AM2 D-387
94926	\N	\N	1488	3997	\N	\N	SNR-28
94927	\N	\N	2604	4342	\N	\N	RMS-038
94928	\N	\N	2605	4343	\N	\N	RMS-038N
94929	\N	\N	1480	3989	\N	\N	SNR-20
94930	\N	\N	1484	3993	\N	\N	SNR-24
94931	\N	\N	2204	3798	\N	\N	RNA-359
94932	\N	\N	2205	3799	\N	\N	RNA-361
94933	\N	\N	1482	3991	\N	\N	SNR-22
94934	\N	\N	2607	4345	\N	\N	RMS-039N
94935	\N	\N	2606	4344	\N	\N	RMS-039
94936	\N	\N	1486	3995	\N	\N	SNR-26
94937	\N	\N	1486	3964	\N	\N	SND-38
94938	\N	\N	1485	3994	\N	\N	SNR-25
94939	\N	\N	2207	3800	\N	\N	RNA-364
94940	\N	\N	2208	3801	\N	\N	RNA-365
94941	\N	\N	2209	3802	\N	\N	RNA-366
94942	\N	\N	1487	3996	\N	\N	SNR-27
94943	\N	\N	2610	4348	\N	\N	RMS-041
94944	\N	\N	1877	2260	\N	\N	LN R-071
94945	\N	\N	1877	2188	\N	\N	LN D-095
94946	\N	\N	1877	2282	\N	\N	LN R-095
94947	\N	\N	1877	2240	\N	\N	LN D-147
94948	\N	\N	1877	2334	\N	\N	LN R-147
94949	\N	\N	1878	2261	\N	\N	LN R-072
94950	\N	\N	1878	2189	\N	\N	LN D-096
94951	\N	\N	1878	2283	\N	\N	LN R-096
94952	\N	\N	1878	2241	\N	\N	LN D-148
94953	\N	\N	1878	2335	\N	\N	LN R-148
94954	\N	\N	2211	3803	\N	\N	RNA-369
94955	\N	\N	2212	3804	\N	\N	RNA-372
94956	\N	\N	2213	3805	\N	\N	RNA-373
94957	\N	\N	2493	2060	\N	\N	LMM R-003
94958	\N	\N	2491	2058	\N	\N	LMM R-001
94959	\N	\N	2492	2059	\N	\N	LMM R-002
94960	\N	\N	2544	4417	\N	\N	KA R-18
94961	\N	\N	2545	4418	\N	\N	KA R-19
94962	\N	\N	2546	4419	\N	\N	KA R-20
94963	\N	\N	2547	4420	\N	\N	KA R-21
94964	\N	\N	2549	4421	\N	\N	KA R-23
94965	\N	\N	2532	4411	\N	\N	KA R-06
94966	\N	\N	2534	4412	\N	\N	KA R-08
94967	\N	\N	1481	3990	\N	\N	SNR-21
94968	\N	\N	2560	4427	\N	\N	KA R-34
94969	\N	\N	2561	4428	\N	\N	KA R-35
94970	\N	\N	2470	2080	\N	\N	LMM R-023
94971	\N	\N	2469	2079	\N	\N	LMM R-022
94972	\N	\N	2598	4338	\N	\N	RMS-034
94973	\N	\N	2554	4424	\N	\N	KA R-28
94974	\N	\N	2556	4425	\N	\N	KA R-30
94975	\N	\N	2498	2065	\N	\N	LMM R-008
94976	\N	\N	2497	2064	\N	\N	LMM R-007
94977	\N	\N	2233	3820	\N	\N	RNA-403
94978	\N	\N	2223	3812	\N	\N	RNA-390
94979	\N	\N	2225	3814	\N	\N	RNA-392
94980	\N	\N	2224	3813	\N	\N	RNA-391
94981	\N	\N	2496	2063	\N	\N	LMM R-006
92598	\N	\N	2496	2018	\N	2496 Normal	LMM D-006
94982	\N	\N	2494	2061	\N	\N	LMM R-004
94983	\N	\N	2495	2062	\N	\N	LMM R-005
94984	\N	\N	2242	3825	\N	\N	RNA-419
94985	\N	\N	2501	2068	\N	\N	LMM R-011
94986	\N	\N	2500	2067	\N	\N	LMM R-010
94987	\N	\N	2012	3435	\N	\N	OM-10D-2
94988	\N	\N	2012	3436	\N	\N	OM-10D-3
94989	\N	\N	2017	3428	\N	\N	OM-6D
94990	\N	\N	2017	3444	\N	\N	OM-15D-2
94991	\N	\N	2499	2066	\N	\N	LMM R-009
94992	\N	\N	2502	2069	\N	\N	LMM R-012
94993	\N	\N	2227	3815	\N	\N	RNA-394
94994	\N	\N	2228	3816	\N	\N	RNA-396
94995	\N	\N	2229	1777	\N	\N	DNA-420
94996	\N	\N	2231	3818	\N	\N	RNA-401
94997	\N	\N	2230	3817	\N	\N	RNA-399
94998	\N	\N	2232	3819	\N	\N	RNA-402
94999	\N	\N	1875	2258	\N	\N	LN R-069
95000	\N	\N	1875	2209	\N	\N	LN D-116
95001	\N	\N	1875	2303	\N	\N	LN R-116
95002	\N	\N	1876	2259	\N	\N	LN R-070
95003	\N	\N	1876	2210	\N	\N	LN D-117
95004	\N	\N	1876	2304	\N	\N	LN R-117
95005	\N	\N	2026	3463	\N	\N	OM-27D-2
95006	\N	\N	2027	3465	\N	\N	OM-28D-2
95007	\N	\N	1882	2265	\N	\N	LN R-076
95008	\N	\N	1882	2305	\N	\N	LN R-118
95009	\N	\N	1882	2211	\N	\N	LN D-118
95010	\N	\N	1883	2266	\N	\N	LN R-077
95011	\N	\N	1883	2306	\N	\N	LN R-119
95012	\N	\N	1883	2212	\N	\N	LN D-119
95013	\N	\N	1884	2267	\N	\N	LN R-078
95014	\N	\N	1884	2307	\N	\N	LN R-120
95015	\N	\N	1884	2213	\N	\N	LN D-120
95016	\N	\N	1890	2272	\N	\N	LN R-084
95017	\N	\N	1890	2196	\N	\N	LN D-103
95018	\N	\N	1890	2290	\N	\N	LN R-103
95019	\N	\N	1890	2249	\N	\N	LN D-156
95020	\N	\N	1890	2343	\N	\N	LN R-156
95021	\N	\N	1891	2273	\N	\N	LN R-085
95022	\N	\N	1891	2197	\N	\N	LN D-104
95023	\N	\N	1891	2291	\N	\N	LN R-104
95024	\N	\N	1891	2250	\N	\N	LN D-157
95025	\N	\N	1891	2344	\N	\N	LN R-157
95026	\N	\N	1879	2262	\N	\N	LN R-073
95027	\N	\N	1879	2190	\N	\N	LN D-097
95028	\N	\N	1879	2284	\N	\N	LN R-097
95029	\N	\N	1879	2242	\N	\N	LN D-149
95030	\N	\N	1879	2336	\N	\N	LN R-149
95031	\N	\N	1880	2263	\N	\N	LN R-074
95032	\N	\N	1880	2191	\N	\N	LN D-098
95033	\N	\N	1880	2285	\N	\N	LN R-098
95034	\N	\N	1880	2243	\N	\N	LN D-150
95035	\N	\N	1880	2337	\N	\N	LN R-150
95036	\N	\N	1909	2301	\N	\N	LN R-114
95037	\N	\N	1909	2332	\N	\N	LN R-145
95038	\N	\N	1909	2238	\N	\N	LN D-145
95039	\N	\N	1910	2302	\N	\N	LN R-115
95040	\N	\N	1910	2333	\N	\N	LN R-146
95041	\N	\N	1910	2239	\N	\N	LN D-146
95042	\N	\N	2518	2049	\N	\N	LMM D-037
95043	\N	\N	2519	2050	\N	\N	LMM D-038
95044	\N	\N	1888	2270	\N	\N	LN R-082
95045	\N	\N	1888	2194	\N	\N	LN D-101
95046	\N	\N	1888	2288	\N	\N	LN R-101
95047	\N	\N	1888	2247	\N	\N	LN D-154
95048	\N	\N	1888	2341	\N	\N	LN R-154
95049	\N	\N	1889	2271	\N	\N	LN R-083
95050	\N	\N	1889	2195	\N	\N	LN D-102
95051	\N	\N	1889	2289	\N	\N	LN R-102
95052	\N	\N	1889	2248	\N	\N	LN D-155
95053	\N	\N	1889	2342	\N	\N	LN R-155
95054	\N	\N	1881	2264	\N	\N	LN R-075
95055	\N	\N	1881	2192	\N	\N	LN D-099
95056	\N	\N	1881	2286	\N	\N	LN R-099
95057	\N	\N	1881	2244	\N	\N	LN D-151
95058	\N	\N	1881	2338	\N	\N	LN R-151
95059	\N	\N	2525	2056	\N	\N	LMM D-044
95060	\N	\N	2524	2055	\N	\N	LMM D-043
95061	\N	\N	2515	2046	\N	\N	LMM D-034
95062	\N	\N	2516	2047	\N	\N	LMM D-035
95063	\N	\N	2528	4409	\N	\N	KA R-02
95064	\N	\N	2530	4410	\N	\N	KA R-04
95065	\N	\N	2028	3467	\N	\N	OM-29D-2
95066	\N	\N	2551	4422	\N	\N	KA R-25
95067	\N	\N	2552	4423	\N	\N	KA R-26
95068	\N	\N	1892	2274	\N	\N	LN R-086
95069	\N	\N	1892	2215	\N	\N	LN D-122
95070	\N	\N	1892	2309	\N	\N	LN R-122
95071	\N	\N	1892	2251	\N	\N	LN D-158
95072	\N	\N	1892	2345	\N	\N	LN R-158
95073	\N	\N	1886	2269	\N	\N	LN R-080
95074	\N	\N	1886	2214	\N	\N	LN D-121
95075	\N	\N	1886	2308	\N	\N	LN R-121
95076	\N	\N	1886	2246	\N	\N	LN D-153
95077	\N	\N	1886	2340	\N	\N	LN R-153
95078	\N	\N	1885	2268	\N	\N	LN R-079
95079	\N	\N	1885	2193	\N	\N	LN D-100
95080	\N	\N	1885	2287	\N	\N	LN R-100
95081	\N	\N	1885	2245	\N	\N	LN D-152
95082	\N	\N	1885	2339	\N	\N	LN R-152
95083	\N	\N	1900	2281	\N	\N	LN R-094
95084	\N	\N	1900	2222	\N	\N	LN D-129
95085	\N	\N	1900	2316	\N	\N	LN R-129
95086	\N	\N	1898	2279	\N	\N	LN R-092
95087	\N	\N	1898	2314	\N	\N	LN R-127
95088	\N	\N	1898	2220	\N	\N	LN D-127
95089	\N	\N	1898	2252	\N	\N	LN D-159
95090	\N	\N	1898	2346	\N	\N	LN R-159
95091	\N	\N	1899	2280	\N	\N	LN R-093
95092	\N	\N	1899	2315	\N	\N	LN R-128
95093	\N	\N	1899	2221	\N	\N	LN D-128
95094	\N	\N	1899	2253	\N	\N	LN D-160
95095	\N	\N	1899	2347	\N	\N	LN R-160
95096	\N	\N	1895	2276	\N	\N	LN R-089
95097	\N	\N	1895	2217	\N	\N	LN D-124
95098	\N	\N	1895	2311	\N	\N	LN R-124
95099	\N	\N	1896	2277	\N	\N	LN R-090
95100	\N	\N	1896	2218	\N	\N	LN D-125
95101	\N	\N	1896	2312	\N	\N	LN R-125
95102	\N	\N	1897	2278	\N	\N	LN R-091
95103	\N	\N	1897	2219	\N	\N	LN D-126
95104	\N	\N	1897	2313	\N	\N	LN R-126
95105	\N	\N	1894	2275	\N	\N	LN R-087
95106	\N	\N	1894	2310	\N	\N	LN R-123
95107	\N	\N	1894	2216	\N	\N	LN D-123
95108	\N	\N	1905	2292	\N	\N	LN R-105
95109	\N	\N	1905	2317	\N	\N	LN R-130
95110	\N	\N	1905	2223	\N	\N	LN D-130
95111	\N	\N	1905	2254	\N	\N	LN D-161
95112	\N	\N	1905	2348	\N	\N	LN R-161
95113	\N	\N	1906	2293	\N	\N	LN R-106
95114	\N	\N	1906	2318	\N	\N	LN R-131
95115	\N	\N	1906	2224	\N	\N	LN D-131
95116	\N	\N	1906	2255	\N	\N	LN D-162
95117	\N	\N	1906	2349	\N	\N	LN R-162
92706	\N	\N	1906	2199	\N	1906 Junctional Nevus	LN D-106
95118	\N	\N	1901	2295	\N	\N	LN R-108
95119	\N	\N	1901	2232	\N	\N	LN D-139
95120	\N	\N	1901	2326	\N	\N	LN R-139
95121	\N	\N	1902	2296	\N	\N	LN R-109
95122	\N	\N	1902	2233	\N	\N	LN D-140
95123	\N	\N	1902	2327	\N	\N	LN R-140
95124	\N	\N	1907	2297	\N	\N	LN R-110
95125	\N	\N	1907	2328	\N	\N	LN R-141
95126	\N	\N	1907	2234	\N	\N	LN D-141
95127	\N	\N	1908	2298	\N	\N	LN R-111
95128	\N	\N	1908	2329	\N	\N	LN R-142
95129	\N	\N	1908	2235	\N	\N	LN D-142
95130	\N	\N	1911	2294	\N	\N	LN R-107
95131	\N	\N	1911	2322	\N	\N	LN R-135
95132	\N	\N	1911	2228	\N	\N	LN D-135
95133	\N	\N	1912	2319	\N	\N	LN R-132
95134	\N	\N	1912	2323	\N	\N	LN R-136
95135	\N	\N	1912	2229	\N	\N	LN D-136
95136	\N	\N	1913	2320	\N	\N	LN R-133
95137	\N	\N	1913	2324	\N	\N	LN R-137
95138	\N	\N	1913	2230	\N	\N	LN D-137
95139	\N	\N	1914	2321	\N	\N	LN R-134
95140	\N	\N	1914	2325	\N	\N	LN R-138
95141	\N	\N	1914	2231	\N	\N	LN D-138
95142	\N	\N	1903	2299	\N	\N	LN R-112
95143	\N	\N	1903	2236	\N	\N	LN D-143
95144	\N	\N	1903	2330	\N	\N	LN R-143
95145	\N	\N	1903	2256	\N	\N	LN D-163
95146	\N	\N	1903	2350	\N	\N	LN R-163
95147	\N	\N	1904	2300	\N	\N	LN R-113
95148	\N	\N	1904	2237	\N	\N	LN D-144
95149	\N	\N	1904	2331	\N	\N	LN R-144
95150	\N	\N	1904	2257	\N	\N	LN D-164
95151	\N	\N	1904	2351	\N	\N	LN R-164
95152	\N	\N	2215	3806	\N	\N	RNA-377
95153	\N	\N	2216	3807	\N	\N	RNA-379
95154	\N	\N	2217	3808	\N	\N	RNA-381
95155	\N	\N	2237	3823	\N	\N	RNA-417
95156	\N	\N	2219	3809	\N	\N	RNA-383
95157	\N	\N	2221	3811	\N	\N	RNA-387
95158	\N	\N	2220	3810	\N	\N	RNA-385
95159	\N	\N	2222	1780	\N	\N	DNA-423
95160	\N	\N	2222	3829	\N	\N	RNA-423
95161	\N	\N	2222	3826	\N	\N	RNA-420
95162	\N	\N	2455	2078	\N	\N	LMM R-021
95163	\N	\N	2454	2077	\N	\N	LMM R-020
95164	\N	\N	2481	4449	\N	\N	LMM R-050
95165	\N	\N	2480	4448	\N	\N	LMM R-049
95166	\N	\N	2482	4450	\N	\N	LMM R-051
95167	\N	\N	1951	3700	\N	\N	RNA-194
95168	\N	\N	1951	1636	\N	\N	DNA-238
95169	\N	\N	1951	3730	\N	\N	RNA-238
95170	\N	\N	1951	3743	\N	\N	RNA-268
95171	\N	\N	1951	1664	\N	\N	DNA-268
95172	\N	\N	1951	3744	\N	\N	RNA-269
95173	\N	\N	1951	1665	\N	\N	DNA-269
95174	\N	\N	1952	3701	\N	\N	RNA-195
95175	\N	\N	1952	1637	\N	\N	DNA-239
95176	\N	\N	1952	3731	\N	\N	RNA-239
95177	\N	\N	1953	3702	\N	\N	RNA-196
95178	\N	\N	1953	1638	\N	\N	DNA-240
95179	\N	\N	2453	2076	\N	\N	LMM R-019
95180	\N	\N	2486	4454	\N	\N	LMM R-055
95181	\N	\N	2487	4455	\N	\N	LMM R-056
95182	\N	\N	2476	20	\N	\N	22-44183B-RNA
95183	\N	\N	2624	4361	\N	\N	RMS-054
95184	\N	\N	2625	4362	\N	\N	RMS-055
95185	\N	\N	2626	4363	\N	\N	RMS-056
95186	\N	\N	2536	4413	\N	\N	KA R-10
95187	\N	\N	2538	4414	\N	\N	KA R-12
95188	\N	\N	2627	4364	\N	\N	RMS-057
95189	\N	\N	2628	4365	\N	\N	RMS-058
95190	\N	\N	2629	4366	\N	\N	RMS-059A
95191	\N	\N	2630	4367	\N	\N	RMS-059B
95192	\N	\N	2294	3837	\N	\N	RNA-431
95193	\N	\N	2295	3838	\N	\N	RNA-432
95194	\N	\N	2296	3839	\N	\N	RNA-433
95195	\N	\N	2297	3840	\N	\N	RNA-434
95196	\N	\N	2298	3841	\N	\N	RNA-435
95197	\N	\N	2268	3344	\N	\N	NM R-100
95198	\N	\N	2269	3344	\N	\N	NM R-100
95199	\N	\N	2270	3345	\N	\N	NM R-101
95200	\N	\N	2631	4368	\N	\N	RMS-060
95201	\N	\N	2632	4369	\N	\N	RMS-061
95202	\N	\N	2504	2071	\N	\N	LMM R-014
95203	\N	\N	2503	2070	\N	\N	LMM R-013
95204	\N	\N	2505	2072	\N	\N	LMM R-015
95205	\N	\N	2633	4370	\N	\N	RMS-062
95206	\N	\N	2634	4371	\N	\N	RMS-062N
95207	\N	\N	2635	4372	\N	\N	RMS-063
95208	\N	\N	2596	4336	\N	\N	RMS-032
95209	\N	\N	2287	3830	\N	\N	RNA-424
95210	\N	\N	2288	3831	\N	\N	RNA-425
95211	\N	\N	2477	4445	\N	\N	LMM R-046
95212	\N	\N	2478	4446	\N	\N	LMM R-047
95213	\N	\N	2479	4447	\N	\N	LMM R-048
95214	\N	\N	2235	3822	\N	\N	RNA-405
92823	\N	\N	2235	1772	\N	2235 Nevus	DNA-405
95215	\N	\N	2234	3821	\N	\N	RNA-404
95216	\N	\N	2456	22	\N	\N	22-104389A2-RNA
95217	\N	\N	2457	26	\N	\N	22-104389C-RNA
95218	\N	\N	2299	3842	\N	\N	RNA-436
95219	\N	\N	2300	3843	\N	\N	RNA-437
95220	\N	\N	2301	3844	\N	\N	RNA-438
95221	\N	\N	2540	4415	\N	\N	KA R-14
95222	\N	\N	2542	4416	\N	\N	KA R-16
95223	\N	\N	2289	3832	\N	\N	RNA-426
95224	\N	\N	2584	4334	\N	\N	RMS-020
95225	\N	\N	2247	27	\N	\N	22-125373-DNA
95226	\N	\N	2582	4332	\N	\N	RMS-018
95227	\N	\N	2488	4456	\N	\N	LMM R-057
95228	\N	\N	2291	3834	\N	\N	RNA-428
95229	\N	\N	2290	3833	\N	\N	RNA-427
95230	\N	\N	2292	3835	\N	\N	RNA-429
95231	\N	\N	2585	4335	\N	\N	RMS-021
95232	\N	\N	2583	4333	\N	\N	RMS-019
95233	\N	\N	2563	4329	\N	\N	RMS-001A
95234	\N	\N	2564	4330	\N	\N	RMS-001B
95235	\N	\N	2565	4331	\N	\N	RMS-001C
95236	\N	\N	2612	4349	\N	\N	RMS-043
95237	\N	\N	2293	3836	\N	\N	RNA-430
95238	\N	\N	2613	4350	\N	\N	RMS-044
95239	\N	\N	2447	3849	\N	\N	RNA-443
95240	\N	\N	2450	2073	\N	\N	LMM R-016
95241	\N	\N	2451	2074	\N	\N	LMM R-017
95242	\N	\N	2452	2075	\N	\N	LMM R-018
95243	\N	\N	2614	4351	\N	\N	RMS-045
95244	\N	\N	2615	4352	\N	\N	RMS-046
95245	\N	\N	2449	3851	\N	\N	RNA-445
95246	\N	\N	2448	3850	\N	\N	RNA-444
95247	\N	\N	2445	3847	\N	\N	RNA-441
95248	\N	\N	2446	3848	\N	\N	RNA-442
95249	\N	\N	2443	3845	\N	\N	RNA-439
95250	\N	\N	2444	3846	\N	\N	RNA-440
95251	\N	\N	2460	3853	\N	\N	RNA-447
95252	\N	\N	2459	3852	\N	\N	RNA-446
95253	\N	\N	2461	3854	\N	\N	RNA-448
95254	\N	\N	2475	852	\N	\N	AM2 R-541
95255	\N	\N	2473	850	\N	\N	AM2 R-539
95256	\N	\N	2474	851	\N	\N	AM2 R-540
95257	\N	\N	2472	849	\N	\N	AM2 R-538
95258	\N	\N	1842	3148	\N	\N	MMR-331
95259	\N	\N	1841	3147	\N	\N	MMR-330
95260	\N	\N	1839	3145	\N	\N	MMR-328
95261	\N	\N	1840	3146	\N	\N	MMR-329
95262	\N	\N	1795	2825	\N	\N	MMD-210
95263	\N	\N	1792	3103	\N	\N	MMR-206
95264	\N	\N	1792	2936	\N	\N	MMD-321
95265	\N	\N	1792	3139	\N	\N	MMR-321
95266	\N	\N	1793	2937	\N	\N	MMD-322
95267	\N	\N	1794	3104	\N	\N	MMR-208
95268	\N	\N	1794	2938	\N	\N	MMD-323
95269	\N	\N	1794	3140	\N	\N	MMR-323
95270	\N	\N	1729	3064	\N	\N	MMR-134
92954	\N	\N	1729	2751	\N	1729 Mel	MMD-134
95271	\N	\N	1667	2666	\N	\N	MMD-46
95272	\N	\N	1667	2682	\N	\N	MMD-64
95273	\N	\N	1667	2722	\N	\N	MMD-104
95274	\N	\N	1668	2723	\N	\N	MMD-105
95275	\N	\N	1668	2883	\N	\N	MMD-268
95276	\N	\N	1788	2935	\N	\N	MMD-320
95277	\N	\N	1787	3101	\N	\N	MMR-201
95278	\N	\N	1787	2934	\N	\N	MMD-319
95279	\N	\N	1704	3049	\N	\N	MMR-112
95280	\N	\N	1704	2907	\N	\N	MMD-292
95281	\N	\N	1704	2826	\N	\N	MMD-211
95282	\N	\N	1705	2906	\N	\N	MMD-291
95283	\N	\N	1705	2827	\N	\N	MMD-212
95284	\N	\N	1706	3050	\N	\N	MMR-114
95285	\N	\N	1706	2908	\N	\N	MMD-293
95286	\N	\N	1706	3132	\N	\N	MMR-293
95287	\N	\N	1706	2828	\N	\N	MMD-213
95288	\N	\N	1706	3105	\N	\N	MMR-213
95289	\N	\N	1699	3044	\N	\N	MMR-96
95290	\N	\N	1709	2734	\N	\N	MMD-117
95291	\N	\N	1710	3053	\N	\N	MMR-118
95292	\N	\N	1710	3106	\N	\N	MMR-214
95293	\N	\N	1710	2910	\N	\N	MMD-295
95294	\N	\N	1710	2829	\N	\N	MMD-214
95295	\N	\N	1708	3052	\N	\N	MMR-116
95296	\N	\N	1711	3053	\N	\N	MMR-118
95297	\N	\N	1711	3106	\N	\N	MMR-214
95298	\N	\N	1711	2910	\N	\N	MMD-295
95299	\N	\N	1711	2829	\N	\N	MMD-214
95300	\N	\N	1833	2864	\N	\N	MMD-249
95301	\N	\N	1861	2965	\N	\N	MMD-350
95302	\N	\N	1862	3167	\N	\N	MMR-351
95303	\N	\N	1808	3112	\N	\N	MMR-228
95304	\N	\N	1808	2939	\N	\N	MMD-324
95305	\N	\N	1808	3141	\N	\N	MMR-324
95306	\N	\N	1809	2940	\N	\N	MMD-325
95307	\N	\N	1809	3142	\N	\N	MMR-325
95308	\N	\N	1801	2894	\N	\N	MMD-279
95309	\N	\N	1801	3108	\N	\N	MMR-221
95310	\N	\N	1801	3130	\N	\N	MMR-279
95311	\N	\N	1802	2895	\N	\N	MMD-280
95312	\N	\N	1777	2799	\N	\N	MMD-184
95313	\N	\N	1778	2922	\N	\N	MMD-307
95314	\N	\N	1779	2801	\N	\N	MMD-186
95315	\N	\N	1779	2923	\N	\N	MMD-308
95316	\N	\N	1779	3137	\N	\N	MMR-308
95317	\N	\N	1942	3691	\N	\N	RNA-185
95318	\N	\N	1942	1626	\N	\N	DNA-228
95319	\N	\N	1942	3724	\N	\N	RNA-228
95321	\N	\N	1941	1625	\N	\N	DNA-227
95322	\N	\N	1941	3723	\N	\N	RNA-227
95323	\N	\N	1943	3692	\N	\N	RNA-186
95324	\N	\N	1943	1627	\N	\N	DNA-229
95325	\N	\N	1828	2859	\N	\N	MMD-244
95326	\N	\N	1760	2885	\N	\N	MMD-270
95327	\N	\N	1759	2884	\N	\N	MMD-269
95328	\N	\N	1759	3081	\N	\N	MMR-167
95329	\N	\N	1761	2886	\N	\N	MMD-271
95330	\N	\N	1761	3082	\N	\N	MMR-169
95331	\N	\N	1790	2819	\N	\N	MMD-204
95332	\N	\N	1790	3102	\N	\N	MMR-204
95333	\N	\N	1791	2820	\N	\N	MMD-205
95334	\N	\N	1631	2982	\N	\N	MMR-06
95335	\N	\N	1781	2925	\N	\N	MMD-310
95336	\N	\N	1780	2802	\N	\N	MMD-187
95337	\N	\N	1780	2924	\N	\N	MMD-309
95338	\N	\N	1762	3083	\N	\N	MMR-170
95339	\N	\N	1830	3121	\N	\N	MMR-246
95340	\N	\N	1832	3122	\N	\N	MMR-248
95341	\N	\N	1648	3004	\N	\N	MMR-28
95342	\N	\N	1648	2677	\N	\N	MMD-59
95343	\N	\N	1649	3005	\N	\N	MMR-29
95344	\N	\N	1649	2728	\N	\N	MMD-111
95345	\N	\N	1635	2986	\N	\N	MMR-10
95346	\N	\N	1810	3113	\N	\N	MMR-230
95347	\N	\N	1810	2898	\N	\N	MMD-283
95348	\N	\N	1811	2899	\N	\N	MMD-284
95349	\N	\N	1864	2968	\N	\N	MMD-353
95350	\N	\N	1863	2967	\N	\N	MMD-352
95351	\N	\N	1636	2631	\N	\N	MMD-11
95352	\N	\N	1936	3685	\N	\N	RNA-179
95353	\N	\N	1936	1620	\N	\N	DNA-222
95354	\N	\N	1936	3720	\N	\N	RNA-222
95355	\N	\N	1935	3684	\N	\N	RNA-178
95356	\N	\N	1935	1619	\N	\N	DNA-221
95357	\N	\N	1935	3719	\N	\N	RNA-221
95358	\N	\N	1937	3686	\N	\N	RNA-180
95359	\N	\N	1937	1621	\N	\N	DNA-223
95360	\N	\N	1427	616	\N	\N	AM2 R-242
93227	\N	\N	1427	332	\N	1427 Lung Metastasis	AM2 D-242
95361	\N	\N	1422	603	\N	\N	AM2 R-225
95362	\N	\N	1425	627	\N	\N	AM2 R-253
95363	\N	\N	1423	341	\N	\N	AM2 D-251
95364	\N	\N	1423	621	\N	\N	AM2 R-247
95365	\N	\N	1423	625	\N	\N	AM2 R-251
95366	\N	\N	1424	622	\N	\N	AM2 R-248
95367	\N	\N	1424	345	\N	\N	AM2 D-255
95368	\N	\N	1424	629	\N	\N	AM2 R-255
93481	\N	\N	1424	338	\N	1424 Cutaneous Metastasis	AM2 D-248
95369	\N	\N	1292	342	\N	\N	AM2 D-252
95370	\N	\N	1292	626	\N	\N	AM2 R-252
95371	\N	\N	6	339	\N	\N	AM2 D-249
95372	\N	\N	6	623	\N	\N	AM2 R-249
95373	\N	\N	7	340	\N	\N	AM2 D-250
95374	\N	\N	7	624	\N	\N	AM2 R-250
95375	\N	\N	4	324	\N	\N	AM2 D-232
95376	\N	\N	4	608	\N	\N	AM2 R-232
95377	\N	\N	1286	325	\N	\N	AM2 D-233
95378	\N	\N	1286	609	\N	\N	AM2 R-233
95379	\N	\N	9	326	\N	\N	AM2 D-236
95380	\N	\N	9	610	\N	\N	AM2 R-236
95381	\N	\N	10	327	\N	\N	AM2 D-237
95382	\N	\N	10	611	\N	\N	AM2 R-237
95383	\N	\N	65	329	\N	\N	AM2 D-239
95384	\N	\N	65	613	\N	\N	AM2 R-239
95385	\N	\N	65	501	\N	\N	AM2 D-440
95386	\N	\N	66	330	\N	\N	AM2 D-240
95387	\N	\N	66	614	\N	\N	AM2 R-240
95388	\N	\N	67	331	\N	\N	AM2 D-241
95389	\N	\N	67	615	\N	\N	AM2 R-241
95390	\N	\N	11	328	\N	\N	AM2 D-238
95391	\N	\N	11	612	\N	\N	AM2 R-238
95392	\N	\N	11	818	\N	\N	AM2 R-500
95393	\N	\N	11	558	\N	\N	AM2 D-500
95394	\N	\N	11	829	\N	\N	AM2 R-512
95395	\N	\N	11	569	\N	\N	AM2 D-512
95396	\N	\N	5	202	\N	\N	AM2 D-104-1
95397	\N	\N	5	574	\N	\N	AM2 D-518
95398	\N	\N	5	834	\N	\N	AM2 R-518
95399	\N	\N	1288	504	\N	\N	AM2 D-444
95400	\N	\N	68	333	\N	\N	AM2 D-243
95401	\N	\N	68	617	\N	\N	AM2 R-243
95402	\N	\N	69	334	\N	\N	AM2 D-244
95403	\N	\N	69	618	\N	\N	AM2 R-244
95404	\N	\N	70	335	\N	\N	AM2 D-245
95405	\N	\N	70	619	\N	\N	AM2 R-245
95406	\N	\N	71	336	\N	\N	AM2 D-246
95407	\N	\N	71	620	\N	\N	AM2 R-246
95408	\N	\N	71	344	\N	\N	AM2 D-254
95409	\N	\N	71	628	\N	\N	AM2 R-254
95410	\N	\N	74	320	\N	\N	AM2 D-226
95411	\N	\N	74	604	\N	\N	AM2 R-226
95412	\N	\N	75	321	\N	\N	AM2 D-227
95413	\N	\N	75	605	\N	\N	AM2 R-227
95414	\N	\N	76	322	\N	\N	AM2 D-228
95415	\N	\N	76	606	\N	\N	AM2 R-228
95416	\N	\N	77	323	\N	\N	AM2 D-229
95417	\N	\N	77	607	\N	\N	AM2 R-229
95418	\N	\N	1623	776	\N	\N	AM2 R-454
95419	\N	\N	1620	505	\N	\N	AM2 D-445
95420	\N	\N	1621	769	\N	\N	AM2 R-446
95421	\N	\N	2034	816	\N	\N	AM2 R-498
95422	\N	\N	2035	817	\N	\N	AM2 R-499
95423	\N	\N	99	819	\N	\N	AM2 R-501
95424	\N	\N	99	559	\N	\N	AM2 D-501
95425	\N	\N	100	590	\N	\N	AM2 D-536
95426	\N	\N	100	847	\N	\N	AM2 R-536
95427	\N	\N	2246	573	\N	\N	AM2 D-517
95428	\N	\N	101	832	\N	\N	AM2 R-516
95429	\N	\N	101	572	\N	\N	AM2 D-516
95430	\N	\N	373	507	\N	\N	AM2 D-447
95431	\N	\N	373	770	\N	\N	AM2 R-447
95432	\N	\N	375	542	\N	\N	AM2 D-484
95433	\N	\N	375	802	\N	\N	AM2 R-484
95434	\N	\N	375	546	\N	\N	AM2 D-487
95435	\N	\N	375	806	\N	\N	AM2 R-487
95436	\N	\N	1575	718	\N	\N	AM2 R-358
95437	\N	\N	1622	775	\N	\N	AM2 R-453
95438	\N	\N	385	820	\N	\N	AM2 R-503
95439	\N	\N	399	821	\N	\N	AM2 R-504
95440	\N	\N	399	561	\N	\N	AM2 D-504
95441	\N	\N	401	591	\N	\N	AM2 D-537
95442	\N	\N	401	848	\N	\N	AM2 R-537
95443	\N	\N	402	822	\N	\N	AM2 R-505
95444	\N	\N	402	562	\N	\N	AM2 D-505
95445	\N	\N	414	550	\N	\N	AM2 D-491
95446	\N	\N	414	810	\N	\N	AM2 R-491
95447	\N	\N	413	508	\N	\N	AM2 D-448
95448	\N	\N	413	771	\N	\N	AM2 R-448
95449	\N	\N	413	549	\N	\N	AM2 D-490
95450	\N	\N	413	809	\N	\N	AM2 R-490
95451	\N	\N	421	552	\N	\N	AM2 D-493
95452	\N	\N	421	812	\N	\N	AM2 R-493
95453	\N	\N	420	772	\N	\N	AM2 R-450
95454	\N	\N	420	509	\N	\N	AM2 D-450
95455	\N	\N	420	292	\N	\N	AM2 D-194
95456	\N	\N	420	551	\N	\N	AM2 D-492
95457	\N	\N	420	811	\N	\N	AM2 R-492
95458	\N	\N	1244	551	\N	\N	AM2 D-492
95459	\N	\N	1244	811	\N	\N	AM2 R-492
95460	\N	\N	1245	552	\N	\N	AM2 D-493
95461	\N	\N	1245	812	\N	\N	AM2 R-493
95462	\N	\N	1618	773	\N	\N	AM2 R-451
95463	\N	\N	1618	553	\N	\N	AM2 D-494
95464	\N	\N	1618	813	\N	\N	AM2 R-494
95465	\N	\N	1619	774	\N	\N	AM2 R-452
95466	\N	\N	1619	554	\N	\N	AM2 D-495
95467	\N	\N	1619	814	\N	\N	AM2 R-495
95468	\N	\N	3318	1955	\N	\N	Kit_181_Muc BRAF_NA
95469	\N	\N	10000	10000	\N	12-6261A_Tumor	NA_12-6261A_Tumor
95470	\N	\N	10001	10001	\N	12-6261B_Tumor	NA_12-6261B_Tumor
95471	\N	\N	10002	10002	\N	12-12366_Tumor	NA_12-12366_Tumor
95472	\N	\N	10003	10003	\N	12-12467_Tumor	NA_12-12467_Tumor
95473	\N	\N	10004	10004	\N	12-12470D_Tumor	NA_12-12470D_Tumor
95474	\N	\N	10005	10005	\N	12-562_Tumor	NA_12-562_Tumor
95475	\N	\N	10006	10006	\N	12-12647_Tumor	NA_12-12647_Tumor
95476	\N	\N	10007	10007	\N	12-12626_Tumor	NA_12-12626_Tumor
95477	\N	\N	10008	10008	\N	12-13587_Tumor	NA_12-13587_Tumor
95478	\N	\N	10009	10009	\N	12-18438A_Tumor	NA_12-18438A_Tumor
95479	\N	\N	10010	10010	\N	12-13152_Tumor	NA_12-13152_Tumor
95480	\N	\N	10011	10011	\N	12-12750B_Tumor	NA_12-12750B_Tumor
95481	\N	\N	10012	10012	\N	12-19596_Tumor	NA_12-19596_Tumor
95482	\N	\N	10013	10013	\N	12-19187A_Tumor	NA_12-19187A_Tumor
95483	\N	\N	10014	10014	\N	12-22172_Normal	NA_12-22172_Normal
95484	\N	\N	10015	10015	\N	12-22172_Tumor	NA_12-22172_Tumor
95485	\N	\N	10016	10016	\N	12-21726A_Tumor	NA_12-21726A_Tumor
95486	\N	\N	10017	10017	\N	12-22901A_Normal	NA_12-22901A_Normal
95487	\N	\N	10018	10018	\N	12-22901A_Tumor	NA_12-22901A_Tumor
95488	\N	\N	10019	10019	\N	12-22776_Normal	NA_12-22776_Normal
95489	\N	\N	10020	10020	\N	BuffyCoat_Tumor	NA_BuffyCoat_Tumor
95490	\N	\N	10021	10021	\N	12-13587B2_Tumor	NA_12-13587B2_Tumor
95491	\N	\N	10022	10021	\N	12-13587B2_Tumor	NA_12-13587B2_Tumor
95492	\N	\N	10023	10021	\N	12-13587B2_Tumor	NA_12-13587B2_Tumor
95493	\N	\N	10024	10024	\N	BuffyCoa_Tumor	NA_BuffyCoa_Tumor
95494	\N	\N	10025	10025	\N	12-22775_Tumor	NA_12-22775_Tumor
95495	\N	\N	10026	10026	\N	12-22794A_Tumor	NA_12-22794A_Tumor
95496	\N	\N	10027	10027	\N	12-22573_Tumor	NA_12-22573_Tumor
95497	\N	\N	10028	10028	\N	12-22582A_Tumor	NA_12-22582A_Tumor
95498	\N	\N	10029	10029	\N	12-22587_Tumor	NA_12-22587_Tumor
95499	\N	\N	10030	10030	\N	12-22592_Tumor	NA_12-22592_Tumor
95500	\N	\N	10031	10031	\N	12-22597_Tumor	NA_12-22597_Tumor
95501	\N	\N	10032	10032	\N	12-22602A_Tumor	NA_12-22602A_Tumor
95502	\N	\N	10033	10033	\N	12-22602B_Tumor	NA_12-22602B_Tumor
95503	\N	\N	10034	10034	\N	12-22603_Tumor	NA_12-22603_Tumor
95504	\N	\N	10035	10035	\N	12-22604_Tumor	NA_12-22604_Tumor
95505	\N	\N	10036	10036	\N	12-22720A_Tumor	NA_12-22720A_Tumor
95506	\N	\N	10037	10037	\N	12-22868_Tumor	NA_12-22868_Tumor
95507	\N	\N	10038	10038	\N	12-22884C_Tumor	NA_12-22884C_Tumor
95508	\N	\N	10039	10039	\N	12-22884D_Tumor	NA_12-22884D_Tumor
95509	\N	\N	10040	10040	\N	12-22886_Tumor	NA_12-22886_Tumor
95620	\N	\N	10151	10151	\N	HWA4_Normal	NA_HWA4_Normal
95510	\N	\N	10041	10041	\N	12-22894B_Tumor	NA_12-22894B_Tumor
95511	\N	\N	10042	10042	\N	12-22898_Tumor	NA_12-22898_Tumor
95512	\N	\N	10043	10043	\N	12-22900_Tumor	NA_12-22900_Tumor
95513	\N	\N	10044	10031	\N	12-22597_Tumor	NA_12-22597_Tumor
95514	\N	\N	10045	10031	\N	12-22597_Tumor	NA_12-22597_Tumor
95515	\N	\N	10046	10031	\N	12-22597_Tumor	NA_12-22597_Tumor
95516	\N	\N	10047	10031	\N	12-22597_Tumor	NA_12-22597_Tumor
95517	\N	\N	10048	10048	\N	WP11_Tumor	NA_WP11_Tumor
95518	\N	\N	10049	10049	\N	WP23_Tumor	NA_WP23_Tumor
95519	\N	\N	10050	10050	\N	WP29_Tumor	NA_WP29_Tumor
95520	\N	\N	10051	10051	\N	PG8_Tumor	NA_PG8_Tumor
95521	\N	\N	10052	10052	\N	KIT37_Tumor	NA_KIT37_Tumor
95522	\N	\N	10053	10053	\N	KIT62_Tumor	NA_KIT62_Tumor
95523	\N	\N	10054	10054	\N	KIT118_Tumor	NA_KIT118_Tumor
95524	\N	\N	10055	10055	\N	KIT181_Tumor	NA_KIT181_Tumor
95525	\N	\N	10056	10056	\N	KIT227_Tumor	NA_KIT227_Tumor
95526	\N	\N	10057	10057	\N	KIT275_Tumor	NA_KIT275_Tumor
95527	\N	\N	10058	10058	\N	Bivona-L1_Tumor	NA_Bivona-L1_Tumor
95528	\N	\N	10059	10059	\N	Bivona-L2_Tumor	NA_Bivona-L2_Tumor
95529	\N	\N	10060	10060	\N	Bivona-L3_Tumor	NA_Bivona-L3_Tumor
95530	\N	\N	10061	10061	\N	Bivona-L4_Tumor	NA_Bivona-L4_Tumor
95531	\N	\N	10062	10062	\N	Bivona-L5_Tumor	NA_Bivona-L5_Tumor
95532	\N	\N	10063	10063	\N	Bivona-L6_Tumor	NA_Bivona-L6_Tumor
95533	\N	\N	10064	10064	\N	10-41439_Melanoma	NA_10-41439_Melanoma
95534	\N	\N	10065	10064	\N	10-41439_Melanoma	NA_10-41439_Melanoma
95535	\N	\N	10066	10066	\N	10-41439_Nevus	NA_10-41439_Nevus
95536	\N	\N	10067	10066	\N	10-41439_Nevus	NA_10-41439_Nevus
95537	\N	\N	10068	10068	\N	10-41439_Normal	NA_10-41439_Normal
95538	\N	\N	10069	10069	\N	11-23681_Melanoma	NA_11-23681_Melanoma
95539	\N	\N	10070	10069	\N	11-23681_Melanoma	NA_11-23681_Melanoma
95540	\N	\N	10071	10071	\N	11-23681_Nevus	NA_11-23681_Nevus
95541	\N	\N	10072	10071	\N	11-23681_Nevus	NA_11-23681_Nevus
95542	\N	\N	10073	10073	\N	11-23681_Normal	NA_11-23681_Normal
95543	\N	\N	10074	10074	\N	11-37533_Melanoma	NA_11-37533_Melanoma
95544	\N	\N	10075	10074	\N	11-37533_Melanoma	NA_11-37533_Melanoma
95545	\N	\N	10076	10076	\N	11-37533_Nevus	NA_11-37533_Nevus
95546	\N	\N	10077	10076	\N	11-37533_Nevus	NA_11-37533_Nevus
95547	\N	\N	10078	10078	\N	11-37533_Normal	NA_11-37533_Normal
95548	\N	\N	10079	10079	\N	KIT262_Tumor	NA_KIT262_Tumor
95549	\N	\N	10080	10080	\N	Dog12_Tumor	NA_Dog12_Tumor
95550	\N	\N	10081	10081	\N	Dog24_Tumor	NA_Dog24_Tumor
95551	\N	\N	10082	10082	\N	Dog43_Tumor	NA_Dog43_Tumor
95552	\N	\N	10083	10083	\N	Dog55_Tumor	NA_Dog55_Tumor
95553	\N	\N	10084	10084	\N	HW3_Tumor	NA_HW3_Tumor
95554	\N	\N	10085	10085	\N	HW3_Normal	NA_HW3_Normal
95555	\N	\N	10086	10086	\N	HW4_Tumor	NA_HW4_Tumor
95556	\N	\N	10087	10087	\N	HW4_Normal	NA_HW4_Normal
95557	\N	\N	10088	10088	\N	HW6_Tumor	NA_HW6_Tumor
95558	\N	\N	10089	10089	\N	HW6_Normal	NA_HW6_Normal
95559	\N	\N	10090	10090	\N	10-86469_Tumor	NA_10-86469_Tumor
95560	\N	\N	10091	10091	\N	11-12273_Tumor	NA_11-12273_Tumor
95561	\N	\N	10092	10092	\N	11-23710_Tumor	NA_11-23710_Tumor
95562	\N	\N	10093	10093	\N	11-30426_Tumor	NA_11-30426_Tumor
95563	\N	\N	10094	10094	\N	11-31904_Tumor	NA_11-31904_Tumor
95564	\N	\N	10095	10095	\N	11-47644_Tumor	NA_11-47644_Tumor
95565	\N	\N	10096	10096	\N	MB_161_Tumor	NA_MB_161_Tumor
95566	\N	\N	10097	10097	\N	MB_161_Normal	NA_MB_161_Normal
95567	\N	\N	10098	10098	\N	MB_327_Tumor	NA_MB_327_Tumor
95568	\N	\N	10099	10099	\N	MB_1454_Normal	NA_MB_1454_Normal
95569	\N	\N	10100	10100	\N	MB_760_Tumor	NA_MB_760_Tumor
95570	\N	\N	10101	10101	\N	MB_1418_Normal	NA_MB_1418_Normal
95571	\N	\N	10102	10102	\N	MB_1029_Tumor	NA_MB_1029_Tumor
95572	\N	\N	10103	10103	\N	MB_1028_Normal	NA_MB_1028_Normal
95573	\N	\N	10104	10104	\N	MB_1046_Tumor	NA_MB_1046_Tumor
95574	\N	\N	10105	10105	\N	MB_1036_Normal	NA_MB_1036_Normal
95575	\N	\N	10106	10106	\N	Bivona-L17_Tumor	NA_Bivona-L17_Tumor
95576	\N	\N	10107	10107	\N	Bivona-L18_Tumor	NA_Bivona-L18_Tumor
95577	\N	\N	10108	10108	\N	Bivona-L19_Tumor	NA_Bivona-L19_Tumor
95578	\N	\N	10109	10056	\N	KIT227_Tumor	NA_KIT227_Tumor
95579	\N	\N	10110	10110	\N	KIT53_Tumor	NA_KIT53_Tumor
95580	\N	\N	10111	10111	\N	KIT313_Tumor	NA_KIT313_Tumor
95581	\N	\N	10112	10112	\N	HW2_Normal	NA_HW2_Normal
95582	\N	\N	10113	10113	\N	HW2_Tumor	NA_HW2_Tumor
95583	\N	\N	10114	10114	\N	HW8_Normal	NA_HW8_Normal
95584	\N	\N	10115	10115	\N	HW8_Tumor	NA_HW8_Tumor
95585	\N	\N	10116	10116	\N	HW9_Normal	NA_HW9_Normal
95586	\N	\N	10117	10117	\N	HW9_Tumor	NA_HW9_Tumor
95587	\N	\N	10118	10118	\N	12-6981_Tumor	NA_12-6981_Tumor
95588	\N	\N	10119	10119	\N	10-55707_Tumor	NA_10-55707_Tumor
95589	\N	\N	10120	10120	\N	11-34950_Tumor	NA_11-34950_Tumor
95590	\N	\N	10121	10121	\N	11-8228_Tumor	NA_11-8228_Tumor
95591	\N	\N	10122	10122	\N	11-84681_Tumor	NA_11-84681_Tumor
95592	\N	\N	10123	10056	\N	KIT227_Tumor	NA_KIT227_Tumor
95593	\N	\N	10124	10124	\N	WM3211_Tumor	NA_WM3211_Tumor
95594	\N	\N	10125	10125	\N	NB2107_Tumor	NA_NB2107_Tumor
95595	\N	\N	10126	10126	\N	London-L1_Tumor	NA_London-L1_Tumor
95596	\N	\N	10127	10127	\N	London-L2_Tumor	NA_London-L2_Tumor
95597	\N	\N	10128	10128	\N	Bivona-L7_Tumor	NA_Bivona-L7_Tumor
95598	\N	\N	10129	10129	\N	Bivona-L8_Tumor	NA_Bivona-L8_Tumor
95599	\N	\N	10130	10130	\N	Bivona-L9_Tumor	NA_Bivona-L9_Tumor
95600	\N	\N	10131	10131	\N	Bivona-L10_Tumor	NA_Bivona-L10_Tumor
95601	\N	\N	10132	10084	\N	HW3_Tumor	NA_HW3_Tumor
95602	\N	\N	10133	10085	\N	HW3_Normal	NA_HW3_Normal
95603	\N	\N	10134	10086	\N	HW4_Tumor	NA_HW4_Tumor
95604	\N	\N	10135	10087	\N	HW4_Normal	NA_HW4_Normal
95605	\N	\N	10136	10088	\N	HW6_Tumor	NA_HW6_Tumor
95606	\N	\N	10137	10089	\N	HW6_Normal	NA_HW6_Normal
95607	\N	\N	10138	10090	\N	10-86469_Tumor	NA_10-86469_Tumor
95608	\N	\N	10139	10091	\N	11-12273_Tumor	NA_11-12273_Tumor
95609	\N	\N	10140	10092	\N	11-23710_Tumor	NA_11-23710_Tumor
95610	\N	\N	10141	10093	\N	11-30426_Tumor	NA_11-30426_Tumor
95611	\N	\N	10142	10094	\N	11-31904_Tumor	NA_11-31904_Tumor
95612	\N	\N	10143	10143	\N	Bivona-L11_Tumor	NA_Bivona-L11_Tumor
95613	\N	\N	10144	10144	\N	HWA1_Tumor	NA_HWA1_Tumor
95614	\N	\N	10145	10145	\N	HWA1_Normal	NA_HWA1_Normal
95615	\N	\N	10146	10146	\N	HWA2_Tumor	NA_HWA2_Tumor
95616	\N	\N	10147	10147	\N	HWA2_Normal	NA_HWA2_Normal
95617	\N	\N	10148	10148	\N	HWA3_Tumor	NA_HWA3_Tumor
95618	\N	\N	10149	10149	\N	HWA3_Normal	NA_HWA3_Normal
95619	\N	\N	10150	10150	\N	HWA4_Tumor	NA_HWA4_Tumor
95621	\N	\N	10152	10152	\N	11-5482_Tumor	NA_11-5482_Tumor
95622	\N	\N	10153	10153	\N	11-79158_Tumor	NA_11-79158_Tumor
95623	\N	\N	10154	10154	\N	DP12-200_Tumor	NA_DP12-200_Tumor
95624	\N	\N	10155	10155	\N	TissueCoreALKControl_Normal	NA_TissueCoreALKControl_Normal
95625	\N	\N	10156	10156	\N	10-59344_Tumor	NA_10-59344_Tumor
95626	\N	\N	10157	10157	\N	11-16253_Tumor	NA_11-16253_Tumor
95627	\N	\N	10158	10158	\N	11-61046_Tumor	NA_11-61046_Tumor
95628	\N	\N	10159	10159	\N	10-56047_Tumor	NA_10-56047_Tumor
95629	\N	\N	10160	10160	\N	12-67298_Tumor	NA_12-67298_Tumor
95630	\N	\N	10161	10161	\N	12-67298_Normal	NA_12-67298_Normal
95631	\N	\N	10162	10162	\N	12-20321_Tumor	NA_12-20321_Tumor
95632	\N	\N	10163	10163	\N	11-96096_Normal	NA_11-96096_Normal
95633	\N	\N	10164	10164	\N	MB1242_Tumor	NA_MB1242_Tumor
95634	\N	\N	10165	10165	\N	MB1241_Normal	NA_MB1241_Normal
95635	\N	\N	10166	10166	\N	MB1423_Tumor	NA_MB1423_Tumor
95636	\N	\N	10167	10167	\N	MB1423_Normal	NA_MB1423_Normal
95637	\N	\N	10168	10168	\N	MB1424__Tumor	NA_MB1424__Tumor
95638	\N	\N	10169	10169	\N	MB1421_Normal	NA_MB1421_Normal
95639	\N	\N	10170	10170	\N	MB1429_Tumor	NA_MB1429_Tumor
95640	\N	\N	10171	10171	\N	MB1428_Normal	NA_MB1428_Normal
95641	\N	\N	10172	10172	\N	12-71679_Tumor	NA_12-71679_Tumor
95642	\N	\N	10173	10173	\N	12-80985B_Tumor	NA_12-80985B_Tumor
95643	\N	\N	10174	10174	\N	12-31996_Tumor	NA_12-31996_Tumor
95644	\N	\N	10175	10175	\N	12-39632_Tumor	NA_12-39632_Tumor
95645	\N	\N	10176	10176	\N	HWA5_Tumor	NA_HWA5_Tumor
95646	\N	\N	10177	10177	\N	HWA5_Normal	NA_HWA5_Normal
95647	\N	\N	10178	10178	\N	HWA6_Tumor	NA_HWA6_Tumor
95648	\N	\N	10179	10179	\N	HWA6_Normal	NA_HWA6_Normal
95649	\N	\N	10180	10180	\N	HWA7_Tumor	NA_HWA7_Tumor
95650	\N	\N	10181	10181	\N	HWA7_Normal	NA_HWA7_Normal
95651	\N	\N	10182	10182	\N	HWA8_Tumor	NA_HWA8_Tumor
95652	\N	\N	10183	10183	\N	HWA8_Normal	NA_HWA8_Normal
95653	\N	\N	10184	10184	\N	HWA9_Tumor	NA_HWA9_Tumor
95654	\N	\N	10185	10185	\N	HWA9_Normal	NA_HWA9_Normal
95655	\N	\N	10186	10186	\N	HWA10_Tumor	NA_HWA10_Tumor
95656	\N	\N	10187	10187	\N	HWA10_Normal	NA_HWA10_Normal
95657	\N	\N	10188	10188	\N	MB1617_Tumor	NA_MB1617_Tumor
95658	\N	\N	10189	10189	\N	MB1609_Normal	NA_MB1609_Normal
95659	\N	\N	10190	10190	\N	WM51_Tumor	NA_WM51_Tumor
95660	\N	\N	10191	10191	\N	wm3918_Tumor	NA_wm3918_Tumor
95661	\N	\N	10192	10192	\N	DM1_Normal	NA_DM1_Normal
95662	\N	\N	10193	10193	\N	DM1_Tumor	NA_DM1_Tumor
95663	\N	\N	10194	10194	\N	DM2_Normal	NA_DM2_Normal
95664	\N	\N	10195	10195	\N	DM2_Tumor	NA_DM2_Tumor
95665	\N	\N	10196	10196	\N	DM5_Normal	NA_DM5_Normal
95666	\N	\N	10197	10197	\N	DM5_Tumor	NA_DM5_Tumor
95667	\N	\N	10198	10198	\N	DM7_Normal	NA_DM7_Normal
95668	\N	\N	10199	10199	\N	DM7_Tumor	NA_DM7_Tumor
95669	\N	\N	10200	10200	\N	DM12_Normal	NA_DM12_Normal
95670	\N	\N	10201	10201	\N	DM12_Tumor	NA_DM12_Tumor
95671	\N	\N	10202	10202	\N	DM13_Normal	NA_DM13_Normal
95672	\N	\N	10203	10203	\N	DM13_Tumor	NA_DM13_Tumor
95673	\N	\N	10204	10204	\N	DM21_Normal	NA_DM21_Normal
95674	\N	\N	10205	10205	\N	DM21_Tumor	NA_DM21_Tumor
95675	\N	\N	10206	10206	\N	DM93_Normal	NA_DM93_Normal
95676	\N	\N	10207	10207	\N	DM93_Tumor	NA_DM93_Tumor
95677	\N	\N	10208	10208	\N	11-20375_Tumor	NA_11-20375_Tumor
95678	\N	\N	10209	10209	\N	11-21491_Tumor	NA_11-21491_Tumor
95679	\N	\N	10210	10210	\N	11-65778_Tumor	NA_11-65778_Tumor
95680	\N	\N	10211	10211	\N	10-88482_Tumor	NA_10-88482_Tumor
95681	\N	\N	10212	10212	\N	11-63178_Tumor	NA_11-63178_Tumor
95682	\N	\N	10213	10213	\N	10-71761_Tumor	NA_10-71761_Tumor
95683	\N	\N	10214	10214	\N	10-84478_Tumor	NA_10-84478_Tumor
95684	\N	\N	10215	10215	\N	10-88475_Tumor	NA_10-88475_Tumor
95685	\N	\N	10216	10216	\N	12-54296_Normal	NA_12-54296_Normal
95686	\N	\N	10217	10217	\N	12-54296_Tumor	NA_12-54296_Tumor
95687	\N	\N	10218	10218	\N	12-54992_Normal	NA_12-54992_Normal
95688	\N	\N	10219	10219	\N	12-54992_Tumor	NA_12-54992_Tumor
95689	\N	\N	10220	10220	\N	WM3622_Tumor	NA_WM3622_Tumor
95690	\N	\N	10221	10221	\N	WM1963_Tumor	NA_WM1963_Tumor
95691	\N	\N	10222	10222	\N	WM8_Tumor	NA_WM8_Tumor
95692	\N	\N	10223	10223	\N	WM3912_Tumor	NA_WM3912_Tumor
95693	\N	\N	10224	10224	\N	DM11_Tumor	NA_DM11_Tumor
95694	\N	\N	10225	10225	\N	DM11_Normal	NA_DM11_Normal
95695	\N	\N	10226	10226	\N	DM14_Tumor	NA_DM14_Tumor
95696	\N	\N	10227	10227	\N	DM14_Normal	NA_DM14_Normal
95697	\N	\N	10228	10228	\N	DM26_Tumor	NA_DM26_Tumor
95698	\N	\N	10229	10229	\N	DM26_Normal	NA_DM26_Normal
95699	\N	\N	10230	10230	\N	DM28_Tumor	NA_DM28_Tumor
95700	\N	\N	10231	10231	\N	DM28_Normal	NA_DM28_Normal
95701	\N	\N	10232	10232	\N	DM29_Tumor	NA_DM29_Tumor
95702	\N	\N	10233	10233	\N	DM29_Normal	NA_DM29_Normal
95703	\N	\N	10234	10234	\N	DM34_Tumor	NA_DM34_Tumor
95704	\N	\N	10235	10235	\N	DM34_Normal	NA_DM34_Normal
95705	\N	\N	10236	10236	\N	DM55_Tumor	NA_DM55_Tumor
95706	\N	\N	10237	10237	\N	DM55_Normal	NA_DM55_Normal
95707	\N	\N	10238	10238	\N	DM79_Tumor	NA_DM79_Tumor
95708	\N	\N	10239	10239	\N	DM79_Normal	NA_DM79_Normal
95709	\N	\N	10240	10240	\N	11-78845_Tumor	NA_11-78845_Tumor
95710	\N	\N	10241	10241	\N	11-81405_Tumor	NA_11-81405_Tumor
95711	\N	\N	10242	10242	\N	11-85075_Tumor	NA_11-85075_Tumor
95712	\N	\N	10243	10243	\N	11-83908_Tumor	NA_11-83908_Tumor
95713	\N	\N	10244	10244	\N	11-85859_Tumor	NA_11-85859_Tumor
95714	\N	\N	10245	10245	\N	11-95663_Tumor	NA_11-95663_Tumor
95715	\N	\N	10246	10246	\N	DM4_Tumor	NA_DM4_Tumor
95716	\N	\N	10247	10247	\N	DM4_Normal	NA_DM4_Normal
95717	\N	\N	10248	10248	\N	DM95_Tumor	NA_DM95_Tumor
95718	\N	\N	10249	10249	\N	DM95_Normal	NA_DM95_Normal
95719	\N	\N	10250	10250	\N	DM96_Tumor	NA_DM96_Tumor
95720	\N	\N	10251	10251	\N	DM96_Normal	NA_DM96_Normal
95721	\N	\N	10252	10252	\N	KIT8_Tumor	NA_KIT8_Tumor
95722	\N	\N	10253	10253	\N	KIT21_Tumor	NA_KIT21_Tumor
95723	\N	\N	10254	10254	\N	KIT55_Tumor	NA_KIT55_Tumor
95724	\N	\N	10255	10255	\N	KIT76_Tumor	NA_KIT76_Tumor
95725	\N	\N	10256	10256	\N	W09-1121_Tumor	NA_W09-1121_Tumor
95726	\N	\N	10257	10257	\N	W09-1121_Normal	NA_W09-1121_Normal
95727	\N	\N	10258	10258	\N	W10-143_Tumor	NA_W10-143_Tumor
95728	\N	\N	10259	10259	\N	S94-31062_Tumor	NA_S94-31062_Tumor
95729	\N	\N	10260	10260	\N	S02-23636A02_Tumor	NA_S02-23636A02_Tumor
95730	\N	\N	10261	10261	\N	S02-33818A03_Tumor	NA_S02-33818A03_Tumor
95731	\N	\N	10262	10262	\N	S02-33818A03_Normal	NA_S02-33818A03_Normal
95732	\N	\N	10263	10263	\N	S05-7439A12_Tumor	NA_S05-7439A12_Tumor
95733	\N	\N	10264	10264	\N	S05-41924_Tumor	NA_S05-41924_Tumor
95734	\N	\N	10265	10265	\N	S06-47079A02_Tumor	NA_S06-47079A02_Tumor
95735	\N	\N	10266	10266	\N	S08-4544A03_Tumor	NA_S08-4544A03_Tumor
95736	\N	\N	10267	10267	\N	S10-26316A2_Tumor	NA_S10-26316A2_Tumor
95737	\N	\N	10268	10268	\N	S10-44069A4_Tumor	NA_S10-44069A4_Tumor
95738	\N	\N	10269	10269	\N	S11-38910A2_Tumor	NA_S11-38910A2_Tumor
95739	\N	\N	10270	10270	\N	KIT192_Tumor	NA_KIT192_Tumor
95740	\N	\N	10271	10271	\N	KIT203_Tumor	NA_KIT203_Tumor
95741	\N	\N	10272	10272	\N	KR_166_Tumor	NA_KR_166_Tumor
95742	\N	\N	10273	10273	\N	KR_2064_Tumor	NA_KR_2064_Tumor
95743	\N	\N	10274	10274	\N	KR_2030_Tumor	NA_KR_2030_Tumor
95744	\N	\N	10275	10275	\N	KR_177_Tumor	NA_KR_177_Tumor
95745	\N	\N	10276	10276	\N	KR_150_Tumor	NA_KR_150_Tumor
95746	\N	\N	10277	10277	\N	KR_229_Tumor	NA_KR_229_Tumor
95747	\N	\N	10278	10278	\N	KR_203_Tumor	NA_KR_203_Tumor
95748	\N	\N	10279	10279	\N	KR_8_Tumor	NA_KR_8_Tumor
95749	\N	\N	10280	10280	\N	KR_5233_Tumor	NA_KR_5233_Tumor
95750	\N	\N	10281	10281	\N	KR_RMK0091B_Tumor	NA_KR_RMK0091B_Tumor
95751	\N	\N	10282	10282	\N	KR_RMK0194C_Tumor	NA_KR_RMK0194C_Tumor
95752	\N	\N	10283	10283	\N	KR_RMK0137C_Tumor	NA_KR_RMK0137C_Tumor
95753	\N	\N	10284	10284	\N	KR_RMK0162C_Tumor	NA_KR_RMK0162C_Tumor
95754	\N	\N	10285	10285	\N	KR_RMK0168C_Tumor	NA_KR_RMK0168C_Tumor
95755	\N	\N	10286	10068	\N	10-41439_Normal	NA_10-41439_Normal
95756	\N	\N	10287	10287	\N	11-23681A+C_Normal	NA_11-23681A+C_Normal
95757	\N	\N	10288	10288	\N	DM10_Tumor	NA_DM10_Tumor
95758	\N	\N	10289	10289	\N	DM10_Normal	NA_DM10_Normal
95759	\N	\N	10290	10290	\N	DM17_Tumor	NA_DM17_Tumor
95760	\N	\N	10291	10291	\N	DM17_Normal	NA_DM17_Normal
95761	\N	\N	10292	10292	\N	DM18_Tumor	NA_DM18_Tumor
95762	\N	\N	10293	10293	\N	DM18_Normal	NA_DM18_Normal
95763	\N	\N	10294	10294	\N	DM22_Tumor	NA_DM22_Tumor
95764	\N	\N	10295	10295	\N	DM22_Normal	NA_DM22_Normal
95765	\N	\N	10296	10296	\N	DM23_Tumor	NA_DM23_Tumor
95766	\N	\N	10297	10297	\N	DM23_Normal	NA_DM23_Normal
95767	\N	\N	10298	10298	\N	DM25_Tumor	NA_DM25_Tumor
95768	\N	\N	10299	10299	\N	DM25_Normal	NA_DM25_Normal
95769	\N	\N	10300	10300	\N	DM6_Tumor	NA_DM6_Tumor
95770	\N	\N	10301	10301	\N	DM37_Tumor	NA_DM37_Tumor
95771	\N	\N	10302	10206	\N	DM93_Normal	NA_DM93_Normal
95772	\N	\N	10303	10207	\N	DM93_Tumor	NA_DM93_Tumor
95773	\N	\N	10304	10304	\N	SM_1_Tumor	NA_SM_1_Tumor
95774	\N	\N	10305	10305	\N	SM_3_Tumor	NA_SM_3_Tumor
95775	\N	\N	10306	10306	\N	SM_4_Tumor	NA_SM_4_Tumor
95776	\N	\N	10307	10307	\N	SM_4_Normal	NA_SM_4_Normal
95777	\N	\N	10308	10308	\N	SM_5_Tumor	NA_SM_5_Tumor
95778	\N	\N	10309	10309	\N	SM_5_Normal	NA_SM_5_Normal
95779	\N	\N	10310	10310	\N	SM7_Tumor	NA_SM7_Tumor
95780	\N	\N	10311	10311	\N	SM_8_Tumor	NA_SM_8_Tumor
95781	\N	\N	10312	10312	\N	SM_11_Tumor	NA_SM_11_Tumor
95782	\N	\N	10313	10313	\N	SM_12_Tumor	NA_SM_12_Tumor
95783	\N	\N	10314	10314	\N	SM_16_Tumor	NA_SM_16_Tumor
95784	\N	\N	10315	10315	\N	SM_16_Normal	NA_SM_16_Normal
95785	\N	\N	10316	10316	\N	SM_18_Tumor	NA_SM_18_Tumor
95786	\N	\N	10317	10317	\N	DM42_Tumor	NA_DM42_Tumor
95787	\N	\N	10318	10318	\N	DM43_Tumor	NA_DM43_Tumor
95788	\N	\N	10319	10319	\N	DM48_Tumor	NA_DM48_Tumor
95789	\N	\N	10320	10320	\N	11-64496_Tumor	NA_11-64496_Tumor
95790	\N	\N	10321	10321	\N	11-71491_Tumor	NA_11-71491_Tumor
95791	\N	\N	10322	10322	\N	11-65756_Tumor	NA_11-65756_Tumor
95792	\N	\N	10323	10323	\N	11-74100_Tumor	NA_11-74100_Tumor
95793	\N	\N	10324	10324	\N	11-74517_Tumor	NA_11-74517_Tumor
95794	\N	\N	10325	10325	\N	10-74513_Tumor	NA_10-74513_Tumor
95795	\N	\N	10326	10326	\N	10-80009_Tumor	NA_10-80009_Tumor
95796	\N	\N	10327	10327	\N	10-91484_Tumor	NA_10-91484_Tumor
95797	\N	\N	10328	10328	\N	11-699_Tumor	NA_11-699_Tumor
95798	\N	\N	10329	10329	\N	11-18560_Tumor	NA_11-18560_Tumor
95799	\N	\N	10330	10330	\N	11-20772_Tumor	NA_11-20772_Tumor
95800	\N	\N	10331	10331	\N	11-19877_Tumor	NA_11-19877_Tumor
95801	\N	\N	10332	10332	\N	11-35616_Tumor	NA_11-35616_Tumor
95802	\N	\N	10333	10333	\N	11-33856_Tumor	NA_11-33856_Tumor
95803	\N	\N	10334	10334	\N	11-38771_Tumor	NA_11-38771_Tumor
95804	\N	\N	10335	10335	\N	11-39639_Tumor	NA_11-39639_Tumor
95805	\N	\N	10336	10211	\N	10-88482_Tumor	NA_10-88482_Tumor
95806	\N	\N	10337	10152	\N	11-5482_Tumor	NA_11-5482_Tumor
95807	\N	\N	10338	10094	\N	11-31904_Tumor	NA_11-31904_Tumor
95808	\N	\N	10339	10158	\N	11-61046_Tumor	NA_11-61046_Tumor
95809	\N	\N	10340	10340	\N	08-27590_Tumor	NA_08-27590_Tumor
95810	\N	\N	10341	10341	\N	08-27590_Normal	NA_08-27590_Normal
95811	\N	\N	10342	10342	\N	06-32942_Tumor	NA_06-32942_Tumor
95812	\N	\N	10343	10343	\N	06-52508_Tumor	NA_06-52508_Tumor
95813	\N	\N	10344	10344	\N	06-52508_Normal	NA_06-52508_Normal
95814	\N	\N	10345	10345	\N	07-04365_Tumor	NA_07-04365_Tumor
95815	\N	\N	10346	10346	\N	07-04365_Normal	NA_07-04365_Normal
95816	\N	\N	10347	10347	\N	07-14044A_Tumor	NA_07-14044A_Tumor
95817	\N	\N	10348	10348	\N	07-14044A_Normal	NA_07-14044A_Normal
95818	\N	\N	10349	10349	\N	07-26247_Tumor	NA_07-26247_Tumor
95819	\N	\N	10350	10350	\N	09-37302_Tumor	NA_09-37302_Tumor
95820	\N	\N	10351	10351	\N	12-79358_Tumor	NA_12-79358_Tumor
95821	\N	\N	10352	10352	\N	12-81302_Tumor	NA_12-81302_Tumor
95822	\N	\N	10353	10353	\N	12-81749_Tumor	NA_12-81749_Tumor
95823	\N	\N	10354	10354	\N	12-97031_Tumor	NA_12-97031_Tumor
95824	\N	\N	10355	10355	\N	12-98736_Tumor	NA_12-98736_Tumor
95825	\N	\N	10356	10356	\N	13-3874_Tumor	NA_13-3874_Tumor
95826	\N	\N	10357	10357	\N	13-3732_Tumor	NA_13-3732_Tumor
95827	\N	\N	10358	10358	\N	13-3889_Tumor	NA_13-3889_Tumor
95828	\N	\N	10359	10359	\N	13-4090B_Tumor	NA_13-4090B_Tumor
95829	\N	\N	10360	10360	\N	13-4136_Tumor	NA_13-4136_Tumor
95830	\N	\N	10361	10361	\N	13-7186_Tumor	NA_13-7186_Tumor
95831	\N	\N	10362	10362	\N	13-25A_Tumor	NA_13-25A_Tumor
95832	\N	\N	10363	10363	\N	11-71241_Tumor	NA_11-71241_Tumor
95833	\N	\N	10364	10364	\N	11-26903_Tumor	NA_11-26903_Tumor
95834	\N	\N	10365	10365	\N	11-28912B_Tumor	NA_11-28912B_Tumor
95835	\N	\N	10366	10366	\N	11-5210D_Tumor	NA_11-5210D_Tumor
95836	\N	\N	10367	10367	\N	10-83193_Tumor	NA_10-83193_Tumor
95837	\N	\N	10368	10368	\N	11-95856_Tumor	NA_11-95856_Tumor
95838	\N	\N	10369	10369	\N	10-23569A_Tumor	NA_10-23569A_Tumor
95839	\N	\N	10370	10370	\N	09-92749_Tumor	NA_09-92749_Tumor
95840	\N	\N	10371	10371	\N	09-72944_Tumor	NA_09-72944_Tumor
95841	\N	\N	10372	10372	\N	10-46536_Tumor	NA_10-46536_Tumor
95842	\N	\N	10373	10373	\N	10-83613A_Tumor	NA_10-83613A_Tumor
95843	\N	\N	10374	10374	\N	K1_1_Tumor	NA_K1_1_Tumor
95844	\N	\N	10375	10375	\N	K1_2_Tumor	NA_K1_2_Tumor
95845	\N	\N	10376	10376	\N	K1_3_Tumor	NA_K1_3_Tumor
95846	\N	\N	10377	10377	\N	London-L20_Melanoma	NA_London-L20_Melanoma
95847	\N	\N	10378	10378	\N	London-L20_Normal	NA_London-L20_Normal
95848	\N	\N	10379	10379	\N	London-L20_Nevus	NA_London-L20_Nevus
95849	\N	\N	10380	10380	\N	London-L15_Normal	NA_London-L15_Normal
95850	\N	\N	10381	10381	\N	London-L23C_Nevus	NA_London-L23C_Nevus
95851	\N	\N	10382	10382	\N	K1_9_Tumor	NA_K1_9_Tumor
95852	\N	\N	10383	10383	\N	K1_10_Tumor	NA_K1_10_Tumor
95853	\N	\N	10384	10384	\N	K1_11_Tumor	NA_K1_11_Tumor
95854	\N	\N	10385	10385	\N	K1_12_Tumor	NA_K1_12_Tumor
95855	\N	\N	10386	10386	\N	K1_13_Tumor	NA_K1_13_Tumor
95856	\N	\N	10387	10387	\N	K1_14_Tumor	NA_K1_14_Tumor
95857	\N	\N	10388	10388	\N	K1_15_Tumor	NA_K1_15_Tumor
95858	\N	\N	10389	10389	\N	K1_16_Tumor	NA_K1_16_Tumor
95859	\N	\N	10390	10390	\N	K1_17_Tumor	NA_K1_17_Tumor
95860	\N	\N	10391	10391	\N	K1_18_Tumor	NA_K1_18_Tumor
95861	\N	\N	10392	10392	\N	K1_19_Tumor	NA_K1_19_Tumor
95862	\N	\N	10393	10393	\N	K1_20_Tumor	NA_K1_20_Tumor
95863	\N	\N	10394	10394	\N	10-32987_Tumor	NA_10-32987_Tumor
95864	\N	\N	10395	10395	\N	06-08042_Tumor	NA_06-08042_Tumor
95865	\N	\N	10396	10396	\N	06-00911_Tumor	NA_06-00911_Tumor
95866	\N	\N	10397	10397	\N	06-21363_Tumor	NA_06-21363_Tumor
95867	\N	\N	10398	10398	\N	06-47334_Tumor	NA_06-47334_Tumor
95868	\N	\N	10399	10399	\N	S12-6332A5_Tumor	NA_S12-6332A5_Tumor
95869	\N	\N	10400	10400	\N	S11-032523A1_Tumor	NA_S11-032523A1_Tumor
95870	\N	\N	10401	10401	\N	S08-1463A2_Tumor	NA_S08-1463A2_Tumor
95871	\N	\N	10402	10402	\N	S12-7093NG176-1_Tumor	NA_S12-7093NG176-1_Tumor
95872	\N	\N	10403	10403	\N	S10-7937B2_Tumor	NA_S10-7937B2_Tumor
95873	\N	\N	10404	10404	\N	S11-21025B1_Tumor	NA_S11-21025B1_Tumor
95874	\N	\N	10405	10405	\N	10-58663_Melanoma	NA_10-58663_Melanoma
95875	\N	\N	10406	10405	\N	10-58663_Melanoma	NA_10-58663_Melanoma
95876	\N	\N	10407	10407	\N	10-58663_Nevus	NA_10-58663_Nevus
95877	\N	\N	10408	10407	\N	10-58663_Nevus	NA_10-58663_Nevus
95878	\N	\N	10409	10409	\N	10-58663_Normal	NA_10-58663_Normal
95879	\N	\N	10410	10410	\N	08-52519_Melanoma	NA_08-52519_Melanoma
95880	\N	\N	10411	10410	\N	08-52519_Melanoma	NA_08-52519_Melanoma
95881	\N	\N	10412	10412	\N	08-52519_Nevus	NA_08-52519_Nevus
95882	\N	\N	10413	10412	\N	08-52519_Nevus	NA_08-52519_Nevus
95883	\N	\N	10414	10414	\N	08-52519_Normal	NA_08-52519_Normal
95884	\N	\N	10415	10415	\N	09-8165_Melanoma	NA_09-8165_Melanoma
95885	\N	\N	10416	10415	\N	09-8165_Melanoma	NA_09-8165_Melanoma
95886	\N	\N	10417	10417	\N	09-8165_Nevus	NA_09-8165_Nevus
95887	\N	\N	10418	10417	\N	09-8165_Nevus	NA_09-8165_Nevus
95888	\N	\N	10419	10419	\N	09-8165_Normal	NA_09-8165_Normal
95889	\N	\N	10420	10420	\N	08-46462_Melanoma	NA_08-46462_Melanoma
95890	\N	\N	10421	10420	\N	08-46462_Melanoma	NA_08-46462_Melanoma
95891	\N	\N	10422	10422	\N	08-46462_Nevus	NA_08-46462_Nevus
95892	\N	\N	10423	10422	\N	08-46462_Nevus	NA_08-46462_Nevus
95893	\N	\N	10424	10424	\N	08-46462_Normal	NA_08-46462_Normal
95894	\N	\N	10425	10425	\N	11-25808_Tumor	NA_11-25808_Tumor
95895	\N	\N	10426	10426	\N	11-42027_Tumor	NA_11-42027_Tumor
95896	\N	\N	10427	10427	\N	12-7775_Tumor	NA_12-7775_Tumor
95897	\N	\N	10428	10207	\N	DM93_Tumor	NA_DM93_Tumor
95898	\N	\N	10429	10429	\N	DM37_Normal	NA_DM37_Normal
95899	\N	\N	10430	10430	\N	DM45_Tumor	NA_DM45_Tumor
95900	\N	\N	10431	10431	\N	DM45_Normal	NA_DM45_Normal
95901	\N	\N	10432	10432	\N	DM16_Tumor	NA_DM16_Tumor
95902	\N	\N	10433	10433	\N	DM16_Normal	NA_DM16_Normal
95903	\N	\N	10434	10434	\N	DM77_Tumor	NA_DM77_Tumor
95904	\N	\N	10435	10435	\N	DM77_Normal	NA_DM77_Normal
95905	\N	\N	10436	10084	\N	HW3_Tumor	NA_HW3_Tumor
95906	\N	\N	10437	10113	\N	HW2_Tumor	NA_HW2_Tumor
95907	\N	\N	10438	10438	\N	HWAcr_Tumor	NA_HWAcr_Tumor
95908	\N	\N	10439	10055	\N	KIT181_Tumor	NA_KIT181_Tumor
95909	\N	\N	10440	10203	\N	DM13_Tumor	NA_DM13_Tumor
95910	\N	\N	10441	10441	\N	DM94_Tumor	NA_DM94_Tumor
95911	\N	\N	10442	10442	\N	DM94_Normal	NA_DM94_Normal
95912	\N	\N	10443	10443	\N	DM98_Tumor	NA_DM98_Tumor
95913	\N	\N	10444	10444	\N	DM98_Normal	NA_DM98_Normal
95914	\N	\N	10445	10445	\N	DM99_Tumor	NA_DM99_Tumor
95915	\N	\N	10446	10446	\N	DM99_Normal	NA_DM99_Normal
95916	\N	\N	10447	10447	\N	DM64_Tumor	NA_DM64_Tumor
95917	\N	\N	10448	10448	\N	DM64_Normal	NA_DM64_Normal
95918	\N	\N	10449	10449	\N	DM51_Tumor	NA_DM51_Tumor
95919	\N	\N	10450	10450	\N	DM58_Tumor	NA_DM58_Tumor
95920	\N	\N	10451	10451	\N	DM59_Tumor	NA_DM59_Tumor
95921	\N	\N	10452	10452	\N	DM31_Tumor	NA_DM31_Tumor
95922	\N	\N	10453	10453	\N	DM36_Tumor	NA_DM36_Tumor
95923	\N	\N	10454	10454	\N	DM74_Tumor	NA_DM74_Tumor
95924	\N	\N	10455	10288	\N	DM10_Tumor	NA_DM10_Tumor
95925	\N	\N	10456	10292	\N	DM18_Tumor	NA_DM18_Tumor
95926	\N	\N	10457	10115	\N	HW8_Tumor	NA_HW8_Tumor
95927	\N	\N	10458	10458	\N	08-43264_Melanoma	NA_08-43264_Melanoma
95928	\N	\N	10459	10458	\N	08-43264_Melanoma	NA_08-43264_Melanoma
95929	\N	\N	10460	10460	\N	08-43264_Nevus	NA_08-43264_Nevus
95930	\N	\N	10461	10460	\N	08-43264_Nevus	NA_08-43264_Nevus
95931	\N	\N	10462	10462	\N	08-43264_Normal	NA_08-43264_Normal
95932	\N	\N	10463	10463	\N	08-51219_Melanoma	NA_08-51219_Melanoma
95933	\N	\N	10464	10463	\N	08-51219_Melanoma	NA_08-51219_Melanoma
95934	\N	\N	10465	10465	\N	08-51219_Nevus	NA_08-51219_Nevus
95935	\N	\N	10466	10465	\N	08-51219_Nevus	NA_08-51219_Nevus
95936	\N	\N	10467	10467	\N	08-51219_Normal	NA_08-51219_Normal
95937	\N	\N	10468	10468	\N	S12-18826_Tumor	NA_S12-18826_Tumor
95938	\N	\N	10469	10469	\N	11-81851_Melanoma	NA_11-81851_Melanoma
95939	\N	\N	10470	10469	\N	11-81851_Melanoma	NA_11-81851_Melanoma
95940	\N	\N	10471	10471	\N	11-81851_Nevus	NA_11-81851_Nevus
95941	\N	\N	10472	10471	\N	11-81851_Nevus	NA_11-81851_Nevus
95942	\N	\N	10473	10473	\N	11-81851_Normal	NA_11-81851_Normal
95943	\N	\N	10474	10474	\N	10-73024_Melanoma	NA_10-73024_Melanoma
95944	\N	\N	10475	10474	\N	10-73024_Melanoma	NA_10-73024_Melanoma
95945	\N	\N	10476	10476	\N	10-73024_Nevus	NA_10-73024_Nevus
95946	\N	\N	10477	10476	\N	10-73024_Nevus	NA_10-73024_Nevus
95947	\N	\N	10478	10478	\N	10-73024_Normal	NA_10-73024_Normal
95948	\N	\N	10479	10479	\N	12_M_Tumor	NA_12_M_Tumor
95949	\N	\N	10480	10480	\N	35_M_Tumor	NA_35_M_Tumor
95950	\N	\N	10481	10481	\N	49_M_Tumor	NA_49_M_Tumor
95951	\N	\N	10482	10195	\N	DM2_Tumor	NA_DM2_Tumor
95952	\N	\N	10483	10483	\N	10-0206_Tumor	NA_10-0206_Tumor
95953	\N	\N	10484	10484	\N	09-0209_Tumor	NA_09-0209_Tumor
95954	\N	\N	10485	10485	\N	13-25110A1_Melanoma	NA_13-25110A1_Melanoma
95955	\N	\N	10486	10486	\N	13-25110A1_Nevus	NA_13-25110A1_Nevus
95956	\N	\N	10487	10487	\N	13-25110A1_Normal	NA_13-25110A1_Normal
95957	\N	\N	10488	10488	\N	13-45163_Melanoma	NA_13-45163_Melanoma
95958	\N	\N	10489	10489	\N	13-45163_Nevus	NA_13-45163_Nevus
95959	\N	\N	10490	10490	\N	13-45163_Normal	NA_13-45163_Normal
95960	\N	\N	10491	10491	\N	DM49_Tumor	NA_DM49_Tumor
95961	\N	\N	10492	10492	\N	DP08-21965C_Tumor	NA_DP08-21965C_Tumor
95962	\N	\N	10493	10493	\N	DP08-21965C_Normal	NA_DP08-21965C_Normal
95963	\N	\N	10494	10494	\N	DP08-4205A_Tumor	NA_DP08-4205A_Tumor
95964	\N	\N	10495	10495	\N	DP08-4205A_Normal	NA_DP08-4205A_Normal
95965	\N	\N	10496	10496	\N	11-50182_Tumor	NA_11-50182_Tumor
95966	\N	\N	10497	10497	\N	11-51553_Tumor	NA_11-51553_Tumor
95967	\N	\N	10498	10498	\N	11-52339_Tumor	NA_11-52339_Tumor
95968	\N	\N	10499	10499	\N	11-55993_Tumor	NA_11-55993_Tumor
95969	\N	\N	10500	10500	\N	11-57051_Tumor	NA_11-57051_Tumor
95970	\N	\N	10501	10501	\N	11-71006_Tumor	NA_11-71006_Tumor
95971	\N	\N	10502	10502	\N	11-76464_Tumor	NA_11-76464_Tumor
95972	\N	\N	10503	10503	\N	11-88431_Tumor	NA_11-88431_Tumor
95973	\N	\N	10504	10504	\N	11-88432_Tumor	NA_11-88432_Tumor
95974	\N	\N	10505	10505	\N	11-88209_Tumor	NA_11-88209_Tumor
95975	\N	\N	10506	10506	\N	Thomas_SK_MEL_23_Tumor	NA_Thomas_SK_MEL_23_Tumor
95976	\N	\N	10507	10507	\N	KIT134_Tumor	NA_KIT134_Tumor
95977	\N	\N	10508	10508	\N	KIT191_Tumor	NA_KIT191_Tumor
95978	\N	\N	10509	10509	\N	KIT205_Tumor	NA_KIT205_Tumor
95979	\N	\N	10510	10510	\N	KIT206_Tumor	NA_KIT206_Tumor
95980	\N	\N	10511	10511	\N	KIT210_Tumor	NA_KIT210_Tumor
95981	\N	\N	10512	10512	\N	KIT217_Tumor	NA_KIT217_Tumor
95982	\N	\N	10513	10513	\N	KIT225_Tumor	NA_KIT225_Tumor
95983	\N	\N	10514	10514	\N	KIT244_Tumor	NA_KIT244_Tumor
95984	\N	\N	10515	10515	\N	KIT260_Tumor	NA_KIT260_Tumor
95985	\N	\N	10516	10516	\N	KIT273_Tumor	NA_KIT273_Tumor
95986	\N	\N	10517	10517	\N	KIT295_Tumor	NA_KIT295_Tumor
95987	\N	\N	10518	10518	\N	11-23878_Tumor	NA_11-23878_Tumor
95988	\N	\N	10519	10519	\N	12-11041_Tumor	NA_12-11041_Tumor
95989	\N	\N	10520	10520	\N	12-55584_Tumor	NA_12-55584_Tumor
95990	\N	\N	10521	10521	\N	11-85416_Tumor	NA_11-85416_Tumor
95991	\N	\N	10522	10522	\N	11-94134_Tumor	NA_11-94134_Tumor
95992	\N	\N	10523	10523	\N	12-2898_Tumor	NA_12-2898_Tumor
95993	\N	\N	10524	10524	\N	12-1782_Tumor	NA_12-1782_Tumor
95994	\N	\N	10525	10525	\N	12-4251_Tumor	NA_12-4251_Tumor
95995	\N	\N	10526	10526	\N	12-8171_Tumor	NA_12-8171_Tumor
95996	\N	\N	10527	10527	\N	12-10777_Tumor	NA_12-10777_Tumor
95997	\N	\N	10528	10528	\N	10_63051C_Normal	NA_10_63051C_Normal
95998	\N	\N	10529	10529	\N	DPN8_Normal	NA_DPN8_Normal
95999	\N	\N	10530	10530	\N	DPN9_Normal	NA_DPN9_Normal
96000	\N	\N	10531	10531	\N	DPN18_Normal	NA_DPN18_Normal
96001	\N	\N	10532	10532	\N	11-21178_Tumor	NA_11-21178_Tumor
96002	\N	\N	10533	10533	\N	13-212_Tumor	NA_13-212_Tumor
96003	\N	\N	10534	10454	\N	DM74_Tumor	NA_DM74_Tumor
96004	\N	\N	10535	10445	\N	DM99_Tumor	NA_DM99_Tumor
96005	\N	\N	10536	10536	\N	KIT230_Tumor	NA_KIT230_Tumor
96006	\N	\N	10537	10537	\N	KIT297_Tumor	NA_KIT297_Tumor
96007	\N	\N	10538	10538	\N	KIT302_Tumor	NA_KIT302_Tumor
96008	\N	\N	10539	10539	\N	KIT316_Tumor	NA_KIT316_Tumor
96009	\N	\N	10540	10540	\N	DM6_Normal	NA_DM6_Normal
96010	\N	\N	10541	10541	\N	DM31_Normal	NA_DM31_Normal
96011	\N	\N	10542	10542	\N	DM36_Normal	NA_DM36_Normal
96012	\N	\N	10543	10543	\N	DM42_Normal	NA_DM42_Normal
96013	\N	\N	10544	10544	\N	DM68_Tumor	NA_DM68_Tumor
96014	\N	\N	10545	10288	\N	DM10_Tumor	NA_DM10_Tumor
96015	\N	\N	10546	10289	\N	DM10_Normal	NA_DM10_Normal
96016	\N	\N	10547	10288	\N	DM10_Tumor	NA_DM10_Tumor
96017	\N	\N	10548	10548	\N	11-50270_Tumor	NA_11-50270_Tumor
96018	\N	\N	10549	10549	\N	12-23578_Tumor	NA_12-23578_Tumor
96019	\N	\N	10550	10550	\N	12-31421_Tumor	NA_12-31421_Tumor
96020	\N	\N	10551	10551	\N	11-13661_Tumor	NA_11-13661_Tumor
96021	\N	\N	10552	10552	\N	RC11-001_Tumor	NA_RC11-001_Tumor
96022	\N	\N	10553	10553	\N	RC11-002_Tumor	NA_RC11-002_Tumor
96023	\N	\N	10554	10554	\N	RC11-003_Tumor	NA_RC11-003_Tumor
96024	\N	\N	10555	10555	\N	RC11-004_Tumor	NA_RC11-004_Tumor
96025	\N	\N	10556	10556	\N	RC11-005_Tumor	NA_RC11-005_Tumor
96026	\N	\N	10557	10557	\N	RC11-021_Tumor	NA_RC11-021_Tumor
96027	\N	\N	10558	10558	\N	RC11-022_Tumor	NA_RC11-022_Tumor
96028	\N	\N	10559	10559	\N	RC11-023_Tumor	NA_RC11-023_Tumor
96029	\N	\N	10560	10560	\N	RC11-024_Tumor	NA_RC11-024_Tumor
96030	\N	\N	10561	10561	\N	Kit298_Tumor	NA_Kit298_Tumor
96031	\N	\N	10562	10562	\N	08-46462_Tumor	NA_08-46462_Tumor
96032	\N	\N	10563	10422	\N	08-46462_Nevus	NA_08-46462_Nevus
96033	\N	\N	10564	10562	\N	08-46462_Tumor	NA_08-46462_Tumor
96034	\N	\N	10565	10424	\N	08-46462_Normal	NA_08-46462_Normal
96035	\N	\N	10566	10566	\N	BN_N1_Tumor	NA_BN_N1_Tumor
96036	\N	\N	10567	10567	\N	BN_N2_Tumor	NA_BN_N2_Tumor
96037	\N	\N	10568	10568	\N	BN_M1_Tumor	NA_BN_M1_Tumor
96038	\N	\N	10569	10569	\N	BN_M2_Tumor	NA_BN_M2_Tumor
96039	\N	\N	10570	10454	\N	DM74_Tumor	NA_DM74_Tumor
96040	\N	\N	10571	10288	\N	DM10_Tumor	NA_DM10_Tumor
96041	\N	\N	10572	10572	\N	SQ13-8208B_Tumor	NA_SQ13-8208B_Tumor
96042	\N	\N	10573	10573	\N	98-18400a_Tumor	NA_98-18400a_Tumor
96043	\N	\N	10574	10574	\N	12-11406A_Tumor	NA_12-11406A_Tumor
96044	\N	\N	10575	10575	\N	08-70283a_Tumor	NA_08-70283a_Tumor
96045	\N	\N	10576	10576	\N	03-34051A1_Tumor	NA_03-34051A1_Tumor
96046	\N	\N	10577	10577	\N	02-42436_Tumor	NA_02-42436_Tumor
96047	\N	\N	10578	10578	\N	11-38149_Normal	NA_11-38149_Normal
96048	\N	\N	10579	10579	\N	13-2939B_Tumor	NA_13-2939B_Tumor
96049	\N	\N	10580	10580	\N	L13-48798_Tumor	NA_L13-48798_Tumor
96050	\N	\N	10581	10581	\N	13-51115A_Tumor	NA_13-51115A_Tumor
96051	\N	\N	10582	10582	\N	11-73238A_Normal	NA_11-73238A_Normal
96052	\N	\N	10583	10583	\N	11-73999_Normal	NA_11-73999_Normal
96053	\N	\N	10584	10584	\N	DM43_Normal	NA_DM43_Normal
96054	\N	\N	10585	10585	\N	DM49_Normal	NA_DM49_Normal
96055	\N	\N	10586	10586	\N	DM58_Normal	NA_DM58_Normal
96056	\N	\N	10587	10587	\N	DM65_Tumor	NA_DM65_Tumor
96057	\N	\N	10588	10207	\N	DM93_Tumor	NA_DM93_Tumor
96058	\N	\N	10589	10288	\N	DM10_Tumor	NA_DM10_Tumor
96059	\N	\N	10590	10590	\N	13-59840_Tumor	NA_13-59840_Tumor
96060	\N	\N	10591	10590	\N	13-59840_Tumor	NA_13-59840_Tumor
96061	\N	\N	10592	10592	\N	Seider_Uveal_Tumor	NA_Seider_Uveal_Tumor
96062	\N	\N	10593	10593	\N	Luping_ROS_1_Tumor	NA_Luping_ROS_1_Tumor
96063	\N	\N	10594	10594	\N	Seider_Roe_Tumor	NA_Seider_Roe_Tumor
96064	\N	\N	10595	10492	\N	DP08-21965C_Tumor	NA_DP08-21965C_Tumor
96065	\N	\N	10596	10292	\N	DM18_Tumor	NA_DM18_Tumor
96066	\N	\N	10597	10496	\N	11-50182_Tumor	NA_11-50182_Tumor
96067	\N	\N	10598	10598	\N	11-41004_Tumor	NA_11-41004_Tumor
96068	\N	\N	10599	10599	\N	11-51223_Tumor	NA_11-51223_Tumor
96069	\N	\N	10600	10600	\N	12-22542_Tumor	NA_12-22542_Tumor
96070	\N	\N	10601	10601	\N	12-42406_Tumor	NA_12-42406_Tumor
96071	\N	\N	10602	10602	\N	12-55875_Tumor	NA_12-55875_Tumor
96072	\N	\N	10603	10603	\N	12-88454_Tumor	NA_12-88454_Tumor
96073	\N	\N	10604	10604	\N	12-98328_Tumor	NA_12-98328_Tumor
96074	\N	\N	10605	10362	\N	13-25A_Tumor	NA_13-25A_Tumor
96075	\N	\N	10606	10606	\N	12-762B_Normal	NA_12-762B_Normal
96076	\N	\N	10607	10607	\N	12-168B_Normal	NA_12-168B_Normal
96077	\N	\N	10608	10608	\N	11-75173_Normal	NA_11-75173_Normal
96078	\N	\N	10609	10609	\N	12-167B_Normal	NA_12-167B_Normal
96079	\N	\N	10610	10610	\N	13-47668_Tumor	NA_13-47668_Tumor
96080	\N	\N	10611	10610	\N	13-47668_Tumor	NA_13-47668_Tumor
96081	\N	\N	10612	10612	\N	12-66661_Tumor	NA_12-66661_Tumor
96082	\N	\N	10613	10613	\N	13-47621_Tumor	NA_13-47621_Tumor
96083	\N	\N	10614	10613	\N	13-47621_Tumor	NA_13-47621_Tumor
96084	\N	\N	10615	10615	\N	13-37371_Tumor	NA_13-37371_Tumor
96085	\N	\N	10616	10615	\N	13-37371_Tumor	NA_13-37371_Tumor
96086	\N	\N	10617	10224	\N	DM11_Tumor	NA_DM11_Tumor
96087	\N	\N	10618	10226	\N	DM14_Tumor	NA_DM14_Tumor
96088	\N	\N	10619	10485	\N	13-25110A1_Melanoma	NA_13-25110A1_Melanoma
96089	\N	\N	10620	10487	\N	13-25110A1_Normal	NA_13-25110A1_Normal
96090	\N	\N	10621	10490	\N	13-45163_Normal	NA_13-45163_Normal
96091	\N	\N	10622	10622	\N	Acral-11_Tumor	NA_Acral-11_Tumor
96092	\N	\N	10623	10623	\N	Acral-11_Normal	NA_Acral-11_Normal
96093	\N	\N	10624	10624	\N	Acral-12_Tumor	NA_Acral-12_Tumor
96094	\N	\N	10625	10625	\N	Acral-12_Normal	NA_Acral-12_Normal
96095	\N	\N	10626	10626	\N	02-2599_Tumor	NA_02-2599_Tumor
96096	\N	\N	10627	10626	\N	02-2599_Tumor	NA_02-2599_Tumor
96097	\N	\N	10628	10628	\N	02-2599C_Tumor	NA_02-2599C_Tumor
96098	\N	\N	10629	10626	\N	02-2599_Tumor	NA_02-2599_Tumor
96099	\N	\N	10630	10630	\N	DM48_Normal	NA_DM48_Normal
96100	\N	\N	10631	10631	\N	DM59_Normal	NA_DM59_Normal
96101	\N	\N	10632	10632	\N	DM68_Normal	NA_DM68_Normal
96102	\N	\N	10633	10248	\N	DM95_Tumor	NA_DM95_Tumor
96103	\N	\N	10634	10422	\N	08-46462_Nevus	NA_08-46462_Nevus
96104	\N	\N	10635	10635	\N	08-46462_MIS	NA_08-46462_MIS
96105	\N	\N	10636	10424	\N	08-46462_Normal	NA_08-46462_Normal
96106	\N	\N	10637	10420	\N	08-46462_Melanoma	NA_08-46462_Melanoma
96107	\N	\N	10638	10638	\N	T07-1120_Tumor	NA_T07-1120_Tumor
96108	\N	\N	10639	10639	\N	T09-8069_Tumor	NA_T09-8069_Tumor
96109	\N	\N	10640	10640	\N	T02-16195_Tumor	NA_T02-16195_Tumor
96110	\N	\N	10641	10641	\N	T00-12011_Tumor	NA_T00-12011_Tumor
96111	\N	\N	10642	10642	\N	T06-6855_Tumor	NA_T06-6855_Tumor
96112	\N	\N	10643	10643	\N	12-18832AA_Tumor	NA_12-18832AA_Tumor
96113	\N	\N	10644	10644	\N	CNS52_Tumor	NA_CNS52_Tumor
96114	\N	\N	10645	10645	\N	CNS53_Tumor	NA_CNS53_Tumor
96115	\N	\N	10646	10646	\N	CNS54_Tumor	NA_CNS54_Tumor
96116	\N	\N	10647	10647	\N	CNS57_Tumor	NA_CNS57_Tumor
96117	\N	\N	10648	10648	\N	CNS57_Normal	NA_CNS57_Normal
96118	\N	\N	10649	10649	\N	BN-N1-Tert_Tumor	NA_BN-N1-Tert_Tumor
96119	\N	\N	10650	10650	\N	BN-N2-Tert_Tumor	NA_BN-N2-Tert_Tumor
96120	\N	\N	10651	10651	\N	BN-M1-Tert_Tumor	NA_BN-M1-Tert_Tumor
96121	\N	\N	10652	10460	\N	08-43264_Nevus	NA_08-43264_Nevus
96122	\N	\N	10653	10405	\N	10-58663_Melanoma	NA_10-58663_Melanoma
96123	\N	\N	10654	10654	\N	12-12039B_Tumor	NA_12-12039B_Tumor
96124	\N	\N	10655	10655	\N	12-22776B3_Tumor	NA_12-22776B3_Tumor
96125	\N	\N	10656	10656	\N	99-29482_Tumor	NA_99-29482_Tumor
96126	\N	\N	10657	10657	\N	99-15313_Tumor	NA_99-15313_Tumor
96127	\N	\N	10658	10658	\N	99-885_Tumor	NA_99-885_Tumor
96128	\N	\N	10659	10659	\N	98-37643_Tumor	NA_98-37643_Tumor
96129	\N	\N	10660	10660	\N	13-25288_Tumor	NA_13-25288_Tumor
96130	\N	\N	10661	10661	\N	09-29997_Tumor	NA_09-29997_Tumor
96131	\N	\N	10662	10662	\N	04-11158_Tumor	NA_04-11158_Tumor
96132	\N	\N	10663	10663	\N	UM4_Tumor	NA_UM4_Tumor
96133	\N	\N	10664	10664	\N	UM5_Tumor	NA_UM5_Tumor
96134	\N	\N	10665	10665	\N	08-84352_Melanoma	NA_08-84352_Melanoma
96135	\N	\N	10666	10665	\N	08-84352_Melanoma	NA_08-84352_Melanoma
96136	\N	\N	10667	10667	\N	08-84352_Nevus	NA_08-84352_Nevus
96137	\N	\N	10668	10668	\N	08-84352_Normal	NA_08-84352_Normal
96138	\N	\N	10669	10669	\N	11-88792_Melanoma	NA_11-88792_Melanoma
96139	\N	\N	10670	10669	\N	11-88792_Melanoma	NA_11-88792_Melanoma
96140	\N	\N	10671	10671	\N	11-88792_Nevus	NA_11-88792_Nevus
96141	\N	\N	10672	10671	\N	11-88792_Nevus	NA_11-88792_Nevus
96142	\N	\N	10673	10673	\N	11-88792_Normal	NA_11-88792_Normal
96143	\N	\N	10674	10674	\N	13-74952_Tumor	NA_13-74952_Tumor
96144	\N	\N	10675	10675	\N	13-75067_Tumor	NA_13-75067_Tumor
96145	\N	\N	10676	10676	\N	Spitz_M1_Tumor	NA_Spitz_M1_Tumor
96146	\N	\N	10677	10677	\N	Spitz_M2_(?)_Tumor	NA_Spitz_M2_(?)_Tumor
96147	\N	\N	10678	10678	\N	Spitz_N1_Tumor	NA_Spitz_N1_Tumor
96148	\N	\N	10679	10679	\N	Spitz_N2_Tumor	NA_Spitz_N2_Tumor
96149	\N	\N	10680	10680	\N	Spitz_N3_Tumor	NA_Spitz_N3_Tumor
96150	\N	\N	10681	10681	\N	BN_Normal	NA_BN_Normal
96151	\N	\N	10682	10682	\N	13-159_Tumor	NA_13-159_Tumor
96152	\N	\N	10683	10683	\N	12-43016_Tumor	NA_12-43016_Tumor
96153	\N	\N	10684	10684	\N	13-34291_Tumor	NA_13-34291_Tumor
96154	\N	\N	10685	10685	\N	GAK_DNA_Tumor	NA_GAK_DNA_Tumor
96155	\N	\N	10686	10686	\N	Yurif_DNA_Tumor	NA_Yurif_DNA_Tumor
96156	\N	\N	10687	10622	\N	Acral-11_Tumor	NA_Acral-11_Tumor
96157	\N	\N	10688	10623	\N	Acral-11_Normal	NA_Acral-11_Normal
96158	\N	\N	10689	10689	\N	DPN26_Tumor	NA_DPN26_Tumor
96159	\N	\N	10690	10610	\N	13-47668_Tumor	NA_13-47668_Tumor
96160	\N	\N	10691	10610	\N	13-47668_Tumor	NA_13-47668_Tumor
96161	\N	\N	10692	10613	\N	13-47621_Tumor	NA_13-47621_Tumor
96162	\N	\N	10693	10613	\N	13-47621_Tumor	NA_13-47621_Tumor
96163	\N	\N	10694	10615	\N	13-37371_Tumor	NA_13-37371_Tumor
96164	\N	\N	10695	10615	\N	13-37371_Tumor	NA_13-37371_Tumor
96165	\N	\N	10696	10430	\N	DM45_Tumor	NA_DM45_Tumor
96166	\N	\N	10697	10450	\N	DM58_Tumor	NA_DM58_Tumor
96167	\N	\N	10698	10193	\N	DM1_Tumor	NA_DM1_Tumor
96168	\N	\N	10699	10195	\N	DM2_Tumor	NA_DM2_Tumor
96169	\N	\N	10700	10430	\N	DM45_Tumor	NA_DM45_Tumor
96170	\N	\N	10701	10238	\N	DM79_Tumor	NA_DM79_Tumor
96171	\N	\N	10702	10207	\N	DM93_Tumor	NA_DM93_Tumor
96172	\N	\N	10703	10579	\N	13-2939B_Tumor	NA_13-2939B_Tumor
96173	\N	\N	10704	10704	\N	11-73238A_Tumor	NA_11-73238A_Tumor
96174	\N	\N	10705	10656	\N	99-29482_Tumor	NA_99-29482_Tumor
96175	\N	\N	10706	10660	\N	13-25288_Tumor	NA_13-25288_Tumor
96176	\N	\N	10707	10662	\N	04-11158_Tumor	NA_04-11158_Tumor
96177	\N	\N	10708	10119	\N	10-55707_Tumor	NA_10-55707_Tumor
96178	\N	\N	10709	10120	\N	11-34950_Tumor	NA_11-34950_Tumor
96179	\N	\N	10710	10121	\N	11-8228_Tumor	NA_11-8228_Tumor
96180	\N	\N	10711	10122	\N	11-84681_Tumor	NA_11-84681_Tumor
96181	\N	\N	10712	10496	\N	11-50182_Tumor	NA_11-50182_Tumor
96182	\N	\N	10713	10713	\N	MIN_7_Normal	NA_MIN_7_Normal
96183	\N	\N	10714	10714	\N	MIN_7_Nevus	NA_MIN_7_Nevus
96184	\N	\N	10715	10715	\N	MIN_7_Tumor	NA_MIN_7_Tumor
96185	\N	\N	10716	10716	\N	MIN_8_Normal	NA_MIN_8_Normal
96186	\N	\N	10717	10717	\N	MIN_8_Nevus	NA_MIN_8_Nevus
96187	\N	\N	10718	10718	\N	MIN_8_Tumor	NA_MIN_8_Tumor
96188	\N	\N	10719	10719	\N	501_Mel_Tumor	NA_501_Mel_Tumor
96189	\N	\N	10720	10720	\N	Sk_Mel_1_Tumor	NA_Sk_Mel_1_Tumor
96190	\N	\N	10721	10721	\N	DPN24_Tumor	NA_DPN24_Tumor
96191	\N	\N	10722	10722	\N	DPN28_Tumor	NA_DPN28_Tumor
96192	\N	\N	10723	10723	\N	DPN29_Tumor	NA_DPN29_Tumor
96193	\N	\N	10724	10724	\N	DPN31_Tumor	NA_DPN31_Tumor
96194	\N	\N	10725	10725	\N	DPN33_Tumor	NA_DPN33_Tumor
96195	\N	\N	10726	10726	\N	DPN40_Tumor	NA_DPN40_Tumor
96196	\N	\N	10727	10726	\N	DPN40_Tumor	NA_DPN40_Tumor
96197	\N	\N	10728	10728	\N	DPN41_Tumor	NA_DPN41_Tumor
96198	\N	\N	10729	10729	\N	DPN42_Tumor	NA_DPN42_Tumor
96199	\N	\N	10730	10730	\N	DPN44_Tumor	NA_DPN44_Tumor
96200	\N	\N	10731	10731	\N	DPN45_Tumor	NA_DPN45_Tumor
96201	\N	\N	10732	10732	\N	DPN46_Tumor	NA_DPN46_Tumor
96202	\N	\N	10733	10733	\N	UM_6_Tumor	NA_UM_6_Tumor
96203	\N	\N	10734	10734	\N	Birt_Hogg_Dube_Tumor	NA_Birt_Hogg_Dube_Tumor
96204	\N	\N	10735	10735	\N	13-1939_Tumor	NA_13-1939_Tumor
96205	\N	\N	10736	10736	\N	13-51657_Tumor	NA_13-51657_Tumor
96206	\N	\N	10737	10737	\N	13-89069_Tumor	NA_13-89069_Tumor
96207	\N	\N	10738	10738	\N	11-1051A_Tumor	NA_11-1051A_Tumor
96208	\N	\N	10739	10739	\N	11-5480_Tumor	NA_11-5480_Tumor
96209	\N	\N	10740	10740	\N	10-73024_Tumor	NA_10-73024_Tumor
96210	\N	\N	10741	10478	\N	10-73024_Normal	NA_10-73024_Normal
96211	\N	\N	10742	10742	\N	09-33283_Melanoma	NA_09-33283_Melanoma
96212	\N	\N	10743	10742	\N	09-33283_Melanoma	NA_09-33283_Melanoma
96213	\N	\N	10744	10744	\N	09-33283_Nevus	NA_09-33283_Nevus
96214	\N	\N	10745	10744	\N	09-33283_Nevus	NA_09-33283_Nevus
96215	\N	\N	10746	10746	\N	09-31895_Melanoma	NA_09-31895_Melanoma
96216	\N	\N	10747	10746	\N	09-31895_Melanoma	NA_09-31895_Melanoma
96217	\N	\N	10748	10748	\N	09-31895_Nevus	NA_09-31895_Nevus
96218	\N	\N	10749	10748	\N	09-31895_Nevus	NA_09-31895_Nevus
96219	\N	\N	10750	10750	\N	09-31895_Normal	NA_09-31895_Normal
96220	\N	\N	10751	10751	\N	R29032-05_Tumor	NA_R29032-05_Tumor
96221	\N	\N	10752	10752	\N	R29032-05_Normal	NA_R29032-05_Normal
96222	\N	\N	10753	10753	\N	01-8297_Tumor	NA_01-8297_Tumor
96223	\N	\N	10754	10754	\N	01-8297_Normal	NA_01-8297_Normal
96224	\N	\N	10755	10755	\N	8298-01_Tumor	NA_8298-01_Tumor
96225	\N	\N	10756	10756	\N	8298-01_Normal	NA_8298-01_Normal
96226	\N	\N	10757	10757	\N	08-53951_Melanoma	NA_08-53951_Melanoma
96227	\N	\N	10758	10757	\N	08-53951_Melanoma	NA_08-53951_Melanoma
96228	\N	\N	10759	10759	\N	08-53951_Nevus	NA_08-53951_Nevus
96229	\N	\N	10760	10759	\N	08-53951_Nevus	NA_08-53951_Nevus
96230	\N	\N	10761	10761	\N	13000212_Tumor	NA_13000212_Tumor
96231	\N	\N	10762	10762	\N	8528-05_Tumor	NA_8528-05_Tumor
96232	\N	\N	10763	10763	\N	1286184b_Tumor	NA_1286184b_Tumor
96233	\N	\N	10764	10764	\N	1286184b_Normal	NA_1286184b_Normal
96234	\N	\N	10765	10765	\N	206436_Tumor	NA_206436_Tumor
96235	\N	\N	10766	10766	\N	35942-04_Tumor	NA_35942-04_Tumor
96236	\N	\N	10767	10767	\N	15329-03_Normal	NA_15329-03_Normal
96237	\N	\N	10768	10768	\N	Z1188-03_Tumor	NA_Z1188-03_Tumor
96238	\N	\N	10769	10769	\N	1185-03_Normal	NA_1185-03_Normal
96239	\N	\N	10770	10770	\N	14514-02_Tumor	NA_14514-02_Tumor
96240	\N	\N	10771	10771	\N	15102-02_Normal	NA_15102-02_Normal
96241	\N	\N	10772	10772	\N	9116-05_Tumor	NA_9116-05_Tumor
96242	\N	\N	10773	10773	\N	24516-06_Tumor	NA_24516-06_Tumor
96243	\N	\N	10774	10774	\N	24516-06_Normal	NA_24516-06_Normal
96244	\N	\N	10775	10775	\N	07-3078_Tumor	NA_07-3078_Tumor
96245	\N	\N	10776	10776	\N	B06-37358_Tumor	NA_B06-37358_Tumor
96246	\N	\N	10777	10777	\N	21590_Tumor	NA_21590_Tumor
96247	\N	\N	10778	10778	\N	21590_Normal	NA_21590_Normal
96248	\N	\N	10779	10779	\N	A2A79@_Tumor	NA_A2A79@_Tumor
96249	\N	\N	10780	10780	\N	356A3-075_Tumor	NA_356A3-075_Tumor
96250	\N	\N	10781	10781	\N	20847-09_Normal	NA_20847-09_Normal
96251	\N	\N	10782	10782	\N	525_Tumor	NA_525_Tumor
96252	\N	\N	10783	10783	\N	PMM_23_Tumor	NA_PMM_23_Tumor
96253	\N	\N	10784	10784	\N	PMM_23_Normal	NA_PMM_23_Normal
96254	\N	\N	10785	10785	\N	UM7_Tumor	NA_UM7_Tumor
96255	\N	\N	10786	10786	\N	UM8_Tumor	NA_UM8_Tumor
96256	\N	\N	10787	10787	\N	UM9_Tumor	NA_UM9_Tumor
96257	\N	\N	10788	10788	\N	UM10_Tumor	NA_UM10_Tumor
96258	\N	\N	10789	10789	\N	UM11_Tumor	NA_UM11_Tumor
96259	\N	\N	10790	10790	\N	Xanthoma_Disseminatum_Tumor	NA_Xanthoma_Disseminatum_Tumor
96260	\N	\N	10791	10657	\N	99-15313_Tumor	NA_99-15313_Tumor
96261	\N	\N	10792	10659	\N	98-37643_Tumor	NA_98-37643_Tumor
96262	\N	\N	10793	10661	\N	09-29997_Tumor	NA_09-29997_Tumor
96472	\N	\N	11003	11003	\N	M230_Tumor	NA_M230_Tumor
96263	\N	\N	10794	10794	\N	13-94981_Tumor	NA_13-94981_Tumor
96264	\N	\N	10795	10795	\N	13-99411A_Tumor	NA_13-99411A_Tumor
96265	\N	\N	10796	10796	\N	13-94484_Tumor	NA_13-94484_Tumor
96266	\N	\N	10797	10797	\N	DM27_Tumor	NA_DM27_Tumor
96267	\N	\N	10798	10798	\N	DM32_Tumor	NA_DM32_Tumor
96268	\N	\N	10799	10799	\N	DM35_Tumor	NA_DM35_Tumor
96269	\N	\N	10800	10800	\N	DM40_Tumor	NA_DM40_Tumor
96270	\N	\N	10801	10069	\N	11-23681_Melanoma	NA_11-23681_Melanoma
96271	\N	\N	10802	10069	\N	11-23681_Melanoma	NA_11-23681_Melanoma
96272	\N	\N	10803	10803	\N	H01.10457/II_Primary	NA_H01.10457/II_Primary
96273	\N	\N	10804	10804	\N	H01.10457/II_Normal	NA_H01.10457/II_Normal
96274	\N	\N	10805	10805	\N	14.20/II_Met1	NA_14.20/II_Met1
96275	\N	\N	10806	10806	\N	HS14.18/I_Met2	NA_HS14.18/I_Met2
96276	\N	\N	10807	10807	\N	HS14.19/D_Primary	NA_HS14.19/D_Primary
96277	\N	\N	10808	10808	\N	HS14.19/D_Nevus	NA_HS14.19/D_Nevus
96278	\N	\N	10809	10809	\N	HS2014.15/7_Met1	NA_HS2014.15/7_Met1
96279	\N	\N	10810	10810	\N	HS2014.15/7_Normal	NA_HS2014.15/7_Normal
96280	\N	\N	10811	10811	\N	HS14.16_Primary	NA_HS14.16_Primary
96281	\N	\N	10812	10812	\N	HS14.16_Normal	NA_HS14.16_Normal
96282	\N	\N	10813	10813	\N	HS14.17/I_Met1	NA_HS14.17/I_Met1
96283	\N	\N	10814	10814	\N	Long-TN1_Normal	NA_Long-TN1_Normal
96284	\N	\N	10815	10815	\N	Long-TN1_Tumor	NA_Long-TN1_Tumor
96285	\N	\N	10816	10816	\N	Long-TN2_Normal	NA_Long-TN2_Normal
96286	\N	\N	10817	10817	\N	Long-TN2_Tumor	NA_Long-TN2_Tumor
96287	\N	\N	10818	10818	\N	D326_Tumor	NA_D326_Tumor
96288	\N	\N	10819	10818	\N	D326_Tumor	NA_D326_Tumor
96289	\N	\N	10820	10820	\N	D366_Tumor	NA_D366_Tumor
96290	\N	\N	10821	10820	\N	D366_Tumor	NA_D366_Tumor
96291	\N	\N	10822	10822	\N	DPN48_Tumor	NA_DPN48_Tumor
96292	\N	\N	10823	10823	\N	11-2532_Tumor	NA_11-2532_Tumor
96293	\N	\N	10824	10824	\N	AST-1_Tumor	NA_AST-1_Tumor
96294	\N	\N	10825	10825	\N	08-18595B_Tumor	NA_08-18595B_Tumor
96295	\N	\N	10826	10826	\N	13-60273_Tumor	NA_13-60273_Tumor
96296	\N	\N	10827	10827	\N	12-52454_Tumor	NA_12-52454_Tumor
96297	\N	\N	10828	10828	\N	12-75125_Tumor	NA_12-75125_Tumor
96298	\N	\N	10829	10829	\N	12-98235A_Tumor	NA_12-98235A_Tumor
96299	\N	\N	10830	10830	\N	13-3619B_Tumor	NA_13-3619B_Tumor
96300	\N	\N	10831	10831	\N	13-67500AL_Normal	NA_13-67500AL_Normal
96301	\N	\N	10832	10832	\N	13-19205_Tumor	NA_13-19205_Tumor
96302	\N	\N	10833	10833	\N	13-48330_Tumor	NA_13-48330_Tumor
96303	\N	\N	10834	10834	\N	13-11086_Tumor	NA_13-11086_Tumor
96304	\N	\N	10835	10835	\N	13-15966_Tumor	NA_13-15966_Tumor
96305	\N	\N	10836	10836	\N	13-39228_Tumor	NA_13-39228_Tumor
96306	\N	\N	10837	10837	\N	13-45942_Tumor	NA_13-45942_Tumor
96307	\N	\N	10838	10838	\N	13-49600_Tumor	NA_13-49600_Tumor
96308	\N	\N	10839	10839	\N	13-59640_Tumor	NA_13-59640_Tumor
96309	\N	\N	10840	10840	\N	13-67817_Tumor	NA_13-67817_Tumor
96310	\N	\N	10841	10841	\N	SP-12-5612(1K)_Normal	NA_SP-12-5612(1K)_Normal
96311	\N	\N	10842	10842	\N	SP-13-14992(1A)_Tumor	NA_SP-13-14992(1A)_Tumor
96312	\N	\N	10843	10843	\N	SP-12-2294-2(2A)_Normal	NA_SP-12-2294-2(2A)_Normal
96313	\N	\N	10844	10844	\N	SP-13-17075(1B)_Tumor	NA_SP-13-17075(1B)_Tumor
96314	\N	\N	10845	10845	\N	SP-42-10361(1A)_Normal	NA_SP-42-10361(1A)_Normal
96315	\N	\N	10846	10846	\N	SP-13-1038(1A)_Tumor	NA_SP-13-1038(1A)_Tumor
96316	\N	\N	10847	10847	\N	S13-13286A6_Tumor	NA_S13-13286A6_Tumor
96317	\N	\N	10848	10848	\N	S13-13286A6_Normal	NA_S13-13286A6_Normal
96318	\N	\N	10849	10849	\N	S11-20884A-A1_Tumor	NA_S11-20884A-A1_Tumor
96319	\N	\N	10850	10850	\N	S11-20884A-A1_Normal	NA_S11-20884A-A1_Normal
96320	\N	\N	10851	10851	\N	S12-6218A-D3_Tumor	NA_S12-6218A-D3_Tumor
96321	\N	\N	10852	10852	\N	S12-6218A-D3_Normal	NA_S12-6218A-D3_Normal
96322	\N	\N	10853	10853	\N	ZS06-11249A-C2_Tumor	NA_ZS06-11249A-C2_Tumor
96323	\N	\N	10854	10854	\N	S12-26125A2_Tumor	NA_S12-26125A2_Tumor
96324	\N	\N	10855	10855	\N	S12-28585A6_Tumor	NA_S12-28585A6_Tumor
96325	\N	\N	10856	10856	\N	S11-2018B5_Tumor	NA_S11-2018B5_Tumor
96326	\N	\N	10857	10857	\N	S13-11748F5_Tumor	NA_S13-11748F5_Tumor
96327	\N	\N	10858	10858	\N	S12-7250E3_Tumor	NA_S12-7250E3_Tumor
96328	\N	\N	10859	10859	\N	S13-3401B3_Tumor	NA_S13-3401B3_Tumor
96329	\N	\N	10860	10860	\N	S13-12947A2_Tumor	NA_S13-12947A2_Tumor
96330	\N	\N	10861	10861	\N	S13-18444A16_Tumor	NA_S13-18444A16_Tumor
96331	\N	\N	10862	10862	\N	ZS07-1210F6_Tumor	NA_ZS07-1210F6_Tumor
96332	\N	\N	10863	10863	\N	ZS10-11930B12_Tumor	NA_ZS10-11930B12_Tumor
96333	\N	\N	10864	10864	\N	S12-28988_Tumor	NA_S12-28988_Tumor
96334	\N	\N	10865	10865	\N	SSS13-1652B2_Tumor	NA_SSS13-1652B2_Tumor
96335	\N	\N	10866	10866	\N	S13-5249_Tumor	NA_S13-5249_Tumor
96336	\N	\N	10867	10780	\N	356A3-075_Tumor	NA_356A3-075_Tumor
96337	\N	\N	10868	10781	\N	20847-09_Normal	NA_20847-09_Normal
96338	\N	\N	10869	10869	\N	London-L1_Normal	NA_London-L1_Normal
96339	\N	\N	10870	10870	\N	London-L1_Nevus	NA_London-L1_Nevus
96340	\N	\N	10871	10871	\N	London-L1_MIS	NA_London-L1_MIS
96341	\N	\N	10872	10872	\N	London-L1_Melanoma	NA_London-L1_Melanoma
96342	\N	\N	10873	10873	\N	London-L14_Normal	NA_London-L14_Normal
96343	\N	\N	10874	10874	\N	London-L14_Nevus	NA_London-L14_Nevus
96344	\N	\N	10875	10874	\N	London-L14_Nevus	NA_London-L14_Nevus
96345	\N	\N	10876	10876	\N	London-L14_Melanoma	NA_London-L14_Melanoma
96346	\N	\N	10877	10876	\N	London-L14_Melanoma	NA_London-L14_Melanoma
96347	\N	\N	10878	10876	\N	London-L14_Melanoma	NA_London-L14_Melanoma
96348	\N	\N	10879	10879	\N	London-L14C_Normal	NA_London-L14C_Normal
96349	\N	\N	10880	10880	\N	London-L14C_Intermediate	NA_London-L14C_Intermediate
96350	\N	\N	10881	10881	\N	08-79358_Melanoma	NA_08-79358_Melanoma
96351	\N	\N	10882	10881	\N	08-79358_Melanoma	NA_08-79358_Melanoma
96352	\N	\N	10883	10883	\N	08-79358_Nevus	NA_08-79358_Nevus
96353	\N	\N	10884	10884	\N	08-79358_Normal	NA_08-79358_Normal
96354	\N	\N	10885	10885	\N	09-45509_Melanoma	NA_09-45509_Melanoma
96355	\N	\N	10886	10885	\N	09-45509_Melanoma	NA_09-45509_Melanoma
96356	\N	\N	10887	10887	\N	09-45509_Nevus	NA_09-45509_Nevus
96357	\N	\N	10888	10888	\N	09-45509_Normal	NA_09-45509_Normal
96358	\N	\N	10889	10889	\N	DM50_Tumor	NA_DM50_Tumor
96359	\N	\N	10890	10890	\N	DM56_Tumor	NA_DM56_Tumor
96360	\N	\N	10891	10891	\N	11-94204_Melanoma	NA_11-94204_Melanoma
96361	\N	\N	10892	10892	\N	11-94204_Nevus	NA_11-94204_Nevus
96362	\N	\N	10893	10893	\N	11-94204_Normal	NA_11-94204_Normal
96363	\N	\N	10894	10894	\N	London-L10_Normal	NA_London-L10_Normal
96364	\N	\N	10895	10895	\N	London-L10_MIS	NA_London-L10_MIS
96365	\N	\N	10896	10896	\N	London-L10_Melanoma	NA_London-L10_Melanoma
96366	\N	\N	10897	10897	\N	London-L10_Intermediate	NA_London-L10_Intermediate
96367	\N	\N	10898	10898	\N	London-L12_Normal	NA_London-L12_Normal
96473	\N	\N	11004	11004	\N	M257_Tumor	NA_M257_Tumor
96368	\N	\N	10899	10899	\N	London-L12_Nevus	NA_London-L12_Nevus
96369	\N	\N	10900	10900	\N	London-L12_Intermediate	NA_London-L12_Intermediate
96370	\N	\N	10901	10901	\N	London-L16_Nevus	NA_London-L16_Nevus
96371	\N	\N	10902	10902	\N	London-L16_Melanoma	NA_London-L16_Melanoma
96372	\N	\N	10903	10903	\N	London-L16A_Normal	NA_London-L16A_Normal
96373	\N	\N	10904	10904	\N	London-L16A_Nevus	NA_London-L16A_Nevus
96374	\N	\N	10905	10905	\N	London-L16A_Melanoma	NA_London-L16A_Melanoma
96375	\N	\N	10906	10906	\N	London-L16B_Intermediate	NA_London-L16B_Intermediate
96376	\N	\N	10907	10906	\N	London-L16B_Intermediate	NA_London-L16B_Intermediate
96377	\N	\N	10908	10908	\N	London-L16B_Normal	NA_London-L16B_Normal
96378	\N	\N	10909	10909	\N	DM15_Tumor	NA_DM15_Tumor
96379	\N	\N	10910	10910	\N	DM19_Tumor	NA_DM19_Tumor
96380	\N	\N	10911	10910	\N	DM19_Tumor	NA_DM19_Tumor
96381	\N	\N	10912	10912	\N	DM46_Tumor	NA_DM46_Tumor
96382	\N	\N	10913	10913	\N	140038340_Tumor	NA_140038340_Tumor
96383	\N	\N	10914	10914	\N	140092090_Normal	NA_140092090_Normal
96384	\N	\N	10915	10915	\N	UM13_Tumor	NA_UM13_Tumor
96385	\N	\N	10916	10916	\N	UM14_Tumor	NA_UM14_Tumor
96386	\N	\N	10917	10917	\N	UM16_Tumor	NA_UM16_Tumor
96387	\N	\N	10918	10918	\N	London-L17_Normal	NA_London-L17_Normal
96388	\N	\N	10919	10919	\N	London-L17_Nevus	NA_London-L17_Nevus
96389	\N	\N	10920	10919	\N	London-L17_Nevus	NA_London-L17_Nevus
96390	\N	\N	10921	10921	\N	London-L17_Melanoma	NA_London-L17_Melanoma
96391	\N	\N	10922	10921	\N	London-L17_Melanoma	NA_London-L17_Melanoma
96392	\N	\N	10923	10923	\N	GAK_Tumor	NA_GAK_Tumor
96393	\N	\N	10924	10924	\N	Yurif_Tumor	NA_Yurif_Tumor
96394	\N	\N	10925	10759	\N	08-53951_Nevus	NA_08-53951_Nevus
96395	\N	\N	10926	10926	\N	08-53951_M1	NA_08-53951_M1
96396	\N	\N	10927	10927	\N	08-53951_M2	NA_08-53951_M2
96397	\N	\N	10928	10928	\N	London-L18_Normal	NA_London-L18_Normal
96398	\N	\N	10929	10929	\N	London-L18_Nevus	NA_London-L18_Nevus
96399	\N	\N	10930	10930	\N	London-L18_Melanoma	NA_London-L18_Melanoma
96400	\N	\N	10931	10930	\N	London-L18_Melanoma	NA_London-L18_Melanoma
96401	\N	\N	10932	10932	\N	London-L21_MIS	NA_London-L21_MIS
96402	\N	\N	10933	10933	\N	London-L21_Intermediate	NA_London-L21_Intermediate
96403	\N	\N	10934	10934	\N	London-L21_Normal	NA_London-L21_Normal
96404	\N	\N	10935	10935	\N	14-16247_Tumor	NA_14-16247_Tumor
96405	\N	\N	10936	10936	\N	13-35959_Tumor	NA_13-35959_Tumor
96406	\N	\N	10937	10937	\N	13-102610_Tumor	NA_13-102610_Tumor
96407	\N	\N	10938	10938	\N	13-99417_Tumor	NA_13-99417_Tumor
96408	\N	\N	10939	10939	\N	13-98534_Tumor	NA_13-98534_Tumor
96409	\N	\N	10940	10940	\N	13-32982A_Tumor	NA_13-32982A_Tumor
96410	\N	\N	10941	10941	\N	13-9916_Tumor	NA_13-9916_Tumor
96411	\N	\N	10942	10942	\N	11-44609F_Tumor	NA_11-44609F_Tumor
96412	\N	\N	10943	10943	\N	12-98575A1_Tumor	NA_12-98575A1_Tumor
96413	\N	\N	10944	10944	\N	DM60_Tumor	NA_DM60_Tumor
96414	\N	\N	10945	10945	\N	DM61_Tumor	NA_DM61_Tumor
96415	\N	\N	10946	10946	\N	DM62_Tumor	NA_DM62_Tumor
96416	\N	\N	10947	10947	\N	DM63_Tumor	NA_DM63_Tumor
96417	\N	\N	10948	10948	\N	DM66_Tumor	NA_DM66_Tumor
96418	\N	\N	10949	10949	\N	DM67_Tumor	NA_DM67_Tumor
96419	\N	\N	10950	10950	\N	DM69_Tumor	NA_DM69_Tumor
96420	\N	\N	10951	10951	\N	DM70_Tumor	NA_DM70_Tumor
96421	\N	\N	10952	10952	\N	DM81_Tumor	NA_DM81_Tumor
96422	\N	\N	10953	10953	\N	London-L2_Normal	NA_London-L2_Normal
96423	\N	\N	10954	10954	\N	London-L2_Intermediate	NA_London-L2_Intermediate
96424	\N	\N	10955	10955	\N	London-L3_Normal	NA_London-L3_Normal
96425	\N	\N	10956	10956	\N	London-L3_Intermediate	NA_London-L3_Intermediate
96426	\N	\N	10957	10957	\N	S12-27617B9_Normal	NA_S12-27617B9_Normal
96427	\N	\N	10958	10958	\N	S12-25164A_Tumor	NA_S12-25164A_Tumor
96428	\N	\N	10959	10959	\N	S12-25164C1_Tumor	NA_S12-25164C1_Tumor
96429	\N	\N	10960	10960	\N	London-L19_Normal	NA_London-L19_Normal
96430	\N	\N	10961	10961	\N	London-L19_Nevus	NA_London-L19_Nevus
96431	\N	\N	10962	10962	\N	London-L19_Melanoma	NA_London-L19_Melanoma
96432	\N	\N	10963	10963	\N	London-L19E_Normal	NA_London-L19E_Normal
96433	\N	\N	10964	10964	\N	London-L19E_Nevus	NA_London-L19E_Nevus
96434	\N	\N	10965	10965	\N	London-L19E_Melanoma	NA_London-L19E_Melanoma
96435	\N	\N	10966	10966	\N	London-L22_MIS	NA_London-L22_MIS
96436	\N	\N	10967	10967	\N	London-L22_Melanoma	NA_London-L22_Melanoma
96437	\N	\N	10968	10968	\N	London-L22_Normal	NA_London-L22_Normal
96438	\N	\N	10969	10969	\N	London-L23_Melanoma	NA_London-L23_Melanoma
96439	\N	\N	10970	10970	\N	London-L23C_Normal	NA_London-L23C_Normal
96440	\N	\N	10971	10971	\N	London-L23C_Melanoma	NA_London-L23C_Melanoma
96441	\N	\N	10972	10972	\N	London-L23D_Normal	NA_London-L23D_Normal
96442	\N	\N	10973	10973	\N	London-L23D_Intermediate	NA_London-L23D_Intermediate
96443	\N	\N	10974	10974	\N	London-L6_Normal	NA_London-L6_Normal
96444	\N	\N	10975	10975	\N	London-L6_Nevus	NA_London-L6_Nevus
96445	\N	\N	10976	10975	\N	London-L6_Nevus	NA_London-L6_Nevus
96446	\N	\N	10977	10977	\N	XD-2_Tumor	NA_XD-2_Tumor
96447	\N	\N	10978	10978	\N	XD-2_Normal	NA_XD-2_Normal
96448	\N	\N	10979	10979	\N	SP-13-006364_Normal	NA_SP-13-006364_Normal
96449	\N	\N	10980	10980	\N	SP-14-001249_Tumor	NA_SP-14-001249_Tumor
96450	\N	\N	10981	10981	\N	SP-13-0185993A_Normal	NA_SP-13-0185993A_Normal
96451	\N	\N	10982	10982	\N	SP-13-0185992B_Tumor	NA_SP-13-0185992B_Tumor
96452	\N	\N	10983	10983	\N	SP-12-003309B_Normal	NA_SP-12-003309B_Normal
96453	\N	\N	10984	10984	\N	SP-13-0212981A_Tumor	NA_SP-13-0212981A_Tumor
96454	\N	\N	10985	10985	\N	SP-13-0068754A_Normal	NA_SP-13-0068754A_Normal
96455	\N	\N	10986	10986	\N	SP-13-0068751C_Tumor	NA_SP-13-0068751C_Tumor
96456	\N	\N	10987	10987	\N	SP-07-0116602_Normal	NA_SP-07-0116602_Normal
96457	\N	\N	10988	10988	\N	12GS-2466_Tumor	NA_12GS-2466_Tumor
96458	\N	\N	10989	10989	\N	SP-09-0150202A_Normal	NA_SP-09-0150202A_Normal
96459	\N	\N	10990	10990	\N	SP-13-006535C_Tumor	NA_SP-13-006535C_Tumor
96460	\N	\N	10991	10991	\N	SP-10-003167A_Normal	NA_SP-10-003167A_Normal
96461	\N	\N	10992	10992	\N	SP-13-009897_Tumor	NA_SP-13-009897_Tumor
96462	\N	\N	10993	10993	\N	SP-12-0087723B_Normal	NA_SP-12-0087723B_Normal
96463	\N	\N	10994	10994	\N	SP-12-020017C_Tumor	NA_SP-12-020017C_Tumor
96464	\N	\N	10995	10995	\N	SP-12-0032671A_Normal	NA_SP-12-0032671A_Normal
96465	\N	\N	10996	10996	\N	SP-13-006337A_Tumor	NA_SP-13-006337A_Tumor
96466	\N	\N	10997	10997	\N	SP-12-0228802A_Normal	NA_SP-12-0228802A_Normal
96467	\N	\N	10998	10998	\N	SP-12-0228801A_Tumor	NA_SP-12-0228801A_Tumor
96468	\N	\N	10999	10999	\N	SP-12-0146612A_Normal	NA_SP-12-0146612A_Normal
96469	\N	\N	11000	11000	\N	SP-12-01466111A_Tumor	NA_SP-12-01466111A_Tumor
96470	\N	\N	11001	11001	\N	SP-10-004335_Normal	NA_SP-10-004335_Normal
96471	\N	\N	11002	11002	\N	SP-13-000848_Tumor	NA_SP-13-000848_Tumor
96474	\N	\N	11005	11005	\N	M285_Tumor	NA_M285_Tumor
96475	\N	\N	11006	11006	\N	M368_Tumor	NA_M368_Tumor
96476	\N	\N	11007	11007	\N	M375_Tumor	NA_M375_Tumor
96477	\N	\N	11008	11008	\N	M418_Tumor	NA_M418_Tumor
96478	\N	\N	11009	11009	\N	C8161_Tumor	NA_C8161_Tumor
96479	\N	\N	11010	11010	\N	London-L4_Normal	NA_London-L4_Normal
96480	\N	\N	11011	11011	\N	London-L4_Nevus	NA_London-L4_Nevus
96481	\N	\N	11012	11012	\N	London-L5_Normal	NA_London-L5_Normal
96482	\N	\N	11013	11013	\N	London-L5_Nevus	NA_London-L5_Nevus
96483	\N	\N	11014	11014	\N	London-L8_Normal	NA_London-L8_Normal
96484	\N	\N	11015	11015	\N	London-L8_Nevus	NA_London-L8_Nevus
96485	\N	\N	11016	11016	\N	London-L9_Normal	NA_London-L9_Normal
96486	\N	\N	11017	11017	\N	London-L9_Intermediate	NA_London-L9_Intermediate
96487	\N	\N	11018	11018	\N	London-L13_Normal	NA_London-L13_Normal
96488	\N	\N	11019	11019	\N	London-L13_Intermediate	NA_London-L13_Intermediate
96489	\N	\N	11020	11019	\N	London-L13_Intermediate	NA_London-L13_Intermediate
96490	\N	\N	11021	11021	\N	London-L15_Nevus	NA_London-L15_Nevus
96491	\N	\N	11022	11022	\N	London-L15_Melanoma	NA_London-L15_Melanoma
96492	\N	\N	11023	11023	\N	1212_Tumor	NA_1212_Tumor
96493	\N	\N	11024	11024	\N	1213_Tumor	NA_1213_Tumor
96494	\N	\N	11025	11025	\N	1214_Tumor	NA_1214_Tumor
96495	\N	\N	11026	11026	\N	3860_Tumor	NA_3860_Tumor
96496	\N	\N	11027	10751	\N	R29032-05_Tumor	NA_R29032-05_Tumor
96497	\N	\N	11028	10753	\N	01-8297_Tumor	NA_01-8297_Tumor
96498	\N	\N	11029	10755	\N	8298-01_Tumor	NA_8298-01_Tumor
96499	\N	\N	11030	10768	\N	Z1188-03_Tumor	NA_Z1188-03_Tumor
96500	\N	\N	11031	10773	\N	24516-06_Tumor	NA_24516-06_Tumor
96501	\N	\N	11032	11032	\N	UM17_Tumor	NA_UM17_Tumor
96502	\N	\N	11033	11033	\N	S12-23475A6_Normal	NA_S12-23475A6_Normal
96503	\N	\N	11034	11034	\N	S12-23475A4_Tumor	NA_S12-23475A4_Tumor
96504	\N	\N	11035	11035	\N	S12-23475C1_Tumor	NA_S12-23475C1_Tumor
96505	\N	\N	11036	11036	\N	13-21725_Normal	NA_13-21725_Normal
96506	\N	\N	11037	11037	\N	SP-14-68521D_Tumor	NA_SP-14-68521D_Tumor
96507	\N	\N	11038	11038	\N	SP-13-208365A_Normal	NA_SP-13-208365A_Normal
96508	\N	\N	11039	11039	\N	SP-14-36134A_Tumor	NA_SP-14-36134A_Tumor
96509	\N	\N	11040	11040	\N	SP-14-73676A_Normal	NA_SP-14-73676A_Normal
96510	\N	\N	11041	11041	\N	SP-14-73671M_Tumor	NA_SP-14-73671M_Tumor
96511	\N	\N	11042	11042	\N	SP-14-7691A_Normal	NA_SP-14-7691A_Normal
96512	\N	\N	11043	11043	\N	SP-14-7691A_Tumor	NA_SP-14-7691A_Tumor
96513	\N	\N	11044	11044	\N	WM3928F_Tumor	NA_WM3928F_Tumor
96514	\N	\N	11045	11045	\N	C037_Tumor	NA_C037_Tumor
96515	\N	\N	11046	11046	\N	C022_Tumor	NA_C022_Tumor
96516	\N	\N	11047	10377	\N	London-L20_Melanoma	NA_London-L20_Melanoma
96517	\N	\N	11048	10378	\N	London-L20_Normal	NA_London-L20_Normal
96518	\N	\N	11049	10379	\N	London-L20_Nevus	NA_London-L20_Nevus
96519	\N	\N	11050	10380	\N	London-L15_Normal	NA_London-L15_Normal
96520	\N	\N	11051	10381	\N	London-L23C_Nevus	NA_London-L23C_Nevus
96521	\N	\N	11052	11052	\N	UM15_Tumor	NA_UM15_Tumor
96522	\N	\N	11053	11053	\N	UM19_Tumor	NA_UM19_Tumor
96523	\N	\N	11054	11054	\N	UM20_Tumor	NA_UM20_Tumor
96524	\N	\N	11055	11055	\N	CP-1_Tumor	NA_CP-1_Tumor
96525	\N	\N	11056	11056	\N	CP-2_Tumor	NA_CP-2_Tumor
96526	\N	\N	11057	11057	\N	CP-3_Tumor	NA_CP-3_Tumor
96527	\N	\N	11058	11058	\N	CP-4_Tumor	NA_CP-4_Tumor
96528	\N	\N	11059	11059	\N	CP-5_Tumor	NA_CP-5_Tumor
96529	\N	\N	11060	11060	\N	CP-6_Tumor	NA_CP-6_Tumor
96530	\N	\N	11061	11061	\N	14-18_Tumor	NA_14-18_Tumor
96531	\N	\N	11062	11062	\N	14-19_Tumor	NA_14-19_Tumor
96532	\N	\N	11063	11063	\N	14-21_Tumor	NA_14-21_Tumor
96533	\N	\N	11064	11064	\N	XD-1_Tumor	NA_XD-1_Tumor
96534	\N	\N	11065	11065	\N	XD-1.1_Tumor	NA_XD-1.1_Tumor
96535	\N	\N	11066	11066	\N	PMM-8_Tumor	NA_PMM-8_Tumor
96536	\N	\N	11067	11067	\N	Long-TN10_Normal	NA_Long-TN10_Normal
96537	\N	\N	11068	11068	\N	Long-TN10_Tumor	NA_Long-TN10_Tumor
96538	\N	\N	11069	11069	\N	Long-TN11_Normal	NA_Long-TN11_Normal
96539	\N	\N	11070	11070	\N	Long-TN11_Tumor	NA_Long-TN11_Tumor
96540	\N	\N	11071	11071	\N	JBP-3_Normal	NA_JBP-3_Normal
96541	\N	\N	11072	11072	\N	JBP-3-MM_Tumor	NA_JBP-3-MM_Tumor
96542	\N	\N	11073	11073	\N	JBP-3-Met1_Tumor	NA_JBP-3-Met1_Tumor
96543	\N	\N	11074	11074	\N	S12-15765B3_Tumor	NA_S12-15765B3_Tumor
96544	\N	\N	11075	11075	\N	S12-4365A8_Normal	NA_S12-4365A8_Normal
96545	\N	\N	11076	11076	\N	S12-4365A7_Tumor	NA_S12-4365A7_Tumor
96546	\N	\N	11077	11077	\N	S12-4365B1_Tumor	NA_S12-4365B1_Tumor
96547	\N	\N	11078	11078	\N	S12-4365C1_Tumor	NA_S12-4365C1_Tumor
96548	\N	\N	11079	11079	\N	S12-9606C4_Normal	NA_S12-9606C4_Normal
96549	\N	\N	11080	11080	\N	S12-9606EE_Tumor	NA_S12-9606EE_Tumor
96550	\N	\N	11081	11081	\N	S12-9606A2_Tumor	NA_S12-9606A2_Tumor
96551	\N	\N	11082	11082	\N	ZS10-972C2_Normal	NA_ZS10-972C2_Normal
96552	\N	\N	11083	11083	\N	ZS10-972A9_Tumor	NA_ZS10-972A9_Tumor
96553	\N	\N	11084	11084	\N	JBP-7-Met_Tumor	NA_JBP-7-Met_Tumor
96554	\N	\N	11085	11085	\N	ZS10-1843A5_Normal	NA_ZS10-1843A5_Normal
96555	\N	\N	11086	11086	\N	ZS10-8439A4_Tumor	NA_ZS10-8439A4_Tumor
96556	\N	\N	11087	11087	\N	ZS10-1843A4_Tumor	NA_ZS10-1843A4_Tumor
96557	\N	\N	11088	11088	\N	ZS10-10558B1_Normal	NA_ZS10-10558B1_Normal
96558	\N	\N	11089	11089	\N	ZS10-10558A10_Tumor	NA_ZS10-10558A10_Tumor
96559	\N	\N	11090	11090	\N	ZS10-10558C1_Tumor	NA_ZS10-10558C1_Tumor
96560	\N	\N	11091	11091	\N	ZS10-3560F1_Normal	NA_ZS10-3560F1_Normal
96561	\N	\N	11092	11092	\N	ZS10-3560A3_Tumor	NA_ZS10-3560A3_Tumor
96562	\N	\N	11093	11093	\N	ZS10-3560C1_Tumor	NA_ZS10-3560C1_Tumor
96563	\N	\N	11094	11094	\N	UM23_Tumor	NA_UM23_Tumor
96564	\N	\N	11095	11095	\N	UM24_Tumor	NA_UM24_Tumor
96565	\N	\N	11096	11096	\N	UM25_Tumor	NA_UM25_Tumor
96566	\N	\N	11097	11097	\N	UM26_Tumor	NA_UM26_Tumor
96567	\N	\N	11098	11098	\N	TCR-Beta-1_Tumor	NA_TCR-Beta-1_Tumor
96568	\N	\N	11099	11099	\N	TCR-Beta-2_Tumor	NA_TCR-Beta-2_Tumor
96569	\N	\N	11100	4599	\N	CP1-80_Tumor	NA_CP1-80_Tumor
96570	\N	\N	11101	4598	\N	CP1-40_Tumor	NA_CP1-40_Tumor
96571	\N	\N	11102	4597	\N	CP1-20_Tumor	NA_CP1-20_Tumor
96572	\N	\N	11103	4596	\N	CP1-10_Tumor	NA_CP1-10_Tumor
96573	\N	\N	11104	4595	\N	CP1-5_Tumor	NA_CP1-5_Tumor
96574	\N	\N	11105	4600	\N	CP1_Normal	NA_CP1_Normal
96575	\N	\N	11106	11106	\N	SMU10-0457_Tumor	NA_SMU10-0457_Tumor
96576	\N	\N	11107	11107	\N	SMU10-0206_Tumor	NA_SMU10-0206_Tumor
96577	\N	\N	11108	11108	\N	SMU10-0240_Tumor	NA_SMU10-0240_Tumor
96578	\N	\N	11109	11109	\N	SCC10-0092_Tumor	NA_SCC10-0092_Tumor
96579	\N	\N	11110	11110	\N	MASCRI-432_Tumor	NA_MASCRI-432_Tumor
96580	\N	\N	11111	11111	\N	RPA08-0209_Tumor	NA_RPA08-0209_Tumor
96581	\N	\N	11112	11112	\N	RPA08-0315_Tumor	NA_RPA08-0315_Tumor
96582	\N	\N	11113	11113	\N	NZM52_Tumor	NA_NZM52_Tumor
96583	\N	\N	11114	11114	\N	NZM40_Tumor	NA_NZM40_Tumor
96584	\N	\N	11115	11115	\N	NZM91_Tumor	NA_NZM91_Tumor
96585	\N	\N	11116	11116	\N	SP-13-198211A_Tumor	NA_SP-13-198211A_Tumor
96586	\N	\N	11117	11117	\N	RNS11P15316B1_Normal	NA_RNS11P15316B1_Normal
96587	\N	\N	11118	11118	\N	9246581-A3_Tumor	NA_9246581-A3_Tumor
96588	\N	\N	11119	11119	\N	9246581-A6_Normal	NA_9246581-A6_Normal
96589	\N	\N	11120	11120	\N	DHM4855-14MP_Tumor	NA_DHM4855-14MP_Tumor
96590	\N	\N	11121	11121	\N	SNPN08289D_Normal	NA_SNPN08289D_Normal
96591	\N	\N	11122	11122	\N	SP-10-143551E_Tumor	NA_SP-10-143551E_Tumor
96592	\N	\N	11123	11123	\N	SP-10-143552A_Normal	NA_SP-10-143552A_Normal
96593	\N	\N	11124	11124	\N	04-SW-12-31366B1_Tumor	NA_04-SW-12-31366B1_Tumor
96594	\N	\N	11125	11125	\N	04-SW-12-31366B6_Normal	NA_04-SW-12-31366B6_Normal
96595	\N	\N	11126	11126	\N	SP-13-63011A_Tumor	NA_SP-13-63011A_Tumor
96596	\N	\N	11127	11127	\N	SP-11-160493A_Normal	NA_SP-11-160493A_Normal
96597	\N	\N	11128	11128	\N	SP-13-87981B_Tumor	NA_SP-13-87981B_Tumor
96598	\N	\N	11129	11129	\N	SP-11-40641B_Normal	NA_SP-11-40641B_Normal
96599	\N	\N	11130	11130	\N	SP-14-125801B_Tumor	NA_SP-14-125801B_Tumor
96600	\N	\N	11131	11131	\N	SP-14-125802A_Normal	NA_SP-14-125802A_Normal
96601	\N	\N	11132	11132	\N	WCRS97-025628_Tumor	NA_WCRS97-025628_Tumor
96602	\N	\N	11133	11133	\N	SCHS10-026422_Tumor	NA_SCHS10-026422_Tumor
96603	\N	\N	11134	11134	\N	SROS12-001198_Tumor	NA_SROS12-001198_Tumor
96604	\N	\N	11135	11135	\N	SROS09-001574_Tumor	NA_SROS09-001574_Tumor
96605	\N	\N	11136	11136	\N	SCHS09-005840-B5_Tumor	NA_SCHS09-005840-B5_Tumor
96606	\N	\N	11137	11137	\N	SACS05-011507_Tumor	NA_SACS05-011507_Tumor
96607	\N	\N	11138	11138	\N	FRSS09-009402-A1_Tumor	NA_FRSS09-009402-A1_Tumor
96608	\N	\N	11139	11139	\N	RCHS07-000380-B1_Tumor	NA_RCHS07-000380-B1_Tumor
96609	\N	\N	11140	11140	\N	SROS11-005030_Tumor	NA_SROS11-005030_Tumor
96610	\N	\N	11141	11141	\N	VALS09-000266_Tumor	NA_VALS09-000266_Tumor
96611	\N	\N	11142	11142	\N	SFOS09-007093_Tumor	NA_SFOS09-007093_Tumor
96612	\N	\N	11143	11143	\N	FRSS09-008805_Tumor	NA_FRSS09-008805_Tumor
96613	\N	\N	11144	11144	\N	RCHS06-004567_Tumor	NA_RCHS06-004567_Tumor
96614	\N	\N	11145	11145	\N	VALS05-014946-E_Tumor	NA_VALS05-014946-E_Tumor
96615	\N	\N	11146	11146	\N	SCHS08-007754_Tumor	NA_SCHS08-007754_Tumor
96616	\N	\N	11147	11147	\N	SFOS12-018173_Tumor	NA_SFOS12-018173_Tumor
96617	\N	\N	11148	11148	\N	SROS00-001103_Tumor	NA_SROS00-001103_Tumor
96618	\N	\N	11149	11149	\N	MTZS94-007340_Tumor	NA_MTZS94-007340_Tumor
96619	\N	\N	11150	11150	\N	SFOS94-003116_Tumor	NA_SFOS94-003116_Tumor
96620	\N	\N	11151	11151	\N	SACS93-027850_Tumor	NA_SACS93-027850_Tumor
96621	\N	\N	11152	11152	\N	SCLS91-006557_Tumor	NA_SCLS91-006557_Tumor
96622	\N	\N	11153	11153	\N	OAKS90-012369_Tumor	NA_OAKS90-012369_Tumor
96623	\N	\N	11154	11154	\N	HAYS02-005731_Tumor	NA_HAYS02-005731_Tumor
96624	\N	\N	11155	11155	\N	SRFS97-002805_Tumor	NA_SRFS97-002805_Tumor
96625	\N	\N	11156	11156	\N	VALS03-019832_Tumor	NA_VALS03-019832_Tumor
96626	\N	\N	11157	11157	\N	SSCS03-014369_Tumor	NA_SSCS03-014369_Tumor
96627	\N	\N	11158	11158	\N	RCHS01-003684_Tumor	NA_RCHS01-003684_Tumor
96628	\N	\N	11159	11159	\N	WCRS99-012800_Tumor	NA_WCRS99-012800_Tumor
96629	\N	\N	11160	11160	\N	HAYS90-005154_Tumor	NA_HAYS90-005154_Tumor
96630	\N	\N	11161	11161	\N	SFOS00-016989_Tumor	NA_SFOS00-016989_Tumor
96631	\N	\N	11162	11162	\N	VALS03-007457_Tumor	NA_VALS03-007457_Tumor
96632	\N	\N	11163	11163	\N	SFO93-005184_Tumor	NA_SFO93-005184_Tumor
96633	\N	\N	11164	11164	\N	DHM50691-14MP5C_Tumor	NA_DHM50691-14MP5C_Tumor
96634	\N	\N	11165	11165	\N	DHM50691-14MP3_Normal	NA_DHM50691-14MP3_Normal
96635	\N	\N	11166	11166	\N	RNS14P13907B1_Tumor	NA_RNS14P13907B1_Tumor
96636	\N	\N	11167	11167	\N	SP-10-197431A_Normal	NA_SP-10-197431A_Normal
96637	\N	\N	11168	11168	\N	DHM57444-14MP_Tumor	NA_DHM57444-14MP_Tumor
96638	\N	\N	11169	11169	\N	SP-12-177322A_Normal	NA_SP-12-177322A_Normal
96639	\N	\N	11170	11170	\N	DHM94457-13SK_Tumor	NA_DHM94457-13SK_Tumor
96640	\N	\N	11171	11171	\N	DHM48742-12MPE_Normal	NA_DHM48742-12MPE_Normal
96641	\N	\N	11172	11172	\N	Laverty13-88354_Tumor	NA_Laverty13-88354_Tumor
96642	\N	\N	11173	11173	\N	ICPMR19684.13A11_Normal	NA_ICPMR19684.13A11_Normal
96643	\N	\N	11174	11174	\N	SP-13-15691B_Tumor	NA_SP-13-15691B_Tumor
96644	\N	\N	11175	11175	\N	SP-13-15691D_Normal	NA_SP-13-15691D_Normal
96645	\N	\N	11176	11176	\N	57059699_Tumor	NA_57059699_Tumor
96646	\N	\N	11177	11177	\N	57269600_Tumor	NA_57269600_Tumor
96647	\N	\N	11178	11178	\N	57213442_Tumor	NA_57213442_Tumor
96648	\N	\N	11179	11179	\N	57346060_Tumor	NA_57346060_Tumor
96649	\N	\N	11180	11180	\N	SROS10-009251_Tumor	NA_SROS10-009251_Tumor
96650	\N	\N	11181	11181	\N	FRSS99-007026_Tumor	NA_FRSS99-007026_Tumor
96651	\N	\N	11182	11182	\N	SCLS04-001045_Tumor	NA_SCLS04-001045_Tumor
96652	\N	\N	11183	11183	\N	OAKS96-014392-G_Tumor	NA_OAKS96-014392-G_Tumor
96653	\N	\N	11184	11184	\N	OAKS96-022398_Tumor	NA_OAKS96-022398_Tumor
96654	\N	\N	11185	11185	\N	OAK84-008979-B_Tumor	NA_OAK84-008979-B_Tumor
96655	\N	\N	11186	11186	\N	ROSS09-022626-A1_Tumor	NA_ROSS09-022626-A1_Tumor
96656	\N	\N	11187	11187	\N	SCHS11-018842-A1_Tumor	NA_SCHS11-018842-A1_Tumor
96657	\N	\N	11188	11188	\N	SSCS03-004945_Tumor	NA_SSCS03-004945_Tumor
96658	\N	\N	11189	11189	\N	WCRS02-022688_Tumor	NA_WCRS02-022688_Tumor
96659	\N	\N	11190	11190	\N	SACS02-020334_Tumor	NA_SACS02-020334_Tumor
96660	\N	\N	11191	11191	\N	HAYS98-001046_Tumor	NA_HAYS98-001046_Tumor
96661	\N	\N	11192	11192	\N	SACS88-019073_Tumor	NA_SACS88-019073_Tumor
96662	\N	\N	11193	11193	\N	SACS87-010145_Tumor	NA_SACS87-010145_Tumor
96663	\N	\N	11194	11194	\N	STRS91-006237_Tumor	NA_STRS91-006237_Tumor
96664	\N	\N	11195	11195	\N	SSCS92-009981_Tumor	NA_SSCS92-009981_Tumor
96665	\N	\N	11196	11196	\N	14-59304A_Normal	NA_14-59304A_Normal
96666	\N	\N	11197	11197	\N	14-59304A_Nevus	NA_14-59304A_Nevus
96667	\N	\N	11198	11198	\N	13-48020_Normal	NA_13-48020_Normal
96668	\N	\N	11199	11199	\N	13-48020_Nevus	NA_13-48020_Nevus
96669	\N	\N	11200	11200	\N	14-13499_Normal	NA_14-13499_Normal
96670	\N	\N	11201	11201	\N	14-13499_Nevus	NA_14-13499_Nevus
96671	\N	\N	11202	11202	\N	13-64515B_Normal	NA_13-64515B_Normal
96672	\N	\N	11203	11203	\N	13-64515B_Nevus	NA_13-64515B_Nevus
96673	\N	\N	11204	11204	\N	13-64515B_Tumor	NA_13-64515B_Tumor
96674	\N	\N	11205	11205	\N	14-22939_Nevus	NA_14-22939_Nevus
96675	\N	\N	11206	11206	\N	14-22939_Tumor	NA_14-22939_Tumor
96676	\N	\N	11207	11207	\N	13-61146_Normal	NA_13-61146_Normal
96677	\N	\N	11208	11208	\N	13-61146_Nevus	NA_13-61146_Nevus
96678	\N	\N	11209	11209	\N	13-61146_Tumor	NA_13-61146_Tumor
96679	\N	\N	11210	11210	\N	57001550_Tumor	NA_57001550_Tumor
96680	\N	\N	11211	11211	\N	57291680_Tumor	NA_57291680_Tumor
96681	\N	\N	11212	11212	\N	London-L3_Tumor	NA_London-L3_Tumor
96682	\N	\N	11213	11213	\N	London-L13_Tumor	NA_London-L13_Tumor
96683	\N	\N	11214	11212	\N	London-L3_Tumor	NA_London-L3_Tumor
96684	\N	\N	11215	11212	\N	London-L3_Tumor	NA_London-L3_Tumor
96685	\N	\N	11216	11212	\N	London-L3_Tumor	NA_London-L3_Tumor
96686	\N	\N	11217	11212	\N	London-L3_Tumor	NA_London-L3_Tumor
96687	\N	\N	11218	11213	\N	London-L13_Tumor	NA_London-L13_Tumor
96688	\N	\N	11219	11213	\N	London-L13_Tumor	NA_London-L13_Tumor
96689	\N	\N	11220	11220	\N	UM33_Tumor	NA_UM33_Tumor
96690	\N	\N	11221	11221	\N	UM35_A_Tumor	NA_UM35_A_Tumor
96691	\N	\N	11222	11222	\N	UM39_Tumor	NA_UM39_Tumor
96692	\N	\N	11223	11223	\N	UM40_Tumor	NA_UM40_Tumor
96693	\N	\N	11224	11224	\N	UM41_Tumor	NA_UM41_Tumor
96694	\N	\N	11225	11225	\N	UM36_Tumor	NA_UM36_Tumor
96695	\N	\N	11226	11226	\N	UM37_Tumor	NA_UM37_Tumor
96696	\N	\N	11227	11213	\N	London-L13_Tumor	NA_London-L13_Tumor
96697	\N	\N	11228	11228	\N	57715138_Tumor	NA_57715138_Tumor
96698	\N	\N	11229	11228	\N	57715138_Tumor	NA_57715138_Tumor
96699	\N	\N	11230	11230	\N	332771_Tumor	NA_332771_Tumor
96700	\N	\N	11231	11231	\N	57723220_Tumor	NA_57723220_Tumor
96701	\N	\N	11232	11232	\N	55875588_Tumor	NA_55875588_Tumor
96702	\N	\N	11233	11233	\N	57714581_Tumor	NA_57714581_Tumor
96703	\N	\N	11234	11234	\N	UM47_Tumor	NA_UM47_Tumor
96704	\N	\N	11235	11235	\N	UM47_Normal	NA_UM47_Normal
96705	\N	\N	11236	11236	\N	Sample_KAM1-T_Tumor	NA_Sample_KAM1-T_Tumor
96706	\N	\N	11237	11237	\N	Sample_KAM106-T_Tumor	NA_Sample_KAM106-T_Tumor
96707	\N	\N	11238	11238	\N	Sample_KAM12-T_Tumor	NA_Sample_KAM12-T_Tumor
96708	\N	\N	11239	11239	\N	Sample_KAM121-T-B_Tumor	NA_Sample_KAM121-T-B_Tumor
96709	\N	\N	11240	11240	\N	Sample_KAM20-T_Tumor	NA_Sample_KAM20-T_Tumor
96710	\N	\N	11241	11241	\N	Sample_KAM3-T-A_Tumor	NA_Sample_KAM3-T-A_Tumor
96711	\N	\N	11242	11242	\N	Sample_KAM35-T_Tumor	NA_Sample_KAM35-T_Tumor
96712	\N	\N	11243	11243	\N	Sample_KAM38-T-B_Tumor	NA_Sample_KAM38-T-B_Tumor
96713	\N	\N	11244	11244	\N	Sample_KAM53-T_Tumor	NA_Sample_KAM53-T_Tumor
96714	\N	\N	11245	11245	\N	Sample_KAM61-T_Tumor	NA_Sample_KAM61-T_Tumor
96715	\N	\N	11246	11246	\N	Sample_KAM7-T_Tumor	NA_Sample_KAM7-T_Tumor
96716	\N	\N	11247	11247	\N	Sample_KAM78-T-III_Tumor	NA_Sample_KAM78-T-III_Tumor
96717	\N	\N	11248	11248	\N	Sample_KAM82-T-B8_Tumor	NA_Sample_KAM82-T-B8_Tumor
96718	\N	\N	11249	11249	\N	Sample_KAM84-T_Tumor	NA_Sample_KAM84-T_Tumor
96719	\N	\N	11250	11250	\N	Sample_KAM94-T_Tumor	NA_Sample_KAM94-T_Tumor
96720	\N	\N	11251	11251	\N	Sample_KAM96-T_Tumor	NA_Sample_KAM96-T_Tumor
\.


--
-- Data for Name: areas; Type: TABLE DATA; Schema: public; Owner: borisbastian
--

COPY public.areas (ar_id, name, area_type, completion_date, image, notes, block, _blockname) FROM stdin;
2857	2857 Unknown	Unknown	\N	\N	\N	\N	\N
1856	1856 Normal	Normal	\N	\N	\N	\N	00-556A
1855	1855 Mel	Mel	\N	\N	\N	\N	00-556B
1857	1857 MIS	MIS	\N	\N	\N	\N	00-556B
2715	2715 Tumor	Tumor	\N	\N	\N	\N	00-001103
2750	2750 Normal	Normal	\N	\N	\N	\N	00-001103B7
1847	1847 Mel	Mel	\N	\N	\N	\N	00-4845
1848	1848 Normal	Normal	\N	\N	\N	\N	00-4845
1820	1820 Mel	Mel	\N	\N	\N	\N	00-5989A2
1821	1821 Normal	Normal	\N	\N	\N	\N	00-5989A2
1098	1098 Mel	Mel	\N	\N	\N	\N	00-06521B T3
1769	1769 Mel	Mel	\N	\N	\N	\N	00-7684A2
936	936 Mel	Mel	\N	\N	\N	\N	00-09653C M1
937	937 Mel	Mel	\N	\N	\N	\N	00-11793E M1
1099	1099 Mel	Mel	\N	\N	\N	\N	00-12952-3 T2
1645	1645 Mel	Mel	\N	\N	\N	\N	00-14127B
938	938 Mel	Mel	\N	\N	\N	\N	00-15034-1B M1
1100	1100 Mel	Mel	\N	\N	\N	\N	00-15364 T2
1027	1027 Mel	Mel	\N	\N	\N	\N	00-16651B T1
632	632 Mel	Mel	\N	\N	\N	\N	00-21551 T3
1033	1033 Mel	Mel	\N	\N	\N	\N	00-23160D T1
1097	1097 Mel	Mel	\N	\N	\N	\N	00-24216D T4
1767	1767 Mel	Mel	\N	\N	\N	\N	00-26584A1
1768	1768 Normal	Normal	\N	\N	\N	\N	00-26584A1
972	972 Mel	Mel	\N	\N	\N	\N	00-27758D M1
633	633 Mel	Mel	\N	\N	\N	\N	01-00027 T1
971	971 Mel	Mel	\N	\N	\N	\N	01-00467B N1
1095	1095 Mel	Mel	\N	\N	\N	\N	01-1112 T2
2730	2730 Tumor	Tumor	\N	\N	\N	\N	01-003845
1765	1765 Mel	Mel	\N	\N	\N	\N	01-6748
1766	1766 Normal	Normal	\N	\N	\N	\N	01-6748
634	634 Mel	Mel	\N	\N	\N	\N	01-07957 T4
1076	1076 Mel	Mel	\N	\N	\N	\N	01-10208A T1
1947	1947 Melanocytoma	Melanocytoma	\N	\N	\N	\N	01-10896
1948	1948 Nevus	Nevus	\N	\N	\N	\N	01-10896
1949	1949 Normal	Normal	\N	\N	\N	\N	01-10896
1803	1803 Mel	Mel	\N	\N	\N	\N	01-11378A2
1804	1804 Normal	Normal	\N	\N	\N	\N	01-11378A2
1053	1053 Mel	Mel	\N	\N	\N	\N	01-15780R T1
1693	1693 Mel	Mel	\N	\N	\N	\N	01-16263
1694	1694 MIS	MIS	\N	\N	\N	\N	01-16263
1096	1096 Mel	Mel	\N	\N	\N	\N	01-17200 T3
1657	1657 Mel	Mel	\N	\N	\N	\N	01-18107A
635	635 Mel	Mel	\N	\N	\N	\N	01-20248 T3
1094	1094 Mel	Mel	\N	\N	\N	\N	01-26615B T2
1851	1851 Mel	Mel	\N	\N	\N	\N	01-34127A
1852	1852 Normal	Normal	\N	\N	\N	\N	01-34127B
2732	2732 Tumor	Tumor	\N	\N	\N	\N	02-000540
974	974 Mel	Mel	\N	\N	\N	\N	02-00594E M1
2254	2254 Tumor	Tumor	2019-07-19 00:00:00-07	\N	Metastatic	\N	02-1274B1
2756	2756 MVP	MVP	\N	\N	\N	\N	02-5203B2
2755	2755 Normal	Normal	\N	\N	\N	\N	02-5203G2
1652	1652 Mel	Mel	\N	\N	\N	\N	02-5600A
636	636 Mel	Mel	\N	\N	\N	\N	02-05776 T1
1023	1023 Mel	Mel	\N	\N	\N	\N	02-05776D T1
1641	1641 Mel	Mel	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. http://64.54.108.147/eSlideTray.php?ImageIds=22989,22990,22991,22992  http://64.54.108.147/eSlideTray.php?ImageIds=21403\n	\N	02-7356
1642	1642 Nevus	Nevus	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. http://64.54.108.147/eSlideTray.php?ImageIds=22989,22990,22991,22992  http://64.54.108.147/eSlideTray.php?ImageIds=21403\n	\N	02-7356
1956	1956 Normal	Normal	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus.	\N	02-7356
2723	2723 Tumor	Tumor	\N	\N	\N	\N	02-008514
1646	1646 Mel	Mel	\N	\N	\N	\N	02-8746A
1647	1647 Mel	Mel	\N	\N	\N	\N	02-8746B
939	939 Mel	Mel	\N	\N	\N	\N	02-11468D M1
2716	2716 Normal	Normal	\N	\N	\N	\N	02-012396A
942	942 Mel	Mel	\N	\N	\N	\N	02-16325B M1
973	973 Mel	Mel	\N	\N	\N	\N	02-16797C M1
1091	1091 Mel	Mel	\N	\N	\N	\N	02-17209C T2
1665	1665 Mel	Mel	\N	\N	\N	\N	02-17626
2717	2717 Tumor	Tumor	\N	\N	\N	\N	02-020334-11
1093	1093 Mel	Mel	\N	\N	\N	\N	02-20495B T2
1724	1724 Mel	Mel	\N	\N	\N	\N	02-20619B
1725	1725 Normal	Normal	\N	\N	\N	\N	02-20619B
1726	1726 MIS	MIS	\N	\N	\N	\N	02-20619B
3871	3871 Tumor	Tumor	\N	\N	\N	\N	02-20629
1090	1090 Mel	Mel	\N	\N	\N	\N	02-20732 T2
941	941 Mel	Mel	\N	\N	\N	\N	02-22662B M1
940	940 Mel	Mel	\N	\N	\N	\N	02-22843 M1
3075	3075 Tumor	Tumor	\N	\N	\N	\N	02-23636A-02
1089	1089 Mel	Mel	\N	\N	\N	\N	02-26442 T4
1092	1092 Mel	Mel	\N	\N	\N	\N	02-28682 T4
1666	1666 Mel	Mel	\N	\N	\N	\N	02-28807
3076	3076 Normal	Normal	\N	\N	\N	\N	02-33818A-03
3077	3077 Tumor	Tumor	\N	\N	\N	\N	02-33818A-03
2774	2774 Tumor	Tumor	\N	\N	\N	\N	02-42436
1660	1660 Mel	Mel	\N	\N	\N	\N	02-49261
2255	2255 Tumor	Tumor	2019-07-19 00:00:00-07	\N	Primary Tumor	\N	02-49261
2754	2754 MVP	MVP	\N	\N	\N	\N	03-197B2
2753	2753 Normal	Normal	\N	\N	\N	\N	03-1978B3
1770	1770 Mel	Mel	\N	\N	\N	\N	03-3075A
1773	1773 Normal	Normal	\N	\N	\N	\N	03-3075A
1771	1771 Mel	Mel	\N	\N	\N	\N	03-3075B
1772	1772 MIS	MIS	\N	\N	\N	\N	03-3075B
943	943 Mel	Mel	\N	\N	\N	\N	03-04925E M1
2741	2741 Tumor	Tumor	\N	\N	\N	\N	03-007239
1088	1088 Mel	Mel	\N	\N	\N	\N	03-08311E T2
1085	1085 Mel	Mel	\N	\N	\N	\N	03-15183D T1
944	944 Mel	Mel	\N	\N	\N	\N	03-16198-1C M1
1714	1714 Normal	Normal	\N	\N	\N	\N	03-16497A
1715	1715 Mel	Mel	\N	\N	\N	\N	03-16497B
1716	1716 MIS	MIS	\N	\N	\N	\N	03-16497B
1086	1086 Mel	Mel	\N	\N	\N	\N	03-17395J T2
1084	1084 Mel	Mel	\N	\N	\N	\N	03-19080C T1
1022	1022 Mel	Mel	\N	\N	\N	\N	03-19132B T1
1079	1079 Mel	Mel	\N	\N	\N	\N	03-19132B T1
1083	1083 Mel	Mel	\N	\N	\N	\N	03-21273-1G T1
1080	1080 Mel	Mel	\N	\N	\N	\N	03-22623A T1
1081	1081 Mel	Mel	\N	\N	\N	\N	03-23238B T2
1827	1827 Normal	Normal	\N	\N	\N	\N	03-24651
1826	1826 Mel	Mel	\N	\N	\N	\N	03-24651
1087	1087 Mel	Mel	\N	\N	\N	\N	03-24659-2 T2
637	637 Mel	Mel	\N	\N	\N	\N	03-26518 T1
976	976 Mel	Mel	\N	\N	\N	\N	03-26518B M1
1854	1854 Normal	Normal	\N	\N	\N	\N	03-29330A
1853	1853 Mel	Mel	\N	\N	\N	\N	03-29330B
1860	1860 MIS	MIS	\N	\N	\N	\N	03-30961A
1858	1858 Mel	Mel	\N	\N	\N	\N	03-30961B
1859	1859 Normal	Normal	\N	\N	\N	\N	03-30961B
2773	2773 Tumor	Tumor	\N	\N	\N	\N	03-34051A1
1721	1721 Mel	Mel	\N	\N	\N	\N	03-39293
1722	1722 Normal	Normal	\N	\N	\N	\N	03-39293
1723	1723 MIS	MIS	\N	\N	\N	\N	03-39293
1713	1713 Mel	Mel	\N	\N	\N	\N	03-44586
1707	1707 Mel	Mel	\N	\N	\N	\N	03-47623B
3451	3451 Not Processed	Not Processed	\N	\N	\N	\N	03-57215A
1944	1944 Mel	Mel	\N	\N	\N	\N	03-57215B
1946	1946 Normal	Normal	\N	\N	\N	\N	03-57215B
1945	1945 Nevus	Nevus	\N	\N	\N	\N	03-57215B
1954	1954 MIS	MIS	\N	\N	\N	\N	03-57215B
1695	1695 Mel	Mel	\N	\N	\N	\N	03-57585A
1696	1696 Normal	Normal	\N	\N	\N	\N	03-57585A
1697	1697 Mel	Mel	\N	\N	\N	\N	03-57585C
1698	1698 Normal	Normal	\N	\N	\N	\N	03-57585E
555	555 Nodular Mel	Nodular Mel	\N	\N	\N	\N	03B12175 (eppendorf)
945	945 Mel	Mel	\N	\N	\N	\N	04-00065-6 M1
1065	1065 Mel	Mel	\N	\N	\N	\N	04-00122C T1
946	946 Mel	Mel	\N	\N	\N	\N	04-01241G M1
639	639 Mel	Mel	\N	\N	\N	\N	04-01809 T4
1078	1078 Mel	Mel	\N	\N	\N	\N	04-01809E T4
1077	1077 Mel	Mel	\N	\N	\N	\N	04-02031D T1
1075	1075 Mel	Mel	\N	\N	\N	\N	04-03311H T2
1073	1073 Mel	Mel	\N	\N	\N	\N	04-03547G T1
2722	2722 Tumor	Tumor	\N	\N	\N	\N	04-003736A
640	640 Mel	Mel	\N	\N	\N	\N	04-05355 T4
1074	1074 Mel	Mel	\N	\N	\N	\N	04-05355B T4
1701	1701 Mel	Mel	\N	\N	\N	\N	04-6689B
1702	1702 Normal	Normal	\N	\N	\N	\N	04-6689B
1703	1703 MIS	MIS	\N	\N	\N	\N	04-6689B
1060	1060 Mel	Mel	\N	\N	\N	\N	04-08148D T1
3869	3869 Tumor	Tumor	\N	\N	\N	\N	04-9498
1066	1066 Mel	Mel	\N	\N	\N	\N	04-11144C T1
1850	1850 Normal	Normal	\N	\N	\N	\N	04-12137A
1849	1849 Mel	Mel	\N	\N	04-12137D, 04-12137E	\N	04-12137D,04-12137E
1072	1072 Mel	Mel	\N	\N	\N	\N	04-13171C T1
1071	1071 Mel	Mel	\N	\N	\N	\N	04-13607 T1
1067	1067 Mel	Mel	\N	\N	\N	\N	04-14508C T1
1064	1064 Mel	Mel	\N	\N	\N	\N	04-14677 T1
1742	1742 Normal	Normal	\N	\N	04-14908A, 04-14908	\N	04-14908
1741	1741 Mel	Mel	\N	\N	04-14908A, 04-14908	\N	04-14908A
1639	1639 Mel	Mel	\N	\N	\N	\N	04-15284
1068	1068 Mel	Mel	\N	\N	\N	\N	04-15616C T2
1070	1070 Mel	Mel	\N	\N	\N	\N	04-15689C T1
1069	1069 Mel	Mel	\N	\N	\N	\N	04-17745B T1
1632	1632 Mel	Mel	\N	\N	\N	\N	04-18467
1063	1063 Mel	Mel	\N	\N	\N	\N	04-18775B T1
977	977 Mel	Mel	\N	\N	\N	\N	04-20471E M1
947	947 Mel	Mel	\N	\N	\N	\N	04-21305-4 M1
1061	1061 Mel	Mel	\N	\N	\N	\N	04-22191D T1
1717	1717 Mel	Mel	\N	\N	\N	\N	04-25639A
1718	1718 Normal	Normal	\N	\N	\N	\N	04-25639A
1719	1719 Mel	Mel	\N	\N	\N	\N	04-25639B
1720	1720 Normal	Normal	\N	\N	\N	\N	04-25639B
1712	1712 Mel	Mel	\N	\N	\N	\N	04-28340
638	638 Mel	Mel	\N	\N	\N	\N	04-28824 T2
1669	1669 Mel	Mel	\N	\N	\N	\N	04-31313A
1670	1670 Normal	Normal	\N	\N	\N	\N	04-31313A
1671	1671 MIS	MIS	\N	\N	\N	\N	04-31313A
1922	1922 Nevus	Nevus	\N	\N	\N	\N	04-34117
1921	1921 Mel	Mel	\N	\N	\N	\N	04-34117
2256	2256 Tumor	Tumor	2019-07-19 00:00:00-07	\N	Primary Tumor	\N	04-35102A
2260	2260 Normal	Normal	2019-07-19 00:00:00-07	\N	Normal	\N	04-35102A
3872	3872 Tumor	Tumor	\N	\N	\N	\N	04-37400
1637	1637 Mel	Mel	\N	\N	\N	\N	04-38345
1734	1734 Mel	Mel	\N	\N	\N	\N	04-50387
1735	1735 Normal	Normal	\N	\N	\N	\N	04-50387
1818	1818 Mel	Mel	\N	\N	\N	\N	04-57347A
1819	1819 Normal	Normal	\N	\N	\N	\N	04-57347A
1640	1640 Mel	Mel	\N	\N	\N	\N	04-59140B
2251	2251 Tumor	Tumor	2019-07-19 00:00:00-07	\N	Metastatic	\N	05-605A2
2259	2259 Normal	Normal	2019-07-19 00:00:00-07	\N	Normal	\N	05-605A2
628	628 Mel	Mel	\N	\N	\N	\N	05-01411 T4
948	948 Mel	Mel	\N	\N	\N	\N	05-01411C N1
1058	1058 Mel	Mel	\N	\N	\N	\N	05-04841C T2
1062	1062 Mel	Mel	\N	\N	\N	\N	05-04949-1C T1
1797	1797 Normal	Normal	\N	\N	\N	\N	05-5976A
1798	1798 MIS	MIS	\N	\N	\N	\N	05-5976A
1796	1796 Mel	Mel	\N	\N	http://64.54.108.147/eSlideTray.php?ImageIds=1021 , 05-5976B, 05-5976C	\N	05-5976B
3452	3452 Not Processed	Not Processed	\N	\N	\N	\N	05-5976C
2738	2738 Tumor	Tumor	\N	\N	\N	\N	05-006815
3078	3078 Tumor	Tumor	\N	\N	\N	\N	05-7439A12
2745	2745 Tumor	Tumor	\N	\N	\N	\N	05-011507
912	912 Mel	Mel	\N	\N	\N	\N	05-12693C M1
1055	1055 Mel	Mel	\N	\N	\N	\N	05-13894C T2
978	978 Mel	Mel	\N	\N	\N	\N	05-14728C M1
642	642 Mel	Mel	\N	\N	\N	\N	05-14988 T3
1059	1059 Mel	Mel	\N	\N	\N	\N	05-14988B T3
2746	2746 Normal	Normal	\N	\N	\N	\N	05-015408
1056	1056 Mel	Mel	\N	\N	\N	\N	05-17080 T2
1643	1643 Mel	Mel	\N	\N	\N	\N	05-19406
1054	1054 Mel	Mel	\N	\N	\N	\N	05-20065-4 T1
949	949 Mel	Mel	\N	\N	\N	\N	05-21257 M1
641	641 Mel	Mel	\N	\N	\N	\N	05-23001 T4
1057	1057 Mel	Mel	\N	\N	\N	\N	05-23001E T4
1051	1051 Mel	Mel	\N	\N	\N	\N	05-24184C T1
1049	1049 Mel	Mel	\N	\N	\N	\N	05-26408 T1
1052	1052 Mel	Mel	\N	\N	\N	\N	05-26627-1B T1
913	913 Mel	Mel	\N	\N	\N	\N	05-27343A M1
1926	1926 Mel	Mel	\N	\N	\N	\N	05-27460
1927	1927 MIS	MIS	\N	\N	\N	\N	05-27460
1928	1928 Nevus	Nevus	\N	\N	\N	\N	05-27460
1929	1929 Normal	Normal	\N	\N	\N	\N	05-27460
1774	1774 Mel	Mel	\N	\N	Light Blue	\N	05-27756A
1775	1775 Mel	Mel	\N	\N	Nevoid Melanoma	\N	05-27756B
1776	1776 Normal	Normal	\N	\N	\N	\N	05-27756B
1629	1629 Mel	Mel	\N	\N	\N	\N	05-28152B
643	643 Mel	Mel	\N	\N	\N	\N	05-29322 T3
1048	1048 Mel	Mel	\N	\N	\N	\N	05-29322B T3
1957	1957 Normal	Normal	\N	\N	\N	\N	05-29484A
2140	2140 Not Processed	Not Processed	\N	\N	\N	\N	05-29484B
2142	2142 Not Processed	Not Processed	\N	\N	\N	\N	05-29484C
2143	2143 Not Processed	Not Processed	\N	\N	\N	\N	05-29484D
2144	2144 Not Processed	Not Processed	\N	\N	\N	\N	05-29484E
2145	2145 Not Processed	Not Processed	\N	\N	\N	\N	05-29484F
1930	1930 Normal	Normal	\N	\N	\N	\N	05-37586A1
1814	1814 Mel	Mel	\N	\N	\N	\N	05-37586A3
1815	1815 Normal	Normal	\N	\N	http://64.54.108.147/eSlideTray.php?ImageIds=1003 , 05-37586A1, 05-37586A3	\N	05-37586A3
1816	1816 MIS	MIS	\N	\N	\N	\N	05-37586A3
1817	1817 Nevus	Nevus	\N	\N	\N	\N	05-37586A3
1931	1931 Mel	Mel	\N	\N	\N	\N	05-37586A3
1932	1932 MIS	MIS	\N	\N	\N	\N	05-37586A3
1933	1933 Nevus	Nevus	\N	\N	\N	\N	05-37586A3
1934	1934 Normal	Normal	\N	\N	\N	\N	05-37586A3
3079	3079 Tumor	Tumor	\N	\N	\N	\N	05-41924
1650	1650 Mel	Mel	\N	\N	\N	\N	05-46869B
1755	1755 Mel	Mel	\N	\N	\N	\N	05-58791
1756	1756 Normal	Normal	\N	\N	\N	\N	05-58791
1655	1655 Mel	Mel	\N	\N	\N	\N	05-66206A
1656	1656 Normal	Normal	\N	\N	\N	\N	05-66206A
2252	2252 Tumor	Tumor	2019-07-19 00:00:00-07	\N	Metastatic	\N	06-521B2
3227	3227 Tumor	Tumor	\N	\N	\N	\N	06-00911
645	645 Mel	Mel	\N	\N	\N	\N	06-01845 T4
1025	1025 Mel	Mel	\N	\N	\N	\N	06-01845E T4
1044	1044 Mel	Mel	\N	\N	\N	\N	06-01846D T1
1510	1510 Normal	Normal	\N	\N	\N	\N	10-13619
426	426 blue nevus+ cellular+  DF like	blue nevus, cellular,  DF like	\N	\N	\N	\N	06-2345
914	914 Mel	Mel	\N	\N	\N	\N	06-03046F N1
1658	1658 Mel	Mel	\N	\N	\N	\N	06-4069
1659	1659 Normal	Normal	\N	\N	\N	\N	06-4069
646	646 Mel	Mel	\N	\N	\N	\N	06-04915 T2
1757	1757 Mel	Mel	\N	\N	\N	\N	06-5249
1758	1758 Normal	Normal	\N	\N	\N	\N	06-5249
644	644 Mel	Mel	\N	\N	\N	\N	06-05518 T4
1043	1043 Mel	Mel	\N	\N	\N	\N	06-05518B T4
1045	1045 Mel	Mel	\N	\N	\N	\N	06-06053B T1
915	915 Mel	Mel	\N	\N	\N	\N	06-06325 M1
2752	2752 MVP	MVP	\N	\N	\N	\N	06-6624A7
2751	2751 Normal	Normal	\N	\N	\N	\N	06-6624D1
3226	3226 Tumor	Tumor	\N	\N	\N	\N	06-08042
629	629 Mel	Mel	\N	\N	\N	\N	06-08092 T3
1633	1633 Mel	Mel	\N	\N	\N	\N	06-8729
1042	1042 Mel	Mel	\N	\N	\N	\N	06-10522-2B T1
1938	1938 MIS	MIS	\N	\N	\N	\N	06-10811
1939	1939 Nevus	Nevus	\N	\N	\N	\N	06-10811
1940	1940 Normal	Normal	\N	\N	\N	\N	06-10811
975	975 Mel	Mel	\N	\N	\N	\N	06-11147 N1
1843	1843 Mel	Mel	\N	\N	\N	\N	06-11151C
1844	1844 MIS	MIS	\N	\N	\N	\N	06-11151C
3455	3455 Not Processed	Not Processed	\N	\N	\N	\N	06-11151D
1845	1845 Normal	Normal	\N	\N	\N	\N	06-11151F
979	979 Mel	Mel	\N	\N	\N	\N	06-12646D M1
647	647 Mel	Mel	\N	\N	\N	\N	06-14812D T2
630	630 Mel	Mel	\N	\N	\N	\N	06-14812E T2
1041	1041 Mel	Mel	\N	\N	\N	\N	06-15453C T1
916	916 Mel	Mel	\N	\N	\N	\N	06-16008-1
653	653 Mel	Mel	\N	\N	\N	\N	06-16759 T1
1037	1037 Mel	Mel	\N	\N	\N	\N	06-16759A T1
648	648 Mel	Mel	\N	\N	\N	\N	06-17441 T2
1034	1034 Mel	Mel	\N	\N	\N	\N	06-17441-2 T2
1039	1039 Mel	Mel	\N	\N	\N	\N	06-17562-2 T1
1784	1784 Normal	Normal	\N	\N	\N	\N	06-17933A
1785	1785 Normal	Normal	\N	\N	\N	\N	06-17933A
1783	1783 Mel	Mel	\N	\N	\N	\N	06-17933B
1651	1651 Mel	Mel	\N	\N	\N	\N	06-18321
2739	2739 Tumor	Tumor	\N	\N	\N	\N	06-018998
1036	1036 Mel	Mel	\N	\N	\N	\N	06-20661-2 T1
1035	1035 Mel	Mel	\N	\N	\N	\N	06-21073E T3
1799	1799 Mel	Mel	\N	\N	http://64.54.108.147/eSlideTray.php?ImageIds=1408 , 06-21115A, 06-21115B	\N	06-21115A
1800	1800 Normal	Normal	\N	\N	\N	\N	06-21115B
2771	2771 Normal	Normal	\N	\N	\N	\N	06-21363
3228	3228 Tumor	Tumor	\N	\N	\N	\N	06-21363
1812	1812 Mel	Mel	\N	\N	\N	\N	06-22923
1813	1813 Normal	Normal	\N	\N	\N	\N	06-22923
1950	1950 Normal	Normal	\N	\N	\N	\N	06-23240A
650	650 Mel	Mel	\N	\N	\N	\N	06-23345 T1
652	652 Mel	Mel	\N	\N	\N	\N	06-23587 T1
1031	1031 Mel	Mel	\N	\N	\N	\N	06-23587B T1
1032	1032 Mel	Mel	\N	\N	\N	\N	06-24998B T2
649	649 Mel	Mel	\N	\N	\N	\N	06-25697 T1
1024	1024 Mel	Mel	\N	\N	\N	\N	06-25697-1 T1
651	651 Mel	Mel	\N	\N	\N	\N	06-27633 T1
1630	1630 Mel	Mel	\N	\N	\N	\N	06-28087
2786	2786 Tumor	Tumor	\N	\N	\N	\N	06-32942
3080	3080 Tumor	Tumor	\N	\N	\N	\N	06-47079A02
3229	3229 Tumor	Tumor	\N	\N	\N	\N	06-47334
1638	1638 Mel	Mel	\N	\N	\N	\N	06-47809B
2787	2787 Tumor	Tumor	\N	\N	\N	\N	06-52508
2788	2788 Normal	Normal	\N	\N	\N	\N	06-52508
1661	1661 Mel	Mel	\N	\N	\N	\N	06-64692B
1700	1700 Mel	Mel	\N	\N	\N	\N	06-65105
1677	1677 Mel	Mel	\N	\N	\N	\N	06-68314
1627	1627 Mel	Mel	\N	\N	\N	\N	06-70035C
1446	1446 Normal	Normal	\N	\N	\N	\N	06-72820A
1836	1836 Normal	Normal	\N	\N	\N	\N	06-73878A
1835	1835 Mel	Mel	\N	\N	http://64.54.108.1/eSlideTray.php?ImageIds=1404 , 06-73878C, 06-73878D	\N	06-73878C
3526	3526 Not Processed	Not Processed	\N	\N	\N	\N	06-73878D
2885	2885 Tumor	Tumor	\N	\N	\N	\N	07-1210F6
2309	2309 Met9	Met9	\N	\N	\N	\N	07-1791
2310	2310 Met10	Met10	\N	\N	\N	\N	07-1841
1311	1311 Normal	Normal	\N	\N	\N	\N	07-2104
1312	1312 Met1	Met1	\N	\N	\N	\N	07-2104
1313	1313 Met2	Met2	\N	\N	\N	\N	07-2104
2305	2305 Met5	Met5	\N	\N	\N	\N	07-2479-1 
2306	2306 Met6	Met6	\N	\N	\N	\N	07-2479-2
2307	2307 Met7	Met7	\N	\N	\N	\N	07-2889-1 
2308	2308 Met8	Met8	\N	\N	\N	\N	07-2889-2
1314	1314 Met3	Met3	\N	\N	\N	\N	07-3001
1426	1426 Met4	Met4	\N	\N	\N	\N	07-3001
2789	2789 Tumor	Tumor	\N	\N	\N	\N	07-04365
2790	2790 Normal	Normal	\N	\N	\N	\N	07-04365
2791	2791 Tumor	Tumor	\N	\N	\N	\N	07-04365
1786	1786 Mel	Mel	\N	\N	\N	\N	07-7626
2813	2813 Normal	Normal	\N	\N	\N	\N	07-011660-2
2744	2744 Tumor	Tumor	\N	\N	\N	\N	07-012236B1
2139	2139 Not Processed	Not Processed	\N	\N	\N	\N	07-13061
2792	2792 Tumor	Tumor	\N	\N	\N	\N	07-14044A
2793	2793 Normal	Normal	\N	\N	\N	\N	07-14044A
2804	2804 Tumor	Tumor	\N	\N	\N	\N	07-20501
654	654 Mel	Mel	\N	\N	\N	\N	07-25593 T2
1050	1050 Mel	Mel	\N	\N	\N	\N	07-25593-2 T2
2794	2794 Tumor	Tumor	\N	\N	\N	\N	07-26247
1662	1662 Mel	Mel	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	07-28805
1663	1663 Normal	Normal	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	07-28805
1664	1664 Nevus	Nevus	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	07-28805
1923	1923 Mel	Mel	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	07-28805
1924	1924 Nevus	Nevus	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	07-28805
1925	1925 Normal	Normal	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	07-28805
1747	1747 Mel	Mel	\N	\N	\N	\N	07-37090
1748	1748 Normal	Normal	\N	\N	\N	\N	07-37090
2042	2042 Nevus	Nevus	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus.	\N	07-37378
1782	1782 Mel	Mel	\N	\N	\N	\N	07-40241A
2037	2037 Normal	Normal	\N	\N	\N	\N	07-41091A
2146	2146 Not Processed	Not Processed	\N	\N	\N	\N	07-41091B
1750	1750 Mel	Mel	\N	\N	\N	\N	07-42908
1751	1751 MIS	MIS	\N	\N	\N	\N	07-42908
1764	1764 Mel	Mel	\N	\N	\N	\N	07-55149
1360	1360 Tumor	Tumor	\N	\N	\N	\N	07-55184
1686	1686 Mel	Mel	\N	\N	\N	\N	07-67657A
1687	1687 Normal	Normal	\N	\N	\N	\N	07-67657A
1688	1688 Mel	Mel	\N	\N	\N	\N	07-67657B
2029	2029 Atypical Melanocytic Proliferation	Atypical Melanocytic Proliferation	\N	\N	\N	\N	07-74058A
3400	3400 Unknown	Unknown	\N	\N	\N	\N	07-74058A
3399	3399 Unknown	Unknown	\N	\N	\N	\N	07-74058A
2000	2000 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	07-74058B
2001	2001 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	07-74058B
961	961 Mel	Mel	\N	\N	\N	\N	11-27846-2 N1
2002	2002 Atypical Melanocytic Proliferation	Atypical Melanocytic Proliferation	\N	\N	\N	\N	07-74058B
1805	1805 Mel	Mel	\N	\N	\N	\N	07-76799A
1806	1806 Normal	Normal	\N	\N	\N	\N	07-76799A
1807	1807 MIS	MIS	\N	\N	\N	\N	07-76799A
1749	1749 Mel	Mel	\N	\N	\N	\N	07-77608
1955	1955 Normal	Normal	\N	\N	\N	\N	07-85201
556	556 Nodular Mel	Nodular Mel	\N	\N	\N	\N	07B2313 (eppendorf)
3087	3087 Tumor	Tumor	\N	\N	\N	\N	08-1463A2
1682	1682 Mel	Mel	\N	\N	\N	\N	08-1851A
1683	1683 Normal	Normal	\N	\N	\N	\N	08-1851A
1684	1684 Mel	Mel	\N	\N	\N	\N	08-1851B
1685	1685 Normal	Normal	\N	\N	\N	\N	08-1851C
3245	3245 Tumor	Tumor	\N	\N	\N	\N	08-4205A
3244	3244 Normal	Normal	\N	\N	\N	\N	08-4205A
3081	3081 Tumor	Tumor	\N	\N	\N	\N	08-4544A03
2261	2261 Normal	Normal	2019-07-19 00:00:00-07	\N	Normal	\N	08-6790A
2257	2257 Tumor	Tumor	2019-07-19 00:00:00-07	\N	Primary Tumor	\N	08-6790B
1743	1743 Mel	Mel	\N	\N	\N	\N	08-8920A
1744	1744 Mel	Mel	\N	\N	\N	\N	08-8920B
1745	1745 Normal	Normal	\N	\N	\N	\N	08-8920B
1746	1746 MIS	MIS	\N	\N	\N	\N	08-8920B
3681	3681 Unknown	Unknown	\N	\N	\N	\N	08-16770
2736	2736 Tumor	Tumor	\N	\N	\N	\N	08-018003
655	655 Mel	Mel	\N	\N	\N	\N	08-21729 T2
950	950 Mel	Mel	\N	\N	\N	\N	08-21729-2 M1
3243	3243 Tumor	Tumor	\N	\N	\N	\N	08-21965C
3242	3242 Normal	Normal	\N	\N	\N	\N	08-21965C
3804	3804 Normal	Normal	\N	\N	\N	\N	08-21965C
3805	3805 Tumor	Tumor	\N	\N	\N	\N	08-21965C
1727	1727 Mel	Mel	\N	\N	\N	\N	08-25654
1728	1728 Normal	Normal	\N	\N	\N	\N	08-25654
2779	2779 Tumor	Tumor	\N	\N	\N	\N	08-27590
2780	2780 Normal	Normal	\N	\N	\N	\N	08-27590
1600	1600 MIS1	MIS1	\N	\N	\N	\N	08-35719A1
1601	1601 Invasive Primary Mel	Invasive Primary Mel	\N	\N	\N	\N	08-35719A1
3270	3270 MELANOMA	MELANOMA	\N	\N	\N	\N	08-43264
3271	3271 MELANOMA	MELANOMA	\N	\N	\N	\N	08-43265
3272	3272 MELANOMA	MELANOMA	\N	\N	\N	\N	08-43266
3273	3273 MELANOMA	MELANOMA	\N	\N	\N	\N	08-43267
3274	3274 MELANOMA	MELANOMA	\N	\N	\N	\N	08-43268
1752	1752 Mel	Mel	\N	\N	\N	\N	08-44748
1753	1753 Normal	Normal	\N	\N	\N	\N	08-44748
2767	2767 Tumor	Tumor	\N	\N	\N	\N	08-46462
2914	2914 Mel	Mel	\N	\N	\N	\N	08-46462
2915	2915 Nevus	Nevus	\N	\N	\N	\N	08-46462
2913	2913 Tumor	Tumor	\N	\N	\N	\N	08-46462
2916	2916 Normal	Normal	\N	\N	\N	\N	08-46462
3296	3296 Mel	Mel	\N	\N	\N	\N	08-46462
3295	3295 Mel	Mel	\N	\N	\N	\N	08-46462
3298	3298 Nevus	Nevus	\N	\N	\N	\N	08-46462
3297	3297 Nevus	Nevus	\N	\N	\N	\N	08-46462
3299	3299 Normal	Normal	\N	\N	\N	\N	08-46462
1917	1917 Mel	Mel	\N	\N	\N	\N	08-48442
1918	1918 MIS	MIS	\N	\N	\N	\N	08-48442
1919	1919 Nevus	Nevus	\N	\N	\N	\N	08-48442
1920	1920 Normal	Normal	\N	\N	\N	\N	08-48442
3280	3280 MELANOMA	MELANOMA	\N	\N	\N	\N	08-51219
3281	3281 MELANOMA	MELANOMA	\N	\N	\N	\N	08-51220
3282	3282 MELANOMA	MELANOMA	\N	\N	\N	\N	08-51221
3283	3283 MELANOMA	MELANOMA	\N	\N	\N	\N	08-51222
3284	3284 MELANOMA	MELANOMA	\N	\N	\N	\N	08-51223
1653	1653 Mel	Mel	\N	\N	\N	\N	08-51663
1654	1654 Normal	Normal	\N	\N	\N	\N	08-51663
3285	3285 MELANOMA	MELANOMA	\N	\N	\N	\N	08-52519
3286	3286 MELANOMA	MELANOMA	\N	\N	\N	\N	08-52519
3288	3288 MELANOMA	MELANOMA	\N	\N	\N	\N	08-52519
3289	3289 MELANOMA	MELANOMA	\N	\N	\N	\N	08-52519
3287	3287 MELANOMA	MELANOMA	\N	\N	\N	\N	08-52519
1958	1958 Normal	Normal	\N	\N	\N	\N	08-65412A
2138	2138 Not Processed	Not Processed	\N	\N	\N	\N	08-65412B
2772	2772 Tumor	Tumor	\N	\N	\N	\N	08-70283a
561	561 Nodular Mel	Nodular Mel	\N	\N	\N	\N	08B8345 (eppendorf)
560	560 Nodular Mel	Nodular Mel	\N	\N	\N	\N	08B9531 (eppendorf)
3426	3426 Tumor	Tumor	\N	\N	\N	\N	09-0209
3071	3071 Normal	Normal	\N	\N	\N	\N	09-1121
3072	3072 Tumor	Tumor	\N	\N	\N	\N	09-1121
2742	2742 Normal	Normal	\N	\N	\N	\N	09-005840
2743	2743 Tumor	Tumor	\N	\N	\N	\N	09-005840
3292	3292 Nevus	Nevus	\N	\N	\N	\N	09-8165
3291	3291 Mel	Mel	\N	\N	\N	\N	09-8165
3290	3290 Mel	Mel	\N	\N	\N	\N	09-8165
3293	3293 Nevus	Nevus	\N	\N	\N	\N	09-8165
3294	3294 Normal	Normal	\N	\N	\N	\N	09-8165
2721	2721 Tumor	Tumor	\N	\N	\N	\N	09-008704
952	952 Mel	Mel	\N	\N	\N	\N	09-13370-1M N1
953	953 Mel	Mel	\N	\N	\N	\N	09-13370-2G N1
2815	2815 Normal	Normal	\N	\N	\N	\N	09-015020-2A
951	951 Mel	Mel	\N	\N	\N	\N	09-15598 M1
1754	1754 Mel	Mel	\N	\N	\N	\N	09-16836
656	656 Mel	Mel	\N	\N	\N	\N	09-21320 T2
954	954 Mel	Mel	\N	\N	\N	\N	09-21320A3 N1-M1
2147	2147 Not Processed	Not Processed	\N	\N	\N	\N	09-22513A
1672	1672 Mel	Mel	\N	\N	\N	\N	09-23922A
1673	1673 Normal	Normal	\N	\N	\N	\N	09-23922A
1674	1674 MIS	MIS	\N	\N	\N	\N	09-23922B
1675	1675 Mel	Mel	\N	\N	\N	\N	09-23922B
1676	1676 Normal	Normal	\N	\N	\N	\N	09-23922B
1680	1680 Mel	Mel	\N	\N	\N	\N	09-31608
2134	2134 Not Processed	Not Processed	\N	\N	\N	\N	09-36483
2800	2800 Tumor	Tumor	\N	\N	\N	\N	09-37302
1626	1626 Mel	Mel	\N	\N	\N	\N	09-48136A
3222	3222 Tumor	Tumor	\N	\N	\N	\N	09-72944
2694	2694 Normal	Normal	\N	\N	\N	\N	09-80101A-2
2695	2695 Tumor	Tumor	\N	\N	\N	\N	09-80101A-2
3401	3401 Unknown	Unknown	\N	\N	\N	\N	09-88536
3402	3402 Unknown	Unknown	\N	\N	\N	\N	09-88536
1644	1644 Mel	Mel	\N	\N	\N	\N	09-90221
3220	3220 Normal	Normal	\N	\N	\N	\N	09-92749
3221	3221 Tumor	Tumor	\N	\N	\N	\N	09-92749
3073	3073 Tumor	Tumor	\N	\N	\N	\N	10-143
2979	2979 Tumor	Tumor	\N	\N	\N	\N	10-0206
2821	2821 MM	MM	\N	\N	10-972A9, 10-972A10, 10-972A17	\N	10-972A17,10-972A9
2820	2820 Normal	Normal	\N	\N	\N	\N	10-972C2
2826	2826 Met	Met	\N	\N	\N	\N	10-1843A4
2822	2822 Normal	Normal	\N	\N	\N	\N	10-1843A5
2148	2148 Not Processed	Not Processed	\N	\N	\N	\N	10-4769A
2733	2733 Tumor	Tumor	\N	\N	\N	\N	10-006275
3089	3089 Tumor	Tumor	\N	\N	\N	\N	10-7937B2
2748	2748 Tumor	Tumor	\N	\N	\N	\N	10-008371A1
2827	2827 MM	MM	\N	\N	\N	\N	10-8439A4
657	657 Mel	Mel	\N	\N	\N	\N	10-10275 T2
955	955 Mel	Mel	\N	\N	\N	\N	10-10275D13 M1
2829	2829 MM	MM	\N	\N	\N	\N	10-10558A10
2830	2830 Met	Met	\N	\N	\N	\N	10-10558C1
917	917 Mel	Mel	\N	\N	\N	\N	10-10942A2 M1
2886	2886 Tumor	Tumor	\N	\N	\N	\N	10-11930B12
1511	1511 Intestine Met 2	Intestine Met 2	\N	\N	Merged: Met 2 and Met 3	\N	10-13619
1512	1512 Met3	Met3	\N	\N	Merged: Met 2 and Met 3	\N	10-13619
1509	1509 Met1	Met1	\N	\N	\N	\N	10-14100
1508	1508 MIS1	MIS1	\N	\N	\N	\N	10-14390
1502	1502 Mel1	Mel1	\N	\N	\N	\N	10-15411B
1513	1513 Brain Met 4	Brain Met 4	\N	\N	Merged: Met 4 and Met 5	\N	10-15514A2
1514	1514 Met5	Met5	\N	\N	Merged: Met 4 and Met 5	\N	10-15514A2
1507	1507 Normal	Normal	\N	\N	\N	\N	10-17734
1503	1503 Normal	Normal	\N	\N	\N	\N	10-18253B
1504	1504 Met1	Met1	\N	\N	\N	\N	10-18253B
956	956 Mel	Mel	\N	\N	\N	\N	10-20397-3 M1
3682	3682 Not Processed	Not Processed	\N	\N	\N	\N	10-22013
3683	3683 Not Processed	Not Processed	\N	\N	\N	\N	10-22319
1736	1736 Mel	Mel	\N	\N	\N	\N	10-23548
1737	1737 MIS	MIS	\N	\N	\N	\N	10-23548
1738	1738 Normal	Normal	\N	\N	\N	\N	10-23548
2769	2769 Normal	Normal	\N	\N	\N	\N	10-23569A
2770	2770 Tumor	Tumor	\N	\N	\N	\N	10-23569A
1739	1739 Normal	Normal	\N	\N	\N	\N	10-25517A
1740	1740 Normal	Normal	\N	\N	\N	\N	10-25517E
3082	3082 Tumor	Tumor	\N	\N	\N	\N	10-26316A2
958	958 Mel	Mel	\N	\N	\N	\N	10-30525-4 M1
957	957 Mel	Mel	\N	\N	\N	\N	10-30890-5 N1
3225	3225 Tumor	Tumor	\N	\N	\N	\N	10-32987
3684	3684 Not Processed	Not Processed	\N	\N	\N	\N	10-38178A1
1505	1505 Met2	Met2	\N	\N	\N	\N	10-39146A1
1506	1506 Met3	Met3	\N	\N	\N	\N	10-39146A2
2762	2762 Normal	Normal	\N	\N	\N	\N	10-41439
2909	2909 Mel	Mel	\N	\N	\N	\N	10-41439
2910	2910 Mel	Mel	\N	\N	\N	\N	10-41439
2912	2912 Nevus	Nevus	\N	\N	\N	\N	10-41439
2911	2911 Nevus	Nevus	\N	\N	\N	\N	10-41439
2854	2854 Normal	Normal	\N	\N	\N	\N	10-42241
1846	1846 Mel	Mel	\N	\N	\N	\N	10-43330
3083	3083 Tumor	Tumor	\N	\N	\N	\N	10-44069A4
3223	3223 Tumor	Tumor	\N	\N	\N	\N	10-46536
2938	2938 Tumor	Tumor	\N	\N	\N	\N	10-55707
2995	2995 Tumor	Tumor	\N	\N	\N	\N	10-56047
911	911 DPN-mm	DPN-mm	\N	\N	\N	\N	10-57426
1235	1235 NEVUS	NEVUS	\N	\N	\N	\N	10-57426
3275	3275 Mel	Mel	\N	\N	\N	\N	10-58663
3276	3276 Mel	Mel	\N	\N	\N	\N	10-58663
3277	3277 Nevus	Nevus	\N	\N	\N	\N	10-58663
3278	3278 Nevus	Nevus	\N	\N	\N	\N	10-58663
3279	3279 Normal	Normal	\N	\N	\N	\N	10-58663
2994	2994 Tumor	Tumor	\N	\N	\N	\N	10-59344
3237	3237 Normal	Normal	\N	\N	Ivanka Normal (for #9)	\N	10-63051C
2996	2996 Tumor	Tumor	\N	\N	\N	\N	10-71761
2766	2766 Tumor	Tumor	\N	\N	\N	\N	10-73024
2999	2999 Tumor	Tumor	\N	\N	\N	\N	10-74513
1002	1002 Tumor	Tumor	\N	\N	NRAS sequencing	\N	10-75211
3000	3000 Tumor	Tumor	\N	\N	\N	\N	10-80009
472	472 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	10-83193
2864	2864 Tumor	Tumor	\N	\N	\N	\N	10-83193
3219	3219 Tumor	Tumor	\N	\N	\N	\N	10-83193
3224	3224 Tumor	Tumor	\N	\N	\N	\N	10-83613A
2997	2997 Tumor	Tumor	\N	\N	\N	\N	10-84478
1980	1980 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	10-86269
2959	2959 Tumor	Tumor	\N	\N	\N	\N	10-86469
3393	3393 Tumor	Tumor	\N	\N	\N	\N	10-86469
3003	3003 Tumor	Tumor	\N	\N	\N	\N	10-88475
2998	2998 Tumor	Tumor	\N	\N	\N	\N	10-88482
3001	3001 Tumor	Tumor	\N	\N	\N	\N	10-88482
3002	3002 Tumor	Tumor	\N	\N	\N	\N	10-91484
562	562 Nodular Mel	Nodular Mel	\N	\N	\N	\N	10B339 (eppendorf)
563	563 Nodular Mel	Nodular Mel	\N	\N	\N	\N	10B7952 (eppendorf)
559	559 Nodular Mel	Nodular Mel	\N	\N	\N	\N	10B18943 (eppendorf)
1330	1330 Tumor	Tumor	\N	\N	\N	\N	11-072
1331	1331 Tumor	Tumor	\N	\N	\N	\N	11-091
1332	1332 Tumor	Tumor	\N	\N	\N	\N	11-133
1333	1333 Tumor	Tumor	\N	\N	\N	\N	11-154
1334	1334 Tumor	Tumor	\N	\N	\N	\N	11-172
1335	1335 Tumor	Tumor	\N	\N	\N	\N	11-256
3020	3020 Tumor	Tumor	\N	\N	\N	\N	11-699
459	459 Spitz mel	Spitz mel	\N	\N	\N	\N	11-1044
2302	2302 Invasive 1	Invasive 1	\N	\N	\N	\N	11-1969-F
1428	1428 MIS1	MIS1	\N	\N	\N	\N	11-1973
1429	1429 Invasive 1	Invasive 1	\N	\N	\N	\N	11-1973
1435	1435 Invasive 2	Invasive 2	\N	\N	\N	\N	11-1973
1436	1436 Invasive 3	Invasive 3	\N	\N	\N	\N	11-1973
1437	1437 Invasive 4	Invasive 4	\N	\N	\N	\N	11-1973
658	658 Mel	Mel	\N	\N	\N	\N	11-03286 T3
959	959 Mel	Mel	\N	\N	\N	\N	11-03286-4 M1
3218	3218 Tumor	Tumor	\N	\N	\N	\N	11-5210D
1321	1321 Tumor	Tumor	\N	\N	\N	\N	11-5482
3004	3004 Tumor	Tumor	\N	\N	\N	\N	11-5482
3021	3021 Tumor	Tumor	\N	\N	\N	\N	11-5482
460	460 Spitz mel	Spitz mel	\N	\N	\N	\N	11-7028
2939	2939 Tumor	Tumor	\N	\N	\N	\N	11-8228
1336	1336 Tumor	Tumor	\N	\N	\N	\N	11-12273
2960	2960 Tumor	Tumor	\N	\N	\N	\N	11-12273
3394	3394 Tumor	Tumor	\N	\N	\N	\N	11-12273
3440	3440 Unknown	Unknown	\N	\N	\N	\N	11-13661
617	617 Tumor	Tumor	\N	\N	\N	\N	11-13665
2154	2154 Capture Area A1	Capture Area A1	\N	\N	\N	\N	11-14908C
3005	3005 Tumor	Tumor	\N	\N	\N	\N	11-16253
3022	3022 Tumor	Tumor	\N	\N	\N	\N	11-18560
473	473 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	11-19048
2253	2253 Tumor	Tumor	2019-07-19 00:00:00-07	\N	Metastatic	\N	11-19653B2
3024	3024 Tumor	Tumor	\N	\N	\N	\N	11-19877
3006	3006 Tumor	Tumor	\N	\N	\N	\N	11-20375
3023	3023 Tumor	Tumor	\N	\N	\N	\N	11-20772
3090	3090 Tumor	Tumor	\N	\N	\N	\N	11-21025B1
2768	2768 Tumor	Tumor	\N	\N	\N	\N	11-21178
3008	3008 Tumor	Tumor	\N	\N	\N	\N	11-21178
3007	3007 Tumor	Tumor	\N	\N	\N	\N	11-21491
2919	2919 Mel	Mel	\N	\N	\N	\N	11-23681
2920	2920 Mel	Mel	\N	\N	\N	\N	11-23681
2921	2921 Nevus	Nevus	\N	\N	\N	\N	11-23681
2922	2922 Nevus	Nevus	\N	\N	\N	\N	11-23681
2150	2150 Normal	Normal	\N	\N	Progression Cases	\N	11-23681A
2090	2090 Normal	Normal	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS1\\H&E	\N	11-23681B
2091	2091 Nevus	Nevus	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS1\\H&E	\N	11-23681B
2092	2092 Mel	Mel	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS1\\H&E	\N	11-23681B
2763	2763 Normal	Normal	\N	\N	\N	\N	11-23681C
1324	1324 Tumor	Tumor	\N	\N	\N	\N	11-23710
1337	1337 Tumor	Tumor	\N	\N	\N	\N	11-23710
2961	2961 Tumor	Tumor	\N	\N	\N	\N	11-23710
3395	3395 Tumor	Tumor	\N	\N	\N	\N	11-23710
3025	3025 Tumor	Tumor	\N	\N	\N	\N	11-25808
3216	3216 Tumor	Tumor	\N	\N	\N	\N	11-26903
659	659 Mel	Mel	\N	\N	\N	\N	11-27846 T3
3217	3217 Tumor	Tumor	\N	\N	\N	\N	11-28912B
2152	2152 Unknown	Unknown	\N	\N	Progression Cases.	\N	11-29719
2962	2962 Tumor	Tumor	\N	\N	\N	\N	11-30426
3396	3396 Tumor	Tumor	\N	\N	\N	\N	11-30426
1320	1320 Tumor	Tumor	\N	\N	\N	\N	11-31904
2963	2963 Tumor	Tumor	\N	\N	\N	\N	11-31904
3031	3031 Tumor	Tumor	\N	\N	\N	\N	11-31904
3397	3397 Tumor	Tumor	\N	\N	\N	\N	11-31904
3086	3086 Tumor	Tumor	\N	\N	\N	\N	11-032523A1
3027	3027 Tumor	Tumor	\N	\N	\N	\N	11-33856
2940	2940 Tumor	Tumor	\N	\N	\N	\N	11-34950
3685	3685 Not Processed	Not Processed	\N	\N	\N	\N	11-35367
3026	3026 Tumor	Tumor	\N	\N	\N	\N	11-35616
1494	1494 Mel1	Mel1	\N	\N	\N	\N	11-36301A1
1495	1495 Mel2	Mel2	\N	\N	\N	\N	11-36301A1
1496	1496 Mel3	Mel3	\N	\N	\N	\N	11-36301A1
1497	1497 Normal	Normal	\N	\N	\N	\N	11-36301A5
1498	1498 MIS	MIS	\N	\N	\N	\N	11-36301A5
1500	1500 Met2	Met2	\N	\N	\N	\N	11-36301C1
1499	1499 LN Met 1	LN Met 1	\N	\N	\N	\N	11-36301C1
1501	1501 Met3	Met3	\N	\N	\N	\N	11-36301C1
1733	1733 Mel	Mel	\N	\N	\N	\N	11-37100B
2923	2923 Mel	Mel	\N	\N	\N	\N	11-37533
2924	2924 Mel	Mel	\N	\N	\N	\N	11-37533
2927	2927 Normal	Normal	\N	\N	\N	\N	11-37533
2926	2926 Nevus	Nevus	\N	\N	\N	\N	11-37533
2925	2925 Nevus	Nevus	\N	\N	\N	\N	11-37533
2059	2059 Nevus	Nevus	\N	\N	Progression Cases. Hunter has already sequenced this case before. \tbastianlab2\\HiSeqData_Hunter\\AperioScansForEvaluation\\22_2. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS3\\H&E	\N	11-37533B
2058	2058 Normal	Normal	\N	\N	Progression Cases. Comments:  normal sample has granulation tissue and fat necrosis, copy number data for all samples looks dirty. Hunter has already sequenced this case before. \tbastianlab2\\HiSeqData_Hunter\\AperioScansForEvaluation\\22_2. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS3\\H&E\n	\N	11-37533B
2060	2060 Mel1	Mel1	\N	\N	Progression Cases. Hunter has already sequenced this case before. \tbastianlab2\\HiSeqData_Hunter\\AperioScansForEvaluation\\22_2. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS3\\H&E	\N	11-37533B
2061	2061 Mel2	Mel2	\N	\N	Progression Cases. Hunter has already sequenced this case before. \tbastianlab2\\HiSeqData_Hunter\\AperioScansForEvaluation\\22_2. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS3\\H&E	\N	11-37533B
2777	2777 Normal	Normal	\N	\N	\N	\N	11-38149
3028	3028 Tumor	Tumor	\N	\N	\N	\N	11-38771
3084	3084 Tumor	Tumor	\N	\N	\N	\N	11-38910A2
3029	3029 Tumor	Tumor	\N	\N	\N	\N	11-39639
3030	3030 Tumor	Tumor	\N	\N	\N	\N	11-42027
474	474 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	11-43354
2811	2811 Tumor	Tumor	\N	\N	\N	\N	11-44609F
3398	3398 Tumor	Tumor	\N	\N	\N	\N	11-47644
469	469 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	11-47908
1959	1959 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	11-48013
2163	2163 	\N	\N	\N	Progression Cases.	\N	11-49127
3033	3033 Tumor	Tumor	\N	\N	\N	\N	11-50182
3032	3032 Tumor	Tumor	\N	\N	\N	\N	11-50270
3034	3034 Tumor	Tumor	\N	\N	\N	\N	11-51553
3035	3035 Tumor	Tumor	\N	\N	\N	\N	11-52339
425	425 Blue + spitz	Blue + spitz	\N	\N	\N	\N	11-53065
3036	3036 Tumor	Tumor	\N	\N	\N	\N	11-55993
3038	3038 Tumor	Tumor	\N	\N	\N	\N	11-57051
470	470 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	11-59209
3009	3009 Tumor	Tumor	\N	\N	\N	\N	11-61046
3037	3037 Tumor	Tumor	\N	\N	\N	\N	11-61046
1323	1323 Tumor	Tumor	\N	\N	\N	\N	11-23710,11-61046
3441	3441 Unknown	Unknown	\N	\N	\N	\N	11-62022
3011	3011 Tumor	Tumor	\N	\N	\N	\N	11-63178
1338	1338 Tumor	Tumor	\N	\N	\N	\N	11-63724
3012	3012 Tumor	Tumor	\N	\N	\N	\N	11-64496
1339	1339 Tumor	Tumor	\N	\N	\N	\N	11-65284
3014	3014 Tumor	Tumor	\N	\N	\N	\N	11-65756
3010	3010 Tumor	Tumor	\N	\N	\N	\N	11-65778
1340	1340 Tumor	Tumor	\N	\N	\N	\N	11-66564
3039	3039 Tumor	Tumor	\N	\N	\N	\N	11-71006
3215	3215 Tumor	Tumor	\N	\N	\N	\N	11-71241
3013	3013 Tumor	Tumor	\N	\N	\N	\N	11-71491
3231	3231 Tumor	Tumor	\N	\N	\N	\N	11-73238A
3232	3232 Normal	Normal	\N	\N	\N	\N	11-73999
3015	3015 Tumor	Tumor	\N	\N	\N	\N	11-74100
3017	3017 Tumor	Tumor	\N	\N	\N	\N	11-74517
3040	3040 Tumor	Tumor	\N	\N	\N	\N	11-76464
2988	2988 Tumor	Tumor	\N	\N	\N	\N	11-78845
3016	3016 Tumor	Tumor	\N	\N	\N	\N	11-79158
1731	1731 Mel	Mel	\N	\N	\N	\N	11-80898
1732	1732 Normal	Normal	\N	\N	\N	\N	11-80898
2989	2989 Tumor	Tumor	\N	\N	\N	\N	11-81405
3806	3806 Mel	Mel	\N	\N	\N	\N	11-81851
3807	3807 Mel	Mel	\N	\N	\N	\N	11-81851
3808	3808 Nevus	Nevus	\N	\N	\N	\N	11-81851
3810	3810 Normal	Normal	\N	\N	\N	\N	11-81851
3809	3809 Nevus	Nevus	\N	\N	\N	\N	11-81851
2991	2991 Tumor	Tumor	\N	\N	\N	\N	11-83908
1341	1341 Tumor	Tumor	\N	\N	\N	\N	11-84681
2941	2941 Tumor	Tumor	\N	\N	\N	\N	11-84681
471	471 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	11-85008
2990	2990 Tumor	Tumor	\N	\N	\N	\N	11-85075
3018	3018 Tumor	Tumor	\N	\N	\N	\N	11-85416
2992	2992 Tumor	Tumor	\N	\N	\N	\N	11-85859
1342	1342 Tumor	Tumor	\N	\N	\N	\N	11-87412
3042	3042 Tumor	Tumor	\N	\N	\N	\N	11-88209
3442	3442 Tumor	Tumor	\N	\N	\N	\N	11-88209
1343	1343 Tumor	Tumor	\N	\N	\N	\N	11-88431
3069	3069 Tumor	Tumor	\N	\N	\N	\N	11-88431
3041	3041 Tumor	Tumor	\N	\N	\N	\N	11-88432
2036	2036 Normal	Normal	\N	\N	\N	\N	11-89154A6
2149	2149 Not Processed	Not Processed	\N	\N	\N	\N	11-89154A7
3857	3857 Not Processed	Not Processed	\N	\N	\N	\N	11-91034
3019	3019 Tumor	Tumor	\N	\N	\N	\N	11-94134
2062	2062 Normal	Normal	\N	\N	Comments:  good normal, copy number data looks dirty. Hunter has already sequenced this case before. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS5\n	\N	11-94204
2063	2063 Nevus	Nevus	\N	\N	Hunter has already sequenced this case before. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS5	\N	11-94204
2064	2064 Mel	Mel	\N	\N	Hunter has already sequenced this case before. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS5	\N	11-94204
2993	2993 Tumor	Tumor	\N	\N	\N	\N	11-95663
2778	2778 Tumor	Tumor	\N	\N	\N	\N	11-95856
3355	3355 Normal	Normal	\N	\N	\N	\N	11-96096
568	568 Nodular Mel	Nodular Mel	\N	\N	\N	\N	11B2562 (eppendorf)
567	567 Nodular Mel	Nodular Mel	\N	\N	\N	\N	11B9724 (eppendorf)
3427	3427 Tumor	Tumor	\N	\N	\N	\N	12_20321A2
1141	1141 Tumor	Tumor	\N	\N	\N	\N	12-073
1142	1142 Tumor	Tumor	\N	\N	\N	\N	12-095
1143	1143 Tumor	Tumor	\N	\N	\N	\N	12-122
1144	1144 Tumor	Tumor	\N	\N	\N	\N	12-169
1329	1329 Tumor	Tumor	\N	\N	\N	\N	12-200
2405	2405 Unknown	Unknown	2015-07-31 00:00:00-07	\N	\N	\N	12-562
3686	3686 Not Processed	Not Processed	\N	\N	\N	\N	12-1450
620	620 Nevus?	Nevus?	\N	\N	\N	\N	12-1782
2322	2322 Tumor	Tumor	\N	\N	\N	\N	12-1782
3043	3043 Tumor	Tumor	\N	\N	\N	\N	12-2898
1438	1438 Normal	Normal	\N	\N	\N	\N	12-3277
1439	1439 Invasive 5	Invasive 5	\N	\N	\N	\N	12-3277
1440	1440 Invasive 6	Invasive 6	\N	\N	\N	\N	12-3277
2458	2458 Normal 2	Normal 2	\N	\N	\N	\N	12-3277
1315	1315 Tumor	Tumor	\N	\N	\N	\N	12-4251
3045	3045 Tumor	Tumor	\N	\N	\N	\N	12-4251
2835	2835 Normal	Normal	\N	\N	\N	\N	12-4365A8
2817	2817 Met1	Met1	\N	\N	\N	\N	12-4365B1
2818	2818 Met2	Met2	\N	\N	\N	\N	12-4365C1
2819	2819 Met2	Met2	\N	\N	\N	\N	12-4365C2
2814	2814 Tumor	Tumor	\N	\N	\N	\N	12-004374B
918	918 Mel	Mel	\N	\N	\N	\N	12-05089-3
660	660 Mel	Mel	\N	\N	\N	\N	12-05858 T3
962	962 Mel	Mel	\N	\N	\N	\N	12-05858A3 M1
2400	2400 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-6261A
2401	2401 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-6261B
3085	3085 Tumor	Tumor	\N	\N	\N	\N	12-6332A5
466	466 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	12-6550
2942	2942 Tumor	Tumor	\N	\N	\N	\N	12-6981
3088	3088 Tumor	Tumor	\N	\N	\N	\N	12-7093NG176-1
3054	3054 Tumor	Tumor	\N	\N	\N	\N	12-7775
3046	3046 Tumor	Tumor	\N	\N	\N	\N	12-8171
1344	1344 Tumor	Tumor	\N	\N	\N	\N	12-9397B
2834	2834 Met	Met	\N	\N	\N	\N	12-9606A2
2831	2831 Normal	Normal	\N	\N	\N	\N	12-9606C4
2832	2832 MM	MM	\N	\N	\N	\N	12-9606E4
2833	2833 MM	MM	\N	\N	\N	\N	12-9606E9
619	619 Nevus?	Nevus?	\N	\N	\N	\N	12-10777
2321	2321 Tumor	Tumor	\N	\N	\N	\N	12-10777
997	997 Tumor	Tumor	\N	\N	PRKC fused cases	\N	12-11041
1322	1322 Tumor	Tumor	\N	\N	\N	\N	12-11041
2250	2250 Tumor	Tumor	\N	\N	\N	\N	12-11041
2328	2328 Tumor	Tumor	\N	\N	\N	\N	12-11041
2776	2776 Tumor	Tumor	\N	\N	\N	\N	12-11406A
661	661 Mel	Mel	\N	\N	\N	\N	12-12352 T3
2402	2402 SCC	SCC	2015-07-31 00:00:00-07	\N	\N	\N	12-12366
2403	2403 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-12467
2404	2404 BCC	BCC	2015-07-31 00:00:00-07	\N	\N	\N	12-12470D
2407	2407 Cellular Dermatofibroma 	Cellular Dermatofibroma 	2015-07-31 00:00:00-07	\N	\N	\N	12-12626
2406	2406 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-12647
2096	2096 Normal	Normal	\N	\N	\N	\N	12-12684
2097	2097 Nevus	Nevus	\N	\N	\N	\N	12-12684
2098	2098 Mel	Mel	\N	\N	\N	\N	12-12684
2411	2411 SCC	SCC	2015-07-31 00:00:00-07	\N	\N	\N	12-12750B
2410	2410 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-13152
2408	2408 SCC	SCC	2015-07-31 00:00:00-07	\N	\N	\N	12-13587B2
2421	2421 SCC	SCC	2015-07-31 00:00:00-07	\N	\N	\N	12-13587B2
2422	2422 SCC	SCC	2015-07-31 00:00:00-07	\N	\N	\N	12-13587B2
2423	2423 SCC	SCC	2015-07-31 00:00:00-07	\N	\N	\N	12-13587B2
3307	3307 Tumor	Tumor	\N	\N	\N	\N	12-15765B3
477	477 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	12-16974B
446	446 DPN+ pure	DPN, pure	\N	\N	\N	\N	12-16974C
2409	2409 SCC+ in situ	SCC, in situ	2015-07-31 00:00:00-07	\N	\N	\N	12-18438A
2935	2935 Tumor	Tumor	\N	\N	\N	\N	12-18826
2764	2764 Tumor	Tumor	\N	\N	\N	\N	12-19018B
2413	2413 Dermatofibroma	Dermatofibroma	2015-07-31 00:00:00-07	\N	\N	\N	12-19187A
2412	2412 SCC+ in situ	SCC, in situ	2015-07-31 00:00:00-07	\N	\N	\N	12-19596
467	467 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	12-20144
2416	2416 Dermatofibroma	Dermatofibroma	2015-07-31 00:00:00-07	\N	\N	\N	12-21726A
2164	2164 Unknown	Unknown	\N	\N	Progression Cases.	\N	12-21933I
2099	2099 Normal	Normal	\N	\N	12-21993C, 12-21993I	\N	12-21993C
2100	2100 Nevus	Nevus	\N	\N	12-21993C, 12-21993I	\N	12-21993I
2101	2101 Mel	Mel	\N	\N	12-21993C, 12-21993I	\N	12-21993I
2414	2414 Normal	Normal	2015-07-31 00:00:00-07	\N	\N	\N	12-22172
2415	2415 SCC+ in situ	SCC, in situ	2015-07-31 00:00:00-07	\N	\N	\N	12-22172
2426	2426 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22573
2427	2427 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22582A
3842	3842 Tumor	Tumor	\N	\N	\N	\N	12-22582C
2428	2428 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22587
2429	2429 Keratosis	Keratosis	2015-07-31 00:00:00-07	\N	\N	\N	12-22592
2430	2430 BCC	BCC	2015-07-31 00:00:00-07	\N	\N	\N	12-22597
2431	2431 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22602A
2432	2432 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22602B
2433	2433 Pilomatricoma+ cystic	Pilomatricoma, cystic	2015-07-31 00:00:00-07	\N	\N	\N	12-22603
2434	2434 BCC	BCC	2015-07-31 00:00:00-07	\N	\N	\N	12-22604
2435	2435 Leiomyoma	Leiomyoma	2015-07-31 00:00:00-07	\N	\N	\N	12-22720A1
2424	2424 SCC	SCC	2015-07-31 00:00:00-07	\N	\N	\N	12-22775
2419	2419 Normal	Normal	2015-07-31 00:00:00-07	\N	\N	\N	12-22776B5
2425	2425 Mel	Mel	2015-07-31 00:00:00-07	\N	\N	\N	12-22794A
2436	2436 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22868
2437	2437 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22884C
2438	2438 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22884D
2439	2439 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22886
2440	2440 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22894B
2441	2441 Melanocytic Nevus	Melanocytic Nevus	2015-07-31 00:00:00-07	\N	\N	\N	12-22898
2442	2442 SCC	SCC	2015-07-31 00:00:00-07	\N	\N	\N	12-22900
2418	2418 Tumor	Tumor	2015-07-31 00:00:00-07	\N	\N	\N	12-22901A
2417	2417 Normal	Normal	2015-07-31 00:00:00-07	\N	\N	\N	12-22901A
3055	3055 Tumor	Tumor	\N	\N	\N	\N	12-23578
455	455 Spitz mel	Spitz mel	\N	\N	\N	\N	12-24027C
1490	1490 Normal	Normal	\N	\N	\N	\N	12-24189A1
1491	1491 Mel1	Mel1	\N	\N	\N	\N	12-24189A1
1492	1492 Mel2	Mel2	\N	\N	\N	\N	12-24189A1
621	621 Nevus?	Nevus?	\N	\N	\N	\N	12-24226
1493	1493 Lung Met 1	Lung Met 1	\N	\N	\N	\N	12-24455
3687	3687 Not Processed	Not Processed	\N	\N	\N	\N	12-24502A1
3696	3696 Not Processed	Not Processed	\N	\N	\N	\N	12-24502B
490	490 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	12-26470
3056	3056 Tumor	Tumor	\N	\N	\N	\N	12-31421
3049	3049 Tumor	Tumor	\N	\N	\N	\N	12-31996
468	468 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	12-32138
463	463 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	12-37217
3050	3050 Tumor	Tumor	\N	\N	\N	\N	12-39632
3697	3697 Not Processed	Not Processed	\N	\N	\N	\N	12-41833E1
1345	1345 Tumor	Tumor	\N	\N	\N	\N	12-48249
880	880 DPN-mm	DPN-mm	\N	\N	\N	\N	12-051311
881	881 MM	MM	\N	\N	\N	\N	12-051311
429	429 common + blue	common + blue	\N	\N	\N	\N	12-51532
464	464 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	12-52736
3091	3091 Normal	Normal	\N	\N	\N	\N	12-54296
3092	3092 Tumor	Tumor	\N	\N	\N	\N	12_54296,12-54296
3093	3093 Normal	Normal	\N	\N	\N	\N	12-54992
3094	3094 Tumor	Tumor	\N	\N	\N	\N	12-54992
3051	3051 Tumor	Tumor	\N	\N	\N	\N	12-55584
2106	2106 Nevus	Nevus	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS11w , 12-57349C, 12-57349E	\N	12-57349C
2107	2107 Mel1	Mel1	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS11w , 12-57349C, 12-57349E	\N	12-57349C
2108	2108 Mel2	Mel2	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS11w , 12-57349C, 12-57349E	\N	12-57349C
2105	2105 Normal	Normal	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS11w , 12-57349C, 12-57349E	\N	12-57349E
2165	2165 Unknown	Unknown	\N	\N	Progression Cases.	\N	12-57797
1346	1346 Tumor	Tumor	\N	\N	\N	\N	12-64897
491	491 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	12-67286
3095	3095 Normal	Normal	\N	\N	\N	\N	12-67298
3096	3096 Tumor	Tumor	\N	\N	\N	\N	12-67298
2093	2093 Normal	Normal	\N	\N	Progression Cases, 12-67568A, 12-67568B	\N	12-67568A
2094	2094 Nevus	Nevus	\N	\N	Progression Cases, 12-67568A, 12-67568B	\N	12-67568B
2095	2095 Mel	Mel	\N	\N	Progression Cases, 12-67568A, 12-67568B	\N	12-67568B
998	998 Tumor	Tumor	\N	\N	PRKC fused cases	\N	12-70514
3052	3052 Tumor	Tumor	\N	\N	\N	\N	12-71679
2102	2102 Normal	Normal	\N	\N	\N	\N	12-79097B
2103	2103 Nevus	Nevus	\N	\N	\N	\N	12-79097B
2104	2104 Mel	Mel	\N	\N	\N	\N	12-79097B
3070	3070 Tumor	Tumor	\N	\N	\N	\N	12-79358
3053	3053 Tumor	Tumor	\N	\N	\N	\N	12-80985B
3057	3057 Tumor	Tumor	\N	\N	\N	\N	12-81302
3058	3058 Tumor	Tumor	\N	\N	\N	\N	12-81749
1628	1628 Mel	Mel	\N	\N	\N	\N	12-85105A
457	457 Spitz mel	Spitz mel	\N	\N	\N	\N	12-91942
2065	2065 Normal	Normal	\N	\N	Progression Cases. \tbastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS12. Comments:  good normal, copy number data looks dirty	\N	12-93589A
2066	2066 Nevus	Nevus	\N	\N	Progression Cases. \tbastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS12.	\N	12-93589A
2067	2067 Mel	Mel	\N	\N	Progression Cases. \tbastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS12.	\N	12-93589A
3059	3059 Tumor	Tumor	\N	\N	\N	\N	12-97031
465	465 cellular blue nevus	cellular blue nevus	\N	\N	\N	\N	12-97918
2812	2812 Tumor	Tumor	\N	\N	\N	\N	12-98575A1
3060	3060 Tumor	Tumor	\N	\N	\N	\N	12-98736
3061	3061 Tumor	Tumor	\N	\N	\N	\N	13-25A
1140	1140 Tumor	Tumor	\N	\N	\N	\N	13-028
1960	1960 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	13-48
1139	1139 Tumor	Tumor	\N	\N	\N	\N	13-074
1138	1138 Tumor	Tumor	\N	\N	\N	\N	13-122
1137	1137 Tumor	Tumor	\N	\N	\N	\N	13-129
1136	1136 Tumor	Tumor	\N	\N	\N	\N	13-140
1135	1135 Tumor	Tumor	\N	\N	\N	\N	13-207
2934	2934 Tumor	Tumor	\N	\N	\N	\N	13-212
2853	2853 Tumor	Tumor	\N	\N	\N	\N	13-2054
2068	2068 Normal	Normal	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS13	\N	13-2138C
2069	2069 Nevus	Nevus	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS13	\N	13-2138C
2070	2070 AMB	AMB	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS13	\N	13-2138C
2071	2071 Mel	Mel	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS13	\N	13-2138C
3234	3234 Tumor	Tumor	\N	\N	\N	\N	13-2939B
3063	3063 Tumor	Tumor	\N	\N	\N	\N	13-3732
3062	3062 Tumor	Tumor	\N	\N	\N	\N	13-3874
3064	3064 Tumor	Tumor	\N	\N	\N	\N	13-3889
3065	3065 Tumor	Tumor	\N	\N	\N	\N	13-4090B
3066	3066 Tumor	Tumor	\N	\N	\N	\N	13-4136
2816	2816 Tumor	Tumor	\N	\N	\N	\N	13-006535C
3067	3067 Tumor	Tumor	\N	\N	\N	\N	13-7186
3382	3382 Tumor	Tumor	\N	\N	\N	\N	13-8208B
2852	2852 Tumor	Tumor	\N	\N	\N	\N	13-9682
2810	2810 Tumor	Tumor	\N	\N	\N	\N	13-9916
2726	2726 Tumor	Tumor	\N	\N	\N	\N	13-10776A1
1961	1961 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	13-11936
2883	2883 Tumor	Tumor	\N	\N	\N	\N	13-12947A2
1678	1678 Mel	Mel	\N	\N	\N	\N	13-14077
1679	1679 Normal	Normal	\N	\N	\N	\N	13-14077
2677	2677 MIS	MIS	\N	\N	\N	\N	13-17186A14
2676	2676 Invasive	Invasive	\N	\N	\N	\N	13-17186A16
2679	2679  (+) Lymph Node	 (+) Lymph Node	\N	\N	\N	\N	13-17186A20
2678	2678 Normal	Normal	\N	\N	\N	\N	13-17186A21
2725	2725 Tumor	Tumor	\N	\N	\N	\N	13-17202A11
2724	2724 Normal	Normal	\N	\N	\N	\N	13-17202C4
2884	2884 Tumor	Tumor	\N	\N	\N	\N	13-18444A16
1529	1529 Mel1	Mel1	\N	\N	\N	\N	13-23696A5
1530	1530 Mel2	Mel2	\N	\N	\N	\N	13-23696A5
1532	1532 Mel4	Mel4	\N	\N	\N	\N	13-23696A5
1531	1531 Mel3	Mel3	\N	\N	\N	\N	13-23696A5
1533	1533 MIS1	MIS1	\N	\N	\N	\N	13-23696A5
662	662 Mel	Mel	\N	\N	\N	\N	13-24372A T1
960	960 Mel	Mel	\N	\N	\N	\N	13-24372B CONSULTA
631	631 Mel	Mel	\N	\N	\N	\N	13-24372B T1
3377	3377 Nevus	Nevus	\N	\N	\N	\N	13-25110A1
3376	3376 Mel	Mel	\N	\N	\N	\N	13-25110A1
3378	3378 Normal	Normal	\N	\N	\N	\N	13-25110A1
663	663 Mel	Mel	\N	\N	\N	\N	13-26846 T4
963	963 Mel	Mel	\N	\N	\N	\N	13-26846A1 N1
1470	1470 Normal	Normal	\N	\N	\N	\N	13-30315A3
1471	1471 Mel1	Mel1	\N	\N	\N	\N	13-30315A3
1472	1472 MIS1	MIS1	\N	\N	\N	\N	13-30315A3
1347	1347 Tumor	Tumor	\N	\N	\N	\N	13-32039
1689	1689 Mel	Mel	\N	\N	\N	\N	13-32289A
1690	1690 Normal	Normal	\N	\N	\N	\N	13-32289A
1691	1691 Mel	Mel	\N	\N	\N	\N	13-32289B
1692	1692 MIS	MIS	\N	\N	\N	\N	13-32289B
3540	3540 Waiting Process	Waiting Process	\N	\N	\N	\N	13-32637
2809	2809 Tumor	Tumor	\N	\N	\N	\N	13-32982A
3541	3541 Waiting Process	Waiting Process	\N	\N	\N	\N	13-33924
2805	2805 Tumor	Tumor	\N	\N	\N	\N	13-35959
3698	3698 Not Processed	Not Processed	\N	\N	\N	\N	13-37513
3380	3380 Nevus	Nevus	\N	\N	\N	\N	13-45163
3379	3379 Mel	Mel	\N	\N	\N	\N	13-45163
3381	3381 Normal	Normal	\N	\N	\N	\N	13-45163
2712	2712 Tumor	Tumor	\N	\N	\N	\N	13-46194
3235	3235 Tumor	Tumor	\N	\N	\N	\N	13-48798
3542	3542 Waiting Process	Waiting Process	\N	\N	\N	\N	13-50059
3236	3236 Tumor	Tumor	\N	\N	\N	\N	13-51115A
1963	1963 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	13-51506A
1962	1962 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	13-51506B
1981	1981 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	13-55769
3230	3230 Tumor	Tumor	\N	\N	\N	\N	13-59840
3233	3233 Tumor	Tumor	\N	\N	\N	\N	13-59840
2699	2699 Tumor	Tumor	\N	\N	\N	\N	13-61266A
2714	2714 Tumor	Tumor	\N	\N	\N	\N	13-62943
2030	2030 Atypical Melanocytic Proliferation	Atypical Melanocytic Proliferation	\N	\N	\N	\N	13-68674
3403	3403 Unknown	Unknown	\N	\N	\N	\N	13-68674
3404	3404 Unknown	Unknown	\N	\N	\N	\N	13-68674
2713	2713 Tumor	Tumor	\N	\N	\N	\N	13-69386B
1348	1348 Tumor	Tumor	\N	\N	\N	\N	13-73582
1349	1349 Tumor	Tumor	\N	\N	\N	\N	13-75788B
2708	2708 Tumor	Tumor	\N	\N	\N	\N	13-90988
2808	2808 Tumor	Tumor	\N	\N	\N	\N	13-98534
2072	2072 Normal	Normal	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS14	\N	13-98648
2073	2073 Nevus	Nevus	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS14	\N	13-98648
2074	2074 Mel	Mel	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS14	\N	13-98648
2807	2807 Tumor	Tumor	\N	\N	\N	\N	13-99417
2806	2806 Tumor	Tumor	\N	\N	\N	\N	13-102610
456	456 Spitz mel	Spitz mel	\N	\N	\N	\N	13-105024A
2031	2031 Atypical Melanocytic Proliferation	Atypical Melanocytic Proliferation	\N	\N	\N	\N	13-107061
3405	3405 Unknown	Unknown	\N	\N	\N	\N	13-107061
3406	3406 Unknown	Unknown	\N	\N	\N	\N	13-107061
566	566 Nodular Mel	Nodular Mel	\N	\N	\N	\N	13B10486 (eppendorf)
1328	1328 Tumor	Tumor	\N	\N	\N	\N	14-077
2727	2727 Tumor	Tumor	\N	\N	\N	\N	14-159A2
2005	2005 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	14-01007
2151	2151 Unknown	Unknown	\N	\N	Progression Cases.	\N	14-2508
664	664 Mel	Mel	\N	\N	\N	\N	14-03473 T3
2701	2701 Tumor	Tumor	\N	\N	\N	\N	14-3598
964	964 Mel	Mel	\N	\N	\N	\N	14-04359A2 N1
2006	2006 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	14-4953
2007	2007 Atypical Melanocytic Proliferation	Atypical Melanocytic Proliferation	\N	\N	\N	\N	14-4953
2008	2008 Atypical Melanocytic Proliferation	Atypical Melanocytic Proliferation	\N	\N	\N	\N	14-4953
2728	2728 Normal	Normal	\N	\N	\N	\N	14-4989D3
2729	2729 Tumor	Tumor	\N	\N	\N	\N	14-4989D3
3786	3786 Not Processed	Not Processed	\N	\N	\N	\N	14-5893
1350	1350 Tumor	Tumor	\N	\N	\N	\N	14-11769
2683	2683 Normal	Normal	\N	\N	\N	\N	14-12190A1
2681	2681 MIS	MIS	\N	\N	\N	\N	14-12190L4
2680	2680 Invasive	Invasive	\N	\N	\N	\N	14-12190L4
2682	2682 Normal	Normal	\N	\N	\N	\N	14-12190L4
2700	2700 Tumor	Tumor	\N	\N	\N	\N	14-13830
1965	1965 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	14-14773
999	999 Tumor	Tumor	\N	\N	PRKC fused cases	\N	14-15427
3068	3068 Tumor	Tumor	\N	\N	\N	\N	14-16247
965	965 Mel	Mel	\N	\N	\N	\N	14-17085A2 M1
622	622 Nevus?	Nevus?	\N	\N	\N	\N	14-29390
3543	3543 Waiting Process	Waiting Process	\N	\N	\N	\N	14-31325
1473	1473 Recurrence 1	Recurrence 1	\N	\N	\N	\N	14-31886
1624	1624 Normal	Normal	\N	\N	\N	\N	14-31886
2702	2702 Tumor	Tumor	\N	\N	\N	\N	14-32353
2078	2078 Normal	Normal	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS17	\N	14-33100
2079	2079 Nevus	Nevus	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS17	\N	14-33100
2080	2080 Mel	Mel	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS17	\N	14-33100
1634	1634 Mel	Mel	\N	\N	\N	\N	14-34758
1534	1534 Skin Met1	Skin Met1	\N	\N	\N	\N	14-35086A
1535	1535 Normal	Normal	\N	\N	Merge:  Both Normal from AM2-099-3	\N	14-37577A5
1536	1536 Skin Met2	Skin Met2	\N	\N	\N	\N	14-37577A5
2703	2703 Tumor	Tumor	\N	\N	\N	\N	14-37911A
452	452 Spitz mel	Spitz mel	\N	\N	\N	\N	14-39393
3787	3787 Not Processed	Not Processed	\N	\N	\N	\N	14-40331B
1351	1351 Tumor	Tumor	\N	\N	\N	\N	14-42631
1001	1001 Tumor	Tumor	\N	\N	NRAS sequencing	\N	14-43805
2171	2171 Unknown	Unknown	\N	\N	\N	\N	14-44611
1352	1352 Tumor	Tumor	\N	\N	\N	\N	14-46549
2081	2081 Normal	Normal	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS18	\N	14-47962
2083	2083 Mel	Mel	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS18	\N	14-47962
2082	2082 Nevus	Nevus	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS18	\N	14-47962
492	492 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	14-48102
2125	2125 Nevus	Nevus	\N	\N	\N	\N	14-50051
2124	2124 Mel	Mel	\N	\N	\N	\N	14-50051
2126	2126 Normal	Normal	\N	\N	\N	\N	14-50051
1539	1539 MIS1	MIS1	\N	\N	\N	\N	14-51352
1540	1540 MIS2	MIS2	\N	\N	\N	\N	14-51352
1625	1625 MIS2 In situ	MIS2 In situ	\N	\N	\N	\N	14-51352
2168	2168 Unknown	Unknown	\N	\N	\N	\N	14-53094\t
2172	2172 Unknown	Unknown	\N	\N	\N	\N	14-53375
2176	2176 Unknown	Unknown	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\T\\T3	\N	14-53894B
1353	1353 Tumor	Tumor	\N	\N	\N	\N	14-57552
3858	3858 Mel	Mel	\N	\N	\N	\N	14-58566
3859	3859 Normal	Normal	\N	\N	\N	\N	14-58566
2177	2177 Unknown	Unknown	\N	\N	Progression Cases. bastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\T\\T5	\N	14-58579
2173	2173 Unknown	Unknown	\N	\N	\N	\N	14-58586
2867	2867 Nevus	Nevus	\N	\N	\N	\N	14-58667
2868	2868 Normal	Normal	\N	\N	\N	\N	14-58667
2869	2869 Nevus	Nevus	\N	\N	\N	\N	14-59304A
2870	2870 Normal	Normal	\N	\N	\N	\N	14-59304A
2861	2861 Nevus	Nevus	\N	\N	\N	\N	14-59332
2862	2862 Normal	Normal	\N	\N	\N	\N	14-59332
454	454 Spitz mel	Spitz mel	\N	\N	\N	\N	14-59414
3864	3864 Tumor	Tumor	\N	\N	\N	\N	14-59956
2174	2174 Unknown	Unknown	\N	\N	\N	\N	14-61297
2825	2825 Normal	Normal	\N	\N	\N	\N	14-61299
2860	2860 Mel	Mel	\N	\N	\N	\N	14-61299
2865	2865 Nevus	Nevus	\N	\N	\N	\N	14-61835
2866	2866 Normal	Normal	\N	\N	\N	\N	14-61835
3866	3866 Tumor	Tumor	\N	\N	\N	\N	14-62335
2075	2075 Normal	Normal	\N	\N	Progression Cases.\tbastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS16	\N	14-64047
2076	2076 Nevus	Nevus	\N	\N	Progression Cases. \tbastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS16	\N	14-64047
1442	1442 MIS1	MIS1	\N	\N	\N	\N	17-88262
2077	2077 Mel	Mel	\N	\N	Progression Cases. \tbastianlab2\\HiSeqData_Hunter\\JJS_T\\AperioScans\\JJS\\JJS16	\N	14-64047
2704	2704 Tumor	Tumor	\N	\N	\N	\N	14-66686B
1964	1964 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	14-70636
2084	2084 Normal	Normal	\N	\N	Progression Cases.	\N	14-73175B
2085	2085 Nevus	Nevus	\N	\N	Progression Cases.	\N	14-73175B
2086	2086 Mel	Mel	\N	\N	Progression Cases.	\N	14-73175B
2111	2111 Mel	Mel	\N	\N	Progression Cases.	\N	14-73175B
2112	2112 Nevus	Nevus	\N	\N	Progression Cases.	\N	14-73175B
2113	2113 Normal	Normal	\N	\N	Progression Cases.	\N	14-73175B
2130	2130 Nevus	Nevus	\N	\N	\N	\N	14-73175B
3862	3862 Tumor	Tumor	\N	\N	\N	\N	14-74770
2088	2088 Nevus	Nevus	\N	\N	Progression Cases. Block is missing (08/15/22) and there are no other blocks to get Normal tissue from.	\N	14-78242
2087	2087 Normal	Normal	\N	\N	Progression Cases. Block is missing (08/15/22) and there are no other blocks to get Normal tissue from.	\N	14-78242
2089	2089 Mel	Mel	\N	\N	Progression Cases. Block is missing (08/15/22) and there are no other blocks to get Normal tissue from.	\N	14-78242
3863	3863 Tumor	Tumor	\N	\N	\N	\N	14-80165
1355	1355 Tumor	Tumor	\N	\N	\N	\N	14-82758
2705	2705 Tumor	Tumor	\N	\N	\N	\N	14-83646
1354	1354 Tumor	Tumor	\N	\N	\N	\N	14-83928
2710	2710 Tumor	Tumor	\N	\N	\N	\N	14-88685
623	623 Nevus?	Nevus?	\N	\N	\N	\N	14-90528
3861	3861 Tumor	Tumor	\N	\N	\N	\N	14-94217A
1356	1356 Tumor	Tumor	\N	\N	\N	\N	14-95595
493	493 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	14-96361
3865	3865 Tumor	Tumor	\N	\N	\N	\N	14-96795
2706	2706 Tumor	Tumor	\N	\N	\N	\N	14-99831
2697	2697 Tumor	Tumor	\N	\N	\N	\N	14-102015A
3860	3860 Tumor	Tumor	\N	\N	\N	\N	14-106005
3868	3868 Tumor	Tumor	\N	\N	\N	\N	14-113574
486	486 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	14-113821
461	461 Spitz mel	Spitz mel	\N	\N	\N	\N	14-115431A
462	462 Spitz mel	Spitz mel	\N	\N	\N	\N	14-115431C
2709	2709 Tumor	Tumor	\N	\N	\N	\N	14-118975
565	565 Nodular Mel	Nodular Mel	\N	\N	\N	\N	14B1910 (eppendorf)
558	558 Nodular Mel	Nodular Mel	\N	\N	\N	\N	14B13985 (eppendorf)
1544	1544 LN Met 3	LN Met 3	\N	\N	\N	\N	15-0176A1
1545	1545 LN Met 4	LN Met 4	\N	\N	\N	\N	15-0176A1
1546	1546 LN Met5	LN Met5	\N	\N	\N	\N	15-00176S2
2032	2032 Atypical Melanocytic Proliferation	Atypical Melanocytic Proliferation	\N	\N	\N	\N	15-1495
3409	3409 Unknown	Unknown	\N	\N	\N	\N	15-1495
665	665 Mel	Mel	\N	\N	\N	\N	15-02416 T2
2707	2707 Tumor	Tumor	\N	\N	\N	\N	15-3641
1519	1519 LN Met 1	LN Met 1	\N	\N	\N	\N	15-3736A1
1515	1515 Mel1	Mel1	\N	\N	\N	\N	15-3736C1
1516	1516 Mel2	Mel2	\N	\N	\N	\N	15-3736C1
1517	1517 Mel3	Mel3	\N	\N	\N	\N	15-3736C1
1518	1518 Mel4	Mel4	\N	\N	\N	\N	15-3736C1
1612	1612 Normal	Normal	\N	\N	\N	\N	15-3736C1
1521	1521 Normal	Normal	\N	\N	\N	\N	15-3736C5
1522	1522 Mel5	Mel5	\N	\N	\N	\N	15-3736C5
1523	1523 Normal	Normal	\N	\N	Merge: AM2-097-1, and AM2-097-2	\N	15-4505A1
1524	1524 Mel1	Mel1	\N	\N	\N	\N	15-4505A1
1525	1525 MIS1	MIS1	\N	\N	\N	\N	15-4505A1
1526	1526 Normal	Normal	\N	\N	Merge: AM2-097-1, and AM2-097-2	\N	15-4505B
1527	1527 LN Met 1	LN Met 1	\N	\N	\N	\N	15-4505C
1528	1528 LN Met 2	LN Met 2	\N	\N	\N	\N	15-4505C
3544	3544 Waiting Process	Waiting Process	\N	\N	\N	\N	15-05771-4
3545	3545 Waiting Process	Waiting Process	\N	\N	\N	\N	15-06395-3
3867	3867 Tumor	Tumor	\N	\N	\N	\N	15-6952
3546	3546 Waiting Process	Waiting Process	\N	\N	\N	\N	15-07035-1
3547	3547 Waiting Process	Waiting Process	\N	\N	\N	\N	15-08075-5
3548	3548 Waiting Process	Waiting Process	\N	\N	\N	\N	15-08126-3
3870	3870 Tumor	Tumor	\N	\N	\N	\N	15-8321
3549	3549 Waiting Process	Waiting Process	\N	\N	\N	\N	15-08727-2
1357	1357 Tumor	Tumor	\N	\N	\N	\N	15-10108
3550	3550 Waiting Process	Waiting Process	\N	\N	\N	\N	15-10294-1
3551	3551 Waiting Process	Waiting Process	\N	\N	\N	\N	15-11029-1
2160	2160 Normal	Normal	\N	\N	Progression Cases.	\N	15-12964B
2277	2277 Mel	Mel	\N	\N	\N	\N	15-12964B
2278	2278 Nevus	Nevus	\N	\N	\N	\N	15-12964B
3552	3552 Waiting Process	Waiting Process	\N	\N	\N	\N	15-13150A1
2166	2166 Normal	Normal	\N	\N	Progression Cases.; 15-14665B, 15-14665C	\N	15-14665B
2280	2280 Nevus	Nevus	\N	\N	15-14665B, 15-14665C	\N	15-14665B
2279	2279 Mel	Mel	\N	\N	15-14665B, 15-14665C	\N	15-14665C
3699	3699 Not Processed	Not Processed	\N	\N	\N	\N	15-14674
436	436 common+ sclerotic dermal component 	common, sclerotic dermal component 	\N	\N	\N	\N	15-16261
2711	2711 Tumor	Tumor	\N	\N	\N	\N	15-16543B
1358	1358 Tumor	Tumor	\N	\N	\N	\N	15-16907A
1476	1476 Mel2	Mel2	\N	\N	\N	\N	15-17010A1
1475	1475 Mel1	Mel1	\N	\N	\N	\N	15-17010A1
1477	1477 Mel3	Mel3	\N	\N	\N	\N	15-17010A1
3700	3700 Not Processed	Not Processed	\N	\N	\N	\N	15-17010A2
1478	1478 Normal	Normal	\N	\N	15-17010C, 15-17010A2	\N	15-17010C1
1479	1479 LN Met 1	LN Met 1	\N	\N	\N	\N	15-17010C1
1489	1489 LN Met 2	LN Met 2	\N	\N	\N	\N	15-17010C1
1520	1520 Met2	Met2	\N	\N	\N	\N	15-18463
424	424 Blue + spitz	Blue + spitz	\N	\N	\N	\N	15-21302
2162	2162 Normal	Normal	\N	\N	Progression Cases.	\N	15-21741
2283	2283 Mel	Mel	\N	\N	\N	\N	15-21741
2284	2284 Nevus	Nevus	\N	\N	\N	\N	15-21741
666	666 Mel	Mel	\N	\N	\N	\N	15-22166 T4
2157	2157 Capture Area D1	Capture Area D1	\N	\N	\N	\N	15-22411
2158	2158 Normal	Normal	\N	\N	Progression Cases.	\N	15-22411
2273	2273 Mel	Mel	\N	\N	\N	\N	15-22411
2274	2274 Nevus	Nevus	\N	\N	\N	\N	15-22411
1610	1610 Invasive Primary Mel	Invasive Primary Mel	\N	\N	\N	\N	15-24753A1
1359	1359 Tumor	Tumor	\N	\N	\N	\N	15-25818
1548	1548 Mel1	Mel1	\N	\N	\N	\N	15-26253A1
1547	1547 Normal	Normal	\N	\N	\N	\N	15-26253A1
1549	1549 Mel2	Mel2	\N	\N	\N	\N	15-26253A1
1550	1550 MIS1	MIS1	\N	\N	\N	\N	15-26253A1
1474	1474 Met1	Met1	\N	\N	\N	\N	15-29364A1
1966	1966 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	15-30226
618	618 Mel	Mel	\N	\N	\N	\N	15-32174 T2
1361	1361 Tumor	Tumor	\N	\N	\N	\N	15-33496
3553	3553 Waiting Process	Waiting Process	\N	\N	\N	\N	15-36291
3554	3554 Waiting Process	Waiting Process	\N	\N	\N	\N	15-36675
1362	1362 Tumor	Tumor	\N	\N	\N	\N	15-41815
625	625 Nevus?	Nevus?	\N	\N	\N	\N	15-42060
1681	1681 Mel	Mel	\N	\N	\N	\N	15-43069A
1443	1443 MIS2	MIS2	\N	\N	\N	\N	17-88262
1983	1983 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	15-43382
2698	2698 Tumor	Tumor	\N	\N	\N	\N	15-45455F
2170	2170 Normal	Normal	\N	\N	\N	\N	15-48134
2271	2271 Mel	Mel	\N	\N	\N	\N	15-48134
2272	2272 Nevus	Nevus	\N	\N	\N	\N	15-48134
1541	1541 Normal	Normal	\N	\N	\N	\N	15-48543A1
1542	1542 Skin Met1	Skin Met1	\N	\N	\N	\N	15-48543A1
3555	3555 Waiting Process	Waiting Process	\N	\N	\N	\N	15-49595
3556	3556 Waiting Process	Waiting Process	\N	\N	\N	\N	15-49595A1
2159	2159 Normal	Normal	\N	\N	Progression Cases.	\N	15-50051
2275	2275 Mel	Mel	\N	\N	\N	\N	15-50051
2276	2276 Nevus	Nevus	\N	\N	\N	\N	15-50051
1363	1363 Tumor	Tumor	\N	\N	\N	\N	15-52489
458	458 Spitz mel	Spitz mel	\N	\N	\N	\N	15-52921B
1364	1364 Tumor	Tumor	\N	\N	\N	\N	15-60391
1365	1365 Tumor	Tumor	\N	\N	\N	\N	15-61456
1366	1366 Tumor	Tumor	\N	\N	\N	\N	15-71393
430	430 common + blue	common + blue	\N	\N	\N	\N	15-72350
1984	1984 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	15-74487
2161	2161 Normal	Normal	\N	\N	Progression Cases.	\N	15-85517
2281	2281 Mel	Mel	\N	\N	\N	\N	15-85517
2282	2282 Nevus	Nevus	\N	\N	\N	\N	15-85517
1982	1982 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	15-86891
1369	1369 Tumor	Tumor	\N	\N	\N	\N	15-87833
1367	1367 Tumor	Tumor	\N	\N	\N	\N	15-88900
1368	1368 Tumor	Tumor	\N	\N	\N	\N	15-92618
1985	1985 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	15-96473
2153	2153 Normal	Normal	\N	\N	Progression Cases.	\N	15-98263
2285	2285 Mel	Mel	\N	\N	\N	\N	15-98263
2286	2286 Nevus	Nevus	\N	\N	\N	\N	15-98263
1967	1967 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	15-99261C
1000	1000 Tumor	Tumor	\N	\N	NRAS sequencing	\N	15-101612
485	485 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	15-101715
1968	1968 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	15-102731B
1455	1455 Nevus	Nevus	\N	\N	\N	\N	15-102927
1370	1370 Tumor	Tumor	\N	\N	\N	\N	15-110181
1371	1371 Tumor	Tumor	\N	\N	\N	\N	15-116253
1372	1372 Tumor	Tumor	\N	\N	\N	\N	15-117186
437	437 common+ sclerotic dermal component 	common, sclerotic dermal component 	\N	\N	\N	\N	15-118245A
1969	1969 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	15-122774
2009	2009 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	15-122795
1373	1373 Tumor	Tumor	\N	\N	\N	\N	15-123058
1552	1552 Normal	Normal	\N	\N	Merge: AM2-102-1, AM2-102-5-2, AM2-102-5-1	\N	16-552A7
1553	1553 Mel1	Mel1	\N	\N	\N	\N	16-552A7
1554	1554 Mel2	Mel2	\N	\N	\N	\N	16-552A7
1555	1555 MIS1	MIS1	\N	\N	\N	\N	16-552A7
1556	1556 MIS2	MIS2	\N	\N	\N	\N	16-552A7
1557	1557 MIS3	MIS3	\N	\N	\N	\N	16-552A7
3527	3527 Waiting Process	Waiting Process	\N	\N	\N	\N	16-00657-2
890	890 Blue Nevus	Blue Nevus	\N	\N	\N	\N	16-1675
1970	1970 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	16-2833
2003	2003 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	16-2833
3528	3528 Waiting Process	Waiting Process	\N	\N	\N	\N	16-03460-1
3529	3529 Waiting Process	Waiting Process	\N	\N	\N	\N	16-04805-2
3530	3530 Waiting Process	Waiting Process	\N	\N	\N	\N	16-05265-2
3531	3531 Waiting Process	Waiting Process	\N	\N	\N	\N	16-05548-2
3532	3532 Waiting Process	Waiting Process	\N	\N	\N	\N	16-05958-2
3533	3533 Waiting Process	Waiting Process	\N	\N	\N	\N	16-06126-2
3534	3534 Waiting Process	Waiting Process	\N	\N	\N	\N	16-06348-2
3535	3535 Waiting Process	Waiting Process	\N	\N	\N	\N	16-06590-2
3536	3536 Waiting Process	Waiting Process	\N	\N	\N	\N	16-06994-1
1988	1988 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	16-8674
1537	1537 Skin Met4	Skin Met4	\N	\N	\N	\N	16-9204
3537	3537 Waiting Process	Waiting Process	\N	\N	\N	\N	16-09944-2
1570	1570 Mel1	Mel1	\N	\N	\N	\N	16-10035A3
1569	1569 Normal	Normal	\N	\N	\N	\N	16-10035A3
1571	1571 Mel2	Mel2	\N	\N	\N	\N	16-10035A3
1573	1573 MIS2	MIS2	\N	\N	\N	\N	16-10035A3
1572	1572 MIS1	MIS1	\N	\N	\N	\N	16-10035A3
1574	1574 LN Met 1	LN Met 1	\N	\N	\N	\N	16-10035C
1375	1375 Tumor	Tumor	\N	\N	\N	\N	16-10466
3538	3538 Waiting Process	Waiting Process	\N	\N	\N	\N	16-10560-1
3539	3539 Waiting Process	Waiting Process	\N	\N	\N	\N	16-10561-3
165	165 DN	DN	\N	\N	\N	\N	16-12574
1374	1374 Tumor	Tumor	\N	\N	\N	\N	16-13909
2180	2180 Mel1	Mel1	\N	\N	\N	\N	16-17132B
2181	2181 Mel2	Mel2	\N	\N	\N	\N	16-17132B
2182	2182 Nevus	Nevus	\N	\N	\N	\N	16-17132B
2183	2183 Normal	Normal	\N	\N	\N	\N	16-17132B
1378	1378 Tumor	Tumor	\N	\N	\N	\N	16-18320A
1386	1386 Tumor	Tumor	\N	\N	\N	\N	16-19890
1376	1376 Tumor	Tumor	\N	\N	\N	\N	16-19895
1377	1377 Tumor	Tumor	\N	\N	\N	\N	16-20360
1538	1538 Skin Met3	Skin Met3	\N	\N	\N	\N	16-21256
1613	1613 Normal	Normal	\N	\N	\N	\N	16-21256
1998	1998 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	16-24795
1379	1379 Tumor	Tumor	\N	\N	\N	\N	16-25723
1381	1381 Tumor	Tumor	\N	\N	\N	\N	16-26672
1385	1385 Tumor	Tumor	\N	\N	\N	\N	16-27084
1380	1380 Tumor	Tumor	\N	\N	\N	\N	16-30292
627	627 Mel	Mel	\N	\N	\N	\N	16-31317 T4
1382	1382 Tumor	Tumor	\N	\N	\N	\N	16-31382
1606	1606 Invasive Primary Mel 1	Invasive Primary Mel 1	\N	\N	\N	\N	16-32182
1607	1607 Invasive Primary Mel 2	Invasive Primary Mel 2	\N	\N	\N	\N	16-32182
3557	3557 Waiting Process	Waiting Process	\N	\N	\N	\N	16-32627A1
427	427 blue nevus+ cellular+  DF like	blue nevus, cellular,  DF like	\N	\N	\N	\N	16-33907
1608	1608 Normal	Normal	\N	\N	\N	\N	16-35844B2
1609	1609 LN Met 1	LN Met 1	\N	\N	\N	\N	16-35844B2
2184	2184 Mel	Mel	\N	\N	\N	\N	16-35900
2185	2185 Nevus	Nevus	\N	\N	\N	\N	16-35900
2186	2186 Normal	Normal	\N	\N	\N	\N	16-35900
3558	3558 Waiting Process	Waiting Process	\N	\N	\N	\N	16-37564A1
1989	1989 Mel	Mel	\N	\N	\N	\N	16-37928A
1383	1383 Tumor	Tumor	\N	\N	\N	\N	16-41709
1387	1387 Tumor	Tumor	\N	\N	\N	\N	16-42062
1390	1390 Tumor	Tumor	\N	\N	\N	\N	16-42198
1384	1384 Tumor	Tumor	\N	\N	\N	\N	16-42657
1990	1990 Atypical Melanocytic Proliferation	Atypical Melanocytic Proliferation	\N	\N	\N	\N	16-44627
1991	1991 Atypical Melanocytic Proliferation	Atypical Melanocytic Proliferation	\N	\N	\N	\N	16-44627
2004	2004 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	16-44627
229	229 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10831	\N	\N	16-48776B
1986	1986 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	16-53528
3559	3559 Waiting Process	Waiting Process	\N	\N	\N	\N	16-53749A1
3560	3560 Waiting Process	Waiting Process	\N	\N	\N	\N	16-53749A2
1388	1388 Tumor	Tumor	\N	\N	\N	\N	16-55411
1987	1987 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	16-55930
1389	1389 Tumor	Tumor	\N	\N	\N	\N	16-56300
1391	1391 Tumor	Tumor	\N	\N	\N	\N	16-63804
2483	2483 Invasive	Invasive	\N	\N	\N	\N	16-74494
2484	2484 MIS	MIS	\N	\N	\N	\N	16-74494
1992	1992 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	16-76143
1392	1392 Tumor	Tumor	\N	\N	\N	\N	16-77392
1971	1971 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	16-77557
1393	1393 Tumor	Tumor	\N	\N	\N	\N	16-80354
494	494 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	16-83056
283	283 Normal	Normal	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22140	\N	\N	16-84820
285	285 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22140	\N	\N	16-84820
284	284 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22140	\N	\N	16-84820
2010	2010 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	16-85059
298	298 Nevus	Nevus	\N	\N	\N	\N	16-88453A
299	299 Mel	Mel	\N	\N	\N	\N	16-88453A
804	804 Normal	Normal	\N	\N	\N	\N	16-88453A
884	884 MIS	MIS	\N	\N	\N	\N	16-88453A
1394	1394 Tumor	Tumor	\N	\N	\N	\N	16-89926
1395	1395 Tumor	Tumor	\N	\N	\N	\N	16-90917
1401	1401 Tumor	Tumor	\N	\N	\N	\N	16-92011
1396	1396 Tumor	Tumor	\N	\N	\N	\N	16-94655
1397	1397 Tumor	Tumor	\N	\N	\N	\N	16-96276
116	116 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10832	\N	\N	16-97347
170	170 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10832	\N	\N	16-97347
182	182 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10832	\N	\N	16-97347
1399	1399 Tumor	Tumor	\N	\N	\N	\N	16-97391
131	131 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10833	\N	\N	16-98043
210	210 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10833	\N	\N	16-98043
204	204 DN	DN	\N	\N	\N	\N	16-98055A
128	128 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10834	\N	\N	16-98055B
205	205 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10834	\N	\N	16-98055B
117	117 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10835	\N	\N	16-98123
197	197 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10835	\N	\N	16-98123
227	227 DN	DN	\N	\N	\N	\N	16-98130
133	133 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10836	\N	\N	16-98328A
214	214 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10836	\N	\N	16-98328A
203	203 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10837	\N	\N	16-98528A
202	202 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10838	\N	\N	16-98733
139	139 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10839	\N	\N	16-98735
230	230 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10839	\N	\N	16-98735
350	350 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22141,25173	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	16-99265
351	351 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22141,25173	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	16-99265
2243	2243 MIS	MIS	\N	\N	\N	\N	16-99265
2244	2244 Nevus	Nevus	\N	\N	\N	\N	16-99265
2245	2245 Normal	Normal	\N	\N	\N	\N	16-99265
355	355 MIS	MIS	\N	\N	\N	\N	16-101803B
354	354 Normal	Normal	\N	\N	\N	\N	16-101803B
356	356 Mel	Mel	\N	\N	\N	\N	16-101803B
772	772 Mel	Mel	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	16-103071
773	773 Nevus	Nevus	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	16-103071
349	349 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24932,25176	Blue: melanoma; Green: normal: Yellow: Nevus.	\N	16-103438
348	348 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24932,25176	Blue: melanoma; Green: normal: Yellow: Nevus.	\N	16-103438
2127	2127 Normal	Normal	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus.	\N	16-103438
1449	1449 Normal	Normal	\N	\N	\N	\N	16-104614H
1430	1430 Normal	Normal	\N	\N	\N	\N	16-105218C
1398	1398 Tumor	Tumor	\N	\N	\N	\N	16-105648
290	290 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24928	\N	\N	16-106975
291	291 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24928	\N	\N	16-106975
289	289 Normal	Normal	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24928	\N	\N	16-106975
296	296 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22138	\N	\N	16-107007
297	297 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22138	\N	\N	16-107007
304	304 Normal	Normal	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22138	\N	\N	16-107007
1448	1448 Normal	Normal	\N	\N	\N	\N	16-108259C
1993	1993 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	16-108474
2117	2117 Mel	Mel	\N	\N	\N	\N	16-109052C
2119	2119 MIS	MIS	\N	\N	\N	\N	16-109052C
2118	2118 Nevus	Nevus	\N	\N	\N	\N	16-109052C
2120	2120 Normal	Normal	\N	\N	\N	\N	16-109052C
280	280 Normal	Normal	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22139,25172	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	16-109659A4
282	282 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22139,25172	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	16-109659A4
281	281 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22139,25172	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	16-109659A4
300	300 Nevus	Nevus	\N	\N	\N	\N	16-110683
301	301 Mel	Mel	\N	\N	\N	\N	16-110683
122	122 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10818	\N	\N	16-117695A
173	173 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10818	\N	\N	16-117695A
185	185 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10818	\N	\N	16-117695A
143	143 DN	DN	\N	\N	\N	\N	16-118014
235	235 DN	DN	\N	\N	\N	\N	16-118014
111	111 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10819	\N	\N	16-118019
224	224 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10819	\N	\N	16-118019
1994	1994 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	16-118278
174	174 DN	DN	\N	\N	\N	\N	16-119063
186	186 DN	DN	\N	\N	\N	\N	16-119063
120	120 DN	DN	\N	\N	\N	\N	16-119311
178	178 DN	DN	\N	\N	\N	\N	16-119311
190	190 DN	DN	\N	\N	\N	\N	16-119311
799	799 Mel	Mel	\N	\N	\N	\N	17-88895
220	220 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10820	\N	\N	16-119333
110	110 DN	DN	\N	\N	\N	\N	16-119467B
207	207 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10821	\N	\N	16-119467B
208	208 DN	DN	\N	\N	\N	\N	16-119467C
130	130 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10822	\N	\N	16-119467D
209	209 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10822	\N	\N	16-119467D
166	166 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10823	\N	\N	16-119468
192	192 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10823	\N	\N	16-119468
114	114 DN	DN	\N	\N	\N	\N	16-125177
168	168 DN	DN	\N	\N	\N	\N	16-125177
180	180 DN	DN	\N	\N	\N	\N	16-125177
171	171 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10824	\N	\N	16-125609
183	183 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10824	\N	\N	16-125609
126	126 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10825	\N	\N	16-125611
200	200 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10825	\N	\N	16-125611
138	138 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10826	\N	\N	16-125621
228	228 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10826	\N	\N	16-125621
199	199 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10827	\N	\N	16-125754
1402	1402 Tumor	Tumor	\N	\N	\N	\N	16-125975
176	176 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10828	\N	\N	16-126258A
188	188 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10828	\N	\N	16-126258A
123	123 DN	DN	\N	\N	\N	\N	16-126284A
195	195 DN	DN	\N	\N	\N	\N	16-126284A
145	145 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10829	\N	\N	16-126714
237	237 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10829	\N	\N	16-126714
223	223 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10830	\N	\N	16-126879A
1400	1400 Tumor	Tumor	\N	\N	\N	\N	16-127388
564	564 Nodular Mel	Nodular Mel	\N	\N	\N	\N	16B8849 (eppendorf)
557	557 Nodular Mel	Nodular Mel	\N	\N	\N	\N	16B10343 (eppendorf)
3561	3561 Waiting Process	Waiting Process	\N	\N	\N	\N	17-00730-3
3562	3562 Waiting Process	Waiting Process	\N	\N	\N	\N	17-00731-3
3563	3563 Waiting Process	Waiting Process	\N	\N	\N	\N	17-00792
601	601 Nodular Mel	Nodular Mel	\N	\N	\N	\N	17-1468II-2
602	602 Nodular Mel	Nodular Mel	\N	\N	\N	\N	17-1741I
1404	1404 Tumor	Tumor	\N	\N	\N	\N	17-2120
226	226 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10847	\N	\N	17-2241
177	177 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10848	\N	\N	17-2270A
189	189 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10848	\N	\N	17-2270A
1403	1403 Tumor	Tumor	\N	\N	\N	\N	17-2869
1995	1995 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	17-3165A
1996	1996 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	17-3165B
3564	3564 Waiting Process	Waiting Process	\N	\N	\N	\N	17-03472-1
135	135 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10870	\N	\N	17-3731
219	219 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10870	\N	\N	17-3731
163	163 DN	DN	\N	\N	\N	\N	17-3739
211	211 DN	DN	\N	\N	\N	\N	17-3739
129	129 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10871	\N	\N	17-3829B
206	206 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10871	\N	\N	17-3829B
1405	1405 Tumor	Tumor	\N	\N	\N	\N	17-6351
1406	1406 Tumor	Tumor	\N	\N	\N	\N	17-6368
3565	3565 Waiting Process	Waiting Process	\N	\N	\N	\N	17-08581-5
3788	3788 Not Processed	Not Processed	\N	\N	\N	\N	17-8769A
1407	1407 Tumor	Tumor	\N	\N	\N	\N	17-8968
3566	3566 Waiting Process	Waiting Process	\N	\N	\N	\N	17-09063-1
3567	3567 Waiting Process	Waiting Process	\N	\N	\N	\N	17-09063-N1
1558	1558 LN Met 1	LN Met 1	\N	\N	\N	\N	17-9337A1
1559	1559 LN Met 2	LN Met 2	\N	\N	\N	\N	17-9337A1
1560	1560 LN Met 3	LN Met 3	\N	\N	\N	\N	17-9337A1
1561	1561 LN Met 4	LN Met 4	\N	\N	\N	\N	17-9337A2
1408	1408 Tumor	Tumor	\N	\N	\N	\N	17-9550
3568	3568 Waiting Process	Waiting Process	\N	\N	\N	\N	17-10231-5
1409	1409 Tumor	Tumor	\N	\N	\N	\N	17-10585
438	438 common+ sclerotic dermal component 	common, sclerotic dermal component 	\N	\N	\N	\N	17-10753
3569	3569 Waiting Process	Waiting Process	\N	\N	\N	\N	17-10987-6
3570	3570 Waiting Process	Waiting Process	\N	\N	\N	\N	17-10987-N2
3571	3571 Waiting Process	Waiting Process	\N	\N	\N	\N	17-11087-5
3572	3572 Waiting Process	Waiting Process	\N	\N	\N	\N	17-11446-5
293	293 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22142	\N	\N	17-12444
292	292 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22142	\N	\N	17-12444
1413	1413 Tumor	Tumor	\N	\N	\N	\N	17-13205
787	787 MIS	MIS	\N	\N	\N	\N	17-13334
788	788 Nevus	Nevus	\N	\N	\N	\N	17-13334
1310	1310 Mel	Mel	\N	\N	\N	\N	17-13334
1564	1564 Normal	Normal	\N	\N	Merge: AM2-102-1, AM2-102-5-2, AM2-102-5-1	\N	17-14203A1
1565	1565 LN Met 9	LN Met 9	\N	\N	\N	\N	17-14203A1
1566	1566 Normal	Normal	\N	\N	Merge: AM2-102-1, AM2-102-5-2, AM2-102-5-1	\N	17-14203A2
1567	1567 LN Met 7	LN Met 7	\N	\N	\N	\N	17-14203A2
1568	1568 LN Met 8	LN Met 8	\N	\N	\N	\N	17-14203A2
1410	1410 Tumor	Tumor	\N	\N	\N	\N	17-14313
142	142 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10841	\N	\N	17-20244B
234	234 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10841	\N	\N	17-20244B
144	144 DN	DN	\N	\N	\N	\N	17-20497A
236	236 DN	DN	\N	\N	\N	\N	17-20497A
140	140 DN	DN	\N	\N	\N	\N	17-20501C
231	231 DN	DN	\N	\N	\N	\N	17-20501C
225	225 DN	DN	\N	\N	\N	\N	17-20900B
193	193 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10842	\N	\N	17-20901
112	112 DN	DN	\N	\N	\N	\N	17-20908
217	217 DN	DN	\N	\N	\N	\N	17-20908
137	137 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10844	\N	\N	17-21049
222	222 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10844	\N	\N	17-21049
125	125 DN	DN	\N	\N	\N	\N	17-21066B
198	198 DN	DN	\N	\N	\N	\N	17-21066B
167	167 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10845	\N	\N	17-21285
194	194 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10845	\N	\N	17-21285
124	124 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10846	\N	\N	17-21476B
196	196 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10846	\N	\N	17-21476B
3701	3701 Not Processed	Not Processed	\N	\N	\N	\N	17-21588
439	439 common+ sclerotic dermal component 	common, sclerotic dermal component 	\N	\N	\N	\N	17-21788B
1543	1543 Brain Met2	Brain Met2	\N	\N	\N	\N	17-21835A3
2122	2122 MIS	MIS	\N	\N	\N	\N	17-23681
2121	2121 Nevus	Nevus	\N	\N	\N	\N	17-23681
2123	2123 Normal	Normal	\N	\N	\N	\N	17-23681
1973	1973 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	17-24139
1411	1411 Tumor	Tumor	\N	\N	\N	\N	17-26078
164	164 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10849	\N	\N	17-26289G
213	213 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10849	\N	\N	17-26289G
169	169 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10850	\N	\N	17-26400
181	181 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10850	\N	\N	17-26400
215	215 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10851	\N	\N	17-26432A
134	134 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10852	\N	\N	17-26432B
216	216 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10852	\N	\N	17-26432B
132	132 DN	DN	\N	\N	\N	\N	17-26447
212	212 DN	DN	\N	\N	\N	\N	17-26447
175	175 DN	DN	\N	\N	\N	\N	17-26455B
187	187 DN	DN	\N	\N	\N	\N	17-26455B
286	286 Normal	Normal	\N	http://64.54.108.121/eSlideTray.php?ImageIds=930	\N	\N	17-26457
288	288 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=930	\N	\N	17-26457
287	287 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=930	\N	\N	17-26457
218	218 DN	DN	\N	\N	\N	\N	17-26969
136	136 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10853	\N	\N	17-27000
221	221 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10853	\N	\N	17-27000
1432	1432 Normal	Normal	\N	\N	\N	\N	17-27224
141	141 DN	DN	\N	\N	\N	\N	17-27380
233	233 DN	DN	\N	\N	\N	\N	17-27380
232	232 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10854	\N	\N	17-27403
3826	3826 Not Processed	Not Processed	\N	\N	\N	\N	17-27410
3827	3827 Not Processed	Not Processed	\N	\N	\N	\N	17-27410
119	119 DN	DN	\N	\N	\N	\N	17-27830B
172	172 DN	DN	\N	\N	\N	\N	17-27830B
184	184 DN	DN	\N	\N	\N	\N	17-27830B
127	127 DN	DN	\N	\N	\N	\N	17-27833
201	201 DN	DN	\N	\N	\N	\N	17-27833
121	121 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10855	\N	\N	17-28040A
179	179 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10855	\N	\N	17-28040A
191	191 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10855	\N	\N	17-28040A
1412	1412 Tumor	Tumor	\N	\N	\N	\N	17-29457B
789	789 Nevus	Nevus	\N	\N	\N	\N	17-31440
790	790 Normal	Normal	\N	\N	\N	\N	17-31440
791	791 Mel	Mel	\N	\N	\N	\N	17-31440
784	784 Mel	Mel	\N	\N	\N	\N	17-32863B
785	785 Nevus	Nevus	\N	\N	\N	\N	17-32863B
786	786 Normal	Normal	\N	\N	\N	\N	17-32863B
885	885 MIS	MIS	\N	\N	\N	\N	17-32863B
305	305 Normal	Normal	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22147	\N	\N	17-33401C
344	344 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22147	\N	\N	17-33401C
343	343 MIS	MIS	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22147	\N	\N	17-33401C
2672	2672 Normal	Normal	\N	\N	\N	\N	17-33973A1
2671	2671 MIS	MIS	\N	\N	\N	\N	17-33973C4
2670	2670 Invasive	Invasive	\N	\N	\N	\N	17-33973D3
146	146 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10856	\N	\N	17-34432B
240	240 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10856	\N	\N	17-34432B
147	147 DN	DN	\N	\N	\N	\N	17-34432C
241	241 DN	DN	\N	\N	\N	\N	17-34432C
148	148 DN	DN	\N	\N	\N	\N	17-34432D
242	242 DN	DN	\N	\N	\N	\N	17-34432D
252	252 DN	DN	\N	\N	\N	\N	17-34448
153	153 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10857	\N	\N	17-34464A
254	254 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10857	\N	\N	17-34464A
154	154 DN	DN	\N	\N	\N	\N	17-34464B
255	255 DN	DN	\N	\N	\N	\N	17-34464B
3702	3702 Not Processed	Not Processed	\N	\N	\N	\N	17-34742
253	253 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10858	\N	\N	17-34977
3828	3828 Not Processed	Not Processed	\N	\N	\N	\N	17-34979
149	149 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10859	\N	\N	17-35486A
243	243 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10859	\N	\N	17-35486A
244	244 DN	DN	\N	\N	\N	\N	17-35486B
250	250 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10860	\N	\N	17-35502A
251	251 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10861	\N	\N	17-35502B
238	238 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10862	\N	\N	17-35589
151	151 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10863	\N	\N	17-35859A
247	247 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10863	\N	\N	17-35859A
248	248 DN	DN	\N	\N	\N	\N	17-35859B
152	152 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10865	\N	\N	17-35859C
249	249 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10865	\N	\N	17-35859C
239	239 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10866	\N	\N	17-35916B
150	150 DN	DN	\N	\N	\N	\N	17-35917A
245	245 DN	DN	\N	\N	\N	\N	17-35917A
246	246 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10867	\N	\N	17-35917B
792	792 Normal	Normal	\N	\N	\N	\N	17-36409
794	794 Mel	Mel	\N	\N	\N	\N	17-36409
793	793 Nevus	Nevus	\N	\N	\N	\N	17-36409
118	118 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10868	\N	\N	17-36614
258	258 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10868	\N	\N	17-36614
256	256 DN	DN	\N	\N	\N	\N	17-36682
3573	3573 Waiting Process	Waiting Process	\N	\N	\N	\N	17-37055
2114	2114 Mel	Mel	\N	\N	\N	\N	17-38404A2
2115	2115 Nevus	Nevus	\N	\N	\N	\N	17-38404A2
2116	2116 Normal	Normal	\N	\N	\N	\N	17-38404A2
1414	1414 Tumor	Tumor	\N	\N	\N	\N	17-42757
781	781 Mel	Mel	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	17-43703
782	782 Nevus	Nevus	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	17-43703
783	783 Normal	Normal	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	17-43703
2135	2135 Not Processed	Not Processed	\N	\N	\N	\N	17-43707
801	801 Nevus	Nevus	\N	\N	\N	\N	17-43712
802	802 Mel	Mel	\N	\N	\N	\N	17-43712
1415	1415 Tumor	Tumor	\N	\N	\N	\N	17-48219
257	257 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10872	\N	\N	17-48595B
800	800 Nevus	Nevus	\N	\N	\N	\N	17-88895
2619	2619 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	17-48914
1416	1416 Tumor	Tumor	\N	\N	\N	\N	17-49361
724	724 DN	DN	\N	\N	\N	\N	17-49739B
3521	3521 DN	DN	\N	\N	\N	\N	17-49739B
1417	1417 Tumor	Tumor	\N	\N	\N	\N	17-50829
3789	3789 Not Processed	Not Processed	\N	\N	\N	\N	17-51847B
440	440 common+ sclerotic dermal component 	common, sclerotic dermal component 	\N	\N	\N	\N	17-52720
1434	1434 Normal	Normal	\N	\N	\N	\N	17-55182C
803	803 Nevus	Nevus	\N	\N	\N	\N	17-55182D
805	805 Mel	Mel	\N	\N	\N	\N	17-55182D
3574	3574 Waiting Process	Waiting Process	\N	\N	\N	\N	17-55712A1
3575	3575 Waiting Process	Waiting Process	\N	\N	\N	\N	17-55712A2
779	779 Mel	Mel	\N	\N	\N	\N	17-56506
780	780 Nevus	Nevus	\N	\N	\N	\N	17-56506
495	495 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	17-61001
795	795 Mel	Mel	\N	\N	\N	\N	17-61108
796	796 Nevus	Nevus	\N	\N	\N	\N	17-61108
797	797 Normal	Normal	\N	\N	\N	\N	17-61108
776	776 Mel	Mel	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	17-61310
777	777 Nevus	Nevus	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	17-61310
778	778 Normal	Normal	\N	\N	Blue: melanoma; Green: normal: Yellow: Nevus. 	\N	17-61310
1433	1433 Normal	Normal	\N	\N	\N	\N	17-62026B
276	276 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10873	\N	\N	17-62251
259	259 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10874	\N	\N	17-62447A
260	260 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10875	\N	\N	17-62447B
158	158 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10876	\N	\N	17-62502A
270	270 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10876	\N	\N	17-62502A
159	159 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10877	\N	\N	17-62502B
271	271 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10877	\N	\N	17-62502B
113	113 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10878	\N	\N	17-62534
264	264 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10878	\N	\N	17-62534
161	161 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10879	\N	\N	17-62813A
273	273 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10879	\N	\N	17-62813A
261	261 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10880	\N	\N	17-62828A
262	262 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10881	\N	\N	17-62828B
275	275 DN	DN	\N	\N	\N	\N	17-63163
267	267 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10882	\N	\N	17-63503
155	155 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10883	\N	\N	17-63837
265	265 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10883	\N	\N	17-63837
278	278 DN	DN	\N	\N	\N	\N	17-63890C
156	156 DN	DN	\N	\N	\N	\N	17-64032
266	266 DN	DN	\N	\N	\N	\N	17-64032
269	269 DN	DN	\N	\N	\N	\N	17-65000
157	157 DN	DN	\N	\N	\N	\N	17-65020B
268	268 DN	DN	\N	\N	\N	\N	17-65020B
279	279 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10884	\N	\N	17-65160B
263	263 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10885	\N	\N	17-65201A
162	162 DN	DN	\N	\N	\N	\N	17-65218B
274	274 DN	DN	\N	\N	\N	\N	17-65218B
160	160 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10886	\N	\N	17-65263C
272	272 DN	DN	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10886	\N	\N	17-65263C
115	115 DN	DN	\N	\N	\N	\N	17-65315B
277	277 DN	DN	\N	\N	\N	\N	17-65315B
302	302 Normal	Normal	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22154	\N	\N	17-68446
303	303 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22154	\N	\N	17-68446
798	798 Nevus	Nevus	\N	\N	\N	\N	17-68446
2178	2178 Normal	Normal	\N	\N	\N	\N	17-68780A
2179	2179 Normal	Normal	\N	\N	\N	\N	17-68780B
2109	2109 Mel	Mel	\N	\N	\N	\N	17-68780C
2110	2110 Normal	Normal	\N	\N	\N	\N	17-68780C
2128	2128 Nevus	Nevus	\N	\N	\N	\N	17-68780C
2129	2129 Mel	Mel	\N	\N	\N	\N	17-68780C
1972	1972 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	17-70204
693	693 DN	DN	\N	\N	\N	\N	17-72429A
3490	3490 DN	DN	\N	\N	\N	\N	17-72429A
702	702 DN	DN	\N	\N	\N	\N	17-72563
3500	3500 DN	DN	\N	\N	\N	\N	17-72563
701	701 DN	DN	\N	\N	\N	\N	17-72580
3499	3499 DN	DN	\N	\N	\N	\N	17-72580
689	689 DN	DN	\N	\N	\N	\N	17-72585A
3486	3486 DN	DN	\N	\N	\N	\N	17-72585A
688	688 DN	DN	\N	\N	\N	\N	17-72585B
3485	3485 DN	DN	\N	\N	\N	\N	17-72585B
690	690 DN	DN	\N	\N	\N	\N	17-72585C
3487	3487 DN	DN	\N	\N	\N	\N	17-72585C
705	705 DN	DN	\N	\N	\N	\N	17-74152D
3503	3503 DN	DN	\N	\N	\N	\N	17-74152D
708	708 DN	DN	\N	\N	\N	\N	17-74282
3506	3506 DN	DN	\N	\N	\N	\N	17-74282
706	706 DN	DN	\N	\N	\N	\N	17-74882A
3504	3504 DN	DN	\N	\N	\N	\N	17-74882A
707	707 DN	DN	\N	\N	\N	\N	17-74882B
3505	3505 DN	DN	\N	\N	\N	\N	17-74882B
2620	2620 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	17-75346
2471	2471 Normal	Normal	\N	\N	\N	\N	17-77365
2485	2485 Normal	Normal	\N	\N	\N	\N	17-81380B
725	725 DN	DN	\N	\N	\N	\N	17-81609B
3522	3522 DN	DN	\N	\N	\N	\N	17-81609B
721	721 DN	DN	\N	\N	\N	\N	17-81767B
3518	3518 DN	DN	\N	\N	\N	\N	17-81767B
720	720 DN	DN	\N	\N	\N	\N	17-81767C
3517	3517 DN	DN	\N	\N	\N	\N	17-81767C
431	431 common + blue	common + blue	\N	\N	\N	\N	17-82364B
692	692 DN	DN	\N	\N	\N	\N	17-82365B
3489	3489 DN	DN	\N	\N	\N	\N	17-82365B
774	774 Mel	Mel	\N	\N	(new HE recut on 5/5/2022)	\N	17-82793A
775	775 Nevus	Nevus	\N	\N	(new HE recut on 5/5/2022)	\N	17-82793A
719	719 DN	DN	\N	\N	\N	\N	17-82806
3516	3516 DN	DN	\N	\N	\N	\N	17-82806
352	352 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22156	\N	\N	17-83378B
353	353 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22156	\N	\N	17-83378B
1441	1441 MIS1	MIS1	\N	\N	\N	\N	17-83378B
1444	1444 MIS2	MIS2	\N	\N	\N	\N	17-83378B
3829	3829 Not Processed	Not Processed	\N	\N	\N	\N	17-83378C
1450	1450 Normal	Normal	\N	\N	\N	\N	17-83378D
704	704 DN	DN	\N	\N	\N	\N	17-85037
3502	3502 DN	DN	\N	\N	\N	\N	17-85037
294	294 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22157	\N	\N	17-88262
295	295 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22157	\N	\N	17-88262
895	895 Normal	Normal	\N	\N	\N	\N	17-88262
2137	2137 Nevus	Nevus	\N	\N	\N	\N	17-89239A
432	432 common + blue	common + blue	\N	\N	\N	\N	17-90774B
2011	2011 Typical Melanotic Macule	Typical Melanotic Macule	\N	\N	\N	\N	17-91629
2621	2621 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	17-91856A
2622	2622 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	17-91856B
695	695 DN	DN	\N	\N	\N	\N	17-91889
3492	3492 DN	DN	\N	\N	\N	\N	17-91889
703	703 DN	DN	\N	\N	\N	\N	17-92405
3501	3501 DN	DN	\N	\N	\N	\N	17-92405
716	716 DN	DN	\N	\N	\N	\N	17-92850
3514	3514 DN	DN	\N	\N	\N	\N	17-92850
728	728 DN	DN	\N	\N	\N	\N	17-93920
3525	3525 DN	DN	\N	\N	\N	\N	17-93920
691	691 DN	DN	\N	\N	\N	\N	17-93945C
3488	3488 DN	DN	\N	\N	\N	\N	17-93945C
710	710 DN	DN	\N	\N	\N	\N	17-93961A
3508	3508 DN	DN	\N	\N	\N	\N	17-93961A
2623	2623 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	17-94254
1451	1451 Normal	Normal	\N	\N	\N	\N	17-95052A
1872	1872 Compound	Compound	\N	\N	http://64.54.108.147/EditRecord.php?TableName=Slide&Ids[]=17451	\N	17-99294B
1447	1447 Normal	Normal	\N	\N	\N	\N	17-99365
2131	2131 Mel	Mel	\N	\N	\N	\N	17-100072A
2133	2133 Normal	Normal	\N	\N	\N	\N	17-100072A
2132	2132 Nevus	Nevus	\N	\N	\N	\N	17-100072A
2616	2616 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	17-102266
433	433 common + blue	common + blue	\N	\N	\N	\N	17-106118B
434	434 common + blue	common + blue	\N	\N	\N	\N	17-106118C
676	676 Junctional	Junctional	\N	\N	LENTIGINOUS INTRAEPIDERMAL PROLIFERATION OF MELANOCYTES, WITH EXTENSION CLOSE TO THE PERIPHERY OF THE BIOPSY	\N	17-109907D
683	683 Compound	Compound	\N	\N	JUNCTIONAL PROLIFERATION OF MELANOCYTES, FAVOR A LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	17-110828C
525	525 Congenital superficial	Congenital superficial	\N	\N	\N	\N	17-111004A
502	502 Junctional	Junctional	\N	\N	\N	\N	17-111004B
526	526 Congenital superficial	Congenital superficial	\N	\N	\N	\N	17-111004C
517	517 Junctional	Junctional	\N	\N	\N	\N	17-111038B
522	522 Congenital superficial	Congenital superficial	\N	\N	\N	\N	17-111040A
510	510 Junctional	Junctional	\N	\N	\N	\N	17-111279
531	531 Compound	Compound	\N	\N	\N	\N	17-111324
504	504 Junctional	Junctional	\N	\N	\N	\N	17-111571
508	508 Junctional	Junctional	\N	\N	\N	\N	17-111657A
509	509 Junctional	Junctional	\N	\N	\N	\N	17-111657B
534	534 Compound	Compound	\N	\N	\N	\N	17-111704A
535	535 Compound	Compound	\N	\N	\N	\N	17-111704B
2636	2636 Invasive	Invasive	\N	\N	\N	\N	17-111862A
2637	2637 MIS	MIS	\N	\N	\N	\N	17-111862B
713	713 DN	DN	\N	\N	\N	\N	17-112277
3511	3511 DN	DN	\N	\N	\N	\N	17-112277
520	520 Junctional	Junctional	\N	\N	\N	\N	17-112365A
503	503 Junctional	Junctional	\N	\N	\N	\N	17-112365B
497	497 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	17-112474
521	521 Junctional	Junctional	\N	\N	\N	\N	17-112588B
726	726 DN	DN	\N	\N	\N	\N	17-112631B
3523	3523 DN	DN	\N	\N	\N	\N	17-112631B
513	513 Junctional	Junctional	\N	\N	\N	\N	17-112653
2617	2617 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	17-113038
532	532 Compound	Compound	\N	\N	\N	\N	17-113511
515	515 Junctional	Junctional	\N	\N	\N	\N	17-114505
529	529 Compound	Compound	\N	\N	\N	\N	17-114552
435	435 common + blue	common + blue	\N	\N	\N	\N	17-115105
516	516 Junctional	Junctional	\N	\N	\N	\N	17-115149A
514	514 Junctional	Junctional	\N	\N	\N	\N	17-115568B
518	518 Junctional	Junctional	\N	\N	\N	\N	17-115571C
519	519 Junctional	Junctional	\N	\N	\N	\N	17-115571D
505	505 Junctional	Junctional	\N	\N	\N	\N	17-115572A
506	506 Junctional	Junctional	\N	\N	\N	\N	17-115588
507	507 Junctional	Junctional	\N	\N	\N	\N	17-115635
1974	1974 Superficial Melanoma	Superficial Melanoma	\N	\N	\N	\N	17-116120
1975	1975 Mel	Mel	\N	\N	\N	\N	17-116120
1976	1976 Invasive Mel 1	Invasive Mel 1	\N	\N	\N	\N	17-116120
722	722 DN	DN	\N	\N	\N	\N	17-117666
3519	3519 DN	DN	\N	\N	\N	\N	17-117666
723	723 DN	DN	\N	\N	\N	\N	17-117775B
3520	3520 DN	DN	\N	\N	\N	\N	17-117775B
675	675 Junctional	Junctional	\N	\N	HYPERMELANOTIC LENTIGINOUS JUNCTIONAL NEVUS	\N	17-118831C
1870	1870 Compound	Compound	\N	\N	HYPERMELANOTIC LENTIGINOUS COMPOUND MELANOCYTIC NEVUS. http://64.54.108.147/EditRecord.php?TableName=Slide&Ids[]=17446	\N	17-118904B
681	681 Junctional	Junctional	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	17-118980
678	678 Junctional	Junctional	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	\N	17-119013
1871	1871 Compound	Compound	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS. http://64.54.108.147/EditRecord.php?TableName=Slide&Ids[]=17448	\N	17-119079A
680	680 Junctional	Junctional	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	17-119302B
679	679 Junctional	Junctional	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	17-119445
1866	1866 Junctional	Junctional	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	17-119451
1865	1865 Junctional	Junctional	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	17-119570C
677	677 Junctional	Junctional	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	17-120049C
1869	1869 Compound	Compound	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	17-120276
1868	1868 Compound	Compound	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	\N	17-120280
441	441 common+ sclerotic dermal component 	common, sclerotic dermal component 	\N	\N	\N	\N	17-120487A
682	682 Junctional	Junctional	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	17-120790
1867	1867 Compound	Compound	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	17-120839
428	428 blue nevus+ cellular+  DF like	blue nevus, cellular,  DF like	\N	\N	\N	\N	17-120984
2638	2638 Normal	Normal	\N	\N	\N	\N	17-122697A
892	892 Mel	Mel	\N	\N	\N	\N	17-125030
893	893 Nevus	Nevus	\N	\N	\N	\N	17-125030
894	894 Normal	Normal	\N	\N	\N	\N	17-125030
709	709 DN	DN	\N	\N	\N	\N	17-125335
3507	3507 DN	DN	\N	\N	\N	\N	17-125335
447	447 balloon cell nevus	balloon cell nevus	\N	\N	\N	\N	17-128346A
345	345 Normal	Normal	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22144	\N	\N	17-130286
346	346 Nevus	Nevus	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22144	\N	\N	17-130286
347	347 Mel	Mel	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22144	\N	\N	17-130286
2618	2618 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	17-130985
624	624 Nevus?	Nevus?	\N	\N	\N	\N	17-132120
2021	2021 Lentiginous Juntional Melanocytic Nevus	Lentiginous Juntional Melanocytic Nevus	\N	\N	\N	\N	18-00192
3576	3576 Waiting Process	Waiting Process	\N	\N	\N	\N	18-00447-2
3577	3577 Waiting Process	Waiting Process	\N	\N	\N	\N	18-00447N1
3578	3578 Waiting Process	Waiting Process	\N	\N	\N	\N	18-02303-1
3579	3579 Waiting Process	Waiting Process	\N	\N	\N	\N	18-05067
3580	3580 Waiting Process	Waiting Process	\N	\N	\N	\N	18-08429-4
3581	3581 Waiting Process	Waiting Process	\N	\N	\N	\N	18-09671-4
3582	3582 Waiting Process	Waiting Process	\N	\N	\N	\N	18-09671N1
2512	2512 Invasive	Invasive	\N	\N	\N	\N	18-12160D
2513	2513 MIS	MIS	\N	\N	\N	\N	18-12160E
2514	2514 Normal	Normal	\N	\N	\N	\N	18-12160F
3703	3703 Not Processed	Not Processed	\N	\N	\N	\N	18-12734
1873	1873 Compound	Compound	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS. http://64.54.108.147/EditRecord.php?TableName=Slide&Ids[]=17458	\N	18-15028
684	684 Compound	Compound	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS. http://64.54.108.147/EditRecord.php?TableName=Slide&Ids[]=17455	\N	18-15165
3704	3704 Not Processed	Not Processed	\N	\N	\N	\N	18-15332A1
3705	3705 Not Processed	Not Processed	\N	\N	\N	\N	18-15332A2
3706	3706 Not Processed	Not Processed	\N	\N	\N	\N	18-15332A3
3707	3707 Not Processed	Not Processed	\N	\N	\N	\N	18-15332A4
3708	3708 Not Processed	Not Processed	\N	\N	\N	\N	18-15332A5
3709	3709 Not Processed	Not Processed	\N	\N	\N	\N	18-15332A6
1874	1874 Compound	Compound	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	\N	18-15487B
685	685 Compound	Compound	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS. http://64.54.108.147/EditRecord.php?TableName=Slide&Ids[]=17460	\N	18-15803
533	533 Compound	Compound	\N	\N	\N	\N	18-17957
512	512 Junctional	Junctional	\N	\N	\N	\N	18-18111A
536	536 Compound	Compound	\N	\N	\N	\N	18-18111B
537	537 Compound	Compound	\N	\N	\N	\N	18-18111C
541	541 Compound	Compound	\N	\N	\N	\N	18-19195A
1582	1582 Invasive Mel 1	Invasive Mel 1	\N	\N	\N	\N	18-22781A1
1581	1581 Normal	Normal	\N	\N	\N	\N	18-22781A1
1583	1583 Invasive Mel 2	Invasive Mel 2	\N	\N	\N	\N	18-22781A1
442	442 compound meloncytic nevus 	compound meloncytic nevus 	\N	\N	\N	\N	18-24908
530	530 Compound	Compound	\N	\N	\N	\N	18-27178A
523	523 Congenital superficial	Congenital superficial	\N	\N	\N	\N	18-27178B
730	730 Tumor	Tumor	\N	\N	\N	\N	18-28169
1551	1551 Salivary Met1	Salivary Met1	\N	\N	\N	\N	18-28886
1614	1614 Normal	Normal	\N	\N	\N	\N	18-28886
3583	3583 Waiting Process	Waiting Process	\N	\N	\N	\N	18-31426A
882	882 DPN-mm	DPN-mm	\N	\N	\N	\N	18-31431
487	487 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	18-34960
1585	1585 Invasive Mel 1	Invasive Mel 1	\N	\N	\N	\N	18-35014A1
1584	1584 Normal	Normal	\N	\N	\N	\N	18-35014A1
1586	1586 LN Met	LN Met	\N	\N	\N	\N	18-35014A1
3710	3710 Not Processed	Not Processed	\N	\N	\N	\N	18-35014B2
524	524 Congenital superficial	Congenital superficial	\N	\N	\N	\N	18-35802B
542	542 Compound	Compound	\N	\N	\N	\N	18-44463B
543	543 Compound	Compound	\N	\N	\N	\N	18-44463C
544	544 Compound	Compound	\N	\N	\N	\N	18-44464
548	548 Congenital superficial	Congenital superficial	\N	\N	\N	\N	18-44465
1977	1977 Mel	Mel	\N	\N	\N	\N	18-44728A
2644	2644 Normal	Normal	\N	\N	\N	\N	18-51740B2
2643	2643 MIS	MIS	\N	\N	\N	\N	18-51740C6
2642	2642 Invasive	Invasive	\N	\N	\N	\N	18-51740C7
715	715 DN	DN	\N	\N	\N	\N	18-52908
3513	3513 DN	DN	\N	\N	\N	\N	18-52908
711	711 DN	DN	\N	\N	\N	\N	18-54612
3509	3509 DN	DN	\N	\N	\N	\N	18-54612
538	538 Compound	Compound	\N	\N	\N	\N	18-57977B
443	443 common+ sclerotic dermal component 	common, sclerotic dermal component 	\N	\N	\N	\N	18-59376
511	511 Junctional	Junctional	\N	\N	\N	\N	18-61924A
727	727 DN	DN	\N	\N	\N	\N	18-65038B
3524	3524 DN	DN	\N	\N	\N	\N	18-65038B
539	539 Compound	Compound	\N	\N	\N	\N	18-65460
540	540 Compound	Compound	\N	\N	\N	\N	18-65957A
2241	2241 Normal	Normal	\N	\N	\N	\N	18-67239
729	729 Normal	Normal	\N	\N	\N	\N	18-68921A
545	545 Compound	Compound	\N	\N	\N	\N	18-69862A
546	546 Compound	Compound	\N	\N	\N	\N	18-69862B
2190	2190 Mel	Mel	\N	\N	\N	\N	18-75585B
2191	2191 Nevus	Nevus	\N	\N	\N	\N	18-75585B
2192	2192 Normal	Normal	\N	\N	\N	\N	18-75585B
444	444 blue nevus+ cellular 	blue nevus, cellular 	\N	\N	\N	\N	18-76281
547	547 Compound	Compound	\N	\N	\N	\N	18-76615
527	527 Congenital superficial	Congenital superficial	\N	\N	\N	\N	18-81165B
2510	2510 MIS	MIS	\N	\N	\N	\N	18-83370A
2509	2509 Invasive	Invasive	\N	\N	\N	\N	18-83370B
448	448 common & balloon	common & balloon	\N	\N	\N	\N	18-85718
1978	1978 Mel	Mel	\N	\N	\N	\N	18-88579
1979	1979 Mel	Mel	\N	\N	\N	\N	18-90413
700	700 DN	DN	\N	\N	\N	\N	18-90550
3498	3498 DN	DN	\N	\N	\N	\N	18-90550
3408	3408 Unknown	Unknown	\N	\N	\N	\N	18-91716
3407	3407 Unknown	Unknown	\N	\N	\N	\N	18-91716
498	498 DPN-mm	DPN-mm	\N	\N	\N	\N	18-95536
496	496 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	18-95537
696	696 DN	DN	\N	\N	\N	\N	18-96108
3493	3493 DN	DN	\N	\N	\N	\N	18-96108
687	687 DN	DN	\N	\N	\N	\N	18-96989
3484	3484 DN	DN	\N	\N	\N	\N	18-96989
2136	2136 	\N	\N	\N	\N	\N	18-97419C
3680	3680 Unknown	Unknown	\N	\N	\N	\N	18-103965B
445	445 common+ sclerotic dermal component 	common, sclerotic dermal component 	\N	\N	\N	\N	18-113402B
694	694 DN	DN	\N	\N	\N	\N	18-119366A
3491	3491 DN	DN	\N	\N	\N	\N	18-119366A
698	698 DN	DN	\N	\N	\N	\N	18-119369B
3496	3496 DN	DN	\N	\N	\N	\N	18-119369B
717	717 DN	DN	\N	\N	\N	\N	18-120470
718	718 DN	DN	\N	\N	\N	\N	18-120587
3515	3515 DN	DN	\N	\N	\N	\N	18-120587
699	699 DN	DN	\N	\N	\N	\N	18-120593B
3497	3497 DN	DN	\N	\N	\N	\N	18-120593B
714	714 DN	DN	\N	\N	\N	\N	18-121006
3512	3512 DN	DN	\N	\N	\N	\N	18-121006
697	697 DN	DN	\N	\N	\N	\N	18-121403A
3494	3494 DN	DN	\N	\N	\N	\N	18-121403A
3495	3495 DN	DN	\N	\N	\N	\N	18-121403A
712	712 DN	DN	\N	\N	\N	\N	18-121415
3510	3510 DN	DN	\N	\N	\N	\N	18-121415
481	481 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	18-121943A
482	482 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	18-121971A
483	483 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	18-121973
484	484 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	18-121986
488	488 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	18-122476
489	489 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	18-122972
478	478 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	18-129422
1256	1256 DN	DN	\N	\N	\N	\N	18-135485
1251	1251 DN	DN	\N	\N	\N	\N	18-135488
1250	1250 DN	DN	\N	\N	\N	\N	18-135492
1249	1249 DN	DN	\N	\N	\N	\N	18-135600
1257	1257 DN	DN	\N	\N	\N	\N	18-136484
528	528 Compound	Compound	\N	\N	\N	\N	18-136508B
1253	1253 DN	DN	\N	\N	\N	\N	18-136716B
1252	1252 DN	DN	\N	\N	\N	\N	18-136721
1254	1254 DN	DN	\N	\N	\N	\N	18-136800A
1258	1258 DN	DN	\N	\N	\N	\N	18-136800B
1259	1259 DN	DN	\N	\N	\N	\N	18-137340A
1262	1262 DN	DN	\N	\N	\N	\N	18-137809B
1260	1260 DN	DN	\N	\N	\N	\N	18-137854C
1261	1261 DN	DN	\N	\N	\N	\N	18-137857
2187	2187 Mel	Mel	\N	\N	\N	\N	18-139329
2188	2188 Nevus	Nevus	\N	\N	\N	\N	18-139329
2189	2189 Normal	Normal	\N	\N	\N	\N	18-139329
2648	2648 Invasive	Invasive	\N	\N	\N	\N	19-360A1
2649	2649 MIS	MIS	\N	\N	\N	\N	19-360A1
2650	2650 Normal	Normal	\N	\N	\N	\N	19-360A2
2690	2690 Invasive	Invasive	\N	\N	\N	\N	19-360A2
889	889 Blue Nevus	Blue Nevus	\N	\N	\N	\N	19-488
891	891 Blue Nevus	Blue Nevus	\N	\N	\N	\N	19-596B
3584	3584 Waiting Process	Waiting Process	\N	\N	\N	\N	19-01043-1
3585	3585 Waiting Process	Waiting Process	\N	\N	\N	\N	19-01043N2
479	479 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	19-1978C
888	888 Blue Nevus	Blue Nevus	\N	\N	\N	\N	19-2118
480	480 nevus or nevus like	nevus or nevus like	\N	\N	\N	\N	19-2264A
886	886 Blue Nevus	Blue Nevus	\N	\N	\N	\N	19-2710
3586	3586 Waiting Process	Waiting Process	\N	\N	\N	\N	19-03114-6
3587	3587 Waiting Process	Waiting Process	\N	\N	\N	\N	19-03114N1
3588	3588 Waiting Process	Waiting Process	\N	\N	\N	\N	19-03361-3
3589	3589 Waiting Process	Waiting Process	\N	\N	\N	\N	19-03736
3590	3590 Waiting Process	Waiting Process	\N	\N	\N	\N	19-03800-4
887	887 Blue Nevus	Blue Nevus	\N	\N	\N	\N	19-4879
3591	3591 Waiting Process	Waiting Process	\N	\N	\N	\N	19-05094-9
3592	3592 Waiting Process	Waiting Process	\N	\N	\N	\N	19-05268-9
3593	3593 Waiting Process	Waiting Process	\N	\N	\N	\N	19-05268N1
3594	3594 Waiting Process	Waiting Process	\N	\N	\N	\N	19-05307-8
2196	2196 Mel	Mel	\N	\N	\N	\N	19-5916
2197	2197 MIS	MIS	\N	\N	\N	\N	19-5916
2198	2198 Nevus	Nevus	\N	\N	\N	\N	19-5916
2199	2199 Normal	Normal	\N	\N	\N	\N	19-5916
3711	3711 Not Processed	Not Processed	\N	\N	\N	\N	19-6410A1
3712	3712 Not Processed	Not Processed	\N	\N	\N	\N	19-6410A2
1263	1263 DN	DN	\N	\N	\N	\N	19-7126B
1264	1264 DN	DN	\N	\N	\N	\N	19-7344
1265	1265 DN	DN	\N	\N	\N	\N	19-7357A
1266	1266 DN	DN	\N	\N	\N	\N	19-7357B
1267	1267 DN	DN	\N	\N	\N	\N	19-7596C
1268	1268 DN	DN	\N	\N	\N	\N	19-7600
1269	1269 DN	DN	\N	\N	\N	\N	19-7601
1270	1270 DN	DN	\N	\N	\N	\N	19-7669
1255	1255 DN	DN	\N	\N	\N	\N	19-7686A
3595	3595 Waiting Process	Waiting Process	\N	\N	\N	\N	19-08527-2
3596	3596 Waiting Process	Waiting Process	\N	\N	\N	\N	19-08527N1
1468	1468 Nevus	Nevus	\N	\N	\N	\N	19-9438B
3597	3597 Waiting Process	Waiting Process	\N	\N	\N	\N	19-09700-4
2156	2156 Capture Area C1	Capture Area C1	\N	\N	\N	\N	19-10031
3830	3830 Single Cell Gene Expression	Single Cell Gene Expression	\N	\N	\N	\N	19-10031-2
1272	1272 DN	DN	\N	\N	\N	\N	19-15130
1278	1278 DN	DN	\N	\N	\N	\N	19-15378
1283	1283 DN	DN	\N	\N	\N	\N	19-15442
3598	3598 Waiting Process	Waiting Process	\N	\N	\N	\N	19-17484
1562	1562 Brain Met 5	Brain Met 5	\N	\N	\N	\N	19-19590
1563	1563 Brain Met 6	Brain Met 6	\N	\N	\N	\N	19-19590
3713	3713 Not Processed	Not Processed	\N	\N	\N	\N	19-20141
1467	1467 Nevus	Nevus	\N	\N	\N	\N	19-21355B
3714	3714 Not Processed	Not Processed	\N	\N	\N	\N	19-23613C4
3599	3599 Waiting Process	Waiting Process	\N	\N	\N	\N	19-25808
1421	1421 NEVUS	NEVUS	\N	\N	\N	\N	19-28178
1274	1274 DN	DN	\N	\N	\N	\N	19-29129
1271	1271 DN	DN	\N	\N	\N	\N	19-29433C
1275	1275 DN	DN	\N	\N	\N	\N	19-30025B
1281	1281 DN	DN	\N	\N	\N	\N	19-30079A
3600	3600 Waiting Process	Waiting Process	\N	\N	\N	\N	19-33672A1
3715	3715 Not Processed	Not Processed	\N	\N	\N	\N	19-34937A2
3716	3716 Not Processed	Not Processed	\N	\N	\N	\N	19-34937S1
2193	2193 Mel	Mel	\N	\N	\N	\N	19-36210A
2194	2194 Nevus	Nevus	\N	\N	\N	\N	19-36210A
2195	2195 Normal	Normal	\N	\N	\N	\N	19-36210A
2238	2238 Mel	Mel	\N	\N	\N	\N	19-36210A
2240	2240 Normal	Normal	\N	\N	\N	\N	19-36210A
2239	2239 Nevus	Nevus	\N	\N	\N	\N	19-36210A
1280	1280 DN	DN	\N	\N	\N	\N	19-37409B
1284	1284 DN	DN	\N	\N	\N	\N	19-37607D
1276	1276 DN	DN	\N	\N	\N	\N	19-37607E
1279	1279 DN	DN	\N	\N	\N	\N	19-37607F
1273	1273 DN	DN	\N	\N	\N	\N	19-37609
1282	1282 DN	DN	\N	\N	\N	\N	19-38090
1277	1277 DN	DN	\N	\N	\N	\N	19-38447
1822	1822 Invasive Mel 1	Invasive Mel 1	\N	\N	\N	\N	19-43366A1
1823	1823 Invasive Mel 2	Invasive Mel 2	\N	\N	\N	\N	19-43366A1
3717	3717 Not Processed	Not Processed	\N	\N	\N	\N	19-43366F
1824	1824 Normal	Normal	\N	\N	\N	\N	19-43366G
1460	1460 Nevus	Nevus	\N	\N	\N	\N	19-43600A
1463	1463 Nevus	Nevus	\N	\N	\N	\N	19-43600B
1588	1588 MIS2	MIS2	\N	\N	\N	\N	19-44348A1
1587	1587 MIS1	MIS1	\N	\N	\N	\N	19-44348A1
1589	1589 Primary Mel 1	Primary Mel 1	\N	\N	\N	\N	19-44348A1
1590	1590 Primary Mel 2	Primary Mel 2	\N	\N	\N	\N	19-44348A1
1591	1591 Normal	Normal	\N	\N	\N	\N	19-44348A1
1592	1592 In Transit Met	In Transit Met	\N	\N	\N	\N	19-44348A1
3718	3718 Not Processed	Not Processed	\N	\N	\N	\N	19-44348A4
1003	1003 Tumor	Tumor	\N	\N	Atypical Spitz tumor-nodule	\N	19-44904
1134	1134 Nevus	Nevus	\N	\N	Atypical Spitz tumor-nevus	\N	19-44904
3601	3601 Waiting Process	Waiting Process	\N	\N	\N	\N	19-44938
1597	1597 MIS1	MIS1	\N	\N	\N	\N	19-44987A1
1599	1599 Invasive Mel 2	Invasive Mel 2	\N	\N	\N	\N	19-44987A1
1598	1598 Invasive Mel 1	Invasive Mel 1	\N	\N	\N	\N	19-44987A1
3719	3719 Not Processed	Not Processed	\N	\N	\N	\N	19-44987C1
1602	1602 Metastatic Mel 2	Metastatic Mel 2	\N	\N	\N	\N	19-51759
1603	1603 Normal 2	Normal 2	\N	\N	\N	\N	19-51759
1593	1593 Normal	Normal	\N	\N	\N	\N	19-52004A1
1594	1594 MIS1	MIS1	\N	\N	\N	\N	19-52004A1
1596	1596 Invasive Primary Mel 2	Invasive Primary Mel 2	\N	\N	\N	\N	19-52004A1
1595	1595 Invasive Primary Mel 1	Invasive Primary Mel 1	\N	\N	\N	\N	19-52004A1
3720	3720 Not Processed	Not Processed	\N	\N	\N	\N	19-52004B1
1445	1445 Nevus	Nevus	\N	\N	\N	\N	19-53945B
1459	1459 Nevus	Nevus	\N	\N	\N	\N	19-59869A
1452	1452 Nevus	Nevus	\N	\N	\N	\N	19-69103
2022	2022 Compound Nevus	Compound Nevus	\N	\N	\N	\N	19-72316
2511	2511 Normal	Normal	\N	\N	\N	\N	19-75051
1464	1464 Nevus	Nevus	\N	\N	\N	\N	19-78038
1461	1461 Nevus	Nevus	\N	\N	\N	\N	19-79825
1462	1462 Nevus	Nevus	\N	\N	\N	\N	19-80535A
878	878 DPN-mm	DPN-mm	\N	\N	\N	\N	19-88385
1465	1465 Nevus	Nevus	\N	\N	\N	\N	19-89855A
3790	3790 Not Processed	Not Processed	\N	\N	\N	\N	19-94061
1997	1997 Lentiginous junctional melanocytic nevus	Lentiginous junctional melanocytic nevus	\N	\N	\N	\N	19-94975
1458	1458 Nevus	Nevus	\N	\N	\N	\N	19-97163
1454	1454 Nevus	Nevus	\N	\N	\N	\N	19-103058B
1453	1453 Nevus	Nevus	\N	\N	\N	\N	19-104449D
1466	1466 Nevus	Nevus	\N	\N	\N	\N	19-105255
879	879 DPN-mm	DPN-mm	\N	\N	\N	\N	19-109646
2597	2597 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	19-111428
1456	1456 Nevus	Nevus	\N	\N	\N	\N	19-115700A
1483	1483 Nevus	Nevus	\N	\N	\N	\N	19-117072A
3791	3791 Not Processed	Not Processed	\N	\N	\N	\N	19-117072A2
1457	1457 Nevus	Nevus	\N	\N	\N	\N	19-117270
2023	2023 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	19-122139
3412	3412 Unknown	Unknown	\N	\N	\N	\N	19-126110
1420	1420 NEVUS	NEVUS	\N	\N	\N	\N	19-135490
1431	1431 Normal	Normal	\N	\N	\N	\N	19-135629A
806	806 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.01.02
807	807 PAM	PAM	\N	\N	\N	\N	19Rig750007.01.01.03
808	808 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.04.02
809	809 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.05.02
810	810 NORMAL	NORMAL	\N	\N	\N	\N	19Rig750007.01.05.03
811	811 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.07.02
996	996 Normal	Normal	\N	\N	\N	\N	19Rig750007.01.07.03
812	812 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.08.03
980	980 Normal	Normal	\N	\N	\N	\N	19Rig750007.01.08.05
813	813 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.10.03
814	814 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.11.02
815	815 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.12.02
816	816 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.13.03
981	981 Normal	Normal	\N	\N	\N	\N	19Rig750007.01.13.04
883	883 Normal	Normal	\N	\N	\N	\N	19Rig750007.01.14.04
818	818 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.15.01
982	982 Normal	Normal	\N	\N	\N	\N	19Rig750007.01.15.03
819	819 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.01.16.02
820	820 NORMAL	NORMAL	\N	\N	\N	\N	19Rig750007.01.16.03
821	821 MELANOMA	MELANOMA	\N	\N	\N	\N	19rig750007.01.17.01
825	825 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.02.02.03
826	826 NORMAL	NORMAL	\N	\N	\N	\N	19Rig750007.02.02.04
827	827 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.02.03.02
983	983 Normal	Normal	\N	\N	\N	\N	19Rig750007.02.03.03
828	828 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.02.04.02
829	829 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.02.05.03
830	830 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.02.08.02
831	831 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.02.09.02
832	832 NORMAL	NORMAL	\N	\N	\N	\N	19Rig750007.02.09.03
833	833 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.02.10.01
834	834 NORMAL	NORMAL	\N	\N	\N	\N	19Rig750007.02.10.02
835	835 MELANOMA	MELANOMA	\N	\N	\N	\N	19rig750007.02.11.01
837	837 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.03.01.03
838	838 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.03.02.03
984	984 Normal	Normal	\N	\N	\N	\N	19Rig750007.03.02.05
839	839 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.03.03.03
840	840 PAM	PAM	\N	\N	\N	\N	19Rig750007.03.03.04
841	841 NORMAL	NORMAL	\N	\N	\N	\N	19Rig750007.03.03.05
842	842 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.03.04.02
985	985 Normal	Normal	\N	\N	\N	\N	19Rig750007.03.04.03
843	843 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.03.05.02
844	844 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.03.07.03
986	986 Normal	Normal	\N	\N	\N	\N	19Rig750007.03.07.05
845	845 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.03.08.03
987	987 Normal	Normal	\N	\N	\N	\N	19Rig750007.03.08.05
846	846 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.03.11.02
988	988 Normal	Normal	\N	\N	\N	\N	19Rig750007.03.11.03
847	847 MELANOMA	MELANOMA	\N	\N	\N	\N	19Rig750007.03.12.02
848	848 NORMAL	NORMAL	\N	\N	\N	\N	19Rig750007.03.12.03
989	989 Normal	Normal	\N	\N	\N	\N	19Rig750007.03.12.05
850	850 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.01.03
851	851 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.02.03
852	852 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.03.03
853	853 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.04.03
854	854 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.05.03
855	855 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.06.03
856	856 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.07.03
990	990 Normal	Normal	\N	\N	\N	\N	19Rig750007.04.07.09
857	857 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.09.03
858	858 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.10.03
859	859 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.12.03
991	991 Normal	Normal	\N	\N	\N	\N	19Rig750007.04.12.08
860	860 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.13.03
992	992 Normal	Normal	\N	\N	\N	\N	19Rig750007.04.13.08
861	861 NEVUS	NEVUS	\N	\N	\N	\N	19Rig750007.04.15.03
863	863 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.01.03
864	864 NORMAL	NORMAL	\N	\N	\N	\N	19Rig750007.05.01.04
865	865 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.02.03
866	866 NORMAL	NORMAL	\N	\N	\N	\N	19Rig750007.05.02.04
867	867 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.04.03
868	868 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.05.03
993	993 Normal	Normal	\N	\N	\N	\N	19Rig750007.05.05.08
869	869 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.06.03
870	870 NORMAL	NORMAL	\N	\N	\N	\N	19Rig750007.05.06.04
994	994 Normal	Normal	\N	\N	\N	\N	19Rig750007.05.06.10
871	871 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.07.03
817	817 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.11.03
872	872 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.13.03
995	995 Normal	Normal	\N	\N	\N	\N	19Rig750007.05.13.09
873	873 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.14.03
874	874 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.15.03
875	875 PAM	PAM	\N	\N	\N	\N	19Rig750007.05.16.01
877	877 PAM	PAM	\N	\N	\N	\N	19Rig750007.06.01
822	822 MELANOMA	MELANOMA	\N	\N	\N	\N	19rig75000701.18.01
823	823 NORMAL	NORMAL	\N	\N	\N	\N	19rig75000701.18.02
3602	3602 Waiting Process	Waiting Process	\N	\N	\N	\N	20-00548-10
3448	3448 Waiting Process	Waiting Process	\N	\N	\N	\N	20-00698
3603	3603 Waiting Process	Waiting Process	\N	\N	\N	\N	20-00782N3
3604	3604 Waiting Process	Waiting Process	\N	\N	\N	\N	20-01244-2
3605	3605 Waiting Process	Waiting Process	\N	\N	\N	\N	20-01665-3
3606	3606 Waiting Process	Waiting Process	\N	\N	\N	\N	20-02956-5
3607	3607 Waiting Process	Waiting Process	\N	\N	\N	\N	20-03009-7
3608	3608 Waiting Process	Waiting Process	\N	\N	\N	\N	20-03009N1
3609	3609 Waiting Process	Waiting Process	\N	\N	\N	\N	20-04152-8
3610	3610 Waiting Process	Waiting Process	\N	\N	\N	\N	20-04546-3
2608	2608 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	20-5264
2609	2609 Normal	Normal	\N	\N	\N	\N	20-5264
3611	3611 Waiting Process	Waiting Process	\N	\N	\N	\N	20-05671-2
3612	3612 Waiting Process	Waiting Process	\N	\N	\N	\N	20-06242
2507	2507 MIS	MIS	\N	\N	\N	\N	20-6751
2506	2506 Invasive	Invasive	\N	\N	\N	\N	20-6751
3613	3613 Waiting Process	Waiting Process	\N	\N	\N	\N	20-7562\t
2663	2663 Normal	Normal	\N	\N	\N	\N	20-8536D
2661	2661 Invasive	Invasive	\N	\N	\N	\N	20-8536E
2662	2662 MIS	MIS	\N	\N	\N	\N	20-8536E
3614	3614 Waiting Process	Waiting Process	\N	\N	\N	\N	20-08679-5
1579	1579 Met1	Met1	\N	\N	\N	\N	20-09338A1
2668	2668 MIS	MIS	\N	\N	\N	\N	20-10245D1
2669	2669 Normal	Normal	\N	\N	\N	\N	20-10245F1
2667	2667 Invasive	Invasive	\N	\N	\N	\N	20-10245H3
2508	2508 Normal	Normal	\N	\N	\N	\N	20-11796D
3721	3721 Not Processed	Not Processed	\N	\N	\N	\N	20-12501A1
3722	3722 Not Processed	Not Processed	\N	\N	\N	\N	20-12501E1
3615	3615 Waiting Process	Waiting Process	\N	\N	\N	\N	20-13577A1
2599	2599 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	20-14475
2600	2600 Normal	Normal	\N	\N	\N	\N	20-14475
2024	2024 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	20-16705
2675	2675 Normal	Normal	\N	\N	\N	\N	20-16903A2
2674	2674 MIS	MIS	\N	\N	\N	\N	20-16903C1
2673	2673 Invasive	Invasive	\N	\N	\N	\N	20-16903C4
2522	2522 MIS	MIS	\N	\N	\N	\N	20-18383A1
2521	2521 Invasive	Invasive	\N	\N	\N	\N	20-18383A1
2523	2523 Normal	Normal	\N	\N	\N	\N	20-18383B2
2557	2557 Normal	Normal	\N	\N	\N	\N	20-18514A
2558	2558 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-18514B
1576	1576 Subcutaneous Met 2	Subcutaneous Met 2	\N	\N	Used to compare CELLDATA and QIAGEN's Kits	\N	20-21458A1
3723	3723 Not Processed	Not Processed	\N	\N	\N	\N	20-21458A2
2601	2601 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	20-23650
3616	3616 Waiting Process	Waiting Process	\N	\N	\N	\N	20-24373A1
1469	1469 Nevus	Nevus	\N	\N	\N	\N	20-25263A
1578	1578 Local Recurrent-Met2	Local Recurrent-Met2	\N	\N	\N	\N	20-26269A1
1580	1580 Local Recurrent-Met3	Local Recurrent-Met3	\N	\N	\N	\N	20-26269A1
1611	1611 Normal	Normal	\N	\N	\N	\N	20-26269A1
1999	1999 blue nevus with ovoid melanocytes	blue nevus with ovoid melanocytes	\N	\N	\N	\N	20-026598
2025	2025 Blue Nevus	Blue Nevus	\N	\N	\N	\N	20-28273
1604	1604 Normal	Normal	\N	\N	\N	\N	20-28721A1
1605	1605 Metastatic Mel 1	Metastatic Mel 1	\N	\N	\N	\N	20-28721A1
2155	2155 Capture Area B1	Capture Area B1	\N	\N	\N	\N	20-30233
3831	3831 Single Cell Gene Expression	Single Cell Gene Expression	\N	\N	\N	\N	20-30233-2
2303	2303 Tumor	Tumor	\N	\N	\N	\N	20-30367
2603	2603 Normal	Normal	\N	\N	\N	\N	20-31361
2602	2602 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	20-31361
2200	2200 Mel	Mel	\N	\N	\N	\N	20-31447
2201	2201 MIS	MIS	\N	\N	\N	\N	20-31447
2202	2202 Nevus	Nevus	\N	\N	\N	\N	20-31447
2203	2203 Normal	Normal	\N	\N	\N	\N	20-31447
1577	1577 Met1	Met1	\N	\N	\N	\N	20-33334A1
1488	1488 Nevus	Nevus	\N	\N	\N	\N	20-34915
2604	2604 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	20-35177
2605	2605 Normal	Normal	\N	\N	\N	\N	20-35177
1480	1480 Nevus	Nevus	\N	\N	\N	\N	20-36120
1484	1484 Nevus	Nevus	\N	\N	\N	\N	20-36500A
2655	2655 Invasive	Invasive	\N	\N	\N	\N	20-37211A
2656	2656 MIS	MIS	\N	\N	\N	\N	20-37211A
2657	2657 Normal	Normal	\N	\N	\N	\N	20-37211I
2204	2204 Mel	Mel	\N	\N	\N	\N	20-43011
2206	2206 Normal	Normal	\N	\N	\N	\N	20-43011
2205	2205 Nevus	Nevus	\N	\N	\N	\N	20-43011
1482	1482 Nevus	Nevus	\N	\N	\N	\N	20-43801
2607	2607 Normal	Normal	\N	\N	\N	\N	20-43970
2606	2606 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	20-43970
1486	1486 Nevus	Nevus	\N	\N	\N	\N	20-48331
1485	1485 Nevus	Nevus	\N	\N	\N	\N	20-48338A
3617	3617 Waiting Process	Waiting Process	\N	\N	\N	\N	20-50565A1
3618	3618 Waiting Process	Waiting Process	\N	\N	\N	\N	20-50565B1
3619	3619 Waiting Process	Waiting Process	\N	\N	\N	\N	20-52125A1
2207	2207 MIS	MIS	\N	\N	\N	\N	20-53075B
2208	2208 Nevus	Nevus	\N	\N	\N	\N	20-53075B
2209	2209 PRAME-positive Nevus	PRAME-positive Nevus	\N	\N	\N	\N	20-53075B
2210	2210 Normal	Normal	\N	\N	\N	\N	20-53075B
3620	3620 Waiting Process	Waiting Process	\N	\N	\N	\N	20-54923B1
3621	3621 Waiting Process	Waiting Process	\N	\N	\N	\N	20-56532
3622	3622 Waiting Process	Waiting Process	\N	\N	\N	\N	20-56832A1
1487	1487 Nevus	Nevus	\N	\N	\N	\N	20-57308
2610	2610 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	20-57917
3724	3724 Not Processed	Not Processed	\N	\N	\N	\N	20-59076A1
1877	1877 Lentigo Simplex	Lentigo Simplex	\N	\N	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, INFLAMED, EXCISED IN PLANES OF SECTION EXAMINED	\N	20-60575
1878	1878 Junctional Melanocytic Nevus	Junctional Melanocytic Nevus	\N	\N	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, INFLAMED, EXCISED IN PLANES OF SECTION EXAMINED	\N	20-60575
2051	2051 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-60974B
2053	2053 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-60974B
2052	2052 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-60974B
2054	2054 Normal	Normal	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-60974B
2611	2611 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	20-64178
2211	2211 Mel	Mel	\N	\N	\N	\N	20-79197A
2212	2212 MIS	MIS	\N	\N	\N	\N	20-79197A
2214	2214 Normal	Normal	\N	\N	\N	\N	20-79197A
2213	2213 Nevus	Nevus	\N	\N	\N	\N	20-79197A
2493	2493 Normal	Normal	\N	\N	\N	\N	20-81257A\n
2491	2491 Invasive	Invasive	\N	\N	\N	\N	20-81257B
2492	2492 MIS	MIS	\N	\N	\N	\N	20-81257B
2543	2543 Normal	Normal	\N	\N	\N	\N	20-82651A
2544	2544 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-82651A
2545	2545 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-82651B
2546	2546 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-82651C
2547	2547 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-82651D
2548	2548 Normal	Normal	\N	\N	\N	\N	20-82651E
2549	2549 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-82651E
2658	2658 Invasive	Invasive	\N	\N	\N	\N	20-83082A3
2659	2659 MIS1	MIS1	\N	\N	\N	\N	20-83082A3
2693	2693 MIS2	MIS2	\N	\N	\N	\N	20-83082A3
2660	2660 Normal	Normal	\N	\N	\N	\N	20-83082B
2531	2531 Normal	Normal	\N	\N	\N	\N	20-91483A
2532	2532 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-91483A
2534	2534 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-91483B
2533	2533 Normal	Normal	\N	\N	\N	\N	20-91483B
2047	2047 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-91914A
2048	2048 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-91914A
2049	2049 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-91914A
2050	2050 Normal	Normal	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-91914A
1481	1481 Nevus	Nevus	\N	\N	\N	\N	20-92494
2559	2559 Normal	Normal	\N	\N	\N	\N	20-98774A
2560	2560 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-98774A
2561	2561 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-98774B
2562	2562 Normal	Normal	\N	\N	\N	\N	20-98774D
2470	2470 MIS	MIS	\N	\N	\N	\N	20-102366B1
2469	2469 Invasive	Invasive	\N	\N	\N	\N	20-102366B2
2598	2598 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	20-103041
2554	2554 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-104213A
2553	2553 Normal	Normal	\N	\N	\N	\N	20-104213A
2555	2555 Normal	Normal	\N	\N	\N	\N	20-104213B
2556	2556 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	20-104213B
2044	2044 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-106642A
2043	2043 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-106642A
2045	2045 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-106642A
2046	2046 Normal	Normal	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	20-106642A
2651	2651 Invasive	Invasive	\N	\N	\N	\N	20-113547A2
2652	2652 MIS1	MIS1	\N	\N	\N	\N	20-113547A2
2691	2691 Invasive	Invasive	\N	\N	20-113547A2, 20-113547A3	\N	20-113547A2
2653	2653 MIS2	MIS2	\N	\N	\N	\N	20-113547A3
2692	2692 Invasive	Invasive	\N	\N	20-113547A2, 20-113547A3	\N	20-113547A3
2654	2654 Normal	Normal	\N	\N	\N	\N	20-113547C2
2498	2498 MIS	MIS	\N	\N	\N	\N	21-457B
2497	2497 Invasive	Invasive	\N	\N	\N	\N	21-457C
3725	3725 Not Processed	Not Processed	\N	\N	\N	\N	21-961A
2233	2233 Normal	Normal	\N	\N	\N	\N	21-1134A
2223	2223 Mel1	Mel1	\N	\N	\N	\N	21-2141
2225	2225 Nevus	Nevus	\N	\N	\N	\N	21-2141
2224	2224 Mel2	Mel2	\N	\N	\N	\N	21-2141
2226	2226 Normal	Normal	\N	\N	\N	\N	21-2141
3623	3623 Waiting Process	Waiting Process	\N	\N	\N	\N	21-03240
3792	3792 Not Processed	Not Processed	\N	\N	\N	\N	21-3841E1
3624	3624 Waiting Process	Waiting Process	\N	\N	\N	\N	21-04018
2646	2646 MIS	MIS	\N	\N	\N	\N	21-4449A3
2645	2645 Invasive	Invasive	\N	\N	\N	\N	21-4449A5
2647	2647 Normal	Normal	\N	\N	\N	\N	21-4449B2
3625	3625 Waiting Process	Waiting Process	\N	\N	\N	\N	21-04690-3
3626	3626 Waiting Process	Waiting Process	\N	\N	\N	\N	21-06796-5
2496	2496 Normal	Normal	\N	\N	\N	\N	21-7055B1
2494	2494 Invasive	Invasive	\N	\N	\N	\N	21-7055B4
2495	2495 MIS	MIS	\N	\N	\N	\N	21-7055B6
3627	3627 Waiting Process	Waiting Process	\N	\N	\N	\N	21-08944-3
3628	3628 Waiting Process	Waiting Process	\N	\N	\N	\N	21-09097A1
3629	3629 Waiting Process	Waiting Process	\N	\N	\N	\N	21-09119-2
3630	3630 Waiting Process	Waiting Process	\N	\N	\N	\N	21-09119-4
3631	3631 Waiting Process	Waiting Process	\N	\N	\N	\N	21-09119N2
3632	3632 Waiting Process	Waiting Process	\N	\N	\N	\N	21-09543-1
3633	3633 Waiting Process	Waiting Process	\N	\N	\N	\N	21-09543-2
3634	3634 Waiting Process	Waiting Process	\N	\N	\N	\N	21-09545-2
3635	3635 Waiting Process	Waiting Process	\N	\N	\N	\N	21-10478-2
3726	3726 Not Processed	Not Processed	\N	\N	\N	\N	21-13227A
3636	3636 Waiting Process	Waiting Process	\N	\N	\N	\N	21-13595A1
3637	3637 Waiting Process	Waiting Process	\N	\N	\N	\N	21-13595C1
3638	3638 Waiting Process	Waiting Process	\N	\N	\N	\N	21-15959
2242	2242 Normal	Normal	\N	\N	\N	\N	21-16708A
3639	3639 Waiting Process	Waiting Process	\N	\N	\N	\N	21-17351
3640	3640 Waiting Process	Waiting Process	\N	\N	\N	\N	21-20002A1
3641	3641 Waiting Process	Waiting Process	\N	\N	\N	\N	21-20305A1
3642	3642 Waiting Process	Waiting Process	\N	\N	\N	\N	21-20367A1
3643	3643 Waiting Process	Waiting Process	\N	\N	\N	\N	21-20368A1
3644	3644 Waiting Process	Waiting Process	\N	\N	\N	\N	21-20368A3
3645	3645 Waiting Process	Waiting Process	\N	\N	\N	\N	21-21081
2501	2501 MIS	MIS	\N	\N	\N	\N	21-21304A1
2500	2500 Invasive	Invasive	\N	\N	\N	\N	21-21304A10
2019	2019 Invasive Melanoma	Invasive Melanoma	\N	\N	\N	\N	21-21314
2020	2020 Invasive Melanoma	Invasive Melanoma	\N	\N	Invasive Melanoma, in situ melanoma, intraepidermal proliferation of atypical melanocytes, Normal	\N	21-21315C
3417	3417 Unknown	Unknown	\N	\N	\N	\N	21-21315C
3416	3416 Unknown	Unknown	\N	\N	\N	\N	21-21315C
3418	3418 Unknown	Unknown	\N	\N	\N	\N	21-21315C
2018	2018 Invasive Melanoma	Invasive Melanoma	\N	\N	\N	\N	21-21316
3414	3414 Unknown	Unknown	\N	\N	\N	\N	21-21316
3415	3415 Unknown	Unknown	\N	\N	\N	\N	21-21324
2013	2013 Intramucosal Melanocytic Nevus	Intramucosal Melanocytic Nevus	\N	\N	\N	\N	21-21334
3411	3411 Unknown	Unknown	\N	\N	\N	\N	21-21334
2015	2015 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	21-21336
2014	2014 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	21-21338
2016	2016 Blue Nevus	Blue Nevus	\N	\N	\N	\N	21-21341
2012	2012 Intramucosal Melanocytic Nevus	Intramucosal Melanocytic Nevus	\N	\N	\N	\N	21-21342
3410	3410 Unknown	Unknown	\N	\N	\N	\N	21-21342
1130	1130 Mel	Mel	\N	\N	\N	\N	94-23180 T4
2017	2017 Invasive Melanoma	Invasive Melanoma	\N	\N	\N	\N	21-21351
2304	2304 Tumor	Tumor	\N	\N	\N	\N	21-21351
3413	3413 Unknown	Unknown	\N	\N	\N	\N	21-21351
2499	2499 Normal	Normal	\N	\N	\N	\N	21-25546B2
3727	3727 Not Processed	Not Processed	\N	\N	\N	\N	21-26009A1
3646	3646 Waiting Process	Waiting Process	\N	\N	\N	\N	21-30633A1
3647	3647 Waiting Process	Waiting Process	\N	\N	\N	\N	21-32669B1
2502	2502 Normal	Normal	\N	\N	\N	\N	21-35943A
3648	3648 Waiting Process	Waiting Process	\N	\N	\N	\N	21-37814A1
2227	2227 Mel	Mel	\N	\N	\N	\N	21-41149
2228	2228 Nevus	Nevus	\N	\N	\N	\N	21-41149
2229	2229 Normal	Normal	\N	\N	\N	\N	21-41149
2231	2231 MIS	MIS	\N	\N	\N	\N	21-44171
2230	2230 Mel	Mel	\N	\N	\N	\N	21-44171
2232	2232 Nevus	Nevus	\N	\N	\N	\N	21-44171
1875	1875 Compound Melanocytic Nevus	Compound Melanocytic Nevus	\N	\N	COMPOUND MELANOCYTIC NEVUS	\N	21-52881
1876	1876 Nevus	Nevus	\N	\N	\N	\N	21-52881
2026	2026 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	21-59477
2027	2027 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	21-59483
1882	1882 Lentigo Simplex	Lentigo Simplex	\N	\N	EVOLVING MELANOMA IN SITU, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	\N	21-59993A
1883	1883 Nevus	Nevus	\N	\N	EVOLVING MELANOMA IN SITU, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	\N	21-59993A
1884	1884 Mel	Mel	\N	\N	EVOLVING MELANOMA IN SITU, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	\N	21-59993A
1890	1890 Lentigo Simplex	Lentigo Simplex	\N	\N	LENTIGO SIMPLEX	\N	21-61319
1891	1891 Seborrheic Keratosis	Seborrheic Keratosis	\N	\N	SEBORRHEIC KERATOSIS	\N	21-61319
1879	1879 Lentigo Simplex	Lentigo Simplex	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	21-61821
1880	1880 Junctional Melanocytic Nevus	Junctional Melanocytic Nevus	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	21-61821
1909	1909 Compound Melanocytic Nevus	Compound Melanocytic Nevus	\N	\N	\N	\N	21-62140A
1910	1910 Compound Melanocytic Nevus	Compound Melanocytic Nevus	\N	\N	\N	\N	21-62140A
2520	2520 Normal	Normal	\N	\N	\N	\N	21-62764
2518	2518 Invasive	Invasive	\N	\N	\N	\N	21-62764
2519	2519 MIS	MIS	\N	\N	\N	\N	21-62764
1888	1888 Nevus	Nevus	\N	\N	MELANOMA, AT LEAST IN SITU, WITH SUPERIMPOSED CHANGES OF REGRESSION	\N	21-63575B
1889	1889 Mel	Mel	\N	\N	MELANOMA, AT LEAST IN SITU, WITH SUPERIMPOSED CHANGES OF REGRESSION	\N	21-63575B
1881	1881 Nevus	Nevus	\N	\N	COMPOUND MELANOCYTIC NEVUS	\N	21-63579A
2525	2525 MIS	MIS	\N	\N	\N	\N	21-79845
2524	2524 Invasive	Invasive	\N	\N	\N	\N	21-79845
2515	2515 Invasive	Invasive	\N	\N	\N	\N	21-83029A
2516	2516 MIS	MIS	\N	\N	\N	\N	21-83029B
2528	2528 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	21-89776A
2527	2527 Normal	Normal	\N	\N	\N	\N	21-89776A
2529	2529 Normal	Normal	\N	\N	\N	\N	21-89776B
2530	2530 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	21-89776B
2028	2028 Intramucosal Nevus	Intramucosal Nevus	\N	\N	\N	\N	21-93208
2550	2550 Normal	Normal	\N	\N	\N	\N	21-96446A1
2551	2551 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	21-96446A1
2552	2552 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	21-96446A2
1892	1892 Lentigo Simplex	Lentigo Simplex	\N	\N	LENTIGO SIMPLEX	\N	21-96630
1886	1886 Nevus	Nevus	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	\N	21-98013A
1885	1885 Nevus	Nevus	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	\N	21-98047
3728	3728 Not Processed	Not Processed	\N	\N	\N	\N	21-108508A
3729	3729 Not Processed	Not Processed	\N	\N	\N	\N	21-108508B
3730	3730 Not Processed	Not Processed	\N	\N	\N	\N	21-108509A
2907	2907 NAN	NAN	\N	\N	\N	\N	21-108509B
3731	3731 Not Processed	Not Processed	\N	\N	\N	\N	21-108509C
3732	3732 Not Processed	Not Processed	\N	\N	\N	\N	21-108509D
3733	3733 Not Processed	Not Processed	\N	\N	\N	\N	21-108509E
2902	2902 Not Processed	Not Processed	\N	\N	\N	\N	21-108510A
3734	3734 Not Processed	Not Processed	\N	\N	\N	\N	21-108510B
3735	3735 Not Processed	Not Processed	\N	\N	\N	\N	21-108510C
1900	1900 Nevus	Nevus	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE	\N	21-110009A
1898	1898 Lentigo Simplex	Lentigo Simplex	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	21-110012A
1899	1899 Nevus	Nevus	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	21-110012A
1895	1895 Lentigo Simplex	Lentigo Simplex	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, INFLAMED	\N	21-110027B
1896	1896 Nevus	Nevus	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, INFLAMED	\N	21-110027B
1897	1897 Nevus	Nevus	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, INFLAMED	\N	21-110027B
1894	1894 Nevus	Nevus	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	\N	21-110504
1905	1905 Lentigo Simplex	Lentigo Simplex	\N	\N	\N	\N	21-112103B
1906	1906 Junctional Nevus	Junctional Nevus	\N	\N	\N	\N	21-112103B
1901	1901 Lentigo Simplex	Lentigo Simplex	\N	\N	\N	\N	21-112195B
1902	1902 Nevus	Nevus	\N	\N	\N	\N	21-112195B
1907	1907 Lentigo Simplex	Lentigo Simplex	\N	\N	\N	\N	21-112195D
1908	1908 Junctional Nevus	Junctional Nevus	\N	\N	\N	\N	21-112195D
1911	1911 Nevus	Nevus	\N	\N	\N	\N	21-112298
1912	1912 Nevus	Nevus	\N	\N	\N	\N	21-112298
1913	1913 Lentigo Simplex	Lentigo Simplex	\N	\N	\N	\N	21-112298
1914	1914 Lentigo Simplex	Lentigo Simplex	\N	\N	\N	\N	21-112298
1903	1903 Lentigo Simplex	Lentigo Simplex	\N	\N	\N	\N	21-112321A
1904	1904 Nevus	Nevus	\N	\N	\N	\N	21-112321A
2215	2215 Mel	Mel	\N	\N	\N	\N	21-118604
2216	2216 Nevus	Nevus	\N	\N	\N	\N	21-118604
2218	2218 Normal	Normal	\N	\N	\N	\N	21-118604
2217	2217 Regressed Area	Regressed Area	\N	\N	\N	\N	21-118604
2237	2237 MIS	MIS	\N	\N	\N	\N	21-118604
2219	2219 Mel	Mel	\N	\N	\N	\N	21-131828
2221	2221 Nevus	Nevus	\N	\N	\N	\N	21-131828
2220	2220 MIS	MIS	\N	\N	\N	\N	21-131828
2222	2222 Normal	Normal	\N	\N	\N	\N	21-131828
2455	2455 Invasive	Invasive	2023-05-19 00:00:00-07	\N	\N	\N	21-135927
2454	2454 MIS	MIS	2023-05-19 00:00:00-07	\N	\N	\N	21-135927
3649	3649 Waiting Process	Waiting Process	\N	\N	\N	\N	22-00847N5
2589	2589 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-854
3650	3650 Waiting Process	Waiting Process	\N	\N	\N	\N	22-00892-16
3651	3651 Waiting Process	Waiting Process	\N	\N	\N	\N	22-01164-2
3652	3652 Waiting Process	Waiting Process	\N	\N	\N	\N	22-03790
3653	3653 Waiting Process	Waiting Process	\N	\N	\N	\N	22-04201-6
3654	3654 Waiting Process	Waiting Process	\N	\N	\N	\N	22-04201N2
3655	3655 Waiting Process	Waiting Process	\N	\N	\N	\N	22-05287-15
3656	3656 Waiting Process	Waiting Process	\N	\N	\N	\N	22-05287N2
3657	3657 Waiting Process	Waiting Process	\N	\N	\N	\N	22-06500-1
3658	3658 Waiting Process	Waiting Process	\N	\N	\N	\N	22-07164-1
2481	2481 MIS	MIS	\N	\N	\N	\N	22-7578
2480	2480 Invasive	Invasive	\N	\N	\N	\N	22-7578
2586	2586 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-8115
3736	3736 Not Processed	Not Processed	\N	\N	\N	\N	22-9055A1
3737	3737 Not Processed	Not Processed	\N	\N	\N	\N	22-9055C1
2482	2482 Normal	Normal	\N	\N	\N	\N	22-15594-4
1951	1951 Mel	Mel	\N	\N	\N	\N	22-17043
1952	1952 Nevus	Nevus	\N	\N	\N	\N	22-17043
1953	1953 Normal	Normal	\N	\N	\N	\N	22-17043
3659	3659 Waiting Process	Waiting Process	\N	\N	\N	\N	22-21012A1
3660	3660 Waiting Process	Waiting Process	\N	\N	\N	\N	22-21012A2
3661	3661 Waiting Process	Waiting Process	\N	\N	\N	\N	22-21012A3
3662	3662 Waiting Process	Waiting Process	\N	\N	\N	\N	22-21012A4
3663	3663 Waiting Process	Waiting Process	\N	\N	\N	\N	22-21012A5
3664	3664 Waiting Process	Waiting Process	\N	\N	\N	\N	22-21031A1
3738	3738 Not Processed	Not Processed	\N	\N	\N	\N	22-25497A1
3739	3739 Not Processed	Not Processed	\N	\N	\N	\N	22-25497A2
3665	3665 Waiting Process	Waiting Process	\N	\N	\N	\N	22-25709C1
2453	2453 Normal	Normal	2023-05-19 00:00:00-07	\N	\N	\N	22-29280
2665	2665 MIS	MIS	\N	\N	\N	\N	22-34510A3
2664	2664 Invasive	Invasive	\N	\N	\N	\N	22-34510A3
2666	2666 Normal	Normal	\N	\N	\N	\N	22-34510B1
3666	3666 Waiting Process	Waiting Process	\N	\N	\N	\N	22-34951
2569	2569 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	22-35051
2486	2486 Invasive	Invasive	\N	\N	\N	\N	22-38234B
2487	2487 MIS	MIS	\N	\N	\N	\N	22-38234B
3667	3667 Waiting Process	Waiting Process	\N	\N	\N	\N	22-42722B1
3740	3740 Not Processed	Not Processed	\N	\N	\N	\N	22-44747A1
3741	3741 Not Processed	Not Processed	\N	\N	\N	\N	22-44747A2
2476	2476 Mel	Mel	\N	\N	\N	\N	22-44813B
2624	2624 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-46448
2625	2625 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-47776
2038	2038 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	22-51092
2039	2039 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	22-51092
2040	2040 Mel	Mel	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	22-51092
2041	2041 Normal	Normal	\N	\N	B:\\HiSeqData_Noel_Chenxu\\Nodular Melanoma Broad Samples\\Manthos NM Images	\N	22-51092
2626	2626 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-51687
2535	2535 Normal	Normal	\N	\N	\N	\N	22-52528-1
2536	2536 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	22-52528-1
2538	2538 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	22-52528-2
2537	2537 Normal	Normal	\N	\N	\N	\N	22-52528-2
2627	2627 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-53879
2574	2574 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	22-59468
2628	2628 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-61674
2629	2629 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-67443
2630	2630 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-67443
2687	2687 Capture Area D1	Capture Area D1	\N	\N	\N	\N	22-73345B
2684	2684 Capture Area A1	Capture Area A1	\N	\N	\N	\N	22-75050A2
2526	2526 Normal	Normal	\N	\N	\N	\N	22-76519A
2294	2294 Mel	Mel	\N	\N	\N	\N	22-80319A1
2295	2295 MIS	MIS	\N	\N	\N	\N	22-80319A1
2296	2296 Nevus	Nevus	\N	\N	\N	\N	22-80319A1
2297	2297 Mel	Mel	\N	\N	\N	\N	22-80319A2
2298	2298 Normal	Normal	\N	\N	\N	\N	22-80319A2
3832	3832 Not Processed	Not Processed	\N	\N	\N	\N	22-80980
2587	2587 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-81230
2268	2268 Met1	Met1	2023-03-29 00:00:00-07	\N	Met1 and Met2 merged	\N	22-81852A
2269	2269 Met2	Met2	2023-03-29 00:00:00-07	\N	Met1 and Met2 merged	\N	22-81852A
2270	2270 Normal	Normal	2023-03-29 00:00:00-07	\N	\N	\N	22-81852B
2588	2588 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-83760
2581	2581 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-83883
3833	3833 Not Processed	Not Processed	\N	\N	\N	\N	22-83923A
2631	2631 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-84696
2590	2590 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-85528
2632	2632 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-88291
2591	2591 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-88969
2592	2592 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-90430
2593	2593 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-91591
2504	2504 MIS	MIS	\N	\N	\N	\N	22-91699A1
2503	2503 Invasive	Invasive	\N	\N	\N	\N	22-91699A4
2505	2505 Normal	Normal	\N	\N	\N	\N	22-91699A7
2633	2633 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-93578
2634	2634 Normal	Normal	\N	\N	\N	\N	22-93578
2594	2594 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-94507
2517	2517 Normal	Normal	\N	\N	\N	\N	22-94741
2635	2635 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-95643
3793	3793 Not Processed	Not Processed	\N	\N	\N	\N	22-95643B
2595	2595 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-95858
2596	2596 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-99877
2287	2287 Mel	Mel	\N	\N	\N	\N	22-101809
2288	2288 Melanocytoma	Melanocytoma	\N	\N	\N	\N	22-101809
2477	2477 Invasive	Invasive	\N	\N	\N	\N	22-102807-2
2478	2478 MIS	MIS	\N	\N	\N	\N	22-102807-2
2479	2479 Normal	Normal	\N	\N	\N	\N	22-102807-4
2235	2235 Nevus	Nevus	\N	\N	\N	\N	22-102809
2234	2234 Mel	Mel	\N	\N	\N	\N	22-102809
2236	2236 Normal	Normal	\N	\N	\N	\N	22-102809
2456	2456 Tumor	Tumor	2023-05-19 00:00:00-07	\N	\N	\N	22-104389A2
2462	2462 Normal	Normal	\N	\N	\N	\N	22-104389A4
2918	2918 Unknown	Unknown	\N	\N	\N	\N	22-104389A4
2917	2917 Unknown	Unknown	\N	\N	\N	\N	22-104389A4
2457	2457 Tumor	Tumor	2023-05-19 00:00:00-07	\N	\N	\N	22-104389C
2299	2299 Mel	Mel	\N	\N	\N	\N	22-104652
2300	2300 Nevus	Nevus	\N	\N	\N	\N	22-104652
2301	2301 Normal	Normal	\N	\N	\N	\N	22-104652
2539	2539 Normal	Normal	\N	\N	\N	\N	22-105120-1
2540	2540 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	22-105120-1
2541	2541 Normal	Normal	\N	\N	\N	\N	22-105120-2
2542	2542 Keratoacanthoma	Keratoacanthoma	\N	\N	\N	\N	22-105120-2
3834	3834 Not Processed	Not Processed	\N	\N	\N	\N	22-107614
2289	2289 Normal	Normal	\N	\N	\N	\N	22-114059B
2576	2576 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-114644
2584	2584 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	22-115140
3794	3794 Not Processed	Not Processed	\N	\N	\N	\N	22-115635C4
2573	2573 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-115763
2686	2686 Capture Area C1	Capture Area C1	\N	\N	\N	\N	22-119466
2572	2572 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-122015
2685	2685 Capture Area B1	Capture Area B1	\N	\N	\N	\N	22-124532-2
2247	2247 tum	tum	\N	\N	\N	\N	22-125373
2577	2577 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-127365
2578	2578 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-127490
2579	2579 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-128532
2580	2580 Blue Nevus	Blue Nevus	\N	\N	\N	\N	22-128941
3795	3795 Not Processed	Not Processed	\N	\N	\N	\N	22-152373
3742	3742 Not Processed	Not Processed	\N	\N	\N	\N	22-510407A1
2582	2582 Blue Nevus	Blue Nevus	\N	\N	\N	\N	23-293
2488	2488 Normal	Normal	\N	\N	\N	\N	23-1012A2
3668	3668 Waiting Process	Waiting Process	\N	\N	\N	\N	23-01133
3669	3669 Waiting Process	Waiting Process	\N	\N	\N	\N	23-01329-1
3670	3670 Waiting Process	Waiting Process	\N	\N	\N	\N	23-02692-3
2291	2291 Nevus	Nevus	\N	\N	\N	\N	23-2718 (block 1)
2290	2290 Mel	Mel	\N	\N	\N	\N	23-2718 (block 1)
2292	2292 Mel	Mel	\N	\N	\N	\N	23-2718 (block 2)
2585	2585 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	23-3020
2639	2639 Invasive	Invasive	\N	\N	\N	\N	23-3314
2640	2640 MIS	MIS	\N	\N	\N	\N	23-3314
3438	3438 Unknown	Unknown	\N	\N	\N	\N	23-3314
3439	3439 Unknown	Unknown	\N	\N	\N	\N	23-3314
3671	3671 Waiting Process	Waiting Process	\N	\N	\N	\N	23-03515-1
3672	3672 Waiting Process	Waiting Process	\N	\N	\N	\N	23-03529-3
2566	2566 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	23-4594
2567	2567 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	23-4595
2571	2571 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	23-4604
3673	3673 Waiting Process	Waiting Process	\N	\N	\N	\N	23-04628-5
3674	3674 Waiting Process	Waiting Process	\N	\N	\N	\N	23-04707-7
2583	2583 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	23-4720
2570	2570 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	23-4742
3675	3675 Waiting Process	Waiting Process	\N	\N	\N	\N	23-05091-4
2575	2575 Blue Nevus	Blue Nevus	\N	\N	\N	\N	23-5230
2568	2568 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	23-5236
3676	3676 Waiting Process	Waiting Process	\N	\N	\N	\N	23-05782-2
3677	3677 Waiting Process	Waiting Process	\N	\N	\N	\N	23-06001-12
3743	3743 Not Processed	Not Processed	\N	\N	\N	\N	23-6349A1
3744	3744 Not Processed	Not Processed	\N	\N	\N	\N	23-6349A2
3745	3745 Not Processed	Not Processed	\N	\N	\N	\N	23-6349A3
3678	3678 Waiting Process	Waiting Process	\N	\N	\N	\N	23-07186-13
2563	2563 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	23-7246A 
2564	2564 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	23-7246B
2565	2565 Congenital Nevus	Congenital Nevus	\N	\N	\N	\N	23-7246C
2612	2612 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	23-7509
3679	3679 Waiting Process	Waiting Process	\N	\N	\N	\N	23-09618
2293	2293 Normal	Normal	\N	\N	\N	\N	23-11588A
2641	2641 Normal	Normal	\N	\N	\N	\N	23-12491
2613	2613 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	23-14412
3835	3835 Not Processed	Not Processed	\N	\N	\N	\N	23-18865
2447	2447 Mel	Mel	\N	\N	\N	\N	23-34755
2450	2450 Normal	Normal	2023-05-19 00:00:00-07	\N	\N	\N	23-37003
2451	2451 MIS	MIS	2023-05-19 00:00:00-07	\N	\N	\N	23-37003
2452	2452 Invasive	Invasive	2023-05-19 00:00:00-07	\N	\N	\N	23-37003
2614	2614 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	23-37594
2615	2615 Spitz Nevus	Spitz Nevus	\N	\N	\N	\N	23-42323
2449	2449 Normal	Normal	\N	\N	\N	\N	23-47727
2448	2448 Nevus	Nevus	\N	\N	\N	\N	23-47727
2445	2445 Nevus	Nevus	\N	\N	\N	\N	23-47967
2446	2446 Normal	Normal	\N	\N	\N	\N	23-47967
2443	2443 Mel	Mel	\N	\N	\N	\N	23-47967
2444	2444 MIS	MIS	\N	\N	\N	\N	23-47967
2460	2460 Nevus	Nevus	\N	\N	\N	\N	23-49347
2459	2459 MIS	MIS	\N	\N	\N	\N	23-49347
2461	2461 Normal	Normal	\N	\N	\N	\N	23-49347
2475	2475 Normal	Normal	\N	\N	\N	\N	23-51956A3
2473	2473 MIS	MIS	\N	\N	\N	\N	23-51956B14
2689	2689 Invasive	Invasive	\N	\N	\N	\N	23-51956B14
2474	2474 MIS	MIS	\N	\N	\N	\N	23-51956B16
2472	2472 Invasive	Invasive	\N	\N	\N	\N	23-51956B17
2688	2688 Invasive	Invasive	\N	\N	\N	\N	23-51956B17
3796	3796 Not Processed	Not Processed	\N	\N	\N	\N	23-83099
3797	3797 Not Processed	Not Processed	\N	\N	\N	\N	23-97273
3798	3798 Not Processed	Not Processed	\N	\N	\N	\N	23-107334C2
2928	2928 Tumor	Tumor	\N	\N	\N	\N	35_M
2929	2929 Tumor	Tumor	\N	\N	\N	\N	49_M
1005	1005 Nodular Mel	Nodular Mel	\N	\N	\N	\N	59/15
924	924 Mel	Mel	\N	\N	\N	\N	85-01186
1124	1124 Mel	Mel	\N	\N	\N	\N	86-04906-2 T2
1118	1118 Mel	Mel	\N	\N	\N	\N	87-14087B T2
1119	1119 Mel	Mel	\N	\N	\N	\N	88-6851-2 T3
923	923 Mel	Mel	\N	\N	\N	\N	89-10432A M1
1133	1133 Mel	Mel	\N	\N	\N	\N	89-10450-1 T2
1127	1127 Mel	Mel	\N	\N	\N	\N	89-13569-1 T2
1109	1109 Mel	Mel	\N	\N	\N	\N	90-07958-1 T2
2718	2718 Tumor	Tumor	\N	\N	\N	\N	90-012097B
1113	1113 Mel	Mel	\N	\N	\N	\N	91-08026A T2
1126	1126 Mel	Mel	\N	\N	\N	\N	91-09968E T3
928	928 Mel	Mel	\N	\N	\N	\N	91-16318 M1
2720	2720 Tumor	Tumor	\N	\N	\N	\N	91-017419
1842	1842 Normal	Normal	\N	\N	\N	\N	92-1608A
1841	1841 Mel	Mel	\N	\N	\N	\N	92-1608B
2719	2719 Tumor	Tumor	\N	\N	\N	\N	92-003527H
1112	1112 Mel	Mel	\N	\N	\N	\N	92-03953C T2
1839	1839 Mel	Mel	\N	\N	\N	\N	92-5109
1840	1840 Normal	Normal	\N	\N	\N	\N	92-5109
1122	1122 Mel	Mel	\N	\N	\N	\N	92-06469A T2
1120	1120 Mel	Mel	\N	\N	\N	\N	92-14752-1 T2
1117	1117 Mel	Mel	\N	\N	\N	\N	92-18572E T3
921	921 Mel	Mel	\N	\N	\N	\N	93-06269-4 N1
1125	1125 Mel	Mel	\N	\N	\N	\N	93-12428-1 T2
1795	1795 Normal	Normal	\N	\N	\N	\N	93-13675A
1792	1792 Mel	Mel	\N	\N	\N	\N	93-13675B
1793	1793 Normal	Normal	\N	\N	\N	\N	93-13675B
1794	1794 MIS	MIS	\N	\N	\N	\N	93-13675B
1132	1132 Mel	Mel	\N	\N	\N	\N	93-13951 T2
1111	1111 Mel	Mel	\N	\N	\N	\N	93-21060-4 T2
920	920 Mel	Mel	\N	\N	\N	\N	94-00143-2 N1
919	919 Mel	Mel	\N	\N	\N	\N	94-00669 N1
1123	1123 Mel	Mel	\N	\N	\N	\N	94-01469-2 T3
1729	1729 Mel	Mel	\N	\N	\N	\N	94-7602A
1730	1730 Normal	Normal	\N	\N	\N	\N	94-7602A
1131	1131 Mel	Mel	\N	\N	\N	\N	94-08318-1 T2
1129	1129 Mel	Mel	\N	\N	\N	\N	94-12246 T3
2731	2731 Tumor	Tumor	\N	\N	\N	\N	94-016368
1128	1128 Mel	Mel	\N	\N	\N	\N	94-18018-2 T3
1121	1121 Mel	Mel	\N	\N	\N	\N	94-19725B T3
966	966 Mel	Mel	\N	\N	\N	\N	94-21132 M1
3074	3074 Tumor	Tumor	\N	\N	\N	\N	94-31062  
925	925 Mel	Mel	\N	\N	\N	\N	95-01141-1 M1
1108	1108 Mel	Mel	\N	\N	\N	\N	95-02325-1 T3
926	926 Mel	Mel	\N	\N	\N	\N	95-05724-1 M1
1667	1667 Mel	Mel	\N	\N	\N	\N	95-5908
1668	1668 Normal	Normal	\N	\N	\N	\N	95-5908
922	922 Mel	Mel	\N	\N	\N	\N	95-05959 M1
2734	2734 Tumor	Tumor	\N	\N	\N	\N	95-007992
1114	1114 Mel	Mel	\N	\N	\N	\N	95-14297-5 T2
1026	1026 Mel	Mel	\N	\N	\N	\N	95-14690F T1
1116	1116 Mel	Mel	\N	\N	\N	\N	95-16013B T3
1788	1788 Normal	Normal	\N	\N	\N	\N	95-21392
1787	1787 Mel	Mel	\N	\N	\N	\N	95-21392
1789	1789 Normal	Normal	\N	\N	\N	\N	95-21392
1115	1115 Mel	Mel	\N	\N	\N	\N	96-02480 T3
1704	1704 Mel	Mel	\N	\N	\N	\N	96-3842
1705	1705 Normal	Normal	\N	\N	\N	\N	96-3842
1706	1706 MIS	MIS	\N	\N	\N	\N	96-3842
2262	2262 Normal	Normal	2019-07-19 00:00:00-07	\N	Normal	\N	96-4039
3799	3799 Not Processed	Not Processed	\N	\N	\N	\N	96-4039A5
3800	3800 Not Processed	Not Processed	\N	\N	\N	\N	96-4039A7
2803	2803 Mel	Mel	\N	\N	\N	\N	96-6536
927	927 Mel	Mel	\N	\N	\N	\N	96-06832D M1
967	967 Mel	Mel	\N	\N	\N	\N	96-07395C M1
1699	1699 Mel	Mel	\N	\N	\N	\N	96-12193
968	968 Mel	Mel	\N	\N	\N	\N	96-13701 M1
2258	2258 Tumor	Tumor	2019-07-19 00:00:00-07	\N	Primary Tumor	\N	96-14850
1709	1709 Normal	Normal	\N	\N	\N	\N	96-18458A
1710	1710 MIS	MIS	\N	\N	\N	\N	96-18458C
1708	1708 Mel	Mel	\N	\N	\N	\N	96-18458E
1711	1711 MIS	MIS	\N	\N	\N	\N	96-18458F
929	929 Mel	Mel	\N	\N	\N	\N	96-18967-1 M1
1110	1110 Mel	Mel	\N	\N	\N	\N	96-20650-1A T3
969	969 Mel	Mel	\N	\N	\N	\N	96-23601-4 M1
1046	1046 Mel	Mel	\N	\N	\N	\N	96-24948 T1
930	930 Mel	Mel	\N	\N	\N	\N	97-01837E M1
1107	1107 Mel	Mel	\N	\N	\N	\N	97-8417 T2
1833	1833 Mel	Mel	\N	\N	\N	\N	97-13166G
1834	1834 Normal	Normal	\N	\N	\N	\N	97-13166G
1861	1861 Mel	Mel	\N	\N	\N	\N	97-23367
1862	1862 Normal	Normal	\N	\N	\N	\N	97-23367
2740	2740 Tumor	Tumor	\N	\N	\N	\N	98-001046
2757	2757 Normal	Normal	\N	\N	\N	\N	98-1056
2758	2758 MVP	MVP	\N	\N	\N	\N	98-1056A9
1808	1808 Mel	Mel	\N	\N	\N	\N	98-1556
1809	1809 Normal	Normal	\N	\N	\N	\N	98-1556
931	931 Mel	Mel	\N	\N	\N	\N	98-02267-5 M1
932	932 Mel	Mel	\N	\N	\N	\N	98-03336-8 M1
933	933 Mel	Mel	\N	\N	\N	\N	98-05054 N1
1801	1801 Mel	Mel	\N	\N	\N	\N	98-6161B
1802	1802 Normal	Normal	\N	\N	\N	\N	98-6161B
1106	1106 Mel	Mel	\N	\N	\N	\N	98-06203-3 T2
1777	1777 Mel	Mel	\N	\N	\N	\N	98-9595B
1778	1778 Normal	Normal	\N	\N	\N	\N	98-9595B
1779	1779 Nevus	Nevus	\N	\N	\N	\N	98-9595B
1942	1942 Nevus	Nevus	\N	\N	\N	\N	98-9595B
1941	1941 Mel	Mel	\N	\N	\N	\N	98-9595B
1943	1943 Normal	Normal	\N	\N	\N	\N	98-9595B
1829	1829 Normal	Normal	\N	\N	\N	\N	98-10389
1828	1828 Mel	Mel	\N	\N	\N	\N	98-10389
1760	1760 Normal	Normal	\N	\N	\N	\N	98-11545
1759	1759 Mel	Mel	\N	\N	\N	\N	98-11545
1761	1761 MIS	MIS	\N	\N	\N	\N	98-11545
1790	1790 Mel	Mel	\N	\N	\N	\N	98-13466
1791	1791 Normal	Normal	\N	\N	\N	\N	98-13466
1631	1631 Mel	Mel	\N	\N	\N	\N	98-16285A2
2775	2775 Tumor	Tumor	\N	\N	\N	\N	98-18400a
2735	2735 Tumor	Tumor	\N	\N	\N	\N	98-019394
1105	1105 Mel	Mel	\N	\N	\N	\N	98-21389A T2
1781	1781 Normal	Normal	\N	\N	\N	\N	98-21806
1780	1780 Mel	Mel	\N	\N	\N	\N	98-21806
970	970 Mel	Mel	\N	\N	\N	\N	98-23221F M1
1762	1762 Mel	Mel	\N	\N	\N	\N	99-3122A
1763	1763 Normal	Normal	\N	\N	\N	\N	99-3122A
1837	1837 Mel	Mel	\N	\N	\N	\N	99-3122A
1838	1838 Normal	Normal	\N	\N	\N	\N	99-3122A
1830	1830 Mel	Mel	\N	\N	\N	\N	99-4387
1831	1831 Normal	Normal	\N	\N	\N	\N	99-4387
1832	1832 MIS	MIS	\N	\N	\N	\N	99-4387
2737	2737 Tumor	Tumor	\N	\N	\N	\N	99-005681
1103	1103 Mel	Mel	\N	\N	\N	\N	99-09753 T2
2747	2747 Normal	Normal	\N	\N	\N	\N	99-012800
2749	2749 Tumor	Tumor	\N	\N	\N	\N	99-012800-2
1028	1028 Mel	Mel	\N	\N	\N	\N	99-13402-3 T1
1648	1648 Mel	Mel	\N	\N	\N	\N	99-14477
1649	1649 Normal	Normal	\N	\N	\N	\N	99-14477
1101	1101 Mel	Mel	\N	\N	\N	\N	99-15953D T2
934	934 Mel	Mel	\N	\N	\N	\N	99-16633E N1
1104	1104 Mel	Mel	\N	\N	\N	\N	99-16706 T2
1635	1635 Mel	Mel	\N	\N	\N	\N	99-18307
1810	1810 Mel	Mel	\N	\N	http://64.54.108.147/eSlideTray.php?ImageIds=1002 , 99-19410B, 99-19410A	\N	99-19410A
1811	1811 Normal	Normal	\N	\N	\N	\N	99-19410B
1082	1082 Mel	Mel	\N	\N	\N	\N	99-19998 T2
1864	1864 Normal	Normal	\N	\N	\N	\N	99-23502A
1863	1863 Mel	Mel	\N	\N	\N	\N	99-23502C
1102	1102 Mel	Mel	\N	\N	\N	\N	99-24969F T4
935	935 Mel	Mel	\N	\N	\N	\N	99-27534 M1
1636	1636 Mel	Mel	\N	\N	\N	\N	99-30301
1936	1936 Nevus	Nevus	\N	\N	\N	\N	99-32835
1935	1935 Mel	Mel	\N	\N	\N	\N	99-32835
1937	1937 Normal	Normal	\N	\N	\N	\N	99-32835
2463	2463 Melanoma Cell Line	Melanoma Cell Line	\N	\N	\N	\N	144 Imat B15
2464	2464 Melanoma Cell Line	Melanoma Cell Line	\N	\N	\N	\N	144 Imat B15-2
2465	2465 Cell Line	Cell Line	\N	\N	\N	\N	144aI WT
573	573 Nodular Mel	Nodular Mel	\N	\N	\N	\N	150/17
1011	1011 Nodular Mel	Nodular Mel	\N	\N	\N	\N	156/13
2466	2466 Cell Line	Cell Line	\N	\N	\N	\N	230 WT
593	593 Nodular Mel	Nodular Mel	\N	\N	\N	\N	351/10 2 (HBD)
594	594 Nodular Mel	Nodular Mel	\N	\N	\N	\N	351/10 4 (HBD)
31	31 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	352-1-15.1
32	32 MIS	MIS	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	352-1-15.1
33	33 MIS	MIS	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	352-1-15.1
34	34 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	352-1-15.1
3746	3746 Not Processed	Not Processed	\N	\N	\N	\N	352-1-15.2
3747	3747 Not Processed	Not Processed	\N	\N	\N	\N	352-1-15.3
42	42 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	385/14
43	43 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	385/14
44	44 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	385/14
45	45 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	385/14
595	595 Nodular Mel	Nodular Mel	\N	\N	\N	\N	467/10  1
3748	3748 Not Processed	Not Processed	\N	\N	\N	\N	534-1-11.1
2341	2341 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-6
18	18 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	also on block 534-1-11.3	\N	534-1-11.2
19	19 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	also on block 534-1-11.3	\N	534-1-11.2
20	20 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	also on block 534-1-11.3	\N	534-1-11.2
21	21 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	534-1-11.2
3749	3749 Not Processed	Not Processed	\N	\N	\N	\N	534-1-11.3
1006	1006 Nodular Mel	Nodular Mel	\N	\N	\N	\N	718/12a
1004	1004 Nodular Mel	Nodular Mel	\N	\N	\N	\N	1135/19
577	577 Nodular Mel	Nodular Mel	\N	\N	\N	\N	1205/17
3801	3801 Cell Line	Cell Line	\N	\N	\N	\N	1205lu-1
3802	3802 Cell Line	Cell Line	\N	\N	\N	\N	1205lu-2
3803	3803 Cell Line	Cell Line	\N	\N	\N	\N	1205LU-3
576	576 Nodular Mel	Nodular Mel	\N	\N	\N	\N	1283/14
552	552 Nodular Mel	Nodular Mel	\N	\N	\N	\N	1485/15 (1485/15 slide)
3750	3750 Not Processed	Not Processed	\N	\N	\N	\N	1586-2-13-A
3751	3751 Not Processed	Not Processed	\N	\N	\N	\N	1586-2-13-B
38	38 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	1586-2-13-C
39	39 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	1586-2-13-C
40	40 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	1586-2-13-C
41	41 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	1586-2-13-C
578	578 Nodular Mel	Nodular Mel	\N	\N	\N	\N	1813/15 3
1020	1020 Nodular Mel	Nodular Mel	\N	\N	\N	\N	2017-07184
1012	1012 Nodular Mel	Nodular Mel	\N	\N	\N	\N	2017-19575
570	570 Nodular Mel	Nodular Mel	\N	\N	\N	\N	2065/12 (2065/117 slide)
572	572 Nodular Mel	Nodular Mel	\N	\N	\N	\N	2227/14 4
35	35 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	2686-1-13.1
36	36 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	2686-1-13.1
37	37 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	2686-1-13.1
1291	1291 Normal	Normal	\N	\N	\N	\N	2686-1-13.2
553	553 Nodular Mel	Nodular Mel	\N	\N	\N	\N	2997/11
598	598 Nodular Mel	Nodular Mel	\N	\N	\N	\N	3188/18
46	46 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	4070/2/13.1
47	47 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	4070/2/13.1
48	48 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	AM2 D-72 not circled on the image, no DNA extracted	\N	4070/2/13.1
3752	3752 Not Processed	Not Processed	\N	\N	\N	\N	4070/2/13.2
3753	3753 Not Processed	Not Processed	\N	\N	\N	\N	4070/2/13.3
3754	3754 Not Processed	Not Processed	\N	\N	\N	\N	4070/3/13.1
3755	3755 Not Processed	Not Processed	\N	\N	\N	\N	4070/3/13.2
3756	3756 Not Processed	Not Processed	\N	\N	\N	\N	4070/3/13.3
574	574 Nodular Mel	Nodular Mel	\N	\N	\N	\N	4136/16
575	575 Nodular Mel	Nodular Mel	\N	\N	\N	\N	4449/16 (4449/16 3 slide)
579	579 Nodular Mel	Nodular Mel	\N	\N	\N	\N	4890/15 8
554	554 Nodular Mel	Nodular Mel	\N	\N	\N	\N	5696/15
582	582 Nodular Mel	Nodular Mel	\N	\N	\N	\N	5698.3 (14.5698.3 slide)
551	551 Nodular Mel	Nodular Mel	\N	\N	\N	\N	5890/08
580	580 Nodular Mel	Nodular Mel	\N	\N	\N	\N	6172.3 (14.6172.3 slide)
1009	1009 Nodular Mel	Nodular Mel	\N	\N	\N	\N	6258/2015
1018	1018 Nodular Mel	Nodular Mel	\N	\N	\N	\N	8716/2016
1014	1014 Nodular Mel	Nodular Mel	\N	\N	\N	\N	10226 2
569	569 Nodular Mel	Nodular Mel	\N	\N	\N	\N	11522/18
581	581 Nodular Mel	Nodular Mel	\N	\N	\N	\N	11649.2 (15.11649.2 slide)
583	583 Nodular Mel	Nodular Mel	\N	\N	\N	\N	12410/09
1017	1017 Nodular Mel	Nodular Mel	\N	\N	\N	\N	14531/14
599	599 Nodular Mel	Nodular Mel	\N	\N	\N	\N	15356/1 (H08.15356/1 slide)
1021	1021 Nodular Mel	Nodular Mel	\N	\N	\N	\N	15864 3
571	571 Nodular Mel	Nodular Mel	\N	\N	\N	\N	16053/12 wy (16053/12 slide)
584	584 Nodular Mel	Nodular Mel	\N	\N	\N	\N	17890/18 (HBD)
3757	3757 Not Processed	Not Processed	\N	\N	\N	\N	19111/14.1\n
85	85 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	19111/14.2
86	86 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	19111/14.3
87	87 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	19111/14.3
88	88 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	19111/14.3
3758	3758 Not Processed	Not Processed	\N	\N	\N	\N	19111/14.4
3759	3759 Not Processed	Not Processed	\N	\N	\N	\N	19111/14.5
90	90 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	21159 A5
91	91 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	21159 A5
3760	3760 Not Processed	Not Processed	\N	\N	\N	\N	21159 A6
89	89 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	21159 G2
3761	3761 Not Processed	Not Processed	\N	\N	\N	\N	21159 G5
1010	1010 Nodular Mel	Nodular Mel	\N	\N	\N	\N	21831/14
92	92 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	38637-16.1
93	93 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	38637-16.1
94	94 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	38637-16.1
95	95 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	38637-16.1
96	96 Mel2	Mel2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	38637-16.1
1285	1285 Met1	Met1	\N	\N	\N	\N	38637-16.2
3762	3762 Not Processed	Not Processed	\N	\N	\N	\N	38637-16.3
1008	1008 Nodular Mel	Nodular Mel	\N	\N	\N	\N	46976B
2696	2696 Tumor	Tumor	\N	\N	\N	\N	61000/00 (LN)
3763	3763 Not Processed	Not Processed	\N	\N	\N	\N	78821-1a\n
3764	3764 Not Processed	Not Processed	\N	\N	\N	\N	78821-1b
15	15 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	78821-1c
16	16 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	78821-1c
17	17 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	78821-1c
3765	3765 Not Processed	Not Processed	\N	\N	\N	\N	78821-2a
3766	3766 Not Processed	Not Processed	\N	\N	\N	\N	78821-2b
28	28 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	also on block 79049-2a	\N	79049-1a
3767	3767 Not Processed	Not Processed	\N	\N	\N	\N	79049-1b
29	29 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	79049-1c
30	30 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	79049-1c
3768	3768 Not Processed	Not Processed	\N	\N	\N	\N	79049-1d
3769	3769 Not Processed	Not Processed	\N	\N	\N	\N	79049-2a
3770	3770 Not Processed	Not Processed	\N	\N	\N	\N	79049-2b
3771	3771 Not Processed	Not Processed	\N	\N	\N	\N	79447-a\n
3772	3772 Not Processed	Not Processed	\N	\N	\N	\N	79447-b
26	26 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	79447-c
27	27 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	79447-c
25	25 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	79447-d
12	12 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	86502b
13	13 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	86502b
14	14 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	86502b
3773	3773 Not Processed	Not Processed	\N	\N	\N	\N	86502c
3774	3774 Not Processed	Not Processed	\N	\N	\N	\N	86502d
3775	3775 Not Processed	Not Processed	\N	\N	\N	\N	86502f
23	23 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	86541-1E
3776	3776 Not Processed	Not Processed	\N	\N	\N	\N	86541-1f
24	24 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	86541-1g
1289	1289 Mel2	Mel2	\N	\N	\N	\N	86541-1g
1290	1290 LN Met	LN Met	\N	\N	also on block 86541-2b	\N	86541-2a
3777	3777 Not Processed	Not Processed	\N	\N	\N	\N	86541-2b
22	22 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	86541-2c
1007	1007 Nodular Mel	Nodular Mel	\N	\N	\N	\N	115016
600	600 Nodular Mel	Nodular Mel	\N	\N	\N	\N	176323
62	62 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	488836A
63	63 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	488836A
64	64 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	488836A
49	49 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	501950A3
50	50 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	501950A3
51	51 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	501950A3
1147	1147 Normal	Normal	\N	\N	\N	\N	501950A3
1146	1146 MIS	MIS	\N	\N	\N	\N	501950A3
1145	1145 Mel1	Mel1	\N	\N	\N	\N	501950A3
3778	3778 Not Processed	Not Processed	\N	\N	\N	\N	501950C
58	58 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	604076
59	59 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	604076
60	60 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	604076
61	61 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	604076
52	52 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	610186A
53	53 Nevus	Nevus	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	610186A
54	54 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	610186A
55	55 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	610186A
56	56 MIS3	MIS3	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	610186A
57	57 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	610186A
3779	3779 Not Processed	Not Processed	\N	\N	\N	\N	610186B\n
3780	3780 Not Processed	Not Processed	\N	\N	\N	\N	610186C
3781	3781 Not Processed	Not Processed	\N	\N	\N	\N	610186D
2937	2937 Not Processed	Not Processed	\N	\N	\N	\N	AM2_D-72
1296	1296 MIS1	MIS1	\N	\N	\N	\N	B06.41962/3
1297	1297 MIS2	MIS2	\N	\N	\N	\N	B06.41962/5
1298	1298 Mel1	Mel1	\N	\N	\N	\N	B06.41962/5
1299	1299 Mel2	Mel2	\N	\N	\N	\N	B06.41962/5
1294	1294 LN Met	LN Met	\N	\N	\N	\N	B13.26332/1
3783	3783 Not Processed	Not Processed	\N	\N	\N	\N	B14. 951 
1300	1300 LN Met	LN Met	\N	\N	\N	\N	B14.2561/12
1427	1427 Lung Metastasis	Lung Metastasis	\N	\N	\N	\N	B15.28523/11
3784	3784 Not Processed	Not Processed	\N	\N	\N	\N	B17.80125 
1148	1148 LN Met 1	LN Met 1	\N	\N	\N	\N	B2007.998/2
1422	1422 Normal	Normal	\N	\N	\N	\N	B2007.998/2
1307	1307 LN Met 1	LN Met 1	\N	\N	\N	\N	B2007.15494/1
1425	1425 Normal	Normal	\N	\N	\N	\N	B2007.15494/1
1423	1423 LN Met 1	LN Met 1	\N	\N	\N	\N	B2008.3067/5
1616	1616 Normal	Normal	\N	\N	\N	\N	B2008.3067/5
1308	1308 Bladder Metastasis	Bladder Metastasis	\N	\N	\N	\N	B2008.24393/1
3782	3782 Not Processed	Not Processed	\N	\N	\N	\N	B2015.54040
1615	1615 Normal	Normal	\N	\N	\N	\N	B62056/15
592	592 Nodular Mel	Nodular Mel	\N	\N	\N	\N	B167003/1B  I
588	588 Nodular Mel	Nodular Mel	\N	\N	\N	\N	B205907 III
590	590 Nodular Mel	Nodular Mel	\N	\N	\N	\N	B206739
591	591 Nodular Mel	Nodular Mel	\N	\N	\N	\N	B215962
587	587 Nodular Mel	Nodular Mel	\N	\N	\N	\N	B224228/2
589	589 Nodular Mel	Nodular Mel	\N	\N	\N	\N	B236709/ 1B
585	585 Nodular Mel	Nodular Mel	\N	\N	\N	\N	B246205/ 1BI
586	586 Nodular Mel	Nodular Mel	\N	\N	\N	\N	B247206/ 1Bl
3813	3813 Lung Cells	Lung Cells	\N	\N	\N	\N	Bivona L1
3814	3814 Lung Cells	Lung Cells	\N	\N	\N	\N	Bivona L2
3815	3815 Lung Cells	Lung Cells	\N	\N	\N	\N	Bivona L3
3816	3816 Lung Cells	Lung Cells	\N	\N	\N	\N	Bivona L4
3817	3817 Lung Cells	Lung Cells	\N	\N	\N	\N	Bivona L5
3818	3818 Lung Cells	Lung Cells	\N	\N	\N	\N	Bivona L6
3819	3819 Lung Cell Line	Lung Cell Line	\N	\N	\N	\N	Bivona L7
3820	3820 Lung Cell Line	Lung Cell Line	\N	\N	\N	\N	Bivona L8
3821	3821 Lung Cell Line	Lung Cell Line	\N	\N	\N	\N	Bivona L9
3811	3811 Lung Cell Line	Lung Cell Line	\N	\N	\N	\N	Bivona L10
3812	3812 Lung Cell Line	Lung Cell Line	\N	\N	\N	\N	Bivona L11
3823	3823 Lung Cell Line	Lung Cell Line	\N	\N	\N	\N	Bivona-L17
3824	3824 Tumor	Tumor	\N	\N	\N	\N	Bivona-L18
3825	3825 Tumor	Tumor	\N	\N	\N	\N	Bivona-L19
2980	2980 Tumor	Tumor	\N	\N	\N	\N	BN_M1
2981	2981 Tumor	Tumor	\N	\N	\N	\N	BN_M2
2982	2982 Normal	Normal	\N	\N	\N	\N	BN_N1
2983	2983 Normal	Normal	\N	\N	\N	\N	BN_N2
2420	2420 Buffy Coat DNA	Buffy Coat DNA	2015-07-31 00:00:00-07	\N	\N	\N	Buffy Coat
2336	2336 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-1
2337	2337 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-2
2338	2338 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-3
2339	2339 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-4
2340	2340 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-5
2342	2342 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-7
2343	2343 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-8
2344	2344 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-9
2345	2345 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-10
2346	2346 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-11
2347	2347 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-12
2348	2348 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-13
2349	2349 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-14
2350	2350 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-15
2351	2351 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-16
2352	2352 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-17
2353	2353 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-18
2354	2354 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-19
2355	2355 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-20
2356	2356 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-21
2357	2357 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-22
2358	2358 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-23
2359	2359 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-24
2360	2360 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-25
2361	2361 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-26
2362	2362 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-27
2363	2363 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-28
2364	2364 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-29
2365	2365 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-30
2366	2366 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-31
2367	2367 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-32
2368	2368 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-33
2369	2369 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-34
2370	2370 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-35
2371	2371 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-36
2372	2372 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-37
2373	2373 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-38
2374	2374 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-39
2375	2375 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-40
2376	2376 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-41
2377	2377 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-42
2378	2378 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-43
2379	2379 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-44
2380	2380 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-45
2381	2381 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-46
2382	2382 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-47
2383	2383 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-48
2384	2384 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-49
2385	2385 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-50
2386	2386 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-51
2387	2387 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-52
2388	2388 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-53
2389	2389 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-54
2390	2390 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-55
2391	2391 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-56
2392	2392 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-57
2393	2393 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-58
2394	2394 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-59
2395	2395 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-60
2396	2396 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-61
2397	2397 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-62
2398	2398 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-63
2399	2399 Cell Line	Cell Line	\N	\N	\N	\N	Cell-Line_Xu-64
2333	2333 Tumor	Tumor	\N	\N	\N	\N	CGH12-067
2848	2848 Tumor	Tumor	\N	\N	\N	\N	CGH12-146
3443	3443 Unknown	Unknown	\N	\N	\N	\N	CGH13-008
3444	3444 Unknown	Unknown	\N	\N	\N	\N	CGH13-010
2851	2851 Tumor	Tumor	\N	\N	\N	\N	CGH13-014
2850	2850 Tumor	Tumor	\N	\N	\N	\N	CGH13-026
3445	3445 Unknown	Unknown	\N	\N	\N	\N	CGH13-026
2849	2849 Normal	Normal	\N	\N	\N	\N	CGH13-034
3446	3446 Unknown	Unknown	\N	\N	\N	\N	CGH13-094
2330	2330 Tumor	Tumor	\N	\N	\N	\N	CGH14-050
2332	2332 Tumor	Tumor	\N	\N	\N	\N	CGH14-147
2331	2331 Tumor	Tumor	\N	\N	\N	\N	CGH15-249
2334	2334 Tumor	Tumor	\N	\N	\N	\N	CGH19-097
2335	2335 Tumor	Tumor	\N	\N	\N	\N	CGH19-097
3852	3852 Normal	Normal	\N	\N	\N	\N	CP1
3847	3847 Tumor	Tumor	\N	\N	\N	\N	CP1-5
3848	3848 Tumor	Tumor	\N	\N	\N	\N	CP1-10
3849	3849 Tumor	Tumor	\N	\N	\N	\N	CP1-20
3850	3850 Tumor	Tumor	\N	\N	\N	\N	CP1-40
3851	3851 Tumor	Tumor	\N	\N	\N	\N	CP1-80
2888	2888 Cell Line - Control	Cell Line - Control	\N	\N	\N	\N	ct-H3K4
2894	2894 Cell Line - Control	Cell Line - Control	\N	\N	\N	\N	ct-H3K4
2889	2889 Cell Line - Control	Cell Line - Control	\N	\N	\N	\N	ct-H3K27
2895	2895 Cell Line - Control	Cell Line - Control	\N	\N	\N	\N	ct-H3K27
2887	2887 Cell Line - Control	Cell Line - Control	\N	\N	\N	\N	ct-Input
2893	2893 Cell Line - Control	Cell Line - Control	\N	\N	\N	\N	ct-Input
2908	2908 Unknown	Unknown	\N	\N	\N	\N	D12_M
3174	3174 Normal	Normal	\N	\N	\N	\N	DM1
3175	3175 Tumor	Tumor	\N	\N	\N	\N	DM1
3099	3099 Tumor	Tumor	\N	\N	\N	\N	DM2
3100	3100 Tumor	Tumor	\N	\N	\N	\N	DM2
3176	3176 Normal	Normal	\N	\N	\N	\N	DM2
3177	3177 Tumor	Tumor	\N	\N	\N	\N	DM2
3101	3101 Normal	Normal	\N	\N	\N	\N	DM4
3102	3102 Tumor	Tumor	\N	\N	\N	\N	DM4
3178	3178 Tumor	Tumor	\N	\N	\N	\N	DM5
3179	3179 Normal	Normal	\N	\N	\N	\N	DM5
3103	3103 Normal	Normal	\N	\N	\N	\N	DM6
3104	3104 Tumor	Tumor	\N	\N	\N	\N	DM6
3180	3180 Normal	Normal	\N	\N	\N	\N	DM7
3181	3181 Tumor	Tumor	\N	\N	\N	\N	DM7
3105	3105 Tumor	Tumor	\N	\N	\N	\N	DM8
3901	3901 Tumor	Tumor	\N	\N	\N	\N	DM8
3106	3106 Normal	Normal	\N	\N	\N	\N	DM10
3107	3107 Tumor	Tumor	\N	\N	\N	\N	DM10
3182	3182 Normal	Normal	\N	\N	\N	\N	DM11
3183	3183 Tumor	Tumor	\N	\N	\N	\N	DM11
3184	3184 Normal	Normal	\N	\N	\N	\N	DM12
3185	3185 Tumor	Tumor	\N	\N	\N	\N	DM12
3109	3109 Tumor	Tumor	\N	\N	\N	\N	DM13
3110	3110 Tumor	Tumor	\N	\N	\N	\N	DM13
3187	3187 Tumor	Tumor	\N	\N	\N	\N	DM13
3186	3186 Normal	Normal	\N	\N	\N	\N	DM13
3111	3111 Tumor	Tumor	\N	\N	\N	\N	DM14
3188	3188 Normal	Normal	\N	\N	\N	\N	DM14
3189	3189 Tumor	Tumor	\N	\N	\N	\N	DM14
3190	3190 Normal	Normal	\N	\N	\N	\N	DM16
3191	3191 Tumor	Tumor	\N	\N	\N	\N	DM16
3112	3112 Normal	Normal	\N	\N	\N	\N	DM17
3113	3113 Tumor	Tumor	\N	\N	\N	\N	DM17
3114	3114 Normal	Normal	\N	\N	\N	\N	DM18
3115	3115 Tumor	Tumor	\N	\N	\N	\N	DM18
3116	3116 Tumor	Tumor	\N	\N	\N	\N	DM18
3192	3192 Normal	Normal	\N	\N	\N	\N	DM21
3193	3193 Tumor	Tumor	\N	\N	\N	\N	DM21
3117	3117 Normal	Normal	\N	\N	\N	\N	DM22
3118	3118 Tumor	Tumor	\N	\N	\N	\N	DM22
3119	3119 Normal	Normal	\N	\N	\N	\N	DM23
3120	3120 Tumor	Tumor	\N	\N	\N	\N	DM23
3121	3121 Normal	Normal	\N	\N	\N	\N	DM25
3122	3122 Tumor	Tumor	\N	\N	\N	\N	DM25
3194	3194 Normal	Normal	\N	\N	\N	\N	DM26
3195	3195 Tumor	Tumor	\N	\N	\N	\N	DM26
3196	3196 Normal	Normal	\N	\N	\N	\N	DM28
3197	3197 Tumor	Tumor	\N	\N	\N	\N	DM28
3198	3198 Tumor	Tumor	\N	\N	\N	\N	DM29
3199	3199 Normal	Normal	\N	\N	\N	\N	DM29
3123	3123 Tumor	Tumor	\N	\N	\N	\N	DM31
3124	3124 Normal	Normal	\N	\N	\N	\N	DM31
3200	3200 Normal	Normal	\N	\N	\N	\N	DM34
3201	3201 Tumor	Tumor	\N	\N	\N	\N	DM34
3126	3126 Normal	Normal	\N	\N	\N	\N	DM36
3125	3125 Tumor	Tumor	\N	\N	\N	\N	DM36
3127	3127 Tumor	Tumor	\N	\N	\N	\N	DM37
3202	3202 Normal	Normal	\N	\N	\N	\N	DM37
3128	3128 Normal	Normal	\N	\N	\N	\N	DM42
3129	3129 Tumor	Tumor	\N	\N	\N	\N	DM42
3130	3130 Normal	Normal	\N	\N	\N	\N	DM43
3131	3131 Tumor	Tumor	\N	\N	\N	\N	DM43
3203	3203 Tumor	Tumor	\N	\N	\N	\N	DM45
3204	3204 Normal	Normal	\N	\N	\N	\N	DM45
3853	3853 Tumor	Tumor	\N	\N	\N	\N	DM45
3132	3132 Tumor	Tumor	\N	\N	\N	\N	DM48
3133	3133 Tumor	Tumor	\N	\N	\N	\N	DM49
3134	3134 Normal	Normal	\N	\N	\N	\N	DM49
3135	3135 Tumor	Tumor	\N	\N	\N	\N	DM51
3205	3205 Normal	Normal	\N	\N	\N	\N	DM55
3206	3206 Tumor	Tumor	\N	\N	\N	\N	DM55
3136	3136 Normal	Normal	\N	\N	\N	\N	DM58
3137	3137 Tumor	Tumor	\N	\N	\N	\N	DM58
3138	3138 Tumor	Tumor	\N	\N	\N	\N	DM59
3165	3165 Tumor	Tumor	\N	\N	\N	\N	DM60
3166	3166 Tumor	Tumor	\N	\N	\N	\N	DM61
3167	3167 Tumor	Tumor	\N	\N	\N	\N	DM62
3168	3168 Tumor	Tumor	\N	\N	\N	\N	DM63
3140	3140 Tumor	Tumor	\N	\N	\N	\N	DM64
3139	3139 Normal	Normal	\N	\N	\N	\N	DM64
3141	3141 Tumor	Tumor	\N	\N	\N	\N	DM65
3169	3169 Tumor	Tumor	\N	\N	\N	\N	DM66
3170	3170 Tumor	Tumor	\N	\N	\N	\N	DM67
3142	3142 Tumor	Tumor	\N	\N	\N	\N	DM68
3171	3171 Tumor	Tumor	\N	\N	\N	\N	DM69
3172	3172 Tumor	Tumor	\N	\N	\N	\N	DM70
3144	3144 Tumor	Tumor	\N	\N	\N	\N	DM74
3143	3143 Tumor	Tumor	\N	\N	\N	\N	DM74
3145	3145 Tumor	Tumor	\N	\N	\N	\N	DM74
3207	3207 Tumor	Tumor	\N	\N	\N	\N	DM77
3208	3208 Normal	Normal	\N	\N	\N	\N	DM77
3209	3209 Tumor	Tumor	\N	\N	\N	\N	DM79
3210	3210 Normal	Normal	\N	\N	\N	\N	DM79
3854	3854 Tumor	Tumor	\N	\N	\N	\N	DM79
3173	3173 Tumor	Tumor	\N	\N	\N	\N	DM81
3146	3146 Tumor	Tumor	\N	\N	\N	\N	DM93
3148	3148 Normal	Normal	\N	\N	\N	\N	DM93
3147	3147 Tumor	Tumor	\N	\N	\N	\N	DM93
3211	3211 Tumor	Tumor	\N	\N	\N	\N	DM93
3213	3213 Normal	Normal	\N	\N	\N	\N	DM93
3212	3212 Tumor	Tumor	\N	\N	\N	\N	DM93
3855	3855 Tumor	Tumor	\N	\N	\N	\N	DM93
3856	3856 Tumor	Tumor	\N	\N	\N	\N	DM93
3149	3149 Normal	Normal	\N	\N	\N	\N	DM94
3150	3150 Tumor	Tumor	\N	\N	\N	\N	DM94
3151	3151 Tumor	Tumor	\N	\N	\N	\N	DM95
3152	3152 Normal	Normal	\N	\N	\N	\N	DM95
3153	3153 Tumor	Tumor	\N	\N	\N	\N	DM96
3154	3154 Normal	Normal	\N	\N	\N	\N	DM96
3155	3155 Normal	Normal	\N	\N	\N	\N	DM98
3156	3156 Tumor	Tumor	\N	\N	\N	\N	DM98
3157	3157 Normal	Normal	\N	\N	\N	\N	DM99
3158	3158 Tumor	Tumor	\N	\N	\N	\N	DM99
3159	3159 Tumor	Tumor	\N	\N	\N	\N	DM99
3160	3160 Tumor	Tumor	\N	\N	\N	\N	DM100
3162	3162 Normal	Normal	\N	\N	\N	\N	DM101
3161	3161 Unknown	Unknown	\N	\N	\N	\N	DM101
3163	3163 Tumor	Tumor	\N	\N	\N	\N	DM101
3164	3164 Tumor	Tumor	\N	\N	\N	\N	DM102
3383	3383 Tumor	Tumor	\N	\N	\N	\N	Dog12
3384	3384 Tumor	Tumor	\N	\N	\N	\N	Dog24
3385	3385 Tumor	Tumor	\N	\N	\N	\N	Dog43
3386	3386 Tumor	Tumor	\N	\N	\N	\N	Dog55
3214	3214 Tumor	Tumor	\N	\N	\N	\N	DP12-200 
3902	3902 Unknown	Unknown	\N	\N	\N	\N	DPN9
1424	1424 Cutaneous Metastasis	Cutaneous Metastasis	\N	\N	\N	\N	H 2008.8956/1
3785	3785 Not Processed	Not Processed	\N	\N	\N	\N	H 2015.1871
2	2 Mel1	Mel1	2018-07-23 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H09.22183/1
1	1 Normal	Normal	2018-07-23 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H09.22183/1
1149	1149 Mel3	Mel3	\N	\N	\N	\N	H09.22183/1
1302	1302 Normal	Normal	\N	\N	\N	\N	H12.27716/7
1303	1303 Mel1	Mel1	\N	\N	\N	\N	H12.27716/7
1309	1309 Mel1	Mel1	\N	\N	\N	\N	H13.3143 
3	3 Met1	Met1	2018-07-23 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H13.5620/1
1150	1150 Normal3	Normal3	\N	\N	\N	\N	H13.5620/1
1151	1151 Met2	Met2	\N	\N	\N	\N	H13.5620/1
1292	1292 Normal	Normal	\N	\N	\N	\N	H13.10897/2
1293	1293 Mel1	Mel1	\N	\N	\N	\N	H13.10897/11
1295	1295 Normal	Normal	\N	\N	\N	\N	H13.21587/1
1301	1301 Cutaneous Metastasis	Cutaneous Metastasis	\N	\N	\N	\N	H13.21587/1
6	6 Normal	Normal	2018-07-24 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H14.26934/2
7	7 MIS1	MIS1	2018-07-24 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H14.26934/2
1304	1304 Subcutaneous Metastasis	Subcutaneous Metastasis	\N	\N	\N	\N	H15.2058/1
4	4 Mel1	Mel1	2018-07-23 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H15.5120/1
1286	1286 Mel2	Mel2	\N	\N	\N	\N	H15.5120/1
9	9 Normal	Normal	2018-07-24 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H15.19121/7
10	10 Mel1	Mel1	2018-07-24 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H15.19121/7
65	65 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H16.660
66	66 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H16.660
67	67 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H16.660
11	11 Met1	Met1	2018-07-24 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H16.872/2
5	5 Met1	Met1	2018-07-23 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H16.5818/2
1617	1617 Normal	Normal	\N	\N	\N	\N	H16.5818/2
1287	1287 Met2	Met2	\N	\N	\N	\N	H18.7977
1288	1288 Normal	Normal	\N	\N	\N	\N	H18.7977
68	68 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H2007.215/5
69	69 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H2007.215/5
70	70 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H2007.215/5
71	71 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H2007.215/5
74	74 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H2007.358/1
75	75 MIS3	MIS3	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H2007.358/1
76	76 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H2007.358/1
77	77 Mel2	Mel2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H2007.358/1
72	72 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H2007.358/3
73	73 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	H2007.358/3
1305	1305 Normal	Normal	\N	\N	\N	\N	H2007.4636/9
1306	1306 Mel1	Mel1	\N	\N	\N	\N	H2007.4636/9
1623	1623 Invasive Mel 1	Invasive Mel 1	\N	\N	\N	\N	H2007.4636/9
8	8 Met1	Met1	2018-07-24 00:00:00-07	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	HS17.35/2
3249	3249 Normal	Normal	\N	\N	\N	\N	HW Acral #1 Cntl
3250	3250 Tumor	Tumor	\N	\N	\N	\N	HW Acral #1 Tumor
3251	3251 Normal	Normal	\N	\N	\N	\N	HW Acral #2 Cntl
3252	3252 Tumor	Tumor	\N	\N	\N	\N	HW Acral #2 Tumor
3253	3253 Normal	Normal	\N	\N	\N	\N	HW Acral #3 Cntl
3254	3254 Tumor	Tumor	\N	\N	\N	\N	HW Acral #3 Tumor
3255	3255 Normal	Normal	\N	\N	\N	\N	HW Acral #4 Cntl
3256	3256 Tumor	Tumor	\N	\N	\N	\N	HW Acral #4 Tumor
3257	3257 Normal	Normal	\N	\N	\N	\N	HW Acral #5 Cntl
3258	3258 Tumor	Tumor	\N	\N	\N	\N	HW Acral #5 Tumor
3259	3259 Normal	Normal	\N	\N	\N	\N	HW Acral #6 Cntl
3260	3260 Tumor	Tumor	\N	\N	\N	\N	HW Acral #6 Tumor
3261	3261 Normal	Normal	\N	\N	\N	\N	HW Acral #7 Cntl
3262	3262 Tumor	Tumor	\N	\N	\N	\N	HW Acral #7 Tumor
3263	3263 Normal	Normal	\N	\N	\N	\N	HW Acral #8 Cntl
3264	3264 Tumor	Tumor	\N	\N	\N	\N	HW Acral #8 Tumor
3269	3269 Tumor	Tumor	\N	\N	\N	\N	HW Acral #8 Tumor
3265	3265 Normal	Normal	\N	\N	\N	\N	HW Acral #9 Cntl
3266	3266 Tumor	Tumor	\N	\N	\N	\N	HW Acral #9 Tumor
3267	3267 Normal	Normal	\N	\N	\N	\N	HW Acral #10 Cntl
3268	3268 Tumor	Tumor	\N	\N	\N	\N	HW Acral #10 Tumor
2943	2943 Normal	Normal	\N	\N	\N	\N	HW2- Normal Curls
2944	2944 Tumor	Tumor	\N	\N	\N	\N	HW2- Tumor Dissect
3246	3246 Tumor	Tumor	\N	\N	\N	\N	HW2- Tumor Dissect
2964	2964 Normal	Normal	\N	\N	\N	\N	HW3-Normal
3388	3388 Normal	Normal	\N	\N	\N	\N	HW3-Normal
2965	2965 Tumor	Tumor	\N	\N	\N	\N	HW3-Tumor
3247	3247 Tumor	Tumor	\N	\N	\N	\N	HW3-Tumor
3387	3387 Tumor	Tumor	\N	\N	\N	\N	HW3-Tumor
2966	2966 Normal	Normal	\N	\N	\N	\N	HW4-Normal
3390	3390 Normal	Normal	\N	\N	\N	\N	HW4-Normal
2967	2967 Tumor	Tumor	\N	\N	\N	\N	HW4-Tumor
3389	3389 Tumor	Tumor	\N	\N	\N	\N	HW4-Tumor
2968	2968 Normal	Normal	\N	\N	\N	\N	HW6-NormalDissect
3392	3392 Normal	Normal	\N	\N	\N	\N	HW6-NormalDissect
2969	2969 Tumor	Tumor	\N	\N	\N	\N	HW6-TumorDissect
3391	3391 Tumor	Tumor	\N	\N	\N	\N	HW6-TumorDissect
2945	2945 Normal	Normal	\N	\N	\N	\N	HW8- Normal Curls
2946	2946 Tumor	Tumor	\N	\N	\N	\N	HW8- Tumor Curls
3248	3248 Tumor	Tumor	\N	\N	\N	\N	HW8- Tumor Curls
2947	2947 Normal	Normal	\N	\N	\N	\N	HW9- Normal gDNA from Blood (129920)
2948	2948 Tumor	Tumor	\N	\N	\N	\N	HW9- Tumor Curls
3304	3304 Normal	Normal	\N	\N	\N	\N	JBP-3
3306	3306 Tumor	Tumor	\N	\N	\N	\N	JBP-3-Met1
3305	3305 Tumor	Tumor	\N	\N	\N	\N	JBP-3-MM
3300	3300 Tumor	Tumor	\N	\N	\N	\N	JBP-7-Met
79	79 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	info from Shanshan's list, some of the images can't be found	\N	K1-A
80	80 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	info from Shanshan's list, some of the images can't be found	\N	K1-A
1620	1620 MIS3	MIS3	\N	\N	\N	\N	K1-A.2
1621	1621 MIS4	MIS4	\N	\N	\N	\N	K1-A.2
81	81 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	info from Shanshan's list, some of the images can't be found	\N	K1-B
1153	1153 LN Met 2	LN Met 2	\N	\N	\N	\N	K1-C
1154	1154 LN Met 1	LN Met 1	\N	\N	\N	\N	K1-C
78	78 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K1-D
2034	2034 MIS2	MIS2	\N	\N	\N	\N	K2-A
2035	2035 MIS3	MIS3	\N	\N	\N	\N	K2-A
83	83 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K2-B
84	84 Mel	Mel	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K2-B
1152	1152 Met1	Met1	\N	\N	\N	\N	K2-C
82	82 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K2-D
99	99 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K3-A-B
100	100 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K3-A-B
2246	2246 Mel2	Mel2	\N	\N	\N	\N	K3-A-B
97	97 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K3-C
101	101 Met1	Met1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K3-C
102	102 Met2	Met2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K3-C
98	98 Normal2	Normal2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K3-D
105	105 MIS2	MIS2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K4-A
104	104 MIS1	MIS1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K4-B
106	106 Mel1	Mel1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K4-B
107	107 Mel2	Mel2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K4-B
108	108 Met1	Met1	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K4-C
109	109 Met2	Met2	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K4-C
1236	1236 LN Met 4	LN Met 4	\N	\N	\N	\N	K4-C-2
1237	1237 LN Met 3	LN Met 3	\N	\N	\N	\N	K4-C-2
103	103 Normal	Normal	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	\N	K4-D
359	359 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K5-A-B
896	896 Mel	Mel	\N	\N	\N	\N	MEL202_DMSO
363	363 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K5-A-B
361	361 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K5-A-B
362	362 MIS2	MIS2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K5-A-B
360	360 Normal 2	Normal 2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K5-D
364	364 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K6-A-D
365	365 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K6-B
366	366 MIS2	MIS2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K6-B
368	368 Mel2	Mel2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K6-B
367	367 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K6-B
1240	1240 MIS2	MIS2	\N	\N	\N	\N	K7-A
371	371 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K7-B
369	369 Normal1	Normal1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K7-B
370	370 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K7-B
1238	1238 MIS4	MIS4	\N	\N	\N	\N	K7-B-2
1239	1239 MIS3	MIS3	\N	\N	\N	\N	K7-B-2
3688	3688 Not Processed	Not Processed	\N	\N	\N	\N	K7-D
374	374 MIS2	MIS2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K8-A
372	372 Normal1	Normal1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K8-A
373	373 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K8-B
375	375 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K8-B
1575	1575 	\N	\N	\N	Do NOT use these nucleic acids, Mel1 and Mel2 were pooled by error.	\N	K8-B
1622	1622 Mel2	Mel2	\N	\N	\N	\N	K8-B
378	378 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K9-A-B
377	377 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K9-A-B
379	379 LN Met 1	LN Met 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K9-C
376	376 Normal1	Normal1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K9-D
380	380 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K10-A
383	383 MIS2	MIS2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K10-A
382	382 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K10-B
384	384 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K10-B
385	385 LN Met 1	LN Met 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K10-C
381	381 Normal 2	Normal 2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K10-C
2033	2033 Met2	Met2	\N	\N	\N	\N	K10-C
3689	3689 Not Processed	Not Processed	\N	\N	\N	\N	K10-D
388	388 MIS3	MIS3	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K11-A
387	387 MIS2	MIS2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K11-B
386	386 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K11-B
389	389 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K11-B
390	390 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K11-D
392	392 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K12-A
393	393 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K12-B
391	391 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K12-D
3690	3690 Not Processed	Not Processed	\N	\N	\N	\N	K13-A
3691	3691 Not Processed	Not Processed	\N	\N	\N	\N	K13-B
394	394 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K13-D
396	396 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K14-A
397	397 Mel 1	Mel 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K14-B
395	395 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K14-D
399	399 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K15-A-B
400	400 MIS2	MIS2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K15-A-B
401	401 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K15-A-B
402	402 Mel2	Mel2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K15-A-B
398	398 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K15-D
3692	3692 Not Processed	Not Processed	\N	\N	\N	\N	K16-A-B
403	403 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K16-D
3693	3693 Not Processed	Not Processed	\N	\N	\N	\N	K17-A
405	405 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K17-B
406	406 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K17-B
404	404 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K17-D
3694	3694 Not Processed	Not Processed	\N	\N	\N	\N	K18-A-B
3695	3695 Not Processed	Not Processed	\N	\N	\N	\N	K19-A-B
408	408 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K20-A-B
410	410 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K20-A-B
409	409 MIS2	MIS2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K20-A-B
407	407 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K20-A-B
414	414 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K21-A-B
411	411 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K21-A-B
413	413 MIS2	MIS2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K21-A-B
412	412 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K21-A-B
417	417 MIS2	MIS2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K22-A-B
415	415 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K22-A-B
416	416 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K22-A-B
418	418 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K22-A-B
1241	1241 MIS3	MIS3	\N	\N	\N	\N	K22-D
1242	1242 Normal2	Normal2	\N	\N	\N	\N	K22-D
422	422 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K23-A-B
421	421 MIS2	MIS2	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K23-A-B
420	420 MIS1	MIS1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K23-A-B
419	419 Normal 1	Normal 1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K23-A-B
1244	1244 MIS1	MIS1	\N	\N	\N	\N	K23-A-B
1245	1245 MIS2	MIS2	\N	\N	\N	\N	K23-A-B
1243	1243 Normal	Normal	\N	\N	\N	\N	K23-D
1618	1618 MIS3	MIS3	\N	\N	\N	\N	K23-D
1619	1619 MIS4	MIS4	\N	\N	\N	\N	K23-D
423	423 Mel1	Mel1	\N	\\HiSeqData_Noel_Chenxu\\HE Images\\Acral Melanoma Project 2_HE_Images\\September_2018	\N	\N	K24-A-B
1013	1013 Nodular Mel	Nodular Mel	\N	\N	\N	\N	K3920/19 A1
3309	3309 Tumor	Tumor	\N	\N	\N	\N	KIT8
3310	3310 Tumor	Tumor	\N	\N	\N	\N	KIT21
3311	3311 Tumor	Tumor	\N	\N	\N	\N	KIT37
3312	3312 Tumor	Tumor	\N	\N	\N	\N	KIT55
3313	3313 Tumor	Tumor	\N	\N	\N	\N	KIT62
3314	3314 Tumor	Tumor	\N	\N	\N	\N	KIT76
3315	3315 Tumor	Tumor	\N	\N	\N	\N	KIT118
3316	3316 Tumor	Tumor	\N	\N	\N	\N	KIT134
3318	3318 Tumor	Tumor	\N	\N	\N	\N	KIT181
3319	3319 Tumor	Tumor	\N	\N	\N	\N	KIT191
3320	3320 Tumor	Tumor	\N	\N	\N	\N	KIT192
3321	3321 Tumor	Tumor	\N	\N	\N	\N	KIT203
3322	3322 Tumor	Tumor	\N	\N	\N	\N	KIT205
3323	3323 Tumor	Tumor	\N	\N	\N	\N	KIT206
3324	3324 Tumor	Tumor	\N	\N	\N	\N	KIT210
3325	3325 Tumor	Tumor	\N	\N	\N	\N	KIT217
3326	3326 Tumor	Tumor	\N	\N	\N	\N	KIT225
2949	2949 Tumor	Tumor	\N	\N	\N	\N	KIT227
3327	3327 Tumor	Tumor	\N	\N	\N	\N	KIT230
3328	3328 Tumor	Tumor	\N	\N	\N	\N	KIT244
3329	3329 Tumor	Tumor	\N	\N	\N	\N	KIT260
3308	3308 Tumor	Tumor	\N	\N	\N	\N	KIT262
3330	3330 Tumor	Tumor	\N	\N	\N	\N	KIT273
3331	3331 Tumor	Tumor	\N	\N	\N	\N	KIT275
3332	3332 Tumor	Tumor	\N	\N	\N	\N	KIT295
3333	3333 Tumor	Tumor	\N	\N	\N	\N	KIT297
3334	3334 Tumor	Tumor	\N	\N	\N	\N	KIT302
3335	3335 Tumor	Tumor	\N	\N	\N	\N	KIT313
3336	3336 Tumor	Tumor	\N	\N	\N	\N	KIT316
3337	3337 Tumor	Tumor	\N	\N	\N	\N	KR_8
3338	3338 Tumor	Tumor	\N	\N	\N	\N	KR_150
3339	3339 Tumor	Tumor	\N	\N	\N	\N	KR_166
3340	3340 Tumor	Tumor	\N	\N	\N	\N	KR_177
3341	3341 Tumor	Tumor	\N	\N	\N	\N	KR_203
3342	3342 Tumor	Tumor	\N	\N	\N	\N	KR_229
3343	3343 Tumor	Tumor	\N	\N	\N	\N	KR_2030
3344	3344 Tumor	Tumor	\N	\N	\N	\N	KR_2064
3345	3345 Tumor	Tumor	\N	\N	\N	\N	KR_5233
3346	3346 Tumor	Tumor	\N	\N	\N	\N	KR_RMK0091B
3347	3347 Tumor	Tumor	\N	\N	\N	\N	KR_RMK0137C
3348	3348 Tumor	Tumor	\N	\N	\N	\N	KR_RMK0162C
3349	3349 Tumor	Tumor	\N	\N	\N	\N	KR_RMK0168C
3350	3350 Tumor	Tumor	\N	\N	\N	\N	KR_RMK0194C
2951	2951 Cell Line	Cell Line	\N	\N	\N	\N	LAL-L Cells
2950	2950 Cell Line	Cell Line	\N	\N	\N	\N	LAL-L Cells
3351	3351 Intermediate	Intermediate	\N	\N	\N	\N	London-L2
3352	3352 Normal	Normal	\N	\N	\N	\N	London-L2
3354	3354 Normal	Normal	\N	\N	\N	\N	London-L3
3353	3353 Intermediate	Intermediate	\N	\N	\N	\N	London-L3
1325	1325 Tumor	Tumor	\N	\N	\N	\N	Lung cancer with ALK fusion
3447	3447 Tumor	Tumor	\N	\N	\N	\N	Luping_ROS_1
2467	2467 Melanoma Cell Line	Melanoma Cell Line	\N	\N	\N	\N	M230 Imat A2
2468	2468 Melanoma Cell Line	Melanoma Cell Line	\N	\N	\N	\N	M230 Imat A3
1016	1016 Nodular Mel	Nodular Mel	\N	\N	\N	\N	M21326/18 A1
1019	1019 Nodular Mel	Nodular Mel	\N	\N	\N	\N	M31513/18
1015	1015 Nodular Mel	Nodular Mel	\N	\N	\N	\N	M32727/18 A1
610	610 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	M040204
1248	1248 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	M040204 Dec2019
611	611 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	M040415
612	612 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	M040416
613	613 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	M040418
614	614 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	M040419A
605	605 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	M100118
616	616 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	M180322
604	604 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	MaMel 152aI
3356	3356 Normal	Normal	\N	\N	\N	\N	MB_161
3357	3357 Tumor	Tumor	\N	\N	\N	\N	MB_161
3358	3358 Tumor	Tumor	\N	\N	\N	\N	MB_327
3359	3359 Tumor	Tumor	\N	\N	\N	\N	MB_760
3360	3360 Normal	Normal	\N	\N	\N	\N	MB_1028
3361	3361 Tumor	Tumor	\N	\N	\N	\N	MB_1029
3362	3362 Normal	Normal	\N	\N	\N	\N	MB_1036
3363	3363 Tumor	Tumor	\N	\N	\N	\N	MB_1046
3364	3364 Normal	Normal	\N	\N	\N	\N	MB_1418
3365	3365 Normal	Normal	\N	\N	\N	\N	MB_1454
3367	3367 Normal	Normal	\N	\N	\N	\N	MB1241
3368	3368 Tumor	Tumor	\N	\N	\N	\N	MB1242
3369	3369 Normal	Normal	\N	\N	\N	\N	MB1421
3371	3371 Tumor	Tumor	\N	\N	\N	\N	MB1423
3370	3370 Normal	Normal	\N	\N	\N	\N	MB1423
3372	3372 Tumor	Tumor	\N	\N	\N	\N	MB1424
3373	3373 Normal	Normal	\N	\N	\N	\N	MB1428
3374	3374 Tumor	Tumor	\N	\N	\N	\N	MB1429
3366	3366 Normal	Normal	\N	\N	\N	\N	MB1609
3375	3375 Tumor	Tumor	\N	\N	\N	\N	MB1617
897	897 Mel	Mel	\N	\N	\N	\N	MEL202_DMSO
898	898 Mel	Mel	\N	\N	\N	\N	MEL202_DMSO
899	899 Mel	Mel	\N	\N	\N	\N	MEL202_Vemu
901	901 Mel	Mel	\N	\N	\N	\N	MEL202_Vemu
900	900 Mel	Mel	\N	\N	\N	\N	MEL202_Vemu
1319	1319 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	Mel290
606	606 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	MM100511
607	607 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	MM100512
608	608 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	MM100513
609	609 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	MM100916
615	615 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	MM160113
673	673 Uveal Mel	Uveal Mel	\N	\N	\N	\N	MP41
674	674 Uveal Mel	Uveal Mel	\N	\N	\N	\N	MP41-YM-R1
597	597 Nodular Mel	Nodular Mel	\N	\N	\N	\N	N-ID 1941
596	596 Nodular Mel	Nodular Mel	\N	\N	\N	\N	N-ID 2225
2952	2952 Cell Line	Cell Line	\N	\N	\N	\N	NB2107
3423	3423 Normal	Normal	\N	\N	\N	\N	P57
3424	3424 Normal	Normal	\N	\N	\N	\N	P57
3419	3419 Cadaver Skin	Cadaver Skin	\N	\N	\N	\N	P57-A-1.0mm
3420	3420 Cadaver Skin	Cadaver Skin	\N	\N	\N	\N	P57-A-2.0mm
3421	3421 Cadaver Skin	Cadaver Skin	\N	\N	\N	\N	P57-B-1.0mm
3422	3422 Cadaver Skin	Cadaver Skin	\N	\N	\N	\N	P57-B-2.0mm
3425	3425 Unknown	Unknown	\N	\N	\N	\N	PG_8
3845	3845 Tumor	Tumor	\N	\N	\N	\N	PG8
3303	3303 Unknown	Unknown	\N	\N	\N	\N	PMM-8
3428	3428 Tumor	Tumor	\N	\N	\N	\N	Seider_Roe
3429	3429 Tumor	Tumor	\N	\N	\N	\N	Seider_Uveal
2891	2891 Cell Line - Knockdown	Cell Line - Knockdown	\N	\N	\N	\N	sh-H3K4
2897	2897 Cell Line - Knockdown	Cell Line - Knockdown	\N	\N	\N	\N	sh-H3K4
2892	2892 Cell Line - Knockdown	Cell Line - Knockdown	\N	\N	\N	\N	sh-H3K27
2898	2898 Cell Line - Knockdown	Cell Line - Knockdown	\N	\N	\N	\N	sh-H3K27
2890	2890 Cell Line - Knockdown	Cell Line - Knockdown	\N	\N	\N	\N	sh-Input
2896	2896 Cell Line - Knockdown	Cell Line - Knockdown	\N	\N	\N	\N	sh-Input
1316	1316 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	SKMEL 1023A
1317	1317 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	SKMEL 1107B
1246	1246 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	SKMel 1107B Dec2019
1318	1318 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	SKMEL 1121B
1247	1247 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	SKMel 1121B Dec2019
2845	2845 Cell Line	Cell Line	\N	\N	SKMEL5-1	\N	SKMEL5-1
2846	2846 Cell Line	Cell Line	\N	\N	SKMEL5-2	\N	SKMEL5-2
2847	2847 Cell Line	Cell Line	\N	\N	SKMEL5-3	\N	SKMEL5-3
2842	2842 Cell Line	Cell Line	\N	\N	SKMEL28-1	\N	SKMEL28-1
2843	2843 Cell Line	Cell Line	\N	\N	SKMEL28-2	\N	SKMEL28-2
2844	2844 Cell Line	Cell Line	\N	\N	SKMEL28-3	\N	SKMEL28-3
2781	2781 Tumor	Tumor	\N	\N	\N	\N	SM_2_Tumor
2782	2782 Tumor	Tumor	\N	\N	\N	\N	SM_3
2783	2783 Normal	Normal	\N	\N	\N	\N	SM_4
2784	2784 Tumor	Tumor	\N	\N	\N	\N	SM_4
2785	2785 Normal	Normal	\N	\N	\N	\N	SM_5
2795	2795 Tumor	Tumor	\N	\N	\N	\N	SM_10_Tumor
2796	2796 Tumor	Tumor	\N	\N	\N	\N	SM_11
2797	2797 Tumor	Tumor	\N	\N	\N	\N	SM_12
2799	2799 Tumor	Tumor	\N	\N	\N	\N	SM_16
2798	2798 Normal	Normal	\N	\N	\N	\N	SM_16
2802	2802 Tumor	Tumor	\N	\N	\N	\N	SM7
3836	3836 Tumor	Tumor	\N	\N	\N	\N	TCR-Beta-1
3837	3837 Tumor	Tumor	\N	\N	\N	\N	TCR-Beta-2
3434	3434 Cell Line	Cell Line	\N	\N	\N	\N	Thomas_SK_MEL_23
2759	2759 Cell Line	Cell Line	\N	\N	\N	\N	Thomas_SK_Mel23
2936	2936 Normal	Normal	\N	\N	\N	\N	TissueCoreALKControl
2930	2930 Human Cadaver Skin - Acral	Human Cadaver Skin - Acral	\N	\N	\N	\N	UCSF-23-041_Biopsy
2931	2931 Human Cadaver Skin - Acral	Human Cadaver Skin - Acral	\N	\N	\N	\N	UCSF-23-041_Biopsy
2932	2932 Human Cadaver Skin - Acral	Human Cadaver Skin - Acral	\N	\N	\N	\N	UCSF-23-041_Biopsy
2933	2933 Human Cadaver Skin - Acral	Human Cadaver Skin - Acral	\N	\N	\N	\N	UCSF-23-041_Biopsy
2984	2984 Human Cadaver Skin - Buttocks	Human Cadaver Skin - Buttocks	\N	\N	\N	\N	UCSF-23-041_Biopsy
2985	2985 Human Cadaver Skin - Buttocks	Human Cadaver Skin - Buttocks	\N	\N	\N	\N	UCSF-23-041_Biopsy
2986	2986 Human Cadaver Skin - Buttocks	Human Cadaver Skin - Buttocks	\N	\N	\N	\N	UCSF-23-041_Biopsy
2987	2987 Human Cadaver Skin - Buttocks	Human Cadaver Skin - Buttocks	\N	\N	\N	\N	UCSF-23-041_Biopsy
3238	3238 Human Cadaver Skin - Face	Human Cadaver Skin - Face	\N	\N	\N	\N	UCSF-23-041_Biopsy
3239	3239 Human Cadaver Skin - Face	Human Cadaver Skin - Face	\N	\N	\N	\N	UCSF-23-041_Biopsy
3240	3240 Human Cadaver Skin - Face	Human Cadaver Skin - Face	\N	\N	\N	\N	UCSF-23-041_Biopsy
3241	3241 Human Cadaver Skin - Face	Human Cadaver Skin - Face	\N	\N	\N	\N	UCSF-23-041_Biopsy
3431	3431 Human Cadaver Skin - Shoulder	Human Cadaver Skin - Shoulder	\N	\N	\N	\N	UCSF-23-041_Biopsy
3430	3430 Human Cadaver Skin - Shoulder	Human Cadaver Skin - Shoulder	\N	\N	\N	\N	UCSF-23-041_Biopsy
3433	3433 Human Cadaver Skin - Shoulder	Human Cadaver Skin - Shoulder	\N	\N	\N	\N	UCSF-23-041_Biopsy
3432	3432 Human Cadaver Skin - Shoulder	Human Cadaver Skin - Shoulder	\N	\N	\N	\N	UCSF-23-041_Biopsy
2760	2760 Uveal Mel	Uveal Mel	\N	\N	Uveal Melanoma, Dr. Seider	\N	UM1_UvealMel
2761	2761 Uveal Mel	Uveal Mel	\N	\N	Uveal Melanoma, Dr. Seider	\N	UM2_UvealMel
3838	3838 Uveal Mel	Uveal Mel	\N	\N	\N	\N	UM23
3839	3839 Uveal Mel	Uveal Mel	\N	\N	\N	\N	UM24
3840	3840 Uveal Mel	Uveal Mel	\N	\N	\N	\N	UM25
3841	3841 Uveal Mel	Uveal Mel	\N	\N	\N	\N	UM26
2836	2836 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	WM8
2837	2837 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	WM51
2838	2838 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	WM1963
2953	2953 Cell Line	Cell Line	\N	\N	\N	\N	WM3211
2839	2839 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	WM3622
2840	2840 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	WM3912
2841	2841 Acral Melanoma Cells	Acral Melanoma Cells	\N	\N	\N	\N	WM3918
3435	3435 Tumor	Tumor	\N	\N	\N	\N	WP 11
3436	3436 Tumor	Tumor	\N	\N	\N	\N	WP 23
3437	3437 Tumor	Tumor	\N	\N	\N	\N	WP 29
3301	3301 Tumor	Tumor	\N	\N	\N	\N	XD-1
3302	3302 Tumor	Tumor	\N	\N	\N	\N	XD-1.1
2900	2900 MM	MM	\N	\N	10-3560A3, 10-3560A4, 10-3560A10	\N	ZS10-3560A3,ZS10-3560A4
2824	2824 MM	MM	\N	\N	10-3560A3, 10-3560A4, 10-3560A10	\N	ZS10-3560A10
2899	2899 Met	Met	\N	\N	\N	\N	ZS10-3560C1\n
2901	2901 Normal	Normal	\N	\N	\N	\N	ZS10-3560F1
2828	2828 Normal	Normal	\N	\N	\N	\N	ZS10-10558B1
10000	12-6261A_Tumor	Tumor	\N	\N	\N	\N	12-6261A
10001	12-6261B_Tumor	Tumor	\N	\N	\N	\N	12-6261B
10002	12-12366_Tumor	Tumor	\N	\N	\N	\N	12-12366
10003	12-12467_Tumor	Tumor	\N	\N	\N	\N	12-12467
10004	12-12470D_Tumor	Tumor	\N	\N	\N	\N	12-12470D
10005	12-562_Tumor	Tumor	\N	\N	\N	\N	12-562
10006	12-12647_Tumor	Tumor	\N	\N	\N	\N	12-12647
10007	12-12626_Tumor	Tumor	\N	\N	\N	\N	12-12626
10008	12-13587_Tumor	Tumor	\N	\N	\N	\N	12-13587
10009	12-18438A_Tumor	Tumor	\N	\N	\N	\N	12-18438A
10010	12-13152_Tumor	Tumor	\N	\N	\N	\N	12-13152
10011	12-12750B_Tumor	Tumor	\N	\N	\N	\N	12-12750B
10012	12-19596_Tumor	Tumor	\N	\N	\N	\N	12-19596
10013	12-19187A_Tumor	Tumor	\N	\N	\N	\N	12-19187A
10014	12-22172_Normal	Normal	\N	\N	\N	\N	12-22172
10015	12-22172_Tumor	Tumor	\N	\N	\N	\N	12-22172
10016	12-21726A_Tumor	Tumor	\N	\N	\N	\N	12-21726A
10017	12-22901A_Normal	Normal	\N	\N	\N	\N	12-22901A
10018	12-22901A_Tumor	Tumor	\N	\N	\N	\N	12-22901A
10019	12-22776_Normal	Normal	\N	\N	\N	\N	12-22776
10020	BuffyCoat_Tumor	Tumor	\N	\N	\N	\N	BuffyCoat
10021	12-13587B2_Tumor	Tumor	\N	\N	\N	\N	12-13587B2
10022	12-13587B2_Tumor	Tumor	\N	\N	\N	\N	12-13587B2
10023	12-13587B2_Tumor	Tumor	\N	\N	\N	\N	12-13587B2
10024	BuffyCoa_Tumor	Tumor	\N	\N	\N	\N	BuffyCoa
10025	12-22775_Tumor	Tumor	\N	\N	\N	\N	12-22775
10026	12-22794A_Tumor	Tumor	\N	\N	\N	\N	12-22794A
10027	12-22573_Tumor	Tumor	\N	\N	\N	\N	12-22573
10028	12-22582A_Tumor	Tumor	\N	\N	\N	\N	12-22582A
10029	12-22587_Tumor	Tumor	\N	\N	\N	\N	12-22587
10030	12-22592_Tumor	Tumor	\N	\N	\N	\N	12-22592
10031	12-22597_Tumor	Tumor	\N	\N	\N	\N	12-22597
10032	12-22602A_Tumor	Tumor	\N	\N	\N	\N	12-22602A
10033	12-22602B_Tumor	Tumor	\N	\N	\N	\N	12-22602B
10034	12-22603_Tumor	Tumor	\N	\N	\N	\N	12-22603
10035	12-22604_Tumor	Tumor	\N	\N	\N	\N	12-22604
10036	12-22720A_Tumor	Tumor	\N	\N	\N	\N	12-22720A
10037	12-22868_Tumor	Tumor	\N	\N	\N	\N	12-22868
10038	12-22884C_Tumor	Tumor	\N	\N	\N	\N	12-22884C
10039	12-22884D_Tumor	Tumor	\N	\N	\N	\N	12-22884D
10040	12-22886_Tumor	Tumor	\N	\N	\N	\N	12-22886
10041	12-22894B_Tumor	Tumor	\N	\N	\N	\N	12-22894B
10042	12-22898_Tumor	Tumor	\N	\N	\N	\N	12-22898
10043	12-22900_Tumor	Tumor	\N	\N	\N	\N	12-22900
10044	12-22597_Tumor	Tumor	\N	\N	\N	\N	12-22597
10045	12-22597_Tumor	Tumor	\N	\N	\N	\N	12-22597
10046	12-22597_Tumor	Tumor	\N	\N	\N	\N	12-22597
10047	12-22597_Tumor	Tumor	\N	\N	\N	\N	12-22597
10048	WP11_Tumor	Tumor	\N	\N	\N	\N	WP11
10049	WP23_Tumor	Tumor	\N	\N	\N	\N	WP23
10050	WP29_Tumor	Tumor	\N	\N	\N	\N	WP29
10051	PG8_Tumor	Tumor	\N	\N	\N	\N	PG8
10052	KIT37_Tumor	Tumor	\N	\N	\N	\N	KIT37
10053	KIT62_Tumor	Tumor	\N	\N	\N	\N	KIT62
10054	KIT118_Tumor	Tumor	\N	\N	\N	\N	KIT118
10055	KIT181_Tumor	Tumor	\N	\N	\N	\N	KIT181
10056	KIT227_Tumor	Tumor	\N	\N	\N	\N	KIT227
10057	KIT275_Tumor	Tumor	\N	\N	\N	\N	KIT275
10058	Bivona-L1_Tumor	Tumor	\N	\N	\N	\N	Bivona-L1
10059	Bivona-L2_Tumor	Tumor	\N	\N	\N	\N	Bivona-L2
10060	Bivona-L3_Tumor	Tumor	\N	\N	\N	\N	Bivona-L3
10061	Bivona-L4_Tumor	Tumor	\N	\N	\N	\N	Bivona-L4
10062	Bivona-L5_Tumor	Tumor	\N	\N	\N	\N	Bivona-L5
10063	Bivona-L6_Tumor	Tumor	\N	\N	\N	\N	Bivona-L6
10064	10-41439_Melanoma	Melanoma	\N	\N	\N	\N	10-41439
10065	10-41439_Melanoma	Melanoma	\N	\N	\N	\N	10-41439
10066	10-41439_Nevus	Nevus	\N	\N	\N	\N	10-41439
10067	10-41439_Nevus	Nevus	\N	\N	\N	\N	10-41439
10068	10-41439_Normal	Normal	\N	\N	\N	\N	10-41439
10069	11-23681_Melanoma	Melanoma	\N	\N	\N	\N	11-23681
10070	11-23681_Melanoma	Melanoma	\N	\N	\N	\N	11-23681
10071	11-23681_Nevus	Nevus	\N	\N	\N	\N	11-23681
10072	11-23681_Nevus	Nevus	\N	\N	\N	\N	11-23681
10073	11-23681_Normal	Normal	\N	\N	\N	\N	11-23681
10074	11-37533_Melanoma	Melanoma	\N	\N	\N	\N	11-37533
10075	11-37533_Melanoma	Melanoma	\N	\N	\N	\N	11-37533
10076	11-37533_Nevus	Nevus	\N	\N	\N	\N	11-37533
10077	11-37533_Nevus	Nevus	\N	\N	\N	\N	11-37533
10078	11-37533_Normal	Normal	\N	\N	\N	\N	11-37533
10079	KIT262_Tumor	Tumor	\N	\N	\N	\N	KIT262
10080	Dog12_Tumor	Tumor	\N	\N	\N	\N	Dog12
10081	Dog24_Tumor	Tumor	\N	\N	\N	\N	Dog24
10082	Dog43_Tumor	Tumor	\N	\N	\N	\N	Dog43
10083	Dog55_Tumor	Tumor	\N	\N	\N	\N	Dog55
10084	HW3_Tumor	Tumor	\N	\N	\N	\N	HW3
10085	HW3_Normal	Normal	\N	\N	\N	\N	HW3
10086	HW4_Tumor	Tumor	\N	\N	\N	\N	HW4
10087	HW4_Normal	Normal	\N	\N	\N	\N	HW4
10088	HW6_Tumor	Tumor	\N	\N	\N	\N	HW6
10089	HW6_Normal	Normal	\N	\N	\N	\N	HW6
10090	10-86469_Tumor	Tumor	\N	\N	\N	\N	10-86469
10091	11-12273_Tumor	Tumor	\N	\N	\N	\N	11-12273
10092	11-23710_Tumor	Tumor	\N	\N	\N	\N	11-23710
10093	11-30426_Tumor	Tumor	\N	\N	\N	\N	11-30426
10094	11-31904_Tumor	Tumor	\N	\N	\N	\N	11-31904
10095	11-47644_Tumor	Tumor	\N	\N	\N	\N	11-47644
10096	MB_161_Tumor	Tumor	\N	\N	\N	\N	MB_161
10097	MB_161_Normal	Normal	\N	\N	\N	\N	MB_161
10098	MB_327_Tumor	Tumor	\N	\N	\N	\N	MB_327
10099	MB_1454_Normal	Normal	\N	\N	\N	\N	MB_1454
10100	MB_760_Tumor	Tumor	\N	\N	\N	\N	MB_760
10101	MB_1418_Normal	Normal	\N	\N	\N	\N	MB_1418
10102	MB_1029_Tumor	Tumor	\N	\N	\N	\N	MB_1029
10103	MB_1028_Normal	Normal	\N	\N	\N	\N	MB_1028
10104	MB_1046_Tumor	Tumor	\N	\N	\N	\N	MB_1046
10105	MB_1036_Normal	Normal	\N	\N	\N	\N	MB_1036
10106	Bivona-L17_Tumor	Tumor	\N	\N	\N	\N	Bivona-L17
10107	Bivona-L18_Tumor	Tumor	\N	\N	\N	\N	Bivona-L18
10108	Bivona-L19_Tumor	Tumor	\N	\N	\N	\N	Bivona-L19
10109	KIT227_Tumor	Tumor	\N	\N	\N	\N	KIT227
10110	KIT53_Tumor	Tumor	\N	\N	\N	\N	KIT53
10111	KIT313_Tumor	Tumor	\N	\N	\N	\N	KIT313
10112	HW2_Normal	Normal	\N	\N	\N	\N	HW2
10113	HW2_Tumor	Tumor	\N	\N	\N	\N	HW2
10114	HW8_Normal	Normal	\N	\N	\N	\N	HW8
10115	HW8_Tumor	Tumor	\N	\N	\N	\N	HW8
10116	HW9_Normal	Normal	\N	\N	\N	\N	HW9
10117	HW9_Tumor	Tumor	\N	\N	\N	\N	HW9
10118	12-6981_Tumor	Tumor	\N	\N	\N	\N	12-6981
10119	10-55707_Tumor	Tumor	\N	\N	\N	\N	10-55707
10120	11-34950_Tumor	Tumor	\N	\N	\N	\N	11-34950
10121	11-8228_Tumor	Tumor	\N	\N	\N	\N	11-8228
10122	11-84681_Tumor	Tumor	\N	\N	\N	\N	11-84681
10123	KIT227_Tumor	Tumor	\N	\N	\N	\N	KIT227
10124	WM3211_Tumor	Tumor	\N	\N	\N	\N	WM3211
10125	NB2107_Tumor	Tumor	\N	\N	\N	\N	NB2107
10126	London-L1_Tumor	Tumor	\N	\N	\N	\N	London-L1
10127	London-L2_Tumor	Tumor	\N	\N	\N	\N	London-L2
10128	Bivona-L7_Tumor	Tumor	\N	\N	\N	\N	Bivona-L7
10129	Bivona-L8_Tumor	Tumor	\N	\N	\N	\N	Bivona-L8
10130	Bivona-L9_Tumor	Tumor	\N	\N	\N	\N	Bivona-L9
10131	Bivona-L10_Tumor	Tumor	\N	\N	\N	\N	Bivona-L10
10132	HW3_Tumor	Tumor	\N	\N	\N	\N	HW3
10133	HW3_Normal	Normal	\N	\N	\N	\N	HW3
10134	HW4_Tumor	Tumor	\N	\N	\N	\N	HW4
10135	HW4_Normal	Normal	\N	\N	\N	\N	HW4
10136	HW6_Tumor	Tumor	\N	\N	\N	\N	HW6
10137	HW6_Normal	Normal	\N	\N	\N	\N	HW6
10138	10-86469_Tumor	Tumor	\N	\N	\N	\N	10-86469
10139	11-12273_Tumor	Tumor	\N	\N	\N	\N	11-12273
10140	11-23710_Tumor	Tumor	\N	\N	\N	\N	11-23710
10141	11-30426_Tumor	Tumor	\N	\N	\N	\N	11-30426
10142	11-31904_Tumor	Tumor	\N	\N	\N	\N	11-31904
10143	Bivona-L11_Tumor	Tumor	\N	\N	\N	\N	Bivona-L11
10144	HWA1_Tumor	Tumor	\N	\N	\N	\N	HWA1
10145	HWA1_Normal	Normal	\N	\N	\N	\N	HWA1
10146	HWA2_Tumor	Tumor	\N	\N	\N	\N	HWA2
10147	HWA2_Normal	Normal	\N	\N	\N	\N	HWA2
10148	HWA3_Tumor	Tumor	\N	\N	\N	\N	HWA3
10149	HWA3_Normal	Normal	\N	\N	\N	\N	HWA3
10150	HWA4_Tumor	Tumor	\N	\N	\N	\N	HWA4
10151	HWA4_Normal	Normal	\N	\N	\N	\N	HWA4
10152	11-5482_Tumor	Tumor	\N	\N	\N	\N	11-5482
10153	11-79158_Tumor	Tumor	\N	\N	\N	\N	11-79158
10154	DP12-200_Tumor	Tumor	\N	\N	\N	\N	DP12-200
10155	TissueCoreALKControl_Normal	Normal	\N	\N	\N	\N	TissueCoreALKControl
10156	10-59344_Tumor	Tumor	\N	\N	\N	\N	10-59344
10157	11-16253_Tumor	Tumor	\N	\N	\N	\N	11-16253
10158	11-61046_Tumor	Tumor	\N	\N	\N	\N	11-61046
10159	10-56047_Tumor	Tumor	\N	\N	\N	\N	10-56047
10160	12-67298_Tumor	Tumor	\N	\N	\N	\N	12-67298
10161	12-67298_Normal	Normal	\N	\N	\N	\N	12-67298
10162	12-20321_Tumor	Tumor	\N	\N	\N	\N	12-20321
10163	11-96096_Normal	Normal	\N	\N	\N	\N	11-96096
10164	MB1242_Tumor	Tumor	\N	\N	\N	\N	MB1242
10165	MB1241_Normal	Normal	\N	\N	\N	\N	MB1241
10166	MB1423_Tumor	Tumor	\N	\N	\N	\N	MB1423
10167	MB1423_Normal	Normal	\N	\N	\N	\N	MB1423
10168	MB1424__Tumor	Tumor	\N	\N	\N	\N	MB1424_
10169	MB1421_Normal	Normal	\N	\N	\N	\N	MB1421
10170	MB1429_Tumor	Tumor	\N	\N	\N	\N	MB1429
10171	MB1428_Normal	Normal	\N	\N	\N	\N	MB1428
10172	12-71679_Tumor	Tumor	\N	\N	\N	\N	12-71679
10173	12-80985B_Tumor	Tumor	\N	\N	\N	\N	12-80985B
10174	12-31996_Tumor	Tumor	\N	\N	\N	\N	12-31996
10175	12-39632_Tumor	Tumor	\N	\N	\N	\N	12-39632
10176	HWA5_Tumor	Tumor	\N	\N	\N	\N	HWA5
10177	HWA5_Normal	Normal	\N	\N	\N	\N	HWA5
10178	HWA6_Tumor	Tumor	\N	\N	\N	\N	HWA6
10179	HWA6_Normal	Normal	\N	\N	\N	\N	HWA6
10180	HWA7_Tumor	Tumor	\N	\N	\N	\N	HWA7
10181	HWA7_Normal	Normal	\N	\N	\N	\N	HWA7
10182	HWA8_Tumor	Tumor	\N	\N	\N	\N	HWA8
10183	HWA8_Normal	Normal	\N	\N	\N	\N	HWA8
10184	HWA9_Tumor	Tumor	\N	\N	\N	\N	HWA9
10185	HWA9_Normal	Normal	\N	\N	\N	\N	HWA9
10186	HWA10_Tumor	Tumor	\N	\N	\N	\N	HWA10
10187	HWA10_Normal	Normal	\N	\N	\N	\N	HWA10
10188	MB1617_Tumor	Tumor	\N	\N	\N	\N	MB1617
10189	MB1609_Normal	Normal	\N	\N	\N	\N	MB1609
10190	WM51_Tumor	Tumor	\N	\N	\N	\N	WM51
10191	wm3918_Tumor	Tumor	\N	\N	\N	\N	wm3918
10192	DM1_Normal	Normal	\N	\N	\N	\N	DM1
10193	DM1_Tumor	Tumor	\N	\N	\N	\N	DM1
10194	DM2_Normal	Normal	\N	\N	\N	\N	DM2
10195	DM2_Tumor	Tumor	\N	\N	\N	\N	DM2
10196	DM5_Normal	Normal	\N	\N	\N	\N	DM5
10197	DM5_Tumor	Tumor	\N	\N	\N	\N	DM5
10198	DM7_Normal	Normal	\N	\N	\N	\N	DM7
10199	DM7_Tumor	Tumor	\N	\N	\N	\N	DM7
10200	DM12_Normal	Normal	\N	\N	\N	\N	DM12
10201	DM12_Tumor	Tumor	\N	\N	\N	\N	DM12
10202	DM13_Normal	Normal	\N	\N	\N	\N	DM13
10203	DM13_Tumor	Tumor	\N	\N	\N	\N	DM13
10204	DM21_Normal	Normal	\N	\N	\N	\N	DM21
10205	DM21_Tumor	Tumor	\N	\N	\N	\N	DM21
10206	DM93_Normal	Normal	\N	\N	\N	\N	DM93
10207	DM93_Tumor	Tumor	\N	\N	\N	\N	DM93
10208	11-20375_Tumor	Tumor	\N	\N	\N	\N	11-20375
10209	11-21491_Tumor	Tumor	\N	\N	\N	\N	11-21491
10210	11-65778_Tumor	Tumor	\N	\N	\N	\N	11-65778
10211	10-88482_Tumor	Tumor	\N	\N	\N	\N	10-88482
10212	11-63178_Tumor	Tumor	\N	\N	\N	\N	11-63178
10213	10-71761_Tumor	Tumor	\N	\N	\N	\N	10-71761
10214	10-84478_Tumor	Tumor	\N	\N	\N	\N	10-84478
10215	10-88475_Tumor	Tumor	\N	\N	\N	\N	10-88475
10216	12-54296_Normal	Normal	\N	\N	\N	\N	12-54296
10217	12-54296_Tumor	Tumor	\N	\N	\N	\N	12-54296
10218	12-54992_Normal	Normal	\N	\N	\N	\N	12-54992
10219	12-54992_Tumor	Tumor	\N	\N	\N	\N	12-54992
10220	WM3622_Tumor	Tumor	\N	\N	\N	\N	WM3622
10221	WM1963_Tumor	Tumor	\N	\N	\N	\N	WM1963
10222	WM8_Tumor	Tumor	\N	\N	\N	\N	WM8
10223	WM3912_Tumor	Tumor	\N	\N	\N	\N	WM3912
10224	DM11_Tumor	Tumor	\N	\N	\N	\N	DM11
10225	DM11_Normal	Normal	\N	\N	\N	\N	DM11
10226	DM14_Tumor	Tumor	\N	\N	\N	\N	DM14
10227	DM14_Normal	Normal	\N	\N	\N	\N	DM14
10228	DM26_Tumor	Tumor	\N	\N	\N	\N	DM26
10229	DM26_Normal	Normal	\N	\N	\N	\N	DM26
10230	DM28_Tumor	Tumor	\N	\N	\N	\N	DM28
10231	DM28_Normal	Normal	\N	\N	\N	\N	DM28
10232	DM29_Tumor	Tumor	\N	\N	\N	\N	DM29
10233	DM29_Normal	Normal	\N	\N	\N	\N	DM29
10234	DM34_Tumor	Tumor	\N	\N	\N	\N	DM34
10235	DM34_Normal	Normal	\N	\N	\N	\N	DM34
10236	DM55_Tumor	Tumor	\N	\N	\N	\N	DM55
10237	DM55_Normal	Normal	\N	\N	\N	\N	DM55
10238	DM79_Tumor	Tumor	\N	\N	\N	\N	DM79
10239	DM79_Normal	Normal	\N	\N	\N	\N	DM79
10240	11-78845_Tumor	Tumor	\N	\N	\N	\N	11-78845
10241	11-81405_Tumor	Tumor	\N	\N	\N	\N	11-81405
10242	11-85075_Tumor	Tumor	\N	\N	\N	\N	11-85075
10243	11-83908_Tumor	Tumor	\N	\N	\N	\N	11-83908
10244	11-85859_Tumor	Tumor	\N	\N	\N	\N	11-85859
10245	11-95663_Tumor	Tumor	\N	\N	\N	\N	11-95663
10246	DM4_Tumor	Tumor	\N	\N	\N	\N	DM4
10247	DM4_Normal	Normal	\N	\N	\N	\N	DM4
10248	DM95_Tumor	Tumor	\N	\N	\N	\N	DM95
10249	DM95_Normal	Normal	\N	\N	\N	\N	DM95
10250	DM96_Tumor	Tumor	\N	\N	\N	\N	DM96
10251	DM96_Normal	Normal	\N	\N	\N	\N	DM96
10252	KIT8_Tumor	Tumor	\N	\N	\N	\N	KIT8
10253	KIT21_Tumor	Tumor	\N	\N	\N	\N	KIT21
10254	KIT55_Tumor	Tumor	\N	\N	\N	\N	KIT55
10255	KIT76_Tumor	Tumor	\N	\N	\N	\N	KIT76
10256	W09-1121_Tumor	Tumor	\N	\N	\N	\N	W09-1121
10257	W09-1121_Normal	Normal	\N	\N	\N	\N	W09-1121
10258	W10-143_Tumor	Tumor	\N	\N	\N	\N	W10-143
10259	S94-31062_Tumor	Tumor	\N	\N	\N	\N	S94-31062
10260	S02-23636A02_Tumor	Tumor	\N	\N	\N	\N	S02-23636A02
10261	S02-33818A03_Tumor	Tumor	\N	\N	\N	\N	S02-33818A03
10262	S02-33818A03_Normal	Normal	\N	\N	\N	\N	S02-33818A03
10263	S05-7439A12_Tumor	Tumor	\N	\N	\N	\N	S05-7439A12
10264	S05-41924_Tumor	Tumor	\N	\N	\N	\N	S05-41924
10265	S06-47079A02_Tumor	Tumor	\N	\N	\N	\N	S06-47079A02
10266	S08-4544A03_Tumor	Tumor	\N	\N	\N	\N	S08-4544A03
10267	S10-26316A2_Tumor	Tumor	\N	\N	\N	\N	S10-26316A2
10268	S10-44069A4_Tumor	Tumor	\N	\N	\N	\N	S10-44069A4
10269	S11-38910A2_Tumor	Tumor	\N	\N	\N	\N	S11-38910A2
10270	KIT192_Tumor	Tumor	\N	\N	\N	\N	KIT192
10271	KIT203_Tumor	Tumor	\N	\N	\N	\N	KIT203
10272	KR_166_Tumor	Tumor	\N	\N	\N	\N	KR_166
10273	KR_2064_Tumor	Tumor	\N	\N	\N	\N	KR_2064
10274	KR_2030_Tumor	Tumor	\N	\N	\N	\N	KR_2030
10275	KR_177_Tumor	Tumor	\N	\N	\N	\N	KR_177
10276	KR_150_Tumor	Tumor	\N	\N	\N	\N	KR_150
10277	KR_229_Tumor	Tumor	\N	\N	\N	\N	KR_229
10278	KR_203_Tumor	Tumor	\N	\N	\N	\N	KR_203
10279	KR_8_Tumor	Tumor	\N	\N	\N	\N	KR_8
10280	KR_5233_Tumor	Tumor	\N	\N	\N	\N	KR_5233
10281	KR_RMK0091B_Tumor	Tumor	\N	\N	\N	\N	KR_RMK0091B
10282	KR_RMK0194C_Tumor	Tumor	\N	\N	\N	\N	KR_RMK0194C
10283	KR_RMK0137C_Tumor	Tumor	\N	\N	\N	\N	KR_RMK0137C
10284	KR_RMK0162C_Tumor	Tumor	\N	\N	\N	\N	KR_RMK0162C
10285	KR_RMK0168C_Tumor	Tumor	\N	\N	\N	\N	KR_RMK0168C
10286	10-41439_Normal	Normal	\N	\N	\N	\N	10-41439
10287	11-23681A+C_Normal	Normal	\N	\N	\N	\N	11-23681A+C
10288	DM10_Tumor	Tumor	\N	\N	\N	\N	DM10
10289	DM10_Normal	Normal	\N	\N	\N	\N	DM10
10290	DM17_Tumor	Tumor	\N	\N	\N	\N	DM17
10291	DM17_Normal	Normal	\N	\N	\N	\N	DM17
10292	DM18_Tumor	Tumor	\N	\N	\N	\N	DM18
10293	DM18_Normal	Normal	\N	\N	\N	\N	DM18
10294	DM22_Tumor	Tumor	\N	\N	\N	\N	DM22
10295	DM22_Normal	Normal	\N	\N	\N	\N	DM22
10296	DM23_Tumor	Tumor	\N	\N	\N	\N	DM23
10297	DM23_Normal	Normal	\N	\N	\N	\N	DM23
10298	DM25_Tumor	Tumor	\N	\N	\N	\N	DM25
10299	DM25_Normal	Normal	\N	\N	\N	\N	DM25
10300	DM6_Tumor	Tumor	\N	\N	\N	\N	DM6
10301	DM37_Tumor	Tumor	\N	\N	\N	\N	DM37
10302	DM93_Normal	Normal	\N	\N	\N	\N	DM93
10303	DM93_Tumor	Tumor	\N	\N	\N	\N	DM93
10304	SM_1_Tumor	Tumor	\N	\N	\N	\N	SM_1
10305	SM_3_Tumor	Tumor	\N	\N	\N	\N	SM_3
10306	SM_4_Tumor	Tumor	\N	\N	\N	\N	SM_4
10307	SM_4_Normal	Normal	\N	\N	\N	\N	SM_4
10308	SM_5_Tumor	Tumor	\N	\N	\N	\N	SM_5
10309	SM_5_Normal	Normal	\N	\N	\N	\N	SM_5
10310	SM7_Tumor	Tumor	\N	\N	\N	\N	SM7
10311	SM_8_Tumor	Tumor	\N	\N	\N	\N	SM_8
10312	SM_11_Tumor	Tumor	\N	\N	\N	\N	SM_11
10313	SM_12_Tumor	Tumor	\N	\N	\N	\N	SM_12
10314	SM_16_Tumor	Tumor	\N	\N	\N	\N	SM_16
10315	SM_16_Normal	Normal	\N	\N	\N	\N	SM_16
10316	SM_18_Tumor	Tumor	\N	\N	\N	\N	SM_18
10317	DM42_Tumor	Tumor	\N	\N	\N	\N	DM42
10318	DM43_Tumor	Tumor	\N	\N	\N	\N	DM43
10319	DM48_Tumor	Tumor	\N	\N	\N	\N	DM48
10320	11-64496_Tumor	Tumor	\N	\N	\N	\N	11-64496
10321	11-71491_Tumor	Tumor	\N	\N	\N	\N	11-71491
10322	11-65756_Tumor	Tumor	\N	\N	\N	\N	11-65756
10323	11-74100_Tumor	Tumor	\N	\N	\N	\N	11-74100
10324	11-74517_Tumor	Tumor	\N	\N	\N	\N	11-74517
10325	10-74513_Tumor	Tumor	\N	\N	\N	\N	10-74513
10326	10-80009_Tumor	Tumor	\N	\N	\N	\N	10-80009
10327	10-91484_Tumor	Tumor	\N	\N	\N	\N	10-91484
10328	11-699_Tumor	Tumor	\N	\N	\N	\N	11-699
10329	11-18560_Tumor	Tumor	\N	\N	\N	\N	11-18560
10330	11-20772_Tumor	Tumor	\N	\N	\N	\N	11-20772
10331	11-19877_Tumor	Tumor	\N	\N	\N	\N	11-19877
10332	11-35616_Tumor	Tumor	\N	\N	\N	\N	11-35616
10333	11-33856_Tumor	Tumor	\N	\N	\N	\N	11-33856
10334	11-38771_Tumor	Tumor	\N	\N	\N	\N	11-38771
10335	11-39639_Tumor	Tumor	\N	\N	\N	\N	11-39639
10336	10-88482_Tumor	Tumor	\N	\N	\N	\N	10-88482
10337	11-5482_Tumor	Tumor	\N	\N	\N	\N	11-5482
10338	11-31904_Tumor	Tumor	\N	\N	\N	\N	11-31904
10339	11-61046_Tumor	Tumor	\N	\N	\N	\N	11-61046
10340	08-27590_Tumor	Tumor	\N	\N	\N	\N	08-27590
10341	08-27590_Normal	Normal	\N	\N	\N	\N	08-27590
10342	06-32942_Tumor	Tumor	\N	\N	\N	\N	06-32942
10343	06-52508_Tumor	Tumor	\N	\N	\N	\N	06-52508
10344	06-52508_Normal	Normal	\N	\N	\N	\N	06-52508
10345	07-04365_Tumor	Tumor	\N	\N	\N	\N	07-04365
10346	07-04365_Normal	Normal	\N	\N	\N	\N	07-04365
10347	07-14044A_Tumor	Tumor	\N	\N	\N	\N	07-14044A
10348	07-14044A_Normal	Normal	\N	\N	\N	\N	07-14044A
10349	07-26247_Tumor	Tumor	\N	\N	\N	\N	07-26247
10350	09-37302_Tumor	Tumor	\N	\N	\N	\N	09-37302
10351	12-79358_Tumor	Tumor	\N	\N	\N	\N	12-79358
10352	12-81302_Tumor	Tumor	\N	\N	\N	\N	12-81302
10353	12-81749_Tumor	Tumor	\N	\N	\N	\N	12-81749
10354	12-97031_Tumor	Tumor	\N	\N	\N	\N	12-97031
10355	12-98736_Tumor	Tumor	\N	\N	\N	\N	12-98736
10356	13-3874_Tumor	Tumor	\N	\N	\N	\N	13-3874
10357	13-3732_Tumor	Tumor	\N	\N	\N	\N	13-3732
10358	13-3889_Tumor	Tumor	\N	\N	\N	\N	13-3889
10359	13-4090B_Tumor	Tumor	\N	\N	\N	\N	13-4090B
10360	13-4136_Tumor	Tumor	\N	\N	\N	\N	13-4136
10361	13-7186_Tumor	Tumor	\N	\N	\N	\N	13-7186
10362	13-25A_Tumor	Tumor	\N	\N	\N	\N	13-25A
10363	11-71241_Tumor	Tumor	\N	\N	\N	\N	11-71241
10364	11-26903_Tumor	Tumor	\N	\N	\N	\N	11-26903
10365	11-28912B_Tumor	Tumor	\N	\N	\N	\N	11-28912B
10366	11-5210D_Tumor	Tumor	\N	\N	\N	\N	11-5210D
10367	10-83193_Tumor	Tumor	\N	\N	\N	\N	10-83193
10368	11-95856_Tumor	Tumor	\N	\N	\N	\N	11-95856
10369	10-23569A_Tumor	Tumor	\N	\N	\N	\N	10-23569A
10370	09-92749_Tumor	Tumor	\N	\N	\N	\N	09-92749
10371	09-72944_Tumor	Tumor	\N	\N	\N	\N	09-72944
10372	10-46536_Tumor	Tumor	\N	\N	\N	\N	10-46536
10373	10-83613A_Tumor	Tumor	\N	\N	\N	\N	10-83613A
10374	K1_1_Tumor	Tumor	\N	\N	\N	\N	K1_1
10375	K1_2_Tumor	Tumor	\N	\N	\N	\N	K1_2
10376	K1_3_Tumor	Tumor	\N	\N	\N	\N	K1_3
10377	London-L20_Melanoma	Melanoma	\N	\N	\N	\N	London-L20
10378	London-L20_Normal	Normal	\N	\N	\N	\N	London-L20
10379	London-L20_Nevus	Nevus	\N	\N	\N	\N	London-L20
10380	London-L15_Normal	Normal	\N	\N	\N	\N	London-L15
10381	London-L23C_Nevus	Nevus	\N	\N	\N	\N	London-L23C
10382	K1_9_Tumor	Tumor	\N	\N	\N	\N	K1_9
10383	K1_10_Tumor	Tumor	\N	\N	\N	\N	K1_10
10384	K1_11_Tumor	Tumor	\N	\N	\N	\N	K1_11
10385	K1_12_Tumor	Tumor	\N	\N	\N	\N	K1_12
10386	K1_13_Tumor	Tumor	\N	\N	\N	\N	K1_13
10387	K1_14_Tumor	Tumor	\N	\N	\N	\N	K1_14
10388	K1_15_Tumor	Tumor	\N	\N	\N	\N	K1_15
10389	K1_16_Tumor	Tumor	\N	\N	\N	\N	K1_16
10390	K1_17_Tumor	Tumor	\N	\N	\N	\N	K1_17
10391	K1_18_Tumor	Tumor	\N	\N	\N	\N	K1_18
10392	K1_19_Tumor	Tumor	\N	\N	\N	\N	K1_19
10393	K1_20_Tumor	Tumor	\N	\N	\N	\N	K1_20
10394	10-32987_Tumor	Tumor	\N	\N	\N	\N	10-32987
10395	06-08042_Tumor	Tumor	\N	\N	\N	\N	06-08042
10396	06-00911_Tumor	Tumor	\N	\N	\N	\N	06-00911
10397	06-21363_Tumor	Tumor	\N	\N	\N	\N	06-21363
10398	06-47334_Tumor	Tumor	\N	\N	\N	\N	06-47334
10399	S12-6332A5_Tumor	Tumor	\N	\N	\N	\N	S12-6332A5
10400	S11-032523A1_Tumor	Tumor	\N	\N	\N	\N	S11-032523A1
10401	S08-1463A2_Tumor	Tumor	\N	\N	\N	\N	S08-1463A2
10402	S12-7093NG176-1_Tumor	Tumor	\N	\N	\N	\N	S12-7093NG176-1
10403	S10-7937B2_Tumor	Tumor	\N	\N	\N	\N	S10-7937B2
10404	S11-21025B1_Tumor	Tumor	\N	\N	\N	\N	S11-21025B1
10405	10-58663_Melanoma	Melanoma	\N	\N	\N	\N	10-58663
10406	10-58663_Melanoma	Melanoma	\N	\N	\N	\N	10-58663
10407	10-58663_Nevus	Nevus	\N	\N	\N	\N	10-58663
10408	10-58663_Nevus	Nevus	\N	\N	\N	\N	10-58663
10409	10-58663_Normal	Normal	\N	\N	\N	\N	10-58663
10410	08-52519_Melanoma	Melanoma	\N	\N	\N	\N	08-52519
10411	08-52519_Melanoma	Melanoma	\N	\N	\N	\N	08-52519
10412	08-52519_Nevus	Nevus	\N	\N	\N	\N	08-52519
10413	08-52519_Nevus	Nevus	\N	\N	\N	\N	08-52519
10414	08-52519_Normal	Normal	\N	\N	\N	\N	08-52519
10415	09-8165_Melanoma	Melanoma	\N	\N	\N	\N	09-8165
10416	09-8165_Melanoma	Melanoma	\N	\N	\N	\N	09-8165
10417	09-8165_Nevus	Nevus	\N	\N	\N	\N	09-8165
10418	09-8165_Nevus	Nevus	\N	\N	\N	\N	09-8165
10419	09-8165_Normal	Normal	\N	\N	\N	\N	09-8165
10420	08-46462_Melanoma	Melanoma	\N	\N	\N	\N	08-46462
10421	08-46462_Melanoma	Melanoma	\N	\N	\N	\N	08-46462
10422	08-46462_Nevus	Nevus	\N	\N	\N	\N	08-46462
10423	08-46462_Nevus	Nevus	\N	\N	\N	\N	08-46462
10424	08-46462_Normal	Normal	\N	\N	\N	\N	08-46462
10425	11-25808_Tumor	Tumor	\N	\N	\N	\N	11-25808
10426	11-42027_Tumor	Tumor	\N	\N	\N	\N	11-42027
10427	12-7775_Tumor	Tumor	\N	\N	\N	\N	12-7775
10428	DM93_Tumor	Tumor	\N	\N	\N	\N	DM93
10429	DM37_Normal	Normal	\N	\N	\N	\N	DM37
10430	DM45_Tumor	Tumor	\N	\N	\N	\N	DM45
10431	DM45_Normal	Normal	\N	\N	\N	\N	DM45
10432	DM16_Tumor	Tumor	\N	\N	\N	\N	DM16
10433	DM16_Normal	Normal	\N	\N	\N	\N	DM16
10434	DM77_Tumor	Tumor	\N	\N	\N	\N	DM77
10435	DM77_Normal	Normal	\N	\N	\N	\N	DM77
10436	HW3_Tumor	Tumor	\N	\N	\N	\N	HW3
10437	HW2_Tumor	Tumor	\N	\N	\N	\N	HW2
10438	HWAcr_Tumor	Tumor	\N	\N	\N	\N	HWAcr
10439	KIT181_Tumor	Tumor	\N	\N	\N	\N	KIT181
10440	DM13_Tumor	Tumor	\N	\N	\N	\N	DM13
10441	DM94_Tumor	Tumor	\N	\N	\N	\N	DM94
10442	DM94_Normal	Normal	\N	\N	\N	\N	DM94
10443	DM98_Tumor	Tumor	\N	\N	\N	\N	DM98
10444	DM98_Normal	Normal	\N	\N	\N	\N	DM98
10445	DM99_Tumor	Tumor	\N	\N	\N	\N	DM99
10446	DM99_Normal	Normal	\N	\N	\N	\N	DM99
10447	DM64_Tumor	Tumor	\N	\N	\N	\N	DM64
10448	DM64_Normal	Normal	\N	\N	\N	\N	DM64
10449	DM51_Tumor	Tumor	\N	\N	\N	\N	DM51
10450	DM58_Tumor	Tumor	\N	\N	\N	\N	DM58
10451	DM59_Tumor	Tumor	\N	\N	\N	\N	DM59
10452	DM31_Tumor	Tumor	\N	\N	\N	\N	DM31
10453	DM36_Tumor	Tumor	\N	\N	\N	\N	DM36
10454	DM74_Tumor	Tumor	\N	\N	\N	\N	DM74
10455	DM10_Tumor	Tumor	\N	\N	\N	\N	DM10
10456	DM18_Tumor	Tumor	\N	\N	\N	\N	DM18
10457	HW8_Tumor	Tumor	\N	\N	\N	\N	HW8
10458	08-43264_Melanoma	Melanoma	\N	\N	\N	\N	08-43264
10459	08-43264_Melanoma	Melanoma	\N	\N	\N	\N	08-43264
10460	08-43264_Nevus	Nevus	\N	\N	\N	\N	08-43264
10461	08-43264_Nevus	Nevus	\N	\N	\N	\N	08-43264
10462	08-43264_Normal	Normal	\N	\N	\N	\N	08-43264
10463	08-51219_Melanoma	Melanoma	\N	\N	\N	\N	08-51219
10464	08-51219_Melanoma	Melanoma	\N	\N	\N	\N	08-51219
10465	08-51219_Nevus	Nevus	\N	\N	\N	\N	08-51219
10466	08-51219_Nevus	Nevus	\N	\N	\N	\N	08-51219
10467	08-51219_Normal	Normal	\N	\N	\N	\N	08-51219
10468	S12-18826_Tumor	Tumor	\N	\N	\N	\N	S12-18826
10469	11-81851_Melanoma	Melanoma	\N	\N	\N	\N	11-81851
10470	11-81851_Melanoma	Melanoma	\N	\N	\N	\N	11-81851
10471	11-81851_Nevus	Nevus	\N	\N	\N	\N	11-81851
10472	11-81851_Nevus	Nevus	\N	\N	\N	\N	11-81851
10473	11-81851_Normal	Normal	\N	\N	\N	\N	11-81851
10474	10-73024_Melanoma	Melanoma	\N	\N	\N	\N	10-73024
10475	10-73024_Melanoma	Melanoma	\N	\N	\N	\N	10-73024
10476	10-73024_Nevus	Nevus	\N	\N	\N	\N	10-73024
10477	10-73024_Nevus	Nevus	\N	\N	\N	\N	10-73024
10478	10-73024_Normal	Normal	\N	\N	\N	\N	10-73024
10479	12_M_Tumor	Tumor	\N	\N	\N	\N	12_M
10480	35_M_Tumor	Tumor	\N	\N	\N	\N	35_M
10481	49_M_Tumor	Tumor	\N	\N	\N	\N	49_M
10482	DM2_Tumor	Tumor	\N	\N	\N	\N	DM2
10483	10-0206_Tumor	Tumor	\N	\N	\N	\N	10-0206
10484	09-0209_Tumor	Tumor	\N	\N	\N	\N	09-0209
10485	13-25110A1_Melanoma	Melanoma	\N	\N	\N	\N	13-25110A1
10486	13-25110A1_Nevus	Nevus	\N	\N	\N	\N	13-25110A1
10487	13-25110A1_Normal	Normal	\N	\N	\N	\N	13-25110A1
10488	13-45163_Melanoma	Melanoma	\N	\N	\N	\N	13-45163
10489	13-45163_Nevus	Nevus	\N	\N	\N	\N	13-45163
10490	13-45163_Normal	Normal	\N	\N	\N	\N	13-45163
10491	DM49_Tumor	Tumor	\N	\N	\N	\N	DM49
10492	DP08-21965C_Tumor	Tumor	\N	\N	\N	\N	DP08-21965C
10493	DP08-21965C_Normal	Normal	\N	\N	\N	\N	DP08-21965C
10494	DP08-4205A_Tumor	Tumor	\N	\N	\N	\N	DP08-4205A
10495	DP08-4205A_Normal	Normal	\N	\N	\N	\N	DP08-4205A
10496	11-50182_Tumor	Tumor	\N	\N	\N	\N	11-50182
10497	11-51553_Tumor	Tumor	\N	\N	\N	\N	11-51553
10498	11-52339_Tumor	Tumor	\N	\N	\N	\N	11-52339
10499	11-55993_Tumor	Tumor	\N	\N	\N	\N	11-55993
10500	11-57051_Tumor	Tumor	\N	\N	\N	\N	11-57051
10501	11-71006_Tumor	Tumor	\N	\N	\N	\N	11-71006
10502	11-76464_Tumor	Tumor	\N	\N	\N	\N	11-76464
10503	11-88431_Tumor	Tumor	\N	\N	\N	\N	11-88431
10504	11-88432_Tumor	Tumor	\N	\N	\N	\N	11-88432
10505	11-88209_Tumor	Tumor	\N	\N	\N	\N	11-88209
10506	Thomas_SK_MEL_23_Tumor	Tumor	\N	\N	\N	\N	Thomas_SK_MEL_23
10507	KIT134_Tumor	Tumor	\N	\N	\N	\N	KIT134
10508	KIT191_Tumor	Tumor	\N	\N	\N	\N	KIT191
10509	KIT205_Tumor	Tumor	\N	\N	\N	\N	KIT205
10510	KIT206_Tumor	Tumor	\N	\N	\N	\N	KIT206
10511	KIT210_Tumor	Tumor	\N	\N	\N	\N	KIT210
10512	KIT217_Tumor	Tumor	\N	\N	\N	\N	KIT217
10513	KIT225_Tumor	Tumor	\N	\N	\N	\N	KIT225
10514	KIT244_Tumor	Tumor	\N	\N	\N	\N	KIT244
10515	KIT260_Tumor	Tumor	\N	\N	\N	\N	KIT260
10516	KIT273_Tumor	Tumor	\N	\N	\N	\N	KIT273
10517	KIT295_Tumor	Tumor	\N	\N	\N	\N	KIT295
10518	11-23878_Tumor	Tumor	\N	\N	\N	\N	11-23878
10519	12-11041_Tumor	Tumor	\N	\N	\N	\N	12-11041
10520	12-55584_Tumor	Tumor	\N	\N	\N	\N	12-55584
10521	11-85416_Tumor	Tumor	\N	\N	\N	\N	11-85416
10522	11-94134_Tumor	Tumor	\N	\N	\N	\N	11-94134
10523	12-2898_Tumor	Tumor	\N	\N	\N	\N	12-2898
10524	12-1782_Tumor	Tumor	\N	\N	\N	\N	12-1782
10525	12-4251_Tumor	Tumor	\N	\N	\N	\N	12-4251
10526	12-8171_Tumor	Tumor	\N	\N	\N	\N	12-8171
10527	12-10777_Tumor	Tumor	\N	\N	\N	\N	12-10777
10528	10_63051C_Normal	Normal	\N	\N	\N	\N	10_63051C
10529	DPN8_Normal	Normal	\N	\N	\N	\N	DPN8
10530	DPN9_Normal	Normal	\N	\N	\N	\N	DPN9
10531	DPN18_Normal	Normal	\N	\N	\N	\N	DPN18
10532	11-21178_Tumor	Tumor	\N	\N	\N	\N	11-21178
10533	13-212_Tumor	Tumor	\N	\N	\N	\N	13-212
10534	DM74_Tumor	Tumor	\N	\N	\N	\N	DM74
10535	DM99_Tumor	Tumor	\N	\N	\N	\N	DM99
10536	KIT230_Tumor	Tumor	\N	\N	\N	\N	KIT230
10537	KIT297_Tumor	Tumor	\N	\N	\N	\N	KIT297
10538	KIT302_Tumor	Tumor	\N	\N	\N	\N	KIT302
10539	KIT316_Tumor	Tumor	\N	\N	\N	\N	KIT316
10540	DM6_Normal	Normal	\N	\N	\N	\N	DM6
10541	DM31_Normal	Normal	\N	\N	\N	\N	DM31
10542	DM36_Normal	Normal	\N	\N	\N	\N	DM36
10543	DM42_Normal	Normal	\N	\N	\N	\N	DM42
10544	DM68_Tumor	Tumor	\N	\N	\N	\N	DM68
10545	DM10_Tumor	Tumor	\N	\N	\N	\N	DM10
10546	DM10_Normal	Normal	\N	\N	\N	\N	DM10
10547	DM10_Tumor	Tumor	\N	\N	\N	\N	DM10
10548	11-50270_Tumor	Tumor	\N	\N	\N	\N	11-50270
10549	12-23578_Tumor	Tumor	\N	\N	\N	\N	12-23578
10550	12-31421_Tumor	Tumor	\N	\N	\N	\N	12-31421
10551	11-13661_Tumor	Tumor	\N	\N	\N	\N	11-13661
10552	RC11-001_Tumor	Tumor	\N	\N	\N	\N	RC11-001
10553	RC11-002_Tumor	Tumor	\N	\N	\N	\N	RC11-002
10554	RC11-003_Tumor	Tumor	\N	\N	\N	\N	RC11-003
10555	RC11-004_Tumor	Tumor	\N	\N	\N	\N	RC11-004
10556	RC11-005_Tumor	Tumor	\N	\N	\N	\N	RC11-005
10557	RC11-021_Tumor	Tumor	\N	\N	\N	\N	RC11-021
10558	RC11-022_Tumor	Tumor	\N	\N	\N	\N	RC11-022
10559	RC11-023_Tumor	Tumor	\N	\N	\N	\N	RC11-023
10560	RC11-024_Tumor	Tumor	\N	\N	\N	\N	RC11-024
10561	Kit298_Tumor	Tumor	\N	\N	\N	\N	Kit298
10562	08-46462_Tumor	Tumor	\N	\N	\N	\N	08-46462
10563	08-46462_Nevus	Nevus	\N	\N	\N	\N	08-46462
10564	08-46462_Tumor	Tumor	\N	\N	\N	\N	08-46462
10565	08-46462_Normal	Normal	\N	\N	\N	\N	08-46462
10566	BN_N1_Tumor	Tumor	\N	\N	\N	\N	BN_N1
10567	BN_N2_Tumor	Tumor	\N	\N	\N	\N	BN_N2
10568	BN_M1_Tumor	Tumor	\N	\N	\N	\N	BN_M1
10569	BN_M2_Tumor	Tumor	\N	\N	\N	\N	BN_M2
10570	DM74_Tumor	Tumor	\N	\N	\N	\N	DM74
10571	DM10_Tumor	Tumor	\N	\N	\N	\N	DM10
10572	SQ13-8208B_Tumor	Tumor	\N	\N	\N	\N	SQ13-8208B
10573	98-18400a_Tumor	Tumor	\N	\N	\N	\N	98-18400a
10574	12-11406A_Tumor	Tumor	\N	\N	\N	\N	12-11406A
10575	08-70283a_Tumor	Tumor	\N	\N	\N	\N	08-70283a
10576	03-34051A1_Tumor	Tumor	\N	\N	\N	\N	03-34051A1
10577	02-42436_Tumor	Tumor	\N	\N	\N	\N	02-42436
10578	11-38149_Normal	Normal	\N	\N	\N	\N	11-38149
10579	13-2939B_Tumor	Tumor	\N	\N	\N	\N	13-2939B
10580	L13-48798_Tumor	Tumor	\N	\N	\N	\N	L13-48798
10581	13-51115A_Tumor	Tumor	\N	\N	\N	\N	13-51115A
10582	11-73238A_Normal	Normal	\N	\N	\N	\N	11-73238A
10583	11-73999_Normal	Normal	\N	\N	\N	\N	11-73999
10584	DM43_Normal	Normal	\N	\N	\N	\N	DM43
10585	DM49_Normal	Normal	\N	\N	\N	\N	DM49
10586	DM58_Normal	Normal	\N	\N	\N	\N	DM58
10587	DM65_Tumor	Tumor	\N	\N	\N	\N	DM65
10588	DM93_Tumor	Tumor	\N	\N	\N	\N	DM93
10589	DM10_Tumor	Tumor	\N	\N	\N	\N	DM10
10590	13-59840_Tumor	Tumor	\N	\N	\N	\N	13-59840
10591	13-59840_Tumor	Tumor	\N	\N	\N	\N	13-59840
10592	Seider_Uveal_Tumor	Tumor	\N	\N	\N	\N	Seider_Uveal
10593	Luping_ROS_1_Tumor	Tumor	\N	\N	\N	\N	Luping_ROS_1
10594	Seider_Roe_Tumor	Tumor	\N	\N	\N	\N	Seider_Roe
10595	DP08-21965C_Tumor	Tumor	\N	\N	\N	\N	DP08-21965C
10596	DM18_Tumor	Tumor	\N	\N	\N	\N	DM18
10597	11-50182_Tumor	Tumor	\N	\N	\N	\N	11-50182
10598	11-41004_Tumor	Tumor	\N	\N	\N	\N	11-41004
10599	11-51223_Tumor	Tumor	\N	\N	\N	\N	11-51223
10600	12-22542_Tumor	Tumor	\N	\N	\N	\N	12-22542
10601	12-42406_Tumor	Tumor	\N	\N	\N	\N	12-42406
10602	12-55875_Tumor	Tumor	\N	\N	\N	\N	12-55875
10603	12-88454_Tumor	Tumor	\N	\N	\N	\N	12-88454
10604	12-98328_Tumor	Tumor	\N	\N	\N	\N	12-98328
10605	13-25A_Tumor	Tumor	\N	\N	\N	\N	13-25A
10606	12-762B_Normal	Normal	\N	\N	\N	\N	12-762B
10607	12-168B_Normal	Normal	\N	\N	\N	\N	12-168B
10608	11-75173_Normal	Normal	\N	\N	\N	\N	11-75173
10609	12-167B_Normal	Normal	\N	\N	\N	\N	12-167B
10610	13-47668_Tumor	Tumor	\N	\N	\N	\N	13-47668
10611	13-47668_Tumor	Tumor	\N	\N	\N	\N	13-47668
10612	12-66661_Tumor	Tumor	\N	\N	\N	\N	12-66661
10613	13-47621_Tumor	Tumor	\N	\N	\N	\N	13-47621
10614	13-47621_Tumor	Tumor	\N	\N	\N	\N	13-47621
10615	13-37371_Tumor	Tumor	\N	\N	\N	\N	13-37371
10616	13-37371_Tumor	Tumor	\N	\N	\N	\N	13-37371
10617	DM11_Tumor	Tumor	\N	\N	\N	\N	DM11
10618	DM14_Tumor	Tumor	\N	\N	\N	\N	DM14
10619	13-25110A1_Melanoma	Melanoma	\N	\N	\N	\N	13-25110A1
10620	13-25110A1_Normal	Normal	\N	\N	\N	\N	13-25110A1
10621	13-45163_Normal	Normal	\N	\N	\N	\N	13-45163
10622	Acral-11_Tumor	Tumor	\N	\N	\N	\N	Acral-11
10623	Acral-11_Normal	Normal	\N	\N	\N	\N	Acral-11
10624	Acral-12_Tumor	Tumor	\N	\N	\N	\N	Acral-12
10625	Acral-12_Normal	Normal	\N	\N	\N	\N	Acral-12
10626	02-2599_Tumor	Tumor	\N	\N	\N	\N	02-2599
10627	02-2599_Tumor	Tumor	\N	\N	\N	\N	02-2599
10628	02-2599C_Tumor	Tumor	\N	\N	\N	\N	02-2599C
10629	02-2599_Tumor	Tumor	\N	\N	\N	\N	02-2599
10630	DM48_Normal	Normal	\N	\N	\N	\N	DM48
10631	DM59_Normal	Normal	\N	\N	\N	\N	DM59
10632	DM68_Normal	Normal	\N	\N	\N	\N	DM68
10633	DM95_Tumor	Tumor	\N	\N	\N	\N	DM95
10634	08-46462_Nevus	Nevus	\N	\N	\N	\N	08-46462
10635	08-46462_MIS	MIS	\N	\N	\N	\N	08-46462
10636	08-46462_Normal	Normal	\N	\N	\N	\N	08-46462
10637	08-46462_Melanoma	Melanoma	\N	\N	\N	\N	08-46462
10638	T07-1120_Tumor	Tumor	\N	\N	\N	\N	T07-1120
10639	T09-8069_Tumor	Tumor	\N	\N	\N	\N	T09-8069
10640	T02-16195_Tumor	Tumor	\N	\N	\N	\N	T02-16195
10641	T00-12011_Tumor	Tumor	\N	\N	\N	\N	T00-12011
10642	T06-6855_Tumor	Tumor	\N	\N	\N	\N	T06-6855
10643	12-18832AA_Tumor	Tumor	\N	\N	\N	\N	12-18832AA
10644	CNS52_Tumor	Tumor	\N	\N	\N	\N	CNS52
10645	CNS53_Tumor	Tumor	\N	\N	\N	\N	CNS53
10646	CNS54_Tumor	Tumor	\N	\N	\N	\N	CNS54
10647	CNS57_Tumor	Tumor	\N	\N	\N	\N	CNS57
10648	CNS57_Normal	Normal	\N	\N	\N	\N	CNS57
10649	BN-N1-Tert_Tumor	Tumor	\N	\N	\N	\N	BN-N1-Tert
10650	BN-N2-Tert_Tumor	Tumor	\N	\N	\N	\N	BN-N2-Tert
10651	BN-M1-Tert_Tumor	Tumor	\N	\N	\N	\N	BN-M1-Tert
10652	08-43264_Nevus	Nevus	\N	\N	\N	\N	08-43264
10653	10-58663_Melanoma	Melanoma	\N	\N	\N	\N	10-58663
10654	12-12039B_Tumor	Tumor	\N	\N	\N	\N	12-12039B
10655	12-22776B3_Tumor	Tumor	\N	\N	\N	\N	12-22776B3
10656	99-29482_Tumor	Tumor	\N	\N	\N	\N	99-29482
10657	99-15313_Tumor	Tumor	\N	\N	\N	\N	99-15313
10658	99-885_Tumor	Tumor	\N	\N	\N	\N	99-885
10659	98-37643_Tumor	Tumor	\N	\N	\N	\N	98-37643
10660	13-25288_Tumor	Tumor	\N	\N	\N	\N	13-25288
10661	09-29997_Tumor	Tumor	\N	\N	\N	\N	09-29997
10662	04-11158_Tumor	Tumor	\N	\N	\N	\N	04-11158
10663	UM4_Tumor	Tumor	\N	\N	\N	\N	UM4
10664	UM5_Tumor	Tumor	\N	\N	\N	\N	UM5
10665	08-84352_Melanoma	Melanoma	\N	\N	\N	\N	08-84352
10666	08-84352_Melanoma	Melanoma	\N	\N	\N	\N	08-84352
10667	08-84352_Nevus	Nevus	\N	\N	\N	\N	08-84352
10668	08-84352_Normal	Normal	\N	\N	\N	\N	08-84352
10669	11-88792_Melanoma	Melanoma	\N	\N	\N	\N	11-88792
10670	11-88792_Melanoma	Melanoma	\N	\N	\N	\N	11-88792
10671	11-88792_Nevus	Nevus	\N	\N	\N	\N	11-88792
10672	11-88792_Nevus	Nevus	\N	\N	\N	\N	11-88792
10673	11-88792_Normal	Normal	\N	\N	\N	\N	11-88792
10674	13-74952_Tumor	Tumor	\N	\N	\N	\N	13-74952
10675	13-75067_Tumor	Tumor	\N	\N	\N	\N	13-75067
10676	Spitz_M1_Tumor	Tumor	\N	\N	\N	\N	Spitz_M1
10677	Spitz_M2_(?)_Tumor	Tumor	\N	\N	\N	\N	Spitz_M2_(?)
10678	Spitz_N1_Tumor	Tumor	\N	\N	\N	\N	Spitz_N1
10679	Spitz_N2_Tumor	Tumor	\N	\N	\N	\N	Spitz_N2
10680	Spitz_N3_Tumor	Tumor	\N	\N	\N	\N	Spitz_N3
10681	BN_Normal	Normal	\N	\N	\N	\N	BN
10682	13-159_Tumor	Tumor	\N	\N	\N	\N	13-159
10683	12-43016_Tumor	Tumor	\N	\N	\N	\N	12-43016
10684	13-34291_Tumor	Tumor	\N	\N	\N	\N	13-34291
10685	GAK_DNA_Tumor	Tumor	\N	\N	\N	\N	GAK_DNA
10686	Yurif_DNA_Tumor	Tumor	\N	\N	\N	\N	Yurif_DNA
10687	Acral-11_Tumor	Tumor	\N	\N	\N	\N	Acral-11
10688	Acral-11_Normal	Normal	\N	\N	\N	\N	Acral-11
10689	DPN26_Tumor	Tumor	\N	\N	\N	\N	DPN26
10690	13-47668_Tumor	Tumor	\N	\N	\N	\N	13-47668
10691	13-47668_Tumor	Tumor	\N	\N	\N	\N	13-47668
10692	13-47621_Tumor	Tumor	\N	\N	\N	\N	13-47621
10693	13-47621_Tumor	Tumor	\N	\N	\N	\N	13-47621
10694	13-37371_Tumor	Tumor	\N	\N	\N	\N	13-37371
10695	13-37371_Tumor	Tumor	\N	\N	\N	\N	13-37371
10696	DM45_Tumor	Tumor	\N	\N	\N	\N	DM45
10697	DM58_Tumor	Tumor	\N	\N	\N	\N	DM58
10698	DM1_Tumor	Tumor	\N	\N	\N	\N	DM1
10699	DM2_Tumor	Tumor	\N	\N	\N	\N	DM2
10700	DM45_Tumor	Tumor	\N	\N	\N	\N	DM45
10701	DM79_Tumor	Tumor	\N	\N	\N	\N	DM79
10702	DM93_Tumor	Tumor	\N	\N	\N	\N	DM93
10703	13-2939B_Tumor	Tumor	\N	\N	\N	\N	13-2939B
10704	11-73238A_Tumor	Tumor	\N	\N	\N	\N	11-73238A
10705	99-29482_Tumor	Tumor	\N	\N	\N	\N	99-29482
10706	13-25288_Tumor	Tumor	\N	\N	\N	\N	13-25288
10707	04-11158_Tumor	Tumor	\N	\N	\N	\N	04-11158
10708	10-55707_Tumor	Tumor	\N	\N	\N	\N	10-55707
10709	11-34950_Tumor	Tumor	\N	\N	\N	\N	11-34950
10710	11-8228_Tumor	Tumor	\N	\N	\N	\N	11-8228
10711	11-84681_Tumor	Tumor	\N	\N	\N	\N	11-84681
10712	11-50182_Tumor	Tumor	\N	\N	\N	\N	11-50182
10713	MIN_7_Normal	Normal	\N	\N	\N	\N	MIN_7
10714	MIN_7_Nevus	Nevus	\N	\N	\N	\N	MIN_7
10715	MIN_7_Tumor	Tumor	\N	\N	\N	\N	MIN_7
10716	MIN_8_Normal	Normal	\N	\N	\N	\N	MIN_8
10717	MIN_8_Nevus	Nevus	\N	\N	\N	\N	MIN_8
10718	MIN_8_Tumor	Tumor	\N	\N	\N	\N	MIN_8
10719	501_Mel_Tumor	Tumor	\N	\N	\N	\N	501_Mel
10720	Sk_Mel_1_Tumor	Tumor	\N	\N	\N	\N	Sk_Mel_1
10721	DPN24_Tumor	Tumor	\N	\N	\N	\N	DPN24
10722	DPN28_Tumor	Tumor	\N	\N	\N	\N	DPN28
10723	DPN29_Tumor	Tumor	\N	\N	\N	\N	DPN29
10724	DPN31_Tumor	Tumor	\N	\N	\N	\N	DPN31
10725	DPN33_Tumor	Tumor	\N	\N	\N	\N	DPN33
10726	DPN40_Tumor	Tumor	\N	\N	\N	\N	DPN40
10727	DPN40_Tumor	Tumor	\N	\N	\N	\N	DPN40
10728	DPN41_Tumor	Tumor	\N	\N	\N	\N	DPN41
10729	DPN42_Tumor	Tumor	\N	\N	\N	\N	DPN42
10730	DPN44_Tumor	Tumor	\N	\N	\N	\N	DPN44
10731	DPN45_Tumor	Tumor	\N	\N	\N	\N	DPN45
10732	DPN46_Tumor	Tumor	\N	\N	\N	\N	DPN46
10733	UM_6_Tumor	Tumor	\N	\N	\N	\N	UM_6
10734	Birt_Hogg_Dube_Tumor	Tumor	\N	\N	\N	\N	Birt_Hogg_Dube
10735	13-1939_Tumor	Tumor	\N	\N	\N	\N	13-1939
10736	13-51657_Tumor	Tumor	\N	\N	\N	\N	13-51657
10737	13-89069_Tumor	Tumor	\N	\N	\N	\N	13-89069
10738	11-1051A_Tumor	Tumor	\N	\N	\N	\N	11-1051A
10739	11-5480_Tumor	Tumor	\N	\N	\N	\N	11-5480
10740	10-73024_Tumor	Tumor	\N	\N	\N	\N	10-73024
10741	10-73024_Normal	Normal	\N	\N	\N	\N	10-73024
10742	09-33283_Melanoma	Melanoma	\N	\N	\N	\N	09-33283
10743	09-33283_Melanoma	Melanoma	\N	\N	\N	\N	09-33283
10744	09-33283_Nevus	Nevus	\N	\N	\N	\N	09-33283
10745	09-33283_Nevus	Nevus	\N	\N	\N	\N	09-33283
10746	09-31895_Melanoma	Melanoma	\N	\N	\N	\N	09-31895
10747	09-31895_Melanoma	Melanoma	\N	\N	\N	\N	09-31895
10748	09-31895_Nevus	Nevus	\N	\N	\N	\N	09-31895
10749	09-31895_Nevus	Nevus	\N	\N	\N	\N	09-31895
10750	09-31895_Normal	Normal	\N	\N	\N	\N	09-31895
10751	R29032-05_Tumor	Tumor	\N	\N	\N	\N	R29032-05
10752	R29032-05_Normal	Normal	\N	\N	\N	\N	R29032-05
10753	01-8297_Tumor	Tumor	\N	\N	\N	\N	01-8297
10754	01-8297_Normal	Normal	\N	\N	\N	\N	01-8297
10755	8298-01_Tumor	Tumor	\N	\N	\N	\N	8298-01
10756	8298-01_Normal	Normal	\N	\N	\N	\N	8298-01
10757	08-53951_Melanoma	Melanoma	\N	\N	\N	\N	08-53951
10758	08-53951_Melanoma	Melanoma	\N	\N	\N	\N	08-53951
10759	08-53951_Nevus	Nevus	\N	\N	\N	\N	08-53951
10760	08-53951_Nevus	Nevus	\N	\N	\N	\N	08-53951
10761	13000212_Tumor	Tumor	\N	\N	\N	\N	13000212
10762	8528-05_Tumor	Tumor	\N	\N	\N	\N	8528-05
10763	1286184b_Tumor	Tumor	\N	\N	\N	\N	1286184b
10764	1286184b_Normal	Normal	\N	\N	\N	\N	1286184b
10765	206436_Tumor	Tumor	\N	\N	\N	\N	206436
10766	35942-04_Tumor	Tumor	\N	\N	\N	\N	35942-04
10767	15329-03_Normal	Normal	\N	\N	\N	\N	15329-03
10768	Z1188-03_Tumor	Tumor	\N	\N	\N	\N	Z1188-03
10769	1185-03_Normal	Normal	\N	\N	\N	\N	1185-03
10770	14514-02_Tumor	Tumor	\N	\N	\N	\N	14514-02
10771	15102-02_Normal	Normal	\N	\N	\N	\N	15102-02
10772	9116-05_Tumor	Tumor	\N	\N	\N	\N	9116-05
10773	24516-06_Tumor	Tumor	\N	\N	\N	\N	24516-06
10774	24516-06_Normal	Normal	\N	\N	\N	\N	24516-06
10775	07-3078_Tumor	Tumor	\N	\N	\N	\N	07-3078
10776	B06-37358_Tumor	Tumor	\N	\N	\N	\N	B06-37358
10777	21590_Tumor	Tumor	\N	\N	\N	\N	21590
10778	21590_Normal	Normal	\N	\N	\N	\N	21590
10779	A2A79@_Tumor	Tumor	\N	\N	\N	\N	A2A79@
10780	356A3-075_Tumor	Tumor	\N	\N	\N	\N	356A3-075
10781	20847-09_Normal	Normal	\N	\N	\N	\N	20847-09
10782	525_Tumor	Tumor	\N	\N	\N	\N	525
10783	PMM_23_Tumor	Tumor	\N	\N	\N	\N	PMM_23
10784	PMM_23_Normal	Normal	\N	\N	\N	\N	PMM_23
10785	UM7_Tumor	Tumor	\N	\N	\N	\N	UM7
10786	UM8_Tumor	Tumor	\N	\N	\N	\N	UM8
10787	UM9_Tumor	Tumor	\N	\N	\N	\N	UM9
10788	UM10_Tumor	Tumor	\N	\N	\N	\N	UM10
10789	UM11_Tumor	Tumor	\N	\N	\N	\N	UM11
10790	Xanthoma_Disseminatum_Tumor	Tumor	\N	\N	\N	\N	Xanthoma_Disseminatum
10791	99-15313_Tumor	Tumor	\N	\N	\N	\N	99-15313
10792	98-37643_Tumor	Tumor	\N	\N	\N	\N	98-37643
10793	09-29997_Tumor	Tumor	\N	\N	\N	\N	09-29997
10794	13-94981_Tumor	Tumor	\N	\N	\N	\N	13-94981
10795	13-99411A_Tumor	Tumor	\N	\N	\N	\N	13-99411A
10796	13-94484_Tumor	Tumor	\N	\N	\N	\N	13-94484
10797	DM27_Tumor	Tumor	\N	\N	\N	\N	DM27
10798	DM32_Tumor	Tumor	\N	\N	\N	\N	DM32
10799	DM35_Tumor	Tumor	\N	\N	\N	\N	DM35
10800	DM40_Tumor	Tumor	\N	\N	\N	\N	DM40
10801	11-23681_Melanoma	Melanoma	\N	\N	\N	\N	11-23681
10802	11-23681_Melanoma	Melanoma	\N	\N	\N	\N	11-23681
10803	H01.10457/II_Primary	Primary	\N	\N	\N	\N	Dummer-KF1-Primary
10804	H01.10457/II_Normal	Normal	\N	\N	\N	\N	Dummer-KF1
10805	14.20/II_Met1	Met1	\N	\N	\N	\N	Dummer-KF1-Met1
10806	HS14.18/I_Met2	Met2	\N	\N	\N	\N	Dummer-KF1-Met2
10807	HS14.19/D_Primary	Primary	\N	\N	\N	\N	Dummer-KF2-Primary
10808	HS14.19/D_Nevus	Nevus	\N	\N	\N	\N	Dummer-KF2
10809	HS2014.15/7_Met1	Met1	\N	\N	\N	\N	Dummer-KF2-Met1
10810	HS2014.15/7_Normal	Normal	\N	\N	\N	\N	Dummer-KF2
10811	HS14.16_Primary	Primary	\N	\N	\N	\N	Dummer-KF3-Primary
10812	HS14.16_Normal	Normal	\N	\N	\N	\N	Dummer-KF3
10813	HS14.17/I_Met1	Met1	\N	\N	\N	\N	Dummer-KF3-Met1
10814	Long-TN1_Normal	Normal	\N	\N	\N	\N	Long-TN1
10815	Long-TN1_Tumor	Tumor	\N	\N	\N	\N	Long-TN1
10816	Long-TN2_Normal	Normal	\N	\N	\N	\N	Long-TN2
10817	Long-TN2_Tumor	Tumor	\N	\N	\N	\N	Long-TN2
10818	D326_Tumor	Tumor	\N	\N	\N	\N	D326
10819	D326_Tumor	Tumor	\N	\N	\N	\N	D326
10820	D366_Tumor	Tumor	\N	\N	\N	\N	D366
10821	D366_Tumor	Tumor	\N	\N	\N	\N	D366
10822	DPN48_Tumor	Tumor	\N	\N	\N	\N	DPN48
10823	11-2532_Tumor	Tumor	\N	\N	\N	\N	11-2532
10824	AST-1_Tumor	Tumor	\N	\N	\N	\N	AST-1
10825	08-18595B_Tumor	Tumor	\N	\N	\N	\N	08-18595B
10826	13-60273_Tumor	Tumor	\N	\N	\N	\N	13-60273
10827	12-52454_Tumor	Tumor	\N	\N	\N	\N	12-52454
10828	12-75125_Tumor	Tumor	\N	\N	\N	\N	12-75125
10829	12-98235A_Tumor	Tumor	\N	\N	\N	\N	12-98235A
10830	13-3619B_Tumor	Tumor	\N	\N	\N	\N	13-3619B
10831	13-67500AL_Normal	Normal	\N	\N	\N	\N	13-67500AL
10832	13-19205_Tumor	Tumor	\N	\N	\N	\N	13-19205
10833	13-48330_Tumor	Tumor	\N	\N	\N	\N	13-48330
10834	13-11086_Tumor	Tumor	\N	\N	\N	\N	13-11086
10835	13-15966_Tumor	Tumor	\N	\N	\N	\N	13-15966
10836	13-39228_Tumor	Tumor	\N	\N	\N	\N	13-39228
10837	13-45942_Tumor	Tumor	\N	\N	\N	\N	13-45942
10838	13-49600_Tumor	Tumor	\N	\N	\N	\N	13-49600
10839	13-59640_Tumor	Tumor	\N	\N	\N	\N	13-59640
10840	13-67817_Tumor	Tumor	\N	\N	\N	\N	13-67817
10841	SP-12-5612(1K)_Normal	Normal	\N	\N	\N	\N	SP-12-5612(1K)
10842	SP-13-14992(1A)_Tumor	Tumor	\N	\N	\N	\N	SP-13-14992(1A)
10843	SP-12-2294-2(2A)_Normal	Normal	\N	\N	\N	\N	SP-12-2294-2(2A)
10844	SP-13-17075(1B)_Tumor	Tumor	\N	\N	\N	\N	SP-13-17075(1B)
10845	SP-42-10361(1A)_Normal	Normal	\N	\N	\N	\N	SP-42-10361(1A)
10846	SP-13-1038(1A)_Tumor	Tumor	\N	\N	\N	\N	SP-13-1038(1A)
10847	S13-13286A6_Tumor	Tumor	\N	\N	\N	\N	S13-13286A6
10848	S13-13286A6_Normal	Normal	\N	\N	\N	\N	S13-13286A6
10849	S11-20884A-A1_Tumor	Tumor	\N	\N	\N	\N	S11-20884A-A1
10850	S11-20884A-A1_Normal	Normal	\N	\N	\N	\N	S11-20884A-A1
10851	S12-6218A-D3_Tumor	Tumor	\N	\N	\N	\N	S12-6218A-D3
10852	S12-6218A-D3_Normal	Normal	\N	\N	\N	\N	S12-6218A-D3
10853	ZS06-11249A-C2_Tumor	Tumor	\N	\N	\N	\N	ZS06-11249A-C2
10854	S12-26125A2_Tumor	Tumor	\N	\N	\N	\N	S12-26125A2
10855	S12-28585A6_Tumor	Tumor	\N	\N	\N	\N	S12-28585A6
10856	S11-2018B5_Tumor	Tumor	\N	\N	\N	\N	S11-2018B5
10857	S13-11748F5_Tumor	Tumor	\N	\N	\N	\N	S13-11748F5
10858	S12-7250E3_Tumor	Tumor	\N	\N	\N	\N	S12-7250E3
10859	S13-3401B3_Tumor	Tumor	\N	\N	\N	\N	S13-3401B3
10860	S13-12947A2_Tumor	Tumor	\N	\N	\N	\N	S13-12947A2
10861	S13-18444A16_Tumor	Tumor	\N	\N	\N	\N	S13-18444A16
10862	ZS07-1210F6_Tumor	Tumor	\N	\N	\N	\N	ZS07-1210F6
10863	ZS10-11930B12_Tumor	Tumor	\N	\N	\N	\N	ZS10-11930B12
10864	S12-28988_Tumor	Tumor	\N	\N	\N	\N	S12-28988
10865	SSS13-1652B2_Tumor	Tumor	\N	\N	\N	\N	SSS13-1652B2
10866	S13-5249_Tumor	Tumor	\N	\N	\N	\N	S13-5249
10867	356A3-075_Tumor	Tumor	\N	\N	\N	\N	356A3-075
10868	20847-09_Normal	Normal	\N	\N	\N	\N	20847-09
10869	London-L1_Normal	Normal	\N	\N	\N	\N	London-L1
10870	London-L1_Nevus	Nevus	\N	\N	\N	\N	London-L1
10871	London-L1_MIS	MIS	\N	\N	\N	\N	London-L1
10872	London-L1_Melanoma	Melanoma	\N	\N	\N	\N	London-L1
10873	London-L14_Normal	Normal	\N	\N	\N	\N	London-L14
10874	London-L14_Nevus	Nevus	\N	\N	\N	\N	London-L14
10875	London-L14_Nevus	Nevus	\N	\N	\N	\N	London-L14
10876	London-L14_Melanoma	Melanoma	\N	\N	\N	\N	London-L14
10877	London-L14_Melanoma	Melanoma	\N	\N	\N	\N	London-L14
10878	London-L14_Melanoma	Melanoma	\N	\N	\N	\N	London-L14
10879	London-L14C_Normal	Normal	\N	\N	\N	\N	London-L14C
10880	London-L14C_Intermediate	Intermediate	\N	\N	\N	\N	London-L14C
10881	08-79358_Melanoma	Melanoma	\N	\N	\N	\N	08-79358
10882	08-79358_Melanoma	Melanoma	\N	\N	\N	\N	08-79358
10883	08-79358_Nevus	Nevus	\N	\N	\N	\N	08-79358
10884	08-79358_Normal	Normal	\N	\N	\N	\N	08-79358
10885	09-45509_Melanoma	Melanoma	\N	\N	\N	\N	09-45509
10886	09-45509_Melanoma	Melanoma	\N	\N	\N	\N	09-45509
10887	09-45509_Nevus	Nevus	\N	\N	\N	\N	09-45509
10888	09-45509_Normal	Normal	\N	\N	\N	\N	09-45509
10889	DM50_Tumor	Tumor	\N	\N	\N	\N	DM50
10890	DM56_Tumor	Tumor	\N	\N	\N	\N	DM56
10891	11-94204_Melanoma	Melanoma	\N	\N	\N	\N	11-94204
10892	11-94204_Nevus	Nevus	\N	\N	\N	\N	11-94204
10893	11-94204_Normal	Normal	\N	\N	\N	\N	11-94204
10894	London-L10_Normal	Normal	\N	\N	\N	\N	London-L10
10895	London-L10_MIS	MIS	\N	\N	\N	\N	London-L10
10896	London-L10_Melanoma	Melanoma	\N	\N	\N	\N	London-L10
10897	London-L10_Intermediate	Intermediate	\N	\N	\N	\N	London-L10
10898	London-L12_Normal	Normal	\N	\N	\N	\N	London-L12
10899	London-L12_Nevus	Nevus	\N	\N	\N	\N	London-L12
10900	London-L12_Intermediate	Intermediate	\N	\N	\N	\N	London-L12
10901	London-L16_Nevus	Nevus	\N	\N	\N	\N	London-L16
10902	London-L16_Melanoma	Melanoma	\N	\N	\N	\N	London-L16
10903	London-L16A_Normal	Normal	\N	\N	\N	\N	London-L16A
10904	London-L16A_Nevus	Nevus	\N	\N	\N	\N	London-L16A
10905	London-L16A_Melanoma	Melanoma	\N	\N	\N	\N	London-L16A
10906	London-L16B_Intermediate	Intermediate	\N	\N	\N	\N	London-L16B
10907	London-L16B_Intermediate	Intermediate	\N	\N	\N	\N	London-L16B
10908	London-L16B_Normal	Normal	\N	\N	\N	\N	London-L16B
10909	DM15_Tumor	Tumor	\N	\N	\N	\N	DM15
10910	DM19_Tumor	Tumor	\N	\N	\N	\N	DM19
10911	DM19_Tumor	Tumor	\N	\N	\N	\N	DM19
10912	DM46_Tumor	Tumor	\N	\N	\N	\N	DM46
10913	140038340_Tumor	Tumor	\N	\N	\N	\N	140038340
10914	140092090_Normal	Normal	\N	\N	\N	\N	140092090
10915	UM13_Tumor	Tumor	\N	\N	\N	\N	UM13
10916	UM14_Tumor	Tumor	\N	\N	\N	\N	UM14
10917	UM16_Tumor	Tumor	\N	\N	\N	\N	UM16
10918	London-L17_Normal	Normal	\N	\N	\N	\N	London-L17
10919	London-L17_Nevus	Nevus	\N	\N	\N	\N	London-L17
10920	London-L17_Nevus	Nevus	\N	\N	\N	\N	London-L17
10921	London-L17_Melanoma	Melanoma	\N	\N	\N	\N	London-L17
10922	London-L17_Melanoma	Melanoma	\N	\N	\N	\N	London-L17
10923	GAK_Tumor	Tumor	\N	\N	\N	\N	GAK
10924	Yurif_Tumor	Tumor	\N	\N	\N	\N	Yurif
10925	08-53951_Nevus	Nevus	\N	\N	\N	\N	08-53951
10926	08-53951_M1	M1	\N	\N	\N	\N	08-53951
10927	08-53951_M2	M2	\N	\N	\N	\N	08-53951
10928	London-L18_Normal	Normal	\N	\N	\N	\N	London-L18
10929	London-L18_Nevus	Nevus	\N	\N	\N	\N	London-L18
10930	London-L18_Melanoma	Melanoma	\N	\N	\N	\N	London-L18
10931	London-L18_Melanoma	Melanoma	\N	\N	\N	\N	London-L18
10932	London-L21_MIS	MIS	\N	\N	\N	\N	London-L21
10933	London-L21_Intermediate	Intermediate	\N	\N	\N	\N	London-L21
10934	London-L21_Normal	Normal	\N	\N	\N	\N	London-L21
10935	14-16247_Tumor	Tumor	\N	\N	\N	\N	14-16247
10936	13-35959_Tumor	Tumor	\N	\N	\N	\N	13-35959
10937	13-102610_Tumor	Tumor	\N	\N	\N	\N	13-102610
10938	13-99417_Tumor	Tumor	\N	\N	\N	\N	13-99417
10939	13-98534_Tumor	Tumor	\N	\N	\N	\N	13-98534
10940	13-32982A_Tumor	Tumor	\N	\N	\N	\N	13-32982A
10941	13-9916_Tumor	Tumor	\N	\N	\N	\N	13-9916
10942	11-44609F_Tumor	Tumor	\N	\N	\N	\N	11-44609F
10943	12-98575A1_Tumor	Tumor	\N	\N	\N	\N	12-98575A1
10944	DM60_Tumor	Tumor	\N	\N	\N	\N	DM60
10945	DM61_Tumor	Tumor	\N	\N	\N	\N	DM61
10946	DM62_Tumor	Tumor	\N	\N	\N	\N	DM62
10947	DM63_Tumor	Tumor	\N	\N	\N	\N	DM63
10948	DM66_Tumor	Tumor	\N	\N	\N	\N	DM66
10949	DM67_Tumor	Tumor	\N	\N	\N	\N	DM67
10950	DM69_Tumor	Tumor	\N	\N	\N	\N	DM69
10951	DM70_Tumor	Tumor	\N	\N	\N	\N	DM70
10952	DM81_Tumor	Tumor	\N	\N	\N	\N	DM81
10953	London-L2_Normal	Normal	\N	\N	\N	\N	London-L2
10954	London-L2_Intermediate	Intermediate	\N	\N	\N	\N	London-L2
10955	London-L3_Normal	Normal	\N	\N	\N	\N	London-L3
10956	London-L3_Intermediate	Intermediate	\N	\N	\N	\N	London-L3
10957	S12-27617B9_Normal	Normal	\N	\N	\N	\N	S12-27617B9
10958	S12-25164A_Tumor	Tumor	\N	\N	\N	\N	S12-25164A
10959	S12-25164C1_Tumor	Tumor	\N	\N	\N	\N	S12-25164C1
10960	London-L19_Normal	Normal	\N	\N	\N	\N	London-L19
10961	London-L19_Nevus	Nevus	\N	\N	\N	\N	London-L19
10962	London-L19_Melanoma	Melanoma	\N	\N	\N	\N	London-L19
10963	London-L19E_Normal	Normal	\N	\N	\N	\N	London-L19E
10964	London-L19E_Nevus	Nevus	\N	\N	\N	\N	London-L19E
10965	London-L19E_Melanoma	Melanoma	\N	\N	\N	\N	London-L19E
10966	London-L22_MIS	MIS	\N	\N	\N	\N	London-L22
10967	London-L22_Melanoma	Melanoma	\N	\N	\N	\N	London-L22
10968	London-L22_Normal	Normal	\N	\N	\N	\N	London-L22
10969	London-L23_Melanoma	Melanoma	\N	\N	\N	\N	London-L23
10970	London-L23C_Normal	Normal	\N	\N	\N	\N	London-L23C
10971	London-L23C_Melanoma	Melanoma	\N	\N	\N	\N	London-L23C
10972	London-L23D_Normal	Normal	\N	\N	\N	\N	London-L23D
10973	London-L23D_Intermediate	Intermediate	\N	\N	\N	\N	London-L23D
10974	London-L6_Normal	Normal	\N	\N	\N	\N	London-L6
10975	London-L6_Nevus	Nevus	\N	\N	\N	\N	London-L6
10976	London-L6_Nevus	Nevus	\N	\N	\N	\N	London-L6
10977	XD-2_Tumor	Tumor	\N	\N	\N	\N	XD-2
10978	XD-2_Normal	Normal	\N	\N	\N	\N	XD-2
10979	SP-13-006364_Normal	Normal	\N	\N	\N	\N	SP-13-006364
10980	SP-14-001249_Tumor	Tumor	\N	\N	\N	\N	SP-14-001249
10981	SP-13-0185993A_Normal	Normal	\N	\N	\N	\N	SP-13-0185993A
10982	SP-13-0185992B_Tumor	Tumor	\N	\N	\N	\N	SP-13-0185992B
10983	SP-12-003309B_Normal	Normal	\N	\N	\N	\N	SP-12-003309B
10984	SP-13-0212981A_Tumor	Tumor	\N	\N	\N	\N	SP-13-0212981A
10985	SP-13-0068754A_Normal	Normal	\N	\N	\N	\N	SP-13-0068754A
10986	SP-13-0068751C_Tumor	Tumor	\N	\N	\N	\N	SP-13-0068751C
10987	SP-07-0116602_Normal	Normal	\N	\N	\N	\N	SP-07-0116602
10988	12GS-2466_Tumor	Tumor	\N	\N	\N	\N	12GS-2466
10989	SP-09-0150202A_Normal	Normal	\N	\N	\N	\N	SP-09-0150202A
10990	SP-13-006535C_Tumor	Tumor	\N	\N	\N	\N	SP-13-006535C
10991	SP-10-003167A_Normal	Normal	\N	\N	\N	\N	SP-10-003167A
10992	SP-13-009897_Tumor	Tumor	\N	\N	\N	\N	SP-13-009897
10993	SP-12-0087723B_Normal	Normal	\N	\N	\N	\N	SP-12-0087723B
10994	SP-12-020017C_Tumor	Tumor	\N	\N	\N	\N	SP-12-020017C
11228	57715138_Tumor	Tumor	\N	\N	\N	\N	57715138
10995	SP-12-0032671A_Normal	Normal	\N	\N	\N	\N	SP-12-0032671A
10996	SP-13-006337A_Tumor	Tumor	\N	\N	\N	\N	SP-13-006337A
10997	SP-12-0228802A_Normal	Normal	\N	\N	\N	\N	SP-12-0228802A
10998	SP-12-0228801A_Tumor	Tumor	\N	\N	\N	\N	SP-12-0228801A
10999	SP-12-0146612A_Normal	Normal	\N	\N	\N	\N	SP-12-0146612A
11000	SP-12-01466111A_Tumor	Tumor	\N	\N	\N	\N	SP-12-01466111A
11001	SP-10-004335_Normal	Normal	\N	\N	\N	\N	SP-10-004335
11002	SP-13-000848_Tumor	Tumor	\N	\N	\N	\N	SP-13-000848
11003	M230_Tumor	Tumor	\N	\N	\N	\N	M230
11004	M257_Tumor	Tumor	\N	\N	\N	\N	M257
11005	M285_Tumor	Tumor	\N	\N	\N	\N	M285
11006	M368_Tumor	Tumor	\N	\N	\N	\N	M368
11007	M375_Tumor	Tumor	\N	\N	\N	\N	M375
11008	M418_Tumor	Tumor	\N	\N	\N	\N	M418
11009	C8161_Tumor	Tumor	\N	\N	\N	\N	C8161
11010	London-L4_Normal	Normal	\N	\N	\N	\N	London-L4
11011	London-L4_Nevus	Nevus	\N	\N	\N	\N	London-L4
11012	London-L5_Normal	Normal	\N	\N	\N	\N	London-L5
11013	London-L5_Nevus	Nevus	\N	\N	\N	\N	London-L5
11014	London-L8_Normal	Normal	\N	\N	\N	\N	London-L8
11015	London-L8_Nevus	Nevus	\N	\N	\N	\N	London-L8
11016	London-L9_Normal	Normal	\N	\N	\N	\N	London-L9
11017	London-L9_Intermediate	Intermediate	\N	\N	\N	\N	London-L9
11018	London-L13_Normal	Normal	\N	\N	\N	\N	London-L13
11019	London-L13_Intermediate	Intermediate	\N	\N	\N	\N	London-L13
11020	London-L13_Intermediate	Intermediate	\N	\N	\N	\N	London-L13
11021	London-L15_Nevus	Nevus	\N	\N	\N	\N	London-L15
11022	London-L15_Melanoma	Melanoma	\N	\N	\N	\N	London-L15
11023	1212_Tumor	Tumor	\N	\N	\N	\N	1212
11024	1213_Tumor	Tumor	\N	\N	\N	\N	1213
11025	1214_Tumor	Tumor	\N	\N	\N	\N	1214
11026	3860_Tumor	Tumor	\N	\N	\N	\N	3860
11027	R29032-05_Tumor	Tumor	\N	\N	\N	\N	R29032-05
11028	01-8297_Tumor	Tumor	\N	\N	\N	\N	01-8297
11029	8298-01_Tumor	Tumor	\N	\N	\N	\N	8298-01
11030	Z1188-03_Tumor	Tumor	\N	\N	\N	\N	Z1188-03
11031	24516-06_Tumor	Tumor	\N	\N	\N	\N	24516-06
11032	UM17_Tumor	Tumor	\N	\N	\N	\N	UM17
11033	S12-23475A6_Normal	Normal	\N	\N	\N	\N	S12-23475A6
11034	S12-23475A4_Tumor	Tumor	\N	\N	\N	\N	S12-23475A4
11035	S12-23475C1_Tumor	Tumor	\N	\N	\N	\N	S12-23475C1
11036	13-21725_Normal	Normal	\N	\N	\N	\N	13-21725
11037	SP-14-68521D_Tumor	Tumor	\N	\N	\N	\N	SP-14-68521D
11038	SP-13-208365A_Normal	Normal	\N	\N	\N	\N	SP-13-208365A
11039	SP-14-36134A_Tumor	Tumor	\N	\N	\N	\N	SP-14-36134A
11040	SP-14-73676A_Normal	Normal	\N	\N	\N	\N	SP-14-73676A
11041	SP-14-73671M_Tumor	Tumor	\N	\N	\N	\N	SP-14-73671M
11042	SP-14-7691A_Normal	Normal	\N	\N	\N	\N	SP-14-7691A
11043	SP-14-7691A_Tumor	Tumor	\N	\N	\N	\N	SP-14-7691A
11044	WM3928F_Tumor	Tumor	\N	\N	\N	\N	WM3928F
11045	C037_Tumor	Tumor	\N	\N	\N	\N	C037
11046	C022_Tumor	Tumor	\N	\N	\N	\N	C022
11047	London-L20_Melanoma	Melanoma	\N	\N	\N	\N	London-L20
11048	London-L20_Normal	Normal	\N	\N	\N	\N	London-L20
11049	London-L20_Nevus	Nevus	\N	\N	\N	\N	London-L20
11050	London-L15_Normal	Normal	\N	\N	\N	\N	London-L15
11051	London-L23C_Nevus	Nevus	\N	\N	\N	\N	London-L23C
11052	UM15_Tumor	Tumor	\N	\N	\N	\N	UM15
11053	UM19_Tumor	Tumor	\N	\N	\N	\N	UM19
11054	UM20_Tumor	Tumor	\N	\N	\N	\N	UM20
11055	CP-1_Tumor	Tumor	\N	\N	\N	\N	CP-1
11056	CP-2_Tumor	Tumor	\N	\N	\N	\N	CP-2
11057	CP-3_Tumor	Tumor	\N	\N	\N	\N	CP-3
11058	CP-4_Tumor	Tumor	\N	\N	\N	\N	CP-4
11059	CP-5_Tumor	Tumor	\N	\N	\N	\N	CP-5
11060	CP-6_Tumor	Tumor	\N	\N	\N	\N	CP-6
11061	14-18_Tumor	Tumor	\N	\N	\N	\N	14-18
11062	14-19_Tumor	Tumor	\N	\N	\N	\N	14-19
11063	14-21_Tumor	Tumor	\N	\N	\N	\N	14-21
11064	XD-1_Tumor	Tumor	\N	\N	\N	\N	XD-1
11065	XD-1.1_Tumor	Tumor	\N	\N	\N	\N	XD-1.1
11066	PMM-8_Tumor	Tumor	\N	\N	\N	\N	PMM-8
11067	Long-TN10_Normal	Normal	\N	\N	\N	\N	Long-TN10
11068	Long-TN10_Tumor	Tumor	\N	\N	\N	\N	Long-TN10
11069	Long-TN11_Normal	Normal	\N	\N	\N	\N	Long-TN11
11070	Long-TN11_Tumor	Tumor	\N	\N	\N	\N	Long-TN11
11071	JBP-3_Normal	Normal	\N	\N	\N	\N	JBP-3
11072	JBP-3-MM_Tumor	Tumor	\N	\N	\N	\N	JBP-3-MM
11073	JBP-3-Met1_Tumor	Tumor	\N	\N	\N	\N	JBP-3-Met1
11074	S12-15765B3_Tumor	Tumor	\N	\N	\N	\N	S12-15765B3
11075	S12-4365A8_Normal	Normal	\N	\N	\N	\N	S12-4365A8
11076	S12-4365A7_Tumor	Tumor	\N	\N	\N	\N	S12-4365A7
11077	S12-4365B1_Tumor	Tumor	\N	\N	\N	\N	S12-4365B1
11078	S12-4365C1_Tumor	Tumor	\N	\N	\N	\N	S12-4365C1
11079	S12-9606C4_Normal	Normal	\N	\N	\N	\N	S12-9606C4
11080	S12-9606EE_Tumor	Tumor	\N	\N	\N	\N	S12-9606EE
11081	S12-9606A2_Tumor	Tumor	\N	\N	\N	\N	S12-9606A2
11082	ZS10-972C2_Normal	Normal	\N	\N	\N	\N	ZS10-972C2
11083	ZS10-972A9_Tumor	Tumor	\N	\N	\N	\N	ZS10-972A9
11084	JBP-7-Met_Tumor	Tumor	\N	\N	\N	\N	JBP-7-Met
11085	ZS10-1843A5_Normal	Normal	\N	\N	\N	\N	ZS10-1843A5
11086	ZS10-8439A4_Tumor	Tumor	\N	\N	\N	\N	ZS10-8439A4
11087	ZS10-1843A4_Tumor	Tumor	\N	\N	\N	\N	ZS10-1843A4
11088	ZS10-10558B1_Normal	Normal	\N	\N	\N	\N	ZS10-10558B1
11089	ZS10-10558A10_Tumor	Tumor	\N	\N	\N	\N	ZS10-10558A10
11090	ZS10-10558C1_Tumor	Tumor	\N	\N	\N	\N	ZS10-10558C1
11091	ZS10-3560F1_Normal	Normal	\N	\N	\N	\N	ZS10-3560F1
11092	ZS10-3560A3_Tumor	Tumor	\N	\N	\N	\N	ZS10-3560A3
11093	ZS10-3560C1_Tumor	Tumor	\N	\N	\N	\N	ZS10-3560C1
11094	UM23_Tumor	Tumor	\N	\N	\N	\N	UM23
11095	UM24_Tumor	Tumor	\N	\N	\N	\N	UM24
11096	UM25_Tumor	Tumor	\N	\N	\N	\N	UM25
11097	UM26_Tumor	Tumor	\N	\N	\N	\N	UM26
11098	TCR-Beta-1_Tumor	Tumor	\N	\N	\N	\N	TCR-Beta-1
11099	TCR-Beta-2_Tumor	Tumor	\N	\N	\N	\N	TCR-Beta-2
11100	CP1-80_Tumor	Tumor	\N	\N	\N	\N	CP1-80
11101	CP1-40_Tumor	Tumor	\N	\N	\N	\N	CP1-40
11102	CP1-20_Tumor	Tumor	\N	\N	\N	\N	CP1-20
11103	CP1-10_Tumor	Tumor	\N	\N	\N	\N	CP1-10
11104	CP1-5_Tumor	Tumor	\N	\N	\N	\N	CP1-5
11105	CP1_Normal	Normal	\N	\N	\N	\N	CP1
11106	SMU10-0457_Tumor	Tumor	\N	\N	\N	\N	SMU10-0457
11107	SMU10-0206_Tumor	Tumor	\N	\N	\N	\N	SMU10-0206
11108	SMU10-0240_Tumor	Tumor	\N	\N	\N	\N	SMU10-0240
11109	SCC10-0092_Tumor	Tumor	\N	\N	\N	\N	SCC10-0092
11110	MASCRI-432_Tumor	Tumor	\N	\N	\N	\N	MASCRI-432
11111	RPA08-0209_Tumor	Tumor	\N	\N	\N	\N	RPA08-0209
11112	RPA08-0315_Tumor	Tumor	\N	\N	\N	\N	RPA08-0315
11113	NZM52_Tumor	Tumor	\N	\N	\N	\N	NZM52
11114	NZM40_Tumor	Tumor	\N	\N	\N	\N	NZM40
11115	NZM91_Tumor	Tumor	\N	\N	\N	\N	NZM91
11116	SP-13-198211A_Tumor	Tumor	\N	\N	\N	\N	SP-13-198211A
11117	RNS11P15316B1_Normal	Normal	\N	\N	\N	\N	RNS11P15316B1
11118	9246581-A3_Tumor	Tumor	\N	\N	\N	\N	9246581-A3
11119	9246581-A6_Normal	Normal	\N	\N	\N	\N	9246581-A6
11120	DHM4855-14MP_Tumor	Tumor	\N	\N	\N	\N	DHM4855-14MP
11121	SNPN08289D_Normal	Normal	\N	\N	\N	\N	SNPN08289D
11122	SP-10-143551E_Tumor	Tumor	\N	\N	\N	\N	SP-10-143551E
11123	SP-10-143552A_Normal	Normal	\N	\N	\N	\N	SP-10-143552A
11124	04-SW-12-31366B1_Tumor	Tumor	\N	\N	\N	\N	04-SW-12-31366B1
11125	04-SW-12-31366B6_Normal	Normal	\N	\N	\N	\N	04-SW-12-31366B6
11126	SP-13-63011A_Tumor	Tumor	\N	\N	\N	\N	SP-13-63011A
11127	SP-11-160493A_Normal	Normal	\N	\N	\N	\N	SP-11-160493A
11128	SP-13-87981B_Tumor	Tumor	\N	\N	\N	\N	SP-13-87981B
11129	SP-11-40641B_Normal	Normal	\N	\N	\N	\N	SP-11-40641B
11130	SP-14-125801B_Tumor	Tumor	\N	\N	\N	\N	SP-14-125801B
11131	SP-14-125802A_Normal	Normal	\N	\N	\N	\N	SP-14-125802A
11132	WCRS97-025628_Tumor	Tumor	\N	\N	\N	\N	WCRS97-025628
11133	SCHS10-026422_Tumor	Tumor	\N	\N	\N	\N	SCHS10-026422
11134	SROS12-001198_Tumor	Tumor	\N	\N	\N	\N	SROS12-001198
11135	SROS09-001574_Tumor	Tumor	\N	\N	\N	\N	SROS09-001574
11136	SCHS09-005840-B5_Tumor	Tumor	\N	\N	\N	\N	SCHS09-005840-B5
11137	SACS05-011507_Tumor	Tumor	\N	\N	\N	\N	SACS05-011507
11138	FRSS09-009402-A1_Tumor	Tumor	\N	\N	\N	\N	FRSS09-009402-A1
11139	RCHS07-000380-B1_Tumor	Tumor	\N	\N	\N	\N	RCHS07-000380-B1
11140	SROS11-005030_Tumor	Tumor	\N	\N	\N	\N	SROS11-005030
11141	VALS09-000266_Tumor	Tumor	\N	\N	\N	\N	VALS09-000266
11142	SFOS09-007093_Tumor	Tumor	\N	\N	\N	\N	SFOS09-007093
11143	FRSS09-008805_Tumor	Tumor	\N	\N	\N	\N	FRSS09-008805
11144	RCHS06-004567_Tumor	Tumor	\N	\N	\N	\N	RCHS06-004567
11145	VALS05-014946-E_Tumor	Tumor	\N	\N	\N	\N	VALS05-014946-E
11146	SCHS08-007754_Tumor	Tumor	\N	\N	\N	\N	SCHS08-007754
11147	SFOS12-018173_Tumor	Tumor	\N	\N	\N	\N	SFOS12-018173
11148	SROS00-001103_Tumor	Tumor	\N	\N	\N	\N	SROS00-001103
11149	MTZS94-007340_Tumor	Tumor	\N	\N	\N	\N	MTZS94-007340
11150	SFOS94-003116_Tumor	Tumor	\N	\N	\N	\N	SFOS94-003116
11151	SACS93-027850_Tumor	Tumor	\N	\N	\N	\N	SACS93-027850
11152	SCLS91-006557_Tumor	Tumor	\N	\N	\N	\N	SCLS91-006557
11153	OAKS90-012369_Tumor	Tumor	\N	\N	\N	\N	OAKS90-012369
11154	HAYS02-005731_Tumor	Tumor	\N	\N	\N	\N	HAYS02-005731
11155	SRFS97-002805_Tumor	Tumor	\N	\N	\N	\N	SRFS97-002805
11156	VALS03-019832_Tumor	Tumor	\N	\N	\N	\N	VALS03-019832
11157	SSCS03-014369_Tumor	Tumor	\N	\N	\N	\N	SSCS03-014369
11158	RCHS01-003684_Tumor	Tumor	\N	\N	\N	\N	RCHS01-003684
11159	WCRS99-012800_Tumor	Tumor	\N	\N	\N	\N	WCRS99-012800
11160	HAYS90-005154_Tumor	Tumor	\N	\N	\N	\N	HAYS90-005154
11161	SFOS00-016989_Tumor	Tumor	\N	\N	\N	\N	SFOS00-016989
11162	VALS03-007457_Tumor	Tumor	\N	\N	\N	\N	VALS03-007457
11163	SFO93-005184_Tumor	Tumor	\N	\N	\N	\N	SFO93-005184
11164	DHM50691-14MP5C_Tumor	Tumor	\N	\N	\N	\N	DHM50691-14MP5C
11165	DHM50691-14MP3_Normal	Normal	\N	\N	\N	\N	DHM50691-14MP3
11166	RNS14P13907B1_Tumor	Tumor	\N	\N	\N	\N	RNS14P13907B1
11167	SP-10-197431A_Normal	Normal	\N	\N	\N	\N	SP-10-197431A
11168	DHM57444-14MP_Tumor	Tumor	\N	\N	\N	\N	DHM57444-14MP
11169	SP-12-177322A_Normal	Normal	\N	\N	\N	\N	SP-12-177322A
11170	DHM94457-13SK_Tumor	Tumor	\N	\N	\N	\N	DHM94457-13SK
11171	DHM48742-12MPE_Normal	Normal	\N	\N	\N	\N	DHM48742-12MPE
11172	Laverty13-88354_Tumor	Tumor	\N	\N	\N	\N	Laverty13-88354
11173	ICPMR19684.13A11_Normal	Normal	\N	\N	\N	\N	ICPMR19684.13A11
11174	SP-13-15691B_Tumor	Tumor	\N	\N	\N	\N	SP-13-15691B
11175	SP-13-15691D_Normal	Normal	\N	\N	\N	\N	SP-13-15691D
11176	57059699_Tumor	Tumor	\N	\N	\N	\N	57059699
11177	57269600_Tumor	Tumor	\N	\N	\N	\N	57269600
11178	57213442_Tumor	Tumor	\N	\N	\N	\N	57213442
11179	57346060_Tumor	Tumor	\N	\N	\N	\N	57346060
11180	SROS10-009251_Tumor	Tumor	\N	\N	\N	\N	SROS10-009251
11181	FRSS99-007026_Tumor	Tumor	\N	\N	\N	\N	FRSS99-007026
11182	SCLS04-001045_Tumor	Tumor	\N	\N	\N	\N	SCLS04-001045
11183	OAKS96-014392-G_Tumor	Tumor	\N	\N	\N	\N	OAKS96-014392-G
11184	OAKS96-022398_Tumor	Tumor	\N	\N	\N	\N	OAKS96-022398
11185	OAK84-008979-B_Tumor	Tumor	\N	\N	\N	\N	OAK84-008979-B
11186	ROSS09-022626-A1_Tumor	Tumor	\N	\N	\N	\N	ROSS09-022626-A1
11187	SCHS11-018842-A1_Tumor	Tumor	\N	\N	\N	\N	SCHS11-018842-A1
11188	SSCS03-004945_Tumor	Tumor	\N	\N	\N	\N	SSCS03-004945
11189	WCRS02-022688_Tumor	Tumor	\N	\N	\N	\N	WCRS02-022688
11190	SACS02-020334_Tumor	Tumor	\N	\N	\N	\N	SACS02-020334
11191	HAYS98-001046_Tumor	Tumor	\N	\N	\N	\N	HAYS98-001046
11192	SACS88-019073_Tumor	Tumor	\N	\N	\N	\N	SACS88-019073
11193	SACS87-010145_Tumor	Tumor	\N	\N	\N	\N	SACS87-010145
11194	STRS91-006237_Tumor	Tumor	\N	\N	\N	\N	STRS91-006237
11195	SSCS92-009981_Tumor	Tumor	\N	\N	\N	\N	SSCS92-009981
11196	14-59304A_Normal	Normal	\N	\N	\N	\N	14-59304A
11197	14-59304A_Nevus	Nevus	\N	\N	\N	\N	14-59304A
11198	13-48020_Normal	Normal	\N	\N	\N	\N	13-48020
11199	13-48020_Nevus	Nevus	\N	\N	\N	\N	13-48020
11200	14-13499_Normal	Normal	\N	\N	\N	\N	14-13499
11201	14-13499_Nevus	Nevus	\N	\N	\N	\N	14-13499
11202	13-64515B_Normal	Normal	\N	\N	\N	\N	13-64515B
11203	13-64515B_Nevus	Nevus	\N	\N	\N	\N	13-64515B
11204	13-64515B_Tumor	Tumor	\N	\N	\N	\N	13-64515B
11205	14-22939_Nevus	Nevus	\N	\N	\N	\N	14-22939
11206	14-22939_Tumor	Tumor	\N	\N	\N	\N	14-22939
11207	13-61146_Normal	Normal	\N	\N	\N	\N	13-61146
11208	13-61146_Nevus	Nevus	\N	\N	\N	\N	13-61146
11209	13-61146_Tumor	Tumor	\N	\N	\N	\N	13-61146
11210	57001550_Tumor	Tumor	\N	\N	\N	\N	57001550
11211	57291680_Tumor	Tumor	\N	\N	\N	\N	57291680
11212	London-L3_Tumor	Tumor	\N	\N	\N	\N	London-L3
11213	London-L13_Tumor	Tumor	\N	\N	\N	\N	London-L13
11214	London-L3_Tumor	Tumor	\N	\N	\N	\N	London-L3
11215	London-L3_Tumor	Tumor	\N	\N	\N	\N	London-L3
11216	London-L3_Tumor	Tumor	\N	\N	\N	\N	London-L3
11217	London-L3_Tumor	Tumor	\N	\N	\N	\N	London-L3
11218	London-L13_Tumor	Tumor	\N	\N	\N	\N	London-L13
11219	London-L13_Tumor	Tumor	\N	\N	\N	\N	London-L13
11220	UM33_Tumor	Tumor	\N	\N	\N	\N	UM33
11221	UM35_A_Tumor	Tumor	\N	\N	\N	\N	UM35_A
11222	UM39_Tumor	Tumor	\N	\N	\N	\N	UM39
11223	UM40_Tumor	Tumor	\N	\N	\N	\N	UM40
11224	UM41_Tumor	Tumor	\N	\N	\N	\N	UM41
11225	UM36_Tumor	Tumor	\N	\N	\N	\N	UM36
11226	UM37_Tumor	Tumor	\N	\N	\N	\N	UM37
11227	London-L13_Tumor	Tumor	\N	\N	\N	\N	London-L13
11229	57715138_Tumor	Tumor	\N	\N	\N	\N	57715138
11230	332771_Tumor	Tumor	\N	\N	\N	\N	332771
11231	57723220_Tumor	Tumor	\N	\N	\N	\N	57723220
11232	55875588_Tumor	Tumor	\N	\N	\N	\N	55875588
11233	57714581_Tumor	Tumor	\N	\N	\N	\N	57714581
11234	UM47_Tumor	Tumor	\N	\N	\N	\N	UM47
11235	UM47_Normal	Normal	\N	\N	\N	\N	UM47
11236	Sample_KAM1-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM1-T
11237	Sample_KAM106-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM106-T
11238	Sample_KAM12-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM12-T
11239	Sample_KAM121-T-B_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM121-T-B
11240	Sample_KAM20-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM20-T
11241	Sample_KAM3-T-A_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM3-T-A
11242	Sample_KAM35-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM35-T
11243	Sample_KAM38-T-B_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM38-T-B
11244	Sample_KAM53-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM53-T
11245	Sample_KAM61-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM61-T
11246	Sample_KAM7-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM7-T
11247	Sample_KAM78-T-III_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM78-T-III
11248	Sample_KAM82-T-B8_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM82-T-B8
11249	Sample_KAM84-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM84-T
11250	Sample_KAM94-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM94-T
11251	Sample_KAM96-T_Tumor	Tumor	\N	\N	\N	\N	Sample_KAM96-T
\.


--
-- Data for Name: block_area_link; Type: TABLE DATA; Schema: public; Owner: borisbastian
--

COPY public.block_area_link (id, block, area) FROM stdin;
31007	1000	1856
31008	1001	1855
31009	1001	1857
31010	1002	2715
31011	1003	2750
31012	1004	1847
31013	1004	1848
31014	1005	1820
31015	1005	1821
31016	1006	1098
31017	1007	1769
31018	1008	936
31019	1009	937
31020	1010	1099
31021	1011	1645
31022	1012	938
31023	1013	1100
31024	1014	1027
31025	1015	632
31026	1016	1033
31027	1017	1097
31028	1018	1767
31029	1018	1768
31030	1019	972
31031	1020	633
31032	1021	971
31033	1022	1095
31034	1023	2730
31035	1024	1765
31036	1024	1766
31037	1025	634
31038	1026	1076
31039	1027	1947
31040	1027	1948
31041	1027	1949
31042	1028	1803
31043	1028	1804
31044	1029	1053
31045	1030	1693
31046	1030	1694
31047	1031	1096
31048	1032	1657
31049	1033	635
31050	1034	1094
31051	1035	1851
31052	1036	1852
31053	1037	2732
31054	1038	974
31055	1039	2254
31056	1040	2756
31057	1041	2755
31058	1042	1652
31059	1043	636
31060	1044	1023
31061	1045	1641
31062	1045	1642
31063	1045	1956
31064	1046	2723
31065	1047	1646
31066	1048	1647
31067	1049	939
31068	1050	2716
31069	1051	942
31070	1052	973
31071	1053	1091
31072	1054	1665
31073	1055	2717
31074	1056	1093
31075	1057	1724
31076	1057	1725
31077	1057	1726
31078	1058	3871
31079	1059	1090
31080	1060	941
31081	1061	940
31082	1062	3075
31083	1063	1089
31084	1064	1092
31085	1065	1666
31086	1066	3076
31087	1066	3077
31088	1067	2774
31089	1068	1660
31090	1068	2255
31091	1069	2754
31092	1070	2753
31093	1071	1770
31094	1071	1773
31095	1072	1771
31096	1072	1772
31097	1073	943
31098	1074	2741
31099	1075	1088
31100	1076	1085
31101	1077	944
31102	1078	1714
31103	1079	1715
31104	1079	1716
31105	1080	1086
31106	1081	1084
31107	1082	1022
31108	1082	1079
31109	1083	1083
31110	1084	1080
31111	1085	1081
31112	1086	1827
31113	1086	1826
31114	1087	1087
31115	1088	637
31116	1089	976
31117	1090	1854
31118	1091	1853
31119	1092	1860
31120	1093	1858
31121	1093	1859
31122	1094	2773
31123	1095	1721
31124	1095	1722
31125	1095	1723
31126	1096	1713
31127	1097	1707
31128	1098	3451
31129	1099	1944
31130	1099	1946
31131	1099	1945
31132	1099	1954
31133	1100	1695
31134	1100	1696
31135	1101	1697
31136	1102	1698
31137	1103	555
31138	1104	945
31139	1105	1065
31140	1106	946
31141	1107	639
31142	1108	1078
31143	1109	1077
31144	1110	1075
31145	1111	1073
31146	1112	2722
31147	1113	640
31148	1114	1074
31149	1115	1701
31150	1115	1702
31151	1115	1703
31152	1116	1060
31153	1117	3869
31154	1118	1066
31155	1119	1850
31156	1122	1072
31157	1123	1071
31158	1124	1067
31159	1125	1064
31160	1126	1742
31161	1127	1741
31162	1128	1639
31163	1129	1068
31164	1130	1070
31165	1131	1069
31166	1132	1632
31167	1133	1063
31168	1134	977
31169	1135	947
31170	1136	1061
31171	1137	1717
31172	1137	1718
31173	1138	1719
31174	1138	1720
31175	1139	1712
31176	1140	638
31177	1141	1669
31178	1141	1670
31179	1141	1671
31180	1142	1922
31181	1142	1921
31182	1143	2256
31183	1143	2260
31184	1144	3872
31185	1145	1637
31186	1146	1734
31187	1146	1735
31188	1147	1818
31189	1147	1819
31190	1148	1640
31191	1149	2251
31192	1149	2259
31193	1150	628
31194	1151	948
31195	1152	1058
31196	1153	1062
31197	1154	1797
31198	1154	1798
31199	1155	1796
31200	1156	3452
31201	1157	2738
31202	1158	3078
31203	1159	2745
31204	1160	912
31205	1161	1055
31206	1162	978
31207	1163	642
31208	1164	1059
31209	1165	2746
31210	1166	1056
31211	1167	1643
31212	1168	1054
31213	1169	949
31214	1170	641
31215	1171	1057
31216	1172	1051
31217	1173	1049
31218	1174	1052
31219	1175	913
31220	1176	1926
31221	1176	1927
31222	1176	1928
31223	1176	1929
31224	1177	1774
31225	1178	1775
31226	1178	1776
31227	1179	1629
31228	1180	643
31229	1181	1048
31230	1182	1957
31231	1183	2140
31232	1184	2142
31233	1185	2143
31234	1186	2144
31235	1187	2145
31236	1188	1930
31237	1189	1814
31238	1189	1815
31239	1189	1816
31240	1189	1817
31241	1189	1931
31242	1189	1932
31243	1189	1933
31244	1189	1934
31245	1190	3079
31246	1191	1650
31247	1192	1755
31248	1192	1756
31249	1193	1655
31250	1193	1656
31251	1194	2252
31252	1195	3227
31253	1196	645
31254	1197	1025
31255	1198	1044
31256	1383	1510
31257	1199	426
31258	1200	914
31259	1201	1658
31260	1201	1659
31261	1202	646
31262	1203	1757
31263	1203	1758
31264	1204	644
31265	1205	1043
31266	1206	1045
31267	1207	915
31268	1208	2752
31269	1209	2751
31270	1210	3226
31271	1211	629
31272	1212	1633
31273	1213	1042
31274	1214	1938
31275	1214	1939
31276	1214	1940
31277	1215	975
31278	1216	1843
31279	1216	1844
31280	1217	3455
31281	1218	1845
31282	1219	979
31283	1220	647
31284	1221	630
31285	1222	1041
31286	1223	916
31287	1224	653
31288	1225	1037
31289	1226	648
31290	1227	1034
31291	1228	1039
31292	1229	1784
31293	1229	1785
31294	1230	1783
31295	1231	1651
31296	1232	2739
31297	1233	1036
31298	1234	1035
31299	1235	1799
31300	1236	1800
31301	1237	2771
31302	1237	3228
31303	1238	1812
31304	1238	1813
31305	1239	1950
31306	1240	650
31307	1241	652
31308	1242	1031
31309	1243	1032
31310	1244	649
31311	1245	1024
31312	1246	651
31313	1247	1630
31314	1248	2786
31315	1249	3080
31316	1250	3229
31317	1251	1638
31318	1252	2787
31319	1252	2788
31320	1253	1661
31321	1254	1700
31322	1255	1677
31323	1256	1627
31324	1257	1446
31325	1258	1836
31326	1259	1835
31327	1260	3526
31328	1261	2885
31329	1262	2309
31330	1263	2310
31331	1264	1311
31332	1264	1312
31333	1264	1313
31334	1265	2305
31335	1266	2306
31336	1267	2307
31337	1268	2308
31338	1269	1314
31339	1269	1426
31340	1270	2789
31341	1270	2790
31342	1270	2791
31343	1271	1786
31344	1272	2813
31345	1273	2744
31346	1274	2139
31347	1275	2792
31348	1275	2793
31349	1276	2804
31350	1277	654
31351	1278	1050
31352	1279	2794
31353	1280	1662
31354	1280	1663
31355	1280	1664
31356	1280	1923
31357	1280	1924
31358	1280	1925
31359	1281	1747
31360	1281	1748
31361	1282	2042
31362	1283	1782
31363	1284	2037
31364	1285	2146
31365	1286	1750
31366	1286	1751
31367	1287	1764
31368	1288	1360
31369	1289	1686
31370	1289	1687
31371	1290	1688
31372	1291	2029
31373	1291	3400
31374	1291	3399
31375	1292	2000
31376	1292	2001
31377	1469	961
31378	1292	2002
31379	1293	1805
31380	1293	1806
31381	1293	1807
31382	1294	1749
31383	1295	1955
31384	1296	556
31385	1297	3087
31386	1298	1682
31387	1298	1683
31388	1299	1684
31389	1300	1685
31390	1301	3245
31391	1301	3244
31392	1302	3081
31393	1303	2261
31394	1304	2257
31395	1305	1743
31396	1306	1744
31397	1306	1745
31398	1306	1746
31399	1307	3681
31400	1308	2736
31401	1309	655
31402	1310	950
31403	1311	3243
31404	1311	3242
31405	1311	3804
31406	1311	3805
31407	1312	1727
31408	1312	1728
31409	1313	2779
31410	1313	2780
31411	1314	1600
31412	1314	1601
31413	1315	3270
31414	1316	3271
31415	1317	3272
31416	1318	3273
31417	1319	3274
31418	1320	1752
31419	1320	1753
31420	1321	2767
31421	1321	2914
31422	1321	2915
31423	1321	2913
31424	1321	2916
31425	1321	3296
31426	1321	3295
31427	1321	3298
31428	1321	3297
31429	1321	3299
31430	1322	1917
31431	1322	1918
31432	1322	1919
31433	1322	1920
31434	1323	3280
31435	1324	3281
31436	1325	3282
31437	1326	3283
31438	1327	3284
31439	1328	1653
31440	1328	1654
31441	1329	3285
31442	1329	3286
31443	1329	3288
31444	1329	3289
31445	1329	3287
31446	1330	1958
31447	1331	2138
31448	1332	2772
31449	1333	561
31450	1334	560
31451	1335	3426
31452	1336	3071
31453	1336	3072
31454	1337	2742
31455	1337	2743
31456	1338	3292
31457	1338	3291
31458	1338	3290
31459	1338	3293
31460	1338	3294
31461	1339	2721
31462	1340	952
31463	1341	953
31464	1342	2815
31465	1343	951
31466	1344	1754
31467	1345	656
31468	1346	954
31469	1347	2147
31470	1348	1672
31471	1348	1673
31472	1349	1674
31473	1349	1675
31474	1349	1676
31475	1350	1680
31476	1351	2134
31477	1352	2800
31478	1353	1626
31479	1354	3222
31480	1355	2694
31481	1355	2695
31482	1356	3401
31483	1356	3402
31484	1357	1644
31485	1358	3220
31486	1358	3221
31487	1359	3073
31488	1360	2979
31489	1363	2820
31490	1364	2826
31491	1365	2822
31492	1371	2148
31493	1372	2733
31494	1373	3089
31495	1374	2748
31496	1375	2827
31497	1376	657
31498	1377	955
31499	1378	2829
31500	1380	2830
31501	1381	917
31502	1382	2886
31503	1383	1511
31504	1383	1512
31505	1384	1509
31506	1385	1508
31507	1386	1502
31508	1387	1513
31509	1387	1514
31510	1388	1507
31511	1389	1503
31512	1389	1504
31513	1390	956
31514	1391	3682
31515	1392	3683
31516	1393	1736
31517	1393	1737
31518	1393	1738
31519	1394	2769
31520	1394	2770
31521	1395	1739
31522	1396	1740
31523	1397	3082
31524	1398	958
31525	1399	957
31526	1400	3225
31527	1401	3684
31528	1402	1505
31529	1403	1506
31530	1404	2762
31531	1404	2909
31532	1404	2910
31533	1404	2912
31534	1404	2911
31535	1405	2854
31536	1406	1846
31537	1407	3083
31538	1408	3223
31539	1409	2938
31540	1410	2995
31541	1411	911
31542	1411	1235
31543	1412	3275
31544	1412	3276
31545	1412	3277
31546	1412	3278
31547	1412	3279
31548	1413	2994
31549	1414	3237
31550	1415	2996
31551	1416	2766
31552	1417	2999
31553	1418	1002
31554	1419	3000
31555	1420	472
31556	1420	2864
31557	1420	3219
31558	1421	3224
31559	1422	2997
31560	1423	1980
31561	1424	2959
31562	1424	3393
31563	1425	3003
31564	1426	2998
31565	1426	3001
31566	1427	3002
31567	1428	562
31568	1429	563
31569	1430	559
31570	1431	1330
31571	1432	1331
31572	1433	1332
31573	1434	1333
31574	1435	1334
31575	1436	1335
31576	1437	3020
31577	1438	459
31578	1439	2302
31579	1440	1428
31580	1440	1429
31581	1440	1435
31582	1440	1436
31583	1440	1437
31584	1441	658
31585	1442	959
31586	1443	3218
31587	1444	1321
31588	1444	3004
31589	1444	3021
31590	1445	460
31591	1446	2939
31592	1447	1336
31593	1447	2960
31594	1447	3394
31595	1448	3440
31596	1449	617
31597	1450	2154
31598	1451	3005
31599	1452	3022
31600	1453	473
31601	1454	2253
31602	1455	3024
31603	1456	3006
31604	1457	3023
31605	1458	3090
31606	1459	2768
31607	1459	3008
31608	1460	3007
31609	1461	2919
31610	1461	2920
31611	1461	2921
31612	1461	2922
31613	1462	2150
31614	1463	2090
31615	1463	2091
31616	1463	2092
31617	1464	2763
31618	1465	1324
31619	1465	1337
31620	1465	2961
31621	1465	3395
31622	1466	3025
31623	1467	3216
31624	1468	659
31625	1470	3217
31626	1471	2152
31627	1472	2962
31628	1472	3396
31629	1473	1320
31630	1473	2963
31631	1473	3031
31632	1473	3397
31633	1474	3086
31634	1475	3027
31635	1476	2940
31636	1477	3685
31637	1478	3026
31638	1479	1494
31639	1479	1495
31640	1479	1496
31641	1480	1497
31642	1480	1498
31643	1481	1500
31644	1481	1499
31645	1481	1501
31646	1482	1733
31647	1483	2923
31648	1483	2924
31649	1483	2927
31650	1483	2926
31651	1483	2925
31652	1484	2059
31653	1484	2058
31654	1484	2060
31655	1484	2061
31656	1485	2777
31657	1486	3028
31658	1487	3084
31659	1488	3029
31660	1489	3030
31661	1490	474
31662	1491	2811
31663	1492	3398
31664	1493	469
31665	1494	1959
31666	1495	2163
31667	1496	3033
31668	1497	3032
31669	1498	3034
31670	1499	3035
31671	1500	425
31672	1501	3036
31673	1502	3038
31674	1503	470
31675	1504	3009
31676	1504	3037
31677	1505	3441
31678	1506	3011
31679	1507	1338
31680	1508	3012
31681	1509	1339
31682	1510	3014
31683	1511	3010
31684	1512	1340
31685	1513	3039
31686	1514	3215
31687	1515	3013
31688	1516	3231
31689	1517	3232
31690	1518	3015
31691	1519	3017
31692	1520	3040
31693	1521	2988
31694	1522	3016
31695	1523	1731
31696	1523	1732
31697	1524	2989
31698	1525	3806
31699	1525	3807
31700	1525	3808
31701	1525	3810
31702	1525	3809
31703	1526	2991
31704	1527	1341
31705	1527	2941
31706	1528	471
31707	1529	2990
31708	1530	3018
31709	1531	2992
31710	1532	1342
31711	1533	3042
31712	1533	3442
31713	1534	1343
31714	1534	3069
31715	1535	3041
31716	1536	2036
31717	1537	2149
31718	1538	3857
31719	1539	3019
31720	1540	2062
31721	1540	2063
31722	1540	2064
31723	1541	2993
31724	1542	2778
31725	1543	3355
31726	1544	568
31727	1545	567
31728	1546	3427
31729	1548	1141
31730	1549	1142
31731	1550	1143
31732	1551	1144
31733	1552	1329
31734	1553	2405
31735	1554	3686
31736	1555	620
31737	1555	2322
31738	1556	3043
31739	1557	1438
31740	1557	1439
31741	1557	1440
31742	1557	2458
31743	1558	1315
31744	1558	3045
31745	1559	2835
31746	1560	2817
31747	1561	2818
31748	1562	2819
31749	1563	2814
31750	1564	918
31751	1565	660
31752	1566	962
31753	1567	2400
31754	1568	2401
31755	1569	3085
31756	1570	466
31757	1571	2942
31758	1572	3088
31759	1573	3054
31760	1574	3046
31761	1575	1344
31762	1576	2834
31763	1577	2831
31764	1578	2832
31765	1579	2833
31766	1580	619
31767	1580	2321
31768	1581	997
31769	1581	1322
31770	1581	2250
31771	1581	2328
31772	1582	2776
31773	1583	661
31774	1584	2402
31775	1585	2403
31776	1586	2404
31777	1587	2407
31778	1588	2406
31779	1589	2096
31780	1589	2097
31781	1589	2098
31782	1590	2411
31783	1591	2410
31784	1592	2408
31785	1592	2421
31786	1592	2422
31787	1592	2423
31788	1593	3307
31789	1594	477
31790	1595	446
31791	1596	2409
31792	1597	2935
31793	1598	2764
31794	1599	2413
31795	1600	2412
31796	1601	467
31797	1602	2416
31798	1603	2164
31799	1604	2099
31800	1605	2100
31801	1605	2101
31802	1606	2414
31803	1606	2415
31804	1607	2426
31805	1608	2427
31806	1609	3842
31807	1610	2428
31808	1611	2429
31809	1612	2430
31810	1613	2431
31811	1614	2432
31812	1615	2433
31813	1616	2434
31814	1617	2435
31815	1618	2424
31816	1619	2419
31817	1620	2425
31818	1621	2436
31819	1622	2437
31820	1623	2438
31821	1624	2439
31822	1625	2440
31823	1626	2441
31824	1627	2442
31825	1628	2418
31826	1628	2417
31827	1629	3055
31828	1630	455
31829	1631	1490
31830	1631	1491
31831	1631	1492
31832	1632	621
31833	1633	1493
31834	1634	3687
31835	1635	3696
31836	1636	490
31837	1637	3056
31838	1638	3049
31839	1639	468
31840	1640	463
31841	1641	3050
31842	1642	3697
31843	1643	1345
31844	1644	880
31845	1644	881
31846	1645	429
31847	1646	464
31848	1647	3091
31849	1648	3093
31850	1648	3094
31851	1649	3051
31852	1650	2106
31853	1650	2107
31854	1650	2108
31855	1651	2105
31856	1652	2165
31857	1653	1346
31858	1654	491
31859	1655	3095
31860	1655	3096
31861	1656	2093
31862	1657	2094
31863	1657	2095
31864	1658	998
31865	1659	3052
31866	1660	2102
31867	1660	2103
31868	1660	2104
31869	1661	3070
31870	1662	3053
31871	1663	3057
31872	1664	3058
31873	1665	1628
31874	1666	457
31875	1667	2065
31876	1667	2066
31877	1667	2067
31878	1668	3059
31879	1669	465
31880	1670	2812
31881	1671	3060
31882	1672	3061
31883	1673	1140
31884	1674	1960
31885	1675	1139
31886	1676	1138
31887	1677	1137
31888	1678	1136
31889	1679	1135
31890	1680	2934
31891	1681	2853
31892	1682	2068
31893	1682	2069
31894	1682	2070
31895	1682	2071
31896	1683	3234
31897	1684	3063
31898	1685	3062
31899	1686	3064
31900	1687	3065
31901	1688	3066
31902	1689	2816
31903	1690	3067
31904	1691	3382
31905	1692	2852
31906	1693	2810
31907	1694	2726
31908	1695	1961
31909	1696	2883
31910	1697	1678
31911	1697	1679
31912	1698	2677
31913	1699	2676
31914	1700	2679
31915	1701	2678
31916	1702	2725
31917	1703	2724
31918	1704	2884
31919	1705	1529
31920	1705	1530
31921	1705	1532
31922	1705	1531
31923	1705	1533
31924	1706	662
31925	1707	960
31926	1708	631
31927	1709	3377
31928	1709	3376
31929	1709	3378
31930	1710	663
31931	1711	963
31932	1712	1470
31933	1712	1471
31934	1712	1472
31935	1713	1347
31936	1714	1689
31937	1714	1690
31938	1715	1691
31939	1715	1692
31940	1716	3540
31941	1717	2809
31942	1718	3541
31943	1719	2805
31944	1720	3698
31945	1721	3380
31946	1721	3379
31947	1721	3381
31948	1722	2712
31949	1723	3235
31950	1724	3542
31951	1725	3236
31952	1726	1963
31953	1727	1962
31954	1728	1981
31955	1729	3230
31956	1729	3233
31957	1730	2699
31958	1731	2714
31959	1732	2030
31960	1732	3403
31961	1732	3404
31962	1733	2713
31963	1734	1348
31964	1735	1349
31965	1736	2708
31966	1737	2808
31967	1738	2072
31968	1738	2073
31969	1738	2074
31970	1739	2807
31971	1740	2806
31972	1741	456
31973	1742	2031
31974	1742	3405
31975	1742	3406
31976	1743	566
31977	1744	1328
31978	1745	2727
31979	1746	2005
31980	1747	2151
31981	1748	664
31982	1749	2701
31983	1750	964
31984	1751	2006
31985	1751	2007
31986	1751	2008
31987	1752	2728
31988	1752	2729
31989	1753	3786
31990	1754	1350
31991	1755	2683
31992	1756	2681
31993	1756	2680
31994	1756	2682
31995	1757	2700
31996	1758	1965
31997	1759	999
31998	1760	3068
31999	1761	965
32000	1762	622
32001	1763	3543
32002	1764	1473
32003	1764	1624
32004	1765	2702
32005	1766	2078
32006	1766	2079
32007	1766	2080
32008	1767	1634
32009	1768	1534
32010	1769	1535
32011	1769	1536
32012	1770	2703
32013	1771	452
32014	1772	3787
32015	1773	1351
32016	1774	1001
32017	1775	2171
32018	1776	1352
32019	1777	2081
32020	1777	2083
32021	1777	2082
32022	1778	492
32023	1779	2125
32024	1779	2124
32025	1779	2126
32026	1780	1539
32027	1780	1540
32028	1780	1625
32029	1781	2168
32030	1782	2172
32031	1783	2176
32032	1784	1353
32033	1785	3858
32034	1785	3859
32035	1786	2177
32036	1787	2173
32037	1788	2867
32038	1788	2868
32039	1789	2869
32040	1789	2870
32041	1790	2861
32042	1790	2862
32043	1791	454
32044	1792	3864
32045	1793	2174
32046	1794	2825
32047	1794	2860
32048	1795	2865
32049	1795	2866
32050	1796	3866
32051	1797	2075
32052	1797	2076
32053	2198	1442
32054	1797	2077
32055	1798	2704
32056	1799	1964
32057	1800	2084
32058	1800	2085
32059	1800	2086
32060	1800	2111
32061	1800	2112
32062	1800	2113
32063	1800	2130
32064	1801	3862
32065	1802	2088
32066	1802	2087
32067	1802	2089
32068	1803	3863
32069	1804	1355
32070	1805	2705
32071	1806	1354
32072	1807	2710
32073	1808	623
32074	1809	3861
32075	1810	1356
32076	1811	493
32077	1812	3865
32078	1813	2706
32079	1814	2697
32080	1815	3860
32081	1816	3868
32082	1817	486
32083	1818	461
32084	1819	462
32085	1820	2709
32086	1821	565
32087	1822	558
32088	1823	1544
32089	1823	1545
32090	1824	1546
32091	1825	2032
32092	1825	3409
32093	1826	665
32094	1827	2707
32095	1828	1519
32096	1829	1515
32097	1829	1516
32098	1829	1517
32099	1829	1518
32100	1829	1612
32101	1830	1521
32102	1830	1522
32103	1831	1523
32104	1831	1524
32105	1831	1525
32106	1832	1526
32107	1833	1527
32108	1833	1528
32109	1834	3544
32110	1835	3545
32111	1836	3867
32112	1837	3546
32113	1838	3547
32114	1839	3548
32115	1840	3870
32116	1841	3549
32117	1842	1357
32118	1843	3550
32119	1844	3551
32120	1845	2160
32121	1845	2277
32122	1845	2278
32123	1846	3552
32124	1847	2166
32125	1847	2280
32126	1848	2279
32127	1849	3699
32128	1850	436
32129	1851	2711
32130	1852	1358
32131	1853	1476
32132	1853	1475
32133	1853	1477
32134	1854	3700
32135	1855	1478
32136	1855	1479
32137	1855	1489
32138	1856	1520
32139	1857	424
32140	1858	2162
32141	1858	2283
32142	1858	2284
32143	1859	666
32144	1860	2157
32145	1860	2158
32146	1860	2273
32147	1860	2274
32148	1861	1610
32149	1862	1359
32150	1863	1548
32151	1863	1547
32152	1863	1549
32153	1863	1550
32154	1864	1474
32155	1865	1966
32156	1866	618
32157	1867	1361
32158	1868	3553
32159	1869	3554
32160	1870	1362
32161	1871	625
32162	1872	1681
32163	2198	1443
32164	1873	1983
32165	1874	2698
32166	1875	2170
32167	1875	2271
32168	1875	2272
32169	1876	1541
32170	1876	1542
32171	1877	3555
32172	1878	3556
32173	1879	2159
32174	1879	2275
32175	1879	2276
32176	1880	1363
32177	1881	458
32178	1882	1364
32179	1883	1365
32180	1884	1366
32181	1885	430
32182	1886	1984
32183	1887	2161
32184	1887	2281
32185	1887	2282
32186	1888	1982
32187	1889	1369
32188	1890	1367
32189	1891	1368
32190	1892	1985
32191	1893	2153
32192	1893	2285
32193	1893	2286
32194	1894	1967
32195	1895	1000
32196	1896	485
32197	1897	1968
32198	1898	1455
32199	1899	1370
32200	1900	1371
32201	1901	1372
32202	1902	437
32203	1903	1969
32204	1904	2009
32205	1905	1373
32206	1906	1552
32207	1906	1553
32208	1906	1554
32209	1906	1555
32210	1906	1556
32211	1906	1557
32212	1907	3527
32213	1908	890
32214	1909	1970
32215	1909	2003
32216	1910	3528
32217	1911	3529
32218	1912	3530
32219	1913	3531
32220	1914	3532
32221	1915	3533
32222	1916	3534
32223	1917	3535
32224	1918	3536
32225	1919	1988
32226	1920	1537
32227	1921	3537
32228	1922	1570
32229	1922	1569
32230	1922	1571
32231	1922	1573
32232	1922	1572
32233	1923	1574
32234	1924	1375
32235	1925	3538
32236	1926	3539
32237	1927	165
32238	1928	1374
32239	1929	2180
32240	1929	2181
32241	1929	2182
32242	1929	2183
32243	1930	1378
32244	1931	1386
32245	1932	1376
32246	1933	1377
32247	1934	1538
32248	1934	1613
32249	1935	1998
32250	1936	1379
32251	1937	1381
32252	1938	1385
32253	1939	1380
32254	1940	627
32255	1941	1382
32256	1942	1606
32257	1942	1607
32258	1943	3557
32259	1944	427
32260	1945	1608
32261	1945	1609
32262	1946	2184
32263	1946	2185
32264	1946	2186
32265	1947	3558
32266	1948	1989
32267	1949	1383
32268	1950	1387
32269	1951	1390
32270	1952	1384
32271	1953	1990
32272	1953	1991
32273	1953	2004
32274	1954	229
32275	1955	1986
32276	1956	3559
32277	1957	3560
32278	1958	1388
32279	1959	1987
32280	1960	1389
32281	1961	1391
32282	1962	2483
32283	1962	2484
32284	1963	1992
32285	1964	1392
32286	1965	1971
32287	1966	1393
32288	1967	494
32289	1968	283
32290	1968	285
32291	1968	284
32292	1969	2010
32293	1970	298
32294	1970	299
32295	1970	804
32296	1970	884
32297	1971	1394
32298	1972	1395
32299	1973	1401
32300	1974	1396
32301	1975	1397
32302	1976	116
32303	1976	170
32304	1976	182
32305	1977	1399
32306	1978	131
32307	1978	210
32308	1979	204
32309	1980	128
32310	1980	205
32311	1981	117
32312	1981	197
32313	1982	227
32314	1983	133
32315	1983	214
32316	1984	203
32317	1985	202
32318	1986	139
32319	1986	230
32320	1987	350
32321	1987	351
32322	1987	2243
32323	1987	2244
32324	1987	2245
32325	1988	355
32326	1988	354
32327	1988	356
32328	1989	772
32329	1989	773
32330	1990	349
32331	1990	348
32332	1990	2127
32333	1991	1449
32334	1992	1430
32335	1993	1398
32336	1994	290
32337	1994	291
32338	1994	289
32339	1995	296
32340	1995	297
32341	1995	304
32342	1996	1448
32343	1997	1993
32344	1998	2117
32345	1998	2119
32346	1998	2118
32347	1998	2120
32348	1999	280
32349	1999	282
32350	1999	281
32351	2000	300
32352	2000	301
32353	2001	122
32354	2001	173
32355	2001	185
32356	2002	143
32357	2002	235
32358	2003	111
32359	2003	224
32360	2004	1994
32361	2005	174
32362	2005	186
32363	2006	120
32364	2006	178
32365	2006	190
32366	2199	799
32367	2007	220
32368	2008	110
32369	2008	207
32370	2009	208
32371	2010	130
32372	2010	209
32373	2011	166
32374	2011	192
32375	2012	114
32376	2012	168
32377	2012	180
32378	2013	171
32379	2013	183
32380	2014	126
32381	2014	200
32382	2015	138
32383	2015	228
32384	2016	199
32385	2017	1402
32386	2018	176
32387	2018	188
32388	2019	123
32389	2019	195
32390	2020	145
32391	2020	237
32392	2021	223
32393	2022	1400
32394	2023	564
32395	2024	557
32396	2025	3561
32397	2026	3562
32398	2027	3563
32399	2028	601
32400	2029	602
32401	2030	1404
32402	2031	226
32403	2032	177
32404	2032	189
32405	2033	1403
32406	2034	1995
32407	2035	1996
32408	2036	3564
32409	2037	135
32410	2037	219
32411	2038	163
32412	2038	211
32413	2039	129
32414	2039	206
32415	2040	1405
32416	2041	1406
32417	2042	3565
32418	2043	3788
32419	2044	1407
32420	2045	3566
32421	2046	3567
32422	2047	1558
32423	2047	1559
32424	2047	1560
32425	2048	1561
32426	2049	1408
32427	2050	3568
32428	2051	1409
32429	2052	438
32430	2053	3569
32431	2054	3570
32432	2055	3571
32433	2056	3572
32434	2057	293
32435	2057	292
32436	2058	1413
32437	2059	787
32438	2059	788
32439	2059	1310
32440	2060	1564
32441	2060	1565
32442	2061	1566
32443	2061	1567
32444	2061	1568
32445	2062	1410
32446	2063	142
32447	2063	234
32448	2064	144
32449	2064	236
32450	2065	140
32451	2065	231
32452	2066	225
32453	2067	193
32454	2068	112
32455	2068	217
32456	2069	137
32457	2069	222
32458	2070	125
32459	2070	198
32460	2071	167
32461	2071	194
32462	2072	124
32463	2072	196
32464	2073	3701
32465	2074	439
32466	2075	1543
32467	2076	2122
32468	2076	2121
32469	2076	2123
32470	2077	1973
32471	2078	1411
32472	2079	164
32473	2079	213
32474	2080	169
32475	2080	181
32476	2081	215
32477	2082	134
32478	2082	216
32479	2083	132
32480	2083	212
32481	2084	175
32482	2084	187
32483	2085	286
32484	2085	288
32485	2085	287
32486	2086	218
32487	2087	136
32488	2087	221
32489	2088	1432
32490	2089	141
32491	2089	233
32492	2090	232
32493	2091	3826
32494	2091	3827
32495	2092	119
32496	2092	172
32497	2092	184
32498	2093	127
32499	2093	201
32500	2094	121
32501	2094	179
32502	2094	191
32503	2095	1412
32504	2096	789
32505	2096	790
32506	2096	791
32507	2097	784
32508	2097	785
32509	2097	786
32510	2097	885
32511	2098	305
32512	2098	344
32513	2098	343
32514	2099	2672
32515	2100	2671
32516	2101	2670
32517	2102	146
32518	2102	240
32519	2103	147
32520	2103	241
32521	2104	148
32522	2104	242
32523	2105	252
32524	2106	153
32525	2106	254
32526	2107	154
32527	2107	255
32528	2108	3702
32529	2109	253
32530	2110	3828
32531	2111	149
32532	2111	243
32533	2112	244
32534	2113	250
32535	2114	251
32536	2115	238
32537	2116	151
32538	2116	247
32539	2117	248
32540	2118	152
32541	2118	249
32542	2119	239
32543	2120	150
32544	2120	245
32545	2121	246
32546	2122	792
32547	2122	794
32548	2122	793
32549	2123	118
32550	2123	258
32551	2124	256
32552	2125	3573
32553	2126	2114
32554	2126	2115
32555	2126	2116
32556	2127	1414
32557	2128	781
32558	2128	782
32559	2128	783
32560	2129	2135
32561	2130	801
32562	2130	802
32563	2131	1415
32564	2132	257
32565	2199	800
32566	2133	2619
32567	2134	1416
32568	2135	724
32569	2135	3521
32570	2136	1417
32571	2137	3789
32572	2138	440
32573	2139	1434
32574	2140	803
32575	2140	805
32576	2141	3574
32577	2142	3575
32578	2143	779
32579	2143	780
32580	2144	495
32581	2145	795
32582	2145	796
32583	2145	797
32584	2146	776
32585	2146	777
32586	2146	778
32587	2147	1433
32588	2148	276
32589	2149	259
32590	2150	260
32591	2151	158
32592	2151	270
32593	2152	159
32594	2152	271
32595	2153	113
32596	2153	264
32597	2154	161
32598	2154	273
32599	2155	261
32600	2156	262
32601	2157	275
32602	2158	267
32603	2159	155
32604	2159	265
32605	2160	278
32606	2161	156
32607	2161	266
32608	2162	269
32609	2163	157
32610	2163	268
32611	2164	279
32612	2165	263
32613	2166	162
32614	2166	274
32615	2167	160
32616	2167	272
32617	2168	115
32618	2168	277
32619	2169	302
32620	2169	303
32621	2169	798
32622	2170	2178
32623	2171	2179
32624	2172	2109
32625	2172	2110
32626	2172	2128
32627	2172	2129
32628	2173	1972
32629	2174	693
32630	2174	3490
32631	2175	702
32632	2175	3500
32633	2176	701
32634	2176	3499
32635	2177	689
32636	2177	3486
32637	2178	688
32638	2178	3485
32639	2179	690
32640	2179	3487
32641	2180	705
32642	2180	3503
32643	2181	708
32644	2181	3506
32645	2182	706
32646	2182	3504
32647	2183	707
32648	2183	3505
32649	2184	2620
32650	2185	2471
32651	2186	2485
32652	2187	725
32653	2187	3522
32654	2188	721
32655	2188	3518
32656	2189	720
32657	2189	3517
32658	2190	431
32659	2191	692
32660	2191	3489
32661	2192	774
32662	2192	775
32663	2193	719
32664	2193	3516
32665	2194	352
32666	2194	353
32667	2194	1441
32668	2194	1444
32669	2195	3829
32670	2196	1450
32671	2197	704
32672	2197	3502
32673	2198	294
32674	2198	295
32675	2198	895
32676	2200	2137
32677	2201	432
32678	2202	2011
32679	2203	2621
32680	2204	2622
32681	2205	695
32682	2205	3492
32683	2206	703
32684	2206	3501
32685	2207	716
32686	2207	3514
32687	2208	728
32688	2208	3525
32689	2209	691
32690	2209	3488
32691	2210	710
32692	2210	3508
32693	2211	2623
32694	2212	1451
32695	2213	1872
32696	2214	1447
32697	2215	2131
32698	2215	2133
32699	2215	2132
32700	2216	2616
32701	2217	433
32702	2218	434
32703	2219	676
32704	2220	683
32705	2221	525
32706	2222	502
32707	2223	526
32708	2224	517
32709	2225	522
32710	2226	510
32711	2227	531
32712	2228	504
32713	2229	508
32714	2230	509
32715	2231	534
32716	2232	535
32717	2233	2636
32718	2234	2637
32719	2235	713
32720	2235	3511
32721	2236	520
32722	2237	503
32723	2238	497
32724	2239	521
32725	2240	726
32726	2240	3523
32727	2241	513
32728	2242	2617
32729	2243	532
32730	2244	515
32731	2245	529
32732	2246	435
32733	2247	516
32734	2248	514
32735	2249	518
32736	2250	519
32737	2251	505
32738	2252	506
32739	2253	507
32740	2254	1974
32741	2254	1975
32742	2254	1976
32743	2255	722
32744	2255	3519
32745	2256	723
32746	2256	3520
32747	2257	675
32748	2258	1870
32749	2259	681
32750	2260	678
32751	2261	1871
32752	2262	680
32753	2263	679
32754	2264	1866
32755	2265	1865
32756	2266	677
32757	2267	1869
32758	2268	1868
32759	2269	441
32760	2270	682
32761	2271	1867
32762	2272	428
32763	2273	2638
32764	2274	892
32765	2274	893
32766	2274	894
32767	2275	709
32768	2275	3507
32769	2276	447
32770	2277	345
32771	2277	346
32772	2277	347
32773	2278	2618
32774	2279	624
32775	2280	2021
32776	2281	3576
32777	2282	3577
32778	2283	3578
32779	2284	3579
32780	2285	3580
32781	2286	3581
32782	2287	3582
32783	2288	2512
32784	2289	2513
32785	2290	2514
32786	2291	3703
32787	2292	1873
32788	2293	684
32789	2294	3704
32790	2295	3705
32791	2296	3706
32792	2297	3707
32793	2298	3708
32794	2299	3709
32795	2300	1874
32796	2301	685
32797	2302	533
32798	2303	512
32799	2304	536
32800	2305	537
32801	2306	541
32802	2307	1582
32803	2307	1581
32804	2307	1583
32805	2308	442
32806	2309	530
32807	2310	523
32808	2311	730
32809	2312	1551
32810	2312	1614
32811	2313	3583
32812	2314	882
32813	2315	487
32814	2316	1585
32815	2316	1584
32816	2316	1586
32817	2317	3710
32818	2318	524
32819	2319	542
32820	2320	543
32821	2321	544
32822	2322	548
32823	2323	1977
32824	2324	2644
32825	2325	2643
32826	2326	2642
32827	2327	715
32828	2327	3513
32829	2328	711
32830	2328	3509
32831	2329	538
32832	2330	443
32833	2331	511
32834	2332	727
32835	2332	3524
32836	2333	539
32837	2334	540
32838	2335	2241
32839	2336	729
32840	2337	545
32841	2338	546
32842	2339	2190
32843	2339	2191
32844	2339	2192
32845	2340	444
32846	2341	547
32847	2342	527
32848	2343	2510
32849	2344	2509
32850	2345	448
32851	2346	1978
32852	2347	1979
32853	2348	700
32854	2348	3498
32855	2349	3408
32856	2349	3407
32857	2350	498
32858	2351	496
32859	2352	696
32860	2352	3493
32861	2353	687
32862	2353	3484
32863	2354	2136
32864	2355	3680
32865	2356	445
32866	2357	694
32867	2357	3491
32868	2358	698
32869	2358	3496
32870	2359	717
32871	2360	718
32872	2360	3515
32873	2361	699
32874	2361	3497
32875	2362	714
32876	2362	3512
32877	2363	697
32878	2363	3494
32879	2363	3495
32880	2364	712
32881	2364	3510
32882	2365	481
32883	2366	482
32884	2367	483
32885	2368	484
32886	2369	488
32887	2370	489
32888	2371	478
32889	2372	1256
32890	2373	1251
32891	2374	1250
32892	2375	1249
32893	2376	1257
32894	2377	528
32895	2378	1253
32896	2379	1252
32897	2380	1254
32898	2381	1258
32899	2382	1259
32900	2383	1262
32901	2384	1260
32902	2385	1261
32903	2386	2187
32904	2386	2188
32905	2386	2189
32906	2387	2648
32907	2387	2649
32908	2388	2650
32909	2388	2690
32910	2389	889
32911	2390	891
32912	2391	3584
32913	2392	3585
32914	2393	479
32915	2394	888
32916	2395	480
32917	2396	886
32918	2397	3586
32919	2398	3587
32920	2399	3588
32921	2400	3589
32922	2401	3590
32923	2402	887
32924	2403	3591
32925	2404	3592
32926	2405	3593
32927	2406	3594
32928	2407	2196
32929	2407	2197
32930	2407	2198
32931	2407	2199
32932	2408	3711
32933	2409	3712
32934	2410	1263
32935	2411	1264
32936	2412	1265
32937	2413	1266
32938	2414	1267
32939	2415	1268
32940	2416	1269
32941	2417	1270
32942	2418	1255
32943	2419	3595
32944	2420	3596
32945	2421	1468
32946	2422	3597
32947	2423	2156
32948	2424	3830
32949	2425	1272
32950	2426	1278
32951	2427	1283
32952	2428	3598
32953	2429	1562
32954	2429	1563
32955	2430	3713
32956	2431	1467
32957	2432	3714
32958	2433	3599
32959	2434	1421
32960	2435	1274
32961	2436	1271
32962	2437	1275
32963	2438	1281
32964	2439	3600
32965	2440	3715
32966	2441	3716
32967	2442	2193
32968	2442	2194
32969	2442	2195
32970	2442	2238
32971	2442	2240
32972	2442	2239
32973	2443	1280
32974	2444	1284
32975	2445	1276
32976	2446	1279
32977	2447	1273
32978	2448	1282
32979	2449	1277
32980	2450	1822
32981	2450	1823
32982	2451	3717
32983	2452	1824
32984	2453	1460
32985	2454	1463
32986	2455	1588
32987	2455	1587
32988	2455	1589
32989	2455	1590
32990	2455	1591
32991	2455	1592
32992	2456	3718
32993	2457	1003
32994	2457	1134
32995	2458	3601
32996	2459	1597
32997	2459	1599
32998	2459	1598
32999	2460	3719
33000	2461	1602
33001	2461	1603
33002	2462	1593
33003	2462	1594
33004	2462	1596
33005	2462	1595
33006	2463	3720
33007	2464	1445
33008	2465	1459
33009	2466	1452
33010	2467	2022
33011	2468	2511
33012	2469	1464
33013	2470	1461
33014	2471	1462
33015	2472	878
33016	2473	1465
33017	2474	3790
33018	2475	1997
33019	2476	1458
33020	2477	1454
33021	2478	1453
33022	2479	1466
33023	2480	879
33024	2481	2597
33025	2482	1456
33026	2483	1483
33027	2484	3791
33028	2485	1457
33029	2486	2023
33030	2487	3412
33031	2488	1420
33032	2489	1431
33033	2490	806
33034	2491	807
33035	2492	808
33036	2493	809
33037	2494	810
33038	2495	811
33039	2496	996
33040	2497	812
33041	2498	980
33042	2499	813
33043	2500	814
33044	2501	815
33045	2502	816
33046	2503	981
33047	2504	883
33048	2505	818
33049	2506	982
33050	2507	819
33051	2508	820
33052	2509	821
33053	2510	825
33054	2511	826
33055	2512	827
33056	2513	983
33057	2514	828
33058	2515	829
33059	2516	830
33060	2517	831
33061	2518	832
33062	2519	833
33063	2520	834
33064	2521	835
33065	2522	837
33066	2523	838
33067	2524	984
33068	2525	839
33069	2526	840
33070	2527	841
33071	2528	842
33072	2529	985
33073	2530	843
33074	2531	844
33075	2532	986
33076	2533	845
33077	2534	987
33078	2535	846
33079	2536	988
33080	2537	847
33081	2538	848
33082	2539	989
33083	2540	850
33084	2541	851
33085	2542	852
33086	2543	853
33087	2544	854
33088	2545	855
33089	2546	856
33090	2547	990
33091	2548	857
33092	2549	858
33093	2550	859
33094	2551	991
33095	2552	860
33096	2553	992
33097	2554	861
33098	2555	863
33099	2556	864
33100	2557	865
33101	2558	866
33102	2559	867
33103	2560	868
33104	2561	993
33105	2562	869
33106	2563	870
33107	2564	994
33108	2565	871
33109	2566	817
33110	2567	872
33111	2568	995
33112	2569	873
33113	2570	874
33114	2571	875
33115	2572	877
33116	2573	822
33117	2574	823
33118	2575	3602
33119	2576	3448
33120	2577	3603
33121	2578	3604
33122	2579	3605
33123	2580	3606
33124	2581	3607
33125	2582	3608
33126	2583	3609
33127	2584	3610
33128	2585	2608
33129	2585	2609
33130	2586	3611
33131	2587	3612
33132	2588	2507
33133	2588	2506
33134	2589	3613
33135	2590	2663
33136	2591	2661
33137	2591	2662
33138	2592	3614
33139	2593	1579
33140	2594	2668
33141	2595	2669
33142	2596	2667
33143	2597	2508
33144	2598	3721
33145	2599	3722
33146	2600	3615
33147	2601	2599
33148	2601	2600
33149	2602	2024
33150	2603	2675
33151	2604	2674
33152	2605	2673
33153	2606	2522
33154	2606	2521
33155	2607	2523
33156	2608	2557
33157	2609	2558
33158	2610	1576
33159	2611	3723
33160	2612	2601
33161	2613	3616
33162	2614	1469
33163	2615	1578
33164	2615	1580
33165	2615	1611
33166	2616	1999
33167	2617	2025
33168	2618	1604
33169	2618	1605
33170	2619	2155
33171	2620	3831
33172	2621	2303
33173	2622	2603
33174	2622	2602
33175	2623	2200
33176	2623	2201
33177	2623	2202
33178	2623	2203
33179	2624	1577
33180	2625	1488
33181	2626	2604
33182	2626	2605
33183	2627	1480
33184	2628	1484
33185	2629	2655
33186	2629	2656
33187	2630	2657
33188	2631	2204
33189	2631	2206
33190	2631	2205
33191	2632	1482
33192	2633	2607
33193	2633	2606
33194	2634	1486
33195	2635	1485
33196	2636	3617
33197	2637	3618
33198	2638	3619
33199	2640	2207
33200	2640	2208
33201	2640	2209
33202	2640	2210
33203	2641	3620
33204	2642	3621
33205	2643	3622
33206	2644	1487
33207	2645	2610
33208	2646	3724
33209	2647	1877
33210	2647	1878
33211	2648	2051
33212	2648	2053
33213	2648	2052
33214	2648	2054
33215	2649	2611
33216	2650	2211
33217	2650	2212
33218	2650	2214
33219	2650	2213
33220	2651	2493
33221	2652	2491
33222	2652	2492
33223	2653	2543
33224	2653	2544
33225	2654	2545
33226	2655	2546
33227	2656	2547
33228	2657	2548
33229	2657	2549
33230	2658	2658
33231	2658	2659
33232	2658	2693
33233	2659	2660
33234	2660	2531
33235	2660	2532
33236	2661	2534
33237	2661	2533
33238	2662	2047
33239	2662	2048
33240	2662	2049
33241	2662	2050
33242	2663	1481
33243	2664	2559
33244	2664	2560
33245	2665	2561
33246	2666	2562
33247	2667	2470
33248	2668	2469
33249	2669	2598
33250	2670	2554
33251	2670	2553
33252	2671	2555
33253	2671	2556
33254	2672	2044
33255	2672	2043
33256	2672	2045
33257	2672	2046
33258	2673	2651
33259	2673	2652
33260	2673	2691
33261	2674	2653
33262	2674	2692
33263	2675	2654
33264	2676	2498
33265	2677	2497
33266	2678	3725
33267	2679	2233
33268	2680	2223
33269	2680	2225
33270	2680	2224
33271	2680	2226
33272	2681	3623
33273	2682	3792
33274	2683	3624
33275	2684	2646
33276	2685	2645
33277	2686	2647
33278	2687	3625
33279	2688	3626
33280	2689	2496
33281	2690	2494
33282	2691	2495
33283	2692	3627
33284	2693	3628
33285	2694	3629
33286	2695	3630
33287	2696	3631
33288	2697	3632
33289	2698	3633
33290	2699	3634
33291	2700	3635
33292	2701	3726
33293	2702	3636
33294	2703	3637
33295	2704	3638
33296	2705	2242
33297	2706	3639
33298	2707	3640
33299	2708	3641
33300	2709	3642
33301	2710	3643
33302	2711	3644
33303	2712	3645
33304	2713	2501
33305	2714	2500
33306	2715	3415
33307	2956	1130
33308	2716	2499
33309	2717	3727
33310	2718	3646
33311	2719	3647
33312	2720	2502
33313	2721	3648
33314	2722	2227
33315	2722	2228
33316	2722	2229
33317	2723	2231
33318	2723	2230
33319	2723	2232
33320	2724	2026
33321	2725	2027
33322	2726	1882
33323	2726	1883
33324	2726	1884
33325	2727	1890
33326	2727	1891
33327	2728	1879
33328	2728	1880
33329	2729	1909
33330	2729	1910
33331	2730	2520
33332	2730	2518
33333	2730	2519
33334	2731	1888
33335	2731	1889
33336	2732	1881
33337	2733	2525
33338	2733	2524
33339	2734	2515
33340	2735	2516
33341	2736	2528
33342	2736	2527
33343	2737	2529
33344	2737	2530
33345	2738	2028
33346	2739	2550
33347	2739	2551
33348	2740	2552
33349	2741	1892
33350	2742	1886
33351	2743	1885
33352	2744	3728
33353	2745	3729
33354	2746	3730
33355	2747	2907
33356	2748	3731
33357	2749	3732
33358	2750	3733
33359	2751	2902
33360	2752	3734
33361	2753	3735
33362	2754	1900
33363	2755	1898
33364	2755	1899
33365	2756	1895
33366	2756	1896
33367	2756	1897
33368	2757	1894
33369	2758	1905
33370	2758	1906
33371	2759	1901
33372	2759	1902
33373	2760	1907
33374	2760	1908
33375	2761	1911
33376	2761	1912
33377	2761	1913
33378	2761	1914
33379	2762	1903
33380	2762	1904
33381	2763	2215
33382	2763	2216
33383	2763	2218
33384	2763	2217
33385	2763	2237
33386	2764	2219
33387	2764	2221
33388	2764	2220
33389	2764	2222
33390	2765	2455
33391	2765	2454
33392	2766	3649
33393	2767	2589
33394	2768	3650
33395	2769	3651
33396	2770	3652
33397	2771	3653
33398	2772	3654
33399	2773	3655
33400	2774	3656
33401	2775	3657
33402	2776	3658
33403	2777	2481
33404	2777	2480
33405	2778	2586
33406	2779	3736
33407	2780	3737
33408	2781	2482
33409	2782	1951
33410	2782	1952
33411	2782	1953
33412	2783	3659
33413	2784	3660
33414	2785	3661
33415	2786	3662
33416	2787	3663
33417	2788	3664
33418	2789	3738
33419	2790	3739
33420	2791	3665
33421	2792	2453
33422	2793	2665
33423	2793	2664
33424	2794	2666
33425	2795	3666
33426	2796	2569
33427	2797	2486
33428	2797	2487
33429	2798	3667
33430	2799	3740
33431	2800	3741
33432	2801	2476
33433	2802	2624
33434	2803	2625
33435	2804	2038
33436	2804	2039
33437	2804	2040
33438	2804	2041
33439	2805	2626
33440	2806	2535
33441	2806	2536
33442	2807	2538
33443	2807	2537
33444	2808	2627
33445	2809	2574
33446	2810	2628
33447	2811	2629
33448	2811	2630
33449	2812	2687
33450	2813	2684
33451	2814	2526
33452	2815	2294
33453	2815	2295
33454	2815	2296
33455	2816	2297
33456	2816	2298
33457	2817	3832
33458	2818	2587
33459	2819	2268
33460	2819	2269
33461	2820	2270
33462	2821	2588
33463	2822	2581
33464	2823	3833
33465	2824	2631
33466	2825	2590
33467	2826	2632
33468	2827	2591
33469	2828	2592
33470	2829	2593
33471	2830	2504
33472	2831	2503
33473	2832	2505
33474	2833	2633
33475	2833	2634
33476	2834	2594
33477	2835	2517
33478	2836	2635
33479	2837	3793
33480	2838	2595
33481	2839	2596
33482	2840	2287
33483	2840	2288
33484	2841	2477
33485	2841	2478
33486	2842	2479
33487	2843	2235
33488	2843	2234
33489	2843	2236
33490	2844	2456
33491	2845	2462
33492	2845	2918
33493	2845	2917
33494	2846	2457
33495	2847	2299
33496	2847	2300
33497	2847	2301
33498	2848	2539
33499	2848	2540
33500	2849	2541
33501	2849	2542
33502	2850	3834
33503	2851	2289
33504	2852	2576
33505	2853	2584
33506	2854	3794
33507	2855	2573
33508	2856	2686
33509	2857	2572
33510	2858	2685
33511	2859	2247
33512	2860	2577
33513	2861	2578
33514	2862	2579
33515	2863	2580
33516	2864	3795
33517	2865	3742
33518	2866	2582
33519	2867	2488
33520	2868	3668
33521	2869	3669
33522	2870	3670
33523	2871	2291
33524	2871	2290
33525	2872	2292
33526	2873	2585
33527	2874	2639
33528	2874	2640
33529	2874	3438
33530	2874	3439
33531	2875	3671
33532	2876	3672
33533	2877	2566
33534	2878	2567
33535	2879	2571
33536	2880	3673
33537	2881	3674
33538	2882	2583
33539	2883	2570
33540	2884	3675
33541	2885	2575
33542	2886	2568
33543	2887	3676
33544	2888	3677
33545	2889	3743
33546	2890	3744
33547	2891	3745
33548	2892	3678
33549	2893	2563
33550	2894	2564
33551	2895	2565
33552	2896	2612
33553	2897	3679
33554	2898	2293
33555	2899	2641
33556	2900	2613
33557	2901	3835
33558	2902	2447
33559	2903	2450
33560	2903	2451
33561	2903	2452
33562	2904	2614
33563	2905	2615
33564	2906	2449
33565	2906	2448
33566	2907	2445
33567	2907	2446
33568	2907	2443
33569	2907	2444
33570	2908	2460
33571	2908	2459
33572	2908	2461
33573	2909	2475
33574	2910	2473
33575	2910	2689
33576	2911	2474
33577	2912	2472
33578	2912	2688
33579	2913	3796
33580	2914	3797
33581	2915	3798
33582	2916	2928
33583	2917	2929
33584	2918	1005
33585	2919	924
33586	2920	1124
33587	2921	1118
33588	2922	1119
33589	2923	923
33590	2924	1133
33591	2925	1127
33592	2926	1109
33593	2927	2718
33594	2928	1113
33595	2929	1126
33596	2930	928
33597	2931	2720
33598	2932	1842
33599	2933	1841
33600	2934	2719
33601	2935	1112
33602	2936	1839
33603	2936	1840
33604	2937	1122
33605	2938	1120
33606	2939	1117
33607	2940	921
33608	2941	1125
33609	2942	1795
33610	2943	1792
33611	2943	1793
33612	2943	1794
33613	2944	1132
33614	2945	1111
33615	2946	920
33616	2947	919
33617	2948	1123
33618	2949	1729
33619	2949	1730
33620	2950	1131
33621	2951	1129
33622	2952	2731
33623	2953	1128
33624	2954	1121
33625	2955	966
33626	2957	3074
33627	2958	925
33628	2959	1108
33629	2960	926
33630	2961	1667
33631	2961	1668
33632	2962	922
33633	2963	2734
33634	2964	1114
33635	2965	1026
33636	2966	1116
33637	2967	1788
33638	2967	1787
33639	2967	1789
33640	2968	1115
33641	2969	1704
33642	2969	1705
33643	2969	1706
33644	2970	2262
33645	2971	3799
33646	2972	3800
33647	2973	2803
33648	2974	927
33649	2975	967
33650	2976	1699
33651	2977	968
33652	2978	2258
33653	2979	1709
33654	2980	1710
33655	2981	1708
33656	2982	1711
33657	2983	929
33658	2984	1110
33659	2985	969
33660	2986	1046
33661	2987	930
33662	2988	1107
33663	2989	1833
33664	2989	1834
33665	2990	1861
33666	2990	1862
33667	2991	2740
33668	2992	2757
33669	2993	2758
33670	2994	1808
33671	2994	1809
33672	2995	931
33673	2996	932
33674	2997	933
33675	2998	1801
33676	2998	1802
33677	2999	1106
33678	3000	1777
33679	3000	1778
33680	3000	1779
33681	3000	1942
33682	3000	1941
33683	3000	1943
33684	3001	1829
33685	3001	1828
33686	3002	1760
33687	3002	1759
33688	3002	1761
33689	3003	1790
33690	3003	1791
33691	3004	1631
33692	3005	2775
33693	3006	2735
33694	3007	1105
33695	3008	1781
33696	3008	1780
33697	3009	970
33698	3010	1762
33699	3010	1763
33700	3010	1837
33701	3010	1838
33702	3011	1830
33703	3011	1831
33704	3011	1832
33705	3012	2737
33706	3013	1103
33707	3014	2747
33708	3015	2749
33709	3016	1028
33710	3017	1648
33711	3017	1649
33712	3018	1101
33713	3019	934
33714	3020	1104
33715	3021	1635
33716	3022	1810
33717	3023	1811
33718	3024	1082
33719	3025	1864
33720	3026	1863
33721	3027	1102
33722	3028	935
33723	3029	1636
33724	3030	1936
33725	3030	1935
33726	3030	1937
33727	3031	2463
33728	3032	2464
33729	3033	2465
33730	3034	573
33731	3035	1011
33732	3036	2466
33733	3037	593
33734	3038	594
33735	3039	31
33736	3039	32
33737	3039	33
33738	3039	34
33739	3040	3746
33740	3041	3747
33741	3042	42
33742	3042	43
33743	3042	44
33744	3042	45
33745	3043	595
33746	3044	3748
33747	3196	2341
33748	3045	18
33749	3045	19
33750	3045	20
33751	3045	21
33752	3046	3749
33753	3047	1006
33754	3048	1004
33755	3049	577
33756	3050	3801
33757	3051	3802
33758	3052	3803
33759	3053	576
33760	3054	552
33761	3055	3750
33762	3056	3751
33763	3057	38
33764	3057	39
33765	3057	40
33766	3057	41
33767	3058	578
33768	3059	1020
33769	3060	1012
33770	3061	570
33771	3062	572
33772	3063	35
33773	3063	36
33774	3063	37
33775	3064	1291
33776	3065	553
33777	3066	598
33778	3067	46
33779	3067	47
33780	3067	48
33781	3068	3752
33782	3069	3753
33783	3070	3754
33784	3071	3755
33785	3072	3756
33786	3073	574
33787	3074	575
33788	3075	579
33789	3076	554
33790	3077	582
33791	3078	551
33792	3079	580
33793	3080	1009
33794	3081	1018
33795	3082	1014
33796	3083	569
33797	3084	581
33798	3085	583
33799	3086	1017
33800	3087	599
33801	3088	1021
33802	3089	571
33803	3090	584
33804	3091	3757
33805	3092	85
33806	3093	86
33807	3093	87
33808	3093	88
33809	3094	3758
33810	3095	3759
33811	3096	90
33812	3096	91
33813	3097	3760
33814	3098	89
33815	3099	3761
33816	3100	1010
33817	3101	92
33818	3101	93
33819	3101	94
33820	3101	95
33821	3101	96
33822	3102	1285
33823	3103	3762
33824	3104	1008
33825	3105	2696
33826	3106	3763
33827	3107	3764
33828	3108	15
33829	3108	16
33830	3108	17
33831	3109	3765
33832	3110	3766
33833	3111	28
33834	3112	3767
33835	3113	29
33836	3113	30
33837	3114	3768
33838	3115	3769
33839	3116	3770
33840	3117	3771
33841	3118	3772
33842	3119	26
33843	3119	27
33844	3120	25
33845	3121	12
33846	3121	13
33847	3121	14
33848	3122	3773
33849	3123	3774
33850	3124	3775
33851	3125	23
33852	3126	3776
33853	3127	24
33854	3127	1289
33855	3128	1290
33856	3129	3777
33857	3130	22
33858	3131	1007
33859	3132	600
33860	3133	62
33861	3133	63
33862	3133	64
33863	3134	49
33864	3134	50
33865	3134	51
33866	3134	1147
33867	3134	1146
33868	3134	1145
33869	3135	3778
33870	3136	58
33871	3136	59
33872	3136	60
33873	3136	61
33874	3137	52
33875	3137	53
33876	3137	54
33877	3137	55
33878	3137	56
33879	3137	57
33880	3138	3779
33881	3139	3780
33882	3140	3781
33883	3141	2937
33884	3144	1296
33885	3145	1297
33886	3145	1298
33887	3145	1299
33888	3146	1294
33889	3147	3783
33890	3148	1300
33891	3149	1427
33892	3150	3784
33893	3151	1148
33894	3151	1422
33895	3152	1307
33896	3152	1425
33897	3153	1423
33898	3153	1616
33899	3154	1308
33900	3155	592
33901	3156	588
33902	3157	590
33903	3158	591
33904	3159	587
33905	3160	589
33906	3161	585
33907	3162	586
33908	3172	3813
33909	3173	3814
33910	3174	3815
33911	3175	3816
33912	3176	3817
33913	3177	3818
33914	3178	3819
33915	3179	3820
33916	3180	3821
33917	3181	3811
33918	3182	3812
33919	3183	3823
33920	3184	3824
33921	3185	3825
33922	3186	2980
33923	3187	2981
33924	3188	2982
33925	3189	2983
33926	3190	2420
33927	3191	2336
33928	3192	2337
33929	3193	2338
33930	3194	2339
33931	3195	2340
33932	3197	2342
33933	3198	2343
33934	3199	2344
33935	3200	2345
33936	3201	2346
33937	3202	2347
33938	3203	2348
33939	3204	2349
33940	3205	2350
33941	3206	2351
33942	3207	2352
33943	3208	2353
33944	3209	2354
33945	3210	2355
33946	3211	2356
33947	3212	2357
33948	3213	2358
33949	3214	2359
33950	3215	2360
33951	3216	2361
33952	3217	2362
33953	3218	2363
33954	3219	2364
33955	3220	2365
33956	3221	2366
33957	3222	2367
33958	3223	2368
33959	3224	2369
33960	3225	2370
33961	3226	2371
33962	3227	2372
33963	3228	2373
33964	3229	2374
33965	3230	2375
33966	3231	2376
33967	3232	2377
33968	3233	2378
33969	3234	2379
33970	3235	2380
33971	3236	2381
33972	3237	2382
33973	3238	2383
33974	3239	2384
33975	3240	2385
33976	3241	2386
33977	3242	2387
33978	3243	2388
33979	3244	2389
33980	3245	2390
33981	3246	2391
33982	3247	2392
33983	3248	2393
33984	3249	2394
33985	3250	2395
33986	3251	2396
33987	3252	2397
33988	3253	2398
33989	3254	2399
33990	3255	2333
33991	3256	2848
33992	3257	3443
33993	3258	3444
33994	3259	2851
33995	3260	2850
33996	3260	3445
33997	3261	2849
33998	3262	3446
33999	3263	2330
34000	3264	2332
34001	3265	2331
34002	3266	2334
34003	3266	2335
34004	3267	3852
34005	3268	3847
34006	3269	3848
34007	3270	3849
34008	3271	3850
34009	3272	3851
34010	3273	2888
34011	3273	2894
34012	3274	2889
34013	3274	2895
34014	3275	2887
34015	3275	2893
34016	3276	2908
34017	3277	3174
34018	3277	3175
34019	3278	3099
34020	3278	3100
34021	3278	3176
34022	3278	3177
34023	3279	3101
34024	3279	3102
34025	3280	3178
34026	3280	3179
34027	3281	3103
34028	3281	3104
34029	3282	3180
34030	3282	3181
34031	3283	3105
34032	3283	3901
34033	3284	3106
34034	3284	3107
34035	3285	3182
34036	3285	3183
34037	3286	3184
34038	3286	3185
34039	3287	3109
34040	3287	3110
34041	3287	3187
34042	3287	3186
34043	3288	3111
34044	3288	3188
34045	3288	3189
34046	3289	3190
34047	3289	3191
34048	3290	3112
34049	3290	3113
34050	3291	3114
34051	3291	3115
34052	3291	3116
34053	3292	3192
34054	3292	3193
34055	3293	3117
34056	3293	3118
34057	3294	3119
34058	3294	3120
34059	3295	3121
34060	3295	3122
34061	3296	3194
34062	3296	3195
34063	3297	3196
34064	3297	3197
34065	3298	3198
34066	3298	3199
34067	3299	3123
34068	3299	3124
34069	3300	3200
34070	3300	3201
34071	3301	3126
34072	3301	3125
34073	3302	3127
34074	3302	3202
34075	3303	3128
34076	3303	3129
34077	3304	3130
34078	3304	3131
34079	3305	3203
34080	3305	3204
34081	3305	3853
34082	3306	3132
34083	3307	3133
34084	3307	3134
34085	3308	3135
34086	3309	3205
34087	3309	3206
34088	3310	3136
34089	3310	3137
34090	3311	3138
34091	3312	3165
34092	3313	3166
34093	3314	3167
34094	3315	3168
34095	3316	3140
34096	3316	3139
34097	3317	3141
34098	3318	3169
34099	3319	3170
34100	3320	3142
34101	3321	3171
34102	3322	3172
34103	3323	3144
34104	3323	3143
34105	3323	3145
34106	3324	3207
34107	3324	3208
34108	3325	3209
34109	3325	3210
34110	3325	3854
34111	3326	3173
34112	3327	3146
34113	3327	3148
34114	3327	3147
34115	3327	3211
34116	3327	3213
34117	3327	3212
34118	3327	3855
34119	3327	3856
34120	3328	3149
34121	3328	3150
34122	3329	3151
34123	3329	3152
34124	3330	3153
34125	3330	3154
34126	3331	3155
34127	3331	3156
34128	3332	3157
34129	3332	3158
34130	3332	3159
34131	3333	3160
34132	3334	3162
34133	3334	3161
34134	3334	3163
34135	3335	3164
34136	3336	3383
34137	3337	3384
34138	3338	3385
34139	3339	3386
34140	3340	3214
34141	3341	3902
34142	3342	1424
34143	3343	3785
34144	3344	2
34145	3344	1
34146	3344	1149
34147	3345	1302
34148	3345	1303
34149	3346	1309
34150	3347	3
34151	3347	1150
34152	3347	1151
34153	3348	1292
34154	3349	1293
34155	3350	1295
34156	3350	1301
34157	3351	6
34158	3351	7
34159	3352	1304
34160	3353	4
34161	3353	1286
34162	3354	9
34163	3354	10
34164	3355	65
34165	3355	66
34166	3355	67
34167	3356	11
34168	3357	5
34169	3357	1617
34170	3358	1287
34171	3358	1288
34172	3359	68
34173	3359	69
34174	3359	70
34175	3359	71
34176	3360	74
34177	3360	75
34178	3360	76
34179	3360	77
34180	3361	72
34181	3361	73
34182	3362	1305
34183	3362	1306
34184	3362	1623
34185	3363	8
34186	3364	3249
34187	3365	3250
34188	3366	3251
34189	3367	3252
34190	3368	3253
34191	3369	3254
34192	3370	3255
34193	3371	3256
34194	3372	3257
34195	3373	3258
34196	3374	3259
34197	3375	3260
34198	3376	3261
34199	3377	3262
34200	3378	3263
34201	3379	3264
34202	3379	3269
34203	3380	3265
34204	3381	3266
34205	3382	3267
34206	3383	3268
34207	3384	2943
34208	3385	2944
34209	3385	3246
34210	3386	2964
34211	3386	3388
34212	3387	2965
34213	3387	3247
34214	3387	3387
34215	3388	2966
34216	3388	3390
34217	3389	2967
34218	3389	3389
34219	3390	2968
34220	3390	3392
34221	3391	2969
34222	3391	3391
34223	3392	2945
34224	3393	2946
34225	3393	3248
34226	3394	2947
34227	3395	2948
34228	3396	3304
34229	3397	3306
34230	3398	3305
34231	3399	3300
34232	3400	79
34233	3400	80
34234	3401	1620
34235	3401	1621
34236	3402	81
34237	3403	1153
34238	3403	1154
34239	3404	78
34240	3405	2034
34241	3405	2035
34242	3406	83
34243	3406	84
34244	3407	1152
34245	3408	82
34246	3409	99
34247	3409	100
34248	3409	2246
34249	3410	97
34250	3410	101
34251	3410	102
34252	3411	98
34253	3412	105
34254	3413	104
34255	3413	106
34256	3413	107
34257	3414	108
34258	3414	109
34259	3415	1236
34260	3415	1237
34261	3416	103
34262	3417	359
34263	3543	896
34264	3417	363
34265	3417	361
34266	3417	362
34267	3418	360
34268	3419	364
34269	3420	365
34270	3420	366
34271	3420	368
34272	3420	367
34273	3421	1240
34274	3422	371
34275	3422	369
34276	3422	370
34277	3423	1238
34278	3423	1239
34279	3424	3688
34280	3425	374
34281	3425	372
34282	3426	373
34283	3426	375
34284	3426	1575
34285	3426	1622
34286	3427	378
34287	3427	377
34288	3428	379
34289	3429	376
34290	3430	380
34291	3430	383
34292	3431	382
34293	3431	384
34294	3432	385
34295	3432	381
34296	3432	2033
34297	3433	3689
34298	3434	388
34299	3435	387
34300	3435	386
34301	3435	389
34302	3436	390
34303	3437	392
34304	3438	393
34305	3439	391
34306	3440	3690
34307	3441	3691
34308	3442	394
34309	3443	396
34310	3444	397
34311	3445	395
34312	3446	399
34313	3446	400
34314	3446	401
34315	3446	402
34316	3447	398
34317	3448	3692
34318	3449	403
34319	3450	3693
34320	3451	405
34321	3451	406
34322	3452	404
34323	3453	3694
34324	3454	3695
34325	3455	408
34326	3455	410
34327	3455	409
34328	3455	407
34329	3456	414
34330	3456	411
34331	3456	413
34332	3456	412
34333	3457	417
34334	3457	415
34335	3457	416
34336	3457	418
34337	3458	1241
34338	3458	1242
34339	3459	422
34340	3459	421
34341	3459	420
34342	3459	419
34343	3459	1244
34344	3459	1245
34345	3460	1243
34346	3460	1618
34347	3460	1619
34348	3461	423
34349	3462	1013
34350	3463	3309
34351	3464	3310
34352	3465	3311
34353	3466	3312
34354	3467	3313
34355	3468	3314
34356	3469	3315
34357	3470	3316
34358	3471	3318
34359	3472	3319
34360	3473	3320
34361	3474	3321
34362	3475	3322
34363	3476	3323
34364	3477	3324
34365	3478	3325
34366	3479	3326
34367	3480	2949
34368	3481	3327
34369	3482	3328
34370	3483	3329
34371	3484	3308
34372	3485	3330
34373	3486	3331
34374	3487	3332
34375	3488	3333
34376	3489	3334
34377	3490	3335
34378	3491	3336
34379	3492	3337
34380	3493	3338
34381	3494	3339
34382	3495	3340
34383	3496	3341
34384	3497	3342
34385	3498	3343
34386	3499	3344
34387	3500	3345
34388	3501	3346
34389	3502	3347
34390	3503	3348
34391	3504	3349
34392	3505	3350
34393	3506	2951
34394	3506	2950
34395	3507	3351
34396	3507	3352
34397	3508	3354
34398	3508	3353
34399	3509	1325
34400	3510	3447
34401	3511	2467
34402	3512	2468
34403	3513	1016
34404	3514	1019
34405	3515	1015
34406	3516	610
34407	3517	1248
34408	3518	611
34409	3519	612
34410	3520	613
34411	3521	614
34412	3522	605
34413	3523	616
34414	3524	604
34415	3525	3356
34416	3525	3357
34417	3526	3358
34418	3527	3359
34419	3528	3360
34420	3529	3361
34421	3530	3362
34422	3531	3363
34423	3532	3364
34424	3533	3365
34425	3534	3367
34426	3535	3368
34427	3536	3369
34428	3537	3371
34429	3537	3370
34430	3538	3372
34431	3539	3373
34432	3540	3374
34433	3541	3366
34434	3542	3375
34435	3543	897
34436	3543	898
34437	3544	899
34438	3544	901
34439	3544	900
34440	3545	1319
34441	3546	606
34442	3547	607
34443	3548	608
34444	3549	609
34445	3550	615
34446	3551	673
34447	3552	674
34448	3553	597
34449	3554	596
34450	3555	2952
34451	3556	3423
34452	3556	3424
34453	3557	3419
34454	3558	3420
34455	3559	3421
34456	3560	3422
34457	3561	3425
34458	3562	3845
34459	3563	3303
34460	3564	3428
34461	3565	3429
34462	3566	2891
34463	3566	2897
34464	3567	2892
34465	3567	2898
34466	3568	2890
34467	3568	2896
34468	3569	1316
34469	3570	1317
34470	3571	1246
34471	3572	1318
34472	3573	1247
34473	3574	2845
34474	3575	2846
34475	3576	2847
34476	3577	2842
34477	3578	2843
34478	3579	2844
34479	3580	2781
34480	3581	2782
34481	3582	2783
34482	3582	2784
34483	3583	2785
34484	3584	2795
34485	3585	2796
34486	3586	2797
34487	3587	2799
34488	3587	2798
34489	3588	2802
34490	3589	3836
34491	3590	3837
34492	3591	3434
34493	3592	2759
34494	3593	2936
34495	3594	2930
34496	3594	2931
34497	3594	2932
34498	3594	2933
34499	3594	2984
34500	3594	2985
34501	3594	2986
34502	3594	2987
34503	3594	3238
34504	3594	3239
34505	3594	3240
34506	3594	3241
34507	3594	3431
34508	3594	3430
34509	3594	3433
34510	3594	3432
34511	3595	2760
34512	3596	2761
34513	3597	3838
34514	3598	3839
34515	3599	3840
34516	3600	3841
34517	3601	2836
34518	3602	2837
34519	3603	2838
34520	3604	2953
34521	3605	2839
34522	3606	2840
34523	3607	2841
34524	3608	3435
34525	3609	3436
34526	3610	3437
34527	3611	3301
34528	3612	3302
34529	11091	2901
34530	11088	2828
34531	1567	10000
34532	1568	10001
34533	1584	10002
34534	1585	10003
34535	1586	10004
34536	1553	10005
34537	1588	10006
34538	1587	10007
34539	10008	10008
34540	1596	10009
34541	1591	10010
34542	1590	10011
34543	1600	10012
34544	1599	10013
34545	1606	10014
34546	1606	10015
34547	1602	10016
34548	1628	10017
34549	1628	10018
34550	10019	10019
34551	10020	10020
34552	1592	10021
34553	1592	10022
34554	1592	10023
34555	10024	10024
34556	1618	10025
34557	1620	10026
34558	1607	10027
34559	1608	10028
34560	1610	10029
34561	1611	10030
34562	1612	10031
34563	1613	10032
34564	1614	10033
34565	1615	10034
34566	1616	10035
34567	10036	10036
34568	1621	10037
34569	1622	10038
34570	1623	10039
34571	1624	10040
34572	1625	10041
34573	1626	10042
34574	1627	10043
34575	1612	10044
34576	1612	10045
34577	1612	10046
34578	1612	10047
34579	10048	10048
34580	10049	10049
34581	10050	10050
34582	3562	10051
34583	3465	10052
34584	3467	10053
34585	3469	10054
34586	3471	10055
34587	3480	10056
34588	3486	10057
34589	10058	10058
34590	10059	10059
34591	10060	10060
34592	10061	10061
34593	10062	10062
34594	10063	10063
34595	1404	10064
34596	1404	10065
34597	1404	10066
34598	1404	10067
34599	1404	10068
34600	1461	10069
34601	1461	10070
34602	1461	10071
34603	1461	10072
34604	1461	10073
34605	1483	10074
34606	1483	10075
34607	1483	10076
34608	1483	10077
34609	1483	10078
34610	3484	10079
34611	3336	10080
34612	3337	10081
34613	3338	10082
34614	3339	10083
34615	10084	10084
34616	10084	10085
34617	10086	10086
34618	10086	10087
34619	10088	10088
34620	10088	10089
34621	1424	10090
34622	1447	10091
34623	1465	10092
34624	1472	10093
34625	1473	10094
34626	1492	10095
34627	3525	10096
34628	3525	10097
34629	3526	10098
34630	3533	10099
34631	3527	10100
34632	3532	10101
34633	3529	10102
34634	3528	10103
34635	3531	10104
34636	3530	10105
34637	3183	10106
34638	3184	10107
34639	3185	10108
34640	3480	10109
34641	10110	10110
34642	3490	10111
34643	10112	10112
34644	10112	10113
34645	10114	10114
34646	10114	10115
34647	10116	10116
34648	10116	10117
34649	1571	10118
34650	1409	10119
34651	1476	10120
34652	1446	10121
34653	1527	10122
34654	3480	10123
34655	3604	10124
34656	3555	10125
34657	10126	10126
34658	3507	10127
34659	10128	10128
34660	10129	10129
34661	10130	10130
34662	10131	10131
34663	10084	10132
34664	10084	10133
34665	10086	10134
34666	10086	10135
34667	10088	10136
34668	10088	10137
34669	1424	10138
34670	1447	10139
34671	1465	10140
34672	1472	10141
34673	1473	10142
34674	10143	10143
34675	10144	10144
34676	10144	10145
34677	10146	10146
34678	10146	10147
34679	10148	10148
34680	10148	10149
34681	10150	10150
34682	10150	10151
34683	1444	10152
34684	1522	10153
34685	10154	10154
34686	3593	10155
34687	1413	10156
34688	1451	10157
34689	1504	10158
34690	1410	10159
34691	1655	10160
34692	1655	10161
34693	10162	10162
34694	1543	10163
34695	3535	10164
34696	3534	10165
34697	3537	10166
34698	3537	10167
34699	10168	10168
34700	3536	10169
34701	3540	10170
34702	3539	10171
34703	1659	10172
34704	1662	10173
34705	1638	10174
34706	1641	10175
34707	10176	10176
34708	10176	10177
34709	10178	10178
34710	10178	10179
34711	10180	10180
34712	10180	10181
34713	10182	10182
34714	10182	10183
34715	10184	10184
34716	10184	10185
34717	10186	10186
34718	10186	10187
34719	3542	10188
34720	3541	10189
34721	3602	10190
34722	10191	10191
34723	3277	10192
34724	3277	10193
34725	3278	10194
34726	3278	10195
34727	3280	10196
34728	3280	10197
34729	3282	10198
34730	3282	10199
34731	3286	10200
34732	3286	10201
34733	3287	10202
34734	3287	10203
34735	3292	10204
34736	3292	10205
34737	3327	10206
34738	3327	10207
34739	1456	10208
34740	1460	10209
34741	1511	10210
34742	1426	10211
34743	1506	10212
34744	1415	10213
34745	1422	10214
34746	1425	10215
34747	1647	10216
34748	1647	10217
34749	1648	10218
34750	1648	10219
34751	3605	10220
34752	3603	10221
34753	3601	10222
34754	3606	10223
34755	3285	10224
34756	3285	10225
34757	3288	10226
34758	3288	10227
34759	3296	10228
34760	3296	10229
34761	3297	10230
34762	3297	10231
34763	3298	10232
34764	3298	10233
34765	3300	10234
34766	3300	10235
34767	3309	10236
34768	3309	10237
34769	3325	10238
34770	3325	10239
34771	1521	10240
34772	1524	10241
34773	1529	10242
34774	1526	10243
34775	1531	10244
34776	1541	10245
34777	3279	10246
34778	3279	10247
34779	3329	10248
34780	3329	10249
34781	3330	10250
34782	3330	10251
34783	3463	10252
34784	3464	10253
34785	3466	10254
34786	3468	10255
34787	10256	10256
34788	10256	10257
34789	10258	10258
34790	10259	10259
34791	10260	10260
34792	10261	10261
34793	10261	10262
34794	10263	10263
34795	10264	10264
34796	10265	10265
34797	10266	10266
34798	10267	10267
34799	10268	10268
34800	10269	10269
34801	3473	10270
34802	3474	10271
34803	3494	10272
34804	3499	10273
34805	3498	10274
34806	3495	10275
34807	3493	10276
34808	3497	10277
34809	3496	10278
34810	3492	10279
34811	3500	10280
34812	3501	10281
34813	3505	10282
34814	3502	10283
34815	3503	10284
34816	3504	10285
34817	1404	10286
34818	10287	10287
34819	3284	10288
34820	3284	10289
34821	3290	10290
34822	3290	10291
34823	3291	10292
34824	3291	10293
34825	3293	10294
34826	3293	10295
34827	3294	10296
34828	3294	10297
34829	3295	10298
34830	3295	10299
34831	3281	10300
34832	3302	10301
34833	3327	10302
34834	3327	10303
34835	10304	10304
34836	3581	10305
34837	3582	10306
34838	3582	10307
34839	3583	10308
34840	3583	10309
34841	3588	10310
34842	10311	10311
34843	3585	10312
34844	3586	10313
34845	3587	10314
34846	3587	10315
34847	10316	10316
34848	3303	10317
34849	3304	10318
34850	3306	10319
34851	1508	10320
34852	1515	10321
34853	1510	10322
34854	1518	10323
34855	1519	10324
34856	1417	10325
34857	1419	10326
34858	1427	10327
34859	1437	10328
34860	1452	10329
34861	1457	10330
34862	1455	10331
34863	1478	10332
34864	1475	10333
34865	1486	10334
34866	1488	10335
34867	1426	10336
34868	1444	10337
34869	1473	10338
34870	1504	10339
34871	1313	10340
34872	1313	10341
34873	1248	10342
34874	1252	10343
34875	1252	10344
34876	1270	10345
34877	1270	10346
34878	1275	10347
34879	1275	10348
34880	1279	10349
34881	1352	10350
34882	1661	10351
34883	1663	10352
34884	1664	10353
34885	1668	10354
34886	1671	10355
34887	1685	10356
34888	1684	10357
34889	1686	10358
34890	1687	10359
34891	1688	10360
34892	1690	10361
34893	1672	10362
34894	1514	10363
34895	1467	10364
34896	1470	10365
34897	1443	10366
34898	1420	10367
34899	1542	10368
34900	1394	10369
34901	1358	10370
34902	1354	10371
34903	1408	10372
34904	1421	10373
34905	10374	10374
34906	10375	10375
34907	10376	10376
34908	10377	10377
34909	10377	10378
34910	10377	10379
34911	10380	10380
34912	10381	10381
34913	10382	10382
34914	10383	10383
34915	10384	10384
34916	10385	10385
34917	10386	10386
34918	10387	10387
34919	10388	10388
34920	10389	10389
34921	10390	10390
34922	10391	10391
34923	10392	10392
34924	10393	10393
34925	1400	10394
34926	1210	10395
34927	1195	10396
34928	1237	10397
34929	1250	10398
34930	10399	10399
34931	10400	10400
34932	10401	10401
34933	10402	10402
34934	10403	10403
34935	10404	10404
34936	1412	10405
34937	1412	10406
34938	1412	10407
34939	1412	10408
34940	1412	10409
34941	1329	10410
34942	1329	10411
34943	1329	10412
34944	1329	10413
34945	1329	10414
34946	1338	10415
34947	1338	10416
34948	1338	10417
34949	1338	10418
34950	1338	10419
34951	1321	10420
34952	1321	10421
34953	1321	10422
34954	1321	10423
34955	1321	10424
34956	1466	10425
34957	1489	10426
34958	1573	10427
34959	3327	10428
34960	3302	10429
34961	3305	10430
34962	3305	10431
34963	3289	10432
34964	3289	10433
34965	3324	10434
34966	3324	10435
34967	10084	10436
34968	10112	10437
34969	10438	10438
34970	3471	10439
34971	3287	10440
34972	3328	10441
34973	3328	10442
34974	3331	10443
34975	3331	10444
34976	3332	10445
34977	3332	10446
34978	3316	10447
34979	3316	10448
34980	3308	10449
34981	3310	10450
34982	3311	10451
34983	3299	10452
34984	3301	10453
34985	3323	10454
34986	3284	10455
34987	3291	10456
34988	10114	10457
34989	1315	10458
34990	1315	10459
34991	1315	10460
34992	1315	10461
34993	1315	10462
34994	1323	10463
34995	1323	10464
34996	1323	10465
34997	1323	10466
34998	1323	10467
34999	10468	10468
35000	1525	10469
35001	1525	10470
35002	1525	10471
35003	1525	10472
35004	1525	10473
35005	1416	10474
35006	1416	10475
35007	1416	10476
35008	1416	10477
35009	1416	10478
35010	10479	10479
35011	2916	10480
35012	2917	10481
35013	3278	10482
35014	1360	10483
35015	1335	10484
35016	1709	10485
35017	1709	10486
35018	1709	10487
35019	1721	10488
35020	1721	10489
35021	1721	10490
35022	3307	10491
35023	10492	10492
35024	10492	10493
35025	10494	10494
35026	10494	10495
35027	1496	10496
35028	1498	10497
35029	1499	10498
35030	1501	10499
35031	1502	10500
35032	1513	10501
35033	1520	10502
35034	1534	10503
35035	1535	10504
35036	1533	10505
35037	3591	10506
35038	3470	10507
35039	3472	10508
35040	3475	10509
35041	3476	10510
35042	3477	10511
35043	3478	10512
35044	3479	10513
35045	3482	10514
35046	3483	10515
35047	3485	10516
35048	3487	10517
35049	10518	10518
35050	1581	10519
35051	1649	10520
35052	1530	10521
35053	1539	10522
35054	1556	10523
35055	1555	10524
35056	1558	10525
35057	1574	10526
35058	1580	10527
35059	10528	10528
35060	10529	10529
35061	3341	10530
35062	10531	10531
35063	1459	10532
35064	1680	10533
35065	3323	10534
35066	3332	10535
35067	3481	10536
35068	3488	10537
35069	3489	10538
35070	3491	10539
35071	3281	10540
35072	3299	10541
35073	3301	10542
35074	3303	10543
35075	3320	10544
35076	3284	10545
35077	3284	10546
35078	3284	10547
35079	1497	10548
35080	1629	10549
35081	1637	10550
35082	1448	10551
35083	10552	10552
35084	10553	10553
35085	10554	10554
35086	10555	10555
35087	10556	10556
35088	10557	10557
35089	10558	10558
35090	10559	10559
35091	10560	10560
35092	10561	10561
35093	1321	10562
35094	1321	10563
35095	1321	10564
35096	1321	10565
35097	3188	10566
35098	3189	10567
35099	3186	10568
35100	3187	10569
35101	3323	10570
35102	3284	10571
35103	10572	10572
35104	3005	10573
35105	1582	10574
35106	1332	10575
35107	1094	10576
35108	1067	10577
35109	1485	10578
35110	1683	10579
35111	10580	10580
35112	1725	10581
35113	1516	10582
35114	1517	10583
35115	3304	10584
35116	3307	10585
35117	3310	10586
35118	3317	10587
35119	3327	10588
35120	3284	10589
35121	1729	10590
35122	1729	10591
35123	3565	10592
35124	3510	10593
35125	3564	10594
35126	10492	10595
35127	3291	10596
35128	1496	10597
35129	10598	10598
35130	10599	10599
35131	10600	10600
35132	10601	10601
35133	10602	10602
35134	10603	10603
35135	10604	10604
35136	1672	10605
35137	10606	10606
35138	10607	10607
35139	10608	10608
35140	10609	10609
35141	10610	10610
35142	10610	10611
35143	10612	10612
35144	10613	10613
35145	10613	10614
35146	10615	10615
35147	10615	10616
35148	3285	10617
35149	3288	10618
35150	1709	10619
35151	1709	10620
35152	1721	10621
35153	10622	10622
35154	10622	10623
35155	10624	10624
35156	10624	10625
35157	10626	10626
35158	10626	10627
35159	10628	10628
35160	10626	10629
35161	3306	10630
35162	3311	10631
35163	3320	10632
35164	3329	10633
35165	1321	10634
35166	1321	10635
35167	1321	10636
35168	1321	10637
35169	10638	10638
35170	10639	10639
35171	10640	10640
35172	10641	10641
35173	10642	10642
35174	10643	10643
35175	10644	10644
35176	10645	10645
35177	10646	10646
35178	10647	10647
35179	10647	10648
35180	10649	10649
35181	10650	10650
35182	10651	10651
35183	1315	10652
35184	1412	10653
35185	10654	10654
35186	10655	10655
35187	10656	10656
35188	10657	10657
35189	10658	10658
35190	10659	10659
35191	10660	10660
35192	10661	10661
35193	10662	10662
35194	10663	10663
35195	10664	10664
35196	10665	10665
35197	10665	10666
35198	10665	10667
35199	10665	10668
35200	10669	10669
35201	10669	10670
35202	10669	10671
35203	10669	10672
35204	10669	10673
35205	10674	10674
35206	10675	10675
35207	10676	10676
35208	10677	10677
35209	10678	10678
35210	10679	10679
35211	10680	10680
35212	10681	10681
35213	10682	10682
35214	10683	10683
35215	10684	10684
35216	10685	10685
35217	10686	10686
35218	10622	10687
35219	10622	10688
35220	10689	10689
35221	10610	10690
35222	10610	10691
35223	10613	10692
35224	10613	10693
35225	10615	10694
35226	10615	10695
35227	3305	10696
35228	3310	10697
35229	3277	10698
35230	3278	10699
35231	3305	10700
35232	3325	10701
35233	3327	10702
35234	1683	10703
35235	1516	10704
35236	10656	10705
35237	10660	10706
35238	10662	10707
35239	1409	10708
35240	1476	10709
35241	1446	10710
35242	1527	10711
35243	1496	10712
35244	10713	10713
35245	10713	10714
35246	10713	10715
35247	10716	10716
35248	10716	10717
35249	10716	10718
35250	10719	10719
35251	10720	10720
35252	10721	10721
35253	10722	10722
35254	10723	10723
35255	10724	10724
35256	10725	10725
35257	10726	10726
35258	10726	10727
35259	10728	10728
35260	10729	10729
35261	10730	10730
35262	10731	10731
35263	10732	10732
35264	10733	10733
35265	10734	10734
35266	10735	10735
35267	10736	10736
35268	10737	10737
35269	10738	10738
35270	10739	10739
35271	1416	10740
35272	1416	10741
35273	10742	10742
35274	10742	10743
35275	10742	10744
35276	10742	10745
35277	10746	10746
35278	10746	10747
35279	10746	10748
35280	10746	10749
35281	10746	10750
35282	10751	10751
35283	10751	10752
35284	10753	10753
35285	10753	10754
35286	10755	10755
35287	10755	10756
35288	10757	10757
35289	10757	10758
35290	10757	10759
35291	10757	10760
35292	10761	10761
35293	10762	10762
35294	10763	10763
35295	10763	10764
35296	10765	10765
35297	10766	10766
35298	10767	10767
35299	10768	10768
35300	10769	10769
35301	10770	10770
35302	10771	10771
35303	10772	10772
35304	10773	10773
35305	10773	10774
35306	10775	10775
35307	10776	10776
35308	10777	10777
35309	10777	10778
35310	10779	10779
35311	10780	10780
35312	10781	10781
35313	10782	10782
35314	10783	10783
35315	10783	10784
35316	10785	10785
35317	10786	10786
35318	10787	10787
35319	10788	10788
35320	10789	10789
35321	10790	10790
35322	10657	10791
35323	10659	10792
35324	10661	10793
35325	10794	10794
35326	10795	10795
35327	10796	10796
35328	10797	10797
35329	10798	10798
35330	10799	10799
35331	10800	10800
35332	1461	10801
35333	1461	10802
35334	10803	10803
35335	10804	10804
35336	10805	10805
35337	10806	10806
35338	10807	10807
35339	10808	10808
35340	10809	10809
35341	10808	10810
35342	10811	10811
35343	10812	10812
35344	10813	10813
35345	10814	10814
35346	10814	10815
35347	10816	10816
35348	10816	10817
35349	10818	10818
35350	10818	10819
35351	10820	10820
35352	10820	10821
35353	10822	10822
35354	10823	10823
35355	10824	10824
35356	10825	10825
35357	10826	10826
35358	10827	10827
35359	10828	10828
35360	10829	10829
35361	10830	10830
35362	10831	10831
35363	10832	10832
35364	10833	10833
35365	10834	10834
35366	10835	10835
35367	10836	10836
35368	10837	10837
35369	10838	10838
35370	10839	10839
35371	10840	10840
35372	10841	10841
35373	10842	10842
35374	10843	10843
35375	10844	10844
35376	10845	10845
35377	10846	10846
35378	10847	10847
35379	10847	10848
35380	10849	10849
35381	10849	10850
35382	10851	10851
35383	10851	10852
35384	10853	10853
35385	10854	10854
35386	10855	10855
35387	10856	10856
35388	10857	10857
35389	10858	10858
35390	10859	10859
35391	10860	10860
35392	10861	10861
35393	10862	10862
35394	10863	10863
35395	10864	10864
35396	10865	10865
35397	10866	10866
35398	10780	10867
35399	10781	10868
35400	10126	10869
35401	10126	10870
35402	10126	10871
35403	10126	10872
35404	10873	10873
35405	10873	10874
35406	10873	10875
35407	10873	10876
35408	10873	10877
35409	10873	10878
35410	10879	10879
35411	10879	10880
35412	10881	10881
35413	10881	10882
35414	10881	10883
35415	10881	10884
35416	10885	10885
35417	10885	10886
35418	10885	10887
35419	10885	10888
35420	10889	10889
35421	10890	10890
35422	1540	10891
35423	1540	10892
35424	1540	10893
35425	10894	10894
35426	10894	10895
35427	10894	10896
35428	10894	10897
35429	10898	10898
35430	10898	10899
35431	10898	10900
35432	10901	10901
35433	10901	10902
35434	10903	10903
35435	10903	10904
35436	10903	10905
35437	10906	10906
35438	10906	10907
35439	10906	10908
35440	10909	10909
35441	10910	10910
35442	10910	10911
35443	10912	10912
35444	10913	10913
35445	10914	10914
35446	10915	10915
35447	10916	10916
35448	10917	10917
35449	10918	10918
35450	10918	10919
35451	10918	10920
35452	10918	10921
35453	10918	10922
35454	10923	10923
35455	10924	10924
35456	10757	10925
35457	10757	10926
35458	10757	10927
35459	10928	10928
35460	10928	10929
35461	10928	10930
35462	10928	10931
35463	10932	10932
35464	10932	10933
35465	10932	10934
35466	1760	10935
35467	1719	10936
35468	1740	10937
35469	1739	10938
35470	1737	10939
35471	1717	10940
35472	1693	10941
35473	1491	10942
35474	1670	10943
35475	3312	10944
35476	3313	10945
35477	3314	10946
35478	3315	10947
35479	3318	10948
35480	3319	10949
35481	3321	10950
35482	3322	10951
35483	3326	10952
35484	3507	10953
35485	3507	10954
35486	3508	10955
35487	3508	10956
35488	10957	10957
35489	10958	10958
35490	10959	10959
35491	10960	10960
35492	10960	10961
35493	10960	10962
35494	10963	10963
35495	10963	10964
35496	10963	10965
35497	10966	10966
35498	10966	10967
35499	10966	10968
35500	10969	10969
35501	10381	10970
35502	10381	10971
35503	10972	10972
35504	10972	10973
35505	10974	10974
35506	10974	10975
35507	10974	10976
35508	10977	10977
35509	10977	10978
35510	10979	10979
35511	10980	10980
35512	10981	10981
35513	10982	10982
35514	10983	10983
35515	10984	10984
35516	10985	10985
35517	10986	10986
35518	10987	10987
35519	10988	10988
35520	10989	10989
35521	10990	10990
35522	10991	10991
35523	10992	10992
35524	10993	10993
35525	10994	10994
35526	11228	11228
35527	10995	10995
35528	10996	10996
35529	10997	10997
35530	10998	10998
35531	10999	10999
35532	11000	11000
35533	11001	11001
35534	11002	11002
35535	11003	11003
35536	11004	11004
35537	11005	11005
35538	11006	11006
35539	11007	11007
35540	11008	11008
35541	11009	11009
35542	11010	11010
35543	11010	11011
35544	11012	11012
35545	11012	11013
35546	11014	11014
35547	11014	11015
35548	11016	11016
35549	11016	11017
35550	11018	11018
35551	11018	11019
35552	11018	11020
35553	10380	11021
35554	10380	11022
35555	11023	11023
35556	11024	11024
35557	11025	11025
35558	11026	11026
35559	10751	11027
35560	10753	11028
35561	10755	11029
35562	10768	11030
35563	10773	11031
35564	11032	11032
35565	11033	11033
35566	11034	11034
35567	11035	11035
35568	11036	11036
35569	11037	11037
35570	11038	11038
35571	11039	11039
35572	11040	11040
35573	11041	11041
35574	11042	11042
35575	11042	11043
35576	11044	11044
35577	11045	11045
35578	11046	11046
35579	10377	11047
35580	10377	11048
35581	10377	11049
35582	10380	11050
35583	10381	11051
35584	11052	11052
35585	11053	11053
35586	11054	11054
35587	11055	11055
35588	11056	11056
35589	11057	11057
35590	11058	11058
35591	11059	11059
35592	11060	11060
35593	11061	11061
35594	11062	11062
35595	11063	11063
35596	3611	11064
35597	3612	11065
35598	3563	11066
35599	11067	11067
35600	11067	11068
35601	11069	11069
35602	11069	11070
35603	3396	11071
35604	3398	11072
35605	3397	11073
35606	11074	11074
35607	11075	11075
35608	11076	11076
35609	11077	11077
35610	11078	11078
35611	11079	11079
35612	11080	11080
35613	11081	11081
35614	11082	11082
35615	11083	11083
35616	3399	11084
35617	11085	11085
35618	11086	11086
35619	11087	11087
35620	11088	11088
35621	11089	11089
35622	11090	11090
35623	11091	11091
35624	11092	11092
35625	11093	11093
35626	3597	11094
35627	3598	11095
35628	3599	11096
35629	3600	11097
35630	3589	11098
35631	3590	11099
35632	3272	11100
35633	3271	11101
35634	3270	11102
35635	3269	11103
35636	3268	11104
35637	3267	11105
35638	11106	11106
35639	11107	11107
35640	11108	11108
35641	11109	11109
35642	11110	11110
35643	11111	11111
35644	11112	11112
35645	11113	11113
35646	11114	11114
35647	11115	11115
35648	11116	11116
35649	11117	11117
35650	11118	11118
35651	11119	11119
35652	11120	11120
35653	11121	11121
35654	11122	11122
35655	11123	11123
35656	11124	11124
35657	11125	11125
35658	11126	11126
35659	11127	11127
35660	11128	11128
35661	11129	11129
35662	11130	11130
35663	11131	11131
35664	11132	11132
35665	11133	11133
35666	11134	11134
35667	11135	11135
35668	11136	11136
35669	11137	11137
35670	11138	11138
35671	11139	11139
35672	11140	11140
35673	11141	11141
35674	11142	11142
35675	11143	11143
35676	11144	11144
35677	11145	11145
35678	11146	11146
35679	11147	11147
35680	11148	11148
35681	11149	11149
35682	11150	11150
35683	11151	11151
35684	11152	11152
35685	11153	11153
35686	11154	11154
35687	11155	11155
35688	11156	11156
35689	11157	11157
35690	11158	11158
35691	11159	11159
35692	11160	11160
35693	11161	11161
35694	11162	11162
35695	11163	11163
35696	11164	11164
35697	11165	11165
35698	11166	11166
35699	11167	11167
35700	11168	11168
35701	11169	11169
35702	11170	11170
35703	11171	11171
35704	11172	11172
35705	11173	11173
35706	11174	11174
35707	11175	11175
35708	11176	11176
35709	11177	11177
35710	11178	11178
35711	11179	11179
35712	11180	11180
35713	11181	11181
35714	11182	11182
35715	11183	11183
35716	11184	11184
35717	11185	11185
35718	11186	11186
35719	11187	11187
35720	11188	11188
35721	11189	11189
35722	11190	11190
35723	11191	11191
35724	11192	11192
35725	11193	11193
35726	11194	11194
35727	11195	11195
35728	1789	11196
35729	1789	11197
35730	11198	11198
35731	11198	11199
35732	11200	11200
35733	11200	11201
35734	11202	11202
35735	11202	11203
35736	11202	11204
35737	11205	11205
35738	11205	11206
35739	11207	11207
35740	11207	11208
35741	11207	11209
35742	11210	11210
35743	11211	11211
35744	3508	11212
35745	11018	11213
35746	3508	11214
35747	3508	11215
35748	3508	11216
35749	3508	11217
35750	11018	11218
35751	11018	11219
35752	11220	11220
35753	11221	11221
35754	11222	11222
35755	11223	11223
35756	11224	11224
35757	11225	11225
35758	11226	11226
35759	11018	11227
35760	11228	11229
35761	11230	11230
35762	11231	11231
35763	11232	11232
35764	11233	11233
35765	11234	11234
35766	11234	11235
35767	11236	11236
35768	11237	11237
35769	11238	11238
35770	11239	11239
35771	11240	11240
35772	11241	11241
35773	11242	11242
35774	11243	11243
35775	11244	11244
35776	11245	11245
35777	11246	11246
35778	11247	11247
35779	11248	11248
35780	11249	11249
35781	11250	11250
35782	11251	11251
\.


--
-- Data for Name: blocks; Type: TABLE DATA; Schema: public; Owner: borisbastian
--

COPY public.blocks (bl_id, name, age, ulceration, thickness, mitoses, p_stage, prim, subtype, slides, slides_left, fixation, storage, scan_number, icd10, diagnosis, notes, micro, gross, clinical, date_added, old_body_site, collection, path_note, ip_dx, body_site_id, patient, project_id, department, path_number, specimen, patient_id, project, patient_ip_id, import_source) FROM stdin;
1002	00-001103	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1767	\N	\N	00-1103	\N	SYNAT1	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1003	00-001103B7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1767	\N	\N	00-1103	B7	SYNAT1	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3094	19111/14.4	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-051_1.4	\N	\N	\N	\N	right heel	\N	\N	\N	\N	25	\N	\N	None	\N	AM2-051	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2118	17-35859C	36	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10865	216.5	DN	\N	The features are similar to those in (B).	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted in C. PL/PL	A) JC17-152, R/O 6 MM ATYPICAL MOLE, B) JC17-153, R/O 6 MM ATYPICAL MOLE, C) JC17-154, R/O 3 MM ATYPICAL MOLE	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS	173543	497	\N	\N	17-35859	C	DN-022	Dysplastic Nevi	IP1082132	AirTable blocks_with_IP_info.csv
1363	10-972C2	54	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of small melanocytes with round to oval nuclei, the junctional component of which consists of nested and solitary melanocytes arrayed along the sides and bases of elongated rete.  There are similar melanocytes within the underlying papillary and reticular dermis, with melanocytes splayed amongst collagen bundles, largely in the upper half of the reticular dermis.	Cylindrical skin segment, 0.8 cm in diameter and 0.3 cm in thickness, trisected and entirely submitted in cassette A.	A-B) R/O DN	\N	\N	\N	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF SUPERFICIAL CONGENITAL TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173504	2289	\N	\N	10-972	C2	SYNAT57	Long-Triple Negative Metastatic Melanoma	IP895542	AirTable blocks_with_IP_info.csv
1364	10-1843A4	10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show clusters of cytologically bland melanocytes, both at the dermal-epidermal junction and in the reticular dermis, where melanocytes lie between reticular dermal collagen bundles.	One outside slide, M10-38.	NEVUS, R/O DYSPLASTIC NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, CONGENITAL PATTERN	529699	2129	\N	\N	10-1843	A4	SYNAT58	2010-2017	IP896413	AirTable blocks_with_IP_info.csv
1365	10-1843A5	10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show clusters of cytologically bland melanocytes, both at the dermal-epidermal junction and in the reticular dermis, where melanocytes lie between reticular dermal collagen bundles.	One outside slide, M10-38.	NEVUS, R/O DYSPLASTIC NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, CONGENITAL PATTERN	529699	2129	\N	\N	10-1843	A5	SYNAT58	Long-Triple Negative Metastatic Melanoma	IP896413	AirTable blocks_with_IP_info.csv
1370	10-3560F1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2263	\N	\N	10-3560	F1	SYNAT59	2010-2017	\N	AirTable blocks_with_IP_info.csv
1366	10-3560A3	66	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.0	\N	\N	Sections show zones of the epidermis that contain a proliferation of keratinocytes with atypical nuclei, and parakeratosis containing inflammatory cells is present in the overlying cornified layer.	Cylindrical skin segment measuring 0.3 cm in diameter and 0.1 cm in thickness.	H/O SCC, BCC, PERSISTENT SCALY PATCH, PRIOR TX X2 LN02	\N	\N	\N	\N	CRUSTED SOLAR KERATOSIS	123144	2263	\N	\N	10-3560	A3	SYNAT59	2010-2017	IP773046	AirTable blocks_with_IP_info.csv
1367	10-3560A4	66	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.0	\N	\N	Sections show zones of the epidermis that contain a proliferation of keratinocytes with atypical nuclei, and parakeratosis containing inflammatory cells is present in the overlying cornified layer.	Cylindrical skin segment measuring 0.3 cm in diameter and 0.1 cm in thickness.	H/O SCC, BCC, PERSISTENT SCALY PATCH, PRIOR TX X2 LN02	\N	\N	\N	\N	CRUSTED SOLAR KERATOSIS	123144	2263	\N	\N	10-3560	A4	SYNAT59	2010-2017	IP773046	AirTable blocks_with_IP_info.csv
1368	10-3560A10	66	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.0	\N	\N	Sections show zones of the epidermis that contain a proliferation of keratinocytes with atypical nuclei, and parakeratosis containing inflammatory cells is present in the overlying cornified layer.	Cylindrical skin segment measuring 0.3 cm in diameter and 0.1 cm in thickness.	H/O SCC, BCC, PERSISTENT SCALY PATCH, PRIOR TX X2 LN02	\N	\N	\N	\N	CRUSTED SOLAR KERATOSIS	123144	2263	\N	\N	10-3560	A10	SYNAT59	2010-2017	IP773046	AirTable blocks_with_IP_info.csv
1371	10-4769A	61	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=23273	238.2	\N	\N	Sections show superficial shave specimen with digitate epidermal hyperplasia with collections of large, atypical, acantholytic keratinocytes in the lower epidermis confined largely to the interadnexal epidermis, with overlying parakeratosis and focal parakeratosis with serum and neutrophils.	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely submitted.	0.6 CM PEARLY PAPULE	\N	\N	\N	The atypical acantholytic keratinocytes extend to the base of the specimen and squamous cell carcinoma cannot be ruled out.  Deeper biopsy or additional treatment measures are recommended.	ACANTHOTIC SOLAR KERATOSIS WITH ACANTHOLYSIS, TRANSECTED AT THE DEEP BIOPSY MARGIN	193399	2046	\N	\N	10-4769	A	SYNAT60	2010-2017	IP852443	AirTable blocks_with_IP_info.csv
1372	10-006275	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1851	\N	\N	10-6275	\N	SYNAT61	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1783	14-53894B	53	\N	\N	\N	T1a	Primary	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26349,26350	172.6	\N	\N	Sections show an asymmetric irregularly nested proliferation of somewhat spindled melanocytes irregularly distributed along the dermo-epidermal junction and within the papillary dermis. Solar elastosis is noted.	Ellipse, 1.9 x 0.9 x 0.5 cm, including a central 0.6 x 0.5 cm brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and submitted with six sections in B. Tips reserved. PL/PL	A) MELANOMA, B) ATYPICAL NEVUS	\N	\N	\N	Melanoma in situ is present to within a millimeter of the peripheral margins.  I have examined additional sections.  Immunostaining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a low proliferative rate of the lesional melanocytes but highlights the asymmetric architecture of this lesion.  I had originally considered the possibility that this was an unusual melanocytic nevus, but due to the asymmetry, irregular nesting, and pagetoid spread of melanocytes highlighted with the immunostain, I think that this lesion is best regarded as a thin melanoma.  I have reviewed this case with Dr. McCalmont who concurs with this assessment.  In terms of staging this is a non-ulcerated lesion and no dermal mitotic figures are noted.  It should be regarded as a pT1a lesion.	MELANOMA, 0.55 MILLIMETERS IN THICKNESS, COMPLETELY BUT NARROWLY EXCISED	222689	2137	\N	\N	14-53894	B	SYNAT112	2010-2017	IP1403832	AirTable blocks_with_IP_info.csv
2057	17-12444	64	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22142	172.5	\N	\N	Sections show a broad and poorly circumscribed proliferation of melanocytes, with a flattish periphery and protuberant, ulcerated center. It features, in the flattish part:  • small nests of plump, oval melanocytes at the sides and bases of elongated rete ridges  • the bases of some adjacent rete ridges are fused, with subjacent fibroplasia • small, round melanocytes in discrete nests in the papillary dermis   In the raised part:  • sheets of large, oval melanocytes with abundant, pale amphophilic cytoplasm and large, pleomorphic vesicular nuclei with large nucleoli  • many mitotic figures  • no maturation and dispersion with descent	Skin segment measuring 1.4 x 1.0 x 0.4 cm, quadrisected and entirely submitted. PL/PL	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA VS. SQUAMOUS CELL CARCINOMA VS. MELANOMA. PAPULE.	\N	\N	Scraping	This amelanotic neoplasm is a high risk lesion and extends to the base of the specimen across a broad front. The final thickness measurement, and pressmen of AJCC stage should be made after complete excision. It seems to have arisen in a dysplastic nevus. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: biopsy Tumor site: right chest Microscopic tumor type: nodular melanoma Breslow thickness: >2.7 mm. Ulceration: yes Margins, peripheral: involved by melanoma in situ, and deep: transected Mitotic index: 10/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): at least pT3b pNX	MELANOMA, AT LEAST 2.7 MM. IN THICKNESS	173529	1100	\N	\N	17-12444	\N	ME-05	Melanoma Epigenetics	IP1741621	AirTable blocks_with_IP_info.csv
1040	02-5203B2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2341	\N	\N	02-5203	B2	SYNAT4	2010-2017	\N	AirTable blocks_with_IP_info.csv
1041	02-5203G2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2341	\N	\N	02-5203	G2	SYNAT4	2010-2017	\N	AirTable blocks_with_IP_info.csv
1330	08-65412A	29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22973	216.6	\N	\N	Sections show relatively circumscribed proliferation of spindled and stellate cells in the dermis, arrayed amongst thickened collagen bundles. Peripherally and deeply, some collagen bundles are markedly thickened (colloquially, collagen balls). There is also focal reticular dermal sclerosis. The superjacent epidermis is slightly acanthotic with basal pigmentation.	Ellipse measuring 1.6 x 0.7 x 0.5 cm, serially sectioned perpendicular to the long axis and entirely submitted with six sections in cassette A.	A-B) DERMATOFIBROMAS	\N	\N	\N	\N	DERMATOFIBROMA, EXCISED IN PLANES OF SECTION EXAMINED	173602	2111	\N	\N	08-65412	A	SYNAT5	Melanoma Epigenetics	IP504172	AirTable blocks_with_IP_info.csv
1023	01-003845	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1761	\N	\N	01-3845	\N	SYNAT2	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1787	14-58586	38	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26346	216.5	\N	\N	Sections show a broad-based proliferation of melanocytes involving the epidermis and mostly, the superficial dermis. There are increased single melanocytes at the dermo-epidermal junction, and some small nests of them, in part positioned at the sides and bases of elongated rete ridges. The surface is papillated, with interconnecting rete ridges that enclose horn pseudocysts. There is basilar hyperpigmentation in the affected area.  Within the dermis are nests, cords and strands of small, round melanocytes.  These cells mature with descent, and lie in part around adnexal structures.	Skin segment measuring 0.9 x 0.7 x 0.1 cm, trisected and entirely submitted. HD/KC	A) CONGENITAL NEVUS VS. DYSPLASTIC NEVUS. VARIEGATED BROWN PAPULE.	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	273562	2193	\N	\N	14-58586	\N	SYNAT115	2010-2017	IP1408527	AirTable blocks_with_IP_info.csv
2212	17-95052A	66	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24930	232.5	\N	\N	Sections show a zone of granulation tissue representing the residuum of a prior biopsy site, flanked by a proliferation of single and nested melanocytes in irregular array along the epidermal-dermal junction.  A compound proliferation of bland melanocytes is also noted.	Oriented ellipse measuring 5.5 x 2.5 x 1.3 cm, including a central 1.8 x 1.1 cm crusted area. With the orienting notch located at the midpoint of one edge placed distally to the grosser, the notch is indicated as superior edge on the requisition form. With the notch designated as 12 o'clock by the grosser, the 9-12-3 o'clock margin is inked blue and the 3-6-9 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in A-F. Tips reserved. CF/CF	MM EXC SEE PATH DT17-88262	\N	\N	Punch	A lentiginous melanocytic nevus is also present.  It too has been completely excised.	HEALING BIOPSY SITE, WITH RESIDUAL MELANOMA IN SITU, COMPLETELY EXCISED (SURGICAL MARGINS ARE FREE OF MALIGNANCY)	433599	1101	\N	\N	17-95052	A	ME-06	Melanoma Epigenetics	IP1818404	AirTable blocks_with_IP_info.csv
2140	17-55182D	51	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22150	172.5	\N	\N	There is a nodular proliferation of histiocytoid cells with atypical enlarged nuclei in partial contiguity with the epidermis. Some cells are wholly intraepidermal. There is little diminishment in cell size with descent in the dermis. Centrally, there is reticular dermal fibrosis as well. To the side, maturing small melanocytes are in nests, cords, and syncytia.	Skin segment measuring 0.8 x 0.5 x 0.2 cm, bisected and entirely submitted in D. CF/CF	A) SKIN TAG VS. NEVUS VS. OTHER. 2.5 MM PINK PAPULE. COMPLETE READ. B) SKIN TAG VS. NEVUS VS OTHER. 2.5 CM PINK PAPULE. COMPLETE READ. C) SKIN TAG VS. NEVUS VS OTHER. 4 MM PINKISH PAPULE. COMPLETE READ. D) NEOPLASM OF UNCERTAIN BEHAVIOR. 6 - 7 MM PINK PAPULE WITHIN CONGENITAL NEVUS. COMPLETE READ.	\N	\N	Scraping	This biopsy demonstrates nodular melanoma ex congenital melanocytic nevus. Immunostaining with SOX-10 and Melan-A demonstrates intense positivity, and thus melanocytic lineage has been confirmed. Some of the atypical melanocytes have reniform nuclei and histiocytoid morphology, and thus I additionally completed a CD1a immunostain, but the stain is completely negative, and thus the remote possibility of an atypical Langerhans cell infiltrate has been excluded. A synoptic is included below.  Procedure: shave biopsy Microscopic tumor type: nodular melanoma (ex melanocytic nevus) Breslow thickness: at least 1.9 mm Ulceration: not detected Margin: deep edge involved Mitotic index: 5 per square mm Vascular invasion: not detected Regression: not detected Pathologic staging (pTNM): at least pT2a	NODULAR MELANOMA OF AT LEAST 1.9 MM IN THICKNESS, ARISING WITHIN A CONGENITAL MELANOCYTIC NEVUS AND INVOLVING THE DEEP EDGE OF THE BIOPSY	139510	1106	\N	\N	17-55182	D	ME-11	Melanoma Epigenetics	IP1784912	AirTable blocks_with_IP_info.csv
1788	14-58667	32	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.7	\N	\N	Sections show acral skin with a well circumscribed proliferation of melanocytes mostly in nests at the dermo-epidermal junction, and within the subjacent superficial dermis.  The junctional melanocytes are plump, oval cells with monomorphous nuclei and the dermal component matures with descent.	Cylindrical skin segment, 0.4 cm in diameter and 0.2 cm in thickness, bisected and entirely submitted. CF/KC	R/O ATYPIA	\N	\N	\N	The margins appear clear in the planes of section examined. There are no worrisome features.	COMPOUND MELANOCYTIC NEVUS	173717	2095	\N	\N	14-58667	\N	SYNAT116	2010-2017	IP1304478	AirTable blocks_with_IP_info.csv
1046	02-008514	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2217	\N	\N	02-8514	\N	SYNAT6	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1050	02-012396A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1884	\N	\N	02-12396	A	SYNAT7	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1990	16-103438	71	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=25176,24932,27427	172.5	\N	REMOVED: ME-14 : Both Nevus and Melanoma have low VAF (BRAF.V600E).	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei, abundant, pale cytoplasm and dusty appearing melanin or both. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer, and some markedly confluent nests.  There are similar or smaller melanocytes in the subjacent dermis, along with fibrosis and a patchy lymphocytic infiltrate. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.0 x 1.0 x 0.1 cm, quadrisected and entirely submitted. KC/KC	5 X 7 CM BLACK RECTANGULAR PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. R/O MELANOMA, SEEP SHAVE REMOVAL	\N	\N	Scraping	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: biopsy Tumor site: left upper back Microscopic tumor type: superficial spreading melanoma Breslow thickness: 0.5 mm. Ulceration: no Margins, peripheral: clear by 1 mm., and deep: clear by 0.4 mm. Mitotic index: 0/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT1a pNX	MELANOMA, 0.5 MM. IN THICKNESS, ARISING IN A NEVUS	273588	1109	\N	\N	16-103438	\N	ME-14	Melanoma Epigenetics	IP1703438	AirTable blocks_with_IP_info.csv
1987	16-99265	37	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22141,25173	172.5	\N	\N	Sections show a proliferation of melanocytes with a biphasic pattern. One population of melanocytes consists of cells with abundant vacuolated cytoplasm and finely divided melanin pigment, and these cells are arrayed irregularly within the epidermis as single cells and nests, with foci of suprabasal scatter.  There are also similar clusters of cells in the superficial dermis.  Deeper in the dermis, there is a second population of smaller melanocytes (comprising melanocytic nevus), arrayed as nests and cords in the superficial reticular dermis. In one area there are delicate spindle cells in the dermis along with histiocytes, likely representing a an area of scar.	Skin segment measuring 1.4 x 1.0 x 0.4 cm, quadrisected and entirely submitted. CF/CF	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. SEBORRHEIC KERATOSIS. 1.4 X 1.1 CM BLACK VERRUCOUS PLAQUE. (SEE PHOTO)	\N	\N	Scraping	I have also shared this case with my colleague, Dr. Philip LeBoit, who agrees with these findings. Diagnostic features of note include:  Procedure: excision Tumor site: back Microscopic tumor type: SSM, non-CSD Breslow thickness: 0.65 mm Ulceration: absent Margins, peripheral and deep: clear Mitotic index: 0/mm2 Microsatellitosis: absent Vascular invasion:  absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT1a pNX	MELANOMA, 0.65 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A SUPERFICIAL CONGENITAL MELANOCYTIC NEVUS	138523	1110	\N	\N	16-99265	\N	ME-15	Melanoma Epigenetics	IP1699195	AirTable blocks_with_IP_info.csv
2196	17-83378D	62	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22440	172.5	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of melanocytes with a broad-based flat area and a dome surfaced and flat based nodular one. The flat area features rete ridges whose bases are fused by a proliferation of small fusiform cells with monomorphous oval nuclei and scant cytoplasm. There is subjacent fibroplasia. The nodular area features a thin epidermis and sheets of large, oval melanocytes with abundant, pale cytoplasm and dusty melanin, and large, pleomorphic vesicular nuclei. There is failure of maturation and dispersion with descent and scattered mitotic figures are present.	Ellipse, 2.5 x 1.7 x 1.3 cm, including a central 2.0 x 1.5 cm variegated brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with three sections in A, two sections each in B-C, and three sections in D. HD/HD	MELANOMA	\N	\N	Punch	The neoplasm may have arisen in a dysplastic nevus. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: excisional biopsy Microscopic tumor type: superficial spreading melanoma Ulceration: no Margins, peripheral: clear by 1 mm., and deep: clear by 7 mm. Mitotic index: 1/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT3a pNX	MELANOMA, 2.5 MM. IN THICKNESS	173525	1111	\N	\N	17-83378	D	ME-16	Melanoma Epigenetics	IP1813443	AirTable blocks_with_IP_info.csv
3140	610186D	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	AM2-029_4, Met	\N	\N	\N	\N	\N	\N	\N	\N	\N	13	\N	\N	None	\N	AM2-029	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3213	Cell-Line_Xu-23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1664	\N	\N	None	\N	SYNAT229	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3129	86541-2b	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Metastasis	AM2-006_2.2	\N	\N	\N	\N	Right inguinal	\N	\N	\N	\N	4	\N	\N	None	\N	AM2-006	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1790	14-59332	22	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	There are nests of melanocytes at the dermo-epidermal junction, in part extending to the side of a dermal component in which there are nests, cords and strands of melanocytes.  These cells mature with descent into the superficial reticular dermis, and lie in part around adnexal structures.	Skin segment measuring 1.5 x 1.1 x 0.2 cm, quadrisected and entirely submitted. PL/KC	1.2 X 1.1 TAN / BROWN COLOR PATCH; R/O ATYP	\N	\N	\N	There are junctional nests lateral to the dermal component, which may have imparted a macular edge to the clinical appearance of this lesion, but no worrisome features are present.	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	528599	1847	\N	\N	14-59332	\N	SYNAT117	2010-2017	IP988413	AirTable blocks_with_IP_info.csv
1792	14-59956	69	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.3	\N	\N	Sections show a deep dermal nested and syncytial proliferation of melanocytes with pale pigmented cytoplasm. Interstitial melanophages are noted. Above this, the dermis is fibrotic, and a lymphohistiocytic infiltrate is apparent concurrently.	Cylindrical skin segment, 0.3 cm in diameter and 0.3 cm in thickness, submitted intact. HD/HD	DARK MACULE, PATIENT TREATED SITE RECENTLY WITH VINEGAR; NEOPLASM OF UNCERTAIN BEHAVIOR VS. BLUE NEVUS, R/O MELANOMA-IN-SITU VS. OTHER	\N	\N	\N	The pigmentation seen here stems from a deep penetrating nevus. The scarring noted concurrently at this site was apparently incited by topical application of acetic acid. There is no evidence of melanoma in situ.	DEEP PENETRATING MELANOCYTIC NEVUS WITH AN OVERLYING INFLAMED SCAR	173304	2339	\N	\N	14-59956	\N	SYNAT118	Dysplastic Nevi	IP1409897	AirTable blocks_with_IP_info.csv
1793	14-61297	27	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26347	216.5	\N	\N	There are nests, cords and strands of cytologically bland melanocytes that extend from the junctional zone into the superficial reticular dermis.  The dermal component matures with descent.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted. CF/KC	R/O ATYPICAL NEVUS	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	139524	2331	\N	\N	14-61297	\N	SYNAT119	2010-2017	IP1411239	AirTable blocks_with_IP_info.csv
1062	02-23636A-02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1865	\N	\N	None	\N	SYNAT10	2010-2017	\N	AirTable blocks_with_IP_info.csv
1066	02-33818A-03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1714	\N	\N	None	\N	SYNAT11	2010-2017	\N	AirTable blocks_with_IP_info.csv
2195	17-83378C	62	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	172.5	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of melanocytes with a broad-based flat area and a dome surfaced and flat based nodular one. The flat area features rete ridges whose bases are fused by a proliferation of small fusiform cells with monomorphous oval nuclei and scant cytoplasm. There is subjacent fibroplasia. The nodular area features a thin epidermis and sheets of large, oval melanocytes with abundant, pale cytoplasm and dusty melanin, and large, pleomorphic vesicular nuclei. There is failure of maturation and dispersion with descent and scattered mitotic figures are present.	Ellipse, 2.5 x 1.7 x 1.3 cm, including a central 2.0 x 1.5 cm variegated brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with three sections in A, two sections each in B-C, and three sections in D. HD/HD	MELANOMA	\N	\N	FFPE	The neoplasm may have arisen in a dysplastic nevus. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: excisional biopsy Microscopic tumor type: superficial spreading melanoma Ulceration: no Margins, peripheral: clear by 1 mm., and deep: clear by 7 mm. Mitotic index: 1/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT3a pNX	MELANOMA, 2.5 MM. IN THICKNESS	173525	1111	\N	\N	17-83378	C	ME-16	Melanoma Epigenetics	IP1813443	AirTable blocks_with_IP_info.csv
1187	05-29484F	26	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22981	172.5	\N	\N	Sections show a cellular area of fibrosis and inflammation due to recent surgery, with no evidence of an atypical melanocytic proliferation. There are small melanocytes with round to oval nuclei in the superficial dermis in one focus away from the biopsy site.	Ellipse, 6.0 x 2.0 x 1.5 cm, including a central 2.3 cm linear scar.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in cassettes A through F, tips returned to container.	CHECK MARGINS; MALIGNANT MELANOMA	\N	\N	FFPE	There is an incidental, predominantly intradermal melanocytic nevus.	SCAR, WITH NO EVIDENCE OF RESIDUAL MELANOMA	173502	1713	\N	\N	05-29484	F	SYNAT15	California Cancer Registry	IP504172	AirTable blocks_with_IP_info.csv
1794	14-61299	37	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26348	216.5	\N	\N	There are nests, cords and strands of cytologically bland melanocytes that extend from the junctional zone into the superficial reticular dermis.  The dermal component matures with descent.	Skin segment measuring 1.3 x 0.7 x 0.1 cm, trisected and entirely submitted. CF/KC	R/O ATYPICAL NEVUS	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	173539	2251	\N	\N	14-61299	\N	SYNAT120	2010-2017	IP1411241	AirTable blocks_with_IP_info.csv
1795	14-61835	21	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	There are nests, cords and strands of cytologically bland melanocytes that extend from the junctional zone into the superficial reticular dermis.  The dermal component matures with descent.	Skin segment measuring 0.9 x 0.7 x 0.1 cm, trisected and entirely submitted. RS/RS	7 MM X 6 MM WITH 2.3 CENTRAL DARK PIGMENTATION, IPIS; NEVUS VS. OTHER	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	139522	1798	\N	\N	14-61835	\N	SYNAT121	2010-2017	IP1411777	AirTable blocks_with_IP_info.csv
1807	14-88685	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1870	\N	\N	14-88685	\N	SYNAT127	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1809	14-94217A	36	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a wedge-shaped proliferation of large oval melanocytes with moderately pleomorphic nuclei and abundant vacuolated cytoplasms, arranged as small nests and fascicles. The apex of the lesion is in the reticular dermis, with a tendency of aggregations to be positioned next to adnexa. There are evenly distributed melanophages.	Cylindrical skin segment, 0.6 cm in diameter and 0.8 cm in thickness, bisected and entirely submitted in A. KC/KC	A) DEEP PENETRATING NEVUS, R/O OTHER, B) NEVUS, R/O ATYPIA (TELEPHONE: 806-6123, MSG OK)	\N	\N	\N	\N	DEEP PENETRATING NEVUS	173507	2127	\N	\N	14-94217	A	SYNAT128	Dysplastic Nevi	IP1444208	AirTable blocks_with_IP_info.csv
1081	03-19080C T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1046	\N	\N	None	\N	MD-169	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2194	17-83378B	62	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22156	172.5	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of melanocytes with a broad-based flat area and a dome surfaced and flat based nodular one. The flat area features rete ridges whose bases are fused by a proliferation of small fusiform cells with monomorphous oval nuclei and scant cytoplasm. There is subjacent fibroplasia. The nodular area features a thin epidermis and sheets of large, oval melanocytes with abundant, pale cytoplasm and dusty melanin, and large, pleomorphic vesicular nuclei. There is failure of maturation and dispersion with descent and scattered mitotic figures are present.	Ellipse, 2.5 x 1.7 x 1.3 cm, including a central 2.0 x 1.5 cm variegated brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with three sections in A, two sections each in B-C, and three sections in D. HD/HD	MELANOMA	\N	\N	Scraping	The neoplasm may have arisen in a dysplastic nevus. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: excisional biopsy Microscopic tumor type: superficial spreading melanoma Ulceration: no Margins, peripheral: clear by 1 mm., and deep: clear by 7 mm. Mitotic index: 1/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT3a pNX	MELANOMA, 2.5 MM. IN THICKNESS	173525	1111	\N	\N	17-83378	B	ME-16	Melanoma Epigenetics	IP1813443	AirTable blocks_with_IP_info.csv
3214	Cell-Line_Xu-24	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2326	\N	\N	None	\N	SYNAT230	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3215	Cell-Line_Xu-25	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2140	\N	\N	None	\N	SYNAT231	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
1076	03-15183D T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1047	\N	\N	None	\N	MD-170	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1037	02-000540	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1771	\N	\N	02-540	\N	SYNAT3	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3389	HW4-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, Melanoma| TUMOR Melanoma, Mucosal nasal sinus	\N	\N	\N	\N	2144	\N	\N	None	\N	SYNAT313	2010-2017	\N	AirTable blocks_with_IP_info.csv
3390	HW6-NormalDissect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, Melanoma| Normal Melanoma, Mucosal vulva	\N	\N	\N	\N	2252	\N	\N	None	\N	SYNAT314	2010-2017	\N	AirTable blocks_with_IP_info.csv
3391	HW6-TumorDissect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, Melanoma| Tumor Melanoma, Mucosal vulva	\N	\N	\N	\N	1831	\N	\N	None	\N	SYNAT315	2010-2017	\N	AirTable blocks_with_IP_info.csv
3392	HW8- Normal Curls	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Mucosal Melanoma, Urethra, Hong Wu	\N	\N	\N	\N	1784	\N	\N	None	\N	SYNAT316	2010-2017	\N	AirTable blocks_with_IP_info.csv
3216	Cell-Line_Xu-26	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2336	\N	\N	None	\N	SYNAT232	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3217	Cell-Line_Xu-27	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1885	\N	\N	None	\N	SYNAT233	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3218	Cell-Line_Xu-28	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1934	\N	\N	None	\N	SYNAT234	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3219	Cell-Line_Xu-29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1948	\N	\N	None	\N	SYNAT235	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3220	Cell-Line_Xu-30	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1857	\N	\N	None	\N	SYNAT236	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3221	Cell-Line_Xu-31	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2189	\N	\N	None	\N	SYNAT237	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3222	Cell-Line_Xu-32	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2012	\N	\N	None	\N	SYNAT238	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3223	Cell-Line_Xu-33	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1936	\N	\N	None	\N	SYNAT239	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3224	Cell-Line_Xu-34	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1797	\N	\N	None	\N	SYNAT240	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3021	99-18307	38	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.4	\N	\N	There is a multinodular proliferation of melanocytes with atypical nuclei beneath a thinned epidermis.  There is little diminishment in melanocyte size with descent in the dermis.  There is marked fibrosis and there are many melanophages.	Skin segment measuring 0.7 x 0.6 x 0.3 cm, trisected and entirely\nsubmitted.	CLINICAL DIAGNOSIS - R/O BLUE NEVUS	\N	\N	Scraping	The lesion measures at least 2.2 mm in thickness, but final thickness awaits complete excision.	MELANOMA, EXTENDING TO THE DEEP MARGIN	102499	148	\N	\N	99-18307	\N	CCR-058	California Cancer Registry	IP193840	AirTable blocks_with_IP_info.csv
2516	19Rig750007.02.08.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	267	\N	\N	None	\N	CM-27	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
3236	Cell-Line_Xu-46	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2163	\N	\N	None	\N	SYNAT252	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3237	Cell-Line_Xu-47	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1849	\N	\N	None	\N	SYNAT253	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3238	Cell-Line_Xu-48	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1710	\N	\N	None	\N	SYNAT254	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3255	CGH12-067	34	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show fibrosing granulation tissue stemming from prior biopsy with a residual array of melanocytes with in the deeper dermis characterized by medium to large melanocytes with abundant amphophilic cytoplasm and pleomorphic nuclei arranged in fascicles and nests.	Ellipse, 1.3 x 0.5 x 0.2 cm, including a central 1.1 x 0.5 cm lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections.	BX PROVEN PROLIFERATION OF ENLARGED MELANOCYTES, 0.4 CM PINK SCAR	\N	\N	\N	ADDENDUM, March 20, 2012: The following note has been modified from that in the original report, a copy of which is on file as .pdfs in our computer system: We continue to favor a melanocytic nevus as the most likely diagnosis.  Comparative genomic hybridization shows no loss or gain of chromosomal material. This favors a benign interpretation, or a low grade neoplasm with limited metastatic potential. About 95% of conventional melanomas show detectable losses or gains with this technique. Nonetheless, the melanocytic proliferation is unusual and has not been removed by this procedure, and further excision to ensure its complete removal is recommended.	RESIDUAL INTRADERMAL PROLIFERATION OF MELANOCYTES, EXTENDING TO BOTH EDGES AND CLOSELY TO THE BASE OF THE SPECIMEN	123298	2025	\N	T	10-75211	A	SYNAT271	2010-2017	IP963226	AirTable blocks_with_IP_info.csv
1182	05-29484A	26	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22976	172.5	\N	\N	Sections show a cellular area of fibrosis and inflammation due to recent surgery, with no evidence of an atypical melanocytic proliferation. There are small melanocytes with round to oval nuclei in the superficial dermis in one focus away from the biopsy site.	Ellipse, 6.0 x 2.0 x 1.5 cm, including a central 2.3 cm linear scar.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in cassettes A through F, tips returned to container.	CHECK MARGINS; MALIGNANT MELANOMA	\N	\N	FFPE	There is an incidental, predominantly intradermal melanocytic nevus.	SCAR, WITH NO EVIDENCE OF RESIDUAL MELANOMA	173502	1713	\N	\N	05-29484	A	SYNAT15	Melanoma Epigenetics	IP504172	AirTable blocks_with_IP_info.csv
1183	05-29484B	26	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22977	172.5	\N	\N	Sections show a cellular area of fibrosis and inflammation due to recent surgery, with no evidence of an atypical melanocytic proliferation. There are small melanocytes with round to oval nuclei in the superficial dermis in one focus away from the biopsy site.	Ellipse, 6.0 x 2.0 x 1.5 cm, including a central 2.3 cm linear scar.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in cassettes A through F, tips returned to container.	CHECK MARGINS; MALIGNANT MELANOMA	\N	\N	FFPE	There is an incidental, predominantly intradermal melanocytic nevus.	SCAR, WITH NO EVIDENCE OF RESIDUAL MELANOMA	173502	1713	\N	\N	05-29484	B	SYNAT15	California Cancer Registry	IP504172	AirTable blocks_with_IP_info.csv
2652	20-81257B	90	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=29789,29790,29791,29792,29793,29794,29795,29796	172.6	\N	\N	Sections show fibrosing granulation tissue stemming from previous biopsy/surgery within a backdrop of marked solar elastosis. There is a residual array of atypical melanocytes, distributed in the lowermost epidermis and in the underlying dermis.	Oriented ellipse measuring 4.8 x 1.3 x 0.5 cm, including a central 3.9 x 1.3 cm area of variegated color/texture. The orienting short suture located at the mid-point of one edge is indicated 12 o'clock on the requisition and is placed toward 12 o'clock, and the long suture indicated 3 o'clock is placed toward the 3 o'clock. The grosser inked 9-12-3 o'clock margin blue and the 3-6-9 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and entirely submitted with six sections each in A-C. CF/CF	LEFT ARM WIDE EXCISION FOR MELANOMA	\N	\N	\N	Invasive and in situ melanoma extensively involve the blue inked and yellow inked peripheral margins.  As per the gross description, this would correspond to variable positivity along the approximate 11-3 o'clock and 3-7 o'clock peripheral margins. Coupling the findings in the original biopsy with the features in this re-excision specimen, the final parameters for reporting per the guidelines of the College of American Pathologists for this melanoma include the following:  Procedure: excision Microscopic tumor type: melanoma in skin with high cumulative sun damage (WHO classification) Breslow thickness: 2.5 mm. Ulceration: present Margins, peripheral: involved by invasive and melanoma in situ (see above); Margins, deep: negative for in situ and invasive melanoma Mitotic index: 2/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT3b pNX	RESIDUAL MELANOMA, BRESLOW THICKNESS 1.9 MM; INVASIVE AND IN SITU MELANOMA IN SITU EXTENDS TO THE INKED PERIPHERAL MARGINS; DEEP MARGINS FREE OF MELANOMA.  SEE NOTE.	173601	800	\N	\N	20-81257	B	LMM-01	Lentigo Maligna Melanoma	IP1127057	AirTable blocks_with_IP_info.csv
3109	78821-2a	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-002_2.1	\N	\N	\N	\N	Sentinel node	\N	\N	\N	\N	2	\N	\N	None	\N	AM2-002	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3108	78821-1c	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-002_1.3	\N	\N	\N	\N	Left Hallux	Punch	\N	\N	\N	2	\N	\N	None	\N	AM2-002	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3110	78821-2b	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-002_2.2	\N	\N	\N	\N	Sentinel node	\N	\N	\N	\N	2	\N	\N	None	\N	AM2-002	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
11244	Sample_KAM53-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
1184	05-29484C	26	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22978	172.5	\N	\N	Sections show a cellular area of fibrosis and inflammation due to recent surgery, with no evidence of an atypical melanocytic proliferation. There are small melanocytes with round to oval nuclei in the superficial dermis in one focus away from the biopsy site.	Ellipse, 6.0 x 2.0 x 1.5 cm, including a central 2.3 cm linear scar.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in cassettes A through F, tips returned to container.	CHECK MARGINS; MALIGNANT MELANOMA	\N	\N	FFPE	There is an incidental, predominantly intradermal melanocytic nevus.	SCAR, WITH NO EVIDENCE OF RESIDUAL MELANOMA	173502	1713	\N	\N	05-29484	C	SYNAT15	California Cancer Registry	IP504172	AirTable blocks_with_IP_info.csv
1208	06-6624A7	63	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.19	\N	\N	The epidermis is thickened by a proliferation of keratinocytes with small, monomorphous nuclei that form bulbous rete ridges.  There is basilar hyperpigmentation.	Deep skin segment, 1.0 x 0.8 x 0.3 cm, margins inked blue, serially sectioned and entirely submitted with five sections.	PIGMENTED LESION	\N	\N	\N	\N	SEBORRHEIC KERATOSIS	173601	2300	\N	\N	06-6624	A7	SYNAT18	2010-2017	IP227601	AirTable blocks_with_IP_info.csv
1209	06-6624D1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2300	\N	\N	06-6624	D1	SYNAT18	2010-2017	\N	AirTable blocks_with_IP_info.csv
2198	17-88262	66	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22157	172.5	\N	\N	Sections show a poorly circumscribed proliferation of melanocytes arranged as single cells and nests within the epidermis and dermis. Within the epidermis, many of the lesional melanocytes are located in pagetoid scatter and single melanocytes predominate over nests in some foci. Similar melanocytes are present in clusters in the underlying dermis and the size of the melanocytes does not diminish with descent into the dermis. There is also a second population of smaller melanocytes arranged as cords and strands between collagen bundles of the reticular dermis and around adnexal structures.	Skin segment measuring 1.8 x 1.5 x 0.1 cm, serially secitoned, and entirely submitted with six sections. HD/HD	VARIEGATED PLAQUE; WORRISOME FOR MM, 15 X 13 MM	\N	\N	Scraping	Synoptic melanoma reporting is included below: Procedure: Shave biopsy Microscopic tumor type: Melanoma, arising in association with a melanocytic nevus with superfical congenital features Breslow thickness: 0.6 mm Ulceration: Absent Margins: + base; + peripheral Mitotic index: 0/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1a	MELANOMA, 0.6 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES AND EXTENDING TO THE BASE AND PERIPHERAL EDGE OF THE SPECIMEN	433599	1101	\N	\N	17-88262	\N	ME-06	Melanoma Epigenetics	IP1818404	AirTable blocks_with_IP_info.csv
2914	23-97273	46	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Extending from the proximal nail matrix distally into the nail bed epithelium in the slides from blocks 4 and 5 is a proliferation of melanocytes with variably enlarged, hyperchromatic or vesicular nuclei, distributed singly or in small nests, in a nearly confluent manner.  There are foci which these cells infiltrate the superficial onychodermis, with dense infiltrates of plasma cells and fibrosis.  Poorly circumscribed basilar proliferation of atypical melanocytes extends along the junctional zone in parts of the en face sections from the medial and lateral peripheral margins.	Oriented fingernail excision measuring 2.6 x 2.1 x 0.4 cm. There is a suture at the midpoint of the distal tip as indicated on the requisition. The surgeon pre-inked the ulnar margin green and the radial margin yellow. The grosser inked the proximal margin blue. An approximately 4 mm strip of the margin is removed with the resulting edges inked orange by the grosser. The peripheral margin is entirely submitted for en face sections in 1-3. The yellow-inked radial margin is submitted in 1, the green-inked ulnar margin is submitted in 2, and the blue-inked proximal margin is submitted in 3. The poles indicating the midpoint of the distal margin is inked black for the radial and ulnar margins (blocks 1-2). The radial pole of the proximal margin (block 3) is inked black. The remaining central portion is serially sectioned from the radial to ulnar direction and entirely submitted with three sections each in 4-5. PL/PL	BIOPSY CONFIRMED MELANOMA IN SITU OF NAIL UNIT, EN BLOC EXCISION OF NAIL UNIT, PLEASE EVALUATE MARGINS AND FOR INVASION COMPONENT, GREEN ON ULNAR SIDE, YELLOW ON RADIAL SIDE (TELEPHONE: 415-845-0515, MSG OK)	\N	\N	\N	Unlike the case in the initial biopsy, an invasive component is present. The thickness is listed as an approximation because the tissue in the area of the thickness melanoma was disrupted by the previous biopsy. Portions of the en face margins are involved.  A specimen diagram will be sent to Dr. Klufas by email, and uploaded to Apex.  Of these areas is on the radial side of the specimen, proximally and the other is on the ulnar side distally.  In both areas, increased numbers of SOX-10 positive cells with PRAME positive nuclei are present.  The deepest extent of the melanoma is its in situ portion, in the proximal part of the nail matrix, where it is less than 1 mm from the deep margin.  Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: biopsy Microscopic tumor type: Ulceration: no Margins, peripheral: involved by melanoma in situ, and deep: clear Mitotic index: 0/mm2 Microsatellitosis: to be determined following re-excision Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT1a pNX	MELANOMA, APPROXIMATELY 0.7 MM IN THICKNESS	173632	2148	\N	\N	23-97273	\N	SYNAT179	Melanoma Epigenetics	IP2626851	AirTable blocks_with_IP_info.csv
1112	04-003736A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2230	\N	\N	04-3736	A	SYNAT16	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3095	19111/14.5	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-051_1.5	\N	\N	\N	\N	Right heel	\N	\N	\N	\N	25	\N	\N	None	\N	AM2-051	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2169	17-68446	63	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22154	172.7	\N	\N	Sections show a proliferation of atypical melanocytes in irregular array within the epidermis and dermis. Within the epidermis, there are melanocytes arranged as nests and single cells. In some areas, there are melanocytes above the basal layer of the epidermis and there are areas in which melanocytes are configured as single cells in confluence. There are nests of similar melanocytes in the dermis. There is a second population of smaller melanocytes arranged as cords and strands between collagen bundles of the reticular dermis and around adnexal structures.	Cylindrical skin segment, 0.6 cm in diameter and 0.4 cm in thickness, bisected and entirely submitted. HD/HD	PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA VS. MELANOMA VS. DYSPLASTIC NEVUS VS. IRRITATED SEBORRHEIC KERATOSIS	\N	\N	Scraping	Synoptic melanoma reporting is included below: Procedure: Punch biopsy Microscopic tumor type: Melanoma, NOS, arising in association with a melanocytic nevus with superficial congenital features Breslow thickness: 0.6 mm Ulceration: Absent Margins: Intraepidermal melanoma extends to the peripheral edge of the specimen Mitotic index: 0/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1a	MELANOMA, 0.6 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES AND EXTENDING INTRAEPIDERMALLY TO THE PERIPHERAL EDGE OF THE SPECIMEN	17733	1105	\N	\N	17-68446	\N	ME-10	Melanoma Epigenetics	IP524944	AirTable blocks_with_IP_info.csv
2915	23-107334C2	46	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show lymph nodes without evidence of metastatic melanoma.	Tissue segment measuring 3.4 x 1.5 x 0.9 cm, serially sectioned perpendicular to the long axis and entirely submitted with four sections in C1 and six sections in C2. Entire node is submitted. ES/ES	A) RIGHT MIDDLE FINGER DISTAL PHALANGE- PROXIMAL LEFT CORNER PREVIOUS MELANOMA IN SITU, B) VOLAR FLAP MARGIN, C) RIGHT AXILLARY SENTINEL LYMPH NODE, D) RIGHT AXILLARY SENTINEL LYMPH NODE #2	\N	\N	\N	There is no evidence of metastatic melanoma in either the routinely-stained section or sections stained with SOX-10 and pan-melanin.	LYMPH NODES, WITH NO EVIDENCE OF METASTATIC MELANOMA	222922	2090	\N	\N	23-107334	C2	SYNAT180	Melanoma Epigenetics	IP2626851	AirTable blocks_with_IP_info.csv
3092	19111/14.2	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Normal	AM2-051_1.2, No metastasis identified	\N	\N	\N	\N	Inguinal lymph node	Punch	\N	\N	\N	25	\N	\N	None	\N	AM2-051	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3093	19111/14.3	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-051_1.3	\N	\N	\N	\N	right heel	Punch	\N	\N	\N	25	\N	\N	None	\N	AM2-051	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2931	91-017419	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2050	\N	\N	91-17419	\N	SYNAT182	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2973	96-6536	84	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.4	\N	\N	Sections show a proliferation composed of small nodular aggregations of basaloid cells positioned between collagen bundles in the dermis.	One slide, GG96-361.	NEW GROWTH OF UNKNOWN DURATION, SLIGHTLY TENDER, 8 MM SMOOTH GRAY NODULE; CLINICAL DIAGNOSIS - BASAL CELL CARCINOMA	\N	\N	\N	In general, examples of BCC with a micronodular pattern display greater local invasiveness than neoplasms with a conventional nodular pattern.	BASAL CELL CARCINOMA, MICRONODULAR PATTERN, EXCORIATED, EXTENDING TO THE DEEP MARGIN	173416	2056	\N	\N	96-6536	\N	SYNAT183	Mucosal Melanoma	IP77652	AirTable blocks_with_IP_info.csv
3212	Cell-Line_Xu-22	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2126	\N	\N	None	\N	SYNAT228	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
1331	08-65412B	29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22974	216.7	\N	\N	Sections show a nodular proliferation of spindled and stellate cells arrayed amongst thickened collagen bundles in the reticular dermis, set beneath an epidermis that is acanthotic with broad, flattened rete.	Ellipse measuring 1.3 x 0.6 x 0.7 cm, serially quadrisected perpendicular to the long axis and entirely submitted in cassette B.\n	A-B) DERMATOFIBROMAS	\N	\N	\N	\N	DERMATOFIBROMA, EXCISED IN PLANES OF SECTION EXAMINED	173702	2111	\N	\N	08-65412	B	SYNAT5	California Cancer Registry	IP504172	AirTable blocks_with_IP_info.csv
3137	610186A	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	Mel 1	AM2-029_1	\N	\N	\N	\N	Left Heel	Scraping	\N	\N	\N	13	\N	\N	None	\N	AM2-029	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3139	610186C	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	AM2-029_3, Met	\N	\N	\N	\N	\N	\N	\N	\N	\N	13	\N	\N	None	\N	AM2-029	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3543	MEL202_DMSO	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Melanoma cell line, treated with DMSO	\N	\N	\N	\N	\N	\N	\N	\N	\N	1329	\N	\N	None	\N	P_MEL202	Melanoma Epigenetics,Cell Line	\N	AirTable blocks_with_IP_info.csv
3544	MEL202_Vemu	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Melanoma cell line, treated with 100ng vemurafenib	\N	\N	\N	\N	\N	\N	\N	\N	\N	1329	\N	\N	None	\N	P_MEL202	Melanoma Epigenetics,Cell Line	\N	AirTable blocks_with_IP_info.csv
2156	17-62828B	31	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10881	216.5	\N	\N	The features are similar to those in (A).	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted in B. KC/KC	A-B) IRREGULAR BROWN MACULE; DYSPLASTIC NEVUS VS. MIS	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	239512	488	\N	\N	17-62828	B	DN-013	Dysplastic Nevi	IP1792659	AirTable blocks_with_IP_info.csv
1989	16-103071	85	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22137,25177	172.6	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly along the epidermal-dermal junction above elastosis, with nests of melanocytes in predominance in many areas, and marked epidermal thinning is noted. There are irregular clusters of similar cells in the superficial dermis, also above elastosis, and no maturation is apparent. A lymphohistiocytic infiltrate with admixed melanophages is present as well. Focally, maturing melanocytes are noted in the subjacent reticular dermis.	Cylindrical skin segment, 0.8 cm in diameter and 0.5 cm in thickness, with the margins inked, trisected and entirely submitted. RS/RS	ATYPICAL PIGMENTED MACULE; R/O MM	\N	\N	Scraping	This biopsy demonstrates melanoma overlying a longstanding melanocytic nevus. Synoptic parameters are included below. Procedure: subtotal excision Microscopic tumor type: melanoma NOS (melanoma ex melanocytic nevus) Breslow thickness: 0.55 mm Ulceration: not detected Margin: periphery involved Mitotic index: 0 Regression: present; partial Pathologic staging (pTNM): pT1a	MELANOMA OF 0.55 MM IN THICKNESS, TRANSECTED AT THE PERIPHERY OF THE BIOPSY	173602	1113	\N	\N	16-103071	\N	ME-18	Melanoma Epigenetics	IP1174641	AirTable blocks_with_IP_info.csv
1055	02-020334-11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2161	\N	\N	None	\N	SYNAT8	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3225	Cell-Line_Xu-35	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1893	\N	\N	None	\N	SYNAT241	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3226	Cell-Line_Xu-36	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2333	\N	\N	None	\N	SYNAT242	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3227	Cell-Line_Xu-37	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2216	\N	\N	None	\N	SYNAT243	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3228	Cell-Line_Xu-38	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2315	\N	\N	None	\N	SYNAT244	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3229	Cell-Line_Xu-39	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2027	\N	\N	None	\N	SYNAT245	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3230	Cell-Line_Xu-40	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2303	\N	\N	None	\N	SYNAT246	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3231	Cell-Line_Xu-41	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2053	\N	\N	None	\N	SYNAT247	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3232	Cell-Line_Xu-42	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1958	\N	\N	None	\N	SYNAT248	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3233	Cell-Line_Xu-43	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2194	\N	\N	None	\N	SYNAT249	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3234	Cell-Line_Xu-44	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1722	\N	\N	None	\N	SYNAT250	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3235	Cell-Line_Xu-45	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2128	\N	\N	None	\N	SYNAT251	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
1186	05-29484E	26	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22980	172.5	\N	\N	Sections show a cellular area of fibrosis and inflammation due to recent surgery, with no evidence of an atypical melanocytic proliferation. There are small melanocytes with round to oval nuclei in the superficial dermis in one focus away from the biopsy site.	Ellipse, 6.0 x 2.0 x 1.5 cm, including a central 2.3 cm linear scar.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in cassettes A through F, tips returned to container.	CHECK MARGINS; MALIGNANT MELANOMA	\N	\N	FFPE	There is an incidental, predominantly intradermal melanocytic nevus.	SCAR, WITH NO EVIDENCE OF RESIDUAL MELANOMA	173502	1713	\N	\N	05-29484	E	SYNAT15	California Cancer Registry	IP504172	AirTable blocks_with_IP_info.csv
3239	Cell-Line_Xu-49	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2240	\N	\N	None	\N	SYNAT255	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3240	Cell-Line_Xu-50	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1814	\N	\N	None	\N	SYNAT256	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3241	Cell-Line_Xu-51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1765	\N	\N	None	\N	SYNAT257	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3242	Cell-Line_Xu-52	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1965	\N	\N	None	\N	SYNAT258	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3243	Cell-Line_Xu-53	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2118	\N	\N	None	\N	SYNAT259	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3244	Cell-Line_Xu-54	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2073	\N	\N	None	\N	SYNAT260	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3245	Cell-Line_Xu-55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1900	\N	\N	None	\N	SYNAT261	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3246	Cell-Line_Xu-56	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1779	\N	\N	None	\N	SYNAT262	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3247	Cell-Line_Xu-57	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2022	\N	\N	None	\N	SYNAT263	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3248	Cell-Line_Xu-58	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2178	\N	\N	None	\N	SYNAT264	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3249	Cell-Line_Xu-59	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2009	\N	\N	None	\N	SYNAT265	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3250	Cell-Line_Xu-60	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2172	\N	\N	None	\N	SYNAT266	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3251	Cell-Line_Xu-61	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1770	\N	\N	None	\N	SYNAT267	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3252	Cell-Line_Xu-62	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1850	\N	\N	None	\N	SYNAT268	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3253	Cell-Line_Xu-63	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1824	\N	\N	None	\N	SYNAT269	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3254	Cell-Line_Xu-64	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2350	\N	\N	None	\N	SYNAT270	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
1157	05-006815	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1819	\N	\N	05-6815	\N	SYNAT22	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1159	05-011507	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1960	\N	\N	05-11507	\N	SYNAT24	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1165	05-015408	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1777	\N	\N	05-15408	\N	SYNAT25	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1185	05-29484D	26	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22979	172.5	\N	\N	Sections show a cellular area of fibrosis and inflammation due to recent surgery, with no evidence of an atypical melanocytic proliferation. There are small melanocytes with round to oval nuclei in the superficial dermis in one focus away from the biopsy site.	Ellipse, 6.0 x 2.0 x 1.5 cm, including a central 2.3 cm linear scar.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in cassettes A through F, tips returned to container.	CHECK MARGINS; MALIGNANT MELANOMA	\N	\N	FFPE	There is an incidental, predominantly intradermal melanocytic nevus.	SCAR, WITH NO EVIDENCE OF RESIDUAL MELANOMA	173502	1713	\N	\N	05-29484	D	SYNAT15	California Cancer Registry	IP504172	AirTable blocks_with_IP_info.csv
3256	CGH12-146	14	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	There is an ulcerated compound proliferation of melanocytes accompanied by pseudocarcinomatous epithelial hyperplasia. Situated at, or just beneath the junctional zone are nests of large fusiform melanocytes with relatively monomorphous oval vesicular nuclei and abundant amphophilic cytoplasm. A very high mitotic rate is evident, with some microscopic fields that contain four or five mitotic figures. Maturation with descent, coupled by a diminution in the sizes of aggregations and in the number of mitotic figures is evident toward the base of the lesion.	Six outside slides, PC12-135434-HD:A1,A2 and one corresponding block (A2).	HEMANGIOMA	\N	\N	\N	The mitotic rate in the upper part of the lesion, and the Ki-67 proliferation rate are both remarkable. The differential diagnosis includes a so-called atypical Spitz tumor and a spitzoid melanoma. The findings exceed those seen in a conventional Spitz's nevus. Comparative genomic hybridization did not show chromosomal gains or losses. Based on these findings, I favor a atypical Spitz tumor, i.e. a lesion with very limited metastatic capability. I would obtain a complete excision, if this has not already been done. The literature on sentinel lymph node biopsy and atypical Spitz tumor suggests a very low rate of involvement beyond local lymph nodes, and casts doubt on the utility of this technique in this setting.	PREDOMINANTLY INTRADERMAL PROLIFERATION OF LARGE, SPITZOID MELANOCYTES	173701	1970	\N	L	12-35761	A	SYNAT272	2010-2017	IP1121579	AirTable blocks_with_IP_info.csv
1058	02-20629	16	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a proliferation of spindled melanocytes with pigmented cytoplasms, surrounded by melanophages.  Collagen bundles are thickened.  The melanocytes extend deeply throughout the reticular dermis and in bulbous fashion into the superficial subcutis.  In one area, an eccrine unit is completely enveloped by the melanocytic proliferation.	Cylindrical skin segment, 0.7 cm in diameter and 0.5 cm in thickness,\ntrisected and totally submitted.	RECURRENT BLUE NEVUS	\N	\N	\N	This lesion shows many features observed in so-called deep penetrating nevus, with deep extension abutting upon the superficial subcutis in one focus.  There are subtle changes of superficial scar in the superficial dermis, which I deduce from the submitted clinical information must stem from a prior biopsy from this site.  If you would like us to retrieve and review the prior specimen, please let us know additional information about its location.	CELLULAR BLUE NEVUS WITH SPINDLED CELLS AND SCLEROSIS	173613	1931	\N	\N	02-20629	\N	SYNAT9	Dysplastic Nevi	IP325354	AirTable blocks_with_IP_info.csv
1707	13-24372B CONSULTA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	937	\N	\N	None	\N	MD-31	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1708	13-24372B T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	937	\N	\N	None	\N	MD-31	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1706	13-24372A T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	937	\N	\N	None	\N	MD-31	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2088	17-27224	71	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22436	216.5	\N	\N	There is a compound proliferation of melanocytes mostly involving the junctional zone and a thickened papillary dermis.  Nests of, and increased numbers of single melanocytes are situated at the sides and bases of elongated rete ridges. The bases of some adjacent rete ridges are fused.  Toward the center of the lesion, smaller melanocytes reside in the papillary dermis.	Skin segment measuring 1.3 x 1.0 x 0.1 cm, quadrisected, and entirely submitted. HD/HD	0.6 CM BROWN MACULE (PERSONAL HISTORY OF MELANOMA)	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, CLARK'S (DYSPLASTIC) TYPE, EXCISED IN THE AVAILABLE PLANES OF SECTION	139522	1119	\N	\N	17-27224	\N	ME-24	Melanoma Epigenetics	IP1732209	AirTable blocks_with_IP_info.csv
1701	13-17186A21	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1173	\N	\N	13-17186	A21	MucM-05	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
1699	13-17186A16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1173	\N	\N	13-17186	A16	MucM-05	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
2059	17-13334	71	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22145	172.5	\N	\N	Sections show a poorly circumscribed proliferation of melanocytes arranged as single cells and nests within the epidermis and dermis. Within the epidermis, many of the lesional melanocytes are located in pagetoid scatter and single melanocytes predominate over nests in some foci. Similar melanocytes are present in clusters in the underlying dermis and these melanocytes are within fibrosis that overlies solar elastosis. There are also collections of small and cytologically bland melanocytes in the dermis that diminish in size with descent and are present within solar elastosis.	Skin segment measuring 1.3 x 0.7 x 0.1 cm, trisected and entirely submitted. CF/CF	1.2 CM PEARLY PATCH	\N	\N	Scraping	There is a background of a melanocytic nevus with superficial congenital features and thus this melanoma most likely arose within a background of a melanocytic nevus. The melanoma is largely not pigmented, which helps to explain why it was clinically perceived as a pearly patch. Synoptic melanoma reporting is included below:  Procedure: Shave biopsy Microscopic tumor type: Superficial spreading, arising in association with a melanocytic nevus with superficial congenital features Breslow thickness: 0.55 mm Ulceration: Absent Margins: + base; + periphery Mitotic index: 0/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1a	MELANOMA, 0.55 MILLIMETERS IN THICKNESS, EXTENDING TO THE BASE AND PERIPHERAL EDGE OF THE SPECIMEN	139522	1119	\N	\N	17-13334	\N	ME-24	Melanoma Epigenetics	IP1732209	AirTable blocks_with_IP_info.csv
1698	13-17186A14	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1173	\N	\N	13-17186	A14	MucM-05	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
1700	13-17186A20	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1173	\N	\N	13-17186	A20	MucM-05	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
1190	05-41924	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2184	\N	\N	05-41924	\N	SYNAT26	2010-2017	\N	AirTable blocks_with_IP_info.csv
2130	17-43712	47	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22149	172.5	\N	\N	Sections show a compound proliferation of melanocytes with vacuolated and finely pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, and associated suprabasal scatter is focally apparent. There are also nests of similar melanocytes in the upper dermis, where a lymphohistiocytic infiltrate with admixed melanophages resides with fibrosis.	Skin segment measuring 1.0 x 0.7 x 0.1 cm, trisected and entirely submitted. CF/CF	R/O APL	\N	\N	Scraping	This biopsy demonstrates a thin invasive melanoma that has developed in conjunction with a small congenital melanocytic nevus, a remnant of which is included subjacent to the melanoma. A brief synoptic is included below. Procedure: shave removal Microscopic tumor type: melanoma ex melanocytic nevus Breslow thickness: 0.65 mm Ulceration: not detected Margin: focally involved by melanoma in situ Mitotic index: 0 Regression: not detected Pathologic staging (pTNM): pT1a	MELANOMA OF 0.65 MM IN THICKNESS, FOCALLY TRANSECTED AT THE PERIPHERY OF THE BIOPSY	173539	1123	\N	\N	17-43712	\N	ME-28	Melanoma Epigenetics	IP741233	AirTable blocks_with_IP_info.csv
2147	17-62026B	47	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22439	172.5	\N	\N	Sections show central iatrogenic fibrosing inflammatory alterations stemming from a procedure, and no evidence of an atypical melanocytic proliferation remains in contiguity with this.	Oriented ellipse, 4.7 x 1.7 x 1.2 cm, including a central 1.0 x 0.5 cm brown area. With the orienting sutured tip placed to the left and indicated medial on the requisition, the sutured tip is designated 9 o'clock by the grosser. The 9-12-3 o'clock margin is inked blue and the 3-6-9 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in A-D. Tips reserved. PL/PL	MM EXCISION, RE-EXC DT17-43712	\N	\N	Scraping	No residuum is apparent, and the final margin is now free. An updated brief synoptic is included below. Procedure: wide excision Microscopic tumor type: melanoma NOS Breslow thickness: 0.65 mm Ulceration: not detected Margin: free of melanoma Mitotic index: 0 Regression: not detected Pathologic staging (pTNM): pT1a	POST-PROCEDURAL SCARRING, WITH NO EVIDENCE OF RESIDUAL MELANOMA	173539	1123	\N	\N	17-62026	B	ME-28	Melanoma Epigenetics	IP741233	AirTable blocks_with_IP_info.csv
1562	12-4365C2	73	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.31	\N	\N	Sections show small rounded and angulate aggregations of atypical basaloid keratinocytes associated with scant inflamed stroma in the dermis, and the surface of the biopsy is ulcerated, with exudate and crust residing above it.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted.	? FIBROMA/IDN	\N	\N	\N	None	ULCERATED INFILTRATIVE BASAL CELL CARCINOMA, INVOLVING THE DEEP EDGE OF THE BIOPSY	173313	1971	\N	\N	12-4365	C2	SYNAT27	Long-Triple Negative Metastatic Melanoma	IP39574	AirTable blocks_with_IP_info.csv
1069	03-197B2	77	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	707.9	\N	\N	Sections show squamous mucosa and salivary gland epithelium, with a sharply circumscribed zone of ulceration and infiltrates of neutrophils.	Two outside slides labeled S02-4228 A1 and A2.	\N	\N	\N	\N	There is no evidence of carcinoma.  The is no clue as to the cause of the ulcer in these sections.  At the time that I evaluated these sections, we had not yet received any clinical information, other than that on the report from Forensic Medical Group.  Please contact us  if your clinical impression does not fit well with our diagnosis.	ULCERATION AND REACTIVE CHANGES	100065	2026	\N	\N	03-197	B2	SYNAT12	2010-2017	IP358509	AirTable blocks_with_IP_info.csv
1070	03-1978B3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2239	\N	\N	03-1978	B3	SYNAT13	2010-2017	\N	AirTable blocks_with_IP_info.csv
3258	CGH13-010	63	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a proliferation of melanocytes arrayed singly and in nests, irregularly within the basal layer of the epidermis, in large part at the sides and bases of elongated rete ridges. Most of the junctional component overlies a zone of paucicellular fibrosis. There are discrete nests of small, round melanocytes in the superficial dermis in some foci, with slightly larger cells in dyscohesive nests in another area, bordering a focally dense lymphocytic infiltrate. A few dermal melanocytes have large, hyperchromatic nuclei. In the mid-reticular dermis near one edge of the specimen are small nests, cords and strands of small, round melanocytes, in a partially perivascular pattern.	Skin segment measuring 0.9 x 0.8 x 0.2 cm, trisected and entirely submitted.  PL/PL	6 MM DARK BROWN IRREGULAR MOLE, PROBABLY MELANOMA, ADJACENT TO OLD BIOPSY SCAR, BUT I AM NOT CONVINCED THEY ARE RELATED (DT08-18690)	\N	\N	\N	ADDENDUM, January 25, 2013: The following note has been modified from that in the original report and later addenda, copies of which are on file as .pdfs in our computer system: The lesion overlies a scar, making it likely that it is related to DT08-18690. Portions of the dermal component with small cells in the current case resemble those in the prior one as well. While some features of the current lesion raise the possibility of melanoma, little pagetoid scatter is present and the lesional melanocytes are largely small and monomorphous (with rare cells having large nuclei). Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows many Ki-67 positive melanocytes in the junctional zone and only a few in the dermis. There is a remnant of an unequivocally benign intradermal melanocytic nevus as well.  Given these findings, I re-examined the sections from the 2008 biopsy, and obtained a similar two-color immunoperoxidase stain on it. There are a few single melanocytes above the basal layer, with a low proliferation rate in both junctional and dermal components. The features still favor a dysplastic (Clark's) nevus rather than melanoma with respect to the initial lesion.  On the basis of morphology, I favor a thin melanoma over a dysplastic (Clark's) nevus in regard to the current persistent/recurrent lesion. A re-excision is certainly appropriate, as the lesion is less than 1 mm. from the margin. We performed comparative genomic hybridization to see if unequivocal findings of melanoma were present. There were several low level aberrations (this may indicate aberrations in a minority of cells, with the effect in in our array graph muted by the presence of other melanocytes without these copy number changes). The aberrations are in areas not typically affected in melanoma, including gains in chr. 2p and 7q, and a loss in 3q. Given these idiosyncratic findings, I asked my colleague and the director of our molecular lab, Dr. Boris Bastian to review the comparative genomic hybridization data. He stated that he would be unable to make a diagnosis of melanoma based on the data alone.  In sum, this is a difficult and borderline recurrent lesion whose differential diagnosis includes a thin melanoma, but falls short of being unequivocal diagnostic, either morphologically, with immunoperoxidase stains or molecular methods.	SCAR AND PERSISTENT COMPOUND PROLIFERATION OF MELANOCYTES WITH ATYPICAL FEATURES	173505	1878	\N	T	12-97432	A	SYNAT274	2010-2017	IP300725	AirTable blocks_with_IP_info.csv
2228	17-111571	37	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted. KC/KC	JC17-520, 5 MM; R/O ATYPICAL	\N	\N	Scraping	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	273588	844	\N	\N	17-111571	\N	LN-024	Lentiginous Nevi 	IP1767762	AirTable blocks_with_IP_info.csv
3259	CGH13-014	63	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show an intradermal proliferation of enlarged epithelioid and fusiform melanocytes. These cells are distributed as nests, cords, and fascicles within reticular dermal sclerosis, and a rare dermal melanocyte in mitosis can be found. A modest juxtaposed lymphocytic infiltrate is also noted. In the background, substantial solar elastosis is appreciable.	One outside slide, S12-49334 A-1 (MR# 30392441) and one corresponding block.	PINK PAPULE 3-4 MM X MONTHS; ? FOLLICULAR CYST VS. BASAL CELL CARCINOMA, WITH DISTANT HISTORY OF MELANOMA - MOLECULAR STUDIES??	\N	\N	\N	I believe this partial biopsy demonstrates a desmoplastic Spitz nevus. To assess primary spitzoid melanoma and metastatic melanoma as additional possibilities in the differential diagnosis, we completed array-based comparative genomic hybridization (aCGH) to screen for chromosomal copy number abnormalities, as can be seen in association with melanoma. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 11p with no other chromosomal gains or losses. Gain in chromosome 11p as a monoaberration has been documented in a subset of Spitz nevi that also harbor HRAS mutation. This genomic aberration has not been demonstrated to be present in association with melanoma. In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. Rather, we have confirmed that this melanocytic nevus represents a Spitz nevus variant with associated gain in chromosome 11p, which implies that HRAS mutation is present. As this is only a partial biopsy, conservative complete reexcision of this site can be considered if the patient is interested in complete removal of any residuum and the prevention of persistence.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5. (Please note that this paper describes a tumor with genomic findings similar to those seen in this case.)	DESMOPLASTIC INTRADERMAL SPITZ NEVUS	173305	2231	\N	L	13-788	A	SYNAT275	2010-2017	IP1185530	AirTable blocks_with_IP_info.csv
2087	17-27000	62	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10853	216.5	DN	\N	Sections show a compound proliferation of melanocytes, with nested and solitary melanocytes distributed relatively evenly along the epidermal-dermal junction.  Similar but slightly smaller cells are in the subjacent superficial dermis.  Many of the constituent melanocytes have abundant vacuolated and pigmented cytoplasm.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/HD	R/O DN	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS WITH PIGMENTED EPITHELIOID MELANOCYTES	122533	535	\N	\N	17-27000	\N	DN-060	Dysplastic Nevi	IP1756322	AirTable blocks_with_IP_info.csv
2680	21-2141	54	\N	\N	\N	None	None	None	20	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26441	172.5	\N	\N	Sections show an ulcerated proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.2 x 1.2 x 0.2 cm, serially sectioned and entirely submitted with five sections. KB/KB	11 X 11 MM, ERYTHEMATOUS WEEPING PAPULE WITH BLACK DOTS UNEVENLY DISTRIBUTED; R/O PIGMENTED BCC VS. MM	\N	ULCERATED MELANOMA, 1.1 mm IN THICKNESS, WITH AN ASSOCIATED MELANOCYTIC NEVUS	FFPE	A synoptic report of potential prognostic factors is listed below: Procedure: saucerization biopsy Microscopic tumor type WHO classification: low cumulative sun damage Breslow thickness: 1.1 mm Ulceration: present Margins, peripheral and deep: deep focally involved by invasive melanoma, peripheral involved by invasive melanoma Mitotic index: 4 per square mm Regression: not identified Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT2b	ULCERATED MELANOMA, 1.1 mm IN THICKNESS, WITH AN ASSOCIATED MELANOCYTIC NEVUS	133559	1154	\N	\N	21-2141	\N	ME-59	Melanoma Epigenetics	IP2267514	AirTable blocks_with_IP_info.csv
3262	CGH13-094	23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	There is a large polypoid segment of modified skin within which there is a relatively well-circumscribed oval mass composed of densely fibrotic stroma, and relatively small round aggregations of large polygonal and oval melanocytes. The latter have abundant homogeneous-appearing eosinophilic cytoplasm and strikingly pleomorphic, vesicular nuclei with large nucleoli. Mitotic figures are rare. The enclosed Ki-67 stain shows a proliferation rate estimated at 5 percent.	Twelve outside slides, 13-SUH-5219 (1A-1B) and corresponding block 1A.	BIOPSY ORIGINATES FROM A 23 YEAR OLD WOMAN WHO PRESENT AT CESAREAN SECTION WITH A PERIANAL MASS, BENIGN LOOKING EXOPHYTIC PERIANAL MASS	\N	\N	\N	Comparative genomic hybridization shows a gain involving chromosome 7q. Isolated gains of 7q can be seen in some Spitz's nevi. In this case, a rearrangement involving the b-raf locus is also present, a finding that we have not encountered in this group. I would regard this lesion as equivalent to an atypical Spitz tumor rather than a Spitz's nevus or spitzoid melanoma. A narrow re-excision despite the difficult site would be prudent. My colleague, Dr. Boris Bastian has reviewed the comparative genomic hybridization data and agrees with this interpretation of it. Atypical Spitz tumors have a high rate of local nodal involvement, as assessed by sentinel lymph node biopsy. However, distant metastasis is very rare, making it unlikely that such biopsies, let alone completion lymphadenectomy based on them are of benefit.	INTRADERMAL PROLIFERATION OF LARGE SPITZOID MELANOCYTES, WITH UNUSUAL GENOMIC FEATURES	173521	2328	\N	L	13-18243	A	SYNAT279	2010-2017	IP1202986	AirTable blocks_with_IP_info.csv
3263	CGH14-050	34	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a roughly oval mass of melanocytes within fibrofatty tissue. At the periphery of the mass are cords and strands of small, round cells with relatively scant pale cytoplasm and monomorphous oval nuclei containing small nucleoli. These cells are separated by thickened collagen bundles in some areas, with a few melanophages. The center of the lesion is more cellular. There are sheets of cells with inconspicuous pale cytoplasm and considerably larger, vesicular nuclei with moderately enlarged reddish nucleoli. Several mitotic figures are evident (but usually 1-2 per mm square). There are occasional multinucleated cells, as well as pseudovascular spaces within the masses of melanocytes. The enclosed immunostains include positive S100 and Melan-A stains, as well as an HMB-45 stain which marks both the smaller and larger melanocytes.	Twelve outside slides, SC14-637:A/1,A/2, XPS-14-931:B/1,B/2 (including five unstained slides cut from block A/1) and two corresponding blocks.	THIRD OPINION, NO HISTORY OF MELANOMA, PRESENT FOR YEARS AND HAD POSSIBLY BEEN INCREASING IN SIZE SLIGHTLY, INTRAOPERATIVELY IT SHELLED OUT EASILY AND DID NOT APPEAR TO BE CONNECTED OR INVOLVING THE OVERLYING EPIDERMIS; THROMBOSED VESSEL	\N	\N	\N	The HMB-45 staining of both components of the lesion is in keeping with both populations deriving from a blue nevus, probably a cellular blue nevus (the quotation marks reflect my unhappiness with the common/cellular dichotomy). The more cellular population lacks the typical nested, or lobular peninsula-like architecture of a cellular blue nevus, nuclei are somewhat enlarged and crowded, and the mitotic rate is higher than in most such lesions. However, the striking cytologic atypia, necrosis and lymphocytic infiltrate seen in some melanomas arising in blue nevi are not evident here. Some would term the current changes atypical blue nevus, a term I am not fond of but may have some applicability in this case. In keeping with this borderline character, comparative genomic hybridization shows an aberration not typically seen in melanoma. There is a gain involving chr. 9, which is often lost in melanoma. A re-excision of this area seems appropriate. In the reference below, the number of aberrations seen in blue nevus-like melanoma was higher than in atypical blue nevi or in conventional cellular blue nevi; with one aberration, and that one not typically associated with melanoma, this intermediate category seems best.  Reference:  Maize JC Jr, McCalmont TH, Carlson JA, Busam KJ, Kutzner H, Bastian BC. Genomic analysis of blue nevi and related dermal melanocytic proliferations. Am J Surg Pathol. 2005 Sep;29(9):1214-20.	ATYPICAL MELANOCYTIC PROLIFERATION ARISING IN A CELLULAR BLUE NEVUS	173788	1883	\N	L	14-15427	A	SYNAT280	2010-2017	IP1365348	AirTable blocks_with_IP_info.csv
2170	17-68780A	68	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=27425	173.51	\N	\N	Sections show a proliferation of atypical and peripherally palisaded basaloid cells, arrayed as rounded nests attached to the undersurface of the epidermis and as rounded aggregations in the dermis. Foci of keratinization are present and sclerotic collagen bundles are positioned between neoplastic keratinocytes.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A) PINK PEARLY PIGMENTED PAPULE; BASAL CELL CARCINOMA, B-C) ATYPICAL BROWN MACULE; ATYPICAL NEVUS	\N	\N	FFPE	\N	SUPERFICIAL/NODULAR BASAL CELL CARCINOMA, NARROWLY EXCISED IN PLANES OF SECTION EXAMINED	139523	1139	\N	\N	17-68780	A	ME-44	Melanoma Epigenetics	IP543552	AirTable blocks_with_IP_info.csv
2171	17-68780B	68	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=27426	216.5	\N	\N	Sections show a compound melanocytic proliferation of cytologically bland melanocytes arrayed as large nests and single cells at the sides and bases of elongated and hyperpigmented rete ridges. Clusters of melanocytes mature with descent in the superficial dermis. There is some papillary dermal fibrosis.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in B. CF/CF	A) PINK PEARLY PIGMENTED PAPULE; BASAL CELL CARCINOMA, B-C) ATYPICAL BROWN MACULE; ATYPICAL NEVUS	\N	\N	FFPE	This nevus has large junctional nests and papillary dermal fibrosis which are features of nevi on the breast.	COMPOUND MELANOCYTIC NEVUS	173505	1139	\N	\N	17-68780	B	ME-44	Melanoma Epigenetics	IP543552	AirTable blocks_with_IP_info.csv
1272	07-011660-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1782	\N	\N	None	\N	SYNAT29	Long-Triple Negative Metastatic Melanoma	\N	AirTable blocks_with_IP_info.csv
1273	07-012236B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2191	\N	\N	07-12236	B1	SYNAT30	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1563	12-004374B	43	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.7	\N	\N	Sections show acral skin with melanocytes singly and in large nests at the dermo-epidermal junction, and within the subjacent superficial dermis.  The dermal component matures with descent.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted.	4 MM PIGMENTED PAPULE THAT HAS INCREASED IN SIZE IN THE LAST 2 YEARS; NEVUS, R/O CHANGE	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS	273766	1815	\N	\N	12-4374	B	SYNAT31	Long-Triple Negative Metastatic Melanoma	IP222047	AirTable blocks_with_IP_info.csv
2369	18-122476	70	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.4	\N	\N	Sections show a proliferation of dendritic melanocytes and melanophages in the superficial dermis. Some melanocytes appear ovoid with pigmented cytoplasm.	Skin segment measuring 0.5 x 0.5 x 0.1 cm, bisected and entirely submitted. CF/PL	IRREGULAR BROWN MACULE; ATYPICAL NEVUS VS. MELANOMA	\N	\N	Scraping	None	BLUE NEVUS, WITH DENDRITIC MELANOCYTES	103431	1186	\N	\N	18-122476	\N	NL-024	Nevus Library	IP594622	AirTable blocks_with_IP_info.csv
3054	1485/15 (1485/15 slide)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1189	\N	\N	None	\N	NM-002	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3065	2997/11	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1190	\N	\N	None	\N	NM-003	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2394	19-2118	26	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.6	\N	\N	There is a dermal proliferation of spindled melanocytes with relatively monomorphous nuclei, disposed between thickened collagen bundles and accompanied by scattered melanophages.  A superficial scar is present.	Elliptical excision, 2.2 x 0.9 x 0.3 cm, including a central 0.7 x 0.6 cm white-gray area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with eight sections. CF/CF	BLUE-GREY PAPULE, WHITE CYSTIC COMPONENT AT LATERAL EDGE (AT SITE OF RECURRENT BLUE NEVUS); BLUE NEVUS, R/O ATYPIA	\N	\N	Scraping	None	BLUE NEVUS, SPINDLE CELL/SCLEROTIC TYPE, COMPLETELY EXCISED	173663	1126	\N	\N	19-2118	\N	ME-31	Melanoma Epigenetics	IP2001940	AirTable blocks_with_IP_info.csv
2172	17-68780C	68	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26200	172.5	\N	EXCLUDED. \n0.7 mm with adjacent Clark. OK but nevus a bit paucicellular	Sections show a compound proliferation of nested melanocytes, both at the junction and within a papillary dermis that is strikingly thickened by lamellar fibroplasia in multiple areas. Some nests of melanocytes within the areas of fibroplasia are disposed horizontally and the melanocytes have small darkly staining nuclei. To the side of these fibrotic areas are a distinct population of small round melanocytes.	Skin segment measuring 1.1 x 0.6 x 0.1 cm, bisected and entirely submitted in C. CF/CF	A) PINK PEARLY PIGMENTED PAPULE; BASAL CELL CARCINOMA, B-C) ATYPICAL BROWN MACULE; ATYPICAL NEVUS	\N	right trunk	FFPE	Melan-a immunohistochemistry demonstrates pagetoid scatter of melanocytes within the epidermis and areas of confluence. There is an associated nevus. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: shave biopsy Microscopic tumor type: nevoid melanoma Breslow thickness: 0.7 mm Ulceration: no Margins, peripheral and deep: peripheral involved, deep free Mitotic index: 0 per square mm Microsatellitosis: not identified Vascular Invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT1a	MELANOMA, 0.7 MM IN THICKNESS	101544	1139	\N	\N	17-68780	C	ME-44	Melanoma Epigenetics	IP543552	AirTable blocks_with_IP_info.csv
1074	03-007239	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1942	\N	\N	03-7239	\N	SYNAT14	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1249	06-47079A02	60	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.7	\N	\N	There is a proliferation of melanocytes with lightly pigmented cytoplasm situated as large round nests and singly along the dermo-epidermal junction.  The melanocytes have relatively monomorphous nuclei.	Ellipse, 0.8 x 0.5 x 0.3 cm, including a central dark brown 0.5 x 0.4 cm pigmented spot.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections.	HISTORY OF MELANOMA, DARKENING LESION	\N	\N	\N	The neoplasm extends to within 1 mm. of the edge of the specimen. There are no worrisome features, however.	JUNCTIONAL MELANOCYTIC NEVUS	173792	2155	\N	\N	06-47079	A02	SYNAT32	2010-2017	IP586773	AirTable blocks_with_IP_info.csv
1711	13-26846A1 N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	938	\N	\N	None	\N	MD-32	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1710	13-26846 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	938	\N	\N	None	\N	MD-32	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1274	07-13061	27	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22975	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and the superficialmost dermis. There are single melanocytes and nests arrayed along the sides and bases of rete, and some of these cells have vacuolated and pigmented cytoplasm and assume an epithelioid configuration. The papillary dermis is expanded by slight fibroplasia and a sparse patchy lymphohistiocytic infiltrate.	Ellipse, 0.9 x 0.5 x 0.8 cm, including a central brown 0.7 x 0.4 cm area.  With margins inked blue, the specimen is serially trisected perpendicular to the long axis and entirely submitted.	DYSPLASTIC NEVUS, R/O MM	\N	\N	\N	This report was reissued on April 7, 2011, to add the patient's UCSF Medical Record number and to forward a copy to UCSF Medical Records.	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173527	2293	\N	\N	07-13061	\N	SYNAT33	California Cancer Registry	IP504172	AirTable blocks_with_IP_info.csv
3090	17890/18 (HBD)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1221	\N	\N	None	\N	NM-44	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3161	B246205/ 1BI	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1222	\N	\N	None	\N	NM-45	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3162	B247206/ 1Bl	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1223	\N	\N	None	\N	NM-46	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3159	B224228/2	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1224	\N	\N	None	\N	NM-47	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3156	B205907 III	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1225	\N	\N	None	\N	NM-48	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2815	22-80319A1	54	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30856	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 3.5 x 1.4 x 0.4 cm, serially sectioned and entirely submitted with three sections each in 1-2. CF/CF	DYSPLASTIC NEVUS VS. MELANOMA. IRREGULAR BROWN MACULE.	\N	\N	\N	A synoptic report of potential prognostic factors is listed below: Procedure: excisional biopsy Microscopic tumor type: superficial spreading melanoma (WHO classification: low cumulative sun damage) Breslow thickness: 1.1 mm Ulceration: absent Margins, peripheral and deep: deep clear, peripheral involved Mitotic index: 2 per square mm Regression: partial regression present Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT2a	MELANOMA, 1.1 mm BRESLOW THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	273588	1160	\N	\N	22-80319	A1	ME-65	Melanoma Epigenetics	IP2482233	AirTable blocks_with_IP_info.csv
2816	22-80319A2	54	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30856,30857	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 3.5 x 1.4 x 0.4 cm, serially sectioned and entirely submitted with three sections each in 1-2. CF/CF	DYSPLASTIC NEVUS VS. MELANOMA. IRREGULAR BROWN MACULE.	\N	\N	\N	A synoptic report of potential prognostic factors is listed below: Procedure: excisional biopsy Microscopic tumor type: superficial spreading melanoma (WHO classification: low cumulative sun damage) Breslow thickness: 1.1 mm Ulceration: absent Margins, peripheral and deep: deep clear, peripheral involved Mitotic index: 2 per square mm Regression: partial regression present Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT2a	MELANOMA, 1.1 mm BRESLOW THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	273588	1160	\N	\N	22-80319	A2	ME-65	Melanoma Epigenetics	IP2482233	AirTable blocks_with_IP_info.csv
3260	CGH13-026	3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	There is a compound proliferation of large, oval and fusiform melanocytes with abundant, pale amphophilic cytoplasm and large, vesicular nuclei. The surface is coarsely papillated. Nests of melanocytes predominate over those distributed singly along the junctional zone, with subtle suprabasilar scatter of single cells in small foci. The overlying epidermis is thinned in the center of the lesion, where very large nests of melanocytes are evident superficially. Smaller ones are seen in the lower part of the lesion.	One outside slide, SCD-12-35582:A, and one corresponding block.	7 X 5 MM TAN OVAL PAPULE X 1 YR W/ RECENT HX RAPID GROWTH AND BLEEDING CENTRALLY, FRIABLE PINK RED RAISED CENTRAL PAPULE; UNUSUAL VV, PYOGENIC GRANULOMA, R/O MM	\N	\N	\N	A p16 immunoperoxidase stain does not show loss of that tumor suppressor gene product. A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows scattered mitotic figures in dermal melanocytes, mostly in the upper part of the lesion. Comparative genomic hybridization shows discrete areas of losses involving chromosome 1p, and to a lesser extent, chromosome 1q. While losses involving chromosome 1p can be seen in melanoma, this is seldom an isolated finding. Under the circumstances, and given the age of the patient I would prefer to regard this lesion as equivalent to a so-called atypical Spitz tumor, rather than assign a diagnosis of spitzoid melanoma. Despite the surgically difficult location, a narrow reexcision to obtain histopathologically clear margins seems warranted. Given the low predictive value of sentinel lymph node positivity in this setting, I do not advise it.	COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES	173208	2156	\N	L	13-479	A	SYNAT276	2010-2017	IP1185221	AirTable blocks_with_IP_info.csv
3261	CGH13-034	36	\N	\N	\N	T2a	Primary	\N	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show melanocytes arrayed in largely dermal fashion. Superficially, there are large nests and syncytia of enlarged epithelioid melanocytes in the upper dermis, and these melanocytes have finely melanized cytoplasm. In a recut section, some of these melanocytes appear spitzoid. More deeply, there are fusiform and dendritic melanocytes that are much smaller residing in the reticular dermis, and interstitial melanophages can be seen.	Four outside slides, CSI-13-225, and one corresponding block.	4 MM BROWN FIRM PAPULE, (+) PIGMENTED AT BASE, ONSET 2 YEARS AGO, INCREASING IN SIZE + COLOR CHANGES X 1 YEAR, 2 SECTIONS IN BOTTLE, PROCESS ALL FRAGMENTS; SK, RULE OUT MM	\N	\N	\N	ADDENDUM, February 8, 2013: As I reported previously, my differential diagnosis included a variant of cellular blue nevus, a combined melanocytic nevus, and melanoma ex blue nevus. Your submitted immunostains demonstrate avid expression of HMB-45, as would be expected with a blue nevus or blue nevus-like melanoma. Cell proliferation analysis was completed via immunoperoxidase staining utilizing a two-color development system in which MART-1 is labeled red and Ki-67 is labeled brown. By this staining method, we found diffuse MART-1 reactivity. The MART-positive cells show slightly elevated nuclear expression of Ki-67, thus implying that cellular proliferation is elevated, which is of potential concern. A p16 immunostain demonstrates preservation of expression, which implies that an underlying anomaly in chromosome 9p is not present. This is the type of challenging case for which array-based comparative genomic hybridization (aCGH) can be applied to screen for genomic copy number anomalies, as can be seen with melanoma. Per your request and approval, completed molecular assessment. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 7, 8, and 22q. The identification of multiple chromosomal copy number aberrations indicates genomic instability, as is stereotypical of malignancies such as melanoma. The aCGH profile that we have defined is incompatible with a benign interpretation.  In summary, the combination of results derived from conventional microscopy coupled with aCGH demonstrates that this atypical melanocytic tumor represents melanoma that has developed secondarily in a blue nevus. This entity can be referred to as 'blue nevus-like melanoma'. With respect to staging, this melanoma is between 1-2 mm in thickness and lacks associated ulceration in the current sections. Therefore, it provisionally represents melanoma of stage pT2a (2009 AJCC Guidelines). The final microstage parameters can be reassessed once this melanoma has been fully extirpated.  This report was reissued on April 24, 2014, to add the patient's UCSF Medical Record number and to forward a copy to UCSF Medical Records.	MELANOMA OF AT LEAST 1.8 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A BLUE NEVUS	100678	2002	\N	L	13-3732	A	SYNAT277	2010-2017	IP1188475	AirTable blocks_with_IP_info.csv
3283	DM8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2244	\N	\N	None	\N	SYNAT278	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
1143	04-35102A	48	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.3	\N	\N	Sections show a multinodular neoplasm of melanocytes that extends from the undersurface of the epidermis to the deep reticular dermis.  In the upper portion of the lesion, there are large and confluent nests of large plump oval melanocytes with vesicular nuclei and pale, vacuolated cytoplasm.  Mitotic figures are easily identified among this population, which does not mature.  At the base of the proliferation in the reticular dermis are interconnecting cords of spindled melanocytes associated with melanophages (which are nearly absent from the upper part of the lesion).  In one tip are nests, cords and strands of smaller, round melanocytes with monomorphous nuclei that aggregate around adnexal structures.	Oriented ellipse measuring 1.8 x 1.0 x 0.7 cm, including 0.7 x 0.7 cm raised central lesion, with tip marked by suture noted by surgeon as the superior pole placed to the left and arbitrarily designated the 12:00 pole, the right tip arbitrarily designated the 6:00 pole. The far aspect of specimen (12:00-3:00-6:00 margin) is inked in blue and the near half of specimen (6:00-9:00-12:00 margin) is inked in yellow. The specimen is serially sectioned and entirely submitted with four sections each in cassettes A and B.	ONE WEEK H/O CHANGE IN PIGMENTED NEVUS-BLEEDING; MELANOMA-NODULAR?	\N	\N	\N	Histopathologic features of possible prognostic importance include: Level: IV Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: high Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent  The excision appears narrow but complete.	MELANOMA, 2.5 MM IN THICKNESS	173316	1166	\N	\N	04-35102	A	MP-02	Hockemeyer Melanoma Progression	IP451504	AirTable blocks_with_IP_info.csv
2631	20-43011	76	\N	\N	\N	None	None	None	20	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26429,26430	172.6	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests.  There are similar melanocytes in the subjacent dermis in nests and strands with scattered mitoses. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.3 x 0.9 x 0.3 cm, quadrisected and entirely submitted. KB/CF	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. DYSPLASTIC NEVUS. PAPULE.	\N	MELANOMA, 2.2 MM IN THICKNESS, NON-ULCERATED	FFPE	The Melan-A component of a PRAME/Melan-A multiplex immunostain highlights the irregular distribution of melanocytes, and PRAME is positive in the melanocytes as well, supporting a diagnosis of melanoma. There are some areas with smaller melanocytes with less PRAME expression that could represent a precursor nevus. Some of the larger cells have a plasmacytoid epithelioid appearance, but BAP-1 staining did not show loss of nuclear expression to indicate possible BAP-1 mutation. There is loss of p16 staining, which can correlate with one of the common genomic aberrations seen in melanomas, namely bi-allelic loss of chromosome 9p21 where the CDKN2A gene that encodes p16 is located. This loss is not entirely specific for melanoma, but is another concerning finding that supports melanoma. A synoptic report of potential prognostic factors is listed below: Procedure: saucerization biopsy Microscopic tumor type, WHO classification: low cumulative sun damage Breslow thickness: 2.2 mm Ulceration: absent Margins, peripheral and deep: deep focally involved by invasive melanoma, peripheral involved by invasive melanoma Mitotic index: 4 mm/2 Regression: partial regression present Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT3a	MELANOMA, 2.2 MM IN THICKNESS, NON-ULCERATED	529699	1149	\N	\N	20-43011	\N	ME-54	Melanoma Epigenetics	IP1919209	AirTable blocks_with_IP_info.csv
1276	07-20501	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1930	\N	\N	07-20501	\N	SYNAT35	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
2467	19-72316	\N	\N	\N	\N	\N	\N	\N	20	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	lip	FFPE	\N	\N	\N	1281	\N	\N	19-72316	\N	OM-23	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2486	19-122139	\N	\N	\N	\N	\N	\N	\N	20	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	gingiva	FFPE	\N	\N	\N	1282	\N	\N	19-122139	\N	OM-24	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2602	20-16705	\N	\N	\N	\N	\N	\N	\N	20	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	buccal	FFPE	\N	\N	\N	1283	\N	\N	20-16705	\N	OM-25	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
3264	CGH14-147	11	\N	\N	\N	T1a	Primary	\N	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a proliferation of melanocytes involving the epidermis and papillary dermis. The span of the junctional component exceeds that of the dermal portion. The lesional melanocytes include many cells with large, irregularly shaped hyperchromatic nuclei and scant cytoplasm. Some have abundant, pale cytoplasm. Nests of melanocytes predominate over those distributed singly along the junctional zone, and some of those nests are confluent. Some areas show maturation and dispersion with descent.	One outside slide, D-2147-14 (LX-14-01265 A-1). One corresponding block received 6-9-14.	COMPOUND NEVUS; ATYPICAL MELANOCYTIC PROLIFERATION	\N	\N	\N	Along with the slides was a report from Barr Dermatopathology suggesting comparative genomic hybridization; per a message from your institution we proceeded with that testing. Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. These include a gain involving chr. 1q, loss of 2p with areas of gain involving 2q but a gain involving the terminal portion of that chromosome, loss involving 4q, and loss involving 9p. Several of these aberrations are commonly found in melanoma.  While formally, this is an AJCC stage pT1a lesion, the prognosis is in a group of cases of this type is even more favorable than in a group of adult patients with conventional AJCC stage pT1a lesions. Spitzoid melanomas in children have a considerably lower rate of extranodal disease. This lesion is well circumscribed and has a margin of about 1 mm. As local recurrence from incomplete excision is rare in lesions of this type, I would suggest a narrow re-excision to achieve 5 mm. margins. Sentinel lymph node biopsy is controversial in this type of case, with childhood spitzoid melanomas having a high rate of nodal involvment, but a much lower rate of extranodal spread. Hence, the prognostic value of the procedure is much less than in an adult patient, and the procedure can lead to overtreatment.	MELANOMA, 0.85 MM. IN THICKNESS	273588	1921	\N	L	14-43805	A	SYNAT281	2010-2017	IP1393739	AirTable blocks_with_IP_info.csv
3266	CGH19-097	3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a dome shaped skin segment with an effaced epidermis that contains occasional nests of spindled and epithelioid melanocytes. Within the dermis there are nests of large epithelioid melanocytes, with occasional large multinucleate melanocytes. The proliferation has a wedge-shaped profile and in the reticular dermis melanocytes are positioned between thickened collagen bundles. There is a sparse lymphocytic infiltrate.	Eleven outside slides, 19/CH18523, including 10 unstained slides. One corresponding block received 6/24/19.	ATYPICAL - LOOKS LIKE MELANOMA BUT 3 Y/O? CGH USEFUL	\N	\N	\N	ADDENDUM, July 19, 2019: Dear Dr. Hitchcock,  Thank you for sending this case in consultation. I agree with you that this spitzoid proliferation is unusual and has a slightly asymmetric architecture. However it does mature and the FISH findings are reassuring. We performed array comparative genomic hybridization specifically on the superficial nodular area within the tumor that shows greater cytomorphologic atypia and mitotic activity. This demonstrated loss of chromosome 9 but no other significant copy number alterations. p16 immunohistochemistry demonstrates strong staining in the majority of the tumor, but no staining in the area that we tested by aCGH. I believe this case represents an atypical Spitz tumor arising in a Spitz nevus due to loss of CDKN2A (on chromosome 9p). The aCGH findings do not support a diagnosis of melanoma.	COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES	173602	1941	\N	N	19-44904	A	SYNAT283	2010-2017	IP2049186	AirTable blocks_with_IP_info.csv
1284	07-41091A	25	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22987	172.3	\N	\N	Sections show inflammation and granulation tissue, with no evidence of an atypical melanocytic proliferation.	Oriented ellipse, 3.5 x 1.5 x 0.7 cm, including a central 1.0 x 1.0 cm defect per MD.  With the orienting sutured tip placed to the left and designated suture @ superior by the surgeon, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from left to right poles and submitted with four sections each in cassettes A and B, tips returned to container.\n	R/O MM	\N	\N	\N	\N	HEALING BIOPSY SITE, WITH NO EVIDENCE OF RESIDUAL MELANOMA	102304	1769	\N	\N	07-41091	A	SYNAT36	Melanoma Epigenetics	IP659911	AirTable blocks_with_IP_info.csv
1285	07-41091B	25	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22988	172.3	\N	\N	Sections show inflammation and granulation tissue, with no evidence of an atypical melanocytic proliferation.	Oriented ellipse, 3.5 x 1.5 x 0.7 cm, including a central 1.0 x 1.0 cm defect per MD.  With the orienting sutured tip placed to the left and designated suture @ superior by the surgeon, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from left to right poles and submitted with four sections each in cassettes A and B, tips returned to container.\n	R/O MM	\N	\N	\N	None	HEALING BIOPSY SITE, WITH NO EVIDENCE OF RESIDUAL MELANOMA	102304	1769	\N	\N	07-41091	B	SYNAT36	Melanoma Epigenetics	IP659911	AirTable blocks_with_IP_info.csv
1297	08-1463A2	56	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.3	\N	\N	Sections show a proliferation of spindled and stellate cells, with intervening thickened collagen bundles and thin-walled vascular spaces.	Skin segment measuring 0.3 x 0.2 x 0.1 cm, bisected and entirely submitted.	3 MM FLESH SHINY PAP; FIBROUS PAP; R/O BCC	\N	\N	\N	\N	ANGIOFIBROMA, ALSO KNOWN AS FIBROUS PAPULE	102370	1837	\N	\N	08-1463	A2	SYNAT37	2010-2017	IP475429	AirTable blocks_with_IP_info.csv
2679	21-1134A	54	\N	\N	\N	\N	\N	\N	3	\N	FFPE	\N	\N	728.79	\N	\N	Sections show a proliferation composed of fascicles of elongated spindled cells with intervening compact collagen bundles.  Mitotic figures are inconspicuous, and there is not pronounced nuclear variability, even in cellular areas.	Excision measuring 4.0 x 2.6 x 1.0 cm, two representative sections submitted in A. KB/KB	A-C) JOINT CYSTIC MASS	\N	\N	FFPE	As a precaution, I performed immunostains.  Beta-catenin shows scattered nuclear positivity among the spindle cells, while the spindle cells show strong diffuse positivity for smooth muscle actin and Cyclin D1 (the latter is considered a surrogate for beta-catenin activation).  The morphology of the tumor cells is similar to those seen in parts B and C. These findings support the above interpretation. I have shared this case with my colleague, Dr. Timothy McCalmont, who agrees with the diagnosis and assessment.	FIBROMATOSIS, CELLULAR PHASE	173616	1156	\N	\N	21-1134	A	ME-61	Melanoma Epigenetics	IP426984	AirTable blocks_with_IP_info.csv
2723	21-44171	54	\N	\N	\N	None	None	None	20	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26443	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.  Numerous melanophages are noted.	Skin segment measuring 1.0 x 0.9 x 0.1 cm, quadrisected and entirely submitted with fragment. BB/BB	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA. DROWN BROWN IRREGULAR PAPULE.	\N	MELANOMA, 1.1 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	Diagnostic features of note include: Procedure: Shave Tumor site: Back Microscopic tumor type: Low CSD Breslow thickness: 1.1 mm Ulceration: Absent Margins, peripheral and deep: Involved Mitotic index: 0 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT2a	MELANOMA, 1.1 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	155566	1156	\N	\N	21-44171	\N	ME-61	Melanoma Epigenetics	IP426984	AirTable blocks_with_IP_info.csv
2851	22-114059B	79	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31605,31606,31607,31608,31609	238.2	\N	\N	Sections show lymph node without evidence of metastatic melanoma.	Tissue segment measuring 2.5 x 1.5 x 1.2 cm is serially sectioned perpendicular to the long axis and submitted with four representative sections in B. BY/BY	A) WIDE EXCISION FOR MELANOMA, B) SENTINEL LYMPH NODE #1 EX VIVO 920 - PERM, C) SENTINEL LYMPH NODE #2 EX VIVO 1100 - PERM, D) SENTINEL LYMPH NODE #1 EX VIVO 2895 - PERM, E) SENTINEL LYMPH NODE #2 EX VIVO 6100 - PERM	\N	\N	\N	Level sections, SOX-10 and Pan-melanocytic cocktail immunostains were examined and do not reveal metastatic melanoma.	LYMPH NODE, WITH NO EVIDENCE OF METASTATIC MELANOMA	173540	1158	\N	\N	22-114059	B	ME-63	Melanoma Epigenetics	IP2503898	AirTable blocks_with_IP_info.csv
2840	22-101809	79	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30863,30864,30865,30866,30867,30868	172.5	\N	\N	Sections show a predominantly intradermal melanocytic proliferation with a triphasic pattern.  There is a peripheral proliferation of small nevoid melanocytes with round nuclei, and these are well spaced from one another. Centrally, there is a proliferation of epithelioid melanocytes with increased cytoplasm and enlarged oval nuclei. These are associated with a delicate infiltrate of lymphocytes. Finally, there is a proliferation of markedly atypical epithelioid melanocytes forming a densely cellular expansile nodule in the deep dermis. These melanocytes show enlarged oval nuclei and increased pale grey cytoplasm.	Two skin segments measuring 1.1 x 0.8 x 0.2 cm in aggregate are serially sectioned and entirely submitted with five sections. No additional tissue noted in vial. BY/BY	8 MM FLESHY PINK PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. NEUROFIBROMA VS. PIGMENTED BCC VS. CYST VS. COLLISION LESION WITH NEUROFIBROMA AND CYST VS. COLLISION NEVUS NEUROFIBROMA AND MELANOCYTIC NEVUS	\N	\N	\N	Immunostains were helpful to characterize the melanocytes. BAP-1 shows loss of nuclear expression in the epithelioid melanocytes but is preserved in the smaller nevoid forms. PRAME shows strong nuclear expression in the most atypical epithelioid melanocytes. A cocktail (MART-1 red, PHH3 brown) highlights mitotic figures in the most atypical dermal melanocytes. p16 shows diffuse expression. These results together support the diagnosis of BAP-1 inactivated melanoma arising in association with a combined BAP-1 inactivated melanocytic nevus. I have shared this case with my colleagues, Dr. Philip LeBoit and Dr. Iwei Yeh, who agree with the diagnosis and assessment.  Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: shave biopsy Tumor site: superior lumbar spine Microscopic tumor type: BAP-1 inactivated Breslow thickness: at least 2.0 mm Ulceration: absent Margins, peripheral and deep: melanoma present at deep tissue edge Mitotic index (per square millimeter): 2 Microsatellitosis: not identified Vascular Invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): at least pT2a pNX	BAP-1 INACTIVATED MELANOMA, BRESLOW THICKNESS AT LEAST 2.0 mm, NON-ULCERATED, ARISING IN ASSOCIATION WITH A BAP-1 INACTIVATED MELANOCYTIC NEVUS	100523	1158	\N	\N	22-101809	\N	ME-63	Melanoma Epigenetics	IP2503898	AirTable blocks_with_IP_info.csv
2902	23-34755	76	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=32270,32271,32272,32273,32274	172.5	\N	\N	Sections show melanocytes arrayed irregularly within the epidermis, including some above the basal layer. Many of the melanocytes have somewhat large and hyperchromatic nuclei. In addition, there are similar melanocytes in the dermis, including some configured as nests and cords. There is inflamed fibrosis in the dermis as well. There are nests and cords of cytologically bland melanocytes in the dermis as well.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted. BY/BY	SUSPICIOUS IRREGULAR MULTI-COLORED MACULE; MELANOMA IN SITU, RULE OUT RECURRENCE	\N	\N	\N	I performed immunoperoxidase staining to further evaluate these microscopic features. The melanocytes do not label with a PRAME stain and a p16 stain labels most of the melanocytes. Despite these staining results, I think that the findings in this biopsy represent a melanoma of 0.6 millimeters in thickness since there are numerous melanocytes in above the basal layer of the epidermis in pagetoid array and since some of the melanocytes have somewhat large and hyperchromatic nuclei. A melanocytic nevus with superficial congenital features is captured in this specimen as well. Synoptic melanoma reporting is included below: Procedure: Shave biopsy Microscopic tumor type: Melanoma, arising in association with a melanocytic nevus Breslow thickness: 0.6 millimeters Ulceration: Absent Margins: The melanoma extends to the base and peripheral edge of the specimen Mitotic index: 0/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1a  I have also shared this case with my colleague, Dr. Thaddeus Mully, who agrees with this assessment.	MELANOMA, 0.6 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS AND EXTENDING TO THE BASE AND PERIPHERAL EDGE OF THE SPECIMEN	139523	1163	\N	\N	23-34755	\N	ME-68	Melanoma Epigenetics	IP1372960	AirTable blocks_with_IP_info.csv
1308	08-018003	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1763	\N	\N	08-18003	\N	SYNAT40	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1311	08-21965C	38	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a central stellate zone of extensive post-surgical fibrosis with an associated lymphohistiocytic and granulomatous infiltrate (including scattered siderophages), spanning the reticular dermis and extending into subjacent subcutis and skeletal muscle. Within this stellate area, there is a background of coarse fibroplasia that probably is strictly post-surgical in nature, but there are also clusters of smaller spindled and stellate cells enmeshed in a myxoid background in storiform fashion. There are also deep areas in which small spindled cells and a fibrous matrix extend into underlying skeletal muscle. Superficially in the skeletal muscle, a giant cell reaction is appreciable.	Four outside slides and accompanying blocks, J08-1072 A-D (M0-257-#1).	SPINDLE CELL CA	\N	\N	\N	A limited immunoperoxidase assessment (with no associated fee) utilizing CD34 was completed. The CD34 stain shows avid labeling of many normal dendritic cells within the dermis and subcutis but does not show CD34 immunopositivity within or in proximity to the zone of post-surgical scarring. I interpret the CD34 immunostaining as lending support to the conclusion that there is no residual sarcoma at this site.	EXTENSIVE POST-SURGICAL FIBROPLASIA, WITH NO CLEAR EVIDENCE OF RESIDUAL SARCOMA	173301	1899	\N	\N	08-21965	C	SYNAT41	2010-2017	IP730606	AirTable blocks_with_IP_info.csv
1211	06-08092 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	945	\N	\N	None	\N	MD-39	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1304	08-6790B	52	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	There is a broad-based and poorly circumscribed proliferation of melanocytes with a flattish periphery and a raised, ulcerated center. The central component features sheets of large oval and spindled melanocytes with strikingly pleomorphic, heterochromatic nuclei, with scattered cells in mitosis. Little maturation with descent to the level of the superficial reticular dermis is evident. The periphery of the lesion features single cells and small nests distributed along the sides and bases of elongated rete ridges in an irregular pattern.	Ellipse measuring 3.5 x 1.3 x 1.0 cm, including two possible notches place to the left and a central pink-red 1.4 x 1.0 cm irregular bordered nodule.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections in cassette A and three sections each in cassettes B and C, tips returned to container.	R/O MM	\N	\N	\N	The intraepidermal component extends to within less than one millimeter of the periphery of the specimen. The neoplasm is ulcerated, has a moderate mitotic rate, and extends into the upper reticular dermis (level IV). Otherwise, there are no findings that would significantly affect prognosis.	MELANOMA, 3.0 MM IN THICKNESS	105543	1167	\N	\N	08-6790	B	MP-03	Hockemeyer Melanoma Progression	IP715431	AirTable blocks_with_IP_info.csv
1117	04-9498	37	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a neoplasm composed of fascicles of melanocytes, involving the superficial and deep dermis, with a propensity for nests to surround adnexal structures or vessels.  The constituent melanocytes have abundant pale cytoplasm with dusty melanin, and pleomorphic nuclei.  They are associated with many melanophages.	Ellipse measuring 1.5 x 1.0 x 1.3 cm, margins inked blue, serially sectioned and entirely submitted with five sections in one cassette.	A) R/O MM, B) ATYPICAL PIGMENTED LESION	\N	\N	\N	Deep penetrating nevus is either a form of blue nevus or closely related to it.  Its name derives from the tendency of its cells to extend into the subcutaneous fat along the paths of adnexa, especially hair follicles. The excision appears to be complete.	DEEP PENETRATING NEVUS	173539	2181	\N	\N	04-9498	\N	SYNAT17	Dysplastic Nevi	IP425897	AirTable blocks_with_IP_info.csv
1068	02-49261	76	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=321	172.5	\N	\N	Sections show a proliferation of melanocytes, largely as single cells or small nests within the epidermis, with foci of pagetoid spread.  The papillary dermis is relatively uninvolved.  The reticular dermis has both large and small nodules of strikingly atypical melanocytes that show little maturation with descent, and contain mitotic figures.	Cylindrical skin segment, 0.4 cm in diameter and 0.6 cm in thickness,\nbisected and entirely submitted.	R/O MM, SEE CHART NOTES	\N	\N	\N	This melanoma has an unusual configuration, with extensive melanoma in situ and scattered nests throughout the reticular dermis.  While I suspect that it is a primary melanoma rather than an epidermotropic metastasis, this determination would best be made after complete excision.  If this is a primary melanoma, it measures at least 4 mm. in thickness, and possibly has microsatellite metastases.  I would appreciate a chance to see sections from the re-excision.	MELANOMA	273588	1165	\N	\N	02-49261	\N	MP-01	Hockemeyer Melanoma Progression	IP353896	AirTable blocks_with_IP_info.csv
1194	06-521B2	24	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.3	\N	\N	Sections show a sessile polypoid segment of skin, containing a largely dermal proliferation of small melanocytes, arrayed as nests and syncytia and strands of cells within the papillary and superficial reticular dermis.  There is slight diminishment in melanocyte size with dermal descent.	Cylindrical skin segment, 0.7 cm in diameter and 0.4 cm in thickness, trisected and totally submitted in cassette B.	A) IDN VS MELANOMA IN SITU, B) IDN	\N	\N	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS OF SUPERFICIAL CONGENITAL TYPE	173305	1166	\N	\N	06-521	B2	MP-02	Hockemeyer Melanoma Progression	IP545586	AirTable blocks_with_IP_info.csv
1316	08-43265	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2054	\N	\N	08-43265	\N	SYNAT42	2010-2017	\N	AirTable blocks_with_IP_info.csv
1319	08-43268	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1719	\N	\N	08-43268	\N	SYNAT45	2010-2017	\N	AirTable blocks_with_IP_info.csv
1303	08-6790A	52	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.5	\N	\N	There is a broad-based and poorly circumscribed proliferation of melanocytes with a flattish periphery and a raised, ulcerated center. The central component features sheets of large oval and spindled melanocytes with strikingly pleomorphic, heterochromatic nuclei, with scattered cells in mitosis. Little maturation with descent to the level of the superficial reticular dermis is evident. The periphery of the lesion features single cells and small nests distributed along the sides and bases of elongated rete ridges in an irregular pattern.	Ellipse measuring 3.5 x 1.3 x 1.0 cm, including two possible notches place to the left and a central pink-red 1.4 x 1.0 cm irregular bordered nodule.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections in cassette A and three sections each in cassettes B and C, tips returned to container.	R/O MM	\N	\N	\N	The intraepidermal component extends to within less than one millimeter of the periphery of the specimen. The neoplasm is ulcerated, has a moderate mitotic rate, and extends into the upper reticular dermis (level IV). Otherwise, there are no findings that would significantly affect prognosis.	MELANOMA, 3.0 MM IN THICKNESS	105543	1167	\N	\N	08-6790	A	MP-03	Hockemeyer Melanoma Progression	IP715431	AirTable blocks_with_IP_info.csv
3265	CGH15-249	16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.6	\N	\N	A broad shave biopsy demonstrates a compound proliferation of enlarged fusiform and epithelioid melanocytes. The background epidermis is acanthotic and harbors these melanocytes distributed in pagetoid fashion, and scattered well-formed pink globules are present concurrently. In fibrotic inflamed dermis below this, maturing nests, cords, and fascicles of similar melanocytes are noted. These melanocytes mature to form small compact nests at the base of the proliferation.	Four outside slides, S-15-28819-B1. One corresponding block received 10/23/15.	IMPRESSION WAS INFLAMED SEBORRHEIC KERATOSIS VS. R/O SCC	\N	\N	\N	Your submitted immunoperoxidase stains demonstrate that the Ki-67 cell proliferation index is low and that expression of p16 is not detectable. To further assess the nature of this proliferation, we first repeated p16 immunohistochemistry and additionally completed NTRK-1 immunostaining. The repeat p16 stain was again negative, while the NTRK-1 immunostain demonstrated significant positivity, and thus underlying NTRK-1 gene fusion may be present. Given the histopathologic findings and the above immunostaining results, the differential diagnosis included a so-called 'atypical Spitz tumor' and spitzoid melanoma. To enable full characterization, we next completed array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies, as would be expected with melanoma. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in proximal chromosome 1p as well as loss in chromosomes 9 and 14q. The identification of multiple chromosomal copy number abnormalities indicates genomic instability, as is stereotypical of melanoma. In short, the molecular findings we have defined are incompatible with interpretation as a melanocytic nevus. Additionally, the loss of chromosome 9 that has been defined via aCGH explains the loss of p16 expression, as the CDKN2A locus is encoded within chromosome 9p.  In summary, the combination of results derived from conventional microscopy coupled with aCGH support interpretation as a thin spitzoid melanoma. This biopsy is only partial in nature and thus reexcision remains indicated, if that has not yet been accomplished. Synoptic melanoma reporting is included below.  Procedure: shave biopsy Microscopic tumor type: spitzoid melanoma Breslow thickness: 1.05 mm Ulceration: not detected Margin: involved Mitotic index: 1/square mm Vascular invasion: not detected Regression: not detected Pathologic staging (pTNM): pT2aNxMx  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	SPITZOID MELANOMA OF 1.05 MM IN THICKNESS, FOCALLY INVOLVING THE DEEP EDGE OF THE BIOPSY	173619	1793	\N	L	15-101612	A	SYNAT282	2010-2017	IP1573327	AirTable blocks_with_IP_info.csv
3393	HW8- Tumor Curls	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Mucosal Melanoma, Urethra, Hong Wu	\N	\N	\N	\N	1662	\N	\N	None	\N	SYNAT317	2010-2017	\N	AirTable blocks_with_IP_info.csv
3394	HW9- Normal gDNA from Blood (129920)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Mucosal Melanoma, Blood, Hong Wu	\N	\N	\N	\N	2089	\N	\N	None	\N	SYNAT318	2010-2017	\N	AirTable blocks_with_IP_info.csv
3395	HW9- Tumor Curls	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Mucosla Melanoma, vulva, Hong Wu	\N	\N	\N	\N	1991	\N	\N	None	\N	SYNAT319	2010-2017	\N	AirTable blocks_with_IP_info.csv
1325	08-51221	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1840	\N	\N	08-51221	\N	SYNAT47	2010-2017	\N	AirTable blocks_with_IP_info.csv
2000	16-110683	62	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	172.7	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei and ample cytoplasm. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 0.9 x 0.7 x 0.1 cm, trisected and entirely submitted. KC/KC	NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA	\N	\N	Scraping	The melanoma is transected at the base of the biopsy and therefore the above measurement represents a minimum thickness.  Based on the findings here the following microstaging parameters apply: Diagnostic features of note include:  Procedure: Shave Tumor site: Foot Microscopic tumor type: Nevoid Breslow thickness: 1.4 millimeters at least Ulceration: Absent Margins, peripheral and deep: Involved Mitotic index: 2/mm2 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT2a at least	MELANOMA, AT LEAST 1.4 MILLIMETERS IN THICKNESS ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	101721	1104	\N	\N	16-110683	\N	ME-09	Melanoma Epigenetics	IP1710779	AirTable blocks_with_IP_info.csv
1454	11-19653B2	35	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, the junctional component of which is composed of single cells and nests arrayed along the sides and bases of elongated pigmented rete. There are small nests and cords of similar melanocytes in the perijunctional dermis, where a lymphohistiocytic infiltrate with admixed melanophages also resides. The superjacent stratum corneum is orthokeratotic with admixed melanin.	Two outside slides, 5011044/311 2973 and one corresponding block.	LESION PRESENT FOR YEARS, TWO TO THREE TONE BROWN WITH IRREGULAR BORDER; COMPOUND NEVUS	\N	\N	\N	There is no evidence of malignancy.	HYPERMELANOTIC LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, EXCISED IN THE AVAILABLE PLANES OF SECTION	100556	1167	\N	\N	11-19653	B2	MP-03	Hockemeyer Melanoma Progression	IP1009091	AirTable blocks_with_IP_info.csv
1339	09-008704	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2206	\N	\N	09-8704	\N	SYNAT50	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1342	09-015020-2A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1743	\N	\N	None	\N	SYNAT51	Long-Triple Negative Metastatic Melanoma	\N	AirTable blocks_with_IP_info.csv
1538	11-91034	10	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	Desmoplastic spits nevus	\N	Sections show a dermal proliferation of large, oval melanocytes with abundant, pale amphophilic cytoplasm and monomorphous oval vesicular nuclei, distributed as small nests in the upper part of the lesion and as smaller nests and singly in the lower part. The lesion has a relatively flat base in the mid-reticular dermis.	Cylindrical skin segment measuring 0.25 cm in diameter and 0.3 cm in thickness. Submitted intact.	CHILD WITH LARGE CALM AROUND ARM & (R) UPPER TRUNK WITH TNTC SMALL DARK BROWN NEVI WITHIN IT, THIS IS A NEW, ROUND, URTICARIAL IN APPEARANCE PLAQUE JUST POSTERIOR TO THE CALM	\N	\N	Scraping	The neoplasm extends to the peripheral edge of the specimen. There are no particularly worrisome findings. Given your description, this could be an agminated Spitz's nevus. A clinical photograph would be gratefully received (it could be sent to me as an email attachment: philip.leboit@ucsf.edu).	SPITZ'S NEVUS, PREDOMINANTLY INTRADERMAL	173688	1184	\N	\N	11-91034	\N	NL-022	Cafe au Lait	IP1080482	AirTable blocks_with_IP_info.csv
2146	17-61310	35	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=25174,22153	172.6	\N	\N	Sections show a broad proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Oval excision measuring 1.4 x 1.3 x 0.3 cm, including a brown surface. With margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with seven sections. KC/KC	IRREGULARLY PIGMENTED PLAQUE; R/O MELANOMA VS. SK VS. NEVUS	\N	\N	Scraping	I have examined additional sections and a Melan-A stain which highlights the markedly irregular and confluent distribution of junctional melanocytes as well as clusters of similar melanocytes in the upper dermis. In additional there is also a proliferation of bland dermal melanocytes that mature with descent. The measurement of this lesion is complicated by large areas in which the epidermis has become detached. I think that this is post excisional biopsy phenomenon and not reflective of clinical ulceration. Diagnostic features of note include:  Procedure: Excisional biopsy Tumor site: Arm Microscopic tumor type: Superficial spreading Breslow thickness: 0.7 millimeters Ulceration: Absent Margins, peripheral and deep: Peripheral involved by melanoma in situ, deep free Mitotic index: 0 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT1a	MELANOMA, APPROXIMATELY 0.7 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173688	1115	\N	\N	17-61310	\N	ME-20	Melanoma Epigenetics	IP1791101	AirTable blocks_with_IP_info.csv
1355	09-80101A-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1859	\N	\N	None	\N	SYNAT54	Uveal Melanoma	\N	AirTable blocks_with_IP_info.csv
1728	13-55769	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	genital mucosa	FFPE	\N	\N	\N	1307	\N	\N	13-55769	\N	OM-49	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1994	16-106975	49	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24928	172.5	\N	\N	Sections show large, oval melanocytes with abundant, pale cytoplasm and large, pleomorphic vesicular nuclei in a nodular mass apposed to the undersurface of the epidermis. Adjacent to this, there are nests, cords and strands of small, round melanocytes in the dermis.  Strands of melanocytes lie between collagen bundles in the reticular dermis and around adnexal structures.	Skin segment measuring 1.3 x 0.7 x 0.2 cm, trisected and entirely submitted. CF/CF	R/O MALIGNANCY	\N	\N	Scraping	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: biopsy Tumor site: left back Microscopic tumor type: nodular Breslow thickness: 1.5 mm. Ulceration: no Margins, peripheral: clear by < 1mm., and deep: clear by < 0.5 mm. Mitotic index: 2/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT2a pNX	MELANOMA, 1.5 MM. IN THICKNESS, ARISING IN A NEVUS WITH CONGENITAL FEATURES	173530	1099	\N	\N	16-106975	\N	ME-04	Melanoma Epigenetics	IP822002	AirTable blocks_with_IP_info.csv
1970	16-88453A	67	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent fibrotic dermis. Zones of epidermal atrophy are noted. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.4 x 1.0 x 0.2 cm, quadrisected and entirely submitted in A. CF/CF	A-B) R/O MM	\N	\N	Scraping	Diagnostic features of note include: Procedure: Shave Tumor site: Back Microscopic tumor type: Nevoid Breslow thickness: 0.84 millimeters Ulceration: Absent Margins, peripheral and deep: Peripheral involved by melanoma in situ, deep free Mitotic index: 0 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT1a	MELANOMA, 0.84 MILLIMETERS IN THICKNESS ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	139522	1103	\N	\N	16-88453	A	ME-08	Melanoma Epigenetics	IP1688270	AirTable blocks_with_IP_info.csv
1361	10-972A9	54	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of small melanocytes with round to oval nuclei, the junctional component of which consists of nested and solitary melanocytes arrayed along the sides and bases of elongated rete.  There are similar melanocytes within the underlying papillary and reticular dermis, with melanocytes splayed amongst collagen bundles, largely in the upper half of the reticular dermis.	Cylindrical skin segment, 0.8 cm in diameter and 0.3 cm in thickness, trisected and entirely submitted in cassette A.	A-B) R/O DN	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF SUPERFICIAL CONGENITAL TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173504	2289	\N	\N	10-972	A9	SYNAT57	Long-Triple Negative Metastatic Melanoma	IP895542	AirTable blocks_with_IP_info.csv
1359	10-143	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1708	\N	\N	10-143	\N	SYNAT56	2010-2017	\N	AirTable blocks_with_IP_info.csv
1369	10-3560C1\n	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2263	\N	\N	10-3560	C1	SYNAT59	2010-2017	\N	AirTable blocks_with_IP_info.csv
2098	17-33401C	85	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22147	172.5	\N	\N	Sections show a poorly circumscribed proliferation of melanocytes arranged as single cells and nests within the epidermis and dermis. Within the epidermis, many of the lesional melanocytes are located in pagetoid scatter and single melanocytes predominate over nests in some foci. Similar melanocytes are present in clusters in the underlying dermis and the size of the melanocytes does not diminish with descent into the dermis.  Centrally, there is a large sheet of atypical melanocytes, some of which have an epithelioid morphology and within which mitotic figures are evident. These melanocytes do not diminish in size with descent into the dermis. The epidermis overlying this focus is ulcerated. There is also proliferation of cytologically bland melanocytes in the dermis that diminish in size with descent into the reticular dermis. There is solar elastosis in the dermis.	Oriented ellipse, 7.0 x 3.0 x 0.7 cm, including a central 2.0 x 2.3 cm brown area. With the orienting notch located at the midpoint of one edge and placed distally to the grosser, the notch is indicated as 12 o'clock on the requisition. The 9-12-3 o'clock margin is inked blue and the 3-6-9 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and submitted with three sections each in A-D and two sections in E. Tips reserved. RS/RS	PRESUMED MM EXC	\N	\N	Scraping	Synoptic melanoma reporting is included below: Procedure: Excision Microscopic tumor type: NOS, arising in association with a melanocytic nevus with superficial congenital features Breslow thickness: 3.5 mm Ulceration: Present Margins: With the orienting suture placed by the surgeon designated as the 12 o'clock position, residual intraepidermal melanoma extends to within 3 millimeters of the peripheral inked margin at approximately the 12-2 and 7-8 o'clock positions Mitotic index: 2/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT3bNxMx	ULCERATED MELANOMA, 3.5 MILLIMETERS IN THICKNESS, NARROWLY EXCISED	333504	1107	\N	\N	17-33401	C	ME-12	Melanoma Epigenetics	IP1762801	AirTable blocks_with_IP_info.csv
1378	10-10558A10	82	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.19	\N	\N	Sections show an epidermis thickened by a sessile, papillated proliferation of basaloid and squamous keratinocytes with monomorphous nuclei.  Thick rete ridges enclose horn pseudocysts.	Cylindrical skin segment, 0.5 cm in diameter and 0.4 cm in thickness, bisected and entirely submitted.	1.0 CM GRAY BROWN FLAT PAPULE; SEB KER VS. PIGMENTED BCC	\N	\N	\N	\N	SEBORRHEIC KERATOSIS	173389	2330	\N	\N	10-10558	A10	SYNAT65	2010-2017	IP644642	AirTable blocks_with_IP_info.csv
1362	10-972A17	54	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of small melanocytes with round to oval nuclei, the junctional component of which consists of nested and solitary melanocytes arrayed along the sides and bases of elongated rete.  There are similar melanocytes within the underlying papillary and reticular dermis, with melanocytes splayed amongst collagen bundles, largely in the upper half of the reticular dermis.	Cylindrical skin segment, 0.8 cm in diameter and 0.3 cm in thickness, trisected and entirely submitted in cassette A.	A-B) R/O DN	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF SUPERFICIAL CONGENITAL TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173504	2289	\N	\N	10-972	A17	SYNAT57	Long-Triple Negative Metastatic Melanoma	IP895542	AirTable blocks_with_IP_info.csv
1888	15-86891	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1308	\N	\N	15-86891	\N	OM-50	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1873	15-43382	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1309	\N	\N	15-43382	\N	OM-51	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1886	15-74487	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1310	\N	\N	15-74487	\N	OM-52	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1892	15-96473	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	hand/foot	FFPE	\N	\N	\N	1311	\N	\N	15-96473	\N	OM-53	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1379	10-10558B1\n	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2330	\N	\N	10-10558	B1	SYNAT65	2010-2017	\N	AirTable blocks_with_IP_info.csv
1380	10-10558C1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2330	\N	\N	10-10558	C1	SYNAT65	2010-2017	\N	AirTable blocks_with_IP_info.csv
2488	19-135490	18	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	Compound melanocytic nevus(conventional)	\N	There are nests, cords and strands of cytologically bland melanocytes that extend from the junctional zone into the superficial reticular dermis. The dermal component matures with descent. There are scattered melanophages in the superficial aspect.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted. PL/PL	BROWN MACULE	\N	\N	Scraping	This nevus does not demonstrate any features of Spitz nevus, but rather has a common acquired morphology.	COMPOUND MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES	101623	1184	\N	\N	19-135490	\N	NL-022	Cafe au Lait	IP1080482	AirTable blocks_with_IP_info.csv
2143	17-56506	56	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	172.7	\N	\N	Sections show a proliferation of atypical melanocytes in irregular array within the epidermis and dermis. Within the epidermis, there are numerous melanocytes in irregular pagetoid array and there are nests of similar melanocytes in the dermis. There is also a second population of smaller melanocytes arranged as cords and strands between collagen bundles of the reticular dermis and around adnexal structures. There are melanocytes that extend into adnexal epithelium as single cells as well.	Skin segment measuring 2.2 x 2.0 x 0.4 cm, with base inked blue, the specimen is serially sectioned and entirely submitted with ten sections. KC/KC	R/O MM	\N	\N	Scraping	Synoptic melanoma reporting based on this partial biopsy is included below. Procedure: Deep shave biopsy Tumor site: Left lower leg Microscopic tumor type: NOS, arising in association with a melanocytic nevus with superficial congenital features Breslow thickness: 1.5 millimeters, at least Ulceration: Absent Margins: + base; + peripheral Mitotic index: 2/mm2 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT2aNxMx	MELANOMA, AT LEAST 1.5 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES	173741	1116	\N	\N	17-56506	\N	ME-21	Melanoma Epigenetics	IP1786249	AirTable blocks_with_IP_info.csv
1405	10-42241	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Mac Millain	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2145	\N	\N	10-42241	\N	SYNAT68	2010-2017	\N	AirTable blocks_with_IP_info.csv
2004	16-118278	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	genital mucosa	FFPE	\N	\N	\N	1319	\N	\N	16-118278	\N	OM-61	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1144	04-37400	18	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a roughly wedge-shaped proliferation of spindled and polygonal melanocytes with abundant vacuolated cytoplasm, which extends deeply in the reticular dermis as nests and fascicles.  There are also a few large junctional nests.  Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous.  There are many interspersed melanophages.	Ellipse measuring 1.3 x 0.8 x 0.7 cm, including 0.7 x 0.6 cm central dark pigmented area, margins inked blue, serially sectioned and entirely submitted with five sections in one cassette.	ATYPICAL NEVUS	\N	\N	\N	None	DEEP PENETRATING NEVUS, COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE FREE OF MELANOCYTIC NEVUS)	173620	1733	\N	\N	04-37400	\N	SYNAT19	Dysplastic Nevi	IP453803	AirTable blocks_with_IP_info.csv
3042	385/14	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-019_1.1	\N	\N	\N	\N	Left foot	Punch	\N	\N	\N	10	\N	\N	None	\N	AM2-019	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1336	09-1121	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2312	\N	\N	09-1121	\N	SYNAT20	2010-2017	\N	AirTable blocks_with_IP_info.csv
1337	09-005840	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2299	\N	\N	09-5840	\N	SYNAT21	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1373	10-7937B2	82	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	232.6	\N	\N	Sections show irregular epidermal hyperplasia with inflamed granulation tissue, but no evidence of an atypical melanocytic proliferation.	Oriented ellipse, 4.0 x 2.2 x 0.8 cm, including a central 1.7 x 1.4 cm lesion area.  With the orienting sutured tip placed to the left and designated suture at medial tip by the surgeon, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from left to right poles and submitted with two sections in cassette B1, one section each in cassettes B2 through B5 and two sections in cassette B6, tips returned to container.\n	A) BCC PER DT09-80352:A, B) MIS PER DT09-80352:B	\N	\N	\N	\N	HEALING BIOPSY SITE, WITH NO EVIDENCE OF RESIDUAL MELANOMA IN SITU	106677	2061	\N	\N	10-7937	B2	SYNAT62	2010-2017	IP164592	AirTable blocks_with_IP_info.csv
1374	10-008371A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2215	\N	\N	10-8371	A1	SYNAT63	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1919	16-8674	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1314	\N	\N	16-8674	\N	OM-56	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1817	14-113821	13	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show a compound proliferation of spindled and spindled melanocytes with enlarged nuclei. The overlying epidermis is hyperkeratotic. In the dermis, single and fascicular melanocytes are positioned amongst collagen bundles, which are thickened.	Cylindrical skin segment, 0.3 cm in diameter and 0.3 cm in thickness. Submitted intact. RS/RS	BORN WITH LARGE CALM...DEVELOPING TNTC DARK NEVI WITHIN IT...AND THESE SMOOTH TAN BROWN PLAQUES (PHOTOS)	\N	\N	Scraping	This biopsy demonstrates a desmoplastic Spitz nevus arising secondarily within a cafe-au-lait macule. An agminated presentation of Spitz nevus or eruptive Spitz nevi is/are intriguing as a potential classification. Immunostaining with ALK demonstrates a lack of positivity, and thus underlying ALK gene fusion has not occurred. In contrast, NTRK1 immunostaining demonstrates considerable cytoplasmic positivity, and thus this Spitz nevus may have been induced by NTRK1 gene fusion. As you know, this biopsy is partial in nature.	DESMOPLASTIC COMPOUND SPITZ NEVUS	173602	1184	\N	\N	14-113821	\N	NL-022	Cafe au Lait	IP1080482	AirTable blocks_with_IP_info.csv
2434	19-28178	17	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	Desmoplastic spits nevus	\N	There is papillated acanthosis. There are vertically or diagonally oriented fascicles of large pale melanocytes with abundant cytoplasm and monomorphous vesicular nuclei that contain small nucleoli. Maturation and dispersion toward the base of the lesion is present.	Skin segment measuring 0.7 x 0.7 x 0.1 cm, trisected and entirely submitted. BY/BY	HISTORY OF LARGE SPECKLED LENTIGINOUS NEVUS WITH AGMINATED DESMOPLASTIC SPITZ WITHIN IT, THIS BIOPSY LESION TODAY IS MORE ATYPICAL THAN HER OTHERS	\N	\N	Scraping	The findings, like those in the previous two biopsies are consistent with Spitz's nevus. The lower part of this lesion is desmoplastic. Given the clinical setting (I reviewed the image that we received with the 2014 biopsy) I do not see features that would require re-excision.	DESMOPLASTIC SPITZ'S NEVUS, COMPOUND	523651	1184	\N	\N	19-28178	\N	NL-022	Cafe au Lait	IP1080482	AirTable blocks_with_IP_info.csv
2947	94-00669 N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	953	\N	\N	None	\N	MD-47	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1429	10B7952 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1200	\N	\N	None	\N	NM-013	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2023	16B8849 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1201	\N	\N	None	\N	NM-014	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1821	14B1910 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1202	\N	\N	None	\N	NM-015	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1743	13B10486 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1203	\N	\N	None	\N	NM-016	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1397	10-26316A2	67	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	709.09	\N	\N	Sections show skin with bulbous rete ridges, basilar hyperpigmentation, some large nuclei among keratinocytes in the lower half of the epidermis, and maturation of the epidermis through a granular layer.  The dermis contains elastotic fibers.	Skin segment measuring 1.0 x 1.0 x 0.1 cm, serially sectioned and entirely submitted with five sections.	1 CM BROWN IRREGULAR NEVUS	\N	\N	\N	Large cell acanthoma is a variant of solar lentigo in which keratinocytes have abnormally enlarged nuclei, especially in the lower half of the epidermis. Despite the resemblance to solar keratosis or Bowen's disease that some lesions show, large cell acanthoma is not associated with squamous cell carcinoma.	LARGE CELL ACANTHOMA	173620	1983	\N	\N	10-26316	A2	SYNAT67	2010-2017	IP666578	AirTable blocks_with_IP_info.csv
2277	17-130286	17	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22144	172.3	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei and ample pigmented cytoplasm. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis that form expansile nests. Scattered dermal mitotic figures are noted. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Ellipse, 1.1 x 0.6 x 0.5 cm, including a central 0.8 x 0.5 cm brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections. RS/RS	TWO-TONED PIGMENTED PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. DYSPLASTIC NEVUS VS. SPITZ NEVUS, ATYPICAL APPEARING MELANOCYTIC LESION, EXCISIONAL BIOPSY	\N	\N	Scraping	I have reviewed this case with Dr. McCalmont who concurs with this diagnosis. Diagnostic features of note include:  Procedure: Excision biopsy Tumor site: Cheek Microscopic tumor type: Nodular Breslow thickness: 1.19 millimeters Ulceration: Absent Margins, peripheral and deep: Free, narrow Mitotic index: 1/mm2 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT2a	MELANOMA, 1.19 MILLIMETERS IN THICKNESS ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	123311	1108	\N	\N	17-130286	\N	ME-13	Melanoma Epigenetics	IP1860925	AirTable blocks_with_IP_info.csv
1578	12-9606E4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2284	\N	\N	12-9606	E4	SYNAT70	2010-2017	\N	AirTable blocks_with_IP_info.csv
1579	12-9606E9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2284	\N	\N	12-9606	E9	SYNAT70	2010-2017	\N	AirTable blocks_with_IP_info.csv
2224	17-111038B	74	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	The microscopic features are similar to those of (A).	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted in B. CF/CF	A-B) R/O DYSP VS. COMP N, C) R/O BCC	\N	\N	Scraping	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	173529	856	\N	\N	17-111038	B	LN-037	Lentiginous Nevi 	IP1772327	AirTable blocks_with_IP_info.csv
2946	94-00143-2 N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	954	\N	\N	None	\N	MD-48	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2940	93-06269-4 N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	955	\N	\N	None	\N	MD-49	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3087	15356/1 (H08.15356/1 slide)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1236	\N	\N	None	\N	NM-61	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3132	176323	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1237	\N	\N	None	\N	NM-63	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2028	17-1468II-2	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1238	\N	\N	None	\N	NM-64	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2819	22-81852A	\N	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	https://64.54.108.121/app/WebViewer/view/image/30414,30415,30416,30417	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1258	\N	\N	22-81852	A	NM-84	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2820	22-81852B	\N	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30418,30419,30420,30421,30422,30423,30424,30425,30426,30427,30428,30429	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1258	\N	\N	22-81852	B	NM-84	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2804	22-51092	\N	\N	\N	\N	\N	\N	\N	20	10	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24190	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1258	\N	\N	22-51092	\N	NM-84	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1292	07-74058B	28	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	232.9	\N	\N	Sections show squamous mucosa with an intraepithelial proliferation of melanocytes. The lesional melanocytes have strikingly large and hyperchromatic nuclei and are scattered erratically in the lower half of the epithelium. There is also submucosal elastosis with scattered melanophages. A contiguous area shows basal pigmentation, submucosal fibrosis, and muting of rete with vacuolar changes.	Skin segment measuring 1.3 x 0.6 x 0.1 cm, bisected and entirely submitted in cassette B.	2 BROWN MACULES	\N	oral mucosa	FFPE	There is also a concurrent/contiguous melanotic macule in this biopsy as well.	MELANOMA IN SITU, FOCALLY TRANSECTED AT THE PERIPHERY OF THE BIOPSY	101044	1262	\N	\N	07-74058	B	OM-01	Oral Mucosa Lesions	IP696592	AirTable blocks_with_IP_info.csv
1291	07-74058A	28	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	238.2	\N	\N	Sections show a mucosal segment with basilar hyperpigmentation and normal numbers of melanocytes along the epithelial-submucosal junction. Parts of the submucosa appear fibrotic and contain melanophages. There is also a focus of vacuolar change with scattered necrotic keratinocytes at the junction. In level sections, scattered enlarged atypical melanocytes are found along the junction toward one edge of the biopsy.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted in cassette A.	2 BROWN MACULES	\N	right lower lip lateral	\N	Level sections show a population of melanocytes with enlarged atypical nuclei focally present within this biopsy. I believe these cells represent a subtle manifestation of the intraepidermal melanoma that is evident in the other biopsy from this patient.	SUBTLE INTRAEPIDERMAL PROLIFERATION OF ENLARGED ATYPICAL MELANOCYTES, PRESENT CONCURRENTLY WITH A MELANOTIC MACULE	101044	1262	\N	\N	07-74058	A	OM-01	Oral Mucosa Lesions	IP696592	AirTable blocks_with_IP_info.csv
1557	12-3277	\N	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31407	\N	\N	Tissue was mounted on LCM slides. Circled images are kept in the server.	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1402	\N	\N	12-3277	\N	WS-01	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
2402	19-4879	78	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.4	\N	\N	There is a dermal proliferation of spindled melanocytes with relatively monomorphous nuclei, disposed between thickened collagen bundles and accompanied by scattered melanophages.	Skin segment measuring 1.0 x 0.7 x 0.2 cm, trisected and entirely submitted. HD/HD	BLUE NEVUS; R/O MELANOMA	\N	\N	Scraping	None	BLUE NEVUS, SPINDLE CELL/SCLEROTIC TYPE	423456	1125	\N	\N	19-4879	\N	ME-30	Melanoma Epigenetics	IP935967	AirTable blocks_with_IP_info.csv
3073	4136/16	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1211	\N	\N	None	\N	NM-33	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1748	14-03473 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	939	\N	\N	None	\N	MD-33	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1826	15-02416 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	940	\N	\N	None	\N	MD-34	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2923	89-10432A M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	957	\N	\N	None	\N	MD-51	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1266	07-2479-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31869	\N	\N	\N	\N	\N	\N	\N	Right forearm	\N	\N	\N	\N	1403	\N	\N	None	\N	WS-02	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
1262	07-1791	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31873	\N	\N	(5-82-149-7)	\N	\N	\N	\N	Liver	\N	\N	\N	\N	1403	\N	\N	07-1791	\N	WS-02	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
2663	20-92494	42	\N	\N	\N	None	None	None	5	0	FFPE	\N	\N	216.5	\N	\N	Sections show a predominantly dermal proliferation of melanocytes without pronounced nuclear variability.	Cylindrical skin segment, 0.5 cm in diameter and 0.6 cm in thickness, bisected and entirely submitted. KB/KB	MORPHOLOGY: TWO-TONED BROWN MACULE, DDX: ATYPICAL NEVUS	\N	\N	FFPE	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	139523	1384	\N	\N	20-92494	\N	SN-21	Sclerotic Nevi	IP2240410	AirTable blocks_with_IP_info.csv
2634	20-48331	35	\N	\N	\N	None	None	None	5	0	FFPE	\N	\N	216.6	\N	\N	Sections show a small dermal proliferation consisting in part of ovoid melanocytes with monomorphous nuclei arranged in fascicles and as single cells with intervening areas displaying fibrosis and sclerosis and containing melanophages.	Skin segment measuring 0.3 x 0.2 x 0.1 cm, submitted intact. HD/HD	FAVOR NEVUS	\N	\N	FFPE	None	BLUE NEVUS	173649	1389	\N	\N	20-48331	\N	SN-26	Sclerotic Nevi	IP2196043	AirTable blocks_with_IP_info.csv
1383	10-13619	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-4; BOX-9	\N	\N	Metastasis	AM2-095-3, endoscopic biopsy	\N	\N	\N	\N	duodenum	Scraping	\N	\N	\N	65	\N	\N	10-13619	\N	AM2-095	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1385	10-14390	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-3; BOX-11	\N	\N	MIS	AM2-095-1	\N	\N	\N	\N	left heel	Scraping	\N	\N	\N	65	\N	\N	10-14390	\N	AM2-095	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1310	08-21729-2 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	930	\N	\N	None	\N	MD-24	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1856	15-18463	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-5; BOX-11	\N	\N	MELANOMA	AM2-096-1, soft tissue, excision	\N	\N	\N	\N	Soft tissue, groin, left, excision, malignant melanoma; left groin	Scraping	\N	\N	\N	66	\N	\N	15-18463	\N	AM2-096	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1830	15-3736C5	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-0	\N	\N	\N	\N	\N	\N	\N	\N	non-tumor and tumor	FFPE	\N	\N	\N	66	\N	\N	15-3736	C5	AM2-096	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1828	15-3736A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-2; BOX-11	\N	\N	Metastasis	AM2-096-2	\N	\N	\N	\N	left inguinal lymph node	Scraping	\N	\N	\N	66	\N	\N	15-3736	A1	AM2-096	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1829	15-3736C1	\N	\N	\N	\N	\N	\N	\N	8	0	FFPE	SLIDE BOX-2; BOX-11	\N	\N	Acrolentiginous melanoma	AM2-096-1, wide excision	\N	\N	\N	\N	left sole 	Scraping	\N	\N	\N	66	\N	\N	15-3736	C1	AM2-096	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1831	15-4505A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-2; BOX-10	\N	\N	Acral melanoma	AM2-097-1, wide excision	\N	\N	\N	\N	left heel 	Scraping	\N	\N	\N	67	\N	\N	15-4505	A1	AM2-097	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2789	22-25497A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-22	http://64.54.108.121/eSlideTray.php?ImageIds=32819	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	67	\N	\N	22-25497	A1	AM2-097	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1832	15-4505B	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-4	\N	\N	Metastasis	AM2-097-2, lymphadenectomy, melanoma, metastatic (1/1)	\N	\N	\N	\N	left inguinal lymph node	Scraping	\N	\N	\N	67	\N	\N	15-4505	B	AM2-097	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2799	22-44747A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-22	http://64.54.108.121/eSlideTray.php?ImageIds=32816	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	67	\N	\N	22-44747	A1	AM2-097	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2790	22-25497A2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-22	http://64.54.108.121/eSlideTray.php?ImageIds=32815	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	67	\N	\N	22-25497	A2	AM2-097	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2891	23-6349A3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-22	http://64.54.108.121/eSlideTray.php?ImageIds=32814	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	67	\N	\N	23-6349	A3	AM2-097	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2040	17-6351	21	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a polypoid segment of skin with a mostly intradermal proliferation of large, oval melanocytes with abundant pale homogeneous appearing cytoplasm and large, oval vesicular nuclei with relatively small nucleoli. These cells are arranged as closely apposed small aggregations with intervening lymphocytes.	One outside slide, 17-013-P82-0021-0 A1 and one corresponding block.	MOLE REMOVAL	\N	\N	\N	The differential diagnosis included an atypical Spitz tumor and a spitzoid melanoma. A BAP-1 immunostain labels the nuclei of keratinocytes in the overlying epidermis, those of lymphocytes and those of the smaller melanocytes, but not the larger, spitzoid ones. This is consistent with BAP-1 loss in the larger spitzoid cells. This loss can be due to mutation in one allele and loss of the other, or to epigenetic mechanisms.  A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product (nearly complete or complete loss in a defined zone is worrisome for melanoma). As loss of p16 can follow BAP-1 loss in multi-step progression toward melanoma, this is a reassuring finding.  A phosphohistone H3/MART-1/tyrosinase two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows up to four mitotic figures in dermal melanocytes/section.  Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows only an interstitial loss in chr. 3p around the area of the BAP-1 gene, and no other gains or losses. This is against progression toward melanoma.  Using the DNA extracted for this procedure, we performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations. Since then, there have been a few cases in which hTERT promoter mutations were not found, but in which the gene was affected by promoter methylation.  In sum, the findings are those of an atypical Spitz tumor with BAP-1 loss, but not progression toward a BAP-1 deficient spitzoid melanoma. A narrow re-excision of this site would still be prudent, as lesions with BAP-1 loss may convert to melanoma at a higher rate than other spitzoid neoplasms.  Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	ATYPICAL SPITZ TUMOR WITH BAP-1 LOSS	173500	722	\N	\N	17-6351	\N	DP-85	CGH Validation	IP1735471	AirTable blocks_with_IP_info.csv
2962	95-05959 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	956	\N	\N	None	\N	MD-50	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3166	BB21-21334	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=3316	\N	\N	B01-322	\N	\N	\N	\N	hard palate	\N	\N	\N	\N	1272	\N	BB	21-21334	\N	OM-11	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
3171	BB21-21351	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=3590	\N	\N	10-21	\N	\N	\N	\N	hard palate	\N	\N	\N	\N	1276	\N	BB	21-21351	\N	OM-15	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2889	23-6349A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-22	http://64.54.108.121/eSlideTray.php?ImageIds=32818	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	67	\N	\N	23-6349	A1	AM2-097	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2800	22-44747A2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-22	http://64.54.108.121/eSlideTray.php?ImageIds=32817	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	67	\N	\N	22-44747	A2	AM2-097	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2890	23-6349A2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-22	http://64.54.108.121/eSlideTray.php?ImageIds=32813	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	67	\N	\N	23-6349	A2	AM2-097	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1833	15-4505C	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-5; BOX-10	\N	\N	Metastasis	AM2-097-3, lymphadenectomy, melanoma, metastatic (1/1)	\N	\N	\N	\N	left popliteal fossa lymph node	Scraping	\N	\N	\N	67	\N	\N	15-4505	C	AM2-097	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2311	18-28169	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	BCC	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	117	\N	\N	18-28169	\N	CCGL-2973	Clinical Cases-BCC	\N	AirTable blocks_with_IP_info.csv
2336	18-68921A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	117	\N	\N	18-68921	A	CCGL-2973	Clinical Cases-BCC	\N	AirTable blocks_with_IP_info.csv
1346	09-21320A3 N1-M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	931	\N	\N	None	\N	MD-25	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2296	18-15332A3	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	MIS	AM2-098-3, post excisional biopsy, wide excision, residual	\N	\N	\N	\N	right heel	Scraping	\N	\N	\N	68	\N	\N	18-15332	A3	AM2-098	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2299	18-15332A6	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-1	\N	\N	MIS	AM2-098-6, post excisional biopsy, wide excision, residual	\N	\N	\N	\N	right heel	Scraping	\N	\N	\N	68	\N	\N	18-15332	A6	AM2-098	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2294	18-15332A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-9; BOX-10; BOX-13	\N	\N	MIS	AM2-098-1, post excisional biopsy, wide excision, residual	\N	\N	\N	\N	Skin, heel, right, status post excisional biopsy, wide excision, melanoma in situ, residual; right heel	FFPE	\N	\N	\N	68	\N	\N	18-15332	A1	AM2-098	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2298	18-15332A5	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	MIS	AM2-098-5, post excisional biopsy, wide excision, residual	\N	\N	\N	\N	right heel	Scraping	\N	\N	\N	68	\N	\N	18-15332	A5	AM2-098	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2430	19-20141	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-9; BOX-10	\N	\N	\N	\N	\N	\N	\N	\N	Skin, heel, right, biopsy, melanoma, recurrent	FFPE	\N	\N	\N	68	\N	\N	19-20141	\N	AM2-098	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2297	18-15332A4	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	MIS	AM2-098-4, post excisional biopsy, wide excision, residual	\N	\N	\N	\N	right heel	Scraping	\N	\N	\N	68	\N	\N	18-15332	A4	AM2-098	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2295	18-15332A2	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-4	\N	\N	MIS	AM2-098-2, post excisional biopsy, wide excision, residual	\N	\N	\N	\N	right heel	Scraping	\N	\N	\N	68	\N	\N	18-15332	A2	AM2-098	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1495	11-49127	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26320	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	743	\N	\N	11-49127	\N	JJS4	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1453	11-19048	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	115	\N	\N	11-19048	\N	BN-011	Nevus Library	\N	AirTable blocks_with_IP_info.csv
1490	11-43354	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	116	\N	\N	11-43354	\N	BN-012	Nevus Library	\N	AirTable blocks_with_IP_info.csv
2569	19Rig750007.05.14.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	298	\N	\N	None	\N	CM-70	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2432	19-23613C4	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-5	\N	\N	MELANOMA	AM2-098-7, wide excision (1) melanoma, recurrent; (2) verrucous hyperplasia	\N	\N	\N	\N	right posterior heel	Scraping	\N	\N	\N	68	\N	\N	19-23613	C4	AM2-098	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2408	19-6410A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-21	http://64.54.108.121/eSlideTray.php?ImageIds=32810	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	71	\N	\N	19-6410	A1	AM2-101	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2409	19-6410A2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-21	http://64.54.108.121/eSlideTray.php?ImageIds=32811	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	71	\N	\N	19-6410	A2	AM2-101	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2291	18-12734	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-21	http://64.54.108.121/eSlideTray.php?ImageIds=32812	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	71	\N	\N	18-12734	\N	AM2-101	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1863	15-26253A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-2; BOX-9	\N	\N	Acrolentiginous melanoma	AM2-101-1, amputation	\N	\N	\N	\N	right great toe	Scraping	\N	\N	\N	71	\N	\N	15-26253	A1	AM2-101	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2312	18-28886	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-2; BOX 3	\N	\N	Metastasis	AM2-101-2, excision	\N	\N	\N	\N	left neck minor salivary gland 	Scraping	\N	\N	\N	71	\N	\N	18-28886	\N	AM2-101	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2048	17-9337A2	\N	\N	\N	\N	\N	\N	\N	8	0	FFPE	SLIDE BOX-5	\N	\N	Metastasis	AM2-102-3, excision	\N	\N	\N	\N	left inguinal lymph node	Scraping	\N	\N	\N	72	\N	\N	17-9337	A2	AM2-102	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2060	17-14203A1	\N	\N	\N	\N	\N	\N	\N	8	0	FFPE	SLIDE BOX-0	\N	\N	\N	\N	\N	\N	\N	\N	Skin, ankle, left, excision, verrucous hyperplasia	FFPE	\N	\N	\N	72	\N	\N	17-14203	A1	AM2-102	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1906	16-552A7	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-2; BOX-10	\N	\N	Acrolentiginous melanoma	AM2-102-1, wide excision	\N	\N	\N	\N	left lateral heel	Scraping	\N	\N	\N	72	\N	\N	16-552	A7	AM2-102	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2128	17-43703	41	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=23270,25079,25175	172.6	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei and abundant, pale cytoplasm and dusty appearing melanin. These cells form both small and large nests in the papillar dermis, with foci in which single cells colonize the basal layer of the epidermis with a small amount of suprabasal scatter. In some areas, junctional melanocytes are present at the sides and bases of rete ridges, with bridging and fibroplasia. There is a dense infiltrate of lymphocytes and melanophages and beneath it, discrete aggregations of small round melanocytes.	Oval excision, 1.1 x 0.7 x 0.5 cm, including a central 0.7 x 0.6 cm dark-brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections. CF/CF	BLACK PAPULE WITH IRREGULARLY PIGMENTED EXTENSION; R/O MM (SEE PHOTO)	\N	\N	Scraping	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: biopsy Microscopic tumor type: superficial spreading melanoma Ulceration: no Margins, peripheral: involved by melanoma in situ, and deep: clear Mitotic index: 1/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT1b pNX	MELANOMA, 0.7 MM. IN THICKNESS, ARISING IN A NEVUS	529699	1117	\N	\N	17-43703	\N	ME-22	Melanoma Epigenetics	IP1773263	AirTable blocks_with_IP_info.csv
1158	05-7439A12	56	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.19	\N	\N	Sections show a proliferation of basosquamoid keratinocytes arrayed in an interanastomosing pattern, with strikingly thickened rete. There are many incorporated squamous eddies as well as focal spongiosis and a sparse infiltrate.	One outside slide, CT05-19314 (05-4297).	4 X 4 WARTY KERATOSIS, R/O INFLAMED BCC	\N	\N	\N	\N	IRRITATED SEBORRHEIC KERATOSIS	300335	1684	\N	\N	05-7439	A12	SYNAT23	2010-2017	IP484151	AirTable blocks_with_IP_info.csv
1131	04-17745B T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1034	\N	\N	None	\N	MD-155	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2429	19-19590	\N	\N	\N	\N	\N	\N	\N	8	0	FFPE	SLIDE BOX-5; BOX-9	\N	\N	Metastasis	AM2-102-4, craniotomy and excision	\N	\N	\N	\N	left posterior frontal lobe of cerebrum	Scraping	\N	\N	\N	72	\N	\N	19-19590	\N	AM2-102	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2047	17-9337A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-5	\N	\N	Metastasis	AM2-102-2, excision	\N	\N	\N	\N	left inguinal lymph node	Scraping	\N	\N	\N	72	\N	\N	17-9337	A1	AM2-102	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2061	17-14203A2	\N	\N	\N	\N	\N	\N	\N	8	0	FFPE	SLIDE BOX-0	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	72	\N	\N	17-14203	A2	AM2-102	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1922	16-10035A3	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-5	\N	\N	Acrolentiginous melanoma	AM2-103-1, amputation, vertical growth phase  amputation, acral lentiginous melanoma, vertical growth phase  	\N	\N	\N	\N	right hallux subungual 	\N	\N	\N	\N	73	\N	\N	16-10035	A3	AM2-103	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2073	17-21588	\N	\N	\N	\N	\N	\N	\N	0	\N	FFPE	\N	\N	\N	Metastasis	AM2-103-3, No slides were sent from TW 	\N	\N	\N	\N	left parietal lobe, cerebrum	\N	\N	\N	\N	73	\N	\N	17-21588	\N	AM2-103	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1923	16-10035C	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-5	\N	\N	\N	AM2-103-2	\N	\N	\N	\N	Lymph node, sentinel, inguinal, right, dissection, melanoma, metastatic (1/1)	\N	\N	\N	\N	73	\N	\N	16-10035	C	AM2-103	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2593	20-09338A1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-6	\N	\N	\N	\N	\N	\N	\N	\N	Lymph node, groin, lower part, right, dissection, melanoma, metastatic	FFPE	\N	\N	\N	74	\N	\N	20-9338	A1	AM2-104	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2307	18-22781A1	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-8	\N	\N	\N	\N	\N	\N	\N	\N	Skin, great toe, subungual, right, amputation, ALM	FFPE	\N	\N	\N	74	\N	\N	18-22781	A1	AM2-104	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2317	18-35014B2	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-6	\N	\N	\N	\N	\N	\N	\N	\N	a lymph node with tumor metastasis. 	FFPE	\N	\N	\N	75	\N	\N	18-35014	B2	AM2-105	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2611	20-21458A2	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-6	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	75	\N	\N	20-21458	A2	AM2-105	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2316	18-35014A1	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-6	\N	\N	\N	\N	\N	\N	\N	\N	Microscopically, sections A1-6 show a cellular spindle cell tumor with hyperchromatic spindle cells arranged in a fascicular pattern. The stroma is collagenous. Focally small nests of more epithelioid cells are noted. Immunohistochemically, the tumor cells (including the more epithelioid cells) are positive for SOX-10 but negative for HMB-45 and Melan-A. A small focus of atypical lentiginous proliferation of melanocytes is noted in the epidermis, suggesting the in situ component. An acral lentiginous melanoma with a nearly pure desmoplastic melanoma component is considered.	FFPE	\N	\N	\N	75	\N	\N	18-35014	A1	AM2-105	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2610	20-21458A1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-7	\N	\N	\N	\N	\N	\N	\N	\N	Soft tissue, inguinal area, left, excision, desmoplastic melanoma, metastatic/recurrent	FFPE	\N	\N	\N	75	\N	\N	20-21458	A1	AM2-105	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2440	19-34937A2	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-8; BOX-9; BOX-10	\N	\N	\N	\N	\N	\N	\N	\N	Skin, heel, right, status post biopsy, wide excision, acral lentiginous melanoma	FFPE	\N	\N	\N	76	\N	\N	19-34937	A2	AM2-106	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2035	17-3165B	44	\N	\N	\N	\N	\N	\N	4	\N	FFPE	\N	\N	709.09	\N	\N	Sections show basilar hyperpigmentation without evidence of a proliferation of melanocytes.  The epidermis is acanthotic and hypergranulotic and there is an underlying patchy lymphohistiocytic infiltrate and a few perijunctional necrotic keratinocytes.	Skin segment measuring 0.7 x 0.3 x 0.1 cm, bisected and entirely submitted in B. HD/HD	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. PIGMENTED SCC INSITU VS LENTIGO. 2MMX3MM BROWN MACULE. #1 SUPERIOR. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. PIGMENTED SCC INSITU VS LENTIGO. 3MMX2MM BROWN MACULE. #2 INFERIOR.	\N	genital mucosa	FFPE	\N	MELANOTIC MACULE, INFLAMED	135578	1320	\N	\N	17-3165	B	OM-62	Oral Mucosa Lesions	IP1729294	AirTable blocks_with_IP_info.csv
2034	17-3165A	44	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	216.5	\N	\N	Sections show an increased number of individual melanocytes, arrayed along the sides and bases of elongated, hyperpigmented rete ridges.	Skin segment measuring 0.6 x 0.2 x 0.1 cm, submitted intact in A. HD/HD	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. PIGMENTED SCC INSITU VS LENTIGO. 2MMX3MM BROWN MACULE. #1 SUPERIOR. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. PIGMENTED SCC INSITU VS LENTIGO. 3MMX2MM BROWN MACULE. #2 INFERIOR.	\N	genital mucosa	FFPE	\N	LENTIGO SIMPLEX	135578	1320	\N	\N	17-3165	A	OM-62	Oral Mucosa Lesions	IP1729294	AirTable blocks_with_IP_info.csv
1402	10-39146A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-4	\N	\N	\N	\N	\N	\N	\N	\N	Skin, lower leg, left, excision, malignant melanoma, metastatic	FFPE	\N	\N	\N	64	\N	\N	10-39146	A1	AM2-094	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1389	10-18253B	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-3	\N	\N	Metastasis	AM2-094-2, lymphadenectomy, malignant melanoma, metastatic (1/1)	\N	\N	\N	\N	lower left inguinal sentinel lymph node	Scraping	\N	\N	\N	64	\N	\N	10-18253	B	AM2-094	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1403	10-39146A2	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-4	\N	\N	\N	\N	\N	\N	\N	\N	Skin, lower leg, left, excision, malignant melanoma, metastatic	FFPE	\N	\N	\N	64	\N	\N	10-39146	A2	AM2-094	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1386	10-15411B	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-3	\N	\N	Acrolentiginous melanoma	AM2-094-1, incisional biopsy, clark level V (5.5 mm in depth), at least stage IIB	\N	\N	\N	\N	left ankle	Scraping	\N	\N	\N	64	\N	\N	10-15411	B	AM2-094	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1388	10-17734	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-0	\N	\N	\N	\N	\N	\N	\N	\N	left ankle , basal hyperpigmentation	FFPE	\N	\N	\N	64	\N	\N	10-17734	\N	AM2-094	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1277	07-25593 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	929	\N	\N	None	\N	MD-23	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1278	07-25593-2 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	929	\N	\N	None	\N	MD-23	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1458	11-21025B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1963	\N	\N	11-21025	B1	SYNAT71	2010-2017	\N	AirTable blocks_with_IP_info.csv
2441	19-34937S1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-8; BOX-9	\N	\N	\N	\N	\N	\N	\N	\N	Lymph node, inguinal, right, sentinel lymph node biopsy, melanoma, metastatic (1/1)	FFPE	\N	\N	\N	76	\N	\N	19-34937	S1	AM2-106	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2450	19-43366A1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-8	\N	\N	\N	\N	\N	\N	\N	\N	Skin, index finger, right, amputation, acral lentiginous melanoma	FFPE	\N	\N	\N	77	\N	\N	19-43366	A1	AM2-107	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2451	19-43366F	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	SLIDE BOX-16	\N	\N	\N	6703137,  (Y21-108507)	\N	\N	\N	\N	\N	\N	\N	\N	\N	77	\N	\N	19-43366	F	AM2-107	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2452	19-43366G	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-7; BOX-16	\N	\N	\N	\N	\N	\N	\N	\N	Lymph node, sentinel, biopsy, melanoma, metastatic (1/1)	FFPE	\N	\N	\N	77	\N	\N	19-43366	G	AM2-107	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2646	20-59076A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-21	http://64.54.108.121/eSlideTray.php?ImageIds=32809	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	78	\N	\N	20-59076	A1	AM2-108	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2456	19-44348A4	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	Skin, foot and leg, right, wide excision, melanoma, satellite and in-transit metastasis, multiple	FFPE	\N	\N	\N	78	\N	\N	19-44348	A4	AM2-108	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2455	19-44348A1	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-8; BOX-10	\N	\N	\N	\N	\N	\N	\N	\N	Skin, foot, right, wide excision, acral lentiginous melanoma	FFPE	\N	\N	\N	78	\N	\N	19-44348	A1	AM2-108	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2624	20-33334A1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-6	\N	\N	\N	\N	\N	\N	\N	\N	Skin, forearm, left, tumor excision, melanoma, metastatic	FFPE	\N	\N	\N	79	\N	\N	20-33334	A1	AM2-109	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2460	19-44987C1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-8	\N	\N	\N	\N	\N	\N	\N	\N	Lymph node, axillary, left, lymphadenectomy, melanoma, metastatic (2/5)	FFPE	\N	\N	\N	79	\N	\N	19-44987	C1	AM2-109	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2459	19-44987A1	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-6	\N	\N	\N	\N	\N	\N	\N	\N	Skin, thumb, left, amputation, acral lentiginous melanoma	FFPE	\N	\N	\N	79	\N	\N	19-44987	A1	AM2-109	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1988	16-101803B	66	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	172.3	\N	\N	There are melanocytes distributed singly and in small nests in lentiginous fashion at the junction, and some suprajunctional scatter of melanocytes is noted. The perijunctional dermis contains a lymphohistiocytic infiltrate with admixed melanophages, and elastosis is present more deeply. In subjunctional fibrosis, plump nests of melanocytes are noted. To the side of this, a large population of small syncytial maturing melanocytes is noted.	Skin segment measuring 1.9 x 1.3 x 0.3 cm, serially sectioned and entirely submitted with five sections in B. RS/RS	A) 12 X 7 MM RED SCALY PLAQUE; POSS NMSC, B) 14 X 11 MM DARK BROWN PLAQUE NEVUS; POSS ATYPIA, C) 4 X 3 MM BROWN MACULE; NEVUS POSS ATYPIA, D) 6 X 5 MM BROWN DARK MACULE; ATYPICAL NEVUS POSS MM	\N	\N	Scraping	A large congenital melanocytic nevus occupies about half of the middle of this specimen. To one side of the melanocytic nevus, there is a second population of atypical melanocytes, and I believe these cells represent a thin invasive melanoma with a mostly nested pattern. Synoptic parameters for this melanoma are listed below. Procedure: shave removal Microscopic tumor type: melanoma ex melanocytic nevus Breslow thickness: 0.65 mm Ulceration: not detected Margin: periphery involved by melanoma in situ Mitotic index: 0 Regression: not significant; inflammation is present Pathologic staging (pTNM): pT1a	MELANOMA OF 0.65 MM IN THICKNESS, CONTIGUOUS WITH A CONGENITAL MELANOCYTIC NEVUS	173316	1112	\N	\N	16-101803	B	ME-17	Melanoma Epigenetics	IP1701781	AirTable blocks_with_IP_info.csv
1583	12-12352 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	936	\N	\N	None	\N	MD-30	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2218	17-106118C	66	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.4	\N	\N	Sections show a domed skin segment harboring a dermal proliferation of melanocytes arrayed as coalescing and maturing nests, cords, and small syncytia with deep neural differentiation in the reticular dermis, which is elastotic.	Skin segment measuring 0.9 x 0.7 x 0.1 cm, trisected and entirely submitted in C. KC/KC	A-D) R/O DYSP VS. COMP N	\N	left posterior neck	Scraping	As for the specimen above, this melanocytic nevus is heavily pigmented and is accompanied in the biopsy by actinic (solar) lentigo.	INTRADERMAL MELANOCYTIC NEVUS	173404	1340	\N	\N	17-106118	C	SM-010	Nevus Library	IP1836502	AirTable blocks_with_IP_info.csv
2217	17-106118B	66	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.4	\N	\N	Sections show a domed skin segment harboring a dermal proliferation of melanocytes arrayed as coalescing and maturing nests, cords, and syncytia in the reticular dermis. There is prominent perijunctional hyperpigmentation. Bud-like rete are above this.	Skin segment measuring 1.0 x 0.6 x 0.1 cm, bisected and entirely submitted in B. KC/KC	A-D) R/O DYSP VS. COMP N	\N	right posterior neck 	Scraping	\N	INTRADERMAL MELANOCYTIC NEVUS WITH COINCIDENTAL OVERLYING ACTINIC LENTIGO	173477	1340	\N	\N	17-106118	B	SM-010	Nevus Library	IP1836502	AirTable blocks_with_IP_info.csv
1440	11-1973	\N	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31406	\N	\N	Tissue was mounted on LCM slides. Circled images are kept in the server.	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1402	\N	\N	11-1973	\N	WS-01	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
1554	12-1450	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31867	\N	\N	\N	\N	\N	\N	\N	Right nasal cavity	\N	\N	\N	\N	1402	\N	\N	12-1450	\N	WS-01	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
1927	16-12574	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	563	\N	\N	16-12574	\N	DN-088	Dysplastic Nevi	\N	AirTable blocks_with_IP_info.csv
2462	19-52004A1	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-6	\N	\N	\N	\N	\N	\N	\N	\N	Skin, thumb, right, amputation, acral lentiginous melanoma	FFPE	\N	\N	\N	80	\N	\N	19-52004	A1	AM2-110	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2463	19-52004B1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-9	\N	\N	\N	\N	\N	\N	\N	\N	Lymph node, axillary, right, sentinel, biopsy, melanoma, metastatic (1/1)	FFPE	\N	\N	\N	80	\N	\N	19-52004	B1	AM2-110	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2618	20-28721A1	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-6; BOX-9	\N	\N	\N	\N	\N	\N	\N	\N	Skin, leg, lower, left, excision, melanoma, metastatic	FFPE	\N	\N	\N	81	\N	\N	20-28721	A1	AM2-111	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2701	21-13227A	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-21	http://64.54.108.121/eSlideTray.php?ImageIds=32807	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	81	\N	\N	21-13227	A	AM2-111	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1314	08-35719A1	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-7; BOX-11	\N	\N	\N	\N	\N	\N	\N	\N	Skin, great toe, left, excision, subungual malignant melanoma	FFPE	\N	\N	\N	81	\N	\N	08-35719	A1	AM2-111	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2599	20-12501E1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	ymph node, groin, left, biopsy, melanoma, metastatic (number examined: 2; number involved: 2)	FFPE	\N	\N	\N	82	\N	\N	20-12501	E1	AM2-112	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2598	20-12501A1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	SLIDE BOX-7; BOX-8	\N	\N	\N	\N	\N	\N	\N	\N	Skin, heel, left, wide excision, acral lentiginous melanoma	FFPE	\N	\N	\N	82	\N	\N	20-12501	A1	AM2-112	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1942	16-32182	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-7; BOX-10	\N	\N	\N	\N	\N	\N	\N	\N	Skin, palm, lateral side, right, excision, acral melanoma, in vertical growth phase	FFPE	\N	\N	\N	83	\N	\N	16-32182	\N	AM2-113	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1945	16-35844B2	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-8; BOX-10	\N	\N	\N	\N	\N	\N	\N	\N	Lymph node, axillary (sentinel), biopsy, melanoma, metastatic	FFPE	\N	\N	\N	83	\N	\N	16-35844	B2	AM2-113	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1861	15-24753A1	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-7	\N	\N	\N	\N	\N	\N	\N	\N	Skin, heel, right, wide excision, acral lentiginous melanoma	FFPE	\N	\N	\N	84	\N	\N	15-24753	A1	AM2-114	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2615	20-26269A1	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-7	\N	\N	\N	\N	\N	\N	\N	\N	Skin, medial foot, right, wide excision, acral lentiginous melanoma, recurrent	FFPE	\N	\N	\N	84	\N	\N	20-26269	A1	AM2-114	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2747	21-108509B	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	\N	\N	\N	\N	5383991; 11-15420J1 (BOX-15)	\N	\N	\N	\N	Soft tissue, back, left, tumor resection, malignant melanoma, metastatic	\N	\N	\N	\N	86	\N	\N	21-108509	B	AM2-116	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2753	21-108510C	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	\N	\N	\N	\N	3876570; 09-38374 (BOX-15)	\N	\N	\N	\N	Skin, sole, right, biopsy, acrolentiginous melanoma	\N	\N	\N	\N	87	\N	\N	21-108510	C	AM2-117	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2751	21-108510A	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	\N	\N	\N	\N	3876570; 11-38925C	\N	\N	\N	\N	Soft tissue, subcutaneous, tumor excision, melanoma, metastatic	\N	\N	\N	\N	87	\N	\N	21-108510	A	AM2-117	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2752	21-108510B	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-14	\N	\N	\N	3876570; 11-11698A1; 11-11698A2	\N	\N	\N	\N	Soft tissue, leg, right, excisional biopsy, melanoma, metastatic	\N	\N	\N	\N	87	\N	\N	21-108510	B	AM2-117	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2865	22-510407A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-20	http://64.54.108.121/eSlideTray.php?ImageIds=32805	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	88	\N	\N	22-510407	A1	AM2-118	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2780	22-9055C1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-20	http://64.54.108.121/eSlideTray.php?ImageIds=32804	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	88	\N	\N	22-9055	C1	AM2-118	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2910	23-51956B14	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=32561,32562,32563,32564,32565,32566,32567,32568,32569,32570,32571,32572,32573,32574,32575,32576,32577,32578,32579,32580,32581,32582,32583,32610,32611,32584,32585,32586,32612,32613,32587,32588,32589	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	89	\N	\N	23-51956	B14	AM2-119	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1998	16-109052C	70	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26198	172.5	\N	Small nevus area	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.  A band like infiltrate of lymphocytes is present and a scar from a prior biopsy is identified.	Ellipse, 7.5 x 2.8 x 1.1 cm, including a central 1.6 x 1.2 cm variegated brown area. With margins inked, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in A-B, three sections each in C-D, and two sections each in E-F. Tips reserved. KC/KC	MALIGNANT MELANOMA, PLEASE CHECK MARGINS	\N	right mid upper back	FFPE	I did not review the prior biopsy.  Based on the findings in the excision specimen the following microstaging parameters apply: Procedure: Excision Tumor site: Back Microscopic tumor type: Nevoid Breslow thickness: 0.62 millimeters Ulceration: Absent Margins, peripheral and deep: Free Mitotic index: 0 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Present Pathologic Staging (pTNM): pT1a	SCAR AND RESIDUAL MELANOMA, 0.62 MILLIMETERS IN THICKNESS, COMPLETELY EXCISED	139524	1137	\N	\N	16-109052	C	ME-42	Melanoma Epigenetics	IP1709134	AirTable blocks_with_IP_info.csv
2324	18-51740B2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	90	\N	\N	18-51740	B2	AM2-120	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2326	18-51740C7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	90	\N	\N	18-51740	C7	AM2-120	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2325	18-51740C6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	90	\N	\N	18-51740	C6	AM2-120	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2685	21-4449A5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	91	\N	\N	21-4449	A5	AM2-121	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2686	21-4449B2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	91	\N	\N	21-4449	B2	AM2-121	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2684	21-4449A3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	91	\N	\N	21-4449	A3	AM2-121	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2388	19-360A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	92	\N	\N	19-360	A2	AM2-122	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2387	19-360A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	92	\N	\N	19-360	A1	AM2-122	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2673	20-113547A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	93	\N	\N	20-113547	A2	AM2-123	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2674	20-113547A3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	93	\N	\N	20-113547	A3	AM2-123	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2675	20-113547C2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	93	\N	\N	20-113547	C2	AM2-123	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2782	22-17043	64	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=20994,20995,20996	172.4	\N	\N	Sections show a bi-phasic proliferation of melanocytes. With larger, epithelioid melanocytes in the superficial dermis and small monomorphous melanocytes underneath.	Skin segment measuring 1.0 x 0.9 x 0.1 cm, quadrisected, and entirely submitted. HD/HD	NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. PIGMENTED BCC. PAPULE.	\N	\N	FFPE	The superficial component of larger melanocytes is PRAME positive and p16 negative, whereas the small melanocytes at the base (representing the nevus) are negative. Diagnostic features of note include:  Procedure: shave biopsy Microscopic tumor type: melanoma on skin with high cumulative sun-induced damage (WHO: high CSD melanoma) Breslow thickness: 0.9 mm (measured to the deepest PRAME positive/p16 negative cell) Ulceration: absent Margins, peripheral and deep: narrow. Deep margin involved by nevus Mitotic index: 1/mm2 Microsatellitosis: absent Vascular invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT1b pNX	MELANOMA, 0.9 mm IN THICKNESS, ARISING IN A PREDOMINANTLY INTRADERMAL NEVUS	445440	1132	\N	\N	22-17043	\N	ME-37	Melanoma Epigenetics	IP1179175	AirTable blocks_with_IP_info.csv
2354	18-97419C	74	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26193	172.5	\N	definite MIS with sclerotic nevus/melanoma component	Sections show a zone of granulation tissue representing the residuum of a prior biopsy site, flanked by a proliferation of atypical melanocytes in irregular array along the junctional zone and in the underlying dermis, with cords of neoplastic melanocytes stacked horizontally between fibrosis. There are small melanocytes with round to oval nuclei in the dermis in one area.	Oriented ellipse, 5.2 x 1.7 x 0.4 cm, including a central 3.0 x 14 cm pink brown area. The orienting notched edge is indicated as medial superior on the requisition form, designated as 12 o'clock, and placed toward 12 o'clock. The 9-12-3 o'clock and 3-6-9 o'clock edges are inked blue and yellow, respectively. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and submitted with submitted with six sections in A, four sections in B, and six sections in C. Tips reserved. HD/HD	EXC OF COMPOUND MELANOCYTIC PROLIFERATION - SEE PATH DT18-70644	\N	chest	FFPE	There is a substantial residuum, which in some areas shows unequivocal features of melanoma. There is also an associated nevus. Diagnostic features of note include:  Procedure: re-excision Tumor site: chest Microscopic tumor type: SSM, melanoma on skin with low cumulative sun-induced damage (low CSD melanoma) Breslow thickness: 1.4mm Ulceration: absent Margins, peripheral and deep: clear Mitotic index: 0/mm2 Microsatellitosis: absent Vascular invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT2a pNX	HEALING BIOPSY SITE, WITH RESIDUAL MELANOMA, 1.4 MM IN THICKNESS, COMPLETELY EXCISED, WITH MARGINS FREE OF NEOPLASM	573535	1133	\N	\N	18-97419	C	ME-38	Melanoma Epigenetics	IP1934546	AirTable blocks_with_IP_info.csv
1819	14-115431C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1363	\N	\N	14-115431	C	SMP58	Spitz Melanoma	\N	AirTable blocks_with_IP_info.csv
1818	14-115431A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1363	\N	\N	14-115431	A	SMP58	Spitz Melanoma	\N	AirTable blocks_with_IP_info.csv
2630	20-37211I	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	94	\N	\N	20-37211	I	AM2-124	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2629	20-37211A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	94	\N	\N	20-37211	A	AM2-124	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2658	20-83082A3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	95	\N	\N	20-83082	A3	AM2-125	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2659	20-83082B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	95	\N	\N	20-83082	B	AM2-125	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2591	20-8536E	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	96	\N	\N	20-8536	E	AM2-126	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2590	20-8536D	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	96	\N	\N	20-8536	D	AM2-126	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3547	MM100512	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	100	\N	\N	None	\N	AMC-03	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3549	MM100916	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	100	\N	\N	None	\N	AMC-03	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
2919	85-01186	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	958	\N	\N	85-1186	\N	MD-52	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3548	MM100513	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	100	\N	\N	None	\N	AMC-03	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3546	MM100511	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	100	\N	\N	None	\N	AMC-03	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3517	M040204 Dec2019	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	101	\N	\N	None	\N	AMC-07	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3516	M040204	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	101	\N	\N	None	\N	AMC-07	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3519	M040416	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	102	\N	\N	None	\N	AMC-08	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3521	M040419A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	102	\N	\N	None	\N	AMC-08	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3518	M040415	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	102	\N	\N	None	\N	AMC-08	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
1232	06-018998	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2078	\N	\N	06-18998	\N	SYNAT28	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3097	21159 A6	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-053_1.2	\N	\N	\N	\N	Left foot	\N	\N	\N	\N	26	\N	\N	None	\N	AM2-053	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3099	21159 G5	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-053_1.4, No metastasis identified	\N	\N	\N	\N	inguinal lymph node	\N	\N	\N	\N	26	\N	\N	None	\N	AM2-053	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3096	21159 A5	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-053_1.1	\N	\N	\N	\N	Left foot	Punch	\N	\N	\N	26	\N	\N	None	\N	AM2-053	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1198	06-01846D T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1014	\N	\N	None	\N	MD-130	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1206	06-06053B T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1015	\N	\N	None	\N	MD-131	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1603	12-21933I	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26324	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1727	\N	\N	12-21933	I	SYNAT83	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
2930	91-16318 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	962	\N	\N	None	\N	MD-56	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1669	12-97918	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	107	\N	\N	12-97918	\N	BN-003	Nevus Library	\N	AirTable blocks_with_IP_info.csv
2764	21-131828	73	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26440	172.6	\N	\N	Sections show a compound melanocytic proliferation with a biphasic pattern.  One population consists of melanocytes, most of which have enlarged oval nuclei (some eccentrically placed) and increased cytoplasm. These melanocytes are irregularly distributed along the dermal-epidermal junction, with some melanocytes present above the basal zone.  Similar melanocytes are present in the subjacent dermis forming an expansile nodule beneath an ulcerated epidermis. The second population consists of melanocytes with cytologically bland nuclei (melanocytic nevus). There is an ulcer.	Ellipse measuring 0.8 x 0.7 x 0.5 cm, including a central 0.5 x 0.4 cm raised brown area. With the margins inked by the grosser, the specimen is trisected perpendicular to the long axis and entirely submitted. BB/CF	MELANOMA	\N	INVASIVE MELANOMA, BRESLOW THICKNESS 1.4 mm, ULCERATED, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: Tumor site: right posterior shoulder Microscopic tumor type: low cumulative sun damage (WHO) Breslow thickness: 1.4 mm Ulceration: present Margins, peripheral and deep: melanoma in situ and nevus present at  peripheral tissue edge; deep tissue edge free Mitotic index (per square millimeter): 15 Microsatellitosis: not identified Vascular Invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT2b pNX	INVASIVE MELANOMA, BRESLOW THICKNESS 1.4 mm, ULCERATED, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	529699	1153	\N	\N	21-131828	\N	ME-58	Melanoma Epigenetics	IP2395063	AirTable blocks_with_IP_info.csv
1322	08-48442	48	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=7265	172.2	\N	\N	Sections show an asymmetrical biphasic compound proliferation of melanocytes. One population consists of enlarged epithelioid melanocytes with amphophilic or finely pigmented cytoplasm, and these cells are distributed singly and in nests along the epidermal-dermal junction in erratic fashion and also reside in the upper dermis. In one central domed nodular area, large atypical melanocytes are arrayed as coalescing nests and fascicles without clear maturation with descent, and these cells are encompassed by dermal fibroplasia. A sparse scattering of melanophages is also evident in the dermis in this area. A second population of melanocytes consists of much smaller cells, mostly dermal in location, consisting of nests and cords that mature with descent.	Skin segment measuring 0.8 x 0.8 x 0.4 cm, trisected and entirely submitted with fragment.	BROWN MACULE WITH CENTRAL, BLACK NODULAR COMPONENT; R/O MELANOMA	\N	\N	FFPE	Our differential diagnosis included an unusual combined melanocytic nevus on one hand, and melanoma arising in association with a melanocytic nevus on the other. To definitively address the differential via molecular means, we completed fluorescence in situ hybridization (FISH) analysis, utilizing a panel of 4 DNA probes (to loci on 6p, 6q, 6cent and 11q) developed by Dr. Boris Bastian of our group. FISH analysis demonstrates an imbalance in chromosome 6q and gain in chromosome 6p, a molecular combination supporting classification as melanoma. In short, based upon the combination of both conventional microscopy and FISH analysis, we believe this lesion represents melanoma and not an unusual melanocytic nevus. In terms of staging, this is a non-ulcerated primary melanoma with invasion of the reticular dermis (Clark's level IV). There is no evidence of associated vascular invasion, neurotropism, or regression. Further excision of this site is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 2.0 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	112208	127	\N	\N	08-48442	\N	CCR-011	Melanoma Epigenetics	IP757083	AirTable blocks_with_IP_info.csv
1896	15-101715	89	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.2	\N	\N	Sections show a compound melanocytic proliferation. Within the dermis, a nodule composed of closely positioned nests of atypical melanocytes with abundant cytoplasm and enlarged nuclei is present. There is little maturation with descent and mitotic figures are present within lesional melanocytes. The neoplastic melanocytes are pigmented and in fascicular array in areas. There is patchy inflammation with scattered melanophages. The surrounding dermis harbors a lymphocytic infiltrate with eosinophils and plasma cells. The epidermis is focally ulcerated.	Three skin segments received in one specimen bottle. The first skin segment, 1.2 x 0.9 x 0.5 cm, with the edges inked blue, quadrisected and entirely submitted. The second skin segment, 1.2 x 0.6 x 0.3 cm, with the edges inked yellow, bisected and entirely submitted. The third skin segment, 1.1 x 0.5 x 0.2 cm, bisected and entirely submitted. RS/RS	MM VS. ANGIOMA, MELANOMA LIKELY - LARGEST PIECE IS TOP OF LESION,2 ND LARGEST PIECE WAS SHAVED WHEN PIGMENT STILL PRESENT AT BASE, SMALLEST PIECE WAS FROM AN EDGE	\N	\N	Scraping	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: biopsy Tumor site: left ear Microscopic tumor type: melanoma, not otherwise classified Breslow thickness: at least 4.6 mm Ulceration: yes Margins, peripheral and deep: peripheral narrow, deep involved Mitotic index: 4 per square mm Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT4b pNX	MELANOMA, AT LEAST 4.6 MM IN THICKNESS, EXTENDING TO THE BASE OF THE BIOPSY	173201	1183	\N	\N	15-101715	\N	NL-021	Nevus Library	IP1573430	AirTable blocks_with_IP_info.csv
2907	23-47967	76	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=32288	172.5	\N	\N	Sections show a compound proliferation of melanocytes with a biphasic pattern.  One population of melanocytes is arrayed in poorly circumscribed fashion along the junction, as irregular nests and single cells, with some cells in pagetoid array. There is a larger nodule of atypical epithelioid melanocytes extending throughout the dermis, in one area. The second population of junctional melanocytes consists of nests of slightly smaller cells arrayed along the junction and in the papillary dermis (melanocytic nevus).	Skin segment measuring 1.3 x 1.2 x 0.1 cm, serially sectioned and entirely submitted with five sections. BB/KB	BCC VS. MELANOCYTIC NEOPLASM	\N	\N	\N	There is an associated nevus. Diagnostic features of note include: Procedure: shave biopsy Tumor site: back Microscopic tumor type: lowcsd Breslow thickness: at least 1.4 mm Ulceration: absent Margins, peripheral and deep: broadly transected at the base, melanoma in situ extending to the periphery Mitotic index: 1/mm2 Microsatellitosis: absent Vascular invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): at least pT2a pNX	MELANOMA, AT LEAST 1.4 mm IN THICKNESS, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	173530	1162	\N	\N	23-47967	\N	ME-67	Melanoma Epigenetics	IP2586261	AirTable blocks_with_IP_info.csv
2122	17-36409	45	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22148	172.7	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei and ample cytoplasm. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and as large elongate nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Cylindrical skin segment, 0.7 cm in diameter and 0.8 cm in thickness, bisected and entirely submitted. KC/KC	PT WITH > 100 NEVI, NOW WITH DARK BLACK / BLUE NODULE; R/O MM VS. PIGMENTED BASAL CELL VS. ATYPICAL NEVUS	\N	\N	Scraping	Diagnostic features of note include: Procedure: Punch Tumor site: Thigh Microscopic tumor type: Nevoid Breslow thickness: 1.28 millimeters Ulceration: Absent Margins, peripheral and deep: Involved by invasive and in situ melanoma Mitotic index: 1/mm2 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT2a	MELANOMA, 1.28 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173777	1121	\N	\N	17-36409	\N	ME-26	Melanoma Epigenetics	IP1765868	AirTable blocks_with_IP_info.csv
2386	18-139329	40	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26411	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes arranged as cellular nests and sheets in the subjacent dermis. Mitotic figures are readily identified.  An atypical mitosis is also noted.  The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.5 x 1.0 x 0.2 cm, quadrisected and entirely submitted. BY/BY	R/O ATYPICAL NEVUS	\N	MELANOMA, 1.7 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	Diagnostic features of note include: Procedure: Deep shave Tumor site: Abdomen Microscopic tumor type: Nevoid Breslow thickness: 1.7 millimeters Ulceration: Absent Margins, peripheral and deep: Free, narrow Mitotic index: 2/mm2 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT2a	MELANOMA, 1.7 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173539	1144	\N	\N	18-139329	\N	ME-49	Melanoma Epigenetics	IP2003493	AirTable blocks_with_IP_info.csv
1349	09-23922B	64	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=330	172.5	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, arranged irregularly within the epidermis, flanking a nodular proliferation of similar melanocytes that do not mature (diminish in size) with descent into the dermis. Many of the melanocytes have pagetoid cytologic features,  i.e., abundant pale cytoplasm that is finely vacuolated, with dusty melanin pigment.	Gross description recorded by digital image.	PREVIOUS HISTORY OF BCC'S, BUT NO ABNORMAL PIGMENTED LESIONS, PRESENTS TODAY FOR SEMI ANNUAL EXAM, HE HAS AN ABNORMAL PIGMENTED COMPLEXION ON HIS LEFT FLANK THAT HAS A BLACK NODULE AND IRREGULAR PIGMENTED MACULES, THE WHOLE 2 CM COMPLEX IS EXCISED	\N	\N	Scraping	Histopathologic features of possible prognostic importance include: Level: III Tumor infiltrating lymphocytes: low Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent Solar elastosis: mild	MELANOMA, 1.0 MM IN THICKNESS, EXTENDING CLOSE TO THE PERIPHERY OF THE BIOPSY	173544	142	\N	\N	09-23922	B	CCR-048	California Cancer Registry	IP824685	AirTable blocks_with_IP_info.csv
2029	17-1741I	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1239	\N	\N	17-1741	I	NM-65	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1261	07-1210F6	82	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.4	\N	\N	There are large angulated nests of basaloid cells in inflamed fibrotic stroma within the dermis, focally separated from that stroma by clefts. Peripheral palisading is focally evident.	One outside slide, 7-6.	DEBULKING LAYER AT TIME OF MOHS' SURGERY OF LESION OF DT06-74049, MORE TISSUE TO RE-DEFINE DIAGNOSIS, THIS SITS OVER TAIL OF PAROTID, BUT DID NOT EXTEND INTO THE PAROTID, I TOOK OF THE DEBULKING LAYER THEN TOOK A SECTION - THE CENTER AND DID H&E FROZEN SECTION ON IT, THE TWO OTHER ENDS CALL THE RESIDUAL TISSUE WHICH HAD BEEN FROZEN WAS PUT IN FORMALIN AND SENT TO YOU WITH THE SLIDE	\N	\N	\N	The neoplasm extends to the base of the specimen.	BASAL CELL CARCINOMA, INFILTRATIVE PATTERN	173404	1699	\N	\N	07-1210	F6	SYNAT34	2010-2017	IP614870	AirTable blocks_with_IP_info.csv
1847	15-14665B	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26328,26329	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	764	\N	\N	15-14665	B	JJS26	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
2483	19-117072A	38	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.5	\N	\N	There is a bi-phasic, dome-shaped proliferation of melanocytes, mostly within the dermis. There are discrete nests of plump, oval to small round melanocytes in the superficial dermis, and beneath them, collections of larger cells with abundant, vacuolated cytoplasm and some neurotization. This second population contains multinucleated melanocytes set in a fibrotic stroma.	Ellipse, 1.8 x 1.1 x 0.9 cm, including a central 1.1 x 1.0 cm elevated area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with four sections in A1 and three sections in A2. HD/HD	A) MORPHOLOGY: 1.6 TAN DOME ITCHY AND INCREASE IN SIZE AND TENDER, DDX: NEOPLASM OF UNCERTAIN BEHAVIOR, NOTES: PLEASE CHECK MARGINS, B) MORPHOLOGY: 5 MM, IRREGULAR BORDER AND COLOR, DDX: NEOPLASM OF UNCERTAIN BEHAVIOR VS. AMH, NOTES: PLEASE CHECK MARGINS	\N	\N	FFPE	This is a biphasic melanocytic tumor with both a conventional nevus seen superficially and a second population of larger melanocytes with abundant cytoplasm set in a sclerotic dermis. To further evaluate this second population, p16 and BAP-1 immunohistochemical stains were performed. The BAP-1 stain demonstrated retention of this nuclear protein, excluding the possibility of a BAP-1 inactivated melanocytoma. The p16 stain was also strongly retained in both populations, confirming that biallelic loss of CDKN2A has not occurred. We additionally performed staining for cilia, which has been shown to be lost in conventional melanoma and retained in nevi. This stain also demonstrated a reassuring pattern of cilia retention in both populations (ref). Overall, the histopathologic pattern seen in this lesion is not classic for any known underlying mechanisms, but has some features of a combined desmoplastic nevus with both conventional and deep penetrating nevus components. The lesion appears focally transected at the periphery and clear at the deep edge. As this lesion is unconventional, reexcision of this site to define a free margin and prevent further persistence is recommended as follow-up management. Dr. McCalmont has also reviewed this case and agrees with the diagnosis.  References: Lang UE, Love NR, Cheung C, McCalmont TH, Kim J. Use of the Ciliation Index to Distinguish Invasive Melanoma From Associated Conventional Melanocytic Nevi. Am J Dermatopathol. 2019 May 22.	COMBINED DESMOPLASTIC AND CONVENTIONAL MELANOCYTIC NEVUS	528599	1386	\N	\N	19-117072	A	SN-23	Sclerotic Nevi	IP2121822	AirTable blocks_with_IP_info.csv
2484	19-117072A2	38	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	There is a bi-phasic, dome-shaped proliferation of melanocytes, mostly within the dermis. There are discrete nests of plump, oval to small round melanocytes in the superficial dermis, and beneath them, collections of larger cells with abundant, vacuolated cytoplasm and some neurotization. This second population contains multinucleated melanocytes set in a fibrotic stroma.	Ellipse, 1.8 x 1.1 x 0.9 cm, including a central 1.1 x 1.0 cm elevated area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with four sections in A1 and three sections in A2. HD/HD	A) MORPHOLOGY: 1.6 TAN DOME ITCHY AND INCREASE IN SIZE AND TENDER, DDX: NEOPLASM OF UNCERTAIN BEHAVIOR, NOTES: PLEASE CHECK MARGINS, B) MORPHOLOGY: 5 MM, IRREGULAR BORDER AND COLOR, DDX: NEOPLASM OF UNCERTAIN BEHAVIOR VS. AMH, NOTES: PLEASE CHECK MARGINS	\N	\N	\N	This is a biphasic melanocytic tumor with both a conventional nevus seen superficially and a second population of larger melanocytes with abundant cytoplasm set in a sclerotic dermis. To further evaluate this second population, p16 and BAP-1 immunohistochemical stains were performed. The BAP-1 stain demonstrated retention of this nuclear protein, excluding the possibility of a BAP-1 inactivated melanocytoma. The p16 stain was also strongly retained in both populations, confirming that biallelic loss of CDKN2A has not occurred. We additionally performed staining for cilia, which has been shown to be lost in conventional melanoma and retained in nevi. This stain also demonstrated a reassuring pattern of cilia retention in both populations (ref). Overall, the histopathologic pattern seen in this lesion is not classic for any known underlying mechanisms, but has some features of a combined desmoplastic nevus with both conventional and deep penetrating nevus components. The lesion appears focally transected at the periphery and clear at the deep edge. As this lesion is unconventional, reexcision of this site to define a free margin and prevent further persistence is recommended as follow-up management. Dr. McCalmont has also reviewed this case and agrees with the diagnosis.  References: Lang UE, Love NR, Cheung C, McCalmont TH, Kim J. Use of the Ciliation Index to Distinguish Invasive Melanoma From Associated Conventional Melanocytic Nevi. Am J Dermatopathol. 2019 May 22.	COMBINED DESMOPLASTIC AND CONVENTIONAL MELANOCYTIC NEVUS	528599	1386	\N	\N	19-117072	A2	SN-23	Melanoma Epigenetics	IP2121822	AirTable blocks_with_IP_info.csv
1267	07-2889-1 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31870	\N	\N	\N	\N	\N	\N	\N	Waist	\N	\N	\N	\N	1403	\N	\N	None	\N	WS-02	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
1263	07-1841	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31872	\N	\N	(D01-44-2)	\N	\N	\N	\N	Liver	\N	\N	\N	\N	1403	\N	\N	07-1841	\N	WS-02	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
1265	07-2479-1 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31868	\N	\N	\N	\N	\N	\N	\N	Right forearm	\N	\N	\N	\N	1403	\N	\N	None	\N	WS-02	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
1269	07-3001	\N	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31405	\N	\N	Tissue was mounted on LCM slides. Circled images are kept in the server.	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1403	\N	\N	07-3001	\N	WS-02	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
1560	12-4365B1	73	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.31	\N	\N	Sections show small rounded and angulate aggregations of atypical basaloid keratinocytes associated with scant inflamed stroma in the dermis, and the surface of the biopsy is ulcerated, with exudate and crust residing above it.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted.	? FIBROMA/IDN	\N	\N	\N	None	ULCERATED INFILTRATIVE BASAL CELL CARCINOMA, INVOLVING THE DEEP EDGE OF THE BIOPSY	173313	1971	\N	\N	12-4365	B1	SYNAT27	Long-Triple Negative Metastatic Melanoma	IP39574	AirTable blocks_with_IP_info.csv
2215	17-100072A	69	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26196	172.6	\N	Good case	Sections show a broad proliferation of melanocytes arranged as single cells and nests within the epidermis and dermis. Within the epidermis, some of the lesional melanocytes are located in pagetoid scatter and single melanocytes predominate over nests in some foci. Similar melanocytes are present in clusters in the underlying dermis and the size of the melanocytes does not diminish with descent into the dermis. The dermal melanocytes are located within fibrosis overlying solar elastosis. There are melanocytes distributed irregularly in the epidermis overlying solar elastosis in some areas as well.  Centrally, in some areas there are melanocytes that mature with descent into the dermis and which extend around adnexal epithelium.  An artifactual rift is present within the epidermis.	Oriented blunted ellipse, 2.2 x 1.3 x 0.7 cm, including a central 1.3 x 0.8 cm brown area. The blunted tip is placed to the left and designated as 9 o'clock by the grosser. The 9-12-3 o'clock margin is inked blue and the 3-6-9 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in A and four in B. CF/CF	R/O ATYPICAL NEVUS	\N	left posterior shoulder	FFPE	The microscopic findings in this specimen are in keeping with a melanoma arising in association with a melanocytic nevus with superfical congenital features. Synoptic melanoma reporting is included below: Procedure: Excisional biopsy Microscopic tumor type: Melanoma, NOS, arising in association with a melanocytic nevus with superfical congenital features Breslow thickness: 1.2 mm Ulceration: Absent Margins: Intraepidermal melanoma extends to within 1-2 millimeters of most of the peripheral inked margins Mitotic index: 1/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT2aNxMx	MELANOMA, 1.2 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES AND WITH CLOSE EXTENSION TO THE PERIPHERAL INKED MARGINS	529698	1135	\N	\N	17-100072	A	ME-40	Melanoma Epigenetics	IP1830366	AirTable blocks_with_IP_info.csv
3204	Cell-Line_Xu-14	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1718	\N	\N	None	\N	SYNAT75	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
2145	17-61108	74	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22152	172.5	\N	\N	Sections show a poorly circumscribed proliferation of melanocytes arranged as single cells and nests within the epidermis and dermis. Within the epidermis, many of the lesional melanocytes are located in pagetoid scatter and single melanocytes predominate over nests in some foci. Similar melanocytes are present in clusters and sheets in the underlying dermis and the size of the melanocytes does not diminish with descent into the dermis.  In addition, mitotic figures are present amid dermal melanocytes. There is a heavy surrounding inflammatory infiltrate. There is also a second population of smaller melanocytes that diminish in size with descent in the dermis and that intercalate with solar elastosis (melanocytic nevus).	Skin segment measuring 1.2 x 1.0 x 0.1 cm, quadrisected and entirely submitted. CF/CF	R/O PIG BCC / INFL SK / DN	\N	\N	Scraping	The findings in this biopsy are in keeping with a melanoma of 0.85 millimeters in thickness arising in association with a melanocytic nevus with superficial congenital features. Is there a history of a changing pigmented lesion? Synoptic melanoma reporting is included below:  Procedure: Shave biopsy Microscopic tumor type: Superficial spreading, arising in association with a melanocytic nevus with superficial congenital features Breslow thickness: 0.85 mm Ulceration: Absent Margins: + base; abuts periphery Mitotic index: 2/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1bNxMx	MELANOMA, 0.85 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTES NEVUS WITH SUPERFICIAL CONGENITAL FEATURES	433599	1122	\N	\N	17-61108	\N	ME-27	Melanoma Epigenetics	IP983876	AirTable blocks_with_IP_info.csv
1722	13-46194	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2060	\N	\N	13-46194	\N	SYNAT97	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2619	20-30233	34	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	238.2	\N	\N	Sections show nests and syncytia of small melanocytes with round to oval nuclei in the upper reticular dermis, jointly with a second population of melanocytes with large nuclei and ample eosinophilic cytoplasm. The proliferation has a protuberant contour.	Skin segment measuring 0.7 x 0.6 x 0.4 cm, bisected and entirely submitted. BY/BY  Subsequently, the wax block was melted down and one section each was submitted in 1 and 2. DM	6 MM DARK TAN PAPULE, PATIENT DARKEST LESION; R/O ATYPIA	\N	\N	FFPE	This biopsy demonstrates an exophytic proliferation that includes a dominant component of conventional/congenital melanocytic nevus as well as a secondary component of BAP-1 inactivated melanocytoma. BAP-1 immunohistochemistry demonstrates a lack of nuclear positivity in the subset of enlarged melanocytes, thereby corroborating that BAP-1 inactivation has occurred in those cells. Expression of p16 is maintained throughout, and thus concomitant CDKN2A deletion has not occurred. Given that the proliferation extends to the base and edge of the specimen, either timely clinical follow-up of the biopsy site (to observe for persistence) or narrow additional removal (to mitigate persistence) can be considered as a management approach.	COMBINED BAP-1 INACTIVATED MELANOCYTOMA (BAP-1 INACTIVATED MELANOCYTIC NEVUS), EXTENDING TO THE BASE AND PERIPHERAL EDGE OF THE SPECIMEN	273588	1395	\N	\N	20-30233	\N	VS-02	Spatial Gene Expression	IP2177811	AirTable blocks_with_IP_info.csv
2423	19-10031	30	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.4	\N	\N	Sections show a proliferation of melanocytes mostly in the dermis beneath an epidermis that is papillated, with interconnecting rete ridges and horn pseudocysts. Nests, cords and strands of melanocytes that diminish in size with descent lie between reticular dermal collagen bundles and surround adnexal structures. There are sebaceous lobules at the bases of some elongated rete ridges. In the center of the lesion is a large, oval area in which there are small discrete aggregations of large, oval melanocytes with abundant, pale cytoplasm and dusty appearing melanin and moderately enlarged nuclei, with interspersed melanophages.	Skin segment measuring 1.0 x 0.8 x 0.6 cm, trisected and entirely submitted. PL/PL Subsequently, the wax block was melted down and two sections were submitted in 1 and one section in 2. DM	1 CM BROWN NODULE INCREASING IN SIZE; R/O DYSPLASIA	\N	\N	FFPE	A beta catenin immunostain labels the nuclei of many of the lesional cells in the center of the lesion, in keeping with the diagnosis of deep penetrating nevus for this component. A recent study from our group shows activation of the beta catenin pathway is a common finding in this entity, and is distinct from the molecular changes in blue nevi, which the entity has some clinical and pathologic features in common with. A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product (nearly complete or complete loss in a defined zone is worrisome for melanoma).  There are only scattered Ki-67 positive nuclei in this component. As some deep penetrating nevus-like melanomas have had mutations in TP53, we obtained a p53 immunostain which is negative.  In sum, the larger melanocytes with more pigmentation in the the center of the lesion represent a rare type of melanocytic proliferation, deep penetrating nevus but not deep penetrating nevus-like melanoma. The deep penetrating nevic component is within 0.3 mm. of the base of the specimen, but lacks findings that could compel re-excision.	COMBINED MELANOCYTIC NEVUS, WITH SUPERFICIAL CONGENITAL FEATURES AND A DEEP PENETRATING NEVIC COMPONENT	173476	1396	\N	\N	19-10031	\N	VS-03	Spatial Gene Expression	IP561112	AirTable blocks_with_IP_info.csv
2958	95-01141-1 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	959	\N	\N	None	\N	MD-53	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2472	19-88385	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	DPN-mm	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	735	\N	\N	19-88385	\N	DPN-01	Deep Penetrating Melanoma	\N	AirTable blocks_with_IP_info.csv
1561	12-4365C1	73	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.31	\N	\N	Sections show small rounded and angulate aggregations of atypical basaloid keratinocytes associated with scant inflamed stroma in the dermis, and the surface of the biopsy is ulcerated, with exudate and crust residing above it.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted.	? FIBROMA/IDN	\N	\N	\N	None	ULCERATED INFILTRATIVE BASAL CELL CARCINOMA, INVOLVING THE DEEP EDGE OF THE BIOPSY	173313	1971	\N	\N	12-4365	C1	SYNAT27	Long-Triple Negative Metastatic Melanoma	IP39574	AirTable blocks_with_IP_info.csv
1384	10-14100	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-5; BOX-9	\N	\N	Metastasis	AM2-095-2	\N	\N	\N	\N	left inguinal lymph node	Scraping	\N	\N	\N	65	\N	\N	10-14100	\N	AM2-095	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1559	12-4365A8	73	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	173.31	\N	\N	Sections show small rounded and angulate aggregations of atypical basaloid keratinocytes associated with scant inflamed stroma in the dermis, and the surface of the biopsy is ulcerated, with exudate and crust residing above it.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted.	? FIBROMA/IDN	\N	\N	\N	\N	ULCERATED INFILTRATIVE BASAL CELL CARCINOMA, INVOLVING THE DEEP EDGE OF THE BIOPSY	173313	1971	\N	\N	12-4365	A8	SYNAT27	2010-2017	IP39574	AirTable blocks_with_IP_info.csv
2076	17-23681	73	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26197	172.5	\N	Small nevus	Sections show a broad compound proliferation of melanocytes with vacuolated and finely pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, and conspicuous associated suprabasal scatter is also apparent. There are also nests and cords of similar melanocytes in the upper dermis, where a lymphohistiocytic infiltrate with admixed melanophages resides jointly with fibroplasia. More deeply, there are maturing melanocytes in nests, cords, and small syncytia.	Skin segment measuring 1.8 x 1.6 x 0.2 cm, serially sectioned and entirely submitted with eight sections. RS/RS	2.0 CM IRREGULAR RED / BLACK PAPULE; ? MM	\N	midline mid lower back	FFPE	This biopsy demonstrates a thin invasive melanoma with associated partial regression that developed overlying a remnant of a small congenital melanocytic nevus. A synoptic is included below. Procedure: shave removal Microscopic tumor type: melanoma ex melanocytic nevus Breslow thickness: 0.5 mm Ulceration: not detected Margin: periphery involved by melanoma in situ Mitotic index: 0 Regression: present; extensive partial Pathologic staging (pTNM): pT1a	MELANOMA OF 0.5 MM IN THICKNESS, EXTENDING INTRAEPIDERMALLY TO THE PERIPHERY OF THE BIOPSY	291511	1136	\N	\N	17-23681	\N	ME-41	Melanoma Epigenetics	IP802036	AirTable blocks_with_IP_info.csv
2678	21-961A	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-21	http://64.54.108.121/eSlideTray.php?ImageIds=32808	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	81	\N	\N	21-961	A	AM2-111	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1546	12_20321A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2040	\N	\N	None	\N	SYNAT76	2010-2017	\N	AirTable blocks_with_IP_info.csv
1547	12_54296	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1688	\N	\N	None	\N	SYNAT77	2010-2017	\N	AirTable blocks_with_IP_info.csv
2717	21-26009A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-21	http://64.54.108.121/eSlideTray.php?ImageIds=32806	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	81	\N	\N	21-26009	A1	AM2-111	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2461	19-51759	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	SLIDE BOX-8; BOX-10	\N	\N	\N	\N	\N	\N	\N	\N	Skin, lower leg, left, biopsy, melanoma, metastatic	FFPE	\N	\N	\N	81	\N	\N	19-51759	\N	AM2-111	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2974	96-06832D M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	961	\N	\N	None	\N	MD-55	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1576	12-9606A2	69	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	698.3	\N	\N	Sections show verrucous epidermal hyperplasia, hypergranulosis and compact hyperkeratosis, and fibrosis of the papillary dermis. Some follicular infundibula are widened or cystically dilated.	One outside slide, G56860, 12-DM-590-1.	R/O VERRUCA	\N	\N	\N	The differential diagnosis includes a resolving keratoacanthoma that has been persistently rubbed.	PRURIGO NODULARIS-LIKE CHANGES	173665	2284	\N	\N	12-9606	A2	SYNAT70	2010-2017	IP1095422	AirTable blocks_with_IP_info.csv
1577	12-9606C4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2284	\N	\N	12-9606	C4	SYNAT70	2010-2017	\N	AirTable blocks_with_IP_info.csv
2745	21-108508B	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-16	\N	\N	\N	6828093; 21-14158B1	\N	\N	\N	\N	Lymph node, sentinel, inguinal, right, lymphadenectomy, melanoma, metastatic(1/1)	\N	\N	\N	\N	85	\N	\N	21-108508	B	AM2-115	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2744	21-108508A	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-16	\N	\N	\N	6828093; 21-14158A1	\N	\N	\N	\N	Skin, second, third and great toe, right, amputation, acral lentiginous melanoma	\N	\N	\N	\N	85	\N	\N	21-108508	A	AM2-115	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2749	21-108509D	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	\N	\N	\N	\N	5383991; 08-40286A (BOX-16)	\N	\N	\N	\N	Digit, thumb, left, amputation, malignant melanoma	\N	\N	\N	\N	86	\N	\N	21-108509	D	AM2-116	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2748	21-108509C	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-16	\N	\N	\N	5383991; 11-15420E1	\N	\N	\N	\N	Lymph node, segmental, right, lymphadenectomy, malignant melanoma, metastatic (1/5)	\N	\N	\N	\N	86	\N	\N	21-108509	C	AM2-116	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2746	21-108509A	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-14	\N	\N	\N	5383991; 12-06252A2, 12-06252A1, 12-06252A3 (BOX-15)	\N	\N	\N	\N	Brain, site not stated, craniotomy and excision, melanoma, metastatic	\N	\N	\N	\N	86	\N	\N	21-108509	A	AM2-116	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2750	21-108509E	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	\N	\N	\N	\N	5383991; 08-40286C	\N	\N	\N	\N	Lymph node, axillary, labeled as C, lymphadenectomy, melanoma, metastatic 	\N	\N	\N	\N	86	\N	\N	21-108509	E	AM2-116	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1572	12-7093NG176-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2283	\N	\N	None	\N	SYNAT79	2010-2017	\N	AirTable blocks_with_IP_info.csv
2126	17-38404A2	72	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26199	172.5	\N	OK, but nevus blends with melanoma	Sections show a proliferation of melanocytes that involves the epidermis and dermis with two populations of cells. One consists of larger melanocytes, some of which have atypical nuclei and ample cytoplasm. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer, and there are similar melanocytes in subjacent fibrotic inflamed dermis as well. The second population consists of deep small melanocytes in nests, cords, and syncytia. There is also an intermediate population of finely pigmented melanocytes that are small and that are accompanied by melanophages.	Oriented ellipse, 2.7 x 1.6 x 0.4 cm, including a central 1.4 x 0.7 cm variegated brown area. The orienting suture is located at the midpoint of one edge, placed distally to the grosser, indicated as superior on the requisition form, and designated as 12 o'clock by the grosser. The 9-12-3 o'clock and 3-6-9 o'clock edges are inked blue and yellow, respectively. The specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections each in A1-A2. HD/HD	A) ? MELANOMA, B-C) VASCULAR LESION, BEING WORKED UP FOR FABRY'S SYNDROME; R/O ANGIOKERATOMA?	\N	right lateral chest	FFPE	At the request of Dr. Silver, this specimen was intended for evaluation by me. I have reissued this report to oblige that request. The previously-issued report contained similar diagnostic content. Please contact me if you have any questions. A synoptic for this melanoma is included below. Procedure: wide excision Microscopic tumor type: melanoma ex melanocytic nevus Breslow thickness: 1.4 mm Ulceration: not detected Margin: free of melanoma Mitotic index: 1 per square mm Vascular invasion: not detected Regression: present; partial Pathologic staging (pTNM): pT2a	MELANOMA OF 1.4 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173578	1138	\N	\N	17-38404	A2	ME-43	Melanoma Epigenetics	IP1767896	AirTable blocks_with_IP_info.csv
2911	23-51956B16	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=32561,32562,32563,32564,32565,32566,32567,32568,32569,32570,32571,32572,32573,32574,32575,32576,32577,32578,32579,32580,32581,32582,32583,32610,32611,32584,32585,32586,32612,32613,32587,32588,32589	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	89	\N	\N	23-51956	B16	AM2-119	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2909	23-51956A3	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=32561,32562,32563,32564,32565,32566,32567,32568,32569,32570,32571,32572,32573,32574,32575,32576,32577,32578,32579,32580,32581,32582,32583,32610,32611,32584,32585,32586,32612,32613,32587,32588,32589	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	89	\N	\N	23-51956	A3	AM2-119	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2097	17-32863B	50	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	172.7	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis with a lymphohistiocytic inflammatory infiltrate. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.1 x 1.1 x 0.1 cm, serially sectioned, and entirely submitted with five sections in B. HD/HD	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. SQUAMOUS CELL CARCINOMA VS. BASAL CELL CARCINOMA. PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA. PAPULE. C) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA. PAPULE. BCC VS. ACROANGIODERMATITIS. D) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA VS. ACROANGIODERMATITIS. PAPULE.	\N	\N	Scraping	A synoptic report of potential prognostic factors is listed below: Procedure: shave biopsy Microscopic tumor type: superficial spreading melanoma, non-chronically sun damaged (non-CSD) skin Breslow thickness: 0.5 mm Ulceration: absent Margins, peripheral and deep: deep negative, peripheral focally positive Mitotic index: 0 mm/2 Regression: not identified Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1a	MELANOMA, 0.5 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173777	1118	\N	\N	17-32863	B	ME-23	Melanoma Epigenetics	IP1762252	AirTable blocks_with_IP_info.csv
2200	17-89239A	63	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26688	172.5	\N	\N	Sections show a compound proliferation of melanocytes with a biphasic pattern.  One population of melanocytes is arrayed in poorly circumscribed fashion along the junction, as irregular nests and single cells, with some cells in pagetoid array.  The second population of melanocytes consists of nests of slightly smaller cells arrayed along the junction and in the papillary dermis (melanocytic nevus).	Skin segment measuring 1.2 x 0.7 x 0.2 cm, trisected and entirely submitted in A. RS/RS	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. MELANOMA. ASYMMETRIC PIGMENTED LESION. PLEASE CHECK MARGINS.. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. MELANOMA. ASYMMETRIC PIGMENTED LESION. PLEASE CHECK MARGINS..	\N	\N	FFPE	This melanoma appears to have arisen within a Clark's/dysplastic nevus. A synoptic report of potential prognostic factors is listed below: Procedure: saucerization biopsy Microscopic tumor type: melanoma ex nevus Breslow thickness: 0.75 mm Ulceration: absent Margins, peripheral and deep: deep <0.5 mm, peripheral positive Mitotic index: 0 mm/2 Regression: not identified Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1a	MELANOMA, 0.75 MM IN THICKNESS, ARISING IN A MELANOCYTIC NEVUS	173532	1141	\N	\N	17-89239	A	ME-46	Melanoma Epigenetics	IP850037	AirTable blocks_with_IP_info.csv
1609	12-22582C	16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.7	Melanocytic Nevus	\N	Sections show a proliferation of nested and solitary melanocytes, relatively evenly distributed along the dermal-epidermal junction. Clusters of similar melanocytes are present in the dermis. There are melanophages in the dermis.	Skin segment measuring 0.4 x 0.3 x 0.1 cm, submitted intact in cassette C.	A) NEOP VS. ATYP POLYP NEVUS, B) NEOP VS. ATYP NEVUS, C) 0.2 X 0.3 CM; NEOP VS. DYSPL NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS	107787	2248	\N	\N	12-22582	C	SYNAT84	Melanocytic Nevus	IP1108400	AirTable blocks_with_IP_info.csv
3098	21159 G2	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Normal	AM2-053_1.3, No metastasis identified	\N	\N	\N	\N	inguinal lymph node	Punch	\N	\N	\N	26	\N	\N	None	\N	AM2-053	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3134	501950A3	\N	\N	\N	\N	\N	\N	\N	12	\N	FFPE	\N	\N	\N	Mel 1	AM2-027_1	\N	\N	\N	\N	Sole	Scraping	\N	\N	\N	12	\N	\N	None	\N	AM2-027	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3135	501950C	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	AM2-027_2	\N	\N	\N	\N	LN	\N	\N	\N	\N	12	\N	\N	None	\N	AM2-027	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2640	20-53075B	38	\N	\N	\N	None	None	None	20	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26431,26432,26433	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Oriented ellipse, 2.5 x 1.2 x 0.7 cm, including a central 1.4 x 1.0 cm variegated brown area. The orienting sutured tip is indicated as 3 o'clock on the requisition form and placed toward 3 o'clock. The 9-12-3 o'clock and 3-6-9 o'clock edges are inked blue and yellow, respectively. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and submitted with four sections each in A-B. The 9 o'clock tip is reserved. HD/HD	NEVUS, R/O ATYPIA	\N	MELANOMA, 1.1 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product, but PRAME staining highlights two distinct populations of melanocytes. PRAME staining is positive in much of the junctional component and is positive in the population of slightly larger melanocytes in the dermis. The findings are consistent with melanoma arising in a pre-existing nevus. A synoptic report of potential prognostic factors is listed below. I have shared this case with my colleague Dr. Timothy McCalmont who agrees with this interpretation. Procedure: excisional biopsy Microscopic tumor type: nevoid melanoma (WHO classification: low cumulative sun damage) Breslow thickness: 1.1 mm Ulceration: absent Margins, peripheral and deep: deep negative, peripheral <1mm Mitotic index: 0 mm/2 Regression: not identified Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT2a	MELANOMA, 1.1 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	528599	1150	\N	\N	20-53075	B	ME-55	Melanoma Epigenetics	IP1769161	AirTable blocks_with_IP_info.csv
2175	17-72563	51	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis contains an infiltrate of lymphocytes and melanophages.	Skin segment measuring 1.1 x 0.8 x 0.1 cm, trisected and entirely submitted. CF/CF	R/O ATYPICAL NEVUS	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGES OF THE SPECIMEN	433599	577	\N	\N	17-72563	\N	DN-102	Dysplastic Nevi	IP1350209	AirTable blocks_with_IP_info.csv
3136	604076	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	Mel 1	AM2-030_1	\N	\N	\N	\N	Right Heel	Scraping	\N	\N	\N	14	\N	\N	None	\N	AM2-030	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1732	13-68674	60	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	Sections show basilar hyperpigmentation of a hyperplastic mucosal epithelium with an increase of small melanocytes in the basal layer. Melanophages are scattered in the submucosa.	Skin segment measuring 0.4 x 0.3 x 0.1 cm, bisected and entirely submitted. RS/RS	DEEPLY PIGMENTED MACULE; R/O MM	\N	right labia minora	\N	In level sections and with SOX-10 immunohistochemistry, the increase in small melanocytes with small nuclei in the basal layer is more apparent than in initial sections. This increase in melanocyte density is not typically observed in melanotic macule. If the clinical lesion is small, a conservative re-excision would be reasonable. I would be happy to review any available clinical photos. Dr. Philip LeBoit has also reviewed this case and agrees with the diagnosis and assessment.	MELANOTIC MACULE WITH INCREASED EPIDERMAL MELANOCYTES, TRANSECTED AT THE PERIPHERY OF THE BIOPSY	205551	1265	\N	\N	13-68674	\N	OM-04	Oral Mucosa Lesions	IP475265	AirTable blocks_with_IP_info.csv
3349	H13.10897/11	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-040_1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	16	\N	\N	None	\N	AM2-040	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3348	H13.10897/2	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-040_2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	16	\N	\N	None	\N	AM2-040	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2763	21-118604	65	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26438	172.5	\N	\N	Sections show an ulcerated proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 2.1 x 1.5 x 0.4 cm, serially sectioned and submitted with five representative sections. BB/BB	2.0 X 1.8 CM ULCERATED BLACK / BROWN PLAQUE, EVALUATE FOR MELANOMA	\N	MELANOMA, 2.9 mm BRESLOW THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	A synoptic report of potential prognostic factors is listed below: Procedure: excisional biopsy Microscopic tumor type: melanoma ex nevus (WHO classification: low cumulative sun damage) Breslow thickness: 2.9 mm Ulceration: present Margins, peripheral and deep: both <1 mm Mitotic index: 12 per square mm Regression: present Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT3b	MELANOMA, 2.9 mm BRESLOW THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	139522	1152	\N	\N	21-118604	\N	ME-57	Melanoma Epigenetics	IP2381778	AirTable blocks_with_IP_info.csv
3146	B13.26332/1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-040_4	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	16	\N	\N	None	\N	AM2-040	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3145	B06.41962/5	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-041_2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	17	\N	\N	None	\N	AM2-041	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3350	H13.21587/1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-041_4	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	17	\N	\N	None	\N	AM2-041	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1742	13-107061	40	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	Sections show labial epithelium with lymphocytes and melanophages in the submucosa, slight spongiosis and enlarged single melanocytes in small numbers along the junctional zone. Some of these have slightly enlarged, hyperchromatic nuclei.	Cylindrical skin segment measuring 0.2 cm in diameter and 0.2 cm in thickness, submitted intact. HD/HD	Melanoma vs. Labial Lentigo Brown macule PRE OP SIZE: 0.4 CM	\N	left inferior vermillion lip	\N	Both a Sox-10 immunostain and levels highlight that the lesional melanocytes have more enlarged nuclei than usual for a labial melanotic macule, and the melanocytes are more unevenly distributed. I would consider additional sampling, or complete removal with margins sufficient to assess circumscription.	SPARSELY CELLULAR JUNCTIONAL PROLIFERATION OF MELANOCYTES	122031	1266	\N	\N	13-107061	\N	OM-05	Oral Mucosa Lesions	IP1349079	AirTable blocks_with_IP_info.csv
3148	B14.2561/12	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-041_5	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	17	\N	\N	None	\N	AM2-041	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3144	B06.41962/3	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-041_1	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	17	\N	\N	None	\N	AM2-041	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3149	B15.28523/11	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	\N	\N	Metastasis	 AM2-042_3, image not shown	\N	\N	\N	\N	Lung Metastasis	Scraping	\N	\N	\N	18	\N	\N	None	\N	AM2-042	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3355	H16.660	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	\N	\N	Mel 1	AM2-042_2	\N	\N	\N	\N	Primary tumor	Scraping	\N	\N	\N	18	\N	\N	None	\N	AM2-042	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3143	B 62056/15	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	\N	\N	MIS2	AM2-042_1	\N	\N	\N	\N	Primary tumor (Punch)	\N	\N	\N	\N	18	\N	\N	None	\N	AM2-042	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3352	H15.2058/1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-043_2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	19	\N	\N	None	\N	AM2-043	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3345	H12.27716/7	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-043_1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	19	\N	\N	None	\N	AM2-043	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3342	H 2008.8956/1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Metastasis	AM2-045_3, two small areas	\N	\N	\N	\N	Dermal Met	\N	\N	\N	\N	20	\N	\N	None	\N	AM2-045	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3153	B2008.3067/5	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Metastasis	AM2-045_2	\N	\N	\N	\N	Lymph Node Met	\N	\N	\N	\N	20	\N	\N	None	\N	AM2-045	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2843	22-102809	82	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=27911	172.5	\N	\N	Sections show a proliferation of atypical melanocytes in irregular array within the epidermis and dermis, as well as a second population of smaller melanocytes arranged as cords and strands between collagen bundles of the reticular dermis and around adnexal structures.	Skin segment measuring 1.4 x 1.1 x 0.2 cm, serially sectioned and enrtirely submitted with five sections. BB/BB	ISK - TX'D, NOW WITH SCAR, PIH VS. MELANOCYTIC PROCESS, 15 X 9 MM	\N	\N	FFPE	Diagnostic features of note include: Procedure: shave biopsy Microscopic tumor type: melanoma on skin with low cumulative sun-induced damage (low CSD melanoma) Breslow thickness: 1.8 mm Ulceration: absent Margins, peripheral and deep: both narrow Mitotic index: 1/mm2 Microsatellitosis: not detected Vascular invasion: not detected Perineural invasion: not detected Regression: absent Pathologic Staging (pTNM): pT2a pNX	MELANOMA, 1.8 mm IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING CLOSE TO THE SPECIMEN BASE AND EDGE	139523	1157	\N	\N	22-102809	\N	ME-62	Melanoma Epigenetics	IP642510	AirTable blocks_with_IP_info.csv
2847	22-104652	63	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30869	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.9 x 1.5 x 0.3 cm, serially sectioned and entirely submitted with six sections. BB/ES	17 MM PLAQUE; POSS MM	\N	\N	\N	Diagnostic features of note include: Procedure: Shave Tumor site: Back Microscopic tumor type: Low chronic sun-damage Breslow thickness: 1.6 mm Ulceration: Present Margins, peripheral and deep: Narrow Mitotic index: 1/mm2 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT2b	MELANOMA, 1.6 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	898589	1161	\N	\N	22-104652	\N	ME-66	Melanoma Epigenetics	IP2506763	AirTable blocks_with_IP_info.csv
1027	01-10896	45	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=5929	216.5	\N	\N	Sections show a predominantly intradermal proliferation of small melanocytes in the superficial and mid-dermis, with cells clustered around appendages or arranged as syncytia or strands within the reticular dermis.  There is a second population of melanocytes with abundant pale to vacuolated cytoplasm and finely divided melanin pigment, accompanied by melanophages.  These latter cells are arrayed in a stroma that shows telangiectasia and focal sclerosis.	Skin segment, 1.0 x 0.8 x 0.5 cm, trisected and totally submitted.	ID NEVUS	\N	\N	FFPE	There is no evidence of melanoma in this biopsy.	COMBINED MELANOCYTIC NEVUS, WITH PIGMENTED EPITHELIOID MELANOCYTES IN THE DERMIS OF A SUPERFICIAL CONGENITAL MELANOCYTIC NEVUS	173502	124	\N	\N	01-10896	\N	CCR-008	Melanoma Epigenetics	IP267299	AirTable blocks_with_IP_info.csv
1045	02-7356	45	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=21403,22649,22992	172.5	\N	\N	Sections show an extensively ulcerated proliferation of large atypical melanocytes in irregular array within the epidermis and dermis, with foci of pagetoid spread, failure to mature and mitoses among dermal melanocytes, as well as a second population of smaller melanocytes arranged as cords and strands between collagen bundles of the superficial reticular dermis and around adnexal structures.	Ellipse measuring 1.6 x 0.8 x 0.5 cm including central black-brown\n0.7 x 0.5 cm pigmented area.  With margins inked blue, five central\nrepresentative sections are submitted, tips returned to container.	? MELANOMA	\N	\N	Scraping	The nevus, but not the melanoma extends to the periphery of the specimen.  There is extensive ulceration, a finding associated with adverse prognostic influence in many studies, and one that makes it difficult to determine an exact thickness.	MELANOMA, APPROXIMATELY 1.4 MM. IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS OF THE CONGENITAL TYPE	173528	124	\N	\N	02-7356	\N	CCR-008	California Cancer Registry	IP267299	AirTable blocks_with_IP_info.csv
1537	11-89154A7	51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=23313	198.2	\N	\N	\N	Two blocks S11-13013:A6 and A7.	MELANOMA SUBMITTED FOR BRAF & NRAS MUTATION ANALYSIS	\N	\N	\N	The histopathological assessment of this melanoma has been documented in UCSF Surgical Pathology report S11-13013. Using this metastatic tumor, we completed KIT and BRAF mutation analysis via Sanger sequencing. The following results were obtained: BRAF exon 15: V600E mutation. NRAS exons 1 and 2: wild-type (non-mutated).	SUBCUTANEOUS METASTATIC MELANOMA	112208	127	\N	\N	11-89154	A7	CCR-011	2010-2017	IP757083	AirTable blocks_with_IP_info.csv
3359	H2007.215/5	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-045_1	\N	\N	\N	\N	Primary tumor	\N	\N	\N	\N	20	\N	\N	None	\N	AM2-045	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3152	B2007.15494/1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-046_2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	21	\N	\N	None	\N	AM2-046	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3154	B2008.24393/1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-046_3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	21	\N	\N	None	\N	AM2-046	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3362	H2007.4636/9	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-046_1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	21	\N	\N	None	\N	AM2-046	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3360	H2007.358/1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 2	AM2-048_1	\N	\N	\N	\N	Primary tumor	\N	\N	\N	\N	22	\N	\N	None	\N	AM2-048	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3361	H2007.358/3	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	MIS1	AM2-048_2	\N	\N	\N	\N	Primary tumor	\N	\N	\N	\N	22	\N	\N	None	\N	AM2-048	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3151	B2007.998/2	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Metastasis	AM2-048_3	\N	\N	\N	\N	Met	\N	\N	\N	\N	22	\N	\N	None	\N	AM2-048	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3400	K1-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	MIS	AM2-049_1.1; AM2-049_1.2	\N	\N	\N	\N	in situ (radial growth phase)	Scraping	\N	\N	\N	23	\N	\N	None	\N	AM2-049	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3404	K1-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Normal	AM2-049_4.1; AM2-049_4.2	\N	\N	\N	\N	normal	Scraping	\N	\N	\N	23	\N	\N	None	\N	AM2-049	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3401	K1-A.2	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	23	\N	\N	None	\N	AM2-049	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3403	K1-C	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Metastasis	AM2-049_3.1;AM2-049_3.2	\N	\N	\N	\N	metastasis	\N	\N	\N	\N	23	\N	\N	None	\N	AM2-049	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1295	07-85201	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=21405	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	131	\N	\N	07-85201	\N	CCR-021	Melanoma Epigenetics	\N	AirTable blocks_with_IP_info.csv
1142	04-34117	43	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=7270	172.4	\N	\N	Sections show nodular aggregations of melanocytes with atypical nuclei in the dermis, lack of maturation of these cells with descent, and their arrangement in irregularly shaped aggregations. Scattered intraepidermal melanocytes are also present.   Patchy inflammation is present mainly surrounding the tumor.  Slight parakeratotic scale-crust and hyperkeratosis is present, but no ulceration is evident.  Lymphovascular invasion is present.  A second population of small round melanocytes arranged in discrete collections is also present.  There is a dilated follicular infundibulum centrally, and there is moderate fibrosis and slight telangiectasia.	Skin segment, 1.5 x 1.0 x 0.5 cm, quadrisected and entirely submitted.	HEMANGIOMA VS NEVI	\N	\N	FFPE	Histopathologic features of possible prognostic importance include: Level IV: Tumor infiltrating lymphocytes: absent Vascular or lymphatic invasion: present Mitotic rate: 4 per 6 high powered fields (moderate) Perineural invasion: absent Ulceration:  absent Regression: absent Microsatellite metastasis: absent  This is a high risk lesion, given its thickness and the presence of vascular invasion.	MELANOMA, 4.00 MILLIMETERS IN THICKNESS, WITH VASCULAR INVASION, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING TO PERIPHERAL AND DEEP BIOPSY MARGINS	173417	131	\N	\N	04-34117	\N	CCR-021	Melanoma Epigenetics	IP450519	AirTable blocks_with_IP_info.csv
1442	11-03286-4 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	933	\N	\N	None	\N	MD-27	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1441	11-03286 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	933	\N	\N	None	\N	MD-27	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1825	15-1495	65	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	There are elongated rete ridges with basilar hyperpigmentation and increased numbers of single melanocytes in the basal layer, with scant cytoplasm and small, round nuclei; a patchy lymphocytic infiltrate with melanophages is present in the subjacent lamina propria.	Skin segment measuring 0.5 x 0.5 x 0.1 cm, bisected and entirely submitted. RS/RS	DARK MACULE; R/O DARK LABIAL LENTIGO VS. OTHER	\N	letf labia majora	\N	Per my telephone discussion with Dr. Ferzli today, the specimen included the entire clinically evident pigmented lesion, which was of recent onset. While melanocytes are sparse, their number is still greater than that usually present in genital melanotic macules, and a few are present in the lamina propria. Immunostaining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a low proliferation rate among the junctional melanocytes, and does not show suprabasilar scatter. In addition, rare single melanocytes are present in the lamina propria, with a zero proliferation rate. A SOX-10 stain shows that the nuclei of the junctional melanocytes are clustered near the bases of elongated rete ridges and also does not show suprabasilar scatter.  I favor a partially transformed lesion that might progress if not fully excised, and given a chance to recur. A narrow re-excision of a few mms. to assure removal seems warranted.	SPARSELY CELLULAR PROLIFERATION OF MELANOCYTES	135577	1267	\N	\N	15-1495	\N	OM-06	Oral Mucosa Lesions	IP1472484	AirTable blocks_with_IP_info.csv
2355	18-103965B	63	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	238.2	\N	\N	Sections show basilar pigmentation with submucosal melanophages. There is solar elastosis in the subepithelial zone as well.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in B. KC/KC	A) IRREGULAR BROWN MACULE; ATYPICAL JUNCTIONAL MELANOCYTIC HYPERPLASIA, IRREGULAR PIGM, MACULES ON LOWER LIP OF RECENT ONSET, ATYPICAL MELANOCYTIC PROLIFERATION, R/O LM, B) SUSPICIOUS IRREGULAR PIGMENTED PATCH ON SUN EXPOSED SKIN; LENTIGO MALIGNA, 6 MM IRREGULARLY PIGM, MACULE ON L LOWER LIP OF RECENT ONSET, LM VS. ATYPICAL MELANOCYTIC PROLIFERATION	\N	left lower lip	\N	With regard to specimen (B), a SOX-10 immunoperoxidase stain also reveals a normal number and distribution of junctional melanocytes, supporting the diagnosis of a labial melanotic macule.	LABIAL MELANOTIC MACULE	201098	1268	\N	\N	18-103965	B	OM-07	Oral Mucosa Lesions	IP1386790	AirTable blocks_with_IP_info.csv
1674	13-48	\N	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	\N	Typical melanotic macule	\N	\N	\N	\N	\N	hand/foot	FFPE	\N	\N	\N	1289	\N	\N	13-48	\N	OM-31	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1695	13-11936	\N	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	\N	Typical melanotic macule	\N	\N	\N	\N	\N	genital mucosa	FFPE	\N	\N	\N	1290	\N	\N	13-11936	\N	OM-32	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1865	15-30226	\N	\N	\N	\N	\N	\N	\N	20	0	FFPE	\N	\N	\N	Typical melanotic macule	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1294	\N	\N	15-30226	\N	OM-36	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1894	15-99261C	34	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	709.09	Typical melanotic macule	\N	Sections show basilar hyperpigmentation without evidence of a proliferation of melanocytes.	Skin segment measuring 1.0 x 0.7 x 0.3 cm, trisected and entirely submitted in C. KC/KC	A) CLINICALLY BENIGN PAPULE WITH MULTIPLE EPISODES OF BLEEDING, B) PROJECTING PAPULE NOTED A FEW DAYS AGO AT THE SITE OF WHAT PT BELIEVES IS A LONGSTANDING "MOLE", C) PIGMENTED LESION THAT APPEARED 1 YEAR AGO, D) PIGMENTED LESION THAT APPEARED 1 YEAR AGO	\N	acral mel macule	FFPE	Melanotic macules occur at a variety of sites, and consist of basilar hyperpigmentation without a significantly increased number of melanocytes.	MELANOTIC MACULE	173714	1295	\N	\N	15-99261	C	OM-37	Oral Mucosa Lesions	IP1570965	AirTable blocks_with_IP_info.csv
1785	14-58566	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2135	\N	\N	14-58566	\N	SYNAT113	2010-2017	\N	AirTable blocks_with_IP_info.csv
3402	K1-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Mel 1	AM2-049_2	\N	\N	\N	\N	invasive (vertical growth phase)	Scraping	\N	\N	\N	23	\N	\N	None	\N	AM2-049	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3406	K2-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Mel	AM2-050_2.1; AM2-050_2.2	\N	\N	\N	\N	invasive (vertical growth phase)	Scraping	\N	\N	\N	24	\N	\N	None	\N	AM2-050	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2096	17-31440	55	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22146	172.5	\N	\N	Sections show a proliferation of atypical melanocytes in irregular array within the epidermis and dermis. Within the epidermis, there are areas in which melanocytes are present above the basal layer of the epidermis and other areas in which they are configured as single cells in confluence. There are nests of similar melanocytes in the dermis. In addition, there is a second population of smaller melanocytes arranged as cords and strands between collagen bundles of the reticular dermis and around adnexal structures. There is solar elastosis in the dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. HD/HD	PATIENT WITH A HISTORY OF METASTATIC MELANOMA, WHO P/W A CHANGING MOLE ON THE BACK, 5 X 6 MM BROWN PAPULE; R/O DYSPLASTIC NEVUS VS. NEOPLASM	\N	\N	Scraping	Synoptic melanoma reporting is included below: Procedure: Shave biopsy Microscopic tumor type: Superficial spreading, arising in association with a melanocytic nevus with superficial congenital features Breslow thickness: 0.5 mm Ulceration: Absent Margins: Intraepidermal melanoma extends to the peripheral edge of the specimen Mitotic index: 0/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1a	MELANOMA, 0.5 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES	273588	1120	\N	\N	17-31440	\N	ME-25	Melanoma Epigenetics	IP266136	AirTable blocks_with_IP_info.csv
2370	18-122972	25	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show acral skin with a small and symmetric proliferation of small melanocytes with round to oval nuclei, positioned singly and as small nests at the epidermal-dermal junction or above it, with accompanying epidermal pigmentation.	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely submitted. CF/PL	A) ATYPICAL NEVUS. 2MM  AND PIGMENT SEEMS TO BE LOCATED IN THE FURROWS AND NOT ON THE RIDGE UNDER DERMATOSCOPY ALTHOUGH SOME AREAS ARE UNCLEAR.	\N	\N	Scraping	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	172710	1187	\N	\N	18-122972	\N	NL-025	Nevus Library	IP1987073	AirTable blocks_with_IP_info.csv
3076	5696/15	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1191	\N	\N	None	\N	NM-004	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3169	BB21-21341	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=3580	\N	\N	56-18	\N	\N	\N	\N	hard palate	\N	\N	\N	\N	1277	\N	BB	21-21341	\N	OM-16	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1857	15-21302	46	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show a dermal proliferation of melanocytes, some of which are large with abundant cytoplasm and ovoid nuclei, and others of which are slender and dendritic and are associated with melanophages.	Cylindrical skin segment, 0.5 cm in diameter and 0.5 cm in thickness, bisected and entirely submitted. PL/PL	ATYPICAL BROWN GREY BARELY ELEVATED PAPULE; ATYPICAL NEVUS VS. BLUE NEVUS VS. MELANOMA VS. NEVUS	\N	right upper arm 	Scraping	Immunostaining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a low proliferation index. A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product. These findings are reassuring, but the proliferation remains unusual, such that conservative re-excision of this site seems warranted.	COMBINED MELANOCYTIC NEVUS, WITH SPITZ'S NEVUS AND BLUE NEVUS ELEMENTS, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	173688	1331	\N	\N	15-21302	\N	SM-001	Nevus Library	IP488197	AirTable blocks_with_IP_info.csv
3407	K2-C	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Metastasis	AM2-050_3.1; AM2-050_3.2	\N	\N	\N	\N	metastasis	\N	\N	\N	\N	24	\N	\N	None	\N	AM2-050	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3405	K2-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	MIS	AM2-050_1.1; AM2-050_1.2	\N	\N	\N	\N	in situ (radial growth phase)	\N	\N	\N	\N	24	\N	\N	None	\N	AM2-050	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3408	K2-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Normal	AM2-050_4.1; AM2-050_4.2	\N	\N	\N	\N	normal	Scraping	\N	\N	\N	24	\N	\N	None	\N	AM2-050	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3103	38637-16.3	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-055_1.3, also looks LN met	\N	\N	\N	\N	inguinal lymph node	\N	\N	\N	\N	27	\N	\N	None	\N	AM2-055	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3101	38637-16.1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 2	AM2-055_1.1	\N	\N	\N	\N	Heel	Punch	\N	\N	\N	27	\N	\N	None	\N	AM2-055	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3102	38637-16.2	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Metastasis	AM2-055_1.2	\N	\N	\N	\N	inguinal lymph node	\N	\N	\N	\N	27	\N	\N	None	\N	AM2-055	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1103	03B12175 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1192	\N	\N	None	\N	NM-005	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2024	16B10343 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1194	\N	\N	None	\N	NM-007	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1822	14B13985 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1195	\N	\N	None	\N	NM-008	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1430	10B18943 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1196	\N	\N	None	\N	NM-009	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1689	13-006535C	53	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.4	\N	\N	Sections show a mostly dermal proliferation of bland variably pigmented melanocytes which involves the superficial reticular and adventitial dermis. There are scattered melanophages.	Skin segment measuring 0.7 x 0.5 x 0.2 cm, bisected and entirely submitted in cassette A.   CF/CF	A-B) BROWN/PINK PAPULE; R/O CANCER	\N	\N	\N	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS, SUPERFICIAL CONGENITAL PATTERN, VARIABLY PIGMENTED	100444	2285	\N	\N	13-6535	C	SYNAT88	Long-Triple Negative Metastatic Melanoma	IP1191278	AirTable blocks_with_IP_info.csv
1702	13-17202A11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1972	\N	\N	13-17202	A11	SYNAT94	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1703	13-17202C4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1972	\N	\N	13-17202	C4	SYNAT94	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2574	19rig75000701.18.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	262	\N	\N	None	\N	CM-18	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2621	20-30367	14	\N	\N	\N	None	None	None	10	0	FFPE	\N	\N	216.3	\N	\N	There are increased numbers of single melanocytes at the sides and bases of elongated rete ridges.  There is basilar hyperpigmentation in the affected area.  Clusters of small, round melanocytes reside in the subjacent dermis.	Four outside slides, D20-012267 (A1), and one corresponding block.	R/O MIS	\N	\N	FFPE	I favor a compound nevus with aberrant PRAME expression, but am obtained a few more stains to further evaluate this lesion. A p16 immunoperoxidase stain shows adequate expression of tumor suppressor gene product (nearly complete or complete absence of staining in a defined zone is worrisome for melanoma). An elastic van Gieson stain no longer contains more than rare papillary dermal cells, precluding a determination as to whether these cells displace the dermal component, as would favor a dysplastic nevus-like melanoma. Given that this lesion is on the forehead of a child, and in my opinion, is more likely to have an immunohistochemical aberration than represent melanoma in situ arising in a nevus, I would follow the site clinically.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS WITH AN ATYPICAL IMMUNOHISTOCHEMICAL FINDING, SEE COMMENT	102388	1330	\N	\N	20-30367	\N	SCH-01	Seattle Children's Hospital -GENOMICS OF CUTANEOUS NEVI AND HEMANGIOMAS IN RING CHROMOSOME 7	IP2177946	AirTable blocks_with_IP_info.csv
3160	B236709/ 1B	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1226	\N	\N	None	\N	NM-49	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3157	B206739	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1227	\N	\N	None	\N	NM-50	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3158	B215962	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1228	\N	\N	None	\N	NM-51	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3155	B167003/1B  I	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1229	\N	\N	None	\N	NM-52	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3037	351/10 2 (HBD)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1230	\N	\N	None	\N	NM-53	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2199	17-88895	69	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	172.4	\N	\N	Sections show a poorly circumscribed proliferation of melanocytes arranged as single cells and nests within the epidermis and dermis. Within the epidermis, many of the lesional melanocytes are located in pagetoid scatter and single melanocytes predominate over nests in some foci. Similar melanocytes are present in clusters in the underlying dermis and the size of the melanocytes does not diminish with descent into the dermis.  Some of the dermal melanocytes are within fibrosis overlying solar elastosis. There is a second population of smaller melanocytes arranged as cords and strands between collagen bundles and elastotic fibers in the reticular dermis.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted with two sections and one fragment. PL/PL	PIGMENTED PAPULE, HISTORY OF MM	\N	\N	Scraping	Preliminary synoptic melanoma reporting, based on this partial biopsy, is included below: Procedure: Shave biopsy Microscopic tumor type: Melanoma, arising in association with a melanocytic nevus with superficial congenital features Breslow thickness: 0.8 mm Ulceration: Absent Margins: + base; + peripheral Mitotic index: 0/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1a	MELANOMA, AT LEAST 0.8 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES AND EXTENDING TO THE BASE AND PERIPHERAL EDGE OF THE SPECIMEN	173405	1131	\N	\N	17-88895	\N	ME-36	Melanoma Epigenetics	IP979333	AirTable blocks_with_IP_info.csv
1897	15-102731B	67	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	709.09	Typical melanotic macule	\N	Sections show acral skin with basilar hyperpigmentation without evidence of a proliferation of melanocytes. Within the deep dermis there is an area of fibrosis with an increase in small nerve bundles, suggesting a traumatic neuroma.	Cylindrical skin segment, 0.3 cm in diameter and 0.5 cm in thickness, submitted intact in B. KC/KC	R/O MELANOMA W/ HUTCHINSON'S FRECKLE, SEE PATH DT15-95455	\N	hand/foot	FFPE	Melan-a immunohistochemistry demonstrates single melanocytes at the dermo-epidermal junction, in keeping with the above diagnosis. Melanotic macules occur at a variety of sites, and consist of basilar hyperpigmentation without a significantly increased number of melanocytes. Within the dermis, there are findings suggestive of scar or traumatic neuroma. Perhaps there was a prior injury at this site which would correspond with the hyperpigmentation?	MELANOTIC MACULE	325678	1296	\N	\N	15-102731	B	OM-38	Oral Mucosa Lesions	IP1567130	AirTable blocks_with_IP_info.csv
1965	16-77557	\N	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	\N	Typical melanotic macule	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1299	\N	\N	16-77557	\N	OM-41	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2173	17-70204	\N	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	\N	Typical melanotic macule	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1300	\N	\N	17-70204	\N	OM-42	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
3038	351/10 4 (HBD)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1231	\N	\N	None	\N	NM-54	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1348	09-23922A	64	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=329	172.5	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, arranged irregularly within the epidermis, flanking a nodular proliferation of similar melanocytes that do not mature (diminish in size) with descent into the dermis. Many of the melanocytes have pagetoid cytologic features,  i.e., abundant pale cytoplasm that is finely vacuolated, with dusty melanin pigment.	Gross description recorded by digital image.	PREVIOUS HISTORY OF BCC'S, BUT NO ABNORMAL PIGMENTED LESIONS, PRESENTS TODAY FOR SEMI ANNUAL EXAM, HE HAS AN ABNORMAL PIGMENTED COMPLEXION ON HIS LEFT FLANK THAT HAS A BLACK NODULE AND IRREGULAR PIGMENTED MACULES, THE WHOLE 2 CM COMPLEX IS EXCISED	\N	\N	Scraping	Histopathologic features of possible prognostic importance include: Level: III Tumor infiltrating lymphocytes: low Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent Solar elastosis: mild	MELANOMA, 1.0 MM IN THICKNESS, EXTENDING CLOSE TO THE PERIPHERY OF THE BIOPSY	173544	142	\N	\N	09-23922	A	CCR-048	California Cancer Registry	IP824685	AirTable blocks_with_IP_info.csv
3043	467/10  1	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1232	\N	\N	None	\N	NM-55	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3554	N-ID 2225	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1233	\N	\N	None	\N	NM-58	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3066	3188/18	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1235	\N	\N	None	\N	NM-60	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2510	19Rig750007.02.02.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	263	\N	\N	None	\N	CM-21	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2511	19Rig750007.02.02.04	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	263	\N	\N	None	\N	CM-21	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2512	19Rig750007.02.03.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	264	\N	\N	None	\N	CM-22	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2513	19Rig750007.02.03.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	264	\N	\N	None	\N	CM-22	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1714	13-32289A	63	\N	\N	\N	T3a	Primary	\N	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=350	172.5	\N	\N	Sections show a broad and poorly circumscribed proliferation of melanocytes involving the epidermis and in a domed area in the center of the lesion, the papillary, and superficial reticular dermis.  In the peripheral portion, nests of melanocytes are distributed at irregular intervals along the junctional zone, and are focally confluent, with subjacent lymphocytic infiltrates.  The domed portion features a thinned epidermis and sheets of melanocytes, with a predominance of cells with large, vesicular nuclei and enlarged nucleoli, and abundant, pale cytoplasm in some areas. There is defective maturation with descent, and mitotic figures are apparent among these cells.	Oriented ellipse measuring 3.3 x 1.7 x 0.7 cm, including a central 1.5 x 1.3 cm raised area. With the orienting sutured tip placed to the left and arbitrarily designated as 12:00 by the grosser, the 12:00-6:00 margin is inked blue and the 6:00-12:00 margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in A and four sections each in B and C. HD/HD	R/O MEL PROCESS VS. CONG NEVUS WITH SK	\N	\N	Scraping	The neoplasm extends to within 2 mm. of the peripheral edge of the specimen. The lesion is not ulcerated, and is therefore stage pT3a per the 2009 AJCC staging schema for melanoma.	MELANOMA, 2.5 MM. IN THICKNESS	273588	145	\N	\N	13-32289	A	CCR-054	California Cancer Registry	IP1217034	AirTable blocks_with_IP_info.csv
1733	13-69386B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2261	\N	\N	13-69386	B	SYNAT99	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1736	13-90988	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1823	\N	\N	13-90988	\N	SYNAT100	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3048	1135/19	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1240	\N	\N	None	\N	NM-66	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1745	14-159A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2008	\N	\N	14-159	A2	SYNAT101	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2077	17-24139	\N	\N	\N	\N	\N	\N	\N	16	0	FFPE	\N	\N	\N	Typical melanotic macule	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1301	\N	\N	17-24139	\N	OM-43	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1715	13-32289B	63	\N	\N	\N	T3a	Primary	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2740	172.5	\N	\N	Sections show a broad and poorly circumscribed proliferation of melanocytes involving the epidermis and in a domed area in the center of the lesion, the papillary, and superficial reticular dermis.  In the peripheral portion, nests of melanocytes are distributed at irregular intervals along the junctional zone, and are focally confluent, with subjacent lymphocytic infiltrates.  The domed portion features a thinned epidermis and sheets of melanocytes, with a predominance of cells with large, vesicular nuclei and enlarged nucleoli, and abundant, pale cytoplasm in some areas. There is defective maturation with descent, and mitotic figures are apparent among these cells.	Oriented ellipse measuring 3.3 x 1.7 x 0.7 cm, including a central 1.5 x 1.3 cm raised area. With the orienting sutured tip placed to the left and arbitrarily designated as 12:00 by the grosser, the 12:00-6:00 margin is inked blue and the 6:00-12:00 margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in A and four sections each in B and C. HD/HD	R/O MEL PROCESS VS. CONG NEVUS WITH SK	\N	\N	Scraping	The neoplasm extends to within 2 mm. of the peripheral edge of the specimen. The lesion is not ulcerated, and is therefore stage pT3a per the 2009 AJCC staging schema for melanoma.	MELANOMA, 2.5 MM. IN THICKNESS	273588	145	\N	\N	13-32289	B	CCR-054	California Cancer Registry	IP1217034	AirTable blocks_with_IP_info.csv
2353	18-96989	9	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10817	216.5	\N	\N	Sections show a compound proliferation of melanocytes, with nested and solitary melanocytes arrayed along the junction.  There are clusters and syncytia of melanocytes in the superficial dermis, and striking cytologic atypism is not apparent.  Small melanocytes are present amongst reticular dermal collagen bundles in some foci in the uppermost reticular dermis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/HD	R/O ATYPIA	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES	173509	564	\N	\N	18-96989	\N	DN-089	Dysplastic Nevi	IP1960988	AirTable blocks_with_IP_info.csv
2254	17-116120	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1302	\N	\N	17-116120	\N	OM-44	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
3164	BB21-21315C	0	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	B15-01O	\N	One outside slide, B15-01-O, and one corresponding block.\nUpdate: Two of five pieces from original block (1) re-embedded into new block (2).	MUCOSA PROJECT, DX: IN SITU MELANOMA	\N	upper gingiva and palate	\N	\N	\N	101006	1279	\N	BB	21-21315	C	OM-18	Oral Mucosa Lesions	IP2283796	AirTable blocks_with_IP_info.csv
1805	14-83646	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2133	\N	\N	14-83646	\N	SYNAT126	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2349	18-91716	37	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly along the dermal-epidermal junction.	Tiny skin segment measuring 0.2 x 0.2 x 0.1 cm, submitted intact. The specimen vial is examined for additional tissue. CF/CF	6 M BROWN MACULE; BOWEN'S, MELANOTIC MACULE, OTHER	\N	gland penis	\N	This lesion has an increased number of junctional melanocytes, which rules out a melanotic macule. However, the cells are regularly distributed and not atypical, rendering melanoma in situ unlikely. I would thus classify this as a borderline lesion and, given its small size, recommend narrow but complete removal to avoid further enlargement and possible progression.	JUNCTIONAL MELANOCYTIC PROLIFERATION, EXTENDING TO THE EDGES OF THE SPECIMEN	115524	1269	\N	\N	18-91716	\N	OM-08	Oral Mucosa Lesions	IP1955698	AirTable blocks_with_IP_info.csv
2487	19-126110	73	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	Sections show a zone of scar, and the epidermis above the scar contains prominent single melanocytes. A perivascular, patchy lymphocytic infiltrate is present in the dermis.	Excision and ellipse received in biopsy bottle. Excision measuring 0.6 x 0.3 x 0.3 cm with the margins inked yellow and ellipse measuring 0.8 x 0.2 x 0.2 cm with the margins inked blue, both trisected perpendicular to the long axis and entirely submitted. PL/PL	A) SCAR VS. MM. VIOLACEOUS SCAR. PLEASE CHECK MARGINS.. HISTORY OF URETHRAL MELANOMA R/O SCAR VS MM. CC: DR. ENBE (HANFORD) AND STANFORD GYN (DR. DAUD).	\N	left labium majus	\N	A SOX-10 immunoperoxidase stain and level sections show single melanocytes at the junction with foci of basilar hyperpigmentation, but they do not show definitive evidence of a persistent melanocytic neoplasm. A PRAME immunostain is negative as well. Positive PRAME staining of the nuclei of the melanocytes would have favored persistent melanoma. These findings are within the spectrum of a genital melanotic macule over a scar. I have shared this case with my colleague Dr. Philip LeBoit who agrees with this interpretation.	SCAR WITH BASILAR HYPERPIGMENTATION, SEE NOTES	135577	1273	\N	\N	19-126110	\N	OM-12	Oral Mucosa Lesions	IP1847018	AirTable blocks_with_IP_info.csv
1772	14-40331B	76	\N	0.45	\N	T1b	Primary	None	\N	\N	\N	\N	\N	172.3	\N	\N	Sections show a vertically oriented zone of inflamed, fibrosing granulation tissue, flanked by a proliferation of enlarged melanocytes distributed at irregular intervals along the dermo-epidermal junction in a broad and poorly circumscribed manner, with some small nests of similar cells in the superficial dermis. There are also a few clusters of small, round melanocytes in the superficial dermis near one of the margins. The subjacent dermis is altered by severe solar elastosis.	Ellipse, 3.1 x 1.1 x 0.8 cm, including a central 2.5 x 0.3 cm linear scar. With the margins inked, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with six sections each in A-B. HD/HD	MALIGNANT MELANOMA RESIDUAL, CHECK MARGINS FINAL LENGTH (REFER TO DT14-36406)	\N	\N	\N	Melanoma in situ extends to one of the peripheral margins, where an incidental intradermal melanocytic nevus is also present. The neoplasm in this specimen is 0.45 mm. in thickness, less than that in the initial biopsy. The AJCC stage of pT1b remains unchanged.	HEALING BIOPSY SITE, WITH RESIDUAL MELANOMA, SEE NOTE RE THICKNESS	123388	1762	\N	\N	14-40331	B	SYNAT108	Melanoma Epigenetics	IP1380659	AirTable blocks_with_IP_info.csv
2274	17-125030	72	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22143	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  There are:  • A peripheral papillated portion in which nests of moderately enlarged melanocytes bridges adjacent rete ridges, with subjacent fibroplasia  • small, round melanocytes in the subjacent dermis in that area • a central nodule in which there are sheets of large, oval melanocytes with abundant, pale cytoplasm and large, pleomorphic vesicular nuclei with large, central nucleoli  • mitotic figures among the larger cells, which do no mature with descent	Skin segment measuring 2.8 x 1.8 x 0.7 cm. Three representative sections submitted. RS/RS	3 CM BRN TO PINK NODULE; POSS SK VS. MM	\N	\N	Scraping	The central, exophytic nodule is melanoma. It arose in a flattish but papillated pre-existent nevus, whose contour resembles that of a seborrheic keratosis, accounting for your observation. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: excisional biopsy Microscopic tumor type: nodular ex nevus Breslow thickness: 5.0 mm. Ulceration: no Margins, peripheral: involved by pre-existent dysplastic nevus, and deep: focally involved Mitotic index: 2/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT4a pNX	MELANOMA, 5 MM. IN THICKNESS, ARISING IN A NEVUS	528599	1124	\N	\N	17-125030	\N	ME-29	Melanoma Epigenetics	IP1855625	AirTable blocks_with_IP_info.csv
2617	20-28273	\N	\N	\N	\N	\N	\N	\N	20	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	lip	FFPE	\N	\N	\N	1284	\N	\N	20-28273	\N	OM-26	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2724	21-59477	\N	\N	\N	\N	\N	\N	\N	20	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	buccal	FFPE	\N	\N	\N	1285	\N	\N	21-59477	\N	OM-27	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2725	21-59483	\N	\N	\N	\N	\N	\N	\N	20	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	buccal	FFPE	\N	\N	\N	1286	\N	\N	21-59483	\N	OM-28	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2396	19-2710	25	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a wedge shaped area in the superficial and deep dermis with sparse bipolar dendritic melanocytes, thickened collagen bundles and melanophages.	Ellipse measuring 1.4 x 0.8 x 0.7 cm, serially sectioned perpendicular to the long axis and entirely submitted with six sections. The specimen vial was examined for additional tissue. PL/PL	LESION ON LEFT BACK - EPIDERMAL CYST	\N	\N	Scraping	The neoplasm extends to the base of the specimen. There are no worrisome features, however.	BLUE NEVUS	173530	1130	\N	\N	19-2710	\N	ME-35	Melanoma Epigenetics	IP2006742	AirTable blocks_with_IP_info.csv
2738	21-93208	\N	\N	\N	\N	\N	\N	\N	20	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	buccal	FFPE	\N	\N	\N	1287	\N	\N	21-93208	\N	OM-29	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1494	11-48013	\N	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	\N	Typical melanotic macule	\N	\N	\N	\N	\N	hand/foot	FFPE	\N	\N	\N	1288	\N	\N	11-48013	\N	OM-30	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1301	08-4205A	43	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show irregular epidermal hyperplasia with fibrosing granulation tissue, but no evidence of an atypical melanocytic proliferation.	Ellipse, 2.2 x 0.8 x 0.2 cm, including a central tan brown 0.7 x 0.6 cm irregular bordered lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections in cassette A and three sections in cassette B, tips returned to container.	ATYPICAL NEVUS (DT07-78376)	\N	\N	\N	\N	HEALING BIOPSY SITE, WITH NO EVIDENCE OF A RESIDUAL MELANOCYTIC NEOPLASM	102734	1939	\N	\N	08-4205	A	SYNAT38	2010-2017	IP700910	AirTable blocks_with_IP_info.csv
1302	08-4544A03	91	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	709.09	\N	\N	There are elongated, rounded rete ridges and hyperpigmentation of the basal layer of the epidermis, and there is solar elastosis within the subjacent dermis. There are many melanophages clustered in the papillary dermis in part of the lesion.	Ellipse,1.6 x 0.8 x 0.3 cm, including a central 0.9 x 0.4 cm dark pigment.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections.	R/O MM/LK/REGRESSION	\N	\N	\N	\N	SOLAR LENTIGO	173404	1967	\N	\N	08-4544	A03	SYNAT39	2010-2017	IP424543	AirTable blocks_with_IP_info.csv
1909	16-2833	\N	\N	\N	\N	\N	\N	\N	16	0	FFPE	\N	\N	\N	Intramucosal nevus	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1298	\N	\N	16-2833	\N	OM-40	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1317	08-43266	41	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show marked solar elastosis, club-shaped rete ridges with basilar hyperpigmentation, and an area in which there are increased numbers of melanocytes both singly and in small nests, mainly in the basal layer of the epidermis. The lesional melanocytes have abundant, pale cytoplasm.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted.	LENTIGO VS. MM IN SITU	\N	\N	\N	The melanocytic proliferation extends to the peripheral edge of the specimen. Its differential diagnosis includes both evolving melanoma in situ and the junctional component of a so-called Miescher's nevus (the wedge shaped nevus found in facial skin, the surface of which can simulate melanoma in situ). This was not clarified by levels.	JUNCTIONAL PROLIFERATION OF MELANOCYTES AND A SOLAR LENTIGO	173307	1736	\N	\N	08-43266	\N	SYNAT43	2010-2017	IP751907	AirTable blocks_with_IP_info.csv
1318	08-43267	39	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.3	\N	\N	Sections show a mostly endophytic, lobular proliferation of keratinocytes with pallid cytoplasms and small, monomorphous nuclei. There are patchy infiltrates of lymphocytes.	Skin segment measuring 0.3 x 0.3 x 0.1 cm.	R/O BCC	\N	\N	\N	There is no evidence of carcinoma in level sections.	TRICHILEMMOMA	173305	1774	\N	\N	08-43267	\N	SYNAT44	2010-2017	IP751908	AirTable blocks_with_IP_info.csv
1779	14-50051	45	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26201	173.31	\N	\N	Beneath an ulcer are rounded nests of peripherally palisaded basaloid cells in the dermis, accompanied by fibromyxoid stroma from which they are separated by clefts.	Skin segment measuring 0.5 x 0.5 x 0.1 cm, bisected and entirely submitted in A. RS/RS	A) NON HEALING LESION; S/P 5FU, B) NODULAR NEOPLASM	\N	\N	FFPE	The neoplasm extends to the base of the specimen.	NODULAR BASAL CELL CARCINOMA	173311	1140	\N	\N	14-50051	\N	ME-45	Melanoma Epigenetics	IP988468	AirTable blocks_with_IP_info.csv
1324	08-51220	19	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.3	\N	\N	Sections show a proliferation of small melanocytes with ovoid nuclei, arrayed as nests and syncytia in a domed configuration in the dermis. There is diminishment in melanocyte size with descent in the dermis, and some deep melanocytes are positioned around vascular and adnexal structures. There is an incidental associated sparse perifollicular lymphohistiocytic infiltrate.	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely submitted.	4 MM SKIN-COLORED PAPULE INCREASING IN SIZE; IDN, COMPOUND NEVUS	\N	\N	\N	None	INTRADERMAL MELANOCYTIC NEVUS (MIESCHER'S NEVUS)	173313	2224	\N	\N	08-51220	\N	SYNAT46	2010-2017	IP759861	AirTable blocks_with_IP_info.csv
1326	08-51222	59	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei in partial contiguity with the epidermis. There is little diminishment in melanocyte size with descent in the dermis. The nodule is composed of coalescing nests and fascicles that do not mature with descent. Many cells are evident in mitosis. There is a flanking lymphohistiocytic infiltrate and diffuse surface ulceration.	One outside slide, S08-9388.	UCSF MELANOMA CLINIC PATIENT	\N	\N	\N	This specimen shows an extensively ulcerated nodular melanoma with invasion limited to the papillary dermis (Clark's level III). I do not see any evidence of associated regression, vascular invasion, or neurotropism in the present sections. There is a great deal of fragmentation, and thus my thickness measurement can only be listed as an approximation.	MELANOMA OF APPROXIMATELY 1.5 MM IN THICKNESS	173619	2243	\N	\N	08-51222	\N	SYNAT48	2010-2017	IP759863	AirTable blocks_with_IP_info.csv
1798	14-66686B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1712	\N	\N	14-66686	B	SYNAT123	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1327	08-51223	15	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a proliferation of large atypical melanocytes in large nodules with zones of necrosis. There are atypical mitotic figures. There are surrounding areas with second population of smaller, hyperpigmented melanocytes arranged as cords and strands between collagen bundles of the reticular dermis and around adnexal structures.	Seventeen outside slides, S08-2691:A1, A2, A3, and three corresponding blocks.	REFERRAL FOR CGH	\N	\N	\N	Comparative genomic hybridization performed on DNA extracted from the specimen revealed several chromosomal aberrations that are frequently seen in melanoma: loss of the short arm of chromosome 1, gain of the short arm of chromosome 6, and loss of the long arm of chromosome 6. These findings confirm the diagnosis above.	MELANOMA, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS OF THE CONGENITAL TYPE	174523	2311	\N	\N	08-51223	\N	SYNAT49	2010-2017	IP692531	AirTable blocks_with_IP_info.csv
1160	05-12693C M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	946	\N	\N	None	\N	MD-40	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1175	05-27343A M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	947	\N	\N	None	\N	MD-41	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1085	03-23238B T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1043	\N	\N	None	\N	MD-166	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3024	99-19998 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1044	\N	\N	None	\N	MD-167	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1083	03-21273-1G T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1045	\N	\N	None	\N	MD-168	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1347	09-22513A	35	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=23271,23272	172.5	\N	\N	There is a well circumscribed, slightly asymmetric compound proliferation of melanocytes that abuts a focally thinned epidermis, and is partially encompassed by epithelial collarettes. There are confluent aggregations of cells with large, vesicular nuclei and central, prominent nucleoli. Some cells have abundant amphophilic cytoplasm, but in many areas of the lesion, cytoplasm is scant and nuclei appear to overlap. Little maturation with descent is evident. The accompanying Ki-67 stained slide shows that there is a moderately elevated (roughly 5%) proliferation rate even in the lower part of the lesion.	Thirteen outside slides, 069-322-0920-0, D09-2956, DJ9005911:1 (Including five unstained slides).	SECOND OPINION, DIFFERENCE OF OPINION OUTLINED IN COVER LETTER, SPITZ'S NEVUS VS. MELANOMA	\N	\N	\N	The neoplasm extends to within a millimeter or so of the peripheral margin. This is a difficult case in which expert dermatopathologists could have differences of opinions. For me, findings against a Spitz's nevus include a thinned rather than thickened epidermis, the presence of epithelial collarettes, and at least in the bulbous portion of the lesion that extends to the deep reticular dermis, very little maturation. The cells are not classic Spitz cells, lacking sufficient amounts of cytoplasm, and their cytoplasm is pale and vacuolated. This having been said, my instinct is that this is not a conventional melanoma, either. It has the silhouette more typically seen in spitzoid melanomas in children and adolescent patients. This patient is obviously older than that age group, but the lesion may be similar. Among such lesions, sentinel lymph nodes are often involved, but distant metastases are rare. Hence, I would be reluctant to tell this patient that their prognosis is that of a 2.3 mm, level IV melanoma. If you or the treating clinician would like us to, we can perform additional testing (analysis for a b-raf mutation, which would not be present in a Spitz's nevus or in a spitzoid melanoma of childhood type, and either fluorescence in situ hybridization or comparative genomic hybridization). I would be happy to discuss these options with you.	MELANOMA, 2.3 MM IN THICKNESS	173508	2329	\N	\N	09-22513	A	SYNAT52	2010-2017	IP823276	AirTable blocks_with_IP_info.csv
2137	17-51847B	70	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	172.5	\N	Good case	Sections show a very broad proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei and ample pigmented cytoplasm. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are hyperchromatic melanocytes in the subjacent fibrotic dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei that tend to mature with descent.	Ellipse, 3.2 x 2.5 x 0.6 cm, including a central 2.0 x 1.6 cm brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in A, four sections in B, and five sections in C. RS/RS	1.7 X 1.6 CM BROWN PATCH W/ IRREGULAR BORDERS AND COLOR; R/O MELANOMA (TELEPHONE: 415-902-7635 OK TO LM)	\N	right axilla	FFPE	Diagnostic features of note include: Procedure: Excision Tumor site: Axilla Microscopic tumor type: Nevoid Breslow thickness: 1.33 millimeters Ulceration: Absent Margins, peripheral and deep: Free Mitotic index: 1/mm2 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT2a	MELANOMA, 1.33 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, COMPLETELY EXCISED	173540	1134	\N	\N	17-51847	B	ME-39	Melanoma Epigenetics	IP524148	AirTable blocks_with_IP_info.csv
1351	09-36483	49	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22972	216.6	\N	\N	Sections show a melanocytic proliferation composed of nests of melanocytes along the junction, with clusters of similar cells in the subjacent dermis.  Many neoplastic cells have pigmented cytoplasm.	Cylindrical skin segment, 0.4 cm in diameter and 0.6 cm in thickness, bisected and entirely submitted.	H/O MELANOMA, IRREGULARLY SHAPED MACULE; R/O MELANOMA	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, WITH MANY HYPERPIGMENTED MELANOCYTES	173688	2314	\N	\N	09-36483	\N	SYNAT53	California Cancer Registry	IP757083	AirTable blocks_with_IP_info.csv
1407	10-44069A4	38	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show central fibrosing granulation tissue and early scar with an associated lymphohistiocytic infiltrate, stemming from past biopsy/surgery, and no residual melanocytic lesion is in evidence.	Ellipse, 1.7 x 0.7 x 0.5 cm, including a central 0.5 x 0.4 cm lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with five sections, tips retained.	SEE PREVIOUS: DT10-34472	\N	\N	\N	\N	POST-BIOPSY SCARRING, WITH NO RESIDUUM	173619	1775	\N	\N	10-44069	A4	SYNAT55	2010-2017	IP929046	AirTable blocks_with_IP_info.csv
2366	18-121971A	61	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show acral skin with nested and solitary melanocytes arrayed at the epidermal-dermal junction, with clusters of similar but smaller melanocytes in the superficial dermis centrally.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, trisected and entirely submitted in A. HD/PL	A) ATYPICAL NEVUS. ATYPICAL RED BROWN MACULE. B) BASAL CELL CARCINOMA. EXCORIATED PAPULE.	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS	173733	1180	\N	\N	18-121971	A	NL-018	Nevus Library	IP599761	AirTable blocks_with_IP_info.csv
2367	18-121973	50	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show acral skin with nested and solitary melanocytes arrayed at the epidermal-dermal junction, with clusters of similar but smaller melanocytes in the superficial dermis.  Most prominently centrally, there are melanocytes above the basal layer, but these are not cytologically atypical.	Skin segment measuring 0.5 x 0.5 x 0.1 cm, bisected and entirely submitted. HD/PL	ATYPICAL DARK BROWN MACULE; ATYPICAL NEVUS	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS	224789	1181	\N	\N	18-121973	\N	NL-019	Nevus Library	IP828094	AirTable blocks_with_IP_info.csv
2368	18-121986	57	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	There are increased single melanocytes along the sides and bases of elongated rete ridges, and small, round melanocytes in the subjacent papillary dermis. There is basilar hyperpigmentation in the affected area.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. HD/PL	6 MM IRREGULAR BROWN MACULE; R/O MM	\N	\N	Scraping	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	528522	1182	\N	\N	18-121986	\N	NL-020	Nevus Library	IP1986075	AirTable blocks_with_IP_info.csv
1851	15-16543B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1666	\N	\N	15-16543	B	SYNAT138	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1082	03-19132B T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1003	\N	\N	None	\N	MD-108	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1300	08-1851C	58	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=396	172.5	\N	\N	There is a proliferation of melanocytes with abundant pale cytoplasm, dusty melanin and striking nuclear pleomorphism that extends from the epidermis into the subcutis at the base of the specimen. Single cells predominate in portions of the lesion, with pagetoid spread; there is no maturation with descent into the dermis and subcutis. Mitoses are easily identified. There are large zones of necrosis, and others in which melanophages predominate over melanocytes.	Oriented excision, 2.3 x 1.5 x 1.0 cm, including a central 1.8 x 1.2 cm dark pigment.  With the orienting sutured end placed to the left and designated suture at 12:00 by the surgeon, the 12 to 3 to 6 o'clock (far) margin is inked blue and the 6 to 9 to 12 o'clock (near) margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from 12 o'clock to 6 o'clock ends (left to right) and entirely submitted with four sections in cassette A, two sections in cassette B, and three sections in cassette C.	R/O MELANOMA	\N	\N	Scraping	This neoplasm extends deeply into the subcutis (level V), has a high mitotic rate and features necrosis en masse. Ulceration is not evident, however. Deeply pigmented melanomas with a peri-appendageal pattern of this type have been called animal-type melanoma. However, the analogy to eccrine melanotic disease is flawed, and there is little evidence that this type of melanoma behaves differently in humans from other forms of melanoma.	MELANOMA, AT LEAST 9 MM IN THICKNESS	173568	151	\N	\N	08-1851	C	CCR-074	California Cancer Registry	IP710492	AirTable blocks_with_IP_info.csv
1874	15-45455F	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1846	\N	\N	15-45455	F	SYNAT139	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2917	49_M	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2275	\N	\N	None	\N	SYNAT140	2010-2017	\N	AirTable blocks_with_IP_info.csv
1955	16-53528	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1312	\N	\N	16-53528	\N	OM-54	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1298	08-1851A	58	\N	\N	\N	\N	\N	\N	12	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=394	172.5	\N	\N	There is a proliferation of melanocytes with abundant pale cytoplasm, dusty melanin and striking nuclear pleomorphism that extends from the epidermis into the subcutis at the base of the specimen. Single cells predominate in portions of the lesion, with pagetoid spread; there is no maturation with descent into the dermis and subcutis. Mitoses are easily identified. There are large zones of necrosis, and others in which melanophages predominate over melanocytes.	Oriented excision, 2.3 x 1.5 x 1.0 cm, including a central 1.8 x 1.2 cm dark pigment.  With the orienting sutured end placed to the left and designated suture at 12:00 by the surgeon, the 12 to 3 to 6 o'clock (far) margin is inked blue and the 6 to 9 to 12 o'clock (near) margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from 12 o'clock to 6 o'clock ends (left to right) and entirely submitted with four sections in cassette A, two sections in cassette B, and three sections in cassette C.	R/O MELANOMA	\N	\N	Scraping	This neoplasm extends deeply into the subcutis (level V), has a high mitotic rate and features necrosis en masse. Ulceration is not evident, however. Deeply pigmented melanomas with a peri-appendageal pattern of this type have been called animal-type melanoma. However, the analogy to eccrine melanotic disease is flawed, and there is little evidence that this type of melanoma behaves differently in humans from other forms of melanoma.	MELANOMA, AT LEAST 9 MM IN THICKNESS	173568	151	\N	\N	08-1851	A	CCR-074	California Cancer Registry	IP710492	AirTable blocks_with_IP_info.csv
1299	08-1851B	58	\N	\N	\N	None	None	None	6	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=395	172.5	\N	\N	There is a proliferation of melanocytes with abundant pale cytoplasm, dusty melanin and striking nuclear pleomorphism that extends from the epidermis into the subcutis at the base of the specimen. Single cells predominate in portions of the lesion, with pagetoid spread; there is no maturation with descent into the dermis and subcutis. Mitoses are easily identified. There are large zones of necrosis, and others in which melanophages predominate over melanocytes.	Oriented excision, 2.3 x 1.5 x 1.0 cm, including a central 1.8 x 1.2 cm dark pigment.  With the orienting sutured end placed to the left and designated suture at 12:00 by the surgeon, the 12 to 3 to 6 o'clock (far) margin is inked blue and the 6 to 9 to 12 o'clock (near) margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from 12 o'clock to 6 o'clock ends (left to right) and entirely submitted with four sections in cassette A, two sections in cassette B, and three sections in cassette C.	R/O MELANOMA	\N	\N	Scraping	This neoplasm extends deeply into the subcutis (level V), has a high mitotic rate and features necrosis en masse. Ulceration is not evident, however. Deeply pigmented melanomas with a peri-appendageal pattern of this type have been called animal-type melanoma. However, the analogy to eccrine melanotic disease is flawed, and there is little evidence that this type of melanoma behaves differently in humans from other forms of melanoma.	MELANOMA, AT LEAST 9 MM IN THICKNESS	173568	151	\N	\N	08-1851	B	CCR-074	California Cancer Registry	IP710492	AirTable blocks_with_IP_info.csv
1101	03-57585C	83	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=427	172.5	\N	\N	Sections show nested and solitary melanocytes, some of which display atypical nuclear features, in irregular array along the epidermal-dermal junction.  Similar melanocytes are present in clusters in the underlying dermis.	Oriented ellipse measuring 4.2 x 3.0 x 1.3 cm, central lesion measuring 3.1 x 1.8 cm, pigmented, with the suture at 12 o'clock, the far aspect of specimen is inked in blue and the near half of specimen is inked in yellow.  The specimen is serially sectioned and submitted with three sections each in cassettes A and E and two sections each in cassettes B through D	R/O MELANOMA	\N	\N	Scraping	There is extensive lymphatic invasion. Histopathologic features of possible prognostic importance include:  Level:  IV Tumor infiltrating lymphocytes: scant Vascular or lymphatic invasion: present Mitotic rate: moderate Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent	MELANOMA, ABOUT 2.2 MM  IN THICKNESS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	139522	154	\N	\N	03-57585	C	CCR-090	California Cancer Registry	IP415901	AirTable blocks_with_IP_info.csv
1959	16-55930	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	genital mucosa	FFPE	\N	\N	\N	1313	\N	\N	16-55930	\N	OM-55	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1375	10-8439A4	29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.7	\N	\N	There is a proliferation of melanocytes, mostly at the dermo-epidermal junction. Most are arranged singly at the sides and bases of elongated rete ridges, but some small nests are also present. There is hyperpigmentation of the basal layer.	Skin segment measuring 0.4 x 0.3 x 0.1 cm.	ATYPICAL NEVUS	\N	\N	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	187724	2276	\N	\N	10-8439	A4	SYNAT64	2010-2017	IP903012	AirTable blocks_with_IP_info.csv
1102	03-57585E	83	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=429	172.5	\N	\N	Sections show nested and solitary melanocytes, some of which display atypical nuclear features, in irregular array along the epidermal-dermal junction.  Similar melanocytes are present in clusters in the underlying dermis.	Oriented ellipse measuring 4.2 x 3.0 x 1.3 cm, central lesion measuring 3.1 x 1.8 cm, pigmented, with the suture at 12 o'clock, the far aspect of specimen is inked in blue and the near half of specimen is inked in yellow.  The specimen is serially sectioned and submitted with three sections each in cassettes A and E and two sections each in cassettes B through D	R/O MELANOMA	\N	\N	Scraping	There is extensive lymphatic invasion. Histopathologic features of possible prognostic importance include:  Level:  IV Tumor infiltrating lymphocytes: scant Vascular or lymphatic invasion: present Mitotic rate: moderate Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent	MELANOMA, ABOUT 2.2 MM  IN THICKNESS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	139522	154	\N	\N	03-57585	E	CCR-090	California Cancer Registry	IP415901	AirTable blocks_with_IP_info.csv
1056	02-20495B T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1055	\N	\N	None	\N	MD-178	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1006	00-06521B T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1060	\N	\N	None	\N	MD-183	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1100	03-57585A	83	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=425	172.5	\N	\N	Sections show nested and solitary melanocytes, some of which display atypical nuclear features, in irregular array along the epidermal-dermal junction.  Similar melanocytes are present in clusters in the underlying dermis.	Oriented ellipse measuring 4.2 x 3.0 x 1.3 cm, central lesion measuring 3.1 x 1.8 cm, pigmented, with the suture at 12 o'clock, the far aspect of specimen is inked in blue and the near half of specimen is inked in yellow.  The specimen is serially sectioned and submitted with three sections each in cassettes A and E and two sections each in cassettes B through D	R/O MELANOMA	\N	\N	Scraping	There is extensive lymphatic invasion. Histopathologic features of possible prognostic importance include:  Level:  IV Tumor infiltrating lymphocytes: scant Vascular or lymphatic invasion: present Mitotic rate: moderate Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent	MELANOMA, ABOUT 2.2 MM  IN THICKNESS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	139522	154	\N	\N	03-57585	A	CCR-090	California Cancer Registry	IP415901	AirTable blocks_with_IP_info.csv
1289	07-67657A	70	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=414	172.5	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei, mitotic figures and abundant pigmentation, in partial contiguity with the epidermis.  There is a permeative infiltrate of lymphocytes, as well as a patchy infiltrate and fibrosis at the periphery. Melanocytes lie in close apposition to small nerve twigs.	Oriented ellipse, 2.1 x 1.4 x 0.7 cm, including a central violaceous 1.1 x 1.0 cm nodule.  With the orienting sutured tip placed to the left, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from left to right tips and entirely submitted with three sections each in cassettes A and B, and four sections in cassette C.	9 X 7 MM BLACK NODULE; PROBABLE MELANOMA	\N	\N	Scraping	This is a non-ulcerated primary melanoma with invasion of the reticular dermis (Clark's level IV). There is focal regression, and perineural invasion involving small nerve twigs. There is no evidence of vascular invasion. Tumor extends within 2 mm of peripheral margins, and changes of regression are present at some peripheral margins. Additional excision is warranted.	MELANOMA, 4.0 MM IN THICKNESS, EXTENDING TO WITHIN 2 MM OF THE PERIPHERAL MARGIN	173526	152	\N	\N	07-67657	A	CCR-083	California Cancer Registry	IP690191	AirTable blocks_with_IP_info.csv
2475	19-94975	38	\N	\N	\N	None	None	None	6	\N	FFPE	\N	\N	216.0	\N	\N	There is a proliferation of melanocytes, mostly at the epithelial-connective tissue junction. Most are arranged singly at the sides and bases of elongated rete ridges, but some small nests are also present. There is hyperpigmentation of the basal layer.	Tissue segment, 0.5 x 0.5 x 0.1 cm, bisected, and entirely submitted. HD/HD	SLIGHTLY IRREGULAR BORDER - SLIGHT RAISED PAPULE, BROWN	\N	oral mucosa	FFPE	There is no evidence of malignancy in the sections. I showed this case to my colleague Dr. I. Yeh who agrees with the above diagnosis.	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	100009	1321	\N	\N	19-94975	\N	OM-63	Oral Mucosa Lesions	IP2099586	AirTable blocks_with_IP_info.csv
1290	07-67657B	70	\N	\N	\N	None	None	None	4	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=415	172.5	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei, mitotic figures and abundant pigmentation, in partial contiguity with the epidermis.  There is a permeative infiltrate of lymphocytes, as well as a patchy infiltrate and fibrosis at the periphery. Melanocytes lie in close apposition to small nerve twigs.	Oriented ellipse, 2.1 x 1.4 x 0.7 cm, including a central violaceous 1.1 x 1.0 cm nodule.  With the orienting sutured tip placed to the left, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from left to right tips and entirely submitted with three sections each in cassettes A and B, and four sections in cassette C.	9 X 7 MM BLACK NODULE; PROBABLE MELANOMA	\N	\N	Scraping	This is a non-ulcerated primary melanoma with invasion of the reticular dermis (Clark's level IV). There is focal regression, and perineural invasion involving small nerve twigs. There is no evidence of vascular invasion. Tumor extends within 2 mm of peripheral margins, and changes of regression are present at some peripheral margins. Additional excision is warranted.	MELANOMA, 4.0 MM IN THICKNESS, EXTENDING TO WITHIN 2 MM OF THE PERIPHERAL MARGIN	173526	152	\N	\N	07-67657	B	CCR-083	California Cancer Registry	IP690191	AirTable blocks_with_IP_info.csv
2323	18-44728A	80	\N	\N	\N	\N	\N	\N	16	0	FFPE	\N	\N	198.5	Mel	\N	Rounded large and small islands and of poorly differentiated epithelial cells infiltrate inflamed connective tissue. Tumor cells are pleomorphic and atypical with large hyperchromatic nuclei but only rare mitoses. Comedo-type necrosis is seen.	Multiple soft tissue fragments and multiple teeth fragments received in one vial. Multiple soft tissue fragments measuring 2.2 x 1.7 x 0.3 cm in aggregate, all entirely submitted with multiple fragments each in A-B. Multiple teeth fragments ranging in measurements from 0.5 x 0.4 x 0.5 cm to 0.7 x 0.7 x 2.2 cm, not run and all reserved. CF/CF	ANTERIOR MANDIBULAR LESION WITH TEETH #23 - #27	\N	oral mucosa	FFPE	This is a poorly differentiated dyscohesive malignancy requiring immunostains to further classify and the results are as follows: S-100: diffusely and strongly positive, supports a diagnosis of melanoma SOX-10: diffusely and strongly positive, supports a diagnosis of melanoma Melan-A: negative BRAF V600E: negative CD138: negative, against a plasma cell malignancy CD3: positive in small lymphocytes, tumor cells are negative, against a T-cell lymphoma CD20: negative, against a B-cell lymphoma keratin: negative, against a carcinoma p63: negative, against a carcinoma  Given the history in 2010 and 2016 of cutaneous melanoma reported to involve the left chest, the findings here are consistent with a metastatic melanoma.  The positive S-100 and SOX-10 stains coupled with the negative keratin and p63 immunostains suggest that this tumor is unlikely to be a squamous cell carcinoma.  The patient is reported to have had a dermatofibroma protuberans (DFSP) involving the right neck in 2014 but there are no features here to support that diagnosis. Dr. J. North, Dr. T. Mully and Dr. P. LeBoit also reviewed this case and concur with the diagnosis.  I showed selected sections to Dr. T. McCalmont who concurs. I notified Dr. Patel of the results on May 2, 2018.	POORLY DIFFERENTIATED MALIGNANCY MOST CONSISTENT WITH METASTATIC MELANOMA	175344	1303	\N	\N	18-44728	A	OM-45	Oral Mucosa Lesions	IP1510187	AirTable blocks_with_IP_info.csv
1395	10-25517A	91	\N	\N	\N	T2a	Primary	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=972	172.6	\N	Re-excision path number for T10-23548	Sections show inflammation and granulation tissue, flanked by a proliferation of melanocytes arrayed irregularly along the junctional zone and in the dermis.	Ellipse, 7.5 x 3.0 x 1.2 cm, including a central black 1.5 x 1.0 cm lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with two sections in cassette A, one section each in cassettes B through H, and two sections in cassette I.	WLE MM	\N	\N	\N	In light of the increased thickness of the residual lesion, this melanoma should now be regarded as a pT2a lesion.  No lymphatic or perineural invasion is noted.  There is no evidence of regression.  Microsatellites are not identified.	HEALING BIOPSY SITE, WITH RESIDUAL MELANOMA, APPROXIMATELY 1.25 MILLIMETERS IN THICKNESS, COMPLETELY EXCISED	173619	157	\N	\N	10-25517	A	CCR-102	California Cancer Registry	IP918121	AirTable blocks_with_IP_info.csv
1396	10-25517E	91	\N	\N	\N	T2a	Primary	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=976	172.6	\N	Re-excision path number for T10-23548	Sections show inflammation and granulation tissue, flanked by a proliferation of melanocytes arrayed irregularly along the junctional zone and in the dermis.	Ellipse, 7.5 x 3.0 x 1.2 cm, including a central black 1.5 x 1.0 cm lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with two sections in cassette A, one section each in cassettes B through H, and two sections in cassette I.	WLE MM	\N	\N	\N	In light of the increased thickness of the residual lesion, this melanoma should now be regarded as a pT2a lesion.  No lymphatic or perineural invasion is noted.  There is no evidence of regression.  Microsatellites are not identified.	HEALING BIOPSY SITE, WITH RESIDUAL MELANOMA, APPROXIMATELY 1.25 MILLIMETERS IN THICKNESS, COMPLETELY EXCISED	173619	157	\N	\N	10-25517	E	CCR-102	California Cancer Registry	IP918121	AirTable blocks_with_IP_info.csv
2535	19Rig750007.03.11.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	277	\N	\N	None	\N	CM-40	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
3061	2065/12 (2065/117 slide)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1207	\N	\N	None	\N	NM-027	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1746	14-01007	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	hand/foot	FFPE	\N	\N	\N	1324	\N	\N	14-1007	\N	OM-67	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1751	14-4953	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1325	\N	\N	14-4953	\N	OM-68	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1393	10-23548	91	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=971	172.6	\N	\N	Sections show a broad and poorly circumscribed proliferation of melanocytes involving the epidermis and dermis. It is composed largely of cells with ample vacuolated and pigmented cytoplasm and atypical nuclei. Single cells and nests are arrayed irregularly within the epidermis, with prominent foci of suprabasal scatter. There are clusters of similar melanocytes in the fibrotic superficial dermis, jointly with an infiltrate of lymphocytes and melanophages. Scattered mitoses are seen. There is solar elastosis as well.	Skin segment measuring 1.1 x 0.7 x 0.1 cm, trisected and entirely submitted.	PARTIAL BX 2 CM RED, BROWN, BLUE PATCH; MELANOCYTIC VS. BCC PIG	\N	\N	\N	Histopathologic features of possible prognostic importance include (but definitive assessment should be performed on the re-excision): Level: III/IV Tumor infiltrating lymphocytes: few, non-brisk Vascular or lymphatic invasion: not identified Mitotic rate: 1 per square mm Perineural invasion: not identified Ulceration: not identified Regression: not identified Microsatellite metastasis: not identified	MELANOMA, AT LEAST 0.4 MM IN THICKNESS, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	173619	157	\N	\N	10-23548	\N	CCR-102	California Cancer Registry	IP918121	AirTable blocks_with_IP_info.csv
1932	16-19895	36	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show melanocytes arrayed in compound fashion with acanthosis. The cells are generally fusiform and finely pigmented. There are large nests and fascicles of melanocytes in the epidermis, and maturing nests, cords, and fascicles of similar melanocytes are in the dermis and also in adnexa. A lymphohistiocytic infiltrate with admixed melanophages is also noted. Some pink globules can be found in the intraepidermal, although they are incompletely formed.	Five outside slides, AID16-01165 A (CN16-374) and one corresponding block.	IMPRESSION WAS PINK PAPULE; REQUEST FOR MOLECULAR ANALYSIS	\N	\N	\N	This biopsy does not demonstrate melanoma. Rather, it demonstrates characteristics that are typical of a variant of Spitz nevus, namely a Spitz nevus with underlying NTRK1 gene fusion. Immunostaining with NTRK1 has been completed and demonstrates avid positivity, and this labeling result corroborates that NTRK1 gene fusion is present. We additionally completed array-based comparative genomic hybridization (aCGH) to screen for copy number loss as a means to fully exclude melanoma from the differential diagnosis. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed a slightly noisy tracing (with possible/equivocal subthreshold loss in chromosome 19) with no significant chromosomal gains or losses. As background for understanding this result, note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. There is a small segmental loss in chromosome 1q at the location of the NTRK1 gene, and it seems likely that this is a consequence of gene fusion. The gene fusion partner cannot be identified by means of the aCGH technique.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. Rather, our results substantiate the diagnosis of Spitz nevus with underlying kinase gene fusion. Please note that this melanocytic tumor involves the edge of the biopsy, and thus conservative complete reexcision of this site can be considered as follow-up management. The intent of reexcision is simply to ensure complete removal and verify that persistence with additional transformation cannot ensue.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	COMPOUND SPITZ NEVUS WITH ASSOCIATED NTRK1 GENE FUSION, FOCALLY TRANSECTED AT THE PERIPHERY OF THE BIOPSY	273578	693	\N	\N	16-19895	\N	DP-56	CGH Validation	IP1619022	AirTable blocks_with_IP_info.csv
1306	08-8920B	61	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=983	172.4	\N	\N	Sections show a compound proliferation of atypical melanocytes, composed largely of cells with ample vacuolated and pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis including within adnexa, with conspicuous associated suprabasal scatter. There are also clusters of similar melanocytes in the superficial dermis, jointly with an infiltrate of lymphocytes and melanophages.	Ellipse, 2.4 x 1.2 x 0.5 cm, including a central dark brown 1.3 x 0.8 cm pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections in cassette A and three sections in cassette B, tips returned to container.	R/O MELANOMA	\N	\N	\N	This is a non-ulcerated primary melanoma with invasion limited to the papillary dermis (Clark's level III). The measurement of thickness does not include a periadventitial focus present at a deeper aspect, as such areas should not be included in this measurement. There is no evidence of associated vascular invasion, neurotropism, or regression. Additional excision is warrranted to ensure that this lesion has been removed completely.	MELANOMA, 0.7 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO WITHIN 1 MILLIMETER OF THE PERIPHERAL MARGIN	173404	158	\N	\N	08-8920	B	CCR-107	California Cancer Registry	IP717561	AirTable blocks_with_IP_info.csv
1305	08-8920A	61	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=982	172.4	\N	\N	Sections show a compound proliferation of atypical melanocytes, composed largely of cells with ample vacuolated and pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis including within adnexa, with conspicuous associated suprabasal scatter. There are also clusters of similar melanocytes in the superficial dermis, jointly with an infiltrate of lymphocytes and melanophages.	Ellipse, 2.4 x 1.2 x 0.5 cm, including a central dark brown 1.3 x 0.8 cm pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections in cassette A and three sections in cassette B, tips returned to container.	R/O MELANOMA	\N	\N	\N	This is a non-ulcerated primary melanoma with invasion limited to the papillary dermis (Clark's level III). The measurement of thickness does not include a periadventitial focus present at a deeper aspect, as such areas should not be included in this measurement. There is no evidence of associated vascular invasion, neurotropism, or regression. Additional excision is warrranted to ensure that this lesion has been removed completely.	MELANOMA, 0.7 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO WITHIN 1 MILLIMETER OF THE PERIPHERAL MARGIN	173404	158	\N	\N	08-8920	A	CCR-107	California Cancer Registry	IP717561	AirTable blocks_with_IP_info.csv
3023	99-19410B	78	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1002	232.6	\N	\N	Sections show nested and solitary melanocytes in irregular array\nwithin the epidermis, including some melanocytes arrayed above the\nbasal zone.  There is a permeative lymphocytic infiltrate in the\nsubjacent papillary dermis.	Cylindrical skin segment, 0.6 cm in diameter and 0.6 cm in thickness,\nbisected and entirely submitted.	A - 3.7 X 2.3 CM IRREGULARLY SHAPED PIGMENTED PLAQUE, HYPERPIGMENTATION, ? REGRESSION, WITH A SUPERFICIAL ULCERATION, B - DARKEST THICKEST AREA; CLINICAL DIAGNOSIS - A) - B) - SUPERFICIAL SPREADING MELANOMA	\N	\N	\N	\N	MELANOMA IN SITU, WITH SUPERIMPOSED LICHENOID INFLAMMATORY REACTION, EXTENDING TO THE PERIPHERAL MARGIN	173619	166	\N	\N	99-19410	B	CCR-134	California Cancer Registry	IP194943	AirTable blocks_with_IP_info.csv
3022	99-19410A	78	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1001	172.6	\N	\N	Sections show a compound proliferation of melanocytes, the junctional\ncomponent of which consists of nested and solitary melanocytes\narrayed irregularly along the junction.  Clusters of similar cells\nare present in the superficial dermis.  In some areas, the density of\nthe melanocytic proliferation along the junctional zone is markedly\ndiminished, and the subjacent papillary dermis is expanded by\nfibrosis accompanied by lymphocytes and melanophages.	Cylindrical skin segment, 0.6 cm in diameter and 0.5 cm in thickness,\nbisected and entirely submitted.	A - 3.7 X 2.3 CM IRREGULARLY SHAPED PIGMENTED PLAQUE, HYPERPIGMENTATION, ? REGRESSION, WITH A SUPERFICIAL ULCERATION, B - DARKEST THICKEST AREA; CLINICAL DIAGNOSIS - A) - B) - SUPERFICIAL SPREADING MELANOMA	\N	\N	\N	In light of the extensive changes of regression, the microstage measurement listed above may underestimate the prognostic risk of this lesion.  Final microstage measurements should be deferred until this lesion has been completely reexcised.	MELANOMA, AT LEAST 0.35 MM IN THICKNESS, WITH AREAS OF PARTIAL AND COMPLETE REGRESSION, AND WITH INVOLVEMENT OF THE PERIPHERAL BIOPSY MARGIN	173619	166	\N	\N	99-19410	A	CCR-134	California Cancer Registry	IP194943	AirTable blocks_with_IP_info.csv
1850	15-16261	59	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show nests, cords and strands of mostly small, round melanocytes extending into the superficial reticular dermis and around a folliculo-sebaceous unit. In the superficial reticular dermis are thickened collagen bundles, with some of the melanocytes in this area that are large, oval cells with pale cytoplasm and slightly enlarged vesicular nuclei.	Cylindrical skin segment, 0.5 cm in diameter and 0.2 cm in thickness, bisected and entirely submitted. CF/CF	R/O PIGMENTED BCC	\N	right proximal flexor forearm 	Scraping	This lesion has a minor, but not worrisome-appearing desmoplastic spitzoid component. A dermal margin is involved, but in my opinion, re-excision is not needed.	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	113605	1342	\N	\N	15-16261	\N	SM-013	Nevus Library	IP1487321	AirTable blocks_with_IP_info.csv
1188	05-37586A1	58	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1003	172.6	\N	\N	Sections show a compound proliferation of melanocytes with a biphasic pattern. One population consists of small melanocytes with small oval or spindled nuclei, positioned in the dermis and accompanied by foci of adipocytic metaplasia(melanocytic nevus).  The second population consists of nested and solitary melanocytes, some of which display atypical nuclei and most with ample vacuolated and pigmented cytoplasm, arrayed irregularly and in pagetoid fashion within the epidermis, with clusters of similar melanocytes within the superficial dermis. The dermal melanocytes are mostly arrayed in a central nodular focus with confluence of nests. There is a variable upper dermal infiltrate of lymphocytes and melanophages.	Ellipse, 4.6 x 1.9 x 1.6 cm, including a central 1.5 x 1.5 cm brown pigmented bump and an off-center 0.3 x 0.2 cm brown area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in cassette A1, two sections each in cassette A2 and A3, and six sections in cassette A4.	IRREG PIGMENTED LESION WITH RAISED AREA; R/O MM	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with a central nodular invasive component that involves the upper reticular dermis (Clark's level IV). There is no evidence of vascular invasion or perineural extension or regression in these sections, and I do not see any evidence of microsatellites in this excisional specimen. Further re-excision of this site is of course warranted to ensure that local eradication has been accomplished.	MELANOMA OF 3.0 MM IN THICKNESS, PRESENT IN CONTINUITY WITH A MELANOCYTIC NEVUS AND EXTENDING WITHIN THE EPIDERMIS QUITE NEAR TO THE PERIPHERAL MARGIN	173649	167	\N	\N	05-37586	A1	CCR-141	California Cancer Registry	IP514299	AirTable blocks_with_IP_info.csv
1382	10-11930B12	68	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.3	\N	\N	Sections show both rounded and angulated aggregations of atypical, peripherally palisaded basaloid cells in the dermis alongside fibromyxoid stroma. Clefts between the epithelium and stroma of the neoplasm are present.  Centrally there is a cystic space.  There is an associated lymphocytic infiltrate.	One outside slide, Q15927. One corresponding block received 3-4-10.	ADNEXAL VS. DILATED PORE	\N	\N	\N	Centrally this carcinoma shows a dilated cystic space.  Multiple level sections were examined and the carcinoma is visualized on the additional sections.  The initial section are non-diagnostic.	NODULAR/INFILTRATIVE BASAL CELL CARCINOMA	173305	2221	\N	\N	10-11930	B12	SYNAT66	2010-2017	IP906503	AirTable blocks_with_IP_info.csv
2315	18-34960	63	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.5	\N	\N	Sections show a broad and poorly circumscribed proliferation of large, epithelioid melanocytes with abundant dusty cytoplasm.  Nests of melanocytes are distributed at irregular intervals along the junctional zone, and are focally confluent.  There are foci in which single melanocytes predominate as well. There are some melanocytes scattered above the basal layer in such areas. The dermis contains aggregates of spindled to epithelioid melanocytes arranged in fascicles between collagen bundles.  The melanocytes show abundant pigmentation.	Skin segment measuring 1.2 x 1.0 x 0.2 cm, quadrisected and entirely submitted. RS/PL	PATIENT WITH A HISTORY OF MELANOMA (EXCISED 3 YRS AGO), 1.1 CM BROWN PLAQUE WITH VARIEGATED PIGMENT, ASYMMETRY AND AN IRREGULAR BORDER; MM VS. DYSPLASTIC NEVUS VS. OTHER	\N	\N	Scraping	An immunohistochemical stain for p16 demonstrated loss of this tumor suppressor protein in the entire lesion.  A Beta-catenin stain highlights nuclear staining in the deep penetrating nevus-like portion of the melanoma, and only membranous staining in the junctional and superficial portions. This findings suggests an acquired activating mutation in the Beta-catenin gene (see reference), which may account for the deep penetrating nature of the dermal component. Dr. McCalmont has also reviewed this case and agrees with the diagnosis.  A synoptic report of potential prognostic factors is listed below:  Procedure: Shave biopsy Microscopic tumor type: Superficial spreading and deep penetrating nevus-like features Breslow thickness: 1.7 mm Ulceration: absent Margins: peripheral negative and deep positive for invasive component Mitotic index: 1 mm/2 Microsatellitosis: not identified Vascular invasion: not identified Regression: absent Perineural invasion: not identified Pathologic staging (pTNM): pT2a  Reference:  Yeh I, Lang UE, Durieux E, Tee MK, Jorapur A, Shain AH, Haddad V, Pissaloux D, Chen X, Cerroni L, Judson RL, LeBoit PE, McCalmont TH, Bastian BC, de la FouchardiËre A. Combined activation of MAP kinase pathway and ﬂ-catenin signaling cause deep penetrating nevi. Nat Commun. 2017 Sep 21;8(1):644.	MELANOMA, 1.7 MM THICKNESS, NON-ULCERATED	152589	1185	\N	\N	18-34960	\N	NL-023	Nevus Library	IP1898705	AirTable blocks_with_IP_info.csv
1010	00-12952-3 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1061	\N	\N	None	\N	MD-184	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2482	19-115700A	48	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.6	\N	GNAQ	Sections show conventional melanocytes and deeply pigmented fusiform melanocytes that commingle.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted in A. PL/PL	A) R/O MIS VS. HYPERMELANOTIC, B) R/O DN, HISTORY OF CLARK'S	\N	\N	FFPE	This papular melanocytic nevus exhibits the commingling of conventional lentiginous melanocytic nevus with deeply pigmented melanocytic nevus resembling a blue nevus.	COMBINED MELANOCYTIC NEVUS	173620	1369	\N	\N	19-115700	A	SN-06	Sclerotic Nevi	IP2120444	AirTable blocks_with_IP_info.csv
1189	05-37586A3	58	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22989	172.6	\N	\N	Sections show a compound proliferation of melanocytes with a biphasic pattern. One population consists of small melanocytes with small oval or spindled nuclei, positioned in the dermis and accompanied by foci of adipocytic metaplasia(melanocytic nevus).  The second population consists of nested and solitary melanocytes, some of which display atypical nuclei and most with ample vacuolated and pigmented cytoplasm, arrayed irregularly and in pagetoid fashion within the epidermis, with clusters of similar melanocytes within the superficial dermis. The dermal melanocytes are mostly arrayed in a central nodular focus with confluence of nests. There is a variable upper dermal infiltrate of lymphocytes and melanophages.	Ellipse, 4.6 x 1.9 x 1.6 cm, including a central 1.5 x 1.5 cm brown pigmented bump and an off-center 0.3 x 0.2 cm brown area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in cassette A1, two sections each in cassette A2 and A3, and six sections in cassette A4.	IRREG PIGMENTED LESION WITH RAISED AREA; R/O MM	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with a central nodular invasive component that involves the upper reticular dermis (Clark's level IV). There is no evidence of vascular invasion or perineural extension or regression in these sections, and I do not see any evidence of microsatellites in this excisional specimen. Further re-excision of this site is of course warranted to ensure that local eradication has been accomplished.	MELANOMA OF 3.0 MM IN THICKNESS, PRESENT IN CONTINUITY WITH A MELANOCYTIC NEVUS AND EXTENDING WITHIN THE EPIDERMIS QUITE NEAR TO THE PERIPHERAL MARGIN	173649	167	\N	\N	05-37586	A3	CCR-141	California Cancer Registry	IP514299	AirTable blocks_with_IP_info.csv
2479	19-105255	57	\N	\N	\N	None	None	None	10	0	FFPE	\N	\N	216.7	\N	GNAQ	Sections show a melanocytic proliferation with two types of cells.  One population of melanocytes consists of small round cells with scant cytoplasm and monomorphous round to oval nuclei. Next to them are dendritic, pigmented melanocytes with inconspicuous nuclei and variable cytoplasmic pigmentation, accompanied by melanophages.	Skin segment measuring 0.4 x 0.3 x 0.1 cm. Submitted intact. BY/BY	A) COMPOUND NEVUS VS. BLUE NEVUS VS DYSPLASTIC NEVUS. 0.2 CM X 0.1 CM TWO-TONED BROWN PAPULE WITH IRREGULAR PIGMENT NETWORK ON DERMOSCOPY.	\N	\N	FFPE	None	COMBINED MELANOCYTIC NEVUS, WITH ORDINARY AND BLUE NEVUS ELEMENTS	173710	1379	\N	\N	19-105255	\N	SN-16	Sclerotic Nevi	IP162083	AirTable blocks_with_IP_info.csv
1438	11-1044	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1361	\N	\N	11-1044	\N	SMP55	Spitz Melanoma	\N	AirTable blocks_with_IP_info.csv
1948	16-37928A	49	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	172.0	\N	\N	There is an epithiotropic poorly circumscribed proliferation of atypical melanocytes, with a few small nests, irregularly distributed within the lamina propria and extending into the basal layer of the epithelium.  Some melanocytes have atypical nuclei.	Three outside slides, CS-16-003019 A1.	SUBSEQUENT EXCISIONS OF THE AREA SURROUNDING THE ORIGINAL EXCISION SITE (SEE DJ16-31388); MELANOMA	\N	oral mucosa	FFPE	Many thanks for asking me to review this case. I agree with your diagnosis that this lesion is a melanoma that shows epitheliotropic and angiotropic features.  The depth of invasion is 1.3 mm measured from the epithelial surface.  This diagnosis is supported by the MART-1 immunostain showing that the tumor cells are positive. Tumor is transected at the deep and one peripheral specimen margin.  Since tumor is present at the specimen margins, staging of the patient followed by wider excision to achieve clear margins by a clinician experienced in this disease would be an appropriate treatment option.  I also shared this H&E sections of this case with Dr. P. LeBoit who concurs.  I spoke to Dr. Peterson about this case on April 22, 2015.	MELANOMA TRANSECTED AT THE DEEP AND ONE PERIPHERAL SPECIMEN MARGIN	101005	1315	\N	\N	16-37928	A	OM-57	Oral Mucosa Lesions	IP1630601	AirTable blocks_with_IP_info.csv
1935	16-24795	\N	\N	\N	\N	\N	\N	\N	4	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1322	\N	\N	16-24795	\N	OM-64	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2616	20-026598	\N	\N	\N	\N	\N	\N	\N	4	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1323	\N	\N	20-26598	\N	OM-65	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1929	16-17132B	79	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26405,26406	172.6	\N	\N	Sections show an ulcerated nodular proliferation of markedly atypical melanocytes.  In the deeper dermal a second population of smaller melanocytes is noted.  Patchy band like infiltrates of lymphocytes and melanophages are present and no proliferation of melanocytes is noted along the dermo-epidermal junction.	Oriented oval excision, 2.3 x 2.2 x 0.7 cm, including a central 2.0 x 1.5 cm raised area. With the orienting notch placed to the left and designated 9 o'clock by the grosser. The 9-12-3 o'clock margin is inked blue and the 3-6-9 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections in A, three sections in B and three sections plus one fragment in C. PL/PL	2.2 X 1.2 CM BLUE / PINK ERODED NODULE; MELANOMA VS. OTHER MALIGNANCY	\N	MELANOMA, APPROXIMATELY 4.6 MILLIMETERS IN THICKNESS	FFPE	I confirmed with melanocytic lineage of this lesion with a positive Melan-A stain.  This stain demonstrates loss of junctional melanocytes compatible with complete regression of the junctional component of this lesion.  The dermal component consist of large nodules of markedly pleomorphic melanocytes.  In the deeper dermis there are clusters of smaller melanocytes indicating a melanocytic nevus.  The large nodular area of melanoma has been completely excised.  Changes of regression extends to all peripheral margins. Diagnostic features of note include:  Procedure: Excision Tumor site: Arm Microscopic tumor type: Nodular Breslow thickness: 4.6 millimeters Ulceration: Present, extensive Margins, peripheral and deep: See above Mitotic index: 4/10 hpf Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Present Pathologic Staging (pTNM): pT4b	MELANOMA, APPROXIMATELY 4.6 MILLIMETERS IN THICKNESS	173688	1142	\N	\N	16-17132	B	ME-47	Melanoma Epigenetics	IP1616233	AirTable blocks_with_IP_info.csv
1414	10-63051C	52	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show central fibrosing granulation tissue and early scar coupled with a mixed infiltrate below an ulcer, and no evidence of an atypical melanocytic proliferation remains in contiguity with this. There are inflamed parakeratosis and exudate above the ulcer base.	Oriented ellipse, 7.1 x 3.0 x 1.0 cm, including a central 2.1 x 2.0 cm lesion, and a satellite dark pigment measuring 1.0 x 0.5 cm. With the orienting superior edge pre-inked red, the near margin is inked yellow during grossing. The specimen is serially sectioned perpendicular to the long axis from left to right poles and submitted with two sections in cassette A, one section each in cassettes B-K, two sections in L, and three sections in cassette M; tips in vial.	MELANOMA EXC	\N	\N	\N	None	POST-SURGICAL ULCERATION, INFLAMMATION, AND SCARRING, WITH NO EVIDENCE OF RESIDUAL MELANOMA	139524	2088	\N	\N	10-63051	C	SYNAT69	2010-2017	IP953239	AirTable blocks_with_IP_info.csv
3118	79447-b	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-007_1.2	\N	\N	\N	\N	Skin	\N	\N	\N	\N	5	\N	\N	None	\N	AM2-007	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3120	79447-d	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-007_1.4	\N	\N	\N	\N	Skin	Punch	\N	\N	\N	5	\N	\N	None	\N	AM2-007	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1545	11B9724 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1204	\N	\N	None	\N	NM-017	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3119	79447-c	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-007_1.3	\N	\N	\N	\N	Skin	Punch	\N	\N	\N	5	\N	\N	None	\N	AM2-007	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1156	05-5976C	53	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections demonstrate a central zone of scar, corresponding to the site of the previous biopsy.  There is a broad and poorly circumscribed proliferation of melanocytes within the epidermis adjacent to the scar, with extensive pagetoid scatter of single cells.  The papillary dermis is markedly thickened and fibrotic.  There are areas in which cords of melanocytes with relatively small, monomorphous nuclei are arranged as horizontally oriented strands beneath a thinned epidermis.  These cells merge with slightly smaller, subjacent ones that are arranged discretely around small vessels and nerve fibers in the upper reticular dermis.	Ellipse measuring 5.9 x 2.7 x 0.7 cm, including 1.8 x 1.1 cm central raised dark pigmented area. With margins inked blue the specimen is serially sectioned perpendicular to the long axis with two central sections each submitted in cassettes A, B, C, D, remainder returned to container.	RE EXCISION MM CHECK MARGINS	\N	\N	\N	There is extensive residual melanoma, both in situ and invasive.  The invasive component consists of small, round or nevoid melanoma cells that merge with the cells of a preexistent nevus near the base of the neoplasm.  The thickness appears slightly greater than in the initial biopsy.  There are no adverse histopathologic findings, such as ulceration, vascular invasion or significant zones of regression (some small ones are present).  The excision appears complete with adequate margins.	SCAR, WITH RESIDUAL MELANOMA, APPROXIMATELY 0.8 MM IN THICKNESS	139522	172	\N	\N	05-5976	C	CCR-148	California Cancer Registry	IP476117	AirTable blocks_with_IP_info.csv
1544	11B2562 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1205	\N	\N	None	\N	NM-018	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3083	11522/18	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1206	\N	\N	None	\N	NM-019	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1154	05-5976A	53	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1019	172.5	\N	\N	Sections demonstrate a central zone of scar, corresponding to the site of the previous biopsy.  There is a broad and poorly circumscribed proliferation of melanocytes within the epidermis adjacent to the scar, with extensive pagetoid scatter of single cells.  The papillary dermis is markedly thickened and fibrotic.  There are areas in which cords of melanocytes with relatively small, monomorphous nuclei are arranged as horizontally oriented strands beneath a thinned epidermis.  These cells merge with slightly smaller, subjacent ones that are arranged discretely around small vessels and nerve fibers in the upper reticular dermis.	Ellipse measuring 5.9 x 2.7 x 0.7 cm, including 1.8 x 1.1 cm central raised dark pigmented area. With margins inked blue the specimen is serially sectioned perpendicular to the long axis with two central sections each submitted in cassettes A, B, C, D, remainder returned to container.	RE EXCISION MM CHECK MARGINS	\N	\N	\N	There is extensive residual melanoma, both in situ and invasive.  The invasive component consists of small, round or nevoid melanoma cells that merge with the cells of a preexistent nevus near the base of the neoplasm.  The thickness appears slightly greater than in the initial biopsy.  There are no adverse histopathologic findings, such as ulceration, vascular invasion or significant zones of regression (some small ones are present).  The excision appears complete with adequate margins.	SCAR, WITH RESIDUAL MELANOMA, APPROXIMATELY 0.8 MM IN THICKNESS	139522	172	\N	\N	05-5976	A	CCR-148	California Cancer Registry	IP476117	AirTable blocks_with_IP_info.csv
1155	05-5976B	53	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1020	172.5	\N	\N	Sections demonstrate a central zone of scar, corresponding to the site of the previous biopsy.  There is a broad and poorly circumscribed proliferation of melanocytes within the epidermis adjacent to the scar, with extensive pagetoid scatter of single cells.  The papillary dermis is markedly thickened and fibrotic.  There are areas in which cords of melanocytes with relatively small, monomorphous nuclei are arranged as horizontally oriented strands beneath a thinned epidermis.  These cells merge with slightly smaller, subjacent ones that are arranged discretely around small vessels and nerve fibers in the upper reticular dermis.	Ellipse measuring 5.9 x 2.7 x 0.7 cm, including 1.8 x 1.1 cm central raised dark pigmented area. With margins inked blue the specimen is serially sectioned perpendicular to the long axis with two central sections each submitted in cassettes A, B, C, D, remainder returned to container.	RE EXCISION MM CHECK MARGINS	\N	\N	\N	There is extensive residual melanoma, both in situ and invasive.  The invasive component consists of small, round or nevoid melanoma cells that merge with the cells of a preexistent nevus near the base of the neoplasm.  The thickness appears slightly greater than in the initial biopsy.  There are no adverse histopathologic findings, such as ulceration, vascular invasion or significant zones of regression (some small ones are present).  The excision appears complete with adequate margins.	SCAR, WITH RESIDUAL MELANOMA, APPROXIMATELY 0.8 MM IN THICKNESS	139522	172	\N	\N	05-5976	B	CCR-148	California Cancer Registry	IP476117	AirTable blocks_with_IP_info.csv
1904	15-122795	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	hand/foot	FFPE	\N	\N	\N	1326	\N	\N	15-122795	\N	OM-69	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1969	16-85059	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	hand/foot	FFPE	\N	\N	\N	1327	\N	\N	16-85059	\N	OM-70	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2202	17-91629	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	hand/foot	FFPE	\N	\N	\N	1328	\N	\N	17-91629	\N	OM-71	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2272	17-120984	16	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show a wedge shaped proliferation of spindled melanocytes with monomorphous nuclei, positioned between thickened collagen bundles and accompanied by melanophages.	Cylindrical skin segment, 0.5 cm in diameter and 0.2 cm in thickness, bisected and entirely submitted. RS/RS	R/O DYSPLASTIC NEVUS	\N	right dorsal hand	Scraping	None	BLUE NEVUS	173663	1335	\N	\N	17-120984	\N	SM-005	Nevus Library	IP1851544	AirTable blocks_with_IP_info.csv
1504	11-61046	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	779	\N	\N	11-61046	\N	KF-08	Fusion RNA	\N	AirTable blocks_with_IP_info.csv
2932	92-1608A	43	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.5	\N	\N	There is a broad, asymmetrical proliferation of melanocytes with\nextensive areas of partial and complete regression, the latter\nevidenced by a thickened and fibrotic papillary dermis, diminished\nrete ridge pattern, and numerous melanophages.  In section C there\nare clusters of melanocytes with atypical nuclei and abundant\ncytoplasm that contain dusty melanin pigment, both at the d-e\njunction and within the superficial dermis.  Beneath the band of\nmelanophages is the residuum of a melanocytic nevus, with small round\nand s-shaped spindled melanocytes.	Ellipse, 4 x 1.9 x 0.8 cm, with surface showing  1 x 1.3 cm irregular\nblack-brown macular patch, tips returned to container, sections\nadjacent to tip embedded in block A, remainder serially sectioned\nwith two sectioned each embedded in blocks B-C, margins inked green.	IRREGULAR BORDERS AND PIGMENTATION OF A MOLE ON UPPER BACK.  MEASURING 1.6 CM IN DIAMETER.  PRESENT FOR MANY YEARS, BUT NO CHANGE IN SIZE, COLOR ON BORDER. CLINICAL DIAGNOSIS - MALIGNANT MELANOMA	\N	\N	\N	\N	MALIGNANT MELANOMA, SUPERFICIAL SPREADING TYPE, 0.5 MM IN THICKNESS, ARISING IN A PRE-EXISTANT MELANOCYTIC NEVUS AND SHOWING LARGE AREAS OF COMPLETE REGRESSION	333504	175	\N	\N	92-1608	A	CCR-155	California Cancer Registry	IP11358	AirTable blocks_with_IP_info.csv
2933	92-1608B	43	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	There is a broad, asymmetrical proliferation of melanocytes with extensive areas of partial and complete regression, the latter evidenced by a thickened and fibrotic papillary dermis, diminished rete ridge pattern, and numerous melanophages.  In section C there are clusters of melanocytes with atypical nuclei and abundant cytoplasm that contain dusty melanin pigment, both at the d-e junction and within the superficial dermis.  Beneath the band of melanophages is the residuum of a melanocytic nevus, with small round and s-shaped spindled melanocytes.	Ellipse, 4 x 1.9 x 0.8 cm, with surface showing  1 x 1.3 cm irregular\nblack-brown macular patch, tips returned to container, sections\nadjacent to tip embedded in block A, remainder serially sectioned\nwith two sectioned each embedded in blocks B-C, margins inked green.	IRREGULAR BORDERS AND PIGMENTATION OF A MOLE ON UPPER BACK.  MEASURING 1.6 CM IN DIAMETER.  PRESENT FOR MANY YEARS, BUT NO CHANGE IN SIZE, COLOR ON BORDER. CLINICAL DIAGNOSIS - MALIGNANT MELANOMA	\N	\N	\N	None	MALIGNANT MELANOMA, SUPERFICIAL SPREADING TYPE, 0.5 MM IN THICKNESS, ARISING IN A PRE-EXISTANT MELANOCYTIC NEVUS AND SHOWING LARGE AREAS OF COMPLETE REGRESSION	333504	175	\N	\N	92-1608	B	CCR-155	California Cancer Registry	IP11358	AirTable blocks_with_IP_info.csv
1420	10-83193	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	114	\N	\N	10-83193	\N	BN-010	Nevus Library	\N	AirTable blocks_with_IP_info.csv
1645	12-51532	42	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.2	\N	\N	Sections show a predominantly dermal proliferation of small melanocytes with round to oval nuclei, coupled with larger spindled cells associated with thickened collagen bundles and melanophages. There is increased cellularity near adnexal structures. In addition, spongiosis of the overlying epidermis is apparent.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted.  SL/SL	? ATYPIA	\N	left ear 	Scraping	This nevus has features of both a blue nevus and of a intradermal melanocytic nevus with congenital features.	COMBINED MELANOCYTIC NEVUS	173201	1336	\N	\N	12-51532	\N	SM-006	Nevus Library	IP368502	AirTable blocks_with_IP_info.csv
1119	04-12137A	86	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1259	172.5	\N	\N	Sections show inflammation and granulation tissue, flanked by a proliferation of melanocytes arrayed irregularly along the junctional zone and in the dermis.  The epidermal component consists of single cells and nests arrayed broadly and confluently within the epithelium, with considerable suprabasal scatter of melanocytes.  There are irregular nests in the papillary and reticular dermis below these areas of intraepidermal involvement, and many of the dermal nests are enveloped by considerable fibrosis.  In some areas, a lichenoid lymphocytic infiltrate expands the papillary dermis, and in other areas, the papillary dermis is fibrotic.	Oriented ellipse 7.5 x 4.5 x 1.5 cm. The far left margin is preinked black. The far right margin is preinked green. The near left margin is preinked red. The near right margin is preinked blue. The intersection of the black and green is labeled as s. The intersection of the the red and blue is labeled as i. The intersection of the black and red is labeled as med. The intersection of the green and blue is labeled as lat. The specimen is bisected along the long axis. The two equal sections of the specimen are serially sectioned perpendicular to the long axis from the left to the right and entirely submitted with 3 sections each in cassettes A, H, and I and 2 sections each in cassettes B, C, D, E, F, G, J, K, L, M, N, O, P, and Q	RE-EXC MM	\N	\N	\N	Upon complete excision, the residual melanoma in this reexcision specimen shows findings identical to those noted in the initial partial biopsy.  In addition, there are focal changes of partial and complete regression in these sections, but I believe that the microstage measurement above is fully representative of the prognosis of this melanoma.  Final surgical margins are uninvolved. This report was reissued on 3/29/2004 to forward a copy to Dr. Malani's office.	RESIDUAL MELANOMA OF 2.3 MILLIMETERS IN THICKNESS, COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE FREE OF MELANOMA CELLS)	173527	177	\N	\N	04-12137	A	CCR-158	California Cancer Registry	IP426119	AirTable blocks_with_IP_info.csv
2269	17-120487A	48	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show a symmetric predominantly dermal proliferation of melanocytes with nests of small round melanocytes in the superficial dermis. Below, melanocytes are positioned in discrete aggregates or singly between thickened collagen bundles in the reticular dermis with a wedge-shaped profile.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted in A. KC/KC	A) 4 X 4 MM BROWN ERYTHEMATOUS PAPULE; NEVUS, R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, B) 4 X 4 MM SLIGHTLY IRREGULAR TAN BROWN MACULE; NEVUS, R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR	\N	left anterior upper arm	Scraping	\N	PREDOMINANTLY INTRADERMAL NEVUS	173649	1347	\N	\N	17-120487	A	SM-018	Nevus Library	IP349912	AirTable blocks_with_IP_info.csv
1121	04-12137E	86	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1263	172.5	\N	\N	Sections show inflammation and granulation tissue, flanked by a proliferation of melanocytes arrayed irregularly along the junctional zone and in the dermis.  The epidermal component consists of single cells and nests arrayed broadly and confluently within the epithelium, with considerable suprabasal scatter of melanocytes.  There are irregular nests in the papillary and reticular dermis below these areas of intraepidermal involvement, and many of the dermal nests are enveloped by considerable fibrosis.  In some areas, a lichenoid lymphocytic infiltrate expands the papillary dermis, and in other areas, the papillary dermis is fibrotic.	Oriented ellipse 7.5 x 4.5 x 1.5 cm. The far left margin is preinked black. The far right margin is preinked green. The near left margin is preinked red. The near right margin is preinked blue. The intersection of the black and green is labeled as s. The intersection of the the red and blue is labeled as i. The intersection of the black and red is labeled as med. The intersection of the green and blue is labeled as lat. The specimen is bisected along the long axis. The two equal sections of the specimen are serially sectioned perpendicular to the long axis from the left to the right and entirely submitted with 3 sections each in cassettes A, H, and I and 2 sections each in cassettes B, C, D, E, F, G, J, K, L, M, N, O, P, and Q	RE-EXC MM	\N	\N	\N	Upon complete excision, the residual melanoma in this reexcision specimen shows findings identical to those noted in the initial partial biopsy.  In addition, there are focal changes of partial and complete regression in these sections, but I believe that the microstage measurement above is fully representative of the prognosis of this melanoma.  Final surgical margins are uninvolved. This report was reissued on 3/29/2004 to forward a copy to Dr. Malani's office.	RESIDUAL MELANOMA OF 2.3 MILLIMETERS IN THICKNESS, COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE FREE OF MELANOMA CELLS)	173527	177	\N	\N	04-12137	E	CCR-158	California Cancer Registry	IP426119	AirTable blocks_with_IP_info.csv
1120	04-12137D	86	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1262	172.5	\N	\N	Sections show inflammation and granulation tissue, flanked by a proliferation of melanocytes arrayed irregularly along the junctional zone and in the dermis.  The epidermal component consists of single cells and nests arrayed broadly and confluently within the epithelium, with considerable suprabasal scatter of melanocytes.  There are irregular nests in the papillary and reticular dermis below these areas of intraepidermal involvement, and many of the dermal nests are enveloped by considerable fibrosis.  In some areas, a lichenoid lymphocytic infiltrate expands the papillary dermis, and in other areas, the papillary dermis is fibrotic.	Oriented ellipse 7.5 x 4.5 x 1.5 cm. The far left margin is preinked black. The far right margin is preinked green. The near left margin is preinked red. The near right margin is preinked blue. The intersection of the black and green is labeled as s. The intersection of the the red and blue is labeled as i. The intersection of the black and red is labeled as med. The intersection of the green and blue is labeled as lat. The specimen is bisected along the long axis. The two equal sections of the specimen are serially sectioned perpendicular to the long axis from the left to the right and entirely submitted with 3 sections each in cassettes A, H, and I and 2 sections each in cassettes B, C, D, E, F, G, J, K, L, M, N, O, P, and Q	RE-EXC MM	\N	\N	\N	Upon complete excision, the residual melanoma in this reexcision specimen shows findings identical to those noted in the initial partial biopsy.  In addition, there are focal changes of partial and complete regression in these sections, but I believe that the microstage measurement above is fully representative of the prognosis of this melanoma.  Final surgical margins are uninvolved. This report was reissued on 3/29/2004 to forward a copy to Dr. Malani's office.	RESIDUAL MELANOMA OF 2.3 MILLIMETERS IN THICKNESS, COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE FREE OF MELANOMA CELLS)	173527	177	\N	\N	04-12137	D	CCR-158	California Cancer Registry	IP426119	AirTable blocks_with_IP_info.csv
1090	03-29330A	83	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1276	172.6	\N	\N	Sections show a broad and poorly circumscribed proliferation of atypical melanocytes, arranged as single cells within the basal layer of the epidermis, flanking a compact, multinodular proliferation of larger melanocytes that do not mature (diminish in size) with descent into the dermis.  The epidermis over the nodule is thinned.  There are some melanocytes scattered above the basal layer just to the side of the nodule.	Oval excision, 5.8 x 2.3 x 1.4 cm (including fat) and 3.0 x 2.5 x 1.4 cm (area with epidermis), including central 2.5 x 2.0 cm dark brown pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in cassettes A, B and D, and one section each in cassettes C, E and F, remainder returned to container.	2.2 X 2.7 IRREGULAR BLACK PIGMENTED MACULE EXCISED WITH 5 MM MARGIN, MELANOMA WITH CENTRAL PAPULE WITHIN A LESION	\N	\N	\N	Melanoma in situ extends to within 2 mm. of the periphery of the specimen.   There are no microscopic findings other than a high mitotic rate (see below) that would substantially change the prognosis indicated by the tumor thickness listed above.  The epidermis, while strikingly thinned, is not truly ulcerated. Histopathologic features of possible prognostic importance include:  Level: III Tumor infiltrating lymphocytes: absent Vascular or lymphatic invasion: absent Mitotic rate: high Perineural invasion: absent Ulceration: absent (see above comment) Regression: absent Microsatellite metastasis: absent	MELANOMA, 1.7 MM  IN THICKNESS	173601	178	\N	\N	03-29330	A	CCR-159	California Cancer Registry	IP387643	AirTable blocks_with_IP_info.csv
1091	03-29330B	83	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1277	172.6	\N	\N	Sections show a broad and poorly circumscribed proliferation of atypical melanocytes, arranged as single cells within the basal layer of the epidermis, flanking a compact, multinodular proliferation of larger melanocytes that do not mature (diminish in size) with descent into the dermis.  The epidermis over the nodule is thinned.  There are some melanocytes scattered above the basal layer just to the side of the nodule.	Oval excision, 5.8 x 2.3 x 1.4 cm (including fat) and 3.0 x 2.5 x 1.4 cm (area with epidermis), including central 2.5 x 2.0 cm dark brown pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in cassettes A, B and D, and one section each in cassettes C, E and F, remainder returned to container.	2.2 X 2.7 IRREGULAR BLACK PIGMENTED MACULE EXCISED WITH 5 MM MARGIN, MELANOMA WITH CENTRAL PAPULE WITHIN A LESION	\N	\N	\N	Melanoma in situ extends to within 2 mm. of the periphery of the specimen.   There are no microscopic findings other than a high mitotic rate (see below) that would substantially change the prognosis indicated by the tumor thickness listed above.  The epidermis, while strikingly thinned, is not truly ulcerated. Histopathologic features of possible prognostic importance include:  Level: III Tumor infiltrating lymphocytes: absent Vascular or lymphatic invasion: absent Mitotic rate: high Perineural invasion: absent Ulceration: absent (see above comment) Regression: absent Microsatellite metastasis: absent	MELANOMA, 1.7 MM  IN THICKNESS	173601	178	\N	\N	03-29330	B	CCR-159	California Cancer Registry	IP387643	AirTable blocks_with_IP_info.csv
1982	16-98130	71	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.6	\N	\N	Sections show a predominantly intradermal proliferation of small melanocytes with round to oval nuclei that mature (diminish in size) with descent in the dermis.  The overlying epidermis shows elongated rete that intertwine.	Cylindrical skin segment, 0.4 cm in diameter and 0.2 cm in thickness, bisected and entirely submitted. CF/CF	4 X 4 MM BROWN PAP; SK VS. CMN R/O ATYPIA	\N	\N	\N	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	106678	550	\N	\N	16-98130	\N	DN-075	Dysplastic Nevi	IP166471	AirTable blocks_with_IP_info.csv
1092	03-30961A	47	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1284	172.5	\N	\N	Sections show a broad, compound proliferation of melanocytes.  In most of the lesion, single cells and small nests are present at the sides and bases of elongated rete ridges.  Centrally, there are some small, round melanocytes in the papillary dermis, but (best seen in slide B) there is a zone in which the surface is elevated, and the papillary dermis is thickened by melanocytes with striking nuclear pleomorphism.  Many of the cells have large, vesicular nuclei, large (and sometimes multiple) eosinophilic nucleoli, show little maturation with descent and contain mitotic figures.  There is some pagetoid spread of similar melanocytes in the epidermis in this small, papular area.	Ellipse measuring 2.5 x 1.4 x 0.5 cm, with irregular border brown pigment measuring 1.5 x 1.0 cm. The margin is inked blue. The specimen is serially sectioned and submitted with four sections each in cassettes A and B.	15 X 9 MM IRREGULAR LESION WITH CENTRAL PAPULAR COMPONENT; MIS, R/O MELANOMA	\N	\N	\N	This lesion apparently arose in the center of a Clark's or dysplastic nevus.  This is an unusual event, as most melanomas that arise in such nevi do so toward one side or the other.	MELANOMA, 0.7 MM IN THICKNESS, ARISING IN A MELANOCYTIC NEVUS OF THE CLARK'S OR DYSPLASTIC TYPE	173528	179	\N	\N	03-30961	A	CCR-162	California Cancer Registry	IP389274	AirTable blocks_with_IP_info.csv
1093	03-30961B	47	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1285	172.5	\N	\N	Sections show a broad, compound proliferation of melanocytes.  In most of the lesion, single cells and small nests are present at the sides and bases of elongated rete ridges.  Centrally, there are some small, round melanocytes in the papillary dermis, but (best seen in slide B) there is a zone in which the surface is elevated, and the papillary dermis is thickened by melanocytes with striking nuclear pleomorphism.  Many of the cells have large, vesicular nuclei, large (and sometimes multiple) eosinophilic nucleoli, show little maturation with descent and contain mitotic figures.  There is some pagetoid spread of similar melanocytes in the epidermis in this small, papular area.	Ellipse measuring 2.5 x 1.4 x 0.5 cm, with irregular border brown pigment measuring 1.5 x 1.0 cm. The margin is inked blue. The specimen is serially sectioned and submitted with four sections each in cassettes A and B.	15 X 9 MM IRREGULAR LESION WITH CENTRAL PAPULAR COMPONENT; MIS, R/O MELANOMA	\N	\N	\N	This lesion apparently arose in the center of a Clark's or dysplastic nevus.  This is an unusual event, as most melanomas that arise in such nevi do so toward one side or the other.	MELANOMA, 0.7 MM IN THICKNESS, ARISING IN A MELANOCYTIC NEVUS OF THE CLARK'S OR DYSPLASTIC TYPE	173528	179	\N	\N	03-30961	B	CCR-162	California Cancer Registry	IP389274	AirTable blocks_with_IP_info.csv
3025	99-23502A	64	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1287	172.6	\N	\N	Sections show skin with severe solar elastosis, and a broad,\nasymmetrical and poorly circumscribed proliferation of atypical\nmelanocytes, focally in a pagetoid pattern within the epidermis and\nforming a plaque - like mass in the papillary dermis without\nevidence of maturation.	Ellipse, measuring 5..0 x 2.0 x 0.8 cm, serially sectioned and\nsubmitted with four sections in block A, three sections each in\nblocks B and C, and six sections in block D, margins pre-inked in\nblack.	1.1 X 0.9 CM BLACK BARELY PALPABLE PLAQUE, MOLE AT SITE X BIRTH OR EARLY CHILDHOOD, MOLE STARTED TO CHANGE X EARLY THIS YEAR, LESION EXCISED WITH 1CM MARGIN	\N	\N	\N	I saw no evidence of a congenital nevus in these sections, but it is possible that the melanoma destroyed a superficial nevus.	MELANOMA, 1.1 MM IN THICKNESS, COMPLETELY EXCISED (SURGICAL MARGINS ARE FREE OF NEOPLASM)	173601	180	\N	\N	99-23502	A	CCR-163	California Cancer Registry	IP199035	AirTable blocks_with_IP_info.csv
2246	17-115105	31	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.0	\N	\N	Sections show a melanocytic proliferation composed of cells with two distinct cytologic appearances. There may also be a third in the form of dendritic cells. There are melanophages scattered in the upper dermis as well.	Skin segment measuring 0.5 x 0.5 x 0.2 cm, bisected and entirely submitted. HD/HD	SHAVE REMOVAL OF 0.5 X 0.6 CMN DARK BROWN PAPULE; COMPOUND NEVUS, R/O MM	\N	right upper lip	Scraping	This biphasic melanocytic nevus includes the commingling of conventional melanocytic nevus with blue nevus. I considered the possibility that deep penetrating nevus might be present as well, but bcl-1 staining is negative, which suggests this is not the case.	COMBINED MELANOCYTIC NEVUS	100031	1341	\N	\N	17-115105	\N	SM-012	Nevus Library	IP1271461	AirTable blocks_with_IP_info.csv
3206	Cell-Line_Xu-16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1813	\N	\N	None	\N	SYNAT153	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3026	99-23502C	64	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1289	172.6	\N	\N	Sections show skin with severe solar elastosis, and a broad, asymmetrical and poorly circumscribed proliferation of atypical melanocytes, focally in a pagetoid pattern within the epidermis and forming a plaque - like mass in the papillary dermis without evidence of maturation.	Ellipse, measuring 5..0 x 2.0 x 0.8 cm, serially sectioned and\nsubmitted with four sections in block A, three sections each in\nblocks B and C, and six sections in block D, margins pre-inked in\nblack.	1.1 X 0.9 CM BLACK BARELY PALPABLE PLAQUE, MOLE AT SITE X BIRTH OR EARLY CHILDHOOD, MOLE STARTED TO CHANGE X EARLY THIS YEAR, LESION EXCISED WITH 1CM MARGIN	\N	\N	\N	I saw no evidence of a congenital nevus in these sections, but it is possible that the melanoma destroyed a superficial nevus.	MELANOMA, 1.1 MM IN THICKNESS, COMPLETELY EXCISED (SURGICAL MARGINS ARE FREE OF NEOPLASM)	173601	180	\N	\N	99-23502	C	CCR-163	California Cancer Registry	IP199035	AirTable blocks_with_IP_info.csv
1047	02-8746A	49	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	172.5	\N	\N	Sections show a broad, asymmetrical compound proliferation of\nmelanocytes featuring a broad area in which the papillary dermis is\nstrikingly fibrotic, with a diminished rete ridge pattern.  Compact\nnests of relatively small melanocytes are present throughout this\nzone, and several contain mitotic figures.  At the other side of the\nlesion is a dome shaped area with spindled melanocytes superficially\nand small, round ones in the deep portion.  Again, some superficial\nmelanocytes are in mitosis.  Maturation with descent appears to be\npresent in this area.  Melanocytes at the base of this zone are\npresent as strands between reticular dermal collagen bundles or\naround small vessels.  A small focus of pagetoid spread is evident at\none edge, with not fibrosis underneath it (as would be present in a\npersistent nevus).	Ellipse measuring 3.2 x 1.2 x 0.4 cm including central dark brown and\nbrown 1.3 x 1.1 cm pigmented area.  With margins inked blue, five\ncentral representative sections are submitted in cassette A and four\nsections in cassette B, tips returned to container.	DYSPLASTIC NEVUS; MELANOMA	\N	\N	Scraping	3/12/2002:  Per my telephone conversation with Dr. Denny Tuffanelli yesterday, there is no history of a previous biopsy or trauma.  In spending more time with these sections today and yesterday, and in reviewing them with my associate, Dr. Timothy McCalmont, I think that this is an unusual melanoma.  There may be evidence of a pre-existent congenital nevus at the base of the specimen, and I did not measure the cells that I believe represent the nevus.  The fibrosis may reflect regression.  I have updated the microscopic description below to incorporate new observations.   3/4/2002:  Some features suggest that this is a persistent nevus, in which the papillary dermis has been altered by a shave biopsy or trauma.  We have a record of a previous nevus from the torso but are unsure as to whether it is from the same site.  Could you kindly inform us whether this is the case, and if not, whether there could be a previous biopsy at this site? If there is none in your files, could you ask the patient?	MELANOMA, 1.05 MM. IN THICKNESS	173570	186	\N	\N	02-8746	A	CCR-206	California Cancer Registry	IP172758	AirTable blocks_with_IP_info.csv
1709	13-25110A1	29	\N	\N	\N	T2a	Primary	\N	\N	\N	\N	\N	\N	172.7	\N	\N	There is a proliferation of melanocytes, some of which have atypical nuclei and ample pigmented cytoplasm, arranged in an irregular pattern along the junction and within the dermis.  Suprabasal scatter of melanocytes is prominent in some areas.  In other areas the melanocytes are bland and mature with descent in the dermis.  There is an infiltrate of lymphocytes and melanophages.	Elliptical excision, 2.8 x 1.3 x 0.9 cm, including a central 1.3 x 1.1 cm brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and submitted with five sections each in A1 and A2. Tips reserved. CF/CF	A) 1.4 X 1.6 CM IRREGULAR/ASYMMETRIC BLACK-PIGMENTED PAPULE WITH RAISED CENTER; MELANOMA, NARROW EXCISIONAL BIOPSY (2 MM MARGIN), B) 0.5 X 0.5 CM ERYTHEMATOUS PAPULE; PYOGENIC GRANULOMA, POSSIBLE ANGIOMA	\N	\N	\N	Melanoma in situ is present < 1 millimeter from the edge of the specimen.  This is a non-ulcerated melanoma.  Based on the 2009 AJCC melanoma staging system, this is a pT2a lesion.	MELANOMA, 1.2 MILLIMETERS IN THICKNESS, COMPLETELY BUT NARROWLY EXCISED	122741	1988	\N	\N	13-25110	A1	SYNAT349	2010-2017	IP1209855	AirTable blocks_with_IP_info.csv
2982	96-18458F	59	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1302	172.4	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly within the epidermis, with foci of pagetoid upward scatter.  Some melanocytes have atypical nuclei.  Aggregations of similar melanocytes are present in the dermis.  There are sheets of atypical melanocytes in the superficial dermis.	Ellipse, 6 x 2.8 x 1 cm, central portion serially sectioned and\nsubmitted with one section each in blocks A through H, margins inked\nblue, tips returned to container.	BLEEDING FRIABLE NODULE; CLINICAL DIAGNOSIS - MELANOMA, DATA ON FILE	\N	\N	\N	This is a high risk primary lesion.  As there is extensive ulceration, the microstage measurment probably underestimates the prognostic risk of this lesion.	MELANOMA, AT LEAST 3.5 MM IN THICKNESS, WITH INTRAEPIDERMAL MELANOMA EXTENDING NEAR TO THE PERIPHERAL BIOPSY MARGIN	104444	194	\N	\N	96-18458	F	CCR-215	California Cancer Registry	IP95222	AirTable blocks_with_IP_info.csv
2981	96-18458E	59	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1301	172.4	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly within the epidermis, with foci of pagetoid upward scatter.  Some melanocytes have atypical nuclei.  Aggregations of similar melanocytes are present in the dermis.  There are sheets of atypical melanocytes in the superficial dermis.	Ellipse, 6 x 2.8 x 1 cm, central portion serially sectioned and\nsubmitted with one section each in blocks A through H, margins inked\nblue, tips returned to container.	BLEEDING FRIABLE NODULE; CLINICAL DIAGNOSIS - MELANOMA, DATA ON FILE	\N	\N	\N	This is a high risk primary lesion.  As there is extensive ulceration, the microstage measurment probably underestimates the prognostic risk of this lesion.	MELANOMA, AT LEAST 3.5 MM IN THICKNESS, WITH INTRAEPIDERMAL MELANOMA EXTENDING NEAR TO THE PERIPHERAL BIOPSY MARGIN	104444	194	\N	\N	96-18458	E	CCR-215	California Cancer Registry	IP95222	AirTable blocks_with_IP_info.csv
1328	08-51663	50	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2743	172.5	\N	\N	Sections show a compound proliferation of atypical melanocytes, composed in part of cells with ample vacuolated and pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with focal associated suprabasal scatter. In one cross section, there is an unusual configuration with coalescing nests and fascicles of pale melanocytes that penetrate into the upper reticular dermis. Many of these dermal melanocytes have slightly spindled morphology.	Cylindrical skin segment, 0.8 cm in diameter and 1.0 cm in thickness, trisected and entirely submitted.	PROB MELANOMA	\N	\N	Scraping	In terms of staging, this is a non-ulcerated primary melanoma with invasion of the reticular dermis (Clark's level IV). There is no evidence of associated vascular invasion, neurotropism, or regression. Further excision of this site is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 1.4 MM IN THICKNESS, EXTENDING INTRAEPIDERMALLY NEAR TO THE PERIPHERY OF THE SPECIMEN	273588	129	\N	\N	08-51663	\N	CCR-015	California Cancer Registry	IP760304	AirTable blocks_with_IP_info.csv
2345	18-85718	9	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.4	\N	\N	There is a proliferation of cytologically bland melanocytes that is in part nested at the dermo-epidermal junction, also involving the superficial dermis. In one half of the specimen, the deep dermal melanocytes demonstrate prominent pale and vacuolated cytoplasm.	Skin segment measuring 0.6 x 0.4 x 0.2 cm, bisected and entirely submitted. KC/KC	4 MM X 4 MM FLESH COLORED PINK PAPULE, HISTORY OF CHANGE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR	\N	left lower neck 	Scraping	This nevus displays prominent balloon cell change.	COMPOUND MELANOCYTIC NEVUS	139498	1354	\N	\N	18-85718	\N	SM-025	Nevus Library	IP1949687	AirTable blocks_with_IP_info.csv
1445	11-7028	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1362	\N	\N	11-7028	\N	SMP56	Spitz Melanoma	\N	AirTable blocks_with_IP_info.csv
2546	19Rig750007.04.07.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	285	\N	\N	None	\N	CM-48	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2547	19Rig750007.04.07.09	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	285	\N	\N	None	\N	CM-48	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2464	19-53945B	48	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.5	\N	MAP2K1	Sections show a dermal proliferation of melanocytes with slightly enlarged round or ovoid nuclei, and scant cytoplasm. The cells are positioned in discrete aggregates or singly between thickened collagen bundles in the reticular dermis.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted in B. HD/HD	A-B) MORPHOLOGY: PAPULE, DDX: NEOPLASM OF UNCERTAIN BEHAVIOR VS. SQUAMOUS CELL CARCINOMA VS. DERMATOFIBROMA	\N	\N	FFPE	This lesion has dense fibrotic stroma, and cells that are on average smaller than those in a classic Spitz's nevus, but larger than those of a common nevus. Some melanocytes express p16, in keeping with a nevus.	DESMOPLASTIC NEVUS	173528	1364	\N	\N	19-53945	B	SN-01	Sclerotic Nevi	IP2058294	AirTable blocks_with_IP_info.csv
2551	19Rig750007.04.12.08	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	288	\N	\N	None	\N	CM-53	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2550	19Rig750007.04.12.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	288	\N	\N	None	\N	CM-53	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2548	19Rig750007.04.09.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	286	\N	\N	None	\N	CM-50	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2549	19Rig750007.04.10.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	287	\N	\N	None	\N	CM-51	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2504	19Rig750007.01.14.04	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	258	\N	\N	None	\N	CM-14	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1078	03-16497A	58	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1307	172.6	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, arranged irregularly within the epidermis, with foci of pagetoid scatter, flanking a nodular proliferation of similar melanocytes that do not mature (diminish in size) with descent into the superficial reticular dermis.  Mitoses are present in areas of the latter component.	Ellipse, 2.5 x 1.3 x 1.0 cm, including central raised tan and brown 1.5 x 1.0 cm pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections each in cassettes A and B, tips returned to container.	R/O SCC AND BCC	\N	\N	\N	Melanoma in situ extends to the periphery of the specimen. There are no microscopic findings that would substantially change the prognosis indicated by the tumor thickness listed above.	MELANOMA, 2.3 MM  IN THICKNESS	173610	207	\N	\N	03-16497	A	CCR-237	California Cancer Registry	IP374810	AirTable blocks_with_IP_info.csv
3207	Cell-Line_Xu-17	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1758	\N	\N	None	\N	SYNAT156	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
1079	03-16497B	58	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1307	172.6	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, arranged irregularly within the epidermis, with foci of pagetoid scatter, flanking a nodular proliferation of similar melanocytes that do not mature (diminish in size) with descent into the superficial reticular dermis.  Mitoses are present in areas of the latter component.	Ellipse, 2.5 x 1.3 x 1.0 cm, including central raised tan and brown 1.5 x 1.0 cm pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections each in cassettes A and B, tips returned to container.	R/O SCC AND BCC	\N	\N	\N	Melanoma in situ extends to the periphery of the specimen. There are no microscopic findings that would substantially change the prognosis indicated by the tumor thickness listed above.	MELANOMA, 2.3 MM  IN THICKNESS	173610	207	\N	\N	03-16497	B	CCR-237	California Cancer Registry	IP374810	AirTable blocks_with_IP_info.csv
2431	19-21355B	63	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.6	\N	MAP2K1	Sections show a dermal proliferation of melanocytes with slightly enlarged round or ovoid nuclei, and scant cytoplasm. The cells are positioned in discrete aggregates or singly between thickened collagen bundles in the reticular dermis.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted in B. PL/PL	A) R/O LENTIGO VS. LM VS. OTHER, B) R/O DF VS. R/O ATYPIA	\N	\N	FFPE	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS WITH A SCLEROTIC STROMA	173601	1380	\N	\N	19-21355	B	SN-17	Sclerotic Nevi	IP90936	AirTable blocks_with_IP_info.csv
1137	04-25639A	56	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1309	172.5	\N	\N	Sections show a strikingly asymmetrical compound proliferation of atypical melanocytes, composed largely of neoplastic cells with ample vacuolated cytoplasm. Single neoplastic cells and nests are arrayed irregularly within the epidermis, with foci of suprabasal scatter.  There are also large irregular clusters of similar melanocytes in the dermis, enveloped by an infiltrate of lymphocytes and melanophages.	Oriented ellipse measuring 2.0 x 1.0 x 1.0 cm, central lesion measuring 0.9 x 0.8 cm, with superior margins preinked black and inferior margins preinked blue. The specimen is serially sectioned and submitted with three sections each in cassettes A and B.	R/O MM	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with an invasive component that involves the superficial reticular dermis (Clark's level IV).  There is no evidence of vascular invasion or perineural extension or regression.  Further re-excision of this site is of course warranted to ensure that local control has been established.	MELANOMA OF 1.1 MILLIMETERS IN THICKNESS, NARROWLY BUT COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE FREE OF MELANOMA CELLS)	173531	208	\N	\N	04-25639	A	CCR-238	California Cancer Registry	IP441707	AirTable blocks_with_IP_info.csv
1320	08-44748	75	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2370	172.4	\N	\N	Sections show a cellular proliferation of elongated spindled cells with atypical and pleomorphic nuclei, arrayed in a vaguely fascicular configuration in a myxoid and highly vascular stroma. Many malignant cells are captured in mitosis. Neither cytoplasmic pigmentation nor keratinization is clearly evident. There is surface ulceration with superjacent exudate and crust.	Skin segment measuring 1.2 x 1.1 x 0.2 cm, quadrisected and entirely submitted.	PINK NODULAR CRUSTED PLAQUE; BCC VS. OTHER NEOPLASM	\N	\N	\N	The lineage of this malignancy was evaluated via immunoperoxidase staining. There is avid diffuse expression of both S100 protein and p75, substantiating melanocytic lineage. A keratin stain is completely negative, excluding carcinoma from the differential diagnosis. There is weak expression of actin with a lack of expression of desmin, and thus there is no support for leiomyosarcoma as  potential consideration. A procollagen stain shows weak reactivity while a CD10 stain is completely negative, and thus there is also no support for pleomorphic sarcoma (atypical fibroxanthoma). In terms of staging, this is an extensively ulcerated melanoma with invasion of the reticular dermis (at least Clark's level IV). Full microstaging cannot be completed because of the partial nature of the biopsy. Further extirpation is warranted, both to eradicate this malignancy locally and to enable full microstage analysis to be completed.	SPINDLED MELANOMA OF AT LEAST 3.0 MM IN THICKNESS	147408	130	\N	\N	08-44748	\N	CCR-020	California Cancer Registry	IP753389	AirTable blocks_with_IP_info.csv
1138	04-25639B	56	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1310	172.5	\N	\N	Sections show a strikingly asymmetrical compound proliferation of atypical melanocytes, composed largely of neoplastic cells with ample vacuolated cytoplasm. Single neoplastic cells and nests are arrayed irregularly within the epidermis, with foci of suprabasal scatter.  There are also large irregular clusters of similar melanocytes in the dermis, enveloped by an infiltrate of lymphocytes and melanophages.	Oriented ellipse measuring 2.0 x 1.0 x 1.0 cm, central lesion measuring 0.9 x 0.8 cm, with superior margins preinked black and inferior margins preinked blue. The specimen is serially sectioned and submitted with three sections each in cassettes A and B.	R/O MM	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with an invasive component that involves the superficial reticular dermis (Clark's level IV).  There is no evidence of vascular invasion or perineural extension or regression.  Further re-excision of this site is of course warranted to ensure that local control has been established.	MELANOMA OF 1.1 MILLIMETERS IN THICKNESS, NARROWLY BUT COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE FREE OF MELANOMA CELLS)	173531	208	\N	\N	04-25639	B	CCR-238	California Cancer Registry	IP441707	AirTable blocks_with_IP_info.csv
1344	09-16836	85	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2371	172.7	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei in partial contiguity with the epidermis which is markedly thinned.  There is little diminishment in melanocyte size with descent in the dermis and mitotic figures are apparent.	Skin segment measuring 0.7 x 0.6 x 0.3 cm, bisected and entirely submitted.	RECENT PAPULE; R/O SCC	\N	\N	\N	S100 and Melan-A immunostains label the neoplastic cells, confirming the melanocytic lineage of this lesion. Keratin stain is by contrast negative. In terms of staging, this is a non-ulcerated primary melanoma with invasion of the reticular dermis (Clark's level IV). Definitive assessment of these and other prognostic features should be deferred to the excision specimen, as these changes extend to biopsy margins.	AMELANOTIC MELANOMA, AT LEAST 2.2 MM IN THICKNESS, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	173741	134	\N	\N	09-16836	\N	CCR-031	California Cancer Registry	IP371067	AirTable blocks_with_IP_info.csv
1280	07-28805	37	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=323,22991	172.6	\N	\N	Sections show an asymmetrical proliferation of large melanocytes with abundant cytoplasm, which fail to mature with descent in the dermis. Mitotic figures are identifiable within the dermal component, including near the base of the lesion. Within the epidermis, melanocytes are arrayed as nests and single cells somewhat irregularly, and there are foci of suprabasal scatter. Within the dermis, melanocytes are arrayed mainly in syncytia and occasional small clusters. They fail to mature with descent. Many have prominent nucleoli. The base of these changes is irregular. Some melanocytes are present adjacent to small nerve twigs. There is an adjacent population of small bland melanocytes arrayed as clusters and syncytia in the superficial reticular dermis (melanocytic nevus). There is slight solar elastosis.	Ellipse measuring 1.0 x 0.5 x 0.6 cm.  With margins inked blue, the specimen is serially quadrisected perpendicular to the long axis and entirely submitted.\n	6 X 7 MM SENSITIVE INFLAMED PAPULE X 8 MONTHS; ? INFLAMED NEVUS	\N	\N	Scraping	Because of the unusual nature of this tumor, I have also shared this case with my colleagues, Drs. Philip LeBoit and Timothy McCalmont, who agree with this diagnosis. Although there are some cytologic features reminiscent of a Spitz's nevus, there is a predominantly sheet-like arrangement of melanocytes which are atypical, and mitotic figures are identifiable within the dermal component, including within deeper aspects of it. There is also a degree of suprabasal scatter of melanocytes within the epidermis, and together, these features are diagnostic of melanoma. There is an associated melanocytic nevus, of superficial congenital pattern. In terms of staging, this is a non-ulcerated primary melanoma of Clark's anatomic level IV, with significant involvement of the reticular dermis. There is no evidence of vascular invasion, or regression. Tumor lies adjacent to small nerve twigs. It is difficult to know if this merely reflects diffuse involvement of the dermis in such areas, which I favor, rather than true neurotropism.  Complete excision of this site is of course warranted. The patient may also be a candidate for sentinel node sampling, based on the guidelines used in many institutions.	MELANOMA, 2.75 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING VERY CLOSE TO THE PERIPHERAL MARGIN, WITH NEVUS PRESENT AT THE PERIPHERAL MARGIN	173688	135	\N	\N	07-28805	\N	CCR-032	California Cancer Registry,Melanoma Epigenetics	IP651337	AirTable blocks_with_IP_info.csv
2129	17-43707	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22437	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1998	\N	\N	17-43707	\N	SYNAT159	2010-2017	\N	AirTable blocks_with_IP_info.csv
2954	94-19725B T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1083	\N	\N	None	\N	MD-206	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2937	92-06469A T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1084	\N	\N	None	\N	MD-207	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2043	17-8769A	53	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a zone of inflammation and granulation tissue, representing a prior biopsy or surgical site, with no evidence of a melanocytic proliferation.	Oriented ellipse, 2.3 x 1.1 x 0.3 cm, including a central 0.5 x 0.4 cm crusted area. With the orienting notched tip placed to the left and designated as 9 o'clock by the grosser, the 9-12-3 o'clock and 3-6-9 o'clock edges are inked blue and yellow, respectively. The specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections each in A-B. HD/HD	EXC MELANO PROLIF, DT17-6212	\N	\N	\N	\N	HEALING BIOPSY SITE, WITH NO EVIDENCE OF A RESIDUAL MELANOCYTIC NEOPLASM	273693	2196	\N	\N	17-8769	A	SYNAT150	Melanoma Epigenetics	IP1576568	AirTable blocks_with_IP_info.csv
1665	12-85105A	67	\N	\N	\N	T4a	Primary	\N	3	\N	FFPE	\N	\N	172.6	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei in the dermis.  Many melanocytes have pigmented cytoplasms.  There are numerous mitotic figures.  No connection to the epidermis is noted, but there are numerous melanophages, dermal fibrosis, and epidermal thinning.	Cylindrical skin segment, 0.7 cm in diameter and 0.6 cm in thickness, trisected and totally submitted in cassette A.    SL/SL	A) 4.8 X 2.6 CM LARGE BLUE PLAQUE; SUSPECT MELANOMA, B) 1.2 X 0.8 CM PINK FIRM SUBQ NODULE; SUSPECT SQ MELANOMA MET	\N	\N	Scraping	Melanoma extends to the base of the biopsy and therefore the the above measurement represents a minimal thickness.  I fail to note any epidermal connection which raises the possibility of a metastatic lesion.  There are numerous melanophages in the papillary dermis which could indicate regression of a pre-existing junctional component.  Perhaps additional diagnostic information will be apparent in the complete excision specimen.  This lesion is not ulcerated and should be regarded as a pT4a melanoma.	MELANOMA, AT LEAST 5.5 MILLIMETERS IN THICKNESS	173649	136	\N	\N	12-85105	A	CCR-034	California Cancer Registry	IP1170922	AirTable blocks_with_IP_info.csv
1177	05-27756A	62	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1354	172.5	\N	\N	Sections show sheets of melanocytes beneath a thin epidermis, with one part of the lesion having oval cells with large, vesicular nuclei and the other small, monomorphous nuclei, the latter cells positioned between thickened collagen bundles and in myxoid stroma.	Ellipse, 2.2 x 1.5 x 0.9 cm, including a central 1.4 x 1.3 cm bump.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections in cassette A and three sections in cassette B.	10 X 20 MM DOME SHAPED PLAQUE WITH 2 DARKER PLAQUES WITH VARIEGATED BROWN/RED COLOR; ? MELANOMA, ? NEVUS	\N	\N	\N	The neoplasm extends to within 1 mm. of the edge of the specimen. Histopathologic features of possible prognostic importance include:  Level: IV Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent  This is an usual lesion, with a desmoplastic component- but with small round rather than spindled melanocytes.	MELANOMA, 3.4 MM  IN THICKNESS	528599	214	\N	\N	05-27756	A	CCR-256	California Cancer Registry	IP504468	AirTable blocks_with_IP_info.csv
2491	19Rig750007.01.01.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	249	\N	\N	None	\N	CM-01	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2490	19Rig750007.01.01.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	249	\N	\N	None	\N	CM-01	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2494	19Rig750007.01.05.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	251	\N	\N	None	\N	CM-05	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2493	19Rig750007.01.05.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	251	\N	\N	None	\N	CM-05	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2496	19Rig750007.01.07.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	252	\N	\N	None	\N	CM-07	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2495	19Rig750007.01.07.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	252	\N	\N	None	\N	CM-07	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2920	86-04906-2 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1086	\N	\N	None	\N	MD-209	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2707	21-20002A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-19	http://64.54.108.121/eSlideTray.php?ImageIds=32752	\N	\N	6840768	\N	\N	\N	\N	Skin, foot, lateral, left, biopsy, melanoma	FFPE	\N	\N	\N	304	\N	\N	21-20002	A1	CME-002	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2638	20-52125A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-19	http://64.54.108.121/eSlideTray.php?ImageIds=32755	\N	\N	6799901	\N	\N	\N	\N	Skin, buttock, left, tumor excision, superficial spreading melanoma	FFPE	\N	\N	\N	305	\N	\N	20-52125	A1	CME-003	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1178	05-27756B	62	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1355	172.5	\N	\N	Sections show sheets of melanocytes beneath a thin epidermis, with one part of the lesion having oval cells with large, vesicular nuclei and the other small, monomorphous nuclei, the latter cells positioned between thickened collagen bundles and in myxoid stroma.	Ellipse, 2.2 x 1.5 x 0.9 cm, including a central 1.4 x 1.3 cm bump.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections in cassette A and three sections in cassette B.	10 X 20 MM DOME SHAPED PLAQUE WITH 2 DARKER PLAQUES WITH VARIEGATED BROWN/RED COLOR; ? MELANOMA, ? NEVUS	\N	\N	\N	The neoplasm extends to within 1 mm. of the edge of the specimen. Histopathologic features of possible prognostic importance include:  Level: IV Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent  This is an usual lesion, with a desmoplastic component- but with small round rather than spindled melanocytes.	MELANOMA, 3.4 MM  IN THICKNESS	528599	214	\N	\N	05-27756	B	CCR-256	California Cancer Registry	IP504468	AirTable blocks_with_IP_info.csv
2476	19-97163	50	\N	\N	\N	None	None	None	10	0	FFPE	\N	\N	216.4	\N	GNAQ	There are nests, cords and strands of small, round melanocytes that mature with descent into the dermis, and a second population of bipolar dendritic melanocytes accompanied by melanophages. The proliferation in part surrounds adnexal structures.	Skin segment measuring 0.2 x 0.1 x 0.1 cm. Submitted intact. BY/BY	1 MM; R/O ATYPICAL NEVUS	\N	\N	FFPE	No evidence of melanoma or significant atypia was detected.	COMBINED MELANOCYTIC NEVUS, WITH BOTH SUPERFICIAL CONGENITAL AND BLUE NEVUS ELEMENTS	173405	1371	\N	\N	19-97163	\N	SN-08	Sclerotic Nevi	IP679852	AirTable blocks_with_IP_info.csv
1072	03-3075B	71	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1362	172.4	\N	\N	Sections show nested melanocytes arrayed irregularly along the epidermal-dermal junction above elastosis, with nests of melanocytes that vary in size and shape.  There are clusters and nests and sheets of similar cells in the dermis, also above elastosis, jointly with an infiltrate of lymphocytes and melanophages and fibrosis, some of which could stem from a prior biopsy.	Ellipse measuring 1.8 x 0.7 x 0.3 cm, margins inked blue serially sectioned and submitted with four segments each in cassettes A and B.	6 MONTH HX OF GROWING IRREGULAR PLAQUE, BX'D BY ANOTHER MD WITH REPORT READ AS ATYPICAL NEVUS, DX:MELANOMA; R/O MELANOMA, EXCISION BX NO ULCERATION	\N	\N	\N	This is a non-ulcerated primary melanoma with an invasive component that involves the reticular dermis (Clark's level IV).  There is no evidence of vascular invasion or perineural extension.  There is evidence of partial regression, and thus the microstage measurement listed above may underestimate the prognostic risk of this lesion.  This patient is a candidate for sentinel node evaluation,  based upon criteria currently employed by the UCSF Melanoma Center.  Further re-excision of this lesion is also warranted to be certain local control has been established. The prior biopsy should be reviewed to see if it holds prognostic importance.  Please forward a report or additional details to my attention and I will make the necessary arrangements.	MELANOMA OF 1.6 MM IN THICKNESS, WITH EXTENSION NEAR TO THE PERIPHERAL BIOPSY MARGIN	173406	217	\N	\N	03-3075	B	CCR-261	California Cancer Registry	IP361387	AirTable blocks_with_IP_info.csv
3113	79049-1c	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-008_1.3	\N	\N	\N	\N	Right hallux	Punch	\N	\N	\N	6	\N	\N	None	\N	AM2-008	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3115	79049-2a	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-008_2.1	\N	\N	\N	\N	Sentinel node	Punch	\N	\N	\N	6	\N	\N	None	\N	AM2-008	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3111	79049-1a	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-008_1.1	\N	\N	\N	\N	Right hallux	Punch	\N	\N	\N	6	\N	\N	None	\N	AM2-008	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3116	79049-2b	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-008_2.2	\N	\N	\N	\N	Sentinel node	\N	\N	\N	\N	6	\N	\N	None	\N	AM2-008	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3114	79049-1d	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 2	AM2-008_1.4	\N	\N	\N	\N	Right hallux	\N	\N	\N	\N	6	\N	\N	None	\N	AM2-008	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3039	352-1-15.1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	\N	\N	\N	\N	\N	Left heel	Punch	\N	\N	\N	7	\N	\N	None	\N	AM2-012	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3040	352-1-15.2	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	4/5 involved	\N	\N	\N	\N	Inguinal lymph node	\N	\N	\N	\N	7	\N	\N	None	\N	AM2-012	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1071	03-3075A	71	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1361	172.4	\N	\N	Sections show nested melanocytes arrayed irregularly along the epidermal-dermal junction above elastosis, with nests of melanocytes that vary in size and shape.  There are clusters and nests and sheets of similar cells in the dermis, also above elastosis, jointly with an infiltrate of lymphocytes and melanophages and fibrosis, some of which could stem from a prior biopsy.	Ellipse measuring 1.8 x 0.7 x 0.3 cm, margins inked blue serially sectioned and submitted with four segments each in cassettes A and B.	6 MONTH HX OF GROWING IRREGULAR PLAQUE, BX'D BY ANOTHER MD WITH REPORT READ AS ATYPICAL NEVUS, DX:MELANOMA; R/O MELANOMA, EXCISION BX NO ULCERATION	\N	\N	\N	This is a non-ulcerated primary melanoma with an invasive component that involves the reticular dermis (Clark's level IV).  There is no evidence of vascular invasion or perineural extension.  There is evidence of partial regression, and thus the microstage measurement listed above may underestimate the prognostic risk of this lesion.  This patient is a candidate for sentinel node evaluation,  based upon criteria currently employed by the UCSF Melanoma Center.  Further re-excision of this lesion is also warranted to be certain local control has been established. The prior biopsy should be reviewed to see if it holds prognostic importance.  Please forward a report or additional details to my attention and I will make the necessary arrangements.	MELANOMA OF 1.6 MM IN THICKNESS, WITH EXTENSION NEAR TO THE PERIPHERAL BIOPSY MARGIN	173406	217	\N	\N	03-3075	A	CCR-261	California Cancer Registry	IP361387	AirTable blocks_with_IP_info.csv
1126	04-14908	80	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	172.6	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, arranged irregularly within the epidermis, flanking a nodular proliferation of similar melanocytes that do not mature (diminish in size) with descent into the superficial reticular dermis.	Ellipse measuring 2.2 x 1.2 x 0.3 cm, margins inked blue, serially sectioned perpendicular to the long axis and entirely submitted with four sections in cassette A and three sections in cassette B.\n	ATYPICAL	\N	\N	\N	Melanoma in situ extends to the periphery of the specimen. Histopathologic features of possible prognostic importance include:  Level: IV Tumor infiltrating lymphocytes: scant Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent  ADDENDUM, 4/12/2004:  The thickness has now been added to the diagnosis line.	MELANOMA, 1.35 MM  IN THICKNESS	173610	219	\N	\N	04-14908	\N	CCR-264	California Cancer Registry	IP431307	AirTable blocks_with_IP_info.csv
1353	09-48136A	56	\N	\N	\N	\N	\N	\N	3	\N	FFPE	\N	\N	172.7	\N	\N	Sections show a proliferation of malignant cells with strikingly atypical nuclei and ample amphophilic cytoplasm arrayed as coalescing nests and sheets, and extensive overlying ulceration is apparent. In some areas of viable epidermis, cells in pagetoid array can be found. The subjacent dermis is fibrotic and inflamed.	Gross description recorded by digital image.	3 CM EXOPHYTIC SESSILE PLAQUE, PURPURIC; R/O PYOGENIC GRANULOMA	\N	\N	Scraping	In light of the gravity of this diagnosis, immunoperoxidase staining to verify lineage was included in our assessment. This malignancy shows avid diffuse expression of both S100 protein and Melan-A, thereby confirming its melanocytic nature. A D2-40 immunostain, which represents a lymphatic endothelial marker, was also completed. There are collections of melanoma cells in the dermis that are fully encircled by D2-40 positive cells, thus suggesting that vascular invasion may have occurred. In terms of staging, this is an extensive ulcerated melanoma with associated Clark's level IV invasion. Although vascular invasion may have occurred, there is no evidence of associated regression or perineural invasion. Further excision is warranted to ensure that local eradication has been accomplished.	ULCERATED MELANOMA OF APPROXIMATELY 9.5 MM IN THICKNESS, EXTENSIVELY TRANSECTED AT THE DEEP EDGE OF THE BIOPSY	423789	137	\N	\N	09-48136	A	CCR-035	California Cancer Registry	IP848899	AirTable blocks_with_IP_info.csv
1127	04-14908A	80	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1365	172.6	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, arranged irregularly within the epidermis, flanking a nodular proliferation of similar melanocytes that do not mature (diminish in size) with descent into the superficial reticular dermis.	Ellipse measuring 2.2 x 1.2 x 0.3 cm, margins inked blue, serially sectioned perpendicular to the long axis and entirely submitted with four sections in cassette A and three sections in cassette B.\n	ATYPICAL	\N	\N	\N	Melanoma in situ extends to the periphery of the specimen. Histopathologic features of possible prognostic importance include:  Level: IV Tumor infiltrating lymphocytes: scant Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent  ADDENDUM, 4/12/2004:  The thickness has now been added to the diagnosis line.	MELANOMA, 1.35 MM  IN THICKNESS	173610	219	\N	\N	04-14908	A	CCR-264	California Cancer Registry	IP431307	AirTable blocks_with_IP_info.csv
1963	16-76143	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1317	\N	\N	16-76143	\N	OM-59	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2944	93-13951 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1094	\N	\N	None	\N	MD-217	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1282	07-37378	25	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=7279	172.3	\N	\N	Sections show a compound melanocytic proliferation with a biphasic pattern. One population consists of melanocytes, some of which have atypical nuclei, with abundant dusty cytoplasmic melanin, that are irregularly distributed along the dermal-epidermal junction, with some melanocytes present above the basal zone. There are defects in circumscription, and the intraepidermal component is quite broad. There is adnexal extension. Similar melanocytes are present in the subjacent dermis, including the adventitial dermis. Rare mitotic figures are evident in this dermal component. The second population consists of melanocytes with cytologically bland nuclei (melanocytic nevus). This population demonstrates maturation with melanocytic descent. There is slight solar elastosis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted.	R/O MM	\N	\N	FFPE	Because of the unusual nature of this lesion, and the relatively young age of the patient, this case was also presented at our Peer Consensus Conference, and my colleague, Dr. Timothy McCalmont, also agrees with this interpretation. In terms of staging, this is a non-ulcerated primary melanoma of Clark's anatomic level at least III. It is somewhat difficult to assess the Clark's level in that there is extensive periadnexal involvement, and it is difficult to assess if there is any genuine involvement of the superficial reticular dermis. As these changes are transected, definitive assessment of thickness, and other such prognostic factors should also be deferred to the complete excision specimen. There is no evidence of vascular invasion, neurotropism, or regression.	MELANOMA, AT LEAST 0.65 MILLIMETER IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING TO THE DEEP MARGIN, AND WITH MELANOMA IN SITU EXTENDING TO PERIPHERAL MARGINS	102304	138	\N	\N	07-37378	\N	CCR-040	California Cancer Registry	IP659911	AirTable blocks_with_IP_info.csv
2961	95-5908	34	\N	\N	\N	None	None	None	25	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2742	172.7	\N	\N	There is irregular epidermal hyperplasia with hyperkeratosis, overlying a compound proliferation of melanocytes with abundant pale, finely vacuolated cytoplasm and dusty melanin pigment.  Pagetoid upward spread of individual melanocytes is evident at one edge of the specimen.	Cylindrical skin segment, 4 mm in diameter, 3 mm in depth.	12 X 10 MM TAN/BROWN IRREGULAR BORDER NEVUS SINCE CHILDHOOD, DEVELOPED DARK BLACK PAPULE IN IT RECENTLY DURING PREGNANCY; CLINICAL DIAGNOSIS - CONGENITAL NEVUS WITH PROBABLE MELANOMA	\N	\N	Scraping	The thickness measurement is preliminary, pending complete excision.  It is somewhat exaggerated by the presence of irregular epidermal hyperplasia over the lesion, and, should this be the deepest area, the prognosis may be somewhat better than implied by this thickness.	MALIGNANT MELANOMA, 1.0 MM IN THICKNESS	173727	140	\N	\N	95-5908	\N	CCR-042	California Cancer Registry	IP60334	AirTable blocks_with_IP_info.csv
1230	06-17933B	58	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1382	172.5	\N	\N	Sections show a broad compound proliferation of atypical melanocytes, composed largely of cells with scant vacuolated and/or pigmented cytoplasm. Single cells and nests are arrayed broadly and in lentiginous fashion within the epidermis, with conspicuous associated suprabasal scatter. There are also tiny clusters of similar melanocytes in the superficial dermis, jointly with an infiltrate of lymphocytes and melanophages. In some areas of the proliferation, somewhat smaller melanocytes are present in broad and lentiginous array.	Ellipse, 3.0 x 1.3 x 1.1 cm, including a central 1.3 x 1.0 cm dark pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections in cassette A and three sections in cassette B, tips returned to container.	R/O DYSPLASIA	\N	\N	\N	Part of this broad lesion includes atypical melanocytes in pagetoid array, a configuration suggesting melanoma, while part consists of somewhat smaller melanocytes arrayed in lentiginous fashion, a configuration that may represent a preceding melanocytic nevus. In terms of staging, I believe this is a non-ulcerated primary melanoma with invasion confined to the papillary dermis (Clark's level II). There is no evidence of vascular invasion, neurotropism, or regression in these sections. In essence, this is a very thin, minimal-risk primary melanoma. Further re-excision of this site is of course warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.3 MM IN THICKNESS, NARROWLY BUT COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE NARROWLY FREE OF INTRAEPIDERMAL MELANOMA)	273588	223	\N	\N	06-17933	B	CCR-273	California Cancer Registry	IP562999	AirTable blocks_with_IP_info.csv
1229	06-17933A	58	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1381	172.5	\N	\N	Sections show a broad compound proliferation of atypical melanocytes, composed largely of cells with scant vacuolated and/or pigmented cytoplasm. Single cells and nests are arrayed broadly and in lentiginous fashion within the epidermis, with conspicuous associated suprabasal scatter. There are also tiny clusters of similar melanocytes in the superficial dermis, jointly with an infiltrate of lymphocytes and melanophages. In some areas of the proliferation, somewhat smaller melanocytes are present in broad and lentiginous array.	Ellipse, 3.0 x 1.3 x 1.1 cm, including a central 1.3 x 1.0 cm dark pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections in cassette A and three sections in cassette B, tips returned to container.	R/O DYSPLASIA	\N	\N	\N	Part of this broad lesion includes atypical melanocytes in pagetoid array, a configuration suggesting melanoma, while part consists of somewhat smaller melanocytes arrayed in lentiginous fashion, a configuration that may represent a preceding melanocytic nevus. In terms of staging, I believe this is a non-ulcerated primary melanoma with invasion confined to the papillary dermis (Clark's level II). There is no evidence of vascular invasion, neurotropism, or regression in these sections. In essence, this is a very thin, minimal-risk primary melanoma. Further re-excision of this site is of course warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.3 MM IN THICKNESS, NARROWLY BUT COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE NARROWLY FREE OF INTRAEPIDERMAL MELANOMA)	273588	223	\N	\N	06-17933	A	CCR-273	California Cancer Registry	IP562999	AirTable blocks_with_IP_info.csv
2970	96-4039	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1168	\N	\N	96-4039	\N	MP-04	Hockemeyer Melanoma Progression	\N	AirTable blocks_with_IP_info.csv
1039	02-1274B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1168	\N	\N	02-1274	B1	MP-04	Hockemeyer Melanoma Progression	\N	AirTable blocks_with_IP_info.csv
2924	89-10450-1 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1095	\N	\N	None	\N	MD-218	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
10825	08-18595B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	UCSF Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1625	\N	\N	08-18595	B	SYNX222	\N	IP711218	Consolidated_data_final.csv
2942	93-13675A	45	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1387	172.5	\N	\N	Sections show an incompletely circumscribed compound proliferation of\natypical melanocytes, with areas in which single cells predominate\nover nests along the junction.  There is prominent upward scatter of\nmelanocytes, and melanocytes with atypical nuclei extend in\naggregates of variable size into the dermis.  There is slight\nsurrounding fibrosis, and there is a patchy lymphoid reaction at the\nbase.	Ellipse, 2.5 x 1.3 x 0.8 cm.  Surface shows a brown macule, 0.6 x 0.6\ncm.  Two sections lateral to tumor submitted as A, central portion of\nellipse submitted as three sections in B.  Tips returned to\ncontainer.	WF WITH CHANGING MOLE 1.5 CM WITH BLACK AREA NEAR TAN AREA X 1-1/2 YEARS; CLINICAL DIAGNOSIS - R/O SS MELANOMA	\N	\N	\N	\N	MALIGNANT MELANOMA, 0.7 MM IN THICKNESS, CLARK'S LEVEL III, SUPERFICIAL SPREADING TYPE, WITH THE IN SITU COMPONENT EXTENDING NEAR TO LATERAL BIOPSY MARGINS	173502	225	\N	\N	93-13675	A	CCR-281	California Cancer Registry	IP35049	AirTable blocks_with_IP_info.csv
2943	93-13675B	45	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1388	172.5	\N	\N	Sections show an incompletely circumscribed compound proliferation of atypical melanocytes, with areas in which single cells predominate over nests along the junction.  There is prominent upward scatter of melanocytes, and melanocytes with atypical nuclei extend in aggregates of variable size into the dermis.  There is slight surrounding fibrosis, and there is a patchy lymphoid reaction at the base.	Ellipse, 2.5 x 1.3 x 0.8 cm.  Surface shows a brown macule, 0.6 x 0.6\ncm.  Two sections lateral to tumor submitted as A, central portion of\nellipse submitted as three sections in B.  Tips returned to\ncontainer.	WF WITH CHANGING MOLE 1.5 CM WITH BLACK AREA NEAR TAN AREA X 1-1/2 YEARS; CLINICAL DIAGNOSIS - R/O SS MELANOMA	\N	\N	\N	None	MALIGNANT MELANOMA, 0.7 MM IN THICKNESS, CLARK'S LEVEL III, SUPERFICIAL SPREADING TYPE, WITH THE IN SITU COMPONENT EXTENDING NEAR TO LATERAL BIOPSY MARGINS	173502	225	\N	\N	93-13675	B	CCR-281	California Cancer Registry	IP35049	AirTable blocks_with_IP_info.csv
2555	19Rig750007.05.01.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	291	\N	\N	None	\N	CM-57	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2557	19Rig750007.05.02.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	292	\N	\N	None	\N	CM-58	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2558	19Rig750007.05.02.04	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	292	\N	\N	None	\N	CM-58	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1946	16-35900	68	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26407	172.2	\N	\N	Sections show a large, poorly circumscribed proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. Smaller foci of these atypical melanocytes are present distinctly separated from the main tumor body. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Two specimens received in one specimen bottle. One skin segment, 1.3 x 1.0 x 0.4 cm, quadrisected and entirely submitted. One tissue segment, 0.6 x 0.5 x 0.2 cm, bisected and entirely submitted. RS/RS	12 X 16 MM, BLACK NODULE WITH SURROUNDING DARK (BLUE), 1 MM MACULAR, 2 PIECES, SECOND SMALLER PIECE MOST MEDIAL; WORRISOME FOR MM WITH MICRO METASTASIS, R/O MALIGNANCY (SEE PHOTOS)	\N	MELANOMA, 2.4 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	Thank you for sending the clinical image of this patient's lesion. A synoptic report of potential prognostic factors is listed below: Procedure: excisional biopsy Microscopic tumor type: melanoma NOS arising in a nevus Breslow thickness: 2.4 mm Ulceration: not identified Margins, peripheral and deep: peripheral negative, deep focally positive Mitotic index: 8 mm/2 Microsatellitosis: present Vascular invasion: not identified Regression: not identified Perineural invasion: not identified Pathologic staging (pTNM): pT3a	MELANOMA, 2.4 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173201	1143	\N	\N	16-35900	\N	ME-48	Melanoma Epigenetics	IP1635170	AirTable blocks_with_IP_info.csv
2471	19-80535A	41	\N	\N	\N	\N	\N	\N	10	0	FFPE	\N	\N	216.5	\N	MAP2K1	There are increased single melanocytes along the sides and bases of elongated rete ridges, and small, round melanocytes that mature to spindled cells in the subjacent dermis. There is basilar hyperpigmentation in the affected area.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A) PINK ON THE EDGES, BROWN ON THE CENTER; R/O ATYPIA, B) 5 X 4 MM THIN BROWN PAP; R/O ATYPIA	\N	\N	FFPE	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	155568	1375	\N	\N	19-80535	A	SN-12	Sclerotic Nevi	IP2085042	AirTable blocks_with_IP_info.csv
2559	19Rig750007.05.04.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	293	\N	\N	None	\N	CM-60	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2560	19Rig750007.05.05.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	294	\N	\N	None	\N	CM-61	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2561	19Rig750007.05.05.08	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	294	\N	\N	None	\N	CM-61	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2563	19Rig750007.05.06.04	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	295	\N	\N	None	\N	CM-62	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1258	06-73878A	63	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1401	172.5	\N	\N	Sections show an irregular proliferation of atypical melanocytes with nests of melanocytes that are distributed at irregular intervals, and are focally confluent.  There are foci in which single melanocytes predominate as well.  The dermis contains aggregates of similar cells and there is solar elastosis.	Cylindrical skin segment measuring 0.4 cm in diameter x 0.9 cm in thickness, bisected and entirely submitted in cassette A.	A) IRREGULAR 8-10 MM MACULE; R/O MELANOMA, B) 2 WK HX OF RAPIDLY GROWING PAPULE; R/O SK, C-D) R/O BCC	\N	\N	\N	ADDENDUM, 5/15/2007: This appears to be a small biopsy from a larger lesion and shows a thin invasive melanoma without ulceration, microsatellites, or vascular invasion. The final pathologic staging should await examination of the completely excised lesion. This case was originally reported by Dr. Richard Kasper, who provided the note above. Drs. Yu and Fu have asked for a comment regarding the Clark's level, and whether regression is evident, as it was in the excision specimen. I have reviewed this slide only. The Clark's level is II, and there is evidence of regression, affecting much of this small punch biopsy specimen.  Its extent is thus better estimated with respect to the lesion upon excision, as reported by me separately.	INVASIVE MELANOMA, 0.35 mm THICK, NON-ULCERATED, WITH INTRAEPIDERMAL COMPONENT PRESENT AT BIOPSY EDGE	173536	232	\N	\N	06-73878	A	CCR-301	California Cancer Registry	IP89612	AirTable blocks_with_IP_info.csv
1098	03-57215A	31	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a large cellular asymmetrical compound proliferation of atypical melanocytes, composed largely of neoplastic cells with ample vacuolated cytoplasm. Single neoplastic cells and nests are arrayed irregularly within the epidermis, with foci of suprabasal scatter.  There is focal ulceration with overlying purulent crust.  There are also clusters of similar melanocytes in the upper dermis, and these cells meld into clusters and tracts of cells with hyperchromatic nuclei that jut into the reticular dermis.  At one edge of the specimen, smaller melanocytes reside in the dermis.	Ellipse, 3.0 x 1.5 x 0.9 cm, including central elevated tan and gray 1.5 x 1.0 cm pigmented lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four central sections in cassette A and three central sections in cassette B, tips returned to container.	R/O MM	\N	\N	\N	In terms of staging, this is an ulcerated primary melanoma with an invasive component that involves the reticular dermis (Clark's level IV).  The melanoma arose in association with a nevus of superficial congenital type, a remnant of which is also apparent in these sections.  There is no evidence of vascular invasion or perineural extension or regression.  Further re-excision of this site is warranted to ensure that local control has been established.	MELANOMA OF 1.7 MILLIMETERS IN THICKNESS, NARROWLY BUT COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE NARROWLY FREE OF MELANOMA CELLS)	100556	233	\N	\N	03-57215	A	CCR-302	Melanoma Epigenetics	IP415531	AirTable blocks_with_IP_info.csv
1099	03-57215B	31	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1406	172.5	\N	\N	Sections show a large cellular asymmetrical compound proliferation of atypical melanocytes, composed largely of neoplastic cells with ample vacuolated cytoplasm. Single neoplastic cells and nests are arrayed irregularly within the epidermis, with foci of suprabasal scatter.  There is focal ulceration with overlying purulent crust.  There are also clusters of similar melanocytes in the upper dermis, and these cells meld into clusters and tracts of cells with hyperchromatic nuclei that jut into the reticular dermis.  At one edge of the specimen, smaller melanocytes reside in the dermis.	Ellipse, 3.0 x 1.5 x 0.9 cm, including central elevated tan and gray 1.5 x 1.0 cm pigmented lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with four central sections in cassette A and three central sections in cassette B, tips returned to container.	R/O MM	\N	\N	FFPE	In terms of staging, this is an ulcerated primary melanoma with an invasive component that involves the reticular dermis (Clark's level IV).  The melanoma arose in association with a nevus of superficial congenital type, a remnant of which is also apparent in these sections.  There is no evidence of vascular invasion or perineural extension or regression.  Further re-excision of this site is warranted to ensure that local control has been established.	MELANOMA OF 1.7 MILLIMETERS IN THICKNESS, NARROWLY BUT COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE NARROWLY FREE OF MELANOMA CELLS)	100556	233	\N	\N	03-57215	B	CCR-302	Melanoma Epigenetics	IP415531	AirTable blocks_with_IP_info.csv
1235	06-21115A	55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1407	172.5	\N	\N	Sections show a compound proliferation of atypical melanocytes, composed largely of cells with ample vacuolated and pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with conspicuous associated suprabasal scatter. There are also many clusters of similar melanocytes in the superficial dermis, jointly with a dense infiltrate of lymphocytes and melanophages. In some areas where the infiltrate is densest, superficial dermal fibroplasia is appreciable. There may also be a reduction in density of melanocytes in some dermal areas.	Oriented ellipse, 1.7 x 1.0 x 0.3 cm, including a central dark brown and brown-black 1.3 x 0.9 cm pigmented area.  With the orienting slit placed to the left, the far margin is inked blue and the near margin is inked green (yellow over blue).  The specimen is serially sectioned perpendicular to the long axis from left to right and entirely submitted with four sections each in cassettes A (3 pieces embedded) and B.	10 X 13 MM BLACK FLAT BUT PALPABLE SLIGHTLY IRREGULAR BORDER GETTING LARGER PAST 4 YEARS, ADVISED BY GYN OVER 1 YEAR AGO TO HAVE IT REMOVED PROMPTLY, INGUINAL LYMPH NODES NOT PALPABLE	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with invasion confined to a strikingly expanded papillary dermis (Clark's level III). There is no evidence of associated vascular invasion or neurotropism in these sections. There are inflammatory changes that could represent an element of evolving partial regression, and thus the microstage measurement listed above may slightly underestimate the prognostic impact of this lesion. However, I suspect that the present microstage thickness is reasonably representative. Further reexcision of this site is of course warranted to be certain that local eradication has been accomplished.	MELANOMA OF 0.85 MM IN THICKNESS, TRANSECTED AT THE PERIPHERAL BIOPSY MARGIN	100556	234	\N	\N	06-21115	A	CCR-303	California Cancer Registry	IP566181	AirTable blocks_with_IP_info.csv
1236	06-21115B	55	\N	\N	\N	None	None	None	\N	\N	\N	\N	https://64.54.108.121/app/WebViewer/view/image/1408	172.5	\N	\N	Sections show a compound proliferation of atypical melanocytes, composed largely of cells with ample vacuolated and pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with conspicuous associated suprabasal scatter. There are also many clusters of similar melanocytes in the superficial dermis, jointly with a dense infiltrate of lymphocytes and melanophages. In some areas where the infiltrate is densest, superficial dermal fibroplasia is appreciable. There may also be a reduction in density of melanocytes in some dermal areas.	Oriented ellipse, 1.7 x 1.0 x 0.3 cm, including a central dark brown and brown-black 1.3 x 0.9 cm pigmented area.  With the orienting slit placed to the left, the far margin is inked blue and the near margin is inked green (yellow over blue).  The specimen is serially sectioned perpendicular to the long axis from left to right and entirely submitted with four sections each in cassettes A (3 pieces embedded) and B.	10 X 13 MM BLACK FLAT BUT PALPABLE SLIGHTLY IRREGULAR BORDER GETTING LARGER PAST 4 YEARS, ADVISED BY GYN OVER 1 YEAR AGO TO HAVE IT REMOVED PROMPTLY, INGUINAL LYMPH NODES NOT PALPABLE	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with invasion confined to a strikingly expanded papillary dermis (Clark's level III). There is no evidence of associated vascular invasion or neurotropism in these sections. There are inflammatory changes that could represent an element of evolving partial regression, and thus the microstage measurement listed above may slightly underestimate the prognostic impact of this lesion. However, I suspect that the present microstage thickness is reasonably representative. Further reexcision of this site is of course warranted to be certain that local eradication has been accomplished.	MELANOMA OF 0.85 MM IN THICKNESS, TRANSECTED AT THE PERIPHERAL BIOPSY MARGIN	100556	234	\N	\N	06-21115	B	CCR-303	California Cancer Registry	IP566181	AirTable blocks_with_IP_info.csv
1217	06-11151D	43	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a densely cellular compound proliferation of atypical melanocytes, composed largely of cells with ample vacuolated or pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with conspicuous associated suprabasal scatter. There are also many clusters of similar melanocytes in the superficial dermis, jointly with an infiltrate of lymphocytes and melanophages and enveloping superficial dermal fibroplasia. There is also deeper scarring stemming from prior biopsy/surgery at this site.	Oriented ellipse, 5.2 x 2.0 x 0.7 cm, including a central brown 0.8 x 0.7 cm pigmented area.  With the orienting sutured tip placed to the left and designated stitch at superior tip by the surgeon, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from left to right pseudotips and submitted with three sections in cassette A and two sections each in cassettes B through F, tips returned to container.	1.2 X 1.2 CM IRREG PIG PLAQUE; MIS; EXCISION MIS (SEE PREV PATH DS06-6467); TELEPHONE: 241-0686	\N	\N	\N	Upon complete excision, it is clear that this lesion represents melanoma. In terms of staging, this is a non-ulcerated primary melanoma with invasion confined to an expanded papillary dermis (Clark's level III). There is no evidence of vascular invasion or perineural extension or regression in these sections.	RESIDUAL MELANOMA OF 0.5 MM IN THICKNESS, COMPLETELY EXCISED (FINAL SURGICAL MARGINS APPEAR FREE OF MELANOMA)	173536	235	\N	\N	06-11151	D	CCR-310	California Cancer Registry	IP551533	AirTable blocks_with_IP_info.csv
1192	05-58791	49	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2373	172.5	\N	\N	There is a broad-based proliferation of melanocytes, most of which have abundant pale cytoplasm and large, pleomorphic, vesicular nuclei. The epidermis is thinned across a broad area, with confluence of junctional nests, and large nests of similar melanocytes amidst a dense lymphocytic infiltrate. There are foci of pagetoid spread. One edge of the specimen features a thickened, fibrotic papillary dermis with few neoplastic melanocytes and a thinned epidermis.	Deep skin segment, 1.5 x 1.3 x 0.3 cm, margins inked blue, serially sectioned and entirely submitted with six sections.	1 CM PEARLY PAPULE WITH BLACK PIGMENT; BCC VS NEVUS, R/O ATYPIA	\N	\N	\N	The neoplasm extends to the edge of the specimen. Histopathologic features of possible prognostic importance include:  Level: III Tumor infiltrating lymphocytes: many Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: present* Microsatellite metastasis: absent  *Extensive regression is currently considered an adverse prognostic factor. As the regressed area extends to the edge of the specimen, it is impossible to tell the proportion of this lesion that is affected by regression (this may be more easily determined after completer excision).	MELANOMA. 0.95 MILLIMETERS IN THICKNESS	173502	141	\N	\N	05-58791	\N	CCR-046	California Cancer Registry	IP535505	AirTable blocks_with_IP_info.csv
1600	12-19596	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	SCC, in situ	\N	\N	\N	\N	\N	Bowen's Disease, pagetoid	\N	\N	\N	\N	2006	\N	\N	12-19596	\N	SYNAT363	2010-2017	\N	AirTable blocks_with_IP_info.csv
2614	20-25263A	66	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.5	\N	MAP2K1	Sections show clusters of cytologically bland melanocytes, both at the dermal-epidermal junction and in the reticular dermis, where melanocytes lie between reticular dermal collagen bundles.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in A. BY/BY	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS. 3MM PINK PAPULE WITH BROWN CENTER. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. NEVUS VS. MMIS. 1.5 MM BLACK MACULE.	\N	\N	FFPE	\N	COMPOUND MELANOCYTIC NEVUS, CONGENITAL PATTERN	273588	1382	\N	\N	20-25263	A	SN-19	Sclerotic Nevi	IP1865438	AirTable blocks_with_IP_info.csv
1218	06-11151F	43	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1417	172.5	\N	\N	Sections show a densely cellular compound proliferation of atypical melanocytes, composed largely of cells with ample vacuolated or pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with conspicuous associated suprabasal scatter. There are also many clusters of similar melanocytes in the superficial dermis, jointly with an infiltrate of lymphocytes and melanophages and enveloping superficial dermal fibroplasia. There is also deeper scarring stemming from prior biopsy/surgery at this site.	Oriented ellipse, 5.2 x 2.0 x 0.7 cm, including a central brown 0.8 x 0.7 cm pigmented area.  With the orienting sutured tip placed to the left and designated stitch at superior tip by the surgeon, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from left to right pseudotips and submitted with three sections in cassette A and two sections each in cassettes B through F, tips returned to container.	1.2 X 1.2 CM IRREG PIG PLAQUE; MIS; EXCISION MIS (SEE PREV PATH DS06-6467); TELEPHONE: 241-0686	\N	\N	\N	Upon complete excision, it is clear that this lesion represents melanoma. In terms of staging, this is a non-ulcerated primary melanoma with invasion confined to an expanded papillary dermis (Clark's level III). There is no evidence of vascular invasion or perineural extension or regression in these sections.	RESIDUAL MELANOMA OF 0.5 MM IN THICKNESS, COMPLETELY EXCISED (FINAL SURGICAL MARGINS APPEAR FREE OF MELANOMA)	173536	235	\N	\N	06-11151	F	CCR-310	California Cancer Registry	IP551533	AirTable blocks_with_IP_info.csv
1216	06-11151C	43	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1414	172.5	\N	\N	Sections show a densely cellular compound proliferation of atypical melanocytes, composed largely of cells with ample vacuolated or pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with conspicuous associated suprabasal scatter. There are also many clusters of similar melanocytes in the superficial dermis, jointly with an infiltrate of lymphocytes and melanophages and enveloping superficial dermal fibroplasia. There is also deeper scarring stemming from prior biopsy/surgery at this site.	Oriented ellipse, 5.2 x 2.0 x 0.7 cm, including a central brown 0.8 x 0.7 cm pigmented area.  With the orienting sutured tip placed to the left and designated stitch at superior tip by the surgeon, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from left to right pseudotips and submitted with three sections in cassette A and two sections each in cassettes B through F, tips returned to container.	1.2 X 1.2 CM IRREG PIG PLAQUE; MIS; EXCISION MIS (SEE PREV PATH DS06-6467); TELEPHONE: 241-0686	\N	\N	\N	Upon complete excision, it is clear that this lesion represents melanoma. In terms of staging, this is a non-ulcerated primary melanoma with invasion confined to an expanded papillary dermis (Clark's level III). There is no evidence of vascular invasion or perineural extension or regression in these sections.	RESIDUAL MELANOMA OF 0.5 MM IN THICKNESS, COMPLETELY EXCISED (FINAL SURGICAL MARGINS APPEAR FREE OF MELANOMA)	173536	235	\N	\N	06-11151	C	CCR-310	California Cancer Registry	IP551533	AirTable blocks_with_IP_info.csv
1035	01-34127A	62	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1425	172.5	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei\nin partial contiguity with the epidermis.  There is suprabasal\nscatter of melanocytes in several foci.  There is little diminishment\nin melanocyte size with descent in the dermis, and dermal melanocytes\ncontain many mitotic figures.  There is marked angiogenesis at the\nbase of the lesion, but no evidence of vascular invasion.	Ellipse measuring 4.6 x 2.3 x 0.7 cm including central raised\nbrown-gray 0.9 x 0.7 x 0.2 cm area.  With margins preinked black,\nthree central representative sections are submitted in cassette A\nand two sections in cassette B, tips returned to container.	8 X 9 X 3 MM VARIEGATED BLUE-BLACK NODULE, PT HAS NOTED THIS HAS BEEN PRESENT SINCE CHILDHOOD, REMOVED WITH 1 CM MARGINS	\N	\N	\N	\N	MELANOMA, 2.4 MM. IN THICKNESS, COMPLETELY EXCISED (SURGICAL MARGINS ARE FREE OF NEOPLASM)	173536	237	\N	\N	01-34127	A	CCR-312	California Cancer Registry	IP290530	AirTable blocks_with_IP_info.csv
3208	Cell-Line_Xu-18	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2041	\N	\N	None	\N	SYNAT158	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
2938	92-14752-1 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1082	\N	\N	None	\N	MD-205	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2945	93-21060-4 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1073	\N	\N	None	\N	MD-196	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1036	01-34127B	62	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1426	172.5	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei in partial contiguity with the epidermis.  There is suprabasal scatter of melanocytes in several foci.  There is little diminishment in melanocyte size with descent in the dermis, and dermal melanocytes contain many mitotic figures.  There is marked angiogenesis at the base of the lesion, but no evidence of vascular invasion.	Ellipse measuring 4.6 x 2.3 x 0.7 cm including central raised\nbrown-gray 0.9 x 0.7 x 0.2 cm area.  With margins preinked black,\nthree central representative sections are submitted in cassette A\nand two sections in cassette B, tips returned to container.	8 X 9 X 3 MM VARIEGATED BLUE-BLACK NODULE, PT HAS NOTED THIS HAS BEEN PRESENT SINCE CHILDHOOD, REMOVED WITH 1 CM MARGINS	\N	\N	\N	None	MELANOMA, 2.4 MM. IN THICKNESS, COMPLETELY EXCISED (SURGICAL MARGINS ARE FREE OF NEOPLASM)	173536	237	\N	\N	01-34127	B	CCR-312	California Cancer Registry	IP290530	AirTable blocks_with_IP_info.csv
1001	00-556B	63	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1428	172.6	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, arranged irregularly within the epidermis, flanking a nodular proliferation of similar melanocytes that do not mature (diminish in size) with descent into the dermis.  There are dense lymphocytic infiltrates, dilated vessels, and fibrosis, overlying severe elastosis.	Oriented ellipse measuring 4.5 x 2.5 x 1.0 cm.  With the sutured tip\nto the left, the superior half of the specimen is inked blue and the\ninferior half is inked yellow.  The specimen is serially sectioned\nand submitted with four sections each in blocks A and C, and three\nsections in block B.	EXCISION OF MELANOMA, SUTURE AT PROXIMAL END; CLINICAL DIAGNOSIS - R/O MELANOMA	\N	\N	\N	None	MELANOMA, 1.4 MM IN THICKNESS, COMPLETELY EXCISED (SURGICAL MARGINS ARE FREE OF NEOPLASM)	173611	238	\N	\N	00-556	B	CCR-313	California Cancer Registry	IP215659	AirTable blocks_with_IP_info.csv
1000	00-556A	63	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1427	172.6	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation\nof atypical melanocytes, arranged irregularly within the epidermis,\nflanking a nodular proliferation of similar melanocytes that do not\nmature (diminish in size) with descent into the dermis.  There are\ndense lymphocytic infiltrates, dilated vessels, and fibrosis,\noverlying severe elastosis.	Oriented ellipse measuring 4.5 x 2.5 x 1.0 cm.  With the sutured tip\nto the left, the superior half of the specimen is inked blue and the\ninferior half is inked yellow.  The specimen is serially sectioned\nand submitted with four sections each in blocks A and C, and three\nsections in block B.	EXCISION OF MELANOMA, SUTURE AT PROXIMAL END; CLINICAL DIAGNOSIS - R/O MELANOMA	\N	\N	\N	\N	MELANOMA, 1.4 MM IN THICKNESS, COMPLETELY EXCISED (SURGICAL MARGINS ARE FREE OF NEOPLASM)	173611	238	\N	\N	00-556	A	CCR-313	California Cancer Registry	IP215659	AirTable blocks_with_IP_info.csv
2948	94-01469-2 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1085	\N	\N	None	\N	MD-208	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2497	19Rig750007.01.08.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	253	\N	\N	None	\N	CM-08	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2498	19Rig750007.01.08.05	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	253	\N	\N	None	\N	CM-08	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2566	19Rig750007.05.11.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	257	\N	\N	None	\N	CM-13	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2503	19Rig750007.01.13.04	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	257	\N	\N	None	\N	CM-13	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2502	19Rig750007.01.13.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	257	\N	\N	None	\N	CM-13	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2941	93-12428-1 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1087	\N	\N	None	\N	MD-210	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2702	21-13595A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-18	http://64.54.108.121/eSlideTray.php?ImageIds=32749	\N	\N	2895628	\N	\N	\N	\N	Skin, thigh, right, wide excision, nodular melanoma	FFPE	\N	\N	\N	303	\N	\N	21-13595	A1	CME-001	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2703	21-13595C1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-19	http://64.54.108.121/eSlideTray.php?ImageIds=32750	\N	\N	2895628	\N	\N	\N	\N	Lymph node, sentinel, inguinal, right, biopsy, melanoma, metastatic (Involved: 4; Examined: 5)	FFPE	\N	\N	\N	303	\N	\N	21-13595	C1	CME-001	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2708	21-20305A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-19	http://64.54.108.121/eSlideTray.php?ImageIds=32751	\N	\N	2895628	\N	\N	\N	\N	Skin, arm, right, excision, melanoma, metastatic	FFPE	\N	\N	\N	303	\N	\N	21-20305	A1	CME-001	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2693	21-09097A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-18	http://64.54.108.121/eSlideTray.php?ImageIds=32748	\N	\N	2895628	\N	\N	\N	\N	2389	FFPE	\N	\N	\N	303	\N	\N	21-9097	A1	CME-001	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2929	91-09968E T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1088	\N	\N	None	\N	MD-211	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2710	21-20368A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-19	http://64.54.108.121/eSlideTray.php?ImageIds=32753	\N	\N	6840768	\N	\N	\N	\N	Skin, foot, left, wide excision, superficial spreading melanoma, Satellite: present, Stage IIIC	FFPE	\N	\N	\N	304	\N	\N	21-20368	A1	CME-002	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2711	21-20368A3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-19	http://64.54.108.121/eSlideTray.php?ImageIds=32754	\N	\N	6840768	\N	\N	\N	\N	Skin, foot, left, wide excision, superficial spreading melanoma, Satellite: present, Stage IIIC	FFPE	\N	\N	\N	304	\N	\N	21-20368	A3	CME-002	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2798	22-42722B1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-18	http://64.54.108.121/eSlideTray.php?ImageIds=32757	\N	\N	6799901	\N	\N	\N	\N	Lung, upper lobe, right, wedge resection, melanoma, metastatic	FFPE	\N	\N	\N	305	\N	\N	22-42722	B1	CME-003	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2641	20-54923B1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-19	http://64.54.108.121/eSlideTray.php?ImageIds=32756	\N	\N	6799901	\N	\N	\N	\N	Lymph node, inguinal, left, biopsy, melanoma, metastatic (positive/total: 1/1)	FFPE	\N	\N	\N	305	\N	\N	20-54923	B1	CME-003	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2643	20-56832A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-17	http://64.54.108.121/eSlideTray.php?ImageIds=32761	\N	\N	6668726	\N	\N	\N	\N	Lymph node, peri-parotid, left, dissection, melanoma, metastatic (1/3)	FFPE	\N	\N	\N	306	\N	\N	20-56832	A1	CME-004	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2721	21-37814A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-17	http://64.54.108.121/eSlideTray.php?ImageIds=32762	\N	\N	6668726	\N	\N	\N	\N	Salivary gland, parotid, right, parotidectomy, melanoma, metastatic 	FFPE	\N	\N	\N	306	\N	\N	21-37814	A1	CME-004	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2433	19-25808	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-18	http://64.54.108.121/eSlideTray.php?ImageIds=32758	\N	\N	6668726	\N	\N	\N	\N	Skin, scalp, temporal, right, excision, nodular melanoma (see comment)	FFPE	\N	\N	\N	306	\N	\N	19-25808	\N	CME-004	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
3124	86502f	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-001_1.4	\N	\N	\N	\N	Right sole	\N	\N	\N	\N	1	\N	\N	None	\N	AM2-001	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3123	86502d	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-001_1.2	\N	\N	\N	\N	Right sole	\N	\N	\N	\N	1	\N	\N	None	\N	AM2-001	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3122	86502c	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 2	AM2-001_1.3	\N	\N	\N	\N	Right sole	\N	\N	\N	\N	1	\N	\N	None	\N	AM2-001	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3121	86502b	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\\HiSeqData_Shanshan\\Acral Melanoma project 2\\HE_Images	\N	Mel 1	Aperio file AM2-001_1.1\n	\N	\N	\N	\N	Right sole	Punch	\N	\N	\N	1	\N	\N	None	\N	AM2-001	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3045	534-1-11.2	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-004_1.2	\N	\N	\N	\N	left plantar skin	Punch	\N	\N	\N	3	\N	\N	None	\N	AM2-004	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3046	534-1-11.3	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	MIS2	AM2-004_1.3	\N	\N	\N	\N	left plantar skin	Punch	\N	\N	\N	3	\N	\N	None	\N	AM2-004	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3044	534-1-11.1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-004_1.1	\N	\N	\N	\N	left plantar skin	\N	\N	\N	\N	3	\N	\N	None	\N	AM2-004	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2786	22-21012A4	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-18	http://64.54.108.121/eSlideTray.php?ImageIds=32768	\N	\N	3340573	\N	\N	\N	\N	  Skin, forehead, right, wide excision, melanoma, recurrent. Microscopically, it shows presence of a few nests of epithelioid melanocytes with nuclear atypia, vacuolated cytoplasm and mitotic activity in the dermis. A recurrent melanoma is considered. Suture granulomas and scar tissue are also seen. Section margins are free (＞3 mm).	FFPE	\N	\N	\N	307	\N	\N	22-21012	A4	CME-005	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2719	21-32669B1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-17	http://64.54.108.121/eSlideTray.php?ImageIds=32764	\N	\N	3340573	\N	\N	\N	\N	Lymph node, pre-auricular, right, lymphadenectomy, melanoma, metastatic (1/1)	FFPE	\N	\N	\N	307	\N	\N	21-32669	B1	CME-005	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2783	22-21012A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-17	http://64.54.108.121/eSlideTray.php?ImageIds=32765	\N	\N	3340573	\N	\N	\N	\N	  Skin, forehead, right, wide excision, melanoma, recurrent. Microscopically, it shows presence of a few nests of epithelioid melanocytes with nuclear atypia, vacuolated cytoplasm and mitotic activity in the dermis. A recurrent melanoma is considered. Suture granulomas and scar tissue are also seen. Section margins are free (＞3 mm).	FFPE	\N	\N	\N	307	\N	\N	22-21012	A1	CME-005	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2718	21-30633A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-17	http://64.54.108.121/eSlideTray.php?ImageIds=32763	\N	\N	3340573	\N	\N	\N	\N	Melanoma, morphologically consistent with superficial spreading type, arising in chronically sun-damaged skin	FFPE	\N	\N	\N	307	\N	\N	21-30633	A1	CME-005	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2785	22-21012A3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-19	http://64.54.108.121/eSlideTray.php?ImageIds=32767	\N	\N	3340573	\N	\N	\N	\N	  Skin, forehead, right, wide excision, melanoma, recurrent. Microscopically, it shows presence of a few nests of epithelioid melanocytes with nuclear atypia, vacuolated cytoplasm and mitotic activity in the dermis. A recurrent melanoma is considered. Suture granulomas and scar tissue are also seen. Section margins are free (＞3 mm).	FFPE	\N	\N	\N	307	\N	\N	22-21012	A3	CME-005	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2787	22-21012A5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-18	http://64.54.108.121/eSlideTray.php?ImageIds=32769	\N	\N	3340573	\N	\N	\N	\N	  Skin, forehead, right, wide excision, melanoma, recurrent. Microscopically, it shows presence of a few nests of epithelioid melanocytes with nuclear atypia, vacuolated cytoplasm and mitotic activity in the dermis. A recurrent melanoma is considered. Suture granulomas and scar tissue are also seen. Section margins are free (＞3 mm).	FFPE	\N	\N	\N	307	\N	\N	22-21012	A5	CME-005	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2397	19-03114-6	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-29	https://64.54.108.121/app/WebViewer/view/image/36096,36097	\N	\N	\N	\N	\N	\N	\N	H19-03114 #6 (head)	FFPE	\N	\N	\N	351	\N	\N	None	\N	CME-049	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2925	89-13569-1 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1089	\N	\N	None	\N	MD-212	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2953	94-18018-2 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1090	\N	\N	None	\N	MD-213	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2951	94-12246 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1091	\N	\N	None	\N	MD-214	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3041	352-1-15.3	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	Left heel	\N	\N	\N	\N	7	\N	\N	None	\N	AM2-012	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3063	2686-1-13.1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-014_1.1	\N	\N	\N	\N	Finger	Punch	\N	\N	\N	8	\N	\N	None	\N	AM2-014	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3064	2686-1-13.2	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-014_1.2	\N	\N	\N	\N	Finger	\N	\N	\N	\N	8	\N	\N	None	\N	AM2-014	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3056	1586-2-13-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Metastasis	AM2-018_1.2, 4 small areas	\N	\N	\N	\N	inguinal lymph node	\N	\N	\N	\N	9	\N	\N	None	\N	AM2-018	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3055	1586-2-13-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-018_1.1	\N	\N	\N	\N	inguinal lymph node	\N	\N	\N	\N	9	\N	\N	None	\N	AM2-018	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3057	1586-2-13-C	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-018_1.3	\N	\N	\N	\N	Hallux	Punch	\N	\N	\N	9	\N	\N	None	\N	AM2-018	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3069	4070/2/13.3	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-022_1.3	\N	\N	\N	\N	finger	\N	\N	\N	\N	11	\N	\N	None	\N	AM2-022	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3072	4070/3/13.3	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-022_1.6, met in 1/17	\N	\N	\N	\N	axillary LN	\N	\N	\N	\N	11	\N	\N	None	\N	AM2-022	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3067	4070/2/13.1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-022_1.1	\N	\N	\N	\N	finger	Punch	\N	\N	\N	11	\N	\N	None	\N	AM2-022	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3068	4070/2/13.2	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-022_1.2	\N	\N	\N	\N	finger	\N	\N	\N	\N	11	\N	\N	None	\N	AM2-022	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3071	4070/3/13.2	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-022_1.5, met in 1/17	\N	\N	\N	\N	axillary LN	\N	\N	\N	\N	11	\N	\N	None	\N	AM2-022	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3070	4070/3/13.1	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-022_1.4, met in 1/17	\N	\N	\N	\N	axillary LN	\N	\N	\N	\N	11	\N	\N	None	\N	AM2-022	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2956	94-23180 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1092	\N	\N	None	\N	MD-215	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2950	94-08318-1 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1093	\N	\N	None	\N	MD-216	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1697	13-14077	66	\N	\N	\N	T2a	Primary	None	15	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2739	172.5	\N	\N	Sections show an asymmetrical and poorly circumscribed compound proliferation of melanocytes. Melanocytes are arranged as irregular single cells and nests within the epidermis and single melanocytes predominate over nests in some foci. In addition, scattered melanocytes are present in the spinous layer. In addition, there are nests and sheets of atypical melanocytes in the underlying dermis and the size of the melanocytes does not diminish with descent into the dermis. Solar elastosis is present in the dermis as well. Scattered mitotic figures are present amid dermal melanocytes as well.	Cylindrical skin segment, 0.3 cm in diameter and 0.4 cm in thickness, submitted intact. HD/HD	BCC	\N	\N	Scraping	A SOX-10 immunoperoxidase stain avidly labels the lesional cells, confirming the diagnosis of melanoma. The melanoma is between 1 and 2 mm in thickness, and is not ulcerated. Therefore,  should no more adverse findings be evident on complete excision, it would be classified as pT2a per the 2009 revision of the AJCC staging system for melanoma. Further treatment at this site is warranted.	MELANOMA, 1.1 MILLIMETERS IN THICKNESS, EXTENDING TO THE LATERAL ASPECTS OF THE SPECIMEN	173526	146	\N	\N	13-14077	\N	CCR-055	California Cancer Registry	IP1198820	AirTable blocks_with_IP_info.csv
2971	96-4039A5	48	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	698.3	\N	\N	Level sections show psoriasiform epidermal hyperplasia and overlying\nhyperkeratosis.  The papillary dermis is fibrotic.  There is solar\nelastosis.	Two skin segments measuring 4 x 3 x 2 mm and 4 x 4 x 4 mm.	1 CM CRUSTED NON-HEALING PLAQUE X 1 YR; CLINICAL DIAGNOSIS - R/O MALIGNANCY	\N	\N	\N	\N	\N	173614	1168	\N	\N	96-4039	A5	MP-04	Melanoma Epigenetics	IP80712	AirTable blocks_with_IP_info.csv
2972	96-4039A7	48	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	698.3	\N	\N	Level sections show psoriasiform epidermal hyperplasia and overlying\nhyperkeratosis.  The papillary dermis is fibrotic.  There is solar\nelastosis.	Two skin segments measuring 4 x 3 x 2 mm and 4 x 4 x 4 mm.	1 CM CRUSTED NON-HEALING PLAQUE X 1 YR; CLINICAL DIAGNOSIS - R/O MALIGNANCY	\N	\N	\N	\N	\N	173614	1168	\N	\N	96-4039	A7	MP-04	Melanoma Epigenetics	IP80712	AirTable blocks_with_IP_info.csv
1115	04-6689B	67	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.6	\N	\N	Sections show a broad, asymmetrical and poorly circumscribed proliferation of large melanocytes, present in a pagetoid pattern within the epidermis in some of the flat areas of the neoplasm.  In others, a dense band-like lymphocytic infiltrate is present, obscuring the junction and causing the rete ridge, dermal papilla pattern to nearly disappear.  Toward the center, a crust overlies a dome-shaped area within which there are sheets of large melanocytes with pleomorphic, vesicular nuclei.  Melanocytes in this area fail to mature with descent and mitotic figures are present in number.  Beneath this area, nests of melanocytes are seen adjacent to an eccrine sweat coil, and in slide B, around a small nerve.	Oriented ellipse measuring 5.5 x 2.2 x 1.2 cm, with central lesion measuring 1.7 x 1.5 cm. The far aspect of the specimen is preinked in blue. The far aspect of specimen is inked in red and the near half of specimen is inked in yellow. The specimen is serially sectioned perpendicular to the long axis from the left to the right and submitted with four sections each in cassettes A and B; tips returned to container\n	RED 2 CM PLAQUE WITH ULCER AT 1/28 BX SITE, NO PRIOR H/O ULCER, NO PIGMENTATION; AMELANOTIC MELANOMA, EXCISIONAL BX WITH 3 MM MARGINS FOR PROGNOSIS	\N	\N	Scraping	Melanoma cells extend around a nerve and into eccrine sweat coils beneath the main part of the lesion.  I did not include these nests in the thickness measurement, as they appear to have extended along adnexal and vascular structures.  There appears to be a recently healed ulcer, but this may reflect the previous biopsy rather than indicate tumor ulceration (which if present, is an unfavorable sign).  There is a moderate mitotic rate. While the excision appears complete, melanoma in situ extends sufficiently close to the edges of the specimen that further surgery seems advisable.  In addition, perineural invasion is present sufficiently close to the base of the specimen that a reexcision that extends to fascia, if present, would be worthwhile.	MELANOMA, AT LEAST 2 MM IN THICKNESS	173605	147	\N	\N	04-6689	B	CCR-057	California Cancer Registry	IP423088	AirTable blocks_with_IP_info.csv
1568	12-6261B	35	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.4	Melanocytic Nevus	\N	Sections show a dermal proliferation of melanocytes arrayed as nests and syncytia that diminish in size with descent in the dermis. The overlying epidermis shows a papillated configuration, with elongated rete that focally intertwine.	Skin segment, 0.5 x 0.4 x 0.4 cm, bisected and entirely submitted in cassette B.	A-B) NEVUS	\N	Neck	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	173403	1895	\N	\N	12-6261	B	SYNAT353	2010-2017	IP1092077	AirTable blocks_with_IP_info.csv
1567	12-6261A	35	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.3	Melanocytic Nevus	\N	Sections show a domed segment of skin, with nests, cords and strands of small round melanocytes in the dermis.	Skin segment measuring 0.8 x 0.8 x 0.1 cm, quadrisected, and entirely submitted in cassette A.	A-B) NEVUS	\N	Cheek	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	173304	1895	\N	\N	12-6261	A	SYNAT353	2010-2017	IP1092077	AirTable blocks_with_IP_info.csv
1540	11-94204	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26321	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	744	\N	\N	11-94204	\N	JJS5	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1584	12-12366	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	SCC	\N	\N	\N	\N	\N	Associated with Solar Keratosis, rt cheek	\N	\N	\N	\N	2036	\N	\N	12-12366	\N	SYNAT354	2010-2017	\N	AirTable blocks_with_IP_info.csv
1553	12-562	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1698	\N	\N	12-562	\N	SYNAT357	2010-2017	\N	AirTable blocks_with_IP_info.csv
1350	09-31608	66	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=386	172.4	\N	\N	Sections show a proliferation of spindled cells with hyperchromatic nuclei positioned between thickened collagen bundles in the upper dermis. A vaguely fascicular configuration is focally apparent. There is no increase in cellularity at the junction. A sparse and patchy lymphocytic infiltrate is also present.	Two skin segments measuring 0.8 x 0.7 x 0.1 cm, trisected, and 0.6 x 0.5 x 0.1 cm, bisected, entirely submitted.	FIBROMA VS. SCLEROSING BCC?	\N	\N	Scraping	There is no evidence of carcinoma. Rather, this biopsy shows early desmoplastic melanoma. We utilized immunoperoxidase staining to confirm lineage. There is avid expression of S100 protein, constituting a staining result that is strongly supportive of the above interpretation. There is general lack of expression of CD10 and procollagen by lesional cells, and thus it is clear that this proliferation is not of fibrous lineage. In terms of staging, this is a non-ulcerated melanoma with Clark's level IV invasion but without associated vascular invasion, perineural invasion, or regression. Further excision is warranted to ensure that local eradication has been accomplished. A call to Dr. Jacoby's cell phone regarding this diagnosis was placed at the time this report was issued, per request.	DESMOPLASTIC MELANOMA OF 1.0 MM IN THICKNESS, INVOLVING THE DEEP EDGE OF THE BIOPSY	173410	149	\N	\N	09-31608	\N	CCR-066	California Cancer Registry	IP832371	AirTable blocks_with_IP_info.csv
10008	12-13587	84	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	686.0	SCC	\N	Sections show a dense and diffuse infiltrate of neutrophils. There are a few islands of epithelial cells within the infiltrate that I interpret as squamous metaplasia of eccrine ductular epithelium. There are also fragments of keratin as seen in ruptured epidermal inclusion cysts.	Skin segment measuring 2.3 x 1.5 x 0.6 cm, with a central 1.6 x 1.4 cm brown area. With the peripheral edges and base inked blue, serially sectioned, with the specimen fragmenting upon sectioning, and entirely submitted with two sections in cassette A1, two sections plus one fragment in cassette A2, and two sections plus three fragments in cassette A3.	\N	\N	\N	\N	A PAS-D stain is negative for fungi, and a Brown-Brenn (Gram) and Fite stain do not reveal bacteria. The differential diagnosis includes a suppurative reaction to a ruptured (and fully digested) cyst or an infectious process not captured in the studies performed. There is no evidence of a neoplasm.	SOLAR KERATOSIS WITH UNDERLYING SUPPURATIVE DERMATITIS	173741	1411	\N	\N	12-13587	A	SYNX8	\N	IP502329	Consolidated_data_final.csv
1613	12-22602A	37	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.4	Melanocytic Nevus	\N	Sections show a predominantly intradermal proliferation of small melanocytes with round to oval nuclei that mature (diminish in size) with descent in the dermis.  The overlying epidermis shows elongated rete that intertwine.	Skin segment measuring 0.5 x 0.5 x 0.3 cm, bisected, wrapped with a fragment and entirely submitted in cassette A.	A-B) COSMETIC SHAVE REMOVAL IDN	\N	Intradermal, anterolateral neck	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	123455	2316	\N	\N	12-22602	A	SYNAT375	Melanocytic Nevus	IP1081809	AirTable blocks_with_IP_info.csv
1614	12-22602B	37	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.4	Melanocytic Nevus	\N	Sections show a dermal proliferation of melanocytes arrayed as nests and syncytia that diminish in size with descent in the dermis. The overlying epidermis shows a papillated configuration, with elongated rete that focally intertwine.	Skin segment measuring 0.6 x 0.5 x 0.3 cm, bisected and entirely submitted in cassette B.	A-B) COSMETIC SHAVE REMOVAL IDN	\N	Intradermal,posteriolateral neck	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	173477	2316	\N	\N	12-22602	B	SYNAT375	Melanocytic Nevus	IP1081809	AirTable blocks_with_IP_info.csv
1622	12-22884C	55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	Melanocytic Nevus	\N	Sections show a predominantly dermal proliferation of melanocytes that diminish in size with descent in the dermis.  Mitotic figures are inconspicuous.  Some small melanocytes are situated between reticular dermal collagen bundles.	Skin segment measuring 0.8 x 0.6 x 0.2 cm, bisected and entirely submitted in cassette C.	A-C) SK, D) IDN	\N	Intradermal, congenital pattern, back	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS, CONGENITAL PATTERN	173502	1676	\N	\N	12-22884	C	SYNAT379	Melanocytic Nevus	IP1108702	AirTable blocks_with_IP_info.csv
10287	11-23681A+C	58	t	\N	3	T4b	Primary	\N	\N	\N	\N	\N	\N	172.5	Ivanka Normal Resequencing	\N	Sections show a large polypoid ulcerated proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, many of which have markedly atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes arranged as an expansile nodule in the subjacent dermis. Focally pigmented aggregates of atypical melanocytes are noted.  There are numerous mitotic figures throughout the full thickness of the lesion.  The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.7 x 1.6 x 0.7 cm, serially sectioned and entirely submitted with four sections in cassette A, three sections in cassette B, and four sections in cassette C (includes fragments on cut).	\N	\N	\N	\N	Histopathologic features of possible prognostic importance include: Level:  IV Tumor infiltrating lymphocytes:  Non-brisk Vascular or lymphatic invasion:  Not identified Dermal mitotic rate:  3/mm2 Perineural invasion:  Not identified Ulceration:  Present Regression:  Not identified Microsatellite metastasis:  Not identified  Based on the 2009 AJCC melanoma staging system, this is a pT4b lesion.	MELANOMA, 5.5 MILLIMETERS IN THICKNESS ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	132590	1440	\N	\N	11-23681	A	SYNX37	\N	IP1013119	Consolidated_data_final.csv
1625	12-22894B	32	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.4	Melanocytic Nevus	\N	Sections show clusters of cytologically bland melanocytes, both at the dermal-epidermal junction and in the reticular dermis, where melanocytes lie between reticular dermal collagen bundles.	Skin segment measuring 1.2 x 0.8 x 0.3 cm, trisected and entirely submitted in cassette B.	A) 0.2 X 0.2 CM PINK-YELLOW PAPULE; R/O IRRITATED SEBACEOUS HYPERPLASIA VS. NEVUS, B) 1.1 X 0.5 CM HYPERPIGMENTED PATCH W/ VARIEGATED PIGMENTATION; R/O DMN VS. MIS S/P DEEP SHAVE BX	\N	Compound, congenital pattern, neck	\N	\N	COMPOUND MELANOCYTIC NEVUS, CONGENITAL PATTERN, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	173450	1694	\N	\N	12-22894	B	SYNAT381	Melanocytic Nevus	IP1108712	AirTable blocks_with_IP_info.csv
1312	08-25654	43	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=387	172.7	\N	\N	Sections show acral skin with a proliferation of melanocytes that extends into the deep reticular dermis. There are large nests positioned at, or just beneath the dermal-epidermal junction, composed of cells with abundant amphophilic cytoplasm and large, pleomorphic, vesicular nuclei that contain large nucleoli. Situated in the upper dermis are slightly smaller, but focally confluent nests of similar cells in which there are occasional mitotic figures. The nuclei in some of these nests appear to overlap. Smaller nests of small, round melanocytes, again with overlapping nuclei extend further into the dermis. There are patchy lymphocytic infiltrates, superficially joined by melanophages.	Cylindrical skin segment, 0.4 cm in diameter and 0.6 cm in thickness, bisected and entirely submitted.	R/O ATYPICAL NEVUS	\N	\N	\N	The thickness is listed as an estimate, as there are small cells near the base of the lesion that could represent either small melanoma cells or those of a pre-existent nevus. I favor the former, in which case the thickness would be closer to 3.0 mm. No ulceration is present, but there is an area in which the papillary dermis is thickened, fibrotic and inflamed that could represent regression. This may be clarified on complete excision. Additionally, the deep dermis is fibrotic. This may be a reaction to chronic inflammation, or could reflect a previous procedure or trauma at this site.	MELANOMA, AT LEAST 2.0 MM IN THICKNESS	173713	150	\N	\N	08-25654	\N	CCR-067	California Cancer Registry	IP734295	AirTable blocks_with_IP_info.csv
10655	12-22776B3	36	f	\N	\N	T2a	Primary	\N	\N	\N	\N	\N	\N	172.9	Iwei Acral Melanoma	\N	Sections show a biopsy site on acral skin with an adjacent, broad proliferation of atypical melanocytes arranged in an irregular pattern within the epidermis, and with similar cells extending broadly into the dermis. There is a dense lichenoid lymphocytic infiltrate. In some areas melanocytes are present in pagetoid array within the epidermis.	Oriented skin excision with curled and twisted appearance, 3.2 x 2.6 x 0.5 cm, including a nearly central 2.3 x 1.6 cm gray-brown area. With the orienting suture at one end placed to the left and designated proximal edge by the surgeon, the far margin is inked blue and the near margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis from proximal to distal and entirely submitted with three sections each in cassettes B1 and B2, two sections each in cassettes B3 through B5, and three sections in cassette B6.	\N	\N	\N	\N	We do not have a record of a prior biopsy on this site. Can you please forward a copy of the previous pathology report to our office. Histopathologic features of possible prognostic importance include:  Level: IV Vascular or lymphatic invasion: absent Dermal mitotic rate: rare mitotic figures Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: not detected Stage: pT2a	BIOPSY SITE WITH RESIDUAL ACRAL MELANOMA, 1.5 MM IN THICKNESS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	666955	1420	\N	\N	12-22776	B	SYNX17	\N	IP1096148	Consolidated_data_final.csv
2632	20-43801	43	\N	\N	\N	None	None	None	5	0	FFPE	\N	\N	216.6	\N	\N	Sections show a predominantly intradermal proliferation of melanocytes, in which nests, cords and strands of small, round cells mature to spindled melanocytes as they extend into the reticular dermis. Some of the dermal melanocytes are pigmented. The overlying epidermis displays elongated, hyperpigmented rete ridges.	Cylindrical skin segment, 0.5 cm in diameter and 0.5 cm in thickness, bisected and entirely submitted. CF/HD	R/O DYSPLASTIC NEVUS VS. MM	\N	\N	FFPE	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES	173641	1385	\N	\N	20-43801	\N	SN-22	Sclerotic Nevi	IP2191480	AirTable blocks_with_IP_info.csv
3209	Cell-Line_Xu-19	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2063	\N	\N	None	\N	SYNAT162	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
2339	18-75585B	57	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26413	172.5	\N	\N	Sections show a compound melanocytic proliferation with a biphasic pattern, as small melanocytes are also present deep to the atypical melanocytes. A lymphohistiocytic infiltrate with admixed melanophages is also noted.	Oriented ellipse, 1.8 x 1.1 x 0.7 cm, including a central 0.8 x 0.6 cm variegated area. The orienting sutured tip is indicated medial on the requisition. This sutured tip is designated 3 o'clock by the grosser and is placed toward 3 o'clock. The 9-12-3 o'clock margin is inked blue and the 3-6-9 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and entirely submitted with three sections each in A-B. BY/BY	6 X 16 MM DARK BROWN TO BLACK PAPULE WITH IRREGULAR ERYTHEMA, BLUE WHITE VEIL, ATYPICAL PIGMENT NETWORK, MEDIAL ASPECT TAGGED; R/O MELANOMA	\N	MELANOMA OF 2.3 MM IN THICKNESS, EXTENDING INTRAEPIDERMALLY TO THE INKED PERIPHERAL MARGIN	FFPE	This specimen demonstrates melanoma overlying a remnant of congenital melanocytic nevus. A brief synoptic is included below. Procedure: subtotal excision Microscopic tumor type: melanoma ex melanocytic nevus Breslow thickness: 2.3 mm Ulceration: not detected Margin: involved by melanoma in situ Mitotic index: 2 per square mm Vascular invasion: not detected Regression: present; partial Pathologic staging (pTNM): pT2a	MELANOMA OF 2.3 MM IN THICKNESS, EXTENDING INTRAEPIDERMALLY TO THE INKED PERIPHERAL MARGIN	102538	1145	\N	\N	18-75585	B	ME-50	Melanoma Epigenetics	IP844686	AirTable blocks_with_IP_info.csv
1474	11-032523A1	62	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.11	\N	\N	Sections show an epidermal proliferation of small keratinocytes arrayed as thickened or interconnecting rete in a specimen with a papillated profile. In addition, there is a band-like lymphohistiocytic infiltrate juxtaposed upon the epidermal-dermal junction, with areas of vacuolar alteration with necrotic keratinocytes.  There is also an area in the mid-dermis in which there is fibrosis along with keloidal collagen.	Skin segment measuring 0.9 x 0.4 x 0.1 cm, bisected and entirely submitted.	R/O BCC	\N	\N	\N	A scar is present in the mid-dermis, and some of the inflammation present in the dermis probably is due to the scarring reaction. I have also shared this case with my colleague, Dr. Thaddeus Mully, who agrees with this assessment.	SEBORRHEIC KERATOSIS WITH AN ADJACENT LICHEN PLANUS-LIKE KERATOSIS	173527	2324	\N	\N	11-32523	A1	SYNAT72	2010-2017	IP939446	AirTable blocks_with_IP_info.csv
2644	20-57308	27	\N	\N	\N	None	None	None	5	0	FFPE	\N	\N	216.7	\N	\N	Sections show a compound proliferation of medium-sized melanocytes, many of which are finely pigmented. There are nests, cords, fascicles, and small syncytia in the dermis, with very focal palisading of cellularity, and the superjacent epidermis contains a prominent component with many nests and fascicles and limited epidermal consumption. Adnexal extension and melanophages are noted. Expression of p16 is avid. The Ki-67 cell proliferation index is low. In one area of deeper dermal extension, the encompassing stroma appears hyalinized.	Seven outside slides, DD20-09516 (A1). Six unstained received 7/24/20.	PRESENT AT LEAST 15 YEARS, RECENTLY DOUBLED IN 6 MONTHS, AND DARKER IN THE CENTER, OCCASIONALLY ITCHY; IMPRESSION WAS R/O DN VS. MELANOMA VS. CONGENITAL NEVUS	\N	\N	FFPE	I fully agree that the histomorphology within these slides closely resembles that of a congenital melanocytic nevus. With that having been noted, please additionally note that I do not believe this tumor is of conventional lineage, meaning that I do not believe that an underlying BRAF or NRAS mutation served as the molecular starting point. Rather, to my eye the histopathologic pattern suggests a small cell Spitz nevus induced by kinase gene fusion. More narrowly, I suspect a Spitz nevus induced by MYO5A/NTRK3 gene fusion. As my diagnosis implies, I believe there is only one population of melanocytes in these sections. There are some large nests that probably correlate with the recent enlargement observed clinically, and there is also stromal hyalinization as an apparent indicator of longevity. There is no evidence of malignancy, and there is also no indication of atypicality, at least not in the conventional sense of that term.  Thank you for providing unstained slides. I will provide additional information regarding molecular findings at a later point in time.	PIGMENTED FASCICULAR COMPOUND SPITZ NEVUS	173733	1390	\N	\N	20-57308	\N	SN-27	Sclerotic Nevi	IP2205057	AirTable blocks_with_IP_info.csv
2984	96-20650-1A T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1072	\N	\N	None	\N	MD-195	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1951	16-42198	48	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	There is a dome surfaced, wedge shaped proliferation of large oval and fusiform melanocytes with abundant pale cytoplasm and large, moderately pleomorphic vesicular nuclei that mature and disperse evenly with descent, with preservation of p16 staining.	Nine outside slides, MS16-8430-1A. One corresponding block received 6/3/16.	RUA SKIN LESION	\N	\N	\N	The accompanying cover letter detailing fluorescence in situ hybridization studies mentions hemizygous deletions of all four chromosomal loci that were tested. I have not encountered this, and asked my colleague, Dr. Boris Bastian, who developed the FISH test for melanoma, for his comments. He was skeptical of this result, and suggested that the testing was done on sections that were too thin. Otherwise, the findings appear to be those of a Spitz's nevus with a characteristic domed surface, wedge shaped base and diminishing cellularity toward the base of the lesion. The retention of p16 is a reassuring finding. A zone of granulation tissue implying a prior biopsy site is present, with a limitation of this evaluation being that if so, the sections from the biopsy are not included.  The margins appear clear in the planes of section examined.  We then tried to verify or refute the presence of chromosomal copy number changes by comparative genomic hybridization, per your message.  Following microdissection and DNA extraction, we performed comparative genomic hybridization. It shows an isolated gain involving chromosome 11p, but no other aberrations, implying that the impression of hemizygous deletions was artifactual. Isolated 11p gain usually corresponds to two copies of 11p joined by a centromere, and has not been seen to date in melanoma. Spitz's nevi with this aberration are likely to have a mutation involving h-ras, and to deeply infiltrate the reticular dermis as single cells, findings that are present here.  References:  van Engen-van Grunsven AC, van Dijk MC, Ruiter DJ, Klaasen A, Mooi WJ, Blokx WA. HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features. Am J Surg Pathol. 2010 Oct;34(10):1436-41.  Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000 Sep;157(3):967-72.	SPITZ'S NEVUS, PREDOMINANTLY INTRADERMAL	173688	707	\N	\N	16-42198	\N	DP-70	CGH Validation	IP1641515	AirTable blocks_with_IP_info.csv
2998	98-6161B	73	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=993	172.5	\N	\N	Sections show nested and solitary melanocytes, some with atypical\nnuclei, arrayed irregularly within the epidermis as both single\ncells and as laterally confluent nests.  In the underlying dermis,\nthere are irregularly-shaped, horizontally-oriented clusters of\nsimilar but slightly smaller melanocytes, which are surrounded by\nfibrosis.  These changes are present above elastosis.  There is a\nbandlike infiltrate of lymphocytes in the papillary dermis.\nMultinucleated melanocytes are present in both the junctional and\nintradermal components.	Cylindrical skin segment measuring 0.3 cm in diameter and 0.3 cm in\nthickness.	B - ERYTHEMATOUS PAPULE, 4X4 MM WITH RING OF PIGMENT, B - AMELANOCYTIC PAPULE IN CENTER OF EVENLY PIGMENTED MACULE; CLINICAL DIAGNOSIS - A) R/O BCC, B) R/O MM, C ) R/O MM, REMAINING DATA ON FILE	\N	\N	\N	Melanomas in which small, round cells predominate in the dermal component have been termed nevoid melanoma, or minimal deviation melanoma. Several studies have suggested that there is no prognostic difference between this form and conventional melanoma.	MELANOMA, MEASURING 0.35 MM IN THICKNESS.	152589	164	\N	\N	98-6161	B	CCR-125	California Cancer Registry	IP136586	AirTable blocks_with_IP_info.csv
3210	Cell-Line_Xu-20	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2233	\N	\N	None	\N	SYNAT163	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
1167	05-19406	87	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.6	\N	\N	There is a proliferation of melanocytes with abundant, pale cytoplasm and dusty appearing melanin in apposition to a thinned epidermis, flanked on one side by a small zone with some pagetoid scatter, and on the other by a thickened and fibrotic papillary dermis, loss of rete ridges and diminished numbers of melanocytes.	Skin segment measuring 1.9 x 1.4 x 0.2 cm, entirely submitted in five sections.	1 YR H/O DK IRREG BLACK PLAQUE; R/O MELANOMA	\N	\N	Scraping	Melanoma in situ is present less than 1 mm. from the peripheral margin. Histopathologic features of possible prognostic importance include:  Level: III Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: present, over 50% in some sections Microsatellite metastasis: absent	MELANOMA, 1.5 MM  IN THICKNESS	173619	126	\N	\N	05-19406	\N	CCR-010	California Cancer Registry	IP496118	AirTable blocks_with_IP_info.csv
2310	18-27178B	66	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with single cells and nests arrayed along the sides and bases of elongated, pigmented rete, and maturing nests, cords, and fascicles of similar cells are present in the upper dermis, which also harbors scattered melanophages. Many lesional melanocytes have finely melanized cytoplasm. Some are fusiform.	Skin segment measuring 1.0 x 0.9 x 0.3 cm, quadrisected and entirely submitted in B. RS/PL	A) NEOPLASM OF UNCERTAIN BEHAVIOR. . B) NEOPLASM OF UNCERTAIN BEHAVIOR. .	\N	\N	Scraping	This broad melanocytic nevus exhibits mixed features of a lentiginous melanocytic nevus and a deep penetrating nevus. Partial balloon cell change is noted.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, EXCISED IN THE AVAILABLE PLANES OF SECTION	528522	861	\N	\N	18-27178	B	LN-043	Lentiginous Nevi 	IP401538	AirTable blocks_with_IP_info.csv
1852	15-16907A	63	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	There are large, pan-dermal and superficial subcutaneous masses of melanocytes with eccentric nuclei and a somewhat plasmacytoid appearance. The nuclei are moderately enlarged and oval, with relatively small nucleoli. It is difficult to find mitotic figures. Occasional pyknotic nuclei are present. The epidermis is uninvolved. The deep subcutis is replaced by dense, paucicellular fibrosis.	Two outside slides, DRVS15-1294-A1. One corresponding block received 3/3/15.	PATIENT WITH HISTORY OF MELANOCYTIC PROLIFERATION IN 2007 ON RIGHT SCALP, ORIGINALLY READ AS 3.2 MM MELANOMA NEVOID TYPE BT STANFORD PATHOLOGY, THE READ AS COMBINED MELANOCYTIC NEVUS BY UCSF, PATIENT PRESENTING WITH TWO LESIONS OF CONCERN, A) 4 MM PINK MACULE ON THE SURGICAL SCAR, B) 1 CM PINK/PURPLE ON A 5 MM STALK NOT TOUCHING THE SCAR LINE (SEE PHOTOS)	\N	\N	\N	\N	INTRADERMAL MELANOCYTIC PROLIFERATION ABOVE A SCAR, WITH IMMUNOHISTOCHEMICAL EVIDENCE OF BAP-1 LOSS, AND MULTIPLE CHROMOSOMAL COPY NUMBER CHANGES, SEE NOTE (B)	143499	675	\N	\N	15-16907	A	DP-38	CGH Validation	IP677717	AirTable blocks_with_IP_info.csv
2305	18-18111C	58	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show an excision specimen of skin with a well-circumscribed small compound proliferation of melanocytes. Within the epidermis, lesional melanocytes are distributed predominantly in small nests and single cells along the sides and the bases of the thin rete ridges. In the dermis, the melanocytes are organized into small nests and cords that exhibit maturation with decent. Melanophages ar scattered in the superficial dermis and there is minimal solar elastosis.	Skin segment measuring 1.0 x 0.8 x 0.1 cm, quadrisected and entirely submitted in C. BY/PL	R/O ATYPICAL NEVI	\N	\N	Scraping	These biopsies all show similar features and appear to represent the patient's signature nevus. There are some features of a Clark's or dysplastic nevus. No evidence of melanoma or significant atypia was detected.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS WITH ASSOCIATED MELANOPHAGES	623544	2001	\N	\N	18-18111	C	LN-056	Lentiginous Nevi 	IP683601	AirTable blocks_with_IP_info.csv
1042	02-5600A	63	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=316	172.6	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei\nin partial contiguity with the epidermis.  There is little\ndiminishment in melanocyte size with descent in the dermis.  The\nconstituent melanocytes have ample vacuolated and pigmented\ncytoplasm, and there are many intervening melanophages as well.  A\nfew scattered single necrotic melanocytes are identifiable, although\nthe number of mitotic figures is not striking.  There is a permeative\nlymphocytic infiltrate near the base of the process, and deeper in\nthe dermis elastosis is evident.	Oriented ellipse measuring 2.1 x 1.0 x 0.4 cm including central 0.8 x\n0.6 cm black lesion.  With the superior margin preinked black and the\ninferior half preinked yellow, three central representative sections\nare submitted in cassette A and two sections in cassette B, tips\nreturned to container.in aggregate	R/O MM	\N	\N	Scraping	This is a non-ulcerated primary melanoma with a nodular pattern.  There is a subtle concurrent element of regression, but I doubt that these findings are sufficiently developed to be of clinical significance. There is no evidence of vascular or perineural invasion in this specimen.	MELANOMA, 1.1 MM IN THICKNESS, NARROWLY BUT COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE FREE OF MELANOMA CELLS)	173688	188	\N	\N	02-5600	A	CCR-208	California Cancer Registry	IP76569	AirTable blocks_with_IP_info.csv
1239	06-23240A	67	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=5995	238.2	\N	\N	Sections show a zone of lymphohistiocytic inflammation and fibrosing granulation tissue, representing a prior biopsy or surgical site, with no evidence of an atypical melanocytic proliferation.	Oriented ellipse measuring 2.9 x 1.3 x 0.7 cm, including central 0.6 x 0.6 cm white area. With 9-3 o'clock edge preinked black, the far margin is inked blue the near margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and submitted with four sections each in cassette A and B, tips returned to container.	LENTIGINOUS PROLIFERATION OF MELANOCYTES (DT06-18879)	\N	\N	FFPE	The atypical melanocytic lesion that once resided her has been completely eradicated. There is an incidental small lentiginous melanocytic nevus within this reexcision specimen.	POST-SURGICAL CHANGES, WITH NO EVIDENCE OF RESIDUAL MELANOCYTIC NEOPLASM	173688	2222	\N	\N	06-23240	A	CCR-209	Melanoma Epigenetics	IP76569	AirTable blocks_with_IP_info.csv
2407	19-5916	81	\N	\N	\N	None	None	None	20	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26423	172.6	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.1 x 1.0 x 0.8 cm, with the base inked, quadrisected and entirely submitted. CF/CF	R/O MM	\N	MELANOMA, 2.2 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	ADDENDUM, January 25, 2019: This report is being reissued to correct the anatomic site of the biopsy.  A synoptic report of potential prognostic factors is listed below:  Procedure: excisional biopsy Microscopic tumor type: superficial spreading melanoma Breslow thickness: 2.2 mm Ulceration: absent Margins, peripheral and deep: both narrow Mitotic index: 2 mm/2 Regression: not identified Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT3a	MELANOMA, 2.2 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173620	1147	\N	\N	19-5916	\N	ME-52	Melanoma Epigenetics	IP1359612	AirTable blocks_with_IP_info.csv
2586	20-05671-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-32	https://64.54.108.121/app/WebViewer/view/image/36039,36040,36041	\N	\N	\N	\N	\N	\N	\N	H20-05671 #2 (head)	FFPE	\N	\N	\N	367	\N	\N	None	\N	CME-065	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2875	23-03515-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-32	https://64.54.108.121/app/WebViewer/view/image/36042,36043	\N	\N	\N	\N	\N	\N	\N	H23-03515 (recurrence 2 years later in right flank) #1	FFPE	\N	\N	\N	368	\N	\N	None	\N	CME-066	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2687	21-04690-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-32	https://64.54.108.121/app/WebViewer/view/image/36042,36043	\N	\N	\N	\N	\N	\N	\N	H21-04690 (right flank) #3	FFPE	\N	\N	\N	368	\N	\N	None	\N	CME-066	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2696	21-09119N2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-33	https://64.54.108.121/app/WebViewer/view/image/36046,36047,36048,36110	\N	\N	\N	\N	\N	\N	\N	H21-09119 N2 occipital lymph node	FFPE	\N	\N	\N	371	\N	\N	21-9119	N2	CME-069	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2694	21-09119-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-33	https://64.54.108.121/app/WebViewer/view/image/36046,36047,36048,36110	\N	\N	\N	\N	\N	\N	\N	H21-09119 #2 (left occiput)	FFPE	\N	\N	\N	371	\N	\N	None	\N	CME-069	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2695	21-09119-4	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-33	https://64.54.108.121/app/WebViewer/view/image/36046,36047,36048,36110	\N	\N	\N	\N	\N	\N	\N	H21-09119 #4 (satellite lesion)	FFPE	\N	\N	\N	371	\N	\N	None	\N	CME-069	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2697	21-09543-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-33	https://64.54.108.121/app/WebViewer/view/image/36049,36050	\N	\N	\N	\N	\N	\N	\N	H21-09543 #1 (right thigh)	FFPE	\N	\N	\N	372	\N	\N	None	\N	CME-070	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2698	21-09543-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-33	https://64.54.108.121/app/WebViewer/view/image/36049,36050	\N	\N	\N	\N	\N	\N	\N	H21-09543 #2 (metastasis in right neck)	FFPE	\N	\N	\N	372	\N	\N	None	\N	CME-070	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2766	22-00847N5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-33	https://64.54.108.121/app/WebViewer/view/image/36051,36052	\N	\N	\N	\N	\N	\N	\N	H22-00847 (left axillary lymph node) N5	FFPE	\N	\N	\N	373	\N	\N	22-847	N5	CME-071	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2699	21-09545-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-33	https://64.54.108.121/app/WebViewer/view/image/36051,36052	\N	\N	\N	\N	\N	\N	\N	H21-09545 #2 (left axilla)	FFPE	\N	\N	\N	373	\N	\N	None	\N	CME-071	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1201	06-4069	76	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=320	172.7	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, arranged irregularly within the epidermis, with foci of pagetoid spread, flanking an ulcerated nodular proliferation of large oval melanocytes that do not mature with descent into the dermis. The latter cells have abundant, pale eosinophilic cytoplasm and large, pleomorphic vesicular nuclei and some are in mitosis.	Ellipse, 1.8 x 1.0 x 0.8 cm, including a central 0.6 x 0.6 cm lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections.	R/O PYOGENIC GRANULOMA	\N	\N	Scraping	Melanoma in situ extends to the periphery of the specimen. Histopathologic features of possible prognostic importance include:  Level: IV Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: present Regression: absent Microsatellite metastasis: absent  The lesion is hypomelanotic, reflecting your clinical impression.	MELANOMA, 3 MM  IN THICKNESS	154799	196	\N	\N	06-4069	\N	CCR-219	California Cancer Registry	IP549135	AirTable blocks_with_IP_info.csv
2844	22-104389A2	2	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=28255,28256,28257,28258,28260,28261,28262,28263	238.2	Tumor	\N	Sections show melanocytes arrayed singly and in clusters irregularly within the epidermis, with a zone of scar that also encompasses similar clusters of cells. Some cells have moderately large spindled nuclei with abundant, pale amphophilic cytoplasm and interspersed melanophages.	Oriented irregular shaped excision, 4.4 x 1.9 x 0.6 cm, including a central 0.9 x 0.7 cm crusted area and generalized brown spots ranging from 0.2 x 0.2 cm to 0.3 x 0.2 cm. The orienting sutured tip is indicated as superior adjacent to lateral campus on the requisition form, designated as 12 o'clock by the grosser, and placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock and 6-9-12 o'clock edges, blue and yellow, respectively. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and entirely submitted with five sections in A1, four sections in A2, five sections in A3, and six sections and fragment in A4. HD/HD	WIDE LOCAL EXCISION MALIGNANT LESIONS RIGHT FACE X4	\N	Right Cheek	FFPE	The residuum is broad and composed of a heterogenous population of melanocytes including some small melanocytes and some large cells. The largest, nodular zone of melanocytes with the most atypical features appears completely excised. There are multi-focal areas of the melanocytoma that are present at the peripheral margins. After reviewing the clinical images, this is not surprising given the large pigmented patch from which these nodular lesions are arising.	SCAR AND RESIDUAL WNT-ACTIVATED/DEEP PENETRATING MELANOCYTOMA, SEE NOTES	173305	411	\N	\N	22-104389	A2	CS-01	Clinical Cases	IP2435904	AirTable blocks_with_IP_info.csv
1030	01-16263	58	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2741	172.5	\N	\N	Sections show a compound proliferation of melanocytes arrayed as irregular nests along the epidermal-dermal junction, with nests and sheets of atypical melanocytes in the underlying dermis.  Most of the melanocytes have atypical nuclei and ample vacuolated and pigmented cytoplasm, and a few dermal mitotic figures are appreciable.  There is an substantial lymphocytic infiltrate in the papillary dermis.	Oval-shaped excision, 1.8 x 1.5 x 1.0 cm, with margins inked blue,\nthree central sections submitted, incorporating the central pigmented\nzone, with tips returned to container.	13 X 11 MM PLAQUE; R/O MM	\N	\N	Scraping	The in situ component of this lesion is arranged in a predominantly nested fashion, resembling the configuration of a dysplastic nevus.  Indeed, it is possible that this melanoma evolved from a dysplastic nevus.  There are changes of regression present, but I doubt that the regressive alteration has significantly influenced the above microstage measurement.  There is no evidence of vascular or perineural invasion, and there is also no evidence of ulceration.  The tip margins of this specimen were not grossed for microscopic assessment, and as it appears that this site will be excised further, I intend to defer further assessment of the specimen tips.  If you prefer for the tips to be examined, please give me a call.	MELANOMA, 1.6 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO WITHIN 1 MM OF THE PERIPHERAL BIOPSY MARGIN	528522	153	\N	\N	01-16263	\N	CCR-086	California Cancer Registry	IP272666	AirTable blocks_with_IP_info.csv
1253	06-64692B	58	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=322	172.5	\N	\N	Sections show sheets and fascicles of spindled malignant cells, many of which have atypical nuclei or were captured in mitosis and many of which have pigmented cytoplasm. There is no maturation with descent. A few similar cells are scattered within the epidermis. There is a background of dermal fibroplasia with a variable infiltrate of lymphocytes and melanophages.	Skin segment measuring 1.2 x 1.0 x 0.7 cm, quadrisected and entirely submitted in cassette B.	A) TWO-TONED NEVUS, B-C) MELANOMA	\N	\N	Scraping	The present partial biopsy shows a non-ulcerated melanoma with invasion of the reticular dermis (Clark's level IV). There is no evidence of vascular invasion, neurotropism, or regression, but these attributes should be reassessed upon complete extirpation.	MELANOMA OF AT LEAST 3.8 MM IN THICKNESS, EXTENSIVELY TRANSECTED AT THE DEEP BIOPSY MARGIN	528599	197	\N	\N	06-64692	B	CCR-220	California Cancer Registry	IP609761	AirTable blocks_with_IP_info.csv
2893	23-7246A 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	413	\N	\N	23-7246	A	DMS-001	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2895	23-7246C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	413	\N	\N	23-7246	C	DMS-001	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2859	22-125373	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=29100,29101,29102,29103,29104,29105,29106,29107,29108,29109,29110	\N	\N	(ST22-7809-A2)	\N	\N	\N	\N	\N	\N	\N	\N	\N	412	\N	\N	22-125373	\N	CS-02	Cell Line	\N	AirTable blocks_with_IP_info.csv
2828	22-90430	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	440	\N	\N	22-90430	\N	DMS-028	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2102	17-34432B	32	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10856	216.5	DN	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted in B. KC/KC	A-D) R/O DN, HISTORY OF CLARK'S, DYSPLASTIC NEVUS	\N	\N	Scraping	The findings are well within the spectrum of those seen in dysplastic (Clark's) nevi. There are no microscopic features that compel re-excision.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE BASE OF THE SPECIMEN	100578	490	\N	\N	17-34432	B	DN-015	Dysplastic Nevi	IP1697427	AirTable blocks_with_IP_info.csv
2901	23-18865	42	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30878	172.4	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Two skin segments measuring 0.9 x 0.9 x 0.3 cm in aggregate. With the larger skin segment quadrisected, a total of five sections is entirely submitted. HD/HD	7 MM BRIGHT PINK SHINY PAPULE WITH DARK BROWN BORDER; R/O PIGMENTED BCC VS. OTHER	\N	\N	\N	Diagnostic features of note include: Procedure: Shave Tumor site: Scalp Microscopic tumor type: High chronic sun-damage Breslow thickness: 2.4 mm at least Ulceration: Present Margins, peripheral and deep: Involved Mitotic index: 3/mm2 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT3b at least	MELANOMA, AT LEAST 2.4 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	102499	1702	\N	\N	23-18865	\N	SYNAT177	Melanoma Epigenetics	IP2557030	AirTable blocks_with_IP_info.csv
1482	11-37100B	65	\N	\N	\N	T1a	Primary	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=970	172.5	\N	\N	Sections show a proliferation of melanocytes distributed as single cells and nests along the sides and bases of elongated pigmented rete. The dermis below this shows considerable elastosis and also superficial fibrosis. There is a sparse superficial dermal lymphohistiocytic infiltrate with admixed melanophages. Near the junction, dermal nests and cords of melanocytes can also be seen.	Skin segment measuring 1.0 x 1.0 x 0.1 cm, quadrisected and entirely submitted in cassette B.	A) R/O MELANOMA WITH ERYTHEMA, B) SL, R/O MELANOMA	\N	\N	\N	With respect to staging, this melanoma is also of stage T1a. As for the specimen above, further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.45 MM IN THICKNESS, EXTENDING INTRAEPIDERMALLY TO THE SPECIMEN PERIPHERY	139522	156	\N	\N	11-37100	B	CCR-099	California Cancer Registry	IP1026539	AirTable blocks_with_IP_info.csv
3089	16053/12 wy (16053/12 slide)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1208	\N	\N	None	\N	NM-029	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3062	2227/14 4	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1209	\N	\N	None	\N	NM-031	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1593	12-15765B3	78	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	There is a proliferation of melanocytes along the dermo-epidermal junction, with small nests and horizontally oriented single cells disposed mostly at the sides and bases of elongated rete ridges above an altered papillary dermis. Many of the melanocytes have large, hyperchromatic nuclei and scant cytoplasm. The bases of some adjacent rete ridges are fused, with subjacent fibroplasia.	Skin segment measuring 1.2 x 1.1 x 0.1 cm, serially sectioned and entirely submitted with five sections.	1 CM HYPERPIGMENTED PATCH; R/O ATYPIA	\N	\N	\N	The neoplasm diminishes in cellularity toward, but extends to the periphery of the specimen. Given the degree of non-spitzoid cytologic atypia, I would consider a narrow re-excision of this site.	JUNCTIONAL MELANOCYTIC NEVUS, CLARK'S (DYSPLASTIC) TYPE	333504	1799	\N	\N	12-15765	B3	SYNAT80	2010-2017	IP1101581	AirTable blocks_with_IP_info.csv
1597	12-18826	75	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.4	\N	\N	Sections show a proliferation of melanocytes arrayed as single cells in lentiginous fashion along the sides and bases of pigmented rete. The dermis deep to this shows elastosis and considerable fibrosis. Scattered perijunctional lymphocytes and melanophages are also apparent.	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely submitted in cassette A.	A-B) HISTORY OF MELANOMA, 3 X 3 MM BR PAPULES	\N	\N	\N	SOX-10 immunostaining and level sections demonstrate a small lesion with only a slight increase in melanocytes at the junction, and this configuration points to interpretation as a lentigo.	LENTIGO SIMPLEX, APPARENTLY EXCISED IN THE AVAILABLE PLANES OF SECTION	333433	2192	\N	\N	12-18826	\N	SYNAT81	2010-2017	IP535712	AirTable blocks_with_IP_info.csv
1598	12-19018B	61	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show an apparently circumscribed, multinodular proliferation of epithelial cells, many of which are polygonal and have abundant pallid eosinophilic cytoplasms.  Ductular differentiation is apparent.	Oriented elliptical excision, 2.0 x 1.3 x 0.8 cm, including a central 1.0 x 1.0 cm pink tan and raised area.  With the orienting suture designated 12:00, posterior tip by the surgeon, the 12:00-6:00 margin is inked blue and the 6:00-12:00 margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from 12:00 to 6:00 tips and entirely submitted with five sections each in cassette A and B.\n	DOME-SHAPED PINK-TAN NODULE WITH POSITIVE DIMPLE SIGN; DERMATOFIBROMA VS. HYPERTROPHIC SCAR, PLEASE CHECK MARGINS	\N	\N	\N	None	CLEAR CELL HIDRADENOMA	101544	2157	\N	\N	12-19018	B	SYNAT82	2010-2017	IP1104835	AirTable blocks_with_IP_info.csv
1617	12-22720A1	46	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	Leiomyoma	\N	Sections show a fascicled dermal proliferation of spindled cells with blunt-ended nuclei and eosinophilic cytoplasm situated in the superficial reticular dermis.  Mitotic figures are inconspicuous.	Ellipse, 1.8 x 0.7 x 0.8 cm, including 0.5 x 0.4 cm central raised area. With the peripheral and deep margins inked blue, the specimen is serially sectioned left to right perpendicular to the long axis and entirely submitted with four sections in cassette A1, three sections in cassette A2.	A) 0.6 X 0.6 CM IRREGULARLY PIGMENTED PAPULE; R/O MALIGNANCY MELANOMA VS. LEIOMYOMA VS. NEVUS, B) 0.5 CM X 0.8 CM PAINFUL ERYTHEMATOUS PLAQUE; R/O LEIOMYOMA	\N	Upper back	\N	\N	LEIOMYOMA, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	174533	1773	\N	\N	12-22720	A1	SYNAT85	2010-2017	IP118827	AirTable blocks_with_IP_info.csv
2120	17-35917A	34	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	DN	\N	Sections show a compound proliferation of melanocytes arrayed largely as nests along the epidermal-dermal junction and in the subjacent superficial dermis, and some neoplastic melanocytes have ample vacuolated and pigmented cytoplasm.  The superficial dermis also contains a permeative infiltrate of lymphocytes.	Cylindrical skin segment, 0.3 cm in diameter and 0.4 cm in thickness, submitted intact in A. CF/CF	A) JUNCTIONAL MELANOCYTIC NEVUS VS. RULE OUT ATYPICAL MELANOCYTIC PROCESS. SOMEWHAT TRIANGULARLY-SHAPED BROWN MACULE WITH PERIPHERAL DOTS ALONG ONE PERIPHERAL EDGE, BUT NOT ALONG THE REST OF THE LESION'S EDGE. LESION SIZE 4 MM; 4 MM P PERFORMED. B) JUNCTIONAL MELANOCYTIC NEVUS VS. SPITZ NEVUS, RULE OUT ATYPICAL MELANOCYTIC PROCESS. REGULAR, SYMMETRIC BROWN MACULE WITH SUBTLE PSEUDOPODS ALL AROUND PERIPHERY. LESION SIZE 2 MM; 3 MM P PERFORMED.	\N	\N	Scraping	April 27, 2017: There is no need for a re-excision.	COMPOUND MELANOCYTIC NEVUS, INFLAMED	239512	493	\N	\N	17-35917	A	DN-018	Dysplastic Nevi	IP1765368	AirTable blocks_with_IP_info.csv
2595	20-10245F1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1170	\N	\N	20-10245	F1	MucM-02	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
2594	20-10245D1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1170	\N	\N	20-10245	D1	MucM-02	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
2596	20-10245H3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1170	\N	\N	20-10245	H3	MucM-02	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
2100	17-33973C4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1171	\N	\N	17-33973	C4	MucM-03	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
2101	17-33973D3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1171	\N	\N	17-33973	D3	MucM-03	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
2099	17-33973A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1171	\N	\N	17-33973	A1	MucM-03	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
1514	11-71241	10	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a predominantly intradermal proliferation of melanocytes with abundant, pale, vacuolated, amphophilic cytoplasm with melanin and medium-sized, oval vesicular nuclei with small nucleoli arranged as nests and fascicles with interspersed melanophages in the upper dermis. There is extension of these melanocytes into the deep dermis along adnexae and neurovascular bundles. A focally dense, lymphohistiocytic inflammatory infiltrate is present concurrently. Mitotic figures are rare.	Skin excision, 0.6 x 0.5 x 0.4 cm, including a central 0.5 x 0.4 cm brown area. With the margins inked blue, the specimen is trisected and entirely submitted.	6 X 4 MM NEVOID NODULE, 2 YEAR HX; SPITZ? CONGENITAL?	\N	\N	\N	There is no evidence of melanoma or atypicality. I have shared this case with my colleague Dr. Beth Ruben who agrees with this interpretation.	DEEP PENETRATING NEVUS	273588	2051	\N	\N	11-71241	\N	SYNAT430	2010-2017	IP1060684	AirTable blocks_with_IP_info.csv
2116	17-35859A	36	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10863	216.5	DN	\N	Sections show a compound proliferation of melanocytes, arrayed in lentiginous and nested fashion along the epidermal-dermal junction and as clusters and syncytia of similar but smaller cells in the subjacent papillary and superficial reticular dermis. Some junctional melanocytes have abundant vacuolated cytoplasm and show fine cytoplasmic pigmentation. There is  lateral extension of junctional melanocytes beyond the last dermal cluster to one side, above slight papillary dermal fibrosis and a sparse infiltrate.	Skin segment measuring 1.1 x 0.8 x 0.2 cm, trisected and entirely submitted in A. PL/PL	A) JC17-152, R/O 6 MM ATYPICAL MOLE, B) JC17-153, R/O 6 MM ATYPICAL MOLE, C) JC17-154, R/O 3 MM ATYPICAL MOLE	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS OF SUPERFICIAL CONGENITAL TYPE	175566	497	\N	\N	17-35859	A	DN-022	Dysplastic Nevi	IP1082132	AirTable blocks_with_IP_info.csv
2117	17-35859B	36	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, with nested and solitary melanocytes distributed relatively evenly along the epidermal-dermal junction.  Similar but slightly smaller cells are in the subjacent superficial dermis.  Many of the constituent melanocytes have abundant vacuolated and pigmented cytoplasm.	Skin segment measuring 1.0 x 0.7 x 0.1 cm, trisected and entirely submitted in B. PL/PL	A) JC17-152, R/O 6 MM ATYPICAL MOLE, B) JC17-153, R/O 6 MM ATYPICAL MOLE, C) JC17-154, R/O 3 MM ATYPICAL MOLE	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS	173529	497	\N	\N	17-35859	B	DN-022	Dysplastic Nevi	IP1082132	AirTable blocks_with_IP_info.csv
2010	16-119467D	52	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10822	216.5	DN	\N	Sections show a compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis contains an infiltrate of lymphocytes and melanophages.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted in D. KC/KC	A) NEOPLASM OF UNCERTAIN BEHAVIOR. 9MM2 HK TAN PINK R/O SK VS. SCC. B) NEOPLASM OF UNCERTAIN BEHAVIOR. 1.2X0.8CM SPECKLED TAN BROWN PATCH, NEVUS R/O ATYPIA. C) NEOPLASM OF UNCERTAIN BEHAVIOR. 5X6MM TAN PINK MACULE, NEVUS R/O ATYPIA. PLEASE CC DR. CYNTHIA STEPHENSEN IN WALNUT CREEK (DDS). D) NEOPLASM OF UNCERTAIN BEHAVIOR. 8MM2 DARK BROWN MACULE, NEVUS R/O ATYPIA.	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	173539	523	\N	\N	16-119467	D	DN-048	Dysplastic Nevi	IP1719660	AirTable blocks_with_IP_info.csv
3012	99-005681	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1950	\N	\N	99-5681	\N	SYNAT191	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1978	16-98043	50	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10833	238.2	DN	\N	Sections show a compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a focally dense infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate. Scattered melanocytes have enlarged nuclei.	Skin segment measuring 0.8 x 0.8 x 0.1 cm, trisected and entirely submitted. RS/RS	ITCHY 5 MM PAPULE WITH PINK AREA; ? MM VS. OTHER	\N	\N	Scraping	This lesion is atypical in that it appears poorly circumscribed and has areas in which single melanocytes predominate. Conservative re-excision of this site is warranted.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, INFLAMED WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	273588	521	\N	\N	16-98043	\N	DN-046	Dysplastic Nevi	IP1697959	AirTable blocks_with_IP_info.csv
1992	16-105218C	85	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22435	172.6	\N	\N	Sections show post-surgical disruption flanked by a proliferation of melanocytes arrayed erratically within the epidermis and dermis. There are cords of hyperchromatic melanocytes in the dermal component.	Ellipse, 7.4 x 2.8 x 1.8 cm, including a central 0.7 x 0.9 cm depression. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and submitted with one section each in A-I. Tips reserved. RS/RS	PRIOR BX MM, CHECK MARGINS PLS	\N	\N	Scraping	An updated melanoma synoptic is included below. Procedure: wide excision Microscopic tumor type: melanoma ex melanocytic nevus Breslow thickness: 0.55 mm Ulceration: not detected Margin: free of melanoma Mitotic index: 0 Regression: not detected Pathologic staging (pTNM): pT1a	RESIDUAL MELANOMA OF 0.55 MM IN THICKNESS, FULLY EXCISED (THE FINAL MARGIN APPEARS FREE OF MELANOMA)	173602	1113	\N	\N	16-105218	C	ME-18	Melanoma Epigenetics	IP1174641	AirTable blocks_with_IP_info.csv
2603	20-16903A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1172	\N	\N	20-16903	A2	MucM-04	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
2605	20-16903C4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1172	\N	\N	20-16903	C4	MucM-04	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
1294	07-77608	85	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=984	172.6	\N	\N	Sections show a proliferation of melanocytes in the epidermis and dermis of a dome shaped segment of skin.  Nests of melanocytes are distributed at irregular intervals along the junctional zone, and are focally confluent.  There are foci in which single melanocytes predominate as well. There are some melanocytes scattered above the basal layer in such areas. The papillary dermis is expanded by large aggregates of similar cells, with little maturation, and areas in which many mitotic figures are found. There are many plasma cells in the adjacent stroma.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted.	CLEAR CELL ACANTHOMA, R/O BCC	\N	\N	\N	The final thickness measurement and a comprehensive evaluation of risk factors should be made after complete excision of this amelanotic lesion. The mitotic rate is high, there is no ulceration and although the interface between the papillary and reticular dermis is obscured, it is likely that this is a level IV lesion.	MELANOMA, AT LEAST 1.6 MM  IN THICKNESS	173611	159	\N	\N	07-77608	\N	CCR-109	California Cancer Registry	IP31137	AirTable blocks_with_IP_info.csv
2604	20-16903C1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1172	\N	\N	20-16903	C1	MucM-04	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
1286	07-42908	68	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=985	172.6	\N	\N	Sections show a compound proliferation of atypical melanocytes, composed largely of cells with vacuolated and pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with conspicuous associated suprabasal scatter. There are also densely juxtaposed clusters of similar melanocytes in the dermis, jointly with an infiltrate of lymphocytes and melanophages. The dermal melanocytes show little maturation with descent. The flanking reticular dermis is strikingly elastotic.	Skin segment measuring 1.1 x 0.9 x 0.3 cm, trisected and entirely submitted.	R/O SEB K	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with invasion of the superficial reticular dermis (Clark's level IV). There is no evidence of associated vascular invasion, neurotropism, or regression. Further re-excision of this site is warranted to ensure that local eradication has been accomplished.	MELANOMA OF AT LEAST 1.3 MM IN THICKNESS, INVOLVING THE DEEP EDGE OF THE BIOPSY	173601	160	\N	\N	07-42908	\N	CCR-112	California Cancer Registry	IP665441	AirTable blocks_with_IP_info.csv
2192	17-82793A	52	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=23367	172.6	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei and abundant, pale cytoplasm. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and small nests, with some present above the basal layer. The epidermis is thickened in the involved area There are melanocytes in the subjacent dermis with  large and irregularly shaped and hyperchromatic nuclei and scant cytoplasm. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei in a separate dome surfaced area, with a partially peri-adnexal pattern in the superficial reticular dermis.	Skin segment measuring 1.0 x 0.9 x 0.5 cm, quadrisected, and entirely submitted in A. HD/HD	A) PINK PAPULE WITH PERIPHERAL MACULAR BROWN PIGMENTATION, ATYPICAL NEVUS VS. OTHER; B) FIRM PINK PAPULE, DERMATOFIBROMA VS. OTHER.	\N	\N	Scraping	Features suggested for reporting per the guidelines of the College of American Pathologists, updated from the report of the prior biopsy include: Procedure: excisional biopsy Microscopic tumor type: superficial spreading melanoma Ulceration: no Margins, peripheral: clear by 1 mm. and deep: clear by < 2 mm. Mitotic index: 0/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT1a pNX	MELANOMA, 0.95 MM. IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173688	1114	\N	\N	17-82793	A	ME-19	Melanoma Epigenetics	IP1812855	AirTable blocks_with_IP_info.csv
3003	98-13466	45	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=991	172.5	\N	\N	Sections show melanocytes in irregular array within the epidermis above a zone of scar, and irregular clusters of melanocytes are present in the underlying dermis.	Skin segment, 1.0 x 1.0 x 0.4 cm, quadrisected longitudinally and\nentirely submitted.	CLINICAL DIAGNOSIS - R/O MM	\N	\N	\N	7/31/98:  Please provide my thanks to your staff for clarifying that a prior biopsy from this patient does exist.  We attempted to retrieve the earlier biopsy from this site, but the outside office that we contacted had no record of this patient.  If the earlier biopsy from this patient can be located in the future, I would like to have an opportunity to review the specimen as part of this consultation.   5/19/98:  There is a clear-cut scar underlying this lesion, implying that it was biopsied previously. Please verify with the patient whether any prior biopsies from this site have been obtained, as any earlier specimens from this site should be re-evaluated to see if they hold any implications for the microstage measurement listed above.  In any event, further re-excision of this lesion is warranted, as the changes of intraepidermal melanoma extend nearly to the periphery of the specimen.	MELANOMA, 0.75 MM IN THICKNESS, PRESENT ABOVE SCAR AND EXTENDING NEAR TO THE PERIPHERAL MARGIN	173502	163	\N	\N	98-13466	\N	CCR-124	California Cancer Registry	IP151039	AirTable blocks_with_IP_info.csv
1487	11-38910A2	53	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.3	\N	\N	Sections show a relatively circumscribed proliferation of dendritic melanocytes and melanophages in the dermis.	Cylindrical skin segment, 0.4 cm in diameter and 0.3 cm in thickness, bisected and entirely submitted.	INCREASING SIZE BR GREY MAC; R/O BLUE NEVUS	\N	\N	\N	\N	BLUE NEVUS	373301	2021	\N	\N	11-38910	A2	SYNAT73	2010-2017	IP1028349	AirTable blocks_with_IP_info.csv
3211	Cell-Line_Xu-21	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2020	\N	\N	None	\N	SYNAT164	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
2856	22-119466	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	https://64.54.108.121/app/WebViewer/view/image/34972	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1400	\N	\N	22-119466	\N	VS-07	Spatial Gene Expression	\N	AirTable blocks_with_IP_info.csv
1755	14-12190A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1174	\N	\N	14-12190	A1	MucM-06	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
1756	14-12190L4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1174	\N	\N	14-12190	L4	MucM-06	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
2081	17-26432A	60	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10851	172.6	\N	\N	Sections show a compound proliferation of melanocytes, the junctional component of which consists of nested and solitary melanocytes in irregular array within the epidermis. Scattered melanocytes have enlarged nuclei and/or a positional above the basal layer.  In some areas with the epidermis, a relatively orderly pattern of nesting is apparent. A few nest of may be in the underlying papillary dermis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted in A. PL/PL	A) ATYPICAL BROWN MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS, B) ATYPICAL BROWN PATCH; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS	\N	\N	\N	This melanoma is AJCC stage Tis (representing a non-invasive tumor with no associated ulceration).	MELANOMA IN SITU, ARISING IN A COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	529699	530	\N	\N	17-26432	A	DN-055	Dysplastic Nevi	IP99195	AirTable blocks_with_IP_info.csv
1203	06-5249	53	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2372	172.7	\N	\N	Sections show a sizable asymmetrical compound proliferation of atypical melanocytes, composed largely of cells with vacuolated and pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with conspicuous associated suprabasal scatter. There are also clusters of similar melanocytes in the superficial dermis, jointly with an infiltrate of lymphocytes and melanophages. In some central cross sections, strikingly atypical melanocytes extend deeply into the dermis, as sizable sheets of cells.	Oval excision, 1.7 x 1.5 x 0.8 cm, including a central raised brown 0.6 x 0.5 x 0.2 cm pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with five central sections, tips returned to container.	R/O MELANOMA	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with an invasive component that extensively involves the reticular dermis (Clark's level IV). There is no evidence of vascular invasion or perineural extension or regression in these sections, and I do not see any associated microsatellites. Further re-excision of this site is of course warranted to ensure that local eradication has been accomplished. This report was reissued on 3/7/2006 to add the patient's UCSF Medical Record number and to forward a copy to UCSF Medical Records.	MELANOMA OF 2.4 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS QUITE NEAR TO THE PERIPHERAL BIOPSY MARGIN	563789	198	\N	\N	06-5249	\N	CCR-221	California Cancer Registry	IP550315	AirTable blocks_with_IP_info.csv
2722	21-41149	52	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26442	172.5	\N	\N	Sections show a compound melanocytic proliferation with a biphasic pattern.  One population consists of melanocytes, most of which have slightly enlarged oval nuclei, that are irregularly distributed along the dermal-epidermal junction, with some melanocytes present above the basal zone. Similar melanocytes are present in the subjacent dermis as expansile, densely cellular nests. Scattered mitotic figures are evident. The second population consists of melanocytes with cytologically bland nuclei (melanocytic nevus), and these are situated in the deeper aspects of the dermis. There is a patchy lymphocytic infiltrate mostly associated with the enlarged cells and expansile nests.	Cylindrical skin segment, 0.8 cm in diameter and 1.3 cm in thickness, trisected and entirely submitted. HD/CF	1 CM WHITE PLAQUE AND 2 CM ILL-DEFINED BLACK BROWN PLAQUE; NEOPLASM OF UNCERTAIN BEHAVIOR, MM	\N	INVASIVE MELANOMA, BRESLOW THICKNESS 2.0 mm, NON-ULCERATED ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: punch biopsy Tumor site: left middle thoracic back Microscopic tumor type: low cumulative sun damage Breslow thickness: 2.0 mm Ulceration: absent Margins, peripheral and deep: invasive melanoma present at peripheral biopsy margin; deep biopsy margin free Mitotic index (per square millimeter): 1 Microsatellitosis: not identified Vascular Invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT2a pNX	INVASIVE MELANOMA, BRESLOW THICKNESS 2.0 mm, NON-ULCERATED ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	528522	1155	\N	\N	21-41149	\N	ME-60	Melanoma Epigenetics	IP2303774	AirTable blocks_with_IP_info.csv
1054	02-17626	53	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=324	172.6	\N	\N	Sections show a thick compound proliferation of melanocytes, with single cells and nests arrayed irregularly and focally in near confluence along the epidermal-dermal junction.  The underlying dermis contains sheets and confluent nests of small melanocytes with irregularly shaped hyperchromatic nuclei and scant cytoplasm, embedded in densely fibrotic stroma, overlying a dermis altered by severe solar elastosis.  Scattered melanocytes with pyknotic nuclei are present, as are rare mitotic figures in melanocytes.  There are some areas with small, round melanocytes in discrete nests as well.	Cylindrical skin segment, 0.6 cm in diameter and 0.3 cm in thickness,\nbisected and totally submitted.	R/O DYSPLASTIC NEVUS	\N	\N	Scraping	This is an unusual form of melanoma with small cells resembling those of a nevus (nevoid melanoma).  There is no reproducible difference in prognosis between this form, and conventional melanoma, however, taking standard prognostic variables into account.  There are areas that could represent a pre-existent nevus that has been colonized by the proliferation.	MELANOMA, 2.4 MM. IN THICKNESS, EXTENDING TO THE PERIPHERAL MARGIN	173611	199	\N	\N	02-17626	\N	CCR-222	California Cancer Registry	IP322353	AirTable blocks_with_IP_info.csv
2489	19-135629A	55	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22441	380.0	\N	\N	Sections show a focally hypergranulotic and hyperkeratotic epidermis beneath which there is an increase in spindled cells and small blood vessels.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A) EROSION WITH SURROUNDING ERYTHEMA TO R ANTIHELIX; FAVOR CNH, B) SMALL VARIEGATED MACULE; FAVOR NEVUS VS. R/O MELANOMA, C) IRREGULAR DARK BROWN MACULE; FAVOR NEVUS	\N	\N	Scraping	\N	CHONDRODERMATITIS NODULARIS HELICIS	100223	1114	\N	\N	19-135629	A	ME-19	Melanoma Epigenetics	IP1812855	AirTable blocks_with_IP_info.csv
2442	19-36210A	49	\N	\N	\N	\N	\N	\N	20	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26508	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.3 x 1.0 x 0.1 cm, quadrisected, and entirely submitted in A. HD/HD	A) PT WITH FAMILY HISTORY MM WITH TWO TONE NODULE WITH RAPID GROWTH; MM VS. ATYPICAL NEVUS VS. PIGMENTED BCC, B) IRREGULAR NEVUS VS. MM VS. CONGENITAL NEVUS	\N	A- MELANOMA, 1.1 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	Diagnostic features of note include: Procedure: Excisional biopsy Tumor site: Back Microscopic tumor type: Nevoid Breslow thickness: 1.1 millimeters Ulceration: Absent Margins, peripheral and deep: Involved Mitotic index: 0 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT2a	MELANOMA, 1.1 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	273588	1146	\N	\N	19-36210	A	ME-51	Melanoma Epigenetics	IP2040437	AirTable blocks_with_IP_info.csv
1505	11-62022	43	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	There is a domed segment of skin with nests of small, round melanocytes in the dermis.  Some melanocytes are multinucleated.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted in cassette B.	A) 2 MO AGO TINY FRECKLE, RAISED UP, IRREG COLOR, 7 MM PAPULE, EXT SUN EXPOSURE; R/O MELANOMA, B) TENDER PAPULE	\N	\N	\N	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	173530	1953	\N	\N	11-62022	\N	SYNAT74	2010-2017	IP948784	AirTable blocks_with_IP_info.csv
1666	12-91942	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1359	\N	\N	12-91942	\N	SMP20	Spitz Melanoma	\N	AirTable blocks_with_IP_info.csv
2965	95-14690F T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1004	\N	\N	None	\N	MD-112	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2898	23-11588A	75	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31601,31602,31603,31604	238.2	\N	\N	Sections show lymph nodes without evidence of metastatic melanoma.	Tissue segment measuring 2.0 x 1.6 x 0.7 cm, three representative sections submitted in A. Lymph node entirely submitted. KB/KB	A) LEFT INGUINAL SENTINEL LYMPH NODE #1, EXVIVO 2600 PERMANENT, B) RIGHT GROIN SENTINEL LYMPH NODE #1 EXVIVO 1200 PERMANENT, C) LEFT GROIN SENTINEL LYMPH NODE #2, EXVIVO 1200 PERMANENT, D) WIDE ABDOMEN MELANOMA - PERMANENT	\N	\N	\N	There is no evidence of metastatic melanoma in either the routinely-stained section or sections stained with SOX-10 and pan-melanin.	LYMPH NODE, WITH NO EVIDENCE OF METASTATIC MELANOMA	105586	1159	\N	\N	23-11588	A	ME-64	Melanoma Epigenetics	IP347366	AirTable blocks_with_IP_info.csv
2871	23-2718 (block 1)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30854	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1159	\N	\N	None	\N	ME-64	Melanoma Epigenetics	\N	AirTable blocks_with_IP_info.csv
2872	23-2718 (block 2)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30855	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1159	\N	\N	None	\N	ME-64	Melanoma Epigenetics	\N	AirTable blocks_with_IP_info.csv
1293	07-76799A	68	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=994	172.4	\N	\N	Sections show a compound proliferation of atypical melanocytes, composed of cells with scant vacuolated and pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with conspicuous associated suprabasal scatter and with scattered gargantuan nests at the junction. There are also irregular clusters of similar melanocytes in the superficial dermis, jointly with subjunctional fibrosis and a patchy dermal lymphohistiocytic infiltrate. The deeper dermis shows a mix of elastosis and fibrosis. Many lesional melanocytes permeate adnexa.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted in cassette A.	A) 1.5 X 1.1 CM PINK TAN SHINY PLAQUE; SK, R/O ATYPIA; B) 3 X 3 MM PEARLY PAPULE; R/O BCC	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with invasion limited to the papillary dermis (Clark's level III). There is no evidence of associated vascular invasion, neurotropism, or regression. Further re-excision of this site is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.8 MM IN THICKNESS, TRANSECTED AT THE PERIPHERY OF THE BIOPSY	173445	165	\N	\N	07-76799	A	CCR-130	California Cancer Registry	IP641150	AirTable blocks_with_IP_info.csv
3016	99-13402-3 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1006	\N	\N	None	\N	MD-114	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1243	06-24998B T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1007	\N	\N	None	\N	MD-118	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1016	00-23160D T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1008	\N	\N	None	\N	MD-119	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1234	06-21073E T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1009	\N	\N	None	\N	MD-121	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1233	06-20661-2 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1010	\N	\N	None	\N	MD-122	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1228	06-17562-2 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1011	\N	\N	None	\N	MD-125	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1222	06-15453C T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1012	\N	\N	None	\N	MD-127	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1213	06-10522-2B T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1013	\N	\N	None	\N	MD-128	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1179	05-28152B	58	\N	\N	\N	None	None	None	3	\N	FFPE	\N	\N	172.6	\N	\N	There is an asymmetrical nodular array composed of confluently disposed nests melanocytes with atypical nuclei and vacuolated and pigmented cytoplasm, in partial contiguity with the epidermis. There is little diminishment in melanocyte size with descent in the dermis. Some melanocytes course deeply in the reticular dermis and adventitial dermis, and some reach the subcutis. There is focal necrosis en masse. At least one cluster is present in a vascular channel.	Ellipse, 2.0 x 1.6 x 1.0 cm, including a central raised 1.3 x 1.2 x 0.3 cm lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections in cassette A and three sections in cassette B.	NINE MONTH HISTORY OF GRAY PINK KERATOTIC TUMOR; R/O MM	\N	\N	Scraping	In terms of staging, this is a non-ulcerated primary melanoma with a nodular invasive component that extends to the superficial subcutis (Clark's level V). There is no evidence of perineural extension or regression in these sections. An obvious focus of vascular invasion is present, but microsatellitosis is not identifiable in the present specimen. Further re-excision of this site is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 7.5 MILLIMETERS IN THICKNESS, FOCALLY ABUTTING THE DEEP BIOPSY MARGIN	173605	200	\N	\N	05-28152	B	CCR-224	California Cancer Registry	IP504864	AirTable blocks_with_IP_info.csv
1087	03-24659-2 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1049	\N	\N	None	\N	MD-172	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1075	03-08311E T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1050	\N	\N	None	\N	MD-173	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1655	12-67298	75	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	None	One block #DT12-55826.	MALIGNANT S-100 POSITIVE SPINDLE CELL NEOPLASM SUBMITTED FOR BRAF MUTATION ANALYSIS	\N	\N	\N	The histopathological diagnosis was established by our previous pathology report DT12-55826. Sanger sequencing of exon 15 of BRAF revealed a V600E mutation.	MALIGNANT S-100 POSITIVE SPINDLE CELL NEOPLASM, BRAF V600E MUTATION DETECTED	100711	1945	\N	\N	12-67298	\N	SYNAT352	2010-2017	IP960004	AirTable blocks_with_IP_info.csv
1256	06-70035C	66	\N	\N	\N	None	None	None	3	\N	FFPE	\N	\N	172.7	\N	\N	Sections show a polypoid proliferation of melanocytes with marked nuclear atypia, markedly expanding the papillary dermis, invading the reticular dermis and impinging upon the subcutaneous fat. There is an adjacent asymmetrical junctional component with confluence of atypical cells as nests and single cells. Maturation is not present, and many mitotic figures are present in the dermal melanocytic population. There is surface ulceration. Tumor islands are present within and adherent to the endothelial surface of vascular spaces.	Oval excision, 2.2 x 2.0 x 1.4 cm, including a central 1.8 x 1.3 cm bump.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with two sections in cassette A, one section each in cassettes B through D, and four sections in cassette E.	2 X 2 CM EXOPHYTIC BEEFY RED PIGMENTED NODULE PRESENT 3-4 MONTHS; R/O MELANOMA; TELEPHONE: 925-287-1586	\N	\N	Scraping	possible prognostic factors include: thickness: 7.15 mm Clark's level: IV (the melanoma impinges upon but does not invade into the underlying subcutaneous fat) ulceration: present microsatellite metastases: not seen lymphovascular invasion: present margins: uninvolved with narrow peripheral epidermal margin of approximately 2 mm mitoses: >15 per sq. mm. regression: absent lymphocytic infiltrate: present and non-brisk  Several studies confirm that a polypoid configuration is not an independent prognostic variable in patients with melanoma.	POLYPOID INVASIVE MELANOMA, 7.15 mm THICK, ULCERATED,  NOT PRESENT AT BIOPSY EDGES (NARROWLY EXCISED)	173701	201	\N	\N	06-70035	C	CCR-225	California Cancer Registry	IP615104	AirTable blocks_with_IP_info.csv
1141	04-31313A	31	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	\N	172.7	\N	\N	Sections show a proliferation of melanocytes with round to oval nuclei arranged in irregular nested and pagetoid fashion within the epidermis as well as in large and confluent nests in the subjacent papillary dermis.  A focally dense lymphocytic infiltrate is present at the base of some, but not all of this population. A distinct population of melanocytes with somewhat smaller nuclei is also present in the dermis, arranged as small, discrete nests.	Oriented ellipse, 3.0 x 1.5 x 0.7 cm, including central slightly elevated tan and brown 1.0 x 0.9 cm pigmented lesion.  With the orienting sutured tip placed to the left, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from the sutured tip to the opposite tip (left to right) and submitted with four sections each in cassettes A and B, tips returned to container.\n	15 X 12 MM PINK/BROWN PLAQUE; R/O MELANOCYTIC PROCESS	\N	\N	Scraping	The excision appears to be complete, but the margins are clear by only 2-3 millimeters. Histopathologic features of possible prognostic importance include:  Level: III Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent  Please note that the dermal portion of this melanoma is partially nevoid, e.g. consists of small round melanocytes.  Several studies show little difference in prognosis with conventional melanoma.	MELANOMA, 0.85 MM  IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173710	202	\N	\N	04-31313	A	CCR-228	California Cancer Registry	IP446906	AirTable blocks_with_IP_info.csv
1139	04-28340	34	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1305	172.5	\N	\N	Sections show a compound proliferation of atypical melanocytes, composed largely of neoplastic cells with ample vacuolated cytoplasm. Single neoplastic cells and nests are arrayed irregularly within the epidermis, with foci of suprabasal scatter.  There are also clusters of similar melanocytes arrayed densely in the superficial dermis, including the reticular dermis. Some atypical clusters are present in vascular channels.  There are smaller melanocytes to the side of these atypical cells, both along the epidermal-dermal junction and in the dermis.	Skin segment measuring 0.9 x 0.7 x 0.2 cm, trisected and entirely submitted.	4 X 10 MM IRREGULAR PIGMENTED PAPULE; MM	\N	\N	\N	This is a non-ulcerated primary melanoma with an invasive component that involves the reticular dermis (Clark's level IV). There is also underlying vascular invasion.  There is no evidence of perineural extension or regression.  Further re-excision of this site is warranted to ensure that local control has been established; this patient is also a candidate for sentinel node evaluation,  based upon criteria currently employed by the UCSF Melanoma Center.	MELANOMA OF 0.8 MILLIMETERS IN THICKNESS, PRESENT IN ASSOCIATION WITH A COMPOUND MELANOCYTIC NEVUS OF SUPERFICIAL CONGENITAL TYPE AND TRANSECTED AT THE PERIPHERAL BIOPSY MARGIN	173526	203	\N	\N	04-28340	\N	CCR-231	California Cancer Registry	IP444742	AirTable blocks_with_IP_info.csv
1224	06-16759 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	928	\N	\N	None	\N	MD-22	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1176	05-27460	26	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	172.5	\N	\N	Sections show a compound proliferation of melanocytes with a biphasic pattern.  One population consists of small melanocytes with round to oval nuclei, positioned in the dermis (melanocytic nevus). These melanocytes demonstrate maturation with melanocytic descent in the dermis. The second population consists of nested and solitary melanocytes, most of which display atypical nuclei, arrayed irregularly and in pagetoid fashion within the epidermis, with clusters of similar melanocytes filling the papillary dermis. Many of these melanocytes are large, and contain abundant dusty cytoplasmic melanin (so-called pagetoid melanocytes), and some are more epithelioid, with abundant pink cytoplasm. This latter population does not demonstrate appreciable maturation, or a significant mitotic rate. There is slight solar elastosis.	Ellipse, 1.3 x 0.7 x 0.1 cm, including a central dark brown-black 0.7 x 0.5 cm pigmented lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with five sections, one tip returned to container.	R/O MALIGNANT MELANOMA	\N	\N	FFPE	In terms of staging, this a non-ulcerated primary melanoma of Clark's anatomic level III. It appears to have arisen in association with a melanocytic nevus as noted. There is no evidence of regression, or vascular or perineural invasion in these sections. Complete reexcision is of course warranted.	MELANOMA, 0.8 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, WITH INTRAEPIDERMAL MELANOMA EXTENDING TO WITHIN 1 MM OF PERIPHERAL BIOPSY MARGINS	173502	168	\N	\N	05-27460	\N	CCR-142	Melanoma Epigenetics	IP504172	AirTable blocks_with_IP_info.csv
10518	11-23878	35	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.6	Iwei CGH, Translocation 	CGH11-109 	Sections show a polypoid compound proliferation of enlarged epithelioid melanocytes distributed along a largely thinned epidermis. There are single melanocytes and nests distributed nearly confluently, and in the dermis below this there are partially-maturing nests and cords of similar melanocytes. In the middle of the proliferation, melanocytes in mitosis are easily found. In a recut section, mitotic figures are again apparent in the upper dermis.	Three outside slides, S11-03153 and one corresponding block.	\N	\N	\N	\N	The architectural features of this lesion favor a Spitz's nevus. The fact that there are dermal melanocytes in mitosis is concerning. Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a moderate proliferation rate in the upper part of the lesion and a low one in the lower part. Array-based comparative genomic hybridization shows no chromosomal gains or losses. In the context of the findings noted above, I believe that this is best interpreted as a Spitz's nevus. The margins appear clear in the planes of section examined.	SPITZ'S NEVUS, COMPOUND	101625	1553	\N	\N	11-23878	A	SYNX150	\N	IP1013316	Consolidated_data_final.csv
1255	06-68314	71	\N	\N	\N	None	None	None	10	\N	FFPE	\N	\N	172.5	\N	\N	Sections show a domed, asymmetrical compound proliferation of atypical melanocytes, composed largely of cells with ample vacuolated and faintly pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with conspicuous associated suprabasal scatter. There are also clusters of similar melanocytes in the superficial dermis, forming a central nodule. There is a patchy lymphohistiocytic infiltrate accompanying the dermal melanocytes.	Skin segment measuring 0.8 x 0.7 x 0.2 cm, trisected and entirely submitted.	NEW PINK PAPULE; BCC, DF, NF, OTHER	\N	\N	Scraping	In terms of staging, this is a non-ulcerated primary melanoma with invasion of the superficial reticular dermis (Clark's level IV). There is no evidence of vascular invasion, neurotropism, or regression. Further re-excision of this site is warranted to ensure that local eradication has been accomplished. This report was reissued on 12/19/2006 to add the patient's UCSF Medical Record number and to forward a copy to UCSF Medical Records.	MELANOMA OF 0.85 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO THE PERIPHERAL MARGIN	173524	204	\N	\N	06-68314	\N	CCR-233	California Cancer Registry	IP613383	AirTable blocks_with_IP_info.csv
1005	00-5989A2	26	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1007	172.5	\N	\N	Sections show a proliferation of small melanocytes with round to oval\nnuclei arranged in irregular fashion within the epidermis as well as\nin the subjacent dermis.  The epidermal component consists largely\nof nests, but areas in which cells with ample vacuolated cytoplasm\nare arrayed at all epidermal levels can be found without difficulty,\nincluding at the leading edges of the proliferation.  In the\nunderlying dermis, nests and sheets of compact cells with\nhyperchromatic nuclei and cytoplasmic pigmentation are noted.  A\ndistinct population of melanocytes with somewhat smaller\nnuclei is also present in the dermis.	Oriented ellipse, 2.5 x 1.0 x 0.6 cm, serially sectioned and\nsubmitted with four sections each in blocks A1 and A2, with tip\nmarked by suture placed to the left, superior half of specimen is\ninked in blue, and inferior half of specimen is inked in yellow.	A - 8 X 6 MM TWO TONED DARK BROWN AND ERYTHEMATOUS MILD BROWN MACULE WITH IRREGULAR BORDERS, B - IRREGULAR SHAPED 5 MM LITE BROWN MACULE, "CROSS" PATTERN; CLINICAL DIAGNOSIS - A) R/O ATYPIA VS IDN-B, B) R/O ATYPIA, REMAINING DATA ON FILE	\N	\N	\N	This lesion could be interpreted as a form of nevoid melanoma, in which the melanoma cells are arrayed in a pattern that vaguely resembles that of a melanocytic nevus.  There have been several studies that have demonstrated that the prognosis of nevoid melanoma is similar to that of conventional melanoma.	MELANOMA, 0.85 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, NARROWLY EXCISED, WITH MARGINS FREE OF NEOPLASM	173536	169	\N	\N	00-5989	A2	CCR-144	California Cancer Registry	IP221092	AirTable blocks_with_IP_info.csv
2995	98-02267-5 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	965	\N	\N	None	\N	MD-59	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1096	03-44586	42	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1306	172.4	\N	\N	Sections show a compound proliferation of melanocytes arrayed as large irregular nests along the epidermal-dermal junction, with nests and sheets of atypical melanocytes in the underlying dermis.  Mitotic figures are not difficult to identify in dermal nests.  Pigmentation is scant.	Skin segment measuring 0.8 x 0.8 x 0.3 cm, trisected and entirely submitted.	RED 4 MM NODULE; NEVUS, R/O BCC	\N	\N	\N	In terms of staging, this is a non-ulcerated nodular primary melanoma with an invasive component that involves the reticular dermis (Clark's level IV).  The lesion appears largely amelanotic.  There is no evidence of vascular invasion or perineural extension or regression.  Complete excision will be necessary for complete staging parameters to be procured.  This patient is a candidate for sentinel node evaluation,  based upon criteria currently employed by the UCSF Melanoma Center.  Further re-excision of this site is of course warranted to ensure local control.	MELANOMA OF AT LEAST 1.5 MILLIMETERS IN THICKNESS	173499	205	\N	\N	03-44586	\N	CCR-234	California Cancer Registry	IP402900	AirTable blocks_with_IP_info.csv
1681	13-2054	5	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.3	\N	\N	Sections show a dome-shaped segment of skin in which there is a compound proliferation of melanocytes, many of which have copious eosinophilic cytoplasm and large nuclei, partially obscured by a dense lymphocytic infiltrate.  Some of the melanocytes within the dermis are quite large and 1 mitotic figure among the mid-dermal melanocytes is identifiable. Dull pink globules are present within the epidermis. The melanocytes within the epidermis are generally smaller than those within the dermis.	Cylindrical skin segment, 0.4 cm in diameter and 0.4 cm in thickness, bisected and entirely submitted.  PL/PL	4 MM PINK PAPULE X 2 YEARS WITH OCCASIONAL BLEEDING; DISCRETE OVAL PINK PAPULE; R/O SPITZ, 4 MM PUNCH ENTIRE LESION	\N	\N	\N	Some of the lesional cells are quite large. Therefore, to further evaluate this lesion, I performed immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown). The stain shows a relatively low proliferation rate of approximately 15% among the lesional cells.  I also considered the possibility of performing comparative genomic hybridization (CGH) on this section. However, it is technically not possible to do this testing on this lesion due to the dense admixed inflammatory infiltrate, since this infiltrate would skew the results.  Therefore, coupling the findings on the routinely stained hematoxylin and eosin section with the low proliferation rate mentioned above, I favor a nevus. Nonetheless, due to the presence of these large cells, in addition to an identifiable mitotic figure within the dermis, a conservative re-excision at this site is warranted. I have also shared this case with my colleagues, Drs. Philip LeBoit and Boris Bastian, who agrees with this diagnosis and assessment.	SPITZ'S NEVUS, COMPOUND TYPE, WITH HALO REACTION, EXTENDING TO THE TISSUE EDGES	103327	2042	\N	\N	13-2054	\N	SYNAT87	2010-2017	IP1186796	AirTable blocks_with_IP_info.csv
2335	18-67239	74	\N	\N	\N	None	None	None	3	\N	FFPE	\N	\N	238.2	\N	\N	Sections show a superficial area of fibrosing granulation tissue, but no evidence of an atypical melanocytic proliferation.	Ellipse, 3.0 x 1.3 x 0.9 cm, including a central 0.9 x 0.4 cm pearly area. With margins inked, the specimen is serially sectioned perpendicular to the long axis and submitted with five sections each in A-B. Tips reserved. KC/KC	A) DYSPLASTIC NEVUS. HEALING BX. PLEASE CHECK MARGINS..	\N	\N	FFPE	None	HEALING BIOPSY SITE, WITH NO EVIDENCE OF A RESIDUAL MELANOCYTIC NEOPLASM	333504	1149	\N	\N	18-67239	\N	ME-54	Melanoma Epigenetics	IP1919209	AirTable blocks_with_IP_info.csv
1571	12-6981	63	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a compound proliferation of melanocytes with features as noted in Dr. Gottlieb's consultation report.	One outside slide, HD12-9831 A.  One corresponding block received 2-6-12.	R/O BCC, R/O MERKEL CELL	\N	NTRK3, Iwei Translocations	\N	I agree with the considerations in Dr. Gottlieb's report. Comparative genomic hybridization did not show chromosomal gains or losses, a finding that is strongly against melanoma and favors a unusual Spitz's nevus. Any lesion this controversial and needed molecular testing for diagnosis should be fully excised, but the findings do not support additional measures beyond that.	COMPOUND PROLIFERATION OF LARGE, SPITZOID MELANOCYTES	17733	2348	\N	\N	12-6981	\N	SYNAT141	2010-2017	IP1092797	AirTable blocks_with_IP_info.csv
2393	19-1978C	76	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.3	\N	\N	Sections show a well circumscribed dermal proliferation of S-shaped spindled cells with small, monomorphous oval or elliptical nuclei and inconspicuous cytoplasm, apposed to thin collagen bundles, forming compactly arranged fascicles separated from one another by thin clefts.	Skin segment measuring 1.0 x 0.6 x 0.2 cm, bisected and entirely submitted in C. BY/BY	A) SQUAMOUS CELL CARCINOMA VS. VERRUCA VULGARIS VS. KA. ERYTHEMATOUS TENDER NODULE WITH HYPERKERATOTIC SCALE. B) SUPERFICIAL BASAL CELL CARCINOMA VS. BOWEN'S DISEASE. PSORIASIFORM PATCH. C) BASAL CELL CARCINOMA VS. DERMAL NEVUS. PEARLY TELANGIECTATIC PAPULE.	\N	\N	Scraping	This lesion is also called palisaded and encapsulated neuroma. It is a benign neoplasm composed of Schwann cells (as is schwannoma) but differs in that many axons are also present.	SOLITARY, CIRCUMSCRIBED NEUROMA	173304	1177	\N	\N	19-1978	C	NL-015	Nevus Library	IP2006010	AirTable blocks_with_IP_info.csv
2395	19-2264A	60	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.4	\N	\N	Sections show a dermal proliferation consisting in part of ovoid melanocytes with monomorphous nuclei arranged in fascicles with intervening areas displaying fibrosis and sclerosis and containing melanophages.	Cylindrical skin segment, 0.5 cm in diameter and 0.5 cm in thickness, bisected and entirely submitted in A. KC/KC	A) 3 MM BLACK / TAN MACULE; R/O MM, B) 5 MM IRREGULARLY BORDERED BROWN / BLACK MACULE; R/O MM	\N	\N	Scraping	\N	BLUE NEVUS	100444	1178	\N	\N	19-2264	A	NL-016	Nevus Library	IP1955064	AirTable blocks_with_IP_info.csv
2365	18-121943A	32	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with a junctional component comprised of single cells and small pigmented nests arrayed along the sides and bases of pigmented rete. Small nests and cords of similar melanocytes are positioned in the subjacent superficial dermis, where scattered melanophages are also evident.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A) 0.8 CM, COLOR VARIEGATION; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS, B) 1.8 CM, BROWN VERRUCOUS PLAQUE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. SK VS. PIGMENTED SCCIS VS. CONDYLOMATA	\N	\N	Scraping	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	110501	1179	\N	\N	18-121943	A	NL-017	Nevus Library	IP1986032	AirTable blocks_with_IP_info.csv
1354	09-72944	29	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.7	\N	\N	Sections show a wedge-shaped proliferation of large oval melanocytes with moderately pleomorphic nuclei and abundant vacuolated cytoplasms, arranged as small nests and fascicles. The apex of the lesion is in the reticular dermis, with a tendency of aggregations to be positioned next to adnexa. There are evenly distributed melanophages.	Cylindrical skin segment, 0.4 cm in diameter and 0.5 cm in thickness, bisected and entirely submitted.	3 MM BLACK MACULE; PROB BLUE NEVUS	\N	\N	\N	None	DEEP PENETRATING NEVUS, EXTENDING TO THE TISSUE EDGE	107705	1697	\N	\N	09-72944	\N	SYNAT148	Deep Penetrating Nevus	IP563362	AirTable blocks_with_IP_info.csv
1065	02-28807	79	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=325	172.4	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly along the epidermal-dermal junction above elastosis, with nests of melanocytes in predominance in many areas. There are clusters of similar cells in the superficial dermis, also above elastosis, and some nests that permeate adnexal epithelium	Skin segment measuring 0.4 x 0.3 x 0.1 cm, bisected and entirely submitted.	R/O KER VS NEVUS	\N	\N	Scraping	This is a non-ulcerated primary melanoma with invasion confined to the papillary dermis (Clark's level II). There is no evidence of vascular or perineural invasion. In short, this is a thin, low-risk primary melanoma. This report was reissued on 1/13/2005 to add the patient's UCSF Medical Record number and to forward a copy to UCSF Medical Records.	MELANOMA OF 0.4 MILLIMETERS IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO THE PERIPHERAL MARGIN	173441	139	\N	\N	02-28807	\N	CCR-041	California Cancer Registry	IP333561	AirTable blocks_with_IP_info.csv
2705	21-16708A	54	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	229.0	\N	\N	\N	Tissue segment, 2.5 x 0.8 x 0.5 cm, serially sectioned perpendicular to the long axis and submitted with four representative sections in A. KB/KB	A) RIGHT SUPRACLAVICULAR SENTINEL LYMPH NODE, COUNT 5500, PERMANENT, B) RIGHT AXILLARY SENTINEL LYMPH NODE #1, COUNT 1755, PERMANENT	\N	\N	FFPE	This first lymph node does not contain detectable metastatic melanoma as assessed by conventional microscopy supplemented by Melan-A and SOX-10 immunohistochemistry.	FREE OF MELANOMA	555556	1154	\N	\N	21-16708	A	ME-59	Melanoma Epigenetics	IP2267514	AirTable blocks_with_IP_info.csv
3001	98-10389	78	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1008	172.5	\N	\N	Sections show a mostly dermal proliferation of atypical melanocytes.  There are a few nested and solitary melanocytes, some with atypical nuclei, arrayed irregularly within the epidermis.  In the underlying dermis, there are irregularly-shaped, horizontally-oriented clusters of similar but slightly smaller melanocytes, which are surrounded by fibrosis.  Maturation is defective, in that cells with large nuclei and eosinophilic nucleoli are present near the base of the neoplasm. These changes are present above elastosis and many small dilated venules.	Skin segment measuring 0.9 x 0.5 x 0.2 cm, bisected and entirely\nsubmitted.	BROWN RED AND BLACK LESION; CLINICAL DIAGNOSIS - R/O MELANOMA, R/O IRRITATED SEBORRHEIC KERATOSIS	\N	\N	\N	Melanomas in which small, round cells predominate in the dermal component have been termed nevoid melanoma, or minimal deviation melanoma. Several studies have suggested that there is no prognostic difference between this form and conventional melanoma.	MELANOMA, 0.85 MM IN THICKNESS, EXTENDING TO THE PERIPHERAL MARGIN	173539	170	\N	\N	98-10389	\N	CCR-146	California Cancer Registry	IP147962	AirTable blocks_with_IP_info.csv
2989	97-13166G	68	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1015	172.5	\N	\N	Sections show a proliferation of atypical melanocytes, arranged irregularly as single cells and nests at the epidermal-dermal junction, and in the dermis without diminishment in size.  There are areas in which the papillary dermis is thickened and fibrotic, with a lichenoid infiltrate of lymphocytes, as well as diminished numbers of melanocytes in comparison to the remainder of the lesion.	Ellipse, 7.0 x 4.3 x 1.3 cm, serially sectioned and submitted with\none section each in blocks A through I and two sections in block J,\nmargins inked blue, tips returned to container.	BLACK LESION; CLINICAL DIAGNOSIS - MELANOMA, REMAINING DATA ON FILE	\N	\N	\N	Regression is currently believed to be an adverse prognostic factor in patients with melanoma.	MELANOMA, 0.4 MM IN THICKNESS, WITH AREAS OF REGRESSION, COMPLETELY EXCISED, WITH MARGINS FREE OF NEOPLASM	139523	171	\N	\N	97-13166	G	CCR-147	California Cancer Registry	IP115935	AirTable blocks_with_IP_info.csv
3010	99-3122A	76	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=3512	172.4	\N	\N	Sections show a compound proliferation of melanocytes, with an\nintraepidermal component consisting predominantly of nests of\nmelanocytes in irregular array.  Irregular clusters of similar\nmelanocytes are also present in the dermis.	Ellipse, measuring 1.0 x 0.5 x 0.2 cm, trisected and entirely\nsubmitted, margins inked blue.	A - TAN BROWN IRREGULARLY PIGMENTED PLAQUE WITH IRREGULAR BORDERS, B - C - BROWN GRAY NODULES; CLINICAL DIAGNOSIS - A) R/O MM, SK, B) - C) R/O MM, SATELLITE NODULE VS SK, REMAINING DATA ON FILE	\N	\N	\N	\N	MELANOMA, 0.8 MM IN THICKNESS, EXTENDING TO THE PERIPHERAL MARGIN	100440	119	\N	\N	99-3122	A	CCR-001	California Cancer Registry	IP178655	AirTable blocks_with_IP_info.csv
3058	1813/15 3	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1215	\N	\N	None	\N	NM-37	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1786	14-58579	33	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26351,26352	216.6	\N	\N	Sections show skin with a compound proliferation of small round melanocytes arranged as nests at the junction, and as nests, cords and strands within the dermis beneath an epidermis that features interconnected rete ridges, horn pseudocysts and a papillated surface. Part of the dermal component surrounds adnexa or lies as strands between reticular dermal collagen bundles. The lesion has a wedge shaped base.	Ellipse measuring 1.5 x 1.0 x 0.7 cm, including a central 0.6 x 0.5 cm brown area. With margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections. RS/KC	R/O DYSPLASTIC NEVUS	\N	\N	\N	The excision appears complete.  There are no worrisome features.	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	173649	1739	\N	\N	14-58579	\N	SYNAT114	2010-2017	IP1408520	AirTable blocks_with_IP_info.csv
1796	14-62335	35	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a dome surfaced proliferation of large oval melanocytes with moderately pleomorphic nuclei and abundant vacuolated cytoplasms, arranged as small nests and fascicles. The apex of the lesion is in the superficial reticular dermis, in part around folliculo-sebaceous units. There are evenly distributed melanophages.	Cylindrical skin segment, 0.6 cm in diameter and 0.5 cm in thickness, bisected and totally submitted. RS/RS	B'D DURING PREGNANCY; ATYPICAL NEVUS VS. MELANOMA	\N	\N	\N	I obtained a few stains to rule out a deep penetrating nevus-like melanoma. A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product, a reassuring finding. Immunostaining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a low proliferation rate. The term deep penetrating nevus refers to a specific melanocytic proliferation that resembles blue nevus clinically and in some histopathologic aspects, but is genomically distinct from it. The neoplasm extends to the peripheral edge of the specimen at the level of the superficial reticular dermis, very focally. There are no microscopic findings that suggest a need for re-excision, however.	DEEP PENETRATING NEVUS	173620	1982	\N	\N	14-62335	\N	SYNAT122	Dysplastic Nevi	IP1412277	AirTable blocks_with_IP_info.csv
1801	14-74770	9	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.3	\N	\N	Sections show a wedge-shaped proliferation of medium-sized oval melanocytes with monomorphic nuclei and amphophilic cytoplasm, arranged as small nests and fascicles. The apex of the lesion is in the reticular dermis, with a tendency of aggregations to be positioned next to adnexa. There are evenly distributed melanophages.	Cylindrical skin segment, 0.3 cm in diameter and 0.5 cm in thickness. Submitted intact. HD/KC	BLACK 4 MM PAPULE; NEVUS, R/O ATYPIA (TELEPHONE: 510-508-8632, OK TO MSG)	\N	\N	\N	This melanocytic nevus has mixed features of a deep penetrating nevus and a congenital pattern nevus. No evidence of melanoma or significant atypicality was detected.	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	173304	2343	\N	\N	14-74770	\N	SYNAT124	Dysplastic Nevi	IP1424729	AirTable blocks_with_IP_info.csv
1803	14-80165	61	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.7	\N	\N	Sections show a neoplasm composed of melanocytes, involving the superficial and deep dermis, with a propensity to aggregate around adnexal structures or vessels.  The constituent melanocytes have abundant pale cytoplasm with dusty melanin, and slightly pleomorphic nuclei.  They are associated with many melanophages.	Skin segment measuring 0.9 x 0.8 x 0.2 cm, quadrisected and entirely submitted. CF/KC	1 CM DARK PAPULE, NEW; R/O MM	\N	\N	\N	A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows that there are no melanocytes in mitosis, which is a findings that supports the diagnosis of a melanocytic nevus. Please note that this unusual nevus extends to the specimen edge and base such that it may persist if not re-excised. My colleague, Dr. Timothy McCalmont, also reviewed these sections and agrees with this assessment.	DEEP PENETRATING NEVUS	173702	2075	\N	\N	14-80165	\N	SYNAT125	Dysplastic Nevi	IP1430130	AirTable blocks_with_IP_info.csv
1812	14-96795	31	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.7	\N	\N	Sections show an inverted wedge-shaped proliferation of spindled and fusiform melanocytes with pale pigmented cytoplasm that extends relatively deeply in the reticular dermis. Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous. Many fascicles are noted. There are interspersed melanophages.	Cylindrical skin segment, 0.4 cm in diameter and 0.7 cm in thickness, bisected and entirely submitted. PL/KC	SUSPICIOUS IRREGULAR MULTI-COLORED MACULE; MELANOMA VS. BLUE NEVUS	\N	\N	\N	This biopsy demonstrates a deep penetrating nevus rather than a blue nevus. There is no evidence of melanoma.	DEEP PENETRATING NEVUS	17733	2226	\N	\N	14-96795	\N	SYNAT129	Dysplastic Nevi	IP1069336	AirTable blocks_with_IP_info.csv
1815	14-106005	11	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.3	\N	\N	Sections show a roughly wedge-shaped proliferation of spindled and polygonal melanocytes, some of which have abundant vacuolated cytoplasms, which extends deeply in the reticular dermis.  Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous.  There are interspersed melanophages. There are also superficial lymphocytic infiltrates with spongiosis of the overlying epidermis and focal parakeratosis. some parafollicular .	Cylindrical skin segment, 0.3 cm in diameter and 0.5 cm in thickness. Submitted intact. RS/RS	BLUE NEVUS, R/O MELANOMA	\N	\N	\N	Deep penetrating nevus is a variant of blue nevus. The dermatitis could reflect eczematous or seborrheic dermatitis, depending on the clinical context.	DEEP PENETRATING NEVUS, WITH OVERLYING SUBACUTE SPONGIOTIC DERMATITIS	173305	2236	\N	\N	14-106005	\N	SYNAT132	Dysplastic Nevi	IP1456016	AirTable blocks_with_IP_info.csv
1816	14-113574	31	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a wedge-shaped neoplasm composed of fascicles of melanocytes, involving the superficial and deep dermis, with a propensity for nests to surround adnexal structures or vessels.  The constituent melanocytes have abundant pale cytoplasm with dusty melanin, and pleomorphic nuclei.  They are associated with melanophages.	Cylindrical skin segment, 0.6 cm in diameter and 0.9 cm in thickness, bisected and entirely submitted. RS/RS	5 MM, NEVUS, CHANGING - GREY, DARK BROWN, R/O BLUE NEVUS / MM	\N	\N	\N	Deep penetrating nevus is either a form of blue nevus or closely related to it.  Its name derives from the tendency of its cells to extend into the subcutaneous fat along the paths of adnexa, especially hair follicles.  Alone among variants of blue nevi, it can feature an intraepidermal component, and its large, ovoid and pale cells are often found in combination with other types of melanocytes in combined nevi (Seab JA, Graham JH, Helwig EB. Deep penetrating nevus.  Am. J. Surg. Pathol. 1989; 13:39; Cooper PH. J. Cutan. Pathol. 1991;19:172-180).	DEEP PENETRATING NEVUS, EXCISED IN PLANES OF SECTION EXAMINED	173610	2167	\N	\N	14-113574	\N	SYNAT133	Dysplastic Nevi	IP1463605	AirTable blocks_with_IP_info.csv
10626	02-2599	51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	757.33	\N	\N	Sections show a domed segment of skin, with a slightly hyperkeratotic\nepidermis above a proliferation of spindled cells and thin-walled\nblood vessels.  There are adipocytes within the core of the lesion.	Polypoid skin fragment, measuring 0.8 x 0.8 x 0.6 cm, trisected and\nentirely submitted.	\N	\N	\N	\N	This lesion displays adipocytes within its core, an alteration similar to that seen in nevus lipomatosus. This is probably a reflection of the hamartomatous nature of this lesion.	ACQUIRED DIGITAL FIBROKERATOMA	666689	1594	\N	\N	02-2599	A	SYNX191	\N	IP307333	Consolidated_data_final.csv
3079	6172.3 (14.6172.3 slide)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1217	\N	\N	None	\N	NM-39	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1582	12-11406A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1979	\N	\N	12-11406	A	SYNAT484	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1332	08-70283a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2320	\N	\N	None	\N	SYNAT485	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1094	03-34051A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1817	\N	\N	03-34051	A1	SYNAT486	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1067	02-42436	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2168	\N	\N	02-42436	\N	SYNAT487	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1836	15-6952	24	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show two tissue fragments that both contain a proliferation composed of fascicles of melanocytes, involving the superficial and deep dermis and adnexal structures.  The constituent melanocytes have abundant pale cytoplasm with dusty melanin, and pleomorphic nuclei.  They are associated with many melanophages.	Two specimens received in one specimen bottle. One cylindrical skin segment, 0.5 cm in diameter and 0.5 cm in thickness, bisected and entirely submitted. One skin segment measuring 0.7 x 0.6 x 0.3 cm, bisected and entirely submitted. RS/RS	6 MM PIGMENTED PAPULE; R/O MM, TWO PIECES (BISECTED)	\N	\N	\N	I did not find phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) positive nuclei in the lesional melanocytes, a finding that supports the benign interpretation of a deep penetrating nevus. The nevus extends to the base and edge of the specimen in the deeper tissue segment. Therefore, this nevus is likely to persist if re-excision is not performed. My colleague, Dr. Timothy McCalmont, also reviewed these sections and agrees with this diagnosis and assessment.	DEEP PENETRATING NEVUS, EXTENDING TO THE BASE AND PERIPHERAL ASPECT OF THE SPECIMEN	139522	2112	\N	\N	15-6952	\N	SYNAT136	Dysplastic Nevi	IP1477972	AirTable blocks_with_IP_info.csv
1840	15-8321	25	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.3	\N	\N	Beneath a superficial zone of fibrosing granulation tissue is a proliferation of large oval melanocytes with monomorphous small, oval nuclei and abundant pale vacuolated cytoplasms, arranged as small nests and fascicles. The apex of the lesion is in the deep reticular dermis, with a tendency of aggregations to be positioned next to adnexa or small vessels. There are clusters of melanophages.	Cylindrical skin segment, 0.4 cm in diameter and 0.3 cm in thickness, bisected and entirely submitted. RS/RS	4 MM PUNCH, SEE PATH DT14-98210	\N	\N	\N	The findings in the residuum are those of a fairly prototypical deep penetrating nevus, with nuclear pleomorphism well within the range of that seen in this entity, and a scarcity of mitotic figures. The deep reticular dermal margins are involved. The term deep penetrating nevus refers to a specific melanocytic proliferation that resembles blue nevus clinically and in some histopathologic aspects, but is genomically distinct from it.	BIOPSY SITE AND SUBJACENT DEEP PENETRATING NEVUS	100388	2124	\N	\N	15-8321	\N	SYNAT137	Dysplastic Nevi	IP1448202	AirTable blocks_with_IP_info.csv
1885	15-72350	20	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show dermal proliferation of small melanocytes with round to oval nuclei, coupled with larger ovoid and spindled melanocytes associated with melanophages. The melanocytes extend into the reticular dermis.	Cylindrical skin segment, 0.5 cm in diameter and 0.3 cm in thickness, bisected and entirely submitted. RS/RS	A) NEOPLASM OF UNCERTAIN BEHAVIOR. DARKLY PIGMENTED MACULE. DARKLY PIGMENTED MACULE; FAVOR BENIGN NEVUS BUT GETTING DARKER..	\N	left medial clavicle 	Scraping	None	COMBINED MELANOCYTIC NEVUS, WITH SUPERFICIAL CONGENITAL AND BLUE NEVUS COMPONENTS	105525	1337	\N	\N	15-72350	\N	SM-007	Nevus Library	IP495959	AirTable blocks_with_IP_info.csv
2190	17-82364B	37	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.4	\N	\N	Sections show a biphasic melanocytic proliferation.  One population of melanocytes consists of small cells with round to oval nuclei. There is a focus where there are also melanocytes with spindled configurations, which display cytoplasmic pigmentation and surrounding melanophages.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in B. RS/RS	A) ATYPICAL NEVUS. ATYPICAL RED BROWN PAPULE. B) ATYPICAL NEVUS. IRREGULAR BROWN PAPULE.	\N	left hairline	Scraping	\N	COMBINED MELANOCYTIC NEVUS, WITH BOTH ORDINARY NEVUS AND SPINDLED BLUE NEVUS ELEMENTS	102422	1338	\N	\N	17-82364	B	SM-008	Nevus Library	IP650361	AirTable blocks_with_IP_info.csv
2201	17-90774B	78	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show a biphasic melanocytic proliferation. There are both conventional melanocytes and dendritic or spindled melanocytes jointly with lymphocytes and melanophages.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted in B. PL/PL	A) NEOPLASM OF UNCERTAIN BEHAVIOR. B) NEOPLASM OF UNCERTAIN BEHAVIOR.	\N	right anterior shoulder	Scraping	This biphasic melanocytic nevus includes the commingling of conventional melanocytic nevus with dendritic blue nevus.	COMBINED MELANOCYTIC NEVUS, EXCISED IN THE AVAILABLE PLANES OF SECTION	102611	1339	\N	\N	17-90774	B	SM-009	Nevus Library	IP1314381	AirTable blocks_with_IP_info.csv
1413	10-59344	9	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a proliferation of melanocytes with a domed surface and a wedge-shaped base. The overlying epidermis is alternatively thinned and irregularly thickened. There are large, confluent nests of cells with relatively monomorphous oval vesicular nuclei and abundant pale amphophilic cytoplasm. Many mitotic figures are present both in the upper and lower parts of the lesion. Both maturation, and dispersion to smaller aggregations toward the inferior edge of the specimen is evident.	Six outside slides, D10-9923 (1&2) and one corresponding block (1).	BX PROVEN ATYPICAL NEVUS, UNUSUAL MELANOCYTIC NEOPLASM, FAVOR SPITZ'S NEVUS, CHECK MARGINS	\N	\N	\N	This lesion has some features that make a conventional Spitz's nevus unlikely, including a thinned epidermis, the extent of confluence of nests and the number of mitotic figures, some of them in the lower half of the lesion. The more striking cytologic atypia seen in the lesions that I term spitzoid melanoma of childhood is not evident. Similar lesions to this one have been reported under a variety of names, including atypical Spitz tumor. They tend to involve local (and sentinel) lymph nodes at a relatively high rate, but distant metastasis is unlikely. Given the sharp circumscription of the lesion, one could consider a re-excision of this site, but I have not seen lesions of this type recur when excised by even a few millimeters. With regard to sentinel lymph node biopsy, there is little prognostic information as there is such a disparity between a percent of patients with nodal involvement and distant metastases. Comparative genomic hybridization does not show clear-cut evidence of chromosomal gains or losses. Because deflections were present in the plotted CGH data, we consulted with our former colleague, Dr. Boris Bastian (now chairman of Pathology at Memorial Sloan-Kettering Medical Center, New York) who agrees that no definite aberrations are present. The lack of aberrations does not exclude the possibility of melanoma, but makes it less likely (aberrations, especially multiple ones in loci characteristic of conventional melanomas would have resulted in an outright diagnosis of melanoma in this case). If one is looking for a more specific name for a lesion like this one, atypical Spitz tumor may be apt.  Please note that a margin of about a millimeter or so is present between the neoplasm and the peripheral margin. Lesions of this type are usually well circumscribed, and do not recur even with narrow excision margins, if the excision margins are histopathologically proven. Hence, I believe that this site could be treated with a reexcision of only a few more millimeters.	COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES	173304	1933	\N	\N	10-59344	\N	SYNAT142	2010-2017	IP953920	AirTable blocks_with_IP_info.csv
2936	92-5109	64	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1027	172.5	\N	\N	Sections show a compound proliferation of atypical melanocytes.  Most of the junctional component consists of individual cells and a few nests located along the bases of rete, but in some areas the melanocytes confluently replace the basal zone.  These melanocytes have atypical nuclei, prominent eosinophilic nucleoli, and finely dusty melanin in their cytoplasm (pagetoid cells), and are seen scattered throughout all zones of the epidermis including the granular layer.  In the subjacent dermis there are similar atypical pagetoid melanocytes with mitotic figures readily identified. Similar cells also infiltrate the fibrous tract of a hair follicle. Below this zone of pagetoid melanocytes there are nests and strands of small nevus cells. There is prominent angiogenesis, but vascular invasion is not apparent.	Cylindrical skin segment, 0.6 cm in diameter, 0.2 cm in depth,\nbisected.	2.3 X 2.8 CM IRREGULAR BORDERED, IRREGULAR PIGMENTED PLAQUE; PATIENT STATES LESION PRESENT ALL HIS LIFE AND HAS ONLY CHANGED IN PAST FEW WEEKS, BUT NO INCREASING IN SIZE; CLINICAL DIAGNOSIS - MELANOMA	\N	\N	\N	The thickness is 1.4 mm, however, final microstage measurements are pending re-excision.	MALIGNANT MELANOMA, ARISING IN ASSOCIATION WITH A PRE-EXISTENT NEVUS, SEE NOTE	173528	174	\N	\N	92-5109	\N	CCR-154	California Cancer Registry	IP14859	AirTable blocks_with_IP_info.csv
10162	12-20321	58	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.19	Brain, right frontal, biopsy: Glioblastoma, WHO Grade IV 	\N	Sections show a polypoid segment of skin with a papillated surface, and the epidermis is expanded by a proliferation of keratinocytes arrayed as interanastomosing rete.	Skin segment, 1.0 x 0.4 x 0.4 cm, bisected and entirely submitted.	\N	\N	\N	\N	\N	POLYPOID SEBORRHEIC KERATOSIS	173404	1460	\N	\N	12-20321	A	SYNX57	\N	IP1102231	Consolidated_data_final.csv
1543	11-96096	55	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show inflammation and granulation tissue, with no evidence of an atypical melanocytic proliferation.	Eighteen outside slides, DI08-6824:C1 through C18.	UCSF MELANOMA CLINIC PATIENT; SUBMITTED FOR CONSULT AND FOR BRAF & NRAS MUTATION ANALYSIS	\N	\N	\N	None	HEALING BIOPSY SITE, WITH NO EVIDENCE OF RESIDUAL MELANOMA	173701	2220	\N	\N	11-96096	\N	SYNAT143	2010-2017	IP1085544	AirTable blocks_with_IP_info.csv
1257	06-72820A	52	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=,24931	216.5	\N	\N	Sections show an area of lymphohistiocytic inflammation and fibrosing granulation tissue due to earlier surgery, with no evidence of residual melanocytic neoplasm.	Ellipse, 3.5 x 1.0 x 0.5 cm, including a central white 0.5 x 0.3 cm area with 1.2 cm linear scar.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with six sections each in cassettes A and B, tips returned to container.	R/O CLARK'S OR DYSPLASTIC NEVUS, CHECK MARGINS	\N	\N	Punch	\N	POST-SURGICAL CHANGES, WITH NO EVIDENCE OF RESIDUAL MELANOCYTIC NEVUS	173532	1105	\N	\N	06-72820	A	ME-10	Melanoma Epigenetics	IP524944	AirTable blocks_with_IP_info.csv
2139	17-55182C	51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22438	216.5	\N	\N	Sections show a array of delicate, wavy spindled cells with perijunctional fibrosis due to irritation.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in C. CF/CF	A) SKIN TAG VS. NEVUS VS. OTHER. 2.5 MM PINK PAPULE. COMPLETE READ. B) SKIN TAG VS. NEVUS VS OTHER. 2.5 CM PINK PAPULE. COMPLETE READ. C) SKIN TAG VS. NEVUS VS OTHER. 4 MM PINKISH PAPULE. COMPLETE READ. D) NEOPLASM OF UNCERTAIN BEHAVIOR. 6 - 7 MM PINK PAPULE WITHIN CONGENITAL NEVUS. COMPLETE READ.	\N	\N	\N	\N	NEUROFIBROMA	172541	1106	\N	\N	17-55182	C	ME-11	Melanoma Epigenetics	IP1784912	AirTable blocks_with_IP_info.csv
1095	03-39293	55	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1311	172.6	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, arranged irregularly within the epidermis, as single cells and nests with an area of pagetoid spread, flanking a nodular proliferation of large melanocytes that do not mature (diminish in size) with descent into the dermis, but are associated with a dense lymphocytic infiltrate.  Between the nodule and the intraepidermal component, the papillary dermis is thickened and fibrotic, with a patchy bandlike lymphocytic infiltrate and diminished numbers of melanocytes.	Ellipse measuring 2.0 x 0.8 x 0.3 cm, multiple raised skins measuring 0.7 x 0.5 cm, with margins inked blue, the specimen is serially sections and submitted in six sections.	NODULAR GROWTH WITHIN A PRE-EXISTING PLAQUE; R/O MELANOMA VS PIGMENTED BCC	\N	\N	\N	9/5/2003:  The thickness is listed above.  Aside from regression and a dense infiltrate of tumor infiltrating lymphocytes, there are no other findings of prognostic import.  Melanoma in situ extends almost to the periphery of the specimen. 9/3/2003:  I will be back in the office on 9/5 and will send a final report with a thickness measurement.  The microscope I am currently at does not have a micrometer.  This appears to be an intermediate risk primary melanoma (level III with regression).	MELANOMA, 1.4 MM  IN THICKNESS	529698	209	\N	\N	03-39293	\N	CCR-240	California Cancer Registry	IP397607	AirTable blocks_with_IP_info.csv
1902	15-118245A	28	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with nested and solitary melanocytes scattered along the junction. There are maturing nests, cords, and syncytia of small melanocytes in the reticular dermis below this. A perifollicular keratin granuloma is present as well.	Cylindrical skin segment, 0.4 cm in diameter and 0.7 cm in thickness, bisected and entirely submitted in A. PL/PL	A) 5 X 4 MM TAN PAPULE; CMN, R/O ATYPIA, B) 5 X 4 MM BROWN PAPULE; DYSPLASTIC CMN, R/O ATYPIA, C) 6 X 4 MM VARIEGATED BROWN PAPULE; CMN, R/O ATYPIA , D) 8 X 5 MM VARIEGATED BROWN PAPULE; CMN, R/O ATYPIA, E) 5 X 5 MM PINK PAPULE; CMN VS. SCAR	\N	right deltoid 	Scraping	\N	COMPOUND MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES	105539	1343	\N	\N	15-118245	A	SM-014	Nevus Library	IP1590062	AirTable blocks_with_IP_info.csv
1059	02-20732 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1052	\N	\N	None	\N	MD-175	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1053	02-17209C T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1053	\N	\N	None	\N	MD-176	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1064	02-28682 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1054	\N	\N	None	\N	MD-177	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1057	02-20619B	49	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1313	172.4	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly along the epidermal-dermal junction above elastosis, with nests of melanocytes in predominance in many areas.  Many of the constituent melanocytes have ample vacuolated and pigmented cytoplasm, and some melanocytes have slightly spindled cytomorphology.  There are clusters of similar cells in the superficial dermis, also above elastosis.  In a central area there are nodular collections of these melanocytes, forming an array that extends through the reticular dermis to the level of the superficial subcutis.  There is also an upper dermal infiltrate of lymphocytes and melanophages scattered throughout this lesion.	Oval-shaped oriented excision measuring 3.0 x 2.2 x 0.8 cm, with tip\nmarked by a single suture at 9 o'clock margin and two notable\nsutures placed at 12 o'clock margin, superior half of specimen is\ninked in blue, and inferior half of specimen is inked in yellow,\nserially sectioned and submitted with four sections each in cassettes\nA and C, three sections in cassette B.	FLAT BLACK NEVUS OF ? DURATION; SSM	\N	\N	\N	This is a non-ulcerated primary melanoma with a central nodular invasive focus that is prognostically worrisome based upon its thickness, and also based upon the fact that the invasive cells extend through the reticular dermis and abut upon the superficial subcutis (thus existing at the Clark's IV/V interface).  I do not see any clear evidence of vascular invasion or perineural extension in these sections.	MELANOMA OF 3.1 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO WITHIN 1 MM OF BOTH PERIPHERAL BIOPSY MARGINS	173410	210	\N	\N	02-20619	B	CCR-241	California Cancer Registry	IP325344	AirTable blocks_with_IP_info.csv
1018	00-26584A1	36	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a proliferation of atypical melanocytes, arranged\nirregularly as single cells and nests at the epidermal-dermal\njunction, and in a central area in the dermis without diminishment in\nsize, where sheets and nodular aggregates are present.  There are\nareas in which the papillary dermis is thickened and fibrotic, with a\nlichenoid infiltrate of lymphocytes and melanophages, as well as\ndiminished numbers of melanocytes in comparison to the remainder of\nthe lesion.	Ellipse, measuring 2.9 x 1.8 x 0.7 cm, serially sectioned and\nsubmitted with three sections in blocks A1 and A2, and two sections\nin block A3, margins inked blue.	CLINICAL DIAGNOSIS - MELANOMA; TELEPHONE: 415-664-8630	\N	\N	\N	Regression is currently believed to be an adverse prognostic factor in patients with melanoma.	MELANOMA, 2.5 MM IN THICKNESS, WITH AREAS OF REGRESSION, EXTENDING TO WITHIN 2 MM OF THE PERIPHERAL BIOPSY MARGIN	172733	212	\N	\N	00-26584	A1	CCR-248	California Cancer Registry	IP241687	AirTable blocks_with_IP_info.csv
1007	00-7684A2	70	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1318	173.5	\N	\N	Sections show a compound proliferation of polygonal neoplastic cells\narrayed as irregular sheets of cells along the epidermal-dermal\njunction, with nests and sheets of similar cells in the underlying\ndermis.  There is extensive necrosis.	Oval-shaped excision measuring 4.0 x 4.0 x 1.5 cm, serially sectioned\nand submitted with two sections each in blocks A1, A10 and A11, one\nsection each in blocks A2, A3, A4, A5, A6, A7, A8, and A9, margins\ninked blue.	A) 4.0 X 3.5 CM BLEEDING FUNGATING NODULE WHICH IS 1.0 X 1.5 CM THICK, B) 2.0 X 3.0/4.0 CM PEARLY ERODED RED PLAQUE; CLINICAL DIAGNOSIS - A) PG VS NODULAR MELANOMA VS BCC, B) BCC	\N	\N	\N	3/29/2000:  An S100 immunostain is positive in the neoplastic cells, confirming the melanocytic lineage of this lesion.  This is a high-risk primary melanoma, based upon lesional thickness.  Consideration could be given to sentinel node evaluation.  Please contact me if you would like additional information regarding this technique.   3/19/2000:  This lesion is likely a melanoma of 12 mm in thickness.	MELANOMA, AT LEAST 12 MM IN THICKNESS, BROADLY TRANSECTED AT THE DEEP BIOPSY MARGIN	273588	213	\N	\N	00-7684	A2	CCR-250	California Cancer Registry	IP222787	AirTable blocks_with_IP_info.csv
10660	13-25288	54	\N	\N	\N	T1b	Primary	\N	\N	\N	\N	\N	\N	172.7	Iwei Acral Melanoma	\N	Sections show acral skin with a fragmented compound proliferation of atypical melanocytes arranged in an irregular pattern within the epidermis, and with similar cells in the dermis. There are also many melanophages and dilated lymphovascular spaces.	A skin segment and multiple tissue fragments received in one specimen bottle. The skin segment, 1.1 x 0.7 x 0.2 cm, serially sectioned perpendicular to the long axis and entirely submitted with five sections. The multiple tissue fragments, 1.0 x 0.5 x 0.1 cm in aggregate, entirely submitted. RS/RS	\N	\N	\N	\N	The tumor is sampled in a fragmented manner, and thus a meaningful estimate of thickness is not possible. It involves the dermis without further orientation. I identified a mitotic figure in routine sections. Occasional mitotic figures are also evident in a phosphohistone H3 immunostain, but such results are used for diagnostic purposes but not currently for staging purposes. There are also areas suspicious for lymphovascular invasion, but this could not be confirmed in  D2-40 immunoperoxidase stain. In short, definitive assessment of prognostic features should be deferred to the excision specimen. In these sections, there does not appear to be ulceration, and thus the staging is T1b preliminarily. This report was reissued on May 28, 2013 to add the patient's UCSF Medical Record number and to forward a copy to UCSF Medical Records.	MELANOMA, INVOLVING ACRAL SKIN, FRAGMENTED	582753	1601	\N	\N	13-25288	A	SYNX198	\N	IP1210033	Consolidated_data_final.csv
1654	12-67286	18	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	There is a compound proliferation melanocytes with a junctional component including nests of large, oval and fusiform melanocytes with abundant, pale amphophilic cytoplasm and large, vesicular nuclei. These bridge adjacent rete ridges and in the center of the lesion are in apposition to a thinned epidermis. Smaller melanocytes with pigmented cytoplasm are present in the papillary dermis, along with a patchy lymphocytic infiltrate joined by melanophages.	Six outside slides, S12-39988 (CD12-103252) including 5 unstained slides.	MELANOCYTIC LESION	\N	\N	Scraping	Comparative genomic hybridization shows an isolated gain involving chromosome 10p. This is not a locus typically gained in melanoma. I would view this as an idiosyncratic aberration, in keeping with the low level of genetic instability seen in atypical Spitz tumors and similar lesions.	COMPOUND PROLIFERATION MELANOCYTES WITH A JUNCTIONAL COMPONENT OF LARGE SPITZOID CELLS	173528	241	\N	\N	12-67286	\N	CGH12-280	Nevus Library	IP1153102	AirTable blocks_with_IP_info.csv
1996	16-108259C	71	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24933	172.5	\N	\N	Sections show no evidence of a residual atypical melanocytic lesion along the junctional zone. Central ulcerative fibrosing inflammatory alterations that are post-procedural are noted.	Oriented ellipse, 6.0 x 2.4 x 0.6 cm, including a central 1.0 x 0.9 cm tan area. With the orienting sutured tip placed to the left and designated 9 o'clock by the grosser, the 9-12-3 o'clock margin is inked blue and the 3-6-9 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and submitted with three sections in A, four sections in B and three sections in C. Tips reserved. PL/PL	HEALING BIOPSY SITE; MALIGNANT MELANOMA, PLEASE CHECK MARGINS	\N	\N	Punch	No residuum is apparent, and the final margin is free. An updated melanoma synoptic is included below. Procedure: wide excision Microscopic tumor type: superficial spreading melanoma Breslow thickness: 0.5 mm Ulceration: not detected Margin: free of melanoma Mitotic index: 0 Regression: not detected Pathologic staging (pTNM): pT1a	FREE OF RESIDUAL MELANOMA	273588	1109	\N	\N	16-108259	C	ME-14	Melanoma Epigenetics	IP1703438	AirTable blocks_with_IP_info.csv
2052	17-10753	28	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show a dome shaped segment of skin with a proliferation of melanocytes with two types of cells. One population consists of clusters of small melanocytes with round to oval monomorphous nuclei. A second population consists of collections of oval and spindled melanocytes with large oval nuclei embedded in between thickened collagen bundles as single cells and as small nests.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted. PL/PL	LM VS. MM VS. MIS, 8 X 8 MM	\N	right lateral antecubital 	Scraping	There are no worrisome features.	COMBINED MELANOCYTIC NEVUS, WITH PREDOMINANTLY INTRADERMAL (ORDINARY) AND DESMOPLASTIC SPITZ'S NEVUS COMPONENTS	100689	1344	\N	\N	17-10753	\N	SM-015	Nevus Library	IP1739922	AirTable blocks_with_IP_info.csv
1013	00-15364 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1062	\N	\N	None	\N	MD-185	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3018	99-15953D T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1063	\N	\N	None	\N	MD-186	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3027	99-24969F T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1064	\N	\N	None	\N	MD-187	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3013	99-09753 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1065	\N	\N	None	\N	MD-188	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3553	N-ID 1941	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1234	\N	\N	None	\N	NM-59	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1991	16-104614H	37	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24934	172.5	\N	\N	Sections show no evidence of a residual atypical melanocytic lesion along the junctional zone. Central ulcerative fibrosing inflammatory alterations that are post-procedural are noted.	Ellipse, 9.7 x 3.4 x 1.2 cm, including a central 1.8 x 1.5 cm depression. In addition, there is a peripherally located 0.3 x 0.3 cm brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections in A, one section each in B-C, one section (bisected) each in D-H, and one section each in I-K. The section in K is a representative section through the peripheral brown area. Tips reserved. RS/RS	MALIGNANT MELANOMA, PLEASE CHECK MARGINS	\N	\N	Punch	No residuum is apparent, and the final margin is free. An incidental lentiginous junctional melanocytic nevus is noted. An updated melanoma synoptic is included below. Procedure: wide excision Microscopic tumor type: melanoma ex melanocytic nevus Breslow thickness: 0.65 mm Ulceration: not detected Margin: free of melanoma Mitotic index: 0 Regression: not detected Pathologic staging (pTNM): pT1a	FREE OF RESIDUAL MELANOMA	139522	1110	\N	\N	16-104614	H	ME-15	Melanoma Epigenetics	IP1699195	AirTable blocks_with_IP_info.csv
2949	94-7602A	56	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1356	172.5	\N	\N	Sections show a compound proliferation of melanocytes, many of which\nhave atypical nuclei.  Nested and solitary melanocytes are arrayed at\nall epidermal levels, and aggregates and sheets of similar\nmelanocytes extend into the underlying dermis, to a maximum depth of\n1.6 mm.  A few melanocytes may extend more deeply, but only in areas\nof the adventitial dermis, where measurement is not utilized by\nconvention.  There are patchy lymphocytic infiltrates that permeate\nthe neoplasm, and there are areas of surrounding fibrosis.	Unoriented ellipse, 5.5 x 1.6 x 0.7 cm, serially sectioned with\nthree sections each submitted in blocks A and C, and two sections\neach in blocks B and D, tips returned to container, margins inked.\nSurface shows irregular brown macule, 1.9 x 0.9 cm.	LARGE IRREGULAR PIGMENTED PLAQUE; CLINICAL DIAGNOSIS - R/O MM	\N	\N	\N	There are broad zones of remote scar in the dermis underlying this neoplasm.  Was any prior surgery performed at this site, or was this a site of prior trauma?  If any prior surgical specimens exist, I would be happy to review them as part of this consultation.   The original report contained an erroneous microstage measurement, which may have been due to a transcription error.  This report contains corrected information (7/19/94).	MALIGNANT MELANOMA, SUPERFICIAL SPREADING TYPE, 1.6 MM IN THICKNESS, CLARK'S LEVEL III, EXCISED	173502	215	\N	\N	94-7602	A	CCR-257	California Cancer Registry	IP43096	AirTable blocks_with_IP_info.csv
1400	10-32987	12	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a roughly wedge-shaped proliferation of spindled and polygonal melanocytes, some of which have abundant vacuolated cytoplasms, which extends deeply in the reticular and adventitial dermis.  Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous.  There are interspersed melanophages, and the stroma is focally sclerotic.	Cylindrical skin segment measuring 0.6 cm in diameter x 0.6 cm in thickness, bisected and entirely submitted.	4 MM BLUE PAPULE; BLUE NEVUS, R/O MELANOMA	\N	\N	\N	None	DEEP PENETRATING NEVUS (A VARIANT OF BLUE NEVUS)	173611	1811	\N	\N	10-32987	\N	SYNAT152	Deep Penetrating Nevus	IP927561	AirTable blocks_with_IP_info.csv
2074	17-21788B	62	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a symmetric compound proliferation of melanocytes. Small nests of small round melanocytes and single melanocytes are arrayed at the sides and bases of elongated rete. Within the dermis, there are nests of melanocytes, and some have abundant amphophilic cytoplasm. Dermal melanocytes mature and disperse to single cells within fibrotic collagen with a wedge shaped lower border.	Oriented ellipse, 2.0 x 0.9 x 0.5 cm, including a central 0.8 x 0.5 cm brown area. With the orienting pre-inked blue tip placed to the left and indicated L pole 9 o'clock on the requisition, the 9-12-3 o'clock margin is inked black and the 3-6-9 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections in A and five sections in B. PL/PL	MALIGNANT MELANOMA VS. CAN, 7 MM IRR BRN PAPULE, MM, CAN, EXCISION	\N	left buttock	Scraping	This nevus has small round melanocytes as well as melanocytes with abundant cytoplasm similar to those in Spitz nevus. The lower portion of the nevus is set within desmoplastic stroma. Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a relatively low proliferation rate in the junctional component and a near zero proliferation rate in the dermal component. The MART-1/tyrosinase component does not reveal more suprabasilar scatter than could be seen in the hematoxylin and eosin stained sections. p16 staining is strong in a subset of the lesional melanocytes, supporting a benign diagnosis. Dr. Philip LeBoit has also reviewed this case and agrees with the diagnosis and assessment. The nevus is completely excised.	COMPOUND MELANOCYTIC NEVUS	173507	1345	\N	\N	17-21788	B	SM-016	Nevus Library	IP1747915	AirTable blocks_with_IP_info.csv
2138	17-52720	31	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.2	\N	\N	Sections show a proliferation of melanocytes involving the epidermis and mostly, the superficial dermis. There are increased single melanocytes at the dermo-epidermal junction, and some small nests of them, in part positioned at the sides and bases of elongated rete ridges. There is basilar hyperpigmentation in the affected area.  Within the dermis are nests, cords and strands of small, round melanocytes.  These cells mature with descent, and lie in part around adnexal structures. Deeper in the dermis is a sclerotic, pauci-cellular area in which there are thin spindled cells and mucin deposition.	Cylindrical skin segment, 0.6 cm in diameter and 0.5 cm in thickness, bisected and entirely submitted. KC/KC	NEVUS WITH CYST, R/O ATYPIA, 5 MM	\N	left posterior earlobe	Scraping	ADDENDUM, June 12, 2017: The dermal and subcutaneous margins are involved, per you inquiry.  Original note:  This unusual lesion has a lower portion that raised the possibility of desmoplastic melanoma arising beneath a nevus, which is a very rare occurrence. The markedly fibrotic area in question has S100+ spindled cells within it, many of which are thin, and long. These also stain with WT-1. Neither stain shows significantly thick fascicles, as would favor desmoplastic melanoma and the nuclei of the cells in question are not markedly atypical. Staining with CD34 shows some foci with a whorled pattern, as can be seen in perineuriomas, and some dendritic processes are positive with epithelial membrane antigen, as can be seen in perineurioma.  In sum, the fibrosing spindle cell area has mixed features of neurofibroma and perineurioma, and the findings do not support a component of desmoplastic melanoma. My colleague, Dr. Timothy McCalmont, also reviewed these sections and agrees with this diagnosis. We do not believe that re-excision is necessary.	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES, WITH A SUBJACENT AREA FEATURING SCHWANNIAN AND PERINEURIOMATOUS DIFFERENTIATION	173222	1346	\N	\N	17-52720	\N	SM-017	Nevus Library	IP1782404	AirTable blocks_with_IP_info.csv
1406	10-43330	104	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1258	172.6	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei in partial contiguity with the epidermis. There is little diminishment in melanocyte size with descent in the dermis. Within the epidermis, single cells and nests are scattered broadly, and cells in pagetoid array can be found. In the dermis, the non-maturing melanocytes show central juxtaposed hemorrhage and are commonly found in mitosis.	Ellipse, 1.0 x 1.0 x 0.3 cm, including a central salmon pink 0.7 x 0.7 cm raised lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections.	PROBABLE NODULAR MELANOMA	\N	\N	\N	This narrow excision contains a nodular non-ulcerated melanoma with associated Clark's level IV invasion. There is no evidence of associated vascular invasion, perineural invasion, or regression. The mitotic index of the invasive component exceeds 10/square mm. Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 3.9 MM IN THICKNESS	173610	176	\N	\N	10-43330	\N	CCR-157	California Cancer Registry	IP937906	AirTable blocks_with_IP_info.csv
1415	10-71761	33	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	There are increased single melanocytes and nests of them along the dermo-epidermal junction, with nests of small, round melanocytes in the papillary dermis as well.	One outside slide, DK10-19623:B.	SECOND OPINION, A) ANGIOMA, B) NEVUS	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS	528522	1868	\N	\N	10-71761	\N	SYNAT144	2010-2017	IP966340	AirTable blocks_with_IP_info.csv
1281	07-37090	86	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1377	172.4	\N	\N	Sections show nested and solitary melanocytes, some of which display atypical nuclear features, in irregular array along the epidermal-dermal junction.  Many melanocytes are scattered above the basal layer.  The epidermis is focally hyperplastic. Similar melanocytes are present in clusters in the underlying dermis, within a zone of fibrosis, occurring over marked elastosis.	Cylindrical skin segment, 0.4 cm in diameter and 0.2 cm in thickness, bisected and entirely submitted.	R/O ATYPIA	\N	\N	\N	Level sections were helpful in demonstrating an invasive component, which was also suggested an initial sections.  In terms of staging, this is a nonulcerated primary melanoma of Clark's anatomic level II, with melanocytes abutting the reticular dermal interface, within a zone of fibrosis. There is no evidence of vascular invasion, neurotropism, or regression. Definitive assessment of thickness and other prognostic factors should be deferred to complete excision of this neoplasm, as I assume this is a small sample of a larger lesion.	MELANOMA, 0.5 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO THE PERIPHERAL MARGINS	173405	220	\N	\N	07-37090	\N	CCR-268	California Cancer Registry	IP659623	AirTable blocks_with_IP_info.csv
3000	98-9595B	61	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22648	172.5	\N	\N	Sections show a compound proliferation of melanocytes arrayed as\nirregular nests along the epidermal-dermal junction, with nests and\nsheets of atypical melanocytes in the underlying dermis.  Smaller\nmelanocytes are present in one peripheral focus (representing\nmelanocytic nevus).	Ellipse, 2.0 x 2.0 x 1.0 cm, serially sectioned and submitted with\nsix pieces in block A1, margins inked blue.	CLINICAL DIAGNOSIS - R/O MELANOMA VS BCC X 2	\N	\N	\N	In one of the cross sections of this biopsy, small melanocytes, which appear to represent remnants of a precursor melanocytic nevus, are present in the superficial dermis.  Further reexcision of this site is warranted.	MELANOMA, 1.6 MM IN THICKNESS, EXTENDING NEAR TO THE PERIPHERAL MARGIN	433599	221	\N	\N	98-9595	B	CCR-269	California Cancer Registry	IP146596	AirTable blocks_with_IP_info.csv
2308	18-24908	25	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with a wedge-shaped profile. Pigmented melanocytes are present along the sides and bases of elongated and hyperpigmented rete. The melanocytes are evenly distributed and mature with descent in the reticular dermis arrayed as single cells and cords between thickened collagen bundles at the base of the biopsy.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted. HD/PL	R/O NEOPLASM OF UNCERTAIN BEHAVIOR, DYSPLASTIC NEVUS, MALIGNANT MELANOMA, 0.4 CM DARK BROWN PAPULE	\N	left scapular back	Scraping	This benign lesion shares a fibrotic dermal reaction with desmoplastic Spitz's nevus, but lacks the large melanocytes seen in that condition.	COMPOUND MELANOCYTIC NEVUS	173530	1348	\N	\N	18-24908	\N	SM-019	Nevus Library	IP1888575	AirTable blocks_with_IP_info.csv
3205	Cell-Line_Xu-15	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2101	\N	\N	None	\N	SYNAT145	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
2330	18-59376	49	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show a symmetric compound proliferation of melanocytes. Small round melanocytes with round or ovoid nuclei and scant cytoplasm are arrayed as nests and single cells along the sides and bases or elongated rete. In the dermis below, nests of melanocytes mature to single cells between desmoplastic collagen bundles with a wedge-shaped profile.	Cylindrical skin segment, 0.6 cm in diameter and 0.6 cm in thickness, bisected and entirely submitted. KC/KC	3 MM IRREGULAR BROWN MACULE; ATYPICAL NEVUS	\N	left lower thigh 	Scraping	In areas, this nevus has features of a blue nevus, perhaps accounting for the clinical appearance.	COMPOUND MELANOCYTIC NEVUS	173726	1349	\N	\N	18-59376	\N	SM-020	Nevus Library	IP1491105	AirTable blocks_with_IP_info.csv
3029	99-30301	71	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.4	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei in contiguity with the epidermis.  There is little diminishment in melanocyte size with descent in the dermis, and there are scattered dermal mitotic figures.	Skin segment measuring 0.7 x 0.5 x 0.2 cm, bisected and entirely\nsubmitted.	PURPLE PAPULE; HEMANGIOMA, MALIGNANCY	\N	\N	Scraping	In the clinical context, these findings probably represent a nodular primary melanoma, but I did consider the possibility that this lesion could represent a metastatic deposit (because of its nodular pathologic appearance). A total skin examination would thus be appropriate. This patient is a candidate for sentinel node evaluation. Please notify me if you would like to receive additional information regarding this technique.	MELANOMA, AT LEAST 2.0 MM IN THICKNESS, EXTENDING TO THE DEEP BIOPSY MARGIN	173406	181	\N	\N	99-30301	\N	CCR-201	California Cancer Registry	IP58570	AirTable blocks_with_IP_info.csv
3008	98-21806	57	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2738	172.6	\N	\N	Sections show sheets and fascicles of spindled neoplastic cells with clear cytoplasm.  There is a subtle overlying component of nested melanocytes in the epidermis.	Cylindrical skin segment, 0.6 cm in diameter and 0.5 cm in thickness,\nbisected and entirely submitted.	4MM PEARLY PAPULE AROSE FEW MOS. AGO IN AREA OF 1.6 X 2CM BROWN MACULE, RED HAIR; CLINICAL DIAGNOSIS - BASAL CELL CARCINOMA IN LENTIGO VS MM	\N	\N	\N	None	MELANOMA, FOCALLY DESMOPLASTIC IN PATTERN, 1.8 MM IN THICKNESS, EXTENDING TO THE PERIPHERAL MARGIN	173611	222	\N	\N	98-21806	\N	CCR-272	California Cancer Registry	IP159379	AirTable blocks_with_IP_info.csv
1416	10-73024	55	\N	\N	\N	T1a	Primary	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.  There is an associated dense band like lymphocytic infiltrate with numerous melanophages.  There are foci of epidermal atrophy with an associated paucity of melanocytes.	Oriented ellipse, 2.8 x 1.5 x 0.5 cm, including a central 0.5 x 0.5 cm lesion and a smaller lesion measuring 0.8 x 1.2 cm.  With the orienting notch placed to the left, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from left to right tips and entirely submitted with five sections each in cassettes A and B.	SPLIT IS PROXIMAL CLUSTER OF BLACK PAPULES, H/O OF PREV NEVUS, CHANGED OVER THE LAST FEW YRS; R/O MELANOMA	\N	\N	\N	Melan-A stains were done and they highlight a broad proliferation of atypical melanocytes at the dermoepidermal junction and above it.  A few nests of atypical melanocytes are also noted in the dermis.  These were difficult to detect on routine staining due to the associated dense band like infiltrate of lymphocytes and melanophages.  The lesion has been completely, but narrowly excised.  Melanoma in situ is present to within 1 millimeter of the 9 o'clock position with the orienting notch designated as 12 o'clock.  In terms of staging this is a thin non-ulcerated melanoma with foci of regression.  No dermal mitotic figures are noted within the small dermal component.  It should be regarded as a pT1a lesion based on the 2009 AJCC melanoma staging system.	MELANOMA, 0.32 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, NARROWLY EXCISED	173611	1890	\N	\N	10-73024	\N	SYNAT155	2010-2017	IP967603	AirTable blocks_with_IP_info.csv
1028	01-11378A2	79	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1392	172.5	\N	\N	Sections show an area of inflammation and fibrosis, representing the\naftermath of a prior biopsy or surgery, flanked by a proliferation\nof melanocytes arrayed as irregular clusters in the epidermis and\ndermis.  The junctional melanocytes are arrayed in predominantly\nnested but confluent fashion, and only rare underlying dermal\nmelanocytes are evident.  The papillary dermis is also expanded by\nfibrosis and an infiltrate of lymphocytes and melanophages.	Ellipse, measuring 5.7 x 2.5 x 0.5 cm, margins inked blue, serially\nsectioned and submitted with three sections in block A1 and two\nsections in block A2, remainder returned to container.	H/O MELANOMA; MELANOMA, 0.25; TELEPHONE:  284-0559	\N	\N	\N	Unfortunately, a full cross section of one of the segments of tissue from this specimen could not be visualized, due to aberrations in the gross sectioning of this specimen.  Based upon all other profiles, it appears that this lesion has been completely excised with a wide margin.  Thus, I believe that surgical margins are negative, despite the fact that there are some limitations in the interpretation of the margins of this excisional specimen.	RESIDUAL MELANOMA OF 0.35MM IN THICKNESS, APPARENTLY COMPLETELY EXCISED (FINAL SURGICAL MARGINS APPEAR FREE OF MELANOMA CELLS)	136563	226	\N	\N	01-11378	A2	CCR-282	California Cancer Registry	IP129632	AirTable blocks_with_IP_info.csv
2994	98-1556	80	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1394	172.4	\N	\N	Sections show a compound proliferation of melanocytes arrayed as irregular nests along the epidermal-dermal junction, with nests and sheets of atypical melanocytes in the underlying dermis.  There is elastosis.	Cylindrical skin segment, 0.5 cm in diameter and 0.3 cm in thickness,\nbisected and entirely submitted.	CLINICAL DIAGNOSIS - R/O BCE	\N	\N	\N	Final microstage measurements have been deferred until this lesion has been completely reexcised.	MELANOMA, 0.95 MM IN THICKNESS, EXTENDING TO THE PERIPHERAL MARGIN	173403	227	\N	\N	98-1556	\N	CCR-287	California Cancer Registry	IP17286	AirTable blocks_with_IP_info.csv
2651	20-81257A\n	90	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=29789,29790,29791,29792,29793,29794,29795,29796	172.6	\N	\N	Sections show fibrosing granulation tissue stemming from previous biopsy/surgery within a backdrop of marked solar elastosis. There is a residual array of atypical melanocytes, distributed in the lowermost epidermis and in the underlying dermis.	Oriented ellipse measuring 4.8 x 1.3 x 0.5 cm, including a central 3.9 x 1.3 cm area of variegated color/texture. The orienting short suture located at the mid-point of one edge is indicated 12 o'clock on the requisition and is placed toward 12 o'clock, and the long suture indicated 3 o'clock is placed toward the 3 o'clock. The grosser inked 9-12-3 o'clock margin blue and the 3-6-9 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and entirely submitted with six sections each in A-C. CF/CF	LEFT ARM WIDE EXCISION FOR MELANOMA	\N	\N	\N	Invasive and in situ melanoma extensively involve the blue inked and yellow inked peripheral margins.  As per the gross description, this would correspond to variable positivity along the approximate 11-3 o'clock and 3-7 o'clock peripheral margins. Coupling the findings in the original biopsy with the features in this re-excision specimen, the final parameters for reporting per the guidelines of the College of American Pathologists for this melanoma include the following:  Procedure: excision Microscopic tumor type: melanoma in skin with high cumulative sun damage (WHO classification) Breslow thickness: 2.5 mm. Ulceration: present Margins, peripheral: involved by invasive and melanoma in situ (see above); Margins, deep: negative for in situ and invasive melanoma Mitotic index: 2/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT3b pNX	RESIDUAL MELANOMA, BRESLOW THICKNESS 1.9 MM; INVASIVE AND IN SITU MELANOMA IN SITU EXTENDS TO THE INKED PERIPHERAL MARGINS; DEEP MARGINS FREE OF MELANOMA.  SEE NOTE.	173601	800	\N	\N	20-81257	A	LMM-01	Lentigo Maligna Melanoma	IP1127057	AirTable blocks_with_IP_info.csv
1193	05-66206A	46	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=318	172.5	\N	\N	Sections show melanocytes arrayed mostly in nests, irregularly and in pagetoid fashion within the epidermis. In the underlying dermis, there are irregularly-shaped, (sometimes) horizontally-oriented clusters of similar but slightly smaller melanocytes, which are enveloped by fibroplasia. In another cross-section, there are melanocytes with ample pale vacuolated and pigmented cytoplasm, arrayed as irregular nests in the dermis and also focally in pagetoid array within the epidermis. The upper dermis shows areas of coarse fibroplasia. There are foci in which the epidermis is missing, which in one area is related to electrocautery. There is also a patchy infiltrate of lymphocytes and melanophages at the base of the proliferation.	Ellipse , 2.3 x 1.6 x 0.6 cm, including a central 1.5 x 1.0 cm lesion with to left of center 0.7 x 0.3 cm depression.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in cassette A and four sections plus fragment (0.6 x 0.4 x 0.2 cm) in cassette B.	R/O MELANOMA VS PIGMENTED BASAL CELL CA	\N	\N	Scraping	In terms of staging, this melanoma invades the superficial reticular dermis (Clark's level IV). I do not see any evidence of vascular invasion, perineural extension, or regression in these sections. It is impossible to determine whether or not ulceration is present, as portions of the epidermis are missing from these sections ( including one area in which the epidermis has been destroyed by electrocautery).	MELANOMA OF 2.0 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS QUITE NEAR TO THE PERIPHERAL BIOPSY MARGIN	139522	192	\N	\N	05-66206	A	CCR-213	California Cancer Registry	IP542950	AirTable blocks_with_IP_info.csv
10834	13-11086	79	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.7	UCSF Wild Type Melanoma	\N	\N	Twenty-three blocks, S13-1165:A1 through A23, received 2-20-13.	\N	\N	\N	\N	The histopathological diagnosis was established by pathology report S13-1165 of UCSF Surgical Pathology. Sanger sequencing of exon 15 of BRAF, exons 1 and 2 of NRAS, and exons 9, 11, 13, 17, and 18 of KIT, which include the known mutational hotspots of these genes, did not reveal any mutations.	MELANOMA	173714	1634	\N	\N	13-11086	A	SYNX231	\N	IP1158926	Consolidated_data_final.csv
1238	06-22923	72	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1397	172.6	\N	\N	Sections show nested and solitary melanocytes arrayed broadly and irregularly along the epidermal-dermal junction above elastosis, with nests of melanocytes in predominance. There are clusters of similar cells in the superficial dermis, also above elastosis and accompanied by considerable subjunctional fibroplasia.	Skin segment measuring 1.2 x 0.8 x 0.2 cm, quadrisected and entirely submitted.	IRREGULAR BROWN MACULE; R/O MM	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with invasion confined to an expanded papillary dermis (Clark's level III). There is no evidence of vascular invasion, neurotropism, or regression in these sections. Further re-excision of this site is of course warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.4 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO THE PERIPHERAL MARGIN	173610	228	\N	\N	06-22923	\N	CCR-290	California Cancer Registry	IP334006	AirTable blocks_with_IP_info.csv
2356	18-113402B	30	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show nested and solitary melanocytes arrayed along the epidermal-dermal junction and in the superficial dermis. There is also a second population of spindled and dendritic melanocytes that are associated with melanophages and sclerosis.	Oriented ellipse, 1.7 x 0.7 x 0.6 cm, including a central 1.0 x 0.6 cm brown area. The orienting notched edge is indicated as 12 o'clock on the requisition form and placed toward 12 o'clock. The 9-12-3 o'clock and 3-6-9 o'clock edges are inked blue and yellow, respectively. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and entirely submitted with three sections each in A-B. HD/HD	1 CM SYMMETRICAL IRREGULAR PLAQUE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA, PLEASE CHECK MARGINS	\N	mid lower back 	Scraping	This biphasic melanocytic nevus includes the commingling of conventional lentiginous melanocytic nevus and desmoplastic nevus. There is no evidence of melanoma.	COMBINED MELANOCYTIC NEVUS, EXCISED IN THE AVAILABLE PLANES OF SECTION	102537	1351	\N	\N	18-113402	B	SM-022	Nevus Library	IP1977457	AirTable blocks_with_IP_info.csv
1489	11-42027	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2104	\N	\N	11-42027	\N	SYNAT154	2010-2017	\N	AirTable blocks_with_IP_info.csv
1147	04-57347A	59	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1398	172.6	\N	\N	Sections show a high-domed area with a proliferation of pleomorphic spindled cells with variably hyperchromatic vesicular nuclei, positioned in areas of dense lymphocytic infiltrates and between thickened collagen bundles in the reticular dermis. There are adjacent zones in which there are increased single melanocytes in the basal layer, some with hyperchromatic nuclei.  There is marked solar elastosis.	Ellipse measuring 4.0 x 1.0 x 1.2 cm, with central lesion, margins inked blue, serially sectioned perpendicular to the long axis and submitted with four sections each in cassettes A and B; tips returned to container.\n	R/O MM	\N	\N	\N	An S100 stain is positive in both very large pleomorphic cells and in smaller spindled ones in areas of fibrosis. Please note that melanoma in situ extends to within 2 mm. of the edge of the specimen.  I did not detect perineural invasion, but a re-excision should be considered, as the margins are more narrow than those usually considered adequate for this neoplasm.  Histopathologic features of possible prognostic importance include:  Level: IV Tumor infiltrating lymphocytes: many Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent  Please note that conventional staging may not be applicable to desmoplastic melanoma, which seems to metastasize systemically less than conventional melanomas of similar thickness.	DESMOPLASTIC MELANOMA, 2.2 MM  IN THICKNESS	173601	229	\N	\N	04-57347	A	CCR-296	California Cancer Registry	IP473755	AirTable blocks_with_IP_info.csv
1086	03-24651	28	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1399	172.5	\N	\N	Sections show a cellular asymmetrical compound proliferation of atypical melanocytes, composed largely of neoplastic cells with ample vacuolated cytoplasm. Single neoplastic cells and nests are arrayed irregularly and nearly confluently within the epidermis, with foci of suprabasal scatter.  There are also clusters of similar melanocytes in the upper dermis, which contains a relatively dense infiltrate of lymphocytes and melanophages.	Ellipse, 1.5 x 0.9 x 0.6 cm, including central light and dark brown 0.8 x 0.5 cm pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with six sections, one tip returned to container.	PIG LESION	\N	\N	\N	This is a non-ulcerated primary melanoma with invasion confined to an expanded papillary dermis (Clark's level III).  There is no evidence of vascular invasion or perineural extension, and there is also no significant evidence of regression.  There are some small melanocytes at the periphery of this melanoma, and thus I believe it developed in association with a melanocytic nevus.  Further re-excision of this site is warranted to ensure local control of this malignancy.	MELANOMA OF 0.9 MILLIMETERS IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS NEAR TO THE PERIPHERAL MARGIN	173509	230	\N	\N	03-24651	\N	CCR-298	California Cancer Registry	IP382964	AirTable blocks_with_IP_info.csv
1760	14-16247	31	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a dome-surfaced compound proliferation of melanocytes featuring markedly elongated, jagged ridges and large oval and fusiform cells with variable amounts of amphophilic cytoplasm and large nuclei, amongst which mitotic figures can be discerned. Fewer of these, and some maturation are present at the base of the lesion, which is relatively flat, and beneath which is a dense lymphocytic infiltrate.	Two outside slides, SPS-14-7904:AI,AII and two corresponding blocks.	ATYPICAL COMPOUND MELANOCYTIC NEOPLASM WITH SPITZOID FEATURES	\N	\N	\N	The silhouette is that of a Spitz's nevus, but I am concerned about the crowding of nuclei and the presence of a focally high mitotic rate. Immunostaining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a relatively high proliferation rate in the dermal component (about 10-15%). A p16 immunoperoxidase stain show a mosaic pattern of loss of that tumor suppressor gene product, an indeterminate pattern. Comparative genomic hybridization shows a gain involving chr. 2p, and a complex combination of gains and losses involving chr. 7q. The breakpoints suggest a gene fusion involving MET on chr. 7 and DTCN1 on chr. 2p, a combination that Dr. Iwei Yeh, who also viewed the comparative genomic hybridization data has previously noted. This may lead to upregulation of braf (near one of the other breakpoints on 7q), in the absence of braf mutation. While the absence of other chromosomal gains and losses is somewhat reassuring, it would be best to view this as a lesion with limited but non-zero metastatic potential, e.g. as an atypical Spitz. These are neoplasms that have feature more atypical than those of a conventional Spitz nevus, but not as worrisome as those of spitzoid melanoma. In aggregate data from over ten studies, local nodal involvment (usually very small deposits) is common, but extranodal metastasis is rare. This dissociation results in sentinel lymph node biopsy having very limited predictive value, and in my opinion, sometimes leading to over-treatment if small deposits lead to completion lymphadenectomy.	COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES, BEST REGARDED AS AN ATYPICAL SPITZ TUMOR	173796	1776	\N	\N	14-16247	\N	SYNAT493	2010-2017	IP1366169	AirTable blocks_with_IP_info.csv
1594	12-16974B	33	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show a circumscribed compound melanocytic proliferation with a multiphasic pattern.  Some of the melanocytes have round to oval nuclei, while others have abundant dusty cytoplasmic melanin and are surrounded by melanophages.  Focally, there are larger polygonal melanocytes with ample eosinophilic cytoplasm (Spitz's nevus cells).	Cylindrical skin segment, 0.5 cm in diameter and 0.5 cm in thickness, bisected and entirely submitted in cassette B.	A-C) R/O DYSPLASTIC NEVUS	\N	\N	Scraping	\N	TRIPHASIC COMBINED MELANOCYTIC NEVUS, WITH ORDINARY, BLUE (PIGMENTED EPITHELIOID), AND SPITZ'S NEVUS ELEMENTS	173711	1175	\N	\N	12-16974	B	NL-013	Nevus Library	IP1102790	AirTable blocks_with_IP_info.csv
2380	18-136800A	52	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted in A. KC/KC	A) 6 MM DARK LENTIGINOUS NEVUS; ATYPICAL NEVUS, R/O MM, B) 1.1 CM PINK BROWN LENTIGINOUS NEVUS; ATYPICAL NEVUS, R/O MM	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173536	607	\N	\N	18-136800	A	DN-132	Dysplastic Nevi	IP1417678	AirTable blocks_with_IP_info.csv
1456	11-20375	2	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a compound proliferation of melanocytes that assumes a domed profile. In some areas, the background epidermis is acanthotic, and in other areas the background epithelium is thinned. In areas where the epithelium is expanded, there are single melanocytes and nests distributed within the epidermis at all levels, and large and well-formed pink globules (Kamino bodies) can be found above dermal papillae. Below this, there are nests and cords of melanocytes that in some areas mature with descent. In areas where the epithelium is thin, a nodular array of non-maturing melanocytes is appreciable. These cells are slightly spindled and epithelioid in morphology and have amphophilic or finely melanized cytoplasm. Within these nodules, melanocytes in mitosis are relatively easily found. A juxtaposed sparse infiltrate of lymphocytes is apparent as well.	One outside slide, 11-051610, and one corresponding block.	7 X 5 MM RED PAPULE THAT HAD BEEN PRESENT FOR ONE YEAR AND OVER THE LAST 1-2 MONTHS HAD BECOME "MORE PAPULAR", SHE HAS AN ADJACENT CONGENITAL NEVUS, CLINICAL DDX WAS PYOGENIC GRANULOMA VS. MOLLUSCUM CONTAGIOSUM VS. JUVENILE XANTHOGRANULOMA, NO FAMILY HISTORY OF MELANOMA, NEGATIVE FISH STUDY, WE WOULD APPRECIATE YOUR EVALUATION FOR COMPARATIVE GENOMIC HYBRIDIZATION	\N	\N	\N	Based upon conventional microscopy, the dominant nodule within this specimen shows a configuration that is worrisome for childhood-type spitzoid melanoma. This nodular proliferation developed secondarily within a preexistent Spitz nevus. I also understand that an adjacent congenital melanocytic nevus was noted clinically. To further assess the nature of this proliferation, we pursued array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, completion of aCGH analysis demonstrated loss in chromosomal 1p with no other associated chromosomal gains or losses. We have observed anomalies involving chromosome 1 in other examples of spitzoid melanoma. In summary, my interpretation of the the combination of results derived from conventional microscopy coupled with aCGH analysis is that a nodule of childhood-type spitzoid melanoma has developed secondarily within a preexistent Spitz nevus. The nodular population of melanocytes within this specimen is 1.6 mm in thickness. Please note that the negative prior analysis via fluorescence in situ hybridization (FISH) is unsurprising, as FISH testing only evaluates loci on chromosomes 6 and 11. To state it differently, the chromosomal anomaly that we have detected could not be identified via FISH.  The designation childhood-type spitzoid melanoma refers to an emerging entity that we believe is distinct from conventional adult melanoma. Such tumors typically lack BRAF mutations and were reported in the past literature under such flawed designations as malignant Spitz nevus. Experience to date suggests a small risk for extension to regional lymph nodes with a low risk for widespread dissemination. The proliferation in this specimen involves the deep edge of the biopsy. Further excision is warranted to ensure that local eradication has been accomplished.	BIPHASIC COMPOUND PROLIFERATION OF ENLARGED SPITZOID MELANOCYTES, INCLUDING A NODULAR POPULATION OF ATYPICAL MELANOCYTES WITH CHROMOSOME 1p LOSS	101624	2152	\N	\N	11-20375	\N	SYNAT157	2010-2017	IP1009813	AirTable blocks_with_IP_info.csv
2237	17-112365B	47	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted in B. KC/KC	A-B) 4 MM BROWN MACULE; POSS ATYPICAL NEVUS	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	139524	843	\N	\N	17-112365	B	LN-023	Lentiginous Nevi 	IP1842838	AirTable blocks_with_IP_info.csv
2453	19-43600A	78	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.6	\N	GNAQ	Sections show a melanocytic proliferation with two types of cells.  One population of melanocytes consists of small round cells with scant cytoplasm and monomorphous round to oval nuclei. Beneath them are dendritic, pigmented melanocytes with inconspicuous nuclei and variable cytoplasmic pigmentation, accompanied by melanophages.	Four skin fragments measuring 1.2 x 0.7 x 0.1 cm in aggregate, one is bisected and all entirely submitted in A. CF/CF	A) 5 MM; R/O ATYP, B) 6 MM; R/O ATYP	\N	\N	FFPE	\N	COMBINED MELANOCYTIC NEVUS, WITH ORDINARY AND BLUE NEVUS ELEMENTS	173619	1373	\N	\N	19-43600	A	SN-10	Sclerotic Nevi	IP1927911	AirTable blocks_with_IP_info.csv
2412	19-7357A	25	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a proliferation of nested and solitary melanocytes, relatively evenly distributed along the dermal-epidermal junction. A few small clusters of similar melanocytes are present in the dermis.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A-B) R/O DN	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS	173611	618	\N	\N	19-7357	A	DN-143	Dysplastic Nevi	IP2011413	AirTable blocks_with_IP_info.csv
2445	19-37607E	72	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound array of melanocytes, with single cells and nests arrayed along the epidermal-dermal junction, distributed along the sides and bases of elongated rete. There are similar melanocytes in the subjacent superficial dermis.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted in E. KC/KC	A) 7 MM X 5 MM DARK BROWN IRREGULAR MACULE ADJACENT TO SK; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, B) 2.5 CM X 2 CM DARK BROWN HYPERKERATOTIC PLAQUE; PROBABLE SK, R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, C) 4 MM X 4 MM VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, D) 5 MM X 6 MM TAN BROWN VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, E) 4 MM X 4 MM DARK BROWN VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, F) 3 X 4 MM TAN BROWN VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	139524	629	\N	\N	19-37607	E	DN-154	Dysplastic Nevi	IP2041843	AirTable blocks_with_IP_info.csv
2682	21-3841E1	68	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.3	\N	\N	There are nests, cords and strands of small, round melanocytes that mature with descent into the dermis.	Skin segment measuring 0.4 x 0.2 x 0.1 cm. Submitted intact in A. BY/BY	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. NEVUS VS. BASAL CELL CARCINOMA VS. ANGIOFIBROMA. FLESH-COLORED PAPULE. PRE OP SIZE: 0.2 CM. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. NEVUS VS. BASAL CELL CARCINOMA VS. ANGIOFIBROMA. FLESH-COLORED PAPULE. PRE OP SIZE: 0.2 CM.	\N	\N	\N	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	192355	2225	\N	\N	21-3841	E1	SYNAT166	Melanoma Epigenetics	IP1199808	AirTable blocks_with_IP_info.csv
1771	14-39393	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1355	\N	\N	14-39393	\N	SMP2	Spitz Melanoma	\N	AirTable blocks_with_IP_info.csv
1791	14-59414	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1356	\N	\N	14-59414	\N	SMP4	Spitz Melanoma	\N	AirTable blocks_with_IP_info.csv
2759	21-112195B	65	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18355	216.5	\N	\N	Sections show a compound array of melanocytes, with single cells and nests arrayed along the epidermal-dermal junction, distributed along the sides and bases of elongated rete. There are similar melanocytes in the subjacent superficial dermis.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted in B. KB/KB	A) 1 CM, WAXY; NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA, B-C) 6 MM, IRREGULAR BORDER AND COLOR; NEOPLASM OF UNCERTAIN BEHAVIOR VS. AMH, D) 7 MM, IRREGULAR BORDER AND COLOR; NEOPLASM OF UNCERTAIN BEHAVIOR VS. AMH	\N	\N	FFPE	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	139512	899	\N	\N	21-112195	B	LN-086	Lentiginous Nevi 	IP2375313	AirTable blocks_with_IP_info.csv
2223	17-111004C	50	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	The histopathology is generally similar to that described for specimen A.	Cylindrical skin segment, 0.5 cm in diameter and 0.4 cm in thickness, bisected and entirely submitted in C. RS/RS	A-C) R/O DYSPLASTIC NEVUS	\N	\N	Scraping	No evidence of melanoma or significant atypicality was detected in any of the three specimens.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, CONGENITAL PATTERN	173710	1929	\N	\N	17-111004	C	LN-045	Lentiginous Nevi 	IP366882	AirTable blocks_with_IP_info.csv
2221	17-111004A	50	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show a compound proliferation of melanocytes with a junctional component arrayed largely as single melanocytes along the sides and bases of rete.  There are also small melanocytes within the dermis, some of which are positioned in the adventitial and reticular dermis. There is melanin pigment in the stratum corneum.	Cylindrical skin segment, 0.6 cm in diameter and 0.3 cm in thickness, bisected and entirely submitted in A. RS/RS	A-C) R/O DYSPLASTIC NEVUS	\N	\N	Scraping	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, CONGENITAL PATTERN	132788	1929	\N	\N	17-111004	A	LN-045	Lentiginous Nevi 	IP366882	AirTable blocks_with_IP_info.csv
2222	17-111004B	50	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	There are increased numbers of single melanocytes and small nests of them positioned at the sides and bases of elongated rete ridges. There is abundant melanin the cornified layer, in the subjacent epidermis and within melanophages in the papillary dermis beneath the lesion.	Cylindrical skin segment, 0.5 cm in diameter and 1.0 cm in thickness, bisected and entirely submitted plus one fragment in B. RS/RS	A-C) R/O DYSPLASTIC NEVUS	\N	\N	Scraping	\N	HYPERMELANOTIC LENTIGINOUS JUNCTIONAL NEVUS	173727	842	\N	\N	17-111004	B	LN-022	Lentiginous Nevi 	IP366882	AirTable blocks_with_IP_info.csv
3273	ct-H3K4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2038	\N	\N	None	\N	SYNAT167	2010-2017	\N	AirTable blocks_with_IP_info.csv
2303	18-18111A	58	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show an excision specimen of skin with a well-circumscribed small junctional proliferation of melanocytes distributed predominantly in small nests and single cells along the sides and the bases of the rete ridges. Melanocytes are focally present above the junction in the center of the lesion. There are melanophages in the superficial dermis and minimal solar elastosis.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in A. BY/PL	R/O ATYPICAL NEVI	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	105539	851	\N	\N	18-18111	A	LN-032	Lentiginous Nevi 	IP683601	AirTable blocks_with_IP_info.csv
2304	18-18111B	58	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show an excision specimen of skin with a well-circumscribed small junctional proliferation of melanocytes distributed predominantly in small nests and single cells along the sides and the bases of the rete ridges. There are melanophages in the superficial dermis and minimal solar elastosis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted in B. BY/PL	R/O ATYPICAL NEVI	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	139524	2001	\N	\N	18-18111	B	LN-056	Lentiginous Nevi 	IP683601	AirTable blocks_with_IP_info.csv
1214	06-10811	77	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22990	172.6	\N	\N	Sections show a broad asymmetrical compound proliferation of melanocytes, with single cells and nests arrayed irregularly along the epidermal-dermal junction and with many single melanocytes in pagetoid array. The underlying dermis contains small melanocytes with hyperchromatic nuclei arrayed in clusters and strands above modest elastosis, enmeshed in part within a central broad zone of exaggerated dermal fibroplasia. Some deep dermal melanocytes have plasmacytoid or oncocytic cytomorphology.	Skin segment, 1.5 x 1.4 x 0.3 cm, serially sectioned and entirely submitted with five sections.	ATYPICAL PIGMENTED LESION	\N	\N	FFPE	In terms of staging, this is a non-ulcerated primary melanoma with an invasive component that involves the superficialmost reticular dermis (Clark's level IV). There is no evidence of vascular invasion or perineural extension or significant regression in these sections. As some of the deep dermal melanocytes in this biopsy have compact cytomorphology, I considered the possibility that there might be a precursor melanocytic nevus at this site. However, I tend to believe this is not the case, and that the entirety of this lesion represents melanoma. Further re-excision of this site is of course warranted to ensure that local eradication has been accomplished.	MELANOMA OF 1.2 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS QUITE NEAR TO THE PERIPHERAL BIOPSY MARGIN	173601	2222	\N	\N	06-10811	\N	CCR-209	Melanoma Epigenetics	IP443105	AirTable blocks_with_IP_info.csv
3274	ct-H3K27	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2247	\N	\N	None	\N	SYNAT169	2010-2017	\N	AirTable blocks_with_IP_info.csv
1740	13-102610	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2323	\N	\N	13-102610	\N	SYNAT495	Wild Type Melanoma	\N	AirTable blocks_with_IP_info.csv
1004	00-4845	83	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1424	172.6	\N	\N	Sections show fibrosis of the papillary dermis, in conjunction with a focally lichenoid papillary dermal lymphocytic infiltrate.  Clusters of melanophages are also present in the dermis.  There are also slightly hyperchromatic spindled cells arrayed in association with sclerosis throughout the superficial reticular dermis, with a sparse infiltrate of surrounding lymphocytes near the deepest of the spindled cells.	Cylindrical skin segment, 0.6 cm in diameter and 0.6 cm in thickness,\nbisected and totally submitted.	IRREG HYPERPIGMENTED MACULE ADJACENT TO PALE PINK PAPULE; CLINICAL DIAGNOSIS - R/O MELANOMA VS PIGMENTED BCC	\N	\N	\N	3/2/2000: A repeat S100 immunostain avidly labels the nests of malignant cells in the dermis, confirming melanocytic lineage and thereby supporting the diagnosis listed above.   2/29/2000:  Level sections clearly show clusters of malignant cells subjacent to the zone of regression, and these changes, in the context of the biopsy, appear to represent melanoma.  However, as overt or specific evidence of melanocytic lineage is not present, a second S100 immunostain will be obtained to confirm the diagnosis.  This stain will be completed later this week.  Please note that this patient is a candidate for sentinel node evaluation, and a decision regarding the application of this technique should be made before a definitive reexcision is performed.   2/28/2000:  An S100 immunostain has been completed, and only scattered dendritic cells show positive labeling.  This staining reaction highlights the presence of non-neoplastic cells, and thus the staining result lends no support to the possibility of a component of desmoplastic melanoma in this lesion. However, these changes may represent regression of conventional melanoma in which no viable neoplasm remains.  Level sections to seek any remaining viable neoplasm have been requested and should be completed shortly, thereby permitting finalization of this report.   2/18/2000:  This pattern is worrisome for regression of a melanocytic neoplasm, and these changes may represent partial regression of a superficial desmoplastic melanoma.	MELANOMA, 2.2 MM IN THICKNESS, WITH EXTENSIVE REGRESSION AND EXTENSION TO THE PERIPHERAL MARGIN	173649	236	\N	\N	00-4845	\N	CCR-311	California Cancer Registry	IP219948	AirTable blocks_with_IP_info.csv
2238	17-112474	67	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.5	\N	\N	None	Block DL17-76060 (S17-8234), received 11-16-17.	ORIGINALLY READ AS DL17-76060; REACCESSIONED FOR CGH TESTING	\N	\N	Scraping	Following microdissection and DNA extraction, we performed comparative genomic hybridization. The hybridization shows gain of chr. 6p, and a loss involving an area on chr. 6q with the ARID1B gene near its breakpoint. Gain of 6p and loss of 6q are commonly found together in melanoma, and the finding of a breakpoint at a gene important in melanomagenesis further supports that diagnosis. The biopsy and re-excision from this lesion correlate for an approximate thickness of 6 mm. A beta-catenin immunostain labels not only the cytoplasm of the lesional melanocytes but also their nuclei. This supports the assessment of a deep penetrating nevic lineage, per a recent study from our group. This lineage includes deep penetrating nevus, indeterminate lesions, and deep penetrating nevus-like melanoma.  In the re-excision, the neoplasm was a fraction of a mm. from the deep margin near the center of the specimen, and a further excision (still deeper, but not necessary wider) seems warranted.  The comparative genomic hybridization data was also reviewed by my colleague, Dr. Boris Bastian who agrees with this interpretation of it.  Reference:  Yeh I, Lang UE, Durieux E, Tee MK, Jorapur A, Shain AH, Haddad V, Pissaloux D, Chen X, Cerroni L, Judson RL, LeBoit PE, McCalmont TH, Bastian BC, de la FouchardiËre A. Combined activation of MAP kinase pathway and ﬂ-catenin signaling cause deep penetrating nevi. Nat Commun. 2017 Sep 21;8(1):644. doi: 10.1038/s41467-017-00758-3. PubMed PMID: 28935960; PubMed Central PMCID: PMC5608693.	MELANOMA, WITH DEEP PENETRATING NEVUS-LIKE FEATURES, 6  MM. IN THICKNESS	273588	246	\N	\N	17-112474	\N	CGH17-240	Nevus Library	IP1806028	AirTable blocks_with_IP_info.csv
2620	20-30233-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	https://64.54.108.121/app/WebViewer/view/image/34969	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1395	\N	\N	None	\N	VS-02	Chromium Single Cell Gene Expression Flex	\N	AirTable blocks_with_IP_info.csv
2424	19-10031-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	https://64.54.108.121/app/WebViewer/view/image/34968	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1396	\N	\N	None	\N	VS-03	Chromium Single Cell Gene Expression Flex	\N	AirTable blocks_with_IP_info.csv
1500	11-53065	60	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show lentiginous elongation and hyperpigmentation of rete, without a definite junctional component. The dermis contains a wedge-shaped proliferation of spindled or epithelioid melanocytes interspersed between sclerotic collagen bundles. To one side, the cells have a more rounded nevoid appearance and are nested superficially. Overall, there is good maturation and symmetry to both components. A few scattered dendritic cells are present.	Skin segment measuring 0.5 x 0.4 x 0.2 cm, bisected and entirely submitted.	R/O ATYPICAL	\N	right lower arm 	Scraping	Despite its occurrence in severely elastotic skin, the lesion has an orderly growth pattern and appears benign. It has combined features, but the dominant pattern is of desmoplastic Spitz nevus. The case has been reviewed with concurrence by Drs. LeBoit and Mully.	TRIPHASIC COMBINED MELANOCYTIC NEVUS, WITH ORDINARY, BLUE, AND SPITZ'S NEVUS ELEMENTS, EXCISED IN PLANES OF SECTION EXAMINED	529611	1332	\N	\N	11-53065	\N	SM-002	Nevus Library	IP1042505	AirTable blocks_with_IP_info.csv
1251	06-47809B	39	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.5	\N	\N	Sections demonstrate an asymmetric compound proliferation of melanocytes at and above the dermal-epidermal junction and within the dermis. There are irregularly arrayed nests and single cells within the epidermis with areas of confluence of melanocytic nests, and with many melanocytes in pagetoid array. There is a dermal inflammatory reaction with lymphocytes and melanophages at the base of the melanocytic proliferation and areas of fibroplasia (with reduction in melanocyte density) adjacent to the proliferation.	Ellipse, 3.3 x 1.8 x 0.8 cm, including a central brown 1.5 x 1.0 cm pigmented area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with three sections each in cassettes A, B and C, tips returned to container.	OVER APPROXIMATELY ONE YEAR, CHANGES IN SHAPE, COLOR & SIZE HAVE OCCURRED WITH ITCHING AND INFLAMMATION (INFLAMED IN CONCAVITY OF SHAPE); INFLAMED SSM VS DN	\N	\N	Scraping	In terms of staging, this is a non-ulcerated primary melanoma with an invasive component that involves the superficialmost reticular dermis (Clark's level IV). There is no evidence of vascular invasion or neurotropism. There are considerable associate changes of complete regression accompanying and flanking this melanoma; in light of the changes of regression, the microstage measurement listed above may underestimate the prognostic impact of this lesion.	MELANOMA OF 1.1 MM IN THICKNESS, COMPLETELY EXCISED (FINAL SURGICAL MARGINS ARE FREE OF MELANOMA)	173544	193	\N	\N	06-47809	B	CCR-214	California Cancer Registry	IP592878	AirTable blocks_with_IP_info.csv
3275	ct-Input	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2208	\N	\N	None	\N	SYNAT170	2010-2017	\N	AirTable blocks_with_IP_info.csv
1309	08-21729 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	930	\N	\N	None	\N	MD-24	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2401	19-03800-4	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-29	https://64.54.108.121/app/WebViewer/view/image/36017	\N	\N	\N	\N	\N	\N	\N	H19-03800 #4 (right cheek)	FFPE	\N	\N	\N	352	\N	\N	None	\N	CME-050	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2350	18-95536	47	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.7	DPN-mm	\N	The microscopic findings are essentially as described in the accompanying pathology report and in the note above.	Seven outside slides, S-18-32980 A1 / HST18-053114 / HST18-055181, and one corresponding block.	18 X 13 MM BLACK PLAQUE; ATYPICAL NEVUS VS. MELANOMA	\N	\N	Scraping	The strong nuclear beta-catenin positivity favors this being in the deep penetrating nevic series, rather than in the classic blue nevic one. The focus of necrosis, and high proliferation rate were features worrisome for a deep penetrating nevus-like melanoma. This diagnosis has been confirmed by molecular studies. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows loss of chr. 10, which is a highly characteristic chromosomal copy number change seen in melanoma, with gains in both chr. 11p and 11q (the gain in chr. 11p is of higher amplitude). The former hints at an h-ras mutation. While h-ras mutated Spitz's nevi have isolated chr. 11p gains, and behave benignly, the presence of additional changes in this case means that its presence does not favor benignity. There is also a loss involving chr. 13q.  My colleague, Dr. Iwei Yeh also viewed the comparative genomic hybridization results, and the sections and agreed with this diagnosis. One of the deep penetrating nevus-like melanomas in our study had an h-ras mutation.  Reference:  Yeh I, Lang UE, Durieux E, Tee MK, Jorapur A, Shain AH, Haddad V, Pissaloux D, Chen X, Cerroni L, Judson RL, LeBoit PE, McCalmont TH, Bastian BC, de la FouchardiËre A. Combined activation of MAP kinase pathway and ﬂ-catenin signaling cause deep penetrating nevi. Nat Commun. 2017 Sep 21;8(1):644. doi: 10.1038/s41467-017-00758-3. PubMed PMID: 28935960; PubMed Central PMCID:PMC5608693.	MELANOMA, 2.2 MM. IN THICKNESS	173727	247	\N	\N	18-95536	\N	CGH18-137	Deep Penetrating Melanoma	IP1959535	AirTable blocks_with_IP_info.csv
2351	18-95537	28	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.7	\N	\N	The microscopic findings are essentially as described in the accompanying pathology reports and in the note above.	Three outside slides, S-18-33098 A1, and one corresponding block.	ATYPICAL NEVUS VS. LESS LIKELY ATYP SK, R/O PIGMENTED TUMOR	\N	\N	Scraping	This unusual spitzoid neoplasm features strikingly confluent junctional nests and nearly, consumption of the epidermis. Paradoxically, there is a very low proliferation rate in the multiplex stain. Following microdissection and DNA extraction, we performed comparative genomic hybridization. It shows several gains of different amplitudes near the terminal portion of chr. 5p, in a pattern suggestive of a TRIO-TERT fusion. Such fusions are seen in pediatric sarcomas, and in the context of a melanocytic neoplasm point toward melanoma. Another area of amplification is present on 20qter.  My colleague, Dr. Iwei Yeh also viewed the comparative genomic hybridization data and slides, and agress with this interpretation.	MELANOMA, 0.7 MM. IN THICKNESS	173723	248	\N	\N	18-95537	\N	CGH18-139	Nevus Library	IP1959536	AirTable blocks_with_IP_info.csv
1283	07-40241A	58	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=986	173.5	\N	\N	Sections show a compound proliferation of melanocytes, some with atypical nuclei, with nests along the sides and bases of elongated rete ridges, with fibroplasia of the papillary dermis.  In areas, a more irregular distribution of melanocytes is present within the epidermis, with many single melanocytes scattered above the basal layer. Small nests of similar melanocytes are present in the papillary dermis.	Skin segment measuring 1.7 x 1.1 x 0.1 cm, including a central black 0.6 x 0.5 cm pigment, serially sectioned and entirely submitted with four sections in cassette A and three sections in cassette B.	ATYPICAL PIGMENTED LESION; R/O MM VS OTHER	\N	\N	\N	The neoplasm extends to within 1 mm. of the peripheral edge of the specimen. Portions of this lesion resemble a dysplastic (Clark's) nevus.  It is difficult to tell whether this is due to the cells of this melanoma being arranged in a pattern that simulates such a nevus, or whether one was pre-existent in this site. There is no evidence of ulceration, regression or other findings that would adversely affect the prognosis of this thin level II lesion.	MELANOMA, 0.3 MM  IN THICKNESS	273588	161	\N	\N	07-40241	A	CCR-113	California Cancer Registry	IP662774	AirTable blocks_with_IP_info.csv
1271	07-7626	54	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=988	172.5	\N	\N	Sections show a broad and poorly circumscribed proliferation of melanocytes.  Nests of melanocytes are distributed at irregular intervals, and are focally confluent.  The papillary dermis is distended by aggregates of similar cells.  The papillary dermis is in one focus thickened and fibrotic, with a patchy bandlike lymphocytic infiltrate and diminished numbers of melanocytes in such areas, when compared to the remainder of the lesion.	Skin segment measuring 1.5 x 1.3 x 0.2 cm, quadrisected and entirely submitted.	MOLE TURNING PINK X 2 YEARS, 1.5 CM TAN, PINK IRRITATED PAPULE > 2 YEARS; R/O IRRITATED SK VS BCC VS MIS	\N	\N	\N	The intraepidermal component of this melanoma extends to the peripheral edge of the specimen. Histopathologic features of possible prognostic importance include:  Level: III Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: present* Microsatellite metastasis: absent, but should be re-evaluated after complete excision  * This is less than 50% of two cross sections.  Some studies show regression is an adverse prognostic finding, but only when greater than that amount.	MELANOMA, 1.0 MM  IN THICKNESS	273588	162	\N	\N	07-7626	\N	CCR-114	California Cancer Registry	IP630157	AirTable blocks_with_IP_info.csv
2466	19-69103	72	\N	\N	\N	None	None	None	5	0	FFPE	\N	\N	216.6	\N	MAP2K1	There are nests, cords and strands of small, round melanocytes that mature with descent into the dermis. In the lower portion of the dermis, melanocytes have a spindled configuration. Some superficial melanocytes are pigmented.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted. HD/HD	5 MM DARK PAPULE; R/O DARK SK VS. ATYPIA	\N	\N	FFPE	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	173620	1365	\N	\N	19-69103	\N	SN-02	Sclerotic Nevi	IP316729	AirTable blocks_with_IP_info.csv
2281	18-00447-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-28	https://64.54.108.121/app/WebViewer/view/image/36007,36008,36106	\N	\N	\N	\N	\N	\N	\N	H18-00447 #2 (upper right chest)	FFPE	\N	\N	\N	346	\N	\N	None	\N	CME-044	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2282	18-00447N1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-28	https://64.54.108.121/app/WebViewer/view/image/36007,36008,36106	\N	\N	\N	\N	\N	\N	\N	H18-00447 N1 (right axilla)	FFPE	\N	\N	\N	346	\N	\N	18-447	N1	CME-044	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2287	18-09671N1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-28	https://64.54.108.121/app/WebViewer/view/image/36011,36012,36013,36107	\N	\N	\N	\N	\N	\N	\N	H18-09671 N1 (right inguinal sentinel)	FFPE	\N	\N	\N	349	\N	\N	18-9671	N1	CME-047	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2286	18-09671-4	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-28	https://64.54.108.121/app/WebViewer/view/image/36011,36012,36013,36107	\N	\N	\N	\N	\N	\N	\N	H18-09671 #4 (waist)	FFPE	\N	\N	\N	349	\N	\N	None	\N	CME-047	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2577	20-00782N3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-28	https://64.54.108.121/app/WebViewer/view/image/36011,36012,36013,36107	\N	\N	\N	\N	\N	\N	\N	H20-00782 N3 (inguinal lymphadenectomy 2 years later)	FFPE	\N	\N	\N	349	\N	\N	20-782	N3	CME-047	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2391	19-01043-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-28	https://64.54.108.121/app/WebViewer/view/image/36014,36015,36016,36108	\N	\N	\N	\N	\N	\N	\N	H19-01043 #1 (left back)	FFPE	\N	\N	\N	350	\N	\N	None	\N	CME-048	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2392	19-01043N2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-29	https://64.54.108.121/app/WebViewer/view/image/36014,36015,36016,36108	\N	\N	\N	\N	\N	\N	\N	H19-01043 N2(left axillary sentinel lymph node)	FFPE	\N	\N	\N	350	\N	\N	19-1043	N2	CME-048	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2400	19-03736	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-29	https://64.54.108.121/app/WebViewer/view/image/36014,36015,36016,36108	\N	\N	\N	\N	\N	\N	\N	H19-03736 (back, metastasis)	FFPE	\N	\N	\N	350	\N	\N	19-3736	\N	CME-048	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2580	20-02956-5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-29	https://64.54.108.121/app/WebViewer/view/image/36018,36019,36020	\N	\N	\N	\N	\N	\N	\N	H20-02956 #5 (recurrence after 1 year, upper right arm, in situ)	FFPE	\N	\N	\N	353	\N	\N	None	\N	CME-051	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2576	20-00698	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-29	https://64.54.108.121/app/WebViewer/view/image/36018,36019,36020	\N	\N	\N	\N	\N	\N	\N	H20-00698	FFPE	\N	\N	\N	353	\N	\N	20-698	\N	CME-051	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2399	19-03361-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-29	https://64.54.108.121/app/WebViewer/view/image/36018,36019,36020	\N	\N	\N	\N	\N	\N	\N	H19-03361 #3 (upper right arm)	FFPE	\N	\N	\N	353	\N	\N	None	\N	CME-051	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2404	19-05268-9	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-30	https://64.54.108.121/app/WebViewer/view/image/36021,36114,36109	\N	\N	\N	\N	\N	\N	\N	H19-05268 #9 (lower right leg)	FFPE	\N	\N	\N	354	\N	\N	None	\N	CME-052	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2405	19-05268N1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-30	https://64.54.108.121/app/WebViewer/view/image/36021,36114,36109	\N	\N	\N	\N	\N	\N	\N	H19-05268 N1 (sentinel inguinal lymph node)	FFPE	\N	\N	\N	354	\N	\N	19-5268	N1	CME-052	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2478	19-104449D	68	\N	\N	\N	\N	\N	\N	10	0	FFPE	\N	\N	216.5	\N	GNAQ	Sections show a proliferation of melanocytes with a biphasic pattern (arrayed as 2 populations of cells).  One population consists of small conventional melanocytes, while the second consists of deeply pigmented fusiform melanocytes with melanophages.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in D. HD/HD	A) R/O DYSP VS. COMP N VS. LPLK, B-E) R/O DYSP VS. COMP N, F) R/O BCC	\N	\N	FFPE	Conventional lentiginous melanocytic nevus is mixed with deeply pigmented spindled melanocytes in this small proliferation.	COMBINED MELANOCYTIC NEVUS, EXCISED IN THE AVAILABLE PLANES OF SECTION	139523	1366	\N	\N	19-104449	D	SN-03	Sclerotic Nevi	IP2109117	AirTable blocks_with_IP_info.csv
2419	19-08527-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-30	https://64.54.108.121/app/WebViewer/view/image/36025,36026	\N	\N	\N	\N	\N	\N	\N	H19-08527 (upper left back) #2	FFPE	\N	\N	\N	357	\N	\N	None	\N	CME-055	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2420	19-08527N1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-30	https://64.54.108.121/app/WebViewer/view/image/36025,36026	\N	\N	\N	\N	\N	\N	\N	H19-08527-N1 (left axillary sentinel lymph node)	FFPE	\N	\N	\N	357	\N	\N	19-8527	N1	CME-055	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2581	20-03009-7	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-31	https://64.54.108.121/app/WebViewer/view/image/36031,36032	\N	\N	\N	\N	\N	\N	\N	H20-03009 (right cheek) #7	FFPE	\N	\N	\N	362	\N	\N	None	\N	CME-060	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2582	20-03009N1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-31	https://64.54.108.121/app/WebViewer/view/image/36031,36032	\N	\N	\N	\N	\N	\N	\N	H20-03009-N1 (sentinel parotid lymph node)	FFPE	\N	\N	\N	362	\N	\N	20-3009	N1	CME-060	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2681	21-03240	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-31	https://64.54.108.121/app/WebViewer/view/image/36034,36035,36036	\N	\N	\N	\N	\N	\N	\N	H21-03240 (subcutaneous metastasis in right upper arm 1 year later)	FFPE	\N	\N	\N	364	\N	\N	21-3240	\N	CME-062	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2776	22-07164-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-31	https://64.54.108.121/app/WebViewer/view/image/36034,36035,36036	\N	\N	\N	\N	\N	\N	\N	H22-07164 (subcutaneous metastasis in right forearm 2 years later) #1	FFPE	\N	\N	\N	364	\N	\N	None	\N	CME-062	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2584	20-04546-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-31	https://64.54.108.121/app/WebViewer/view/image/36034,36035,36036	\N	\N	\N	\N	\N	\N	\N	H20-04546 (dorsum of right hand, with satellite lesion) #3	FFPE	\N	\N	\N	364	\N	\N	None	\N	CME-062	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2683	21-04018	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-32	https://64.54.108.121/app/WebViewer/view/image/36039,36040,36041	\N	\N	\N	\N	\N	\N	\N	H21-04018 (subcutaneous metastasis in head 1 year later)	FFPE	\N	\N	\N	367	\N	\N	21-4018	\N	CME-065	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2770	22-03790	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-32	https://64.54.108.121/app/WebViewer/view/image/36039,36040,36041	\N	\N	\N	\N	\N	\N	\N	H22-03790 (subcutaneous metastasis in cheek)	FFPE	\N	\N	\N	367	\N	\N	22-3790	\N	CME-065	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1528	11-85008	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	113	\N	\N	11-85008	\N	BN-009	Nevus Library	\N	AirTable blocks_with_IP_info.csv
2779	22-9055A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-20	http://64.54.108.121/eSlideTray.php?ImageIds=32803	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	88	\N	\N	22-9055	A1	AM2-118	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2912	23-51956B17	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=32561,32562,32563,32564,32565,32566,32567,32568,32569,32570,32571,32572,32573,32574,32575,32576,32577,32578,32579,32580,32581,32582,32583,32610,32611,32584,32585,32586,32612,32613,32587,32588,32589	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	89	\N	\N	23-51956	B17	AM2-119	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2772	22-04201N2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-34	https://64.54.108.121/app/WebViewer/view/image/36055,36056	\N	\N	\N	\N	\N	\N	\N	H22-04201 (right inguinal lymph node) N2	FFPE	\N	\N	\N	376	\N	\N	22-4201	N2	CME-074	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2771	22-04201-6	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-34	https://64.54.108.121/app/WebViewer/view/image/36055,36056	\N	\N	\N	\N	\N	\N	\N	H22-04201 (lower right leg) #6	FFPE	\N	\N	\N	376	\N	\N	None	\N	CME-074	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2773	22-05287-15	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-34	https://64.54.108.121/app/WebViewer/view/image/36057,36058	\N	\N	\N	\N	\N	\N	\N	H22-05287 (upper right arm) #15	FFPE	\N	\N	\N	377	\N	\N	None	\N	CME-075	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2774	22-05287N2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-34	https://64.54.108.121/app/WebViewer/view/image/36057,36058	\N	\N	\N	\N	\N	\N	\N	H22-05287 (right axillary lymph node) N2	FFPE	\N	\N	\N	377	\N	\N	22-5287	N2	CME-075	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2027	17-00792	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-36	https://64.54.108.121/app/WebViewer/view/image/36072,36073	\N	\N	\N	\N	\N	\N	\N	H17-00792 (chest metastasis after 6 months)	FFPE	\N	\N	\N	391	\N	\N	17-792	\N	CME-089	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1911	16-04805-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-36	https://64.54.108.121/app/WebViewer/view/image/36072,36073	\N	\N	\N	\N	\N	\N	\N	H16-04805 #2 (abdomen)	FFPE	\N	\N	\N	391	\N	\N	None	\N	CME-089	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2700	21-10478-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-37	https://64.54.108.121/app/WebViewer/view/image/36076,36077	\N	\N	\N	\N	\N	\N	\N	H21-10478 (December 2021 right upper back) #2	FFPE	\N	\N	\N	394	\N	\N	None	\N	CME-092	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1914	16-05958-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-36	https://64.54.108.121/app/WebViewer/view/image/36076,36077	\N	\N	\N	\N	\N	\N	\N	H16-05958 #2 (right thoracic side)	FFPE	\N	\N	\N	394	\N	\N	None	\N	CME-092	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1566	12-05858A3 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	935	\N	\N	None	\N	MD-29	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2769	22-01164-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-34	https://64.54.108.121/app/WebViewer/view/image/36054	\N	\N	\N	\N	\N	\N	\N	H22-01164 (left back) #2	FFPE	\N	\N	\N	375	\N	\N	None	\N	CME-073	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2775	22-06500-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-34	https://64.54.108.121/app/WebViewer/view/image/36059,36111	\N	\N	\N	\N	\N	\N	\N	H22-06500 (right chest) #1	FFPE	\N	\N	\N	378	\N	\N	None	\N	CME-076	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1986	16-98735	69	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10839	216.5	DN	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 1.1 x 0.9 x 0.1 cm, quadrisected and entirely submitted. KC/KC	IRREGULAR PIGMENTED PAPULE	\N	\N	Scraping	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, NARROWLY EXCISED IN PLANES OF SECTION EXAMINED	173529	545	\N	\N	16-98735	\N	DN-070	Dysplastic Nevi	IP1698660	AirTable blocks_with_IP_info.csv
2492	19Rig750007.01.04.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	250	\N	\N	None	\N	CM-04	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2499	19Rig750007.01.10.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	254	\N	\N	None	\N	CM-10	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2500	19Rig750007.01.11.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	255	\N	\N	None	\N	CM-11	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2046	17-09063-N1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-38	https://64.54.108.121/app/WebViewer/view/image/36088,36089	\N	\N	\N	\N	\N	\N	\N	H17-09063 N1 (axillary sentinel lymph node)	FFPE	\N	\N	\N	405	\N	\N	None	\N	CME-103	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2045	17-09063-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-38	https://64.54.108.121/app/WebViewer/view/image/36088,36089	\N	\N	\N	\N	\N	\N	\N	H17-09063 #1 (right forearm)	FFPE	\N	\N	\N	405	\N	\N	None	\N	CME-103	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2053	17-10987-6	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-38	https://64.54.108.121/app/WebViewer/view/image/36092,36093,36113	\N	\N	\N	\N	\N	\N	\N	H17-10987 #6 (back)	FFPE	\N	\N	\N	408	\N	\N	None	\N	CME-106	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2054	17-10987-N2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-39	https://64.54.108.121/app/WebViewer/view/image/36092,36093	\N	\N	\N	\N	\N	\N	\N	H17-10987 N2 (axillary lymph node)	FFPE	\N	\N	\N	408	\N	\N	None	\N	CME-106	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2845	22-104389A4	2	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=28255,28256,28257,28258,28260,28261,28262,28263	238.2	Normal	\N	Sections show melanocytes arrayed singly and in clusters irregularly within the epidermis, with a zone of scar that also encompasses similar clusters of cells. Some cells have moderately large spindled nuclei with abundant, pale amphophilic cytoplasm and interspersed melanophages.	Oriented irregular shaped excision, 4.4 x 1.9 x 0.6 cm, including a central 0.9 x 0.7 cm crusted area and generalized brown spots ranging from 0.2 x 0.2 cm to 0.3 x 0.2 cm. The orienting sutured tip is indicated as superior adjacent to lateral campus on the requisition form, designated as 12 o'clock by the grosser, and placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock and 6-9-12 o'clock edges, blue and yellow, respectively. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and entirely submitted with five sections in A1, four sections in A2, five sections in A3, and six sections and fragment in A4. HD/HD	WIDE LOCAL EXCISION MALIGNANT LESIONS RIGHT FACE X4	\N	Right Cheek	FFPE	The residuum is broad and composed of a heterogenous population of melanocytes including some small melanocytes and some large cells. The largest, nodular zone of melanocytes with the most atypical features appears completely excised. There are multi-focal areas of the melanocytoma that are present at the peripheral margins. After reviewing the clinical images, this is not surprising given the large pigmented patch from which these nodular lesions are arising.	SCAR AND RESIDUAL WNT-ACTIVATED/DEEP PENETRATING MELANOCYTOMA, SEE NOTES	173305	411	\N	\N	22-104389	A4	CS-01	Clinical Cases	IP2435904	AirTable blocks_with_IP_info.csv
1926	16-10561-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-37	https://64.54.108.121/app/WebViewer/view/image/36083	\N	\N	\N	\N	\N	\N	\N	H16-10561 (left forearm, in situ) #3	FFPE	\N	\N	\N	400	\N	\N	None	\N	CME-098	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2501	19Rig750007.01.12.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	256	\N	\N	None	\N	CM-12	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1536	11-89154A6	51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=23311	198.2	\N	\N	\N	Two blocks S11-13013:A6 and A7.	MELANOMA SUBMITTED FOR BRAF & NRAS MUTATION ANALYSIS	\N	\N	\N	The histopathological assessment of this melanoma has been documented in UCSF Surgical Pathology report S11-13013. Using this metastatic tumor, we completed KIT and BRAF mutation analysis via Sanger sequencing. The following results were obtained: BRAF exon 15: V600E mutation. NRAS exons 1 and 2: wild-type (non-mutated).	SUBCUTANEOUS METASTATIC MELANOMA	112208	127	\N	\N	11-89154	A6	CCR-011	2010-2017	IP757083	AirTable blocks_with_IP_info.csv
2846	22-104389C	2	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=28255,28256,28257,28258,28260,28261,28262,28263	238.2	Tumor	\N	The histopathology is generally similar to that described for specimen A.	Ellipse, 1.1 x 0.4 x 0.3 cm, including a central 0.4 x 0.3 cm elevated area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections in C. HD/HD	WIDE LOCAL EXCISION MALIGNANT LESIONS RIGHT FACE X4	\N	Right Cheek	FFPE	\N	WNT-ACTIVATED/DEEP PENETRATING MELANOCYTOMA, EXTENDING TO THE PERIPHERAL MARGIN	110003	411	\N	\N	22-104389	C	CS-01	Clinical Cases	IP2435904	AirTable blocks_with_IP_info.csv
2801	22-44813B	23	\N	\N	\N	\N	\N	\N	10	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31083,31084,31085,31086,31087,31088	238.2	\N	\N	The features are similar to those in (A), except that the proliferation is larger, with an exophytic profile and extension through the depth of the reticular dermis with a wedge-shaped lower profile. There is overlying parakeratosis Dermal mitotic figures are present including near the base of the biopsy. Slight maturation is present. Small melanocytes are present in the flanking epidermis on both sides of the larger melanocytes.	One outside slide, DP22-01833 (B1), and one corresponding block.	A-D) NO HISTORY PROVIDED, EXCISION; CONGENITAL NEVUS VS. OTHER	\N	\N	FFPE	\N	WNT-ACTIVATED MELANOCYTOMA	173105	411	\N	\N	22-44813	B	CS-01	Clinical Cases	IP2435904	AirTable blocks_with_IP_info.csv
2894	23-7246B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	413	\N	\N	23-7246	B	DMS-001	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2571	19Rig750007.05.16.01	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	300	\N	\N	None	\N	CM-72	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2829	22-91591	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	441	\N	\N	22-91591	\N	DMS-029	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2834	22-94507	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	442	\N	\N	22-94507	\N	DMS-030	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2838	22-95858	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	443	\N	\N	22-95858	\N	DMS-031	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2839	22-99877	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	444	\N	\N	22-99877	\N	DMS-032	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2481	19-111428	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	445	\N	\N	19-111428	\N	DMS-033	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2669	20-103041	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	446	\N	\N	20-103041	\N	DMS-034	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2203	17-91856A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	464	\N	\N	17-91856	A	DMS-052	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2204	17-91856B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	464	\N	\N	17-91856	B	DMS-052	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
1470	11-28912B	54	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a dome surfaced, wedge-based proliferation of large oval melanocytes with moderately enlarged oval vesicular nuclei and abundant pale, vacuolated cytoplasms, arranged as large nests and fascicles superficially and as smaller aggregations in the deep reticular dermis. Some nuclear pleomorphism is present. There are evenly distributed melanophages. Mitoses appear to be rare, and mostly superficial.	Two skin segments, one measuring 0.5 x 0.3 x 0.1 cm, intact, and the other measuring 0.7 x 0.6 x 0.1 cm, bisected, all entirely submitted in cassette B.	A) ? NEOPLASM, R/O DF, B) ? NEOPLASM; R/O ATYPICAL NEVUS, C) R/O VK VS. CONDYLOMA (-) HPV TYPING IF NEEDED	\N	\N	\N	The neoplasm extends to the base of the specimen in the deeper piece. This is an unusual lesion whose appearance is similar in some respects to that of blue nevus, clinically and histopathologically, but is genomically different. While most of the findings are reassuring, I would still consider a narrow re-excision as there are rare lesions in which the appearance that most of the lesion has been removed is deceptive.	DEEP PENETRATING NEVUS	173533	1909	\N	\N	11-28912	B	SYNAT149	Deep Penetrating Nevus	IP1018350	AirTable blocks_with_IP_info.csv
1898	15-102927	61	\N	\N	\N	None	None	None	5	0	FFPE	\N	\N	216.6	\N	MAP2K1	Sections show a dermal proliferation of small melanocytes with round to oval nuclei, coupled with spindled cells associated with thickened collagen. There is solar elastosis in the dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. RS/RS	A) RULE-OUT ATYPICAL MELANOCYTIC PROCESS. PINK SCALY PAPULE WITH PERIPHERAL BROWN PIGMENTATION AND BROWN DOTS AND CLODS AT PERIPHERY. PMH MMIS.	\N	\N	FFPE	None	COMBINED MELANOCYTIC NEVUS, WITH ORDINARY (CONGENITAL) AND BLUE NEVUS COMPONENTS	173688	1368	\N	\N	15-102927	\N	SN-05	Sclerotic Nevi	IP1374483	AirTable blocks_with_IP_info.csv
2485	19-117270	34	\N	\N	\N	None	None	None	5	0	FFPE	\N	\N	216.6	\N	MAP2K1	Sections show a wedge shaped dermal proliferation of melanocytes of two types, both positioned in discrete aggregates or singly between thickened collagen bundles in the reticular dermis. There are cells with slightly enlarged round or ovoid nuclei, and scant cytoplasm, as well as typical Spitz cells, large, oval melanocytes with abundant, pale cytoplasm and monomorphous oval vesicular nuclei.	Ellipse, 2.0 x 0.9 x 0.3 cm, including a central 0.5 x 0.5 cm white area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with nine sections. PL/PL	DDX: NEOPLASM OF UNCERTAIN BEHAVIOR VS. PROBABLE COMBINED NEVUS (SEE PATH), UNCERTAIN BEHAVIOR, NOTES: PLEASE CHECK MARGINS	\N	\N	FFPE	The excision is complete. The residual lesion seen here has the wedge shaped, dense fibrous stroma, and and some large oval cells as would be typical for a desmoplastic Spitz's nevus, but also has some cells with small nuclei and scant cytoplasm. The excision is complete, and there are no particularly worrisome features.	BIOPSY SITE CHANGES AND RESIDUAL DESMOPLASTIC NEVUS	273692	1370	\N	\N	19-117270	\N	SN-07	Sclerotic Nevi	IP2115907	AirTable blocks_with_IP_info.csv
2065	17-20501C	69	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	238.2	DN	\N	Sections show a broad compound proliferation of melanocytes, with a junctional component that extends lateral to the small underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  Scattered melanocytes have enlarged nuclei. There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate and are present above the basal layer.	Skin segment plus one fragment measuring 1.3 x 1.3 x 0.3 cm in aggregate. The skin segment is serially sectioned and entirely submitted with five sections. All submitted in C. RS/RS	A) 6 X 7 MM TAN REGULAR MACULE; FAVOR LENTIGO, B) PINK KERATOTIC 6 X 6 MM PAPULE; HAK, R/O NMSC, C) 1 X 6 MM TAN PAPULE WITH AMORPHOUS PIGMENT AND GREY DOT AT PERIPHERY WITH BACKGROUND ERYTHEMA; ? ATYPIA (TELEPHONE: 707-648-3733 MSG OK)	\N	\N	Scraping	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes. Re-excision of this site is warranted to assure that the lesion is removed to prevent regrowth or progression to melanoma.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING TO THE EDGES OF THE SPECIMEN	333504	546	\N	\N	17-20501	C	DN-071	Dysplastic Nevi	IP183716	AirTable blocks_with_IP_info.csv
1225	06-16759A T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	928	\N	\N	None	\N	MD-22	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2505	19Rig750007.01.15.01	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	259	\N	\N	None	\N	CM-15	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2506	19Rig750007.01.15.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	259	\N	\N	None	\N	CM-15	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2508	19Rig750007.01.16.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	260	\N	\N	None	\N	CM-16	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2837	22-95643B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	475	\N	\N	22-95643	B	DMS-063	DNA Methylation Study	\N	AirTable blocks_with_IP_info.csv
2836	22-95643	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	475	\N	\N	22-95643	\N	DMS-063	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
1663	12-81302	17	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	A shave biopsy has been removed in multiple layers. In the superficial portions of the specimen, there is the surface of a compound proliferation of melanocytes, and central ulceration is prominent. To the side of the ulceration, single melanocytes and nests are sparsely distributed within the epidermis. In the dermis below this, non-maturing nests and sheets of similar melanocytes are apparent. In deeper segments of tissue, there are also similar non-maturing nests and large aggregations. Many of the constituent melanocytes in the dermis have amphophilic or finely melanized cytoplasm, and a juxtaposed infiltrate of lymphocytes and melanophages is also noted.	Three outside slides, WCS-12-06587 (R12-21441/DC12-5467).  One corresponding block received 10-29-12.	RIGHT DORSAL FOOT LESION; REFERRAL FOR POSSIBLE CGH TESTING	\N	\N	\N	Based upon attributes evaluated by conventional microscopy, I believe this tumor represents melanoma. Per your request, we additionally completed array-based comparative genomic hybridization (aCGH) to screen this tumor for chromosomal copy number abnormalities, as can be seen with melanoma. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 1q and loss in chromosomes 1p and 9. The identification of multiple chromosomal copy number abnormalities indicates genomic instability, as is typical of malignancies such as melanoma. This melanoma is probably best considered to represents an example of 'childhood-type spitzoid melanoma'. This designation refers to an emerging entity that we believe may be prognostically distinct from conventional adult melanoma. Such tumors commonly lack BRAF mutations and were reported in the past literature under such flawed designations as malignant Spitz nevus. Experience to date suggests a small risk for extension to regional lymph nodes with a low risk for widespread dissemination (in comparison to conventional adult melanoma).  In summary, the combination of results derived from conventional microscopy coupled with aCGH points to interpretation as melanoma. This tumor is ulcerated, but the mother has reported to me that pressure from distance running shoes may have been contributory to surface erosion. The final microstage parameters can be reassessed once this melanoma has been fully extirpated.	MELANOMA OF AT LEAST 1.8 MM IN THICKNESS, INVOLVING THE DEEP EDGE OF THE BIOPSY	173788	2153	\N	\N	12-81302	\N	SYNAT147	2010-2017	IP1167119	AirTable blocks_with_IP_info.csv
3276	D12_M	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2346	\N	\N	None	\N	SYNAT173	2010-2017	\N	AirTable blocks_with_IP_info.csv
2014	16-125611	25	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10825	216.5	DN	\N	Sections show a zone of inflammation and granulation tissue, representing the aftermath of a prior biopsy, with an adjacent compound proliferation of melanocytes limited to the epidermal-dermal junction and the superficial dermis.	Oriented ellipse, 1.9 x 1.0 x 0.6 cm, including a central 1.0 x 0.9 cm variegated brown area. With the orienting sutured tip placed to the left and indicated as 12 o'clock, medial tip on the requisition form, the 12-3-6 o'clock and 6-9-12 o'clock edges are inked blue and yellow, respectively. The specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in A and four sections in B. HD/HD	A) COMPOUND NEVUS WITH MODERATE ATYPIA. APPROPRIATELY HEALING BIOPSY SITE. PREVIOUS ACCESSION #: DT16-113705. PLEASE CHECK MARGINS. SUTURE PLACED AT 12 O'CLOCK MEDIAL TIP..	\N	\N	Scraping	None	HEALING BIOPSY SITE WITH RESIDUAL COMPOUND CLARK'S (DYSPLASTIC) NEVUS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	173544	480	\N	\N	16-125611	\N	DN-005	Dysplastic Nevi	IP1713848	AirTable blocks_with_IP_info.csv
2157	17-63163	69	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 0.9 x 0.4 x 0.1 cm, bisected and entirely submitted. KC/KC	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS. PIGMENTED MACULE.	\N	\N	\N	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	528599	547	\N	\N	17-63163	\N	DN-072	Dysplastic Nevi	IP1572575	AirTable blocks_with_IP_info.csv
2089	17-27380	75	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.7	DN	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/HD	5 MM ASYMMETRICAL BROWN MACULE; POSS ATYPICAL NEVUS	\N	\N	Scraping	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	234789	548	\N	\N	17-27380	\N	DN-073	Dysplastic Nevi	IP1756705	AirTable blocks_with_IP_info.csv
2573	19rig75000701.18.01	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	262	\N	\N	None	\N	CM-18	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2623	20-31447	43	\N	\N	\N	None	None	None	20	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26427,26428	172.4	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.8 x 1.4 x 0.1 cm is serially sectioned and entirely submitted with five sections. BY/BY	14 X 12 MM, TAN / BROWN MACULE WITH CENTRAL PAPULES, SOMEWHAT IRREGULARLY DISTRIBUTED PIGMENT; R/O DYSPLASIA VS. MM	\N	MELANOMA, 1.8 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	This melanoma measures at least 1.8 mm in thickness and was focally transected at the specimen base. An associated melanocytic nevus is present. A synoptic report of potential prognostic factors is listed below: Procedure: saucerization biopsy Microscopic tumor type: superficial spreading melanoma (WHO classification: low cumulative sun damage) Breslow thickness: at least 1.8 mm Ulceration: absent Margins, peripheral and deep: deep involved by invasive melanoma, peripheral involved by melanoma in situ Mitotic index: 4 mm/2 Regression: not identified Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT2a	MELANOMA, 1.8 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173450	1148	\N	\N	20-31447	\N	ME-53	Melanoma Epigenetics	IP2179033	AirTable blocks_with_IP_info.csv
1569	12-6332A5	8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a papillated epidermis with a symmetric melanocytic proliferation composed of nests of small melanocytes along the junction, with clusters of similar cells in the subjacent dermis.  Many neoplastic cells have pigmented cytoplasm, and there are also surrounding melanophages in the center of the lesion.  Melanocytes in the reticular dermis surround adnexal structures.	Cylindrical skin segment measuring 0.3 cm in diameter and 0.3 cm in thickness. Submitted intact in cassette A.	A) PINK PAPULE WITH DARKLY HYPERPIGMENTED MACULE IN CENTER; SPITZ, PSCN (4 MM PUNCH OF 4 MM LESION), B) 2 MM TAN PAPULE; CMN	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, CONGENITAL PATTERN, WITH MANY MELANOPHAGES	105524	2228	\N	\N	12-6332	A5	SYNAT78	2010-2017	IP1092148	AirTable blocks_with_IP_info.csv
1944	16-33907	67	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a proliferation of spindled and dendritic melanocytes enmeshed in thickened, sclerotic collagen. The lesional cells show considerable cytoplasmic pigmentation and scattered accompanying melanophages are appreciable as well. Focal post-traumatic ulceration is noted.	Skin segment measuring 1.0 x 0.9 x 0.3 cm, quadrisected and entirely submitted. RS/RS	R/O DF	\N	left upper lateral back 	Scraping	This biopsy demonstrates a lightly pigmented blue nevus rather than a dermatofibroma.	DESMOPLASTIC BLUE NEVUS	273588	1334	\N	\N	16-33907	\N	SM-004	Nevus Library	IP1633163	AirTable blocks_with_IP_info.csv
2864	22-152373	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2177	\N	\N	22-152373	\N	SYNAT176	Melanoma Epigenetics	\N	AirTable blocks_with_IP_info.csv
2509	19rig750007.01.17.01	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	261	\N	\N	None	\N	CM-17	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2150	17-62447B	29	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10875	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 1.0 x 0.7 x 0.1 cm, trisected and entirely submitted in B. HD/HD	A) 9 X 8 MM ASYMMETRICALLY PIGMENTED MACULE; POSS ATYPICAL NEVUS, B) 8 MM ASYMMETRICALLY PIGMENTED MACULE; POSS ATYPICAL NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	528522	485	\N	\N	17-62447	B	DN-010	Dysplastic Nevi	IP1792269	AirTable blocks_with_IP_info.csv
2149	17-62447A	29	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10874	216.5	\N	\N	Sections show a compound proliferation of melanocytes composed of single and nested cells positioned along the epidermal-dermal junction, with similar cells in clusters and syncytia in the underlying dermis, with some cells arrayed in the superficial reticular and adventitial dermis.  The junctional melanocytes extend far lateral to those in the dermis. Bridging of adjacent rete ridges by nests of melanocytes is present in these areas.	Skin segment measuring 1.1 x 0.8 x 0.1 cm, trisected, and entirely submitted in A. HD/HD	A) 9 X 8 MM ASYMMETRICALLY PIGMENTED MACULE; POSS ATYPICAL NEVUS, B) 8 MM ASYMMETRICALLY PIGMENTED MACULE; POSS ATYPICAL NEVUS	\N	\N	\N	This lesion is atypical in that it shows irregular architectural features and a junctional component that extends considerably lateral of the dermal component. Conservative re-excision of this site is warranted to ensure complete removal and further progression of this lesion.	SUPERFICIAL CONGENITAL MELANOCYTIC NEVUS, COMPOUND TYPE, WITH LATERAL EXTENSION OF THE JUNCTIONAL COMPONENT, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	173527	485	\N	\N	17-62447	A	DN-010	Dysplastic Nevi	IP1792269	AirTable blocks_with_IP_info.csv
2012	16-125177	28	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/HD	R/O SCABIES	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173524	483	\N	\N	16-125177	\N	DN-008	Dysplastic Nevi	IP1660916	AirTable blocks_with_IP_info.csv
1943	16-32627A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-23	http://64.54.108.121/eSlideTray.php?ImageIds=32774	\N	\N	6205395	\N	\N	\N	\N	Skin, scalp, right, bottle 1, wide excision, malignant melanoma with vertical growth phase	FFPE	\N	\N	\N	312	\N	\N	16-32627	A1	CME-010	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2148	17-62251	70	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	64.54.108.121/eSlideTray.php?ImageIds=10873	238.2	\N	\N	Sections show a compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate and are present above the basal layer.	Skin segment measuring 1.1 x 0.9 x 0.1 cm, quadrisected and entirely submitted plus fragments. RS/RS	IRREG BROWN PATCH, NEOPLASM NOS L UPPER BACK; R/O MM, SHAVE BX AFTER CONSTANT W.C - SPECKLED, ISK #1 LN2 / W.C (+) COMPONENT LSC + STOP ___ (SEE PHOTO)	\N	\N	\N	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes. Conservative re-excision of this site is warranted to ensure complete removal and prevent progression to melanoma.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	173530	549	\N	\N	17-62251	\N	DN-074	Dysplastic Nevi	IP1792072	AirTable blocks_with_IP_info.csv
2155	17-62828A	31	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10880	216.5	\N	\N	Sections show a compound proliferation of melanocytes with a flattish profile, the junctional component of which is composed of single and nested melanocytes arrayed along the sides and bases of elongated rete, above a papillary dermis expanded by fibrosis.  There is a central dermal component of small melanocytes near the epidermal-dermal junction.	Skin segment measuring 1.0 x 0.8 x 0.1 cm, trisected and entirely submitted in A. KC/KC	A-B) IRREGULAR BROWN MACULE; DYSPLASTIC NEVUS VS. MIS	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	102539	488	\N	\N	17-62828	A	DN-013	Dysplastic Nevi	IP1792659	AirTable blocks_with_IP_info.csv
2104	17-34432D	32	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.7	DN	\N	Sections show a junctional proliferation of melanocytes without striking nuclear variability.  The proliferation has a flat configuration, when viewed from scanning magnification.  There is fibrosis of the papillary dermis.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted in D. KC/KC	A-D) R/O DN, HISTORY OF CLARK'S, DYSPLASTIC NEVUS	\N	\N	Scraping	\N	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173710	490	\N	\N	17-34432	D	DN-015	Dysplastic Nevi	IP1697427	AirTable blocks_with_IP_info.csv
2103	17-34432C	32	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	238.2	DN	\N	Sections show a proliferation of melanocytes in which nested and single cells are arrayed along the junction, above a papillary dermis that shows fibrosis, some of which is lamellar in pattern.  Single melanocytes are increased in number in some areas, with some melanocytes present above the basal zone.	Skin segment measuring 0.9 x 0.5 x 0.1 cm, bisected and entirely submitted in C. KC/KC	A-D) R/O DN, HISTORY OF CLARK'S, DYSPLASTIC NEVUS	\N	\N	Scraping	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes. Conservative re-excision of this site is warranted.	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING TO THE EDGE OF THE SPECIMEN	173610	490	\N	\N	17-34432	C	DN-015	Dysplastic Nevi	IP1697427	AirTable blocks_with_IP_info.csv
2650	20-79197A	57	\N	\N	\N	\N	\N	\N	20	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26437	172.6	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis arranged as expansile nests. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.1 x 0.9 x 0.4 cm, quadrisected, and entirely submitted in A. KB/HD	A) MORPHOLOGY: IRREGULAR BROWN PAPULE, SIZE: 1 CM, DDX: ATYPICAL NEVUS, B) MORPHOLOGY: IRREGULAR BROWN MACULE, SIZE: 0.4 CM, DDX: ATYPICAL NEVUS, C) MORPHOLOGY: IRREGULAR BROWN MACULE, SIZE: 0.2 CM, DDX: ATYPICAL NEVUS	\N	A- MELANOMA, 1.5 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	FFPE	Diagnostic features of note include: Procedure: Excisional biopsy Tumor site: Arm Microscopic tumor type: Nevoid Breslow thickness: 1.5 millimeters Ulceration: Absent Margins, peripheral and deep: Peripheral narrow, deep free Mitotic index: 1/mm2 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT2a	MELANOMA, 1.5 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	523654	1151	\N	\N	20-79197	A	ME-56	Melanoma Epigenetics	IP264110	AirTable blocks_with_IP_info.csv
1105	04-00122C T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1030	\N	\N	None	\N	MD-151	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1124	04-14508C T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1032	\N	\N	None	\N	MD-153	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2927	90-012097B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1994	\N	\N	90-12097	B	SYNAT181	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1129	04-15616C T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1033	\N	\N	None	\N	MD-154	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2111	17-35486A	32	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10859	216.5	DN	\N	Sections show a compound proliferation of melanocytes with round to oval nuclei and scant cytoplasm, arrayed as nests along the epidermal-dermal junction and as small clusters in the subjacent dermis.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted in A. KC/KC	A-B) NEVUS, R/O ATYPIA	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS	173530	491	\N	\N	17-35486	A	DN-016	Dysplastic Nevi	IP1764932	AirTable blocks_with_IP_info.csv
2121	17-35917B	34	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10867	216.5	\N	\N	Sections show a compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis contains an infiltrate of lymphocytes and melanophages.	One cylindrical skin segment and one tissue segment received in one specimen vial. Cylindrical skin segment, 0.4 cm in diameter and 0.6 cm in thickness, bisected. Tissue segment measuring 0.5 x 0.2 x 0.2 cm, intact. All entirely submitted in B. CF/CF	A) JUNCTIONAL MELANOCYTIC NEVUS VS. RULE OUT ATYPICAL MELANOCYTIC PROCESS. SOMEWHAT TRIANGULARLY-SHAPED BROWN MACULE WITH PERIPHERAL DOTS ALONG ONE PERIPHERAL EDGE, BUT NOT ALONG THE REST OF THE LESION'S EDGE. LESION SIZE 4 MM; 4 MM P PERFORMED. B) JUNCTIONAL MELANOCYTIC NEVUS VS. SPITZ NEVUS, RULE OUT ATYPICAL MELANOCYTIC PROCESS. REGULAR, SYMMETRIC BROWN MACULE WITH SUBTLE PSEUDOPODS ALL AROUND PERIPHERY. LESION SIZE 2 MM; 3 MM P PERFORMED.	\N	\N	\N	The findings are well within the spectrum of those seen in dysplastic (Clark's) nevi. There are no microscopic features that compel re-excision.	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	101523	493	\N	\N	17-35917	B	DN-018	Dysplastic Nevi	IP1765368	AirTable blocks_with_IP_info.csv
2934	92-003527H	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2286	\N	\N	92-3527	H	SYNAT184	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1130	04-15689C T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1035	\N	\N	None	\N	MD-156	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1123	04-13607 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1036	\N	\N	None	\N	MD-157	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1980	16-98055B	43	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10834	216.6	DN	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 1.0 x 0.6 x 0.1 cm, bisected and entirely submitted in B. RS/RS	A-C) NEOP UNC VS. DYSPLASTIC NEVUS	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173620	505	\N	\N	16-98055	B	DN-030	Dysplastic Nevi	IP834471	AirTable blocks_with_IP_info.csv
1979	16-98055A	43	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.7 x 0.7 x 0.1 cm, trisected and entirely submitted in A. RS/RS	A-C) NEOP UNC VS. DYSPLASTIC NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING CLOSE TO THE EDGES OF THE SPECIMEN	152589	505	\N	\N	16-98055	A	DN-030	Dysplastic Nevi	IP834471	AirTable blocks_with_IP_info.csv
2952	94-016368	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2268	\N	\N	94-16368	\N	SYNAT185	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2957	94-31062  	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2313	\N	\N	94-31062	\N	SYNAT186	2010-2017	\N	AirTable blocks_with_IP_info.csv
2963	95-007992	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2183	\N	\N	95-7992	\N	SYNAT187	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3006	98-019394	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2291	\N	\N	98-19394	\N	SYNAT188	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1122	04-13171C T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1037	\N	\N	None	\N	MD-158	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1111	04-03547G T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1038	\N	\N	None	\N	MD-159	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1632	12-24226	43	\N	\N	\N	T1a	Primary	None	\N	\N	\N	\N	\N	172.5	\N	from Swapna	Sections show a broad, asymmetrical, and badly circumscribed compound proliferation of enlarged epithelioid melanocytes. There are single melanocytes and nests distributed along the junction, and subtle areas of suprabasal scatter can be found. In the perijunctional dermis, some cross sections show non-maturing nests and cords of cytologically similar melanocytes. Other areas show a patchy perijunctional infiltrate of lymphocytes and melanophages. Very focally, the epidermal surface has overlying parakeratosis, suggesting trauma or irritation.	Three outside slides, D12-10741 and one corresponding block.	SHAVE BIOPSY IN TWO PIECES; R/O MELANOMA	\N	\N	\N	The differential diagnosis included a thin melanoma on one hand and an unconventional melanocytic nevus on the other, and the former possibility proves to represent the best interpretation for this atypical melanocytic proliferation. To fully substantiate the nature of this proliferation, we completed array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 4p, 5p, and 7p as well as loss in chromosomes 6p, 9p, and 12p. The identification of multiple chromosomal copy number aberrations suggests genomic instability, as is typical of malignancies such as melanoma. In summary, the combination of results derived from conventional microscopy coupled with aCGH points to a diagnosis of melanoma. With respect to staging, this melanoma is less than 1 mm in thickness, lacks associated ulceration, and does not have detectable melanocytes in mitosis in its invasive component. Therefore, it represents a melanoma of stage pT1a (2009 AJCC Guidelines). Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.6 MM IN THICKNESS, EXTENDING INTRAEPIDERMALLY TO THE SPECIMEN PERIPHERY	528522	641	\N	\N	12-24226	\N	DP-04	Possible TERT Fusion	IP1110044	AirTable blocks_with_IP_info.csv
1808	14-90528	62	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	from Swapna	Sections show a domed compound proliferation of melanocytes with single cells and nests arrayed along the junction. The junctional melanocytes are pale and have heavily pigmented cytoplasm, and pigmented hyperkeratosis is above them. In the dermis, there are maturing nests, cords, and small syncytia of similar melanocytes, and those superficially are heavily pigmented, while those more deeply exhibit limited neural differentiation in a central focus. There are some superficial dermal or perijunctional melanocytes in mitosis. Many superficial dermal melanophages are also noted.	Five outside slides, SD-14-32477 (A1). One corresponding block received 10-28-14.	SECOND OPINION	\N	\N	\N	Given the small overall size, good lateral demarcation, gradient of maturation, and deep neural differentiation that are apparent in association with this tumor, I believe it represents melanocytic nevus and not melanoma. There are several perijunctional melanocytes in mitosis, which is unconventional and of some concern. That said, I do not see how a microscopic diagnosis of melanoma could be easily rendered, given the characteristics mentioned in the first sentence of this paragraph. Per a clinical request, we completed array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies as an ancillary means of assessment. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 15q as a monoaberration (and also subthreshold gain in chromosome 20q) with no other associated chromosomal gains or losses. As background for understanding this result, note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. Gain in 15q is an anomaly that we have identified in a subset of melanocytic nevi with spitzoid features.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. Rather, our analysis has identified an uncommon monoaberration that we have identified in a subset of Spitz nevi or partially transformed Spitz tumors. In the available sections, this melanocytic proliferation appears narrowly excised. Clinical monitoring of the biopsy site can be utilized to verify that no persistence ensues. Given the complexity of this assessment, conservative complete reexcision of this site could also be considered as follow-up management.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	COMPOUND PROLIFERATION OF HEAVILY PIGMENTED MELANOCYTES, CONSISTENT WITH A COMPOUND MELANOCYTIC NEVUS	897777	643	\N	\N	14-90528	\N	DP-06	Possible TERT Fusion	IP1440512	AirTable blocks_with_IP_info.csv
2279	17-132120	25	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	from Swapna	The lesion has a domed surface and a flat base. I has large polygonal and fusiform melanocytes with abundant, pale cytoplasm and dusty appearing melanin and enlarged nuclei superficially and smaller cells more deeply. Areas feature a syncytial arrangement, rather than discrete aggregations. I did not encounter mitotic figures in dermal melanocytes.	One outside slide, S-90406. One corresponding block received 1/10/18.	BIOPSY LEFT FOREARM	\N	\N	\N	The differential diagnosis posed by these sections includes a Spitz's nevus, an atypical Spitz tumor and spitzoid melanoma. The asymmetry of the lesion and presence of many cells with abundant, pale cytoplasm and dusty appearing melanin is against a Spitz's nevus and favors one of the other two categories. A phosphohistone H3/MART-1/tyrosinase two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows several positive nuclei in the upper or mid-part of the lesion.  While only a small minority of the melanocytes are p16 positive, I did not find extensive areas completely lacking p16 positive cells, as can be seen with bi-allelic loss of CDKN2A. Such areas can in some cases indicate melanoma.  Following microdissection and DNA extraction, we performed comparative genomic hybridization. Comparative genomic hybridization shows no significant chromosomal copy number changes. An idiosyncratic finding- a loss of a small pericentromeric area in chr. 9q was present. This area does not contain any tumor suppressor genes known to play a role in melanomagenesis. About 95% of conventional melanomas show significant losses or gains with this technique.  Using the DNA extracted for CGH, we also performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations. Since then, there have been a few cases in which hTERT promoter mutations were not found, but in which the gene was affected by promoter methylation.  An atypical Spitz tumor seems to be the best category for this lesion. These are neoplasms that have features more atypical than those of a conventional Spitz nevus, but not as worrisome as those of spitzoid melanoma. In aggregate data from over ten studies, local nodal involvment (usually very small deposits) is common, but extranodal metastasis is rare. This dissociation results in sentinel lymph node biopsy having very limited predictive value, and in my opinion, sometimes leading to over-treatment if small deposits lead to completion lymphadenectomy. As the the base of the specimen is involved, conservative re-excision of this site is warranted.   Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	ATYPICAL SPITZ TUMOR	173610	644	\N	\N	17-132120	\N	DP-07	Possible TERT Fusion	IP1862784	AirTable blocks_with_IP_info.csv
1871	15-42060	48	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	from Swapna	There is a compound proliferation of melanocytes featuring a predominant population of large round to oval cells with abundant pale cytoplasm and dusty melanin, and moderately enlarged round nuclei. These are arranged as large and confluent nests at the junction, in some cases bridging adjacent ridges, and encased within dense fibrotic stroma in the center of the lesion (with a much less prominent junctional component in this area). The cells contrast with cords and strands of small round melanocytes in a looser configuration in one focus.	Five outside slides, USP(DP)15-13953 A1 and one corresponding block.	CHANGING NEVUS, R/O DYSPLASTIC NEVUS, CHECK MARGINS	\N	\N	\N	The differential diagnosis included a nevus of special site, and melanoma arising in a pre-existent nevus with superficial congenital features. Based on the findings seen in the hematoxylin and eosin stained sections, I was quite concerned re the possibility of melanoma. Both entities can have confluent junctional nests composed of melanocytes with abundant, pale, vacuolated cytoplasm, but in this case, the confluent nests extend above dermal papillae, and are accompanied a dermal component encased in sclerotic stroma. The enclosed immunostains are not decisive. Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. These include loss involving chr. 3, loss involving chr. 5p with small gains in the peri-centromeric area of 5p, areas of gain and loss involving chr. 7p in a pattern suggesting chromothripsis, gain of 7q, loss of 8p, loss of 11q, and gains and losses of 21q. While the the individual loci are not stereotypically altered in melanoma, taken together the findings strongly favor that diagnosis, including the presence of chromothripsis.  The neoplasm extends to the base of the specimen.	MELANOMA, 1.2 MM. IN THICKNESS	105586	645	\N	\N	15-42060	\N	DP-08	Possible TERT Fusion	IP1513334	AirTable blocks_with_IP_info.csv
2992	98-1056	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1876	\N	\N	98-1056	\N	SYNAT190	2010-2017	\N	AirTable blocks_with_IP_info.csv
2993	98-1056A9	38	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.19	\N	\N	Sections show a proliferation of small basaloid keratinocytes,\narrayed as interanastomosing rete.  There are horn pseudocysts.	Skin segment measuring 0.8 x 0.5 x 0.3 cm, bisected and entirely\nsubmitted.	CLINICAL DIAGNOSIS - R/O NEVUS	\N	\N	\N	\N	SEBORRHEIC KERATOSIS	101499	1876	\N	\N	98-1056	A9	SYNAT190	2010-2017	IP138629	AirTable blocks_with_IP_info.csv
2113	17-35502A	44	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10860	216.6	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis. There is focal parakeratosis.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted in A. HD/HD	A) IRREG 8 MM MACULE; R/O DYSPL CN VS. OTHER, B) HAZY 7 MM MACULE; R/O DYSPL CN VS. OTHER	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	733602	510	\N	\N	17-35502	A	DN-035	Dysplastic Nevi	IP1764948	AirTable blocks_with_IP_info.csv
1530	11-85416	49	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	There is a compound proliferation of melanocytes mostly involving the junctional zone and a thickened papillary dermis.  Nests of, and increased numbers of single melanocytes are situated at the sides and bases of elongated rete ridges. The bases of some adjacent rete ridges are fused by junctional nests, some of which have horizontally oriented spindled cells.  Toward the center of the lesion, smaller melanocytes reside in the papillary dermis. A focally dense lymphocytic infiltrate ascends to the junction.	One outside slide, M11-6000. One corresponding block received 11-21-11.	MELANOMA	\N	\N	\N	In addition to the findings noted below, levels show that the lesion is considerably thicker than in the initial sections, and has more confluence of junctional nests. A zone of paucicellular fibrosis is present beneath part of the lesion, consistent with a scar. Immunoperoxidase stained sections prepared in our laboratory show that a small minority of cells are p16 positive. This finding is less common in nevi than in melanoma. Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a very low proliferation rate, which in contrast is a reassuring finding. Similarly, only rare cells are positive in a phosphohistone H3 immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle).  Due to the difficult nature of this case, we obtained comparative genomic hybridization. This showed an isolated gain involving chromosome 7q. We have seen this aberration mainly in Spitz's nevi. While this is not a classic Spitz's nevus, the junctional component has some spitzoid features, and in this context I cannot interpret the current findings as supporting melanoma. Given the unusual nature of this lesion, I would still obtain a narrow re-excision of this site, however.	COMPOUND MELANOCYTIC NEVUS WITH SOME SPITZOID FEATURES	102538	1669	\N	\N	11-85416	\N	SYNAT351	2010-2017	IP1074864	AirTable blocks_with_IP_info.csv
1570	12-6550	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	108	\N	\N	12-6550	\N	BN-004	Nevus Library	\N	AirTable blocks_with_IP_info.csv
2522	19Rig750007.03.01.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	270	\N	\N	None	\N	CM-30	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2991	98-001046	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2151	\N	\N	98-1046	\N	SYNAT189	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2465	19-59869A	45	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.4	\N	MAP2K1	Sections show a compound proliferation of melanocytes with mostly single melanocytes at the dermo-epidermal junction and oval and spindled melanocytes positioned between thickened collagen bundles in the dermis.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted in A. BY/BY	A) R/O BASAL CELL CARCINOMA - PRIMARY, SEBACEOUS GLAND HYPERPLASIA, PINK TRANSLUCENT PEARLY PAPULE WITH ARBORIZING TELANGIECTASIA, B-C) R/O NEOPLASM OF UNCERTAIN BEHAVIOR OF SKIN, COMPOUND NEVUS OF SKIN, DYSPLASTIC NEVUS OF SKIN, VARIEGATED TAN, BROWN AND ERYTHEMATOUS LESION	\N	\N	FFPE	This benign lesion shares a fibrotic dermal reaction with desmoplastic Spitz nevus, but lacks the large melanocytes seen in that condition.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS WITH DESMOPLASTIC FEATURES	173441	1372	\N	\N	19-59869	A	SN-09	Sclerotic Nevi	IP2064255	AirTable blocks_with_IP_info.csv
2264	17-119451	31	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18177	216.7	\N	\N	Sections show a junctional proliferation of melanocytes in single cell array at the sides and bases of elongated rete ridges.  Some small nests are also present. There is hyperpigmentation of the basal layer and melanophages in the papillary dermis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted. RS/RS	6 X 5 MM NOTCHED IRREGULARLY PIGMENTED MACULE; R/O MELANOMA	\N	\N	\N	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173711	830	\N	\N	17-119451	\N	LN-10	Lentiginous Nevi 	IP1849990	AirTable blocks_with_IP_info.csv
2470	19-79825	50	\N	\N	\N	None	None	None	10	0	FFPE	\N	\N	216.5	\N	MAP2K1	There are increased single melanocytes and small nests of them along the sides and bases of elongated rete ridges. Small, round melanocytes in the subjacent papillary dermis mature to spindled melanocytes. There is basilar hyperpigmentation in the affected area.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted. BY/BY	MORPHOLOGY: COLOR VARIEGATION AND BORDER IRREGULARITY AND 3 MM, DDX: NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS	\N	\N	FFPE	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	345533	1374	\N	\N	19-79825	\N	SN-11	Sclerotic Nevi	IP1933035	AirTable blocks_with_IP_info.csv
2524	19Rig750007.03.02.05	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	271	\N	\N	None	\N	CM-31	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2523	19Rig750007.03.02.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	271	\N	\N	None	\N	CM-31	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2151	17-62502A	49	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10876	216.5	DN	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 1.2 x 0.7 x 0.1 cm, trisected, and entirely submitted in A. HD/HD	A-B) CHANGING MELANOCYTIC NEVUS	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE	173544	519	\N	\N	17-62502	A	DN-044	Dysplastic Nevi	IP1792328	AirTable blocks_with_IP_info.csv
2152	17-62502B	49	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10877	238.2	DN	\N	Sections show a compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate and are present above the basal layer.	Skin segment measuring 1.5 x 1.0 x 0.1 cm, quadrisected, and entirely submitted in B. HD/HD	A-B) CHANGING MELANOCYTIC NEVUS	\N	\N	Scraping	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes. Conservative re-excision of this site is warranted.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT	139524	519	\N	\N	17-62502	B	DN-044	Dysplastic Nevi	IP1792328	AirTable blocks_with_IP_info.csv
2032	17-2270A	46	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10848	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and superficial dermis.  Junctional nests extend beyond the dermal component, bridge rete ridges in some areas, and are accompanied by lamellar fibrosis.	Ellipse, 1.0 x 0.7 x 0.2 cm, including a central 0.7 x 0.5 cm brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with five sections in A. HD/HD	A-B) R/O DYSPLASTIC NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGES OF THE SPECIMEN	173539	513	\N	\N	17-2270	A	DN-038	Dysplastic Nevi	IP1731355	AirTable blocks_with_IP_info.csv
2469	19-78038	74	\N	\N	\N	None	None	None	5	0	FFPE	\N	\N	216.6	\N	MAP2K1	Sections show a compound proliferation of melanocytes with spindled melanocytes positioned between thickened collagen bundles in the dermis.	Skin segment measuring 0.5 x 0.5 x 0.1 cm, bisected and entirely submitted. KC/KC	MORPHOLOGY: FIRM PINK / BROWN PAPULE, DDX: CONGENITAL NEVUS VS. SPITZ VS. OTHER	\N	\N	FFPE	This benign lesion shares a fibrotic dermal reaction with desmoplastic Spitz's nevus, but lacks the large melanocytes seen in that condition.	COMPOUND MELANOCYTIC NEVUS WITH DESMOPLASTIC FEATURES	424655	1377	\N	\N	19-78038	\N	SN-14	Sclerotic Nevi	IP144115	AirTable blocks_with_IP_info.csv
2473	19-89855A	44	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.5	\N	MAP2K1	Sections show a compound proliferation of melanocytes with spindled melanocytes positioned between thickened collagen bundles in the dermis. There are scattered pigmented melanophages in the dermis.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted in A. BY/BY	A) MORPHOLOGY: IRREGULAR BROWN MACULE, DDX: ATYPICAL NEVUS, SIZE 0.4 CM, B) MORPHOLOGY: DOME-SHAPED PINK-TAN NODULE WITH POSITIVE DIMPLE SIGN, DDX: DERMATOFIBROMA, SIZE 0.8 CM	\N	\N	FFPE	This benign lesion has some features of a deep penetrating nevus in a the background of a fibrotic stroma. Dr. McCalmont has also reviewed this case and agrees with the diagnosis.	COMPOUND MELANOCYTIC NEVUS WITH DESMOPLASTIC FEATURES	173536	1378	\N	\N	19-89855	A	SN-15	Sclerotic Nevi	IP2094427	AirTable blocks_with_IP_info.csv
3014	99-012800	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2199	\N	\N	99-12800	\N	SYNAT192	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3015	99-012800-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2199	\N	\N	None	\N	SYNAT192	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2528	19Rig750007.03.04.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	273	\N	\N	None	\N	CM-33	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2529	19Rig750007.03.04.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	273	\N	\N	None	\N	CM-33	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2009	16-119467C	52	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with a flattish profile, the junctional component of which is composed of single and nested melanocytes arrayed along the sides and bases of elongated rete, above a papillary dermis expanded by fibrosis.  There is a central dermal component of small melanocytes near the epidermal-dermal junction.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted in C. KC/KC	A) NEOPLASM OF UNCERTAIN BEHAVIOR. 9MM2 HK TAN PINK R/O SK VS. SCC. B) NEOPLASM OF UNCERTAIN BEHAVIOR. 1.2X0.8CM SPECKLED TAN BROWN PATCH, NEVUS R/O ATYPIA. C) NEOPLASM OF UNCERTAIN BEHAVIOR. 5X6MM TAN PINK MACULE, NEVUS R/O ATYPIA. PLEASE CC DR. CYNTHIA STEPHENSEN IN WALNUT CREEK (DDS). D) NEOPLASM OF UNCERTAIN BEHAVIOR. 8MM2 DARK BROWN MACULE, NEVUS R/O ATYPIA.	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, NARROWLY EXCISED IN PLANES OF SECTION EXAMINED	173531	523	\N	\N	16-119467	C	DN-048	Dysplastic Nevi	IP1719660	AirTable blocks_with_IP_info.csv
2008	16-119467B	52	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10821	216.5	DN	\N	Sections show a compound proliferation of melanocytes in which nested and solitary cells are arrayed relatively evenly above a papillary dermis that displays nests of similar melanocytes, fibrosis, and a lymphocytic infiltrate. There is focal spongiosis.	Skin segment measuring 1.4 x 1.0 x 0.2 cm, quadrisected and entirely submitted in B. KC/KC	A) NEOPLASM OF UNCERTAIN BEHAVIOR. 9MM2 HK TAN PINK R/O SK VS. SCC. B) NEOPLASM OF UNCERTAIN BEHAVIOR. 1.2X0.8CM SPECKLED TAN BROWN PATCH, NEVUS R/O ATYPIA. C) NEOPLASM OF UNCERTAIN BEHAVIOR. 5X6MM TAN PINK MACULE, NEVUS R/O ATYPIA. PLEASE CC DR. CYNTHIA STEPHENSEN IN WALNUT CREEK (DDS). D) NEOPLASM OF UNCERTAIN BEHAVIOR. 8MM2 DARK BROWN MACULE, NEVUS R/O ATYPIA.	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, INFLAMED, EXTENDING TO THE EDGE OF THE SPECIMEN	528599	523	\N	\N	16-119467	B	DN-048	Dysplastic Nevi	IP1719660	AirTable blocks_with_IP_info.csv
3031	144 Imat B15	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2007	\N	\N	None	\N	SYNAT193	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3032	144 Imat B15-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1808	\N	\N	None	\N	SYNAT194	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3033	144aI WT	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1668	\N	\N	None	\N	SYNAT195	Cell Line	\N	AirTable blocks_with_IP_info.csv
3036	230 WT	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2109	\N	\N	None	\N	SYNAT196	Cell Line	\N	AirTable blocks_with_IP_info.csv
3050	1205lu-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1830	\N	\N	None	\N	SYNAT197	Cell Line	\N	AirTable blocks_with_IP_info.csv
3051	1205lu-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1974	\N	\N	None	\N	SYNAT198	Cell Line	\N	AirTable blocks_with_IP_info.csv
3052	1205LU-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2081	\N	\N	None	\N	SYNAT199	Cell Line	\N	AirTable blocks_with_IP_info.csv
2105	17-34448	58	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, and the dermal melanocytes diminish in size with descent.  The overlying epidermis is acanthotic, with elongated rete that intertwine.	Skin segment measuring 0.8 x 0.4 x 0.1 cm, bisected and entirely submitted. HD/HD	8 MM IRP WITH NEW HYPERPIGMENTATION; R/O ATYPICAL NEVUS	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS	139523	527	\N	\N	17-34448	\N	DN-052	Dysplastic Nevi	IP1572932	AirTable blocks_with_IP_info.csv
1447	11-12273	2	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.2	\N	\N	Sections show a cellular, exophytic, polypoid compound proliferation of melanocytes. Within the background epidermis, which is thin, there are single melanocytes and nests distributed erratically, and cells above the junction can be found. The dermis below this contains large and irregular nests of similar melanocytes that lack maturation with descent in the dermis. An increase in dermal vascularity is appreciable. Dermal melanocytes in mitosis are easily found.	Seven outside slides, S10-40898 A1 (DC11-357, DEE-12580) and one corresponding block.	LARGE PEARLY PAPULE ON L PINNA FOR 2-3 WEEKS; FAVOR PYOGENIC GRANULOMA	\N	Iwei, CGH Array run| ROS1 Translocation case	\N	Our differential diagnosis included childhood-type spitzoid melanoma on one hand and a peculiar cellular Spitz nevus on the other. To address this differential, we completed array-based comparative genomic hybridization (aCGH) analysis to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, aCGH analysis demonstrated gain in chromosome 1q and loss of chromosome 6q. The identification of multiple chromosomal gains and losses is not known to occur in Spitz nevi and favors instead the above interpretation. The designation childhood-type spitzoid melanoma refers to an emerging entity that we believe is distinct from conventional adult melanoma. Such tumors typically lack BRAF mutations and were reported in the past literature under such flawed designations as malignant Spitz nevus. Experience to date suggests a small risk for extension to regional lymph nodes with a low risk for widespread dissemination.  This proliferation has not been adequately excised. Further excision is warranted to ensure that local eradication has been accomplished.	CHILDHOOD-TYPE SPITZOID MELANOMA OF 2.9 MM IN THICKNESS	102270	653	\N	\N	11-12273	\N	DP-16	CGH Validation	IP1001710	AirTable blocks_with_IP_info.csv
1658	12-70514	6	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.4	\N	from Swapna	There is a compound proliferation of large, oval and fusiform melanocytes with abundant, pale amphophilic cytoplasm and large, vesicular nuclei. The lesion has a domed surface and a wedge shaped base. Cohesive aggregations of melanocytes are present within the superficial subcutis, without much dispersion or maturation. There are scattered mitotic figures in both the superficial and deep dermal parts of the lesion.	One hematoxylin and eosin-stained section prepared from outside block labeled L12-8883.	SPITZ; REFERRED FOR CGH OR FISH TESTING	\N	\N	\N	Comparative genomic hybridization shows multiple chromosomal aberrations indicative of melanoma. These include gains involving chromosomes 1p, 8q, and 11q, with losses involving chromosome 9, and a portion of 17q. Many of these are frequent aberrations in melanoma. Currently, I use the term Spitzoid melanoma, childhood type, for an emerging class of lesions that usually but not exclusively occur in children and teens, often lack b-raf mutations (which are present in most melanomas in adults) and have a propensity to involve local lymph nodes. Systemic spread either occurs infrequently or it does so in a delayed fashion compared to adult melanoma. These are findings that would support conservative treatment. Most lesions of this type are deeper, but usually not much wider than their exophytic portions, and even when they are, are well circumscribed. While sentinel nodes are often positive, this positivity has much less predictive value for systemic spread than is the case with adult melanoma.  The lesion is nominally 4.2 mm in thickness, but as implied above, the prognosis in cases of this type is considerably better than in adult melanomas of comparable thickness.	SPITZOID MELANOMA, CHILDHOOD TYPE	104444	647	\N	\N	12-70514	\N	DP-10	PRKC Fused Cases	IP1156331	AirTable blocks_with_IP_info.csv
3091	19111/14.1\n	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-051_1.1	\N	\N	\N	\N	right heel	\N	\N	\N	\N	25	\N	\N	None	\N	AM2-051	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2533	19Rig750007.03.08.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	276	\N	\N	None	\N	CM-37	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2534	19Rig750007.03.08.05	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	276	\N	\N	None	\N	CM-37	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
3106	78821-1a\n	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-002_1.1	\N	\N	\N	\N	Left Hallux	\N	\N	\N	\N	2	\N	\N	None	\N	AM2-002	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3117	79447-a\n	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 2	AM2-007_1.1	\N	\N	\N	\N	Skin	\N	\N	\N	\N	5	\N	\N	None	\N	AM2-007	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3138	610186B\n	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	AM2-029_2	\N	\N	\N	\N	LN	\N	\N	\N	\N	13	\N	\N	None	\N	AM2-029	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2082	17-26432B	60	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10852	238.2	DN	\N	Sections show a compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate and are present above the basal layer.	Skin segment measuring 1.1 x 1.0 x 0.2 cm, quadrisected and entirely submitted in B. PL/PL	A) ATYPICAL BROWN MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS, B) ATYPICAL BROWN PATCH; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS	\N	\N	Scraping	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, EXCISED IN PLANES OF SECTION EXAMINED	139522	530	\N	\N	17-26432	B	DN-055	Dysplastic Nevi	IP99195	AirTable blocks_with_IP_info.csv
3105	61000/00 (LN)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1816	\N	\N	None	\N	SYNAT200	Dysplastic Nevi	\N	AirTable blocks_with_IP_info.csv
3141	AM2_D-72	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1716	\N	\N	None	\N	SYNAT201	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1619	12-22776B5	36	\N	\N	\N	T2a	Primary	\N	\N	\N	\N	\N	\N	172.9	Acral melanoma	\N	Sections show a biopsy site on acral skin with an adjacent, broad proliferation of atypical melanocytes arranged in an irregular pattern within the epidermis, and with similar cells extending broadly into the dermis. There is a dense lichenoid lymphocytic infiltrate. In some areas melanocytes are present in pagetoid array within the epidermis.	Oriented skin excision with curled and twisted appearance, 3.2 x 2.6 x 0.5 cm, including a nearly central 2.3 x 1.6 cm gray-brown area. With the orienting suture at one end placed to the left and designated proximal edge by the surgeon, the far margin is inked blue and the near margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis from proximal to distal and entirely submitted with three sections each in cassettes B1 and B2, two sections each in cassettes B3 through B5, and three sections in cassette B6.	A-B) 172.7: TELEPHONE 3-2384 (SURGICENTER)	\N	Biopsy site w/residual Acral,Toe web	\N	We do not have a record of a prior biopsy on this site. Can you please forward a copy of the previous pathology report to our office. Histopathologic features of possible prognostic importance include:  Level: IV Vascular or lymphatic invasion: absent Dermal mitotic rate: rare mitotic figures Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: not detected Stage: pT2a	BIOPSY SITE WITH RESIDUAL ACRAL MELANOMA, 1.5 MM IN THICKNESS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	666955	2146	\N	\N	12-22776	B5	SYNAT86	2010-2017	IP1096148	AirTable blocks_with_IP_info.csv
3163	BB21-21314	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	B11-01	\N	\N	\N	\N	hard palate	\N	\N	\N	\N	2057	\N	BB	21-21314	\N	SYNAT202	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
3172	Bivona L1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	1674	\N	\N	None	\N	SYNAT203	2010-2017	\N	AirTable blocks_with_IP_info.csv
3173	Bivona L2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	2065	\N	\N	None	\N	SYNAT204	2010-2017	\N	AirTable blocks_with_IP_info.csv
3174	Bivona L3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	1780	\N	\N	None	\N	SYNAT205	2010-2017	\N	AirTable blocks_with_IP_info.csv
3175	Bivona L4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	2258	\N	\N	None	\N	SYNAT206	2010-2017	\N	AirTable blocks_with_IP_info.csv
3176	Bivona L5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	2349	\N	\N	None	\N	SYNAT207	2010-2017	\N	AirTable blocks_with_IP_info.csv
3177	Bivona L6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	2271	\N	\N	None	\N	SYNAT208	2010-2017	\N	AirTable blocks_with_IP_info.csv
3178	Bivona L7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Bivona Lung Cell Line	\N	\N	\N	\N	1992	\N	\N	None	\N	SYNAT209	2010-2017	\N	AirTable blocks_with_IP_info.csv
3179	Bivona L8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Bivona Lung Cell Line	\N	\N	\N	\N	2067	\N	\N	None	\N	SYNAT210	2010-2017	\N	AirTable blocks_with_IP_info.csv
3180	Bivona L9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Bivona Lung Cell Line	\N	\N	\N	\N	1940	\N	\N	None	\N	SYNAT211	2010-2017	\N	AirTable blocks_with_IP_info.csv
3181	Bivona L10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Bivona Lung Cell Line	\N	\N	\N	\N	2241	\N	\N	None	\N	SYNAT212	2010-2017	\N	AirTable blocks_with_IP_info.csv
3182	Bivona L11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Bivona Lung Cell Line	\N	\N	\N	\N	1756	\N	\N	None	\N	SYNAT213	2010-2017	\N	AirTable blocks_with_IP_info.csv
3191	Cell-Line_Xu-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2297	\N	\N	None	\N	SYNAT215	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3133	488836A	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	Mel 1	AM2-039_1	\N	\N	\N	\N	Ungueal	Scraping	\N	\N	\N	15	\N	\N	None	\N	AM2-039	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3017	99-14477	41	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=313	172.6	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, arranged irregularly within the epidermis, flanking a multinodular proliferation of similar melanocytes that do not mature (diminish in size) with descent into the dermis.	Ellipse measuring 0.6 x 0.6 x 0.6 cm, trisected and entirely\nsubmitted, margins inked blue.	6.0 MM MELANOMA	\N	\N	Scraping	Melanocytes extend to a greater depth in the perifollicular adventitial dermis, but these are not conventionally measured to determine thickness.	MELANOMA, 1.0 MM IN THICKNESS, EXTENDING TO THE PERIPHERAL MARGIN	173601	122	\N	\N	99-14477	\N	CCR-005	California Cancer Registry	IP190010	AirTable blocks_with_IP_info.csv
1080	03-17395J T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1048	\N	\N	None	\N	MD-171	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2908	23-49347	56	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=32371	172.4	\N	\N	Sections show a poorly-circumscribed proliferation of nested and solitary melanocytes, some of which have atypical nuclei, distributed irregularly within the epidermis.  There are also clusters of cytologically bland melanocytes in the dermis.	Skin segment measuring 1.1 x 0.8 x 0.1 cm, trisected and entirely submitted. BY/KB	MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA	\N	\N	\N	None	MELANOMA IN SITU, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	173404	1164	\N	\N	23-49347	\N	ME-69	Melanoma Epigenetics	IP434922	AirTable blocks_with_IP_info.csv
1223	06-16008-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	950	\N	\N	None	\N	MD-44	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1381	10-10942A2 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	951	\N	\N	None	\N	MD-45	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2144	17-61001	6	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	The microscopic findings are essentially as described in the accompanying pathology report and in the note above.	Two outside slides, D17-58 (A-B), and one corresponding block (1B).	CHANGING DARK PAPULE LEFT BUTTOCK; HEMOSIDEROTIC DX, SPITZ, BLUE NEVUS/CELLULAR	\N	\N	Scraping	Much of the lesion has a composition of classic Spitz cells, with a portion (including bulbous aggregations that protrude into the deep reticular dermis) that are composed of pulverocytes*. The latter raises the possibility of additional transformation, vs. the presence of a combined deep penetrating nevic component. This is not supported by a beta catenin immunostain, which shows only cytoplasmic membranous staining, and not nuclear staining, as we have seen in a proportion of deep penetrating nevi (manuscript in press, Nature Genetics). There is nearly complete loss of p16 staining, which can correlate with one of the common genomic aberrations seen in melanocytic neoplasm, bi-allelic loss of chr. 9p, where the gene, CDKN2A that encodes p16 is located. This loss of staining can also occur by epigenetic means, and is not entirely specific for melanoma.  A phosphohistone H3/MART-1/tyrosinase two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows at least one deep mitotic figure and several superficial melanocytes with positive nuclei.  Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows a loss involving chr. 9, but not in a pattern that would correlate with homozygous loss of CDKN2A, which encodes p16. There are near-threshold gains and losses around the centromere of chr. 10. These do not have breakpoints around known melanoma-associated genes. Dr. Boris Bastian also viewed the chr. 10 results, and would not make a diagnosis of melanoma based on them.  Following the same microdissection and DNA extraction for CGH, we performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations. Since then, there have been a few cases in which hTERT promoter mutations were not found, but in which the gene was affected by promoter methylation.  Given these findings, an atypical Spitz tumor may be the best category for this lesion. These are neoplasms that have features more atypical than those of a conventional Spitz nevus, but not as worrisome as those of spitzoid melanoma. In aggregate data from over ten studies, local nodal involvment (usually very small deposits) is common, but extranodal metastasis is rare. This dissociation results in sentinel lymph node biopsy having very limited predictive value, and in my opinion, sometimes leading to over-treatment if small deposits lead to completion lymphadenectomy. The value of the latter is questionable, especially given the results of the multi-center trial just reported in N. Engl. J. Med. 2017 Jun 8;376(23):2211-2222.   Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.    *This term is introduced in Massi G, LeBoit P. Histologic Diagnosis of Nevi and Melanoma, 2nd Edition, Springer-Verlag, Berlin Heidelberg, 2014 p. 57, and refers to cells with abundant, pale cytoplasm and dusty appearing melanin, deriving from the Latin term for dust; such cells are only unusually present in Spitz's nevi	ATYPICAL SPITZ TUMOR	173507	245	\N	\N	17-61001	\N	CGH17-135	Nevus Library	IP1790788	AirTable blocks_with_IP_info.csv
2536	19Rig750007.03.11.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	277	\N	\N	None	\N	CM-40	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2106	17-34464A	62	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10857	216.5	DN	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 1.2 x 0.8 x 0.1 cm, trisected and entirely submitted in A. CF/CF	A-B) PT WITH HISTORY OF MM, R/O MM	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	139523	536	\N	\N	17-34464	A	DN-061	Dysplastic Nevi	IP1725842	AirTable blocks_with_IP_info.csv
2107	17-34464B	62	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	DN	\N	The features are similar to those in (A).	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted in B. CF/CF	A-B) PT WITH HISTORY OF MM, R/O MM	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	139523	536	\N	\N	17-34464	B	DN-061	Dysplastic Nevi	IP1725842	AirTable blocks_with_IP_info.csv
1691	13-8208B	55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	173.51	\N	\N	The features are similar to those in (A).	Skin segment measuring 0.5 x 0.3 x 0.2 cm, submitted intact in cassette B.  RS/RS	A-B) R/O BCC	\N	\N	\N	\N	BASAL CELL CARCINOMA, SUPERFICIAL AND NODULAR PATTERNS, EXTENDING TO THE EDGE AND BASE OF THE SPECIMEN	101505	2237	\N	\N	13-8208	B	SYNAT89	2010-2017	IP1192951	AirTable blocks_with_IP_info.csv
1692	13-9682	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2175	\N	\N	13-9682	\N	SYNAT90	2010-2017	\N	AirTable blocks_with_IP_info.csv
1694	13-10776A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2198	\N	\N	13-10776	A1	SYNAT91	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3078	5890/08	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1188	\N	\N	None	\N	NM-001	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3333	DM100	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1709	\N	\N	None	\N	SYNAT284	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3334	DM101	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2094	\N	\N	None	\N	SYNAT285	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3335	DM102	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1981	\N	\N	None	\N	SYNAT286	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
1759	14-15427	34	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	from Swapna	Sections show a roughly oval mass of melanocytes within fibrofatty tissue. At the periphery of the mass are cords and strands of small, round cells with relatively scant pale cytoplasm and monomorphous oval nuclei containing small nucleoli. These cells are separated by thickened collagen bundles in some areas, with a few melanophages. The center of the lesion is more cellular. There are sheets of cells with inconspicuous pale cytoplasm and considerably larger, vesicular nuclei with moderately enlarged reddish nucleoli. Several mitotic figures are evident (but usually 1-2 per mm square). There are occasional multinucleated cells, as well as pseudovascular spaces within the masses of melanocytes. The enclosed immunostains include positive S100 and Melan-A stains, as well as an HMB-45 stain which marks both the smaller and larger melanocytes.	Twelve outside slides, SC14-637:A/1,A/2, XPS-14-931:B/1,B/2 (including five unstained slides cut from block A/1) and two corresponding blocks.	THIRD OPINION, NO HISTORY OF MELANOMA, PRESENT FOR YEARS AND HAD POSSIBLY BEEN INCREASING IN SIZE SLIGHTLY, INTRAOPERATIVELY IT SHELLED OUT EASILY AND DID NOT APPEAR TO BE CONNECTED OR INVOLVING THE OVERLYING EPIDERMIS; THROMBOSED VESSEL	\N	\N	\N	The HMB-45 staining of both components of the lesion is in keeping with both populations deriving from a blue nevus, probably a cellular blue nevus (the quotation marks reflect my unhappiness with the common/cellular dichotomy). The more cellular population lacks the typical nested, or lobular peninsula-like architecture of a cellular blue nevus, nuclei are somewhat enlarged and crowded, and the mitotic rate is higher than in most such lesions. However, the striking cytologic atypia, necrosis and lymphocytic infiltrate seen in some melanomas arising in blue nevi are not evident here. Some would term the current changes atypical blue nevus, a term I am not fond of but may have some applicability in this case. In keeping with this borderline character, comparative genomic hybridization shows an aberration not typically seen in melanoma. There is a gain involving chr. 9, which is often lost in melanoma. A re-excision of this area seems appropriate. In the reference below, the number of aberrations seen in blue nevus-like melanoma was higher than in atypical blue nevi or in conventional cellular blue nevi; with one aberration, and that one not typically associated with melanoma, this intermediate category seems best.  Reference:  Maize JC Jr, McCalmont TH, Carlson JA, Busam KJ, Kutzner H, Bastian BC. Genomic analysis of blue nevi and related dermal melanocytic proliferations. Am J Surg Pathol. 2005 Sep;29(9):1214-20.	ATYPICAL MELANOCYTIC PROLIFERATION ARISING IN A CELLULAR BLUE NEVUS	173788	648	\N	\N	14-15427	\N	DP-11	PRKC Fused Cases	IP1365348	AirTable blocks_with_IP_info.csv
2260	17-119013	23	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18167	216.5	\N	\N	There are increased numbers of single melanocytes at the sides and bases of elongated rete ridges.  There is basilar hyperpigmentation in the affected area.  Small clusters of small, round melanocytes reside in the subjacent dermis.	Skin segment measuring 0.5 x 0.3 x 0.1 cm, bisected and entirely submitted. HD/HD	ATYPICAL DARK BROWN MACULE; ATYPICAL NEVUS VS. LENTIGINOUS NEVUS	\N	\N	\N	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	273588	825	\N	\N	17-119013	\N	LN-05	Lentiginous Nevi 	IP1849540	AirTable blocks_with_IP_info.csv
2262	17-119302B	45	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18171	216.7	\N	\N	Sections show a junctional proliferation of melanocytes in single cell array at the sides and bases of elongated rete ridges. Some small nests are also present. There is hyperpigmentation of the basal layer and melanophages are present in the papillary dermis.	Skin segment measuring 0.9 x 0.7 x 0.1 cm, trisected and entirely submitted in B. CF/CF	A-B) R/O DN, C) R/O BCC	\N	\N	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173798	827	\N	\N	17-119302	B	LN-07	Lentiginous Nevi 	IP1849840	AirTable blocks_with_IP_info.csv
1696	13-12947A2	26	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show nested and solitary melanocytes scattered along the dermal-epidermal junction, and the constituent melanocytes have ample finely melanized cytoplasm. The dermis below this is diffusely fibrotic and holds a superficial lymphohistiocytic infiltrate with admixed melanophages.	Two skin segments received in one specimen bottle. The first skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted. The second skin segment measuring 0.7 x 0.4 x 0.1 cm, bisected and entirely submitted. Both submitted in A. RS/RS	A) R/O RECURRING NEVUS, B) R/O NEVUS	\N	\N	\N	Thank you for assisting us in the retrieval of the original biopsy from this site, which has now been reviewed as our specimen DS13-16516. The prior biopsy demonstrates a compound melanocytic nevus, and by extension the population of melanocytes seen here can be interpreted as representing a persistent melanocytic nevus. There is no evidence of malignancy. Please note that the persistent lesion extends close to the edge of the biopsy in the available sections.	PERSISTENT JUNCTIONAL MELANOCYTIC NEVUS	173527	1907	\N	\N	13-12947	A2	SYNAT92	2010-2017	IP1197690	AirTable blocks_with_IP_info.csv
1730	13-61266A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2250	\N	\N	13-61266	A	SYNAT93	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1704	13-18444A16	88	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	709.01	\N	\N	Sections show absence of melanocytes along the junction.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A) VITILIGINOUS SKIN - DEPIGMENTED; R/O CTCL, B) NORMAL SKIN; TELEPHONE: 810-5563 (SHARLENE-DAUGHTER/LM)	\N	\N	\N	A Melan-A stain shows absence of melanocytes at the dermo-epidermal junction a finding of late stage vitiligo.  Neither biopsy shows any significant amount of inflammation.  There is no evidence of a lymphoproliferative disorder.	VITILIGO	173405	2295	\N	\N	13-18444	A16	SYNAT95	Unknown	IP1203187	AirTable blocks_with_IP_info.csv
1334	08B9531 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1197	\N	\N	None	\N	NM-010	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1731	13-62943	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2004	\N	\N	13-62943	\N	SYNAT96	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1333	08B8345 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1198	\N	\N	None	\N	NM-011	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1428	10B339 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1199	\N	\N	None	\N	NM-012	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1118	04-11144C T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1031	\N	\N	None	\N	MD-152	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3364	HW Acral #1 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2185	\N	\N	None	\N	SYNAT288	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3365	HW Acral #1 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1947	\N	\N	None	\N	SYNAT289	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3366	HW Acral #2 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2047	\N	\N	None	\N	SYNAT290	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3367	HW Acral #2 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2154	\N	\N	None	\N	SYNAT291	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2538	19Rig750007.03.12.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	278	\N	\N	None	\N	CM-41	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2539	19Rig750007.03.12.05	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	278	\N	\N	None	\N	CM-41	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2537	19Rig750007.03.12.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	278	\N	\N	None	\N	CM-41	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
3004	98-16285A2	37	\N	\N	\N	\N	\N	\N	3	\N	FFPE	\N	\N	172.5	\N	\N	Sections show a compound proliferation of melanocytes arrayed as\nirregular nests along the epidermal-dermal junction, with nests and\nsheets of atypical melanocytes in the underlying dermis.  There is a\nbandlike infiltrate of lymphocytes in the papillary dermis.	Ellipse, 3.5 x 1.7 x 1.2 cm, serially sectioned and submitted, tips\nreturned to container.	CLINICAL DIAGNOSIS - VIOLACEOUS NODULE, R/O MELANOMA	\N	\N	Scraping	The melanoma extends near to the periphery of the specimen.  In light of the changes of regression, the microstage measurement listed above may underestimate the prognostic risk of this lesion.	MELANOMA, 3.2 MM IN THICKNESS, WITH SUPERIMPOSED LICHENOID LYMPHOCYTIC INFILTRATE AND CHANGES OF REGRESSION	139524	195	\N	\N	98-16285	A2	CCR-217	California Cancer Registry	IP153858	AirTable blocks_with_IP_info.csv
2421	19-9438B	84	\N	\N	\N	\N	\N	\N	10	0	FFPE	\N	\N	216.6	\N	MAP2K1	Sections show a dermal proliferation of melanocytes with slightly enlarged round or ovoid nuclei, and scant cytoplasm. The cells are positioned in discrete aggregates or singly between thickened collagen bundles in the reticular dermis.	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely submitted in B. KC/KC	A) PINK PEARLY PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA, B) RED BROWN PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS	\N	\N	FFPE	\N	INTRADERMAL MELANOCYTIC NEVUS	529698	1381	\N	\N	19-9438	B	SN-18	Sclerotic Nevi	IP182592	AirTable blocks_with_IP_info.csv
2259	17-118980	44	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18173	216.6	\N	\N	Sections show a junctional proliferation of melanocytes in single cell array at the sides and bases of elongated rete ridges.  Some small nests are also present. There is hyperpigmentation of the basal layer and melanophages in the papillary dermis.	Cylindrical skin segment, 0.6 cm in diameter and 0.3 cm in thickness, bisected and entirely submitted. PL/PL	R/O DYSPLASTIC NEVUS VS. MM	\N	\N	\N	Melan-a immunohistochemistry demonstrates that the lentiginous junctional melanocytic proliferation is limited to the biopsy. Melanocytes are also limited to the lower epidermis and spare suprapapillary plates.	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	222612	828	\N	\N	17-118980	\N	LN-08	Lentiginous Nevi 	IP1629847	AirTable blocks_with_IP_info.csv
2270	17-120790	59	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18175	216.7	\N	\N	Sections show a junctional proliferation of melanocytes in single cell array at the sides and bases of elongated rete ridges.  Some small nests are also present. There is hyperpigmentation of the basal layer and melanophages in the papillary dermis.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted. CF/CF	R/O ATYPIA	\N	\N	\N	The benign diagnosis listed above is based in part upon the presumption that nearly the entirety of this lesion has been captured by this biopsy, indicating that the lesion at hand is small. If this is instead a partial biopsy of a larger lesion, then the present histopathology may not be fully representative.	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	17722	829	\N	\N	17-120790	\N	LN-09	Lentiginous Nevi 	IP1851350	AirTable blocks_with_IP_info.csv
2267	17-120276	43	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18183	216.5	\N	\N	Sections show a proliferation of solitary melanocytes and small nests of them arrayed along the sides and bases of elongated and pigmented rete ridges. There are many melanophages within the underlying superficial dermis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/HD	6 MM HYPERPIGMENTED MACULE; R/O MELANOMA	\N	\N	\N	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173526	833	\N	\N	17-120276	\N	LN-13	Lentiginous Nevi 	IP1850825	AirTable blocks_with_IP_info.csv
2220	17-110828C	56	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18185	238.2	\N	\N	There is a proliferation of melanocytes, mostly at the dermo-epidermal junction. Most are arranged singly at the sides and bases of elongated rete ridges, but some small nests are also present. There is hyperpigmentation of the basal layer. There is solar elastosis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted in C. HD/HD	A) 4 MM SCALY PAPULE; AK VS. SCC, B) 7 MM SCALY PAPULE; AK VS. SCC, C) 4 MM BROWN MACULE; NEVUS, POSS ATYPIA, D) 6 MM BROWN PAPULE; NEVUS, POSS ATYPIA	\N	\N	\N	The proliferation in (C) has a lentiginous pattern and occurs in sun damaged skin with close extension to the specimen periphery. Given the histopathologic overlap of early lentigo maligna melanoma in situ and lentiginous nevi, either conservative re-excision or clinical follow up to monitor for recurrence is recommended.	JUNCTIONAL PROLIFERATION OF MELANOCYTES, FAVOR A LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173610	834	\N	\N	17-110828	C	LN-14	Lentiginous Nevi 	IP1614923	AirTable blocks_with_IP_info.csv
3506	LAL-L Cells	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas 	\N	\N	\N	\N	1685	\N	\N	None	\N	SYNAT320	2010-2017	\N	AirTable blocks_with_IP_info.csv
2177	17-72585A	16	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	238.2	\N	\N	Sections show a proliferation of enlarged melanocytes in irregular array within the epidermis and dermis amidst fibrosis, flanked by a second population of smaller melanocytes arranged as cords and strands between collagen bundles of the reticular dermis and around adnexal structures.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted in A. The contents of the specimen bottle filtered. RS/RS	A) MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED NEVUS WITH POSSIBLE CYST, B) MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOTIC NEVUS, C) NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED NEVUS	\N	\N	\N	This lesion is atypical in that it contains an area with enlarged melanocytes in irregular array at the dermo-epidermal junction and in the dermis, extending to the base. I performed immunoperoxidase staining in order to further evaluate this lesion. The cells in the area described above are strongly positive for p16 and show no labeling with a Ki-67 stain, supporting the notion that this is not melanoma. I have also shared this case with my colleagues, Dr. Philip LeBoit and Dr. McCalmont, who agree with these findings. Conservative re-excision of this site is warranted.	ATYPICAL COMPOUND MELANOCYTIC PROLIFERATION ARISING WITHIN A COMPOUND MELANOCYTIC NEVUS, CONGENITAL PATTERN, EXTENDING TO THE BASE OF THE SPECIMEN	529698	565	\N	\N	17-72585	A	DN-090	Dysplastic Nevi	IP1177975	AirTable blocks_with_IP_info.csv
2178	17-72585B	16	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.4	\N	\N	Sections show a compound proliferation of melanocytes, with nested and solitary melanocytes arrayed along the junction.  There are clusters and syncytia of melanocytes in the superficial dermis, and striking cytologic atypism is not apparent.  Small melanocytes are present amongst reticular dermal collagen bundles in some foci in the uppermost reticular dermis.	Skin segment measuring 0.8 x 0.6 x 0.2 cm, bisected and entirely submitted in B. RS/RS	A) MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED NEVUS WITH POSSIBLE CYST, B) MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOTIC NEVUS, C) NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES	173404	565	\N	\N	17-72585	B	DN-090	Dysplastic Nevi	IP1177975	AirTable blocks_with_IP_info.csv
3511	M230 Imat A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2162	\N	\N	None	\N	SYNAT321	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3512	M230 Imat A3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1862	\N	\N	None	\N	SYNAT322	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3538	MB1424	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2282	\N	\N	None	\N	SYNAT323	2010-2017	\N	AirTable blocks_with_IP_info.csv
2258	17-118904B	89	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18187	216.6	\N	\N	There are increased numbers of single melanocytes and small nests of them positioned along the sides and bases of elongated rete ridges. Small, round melanocytes are present in small collections in the subjacent papillary dermis. There are flecks of melanin within lamellar hyperkeratosis above the lesion, hyperpigmentation of the lesional epidermis, and a subjacent infiltrate of lymphocytes and melanophages.	Skin segment measuring 0.5 x 0.5 x 0.1 cm, bisected and entirely submitted in B. CF/CF	A) R/O MALIGNANCY, B) NEVUS, R/O ATYPIA	\N	\N	\N	\N	HYPERMELANOTIC LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	173602	835	\N	\N	17-118904	B	LN-15	Lentiginous Nevi 	IP1849428	AirTable blocks_with_IP_info.csv
2261	17-119079A	51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18189	216.5	\N	\N	There are increased numbers of single melanocytes at the sides and bases of elongated rete ridges. There is basilar hyperpigmentation in the affected area. Clusters of small, round melanocytes reside in the subjacent dermis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted in A. RS/RS	A) NEOPLASM OF UNCERTAIN BEHAVIOR. . SCC. B) NEOPLASM OF UNCERTAIN BEHAVIOR. . SCC. C) NEOPLASM OF UNCERTAIN BEHAVIOR. . SCC.	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	273588	836	\N	\N	17-119079	A	LN-16	Lentiginous Nevi 	IP1692384	AirTable blocks_with_IP_info.csv
2179	17-72585C	16	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.7	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability, arrayed as nests along the junctional zone and within the underlying dermis.  The overlying epidermis is papillated and hyperkeratotic.	Skin segment measuring 1.0 x 0.8 x 0.2 cm, trisected and entirely submitted in C. RS/RS	A) MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED NEVUS WITH POSSIBLE CYST, B) MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOTIC NEVUS, C) NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS	17723	565	\N	\N	17-72585	C	DN-090	Dysplastic Nevi	IP1177975	AirTable blocks_with_IP_info.csv
1254	06-65105	84	\N	\N	\N	None	None	None	4	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1691	172.5	\N	\N	Sections show a proliferation of large melanocytes with large, pleomorphic vesicular nuclei and abundant, pale cytoplasm.  There is an intraepidermal component, and a massive, nodular dermal one. Nests of melanocytes are distributed at irregular intervals along the dermo-epidermal junction, and are focally confluent.  There are foci in which single melanocytes predominate as well. There are some melanocytes scattered above the basal layer in such areas. The dermal component is dominate by a large oval mass in which mitoses are easily found, with no maturation toward the base of the lesion. The papillary dermis is thickened and fibrotic at one the edge of the specimen, with fewer lesional melanocytes than in the rest of the specimen.	Ellipse, 1.5 x 1.1 x 1.0 cm, including a central 1.2 x 1.0 cm lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections.	RAPIDLY GROWING FIRM NODULAR LESION; MELANOMA, ? FIBROMA/ SARCOMA, ? LIPOMA, ?	\N	\N	Scraping	Histopathologic features of possible prognostic importance include: Level: V Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: high Perineural invasion: absent Ulceration: present Regression: present* Microsatellite metastasis: absent**  *The extent of regression cannot be evaluated after complete excision (some regard the extent, rather than the mere presence of regression as important for prognosis, but this is already a high risk lesion **This finding is best evaluated after complete excision	MELANOMA, 7.3 MM  IN THICKNESS	173540	206	\N	\N	06-65105	\N	CCR-235	California Cancer Registry	IP592825	AirTable blocks_with_IP_info.csv
3556	P57	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2277	\N	\N	None	\N	SYNAT324	Mutation Burden in Normal Skin	\N	AirTable blocks_with_IP_info.csv
3557	P57-A-1.0mm	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2176	\N	\N	None	\N	SYNAT325	Mutation Burden in Normal Skin	\N	AirTable blocks_with_IP_info.csv
3558	P57-A-2.0mm	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2170	\N	\N	None	\N	SYNAT326	Mutation Burden in Normal Skin	\N	AirTable blocks_with_IP_info.csv
3559	P57-B-1.0mm	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2028	\N	\N	None	\N	SYNAT327	Mutation Burden in Normal Skin	\N	AirTable blocks_with_IP_info.csv
3560	P57-B-2.0mm	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2107	\N	\N	None	\N	SYNAT328	Mutation Burden in Normal Skin	\N	AirTable blocks_with_IP_info.csv
3561	PG_8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1706	\N	\N	None	\N	SYNAT329	2010-2017	\N	AirTable blocks_with_IP_info.csv
3566	sh-H3K4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1926	\N	\N	None	\N	SYNAT330	2010-2017	\N	AirTable blocks_with_IP_info.csv
3567	sh-H3K27	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1728	\N	\N	None	\N	SYNAT331	2010-2017	\N	AirTable blocks_with_IP_info.csv
3568	sh-Input	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1790	\N	\N	None	\N	SYNAT332	2010-2017	\N	AirTable blocks_with_IP_info.csv
1636	12-26470	4	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	Sections show an asymmetrical compound proliferation of fusiform and epithelioid melanocytes that are enlarged. Within the epidermis, which is centrally thinned, single melanocytes and nests are distributed erratically, and some scatter above the junction can be seen. In fibrotic dermis below this, two zones of melanocytes can be seen. In a superficial area, slightly fibrotic dermis holds non-maturing nests and syncytia of large epithelioid melanocytes, several of which can be found in mitosis. A patchy juxtaposed lymphocytic infiltrate is present concurrently. In a subjacent sclerotic zone, similar melanocytes are distributed interstitially as cords and thin fascicles.	Two outside slides, WCRS12-8356/DRMC12-2194 (MR:13117741). One corresponding block received 4-20-12.	RAPIDLY GROWING 9 MM RED PAPULE WITH A DARK BROWN PINPOINT MACULE; SPITZ'S NEVUS VS. MELANOMA VS. SPITZOID MELANOMA OF CHILDHOOD	\N	\N	Scraping	ADDENDUM, May 18, 2012: As I reported previously, the differential diagnosis includes a highly unconventional Spitz nevus on one hand and childhood-type spitzoid melanoma on the other. Based solely upon conventional microscopical parameters, an unequivocal diagnosis is not possible. This is the type of challenging case for which comparative genomic hybridization (CGH) can be of value, and we proceeded with CGH analysis, as per your request. After extraction of tumoral DNA from the tissue block, application of aCGH revealed small segmental areas of gain and loss in chromosome 11q but other significant chromosomal gains or losses are lacking. Interestingly, these areas of anomalous genomic copy number do not involve the location of the CCND1 (cyclin-D1) gene, as might be seen in association with melanoma. In summary, the combination of results derived from conventional microscopy coupled with aCGH has yielded an ambiguous result. We have not identified microscopic findings or molecular aberrations that are conclusively diagnostic of childhood-type melanoma. Summing all of the available information, I favor an unconventional Spitz nevus as the best overall classification for this case. Complete reexcision of this site will be necessary in follow-up, but no other surgical intervention is indicated once local clearance has been achieved.  Dr. Denianke, I would be happy to discuss this case with you by telephone.	ATYPICAL COMPOUND SPITZOID MELANOCYTIC PROLIFERATION, TRANSECTED AT THE SPECIMEN PERIPHERY	424655	240	\N	\N	12-26470	\N	CGH12-109	Nevus Library	IP1112288	AirTable blocks_with_IP_info.csv
2540	19Rig750007.04.01.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	279	\N	\N	None	\N	CM-42	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2063	17-20244B	84	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10841	216.5	DN	\N	Sections show a compound array of melanocytes, with single cells and nests arrayed along the epidermal-dermal junction, distributed along the sides and bases of elongated rete. There are similar melanocytes in the subjacent superficial dermis.	Two skin fragments measuring 0.9 x 0.7 x 0.1 cm in aggregate, one is bisected and all entirely submitted in B. CF/CF	A-B) R/O IRRITATED ID NEVUS, 0.6 X 0.6 CM	\N	\N	Scraping	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	139523	560	\N	\N	17-20244	B	DN-085	Dysplastic Nevi	IP1164464	AirTable blocks_with_IP_info.csv
2213	17-99294B	22	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18192	216.5	\N	\N	Sections show a proliferation of melanocytes with a biphasic pattern (arrayed as 2 populations of cells).  One population consists of small melanocytes with ovoid nuclei, arrayed in a lentiginous pattern along the epidermal-dermal junction (with single cells and nests along the sides and bases of rete) and as small clusters in the superficial dermis.  The second population consists of melanocytes that exhibit finely pigmented cytoplasm, and there are intervening melanophages.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in B. HD/HD	A) CYT17-1556, R/O ATYPICAL, PINK BROWN MACULE WITH IRREGULAR BORDERS, LESION SIZE: 5 MM, B) CYT17-1557, R/O ATYPICAL, DARK BACK MACULE, LESION SIZE: 3 MM	\N	\N	\N	\N	COMBINED MELANOCYTIC NEVUS	528522	837	\N	\N	17-99294	B	LN-17	Lentiginous Nevi 	IP1154787	AirTable blocks_with_IP_info.csv
1585	12-12467	31	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	Melanocytic Nevus	\N	Sections show a domed segment of skin, with nests, cords and strands of small round melanocytes in the dermis.	Skin segment measuring 0.4 x 0.3 x 0.2 cm, submitted intact in cassette B.	A) 0.7 X 0.6 CM; NEOP VS. ID NEVUS, B) 0.5 X 0.5 CM; NEOP VS. ID NEVUS, C) 0.7 X 0.6 CM; NEOP VS. DYSP NEVUS, D) 0.7 X 0.7 CM; NEOP VS. ID NEVUS	\N	Predominately intradermal, rt breast	\N	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	101581	1834	\N	\N	12-12467	\N	SYNAT355	2010-2017	IP1098283	AirTable blocks_with_IP_info.csv
1588	12-12647	52	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.51	Melanocytic Nevus	\N	Sections show a neoplastic proliferation of atypical, peripherally palisaded basaloid cells arranged as aggregations attached to the undersurface of the epidermis and as nodules within the dermis.	Skin segment measuring 1.0 x 0.9 x 0.1 cm, trisected and entirely submitted with one additional fragment.	R/O SCC: TELEPHONE 925-212-5590	\N	Intradermal, right breast	\N	None	BASAL CELL CARCINOMA, SUPERFICIAL AND NODULAR PATTERNS, EXTENDING TO THE DEEP MARGIN	333504	2246	\N	\N	12-12647	\N	SYNAT358	2010-2017	IP858006	AirTable blocks_with_IP_info.csv
1587	12-12626	28	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	Cellular Dermatofibroma 	\N	Sections show a cellular proliferation of spindled and stellate cells, arranged amongst thickened collagen bundles in some areas. The overlying epidermis is acanthotic.	Cylindrical skin segment, 0.8 cm in diameter and 0.5 cm in thickness, trisected and totally submitted.	DF	\N	Right Arm	\N	None	CELLULAR DERMATOFIBROMA	173602	1678	\N	\N	12-12626	\N	SYNAT359	2010-2017	IP1098442	AirTable blocks_with_IP_info.csv
1596	12-18438A	81	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	232.5	SCC, in situ	\N	The epidermis is thickened, with widened rete ridges and keratinocytes that confluently have large, atypical nuclei.  Keratinocytes in the basal layer have smaller nuclei than do the cells above them in some areas.  There are patchy infiltrates of lymphocytes.	Skin segment measuring 1.0 x 0.5 x 0.1 cm, bisected and entirely submitted.	? BOWEN'S DISEASE	\N	\N	\N	The neoplasm extends to the edge of the specimen.	SQUAMOUS CELL CARCINOMA IN SITU (BOWEN'S DISEASE)	102538	2083	\N	\N	12-18438	A	SYNAT360	2010-2017	IP1104255	AirTable blocks_with_IP_info.csv
1151	05-01411C N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	944	\N	\N	None	\N	MD-38	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1150	05-01411 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	944	\N	\N	None	\N	MD-38	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2183	17-74882B	58	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	The features are similar to those in (A).	Skin segment measuring 1.2 x 0.8 x 0.1 cm, trisected and entirely submitted in B. CF/PL	A) ATYPICAL NEVUS VS. BENIGN NEVUS VS. MELANOMA. 0.8 CM, UNEVEN COLOR. CC LEENA KAMAT, MD. B) ATYPICAL NEVUS VS. BENIGN NEVUS VS. MELANOMA. 1.0 CM, UNEVEN COLOR.	\N	\N	\N	There are no worrisome features.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE BASE OF THE SPECIMEN	172541	581	\N	\N	17-74882	B	DN-106	Dysplastic Nevi	IP1804838	AirTable blocks_with_IP_info.csv
2182	17-74882A	58	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 1.1 x 0.8 x 0.1 cm, trisected and entirely submitted in A. CF/PL	A) ATYPICAL NEVUS VS. BENIGN NEVUS VS. MELANOMA. 0.8 CM, UNEVEN COLOR. CC LEENA KAMAT, MD. B) ATYPICAL NEVUS VS. BENIGN NEVUS VS. MELANOMA. 1.0 CM, UNEVEN COLOR.	\N	\N	\N	There are no worrisome features.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	139510	581	\N	\N	17-74882	A	DN-106	Dysplastic Nevi	IP1804838	AirTable blocks_with_IP_info.csv
2542	19Rig750007.04.03.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	281	\N	\N	None	\N	CM-44	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1859	15-22166 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	941	\N	\N	None	\N	MD-35	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1866	15-32174 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	942	\N	\N	None	\N	MD-36	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1591	12-13152	71	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	Melanocytic Nevus	\N	Sections show a broad compound proliferation of melanocytes, with a junctional component composed of nested and single melanocytes that extend lateral to an underlying papillary dermal component of similar cells.  The papillary dermis shows fibrosis, some in a lamellar configuration.	Skin segment measuring 1.3 x 1.2 x 0.1 cm, quadrisected and entirely submitted.	UNKNOWN DURATION OF 7 MM, WELL-DEMARCATED, 1/2 TAN, 1/2 BROWN MACULE; R/O DYSPLASTIC NEVUS	\N	Compound, Clarks or Dysplastic type, back	\N	The neoplasm extends to the base of the specimen in one small focus but is widely excised towards the periphery. The findings are well within the spectrum of those seen in dysplastic (Clark's) nevi. There are no microscopic features that compel re-excision.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE	273588	2340	\N	\N	12-13152	\N	SYNAT361	2010-2017	IP1098968	AirTable blocks_with_IP_info.csv
1590	12-12750B	91	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	173.32	SCC	\N	Sections show a proliferation composed of atypical keratinocytes, arrayed as irregular nests that infiltrate the dermis.  There are keratotic whorls and pale keratinocytes. The mitotic rate is high.	Skin segment measuring 0.8 x 0.7 x 0.2 cm, trisected and entirely submitted in cassette B.	A) ? LARGE ACTINIC KERATOSIS OR IRRITATED SEBORRHEIC KERATOSIS, R/O SQ CELL CA (2 PIECES), B) ? IRRITATED SEBORRHEIC KERATOSIS, R/O BASAL OR SQ CELL CA	\N	Forehead	\N	\N	SQUAMOUS CELL CARCINOMA, EXTENDING TO THE DEEP BIOPSY MARGIN	123398	1812	\N	\N	12-12750	B	SYNAT362	2010-2017	IP114451	AirTable blocks_with_IP_info.csv
1599	12-19187A	48	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.7	Dermatofibroma	\N	There is a dermal proliferation of spindled cells, arranged as interconnecting fascicles. These are more compactly arranged in the center of the lesion than at its periphery, where these cells progressively are interspersed between reticular dermal collagen bundles. The overlying epidermis is thickened.	Cylindrical skin segment, 0.5 cm in diameter and 0.4 cm in thickness, bisected and entirely submitted in cassette A.	A) INDURATED PAPULE; FAVOR DF, B) SKIN-COLORED TRANSLUCENT PAPULE; FAVOR NF VS. NEVUS	\N	Shin	\N	\N	DERMATOFIBROMA	187724	2113	\N	\N	12-19187	A	SYNAT364	2010-2017	IP1105004	AirTable blocks_with_IP_info.csv
1606	12-22172	29	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.1	SCC, in situ	\N	Sections show a predominantly dermal proliferation of melanocytes without pronounced nuclear variability.	Ellipse, 0.9 x 0.5 x 0.4 cm, including a central 0.6 x 0.4 cm tan-brown area. With the margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in one cassette.	6 MM GROWING PAPULE; R/O IDN VS. OTHER	\N	Bowen's Disease,Left lateral back	\N	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	123122	1892	\N	\N	12-22172	\N	SYNAT365	2010-2017	IP1107990	AirTable blocks_with_IP_info.csv
2980	96-18458C	59	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1299	172.4	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly within the epidermis, with foci of pagetoid upward scatter.  Some melanocytes have atypical nuclei.  Aggregations of similar melanocytes are present in the dermis.  There are sheets of atypical melanocytes in the superficial dermis.	Ellipse, 6 x 2.8 x 1 cm, central portion serially sectioned and\nsubmitted with one section each in blocks A through H, margins inked\nblue, tips returned to container.	BLEEDING FRIABLE NODULE; CLINICAL DIAGNOSIS - MELANOMA, DATA ON FILE	\N	\N	\N	This is a high risk primary lesion.  As there is extensive ulceration, the microstage measurment probably underestimates the prognostic risk of this lesion.	MELANOMA, AT LEAST 3.5 MM IN THICKNESS, WITH INTRAEPIDERMAL MELANOMA EXTENDING NEAR TO THE PERIPHERAL BIOPSY MARGIN	104444	194	\N	\N	96-18458	C	CCR-215	California Cancer Registry	IP95222	AirTable blocks_with_IP_info.csv
1723	13-48798	82	\N	\N	\N	T2a	Primary	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly and focally somewhat confluently along the junction. In the dermis and upper subcutis below this, there is a population of enlarged fusiform melanocytes with finely melanized cytoplasm coupled with a permeative lymphohistiocytic infiltrate with admixed melanophages and extensive dermal fibroplasia.	Six outside slides, DN13-21643, and one corresponding block.	HISTORY OF MELANOMA (1981), 1.5 X 3 CM LESION GREW IN 2 YEARS; MELANOMA? PRIMARY OR METASTATIC?	\N	\N	\N	Given the overall histopathologic configuration and the presence of melanoma in situ involving the epidermis and focally involving adnexa, I believe this biopsy demonstrates a primary blue nevus-like melanoma rather than metastatic melanoma. SOX-10 staining was included in our assessment and demonstrates avid labeling of the component of melanoma in situ and also demonstrates strong positive labeling of a population of atypical melanocytes in the dermis, thereby confirming that a component of invasive melanoma is present. There is also extensive partial regression in the dermis. With respect to staging, this melanoma is between 1-2 mm in thickness and lacks associated ulceration. Therefore, it represents melanoma of stage pT2a (2009 AJCC Guidelines). (Since the thickness of the zone of regression extends to a thickness of 2.9 mm, one could also also make a case that AJCC stage pT3a would be appropriate.) The final microstage parameters can be reassessed once this melanoma has been fully extirpated.	MELANOMA OF AT 1.85 MM IN THICKNESS, TRANSECTED AT THE PERIPHERY OF THE BIOPSY	173620	2245	\N	\N	13-48798	\N	SYNAT98	2010-2017	IP1290801	AirTable blocks_with_IP_info.csv
2918	59/15	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1241	\N	\N	None	\N	NM-67	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3047	718/12a	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1242	\N	\N	None	\N	NM-68	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1602	12-21726A	29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.7	Dermatofibroma	\N	Sections show a dome shaped, cellular proliferation of spindled and stellate cells, arranged amongst thickened collagen bundles in some areas. The overlying epidermis is acanthotic.	Ellipse, 1.7 x 1.0 x 0.4 cm, including a central 0.8 x 0.7 cm pearly pink and raised area.  With the peripheral and deep margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections each in cassettes A and B.	POSSIBLE IDN, R/O MELANOTIC MELANOMA	\N	A Melan-A stain (-), leg	\N	A Melan-A stain is negative.	CELLULAR DERMATOFIBROMA	173740	1856	\N	\N	12-21726	A	SYNAT366	2010-2017	IP1107544	AirTable blocks_with_IP_info.csv
1628	12-22901A	67	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.3	Melanocytic Nevus	\N	Sections show a predominantly dermal proliferation of melanocytes without pronounced nuclear variability.	Ellipse, 1.1 x 0.6 x 0.35 cm, including a central 0.7 x 0.5 cm white-tan raised area.  With the margins inked blue, the specimen is serially sectioned and entirely submitted with three sections each in cassettes A and B.	NEVUS	\N	Intradermal, forehead	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	123398	1677	\N	\N	12-22901	A	SYNAT367	Melanocytic Nevus	IP1108719	AirTable blocks_with_IP_info.csv
2189	17-81767C	72	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, and the dermal melanocytes diminish in size with descent.  The overlying epidermis is acanthotic, with elongated rete that intertwine.	Skin segment measuring 1.1 x 0.8 x 0.1 cm, trisected and entirely submitted in C. RS/RS	A) POSSIBLE BASAL CELL, B-C) GROWING LESIONS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS	101532	594	\N	\N	17-81767	C	DN-119	Dysplastic Nevi	IP339970	AirTable blocks_with_IP_info.csv
2188	17-81767B	72	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, with nested and solitary melanocytes arrayed along the junction.  There are clusters and syncytia of melanocytes in the superficial dermis, and striking cytologic atypism is not apparent.  Small melanocytes are present amongst reticular dermal collagen bundles in some foci in the uppermost reticular dermis. In one area there is marked fibrosis of the superficial dermis with melanocytes intercalated between thickened collagen bundles.	Skin segment measuring 1.3 x 1.2 x 0.1 cm, serially sectioned and entirely submitted with six sections in B. RS/RS	A) POSSIBLE BASAL CELL, B-C) GROWING LESIONS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES WITH AREAS OF FIBROSIS	152589	594	\N	\N	17-81767	B	DN-119	Dysplastic Nevi	IP339970	AirTable blocks_with_IP_info.csv
3131	115016	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1243	\N	\N	None	\N	NM-69	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1749	14-3598	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2069	\N	\N	14-3598	\N	SYNAT102	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3104	46976B	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1244	\N	\N	None	\N	NM-70	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3080	6258/2015	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1245	\N	\N	None	\N	NM-71	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3100	21831/14	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1246	\N	\N	None	\N	NM-72	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1620	12-22794A	49	\N	\N	\N	T1b	Primary	\N	\N	\N	\N	\N	\N	172.6	Mel	\N	Sections show an asymmetrical proliferation of nested and solitary melanocytes with atypical nuclear features, and dusty cytoplasms. They are arrayed irregularly within the epidermis, with foci of suprabasal scatter of cells.  Larger clusters of similar melanocytes are present in the dermis.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted in cassette A.	A) R/O PIGMENTED BCC, B) R/O BCC: TELEPHONE 530-365-9295 (OK TO LM)	\N	Level III, right shoulder	\N	Histopathologic features of possible prognostic importance include: Level:III Tumor infiltrating lymphocytes: absent Vascular or lymphatic invasion: not detected Dermal mitotic rate: 1/ HPF Perineural invasion: not detected Ulceration: not detected Regression: not detected Microsatellite metastasis: not detected Solar elastosis: moderate Stage: pT1b	MELANOMA, 0.80 MM IN THICKNESS, EXTENDING TO THE PERIPHERY OF THE BIOPSY	173620	1873	\N	\N	12-22794	A	SYNAT370	2010-2017	IP454633	AirTable blocks_with_IP_info.csv
1608	12-22582A	16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.4	Melanocytic Nevus	\N	Sections show a proliferation of melanocytes arrayed singly and as nests along the epidermal-dermal junction, with clusters and strands of similar cells in the underlying dermis.  In some areas within dermal clusters, melanocytes are separated by clefts, in a pattern that resembles vascular channels.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted in cassette A.	A) NEOP VS. ATYP POLYP NEVUS, B) NEOP VS. ATYP NEVUS, C) 0.2 X 0.3 CM; NEOP VS. DYSPL NEVUS	\N	Compound,  Neck	\N	\N	COMPOUND MELANOCYTIC NEVUS	173441	2248	\N	\N	12-22582	A	SYNAT84	2010-2017	IP1108400	AirTable blocks_with_IP_info.csv
1616	12-22604	83	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.31	BCC	\N	Sections show a neoplastic proliferation of atypical basaloid keratinocytes arrayed as jagged aggregates in infiltrative array, and the surrounding stroma displays evidence of coarse fibrosis in the form of thickened (keloidal) collagen bundles.	Skin segment measuring 0.4 x 0.25 x 0.1 cm. Submitted intact.	PEARLY TELANGIECTATIC PAPULE; R/O BCC	\N	Infiltrative, Keloidal stroma, nasal bridge	\N	None	INFILTRATIVE BASAL CELL CARCINOMA, WITH KELOIDAL STROMA, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	103341	1980	\N	\N	12-22604	\N	SYNAT377	2010-2017	IP1108422	AirTable blocks_with_IP_info.csv
10036	12-22720A	46	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	Leiomyoma	Upper back	Sections show a fascicled dermal proliferation of spindled cells with blunt-ended nuclei and eosinophilic cytoplasm situated in the superficial reticular dermis.  Mitotic figures are inconspicuous.	Ellipse, 1.8 x 0.7 x 0.8 cm, including 0.5 x 0.4 cm central raised area. With the peripheral and deep margins inked blue, the specimen is serially sectioned left to right perpendicular to the long axis and entirely submitted with four sections in cassette A1, three sections in cassette A2.	\N	\N	\N	\N	\N	LEIOMYOMA, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	174533	1432	\N	\N	12-22720	A	SYNX29	\N	IP118827	Consolidated_data_final.csv
1621	12-22868	11	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	Melanocytic Nevus	\N	Sections show a dermal proliferation of melanocytes arrayed as nests and syncytia that diminish in size with descent in the dermis. The overlying epidermis shows a papillated configuration, with elongated rete that focally intertwine.	Skin segment measuring 0.9 x 0.8 x 0.6 cm, trisected and entirely submitted.	R/O TRAUMATIZED NEVUS	\N	Intradermal, back	\N	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	173532	1829	\N	\N	12-22868	\N	SYNAT378	Melanocytic Nevus	IP1108686	AirTable blocks_with_IP_info.csv
2552	19Rig750007.04.13.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	289	\N	\N	None	\N	CM-54	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2553	19Rig750007.04.13.08	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	289	\N	\N	None	\N	CM-54	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
3035	156/13	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1247	\N	\N	None	\N	NM-73	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3060	2017-19575	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1248	\N	\N	None	\N	NM-74	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3462	K3920/19 A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1249	\N	\N	None	\N	NM-75	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3082	10226 2	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1250	\N	\N	None	\N	NM-76	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3515	M32727/18 A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1251	\N	\N	None	\N	NM-77	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3513	M21326/18 A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1252	\N	\N	None	\N	NM-78	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3086	14531/14	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1253	\N	\N	None	\N	NM-79	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1752	14-4989D3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1690	\N	\N	14-4989	D3	SYNAT103	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3081	8716/2016	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1254	\N	\N	None	\N	NM-80	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3514	M31513/18	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1255	\N	\N	None	\N	NM-81	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1624	12-22886	35	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.4	Melanocytic Nevus	\N	Sections show nests, cords and strands of small round melanocytes in the dermis.  These cells mature with descent.  There are admixed adipocytes.	Skin segment measuring 0.4 x 0.4 x 0.2 cm, bisected and entirely submitted.	IDN	\N	Lipoid Metaplasia, right neck	\N	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS WITH LIPOID METAPLASIA (A SENESCENT CHANGE)	173405	1969	\N	\N	12-22886	\N	SYNAT380	Melanocytic Nevus	IP337537	AirTable blocks_with_IP_info.csv
1149	05-605A2	44	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.11	\N	\N	Sections show an epidermis expanded by a proliferation of keratinocytes arrayed as broad interconnected rete.  Some keratinocytes are deeply pigmented, and melanophages are present in the papillary dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted in cassette A.	R/O BCC	\N	\N	\N	\N	HYPERPIGMENTED SEBORRHEIC KERATOSIS	173536	1165	\N	\N	05-605	A2	MP-01	Hockemeyer Melanoma Progression	IP401771	AirTable blocks_with_IP_info.csv
3084	11649.2 (15.11649.2 slide)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1218	\N	\N	None	\N	NM-40	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1409	10-55707	21	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.3	\N	\N	Sections show a domed, cellular, laterally demarcated compound proliferation of enlarged epithelioid melanocytes. The background epidermis is acanthotic but is also focally thinned. Within the epidermis and along the junction, there are single melanocytes and nests distributed relatively densely, and some of the junctional nests are sizable. In the dermis below this, nests and cords of coalescing and partially-maturing melanocytes extend relatively deeply, where a flanking lymphohistiocytic infiltrate can also be seen.	Nine outside slides, SN10-2916-1, and one corresponding block.	LESION	\N	ALK, Iwei Translocations	\N	ADDENDUM, November 10, 2010: Per a clinical request, we completed comparative genomic hybridization (CGH) analysis of this tumor. Genomic analysis revealed loss in chromosomes 2p, 6q, 8p, and 12q, and loss of the entirety of chromosome 18 is also apparent. The presence of multiple genomic anomalies points to spitzoid melanoma as the best interpretation. Please note that childhood-type spitzoid melanoma represents an emerging entity that we believe is distinct from conventional adult melanoma. Cases reported in the literature as malignant Spitz nevus probably represent the same entity. With respect to clinical behavior, there is a risk for extension to regional lymph nodes, but our experience to date suggests that the risk for seeding of widespread metastatic disease is low. This proliferation is narrowly excised in the available sections. Further excision remains warranted to ensure that local eradication has been accomplished.  As we reported previously, our differential diagnosis included a cellular epithelioid Spitz nevus on one hand and so-called childhood-type spitzoid melanoma on the other. The latter has now been proven as the diagnosis for this case based upon the results of aCGH analysis. We also completed immunoperoxidase staining utilizing a two-color development system (with MART-1 labeled red and Ki-67 labeled brown) was included in our evaluation. By this staining method, we found diffuse MART-1 reactivity. Although the overall labeling index is modest, the MART-positive cells show focally increased nuclear expression of Ki-67, especially in the upper half of the proliferation, thus implying that cellular proliferation is focally elevated. This staining result is diagnostically inconclusive.	CHILDHOOD-TYPE SPITZOID MELANOMA OF 2.9 MM IN THICKNESS	173300	1968	\N	\N	10-55707	\N	SYNAT384	2010-2017	IP950283	AirTable blocks_with_IP_info.csv
1476	11-34950	35	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a domed compound proliferation of enlarged slightly spindled melanocytes that is somewhat asymmetrical. The background epidermis is acanthotic and hyperkeratotic, and a rare large nest can be found at the junction. In fibrotic dermis below this, there are nests, cords, and fascicles of similar melanocytes that mature with descent in the dermis. One peripheral edge of the specimen lacks clears circumscription, and an increase in vasculature can be found around the proliferation as well. Rare superficial dermal melanocytes in mitosis can be seen. There is also a juxtaposed patchy lymphocytic infiltrate.	One outside slide, S-11-10561 / 1-A-2, and one corresponding block.	2-MO H/O PAINFUL PERSISTENT PAPULE, 0.9 X 0.5 CM; PROBABLE KELOID, R/O PSEUDOLYMPHOMA, SPITZ NEVUS	\N	ALK, Iwei Translocations	\N	I believe this proliferation represents an unusual compound desmoplastic Spitz nevus. To further assess spitzoid melanoma as a potential consideration in the differential diagnosis, we pursued array-based comparative genomic hybridization (aCGH) analysis to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, aCGH analysis did not reveal any chromosomal gains or losses. As you probably know, the identification of genomic gain or loss is common to the vast majority of melanomas. In summary, the combination of results derived from conventional microscopy coupled with aCGH points to interpretation as a desmoplastic Spitz nevus rather than melanoma. This proliferation is focally present at the periphery of this biopsy. Further excision can be considered to ensure that local eradication has been accomplished and that persistence does not ensue.	DESMOPLASTIC COMPOUND SPITZOID NEOPLASM, CONSISTENT WITH A DESMOPLASTIC COMPOUND SPITZ NEVUS	173625	2059	\N	\N	11-34950	\N	SYNAT385	2010-2017	IP1024388	AirTable blocks_with_IP_info.csv
1739	13-99417	68	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.9	\N	\N	None	Eight slides/blocks S13-26334:A1 through A8.	MELANOMA SUBMITTED FOR KIT & BRAF MUTATION ANALYSIS	\N	\N	\N	Please refer to UCSF Surgical Pathology report S13-26334 for the histopathologic analysis regarding this tumor. Sanger sequencing of exon 15 of BRAF,  and exons 11, 13, 17, and 18 of KIT, which include the known mutational hotspots of these genes, did not reveal any mutations.	MELANOMA, NO MUTATIONS DETECTED IN KIT OR BRAF	222922	1711	\N	\N	13-99417	\N	SYNAT160	Wild Type Melanoma	IP2344638	AirTable blocks_with_IP_info.csv
3059	2017-07184	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1256	\N	\N	None	\N	NM-82	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3088	15864 3	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1257	\N	\N	None	\N	NM-83	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2672	20-106642A	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22687	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1259	\N	\N	20-106642	A	NM-85	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1737	13-98534	45	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.4	\N	\N	None	Block S13-23549:B.	MELANOMA SUBMITTED FOR BRAF MUTATION ANALYSIS	\N	\N	\N	The histopathological diagnosis was established by pathology report S13-23549 of UCSF Surgical Pathology. Sanger sequencing of exon 15 of BRAF revealed no mutation.	MELANOMA, NO BRAF MUTATION DETECTED	173405	2055	\N	\N	13-98534	\N	SYNAT161	Wild Type Melanoma	IP1340550	AirTable blocks_with_IP_info.csv
1424	10-86469	16	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show an ulcerated proliferation of large oval and fusiform melanocytes with a domed surface. The epidermis is irregularly hyperplastic in some areas, and relatively thinned in others. There are large, confluent nests of cells with abundant amphophilic cytoplasm and large, vesicular nuclei superficially, with smaller aggregations of somewhat smaller cells toward the base of the lesion. Scattered mitotic figures are present. The enclosed immunoperoxidase-stained sections show retention of p16 staining by most of the nuclei, and a relatively high proliferation rate.	Six outside slides, GHS-10-7835, D10-9413:A. One corresponding block received 1/26/2011.	EXCORIATED COMPOUND MELANOCYTIC PROLIFERATION	\N	Iwei, CGH Array run| NTRK3 Translocation case	\N	This proliferation shows conflicting criteria, including some attributes (large confluent nests, a high proliferation index, easily-identifiable dermal mitotic figures, a thinned epidermis, and focal ulceration) that raised the possibility of spitzoid melanoma as a potential consideration in the differential diagnosis. The differential diagnosis also includes a traumatized cellular Spitz nevus. We received the tissue block and utilized it to pursue array-based comparative genomic hybridization (aCGH). After extraction of tumoral DNA from the tissue block, aCGH analysis did not reveal any chromosomal gains or losses. As you probably know, genomic gains and losses can be identified in the vast majority of melanomas, including proliferations within the spectrum of so-called childhood-type spitzoid melanoma. In short, the lack of demonstrable genomic anomalies in this specimen does not provide direct support for a diagnosis of spitzoid melanoma. I recommend complete excision of this site in follow-up. If the resultant reexcision specimen does not contain any residuum, then I view a traumatized hypercellular Spitz nevus as the most likely diagnostic possibility. If a nodular residuum is found below the site of the present biopsy, then it should be reassessed jointly with this specimen.	ULCERATED COMPOUND PROLIFERATION OF ENLARGED SPITZOID MELANOCYTES, INVOLVING THE DEEP EDGE OF THE BIOPSY	173701	2203	\N	\N	10-86469	\N	SYNAT387	2010-2017	IP981048	AirTable blocks_with_IP_info.csv
1472	11-30426	18	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	There is a proliferation of large melanocytes with a domed surface and a wedge-shaped base. Large nests predominate superficially, and are composed of cells with abundant pale vacuolated cytoplasm and dusty melanin, and large pleomorphic vesicular nuclei. The sizes of the aggregations and of the cells that comprise them diminish with descent, and the cytoplasm in the underlying dermis is less vacuolated and less pigmented.	One outside slide, S11-16547-2, SHD11-79642:A6 and one corresponding block.	SPITZOID MELANOCYTIC PROLIFERATION SUBMITTED FOR CGH ANALYSIS	\N	Iwei, CGH Array run| NTRK3 Translocation case	\N	Comparative genomic hybridization shows losses involving 6p and 16q. 6p gain is common in melanoma, but 6p loss is unusual. 16q loss is infrequent, but a repeatable event in melanoma. Given the combination of these features and the findings in the hematoxylin and eosin-stained sections, I believe that melanoma is the most appropriate diagnosis here. The base of the specimen is focally involved. The final thickness measurement should be made after complete excision.	MELANOMA, 2.3 MM. IN THICKNESS	173727	2029	\N	\N	11-30426	\N	SYNAT388	2010-2017	IP1019864	AirTable blocks_with_IP_info.csv
10839	13-59640	69	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	198.2	UCSF Wild Type Melanoma	\N	\N	Block S13-14324:A1.	\N	\N	\N	\N	The histopathological diagnosis was established by pathology report S13-14324 of UCSF Surgical Pathology. Sanger sequencing of exon 15 of BRAF did not reveal mutations.	METASTATIC MELANOMA, NO MUTATION IN BRAF DETECTED	222922	1639	\N	\N	13-59640	A	SYNX236	\N	IP1276884	Consolidated_data_final.csv
1522	11-79158	17	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show enlarged epithelioid and slightly spindled melanocytes arrayed asymmetrically in epidermis and dermis. Within the epidermis, there are single melanocytes and nests distributed centrally, and thinning of the epidermis is noted. In the dermis, there are nests, fascicles, syncytia, and sheets of melanocytes, and encompassing sclerosis is focally apparent. There is a deep nodular focus in which a bulbous extension of melanocytes extends through most of the reticular dermis.	Six outside slides (five unstained), S11-50264 (CD11-155069).	REQUEST FOR CGH ANALYSIS OF MELANOCYTIC TUMOR	\N	\N	\N	The differential diagnosis includes an unconventional deep penetrating nevus or combined melanocytic nevus as well as low-grade melanoma. To further address this differential, we pursued array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic copy number anomalies, as per your request. After extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in distal chromosome 1q as well as focal gain and focal loss in distal chromosome 15q. This represents an ambiguous aCGH result. We have observed 15q gain in association with Spitz nevi, but the fact that multiple chromosomal gains and losses have been identified indicates that the interpretation is less than straightforward. In summary, the combination of results derived from conventional microscopy coupled with aCGH has yielded an ambiguous result. Based solely upon conventional microscopy, I favor a peculiar melanocytic nevus as most likely. The proliferation extends quite close to the inked margins of excision. Further excision is warranted to ensure that local eradication has been accomplished.	NODULAR COMPOUND PROLIFERATION OF ENLARGED SPITZOID MELANOCYTES	173676	1764	\N	\N	11-79158	\N	SYNAT390	2010-2017	IP1068606	AirTable blocks_with_IP_info.csv
1753	14-5893	82	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.52	\N	\N	Sections show a small cyst in the superficial dermis lined by squamous epithelium that forms laminated keratin via a granular layer, with fibrosis of the adjacent dermis and an infiltrate of plasma cells.	Ellipse, 1.6 x 0.6 x 0.7 cm, with a central 0.9 x 0.4 cm area of variegated color and texture. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with seven sections. RS/RS	SEE DT13-59530	\N	\N	\N	None	POST-BIOPSY SCAR, WITH NO EVIDENCE OF RESIDUAL SQUAMOUS CELL CARCINOMA	173566	2325	\N	\N	14-5893	\N	SYNAT104	Melanoma Epigenetics	IP370740	AirTable blocks_with_IP_info.csv
1451	11-16253	4	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a sessile, exophytic, compound proliferation of enlarged melanocytes. Within the epidermis, which is acanthotic and hyperkeratotic, there are single melanocytes and nests and fascicles of melanocytes distributed somewhat unevenly. Some collections of melanocytes extend above the junction. In dermis below this, there are nests and fascicles of melanocytes that are encompassed by fibrotic dermis. Very large and coalescing fascicles are present in the subjunctional zone, but maturation into smaller nests, cords, and fascicles is apparent more deeply. Part of the proliferation encompasses a folliculosebaceous unit. Dermal melanocytes in mitosis can be found but are uncommon.	One outside slide, CS11-1999. One corresponding block received 3-8-11.	AMELANOTIC MELANOMA VS. DFSP, FAVOR SPITZ NEVUS, ? ATYPIA	\N	\N	\N	This proliferation does not represent a conventional Spitz nevus. Rather, our differential diagnosis included a hypercellular Spitz nevus on one hand and so-called childhood-type spitzoid melanoma on the other. To further address this differential, we pursued array-based comparative genomic hybridization (aCGH) analysis to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, aCGH analysis demonstrated loss of a small segment of distal chromosome 7q and gain in the proximal portion of chromosome 11p. Chromosome 11p gain can be seen in association with Spitz nevi, especially, large and cellular Spitz nevi, and this molecular aberration is not common to melanoma. The segment of chromosomal loss in 7q is quite small and is not believed to be diagnostically significant. In summary, the combination of results derived from conventional microscopy coupled with aCGH points to interpretation as a cellular Spitz nevus. We have not demonstrated molecular anomalies via aCGH that are supportive of a diagnosis of childhood-type spitzoid melanoma. This proliferation has been fully excised by means of this specimen, and I do not believe that further surgery at this site is indicated.	CELLULAR COMPOUND SPITZOID NEOPLASM, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	173508	2280	\N	\N	11-16253	\N	SYNAT391	2010-2017	IP1005690	AirTable blocks_with_IP_info.csv
1404	10-41439	67	\N	\N	\N	T1b	Primary	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a proliferation of melanocytes involving the epidermis, papillary and superficial reticular dermis. One population of melanocytes consists of cells with abundant vacuolated cytoplasm and finely divided melanin pigment, and these cells are arrayed irregularly within the epidermis as single cells and nests, with foci of suprabasal scatter.  There are also similar clusters of cells in the superficial dermis, forming confluent nests, with no maturation and a mitotic figure among the dermal melanocytes.  Beneath this is a zone of paucicellular fibrosis, with horizontally oriented, closely apposed collagen bundles. Deeper in the dermis, there is a second population of smaller melanocytes (comprising melanocytic nevus), arrayed as nests and cords in the superficial reticular dermis, in part around epithelial adnexal structures.	Ellipse, 1.2 x 1.0 x 0.1 cm, including a central pink-tan 0.9 x 0.8 cm lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections plus a fragment.	R/O MELANOMA	\N	 MELANOMA, 0.65 MM IN THICKNESS, ARISING IN A PRE-EXISTENT MELANOCYTIC NEVUS MELANOMA, 0.65 MM IN THICKNESS, ARISING IN A PRE-EXISTENT MELANOCYTIC NEVUS	\N	The nevus has a congenital pattern. The intraepidermal component of this melanoma extends to the peripheral edge of the specimen. The lesion is less than 1 mm in thickness, is not ulcerated, but has a mitotic figures in its dermal component. Therefore it should be classified as T1b per the 2009 revision of the AJCC staging system for melanoma. A superficial scar is also present. If this area was previously biopsied (we do not know of any in our files), the slides from it should be reviewed to make sure that the prognostic information above is correct.	MELANOMA, 0.65 MM  IN THICKNESS, ARISING IN A PRE-EXISTENT MELANOCYTIC NEVUS	139524	2123	\N	\N	10-41439	\N	SYNAT392	2010-2017	IP936014	AirTable blocks_with_IP_info.csv
3569	SKMEL 1023A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	903	\N	\N	None	\N	MC-01	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
1410	10-56047	49	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a moderately narrow, relatively symmetrical proliferation of large oval melanocytes involving the superficial dermis. The lesional cells have abundant amphophilic cytoplasm and moderately pleomorphic, vesicular nuclei. Relatively small nests are present, with even smaller aggregations toward the base of the lesion. A sparse lymphocytic infiltrate is present.	Two outside slides, D10-5276, and one corresponding block.	ENLARGING LESION	\N	\N	\N	The enclosed Ki-67 stain is difficult to interpret, as many lymphocytes are present. A few mitotic figures are present, including one in the lower half of the lesion. Immunoperoxidase staining performed in our laboratory using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) to more specifically evaluate the proliferation rate in melanocytes shows a very low labeling rate, although a few positive nuclei are present near the base of the lesion. A p16 stain labels only rare cells (less than 5%). My initial assessment of this lesion was that it is not a conventional Spitz's nevus, but a lesion with low metastatic potential (referred to as atypical Spitz tumor in some studies). However, comparative genomic hybridization shows a loss of chromosome 9, and a gain involving most of chromosome 7. The chromosome 9 loss corroborates the near-total absence of staining for p16, as the gene is located on 9p. Gains involving chromosome 7 and losses involving chromosome 9 are common aberrations in melanoma.  Hence, I believe an outright diagnosis of melanoma is more apt.  The lesion appears to have been narrowly excised.	MELANOMA, 1.7 MM IN THICKNESS	173508	1693	\N	\N	10-56047	\N	SYNAT393	2010-2017	IP950623	AirTable blocks_with_IP_info.csv
1757	14-13830	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2190	\N	\N	14-13830	\N	SYNAT105	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1765	14-32353	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2030	\N	\N	14-32353	\N	SYNAT106	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1770	14-37911A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1906	\N	\N	14-37911	A	SYNAT107	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2662	20-91914A	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22686	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1260	\N	\N	20-91914	A	NM-86	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2648	20-60974B	\N	\N	\N	\N	\N	\N	\N	10	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22654	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1261	\N	\N	20-60974	B	NM-87	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2976	96-12193	44	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1690	172.5	\N	\N	Sections show nested and solitary melanocytes, some with atypical nuclear features, in irregular array along the dermo-epidermal junction.  Aggregates of similar melanocytes are present in the underlying dermis.	Skin segment measuring 8 x 5 x 1 mm, bisected longitudinally.	A - 2 X 3 CM PLAQUE; CLINICAL DIAGNOSIS - R/O BCC	\N	\N	Scraping	None	MELANOMA, AT LEAST 0.4 MM IN THICKNESS, EXTENDING TO THE DEEP BIOPSY MARGIN, FINAL MICROSTAGING PENDING COMPLETE REEXCISION	173525	216	\N	\N	96-12193	\N	CCR-258	California Cancer Registry	IP88957	AirTable blocks_with_IP_info.csv
1460	11-21491	14	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show enlarged melanocytes arrayed as gargantuan nests and fascicles in compound fashion in concert with acanthosis in a sessile polypoid skin segment. The acanthotic epidermis is focally eroded. In the dermis, non-maturing and coalescing fascicles of melanocytes are coupled with a sparse encompassing lymphohistiocytic infiltrate, and cells in mitosis are relatively easily found.	Four outside slides, S11-10002:1A,1B and one corresponding block (1A).	REFERRED FOR EXCISION, RAISED PEDUNCULATED IRRITATED NEVUS, ONSET THREE MONTHS AGO, ALSO HAS LESIONS ON LOWER ABDOMEN, PURPLISH, ? HEMANGIOMA	\N	\N	\N	The cellularity of this process raised concern for the possibility of childhood-type spitzoid melanoma as a potential alternative i the differential diagnosis. The best means to assess or refute this possibility is to complete array-based comparative genomic hybridization (aCGH) analysis, which we pursued. After extraction of tumoral DNA from the tissue block, aCGH analysis did not reveal any chromosomal gains or losses. As you know, the vast majority of melanomas, including childhood-type melanomas, harbor various genomic anomalies. In summary, the combination of results derived from conventional microscopy coupled with aCGH does not provide support for a diagnosis of melanoma. I believe this unusual proliferation represents a hypercellular Spitz nevus. The process appears excised in the available planes of section.	HYPERCELLULAR COMPOUND PROLIFERATION OF MELANOCYTES, CONSISTENT WITH A HYPERCELLULAR SPITZ NEVUS	173502	1691	\N	\N	11-21491	\N	SYNAT395	2010-2017	IP1010929	AirTable blocks_with_IP_info.csv
1555	12-1782	37	\N	\N	\N	T2a	Primary	None	\N	\N	\N	\N	\N	172.4	\N	from Swapna	There is a broad-based melanocytic proliferation with a flat peripheral area and a raised central one. The peripheral portion features discrete nests of small round melanocytes. The raised portion has a relatively thin epidermis, large irregularly shaped and focally confluent nests of large oval and fusiform melanocytes superficially, and smaller ones embedded in a dense lymphocytic infiltrate more deeply. The larger melanocytes include some cells with very large, hyperchromatic nuclei, prominent nuclear pseudoinclusions, or large nucleoli. A few mitotic figures are present, mainly in melanocytes in the upper part of the lesion.	Four outside slides, TT12-7000012-(1&2) and two corresponding blocks.	EXCISION SCALP LESION	\N	Iwei CGH, 7Q Gain 	\N	Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a relatively high proliferation rate in the superficial part of the lesion but a low one in the deeper portions. This finding is not decisive. A p16 stain shows a complete loss of expression in the larger cells, while some smaller melanocytes near the edge of the specimen retain expression. This finding is worrisome for melanoma arising in a nevus. As the changes were somewhat equivocal, we obtained comparative genomic hybridization. This shows set of chromosomal gains and loss diagnostic of melanoma, including a gain involving 3q, complex rearrangements involving chromosomes 5p and 7p, loss of 7qter and 8p, a gain of 8q, a loss involving 9p, and a loss involving 21q. The loss involving 9p correslates with the negative p16 immunoperoxidase stain noted above.  The nevus extends to a peripheral margin, and the melanomatous component to within less than 1 mm of it. The lesion is not ulcerated, making it stage T2a in the 2009 AJCC staging schema for melanoma.	MELANOMA, 1.4 MM. IN THICKNESS	173406	640	\N	\N	12-1782	\N	DP-03	Possible TERT Fusion	IP1087598	AirTable blocks_with_IP_info.csv
1511	11-65778	22	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a compound, wedge-shaped, slightly asymmetrical proliferation of spindled and epithelioid melanocytes arrayed as nests and fascicles which are vertically oriented in the dermis and focally along the junction of an epidermis that is acanthotic. Within the dermis, similar melanocytes are present in clusters, fascicles, and interstitially. Mitotic figures are evident very focally within the dermal component, including within deeper aspects of it. There is a patchy juxtaposed lymphocytic infiltrate.	One outside slide, S11-29473 A1 and one corresponding block.	ATYPICAL MELANOCYTIC NEVUS	\N	\N	\N	Our differential diagnosis for this spitzoid tumor included an unconventional Spitz nevus on one hand and spitzoid melanoma on the other. To further assess this differential via molecular means, we completed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed loss of chromosome 7p as well as focal gain in chromosome 7q. No other chromosomal copy number aberrations were identified. As background, please note that chromosomal copy number aberrations involving multiple chromosomes can be identified in the vast majority of melanomas evaluated via aCGH, while most melanocytic nevi lack such aberrations. A subset of Spitz nevi demonstrate aberrations involving a single chromosome, including chromosomes 7, 11, and 15. In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced clear support for a diagnosis of melanoma. Rather, I believe this proliferation represents an unconventional Spitz nevus with associated gain in chromosome 7q. My colleague, Dr. Boris Bastian, reviewed the aCGH tracing for this case and is in agreement with my diagnostic interpretation.  We recommend complete reexcision of this site in follow-up to be certain there is not possibility of local persistence.	COMPOUND SPITZOID MELANOCYTIC PROLIFERATION, FOCALLY ABUTTING THE INKED SPECIMEN PERIPHERY	333504	2085	\N	\N	11-65778	\N	SYNAT396	2010-2017	IP1055221	AirTable blocks_with_IP_info.csv
1469	11-27846-2 N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	934	\N	\N	None	\N	MD-28	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1307	08-16770	32	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	Sections show an increased number of individual melanocytes, arrayed along the sides and bases of elongated, hyperpigmented rete. Only a rare melanocyte shows nuclear enlargement. There may be rare tiny admixed nests present. A few lesional melanocytes are present in the lowermost stratum spinosum.	Skin segment measuring 0.7 x 0.4 x 0.1 cm, bisected and entirely submitted.	LABIAL MELANOSIS	\N	left labia minora	\N	There is no evidence of a genital melanotic macule, as the degree of cellularity along the junction is greater than what is stereotypically associated with that entity. Does this biopsy include the entire clinical pigmented lesion? If so, then the differential diagnosis lies between a lentigo simplex on one hand, and an evolving lentiginous junctional melanocytic nevus on the other. Is this instead a partial biopsy of a larger pigmented lesion? If so, then the present findings are somewhat more worrisome, as circumscription cannot be fully ascertained, and thus ongoing close clinical follow-up or conservative complete reexcision of this site should be considered. We apologize for the brief delay in reporting. Level sections were not immediately ordered because of an oversight in the laboratory. Again, we apologize for any inconvenience caused.	INTRAEPIDERMAL PROLIFERATION OF MELANOCYTES WITH A LENTIGO SIMPLEX-LIKE CONFIGURATION	205552	1263	\N	\N	08-16770	\N	OM-02	Oral Mucosa Lesions	IP725411	AirTable blocks_with_IP_info.csv
1426	10-88482	74	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show markedly sun-damaged skin with a well-circumscribed, wedge-shaped to somewhat rectangular proliferation of melanocytes that mostly involves the dermis. Most of the proliferation is embedded in markedly fibrotic stroma, which displaces the elastotic material. There are large nests of large oval melanocytes superficially. These cells have pale amphophilic cytoplasm with large, relatively monomorphous vesicular nuclei. The aggregates, the cells themselves and the sizes of their nuclei diminish with descent. Although the enclosed Ki-67 double-stained sections show a very low proliferative rate, a mitotic figure is present within a high power field of the base of the specimen.	Seven outside slides, OS10-24774. One corresponding block received 12-14-10.	SPITZ NEVUS VS. MELANOCYTIC TUMOR OF UNCERTAIN MALIGNANT POTENTIAL VS. SPITZOID MELANOMA	\N	\N	\N	There are conflicting findings, as noted in your cover letter. The architectural features of the lesion could well be those of a Spitz's nevus, but the setting, in an older patient, in severely sun-damaged skin with, and presence of deep mitotic figures is worrisome. A p16 stain is positive in about 30% of lesional nuclei. Testing with comparative genomic hybridization shows a gain involving much of the long arm of chromosome 15 (15q), and one involving 22q. Although these are not among the very most commonly affected loci in melanoma, gains in both of these areas are seen in a proportion of typical melanomas.  The lesion extends to within 1 mm of the margin in the reticular dermis. It is not ulcerated, and hence is a T3a primary melanoma in the 2009 AJCC staging schema for melanoma.	DESMOPLASTIC MELANOMA, 3.8 MM. IN THICKNESS	173610	2034	\N	\N	10-88482	\N	SYNAT397	2010-2017	IP983061	AirTable blocks_with_IP_info.csv
1506	11-63178	41	\N	\N	\N	T1b	Primary	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a slightly asymmetrical, compound proliferation of melanocytes, many of which have abundant dusty cytoplasmic melanin, and some of which are slightly spindled. These are arrayed irregularly within the epidermis as nests and single cells with focal suprabasal scatter. Within the dermis, similar melanocytes are arrayed in clusters and small fascicles or syncytia, and these do not mature with descent. A single dermal melanocyte in mitosis is apparent in a recut section. There is periadnexal extension. There are numerous admixed melanophages, and a patchy lymphocytic infiltrate. There is solar elastosis appreciable.	Two outside slides, P11-01555 / B. One corresponding block received 9-9-11.	A) 2 MM BROWN MACULE, B) 4 MM DARK-BLUE/BLACK PAPULE	\N	\N	\N	Our differential diagnosis included a peculiar deep penetrating melanocytic nevus on one hand and melanoma on the other, and we did not believe this differential could be conclusively resolved based solely upon conventional microscopy. Per your request, we thus completed array-based comparative genomic hybridization (aCGH) to screen this tumor for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed copy number loss in chromosomes 3, 9, and 10. The identification of multiple chromosomal copy number aberrations is indicative of genomic instability and is confirmatory of a diagnosis of melanoma. Please note that melanocytic nevi do not have associated chromosomal copy number aberrations involving multiple chromosomes. In essence, the aCGH result has proven that this proliferation cannot represent a melanocytic nevus. In summary, the combination of results derived from conventional microscopy coupled with aCGH is confirmatory of a diagnosis of melanoma. With respect to staging, this melanoma is less than 1 mm in thickness and lacks associated ulceration, yet melanocytes in mitosis are detectable in its invasive component. Therefore, this represents melanoma of stage pT1b (2009 AJCC Guidelines). Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.9 MM IN THICKNESS, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	173649	2302	\N	\N	11-63178	\N	SYNAT398	2010-2017	IP1052621	AirTable blocks_with_IP_info.csv
2247	17-115149A	50	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show a proliferation of solitary melanocytes and small nests of them arrayed along the sides and bases of elongated and pigmented rete ridges. There are many melanophages within the underlying superficial dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted in A. PL/PL	A) IRREGULAR BROWN PAPULE; ATYPICAL NEVUS, B) INFLAMED PIGMENTED PAPULE WITH HEMORRHAGIC CRUSTING; IRRITATED NEVUS VS. VV	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173727	855	\N	\N	17-115149	A	LN-036	Lentiginous Nevi 	IP1845642	AirTable blocks_with_IP_info.csv
1659	12-71679	41	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a broad-based compound proliferation of melanocytes in which the junctional component outflanks the centrally positioned intradermal one. There are closely apposed nests of moderately enlarged fusiform melanocytes with monomorphous oval nuclei and pale, lightly pigmented cytoplasm at the junction, extending into the upper portions of folliculosebaceous units. A few incipient Kamino bodies are present. There is a central focus in which nests of progressively smaller cells are embedded within fibrotic stroma. I did not detect mitotic figures in the dermal component. The enclosed two-color immunoperoxidase-stained sections show a moderate proliferation rate in melanocytes in the papillary dermis, with considerably less staining toward the base of the lesion.	Four outside slides, KC12-1201 2A. One corresponding block received 9-28-12.	R/O HEMANGIOMA VS. DYSPLASTIC NEVUS	\N	\N	\N	Comparative genomic hybridization has been performed, and while not technically optimal, shows no chromosomal aberrations. Especially given this result, I favor an unusual nevus in the Spitz/pigmented spindle cell nevus spectrum. As the junctional nests are closely apposed, resulting in a hypercellular appearance, a spitzoid melanoma is also in the differential diagnosis, albeit less likely. In any case that is at this level of difficulty, a narrow reexcision is appropriate.	COMPOUND PROLIFERATION OF LARGE SOMEWHAT SPITZOID MELANOCYTES	105536	1679	\N	\N	12-71679	\N	SYNAT399	2010-2017	IP1157496	AirTable blocks_with_IP_info.csv
1662	12-80985B	7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a residual dermal proliferation of enlarged fusiform melanocytes arrayed as a wedge-shaped nodule of coalescing fascicles in the reticular dermis. There is a juxtaposed sparse permeative lymphohistiocytic infiltrate, and a swath of post-procedural fibrosing inflammatory alterations sits above this. There is no ulceration. Combining both specimens, a tumor thickness of 1.4 mm is appreciable.	One outside slide, 12-050491 and one corresponding block.	BIOPSY AND REEXCISION OF COMPOUND ATYPICAL SPITZOID MELANOCYTIC PROLIFERATION (FOR CGH)	\N	\N	\N	Our differential diagnosis included both an unconventional Spitz nevus on one hand and childhood-type spitzoid melanoma on the other. Per your request, we completed array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies, as can be seen in association with melanoma. After extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in chromosome 8p as well as segmental loss of chromosome 12q and loss of distal chromosome 15q. The identification of multiple chromosomal copy number abnormalities provides confirmation that this tumor does not represent a conventional Spitz nevus. However, the several small segmental genomic aberrations we have identified are not specifically diagnostic of melanoma, either. Thus, this tumor can be considered an example of 'atypical Spitz tumor or 'Spitz tumor of ambiguous potential'. Dr. Boris Bastian has reviewed the molecular results and is in agreement with this interpretation.  The small residuum seen here is non-ulcerated and appears excised in the available planes of section.	RESIDUAL ATYPICAL COMPOUND SPITZOID NEOPLASM, EXCISED IN THE AVAILABLE PLANES OF SECTION	173305	1672	\N	\N	12-80985	B	SYNAT400	2010-2017	IP1166802	AirTable blocks_with_IP_info.csv
1641	12-39632	5	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a compound proliferation of large spindled and epithelioid melanocytes, the junctional component of which is arrayed with the lowermost sections of an epithelium that is acanthotic and hyperkeratotic, with thinning of the epidermis over some large nests. Some single melanocytes are scattered above the basal layer. Rare small Kamino bodies are present. In the dermis, melanocytes are arrayed as nests and syncytia. There is some maturation, but some larger melanocytes persist at the base. There is deep adnexal extension. The stroma is focally myxoid.	Skin segment measuring 0.7 x 0.6 x 0.3 cm, bisected and entirely submitted.	HIGHLY IRREGULAR APPEARING LESION	\N	\N	\N	ADDENDUM, June 29, 2012: While there are features in common with a Spitz's nevus, there are also unusual features, including deep adnexal extension, marked thinning of the epidermis over some junctional nests, and a lack of complete maturation of the dermal component. We were interested in performing comparative genomic hybridization. This is a molecular technique that uses lesional tissue from the paraffin block. It is based on the presence of chromosomal gains and losses in about 95% of melanomas, but with the exception of a gain of 11p, a lack of them in Spitz's nevi. A reference on this technique and its applicability to this differential diagnosis is listed below. Thank you for informing us that we could proceed with this testing. This shows no significant loss or gain of chromosomal material. This favors a benign interpretation. About 95% of conventional melanomas show detectable losses or gains with this technique. Because of the unusual findings noted, however, complete re-excision of this site is of course warranted.  Reference:  Bastian BC, Wassermann U, Pinkel D, LeBoit PE. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol. 1999 Dec;113(6):1065-9.	COMPOUND PROLIFERATION OF LARGE SPINDLED AND EPITHELIOID MELANOCYTES, PROBABLY AN UNUSUAL SPITZ'S NEVUS, EXTENDING TO THE EDGE OF THE SPECIMEN	173508	1732	\N	\N	12-39632	\N	SYNAT402	2010-2017	IP1125450	AirTable blocks_with_IP_info.csv
1422	10-84478	16	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a domed, cellular and somewhat asymmetrical compound proliferation of enlarged spindled and epithelioid melanocytes. Within the epidermis, which is markedly acanthotic, there are strikingly enlarged nests and fascicles of melanocytes distributed somewhat unevenly, and centrally an area of erosion is capped by neutrophilic exudate. There are large nests and fascicles of similar melanocytes in the underlying dermis, and partial maturation with descent in the dermis is appreciable. In the deepest extent of the lesion, the lesional melanocytes extend amongst adnexal structures. A patchy dermal lymphocytic infiltrate is present concurrently. A number of dermal melanocytes in mitosis can be found.	Two outside slides, 1032157 01B. Two corresponding blocks received 11/24/10 (01A & 01B).	RULE OUT BASAL CELL CARCINOMA	\N	\N	\N	ADDENDUM, January 14, 2011: As noted previously, my differential diagnosis includes a hypercellular Spitz nevus on one hand and childhood-type spitzoid melanoma on the other, and I favor the former possibility as most likely. As this differential diagnosis is best addressed by inclusion of the results of molecular analysis, we pursued comparative genomic hybridization analysis via tissue array methodology (aCGH). After extraction of tumoral DNA, aCGH assessment demonstrated gain in chromosome 7q and no other genomic aberrations. Chromosome 7q gain as a monoaberration does not presently have defined significance. We have observed it in melanocytic tumors interpreted ambiguously. A monoaberration in chromosome 7q is not sufficient to warrant interpretation as childhood-type spitzoid melanoma. In summary, based upon the combination of conventional microscopy coupled with aCGH results, I continue to favor a hypercellular Spitz nevus as most likely. As this interpretation is not unequivocal, further excision of this site is warranted to ensure that local eradication has been accomplished and that persistence cannot ensue.	COMPOUND SPITZOID NEOPLASM, FOCALLY ABUTTING THE PERIPHERY OF THE BIOPSY	173649	2142	\N	\N	10-84478	\N	SYNAT403	2010-2017	IP979057	AirTable blocks_with_IP_info.csv
1775	14-44611	72	\N	\N	1	T1b	Primary	Superficial spreading	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26343,26344	172.6	\N	\N	Sections show a broad and poorly circumscribed compound proliferation of melanocytes. Within the epidermis many of the lesional melanocytes are located in pagetoid scatter and single melanocytes predominate over nests in some foci. Many of the lesional melanocytes contain abundant dusty melanin within their cytoplasm. There are nests, cords and strands of similar melanocytes in the dermis and the size of the melanocytes generally does not diminish with descent. In addition, there are numerous mitotic figures evident among the dermal melanocytes. The melanocytes in the dermis are present within fibrosis which overlies solar elastosis.  A surrounding lymphohistiocytic infiltrate is present as well.  There is also a domed/papillated proliferation of keratinocytes with uniform nuclei arrayed as interanastomosing rete that expand the epidermis. Small pseudocystic spaces are focally entrapped by the interconnecting rete.	Ellipse, 1.4 x 1.0 x 0.5 cm, with a central 0.8 x 0.7 cm brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections. RS/RS	8 MM TAN, BROWN, BLK IRREGULAR PAPULE, EXCISED; R/O MM	\N	\N	\N	A synoptic report of potential prognostic factors is listed below: Procedure: Punch biopsy Microscopic tumor type: Superficial spreading Breslow thickness: 0.7 mm Ulceration: not present Margins, peripheral and deep: Intraepidermal melanoma extends to within 0.8 millimeters of the peripheral edge of the specimen. The deep margin is free. Mitotic index: > 1/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1bNxMx  Further treatment at this site is warranted.	MELANOMA, 0.7 MILLIMETERS IN THICKNESS, WITH CLOSE EXTENSION TO THE SPECIMEN PERIPHERY	173611	1788	\N	\N	14-44611	\N	SYNAT109	2010-2017	IP1394545	AirTable blocks_with_IP_info.csv
2627	20-36120	47	\N	\N	\N	None	None	None	5	0	FFPE	\N	\N	216.5	\N	\N	Sections show a broad but symmetric intradermal proliferation of melanocytes. In the central and superficial aspect of the proliferation, there are balloon melanocytes arrayed as nests that become smaller in size and disperse with depth in the dermis. Admixed, there are also melanocytes with round nuclei and scant vacuolated cytoplasm. Surrounding this population of melanocytes are dendritic and spindled melanocytes dispersed between thickened collagen bundles. Melanophages are scattered throughout the proliferation.	Six outside slides, SS20-12875 / S-20-1791 A1, and one corresponding block.	RECURRENT NEVUS	\N	\N	FFPE	This appears to be a blue nevus with balloon cell change, and this is supported by the diffuse positivity for HMB45 demonstrated in your immunostain. Given the breadth of the lesion, I further evaluated BAP-1, p16 and PRAME immunochemistry to screen for changes associated with melanoma. BAP-1 is retained and p16 demonstrates mosaic positivity, including in some ballooned melanocytes. The melanocytes are negative for PRAME overexpression. The immunohistochemical results support the above benign diagnosis.	BLUE NEVUS WITH BALLOON CELL CHANGE	173507	1383	\N	\N	20-36120	\N	SN-20	Sclerotic Nevi	IP2183737	AirTable blocks_with_IP_info.csv
1248	06-32942	36	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a broad, asymmetrical, compound proliferation of large and strikingly atypical spindled melanocytes, extensively involving both epidermis and dermis. Along the junction, there are nests and fascicles of melanocytes disposed erratically and somewhat confluently, and many intraepidermal nests are large and irregular. There are confluent nests and fascicles of melanocytes distributed throughout the upper reticular dermis, with little maturation with dermal descent and with dermal mitotic figures readily identifiable. The background epidermis is acanthotic and hyperkeratotic and is centrally partially ablated by ulceration, with superjacent exudate and crust.	Skin segment measuring 1.2 x 0.9 x 0.4 cm, trisected and entirely submitted.	MELANOMA	\N	\N	\N	In terms of staging, this is a focally ulcerated melanoma with a nodular invasive component, with extensive involvement of the reticular dermis (Clark's level IV). I do not see any evidence of vascular invasion, perineural extension, or regression. Further re-excision of this site is of course warranted to be certain that local eradication has been accomplished.	MELANOMA OF 3.3 MM IN THICKNESS, FOCALLY TRANSECTED AT THE DEEP BIOPSY MARGIN	222533	2003	\N	\N	06-32942	\N	SYNAT408	Spitzoid Melanoma	IP578011	AirTable blocks_with_IP_info.csv
1521	11-78845	19	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show enlarged epithelioid melanocytes arranged as large nests at the dermo-epidermal junction and as irregular large and small nests in the dermis.  Some of the dermal melanocytes are smaller.  Scattered mitotic figures are noted near the surface of the lesion and one is atypical.  The overlying epidermis shows focal crusting.	Skin segment measuring 0.4 x 0.3 x 0.1 cm. Submitted intact.	R/O HEMANGIOMA	\N	\N	\N	Array chromosomal genomic hybridization studies were performed on this case.  They reveal a gain of chromosome 13q.  This finding, while unusual, is not known to be associated with melanoma.  The overall histopathology of this case including enlarged melanocytes and scattered mitotic figures, one of which is atypical remains worrisome however, and the exact biologic potential of this lesion cannot be completely predicted.  Most larger series of this rare diagnostic category indicate that most patients are alive and well after treatment, which includes excision, and can include sentinel lymph node biopsy, (which may show metastatic foci).  Rare patients succumb to metastatic disease.  In this case, since the lesion extends to the edges of the specimen, a full thickness re-excision with a minimum of 5 millimeter margins is recommended.  I have reviewed this case with Dr. LeBoit who concurs with the diagnosis and treatment recommendationl.  The reference below represents one of the larger series related to this entity. Ludgate MW et al The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer. 2009 Feb 1;115(3):631-41.	ATYPICAL SPITZ TUMOR, EXTENDING TO THE TISSUE EDGES	173530	1910	\N	\N	11-78845	\N	SYNAT410	2010-2017	IP1068293	AirTable blocks_with_IP_info.csv
2562	19Rig750007.05.06.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	295	\N	\N	None	\N	CM-62	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2564	19Rig750007.05.06.10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	295	\N	\N	None	\N	CM-62	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1260	06-73878D	63	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1404	173.6	\N	\N	Sections show rounded nests of peripherally palisaded basaloid cells accompanied by fibromyxoid stroma from which they are separated by clefts.  Some aggregations have small round spaces between their epithelial cells, containing mucin.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted in cassette D.	A) IRREGULAR 8-10 MM MACULE; R/O MELANOMA, B) 2 WK HX OF RAPIDLY GROWING PAPULE; R/O SK, C-D) R/O BCC	\N	\N	\N	\N	BASAL CELL CARCINOMA, NODULAR (ADENOID) PATTERN, TRANSECTED AT THE DEEP BIOPSY EDGE	522697	232	\N	\N	06-73878	D	CCR-301	California Cancer Registry	IP89612	AirTable blocks_with_IP_info.csv
1356	09-88536	47	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	Sections show vacuolar alteration and an increase in cellularity along the epidermal-dermal junction, where scattered necrotic keratinocytes are apparent. The fibrotic submucosa below this holds a lymphohistiocytic infiltrate with admixed melanophages.	Cylindrical skin segment (rc'd in 2 pcs) measuring 0.3 cm in diameter and 0.4 cm in thickness in aggregate (head=0.3 cm in diameter and 0.1 cm in thickness, stem=0.2 cm in diameter and 0.4 cm in thickness); all submitted.	NEVUS, R/O ATYPIA VS. LABIAL MACULE	\N	left labia	\N	My differential diagnosis included a lichenoid form of vulvitis as well as an inflamed pigmented lesion, such as an inflamed melanotic macule, and I favor the former possibility as most likely. Melan-A and MiTF immunostains were both completed as part of our assessment and both show a normal (or perhaps slightly elevated) density of melanocytes, thereby suggesting that there is not a melanocytic lesion at this site. An elastic tissue (EVG) stain shows a loss of fine elastic fibrils in the perijunctional zone, which, when coupled with the lichenoid infiltrate observed in conventional sections, raises lichen sclerosus et atrophicus as a potential consideration. A PAS-D stain was completed as well and shows focal slight accentuation of the perijunctional basement membrane, as can also be seen with lichen sclerosus. Is there any indication of lichen sclerosus from a clinical perspective?	LICHENOID MUCOSITIS WITH ASSOCIATED POST-INFLAMMATORY HYPERPIGMENTATION	104587	1264	\N	\N	09-88536	\N	OM-03	Oral Mucosa Lesions	IP840903	AirTable blocks_with_IP_info.csv
1524	11-81405	16	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a pedunculated proliferation of large oval melanocytes seen beneath an irregularly hyperplastic and focally atrophic epidermis, encompassed by epithelial collarettes. Extending from the junctional zone to the flat base of the lesion in the upper reticular dermis is a proliferation of large oval melanocytes with relatively monomorphous oval vesicular nuclei that contain small nucleoli. These cells have moderate amounts of eosinophilic cytoplasm. Scattered mitotic figures are present in both the upper and lower portions of the proliferation.	One outside slide, K15783-11 and one corresponding block.	RED EXOPHYTIC LESION; HEMANGIOMA?	\N	\N	\N	The architectural features of this lesion differ from those of a classic Spitz's nevus by virtue of having epithelial collarettes and a focally thinned epidermis. The dermal component features striking confluence of nests, and a mitotic rate higher than that in most Spitz's nevi. For these reasons, we performed comparative genomic hybridization. No chromosomal gains or losses were detected. In the context of the histopathologic findings, I favor an unusual Spitz's nevus. The lesion appears to have been narrowly removed.	COMPOUND PROLIFERATION OF LARGE, SPITZOID MELANOCYTES, WITH FEATURES FAVORING AN UNUSUAL SPITZ'S NEVUS	713789	1853	\N	\N	11-81405	\N	SYNAT411	2010-2017	IP1070853	AirTable blocks_with_IP_info.csv
2216	17-102266	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	459	\N	\N	17-102266	\N	DMS-047	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
1529	11-85075	20	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a broad, slightly asymmetrical and compound proliferation of enlarged slightly spindled and epithelioid melanocytes. Within the epidermis, single melanocytes and nests are distributed along the sides and bases of elongated rete, and in one focus there is scatter of melanocytes above the junction. In fibrotic and sclerotic reticular dermis below this, there are partially maturing nests, cords, and fascicles of similar melanocytes distributed broadly, and extension to the inked edges of the specimen is noted. A multifocal juxtaposed lymphocytic infiltrate is present concurrently. The melanocytes in the dermis show avid expression of p16 and have a low Ki-67 cell proliferation index. Dermal melanocytes in mitosis are not easily found.	Nine outside slides, SP11-6973:A, and B, and one corresponding block, B.	LESION WITH CONFLICTING CRITERIA, WITH FEATURES THAT SUGGEST ATYPICAL SPITZ NEVUS VS. SPITZOID MELANOMA	\N	\N	\N	As discussed in your correspondence, the differential diagnosis includes an unconventional desmoplastic Spitz nevus on one hand and spitzoid melanoma on the other, and I believe the former possibility represents the correct interpretation for this case. To further substantiate the nature of this proliferation, we pursued array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated chromosomal copy number aberrations. After extraction of tumoral DNA from the tissue block, application of aCGH revealed a tiny segmental gain in chromosome 7q with no other associated chromosomal gains or losses. This is an aberration that we have identified in association with a small number of desmoplastic Spitz nevi. As you know, most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. (Importantly, only a small segmental aberration involving a single chromosome was identified in association with this proliferation, and thus the aCGH profile is not suggestive of melanoma.) In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. I believe this proliferation represents an unusual desmoplastic Spitz nevus. As this biopsy is only partial in nature, further excision is recommended to ensure that local eradication has been accomplished.	DESMOPLASTIC COMPOUND SPITZOID MELANOCYTIC PROLIFERATION, CONSISTENT WITH A DESMOPLASTIC SPITZ NEVUS	173727	1747	\N	\N	11-85075	\N	SYNAT412	2010-2017	IP1074523	AirTable blocks_with_IP_info.csv
1526	11-83908	4	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show enlarged melanocytes arrayed in compound fashion within a sessile, protuberant skin segment. There are single melanocytes and nests and fascicles of melanocytes within the epidermis, which is thinned, and in the dermis there are partially-maturing nests and sheets of melanocytes coupled with a lymphohistiocytic infiltrate.	One hematoxylin and eosin-stained section prepared from outside block labeled  S11-3281.	ELEVATED INTRADERMAL NEVUS, FAST GROWING	\N	\N	\N	This proliferation does not represent a conventional Spitz nevus. Rather, our differential diagnosis included an atypical Spitz nevus on one hand and childhood-type spitzoid melanoma on the other. Cell proliferation analysis was completed via immunoperoxidase staining utilizing a two-color development system in which MART-1 is labeled red and Ki-67 is labeled brown. By this staining method, we found diffuse MART-1 reactivity. The MART-positive cells show modestly elevated nuclear expression of Ki-67, thus implying that cellular proliferation is elevated. This staining result is of concern but is not specifically diagnostic. To more fully assess the nature of this proliferation, we also completed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed equivocal segmental loss in distal chromosome 8p with no other chromosomal gains or losses. As you probably know, most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. The aCGH profile that we have defined here is not specific.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced clear support for a diagnosis of melanoma. Rather, I favor an unconventional (or atypical) Spitz nevus as most likely. The proliferation abuts the specimen periphery in the available sections. In light of this, conservative complete reexcision of this site represents a follow-up step worthy of consideration. If there is no apparent residuum, then close clinical monitoring of the biopsy site could also be considered as a possibility.	COMPOUND SPITZOID MELANOCYTIC PROLIFERATION	173305	1889	\N	\N	11-83908	\N	SYNAT413	2010-2017	IP1073356	AirTable blocks_with_IP_info.csv
1531	11-85859	45	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	The submitted level sections demonstrate a sessile skin segment that harbors a dermal proliferation of melanocytes arrayed in nested, fascicular, and syncytial fashion. Near the junctional zone, epithelioid melanocytes with pale or finely melanized cytoplasm are arrayed in coalescing fashion, and subjacent to this there are coalescing fascicles of slightly spindled melanocytes with similar cytoplasmic qualities. As one extends more deeply in the dermis, the melanocytes become smaller with descent and occasionally are wrapped around tiny peripheral nerves or abut vascular channels. Extension into the subjacent reticular dermis is coupled with a marked diminishment in cell size and an interstitial distribution. Dermal melanocytes in mitosis are not easily found, and the Ki-67 cell proliferation index appears to be relatively low.	Eleven outside slides, 11-31668:A1-1 through A1-11, and one corresponding block, A1.	MELANOCYTIC LESION, DESCRIBED AS A "SUSPICIOUS MOLE	\N	\N	\N	ADDENDUM, January 10, 2012: As I reported previously, some of the constituent melanocytes have enlarged nuclei, this proliferation could also be interpreted as a spitzoid deep penetrating nevus (or perhaps as a Spitz nevus). Per your request, we completed array-based comparative genomic hybridization (aCGH) assessment of this tumor to screen for melanoma-associated genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in chromosome 9 with equivocal segmental loss in chromosomes 7p and 8p. The identification of chromosome 9 loss represents an ambiguous aCGH result. We have identified chromosome 9 loss as a monoaberration in some melanomas, but we have also found chromosome 9 loss in proliferations in which the best expert microscopic interpretation was as a melanocytic nevus. In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced an unequivocal diagnosis. Based solely upon conventional microscopy, I favor an unconventional deep penetrating melanocytic nevus as most likely. The results of our aCGH analysis have additionally raised melanoma of 1.6 mm in thickness as a diagnostic possibility. The proliferation appears excised in the available planes of section in the current specimen. Additional excision and ongoing clinical follow-up will be necessary in light of the fact that melanoma has now been raised as a distinct possibility in the differential diagnosis.	INTRADERMAL PROLIFERATION OF MELANOCYTES, WITH MANY ATTRIBUTES OF A DEEP PENETRATING MELANOCYTIC NEVUS	173508	1721	\N	\N	11-85859	\N	SYNAT414	2010-2017	IP1075307	AirTable blocks_with_IP_info.csv
2628	20-36500A	32	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.5	\N	\N	Sections show a predominantly intradermal proliferation of melanocytes with a wedge shaped profile. Nests of melanocytes with round nuclei and scant cytoplasm are present in the superficial dermis. They mature to single melanocytes and cords of them positioned between thickened collagen bundles in the dermis below.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A) 3 X 3 MM, B) 2 X 3 MM, A-B) MORPHOLOGY: SUSPICIOUS IRREGULAR MULTI-COLORED MACULE AND 3 X 3 MM, DDX: MELANOMA VS. PIGMENTED BASAL CELL CARCINOMA VS. DYSPLASTIC NEVUS VS. ATYPICAL NEVUS	\N	\N	FFPE	This benign lesion shares a fibrotic dermal reaction with desmoplastic Spitz's nevus, but lacks the large melanocytes seen in that condition.	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	273588	1387	\N	\N	20-36500	A	SN-24	Sclerotic Nevi	IP2184119	AirTable blocks_with_IP_info.csv
2635	20-48338A	56	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.2	\N	\N	Sections show a dome shaped skin segment with a compound proliferation of melanocytes with spindled melanocytes evenly positioned between slightly thickened collagen bundles in the dermis. The dermal component matures with descent.	Skin segment measuring 0.4 x 0.2 x 0.1 cm. Submitted intact with fragment in A. BB/BB	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA. ERYTHEMATOUS SCALY PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA. ERYTHEMATOUS SCALY PAPULE.	\N	\N	FFPE	\N	COMPOUND MELANOCYTIC NEVUS	173230	1388	\N	\N	20-48338	A	SN-25	Sclerotic Nevi	IP515987	AirTable blocks_with_IP_info.csv
1781	14-53094\t	80	\N	\N	\N	T1b	Primary	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26338	172.7	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of melanocytes involving the epidermis and superficial dermis. There are foci in which single melanocytes predominate along the junction, with some of them scattered above the basal layer. Nests of melanocytes are distributed at irregular intervals along the junctional zone, and are focally confluent.  The lesional melanocytes have moderately abundant pale cytoplasm and variably large nuclei at the dermo-epidermal junction with areas in which the dermal component contains aggregates of similar but smaller cells, and a focally dense lymphocytic infiltrate. Several mitotic figures are present in the upper part of the dermal component.	Skin segment measuring 1.5 x 1.5 x 0.2 cm, serially sectioned and entirely submitted with five sections. PL/PL	1.2 X 1.1 CM; R/O MM	\N	\N	\N	The intraepidermal component of this melanoma extends to within 1 mm. of  the peripheral edge of the specimen. While the lesion is not ulcerated, the presence of several melanocytes in mitosis in the dermis qualifies this lesion as T1b in the 2009 AJCC staging classification for melanoma. Some of the smaller melanocytes in the superficial dermis may be those of a pre-existent melanocytic nevus. Re-excision of this site is of course appropriate.	MELANOMA, 0.9 MM. IN THICKNESS	173710	2219	\N	\N	14-53094	\N	SYNAT110	Melanoma Evolution	IP1403032	AirTable blocks_with_IP_info.csv
1802	14-78242	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26310,26311, 26195	\N	\N	Smallish nevus but good\n	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	759	\N	\N	14-78242	\N	JJS20	Melanoma Evolution,Melanoma Epigenetics	\N	AirTable blocks_with_IP_info.csv
1541	11-95663	24	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a proliferation of large fusiform and oval melanocytes involving the superficial, mid and focally the deep reticular dermis. There are fascicles of cells with large vesicular or diffusely hyperchromatic nuclei and relatively small nucleoli, some positioned along the axes of folliculosebaceous units. There is dispersion from large to smaller groups in the interstitial reticular dermis. I did not detect expansile-appearing aggregations of melanocytes or melanocytes in mitosis.	One outside slide, S11-12286:A1. One corresponding block received 1-3-12.	A) DERMATOFIBROMA, B) 4 MM NEVUS	\N	\N	\N	The differential diagnosis includes an unusual Spitz's nevus, as well as a low-grade spitzoid melanoma. Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a low proliferation rate (my estimate is between 1 and 3%). A phosphohistone H3 immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows positive nuclei among the large, spindled melanocytes. Comparative genomic hybridization shows gains and losses in portions of both the short and long arms of chromosome 7, and and area of loss near the terminal portion of chromosome 16q. While chromosome 7q gains can occur in some Spitz's nevi, the mixture of gains and losses within the same chromosome seen here favors a spitzoid melanoma. If the lesion has been re-excised, I would prefer to issue a final report after seeing the residuum.	INTRADERMAL PROLIFERATION OF LARGE SOMEWHAT SPITZOID MELANOCYTES, WITH GENOMIC FINDINGS WORRISOME FOR MELANOMA	173406	2139	\N	\N	11-95663	\N	SYNAT415	2010-2017	IP1085111	AirTable blocks_with_IP_info.csv
1275	07-14044A	45	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show an asymmetrical, poorly circumscribed, compound proliferation of melanocytes, many of which have atypical nuclei. There are irregular clusters of similar melanocytes in the underlying dermis. Many of the melanocytes are spindled or epithelioid, and some perimelanocytic clefts are evident. Melanocytes are scattered above the basal layer. Mitotic figures are evident within the dermal component which fails to mature with descent in the dermis. The overlying epidermis is thickened and hyperkeratotic. There is focal hemorrhagic crust.	Oval excision, 1.1 x 0.8 x 0.3 cm, including a central 0.7 x 0.5 cm lesion.  With margins inked blue, the specimen is serially quadrisected perpendicular to the long axis and entirely submitted.	R/O MELANOMA	\N	\N	\N	Although there are some features reminiscent of a Spitz's nevus, this is a markedly asymmetrical and poorly circumscribed neoplasm. In terms of staging, this is a non-ulcerated melanoma of Clark's anatomic level IV, expanding the papillary dermis and involving the superficial reticular dermis. There is no evidence of vascular invasion, neurotropism, or regression. Complete excision is of course warranted.	MELANOMA, 1.2 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS CLOSE TO THE PERIPHERAL MARGIN	173601	2214	\N	\N	07-14044	A	SYNAT416	Spitzoid Melanoma	IP636575	AirTable blocks_with_IP_info.csv
2565	19Rig750007.05.07.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	296	\N	\N	None	\N	CM-63	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1279	07-26247	46	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a compound proliferation of large spindled and epithelioid melanocytes, the junctional component of which is arrayed with the lowermost sections of an epithelium that is slightly acanthotic and hyperkeratotic. The junctional component is asymmetrical, and extends far lateral to the dermal component at one edge.  Rare melanocytes are positioned above the basal layer, and there is focal crust and serum.  The dermal component is also asymmetrical.  It consists of large and small clusters and syncytia of similar melanocytes, with slight dispersion of the base, but with little diminishment in size with the dermal descent.  Many mitotic figures are identifiable within the dermal component, in the superficial and mid dermal components mainly. Minimal solar elastosis is evident.	Skin segment measuring 1.2 x 0.7 x 0.3 cm, bisected (fragmented upon embedding into 3 pieces) and entirely submitted.	HAD RED SPOT BELOW RT PATELLA 5 MONTHS AGO, CENTER TURNED BLACK, HAS BLED TWICE AFTER CUT IT SHAVING HER LEG, THE GROWTH IS 8 X 12 MM WITH 6 MM BLACK PAPULE IN CENTER - FLESH AREA, SUPERIORLY IS REDDISH, FLAT AREA BELOW IT IS LIGHT BROWN	\N	\N	\N	We have examined this problematic lesion on several occasions since its receipt. Although there are some features similar to those seen in a Spitz's nevus, and in fact, we considered an unusual Spitz's nevus as an alternative diagnosis, this proliferation is markedly asymmetrical.  In addition, mitotic figures are readily evident within the dermal component.  I have also shared this case with my colleague, Dr. Philip LeBoit, who agrees that melanoma is a more appropriate diagnosis based on these findings. In terms of staging, this is a nonulcerated primary melanoma of Clark's anatomic level at least IV. There is no evidence of vascular invasion, neurotropism, or regression. Definitive assessment of thickness as well as other prognostic factors should also be deferred to the complete excision specimen.	MELANOMA, AT LEAST 2.3 MM IN THICKNESS, EXTENDING TO THE EDGES AND BASE OF THE SPECIMEN	32765	2294	\N	\N	07-26247	\N	SYNAT417	Spitzoid Melanoma	IP208441	AirTable blocks_with_IP_info.csv
1999	16-109659A4	67	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22139,25172	172.4	\N	\N	Sections show a very local multilobular proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, with atypical nuclei. These cells for expansile nests.  Separate nodular foci are present and a collection of these cells is noted in a blood vessel. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.  Biopsy site changes are noted.	Oriented oval excision, 5.8 x 5.5 x 2.0 cm, including a central 2.7 x 2.0 cm raised area. With the orienting single suture located at the midpoint of one edge and placed distally to the grosser, the single suture is indicated 12 o'clock on the requisition. There are double sutures at 3 o'clock, triple sutures at 6 o'clock and quadruple sutures at 9 o'clock as indicated on the requisition. The 9-12-3 o'clock margin is inked blue and the 3-6-9 o'clock margin is inked yellow. Six representative sections submitted with two half-sections (one section) in A1, one-half section each in A2-A9 and two half sections (one section) in A10. PL/PL	A) RIGHT PARIETAL SCALP MELANOMA, B) RIGHT NECK SENTINEL LYMPH NODE #1 EXVIVO 1780, C) RIGHT NECK SENTINEL LYMPH NODE #2 EXVIVO 1000, D) RIGHT NECK SENTINEL LYMPH NODE #3 EXVIVO 400, E) RIGHT NECK SENTINEL LYMPH NODE #4 EXVIVO 500, F) RIGHT NECK SENTINEL LYMPH NODE #5 EXVIVO 5000	\N	\N	Scraping	This excision specimen demonstrates a very thick melanoma that has arisen in association with a congenital melanocytic nevus.  Microsatellite metastases are noted and a focus of vascular invasion is present. Diagnostic features of note include:  Procedure: Excision Tumor site: Scalp Microscopic tumor type: Nevoid Breslow thickness: 12.0 millimeters Ulceration: Present (I assume this is from the prior biopsies) Margins, peripheral and deep: Free Mitotic index: 2/mm2 Microsatellitosis: Present Vascular invasion: Present Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT4a (as initial biopsy was not reported as ulcerated)N2c	MELANOMA, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, APPROXIMATELY 12.0 MILLIMETERS IN THICKNESS, COMPLETELY EXCISED	172438	1096	\N	\N	16-109659	A4	ME-01	Melanoma Epigenetics	IP1687145	AirTable blocks_with_IP_info.csv
1352	09-37302	66	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show an asymmetrical and poorly circumscribed, compound proliferation of spindled to epithelioid melanocytes, many of which have atypical nuclei, arrayed as irregular nests and single melanocytes within the epidermis, with adnexal extension, and areas of suprabasal scatter.  There are irregular clusters of similar melanocytes in the underlying papillary dermis along with some slightly smaller ones.  The overlying epidermis is thickened, with intertwining rete. There is a patchy infiltrate of lymphocytes.	Ellipse, 1.0 x 0.7 x 0.5 cm. With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections.\n	IRRITATED SK VS. OTHER	\N	\N	\N	This is a non-ulcerated melanoma with associated Clark's level II invasion. The measurement of thickness may be a slight overestimate, as there is epidermal hyperplasia. There is no evidence of associated vascular invasion, perineural invasion, or regression.	MELANOMA, 0.8 MM IN THICKNESS, EXTENDING INTRAEPIDERMALLY TO THE PERIPHERY OF THE BIOPSY	529698	2200	\N	\N	09-37302	\N	SYNAT418	Spitzoid Melanoma	IP838065	AirTable blocks_with_IP_info.csv
1661	12-79358	25	\N	\N	1	T1b	Primary	None	\N	\N	\N	\N	\N	172.6	\N	\N	There is a compound proliferation of melanocytes mostly involving the superficial dermis. The surface is slightly domed and slightly papillated. The predominant population consists of large oval melanocytes with pale, variably vacuolated and lightly pigmented cytoplasm with relatively monomorphous oval vesicular nuclei that contain small nucleoli. There are large aggregations of these cells within dermal papillae, and progressively smaller ones, with cytologic maturation toward the upper reticular dermis. Additionally, discrete nests of small round melanocytes are present.	One outside slide, PD903226 / A, and one corresponding block.	DYSPLASTIC NEVUS VS. IRRITATED NEVUS	\N	\N	\N	The differential diagnosis included a combined (deep penetrating or Spitz) and superficial congenital nevus, and melanoma arising in a nevus. Comparative genomic hybridization shows losses involving chromosomes 9p, areas of both 10 p and q and 14. Losses involving chromosomes 9p and 10 are among the most commonly seen in melanoma. While the lesion is not ulcerated, the presence of a melanocytes in mitosis in the dermis (low mitotic rate, 1 per mm2) qualifies this lesion as T1b in the 2009 AJCC staging classification for melanoma. A pre-existent melanocytic nevus with congenital features is also present.	MELANOMA, 0.7 MM. IN THICKNESS	173611	1932	\N	\N	12-79358	\N	SYNAT419	2010-2017	IP1165175	AirTable blocks_with_IP_info.csv
1664	12-81749	6	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a small excisional specimen that harbors a compound proliferation of enlarged fusiform and epithelioid melanocytes. A modest number of giant fascicles of these melanocytes are distributed asymmetrically along the junction, and portions of the background epidermis show irregular acanthosis. In fibrotic dermis below this, there are large nests, cords, and fascicles of similar melanocytes that extend through the reticular dermis into the upper subcutis. The melanocytes diminish slightly in size with descent in the dermis, but many melanocytes in mitosis can be found, including mitotic figures within deep melanocytic aggregates. The fibroplasia that is present stems, in part, from a prior biopsy in this region.	Six outside slides, S12-41686 / 1 (RS12-11612 / B), including five unstained slides.	R/O MELANOMA, REVIEW AND CGH ANALYSIS	\N	\N	\N	Our differential diagnosis included a highly unconventional Spitz nevus on one hand and childhood-type spitzoid melanoma on the other. As per your request, we completed array-based comparative genomic hybridization (aCGH) to screen for chromosomal copy number abnormalities, as can be seen with melanoma. After extraction of tumoral DNA from the tissue block, application of aCGH revealed no chromosomal gains or losses. As you know, most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. Rather, the results of our assessment favor interpretation as an unconventional melanocytic nevus. Please note that this melanocytic proliferation focally involves the deep edge of the current specimen. Reexcision may be necessary to ensure that local eradication has been accomplished. Close clinical follow-up of the specimen site is warranted at a minimum.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	COMPOUND PROLIFERATION OF ENLARGED SPITZOID MELANOCYTES, CONSISTENT WITH AN UNCONVENTIONAL COMPOUND SPITZ NEVUS	173201	2066	\N	\N	12-81749	\N	SYNAT420	2010-2017	IP1167566	AirTable blocks_with_IP_info.csv
1671	12-98736	68	\N	\N	\N	T2a	Primary	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show enlarged epithelioid and fusiform melanocytes arrayed in compound fashion with lateral extension of the intraepidermal component. There are single melanocytes and nests and fascicles of melanocytes in acanthotic epidermis, and some scatter in the stratum spinosum is appreciable. Rare small pink globules are noted. In the dermis, there are nests, cords, and small syncytia of similar melanocytes, and some melanocytes seem to have granular cytoplasm. Partial maturation is noted.	Three outside slides, PC12-352427-HD and one corresponding block.	LESION IS SAID TO HAVE BEEN PRESENT FOR QUITE SOME TIME	\N	\N	\N	ADDENDUM, January 25, 2013: As I reported previously, our differential diagnosis included an unconventional Spitz nevus and nevoid/spitzoid melanoma. Your Ki-67 immunostain shows a low cell proliferation index, which is reassuring but not definitive. We also completed a p16 immunostain and demonstrated retention of positive expression, as can be seen with melanocytic nevi. Per your approval, we pursued array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies, as can be seen with melanoma. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 5q, 7, and 15q. The identification of multiple genomic copy number abnormalities suggests genomic instability and favors melanoma as most likely. However, some of the genomic aberrations that have been identified, such as gain in chromosome 15q, are not anomalies that are specific to melanoma (it can also be seen in some Spitz tumors).  In summary, the combination of results derived from conventional microscopy coupled with aCGH favors a diagnosis melanoma. With respect to staging, this melanoma is between 1-2 mm in thickness and lacks associated ulceration. Therefore, it represents melanoma of stage pT2a (2009 AJCC Guidelines). Further excision is warranted to ensure that local eradication has been accomplished.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	MELANOMA OF 1.3 MM IN THICKNESS, EXTENDING INTRAEPIDERMALLY TO THE SPECIMEN PERIPHERY	173628	2279	\N	\N	12-98736	\N	SYNAT422	2010-2017	IP1184553	AirTable blocks_with_IP_info.csv
1685	13-3874	2	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a protuberant compound proliferation of enlarged melanocytes with a partially polypoid profile. There are single melanocytes and nests and fascicles of melanocytes arrayed relatively confluently along the junction of a hyperkeratotic epidermis, and partially maturing nests, cords, and fascicles of melanocytes reside in the dermis below this, extending deeply. An element of superficial dermal edema is also noted.	One outside slide, DPR-12-11014:A1, and one corresponding block, DP12-11014:A1.	5 X 6 MM PINK PAPULE; SPITZ'S NEVUS VS. JXG	\N	\N	\N	Our differential diagnosis included an unconventional (and hypercellular) Spitz nevus and spitzoid melanoma. To more fully assess this differential diagnosis, per your request, we completed array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies, as can be seen with melanoma. After extraction of tumoral DNA from the tissue block, application of aCGH revealed no chromosomal gains or losses. As background for understanding this result, please note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. Rather, our histopathologic and molecular assessment points to interpretation as a Spitz nevus. This melanocytic tumor appears narrowly excised in the available planes of section.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	PARTIALLY POLYPOID COMPOUND PROLIFERATION OF ENLARGED MELANOCYTES, CONSISTENT WITH A POLYPOID COMPOUND SPITZ NEVUS	173304	2032	\N	\N	13-3874	\N	SYNAT423	2010-2017	IP1188617	AirTable blocks_with_IP_info.csv
2625	20-34915	26	\N	\N	\N	None	None	None	5	0	FFPE	\N	\N	216.6	\N	\N	Sections show a proliferation of melanocytes arrayed as maturing nests, cords, and syncytia with multinucleation, and deeply the melanocytes transition to fusiform cells in collagenous hypervascular stroma with an associated lymphohistiocytic infiltrate. The cells of interest have a low Ki-67 cell proliferation index. Expression of p16 is retained	Six outside slides, DF0222362 Jar 1, Bk 4. Four unstained received 5/13/20.	IMPRESSION WAS ATYPICAL NEVUS	\N	\N	FFPE	This represents a so-called perineuriomatous melanocytic nevus. Melanoma is not present here.	DESMOPLASTIC MELANOCYTIC NEVUS WITH ASSOCIATED DEEP NERVE SHEATH DIFFERENTIATION	173688	1391	\N	\N	20-34915	\N	SN-28	Sclerotic Nevi	IP2182521	AirTable blocks_with_IP_info.csv
1684	13-3732	36	\N	\N	\N	T2a	Primary	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show melanocytes arrayed in largely dermal fashion. Superficially, there are large nests and syncytia of enlarged epithelioid melanocytes in the upper dermis, and these melanocytes have finely melanized cytoplasm. In a recut section, some of these melanocytes appear spitzoid. More deeply, there are fusiform and dendritic melanocytes that are much smaller residing in the reticular dermis, and interstitial melanophages can be seen.	Four outside slides, CSI-13-225, and one corresponding block.	4 MM BROWN FIRM PAPULE, (+) PIGMENTED AT BASE, ONSET 2 YEARS AGO, INCREASING IN SIZE + COLOR CHANGES X 1 YEAR, 2 SECTIONS IN BOTTLE, PROCESS ALL FRAGMENTS; SK, RULE OUT MM	\N	\N	\N	ADDENDUM, February 8, 2013: As I reported previously, my differential diagnosis included a variant of cellular blue nevus, a combined melanocytic nevus, and melanoma ex blue nevus. Your submitted immunostains demonstrate avid expression of HMB-45, as would be expected with a blue nevus or blue nevus-like melanoma. Cell proliferation analysis was completed via immunoperoxidase staining utilizing a two-color development system in which MART-1 is labeled red and Ki-67 is labeled brown. By this staining method, we found diffuse MART-1 reactivity. The MART-positive cells show slightly elevated nuclear expression of Ki-67, thus implying that cellular proliferation is elevated, which is of potential concern. A p16 immunostain demonstrates preservation of expression, which implies that an underlying anomaly in chromosome 9p is not present. This is the type of challenging case for which array-based comparative genomic hybridization (aCGH) can be applied to screen for genomic copy number anomalies, as can be seen with melanoma. Per your request and approval, completed molecular assessment. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 7, 8, and 22q. The identification of multiple chromosomal copy number aberrations indicates genomic instability, as is stereotypical of malignancies such as melanoma. The aCGH profile that we have defined is incompatible with a benign interpretation.  In summary, the combination of results derived from conventional microscopy coupled with aCGH demonstrates that this atypical melanocytic tumor represents melanoma that has developed secondarily in a blue nevus. This entity can be referred to as 'blue nevus-like melanoma'. With respect to staging, this melanoma is between 1-2 mm in thickness and lacks associated ulceration in the current sections. Therefore, it provisionally represents melanoma of stage pT2a (2009 AJCC Guidelines). The final microstage parameters can be reassessed once this melanoma has been fully extirpated.  This report was reissued on April 24, 2014, to add the patient's UCSF Medical Record number and to forward a copy to UCSF Medical Records.	MELANOMA OF AT LEAST 1.8 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A BLUE NEVUS	100678	1810	\N	\N	13-3732	\N	SYNAT424	2010-2017	IP1188475	AirTable blocks_with_IP_info.csv
1687	13-4090B	50	\N	\N	\N	T2a	Primary	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a compound proliferation of melanocytes that is well-circumscribed and symmetric. Large nests of melanocytes with moderately large nuclei and moderate amounts of pale cytoplasm are present at the size and bases of elongated rete ridges. Some adjacent rete ridges are fused at their bases and the underlying papillary dermis is fibrotic.  Centrally, the epidermis is effaced with large nests of melanocytes within sclerotic collagen below. There is a focal patchy lymphocytic infiltrate with scattered melanophages throughout the lesion.  The proliferation demonstrates even maturation with descent into the reticular dermis and there is a periadnexal distribution. One dermal mitosis is noted which may be within a melanocyte.	Ellipse, 2.2 x 1.3 x 0.8 cm, including a central 1.4 x 0.7 cm brown area. With the margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with three sections in cassette A, two sections each in cassettes B and C, and three sections in cassette D.  SL/SL	13 X 7 MM PURPLE BLACK CHANGING (LESION X 10 YRS), LAST MEASURED 3/2011 10 X 5 MM	\N	\N	\N	ADDENDUM, February 21, 2013: The following note has been modified from that in the original report and later addenda, copies of which are on file as .pdfs in our computer system: A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) does not demonstrate mitoses within melanocytes, and only rare cells have nuclear phosphohistone H3 staining.  Comparative genomic hybridization shows gains of chromosome 1q, 6, and 15.  The presence of genomic aberrations in this melanocytic neoplasm argues that this represents melanoma and not a severely atypical dysplastic nevus. The lesion is greater than 1 mm in thickness, is not ulcerated, and does not have detectable mitotic figures in its dermal component. Therefore it should be classified as T2a per the 2009 revision of the AJCC staging system for melanoma.	MELANOMA, 1.1 MM IN THICKNESS, FULLY EXCISED (THE FINAL MARGIN APPEARS FREE OF MELANOMA)	100556	2310	\N	\N	13-4090	B	SYNAT426	2010-2017	IP1188833	AirTable blocks_with_IP_info.csv
1688	13-4136	5	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a roughly wedge-shaped proliferation of large oval and fusiform melanocytes with abundant pale cytoplasm and large oval vesicular nuclei with prominent and sometimes multiple, large central nucleoli. A few mitotic figures are seen amongst the lesional cells. There are some melanocytes with scant cytoplasm and others whose nuclei appear to overlap. The overlying epidermis is irregularly hyperplastic, and subepidermal granulation tissue is focally evident.	Three outside slides, D13-556 / 1-3.  Three corresponding blocks received 1-28-13.	REEXCISION (SEE L12-93693).	\N	\N	\N	The residuum has some worrisome features. The changes in the initial biopsy suggested a minor population of cells with copy number aberrations involving whole chromosomes, a pattern usually seen in proliferative nodules rather than in atypical Spitz tumors or spitzoid melanomas. The same findings were seen in the repeat testing, indicating that the copy number aberrations are in a significant portion of the lesion, and not just in a minor component. I favor regarding this lesion as an atypical Spitz tumor and not just as a Spitz's nevus. The removal appears complete. While lesions of this type have a high probability of involving a sentinel lymph node, the predictive value of this for distant metastasis is very low.	HEALING BIOPSY SITE AND RESIDUAL INTRADERMAL PROLIFERATION OF LARGE, SPITZOID MELANOCYTES	173305	2229	\N	\N	13-4136	\N	SYNAT427	2010-2017	IP1179510	AirTable blocks_with_IP_info.csv
1690	13-7186	59	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a broad, asymmetrical, and incompletely circumscribed compound proliferation of enlarged fusiform and epithelioid melanocytes. These cells are distributed singly and in nests and fascicles along the junction, and areas of thinning are noted. In the dermis below this, the constituent cells mature to form nests, sheets, and syncytia that fill and expand the papillary and superficial reticular dermis. The constituent melanocytes have amphophilic cytoplasm that is sometimes finely melanized, and scattered accompanying melanophages are noted. Only rare dermal mitotic figures can be found. The tumor thickness is 2.2 mm.	Four outside slides, SH-13-2468 (B1-B2) and corresponding block B2.	CHANGING MOLE X 10 YRS	\N	\N	\N	ADDENDUM, March 14, 2013: As I reported previously, my differential diagnosis included an unconventional melanocytic nevus and nevoid melanoma. Your submitted immunoperoxidase stains included a Ki-67 stain that demonstrates a low cell proliferation index. We additionally completed p16 and BAP-1 immunostains in our assessment. There is a marked loss of p16 expression, which implied that underlying loss in chromosome 9p might be present (this proved not to be the case, as is discussed further below). There is preservation of BAP-1 expression, and thus there is not an underlying anomaly in chromosome 3p. Per your approval, we pursued array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies, as can be seen with melanoma. After extraction of tumoral DNA from the tissue block, application of aCGH revealed several contiguous areas of gain within chromosome 15q with no other associated chromosomal gains or losses. (With specific reference to chromosome 9, no gain or loss was found.) We have observed gain in chromosome 15q as a monoaberration in a series of atypical Spitz (or pigmented spindle cell) nevi, and this genomic anomaly is not believed to be indicative of a diagnosis of melanoma. Rather, we believe the gain is a consequence of NTRK3 gene rearrangement.  In summary, although I had reservations regarding the possibility of nevoid melanoma based upon conventional histopathologic findings, the combination of results derived from conventional microscopy coupled with aCGH favors instead interpretation as an unconventional melanocytic nevus (or unconventional Spitz/Reed nevus). My colleague, Dr. Boris Bastian, has reviewed the molecular findings for this case and is in agreement with my diagnosis. Given the complexity of this case, it would certainly be reasonable to complete reexcision of this site in follow-up.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	HYPERCELLULAR COMPOUND PROLIFERATION OF ENLARGED SPITZOID MELANOCYTES, FOCALLY TRANSECTED AT THE SPECIMEN PERIPHERY	173727	2033	\N	\N	13-7186	\N	SYNAT428	2010-2017	IP1191929	AirTable blocks_with_IP_info.csv
1672	13-25A	48	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a relatively narrowly based lesion in which a thickened epidermis with rounded rete ridges overlies a dermal proliferation of melanocytes, with moderate amphophilic cytoplasm and enlarged nuclei, some hyperchromatic, distributed singly or in small collections in the dermis. There is elastotic stroma. The enclosed two-color immunostain shows that there is a low proliferation rate among the lesional melanocytes.	Three outside slides, D12-48401, and one corresponding block.	A) ERYTHEMATOUS NODULE; DF, B) EXCISION WITH 1 CM MARGINS OF DERMAL MELANOCYTIC PROLIFERATION	\N	\N	\N	\N	MELANOMA, 1.2 MM. IN THICKNESS	173602	1757	\N	\N	13-25	A	SYNAT429	2010-2017	IP1184767	AirTable blocks_with_IP_info.csv
3127	86541-1g	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	MIS1	AM2-006_1.3	\N	\N	\N	\N	Heel	Punch	\N	\N	\N	4	\N	\N	None	\N	AM2-006	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3126	86541-1f	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-006_1.2	\N	\N	\N	\N	Heel	\N	\N	\N	\N	4	\N	\N	None	\N	AM2-006	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3125	86541-1E	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Mel 1	AM2-006_1.1	\N	\N	\N	\N	Heel	Punch	\N	\N	\N	4	\N	\N	None	\N	AM2-006	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3128	86541-2a	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Metastasis	AM2-006_2.1	\N	\N	\N	\N	Right inguinal	\N	\N	\N	\N	4	\N	\N	None	\N	AM2-006	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3130	86541-2c	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	Normal	AM2-006_2.3	\N	\N	\N	\N	Right inguinal	Punch	\N	\N	\N	4	\N	\N	None	\N	AM2-006	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2214	17-99365	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=24929	\N	\N	\N	\N	\N	\N	\N	\N	Punch	\N	\N	\N	1100	\N	\N	17-99365	\N	ME-05	Melanoma Epigenetics	\N	AirTable blocks_with_IP_info.csv
3107	78821-1b	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-002_1.2	\N	\N	\N	\N	Left Hallux	\N	\N	\N	\N	2	\N	\N	None	\N	AM2-002	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1782	14-53375	68	\N	\N	\N	T1a	Primary	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26345	172.6	\N	\N	Sections show an asymmetric proliferation of melanocytes distributed singly and as variably sized nests along the junction and within the subjacent dermis. Scattered melanocytes are also present above the basal layer. Nests of melanocytes focally extend along adnexal epithelium. Nuclear pleomorphism and hyperchromasia are noted. The dermis is elastotic.	Skin segment, 1.5 x 0.7 x 0.1 cm, trisected and entirely submitted. PL/CL	15 X 9 MM, NEW HYPERPIGMENTED PATCH WITH SUPERIOR ERYTHEMATOUS SENSITIVE-TO-TOUCH PATCH; R/O DN VS. MM VS. INFLAM AK	\N	\N	\N	With respect to staging, this non-ulcerated melanoma does not have melanocytes in mitosis in its small invasive component. Therefore, it represents a melanoma of stage pT1a (2009 AJCC Guidelines). The final microstage parameters can be reassessed once this melanoma has been fully extirpated.	MELANOMA OF 0.5 MM IN THICKNESS, INVOLVING THE DEEP EDGE OF THE BIOPSY	173688	2207	\N	\N	14-53375	\N	SYNAT111	2010-2017	IP1403313	AirTable blocks_with_IP_info.csv
2280	18-00192	\N	\N	\N	\N	\N	\N	\N	20	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	palate	FFPE	\N	\N	\N	1280	\N	\N	18-192	\N	OM-22	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1813	14-99831	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1673	\N	\N	14-99831	\N	SYNAT130	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1814	14-102015A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2204	\N	\N	14-102015	A	SYNAT131	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1820	14-118975	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1803	\N	\N	14-118975	\N	SYNAT134	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1997	16-108474	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1318	\N	\N	16-108474	\N	OM-60	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1827	15-3641	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2079	\N	\N	15-3641	\N	SYNAT135	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1063	02-26442 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1051	\N	\N	None	\N	MD-174	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3020	99-16706 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1066	\N	\N	None	\N	MD-189	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3007	98-21389A T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1067	\N	\N	None	\N	MD-190	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2999	98-06203-3 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1068	\N	\N	None	\N	MD-191	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2988	97-8417 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1069	\N	\N	None	\N	MD-192	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2959	95-02325-1 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1070	\N	\N	None	\N	MD-193	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2926	90-07958-1 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1071	\N	\N	None	\N	MD-194	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1940	16-31317 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	943	\N	\N	None	\N	MD-37	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1296	07B2313 (eppendorf)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1193	\N	\N	None	\N	NM-006	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1778	14-48102	26	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.7	\N	\N	There is a compound proliferation of large, oval and fusiform melanocytes with abundant, pale amphophilic cytoplasm and large, vesicular nuclei and large, central nucleoli, some eosinophilic. The lesion is raised, and nearly pedunculated. There is irregular epidermal hyperplasia overlying large confluent nests of the above-mentioned cells, with areas in nests are confluent both in the upper and lower parts of the lesion. Many admixed melanophages are present.	One outside slide, S12235/14 / A2, and one corresponding block.	PT PREGNANT 26 WEEKS, RAPIDLY GROWING LESION; ? PYOGENIC GRANULOMA, BUT EXCLUDE MELANOMA, DIFFERENTIAL IS ATYPICAL SPITZ TUMOUR VS. SPITZOID MELANOMA	\N	\N	Scraping	Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in Spitz nevi. These include gains of 1q, a gain involving the distal part of 5q, a gain of 6p and a loss of 6q, a low level gain of chr. 7, a loss of chr. 9p, an amplification involving chr. 10p, loss of chr. 11, and loss of chr. 14.	MELANOMA, 2.5 MM. IN THICKNESS	101721	242	\N	\N	14-48102	\N	CGH14-145	Nevus Library	IP1398038	AirTable blocks_with_IP_info.csv
2967	95-21392	53	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1383	172.5	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly within the epidermis, with foci of pagetoid upward scatter.  Some melanocytes have atypical nuclei.  Aggregations of similar melanocytes are present in the dermis.	Cylindrical skin segment, 7 mm in diameter, 6 mm in depth, bisected.	GROWING MOLE 5 X 6 MM, BLACK WITH FAINT ERYTHEMA. CLINICAL DIAGNOSIS - R/O MELANOMA	\N	\N	\N	A few small and bland melanocytes are present at the base of this proliferation, and these changes probably represent a precursor melanocytic nevus.  The bulk of the present lesion consists of melanoma.	MELANOMA, 0.95 MM IN THICKNESS, EXTENDING NEAR TO THE PERIPHERAL BIOPSY MARGIN	173527	224	\N	\N	95-21392	\N	CCR-274	California Cancer Registry	IP51560	AirTable blocks_with_IP_info.csv
2543	19Rig750007.04.04.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	282	\N	\N	None	\N	CM-45	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2544	19Rig750007.04.05.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	283	\N	\N	None	\N	CM-46	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
3085	12410/09	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1220	\N	\N	None	\N	NM-43	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2990	97-23367	56	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1430	172.6	\N	\N	Sections show nested and solitary melanocytes, some with atypical nuclei, arrayed irregularly within the epidermis.  In the underlying dermis, there are irregularly-shaped, horizontally-oriented clusters of similar but slightly smaller melanocytes, which are surrounded by fibrosis.  These changes are present above elastosis.  There is pagetoid upward spread.  Large spindled melanocytes are seen at the base of the lesion.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely\nsubmitted.	CLINICAL DIAGNOSIS - R/O MELANOMA, R/O BCC	\N	\N	\N	Melanomas in which small, round cells predominate in the dermal component have been termed nevoid melanoma, or minimal deviation melanoma. Several studies have suggested that there is no prognostic difference between this form and conventional melanoma.	MELANOMA, 1.2 MM IN THICKNESS, EXTENDING TO THE DEEP MARGIN	173601	239	\N	\N	97-23367	\N	CCR-316	California Cancer Registry	IP126136	AirTable blocks_with_IP_info.csv
2521	19rig750007.02.11.01	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	302	\N	\N	None	\N	CM-76	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1716	13-32637	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-25	http://64.54.108.121/eSlideTray.php?ImageIds=32770	\N	\N	4611431	\N	\N	\N	\N	Skin, chest, right, biopsy, consistent with superficial spreading malignant melanoma	FFPE	\N	\N	\N	308	\N	\N	13-32637	\N	CME-006	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1718	13-33924	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-25	http://64.54.108.121/eSlideTray.php?ImageIds=32771	\N	\N	2875342	\N	\N	\N	\N	Skin, scalp, frontal, right, incision, malignant melanoma	FFPE	\N	\N	\N	309	\N	\N	13-33924	\N	CME-007	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1724	13-50059	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-25	http://64.54.108.121/eSlideTray.php?ImageIds=32772	\N	\N	2191834	\N	\N	\N	\N	Skin, scalp, nodular melanoma	FFPE	\N	\N	\N	310	\N	\N	13-50059	\N	CME-008	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1763	14-31325	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-25	http://64.54.108.121/eSlideTray.php?ImageIds=32773	\N	\N	5926196	\N	\N	\N	\N	Skin, flank, left, biopsy, melanoma	FFPE	\N	\N	\N	311	\N	\N	14-31325	\N	CME-009	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2477	19-103058B	66	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.5	\N	GNAQ	Sections show conventional melanocytes overlying deeply pigmented fusiform melanocytes.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted in B. HD/HD	A) 3 MM DARK BROWN PAPULE WITH NO PIGMENT NETWORK; R/O ATYPIA VS. NEVUS, B) CONTIGUOUS WITH SK, 4 MM DARK BROWN TO BLACK PAPULE; R/O SK	\N	\N	FFPE	This biopsy contains a combined spindle cell deep penetrating nevus. There is no evidence of malignancy or atypicality.	COMBINED MELANOCYTIC NEVUS	273588	1367	\N	\N	19-103058	B	SN-04	Sclerotic Nevi	IP2107719	AirTable blocks_with_IP_info.csv
2905	23-42323	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	458	\N	\N	23-42323	\N	DMS-046	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2266	17-120049C	49	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18165	216.5	\N	\N	The features are similar to those in (B).	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted in C. KC/KC	A-C) 0.6 X 0.6 CM; R/O DYSP	\N	\N	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	273588	824	\N	\N	17-120049	C	LN-04	Lentiginous Nevi 	IP932194	AirTable blocks_with_IP_info.csv
2263	17-119445	42	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18169	216.7	\N	\N	Sections show acral skin with a proliferation of small melanocytes with round to oval nuclei, positioned singly and as small nests at the epidermal-dermal junction with accompanying epidermal pigmentation. There are papillary dermal melanophages and columns of pigment in the stratum corneum.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/HD	NEW 2 - 3 MM PIGMENTED ACRAL NEVUS	\N	\N	\N	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173788	826	\N	\N	17-119445	\N	LN-06	Lentiginous Nevi 	IP1849984	AirTable blocks_with_IP_info.csv
3075	4890/15 8	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1216	\N	\N	None	\N	NM-38	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1618	12-22775	69	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.52	SCC	\N	Sections show a papillated to crateriform proliferation of atypical keratinocytes with central and overlying ortho- and parakeratosis. Keratinocytes with atypical nuclei are scattered throughout the proliferation.	Skin segment measuring 1.0 x 0.8 x 0.3 cm, trisected and entirely submitted.	0.8 X 1 CM DOME-SHAPED HYPERKERATOTIC PAPULE; KA VS. SCC: TELEPHONE 650-465-3946 (CELL)	\N	Crateriform, chest	\N	None	CRATERIFORM SQUAMOUS CELL CARCINOMA, EXTENDING TO THE BASE OF THE SPECIMEN	173527	1919	\N	\N	12-22775	\N	SYNAT369	2010-2017	IP249102	AirTable blocks_with_IP_info.csv
1607	12-22573	23	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	Melanocytic Nevus	\N	Sections show a dermal proliferation of melanocytes arrayed as nests and syncytia that diminish in size with descent in the dermis. The overlying epidermis shows a papillated configuration, with elongated rete that focally intertwine. There are numerous horn pseudocysts.	Skin segment measuring 1.1 x 1.0 x 0.5 cm, quadrisected and entirely submitted.	BROWN PAPULE WITH A BLACK DOT; R/O MIS	\N	Intradermal, breast	\N	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	192588	2103	\N	\N	12-22573	\N	SYNAT371	2010-2017	IP1108391	AirTable blocks_with_IP_info.csv
2906	23-47727	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=32275,32276,32277,32278,32279	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1163	\N	\N	23-47727	\N	ME-68	Melanoma Epigenetics	\N	AirTable blocks_with_IP_info.csv
1626	12-22898	35	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	Melanocytic Nevus	\N	Sections show a predominantly intradermal proliferation of small melanocytes with round to oval nuclei that mature (diminish in size) with descent in the dermis.  The overlying epidermis shows elongated rete that intertwine.	Skin segment measuring 0.7 x 0.6 x 0.2 cm, bisected and entirely submitted.	CONGENITAL NEVUS	\N	Intradermal, rt upper arm	\N	None	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	173688	2182	\N	\N	12-22898	\N	SYNAT382	Melanocytic Nevus	IP445158	AirTable blocks_with_IP_info.csv
1627	12-22900	59	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.32	SCC	\N	Sections show a proliferation composed of atypical keratinocytes, arrayed as irregular nests that infiltrate the dermis.  Foci of keratinization are apparent.	Skin segment measuring 0.7 x 0.4 x 0.1 cm, bisected and entirely submitted.	R/O BCC	\N	Eyebrow	\N	None	SQUAMOUS CELL CARCINOMA, EXTENDING TO THE DEEP BIOPSY MARGIN	102345	2255	\N	\N	12-22900	\N	SYNAT383	2010-2017	IP2427054	AirTable blocks_with_IP_info.csv
1031	01-17200 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1058	\N	\N	None	\N	MD-181	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1486	11-38771	17	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show enlarged epithelioid melanocytes arrayed in compound fashion. Within the acanthotic epidermis, single melanocytes and nests that vary in size can be seen. Non-maturing nests, small syncytia, and cords can be seen in fibrotic upper dermis, and some of these melanocytes are captured in mitosis. The background epidermis, while generally acanthotic, is focally thinned.	One outside slide, BT11-09846 (DC11-2858), and one corresponding block, BT11-09846.	TRAUMATIZED MELANOCYTIC NEOPLASM FROM THE FOOT	\N	\N	\N	Based upon conventional microscopy, I believe this proliferation represents melanoma. Per your request, we completed array-based comparative genomic hybridization (aCGH) to screen this tissue for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, aCGH analysis demonstrated focal gain in chromosome 1p, gain in chromosome 7q, and losses in chromosomes 1p, distal 1q, 2p, and 14q. As you know, the identification of multiple genomic gains and losses is incompatible with a diagnosis of melanocytic nevus and points squarely to a diagnosis of melanoma. Given the number of aberrations that are present here, I believe this malignancy represents conventional melanoma and not a form of childhood-type melanoma. This melanoma is non-ulcerated and shows associated Clark's level IV invasion. Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 1.75 MM IN THICKNESS, FOCALLY TRANSECTED AT THE SPECIMEN PERIPHERY	173713	2232	\N	\N	11-38771	\N	SYNAT394	2010-2017	IP1028210	AirTable blocks_with_IP_info.csv
1592	12-13587B2	84	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	173.72	SCC	\N	There is an exo-endophytic proliferation of keratinocytes.  Some areas have lobules composed of cells with abundant pale cytoplasm and central foci of abrupt keratinization, while others are composed of cells with a high nuclear to cytoplasmic ratio, and atypical nuclei. The flanking epidermis shows atypical keratinocytes that in several areas involve the entire thickness of the epithelium.	Skin segment measuring 2.3 x 1.6 x 0.6 cm, with a central 1.6 x 1.0 cm raised area. With the peripheral edges and base inked blue, serially sectioned and entirely submitted with two sections each in cassettes B1 thru B3.	A-B) R/O KA	\N	Ext deep margins, leg	\N	While there are some features of keratoacanthoma, the preponderance of atypical keratinocytes and broad zones of squamous cell carcinoma in situ involving the flanking epidermis rules out this possibility.	SQUAMOUS CELL CARCINOMA, EXTENDING TO THE DEEP MARGIN	173740	2082	\N	\N	12-13587	B2	SYNAT368	2010-2017	IP502329	AirTable blocks_with_IP_info.csv
2935	92-03953C T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1074	\N	\N	None	\N	MD-197	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2928	91-08026A T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1075	\N	\N	None	\N	MD-198	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2964	95-14297-5 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1076	\N	\N	None	\N	MD-199	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2968	96-02480 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1077	\N	\N	None	\N	MD-200	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2966	95-16013B T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1078	\N	\N	None	\N	MD-201	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2939	92-18572E T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1079	\N	\N	None	\N	MD-202	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2921	87-14087B T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1080	\N	\N	None	\N	MD-203	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2922	88-6851-2 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1081	\N	\N	None	\N	MD-204	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3170	BB21-21342	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=3581	\N	\N	78-18	\N	\N	\N	\N	gingiva	\N	\N	\N	\N	1271	\N	BB	21-21342	\N	OM-10	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1488	11-39639	11	\N	\N	\N	T2a	Primary	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a dome shaped segment of skin with a few well formed junctional nests of melanocytes with abundant, pale cytoplasm and pleomorphic, heterochromatic nuclei, and irregularly shaped aggregations of similar cells, as well as ones with scant cytoplasm in the subjacent dermis. These are positioned between collagen bundles in the superficial reticular dermis toward the base of the lesion. The nuclei are crowded together in some foci. The enclosed immunoperoxidase stains show that no melanocytic nuclei are positive for the mitotic marker, phosphohistone H3.	Three outside slides, D11-18326 A and one corresponding block.	PINK PAPULE; SPITZ NEVUS	\N	\N	\N	The neoplasm extends to the base of the specimen. Comparative genomic hybridization shows losses involving chromosomes 7p and 9q. Such focused gains or losses, involving only parts of chromosomes rather than whole ones are not seen in so-called proliferating nodules in congenital nevi. Chromosome 9 losses are common in melanoma. The small size of the cells indicates that this is a nevoid or small cell melanoma. The latter is one of the few forms of melanoma that can occur in children. The configuration suggests that this lesion will be (after complete excision) less than 2 mms, and is most likely T2a in the 2009 AJCC staging schema for melanoma.	MELANOMA, 1.2 MM. IN THICKNESS	173721	1861	\N	\N	11-39639	\N	SYNAT405	2010-2017	IP1029078	AirTable blocks_with_IP_info.csv
1313	08-27590	24	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	See above.	Two outside slides, 6110/08 and one corresponding block.	CLINICALLY ANGIOMA OR A FIBROMA SUSPECTED	\N	\N	\N	Both Dr. McCalmont and I favor melanoma over a Spitz's nevus; neither of can rule out melanoma arising in a Spitz's nevus (this diagnosis can be difficult to prove!). The central portion of the lesion is ulcerated, has a thin epidermis, is surrounded by epithelial collarettes and contains melanocytes with striking nuclear atypia, even in the lower half of the lesion. The nests in this area are strikingly confluent. The peripheral part of the lesion resembles a Spitz's nevus, with smaller cells in discrete nests along the dermo-epidermal junction, and some Kamino bodies (highlighted in the PAS stain). The thickness of 3.8 mm. may have been established on examination of a different slide from this one.	MELANOMA, ABOUT 3 MILLIMETERS IN THICKNESS IN THESE SECTIONS	173740	1726	\N	\N	08-27590	\N	SYNAT407	Spitzoid Melanoma	IP736231	AirTable blocks_with_IP_info.csv
1439	11-1969-F	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Tissue was mounted on LCM slides.	\N	\N	\N	\N	\N	\N	\N	\N	\N	1402	\N	\N	None	\N	WS-01	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
1686	13-3889	27	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a broad-based proliferation of melanocytes extending from the junctional zone to the deep reticular dermis. The undersurface of the lesion has a jagged border. The epidermis is hyperplastic, with nests of small fusiform cells with lightly pigmented cytoplasm. The most striking findings are in the dermis, where thin fascicles and singly dispersed cells with large, diffusely hyperchromatic nuclei are present between thin but closely apposed collagen bundles. Maturation with descent is imperfect. Neither expansile-appearing aggregations nor mitotic figures in dermal melanocytes are evident. The enclosed immunoperoxidase-stained sections show an absence of HMB45 staining and a very low proliferative rate.	Ten outside slides, SH-12-0057700 A.1-A.2  Two corresponding blocks received 1-25-13.	FIRM PINK/BROWN PAPULE WITH AN ATYPICAL AREA OF PIGMENTATION; R/O DERMATOFIBROMA	\N	\N	\N	This unusual lesion has some features of a desmoplastic Spitz's nevus, but more nuclei are hyperchromatic than vesicular, and many, even toward the base of the lesion are quite large. Also, the undersurface is more irregular than in most desmoplastic Spitz nevi. For these reasons, we obtained comparative genomic hybridization on this challenging case. This showed a loss of chr. 7p, and a gain involving chr. 15q. Gains, rather than losses of chr. 7p are common in melanoma. Gains of 15q can be seen in melanoma, but usually in concert with other aberrations. Hence, the findings do not provide unequivocal support for melanoma, but do indicate copy number changes not seen in routine Spitz's nevi. I would re-excision this site, and consider this as a lesion with some metastatic potential. I would expect the behavior of a group of lesions with similar findings to these to be better than that of a group of melanomas of comparable thickness.	COMPOUND PROLIFERATION OF LARGE, ATYPICAL MELANOCYTES	173620	1783	\N	\N	13-3889	\N	SYNAT425	2010-2017	IP1188632	AirTable blocks_with_IP_info.csv
1443	11-5210D	46	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.7	\N	\N	Sections show a wedge-shaped proliferation of large oval melanocytes with moderately pleomorphic nuclei and abundant vacuolated cytoplasms, arranged as small nests and fascicles. The apex of the lesion is in the reticular dermis, with a tendency of aggregations to be positioned next to adnexa. There are evenly distributed melanophages.	Cylindrical skin segment, 0.6 cm in diameter and 0.8 cm in thickness, bisected and totally submitted in cassette D.	A-C) IRREGULARLY SHAPED COLORED MACULE; R/O CLARK'S, D) BLACK NODULE; R/O NEVUS VS. MELANOMA	\N	\N	\N	\N	DEEP PENETRATING NEVUS	173726	2121	\N	\N	11-5210	D	SYNAT432	Deep Penetrating Nevus	IP873475	AirTable blocks_with_IP_info.csv
1630	12-24027C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1357	\N	\N	12-24027	C	SMP11	Spitz Melanoma	\N	AirTable blocks_with_IP_info.csv
1450	11-14908C	34	\N	\N	\N	T1a	Primary	None	\N	\N	FFPE	\N	\N	172.6	\N	\N	Sections show melanocytes arrayed in biphasic and compound fashion. One population consists of maturing nests and cords of smallish melanocytes arrayed toward one edge of the specimen. The second larger population includes slightly spindled and epithelioid melanocytes with ample finely melanized cytoplasm. These cells are arrayed as large nests and single cells along the junction with limited intraspinous scatter, and nests of similar melanocytes reside in the perijunctional dermis jointly with an obscuring lymphohistiocytic infiltrate with admixed melanophages.	Ellipse, 2.4 x 1.3 x 0.8 cm, including a central 0.8 x 0.7 cm brown area. With the edges inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections each in A through C.  Subsequently, the wax block C was melted down, three sections were submitted in C1 and one section submitted in C2.	R/O MELANOMA	\N	\N	FFPE	Our differential diagnosis included melanoma ex melanocytic nevus on one hand and a peculiar combined melanocytic nevus on the other, and it is now clear that the former possibility represents the correct interpretation of this melanocytic proliferation. To further assess the nature of this proliferation via molecular means, we completed fluorescence in situ hybridization (FISH) analysis to screen for melanoma-associated genomic anomalies. FISH analysis was fulfilled utilizing a panel of 4 DNA probes (to loci on 6p, 6q, 6cent and 11q) and demonstrated an imbalance in chromosome 6q at the location of the MYB gene as well as gain in chromosome 11q at the location of the CCND1 (cyclin-D1) gene. Both of these genomic anomalies are highly associated with the diagnosis of melanoma and are thus confirmatory of the above diagnosis. This melanoma is less than 1 mm in thickness, lacks associated ulceration, and does not have detectable melanocytes in mitosis in its invasive component. Therefore, it represents a melanoma of stage T1a per the 2009 revision of the AJCC staging system. Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.65 MM IN THICKNESS, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	173688	1394	\N	\N	11-14908	C	VS-01	Spatial Gene Expression	IP1004345	AirTable blocks_with_IP_info.csv
1542	11-95856	32	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.7	\N	\N	Sections show a relatively symmetric and well-circumscribed, roughly wedge-shaped proliferation of spindled and polygonal large melanocytes, some of which have abundant vacuolated cytoplasms, which extends deeply in the reticular dermis around a follicle.  Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous.  There are interspersed densely pigmented melanophages.	Cylindrical skin segment plus fragments, 0.7 cm in diameter and 0.4 cm in thickness in aggregate, trisected and totally submitted.	R/O NEW BLACK NEVUS	\N	\N	\N	While the findings are diagnostic of deep penetrating nevus, the melanocytes are large and conservative excision is recommended.  The excision should extend to the subcutaneous fat, as the lesion is broadly transected at the base of the punch specimen, and only needs to be slightly wider than the biopsy, as the lesion extends focally to the peripheral edge of the specimen. Dr. Philip LeBoit has also reviewed this case and agrees with the diagnosis and assessment.	DEEP PENETRATING NEVUS, EXTENDING FOCALLY TO THE EDGE AND BASE OF THE SPECIMEN	173719	1954	\N	\N	11-95856	\N	SYNAT433	2010-2017	IP1085304	AirTable blocks_with_IP_info.csv
1394	10-23569A	29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a wedge-shaped proliferation of large oval melanocytes with moderately pleomorphic nuclei and abundant vacuolated cytoplasms, arranged as small nests and fascicles. The apex of the lesion is in the reticular dermis, with a tendency of aggregations to be positioned next to adnexa. There are evenly distributed melanophages. Mitoses are not readily identified.	Ellipse, 1.4 x 0.4 x 0.3 cm, including a central raised 0.7 x 0.4 cm lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections in cassette A.	A) R/O ATYPICAL BLUE NEVUS VS. SPITZ NEVUS, B) DYSPLASTIC NEVUS	\N	\N	\N	Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a low proliferative rate thereby supporting the above interpretation.	DEEP PENETRATING NEVUS, NARROWLY EXCISED IN PLANES OF SECTION EXAMINED	174526	2201	\N	\N	10-23569	A	SYNAT434	Deep Penetrating Nevus	IP918142	AirTable blocks_with_IP_info.csv
2858	22-124532-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	https://64.54.108.121/app/WebViewer/view/image/34971	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1399	\N	\N	None	\N	VS-06	Spatial Gene Expression	\N	AirTable blocks_with_IP_info.csv
1358	09-92749	31	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a wedge-shaped proliferation of large oval melanocytes with moderately pleomorphic nuclei and abundant vacuolated cytoplasms, arranged as small nests and fascicles. The apex of the lesion is in the reticular dermis, with a tendency of aggregations to be positioned next to adnexa. There are evenly distributed melanophages.  Thickened collagen bundles are noted within and adjacent to the melanocytic proliferation.	Cylindrical skin segment, 0.8 cm in diameter and 1.3 cm in thickness, quadrisected and entirely submitted.	1 CM BLACK NODULE VERY FIRM; R/O NEVUS VS. MELANOMA VS. DF	\N	\N	\N	There are thickened, sclerotic collagen bundles associated with this nevus.	DEEP PENETRATING NEVUS, EXCISED IN PLANES OF SECTION EXAMINED	173539	1717	\N	\N	09-92749	\N	SYNAT435	Deep Penetrating Nevus	IP893515	AirTable blocks_with_IP_info.csv
1485	11-38149	54	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show an area of inflamed granulation tissue with no evidence of residual melanocytic neoplasm.	Ellipse measuring 2.0 x 1.2 x 0.9 cm.  With the margin inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in cassette A and four sections in cassette B.	RE-EXC DEEP PENETRATING NEVUS	\N	\N	\N	None	HEALING BIOPSY SITE, WITH NO EVIDENCE OF A RESIDUAL DEEP PENETRATING NEVUS	173533	1751	\N	\N	11-38149	\N	SYNAT438	Deep Penetrating Nevus	IP1018350	AirTable blocks_with_IP_info.csv
1408	10-46536	6	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a neoplasm composed of fascicles of melanocytes, involving the superficial and deep dermis, with a propensity for nests to surround adnexal structures.  The constituent melanocytes have abundant pale cytoplasm with dusty melanin, and pleomorphic nuclei.  At the periphery of the neoplasm small collections of melanocytes interweave with thickened collagen bundles. They are associated with many melanophages.  There are lymphocytes throughout the neoplasm.   There is also vacuolar interface change with dyskeratotic keratinocytes.	Cylindrical skin segment, 0.4 cm in diameter and 0.5 cm in thickness, bisected and entirely submitted.	PT WITH NEUROBLASTOMA & 3 X 3 MM BLUISH PAPULE WITH SURROUNDING HALO; R/O BLUE NEVUS VS. CONGENITAL MELANOCYTIC NEVUS VS. METS FROM NEUROBLASTOMA: TELEPHONE 559-589-1501	\N	\N	\N	There is also vacuolar interface change with dyskeratotic keratinocytes.  The epidermal changes and the inflammation surrounding the melanocytic nevus may be related to this patient's recent radio-therapy.  Dr. Philip LeBoit has also reviewed this case and agrees with the diagnosis.	BLUE NEVUS WITH FEATURES OF DEEP PENETRATING NEVUS, INFLAMED, EXTENDING TO THE EDGE OF THE SPECIMEN	273588	1675	\N	\N	10-46536	\N	SYNAT436	Deep Penetrating Nevus	IP941112	AirTable blocks_with_IP_info.csv
1421	10-83613A	51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a two stage biopsy of a roughly wedge-shaped proliferation of spindled and polygonal melanocytes, some of which have abundant vacuolated cytoplasms, which extends deeply in the mid reticular dermis, with a couple of clusters in the lower reticular dermis/subcutis interface.  Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous.  There are interspersed melanophages.	Two skin segments, one measuring 1.2 x 0.9 x 0.2 cm, quadrisected, and the other measuring 1.4 x 1.2 x 0.4 cm, serially sectioned, all entirely submitted with four sections in cassette A and five sections in cassette B.	BROWN NODULE, I SHAVE IT FLUSH WITH SKIN INITIALLY, BUT THEN WAS PIGMENT AT THE BASE SO I DID A DEEPER SHAVE OF THE SAME SPOT, ONLY SP. B WAS SUBMITTED TO UCSF	\N	\N	\N	The lesion appears excised in planes of section examined. The lesion is broad, but mitotic activity is not prominent. A Ki-67/Melan A stain was obtained to evaluate proliferative activity and it is very low, consistent with the H and E impression of a benign nevus. The case (except Ki-67 stain) was reviewed with concurrence by Dr. McCalmont.	DEEP PENETRATING NEVUS	101624	2169	\N	\N	10-83613	A	SYNAT437	Deep Penetrating Nevus	IP978192	AirTable blocks_with_IP_info.csv
2812	22-73345B	29	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	https://64.54.108.121/app/WebViewer/view/image/34973	216.3	\N	\N	\N	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted in B. KB/KB	A-B) R/O DN	\N	\N	FFPE	A portion of this lesion had small to medium-sized epithelioid cells, an appearance suggesting a population that had undergone inactivation of the tumor suppressor gene, BAP-1. This was confirmed by an immunostain performed in our laboratory, and other stains do not support additional neoplastic transformation. The neoplasm extends to the base of the specimen. A narrow re-excision of this site would still be prudent, as lesions with BAP-1 loss may convert to melanoma at a higher rate than other nevi. Most spitzoid neoplasms with BAP-1 loss are sporadic. Toward making sure that this patient does not have a germline mutation in BAP-1, the clinician should undertake a full body skin exam to see if other lesions clinically similar to this one or to the ones depicted in the reference below might be present. Also, the absence of a family history of similar lesions, and both cutaneous and uveal melanoma, or mesothelioma should be confirmed.  Additionally, I would consider obtaining testing for a germline mutation in BAP-1. This appears to be present in a significant percentage of patients with BAP-1 inactivated spitzoid lesions, and is available through several sources (we do not do it in our laboratory, but see Invitae.com and GeneDx.com).  Reference:  Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, R¸tten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. Germline mutations in BAP-1 predispose to melanocytic tumors. Nat Genet. 2011 Aug 28;43(10):1018-21. doi: 10.1038/ng.910. PubMed PMID: 21874003.	COMBINED MELANOCYTIC NEVUS WITH CONVENTIONAL AND BAP-1 INACTIVATED COMPONENTS	173304	1401	\N	\N	22-73345	B	VS-08	Spatial Gene Expression	IP2475216	AirTable blocks_with_IP_info.csv
1601	12-20144	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	109	\N	\N	12-20144	\N	BN-005	Nevus Library	\N	AirTable blocks_with_IP_info.csv
1128	04-15284	52	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.7	\N	\N	There is a proliferation of small and large melanocytes arranged as irregularly shaped and focally confluent nests along the junction, with some pagetoid scatter of single cells.  A dense band-like infiltrate of lymphocytes and melanophages obscures the junctional zone and thickens the papillary dermis.  Occasional large cells reside within the infiltrate.	Skin segment, 1.0 x 0.8 x 0.2 cm, trisected and totally submitted.	CHANGING PIGMENTED LESION; ?DERMAL NEVUS, ?KERATOSIS, R/O MELANOMA	\N	\N	Scraping	Immunoperoxidase staining with Melan-A and S100 protein show that the there are occasional large, positively stained cells within the papillary dermis.  Although the thickness of this neoplasm is nominally 0.4 mm, the tumor volume is less than is usual for this thickness, and this may be a positive prognostic attribute.	MELANOMA. 0.4 MM IN THICKNESS	562711	118	\N	\N	04-15284	\N	CCR-	California Cancer Registry	IP431683	AirTable blocks_with_IP_info.csv
1452	11-18560	60	\N	\N	\N	T1a	Primary	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a broad, incompletely circumscribed compound proliferation of melanocytes. Within the epidermis, which is psoriasiform in some areas and thinned in others, there are single melanocytes and nests distributed broadly. Many of these melanocytes are arrayed in lentiginous fashion along the sides and bases of rete ridges, and limited scatter of melanocytes into the stratum spinosum can also be seen. In fibrotic perijunctional dermis below this, there are partially-maturing nests, cords, and fascicles of similar melanocytes. Many melanocytes, both epidermal and dermal, have scant finely melanized cytoplasm. In the upper dermis, scattered melanophages can be seen. There is also an element of reticular dermal elastosis.	Four outside slides, 11DP1358:A.  One corresponding block received 3-17-11.	R/O MELANOMA	\N	\N	\N	Our differential diagnosis included a fibrotic dysplastic nevus on one hand and nevoid melanoma on the other, and based solely upon conventional microscopy I favored the latter possibility as most likely. In an effort to provide a more definitive analysis of this proliferation, we completed array-based comparative genomic hybridization (aCGH) analysis to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, aCGH analysis demonstrated gain in chromosome 6p and loss in chromosome 7q. The gain in chromosome 6p includes the location of the RREB1 gene, and mutations in RREB1 are common to melanoma. In summary, the combination of results derived from conventional microscopy coupled with aCGH has confirmed a diagnosis of melanoma. With respect to staging, this melanoma is less than 1 mm in thickness, lacks associated ulceration, and does not have detectable melanocytes in mitosis in its invasive component. Therefore, it represents a melanoma of stage T1a per the 2009 revision of the AJCC staging system. Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.7 MM IN THICKNESS, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	133596	1914	\N	\N	11-18560	\N	SYNAT439	2010-2017	IP1007998	AirTable blocks_with_IP_info.csv
3053	1283/14	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1213	\N	\N	None	\N	NM-35	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
3049	1205/17	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1214	\N	\N	None	\N	NM-36	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1725	13-51115A	68	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a proliferation of nested and solitary melanocytes arrayed irregularly and confluently within the epidermis and dermis. The constituent melanocytes display atypical nuclear features and have abundant vacuolated and heavily pigmented cytoplasm, and some melanocytes are scattered above the epidermal-dermal junction. In the dermis, there is a syncytial array of non-maturing melanocytes with associated early necrosis and many melanophages.	Skin segment measuring 0.8 x 0.6 x 0.3 cm, bisected and entirely submitted in A. PL/PL	A) HYPERKERATOTIC, PIGMENTED CHANGING PAPULE; R/O MM, B) SAME LESION, DEEP TO (A), CLINICALLY VISIBLE RESIDUAL PIGMENTED LESION REMOVED BY PUNCH; R/O MM	\N	\N	\N	\N	INVASIVE MELANOMA	173502	2287	\N	\N	13-51115	A	SYNAT488	2010-2017	IP380899	AirTable blocks_with_IP_info.csv
3167	BB21-21336	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=3318	\N	\N	B11-073	\N	\N	\N	\N	hard palate	\N	\N	\N	\N	1275	\N	BB	21-21336	\N	OM-14	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
3165	BB21-21316	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	18-19	\N	\N	\N	\N	gingiva	\N	\N	\N	\N	1278	\N	BB	21-21316	\N	OM-17	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2517	19Rig750007.02.09.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	268	\N	\N	None	\N	CM-28	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2371	18-129422	34	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show a nodular dermal proliferation consisting in part of ovoid melanocytes with monomorphous nuclei arranged in fascicles with intervening areas displaying fibrosis and sclerosis and containing melanophages.	Cylindrical skin segment measuring 0.7 cm in diameter and 0.3 cm in thickness. With the margins inked, the specimen is trisected, and entirely submitted. HD/HD	RAPIDLY ENLARGING BLACK PAPULE, PRESENT X 6 YRS WITH RAPID ENLARGEMENT X 2 YRS; BLUE NEVUS, R/O MELANOMA	\N	\N	Scraping	None	BLUE NEVUS	173663	1176	\N	\N	18-129422	\N	NL-014	Nevus Library	IP1993538	AirTable blocks_with_IP_info.csv
10656	99-29482	46	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.7	Iwei Acral Melanoma	\N	Sections show acral skin with a proliferation of atypical melanocytes\narranged in a pagetoid pattern within the epidermis, and with similar\ncells in the deep reticular dermis.  There is confluence of\nmelanocytes at the junction.	Cylindrical skin segment plus fragment, measuring 0.4 cm in diameter\nand 0.7 cm in thickness in aggregate.	\N	\N	\N	\N	The neoplasm measures over 1 mm. in these sections.	MELANOMA, FINAL THICKNESS TO AWAIT COMPLETE EXCISION	173713	1597	\N	\N	99-29482	A	SYNX194	\N	IP205015	Consolidated_data_final.csv
1508	11-64496	5	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a dome-surfaced, somewhat wedge-shaped proliferation of large fusiform melanocytes that extends from the junctional zone into the subcutis. The cellularity of the lesion is densest toward the base. The overlying epidermis has jagged rete ridges, is moderately thickened and contains foci in which there are increased numbers of single melanocytes, some above the basal layer, but is mostly uninvolved. Within the dermis, fascicles of cells with abundant eosinophilic cytoplasm and large, pleomorphic, vesicular nuclei that contain large nucleoli are present within fibrotic stroma. Clefts demarcate adjacent melanocytes from one another. Mitotic figures are rare, but at least one is present a short distance from the base of the lesion. The enclosed immunoperoxidase-stained sections include S100 and Melan-A stains that highlight the fascicular structure of the lesion, and HMB45 stain that shows some positivity throughout the entire thickness of the lesion, and a Ki-67 stain showing what appears to be an elevated proliferation rate (this is difficult to judge, as there are admixed lymphocytes).	Thirteen outside slides, CS11-1847 (including six unstained slides).  One corresponding block received 9-7-11.	RECENTLY ENLARGING LESION	\N	\N	\N	The findings are equivalent to those published in the literature as atypical Spitz tumor. Lesions of this type are generally well circumscribed. In this case, the dermal and subcutaneous margins appear involved, and a narrow reexcision should be performed to prevent regrowth. My experience is that lesions of this type seldom recur with 5 mm margins. Involvement of local lymph nodes is common, but distant metastasis is rare. We obtained comparative genomic hybridization on this case. There is a clear cut loss involving chromosome 1p, without other aberrations. Certain chromosomal gains and losses are typical of melanoma, but this is not one of them. Idiosyncratic ones such as those seen here may occur in so-called atypical Spitz tumors. In general, Spitz's nevi have gains of 11p alone, 7q alone, or no aberrations. Hence, the results are intermediate, and although abnormal are not interpretable as melanoma.  Dr. Boris Bastian, my colleague who developed diagnostic comparative genomic hybridization also reviewed the results of this test and agrees with this interpretation of it.	MOSTLY INTRADERMAL PROLIFERATION OF LARGE, SPITZOID MELANOCYTES	123289	1935	\N	\N	11-64496	\N	SYNAT440	2010-2017	IP1053939	AirTable blocks_with_IP_info.csv
2527	19Rig750007.03.03.05	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	272	\N	\N	None	\N	CM-32	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
3168	BB21-21338	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=3320	\N	\N	B13-164	\N	\N	\N	\N	soft palate	\N	\N	\N	\N	1274	\N	BB	21-21338	\N	OM-13	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2346	18-88579	\N	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	\N	Mel	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1304	\N	\N	18-88579	\N	OM-46	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2347	18-90413	\N	\N	\N	\N	\N	\N	\N	16	0	FFPE	\N	\N	\N	Mel	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1305	\N	\N	18-90413	\N	OM-47	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1423	10-86269	\N	\N	\N	\N	\N	\N	\N	6	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	genital mucosa	FFPE	\N	\N	\N	1306	\N	\N	10-86269	\N	OM-48	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1595	12-16974C	33	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show a roughly wedge-shaped proliferation of spindled and polygonal melanocytes, some of which have abundant vacuolated cytoplasms, which extends within the reticular dermis.  Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous.  There are interspersed melanophages.	Cylindrical skin segment measuring 0.6 cm in diameter and 0.6 cm in thickness. The specimen is bisected (fragmented while cutting), and entirely submitted with two sections and fragment in cassette C.	A-C) R/O DYSPLASTIC NEVUS	\N	right knee lateral	Scraping	\N	DEEP PENETRATING NEVUS (PIGMENTED EPITHELIOID MELANOCYTIC NEVUS), SUPERFICIAL TYPE, A VARIANT OF BLUE NEVUS	102733	1949	\N	\N	12-16974	C	SM-023	Nevus Library	IP1102790	AirTable blocks_with_IP_info.csv
2309	18-27178A	66	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, the junctional component of which is composed of single cells and small nests arrayed along the sides and bases of pigmented rete. There are nests and cords of similar melanocytes in the superficial dermis, where scattered melanophages are also in residence. The superjacent stratum corneum is orthokeratotic with admixed melanin.	Skin segment measuring 1.2 x 1.0 x 0.2 cm, quadrisected and entirely submitted in A. RS/PL	A) NEOPLASM OF UNCERTAIN BEHAVIOR. . B) NEOPLASM OF UNCERTAIN BEHAVIOR. .	\N	\N	Scraping	There appear to be two melanocytic nevi apparent in side-by-side fashion in this biopsy.	LENTIGINOUS COMPOUND MELANOCYTIC NEVI, EXCISED IN THE AVAILABLE PLANES OF SECTION	139511	2211	\N	\N	18-27178	A	LN-050	Lentiginous Nevi 	IP401538	AirTable blocks_with_IP_info.csv
2715	21-21324	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2015	\N	\N	21-21324	\N	SYNAT168	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
11207	13-61146	26	\N	\N	\N	T1a	Primary	\N	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a proliferation of melanocytes with a biphasic pattern. One population of melanocytes consists of cells with abundant vacuolated cytoplasm and finely divided melanin pigment, and these cells are arrayed irregularly within the epidermis as single cells and nests, with foci of suprabasal scatter.  There are also similar clusters of cells in the superficial dermis, surrounded by a lymphocytic infiltrate.  Laterally in the superficial dermis, there is a second population of smaller melanocytes (comprising melanocytic nevus), arrayed as nests and cords.	Ellipse, 1.0 x 0.7 x 0.4 cm, including a central 0.8 x 0.7 cm brown area. With the margins inked, the specimen is quadrisected perpendicular to the long axis and entirely submitted. PL/PL	\N	\N	\N	\N	This biopsy demonstrates a thin invasive melanoma that has developed in conjunction with a small congenital melanocytic nevus. With respect to staging, this non-ulcerated melanoma does not have melanocytes in mitosis in its small invasive component. Therefore, it represents a melanoma of stage pT1a (2009 AJCC Guidelines). Both the melanoma and the melanocytic nevus appear narrowly excised in the available sections.	MELANOMA OF 0.45 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173649	1661	\N	\N	13-61146	A	SYNX258	\N	IP1303150	Consolidated_data_final.csv
3552	MP41-YM-R1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1393	\N	\N	None	\N	UV-02	Uveal Melanoma	\N	AirTable blocks_with_IP_info.csv
2514	19Rig750007.02.04.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	265	\N	\N	None	\N	CM-23	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2825	22-85528	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	438	\N	\N	22-85528	\N	DMS-026	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2827	22-88969	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	439	\N	\N	22-88969	\N	DMS-027	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2601	20-14475	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	447	\N	\N	20-14475	\N	DMS-035	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2612	20-23650	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	448	\N	\N	20-23650	\N	DMS-036	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2622	20-31361	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	449	\N	\N	20-31361	\N	DMS-037	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2626	20-35177	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	450	\N	\N	20-35177	\N	DMS-038	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2541	19Rig750007.04.02.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	280	\N	\N	None	\N	CM-43	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1110	04-03311H T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1039	\N	\N	None	\N	MD-161	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1026	01-10208A T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1040	\N	\N	None	\N	MD-162	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2038	17-3739	49	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	DN	\N	Sections show a compound melanocytic proliferation, composed largely of nests arrayed along the epidermal-dermal junction, with extension lateral to papillary dermal clusters of similar cells.  There is subepithelial fibrosis, some of which is lamellar in configuration.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted. PL/PL	SOFT HAZY TAN PAPULE; R/O COMP NEVUS VS. OTHER	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173536	518	\N	\N	17-3739	\N	DN-043	Dysplastic Nevi	IP891221	AirTable blocks_with_IP_info.csv
1468	11-27846 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	934	\N	\N	None	\N	MD-28	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3190	Buffy Coat	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Buffy Coat:  This is DNA that was derived from the Buffy Coat layer of a patient sample with a strong family history of Melanoma. 	\N	\N	\N	\N	Family History (9 members) have melanoma	\N	\N	\N	\N	2266	\N	\N	None	\N	SYNAT214	2010-2017	\N	AirTable blocks_with_IP_info.csv
3192	Cell-Line_Xu-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2098	\N	\N	None	\N	SYNAT216	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3193	Cell-Line_Xu-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1683	\N	\N	None	\N	SYNAT217	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
2031	17-2241	74	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10847	238.2	\N	\N	Sections show a broad compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying small dermal component. There is a broad zone of papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate and are present above the basal layer.	Skin segment measuring 1.0 x 0.9 x 0.1 cm, quadrisected and entirely submitted. KC/KC	13 X 11 MM; R/O LM VS. MM VS. MIS	\N	\N	\N	This lesion is atypical in that it displays areas in which single cells predominate and a limited degree of intraepithelial scatter of melanocytes.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING TO THE EDGES OF THE SPECIMEN	102538	555	\N	\N	17-2241	\N	DN-080	Dysplastic Nevi	IP1731326	AirTable blocks_with_IP_info.csv
3574	SKMEL5-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2195	\N	\N	None	\N	SYNAT333	Melanocyte Cell Line	\N	AirTable blocks_with_IP_info.csv
3575	SKMEL5-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2202	\N	\N	None	\N	SYNAT334	Melanocyte Cell Line	\N	AirTable blocks_with_IP_info.csv
3576	SKMEL5-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2174	\N	\N	None	\N	SYNAT335	Melanocyte Cell Line	\N	AirTable blocks_with_IP_info.csv
1345	09-21320 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	931	\N	\N	None	\N	MD-25	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1515	11-71491	22	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show enlarged slightly spindled and epithelioid melanocytes arrayed in compound fashion. There is good lateral demarcation and slight asymmetry. Single melanocytes and nests and fascicles of melanocytes are apparent along the junction in concert with epidermal hyperplasia, and some junctional fascicles have encompassing myxoid stroma. There are partially-maturing nests and cords of epithelioid melanocytes in the dermis below this, and cells in mitosis can occasionally be found. A sparse and patchy juxtaposed lymphocytic infiltrate is also noted.	Nine outside slides, D11-35107 / 1-2, and two corresponding blocks.	ENLARGING LESION X 3 MONTHS, SMALL, WELL CIRCUMSCRIBED, SYMMETRICAL, MELANOCYTIC; NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	\N	This melanocytic proliferation shows some Spitz nevus-like attributes but also some unconventional features, including partial loss of p16 expression and occasional dermal melanocytes in mitosis. In light of this, we completed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies as an additional step in assessment. After extraction of tumoral DNA from the tissue block, application of aCGH revealed no chromosomal copy number gains or losses. The vast majority of melanomas analyzed by aCGH have associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack demonstrable aberrations. In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. I continue to favor an unconventional Spitz nevus as the best interpretation of this tumor, which appears excised in the available planes of section.	COMPOUND SPITZOID MELANOCYTIC PROLIFERATION, CONSISTENT WITH A COMPOUND SPITZ NEVUS	173531	1957	\N	\N	11-71491	\N	SYNAT441	2010-2017	IP1060934	AirTable blocks_with_IP_info.csv
2567	19Rig750007.05.13.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	297	\N	\N	None	\N	CM-69	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2568	19Rig750007.05.13.09	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	297	\N	\N	None	\N	CM-69	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2545	19Rig750007.04.06.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	284	\N	\N	None	\N	CM-47	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1207	06-06325 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	949	\N	\N	None	\N	MD-43	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2784	22-21012A2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-17	http://64.54.108.121/eSlideTray.php?ImageIds=32766	\N	\N	3340573	\N	\N	\N	\N	  Skin, forehead, right, wide excision, melanoma, recurrent. Microscopically, it shows presence of a few nests of epithelioid melanocytes with nuclear atypia, vacuolated cytoplasm and mitotic activity in the dermis. A recurrent melanoma is considered. Suture granulomas and scar tissue are also seen. Section margins are free (＞3 mm).	FFPE	\N	\N	\N	307	\N	\N	22-21012	A2	CME-005	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2332	18-65038B	84	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10893	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted in B. KC/KC	A) PINK PAPULE; BASAL CELL CARCINOMA, B) ATYPICAL BROWN MACULE; ATYPICAL NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	174566	600	\N	\N	18-65038	B	DN-125	Dysplastic Nevi	IP439323	AirTable blocks_with_IP_info.csv
2378	18-136716B	67	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a proliferation composed predominantly of nests of melanocytes arrayed along the junctional zone, above a papillary dermis that is expanded by fibrosis.  There is an infiltrate of lymphocytes and melanophages.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted in B. BY/BY	A) ATYPICAL RED BROWN PAPULE; ATYPICAL NEVUS, B) ATYPICAL GRAY BROWN MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. NEVUS WITH REGRESSION	\N	\N	\N	December 21, 2018: The lesion appears adequately treated and no further re-excision seems necessary on histopathologic grounds.	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH SUPERIMPOSED CHANGES OF REGRESSION, EXCISED IN PLANES OF SECTION EXAMINED	174566	606	\N	\N	18-136716	B	DN-131	Dysplastic Nevi	IP126817	AirTable blocks_with_IP_info.csv
3550	MM160113	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	103	\N	\N	None	\N	AMC-12	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
2435	19-29129	44	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate. Scattered melanocytes have enlarged nuclei.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted. BY/BY	R/O DN	\N	\N	\N	This lesion is atypical in that it displays scattered atypical melanocytes. Conservative re-excision of this site is recommended.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT	139524	627	\N	\N	19-29129	\N	DN-152	Dysplastic Nevi	IP1663236	AirTable blocks_with_IP_info.csv
1895	15-101612	16	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	from Swapna	A broad shave biopsy demonstrates a compound proliferation of enlarged fusiform and epithelioid melanocytes. The background epidermis is acanthotic and harbors these melanocytes distributed in pagetoid fashion, and scattered well-formed pink globules are present concurrently. In fibrotic inflamed dermis below this, maturing nests, cords, and fascicles of similar melanocytes are noted. These melanocytes mature to form small compact nests at the base of the proliferation.	Four outside slides, S-15-28819-B1. One corresponding block received 10/23/15.	IMPRESSION WAS INFLAMED SEBORRHEIC KERATOSIS VS. R/O SCC	\N	\N	\N	Your submitted immunoperoxidase stains demonstrate that the Ki-67 cell proliferation index is low and that expression of p16 is not detectable. To further assess the nature of this proliferation, we first repeated p16 immunohistochemistry and additionally completed NTRK-1 immunostaining. The repeat p16 stain was again negative, while the NTRK-1 immunostain demonstrated significant positivity, and thus underlying NTRK-1 gene fusion may be present. Given the histopathologic findings and the above immunostaining results, the differential diagnosis included a so-called 'atypical Spitz tumor' and spitzoid melanoma. To enable full characterization, we next completed array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies, as would be expected with melanoma. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in proximal chromosome 1p as well as loss in chromosomes 9 and 14q. The identification of multiple chromosomal copy number abnormalities indicates genomic instability, as is stereotypical of melanoma. In short, the molecular findings we have defined are incompatible with interpretation as a melanocytic nevus. Additionally, the loss of chromosome 9 that has been defined via aCGH explains the loss of p16 expression, as the CDKN2A locus is encoded within chromosome 9p.  In summary, the combination of results derived from conventional microscopy coupled with aCGH support interpretation as a thin spitzoid melanoma. This biopsy is only partial in nature and thus reexcision remains indicated, if that has not yet been accomplished. Synoptic melanoma reporting is included below.  Procedure: shave biopsy Microscopic tumor type: spitzoid melanoma Breslow thickness: 1.05 mm Ulceration: not detected Margin: involved Mitotic index: 1/square mm Vascular invasion: not detected Regression: not detected Pathologic staging (pTNM): pT2aNxMx  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	SPITZOID MELANOMA OF 1.05 MM IN THICKNESS, FOCALLY INVOLVING THE DEEP EDGE OF THE BIOPSY	173619	649	\N	\N	15-101612	\N	DP-12	NRAS Amplified	IP1573327	AirTable blocks_with_IP_info.csv
1509	11-65284	26	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a compound proliferation of melanocytes that is relatively symmetrical, has good lateral demarcation, but is biphasic or multiphasic in its composition. Along the junction, there are single melanocytes and nests distributed at the sides and bases of rete ridges, and most of these melanocytes are relatively small. Many of them have finely melanized cytoplasm. In perijunctional dermis below this, a wedge-shaped array of maturing nests, cords, and syncytia of similar melanocytes can be seen. Centrally, additional melanocyte morphologies are noted. In some areas, there are enlarged epithelioid melanocytes with finely vacuolated cytoplasm. In other areas, there are enlarged epithelioid melanocytes positioned singly and in cords between thickened collagen bundles. A juxtaposed sparse infiltrate of lymphocytes and melanophages is noted.	Five outside slides, 11-RSC-17793:1A,1B. One corresponding block (1B) received 9-8-11.	MOLE	\N	\N	\N	I believe this proliferation represents a combined melanocytic nevus. It includes the commingling of conventional melanocytic nevus, balloon cell nevus, and desmoplastic Spitz nevus. I do not believe that melanoma is present. However, as there has been diagnostic variability with respect to the interpretation of this proliferation, we pursued array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed a small segmental gain in chromosome 3p and also focal loss in chromosome 3p; no other chromosomal copy number aberrations were found. Loss of chromosome 3p occurred at the location of the BAP-1 gene and has been correlated with mutations in the BAP-1 gene (further explanation is included below). As you probably know, the vast majority of melanomas analyzed via aCGH contain multiple chromosomal copy number gains and/or losses, while virtually all melanocytic nevi lack associated copy number gains or losses. The identification of focal aberrations limited to chromosome 3p has been documented within melanocytic nevi and is not considered to represent molecular support for a diagnosis of melanoma.  Mutations in the BAP-1 gene can be seen in epithelioid melanocytic nevi that occur in familial fashion. A link to some ocular melanomas has also been established. If epithelioid melanocytic nevus are noted in this patient or in other family members, additional molecular assessment of such lesions may be indicated. Reference: Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011 Aug 28. doi: 10.1038/ng.910. [Epub ahead of print] PubMed PMID: 21874003.	BIPHASIC COMPOUND PROLIFERATION OF MELANOCYTES, CONSISTENT WITH A COMBINED MELANOCYTIC NEVUS	173619	656	\N	\N	11-65284	\N	DP-19	CGH Validation	IP1054727	AirTable blocks_with_IP_info.csv
1615	12-22603	69	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.3	Pilomatricoma, cystic	\N	There is a cystic space lined in part by matrical (basaloid) cells, and shadow cells are also apparent.	Two cystic fragments, one measuring 0.7 x 0.6 x 0.2 cm and the other 0.6 x 0.35 x 0.3 cm. The larger is bisected and the smaller is intact, all wrapped with a fragment and entirely submitted.	VARIEGATED ERYTHEM PAPULOCYSTIC LESION; FAVOR FOLLIC CYST VS. CYSTIC BCC VS. PILOMATRIXOMA	\N	Forehead	\N	None	CYSTIC PILOMATRICOMA	123398	2351	\N	\N	12-22603	\N	SYNAT376	2010-2017	IP1108421	AirTable blocks_with_IP_info.csv
1754	14-11769	14	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show enlarged fusiform melanocytes arrayed irregularly within the epidermis and dermis in large fascicles that are centrally maturing, an melanocytes in mitosis are easily found in the upper dermis. The background epidermis is acanthotic and verrucous, and the fibrotic encompassing dermis holds a lymphohistiocytic infiltrate and ectatic vessels.	Two outside slides, EFG17-14 (1-2) and one corresponding block Jo-13-1-20651-2.	FOR 2 MONTHS HAD SOMETIMES BLEEDING LESION; NEVUS, HEMANGIOMA, R/O MELANOMA	\N	\N	\N	My differential diagnosis included a hyperproliferative polypoid Spitz nevus, an HRAS-mutated Spitz nevus, and spitzoid melanoma. Based solely upon the examination of microscopic sections, I initially favored either of the former two possibilities as most likely, but I cannot fully exclude melanoma based solely upon histopathologic parameters. (An HRAS-mutated Spitz nevus has now been excluded from the differential diagnosis on molecular grounds, as is discussed further in the sentences that follow.) Per your request, we completed comparative genomic hybridization (CGH) as part of our assessment. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in distal chromosome 6q with no other associated chromosomal gains or losses. Loss in chromosome 6q can be seen in association with melanoma but typically involves the MYB gene; in this instance, the loss of 6q may fall distal to the MYB gene locus. There is not gain in chromosome 11p present, and thus an HRAS-mutated Spitz nevus can be excluded from diagnostic consideration.  In summary, the combination of results derived from conventional microscopy coupled with CGH has not produced an entirely straightforward result. The differential diagnosis lies between an atypical Spitz nevus/tumor with associated distal chromosome 6q loss on one hand and spitzoid melanoma of 3.4 mm in thickness on the other. As melanoma cannot be excluded from the differential diagnosis, I believe that melanoma should be considered the functional diagnosis for this case.  If staged as melanoma, this non-ulcerated tumor is between 2-4 mm and thus represents stage pT3a (2009 AJCC Guidelines). Complete local removal has already been achieved.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	POLYPOID COMPOUND PROLIFERATION OF ENLARGED SPITZOID MELANOCYTES, 3.4 MM IN THICKNESS, EXCISED IN THE AVAILABLE PLANES OF SECTION	123298	667	\N	\N	14-11769	\N	DP-30	CGH Validation	IP1361690	AirTable blocks_with_IP_info.csv
1510	11-65756	2	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a somewhat asymmetrical, dome-surfaced proliferation of melanocytes with irregular epidermal hyperplasia in some areas and a relatively thin epidermis in others. Jagged rete ridges, hypergranulosis and a mixture of lamellar hyperkeratosis and compact hyperkeratosis are present. Extending from the junctional zone to the base of the specimen in the superficial reticular dermis are variably confluent nests of large oval melanocytes with striking nuclear pleomorphism. Both large vesicular nuclei with large central nucleoli and hyperchromatic nuclei are present. Some maturation with descent is evident, and the aggregations near the base of the specimen are considerably smaller than those situated more superficially. Many multinucleated melanocytes are also seen. The accompanying immunoperoxidase-stained sections include a p16 stain in which most of the cells fail to react. Among the minority which are positive, a disproportionate number are multinucleated.	Eight outside slides, SD-11-27155:A1,A2 and one corresponding block (A1).	SECOND OPINION, FLESH-COLORED PAPULE WITH TELANGIECTASIA; PYOGENIC GRANULOMA VS. WART VS. JXG	\N	\N	\N	I agree with the considerations noted in your report. Given the clinical setting, we obtained comparative genomic hybridization. This shows multiple chromosomal aberrations, which in concert with the histopathologic findings favor interpretation as a spitzoid melanoma rather than as an unusual Spitz's nevus. These aberrations include losses involving most of chromosome 2 (with a gain of a smaller focus in the same chromosome), and gains involving chromosome 7q, 9p, 17q and 19p. Finding gains and losses in the same chromosome, as in chromosome 2 in this case is particularly suggestive of melanoma, as is the sheer number of aberrations; both point to a high degree of genomic instability. Some of the aberrations seen in this case are idiosyncratic (such as the gain in 9p; 9p is usually lost in melanoma) while others are characteristic of melanomas in adults (such as the gain in 7q). The lesion measures 2.2 mm in thickness, and may prove to be thicker on complete excision. Lesions of this type often involve sentinel lymph nodes, but the predictive value vis-a-vis extranodal metastatic spread is limited. If there are interesting or unusual findings in the reexcision specimen, I would be interested in viewing the sections as part of this consultation.	SPITZOID MELANOMA	173649	2130	\N	\N	11-65756	\N	SYNAT442	2010-2017	IP1055199	AirTable blocks_with_IP_info.csv
1660	12-79097B	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26322	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	745	\N	\N	12-79097	B	JJS6	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
2389	19-488	51	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.6	\N	\N	Sections show a proliferation of pigmented, bipolar dendritic melanocytes in the superficial dermis, accompanied by melanophages and by thickened collagen bundles.	Cylindrical skin segment and skin segment received. Cylindrical skin segment, 0.5 cm in diameter and 0.2 cm in thickness. Skin segment measuring 0.5 x 0.4 x 0.1 cm. Each bisected and all entirely submitted. KC/KC	4 MM BLACK PAPULE THAT IS GETTING BIGGER AND DARKER; R/O ATYPIA	\N	\N	Scraping	None	BLUE NEVUS	173676	1127	\N	\N	19-488	\N	ME-32	Melanoma Epigenetics	IP2004512	AirTable blocks_with_IP_info.csv
1908	16-1675	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	1128	\N	\N	16-1675	\N	ME-33	Melanoma Epigenetics	\N	AirTable blocks_with_IP_info.csv
1457	11-20772	29	\N	\N	\N	T3a	Primary	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a sessile polypoid compound proliferation of large spindled and epithelioid melanocytes, the sparse junctional component of which is arrayed with the lowermost sections of an epithelium that is slightly acanthotic and hyperkeratotic. The dermal component contains similar melanocytes in clusters and sheets. There are rare mitotic figures. The papillary dermis is edematous.	Six outside slides, D11-10315 and one corresponding block.	R/O PYOGENIC GRANULOMA	\N	\N	\N	Thank you for your kind accompanying letter. I agree with you that while a Spitz's nevus seemed possible in initial sections, there are some unconventional features, and rare mitoses are evident in the dermal component, raising the possibility of Spitzoid melanoma. The enclosed Ki-67 immunoperoxidase stains indicates a low proliferation index, however. As you suggested, we performed comparative genomic hybridization to determine whether this tumor contains clonal DNA copy number changes that may be of value in the differential diagnosis. This reveals multiple aberrations, including losses or gains affecting nearly all of chromosomes 7, 8, and 9, and gains on chromosome 5. These results strongly support a diagnosis of melanoma. Of note is that none of these aberrations would have been detected via fluorescence in situ hybridization, and these aberrations are not those associated with spitzoid melanoma of childhood. I have shared this case with my colleagues, Drs. Philip LeBoit and Timothy McCalmont, who agree with this diagnosis. Histopathologic features of possible prognostic importance include the following. Definitive assessment of prognostic features should be deferred to the excision specimen.  Level: IV Tumor infiltrating lymphocytes: scant Vascular or lymphatic invasion: not evident Dermal mitotic rate: greater than 1/sq mm Perineural invasion: not evident Ulceration: none Regression: none Microsatellite metastasis: cannot assess AJCC stage: T3a preliminary	COMPOUND PROLIFERATION OF LARGE SPINDLED AND EPITHELIOID MELANOCYTES, GENOMICALLY MELANOMA, AT LEAST 3.9 MM IN THICKNESS, EXTENDING TO THE SPECIMEN BASE	173719	1944	\N	\N	11-20772	\N	SYNAT151	2010-2017	IP1010210	AirTable blocks_with_IP_info.csv
3034	150/17	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1210	\N	\N	None	\N	NM-032	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1647	12-54296	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1689	\N	\N	12-54296	\N	SYNAT404	2010-2017	\N	AirTable blocks_with_IP_info.csv
1741	13-105024A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1358	\N	\N	13-105024	A	SMP12	Spitz Melanoma	\N	AirTable blocks_with_IP_info.csv
1648	12-54992	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1855	\N	\N	12-54992	\N	SYNAT406	2010-2017	\N	AirTable blocks_with_IP_info.csv
10836	13-39228	77	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.4	UCSF Wild Type Melanoma	\N	\N	Blocks S12-7524:A1 through A7.	\N	\N	\N	\N	The histopathological diagnosis was established by pathology report S12-7524 of UCSF Surgical Pathology. Sanger sequencing of exon 15 of BRAF, exons 1 and 2 of NRAS, and exons 11, 13, 17, and 18 of KIT, which include the known mutational hotspots of these genes, did not reveal any mutations.	MELANOMA, MUTATIONAL ANALYSIS FOR BRAF, NRAS, AND KIT DID NOT DETECT ANY MUTATIONS	173417	1636	\N	\N	13-39228	A	SYNX233	\N	IP1104118	Consolidated_data_final.csv
10837	13-45942	69	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	198.2	UCSF Wild Type Melanoma	\N	\N	Block S11-9752.	\N	\N	\N	\N	The histopathological diagnosis was established by pathology report S11-9752 of UCSF Surgical Pathology. Sanger sequencing of exons 11, 13, 17, and 18 of KIT, which include the known mutational hotspots, did not yield any mutations.	METASTATIC MELANOMA, NO KIT MUTATIONS DETECTED	925	1637	\N	\N	13-45942	A	SYNX234	\N	IP1005877	Consolidated_data_final.csv
2554	19Rig750007.04.15.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NEVUS	Grp 4 - Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	290	\N	\N	None	\N	CM-56	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1022	01-1112 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1057	\N	\N	None	\N	MD-180	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1019	00-27758D M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	996	\N	\N	None	\N	MD-100	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1052	02-16797C M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	997	\N	\N	None	\N	MD-101	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1038	02-00594E M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	998	\N	\N	None	\N	MD-102	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1215	06-11147 N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	999	\N	\N	None	\N	MD-103	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1134	04-20471E M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1000	\N	\N	None	\N	MD-105	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1162	05-14728C M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1001	\N	\N	None	\N	MD-106	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1219	06-12646D M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1002	\N	\N	None	\N	MD-107	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1017	00-24216D T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1059	\N	\N	None	\N	MD-182	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1799	14-70636	\N	\N	\N	\N	\N	\N	\N	22	0	FFPE	\N	\N	\N	Typical melanotic macule	\N	\N	\N	\N	\N	acral mel macule	FFPE	\N	\N	\N	1292	\N	\N	14-70636	\N	OM-34	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2986	96-24948 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1016	\N	\N	None	\N	MD-132	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1949	16-41709	80	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show acral skin with large, oval nests of large, oval melanocytes with abundant, pale cytoplasm and monomorphous oval vesicular nuclei, within fibrotic stroma and with relatively evenly distributed melanophages.	Four outside slides, ES-16-7020 (A1-A4), and one corresponding block (A1).	THICK ERYTH PAPULE AND PIGMENTED PAPULE; NUB VS. MELANOMA	\N	\N	\N	A BAP-1 immunostain shows no loss of nuclear staining. The stain was performed as some blue nevus-like melanoma show BAP-1 loss due to mutation in one allele and loss of part or all of chromosome 3p or chr. 3. A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product (nearly complete or complete loss in a defined zone is worrisome for melanoma).  I did not find mitotic figures in dermal melanocytes in a phosphohistone H3/Melan-A two color immunostain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle), a finding against melanoma. The stain did show a minor junctional component and a few melanocytes scattered singly above the junction, against a cellular blue nevus.  Given this latter finding, I favor an unusually mitotically quiescent melanoma, and advise re-excision on that basis, despite the difficulties at this site. The thickness in these sections is problematic, given that only a tiny portion of epidermis is included, and the pieces are not optimally oriented. I estimate the thickness as about 2 mm.  If a definitive diagnosis is needed before additional surgery, we could perform comparative genomic hybridization (this is an authorized service if the patient's insurance is via Medicare, as our lab has a Z code from MolDx).  ADDENDUM, May  9, 2016:  We will proceed with comparative genomic hybridization, per your message.  ADDENDUM, May 31, 2016:  Following microdissection and DNA extraction, we performed comparative genomic hybridization. It shows an interesting array of aberrations, including evidence of a complex pattern of chromosomal fragmentation and re-jointing of chr. 7q, a loss involving chr. 10p and the pericentromeric area of 10q, two narrow areas of gain on chr 15 within the TRPM1 and MYO5A genes, respectively, a loss involving chr. 21q, and gain involving the pericentromeric area of chr. 22p with a breakpoint at the MAPK1 gene. Of these, chr. 10 loss if often found in melanoma, and complex chromosomal rearrangments like the one involving chr. 7q also point to melanoma. MAPK1 gain is present in only 1.5% of melanomas, with an unknown percentage having a focussed gain involving a narrow area around the gene. Whether the gains involving TRPM1 and MYO5A, both of which are involved in melanocytic tumor progression are significant or not is unknown.  The reporting of this case was delayed, as I wanted to go over the comparative genomic hybridization data with my colleagues, Dr. Boris Bastian and Iwei Yeh.	MELANOMA, AT LEAST 2.5 MM. IN THICKNESS	582721	700	\N	\N	16-41709	\N	DP-63	CGH Validation	IP1641025	AirTable blocks_with_IP_info.csv
1938	16-27084	9	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a partially polypoid intradermal proliferation of enlarged epithelioid melanocytes. These cells are distributed as nests, cords, and sheets in the upper dermis, and encompassing collagenous stroma is noted. A number of the cells are multinucleated. More deeply in the dermis, similar melanocytes are distributed as large lobules with a flanking lymphohistiocytic infiltrate. In slide A3, areas of dermal fibrosis that may represent scar are concurrently apparent.	Three outside slides, DPP-16-4718 (A1-A3), and one corresponding block (A2).	PATIENT WITH ATYPICAL INTRADERMAL MELANOCYTIC PROLIFERATION	\N	\N	\N	Immunohistochemistry to further assess the nature of this proliferation was included in our assessment. Phosphohistone-H3 staining demonstrates that the mitotic index is significantly elevated (4 per square millimeter). BAP-1 expression is preserved, and thus a so-called 'BAPoma' has been excluded from the differential diagnosis. Immunostaining with p16 demonstrates partial mosaic immunopositivity; since there is significant loss of expression in a superficial nodular area, we additionally completed fluorescence in situ hybridization (FISH) to better assess the copy number status of the CDKN2A locus. No copy number loss was identified in the CDKN2A FISH assessment, and this implies that the loss of p16 expression documented by immunohistochemistry is probably epigenetic in nature (and thus it cannot be taken as being diagnostically meaningful). Given the elevated mitotic index, my differential diagnosis included an ambiguous/indeterminate Spitz tumor on one hand and pediatric spitzoid melanoma on the other. The best current means to comprehensively evaluate the nature of a proliferation such as this one is to complete array-based comparative genomic hybridization (aCGH) to screen for copy number anomalies throughout the genome. After receipt of payor authorization, we thus initiated aCGH assessment. This consisted of microdissection of tumor followed by extraction of tumoral DNA from the tissue block and application of aCGH, which demonstrated gain in chromosome 4p as well as loss in chromosomes 4q, 5q, 9q, 16q, and 22q. The identification of multiple chromosomal copy number abnormalities indicates genomic instability, as is stereotypical of melanoma.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has provided support for a diagnosis of pediatric spitzoid melanoma. The AJCC staging parameters that are applied to the assessment of adult melanoma are not known to be reflective of prognosis in the pediatric setting. With that said, for the sake of completeness, please note that this relatively thick tumor is non-ulcerated. As noted above, the mitotic index is 4 per square millimeter. The margin of excision is narrow in the available sections.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	POLYPOID INTRADERMAL PROLIFERATION OF ENLARGED SPITZOID MELANOCYTES, CONSISTENT WITH SPITZOID MELANOMA OF 8.2 MM IN THICKNESS	139522	702	\N	\N	16-27084	\N	DP-65	CGH Validation	IP1626264	AirTable blocks_with_IP_info.csv
3077	5698.3 (14.5698.3 slide)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1219	\N	\N	None	\N	NM-41	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
1518	11-74100	36	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show enlarged slightly spindled and epithelioid melanocytes arrayed in compound fashion. There are single melanocytes and nests and fascicles of melanocytes within the epidermis, which is partially acanthotic and hyperkeratotic, and limited intraspinous scatter is noted. There are also many small pink globules within the epidermis. The dermis below this holds maturing nests and fascicles in concert with fibrosis, and a juxtaposed sparse lymphohistiocytic infiltrate is also  noted.	Three outside slides, D11-38152, and one corresponding block.	SHAVE BIOPSY OF A 0.8 CM CRESCENT-SHAPED, PINK AND BROWN PAPULE; NEVUS, RULE OUT ATYPIA	\N	\N	\N	Based upon conventional microscopical attributes, I favored interpretation as an unconventional Spitz nevus occurring in adulthood, although I understand that your group viewed this possibility as improbable. In light of this ambiguous diagnostic situation, we pursued array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic copy anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed no chromosomal gains or losses. As you know, most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced clear support for a diagnosis of melanoma. Rather, I believe this melanocytic proliferation represents an unconventional melanocytic nevus. This process is transected at the periphery of the current specimen. In light of this, further excision is recommended to ensure that local eradication has been accomplished.	COMPOUND SPITZOID MELANOCYTIC PROLIFERATION, CONSISTENT WITH AN UNCONVENTIONAL COMPOUND SPITZ NEVUS	133559	1749	\N	\N	11-74100	\N	SYNAT443	2010-2017	IP1063547	AirTable blocks_with_IP_info.csv
1519	11-74517	7	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.3	\N	\N	There is a dome-surfaced proliferation of large oval melanocytes involving both the junctional zone of a thinned epidermis and the superficial dermis beneath it. Nests predominate over single cells along the junction. The lesional cells have abundant amphophilic cytoplasm and large oval vesicular nuclei with relatively small nucleoli. Many superficial dermal nests are extensively confluent or oddly shaped, and many mitotic figures are present, some of them atypical. Smaller nests composed of more mature-appearing and less mitotically active cells are evident toward the base of the lesion.	One outside slide, SCD-11-37655:A1. One corresponding block received 10/14/11.	SPITZOID MELANOCYTIC NEOPLASM; PYOGENIC GRANULOMA VS. ATYPICAL SPITZ NEVUS	\N	\N	\N	The findings are not those of a conventional Spitz's nevus. The thinned epidermis, mitotic rate and large, confluent nests in the superficial part of the lesion are all worrisome features. Comparative genomic hybridization shows multiple chromosomal losses including 8p, 9, 14 and 16. Several of these, most notably 8p and 9 are commonly lost in melanoma. Given these findings, despite the age of the patient, I believe that this lesion is best viewed as a spitzoid melanoma of childhood. I use this term for an emerging class of lesions that have a spitzoid morphology and a propensity to involve local lymph nodes. Systemic spread either occurs infrequently or it does so in a delayed fashion compared to adult melanoma. This makes sentinel lymph node biopsy less predictive than in adult melanoma. The thickness in this case is at least 1.8 mm as the lesion is transected. Thickness and prognosis are also not coupled in the same manner as in adult melanoma and the prognosis is also considerably better than with an adult lesion of the same thickness. Also, lesions of this type tend to be well circumscribed and excision margins can be considerably less.	SPITZOID MELANOMA, CHILDHOOD TYPE	173304	1729	\N	\N	11-74517	\N	SYNAT444	2010-2017	IP1063964	AirTable blocks_with_IP_info.csv
1417	10-74513	44	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a domed, hypercellular compound proliferation of slender spindled melanocytes distributed as irregular fascicles in compound fashion. The background epidermis is acanthotic in irregular fashion. Toward one edge of the specimen, vertically-oriented and incompletely-maturing fascicles of said melanocytes can be seen, and the dermis encompassing them is coarse and vascularized. Within large fascicles, occasional juxtaposed neutrophils, occasional single necrotic melanocytes, and occasional melanocytes in mitosis can be found. Toward one edge of the specimen, there is an area of lesser cellularity that shows a greater degree of maturation with descent.	Seven outside slides, DN10-034669 and one corresponding block.	DF/NEVUS	\N	\N	\N	Our differential diagnosis included a hypercellular Spitz nevus on one hand and spitzoid melanoma on the other, and the latter possibility proves to represent the correct classification for this tumor. To more fully establish the nature of this process, we completed comparative genomic hybridization via an array methodology (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, aCGH analysis demonstrated gains in chromosomes 1q, 6p, 7, and 19, and losses in chromosomes 6q, 9, and 16q were also apparent. The documentation of multiple chromosomal anomalies is strongly supportive of the above diagnosis of melanoma. The above microstage thickness measurement is provisional and should be revised once complete excision has been accomplished. This melanoma is nonulcerated and shows associated Clark's level IV invasion. Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF AT LEAST 1.4 MM IN THICKNESS, INVOLVING THE DEEP EDGE OF THE BIOPSY	173508	1842	\N	\N	10-74513	\N	SYNAT445	2010-2017	IP969092	AirTable blocks_with_IP_info.csv
1419	10-80009	7	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a dome-surfaced proliferation of large oval melanocytes involving the junctional zone, a thickened papillary dermis and the upper portion of the reticular dermis centered around a folliculosebaceous unit. The lesion is relatively symmetrical, and well circumscribed. Only a few junctional nests are present, with slightly increased numbers of single melanocytes, mostly over the apex of the lesion. The superficial dermal portion of the proliferation consists of cells with abundant amphophilic cytoplasm and pleomorphic, vesicular nuclei, some of which have large and/or multiple nucleoli. Somewhat smaller cells are seen in smaller aggregations toward the base of the lesion. Several deep mitotic figures are evident, including one within a high power microscopic field of the deep edge of the lesion (a so-called marginal mitosis).	Three outside slides, DE-10-012089:A1.	SPITZ NEVUS	\N	\N	\N	The enclosed images appear to show a relatively low Ki-67 labeling rate in a two-color immunoperoxidase stain (some positive nuclei are present in the enclosed Ki-67 stain, but it is difficult to evaluate how many are in melanocytes). I agree that this lesion has several features that push the limits for the diagnosis of Spitz's nevus, including a relatively thin epidermis, above-average nuclear pleomorphism and the presence of several deep mitotic figures. There are many dermatopathologists who would classify this as a so-called atypical Spitz tumor, a diagnostic term that is, unfortunately, used in different ways by different observers. However, it captures the sense that the lesion does not conform to the standard features of a Spitz's nevus, but does not have sufficiently atypical findings for an outright diagnosis of melanoma. Comparative genomic hybridization with an array based method shows an isolated gain involving the terminal end of 7q. This aberration, when seen without other gains or losses usually occurs in benign lesions (similar to gains of 11p). Hence, an unusual Spitz's nevus is the most likely finding. A narrow re-excision would still be appropriate.	PREDOMINANTLY INTRADERMAL PROLIFERATION OF LARGE, SPITZOID MELANOCYTES	173525	2259	\N	\N	10-80009	\N	SYNAT446	2010-2017	IP974588	AirTable blocks_with_IP_info.csv
3551	MP41	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1392	\N	\N	None	\N	UV-01	Uveal Melanoma	\N	AirTable blocks_with_IP_info.csv
1268	07-2889-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31871	\N	\N	\N	\N	\N	\N	\N	Waist	\N	\N	\N	\N	1403	\N	\N	None	\N	WS-02	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
1264	07-2104	\N	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31404	\N	\N	Tissue was mounted on LCM slides. Circled images are kept in the server.	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	1403	\N	\N	07-2104	\N	WS-02	Werner Syndrome	\N	AirTable blocks_with_IP_info.csv
1427	10-91484	25	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show an asymmetrical, incompletely circumscribed, compound proliferation of enlarged spindled and epithelioid melanocytes with finely melanized cytoplasm. Within the background epidermis, which is slightly acanthotic, there are single melanocytes and nests distributed nearly confluently, and prominent suprabasal scatter is appreciable. In the dermis below this, there are partially-maturing nests, cords, and syncytia of cytologically similar melanocytes, and scattered dermal melanophages and lymphocytes can also be seen.	Two outside slides, S-10-29362:1A and one corresponding block.	CLAIMS HAS NOTICED FOR 1 1/2 YEARS AND IS INCREASING IN SIZE; NEVUS	\N	\N	\N	My differential diagnosis included a peculiar melanocytic nevus on one hand and melanoma on the other, and I believe the latter possibility represents the best interpretation of this atypical melanocytic proliferation. To more fully evaluate this tumor, we pursued array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, aCGH analysis demonstrated clear loss of chromosome 9 with possible gain in chromosomes 5 and 7. (Because of a technical shortcoming, we repeated the molecular analysis; I apologize for the delay this provoked.) Loss in chromosome 9 is a common molecular event in association with melanoma and lends support to the above interpretation. This melanoma is non-ulcerated and displays associated Clark's level IV invasion. Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 1.1 MM IN THICKNESS, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	173765	2117	\N	\N	10-91484	\N	SYNAT447	2010-2017	IP986063	AirTable blocks_with_IP_info.csv
1437	11-699	6	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show acral skin with a deep dermal and subcutaneous fibrotic mass containing nests of melanocytes with abundant amphophilic cytoplasm and moderately enlarged oval vesicular nuclei, some of which are diffusely hyperchromatic. There are scattered pyknotic nuclei. Mitotic figures appear rare.	Eleven outside slides (ten unstained), S10-55992 (S10-2413).	MELANOCYTIC TUMOR SUBMITTED FOR COMPARATIVE GENOMIC HYBRIDIZATION, LINEAGE ESTABLISHED AS MELANOCYTIC BY IMMUNOPEROXIDASE STAINS AT SLOAN-KETTERING	\N	\N	\N	Comparative genomic hybridization shows an area of loss involving the long arm of chromosome 7, with a gain of the distal portion of the long arm of chromosome 7. The data from this case has been forwarded to Dr. Boris Bastian to try to determine where the breakpoint in this aberrant area is. There is also an area of loss in the terminal portion of chromosome 16q. The findings favor classification as melanoma. Given the monomorphous nuclei and the age of the patient, this may represent a variant with a prognosis different from that which would be inferred by the lesional thickness.	INTRADERMAL PROLIFERATION OF LARGE, SOMEWHAT SPITZOID MELANOCYTES	174789	2096	\N	\N	11-699	\N	SYNAT448	2010-2017	IP990136	AirTable blocks_with_IP_info.csv
1478	11-35616	17	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a sizable, deeply-situated, multinodular dermal and subcutaneous proliferation of enlarged slightly spindled and epithelioid melanocytes, some of which have finely melanized cytoplasm. Others have amphophilic cytoplasm. Gargantuan collections of cells are enmeshed in a sclerotic backdrop in concert with a juxtaposed lymphohistiocytic infiltrate, and melanocytes in mitosis can be found.	Six outside slides, S11-16670 (including 5 unstained slides).	BULKY MELANOCYTIC TUMOR	\N	\N	\N	We completed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies, per your request. After extraction of tumoral DNA from the tissue block, aCGH analysis demonstrates possible loss in distal chromosome 4p and loss in chromosomes 7q and 11 (in actual fact, there are both gains and losses in chromosome 7q; the observed pattern is quite exceptional). There is gain in chromosomes 5p, 8, 9p, 14p, and 20. The presence of multiple chromosomal copy number changes corroborates the above diagnosis of melanoma. Given the number and diversity of the chromosomal aberrations that have been found, the more favorable prognosis that is associated with so-called childhood-type spitzoid melanoma cannot be expected here. I do not have the full thickness of this melanoma apparent in the sections available to me, and thus the above thickness measurement is provisional. This melanoma invades deep into the subcutis and approaches superficial skeletal muscle.	SPITZOID MELANOMA EXCEEDING 6 MM IN THICKNESS	173712	1707	\N	\N	11-35616	\N	SYNAT450	2010-2017	IP1025054	AirTable blocks_with_IP_info.csv
1475	11-33856	29	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a broad, somewhat asymmetrical, and incompletely circumscribed compound proliferation of enlarged slightly spindled and epithelioid melanocytes. Only small numbers of melanocytes are distributed along the junction. Within the dermis, there are nests, cords, and fascicles of melanocytes that are similar to those seen intraepidermally, and these cells are entrapped in a coarse collagenous matrix. In some areas, a subjacent lymphohistiocytic infiltrate can be seen, and some of the dermal melanocytes have fine cytoplasmic melanization. Only an occasional melanocyte in mitosis can be found.	One outside slide, S-11-12116:A1-1. One corresponding block received 5-23-11.	LESION RECENTLY CHANGING IN COLOR AND SIZE	\N	\N	\N	Our differential diagnosis for this proliferation included an unconventional Spitz nevus on one hand and melanoma on the other. Cell proliferation analysis was completed via immunoperoxidase staining utilizing a two-color development system in which MART-1 is labeled red and Ki-67 is labeled brown. By this staining method, we found diffuse MART-1 reactivity. The MART-positive cells show increased nuclear expression of Ki-67, especially in the upper dermis, thus implying that cellular proliferation is elevated. This staining result was of potential concern but is not diagnostically decisive. In light of diagnostic ambiguity, we next pursued array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, aCGH analysis demonstrated gain in chromosome 11p. A small segmental loss in chromosome 14q was also noted. Gain in chromosome 11p is commonly found as an aberration in desmoplastic Spitz tumors with associated HRAS mutation.  In summary, the combination of results derived from conventional microscopy coupled with aCGH analysis points to interpretation as an unconventional (HRAS-mutated) Spitz nevus. This proliferation is focally transected at the periphery of the current specimen. Further excision is recommended to ensure that local eradication has been accomplished.  A pertinent reference can be found at the following citation: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	COMPOUND SPITZOID NEOPLASM, CONSISTENT WITH A DESMOPLASTIC COMPOUND SPITZ NEVUS	173600	2125	\N	\N	11-33856	\N	SYNAT451	2010-2017	IP1023294	AirTable blocks_with_IP_info.csv
1321	08-46462	28	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	Melanoma with nevus	There are nests of melanocytes at the dermo-epidermal junction, and nests, cords and strands of melanocytes within the subjacent dermis.  These cells mature with descent, and lie in part around adnexal structures.	Cylindrical skin segment measuring 0.7 cm in diameter x 0.7 cm in thickness, trisected and entirely submitted in cassette B.	A) 1.4 CM X 1.2 CM RED/BLACK ULCERATED PLAQUE; MELANOMA, B) 7 MM TWO-TONED BROWN PAPULE; NEVUS, MELANOMA	\N	\N	\N	The excision is complete.	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	273588	2186	\N	\N	08-46462	\N	SYNAT455	2010-2017	IP755103	AirTable blocks_with_IP_info.csv
1412	10-58663	52	\N	\N	\N	T2a	Primary	None	\N	\N	\N	\N	\N	172.5	\N	Melanoma with nevus	Sections show a broad-based proliferation of melanocytes with a markedly asymmetric configuration, involving the epidermis and superficial dermis. One part of the lesion features interconnecting rete ridges with subjacent nests, cords and strands of small round melanocytes, with clusters of adipocytes admixed with them. The other portion features a thickened epidermis with a relatively flat rete ridge pattern, a basal layer sparsely colonized by melanocytes with large, hyperchromatic nuclei, and a fibrotic stroma containing nests of similar cells, some with scant and some with abundant pale cytoplasm. There is little maturation with descent.	Skin segment measuring 1.7 x 1.2 x 0.1 cm, serially sectioned and entirely submitted with five sections.	ATYPICAL PIGMENTED SK; R/O MM	\N	\N	\N	The lesion is not ulcerated, and hence this is a T2a primary melanoma in the 2009 AJCC staging classification. The mitotic rate is low, and I did not encounter other features that would have a significant prognostic impact.	MELANOMA, 1.7 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A PRE-EXISTENT NEVUS	139524	2173	\N	\N	10-58663	\N	SYNAT452	2010-2017	IP953239	AirTable blocks_with_IP_info.csv
1329	08-52519	68	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.3	\N	Melanoma with nevus	Sections show a bilobed, somewhat polypoid proliferation of melanocytes in a biphasic pattern. The smaller lobe contains an intradermal proliferation of bland melanocytes, which demonstrate a degree of neural differentiation (melanocytic nevus). In the other more polypoid zone, there is a markedly asymmetrical proliferation of atypical melanocytes, which are morphologically heterogeneous, arrayed as irregular clusters and syncytia. In many areas, these fail to mature with descent. Mitotic figures are evident within the dermal component. In areas near the base, there is also a population of smaller melanocytes. Some are in continuity with some of the larger ones overlying them, while others are somewhat bland and may demonstrate a degree of maturation with melanocytic descent. There is fibrosis, and a patchy lymphocytic infiltrate, as well as dilated lymphovascular spaces.	Skin segment measuring 0.7 x 0.5 x 0.4 cm, bisected and entirely submitted.	SINGLE PINK PAPULE WITH BROWN APICAL PORTION; R/O MIS	\N	\N	\N	In one area, there is a neurotized intradermal nevus. In the larger more polypoid zone adjacent to this, there is a markedly asymmetrical proliferation of more atypical melanocytes, with mitotic figures evident within the dermal component, compatible with melanoma. There is also a population of somewhat smaller melanocytes near the base of this proliferation. Some of these probably represent small cells of melanoma, while there may some nevus present there as well. The measurement of thickness is thus based on my best judgment as to what represents the component of melanoma. In terms of other staging parameters, this is a non-ulcerated primary melanoma of Clark's anatomic level IV. There are no other features which would have a significant impact on prognosis. Complete re-excision is of course warranted. I have also shared this unusual case with my colleagues, Drs. Philip LeBoit and Timothy McCalmont, who agree with these findings.	MELANOMA, 1.7 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	173399	2072	\N	\N	08-52519	\N	SYNAT453	2010-2017	IP761160	AirTable blocks_with_IP_info.csv
1860	15-22411	63	\N	\N	\N	T1a	Primary	Superficial spreading	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26313	172.5	\N	\N	Sections show a compound proliferation of melanocytes with a biphasic pattern.  One population consists of melanocytes with variable nuclei that are arrayed irregularly along the epidermal-dermal junction and within the dermis. Within the epidermis, there are numerous melanocytes in pagetoid scatter and single epithelioid melanocytes predominate over nests in some foci. There are nests of similar melanocytes in the underlying dermis. There is also a second population of smaller and cytologically melanocytes that diminish in size with descent in the dermis and extend into the reticular dermis.	Skin segment measuring 1.0 x 0.7 x 0.2 cm, trisected, and entirely submitted. HD/HD	DARK PAPULE, SLIGHTLY IRREGULAR ATYPICAL NEVUS VS. SK, DOUBT MELANOMA	\N	\N	FFPE	In addition to the melanoma, there is a melanocytic nevus with superficial congenital features that intermingles with the melanoma that is present in this specimen. Therefore, it is most likely that the melanoma arose within a melanocytic nevus. Is there a clinical history of a changing pigmented lesion? Synoptic melanoma reporting is included below:  Procedure: Scoop shave biopsy Microscopic tumor type: Superficial spreading Breslow thickness:  0.8 mm Ulceration: absent Margins: Intraepidermal melanoma extends to within 1 millimeter of the specimen edge Mitotic index: 0 mm/2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT1a  Further treatment at this site is warranted to ensure that local eradication has been accomplished.	MELANOMA, 0.8 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173531	1397	\N	\N	15-22411	\N	VS-04_JJS22	Melanoma Evolution,Spatial Gene Expression	IP1199550	AirTable blocks_with_IP_info.csv
1338	09-8165	59	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	Melanoma with nevus	Sections show a markedly atypical, compound proliferation of melanocytes, with a subtly biphasic pattern. Within the epidermis, there are atypical melanocytes, arrayed as nests, single cells, and in zones of near confluence, with an area in which the epidermis is disrupted. Similar melanocytes are present in clusters and syncytia within the papillary dermis, filling it, and extending to the reticular dermal interface. Near the base of the specimen, there is another population of somewhat smaller bland melanocytes, arrayed as clusters and syncytia, and these demonstrate maturation with melanocytic descent (melanocytic nevus). There is a patchy lymphocytic infiltrate, and scattered melanophages.	Ellipse, 2.2 x 1.1 x 0.9 cm, including a central 1.0 x 0.8 cm dark pigmentation.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with six central sections, tips returned to container.	R/O MM VS. PIGMENTED SK VS. CONGENITAL NEVUS	\N	\N	\N	In terms of staging, this is a probably non-ulcerated, primary melanoma of Clark's anatomic level III/IV, extending to and possibly involving the papillary dermal-superficial reticular dermal interface. Measurement of thickness is an approximation, as the epidermis is disrupted overlying the thickest portion of the neoplasm. While there is near confluence of melanocytes in this zone, it is difficult to know whether ulceration has occurred. I suspect that it has not. There is no evidence of neurotropism, vascular invasion, or regression in these sections. Additional excision is warranted to achieve standard margins for a tumor of these staging parameters. This case was reissued on April 20, 2009 to add the patient's UCSF medical record number.	MELANOMA, APPROXIMATELY 1 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING TO WITHIN 2 MM OF THE PERIPHERY OF THE EXCISION	173568	1730	\N	\N	09-8165	\N	SYNAT454	2010-2017	IP458841	AirTable blocks_with_IP_info.csv
3074	4449/16 (4449/16 3 slide)	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1212	\N	\N	None	\N	NM-34	Nodular Melanoma	\N	AirTable blocks_with_IP_info.csv
2813	22-75050A2	71	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	https://64.54.108.121/app/WebViewer/view/image/34970	238.2	\N	\N	Sections show skin with marked elastosis. Centrally, there is a dermal proliferation of melanocytes with small round nuclei and scant cytoplasm that mature with descent in the dermis. Deep and to the sides of this is a second population of melanocytes with expanded pigmented cytoplasm and oval nuclei with open chromatin arrayed as nests. There are scattered melanophages alongside thickened collagen bundles.	Skin segment measuring 0.7 x 0.7 x 0.1 cm, trisected and entirely submitted in A. BY/BY Subsequently, the wax block was melted down and entirely resubmitted with one section in A1 and two sections in A2. JC	A) SUSPICIOUS IRREGULAR MULTI-COLORED PAPULE; ATYPICAL PIGMENTED LESION, B) PEARLY TELANGIECTATIC PAPULE; BASAL CELL CARCINOMA VS. SEBACEOUS HYPERPLASIA	\N	\N	FFPE	Wnt-activated melanocytomas were previously known as deep penetrating nevi. This example retains p16 expression and does not express PRAME, arguing against melanoma. They typically harbor activating mutations of CTNNB1 and are considered low-grade melanocytic neoplasms with benign behavior. The melanocytoma broadly extends to the base of the biopsy. A re-excision of the site is recommended to ensure complete removal. Reference: Combined activation of MAP kinase pathway and ﬂ-catenin signaling cause deep penetrating nevi. Yeh I, Lang UE, Durieux E, Tee MK, Jorapur A, Shain AH, Haddad V, Pissaloux D, Chen X, Cerroni L, Judson RL, LeBoit PE, McCalmont TH, Bastian BC, de la FouchardiËre A. Nat Commun. 2017 Sep 21;8(1):644.	WNT-ACTIVATED MELANOCYTOMA ARISING WITH ASSOCIATED PRECURSOR MELANOCYTIC NEVUS	173727	1398	\N	\N	22-75050	A2	VS-05	Spatial Gene Expression	IP2476934	AirTable blocks_with_IP_info.csv
1762	14-29390	60	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.9	\N	from Swapna	See UCSF Surgical Pathology report S14-7672.	One outside slide, S14-7672 (14N-7254:2B), and one corresponding block.	REFERRAL FOR MOLECULAR TESTING	\N	\N	\N	The comparative genomic hybridization array graph shows a baseline shift, but there are clear losses of 1, 2, 5q, 14q, 17p, 18, 21, 22 and chromothripsis in 5p. A detailed look at chr. 3p shows no bap-1 loss. The multiple aberrations and presence of chromothripsis, in the context of a lesion with this degree of atypicality favor a melanoma. We did not find aberrations in b-raf, gnaq or gna-11. BRAF exon 15: wild-type. GNAQ exons 4 and 5: wild-type. GNA11 exons 4 and 5: wild-type.	MELANOMA	666955	642	\N	\N	14-29390	\N	DP-05	Possible TERT Fusion	IP1379315	AirTable blocks_with_IP_info.csv
1237	06-21363	20	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a roughly wedge-shaped infiltrate of spindled and polygonal melanocytes, some of which have ample vacuolated and pigmented cytoplasm, positioned in the superficial dermis and along the epidermal-dermal junction, where rare nests can be found. Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are hard to find. There are interspersed melanophages and also scattered interstitial lymphocytes and histiocytes.	Cylindrical skin excision, 0.6 cm in diameter and 0.9 cm in thickness, including a central gray-brown 0.4 cm pigmented spot.  With margins inked blue, the specimen is serially bisected perpendicular to the short axis and totally submitted.	R/O MELANOMA	\N	\N	\N	This lesion represents a bit of a hybrid, showing some features of a desmoplastic pigmented Spitz's nevus and also some features of a so-called deep penetrating nevus. I do not believe these changes signify melanoma.	HEAVILY PIGMENTED COMPOUND MELANOCYTIC NEVUS, EXCISED IN PLANES OF SECTION EXAMINED	529698	1670	\N	\N	06-21363	\N	SYNAT456	Deep Penetrating Nevus	IP566429	AirTable blocks_with_IP_info.csv
1250	06-47334	34	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a dome surfaced, roughly wedge-shaped proliferation of large oval melanocytes, most of which have abundant vacuolated cytoplasms, which extends deeply in the reticular dermis.  Some melanocyte nuclei are modestly enlarged.  There are interspersed melanophages.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted.	PT IS 6 MONTHS PREGNANT, CHANGING MOLE	\N	\N	\N	The base of the specimen is focally involved. There are no worrisome features, however.	DEEP PENETRATING NEVUS	173601	2238	\N	\N	06-47334	\N	SYNAT457	Deep Penetrating Nevus	IP454219	AirTable blocks_with_IP_info.csv
1466	11-25808	41	\N	\N	\N	T1b	Primary	None	\N	\N	\N	\N	\N	172.7	\N	\N	There is a broad-based proliferation of melanocytes involving the epidermis and superficial dermis. The epidermis is hyperplastic, and there are increased numbers of single melanocytes and both small and large nests of them positioned at irregular intervals along the junction. Some branching rete ridges are evident, with subjacent fibrosis. There are nests, cords and strands of plump oval to small round melanocytes in the subjacent dermis, with some tendency to cluster around the upper parts of adnexal structures.	One outside slide, ND11-734. One corresponding block received 4/15/11.	RULE OUT ATYPIA	\N	\N	\N	The neoplasm extends to the peripheral edge of the specimen. While the distribution of melanocytes within the epidermis is irregular, and some of the cells in the dermis are moderately enlarged, other features raise the possibility of an unusual congenital nevus. The dermal component matures with descent in areas, and mostly has discrete aggregations of cells. As nevoid melanoma is in the differential diagnosis, I obtained immunoperoxidase stains. These include an HMB45 stain, strongly positive at the dermo-epidermal junction and weakly positive within only the superficial-most melanocytes. Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a near zero proliferation rate in the dermal melanocytes.  A scout section (the hematoxylin and eosin stained recut that we obtain at the time that sections are cut for immunoperoxidase stains) contained several melanocytes in mitosis. B  Comparative genomic hybridization shows a gain involving chromosome 7, a loss of chromosome 9, and a gain of most of chromosome 14. This combination of features indicates melanoma. Whether a component of nevus is also present could not be determined.  While the lesion is not ulcerated, the presence of melanocytes in mitosis in the dermis qualifies this lesion as T1b in the 2009 AJCC staging classification for melanoma.	MELANOMA, 0.7 MM. IN THICKNESS	173726	1792	\N	\N	11-25808	\N	SYNAT458	2010-2017	IP1015246	AirTable blocks_with_IP_info.csv
1573	12-7775	24	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a broad based proliferation of large, oval and fusiform melanocytes, positioned as nests along the undersurface of an irregularly hyperplastic epidermis, and as smaller aggregations in a fibrotic superficial dermis. There are clefts between melanocytes and between them and  the adjacent epidermis. Melanocytes mature with descent within the dermis, and the sizes of their aggregations also diminish with descent. Several mitotic figures are present, including some near the base of the specimen.	Three outside slides, D12-8697 and one corresponding block.	SEBORRHEIC KERATOSIS, R/O ATYPIA, CHECK MARGINS CLINICALLY; CONCERN RE SPITZIOD MELANOMA ON PATHOLOGIC EXAMINATION; REQUEST FOR CONSULTATION AND COMPARATIVE GENOMIC HYBRIDIZATION IN COVER LETTER	\N	\N	\N	Comparative genomic hybridization shows a narrow gain involving an area of chromosome 7q and a narrow gain with higher amplitude involving a second area of 7q. Isolated gains involving chromosome 7q can occur in Spitz's nevus. My colleague, Dr. Boris Bastian examined the comparative genomic hybridization examined the comparative genomic hybridization data and notes that the larger gain includes the MET locus. This finding has been seen previously in Spitz's nevus. Given that the changes are less straightforward than the finding of no gains or losses, or of an isolated gain of 11p or of the entire 7q arm, I would like to leave the diagnosis somewhat ambiguous, but favoring a Spitz's nevus. The neoplasm extends to the base of the specimen across a broad front, and if there is a significant residuum on re-excision, I would be interested in viewing the sections.	COMPOUND PROLIFERATION OF LARGE, SPITZOID MELANOCYTES, WITH FINDINGS FAVORING AN UNUSUAL SPITZ'S NEVUS	173508	2272	\N	\N	12-7775	\N	SYNAT459	2010-2017	IP1093591	AirTable blocks_with_IP_info.csv
1968	16-84820	62	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22140	172.6	\N	\N	Sections show a proliferation of melanocytes with a dome surfaced and a flattish portion. The domed area features large, oval melanocytes with abundant, pale cytoplasm and dusty appearing melanin and enlarged nuclei in a pagetoid pattern in the epidermis and as large nests in fibrotic stroma in the superficial dermis. To the side of these changes, there are plump, oval to small round melanocytes in discrete nests in the papillary dermis.	Cylindrical skin segment measuring 0.9 cm in diameter and 0.6 cm in thickness, with the margins inked, quadrisected and entirely submitted. CF/CF	IRREGULAR BROWN PAPULE; MELANOMA	\N	\N	Scraping	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: biopsy Tumor site: right arm Microscopic tumor type: superficial spreading melanoma Breslow thickness: 1.2 mm. Ulceration: no Margins, peripheral: clear by 2 mm. of melanoma, involved by nevus, and deep: unequivocal clear Mitotic index: 1/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT2a pNX	MELANOMA, 1.2 MM. IN THICKNESS, ARISING IN A NEVUS	273699	1097	\N	\N	16-84820	\N	ME-02	Melanoma Epigenetics	IP1684607	AirTable blocks_with_IP_info.csv
1315	08-43264	50	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a proliferation of melanocytes involving the epidermis and papillary dermis. A large portion of the lesion is a predominantly intradermal proliferation of melanocytes, in which nests, cords and strands of small, round cells mature as they extend into the superficial reticular dermis.  Near the periphery, there are large melanocytes with abundant pale cytoplasm in pagetoid array within the epidermis, with single melanocytes that predominate over nests in some areas. A few similar cells reside in the subjacent papillary dermis.	Ellipse, 2.2 x 1.0 x 0.3 cm, including a central brown 0.6 x 0.4 cm macule.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and submitted with five central sections, tips returned to container.\n	ATYPICAL PIGMENTED LESION	\N	\N	\N	The neoplasm extends to within 1 mm. of the peripheral edge of the specimen. There are no microscopic findings that would substantially change the prognosis indicated by the tumor thickness listed above. The lesion is not ulcerated, and only involves a portion of the papillary dermis (level II).	MELANOMA, 0.5 MM  IN THICKNESS, ARISING IN A MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	173529	2086	\N	\N	08-43264	\N	SYNAT460	2010-2017	IP179649	AirTable blocks_with_IP_info.csv
1323	08-51219	65	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	The histopathology is generally similar to that described for specimen DH08-51219B, with a greater degree of subjunctional fibroplasia apparent.	Ellipse, 2.0 x 0.9 x 0.6 cm, including a central variegated brown 1.5 x 0.8 cm plaque.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections each in cassettes C1 and C2.	A-C) LONG-TIME ATYPICAL NEVI; A) 8 MM TRANSVERSE; B) 4 MM LONG X 1.1 CM; C) 6 MM LONG X 1.4 CM TRANSVERSE; A-C) R/O ATYPICAL NEVI	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with invasion confined to the papillary dermis (Clark's level III). Further excision of this site is warranted.	MELANOMA OF 0.55 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS AND EXTENDING NEAR TO THE PERIPHERY OF THE SPECIMEN	173539	1744	\N	\N	08-51219	\N	SYNAT461	2010-2017	IP754897	AirTable blocks_with_IP_info.csv
1199	06-2345	40	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.4	\N	\N	Sections show a deep and partially wedge-shaped proliferation of slightly spindled and ovoid melanocytes, some with vacuolated and pigmented cytoplasm, which extends deeply in the reticular and adventitial dermis. Some deep melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous. There are many interspersed melanophages. Superficially, these cells meld with a population of heavily pigmented spindled melanocytes enmeshed in sclerosis.	Cylindrical skin segment, 0.5 cm in diameter and 0.4 cm in thickness, bisected and entirely submitted.	4 X 3 MM BLUISH PAPULE; ?RECURRENT BLUE NEVUS, R/O ATYPICAL PIGMENTED LESION	\N	left scalp	Scraping	This lesion could also be interpreted as a combined melanocytic nevus, with an admixture of deep penetrating nevus and conventional blue nevus. There is no evidence of melanoma.	CELLULAR BLUE NEVUS	173417	1333	\N	\N	06-2345	\N	SM-003	Nevus Library	IP395583	AirTable blocks_with_IP_info.csv
1191	05-46869B	37	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=314	172.6	\N	\N	Sections show skin with a broad and poorly circumscribed proliferation of melanocytes.  Nests of melanocytes are distributed at irregular intervals, and are focally confluent.  There are foci in which single melanocytes predominate as well.  \nThere are some melanocytes scattered above the basal layer in such areas.  There is a domed area, in which large, oval melanocytes with large, pleomorphic vesicular nuclei form sheets in the papillary dermis. A minor population of melanocytes with small, monomorphous nuclei are clustered around a pilosebaceous unit at the base of the lesion.	Skin segment measuring 1.0 x 0.8 x 0.2 cm, trisected and entirely submitted in cassette B.	A) ANGIOMA; B) 10 X 6 MM; IDN	\N	\N	Scraping	Melanoma in situ extends to the periphery of the specimen. Histopathologic features of possible prognostic importance include:  Level: III Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent	MELANOMA, 1.0 MM  IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS OF THE CONGENITAL TYPE	173610	185	\N	\N	05-46869	B	CCR-205	California Cancer Registry	IP523582	AirTable blocks_with_IP_info.csv
1014	00-16651B T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1005	\N	\N	None	\N	MD-113	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3522	M100118	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	99	\N	\N	None	\N	AMC-02	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3523	M180322	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	104	\N	\N	None	\N	AMC-13	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
1640	12-37217	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	105	\N	\N	12-37217	\N	BN-001	Nevus Library	\N	AirTable blocks_with_IP_info.csv
1646	12-52736	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	106	\N	\N	12-52736	\N	BN-002	Nevus Library	\N	AirTable blocks_with_IP_info.csv
1525	11-81851	67	\N	\N	5	None	None	None	\N	\N	\N	\N	\N	172.4	\N	\N	Sections show nodular aggregations of melanocytes with atypical nuclei in the dermis, lack of maturation of these cells with descent, and their arrangement in irregularly shaped aggregations. There is a flanking intraepidermal component with pagetoid growth pattern.  A second population of small round melanocytes arranged in discrete collections is also present. Some of these melanocytes show neuroid differentiation.	Skin segment measuring 0.7 x 0.5 x 0.5 cm, bisected and entirely submitted.	R/O INFLAMED NEVUS, PYOGENIC GRANULOMA	\N	\N	\N	The melanoma arose in continuity with an intradermal melanocytic nevus. Histopathologic features of possible prognostic importance include: Level: IV Tumor infiltrating lymphocytes: non-brisk Vascular or lymphatic invasion: non detected Dermal mitotic rate:  5/mm2 Perineural invasion: not detected Ulceration: absent Regression: absent Microsatellite metastasis: absent Solar elastosis: moderate (non-CSD) WHO type: superficial spreading melanoma	MELANOMA, 1.9 MM IN THICKNESS, EXTENDING CLOSE TO THE PERIPHERY OF THE BIOPSY	173404	2045	\N	\N	11-81851	\N	SYNAT462	2010-2017	IP1071299	AirTable blocks_with_IP_info.csv
1721	13-45163	58	\N	\N	\N	T1a	Primary	melanoma on non-chronically sun-damaged skin, SSM	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a compound melanocytic proliferation with a biphasic pattern.  One population consists of melanocytes, most of which have atypical nuclei, that are irregularly distributed along the dermal-epidermal junction, with some melanocytes present above the basal zone.  Similar melanocytes are present in the subjacent dermis. The second population consists of melanocytes with cytologically bland nuclei arranged in wedge-shaped array  (melanocytic nevus).	Ellipse, 1.8 x 0.9 x 0.3 cm, including a central 0.9 x 0.7 cm variegated brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with eight sections. PL/PL	1 CM BROWN/BLACK ROUND MACULE	\N	\N	\N	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: excision Tumor site: back Microscopic tumor type: melanoma on non-chronically sun-damaged skin, SSM Breslow thickness: 0.4 Ulceration: no Margins, peripheral and deep: Intraepidermal component extending close to the peripheral margin Mitotic index: none detected Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT1a pNX Solar elastosis: mild	MELANOMA, 0.4 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING CLOSE TO THE PERIPHERY OF THE BIOPSY	139524	1966	\N	\N	13-45163	\N	SYNAT463	2010-2017	IP468757	AirTable blocks_with_IP_info.csv
1496	11-50182	55	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a domed segment of skin with a dermal proliferation of enlarged fusiform melanocytes with abundant, pale cytoplasm and dusty appearing melanin. These melanocytes are arranged as thick and thin interconnecting fascicles with interspersed melanophages. The aggregations are more closely apposed in the upper part of the lesion than near the base of the specimen. Mitoses are present (around 1 per 5 400x fields). Some melanocytes have large, hyperchromatic nuclei.	Two outside slides, D11-10392. One corresponding block received 7/25/11.	TWO-TONED CHANGING LESION; REQUEST FOR CGH FROM DR VENNA	\N	\N	\N	ADDENDUM, August 18, 2011: Our differential diagnosis included an atypical cellular blue nevus on one hand and blue nevus-like melanoma on the other. Cell proliferation analysis was completed via immunoperoxidase staining utilizing a two-color development system in which MART-1 is labeled red and Ki-67 is labeled brown. By this staining method, we found diffuse MART-1 reactivity and a low Ki-67 cell proliferation index. We also completed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue bock, application of aCGH demonstrated segmental gain in chromosome 7q and loss of chromosome 9q. The presence of multiple chromosomal losses suggests genomic instability and favors interpretation as melanoma. In summary, the combination of results derived from conventional microscopy coupled with aCGH favors interpretation as blue nevus-like (or deep penetrating nevus-like) melanoma. With respect to staging, this tumor is non-ulcerated and shows associated Clark's level IV invasion. Further excision is warranted to permit further microstage assessment and to ensure that local eradication has been accomplished.	ATYPICAL INTRADERMAL PROLIFERATION OF ENLARGED SPINDLED MELANOCYTES, CONSISTENT WITH MELANOMA OF 1.9 MM IN THICKNESS	173502	1827	\N	\N	11-50182	\N	SYNAT464	2010-2017	IP1039621	AirTable blocks_with_IP_info.csv
1498	11-51553	14	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.3	\N	\N	There is a compound proliferation of melanocytes that extends into the deep reticular dermis. The epidermis overlying the proliferation is thinned. There are nests and single melanocytes along the junction, and most have abundant pale, vacuolated cytoplasm and some have enlarged oval vesicular nuclei. A limited degree of pagetoid scatter is present. Within the subjacent dermis there are coalescing nests, cords, and small syncytia of similar-appearing cells, some of which have even more abundant cytoplasm or larger and more hyperchromatic nuclei. Interspersed amidst these cells are foci in which melanocytes with smaller and more monomorphous nuclei predominate. Near the base of the proliferation are lymphoid nodules. A permeative component to the infiltrate in the reticular dermis is also noted.	One outside slide, D11-25135 and one corresponding block.	CHANGING MOLE WHICH BLEEDS OCCASIONALLY AND HAS BEEN PRESENT FOR ONE AND A HALF YEARS	\N	\N	\N	The findings are not those of a conventional congenital, Spitz or deep penetrating melanocytic nevus. Immunoperoxidase staining using two colors (with MART-1/tyrosinase labeled red and Ki-67 labeled brown) shows a relatively low cell proliferation index. However, some positively-labeled nuclei are apparent even in the deep dermis, which is of concern. We also completed array-based comparative genomic hybridization (aCGH) to further address the differential diagnosis between melanocytic nevus and melanoma. After extraction of tumoral DNA from the tissue block, application of aCGH revealed segmental gain in chromosome 7p and also in 7q. The presence of multiple chromosomal copy number aberrations indicates genomic instability and favors interpretation as melanoma. We have not observed gain in chromosome 7 in melanocytic nevi of any type.  In summary, the combination of results derived from conventional microscopy coupled with aCGH favors interpretation as an unconventional melanoma occurring in childhood. We refer to tumors within this spectrum as childhood-type melanomas. The designation childhood-type melanoma refers to an emerging tumor category that we believe is distinct from conventional (or adult-type) melanoma. Such tumors typically lack BRAF mutations and were reported in the past literature under such flawed designations as malignant Spitz nevus. Experience to date suggests a small risk for extension to regional lymph nodes with a low risk for widespread dissemination.  This tumor is 4.2 mm in thickness and is non-ulcerated. Further excision is warranted to ensure that local eradication has been accomplished. I have received a call from Dr. Saadia Raza and will be returning her call to discuss the case.	ATYPICAL COMPOUND PROLIFERATION OF MELANOCYTES; GAIN IN CHROMOSOMES 7p AND 7q APPARENT VIA COMPARATIVE GENOMIC HYBRIDIZATION	173304	2150	\N	\N	11-51553	\N	SYNAT465	2010-2017	IP1040993	AirTable blocks_with_IP_info.csv
3520	M040418	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	102	\N	\N	None	\N	AMC-08	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
1501	11-55993	48	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a partial biopsy that contains a compound proliferation of enlarged melanocytes that are slightly spindled or epithelioid in morphology. Within the epidermis, nests and fascicles of enlarged melanocytes are positioned at the junction in concert with acanthosis, and clefts separate some melanocytic fascicles from the epithelium. In the dermis below this, there are maturing nests, cords, and small syncytia of similar melanocytes, and a juxtaposed permeative lymphohistiocytic infiltrate is also noted. An element of reticular dermal elastosis can be seen.	Three outside slides, D11-27883 and one corresponding block.	1.5 CM PINK PLAQUE WITH DARKER MACULE ON THE UPPER ASPECT ON THE LEFT THIGH POSTERIOR; NEVUS VS. MELANOMA	\N	\N	\N	This partial biopsy raised a differential diagnosis between the center of a Spitz nevus on one hand and melanoma on the other. To more fully address this differential, we completed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 4, gain in distal chromosome 7q, loss of chromosome 9, and gain in chromosome 15q. The identification of multiple genomic gains and losses confirms the presence of genomic instability, which is confirmatory of a diagnosis of melanoma. As you probably know, the aCGH profile that has been demonstrated is incompatible with a diagnosis of melanocytic nevus. Please note that this melanoma would not be diagnosable via application of fluorescence in situ hybridization (FISH). The current FISH approach that is utilized analyzes (and thus potentially demonstrates) aberrations involving only chromosomes 6 and 11. This melanoma, which has multiple aberrations involving other chromosomes, would have a normal FISH profile. (This is not uncommon in spitzoid melanomas.)  In summary, the combination of results derived from conventional microscopy coupled with aCGH points to interpretation as melanoma. This is a non-ulcerated melanoma with associated Clark's level IV invasion. The final microstage parameters should be reassessed once this melanoma has been fully extirpated.	MELANOMA OF 0.95 MM IN THICKNESS	173765	1801	\N	\N	11-55993	\N	SYNAT467	2010-2017	IP1045436	AirTable blocks_with_IP_info.csv
1502	11-57051	53	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.7	\N	\N	There is a broad-based and asymmetrical proliferation of melanocytes mostly involving the epidermis (chiefly the junctional zone within it) and the superficial dermis. There are elongated rete ridges, with increased numbers of single melanocytes at the sides and bases of a few, and nests of them toward the bases of more. Toward one end of the specimen, junctional nests are particularly confluent and crowded together. Toward the center of the lesion, nests of plump oval to small round melanocytes lie within fibrotic stroma. The epidermis above this central area is more markedly thickened and has a thick granular and a partially compact cornified layer.	One outside slide, CB11-3582-2. One corresponding block received 8/25/11.	2ND OPINION, INITIAL BIOPSY AND EXCISION OF RIGHT CALF LESION; R/O DN (ALSO INCLUDED WAS A FOREHEAD BIOPSY; R/O BCC)	\N	\N	\N	The differential diagnosis was between a thin melanoma and an unusual nevus. A slight degree of pagetoid scatter is present, which may be due to irritation (this is suggested by the findings of lichen simplex chronicus in the overlying epidermis). We performed comparative genomic hybridization, which shows a gain involving chromosome 7q. We have noted isolated gains of 7q in Spitz nevi, but not melanoma. Given this result, I favor a benign interpretation, specifically a nevus in which there are the architectural features of a dysplastic (Clark's) nevus and (only well developed in some nests) the cytologic features of a Spitz's nevus. Given the unusual nature of the lesion, and its proximity to the peripheral margins, I would consider a narrow re-excision of the site.	SPITZOID CLARK'S NEVUS, COMPOUND	173711	1973	\N	\N	11-57051	\N	SYNAT468	2010-2017	IP1046494	AirTable blocks_with_IP_info.csv
1520	11-76464	7	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.4	\N	\N	Sections show a well-circumscribed but asymmetrical compound proliferation of melanocytes involving the junctional zone and the superficial dermis, extending within a pilosebaceous unit to the level of the deep reticular dermis in one focus. An aggregate of melanocytes abuts a lymphatic space at the same level. Nests predominate over single cells along the junction, and are in part composed of cells with polygonal outlines, abundant pale, vacuolated cytoplasm, dusty melanin and large but monomorphous vesicular nuclei that contain moderately sized nucleoli. These cells merge with melanocytes that have moderate-sized nuclei and scant cytoplasm toward the base of the lesion. Several mitotic figures are seen in the more pale-appearing melanocytes in the upper part of the proliferation.	Ten outside slides, SSL11-8420:A1, including nine unstained slides.  One corresponding block received 10-20-11.	RULE OUT COMPOUND NEVUS VS. SPITZ NEVUS (CLINICAL INFORMATION FROM ENCLOSED OUTSIDE PATHOLOGY REPORT)	\N	\N	\N	Comparative genomic hybridization shows a gain involving chromosome 7q. Isolated 7q gains (such as that seen here) are present in a small group of Spitz's nevus, and we have not yet encountered isolated 7q gains in melanoma. There is diminished binding of the lesional DNA to probes representing chromosome 19, but this is a common artifactual problem due to high GC content. The lesion extends to within 1 mm. of the peripheral edge of the specimen. I would consider a very narrow re-excision to achieve 5 mm margins, but the findings seen here do not, in my opinion, support more than that.	SPITZ'S NEVUS, COMPOUND	554434	1753	\N	\N	11-76464	\N	SYNAT470	2010-2017	IP1065911	AirTable blocks_with_IP_info.csv
1649	12-55584	6	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a compound proliferation of large, oval and fusiform melanocytes with abundant, pale amphophilic cytoplasm and large, vesicular nuclei. Overlying the lesion is irregular epidermal hyperplasia. There are confluent nests of large oval melanocytes that form sheets in some areas. Many mitotic figures are present superficially, and some in the lower portions of the lesion as well.	One outside slide, KA12-11802 (12-4953) and one corresponding block.	R/O SPITZ NEVUS/KERATOTIC NEVUS > VERRUCA VULGARIS	\N	\N	\N	The attached insurance information noted a request for comparative genomic hybridization which has now been performed, and shows multiple aberrations, with losses involving peri-centromeric areas of chromosomes 7q and 12q, and a peri-telomeric focus of 18q. The presence of multiple aberrations is worrisome, and is not in keeping with the diagnosis of a Spitz's nevus. As the aberrations are not typical of melanoma, I would consider this as equivalent to what has been reported in the literature as an atypical Spitz tumor. The vast majority of such cases have a favorable outcome, regardless of sentinel lymph node status. If a re-excision of this site shows a significant residuum, I would be interested in viewing the slides.	COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES	173305	2052	\N	\N	12-55584	\N	SYNAT350	2010-2017	IP1141397	AirTable blocks_with_IP_info.csv
1535	11-88432	20	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show enlarged slightly spindled and epithelioid melanocytes arrayed in compound fashion within a sessile and partially polypoid skin segment. There are very large nests and fascicles of melanocytes intraepidermally, and similar melanocytes are arrayed in partially maturing fashion in dermis below this. The constituent melanocytes have finely melanized or amphophilic cytoplasm. It is not difficult to identify dermal melanocytes in mitosis.	One outside slide, RMC11-519 (DC11-5529) and one corresponding block.	HAS "TRIPLED IN SIZE IN THE LAST YEAR", RED BROWN AND CRUSTED	\N	\N	\N	My differential diagnosis included a highly unconventional Spitz nevus on one hand and spitzoid melanoma on the other, and after completion of our analysis of this tumor, the latter possibility proves to represent the best diagnosis for this case. To more fully evaluate the nature of this proliferation, we completed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 7q as well as loss in chromosomes 1q, 5q, 7q, 9, 10q, 13p, 14q, and 16q. The identification of multiple genomic aberrations indicates genomic instability, as is stereotypical of melanoma. Please note that the aCGH profile that we have defined is incompatible with interpretation as any type of melanocytic nevus. In short, an atypical Spitz nevus has been excluded from the differential diagnosis by means of our molecular results. In summary, the combination of results derived from conventional microscopy coupled with has demonstrated that this atypical melanocytic proliferation represents spitzoid melanoma. This melanoma is non-ulcerated and shows Clark's level IV invasion. Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 2.5 MM IN THICKNESS, FOCALLY INVOLVING THE DEEP EDGE OF THE SPECIMEN	139523	2147	\N	\N	11-88432	\N	SYNAT471	2010-2017	IP1077880	AirTable blocks_with_IP_info.csv
1533	11-88209	7	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.4	\N	\N	Sections show a papillated segment of skin with a predominantly dermal proliferation of melanocytes, most of which have abundant, pale cytoplasm and large, oval vesicular nuclei. The overlying epidermis is focally hyperplastic. A few junctional nests are present. The dermal aggregations are variably confluent. The cells toward the base of the specimen are smaller, and have smaller and more monomorphous nuclei than those superficially. It is difficult to find mitotic figures. The enclosed immunoperoxidase stains show that the junctional melanocytes and some superficial dermal ones stain with HMB-45 and that the Ki-67 labeling rate is up to 5% or so in some areas.	Six outside slides, FT11-71845 (AX11-1474/RSS11-18539).  Fifteen corresponding (unstained) slides received 12-5-11.	ORIGINAL BIOPSY OF PATH DL11-81921	\N	\N	\N	Comparative genomic hybridization shows multiple chromosomal aberrations indicative of melanoma. These include a loss involving chromosome 6p, a partial loss of 6q, an amplification (high level copy number gain) of 7q, a loss of 9p and a loss of 9qter. Losses involving 6q and 9p are particularly common in melanoma. While isolated gains involving chromosome 7q can be seen in Spitz's nevus, gene amplifications (gains of not just an extra copy, but many extra copies) are not. Dr. Boris Bastian also reviewed the comparative genomic hybridization data and agrees with this interpretation of it.  The lesion is broadly transected, and may be considerably thicker than the 3.2 mm that I measured on the slide. Given the comparative genomic hybridization results and morphology, I believe that this lesion should be classified as a spitzoid melanoma of childhood, i.e., an emerging class of lesions that usually lack b-raf mutations (which are present in most melanomas) and have a propensity to involve local lymph nodes. Systemic spread either occurs infrequently or it does so in a delayed fashion compared to adult melanoma. Most lesions of this type are well circumscribed and relatively narrow re-excision margins are adequate for local control. The value of sentinel lymph node biopsy seems even less than in adult melanoma, as the predictive value of nodal involvement for distant disease is less, and there is little evidence that completion lymphadenectomy has an effect on survival.	SPITZOID MELANOMA OF CHILDHOOD	173403	1920	\N	\N	11-88209	\N	SYNAT472	2010-2017	IP1071369	AirTable blocks_with_IP_info.csv
1539	11-94134	0	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show enlarged epithelioid and slightly spindled melanocytes arrayed irregularly within the epidermis and dermis. The lesion shows reasonable lateral demarcation but is asymmetrical. Within the epidermis, enlarged melanocytes are present at both the epidermal-dermal junction and also above the junction, particularly toward one edge. In fibrotic dermis below this, partially maturing but enlarged epithelioid melanocytes are apparent, and occasional melanocytes in mitosis can be found. Some melanocytes are also multinucleate.	Two outside slides, EFG 296-11 (ML11157016:A,B) and one corresponding block (B).	9 X 6 MM GROWING LESION	\N	\N	\N	Our differential diagnosis included a highly unconventional Spitz nevus on one hand and nevoid melanoma on the other. As a certain diagnosis often cannot be rendered in this context based solely upon conventional microscopy, we additionally completed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed a segmental gain in chromosome 7q with no other chromosomal gains or losses. We have identified gain in chromosome 7q in a small series of unconventional Spitz nevi. In contrast, gain in chromosome 7q as a monoaberration has not been documented in melanoma, in my experience. In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. Rather, I believe this melanocytic proliferation represents an unconventional Spitz nevus.	COMPOUND SPITZOID MELANOCYTIC PROLIFERATION, EXCISED IN THE AVAILABLE PLANES OF SECTION	173720	1866	\N	\N	11-94134	\N	SYNAT473	2010-2017	IP1083582	AirTable blocks_with_IP_info.csv
1556	12-2898	29	\N	\N	\N	T3a	Primary	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a proliferation of melanocytes with a domed surface and a wedge shaped base. The overlying epidermis is slightly thickened, with a few discrete junctional nests. Within most of the dermal component, small fusiform melanocytes with lightly pigmented cytoplasm predominate. These cells have monomorphous oval, vesicular nuclei with small nucleoli. Melanocytes mature with descent within the dermis, and the sizes of their aggregations also diminish with descent. At the flanks of the lesion, smaller melanocytes are evident at the junction and in the superficial dermis. Some of the deeper melanocytes are peri-adnexal or bulge into a lymphatic vessel.	One outside slide, DPR-12-00019:A1, and one corresponding block.	NEW DARK BROWN IRREGULARLY PIGMENTED TENDER PAPULE", COMPARATIVE GENOMIC HYBRIDIZATION REQUESTED IN COVER LETTER	\N	\N	\N	Comparative genomic hybridization shows a gain involving chromosome 7, but no other aberrations. Gains of chromosome 7 are relatively common in melanoma. The lesion is not ulcerated, and hence is stage T3a in the 2009 AJCC classification. The configuration suggests that the final thickness will not be substantially greater than that seen here.	MELANOMA, AT LEAST 2.3 MM. IN THICKNESS	129522	2308	\N	\N	12-2898	\N	SYNAT474	2010-2017	IP1088714	AirTable blocks_with_IP_info.csv
10757	08-53951	17	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.3	Ivanka Patient Melanoma	\N	Sections show an asymmetrical, compound proliferation of melanocytes which is well-circumscribed. There is a slightly biphasic pattern, with larger atypical melanocytes with more abundant dusty cytoplasmic melanin within the epidermis arrayed irregularly as nests and single cells. Melanocytes are scattered above the basal layer in this zone as well. Similar melanocytes are present within the dermis as clusters which demonstrate deficient maturation with descent. Mitotic figures are evident within the epidermal component, but not within the dermal component in this area. At the periphery, there is also a compound proliferation of smaller and bland melanocytes, arrayed as small nests along the junction, and as nests and syncytia in the dermis. These melanocytes mature with descent. Some of them contain dusty cytoplasmic melanin, but less abundant than those in the aforementioned atypical zone. There is a patchy lymphocytic infiltrate, especially surrounding the population of larger atypical melanocytes.	Oriented ellipse, 1.4 x 0.8 x 0.3 cm, including a central multi-colored (dark brown, light brown, red) 0.7 x 0.7 cm papule.  With the orienting sutured tip placed to the left and designated tagged @ superior by the surgeon, the far margin is inked blue and the near margin is inked yellow.  The specimen is serially sectioned perpendicular to the long axis from left to right poles and submitted with three sections each in cassettes A and B, one tip returned to container.	\N	\N	\N	\N	Although nevi on the scalp and hairline on children can demonstrate unusual features, the findings in a portion of this lesion exceed what would be expected in that setting. These include a markedly irregular distribution of atypical melanocytes which appear morphologically distinct from those of the surrounding nevus, as well significant suprabasal scatter of melanocytes, and a lack of maturation of the dermal component in that area. I have also shared this case with my colleague, Dr. Philip LeBoit, who agrees with this diagnosis. In terms of staging, this is a non-ulcerated melanoma of Clark's anatomic level III, with atypical melanocytes expanding the papillary dermis and abutting the reticular dermis. There are no other features which would have an impact on prognosis apart from those given above. Reexcision of this site with standard margins is of course warranted.	MELANOMA, 0.9 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING CLOSE TO PERIPHERAL EXCISION MARGINS	191323	1619	\N	\N	08-53951	A	SYNX216	\N	IP596372	Consolidated_data_final.csv
3030	99-32835	39	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	172.5	\N	\N	Partially encompassed by epithelial collarettes is a proliferation of relatively small melanocytes, with hyperchromatic nuclei, focally in pagetoid array within the epidermis and in compact nests within the papillary dermis.  There is an infiltrate of lymphocytes and melanophages.  To one side are small, round melanocytes arranged as cords and strands within edematous stroma.	Skin segment measuring 0.7 x 0.5 x 0.2 cm, trisected and entirely\nsubmitted.	5 X 3 MM PIGMENTED PAPULE	\N	\N	FFPE	This is a very small melanoma, with an unusual pattern.  It is composed of small nevoid cells.  It extends close to the base of the specimen.	MELANOMA, 0.4 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173533	173	\N	\N	99-32835	\N	CCR-151	Melanoma Epigenetics	IP208368	AirTable blocks_with_IP_info.csv
1777	14-47962	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26306,26339	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	757	\N	\N	14-47962	\N	JJS18	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1677	13-129	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	785	\N	\N	13-129	\N	KIT-04	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1459	11-21178	2	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a domed, somewhat papillated segment of skin with a proliferation of large oval melanocytes that extends from the junctional zone to the base of the specimen in the superficial reticular dermis. Large junctional and superficial dermal nests are present, composed of cells with large oval vesicular nuclei, small nucleoli and abundant amphophilic cytoplasm. The sizes of aggregations and of the cells that comprise them diminish toward the base of the specimen, where small nests are positioned between thickened collagen bundles. A focally dense lymphocytic infiltrate is evident. There are scattered mitotic figures.	Skin segment measuring 0.9 x 0.6 x 0.2 cm, bisected and entirely submitted.	7 X 6 MM PINK NODULE; SPITZ VS. JXG VS. MASTOCYTOMA	\N	\N	\N	The lesion is extensively transected at the base of the specimen. The majority of findings favor an inflamed Spitz's nevus. There are rare cases in which large nodular collections of more atypical-appearing cells are evident in the deep reticular dermis, and are only evident on reexcision. Comparative genomic hybridization shows no detectable chromosomal gains or losses. While the quality of the DNA that we extracted is not optimal, it is reasonable.  Most lesions of this type are well circumscribed. Hence, despite this result, I would still consider a slightly wider, but deeper (full thickness) reexcision to remove the remainder of the lesion and to make sure that a more atypical, deep component is not evident.	INFLAMED COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES, PROBABLY AN UNUSUAL SPITZ'S NEVUS	107705	1854	\N	\N	11-21178	\N	SYNAT476	2010-2017	IP1010616	AirTable blocks_with_IP_info.csv
1497	11-50270	19	\N	\N	\N	T2a	Primary	None	\N	\N	\N	\N	\N	172.5	\N	\N	There is a domed proliferation of large oval and spindled melanocytes with oval vesicular nuclei and amphophilic cytoplasm involving the junctional zone of a thickened epidermis, and stratum spinosum above this, and the subjacent upper dermis. Nests predominate over single melanocytes along the epidermal-dermal junction. A few Kamino bodies are present. Clear suprabasilar scatter of single melanocytes is present within the epidermis. Melanocyte aggregations perhaps diminish in size with descent. There is a lymphohistiocytic infiltrate with admixed melanophages in the dermis. The dermal melanocytes include a few in mitosis. The enclosed immunoperoxidase stains show that most of the dermal melanocytes express HMB-45. When viewed at scanning magnification, the proliferation is asymmetrical. It also shows considerable scatter of melanocytes above the junction at its leading edges.	Three outside slides, WD11-7670. One corresponding block received 7-20-11.	DYSPLASTIC", SUBMITTED FOR COMPARATIVE GENOMIC HYBRIDIZATION	\N	\N	\N	This atypical melanocytic proliferation was evaluated by both immunohistochemistry and by molecular methods. Immunoperoxidase stained sections prepared in our laboratory show that while the intraepidermal component has only patchy expression of p16, the dermal component strongly expresses this determinant. A phosphohistone H3 immunoperoxidase stain (which labels melanocytes in mitosis) labels nuclei in the dermis, but these cells are mostly lymphocytes (that said, melanocytes in mitosis can be seen in conventional sections, so it is clear that cell proliferation was ongoing prior to biopsy). The aforementioned immunostaining results are inconclusive. We also completed array-based comparative genomic hybridization (aCGH) analysis to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH demonstrated gains in chromosomes 5p, 6, 7, 12, 21, and 22. A small segmental loss in chromosome 9q was also found. As you probably know, the identification of multiple chromosomal copy number aberrations indicates genomic instability and is stereotypical of melanoma. The finding of multiple genomic anomalies is incompatible with a diagnosis of melanocytic nevus.  In summary, the combination of results derived from conventional microscopy coupled with aCGH analysis points to interpretation as melanoma. This melanoma is non-ulcerated and shows Clark's level IV invasion. Further excision is warranted to ensure that local eradication has been accomplished. This melanoma is of stage pT2a (2009 AJCC guidelines).	MELANOMA OF 1.4 MM IN THICKNESS	173507	1995	\N	\N	11-50270	\N	SYNAT478	2010-2017	IP1039709	AirTable blocks_with_IP_info.csv
1629	12-23578	42	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a zone of fibrosing inflammatory alterations beneath which is a proliferation of melanocytes with a wedge shaped configuration. Superficially, there are large ovoid melanocytes with abundant, pale amphophilic cytoplasm and large, vesicular nuclei as well as prominent, central nucleoli. These cells are positioned just beneath the epidermis, and a few cells in mitosis are evident. Deeper and to the side in the dermis, small  melanocytes are apparent as maturing nests, cords, and syncytia.	Three outside slides, SROS12-3933:A1 through A3 (DRMC12-1872/MR:07670919), and three corresponding blocks.	EXCISION OF PATH DL12-16031, SPITZ NEOPLASM, R/O RESIDUAL, CHECK MARGINS	\N	\N	\N	The residuum seen here posed a microscopic differential diagnosis of a combined Spitz nevus on one hand and spitzoid melanoma arising in association with a congenital melanocytic nevus on the other. Per your request, we pursued array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed a small gain in chromosome 7q with no other significant gains or losses. We have encountered this anomaly in a series of spitzoid tumors that either represent unconventional Spitz nevi or represent unclassifiable spitzoid tumors with indolent behavior. The molecular findings that we have identified do not point to interpretation as spitzoid melanoma. In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of spitzoid melanoma. This unconventional melanocytic proliferation has been excised by means of this specimen.	RESIDUAL DESMOPLASTIC COMPOUND PROLIFERATION OF MELANOCYTES, EXCISED IN THE AVAILABLE PLANES OF SECTION	222596	2010	\N	\N	12-23578	\N	SYNAT479	2010-2017	IP1101847	AirTable blocks_with_IP_info.csv
10601	12-42406	44	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	Iwei 7Q Gain	CGH12-188 	Sections show a compound proliferation of melanocytes, many of which are large, and spindled to epithelioid, arrayed as nests and some single cells along the junctional zone, and as clusters and syncytia within the dermis. Some slightly smaller but similar melanocytes are also present, and many melanocytes are positioned between thickened/sclerotic collagen bundles. There is a patchy lymphocytic infiltrate. Occasional dermal mitotic figures are evident.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted.	\N	\N	\N	\N	ADDENDUM, July 19, 2012: As you know, our differential diagnosis included an unconventional desmoplastic Spitz nevus on one hand and spitzoid melanoma on the other. To more fully address that differential diagnosis, we completed array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 11p as well as focal gain and loss in chromosome 7q. The identification of 11p gain indicates a desmoplastic Spitz nevus with associated HRAS mutation (a reference regarding this entity is listed below). The additional identification of an anomaly involving chromosome 7 is meaningless in the context of 11p gain. In our prior evaluation of this tumor, p16 immunostaining was completed and a near-total loss of expression is apparent. This result implied that a genomic copy number anomaly involving chromosome 9p might be present. However, our aCGH analysis proves this is not the case. Rather, molecular assessment proves that a copy number anomaly involving chromosome 9 is not present.  A reexcision from this site has been received as our case 12-46583. Please refer to that case for additional information.  Reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	COMPOUND PROLIFERATION OF ENLARGED SPINDLED AND EPITHELIOID MELANOCYTES, CONSISTENT WITH AN UNCONVENTIONAL DESMOPLASTIC SPITZ NEVUS	17723	1582	\N	\N	12-42406	A	SYNX179	\N	IP1128224	Consolidated_data_final.csv
2507	19Rig750007.01.16.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 1: Mel + sun in PAM	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	260	\N	\N	None	\N	CM-16	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1767	14-34758	49	\N	\N	1	T1a	Primary	Superficial spreading	5	\N	FFPE	\N	\N	172.5	\N	\N	Sections show a compound proliferation of melanocytes, some with atypical nuclei, arranged in some areas as nests along the sides and bases of elongated rete ridges, with fibroplasia of the papillary dermis.  In other areas, a more irregular distribution of melanocytes is present within the epidermis, and single melanocytes predominate over nests in some areas while scattered intraspinous melanocytes are apparent in some foci as well. Nests of melanocytes are present in the dermis as well, and some of the dermal melanocytes are large and have hyperchromatic nuclei. There are also areas in which the dermis is thickened and fibrotic, with a patchy bandlike lymphohistiocytic infiltrate that includes numerous melanophages and diminished numbers of melanocytes in such areas, when compared to the remainder of the lesion.	Cylindrical skin segment, 0.6 cm in diameter and 0.6 cm in thickness, bisected and totally submitted. PL/PL	SOFT TISSUE MASS, NOS, 6 MM PUNCH BX, 2 CM HYPERKER IRREGULAR PIG LESION	\N	\N	Scraping	The melanoma extends only to one peripheral edge of this biopsy such that it gave the initial impression that the lesion might be small and partially captured in this specimen. However, I discussed the case by telephone with Dr. Dasilva who confirmed that the lesion indeed measured  2 cm in diameter and that only the edge of the lesion was captured in this biopsy. In light of this additional information, the microscopic features in this specimen are in keeping with melanoma. A synoptic report of potential prognostic factors is listed below:  Procedure: Punch biopsy Microscopic tumor type: Superficial spreading Breslow thickness:  0.95 mm Ulceration: Not present Margins, peripheral and deep: + peripheral; 5 millimeters from deep Mitotic index: < 1/mm2 Microsatellitosis: not evident Vascular invasion: None identified in a section stained with D2-40 Regression: Partial Pathologic staging (pTNM): pT1a, should no more adverse findings be evident on complete excision  My colleague, Dr. Timothy McCalmont, also reviewed these sections and agrees with this assessment.	MELANOMA, 0.95 MILLIMETERS IN THICKNESS AND WITH PARTIAL REGRESSION, EXTENDING TO THE PERIPHERAL EDGE OF THE SPECIMEN	139524	120	\N	\N	14-34758	\N	CCR-003	California Cancer Registry	IP1384692	AirTable blocks_with_IP_info.csv
1637	12-31421	60	\N	\N	\N	T1a	Primary	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a slightly asymmetrical, broad, yet laterally demarcated compound proliferation of melanocytes. There are single melanocytes and nests distributed at the junction, and virtually all melanocytes are immediately at the junction. Some of the junctional nests centrally are large. Below the junction, striking lamellar fibroplasia is coupled with a patchy lymphohistiocytic infiltrate with admixed melanophages. Centrally, there are also some partially maturing but large dermal nests, and deep to this, modest elastosis is appreciable.	Three outside slides, D12-12414 and one corresponding block.	R/O LMN	\N	\N	\N	My differential diagnosis included an unconventional melanocytic nevus and nevoid melanoma, and after completion of molecular analysis, I believe the latter possibility represent the best interpretation for this atypical melanocytic tumor. Immunohistochemistry for p16 has been completed and demonstrates significant loss of expression, and thus an underlying anomaly in chromosome 9p was suspected. To more fully substantiate the nature of this proliferation, we completed array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 5p, 5q, and 7q, as well as loss in chromosomes 5q  and 9. The identification of multiple copy number aberrations indicates genomic instability, as is stereotypical of malignancies such as melanoma. Additionally, the fact that chromosome 9 loss has been documented correlates with the loss of p16 expression that was documented immunohistochemically. In summary, the combination of results derived from conventional microscopy coupled with aCGH points to interpretation as nevoid melanoma. With respect to staging, this melanoma is less than 1 mm in thickness, lacks associated ulceration, and does not have detectable melanocytes in mitosis in its invasive component. Therefore, it represents a melanoma of stage pT1a (2009 AJCC Guidelines). Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.75 MM IN THICKNESS, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	102537	1740	\N	\N	12-31421	\N	SYNAT480	2010-2017	IP1117239	AirTable blocks_with_IP_info.csv
1448	11-13661	55	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.3	\N	\N	Sections show an intradermal and superficial subcutaneous proliferation of plump spindled melanocytes distributed in wedge-shaped fashion within a skin segment that shows marked superficial elastosis. Cellularity is accentuated in the perifollicular adventitial dermis. Focal extension into fatty tissue is also apparent.	Two outside slides, AS11-9989:1 and 2, and two corresponding blocks.	PIGMENTED NODULE FOR 2 MONTHS; R/O MM, R/O BLUE NEVUS;" CGH PLEASE	\N	\N	\N	Our differential diagnosis included an atypical cellular blue nevus on one hand and blue nevus-like melanoma on the other, and the latter possibility proves to represent the correct interpretation of this proliferation. To further assess the aforementioned differential diagnosis and screen this tissue for melanoma-associated genomic anomalies, we completed array-based comparative genomic hybridization (aCGH). After extraction of tumoral DNA from the tissue block, aCGH analysis demonstrated gains in chromosomes 1, 2, 6p, 7, and 8, as well as losses in chromosomes 6q, 11, and 22q. The identification of multiple chromosomal gains and losses decisively proves that this proliferation does not represent a melanocytic nevus but instead constitutes melanoma. Presuming this to be a primary lesion, the melanoma within this biopsy is non-ulcerated and focally invades the superficial subcutis (Clark's level V). If there is any history of melanoma, the possibility of a blue nevus-like metastasis s of melanoma could also be considered. Further excision is warranted to ensure that local eradication has been accomplished.  This report was reissued on March 29, 2011, after correcting a typographical error.	BLUE NEVUS-LIKE MELANOMA OF 2.9 MM IN THICKNESS	103362	2070	\N	\N	11-13661	\N	SYNAT481	2010-2017	IP1003098	AirTable blocks_with_IP_info.csv
10610	13-47668	65	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.6	Iwei DPN  	\N	Sections show a proliferation of melanocytes with two separate cellular components (a biphasic pattern).  There is a roughly wedge shaped dermal infiltrate of melanocytes arranged in nests of cells with abundant pale cytoplasm, with many melanophages.  Another more superficial component is arranged as nests, syncytia, and strands of smaller melanocytes with round to oval nuclei and little cytoplasm. Solar elastosis is present in the dermis.	Cylindrical skin segment, 0.4 cm in diameter and 0.5 cm in thickness, bisected and entirely submitted. RS/RS	\N	\N	\N	\N	This melanocytic nevus shows features of both a conventional melanocytic nevus and a deep penetrating nevus.	COMBINED MELANOCYTIC NEVUS, EXCISED IN THE AVAILABLE PLANES OF SECTION	424655	1590	\N	\N	13-47668	A	SYNX187	\N	IP298118	Consolidated_data_final.csv
10643	12-18832AA	70	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	702.0	\N	\N	Sections show an intraepithelial proliferation of atypical keratinocytes confined largely to the interadnexal epidermis, with overlying parakeratosis.	Skin segment measuring 0.5 x 0.2 x 0.1 cm. Submitted intact.	\N	\N	\N	\N	Level sections show similar findings.	SOLAR KERATOSIS	100058	1595	\N	\N	12-18832	A	SYNX192	\N	IP1104649	Consolidated_data_final.csv
1683	13-2939B	71	\N	\N	\N	T4b	Primary	None	\N	\N	\N	\N	\N	172.5	\N	\N	There is a nodular proliferation of melanocytes with atypical nuclei in contiguity with the epidermis. The melanocytes are pigmented and epithelioid or fusiform, and coalescing fascicles and sheets of cells are apparent and are accompanied by many melanophages. There is little diminishment in melanocyte size with descent in the dermis. Deep extension into the subcutis is present centrally. To the side of this, many similar epidermal melanocytes are apparent singly and in small nests and fascicles. A perijunctional lymphohistiocytic infiltrate with admixed melanophages is also noted.	Oriented oval excision, 1.5 x 1.5 x 1.2 cm, including a central 0.9 x 0.9 cm violaceous pink and raised area.  With the orienting sutured end arbitrarily designated 12 o'clock by the grosser, the 12 to 6 o'clock margin is inked blue and the 6 to 12 o'clock margin is inked yellow; entirely submitted with two sections each in A-C. HD/HD	MELANOMA	\N	\N	\N	This biopsy demonstrates a 'deep penetrating' melanoma with a nodular invasive component that extends into the upper subcutis. The invasive component has been fully excised, but flanking melanoma in situ is transected at the inked specimen periphery. With respect to staging, this melanoma exceeds 4 mm in thickness and shows focal associated ulceration. Therefore, it represents a melanoma of stage pT4b (2009 AJCC Guidelines). Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 8.3 MM IN THICKNESS, EXTENDING INTRAEPIDERMALLY TO THE INKED SPECIMEN MARGIN	172599	1913	\N	\N	13-2939	B	SYNAT482	Deep Penetrating Nevus	IP1187682	AirTable blocks_with_IP_info.csv
10628	02-2599C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1594	\N	\N	02-2599	C	SYNX191	\N	IP307333	Consolidated_data_final.csv
1516	11-73238A	56	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show skin in a polypoid configuration.  A compound proliferation of melanocytes composed of single cells and nests along the sides and bases of elongated rete ridges is present. Nests, cords and syncytia of melanocytes with small to medium round nuclei and scant amphophilic cytoplasm are present in the papillary dermis and exhibit maturation with descent into the reticular dermis.	Skin segment measuring 0.9 x 0.7 x 0.4 cm, trisected and entirely submitted in cassette A.	A-B) NEOPLASM NOS, IRRITATED ACROCHORDON	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, POLYPOID	173530	2353	\N	\N	11-73238	A	SYNAT489	2010-2017	IP987085	AirTable blocks_with_IP_info.csv
1517	11-73999	25	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.7	\N	\N	Sections show a compound proliferation of melanocytes.  A few small junctional nests of melanocytes are present at the periphery.  Nests, cords and syncytia of melanocytes with small to medium round nuclei and scant amphophilic cytoplasm are present in the papillary dermis and exhibit maturation with descent into the reticular dermis with accentuation around adnexae. The overlying epidermis is papillated.	Skin segment measuring 1.3 x 1.1 x 0.3 cm, quadrisected and entirely submitted.	LARGE CONGENITAL NEVUS, RECENTLY CHANGING WITH IRREGULAR PIGMENT; R/O CONGENITAL NEVUS VS. MELANOMA	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	173714	2049	\N	\N	11-73999	\N	SYNAT490	2010-2017	IP1063446	AirTable blocks_with_IP_info.csv
10598	11-41004	8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.3	Iwei 7Q Gain	CGH11-202 	Sections show a predominantly dermal proliferation of large melanocytes, with a domed surface and a wedge shaped base. The lesional melanocytes are fusiform, with abundant, pale amphophilic cytoplasm and large, pleomorphic vesicular and heterochromatic nuclei, some with large nucleoli. A few mitotic figures are present in melanocytes well within the dermis. While there is a greater degree of cellularity in the upper than in the lower part of the lesion, some of the aggregations toward the base of the lesion are substantial. The enclosed immunoperoxidase stains show that many nuclei are Ki-67 positive, but many of these may be those of lymphocytes.	Seven outside slides, SC11-2567.	\N	\N	\N	\N	The neoplasm extends to the peripheral dermal edge of the specimen. Many features favor a Spitz's nevus, but there are large aggregations deep in the lesion, a few mitotic figures at the level of the mid-reticular dermis and the melanocytic nuclei are more pleomorphic than usual. Complete excision, despite the cosmetically sensitive area is warranted.  Comparative genomic hybridization shows a gain involving chromosome 11p, and also one involving 7q. Isolated 11p gain usually corresponds to the formation of an isochromosome (two copies of 11p joined by a centromere), and has not been seen to date in melanoma. Spitz's nevi with this aberration are likely to have a mutation involving h-ras, and to deeply infiltrate the reticular dermis as single cells, findings that are present here. In this case, the 11p gain is not isolated but is associated by a gain of 7q. I consulted with Dr. Boris Bastian, at Sloan-Kettering Cancer Center, New York, a colleague whose laboratory developed diagnostic comparative genomic hybridization when he was here at UCSF. He has not seen these two aberrations together, and heretofore regarded them as mutually exclusive. He believes that the current CGH picture still favors Spitz's nevus, even though the 11p aberration is not an isolated one.  References:  van Engen-van Grunsven AC, van Dijk MC, Ruiter DJ, Klaasen A, Mooi WJ, Blokx WA. HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features. Am J Surg Pathol. 2010 Oct;34(10):1436-41.  Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000 Sep;157(3):967-72.	PREDOMINANTLY INTRADERMAL SPITZ'S NEVUS WITH SOME UNUSUAL FEATURES	102353	1579	\N	\N	11-41004	A	SYNX176	\N	IP1030443	Consolidated_data_final.csv
1729	13-59840	52	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a papillated segment of skin in which there is a proliferation of melanocytes with two separate cellular components (a biphasic pattern).  There is a roughly wedge shaped dermal infiltrate of melanocytes arranged in nests of cells with abundant pale cytoplasm, with many melanophages.  Another component is arranged as nests, syncytia, and strands of smaller melanocytes with round to oval nuclei and little cytoplasm.	Multiple tissue fragments, 1.6 x 1.3 x 0.3 cm in aggregate, entirely submitted. RS/RS	R/O DYSPLASTIC NEVUS	\N	\N	\N	None	COMBINED MELANOCYTIC NEVUS, WITH SUPERFICIAL CONGENITAL AND DEEP PENETRATING NEVUS COMPONENTS	528599	2171	\N	\N	13-59840	\N	SYNAT491	2010-2017	IP352453	AirTable blocks_with_IP_info.csv
10654	12-12039B	35	\N	\N	\N	T1a	Primary	\N	\N	\N	\N	\N	\N	172.7	Iwei Acral Melanoma	\N	Sections show acral skin with a proliferation of melanocytes arranged singly and in small nests along the dermo-epidermal junction in a broad area. There is a small focus in which the melanocytes have abundant, pale amphophilic cytoplasm and enlarged nuclei, with pagetoid scatter in the epidermis and clusters of similar cells in the superficial dermis, accompanied there by fibrosis and a patchy lymphocytic infiltrate.	Skin segment measuring 1.0 x 0.8 x 0.1 cm, quadrisected perpendicular to the long axis and entirely submitted in cassette B.	\N	\N	\N	\N	The intraepidermal component of this melanoma extends to the peripheral edge of the specimen. The lesion is less than 1 mm in thickness, is not ulcerated, and does not have detectable mitotic figures in its dermal component. Therefore it should be classified as T1a per the 2009 revision of the AJCC staging system for melanoma.	MELANOMA, 0.35 MM. IN THICKNESS	176788	1596	\N	\N	12-12039	B	SYNX193	\N	IP1097855	Consolidated_data_final.csv
10599	11-51223	10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.3	Iwei 7Q Gain	CGH11-215 	There is a broad and poorly circumscribed proliferation of melanocytes with a papillated surface. At the periphery, increased numbers of single melanocytes and small nests are present along and above the junction. Many of these cells are spindled, and some have large, hyperchromatic nuclei or pigmented dendrites. The overlying epidermis has pigmentation of its keratinocytes. Centrally, in the papillated part of the proliferation, there are large nests and fascicles of large fusiform melanocytes with lightly pigmented cytoplasm and oval, vesicular nuclei that extend from the junctional zone into the superficial reticular dermis. Some of the superficial nests are confluent and oddly shaped. A few mitotic figures are present among them. They are a few large Kamino bodies. Toward the base of the proliferation, somewhat smaller cells colonize adnexal structures. A perijunctional lymphohistiocytic infiltrate with admixed melanophages is also noted.	Four outside slides, SK11-11019 B and one corresponding block.	\N	\N	\N	\N	Our differential diagnosis included a peculiar pigmented spindle cell nevus on one hand and spitzoid melanoma on the other. To more comprehensively assess this differential diagnosis, we pursued array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH demonstrated possible gain in chromosome 2q, gain in chromosome 5p, loss in terminal chromosome 5q, loss in 6q, gain in 7q, and segmental gain in 11q. As you know, the identification of multiple genomic gains and losses is indicative of genomic instability and is incompatible with a diagnosis of melanocytic nevus. In summary, the combination of results derived from conventional microscopy coupled with aCGH points to interpretation as melanoma. The designation childhood-type spitzoid melanoma refers to an emerging entity that we believe is distinct from conventional adult melanoma. Such tumors lack BRAF mutations and were reported in the past literature under such flawed designations as malignant Spitz nevus. Experience to date suggests a small risk for extension to regional lymph nodes with low risk for widespread dissemination. In our experience, most tumors of this type are of very low grade.  With respect to staging parameters, this melanoma is non-ulcerated and shows associated Clark's level IV invasion. Further excision is warranted to ensure that local eradication has been accomplished.	CHILDHOOD-TYPE SPITZOID MELANOMA OF 1.3 MM IN THICKNESS	173305	1580	\N	\N	11-51223	A	SYNX177	\N	IP1040663	Consolidated_data_final.csv
10600	12-22542	62	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.6	Iwei 7Q Gain	CGH12-088 	Sections show acral skin with a broad-based pan-dermal and superficial subcutaneous proliferation of large oval melanocytes. The constituent cells are arranged as discrete nests and interconnecting fascicles within fibrotic stroma. The cells have abundant amphophilic cytoplasm and enlarged, oval vesicular nuclei. Scattered mitotic figures are evident. There is no significant intraepidermal component, nor do areas show significant pigmentation. The enclosed immunoperoxidase stains include an S100 preparation labeling nearly all of the constituent cells, paralleled by similar staining with Melan-A and HMB45. There is no loss of nuclear or cytoplasmic staining for p16 protein. A Ki-67 stain shows a low proliferative rate.	Ten outside slides, SV12-1858:B1 and B2, and one corresponding block (B2).	\N	\N	\N	\N	The configuration of this lesion is unusual (it is more bottom-heavy than most spitzoid proliferations). Comparative genomic hybridization shows a gain of part of chromosome 7q and a loss of part of that chromosome, and a gain of part of chromosome 11p and a loss of part of that chromosome, but no other aberrations. Spitz's nevi with chromosome 11p gains are likely to have a mutation involving h-ras, and to deeply infiltrate the reticular dermis as single cells, findings that are present here. Because of the presence of losses in both chromosomes as well as gains, I asked my colleague, Dr. Boris Bastian to review the findings as well, and he agrees with this interpretation. References:  van Engen-van Grunsven AC, van Dijk MC, Ruiter DJ, Klaasen A, Mooi WJ, Blokx WA. HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features. Am J Surg Pathol. 2010 Oct;34(10):1436-41.  Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000 Sep;157(3):967-72.	SPITZ'S NEVUS, PREDOMINANTLY INTRADERMAL	672655	1581	\N	\N	12-22542	A	SYNX178	\N	IP1108360	Consolidated_data_final.csv
10602	12-55875	5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	173.5	Iwei 7Q Gain	CGH12-227 	There is a large, a pedunculated segment of skin with a proliferation of large, oval, fusiform and spindled cells throughout the dermis. The overlying epidermis is irregularly hyperplastic. The lesional melanocytes form closely apposed fascicles, and have homogeneous appearing eosinophilic cytoplasm, with adjacent cells delineated by clefts. Some cells have coarse chromatin, large, and sometimes multiple nucleoli. Scattered mitotic figures are present. Little diminution in cellularity is present toward the base of the specimen.	Three outside slides, SP12-11271 / A1-A3 (R12-15385 / A).  Three corresponding blocks received 7-30-12.	\N	\N	\N	\N	I note the considerations in Dr. Barnhill's report, and in large part agree. The extreme nuclear pleomorphism, with large bizarre nuclei, some containing macronucleoli and configuration of the lesion are findings by light microscopy against a conventional Spitz's nevus, or a well characterized variant. Morphologically, I favored designation as spitzoid melanoma of childhood. After discussion of the case with the child's dermatologist, Dr. Aimee Smidt, we have proceeded with comparative genomic hybridization. This showed multiple aberrations, consistent with melanoma. These included a set of aberrations involving chromosome 6p, with high level amplifications of the peri-telomeric and peri-centromeric areas, and a loss of the broader area in between them. Other losses include 8p, 11q and 19q, with a gain involving 19p.  The lesion is over 7 mm in thickness, which ordinarily would qualify this non-ulcerated neoplasm as stage T4 melanoma. While there is a propensity for lesions like this one to involve local lymph nodes, systemic spread either occurs infrequently or it does so in a delayed fashion compared to adult melanoma. This lessens the predictive value of sentinel lymph node biopsy and the therapeutic value of completion lymphadenectomy even when nodes are positive.	SPITZOID MELANOMA, CHILDHOOD TYPE	173507	1583	\N	\N	12-55875	A	SYNX180	\N	IP1141688	Consolidated_data_final.csv
10603	12-88454	67	\N	\N	\N	T1a	Primary	\N	\N	\N	\N	\N	\N	172.5	Iwei 7Q Gain	CGH12-376 	Sections show a proliferation of melanocytes involving the epidermis and papillary dermis. There are plump, oval melanocytes with moderate amounts of pale cytoplasm and monomorphous small nuclei arranged as nests along the dermo-epidermal junction, with large, confluent nests in the subjacent papillary dermis. Some pagetoid scatter of single melanocytes is present, much better seen in the Melan-A immunoperoxidase stain than in the hematoxylin and eosin stained sections.	Seven outside slides, DA12-04997 / A (A12-3268 / A1). One corresponding block received 11/27/12.	\N	\N	\N	\N	The pagetoid scatter (revealed in your Melan-A immunoperoxidase stain) and the confluence of nests in the superficial dermis are findings worrisome for melanoma. The mostly nested pattern seen here would be unusual for a dysplastic (Clark's) nevus in a patient of this age. On the other hand, immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) performed in our laboratory shows almost no labelling of the nuclei of dermal melanocytes with Ki-67. Because of these conflicting criteria, we obtained comparative genomic hybridization. This showed multiple chromosomal aberrations indicative of melanoma. The include gains involving chromosomes 1p, 6p and 7q, with a loss involving 9q. Several of these aberrations are typical ones seen in melanoma.  The intraepidermal component of this melanoma extends to the peripheral edge of the specimen. The lesion is less than 1 mm in thickness, is not ulcerated, and does not have detectable mitotic figures in its dermal component. Therefore it should be classified as T1a per the 2009 revision of the AJCC staging system for melanoma.	MELANOMA, 0.6 MM. IN THICKNESS	173531	1584	\N	\N	12-88454	A	SYNX181	\N	IP1174271	Consolidated_data_final.csv
2474	19-94061	87	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show acral skin with a proliferation of melanocytes with large hyperchromatic nuclei and scant cytoplasm singly and in small nests along and above the dermo-epidermal junction, and in inflamed fibrotic stroma in the superficial dermis in the center of the specimen.	Ellipse, 1.3 x 0.6 x 0.4 cm, including a central 0.8 x 0.3 cm variegated brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with five sections. HD/HD	PREVIOUS PATH DT12-23088 (3/28/12)	\N	\N	\N	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: incisional biopsy Microscopic tumor type: acral melanoma Breslow thickness: 1.3 mm. Ulceration: no Margins, peripheral: involved by melanoma in situ, and deep: clear by < 2 mm. Mitotic index: 0/mm2 Microsatellitosis: to be determined following complete excision Vascular Invasion: to be determined following complete excision Perineural invasion: to be determined following complete excision Regression: absent Pathologic Staging (pTNM): pT2a pNX	MELANOMA, 1.3 MM. IN THICKNESS	173732	2115	\N	\N	19-94061	\N	SYNAT165	Melanoma Epigenetics	IP370740	AirTable blocks_with_IP_info.csv
2518	19Rig750007.02.09.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	268	\N	\N	None	\N	CM-28	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2519	19Rig750007.02.10.01	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	269	\N	\N	None	\N	CM-29	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2520	19Rig750007.02.10.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	269	\N	\N	None	\N	CM-29	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1287	07-55149	57	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2735	172.6	\N	\N	Sections show a compound proliferation of melanocytes, arrayed singly and in small clusters within the epidermis, with a lack of clear circumscription. There are similar cells singly and in small irregular clusters within the superficial dermis, which also displays fibroplasia and a permeative lymphohistiocytic infiltrate with admixed melanophages. There is elastosis evident more deeply.	Cylindrical skin segment, 0.8 cm in diameter and 0.6 cm in thickness, quadrisected and entirely submitted.	IRREGULAR PIGMENTED PLAQUE; 1 1/2 X 1 CM; R/O MELANOMA	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with invasion limited to the papillary dermis (Clark's level III). There is no evidence of associated vascular invasion or neurotropism. In light of the changes of regression, the microstage measurement listed above may underestimate the prognostic impact of this lesion. However, I believe that the microstage thickness listed above is reasonably representative. Further re-excision of this site is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.6 MM IN THICKNESS, WITH ASSOCIATED CHANGES OF PARTIAL REGRESSION	529699	121	\N	\N	07-55149	\N	CCR-004	California Cancer Registry	IP677682	AirTable blocks_with_IP_info.csv
1011	00-14127B	33	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	172.5	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation\nof atypical melanocytes, arranged irregularly within the epidermis,\nflanking a multinodular proliferation of similar melanocytes that\ndo not mature (diminish in size) with descent into the dermis.\nThere are many mitotic figures the dermal component.  There is\nbuckshot scatter of melanocytes in the epidermis at the edges of\nthe specimen.	Cylindrical skin segment, 0.6 cm in diameter and 0.6 cm in thickness,\nbisected and totally submitted in block B.	A - 5 X 4 MM RED RAISED OVAL SHAPED W/LIGHT GRAY STREAK WITHIN, B - 8 X 7 MM RAISED BROWN MOLE SUPERIOR ASPECT OVERLAPPING LIGHT BROWN PATCH, ASYMMETRICAL TWO-TONED BROWN AND DARK BROWN	\N	\N	Scraping	\N	MELANOMA, 1.85 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO THE PERIPHERAL MARGIN	321533	123	\N	\N	00-14127	B	CCR-007	California Cancer Registry	IP229230	AirTable blocks_with_IP_info.csv
10604	12-98328	8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.7	Iwei 7Q Gain	CGH13-007 	There is a broad-based, roughly wedge-shaped pan-dermal and superficial subcutaneous proliferation of large oval and fusiform melanocytes. The overlying epidermis is irregularly hyperplastic, with, in one focus, a subjacent area of inflamed fibrosing granulation tissue containing histiocytes with granular material in their cytoplasm (aluminum chloride residue). The subjacent melanocytic proliferation consists of thin fascicles of cells with abundant pale amphophilic cytoplasm and oval vesicular nuclei with variable chromatin (finely stippled in some cells, and with large nucleoli in others). An infiltrate of lymphocytes, plasma cells and eosinophils is present.	Three outside slides, D12-26205:1, 2, and 3, and three corresponding blocks.	\N	\N	\N	\N	An ALK stain was negative (performed as some spitzoid lesions with very long vertically oriented fascicles are ALK positive). Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a relatively high proliferation rate in deep dermal melanocytes, with about 10% of nuclei positive in some aggregations). A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows scattered mitotic figures in both superficial and deep melanocytes. The proliferation rate and lack of maturation with descent are worrisome, raising the possibility of a spitzoid melanoma. Comparative genomic hybridization shows gains involving the distal portion of chromosome 7q and 11p. These two aberrations are found in a minority of Spitz's nevi, usually in isolation, but occasionally together. The deeply infiltrative pattern is one associated with 11p gain; we are in the process of analyzing the findings in Spitz's nevi with 7q gain, and those with both aberrations. Given this result, I would follow the site clinically.	COMPOUND SPITZ'S NEVUS	123746	1585	\N	\N	12-98328	A	SYNX182	\N	IP1176562	Consolidated_data_final.csv
10606	12-762B	51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.3	Iwei DPN (Control Normal Nevus)	\N	Sections show is a dome surfaced segment of skin with nests of small, round melanocytes in the dermis with increased numbers distributed around adnexal structures.	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely submitted in cassette B.	\N	\N	\N	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	173312	1586	\N	\N	12-762	B	SYNX183	\N	IP1086578	Consolidated_data_final.csv
10607	12-168B	71	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.3	Iwei DPN (Control Normal Nevus)	\N	Sections show a domed segment of skin, with nests, cords and strands of small round melanocytes in the dermis, in part in a peri-adnexal pattern.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted in cassette B.	\N	\N	\N	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	173340	1587	\N	\N	12-168	B	SYNX184	\N	IP1080712	Consolidated_data_final.csv
10608	11-75173	52	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	Iwei DPN (Control Normal Nevus)	\N	Sections show a compound proliferation of melanocytes composed of single cells and nests along the sides and bases of elongated rete ridges. Nests, cords and syncytia of melanocytes with small to medium round nuclei and scant amphophilic cytoplasm are present in the papillary dermis and exhibit maturation with descent into the superficial reticular dermis.  Overlying rete ridges are elongated and interanastomosing.	Skin segment measuring 1.0 x 0.6 x 0.4 cm, bisected and entirely submitted.\n	\N	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	173525	1588	\N	\N	11-75173	A	SYNX185	\N	IP1064620	Consolidated_data_final.csv
10609	12-167B	32	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	Iwei DPN (Control Normal Nevus)	\N	Sections show nests, cords and strands of small, round melanocytes in the dermis.  Strands of melanocytes lie between collagen bundles in the reticular dermis and around adnexal structures.	Skin segment measuring 0.7 x 0.6 x 0.2 cm, bisected and entirely submitted in cassette B.	\N	\N	\N	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	333504	1589	\N	\N	12-167	B	SYNX186	\N	IP671051	Consolidated_data_final.csv
10612	12-66661	51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.1	Iwei DPN  	\N	Sections show a melanocytic proliferation composed of cells with two distinct cytologic appearances.  One population is composed of cells with abundant pale cytoplasm, arranged in small clusters accompanied by melanophages. The other consists of small melanocytes with round to oval nuclei, arranged in nests and cords.	Two skin segments, one measuring 0.45 x 0.3 x 0.1 cm and the other 0.35 x 0.2 x 0.1 cm, both submitted intact.   SL/SL	\N	\N	\N	\N	The nevus has combined components, the deep penetrating nevus portion of which may account for a darker portion clinically. This is a benign variant that has also been given other names such as clonal nevus and others.	COMBINED MELANOCYTIC NEVUS, WITH COMPONENTS OF ORDINARY MELANOCYTIC NEVUS AND DEEP PENETRATING NEVUS	173121	1591	\N	\N	12-66661	A	SYNX188	\N	IP1152477	Consolidated_data_final.csv
10613	13-47621	24	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	Iwei DPN  	\N	Sections show a compound proliferation of melanocytes with two separate cellular components (a biphasic pattern).  There are melanocytes arranged in nests of cells with abundant pale cytoplasm, with many melanophages.  Another component is arranged as nests, syncytia, and strands of smaller melanocytes with round to oval nuclei and little cytoplasm.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted. HD/HD	\N	\N	\N	\N	This neoplasm has features of both a superficial congenital melanocytic nevus and a deep penetrating nevus. There is no evidence of melanoma or atypicality.	COMBINED MELANOCYTIC NEVUS	528522	1592	\N	\N	13-47621	A	SYNX189	\N	IP1288923	Consolidated_data_final.csv
10615	13-37371	29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.6	Iwei DPN  	\N	Sections show a compound proliferation of small melanocytes with ovoid nuclei, and slight diminishment in the size of melanocytes with descent in the dermis is appreciable.  Most of the dermal melanocytes are arrayed as syncytia. Some dermal melanocytes have ample, finely melanized cytoplasm and are slightly larger in size.  There are many surrounding melanophages in the dermis.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted. HD/HD	\N	\N	\N	\N	This biphasic melanocytic nevus includes the commingling of congenital melanocytic nevus with deep penetrating nevus.	COMBINED MELANOCYTIC NEVUS, EXCISED IN THE AVAILABLE PLANES OF SECTION	173688	1593	\N	\N	13-37371	A	SYNX190	\N	IP1278673	Consolidated_data_final.csv
10657	99-15313	55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.6	Iwei Acral Melanoma	\N	There is a proliferation of atypical melanocytes, arranged as\nconfluent nests at the junctions with focal pagetoid spread, with\nextension of smaller but cytologically atypical melanocytes into the\nsubjacent dermis.  Squamatization of eccrine ducts in prominent.	Cylindrical skin segment measuring 0.3 cm in diameter and 0.3 cm in\nthickness.	\N	\N	\N	\N	A PAS-D stain ordered at the time that this specimen was grossed in does not reveal dermatophytes.	MELANOMA, INVOLVING ACRAL SKIN, 2.0 MM IN THICKNESS; FINAL THICKNESS TO AWAIT COMPLETE EXCISION	173622	1598	\N	\N	99-15313	A	SYNX195	\N	IP190846	Consolidated_data_final.csv
10658	99-885	25	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.7	Iwei Acral Melanoma	\N	Sections show acral skin with a proliferation of atypical melanocytes\narranged in an irregular pattern within the epidermis, and with\nsimilar cells in the papillary dermis.  There are foci of pagetoid\nupward spread.  While some of the dermal cells are small, others have\nlarge nuclei and are different in appearance from their counterparts\nat the same level of the dermis.	Skin segment measuring 0.9 x 0.7 x 0.2 cm, trisected and entirely\nsubmitted.	\N	\N	\N	\N	\N	MELANOMA, 0.70 MM IN THICKNESS, INVOLVING ACRAL SKIN, EXTENDING TO THE PERIPHERAL MARGIN	323788	1599	\N	\N	99-885	A	SYNX196	\N	IP176418	Consolidated_data_final.csv
10659	98-37643	44	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.7	Iwei Acral Melanoma	\N	Sections show acral skin with a proliferation of atypical melanocytes\narranged in an irregular pattern within the epidermis, and with\nsimilar cells in the papillary dermis.  The pattern is predominantly\nnested, with striking irregularity among nests.	Cylindrical skin segment, 0.7 cm in diameter and 0.3 cm in thickness,\ntrisected and entirely submitted.	\N	\N	\N	\N	In light of the presence of some degree of epidermal hyperplasia, the microstage measurement listed above probably overestimates the prognostic risk of this lesion, as the measurement is inflated by the epidermal changes.	MELANOMA, 0.7 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO THE PERIPHERAL MARGIN	173717	1600	\N	\N	98-37643	A	SYNX197	\N	IP175216	Consolidated_data_final.csv
1387	10-15514A2	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-3; BOX-9; BOX-16	\N	\N	Metastasis	AM2-095-4	\N	\N	\N	\N	left cerebellum	Scraping	\N	\N	\N	65	\N	\N	10-15514	A2	AM2-095	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
10661	09-29997	53	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.6	Iwei Acral Melanoma	\N	Sections show distorted nail bed epithelium, containing a proliferation of atypical melanocytes arranged in an irregular pattern within the epidermis, and with similar cells in sheets in the dermis. Only scant melanin pigment is present. In the portion of epithelium, there is suprabasal scatter of melanocytes, and they may also be present in the overlying stratum corneum. The nail plate is markedly dystrophic.	Two cylindrical skin segments, one measuring 0.3 cm in diameter and 0.2 cm in thickness, inked blue, and the other measuring 0.3 cm in diameter and 0.1 cm in thickness, both submitted intact.	\N	\N	\N	\N	I have also had the opportunity to review the prior biopsy from this patient, and the current findings are now diagnostic for melanoma. The lineage of the neoplastic cells was confirmed in a Melan-A immunostain, as the tumor displays only scant pigment. With regard to the staging of subungual melanoma, Clark's levels are not reported, as the typical arrangement of papillary and reticular dermis is not present in the nail unit per se. The exception is for Clark's level V, which is assigned when periosteal involvement is present. That finding cannot be assessed in the current sections. There is no evidence of lymphovascular or perineural invasion in these sections. However, given the potentially large size of the area of involvement indicated in the clinical photographs we received previously, definitive assessment of all prognostic features should be deferred to the complete reexcision specimen.	SUBUNGUAL MELANOMA, AT LEAST 1 MM IN THICKNESS, EXTENDING TO THE PERIPHERY OF THE BIOPSY	252688	1602	\N	\N	09-29997	A	SYNX199	\N	IP310907	Consolidated_data_final.csv
10735	13-1939	26	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	Iwei Translocation	CGH13-027 NTRK3	There is a compound proliferation of large, oval melanocytes with abundant, pale slightly vacuolated amphophilic cytoplasm and large, vesicular nuclei with large central nucleoli. The lesion has a raised, slightly papillated surface, and a relatively thin epidermis. The lesional melanocytes are in closely apposed aggregations in the upper part of the lesion with a more dispersed pattern lower in it. Melanocytes mature with descent within the dermis, and the sizes of their aggregations also diminish with descent. The enclosed two-color immunostain shows that there is a low proliferation rate among the lesional melanocytes. A p16 immunoperoxidase stain does not show loss of that tumor suppressor gene product.	Six outside slides, S12-19782, S12-2604:C, and one corresponding block.	\N	\N	\N	\N	Comparative genomic hybridization shows an isolated loss of an interstitial area in chromosome 3p that contains the BAP-1 gene. Immunoperoxidase staining for BAP-1 shows loss of nuclear staining in the lesional melanocytes implying a mutation in the remaining allele; this aberration has been seen in a recently described subset of spitzoid lesions: 1: Wiesner T, Murali R, Fried I, Cerroni L, Busam K, Kutzner H, Bastian BC. A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression. Am J Surg Pathol. 2012 Jun;36(6):818-30. PMID: 22367297.  2: Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, R¸tten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011 Aug 28;43(10):1018-21. doi: 10.1038/ng.910. PubMed PMID: 21874003.  I would look at the clinical images in paper #2 and biopsy any nevi similar to this one, or to those in the article. A family history of ocular or cutaneous melanoma, or synovial sarcoma should also be obtained. Most lesions of this type are spontaneous, however. A very narrow re-excision to prevent regrowth would be prudent. If there was a pre-operative photograph, we would greatly appreciate having it for our teaching collection.  To date, there is no link between tanning booth or UV exposure and nevi of this type.	COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES WITH A BAP-1 ABERRATION	173505	1611	\N	\N	13-1939	A	SYNX208	\N	IP1186681	Consolidated_data_final.csv
10736	13-51657	9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	Iwei Translocation	CGH13-268 MET	Sections show a domed compound proliferation of enlarged fusiform melanocytes with amphophilic cytoplasm. These cells are distributed singly and in nests and large fascicles within the epidermis, which is acanthotic, and limited scatter above the junction can be seen. Some large nests are accompanied by perijunctional edema, and some mitotic figures can be found within large junctional collections. In fibrotic dermis below this, there are much smaller nests and cords of similar melanocytes, but most of the dermis cannot be visualized because of the superficial nature of the biopsy.	Six outside slides, MS-13-0007857 A1. One corresponding block received 7-12-13.	\N	\N	\N	\N	ADDENDUM, August 9, 2013: As I reported previously, I am in general agreement with your suggested interpretation of this case. I favor the surface of a compound Spitz nevus, but some unconventional (or atypical) features are present, and the extent of subjacent dermal involvement cannot be evaluated because of the superficial nature of the biopsy. There are at least two ways to proceed in the management of this case. One is to complete conservative reexcision of this site and obtain any residuum for further histopathologic assessment. The other is to pursue comparative genomic hybridization (CGH) to screen this tumor for chromosomal copy number abnormalities, as can be found in association with spitzoid melanoma. (The latter option was selected, as is discussed further below.) Per a clinical request, we completed CGH analysis to screen for genomic copy number anomalies. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in distal chromosome 7q with no other chromosomal gains or losses. As background for understanding this result, please note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while most melanocytic nevi lack such aberrations. We have identified gain in chromosome 7q as a monoaberration in a subset of unconventional Spitz nevi.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of spitzoid melanoma. Rather, our analysis supports interpretation as an unconventional Spitz nevus. Given the complexity of this assessment, reexcision of this site would be reasonable to ensure local control and prevent persistence.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	COMPOUND PROLIFERATION OF ENLARGED SPITZOID MELANOCYTES, CONSISTENT WITH THE SURFACE OF AN UNCONVENTIONAL COMPOUND SPITZ NEVUS	173304	1612	\N	\N	13-51657	A	SYNX209	\N	IP1293660	Consolidated_data_final.csv
1717	13-32982A	54	\N	1.05	1	T2a	Primary	 Melanoma	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a segment of acral skin in which there is a scar. In addition, there is a biphasic proliferation of melanocytes. One population is composed of both spindled and epithelioid melanocytes, many of which contain dusty melanin within their cytoplasm.  These melanocytes are configured as single cells and nests along the dermo-epidermal junction and as nests, cords and single cells in the underlying dermis. The size of the melanocytes does not diminish with descent into the dermis. There is also a population of cytologically bland cells arranged as nests along the junction and as maturing nests cords and strands in the underlying dermis.	One elliptical excision and one tissue fragment received in one bottle. Ellipse, 2.7 x 1.2 x 0.4 cm, including a central 1.2 x 0.7 cm depressed grayish-brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with seven sections in A and six in B. Tissue fragment measuring 0.9 x 0.3 x 0.2 cm, submitted intact in B. CF/CF	5 X 5 MM MELANOMA, SEE DT13-25288	\N	\N	\N	It is now evident that this neoplasm represents a melanoma of 1.05 millimeters in thickness. A melanocytic nevus is also present intermingled with the melanoma, and thus the melanoma likely arose within the nevus. Given the thickness of the melanoma in combination with the proximity of it to the inked margin, a re-excision at this site is warranted. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: Excision Tumor site:  R. lateral foot Microscopic tumor type:  Melanoma Breslow thickness: 1.05 millimeters Ulceration: no Margins, peripheral and deep: 0.4 millimeters to the deep margin and 1.5 millimeters to the peripheral margins Mitotic index: < 1/mm2, although a dermal mitotic figure was identified in the initial biopsy of the melanoma (13-25288) Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT2aNXMX  I have also shared this case with my colleague, Dr. Thaddeus Mully, who agrees with this assessment.  This report was reissued on May 28, 2013 to add the patient's UCSF Medical Record number.	SCAR, WITH RESIDUAL MELANOMA, 1.05 MILLIMETERS IN THICKNESS, ABUTTING THE INKED MARGINS	582753	2110	\N	\N	13-32982	A	SYNAT492	Wild Type Melanoma	IP1210033	AirTable blocks_with_IP_info.csv
10665	08-84352	36	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.4	Ivanka Patient Melanoma	\N	Sections show an asymmetrical, compound melanocytic proliferation with a biphasic pattern. One population consists of melanocytes, most of which have atypical nuclei, that are irregularly distributed along the dermal-epidermal junction, with some melanocytes present above the basal zone. Similar melanocytes are present in the subjacent dermis. There are mitotic figures within the epidermis, and within the perijunctional and deeper dermis. The second population consists of melanocytes with cytologically bland nuclei (melanocytic nevus). This latter population is arrayed as nests and single cells along the sides and bases of elongate and focally fused rete ridges, with similar small melanocytes present within a fibrotic papillary dermis.	Skin segment measuring 1.4 x 0.9 x 0.2 cm, trisected and entirely submitted in cassette A.	\N	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma of Clark's anatomic level III/IV, abutting the reticular dermal interface. There is no evidence of associated vascular invasion, neurotropism, or regression. Additional excision is of course warranted to ensure that this lesion has been removed in its entirety.	MELANOMA, 0.9 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING TO WITHIN 1 MM OF THE PERIPHERAL EDGE AND BASE OF THE SPECIMEN	123493	1604	\N	\N	08-84352	A	SYNX201	\N	IP792993	Consolidated_data_final.csv
3002	98-11545	36	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=2374	172.4	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly within the epidermis, with foci of pagetoid upward scatter.  Some melanocytes have atypical nuclei.  Aggregations of similar melanocytes are present in the dermis.	Cylindrical skin segment, 0.9 cm in diameter and 0.5 cm in thickness,\ntrisected and entirely submitted.	PIGMENTED LESION; CLINICAL DIAGNOSIS - R/O MALIGNANT MELANOMA	\N	\N	\N	None	MELANOMA, 1.2 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO THE PERIPHERAL MARGIN	173406	143	\N	\N	98-11545	\N	CCR-049	California Cancer Registry	IP149118	AirTable blocks_with_IP_info.csv
1173	05-26408 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1017	\N	\N	None	\N	MD-135	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1172	05-24184C T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1018	\N	\N	None	\N	MD-137	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1174	05-26627-1B T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1019	\N	\N	None	\N	MD-138	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
10669	11-88792	56	\N	\N	\N	T1a	Primary	\N	\N	\N	\N	\N	\N	172.7	Ivanka Patient Melanoma	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with numerous cells present above the basal layer.  There are similar melanocytes in the subjacent dermis and some of them surround eccrine ducts.  The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.  These cells tend to mature with descent.	Skin segment, 1.5 x 1.0 x 0.1 cm, quadrisected, and entirely submitted.	\N	\N	\N	\N	Melanoma in situ extends along eccrine glands to the base of the specimen.  In terms of staging, this is a thin, non-ulcerated melanoma.  No dermal mitotic figures are noted.  Based on the 2009 AJCC melanoma staging system, this is a pT1a lesion.	MELANOMA, 0.45 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173710	1605	\N	\N	11-88792	A	SYNX202	\N	IP787073	Consolidated_data_final.csv
10835	13-15966	65	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.9	UCSF Wild Type Melanoma	\N	\N	Blocks S12-25910:A.	\N	\N	\N	\N	The histopathological diagnosis was established by pathology report S12-25910 of UCSF Surgical Pathology. Sanger sequencing of exon 15 of BRAF, exons 1 and 2 of NRAS, and exons 9, 11, 13, 17, and 18 of KIT, which include the known mutational hotspots of these genes, were performed on block (A2) and no mutations were detected. Because there was only a tiny focus from which pure populations of neoplastic cells could be microdissected, the risk of a false negative results is increased.	MELANOMA	222922	1635	\N	\N	13-15966	A	SYNX232	\N	IP1200709	Consolidated_data_final.csv
10674	13-74952	2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	Iwei DPN	CGH13-324 	There is a mostly intradermal proliferation of large, oval melanocytes with abundant pale cytoplasm and large, but monomorphous oval vesicular nuclei. The overlying epidermis is thinned, with much of the lesion in an expanded papillary dermis, surrounded by epithelial collarettes. There are patchy lymphocytic infiltrates throughout the lesion. There are scattered mitotic figures. There is limited maturation with descent.	One outside slide, DPR-13-8644 / A1, and one corresponding block.	\N	\N	\N	\N	The differential diagnosis includes an atypical Spitz tumor and a spitzoid melanoma. To provide some context for the eventual findings, I performed a few immunostains. A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows many nuclei with what appear to be mitotic figures in melanocytes in the lower half of the lesion. A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product. Comparative genomic hybridization shows gains involving chromosomes 12p and 15q. This is an unusual result. I shared the comparative genomic hybridization data with my colleagues, Drs. Boris Bastian and Iwei Yeh. They do not regard these aberrations as indicating melanoma, as more typical ones would. There may be a gene fusion mechanism in this case, as has been seen with other spitzoid lesions in studies from their lab.  An atypical Spitz tumor may be the best category for this lesion. These are neoplasms that have feature more atypical than those of a conventional Spitz nevus, but not as worrisome as those of spitzoid melanoma. In aggregate data from over ten studies, local nodal involvment (usually very small deposits) is common, but extranodal metastasis is rare. This dissociation results in sentinel lymph node biopsy having very limited predictive value, and in my opinion, sometimes leading to over-treatment if small deposits lead to completion lymphadenectomy. If there are significant findings on re-excision, I would appreciate a chance to see the sections. Most lesions of this type are well circumscribed, and the re-excision should be deeper, but necessarily more than a few mms. wider that the prior biopsy site or an visible residuum.	PREDOMINANTLY INTRADERMAL PROLIFERATION OF LARGE, SPITZOID MELANOCYTES, BEST REGARDED AS AN ATYPICAL SPITZ TUMOR	173304	1606	\N	\N	13-74952	A	SYNX203	\N	IP1316957	Consolidated_data_final.csv
10675	13-75067	10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.3	Iwei Translocation	CGH13-331 ETV6 Fusion	Sections show a compound, wedge-shaped proliferation of large oval melanocytes with  pleomorphic vesicular nuclei and abundant vacuolated cytoplasms, arranged as small nests and fascicles. Only a few junctional nests are present. The apex of the lesion is in the superficial subcutis dermis. There are evenly distributed melanophages.	Cylindrical skin segment, 0.4 cm in diameter and 0.6 cm in thickness, bisected and entirely submitted. RS/RS	\N	\N	\N	\N	ADDENDUM, October  4, 2013: The following note has been modified from that in the original report and later addenda, copies of which are on file as .pdfs in our computer system: The overall findings are those of a so-called deep penetrating nevus. These are unusual melanocytic lesions with some features similar to those of blue nevus, but with a different genomic origin and the presence of some junctional nests. There are deep penetrating nevus-like melanomas, and in some controversies about the essential nature of this entity. Hence, I performed immunostaining. Immunostaining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a high proliferative rate in the lesional cells, with up to 30% of the cells in occasional nests having positively stained nuclei. A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows only rare positive nuclei. A p16 immunoperoxidase stain does not show loss of that tumor suppressor gene product.  Given the unusual features in the hematoxylin and eosin-stained sections (the degree of confluence of dermal aggregations, and the degree of nuclear pleomorphism), as well as the high proliferative rate noted above, one would ideally achieve unequivocally clear margins around such a lesion. The current margins are less than 0.2 mm.  Following our discussion, and the history of brain tumor followed by radiation, I have requested a p53 immunoperoxidase stain, as some neoplasms due to radiation have p53 mutations that stabilize the protein, and lead to immunohistochemical positivity. The staining is negative.  Comparative genomic hybridization did not show chromosomal gains or losses, a finding that is strongly against melanoma.	DEEP PENETRATING NEVUS WITH SOME ATYPICAL FEATURES, WITH NO  ABERRATIONS SEEN WITH COMPARATIVE GENOMIC HYBRIDIZATION	173305	1607	\N	\N	13-75067	A	SYNX204	\N	IP1317072	Consolidated_data_final.csv
10775	07-3078	68	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	232.6	Iwei Pediatric Melanoma (PMM)	\N	Sections show a melanocytic proliferation composed largely of single cells arrayed in near-continuous fashion within some parts of the lower epidermis, above a reticular dermis with considerable elastosis. Some single cells are scattered above the junction.	One outside slide, 07-139 and one corresponding block.	\N	\N	\N	\N	Further re-excision of this site is warranted to ensure that local eradication has been accomplished.	MELANOMA IN SITU, TRANSECTED AT THE PERIPHERAL BIOPSY MARGIN	733602	1620	\N	\N	07-3078	A	SYNX217	\N	IP625607	Consolidated_data_final.csv
1586	12-12470D	98	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	173.61	BCC	\N	Sections show nodular aggregations of atypical, peripherally palisaded basaloid cells. In some areas, angulate aggregations of similar cells are apparent in infiltrative array. There is enveloping cellular stroma. There is crush artifact.	Multiple tissue segments measuring 1.0 x 0.9 x 0.2 cm in aggregate.  The specimen is filtered, serially sectioned, wrapped and entirely submitted in cassette D.	(+) HISTORY OF MM, A) 0.7 X 0.5 CM, B) 0.9 X 1.0 CM, C) 1.4 X 0.8 CM, D) 1.3 X 0.7 CM; A-D) NEOP VS. BCC (C&D DONE AT TIME OF BX)	\N	Nodular/Infiltrative, upper anterior forearm	\N	The neoplasm extends to the edges of the specimen.	NODULAR/INFILTRATIVE BASAL CELL CARCINOMA	423654	2197	\N	\N	12-12470	D	SYNAT356	2010-2017	IP192328	AirTable blocks_with_IP_info.csv
1800	14-73175B	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26307,26202,26340	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	758	\N	\N	14-73175	B	JJS19	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1676	13-122	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	786	\N	\N	13-122	\N	KIT-05	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1675	13-074	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	787	\N	\N	13-74	\N	KIT-06	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1673	13-028	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	788	\N	\N	13-28	\N	KIT-07	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1548	12-073	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	789	\N	\N	12-73	\N	KIT-08	Kit mutants	\N	AirTable blocks_with_IP_info.csv
10737	13-89069	17	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.4	Iwei DPN	CGH13-365 DPN-like Melanoma	Sections show a punch biopsy harboring a compound proliferation of heavily pigmented melanocytes that is biphasic in its composition. Deep within the specimen, there are dendritic and thin spindled melanocytes distributed interstitially amongst coarse collagenous stroma in concert with numerous melanophages, and this comprises one population of cells. In the upper dermis, the epidermis, and the perifollicular dermis, there is a second population of larger ovoid and fusiform melanocytes with abundant pale cytoplasm. These cells are also accompanied by many melanophages and have a slightly elevated cell proliferation index. Within the epidermis, scatter of some melanocytes above the junction can be seen.	Three outside slides, DP13-14246, and one corresponding block.	\N	\N	\N	\N	The histopathologic findings in this initial biopsy were worrisome for melanoma ex blue nevus. We completed comparative genomic hybridization (CGH) to screen for chromosomal copy number abnormalities, as can be seen in association with melanoma, and the results of this analysis are discussed in association with the specimen that follows.	BIPHASIC COMPOUND PROLIFERATION OF HEAVILY PIGMENTED MELANOCYTES, INCLUDING A COMPONENT OF BLUE NEVUS	173406	1613	\N	\N	13-89069	A	SYNX210	\N	IP1331074	Consolidated_data_final.csv
10738	11-1051A	30	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.5	Iwei Blue Nevus Melanoma	CGH11-018 	Sections show lactiferous ducts in fibrofatty tissue, with masses of plump oval melanocytes that have monomorphous, vesicular nuclei and inconspicuous cytoplasm in several areas. There are scattered melanophages in some areas, as well as clusters of bipolar, dendritic melanocytes in others. The most cellular areas of the proliferation have crowded, somewhat larger oval vesicular nuclei with many pyknotic cells amongst them. Mitotic figures are difficult to find.	Two outside slides, PC10-3033:A1,A2.	\N	\N	\N	\N	\N	MELANOMA, ARISING IN ASSOCIATION WITH A CELLULAR BLUE NEVUS	173504	1614	\N	\N	11-1051	A	SYNX211	\N	IP990488	Consolidated_data_final.csv
1153	05-04949-1C T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1027	\N	\N	None	\N	MD-148	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1133	04-18775B T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1028	\N	\N	None	\N	MD-149	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1125	04-14677 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1029	\N	\N	None	\N	MD-150	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2570	19Rig750007.05.15.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	299	\N	\N	None	\N	CM-71	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
1639	12-32138	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	110	\N	\N	12-32138	\N	BN-006	Nevus Library	\N	AirTable blocks_with_IP_info.csv
2866	23-293	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	430	\N	\N	23-293	\N	DMS-018	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2882	23-4720	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	431	\N	\N	23-4720	\N	DMS-019	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
1967	16-83056	11	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	There is an ulcerated, mostly intradermal proliferation of large, oval and fusiform melanocytes with abundant pale cytoplasm and large, vesicular nuclei. These cells are present in confluent fascicles and sheets, with scattered relatively deep mitotic figures and little maturation or dispersion with descent. There is retention of p16 staining.	Nine outside slides, S16-27822 (A1-A2), including three unstained slides (A2), and one corresponding block (A2).	LESION, HISTORY OF BLEEDING, TREATMENT FOR WART AND PRESUMED KELOID (INTRALESIONAL STEROID INJECTION); ATYPICAL SPITZ TUMOR VS. SPITZOID MELANOMA	\N	\N	Scraping	The differential diagnosis includes an atypical Spitz tumor and a spitzoid melanoma. It is unclear from the history if the ulceration is spontaneous, or due to treatment or trauma. Given the degree of nuclear pleomorphism and the sheet-like growth pattern, I proposed that molecular testing would be advantageous to see if chromosomal copy number changes, as seen in melanoma are present here. I had also proposed hTERT promoter mutation analysis, but my understanding is that insurance has denied coverage for this test. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows losses involving chr. 9, 13 and 18q, and a possible loss of the peri-centromeric area on chr. 10p. Losses involving chromosomes 9 and 10 are common in melanoma. The loss involving chr. 9 was not accentuated in the area of 9p that contains CDKN2A, making it unlikely that there is a homozygous deletion. This correlates with the preservation of p16 staining by immunohistochemistry.  Given the ulceration, histopathologic findings and the results of comparative genomic hybridization, I would regard this as a relatively high risk atypical Spitz tumor, if not spitzoid melanoma. It would be advantageous to also have the results of hTERT promoter testing.	ATYPICAL SPITZ TUMOR, ULCERATED, WITH SEVERAL CHROMOSOMAL COPY NUMBER CHANGES	173201	244	\N	\N	16-83056	\N	CGH16-200	Nevus Library	IP1682818	AirTable blocks_with_IP_info.csv
3490	KIT313	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1897	\N	\N	None	\N	SYNAT562	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3536	MB1421	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1781	\N	\N	None	\N	SYNAT563	2010-2017	\N	AirTable blocks_with_IP_info.csv
3563	PMM-8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1943	\N	\N	None	\N	SYNAT564	2010-2017	\N	AirTable blocks_with_IP_info.csv
10739	11-5480	72	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.5	Iwei Blue Nevus Melanoma	CGH11-027 	Sections show segments of breast parenchyma, and within these segments there is a proliferation of plump spindled and slender dendritic melanocytes encompassed by a sclerotic fibrous matrix. In many areas, the proliferation consists of small dendritic melanocytes encompassed by this matrix and accompanied by an infiltrate of many melanophages. In other, more cellular foci, there are nodules composed of coalescing fascicles of plump spindled melanocytes with pale or faintly melanized cytoplasm. In these cellular areas, melanophages are few in number. Cells in mitosis are focally present but are not readily identifiable. The Ki-67 cell proliferation index is extremely low.	Twenty-seven outside slides, S10-8040:E1-E3,E5,E6,E8,E9,E13 and two corresponding blocks (E8,E9).	\N	\N	\N	\N	Based solely upon conventional microscopical assessment, I was agreement with the interpretation of Dr. Wick: I favored interpretation of this proliferation as a cellular blue nevus and was not convinced that a component of melanoma was present. However, given the diagnostic controversy that had surrounded this case, we pursued array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block (from a hypercellular focus), aCGH analysis was completed and demonstrated gains in chromosomes 6p, 8q, and 17q as well as losses in chromosomes 6q, 9p, 11q, and 16q. The presence of multiple chromosomal gains and losses is not an alteration that is known to occur in cellular blue nevi (or even in so-called atypical cellular blue nevi) and suggests instead that a component of melanoma is present. In summary, based upon the combination of results derived from conventional microscopy and aCGH, I believe this breast lesion includes a component of blue nevus-like melanoma that developed within a background of cellular blue nevus. The component of melanoma is not obvious and fully distinctive microscopically, at least to my eye, and thus molecular assessment proved to be instrumental in rendering the above interpretation. This melanoma cannot be staged by conventional microscopical parameters.  I do not know the status of the final surgical margin for this case. The fact that this specimen is listed as a mastectomy specimen leads me to presume that complete excision has been achieved.	BLUE NEVUS-LIKE MELANOMA, ARISING WITHIN AN INTRAMAMMARY CELLULAR BLUE NEVUS	173505	1615	\N	\N	11-5480	A	SYNX212	\N	IP994917	Consolidated_data_final.csv
10746	09-31895	80	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.6	Ivanka Patient Melanoma  	\N	\N	Skin segment measuring 1.0 x 0.9 x 0.2 cm, trisected and entirely submitted.	\N	\N	\N	\N	This biopsy contains two populations of melanocytes within it, with one population representing superficially invasive melanoma and with the other population representing a longstanding melanocytic nevus. This is a non-ulcerated melanoma with associated Clark's level III invasion. There is no evidence of associated vascular or perineural invasion. Associated partial regression is apparent; in light of the associated regression, the microstage measurement listed above may underestimate the prognostic impact of this melanoma. Melanoma is transected at the periphery of the biopsy. Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.55 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173649	1617	\N	\N	09-31895	A	SYNX214	\N	IP79298	Consolidated_data_final.csv
2525	19Rig750007.03.03.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	272	\N	\N	None	\N	CM-32	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2526	19Rig750007.03.03.04	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	272	\N	\N	None	\N	CM-32	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
10753	01-8297	34	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	110.9	Iwei Pediatric Melanoma	\N	Sections show spongiosis with an altered cornified layer.	One outside slide, 01-04664 (01-0708).	\N	\N	\N	\N	3/15/2001:  A PAS-D stain confirms the presence of hyphae in the cornified layer.   3/12/2001:  I suspect dermatophytosis.	DERMATOPHYTOSIS	173610	1618	\N	\N	01-8297	A	SYNX215	\N	IP264700	Consolidated_data_final.csv
10794	13-94981	25	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	Iwei Translocation	CGH13-392 	There is a relatively narrowly based, and somewhat wedge-shaped compound proliferation of melanocytes that mostly involves the junctional zone and superficial dermis. There are nests of large oval cells at the junction, with some confluence of them. Some of these have homogeneous, and some vacuolated cytoplasm with dusty melanin. There are pleomorphic, vesicular nuclei with large nucleoli. Nuclear maturation and dispersion are both evident with descent. There are focally dense lymphocytic infiltrates. A mitotic figure is present in the mid-dermal portion of the lesion, either in a melanocyte or in a stromal cell. The enclosed Mart-1 stained sections highlight that the lesion has an irregular lower contour. A gradient of HMB-45 staining is present, mostly at the junction.	Five outside slides, M13-32431 1A (SU-13-25161 A).  One corresponding block received 11-26-13.	\N	\N	\N	\N	This spitzoid proliferation has marked confluence of both junctional nests and dermal ones, and in the thinner sections, some pulverocytes.* It also has an uneven lower border. These findings raised the possibility of a spitzoid melanoma. Comparative genomic hybridization shows chromosomal amplifications involving areas on 7p (near the terminal end) and 7q. The latter includes part of the b-raf gene. The fusion partner for b-raf in this case may be MAD1L1, a gene that has been seen as a fusion partner in other such cases. My colleague, Dr. Iwei Yeh also reveiwed the comparative genomic hybridization data and agrees with this interpretation of it.  Spitzoid lesions with b-raf fusions lack b-raf mutations (i.e. the sequence of the gene is wild type, but there is a break in the gene and the chromosome is attached at the breakpoint to its fusion partner). This mechanism can occur in Spitz's nevi, atypical Spitz tumors and in melanoma. An overview of the subject of braf fusions is in the paper from our group referenced below. The absence of other abberations in this lesion, with the exception of a low level loss involving chromosome 14q is against an outright diagnosis of spitzoid melanoma.  An atypical Spitz tumor may be the best category for this lesion. These are neoplasms that have feature more atypical than those of a conventional Spitz nevus, but not as worrisome as those of spitzoid melanoma. In aggregate data from over ten studies, local nodal involvment (usually very small deposits) is common, but extranodal metastasis is rare. This dissociation results in sentinel lymph node biopsy having very limited predictive value, and in my opinion, sometimes leading to over-treatment if small deposits lead to completion lymphadenectomy.  Reference:  Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M, Rocchi S, Bahadoran P, McCalmont TH, LeBoit PE, Burton EA, Bollag G, Ballotti R, Bastian BC. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res. 2013 Nov;26(6):845-51. doi: 10.1111/pcmr.12148. Epub 2013 Aug 19. PubMed PMID: 23890088; PubMed Central PMCID: PMC3808507.   *This term is introduced in Massi G, LeBoit P. Histologic Diagnosis of Nevi and Melanoma, 2nd Edition, Springer-Verlag, Berlin Heidelberg, 2014 p. 57, and refers to cells with abundant, pale cytoplasm and dusty appearing melanin, deriving from the Latin term for dust	COMPOUND PROLIFERATION OF LARGE, ATYPICAL MELANOCYTES, BEST REGARDED AS AN ATYPICAL SPITZ TUMOR	173530	1621	\N	\N	13-94981	A	SYNX218	\N	IP1336996	Consolidated_data_final.csv
10795	13-99411A	17	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	Iwei Translocation	CGH13-399 	An asymmetrical polypoid compound proliferation of melanocytes is quite protuberant. Near the base of the polyp, a small junctional component that consists of single melanocytes and pigmented nests can be seen. In the dermis below this, a syncytial array of fusiform and epithelioid melanocytes with slightly enlarged nuclei can be seen. In some areas, the background stroma is collagenous and has a vaguely whorled configuration. Although the constituent melanocytes are enlarged, cells in mitosis are not easily found.	One outside slide, DPR-13-11019:A1 and one corresponding block.	\N	\N	\N	\N	To further assess this proliferation, limited immunoperoxidase staining was first completed as part of our assessment. CD34 staining demonstrates relatively diffuse fingerprint positivity, thereby corroborating that neural differentiation is present. An EMA immunostain proved to be completely negative, and thus there is not proof of perineurial differentiation (nevertheless, I suspect it may be present). Per the request of Dr. Vetto, we additionally completed array-based comparative genomic hybridization (aCGH) to screen for chromosomal copy number abnormalities. as can be seen with melanoma. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in in chromosome 9, loss of much of chromosome 7, and loss of distal chromosome 2. The identification of multiple chromosomal copy number abnormalities, with loss of chromosome 9 as the dominant finding, indicates that melanoma cannot be excluded from the differential diagnosis. However, based upon conventional microscopy, I cannot render a conclusive diagnosis of melanoma.  In short, this represents an ambiguous melanocytic tumor. If interpreted as melanoma, the tumor is 1.95 mm in thickness and is non-ulcerated.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	ATYPICAL POLYPOID COMPOUND PROLIFERATION OF MELANOCYTES; GENOMIC LOSSES HAVE BEEN IDENTIFIED VIA COMPARATIVE GENOMIC HYBRIDIZATION	101406	1622	\N	\N	13-99411	A	SYNX219	\N	IP1341428	Consolidated_data_final.csv
10796	13-94484	3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	Iwei Translocation	CGH13-394 	Sections show melanocytes arrayed in compound fashion in a large polypoid skin segment. There are single melanocytes and large pale nests of melanocytes within the epidermis, and limited intraspinous scatter is noted. In the vast subjacent dermis in the center of the polyp, there is a large nodular population of melanocytes that is somewhat biphasic. There are smaller ovoid and fusiform melanocytes arrayed as nests, cords, fascicles, and syncytia, and there is also a large syncytial population of enlarged epithelioid melanocytes with amphophilic or pale cytoplasm. A patchy lymphohistiocytic infiltrate is noted as well.	Two outside slides, S13-5421. One corresponding block received 11-18-13.	\N	\N	\N	\N	This large polypoid tumor does not represent a variant of conventional Spitz nevus. Rather, our differential diagnosis includes an unusual combined melanocytic nevus or unconventional Spitz nevus, an 'atypical Spitz tumor' (a provisional diagnostic category), and childhood spitzoid melanoma. We completed BAP-1 immunoperoxidase staining as part of our evaluation, as BAP-1 loss (within chromosome 3p) can be detected in a subset of Spitz tumors with enlarged epithelioid melanocytes, similar to those seen here. The BAP-1 immunostain demonstrates preserved nuclear positivity throughout, thereby indicating that BAP-1 loss is not present. This is the type of challenging tumor for which array-based comparative genomic hybridization (aCGH) can be of value. This technique was applied, as per your approval. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in distal chromosome 7 with no other associated chromosomal gains or losses. Gain in chromosome 7q suggests a Spitz nevus with associated MET genetic fusion. MET immunostaining was additionally completed and demonstrates positivity, thereby corroborating the possibility suggested in the preceding sentence.  This is an unusual melanocytic tumor. I believe it is benign, but follow-up studies of tumors of this type have not been completed. Conservative complete reexcision of this site would be reasonable to consider to ensure complete tumor removal and prevent persistence.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	POLYPOID COMPOUND PROLIFERATION OF ENLARGED EPITHELIOID MELANOCYTES, CONSISTENT WITH AN UNCONVENTIONAL POLYPOID SPITZ NEVUS	173707	1623	\N	\N	13-94484	A	SYNX220	\N	IP1336499	Consolidated_data_final.csv
3507	London-L2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1937	\N	\N	None	\N	SYNAT657	2010-2017	\N	AirTable blocks_with_IP_info.csv
3469	KIT118	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Known Mutations	\N	\N	\N	\N	2035	\N	\N	None	\N	SYNAT658	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3337	Dog24	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka, Dog Melanoma| mucosal melanomas-non-pigmented	\N	\N	\N	\N	1872	\N	\N	None	\N	SYNAT659	2010-2017	\N	AirTable blocks_with_IP_info.csv
3533	MB_1454	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1735	\N	\N	None	\N	SYNAT660	2010-2017	\N	AirTable blocks_with_IP_info.csv
3587	SM_16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2138	\N	\N	None	\N	SYNAT661	Spitzoid Melanoma	\N	AirTable blocks_with_IP_info.csv
1231	06-18321	67	\N	\N	\N	None	None	None	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=315	172.5	\N	\N	Sections show a compound proliferation of atypical melanocytes, composed largely of cells with ample vacuolated and pigmented cytoplasm. Single cells and nests are arrayed irregularly and confluently within the epidermis, with conspicuous associated suprabasal scatter. There are also clusters of similar melanocytes arrayed densely in the superficial dermis, jointly with an infiltrate of lymphocytes and melanophages. There is elastosis more deeply.	Ellipse measuring 0.8 x 0.5 x 0.3 cm.  With margins inked blue, the specimen is serially trisected perpendicular to the long axis and entirely submitted.	IRRIT SEB KERATOSIS; R/O DYSPLASIA	\N	\N	Scraping	In terms of staging, this is a non-ulcerated primary melanoma with an invasive component that involves the reticular dermis (Clark's level IV). There is no evidence of vascular invasion or perineural extension or regression in these sections. Further re-excision of this site is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 1.2 MM IN THICKNESS, TRANSECTED AT THE PERIPHERAL BIOPSY MARGIN	105539	125	\N	\N	06-18321	\N	CCR-009	California Cancer Registry	IP563387	AirTable blocks_with_IP_info.csv
10823	11-2532	64	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.4	Iwei Blue Nevus Like Melanoma	CGH11-023 	Sections show a cellular nodular proliferation of plump spindled melanocytes that spans the full reticular dermis and focally juts into the uppermost subcutis. The lesional melanocytes are slightly spindled and have cytoplasmic pigmentation that varies in degree. Centrally, the degree of cytoplasmic melanization is marked. Melanocytes in mitosis are easily found. In one of the two available sections, there is a central focus of degeneration that is colonized by many melanophages.	One outside slide, W11-270:A and one corresponding block.	\N	\N	\N	\N	Our differential diagnosis included so-called atypical cellular blue nevus on one hand and blue nevus-like melanoma on the other, and the latter possibility proves to represent the correct interpretation for this atypical melanocytic proliferation. To further establish the diagnosis for this tumor, we employed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block aCGH analysis revealed loss in chromosome 3 (3p and 3q) as well as losses in distal chromosome 9q and chromosome 19p. The documentation of multiple chromosomal gains and losses supports interpretation as melanoma, and the documentation of chromosome 3 loss, in particular, has been associated with blue nevus-like melanoma. I also considered the possibility of a metastasis of melanoma in my differential diagnosis, but I view this as unlikely. If there is any history of melanoma in this patient, please keep me informed.  This melanoma is non-ulcerated and shows associated Clark's level V invasion. Further excision is warranted to ensure that local eradication has been accomplished.	BLUE NEVUS-LIKE MELANOMA OF 5.6 MM IN THICKNESS, PARTIALLY CAPTURED VIA BIOPSY	102499	1624	\N	\N	11-2532	A	SYNX221	\N	IP991969	Consolidated_data_final.csv
10826	13-60273	60	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.3	UCSF Wild Type Melanoma	\N	\N	Six slides, S13-16054:A3 through A8, and six corresponding blocks.	\N	\N	\N	\N	The histopathological diagnosis was established by pathology report S13-16054:A of UCSF Surgical Pathology. Sanger sequencing of exon 15 of BRAF, exons 1 and 2 of NRAS, and exons 11, 13, 17, and 18 of KIT, which include the known mutational hotspots of these genes, did not reveal mutations.	MELANOMA, NO MUTATIONS DETECTED IN BRAF, KIT AND NRAS	173316	1626	\N	\N	13-60273	A	SYNX223	\N	IP841587	Consolidated_data_final.csv
2532	19Rig750007.03.07.05	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	275	\N	\N	None	\N	CM-36	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2531	19Rig750007.03.07.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	275	\N	\N	None	\N	CM-36	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
10827	12-52454	89	\N	\N	\N	T4a	Primary	\N	\N	\N	\N	\N	\N	172.4	UCSF Wild Type Melanoma	\N	Sections show a dermal neoplasm comprised of markedly atypical pigmented and spindled melanocytes arranged as cellular fascicles.  Numerous mitotic figures are noted throughout the full thickness of the lesion.  The atypical melanocytes encircle small nerve twigs.	Two specimens received in the same container. The first specimen is a Cylindrical skin segment, 0.4 cm in diameter and 0.4 cm in thickness, bisected. The second specimen is a 0.5 x 0.2 x 0.5 cm skin segment. A total of three pieces entirely submitted.   HD/HD	\N	\N	\N	\N	No connection to the epidermis is seen and as before a metastasis is possible.  Foci of perineural infiltration are identified.  If this is a primary lesion it would be a stage pT4a melanoma based on the 2009 AJCC melanoma staging system.	MELANOMA, APPROXIMATELY 5.0 MILLIMETERS IN THICKNESS, EXTENDING TO THE TISSUE EDGES	173410	1627	\N	\N	12-52454	A	SYNX224	\N	IP1032345	Consolidated_data_final.csv
10828	12-75125	26	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	UCSF Wild Type Melanoma	\N	Sections show a neoplasm composed of fascicles of melanocytes, involving the superficial and deep dermis, with a wedge-shaped configuration.  Some of the constituent melanocytes have abundant pale cytoplasm with dusty melanin and pleomorphic nuclei while others have abundant dull pink eosinophilic cytoplasm.  There are many admixed melanophages. In general, the size of the melanocytes does not diminish with descent into the dermis and many of the lesional melanocytes have prominent nucleoli.	Elliptical excision measuring 0.8 x 0.7 x 0.3 cm, including a central 0.5 x 0.4 cm pink tan area.  With the peripheral and deep margins inked blue, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with four sections.   HD/HD	\N	\N	\N	\N	My initial differential diagnosis included an unusual combined melanocytic nevus with features of a deep penetrating nevus and other features of a Spitz's nevus and melanoma. To further evaluate for this differential diagnosis, I initially performed a phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle). The stain showed only a few melanocytes in mitosis or near to mitosis, which was reassuring.  Nonetheless, as an additional diagnositic maneuver, I performed comparative genomic hybridization on this case after receiving authorization from the clinical team who had discussed the testing with the family. This is a technique that assesses chromosomal gains or losses, which are found in melanoma and not in nevi.  The comparative genomic hybridization showed losses involving portions of chromosome 9p and 10q. The presence of two chromosomal losses is abnormal and supportive of melanoma. The melanoma measures 2.6 millimeter in thickness and is present in the tip margin. Therefore, by conventional AJCC melanoma staging guidelines, this would be considered a pT3a melanoma. However, given the spitzoid morphology of many of the cells, it is possible that this melanoma would behave in a less aggressive fashion compared with a conventional melanoma of equivalent thickness. My colleague, Dr. Timothy McCalmont, also reviewed these sections and agrees with this assessment.  This report was reissued on November 27, 2012 to add the patient's UCSF Medical Record number.	INTRADERMAL ATYPICAL MELANOCYTIC PROLIFERATION, GENOMICALLY CONSISTENT WITH MELANOMA	102735	1628	\N	\N	12-75125	A	SYNX225	\N	IP1160942	Consolidated_data_final.csv
1357	09-90221	65	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.3	\N	\N	There is a broad, asymmetric and poorly circumscribed atypical melanocytic neoplasm characterized by large nests and sheets of melanocytes along an atrophic epidermis and throughout the papillary and reticular dermis. In some areas, there are small nests and individual melanocytes in the spinous and granular layers of the epidermis. There is focal fibrosis with melanophages. The melanocytes vary greatly in size from small to large with nuclear pleomorphism and many atypical mitoses.  Two of the sections have ulceration without crust and melanocytes throughout the dermis.	Two skin segments, one measuring 0.9 x 0.5 x 0.1 cm, bisected (fragmented upon cutting), and the other measuring, 0.8 x 0.5 x 0.1 cm, bisected, all entirely submitted.	PIGMENTED NEOPLASM	\N	\N	Scraping	The melanoma extends to at least a Clark level IV and is broadly transected.  The thickness measurement was taken from the thickest shave specimen. There is an additional separate shave specimen with melanoma throughout the dermis and extending to the base, measuring 0.4 millimeters in thickness.  It is unclear exactly how the two specimens are oriented relative to each other, but it is possible that the two measurements should be considered additive and the melanoma thickness may be considered up to at least 1.3 millimeters.  The excisional specimen will be necessary to further characterize the melanoma and its prognostic factors. The melanoma also extends to the peripheral edge of the biopsy and complete excision to ensure its complete removal is, of course, warranted.  Dr. Beth Ruben has reviewed this case and agrees with the diagnosis. ADDENDUM, July 17, 2011: The following note has been modified from that in the original report, a copy of which is on file as .pdfs in our computer system:  This report was re-issued after the medical record number was added to the case record.	MELANOMA, MEASURING AT LEAST 0.9 MILLIMETERS IN THICKNESS, TRANSECTED, NON-ULCERATED	173307	128	\N	\N	09-90221	\N	CCR-014	California Cancer Registry	IP890987	AirTable blocks_with_IP_info.csv
10829	12-98235A	60	\N	\N	\N	T4b	Primary	\N	\N	\N	\N	\N	\N	172.2	UCSF Wild Type Melanoma	\N	There is an ulcerated, multi-nodular proliferation of large, atypical melanocytes in partial apposition to a thinned epidermis. The lesional melanocytes have variably pigmented cytoplasm, large, hyperchromatic nuclei and a high mitotic rate. Maturation with descent is faulty. A focally dense lymphocytic infiltrate with melanophages is present.	Nodular skin fragment measuring 1.5 x 1.2 x 0.8 cm.  With the base inked blue, the specimen is quadrisected and fragmented upon quadrisection, all entirely submitted with four sections and one fragment in cassette A.  PL/PL	\N	\N	\N	\N	The epidermal margin is clear by about 1 mm., and the deep margin by 1.7 mm. in most of the cross-sections, but margins cannot be evaluated in one cross section. Even though an intraepidermal component is not present, the multinodular configuration suggests are primary melanoma, rather than a metastasis to this site. Given the ulceration, this is a stage T4b lesion in the 2009 AJCC staging schema for melanoma.	MELANOMA, 5.5 MM. IN THICKNESS	102285	1629	\N	\N	12-98235	A	SYNX226	\N	IP1184052	Consolidated_data_final.csv
10830	13-3619B	72	\N	\N	\N	T3b	Primary	None	\N	\N	\N	\N	\N	172.7	UCSF Wild Type Melanoma	\N	Sections show a proliferation of markedly atypical melanocytes arranged as large, irregular confluent nests at the dermo-epidermal junction and above it and as smaller irregular nest in the dermis.  Many of the melanocytes have ample cytoplasm that contains melanin pigment.  Numerous melanophages are also noted.  The epidermis has a papillated contour and shows ulceration.	Elliptical excision measuring 2.5 x 1.3 x 0.4 cm, including a central 1.4 x 0.9 cm brown black raised area.  With the peripheral and deep margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections each in cassettes A and B and three sections in cassette C.   HD/HD	\N	\N	\N	\N	Melanoma in situ is present 1-2 millimeters from the lateral margins.  This melanoma is ulcerated.  It should be regarded as a pT3b lesion.	MELANOMA, APPROXIMATELY 2.1 MILLIMETERS IN THICKNESS, COMPLETELY BUT NARROWLY EXCISED	173711	1630	\N	\N	13-3619	B	SYNX227	\N	IP1188362	Consolidated_data_final.csv
10831	13-67500AL	27	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	Dr. Schulman Xanthoma Disseminatum	\N	There is a massive polypoid segment of skin with a fibrotic dermis, within which there are aggregates of foamy histiocytes, as well as scattered giant cells, some of them Touton-type and some of them Langhans' type. There are focally dense lymphocytic infiltrates as well.	Five outside slides, S13-3960 / A1-A5, and one corresponding block (A1).	\N	\N	\N	\N	Immunoperoxidase studies performed in our laboratory show that the large pale cells are S100 negative, against an unusual presentation of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). The vacuolated cells are adipophilin positive, consistent with their being lipid-laden histiocytes. There are many admixed factor XIIIa-positive cells, some of them small and dendritic, but others large and more histiocytic-appearing. This mixture of cells is consistent with an adult analogue of juvenile xanthogranuloma, presenting as a particularly large lesion.	XANTHOGRANULOMA	100556	1631	\N	\N	13-67500	A	SYNX228	\N	IP1309505	Consolidated_data_final.csv
10832	13-19205	74	\N	\N	\N	T3b	Primary	\N	\N	\N	\N	\N	\N	172.5	UCSF Wild Type Melanoma	\N	Sections show a broad and poorly circumscribed proliferation of atypical epithelioid melanocytes.  Nests of melanocytes are distributed at irregular intervals along the junctional zone, and are focally confluent.  There are foci in which single melanocytes predominate as well. There are some melanocytes scattered above the basal layer in such areas. The papillary and reticular dermis contains aggregates of similar cells.  The epidermis shows focal ulceration and there is an overlying hemorrhagic scale crust.	Skin segment measuring 1.4 x 1.1 x 0.4 cm, serially sectioned and entirely submitted with five sections. CF/CF	\N	\N	\N	\N	Invasive melanoma abuts the edge of the specimen.  Focal ulceration is also noted.  Based on the 2009 AJCC melanoma staging system, this is a pT3b lesion.	MELANOMA, APPROXIMATELY 2.1 MILLIMETERS IN THICKNESS	173502	1632	\N	\N	13-19205	A	SYNX229	\N	IP1203948	Consolidated_data_final.csv
10833	13-48330	82	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	198.2	UCSF Wild Type Melanoma	\N	Sections show dermal nodule composed of sheets and cords of melanocytes with atypical nuclei. There are scattered mitotic figures as well as areas of pigmentation. A surrounding sparse lymphoplasmacytic infiltrate is also present. A junctional melanocytic proliferation is not present. The dermis is altered by solar elastosis.	Cylindrical skin segment measuring 0.6 cm in diameter and 0.6 cm in thickness. The specimen is filtered, bisected, and entirely submitted. HD/HD	\N	\N	\N	\N	\N	METASTATIC MELANOMA	\N	1633	\N	\N	13-48330	A	SYNX230	\N	IP467959	Consolidated_data_final.csv
10838	13-49600	66	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.9	UCSF Wild Type Melanoma	\N	\N	Block S13-12304:G5.	\N	\N	\N	\N	The histopathological diagnosis was established by pathology report S13-12304 of UCSF Surgical Pathology. No mutations were detected by Sanger sequencing of exon 15 of BRAF, exons 1 and 2 of NRAS, and exons 11, 13, 17, and 18 of KIT, which include the known mutational hotspots of these genes.	MELANOMA, NO MUTATIONS DETECTED IN BRAF, NRAS, AND KIT	666955	1638	\N	\N	13-49600	A	SYNX235	\N	IP61201	Consolidated_data_final.csv
10840	13-67817	71	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	198.2	UCSF Wild Type Melanoma	\N	\N	Blocks S13-8339:A and D.	\N	\N	\N	\N	The histopathological diagnosis was established by pathology report S13-8339 of UCSF Surgical Pathology. I reviewed the sections, and marked them for microdissection. The results of Sanger sequencing are as follows:  BRAF exon 15: wild-type. NRAS exons 1 and 2: wild-type. KIT exons 11, 13, 17 and 18:  wild-type.	METASTATIC MELANOMA, WITH NO DETECTED MUTATIONS OF KIT, BRAF AND NRAS	176788	1640	\N	\N	13-67817	A	SYNX237	\N	IP1199676	Consolidated_data_final.csv
1581	12-11041	9	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	from Swapna	Sections show a nodular pan-dermal and superficial subcutaneous proliferation of fusiform and slightly spindled cells with pale or amphophilic cytoplasm. The cells are distributed interstitially in a sclerotic reticular dermis, and extension into the subjacent subcutis in somewhat infiltrative fashion is noted. There is not maturation with descent in the dermis. In both the dermis and subcutis, a nested or fascicular configuration is apparent. With close scrutiny, occasional cells in mitosis can be found.	One outside slide, P-12-01072:A1-16, and one corresponding block, P-12-01072:A1.	HISTORY OF HURLER'S, STATUS POST BONE MARROW TRANSPLANT, NOW WITH A NODULAR LESION	\N	\N	\N	A SOX-10 immunostain shows diffuse immunopositivity, and this staining result indicates that this atypical proliferation is of melanocytic lineage. With that established, our differential diagnosis included a highly unconventional melanocytic nevus on one hand and spitzoid melanoma on the other. We included array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic copy number anomalies, as per your request. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 1q, 5, 8, and 17q, and loss in chromosomes 9 and 12q was also documented. The documentation of multiple chromosomal aberrations confirms genomic instability, as is stereotypical of melanoma. The aCGH profile that we have documented is incompatible with any type of melanocytic nevus. In summary, the combination of results derived from conventional microscopy coupled with aCGH points to interpretation as melanoma. This deeply invasive, thick tumor is non-ulcerated but demonstrates associated subcutaneous involvement. Further excision remains warranted to ensure that local eradication has been accomplished.	MELANOMA OF 6.5 MM IN THICKNESS, TRANSECTED AT THE SPECIMEN PERIPHERY	173676	646	\N	\N	12-11041	\N	DP-09	PRKC Fused Cases	IP1096857	AirTable blocks_with_IP_info.csv
10881	08-79358	61	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	Ivanka Patient Melanoma	\N	Sections show a well-circumscribed compound proliferation of melanocytes limited to the junctional zone and superficial dermis.  Junctional nests extend beyond the dermal component, bridge rete ridges in some areas, and are accompanied by lamellar fibrosis. There is solar elastosis. There are zones within the epidermis characterized by cytoplasmic vacuolization of keratinocytes, coarse keratohyaline and trichohyaline-like granules, and hyperkeratosis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted in cassette A.	\N	\N	\N	\N	The findings are well within the spectrum of those seen in dysplastic (Clark's) nevi. There are no microscopic features that compel re-excision.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING CLOSE TO THE EDGE AND BASE OF THE SPECIMEN	139522	1641	\N	\N	08-79358	A	SYNX238	\N	IP172751	Consolidated_data_final.csv
10885	09-45509	55	f	\N	1	\N	\N	\N	\N	\N	\N	\N	\N	172.6	Ivanka Patient Melanoma	\N	Sections show sun damaged skin with a proliferation of melanocytes involving the superficial dermis. There are nests, cords and strands of small, round melanocytes that mature with descent, flanking a central focus in which large melanocytes with abundant, pale cytoplasm and dusty appearing melanin and large, pleomorphic vesicular nuclei are present in fibrotic stroma, with incomplete maturation toward the base of the lesion.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted.	\N	\N	\N	\N	The nevus extends to a peripheral edge, and the melanoma nearly to the base of the specimen. Histopathologic features of possible prognostic importance include:  Level: III Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: low (one mitotic figure identified; 1/mm2)* Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent  * some studies have found that melanomas in which a mitotic figure is present in the dermis have a less favorable prognosis than do ones with without this finding.	MELANOMA, 0.9 MM  IN THICKNESS, ARISING IN A PRE-EXISTENT MELANOCYTIC NEVUS	173688	1642	\N	\N	09-45509	A	SYNX239	\N	IP846272	Consolidated_data_final.csv
1693	13-9916	82	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	None	Block DL13-9684:A (12-3263/PS12-4904:A), received 2-12-13.	MELANOMA SUBMITTED FOR BRAF & NRAS MUTATION ANALYSIS	\N	\N	\N	The histopathological diagnosis was established by pathology report PS12-4904 of Mills Peninsula Health Services. Sanger sequencing of exon 15 of BRAF and exons 1 and 2 of NRAS, which include the known mutational hotspots of these genes, was performed. No mutations were detected.	MELANOMA	173604	1795	\N	\N	13-9916	\N	SYNAT496	Wild Type Melanoma	IP1194427	AirTable blocks_with_IP_info.csv
1491	11-44609F	91	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.3	\N	\N	Sections show a proliferation of spindled melanocytes with hyperchromatic nuclei, positioned between markedly thickened collagen bundles in the dermis in broad areas. Some multinucleate melanocytes are present. The cellularity of the lesion diminishes toward the deep reticular dermis. To the side of these changes, melanocytes with enlarged nuclei are present singly and in small nests in the basal layer of the epidermis in a poorly circumscribed pattern. Atypical keratinocytes thicken the epidermis, forming buds that protrude into the papillary dermis but mature toward a parakeratotic surface in diverse other foci. There is marked solar elastosis.	Ellipse, 5.7 x 2.5 x 0.8 cm, including a central 2.5 x 1.3 cm white-tan rough area and a marginal 1.2 x 0.7 cm pale-white area adjacent to one tip. The tip with adjacent pale-white area is placed to the left. With the far margin inked blue and the near margin inked yellow, the specimen is serially sectioned perpendicular to the long axis from left to right tips and entirely submitted with three  sections in cassette A, two sections each in cassettes B through H, and three sections each in cassettes I and J.	DS11-39631, RE-EXCISION OF MELANOMA	\N	\N	\N	An extensive area of melanoma in situ is present. The invasive melanoma is essentially entirely desmoplastic. Some studies have suggested that pure desmoplastic melanomas have a more favorable prognosis, vis a vis distant metastasis, especially to sentinel nodes than do melanomas in which only part of the invasive component is desmoplastic. Some perineural invasion is present, within 3 mm of the yellow inked margin in slide F (near 9 o'clock, with your suture designated as 12 o'clock). There is melanoma in situ and within 1 mm of the blue inked margin in slides F and G (near 3 o'clock, with your suture designated as 12 o'clock). Extensive solar keratosis is also evident. Several old scars are present in the dermis as well, one accounting for the pale area in the gross description.  Reference:  George E, McClain SE, Slingluff CL, Polissar NL, Patterson JW. Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis. J Cutan Pathol. 2009 Apr;36(4):425-32.	DESMOPLASTIC MELANOMA, 4.8 MM. IN THICKNESS	173316	1752	\N	\N	11-44609	F	SYNAT497	Wild Type Melanoma	IP1029070	AirTable blocks_with_IP_info.csv
2381	18-136800B	52	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound melanocytic proliferation, composed largely of nests arrayed along the epidermal-dermal junction, with extension lateral to papillary dermal clusters of similar cells.  There is subepithelial fibrosis, some of which is lamellar in configuration.	Skin segment measuring 1.5 x 0.9 x 0.1 cm, quadrisected and entirely submitted in B. KC/KC	A) 6 MM DARK LENTIGINOUS NEVUS; ATYPICAL NEVUS, R/O MM, B) 1.1 CM PINK BROWN LENTIGINOUS NEVUS; ATYPICAL NEVUS, R/O MM	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	101532	2080	\N	\N	18-136800	B	DN-136	Dysplastic Nevi	IP1417678	AirTable blocks_with_IP_info.csv
2236	17-112365A	47	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show skin with hyperpigmentation of the basal layer.  There are slightly elongated, rounded rete ridges. There are scattered melanophages in a band-like array in the papillary dermis. There is solar elastosis of the subjacent dermis.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted in A. KC/KC	A-B) 4 MM BROWN MACULE; POSS ATYPICAL NEVUS	\N	\N	Scraping	\N	SOLAR LENTIGO WITH POST-INFLAMMATORY PIGMENTARY ALTERATION	528522	2292	\N	\N	17-112365	A	LN-040	Lentiginous Nevi 	IP1842838	AirTable blocks_with_IP_info.csv
2454	19-43600B	78	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	216.5	\N	GNAQ	The microscopic features are similar to those of (A), with the addition of a few junctional nests.	Three skin fragments measuring 0.7 x 0.6 x 0.1 cm in aggregate, one is bisected and all entirely submitted in B. CF/CF	A) 5 MM; R/O ATYP, B) 6 MM; R/O ATYP	\N	\N	FFPE	\N	COMBINED MELANOCYTIC NEVUS, WITH ORDINARY AND BLUE NEVUS ELEMENTS	111501	1731	\N	\N	19-43600	B	SN-13	Sclerotic Nevi	IP1927911	AirTable blocks_with_IP_info.csv
2413	19-7357B	25	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 1.0 x 0.8 x 0.1 cm, trisected and entirely submitted with one fragment in B. CF/CF	A-B) R/O DN	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	173502	2298	\N	\N	19-7357	B	DN-144	Dysplastic Nevi	IP2011413	AirTable blocks_with_IP_info.csv
2444	19-37607D	72	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with a flattish profile, the junctional component of which is composed of single and nested melanocytes arrayed along the sides and bases of elongated rete, above a papillary dermis expanded by fibrosis.  There is a central dermal component of small melanocytes near the epidermal-dermal junction.	Skin segment measuring 1.0 x 0.7 x 0.1 cm, trisected and entirely submitted in D. KC/KC	A) 7 MM X 5 MM DARK BROWN IRREGULAR MACULE ADJACENT TO SK; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, B) 2.5 CM X 2 CM DARK BROWN HYPERKERATOTIC PLAQUE; PROBABLE SK, R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, C) 4 MM X 4 MM VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, D) 5 MM X 6 MM TAN BROWN VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, E) 4 MM X 4 MM DARK BROWN VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, F) 3 X 4 MM TAN BROWN VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173530	2011	\N	\N	19-37607	D	DN-162	Dysplastic Nevi	IP2041843	AirTable blocks_with_IP_info.csv
2446	19-37607F	72	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in F. KC/KC	A) 7 MM X 5 MM DARK BROWN IRREGULAR MACULE ADJACENT TO SK; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, B) 2.5 CM X 2 CM DARK BROWN HYPERKERATOTIC PLAQUE; PROBABLE SK, R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, C) 4 MM X 4 MM VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, D) 5 MM X 6 MM TAN BROWN VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, E) 4 MM X 4 MM DARK BROWN VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, F) 3 X 4 MM TAN BROWN VARIEGATED MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173529	2120	\N	\N	19-37607	F	DN-157	Dysplastic Nevi	IP2041843	AirTable blocks_with_IP_info.csv
2760	21-112195D	65	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18356	216.6	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion.	Skin segment measuring 1.0 x 0.7 x 0.1 cm, trisected and entirely submitted in D. KB/KB	A) 1 CM, WAXY; NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA, B-C) 6 MM, IRREGULAR BORDER AND COLOR; NEOPLASM OF UNCERTAIN BEHAVIOR VS. AMH, D) 7 MM, IRREGULAR BORDER AND COLOR; NEOPLASM OF UNCERTAIN BEHAVIOR VS. AMH	\N	\N	FFPE	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	102611	2352	\N	\N	21-112195	D	LN-087	Lentiginous Nevi 	IP2375313	AirTable blocks_with_IP_info.csv
1921	16-09944-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-37	https://64.54.108.121/app/WebViewer/view/image/36082	\N	\N	\N	\N	\N	\N	\N	H16-09944 (left cheek, in situ) #2	FFPE	\N	\N	\N	399	\N	\N	None	\N	CME-097	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2877	23-4594	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	414	\N	\N	23-4594	\N	DMS-002	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
1288	07-55184	55	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a domed and partially polypoid proliferation of melanocytes with a biphasic pattern. One population of melanocytes consists of relatively small cells with scant or amphophilic cytoplasm, arrayed as dermal nests, cords, and syncytia. A small number of these melanocytes have more abundant vacuolated cytoplasm and are multinucleate. The second population consists of large epithelioid melanocytes with enlarged nuclei and ample eosinophilic cytoplasm, arrayed singly and in small clusters, partially commingling with the first population. There is permeative lymphohistiocytic infiltrate, mostly associated with the large epithelioid melanocytes. Subsequently, in three additional slides received, occasional dermal melanocytes in mitosis are evident.	Two outside slides, S07-26466 (MSUR-07-03218).  Three additional slides received 09/05/07.  Three additional immunoperoxidase stained slides, IP07-3648 (S07-26466) received 9/11/07. One corresponding block (M07-3218) received 3-23-15.	UCSF MELANOMA CLINIC PATIENT	\N	\N	\N	Dr. Denianke, we have completed comparative genomic hybridization (CGH) of this 2007 specimen, and results will incorporated into the final reporting of other reports for this patient. Please refer to reports 15-16907 and 15-27070 for additional information. My addendum commentary regarding this specimen, from 2007, follows below. ADDENDUM, September 14, 2007: After my original interpretation of this case as a combined melanocytic nevus, I received 3 additional slides of this tissue from Dr. Sundram. The new slides highlight occasional dermal melanocytes in mitosis. I also received HMB-45 and Ki-67 stains completed at Stanford Pathology. The HMB-45 stain is completely non-reactive, while the Ki-67 stain shows scattered positively-labeled nuclei, with a low overall labeling rate. I interpret the Ki-67 immunostaining results as supportive of a benign diagnosis and I continue to favor a diagnosis of combined melanocytic nevus (with the commingling of both conventional melanocytic nevus and epithelioid Spitz's nevus).  Dr. Philip LeBoit reviewed this case independently (including review of the 3 additional slides and the immunoperoxidase stains) and came to an identical diagnosis. We do not believe this lesion should be considered to represent melanoma.	MELANOCYTIC TUMOR, HISTORICALLY INTERPRETED AS A COMBINED MELANOCYTIC NEVUS	173406	2242	\N	\N	07-55184	\N	DP-40	CGH Validation	IP677717	AirTable blocks_with_IP_info.csv
11198	13-48020	66	\N	\N	\N	T1a	Primary	\N	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent fibrotic dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Ellipse measuring 1.4 x 1.3 x 0.3 cm, including a central 1.1 x 1.0 cm variegated brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with five sections. HD/HD	\N	\N	\N	\N	Melanoma in situ is present < 2 millimeters from the edge of the specimen.  This is a non-ulcerated melanoma and no dermal mitotic figures are noted.  Based on the 2009 AJCC melanoma staging system, this is a pT1a lesion.  I have reviewed this case with Dr. McCalmont who concurs with the diagnosis.	MELANOMA, 0.75 MILLIMETERS IN THICKNESS ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	273588	1657	\N	\N	13-48020	A	SYNX254	\N	IP1289322	Consolidated_data_final.csv
11200	14-13499	84	\N	\N	\N	T1a	Primary	\N	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  Some bridging of rete is noted.  There are a few clusters similar melanocytes in the subjacent fibrotic dermis. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 1.1 x 0.7 x 0.1 cm, trisected and entirely submitted. PL/PL	\N	\N	\N	\N	Melanoma in situ is present a fraction of a millimeter from the edge of the specimen.  I have examined additional sections and a Melan-A stain.  The immunostain highlights areas of increased confluence of junctional melanocytes as well as scattered melanocytes above the dermo-epidermal junction.  Within the fibrotic dermis a few nests of melanocytes are also present.  There is also a small population of bland dermal melanocytes that represent a melanocytic nevus.  This is a non-ulcerated melanoma and no dermal mitotic figures are noted.  Based on the 2009 AJCC melanoma staging system, this is a pT1a lesion.	MELANOMA, 0.62 MILLIMETERS IN THICKNESS ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	273588	1658	\N	\N	14-13499	A	SYNX255	\N	IP1363420	Consolidated_data_final.csv
11205	14-22939	62	f	\N	\N	T1b	Primary	superficial spreading	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a compound melanocytic proliferation with a biphasic pattern.  One population consists of melanocytes, most of which have atypical nuclei, that are irregularly distributed along the dermal-epidermal junction, with some melanocytes present above the basal zone.  Similar melanocytes are present in the subjacent dermis and mitotic figures are readily identified.  The second population consists of melanocytes with cytologically bland nuclei (melanocytic nevus) which mature with descent.  There is an infiltrate of lymphocytes and melanophages.	Skin segment, 1.1 x 0.9 x 0.1 cm, quadrisected, and entirely submitted. HD/HD	\N	\N	\N	\N	Diagnostic features of note include the following. Definitive assessment of prognostic features should be deferred to the excision specimen, although I suspect the thickest areas are sampled herein. Because mitotic figures are evident in number in the dermal component, this lesion is staged as T1b. Procedure: shave biopsy Microscopic tumor type: superficial spreading Breslow thickness: 0.7 mm Ulceration: none Margins, peripheral and deep: involved Mitotic index: 4/square mm Microsatellitosis: cannot assess Vascular invasion: not evident Perineural invasion: not evident Regression: not evident Pathologic Staging (pTNM): pT1b pNX	MELANOMA, 0.7 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING TO THE EDGE AND BASE OF THE SPECIMEN	173601	1660	\N	\N	14-22939	A	SYNX257	\N	IP1372863	Consolidated_data_final.csv
2211	17-94254	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	465	\N	\N	17-94254	\N	DMS-053	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2802	22-46448	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	466	\N	\N	22-46448	\N	DMS-054	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
11202	13-64515B	57	f	\N	1	T2a	Primary	 Superficial spreading	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a compound melanocytic proliferation with a biphasic pattern.  One population is composed of a proliferation of melanocytes arranged in an asymmetrical and poorly circumscribed fashion both along the dermo-epidermal junction and within the dermis. Many of these melanocytes are spindled and heavily pigmented. Single melanocytes predominate over nests in some areas along the dermo-epidermal junction and melanocytes track down adnexa as single cells. There are nests, cords and strands of similar melanocytes in the underlying dermis, where the size of the melanocytes generally does not diminish with descent. There is also a population of darker-staining melanocytes that diminish in size with descent into the dermis. Both an infundibular follicular cyst and a broad dermal scar are apparent as well.	Elliptical excision, 3.8 x 1.3 x 0.7 cm, including a central 1.3 x 0.8 cm raised brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and submitted with six sections each in A and B. Tips reserved. CF/CF	\N	\N	\N	\N	Part of this proliferation probably represents a melanocytic nevus, and thus the melanoma likely arose within a melanocytic nevus. Is there a history of a long-standing pigmented lesion at this site with recent change? Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a modest proliferation rate among the dermal melanocytes. A broad dermal scar is present within this specimen as well. The scar is in close proximity to an infundibular follicular cyst, and thus it is possible that the scar arose due to cyst rupture. However, it is also possible that the scar is due to a former procedure at this site. Is there a history of a former biopsy? Diagnostic features of note include:  Procedure: Excisional biopsy Tumor site: Right upper back Microscopic tumor type:  Superficial spreading Breslow thickness: 1.2 millimeters Ulceration: not present Margins, peripheral and deep: The melanoma is located within approximately 2 millimeters of the lateral margins and 5 millimeters of the deep margin Mitotic index: < 1/mm2 Microsatellitosis: not identified Vascular invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT2aNxMx  Given the proximity of the melanoma to the lateral inked margins, further treatment at this site is warranted. I have also shared this case with my colleague, Dr. Philip LeBoit, who agrees with this assessment.	MELANOMA, 1.2 MILLIMETERS IN THICKNESS, EXTENDING TO WITHIN APPROXIMATELY 2 MILLIMETERS OF THE LATERAL INKED MARGINS	139522	1659	\N	\N	13-64515	B	SYNX256	\N	IP1292049	Consolidated_data_final.csv
11061	14-18	73	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	707.9	AGL Sample	13 Cycle Post Hybridization LM-PCR	Sections show a zone of ulceration, with necrosis and a fibrinopurulent exudate, as well as an adjacent proliferation of small vessels arrayed in inflamed stroma. There is hyperkeratotic debris with neutrophils and bacteria.	One hematoxylin and eosin-stained section prepared from outside block labeled 13-11325.	\N	\N	\N	\N	Thank you for sending the clinical image of this patient's lesion. I do not see evidence of a malignancy in this biopsy. There are some bacteria, but they are superficial and likely represent secondary impetiginization rather than a primary infection. The clinical and histopathologic findings seem to fit closest with those seen in erosive pustular dermatosis of the scalp.	ULCERATION WITH HYPERKERATOSIS AND GRANULATION TISSUE	100432	1653	\N	\N	14-18	A	SYNX250	\N	IP703498	Consolidated_data_final.csv
11062	14-19	70	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.3	AGL Sample	13 Cycle Post Hybridization LM-PCR	Sections show basilar pigmentation with prominent, enlarged single melanocytes along the dermo-epidermal junction. There is solar elastosis.	One hematoxylin and eosin-stained section prepared from outside block labeled 13-11407.	\N	\N	\N	\N	Level sections and a Sox-10 stain show a subtle proliferation of melanocytes with atypical nuclei above elastosis. While the melanocytic density is not very high, the findings are more consistent with early melanoma in situ than a solar lentigo. The proliferation extends to the specimen periphery. Additional treatment to ensure complete removal would be prudent. I have shared this case with my colleague Dr. Timothy McCalmont who agrees with this interpretation.	ATYPICAL INTRAEPIDERMAL MELANOCYTIC PROLIFERATION, CONSISTENT WITH SUBTLE MELANOMA IN SITU	173305	1654	\N	\N	14-19	A	SYNX251	\N	IP1349938	Consolidated_data_final.csv
11063	14-21	65	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.7	AGL Sample	13 Cycle Post Hybridization LM-PCR	An excisional specimen demonstrates a compound proliferation of melanocytes that is subtly biphasic in configuration. Centrally, hypocellular sclerotic scarring is noted, and this stems from prior biopsies in this vicinity. Above this, there is a broad and badly circumscribed intraepidermal population of enlarged melanocytes. These cells are distributed singly and in small nests in lentiginous fashion along the junction, and prominent scatter of melanocytes above the junction is also noted. In various areas in the dermis below this, maturing nests, cords, and small syncytia of smaller melanocytes are noted.	Eight outside slides, VS-13-8199 1A-1E.	\N	\N	\N	\N	I believe there are two populations of melanocytes within this specimen, with the badly circumscribed intraepidermal population of melanocytes representing melanoma in situ and with the smaller subjacent dermal melanocytes representing persistent melanocytic nevus. The component of melanoma in situ appears narrowly excised in the available planes of section. I do believe that reexcision of this site would be appropriate.	MELANOMA IN SITU, ARISING IN ASSOCIATION WITH A PERSISTENT ACRAL MELANOCYTIC NEVUS	173788	1655	\N	\N	14-21	A	SYNX252	\N	IP1349940	Consolidated_data_final.csv
2515	19Rig750007.02.05.03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 2 Mel in Nevus	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	266	\N	\N	None	\N	CM-24	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
10682	13-159	17	\N	\N	\N	T3a	Primary	\N	\N	\N	\N	\N	\N	172.7	Iwei 7Q Gain	CGH13-016 	Sections show a dome-shaped segment of acral skin in which there is a compound proliferation of melanocytes, some of which are large and epithelioid, and the junctional component of which is arrayed with the lowermost sections of an epithelium that is slightly acanthotic and hyperkeratotic. Many of the lesional cells contain large nucleoli. In some areas within the dermis, the lesional cells are configured as confluence sheets without significant intervening stroma. The size of the melanocytes does not diminish with descent into the dermis.	Cylindrical skin segment, 0.9 cm in diameter and 0.5 cm in thickness, trisected and totally submitted.   CF/CF	\N	\N	\N	\N	Thank you also for informing me that the lesion has been present on the patient since age four and has grown steadily with the patient. However, the patient recently noted a more rapid rate of growth. My initial differential diagnosis included an unusual nevus with Spitzoid features and melanoma. To further evaluate for this differential diagnosis, I performed comparative genomic hybridization on this specimen. This is a molecular technique that evaluates for the presence of chromosomal gains or losses. It is based on the presence of chromosomal gains and losses in about 95% of melanomas, but with the exception of a gain of 11p, a lack of them in Spitz's nevi.  The comparative genomic hybridization has now been completed and it shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi.  In particular there is a loss of chromosome 6q, a gain of chromosome 7q, both a loss and a gain of chromosome 12p and a gain of chromosome 18q. The presence of multiple gains and losses supports the diagnosis of melanoma.  With regard to staging, the melanoma is between 2-4 millimeters in thickness and is not ulcerated. Therefore it should be classified as pT3a per the 2009 revision of the AJCC staging system for melanoma.  My colleague, Dr. Timothy McCalmont, also reviewed these sections and agrees with this diagnosis and assessment.	MELANOMA, 3.1 MILLIMETERS IN THICKNESS, EXTENDING TO THE TISSUE EDGES	101721	1608	\N	\N	13-159	A	SYNX205	\N	IP1183551	Consolidated_data_final.csv
10683	12-43016	72	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	Iwei Translocation	CGH12-163 	There is a somewhat dome-shaped segment of skin that extends to the level of the superficial reticular dermis. There are large, compactly arranged nests of plump oval to slightly spindled melanocytes both at the junction and in the subjacent, fibrotic dermis. These cells have relatively monomorphous nuclei, diffuse hyperchromasia, and relatively abundant pale, somewhat fibrillar-appearing cytoplasm. There are areas in which some maturation and dispersion with descent appear to be present. The accompanying immunoperoxidase-stained sections show a very low proliferative rate amongst the dermal melanocytes with a Ki-67/Melan-A double stain, and HMB45 staining is limited to the junctional zone.	Seven outside slides, SH-12-22523:A.1-1 and A1, and one corresponding block, SH12-22523:A1.	\N	\N	\N	\N	The differential diagnosis included both an unusual nevus (probably the upper part of a superficial congenital nevus) and nevoid melanoma. The latter diagnosis is raised by the presence of very large nests, and the somewhat unusual cytologic features. Comparative genomic hybridization shows losses involving parts of chromosome 15 (discrete areas on both the short and long arms, but not the entire chromosome). This chromosome is not commonly lost in melanoma, and the meaning of this finding is not clear. I believe that the best interpretation is as a partially transformed lesion that is not diagnostic of melanoma, but should be completely excised.	COMPOUND PROLIFERATION OF MELANOCYTES WITH UNUSUAL FEATURES	321300	1609	\N	\N	12-43016	A	SYNX206	\N	IP1128829	Consolidated_data_final.csv
2704	21-15959	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-23	http://64.54.108.121/eSlideTray.php?ImageIds=32793	\N	\N	5839734	\N	\N	\N	\N	Skin, thigh, lateral, right, tumor biopsy, melanoma in situ, at least (see description)	FFPE	\N	\N	\N	328	\N	\N	21-15959	\N	CME-026	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2706	21-17351	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-24	http://64.54.108.121/eSlideTray.php?ImageIds=32794	\N	\N	4085044	\N	\N	\N	\N	Skin, forearm, left, incisional biopsy, superficial spreading melanoma	FFPE	\N	\N	\N	329	\N	\N	21-17351	\N	CME-027	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2613	20-24373A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-24	http://64.54.108.121/eSlideTray.php?ImageIds=32795	\N	\N	6478917	\N	\N	\N	\N	Skin,thigh,left lateral,excision,nodular melanoma 	FFPE	\N	\N	\N	330	\N	\N	20-24373	A1	CME-028	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1947	16-37564A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-26	http://64.54.108.121/eSlideTray.php?ImageIds=32796	\N	\N	2086921	\N	\N	\N	\N	Skin, scalp, frontal, right, wide excision, melanoma in situ	FFPE	\N	\N	\N	331	\N	\N	16-37564	A1	CME-029	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2313	18-31426A	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-26	http://64.54.108.121/eSlideTray.php?ImageIds=32797	\N	\N	6583945	\N	\N	\N	\N	Skin, scalp, frontal, left, main lesion, biopsy, melanoma 	FFPE	\N	\N	\N	332	\N	\N	18-31426	A	CME-030	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2712	21-21081	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-23	http://64.54.108.121/eSlideTray.php?ImageIds=32798	\N	\N	3631303	\N	\N	\N	\N	Skin, forehead, left, biopsy, lentigo maligna melanoma	FFPE	\N	\N	\N	333	\N	\N	21-21081	\N	CME-031	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2795	22-34951	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-23	http://64.54.108.121/eSlideTray.php?ImageIds=32799	\N	\N	3902497	\N	\N	\N	\N	Skin, buttock, right, biopsy, superficial spreading melanoma	FFPE	\N	\N	\N	334	\N	\N	22-34951	\N	CME-032	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2788	22-21031A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-23	http://64.54.108.121/eSlideTray.php?ImageIds=32800	\N	\N	6336181	\N	\N	\N	\N	Skin, chest left, wide excision, mixed superficial spreading and desmoplastic melanoma	FFPE	\N	\N	\N	335	\N	\N	22-21031	A1	CME-033	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2791	22-25709C1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-23	http://64.54.108.121/eSlideTray.php?ImageIds=32801	\N	\N	5489820	\N	\N	\N	\N	Skin, labia majora, tumor biopsy, melanoma	FFPE	\N	\N	\N	336	\N	\N	22-25709	C1	CME-034	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2897	23-09618	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-23	http://64.54.108.121/eSlideTray.php?ImageIds=32802	\N	\N	3396383	\N	\N	\N	\N	Skin, back, right side, excision, superficial spreading melanoma	FFPE	\N	\N	\N	337	\N	\N	23-9618	\N	CME-035	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2870	23-02692-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-27	https://64.54.108.121/app/WebViewer/view/image/35999	\N	\N	\N	\N	\N	\N	\N	H23-02692 #3 (lower right leg)	FFPE	\N	\N	\N	338	\N	\N	None	\N	CME-036	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2876	23-03529-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-27	https://64.54.108.121/app/WebViewer/view/image/36000	\N	\N	\N	\N	\N	\N	\N	H23-03529 #3 (left cheek, in situ)	FFPE	\N	\N	\N	339	\N	\N	None	\N	CME-037	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2881	23-04707-7	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-27	https://64.54.108.121/app/WebViewer/view/image/36001	\N	\N	\N	\N	\N	\N	\N	H23-04707 #7 (lower right leg)	FFPE	\N	\N	\N	340	\N	\N	None	\N	CME-038	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2884	23-05091-4	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-27	https://64.54.108.121/app/WebViewer/view/image/36002	\N	\N	\N	\N	\N	\N	\N	H23-05091 #4 (right cheek)	FFPE	\N	\N	\N	341	\N	\N	None	\N	CME-039	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2880	23-04628-5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-27	https://64.54.108.121/app/WebViewer/view/image/36003	\N	\N	\N	\N	\N	\N	\N	H23-04628 #5 (left cheek)	FFPE	\N	\N	\N	342	\N	\N	None	\N	CME-040	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2887	23-05782-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-27	https://64.54.108.121/app/WebViewer/view/image/36004	\N	\N	\N	\N	\N	\N	\N	H23-05782 #2 (nose, in situ)	FFPE	\N	\N	\N	343	\N	\N	None	\N	CME-041	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2888	23-06001-12	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-27	https://64.54.108.121/app/WebViewer/view/image/36005	\N	\N	\N	\N	\N	\N	\N	H23-06001 #12 (upper right thigh)	FFPE	\N	\N	\N	344	\N	\N	None	\N	CME-042	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2892	23-07186-13	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-27	https://64.54.108.121/app/WebViewer/view/image/36006	\N	\N	\N	\N	\N	\N	\N	H23-07186 #13 (lower left leg)	FFPE	\N	\N	\N	345	\N	\N	None	\N	CME-043	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2283	18-02303-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-28	https://64.54.108.121/app/WebViewer/view/image/36009	\N	\N	\N	\N	\N	\N	\N	H18-02303 #1 (left shoulder, in situ)	FFPE	\N	\N	\N	347	\N	\N	None	\N	CME-045	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2285	18-08429-4	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-28	https://64.54.108.121/app/WebViewer/view/image/36010	\N	\N	\N	\N	\N	\N	\N	H18-08429 #4 (right cheek)	FFPE	\N	\N	\N	348	\N	\N	None	\N	CME-046	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1048	02-8746B	49	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.5	\N	\N	Sections show a broad, asymmetrical compound proliferation of melanocytes featuring a broad area in which the papillary dermis is strikingly fibrotic, with a diminished rete ridge pattern.  Compact nests of relatively small melanocytes are present throughout this zone, and several contain mitotic figures.  At the other side of the lesion is a dome shaped area with spindled melanocytes superficially and small, round ones in the deep portion.  Again, some superficial melanocytes are in mitosis.  Maturation with descent appears to be present in this area.  Melanocytes at the base of this zone are present as strands between reticular dermal collagen bundles or around small vessels.  A small focus of pagetoid spread is evident at one edge, with not fibrosis underneath it (as would be present in a persistent nevus).	Ellipse measuring 3.2 x 1.2 x 0.4 cm including central dark brown and\nbrown 1.3 x 1.1 cm pigmented area.  With margins inked blue, five\ncentral representative sections are submitted in cassette A and four\nsections in cassette B, tips returned to container.	DYSPLASTIC NEVUS; MELANOMA	\N	\N	Scraping	3/12/2002:  Per my telephone conversation with Dr. Denny Tuffanelli yesterday, there is no history of a previous biopsy or trauma.  In spending more time with these sections today and yesterday, and in reviewing them with my associate, Dr. Timothy McCalmont, I think that this is an unusual melanoma.  There may be evidence of a pre-existent congenital nevus at the base of the specimen, and I did not measure the cells that I believe represent the nevus.  The fibrosis may reflect regression.  I have updated the microscopic description below to incorporate new observations.   3/4/2002:  Some features suggest that this is a persistent nevus, in which the papillary dermis has been altered by a shave biopsy or trauma.  We have a record of a previous nevus from the torso but are unsure as to whether it is from the same site.  Could you kindly inform us whether this is the case, and if not, whether there could be a previous biopsy at this site? If there is none in your files, could you ask the patient?	MELANOMA, 1.05 MM. IN THICKNESS	173570	186	\N	\N	02-8746	B	CCR-206	California Cancer Registry	IP172758	AirTable blocks_with_IP_info.csv
2403	19-05094-9	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-30	https://64.54.108.121/app/WebViewer/view/image/36023	\N	\N	\N	\N	\N	\N	\N	19-05094-9 (right cheek)	FFPE	\N	\N	\N	355	\N	\N	None	\N	CME-053	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2406	19-05307-8	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-30	https://64.54.108.121/app/WebViewer/view/image/36024	\N	\N	\N	\N	\N	\N	\N	H19-05307 #8 (right forearm, in situ)	FFPE	\N	\N	\N	356	\N	\N	None	\N	CME-054	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2422	19-09700-4	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-30	https://64.54.108.121/app/WebViewer/view/image/36027	\N	\N	\N	\N	\N	\N	\N	H19-09700 (mid-abdomen) #4	FFPE	\N	\N	\N	358	\N	\N	None	\N	CME-056	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2578	20-01244-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-30	https://64.54.108.121/app/WebViewer/view/image/36028	\N	\N	\N	\N	\N	\N	\N	H20-01244 (right cheek, in situ) #2	FFPE	\N	\N	\N	359	\N	\N	None	\N	CME-057	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2575	20-00548-10	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-31	https://64.54.108.121/app/WebViewer/view/image/36029	\N	\N	\N	\N	\N	\N	\N	H20-00548 (right cheek) #10	FFPE	\N	\N	\N	360	\N	\N	None	\N	CME-058	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2579	20-01665-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-31	https://64.54.108.121/app/WebViewer/view/image/36030	\N	\N	\N	\N	\N	\N	\N	H20-01665 (lower right eyelid) #3	FFPE	\N	\N	\N	361	\N	\N	None	\N	CME-059	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2583	20-04152-8	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-31	https://64.54.108.121/app/WebViewer/view/image/36033	\N	\N	\N	\N	\N	\N	\N	H20-04152 (right cheek) #8	FFPE	\N	\N	\N	363	\N	\N	None	\N	CME-061	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2592	20-08679-5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-32	https://64.54.108.121/app/WebViewer/view/image/36037	\N	\N	\N	\N	\N	\N	\N	H20-08679 (lower left leg, in situ) #5	FFPE	\N	\N	\N	365	\N	\N	None	\N	CME-063	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2587	20-06242	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-32	https://64.54.108.121/app/WebViewer/view/image/36038	\N	\N	\N	\N	\N	\N	\N	H20-06242 (back)	FFPE	\N	\N	\N	366	\N	\N	20-6242	\N	CME-064	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2688	21-06796-5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-32	https://64.54.108.121/app/WebViewer/view/image/36044	\N	\N	\N	\N	\N	\N	\N	H21-06796 (right upper back) #5	FFPE	\N	\N	\N	369	\N	\N	None	\N	CME-067	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2692	21-08944-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-33	https://64.54.108.121/app/WebViewer/view/image/36045	\N	\N	\N	\N	\N	\N	\N	H21-08944 (left cheek) #3	FFPE	\N	\N	\N	370	\N	\N	None	\N	CME-068	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2768	22-00892-16	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-34	https://64.54.108.121/app/WebViewer/view/image/36053	\N	\N	\N	\N	\N	\N	\N	H22-00892 (right head) #16	FFPE	\N	\N	\N	374	\N	\N	None	\N	CME-072	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2868	23-01133	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-34	https://64.54.108.121/app/WebViewer/view/image/36060	\N	\N	\N	\N	\N	\N	\N	H23-01133 (right cheek)	FFPE	\N	\N	\N	379	\N	\N	23-1133	\N	CME-077	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2869	23-01329-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-35	https://64.54.108.121/app/WebViewer/view/image/36061	\N	\N	\N	\N	\N	\N	\N	H23-01329 (lower right leg) #1	FFPE	\N	\N	\N	380	\N	\N	None	\N	CME-078	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1834	15-05771-4	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-35	https://64.54.108.121/app/WebViewer/view/image/36062	\N	\N	\N	\N	\N	\N	\N	H15-05771 #4 (upper left arm)	FFPE	\N	\N	\N	381	\N	\N	None	\N	CME-079	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1835	15-06395-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-35	https://64.54.108.121/app/WebViewer/view/image/36063	\N	\N	\N	\N	\N	\N	\N	H15-06395 #3 (back)	FFPE	\N	\N	\N	382	\N	\N	None	\N	CME-080	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1837	15-07035-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-35	https://64.54.108.121/app/WebViewer/view/image/36064	\N	\N	\N	\N	\N	\N	\N	H15-07035 #1 (lower left leg)	FFPE	\N	\N	\N	383	\N	\N	None	\N	CME-081	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1838	15-08075-5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-35	https://64.54.108.121/app/WebViewer/view/image/36065	\N	\N	\N	\N	\N	\N	\N	H15-08075 #5 (left buttock)	FFPE	\N	\N	\N	384	\N	\N	None	\N	CME-082	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1839	15-08126-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-35	https://64.54.108.121/app/WebViewer/view/image/36066	\N	\N	\N	\N	\N	\N	\N	H15-08126 #3 (left back)	FFPE	\N	\N	\N	385	\N	\N	None	\N	CME-083	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1841	15-08727-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-35	https://64.54.108.121/app/WebViewer/view/image/36067	\N	\N	\N	\N	\N	\N	\N	H15-08727 #2 (right flank)	FFPE	\N	\N	\N	386	\N	\N	None	\N	CME-084	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1843	15-10294-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-35	https://64.54.108.121/app/WebViewer/view/image/36068	\N	\N	\N	\N	\N	\N	\N	H15-10294 #1 (lower left abdomen)	FFPE	\N	\N	\N	387	\N	\N	None	\N	CME-085	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1912	16-05265-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-36	https://64.54.108.121/app/WebViewer/view/image/36074	\N	\N	\N	\N	\N	\N	\N	H16-05265 #2 (left hip)	FFPE	\N	\N	\N	392	\N	\N	None	\N	CME-090	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1913	16-05548-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-36	https://64.54.108.121/app/WebViewer/view/image/36075	\N	\N	\N	\N	\N	\N	\N	H16-05548 #2 (right cheek)	FFPE	\N	\N	\N	393	\N	\N	None	\N	CME-091	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1915	16-06126-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-37	https://64.54.108.121/app/WebViewer/view/image/36078	\N	\N	\N	\N	\N	\N	\N	H16-06126 #2 (left cheek)	FFPE	\N	\N	\N	395	\N	\N	None	\N	CME-093	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1916	16-06348-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-37	https://64.54.108.121/app/WebViewer/view/image/36079	\N	\N	\N	\N	\N	\N	\N	H16-06348 #2 (lower right leg)	FFPE	\N	\N	\N	396	\N	\N	None	\N	CME-094	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1917	16-06590-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-37	https://64.54.108.121/app/WebViewer/view/image/36080	\N	\N	\N	\N	\N	\N	\N	H16-06590 #2 (left back)	FFPE	\N	\N	\N	397	\N	\N	None	\N	CME-095	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1918	16-06994-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-37	https://64.54.108.121/app/WebViewer/view/image/36081	\N	\N	\N	\N	\N	\N	\N	H16-06994 #1 (left hip)	FFPE	\N	\N	\N	398	\N	\N	None	\N	CME-096	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2050	17-10231-5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-39	https://64.54.108.121/app/WebViewer/view/image/36095	\N	\N	\N	\N	\N	\N	\N	H17-10231 #5 (right cheek)	FFPE	\N	\N	\N	410	\N	\N	None	\N	CME-108	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2878	23-4595	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	415	\N	\N	23-4595	\N	DMS-003	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2979	96-18458A	59	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1297	172.4	\N	\N	Sections show nested and solitary melanocytes arrayed irregularly\nwithin the epidermis, with foci of pagetoid upward scatter.  Some\nmelanocytes have atypical nuclei.  Aggregations of similar\nmelanocytes are present in the dermis.  There are sheets of atypical\nmelanocytes in the superficial dermis.	Ellipse, 6 x 2.8 x 1 cm, central portion serially sectioned and\nsubmitted with one section each in blocks A through H, margins inked\nblue, tips returned to container.	BLEEDING FRIABLE NODULE; CLINICAL DIAGNOSIS - MELANOMA, DATA ON FILE	\N	\N	\N	This is a high risk primary lesion.  As there is extensive ulceration, the microstage measurment probably underestimates the prognostic risk of this lesion.	MELANOMA, AT LEAST 3.5 MM IN THICKNESS, WITH INTRAEPIDERMAL MELANOMA EXTENDING NEAR TO THE PERIPHERAL BIOPSY MARGIN	104444	194	\N	\N	96-18458	A	CCR-215	California Cancer Registry	IP95222	AirTable blocks_with_IP_info.csv
2886	23-5236	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	416	\N	\N	23-5236	\N	DMS-004	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2796	22-35051	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	417	\N	\N	22-35051	\N	DMS-005	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2883	23-4742	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	418	\N	\N	23-4742	\N	DMS-006	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2879	23-4604	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	419	\N	\N	23-4604	\N	DMS-007	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2857	22-122015	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	420	\N	\N	22-122015	\N	DMS-008	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2855	22-115763	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	421	\N	\N	22-115763	\N	DMS-009	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2809	22-59468	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	422	\N	\N	22-59468	\N	DMS-010	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2885	23-5230	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	423	\N	\N	23-5230	\N	DMS-011	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2852	22-114644	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	424	\N	\N	22-114644	\N	DMS-012	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2860	22-127365	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	425	\N	\N	22-127365	\N	DMS-013	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2861	22-127490	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	426	\N	\N	22-127490	\N	DMS-014	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2862	22-128532	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	427	\N	\N	22-128532	\N	DMS-015	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2863	22-128941	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	428	\N	\N	22-128941	\N	DMS-016	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2822	22-83883	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	429	\N	\N	22-83883	\N	DMS-017	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2853	22-115140	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	432	\N	\N	22-115140	\N	DMS-020	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2873	23-3020	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	433	\N	\N	23-3020	\N	DMS-021	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2778	22-8115	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	434	\N	\N	22-8115	\N	DMS-022	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2823	22-83923A	45	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30859,30860,30861	172.5	\N	\N	Sections show a compound melanocytic proliferation with a biphasic pattern.  One population consists of melanocytes, most of which have increased pale grey cytoplasm and enlarged irregular nuclei with a central nucleolus. These melanocytes are irregularly distributed along the dermal-epidermal junction as single cells and irregular, expansile nests. There are areas of confluence and pagetoid scatter. Similar melanocytes are present in the subjacent dermis. In the dermis, there is a second population of smaller melanocytes with cytologically bland nuclei (melanocytic nevus). There is a separate dermal proliferation of spindled and stellate cells arrayed amongst thickened collagen bundles in the reticular dermis (incidental dermatofibroma).	Ellipse, 3.0 x 1.4 x 0.9 cm, including a central 1.9 x 1.3 cm dark brown elevated area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis, and submitted with four sections each in A1-A2 and three sections in A3. Tips reserved. HD/HD	A) 2 X 1.5 CM IRREGULAR BLACK / BROWN / PINK PLAQUE; MELANOMA VS. SK, B) 0.8 X 0.6 CM IRREGULAR BROWN PAPULE; R/O MELANOMA	\N	\N	\N	There is also an incidental dermatofibroma captured herein. Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: excisional biopsy Tumor site: upper midline back Microscopic tumor type: low cumulative sun damage (WHO) Breslow thickness: 1.2 mm Ulceration: absent Margins, peripheral and deep: melanoma in situ present at inked peripheral margin; deep margin free Mitotic index (per square millimeter): 1 Microsatellitosis: not identified Vascular Invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT2a pNX	MELANOMA, BRESLOW THICKNESS 1.2 mm, NON-ULCERATED, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	172599	1748	\N	\N	22-83923	A	SYNAT171	2010-2017	IP2060770	AirTable blocks_with_IP_info.csv
1925	16-10560-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-37	https://64.54.108.121/app/WebViewer/view/image/36084	\N	\N	\N	\N	\N	\N	\N	H16-10560 (right shoulder) #1	FFPE	\N	\N	\N	401	\N	\N	None	\N	CME-099	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2025	17-00730-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-38	https://64.54.108.121/app/WebViewer/view/image/36085	\N	\N	\N	\N	\N	\N	\N	H17-00730 #3 (left nasal ala)	FFPE	\N	\N	\N	402	\N	\N	None	\N	CME-100	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2026	17-00731-3	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-38	https://64.54.108.121/app/WebViewer/view/image/36086	\N	\N	\N	\N	\N	\N	\N	H17-00731 #3 (right thigh)	FFPE	\N	\N	\N	403	\N	\N	None	\N	CME-101	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2036	17-03472-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-38	https://64.54.108.121/app/WebViewer/view/image/36087,36112	\N	\N	\N	\N	\N	\N	\N	H17-03472 #1 (left anterior chest, in situ)	FFPE	\N	\N	\N	404	\N	\N	None	\N	CME-102	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2042	17-08581-5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-38	https://64.54.108.121/app/WebViewer/view/image/36090	\N	\N	\N	\N	\N	\N	\N	H17-08581 #5 (right shoulder)	FFPE	\N	\N	\N	406	\N	\N	None	\N	CME-104	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2818	22-81230	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	435	\N	\N	22-81230	\N	DMS-023	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2821	22-83760	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	436	\N	\N	22-83760	\N	DMS-024	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2767	22-854	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	437	\N	\N	22-854	\N	DMS-025	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2817	22-80980	78	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30858	172.4	\N	\N	Sections show a proliferation of melanocytes that involves the epidermis and dermis, with two populations of cells.  One consists of larger melanocytes, some of which have atypical nuclei. These cells are irregularly distributed along the dermal-epidermal junction as both single cells and nests, with some present above the basal layer.  There are similar melanocytes in the subjacent dermis which form an expansile nodule. The second population of melanocytes is composed of discrete aggregates of small, round cells with monomorphous nuclei.	Skin segment measuring 2.0 x 1.5 x 0.6 cm, serially sectioned and entirely submitted with five sections plus fragments. CF/CF	BLACK TO GREY NODULE; MELANOMA VS. LESS LIKELY ATYPICAL NEVUS	\N	\N	\N	Diagnostic features of note include: Procedure: Biopsy Tumor site: Scalp Microscopic tumor type: High chronic sun-damage Breslow thickness: 6.0 mm at least Ulceration: Present Margins, peripheral and deep: Involved Mitotic index: 2/mm2 Microsatellitosis: Absent Vascular invasion: Absent Perineural invasion: Absent Regression: Absent Pathologic Staging (pTNM): pT4b	MELANOMA, AT LEAST 6.0 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	102485	2223	\N	\N	22-80980	\N	SYNAT172	Melanoma Epigenetics	IP2482899	AirTable blocks_with_IP_info.csv
2633	20-43970	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	451	\N	\N	20-43970	\N	DMS-039	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2585	20-5264	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	452	\N	\N	20-5264	\N	DMS-040	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2645	20-57917	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	453	\N	\N	20-57917	\N	DMS-041	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2649	20-64178	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	454	\N	\N	20-64178	\N	DMS-042	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2896	23-7509	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	455	\N	\N	23-7509	\N	DMS-043	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2900	23-14412	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	456	\N	\N	23-14412	\N	DMS-044	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2242	17-113038	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	460	\N	\N	17-113038	\N	DMS-048	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2278	17-130985	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	461	\N	\N	17-130985	\N	DMS-049	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2133	17-48914	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	462	\N	\N	17-48914	\N	DMS-050	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2184	17-75346	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	463	\N	\N	17-75346	\N	DMS-051	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2803	22-47776	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	467	\N	\N	22-47776	\N	DMS-055	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2805	22-51687	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	468	\N	\N	22-51687	\N	DMS-056	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2808	22-53879	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	469	\N	\N	22-53879	\N	DMS-057	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2810	22-61674	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	470	\N	\N	22-61674	\N	DMS-058	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2811	22-67443	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	471	\N	\N	22-67443	\N	DMS-059	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2824	22-84696	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	472	\N	\N	22-84696	\N	DMS-060	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2826	22-88291	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	473	\N	\N	22-88291	\N	DMS-061	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2833	22-93578	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	474	\N	\N	22-93578	\N	DMS-062	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
2011	16-119468	15	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10823	216.4	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and papillary dermis, with a partially raised surface, and extension of junctional nests to the side of the dermal component.	Skin segment measuring 1.0 x 0.8 x 0.1 cm, trisected and entirely submitted. KC/KC	A) ATYPICAL NEVUS VS. MELANOMA VS. BENIGN NEVUS. 0.6 CM, IRREGULAR BORDERS. CC DENISE O'RIORDAN, MD.	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	100449	476	\N	\N	16-119468	\N	DN-001	Dysplastic Nevi	IP1458214	AirTable blocks_with_IP_info.csv
2067	17-20901	18	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10842	216.5	\N	\N	Section show a broad compound proliferation of melanocytes arrayed in mostly nested fashion mostly along the junction and within a thickened and fibrotic papillary dermis.  There is a dense superficial dermal infiltrate of lymphocytes.	Skin segment measuring 1.9 x 0.6 x 0.1 cm, bisected and entirely submitted plus one fragment. RS/RS	R/O ATYPICAL NEVUS	\N	\N	\N	The lesion is broad and extends to the edges. Conservative re-excision of this site is recommended to prevent re-growth and/or evolution towards melanoma.	COMPOUND MELANOCYTIC NEVUS, CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO PERIPHERAL MARGINS	528599	477	\N	\N	17-20901	\N	DN-002	Dysplastic Nevi	IP1750156	AirTable blocks_with_IP_info.csv
2071	17-21285	23	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10845	216.5	\N	\N	Sections show a compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis contains an infiltrate of lymphocytes and melanophages. The papillary dermis is fibrotic.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted. RS/RS	A) NEOPLASM OF UNCERTAIN BEHAVIOR. BLACK MACULE.	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	173528	479	\N	\N	17-21285	\N	DN-004	Dysplastic Nevi	IP1750551	AirTable blocks_with_IP_info.csv
1212	06-8729	50	\N	\N	\N	None	None	None	4	\N	FFPE	\N	\N	173.5	\N	\N	Sections show a broad asymmetrical compound proliferation of melanocytes, some with atypical nuclei, arranged in some areas as single cells and nests along the sides and bases of elongated rete ridges, with fibroplasia of the papillary dermis. There is extensive subjacent dermal fibroplasia with a superficial infiltrate of lymphocytes and melanophages. In a central area, nodular array of strikingly atypical epithelioid melanocytes is evident in partial continuity with the epidermal-dermal junction, and some of these larger cells are captured in mitosis.	Skin segment, 2.6 x 1.5 x 0.4 cm, including a 0.9 x 0.7 cm raised area, serially sectioned perpendicular to the long axis and entirely submitted with seven sections.	PT WITH VIOLACEOUS PAPULE WITH ADJACENT TAN-BROWN PATCH; NEVUS, R/O ATYPIA	\N	\N	Scraping	This is an extraordinarily broad melanoma with a central nodular invasive component and with extensive associated partial and complete regression. In light of the changes of regression, the microstage measurement listed above may underestimate the prognostic impact of this lesion. In terms of staging, this is a non-ulcerated primary melanoma with invasion confined to an strikingly expanded papillary dermis (Clark's level III). There is no evidence of associated vascular invasion, perineural extension or microsatellitosis in these sections. Further re-excision of this site is of course warranted to ensure that local eradication has been accomplished.	MELANOMA OF AT LEAST 2.2 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS QUITE NEAR TO THE PERIPHERAL BIOPSY MARGIN	173502	132	\N	\N	06-8729	\N	CCR-024	California Cancer Registry	IP553795	AirTable blocks_with_IP_info.csv
2162	17-65000	68	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show basilar pigmentation of plump elongated rete ridges above elastosis, with no significant increase in the number of junctional melanocytes.  There are clusters of melanophages in the superficial dermis.	Skin segment measuring 1.2 x 1.0 x 0.1 cm, quadrisected, and entirely submitted. HD/HD	UNEVENLY PIGMENTED MACULE; R/O MALIGNANCY (1 X 1 CM)	\N	\N	\N	None	SOLAR LENTIGO, WITH SUPERIMPOSED POST-INFLAMMATORY PIGMENTARY ALTERATION	139522	516	\N	\N	17-65000	\N	DN-041	Dysplastic Nevi	IP1794850	AirTable blocks_with_IP_info.csv
2019	16-126284A	24	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	DN	\N	Sections show a compound melanocytic proliferation, composed largely of nests arrayed along the epidermal-dermal junction, with extension lateral to papillary dermal clusters of similar cells.  There is subepithelial fibrosis, some of which is lamellar in configuration in one area in the center.	Skin segment, 1.1 x 0.9 x 0.2 cm, trisected and totally submitted in A. CF/CF	A) 9 MM PINK / BROWN PAPULE WITH CENTRAL BROWN / BLACK DOT; DYSPLASTIC NEVUS, R/O MM, B) PINK ERODED PAPULE; EXCORIATED FOLLICULITIS, R/O NMSC	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	174533	481	\N	\N	16-126284	A	DN-006	Dysplastic Nevi	IP1726527	AirTable blocks_with_IP_info.csv
2850	22-107614	76	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=30870,30871,30872,30873,30874,30875,30876	172.5	\N	\N	Sections show a polypoid proliferation of cytologically malignant epithelioid melanocytes forming an expansile nodule in the dermis. These melanocytes contain increased amphophilic cytoplasm and enlarged oval-irregular nuclei with conspicuous nucleoli and are associated with a delicate lymphocytic infiltrate. The overlying epidermis shows a polypoid architecture and there is focal ulceration present. There is a dense lichenoid lymphohistiocytic inflammatory infiltrate with numerous melanophages and fibrosis aligned along the adjacent epidermis. Towards one edge of the biopsy, there is an adjacent lentiginous compound proliferation of smaller cytologically bland melanocytes (lentiginous compound melanocytic nevus).	Two skin segments received in vial. Skin segment one measuring 1.3 x 0.9 x 0.2 cm, two representative sections submitted. Skin segment two measuring 1.5 x 1.4 x 1.3 cm, two representative sections submitted. KB/ES	4 X 2 CM BLACK PATCH WITH SATELLITE PAPULES AND CENTRAL CRUST; POSSIBLE MELANOMA	\N	\N	\N	Immunostains for SOX-10 highlight the epithelioid tumor cells and the adjacent melanocytic nevus while Melan-A highlights only the compound melanocytic nevus. The tumor cells are negative for p40. BAP-1 shows preserved nuclear expression throughout. I have shared this case with my colleague, Dr. Thaddeus Mully, who agrees with the diagnosis and assessment. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: deep shave biopsy Tumor site: right chest Microscopic tumor type: low cumulative sun damage (WHO) Breslow thickness: 7 mm Ulceration: present Margins, peripheral and deep: changes of regression present at the peripheral and focally the deep tissue edge; nevus present at the peripheral and deep tissue edge Mitotic index (per square millimeter): 1 Microsatellitosis: to be determined in the resection specimen Vascular Invasion: not identified Perineural invasion: not identified Regression: present, extensive Pathologic Staging (pTNM): pT4b pNX	MELANOMA, BRESLOW THICKNESS 7.0 mm, WITH ULCERATION AND REGRESSION	173526	1772	\N	\N	22-107614	\N	SYNAT174	2010-2017	IP2509746	AirTable blocks_with_IP_info.csv
2854	22-115635C4	55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a broad and poorly circumscribed proliferation of melanocytes within the nail matrix and nail bed epithelium. A broad area features increased numbers of single melanocytes with large and irregularly shaped nuclei and scant cytoplasm positioned at irregular intervals, with a nodular proliferation of cells with even larger nuclei in the proximal nail bed, without evidence of maturation and dispersion with descent.	Oriented distal phalanx measuring 2.7 x 3.2 x 1.6 cm, including a central 2.1 x 1.7 cm area of variegated color and texture. With the midpoint of the dorsal proximal margin designated 12 o'clock by the grosser, the grosser inked the 9-12 o'clock margin black and the 12-3 o'clock margin blue. An approximately 0.3 cm intact crescent (9 to 3 o'clock) is removed parallel to the plane of amputation. This crescent is submitted intact in C1 for en-face sections with the true margin embedded down. From the remaining portion, eight central representative sections are submitted with two sections each in C2-C5. The bone and the remaining tissue are reserved. CF/CF	A) RIGHT INGUINAL SENTINEL LYMPH NODE # 1 HOT AND BLUE PROXIMAL BELOW SAPHENOUS VEIN EX VIVO 5500, B) RIGHT INGUINAL SENTINEL LYMPH NODE # 2 HOT AND BLUE SUPERFICIAL SAPHENOUS VEIN EX VIVO 4900, C) RIGHT GREATER TOE WITH SUBUNGUAL MELANOMA, D) ADDITIONAL POSTERIOR FLAP RIGHT GREATER TOE MARGIN, E) ADDITIONAL POSTERIOR FLAT RIGHT GREATER TOE MARGIN # 2, A-E) MELANOMA	\N	\N	\N	Features suggested for reporting per the guidelines of the College of American Pathologists, updated from the report of the prior biopsy include: Procedure: re-excision Microscopic tumor type: acral Ulceration: no Margins, peripheral and deep: both clear Mitotic index: 2/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT4a pNX  The proximal margin was evaluated with en face sections.	MELANOMA, 5 MM IN THICKNESS	176788	1860	\N	\N	22-115635	C4	SYNAT175	Melanoma Epigenetics	IP908318	AirTable blocks_with_IP_info.csv
2070	17-21066B	26	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	238.2	DN	\N	Sections show a compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages. Some of melanocytes are spindled or epithelioid.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate and are present above the basal layer. There are areas with slight spongiosis and parakeratosis.	Skin segment measuring 0.5 x 0.3 x 0.1 cm, bisected and entirely submitted in B. HD/HD	A) RED BROWN PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR, ENLARGING NEVUS, PT WITH SIGNIFICANT HISTORY OF ATYPICAL NEVI, B) RED PAPULE WITH BROWN EDGE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. MELANOMA	\N	\N	Scraping	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes. As it extends close to the edge of the biopsy, a re-excision is warranted.	IRRITATED COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	173726	482	\N	\N	17-21066	B	DN-007	Dysplastic Nevi	IP711299	AirTable blocks_with_IP_info.csv
2119	17-35916B	29	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10866	216.5	\N	\N	Sections show a compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis contains an infiltrate of lymphocytes and melanophages. There is focal parakeratosis.	Cylindrical skin segment, 0.6 cm in diameter and 1.4 cm in thickness, bisected and entirely submitted in B. CF/CF	A) RULE-OUT ATYPICAL MELANOCYTIC PROCESS. HEART-SHAPED BROWN MACULE WITH + UGLY DUCKLING SIGN, AND WITH COLORED OF BROWN, GRAY, RED AND PERIPHERAL DARK BLOTCH (ROSETTE?) ON DERMOSCOPY. LESION SIZE 6 MM; 6 MM P PERFORMED. B) JUNCTIONAL MELANOCYTIC NEVUS VS. RULE OUT ATYPICAL MELANOCYTIC PROCESS. DARK BROWN MACULE WITH IRREGULAR BORDER & + UGLY DUCKLING SIGN WITH COLORS OF BLACK, BROWN, RED. LESION SIZE 7 MM; 8 MM P PERFORMED.	\N	\N	\N	Similar as in (A), there are no signs that compel a re-excision.	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	345533	484	\N	\N	17-35916	B	DN-009	Dysplastic Nevi	IP1765367	AirTable blocks_with_IP_info.csv
2072	17-21476B	30	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10846	238.2	DN	\N	Sections show a compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate and a few are present above the basal layer. Scattered melanocytes have enlarged nuclei. There is a papular dermal component composed largely of small melanocytes, which mature with descent into the dermis. There is a bandlike infiltrate of lymphocytes in the papillary dermis, which focally obscures the dermo-epidermal junction.	Ellipse, 2.9 x 1.1 x 0.8 cm, including a central 1.0 x 0.8 cm brown area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and submitted with five sections in A and four sections in B. Tips reserved. RS/RS	A) NEOPLASM OF UNCERTAIN BEHAVIOR. . PLEASE CHECK MARGINS..	\N	\N	Scraping	This lesion is atypical in that it displays significant architectural and cytologic atypia, representing the high end of dysplastic nevus.	INFLAMED COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	423566	486	\N	\N	17-21476	B	DN-011	Dysplastic Nevi	IP1745878	AirTable blocks_with_IP_info.csv
2016	16-125754	30	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10827	216.5	\N	\N	Sections show a circumscribed and symmetrical compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis contains an infiltrate of lymphocytes and melanophages.	Ellipse, 1.6 x 0.7 x 0.6 cm, including a central 0.5 x 0.5 cm brown area. With margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections. KC/KC	6 MM DEEPLY PIGMENTED PAPULE WITH IRREG BORDER, BLONDE HAIRED, BLUE EYES, SURFER	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	528599	487	\N	\N	16-125754	\N	DN-012	Dysplastic Nevi	IP1725994	AirTable blocks_with_IP_info.csv
1981	16-98123	32	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10835	216.5	DN	\N	Sections show a broad compound proliferation of melanocytes, with a junctional component composed of nested and single melanocytes that extend lateral to an underlying papillary dermal component of similar cells.  The papillary dermis shows fibrosis, some in a lamellar configuration.	Skin segment measuring 1.0 x 1.0 x 0.1 cm, quadrisected and entirely submitted. CF/CF	9 MM BROWN NEVUS; R/O MM	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	333504	489	\N	\N	16-98123	\N	DN-014	Dysplastic Nevi	IP1698042	AirTable blocks_with_IP_info.csv
2913	23-83099	51	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=34332,34333,34334	172.6	\N	\N	Sections show a compound melanocytic proliferation with a biphasic pattern.  One population consists of melanocytes, most of which have atypical nuclei, that are irregularly distributed along the dermal-epidermal junction, with some melanocytes present above the basal zone.  Similar melanocytes are present in the subjacent dermis. The second population consists of melanocytes with cytologically bland nuclei (melanocytic nevus).	Ellipse, 4.2 x 1.7 x 0.7 cm, including a central 2.0 x 1.3 cm black-white area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections each in 1-3. Tips reserved. BY/BY	15 X 24 MM, MM - CHECK MARGINS	\N	\N	\N	Diagnostic features of note include: Procedure: excision Tumor site: shoulder Microscopic tumor type: melanoma on skin with low cumulative sun-induced damage (low CSD melanoma) Breslow thickness: 0.9 mm Ulceration: absent Margins, peripheral and deep: not involved Mitotic index: 0/mm2 Microsatellitosis: absent Vascular invasion: absent Perineural invasion: absent Regression: present Pathologic Staging (pTNM): pT1b pNX	MELANOMA, 0.9 mm IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	529699	2100	\N	\N	23-83099	\N	SYNAT178	Melanoma Epigenetics	IP2621535	AirTable blocks_with_IP_info.csv
2165	17-65201A	33	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10885	216.5	\N	\N	Sections show a compound proliferation of melanocytes with a flattish profile, the junctional component of which is composed of single and nested melanocytes arrayed along the sides and bases of elongated rete, above a papillary dermis expanded by fibrosis.  There is a central dermal component of small melanocytes near the epidermal-dermal junction.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted plus one fragment in A. RS/RS	A) 6 MM HYPERPIGMENTED MACULE W/ UNDERLYING ASYMMETRIC PIGMENT + ERYTHEMA; MELANOCYTIC NEVUS VS. OTHER W/ ATYPIA, B) 6 MM TAN-BROWN SOFT PAPULE, CONSTANTLY IRRITATED DUE TO LOCATION; IDN VS. OTHER MELANOCYTIC NEVUS, C) 8 MM HYPERPIGMENTED SOFT PAPULE, CONSTANTLY IRRITATED DUE TO LOCATION; IDN VS. OTHER MELANOCYTIC NEVUS	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGES OF THE SPECIMEN	333504	492	\N	\N	17-65201	A	DN-017	Dysplastic Nevi	IP1795054	AirTable blocks_with_IP_info.csv
2153	17-62534	35	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10878	216.5	DN	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 1.3 x 1.0 x 0.1 cm, quadrisected and entirely submitted. PL/PL	1.2 CM X 8 MM BROWN PATCH WITH HYPERPIGMENTED BORDER NEVUS; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	139523	495	\N	\N	17-62534	\N	DN-020	Dysplastic Nevi	IP1792363	AirTable blocks_with_IP_info.csv
2018	16-126258A	36	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10828	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.9 x 0.7 x 0.1 cm, trisected and entirely submitted in A. PL/PL	A) 8 MM IRREGULAR DARK / BROWN MACULE; NEVUS, R/O MM, B) APPROX 6 MM SCAR AT SITE OF LIKELY PRIOR NEVUS BIOPSY NOW WITH 3 MM BLACK DOT CENTRALLY, INITIAL PATH NOT AVAILABLE; REPIGMENTATION, R/O MM	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173527	496	\N	\N	16-126258	A	DN-021	Dysplastic Nevi	IP1726501	AirTable blocks_with_IP_info.csv
2005	16-119063	37	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis is fibrotic and contains an infiltrate of lymphocytes and melanophages.	Skin segment measuring 1.0 x 0.7 x 0.1 cm, trisected and entirely submitted. CF/CF	7 X 6 MM IRREGULAR MACULE; R/O MELANOMA	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	273588	498	\N	\N	16-119063	\N	DN-023	Dysplastic Nevi	IP1719254	AirTable blocks_with_IP_info.csv
2013	16-125609	38	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10824	216.5	\N	\N	Sections show a compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis contains an infiltrate of lymphocytes and melanophages.	Cylindrical skin segment measuring 0.8 cm in diameter and 1.0 cm in thickness. With the margins inked, the specimen is trisected, and entirely submitted. HD/HD	PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	273588	499	\N	\N	16-125609	\N	DN-024	Dysplastic Nevi	IP1408533	AirTable blocks_with_IP_info.csv
1984	16-98528A	39	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10837	216.5	\N	\N	Sections show a compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. The superficial melanocytes have finely vacuolated and pigmented cytoplasm,  where as the ones underneath are small with almost no cytoplasm.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted in A. HD/HD	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. NEVUS. MACULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. NEVUS. MACULE.	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	129522	500	\N	\N	16-98528	A	DN-025	Dysplastic Nevi	IP1698449	AirTable blocks_with_IP_info.csv
1976	16-97347	41	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10832	216.6	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. CF/CF	1 CM, ATYPICAL PIGMENTED LESION, AND IRREGULAR BROWN MACULE; ATYPICAL NEVUS VS. MELANOMA	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	529698	501	\N	\N	16-97347	\N	DN-026	Dysplastic Nevi	IP438654	AirTable blocks_with_IP_info.csv
2001	16-117695A	42	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10818	216.5	\N	\N	Sections show a compound proliferation of melanocytes in which nested and solitary cells are arrayed relatively evenly above a papillary dermis that displays nests of similar melanocytes, fibrosis, and a lymphocytic infiltrate.	Skin segment measuring 1.1 x 0.7 x 0.1 cm, trisected, and entirely submitted in A. HD/HD	A) 6 MM DARK BROWN W/ IRREGULAR PIGMENT; ATYPICAL NEVUS POSS MM, B) 4 MM DARK BROWN W/ IRREGULAR PIGMENT; ATYPICAL NEVUS POSS MM	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, INFLAMED, EXTENDING TO THE EDGE OF THE SPECIMEN	102537	502	\N	\N	16-117695	A	DN-027	Dysplastic Nevi	IP1717875	AirTable blocks_with_IP_info.csv
2161	17-64032	43	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	DN	\N	Sections show a compound proliferation of melanocytes with a flattish profile, the junctional component of which is composed of single and nested melanocytes arrayed along the sides and bases of elongated rete, above a papillary dermis expanded by fibrosis.  There is a central dermal component of small melanocytes near the epidermal-dermal junction.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted. KC/KC	0.7 CM PIGMENTED PAPULE, STANDS OUT; R/O ATYPICAL NEVUS	\N	\N	Scraping	The findings are well within the spectrum of those seen in dysplastic (Clark's) nevi. There are no microscopic features that compel re-excision.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	528599	506	\N	\N	17-64032	\N	DN-031	Dysplastic Nevi	IP1793874	AirTable blocks_with_IP_info.csv
2159	17-63837	42	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10883	216.5	DN	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted. KC/KC	JC17-264, 4 MM; R/O ATYPICAL, PINK MACULE WITH BROWN EDGE	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	139523	503	\N	\N	17-63837	\N	DN-028	Dysplastic Nevi	IP342191	AirTable blocks_with_IP_info.csv
2092	17-27830B	43	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	DN	\N	Sections show a compound proliferation of melanocytes, with nested and solitary melanocytes distributed relatively evenly along the epidermal-dermal junction.  Similar but slightly smaller cells are in the subjacent superficial dermis.  Many of the constituent melanocytes have abundant vacuolated and pigmented cytoplasm.	Cylindrical skin segment, 0.6 cm in diameter and 0.6 cm in thickness, bisected and entirely submitted in B. PL/PL	A-B) NEVUS, R/O ATYPIA	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS	139523	504	\N	\N	17-27830	B	DN-029	Dysplastic Nevi	IP709271	AirTable blocks_with_IP_info.csv
2093	17-27833	44	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	DN	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned in areas along the junction, above a papillary dermis that is expanded by slight fibrosis, with areas where only fibrosis and no nests of melanocytes are present.	Skin segment measuring 1.4 x 1.0 x 0.1 cm, quadrisected and entirely submitted. PL/PL	11 X 7 MM IRREGULARLY PIGMENTED PATCH	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AREAS OF REGRESSION,  EXCISED IN PLANES OF SECTION EXAMINED	173527	507	\N	\N	17-27833	\N	DN-032	Dysplastic Nevi	IP1757164	AirTable blocks_with_IP_info.csv
1985	16-98733	44	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10838	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Oval excision measuring 1.2 x 1.1 x 0.7 cm, including a central 0.7 x 0.7 cm brown area. With margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections. KC/KC	8 X 6 MM BR TAN PINK OVAL MAC; R/O DN, PLEASE CHECK MARGINS	\N	\N	\N	There are no worrisome features.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE PERIPHERAL MARGIN	173507	508	\N	\N	16-98733	\N	DN-033	Dysplastic Nevi	IP1494176	AirTable blocks_with_IP_info.csv
2084	17-26455B	44	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted in B. HD/HD	A) 6 MM PINK PALUP; NEOPLASM OF UNCERTAIN BEHAVIOR VS. BENIGN NEVUS, B) BROWN AND TAN PAPULE AND 6 X 4 MM; NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. INTRADERMAL NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173556	509	\N	\N	17-26455	B	DN-034	Dysplastic Nevi	IP1755773	AirTable blocks_with_IP_info.csv
2110	17-34979	45	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	no tissue extracted	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 0.9 x 0.7 x 0.1 cm, trisected and entirely submitted. HD/HD	0.6 CM DARKER BROWN MACULE	\N	\N	\N	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	528599	511	\N	\N	17-34979	\N	DN-036	Dysplastic Nevi	IP1689367	AirTable blocks_with_IP_info.csv
2158	17-63503	45	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10882	216.5	\N	\N	Sections show a compound proliferation of melanocytes with a flattish profile, the junctional component of which is composed of single and nested melanocytes arrayed along the sides and bases of elongated rete, above a papillary dermis expanded by fibrosis.  There is a central dermal component of small melanocytes near the epidermal-dermal junction.	Skin segment measuring 1.0 x 0.8 x 0.1 cm, trisected and entirely submitted. HD/HD	IRREGULAR MACULE; R/O ATYPIA	\N	\N	\N	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	102537	512	\N	\N	17-63503	\N	DN-037	Dysplastic Nevi	IP1793343	AirTable blocks_with_IP_info.csv
2006	16-119311	46	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	DN	\N	Sections show a proliferation of melanocytes arrayed along the epidermal-dermal junction and within the papillary dermis, with elongated and hyperpigmented rete which bear both nested and solitary melanocytes. The papillary dermis shows fibrosis, some of which is lamellar in configuration, and a sparse infiltrate.	Skin segment measuring 1.0 x 0.8 x 0.2 cm, trisected and entirely submitted. KC/KC	PIGMENTED NEOPLASM; R/O ATYPIA	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	139524	514	\N	\N	16-119311	\N	DN-039	Dysplastic Nevi	IP1719503	AirTable blocks_with_IP_info.csv
2163	17-65020B	36	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.6	DN	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted in B. RS/RS	A) CYT17-933, R/O BCC, PEARLY PATCH, LESION SIZE 6 MM, B) CYT17-934, R/O ATYPIA, PINK BROWN PAPULE WITH IRREGULAR BORDER, LESION SIZE 7 X 4 MM, C) CYT17-935, R/O ATYPIA, PINK BROWN PAPULE WITH IRREGULAR BORDERS, LESION SIZE 6 X 5 MM	\N	\N	Scraping	July 17, 2017: There are no worrisome features that would compel a re-excision.	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	529698	515	\N	\N	17-65020	B	DN-040	Dysplastic Nevi	IP87016	AirTable blocks_with_IP_info.csv
2094	17-28040A	46	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10855	216.5	DN	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Cylindrical skin segment, 1.1 cm in diameter and 0.6 cm in thickness, with the margins inked, serially sectioned and entirely submitted with five sections in A. RS/RS	A) 7 MM REDDISH BROWN MACULE IRREG PIGMENT NEW SINCE 2014; R/O ATYP NEVUS VS. MEL, B) 9 MM IRREG BROWN MACULE CHANGED SINCE 2014; R/O ATYP NEVUS (TELEPHONE: 646-243-7108 MSG OK)	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	100556	517	\N	\N	17-28040	A	DN-042	Dysplastic Nevi	IP884112	AirTable blocks_with_IP_info.csv
1200	06-03046F N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	948	\N	\N	None	\N	MD-42	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2091	17-27410	50	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	no tissue extracted	Sections show a compound proliferation of melanocytes, and the dermal melanocytes diminish in size with descent.  The overlying epidermis is acanthotic, with elongated rete that intertwine.	Skin segment measuring 1.2 x 1.0 x 0.3 cm, quadrisected longitudinally and entirely submitted. RS/RS	ERYTHEMATOUS PATCH WITH BROWN EDGE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. MELANOMA, PLEASE SECTION LONGITUDINALLY, BROWN PIGMENT IS AT ONE EDGE OF THE ELLIPTICAL LESION	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS	173505	520	\N	\N	17-27410	\N	DN-045	Dysplastic Nevi	IP465995	AirTable blocks_with_IP_info.csv
1983	16-98328A	55	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10836	238.2	DN	\N	Sections show a circumscribed compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate and a few are present above the basal layer in some areas. There are patchy infiltrates of lymphocytes.	Ellipse, 1.8 x 1.1 x 0.8 cm, including a central 1.1 x 0.8 cm brown area. With margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with seven sections in A. KC/KC	A) SUSPECT MELANOMA EXCISIONAL BX, B) SUSPECT NMSC (TELEPHONE: 415-531-1244 MSG OK)	\N	\N	Scraping	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, INFLAMED, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	173531	524	\N	\N	16-98328	A	DN-049	Dysplastic Nevi	IP1698249	AirTable blocks_with_IP_info.csv
2039	17-3829B	51	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10871	216.5	DN	\N	Sections show a proliferation of melanocytes arrayed along the epidermal-dermal junction and within the papillary dermis, with elongated and hyperpigmented rete which bear both nested and solitary melanocytes. The papillary dermis shows fibrosis, some of which is lamellar in configuration, and a sparse infiltrate.	Skin segment measuring 1.1 x 1.1 x 0.1 cm, serially sectioned and entirely submitted with five sections in B. KC/KC	A) BASAL CELL CARCINOMA VS. ACTINIC KERATOSIS. SHINY PATCH, 0.4 CM. CC STEVEN DAGG, MD. B) ATYPICAL NEVUS VS. BENIGN NEVUS VS. MELANOMA. UNEVENLY PIGMENTED GROWTH, 0.9 CM DIAMETER.	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	139510	522	\N	\N	17-3829	B	DN-047	Dysplastic Nevi	IP1732930	AirTable blocks_with_IP_info.csv
2002	16-118014	84	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.6	DN	\N	Sections show a compound proliferation of melanocytes with round to oval nuclei and scant cytoplasm, arrayed as nests along the epidermal-dermal junction and as small clusters in the subjacent dermis. There is solar elastosis.	Skin segment measuring 1.1 x 0.6 x 0.1 cm, bisected and entirely submitted. KC/KC	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. MELANOMA VS. BENIGN NEVUS. MACULE.	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS	112610	561	\N	\N	16-118014	\N	DN-086	Dysplastic Nevi	IP1647593	AirTable blocks_with_IP_info.csv
2083	17-26447	56	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	DN	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis. Scattered melanocytes have enlarged nuclei.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/HD	IRREGULARLY PIGMENTED MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173533	525	\N	\N	17-26447	\N	DN-050	Dysplastic Nevi	IP1755765	AirTable blocks_with_IP_info.csv
2086	17-26969	57	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	238.2	\N	\N	Sections show a compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction and on one side scattered melanocytes have enlarged nuclei.	Skin segment measuring 1.2 x 0.8 x 0.1 cm, trisected and entirely submitted. RS/RS	PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	\N	This lesion is atypical in that it is asymmetrical, with a area of larger melanocytes towards one edge. Conservative re-excision of this site is warranted.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING TO THE EDGE OF THE SPECIMEN	173539	526	\N	\N	17-26969	\N	DN-051	Dysplastic Nevi	IP313644	AirTable blocks_with_IP_info.csv
2109	17-34977	59	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10858	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.9 x 0.7 x 0.2 cm, trisected and entirely submitted. HD/HD	0.6 CM SLIGHTLY IRREGULAR BROWN MACULE	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	172599	528	\N	\N	17-34977	\N	DN-053	Dysplastic Nevi	IP1764420	AirTable blocks_with_IP_info.csv
2384	18-137854C	77	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound melanocytic proliferation, composed largely of nests arrayed along the epidermal-dermal junction, with extension lateral to papillary dermal clusters of similar cells.  There is subepithelial fibrosis, some of which is lamellar in configuration.	Skin segment measuring 1.0 x 0.6 x 0.1 cm, bisected and entirely submitted in C. HD/HD	A) R/O AK / SK, B) 6 MM; R/O DN, C) 9; R/O DN	\N	\N	\N	There are no worrisome features.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	222533	613	\N	\N	18-137854	C	DN-138	Dysplastic Nevi	IP477134	AirTable blocks_with_IP_info.csv
1564	12-05089-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	952	\N	\N	None	\N	MD-46	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1872	15-43069A	62	\N	\N	1	T4b	Primary	nodular	8	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=343	172.6	\N	\N	There is a multi-nodular proliferation of large, oval melanocytes in partial apposition to a thinned and focally ulcerated epidermis. The lesional cells have abundant, pale cytoplasm and dusty appearing melanin and large, oval vesicular nuclei with large, central nucleoli. Maturation with descent is absent. There are a few mitotic figures within dermal melanocytes.	Skin segment measuring 2.2 x 1.8 x 0.5 cm, serially sectioned, and entirely submitted with four sections each in A-B. HD/HD	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. BASAL CELL CARCINOMA VS. SQUAMOUS CELL CARCINOMA. 2.3 X 2.5 CM FUNGATING MASS ON L FOREARM. NO SATELLITE LESIONS. NO OLECRANON LAN. NO L AXILLARY LAN	\N	\N	Scraping	The neoplasm extends to the base of the specimen across a broad front. The final thickness measurement should be made after complete excision. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: biopsy Tumor site: as above Microscopic tumor type: nodular Breslow thickness: as above Ulceration: yes Margins, peripheral and deep: both involved Mitotic index: 1/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT4b pNX	MELANOMA, AT LEAST 5 MM. IN THICKNESS	173610	144	\N	\N	15-43069	A	CCR-051	California Cancer Registry	IP116836	AirTable blocks_with_IP_info.csv
2167	17-65263C	59	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10886	216.5	DN	\N	There is a compound proliferation of melanocytes in which junctional nests are inconspicuous.  There are slightly elongated rete and papillary dermal fibrosis, some of which is lamellar.	Skin segment measuring 1.0 x 0.9 x 0.1 cm, quadrisected and entirely submitted in C. CF/CF	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED NEVUS. PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS. PIGMENTED MACULE. C) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS. PAPULE AND PIGMENTED MACULE.	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS, CLARK'S (DYSPLASTIC) TYPE, WITH INVOLUTIONAL CHANGES, EXCISED IN PLANES OF SECTION EXAMINED	139523	529	\N	\N	17-65263	C	DN-054	Dysplastic Nevi	IP1662759	AirTable blocks_with_IP_info.csv
3194	Cell-Line_Xu-4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1845	\N	\N	None	\N	SYNAT218	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3195	Cell-Line_Xu-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2234	\N	\N	None	\N	SYNAT219	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3196	Cell-Line_Xu-6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2274	\N	\N	None	\N	SYNAT220	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3197	Cell-Line_Xu-7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1725	\N	\N	None	\N	SYNAT221	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3198	Cell-Line_Xu-8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2106	\N	\N	None	\N	SYNAT222	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3199	Cell-Line_Xu-9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1875	\N	\N	None	\N	SYNAT223	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3200	Cell-Line_Xu-10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1952	\N	\N	None	\N	SYNAT224	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3201	Cell-Line_Xu-11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1986	\N	\N	None	\N	SYNAT225	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
2556	19Rig750007.05.01.04	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NORMAL	Grp 5 - PAM with sunexposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	291	\N	\N	None	\N	CM-57	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
3202	Cell-Line_Xu-12	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2305	\N	\N	None	\N	SYNAT226	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3203	Cell-Line_Xu-13	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1918	\N	\N	None	\N	SYNAT227	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
1109	04-02031D T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1041	\N	\N	None	\N	MD-163	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1084	03-22623A T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1042	\N	\N	None	\N	MD-165	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2206	17-92405	54	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/HD	R/O DN, MM	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	273588	578	\N	\N	17-92405	\N	DN-103	Dysplastic Nevi	IP1822602	AirTable blocks_with_IP_info.csv
3257	CGH13-008	20	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	There is a proliferation of large, oval and fusiform melanocytes with a domed surface, marked epidermal hyperplasia with blunt rete ridges, and dermal fascicles and nests of melanocytes with abundant, pale amphophilic cytoplasm and large, vesicular nuclei containing large nucleoli. Some mature with descent is evident. The enclosed Ki-67 stain is difficult to evaluate, as many nuclei in the dermis are positive but some may be those of infiltrating lymphocytes.	Seven outside slides, B12-200322 (S12-12868). One corresponding block received 12-3-12.	NO SPECIFIC CLINICAL INFORMATION GIVEN, MANY FEATURES IN COMMON WITH SPITZ'S NEVUS NOTED IN COVER LETTER, AS WELL AS LESS CHARACTERISTIC FEATURES	\N	\N	\N	A focus of lymphatic invasion is present in the superficial portion of the the scout section (the hematoxylin and eosin stained recut that we obtain at the time that sections are cut for immunoperoxidase stains). A p16 immunoperoxidase stain does not show loss of that tumor suppressor gene product. Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a very low proliferation rate in the dermal component, with only scattered melanocytes staining for the MART-1/tyrosinase component. The base of the specimen is focally involved. Comparative genomic hybridization shows loss of chromosome 14 q, and a gain of 22q. These chromosomal aberrations have been seen in melanoma, but are uncommon. In the face of the other findings and the young age of the patient I would not regard it as sufficient for a diagnosis of spitzoid melanoma. I would regard this lesion as equivalent to an atypical Spitz tumor; many series of such cases have shown only rare involvement beyond local nodes. The base of the specimen is focally involved.  My colleague, Dr. Boris Bastian has reviewed the comparative genomic hybridization data and agrees with this interpretation of it.	MOSTLY INTRADERMAL PROLIFERATION OF LARGE SPITZOID MELANOCYTES, BEST CONSIDERED AS AN ATYPICAL SPITZ TUMOR	173202	2309	\N	L	12-89621	A	SYNAT273	2010-2017	IP1175438	AirTable blocks_with_IP_info.csv
3340	DP12-200 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2131	\N	DP	12-200	\N	SYNAT287	2010-2017	\N	AirTable blocks_with_IP_info.csv
2166	17-65218B	62	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	238.2	DN	\N	Sections show a compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate.	Skin segment measuring 0.7 x 0.7 x 0.1 cm, trisected and entirely submitted in B. KC/KC	A-B) R/O DYSPLASTIC NEVUS	\N	\N	Scraping	This lesion is atypical in that it displays areas where melanocytes are arranged as single cells along the basal layer. Conservative re-excision of this site is warranted.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING TO THE EDGE OF THE SPECIMEN	239512	537	\N	\N	17-65218	B	DN-062	Dysplastic Nevi	IP464470	AirTable blocks_with_IP_info.csv
2037	17-3731	60	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10870	216.5	DN	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 1.0 x 0.6 x 0.1 cm, bisected and entirely submitted. PL/PL	NEVUS, R/O ATYPIA	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	139523	531	\N	\N	17-3731	\N	DN-056	Dysplastic Nevi	IP28684	AirTable blocks_with_IP_info.csv
2069	17-21049	60	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10844	216.5	DN	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. CF/CF	IRREGULAR BROWN PAPULE; ATYPICAL NEVUS	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	345533	532	\N	\N	17-21049	\N	DN-057	Dysplastic Nevi	IP899509	AirTable blocks_with_IP_info.csv
2079	17-26289G	61	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10849	216.5	DN	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Cylindrical skin segment, 0.4 cm in diameter and 0.4 cm in thickness, bisected and entirely submitted in G. RS/RS	A) 6 X 5 MM VARIEG BRN TAN MAC; R/O DYSPLASTIC NEVUS, B) 10 X 8 MM VARIEG BRN MAC; CMN, R/O ATYPIA, C) 11 X 7 MM VARIEG TAN MAC, D) 4 X 3 MM VARIEG BRN MAC; CMN, R/O DYSPLASTIC NEVUS, E) 7 X 8 MM VARIEG BRN MAC; CMN, R/O ATYPIA, F) 3 X 3 MM BRN MAC INLINE WITH #1.2; CMN, R/O ATYPIA, G) 11 X 7 MM PINK TAN PAP; CMN, R/O ATYPIA, H) 5 X 4 MM BRN IRREG PAP; CMN, R/O ATYPIA, I) 8 X 4 MM PINK PAP; R/O BCC, J) 1 CM X 8 MM PINK PAP; R/O BCC, K) 1 CM X 8 MM PINK PATCH; R/O BOWEN'S	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGES OF THE SPECIMEN	173527	533	\N	\N	17-26289	G	DN-058	Dysplastic Nevi	IP1691692	AirTable blocks_with_IP_info.csv
2154	17-62813A	61	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10879	238.2	DN	\N	Sections show a melanocytic proliferation with nested and solitary melanocytes arrayed along the sides and bases of elongated rete and also occasionally above the junction, with lymphocytes and melanophages in the superficial dermis.	Oriented ellipse measuring 2.0 x 0.9 x 0.3 cm, including a central 0.6 x 0.6 cm brown area. With the blue dyed tip placed to the left and indicated as upper pole on the requisition form, this pole is designated as 12 o'clock by the grosser. The 12-3-6 o'clock margin is inked red and the 6-9-12 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections in A and three in B. CF/CF	SUSPICOUS IRREGULAR MULTI-COLORED MACULE; MALIGNANT MELANOMA IN SITU VS. CA, 6 MM, MIS, CAN, EXCISION	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS WITH ATYPICAL FEATURES, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	173777	534	\N	\N	17-62813	A	DN-059	Dysplastic Nevi	IP1275465	AirTable blocks_with_IP_info.csv
3368	HW Acral #3 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1852	\N	\N	None	\N	SYNAT292	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3369	HW Acral #3 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2321	\N	\N	None	\N	SYNAT293	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3370	HW Acral #4 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2288	\N	\N	None	\N	SYNAT294	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3371	HW Acral #4 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1789	\N	\N	None	\N	SYNAT295	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3372	HW Acral #5 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	2064	\N	\N	None	\N	SYNAT296	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3373	HW Acral #5 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	1768	\N	\N	None	\N	SYNAT297	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3374	HW Acral #6 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, All	\N	\N	\N	\N	1700	\N	\N	None	\N	SYNAT298	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3375	HW Acral #6 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, All	\N	\N	\N	\N	2014	\N	\N	None	\N	SYNAT299	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3376	HW Acral #7 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, All	\N	\N	\N	\N	1912	\N	\N	None	\N	SYNAT300	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3377	HW Acral #7 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	1881	\N	\N	None	\N	SYNAT301	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3378	HW Acral #8 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, All	\N	\N	\N	\N	1898	\N	\N	None	\N	SYNAT302	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3379	HW Acral #8 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	1839	\N	\N	None	\N	SYNAT303	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3380	HW Acral #9 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, All	\N	\N	\N	\N	1822	\N	\N	None	\N	SYNAT304	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3381	HW Acral #9 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	2254	\N	\N	None	\N	SYNAT305	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3382	HW Acral #10 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect | Barcode mismatch comment in note	\N	\N	\N	\N	1671	\N	\N	None	\N	SYNAT306	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3383	HW Acral #10 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	1877	\N	\N	None	\N	SYNAT307	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3384	HW2- Normal Curls	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Mucosal Melanoma, vulva, Hong Wu	\N	\N	\N	\N	2062	\N	\N	None	\N	SYNAT308	2010-2017	\N	AirTable blocks_with_IP_info.csv
3385	HW2- Tumor Dissect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Mucosal Melanoma, vulva, Hong Wu	\N	\N	\N	\N	2024	\N	\N	None	\N	SYNAT309	2010-2017	\N	AirTable blocks_with_IP_info.csv
3386	HW3-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, Melanoma| Normal Melanoma, Mucosal nasal sinus	\N	\N	\N	\N	1962	\N	\N	None	\N	SYNAT310	2010-2017	\N	AirTable blocks_with_IP_info.csv
3387	HW3-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, Melanoma| TUMOR Mucosal Melanoma, nasal sinus	\N	\N	\N	\N	2188	\N	\N	None	\N	SYNAT311	2010-2017	\N	AirTable blocks_with_IP_info.csv
3388	HW4-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, Melanoma| Normal Melanoma, Mucosal nasal sinus	\N	\N	\N	\N	2071	\N	\N	None	\N	SYNAT312	2010-2017	\N	AirTable blocks_with_IP_info.csv
2068	17-20908	64	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	DN	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile. There is abundant melanin in the cornified layer.	Skin segment measuring 1.2 x 0.6 x 0.1 cm, bisected and entirely submitted. PL/PL	RETICULATED SK VS. MELANOCYTIC NEOPLASM	\N	\N	Scraping	This lesion is quite broad and a re-excision may be prudent to prevent regrowth and possible evolution towards melanoma.	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	173556	538	\N	\N	17-20908	\N	DN-063	Dysplastic Nevi	IP1750163	AirTable blocks_with_IP_info.csv
2124	17-36682	67	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	238.2	\N	\N	Sections show a proliferation of melanocytes in which nested and single cells are arrayed along the junction, above a papillary dermis that shows fibrosis, some of which is lamellar in pattern.  Single melanocytes are increased in number in some areas, with some melanocytes present above the basal zone.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted. RS/RS	5 MM BROWN AND PINK MACULE	\N	\N	\N	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes, so that I cannot rule out an evolving melanoma in situ. Conservative re-excision of this site is warranted.	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	273588	541	\N	\N	17-36682	\N	DN-066	Dysplastic Nevi	IP1766150	AirTable blocks_with_IP_info.csv
2021	16-126879A	68	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10830	216.7	\N	\N	Sections show a compound melanocytic proliferation, composed largely of nests arrayed along the epidermal-dermal junction, with extension lateral to papillary dermal clusters of similar cells.  There is subepithelial fibrosis, some of which is lamellar in configuration.	Skin segment measuring 1.1 x 0.8 x 0.1 cm, trisected and entirely submitted in A. CF/CF	A-C) 0.6 X 0.6; R/O DYSP NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	122777	542	\N	\N	16-126879	A	DN-067	Dysplastic Nevi	IP1705946	AirTable blocks_with_IP_info.csv
2015	16-125621	68	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10826	216.5	DN	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 1.0 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/HD	A) MELANOMA VS. NEVUS. SUSPICIOUS IRREGULAR MULTI-COLORED MACULE.	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	345542	543	\N	\N	16-125621	\N	DN-068	Dysplastic Nevi	IP1725860	AirTable blocks_with_IP_info.csv
2168	17-65315B	71	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.7	DN	\N	Sections show a compound proliferation of melanocytes with a flattish profile, the junctional component of which is composed of single and nested melanocytes arrayed along the sides and bases of elongated rete, above a papillary dermis expanded by fibrosis.  There is a central dermal component of small melanocytes near the epidermal-dermal junction.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted in B. RS/RS	A) ASYMMETRICAL 7 MM BROWN MACULE; POSS ATYPICAL NEVUS, B) 6 MM BROWN MACULE; POSS ATYPICAL NEVUS	\N	\N	Scraping	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	897777	551	\N	\N	17-65315	B	DN-076	Dysplastic Nevi	IP1795170	AirTable blocks_with_IP_info.csv
1259	06-73878C	63	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1403	173.2	\N	\N	Sections show a nodular proliferation of peripherally palisaded basaloid cells with some neoplastic cells in mitosis, others in necrosis, and an area of surface ulceration.	Skin segment measuring 0.7 x 0.4 x 0.1 cm, bisected and entirely submitted in cassette C.	A) IRREGULAR 8-10 MM MACULE; R/O MELANOMA, B) 2 WK HX OF RAPIDLY GROWING PAPULE; R/O SK, C-D) R/O BCC	\N	\N	\N	\N	NODULAR BASAL CELL CARCINOMA, ULCERATED LESION, TRANSECTED AT THE DEEP BIOPSY EDGE	112210	232	\N	\N	06-73878	C	CCR-301	California Cancer Registry	IP89612	AirTable blocks_with_IP_info.csv
2164	17-65160B	73	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10884	216.5	\N	\N	Sections show a compound proliferation of melanocytes with a flattish profile, the junctional component of which is composed of single and nested melanocytes arrayed along the sides and bases of elongated rete, above a papillary dermis expanded by fibrosis.  There is a central dermal component of small melanocytes near the epidermal-dermal junction.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in B. HD/HD	A) 6 MM X 5 MM ROUND, VERY UNEVEN PAPULE; CMN, R/O ATYPIA, B) 6 MM X 7 MM ROUND, DARK UNEVEN PIGMENTED MACULE; CMN, R/O ATYPIA	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	876543	552	\N	\N	17-65160	B	DN-077	Dysplastic Nevi	IP1795010	AirTable blocks_with_IP_info.csv
2123	17-36614	80	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10868	216.5	DN	\N	Sections show a junctional proliferation of melanocytes without striking nuclear variability.  The proliferation has a flat configuration, when viewed from scanning magnification.  There is fibrosis of the papillary dermis.	Skin segment measuring 1.0 x 0.8 x 0.1 cm, trisected and entirely submitted. PL/PL	7 MM ASYMMETRICAL BROWN MACULE; POSS ATYPICAL NEVUS	\N	\N	Scraping	None	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173531	559	\N	\N	17-36614	\N	DN-084	Dysplastic Nevi	IP1766078	AirTable blocks_with_IP_info.csv
1954	16-48776B	73	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10831	216.5	\N	\N	Sections show a compound proliferation of melanocytes in which both single cells and small nests are present along the sides and bases of elongated rete, extending well beyond a papillary dermal component of similar small melanocytes.  There is papillary dermal fibrosis, some of which is lamellar in configuration. There is an infiltrate of lymphocytes and melanophages in the superficial dermis.	Skin segment measuring 1.4 x 0.7 x 0.1 cm, trisected, wrapped, and entirely submitted in B. HD/HD	A) 7 X 4 MM PIGMENTED MACULE WITH IRREGULAR GREY COLOR, 8 MM PUNCH; NEVUS, MELANOMA, B) ABDOMEN 1.1 X 0.7 DARK BROWN MACULE WITH ___ OF IRREGULAR PIGMENTATION; NEVUS, MELANOMA, C) 3 X 3 FLAT PEARLY PAPULE; BCC, SK (TELEPHONE:  415-982-6614 MSG OK)	\N	\N	\N	Broad-based lentiginous Clark's or dysplastic nevi are often present on the backs of older (especially male) patients. These lesions are an exception to the rule that predominantly junctional melanocytic lesions in older patients are melanomas.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173528	553	\N	\N	16-48776	B	DN-078	Dysplastic Nevi	IP546	AirTable blocks_with_IP_info.csv
2160	17-63890C	72	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, in which only a few junctional nests lie above a papillary dermis that shows marked fibrosis.  Clusters of cytologically bland melanocytes are present in the papillary dermis.	Skin segment measuring 0.8 x 0.8 x 0.1 cm, trisected and entirely submitted in C. KC/KC	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA VS. SQUAMOUS CELL CARCINOMA VS. IRRITATED SEBORRHEIC KERATOSIS. PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. SQUAMOUS CELL CARCINOMA VS. ACTINIC KERATOSIS VS. BASAL CELL CARCINOMA. PAPULE. C) MELANOMA VS. NEVUS VS. PIGMENTED SEBORRHEIC KERATOSIS. SUSPICIOUS IRREGULAR MULTI-COLORED PAPULE.	\N	\N	\N	The architectural features of this lesion suggest that this is a so-called dysplastic or Clark's nevus in which much of the junctional component has involuted.	COMPOUND MELANOCYTIC NEVUS, WITH INVOLUTIONAL CHANGES	139512	554	\N	\N	17-63890	C	DN-079	Dysplastic Nevi	IP1793730	AirTable blocks_with_IP_info.csv
3577	SKMEL28-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1802	\N	\N	None	\N	SYNAT336	Melanocyte Cell Line	\N	AirTable blocks_with_IP_info.csv
3578	SKMEL28-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1886	\N	\N	None	\N	SYNAT337	Melanocyte Cell Line	\N	AirTable blocks_with_IP_info.csv
3579	SKMEL28-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1848	\N	\N	None	\N	SYNAT338	Melanocyte Cell Line	\N	AirTable blocks_with_IP_info.csv
3580	SM_2_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1917	\N	\N	None	\N	SYNAT339	Spitzoid Melanoma	\N	AirTable blocks_with_IP_info.csv
3584	SM_10_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1786	\N	\N	None	\N	SYNAT340	Spitzoid Melanoma	\N	AirTable blocks_with_IP_info.csv
3592	Thomas_SK_Mel23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2260	\N	\N	None	\N	SYNAT341	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3594	UCSF-23-041_Biopsy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1858	\N	\N	None	\N	SYNAT342	Mutation Burden in Normal Skin,Willed Body Program	\N	AirTable blocks_with_IP_info.csv
3595	UM1_UvealMel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1990	\N	\N	None	\N	SYNAT343	Uveal Melanoma	\N	AirTable blocks_with_IP_info.csv
3596	UM2_UvealMel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2334	\N	\N	None	\N	SYNAT344	Uveal Melanoma	\N	AirTable blocks_with_IP_info.csv
3607	WM3918	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	wt/wt Cell Line DNA	\N	\N	\N	\N	1891	\N	\N	None	\N	SYNAT345	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3608	WP 11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Autopsy	\N	\N	\N	\N	2345	\N	\N	None	\N	SYNAT346	2010-2017	\N	AirTable blocks_with_IP_info.csv
3609	WP 23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Autopsy	\N	\N	\N	\N	2281	\N	\N	None	\N	SYNAT347	2010-2017	\N	AirTable blocks_with_IP_info.csv
3610	WP 29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Autopsy	\N	\N	\N	\N	1800	\N	\N	None	\N	SYNAT348	2010-2017	\N	AirTable blocks_with_IP_info.csv
1425	10-88475	28	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a well-circumscribed, dome-surfaced proliferation of melanocytes involving the junctional zone and superficial dermis. The base of the lesion is relatively flat, except in a central area where melanocytes extend along the access of an eccrine duct. The overlying epidermis is irregularly hyperplastic, with jagged rete ridges and a thick spinous layer. There are large, confluent nests of large oval melanocytes along the junction. These cells have monomorphous oval vesicular nuclei, small nucleoli and abundant pale eosinophilic cytoplasm. Many mitotic figures are present, both in the superficial and deep portions of the lesion. There is some maturation with descent, and in the central, peri-adnexal area, some myxoid stroma is present.	Four outside slides, B8538/10. One corresponding block received 1-14-11.	PIGMENTED PAPULE	\N	\N	\N	ADDENDUM, February 14, 2011: The following note has been modified from that in the original report, a copy of which is on file as .pdfs in our computer system: While the architectural features of this lesion favor a Spitz's nevus, some of the cytologic features are of concern (many cells have less cytoplasm than classic Spitz cells typically do), and many more mitotic figures are present than in most Spitz nevi. Additionally, the striking confluence of junctional nests is of concern.  Comparative genomic hybridization shows no chromosomal gains or losses. Given these findings, I am unable to render a diagnosis of spitzoid melanoma, and favor a unusual Spitz's nevus. The lesion appears to have been removed with a margin of about 3 mm on one side. It is very well circumscribed, and lesions of this type seldom recur in the scar from the previous biopsy. Also, it is very common for spitzoid lesions of all types (including benign Spitz nevi) to have small clusters of spitzoid melanocytes in a sentinel lymph node. The predictive value of this finding is very low, and I, for this reason, would not endorse this approach.	COMPOUND PROLIFERATION OF LARGE, SPITZOID MELANOCYTES	173727	1734	\N	\N	10-88475	\N	SYNAT146	2010-2017	IP983054	AirTable blocks_with_IP_info.csv
2969	96-3842	65	\N	\N	\N	None	None	None	15	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1295	172.4	\N	\N	Sections show a proliferation of nested and solitary melanocytes, some of which have atypical nuclei, irregularly distributed above elastosis.  There is pronounced involvement of adnexal epithelium. Clusters of similar melanocytes are present in the adventitial dermis.	Cylindrical skin segment, 5 mm in diameter, 6 mm in depth, bisected.	IRREGULAR BLACK PAPULE ON VERTEX SCALP, CLINICAL DIAGNOSIS - R/O MELANOMA	\N	\N	Scraping	The reexcision specimen from this site did not reveal any residual neoplasm, so I returned to this original biopsy to obtain a thickness measurement.  Please note that much of the invasive melanoma is present within the adventitial dermis around follicular structures, and thus the microstage measurement listed above probably overestimates the prognostic risk of this lesion.	MELANOMA, APPROXIMATELY 1.0 MM IN THICKNESS, EXTENDING TO THE PERIPHERAL BIOPSY MARGIN (MICROSTAGE MEASUREMENT REVISED 3/27/96)	173406	182	\N	\N	96-3842	\N	CCR-202	California Cancer Registry	IP80606	AirTable blocks_with_IP_info.csv
2064	17-20497A	75	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.6	DN	\N	Sections show nested and solitary melanocytes arrayed along the sides and bases of elongated and pigmented rete. There are many melanophages within the underlying superficial dermis. There is a bandlike infiltrate of lymphocytes in the papillary dermis. There is a focus with keratinous debris engulfed by macrophages, some of which are multinucleate and some of which display clefts within their cytoplasm.	Cylindrical skin segment, 0.6 cm in diameter and 0.9 cm in thickness, bisected and entirely submitted in A. RS/RS	A) 4 MM DARK BROWN MACULE; LENTIGO VS. MELANOMA, B) 2 X 1 CM SCAR LIKE NODULE, PT DENIES TRAUMA OR PROCEDURE; R/O SCAR ? DFSP (TELEPHONE: 650-755-7521 RUSSIAN)	\N	\N	Scraping	There is an incidental keratin granuloma.	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS WITH MANY SUPERFICIAL DERMAL MELANOPHAGES	173619	556	\N	\N	17-20497	A	DN-081	Dysplastic Nevi	IP898098	AirTable blocks_with_IP_info.csv
2090	17-27403	76	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10854	216.6	\N	\N	Sections show a proliferation of melanocytes arrayed along the epidermal-dermal junction and within the papillary dermis, with elongated and hyperpigmented rete which bear both nested and solitary melanocytes. The papillary dermis shows fibrosis, some of which is lamellar in configuration, and a sparse infiltrate. There is solar elastosis.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted. RS/RS	ATYPICAL RED BROWN MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173611	557	\N	\N	17-27403	\N	DN-082	Dysplastic Nevi	IP111660	AirTable blocks_with_IP_info.csv
2132	17-48595B	78	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10872	238.2	\N	\N	Sections show a broad, compound melanocytic neoplasm in which junctional nests extends to either side of a central dermal component.  The junctional nests are located both at the sides and bases of elongated rete ridges, and contain a proportion of cytologically atypical cells.  Pagetoid upward migration is not present to a significant degree.  The papillary dermis shows marked fibrosis in the center and contains some melanocytes similar to those in the junctional zone, as well as smaller cells.	Skin segment measuring 1.2 x 1.0 x 0.1 cm, quadrisected and entirely submitted in B. PL/PL	A) TRANSLUCENT PG; R/O HIDROCYSTOMA VS. BCC, B) R/O DN, C) R/O AK / SCC	\N	\N	\N	This lesion is atypical in that it displays lack of maturation of dermal melanocytes. Conservative re-excision of this site is warranted to prevent the lesion to persist and evolve towards melanoma.	COMPOUND MELANOCYTIC NEVUS, WITH SEVERE DYSPLASIA AND PARTIAL REGRESSION, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	529698	558	\N	\N	17-48595	B	DN-083	Dysplastic Nevi	IP1567816	AirTable blocks_with_IP_info.csv
2020	16-126714	87	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10829	216.5	DN	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 1.4 x 0.9 x 0.1 cm, trisected and entirely submitted. PL/PL	7 MM IRREGULAR BROWN PATCH; R/O MELANOMA	\N	\N	Scraping	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	105575	562	\N	\N	16-126714	\N	DN-087	Dysplastic Nevi	IP1683560	AirTable blocks_with_IP_info.csv
2209	17-93945C	17	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes composed of single and nested cells positioned along the epidermal-dermal junction, with similar cells in clusters and syncytia in the underlying dermis, with some cells arrayed in the superficial reticular and adventitial dermis.  Scattered melanocytes have enlarged nuclei. The junctional melanocytes extend lateral to those in the dermis.	Skin segment measuring 1.1 x 0.8 x 0.2 cm, trisected and entirely submitted in C. CF/CF	A) 5 MM 2 TONED ASYM BROWN PAPULE; R/O ATYPICAL NEVUS VS. MM, B) 4 MM 2 TONED ASYM BROWN PAPULE; R/O ATYPICAL NEVUS VS. MM, C) 7 MM 2 TONED ASYM BROWN PAPULE; R/O ATYPICAL NEVUS VS. MM	\N	\N	\N	This lesion shows some attributes of a so-called Clark's or dysplastic nevus.	SUPERFICIAL CONGENITAL MELANOCYTIC NEVUS, COMPOUND TYPE, WITH LATERAL EXTENSION OF THE JUNCTIONAL COMPONENT, EXCISED IN PLANES OF SECTION EXAMINED	138523	566	\N	\N	17-93945	C	DN-091	Dysplastic Nevi	IP1824168	AirTable blocks_with_IP_info.csv
2191	17-82365B	20	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a proliferation of nested and solitary melanocytes, relatively evenly distributed along the dermal-epidermal junction. Clusters of similar melanocytes are present in the dermis.	Skin segment measuring 0.8 x 0.6 x 0.2 cm, bisected and entirely submitted in B. RS/RS	A) 4 MM SOFT BROWN PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED NEVUS, B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED COMPOUND NEVUS VS. CLARK'S NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS	528599	567	\N	\N	17-82365	B	DN-092	Dysplastic Nevi	IP1812422	AirTable blocks_with_IP_info.csv
2174	17-72429A	29	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction of an epidermis with elongated rete ridges, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 1.0 x 0.7 x 0.1 cm, trisected and entirely submitted in A. CF/CF	A-B) IRREGULAR BROWN MACULE; R/O DYSPLASTIC NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173522	568	\N	\N	17-72429	A	DN-093	Dysplastic Nevi	IP1802357	AirTable blocks_with_IP_info.csv
2357	18-119366A	32	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, with nested and solitary melanocytes distributed relatively evenly along the epidermal-dermal junction.  Similar but slightly smaller cells are in the subjacent superficial dermis.  Many of the constituent melanocytes have abundant vacuolated and pigmented cytoplasm.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted in A. HD/PL	A-C) COLOR VARIEGATION AND BORDER IRREGULARLY; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS	101532	569	\N	\N	18-119366	A	DN-094	Dysplastic Nevi	IP1908323	AirTable blocks_with_IP_info.csv
2205	17-91889	35	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes composed of single and nested cells positioned along the epidermal-dermal junction, with similar cells in clusters and syncytia in the underlying dermis, with some cells arrayed in the superficial reticular and adventitial dermis.  The junctional melanocytes and superficial dermal melanocytes extend far lateral to one side to those in the deeper dermis.	Skin segment measuring 1.0 x 0.9 x 0.3 cm, quadrisected, and entirely submitted. HD/HD	7 X 5 MM PINK / TAN DOME SHAPED PAP WITH BROWN PIGMENTATION EXTENDING BEYOND THE BORDER; ATYPICAL NEVUS, R/O DYSPLASIA	\N	\N	\N	This lesion is atypical in that it displays a one-sided significant extension of its superficial component, which is that of a dysplastic nevus. As this portion extends to the tissue edges, I recommend further excision to ensure complete removal.	SUPERFICIAL CONGENITAL MELANOCYTIC NEVUS, COMPOUND TYPE, WITH ASYMMETRICAL LATERAL EXTENSION OF THE JUNCTIONAL COMPONENT, EXTENDING TO THE EDGE OF THE SPECIMEN	173502	570	\N	\N	17-91889	\N	DN-095	Dysplastic Nevi	IP1822073	AirTable blocks_with_IP_info.csv
2352	18-96108	39	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10897	216.5	\N	\N	Sections show a circumscribed compound melanocytic proliferation, composed largely of nests arrayed along the epidermal-dermal junction, with extension lateral to papillary dermal clusters of similar cells.  There is subepithelial fibrosis, some of which is lamellar in configuration.	Skin segment measuring 1.5 x 0.9 x 0.2 cm, quadrisected and entirely submitted. RS/RS	1.3 CM HAZY BROWN PATCH; R/O DYSPL CN VS. OTHER	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	101532	571	\N	\N	18-96108	\N	DN-096	Dysplastic Nevi	IP720723	AirTable blocks_with_IP_info.csv
2275	17-125335	60	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a small, roughly wedge-shaped proliferation composed of small melanocytes with round or ovoid nuclei that diminish in size with descent in the dermis. In level sections, a separate tissue section shows a symmetric junctional melanocytic proliferation arrayed along the sides and bases of hyperpigmented rete above many papillary dermal melanophages.	Cylindrical skin segment, 0.8 cm in diameter and 0.4 cm in thickness, with the margins inked, trisected and entirely submitted. PL/PL	PT WITH CHURG STRAUSS ON IMMUNE SUPPRESSION WHO PRESENTS WITH A 6 MM IRREGULAR NEVUS WITH A LATERAL FLESH COLORED PAPULE AND MEDIAL IRREGULAR BROWN MACULE; ATYPICAL NEVUS, MIS, CONGENITAL NEVUS WITH ATYPIA (TELEPHONE: 707-799-2405 MSG OK)	\N	\N	\N	In level sections, a second nevus is identified.	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS AND ADJACENT LENTIGINOUS JUNCTIONAL NEVUS	273588	583	\N	\N	17-125335	\N	DN-108	Dysplastic Nevi	IP1855930	AirTable blocks_with_IP_info.csv
2363	18-121403A	39	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10892	216.5	\N	\N	Sections show a compound melanocytic proliferation, composed largely of nests arrayed along the epidermal-dermal junction, with extension lateral to papillary dermal clusters of similar cells.  There is subepithelial fibrosis, some of which is lamellar in configuration.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted in A. HD/HD	A-B) R/O DYSPLASIA	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	139512	572	\N	\N	18-121403	A	DN-097	Dysplastic Nevi	IP1312981	AirTable blocks_with_IP_info.csv
2358	18-119369B	40	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10888	216.5	\N	\N	Sections show a compound proliferation of melanocytes, and the dermal melanocytes diminish in size with descent.  The overlying epidermis is acanthotic, with elongated rete that intertwine.	Skin segment measuring 1.1 x 0.9 x 0.1 cm, quadrisected and entirely submitted with four sections and fragment in B. HD/PL	A-C) ATYPICAL NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS	131544	573	\N	\N	18-119369	B	DN-098	Dysplastic Nevi	IP1983455	AirTable blocks_with_IP_info.csv
2361	18-120593B	41	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10890	216.5	\N	\N	Sections show a broad, circumscribed compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis contains an infiltrate of lymphocytes and melanophages.	Skin segment measuring 1.1 x 0.8 x 0.1 cm, trisected and entirely submitted in B. CF/PL	A) 5 M WAXY PAPULE; SK, PIGMENTED BCC, MM, B) 8 M TELANGIECTATIC NEVUS R/O MM	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	101532	574	\N	\N	18-120593	B	DN-099	Dysplastic Nevi	IP1984680	AirTable blocks_with_IP_info.csv
2348	18-90550	48	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10895	238.2	\N	\N	Sections show a broad but relatively symmetrical compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, with melanocytes showing random nuclear atypia and spindled configurations, where as the cells underneath are small and round.	Oriented ellipse, 4.3 x 1.8 x 0.8 cm, including a central 1.7 x 1.4 cm brown area. The orienting sutured tip is indicated medially on the requisition. This tip is designated 3 o'clock by the grosser and is placed toward 3 o'clock. The 9-12-3 o'clock margin is inked blue and the 3-6-9 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and submitted with four sections in A, three sections in B, and five sections in C. Tips reserved. KC/KC	A) NEOPLASM OF UNCERTAIN BEHAVIOR. 2.0 X 1.1 CM IRREGULAR BROWN PAPULE WITH H/O SIGNIFICANT GROWTH, NEVUS R/O ATYPIA. SUTURE PLACED MEDIALLY, PLEASE CHECK MARGINS.. CC: DR. TRICIA YEAP, (PCP IN WALNUT CREEK).	\N	\N	\N	This lesion shows an atypical junctional and superficial dermal component. It has been adequately removed.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	528522	575	\N	\N	18-90550	\N	DN-100	Dysplastic Nevi	IP605933	AirTable blocks_with_IP_info.csv
2176	17-72580	48	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a circumscribed and symmetrical compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis contains an infiltrate of lymphocytes and melanophages. Some melanocytes are present above the basal layer.	Skin segment measuring 1.1 x 0.6 x 0.1 cm, with the margins inked, serially sectioned and entirely submitted with five sections. RS/RS	6 X 4 MM DARK BROWN TO BLACK IRREGULAR MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR, PLEASE CHECK MARGINS	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	345533	576	\N	\N	17-72580	\N	DN-101	Dysplastic Nevi	IP698516	AirTable blocks_with_IP_info.csv
2197	17-85037	54	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10887	238.2	\N	\N	Sections show a compound proliferation of melanocytes, with a junctional component that extends lateral to the underlying dermal component, which is accompanied by papillary dermal fibrosis and a sparse infiltrate of lymphocytes and melanophages.  There are nested and solitary melanocytes along the junction, and in some areas solitary melanocytes predominate and are present above the basal layer.	Skin segment measuring 1.1 x 0.7 x 0.1 cm, trisected and entirely submitted. CF/CF	R/O DYSPLASIA	\N	\N	\N	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes. Conservative re-excision of this site is warranted.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH AN ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING TO THE EDGE OF THE SPECIMEN	173530	579	\N	\N	17-85037	\N	DN-104	Dysplastic Nevi	IP373264	AirTable blocks_with_IP_info.csv
2180	17-74152D	55	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 1.7 x 1.2 x 0.1 cm, serially sectioned and entirely submitted with five sections in D. RS/PL	A) NEOP UNC VS. DYSPLASTIC NEVUS, 0.6 X 0.6, B-C) NEOP UNC VS. LENTIGO, 0.6 X 0.6, D-E) NEOP UNC VS. DYSPLASTIC NEVUS, 1.1 X 1.1, F) NEOP UNC VS. DYSPLASTIC NEVUS, 0.6 X 0.6	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	528522	580	\N	\N	17-74152	D	DN-105	Dysplastic Nevi	IP255809	AirTable blocks_with_IP_info.csv
2181	17-74282	58	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 1.0 x 0.9 x 0.1 cm, quadrisected and entirely submitted. HD/PL	MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	152589	582	\N	\N	17-74282	\N	DN-107	Dysplastic Nevi	IP1804228	AirTable blocks_with_IP_info.csv
2210	17-93961A	61	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a broad compound proliferation of melanocytes, with a junctional component composed of nested and single melanocytes that extend lateral to an underlying papillary dermal component of similar cells.  The papillary dermis shows broad zones of fibrosis, some in a lamellar configuration.	Skin segment measuring 1.1 x 0.8 x 0.1 cm, trisected, and entirely submitted in A. HD/HD	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. NEVUS VS. MELANOMA. PAPULE. B) MELANOMA IN SITU. SUSPICIOUS IRREGULAR MULTI-COLORED MACULE. MELANOMA IN SITU (DT17-75711), NOW EXCISED WITH 1 CM MARGINS.  PLEASE CHECK MARGINS..	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	222566	584	\N	\N	17-93961	A	DN-109	Dysplastic Nevi	IP1805672	AirTable blocks_with_IP_info.csv
2328	18-54612	61	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a broad compound proliferation of melanocytes, with a junctional component composed of nested and single melanocytes that extend far lateral to an underlying papillary dermal component of similar cells.  The papillary dermis shows fibrosis, some in a lamellar configuration.	Skin segment measuring 1.5 x 0.8 x 0.1 cm, trisected and entirely submitted. RS/PL	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS. TWO TONED DARK BROWN PATCH.	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173529	585	\N	\N	18-54612	\N	DN-110	Dysplastic Nevi	IP650724	AirTable blocks_with_IP_info.csv
2364	18-121415	62	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a proliferation of melanocytes arrayed along the epidermal-dermal junction and within the papillary dermis, with elongated and hyperpigmented rete which bear both nested and solitary melanocytes. The papillary dermis shows fibrosis, some of which is lamellar in configuration, and a sparse infiltrate.	Skin segment measuring 0.8 x 0.8 x 0.1 cm, trisected and entirely submitted. BY/BY	R/O MELANOMA	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	139522	586	\N	\N	18-121415	\N	DN-111	Dysplastic Nevi	IP1985504	AirTable blocks_with_IP_info.csv
2240	17-112631B	82	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a mostly dermal proliferation of melanocytes, arrayed as nests and strands and syncytia that diminish in size with descent in the dermis.  Small melanocytes are splayed between collagen bundles in the superficial reticular dermis.	Multiple skin segments measuring 0.9 x 0.8 x 0.2 cm in aggregate, sectioned and entirely submitted in B. PL/PL	A) 3 MM X 2 MM BLUE BLACK MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. BLUE NEVUS VS. ATYPICAL PIGMENTED LESION, NOTES #1, B) 7 MM X 5 MM PINK BROWN PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. SYMPTOMATIC IDN, NOTES #2	\N	\N	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	876543	599	\N	\N	17-112631	B	DN-124	Dysplastic Nevi	IP1843109	AirTable blocks_with_IP_info.csv
2235	17-112277	64	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.6	\N	\N	Sections show a compound proliferation of melanocytes, with nested and solitary melanocytes arrayed along the junction.  There are clusters and syncytia of melanocytes in the superficial dermis, and striking cytologic atypism is not apparent.  Small melanocytes are present amongst reticular dermal collagen bundles in some foci in the uppermost reticular dermis.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted. RS/RS	4 X 4 MM SLIGHTLY IRREGULAR TAN BROWN PAPULE; NEVUS, R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES	529699	587	\N	\N	17-112277	\N	DN-112	Dysplastic Nevi	IP781920	AirTable blocks_with_IP_info.csv
2362	18-121006	64	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10891	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. CF/PL	6 X 5 MM, HISTORY MM X 2, IRREG CHANGING MACULE; DN VS. MM	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	105539	588	\N	\N	18-121006	\N	DN-113	Dysplastic Nevi	IP556850	AirTable blocks_with_IP_info.csv
2327	18-52908	63	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 1.0 x 0.8 x 0.1 cm, trisected and entirely submitted. RS/PL	R/O DN, PARTIAL LESION	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGES OF THE SPECIMEN	291511	589	\N	\N	18-52908	\N	DN-114	Dysplastic Nevi	IP1916757	AirTable blocks_with_IP_info.csv
2207	17-92850	68	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	172.4	\N	\N	Sections show nested and solitary melanocytes in irregular array within the epidermis, including some melanocytes arrayed above the basal zone.  There is a permeative lymphocytic infiltrate in the subjacent papillary dermis, which is focally fibrotic.	Skin segment measuring 1.1 x 1.1 x 0.1 cm, serially sectioned, and entirely submitted with five sections. HD/HD	A) ATYPICAL MELANOCYTIC PROLIFERATION. . PLEASE CHECK MARGINS. SEE PHOTO.	\N	\N	\N	This melanoma is AJCC stage Tis (representing a non-invasive tumor with no associated ulceration).	MELANOMA IN SITU, WITH SUPERIMPOSED LICHENOID INFLAMMATORY REACTION, EXTENDING TO THE EDGE OF THE SPECIMEN	524456	590	\N	\N	17-92850	\N	DN-115	Dysplastic Nevi	IP1596350	AirTable blocks_with_IP_info.csv
2359	18-120470	69	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a junctional proliferation of melanocytes arrayed mostly as nests at the sides and bases of elongated rete ridges, with marked fibrosis of the papillary dermis and a sparse infiltrate. There are similar melanocytes, in nests and diffusely in the underlying superficial dermis. The epidermis is thickened, with interconnecting rete ridges and horn pseudocysts towards one edge.	Skin segment measuring 1.4 x 1.0 x 0.1 cm, quadrisected and entirely submitted. BY/PL	ATYPICAL PIGMENTED PAPULE; R/O DYSPLASTIC NEVUS	\N	\N	\N	There is an incidental seborrheic keratosis.	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	273588	591	\N	\N	18-120470	\N	DN-116	Dysplastic Nevi	IP1984557	AirTable blocks_with_IP_info.csv
2360	18-120587	69	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10889	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. CF/PL	PIGMENTED NEOPLASM	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173581	592	\N	\N	18-120587	\N	DN-117	Dysplastic Nevi	IP1779775	AirTable blocks_with_IP_info.csv
2193	17-82806	70	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	238.2	\N	\N	Sections show a proliferation of melanocytes in which nested and single cells are arrayed along the junction, above a papillary dermis that shows fibrosis, some of which is lamellar in pattern.  Single melanocytes are increased in number in some areas, with some melanocytes present above the basal zone.	Skin segment measuring 1.0 x 0.6 x 0.1 cm, bisected and entirely submitted. PL/PL	R/O DN	\N	\N	\N	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes. Conservative re-excision of this site is warranted.	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING TO THE EDGE OF THE SPECIMEN	273588	593	\N	\N	17-82806	\N	DN-118	Dysplastic Nevi	IP877561	AirTable blocks_with_IP_info.csv
2255	17-117666	75	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10840	238.2	\N	\N	Sections show a proliferation of melanocytes in which nested and single cells are arrayed along the junction, above a papillary dermis that shows marked fibrosis, some of which is lamellar in pattern.  Bridging of adjacent rete ridges by nests of melanocytes is present. Single melanocytes are increased in number in some areas, with some melanocytes present above the basal zone.	Skin segment measuring 1.6 x 1.3 x 0.1 cm, serially sectioned and entirely submitted with five sections. CF/CF	1.1 CM BROWN IRREGULAR PATCH; NEOPLASM OF UNCERTAIN BEHAVIOR VS. INDLAMED SOLAR LENTIGO, R/O MIS, PLEASE CHECK MARGINS (SEE PHOTO)	\N	\N	\N	This lesion is atypical in that it displays a limited degree of intraepithelial scatter of melanocytes. Conservative re-excision of this site is recommended.	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH ATYPICAL INTRAEPIDERMAL COMPONENT, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	529698	595	\N	\N	17-117666	\N	DN-120	Dysplastic Nevi	IP1588836	AirTable blocks_with_IP_info.csv
2256	17-117775B	77	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a predominantly intradermal proliferation of small melanocytes that progressively diminish in size with descent in the dermis.  There are areas in which small melanocytes are spindled in shape and embedded in fibrillar matrix.	Skin segment measuring 0.8 x 0.7 x 0.3 cm, trisected and entirely submitted in B. HD/HD	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA VS. SEBACEOUS GLAND HYPERPLASIA. PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA VS. INTRADERMAL NEVUS. PAPULE.	\N	\N	\N	\N	INTRADERMAL MELANOCYTIC NEVUS, WITH NEUROTIZATION, A SENESCENT CHANGE	273588	596	\N	\N	17-117775	B	DN-121	Dysplastic Nevi	IP1499470	AirTable blocks_with_IP_info.csv
2398	19-03114N1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-29	https://64.54.108.121/app/WebViewer/view/image/36096,36097	\N	\N	\N	\N	\N	\N	\N	H19-03114 N1 (sentinel cervical lymph node: accessory nerve area)	FFPE	\N	\N	\N	351	\N	\N	19-3114	N1	CME-049	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2135	17-49739B	78	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a symmetrical and circumscribed compound proliferation of melanocytes, with single cells and nests arrayed along the sides and bases of elongated rete ridges and with some nests positioned within the papillary dermis. Some of the junctional melanocytes are pigmented and spindled in configuration and are separated from adjacent structures by small clefts. There is solar elastosis.	Skin segment measuring 0.7 x 0.4 x 0.1 cm, bisected and entirely submitted in B. PL/PL	A) NEOPLASM OF UNCERTAIN BEHAVIOR. ATYPICAL BROWN PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR. ATYPICAL BROWN MACULE.	\N	\N	\N	The findings are well within the spectrum of those seen in dysplastic (Clark's) nevi. There are no microscopic features that compel re-excision.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, WITH SOME FEATURES OF PIGMENTED SPINDLE CELL NEVUS (A VARIANT OF SPITZ'S NEVUS), EXCISED IN PLANES OF SECTION EXAMINED	139524	597	\N	\N	17-49739	B	DN-122	Dysplastic Nevi	IP302644	AirTable blocks_with_IP_info.csv
2187	17-81609B	80	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a broad compound proliferation of melanocytes, with a junctional component composed of nested and single melanocytes that extend lateral to an underlying papillary dermal component of similar cells.  The papillary dermis shows fibrosis, some in a lamellar configuration.	Skin segment measuring 1.4 x 0.8 x 0.1 cm, trisected, and entirely submitted in B. HD/HD	A) NEOPLASM OF UNCERTAIN BEHAVIOR. EROSION. 4 MONTH HISTORY OF SLOWLY EXPANDING EROSION ON THE RIGHT POSTERIOR SHOULDER. THE EROSION IS PAINLESS AND THE PATIENT ADAMANTLY DENIES PICKING AT THE LESION; R/O BASAL CELL CARCINOMA VS. EXCORIATION VS. INFECTION. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED SEBORRHEIC KERATOSIS VS. MELANOMA VS. NEVUS. PAPULE.	\N	\N	\N	This lesion is atypical in that it is quite broad and, because it extends to the edges of the biopsy, its circumscription cannot be assessed. Conservative re-excision of this site is warranted to ensure complete removal.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	110501	598	\N	\N	17-81609	B	DN-123	Dysplastic Nevi	IP1811650	AirTable blocks_with_IP_info.csv
2208	17-93920	82	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	\N	172.6	\N	\N	Sections show a compound proliferation of melanocytes, the junctional component of which consists of nested and solitary melanocytes in irregular array within the epidermis.  In some areas with the epidermis, a more orderly pattern of nesting is apparent. There is solar elastosis.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted. PL/PL	6 X 5 MM CHANGING PIGMENTED MACULE; DN VS. MM	\N	\N	\N	This melanoma is AJCC stage Tis (representing a non-invasive tumor with no associated ulceration).	MELANOMA IN SITU, ARISING IN A COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	113603	601	\N	\N	17-93920	\N	DN-126	Dysplastic Nevi	IP749893	AirTable blocks_with_IP_info.csv
2375	18-135600	60	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted. BY/BY	ATYPICAL RED / BROWN PATCH; ATYPICAL NEVUS	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	101544	602	\N	\N	18-135600	\N	DN-127	Dysplastic Nevi	IP777076	AirTable blocks_with_IP_info.csv
1933	16-20360	46	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	The microscopic findings are essentially as described in the accompanying pathology report.	Six outside slides, SH-16-9238-A1, and one corresponding block.	ERYTHEMA, RAISED, ABOUT 1.2 CM DIAMETER, LOOKS INFLAMED, ITCHY	\N	\N	\N	The differential diagnosis includes an atypical Spitz tumor and a spitzoid melanoma. Following microdissection and DNA extraction, we performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations.  Following the above DNA extraction, we performed comparative genomic hybridization, and found losses involving chrs. 9 and 10. These are commonly found in melanoma. The chr. 9 loss appears to be heterozygous, as p16 is preserved by immunohistochemistry. Putting this all together, the maturation and dispersion with descent, and absence of hTERT promoter mutation are against a fully malignant neoplasm while the comparative genomic hybridization result somewhat favors melanoma, but not as much as if there was a homozygous chr. 9 or 9p loss.  An atypical Spitz tumor may be the best category for this lesion. These are neoplasms that have features more atypical than those of a conventional Spitz nevus, but not as worrisome as those of spitzoid melanoma. In aggregate data from over ten studies, local nodal involvment (usually very small deposits) is common, but extranodal metastasis is rare. This dissociation results in sentinel lymph node biopsy having very limited predictive value, and in my opinion, sometimes leading to over-treatment if small deposits lead to completion lymphadenectomy.   Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	PREDOMINANTLY INTRADERMAL PROLIFERATION OF LARGE, SPITZOID MELANOCYTES, FAVOR AN ATYPICAL SPITZ TUMOR	173649	694	\N	\N	16-20360	\N	DP-57	CGH Validation	IP1619491	AirTable blocks_with_IP_info.csv
2374	18-135492	42	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a circumscribed compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis. Bridging of adjacent rete ridges by nests of melanocytes is present. There are bland melanocytes in the subjacent dermis.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted. BY/BY	1 X 0.7 CM IRREGULAR TAN BROWN PATCH; NEVUS, R/O ATYPIA, NUB	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE BASE OF THE SPECIMEN	529698	603	\N	\N	18-135492	\N	DN-128	Dysplastic Nevi	IP1697627	AirTable blocks_with_IP_info.csv
2373	18-135488	63	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability. Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis and nests of similar melanocytes are present in the superficial dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. BY/BY	6 X 4 MM MEDIUM BROWN IRREGULAR MACULE WITH DARK BROWN CENTER; R/O ATYPICAL NEVUS, NUB	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED \t	273578	604	\N	\N	18-135488	\N	DN-129	Dysplastic Nevi	IP681488	AirTable blocks_with_IP_info.csv
2379	18-136721	50	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. CF/CF	ATYPICAL NEVUS	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173530	605	\N	\N	18-136721	\N	DN-130	Dysplastic Nevi	IP2000868	AirTable blocks_with_IP_info.csv
1890	15-88900	7	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a large, oval dermal mass of plasmacytoid cells similar to the population in part of the nodule in (A), with adjacent fibrosis, and elongated rete ridges with basilar hyperpigmentation and increased numbers of basilar melanocytes.	One hematoxylin and eosin-stained section prepared from outside block labeled SP15-9506 D5.	A-B) GIANT CONGENITAL NEVUS, BILATERAL AXILLARY ADENOPATHY, MULTIPLE PROLIFERATIVE NODULES	\N	\N	\N	None	SAME AS (A)	101532	684	\N	\N	15-88900	\N	DP-47	CGH Validation	IP1528823	AirTable blocks_with_IP_info.csv
2418	19-7686A	59	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a compound proliferation of melanocytes with a flat profile from scanning magnification.  The junctional component consists largely of nests of epithelioid melanocytes, some of which have enlarged nuclei and are separated from each other by small clefts.  Clusters of similar melanocytes are also present in the subjacent superficial dermis, where lamellar fibrosis is apparent. There is solar elastosis.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in A. PL/PL	A) R/O BCC, B) FAVOR IRRIT SK, R/O PIG BCC (TELEPHONE: 415-317-6230 MSG OK)	\N	\N	\N	This lesion is atypical in that it displays larger melanocytes with irregularly sized nuclei. Conservative re-excision of this site is warranted.	COMPOUND CLARK'S OR DYSPLASTIC NEVUS WITH EPITHELIOID MELANOCYTES, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	173620	608	\N	\N	19-7686	A	DN-133	Dysplastic Nevi	IP881926	AirTable blocks_with_IP_info.csv
2372	18-135485	40	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/HD	6 X 5 MM DARK BROWN SLIGHTLY IRREGULAR MACULE DARKEST LESION ON FULL BODY SKIN CHECK; NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	345543	609	\N	\N	18-135485	\N	DN-134	Dysplastic Nevi	IP1658571	AirTable blocks_with_IP_info.csv
2376	18-136484	54	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted. BY/BY	IRREGULAR PIGMENTED MACULE, ~1 CM	\N	\N	\N	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173526	610	\N	\N	18-136484	\N	DN-135	Dysplastic Nevi	IP2000624	AirTable blocks_with_IP_info.csv
2382	18-137340A	44	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with round to oval nuclei and scant cytoplasm, arrayed as nests along the epidermal-dermal junction and as small clusters in the subjacent dermis.	Skin segment measuring 0.9 x 0.9 x 0.1 cm, quadrisected and entirely submitted in A. KC/KC	A) CHANGING IN SIZE AND 5.2 CM; ATYPICAL NEVUS, B) 3 MM AND ASYMMETRICAL NEVUS; ATYPICAL NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS	273588	612	\N	\N	18-137340	A	DN-137	Dysplastic Nevi	IP1431131	AirTable blocks_with_IP_info.csv
2385	18-137857	75	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.9 x 0.3 x 0.1 cm, bisected and entirely submitted. HD/HD	NEVUS	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173530	614	\N	\N	18-137857	\N	DN-139	Dysplastic Nevi	IP2002013	AirTable blocks_with_IP_info.csv
2383	18-137809B	70	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.7	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted in B. BY/BY	A) ATYPICAL NEVUS VS. MELANOMA VS. BENIGN NEVUS. BROWN PATCH IRREGULAR BORDERS 0.6 CM. CC: MARGO ESTRIN, MD AND SALLY DAVIS, MD. B) ATYPICAL NEVUS VS. MELANOMA VS. BENIGN NEVUS. BICOLORED PIGMENTED PATCH 0.7 CM.	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173711	615	\N	\N	18-137809	B	DN-140	Dysplastic Nevi	IP171892	AirTable blocks_with_IP_info.csv
2410	19-7126B	35	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.8 x 0.6 x 0.2 cm, bisected and entirely submitted in B. PL/PL	A-C) R/O MELANOMA	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	133559	616	\N	\N	19-7126	B	DN-141	Dysplastic Nevi	IP2011182	AirTable blocks_with_IP_info.csv
2411	19-7344	73	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a broad compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis. Bridging of adjacent rete ridges by nests of melanocytes is present. There is an encompassing lymphocytic infiltrate.	Skin segment measuring 1.0 x 1.0 x 0.1 cm, quadrisected, and entirely submitted. HD/HD	LICHENOID KERATOSIS VS. BCC	\N	\N	\N	This lesion is broad and has irregular architectural features. Conservative re-excision of this site is warranted to ensure complete removal.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, INFLAMED, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	100589	617	\N	\N	19-7344	\N	DN-142	Dysplastic Nevi	IP266145	AirTable blocks_with_IP_info.csv
2414	19-7596C	76	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted in C. KC/KC	A) RULE-OUT ATYPICAL MELANOCYTIC PROCESS. SUSPICOUS IRREGULAR MULTI-COLORED MACULE. B) RULE-OUT ATYPICAL MELANOCYTIC PROCESS. SUSPICOUS IRREGULAR MULTI-COLORED MACULE. C) RULE-OUT DYSPLASTIC NEVUS. IRREGULAR BROWN MACULE.	\N	\N	\N	The findings are well within the spectrum of those seen in dysplastic (Clark's) nevi. There are no microscopic features that compel re-excision.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	239512	620	\N	\N	19-7596	C	DN-145	Dysplastic Nevi	IP2011652	AirTable blocks_with_IP_info.csv
2415	19-7600	36	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a junctional proliferation of melanocytes, arrayed largely as nests and accompanied by papillary dermal fibrosis and partially obscured by a permeative lymphocytic infiltrate.	Skin segment measuring 1.0 x 0.6 x 0.1 cm, bisected and entirely submitted. KC/KC	5 X 5 MM, ATYPICAL MACULE; R/O DYSPLASTIC NEVUS VS. MM	\N	\N	\N	None	PREDOMINANTLY JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, ACCOMPANIED BY A HALO REACTION, EXCISED IN PLANES OF SECTION EXAMINED	333504	621	\N	\N	19-7600	\N	DN-146	Dysplastic Nevi	IP2011656	AirTable blocks_with_IP_info.csv
2416	19-7601	72	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a junctional proliferation of melanocytes arranged singly or as small nests in the basal layer above papillary dermal fibroplasia. A perijunctional lymphohistiocytic infiltrate with admixed melanophages is also present. There is solar elastosis.	Skin segment measuring 1.4 x 1.4 x 0.1 cm, serially sectioned and entirely submitted with five sections. KC/KC	1.5 CM X 8 MM ASYMMETRICALLY PIGMENTED PATCH; POSS MM	\N	\N	\N	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	139522	622	\N	\N	19-7601	\N	DN-147	Dysplastic Nevi	IP2011657	AirTable blocks_with_IP_info.csv
2436	19-29433C	54	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 1.2 x 0.8 x 0.1 cm, trisected, and entirely submitted in C. HD/HD	A) CYT19-446, R/O ATYPICAL, DARK MACULE WITH IRREGULAR BORDERS, LESION SIZE 0.6 X 0.5 CM, B) CYT19-447, R/O ATYPICAL, PINK BROWN MACULE IRREGULAR COLOR DISTRIBUTION, LESION SIZE 1.2 X 1.1 CM, C) CYT19-448, R/O ATYPICAL, PINK BROWN WITH IRREGULAR COLOR DISTRIBUTION, LESION SIZE 1.1 X 0.5 CM	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	139524	624	\N	\N	19-29433	C	DN-149	Dysplastic Nevi	IP630209	AirTable blocks_with_IP_info.csv
2425	19-15130	48	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a broad compound proliferation of atypical melanocytes composed largely of cells with vacuolated and finely pigmented cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, with conspicuous associated suprabasal scatter. There are also clusters of similar melanocytes in the superficial dermis, jointly with a dense infiltrate of lymphocytes and melanophages.	Skin segment measuring 1.6 x 1.2 x 0.1 cm, serially sectioned and entirely submitted with five sections. CF/CF	R/O DYSPLASTIC NEVUS VS. MM, 2 X 1 CM	\N	\N	\N	Immunostaining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows much more pagetoid scatter than could be discerned in the hematoxylin and eosin stained sections. A p16 immunoperoxidase shows retention of expression. Diagnostic features of note include:  Procedure: shave biopsy Tumor site: abdomen Microscopic tumor type: melanoma on skin with low cumulative sun-induced damage (WHO: low CSD melanoma); SSM Breslow thickness: 0.6 mm Ulceration: absent Margins, peripheral and deep: narrowly clear Mitotic index: 0/mm2 Microsatellitosis: absent Vascular invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT1a pNX  My colleague, Dr. Timothy McCalmont, also reviewed these sections and agrees with this diagnosis.	MELANOMA, 0.6 MM IN THICKNESS, NARROWLY EXCISED IN PLANES OF SECTION EXAMINED	222533	625	\N	\N	19-15130	\N	DN-150	Dysplastic Nevi	IP2019231	AirTable blocks_with_IP_info.csv
1145	04-38345	48	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.5	\N	\N	Sections show a compound proliferation of atypical melanocytes, composed largely of neoplastic cells with ample vacuolated cytoplasm. Single neoplastic cells and nests are arrayed irregularly within the epidermis, with foci of suprabasal scatter.  There are also clusters of similar melanocytes in the superficial dermis.  The clusters in the dermis are enveloped by a complex fibrosing inflammatory reaction, with an infiltrate of lymphocytes and melanophages that varies in density.  In some areas, there is a marked reduction in the number of melanocytes, with an underlying fibrotic papillary dermis that contains a sparse infiltrate of lymphocytes and melanophages.	Skin segment measuring 0.9 x 0.8 x 0.2 cm, trisected and entirely submitted.	IRREGULAR PIGMENTED LESION	\N	\N	Scraping	This is a non-ulcerated primary melanoma with invasion confined to a strikingly expanded papillary dermis (Clark's level III). There is a prominent associated component of partial and focal complete regression, and thus the microstage measurement listed above may underestimate the prognostic impact of this lesion. There is no evidence of associated vascular invasion or perineural extension in these sections. Further reexcision of this site is warranted to be certain that local eradication of this melanoma has been accomplished.	MELANOMA OF 1.0 MILLIMETER IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS QUITE NEAR TO THE PERIPHERAL BIOPSY MARGIN	222533	183	\N	\N	04-38345	\N	CCR-203	California Cancer Registry	IP454748	AirTable blocks_with_IP_info.csv
2447	19-37609	53	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, arrayed in mostly nested fashion along the junction and as small clusters in the dermis, with the overall lesion showing a flat profile from low magnification. Many of the constituent melanocytes have finely vacuolated and pigmented cytoplasm, and the superficial dermis contains an infiltrate of lymphocytes and melanophages.	Skin segment measuring 1.0 x 0.6 x 0.1 cm, bisected and entirely submitted. KC/KC	7 MM X 5 MM REDDISH PINK VARIEGATED MACULAR; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	\N	The lesion is broad and not well circumscribed. A conservative re-excision may be prudent.	COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	139511	626	\N	\N	19-37609	\N	DN-151	Dysplastic Nevi	IP2041845	AirTable blocks_with_IP_info.csv
2437	19-30025B	66	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a melanocytic proliferation in which single melanocytes and melanocytes in small nests are positioned along the sides and bases of elongated and pigmented rete ridges, above a fibrotic papillary dermis.	Skin segment measuring 1.1 x 0.6 x 0.1 cm, bisected and entirely submitted in B. PL/PL	A) R/O BOWEN'S VS. SUP BCC, B) ATYPICAL NEVUS, R/O SSM	\N	\N	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	139523	628	\N	\N	19-30025	B	DN-153	Dysplastic Nevi	IP143268	AirTable blocks_with_IP_info.csv
2449	19-38447	79	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a melanocytic proliferation in which single cells predominate, in irregular array within the epidermis.  There are foci of pagetoid scatter.  There is a bandlike infiltrate of lymphocytes in the papillary dermis.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted. CF/CF	ATYPICAL NEVUS	\N	\N	\N	An immunoperoxidase for SOX-10 shows poor circumscription and broad zones of pagetoid scatter. This melanoma is AJCC stage Tis (representing a non-invasive tumor with no associated ulceration).	EVOLVING MELANOMA IN SITU, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	102537	630	\N	\N	19-38447	\N	DN-155	Dysplastic Nevi	IP2042685	AirTable blocks_with_IP_info.csv
2426	19-15378	47	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a compound proliferation of melanocytes, with solitary and nested melanocytes arrayed along the junctional zone above a papillary dermis that contains melanocytes jointly with lamellar fibrosis and melanophages.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted. CF/CF	5 MM, COLOR VARIEGATION; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS, AMP	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	102611	631	\N	\N	19-15378	\N	DN-156	Dysplastic Nevi	IP2019479	AirTable blocks_with_IP_info.csv
2443	19-37409B	68	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 0.9 x 0.7 x 0.1 cm, trisected and entirely submitted in B. KC/KC	A-B) R/O DYSPLASTIC NEVUS	\N	\N	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	139524	633	\N	\N	19-37409	B	DN-158	Dysplastic Nevi	IP2041641	AirTable blocks_with_IP_info.csv
2438	19-30079A	60	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted in A. HD/HD	A) ATYPICAL NEVUS VS. SEBORRHEIC KERATOSIS VS. MELANOMA VS. BENIGN NEVUS. DARKLY PIGMENTED LINEAR MACULE, 0.6 CM. CC: NATHALIE MICHAUD, MD. B) IRRITATED NEVUS VS. ATYPICAL NEVUS. 0.4 CM, ERYTHEMATOUS TAN PAPULE.	\N	\N	\N	There are no worrisome features.	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, FOCALLY EXTENDING TO THE BASE OF THE SPECIMEN	139522	634	\N	\N	19-30079	A	DN-159	Dysplastic Nevi	IP1858202	AirTable blocks_with_IP_info.csv
2448	19-38090	63	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes without striking nuclear variability that shows a relatively flat configuration, when viewed from scanning magnification.  Nested and solitary melanocytes are positioned along the junction, above a papillary dermis that is expanded by slight fibrosis.	Skin segment measuring 1.5 x 1.3 x 0.1 cm, serially sectioned and entirely submitted with five sections. CF/CF	A) ATYPICAL NEVUS. 12 X 10 MM OVAL BROWN PAPULE WITH SLIGHT ASYMMETRY OF PIGMENTATION. PLEASE CHECK MARGINS. PHOTO.	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	528599	635	\N	\N	19-38090	\N	DN-160	Dysplastic Nevi	IP2042328	AirTable blocks_with_IP_info.csv
2427	19-15442	56	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with a flattish profile, the junctional component of which is composed of single and nested melanocytes arrayed along the sides and bases of elongated rete, above a papillary dermis expanded by fibrosis.  There is a central dermal component of small melanocytes near the epidermal-dermal junction.	Skin segment measuring 1.3 x 1.0 x 0.2 cm, with the based inked, quadrisected and entirely submitted. CF/CF	0.9 X 0.6 CM DARK BROWN PAP WITH IRREGULAR BORDERS ON RIGHT MID LAT BACK	\N	\N	\N	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	139524	636	\N	\N	19-15442	\N	DN-161	Dysplastic Nevi	IP2019543	AirTable blocks_with_IP_info.csv
1901	15-117186	21	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.2	\N	\N	Sections show melanocytes arrayed irregularly within the epidermis, and incompletely maturing nests, cords, and fascicles of similar melanocytes are in the dermis below this. The tumor is relatively large in size. The cells of interest are often fusiform and are enlarged. Pale pigmented cytoplasm is noted. Cells in mitosis can be found.	One outside slide, DN15-48616, and one corresponding block.	FLESH-COLORED PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS	\N	\N	\N	This biopsy demonstrates an atypical melanocytic tumor with a differential diagnosis including a mitotically-active deep penetrating nevus on one hand and spitzoid or deep penetrating melanoma on the other. Immunostaining with p16 demonstrates significant loss of expression in over 50% of the tumor, which was of concern. In my original version of this report, I indicated that melanoma could not be excluded from the differential diagnosis based strictly upon microscopic and immunohistochemical findings, and the subsequent molecular evaluation that has now been completed (and that is discussed further below) has confirmed the diagnosis of melanoma. To clarify the nature of this proliferation, molecular assessment was completed (with appropriate payor authorization) via array-based comparative genomic hybridization (aCGH). After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 8q; loss in chromosomes 2p, 3, 5p, 9, and 11p; and segmental gain and loss in chromosomes 1 and 7q. The identification of multiple areas with copy number gain and loss indicates genomic instability, as is stereotypical of melanoma. In short, the molecular findings we have identified are incompatible with a benign interpretation and favor instead a diagnosis of melanoma.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.  Synoptic melanoma reporting has now been included below.  Procedure: shave removal Microscopic tumor type: spitzoid or deep penetrating melanoma Breslow thickness: at least 2.3 mm Ulceration: not detected Margin: deep edge involved by melanoma Mitotic index: 2-3/square mm Vascular invasion: not detected Regression: not detected Pathologic staging (pTNM): pT3aNxMx	MELANOMA OF AT LEAST 2.3 MM IN THICKNESS, INVOLVING THE DEEP EDGE OF THE BIOPSY	102270	689	\N	\N	15-117186	\N	DP-52	CGH Validation	IP1588995	AirTable blocks_with_IP_info.csv
1449	11-13665	36	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	from Swapna	Sections show a polypoid segment of anal mucosa with a large, multinodular proliferation of neoplastic cells with amphophilic cytoplasm and large, pleomorphic vesicular nuclei. Foci of necrosis, many mitotic figures and clusters of melanophages are present. The enclosed immunoperoxidase stains show that the neoplastic cells are positive for HMB45 and Melan-A. Some areas feature enlarged single melanocytes colonizing the basal layer of the epithelium.	Seven outside slides, SROS11-255: A1,A2,A3. One corresponding block (A1) received 4/5/11.	UCSF MELANOMA CLINIC PATIENT	\N	\N	\N	ADDENDUM, April 29, 2011: The following note has been modified from that in the original report, a copy of which is on file as .pdfs in our computer system: The neoplasm extends to the edges of some of the sections, but whether these are true margins or not cannot be determined. There is a significant intraepithelial component, which led to my original supposition that this was a primary melanoma.  Given the findings on re-examination of a previous case in our files, 00-33973, we performed comparative genomic hybridization on both specimens. This specimen showed many genomic aberrations, including some commonly found in melanoma. These included a gain involving 1q, gains and losses in small areas on 5p, a loss on 5q, a gain of 6p and a loss of 6q, a loss of 8p and a gain of 8q, a gain near the end of 10q, a loss of 11q and a gain of 18p with a loss involving 18q. The quality of this hybridization was excellent, while the 2000 hybridization was not as good. However, there are clear aberrations in the 2000 hybridization shared by this one, including those involving 6p and 6q, and 8q. Also, there are clear inflections in the array of the 2000 case at most of the other sites that have aberrations in the current material. This strongly suggests that the current anal lesion is a metastasis from the 2000 cutaneous lesion and not a new primary tumor.	MELANOMA, 12 MM. IN THICKNESS	173521	638	\N	\N	11-13665	\N	DP-01	Possible TERT Fusion	IP249076	AirTable blocks_with_IP_info.csv
1146	04-50387	65	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1364	173.5	\N	\N	Sections show a broad and extremely poorly circumscribed compound proliferation of melanocytes, some with atypical nuclei, arranged above fibroplasia of the papillary dermis. There are single cells and nests arrayed broadly in somewhat lentiginous fashion, with many single melanocytes in pagetoid array. The dermis holds horizontal aggregations of melanocytes enveloped by fibrosis, with a sparse infiltrate of lymphocytes and melanophages also evident, and with elastosis more deeply.	Skin segment measuring 1.1 x 0.8 x 0.1 cm, trisected and entirely submitted.	LARGE IRREGULAR PIGMENTED LESION	\N	\N	\N	Although this lesion shows some dysplastic nevus-like attributes, it is extremely broad and asymmetrical and includes melanocytes in pagetoid array within the epidermis, a combination that favors the above diagnosis. In terms of staging, this is a non-ulcerated primary melanoma with invasion confined to an expanded papillary dermis (Clark's level III). There is no evidence of vascular invasion or perineural extension or regression. Further re-excision of this site is warranted to ensure that local control has been established.	MELANOMA OF 0.35 MILLIMETERS IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO THE PERIPHERAL MARGIN	173582	218	\N	\N	04-50387	\N	CCR-263	California Cancer Registry	IP466795	AirTable blocks_with_IP_info.csv
1774	14-43805	11	\N	\N	\N	T1a	Primary	None	\N	\N	\N	\N	\N	172.5	\N	from Swapna	Sections show a proliferation of melanocytes involving the epidermis and papillary dermis. The span of the junctional component exceeds that of the dermal portion. The lesional melanocytes include many cells with large, irregularly shaped hyperchromatic nuclei and scant cytoplasm. Some have abundant, pale cytoplasm. Nests of melanocytes predominate over those distributed singly along the junctional zone, and some of those nests are confluent. Some areas show maturation and dispersion with descent.	One outside slide, D-2147-14 (LX-14-01265 A-1). One corresponding block received 6-9-14.	COMPOUND NEVUS; ATYPICAL MELANOCYTIC PROLIFERATION	\N	\N	\N	Along with the slides was a report from Barr Dermatopathology suggesting comparative genomic hybridization; per a message from your institution we proceeded with that testing. Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. These include a gain involving chr. 1q, loss of 2p with areas of gain involving 2q but a gain involving the terminal portion of that chromosome, loss involving 4q, and loss involving 9p. Several of these aberrations are commonly found in melanoma.  While formally, this is an AJCC stage pT1a lesion, the prognosis is in a group of cases of this type is even more favorable than in a group of adult patients with conventional AJCC stage pT1a lesions. Spitzoid melanomas in children have a considerably lower rate of extranodal disease. This lesion is well circumscribed and has a margin of about 1 mm. As local recurrence from incomplete excision is rare in lesions of this type, I would suggest a narrow re-excision to achieve 5 mm. margins. Sentinel lymph node biopsy is controversial in this type of case, with childhood spitzoid melanomas having a high rate of nodal involvment, but a much lower rate of extranodal spread. Hence, the prognostic value of the procedure is much less than in an adult patient, and the procedure can lead to overtreatment.	MELANOMA, 0.85 MM. IN THICKNESS	273588	650	\N	\N	14-43805	\N	DP-13	NRAS Amplified	IP1393739	AirTable blocks_with_IP_info.csv
1905	15-123058	9	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Key features include a compound distribution, a small intraepidermal component, a substantial and deep dermal component that is peripherally infiltrative, and a number of melanocytes in mitosis. The cells of interest are fusiform and finely pigmented. Some have large nuclei.	Four outside slides, ES15-58684-A1. One corresponding block received 12/29/15.	0.5 X 0.5 CM LESION	\N	\N	\N	The conventional histopathologic findings are suggestive of a mitotically-active spitzoid deep penetrating nevus. Your submitted immunostains demonstrate that p16 expression is generally preserved, which is in keeping with interpretation as a melanocytic nevus. That said, given the presence of deep mitotic figures in this tumor, we found it difficult to fully exclude pediatric melanoma from the differential diagnosis on strictly histopathologic grounds. In light of this, I recommended molecular analysis via either comparative genomic hybridization or fluorescence in situ hybridization (FISH) to screen for genomic copy number anomalies, as would be expected with melanoma. After receipt of payor authorization, we proceed with array-based comparative genomic hybridization (aCGH). After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed loss of distal chromosome 5q as a monoaberration with no other associated chromosomal gains or losses (there is also equivocal gain in chromosome 7p, but this is a distinctly subthreshold finding). As background for understanding this result, note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. The identification of a monoaberration, and in particular a monoaberration involving chromosome 5q, does not provide support for a molecular diagnosis of melanoma.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a molecular diagnosis of melanoma. Rather, our combined histopathologic and molecular findings support interpretation as an atypical melanocytic nevus (or as a 'partially transformed' tumor). As this biopsy is only partial in nature, reexcision of this site is indicated as follow-up management, if that has not yet been done. The intent of reexcision is simply to ensure complete removal and verify that persistence with additional transformation cannot ensue.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	MITOTICALLY-ACTIVE COMPOUND PROLIFERATION OF ENLARGED MELANOCYTES, WITH LOSS OF DISTAL CHROMOSOME 5q DOCUMENTED VIA COMPARATIVE GENOMIC HYBRIDIZATION	173711	690	\N	\N	15-123058	\N	DP-53	CGH Validation	IP1594906	AirTable blocks_with_IP_info.csv
2457	19-44904	3	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	from Swapna	Sections show a dome shaped skin segment with an effaced epidermis that contains occasional nests of spindled and epithelioid melanocytes. Within the dermis there are nests of large epithelioid melanocytes, with occasional large multinucleate melanocytes. The proliferation has a wedge-shaped profile and in the reticular dermis melanocytes are positioned between thickened collagen bundles. There is a sparse lymphocytic infiltrate.	Eleven outside slides, 19/CH18523, including 10 unstained slides. One corresponding block received 6/24/19.	ATYPICAL - LOOKS LIKE MELANOMA BUT 3 Y/O? CGH USEFUL	\N	\N	\N	ADDENDUM, July 19, 2019: Dear Dr. Hitchcock,  Thank you for sending this case in consultation. I agree with you that this spitzoid proliferation is unusual and has a slightly asymmetric architecture. However it does mature and the FISH findings are reassuring. We performed array comparative genomic hybridization specifically on the superficial nodular area within the tumor that shows greater cytomorphologic atypia and mitotic activity. This demonstrated loss of chromosome 9 but no other significant copy number alterations. p16 immunohistochemistry demonstrates strong staining in the majority of the tumor, but no staining in the area that we tested by aCGH. I believe this case represents an atypical Spitz tumor arising in a Spitz nevus due to loss of CDKN2A (on chromosome 9p). The aCGH findings do not support a diagnosis of melanoma.	COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES	173602	652	\N	\N	19-44904	\N	DP-15	Atypical Spitz Progression	IP2049186	AirTable blocks_with_IP_info.csv
1811	14-96361	37	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	238.2	\N	\N	Sections show a segment of acral skin with a compound melanocytic proliferation.  There are large polygonal, ovoid, and spindled melanocytes in nests separated by clefts from the overlying hyperplastic epidermis, and similar cells are present in collections in the dermis.  Within the epidermis, some of the melanocytes are within the spinous layer. In the dermis, some of the melanocytes contain abundant eosinophilic cytoplasm, but the size of the melanocytes appears to diminish with descent. The melanocytes extend into the reticular dermis.	Ovoid excision measuring 1.0 x 1.0 x 0.2 cm, including a central 0.8 x 0.7 cm pink-brown area. With margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections. HD/KC	0.7 X 0.9 CM TWO-TONED PLAQUE W/ DARK EDGES, HISTORY OF RAPID GROWTH; ACRAL NEVUS, R/O ATYPIA / MELANOMA VS. DERMATOFIBROMA VS. OTHER	\N	\N	Scraping	ADDENDUM, November 16, 2014: The following note has been modified from that in the original report and later addenda, copies of which are on file as .pdfs in our computer system: The junctional component is unusual since melanocytes are arranged in a somewhat irregular array, since many of these melanocytes are large and contain abundant eosinophilic cytoplasm and since there are foci in which single melanocytes predominate over nests. There are clusters of similar melanocytes in the underlying dermis.  Due to these unusual features, I sought to further evaluate this specimen via immunoperoxidase staining. Staining for BAP-1 did not show loss of nuclear staining, as would point to a mutation in that gene (present in a specific subset of Spitz's nevi and other spitzoid lesions). By contrast, there was loss of p16 staining among a subset of the junctional and dermal melanocytes, which can correlate with one of the common genomic aberrations seen in melanocytic neoplasms, bi-allelic loss of chr. 9p, where the gene, CDKN2A that encodes p16 is located.  Given the features on the routinely stained hematoxylin and eosin section, in concert with the partial loss of p16, a definitive diagnosis could not be reached based on these data. Therefore, after receiving authorization to proceed with comparative genomic hybridization (CGH) testing, following microdissection and DNA extraction, we performed CGH to further evaluate this proliferation.  The testing revealed gains of chromosome 7q and 10p. Otherwise, no significant abnormalities were detected. Interestingly, there were no abnormalities of chromosome 9p and thus the loss of p16 staining probably is not significant. The chromosomal abnormalities detected by the CGH study can be seen in atypical Spitz tumors, which is the category into which I would classify this lesion. The CGH results do not support the diagnosis of melanoma, since, in melanoma, there are usually many chromosomal abnormalities detected. Given that this atypical Spitz tumor has been narrow excised, I think that the site could be clinically monitored or a narrow re-excision could be performed. Both Drs. Boris Bastian and Philip LeBoit have reviewed this case and agree with this assessment.	COMPOUND MELANOCYTIC PROLIFERATION, EXTENDING TO WITHIN 0.3 MILLIMETERS OF THE PERIPHERAL INKED MARGIN	672655	243	\N	\N	14-96361	\N	CGH14-348	Nevus Library	IP1446353	AirTable blocks_with_IP_info.csv
1512	11-66564	22	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show an asymmetrical compound proliferation of melanocytes. Within the epidermis, there are large melanocytes with abundant dusty cytoplasmic melanin as well as some smaller ones, and in some areas there is marked confluence of large nests, and these nests include a combination of both melanocytic phenotypes within them. The intraepidermal component extends asymmetrically lateral to a dermal component of similar large cells, many of them in clusters and short fascicles. An encompassing lymphohistiocytic infiltrate with admixed melanophages is also noted. A number of dermal mitotic figures are evident, including some at the very base of the proliferation.	One outside slide, MKS-11-008738 A1-1 and one corresponding block.	MOLE INCREASING IN SIZE AND CHANGING IN COLOR OVER PREVIOUS 2 MONTHS	\N	\N	\N	ADDENDUM, October 10, 2011: Our differential diagnosis for this atypical melanocytic proliferation included melanoma on one hand and a highly atypical melanocytic nevus on the other. To more fully address this differential diagnosis via molecular means, we completed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gains in chromosomes 7p, 13q, and 20, and losses in chromosomes 9, 11p (segmental), and 11q were also noted. The presence of multiple chromosomal copy number aberrations indicates the presence of genomic instability, and this molecular finding points directly to classification as melanoma. In short, the molecular results we have demonstrated are incompatible with any type of melanocytic nevus. In summary, the combination of results derived from conventional microscopy coupled with has provided clear evidence in support of a diagnosis of melanoma. This melanoma is non-ulcerated and shows associated Clark's level IV invasion. Further excision is warranted to ensure that local eradication has been accomplished, if that has not yet been accomplished.	MELANOMA OF 1.6 MM IN THICKNESS, TRANSECTED AT THE SPECIMEN PERIPHERY	173602	657	\N	\N	11-66564	\N	DP-20	CGH Validation	IP1056007	AirTable blocks_with_IP_info.csv
1773	14-42631	23	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a roughly symmetrical compound melanocytic proliferation with a domed surface.  The overlying epidermis is thickened, with hyperplasia of the spinous layer, hypergranulosis and compact hyperkeratosis. Situated at the epidermal-dermal junction are nests of large oval melanocytes, some of which are separated from the epidermis by clefts.  The junctional melanocytes have abundant cytoplasm and large vesicular nuclei. Kamino bodies (dull pink globules) are present. Many melanocytes have abundant, pale cytoplasm and dusty appearing melanin and strikingly large, pleomorphic vesicular nuclei.	One outside slide, JS-14-25671 / A1, and one corresponding block.	DARK IRREGULARLY PIGMENTED PLAQUE, PT HAS A COUPLE OF OTHER SMALLER LIGHTER NEVI ON BUTTOCKS ALSO; NEOPLASM OF UNCERTAIN BEHAVIOR VS. COMPOUND NEVUS, R/O ATYPIA OR DYSPLASIA	\N	\N	\N	Per your cover letter, we performed comparative genomic hybridization. This unusual lesion has the silhouette of a Spitz's nevus, and has many Kamino bodies. However, many of the lesional melanocytes are pulverocytes* and some nuclei near the base of the specimen have strikingly atypical nuclei. Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. There is a small interstitial deletion in chr. 4q of unknown significance. Areas of loss involving chr. 9q are present. Losses involving chr. 9 or 9p are the most common aberrations in melanoma; losses of 9q with preservation of 9p are less common and seem less significant. A small interstitial gain within chr. 10q is present. The most important aberration is a cluster of high level amplifications and losses involving chr. 12q. These include an amplification that my colleague, Dr. Iwei Yeh pointed out to me includes the CDK4 locus. In past work from our group, gains of CDK4 were seen in melanomas that were wild type for b-raf and n-ras.  Given the above findings, a spitzoid melanoma rather than a spitzoid melanoma is the best interpretation for this neoplasm, despite the presence of Kamino bodies.  *This term is introduced in Massi G, LeBoit P. Histologic Diagnosis of Nevi and Melanoma, 2nd Edition, Springer-Verlag, Berlin Heidelberg, 2014 p. 57, and refers to cells with abundant, pale cytoplasm and dusty appearing melanin, deriving from the Latin term for dust; such cells, referred to by the late Dr. A. Bernard Ackerman as pagetoid melanocytes (a confusing term, as it can be used for cells with pagetoid scatter) are unusual in Spitz's nevus.	MELANOMA, 0.95 MM. IN THICKNESS	173507	668	\N	\N	14-42631	\N	DP-31	CGH Validation	IP1392565	AirTable blocks_with_IP_info.csv
1924	16-10466	41	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show melanocytes arrayed in compound fashion with a mostly nested configuration and good lateral demarcation. There are many large nests and fascicles of melanocytes at the junction, and maturing nests, cords, and fascicles of similar melanocytes are in the perijunctional dermis with a lymphohistiocytic infiltrate. Focal adnexal extension is noted. There are occasional pink globules.	Three outside slides, S16-2862-A1, and one corresponding block.	10 X 6 MM PINK/BROWN OVAL WELL-CIRCUMSCRIBED PLAQUE	\N	\N	\N	This specimen does not demonstrate melanoma. Rather, this specimen contains a Spitz nevus (or Spitz tumor) with associated NTRK1 gene fusion. Immunohistochemistry was included in our assessment to more fully characterize the tumor. The cells of interest avidly express NTRK1, and this labeling result corroborates that NTRK1 gene fusion has occurred. ALK immunostaining is negative, and thus there is no indication of ALK gene fusion. A p16 immunostain demonstrates mosaic immunopositivity, and thus biallelic loss of chromosome 9p has not occurred. As you probably know, total loss of p16 expression can be considered a concerning immunohistochemical finding, but that is not present here. Kinase gene fusion, including ALK and NTRK1 gene fusion, represents a not uncommon mechanism of induction of Spitz nevi. Such tumors are only partially transformed and thus are self limited in behavior.  Per request, we completed array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies, as would be expected with melanoma. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in distal chromosome 11q as a monoaberration with no other associated chromosomal gains or losses. As background for understanding this result, note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. The monoaberration involving chromosome 11q that has been defined represents a direct consequence of NTRK1 fusion, as the area of loss initiates in the vicinity of the NTRK1 gene.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. Rather, our histopathologic, immunohistochemical, and molecular results are confirmatory of the diagnosis of Spitz nevus with associated NTRK1 gene fusion.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	COMPOUND SPITZ NEVUS WITH ASSOCIATED NTRK1 GENE FUSION	139524	692	\N	\N	16-10466	\N	DP-55	CGH Validation	IP1609493	AirTable blocks_with_IP_info.csv
1611	12-22592	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Keratosis, Atrophic Solar 	\N	\N	\N	\N	\N	Scalp	\N	\N	\N	\N	1821	\N	\N	12-22592	\N	SYNAT373	2010-2017	\N	AirTable blocks_with_IP_info.csv
1532	11-87412	85	\N	\N	\N	T3a	Primary	None	\N	\N	\N	\N	\N	172.7	\N	\N	There is a segment of severely sun-damaged skin with a wedge-shaped, somewhat asymmetrical proliferation of large oval and spindled melanocytes in the superficial dermis. These are compactly arranged in the upper part of the lesion, with smaller aggregations of somewhat smaller cells dispersed between thickened collagen bundles toward the lower portion of it.	Three outside slides, SW11-6722-A:1-1, A:2-1, and A:3-1, and one corresponding block, A:3.	SPINDLE CELL PROLIFERATION, SEE DL11-77917	\N	\N	\N	Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a low proliferation rate in the upper part of the lesion and a near zero proliferation rate in the lower part. A phosphohistone H3 immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows only rare positive nuclei in the upper part of the lesion. Comparative genomic hybridization shows multiple chromosomal gains and losses diagnostic of melanoma. There are losses involving chromosomes 1q, 7p, 9 and a small portion of 12q. There are gains involving 6q, 7q and 8. Several of these aberrations are commonly found in melanoma, and the large number of aberrations is strong evidence favoring that diagnosis.  I have listed the thickness as at least 1.6 mm. as there was a initial biopsy with a melanocytic proliferation that measures 1 mm in thickness. I cannot tell the exact area in which the intial biopsy overlay the specimen, but it is likely that the thickness was over 2 mm and hence that this was a T3a melanoma.	MELANOMA, AT LEAST 1.6 MM. IN THICKNESS	562711	659	\N	\N	11-87412	\N	DP-22	CGH Validation	IP1076860	AirTable blocks_with_IP_info.csv
1575	12-9397B	20	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a broad based and asymmetrical proliferation of melanocytes involving the epidermis, papillary and superficial reticular dermis. There is a mostly junctional flatter area featuring discrete nests of melanocytes with abundant, pale lightly pigmented cytoplasm and small, monomorphous nuclei, and intervening basilar hyperpigmentation. The raised area features large, compact nests of melanocytes with small round to oval nuclei, small nucleoli and scattered mitotic figures. Some mature with descent is present, and smaller cells lie in between collagen bundles in the superficial reticular dermis and around blood vascular and lymphatic vessels.	Three outside slides, S08-851. One corresponding block received 2-14-12.	2ND OPINION, A) POSTERIOR NECK LESION, B) PIGMENTED IRREGULAR LESION; R/O ATYPIA, C) REEXCISION OF PIGMENTED IRREGULAR LESION, D) BOWEL INTUSSUSCEPTION, POSSIBLE MELANOMA	\N	\N	\N	This lesion has many features of the superficial form of compound congenital nevus. The nests in the more raised area of the lesion are compactly arranged, and melanocytes in mitosis are readily found. The sections are somewhat thick, which may exaggerate the cellularity in the larger nests. The differential diagnosis included a nevus with some unusual features, including mitotic figures (which can occur in benign nevi), and an unusual nevoid melanoma. Per my discussion with Dr. Spitler, we requested the blocks from the skin lesion (this part of the case) and from (D) for comparative genomic hybridization. This was to see if chromosomal aberrations typical of melanoma are present in the skin lesion, and if so, if they are the same ones as are present in the intestinal metastasis.  Comparative genomic hybridization shows findings indicative of melanoma in this unusual case. There are multiple chromosomal gains and losses, some of them involving areas that are frequently aberrant in melanoma. The aberrations in this case include a loss involving 5q, a loss of 6qtr, chromosome 9, a complex rearrangement involving 11q with multiple gains and losses, a loss of 12p and a gain of 13. The pattern seen here overlaps with that found in a separate CGH reaction from DNA extracted from the bowel metastasis (see part D, below).	MELANOMA, 1.0 MM IN THICKNESS	173619	661	\N	\N	12-9397	B	DP-24	CGH Validation	IP1095213	AirTable blocks_with_IP_info.csv
1653	12-64897	19	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.6	\N	\N	There is a multinodular dermal proliferation of large, oval melanocytes with abundant, amphophilic cytoplasm and large, vesicular or hyperchromatic nuclei in the dermis, sparing the epidermis. Occasional melanocytes have abundant, pale cytoplasm and dusty appearing melanin. There is a lack of maturation or dispersion with descent. There are admixed lymphocytic infiltrates.	One hematoxylin and eosin-stained section prepared from outside block labeled Y12-2899 A1. Three additional corresponding slides (A1 and A2) received 8-31-12.	SPITZ	\N	\N	\N	Comparative genomic hybridization shows several chromosomal aberrations indicative of melanoma. There are losses involving chromosomes 4, 9, 11 and 14 with gains involving chromosomes 19p and 20q. Chromosome 9 is the most commonly lost chromosome in melanoma, and when present along with other multiple other aberrations supports the diagnosis of melanoma. Given the age of the patient and spitzoid morphology, the prognosis may be more favorable than the thickness would indicate. The margin is focally involved at the level of the deep reticular dermis.	MELANOMA, 3.4 MM. IN THICKNESS	173602	663	\N	\N	12-64897	\N	DP-26	CGH Validation	IP1150713	AirTable blocks_with_IP_info.csv
1713	13-32039	25	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a dome shaped segment of skin with an intradermal proliferation of large, oval melanocytes with abundant, pale amphophilic cytoplasm and large, vesicular nuclei containing moderately enlarged nucleoli. The lesional melanocytes are distributed singly or in small collections. The enclosed immunoperoxidase stains show that there is a relatively low proliferation rate and that there is retention of p16 tumor suppressor protein staining.	Five outside slides, S13-02977 (REB13-3963). One corresponding block received 5-1-13.	EXOPHYTIC SMOOTH BROWN NODULE, ABOUT 10 X 18 MM; POSSIBLE NEVUS, R/O MALIGNANCY  (SEE CLINICAL IMAGES)	\N	\N	\N	Thank you for sending the clinical image of this patient's lesion. The neoplasm extends to the base of the specimen across a broad front. Comparative genomic hybridization shows several genomic aberrations. These include gains involving chromosomes 5 and 17, and a complex rearrangement involving chromosome 7. The latter includes an amplification of the promoter region of b-raf, with loss of most the rest of that gene. Our group has identified similar b-raf fusions as a driver in cases in which b-raf mutation is absent (abstract ASCO, 2013). My colleague, Dr. Boris Bastian has also reviewed the comparative genomic hybridization data and agrees with this interpretation of it.  Based on the findings by conventional histopathology and by comparative genomic hybridization, I would assess this as a atypical Spitz tumor- a proliferation of melanocytes with features intermediate between Spitz's nevus and spitzoid melanoma. Lesions of this type often involve local lymph nodes, but seldom have distant metastases. Because of the lack of predictive value, sentinel lymph node biopsy can lead to over-treatment. If there were to be distant metastasis in the future, treatment with a b-raf inhibitor might be indicated, as lesions with b-raf fusions like this one can respond to agents targeting b-raf, despite the absence of driver mutations.	MOSTLY INTRADERMAL PROLIFERATION OF LARGE SPITZOID MELANOCYTES, BEST REGARDED AS AN ATYPICAL SPITZ TUMOR	17722	664	\N	\N	13-32039	\N	DP-27	CGH Validation	IP1216784	AirTable blocks_with_IP_info.csv
1623	12-22884D	55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.0	Melanocytic Nevus	\N	Sections show a domed segment of skin, with nests, cords and strands of small round melanocytes in the dermis.	Skin segment measuring 0.4 x 0.3 x 0.1 cm, submitted intact in cassette D.	A-C) SK, D) IDN	\N	Intradermal, left lower lip	\N	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	201098	1676	\N	\N	12-22884	D	SYNAT379	Melanocytic Nevus	IP1108702	AirTable blocks_with_IP_info.csv
1734	13-73582	18	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a compound proliferation of large oval melanocytes that extends from the junctional zone to the base of the specimen in the mid-reticular dermis. The center of the lesion features irregular epidermal hyperplasia and parakeratotic scale-crust, with subepidermal fibrin deposits. In the upper part of the lesion, there are large confluent nests of melanocytes with indistinct cell borders, pale vacuolated cytoplasm and pleomorphic nuclei. More discrete aggregations of slightly smaller cells are positioned between collagen bundles toward the base of the lesion. The enclosed Ki-67 stain shows a moderate proliferation rate among the lesional melanocytes.	Three outside slides, DC13-489, SCC13-2099, DT13-4756 and one corresponding block.	SPITZ NEVUS, R/O MELANOMA	\N	\N	\N	The mode of biopsy precluded an evaluation of some architectural features. Comparative genomic hybridization shows an amplification involving chromosome 7q. Isolated gains involving this area have been seen in Spitz's nevi, with several different morphologies. High level copy number gains or amplifications involving 7q can occur in such lesions when there are gene fusions involving b-raf, where the fusion partner is within 7q. The subject of spitzoid lesions with b-raf fusions is discussed in the paper below. Given the findings seen here, and this genomic result, I believe that a conventional melanoma can be excluded. The most likely possibility is that this is a Spitz's nevus with a b-RAF fusion, and some unusual morphologic features. Ideally, complete excision with a narrow margin of uninvolved skin would be attained. It is difficult to make a suggestion regarding complete removal without knowing what this would entail at this site.  Reference:  Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M, Rocchi S, Bahadoran P, McCalmont TH, Leboit PE, Burton EA, Bollag G, Ballotti R,  Bastian BC. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res. 2013 Jul 24. doi: 10.1111/pcmr.12148. [Epub ahead of print] PubMed PMID: 23890088.	COMPOUND PROLIFERATION OF LARGE, SPITZOID MELANOCYTES, WITH GENOMIC FEATURES FAVORING AN UNUSUAL SPITZ'S NEVUS	172340	665	\N	\N	13-73582	\N	DP-28	CGH Validation	IP1315587	AirTable blocks_with_IP_info.csv
1735	13-75788B	45	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	198.2	\N	\N	Sections show nodular aggregations of large, epithelioid cells similar to those in (A), with more nuclear pleomorphism and hyperchromasia. There is variably intense staining with low molecular weight, and pan-keratin.	Seven outside slides, 12SSH7050 (1A - 1A3) and one corresponding block (1A), received 9-25-13.	PT WITH METASTATIC MELANOMA TO THE LYMPH NODES, NO PRIMARY EVER FOUND, HALO NEVUS ENLARGING (POSSIBLE CGH)	\N	\N	\N	The findings in the hematoxylin and eosin-stained sections in (A)suggested a Spitz's nevus with a halo reaction. While the morphology suggested a BAP-1 mutation, staining for BAP-1 did not show loss of nuclear staining, as would point to a mutation in that gene (present in a specific subset of Spitz's nevi and other spitzoid lesions). One can occasionally see retention of immunohistochemical staining with BAP-1 mutations, however. Immunostaining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a relatively low proliferation rate in the dermal melanocytes. Given the keratin positivity in (B) I also obtaining a keratin stain in (A), but it is negative.  A Fontana stain shows complete loss of melanin from the basal layer of the epidermis, in keeping with the history of a halo. Comparative genomic hybridization in (A) did not show chromosomal gains or losses, a finding that is strongly against melanoma.  We also reviewed the sections from the metastasis, see part (B) below. Staining for BAP-1 in (B) shows no loss of that protein (the same result as in (A). Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. While the hybridization was of low quality (probably due to the presence of necrosis en masse), there were gains in 3q, 5p, 6p, 8q and 10p, and losses in 6q, 9 and 10p, among others.  In sum, the findings point to the two lesions as being unrelated.	METASTATIC MELANOMA	173541	666	\N	\N	13-75788	B	DP-29	CGH Validation	IP1317793	AirTable blocks_with_IP_info.csv
1776	14-46549	36	\N	\N	\N	T3a	Primary	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show melanocytes arrayed in compound fashion in a sessile specimen. There are large fusiform, epithelioid, and plasmacytoid melanocytes that are distributed in some very large nests and in collagenous dermal stroma. Cells in mitosis can be found in the perijunctional zone.	Three outside slides, COV14-697 A1 and one corresponding block.	MOLE REMOVAL	\N	\N	\N	Per your approval, we completed array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies, as can be seen with melanoma, at a reduced fee. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 1q, 8q, 20q, and 21q with gain and loss in chromosome 3q and with loss of distal chromosome 6q. The identification of multiple chromosomal copy number abnormalities indicates genomic instability, as is stereotypical of melanoma. The aCGH profile that we have defined is essentially incompatible with a benign interpretation. With respect to staging, this non-ulcerated melanoma is between 2-4 mm and thus represents melanoma of stage pT3a (2009 AJCC Guidelines). Further excision is warranted to ensure that local control has been established.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	MELANOMA OF 3.8 MM IN THICKNESS, FOCALLY INVOLVING THE DEEP EDGE OF THE BIOPSY	173727	669	\N	\N	14-46549	\N	DP-32	CGH Validation	IP1396485	AirTable blocks_with_IP_info.csv
1247	06-28087	59	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.6	\N	\N	Sections show skin with a moderate degree of solar elastosis. There is a moderately broad but poorly circumscribed proliferation of melanocytes, arranged singly and as both small and large nests along the junction, with areas in which junctional nests are confluent. There is a central area in which rete ridges are lost, the papillary dermis is fibrotic, and there are small nests of melanocytes within it accompanied by lymphocytes and melanophages.	Excision measuring 1.0 x 0.8 x 0.3 cm, including central 0.8 x 0.7 cm pigmented area.  With margins inked blue, the specimen is serially quadrisected and entirely submitted.	R/O MELANOMA	\N	\N	Scraping	The intraepidermal portion of this lesion extends to within less than 1 mm of the edges of the specimen. The lesion is unusual, in that most of the constituent melanocytes are not strikingly atypical on a cytologic basis. There is no evidence of ulceration or of other microscopic findings that would have an adverse prognostic influence. Histopathologic features of possible prognostic importance include:  Level: II Tumor infiltrating lymphocytes: moderate Vascular or lymphatic invasion: absent Mitotic rate: n/a Perineural invasion: absent Ulceration: absent Regression: absent Microsatellite metastasis: absent	MELANOMA, 0.4 MM IN THICKNESS	173620	184	\N	\N	06-28087	\N	CCR-204	California Cancer Registry	IP573155	AirTable blocks_with_IP_info.csv
1473	11-31904	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	777	\N	\N	11-31904	\N	KF-02	Fusion RNA	\N	AirTable blocks_with_IP_info.csv
1858	15-21741	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26317	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	766	\N	\N	15-21741	\N	JJS28	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1961	16-63804	15	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a compound proliferation of melanocytes arrayed as a few small nests along the epidermal-dermal junction, and as nests, cords and strands that extend into the superficial reticular dermis and are distributed around adnexa. Markedly fibrotic stroma is present in some areas, and there are dermal melanocytes with abundant, pale cytoplasm.	Skin segment measuring 0.7 x 0.6 x 0.3 cm, bisected and entirely submitted. HD/HD	IRREGULAR BROWN PAPULE AND 3 SHADE COLOR; ATYPICAL NEVUS	\N	\N	\N	The overall findings favor a nevus with congenital features, but some peculiar features are present, including some larger cells in the dermal component and fibrotic stroma. A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product (nearly complete or complete loss in a defined zone is worrisome for melanoma).  Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a relatively low proliferation rate in the junctional component and a moderately elevated proliferation rate in a mid-portion of the dermal component. The MART-1/tyrosinase component does not reveal more suprabasilar scatter than could be seen in the hematoxylin and eosin stained sections.  The findings are peculiar, and in another setting, I would consider complete excision. There may be a role for adjunctive testing, and follow up rather than excision if the results point to a benign lesion. I would be happy to discuss this with you.  ADDENDUM, July  6, 2016:  Per your message, we will proceed with comparative genomic hybridization. Results are usually available in 3-4 weeks.  ADDENDUM #2, July 30, 2016:  Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows a gain involving an area on distal chr. 7q, with a breakpoint within the b-raf gene. We have seen this pattern in Spitz nevi with braf gene fusions (e.g. fusions of b-raf with another partner on the same chromosome). These fusions activate b-raf transcription, and are much rarer than are b-raf mutations. While b-raf gene fusions can occasionally occur in melanoma, these are very rare and would be expected to be accompanied by other chromosomal copy number changes. Also, the morphology of some of these cases has had single melanocytes permeating the deep reticular dermis similar to the appearance here.  The neoplasm extends to the base of the specimen. Given this result by comparative genomic hybridization, I favor an unusual nevus with some spitzoid features. I believe that the site could be periodically followed.	COMPOUND MELANOCYTIC NEVUS WITH SOME UNUSUAL FEATURES, SEE COMMENT	128529	708	\N	\N	16-63804	\N	DP-71	CGH Validation	IP1663322	AirTable blocks_with_IP_info.csv
1784	14-57552	36	\N	\N	\N	T2a	Primary	None	\N	\N	\N	\N	\N	172.5	\N	\N	A partially circumscribed, hypercellular compound proliferation of enlarged fusiform and epithelioid melanocytes has associated epithelial hyperplasia with areas of thinning. In this background epidermis, melanocytes are distributed confluently and sometimes in pagetoid fashion. There is limited extension of these melanocytes along adnexal epithelium and into the perijunctional dermis, where a lymphohistiocytic infiltrate with admixed melanophages is noted.	Two outside slides, ES14-26948 (A1), and one corresponding block.	HISTORY OF NEVUS FOR A LONG TIME BUT WHICH IS CURRENTLY CHANGING IN COLOR AND COMPOSITION, IRREGULAR DARK BROWN TO BLACK MOLE WITH HALO EFFECT; ABNORMAL NEVUS	\N	\N	\N	My differential diagnosis included both minimally invasive melanoma on one hand and an unusual inflamed Spitz nevus on the other, and after the completion of the assessment that is delineated in the sentences that follow, the former possibility has been substantiated as the best overall diagnosis for this case. Immunostaining with p16 demonstrates diffuse preserved expression, and this staining result implies that the loss of CDKN2A function (and loss of p16 expression) that can be seen n association with many examples of melanoma is not apparent here (this finding was borne out by molecular assessment, as is discussed in the paragraph that follows). Given the unusual and challenging histomorphology, we proceed with array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies, as would be expected with melanoma and as per your approval. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in chromosomes 8p, 10, and 11q, and additionally there was a focused gain in chromosome 11q at the location of the CCND1 gene. The identification of multiple copy number abnormalities indicates genomic instability, as is stereotypical of melanoma, and in particular the finding of CCND1 gain is associated with the diagnosis of melanoma. As was alluded to in the paragraph above, chromosome 9 was found to be without aberrations, and thus the preserved expression of p16 that has been documented is appropriate, even in the context of a diagnosis of melanoma.  In summary, based upon the analysis of both histopathologic and molecular attributes, we have confirmed a diagnosis of spitzoid melanoma. This melanoma is only minimally invasive, and its overall microstage thickness has been inflated by associated acanthosis. With respect to staging, this non-ulcerated tumor is between 1-2 mm in thickness and thus is technically staged as a melanoma of stage pT2a (2009 AJCC Guidelines), although I suspect stage pT1a is more reflective of the situation, since the dermal involvement seen here is minimal.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	MELANOMA OF 1.1 MM IN THICKNESS, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	173528	670	\N	\N	14-57552	\N	DP-33	CGH Validation	IP1407492	AirTable blocks_with_IP_info.csv
1806	14-83928	31	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a large pan-dermal population of atypical spindle cells that completely lacks maturation. These cells are arrayed in coalescing fascicles within the larger nodule, and cells and mytosis are commonly found.  Some of the cells of interest form rounded, lumen-like spaces.  The encompassing dermis is fibrotic and highly vascular with congested vessels.  Accompanying immunostains demonstrate expression of SOX-10 and S100 protein, Patchy expression of MelanA and HMB-45, and preserved nuclear expression of INI-1.	Twenty-one outside slides, DC14-03059 (A-C) (GLC-14-03777), and one corresponding block (C).	R/O CYST VS. LIPOMA VS. JXG	\N	\N	\N	Our differential diagnosis included melanoma and so-called paraganglioma-like dermal melanocytic tumor, and the observed degree of cytologic atypicality and the elevated mitotic index associated are concerning for the former possibility. A detailed molecular analysis of the latter entity has not yet been completed, but chromosomal copy number abnormalities would likely be infrequent in that context (given that it is said to be a low-risk tumor). To attempt to clarify the diagnosis, we additionally completed comparative genomic hybridization (CGH) to screen for chromosomal copy number abnormalities, as would be expected with melanoma. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed a focused deletion involving chromosome 5q as a monoaberration with no other associated chromosomal gains or losses. (The deletion in chromosome 5q includes the APC gene, which is part of the WNT signaling pathway.) As background for understanding this result, note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. In summary, the combination of results derived from aCGH has not produced confirmation of a molecular diagnosis of melanoma. Although it is impossible to exclude melanoma on histopathologic grounds, the molecular result that has been obtained suggests that this tumor may be of ambiguous or low-grade biologic potential. In short, classification as a paraganglioma-like melanocytic tumor (or as a similar form of low-grade tumor) can be considered plausible from a molecular standpoint. Dr. Boris Bastian has reviewed the molecular data for this case and agrees that the molecular result should not be viewed as being confirmatory of a diagnosis of melanoma.  This tumor is 7.9 mm in thickness and is non-ulcerated. It has not yet been adequately excised.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	PLEOMORPHIC SPINDLE CELL TUMOR WITH S100-IMMUNOPOSITIVITY AND A LACK OF SIGNIFICANT GENOMIC COPY NUMBER ABERRATIONS	173604	671	\N	\N	14-83928	\N	DP-34	CGH Validation	IP1433898	AirTable blocks_with_IP_info.csv
1804	14-82758	8	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a pedunculated segment of skin with a mostly papillary dermal proliferation of large, oval melanocytes with homogeneous appearing eosinophilic cytoplasm and markedly pleomorphic and heterochromatic vesicular nuclei, some with large, central nucleoli. Some maturation with descent is evident. Several mitotic figures are present. A patchy lymphocytic infiltrate is also seen.	Six outside slides, D-14-00845 (A1) (HR14-31395-A), and one corresponding block.	PATIENT WITH A FIVE-MONTH HISTORY OF A GROWTH ON HIS LEFT HAND, DIGIT FOUR, THE LESION WAS FROZEN A FEW WEEKS AGO AND TURNED RED BUT DID NOT GO AWAY, WHEN HE PRESENTED TO ME, HE HAD A PINK DOME-SHAPED PAPULE ON THE DORSAL ASPECT OF THE DIGIT, 0.5 CM PAPULE; R/O PYOGENIC GRANULOMA	\N	\N	\N	ADDENDUM, October  5, 2014 The following note has been modified from that in the original report and preceding addenda, copies of which are on file as .pdfs in our computer system; the new material is bracketed with asterisks: The differential diagnosis includes an atypical Spitz tumor and spitzoid melanoma.  *** Comparative genomic hybridization shows no significant chromosomal gains or losses. This is a reassuring finding, and could signify that the chromosomal copy number changes seen in fluorescence in situ hybridization might reflect changes in a minor population. I would regard this as an atypical Spitz tumor, and obtain a re-excision (given the configuration, not much wider, but deeper). ***	PREDOMINANTLY INTRADERMAL PROLIFERATION OF LARGE, SPITZOID MELANOCYTES, BEST VIEWED AS AN ATYPICAL SPITZ TUMOR	173613	672	\N	\N	14-82758	\N	DP-35	CGH Validation	IP1432726	AirTable blocks_with_IP_info.csv
1810	14-95595	4	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	A broad shave biopsy demonstrates a compound proliferation of enlarged fusiform and epithelioid melanocytes. The background epidermis is partially acanthotic but also significantly thinned, and melanocytes are in pagetoid array within it. There are non-maturing melanocytes distributed diffusely within the dermis below this, where occasional melanocytes in mitosis can be found. The melanocytes are distributed somewhat syncytially and permeate superficial skeletal muscle. The Ki-67 cell proliferation index is elevated.	Four outside slides, SD14-7940 (A1), and one corresponding block.	5 MM YELLOW PAPULE; IMPRESSION INCLUDED JUVENILE XANTHOGRANULOMA, VERRUCA, OTHER	\N	\N	\N	Based upon the observed histopathologic findings coupled with the elevated Ki-67 cell proliferation index and the loss of p16 expression that you demonstrated, I found this tumor worrisome for childhood spitzoid melanoma. To further explore the nature of this proliferation, we completed array-based comparative genomic hybridization (aCGH) analysis to screen for genomic copy number anomalies. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in distal chromosome 7q as a monoaberration with no other associated chromosomal gains or losses. The area of gain includes the BRAF gene, but there is no indication of a BRAF gene fusion. As background for understanding this result, note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. The identification of monoaberrations is generally considered non-supportive of the diagnosis of melanoma. Additionally, the aCGH tracing does not demonstrate loss in chromosome 9p, thus indicating that the loss of p16 expression that has been demonstrated is likely epigenetic in nature. After completion of aCGH, BAP-1 immunohistochemistry was additionally completed. Strong expression was observed, indicating that loss of this tumor suppressor protein has not occurred (this corroborates the normal result observed with respect to chromosome 3p in the aCGH tracing). In summary, the interpretation of this tumor is not straightforward. Summing all of the available findings, we have defined a spitzoid melanocytic tumor that has epigenetic loss of p16 expression and that has an associated genomic monoaberration involving distal chromosome 7q. This combination suggests that this tumor does not represent childhood spitzoid melanoma but rather represents a partially transformed Spitz tumor ('atypical Spitz tumor'). Since the current biopsy is only partial in nature, reexcision of the remainder of this tumor will be necessary as follow-up care.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.  This report was reissued on December 10, 2014, after correcting a typographical error. (A dropped word was inserted.)	ATYPICAL COMPOUND PROLIFERATION OF MELANOCYTES, INVOLVING THE DEEP EDGE OF THE BIOPSY	101044	673	\N	\N	14-95595	\N	DP-36	CGH Validation	IP1445586	AirTable blocks_with_IP_info.csv
1842	15-10108	14	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a compound proliferation of melanocytes, with nested and solitary melanocytes arrayed irregularly along the junction.  There are clusters and syncytia of melanocytes arrayed irregularly in the superficial dermis, which is fibrotic, and some melanocytes are larger.  Small melanocytes are present amongst reticular dermal collagen bundles in some foci in the uppermost reticular dermis, but some are larger as well. The epidermis is largely folded in initial sections.	One outside slide, N15-33-GB (15-DM-462-1). One corresponding block received 2/6/15.	STRONG FAMILY HISTORY OF MELANOMA, NEW PINK LESION ON BACK	\N	\N	\N	ADDENDUM, March 13, 2015: While there are some features suggesting a Spitz's nevus, there is an irregular distribution of melanocytes and incomplete maturation. Immunostaining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows a relatively low proliferation index. A p16 immunoperoxidase stain shows partial retention of that tumor suppressor gene product. BAP-1 staining is also preserved (this can be lost in a subset of Spitzoid proliferations). To assess whether this may reflect an emerging class of Spitzoid neoplasms with genetic fusion events, I also examined ALK and NTRK-1 which are not overexpressed. For further assessment of this proliferation, to exclude the possibility of Spitzoid melanoma, I was interested in obtaining comparative genomic hybridization on this case. This is a technique that assesses chromosomal gains or losses, which (with the exception of a gain of 11p, and few other specific, less common aberrations) are found in melanoma and not in Spitz's nevus. Dr. Timothy McCalmont, also reviewed these sections and agreed with this assessment.  We subsequently received your message authorizing comparative genomic hybridization and this has now been completed. The results are unusual but do not support a diagnosis of melanoma, nor is there an 11p gain as in some Spitz's nevi. I asked my colleagues Drs. Bastian and Yeh, of our molecular unit, to analyze these findings further. There are a complex array of small gains and losses involving a portion of chromosome 7q mainly, and a loss of a portion of 12p. Such anomalies have not been characterized or associated with a specific melanocytic entity to date. Thus, an atypical nevus is likely. However, as there are aberrations and unusual histologic features, as above, re-excision of this site is warranted as noted in the initial report.	COMPOUND MELANOCYTIC PROLIFERATION, WITH SPITZOID FEATURES, EXTENDING TO THE EDGE AND BASE OF THE SPECIMEN	173530	674	\N	\N	15-10108	\N	DP-37	CGH Validation	IP1481138	AirTable blocks_with_IP_info.csv
1862	15-25818	19	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a mostly intradermal proliferation of large, oval melanocytes with abundant pale cytoplasm and large, vesicular nuclei. The lesion has a pedunculated contour. There are elongated rete ridges with basilar hyperpigmentation and increased numbers of single melanocytes toward the edge of the lesion. In its core, there are strands of large, oval melanocytes with fibrotic stroma.	Seven outside slides, NF-15-3476-ND, including six unstained slides. One corresponding block received 4-3-15.	0.9 CM SHAVE, APL	\N	\N	\N	ADDENDUM, April 24, 2015: The following note has been modified from that in the original report and later addenda, copies of which are on file as .pdfs in our computer system: The differential diagnosis included an atypical Spitz tumor and a spitzoid melanoma.  A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product. However, an A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows several mitotic figures in the lower part of the lesion including one marginal mitosis. Given this, I suggested obtaining comparative genomic hybridization. This showed an interstitial loss involving chr. 3p, as well as a loss involving the terminal part of chr. 19p. The interstitial area in 3p includes the BAP-1 gene. The loss of chr. 19p is not one associated with melanoma.  The morphology is not stereotypic for a spitzoid lesion with BAP-1 loss. However, there is a predominant population of epithelioid melanocytes with pale cytoplasm, so it seems compatible.  Please also note that the junctional component of this lesion is at a margin, and that the lesional thickness is 4 mm. Local control with atypical Spitz tumor and spitzoid melanomas can be achieved with more narrow margins than conventional melanoma, and the metastatic risk is much less than that of a conventional melanoma of comparable thickness.	ATYPICAL SPITZ TUMOR	102537	676	\N	\N	15-25818	\N	DP-39	CGH Validation	IP1496980	AirTable blocks_with_IP_info.csv
1867	15-33496	48	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a compound proliferation of melanocytes that is slightly asymmetrical. Along the junction, single melanocytes and large fascicles of finely pigmented melanocytes are noted, and these fascicles are noteworthy for the presence of ample myxoid change. In the dermis below this, partially maturing nests, cords, and syncytia of similar melanocytes are noted. In some areas in the dermis, the melanocytes become epithelioid or spindled in configuration, and a flanking infiltrate of lymphocytes and melanophages is noted. Scattered melanophages are present concurrently (Microscopic description by Dr. Timothy McCalmont).	Five outside slides, SLNS15-5627 (A1). One corresponding block received 4/24/15.	6 MM PIGMENTED LESION RECENTLY CHANGING WITH SOME IRREGULAR DERMOSCOPIC FEATURES, NO PHOTO AVAILABLE; R/O PIGMENTED SEBORRHEIC KERATOSIS VS. ATYPICAL NEVUS VS. MELANOMA	\N	\N	\N	ADDENDUM, May 11, 2015: Dr. Timothy McCalmont's initial note read:  The differential diagnosis lies between myxoid melanoma on one hand and a myxoid melanocytic nevus on the other. On balance, I favor the former possibility as most likely, but I do not believe that an utterly definitive diagnosis is possible based solely on histopathologic parameters. Given the extremely unusual configuration of this tumor, molecular analysis has been recommended.  We are just in receipt of the tissue block and will proceed with array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies. A diagnostic delay of approximately 3 weeks will ensue while molecular testing is completed.  Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. These include a gain of chr. 5p, loss of 5q, loss of 6qter, loss of 9, loss of a pericentromeric area of 12, loss of 17 and losses and gains in a complex pattern in chr. 22. This melanoma has myxoid stroma, a finding of histopathologic interest, but not relevant to clinical behavior. A superficial dermal margin is involved.	MELANOMA, 1.2 MM IN THICKNESS	173688	678	\N	\N	15-33496	\N	DP-41	CGH Validation	IP1030082	AirTable blocks_with_IP_info.csv
1870	15-41815	68	\N	\N	\N	T2a	Primary	nevoid melanoma	\N	\N	\N	\N	\N	172.7	\N	\N	There are nests, cords and strands of round melanocytes within the superficial dermis, which exhibit some degree of maturation with descent. There are also portions of the proliferation with clusters of larger melanocytes, some with vacuolated cytoplasm and medium-sized to large nuclei. Scattered mitoses are noted and there are epithelial collarettes present.	Cylindrical skin segment, 0.6 cm in diameter and 1.0 cm in thickness, bisected and entirely submitted. CF/CF	FIRM PAPULE W/ IRREGULAR PIGMENTATION; ? NEVUS VS. DF (TELEPHONE: 415-863-4204 - NEED RUSSIAN INTERPRETER, OK TO LMSG)	\N	\N	\N	Immunostaining using Ki-67 shows an elevated proliferation rate of the melanocytes in some areas (>10%), and p16 staining shows complete loss of staining in the larger population of atypical melanocytes with retained staining in the benign nevus portion. Given these concerning features, additional testing was performed with fluorescent in situ hybridization (FISH) using four probes (to loci on 6p, 6q, 6cent and 11q) and two probes to chromosome 9 (cep9 and 9p21) to assess for CDKN2A loss. The four probe cocktail showed polyploidy which is an ambiguous result that can be seen in both melanomas and some Spitz nevi, while the chromosome 9 probes showed homozygous loss of 9p21. The latter finding in the context of the other findings in this case supports a diagnosis of melanoma. I have shared this case with my colleague Dr. Philip LeBoit who agrees with this interpretation. A synoptic report of potential prognostic factors is listed below: Procedure: punch biopsy Microscopic tumor type: nevoid melanoma Breslow thickness: 1.5 mm Ulceration: absent Margins, peripheral and deep: peripheral positive for nevus, melanoma within 0.5 mm, deep neg Mitotic index: 1 mm/2 Regression: not identified Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT2a	MELANOMA, 1.5 MM IN THICKNESS, NON-ULCERATED, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	173701	679	\N	\N	15-41815	\N	DP-42	CGH Validation	IP1513088	AirTable blocks_with_IP_info.csv
1880	15-52489	16	\N	\N	\N	T1a	Primary	nevoid melanoma ex 'BAPoma'	\N	\N	\N	\N	\N	172.5	\N	\N	A broad shave biopsy contains a broad compound proliferation of melanocytes that is biphasic or triphasic in its composition. Within the epidermis, large fusiform and epithelioid melanocytes are distributed confluently, and the cells extend into the stratum spinosum, the stratum granulosum, and adnexal epithelium. In the dermis below this, a polymorphous melanocytic population is noted. There are large melanocytes in the upper dermis that are similar to those seen intraepidermally, while smaller hyperchromatic melanocytes are present more deeply in the dermis. Scattered only occasionally, there are also extremely large epithelioid melanocytes with ample cytoplasm. Much of the dermis appear fibrotic, and a scattered infiltrate of lymphocytes and eosinophils is also noted.	Four outside slides, 15-AD-26995-1A, and one corresponding block.	IMPRESSION WAS R/O R/O DYSPLASTIC NEVUS	\N	\N	\N	Array-based comparative genomic hybridization (aCGH) has been completed as per payor authorization. My previously-reported histopathologic analysis of this tumor remains in this report and is included in full below the line of asterisks that has been inserted (below). With respect to molecular assessment, after microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed segmental loss of chromosome 3p as a monoaberration with no other associated chromosomal gains or losses. As background for understanding this result, note that many melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. The identification of chromosome 3p loss confirms that BAP-1 genomic loss has occurred in this tumor. There are a number of reasons why aCGH analysis could fail to identify additional copy number change in a component of melanoma, including an inherent lack of copy number change in the given tumor, the effects of contaminating normal cells, or sampling error. In summary, the combination of results derived from conventional microscopy coupled with aCGH has confirmed the presence of BAP-1 genomic loss. Analysis by aCGH has not demonstrated a molecular footprint that is diagnostic of melanoma, but I still believe a component of melanoma is present on histopathologic grounds.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.  *************************************************************************************************************************** Objectively, I believe the histomorphology in your submitted slides point to a diagnosis of nevoid melanoma ex melanocytic nevus. Your submitted phosphohistone immunostain labels melanocytes in mitosis, most of which appear to be intraepidermal in distribution. We additionally completed p16 and BAP-1 immunostains as part of our assessment. The p16 stain demonstrates partial loss of expression, and thus hemizygous loss of chromosome 9p may be present in this tumor. The BAP-1 stain demonstrates loss of nuclear positivity in a subset of large epithelioid cells within this polymorphic tumor, and this labeling result indicates that BAP-1 genomic loss has occurred. In short, I believe this biopsy demonstrates melanoma ex 'BAPoma'.  Deletions (or loss) in BAP-1 can be detected by comparative genomic hybridization (CGH), and the presence of genomic loss can also be inferred by the identification of loss of nuclear BAP-1 expression by immunoperoxidase staining, as has been demonstrated here. Loss of BAP-1 can be accompanied by mutations in the remaining BAP-1 allele, which can be somatically acquired or inherited (germline). Inherited mutations of BAP-1 have recently been associated with a new cancer susceptibility syndrome, which is characterized by the occurrence of multiple skin-colored papules in affected individuals, only a minority of which develop uveal or cutaneous melanoma. Affected family members have had many (5 to >50) of the clinically innocuous yet histopathologically distinct melanocytic tumors, whereas there were few melanomas, suggesting that malignant potential is very low. Independently, germline mutations of BAP-1 have also been reported to be associated with familial mesothelioma.  The significance of this tumor in this patient needs to be judged in the larger familial context. If this is a solitary papule in a patient with no other similar lesions, then the BAP-1 alteration may be sporadic. If this patient has multiple similar papules or if there are similar papules in other family members, then the possibility of an underlying syndrome (with germline mutation) may be deserving of further consideration. If there is clinical interest in further corroborating the above diagnosis by means of comparative genomic hybridization (CGH), please let me know and we can proceed once authorization has been received.  Synoptic melanoma reporting is included below.  Procedure: shave removal Microscopic tumor type: nevoid melanoma ex 'BAPoma' Breslow thickness: 0.65 mm Ulceration: not detected Margin: deep edge involved Mitotic index: 0 Regression: not detected Pathologic staging (pTNM): pT1aNxMx	POLYMORPHOUS COMPOUND PROLIFERATION OF MELANOCYTES, INCLUDING BOTH MELANOMA OF 0.65 MM IN THICKNESS AND AN ATYPICAL COMBINED MELANOCYTIC NEVUS WITH ASSOCIATED BAP-1 GENOMIC LOSS	173568	680	\N	\N	15-52489	\N	DP-43	CGH Validation	IP1523838	AirTable blocks_with_IP_info.csv
1766	14-33100	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26304,26305	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	756	\N	\N	14-33100	\N	JJS17	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
2960	95-05724-1 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	960	\N	\N	None	\N	MD-54	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
10019	12-22776	36	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.7	Melanoma, Acral	\N	Sections show a proliferation of nested and solitary melanocytes, relatively evenly distributed along the dermal-epidermal junction. Clusters of similar melanocytes are present in the dermis.	Oriented ellipse, 1.6 x 0.9 x 0.3 cm, including a central 0.4 x 0.3 cm brown area. With the orienting suture at one tip placed to the left and designated proximal by the surgeon, the far margin is inked blue and the near margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis from proximal to distal and entirely submitted with four sections each in cassettes A1 and A2.	\N	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS ON ACRAL SKIN, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	107722	1420	\N	\N	12-22776	A	SYNX17	\N	IP1096148	Consolidated_data_final.csv
1882	15-60391	22	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	The available tissue sections demonstrate a segment of acral skin harboring a broad, asymmetrical, and compound proliferation of large fusiform and epithelioid melanocytes. These cells are distributed in pagetoid and lentiginous fashion within the epidermis, and conspicuous extension down eccrine epithelium is noted. In one cross section, an area of erosion and reactive acanthosis is noted. In the perijunctional dermis and also the reticular dermis, there is a relatively diffuse array of fusiform melanocytes that extend through collagenous tissue into the upper subcutis. Cells in mitosis can occasionally be found. Much of the distribution of melanocytes in the dermis is fascicular, but a sheet-like pattern is focally apparent.	One outside slide, PCS-15-2278-A1, and one corresponding block.	SECOND OPINION	\N	\N	\N	I believe that the conventional histopathologic findings support a diagnosis of spitzoid melanoma. We completed p16 immunohistochemistry as an initial step in assessment, and significant diffuse partial positivity is apparent. This is prognostically significant, as it implies that biallelic loss of chromosome 9p, which represents a negative prognostic indicator, is unlikely to be present. Comparative genomic hybridization (CGH) was also included in our assessment. The application of CGH permits screening for genomic copy number anomalies. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 7p, gain and loss in 7q and 10p, and gain in 11q. The identification of multiple chromosomal copy number gains and losses indicates genomic instability, as would be expected with melanoma, and can be considered confirmatory of the above diagnosis.  This tumor is ulcerated and its full thickness can be reassessed upon complete excision. Please note that the conventional staging parameters associated with melanoma in adulthood are not known to be predictive of prognosis in the pediatric setting.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	SPITZOID MELANOMA OF AT LEAST 2.9 MM IN THICKNESS, INCOMPLETELY EXCISED	173716	681	\N	\N	15-60391	\N	DP-44	CGH Validation	IP1531774	AirTable blocks_with_IP_info.csv
1883	15-61456	44	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show melanocytes arrayed as many large fascicles in the epidermis with acanthosis, and good lateral demarcation is noted. There are maturing fascicles in the perijunctional dermis jointly with slight myxoid change and a lymphohistiocytic infiltrate.	One outside slide, DE-15-009578 and one corresponding block\nSeven outside slides, DE-12-013912 A1.	6 MM RED-BROWN SYMMETRIC PLUMP PAPULE, FATHER DIED AT AGE 62 OF METASTATIC MELANOMA IN 2012, THREE MONTHS AFTER BEING DIAGNOSED, ALSO INCLUDED FOR REFERENCE IS AN EARLIER BIOPSY OF ANOTHER LESION (LEFT INNER CALF) BIOPSIED IN 2012	\N	\N	\N	This addendum report has been issued to comprehensively document the date of service. Molecular assessment (the results of which are discussed below) was initiated on July 29, 2015. Data became available during the subsequent week, and my final interpretation of the molecular data was completed on August 7, 2015. As I have discussed with you, this biopsy demonstrates a configuration that fits with a diagnosis of 'NTRK1-oma', namely a Spitz nevus/tumor with associated NTRK1 gene fusion. NTRK1 immunohistochemistry has been completed and demonstrates remarkable positivity, and this labeling result implies that underlying NTRK1 gene fusion has occurred. Gene fusion is merely a mechanism of tumor development and does not provide information regarding clinical behavior, but my impression, based upon histopathologic characteristics, is that this tumor is only partially transformed and thus holds no adverse clinical implications.  Given the high clinical concern, we completed ancillary assessment to further substantiate the nature of this tumor. This was completed by array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies, as would be expected with melanoma. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed no chromosomal gains or losses. As background for understanding this result, note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. Rather, I believe this tumor is unusual but essentially equivalent to a melanocytic nevus. Dr. Rosenman should follow the site to verify that no persistence ensues, if no reexcision is planned.  Please note that I have also retrospectively reviewed a 2012 biopsy from this patient as part of my evaluation. My retrospective diagnosis for the prior specimen is that it demonstrates a 'pagetoid' pigmented spindle cell nevus. Some tumors within the spectrum of pigmented spindle cell nevus are induced by NTRK1 gene fusion, and thus it is conceivable that this patient's prior tumor and current tumor are mechanistically related. We understand that the old tissue block has been exhausted, and thus no further testing in that regard will be possible.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	COMPOUND SPITZ TUMOR/NEVUS WITH ASSOCIATED NTRK1 GENE FUSION, EXCISED IN THE AVAILABLE PLANES OF SECTION	105575	682	\N	\N	15-61456	\N	DP-45	CGH Validation	IP1532843	AirTable blocks_with_IP_info.csv
1884	15-71393	7	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	There is a compound proliferation of melanocytes with a domed surface, epidermal hyperplasia, a few moderately sized nests at the dermo-epidermal junction and nests, cords and strands in a peri-adnexal pattern in the dermis. The superficial melanocytes have moderately large amounts of cytoplasm and enlarged nuclei, with small, round melanocytes predominating toward the base of the lesion.	Eight outside slides, P15-16595-A1, including five unstained slides. One corresponding block received 8/5/15.	NEW FIRM HYPERPIG NODULE; R/O ATYPIA	\N	\N	\N	The features seemed in part to be a mixture of those of a Spitz's nevus and those of a superficial congenital nevus, but some raised the possibility of a nevoid melanoma, necessitating additional studies. As some Spitz's nevi with cells that have less cytoplasm than usual have NTRK1 gene fusions, I obtained that immunostain, but the strong staining seen in that situation is not present. A p16 immunostain shows that this tumor suppressor protein is retained only in a minority of cells, but these are distributed evenly, and not in a pattern suggesting loss of p16 in a clonal population, as could reflect bi-allelic loss of CDKN2A as would favor melanoma. A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) has now been repeated (the first try resulted in a slide in which much of the tissue had fallen off), and shows a marginal mitosis as well as one in the mid-portion of the lesion.  Marginal mitoses are mentioned in the reference below as a finding favoring melanoma over Spitz's nevus, and also emerged in the results of an expert panel in 2008 evaluating melanocytic neoplasms of unknown malignant potential.  Given this finding, I suggested comparative genomic hybridization, which has now been completed. It shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. These include loss of chr. 1p, chr. 2, gain of 4q, loss of 5, gain of 6p and loss of 6q, gains of 7 and 8, losses of 9 and 10, loss of 13, gain of 15, loss of 16 and gain of 19. Many of these are copy number changes often found in melanoma.  A recent study from St. Jude's Medical Center, referenced below suggests that hTERT mutation analysis is more important than chromosomal copy number changes in determining the potential for childhood spitzoid melanomas to spread beyond local nodes. In this case, this may not be as important, as the morphology is more nevoid than spitzoid. This testing is not commercially available, but we hope to have it set up in our lab in several months time. In the interim, it is available at St. Jude's, but only for patients being seen there clinically.  References:  Crotty KA. Spitz naevus: histological features and distinction from malignant melanoma. Australas J Dermatol. 1997 Jun;38 Suppl 1:S49-53.  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	MELANOMA, 2.3 MM. IN THICKNESS	173719	683	\N	\N	15-71393	\N	DP-46	CGH Validation	IP1542843	AirTable blocks_with_IP_info.csv
1928	16-13909	36	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	See report 15-95056 for histopathologic details.	Block DL15-92056 (DPR15-08971:A1).	SEE DL15-92056; FOR CGH TESTING	\N	\N	\N	The diagnosis of melanoma has been based in large part on the results of array-based comparative genomic hybridization (aCGH) analysis. Please refer to my addendum report of case 15-92056 for the full interpretation of this tumor. With respect to aCGH analysis, after microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in chromosomes 1q, 9, and 17p. There is also subthreshold loss in chromosomes 19 and 22q. The significance of these findings is discussed further in the addendum report to case 15-92056. The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	ATYPICAL COMPOUND PROLIFERATION OF MELANOCYTES, CONSISTENT WITH MELANOMA OF 1.65 MM IN THICKNESS	173549	691	\N	\N	16-13909	\N	DP-54	CGH Validation	IP1563705	AirTable blocks_with_IP_info.csv
1891	15-92618	62	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections from PS09-5773 show a dome surfaced and wedge-based, predominantly dermal proliferation of plump, oval to small round melanocytes in severely sun damaged skin. Melanocytes mature with descent within the dermis, and the sizes of their aggregations also diminish with descent.   Sections from 13-1009 show a similar lesion with more spindled and pigmented dendritic cells in one part of the lesion, and some cells with large, oval vesicular nuclei.   Sections from 15-5372 shows a large, nodular proliferation of large, oval melanocytes with marked nuclear pleomorphism, and variable proportions of pigmented, bipolar dendritic melanocytes and melanophages. Areas that are more cytologically bland are also present. A junctional component is evident to the side of the nodule, with small nests of cytologically bland melanocytes bridging adjacent ridges, and basilar hyperpigmentation. A broad zone of paucicellular fibrosis is present to the side of the nodule.	Six outside slides, PS09-5773 (A-B) (13-1009, 184965-JDI) (DC15-4002) (15A-5372, 15B-5372), and three corresponding blocks.	RECURRENT DOUBLE NEVUS (SEE COVER LETTER)	\N	\N	\N	This persistent/recurrent lesion had prior biopsies with considerably less worrisome features. Given this, and the resemblance in areas to a cellular blue nevus we obtained comparative genomic hybridization. Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. These include gains of chrs. 2, 4q, 15q, 18p and parts of 22, and losses involving 3p, 5qter, 9p, 10q, 11q, 19 and part of 22. The interstitial loss on chr. 3p flanks the BAP-1 locus, which can be lost in some blue nevus-like melanomas. The loss involving chr. 9p has a step-down around CDKN2A, which codes for p16, indicating a bi-allelic deletion.  The prior biopsies show a progression of increasingly atypical changes leading to the current lesion. This can occur with lesions in the cellular blue nevus spectrum. The excision appears to be complete in the current sections.	MELANOMA, 4.1 MM. IN THICKNESS	173610	685	\N	\N	15-92618	\N	DP-48	CGH Validation	IP1564268	AirTable blocks_with_IP_info.csv
1899	15-110181	38	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	There is a well circumscribed compound proliferation of moderately large, oval melanocytes. The lesion has a domed surface and a flat base. The lesional melanocytes have small amounts of pale amphophilic cytoplasm and monomorphous vesicular nuclei. Please see note above for additional details.	Two outside slides, D15-40415. One corresponding block received 11/20/15.	PIGMENTED LESION OF UNCERTAIN DURATION	\N	\N	\N	The cells are smaller than classic Spitz cells, but a Spitz's nevus may yet prove to be the best designation here. There are some poorly formed Kamino bodies, supporting this. The inter-retial epidermis is relatively thin for a Spitz's nevus, and the mitotic figures are cautionary. I would consider obtaining fluorescence in situ or comparative genomic hybridization, although based on this material alone, I would favor a Spitz's nevus. ADDENDUM, November 17, 2015:  Per our telephone discussion today, the patient would like us to perform comparative genomic hybridization.  ADDENDUM, December 18, 2015:  Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. These include losses of the peri-terminal areas of chr. 5p and 5q, 6q, an interstitial area on 9p (not including CDKN2A) and 22q and evidence of a complex rearrangement involving chrs. 7 and 8. Of these, chr. 6q loss is common in melanoma, and given the other aberrations, melanoma is the best interpretation of this data (as opposed to an atypical Spitz tumor).	MELANOMA, 1.3 MM. IN THICKNESS	173727	687	\N	\N	15-110181	\N	DP-50	CGH Validation	IP1581959	AirTable blocks_with_IP_info.csv
1148	04-59140B	47	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.5	\N	\N	There is an ulcerated neoplasm of melanocytes that extensively involves the epidermis, with a central, raised area in which neoplastic cells extend into the superficial reticular dermis.  Striking cytologic atypia, scattered mitotic figures and failure to mature with descent are all evident.  Plasma cells are present at the base of the specimen.	Skin segment, 1.4 x 1.2 x 0.4 cm, with the specimen noted by the surgeon and preinked as follows: superior margin preinked red, the left-inferior margin preinked yellow, the right-inferior margin preinked blue. The specimen is serially sectioned perpendicular to the long axis and entirely submitted with three sections each in cassettes A and B.	R/O MM	\N	\N	Scraping	Melanoma in situ extends to the peripheral margin. Histopathologic features of possible prognostic importance include:  Level: IV Tumor infiltrating lymphocytes: few Vascular or lymphatic invasion: absent Mitotic rate: low Perineural invasion: absent Ulceration: present Regression: absent Microsatellite metastasis: absent	MELANOMA, 1.8 MM  IN THICKNESS	173507	187	\N	\N	04-59140	B	CCR-207	California Cancer Registry	IP475548	AirTable blocks_with_IP_info.csv
1097	03-47623B	50	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1296	172.4	\N	\N	Sections show a proliferation of atypical melanocytes in nodular array within the epidermis and dermis, as well as a second population of smaller melanocytes arranged as cords and strands between collagen bundles of the reticular dermis and around adnexal structures.  The atypical melanocytes have epithelioid cytomorphology and ample vacuolated and pigmented cytoplasm, and are arrayed as irregular nests along the epidermal-dermal junction, with nests and sheets of atypical melanocytes in the papillary and reticular dermis.  There is a dense permeative lymphocytic infiltrate with many melanophages, and there are areas of dermal fibrosis.	Skin segment measuring 1.1 x 1.0 x 0.3 cm, quadrisected and entirely submitted.	ATYPICAL NEVI	\N	\N	\N	In terms of staging, this is a non-ulcerated primary melanoma with an invasive component that involves the reticular dermis (Clark's level IV).  There is no evidence of vascular invasion or perineural extension.  There is an element of associated partial regression, and thus the microstage measurement listed above may slightly underestimate the prognostic impact of this melanoma.  Regressive changes abut the peripheral margin of this biopsy, and thus further excision of this site will be necessary to ensure local control.	MELANOMA OF 1.6 MILLIMETERS IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS OF CONGENITAL TYPE	173439	190	\N	\N	03-47623	B	CCR-211	California Cancer Registry	IP405938	AirTable blocks_with_IP_info.csv
1024	01-6748	76	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1316	172.4	\N	\N	Sections show nested and solitary melanocytes, some of which display atypical nuclei, in irregular array along the epidermal-dermal junction.  Similar melanocytes are present in clusters in the underlying dermis, along with some melanocytes with nearly clear appearing vacuolated cytoplasm.  There are many melanophages in the papillary dermis.	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely\nsubmitted.	R/O MELANOMA	\N	\N	\N	3/5/2001:  The thickness is now listed above.  2/27/2001:  Measurement of this specimen will be delayed as I do not have access to a micrometer at this moment, but I estimate the thickness at less than 1.0 mm.  While the configuration suggests that this specimen will provide the thickness of record, that judgment should be made following complete excision.	MELANOMA, 0.8 MM IN THICKNESS, EXTENDING TO THE PERIPHERAL MARGIN	173406	211	\N	\N	01-6748	\N	CCR-247	California Cancer Registry	IP263151	AirTable blocks_with_IP_info.csv
3011	99-4387	70	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=1400	172.5	\N	\N	Sections show an asymmetrical and poorly circumscribed proliferation of atypical melanocytes, focally in a pagetoid pattern, arranged irregularly within the epidermis, flanking a nodular proliferation of similar melanocytes that do not mature (diminish in size) with descent into the dermis.	Ellipse measuring 1.1 x 0.9 x 0.4 cm, quadrisected and entirely\nsubmitted, margins inked blue.	8.0 X 9.0 MM IRREGULAR MACULE SINCE 12/98; CLINICAL DIAGNOSIS - LENTIGO VS LENTIGO MALIGNA VS NEVUS, R/O MELANOMA	\N	\N	\N	None	MELANOMA, 0.8 MM IN THICKNESS, EXTENDING TO WITHIN 1 MM OF THE PERIPHERAL BIOPSY MARGIN	576544	231	\N	\N	99-4387	\N	CCR-300	California Cancer Registry	IP179920	AirTable blocks_with_IP_info.csv
2390	19-596B	56	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.7	\N	\N	Sections show a proliferation of spindled and dendritic melanocytes enmeshed in thickened, sclerotic collagen. The lesional cells show considerable cytoplasmic pigmentation and scattered accompanying melanophages are appreciable as well.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in B. PL/PL	A) PATCH AND MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS, B) MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. DERMATOFIBROMA	\N	\N	Scraping	There is no evidence of melanoma or a dysplastic nevus.	DESMOPLASTIC BLUE NEVUS	123747	1129	\N	\N	19-596	B	ME-34	Melanoma Epigenetics	IP2004620	AirTable blocks_with_IP_info.csv
3509	Lung cancer with ALK fusion	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	780	\N	\N	None	\N	KF-10	Fusion RNA	\N	AirTable blocks_with_IP_info.csv
1744	14-077	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	782	\N	\N	14-77	\N	KIT-01	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1846	15-13150A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-25	http://64.54.108.121/eSlideTray.php?ImageIds=32775	\N	\N	3469335	\N	\N	\N	\N	Skin, thigh, inner, left, wide excision, superficial spreading melanoma	FFPE	\N	\N	\N	313	\N	\N	15-13150	A1	CME-011	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2268	17-120280	34	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18181	216.5	\N	\N	Sections show a symmetric compound melanocytic proliferation. There are increased numbers of single melanocytes at the sides and bases of elongated rete ridges.  There is basilar hyperpigmentation in the affected area. Clusters of small, round melanocytes reside in the subjacent dermis and mature with descent.	Skin segment measuring 1.1 x 0.9 x 0.1 cm, quadrisected, and entirely submitted. HD/HD	6 MM BLACK MACULE; R/O MM	\N	\N	\N	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	333504	832	\N	\N	17-120280	\N	LN-12	Lentiginous Nevi 	IP1850829	AirTable blocks_with_IP_info.csv
1610	12-22587	12	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.4	Melanocytic Nevus	\N	Sections show a melanocytic proliferation composed of nests of melanocytes along the junction, with clusters of similar cells in the subjacent dermis.  Many superficial melanocytes have pigmented cytoplasm, and there are also surrounding melanophages.	Cylindrical skin segment, 0.6 cm in diameter and 0.5 cm in thickness, bisected and totally submitted.	DARK 4 MM PAP; R/O MM	\N	Compound, hyperpigmented melanocytes,neck	\N	None	COMPOUND MELANOCYTIC NEVUS, WITH HYPERPIGMENTED MELANOCYTES	173477	1871	\N	\N	12-22587	\N	SYNAT372	2010-2017	IP1108405	AirTable blocks_with_IP_info.csv
1612	12-22597	87	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.41	BCC	\N	Sections show a proliferation of small nodular collections of basaloid keratinocytes in poorly-circumscribed array.	Skin segment measuring 0.9 x 0.8 x 0.1 cm, trisected and entirely submitted.	SIZE 1.6 X 1.4 CM, C&D DONE AT SAME TIME AS BX; R/O BCC	\N	Micronodular, neck	\N	None	BASAL CELL CARCINOMA, MICRONODULAR PATTERN, EXTENDING TO THE EDGE AND TO THE BASE OF THE SPECIMEN	173450	1794	\N	\N	12-22597	\N	SYNAT374	2010-2017	IP575947	AirTable blocks_with_IP_info.csv
1446	11-8228	4	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show an asymmetrical and focally ulcerated compound proliferation of slender spindled melanocytes with heavily melanized cytoplasm. There is a small junctional component jointly with marked acanthosis, and below this coalescing fascicles of non-maturing melanocytes reside in the dermis, where many interstitial melanophages are apparent.	One outside slide, S11-3178 and one corresponding block.	AFRICAN-AMERICAN BOY WITH A BROWN-BLACK PAPULE	\N	ALK, Iwei Translocations	\N	Our differential diagnosis included an unusual hypermelanotic spindled melanocytic nevus on one hand and childhood-type melanoma on the other. To more fully assess this differential, array-based comparative genomic hybridization (aCGH) was utilized to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, aCGH analysis did not demonstrate chromosomal gains or losses. GNAQ and GNA11 gene sequencing was also completed, and GNAQ exon 5 and GNA11 exon 5 were both found to be wild-type (non-mutated). Based upon the results derived from conventional microscopy and molecular assessment, I offer the following conclusions:  1. The lack of genomic aberrations, as demonstrated by aCGH analysis, speaks against melanoma as a possibility and favors interpretation as a peculiar melanocytic nevus. I do not believe this lesion should be interpreted as a pigmented epithelioid melanocytoma (with respect to that diagnostic term, this proliferation is composed of melanocytes that have distinctly spindled cytomorphology).  2. The lack of mutation in GNAQ or GNA11 suggests that this proliferation fits better on the spectrum of pigmented spindle cell nevus or plexiform spindle cell nevus rather than blue nevus.  3. The proliferation is unusual and involves the deep edge of this biopsy. Further excision is thus warranted to ensure that local eradication has been accomplished and that persistence cannot ensue.	ULCERATED COMPOUND PROLIFERATION OF STRIKINGLY HYPERPIGMENTED/SPINDLED MELANOCYTES	173417	1916	\N	\N	11-8228	\N	SYNAT386	2010-2017	IP997665	AirTable blocks_with_IP_info.csv
1252	06-52508	63	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show an asymmetrical, compound proliferation of melanocytes, many of which have atypical nuclei, many of them with a spindled configuration. There is adnexal extension, focal confluence of junctional melanocytes, and also, adnexal extension. Suprabasal scatter of melanocytes is also present. There are irregular clusters of similar melanocytes in the underlying dermis. There is a bandlike infiltrate of lymphocytes in the papillary dermis. The overlying epidermis is thickened and hyperkeratotic.	Skin segment measuring 0.8 x 0.8 x 0.4 cm, margins inked blue, trisected and entirely submitted.	SINGLE PPP X 3 MONTHS	\N	\N	\N	This neoplasm has some cytologic and architectural features in common with a Spitz's nevus. However, atypical melanocytes are focally confluent, there is significant adnexal extension, as well as significant suprabasal scatter of melanocytes. These changes are in keeping with melanoma. In addition, it appears in slightly sun-damaged skin. In terms of staging, this is a thin primary melanoma, non-ulcerated, of Clark's anatomic level II. The dermis is partially obscured by a dense lichenoid infiltrate, and the thickness above is my best judgment in this context. There is no evidence of neurotropism, vascular invasion, or regression in these sections. Complete reexcision is of course warranted. I have also shared this case with my colleague, Dr. Philip LeBoit, who agrees with the diagnosis of melanoma.	MELANOMA, APPROXIMATELY 0.5 MM IN THICKNESS, WITH MELANOMA IN SITU EXTENDING CLOSE TO PERIPHERAL MARGINS	173536	1807	\N	\N	06-52508	\N	SYNAT409	Spitzoid Melanoma	IP597577	AirTable blocks_with_IP_info.csv
2340	18-76281	78	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show a dermal proliferation of spindled melanocytes with bland nuclei, and bipolar dendritic melanocytes with pigmented cytoplasm. These cells are accompanied by fibrosis and melanophages.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted. RS/RS	0.2 CM GREYISH PAPULE	\N	left mid lateral forearm 	Scraping	None	BLUE NEVUS	177611	1350	\N	\N	18-76281	\N	SM-021	Nevus Library	IP1940225	AirTable blocks_with_IP_info.csv
1467	11-26903	41	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a roughly wedge-shaped proliferation of spindled and polygonal melanocytes, some of which have abundant vacuolated cytoplasms, which extends deeply in the reticular dermis.  Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous.  There are interspersed melanophages.	Cylindrical skin segment, 0.6 cm in diameter and 0.3 cm in thickness, bisected and entirely submitted.	BLUE NEVUS VS. PIGMENTED BCC	\N	\N	\N	The lesion has characteristic features of deep penetrating nevus, a benign lesion some consider a variant of blue nevus. It appears excised in planes of section examined. Case reviewed with concurrence by Drs. McCalmont, Ruben and Mully.	DEEP PENETRATING NEVUS	139523	2253	\N	\N	11-26903	\N	SYNAT431	2010-2017	IP1016341	AirTable blocks_with_IP_info.csv
2720	21-35943A	75	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show granulation tissue and inflammation, with no evidence of an atypical melanocytic proliferation.	Ellipse measuring 5.7 x 1.1 x 0.6 cm, including a central 4.1 x 0.3 cm scar. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and submitted with four sections each in A-B. Tips reserved. BB/BB	A) MALIGNANT MELANOMA. PLEASE CHECK MARGINS. RE-EXCISION FROM 1/4/21, DT21-457	\N	\N	\N	\N	HEALING BIOPSY SITE, WITH NO EVIDENCE OF RESIDUAL MELANOMA IN SITU	173611	802	\N	\N	21-35943	A	LMM-03	Lentigo Maligna Melanoma	IP2011798	AirTable blocks_with_IP_info.csv
1513	11-71006	29	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a dome shaped segment of skin with irregular epidermal hyperplasia, and confluent nests of large, oval melanocytes with abundant, pale amphophilic cytoplasm and large, vesicular nuclei within the dermis. Many necrotic melanocytes are evident. The enclosed immunoperoxidase stains show that there is strong staining for cyclin D1 throughout the thickness of the lesion. There is negligible staining with HMB45.	Ten outside slides, S-11-10063:A-1-2, 1-3, 1-5 through 1-9, 1-11, 1-14 and 1-16 (S-2130-11), and one corresponding block, 2130-11.	CAUTERY REMOVAL; SPITZOID LESION (SEE DETAILED LETTER AND REPORT)	\N	\N	\N	As there were some findings worrisome for a spitzoid melanoma rather than a Spitz's nevus. I proposed obtaining comparative genomic hybridization on this case. This showed an isolated gain of 7q, an aberration that when unaccompanied by others favors a Spitz's nevus. Given the worrisome histopathologic findings, I would still obtain a re-excision if it has not been done, even though the base may have been cauterized. I reviewed the comparative genomic hybridization data with Dr. Boris Bastian, who agreed regarding the implications of this finding.	COMPOUND PROLIFERATION OF LARGE, SPITZOID MELANOCYTES, PROBABLY AN UNUSUAL SPITZ'S NEVUS	192799	2265	\N	\N	11-71006	\N	SYNAT469	2010-2017	IP1060449	AirTable blocks_with_IP_info.csv
2572	19Rig750007.06.01	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PAM	Grp 6 PAM without sun exposure	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	301	\N	\N	None	\N	CM-73	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
10662	04-11158	54	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.6	Iwei Acral Melanoma	\N	Sections show acral skin with a proliferation of strikingly atypical melanocytes arranged in an irregular and focally pagetoid pattern within the epidermis, and with sheets similar cells throughout the dermis.  Slightly smaller ones are present near one edge.	Cylindrical skin segment measuring 0.3 cm in diameter and 0.3 cm in thickness.	\N	\N	\N	\N	This appears to be a primary melanoma of about 2 mm in thickness.  The final thickness measurement should be made after complete excision.  There may be cells of a pre-existent nevus as well (but I cannot distinguish them with certainty from small melanoma cells),	MELANOMA	173616	1603	\N	\N	04-11158	A	SYNX200	\N	IP427557	Consolidated_data_final.csv
1903	15-122774	\N	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	\N	Typical melanotic macule	\N	\N	\N	\N	\N	hand/foot	FFPE	\N	\N	\N	1297	\N	\N	15-122774	\N	OM-39	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
10742	09-33283	42	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	173.4	Ivanka Patient Melanoma  	\N	Sections show nodular aggregations of atypical, peripherally palisaded basaloid cells. Very focally, tiny angulate aggregations of similar cells are apparent in infiltrative array. There is enveloping inflamed cellular stroma.	Skin segment measuring 0.4 x 0.3 x 0.1 cm in cassette A.	\N	\N	\N	\N	\N	NODULAR BASAL CELL CARCINOMA, INVOLVING THE DEEP EDGE OF THE BIOPSY	173441	1616	\N	\N	09-33283	A	SYNX213	\N	IP834046	Consolidated_data_final.csv
2530	19Rig750007.03.05.02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	MELANOMA	Grp 3 Mel without sun in PAM/de novo	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	274	\N	\N	None	\N	CM-34	Conjunctival Melanoma	\N	AirTable blocks_with_IP_info.csv
2904	23-37594	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	457	\N	\N	23-37594	\N	DMS-045	Superficial Congenital Nevi	\N	AirTable blocks_with_IP_info.csv
10684	13-34291	47	\N	\N	\N	T2a	Primary	\N	\N	\N	\N	\N	\N	172.2	Iwei Translocation	CGH13-166 	Sections show an asymmetrical compound proliferation of melanocytes that is distinctly biphasic in its composition. One population consists of melanocytes with small amounts of amphophilic or vacuolated cytoplasm. These cells are distributed singly and in many nests within the epidermis and focally within adnexa, and maturing nests, cords, and syncytia of similar melanocytes can be seen in the dermis below this. The second population of larger epithelioid melanocytes has pale, ballooned, or finely pigmented cytoplasm. These cells are distributed erratically along the junction and in pagetoid fashion within adnexa, and several large nests of these melanocytes are present in the dermis as well. A patchy infiltrate of lymphocytes and melanophages is present in the dermis, concurrently. There is marked elastosis. In accompanying immunostains, the Ki-67 cell proliferation index is low.	Three outside slides, DN13-015188 and one corresponding block.	\N	\N	\N	\N	My differential diagnosis included both an atypical combined melanocytic nevus on one hand and nevoid (or deep penetrating) melanoma on the other. To more fully assess this differential diagnosis and to screen for genomic copy number anomalies, as can be seen with melanoma, we pursued array-based comparative genomic hybridization (aCGH). After extraction of tumoral DNA from the tissue block, application of aCGH revealed loss of chromosome 6q and gain in chromosome 15q. (The loss in chromosome 6q includes the location of the MYB gene that is assayed as part of standard fluorescence in situ hybridization copy number analysis of melanocytic tumors.) No other substantive chromosomal copy number gains or losses were noted. The identification of multiple copy number abnormalities suggests genomic instability, as is typical of malignancies such as melanoma. In summary, the combination of results derived from conventional microscopy coupled with aCGH favors interpretation as nevoid melanoma. With respect to staging, this melanoma is between 1-2 mm in thickness and lacks associated ulceration. Therefore, it represents melanoma of stage pT2a (2009 AJCC Guidelines). Further excision is warranted to ensure that local control has been established.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	MELANOMA OF 1.7 MM IN THICKNESS, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	120288	1610	\N	\N	13-34291	A	SYNX207	\N	IP1275593	Consolidated_data_final.csv
2056	17-11446-5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-38	https://64.54.108.121/app/WebViewer/view/image/36091	\N	\N	\N	\N	\N	\N	\N	H17-11446 (left popliteal) #5	FFPE	\N	\N	\N	407	\N	\N	None	\N	CME-105	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2055	17-11087-5	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-39	https://64.54.108.121/app/WebViewer/view/image/36094	\N	\N	\N	\N	\N	\N	\N	H17-11087 #5 (right auricle, in situ)	FFPE	\N	\N	\N	409	\N	\N	None	\N	CME-107	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2003	16-118019	65	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10819	216.7	DN	\N	Sections show a compound melanocytic proliferation, composed largely of nests arrayed along the epidermal-dermal junction, with extension lateral to papillary dermal clusters of similar cells.  There is subepithelial fibrosis. There is solar elastosis.	Skin segment measuring 1.1 x 1.0 x 0.1 cm, quadrisected and entirely submitted. KC/KC	A) MELANOMA VS. NEVUS. SUSPICIOUS IRREGULAR MULTI-COLORED MACULE.	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173710	539	\N	\N	16-118019	\N	DN-064	Dysplastic Nevi	IP1034557	AirTable blocks_with_IP_info.csv
1418	10-75211	34	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	from Swapna	Sections show fibrosing granulation tissue stemming from prior biopsy with a residual array of melanocytes with in the deeper dermis characterized by medium to large melanocytes with abundant amphophilic cytoplasm and pleomorphic nuclei arranged in fascicles and nests.	Ellipse, 1.3 x 0.5 x 0.2 cm, including a central 1.1 x 0.5 cm lesion.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections.	BX PROVEN PROLIFERATION OF ENLARGED MELANOCYTES, 0.4 CM PINK SCAR	\N	\N	\N	ADDENDUM, March 20, 2012: The following note has been modified from that in the original report, a copy of which is on file as .pdfs in our computer system: We continue to favor a melanocytic nevus as the most likely diagnosis.  Comparative genomic hybridization shows no loss or gain of chromosomal material. This favors a benign interpretation, or a low grade neoplasm with limited metastatic potential. About 95% of conventional melanomas show detectable losses or gains with this technique. Nonetheless, the melanocytic proliferation is unusual and has not been removed by this procedure, and further excision to ensure its complete removal is recommended.	RESIDUAL INTRADERMAL PROLIFERATION OF MELANOCYTES, EXTENDING TO BOTH EDGES AND CLOSELY TO THE BASE OF THE SPECIMEN	123298	651	\N	\N	10-75211	\N	DP-14	NRAS Amplified	IP963226	AirTable blocks_with_IP_info.csv
2983	96-18967-1 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	963	\N	\N	None	\N	MD-57	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2987	97-01837E M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	964	\N	\N	None	\N	MD-58	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1507	11-63724	8	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show large, irregularly shaped areas of subcutaneous tissue and dermis in which there are poorly circumscribed masses of plump oval to spindled cells with pale amphophilic cytoplasm, and distinct cytoplasmic borders and oval, vesicular nuclei that have small nucleoli. The latter are irregular in shape, but not strikingly atypical. Mitotic figures are very few. The enclosed immunoperoxidase-stained sections demonstrate that the proliferation is S100 and Melan-A positive.	Eleven outside slides, SD11-6824:1-11 and one corresponding block (SD11-6824:5). Three additional slides received 12/27/18.	EXCISIONAL BIOPSY OF SR09-1700/DL09-34832	\N	\N	\N	The recurrent lesion has areas of striking cellularity, but these are not overtly malignant. Comparative genomic hybridization shows a similar loss of 5pter and 5qter as was present in 2009. There is a small peri-centromeric deletion, and we are reviewing the 2009 data (done by a different method- we currently use array CGH and at that time we were using metaphase CGH) to see if was present then. This set of mutations has not been linked to melanoma. I would regard this as a low grade neoplasm that will probably grow slowly. The risk of overt malignancy may be tempered by the loss involving 5pter, which contains the catalytic subunit of telomerase, but this is speculative. My colleague Dr. Boris Bastian also reviewed the CGH data. Mutational analysis for two genes mutated in most blue nevus was also performed.  GNAQ exon 5: wild-type. GNA11 exon 5: wild-type.  If local control of this unusual lesion becomes an issue, we can perform analyses for b-raf and other genes linked to initiation in melanocytic lesions.	BLUE NEVUS-LIKE MELANOCYTIC PROLIFERATION	173311	655	\N	\N	11-63724	\N	DP-18	CGH Validation	IP835595	AirTable blocks_with_IP_info.csv
1900	15-116253	63	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	A biopsy from 2009 demonstrates a compound proliferation of melanocytes with single melanocytes and small pigmented nests distributed in lentiginous fashion at the junction. There is slight perijunctional fibrosis below this, and nests and cords of melanocytes are present in the perijunctional dermis as well. More deeply, elastosis is noted. A biopsy from the current year demonstrates a broad compound proliferation of melanocytes distributed in conjunction with upper dermal fibrosis that is apparently post-procedural. There are single melanocytes and nests distributed relatively confluently along the junction, and some nests and melanocytes are large. Scatter of melanocytes above the junction and in adnexa can also be seen. The fibrotic perijunctional dermis contains nests and cords of cytologically similar melanocytes jointly with an infiltrate of lymphocytes and melanophages.	One outside slide, D09-11415-B. Seven outside slides, D15-43009-A1, and one corresponding block; said to be from the same general location as the 2009 specimen.	1.2 CM BROWN, IRREGULAR PATCH; R/O MELANOMA	\N	\N	\N	Like you, I believe the 2015 specimen from this patient represents a thin invasive melanoma. To clarify the nature of this tumor, we completed comparative genomic hybridization (CGH) to screen for chromosomal copy number abnormalities, as would be expected in association with melanoma. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 6p and 7q as well as small losses in distal chromosomes 4p and 6q. The areas of gain include the RREB1 and BRAF genes and the area of loss within chromosome 6q includes the MYB gene, and all of these loci are known to be instrumental in the pathogenesis of melanoma. In short, the molecular findings are supportive of a diagnosis of melanoma. The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	ATYPICAL COMPOUND PROLIFERATION OF MELANOCYTES, CONSISTENT WITH MELANOMA OF 0.5 MM IN THICKNESS	173536	688	\N	\N	15-116253	\N	DP-51	CGH Validation	IP1588055	AirTable blocks_with_IP_info.csv
2058	17-13205	11	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	The microscopic findings are essentially as described in the accompanying pathology report and in the note above.	Three outside slides, SU17-1576-1 (AX17-96), and one corresponding block.	SECOND OPINION, REQUEST FOR GENETIC STUDIES IN COVER LETTER FOLLOWING DISCUSSION WITH CLINICIAN	\N	\N	\N	As you note, the differential diagnosis includes an atypical Spitz tumor and a spitzoid melanoma. The findings are more atypical than those of a Spitz's nevus. The worrisome aspects include variable cellularity at the same stratum of the dermis, the degree of nuclear pleomorphism and heterochromasia, and mitotic figures relatively deep in the lesion. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows losses involving chromosomes 9, 13 and 14, and a gain involving chr. 15. While chromosome 9 loss is common in melanoma, it can occur as an isolated finding in benign spitzoid neoplasms. In this case, it is not accompanied by other common chromosomal copy number changes seen in melanoma, but by two relatively idiosyncratic ones (loss of chrs. 13 and 14) and by an intermediate frequency one.  Following the same microdissection and DNA extraction, we also performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations. Since then, there have been a few cases in which hTERT promoter mutations were not found, but in which the gene was affected by promoter methylation.  Given these findings, I favor an atypical Spitz tumor with a low risk of extranodal spread, but a higher one that if the CGH profile had been negative. My colleague, Dr. Boris Bastian also viewed the CGH array data and agrees with this interpretation of it. If it has not yet been done, a narrow re-excision of this site seems prudent.  Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	INTRADERMAL PROLIFERATION OF LARGE, SPITZOID MELANOCYTES, SEE COMMENT	173719	730	\N	\N	17-13205	\N	DP-93	CGH Validation	IP1742388	AirTable blocks_with_IP_info.csv
1492	11-47644	13	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a compound proliferation of enlarged epithelioid and spindled melanocytes with finely yet heavily pigmented cytoplasm. Single melanocytes and nests are distributed relatively confluently along the junction, and in some areas the background epithelium is slightly thinned. Limited scatter of melanocytes above the junction can be seen. In fibrotic perijunctional dermis below this, non-maturing or partially-maturing nests, fascicles, and cords of similar melanocytes can be seen. A patchy associated infiltrate of lymphocytes and melanophages is also noted.	Two outside slides, D11-6279:A1 and A2. Two corresponding blocks received 7-7-11.	COMPOUND SPITZ NEVUS, REEXCISION	\N	Iwei, CGH Array run| BRAF Translocation case	\N	This atypical melanocytic proliferation does not represent a conventional Spitz nevus. Rather, our differential diagnosis included an atypical Spitz nevus on one hand and melanoma on the other. To more fully assess this differential, we pursued array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, aCGH analysis demonstrated gain in chromosomes 2, 7q, 11q, 12, 13, 15, and 19. A segmental gain in chromosome 11p was also documented. As you probably know, the identification of multiple chromosomal gains or losses can be documented in most melanomas. In contrast, chromosomal gain/loss is not known to occur in melanocytic nevi. In summary, the combination of results derived from conventional microscopy coupled with aCGH points clearly to a diagnosis of melanoma. With respect to staging, this melanoma is non-ulcerated and shows Clark's level IV invasion. Further excision is warranted to ensure that local eradication has been accomplished.  Based upon the above clinical synopsis, we presume that a prior biopsy from this site was obtained. We have not reviewed that earlier specimen.	MELANOMA OF 1.3 MM IN THICKNESS, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	373719	1805	\N	\N	11-47644	\N	SYNAT389	2010-2017	IP1037083	AirTable blocks_with_IP_info.csv
2225	17-111040A	70	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	There are increased numbers of single melanocytes and there are some small nests of them positioned at the sides and bases of elongated rete ridges. There is basilar hyperpigmentation in the area of the proliferation. Nests of small, round melanocytes reside in the subjacent dermis.	Skin segment measuring 1.2 x 0.9 x 0.1 cm, quadrisected and entirely submitted in A. CF/CF	A-B) R/O DYSP VS. COMP N	\N	\N	Scraping	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	528523	860	\N	\N	17-111040	A	LN-042	Lentiginous Nevi 	IP1841501	AirTable blocks_with_IP_info.csv
1638	12-31996	8	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a domed compound proliferation of enlarged melanocytes, and the epidermis above these cells is thinned. There are very large nests and fascicles of melanocytes just below the junction, and a few central nests are noted above this. In dermis below this, partially-maturing nests, fascicles, and cords of similar melanocytes can be seen, and a number of dermal melanocytes in mitosis can be identified.	Three outside slides, STRS12-7480 A1 (DRMC12-2648, MR# 12546629). One additional outside slide, STRS12-7480:A1-2 (12546629), received 05/07/12.  One corresponding block received 5-11-12.	LESION PRESENT APPROX 6 MONTHS; HEMANGIOMA VS. SPITZ NEVUS	\N	\N	\N	ADDENDUM, June 7, 2012: Our differential diagnosis included an unconventional Spitz nevus on one hand and so-called childhood-type spitzoid melanoma. Thank you for arranging for p16 immunostaining to be completed in your laboratory; relatively avid expression of p16 was documented. We also received a clinical request for us to complete array-based comparative genomic hybridization (aCGH) to screen for genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in chromosome 9 with no other chromosomal gains or losses. Loss in chromosome 9 represents a relatively common aberration in childhood spitzoid melanoma, but we do not consider it sufficient to be fully decisive from a diagnostic standpoint (most melanomas have multiple genomic aberrations). In summary, the combination of results derived from conventional microscopy coupled with aCGH raises childhood-type spitzoid melanoma as a possibility, but these molecular findings are not decisively diagnostic. This atypical melanocytic proliferation is 2.1 mm in thickness and involves the deep edge of the current specimen. Complete reexcision of this site is warranted in follow-up. My personal opinion is that nodal assessment is not beneficial in this context, as any results found do not correlate with prognosis, in contrast to experience with adult melanoma.	ATYPICAL COMPOUND SPITZOID MELANOCYTIC PROLIFERATION, WITH LOSS OF CHROMOSOME 9 DEMONSTRATED BY MOLECULAR ASSESSMENT	173507	1894	\N	\N	12-31996	\N	SYNAT401	2010-2017	IP1148421	AirTable blocks_with_IP_info.csv
1668	12-97031	48	\N	\N	\N	T1b	Primary	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a domed dermal proliferation of melanocytes arrayed as partially-maturing nests, cords, and small syncytia. The background epidermis is slightly acanthotic and is capped focally by parakeratosis. In the dermis, some perijunctional melanocytes are enlarged and epithelioid.	Four outside slides, DS12-132130 / A1, and one corresponding block. One additional slide (DS12-132130-A1 DC1) received 12/28/12.	R/O BASAL CELL CARCINOMA	\N	\N	\N	ADDENDUM, January 18, 2013: As I indicated previously, cell proliferation analysis was completed via immunoperoxidase staining utilizing a two-color development system in which MART-1 is labeled red and Ki-67 is labeled brown. By this staining method, we found diffuse MART-1 reactivity. Similar to what was seen in your special stain, the MART-positive cells show low nuclear expression of Ki-67, thus implying that cellular proliferation is very low. This finding can be seen in association with melanocytic nevi but is not definitively diagnostic (a low cell proliferation index can also be seen in the context of nevoid melanoma). One of your original slides demonstrates multiple melanocytes in mitosis, and this finding proved to be worrisome for melanoma. To further clarify the nature of this tumor, we completed comparative genomic hybridization (CGH) to screen for genomic copy number anomalies, as can be seen with melanoma. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 1q and 7 as well as loss in chromosomes 9, 10q, and 22q. The identification of multiple chromosomal copy number abnormalities indicates genomic instability, as is stereotypical of malignancies such as melanoma. The genomic profile that we have defined excludes a melanocytic nevus from the differential diagnosis.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has confirmed the diagnosis of melanoma. With respect to staging, this melanoma is less than 1 mm in thickness and lacks associated ulceration, yet melanocytes in mitosis are detectable in its invasive component. Therefore, this provisionally represents melanoma of stage pT1b (2009 AJCC Guidelines). The final microstage parameters can be reassessed once this melanoma has been fully extirpated.	NEVOID MELANOMA OF AT LEAST 0.8 MM IN THICKNESS, INVOLVING THE DEEP EDGE OF THE BIOPSY	173702	1838	\N	\N	12-97031	\N	SYNAT421	2010-2017	IP1182848	AirTable blocks_with_IP_info.csv
1930	16-18320A	29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	\N	\N	There is a well-circumscribed oval mass composed of spindled cells with monomorphous nuclei and inconspicuous cytoplasm disposed as relatively closely apposed fascicles.	Tissue segment measuring 1.2 x 0.9 x 0.6 cm, trisected and entirely submitted in A. PL/PL	A) CYST. SUBCUTANEOUS PAPULE. PLEASE CHECK MARGINS.. PLEASE CHECK MARGINS.. B) NEUROFIBROMA VS. SCHWANNOMA VS LEIOMYOMA. . PLEASE CHECK MARGINS..	\N	\N	\N	The configuration initially suggested a schwannoma. The cells of interest are positive with S100 protein, in keeping with a schwannoma, but an epithelial membrane antigen positive capsule is not present with that stain. Also, there are no cellular (Antoni A) and myxoid, less cellular (Antoni B) areas, and a small focus features melanophages. Neurofilament protein immunostaining is negative, unlike the case in palisaded and encapsulated neuroma (which should also have an EMA positive capsule). There is focal positivity with two melanocytic markers, Melan-A and HMB45. The latter is positive in fewer cells than would be expected in a cellular blue nevus. A p16 stain shows large areas with only a few positive cells, and some with none, worrisome for melanoma. A focally elevated Ki-67 cell proliferation index is present. ALK was obtained, given the long fascicles, but is negative (unlike the case in spitzoid melanocytic neoplasms with ALK gene fusions). A p53 immunoperoxidase stain does not show aberrant expression. Mutation of TP53 and overexpression of p53 is uncommon in primary melanomas in general, but occurs in many desmoplastic melanomas, which some aspects of this case raised.  Comparative genomic hybridization shows multiple aberrations, including a gain involving chr. 2q, gains involving chr. 4p, gains and losses involving chr. 9, and a gain involving chr. 15q. The loss involving chr. 9 includes two levels in the CDKN2A area, suggesting a homozygous loss, worrisome for melanoma; there may also be a rearrangement involving NTRK3. The genomic data were also reviewed by my colleague, Dr. Iwei Yeh.  Given these results, I believe that this neoplasm should be treated in a manner adequate for a low grade melanoma/melanocytic tumor of unknown malignant potential, with complete excision (the lesion in these sections is an oval mass with essentially positive margins around much of it.	SPINDLE CELL MELANOCYTIC NEOPLASM WITH ATYPICAL FEATURES, SEE COMMENT	173604	695	\N	\N	16-18320	A	DP-58	CGH Validation	IP1617429	AirTable blocks_with_IP_info.csv
1937	16-26672	37	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a dome surfaced compound proliferation of large, oval melanocytes with abundant, pale amphophilic cytoplasm and large, vesicular nuclei. The lesion has a domed surface and an irregular but partly wedge shaped base. Nests of melanocytes predominate over single cells along the junction .Many of the superficial melanocytes have abundant, pale cytoplasm and dusty appearing melanin and a few are in mitosis. Melanocytes mature with descent within the dermis in some but not all areas, and the sizes of their aggregations also diminish with descent. A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product. The enclosed two-color immunostain shows that there is a low proliferation rate among the lesional melanocytes.	Four outside slides, 16-6675.S (1A), and one corresponding block.	PEARLY TELANGIECTATIC PAPULE WITH BEADS OF PIGMENTATION; R/O SPITZ NEVUS VS. SPITZOID MELANOMA	\N	\N	\N	The differential diagnosis posed by these sections includes a Spitz's nevus, an atypical Spitz tumor and spitzoid melanoma. Some unusual features present here include many pulverocytes* in the upper part of the lesion, and several mitotic figures in the mid-dermal portion, as well as a notched lesional undersurface. While I favored an atypical Spitz tumor, I wanted to obtain comparative genomic hybridization to assess chromosomal copy number changes. This was approved by the insurance carrier.  A recent study (see reference below) suggests that hTERT promoter mutation status may be even more predictive of aggressive behavior in atypical spitzoid neoplasms than are chromosomal copy number changes.  Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows only a gain on chromosome 7q, with an area of loss of the terminal part of 7q. The breakpoint for the 7q gain is at the braf locus, as can be seen in lesions with wild type b-raf, but a gene fusion involving b-raf and another partner. b-raf gene fusions can occur in both some Spitz's nevi and atypical Spitz tumors and in some melanomas. Most melanomas with these fusions have other aberrations as well, which are absent here.  I favor an atypical Spitz tumor with a b-raf fusion, but would still favor obtaining a study to determine hTERT promoter status.  Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES, FAVOR ATYPICAL SPITZ TUMOR, SEE COMMENT	173641	698	\N	\N	16-26672	\N	DP-61	CGH Validation	IP1625850	AirTable blocks_with_IP_info.csv
1941	16-31382	37	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	The microscopic findings are essentially as described in the accompanying pathology report and in the note above.	Eight outside slides, DP-16-5687. One corresponding block received 4/21/16.	R/O SK (CLINICAL INFORMATION FROM ENCLOSED OUTSIDE PATHOLOGY REPORT)	\N	\N	\N	The lower part of the lesion appears to be a nevus with congenital features. The upper part has, as you note, very large and confluent nests of somewhat larger cells, raising the possibility of so-called nevoid verrucous melanoma. Findings that held me back from that diagnosis included: - a scarcity of mitotic figures in dermal nests. Most of the cells in the phosphohistone H3 stain are keratinocytes or are melanocytes in junctional nests. - the larger melanocytes do not stuff the papillations, as they can in nevoid verrucous melanoma - areas of transition, where the larger cells appear to mature with descent - a lack of a lymphocytic infiltrate beneath the larger cells  Following microdissection and DNA extraction, we performed comparative genomic hybridization. It showed a gain involving chr. 6p and a loss involving chr. 6q. These are both common aberrations in melanoma. A loss of chr. 16q (of uncertain significance) was also found. Given these results, I have measured the larger nests in the dermis to establish the thickness above.	MELANOMA, 1.3 MM. IN THICKNESS	139524	699	\N	\N	16-31382	\N	DP-62	CGH Validation	IP1630595	AirTable blocks_with_IP_info.csv
1952	16-42657	57	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	There is a compound proliferation of large, oval and fusiform melanocytes with abundant, pale amphophilic cytoplasm and large, pleomorphic vesicular nuclei, set in severely sun damaged skin. There is irregular epidermal hyperplasia with focal ulceration, a patchy lymphocytic infiltrate and a distribution of melanocytes detailed in the note above.	Eleven outside slides, DC16-2805 (A1-A2), and one corresponding block (A2).	SOLITARY TUMOR, THE TUMOR HAS BEEN REPORTEDLY PRESENT FOR FOUR MONTHS, AND A RAPID INCREASE IN SIZE WAS ALSO DOCUMENTED; DERMATOFIBROMA VS. BCC RAPID INCREASE IN SIZE	\N	\N	\N	This new addendum report has been simplified for ease in readability. Please refer to preceding versions of this report for the detailed information that Dr. LeBoit previously included. All prior versions of this report are on file in our unit in .pdf fashion and can be supplied to you upon request. Our prior comparative genomic hybridization (CGH) analysis established this tumor as an HRAS-mutated Spitz nevus. TERT promoter analysis was additionally initiated by Dr. LeBoit and has now been completed. The TERT promoter region was found to be of wild-type.  HRAS-mutated Spitz nevi are not known to hold any adverse potential. The confirmation that no TERT promoter mutation is present is concordant with that.	SPITZ NEVUS, PREDOMINANTLY INTRADERMAL (HRAS-MUTATED SPITZ NEVUS)	173602	701	\N	\N	16-42657	\N	DP-64	CGH Validation	IP1641978	AirTable blocks_with_IP_info.csv
2762	21-112321A	80	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18357	216.7	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted in A. KB/KB	A) ATYPICAL BROWN MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR, B) ATYPICAL BROWN PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL PIGMENTED LESION VS. PIGMENTED SEBORRHEIC KERATOSIS	\N	\N	FFPE	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173714	901	\N	\N	21-112321	A	LN-088	Lentiginous Nevi 	IP847876	AirTable blocks_with_IP_info.csv
2085	17-26457	60	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=930	172.5	\N	\N	Sections show a proliferation of atypical melanocytes in irregular array within the epidermis and dermis, with some cells having a spindled shape with surrounding fibrosis. There is also a second population of smaller melanocytes arranged as cords and strands between collagen bundles of the reticular dermis and around adnexal structures.	Skin segment measuring 1.2 x 1.2 x 0.4 cm, serially sectioned and entirely submitted with five sections. RS/RS	SUSPICIOUS IRREGULAR MULTI-COLORED PAPULE; MALIGNANT MELANOMA VS. DYSPLASTIC NEVUS, RULE OUT MELANOMA ARISING IN AN IDN, SOFT PINK PAPULE WITH ADJACENT SPREADING AREA OF PIGMENTATION	\N	\N	Scraping	Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) shows focal significant pagetoid scatter in the MART-1 component. MART-1 expression is significantly reduced in the invasive melanoma component. The Ki-67 proliferation rate of the dermal melanocytes in the nevus component is very  low (<1%). p16 immunoreactivity is strong in the nevus, and completely absent in most of the dermal component of the melanoma. Diagnostic features of note include:  Procedure: shave biopsy Tumor site: back Microscopic tumor type: SSM with a desmoplastic component, melanoma on non-chronically sun-damaged skin (non-CSD) Breslow thickness: 2.2 mm Ulceration: absent Margins, peripheral and deep: deep and peripheral margin focally involved by nevus Mitotic index: 1/mm2 Microsatellitosis: absent Vascular invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT3a pNX	MELANOMA, 2.2 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS, EXTENDING CLOSE TO THE SPECIMEN BASE AND EDGE	291511	1098	\N	\N	17-26457	\N	ME-03	Melanoma Epigenetics	IP1755775	AirTable blocks_with_IP_info.csv
1950	16-42062	12	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a coarsely papillated, mostly intradermal proliferation of large, oval melanocytes with abundant pale amphophilic cytoplasm and large, pleomorphic vesicular nuclei. Large nests are present superficially with confluent tracts of cells in sclerotic stroma deeper in the lesion, with limited maturation with descent.	Skin segment measuring 2.3 x 1.5 x 0.8 cm. With the base inked, the specimen is serially sectioned and entirely submitted with three sections each in A and B. CF/CF	2.5 X 2 CM PIGMENTED PLAQUE WITH 1.5 X 2 CM CENTRAL PEDUNCULATED PORTION	\N	\N	\N	The differential diagnosis includes an atypical Spitz tumor and a spitzoid melanoma. A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product (nearly complete or complete loss in a defined zone is worrisome for melanoma).  Given the prominent fascicles, I obtained an ALK immunoperoxidase stain. The ALK gene can be involved in a gene fusion, with resultant overexpression in a subset of Spitz's nevi with this morphologic finding. The stain is negative in this case, however.  Staining for BAP-1 did not show loss of nuclear staining, as would point to a mutation in that gene (present in a specific subset of Spitz's nevi and other spitzoid lesions).  A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows scattered positive nuclei, some well within the lesion.  Given that the lesion is broad and does not have a typical pattern for either a conventional Spitz's nevus or one identifiable as associated with a common spitzoid gene fusion, I obtained comparative genomic hybridization, and Medi-Cal authorized this testing. Following microdissection and DNA extraction, we performed CGH. which showed a high level gain of chr. 7q. An interstitial gain involving a gene, CDH19 was also identified. We have seen gains of 7q, which contains braf in some Spitz's nevi and atypical Spitz tumors.  An atypical Spitz tumor may be the best category for this lesion. These are neoplasms that have features more atypical than those of a conventional Spitz nevus, but not as worrisome as those of spitzoid melanoma. In aggregate data from over ten studies, local nodal involvment (usually very small deposits) is common, but extranodal metastasis is rare. This dissociation results in sentinel lymph node biopsy having very limited predictive value, and in my opinion, sometimes leading to over-treatment if small deposits lead to completion lymphadenectomy. If there is a significant residuum on re-excision, I would appreciate a chance to see the sections. Please let me know as well if you have an available pre-biopsy clinical image.	ATYPICAL SPITZ TUMOR	173534	704	\N	\N	16-42062	\N	DP-67	CGH Validation	IP1641378	AirTable blocks_with_IP_info.csv
1953	16-44627	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	oral mucosa	FFPE	\N	\N	\N	1316	\N	\N	16-44627	\N	OM-58	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
2276	17-128346A	27	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show a predominantly dermal proliferation of melanocytes that diminish in size with descent in the dermis.  There are nests and syncytia of relatively small melanocytes superficially, with nests and strands of similar cells deeper in the specimen.  The overlying epidermis displays elongated rete that intertwine. Some melanocytes have vacuolated cytoplasm.	Cylindrical skin segment, 0.5 cm in diameter and 0.9 cm in thickness, bisected and entirely submitted in A. RS/RS	A-B) 4 MM BROWN PAPULE; CPD NEVUS, C) 3 MM BROWN PAPULE; CPD NEVUS, D) 4 MM BROWN PAPULE; CPD NEVUS, E) 3.5 MM BROWN PAPULE; CPD NEVUS, F) 2.5 MM BROWN PAPULE; CPD NEVUS, G) 6 X 8 MM BROWN PAPULE; CPD NEVUS, H) 5 MM BROWN PAPULE; CPD NEVUS, I) 3 MM BROWN PAPULE; CPD NEVUS	\N	left upper arm 	Scraping	\N	PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS	173649	1353	\N	\N	17-128346	A	SM-024	Nevus Library	IP1787557	AirTable blocks_with_IP_info.csv
1032	01-18107A	80	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=319	172.7	\N	\N	Sections show a proliferation of cells with atypical nuclei and ample\ncytoplasm, arrayed as confluent nests and sheets in the dermis, with\nextensive overlying ulceration.  There are many mitotic figures.\nThere are many single melanocytes in the basal layer of an\nirregularly hyperplastic epidermis.	Skin segment, 1.0 x 0.6 x 0.3 cm, bisected and totally submitted.	A) 8 X 5 MM ERYTHEMATOUS PAPULE; R/O MELANOMA VS VERRUCA, B) 1 CM BLACK MACULE; R/O MEL	\N	\N	Scraping	\N	MELANOMA, AT LEAST 3.0 MM. IN THICKNESS, ULCERATED, EXTENDING TO THE DEEP MARGIN	173713	133	\N	\N	01-18107	A	CCR-029	California Cancer Registry	IP129670	AirTable blocks_with_IP_info.csv
1523	11-80898	84	\N	\N	\N	T1a	Primary	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=952	172.4	\N	\N	Sections show a compound proliferation of melanocytes with vacuolated pale cytoplasm. Single cells and nests are arrayed irregularly within the epidermis, and conspicuous associated suprabasal scatter is apparent. There are also nests of similar melanocytes in fibrotic upper dermis, where a lymphohistiocytic infiltrate also resides. Part of the background epidermis is atypical and is capped by parakeratosis.	Skin segment measuring 1.0 x 0.9 x 0.1 cm, trisected and entirely submitted.	ATP BR PATCH; R/O PIG AK/SCC IN SITU/MIS/OTHER	\N	\N	\N	This melanoma has occurred in collision with a solar keratosis. With respect to staging, this melanoma is less than 1 mm in thickness, lacks associated ulceration, and does not have detectable melanocytes in mitosis in its invasive component. Therefore, it represents a melanoma of stage pT1a (2009 AJCC Guidelines). Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.55 MM IN THICKNESS, EXTENDING INTRAEPIDERMALLY TO THE SPECIMEN PERIPHERY	173406	155	\N	\N	11-80898	\N	CCR-097	California Cancer Registry	IP61385	AirTable blocks_with_IP_info.csv
1993	16-105648	9	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a pedunculated compound proliferation of large, oval melanocytes with abundant, pale amphophilic cytoplasm and large, pleomorphic vesicular nuclei. The overlying epidermis is relatively thin. Large nests predominate throughout the expanded papillary dermis with small nests of smaller cells in the subjacent superficial reticular dermis.	Two outside slides, S16-38422-A1, and one corresponding block.	LESION HAS BEEN PRESENT FOR SEVERAL MONTHS, IT ITCHES AND HAS BLED IF SCRATCHED OR INJURED, HE HAS NO HISTORY OF ATYPICAL NEVI OR MELANOMA, IT IS DESCRIBED AS A 3 MM ERYTHEMATOUS ROUND PAPULE; POSSIBLE PYOGENIC GRANULOMA	\N	\N	\N	A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product (nearly complete or complete loss in a defined zone is worrisome for melanoma). A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) shows a few mitotic figures in the upper part of the lesion and one near its base, the latter a worrisome finding.  Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows losses involving chromosomes 9 and 14. While chromosomes 9 loss is common in melanoma, it can be seen as an isolated finding, or along with chromosomal copy number changes affecting less significant sites in some partially transformed lesions. Chr. 14 loss is not characteristic of melanoma.  Following microdissection and DNA extraction, we performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations. Since then, there have been a few cases in which hTERT promoter mutations were not found, but in which the gene was affected by promoter methylation.  Taking these findings into account together with the histopathologic findings, an atypical Spitz tumor may be the best category for this lesion. These are neoplasms that have features more atypical than those of a conventional Spitz nevus, but not as worrisome as those of spitzoid melanoma. In aggregate data from over ten studies, local nodal involvment (usually very small deposits) is common, but extranodal metastasis is rare. This dissociation results in sentinel lymph node biopsy having very limited predictive value, and in my opinion, sometimes leading to over-treatment if small deposits lead to completion lymphadenectomy. The neoplasm extends to the base of the specimen, and a narrow re-excision still seems warranted.   Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES, FAVOR AN ATYPICAL SPITZ TUMOR	173305	715	\N	\N	16-105648	\N	DP-78	CGH Validation	IP1705676	AirTable blocks_with_IP_info.csv
1132	04-18467	85	\N	\N	\N	None	None	None	5	\N	FFPE	\N	\N	172.3	\N	\N	Sections show sheets and fascicles of spindled neoplastic cells, many of which have atypical nuclei or were captured in mitosis.  There are nests and fascicles of melanocytes scattered along the epidermal-dermal junction at the periphery of the biopsy, with lateral extension above elastosis.  There is a sparse dermal infiltrate with lymphocytes and melanophages.	Skin segment measuring 0.8 x 0.7 x 0.2 cm, trisected and entirely submitted.	BLACK 6 MM NODULE; IRR SK, R/O MELANOMA IN SITU COMPOUND	\N	\N	Scraping	In terms of staging, this is a non-ulcerated primary melanoma with an invasive component that involves the reticular dermis (Clark's level IV).  There is no evidence of vascular invasion or perineural extension or regression in this initial partial biopsy.  Final microstage assessment must of course be deferred until this  lesion has been completely reexcised.	MELANOMA OF 1.6 MILLIMETERS IN THICKNESS, TRANSECTED AT THE DEEP BIOPSY MARGIN	100333	191	\N	\N	04-18467	\N	CCR-212	California Cancer Registry	IP434866	AirTable blocks_with_IP_info.csv
2271	17-120839	67	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18179	216.4	\N	\N	Sections show a junctional proliferation of melanocytes in single cell array at the sides and bases of elongated rete ridges.  Some small nests are also present. There is hyperpigmentation of the basal layer and melanophages in the papillary dermis.	Skin segment measuring 0.5 x 0.3 x 0.1 cm, bisected and entirely submitted. HD/HD	R/O LENTIGO, HISTORY OF MELANOMA IN SITU	\N	\N	\N	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173406	831	\N	\N	17-120839	\N	LN-11	Lentiginous Nevi 	IP1562416	AirTable blocks_with_IP_info.csv
2377	18-136508B	26	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.6	\N	\N	Sections show a compound array of melanocytes, with single cells and nests arrayed along the epidermal-dermal junction, distributed along the sides and bases of elongated rete. There are similar melanocytes in the subjacent superficial dermis.	Skin segment measuring 0.4 x 0.3 x 0.1 cm, submitted intact in B. PL/PL	A-C) R/O DYSPLASTIC NEVI VS. MM	\N	\N	Scraping	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	173610	865	\N	\N	18-136508	B	LN-048	Lentiginous Nevi 	IP1911688	AirTable blocks_with_IP_info.csv
2743	21-98047	45	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18341	216.4	\N	\N	Sections show a compound array of melanocytes, with single cells and nests arrayed along the epidermal-dermal junction, distributed along the sides and bases of elongated rete. There are similar melanocytes in the subjacent superficial dermis.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted. BY/BY	4 MM IRREGULAR BROWN MACULE WITH CENTRAL CLEARING; NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. SL VS. MIS	\N	\N	FFPE	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	173441	887	\N	\N	21-98047	\N	LN-074	Lentiginous Nevi 	IP558857	AirTable blocks_with_IP_info.csv
1960	16-56300	23	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show acral skin with a mostly intradermal proliferation of large oval cells that form sheets in the superficial dermis with a more discrete fascicular pattern toward the base of the specimen, where similar but smaller cells predominate.	One hematoxylin and eosin-stained section prepared from outside block labeled W16-1703 1A.	12 MM FIRM FLESH COLORED PAPULE/NODULE OVER THE DISTAL PROXIMAL NAIL FOLD, NO NAIL DYSTROPHY; R/O NEUROFIBROMA VS. ACQUIRED DIGITAL FIBROMA KERATOMA	\N	\N	\N	The enclosed records indicate that immunostains were done at the Univ. of Utah, including one showing a low (1%) proliferation rate, and that the Myriad MyPath score favored benignity (-7.7). The reports also indicate a deep mitotic figure. Staining for BAP-1 did not show loss of nuclear staining, as would point to a mutation in that gene (present in a specific subset of Spitz's nevi and other spitzoid lesions).  There is nearly complete loss of p16 staining, which can correlate with one of the common genomic aberrations seen in melanocytic neoplasm, bi-allelic loss of chr. 9p, where the gene, CDKN2A that encodes p16 is located. This loss of staining can also occur by epigenetic means, and is not entirely specific for melanoma.  The findings made a nevoid melanoma a strong consideration. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This showed a loss involving chr. 9, with at step down in the CGH array graph surrounding the CDKN2A locus, in keeping with homozygous loss of this gene. This, in my opinion, favors melanoma. The final thickness measurement should be made after complete excision.	MELANOMA, 3.1 MM. IN THICKNESS	333788	706	\N	\N	16-56300	\N	DP-69	CGH Validation	IP1655740	AirTable blocks_with_IP_info.csv
1966	16-80354	56	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	An excisional specimen demonstrates a compound proliferation of enlarged fusiform melanocytes with finely pigmented cytoplasm. There are single melanocytes and nests and fascicles of melanocytes present within the epidermis, and limited suprajunctional scatter can be seen. In the dermis below this, the fusiform melanocytes mature as coalescing nests, fascicles, and syncytia, and a scattered infiltrate of lymphocytes and melanophages can be seen. The dermis is elastotic.	Three outside slides, DPR-16-8373-A1, and one corresponding block.	6 MM DEEP BROWN PAPULE WITH ECCENTRIC RED BORDER; DYSPLASTIC NEVUS VS. MELANOMA	\N	\N	\N	My differential diagnosis included a deep penetrating nevus (plexiform spindle cell nevus), a variant of Spitz nevus, and melanoma. Your submitted immunostain for p16 shows partial loss of expression, and this finding is diagnostically inconclusive (although a loss of chromosome 9 was ultimately confirmed to be present, as is discussed in the paragraph that follows). To further evaluate this tumor, we completed phosphohistone-H3 immunostaining to assess the mitotic index. In the resultant immunostain, rather dramatic maturation is apparent, and only a small number of perijunctional melanocytes in mitosis can be identified. To clarify the differential diagnosis, we completed array-based comparative genomic hybridization (aCGH) to screen for chromosomal copy number gain or loss. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 12p and 15q as well as loss in chromosomes 1p, 2p, centromeric 7p, 9, centromeric 12q, 13q, 17, and 18. The identification of multiple chromosomal copy number abnormalities indicates genomic instability, as is typical of melanoma. In short, the aCGH result confirms the diagnosis of melanoma and excludes any type of melanocytic nevus from the differential diagnosis.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.  Synoptic melanoma reporting is included below.  Procedure: narrow excision Microscopic tumor type: melanoma NOS Breslow thickness: 1.05 mm Ulceration: not detected Margin: narrow / equivocal Mitotic index: 1 per square mm Vascular invasion: not detected Regression: not significant Pathologic staging (pTNM): pT2aNxMx	MELANOMA OF 1.05 MM IN THICKNESS, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	173726	710	\N	\N	16-80354	\N	DP-73	CGH Validation	IP1680083	AirTable blocks_with_IP_info.csv
1971	16-89926	36	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show melanocytes arrayed focally in the epidermis with acanthosis, and partially maturing nests, cords, and fascicles of melanocytes are in collagenous dermis below this. The cells of interest are enlarged and often fusiform. A lymphohistiocytic infiltrate is noted.	Five outside slides, ST16-4992-A1, and one corresponding block.	NO HISTORY OF PREVIOUS MELANOMA	\N	\N	\N	My differential diagnosis included a large desmoplastic Spitz nevus, an HRAS-mutated Spitz nevus, and a kinase fusion Spitz nevus. Immunostaining demonstrated mosaic expression of p16, and thus biallelic loss in CDKN2A is not present in association with this tumor (the fact that there is not CDKN2A loss at all was subsequently documented by molecular methods, as is discussed in the paragraph that follows). An ALK stain is negative, and thus underlying ALK gene fusion is not present. My residual differential included an HRAS-mutated desmoplastic Spitz nevus, and array-based comparative genomic hybridization (aCGH) was completed to fully clarify the diagnosis. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 11p as a monoaberration with no other associated chromosomal gains or losses. As background for understanding this result, note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. The identification of gain in chromosome 11p is highly correlated with HRAS mutation, and this finding corroborates the diagnosis of HRAS-mutated Spitz nevus.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. Rather, our analysis confirms that this represents a variant of Spitz nevus, namely a Spitz nevus with HRAS mutation and gain. With respect to management, the inked edge of the specimen is focally involved, and thus conservative complete reexcision can be considered as a means to prevent persistence.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5. Please note that this reference includes discussion of a tumor with characteristics similar to this one.	HRAS-MUTATED DESMOPLASTIC SPITZ NEVUS	173450	711	\N	\N	16-89926	\N	DP-74	CGH Validation	IP1689756	AirTable blocks_with_IP_info.csv
1972	16-90917	40	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	The microscopic findings are essentially as described in the accompanying pathology report and in the note above.	Seven outside slides, KA16-20753 (A1-A2), and one corresponding block (A2).	IRREGULAR BROWN MACULE; DYSPLASTIC NEVUS	\N	\N	\N	The majority of features in the submitted slides favored an atypical Spitz tumor over spitzoid melanoma. The lesional melanocytes have monomorphous nuclei, and in most of the lesion nests are moderately sized superficially, and quite small along the base of the lesion. However, there were some areas in which disproportionately large nests are present toward the lesional base. Given this feature, I obtained comparative genomic hybridization. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. There are losses involving chromosomes 1p, 3p, 6q, 8p, 12p and 17q and a gain involving 8q. There are sub-threshold, possible aberrations as well- possible loss of 14 and possible gains of 1q and 6p. Some of the above chromosomal copy number changes are typical ones seen in melanoma.  Given these findings, I favor treating this lesion as melanoma, despite the findings by morphology and immunohistochemistry.	MELANOMA, 2.2 MM. IN THICKNESS	173507	712	\N	\N	16-90917	\N	DP-75	CGH Validation	IP1690755	AirTable blocks_with_IP_info.csv
1974	16-94655	73	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a very broad-based compound proliferation of melanocytes involving the junctional zone and superficial dermis.  Junctional nests extend beyond the dermal component, bridge rete ridges, and are accompanied by lamellar fibroplasia.  The center of the lesion has a different pattern.  The normal pattern of rete ridges and dermal papillae has been lost in two closely apposed areas, and junctional melanocytes are far fewer than at the periphery. The subjacent papillary dermis in this area has more marked fibrosis than is present at the periphery.  The dermal component consists of compactly arranged cords and strands of melanocytes with coarse chromatin set in dense fibrotic stroma.	Six outside slides, SW16-6248 (A1-A2) (TC16-59816-A). Two corresponding blocks received 9/29/16.	ATYPICAL NEVUS VS. MELANOMA	\N	\N	\N	The differential diagnosis included a dysplastic (Clark's) nevus and a melanoma simulating one. The architectural features are similar to those of some dysplastic nevi as described in the papers cited below. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This found a gain of chr. 6p, and an interstitial deletion involving chr. 15q. Chr. 6p gain is a common aberration in melanoma. While the 15q loss is not, its presence shows additional chromosomal instability.  Given the absence of ulceration or of mitotic figures in the dermal component, I would assess this as a AJCC stage pT1a melanoma. The intraepidermal component of this melanoma extends to within 1 mm. of  the peripheral edge of the specimen.	MELANOMA, 0.75 MM. IN THICKNESS	173508	713	\N	\N	16-94655	\N	DP-76	CGH Validation	IP1694537	AirTable blocks_with_IP_info.csv
1975	16-96276	25	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	There is a pedunculated segment of skin with a compound proliferation of large, and small oval melanocytes with the large cells having homogeneous appearing abundant, pale amphophilic cytoplasm and large, vesicular nuclei, and the smaller ones scant cytoplasm and smaller nuclei with coarse chromatin. A permeative lymphocytic infiltrate is present.	One outside slide, S16-19348-A1, and one corresponding block.	HISTORY OF MELANOMA (RIGHT ARM), RIGHT THIGH IRRITATED SKIN LESION, 4-PROBE FISH FOR ATYPICAL SPITZ LESION	\N	\N	\N	Our preferred technique for spitzoid neoplasm that are over 0.4 mm. thick is comparative genomic hybridization rather than fluorescence in situ hybridization, as this interrogates sites spanning the genome, rather than a few loci. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows losses involving chromosomes 9 and 10, which are among the most common chromosomal aberrations in melanoma. While isolated chr. 9 loss can be seen in some atypical Spitz tumors, the addition of clear-cut chr. 10 loss makes that unlikely.	MELANOMA, 2.2 MM. IN THICKNESS	173727	714	\N	\N	16-96276	\N	DP-77	CGH Validation	IP1696172	AirTable blocks_with_IP_info.csv
1977	16-97391	7	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a proliferation of large, oval melanocytes with abundant, pale cytoplasm and large, pleomorphic vesicular nuclei that has a bosselated surface. There are prominent junctional nests at the edges of the lesion and a thin epidermis with fewer junctional nests centrally. Other features are as noted above.	Seven outside slides, RWCS16-10413-A1. One corresponding block received 11/9/16.	LESION	\N	\N	\N	I note the area mentioned in your cover letter as showing diminished p16 immunostaining. There are enough interspersed cells still present that I doubt that this represents a focus in which there is homozygous CDKN2A loss. While the overall size and cellularity of this lesion are daunting, the maturation and dispersion with descent, and flat base are reassuring findings. Despite the difficult site, a re-excision would be wise. We can provide additional confirmation by hTERT promoter mutation analysis, comparative genomic hybridization or both. ADDENDUM, November 11, 2016:  Per Dr. Rao's request, we will proceed with testing.  ADDENDUM, December  1, 2016:  Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows a gain and an loss on chr. 7q, and a loss involving chromosome 9. While chromosomes 9 loss is common in melanoma, it can be seen as an isolated finding, or along with chromosomal copy number changes affecting less significant sites in some partially transformed lesions. The changes on chr. 7q signify a b-raf rearrangement (not mutation, but fusion of the wild type gene) as can be seen in a subset of spitzoid lesions.  Following microdissection and DNA extraction, we performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations. Since then, there have been a few cases in which hTERT promoter mutations were not found, but in which the gene was affected by promoter methylation.  Taking these findings into account together with the histopathologic findings, an atypical Spitz tumor may be the best category for this lesion. These are neoplasms that have features more atypical than those of a conventional Spitz nevus, but not as worrisome as those of spitzoid melanoma. In aggregate data from over ten studies, local nodal involvment (usually very small deposits) is common, but extranodal metastasis is rare. This dissociation results in sentinel lymph node biopsy having very limited predictive value, and in my opinion, sometimes leading to over-treatment if small deposits lead to completion lymphadenectomy. A narrow re-excision still seems warranted.   Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	ATYPICAL SPITZ TUMOR, SEE COMMENT	100222	716	\N	\N	16-97391	\N	DP-79	CGH Validation	IP1697302	AirTable blocks_with_IP_info.csv
2022	16-127388	14	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	A domed compound proliferation of strikingly large and variable melanocytes has a wedge-shaped profile with deep folliculocentricity. At the junction, there are irregular large nests and fascicles of melanocytes distributed irregularly, and focal thinning of the otherwise acanthotic epidermis is noted. Focal extension above the junction can be found. Similar large epithelioid and fusiform melanocytes are arrayed in collagenous dermis below this, where partial pigmentation and incomplete maturation are noted. There is an infiltrate of lymphocytes and melanophages as well.	Four outside slides, SK16-24757-A1, and one block.	IMPRESSION WAS 'HEMANGIOMA?'	\N	\N	\N	Your submitted p16 immunostain demonstrates near-total loss of expression, which was of concern as a potential indicator of chromosome 9 loss (more narrowly as an indicator of CDKN2A genomic loss). To fully delineate the genomic profile of this atypical proliferation, we completed array-based comparative genomic hybridization (aCGH) to screen for chromosomal copy number gain or loss throughout the genome. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed subthreshold loss in chromosome 9p coupled with low amplitude loss in chromosome 6q and low amplitude gain in chromosome 15q. As all of the molecular findings are of low amplitude, the observed results do not support interpretation as frank spitzoid melanoma. The most significant finding is loss in chromosome 9; this can be seen in melanoma as well as in histopathologically ambiguous proliferations within the spectrum of 'atypical Spitz tumor'. I believe the latter categorization represents the best classification for this proliferation. The low amplitude changes observed within chromosomes 6q and 15q may be an indication of partial transformation by a subpopulation of melanocytes.  In summary, the combination of results derived from conventional microscopy coupled with aCGH do not support interpretation as frank spitzoid melanoma. Rather, I believe this histopathologically ambiguous proliferation is best categorized as an atypical Spitz tumor. The removal at present is equivocally narrow, and additional excision is indicated to ensure that local removal has been accomplished.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	COMPOUND PROLIFERATION OF ENLARGED ATYPICAL SPITZOID MELANOCYTES, FOCALLY ABUTTING THE INKED SPECIMEN MARGIN	17723	717	\N	\N	16-127388	\N	DP-80	CGH Validation	IP1727647	AirTable blocks_with_IP_info.csv
1973	16-92011	16	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.3	\N	\N	Sections show melanocytes arrayed in compound fashion in each of two specimens. In an initial partial biopsy, there are melanocytes arrayed in lentiginous fashion and in limited pagetoid fashion and also in adnexa, and below this there are both large melanocytes with pale pigmented cytoplasm as well as smaller melanocytes with lesser pigmentation. The reexcision specimen demonstrates a limited residuum that is partially similar and that is obscured by a permeative lymphohistiocytic infiltrate with admixed melanophages.	One outside slide, D16-11636-A. Nine additional slides (levels and eight unstained) and one corresponding block received 1/5/17.\nThree outside slides, HD16-699 (A3-A4), and two blocks.	PATIENT WHO HAD A MOLE THAT HAD BEEN RECENTLY CHANGING	\N	\N	\N	Both an initial biopsy and a subsequent excision have been evaluated jointly as the basis for this consultation, and the findings in the two are generally similar. I agree with Dr. Sigal that the microscopic findings are worrisome for nevoid melanoma, and that diagnosis has now been substantiated by molecular means, as is discussed in the paragraph that follows. After receiving authorization to complete molecular testing, we applied array-based comparative genomic hybridization (aCGH) to screen for chromosomal copy number gain or loss, as can be seen with melanoma. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in telomeric chromosome 9 as well as subthreshold gain in chromosome 15q and in telomeric 13q. Additionally, we found loss in chromosomes 1, 2p, 9p, 10p, and centromeric 10q. There was subthreshold loss in telomeric chromosome 11q as well. The identification of multiple chromosomal gains and losses can be taken as being confirmatory of the diagnosis of melanoma.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	NEVOID MELANOMA OF 1.1 MM IN THICKNESS, FULLY EXCISED (THE FINAL MARGIN APPEARS FREE OF MELANOMA)	123398	718	\N	\N	16-92011	\N	DP-81	CGH Validation	IP1691865	AirTable blocks_with_IP_info.csv
2017	16-125975	65	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show melanocytes arrayed irregularly within the epidermis, which is strikingly thinned, and ovoid melanocytes are arrayed syncytially in a swath of the upper dermis below this. Deeper yet, there are fusiform melanocytes in fascicles. Some melanocytes are heavily pigmented, and melanophages are noted as well. A reexcision specimen consists largely of the fusiform component below central ulcerative fibrosing inflammatory alterations that are post-procedural.	Three outside slides, DPR-16-14154-A1; block received 1/5/17.\nEight outside slides, DPR-16-14772 (A1-A5), and one block (A4).	IRREG PIGMENTED LESION	\N	\N	\N	Both an initial biopsy and a subsequent excision have been evaluated jointly as the basis for this consultation, and the findings in both are generally similar and complementary. Based upon the findings in both, my differential diagnosis included a cellular blue nevus with perijunctional hypercellularity, an atypical cellular blue nevus, and blue nevus-like melanoma. Please note that the most atypical portion of the entire process is the hypercellularity seen in the perijunctional zone in the initial biopsy. Your p16 stain demonstrates generally preserved expression. Immunostaining for BAP-1 and phosphohistone-H3 was additionally completed, and the BAP-1 stain demonstrates preserved nuclear expression while the phosphohistone-H3 stain demonstrates that the mitotic index is low (<1 per square mm). These immunoperoxidase findings do not provide clear support to interpretation as melanoma and fit better with interpretation as an atypical melanocytic nevus.  Molecular assessment via array-based comparative genomic hybridization (aCGH) was recommended and has now been completed. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed a focused loss in chromosome 4q and subthreshold gain in telomeric chromosome 9q with no other additional chromosomal gains or losses. As background for understanding this result, note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. The two tiny aberrations that we have identified are not of diagnostic significance and are not known to be associated with blue nevus-like melanoma.  In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced support for a diagnosis of melanoma. Rather, our analysis fits with interpretation as an atypical cellular blue nevus. The tumor has been excised by means of the second specimen in this sequence, an no additional surgery at this site is recommended.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	ATYPICAL CELLULAR BLUE NEVUS, FULLY EXCISED (THE FINAL MARGIN APPEARS UNINVOLVED)	100589	719	\N	\N	16-125975	\N	DP-82	CGH Validation	IP1726217	AirTable blocks_with_IP_info.csv
2033	17-2869	14	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a focally ulcerated proliferation of large oval and fusiform melanocytes with oval vesicular nuclei and abundant, pale amphophilic cytoplasm involving the junctional zone of a thickened epidermis and the subjacent superficial dermis. Large nests of similar melanocytes are present in the papillary dermis and melanocytes in mitosis are observed. There is uneven maturation of melanocytes with descent within the dermis and nests of melanocytes with small hyperchromatic nuclei and scant cytoplasm admixed with melanocytes with abundant amphophilic cytoplasm and vesicular nuclei. There is a patchy lymphocytic infiltrate.	Skin segment measuring 0.7 x 0.6 x 0.2 cm, bisected and entirely submitted. KC/KC	EXCORIATED RED PAP 5 - 6 MM; ADNEXAL VS. NEVUS	\N	\N	\N	This ulcerated spitzoid melanoma demonstrates uneven maturation of melanocytes and dermal mitoses. The tumor is negative for p16, indicating loss of this tumor suppressor. The initiating oncogene in this tumor remains unknown as it is negative for ALK and only moderately positive for NTRK1, indicating the absence of ALK or NTRK1 fusion. In this challenging case, additional molecular studies were performed. By array comparative genomic hybridization, the tumor demonstrates loss of chromosome 6q and chromosome 9. These findings support a diagnosis of spitzoid melanoma. A TERT promoter mutation is not identified.  While the prognostic features used for melanoma in adults may have different implications for pediatric patients, they are provided below:  Microscopic tumor type: spitzoid Breslow thickness: at least 1.2 mm Ulceration: yes Margins, peripheral and deep: both involved Mitotic index: 3 per square mm Microsatellitosis: not identified Vascular Invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT2b  The clinical utility of sentinel node biopsy in pediatric patients, particularly those with spitzoid melanoma is controversial.  References: 1. Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	SPITZOID MELANOMA, EXTENDING TO THE EDGE AND BASE OF THE BIOPSY	123644	720	\N	\N	17-2869	\N	DP-83	CGH Validation	IP1731960	AirTable blocks_with_IP_info.csv
2030	17-2120	8	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	A sequence of level sections demonstrates a compound proliferation of enlarged epithelioid and fusiform melanocytes distributed in association with post-procedural scarring and a lymphohistiocytic infiltrate. In the available level sections, small numbers of melanocytes are positioned at the junction and along the junction of adnexal epithelium to the dermis, but most melanocytes are intradermal in distribution. Some of the constituent cells are extremely large with plasmacytoid or epithelioid morphology. In a sequence of slides labeled WP16-2671-A1, a more orderly configuration is apparent, and melanocytes are distributed in compound fashion with maturing nests, cords, and fascicles in the dermis . A series of three unrelated slides (16-2671-B1) shows a congenital melanocytic nevus of the face as an incidental additional finding.	Twenty-two slides, WP16-2671 (A1-A2) (HI16-1471, A1-A2), and two blocks.\nThree slides, WP16-2671 (B1-B2), and two blocks.	REEXCISION OF LEFT POSTERIOR THIGH MELANOCYTIC LESION; CONCERNED FOR AN ATYPICAL SPITZ TUMOR VS. SPITZ OR MELANOMA; PREVIOUS BIOPSY DIAGNOSED ELSEWHERE AS INTRADERMAL SPITZ NEVUS WITH MODERATE CYTOLOGIC ATYPIA	\N	\N	\N	The original immunoperoxidase stains that were received demonstrate that p16 expression is preserved and additionally demonstrate that the Ki-67 cell proliferation index is only modestly elevated, and these two findings suggest that frank pediatric spitzoid melanoma is unlikely. After the examination of recut sections, it became clear that only one of the two submitted blocks was exhausted of tissue. A BAP-1 immunostain of the viable tissue block demonstrates preserved nuclear positivity, and thus BAP-1 genomic loss has not occurred in this tumor. A repeat p16 stain demonstrates loss of positivity in a small population of enlarged melanocytes, and this fits with an emerging clone of atypical spitzoid tumor cells. Per your authorization, array-based comparative genomic hybridization (aCGH) was also applied to screen for chromosomal copy number gain or loss throughout the genome. After microdissection of the key area of the tumor followed by extraction of tumoral DNA from the tissue block, the application of aCGH revealed gain in centromeric chromosome 1p, loss in telomeric chromosome 1q, gain and loss in chromosome 7q with associated chromothripsis, and loss in chromosome 9. A marked focal gain in chromosome 7q is apparent at the location of BRAF, and this is probably an indicator of BRAF gene fusion.  In summary, the combination of results derived from conventional microscopy coupled with immunohistochemistry and aCGH suggests that frank spitzoid melanoma is not present here. Rather, we have identified an emerging spitzoid clone characterized by loss in CDKN2A and BRAF gene fusion. The secondary clone is best categorized as an 'atypical Spitz tumor', and the case as a whole can be viewed as an 'atypical Spitz tumor' arising focally within a Spitz nevus. With respect to management, the tumor appears narrowly excised in the current planes of section. Clinical follow-up of the surgical site is warranted, at a minimum (to verify that no persistence ensues), and additional excision can also be considered to ensure local removal.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	RESIDUAL COMPOUND PROLIFERATION OF ENLARGED SPITZOID MELANOCYTES; LIMITED GENOMIC ABERRATIONS HAVE BEEN IDENTIFIED BY MOLECULAR ANALYSIS	173726	721	\N	\N	17-2120	\N	DP-84	CGH Validation	IP1731205	AirTable blocks_with_IP_info.csv
2044	17-8968	22	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	The microscopic findings are essentially as described in the accompanying pathology report and in the note above.	Ten outside slides, P17-146-A1, and one corresponding block.	LESION	\N	\N	\N	While I favored a Spitz's nevus based on the submitted slides, the proliferation rate is, as you note very high. Following microdissection and DNA extraction, we performed comparative genomic hybridization. We found losses involving chr 6q, 9p and 13q. The first two are commonly found in melanoma.  As the CGH findings were unexpected, we performed sequencing to see if there was a mutation in the hTERT promoter gene. A recent study (see reference below) suggests that hTERT promoter mutation status is closely linked to aggressive behavior in atypical spitzoid neoplasms than are chromosomal copy number changes. Using the DNA extracted for CGH, we performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations. Since then, there have been a few cases in which hTERT promoter mutations were not found, but in which the gene was affected by promoter methylation.  Given these findings, I would obtain a complete re-excision, but I would not regard this lesion as melanoma. It fits into the broad category of atypical Spitz tumors, with more genomic than histopathologic aberrancy.  Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	COMPOUND PROLIFERATION OF LARGE SPITZOID MELANOCYTES, SEE COMMENT	129522	724	\N	\N	17-8968	\N	DP-87	CGH Validation	IP1738128	AirTable blocks_with_IP_info.csv
2842	22-102807-4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	815	\N	\N	None	\N	LMM-16	Lentigo Maligna Melanoma	\N	AirTable blocks_with_IP_info.csv
2049	17-9550	38	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show an asymmetrical compound proliferation of hyperchromatic melanocytes. Within the epidermis, which is partially thinned, there is single melanocytes and nests distributed nearly confluently, and associated pagetoid scatter is noted. In the dermis below this, incompletely maturing nests, cords, fascicles, and small syncytia of finely pigmented melanocytes are noted, and interstitial melanophages are also apparent. Pigmentation by melanocytes is retained through all of the thickness of the dermal component. Reevaluation of the intraepidermal component in a recut section, after the receipt of the molecular result, affirms that much of it is composed of fusiform melanocytes in fascicles.	Three outside slides, CT17-1057, and one block.	NEVUS ON THE RIGHT DORSAL FOOT OF PATIENT, THE PATIENT BELIEVES IT HAS BEEN PRESENT FOR MANY YEARS, ALTHOUGH THE DERMATOLOGIST QUESTIONS HIS ACCURACY AS A HISTORIAN, ATYPICAL NEVUS, NEVOID MM	\N	\N	\N	My differential diagnosis included an atypical melanocytic nevus on one hand and nevoid melanoma on the other, and based upon the analysis delineated in the sentences that follow, it becomes clear that the former possibility represents the best overall categorization. Your submitted phosphohistone-H3 immunostain demonstrates that the mitotic index is low, but this finding is of little diagnostic comfort, as the mitotic rate in many examples of nevoid melanoma approaches zero. Immunohistochemistry for p16 was additionally completed and demonstrates mosaic positivity, and this implies that biallelic loss in CDKN2A is not apparent in this tumor. (If biallelic loss was present, it would compellingly favor the diagnosis of melanoma.) The defined findings were certainly plausible as an atypical melanocytic nevus, but I did not feel that nevoid melanoma of 0.75 mm in thickness could be excluded on histopathologic grounds. In light of this and as per your authorization, we additionally completed array-based comparative genomic hybridization (aCGH) to screen for chromosomal copy number gain or loss, as would be expected in association with melanoma. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 7q with loss of telomeric chromosome 6q (not involving the MYB gene) with no other associated gains or losses. The gain in chromosome 7q includes a spike in the vicinity of 7q34, and this finding suggests that BRAF gene fusion has occurred. As background for fully understanding the molecular result, note that most melanomas analyzed via aCGH demonstrate multiple associated significant chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations or show a monoaberration, as is apparent here (the loss of telomeric 6q is trivial and is not of larger diagnostic significance, and thus the gain in 7q qualifies as a monoaberration).  In summary, the combination of results derived from conventional microscopy coupled with aCGH has not produced confirmation of a diagnosis of nevoid melanoma. Rather, I believe the proliferation represents a partially transformed melanocytic nevus with underlying BRAF gene fusion. Returning to the slide after analyzing the molecular findings, there are subtle spitzoid characteristics that I did not fully appreciate in my prior evaluation. Based upon these findings coupled with the molecular result, I believe this melanocytic nevus is best categorized within the spectrum of Spitz nevus.  Gene fusion, including BRAF gene fusion, represents a not uncommon mechanism of induction of Spitz nevi and Spitz tumors. Such tumors are only minimally or partially transformed and typically hold no larger clinical potential. With that said, as this biopsy is only partial in nature, conservative complete reexcision can be considered as follow-up management. The intent of reexcision is simply to ensure complete removal and verify that persistence with additional transformation cannot ensue.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	ATYPICAL COMPOUND SPITZ NEVUS WITH BRAF GENE FUSION, INVOLVING THE DEEP EDGE OF THE BIOPSY	173788	725	\N	\N	17-9550	\N	DP-88	CGH Validation	IP1738711	AirTable blocks_with_IP_info.csv
2051	17-10585	39	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.4	\N	\N	There is a dome shaped segment of skin. There are small, round melanocytes arranged as compact nests, separated from one another by clefts in some areas, and large, oval cells with pleomorphic, irregularly shaped and heterochromatic nuclei in others.	Seven outside slides, SH-17-3220-A1, and one corresponding block.	MELANOCYTIC LESION	\N	\N	\N	The differential diagnosis includes a combined atypical Spitz tumor and a spitzoid melanoma arising in a nevus. Staining for BAP-1 did not show loss of nuclear staining, as would point to a mutation in that gene (present in a specific subset of Spitz's nevi and other spitzoid lesions). However, there is nearly complete loss of p16 staining, which can correlate with one of the common genomic aberrations seen in melanocytic neoplasm, bi-allelic loss of chr. 9p, where the gene, CDKN2A that encodes p16 is located. This loss of staining can also occur by epigenetic means, and is not entirely specific for melanoma.  Following microdissection and DNA extraction, we performed comparative genomic hybridization.  It shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. The chromosomal copy number changes that we found include loss of chr. 1p, loss involving much of chr. 4, gain of 8q, loss of 9p, loss of 10, loss of 22. Many of these are classic aberrations seen in melanoma. The loss of chr. 9p correlates with the absence of p16 by immunohistochemistry. The neoplasm extends to the base of the specimen.	MELANOMA, AT LEAST 1.6 MM. IN THICKNESS	173403	726	\N	\N	17-10585	\N	DP-89	CGH Validation	IP1739754	AirTable blocks_with_IP_info.csv
2062	17-14313	7	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show melanocytes arrayed in compound fashion in a partial incisional specimen. The cells of interest are large and fusiform or epithelioid. There are large junctional or perijunctional nests, and maturing nests, cords, and fascicles of similar melanocytes are in collagenous dermis below this. There are perijunctional fibrosing inflammatory alterations that are probably due to a prior biopsy, and entrapped cystic folliculosebaceous units are noted.	Six outside slides, S17-957 (A1-A2). One block (A2) received 2-24-17.	PATIENT WITH SPITZ NEVUS	\N	\N	\N	This apparent reexcision specimen demonstrates the substantial residuum of a Spitz tumor. My differential diagnosis included a large desmoplastic Spitz nevus, a so-called HRAS-mutated Spitz nevus, and an 'atypical Spitz tumor'. As is discussed in the paragraphs that follow, the diagnosis of HRAS-mutated Spitz nevus has now been confirmed. Ancillary analysis was recommended and has been completed, as per your authorization. Immunohistochemistry for p16 was completed to assess (or infer) the copy number status of CDKN2A, and mosaic immunopositivity has been demonstrated; this implies that significant genomic loss in CDKN2A has not occurred. Array-based comparative genomic hybridization (aCGH) was additionally completed to screen for chromosomal copy number gain or loss throughout the genome. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed isolated gain in chromosome 11p as a monoaberration with no additional chromosomal gains or losses. As background for understanding this result, note that most melanomas analyzed via aCGH demonstrate multiple associated chromosomal copy number gains or losses, while virtually all melanocytic nevi lack such aberrations. The identification of isolated gain in chromosome 11p corresponds to mutation in HRAS and can be considered confirmatory of the above diagnosis.  In summary, the combination of results derived from conventional microscopy coupled with aCGH confirms the diagnosis of HRAS-mutated Spitz nevus. The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5. Please note that this citation discusses a case with molecular findings identical to this tumor.	(RESIDUAL) HRAS-MUTATED DESMOPLASTIC SPITZ NEVUS	173306	727	\N	\N	17-14313	\N	DP-90	CGH Validation	IP1743507	AirTable blocks_with_IP_info.csv
2078	17-26078	2	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	There is a zone of fibrosing granulation tissue, adjacent to which is a vertically oriented compound pan-dermal and superificial subcutaneous proliferation of large, oval melanocytes. These cells of interest form very large nests associated with irregular epidermal hyperplasia, foci of erosion, some suprabasilar scatter, some dispersion in the deep reticular dermis, and a large vertically oriented oval mass in the subcutis. Many mitotic figures are present superficially and a few more deeply.	Two outside slides, P17-1100 (A-B). One corresponding block (B) received 3/27/17.	NEVUS	\N	\N	\N	The very large size of the superficial nests, the number of mitotic figures within them, and the large bulbous mass that protrudes into the superficial subcutis are features that lie beyond those of a Spitz's nevus and make the differential diagnosis between that of an atypical Spitz tumor and a spitzoid melanoma. Some relatively deep mitotic figures are present as well. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows a complex pattern of gains and losses on chr. 3p including an amplification of an area around MiTF. While the area of loss encompassed the BAP-1 gene on chr. 3p, no loss of BAP-1 was seen by immunohistochemistry, making it unlikely that a BAP-1 mutation was present. MiTF amplifications are usually found in high grade melanomas, and seldom in spitzoid lesions in children. There is a loss of chr. 6q, and a gain of chr. 7. A gain of part of chr. X is also present. The chr. 6q loss has a copy number transition around ROS1, which can point to a ROS gene fusion.  Following microdissection and DNA extraction, we performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations. Since then, there have been a few cases in which hTERT promoter mutations were not found, but in which the gene was affected by promoter methylation.  In sum, while the hTERT promoter gene was wild type, the findings by CGH included MiTF amplification, which in addition to the other chromosomal copy number changes favors melanoma. My colleague Dr. Iwei Yei also reviewed the sections and CGH data, and agree with this interpretation. I would note that spitzoid melanomas in children have a much better prognosis than conventional ones of the same thickness in adults. The neoplasm extends to the base of the specimen.  Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	MELANOMA, 4.5 MM. IN THICKNESS	173701	728	\N	\N	17-26078	\N	DP-91	CGH Validation	IP1755396	AirTable blocks_with_IP_info.csv
2095	17-29457B	56	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.5	\N	\N	There is a mostly intradermal proliferation of large, oval melanocytes in which particularly large cells with abundant, pale cytoplasm and irregularly shaped nuclei predominate superficially. Some of these nuclei are very large.	Skin segment measuring 0.5 x 0.5 x 0.1 cm, bisected and entirely submitted in B. RS/RS	A) 3 X 4 MM SCALY PAPULE; AK VS. SCC, B) 4 X 4 MM RED PAPULE; IDN VS. BCC, C) 8 X 5 MM BROWN MACULE; NEVUS, POSS ATYPIA, D) POSSIBLE GA	\N	\N	\N	A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product (nearly complete or complete loss in a defined zone is worrisome for melanoma). I did not find mitotic figures in dermal melanocytes in a phosphohistone H3/Melan-A two color immunostain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle), a finding against melanoma.  Given the degree of nuclear pleomorphism, without other findings strongly favoring melanoma, I obtain comparative genomic hybridization.  Following microdissection and DNA extraction, we performed this study. The findings include losses involving chromosomes 3, 9, and 16q, with the chr. 9 loss a common one found in melanoma. Other subthreshold losses include chromosomes 5q and 7p.  Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: biopsy Microscopic tumor type: nodular Ulceration: no Margins, peripheral: clear by < 1 mm. and deep: involved Mitotic index: 0/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT2a pNX	MELANOMA, AT LEAST 1.1 MM. IN THICKNESS	102538	729	\N	\N	17-29457	B	DP-92	CGH Validation	IP80460	AirTable blocks_with_IP_info.csv
1499	11-52339	31	\N	\N	\N	T1b	Primary	None	\N	\N	\N	\N	\N	172.7	\N	\N	There is a domed and flattish yet asymmetrical proliferation of large ovoid and spindled melanocytes involving the epidermis and dermis. The epidermis overlying the proliferation has a slightly elevated surface and is acanthotic with a thickened granular layer and a thin but partially compact cornified layer. Situated at the junction and focally above the junction are large melanocytes with abundant pale amphophilic cytoplasm and pleomorphic, vesicular and heterochromatic nuclei. Smaller aggregations of similar cells disperse and partially mature toward the base of the lesion. A few mitotic figures are evident in junctional melanocytes and rarely in dermal melanocytes. A juxtaposed lymphohistiocytic infiltrate is present concurrently.	Three outside slides, PANS11-14530 A1. One corresponding block received 7-25-11.	HX OF MELANOMA IN SITU ON THE LEFT FOREARM DIAGNOSED IN 2002 AND AN ATYPICAL MELANOCYTIC LESION ON THE LEFT LOWER BACK AT LEFT UPPER ARM, NOW WITH 7 MM PINK PAPULE; MELANOMA?	\N	\N	\N	To assess a differential diagnosis between an unconventional Spitz nevus on one hand and melanoma on the other, we completed array-based comparative genomic hybridization (aCGH) to screen for melanoma-associated genomic anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in chromosome 1p, segmental loss of chromosome 1q, loss in chromosome 2p, 2 segmental gains in chromosome 7q, and loss of chromosome 9. The identification of multiple chromosomal copy number aberrations indicates genomic instability and points to interpretation as melanoma. The identification of multiple chromosomal gains and losses is incompatible with any form of Spitz nevus. In summary, the combination of results derived from conventional microscopy coupled with aCGH confirm that this proliferation represents melanoma and not a Spitz nevus. With respect to staging, this melanoma is less than 1 mm in thickness and lacks associated ulceration, yet melanocytes in mitosis are detectable in its dermal component. Therefore, this represents melanoma of stage pT1b (2009 AJCC Guidelines). Further excision is warranted to ensure that local eradication has been accomplished.	MELANOMA OF 0.85 MM IN THICKNESS, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	173727	2249	\N	\N	11-52339	\N	SYNAT466	2010-2017	IP1041779	AirTable blocks_with_IP_info.csv
1171	05-23001E T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	916	\N	\N	None	\N	MD-10	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2127	17-42757	43	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	There is a narrowly based proliferation of large oval melanocytes with abundant pale cytoplasm and from small and monomorphous to large and pleomorphic nuclei. The latter diminish toward the base of the specimen, with some dispersion.	Five outside slides, SFS17-14484-1A, and one corresponding block.	PATIENT HAS A HISTORY OF DYSPLASTIC NEVI AND SCCIS, ERYTHEMATOUS HYPERKERATOTIC PAPULE (SEE PHOTO)	\N	\N	\N	This lesion has more strikingly pleomorphism than most desmoplastic Spitz's nevi have, and is in the setting of dyschromic skin with other atypical appearing pigmented lesions. p16 is entirely negative, raising the possibility of a homozygous deletion of chromosome 9p/CDKN2A. Following microdissection and DNA extraction, we performed comparative genomic hybridization. It shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi in adult patients. The aberrations include loss of the pericentromeric area of chr. 1p and loss of 1q, loss of the distal part of chr. 6q, loss of chr. 9, and loss of chr. 17. Losses of chr. 6q and 9 are common in melanoma, although usually the entire arm of chr. 6q is lost. Gains of 1p are common in melanoma rather than losses of it. However, taking into account the atypical histopathologic features and these aberrations, I favor the diagnosis above.  Given the absence of ulceration or of mitotic figures in the dermal component, I would assess this as a AJCC stage pT1a melanoma, pending re-excision (which could show deeper lesional melanocytes).	MELANOMA, AT LEAST 0.9 MM. IN THICKNESS	173619	731	\N	\N	17-42757	\N	DP-94	CGH Validation	IP1772311	AirTable blocks_with_IP_info.csv
2131	17-48219	17	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a proliferation of melanocytes with two separate cellular components (a biphasic pattern). There are both small conventional melanocytes in nests and syncytia as well as large fusiform and ovoid melanocytes with finely pigmented cytoplasm. The latter cells are arrayed in coalescing nests, cords, fascicles, and syncytia throughout the upper and lower reticular dermis and also in the adventitial dermis without clear circumscription. In the upper dermis, some fusiform melanocytes are enlarged. A robust deep lymphohistiocytic infiltrate with admixed melanophages is also noted -- and this includes some lymphoid follicles. There are also fascicles that encompass peripheral nerves.	21 slides, CE-17-001314 A1 & A2 (17-3142 A & B) and two blocks.	? SPITZ NEVUS, R/O DYSPLASTIC NEVUS, ? DERMATOFIBROMA	\N	\N	\N	The discussion that follows has been modified to integrate molecular results. This unusual tumor includes both conventional melanocytic nevus and a secondary component resembling a deep penetrating nevus, and the latter component exhibits associated neurotropism and adnexotropism. Your immunoperoxidase stains demonstrate that expression of p16 is generally preserved and that the Ki-67 cell proliferation index is low, and both of these labeling results are as would be expected with a melanocytic nevus, or at least do not provide clear support to interpretation as melanoma. Immunostaining for beta catenin was included in our evaluation and is negative. Some but not all examples of deep penetrating nevus exhibit nuclear positivity with beta catenin immunohistochemistry, as activating mutations in beta catenin are common to their pathogenesis.  In terms of potential considerations in the differential diagnosis, I found myself unable to render a diagnosis of neurotropic melanoma (arising in conjunction with a melanocytic nevus) on histopathologic grounds, but obviously the finding of marked neurotropism is extreme and unusual. To clarify the diagnosis, we additionally completed array-based comparative genomic hybridization (aCGH) to screen for chromosomal copy number gain or loss, as per your authorization. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed loss in chromosome 1p, focal loss in telomeric chromosome 2q, and gain in telomeric chromosome 7q, including the region where BRAF is encoded. This unusual molecular result with multiple small aberrations does not provide support to interpretation as frank melanoma but also indicates that this proliferation does not represent any form of conventional melanocytic nevus. In short, these combined histopathologic and molecular results suggest a partially transformed tumor; the findings we have defined are roughly equivalent to what is often termed 'atypical Spitz tumor'. My colleague, Dr. Iwei Yeh, also reviewed the molecular results for this case and is in agreement that the defined findings do not support interpretation as melanoma.  The neurotropic component of this unusual tumor extends focally to the inked specimen margin. Reexcision to obtain a free margin is recommended.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5.	ATYPICAL COMBINED DEEP PENETRATING NEVUS-LIKE MELANOCYTIC PROLIFERATION WITH ASSOCIATED NEUROTROPISM	173526	732	\N	\N	17-48219	\N	DP-95	CGH Validation	IP1777827	AirTable blocks_with_IP_info.csv
2134	17-49361	81	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	There is a dome surfaced compound proliferation of melanocytes with a thin overlying epidermis. Many small Kamino bodies are present. Nests of small fusiform melanocytes are present irregularly along the dermo-epidermal junction, and compact nests of small, oval melanocytes are embedded in fibrotic stroma in the dermis.	One outside slide, 17-02845 A (H-70147). One corresponding block received 5/23/17.	R/O BCC (SEE PHOTO)	\N	\N	\N	Many features favored a Spitz's nevus, although the patient is considerably older than most with that diagnosis. Given the setting, we obtained comparative genomic hybridization to see if chromosomal copy number changes as occur in melanoma but not in Spitz's nevus were present. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. These included several that are typical of melanoma, including a gain involving chr. 6p and a loss involving chr. 9. A subthreshold loss of chr. 6q was also present (indicating that this may be in a subset of cells).  The final thickness measurement should be made after complete excision.	MELANOMA, AT LEAST 0.6 MM. IN THICKNESS	128547	733	\N	\N	17-49361	\N	DP-96	CGH Validation	IP655827	AirTable blocks_with_IP_info.csv
2136	17-50829	57	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	The microscopic findings are essentially as described in the accompanying pathology report and in the note above.	Eighteen outside slides, S17-28577 (A1-A2), and two corresponding blocks.	1.4 CM IRREGULARLY PIGMENTED PLAQUE-MELANOMA FAVORED (SEE PHOTOS)	\N	\N	\N	I agree that the differential diagnosis includes both a nevoid melanoma resembling a dysplastic nevus, and a lesion at the upper end of the spectrum for dysplastic nevus. While the peripheral component is mostly nested, featuring bridging and fibroplasia, there is more pagetoid scatter in the Mart-1 immunostains than could be appreciated in the hematoxylin eosin-stained sections. Also, as you note there is compression of the elastic fiber network, and although the dermal melanocytes are relatively small they have slightly more cytoplasm than in most dysplastic nevi. Given the difficulties of this case, I obtained comparative genomic hybridization to see if chromosomal copy number changes as found in melanoma were present or not. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This showed a gain involving the terminal portion of chr. 2q, and one involving chr. 6p. While the number of chromosomal copy number changes is limited, gain of chr. 6p is highly characteristic of melanoma and in the context of the microscopic findings is, in my opinion, sufficient for a diagnosis of melanoma. I included the larger of the dermal cells in the thickness, but not the small, round melanocytes loosely arranged at the base of the papillary dermis (which may be those of a pre-existent nevus).  Given the absence of ulceration or of mitotic figures in the dermal component, I would assess this as a AJCC stage pT1a melanoma.	MELANOMA, 0.6 MM. IN THICKNESS	273588	734	\N	\N	17-50829	\N	DP-97	CGH Validation	IP1780487	AirTable blocks_with_IP_info.csv
1483	11-37533	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 RESIDUAL MELANOMA, 0.75 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A RESIDUAL MELANOMA, 0.75 MM IN THICKNESS, ARISING IN ASSOCIATION WITH A SUPERFICIAL CONGENITAL MELANOCYTIC NEVUS, WITH MELANOMA IN SITU PRESENT WITHIN 1 MM OF THE EDGE OF THE SPECIMEN	\N	\N	\N	\N	742	\N	\N	11-37533	\N	JJS3	2010-2017	\N	AirTable blocks_with_IP_info.csv
1589	12-12684	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26342	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	746	\N	\N	12-12684	\N	JJS7	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1652	12-57797	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26325	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	748	\N	\N	12-57797	\N	JJS9	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1667	12-93589A	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26298	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	751	\N	\N	12-93589	A	JJS12	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1682	13-2138C	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26299	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	752	\N	\N	13-2138	C	JJS13	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1738	13-98648	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26300,26301	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	753	\N	\N	13-98648	\N	JJS14	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1747	14-2508	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26302	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	754	\N	\N	14-2508	\N	JJS15	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1797	14-64047	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26303,26327	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	755	\N	\N	14-64047	\N	JJS16	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1549	12-095	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	790	\N	\N	12-95	\N	KIT-09	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1550	12-122	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	791	\N	\N	12-122	\N	KIT-10	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1551	12-169	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	792	\N	\N	12-169	\N	KIT-11	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1552	12-200	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	793	\N	\N	12-200	\N	KIT-12	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1431	11-072	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	794	\N	\N	11-72	\N	KIT-13	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1432	11-091	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	795	\N	\N	11-91	\N	KIT-14	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1433	11-133	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	796	\N	\N	11-133	\N	KIT-15	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1434	11-154	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	797	\N	\N	11-154	\N	KIT-16	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1435	11-172	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	798	\N	\N	11-172	\N	KIT-17	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1436	11-256	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	799	\N	\N	11-256	\N	KIT-18	Kit mutants	\N	AirTable blocks_with_IP_info.csv
2742	21-98013A	68	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18342	216.7	\N	\N	Sections show a compound array of melanocytes, with single cells and nests arrayed along the epidermal-dermal junction, distributed along the sides and bases of elongated rete. There are similar melanocytes in the subjacent superficial dermis.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in A. HD/HD	A-B) R/O DN	\N	\N	FFPE	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	154799	888	\N	\N	21-98013	A	LN-075	Lentiginous Nevi 	IP2361035	AirTable blocks_with_IP_info.csv
2903	23-37003	73	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=31834,31835,31836,31837,31838,31839,31840	172.3	\N	 (prior bx T23-31171)	Sections show inflammation and granulation tissue, flanked by a proliferation of melanocytes arrayed irregularly along the junctional zone and as nests in the dermis. The dermal melanocytes do not show significant maturation and mitotic figures are present.	Oriented ellipse, 2.1 x 1.1 x 0.3 cm, including a central 1.0 x 0.9 cm white-tan area. The orienting notch is located at the midpoint of one edge. This notch is indicated 9 o'clock on the requisition and is placed toward 9 o'clock. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and entirely submitted with four sections each in 1-2. KB/KB	MM EXCISION, REFER TO SLIDE, #DT23-31171	\N	\N	\N	There is a residuum of invasive melanoma, which when measured away from adnexal structures has a Breslow depth greater than observed in the prior biopsy. A brief synoptic is included below.  Procedure: excision Microscopic tumor type: high cumulative sun-damage melanoma Breslow thickness: 1.3 mm Ulceration: not detected Margin: melanoma in situ extends to within 1 mm of both peripheral margins in the central portions of the ellipse Mitotic index: 2 per square mm Regression: not detected Pathologic staging (pTNM): pT2a	HEALING BIOPSY SITE, WITH RESIDUAL MELANOMA, 1.3 mm IN THICKNESS	321300	805	\N	\N	23-37003	\N	LMM-06	Lentigo Maligna Melanoma	IP2569388	AirTable blocks_with_IP_info.csv
1015	00-21551 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	907	\N	\N	None	\N	MD-01	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1020	01-00027 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	908	\N	\N	None	\N	MD-02	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1025	01-07957 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	909	\N	\N	None	\N	MD-03	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1033	01-20248 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	910	\N	\N	None	\N	MD-04	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2730	21-62764	64	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a proliferation of nested and solitary melanocytes, some of which have atypical nuclei, irregularly distributed above marked elastosis.  Clusters of similar melanocytes are present in the dermis amidst a variable lymphohistiocytic  inflammatory infiltrate.	Skin segment measuring 1.5 x 1.1 x 0.1 cm, serially sectioned, and entirely submitted with five sections. HD/HD	JUNCTIONAL NEVUS, 11 X 8 MM; R/O MM	\N	\N	\N	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: Tumor site: right proximal forearm Microscopic tumor type: high cumulative sun damage (WHO) Breslow thickness: 0.6 mm Ulceration: absent Margins, peripheral and deep: melanoma in situ extends close to the peripheral tissue edge; deep tissue edge free Mitotic index: 1 Microsatellitosis: not identified Vascular Invasion:  not identified Perineural invasion: not identified Regression: present, focal Pathologic Staging (pTNM): pT1a pNX	INVASIVE MELANOMA, BRESLOW THICKNESS 0.6 mm, NON-ULCERATED	113605	812	\N	\N	21-62764	\N	LMM-13	Lentigo Maligna Melanoma	IP2325554	AirTable blocks_with_IP_info.csv
1034	01-26615B T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1056	\N	\N	None	\N	MD-179	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2300	18-15487B	55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18209	216.7	\N	\N	Sections show a compound proliferation of melanocytes with a junctional component comprised of single cells and small pigmented nests arrayed along the sides and bases of pigmented rete. Small nests and cords of similar melanocytes are positioned in the subjacent superficial dermis, where scattered melanophages are also evident.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted in B. KC/KC	A) ATYPICAL NEVUS VS. BENIGN NEVUS VS. MELANOMA. 0.6 CM UNEVEN PIGMENT. CC: ANDREA ASHBY, MD. B) ATYPICAL NEVUS VS. BENIGN NEVUS VS. MELANOMA. UNEVENLY PIGMENTED MACULE 0.5 CM.	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	592733	841	\N	\N	18-15487	B	LN-21	Lentiginous Nevi 	IP1078920	AirTable blocks_with_IP_info.csv
2265	17-119570C	59	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18159	216.7	\N	\N	Sections show a junctional proliferation of melanocytes in single cell array at the sides and bases of elongated rete ridges.  Some small nests are also present. There is hyperpigmentation of the basal layer and melanophages in the papillary dermis.	Skin segment measuring 0.7 x 0.7 x 0.1 cm, trisected and entirely submitted in C. HD/HD	A-B) 6 MM; R/O IRRITATED NEVUS, C) 6 MM; R/O MELANOMA	\N	\N	\N	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173727	821	\N	\N	17-119570	C	LN-01	Lentiginous Nevi 	IP1817562	AirTable blocks_with_IP_info.csv
2257	17-118831C	68	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18161	216.6	\N	\N	Sections show a small and symmetric proliferation with increased numbers of single melanocytes and small nests of them positioned at the sides and bases of elongated rete ridges. There is abundant melanin the cornified layer, in the subjacent epidermis and within melanophages in the papillary dermis beneath the lesion. There is solar elastosis.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted in C. CF/CF	A-B) R/O BCC, C) R/O MM	\N	\N	\N	\N	HYPERMELANOTIC LENTIGINOUS JUNCTIONAL NEVUS	173619	822	\N	\N	17-118831	C	LN-02	Lentiginous Nevi 	IP842282	AirTable blocks_with_IP_info.csv
1181	05-29322B T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	918	\N	\N	None	\N	MD-12	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2219	17-109907D	33	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18163	238.2	\N	\N	Sections show a proliferation of melanocytes arrayed as single cells and pigmented nests in lentiginous fashion along the sides and bases of pigmented rete. Some intraspinous melanocytes are noted. The dermis deep to this shows elastosis. Slight subjunctional fibroplasia and scattered perijunctional lymphocytes and melanophages are also apparent.	Cylindrical skin segment, 0.8 cm in diameter and 0.4 cm in thickness, with the margins inked, trisected and entirely submitted. RS/RS	A-B) CHANGING NEVUS, PROB IDN, C-D) R/O MELANOMA	\N	\N	\N	The differential diagnosis lies between a lentiginous melanocytic nevus occurring within dermatoheliotic skin on one hand and early lentiginous melanoma in situ on the other. While I favor an atypical melanocytic nevus as most likely, early melanoma in situ cannot be excluded, and thus reexcision is recommended as follow-up management.	LENTIGINOUS INTRAEPIDERMAL PROLIFERATION OF MELANOCYTES, WITH EXTENSION CLOSE TO THE PERIPHERY OF THE BIOPSY	173610	823	\N	\N	17-109907	D	LN-03	Lentiginous Nevi 	IP1840351	AirTable blocks_with_IP_info.csv
2301	18-15803	34	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18205	216.5	\N	\N	There are increased numbers of single melanocytes at the sides and bases of elongated rete ridges. There is basilar hyperpigmentation in the affected area. Clusters of small, round melanocytes reside in the subjacent dermis along with scattered melanophages.	Cylindrical skin segment, 0.6 cm in diameter and 0.3 cm in thickness, bisected and entirely submitted. CF/PL	R/O MM, 6 MM LESION	\N	\N	\N	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	173530	840	\N	\N	18-15803	\N	LN-20	Lentiginous Nevi 	IP1879395	AirTable blocks_with_IP_info.csv
2251	17-115572A	60	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.4	\N	\N	There is a proliferation of melanocytes, mostly at the dermo-epidermal junction. Most are arranged singly at the sides and bases of elongated rete ridges, but some small nests are also present. There is hyperpigmentation of the basal layer. There is solar elastosis.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted in A. HD/HD	A) R/O LENTIGO, 0.6 X 0.6, B) NEOP UNC VS. SCAR VS. BCC, 0.6 X 0.6	\N	\N	Scraping	The proliferation has a lentiginous pattern and occurs in heavily sun damaged skin. The above interpretation is based on the assumption that this biopsy represents the entire lesion. If this is a partial biopsy of a larger lesion, conservative excision is recommended so that the entire proliferation can be assessed.	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173404	845	\N	\N	17-115572	A	LN-025	Lentiginous Nevi 	IP1846067	AirTable blocks_with_IP_info.csv
2252	17-115588	41	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	There are increased numbers of single melanocytes and small nests of them positioned at the sides and bases of elongated rete ridges. There is abundant melanin the cornified layer, in the subjacent epidermis and within melanophages in the papillary dermis beneath the lesion. Some melanocytes have fusiform nuclei.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted. PL/PL	SIZE 0.4 CM, IRREGULAR BROWN MACULE; ATYPICAL NEVUS	\N	\N	Scraping	This lesion shows some features of a pigmented spindle cell nevus, which most observers consider a variant of Spitz's nevus. No evidence of melanoma or significant atypia was detected.	HYPERMELANOTIC LENTIGINOUS JUNCTIONAL NEVUS, EXCISED IN THE AVAILABLE PLANES OF SECTION	273588	846	\N	\N	17-115588	\N	LN-026	Lentiginous Nevi 	IP1846085	AirTable blocks_with_IP_info.csv
2253	17-115635	62	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	There are increased numbers of single melanocytes and small nests of them positioned at the sides and bases of elongated rete ridges. There is abundant melanin the cornified layer, in the subjacent epidermis and within melanophages in the papillary dermis beneath the lesion. There is solar elastosis.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted. CF/CF	DARK BROWN MACULE, NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. NEVUS	\N	\N	Scraping	None	HYPERMELANOTIC LENTIGINOUS JUNCTIONAL NEVUS	128547	847	\N	\N	17-115635	\N	LN-027	Lentiginous Nevi 	IP1463681	AirTable blocks_with_IP_info.csv
2226	17-111279	46	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a proliferation of solitary melanocytes and small nests of them arrayed along the sides and bases of elongated and pigmented rete ridges. There are many melanophages within the underlying superficial dermis.	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely submitted. CF/CF	R/O DN	\N	\N	Scraping	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173568	849	\N	\N	17-111279	\N	LN-030	Lentiginous Nevi 	IP1841740	AirTable blocks_with_IP_info.csv
2331	18-61924A	25	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show nested and solitary melanocytes arrayed along the sides and bases of elongated and pigmented rete, and the stratum corneum above them is laced with melanin. Scattered lymphocytes and melanophages are present in the perijunctional dermis.	Skin segment measuring 0.5 x 0.2 x 0.1 cm. Submitted intact in A. BY/BY	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS.	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, INFLAMED	173798	850	\N	\N	18-61924	A	LN-031	Lentiginous Nevi 	IP1791157	AirTable blocks_with_IP_info.csv
2241	17-112653	71	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion. The specimen is partially tangentially sectioned. There is solar elastosis in the dermis.	Cylindrical skin segment measuring 0.8 cm in diameter and 0.5 cm in thickness, with the margins inked, trisected and entirely submitted. CF/CF	UNKNOWN DURATION OF IRREGULAR DARK - BROWN MACULE; R/O DYSPLASIA APPROX EQUAL TO 6 MM DIAMETER	\N	\N	Scraping	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173765	852	\N	\N	17-112653	\N	LN-033	Lentiginous Nevi 	IP512135	AirTable blocks_with_IP_info.csv
2248	17-115568B	59	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	There is a compound proliferation of melanocytes mostly involving the junctional zone and a thickened papillary dermis.  Nests of, and increased numbers of single melanocytes are situated at the sides and bases of elongated rete ridges. The bases of some adjacent rete ridges are fused.  Toward the center of the lesion, smaller melanocytes reside in the papillary dermis. A perivascular, patchy lymphocytic infiltrate is present in the dermis.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted in B. HD/HD	A-D) R/O DYSP NEVUS, 0.6 X 0.6	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS, CLARK'S (DYSPLASTIC) TYPE, NARROWLY EXCISED IN THE AVAILABLE PLANES OF SECTION	173539	853	\N	\N	17-115568	B	LN-034	Lentiginous Nevi 	IP185229	AirTable blocks_with_IP_info.csv
2244	17-114505	54	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	There is a proliferation of melanocytes, mostly at the dermo-epidermal junction. Most are arranged singly at the sides and bases of elongated rete ridges, but some small nests are also present. There is hyperpigmentation of the basal layer.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted. RS/RS	IRREGULAR BROWN PAPULE; ATYPICAL NEVUS VS. BENIGN NEVUS	\N	\N	Scraping	As the lesion is in sun-damaged skin and its circumscription was difficult to evaluate in the hematoxylin and eosin stained sections, I obtained a SOX-10 immunostain. It shows no suprabasilar scatter, and in the stain, the lesion appears well circumscribed. Given these results, I do not believe that re-excision is necessary.	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	575533	854	\N	\N	17-114505	\N	LN-035	Lentiginous Nevi 	IP1812345	AirTable blocks_with_IP_info.csv
2318	18-35802B	55	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with single melanocytes and nests arrayed along the sides and bases of pigmented rete, and many nests, cords, and small syncytia are below this. Some melanocytes have pale pigmented cytoplasm. There are scattered lymphocytes and melanophages.	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely submitted in B. RS/RS	A) COLOR VARIEGATION and BRODER IRREGULARITY; NEOPLASM OF UNCERTAIN BEHAVIOR VS. CHANGING SK VS. AMP, SIZE 1.3 MM, B) TWO-TINED PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS, SIZE 0.5 MM	\N	\N	Scraping	This melanocytic nevus is deeply pigmented but otherwise unremarkable. There is no evidence of melanoma or a dysplastic nevus.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	567566	862	\N	\N	18-35802	B	LN-044	Lentiginous Nevi 	IP1899554	AirTable blocks_with_IP_info.csv
2342	18-81165B	51	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show skin with clusters of cytologically bland melanocytes, both at the dermal-epidermal junction and in the reticular dermis, where melanocytes lie between reticular dermal collagen bundles. A few dermal melanocytes have balloon cell change to their cytoplasms and artifactual clefts separate a few nuclei and nests. There is tattoo pigment within the adjacent dermis and macrophages in these areas.	Skin segment measuring 0.8 x 0.8 x 0.1 cm, trisected and entirely submitted in B. HD/HD	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. SQUAMOUS CELL CARCINOMA VS. SCCIS. PATCH. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. NEVUS. PAPULE. 0.5 X 0.5 CM	\N	\N	Scraping	Tattoo pigment is present in the dermis in specimen (B). I presume that this biopsy was taken from within a decorative tattoo.	COMPOUND MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES	273588	864	\N	\N	18-81165	B	LN-047	Lentiginous Nevi 	IP1945117	AirTable blocks_with_IP_info.csv
2245	17-114552	46	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	None	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely submitted. RS/RS	PIGMENTED PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS	\N	\N	Scraping	This small and heavily pigmented melanocytic nevus is of the 'hypermelanotic' type. There is no evidence of melanoma or a dysplastic nevus.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	173504	866	\N	\N	17-114552	\N	LN-049	Lentiginous Nevi 	IP630078	AirTable blocks_with_IP_info.csv
2227	17-111324	78	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted. HD/HD	6 MM VARIEGATED MACULE; R/O ATYPIA	\N	\N	Scraping	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	100589	868	\N	\N	17-111324	\N	LN-051	Lentiginous Nevi 	IP403180	AirTable blocks_with_IP_info.csv
2329	18-57977B	57	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes, the junctional component of which is composed of single cells and small nests arrayed along the sides and bases of pigmented rete. There are nests and cords of similar melanocytes in the superficial dermis, where scattered melanophages are also in residence. The superjacent stratum corneum is orthokeratotic with admixed melanin.	Skin segment measuring 0.5 x 0.5 x 0.1 cm, bisected and entirely submitted in B. RS/RS	A) 3 X 3 MM DARK BROWN MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR, B) 4 X 4 MM DARK BROWN MACULE; R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	Scraping	This second melanocytic nevus is of the 'hypermelanotic' type. There is no evidence of malignancy or atypicality.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	291511	873	\N	\N	18-57977	B	LN-058	Lentiginous Nevi 	IP1921853	AirTable blocks_with_IP_info.csv
3005	98-18400a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1985	\N	\N	None	\N	SYNAT483	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
11036	13-21725	48	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	238.2	G. Long, Triple Negative "Wild Type" MM Cases (Australia)	\N	Sections show an area of inflammation and granulation tissue, with no evidence of a lymphoma.	Ellipse measuring 2.2 x 0.9 x 0.2 cm, including a central 0.5 x 0.5 cm pink tan area.  With the margins inked, the specimen is serially sectioned perpendicular to the long axis, and entirely submitted with ten sections. HD/HD	\N	\N	\N	\N	\N	HEALING BIOPSY SITE, WITH NO EVIDENCE OF RESIDUAL LYMPHOMA	173620	1652	\N	\N	13-21725	A	SYNX249	\N	IP1175186	Consolidated_data_final.csv
2729	21-62140A	72	\N	\N	\N	\N	\N	\N	30	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18343	216.5	\N	\N	Sections show a compound proliferation of melanocytes with a flattish profile, the junctional component of which is composed of single and nested melanocytes arrayed along the sides and bases of elongated rete, above a papillary dermis expanded by fibrosis.  There is a central dermal component of small melanocytes near the epidermal-dermal junction.	Two skin segments measuring 1.1 x 0.8 x 0.1 cm in aggregate, each sectioned and all entirely submitted with five sections in A. KB/KB	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL PIGMENTED LESION. IRREGULAR BROWN MACULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL PIGMENTED LESION. IRREGULAR BROWN MACULE.	\N	\N	FFPE	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF THE SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173531	889	\N	\N	21-62140	A	LN-076	Lentiginous Nevi 	IP225884	AirTable blocks_with_IP_info.csv
1202	06-04915 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	921	\N	\N	None	\N	MD-15	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1197	06-01845E T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	920	\N	\N	None	\N	MD-14	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1196	06-01845 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	920	\N	\N	None	\N	MD-14	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1221	06-14812E T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	922	\N	\N	None	\N	MD-16	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1220	06-14812D T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	922	\N	\N	None	\N	MD-16	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2333	18-65460	11	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion. There are nests of small and cytologically bland melanocytes in the dermis.  There are a few small melanocytes above the basal layer of the epidermis.	Skin segment measuring 1.0 x 0.9 x 0.1 cm, quadrisected and entirely submitted. KC/KC	1.0 CM IRREGULAR PIGMENTED PAPULE	\N	\N	Scraping	A SOX-10 immunoperoxidase stain highlights that most of the intraepidermal melanocytes are within the basal layer of the epidermis. This staining result, in concert with the findings on the routinely-stained section, supports that the features in this biopsy represent a lentiginous compound melanocytic nevus. The SOX-10 stain does show a few melanocytes above the basal layer of the epidermis, but since these melanocytes are small and cytologically bland and since this proliferation was taken from the anterior shin, these suprabasilar melanocytes most likely due to trauma/irritation. I have also shared this case with my colleague, Dr. Thaddeus Mully, who agrees with this assessment.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	173741	874	\N	\N	18-65460	\N	LN-059	Lentiginous Nevi 	IP1929354	AirTable blocks_with_IP_info.csv
2334	18-65957A	51	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of small melanocytes with round to oval nuclei, the junctional component of which consists of nested and solitary melanocytes arrayed along the sides and bases of elongated rete.  There are similar melanocytes within the underlying papillary and reticular dermis, with melanocytes splayed amongst collagen bundles, largely in the upper half of the reticular dermis.	Skin segment measuring 0.9 x 0.9 x 0.1 cm, quadrisected and entirely submitted in A. RS/RS	A) CYT18-1117, 7 MM; R/O ATYPICAL VS. SK, B) CYT18-1118, 1 CM X 5 MM; R/O ATYPICAL	\N	\N	Scraping	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS OF SUPERFICIAL CONGENITAL TYPE	173525	875	\N	\N	18-65957	A	LN-060	Lentiginous Nevi 	IP1929851	AirTable blocks_with_IP_info.csv
2306	18-19195A	74	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	There are increased numbers of single melanocytes at the sides and bases of elongated rete ridges.  There is basilar hyperpigmentation in the affected area.  Clusters of small, round melanocytes reside in the subjacent dermis. There are superficial dermal melanophages.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted in A. RS/PL	A) CYT18-236, BROWN MACULE WITH IRRITATED BASE, LESION SIZE 5 MM; R/O ATYPICAL, B) CYT18-237, LESION SIZE 3 MM, FIRM BLACK PAPULE; R/O INTERACTED HEMANGIOMA VS. ATYPICAL	\N	\N	Scraping	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	528522	876	\N	\N	18-19195	A	LN-061	Lentiginous Nevi 	IP1487591	AirTable blocks_with_IP_info.csv
2321	18-44464	41	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show skin with a compound proliferation of bland melanocytes arranged in predominantly single cells and small nests within the sides and bases of elongated rete ridges. Within the dermis, similar melanocytes are arranged in maturing nests, cords, and single cells amidst melanophages.	Skin segment measuring 1.0 x 1.0 x 0.1 cm, quadrisected and entirely submitted. HD/PL	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. MELANOMA VS. NEVUS. MACULE.	\N	\N	Scraping	In the junctional component, there are nests that extend to the specimen periphery that are separated from the remainder of the neoplasm that appear to represent a second melanocytic nevus. Given this focus of irregular junctional distribution, clinical follow-up is recommended.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, SEE NOTES	139512	878	\N	\N	18-44464	\N	LN-064	Lentiginous Nevi 	IP1908258	AirTable blocks_with_IP_info.csv
2647	20-60575	68	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18347	216.5	\N	\N	Sections show a proliferation of melanocytes arrayed along the epidermal-dermal junction, with single cells and nests arrayed along the sides and bases of elongated, hyperpigmented rete.  The underlying papillary dermis is expanded by fibrosis and contains a permeative lymphocytic infiltrate.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted. BY/KB	A) DYSPLASTIC NEVUS VS. MELANOMA IN SITU. DARK BROWN IRREGULAR 5MM X 5MM MACULE WITH IRREGULAR PIGMENT NETWORK ON DERMOSCOPY.	\N	\N	FFPE	None	JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, INFLAMED, EXCISED IN PLANES OF SECTION EXAMINED	173504	883	\N	\N	20-60575	\N	LN-070	Lentiginous Nevi 	IP1156616	AirTable blocks_with_IP_info.csv
2728	21-61821	63	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18338	216.6	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion. There are elongated rete ridges with hyperpigmentation of the basal layer. The dermis is altered by solar elastosis.	Skin segment measuring 1.0 x 0.7 x 0.1 cm, trisected and entirely submitted. KB/CF	TWO COLORS IRREGULAR COLOR AND BORDER; NEOPLASM OF UNCERTAIN BEHAVIOR VS. AMH	\N	\N	FFPE	There is a background of solar lentigo.	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	202612	884	\N	\N	21-61821	\N	LN-071	Lentiginous Nevi 	IP1860574	AirTable blocks_with_IP_info.csv
2732	21-63579A	66	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18339	216.5	\N	\N	Sections show a compound proliferation of melanocytes, and the dermal melanocytes diminish in size with descent.  The overlying epidermis is acanthotic, with elongated rete that intertwine.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A) 4 MM X 2 MM IRREGULARLY PIGMENTED PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. R/O ATYPICAL NEVUS, PLEASE CHECK MARGINS, B) 7 MM X 5 MM IRREGULAR BROWN PATCH WITH HOMOGENEOUS, GLOBULAR AND FINGERPRINT NETWORKS; NEOPLASM OF UNCERTAIN BEHAVIOR VS. SOLAR LENTIGO, R/O MELANOMA IN SITU, PLEASE CHECK MARGINS, C) PINK SCALY VERRUCOUS PAPULE WITH FOCAL PINPOINT THROMBOSED CAPILLARIES; NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED SEBORRHEIC KERATOSIS VS. INFLAMED VERRUCA VULGARIS VS. SQUAMOUS CELL CARCINOMA	\N	\N	FFPE	\N	COMPOUND MELANOCYTIC NEVUS	101532	885	\N	\N	21-63579	A	LN-072	Lentiginous Nevi 	IP2326379	AirTable blocks_with_IP_info.csv
2726	21-59993A	88	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18340	172.5	\N	\N	Sections show an asymmetrical, poorly circumscribed melanocytic proliferation in which single cells predominate, in irregular array within the epidermis.  There is solar elastosis.	Skin segment measuring 1.3 x 0.9 x 0.1 cm, trisected and entirely submitted in A. BB/BB	A) CYT21-469, 1.0 X 1.2 CM; BROWN UNEVEN PIGMENT, B) CYT21-470, 0.2 X 0.2 CM DARK MACULE; A-B) R/O ATYPICAL	\N	\N	FFPE	This melanoma is AJCC stage Tis (representing a non-invasive tumor with no associated ulceration).	EVOLVING MELANOMA IN SITU, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	139522	886	\N	\N	21-59993	A	LN-073	Lentiginous Nevi 	IP1020374	AirTable blocks_with_IP_info.csv
2731	21-63575B	89	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18344	172.5	\N	\N	Sections show atypical melanocytes arranged singly and in nests within the epidermis.  In some areas, there are diminished numbers of melanocytes in concert with a thickened and fibrotic papillary dermis that contains lymphocytes and melanophages.	Skin segment measuring 0.7 x 0.7 x 0.1 cm, trisected and entirely submitted in B. CF/CF	A) KERATOTIC PINK PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. R/O KERATOACANTHOMA SQUAMOUS CELL CARCINOMA, B) IRREGULAR BROWN MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. R/O ATN VS. SOLAR LENTIGO, PLEASE CHECK MARGINS, C) IRREGULAR BROWN PATCH WITH THUMBPRINT HOMOGENEOUS PIGMENT PATTERN; NEOPLASM OF UNCERTAIN BEHAVIOR VS. R/O SOLAR LENTIGO VS. MELANOMA IN SITU, PLEASE CHECK MARGINS, D) ILL-DEFINED BROWN PATCH WITH THUMBPRINT HOMOGENOUS PIGMENT PATTERN; NEOPLASM OF UNCERTAIN BEHAVIOR VS. SO;AR LENTIGO'S, MELANOMA IN SITU, PLEASE CHECK MARGINS, E) KERATOTIC PAPULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. R/O SQUAMOUS CELL CARCINOMA, PLEASE CHECK MARGINS	\N	\N	FFPE	This melanoma is AJCC stage Tis (representing a non-invasive tumor with no associated ulceration).	MELANOMA, AT LEAST IN SITU, WITH SUPERIMPOSED CHANGES OF REGRESSION	173525	890	\N	\N	21-63575	B	LN-077	Lentiginous Nevi 	IP2326375	AirTable blocks_with_IP_info.csv
2727	21-61319	74	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18345	216.5	\N	\N	There is a narrowly based lesion in which there are thin, elongated rete ridges with increased numbers of melanocytes arranged as single cells along their sides and bases. The basal layer is hyperpigmented.  There are infiltrates of lymphocytes and melanophages in the subjacent papillary dermis. The epidermis is focally thickened, with interconnecting rete ridges and horn pseudocysts.	Skin segment measuring 1.1 x 0.7 x 0.1 cm, trisected and entirely submitted. KB/KB	DARK BROWN MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. LMN VS. LENTIGO / EVOLVING SEBORRHEIC KERATOSIS VS. MALIGNANT MELANOMA	\N	\N	FFPE	There is an incidental seborrheic keratosis.	LENTIGO SIMPLEX	173529	891	\N	\N	21-61319	\N	LN-078	Lentiginous Nevi 	IP278814	AirTable blocks_with_IP_info.csv
2741	21-96630	74	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18346	216.7	\N	\N	There is a narrowly based lesion in which there are thin, elongated rete ridges with increased numbers of melanocytes arranged as single cells along their sides and bases. The basal layer is hyperpigmented.  There are infiltrates of lymphocytes and melanophages in the subjacent papillary dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. BY/BY	NEVUS, R/O ATYPIA	\N	\N	FFPE	None	LENTIGO SIMPLEX	173765	892	\N	\N	21-96630	\N	LN-079	Lentiginous Nevi 	IP968238	AirTable blocks_with_IP_info.csv
2757	21-110504	61	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18349	216.7	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion.	Skin segment measuring 0.5 x 0.5 x 0.1 cm, bisected and entirely submitted. BY/BY	ATYPICAL MACULE; NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	FFPE	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173711	893	\N	\N	21-110504	\N	LN-080	Lentiginous Nevi 	IP2373605	AirTable blocks_with_IP_info.csv
2756	21-110027B	79	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18350	216.5	\N	\N	Sections show a compound proliferation of melanocytes, and the junctional component show areas in which melanocytes are arrayed singly along the sides and bases of elongated rete ridges.  The small melanocytes that constitute the dermal component are surrounded by a permeative infiltrate of lymphocytes.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in B. KB/KB	A-B) R/O ATYPICAL MELANOCYTIC PROCESS	\N	\N	FFPE	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, INFLAMED	528599	894	\N	\N	21-110027	B	LN-081	Lentiginous Nevi 	IP981802	AirTable blocks_with_IP_info.csv
2755	21-110012A	75	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18351	216.5	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A) TWO COLOR, IRREGULAR BORDERS; NEOPLASM OF UNCERTAIN BEHAVIOR VS. AMH, B) 4 MM, IRREGULAR BORDER AND COLOR; NEOPLASM OF UNCERTAIN BEHAVIOR VS. AMH	\N	\N	FFPE	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	101523	895	\N	\N	21-110012	A	LN-082	Lentiginous Nevi 	IP2281905	AirTable blocks_with_IP_info.csv
2754	21-110009A	68	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18352	216.5	\N	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 0.7 x 0.5 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A) 6 MM, 2 COLORS; NEOPLASM OF UNCERTAIN BEHAVIOR VS. AMH, B) 7 MM, WAXY, 2 COLORS; NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA	\N	\N	FFPE	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE	129588	896	\N	\N	21-110009	A	LN-083	Lentiginous Nevi 	IP2373107	AirTable blocks_with_IP_info.csv
2758	21-112103B	75	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18353	216.5	\N	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 0.9 x 0.6 x 0.1 cm, bisected and entirely submitted in B. BY/BY	A) 0.7; R/O BCC, B) 0.7; R/O SK VS. DN, C) 3 MM; R/O BCC	\N	\N	FFPE	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	433599	897	\N	\N	21-112103	B	LN-084	Lentiginous Nevi 	IP1386399	AirTable blocks_with_IP_info.csv
2761	21-112298	52	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18354	216.5	\N	\N	Sections show a compound array of melanocytes, with single cells and nests arrayed along the epidermal-dermal junction, distributed along the sides and bases of elongated rete. There are similar melanocytes in the subjacent superficial dermis.	Skin segment measuring 0.4 x 0.4 x 0.1 cm, bisected and entirely submitted. CF/CF	SIM; R/O ATYPIA	\N	\N	FFPE	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, EXCISED IN PLANES OF SECTION EXAMINED	101532	898	\N	\N	21-112298	\N	LN-085	Lentiginous Nevi 	IP1358879	AirTable blocks_with_IP_info.csv
2996	98-03336-8 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	966	\N	\N	None	\N	MD-60	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2997	98-05054 N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	967	\N	\N	None	\N	MD-61	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3019	99-16633E N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	968	\N	\N	None	\N	MD-62	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3028	99-27534 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	969	\N	\N	None	\N	MD-63	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1008	00-09653C M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	970	\N	\N	None	\N	MD-64	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1009	00-11793E M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	971	\N	\N	None	\N	MD-65	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1012	00-15034-1B M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	972	\N	\N	None	\N	MD-66	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1049	02-11468D M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	973	\N	\N	None	\N	MD-67	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1061	02-22843 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	974	\N	\N	None	\N	MD-68	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1060	02-22662B M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	975	\N	\N	None	\N	MD-69	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1051	02-16325B M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	976	\N	\N	None	\N	MD-70	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1073	03-04925E M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	977	\N	\N	None	\N	MD-71	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1077	03-16198-1C M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	978	\N	\N	None	\N	MD-72	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1881	15-52921B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1360	\N	\N	15-52921	B	SMP48	Spitz Melanoma	\N	AirTable blocks_with_IP_info.csv
1104	04-00065-6 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	979	\N	\N	None	\N	MD-73	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1106	04-01241G M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	980	\N	\N	None	\N	MD-74	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1135	04-21305-4 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	981	\N	\N	None	\N	MD-75	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1169	05-21257 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	982	\N	\N	None	\N	MD-77	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1343	09-15598 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	983	\N	\N	None	\N	MD-79	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1390	10-20397-3 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	985	\N	\N	None	\N	MD-84	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1399	10-30890-5 N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	986	\N	\N	None	\N	MD-85	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1398	10-30525-4 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	987	\N	\N	None	\N	MD-86	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1750	14-04359A2 N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	988	\N	\N	None	\N	MD-92	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1761	14-17085A2 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	989	\N	\N	None	\N	MD-93	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2975	96-07395C M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	991	\N	\N	None	\N	MD-95	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2977	96-13701 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	992	\N	\N	None	\N	MD-96	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2985	96-23601-4 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	993	\N	\N	None	\N	MD-97	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
3009	98-23221F M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	994	\N	\N	None	\N	MD-98	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1021	01-00467B N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	995	\N	\N	None	\N	MD-99	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2293	18-15165	44	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18197	216.5	\N	\N	There are increased numbers of single melanocytes at the sides and bases of elongated rete ridges. There is basilar hyperpigmentation in the affected area. Clusters of small, round melanocytes reside in the subjacent dermis.	Skin segment measuring 0.8 x 0.6 x 0.1 cm, bisected and entirely submitted. KC/PL	ASYMMETRICALLY PIGMENTED MACULE; POSS ATYPICAL NEVUS	\N	\N	\N	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	139522	838	\N	\N	18-15165	\N	LN-18	Lentiginous Nevi 	IP1878752	AirTable blocks_with_IP_info.csv
2292	18-15028	55	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18202	216.4	\N	\N	There are increased numbers of single melanocytes at the sides and bases of elongated rete ridges. There is basilar hyperpigmentation in the affected area. Clusters of small, round melanocytes reside in the subjacent dermis.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted. CF/PL	R/O DYSPLASTIC NEVUS VS. LENTIGO	\N	\N	\N	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	173477	839	\N	\N	18-15028	\N	LN-19	Lentiginous Nevi 	IP260019	AirTable blocks_with_IP_info.csv
1995	16-107007	67	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=22138	172.6	\N	\N	Sections show an irregularly distributed proliferation of enlarged atypical pigmented melanocytes. Nests of melanocytes are distributed at irregular intervals along the junctional zone, and are focally confluent.  There are foci in which single melanocytes predominate as well. There are some melanocytes scattered above the basal layer in such areas. The dermis contains aggregates of similar cells with defective maturation that are surrounded by a brisk lymphocytic infiltrate. To the side of these changes, there are small melanocytes with round to oval nuclei in the superficial dermis. The dermis displays marked solar elastosis.	Skin segment measuring 1.0 x 0.8 x 0.1 cm, trisected and entirely submitted. HD/HD	RED, SCALY PAPULE; ? MM VS. ISK	\N	\N	Scraping	This melanoma is present adjacent to a common nevus. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: shave biopsy Microscopic tumor type: melanoma, NOS Breslow thickness: 0.75 mm Ulceration: no Margins, peripheral and deep: melanoma is present near the peripheral and deep edges of the biopsy Mitotic index: 1 per square mm Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Tumor-infiltrating lymphocytes: brisk Pathologic Staging (pTNM): pT1b pNX	MELANOMA, 0.75 MM IN THICKNESS	422655	1102	\N	\N	16-107007	\N	ME-07	Melanoma Epigenetics	IP1707061	AirTable blocks_with_IP_info.csv
1758	14-14773	\N	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	\N	Typical melanotic macule	\N	\N	\N	\N	\N	acral mel macule	FFPE	\N	\N	\N	1293	\N	\N	14-14773	\N	OM-35	Oral Mucosa Lesions	\N	AirTable blocks_with_IP_info.csv
1029	01-15780R T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1020	\N	\N	None	\N	MD-139	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1168	05-20065-4 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1021	\N	\N	None	\N	MD-140	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1161	05-13894C T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1022	\N	\N	None	\N	MD-141	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1166	05-17080 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1023	\N	\N	None	\N	MD-142	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1152	05-04841C T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1024	\N	\N	None	\N	MD-144	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1116	04-08148D T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1025	\N	\N	None	\N	MD-146	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1136	04-22191D T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1026	\N	\N	None	\N	MD-147	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1465	11-23710	9	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.3	\N	KF-09, AND DP-17 are the same patient	Sections show enlarged spindled and fusiform melanocytes arrayed in nests and fascicles in compound fashion. Large nests and fascicles are apparent at the junction in concert with acanthosis (and also central erosion), and many coalescing fascicles reside in the dermis and upper subcutis below that in concert with a lymphohistiocytic infiltrate. There is only partial maturation with descent. Dermal melanocytes in mitosis can be found, especially in the upper half of the proliferation.	Five outside slides, S11-11651 and one corresponding block.	PYOGENIC GRANULOMA	\N	Iwei, CGH Array run| ROS1 Translocation case	\N	As you note in your correspondence regarding this case, this proliferation does not represent a conventional Spitz nevus. The lesion is ulcerated, has a high overall cellularity and has a nodular component in the subcutis. Comparative genomic hybridization shows loss of chromosome 6q, an aberration that is common in melanoma. There is also a gain of a small area in the distal part of 5q. Given these findings, I believe that this is best assessed as a spitzoid melanoma of childhood. I use this term for an emerging class of lesions that usually lack b-raf mutations (which are present in most melanomas) and have a propensity to involve local lymph nodes. Systemic spread either occurs infrequently or it does so in a delayed fashion compared to adult melanoma.  While the thickness is approximately 4.5 mm., it would be a mistake to use prognostic data from adult melanoma cases in this setting. The prognosis is far better. As the lesion extends to a dermal margins, a narrow re-excision is reasonable. Lesions of this type are usually well circumscribed, and I have not seen regrowth when narrow but clear margins have been obtained. The role of sentinel lymph nodes is debatable, as sentinel lymph node involvement is common, but distant metastasis is rare.	SPITZOID MELANOMA, CHILDHOOD TYPE	173307	654	\N	\N	11-23710	\N	DP-17	CGH Validation,Fusion RNA	IP1013148	AirTable blocks_with_IP_info.csv
1527	11-84681	9	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.7	\N	\N	There is a broad-based, dome-surfaced proliferation of large oval melanocytes coupled with irregular epidermal hyperplasia, compact hyperkeratosis and a proliferation of melanocytes that is broadly transected at the base of the specimen in the superficial reticular dermis. The lesional cells are large, fusiform or polygonal, and have large, pleomorphic heterochromatic nuclei, some with prominent intranuclear inclusions.	One outside slide, S11-21609:A/1.	6 MM FLAT PINK AND BROWN VERRUCOUS PAPULE PRESENT FOR APPROXIMATELY ONE YEAR, BROWN/PINK/HEMORRHAGIC PAPULE; LIKELY WART, R/O NEVUS WITH ATYPIA; DESPITE THE PATIENT'S YOUNG AGE, THE ASYMMETRIC DISTRIBUTION OF MELANOCYTES, PROMINENT SPINOUS LAYER INVOLVEMENT, AND MELANOCYTE NUCLEAR PLEOMORPHISM ARE VERY CONCERNING FOR A MELANOMA	\N	ROS1, Iwei Translocations	\N	Comparative genomic hybridization shows losses involving chromosomes 6q, 10q and 12q. Loss of 6q and involving chromosome 10 are among the most common aberrations in melanoma. The final thickness measurement should be made after complete excision. The portion of the lesion seen in these sections is just over 1 mm in thickness, but not ulcerated. The final thickness measurement should be made after complete excision. In determining re-excision margins, please keep in mind that most spitzoid melanomas in children are well circumscribed and recurrence at the biopsy site due to residual neoplastic melanocytes is rare, regardless of thickness, even with very narrow (e.g. 5 mm) margins. Also, involvement of sentinel lymph nodes is more common than in adult melanoma, but distant metastasis is much less frequent. Therefore, the role of sentinel lymph node biopsy is questionable.	MELANOMA WITH SPITZOID FEATURES	987777	658	\N	\N	11-84681	\N	DP-21	CGH Validation	IP1074129	AirTable blocks_with_IP_info.csv
1534	11-88431	53	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show enlarged melanocytes arrayed irregularly within the epidermis, which is acanthotic, and non-maturing melanocytes in nests and fascicles are positioned in fibrotic dermis below this. The constituent melanocytes are generally spindled. Some are strikingly nucleomegalic. Dermal melanocytes in mitosis can be found. There is parakeratosis within orthohyperkeratosis above this.	Four outside slides, ES11-15479 (DC11-6719) and one corresponding block.	ONE YEAR HISTORY OF WARTY EXPANDING LESION, AREA SURROUNDING DARKLY PIGMENTED BUT SUPERFICIAL, NOT IN PROXIMITY TO ANY NAIL OR NAIL BED REGION, NO PERSONAL HX OF MELANOMA BUT PATIENT'S MOTHER DIED SOME YEARS AGO FROM METASTATIC MELANOMA	\N	\N	\N	Based upon results derived from conventional microscopy, I favored melanoma over an unconventional Spitz nevus as most likely. To further substantiate this diagnosis, analysis via array-based comparative genomic hybridization (aCGH) was completed to screen for melanoma-associated genomic copy number anomalies. After extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosomes 12q, 18q, 20q, and 22q as well as loss in chromosomes 3q, 8p, 9p, 12q, 15p, and 16q. The identification of multiple genomic aberrations confirms the presence of genomic instability, as is stereotypical of melanoma. Please note that the aCGH profile that we have defined is incompatible with interpretation as any type of melanocytic nevus. In short, a benign interpretation has been excluded from the differential diagnosis by means of our molecular results. In summary, the combination of results derived from conventional microscopy coupled with has demonstrated that this atypical melanocytic proliferation represents spitzoid melanoma. This melanoma is non-ulcerated and shows Clark's level IV invasion. The final microstage parameters can be reassessed once this melanoma has been fully extirpated.	MELANOMA OF AT LEAST 2.3 MM IN THICKNESS, INVOLVING THE DEEP EDGE OF THE BIOPSY	173622	660	\N	\N	11-88431	\N	DP-23	CGH Validation	IP1077879	AirTable blocks_with_IP_info.csv
1493	11-47908	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	111	\N	\N	11-47908	\N	BN-007	Nevus Library	\N	AirTable blocks_with_IP_info.csv
1503	11-59209	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	cellular blue nevus	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	112	\N	\N	11-59209	\N	BN-008	Nevus Library	\N	AirTable blocks_with_IP_info.csv
3453	K18-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-077	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	47	\N	\N	None	\N	AM2-077	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3454	K19-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-078	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	48	\N	\N	None	\N	AM2-078	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3455	K20-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-079	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	49	\N	\N	None	\N	AM2-079	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3456	K21-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-080	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	50	\N	\N	None	\N	AM2-080	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3461	K24-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-083	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	53	\N	\N	None	\N	AM2-083	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3524	MaMel 152aI	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	98	\N	\N	None	\N	AMC-01	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
2417	19-7669	79	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.5	\N	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted. CF/CF	R/O DYSPLASTIC NEVUS, 0.6 X 0.6 CM	\N	\N	\N	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	528599	623	\N	\N	19-7669	\N	DN-148	Dysplastic Nevi	IP11027	AirTable blocks_with_IP_info.csv
1844	15-11029-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-36	https://64.54.108.121/app/WebViewer/view/image/36069	\N	\N	\N	\N	\N	\N	\N	H15-11029 #1 (upper right chest)	FFPE	\N	\N	\N	388	\N	\N	None	\N	CME-086	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1907	16-00657-2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-36	https://64.54.108.121/app/WebViewer/view/image/36070	\N	\N	\N	\N	\N	\N	\N	H16-00657 #2 (left back)	FFPE	\N	\N	\N	389	\N	\N	None	\N	CME-087	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1910	16-03460-1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-36	https://64.54.108.121/app/WebViewer/view/image/36071	\N	\N	\N	\N	\N	\N	\N	H16-03460 #1 (lower right limb)	FFPE	\N	\N	\N	390	\N	\N	None	\N	CME-088	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1565	12-05858 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	935	\N	\N	None	\N	MD-29	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2341	18-76615	40	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with single cells and nests arrayed along the sides and bases of elongated, pigmented rete, and maturing nests and cords of similar cells are present in the upper dermis, which also harbors scattered lymphocytes and melanophages. Many lesional melanocytes have finely melanized cytoplasm.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted. BY/BY	6 MM IRREG BROWN PAPULE; R/O DYSPL CN VS. OTHER	\N	\N	Scraping	There is partial balloon cell change or oncocytic metaplasia associated with this deeply pigmented melanocytic nevus. There is no evidence of malignancy or atypicality.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	273588	880	\N	\N	18-76615	\N	LN-067	Lentiginous Nevi 	IP109853	AirTable blocks_with_IP_info.csv
2322	18-44465	31	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show skin with a compound proliferation of bland melanocytes arranged in predominantly single cells and small nests within the sides and bases of elongated rete ridges amidst darkly pigmented keratinocytes.Within the dermis, melanocytes are arranged in both medium-sized and small nests and single cells. In some foci, melanocytes are arranged adjacent to dermal blood vessels There are rare flecks of melanin pigment in the overlying stratum corneum.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted. HD/PL	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. NEVUS VS. MELANOMA VS. DYSPLASTIC NEVUS. MACULE.	\N	\N	FFPE	None	HYPERMELANOTIC LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	17733	881	\N	\N	18-44465	\N	LN-068	Lentiginous Nevi 	IP1908259	AirTable blocks_with_IP_info.csv
2639	20-52881	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=18348	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	882	\N	\N	20-52881	\N	LN-069	Lentiginous Nevi 	\N	AirTable blocks_with_IP_info.csv
1869	15-36675	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-25	http://64.54.108.121/eSlideTray.php?ImageIds=32776	\N	\N	4377899	\N	\N	\N	\N	Skin, thigh, lateral, left, wide excision, superficial spreading melanoma	FFPE	\N	\N	\N	314	\N	\N	15-36675	\N	CME-012	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1868	15-36291	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-25	http://64.54.108.121/eSlideTray.php?ImageIds=32777	\N	\N	5908581	\N	\N	\N	\N	Skin, posterior thigh, right, status post-biopsy, wide excision, melanoma in situ, residual	FFPE	\N	\N	\N	315	\N	\N	15-36291	\N	CME-013	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2125	17-37055	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-26	http://64.54.108.121/eSlideTray.php?ImageIds=32782	\N	\N	4457955	\N	\N	\N	\N	Skin, shin, right, wide excision, melanoma, arising from nevus	FFPE	\N	\N	\N	318	\N	\N	17-37055	\N	CME-016	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1455	11-19877	49	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a predominantly dermal proliferation of melanocytes partially encompassed by epithelial collarettes, with a protuberant configuration. The lesional melanocytes are arranged in discrete nests, cords and strands. Most are plump, oval to small round melanocytes that mature with descent, with a minor population of melanocytes with large, oval vesicular nuclei and more prominent nucleoli.	One outside slide, K05-13644.	SECOND OPINION, "RECURRENT NEVUS	\N	\N	\N	None	MELANOMA, 1.1 MM IN THICKNESS	173688	2270	\N	\N	11-19877	\N	SYNAT449	2010-2017	IP1009315	AirTable blocks_with_IP_info.csv
1574	12-8171	82	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.4	\N	\N	Sections show a predominantly dermal proliferation of melanocytes. The overlying epidermis is slightly thickened, with a thick granular layer and compact hyperkeratosis. Within an area of fibrosis in the upper part of the lesion are small discrete aggregations of small, round melanocytes. These abut a larger population of large, oval melanocytes with abundant, pale cytoplasm and dusty appearing melanin, and monomorphous oval vesicular nuclei containing small nucleoli. There are many admixed melanophages. The enclosed immunoperoxidase stains show the melanocytes are strongly and uniformly Melan-A positive, and have (for a melanocytic neoplasm) a relatively high Ki-67 labelling rate (roughly 15-20%).	Three outside slides, W12-2042 / B, and one corresponding block.	1 CM BLUE-BLACK PAPULE; R/O MM	\N	\N	\N	While a combined deep penetrating nevus (with a minor component of conventional intradermal melanocytic nevus) is a plausible diagnosis based only on the morphology of the melanocytes, the lesion is in severely sun damaged skin and has a higher proliferation rate than is typical for such lesions (although this does not translate into a high mitotic rate). Comparative genomic hybridization shows numerous chromosomal aberrations including a rearrangement of 5q, a loss of 6q, a gain of 7q, a gain of 15q, a loss of 18q and a gain of 19. These findings are not compatible with a deep penetrating nevus, and include aberrations typical of melanoma.	MELANOMA, 3.3 MM. IN THICKNESS	423456	2044	\N	\N	12-8171	\N	SYNAT475	2010-2017	IP1093987	AirTable blocks_with_IP_info.csv
1680	13-212	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1766	\N	\N	13-212	\N	SYNAT477	2010-2017	\N	AirTable blocks_with_IP_info.csv
1719	13-35959	43	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	None	Block DL13-32481 (PL13-8590), received 5-28-13.	MELANOMA SUBMITTED FOR BRAF MUTATION ANALYSIS	\N	\N	\N	The histopathological diagnosis was established by our previous pathology report DL13-32481. Sanger sequencing of exon 15 of BRAF revealed no mutation.	MELANOMA, NO BRAF MUTATION DETECTED	333504	1896	\N	\N	13-35959	\N	SYNAT494	Wild Type Melanoma	IP1217226	AirTable blocks_with_IP_info.csv
1670	12-98575A1	62	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	198.2	\N	\N	Sections show pulmonary parenchyma with fascicles of spindled cells with large, hyperchromatic nuclei embedded in fibrotic stroma, with S100 and Sox-10 positivity in the immunoperoxidase stained sections.	Nine outside (unstained) slides, S12-27867:B1.	MELANOMA SUBMITTED FOR MOLECULAR TESTING	\N	\N	\N	No mutations were found in the oncogenes that we sequenced. The specific results are below: BRAF exon 15: wild-type. NRAS exons 1 and 2: wild-type. KIT exons 9, 11, 13, 17 and 18:  wild-type.	METASTATIC MELANOMA	666955	2235	\N	\N	12-98575	A1	SYNAT498	Wild Type Melanoma	IP824297	AirTable blocks_with_IP_info.csv
1789	14-59304A	11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	216.4	\N	\N	Sections show a compound proliferation of plump, oval to small round melanocytes, arrayed as a few small nests along the epidermal-dermal junction, and as nests, cords and strands that extend into the superficial reticular dermis and are distributed around adnexa.	Skin segment measuring 0.8 x 0.5 x 0.1 cm, bisected and entirely submitted in A. CF/CF	A-B) R/O DN	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS WITH CONGENITAL FEATURES	173416	1809	\N	\N	14-59304	A	SYNAT499	2010-2017	IP1409245	AirTable blocks_with_IP_info.csv
2239	17-112588B	75	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	There is a proliferation of melanocytes, mostly at the dermo-epidermal junction. Most are arranged singly at the sides and bases of elongated rete ridges, but some small nests are also present. There is hyperpigmentation of the basal layer.	Skin segment measuring 0.9 x 0.7 x 0.1 cm, trisected and entirely submitted in B. HD/HD	A) CYT17-1735, R/O BCC, 5 MM, B) CYT17-1736, R/O ATYPIA, 6 MM	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, EXCISED IN PLANES OF SECTION EXAMINED	122533	859	\N	\N	17-112588	B	LN-041	Lentiginous Nevi 	IP1843066	AirTable blocks_with_IP_info.csv
3327	DM93	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	2037	\N	\N	None	\N	SYNAT504	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3310	DM58	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1745	\N	\N	None	\N	SYNAT505	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3588	SM7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1682	\N	\N	None	\N	SYNAT506	Spitzoid Melanoma	\N	AirTable blocks_with_IP_info.csv
3508	London-L3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2016	\N	\N	None	\N	SYNAT507	2010-2017	\N	AirTable blocks_with_IP_info.csv
3480	KIT227	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2318	\N	\N	None	\N	SYNAT508	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3285	DM11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2160	\N	\N	None	\N	SYNAT509	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3541	MB1609	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma	\N	\N	\N	\N	2018	\N	\N	None	\N	SYNAT510	2010-2017	\N	AirTable blocks_with_IP_info.csv
3298	DM29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1925	\N	\N	None	\N	SYNAT511	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3492	KR_8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2210	\N	\N	None	\N	SYNAT512	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3472	KIT191	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2043	\N	\N	None	\N	SYNAT513	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3527	MB_760	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2093	\N	\N	None	\N	SYNAT514	2010-2017	\N	AirTable blocks_with_IP_info.csv
3323	DM74	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1663	\N	\N	None	\N	SYNAT515	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3396	JBP-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1687	\N	\N	None	\N	SYNAT516	2010-2017	\N	AirTable blocks_with_IP_info.csv
3300	DM34	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2344	\N	\N	None	\N	SYNAT517	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3279	DM4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2019	\N	\N	None	\N	SYNAT518	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3601	WM8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2337	\N	\N	None	\N	SYNAT519	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3297	DM28	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2074	\N	\N	None	\N	SYNAT520	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3288	DM14	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2000	\N	\N	None	\N	SYNAT521	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3398	JBP-3-MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2091	\N	\N	None	\N	SYNAT522	2010-2017	\N	AirTable blocks_with_IP_info.csv
3187	BN_M2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2116	\N	\N	None	\N	SYNAT523	2010-2017	\N	AirTable blocks_with_IP_info.csv
3338	Dog43	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka, Dog Melanoma| melanocytoma	\N	\N	\N	\N	1869	\N	\N	None	\N	SYNAT524	2010-2017	\N	AirTable blocks_with_IP_info.csv
3330	DM96	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1836	\N	\N	None	\N	SYNAT525	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3282	DM7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	1882	\N	\N	None	\N	SYNAT526	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3537	MB1423	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1978	\N	\N	None	\N	SYNAT527	2010-2017	\N	AirTable blocks_with_IP_info.csv
3539	MB1428	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1904	\N	\N	None	\N	SYNAT528	2010-2017	\N	AirTable blocks_with_IP_info.csv
3313	DM61	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2227	\N	\N	None	\N	SYNAT529	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3277	DM1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	2307	\N	\N	None	\N	SYNAT530	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3565	Seider_Uveal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2166	\N	\N	None	\N	SYNAT531	2010-2017	\N	AirTable blocks_with_IP_info.csv
3326	DM81	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1864	\N	\N	None	\N	SYNAT532	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3483	KIT260	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2256	\N	\N	None	\N	SYNAT533	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3535	MB1242	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1746	\N	\N	None	\N	SYNAT534	2010-2017	\N	AirTable blocks_with_IP_info.csv
3611	XD-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2317	\N	\N	None	\N	SYNAT535	2010-2017	\N	AirTable blocks_with_IP_info.csv
3531	MB_1046	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1977	\N	\N	None	\N	SYNAT536	2010-2017	\N	AirTable blocks_with_IP_info.csv
3397	JBP-3-Met1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1928	\N	\N	None	\N	SYNAT537	2010-2017	\N	AirTable blocks_with_IP_info.csv
3495	KR_177	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1750	\N	\N	None	\N	SYNAT538	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3271	CP1-40	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1701	\N	\N	None	\N	SYNAT539	2010-2017	\N	AirTable blocks_with_IP_info.csv
3269	CP1-10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1997	\N	\N	None	\N	SYNAT540	2010-2017	\N	AirTable blocks_with_IP_info.csv
3466	KIT55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2048	\N	\N	None	\N	SYNAT541	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3267	CP1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1835	\N	\N	None	\N	SYNAT542	2010-2017	\N	AirTable blocks_with_IP_info.csv
3585	SM_11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1843	\N	\N	None	\N	SYNAT543	Spitzoid Melanoma	\N	AirTable blocks_with_IP_info.csv
3312	DM60	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1754	\N	\N	None	\N	SYNAT544	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3307	DM49	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2205	\N	\N	None	\N	SYNAT545	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3486	KIT275	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Known Mutations	\N	\N	\N	\N	1723	\N	\N	None	\N	SYNAT546	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3482	KIT244	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1818	\N	\N	None	\N	SYNAT547	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3268	CP1-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2084	\N	\N	None	\N	SYNAT548	2010-2017	\N	AirTable blocks_with_IP_info.csv
1195	06-00911	57	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a roughly wedge-shaped proliferation of spindled and polygonal melanocytes, some of which have abundant vacuolated cytoplasms, which extends deeply in the reticular dermis and also in the adventitial dermis around a folliculosebaceous unit. Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous. There are interspersed melanophages.	Cylindrical skin excision, 0.4 cm in diameter and 0.6 cm in thickness, margins inked blue, bisected and entirely submitted.	ODD 4 MM DARK PAPULE; MOLE VS NODULAR MM	\N	\N	\N	None	DEEP PENETRATING NEVUS	173610	2347	\N	\N	06-911	\N	SYNAT549	Deep Penetrating Nevus	IP545976	AirTable blocks_with_IP_info.csv
3501	KR_RMK0091B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1832	\N	\N	None	\N	SYNAT550	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3286	DM12	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	1705	\N	\N	None	\N	SYNAT551	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3304	DM43	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2136	\N	\N	None	\N	SYNAT552	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3305	DM45	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1888	\N	\N	None	\N	SYNAT553	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3311	DM59	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2179	\N	\N	None	\N	SYNAT554	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3602	WM51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	wt/wt Cell Line DNA	\N	\N	\N	\N	1720	\N	\N	None	\N	SYNAT555	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3582	SM_4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2023	\N	\N	None	\N	SYNAT556	Spitzoid Melanoma	\N	AirTable blocks_with_IP_info.csv
3479	KIT225	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2301	\N	\N	None	\N	SYNAT557	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3586	SM_12	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2076	\N	\N	None	\N	SYNAT558	Spitzoid Melanoma	\N	AirTable blocks_with_IP_info.csv
3477	KIT210	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1951	\N	\N	None	\N	SYNAT559	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3542	MB1617	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma | Barcode mismatch comment in note	\N	\N	\N	\N	1692	\N	\N	None	\N	SYNAT560	2010-2017	\N	AirTable blocks_with_IP_info.csv
3291	DM18	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1844	\N	\N	None	\N	SYNAT561	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
2115	17-35589	18	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10862	216.5	\N	\N	Sections show a compound proliferation of melanocytes, with nested and solitary melanocytes arrayed along the junction.  There are clusters and syncytia of melanocytes in the superficial dermis, and striking cytologic atypism is not apparent.  Small melanocytes are present amongst reticular dermal collagen bundles in some foci in the uppermost reticular dermis.	Oriented ellipse, 4.7 x 1.7 x 0.8 cm, including a central 1.8 x 1.2 cm brown area. With the sutured tip placed to the left, this tip is indicated as laterally at 12 o'clock on the requisition. The 12-3-6 o'clock margin is inked blue and the 6-9-12 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and submitted with three sections each in A-D. Tips reserved. RS/RS	1.6 X 1.4 CM TAN PATCH, PROBABLE CONGENITAL NEVUS, R/O ATYPIA, NEOPLASM OF UNCERTAIN BEHAVIOR	\N	\N	\N	None	COMPOUND MELANOCYTIC NEVUS WITH SUPERFICIAL CONGENITAL FEATURES, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	110501	478	\N	\N	17-35589	\N	DN-003	Dysplastic Nevi	IP1765035	AirTable blocks_with_IP_info.csv
3500	KR_5233	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2097	\N	\N	None	\N	SYNAT565	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3303	DM42	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1923	\N	\N	None	\N	SYNAT566	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3465	KIT37	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Known Mutations	\N	\N	\N	\N	2134	\N	\N	None	\N	SYNAT567	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3328	DM94	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1984	\N	\N	None	\N	SYNAT568	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3185	Bivona-L19	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2338	\N	\N	None	\N	SYNAT569	2010-2017	\N	AirTable blocks_with_IP_info.csv
3470	KIT134	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2335	\N	\N	None	\N	SYNAT570	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3316	DM64	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2273	\N	\N	None	\N	SYNAT571	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3504	KR_RMK0168C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2264	\N	\N	None	\N	SYNAT572	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3284	DM10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2141	\N	\N	None	\N	SYNAT573	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3600	UM26	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1975	\N	\N	None	\N	SYNAT574	Uveal Melanoma	\N	AirTable blocks_with_IP_info.csv
3336	Dog12	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka, Dog Melanoma| mucosal melanoma +EIN	\N	\N	\N	\N	2296	\N	\N	None	\N	SYNAT575	2010-2017	\N	AirTable blocks_with_IP_info.csv
3189	BN_N2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2304	\N	\N	None	\N	SYNAT576	2010-2017	\N	AirTable blocks_with_IP_info.csv
3532	MB_1418	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1742	\N	\N	None	\N	SYNAT577	2010-2017	\N	AirTable blocks_with_IP_info.csv
3564	Seider_Roe	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2122	\N	\N	None	\N	SYNAT578	2010-2017	\N	AirTable blocks_with_IP_info.csv
3332	DM99	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2105	\N	\N	None	\N	SYNAT579	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3294	DM23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2290	\N	\N	None	\N	SYNAT580	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3494	KR_166	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1759	\N	\N	None	\N	SYNAT581	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3287	DM13	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	2212	\N	\N	None	\N	SYNAT582	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3308	DM51	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1987	\N	\N	None	\N	SYNAT583	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3562	PG8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Autopsy	\N	\N	\N	\N	1863	\N	\N	None	\N	SYNAT584	2010-2017	\N	AirTable blocks_with_IP_info.csv
3292	DM21	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	1681	\N	\N	None	\N	SYNAT585	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3339	Dog55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka, Dog Melanoma| acral melanoma	\N	\N	\N	\N	1778	\N	\N	None	\N	SYNAT586	2010-2017	\N	AirTable blocks_with_IP_info.csv
3491	KIT316	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1804	\N	\N	None	\N	SYNAT587	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3464	KIT21	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2013	\N	\N	None	\N	SYNAT588	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3497	KR_229	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1964	\N	\N	None	\N	SYNAT589	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
1270	07-04365	59	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show an asymmetrical, compound proliferation of melanocytes, many of which have atypical nuclei. Many of the junctional melanocytes have spindled or epithelioid cytology, and there are some perimelanocytic clefts. There are many melanocytes present above the basal layer. The epidermis is thinned overlying some of the junctional nests. Small Kamino bodies are evident. There are irregular clusters of similar melanocytes in the underlying dermis, and also, a subtle population of perhaps slightly smaller melanocytes towards the base. These are in continuity with larger melanocytes in general, however. The overlying epidermis is thickened and hyperkeratotic, and there are also areas of thinning of the epidermis as noted. The proliferation is fairly well-circumscribed, although there are minor defects in lateral circumscription noted. There is surrounding slight solar elastosis, and a patchy lymphocytic infiltrate. The papillary dermis is focally fibrotic.	Slightly irregular ellipse, 1.7 x 1.1 x 0.3 cm, including a central brown 0.7 x 0.5 cm area.  With margins inked blue, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections.	R/O MELANOMA	\N	\N	\N	This example of melanoma has a pattern reminiscent of that seen in a Spitz's nevus. However, it is broad, markedly asymmetrical, and demonstrates focal defects in circumscription. There are even occasional Kamino bodies, which are relatively small but well formed, a feature also seen in Spitz's nevi. There is a population of somewhat smaller cells in some areas as well. Thus, although this would be an unusual occurrence, we cannot completely exclude the possibility of melanoma arising in a background of Spitz's nevus. I have also shared this case with my colleagues, Drs. Philip LeBoit and Timothy McCalmont, who agree with these findings. In terms of staging, this is a non-ulcerated primary melanoma of Clark's anatomic level at least III, filling and expanding the papillary dermis. I cannot completely exclude the possibility of superficial involvement of the reticular dermis, as the interface is obscured by the tumor and by a lymphocytic infiltrate. There is no evidence of vascular invasion, neurotropism, or regression. There are also no microsatellites noted. Complete excision is of course warranted.	MELANOMA, WITH SPITZOID FEATURES, 0.8 MM IN THICKNESS, EXTENDING WITHIN THE EPIDERMIS TO WITHIN 2 MM OF THE PERIPHERAL MARGIN	173701	2149	\N	\N	07-4365	\N	SYNAT590	Spitzoid Melanoma	IP617346	AirTable blocks_with_IP_info.csv
3529	MB_1029	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1696	\N	\N	None	\N	SYNAT591	2010-2017	\N	AirTable blocks_with_IP_info.csv
3503	KR_RMK0162C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2108	\N	\N	None	\N	SYNAT594	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3496	KR_203	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1704	\N	\N	None	\N	SYNAT595	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3498	KR_2030	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2267	\N	\N	None	\N	SYNAT596	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3555	NB2107	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Wistar Cell Lines, passage 5, wt/wt	\N	\N	\N	\N	1787	\N	\N	None	\N	SYNAT597	2010-2017	\N	AirTable blocks_with_IP_info.csv
3301	DM36	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1715	\N	\N	None	\N	SYNAT598	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3321	DM69	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1828	\N	\N	None	\N	SYNAT599	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3488	KIT297	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1755	\N	\N	None	\N	SYNAT600	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3471	KIT181	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Known Mutations	\N	\N	\N	\N	2269	\N	\N	None	\N	SYNAT601	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3489	KIT302	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2218	\N	\N	None	\N	SYNAT602	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3505	KR_RMK0194C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1976	\N	\N	None	\N	SYNAT603	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3317	DM65	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2209	\N	\N	None	\N	SYNAT604	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3599	UM25	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2332	\N	\N	None	\N	SYNAT605	Uveal Melanoma	\N	AirTable blocks_with_IP_info.csv
1210	06-08042	15	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	216.6	\N	\N	Sections show a nodular and somewhat wedge-shaped proliferation of slightly spindled and epithelioid melanocytes, most of which have abundant vacuolated cytoplasms, which extends deeply in the reticular dermis in bulbous fashion. Some melanocyte nuclei are enlarged, but there is not extreme pleomorphism and mitotic figures are inconspicuous. There are interspersed melanophages in large numbers.	Cylindrical skin segment, 0.5 cm in diameter and 0.6 cm in thickness, bisected and entirely submitted.	DARK BLUE NODULE; ANGIOMA, BLUE NEVUS, R/O ATYPIA	\N	\N	\N	This lesion could also be interpreted as an epithelioid blue nevus.	DEEP PENETRATING NEVUS	173611	1791	\N	\N	06-8042	\N	SYNAT606	Deep Penetrating Nevus	IP553108	AirTable blocks_with_IP_info.csv
3589	TCR-Beta-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2092	\N	\N	None	\N	SYNAT607	2010-2017	\N	AirTable blocks_with_IP_info.csv
3598	UM24	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2159	\N	\N	None	\N	SYNAT608	Uveal Melanoma	\N	AirTable blocks_with_IP_info.csv
3295	DM25	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1956	\N	\N	None	\N	SYNAT609	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3476	KIT206	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2213	\N	\N	None	\N	SYNAT610	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3591	Thomas_SK_MEL_23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2068	\N	\N	None	\N	SYNAT611	Melanoma Cell Line	\N	AirTable blocks_with_IP_info.csv
3320	DM68	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1955	\N	\N	None	\N	SYNAT612	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3510	Luping_ROS_1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1989	\N	\N	None	\N	SYNAT613	2010-2017	\N	AirTable blocks_with_IP_info.csv
1360	10-0206	34	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.3	\N	\N	Sections show irregular aggregations of atypical basaloid to squamoid keratinocytes, with focal epithelial-stromal clefting.	Four outside slides, CPP-09-35739:A1.	REVIEW OF OUTSIDE SLIDES PRIOR TO MICROGRAPHIC SURGERY	\N	\N	\N	I favor basal cell carcinoma over squamous cell carcinoma. Ber-EP4 and keratin immunoperoxidase stains were attempted by the referring laboratory, but no tumor remains in those sections. The pattern of tumor is not fully classifiable as little is present.	INVASIVE CARCINOMA, FAVOR BASAL CELL CARCINOMA, EXTENDING TO THE SPECIMEN BASE	373314	1695	\N	\N	10-206	\N	SYNAT614	2010-2017	IP894776	AirTable blocks_with_IP_info.csv
3293	DM22	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1667	\N	\N	None	\N	SYNAT615	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3583	SM_5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1841	\N	\N	None	\N	SYNAT616	Spitzoid Melanoma	\N	AirTable blocks_with_IP_info.csv
3299	DM31	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2262	\N	\N	None	\N	SYNAT617	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3530	MB_1036	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1996	\N	\N	None	\N	SYNAT618	2010-2017	\N	AirTable blocks_with_IP_info.csv
3290	DM17	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2017	\N	\N	None	\N	SYNAT619	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3474	KIT203	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1993	\N	\N	None	\N	SYNAT620	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3534	MB1241	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1902	\N	\N	None	\N	SYNAT621	2010-2017	\N	AirTable blocks_with_IP_info.csv
3590	TCR-Beta-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1911	\N	\N	None	\N	SYNAT622	2010-2017	\N	AirTable blocks_with_IP_info.csv
3468	KIT76	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1938	\N	\N	None	\N	SYNAT623	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3341	DPN9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2257	\N	\N	None	\N	SYNAT624	2010-2017	\N	AirTable blocks_with_IP_info.csv
3329	DM95	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1785	\N	\N	None	\N	SYNAT625	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3188	BN_N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1908	\N	\N	None	\N	SYNAT626	2010-2017	\N	AirTable blocks_with_IP_info.csv
3281	DM6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1999	\N	\N	None	\N	SYNAT627	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3325	DM79	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1959	\N	\N	None	\N	SYNAT628	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3399	JBP-7-Met	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2342	\N	\N	None	\N	SYNAT629	2010-2017	\N	AirTable blocks_with_IP_info.csv
3597	UM23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2039	\N	\N	None	\N	SYNAT630	Uveal Melanoma	\N	AirTable blocks_with_IP_info.csv
3484	KIT262	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2099	\N	\N	None	\N	SYNAT631	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3473	KIT192	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1903	\N	\N	None	\N	SYNAT632	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3306	DM48	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1703	\N	\N	None	\N	SYNAT633	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3606	WM3912	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2180	\N	\N	None	\N	SYNAT634	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3478	KIT217	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1867	\N	\N	None	\N	SYNAT635	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3314	DM62	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2114	\N	\N	None	\N	SYNAT636	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3467	KIT62	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Known Mutations	\N	\N	\N	\N	2031	\N	\N	None	\N	SYNAT638	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3502	KR_RMK0137C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1961	\N	\N	None	\N	SYNAT639	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3331	DM98	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1825	\N	\N	None	\N	SYNAT640	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3493	KR_150	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2005	\N	\N	None	\N	SYNAT641	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3318	DM66	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2306	\N	\N	None	\N	SYNAT642	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3604	WM3211	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Wistar Cell Lines, passage 61, wt/wt	\N	\N	\N	\N	1738	\N	\N	None	\N	SYNAT643	Cell Line	\N	AirTable blocks_with_IP_info.csv
3272	CP1-80	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1796	\N	\N	None	\N	SYNAT644	2010-2017	\N	AirTable blocks_with_IP_info.csv
3289	DM16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2187	\N	\N	None	\N	SYNAT645	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3475	KIT205	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2143	\N	\N	None	\N	SYNAT646	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3319	DM67	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1665	\N	\N	None	\N	SYNAT647	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3184	Bivona-L18	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1737	\N	\N	None	\N	SYNAT648	2010-2017	\N	AirTable blocks_with_IP_info.csv
3463	KIT8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2164	\N	\N	None	\N	SYNAT649	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3603	WM1963	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1826	\N	\N	None	\N	SYNAT650	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3612	XD-1.1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1686	\N	\N	None	\N	SYNAT651	2010-2017	\N	AirTable blocks_with_IP_info.csv
3186	BN_M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1915	\N	\N	None	\N	SYNAT652	2010-2017	\N	AirTable blocks_with_IP_info.csv
3270	CP1-20	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2058	\N	\N	None	\N	SYNAT653	2010-2017	\N	AirTable blocks_with_IP_info.csv
3324	DM77	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2119	\N	\N	None	\N	SYNAT654	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3485	KIT273	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1724	\N	\N	None	\N	SYNAT655	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3526	MB_327	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1833	\N	\N	None	\N	SYNAT656	2010-2017	\N	AirTable blocks_with_IP_info.csv
2112	17-35486B	32	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.5	\N	\N	Sections show a compound array of melanocytes, with single cells and nests arrayed along the epidermal-dermal junction, distributed along the sides and bases of elongated rete. There are similar melanocytes in the subjacent superficial dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted in B. KC/KC	A-B) NEVUS, R/O ATYPIA	\N	\N	\N	\N	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	173531	491	\N	\N	17-35486	B	DN-016	Dysplastic Nevi	IP1764932	AirTable blocks_with_IP_info.csv
2080	17-26400	35	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10850	216.5	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.8 x 0.7 x 0.1 cm, trisected and entirely submitted. KC/KC	TAN MACULE W/ FOCAL AREA OF DARK PIG CHANGING NEVUS; POSS MM	\N	\N	Scraping	None	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	172541	494	\N	\N	17-26400	\N	DN-019	Dysplastic Nevi	IP1755718	AirTable blocks_with_IP_info.csv
2114	17-35502B	44	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10861	216.5	\N	\N	Sections show a compound melanocytic proliferation, composed largely of nests arrayed along the epidermal-dermal junction, with extension lateral to papillary dermal clusters of similar cells.  There is subepithelial fibrosis, some of which is lamellar in configuration.	Skin segment measuring 0.6 x 0.5 x 0.1 cm, bisected and entirely submitted in B. HD/HD	A) IRREG 8 MM MACULE; R/O DYSPL CN VS. OTHER, B) HAZY 7 MM MACULE; R/O DYSPL CN VS. OTHER	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXTENDING TO THE EDGE OF THE SPECIMEN	105525	510	\N	\N	17-35502	B	DN-035	Dysplastic Nevi	IP1764948	AirTable blocks_with_IP_info.csv
2007	16-119333	67	\N	\N	\N	None	None	None	\N	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=10820	216.6	\N	\N	Sections show a junctional proliferation of melanocytes composed of nested and solitary melanocytes arrayed along the epidermal-dermal junction, with some single melanocytes arrayed along the sides and bases of elongated rete.  The papillary dermis is expanded by fibrosis and the lesion assumes a flat profile.	Skin segment measuring 1.1 x 0.8 x 0.1 cm, trisected and entirely submitted. RS/RS	9 MM IRREGULAR PIG PAP	\N	\N	\N	None	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173619	540	\N	\N	16-119333	\N	DN-065	Dysplastic Nevi	IP529433	AirTable blocks_with_IP_info.csv
1643	12-48249	54	\N	\N	\N	T1a	Primary	None	\N	\N	\N	\N	\N	172.5	\N	\N	There is a compound proliferation of melanocytes involving the epidermis and superficial dermis. The lesion is broad, has a slightly domed surface, and where it can be ascertained, appears well circumscribed. There are evenly elongated, round-based rete ridges, some of which are bridged by oval nests of large oval melanocytes that have abundant pale cytoplasm and slightly enlarged nuclei. Single melanocytes with scant cytoplasm are also present in the basal layer of the epidermis in between the ridges, and very focally above them. Within the superficial dermis, especially in the center of the lesion are poorly formed fascicles of spindled melanocytes with scant cytoplasm and variably sized, hyperchromatic nuclei. Toward one edge of the specimen, the dermis contains vertically oriented vessels and closely apposed, thin collagen bundles.	Five outside slides, D12-18979:1 and 2. Two corresponding blocks received 7-5-12.	R/O RECURRENT DYSPLASTIC NEVUS	\N	\N	\N	ADDENDUM, July  5, 2012: The following note has been modified from that in the original report, a copy of which is on file as a .pdf in our computer system: The neoplasm extends to the peripheral edge of the specimen.  The melanocytic proliferation has the overall architectural features of a dysplastic nevus, but has very large and confluent junctional nests, and a dermal component with some desmoplastic features. The differential diagnosis included an unusual dysplastic (Clark's) nevus and a dysplastic nevus-like pattern of melanoma.  Comparative genomic hybridization shows many chromosomal gains and losses, indicative of a level of genomic instability seen in melanoma and not in nevi. These included losses involving chromosome 3q, 8p, and 9p, and multiple areas of gains and losses on chromosome 11q. Losses of 9p are the most common aberrations in melanoma, and while not specific, when associated with other abnormalities point to that diagnosis.  The lesion is less than 1 mm in thickness, is not ulcerated, and does not have detectable mitotic figures in its dermal component. Therefore it should be classified as T1a per the 2009 revision of the AJCC staging system for melanoma.	MELANOMA, 0.45 MM. IN THICKNESS	173532	662	\N	\N	12-48249	\N	DP-25	CGH Validation	IP1134062	AirTable blocks_with_IP_info.csv
1889	15-87833	15	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	Sections show a compound proliferation of spitzoid melanocytes. Along the junction, there are melanocytes arranged as nests and single cells mostly within the lower epidermis. Many of the melanocytes are epithelioid and contain abundant eosinophilic cytoplasm, while some are more spindled. The overlying epidermis is acanthotic and hypergranulotic. Within the dermis, there are nests and some near sheets of similar melanocytes. Scattered dermal mitotic figures are apparent among dermal melanocytes, including some in the deep dermis. In some areas, there is diminishment in the size of melanocytes with descent into the dermis, while in other foci, large epithelioid melanocytes are present in the lower portion of the proliferation.	One hematoxylin and eosin-stained section prepared from outside block labeled 15-6056-A.	SECOND OPINION, R/O WART (SEE PHOTO)	\N	\N	\N	In the initial routine section, there were two populations of Spitzoid melanocytes. One population was composed of relatively small epithelioid melanocytes that diminished in size with descent and that were located mostly at the periphery of the proliferation. The other population was composed of large epithelioid melanocytes, many with atypical nuclei and some in mitosis, that formed large nests and near sheets within the central aspect of the specimen. This central population of melanocytes was concerning for Spitzoid melanoma while the peripheal population was suggestive of a Spitz nevus. In order to further evaluate this neoplasm, I performed immunoperoxidase staining. A phosphohistone H3/Melan-A two color immunoperoxidase stain (this stain labels melanocytes in mitosis, or very close to mitosis in the cell cycle) demonstrates a non-trivial number of melanocytes in mitosis within the dermal component of this proliferation.  Staining with p16 demonstrates significant loss of p16 staining among melanocytes within the central aspect of the proliferation (i.e. those concerning for Spitzoid melanoma) but no loss in the peripheral melanocytes. This loss can correlate with one of the common genomic aberrations seen in melanocytic neoplasm, bi-allelic loss of chr. 9p, where the gene, CDKN2A that encodes p16, is located. This loss of staining can also occur by epigenetic means, and is not entirely specific for melanoma. Nonetheless, detection of this loss within the morphologically atypical melanocytes is concerning. While I favored a Spitzoid melanoma arising in a Spitz nevus for the above mentioned reasons, I did not think that an unequivocal diagnosis could be rendered based on the above data. Therefore, after receiving authorization from the clinical team, I (1) completed FISH analysis for chromosome 9p in order to determine if the loss of p16 staining mentioned above represented an authentic mutation in this genetic locus of an epigenetic phenomenon and (2) completed array-based comparative genomic hybridization (aCGH) since FISH analysis only tests for one genetic locus.  The FISH testing did not show homozygous loss of chromosome 9p and thus the loss of p16 appears to be an epigenetic phenomenon.  The aCGH reveals a small sub-centromeric gain on chromosome 1q, a loss on chromosome 6q and a gain of chromosome 21q. The loss on chromosome 1 is bordered by TPM3, which is a gene involved in a range of fusions, and thus it is possible that a fusion has occurred. While the presence of these three abnormalities detected on the aCGH is worrisome, it is not sufficiently atypical to render an unequivocal diagnosis of Spitzoid melanoma. I think it is best to regard this lesion as representing an atypical Spitz tumor, which is a Spitzoid neoplasm that shows more atypicality than a conventional Spitz tumor but is not sufficiently atypical to warrant an unequivocal diagnosis of Spitzoid melanoma. Fusions occur relatively frequently in atypical Spitz tumors, which might have been the case herein.  Given that this proliferation extends to the base and peripheral aspect of the specimen, I think that it should be re-excised with a few millimeters of a margin.  My colleagues, Dr. Timothy McCalmont and Boris Bastian, also reviewed these sections and agree with this assessment.	BIPHASIC ATYPICAL SPITZOID TUMOR, EXTENDING TO THE BASE AND PERIPHERAL ASPECT OF THE SPECIMEN	132799	686	\N	\N	15-87833	\N	DP-49	CGH Validation	IP1559454	AirTable blocks_with_IP_info.csv
1936	16-25723	30	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show melanocytes arrayed irregularly and focally confluently within the epidermis, with clusters of similar cells within the subjacent dermis with extensive fibrosis. Many of the melanocytes have spindled cytomorphology with large vesicular nuclei.	One outside slide, OJ16-233. One corresponding block received 3/22/16.	PATIENT WITH A 1.1 CM IRREG PIGMENTED LESION; ? SPITZOID NEVUS	\N	\N	\N	There is marked confluence and asymmetry in the junctional component of this proliferation and prominent fibrosis associated with the dermal melanocytes. Most of the melanocytes have spindled nuclei with amphophilic cytoplasm. Given the long, vertically oriented fascicles in the dermis, I obtained NTRK-1 and ALK immunoperoxidase stains. These genes can be involved in a gene fusion, with resultant overexpression in a subset of Spitz's nevi with this morphologic finding. The stains are negative in this case, however. The differential diagnosis includes an atypical pigmented spindle cell nevus or plexiform spindle cell nevus, atypical Spitz tumor, and spitzoid melanoma. Immunoperoxidase staining using two colors (MART-1/tyrosinase labeled red, Ki-67 labeled brown) does not show significant pagetoid scatter in the MART-1 component beyond what was evident in the hematoxylin and eosin stained sections, and the Ki-67 proliferation rate of the lesional melanocytes is around 5%. A p16 immunoperoxidase stain does not show significant loss of that tumor suppressor gene product. Given the ambiguous findings in the routine sections and immunoperoxidase workup, I obtained comparative genomic hybridization to assess for melanoma associated chromosomal abnormalities. This showed multiple chromosomal gains and losses including 1p and 8q loss, 7p and 15q gain, a complex pattern of both gains and losses on 7q including findings that suggest a BRAF fusion event, and an isolated interstitial deletion involving a portion of chromosome 3p containing the BAP-1 gene. Analysis for a tert promoter mutation was negative.  Given the genetic findings of multiple chromosomal gains and losses, including regions frequently seen in melanoma, I believe the best diagnosis for this case is a spitzoid melanoma and not an atypical Spitz tumor. I shared this case with my colleague Dr. Philip LeBoit who agrees with this interpretation.  A synoptic report of potential prognostic factors is listed below:  Procedure: shave biopsy Microscopic tumor type: spitzoid Breslow thickness: at least 1.3 mm Ulceration: absent Margins, peripheral and deep: both + Mitotic index: 0 mm/2 Microsatellitosis: cannot assess Vascular invasion: not identified Regression: not identified Perineural invasion: not identified Pathologic staging (pTNM): at least pT2a	MELANOMA, AT LEAST 1.3 MM IN THICKNESS, TRANSECTED ACROSS THE SPECIMEN BASE	123724	696	\N	\N	16-25723	\N	DP-59	CGH Validation	IP1624894	AirTable blocks_with_IP_info.csv
1939	16-30292	11	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	There is a mostly intradermal proliferation of large, oval and polygonal melanocytes with abundant homogeneous appearing cytoplasm and large, pleomorphic vesicular nuclei, singly and in small nests in the dermis without much maturation and dispersion with descent.	Seven outside slides, S16-4576-A1, and one corresponding block.	MOLE; R/O CANCER	\N	\N	\N	The differential diagnosis includes an atypical Spitz tumor and a spitzoid melanoma. There is nearly complete loss of p16 staining, which can correlate with one of the common genomic aberrations seen in melanocytic neoplasm, bi-allelic loss of chr. 9p, where the gene, CDKN2A that encodes p16 is located. This loss of staining can also occur by epigenetic means, and is not entirely specific for melanoma. Following microdissection and DNA extraction, we performed comparative genomic hybridization. This shows a gain involving chr. 2, and losses involving chrs. 6q and 9. The depression in the CGH array graph suggests heterozygous rather than homozygous chr. 9 loss. Losses of chrs. 6q and 9 are common aberrations seen in atypical Spitz tumors and in melanoma, but not in conventional Spitz's nevi.  Following microdissection and DNA extraction, we performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations.  Based on these findings, I favor an atypical Spitz tumor. These are neoplasms that have features more atypical than those of a conventional Spitz nevus, but not as worrisome as those of spitzoid melanoma. In aggregate data from over ten studies, local nodal involvment (usually very small deposits) is common, but extranodal metastasis is rare. This dissociation results in sentinel lymph node biopsy having very limited predictive value, and in my opinion, sometimes leading to over-treatment if small deposits lead to completion lymphadenectomy. The lesion is broadly transected, and a re-excision (not much wider- I would suggest 5 mm. or so around the prior biopsy site or any residuum), but deeper)  Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	PREDOMINANTLY INTRADERMAL PROLIFERATION OF LARGE, SPITZOID MELANOCYTES, FAVOR AN ATYPICAL SPITZ TUMOR	173207	697	\N	\N	16-30292	\N	DP-60	CGH Validation	IP1629500	AirTable blocks_with_IP_info.csv
1931	16-19890	15	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.3	\N	\N	The microscopic findings are essentially as described in the accompanying pathology report and in the note above.	Three outside slides, 16S-01754 1A1-1B2. Three additional slides (ALK-1 & p16 stains for A1) received 3/14/16. Three additional slides (ALK-1 & p16 stains for 1B) received 3/18/16. One corresponding block (1B) received 3/30/16.	2ND OPINION, NEVUS; NUB	\N	\N	\N	This proliferation of spitzoid cells shows large bulbous aggregations extending into the subcutis, as can be seen both in atypical Spitz tumors and spitzoid melanoma. There are mitotic figures in the deep portion of the lesion, including some so-called marginal mitoses. As there are thin, pointed ridges and long, vertically oriented fascicles, I suggested an ALK immunostain (along with p16). The stained sections have now been received. The ALK stain is negative, excluding that variant of spitzoid neoplasm. There is a mosaic pattern of staining for p16, sufficient to exclude the possibility of a bi-allelic deletion of chr. 9p, which can be found in melanoma (the absence of which does not exclude the diagnosis, however).  The differential diagnosis included an atypical Spitz tumor and spitzoid melanoma.  Following microdissection and DNA extraction, we performed comparative genomic hybridization. Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. These included gains involving chromosomes 2p, 3p, 4p, and 8q and losses involving 3q and 4q. C-myc is on chr. 8q, and gains of this chromosome are a repeatable aberration in melanoma, while many of the other aberrations are not.  Currently, I use the term spitzoid melanoma, childhood type, for an emerging class of lesions that usually but not exclusively occur in children and teens, lack b-raf mutations (which are present in most melanomas in adults) and have a propensity to involve local lymph nodes. Systemic spread either occurs infrequently or it does so in a delayed fashion compared to adult melanoma. These are findings that would support conservative treatment. Most lesions of this type are deeper, but usually not much wider than their exophytic portions, and even when they are, are well circumscribed. While sentinel nodes are often positive, this positivity has much less predictive value for systemic spread than is the case with adult melanoma.  We will contact you if testing for hTERT promoter mutations again becomes available in our lab.  ADDENDUM, June 29, 2016:  Per my discussion with Dr. Dohil, we will be performing hTERT promoter mutation analysis; please expect results in 2-3 weeks.  ADDENDUM, July 13, 2016:  Following microdissection and DNA extraction, we performed sequencing of the hTERT promoter gene. This test detects TERT promoter mutations on chromosome 5 between nucleotides 1,295,155 to 1,295,355; including mutations at g.1295161 A>C; g.1295228 C>T; g.1295250 C>T. Such mutations occur in melanoma, and in the context of atypical spitzoid neoplasms have been linked to the capacity for spread beyond local lymph nodes. No mutations were found, lessening concern regarding the chance for such spread. In the study cited below, the only cases with fatal outcomes were in patients who had hTERT promoter mutations. Hence, even though the designation spitzoid melanoma may be apt morphologically, the prognosis would be expected to be better than in conventional melanomas of this thickness.  Reference:  Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200. PubMed PMID: 26061100; PubMed Central PMCID: PMC4462090.	SPITZOID MELANOMA, 3.5 MM. IN THICKNESS	173305	703	\N	\N	16-19890	\N	DP-66	CGH Validation	IP1619017	AirTable blocks_with_IP_info.csv
1848	15-14665C	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26328,26329	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	764	\N	\N	15-14665	C	JJS26	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1679	13-207	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	783	\N	\N	13-207	\N	KIT-02	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1678	13-140	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	784	\N	\N	13-140	\N	KIT-03	Kit mutants	\N	AirTable blocks_with_IP_info.csv
1958	16-55411	65	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.4	\N	\N	There is a mostly intradermal proliferation of melanocytes in part composed of large, oval and fusiform cells with abundant pale homogeneous appearing cytoplasm and large, vesicular nuclei, in a background of smaller cells. There is nearly complete loss of p16, except in small, round cells near the base of the specimen. A Ki-67 stain shows positive nuclei in number only just beneath the epidermis.	Eleven outside slides, S16-17518-1A (000675315-AM), and one corresponding block.	MELANOCYTIC NEVUS OF NECK	\N	\N	\N	The differential diagnosis included a combined lesion with banal nevus and an atypical Spitz tumor and a spitzoid melanoma arising in a nevus. The nearly complete loss of p16 was of concern. Following microdissection and DNA extraction, we performed comparative genomic hybridization. Comparative genomic hybridization shows multiple chromosomal gains and losses, indicating a level of genomic instability found in melanoma and not in nevi. These include losses involving chr. 1q, a gain involving the terminal end of 7q, a loss involving chr. 9p with a pattern suggesting that the loss of CDKN2A is homozygous, and correlating with the negative p16 stain, and losses involving chr. 17. The findings are unusual in that the smaller cells have cytological features resembling those of a conventional nevus and the larger ones, resembling those of a Spitz's nevus.  The neoplasm extends to the base of the specimen. The final thickness measurement should be made after complete excision.  ADDENDUM, June 30, 2016:  Staining for the protein product of the V600e mutation of b-raf is positive. I obtained this stain out of interest, as Spitz's nevi with chr. 7q gain usually have gene fusions involving b-raf, but the b-raf gene is wild type (not mutated). The result implies that the chr. 7q gain seen here is not due to a b-raf fusion. There is no fee for the stain, but it may be relevant for treatment if there is metastatic disease in the future.	MELANOMA, 2.1 MM. IN THICKNESS	173405	705	\N	\N	16-55411	\N	DP-68	CGH Validation	IP1654849	AirTable blocks_with_IP_info.csv
1170	05-23001 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	916	\N	\N	None	\N	MD-10	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1227	06-17441-2 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	923	\N	\N	None	\N	MD-17	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1226	06-17441 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	923	\N	\N	None	\N	MD-17	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1244	06-25697 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	924	\N	\N	None	\N	MD-18	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1245	06-25697-1 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	924	\N	\N	None	\N	MD-18	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
11241	Sample_KAM3-T-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11194	STRS91-006237	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	39	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2660	20-91483A	79	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33798	173.72	\N	\N	There is a roughly symmetrical, crateriform proliferation of keratinocytes, with papillations that protrude into the central zone of cornification. Orthokeratotic material predominates centrally. There is a thick lining of keratinocytes, most of which have abundant, pale eosinophilic cytoplasm. The lesional keratinocytes toward the periphery of the neoplasm have larger nuclei and less abundant cytoplasm.	Ellipse, 3.4 x 1.5 x 0.6 cm, including a central 1.3 x 1.3 cm elevated area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis, and submitted with five sections in A and four sections in B. Tips reserved. HD/HD	MORPHOLOGY: SMOOTH PINK NODULE WITH CENTRAL ROUGH AREA, DDX: KERATOACANTHOMA, NOTES: PLEASE CHECK MARGINS	\N	\N	FFPE	\N	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	123746	768	\N	\N	20-91483	A	KA-02	Keratoacanthoma	IP2239395	AirTable blocks_with_IP_info.csv
2661	20-91483B	79	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33799	173.72	\N	\N	There is a roughly symmetrical, crateriform proliferation of keratinocytes, with papillations that protrude into the central zone of cornification. Orthokeratotic material predominates centrally. There is a thick lining of keratinocytes, most of which have abundant, pale eosinophilic cytoplasm. The lesional keratinocytes toward the periphery of the neoplasm have larger nuclei and less abundant cytoplasm.	Ellipse, 3.4 x 1.5 x 0.6 cm, including a central 1.3 x 1.3 cm elevated area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis, and submitted with five sections in A and four sections in B. Tips reserved. HD/HD	MORPHOLOGY: SMOOTH PINK NODULE WITH CENTRAL ROUGH AREA, DDX: KERATOACANTHOMA, NOTES: PLEASE CHECK MARGINS	\N	\N	FFPE	None	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	123746	768	\N	\N	20-91483	B	KA-02	Keratoacanthoma	IP2239395	AirTable blocks_with_IP_info.csv
2654	20-82651B	97	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33776	173.62	\N	\N	Section show a mostly endophytic neoplasm of keratinocytes, some of which have abundant pale cytoplasm, with nuclear atypia being more pronounced at the peripheries of lobules.	Oriented ellipse measuring 5.8 x 2.3 x 2.1 cm, including a central 1.7 x 1.6 cm raised crusted area. The orienting blue dye at one tip is indicated 12 o'clock (upper pole) on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin black and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with three sections in A, one each in B-D, and three in E. Tips reserved. CF/CF	DDX: KERATOACANTHOMA	\N	\N	FFPE	None	SQUAMOUS CELL CARCINOMA, KERATOACANTHOMA TYPE, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM).	222611	771	\N	\N	20-82651	B	KA-05	Keratoacanthoma	IP2230518	AirTable blocks_with_IP_info.csv
2657	20-82651E	97	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33779	173.62	\N	\N	Section show a mostly endophytic neoplasm of keratinocytes, some of which have abundant pale cytoplasm, with nuclear atypia being more pronounced at the peripheries of lobules.	Oriented ellipse measuring 5.8 x 2.3 x 2.1 cm, including a central 1.7 x 1.6 cm raised crusted area. The orienting blue dye at one tip is indicated 12 o'clock (upper pole) on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin black and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with three sections in A, one each in B-D, and three in E. Tips reserved. CF/CF	DDX: KERATOACANTHOMA	\N	\N	FFPE	None	SQUAMOUS CELL CARCINOMA, KERATOACANTHOMA TYPE, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM).	222611	771	\N	\N	20-82651	E	KA-05	Keratoacanthoma	IP2230518	AirTable blocks_with_IP_info.csv
2653	20-82651A	97	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33775	173.62	\N	\N	Section show a mostly endophytic neoplasm of keratinocytes, some of which have abundant pale cytoplasm, with nuclear atypia being more pronounced at the peripheries of lobules.	Oriented ellipse measuring 5.8 x 2.3 x 2.1 cm, including a central 1.7 x 1.6 cm raised crusted area. The orienting blue dye at one tip is indicated 12 o'clock (upper pole) on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin black and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with three sections in A, one each in B-D, and three in E. Tips reserved. CF/CF	DDX: KERATOACANTHOMA	\N	\N	FFPE	\N	SQUAMOUS CELL CARCINOMA, KERATOACANTHOMA TYPE, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM).	222611	771	\N	\N	20-82651	A	KA-05	Keratoacanthoma	IP2230518	AirTable blocks_with_IP_info.csv
2656	20-82651D	97	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33778	173.62	\N	\N	Section show a mostly endophytic neoplasm of keratinocytes, some of which have abundant pale cytoplasm, with nuclear atypia being more pronounced at the peripheries of lobules.	Oriented ellipse measuring 5.8 x 2.3 x 2.1 cm, including a central 1.7 x 1.6 cm raised crusted area. The orienting blue dye at one tip is indicated 12 o'clock (upper pole) on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin black and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with three sections in A, one each in B-D, and three in E. Tips reserved. CF/CF	DDX: KERATOACANTHOMA	\N	\N	FFPE	None	SQUAMOUS CELL CARCINOMA, KERATOACANTHOMA TYPE, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM).	222611	771	\N	\N	20-82651	D	KA-05	Keratoacanthoma	IP2230518	AirTable blocks_with_IP_info.csv
2739	21-96446A1	78	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33780	173.62	\N	\N	Sections show a papillated to crateriform proliferation of atypical keratinocytes, some of which have ample pallid cytoplasm. Orthokeratotic material predominates centrally, and nuclear variability is most pronounced at the lesion's periphery.  The peripheral margins of the specimen are not involved by neoplasm.	Oriented ellipse, 4.9 x 2.2 x 1.0 cm, including a central 1.7 x 1.6 cm raised area. The orienting sutured tip is indicated 9 o'clock on the requisition and is placed toward 9 o'clock. The grosser inked the 9-12-3 o'clock margin blue and the 3-6-9 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and submitted with four sections in A1, two sections each in A2-A3, and four sections in A4. Tips reserved. BY/BY	A) PROBABLE KERATOACANTHOMA, B) BCCA	\N	\N	FFPE	\N	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	106678	772	\N	\N	21-96446	A1	KA-06	Keratoacanthoma	IP2359460	AirTable blocks_with_IP_info.csv
2740	21-96446A2	78	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33781	173.62	\N	\N	Sections show a papillated to crateriform proliferation of atypical keratinocytes, some of which have ample pallid cytoplasm. Orthokeratotic material predominates centrally, and nuclear variability is most pronounced at the lesion's periphery.  The peripheral margins of the specimen are not involved by neoplasm.	Oriented ellipse, 4.9 x 2.2 x 1.0 cm, including a central 1.7 x 1.6 cm raised area. The orienting sutured tip is indicated 9 o'clock on the requisition and is placed toward 9 o'clock. The grosser inked the 9-12-3 o'clock margin blue and the 3-6-9 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and submitted with four sections in A1, two sections each in A2-A3, and four sections in A4. Tips reserved. BY/BY	A) PROBABLE KERATOACANTHOMA, B) BCCA	\N	\N	FFPE	\N	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	106678	772	\N	\N	21-96446	A2	KA-06	Keratoacanthoma	IP2359460	AirTable blocks_with_IP_info.csv
2671	20-104213B	72	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33785	173.72	\N	\N	There is a roughly symmetrical, crateriform proliferation of keratinocytes, with papillations that protrude into the central zone of cornification. Orthokeratotic material predominates centrally. There is a thick lining of keratinocytes, most of which have abundant, pale eosinophilic cytoplasm. The lesional keratinocytes toward the periphery of the neoplasm have larger nuclei and less abundant cytoplasm.	Ellipse, 4.2 x 1.7 x 0.7 cm, including a central 1.4 x 1.2 cm raised crusted area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and submitted with five sections each in A-B. Tips reserved. CF/BB	KERATOTIC NODULE	\N	\N	FFPE	None	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	173711	773	\N	\N	20-104213	B	KA-07	Keratoacanthoma	IP2252203	AirTable blocks_with_IP_info.csv
2670	20-104213A	72	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33784	173.72	\N	\N	There is a roughly symmetrical, crateriform proliferation of keratinocytes, with papillations that protrude into the central zone of cornification. Orthokeratotic material predominates centrally. There is a thick lining of keratinocytes, most of which have abundant, pale eosinophilic cytoplasm. The lesional keratinocytes toward the periphery of the neoplasm have larger nuclei and less abundant cytoplasm.	Ellipse, 4.2 x 1.7 x 0.7 cm, including a central 1.4 x 1.2 cm raised crusted area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and submitted with five sections each in A-B. Tips reserved. CF/BB	KERATOTIC NODULE	\N	\N	FFPE	\N	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	173711	773	\N	\N	20-104213	A	KA-07	Keratoacanthoma	IP2252203	AirTable blocks_with_IP_info.csv
2609	20-18514B	80	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33787	173.62	\N	\N	Sections show a lobular and crateriform proliferation of keratinocytes, in large part composed of cells with abundant pale pink cytoplasm. Elastotic fibers are evident between the keratinocytes near the periphery. Nuclear atypicality is most pronounced in the most peripheral keratinocytes. There is a surrounding infiltrate of lymphocytes and granulocytes.	Elliptical excision, 3.6 x 1.7 x 1.1 cm, including a central 2.1 x 1.5 cm raised area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in A, three in B, and five in C. CF/CF	MORPHOLOGY: ERYTHEMATOUS TENDER NODULE WITH HYPERKERATOTIC SCALE, DDX: SQUAMOUS CELL CARCINOMA	\N	\N	FFPE	None	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	173622	774	\N	\N	20-18514	B	KA-08	Keratoacanthoma	IP2166036	AirTable blocks_with_IP_info.csv
1335	09-0209	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1905	\N	\N	09-209	\N	SYNAT672	2010-2017	\N	AirTable blocks_with_IP_info.csv
2664	20-98774A	51	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33789	173.62	\N	\N	There is a roughly symmetrical, crateriform proliferation of keratinocytes, with papillations that protrude into the central zone of cornification. Orthokeratotic material predominates centrally. There is a thick lining of keratinocytes, most of which have abundant, pale eosinophilic cytoplasm. The lesional keratinocytes toward the periphery of the neoplasm have larger nuclei and less abundant cytoplasm.	Oriented ellipse, 4.5 x 1.8 x 1.4 cm, including a central 1.5 x 1.5 cm elevated area. The orienting notched tip is indicated superior on the requisition and is designated 12 o'clock by the grosser. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with three sections in A, two sections each in B-C, and three sections in D. Tips reserved. HD/KB	MORPHOLOGY: ERYTHEMATOUS TENDER NODULE WITH CENTRAL KERATIN PLUG, DDX: KERATOACANTHOMA, NOTES: PLEASE CHECK MARGINS	\N	\N	FFPE	\N	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	173620	775	\N	\N	20-98774	A	KA-09	Keratoacanthoma	IP2246722	AirTable blocks_with_IP_info.csv
2665	20-98774B	51	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33790	173.62	\N	\N	There is a roughly symmetrical, crateriform proliferation of keratinocytes, with papillations that protrude into the central zone of cornification. Orthokeratotic material predominates centrally. There is a thick lining of keratinocytes, most of which have abundant, pale eosinophilic cytoplasm. The lesional keratinocytes toward the periphery of the neoplasm have larger nuclei and less abundant cytoplasm.	Oriented ellipse, 4.5 x 1.8 x 1.4 cm, including a central 1.5 x 1.5 cm elevated area. The orienting notched tip is indicated superior on the requisition and is designated 12 o'clock by the grosser. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with three sections in A, two sections each in B-C, and three sections in D. Tips reserved. HD/KB	MORPHOLOGY: ERYTHEMATOUS TENDER NODULE WITH CENTRAL KERATIN PLUG, DDX: KERATOACANTHOMA, NOTES: PLEASE CHECK MARGINS	\N	\N	FFPE	None	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	173620	775	\N	\N	20-98774	B	KA-09	Keratoacanthoma	IP2246722	AirTable blocks_with_IP_info.csv
2691	21-7055B6	87	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=29797,29798,29799,29800,29801,29802,29803,29804,29805,29806,29807,29808,29809,29810,29811	172.4	\N	\N	\N	Oriented oval excision measuring 8.5 x 4.8 x 1.4 cm, including a central 1.6 x 1.4 cm depressed area and a peripheral 5.0 x 4.5 cm pink-brown area. The orienting single staple at one pole is indicated 12:00 on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with a total of fifteen representative sections with one in B1, two each (bisected in halves) in B2-B14, and one (bisected) in B15. HD/CF	A) LEFT NECK NON-SENTINEL LYMPH NODES, B) POSTERIOR SCALP LESION, C) LEFT NECK SENTINEL LYMPH NODE #1, A-C) MELANOMA OF SCALP	\N	\N	\N	Dr. George, this case has been extensively discussed with Dr. Saylor of Dermatology. Dr. Saylor, as I discussed with you, upon re-review of prior specimen 20-110140-A, I believe focal melanoma in situ is apparent, and extensive in situ melanoma is also apparent in this new tissue. In short, it becomes fully clear that this tumor represents primary melanoma and not a metastasis. An updated brief synoptic is included below. Procedure: wide excision with SLNB Microscopic tumor type: lentigo maligna melanoma with nodular invasion Final Breslow thickness: 3.7 mm Ulceration: present Peripheral margin: narrow (2 mm) in the 12-3 o'clock quadrant Deep margin: centrally narrow (2 mm or so) Mitotic index: 7 per square mm Vascular invasion: not detected Perineural invasion: not detected Regression: present; partial Pathologic staging (pTNM): pT3bN0Mx	RESIDUAL MELANOMA OF 3.7 MM IN THICKNESS	173439	801	\N	\N	21-7055	B6	LMM-02	Lentigo Maligna Melanoma	IP554241	AirTable blocks_with_IP_info.csv
2689	21-7055B1	87	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=29797,29798,29799,29800,29801,29802,29803,29804,29805,29806,29807,29808,29809,29810,29811	172.4	\N	\N	\N	Oriented oval excision measuring 8.5 x 4.8 x 1.4 cm, including a central 1.6 x 1.4 cm depressed area and a peripheral 5.0 x 4.5 cm pink-brown area. The orienting single staple at one pole is indicated 12:00 on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with a total of fifteen representative sections with one in B1, two each (bisected in halves) in B2-B14, and one (bisected) in B15. HD/CF	A) LEFT NECK NON-SENTINEL LYMPH NODES, B) POSTERIOR SCALP LESION, C) LEFT NECK SENTINEL LYMPH NODE #1, A-C) MELANOMA OF SCALP	\N	\N	\N	Dr. George, this case has been extensively discussed with Dr. Saylor of Dermatology. Dr. Saylor, as I discussed with you, upon re-review of prior specimen 20-110140-A, I believe focal melanoma in situ is apparent, and extensive in situ melanoma is also apparent in this new tissue. In short, it becomes fully clear that this tumor represents primary melanoma and not a metastasis. An updated brief synoptic is included below. Procedure: wide excision with SLNB Microscopic tumor type: lentigo maligna melanoma with nodular invasion Final Breslow thickness: 3.7 mm Ulceration: present Peripheral margin: narrow (2 mm) in the 12-3 o'clock quadrant Deep margin: centrally narrow (2 mm or so) Mitotic index: 7 per square mm Vascular invasion: not detected Perineural invasion: not detected Regression: present; partial Pathologic staging (pTNM): pT3bN0Mx	RESIDUAL MELANOMA OF 3.7 MM IN THICKNESS	173439	801	\N	\N	21-7055	B1	LMM-02	Lentigo Maligna Melanoma	IP554241	AirTable blocks_with_IP_info.csv
2690	21-7055B4	87	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=29797,29798,29799,29800,29801,29802,29803,29804,29805,29806,29807,29808,29809,29810,29811	172.4	\N	\N	\N	Oriented oval excision measuring 8.5 x 4.8 x 1.4 cm, including a central 1.6 x 1.4 cm depressed area and a peripheral 5.0 x 4.5 cm pink-brown area. The orienting single staple at one pole is indicated 12:00 on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with a total of fifteen representative sections with one in B1, two each (bisected in halves) in B2-B14, and one (bisected) in B15. HD/CF	A) LEFT NECK NON-SENTINEL LYMPH NODES, B) POSTERIOR SCALP LESION, C) LEFT NECK SENTINEL LYMPH NODE #1, A-C) MELANOMA OF SCALP	\N	\N	\N	Dr. George, this case has been extensively discussed with Dr. Saylor of Dermatology. Dr. Saylor, as I discussed with you, upon re-review of prior specimen 20-110140-A, I believe focal melanoma in situ is apparent, and extensive in situ melanoma is also apparent in this new tissue. In short, it becomes fully clear that this tumor represents primary melanoma and not a metastasis. An updated brief synoptic is included below. Procedure: wide excision with SLNB Microscopic tumor type: lentigo maligna melanoma with nodular invasion Final Breslow thickness: 3.7 mm Ulceration: present Peripheral margin: narrow (2 mm) in the 12-3 o'clock quadrant Deep margin: centrally narrow (2 mm or so) Mitotic index: 7 per square mm Vascular invasion: not detected Perineural invasion: not detected Regression: present; partial Pathologic staging (pTNM): pT3bN0Mx	RESIDUAL MELANOMA OF 3.7 MM IN THICKNESS	173439	801	\N	\N	21-7055	B4	LMM-02	Lentigo Maligna Melanoma	IP554241	AirTable blocks_with_IP_info.csv
2676	21-457B	75	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=28275,28276,28277,28278,28279,28280,30985	172.6	\N	\N	Sections show post-procedural fibrosing inflammatory alterations coupled with a broad and confluent population of atypical melanocytes, some of which are fusiform. A lymphohistiocytic infiltrate is noted in the perijunctional zone. The background epidermis is thinned or muted. Old fibrosis is also noted.	Oriented oval, 4.2 x 3.1 x 0.9 cm, including a central 1.9 x 1.3 cm variegated brown area. The orienting yellow-green pole is indicated 9 o'clock on the requisition and is placed toward 9 o'clock. The submitting office pre-inked the 9-12 o'clock margin red, the 12-3 o'clock margin red, the 3-6 o'clock margin blue, and the 6-9 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and submitted with two sections each in A-E and one section in F. 3 o'clock pole reserved. BY/BY	MALIGNANT MELANOMA. PLEASE CHECK MARGINS.	\N	\N	\N	Upon wider excision, it becomes clear that this melanoma is of the lentigo maligna subtype. There is old scar in part of the dermis, and thus a preceding biopsy from some time ago may have been obtained. The final margin is free but is extremely narrow (1 mm or so) in the 3-6 and 6-9 o'clock quadrants. An updated brief synoptic is included below.  Procedure: wide excision Microscopic tumor type: lentigo maligna melanoma Final Breslow thickness: 0.6 mm Ulceration: not detected Peripheral margin: narrow in 3-6 and 6-9 o'clock quadrants Deep margin: widely free Mitotic index: 1 per square mm Regression: not significant Vascular invasion: not detected Perineural invasion: not detected Pathologic staging (pTNM): pT1a	RESIDUAL MELANOMA OF 0.6 MM IN THICKNESS, FULLY EXCISED (THE FINAL MARGIN APPEARS FREE BUT IS FOCALLY NARROW)	173611	802	\N	\N	21-457	B	LMM-03	Lentigo Maligna Melanoma	IP2011798	AirTable blocks_with_IP_info.csv
2677	21-457C	75	\N	\N	\N	None	None	None	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=28275,28276,28277,28278,28279,28280,30985	172.6	\N	\N	Sections show post-procedural fibrosing inflammatory alterations coupled with a broad and confluent population of atypical melanocytes, some of which are fusiform. A lymphohistiocytic infiltrate is noted in the perijunctional zone. The background epidermis is thinned or muted. Old fibrosis is also noted.	Oriented oval, 4.2 x 3.1 x 0.9 cm, including a central 1.9 x 1.3 cm variegated brown area. The orienting yellow-green pole is indicated 9 o'clock on the requisition and is placed toward 9 o'clock. The submitting office pre-inked the 9-12 o'clock margin red, the 12-3 o'clock margin red, the 3-6 o'clock margin blue, and the 6-9 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and submitted with two sections each in A-E and one section in F. 3 o'clock pole reserved. BY/BY	MALIGNANT MELANOMA. PLEASE CHECK MARGINS.	\N	\N	\N	Upon wider excision, it becomes clear that this melanoma is of the lentigo maligna subtype. There is old scar in part of the dermis, and thus a preceding biopsy from some time ago may have been obtained. The final margin is free but is extremely narrow (1 mm or so) in the 3-6 and 6-9 o'clock quadrants. An updated brief synoptic is included below.  Procedure: wide excision Microscopic tumor type: lentigo maligna melanoma Final Breslow thickness: 0.6 mm Ulceration: not detected Peripheral margin: narrow in 3-6 and 6-9 o'clock quadrants Deep margin: widely free Mitotic index: 1 per square mm Regression: not significant Vascular invasion: not detected Perineural invasion: not detected Pathologic staging (pTNM): pT1a	RESIDUAL MELANOMA OF 0.6 MM IN THICKNESS, FULLY EXCISED (THE FINAL MARGIN APPEARS FREE BUT IS FOCALLY NARROW)	173611	802	\N	\N	21-457	C	LMM-03	Lentigo Maligna Melanoma	IP2011798	AirTable blocks_with_IP_info.csv
2713	21-21304A1	88	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=29812,29813,29814,29815,29816,29817,29818,29819,29820,29821,29822,30986,30987	172.3	\N	\N	Sections show post-procedural fibrosing inflammatory alterations coupled with a broad compound residuum with focal epidermal effacement, deep multifocal adnexal involvement, and a patchy perijunctional lymphohistiocytic infiltrate.	Oriented oval, 4.3 x 3.1 x 0.8 cm, including a central 2.4 x 1.1 cm raised area of variegated color. The orienting single stapled pole is indicated as 12 o'clock on the requisition and placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and entirey submitted with three sections in A1, one section each in A2-A9, and two sections each in A10-A11. BB/BB	A) RIGHT CHEEK LESION - PERMANENT, B) SENTINEL TISSUE - PERMANENT	\N	\N	\N	A broad residuum of lentigo maligna melanoma is apparent in this reexcision specimen, and the final inked margin is involved by melanoma in situ between 1-5 o'clock and again between 7-11 o'clock. The deep margin is free. An updated brief synoptic is included below. Procedure: wide excision with SLNB Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 1.7 mm Ulceration: not detected Peripheral margin: involved Deep margin: free Mitotic index: 2 per square mm Vascular invasion: not detected Perineural invasion: not detected Regression: not significant Pathologic staging (pTNM): pT2aN0Mx	EXTENSIVE RESIDUAL MELANOMA OF 1.7 MM IN THICKNESS, PROMINENTLY INVOLVING THE INKED PERIPHERAL SURGICAL MARGIN	173305	803	\N	\N	21-21304	A1	LMM-04	Lentigo Maligna Melanoma	IP2283785	AirTable blocks_with_IP_info.csv
2716	21-25546B2	88	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.3	\N	\N	Sections show central fibrosing granulation tissue and early scar coupled with a lymphohistiocytic infiltrate, and no evidence of an atypical melanocytic proliferation remains in contiguity with this.	Oriented oval measuring 4.2 x 0.5 x 0.6 cm. The orienting pre-inked blue edge is indicated true margin on the requisition and is placed toward 12-3-6 o'clock. The submitting clinician pre-inked the 12-3-6 o'clock margin blue and the grosser inked 6-9-12 o'clock edge yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and entirely submitted with seven sections each in B1-B2 and six sections in B3. BY/BY	A) RIGHT CHEEK LESION, SUPERIOR MEDIAL MARGIN, TRUE MARGIN IS INKED (PERMANENT), B) RIGHT CHEEK LESION, INFERIOR MEDIAL MARGIN, TRUE MARGIN IS INKED (PERMANENT), C) RIGHT CHEEK LESION, INFERIOR LATERAL MARGIN, TRUE MARGIN IS INKED (PERMANENT), D) RIGHT CHEEK LESION, SUPERIOR LATERAL MARGIN, TRUE MARGIN IS INKED (PERMANENT)	\N	\N	\N	\N	POST-BIOPSY SCARRING, WITH NO EVIDENCE OF RESIDUAL MELANOMA	173305	803	\N	\N	21-25546	B2	LMM-04	Lentigo Maligna Melanoma	IP2283785	AirTable blocks_with_IP_info.csv
2714	21-21304A10	88	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=29812,29813,29814,29815,29816,29817,29818,29819,29820,29821,29822,30986,30987	172.3	\N	\N	Sections show post-procedural fibrosing inflammatory alterations coupled with a broad compound residuum with focal epidermal effacement, deep multifocal adnexal involvement, and a patchy perijunctional lymphohistiocytic infiltrate.	Oriented oval, 4.3 x 3.1 x 0.8 cm, including a central 2.4 x 1.1 cm raised area of variegated color. The orienting single stapled pole is indicated as 12 o'clock on the requisition and placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and entirey submitted with three sections in A1, one section each in A2-A9, and two sections each in A10-A11. BB/BB	A) RIGHT CHEEK LESION - PERMANENT, B) SENTINEL TISSUE - PERMANENT	\N	\N	\N	A broad residuum of lentigo maligna melanoma is apparent in this reexcision specimen, and the final inked margin is involved by melanoma in situ between 1-5 o'clock and again between 7-11 o'clock. The deep margin is free. An updated brief synoptic is included below. Procedure: wide excision with SLNB Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 1.7 mm Ulceration: not detected Peripheral margin: involved Deep margin: free Mitotic index: 2 per square mm Vascular invasion: not detected Perineural invasion: not detected Regression: not significant Pathologic staging (pTNM): pT2aN0Mx	EXTENSIVE RESIDUAL MELANOMA OF 1.7 MM IN THICKNESS, PROMINENTLY INVOLVING THE INKED PERIPHERAL SURGICAL MARGIN	173305	803	\N	\N	21-21304	A10	LMM-04	Lentigo Maligna Melanoma	IP2283785	AirTable blocks_with_IP_info.csv
10383	K1_10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2588	20-6751	90	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.3	\N	\N	Sections show a broad and poorly circumscribed proliferation melanocytes, with a peripheral portion composed of mostly solitary melanocytes, with a few small nests, irregularly distributed within the basal layer of the epidermis above a dermis that shows severe solar elastosis.  Some melanocytes have atypical nuclei, abundant, pale cytoplasm or both. There are progressively larger and more confluent junctional nests toward the center of the lesion. There are large nests of similar melanocytes in the dermis, with mitotic figures among their cells, and little maturation and dispersion with descent.	Oriented ellipse, 4.8 x 1.1 x 0.2 cm, including a central 0.7 x 0.6 cm crusted area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and submitted with eight sections. Tips reserved. BY/BY	A) MALIGNANT MELANOMA IN SITU. . PLEASE CHECK MARGINS (PHOTO)	\N	\N	FFPE	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: biopsy Microscopic tumor type: melanoma in skin with high cumulative sun damage (WHO classification) Breslow thickness: 1.4 mm. Ulceration: no Margins, peripheral: involved, and deep: clear by < 1 mm. Mitotic index: 4/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT2a pNX	MELANOMA, 1.4 MM. IN THICKNESS	173304	808	\N	\N	20-6751	\N	LMM-09	Lentigo Maligna Melanoma	IP2097439	AirTable blocks_with_IP_info.csv
2830	22-91699A1	94	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=28283,28284,28285,28286,28287,28288,28289	172.6	\N	\N	Sections show inflammation and granulation tissue, flanked by a proliferation of melanocytes arrayed irregularly along the junctional zone. Centrally, the epidermis is effaced above a nodular proliferation of atypical melanocytes. The dermis displays marked solar elastosis.	Oriented ellipse, 5.7 x 2.4 x 1.1 cm, including a central 1.2 x 1.2 cm raised area. The orienting short sutured tip is indicated 12 o'clock on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with two sections in A1, one section each in A2-A5, and two sections in A6. Subsequently, the 12 o'clock tip is serially sectioned and four sections, adjacent to those in block A1, are submitted in A7. Tips reserved. KB/KB	A) LEFT ARM WIDE EXCISION MELANOMA - PERMANENT, B) LEFT UPPER ARM SKIN LESION - PERMANENT, C) LEFT ARM WIDE EXCISION; R/O SQUAMOUS CELL CARCINOMA - PERMANENT	\N	\N	\N	In this excisional biopsy, there is a component of lentiginous melanoma in situ. Procedure: excision Microscopic tumor type: high-CSD melanoma Breslow thickness: 4.9 mm Ulceration: present Margins, peripheral and deep: free Mitotic index: 2/mm2 Microsatellitosis: not identified Vascular invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT4b	HEALING BIOPSY SITE, WITH RESIDUAL MELANOMA OF 4.9 MM IN THICKNESS, FULLY EXCISED (THE FINAL MARGIN APPEARS FREE OF MELANOMA)	173601	804	\N	\N	22-91699	A1	LMM-05	Lentigo Maligna Melanoma	IP1692985	AirTable blocks_with_IP_info.csv
2831	22-91699A4	94	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=28283,28284,28285,28286,28287,28288,28289	172.6	\N	\N	Sections show inflammation and granulation tissue, flanked by a proliferation of melanocytes arrayed irregularly along the junctional zone. Centrally, the epidermis is effaced above a nodular proliferation of atypical melanocytes. The dermis displays marked solar elastosis.	Oriented ellipse, 5.7 x 2.4 x 1.1 cm, including a central 1.2 x 1.2 cm raised area. The orienting short sutured tip is indicated 12 o'clock on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with two sections in A1, one section each in A2-A5, and two sections in A6. Subsequently, the 12 o'clock tip is serially sectioned and four sections, adjacent to those in block A1, are submitted in A7. Tips reserved. KB/KB	A) LEFT ARM WIDE EXCISION MELANOMA - PERMANENT, B) LEFT UPPER ARM SKIN LESION - PERMANENT, C) LEFT ARM WIDE EXCISION; R/O SQUAMOUS CELL CARCINOMA - PERMANENT	\N	\N	\N	In this excisional biopsy, there is a component of lentiginous melanoma in situ. Procedure: excision Microscopic tumor type: high-CSD melanoma Breslow thickness: 4.9 mm Ulceration: present Margins, peripheral and deep: free Mitotic index: 2/mm2 Microsatellitosis: not identified Vascular invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT4b	HEALING BIOPSY SITE, WITH RESIDUAL MELANOMA OF 4.9 MM IN THICKNESS, FULLY EXCISED (THE FINAL MARGIN APPEARS FREE OF MELANOMA)	173601	804	\N	\N	22-91699	A4	LMM-05	Lentigo Maligna Melanoma	IP1692985	AirTable blocks_with_IP_info.csv
2792	22-29280	60	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show central iatrogenic fibrosing inflammatory alterations stemming from a procedure, and no evidence of an atypical melanocytic proliferation remains in contiguity with this.	Ellipse, 7.9 x 2.4 x 0.8 cm, including a central 1.0 x 0.8 cm pink area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and submitted with two sections each in 1-4. Tips reserved. BY/BY	0.9 X 1.0 MACULE PREVIOUSLY BIOPSIED & CONSISTENT WITH MELANOMA, 0.6 MM BRESLOW, HER FOR EXCISION, PLEASE CHECK MARGINS (TELEPHONE: 415-867-0936)	\N	\N	\N	Final synoptic melanoma reporting, including information derived from the earlier specimen from this site, is included below. Procedure: excision Microscopic tumor type: low cumulative sun-damaged skin (WHO) Breslow thickness: 0.6 mm Ulceration: absent Margins, peripheral and deep: negative for melanoma Mitotic index (per square millimeter): 0 Vascular invasion: not identified Regression: not identified Pathologic staging (pTNM): pT1a pNX	POST-BIOPSY SCARRING, WITH NO EVIDENCE OF RESIDUAL MELANOMA	173532	806	\N	\N	22-29280	\N	LMM-07	Lentigo Maligna Melanoma	IP2399198	AirTable blocks_with_IP_info.csv
2765	21-135927	60	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a proliferation of nested and solitary melanocytes, some of which have atypical nuclei, irregularly distributed above elastosis.  Clusters of similar melanocytes are present in the dermis.	Skin segment measuring 1.2 x 1.0 x 0.1 cm, quadrisected, and entirely submitted. HD/HD	EVOLVING 8 CM IRREGULAR PAPULE RETICULAR & ERYTHEMATOUS PAPULE; R/O ATYPIA, HISTORY OF MM (TELEPHONE: 415-867-0936, MSG OK)	\N	\N	\N	Procedure: shave biopsy Microscopic tumor type: low cumulative sun-damaged skin (WHO) Breslow thickness: 0.6 mm Ulceration: absent Margins, peripheral and deep: melanoma in situ within 1 mm of the peripheral tissue edge; deep tissue edge free Mitotic index (per square millimeter): 0 Vascular invasion: not identified Regression: not identified Pathologic staging (pTNM): pT1a	INVASIVE MELANOMA, BRESLOW THICKNESS 0.6 mm, NON-ULCERATED	187724	806	\N	\N	21-135927	\N	LMM-07	Lentigo Maligna Melanoma	IP2399198	AirTable blocks_with_IP_info.csv
1376	10-10275 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	932	\N	\N	None	\N	MD-26	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2667	20-102366B1	95	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	172.4	\N	\N	Sections show a proliferation of nested and solitary melanocytes, which have atypical enlarged nuclei with conspicuous nucleoli, irregularly distributed above elastosis with melanin pigmentation.  Sheets of similar melanocytes efface the underlying dermis.	Two oval excisions received in vial. One measures 2.5 x 1.6 x 0.4 cm, including a central 1.4 x 1.0 cm raised area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections each in B1-B2. The other measures 1.3 x 0.8 x 0.2 cm. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections in B3. BY/CF	A-B) SKIN CANCER	\N	\N	FFPE	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: excisional biopsy Tumor site: right frontal scalp Microscopic tumor type: high cumulative sun damage Breslow thickness: at least 4.7 mm Ulceration: not identified Margins, peripheral and deep: invasive melanoma present peripheral and deep tissue edge; melanoma in situ extends to the peripheral tissue edge Mitotic index (per square millimeter): 17 Microsatellitosis: not identified Vascular Invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT4a pNX	INVASIVE MELANOMA, BRESLOW THICKNESS AT LEAST 4.7 mm, NON-ULCERATED; INVASIVE MELANOMA PRESENT AT DEEP AND PERIPHERAL TISSUE EDGES	146466	807	\N	\N	20-102366	B1	LMM-08	Lentigo Maligna Melanoma	IP115267	AirTable blocks_with_IP_info.csv
2668	20-102366B2	95	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	172.4	\N	\N	Sections show a proliferation of nested and solitary melanocytes, which have atypical enlarged nuclei with conspicuous nucleoli, irregularly distributed above elastosis with melanin pigmentation.  Sheets of similar melanocytes efface the underlying dermis.	Two oval excisions received in vial. One measures 2.5 x 1.6 x 0.4 cm, including a central 1.4 x 1.0 cm raised area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections each in B1-B2. The other measures 1.3 x 0.8 x 0.2 cm. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with six sections in B3. BY/CF	A-B) SKIN CANCER	\N	\N	FFPE	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: excisional biopsy Tumor site: right frontal scalp Microscopic tumor type: high cumulative sun damage Breslow thickness: at least 4.7 mm Ulceration: not identified Margins, peripheral and deep: invasive melanoma present peripheral and deep tissue edge; melanoma in situ extends to the peripheral tissue edge Mitotic index (per square millimeter): 17 Microsatellitosis: not identified Vascular Invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT4a pNX	INVASIVE MELANOMA, BRESLOW THICKNESS AT LEAST 4.7 mm, NON-ULCERATED; INVASIVE MELANOMA PRESENT AT DEEP AND PERIPHERAL TISSUE EDGES	146466	807	\N	\N	20-102366	B2	LMM-08	Lentigo Maligna Melanoma	IP115267	AirTable blocks_with_IP_info.csv
2343	18-83370A	55	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	172.4	\N	\N	Sections show a broad and poorly circumscribed proliferation of mostly solitary melanocytes, with a few large nests, irregularly distributed within the basal layer of the epidermis above a dermis that shows severe solar elastosis.  Some melanocytes have atypical nuclei, abundant, pale cytoplasm or both. There are rounded nests of similar melanocytes in the superficial and mid- dermis.	Oriented ellipse, 2.0 x 0.8 x 0.5 cm, including a central 1.0 x 0.6 cm brown patch. The orienting sutured tip is indicated 12 o'clock on the requisition and is placed toward 12 o'clock. The 12-3-6 o'clock margin is inked blue and the 6-9-12 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and entirely submitted with four sections each in A-B. BY/BY	A) IRREGULAR TAN, GREYISH BROWN AND PINK CM PATCH WITH SUPERIOR MORE SEBORRHEIC KERATOSIS LIKE WAXY TAN PAPULE WITH HORN CYSTS. POSSIBLE COLLISION TUMOR CONSTITUTED BY SEBORRHEIC KERATOSIS AND MALIGNANT MELANOMA. PATIENT WITH STRONG FAMILY HISTORY OF MALIGNANT MELANOMA, INCLUDING YOUNG ONSET STAGE III MELANOMA IN HIS MOTHER; MALIGNANT MELANOMA SUTURE TAGGED 12 O'CLOCK, SUPERIOR ASPECT.	\N	\N	FFPE	Areas of melanoma in situ either extend to the margins, or to within less than 1 mm. of the margins flanking the biopsy site. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: excisional biopsy Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 1.3 mm. Ulceration: no Margins, peripheral: involved by melanoma in situ, and deep: clear Mitotic index: 0/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT2a pNX	MELANOMA, 1.3 MM. IN THICKNESS	172438	809	\N	\N	18-83370	A	LMM-10	Lentigo Maligna Melanoma	IP1469433	AirTable blocks_with_IP_info.csv
2344	18-83370B	55	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.4	\N	\N	Sections show a broad and poorly circumscribed proliferation of mostly solitary melanocytes, with a few large nests, irregularly distributed within the basal layer of the epidermis above a dermis that shows severe solar elastosis.  Some melanocytes have atypical nuclei, abundant, pale cytoplasm or both. There are rounded nests of similar melanocytes in the superficial and mid- dermis.	Oriented ellipse, 2.0 x 0.8 x 0.5 cm, including a central 1.0 x 0.6 cm brown patch. The orienting sutured tip is indicated 12 o'clock on the requisition and is placed toward 12 o'clock. The 12-3-6 o'clock margin is inked blue and the 6-9-12 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and entirely submitted with four sections each in A-B. BY/BY	A) IRREGULAR TAN, GREYISH BROWN AND PINK CM PATCH WITH SUPERIOR MORE SEBORRHEIC KERATOSIS LIKE WAXY TAN PAPULE WITH HORN CYSTS. POSSIBLE COLLISION TUMOR CONSTITUTED BY SEBORRHEIC KERATOSIS AND MALIGNANT MELANOMA. PATIENT WITH STRONG FAMILY HISTORY OF MALIGNANT MELANOMA, INCLUDING YOUNG ONSET STAGE III MELANOMA IN HIS MOTHER; MALIGNANT MELANOMA SUTURE TAGGED 12 O'CLOCK, SUPERIOR ASPECT.	\N	\N	FFPE	Areas of melanoma in situ either extend to the margins, or to within less than 1 mm. of the margins flanking the biopsy site. Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: excisional biopsy Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 1.3 mm. Ulceration: no Margins, peripheral: involved by melanoma in situ, and deep: clear Mitotic index: 0/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT2a pNX	MELANOMA, 1.3 MM. IN THICKNESS	172438	809	\N	\N	18-83370	B	LMM-10	Lentigo Maligna Melanoma	IP1469433	AirTable blocks_with_IP_info.csv
1823	15-0176A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-0; BOX-11	\N	\N	\N	\N	\N	\N	\N	\N	metastatic lymph node	FFPE	\N	\N	\N	70	\N	\N	15-176	A1	AM2-100	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2288	18-12160D	76	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.4	\N	\N	Sections show a broad and poorly circumscribed proliferation of solitary melanocytes, with small but variably confluent nests, irregularly distributed within the basal layer of the epidermis above a dermis that shows severe solar elastosis.  Some intraepidermal melanocytes have atypical nuclei. There are very large masses of melanocytes with a greater degree of nuclear pleomorphism in the dermis and subcutis, with a high mitotic rate and a lack of maturation and dispersion with descent.	Oriented ellipse, 4.9 x 2.3 x 0.9 cm, including a central 3.0 x 2.2 cm variegated black-blue area. With the orienting sutured tip placed to the left and designated 12 o'clock by the grosser, the 12-3-6 o'clock margin is inked blue and the 6-9-12 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and submitted with four sections in A and two sections each in B-F. Tips reserved. HD/PL	PLAQUE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. SEBORRHEIC KERATOSIS, SEVERAL MONTH H/O GROWING BLACK/BLUE IRREGULAR 2.7 X 2.0 CM PLAQUE, SUBMITTED NOW AS EXCISIONAL BIOPSY, R/O MELANOMA	\N	\N	FFPE	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: excisional biopsy Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 6.8 mm. Ulceration: no Margins, peripheral: clear by < 1 mm., and deep: clear by 2 mm. Mitotic index: 10/mm2 Microsatellitosis: present Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT4a pNX  A very large microsatellite is present and included in the thickness measurement.	MELANOMA, 6.8 MM. IN THICKNESS	173410	810	\N	\N	18-12160	D	LMM-11	Lentigo Maligna Melanoma	IP1875716	AirTable blocks_with_IP_info.csv
2290	18-12160F	76	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.4	\N	\N	Sections show a broad and poorly circumscribed proliferation of solitary melanocytes, with small but variably confluent nests, irregularly distributed within the basal layer of the epidermis above a dermis that shows severe solar elastosis.  Some intraepidermal melanocytes have atypical nuclei. There are very large masses of melanocytes with a greater degree of nuclear pleomorphism in the dermis and subcutis, with a high mitotic rate and a lack of maturation and dispersion with descent.	Oriented ellipse, 4.9 x 2.3 x 0.9 cm, including a central 3.0 x 2.2 cm variegated black-blue area. With the orienting sutured tip placed to the left and designated 12 o'clock by the grosser, the 12-3-6 o'clock margin is inked blue and the 6-9-12 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and submitted with four sections in A and two sections each in B-F. Tips reserved. HD/PL	PLAQUE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. SEBORRHEIC KERATOSIS, SEVERAL MONTH H/O GROWING BLACK/BLUE IRREGULAR 2.7 X 2.0 CM PLAQUE, SUBMITTED NOW AS EXCISIONAL BIOPSY, R/O MELANOMA	\N	\N	FFPE	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: excisional biopsy Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 6.8 mm. Ulceration: no Margins, peripheral: clear by < 1 mm., and deep: clear by 2 mm. Mitotic index: 10/mm2 Microsatellitosis: present Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT4a pNX  A very large microsatellite is present and included in the thickness measurement.	MELANOMA, 6.8 MM. IN THICKNESS	173410	810	\N	\N	18-12160	F	LMM-11	Lentigo Maligna Melanoma	IP1875716	AirTable blocks_with_IP_info.csv
3545	Mel290	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	906	\N	\N	None	\N	MC-04	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
2734	21-83029A	83	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	172.0	\N	\N	Sections show a broad and poorly circumscribed proliferation of mostly solitary melanocytes, with some confluent nests, irregularly distributed within the basal layer of the epidermis above a dermis that shows severe solar elastosis.  Some melanocytes have atypical nuclei, abundant, pale cytoplasm or both. There are sheets of similar melanocytes in the dermis in several areas, without appropriate maturation and dispersion with descent.	Oval excision measuring 2.0 x 1.7 x 0.7 cm, including a central 0.8 x 0.8 cm white-gray area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections each in A-B. CF/KB	MELANOMA, PLEASE CHECK MARGINS	\N	\N	FFPE	ADDENDUM, August 17, 2021: Per our telephone discussion, I had not realized that this is a re-excision of a prior biopsy that showed a melanoma that was 2.5 mm in thickness. That thickness is significantly greater than the thickness seen in the residuum. I have revised the diagnosis above to reflect this, and amended the synoptic data below, after reviewing the previous report, and re-reviewing the slides.  Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: re-excision Microscopic tumor type: melanoma in skin with high cumulative sun damage (WHO classification) Breslow thickness: 2.5 mm Ulceration: no Margins, peripheral: involved by melanoma in situ, and deep: clear Mitotic index: 1/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT3a pNX	BIOPSY SITE AND RESIDUAL MELANOMA, SEE COMMENT RE THICKNESS	101038	811	\N	\N	21-83029	A	LMM-12	Lentigo Maligna Melanoma	IP1380659	AirTable blocks_with_IP_info.csv
2835	22-94741	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	811	\N	\N	22-94741	\N	LMM-12	Lentigo Maligna Melanoma	\N	AirTable blocks_with_IP_info.csv
1964	16-77392	36	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	238.2	\N	\N	A shave biopsy demonstrates a compound proliferation of large epithelioid and fusiform melanocytes with pale pigmented cytoplasm. These cells are distributed in giant nests and fascicles that are stuffed in dermal papillae below a thinned epidermis, and interstitial cords and fascicles of similar melanocytes extend in badly-circumscribed fashion in the dermis below this. A patchy infiltrate of lymphocytes and melanophages is present concurrently. Scattered cells in mitosis are identifiable, and some of these have been marked within the submitted slides.	One outside slide, JS-16-43216-A1. One block received 8-18-16.	IMPRESSION WAS DERMATOFIBROMA VS. VASCULAR VS. ATYPICAL NEVUS	\N	\N	\N	As has been clear from prior reporting of this case, this specimen does not contain any type of conventional melanocytic nevus. Rather, this tumor shows many histopathologic features that were considered worrisome for nevoid melanoma with pseudomaturation. The gargantuan nests of melanocytes that are present superficially and the elevated mitotic index are both features that were considered to be of concern. I additionally considered the possibility of an epidermotropic metastasis of melanoma in my differential diagnosis. However, that would only be germane in the context of a patient with an existing history of melanoma and thus can be excluded in the interpretation of this specimen. To add additional diagnostic information, we completed array-based comparative genomic hybridization (aCGH) to screen for chromosomal copy number gain or loss, as can be seen in association with melanoma. After microdissection of tumor followed by extraction of tumoral DNA from the tissue block, application of aCGH revealed gain in chromosome 11p as well as loss in chromone 22q with no other associated genomic gains or losses. Loss in chromosome 22q is a rare molecular finding and is likely of no larger significance. Gain in chromosome 11p has been identified in a subset of Spitz tumors and is highly correlated with underlying HRAS mutation.  In summary, the combination of results derived from conventional microscopy coupled with aCGH suggests that this proliferation represents an HRAS-mutated Spitz tumor rather than a frank melanoma. What is unusual about this case is that the microscopic findings are quite different from most examples of that entity. With that said, the molecular findings seem clear cut. Long-term follow-up studies of HRAS-mutated Spitz tumors suggests that they are functionally benign and thus are of no larger clinical significance. As the deep edge of this biopsy is involved, conservative reexcision is recommended to be certain that full local removal has been accomplished.  The technical methodology utilized in our aCGH analysis is described in the following reference: McCalmont TH, Vemula S, Sands P, Bastian BC. Molecular-microscopical correlation in dermatopathology. J Cutan Pathol. 2011; 38:323-5. Please note that this citation includes a discussion of an HRAS-mutated tumor with histopathologic findings that are more conventional of this entity, in contrast to the findings seen here.	COMPOUND MELANOCYTIC TUMOR WITH ASSOCIATED GENOMIC GAIN IN CHROMOSOME 11p, FOCALLY INVOLVING THE DEEP EDGE OF THE BIOPSY	173628	709	\N	\N	16-77392	\N	DP-72	CGH Validation	IP1677083	AirTable blocks_with_IP_info.csv
2637	20-50565B1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-17	http://64.54.108.121/eSlideTray.php?ImageIds=32760	\N	\N	6668726	\N	\N	\N	\N	Skin, scalp, frontal, left, biopsy, no evidence of malignancy	FFPE	\N	\N	\N	306	\N	\N	20-50565	B1	CME-004	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2636	20-50565A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-17	http://64.54.108.121/eSlideTray.php?ImageIds=32759	\N	\N	6668726	\N	\N	\N	\N	 Microscopically, section A1 shows a nodule of pigmented ovoid to epithelioid melanocytes with hyperchromatic nuclei in the subcutis. It is consistent with a recurrent or in transit metastatic melanoma. Please correlate with clinical findings.	FFPE	\N	\N	\N	306	\N	\N	20-50565	A1	CME-004	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
3448	K16-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-075-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	45	\N	\N	None	\N	AM2-075	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3449	K16-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-075-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	45	\N	\N	None	\N	AM2-075	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2735	21-83029B	83	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.0	\N	\N	Sections show a broad and poorly circumscribed proliferation of mostly solitary melanocytes, with some confluent nests, irregularly distributed within the basal layer of the epidermis above a dermis that shows severe solar elastosis.  Some melanocytes have atypical nuclei, abundant, pale cytoplasm or both. There are sheets of similar melanocytes in the dermis in several areas, without appropriate maturation and dispersion with descent.	Oval excision measuring 2.0 x 1.7 x 0.7 cm, including a central 0.8 x 0.8 cm white-gray area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with four sections each in A-B. CF/KB	MELANOMA, PLEASE CHECK MARGINS	\N	\N	FFPE	ADDENDUM, August 17, 2021: Per our telephone discussion, I had not realized that this is a re-excision of a prior biopsy that showed a melanoma that was 2.5 mm in thickness. That thickness is significantly greater than the thickness seen in the residuum. I have revised the diagnosis above to reflect this, and amended the synoptic data below, after reviewing the previous report, and re-reviewing the slides.  Features suggested for reporting per the guidelines of the College of American Pathologists include:  Procedure: re-excision Microscopic tumor type: melanoma in skin with high cumulative sun damage (WHO classification) Breslow thickness: 2.5 mm Ulceration: no Margins, peripheral: involved by melanoma in situ, and deep: clear Mitotic index: 1/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT3a pNX	BIOPSY SITE AND RESIDUAL MELANOMA, SEE COMMENT RE THICKNESS	101038	811	\N	\N	21-83029	B	LMM-12	Lentigo Maligna Melanoma	IP1380659	AirTable blocks_with_IP_info.csv
1043	02-05776 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	911	\N	\N	None	\N	MD-05	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1044	02-05776D T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	911	\N	\N	None	\N	MD-05	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2733	21-79845	84	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a proliferation of cells with atypical nuclei and ample cytoplasm arrayed in nodular fashion below a crusted ulceration. There is poor maturation with an uptick in the mitotic index. To the side, there is superficial compound involvement by smaller melanocytes with pagetoid scatter, adnexal extension, and a lymphohistiocytic infiltrate with admixed melanophages.	Skin segment measuring 2.1 x 1.7 x 0.7 cm. Three sections submitted. BY/BY	ULCERATED 2 CM IRREGULAR NODULE / PLAQUE; CANCER FORM  (TELEPHONE: 415-391-7597, MSG OK)	\N	\N	\N	This tissue contain a significantly invasive melanoma with prominent associated adnexal extension. A brief synoptic is included below. Procedure: narrow excision Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 2.7 mm Ulceration: prominent Margin: narrow Mitotic index: 7 per square mm Vascular invasion: not detected Microsatellitosis: not detected Perineural invasion: not detected Regression: present; partial Pathologic staging (pTNM): pT3b	MELANOMA OF 2.7 MM IN THICKNESS	173619	814	\N	\N	21-79845	\N	LMM-15	Lentigo Maligna Melanoma	IP49555	AirTable blocks_with_IP_info.csv
1893	15-98263	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26312	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	760	\N	\N	15-98263	\N	JJS21	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1879	15-50051	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26314	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	761	\N	\N	15-50051	\N	JJS23	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1875	15-48134	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26341	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	762	\N	\N	15-48134	\N	JJS24	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1845	15-12964B	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26315	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	763	\N	\N	15-12964	B	JJS25	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
2916	35_M	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1760	\N	\N	None	\N	SYNAT671	2010-2017	\N	AirTable blocks_with_IP_info.csv
2814	22-76519A	85	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.4	\N	\N	Sections show irregular epidermal hyperplasia with inflamed granulation tissue, but no evidence of an atypical melanocytic proliferation.	Excision measuring 1.8 x 1.2 x 0.4 cm. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with seven sections in A. KB/KB	A) BX PROVEN MIS, THIS IS A DEBULKING SPECIMEN, PERIPHERAL MARGINS TO BE CLEARED WITH MOHS; PLEASE R/O INVASIVE COMPONENT, B) HEMORRHAGIC CRUSTED PAPULE X SEVERAL MONTHS (0.8 X 0.8 CM); SCC VS. ISK VS. MELANOMA VS. PYOGENIC GRANULOMA	\N	\N	\N	Biopsy site changes extend to the edge of this Mohs debulk specimen.	HEALING BIOPSY SITE, WITH NO EVIDENCE OF INVASIVE MELANOMA	173416	814	\N	\N	22-76519	A	LMM-15	Lentigo Maligna Melanoma	IP49555	AirTable blocks_with_IP_info.csv
2777	22-7578	74	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.4	\N	\N	Sections show a broad and poorly circumscribed proliferation of mostly solitary melanocytes, with a few small nests, irregularly distributed within the basal layer of the epidermis above a dermis that shows severe solar elastosis.  Some melanocytes have atypical nuclei. There are nests of similar melanocytes in the dermis.	Skin segment measuring 1.8 x 1.2 x 0.2 cm, serially sectioned and entirely submitted with five sections. KB/KB	MELANOMA VS. SK	\N	\N	\N	Procedure: shave biopsy Microscopic tumor type: high cumulative sun damaged skin Breslow thickness: 0.9 mm Ulceration: absent Margin: peripheral and deep edges of the specimen involved by melanoma in situ (deep edge via adnexal extension), edges are uninvolved by invasive melanoma Mitotic index: 2/mm2 Vascular invasion: absent Regression: absent Pathologic staging (pTNM): pT1b	MELANOMA, 0.9 MM IN THICKNESS	173410	816	\N	\N	22-7578	\N	LMM-17	Lentigo Maligna Melanoma	IP150179	AirTable blocks_with_IP_info.csv
2781	22-15594-4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	816	\N	\N	None	\N	LMM-17	Lentigo Maligna Melanoma	\N	AirTable blocks_with_IP_info.csv
1088	03-26518 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	912	\N	\N	None	\N	MD-06	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1089	03-26518B M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	912	\N	\N	None	\N	MD-06	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1107	04-01809 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	914	\N	\N	None	\N	MD-08	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1108	04-01809E T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	914	\N	\N	None	\N	MD-08	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1113	04-05355 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	915	\N	\N	None	\N	MD-09	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1114	04-05355B T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	915	\N	\N	None	\N	MD-09	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1962	16-74494	89	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.7	\N	\N	Sections show a broad and poorly circumscribed proliferation of melanocytes.  Nests of melanocytes are distributed at irregular intervals along the junctional zone, and are focally confluent.  There are foci in which single melanocytes predominate as well. There are some melanocytes scattered above the basal layer in such areas. The dermis contains aggregates of similar cells displacing solar elastosis.	Skin segment measuring 1.7 x 1.4 x 0.2 cm, serially sectioned and entirely submitted with six sections. RS/RS	NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED SEBORRHEIC KERATOSIS VS. MMIS	\N	\N	\N	A synoptic report of potential prognostic factors is listed below: Procedure: shave biopsy Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 1.6 mm Ulceration: absent Margins, peripheral and deep: deep focally positive, peripheral positive Mitotic index: 1 mm/2 Regression: not identified Perineural invasion: not identified Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT2a	MELANOMA, 1.6 MM IN THICKNESS, NON-ULCERATED	173710	817	\N	\N	16-74494	\N	LMM-18	Lentigo Maligna Melanoma	IP1674137	AirTable blocks_with_IP_info.csv
2186	17-81380B	90	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	173.62	\N	\N	Sections show a focus of fibrosing granulation tissue and an adjacent crateriform, exo-endophytic proliferation of keratinocytes, with a central mass of cornified cells. One part of the lining is composed of cytologically bland keratinocytes that mature through a granular layer. There is fibrosis beneath this portion. Other areas have lobules of keratinocytes with large, vesicular nuclei and abundant, pale eosinophilic cytoplasm.	Ellipse, 3.5 x 1.3 x 0.8 cm, including a central 1.5 x 1.0 m white area. With margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with eight sections in A and seven sections in B. KC/KC	HEALING BX SITE, DDX KERATOACANTHOMA, PLEASE CHECK MARGINS	\N	\N	\N	The neoplasm extends to the base of the specimen. In my opinion, keratoacanthoma is a form of squamous cell carcinoma that involutes in the majority of cases. In this case, part of the lesion shows signs of involution, but part does not. Persistence of a lesion thought to be a keratoacanthoma should trigger re-evaluation.	BIOPSY SITE AND RESIDUAL KERATOACANTHOMA, PARTIALLY INVOLUTED, WITH A RESIDUAL PROLIFERATIVE AREA, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	173611	817	\N	\N	17-81380	B	LMM-18	Lentigo Maligna Melanoma	IP1674137	AirTable blocks_with_IP_info.csv
2867	23-1012A2	85	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	173.62	\N	\N	Sections show central post-procedural fibrosing inflammatory alterations, and no residual atypical keratinocytic proliferation remains in the dermis in contiguity with this. There is solar elastosis.	Ellipse, 3.6 x 1.6 x 0.2 cm, including a central 1.0 x 1.0 cm pink beige area. With the margins inked by the grosser, the specimen is serially sectioned perpendicular to the long axis and submitted with five sections each in A1-A2. Tips reserved. HD/HD	A) SQUAMOUS CELL CARCINOMA. HEALING BX SITE. PLEASE CHECK MARGINS. B) SQUAMOUS CELL CARCINOMA. HEALING BX SITE. PLEASE CHECK MARGINS.	\N	\N	\N	\N	POST-BIOPSY SCARRING, WITH NO EVIDENCE OF RESIDUAL CARCINOMA	113605	818	\N	\N	23-1012	A2	LMM-19	Lentigo Maligna Melanoma	IP2376091	AirTable blocks_with_IP_info.csv
2797	22-38234B	84	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.5	\N	\N	Sections show a broad and poorly circumscribed proliferation of melanocytes.  Nests of melanocytes are distributed at irregular intervals along the junctional zone, and are focally confluent.  There are foci in which single melanocytes predominate as well. There are some melanocytes scattered above the basal layer in such areas. The dermis contains large irregular aggregates of similar melanocytes within inflamed fibrosis. There is a scar in the dermis below, centrally.	Skin segment measuring 1.4 x 0.9 x 0.2 cm, trisected and entirely submitted in B. BY/BY	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA. PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. IRRITATED SEBORRHEIC KERATOSIS VS. MELANOMA. PAPULE.	\N	\N	\N	A brief synoptic is included below. Procedure: biopsy Microscopic tumor type: high-CSD melanoma Breslow thickness: 0.5 mm Ulceration: not detected Margin: intraepidermal melanoma extends to the periphery of the biopsy Mitotic index: 0 Regression: not detected Pathologic staging (pTNM): pT1a	MELANOMA OF 0.5 mm IN THICKNESS	139522	818	\N	\N	22-38234	B	LMM-19	Lentigo Maligna Melanoma	IP2376091	AirTable blocks_with_IP_info.csv
1140	04-28824 T2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	913	\N	\N	None	\N	MD-07	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2273	17-122697A	64	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.1	\N	\N	Sections show skin without evidence of a proliferation of melanocytes along the dermo-epidermal junction.	Oriented excision measuring 1.1 x 0.4 x 0.4 cm. The green pre-inked edge is placed distally to the grosser and indicated as peripheral margin on the requisition form. At grossing, the left half of the peripheral margin is re-inked blue and the right half is re-inked red. The opposite surgical margin is inked black. The specimen is submitted intact in A for en-face sectioning. CF/CF	A-B) SLOW MOHS OF PATH DT17-121515 (SEE PHOTO)	\N	\N	\N	There is no evidence of the melanoma in situ seen at the edge of one of the previous margins. Procedure: re-excision, with slow Mohs' method Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 1.2 mm. Ulceration: no Margins, peripheral: clear, distance not known (best estimated by the clinician, as slow Mohs was performed), and deep: clear by 4 mm. Mitotic index: 3/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT2a pNX	PERIPHERAL MARGIN, NO MELANOMA IN SITU IDENTIFIED	173101	819	\N	\N	17-122697	A	LMM-20	Lentigo Maligna Melanoma	IP1814097	AirTable blocks_with_IP_info.csv
2233	17-111862A	64	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.1	\N	\N	There is a zone of fibrosing granulation tissue, corresponding to the site of a previous biopsy. There is a broad and poorly circumscribed proliferation of mostly solitary melanocytes, with a few small nests, irregularly distributed within the basal layer of the epidermis above a dermis that shows severe solar elastosis.  Some melanocytes have atypical nuclei, abundant, pale cytoplasm or both. There is a narrowly based, dome surfaced area in which similar cells are present in irregularly sized nests in the dermis, with some large nuclei deeply, and scattered mitotic figures among them.	Excision measuring 2.7 x 1.8 x 0.5 cm, six representative sections submitted in A. PL/PL	A) SLOW MOHS OF PATH #DT17-84030 ENFACE, B-H) PERIPHERAL MARGINS INKED IN GREEN (SEE PHOTO)	\N	\N	\N	Most of the surface of this piece is covered by melanoma in situ, with a small area (which would have been a papule, clinically) in which there is invasive melanoma. Features suggested for reporting per the guidelines of the College of American Pathologists, updated from the report of the prior biopsy include:  Procedure: re-excision, with slow Mohs' method Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 1.2 mm. Ulceration: no Margins, peripheral: involved by melanoma in situ, see B and C below, and deep: clear by 4 mm. Mitotic index: 3/mm2 Microsatellitosis: absent Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT2a pNX	BIOPSY SITE AND ADJACENT MELANOMA, 1.2 MM. IN THICKNESS	101109	819	\N	\N	17-111862	A	LMM-20	Lentigo Maligna Melanoma	IP1814097	AirTable blocks_with_IP_info.csv
2899	23-12491	97	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.3	\N	\N	Sections show a zone of fibrosis with an associated lymphohistiocytic infiltrate, representing a prior biopsy/surgical site, flanked by a proliferation of melanocytes in irregular array within the contiguous epidermis.	Oriented oval, 1.7 x 1.5 x 0.3 cm, including a central 0.8 x 0.8 cm scaly area. The orienting pre-inked blue edge is indicated 6-12 and is placed toward 6-9-12 o'clock. The submitting office pre-inked the 6-9-12 o'clock margin blue and the 12-3-6 o'clock margin green. The grosser inked the 3-6-9 o'clock margin black. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and entirely submitted with three sections each in 1-2. BY/BY	MALIGNANT MELANOMA, PLEASE CHECK MARGINS	\N	\N	\N	No residual invasive melanoma was identified. The staging remains the same as reported previously. A synoptic report with information incorporated from the original biopsy is below. There is an incidental seborrheic keratosis. Procedure: re-excision Microscopic tumor type: High cumulative sun-damaged skin Breslow thickness:  1.3 millimeters Ulceration: Not identified Margins: clear Mitotic index: 0/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT2aNxMx	SCAR, WITH RESIDUAL MELANOMA IN SITU, COMPLETELY EXCISED (MARGINS ARE FREE OF MELANOMA)	173316	820	\N	\N	23-12491	\N	LMM-21	Lentigo Maligna Melanoma	IP746083	AirTable blocks_with_IP_info.csv
1887	15-85517	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26316	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	765	\N	\N	15-85517	\N	JJS27	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
2249	17-115571C	39	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	The histopathology is generally similar to that described for specimen A.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in C. HD/HD	A) R/O LENTIGO, 0.6 X 0.6, B-E) R/O COMPOUND NEVUS, 0.6 X 0.6,	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	17723	857	\N	\N	17-115571	C	LN-038	Lentiginous Nevi 	IP1840629	AirTable blocks_with_IP_info.csv
2250	17-115571D	39	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	The histopathology is generally similar to that described for specimen A.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in D. HD/HD	A) R/O LENTIGO, 0.6 X 0.6, B-E) R/O COMPOUND NEVUS, 0.6 X 0.6,	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173799	857	\N	\N	17-115571	D	LN-038	Lentiginous Nevi 	IP1840629	AirTable blocks_with_IP_info.csv
2874	23-3314	97	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.3	\N	\N	Sections show a poorly circumscribed proliferation of melanocytes arranged as single cells and nests within the epidermis and dermis. Within the epidermis, many of the lesional melanocytes are located in pagetoid scatter and single melanocytes predominate over nests in some foci. Similar melanocytes are present in clusters in the underlying dermis and the size of the melanocytes does not diminish with descent into the dermis. Solar elastosis is present in the underlying dermis.	Skin segment measuring 1.0 x 0.8 x 0.1 cm, trisected and entirely submitted. HD/HD	R/O MELANOMA VS. SK	\N	\N	\N	Preliminary synoptic melanoma reporting, based on this partial biopsy, is included below: Procedure: Shave biopsy Microscopic tumor type: High cumulative sun-damaged skin Breslow thickness:  1.3 millimeters, at least Ulceration: Not identified Margins: The melanoma extends to the base and peripheral edge of the specimen Mitotic index: 0/mm2 Microsatellitosis: not identified Vascular invasion: not identified Pathologic staging (pTNM): pT2aNxMx	MELANOMA, AT LEAST 1.3 MILLIMETERS IN THICKNESS, EXTENDING TO THE BASE AND PERIPHERAL EDGE OF THE SPECIMEN	173316	820	\N	\N	23-3314	\N	LMM-21	Lentigo Maligna Melanoma	IP746083	AirTable blocks_with_IP_info.csv
2338	18-69862B	50	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show an array of nested and solitary melanocytes with relatively small nuclei positioned along the sides and bases of elongated rete subjacent to a compact cornified layer that contains melanin. The superficial dermis contains similar cells in small clusters, and also displays an infiltrate of lymphocytes and melanophages.	Skin segment measuring 0.6 x 0.4 x 0.1 cm, bisected and entirely submitted in B. HD/HD	A) ATYPICAL NEVUS. IRREGULAR BROWN MACULE. ATYPICAL LESION, APPEARS SLIGHTLY LARGER COMPARED WITH PREVIOUS PHOTO. B) ATYPICAL NEVUS. IRREGULAR BROWN MACULE.	\N	\N	Scraping	Similar to specimen (A), in specimen (B), a SOX-10 immunoperoxidase stain confirms that most of the intraepidermal melanocytes are within the basal layer of the epidermis. Coupling this staining result with the findings on the routinely-stained section, the features in this biopsy are those of a hypermelanotic lentiginous compound melanocytic nevus.	HYPERMELANOTIC LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	102588	879	\N	\N	18-69862	B	LN-065	Lentiginous Nevi 	IP128042	AirTable blocks_with_IP_info.csv
2337	18-69862A	50	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes with single cells and nests arrayed along the junction at the sides and bases of slender elongated rete. There are similar melanocytes arrayed as nests and cords in the dermis below this. There is solar elastosis in the dermis.	Skin segment measuring 0.7 x 0.6 x 0.1 cm, bisected and entirely submitted in A. HD/HD	A) ATYPICAL NEVUS. IRREGULAR BROWN MACULE. ATYPICAL LESION, APPEARS SLIGHTLY LARGER COMPARED WITH PREVIOUS PHOTO. B) ATYPICAL NEVUS. IRREGULAR BROWN MACULE.	\N	\N	Scraping	In specimen (A), a SOX-10 immunoperoxidase stain highlights that most of the intraepidermal melanocytes are within the basal layer of the epidermis. Coupling this staining result with the findings on the routinely-stained section, I think that the findings in this biopsy represent a lentiginous compound melanocytic nevus. Nonetheless, this benign listed is based in part upon the presumption that the entirety or near entirety of this lesion has been captured by this biopsy, indicating that the lesion at hand is small with good lateral demarcation. If this is instead a partial biopsy of a larger lesion, then the present histopathology may not be fully representative.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	173527	879	\N	\N	18-69862	A	LN-065	Lentiginous Nevi 	IP128042	AirTable blocks_with_IP_info.csv
1726	13-51506A	33	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	709.09	Typical melanotic macule	\N	Sections show basilar hyperpigmentation without evidence of a proliferation of melanocytes.	Seven skin segments ranging in measurement from 0.2 x 0.1 x 0.1 cm to 0.8 x 0.4 x 0.1 cm, with the largest segment bisected, all entirely submitted in A. PL/PL	A-B) R/O LENTIGO MALIGNA	\N	genital mucosa	FFPE	\N	MELANOTIC MACULE	205551	1291	\N	\N	13-51506	A	OM-33	Oral Mucosa Lesions	IP1293509	AirTable blocks_with_IP_info.csv
1727	13-51506B	33	\N	\N	\N	\N	\N	\N	30	0	FFPE	\N	\N	709.09	Typical melanotic macule	\N	The microscopic features are similar to those of (A).	Three skin segments ranging in measurement from 0.4 x 0.2 x 0.1 cm to 1.0 x 0.5 x 0.1 cm, with the largest segment bisected and the remainder intact, all entirely submitted in B. PL/PL	A-B) R/O LENTIGO MALIGNA	\N	genital mucosa	FFPE	Melanotic macules occur at a variety of sites, and consist of basilar hyperpigmentation without a significantly increased number of melanocytes.	MELANOTIC MACULE	135577	1291	\N	\N	13-51506	B	OM-33	Oral Mucosa Lesions	IP1293509	AirTable blocks_with_IP_info.csv
3347	H13.5620/1	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Metastasis	AM2-057_2	\N	\N	\N	\N	TBD	Scraping	\N	\N	\N	28	\N	\N	None	\N	AM2-057	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3344	H09.22183/1	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Primary tumor	AM2-057_1	\N	\N	\N	\N	TBD	Scraping	\N	\N	\N	28	\N	\N	None	\N	AM2-057	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3358	H18.7977	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-058_3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	29	\N	\N	None	\N	AM2-058	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2736	21-89776A	87	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33796	173.52	\N	\N	There is a roughly symmetrical, crateriform proliferation of keratinocytes, with papillations that protrude into the central zone of cornification. Orthokeratotic material predominates centrally. There is a thick lining of keratinocytes, most of which have abundant, pale eosinophilic cytoplasm. The lesional keratinocytes toward the periphery of the neoplasm have larger nuclei and less abundant cytoplasm. A perivascular, patchy lymphocytic infiltrate is present in the dermis.	Oriented ellipse, 2.9 x 1.3 x 0.7 cm, including a central 0.8 x 0.6 cm raised area. The orienting sutured tip is indicated lateral on the requisition. The orienting sutured tip is designated 9 o'clock by the grosser and is placed toward 9 o'clock. The grosser inked the 9-12-3 o'clock margin blue and the 3-6-9 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and submitted with five sections in A and three sections in B. Tips reserved. BY/BY	1 CM X 1 CM HYPERKERATOTIC RED CRUSTED PAPULE; R/O SCC	\N	\N	FFPE	\N	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	174529	767	\N	\N	21-89776	A	KA-01	Keratoacanthoma	IP2352756	AirTable blocks_with_IP_info.csv
2737	21-89776B	87	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33797	173.52	\N	\N	There is a roughly symmetrical, crateriform proliferation of keratinocytes, with papillations that protrude into the central zone of cornification. Orthokeratotic material predominates centrally. There is a thick lining of keratinocytes, most of which have abundant, pale eosinophilic cytoplasm. The lesional keratinocytes toward the periphery of the neoplasm have larger nuclei and less abundant cytoplasm. A perivascular, patchy lymphocytic infiltrate is present in the dermis.	Oriented ellipse, 2.9 x 1.3 x 0.7 cm, including a central 0.8 x 0.6 cm raised area. The orienting sutured tip is indicated lateral on the requisition. The orienting sutured tip is designated 9 o'clock by the grosser and is placed toward 9 o'clock. The grosser inked the 9-12-3 o'clock margin blue and the 3-6-9 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and submitted with five sections in A and three sections in B. Tips reserved. BY/BY	1 CM X 1 CM HYPERKERATOTIC RED CRUSTED PAPULE; R/O SCC	\N	\N	FFPE	None	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	174529	767	\N	\N	21-89776	B	KA-01	Keratoacanthoma	IP2352756	AirTable blocks_with_IP_info.csv
11249	Sample_KAM84-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
3353	H15.5120/1	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Primary tumor	AM2-058_1, no matched normal	\N	\N	\N	\N	TBD	Scraping	\N	\N	\N	29	\N	\N	None	\N	AM2-058	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3357	H16.5818/2	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Metastasis	AM2-058_2	\N	\N	\N	\N	TBD	Scraping	\N	\N	\N	29	\N	\N	None	\N	AM2-058	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3351	H14.26934/2	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Primary tumor	AM2-059_1	\N	\N	\N	\N	TBD	Scraping	\N	\N	\N	30	\N	\N	None	\N	AM2-059	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3363	HS17.35/2	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Metastasis	AM2-059_2	\N	\N	\N	\N	TBD	Scraping	\N	\N	\N	30	\N	\N	None	\N	AM2-059	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3354	H15.19121/7	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Primary tumor	AM2-060_1	\N	\N	\N	\N	TBD	Scraping	\N	\N	\N	31	\N	\N	None	\N	AM2-060	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3356	H16.872/2	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Metastasis	AM2-060_2	\N	\N	\N	\N	TBD	Scraping	\N	\N	\N	31	\N	\N	None	\N	AM2-060	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3410	K3-C	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Metastasis	AM2-061_3, microdissected	\N	\N	\N	\N	Lymph node metastasis	Scraping	\N	\N	\N	32	\N	\N	None	\N	AM2-061	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3411	K3-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Normal	AM2-061_1	\N	\N	\N	\N	Normal lymphocyte	Scraping	\N	\N	\N	32	\N	\N	None	\N	AM2-061	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3409	K3-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Mel 1	AM2-061_2	\N	\N	\N	\N	Melanoma in-situ and invasive melanoma components	Scraping	\N	\N	\N	32	\N	\N	None	\N	AM2-061	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3413	K4-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Mel 2	AM2-062_3	\N	\N	\N	\N	Invasive primary	Scraping	\N	\N	\N	33	\N	\N	None	\N	AM2-062	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3415	K4-C-2	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	\N	\N	\N	AM2-062-5	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	33	\N	\N	None	\N	AM2-062	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3416	K4-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Normal	AM2-062_1	\N	\N	\N	\N	Normal skin	Scraping	\N	\N	\N	33	\N	\N	None	\N	AM2-062	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3414	K4-C	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	Metastasis	AM2-062_4, microdissected	\N	\N	\N	\N	Metastasis, unknown location. Necrotic and ulcerated	Scraping	\N	\N	\N	33	\N	\N	None	\N	AM2-062	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1464	11-23681C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	740	\N	\N	11-23681	C	JJS1	2010-2017	\N	AirTable blocks_with_IP_info.csv
1463	11-23681B	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26308,26292	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	740	\N	\N	11-23681	B	JJS1	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1461	11-23681	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 MELANOMA, 5.5 MILLIMETERS IN THICKNESS ARISING IN ASSOCIATION WITH A MELANOMA, 5.5 MILLIMETERS IN THICKNESS ARISING IN ASSOCIATION WITH A MELANOCYTIC NEVUS	\N	\N	\N	\N	740	\N	\N	11-23681	\N	JJS1	2010-2017	\N	AirTable blocks_with_IP_info.csv
1462	11-23681A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26294	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	740	\N	\N	11-23681	A	JJS1	2010-2017	\N	AirTable blocks_with_IP_info.csv
2480	19-109646	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	DPN-mm	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	736	\N	\N	19-109646	\N	DPN-02	Deep Penetrating Melanoma	\N	AirTable blocks_with_IP_info.csv
1484	11-37533B	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26293,26318,26319	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	742	\N	\N	11-37533	B	JJS3	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1644	12-051311	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	DPN-mm	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	737	\N	\N	12-51311	\N	DPN-03	Deep Penetrating Melanoma	\N	AirTable blocks_with_IP_info.csv
2314	18-31431	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	DPN-mm	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	738	\N	\N	18-31431	\N	DPN-05	Deep Penetrating Melanoma	\N	AirTable blocks_with_IP_info.csv
1411	10-57426	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	DPN-mm	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	739	\N	\N	10-57426	\N	DPN-06	Deep Penetrating Melanoma	\N	AirTable blocks_with_IP_info.csv
1605	12-21993I	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	747	\N	\N	12-21993	I	JJS8	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1604	12-21993C	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26323	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	747	\N	\N	12-21993	C	JJS8	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1471	11-29719	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26309	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	741	\N	\N	11-29719	\N	JJS2	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1657	12-67568B	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26295,26296	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	749	\N	\N	12-67568	B	JJS10	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1656	12-67568A	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26295,26296	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	749	\N	\N	12-67568	A	JJS10	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1650	12-57349C	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26297,26326	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	750	\N	\N	12-57349	C	JJS11	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
1651	12-57349E	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=26297,26326	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	750	\N	\N	12-57349	E	JJS11	Melanoma Evolution	\N	AirTable blocks_with_IP_info.csv
3412	K4-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	MIS2	AM2-062_2	\N	\N	\N	\N	Melanoma in-situ	Scraping	\N	\N	\N	33	\N	\N	None	\N	AM2-062	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3418	K5-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-063_2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	34	\N	\N	None	\N	AM2-063	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3417	K5-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-063_1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	34	\N	\N	None	\N	AM2-063	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3420	K6-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-065-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	35	\N	\N	None	\N	AM2-065	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3419	K6-A-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-065-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	35	\N	\N	None	\N	AM2-065	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3421	K7-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-066-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	36	\N	\N	None	\N	AM2-066	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3422	K7-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-066-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	36	\N	\N	None	\N	AM2-066	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3424	K7-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-066-3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	36	\N	\N	None	\N	AM2-066	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3423	K7-B-2	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	\N	\N	\N	AM2-066-4	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	36	\N	\N	None	\N	AM2-066	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3426	K8-B	\N	\N	\N	\N	\N	\N	\N	5	0	FFPE	\N	\N	\N	\N	AM2-067-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	37	\N	\N	None	\N	AM2-067	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3425	K8-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-067-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	37	\N	\N	None	\N	AM2-067	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3429	K9-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-068-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	38	\N	\N	None	\N	AM2-068	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3428	K9-C	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-068-3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	38	\N	\N	None	\N	AM2-068	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3427	K9-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-068-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	38	\N	\N	None	\N	AM2-068	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2806	22-52528-1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33800	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	769	\N	\N	None	\N	KA-03	Keratoacanthoma	\N	AirTable blocks_with_IP_info.csv
2807	22-52528-2	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33801	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	769	\N	\N	None	\N	KA-03	Keratoacanthoma	\N	AirTable blocks_with_IP_info.csv
2848	22-105120-1	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33802	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	770	\N	\N	None	\N	KA-04	Keratoacanthoma	\N	AirTable blocks_with_IP_info.csv
2849	22-105120-2	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33803	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	770	\N	\N	None	\N	KA-04	Keratoacanthoma	\N	AirTable blocks_with_IP_info.csv
3430	K10-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-069-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	39	\N	\N	None	\N	AM2-069	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2655	20-82651C	97	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33777	173.62	\N	\N	Section show a mostly endophytic neoplasm of keratinocytes, some of which have abundant pale cytoplasm, with nuclear atypia being more pronounced at the peripheries of lobules.	Oriented ellipse measuring 5.8 x 2.3 x 2.1 cm, including a central 1.7 x 1.6 cm raised crusted area. The orienting blue dye at one tip is indicated 12 o'clock (upper pole) on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin black and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with three sections in A, one each in B-D, and three in E. Tips reserved. CF/CF	DDX: KERATOACANTHOMA	\N	\N	FFPE	None	SQUAMOUS CELL CARCINOMA, KERATOACANTHOMA TYPE, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM).	222611	771	\N	\N	20-82651	C	KA-05	Keratoacanthoma	IP2230518	AirTable blocks_with_IP_info.csv
10860	S13-12947A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Patient Melanoma  	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10642	T06-6855	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2608	20-18514A	80	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33786	173.62	\N	\N	Sections show a lobular and crateriform proliferation of keratinocytes, in large part composed of cells with abundant pale pink cytoplasm. Elastotic fibers are evident between the keratinocytes near the periphery. Nuclear atypicality is most pronounced in the most peripheral keratinocytes. There is a surrounding infiltrate of lymphocytes and granulocytes.	Elliptical excision, 3.6 x 1.7 x 1.1 cm, including a central 2.1 x 1.5 cm raised area. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with five sections in A, three in B, and five in C. CF/CF	MORPHOLOGY: ERYTHEMATOUS TENDER NODULE WITH HYPERKERATOTIC SCALE, DDX: SQUAMOUS CELL CARCINOMA	\N	\N	FFPE	\N	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	173622	774	\N	\N	20-18514	A	KA-08	Keratoacanthoma	IP2166036	AirTable blocks_with_IP_info.csv
2666	20-98774D	51	\N	\N	\N	None	None	None	10	\N	FFPE	\N	http://64.54.108.121/eSlideTray.php?ImageIds=33792	173.62	\N	\N	There is a roughly symmetrical, crateriform proliferation of keratinocytes, with papillations that protrude into the central zone of cornification. Orthokeratotic material predominates centrally. There is a thick lining of keratinocytes, most of which have abundant, pale eosinophilic cytoplasm. The lesional keratinocytes toward the periphery of the neoplasm have larger nuclei and less abundant cytoplasm.	Oriented ellipse, 4.5 x 1.8 x 1.4 cm, including a central 1.5 x 1.5 cm elevated area. The orienting notched tip is indicated superior on the requisition and is designated 12 o'clock by the grosser. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with three sections in A, two sections each in B-C, and three sections in D. Tips reserved. HD/KB	MORPHOLOGY: ERYTHEMATOUS TENDER NODULE WITH CENTRAL KERATIN PLUG, DDX: KERATOACANTHOMA, NOTES: PLEASE CHECK MARGINS	\N	\N	FFPE	None	KERATOACANTHOMA, COMPLETELY EXCISED (MARGINS FREE OF NEOPLASM)	173620	775	\N	\N	20-98774	D	KA-09	Keratoacanthoma	IP2246722	AirTable blocks_with_IP_info.csv
3431	K10-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-069-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	39	\N	\N	None	\N	AM2-069	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3432	K10-C	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-069-4	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	39	\N	\N	None	\N	AM2-069	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3433	K10-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-069-3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	39	\N	\N	None	\N	AM2-069	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3435	K11-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-070-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	40	\N	\N	None	\N	AM2-070	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
10479	12_M	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter, Desmoplastic Melanoma Amplicon Sequence	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
1444	11-5482	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	778	\N	\N	11-5482	\N	KF-05	Fusion RNA	\N	AirTable blocks_with_IP_info.csv
1558	12-4251	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	776	\N	\N	12-4251	\N	KF-01	Fusion RNA	\N	AirTable blocks_with_IP_info.csv
3436	K11-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-070-3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	40	\N	\N	None	\N	AM2-070	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3434	K11-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-070-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	40	\N	\N	None	\N	AM2-070	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3437	K12-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-071-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	41	\N	\N	None	\N	AM2-071	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3439	K12-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-071-3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	41	\N	\N	None	\N	AM2-071	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3438	K12-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-071-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	41	\N	\N	None	\N	AM2-071	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3440	K13-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-072-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	42	\N	\N	None	\N	AM2-072	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3441	K13-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-072-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	42	\N	\N	None	\N	AM2-072	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3442	K13-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-072-3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	42	\N	\N	None	\N	AM2-072	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3443	K14-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-073-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	43	\N	\N	None	\N	AM2-073	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
10150	HWA4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 Acral Melanoma, FFPE Curls	Hong Wu	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10979	SP-13-006364	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10063	Bivona-L6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11006	M368	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10176	HWA5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2597	20-11796D	90	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.3	\N	\N	Sections show a zone of fibrosing granulation tissue, representing a prior biopsy site, with a subtle proliferation composed mostly of enlarged single melanocytes in irregular array along the epidermal-dermal junction in a narrowly based but poorly circumscribed area. There is a dense infiltrate of neutrophils in a cavity in the dermis.	Elliptical excision, 6.1 x 1.3 x 0.4 cm, including a central 5.3 x 0.3 cm scar. With the margins inked, the specimen is serially sectioned perpendicular to the long axis and entirely submitted with seven sections in A and six each in B-D. CF/CF	A) MELANOMA IN SITU. . PLEASE CHECK MARGINS..(PHOTO)	\N	\N	FFPE	None	HEALING BIOPSY SITE, WITH SUBTLE RESIDUAL MELANOMA IN SITU, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	173304	808	\N	\N	20-11796	D	LMM-09	Lentigo Maligna Melanoma	IP2097439	AirTable blocks_with_IP_info.csv
3112	79049-1b	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	AM2-008_1.2	\N	\N	\N	\N	Right hallux	\N	\N	\N	\N	6	\N	\N	None	\N	AM2-008	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
10811	Dummer-KF3-Primary	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions in Atypical Spitzoid Lesions, Dr. Dummer, University Hospital Zurich, HS14.16 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11122	SP-10-143551E	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	JM	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10560	RC11-024	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	blue nevus-like melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10531	DPN18	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2832	22-91699A7	94	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	http://64.54.108.121/eSlideTray.php?ImageIds=28283,28284,28285,28286,28287,28288,28289	172.6	\N	\N	Sections show inflammation and granulation tissue, flanked by a proliferation of melanocytes arrayed irregularly along the junctional zone. Centrally, the epidermis is effaced above a nodular proliferation of atypical melanocytes. The dermis displays marked solar elastosis.	Oriented ellipse, 5.7 x 2.4 x 1.1 cm, including a central 1.2 x 1.2 cm raised area. The orienting short sutured tip is indicated 12 o'clock on the requisition and is placed toward 12 o'clock. The grosser inked the 12-3-6 o'clock margin blue and the 6-9-12 o'clock margin yellow. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and submitted with two sections in A1, one section each in A2-A5, and two sections in A6. Subsequently, the 12 o'clock tip is serially sectioned and four sections, adjacent to those in block A1, are submitted in A7. Tips reserved. KB/KB	A) LEFT ARM WIDE EXCISION MELANOMA - PERMANENT, B) LEFT UPPER ARM SKIN LESION - PERMANENT, C) LEFT ARM WIDE EXCISION; R/O SQUAMOUS CELL CARCINOMA - PERMANENT	\N	\N	\N	In this excisional biopsy, there is a component of lentiginous melanoma in situ. Procedure: excision Microscopic tumor type: high-CSD melanoma Breslow thickness: 4.9 mm Ulceration: present Margins, peripheral and deep: free Mitotic index: 2/mm2 Microsatellitosis: not identified Vascular invasion: not identified Perineural invasion: not identified Regression: not identified Pathologic Staging (pTNM): pT4b	HEALING BIOPSY SITE, WITH RESIDUAL MELANOMA OF 4.9 MM IN THICKNESS, FULLY EXCISED (THE FINAL MARGIN APPEARS FREE OF MELANOMA)	173601	804	\N	\N	22-91699	A7	LMM-05	Lentigo Maligna Melanoma	IP1692985	AirTable blocks_with_IP_info.csv
2066	17-20900B	69	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	216.7	\N	\N	Sections show a compound proliferation of melanocytes limited to the junctional zone and to a thickened papillary dermis, with lateral extension of the junctional component above a fibrotic papillary dermis.	Skin segment measuring 0.7 x 0.7 x 0.1 cm, trisected and entirely submitted in B. RS/RS	A) R/O SK, B) R/O NEVUS	\N	\N	\N	\N	COMPOUND MELANOCYTIC NEVUS, SO-CALLED CLARK'S OR DYSPLASTIC TYPE, EXCISED IN PLANES OF SECTION EXAMINED	173724	544	\N	\N	17-20900	B	DN-069	Dysplastic Nevi	IP83591	AirTable blocks_with_IP_info.csv
10651	BN-M1-Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Amplicon Seq: Hunter Melanoma In Nevus (Blue Nevus)	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2185	17-77365	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	807	\N	\N	17-77365	\N	LMM-08	Lentigo Maligna Melanoma	\N	AirTable blocks_with_IP_info.csv
3570	SKMEL 1107B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	904	\N	\N	None	\N	MC-02	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3571	SKMel 1107B Dec2019	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	904	\N	\N	None	\N	MC-02	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3573	SKMel 1121B Dec2019	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	905	\N	\N	None	\N	MC-03	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3572	SKMEL 1121B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	905	\N	\N	None	\N	MC-03	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
10382	K1_9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11074	S12-15765B3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11035	S12-23475C1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal Benhamida Lymph Node Metastasis	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2468	19-75051	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	809	\N	\N	19-75051	\N	LMM-10	Lentigo Maligna Melanoma	\N	AirTable blocks_with_IP_info.csv
2978	96-14850	60	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	\N	Sections show a polypoid proliferation of melanocytes with marked nuclear atypia, markedly expanding the papillary dermis. Maturation is not present, and mitotic figures are present in the dermal melanocytic population.	Skin segment measuring 11 x 10 x 4 mm, bisected.	CLINICAL DIAGNOSIS - PYOGENIC GRANULOMA	\N	\N	\N	Several studies confirm that a polypoid configuration is not an independent prognostic variable in patients with melanoma.	MELANOMA, 2.0 MM IN THICKNESS, POLYPOID	173604	1168	\N	\N	96-14850	\N	MP-04	Hockemeyer Melanoma Progression	IP91614	AirTable blocks_with_IP_info.csv
10731	DPN45	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10800	DM40	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Desmoplastic Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10849	S11-20884A-A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	DPN-like Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10806	Dummer-KF1-Met2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions in Atypical Spitzoid Lesions, Dr. Dummer, University Hospital Zurich, HS14.18/I 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10785	UM7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2289	18-12160E	76	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	172.4	\N	\N	Sections show a broad and poorly circumscribed proliferation of solitary melanocytes, with small but variably confluent nests, irregularly distributed within the basal layer of the epidermis above a dermis that shows severe solar elastosis.  Some intraepidermal melanocytes have atypical nuclei. There are very large masses of melanocytes with a greater degree of nuclear pleomorphism in the dermis and subcutis, with a high mitotic rate and a lack of maturation and dispersion with descent.	Oriented ellipse, 4.9 x 2.3 x 0.9 cm, including a central 3.0 x 2.2 cm variegated black-blue area. With the orienting sutured tip placed to the left and designated 12 o'clock by the grosser, the 12-3-6 o'clock margin is inked blue and the 6-9-12 o'clock margin is inked yellow. The specimen is serially sectioned perpendicular to the long axis and submitted with four sections in A and two sections each in B-F. Tips reserved. HD/PL	PLAQUE; NEOPLASM OF UNCERTAIN BEHAVIOR VS. MELANOMA VS. SEBORRHEIC KERATOSIS, SEVERAL MONTH H/O GROWING BLACK/BLUE IRREGULAR 2.7 X 2.0 CM PLAQUE, SUBMITTED NOW AS EXCISIONAL BIOPSY, R/O MELANOMA	\N	\N	FFPE	Features suggested for reporting per the guidelines of the College of American Pathologists include: Procedure: excisional biopsy Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 6.8 mm. Ulceration: no Margins, peripheral: clear by < 1 mm., and deep: clear by 2 mm. Mitotic index: 10/mm2 Microsatellitosis: present Vascular Invasion: absent Perineural invasion: absent Regression: absent Pathologic Staging (pTNM): pT4a pNX  A very large microsatellite is present and included in the thickness measurement.	MELANOMA, 6.8 MM. IN THICKNESS	173410	810	\N	\N	18-12160	E	LMM-11	Lentigo Maligna Melanoma	IP1875716	AirTable blocks_with_IP_info.csv
2439	19-33672A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-24	http://64.54.108.121/eSlideTray.php?ImageIds=32787	\N	\N	6685202	\N	\N	\N	\N	Skin, back, right, wide excision, superficial spreading melanoma	FFPE	\N	\N	\N	322	\N	\N	19-33672	A1	CME-020	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2458	19-44938	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-24	http://64.54.108.121/eSlideTray.php?ImageIds=32788	\N	\N	5910996	\N	\N	\N	\N	Skin, foot, dorsal, right, wide excision, superficial spreading melanoma, with spitzoid features	FFPE	\N	\N	\N	323	\N	\N	19-44938	\N	CME-021	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2606	20-18383A1	70	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.4	\N	\N	Sections show nested and solitary melanocytes with atypical nuclear features in irregular array along and above the epidermal-dermal junction. Similar melanocytes are present in irregular large nests in the underlying dermis. A lymphohistiocytic infiltrate with admixed melanophages is noted, and maturing melanocytes are focally noted as well.	Oriented ovoid, 2.3 x 1.7 x 0.7 cm, including a central 1.3 x 1.0 cm brown area. The orienting sutured pole is indicated as 12 o'clock on the requisition form and placed toward 12 o'clock. The 12-3-6 o'clock and 6-9-12 o'clock edges are inked blue and yellow, respectively. The specimen is serially sectioned perpendicular to the long axis from 12 to 6 o'clock and entirely submitted with four sections each in A1-A2. HD/HD	A) R/O MM VS. SEB K, B) PROVEN INVASIVE SCC, WELL DIFF, CHECK MARGINS	\N	\N	\N	Incidental melanocytic nevus, actinic keratosis, and seborrheic keratosis are also noted in this tissue. A brief synoptic is included below. Procedure: narrow excision Microscopic tumor type: lentigo maligna melanoma Breslow thickness: 0.8 mm Ulceration: not detected Margin: periphery involved, deep free Mitotic index: 1 per square millimeter Vascular invasion: not detected Regression: not detected Pathologic staging (pTNM): pT1b	MELANOMA OF 0.8 MM THICKNESS, WITH IN SITU MELANOMA ABUTTING THE INKED PERIPHERAL SURGICAL MARGIN	173404	813	\N	\N	20-18383	A1	LMM-14	Lentigo Maligna Melanoma	IP2165905	AirTable blocks_with_IP_info.csv
2607	20-18383B2	70	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	173.62	\N	\N	Sections show ulceration. There are slight fibroplasia and a subtle lymphohistiocytic infiltrate below the ulcer. No contiguous residual carcinoma is noted.	Oriented ellipse, 1.3 x 1.0 x 0.2 cm, including a central 0.5 x 0.5 cm depressed area. The orienting sutured edge is indicated as 12 o'clock on the requisition form and placed toward 12 o'clock. The 9-12-3 o'clock and 3-6-9 o'clock edges are inked blue and yellow, respectively. The specimen is serially sectioned perpendicular to the long axis from 9 to 3 o'clock and entirely submitted with three sections in B1 and two sections in B2. HD/HD	A) R/O MM VS. SEB K, B) PROVEN INVASIVE SCC, WELL DIFF, CHECK MARGINS	\N	\N	\N	No residuum is apparent, and the final margin is now free.	ULCERATION, WITH NO EVIDENCE OF RESIDUAL SQUAMOUS CELL CARCINOMA	173614	813	\N	\N	20-18383	B2	LMM-14	Lentigo Maligna Melanoma	IP2165905	AirTable blocks_with_IP_info.csv
11179	57346060	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10809	Dummer-KF2-Met1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions in Atypical Spitzoid Lesions, Dr. Dummer, University Hospital Zurich, HS2014.15/7 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10894	London-L10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2841	22-102807-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	815	\N	\N	None	\N	LMM-16	Lentigo Maligna Melanoma	\N	AirTable blocks_with_IP_info.csv
2234	17-111862B	64	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	172.1	\N	\N	Sections show increased numbers of solitary melanocytes and some small nests of them, irregularly distributed within the epidermis above a dermis with severe solar elastosis.  Some melanocytes have large, hyperchromatic nuclei.	Oriented excision measuring 1.3 x 0.5 x 0.2 cm. With the orienting pre-inked green margin placed distally to the grosser, the edge toward the grosser is inked yellow. The specimen is submitted intact for en face sections in B. PL/PL	A) SLOW MOHS OF PATH #DT17-84030 ENFACE, B-H) PERIPHERAL MARGINS INKED IN GREEN (SEE PHOTO)	\N	\N	\N	This lesion shows the lentigo maligna pattern of melanoma in situ.	MELANOMA IN SITU	101109	819	\N	\N	17-111862	B	LMM-20	Lentigo Maligna Melanoma	IP1814097	AirTable blocks_with_IP_info.csv
11037	SP-14-68521D	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G. Long, Triple Negative "Wild Type" MM Cases (Australia)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11159	WCRS99-012800	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	111	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11242	Sample_KAM35-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10847	S13-13286A6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Translocation	NTRK3	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
1164	05-14988B T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	917	\N	\N	None	\N	MD-11	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1163	05-14988 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	917	\N	\N	None	\N	MD-11	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
2230	17-111657B	74	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion.	Skin segment measuring 0.6 x 0.6 x 0.1 cm, bisected and entirely submitted in B. PL/PL	A) 0.6 X 0.6 CM; R/O DYSP VS. MM, B) 0.6 X 0.6 CM; R/O DYSP VS. MM, C) 0.6 X 0.6 CM; R/O DYSP VS. MM, D) 0.6 X 0.6 CM; R/O DYSP VS. MM, E) 0.6 X 0.6 CM; R/O DYSP VS. MM	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	433599	848	\N	\N	17-111657	B	LN-028	Lentiginous Nevi 	IP531322	AirTable blocks_with_IP_info.csv
2229	17-111657A	74	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	172.5	\N	\N	Sections show a proliferation of nested and solitary melanocytes that are irregularly distributed within the epidermis. Some melanocytes have atypical nuclei. The dermis contains solar elastosis.	Skin segment measuring 0.5 x 0.4 x 0.1 cm, bisected and entirely submitted in A. PL/PL	A) 0.6 X 0.6 CM; R/O DYSP VS. MM, B) 0.6 X 0.6 CM; R/O DYSP VS. MM, C) 0.6 X 0.6 CM; R/O DYSP VS. MM, D) 0.6 X 0.6 CM; R/O DYSP VS. MM, E) 0.6 X 0.6 CM; R/O DYSP VS. MM	\N	\N	Scraping	This melanoma is AJCC stage Tis (representing a non-invasive tumor with no associated ulceration).	MELANOMA IN SITU, EXTENDING CLOSE TO THE EDGE OF THE SPECIMEN	139522	848	\N	\N	17-111657	A	LN-028	Lentiginous Nevi 	IP531322	AirTable blocks_with_IP_info.csv
11113	NZM52	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jillian Cell Lines	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10640	T02-16195	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10730	DPN44	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11040	SP-14-73676A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G. Long, Triple Negative "Wild Type" MM Cases (Australia)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11046	C022	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10256	W09-1121	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_1	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10676	Spitz_M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Melanoma in Nevus: Spitzoid Melanoma/Nevus samples	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10916	UM14	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11128	SP-13-87981B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	GJ	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10864	S12-28988	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10734	Birt_Hogg_Dube	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Metastatic Melanoma (KIT, NRAS, BRAF)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10987	SP-07-0116602	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11085	ZS10-1843A5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10761	13000212	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dr. A. Fouchardiere Project	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11069	Long-TN11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10788	UM10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10863	ZS10-11930B12	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10528	10_63051C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Normal (for #9) 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10972	London-L23D	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10725	DPN33	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10853	ZS06-11249A-C2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Patient Melanoma (Hunter Extraction)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11076	S12-4365A7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11160	HAYS90-005154	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	77	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11245	Sample_KAM61-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11188	SSCS03-004945	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	46	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11127	SP-11-160493A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	FN	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11180	SROS10-009251	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	19	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11080	S12-9606EE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11230	332771	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma (choroidal melanoma, right eye)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10402	S12-7093NG176-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10389	K1_16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10858	S12-7250E3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Patient Melanoma  	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11026	3860	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Samples	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10857	S13-11748F5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Patient Melanoma  	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11145	VALS05-014946-E	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	54	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11173	ICPMR19684.13A11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10901	London-L16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11154	HAYS02-005731	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	98	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2243	17-113511	\N	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	869	\N	\N	17-113511	\N	LN-052	Lentiginous Nevi 	\N	AirTable blocks_with_IP_info.csv
1180	05-29322 T3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	918	\N	\N	None	\N	MD-12	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
10898	London-L12	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10558	RC11-022	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	blue nevus-like melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10403	S10-7937B2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10561	Kit298	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	blue nevus-like melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10114	HW8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Mucosal Melanoma, Urethra, Hong Wu	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10392	K1_19	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11053	UM19	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10645	CNS53	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10994	SP-12-020017C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11107	SMU10-0206	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Australian DM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10304	SM_1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Spitzoid Melanoma Maria	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11054	UM20	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11164	DHM50691-14MP5C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10771	15102-02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10316	SM_18	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Spitzoid Melanoma Maria	| Barcode mismatch comment in note	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11120	DHM4855-14MP	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	MLH	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10818	D326	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Blue Nevus-like Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11185	OAK84-008979-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	112	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11033	S12-23475A6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal Benhamida Lymph Node Metastasis	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10388	K1_15	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11059	CP-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11237	Sample_KAM106-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11163	SFO93-005184	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	103	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10766	35942-04	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11247	Sample_KAM78-T-III	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11090	ZS10-10558C1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10777	21590	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11140	SROS11-005030	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	30	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11161	SFOS00-016989	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	69	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10681	BN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Melanoma in Nevus: Blue Nevus Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11086	ZS10-8439A4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10724	DPN31	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10989	SP-09-0150202A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11077	S12-4365B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11108	SMU10-0240	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Australian DM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11060	CP-6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11248	Sample_KAM82-T-B8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10641	T00-12011	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10266	S08-4544A03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_11	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10855	S12-28585A6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Patient Melanoma  	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11165	DHM50691-14MP3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10844	SP-13-17075(1B)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Georgina Long, Royal Prince Alfred Hosiptal, Australia (Triple Negative wild type melanomas)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10050	WP29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Autopsy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11124	04-SW-12-31366B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	AH	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10178	HWA6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, All	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10126	London-L1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas 	N5_15 and N5_16 are the exact same template done in duplicate with two different barcodes	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10982	SP-13-0185992B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10873	London-L14	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11042	SP-14-7691A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G. Long, Triple Negative "Wild Type" MM Cases (Australia)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10556	RC11-005	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	blue nevus-like melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10622	Acral-11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11186	ROSS09-022626-A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	115	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10058	Bivona-L1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10856	S11-2018B5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Patient Melanoma  	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11052	UM15	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10859	S13-3401B3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Patient Melanoma  	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11246	Sample_KAM7-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11243	Sample_KAM38-T-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11004	M257	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10797	DM27	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Desmoplastic Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2232	17-111704B	70	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show a proliferation of solitary and nested melanocytes arrayed along the sides and bases of elongated rete along the epidermal-dermal junction.  Some rete harbor single melanocytes in lentigo-like fashion.	Skin segment measuring 0.4 x 0.2 x 0.1 cm, submitted intact in B. CF/CF	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS. ATYPICAL BROWN PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS. ATYPICAL BROWN MACULE.	\N	\N	Scraping	\N	LENTIGINOUS JUNCTIONAL MELANOCYTIC NEVUS	173714	871	\N	\N	17-111704	B	LN-054	Lentiginous Nevi 	IP327995	AirTable blocks_with_IP_info.csv
2231	17-111704A	70	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.7	\N	\N	Sections show a proliferation of nested and solitary melanocytes, relatively evenly distributed along the dermal-epidermal junction. Clusters of similar melanocytes are present in the dermis.	Skin segment measuring 0.4 x 0.3 x 0.1 cm, submitted intact in A. CF/CF	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS. ATYPICAL BROWN PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. ATYPICAL NEVUS. ATYPICAL BROWN MACULE.	\N	\N	Scraping	\N	COMPOUND MELANOCYTIC NEVUS	173710	871	\N	\N	17-111704	A	LN-054	Lentiginous Nevi 	IP327995	AirTable blocks_with_IP_info.csv
2302	18-17957	51	\N	\N	\N	None	None	None	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show a compound proliferation of melanocytes composed of  single and nested melanocytes arrayed along the epidermal-dermal  junction, positioned along the sides and bases of pigmented, elongated rete ridges.  There are similar melanocytes in the subjacent dermis. There is a focal dense infiltrate of lymphocytes and melanophages.	Skin segment measuring 0.5 x 0.5 x 0.1 cm, bisected and entirely submitted. RS/RS	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS. RED BROWN MACULE.	\N	\N	Scraping	None	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS, INFLAMED	155566	870	\N	\N	18-17957	\N	LN-053	Lentiginous Nevi 	IP825795	AirTable blocks_with_IP_info.csv
1205	06-05518B T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	919	\N	\N	None	\N	MD-13	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1204	06-05518 T4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	919	\N	\N	None	\N	MD-13	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
11126	SP-13-63011A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	FN	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10781	20847-09	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10376	K1_3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10988	12GS-2466	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10404	S11-21025B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10915	UM13	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10917	UM16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11175	SP-13-15691D	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10996	SP-13-006337A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10985	SP-13-0068754A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10663	UM4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10112	HW2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Mucosal Melanoma, vulva, Hong Wu	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10679	Spitz_N2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Melanoma in Nevus: Spitzoid Melanoma/Nevus samples	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10311	SM_8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Spitzoid Melanoma Maria	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11067	Long-TN10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10822	DPN48	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN-like Melanoma: MSK 13-53190-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11125	04-SW-12-31366B6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	AH	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10789	UM11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11119	9246581-A6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	JG	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10960	London-L19	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11195	SSCS92-009981	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	22	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10999	SP-12-0146612A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10910	DM19	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11091	ZS10-3560F1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10923	GAK	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11130	SP-14-125801B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	CG	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2319	18-44463B	61	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show skin with a compound proliferation of bland melanocytes. Within the epidermis, heavily pigmented melanocytes are arranged in predominantly single cells within the basilar layer of the epidermis. There is overlying lamellar hyperkertosis with flecks of melanin pigment within the stratum corneum. There is focal bridging of elongated rete ridges. Within the dermis, similar melanocytes are arranged in maturing nests and cords within a fibrotic dermis that holds melanophages and few lymphocytes. There is perijunctional lamellar fibroplasia.	Two skin segments measuring 0.8 x 0.5 x 0.1 cm in aggregate, sectioned and entirely submitted with three sections in B. HD/PL	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA VS. HEMANGIOMA. PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. MELANOMA VS. NEVUS. MACULE. C) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. MELANOMA VS. NEVUS. MACULE.	\N	\N	Scraping	\N	HYPERMELANOTIC LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	239512	877	\N	\N	18-44463	B	LN-062	Lentiginous Nevi 	IP1908257	AirTable blocks_with_IP_info.csv
2320	18-44463C	61	\N	\N	\N	\N	\N	\N	\N	0	FFPE	\N	\N	216.5	\N	\N	Sections show skin with a compound proliferation of bland melanocytes arranged in predominantly single cells and small nests within the sides and bases of elongated rete ridges. There is focal bridging of these rete ridges. Within the dermis, similar melanocytes are arranged in maturing nests, cords, and single cells amidst melanophages. There are rare flecks of melanin pigment in the overlying stratum corneum.	Skin segment measuring 1.0 x 0.7 x 0.1 cm, trisected and entirely submitted in C. HD/PL	A) NEOPLASM OF UNCERTAIN BEHAVIOR VS. BASAL CELL CARCINOMA VS. HEMANGIOMA. PAPULE. B) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. MELANOMA VS. NEVUS. MACULE. C) NEOPLASM OF UNCERTAIN BEHAVIOR VS. DYSPLASTIC NEVUS VS. MELANOMA VS. NEVUS. MACULE.	\N	\N	Scraping	There is a focus of acantholytic dyskeratosis, which could be incidental, or indicative of Grover's disease, depending on the clinical context.	LENTIGINOUS COMPOUND MELANOCYTIC NEVUS	139511	877	\N	\N	18-44463	C	LN-062	Lentiginous Nevi 	IP1908257	AirTable blocks_with_IP_info.csv
11016	London-L9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11112	RPA08-0315	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Australian DM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10984	SP-13-0212981A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11034	S12-23475A4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal Benhamida Lymph Node Metastasis	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
3280	DM5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	1927	\N	\N	None	\N	SYNAT592	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3487	KIT295	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1946	\N	\N	None	\N	SYNAT593	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
10906	London-L16B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10983	SP-12-003309B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11144	RCHS06-004567	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	70	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10980	SP-14-001249	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10375	K1_2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10728	DPN41	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10763	1286184b	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10182	HWA8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10913	140038340	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions (University Hospital Erlangen, Germany)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10494	DP08-4205A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10557	RC11-021	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	blue nevus-like melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11008	M418	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11236	Sample_KAM1-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11174	SP-13-15691B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11166	RNS14P13907B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11146	SCHS08-007754	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	2	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10049	WP23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Autopsy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11093	ZS10-3560C1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10168	MB1424_	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Tumor, Thumb, Frozen Tissue DNA extracted by Denver	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10889	DM50	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10116	HW9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Mucosal Melanoma, Blood, Hong Wu	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11168	DHM57444-14MP	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11167	SP-10-197431A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10259	S94-31062	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_4	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10851	S12-6218A-D3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Blue Nevus Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10918	London-L17	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10912	DM46	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10554	RC11-003	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	blue nevus-like melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10191	wm3918	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	wt/wt Cell Line DNA	Wistar	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11155	SRFS97-002805	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	67	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10639	T09-8069	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11192	SACS88-019073	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	64	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11111	RPA08-0209	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Australian DM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11138	FRSS09-009402-A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	105	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11233	57714581	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma (choroidal lesion, left eye)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10143	Bivona-L11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Bivona Lung Cell Line	N/A|Bivona Lung Cell Line	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10808	Dummer-KF2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions in Atypical Spitzoid Lesions, Dr. Dummer, University Hospital Zurich, HS14.19/D 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11176	57059699	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10678	Spitz_N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Melanoma in Nevus: Spitzoid Melanoma/Nevus samples	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11089	ZS10-10558A10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10553	RC11-002	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	blue nevus-like melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11123	SP-10-143552A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	JM	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11190	SACS02-020334	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	100	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10374	K1_1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11162	VALS03-007457	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	117	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10991	SP-10-003167A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10387	K1_14	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10716	MIN_8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Melanoma In Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10267	S10-26316A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_12	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10799	DM35	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Desmoplastic Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11183	OAKS96-014392-G	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	74	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10269	S11-38910A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_14	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11055	CP-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10638	T07-1120	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11010	London-L4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11234	UM47	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10986	SP-13-0068751C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11170	DHM94457-13SK	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10391	K1_18	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11121	SNPN08289D	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	MLH	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10061	Bivona-L4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
3581	SM_3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1741	\N	\N	None	\N	SYNAT637	Spitzoid Melanoma	\N	AirTable blocks_with_IP_info.csv
10997	SP-12-0228802A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
2955	94-21132 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	990	\N	\N	None	\N	MD-94	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1240	06-23345 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	925	\N	\N	None	\N	MD-19	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1246	06-27633 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	926	\N	\N	None	\N	MD-20	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1242	06-23587B T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	927	\N	\N	None	\N	MD-21	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1241	06-23587 T1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	927	\N	\N	None	\N	MD-21	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1341	09-13370-2G N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	984	\N	\N	None	\N	MD-80	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1340	09-13370-1M N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	984	\N	\N	None	\N	MD-80	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
11110	MASCRI-432	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Australian DM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10769	1185-03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
3309	DM55	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1922	\N	\N	None	\N	SYNAT662	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3322	DM70	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2278	\N	\N	None	\N	SYNAT663	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3278	DM2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	1680	\N	\N	None	\N	SYNAT664	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3481	KIT230	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2132	\N	\N	None	\N	SYNAT665	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3528	MB_1028	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1901	\N	\N	None	\N	SYNAT666	2010-2017	\N	AirTable blocks_with_IP_info.csv
3499	KR_2064	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1924	\N	\N	None	\N	SYNAT667	Rasopathy Syndrome	\N	AirTable blocks_with_IP_info.csv
3315	DM63	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2319	\N	\N	None	\N	SYNAT668	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3605	WM3622	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1887	\N	\N	None	\N	SYNAT669	Acral Melanoma Cell Culture	\N	AirTable blocks_with_IP_info.csv
3296	DM26	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1820	\N	\N	None	\N	SYNAT670	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
3457	K22-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-081	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	51	\N	\N	None	\N	AM2-081	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3460	K23-D	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AM2-082-2; AM2-082-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	52	\N	\N	None	\N	AM2-082	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3459	K23-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-082	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	52	\N	\N	None	\N	AM2-082	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3150	B17.80125 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Metastasis	AM2-084-3, dermal/subcutaneous metastasis, stage III A	\N	\N	\N	\N	left groin	\N	\N	\N	\N	54	\N	\N	None	\N	AM2-084	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3343	H 2015.1871	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AM2-084-1, Didn't receive slides	\N	\N	\N	\N	\N	\N	\N	\N	\N	54	\N	\N	None	\N	AM2-084	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3142	B 2015.54040	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AM2-084-2, Didn't receive slides	\N	\N	\N	\N	\N	\N	\N	\N	\N	54	\N	\N	None	\N	AM2-084	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3147	B14. 951 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AM2-085-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	55	\N	\N	None	\N	AM2-085	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3346	H13.3143 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AM2-085-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	55	\N	\N	None	\N	AM2-085	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1764	14-31886	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-3; BOX-4; BOX-12	\N	\N	Acrolentiginous melanoma	AM2-086-2, recurrent	\N	\N	\N	\N	right heel	Scraping	\N	\N	\N	56	\N	\N	14-31886	\N	AM2-086	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1864	15-29364A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-2	\N	\N	Metastasis	AM2-086-3	\N	\N	\N	\N	right inguinal lymph node	Scraping	\N	\N	\N	56	\N	\N	15-29364	A1	AM2-086	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1712	13-30315A3	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-3; BOX-9; BOX-13	\N	\N	Acrolentiginous melanoma	 AM2-086-1, wide excision, pT4bN0	\N	\N	\N	\N	right heel	Scraping	\N	\N	\N	56	\N	\N	13-30315	A3	AM2-086	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1392	10-22319	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	Acrolentiginous melanoma	AM2-087-1, subtotal amputation, stage IIA at least	\N	\N	\N	\N	left thumb	Scraping	\N	\N	\N	57	\N	\N	10-22319	\N	AM2-087	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1849	15-14674	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	Metastasis	AM2-087-2, Soft tissue, echo-guided biopsy	\N	\N	\N	\N	left axillary	Scraping	\N	\N	\N	57	\N	\N	15-14674	\N	AM2-087	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1854	15-17010A2	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-0	\N	\N	\N	\N	\N	\N	\N	\N	non-tumor	FFPE	\N	\N	\N	58	\N	\N	15-17010	A2	AM2-088	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1853	15-17010A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-2; BOX-8; BOX-13	\N	\N	Acral melanoma	AM2-088-1, wide excision	\N	\N	\N	\N	left sole	Scraping	\N	\N	\N	58	\N	\N	15-17010	A1	AM2-088	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1855	15-17010C1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-2; BOX-8	\N	\N	Metastasis	AM2-088-2, metastatic melanoma (2/6)	\N	\N	\N	\N	left  inguinal and femoral lymph node	Scraping	\N	\N	\N	58	\N	\N	15-17010	C1	AM2-088	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1635	12-24502B	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	Metastasis	AM2-089-2, labeled as 2, lymphadenectomy, 	\N	\N	\N	\N	right inguinal lymph node	Scraping	\N	\N	\N	59	\N	\N	12-24502	B	AM2-089	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1634	12-24502A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	Acrolentiginous melanoma	AM2-089-1	\N	\N	\N	\N	right heel	Scraping	\N	\N	\N	59	\N	\N	12-24502	A1	AM2-089	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2142	17-55712A2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-26	http://64.54.108.121/eSlideTray.php?ImageIds=32784	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	319	\N	\N	17-55712	A2	CME-017	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2141	17-55712A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-26	http://64.54.108.121/eSlideTray.php?ImageIds=32783	\N	\N	5762876	\N	\N	\N	\N	Skin, back, right side, biopsy, malignant melanoma, superficial spreading type	FFPE	\N	\N	\N	319	\N	\N	17-55712	A1	CME-017	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
3444	K14-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-073-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	43	\N	\N	None	\N	AM2-073	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3445	K14-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-073-3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	43	\N	\N	None	\N	AM2-073	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3447	K15-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-074-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	44	\N	\N	None	\N	AM2-074	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3446	K15-A-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	BLACK BOX 1	\N	\N	\N	AM2-074-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	44	\N	\N	None	\N	AM2-074	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2041	17-6368	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	723	\N	\N	17-6368	\N	DP-86	CGH Validation	\N	AirTable blocks_with_IP_info.csv
3302	DM37	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2327	\N	\N	None	\N	SYNAT500	Desmoplastic Melanoma	\N	AirTable blocks_with_IP_info.csv
2794	22-34510B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1169	\N	\N	22-34510	B1	MucM-01	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
2793	22-34510A3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1169	\N	\N	22-34510	A3	MucM-01	Mucosal Melanoma	\N	AirTable blocks_with_IP_info.csv
3183	Bivona-L17	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2077	\N	\N	None	\N	SYNAT501	2010-2017	\N	AirTable blocks_with_IP_info.csv
3525	MB_161	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2102	\N	\N	None	\N	SYNAT502	2010-2017	\N	AirTable blocks_with_IP_info.csv
3540	MB1429	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2087	\N	\N	None	\N	SYNAT503	2010-2017	\N	AirTable blocks_with_IP_info.csv
11177	57269600	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10990	SP-13-006535C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10824	AST-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dermpath - Atypical Spitz Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10386	K1_13	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10131	Bivona-L10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Bivona Lung Cell Line	N/A|Bivona Lung Cell Line	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11132	WCRS97-025628	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	17	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11038	SP-13-208365A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G. Long, Triple Negative "Wild Type" MM Cases (Australia)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11181	FRSS99-007026	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	32	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10958	S12-25164A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal Benhamida Melanoma and Metastasis Project (Lymph Node)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10130	Bivona-L9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Bivona Lung Cell Line	N/A|Bivona Lung Cell Line	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11025	1214	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Samples	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11001	SP-10-004335	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11116	SP-13-198211A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	DH	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10401	S08-1463A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10559	RC11-023	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	blue nevus-like melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10144	HWA1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, FFPE Curls	Hong Wu	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11226	UM37	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11222	UM39	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10377	London-L20	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Dysplastic Nevus	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11012	London-L5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11211	57291680	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	uveal melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11182	SCLS04-001045	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	60	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11220	UM33	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Soyer Microbiopsy Study	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10862	ZS07-1210F6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Patient Melanoma  	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10719	501_Mel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10780	356A3-075	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10890	DM56	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10723	DPN29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11134	SROS12-001198	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	90	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10762	8528-05	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10963	London-L19E	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11114	NZM40	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jillian Cell Lines	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11250	Sample_KAM94-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10148	HWA3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, FFPE Curls	Hong Wu	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10020	BuffyCoat	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11172	Laverty13-88354	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10400	S11-032523A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11191	HAYS98-001046	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	75	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10555	RC11-004	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	blue nevus-like melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10385	K1_12	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10909	DM15	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Desmoplastic Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10646	CNS54	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11193	SACS87-010145	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	50	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10261	S02-33818A03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_6	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11009	C8161	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11078	S12-4365C1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10732	DPN46	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10782	525	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10720	Sk_Mel_1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11221	UM35_A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10969	London-L23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10264	S05-41924	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_9	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10932	London-L21	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10713	MIN_7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Melanoma In Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10268	S10-44069A4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_13	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10772	9116-05	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11224	UM41	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10787	UM9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11157	SSCS03-014369	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	58	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11039	SP-14-36134A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G. Long, Triple Negative "Wild Type" MM Cases (Australia)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10263	S05-7439A12	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_8	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10492	DP08-21965C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10721	DPN24	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10959	S12-25164C1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal Benhamida Melanoma and Metastasis Project (Lymph Node)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10846	SP-13-1038(1A)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Georgina Long, Royal Prince Alfred Hosiptal, Australia (Triple Negative wild type melanomas)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11082	ZS10-972C2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11231	57723220	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma (choroidal melanoma, right eye)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10088	HW6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, Melanaoma| Tumor Melanoma, Mucosal vulva	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11079	S12-9606C4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11135	SROS09-001574	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	92	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10993	SP-12-0087723B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11171	DHM48742-12MPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10854	S12-26125A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Patient Melanoma  	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10580	L13-48798	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN (DPN like Melanoma)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11210	57001550	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	uveal melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10966	London-L22	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11131	SP-14-125802A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	CG	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10048	WP11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Autopsy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10390	K1_17	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11056	CP-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10110	KIT53	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Melanoma, Heel	_Acral_NRAS	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10768	Z1188-03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10924	Yurif	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11189	WCRS02-022688	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	47	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10146	HWA2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, FFPE Curls	Hong Wu	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11005	M285	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11251	Sample_KAM96-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10807	Dummer-KF2-Primary	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions in Atypical Spitzoid Lesions, Dr. Dummer, University Hospital Zurich, HS14.19/D 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10843	SP-12-2294-2(2A)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Georgina Long, Royal Prince Alfred Hosiptal, Australia (Triple Negative wild type melanomas)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10992	SP-13-009897	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10180	HWA7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10865	SSS13-1652B2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11023	1212	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Samples	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10790	Xanthoma_Disseminatum	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dr. Shulman Xanthoma Disseminatum	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10572	SQ13-8208B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dr. Perry, Melanocytic Shwannoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10779	A2A79@	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10755	8298-01	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10128	Bivona-L7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Bivona Lung Cell Line	N/A|Bivona Lung Cell Line	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11169	SP-12-177322A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Long Australian Wild Type Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10086	HW4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, Melanaoma| TUMOR Melanoma, Mucosal nasal sinus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11092	ZS10-3560A3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10381	London-L23C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Dysplastic Nevus	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11109	SCC10-0092	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Australian DM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10866	S13-5249	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10798	DM32	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Desmoplastic Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10686	Yurif_DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10914	140092090	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions (University Hospital Erlangen, Germany)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11083	ZS10-972A9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11118	9246581-A3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	JG	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10816	Long-TN2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type"), Georgina Long, Australia, SP-12-13739, Phu	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10928	London-L18	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11002	SP-13-000848	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11232	55875588	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10677	Spitz_M2_(?)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Melanoma in Nevus: Spitzoid Melanoma/Nevus samples	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10804	Dummer-KF1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions in Atypical Spitzoid Lesions, Dr. Dummer, University Hospital Zurich, H01.10457/II 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11187	SCHS11-018842-A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	119	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10842	SP-13-14992(1A)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Georgina Long, Royal Prince Alfred Hosiptal, Australia (Triple Negative wild type melanomas)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11018	London-L13	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10770	14514-02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11057	CP-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11228	57715138	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma, left eye, s/p enucleation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10722	DPN28	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11032	UM17	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10957	S12-27617B9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal Benhamida Melanoma and Metastasis Project (Lymph Node)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11151	SACS93-027850	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	27	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10879	London-L14C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11003	M230	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10260	S02-23636A02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_5	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11137	SACS05-011507	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	99	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10258	W10-143	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_3	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11058	CP-4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11117	RNS11P15316B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	DH	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10733	UM_6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dr. Seider Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11045	C037	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11044	WM3928F	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10773	24516-06	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11000	SP-12-01466111A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10689	DPN26	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10841	SP-12-5612(1K)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Georgina Long, Royal Prince Alfred Hosiptal, Australia (Triple Negative wild type melanomas)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10552	RC11-001	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	blue nevus-like melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10468	S12-18826	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Alain Algazi	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10399	S12-6332A5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11139	RCHS07-000380-B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	28	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10903	London-L16A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10812	Dummer-KF3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions in Atypical Spitzoid Lesions, Dr. Dummer, University Hospital Zurich, HS14.16 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10685	GAK_DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11081	S12-9606A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10977	XD-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Xanthoma Disseminatum Project	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11156	VALS03-019832	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	124	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11150	SFOS94-003116	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	49	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11129	SP-11-40641B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type")	GJ	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10814	Long-TN1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatic Melanomas ("wild type"), Georgina Long, Australia, SP-12-18648, Nugent	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10062	Bivona-L5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11184	OAKS96-022398	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	109	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10650	BN-N2-Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Amplicon Seq: Hunter Melanoma In Nevus (Blue Nevus)	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11007	M375	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Thomas Wild Type Cell Line DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10647	CNS57	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10438	HWAcr	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, FCCC, Dissect, Acral Melanoma, Dissect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10393	K1_20	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Sample	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11141	VALS09-000266	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	72	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11149	MTZS94-007340	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	45	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11024	1213	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AGL Samples	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10981	SP-13-0185993A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11147	SFOS12-018173	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	5	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10024	BuffyCoa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Family History (9 members) have melanoma	Collaborated with Robert Nussbaum to get this blood	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10380	London-L15	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Dysplastic Nevus	13 Cycle Post Hybridization LM-PCR	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10998	SP-12-0228801A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10059	Bivona-L2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11238	Sample_KAM12-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10624	Acral-12	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10729	DPN42	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10776	B06-37358	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10845	SP-42-10361(1A)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Georgina Long, Royal Prince Alfred Hosiptal, Australia (Triple Negative wild type melanomas)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10186	HWA10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10154	DP12-200	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	RT, Upper Arm, Polypoid Pyogenic Granuloma (Lobular Capillary Hemangioma)	Dr. Lutzky's Case	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10644	CNS52	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11225	UM36	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11136	SCHS09-005840-B5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	93	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10765	206436	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11178	57213442	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10813	Dummer-KF3-Met1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions in Atypical Spitzoid Lesions, Dr. Dummer, University Hospital Zurich, HS14.17/I 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10805	Dummer-KF1-Met1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions in Atypical Spitzoid Lesions, Dr. Dummer, University Hospital Zurich, 14.20/II 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10129	Bivona-L8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Bivona Lung Cell Line	N/A|Bivona Lung Cell Line	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10783	PMM_23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10751	R29032-05	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10726	DPN40	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11223	UM40	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10184	HWA9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Acral Melanoma, Dissect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10803	Dummer-KF1-Primary	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kinase Fusions in Atypical Spitzoid Lesions, Dr. Dummer, University Hospital Zurich, H01.10457/II 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10664	UM5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10995	SP-12-0032671A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Triple Negative Metastatitc Melanoma (Wild Type). Dr. Long, Royal Prince Alfred Hospital, Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10265	S06-47079A02	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jantima CNS	N14_10	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10820	D366	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Blue Nevus-like Melanoma: S06-35322	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11133	SCHS10-026422	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	41	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11240	Sample_KAM20-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10384	K1_11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10767	15329-03	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Pediatric Melanoma (PMM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10861	S13-18444A16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Ivanka Patient Melanoma  	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10529	DPN8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei DPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11106	SMU10-0457	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Australian DM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10060	Bivona-L3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Lung Cells	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11014	London-L8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11148	SROS00-001103	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	10	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11239	Sample_KAM121-T-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11075	S12-4365A8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10084	HW3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, Melanaoma| TUMOR Mucosal Melanoma, nasal sinus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11115	NZM91	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jillian Cell Lines	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11158	RCHS01-003684	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	86	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11088	ZS10-10558B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10974	London-L6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dysplastic Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11143	FRSS09-008805	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	63	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11142	SFOS09-007093	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	18	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10786	UM8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Uveal Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11153	OAKS90-012369	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	9	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11087	ZS10-1843A4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Jamal MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
11041	SP-14-73671M	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G. Long, Triple Negative "Wild Type" MM Cases (Australia)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10680	Spitz_N3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Melanoma in Nevus: Spitzoid Melanoma/Nevus samples	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
1377	10-10275D13 M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	932	\N	\N	None	\N	MD-26	Melanoma Prognosis	\N	AirTable blocks_with_IP_info.csv
1477	11-35367	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	Acrolentiginous melanoma	AM2-091-1, AM2-091-2, labeled as "A", wide excision, Stage IIIC	\N	\N	\N	\N	left heel	Scraping	\N	\N	\N	61	\N	\N	11-35367	\N	AM2-091	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1479	11-36301A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-0	\N	\N	\N	\N	\N	\N	\N	\N	tumor	FFPE	\N	\N	\N	61	\N	\N	11-36301	A1	AM2-091	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1480	11-36301A5	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-0	\N	\N	\N	\N	\N	\N	\N	\N	non-tumor and melanoma in situ	FFPE	\N	\N	\N	61	\N	\N	11-36301	A5	AM2-091	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1481	11-36301C1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-0	\N	\N	\N	\N	\N	\N	\N	\N	groin metastatic lymph node	FFPE	\N	\N	\N	61	\N	\N	11-36301	C1	AM2-091	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1401	10-38178A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	Acrolentiginous melanoma	AM2-092-1, amputation, pT1aN0	\N	\N	\N	\N	left great toe	Scraping	\N	\N	\N	62	\N	\N	10-38178	A1	AM2-092	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1642	12-41833E1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	Metastasis	AM2-092-2, malignant melanoma, metastatic (3/6)	\N	\N	\N	\N	left inguinal lymph node	Scraping	\N	\N	\N	62	\N	\N	12-41833	E1	AM2-092	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1391	10-22013	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	Acrolentiginous melanoma	AM2-093-1, pT4b	\N	\N	\N	\N	left sole	Scraping	\N	\N	\N	63	\N	\N	10-22013	\N	AM2-093	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1720	13-37513	\N	\N	\N	\N	\N	\N	\N	0	\N	\N	\N	\N	\N	Metastasis	AM2-093-2, No slides were sent from TW, ultrasound-guided biopsy, malignant melanoma, metastatic	\N	\N	\N	\N	right subpleural lung	\N	\N	\N	\N	63	\N	\N	13-37513	\N	AM2-093	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3451	K17-B	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-076-1	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	46	\N	\N	None	\N	AM2-076	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3450	K17-A	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-076-2	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	46	\N	\N	None	\N	AM2-076	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3452	K17-D	\N	\N	\N	\N	\N	\N	\N	5	\N	FFPE	\N	\N	\N	\N	AM2-076-3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	46	\N	\N	None	\N	AM2-076	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
3458	K22-D	\N	\N	\N	\N	\N	\N	\N	10	\N	FFPE	\N	\N	\N	\N	AM2-081-3	\N	\N	\N	\N	\N	Scraping	\N	\N	\N	51	\N	\N	None	\N	AM2-081	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1631	12-24189A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-3; BOX-12	\N	\N	Acrolentiginous melanoma	AM2-090-1, amputation	\N	\N	\N	\N	right 4-5th toe 	Scraping	\N	\N	\N	60	\N	\N	12-24189	A1	AM2-090	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1633	12-24455	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-3	\N	\N	Metastasis	AM2-090-2, bronchoscopic biopsy	\N	\N	\N	\N	right lower lobe lung	Scraping	\N	\N	\N	60	\N	\N	12-24455	\N	AM2-090	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1934	16-21256	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-1; BOX-10	\N	\N	Metastasis	AM2-099-5, biopsy	\N	\N	\N	\N	left leg	Scraping	\N	\N	\N	69	\N	\N	16-21256	\N	AM2-099	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1769	14-37577A5	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-5	\N	\N	Metastasis	AM2-099-3, larger specimen, wide excision	\N	\N	\N	\N	left lateral lower leg	Scraping	\N	\N	\N	69	\N	\N	14-37577	A5	AM2-099	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1768	14-35086A	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-1; BOX-9	\N	\N	Metastasis	AM2-099-2, biopsy	\N	\N	\N	\N	left lower ankle	Scraping	\N	\N	\N	69	\N	\N	14-35086	A	AM2-099	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1920	16-9204	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-1	\N	\N	Metastasis	AM2-099-4, biopsy	\N	\N	\N	\N	left posterior leg	Scraping	\N	\N	\N	69	\N	\N	16-9204	\N	AM2-099	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1705	13-23696A5	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-3; BOX-9	\N	\N	Acrolentiginous melanoma	AM2-099-1, wide excision	\N	\N	\N	\N	left sole	Scraping	\N	\N	\N	69	\N	\N	13-23696	A5	AM2-099	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2075	17-21835A3	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-2; BOX-12	\N	\N	Metastasis	AM2-100-4	\N	\N	\N	\N	Brain, site not stated	Scraping	\N	\N	\N	70	\N	\N	17-21835	A3	AM2-100	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
2108	17-34742	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	\N	\N	\N	Metastasis	AM2-100-5	\N	\N	\N	\N	right inguinal area	Scraping	\N	\N	\N	70	\N	\N	17-34742	\N	AM2-100	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1876	15-48543A1	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-2; BOX-12	\N	\N	Metastasis	AM2-100-3, wide excision	\N	\N	\N	\N	right dorsal foot 	Scraping	\N	\N	\N	70	\N	\N	15-48543	A1	AM2-100	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1780	14-51352	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-1; BOX-11	\N	\N	Acral melanoma	AM2-100-1, wide excision; AM2-100-2, lymphadenectomy, melanoma, metastatic (1/2),  but only one set of slides was sent with the ID# 14-51352. No lymph node in the sample provided. 	\N	\N	\N	\N	right third and fourth toe	Scraping	\N	\N	\N	70	\N	\N	14-51352	\N	AM2-100	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1824	15-00176S2	\N	\N	\N	\N	\N	\N	\N	8	\N	FFPE	SLIDE BOX-0	\N	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	70	\N	\N	15-176	S2	AM2-100	Acral Melanoma	\N	AirTable blocks_with_IP_info.csv
1878	15-49595A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-25	http://64.54.108.121/eSlideTray.php?ImageIds=32778	\N	\N	6294524	\N	\N	\N	\N	Skin, upper arm, right, status post excision, wide excision, malignant melanoma, residual	FFPE	\N	\N	\N	316	\N	\N	15-49595	A1	CME-014	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1877	15-49595	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-25	http://64.54.108.121/eSlideTray.php?ImageIds=32779	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	316	\N	\N	15-49595	\N	CME-014	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1956	16-53749A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-26	http://64.54.108.121/eSlideTray.php?ImageIds=32780	\N	\N	5483587	\N	\N	\N	\N	Skin, pubic, excision, melanoma, superficial spreading	FFPE	\N	\N	\N	317	\N	\N	16-53749	A1	CME-015	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1957	16-53749A2	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-26	http://64.54.108.121/eSlideTray.php?ImageIds=32781	\N	\N	\N	\N	\N	\N	\N	\N	FFPE	\N	\N	\N	317	\N	\N	16-53749	A2	CME-015	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
11152	SCLS91-006557	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Kaiser Acral Melanoma	68	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
10649	BN-N1-Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Amplicon Seq: Hunter Melanoma In Nevus (Blue Nevus)	\N	\N	\N	\N	\N	\N	\N	\N	\N	1421	\N	\N	\N	\N	SYNX18	\N	\N	Consolidated_data_final.csv
3593	TissueCoreALKControl	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2322	\N	\N	None	\N	SYNAT673	2010-2017	\N	AirTable blocks_with_IP_info.csv
2284	18-05067	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-26	http://64.54.108.121/eSlideTray.php?ImageIds=32785	\N	\N	6535383	\N	\N	\N	\N	Skin, thigh, right, biopsy, melanoma (see descriptions)	FFPE	\N	\N	\N	320	\N	\N	18-5067	\N	CME-018	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2428	19-17484	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-24	http://64.54.108.121/eSlideTray.php?ImageIds=32786	\N	\N	2244268	\N	\N	\N	\N	Skin, temporal, left, biopsy, melanoma	FFPE	\N	\N	\N	321	\N	\N	19-17484	\N	CME-019	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2589	20-7562\t	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-23	http://64.54.108.121/eSlideTray.php?ImageIds=32789	\N	\N	6739663	\N	\N	\N	\N	Skin, nipple, right, wide excision, superficial spreading melanoma	FFPE	\N	\N	\N	324	\N	\N	20-7562	\N	CME-022	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2600	20-13577A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-24	http://64.54.108.121/eSlideTray.php?ImageIds=32790	\N	\N	1951217	\N	\N	\N	\N	Skin, scalp, site not specified, biopsy, nodular melanoma	FFPE	\N	\N	\N	325	\N	\N	20-13577	A1	CME-023	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2642	20-56532	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-24	http://64.54.108.121/eSlideTray.php?ImageIds=32791	\N	\N	6805784	\N	\N	\N	\N	Skin, umbilicus, tumor biopsy, superficial spreading melanoma	FFPE	\N	\N	\N	326	\N	\N	20-56532	\N	CME-024	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
2709	21-20367A1	\N	\N	\N	\N	\N	\N	\N	10	10	FFPE	SLIDE BOX-24	http://64.54.108.121/eSlideTray.php?ImageIds=32792	\N	\N	6169532	\N	\N	\N	\N	Skin, forearm, left, wide excision, superficial spreading melanoma	FFPE	\N	\N	\N	327	\N	\N	21-20367	A1	CME-025	Cutaneous Melanoma Ethnicities	\N	AirTable blocks_with_IP_info.csv
1580	12-10777	25	\N	\N	\N	None	None	None	\N	\N	\N	\N	\N	172.6	\N	from Swapna	There is a compound proliferation of large oval, fusiform and polygonal melanocytes involving a segment of skin with a raised and slightly papillated surface. The junctional component is limited, consisting of increased numbers of single melanocytes and small nests of them, mostly at one edge of the specimen. Within the dermis are small aggregations of melanocytes with abundant, pale amphophilic cytoplasm and large, pleomorphic vesicular, heterochromatic nuclei, embedded in fibrotic stroma. Little mature with descent is evident. There are subepidermal fibrin deposits, with edema and extravasated erythrocytes.	One outside slide, 014855-AD, and one corresponding block.	PINK-CRUSTED PLAQUE; IMPRESSION OF RULE OUT SCC	\N	\N	\N	The differential diagnosis posed by these sections was that between a traumatized Spitz's nevus with unusual features (including striking nuclear pleomorphism) and melanoma. Comparative genomic hybridization shows chromosomal amplifications involving 5p, 7p, 12q and 22q; there is a probable gain involving 6p and one involving 8q as well. The number of aberrations is inconsistent with a Spitz's nevus, as are the multiple amplifications (gains of 11p and 7q can be seen as isolated phenomena in Spitz's nevi, but chromosomal amplifications are not generally found). The final thickness and AJCC stage will need to await complete removal of the remainder of the lesion. Any comments regarding treatment would be premature.	MELANOMA, AT LEAST 1.8 MM IN THICKNESS	173622	639	\N	\N	12-10777	\N	DP-02	Possible TERT Fusion	IP1096593	AirTable blocks_with_IP_info.csv
\.


--
-- Data for Name: na_sl_link; Type: TABLE DATA; Schema: public; Owner: borisbastian
--

COPY public.na_sl_link (id, input_vol, input_amount, nucacid_id, sample_lib_id, date) FROM stdin;
16149	50	512	1	752	2024-02-29 00:00:00-08
16150	50	210	2	753	2024-02-29 00:00:00-08
16151	50	1000	3	754	2024-02-29 00:00:00-08
16152	50	1000	4	755	2024-02-29 00:00:00-08
16153	50	480	5	756	2024-02-29 00:00:00-08
16154	Infinity	75.7	6	1	2024-02-29 00:00:00-08
16155	50	1000	7	751	2024-02-29 00:00:00-08
16156	50	330	8	758	2024-02-29 00:00:00-08
16157	50	1000	9	757	2024-02-29 00:00:00-08
16158	72	100	10	813	2024-02-29 00:00:00-08
16159	106	100	11	814	2024-02-29 00:00:00-08
16160	74	100	12	815	2024-02-29 00:00:00-08
16161	98	100	13	816	2024-02-29 00:00:00-08
16162	13	15.6	14	1020	2024-02-29 00:00:00-08
16163	13	15.6	14	812	2024-02-29 00:00:00-08
16164	Infinity	11.4	15	2	2024-02-29 00:00:00-08
16165	Infinity	39.6	16	3	2024-02-29 00:00:00-08
16166	Infinity	42.7	17	4	2024-02-29 00:00:00-08
16167	Infinity	100	18	5	2024-02-29 00:00:00-08
16168	0	\N	20	1819	2024-02-29 00:00:00-08
16169	0	\N	21	1441	2024-02-29 00:00:00-08
16170	47	200	22	359	2024-02-29 00:00:00-08
16171	47	200	22	356	2024-02-29 00:00:00-08
16172	0	\N	25	1442	2024-02-29 00:00:00-08
16173	79	200	26	360	2024-02-29 00:00:00-08
16174	79	200	26	357	2024-02-29 00:00:00-08
16175	3	100	28	358	2024-02-29 00:00:00-08
16176	50	1000	29	761	2024-02-29 00:00:00-08
16177	50	400	30	765	2024-02-29 00:00:00-08
16178	3	100	31	825	2024-02-29 00:00:00-08
16179	9	100	32	826	2024-02-29 00:00:00-08
16180	53	100	33	818	2024-02-29 00:00:00-08
16181	40	100	34	819	2024-02-29 00:00:00-08
16182	14	12	35	1021	2024-02-29 00:00:00-08
16183	14	12	35	817	2024-02-29 00:00:00-08
16184	0	\N	36	6	2024-02-29 00:00:00-08
16185	50	554	37	760	2024-02-29 00:00:00-08
16186	50	1000	38	759	2024-02-29 00:00:00-08
16187	28	100	39	820	2024-02-29 00:00:00-08
16188	17	100	40	821	2024-02-29 00:00:00-08
16189	120	37	41	822	2024-02-29 00:00:00-08
16190	85	100	42	823	2024-02-29 00:00:00-08
16191	97	100	43	824	2024-02-29 00:00:00-08
16192	50	1000	44	766	2024-02-29 00:00:00-08
16193	50	1000	45	772	2024-02-29 00:00:00-08
16194	Infinity	100	46	7	2024-02-29 00:00:00-08
16195	50	371	47	768	2024-02-29 00:00:00-08
16196	50	1000	48	769	2024-02-29 00:00:00-08
16197	50	157	49	767	2024-02-29 00:00:00-08
16198	50	497	50	770	2024-02-29 00:00:00-08
16199	50	1000	51	771	2024-02-29 00:00:00-08
16200	50	1000	52	750	2024-02-29 00:00:00-08
16201	50	1000	53	749	2024-02-29 00:00:00-08
16202	50	1000	54	773	2024-02-29 00:00:00-08
16203	50	750	55	764	2024-02-29 00:00:00-08
16204	50	500	56	762	2024-02-29 00:00:00-08
16205	50	250	57	763	2024-02-29 00:00:00-08
16206	26	1000	58	774	2024-02-29 00:00:00-08
16207	50	1000	59	775	2024-02-29 00:00:00-08
16208	Infinity	100	60	8	2024-02-29 00:00:00-08
16209	12	444	61	776	2024-02-29 00:00:00-08
16210	113	773	62	777	2024-02-29 00:00:00-08
16211	56	670	63	778	2024-02-29 00:00:00-08
16212	97	1000	64	783	2024-02-29 00:00:00-08
16213	21	1000	65	784	2024-02-29 00:00:00-08
16214	26	1000	66	785	2024-02-29 00:00:00-08
16215	12	1000	67	786	2024-02-29 00:00:00-08
16216	7	278	68	787	2024-02-29 00:00:00-08
16217	86	370	69	788	2024-02-29 00:00:00-08
16218	176	1000	70	789	2024-02-29 00:00:00-08
16219	22	1000	71	790	2024-02-29 00:00:00-08
16220	10	208	72	791	2024-02-29 00:00:00-08
16221	312	1000	73	792	2024-02-29 00:00:00-08
16222	8	303	74	793	2024-02-29 00:00:00-08
16223	211	981	75	794	2024-02-29 00:00:00-08
16224	40	604	76	795	2024-02-29 00:00:00-08
16225	75	700	77	782	2024-02-29 00:00:00-08
16226	50	500	78	781	2024-02-29 00:00:00-08
16227	50	250	79	780	2024-02-29 00:00:00-08
16228	50	100	80	779	2024-02-29 00:00:00-08
16229	52	250	81	1212	2024-02-29 00:00:00-08
16230	0	\N	82	1446	2024-02-29 00:00:00-08
16231	0	\N	84	1447	2024-02-29 00:00:00-08
16232	0	\N	85	1448	2024-02-29 00:00:00-08
16233	Infinity	71.4	90	12	2024-02-29 00:00:00-08
16234	Infinity	40.7	91	1168	2024-02-29 00:00:00-08
16235	Infinity	100	92	892	2024-02-29 00:00:00-08
16236	Infinity	100	93	15	2024-02-29 00:00:00-08
16237	Infinity	67.4	94	16	2024-02-29 00:00:00-08
16238	Infinity	100	95	17	2024-02-29 00:00:00-08
16239	Infinity	100	96	18	2024-02-29 00:00:00-08
16240	Infinity	100	97	19	2024-02-29 00:00:00-08
16241	0	\N	100	69	2024-02-29 00:00:00-08
16242	90	271	125	2929	2024-02-29 00:00:00-08
16243	0	\N	126	590	2024-02-29 00:00:00-08
16244	7	250	127	578	2024-02-29 00:00:00-08
16245	7	250	127	577	2024-02-29 00:00:00-08
16246	0	\N	128	3131	2024-02-29 00:00:00-08
16247	0	\N	129	629	2024-02-29 00:00:00-08
16248	5	250	130	3128	2024-02-29 00:00:00-08
16249	5	250	130	603	2024-02-29 00:00:00-08
16250	5	250	130	562	2024-02-29 00:00:00-08
16251	5	250	130	70	2024-02-29 00:00:00-08
16252	5	250	130	21	2024-02-29 00:00:00-08
16253	5	250	130	20	2024-02-29 00:00:00-08
16254	2	250	131	536	2024-02-29 00:00:00-08
16255	41	250	132	585	2024-02-29 00:00:00-08
16256	41	250	132	561	2024-02-29 00:00:00-08
16257	3	250	133	3104	2024-02-29 00:00:00-08
16258	3	250	133	565	2024-02-29 00:00:00-08
16259	3	250	133	538	2024-02-29 00:00:00-08
16260	3	250	133	537	2024-02-29 00:00:00-08
16261	9	250	134	518	2024-02-29 00:00:00-08
16262	9	250	134	516	2024-02-29 00:00:00-08
16263	3	350	135	2904	2024-02-29 00:00:00-08
16264	3	350	135	648	2024-02-29 00:00:00-08
16265	1	250	136	2908	2024-02-29 00:00:00-08
16266	1	250	136	519	2024-02-29 00:00:00-08
16267	1	250	136	517	2024-02-29 00:00:00-08
16268	5	250	137	520	2024-02-29 00:00:00-08
16269	5	250	137	13	2024-02-29 00:00:00-08
16270	3	350	138	558	2024-02-29 00:00:00-08
16271	5	250	139	521	2024-02-29 00:00:00-08
16272	5	250	139	14	2024-02-29 00:00:00-08
16273	14	350	140	31	2024-02-29 00:00:00-08
16274	9	350	141	32	2024-02-29 00:00:00-08
16275	215	338	142	30	2024-02-29 00:00:00-08
16276	7	350	143	33	2024-02-29 00:00:00-08
16277	35	250	144	522	2024-02-29 00:00:00-08
16278	4	250	145	523	2024-02-29 00:00:00-08
16279	29	250	146	524	2024-02-29 00:00:00-08
16280	6	350	147	34	2024-02-29 00:00:00-08
16281	17	250	148	525	2024-02-29 00:00:00-08
16282	50	142	149	526	2024-02-29 00:00:00-08
16283	12	350	150	35	2024-02-29 00:00:00-08
16284	13	250	151	527	2024-02-29 00:00:00-08
16285	0	\N	152	591	2024-02-29 00:00:00-08
16286	6	350	153	36	2024-02-29 00:00:00-08
16287	8	350	154	37	2024-02-29 00:00:00-08
16288	6	350	155	574	2024-02-29 00:00:00-08
16289	6	350	155	38	2024-02-29 00:00:00-08
16290	25	250	156	528	2024-02-29 00:00:00-08
16291	5	350	157	80	2024-02-29 00:00:00-08
16292	5	350	157	39	2024-02-29 00:00:00-08
16293	2	250	158	575	2024-02-29 00:00:00-08
16294	2	250	158	529	2024-02-29 00:00:00-08
16295	41	250	159	530	2024-02-29 00:00:00-08
16296	4	250	162	531	2024-02-29 00:00:00-08
16297	45	250	163	532	2024-02-29 00:00:00-08
16298	5	250	166	576	2024-02-29 00:00:00-08
16299	5	250	166	533	2024-02-29 00:00:00-08
16300	33	250	167	534	2024-02-29 00:00:00-08
16301	7	250	170	535	2024-02-29 00:00:00-08
16302	17	250	171	23	2024-02-29 00:00:00-08
16303	17	250	171	22	2024-02-29 00:00:00-08
16304	3	250	174	25	2024-02-29 00:00:00-08
16305	3	250	174	24	2024-02-29 00:00:00-08
16306	2	250	175	26	2024-02-29 00:00:00-08
16307	7	250	177	27	2024-02-29 00:00:00-08
16308	14	250	178	28	2024-02-29 00:00:00-08
16309	6	250	181	29	2024-02-29 00:00:00-08
16310	0	\N	182	40	2024-02-29 00:00:00-08
16311	4	350	183	559	2024-02-29 00:00:00-08
16312	0	\N	184	41	2024-02-29 00:00:00-08
16313	Infinity	90	1337	279	2024-02-29 00:00:00-08
16314	0	\N	185	539	2024-02-29 00:00:00-08
16315	0	\N	186	560	2024-02-29 00:00:00-08
16316	50	1520	187	2909	2024-02-29 00:00:00-08
16317	50	1520	187	567	2024-02-29 00:00:00-08
16318	50	1520	187	540	2024-02-29 00:00:00-08
16319	0	\N	188	2926	2024-02-29 00:00:00-08
16320	0	\N	189	579	2024-02-29 00:00:00-08
16321	0	\N	190	541	2024-02-29 00:00:00-08
16322	0	\N	191	2927	2024-02-29 00:00:00-08
16323	0	\N	192	580	2024-02-29 00:00:00-08
16324	0	\N	193	2924	2024-02-29 00:00:00-08
16325	0	\N	193	606	2024-02-29 00:00:00-08
16326	0	\N	193	73	2024-02-29 00:00:00-08
16327	11	666	194	2910	2024-02-29 00:00:00-08
16328	11	666	194	581	2024-02-29 00:00:00-08
16329	0	\N	195	2928	2024-02-29 00:00:00-08
16330	0	\N	195	568	2024-02-29 00:00:00-08
16331	0	\N	196	2911	2024-02-29 00:00:00-08
16332	0	\N	196	582	2024-02-29 00:00:00-08
16333	44	250	198	42	2024-02-29 00:00:00-08
16334	13	250	199	43	2024-02-29 00:00:00-08
16335	6	250	200	607	2024-02-29 00:00:00-08
16336	5	250	201	44	2024-02-29 00:00:00-08
16337	39	333	202	3133	2024-02-29 00:00:00-08
16338	52	250	203	45	2024-02-29 00:00:00-08
16339	2	250	205	608	2024-02-29 00:00:00-08
16340	302	250	206	46	2024-02-29 00:00:00-08
16341	3	250	207	47	2024-02-29 00:00:00-08
16342	8	250	208	609	2024-02-29 00:00:00-08
16343	48	286.6	209	48	2024-02-29 00:00:00-08
16344	12	300	210	542	2024-02-29 00:00:00-08
16345	39	300	211	736	2024-02-29 00:00:00-08
16346	39	300	211	49	2024-02-29 00:00:00-08
16347	48	195.4	212	630	2024-02-29 00:00:00-08
16348	48	195.4	212	623	2024-02-29 00:00:00-08
16349	31	300	213	596	2024-02-29 00:00:00-08
16350	31	300	213	543	2024-02-29 00:00:00-08
16351	48	243.4	214	51	2024-02-29 00:00:00-08
16352	26	300	215	52	2024-02-29 00:00:00-08
16353	48	137.3	216	53	2024-02-29 00:00:00-08
16354	44	300	217	54	2024-02-29 00:00:00-08
16355	48	298.6	218	544	2024-02-29 00:00:00-08
16356	48	145.9	219	636	2024-02-29 00:00:00-08
16357	31	300	220	597	2024-02-29 00:00:00-08
16358	31	300	220	545	2024-02-29 00:00:00-08
16359	31	300	220	121	2024-02-29 00:00:00-08
16360	45	300	221	598	2024-02-29 00:00:00-08
16361	45	300	221	592	2024-02-29 00:00:00-08
16362	48	73.9	222	631	2024-02-29 00:00:00-08
16363	48	73.9	222	55	2024-02-29 00:00:00-08
16364	48	193.4	223	643	2024-02-29 00:00:00-08
16365	48	193.4	223	637	2024-02-29 00:00:00-08
16366	48	171.8	224	599	2024-02-29 00:00:00-08
16367	44	300	225	593	2024-02-29 00:00:00-08
16368	48	273.1	226	633	2024-02-29 00:00:00-08
16369	48	273.1	226	624	2024-02-29 00:00:00-08
16370	8	300	227	3105	2024-02-29 00:00:00-08
16371	8	300	227	613	2024-02-29 00:00:00-08
16372	8	300	227	583	2024-02-29 00:00:00-08
16373	6	300	228	3106	2024-02-29 00:00:00-08
16374	6	300	228	622	2024-02-29 00:00:00-08
16375	6	300	228	614	2024-02-29 00:00:00-08
16376	48	67.7	229	56	2024-02-29 00:00:00-08
16377	48	185.3	230	546	2024-02-29 00:00:00-08
16378	48	272.6	231	625	2024-02-29 00:00:00-08
16379	48	48	232	638	2024-02-29 00:00:00-08
16380	6	300	233	2925	2024-02-29 00:00:00-08
16381	6	300	233	569	2024-02-29 00:00:00-08
16382	48	186.2	234	615	2024-02-29 00:00:00-08
16383	48	186.2	234	584	2024-02-29 00:00:00-08
16384	48	124.8	235	639	2024-02-29 00:00:00-08
16385	48	277	236	626	2024-02-29 00:00:00-08
16386	48	107.5	237	57	2024-02-29 00:00:00-08
16387	24	300	238	586	2024-02-29 00:00:00-08
16388	24	300	238	547	2024-02-29 00:00:00-08
16389	7	300	239	550	2024-02-29 00:00:00-08
16390	39	300	240	58	2024-02-29 00:00:00-08
16391	8	300	241	570	2024-02-29 00:00:00-08
16392	8	300	241	549	2024-02-29 00:00:00-08
16393	12	300	242	548	2024-02-29 00:00:00-08
16394	23	300	243	50	2024-02-29 00:00:00-08
16395	13	300	244	59	2024-02-29 00:00:00-08
16396	6	300	245	60	2024-02-29 00:00:00-08
16397	8	300	248	616	2024-02-29 00:00:00-08
16398	8	300	248	551	2024-02-29 00:00:00-08
16399	48	54.2	249	644	2024-02-29 00:00:00-08
16400	48	54.2	249	640	2024-02-29 00:00:00-08
16401	263	84	250	3101	2024-02-29 00:00:00-08
16402	28	300	251	2912	2024-02-29 00:00:00-08
16403	28	300	251	621	2024-02-29 00:00:00-08
16404	28	300	251	617	2024-02-29 00:00:00-08
16405	48	91.7	252	618	2024-02-29 00:00:00-08
16406	48	91.7	252	610	2024-02-29 00:00:00-08
16407	6	300	253	61	2024-02-29 00:00:00-08
16408	14	300	254	587	2024-02-29 00:00:00-08
16409	14	300	254	552	2024-02-29 00:00:00-08
16410	48	102.2	255	641	2024-02-29 00:00:00-08
16411	14	300	256	588	2024-02-29 00:00:00-08
16412	14	300	256	553	2024-02-29 00:00:00-08
16413	28	300	257	2333	2024-02-29 00:00:00-08
16414	28	300	257	554	2024-02-29 00:00:00-08
16415	48	101.3	258	735	2024-02-29 00:00:00-08
16416	48	214.1	259	627	2024-02-29 00:00:00-08
16417	10	300	260	571	2024-02-29 00:00:00-08
16418	10	300	260	555	2024-02-29 00:00:00-08
16419	37	300	261	589	2024-02-29 00:00:00-08
16420	37	300	261	556	2024-02-29 00:00:00-08
16421	48	224.2	262	632	2024-02-29 00:00:00-08
16422	48	224.2	262	62	2024-02-29 00:00:00-08
16423	23	300	263	612	2024-02-29 00:00:00-08
16424	23	300	263	63	2024-02-29 00:00:00-08
16425	8	300	264	572	2024-02-29 00:00:00-08
16426	8	300	264	557	2024-02-29 00:00:00-08
16427	Infinity	86.8	1338	280	2024-02-29 00:00:00-08
16428	157	71	266	75	2024-02-29 00:00:00-08
16429	48	67.7	267	76	2024-02-29 00:00:00-08
16430	48	67.7	267	64	2024-02-29 00:00:00-08
16431	48	32.7	268	78	2024-02-29 00:00:00-08
16432	48	32.7	268	65	2024-02-29 00:00:00-08
16433	48	68.6	269	66	2024-02-29 00:00:00-08
16434	48	138.2	270	628	2024-02-29 00:00:00-08
16435	48	77.3	271	67	2024-02-29 00:00:00-08
16436	9	300	272	3107	2024-02-29 00:00:00-08
16437	9	300	272	647	2024-02-29 00:00:00-08
16438	9	300	272	620	2024-02-29 00:00:00-08
16439	9	300	272	611	2024-02-29 00:00:00-08
16440	21	300	273	68	2024-02-29 00:00:00-08
16441	32	999	277	2906	2024-02-29 00:00:00-08
16442	32	999	277	645	2024-02-29 00:00:00-08
16443	32	999	277	573	2024-02-29 00:00:00-08
16444	23	999	281	3130	2024-02-29 00:00:00-08
16445	23	999	281	605	2024-02-29 00:00:00-08
16446	23	999	281	566	2024-02-29 00:00:00-08
16447	23	999	281	72	2024-02-29 00:00:00-08
16448	46	999	282	600	2024-02-29 00:00:00-08
16449	46	999	282	594	2024-02-29 00:00:00-08
16450	46	999	282	564	2024-02-29 00:00:00-08
16451	25	999	283	3129	2024-02-29 00:00:00-08
16452	25	999	283	604	2024-02-29 00:00:00-08
16453	25	999	283	563	2024-02-29 00:00:00-08
16454	25	999	283	71	2024-02-29 00:00:00-08
16455	19	999	284	2905	2024-02-29 00:00:00-08
16456	19	999	284	601	2024-02-29 00:00:00-08
16457	19	999	284	595	2024-02-29 00:00:00-08
16458	0	\N	285	74	2024-02-29 00:00:00-08
16459	0	\N	286	2903	2024-02-29 00:00:00-08
16460	0	\N	287	2902	2024-02-29 00:00:00-08
16461	0	\N	288	642	2024-02-29 00:00:00-08
16462	72	666	289	84	2024-02-29 00:00:00-08
16463	72	666	289	77	2024-02-29 00:00:00-08
16464	32	258	290	602	2024-02-29 00:00:00-08
16465	96	259	291	619	2024-02-29 00:00:00-08
16466	96	328	292	634	2024-02-29 00:00:00-08
16467	96	228	293	737	2024-02-29 00:00:00-08
16468	20	333	298	646	2024-02-29 00:00:00-08
16469	27	333	299	649	2024-02-29 00:00:00-08
16470	29	333	302	82	2024-02-29 00:00:00-08
16471	70	333	303	83	2024-02-29 00:00:00-08
16472	96	67	311	685	2024-02-29 00:00:00-08
19097	0	\N	4494	1316	2024-02-29 00:00:00-08
16473	29	583	312	2939	2024-02-29 00:00:00-08
16474	29	583	312	686	2024-02-29 00:00:00-08
16475	27	583	313	2932	2024-02-29 00:00:00-08
16476	27	583	313	2876	2024-02-29 00:00:00-08
16477	27	583	313	117	2024-02-29 00:00:00-08
16478	27	583	313	116	2024-02-29 00:00:00-08
16479	27	583	313	115	2024-02-29 00:00:00-08
16480	96	227	315	688	2024-02-29 00:00:00-08
16481	49	333	316	689	2024-02-29 00:00:00-08
16482	80	333	317	690	2024-02-29 00:00:00-08
16483	63	333	324	3137	2024-02-29 00:00:00-08
16484	88	63	326	693	2024-02-29 00:00:00-08
16485	10	333	327	3134	2024-02-29 00:00:00-08
16486	88	254	328	650	2024-02-29 00:00:00-08
16487	88	99	331	2933	2024-02-29 00:00:00-08
16488	10	333	332	2934	2024-02-29 00:00:00-08
16489	96	20	348	100	2024-02-29 00:00:00-08
16490	96	490	350	723	2024-02-29 00:00:00-08
16491	96	490	350	85	2024-02-29 00:00:00-08
16492	96	42	352	101	2024-02-29 00:00:00-08
16493	96	390.7	354	118	2024-02-29 00:00:00-08
16494	96	390.7	354	87	2024-02-29 00:00:00-08
16495	96	244.8	355	88	2024-02-29 00:00:00-08
16496	95	116.9	379	673	2024-02-29 00:00:00-08
16497	30	333	380	3132	2024-02-29 00:00:00-08
16498	29	333	381	3115	2024-02-29 00:00:00-08
16499	29	333	381	658	2024-02-29 00:00:00-08
16500	83	333	389	666	2024-02-29 00:00:00-08
16501	79	333	390	89	2024-02-29 00:00:00-08
16502	96	145	391	90	2024-02-29 00:00:00-08
16503	96	208	392	3102	2024-02-29 00:00:00-08
16504	35	333	396	675	2024-02-29 00:00:00-08
16505	35	333	396	97	2024-02-29 00:00:00-08
16506	35	333	396	91	2024-02-29 00:00:00-08
16507	0	\N	397	676	2024-02-29 00:00:00-08
16508	31	333	398	3110	2024-02-29 00:00:00-08
16509	31	333	398	659	2024-02-29 00:00:00-08
16510	96	141.1	402	713	2024-02-29 00:00:00-08
16511	10	333	403	2937	2024-02-29 00:00:00-08
16512	10	333	403	122	2024-02-29 00:00:00-08
16513	10	333	403	92	2024-02-29 00:00:00-08
16514	61	333	408	677	2024-02-29 00:00:00-08
16515	61	333	408	668	2024-02-29 00:00:00-08
16516	96	253.4	409	93	2024-02-29 00:00:00-08
16517	8	333	411	705	2024-02-29 00:00:00-08
16518	8	333	411	696	2024-02-29 00:00:00-08
16519	74	333	412	669	2024-02-29 00:00:00-08
16520	96	265	413	670	2024-02-29 00:00:00-08
16521	96	134.4	414	94	2024-02-29 00:00:00-08
16522	88	115	416	2913	2024-02-29 00:00:00-08
16523	96	189	420	671	2024-02-29 00:00:00-08
16524	95	149	421	95	2024-02-29 00:00:00-08
16525	0	\N	424	3111	2024-02-29 00:00:00-08
16526	57	333	425	722	2024-02-29 00:00:00-08
16527	57	333	425	697	2024-02-29 00:00:00-08
16528	95	307	426	123	2024-02-29 00:00:00-08
16529	95	307	426	98	2024-02-29 00:00:00-08
16530	Infinity	40	1339	281	2024-02-29 00:00:00-08
16531	96	22	433	102	2024-02-29 00:00:00-08
16532	95	115	436	96	2024-02-29 00:00:00-08
16533	95	115.9	439	730	2024-02-29 00:00:00-08
16534	9	333	441	695	2024-02-29 00:00:00-08
16535	9	333	441	678	2024-02-29 00:00:00-08
16536	22	333	443	665	2024-02-29 00:00:00-08
16537	95	291.7	445	661	2024-02-29 00:00:00-08
16538	95	268.9	446	662	2024-02-29 00:00:00-08
16539	45	333	447	663	2024-02-29 00:00:00-08
16540	32	333	448	2917	2024-02-29 00:00:00-08
16541	32	333	448	653	2024-02-29 00:00:00-08
16542	44	333	453	664	2024-02-29 00:00:00-08
16543	17	333	454	2916	2024-02-29 00:00:00-08
16544	17	333	454	654	2024-02-29 00:00:00-08
16545	7	333	455	2930	2024-02-29 00:00:00-08
16546	78	1200	456	2907	2024-02-29 00:00:00-08
16547	78	1200	456	2873	2024-02-29 00:00:00-08
16548	78	1200	456	2870	2024-02-29 00:00:00-08
16549	78	1200	456	740	2024-02-29 00:00:00-08
16550	78	1200	456	110	2024-02-29 00:00:00-08
16551	78	1200	456	107	2024-02-29 00:00:00-08
16552	63	333	457	2918	2024-02-29 00:00:00-08
16553	63	333	457	742	2024-02-29 00:00:00-08
16554	190	317	466	682	2024-02-29 00:00:00-08
16555	87	333	467	706	2024-02-29 00:00:00-08
16556	9	333	468	683	2024-02-29 00:00:00-08
16557	8	333	469	698	2024-02-29 00:00:00-08
16558	95	84.6	471	707	2024-02-29 00:00:00-08
16559	75	333	472	699	2024-02-29 00:00:00-08
16560	95	91.4	475	738	2024-02-29 00:00:00-08
16561	7	333	478	660	2024-02-29 00:00:00-08
16562	0	\N	480	3114	2024-02-29 00:00:00-08
16563	84	333	482	709	2024-02-29 00:00:00-08
16564	95	214	483	710	2024-02-29 00:00:00-08
16565	95	177	484	711	2024-02-29 00:00:00-08
16566	9	333	485	3112	2024-02-29 00:00:00-08
16567	9	333	485	712	2024-02-29 00:00:00-08
16568	30	333	486	3113	2024-02-29 00:00:00-08
16569	30	333	486	655	2024-02-29 00:00:00-08
16570	136	333	492	657	2024-02-29 00:00:00-08
16571	51	1200	493	2874	2024-02-29 00:00:00-08
16572	51	1200	493	2871	2024-02-29 00:00:00-08
16573	51	1200	493	741	2024-02-29 00:00:00-08
16574	51	1200	493	111	2024-02-29 00:00:00-08
16575	51	1200	493	108	2024-02-29 00:00:00-08
16576	51	1200	493	106	2024-02-29 00:00:00-08
16577	49	333	494	3053	2024-02-29 00:00:00-08
16578	95	103	495	674	2024-02-29 00:00:00-08
16579	95	238.5	496	679	2024-02-29 00:00:00-08
16580	88	210	566	3125	2024-02-29 00:00:00-08
16581	95	165.3	497	680	2024-02-29 00:00:00-08
16582	190	205.2	498	681	2024-02-29 00:00:00-08
16583	26	333	499	2931	2024-02-29 00:00:00-08
16584	45	333	502	700	2024-02-29 00:00:00-08
16585	95	115.9	503	701	2024-02-29 00:00:00-08
16586	54	333	506	3103	2024-02-29 00:00:00-08
16587	54	333	506	731	2024-02-29 00:00:00-08
16588	95	249	508	732	2024-02-29 00:00:00-08
16589	95	100.7	510	2877	2024-02-29 00:00:00-08
16590	95	180	511	733	2024-02-29 00:00:00-08
16591	380	278	512	739	2024-02-29 00:00:00-08
16592	95	228	513	734	2024-02-29 00:00:00-08
16593	95	159	514	714	2024-02-29 00:00:00-08
16594	95	280	515	3135	2024-02-29 00:00:00-08
16595	33	333	516	3108	2024-02-29 00:00:00-08
16596	33	333	516	702	2024-02-29 00:00:00-08
16597	50	333	517	3136	2024-02-29 00:00:00-08
16598	18	333	518	3109	2024-02-29 00:00:00-08
16599	18	333	518	715	2024-02-29 00:00:00-08
16600	34	333	519	716	2024-02-29 00:00:00-08
16601	43	333	520	717	2024-02-29 00:00:00-08
16602	95	247	522	2935	2024-02-29 00:00:00-08
16603	61	333	523	2914	2024-02-29 00:00:00-08
16604	61	333	523	703	2024-02-29 00:00:00-08
16605	53	333	524	2936	2024-02-29 00:00:00-08
16606	95	118.8	525	704	2024-02-29 00:00:00-08
16607	191	105	526	718	2024-02-29 00:00:00-08
16608	43	333	527	719	2024-02-29 00:00:00-08
16609	180	333	528	720	2024-02-29 00:00:00-08
16610	95	100	529	724	2024-02-29 00:00:00-08
16611	95	150	530	725	2024-02-29 00:00:00-08
16612	95	130	532	726	2024-02-29 00:00:00-08
16613	95	264	533	99	2024-02-29 00:00:00-08
16614	95	121	534	727	2024-02-29 00:00:00-08
16615	64	333	536	721	2024-02-29 00:00:00-08
16616	95	61	538	728	2024-02-29 00:00:00-08
16617	18	20	539	2867	2024-02-29 00:00:00-08
16618	18	20	539	2864	2024-02-29 00:00:00-08
16619	18	20	539	103	2024-02-29 00:00:00-08
16620	9	42	540	2868	2024-02-29 00:00:00-08
16621	9	42	540	2865	2024-02-29 00:00:00-08
16622	9	42	540	104	2024-02-29 00:00:00-08
16623	10	22	541	2869	2024-02-29 00:00:00-08
16624	10	22	541	2866	2024-02-29 00:00:00-08
16625	10	22	541	105	2024-02-29 00:00:00-08
16626	88	38.7	542	113	2024-02-29 00:00:00-08
16627	148	1200	543	2875	2024-02-29 00:00:00-08
16628	148	1200	543	2872	2024-02-29 00:00:00-08
16629	148	1200	543	748	2024-02-29 00:00:00-08
16630	148	1200	543	112	2024-02-29 00:00:00-08
16631	148	1200	543	109	2024-02-29 00:00:00-08
16632	37	333	544	743	2024-02-29 00:00:00-08
16633	37	333	544	120	2024-02-29 00:00:00-08
16634	37	333	544	114	2024-02-29 00:00:00-08
16635	88	141.7	546	2938	2024-02-29 00:00:00-08
16636	50	180	547	746	2024-02-29 00:00:00-08
16637	15	333	548	119	2024-02-29 00:00:00-08
16638	69	333	549	2919	2024-02-29 00:00:00-08
16639	30	333	550	2920	2024-02-29 00:00:00-08
16640	88	142	551	2921	2024-02-29 00:00:00-08
16641	88	115	552	124	2024-02-29 00:00:00-08
16642	88	188	553	125	2024-02-29 00:00:00-08
16643	88	120	554	2922	2024-02-29 00:00:00-08
16644	69	333	555	2923	2024-02-29 00:00:00-08
16645	90	14	557	3116	2024-02-29 00:00:00-08
16646	72	333	558	3117	2024-02-29 00:00:00-08
16647	88	191	559	3118	2024-02-29 00:00:00-08
16648	33	333	560	3119	2024-02-29 00:00:00-08
16649	88	201	561	3120	2024-02-29 00:00:00-08
16650	88	286	562	3121	2024-02-29 00:00:00-08
16651	88	197	564	3123	2024-02-29 00:00:00-08
16652	69	333	565	3124	2024-02-29 00:00:00-08
16653	58	333	567	3126	2024-02-29 00:00:00-08
16654	88	152	568	3127	2024-02-29 00:00:00-08
16655	0	\N	570	1949	2024-02-29 00:00:00-08
16656	0	\N	571	1950	2024-02-29 00:00:00-08
16657	0	\N	573	179	2024-02-29 00:00:00-08
16658	0	\N	575	1951	2024-02-29 00:00:00-08
16659	0	\N	577	1952	2024-02-29 00:00:00-08
16660	0	\N	578	1953	2024-02-29 00:00:00-08
16661	0	\N	581	1955	2024-02-29 00:00:00-08
16662	0	\N	582	1956	2024-02-29 00:00:00-08
16663	0	\N	584	1954	2024-02-29 00:00:00-08
16664	0	\N	585	180	2024-02-29 00:00:00-08
16665	3	100	604	1751	2024-02-29 00:00:00-08
16666	5	400	605	1749	2024-02-29 00:00:00-08
16667	5	400	605	132	2024-02-29 00:00:00-08
16668	5	400	605	129	2024-02-29 00:00:00-08
16669	5	400	605	126	2024-02-29 00:00:00-08
16670	7	400	606	1750	2024-02-29 00:00:00-08
16671	7	400	606	133	2024-02-29 00:00:00-08
16672	7	400	606	130	2024-02-29 00:00:00-08
16673	7	400	606	127	2024-02-29 00:00:00-08
16674	1	100	607	1752	2024-02-29 00:00:00-08
16675	1	600	608	1759	2024-02-29 00:00:00-08
16676	1	600	608	1758	2024-02-29 00:00:00-08
16677	1	600	608	1755	2024-02-29 00:00:00-08
16678	1	600	608	190	2024-02-29 00:00:00-08
16679	1	600	608	152	2024-02-29 00:00:00-08
16680	1	600	608	151	2024-02-29 00:00:00-08
16681	3	100	609	1756	2024-02-29 00:00:00-08
16682	0	100	611	136	2024-02-29 00:00:00-08
16683	11	300	612	154	2024-02-29 00:00:00-08
16684	11	300	612	153	2024-02-29 00:00:00-08
16685	11	300	612	137	2024-02-29 00:00:00-08
16686	4	100	615	1760	2024-02-29 00:00:00-08
16687	0	100	616	1761	2024-02-29 00:00:00-08
16688	14	400	634	1780	2024-02-29 00:00:00-08
16689	14	400	634	1774	2024-02-29 00:00:00-08
16690	14	400	634	191	2024-02-29 00:00:00-08
16691	14	400	634	155	2024-02-29 00:00:00-08
16692	9	300	644	157	2024-02-29 00:00:00-08
16693	9	300	644	156	2024-02-29 00:00:00-08
16694	9	300	644	138	2024-02-29 00:00:00-08
16695	11	300	645	159	2024-02-29 00:00:00-08
16696	11	300	645	158	2024-02-29 00:00:00-08
16697	11	300	645	139	2024-02-29 00:00:00-08
16698	13	400	646	135	2024-02-29 00:00:00-08
16699	13	400	646	134	2024-02-29 00:00:00-08
16700	13	400	646	131	2024-02-29 00:00:00-08
16701	13	400	646	128	2024-02-29 00:00:00-08
16702	10	300	647	161	2024-02-29 00:00:00-08
16703	10	300	647	160	2024-02-29 00:00:00-08
16704	10	300	647	140	2024-02-29 00:00:00-08
16705	Infinity	45.2	1340	282	2024-02-29 00:00:00-08
16706	5	300	662	163	2024-02-29 00:00:00-08
16707	5	300	662	162	2024-02-29 00:00:00-08
16708	5	300	662	141	2024-02-29 00:00:00-08
16709	4	100	673	1795	2024-02-29 00:00:00-08
16710	2	100	674	1796	2024-02-29 00:00:00-08
16711	2	100	675	142	2024-02-29 00:00:00-08
16712	2	100	676	1797	2024-02-29 00:00:00-08
16713	2	100	677	1798	2024-02-29 00:00:00-08
16714	6	100	678	1799	2024-02-29 00:00:00-08
16715	4	100	682	1800	2024-02-29 00:00:00-08
16716	5	100	684	1782	2024-02-29 00:00:00-08
16717	17	400	692	1786	2024-02-29 00:00:00-08
16718	17	400	692	1785	2024-02-29 00:00:00-08
16719	17	400	692	1783	2024-02-29 00:00:00-08
16720	17	400	692	164	2024-02-29 00:00:00-08
16721	20	298	693	200	2024-02-29 00:00:00-08
16722	20	298	693	165	2024-02-29 00:00:00-08
16723	20	298	693	143	2024-02-29 00:00:00-08
16724	1	100	695	1784	2024-02-29 00:00:00-08
16725	2	100	696	1735	2024-02-29 00:00:00-08
16726	3	100	697	1736	2024-02-29 00:00:00-08
16727	5	100	699	1737	2024-02-29 00:00:00-08
16728	5	100	703	1738	2024-02-29 00:00:00-08
16729	0	\N	705	145	2024-02-29 00:00:00-08
16730	4	100	708	1739	2024-02-29 00:00:00-08
16731	20	70.4	716	1775	2024-02-29 00:00:00-08
16732	32	300	720	167	2024-02-29 00:00:00-08
16733	32	300	720	166	2024-02-29 00:00:00-08
16734	32	300	720	144	2024-02-29 00:00:00-08
16735	5	100	721	1727	2024-02-29 00:00:00-08
16736	3	100	722	1728	2024-02-29 00:00:00-08
16737	2	100	726	1729	2024-02-29 00:00:00-08
16738	Infinity	60	1341	283	2024-02-29 00:00:00-08
16739	5	100	728	1730	2024-02-29 00:00:00-08
16740	2	100	729	1731	2024-02-29 00:00:00-08
16741	4	100	730	1732	2024-02-29 00:00:00-08
16742	19	100	731	1733	2024-02-29 00:00:00-08
16743	5	100	740	1740	2024-02-29 00:00:00-08
16744	1	100	741	1741	2024-02-29 00:00:00-08
16745	3	100	742	1742	2024-02-29 00:00:00-08
16746	4	100	749	1734	2024-02-29 00:00:00-08
16747	4	100	753	1790	2024-02-29 00:00:00-08
16748	6	100	754	1791	2024-02-29 00:00:00-08
16749	1	100	755	1792	2024-02-29 00:00:00-08
16750	0	\N	756	1754	2024-02-29 00:00:00-08
16751	16	100	758	1753	2024-02-29 00:00:00-08
16752	6	100	775	1762	2024-02-29 00:00:00-08
16753	8	100	777	1776	2024-02-29 00:00:00-08
16754	10	100	778	1777	2024-02-29 00:00:00-08
16755	19	200	783	1789	2024-02-29 00:00:00-08
16756	19	200	783	201	2024-02-29 00:00:00-08
16757	0	\N	784	181	2024-02-29 00:00:00-08
16758	0	\N	785	182	2024-02-29 00:00:00-08
16759	9	100	790	1778	2024-02-29 00:00:00-08
16760	47	400	791	1781	2024-02-29 00:00:00-08
16761	47	400	791	1779	2024-02-29 00:00:00-08
16762	47	400	791	192	2024-02-29 00:00:00-08
16763	47	400	791	168	2024-02-29 00:00:00-08
16764	33	200	793	169	2024-02-29 00:00:00-08
16765	33	200	793	146	2024-02-29 00:00:00-08
16766	21	200	804	170	2024-02-29 00:00:00-08
16767	21	200	804	147	2024-02-29 00:00:00-08
16768	9	100	806	1763	2024-02-29 00:00:00-08
16769	9	100	809	1764	2024-02-29 00:00:00-08
16770	4	100	810	1765	2024-02-29 00:00:00-08
16771	26	200	815	1788	2024-02-29 00:00:00-08
16772	26	200	815	1787	2024-02-29 00:00:00-08
16773	8	200	818	194	2024-02-29 00:00:00-08
16774	8	200	818	193	2024-02-29 00:00:00-08
16775	33	300	819	1771	2024-02-29 00:00:00-08
16776	33	300	819	1766	2024-02-29 00:00:00-08
16777	33	300	819	148	2024-02-29 00:00:00-08
16778	24	200	821	1743	2024-02-29 00:00:00-08
16779	24	200	821	149	2024-02-29 00:00:00-08
16780	47	300	822	1748	2024-02-29 00:00:00-08
16781	47	300	822	1744	2024-02-29 00:00:00-08
16782	47	300	822	150	2024-02-29 00:00:00-08
16783	46	300	830	1794	2024-02-29 00:00:00-08
16784	46	300	830	183	2024-02-29 00:00:00-08
16785	46	300	830	171	2024-02-29 00:00:00-08
16786	21	200	831	1793	2024-02-29 00:00:00-08
16787	21	200	831	172	2024-02-29 00:00:00-08
16788	25	400	832	1768	2024-02-29 00:00:00-08
16789	25	400	832	1767	2024-02-29 00:00:00-08
16790	25	400	832	184	2024-02-29 00:00:00-08
16791	25	400	832	173	2024-02-29 00:00:00-08
16792	46	400	833	1773	2024-02-29 00:00:00-08
16793	46	400	833	1772	2024-02-29 00:00:00-08
16794	46	400	833	185	2024-02-29 00:00:00-08
19098	0	\N	4495	1318	2024-02-29 00:00:00-08
16795	46	400	833	174	2024-02-29 00:00:00-08
16796	5	100	834	1757	2024-02-29 00:00:00-08
16797	5	100	837	175	2024-02-29 00:00:00-08
16798	10	100	838	176	2024-02-29 00:00:00-08
16799	38	500	841	197	2024-02-29 00:00:00-08
16800	38	500	841	196	2024-02-29 00:00:00-08
16801	38	500	841	195	2024-02-29 00:00:00-08
16802	38	500	841	186	2024-02-29 00:00:00-08
16803	38	500	841	177	2024-02-29 00:00:00-08
16804	18	400	842	199	2024-02-29 00:00:00-08
16805	18	400	842	198	2024-02-29 00:00:00-08
16806	18	400	842	187	2024-02-29 00:00:00-08
16807	18	400	842	178	2024-02-29 00:00:00-08
16808	6	100	845	1801	2024-02-29 00:00:00-08
16809	8	100	846	188	2024-02-29 00:00:00-08
16810	40	225	847	1770	2024-02-29 00:00:00-08
16811	40	225	847	1769	2024-02-29 00:00:00-08
16812	40	225	847	189	2024-02-29 00:00:00-08
16813	40	271	848	1747	2024-02-29 00:00:00-08
16814	40	271	848	1746	2024-02-29 00:00:00-08
16815	40	271	848	1745	2024-02-29 00:00:00-08
16816	Infinity	100	853	860	2024-02-29 00:00:00-08
16817	Infinity	100	854	861	2024-02-29 00:00:00-08
16818	Infinity	100	855	862	2024-02-29 00:00:00-08
16819	Infinity	100	856	863	2024-02-29 00:00:00-08
16820	Infinity	100	857	864	2024-02-29 00:00:00-08
16821	Infinity	100	858	865	2024-02-29 00:00:00-08
16822	Infinity	100	859	866	2024-02-29 00:00:00-08
16823	Infinity	100	860	867	2024-02-29 00:00:00-08
16824	Infinity	100	861	868	2024-02-29 00:00:00-08
16825	Infinity	100	862	869	2024-02-29 00:00:00-08
16826	Infinity	100	863	870	2024-02-29 00:00:00-08
16827	Infinity	100	864	871	2024-02-29 00:00:00-08
16828	50	245	1059	2037	2024-02-29 00:00:00-08
16829	Infinity	100	865	872	2024-02-29 00:00:00-08
16830	Infinity	100	866	873	2024-02-29 00:00:00-08
16831	Infinity	100	867	874	2024-02-29 00:00:00-08
16832	Infinity	100	868	875	2024-02-29 00:00:00-08
16833	0	\N	869	876	2024-02-29 00:00:00-08
16834	0	\N	870	877	2024-02-29 00:00:00-08
16835	0	\N	871	878	2024-02-29 00:00:00-08
16836	0	\N	872	879	2024-02-29 00:00:00-08
16837	0	\N	873	880	2024-02-29 00:00:00-08
16838	0	\N	874	881	2024-02-29 00:00:00-08
16839	0	\N	875	882	2024-02-29 00:00:00-08
16840	0	\N	876	883	2024-02-29 00:00:00-08
16841	0	\N	877	884	2024-02-29 00:00:00-08
16842	0	\N	878	885	2024-02-29 00:00:00-08
16843	\N	\N	879	886	2024-02-29 00:00:00-08
16844	\N	\N	880	887	2024-02-29 00:00:00-08
16845	\N	\N	881	888	2024-02-29 00:00:00-08
16846	\N	\N	882	889	2024-02-29 00:00:00-08
16847	\N	\N	883	890	2024-02-29 00:00:00-08
16848	\N	\N	884	891	2024-02-29 00:00:00-08
16849	Infinity	100	885	844	2024-02-29 00:00:00-08
16850	Infinity	100	886	796	2024-02-29 00:00:00-08
16851	Infinity	62.7	887	845	2024-02-29 00:00:00-08
16852	Infinity	9.1	888	846	2024-02-29 00:00:00-08
16853	Infinity	100	889	797	2024-02-29 00:00:00-08
16854	Infinity	100	890	798	2024-02-29 00:00:00-08
16855	Infinity	100	891	799	2024-02-29 00:00:00-08
16856	Infinity	100	892	800	2024-02-29 00:00:00-08
16857	Infinity	100	893	801	2024-02-29 00:00:00-08
16858	Infinity	100	894	202	2024-02-29 00:00:00-08
16859	Infinity	100	895	203	2024-02-29 00:00:00-08
16860	Infinity	100	896	204	2024-02-29 00:00:00-08
16861	Infinity	100	897	205	2024-02-29 00:00:00-08
16862	Infinity	100	898	206	2024-02-29 00:00:00-08
16863	48	105.6	899	2353	2024-02-29 00:00:00-08
16864	48	134.9	900	2354	2024-02-29 00:00:00-08
16865	47	184.8	901	2407	2024-02-29 00:00:00-08
16866	50	54.7	902	2355	2024-02-29 00:00:00-08
16867	45	26.7	903	2622	2024-02-29 00:00:00-08
16868	49	54.2	904	2356	2024-02-29 00:00:00-08
16869	49	53.8	905	2623	2024-02-29 00:00:00-08
16870	47	37.6	906	2357	2024-02-29 00:00:00-08
16871	47	94.1	907	2358	2024-02-29 00:00:00-08
16872	19	250	909	2359	2024-02-29 00:00:00-08
16873	48	76.3	910	2360	2024-02-29 00:00:00-08
16874	Infinity	100	915	988	2024-02-29 00:00:00-08
16875	Infinity	12.4	916	989	2024-02-29 00:00:00-08
16876	Infinity	84.3	917	990	2024-02-29 00:00:00-08
16877	Infinity	69.4	918	991	2024-02-29 00:00:00-08
16878	Infinity	100	919	992	2024-02-29 00:00:00-08
16879	Infinity	94.6	920	993	2024-02-29 00:00:00-08
16880	Infinity	74.3	921	893	2024-02-29 00:00:00-08
16881	Infinity	100	922	894	2024-02-29 00:00:00-08
16882	\N	\N	923	956	2024-02-29 00:00:00-08
16883	\N	\N	924	957	2024-02-29 00:00:00-08
16884	\N	\N	925	958	2024-02-29 00:00:00-08
16885	Infinity	100	926	1069	2024-02-29 00:00:00-08
16886	Infinity	100	927	1070	2024-02-29 00:00:00-08
16887	Infinity	120	928	1085	2024-02-29 00:00:00-08
16888	Infinity	100	929	1071	2024-02-29 00:00:00-08
16889	\N	\N	930	959	2024-02-29 00:00:00-08
16890	Infinity	100	931	895	2024-02-29 00:00:00-08
16891	Infinity	34	932	896	2024-02-29 00:00:00-08
16892	\N	\N	933	960	2024-02-29 00:00:00-08
16893	\N	\N	934	961	2024-02-29 00:00:00-08
16894	Infinity	100	935	214	2024-02-29 00:00:00-08
16895	Infinity	100	936	215	2024-02-29 00:00:00-08
16896	Infinity	100	937	897	2024-02-29 00:00:00-08
16897	\N	\N	938	962	2024-02-29 00:00:00-08
16898	\N	\N	939	963	2024-02-29 00:00:00-08
16899	Infinity	100	940	1072	2024-02-29 00:00:00-08
16900	Infinity	54.3	941	1073	2024-02-29 00:00:00-08
16901	Infinity	54	942	1074	2024-02-29 00:00:00-08
16902	Infinity	100	943	1075	2024-02-29 00:00:00-08
16903	Infinity	100	944	898	2024-02-29 00:00:00-08
16904	Infinity	60.2	945	1076	2024-02-29 00:00:00-08
16905	Infinity	93.2	946	216	2024-02-29 00:00:00-08
16906	Infinity	100	947	217	2024-02-29 00:00:00-08
16907	Infinity	100	948	1077	2024-02-29 00:00:00-08
16908	Infinity	120	949	1086	2024-02-29 00:00:00-08
16909	50	210	950	1991	2024-02-29 00:00:00-08
16910	Infinity	100	951	1078	2024-02-29 00:00:00-08
16911	Infinity	100	952	1079	2024-02-29 00:00:00-08
16912	Infinity	100	953	1080	2024-02-29 00:00:00-08
16913	36	250	954	1992	2024-02-29 00:00:00-08
16914	24	250	955	2307	2024-02-29 00:00:00-08
16915	Infinity	45.1	956	218	2024-02-29 00:00:00-08
16916	Infinity	100	957	1081	2024-02-29 00:00:00-08
16917	Infinity	100	958	1082	2024-02-29 00:00:00-08
16918	Infinity	100	959	1083	2024-02-29 00:00:00-08
16919	Infinity	100	960	1084	2024-02-29 00:00:00-08
16920	Infinity	100	961	219	2024-02-29 00:00:00-08
16921	Infinity	120	962	1087	2024-02-29 00:00:00-08
16922	Infinity	25.6	963	220	2024-02-29 00:00:00-08
16923	0	51.4	964	1179	2024-02-29 00:00:00-08
16924	0	100	965	1180	2024-02-29 00:00:00-08
16925	0	67.8	966	1181	2024-02-29 00:00:00-08
16926	50	233	1060	2038	2024-02-29 00:00:00-08
16927	1	70.9	967	1182	2024-02-29 00:00:00-08
16928	Infinity	120	968	1088	2024-02-29 00:00:00-08
16929	0	93.5	969	1089	2024-02-29 00:00:00-08
16930	40	250	970	1993	2024-02-29 00:00:00-08
16931	36	250	971	1994	2024-02-29 00:00:00-08
16932	35	250	972	1995	2024-02-29 00:00:00-08
16933	Infinity	31.1	973	1090	2024-02-29 00:00:00-08
16934	Infinity	100	974	1091	2024-02-29 00:00:00-08
16935	50	212	975	1996	2024-02-29 00:00:00-08
16936	50	129.5	976	1997	2024-02-29 00:00:00-08
16937	50	129.5	976	222	2024-02-29 00:00:00-08
16938	43	250	977	1998	2024-02-29 00:00:00-08
16939	43	250	977	223	2024-02-29 00:00:00-08
16940	Infinity	65.5	978	1092	2024-02-29 00:00:00-08
16941	Infinity	100	979	1093	2024-02-29 00:00:00-08
16942	Infinity	89.5	980	224	2024-02-29 00:00:00-08
16943	1	82.9	981	225	2024-02-29 00:00:00-08
16944	0	100	982	226	2024-02-29 00:00:00-08
16945	1	100	983	227	2024-02-29 00:00:00-08
16946	0	78.3	984	228	2024-02-29 00:00:00-08
16947	Infinity	100	985	229	2024-02-29 00:00:00-08
16948	Infinity	100	986	908	2024-02-29 00:00:00-08
16949	Infinity	30.3	987	909	2024-02-29 00:00:00-08
16950	Infinity	100	988	230	2024-02-29 00:00:00-08
16951	Infinity	100	989	910	2024-02-29 00:00:00-08
16952	Infinity	74.6	990	911	2024-02-29 00:00:00-08
16953	34	250	991	2309	2024-02-29 00:00:00-08
16954	Infinity	100	992	231	2024-02-29 00:00:00-08
16955	50	219.5	993	1999	2024-02-29 00:00:00-08
16956	41	250	994	2308	2024-02-29 00:00:00-08
16957	6	250	995	2510	2024-02-29 00:00:00-08
16958	8	250	996	2515	2024-02-29 00:00:00-08
16959	30	250	997	2310	2024-02-29 00:00:00-08
16960	Infinity	71.2	998	232	2024-02-29 00:00:00-08
16961	10	250	999	2334	2024-02-29 00:00:00-08
16962	Infinity	71.6	1000	233	2024-02-29 00:00:00-08
16963	14	250	1001	2000	2024-02-29 00:00:00-08
16964	39	250	1002	2001	2024-02-29 00:00:00-08
16965	10	250	1003	2335	2024-02-29 00:00:00-08
16966	6	250	1004	2511	2024-02-29 00:00:00-08
16967	6	250	1004	2002	2024-02-29 00:00:00-08
16968	Infinity	100	1005	1103	2024-02-29 00:00:00-08
16969	Infinity	88.5	1006	1104	2024-02-29 00:00:00-08
16970	Infinity	13.6	1007	1105	2024-02-29 00:00:00-08
16971	Infinity	96.2	1008	1106	2024-02-29 00:00:00-08
16972	Infinity	100	1009	1107	2024-02-29 00:00:00-08
16973	Infinity	100	1010	1108	2024-02-29 00:00:00-08
16974	Infinity	68.6	1011	1109	2024-02-29 00:00:00-08
16975	Infinity	29.1	1012	1110	2024-02-29 00:00:00-08
16976	Infinity	100	1013	1111	2024-02-29 00:00:00-08
16977	Infinity	71.1	1014	1112	2024-02-29 00:00:00-08
16978	Infinity	100	1015	1113	2024-02-29 00:00:00-08
16979	48	250	1016	2003	2024-02-29 00:00:00-08
16980	50	212	1017	2004	2024-02-29 00:00:00-08
16981	30	250	1018	2005	2024-02-29 00:00:00-08
16982	33	250	1019	2006	2024-02-29 00:00:00-08
16983	8	250	1020	2512	2024-02-29 00:00:00-08
16984	Infinity	100	1021	234	2024-02-29 00:00:00-08
16985	50	250	1022	2311	2024-02-29 00:00:00-08
16986	41	250	1023	2007	2024-02-29 00:00:00-08
16987	43	250	1024	2008	2024-02-29 00:00:00-08
16988	10	250	1025	2336	2024-02-29 00:00:00-08
16989	8	250	1026	2514	2024-02-29 00:00:00-08
16990	23	250	1027	2009	2024-02-29 00:00:00-08
16991	29	250	1028	2010	2024-02-29 00:00:00-08
16992	26	250	1029	2011	2024-02-29 00:00:00-08
16993	44	250	1030	2012	2024-02-29 00:00:00-08
16994	50	94.5	1031	2312	2024-02-29 00:00:00-08
16995	10	250	1032	2337	2024-02-29 00:00:00-08
16996	50	238	1033	2013	2024-02-29 00:00:00-08
16997	37	250	1034	2014	2024-02-29 00:00:00-08
16998	45	250	1035	2015	2024-02-29 00:00:00-08
16999	50	242	1036	2016	2024-02-29 00:00:00-08
17000	39	250	1037	2017	2024-02-29 00:00:00-08
17001	32	250	1038	2314	2024-02-29 00:00:00-08
17002	33	250	1039	2018	2024-02-29 00:00:00-08
17003	50	185	1040	2019	2024-02-29 00:00:00-08
17004	50	185.5	1041	2020	2024-02-29 00:00:00-08
17005	41	250	1042	2021	2024-02-29 00:00:00-08
17006	23	250	1043	2022	2024-02-29 00:00:00-08
17007	50	248	1044	2023	2024-02-29 00:00:00-08
17008	44	250	1045	2024	2024-02-29 00:00:00-08
17009	14	250	1046	2025	2024-02-29 00:00:00-08
17010	50	213	1047	2026	2024-02-29 00:00:00-08
17011	9	250	1048	2513	2024-02-29 00:00:00-08
17012	50	232	1049	2027	2024-02-29 00:00:00-08
17013	42	250	1050	2028	2024-02-29 00:00:00-08
17014	9	250	1051	2029	2024-02-29 00:00:00-08
17015	33	250	1052	2030	2024-02-29 00:00:00-08
17016	30	250	1053	2031	2024-02-29 00:00:00-08
17017	20	250	1054	2032	2024-02-29 00:00:00-08
17018	50	208	1055	2033	2024-02-29 00:00:00-08
17019	9	250	1056	2034	2024-02-29 00:00:00-08
17020	45	250	1057	2035	2024-02-29 00:00:00-08
17021	41	250	1058	2036	2024-02-29 00:00:00-08
17022	29	250	1061	2039	2024-02-29 00:00:00-08
17023	50	195.5	1062	2040	2024-02-29 00:00:00-08
17024	40	250	1063	2041	2024-02-29 00:00:00-08
17025	31	250	1064	2042	2024-02-29 00:00:00-08
17026	21	250	1065	2043	2024-02-29 00:00:00-08
17027	10	250	1066	2044	2024-02-29 00:00:00-08
17028	16	250	1067	2045	2024-02-29 00:00:00-08
17029	40	250	1068	2046	2024-02-29 00:00:00-08
17030	42	250	1069	2047	2024-02-29 00:00:00-08
17031	41	250	1070	2048	2024-02-29 00:00:00-08
17032	51	202	1071	2049	2024-02-29 00:00:00-08
17033	38	250	1072	2050	2024-02-29 00:00:00-08
17034	10	250	1073	2338	2024-02-29 00:00:00-08
17035	50	250	1074	2051	2024-02-29 00:00:00-08
17036	38	250	1075	2052	2024-02-29 00:00:00-08
17037	34	250	1076	2053	2024-02-29 00:00:00-08
17038	50	149	1077	2054	2024-02-29 00:00:00-08
17039	51	162	1078	2055	2024-02-29 00:00:00-08
17040	51	197	1079	2056	2024-02-29 00:00:00-08
17041	35	250	1080	2057	2024-02-29 00:00:00-08
17042	38	250	1081	2058	2024-02-29 00:00:00-08
17043	50	106	1082	2059	2024-02-29 00:00:00-08
17044	50	119	1083	2165	2024-02-29 00:00:00-08
17045	50	199	1084	2166	2024-02-29 00:00:00-08
17046	50	208	1085	2167	2024-02-29 00:00:00-08
17047	50	189	1086	2168	2024-02-29 00:00:00-08
17048	50	249	1087	2169	2024-02-29 00:00:00-08
17049	50	159	1088	2170	2024-02-29 00:00:00-08
17050	50	150	1089	2171	2024-02-29 00:00:00-08
17051	50	129	1090	2172	2024-02-29 00:00:00-08
17052	50	215	1091	2173	2024-02-29 00:00:00-08
17053	50	235	1092	2174	2024-02-29 00:00:00-08
17054	50	201	1093	2175	2024-02-29 00:00:00-08
17055	49	143	1094	2176	2024-02-29 00:00:00-08
17056	50	106	1095	2177	2024-02-29 00:00:00-08
17057	50	220	1096	2178	2024-02-29 00:00:00-08
17058	10	250	1097	2339	2024-02-29 00:00:00-08
17059	10	250	1098	2341	2024-02-29 00:00:00-08
17060	37	250	1099	2313	2024-02-29 00:00:00-08
17061	10	250	1100	2342	2024-02-29 00:00:00-08
17062	10	250	1101	2340	2024-02-29 00:00:00-08
17063	11	250	1103	2517	2024-02-29 00:00:00-08
17064	Infinity	22	1104	235	2024-02-29 00:00:00-08
17065	Infinity	100	1105	1114	2024-02-29 00:00:00-08
17066	22	250	1106	2468	2024-02-29 00:00:00-08
17067	48	43	1107	2469	2024-02-29 00:00:00-08
17068	48	125	1108	2470	2024-02-29 00:00:00-08
17069	18	250	1109	2373	2024-02-29 00:00:00-08
17070	33	250	1110	2374	2024-02-29 00:00:00-08
17071	9	250	1111	2471	2024-02-29 00:00:00-08
17072	27	250	1112	2472	2024-02-29 00:00:00-08
17073	6	250	1113	2473	2024-02-29 00:00:00-08
17074	48	180	1114	2474	2024-02-29 00:00:00-08
17075	28	250	1115	2475	2024-02-29 00:00:00-08
17076	48	141	1116	2476	2024-02-29 00:00:00-08
17077	48	48	1117	2477	2024-02-29 00:00:00-08
17078	17	250	1118	2478	2024-02-29 00:00:00-08
17079	24	250	1119	2479	2024-02-29 00:00:00-08
17080	48	132	1120	2480	2024-02-29 00:00:00-08
17081	16	250	1121	2481	2024-02-29 00:00:00-08
17082	27	250	1122	2375	2024-02-29 00:00:00-08
17083	49	23	1123	493	2024-02-29 00:00:00-08
17084	10	250	1124	2482	2024-02-29 00:00:00-08
17085	48	55	1126	2376	2024-02-29 00:00:00-08
17086	40	250	1127	2483	2024-02-29 00:00:00-08
17087	26	250	1128	494	2024-02-29 00:00:00-08
17088	13	250	1129	2484	2024-02-29 00:00:00-08
17089	5	250	1130	2377	2024-02-29 00:00:00-08
17090	46	250	1131	2498	2024-02-29 00:00:00-08
17091	16	250	1132	2408	2024-02-29 00:00:00-08
17092	35	250	1134	2499	2024-02-29 00:00:00-08
17093	14	250	1135	2500	2024-02-29 00:00:00-08
17094	17	250	1136	495	2024-02-29 00:00:00-08
17095	6	250	1137	2501	2024-02-29 00:00:00-08
17096	12	250	1138	2502	2024-02-29 00:00:00-08
17097	10	250	1139	2485	2024-02-29 00:00:00-08
17098	4	250	1140	2486	2024-02-29 00:00:00-08
17099	48	220	1141	2487	2024-02-29 00:00:00-08
17100	5	250	1142	2535	2024-02-29 00:00:00-08
17101	7	250	1143	2543	2024-02-29 00:00:00-08
17102	48	153	1144	2488	2024-02-29 00:00:00-08
17103	17	250	1145	2378	2024-02-29 00:00:00-08
17104	46	250	1146	2379	2024-02-29 00:00:00-08
17105	43	250	1147	496	2024-02-29 00:00:00-08
17106	13	250	1148	2380	2024-02-29 00:00:00-08
17107	48	42	1149	2489	2024-02-29 00:00:00-08
17108	48	164	1150	2490	2024-02-29 00:00:00-08
17109	48	135	1151	2491	2024-02-29 00:00:00-08
17110	48	127	1152	2492	2024-02-29 00:00:00-08
17111	48	236	1153	2544	2024-02-29 00:00:00-08
17112	48	110.9	1154	2545	2024-02-29 00:00:00-08
17113	48	144	1155	2546	2024-02-29 00:00:00-08
17114	12	250	1156	2547	2024-02-29 00:00:00-08
17115	25	250	1157	2548	2024-02-29 00:00:00-08
17116	10	250	1158	2549	2024-02-29 00:00:00-08
17117	48	115.7	1159	2550	2024-02-29 00:00:00-08
17118	48	77.8	1160	2551	2024-02-29 00:00:00-08
17119	6	250	1161	2552	2024-02-29 00:00:00-08
17120	19	250	1162	2553	2024-02-29 00:00:00-08
17121	48	111.8	1165	2554	2024-02-29 00:00:00-08
17122	14	250	1168	2555	2024-02-29 00:00:00-08
17123	48	222.2	1169	2556	2024-02-29 00:00:00-08
17124	48	106.6	1170	2557	2024-02-29 00:00:00-08
17125	48	115.2	1171	2558	2024-02-29 00:00:00-08
17126	96	226	1174	2602	2024-02-29 00:00:00-08
17127	55	250	1175	2603	2024-02-29 00:00:00-08
17128	14	250	1176	2604	2024-02-29 00:00:00-08
17129	97	48	1177	2605	2024-02-29 00:00:00-08
17130	95	42	1178	2606	2024-02-29 00:00:00-08
17131	93	18	1179	2607	2024-02-29 00:00:00-08
17132	85	250	1180	2608	2024-02-29 00:00:00-08
17133	96	108	1181	2609	2024-02-29 00:00:00-08
17134	1	250	1182	2610	2024-02-29 00:00:00-08
17135	5	250	1183	2611	2024-02-29 00:00:00-08
17136	6	250	1184	2612	2024-02-29 00:00:00-08
17137	49	250	1185	2613	2024-02-29 00:00:00-08
17138	5	250	1186	2614	2024-02-29 00:00:00-08
17139	96	115	1187	2615	2024-02-29 00:00:00-08
17140	5	250	1188	2616	2024-02-29 00:00:00-08
17141	47	18	1189	2617	2024-02-29 00:00:00-08
17142	48	244	1190	2618	2024-02-29 00:00:00-08
17143	\N	\N	1191	1004	2024-02-29 00:00:00-08
17144	\N	\N	1192	1005	2024-02-29 00:00:00-08
17145	\N	\N	1193	1006	2024-02-29 00:00:00-08
17146	\N	\N	1194	1007	2024-02-29 00:00:00-08
17147	\N	\N	1195	1008	2024-02-29 00:00:00-08
17148	\N	\N	1196	1009	2024-02-29 00:00:00-08
17149	\N	\N	1197	1010	2024-02-29 00:00:00-08
17150	\N	\N	1198	1011	2024-02-29 00:00:00-08
17151	\N	\N	1199	1012	2024-02-29 00:00:00-08
17152	\N	\N	1200	1013	2024-02-29 00:00:00-08
17153	\N	\N	1201	1014	2024-02-29 00:00:00-08
17154	\N	\N	1202	1015	2024-02-29 00:00:00-08
17155	\N	\N	1203	1016	2024-02-29 00:00:00-08
17156	\N	\N	1204	1017	2024-02-29 00:00:00-08
17157	Infinity	100	1205	1137	2024-02-29 00:00:00-08
17158	Infinity	97	1206	1138	2024-02-29 00:00:00-08
17159	Infinity	100	1207	1139	2024-02-29 00:00:00-08
17160	Infinity	100	1208	1140	2024-02-29 00:00:00-08
17161	Infinity	95.9	1209	1141	2024-02-29 00:00:00-08
17162	Infinity	100	1210	1142	2024-02-29 00:00:00-08
17163	0	\N	1212	1563	2024-02-29 00:00:00-08
17164	0	\N	1212	1561	2024-02-29 00:00:00-08
17165	0	\N	1213	1564	2024-02-29 00:00:00-08
17166	0	\N	1213	1562	2024-02-29 00:00:00-08
17167	0	\N	1214	1565	2024-02-29 00:00:00-08
17168	0	\N	1215	1566	2024-02-29 00:00:00-08
17169	0	\N	1216	1567	2024-02-29 00:00:00-08
17170	\N	\N	1220	1519	2024-02-29 00:00:00-08
17171	\N	\N	1221	1520	2024-02-29 00:00:00-08
17172	0	\N	1222	1521	2024-02-29 00:00:00-08
17173	0	\N	1223	1522	2024-02-29 00:00:00-08
17174	0	\N	1224	1523	2024-02-29 00:00:00-08
17175	0	\N	1225	1524	2024-02-29 00:00:00-08
17176	0	\N	1226	1525	2024-02-29 00:00:00-08
17177	0	\N	1227	1526	2024-02-29 00:00:00-08
17178	0	\N	1228	1527	2024-02-29 00:00:00-08
17179	0	\N	1229	1528	2024-02-29 00:00:00-08
17180	0	\N	1230	1529	2024-02-29 00:00:00-08
17181	Infinity	54	1336	278	2024-02-29 00:00:00-08
17182	0	\N	1231	1530	2024-02-29 00:00:00-08
17183	0	\N	1232	1531	2024-02-29 00:00:00-08
17184	0	\N	1233	1532	2024-02-29 00:00:00-08
17185	0	\N	1234	1533	2024-02-29 00:00:00-08
17186	0	\N	1235	1534	2024-02-29 00:00:00-08
17187	0	\N	1236	1535	2024-02-29 00:00:00-08
17188	0	\N	1237	1536	2024-02-29 00:00:00-08
17189	0	\N	1238	1537	2024-02-29 00:00:00-08
17190	0	\N	1239	1538	2024-02-29 00:00:00-08
17191	0	\N	1240	1539	2024-02-29 00:00:00-08
17192	0	\N	1241	1540	2024-02-29 00:00:00-08
17193	0	\N	1242	1541	2024-02-29 00:00:00-08
17194	0	\N	1243	1542	2024-02-29 00:00:00-08
17195	0	\N	1244	1543	2024-02-29 00:00:00-08
17196	0	\N	1245	1544	2024-02-29 00:00:00-08
17197	0	\N	1246	1545	2024-02-29 00:00:00-08
17198	0	\N	1247	1549	2024-02-29 00:00:00-08
17199	0	\N	1248	1550	2024-02-29 00:00:00-08
17200	0	\N	1249	1551	2024-02-29 00:00:00-08
17201	0	\N	1250	1552	2024-02-29 00:00:00-08
17202	0	\N	1251	1557	2024-02-29 00:00:00-08
17203	0	\N	1252	1558	2024-02-29 00:00:00-08
17204	0	\N	1253	1559	2024-02-29 00:00:00-08
17205	0	\N	1254	1560	2024-02-29 00:00:00-08
17206	0	\N	1255	1553	2024-02-29 00:00:00-08
17207	0	\N	1256	1554	2024-02-29 00:00:00-08
17208	0	\N	1257	1555	2024-02-29 00:00:00-08
17209	0	\N	1258	1556	2024-02-29 00:00:00-08
17210	0	\N	1259	1546	2024-02-29 00:00:00-08
17211	0	\N	1260	1547	2024-02-29 00:00:00-08
17212	0	\N	1261	1548	2024-02-29 00:00:00-08
17213	0	\N	1262	1609	2024-02-29 00:00:00-08
17214	0	\N	1263	1608	2024-02-29 00:00:00-08
17215	\N	\N	1264	964	2024-02-29 00:00:00-08
17216	\N	\N	1265	965	2024-02-29 00:00:00-08
17217	\N	\N	1266	966	2024-02-29 00:00:00-08
17218	\N	\N	1267	967	2024-02-29 00:00:00-08
17219	Infinity	78.2	1268	912	2024-02-29 00:00:00-08
17220	Infinity	100	1269	913	2024-02-29 00:00:00-08
17221	0	\N	1271	286	2024-02-29 00:00:00-08
17222	Infinity	100	1272	242	2024-02-29 00:00:00-08
17223	\N	\N	1273	287	2024-02-29 00:00:00-08
17224	Infinity	97.8	1274	994	2024-02-29 00:00:00-08
17225	Infinity	33.5	1275	995	2024-02-29 00:00:00-08
17226	Infinity	72	1276	243	2024-02-29 00:00:00-08
17227	Infinity	90.1	1277	1036	2024-02-29 00:00:00-08
17228	\N	\N	1278	288	2024-02-29 00:00:00-08
17229	Infinity	97.8	1279	1037	2024-02-29 00:00:00-08
17230	Infinity	80.6	1280	1038	2024-02-29 00:00:00-08
17231	\N	\N	1281	290	2024-02-29 00:00:00-08
17232	Infinity	100	1283	244	2024-02-29 00:00:00-08
17233	\N	\N	1284	291	2024-02-29 00:00:00-08
17234	Infinity	31.3	1285	1039	2024-02-29 00:00:00-08
17235	Infinity	100	1286	1040	2024-02-29 00:00:00-08
17236	Infinity	100	1287	1041	2024-02-29 00:00:00-08
17237	\N	\N	1288	1042	2024-02-29 00:00:00-08
17238	Infinity	12	1289	1044	2024-02-29 00:00:00-08
17239	Infinity	100	1290	1045	2024-02-29 00:00:00-08
17240	Infinity	30.8	1291	1046	2024-02-29 00:00:00-08
17241	Infinity	10.3	1292	1047	2024-02-29 00:00:00-08
17242	Infinity	76.5	1293	1048	2024-02-29 00:00:00-08
17243	Infinity	24.5	1294	1049	2024-02-29 00:00:00-08
17244	Infinity	16.2	1295	245	2024-02-29 00:00:00-08
17245	Infinity	40.3	1296	246	2024-02-29 00:00:00-08
17246	Infinity	28.6	1297	247	2024-02-29 00:00:00-08
17247	Infinity	47.4	1298	248	2024-02-29 00:00:00-08
17248	Infinity	100	1299	1050	2024-02-29 00:00:00-08
17249	Infinity	35.2	1300	249	2024-02-29 00:00:00-08
17250	Infinity	100	1301	1053	2024-02-29 00:00:00-08
17251	Infinity	100	1302	250	2024-02-29 00:00:00-08
17252	Infinity	91.8	1303	1054	2024-02-29 00:00:00-08
17253	Infinity	44.8	1304	1055	2024-02-29 00:00:00-08
17254	Infinity	26.9	1305	251	2024-02-29 00:00:00-08
17255	Infinity	100	1306	252	2024-02-29 00:00:00-08
17256	Infinity	100	1307	253	2024-02-29 00:00:00-08
17257	Infinity	100	1308	254	2024-02-29 00:00:00-08
17258	Infinity	100	1309	255	2024-02-29 00:00:00-08
17259	Infinity	100	1310	256	2024-02-29 00:00:00-08
17260	Infinity	35.8	1311	257	2024-02-29 00:00:00-08
17261	Infinity	100	1312	258	2024-02-29 00:00:00-08
17262	Infinity	60.1	1313	259	2024-02-29 00:00:00-08
17263	Infinity	10	1314	260	2024-02-29 00:00:00-08
17264	Infinity	36.2	1315	261	2024-02-29 00:00:00-08
17265	\N	\N	1316	262	2024-02-29 00:00:00-08
17266	Infinity	100	1317	264	2024-02-29 00:00:00-08
17267	Infinity	45.7	1318	1051	2024-02-29 00:00:00-08
17268	Infinity	100	1319	1052	2024-02-29 00:00:00-08
17269	Infinity	10.1	1320	265	2024-02-29 00:00:00-08
17270	Infinity	69.6	1321	266	2024-02-29 00:00:00-08
17271	Infinity	73.6	1322	996	2024-02-29 00:00:00-08
17272	Infinity	100	1323	997	2024-02-29 00:00:00-08
17273	Infinity	100	1324	998	2024-02-29 00:00:00-08
17274	Infinity	29.5	1325	999	2024-02-29 00:00:00-08
17275	Infinity	89.6	1326	267	2024-02-29 00:00:00-08
17276	Infinity	100	1327	268	2024-02-29 00:00:00-08
17277	Infinity	77.8	1328	269	2024-02-29 00:00:00-08
17278	\N	\N	1329	270	2024-02-29 00:00:00-08
17279	Infinity	10	1330	272	2024-02-29 00:00:00-08
17280	Infinity	38	1331	273	2024-02-29 00:00:00-08
17281	Infinity	30.7	1332	274	2024-02-29 00:00:00-08
17282	Infinity	100	1333	275	2024-02-29 00:00:00-08
17283	Infinity	100	1334	276	2024-02-29 00:00:00-08
17284	Infinity	49.6	1335	277	2024-02-29 00:00:00-08
17285	Infinity	100	1342	284	2024-02-29 00:00:00-08
17286	Infinity	100	1343	285	2024-02-29 00:00:00-08
17287	14	34.3	1344	940	2024-02-29 00:00:00-08
17288	1	100	1345	941	2024-02-29 00:00:00-08
17289	9	89.9	1346	942	2024-02-29 00:00:00-08
17290	1	100	1347	943	2024-02-29 00:00:00-08
17291	0	38.3	1348	944	2024-02-29 00:00:00-08
17292	12	32.6	1349	945	2024-02-29 00:00:00-08
17293	14	51.5	1350	946	2024-02-29 00:00:00-08
17294	3	100	1351	947	2024-02-29 00:00:00-08
17295	0	\N	1352	972	2024-02-29 00:00:00-08
17296	0	\N	1353	973	2024-02-29 00:00:00-08
17297	8	100	1354	948	2024-02-29 00:00:00-08
17298	3	100	1355	949	2024-02-29 00:00:00-08
17299	Infinity	67.5	1356	950	2024-02-29 00:00:00-08
17300	1	100	1357	951	2024-02-29 00:00:00-08
17301	\N	\N	1358	974	2024-02-29 00:00:00-08
17302	\N	\N	1359	975	2024-02-29 00:00:00-08
17303	Infinity	100	1360	292	2024-02-29 00:00:00-08
17304	Infinity	31.3	1361	293	2024-02-29 00:00:00-08
17305	18	39.6	1362	952	2024-02-29 00:00:00-08
17306	1	16.4	1363	953	2024-02-29 00:00:00-08
17307	\N	\N	1364	976	2024-02-29 00:00:00-08
17308	\N	\N	1365	977	2024-02-29 00:00:00-08
17309	\N	\N	1366	978	2024-02-29 00:00:00-08
17310	\N	\N	1367	979	2024-02-29 00:00:00-08
17311	\N	\N	1368	980	2024-02-29 00:00:00-08
17312	\N	\N	1369	981	2024-02-29 00:00:00-08
17313	\N	\N	1370	982	2024-02-29 00:00:00-08
17314	\N	\N	1371	983	2024-02-29 00:00:00-08
17315	Infinity	62	1372	294	2024-02-29 00:00:00-08
17316	Infinity	31.6	1373	295	2024-02-29 00:00:00-08
17317	Infinity	22	1374	297	2024-02-29 00:00:00-08
17318	\N	\N	1375	984	2024-02-29 00:00:00-08
17319	\N	\N	1376	985	2024-02-29 00:00:00-08
17320	Infinity	57.2	1377	298	2024-02-29 00:00:00-08
17321	Infinity	100	1378	299	2024-02-29 00:00:00-08
17322	\N	\N	1379	986	2024-02-29 00:00:00-08
17323	\N	\N	1380	987	2024-02-29 00:00:00-08
17324	Infinity	10	1381	301	2024-02-29 00:00:00-08
17325	2	45.7	1382	954	2024-02-29 00:00:00-08
17326	7	100	1383	955	2024-02-29 00:00:00-08
17327	0	\N	1387	2801	2024-02-29 00:00:00-08
17328	0	\N	1389	2802	2024-02-29 00:00:00-08
17329	0	\N	1391	2803	2024-02-29 00:00:00-08
17330	0	\N	1392	2804	2024-02-29 00:00:00-08
17331	0	\N	1393	2805	2024-02-29 00:00:00-08
17332	0	\N	1394	2806	2024-02-29 00:00:00-08
17333	0	\N	1395	2807	2024-02-29 00:00:00-08
17334	0	\N	1396	2808	2024-02-29 00:00:00-08
17335	0	\N	1397	2809	2024-02-29 00:00:00-08
17336	0	\N	1398	2810	2024-02-29 00:00:00-08
17337	0	\N	1399	2811	2024-02-29 00:00:00-08
17338	0	\N	1401	2812	2024-02-29 00:00:00-08
17339	0	\N	1402	2813	2024-02-29 00:00:00-08
17340	0	\N	1403	2814	2024-02-29 00:00:00-08
17341	0	\N	1404	2815	2024-02-29 00:00:00-08
17342	0	\N	1405	2816	2024-02-29 00:00:00-08
17343	0	\N	1408	2817	2024-02-29 00:00:00-08
17344	0	\N	1410	2818	2024-02-29 00:00:00-08
17345	0	\N	1414	2819	2024-02-29 00:00:00-08
17346	0	\N	1415	2820	2024-02-29 00:00:00-08
17347	0	\N	1416	2821	2024-02-29 00:00:00-08
17348	0	\N	1417	2822	2024-02-29 00:00:00-08
17349	0	\N	1418	2823	2024-02-29 00:00:00-08
17350	0	\N	1419	2824	2024-02-29 00:00:00-08
17351	18	52	1420	1616	2024-02-29 00:00:00-08
17352	0	\N	1421	236	2024-02-29 00:00:00-08
17353	64	250	1422	1629	2024-02-29 00:00:00-08
17354	27	250	1423	1630	2024-02-29 00:00:00-08
17355	0	\N	1424	1654	2024-02-29 00:00:00-08
17356	96	59.8	1425	1655	2024-02-29 00:00:00-08
17357	0	\N	1426	1631	2024-02-29 00:00:00-08
17358	350	60.5	1427	1656	2024-02-29 00:00:00-08
17359	512	247.7	1428	1632	2024-02-29 00:00:00-08
17360	553	250	1429	1633	2024-02-29 00:00:00-08
17361	Infinity	48	1430	1657	2024-02-29 00:00:00-08
17362	48	92.2	1431	1592	2024-02-29 00:00:00-08
17363	38	250	1432	1593	2024-02-29 00:00:00-08
17364	154	70.6	1433	1658	2024-02-29 00:00:00-08
17365	231	126.7	1434	1659	2024-02-29 00:00:00-08
17366	48	213.6	1435	1604	2024-02-29 00:00:00-08
17367	13	250	1436	1605	2024-02-29 00:00:00-08
17368	66	60.5	1437	1634	2024-02-29 00:00:00-08
17369	Infinity	66.2	1438	1660	2024-02-29 00:00:00-08
17370	48	94.6	1439	1594	2024-02-29 00:00:00-08
17371	23	250	1440	1595	2024-02-29 00:00:00-08
17372	0	\N	1441	1661	2024-02-29 00:00:00-08
17373	67	94.5	1442	1662	2024-02-29 00:00:00-08
17374	75	65.6	1443	1617	2024-02-29 00:00:00-08
17375	91	194.7	1444	1610	2024-02-29 00:00:00-08
17376	60	229	1445	1611	2024-02-29 00:00:00-08
17377	11	250	1446	1618	2024-02-29 00:00:00-08
17378	75	250	1447	1612	2024-02-29 00:00:00-08
17379	48	122.4	1448	1619	2024-02-29 00:00:00-08
17380	20	250	1449	1613	2024-02-29 00:00:00-08
17381	41	250	1451	1620	2024-02-29 00:00:00-08
17382	48	92.2	1452	1596	2024-02-29 00:00:00-08
17383	48	99.8	1453	1597	2024-02-29 00:00:00-08
17384	46	250	1454	1598	2024-02-29 00:00:00-08
17385	48	123.4	1455	1599	2024-02-29 00:00:00-08
17386	48	198.7	1456	1621	2024-02-29 00:00:00-08
17387	0	\N	1457	1663	2024-02-29 00:00:00-08
17388	17	250	1458	1600	2024-02-29 00:00:00-08
17389	48	115.2	1459	1601	2024-02-29 00:00:00-08
17390	48	96.5	1460	1622	2024-02-29 00:00:00-08
17391	27	250	1461	1623	2024-02-29 00:00:00-08
17392	0	\N	1462	237	2024-02-29 00:00:00-08
17393	48	78.7	1463	1624	2024-02-29 00:00:00-08
17394	0	\N	1464	238	2024-02-29 00:00:00-08
17395	17	250	1465	1606	2024-02-29 00:00:00-08
17396	13	250	1466	1607	2024-02-29 00:00:00-08
17397	48	110	1467	1625	2024-02-29 00:00:00-08
17398	0	\N	1468	1665	2024-02-29 00:00:00-08
17399	0	\N	1468	1664	2024-02-29 00:00:00-08
17400	48	184.3	1469	1602	2024-02-29 00:00:00-08
17401	48	74.9	1470	1603	2024-02-29 00:00:00-08
17402	48	239	1471	1614	2024-02-29 00:00:00-08
17403	Infinity	72.1	1472	1666	2024-02-29 00:00:00-08
17404	97	160.1	1473	1615	2024-02-29 00:00:00-08
17405	91	50.1	1474	1626	2024-02-29 00:00:00-08
17406	99	73.8	1475	1627	2024-02-29 00:00:00-08
17407	149	51.7	1476	1635	2024-02-29 00:00:00-08
17408	95	49.4	1477	1628	2024-02-29 00:00:00-08
17409	145	110.6	1479	1636	2024-02-29 00:00:00-08
17410	117	92.2	1480	1667	2024-02-29 00:00:00-08
17411	161	154.1	1483	1637	2024-02-29 00:00:00-08
17412	71	110.7	1484	1668	2024-02-29 00:00:00-08
17413	105	79.6	1485	1669	2024-02-29 00:00:00-08
17414	201	57.2	1487	1670	2024-02-29 00:00:00-08
17415	96	117.1	1488	1638	2024-02-29 00:00:00-08
17416	96	183.4	1489	1639	2024-02-29 00:00:00-08
17417	0	\N	1490	1671	2024-02-29 00:00:00-08
17418	15	250	1491	1672	2024-02-29 00:00:00-08
17419	27	250	1492	1640	2024-02-29 00:00:00-08
17420	21	250	1493	1641	2024-02-29 00:00:00-08
17421	48	108	1494	1642	2024-02-29 00:00:00-08
17422	48	71	1495	1643	2024-02-29 00:00:00-08
17423	48	70	1496	1644	2024-02-29 00:00:00-08
17424	1	250	1497	1645	2024-02-29 00:00:00-08
17425	12	250	1498	1646	2024-02-29 00:00:00-08
17426	6	250	1499	1647	2024-02-29 00:00:00-08
17427	0	\N	1501	1701	2024-02-29 00:00:00-08
17428	0	\N	1502	1702	2024-02-29 00:00:00-08
17429	\N	\N	1503	239	2024-02-29 00:00:00-08
17430	90	205	1504	1723	2024-02-29 00:00:00-08
17431	23	333	1506	1714	2024-02-29 00:00:00-08
17432	90	78	1507	1715	2024-02-29 00:00:00-08
17433	90	21.6	1511	1716	2024-02-29 00:00:00-08
17434	90	19.8	1512	1717	2024-02-29 00:00:00-08
17435	90	104	1516	1703	2024-02-29 00:00:00-08
17436	32	333	1518	1718	2024-02-29 00:00:00-08
17437	90	112.5	1519	1719	2024-02-29 00:00:00-08
17438	71	333	1520	1704	2024-02-29 00:00:00-08
17439	90	46	1521	1720	2024-02-29 00:00:00-08
17440	90	42	1522	1721	2024-02-29 00:00:00-08
17441	90	72	1523	1722	2024-02-29 00:00:00-08
17442	91	30	1524	240	2024-02-29 00:00:00-08
17443	90	136	1525	241	2024-02-29 00:00:00-08
17444	21	150	1531	1464	2024-02-29 00:00:00-08
17445	90	111	1533	1705	2024-02-29 00:00:00-08
17446	89	73	1534	1706	2024-02-29 00:00:00-08
17447	70	250	1535	1707	2024-02-29 00:00:00-08
17448	90	224	1536	1708	2024-02-29 00:00:00-08
17449	90	96	1539	1709	2024-02-29 00:00:00-08
17450	61	250	1542	1710	2024-02-29 00:00:00-08
17451	24	250	1544	1724	2024-02-29 00:00:00-08
17452	13	150	1562	1470	2024-02-29 00:00:00-08
17453	71	150	1573	1477	2024-02-29 00:00:00-08
17454	11	150	1585	1479	2024-02-29 00:00:00-08
17455	72	150	1586	1480	2024-02-29 00:00:00-08
17456	61	150	1587	1481	2024-02-29 00:00:00-08
17457	88	150	1588	1482	2024-02-29 00:00:00-08
17458	88	150	1589	1483	2024-02-29 00:00:00-08
19099	0	\N	4496	1320	2024-02-29 00:00:00-08
17459	23	150	1593	1486	2024-02-29 00:00:00-08
17460	60	150	1597	1466	2024-02-29 00:00:00-08
17461	40	150	1638	1487	2024-02-29 00:00:00-08
17462	18	150	1655	1491	2024-02-29 00:00:00-08
17463	0	\N	1671	1926	2024-02-29 00:00:00-08
17464	0	\N	1674	1929	2024-02-29 00:00:00-08
17465	0	\N	1675	1936	2024-02-29 00:00:00-08
17466	0	\N	1688	1930	2024-02-29 00:00:00-08
17467	0	\N	1694	1934	2024-02-29 00:00:00-08
17468	0	\N	1699	1937	2024-02-29 00:00:00-08
17469	0	\N	1700	1935	2024-02-29 00:00:00-08
17470	0	\N	1701	1938	2024-02-29 00:00:00-08
17471	0	\N	1702	1939	2024-02-29 00:00:00-08
17472	0	\N	1710	1931	2024-02-29 00:00:00-08
17473	0	\N	1711	1932	2024-02-29 00:00:00-08
17474	156	250	1716	1400	2024-02-29 00:00:00-08
17475	9	350	1717	1341	2024-02-29 00:00:00-08
17476	10	350	1718	1342	2024-02-29 00:00:00-08
17477	9	350	1719	1343	2024-02-29 00:00:00-08
17478	30	250	1720	1344	2024-02-29 00:00:00-08
17479	90	250	1721	1345	2024-02-29 00:00:00-08
17480	32	200	1722	1346	2024-02-29 00:00:00-08
17481	176	116	1723	1347	2024-02-29 00:00:00-08
17482	12	250	1724	1348	2024-02-29 00:00:00-08
17483	52	250	1725	1349	2024-02-29 00:00:00-08
17484	88	153	1726	1350	2024-02-29 00:00:00-08
17485	12	250	1727	1351	2024-02-29 00:00:00-08
17486	34	250	1728	1352	2024-02-29 00:00:00-08
17487	264	190	1729	1353	2024-02-29 00:00:00-08
17488	12	250	1730	1394	2024-02-29 00:00:00-08
17489	70	250	1731	1395	2024-02-29 00:00:00-08
17490	46	250	1732	1396	2024-02-29 00:00:00-08
17491	12	250	1733	1354	2024-02-29 00:00:00-08
17492	52	250	1734	1355	2024-02-29 00:00:00-08
17493	46	250	1735	1356	2024-02-29 00:00:00-08
17494	125	250	1736	1357	2024-02-29 00:00:00-08
17495	32	250	1737	1358	2024-02-29 00:00:00-08
17496	16	250	1738	1359	2024-02-29 00:00:00-08
17497	88	131	1739	1360	2024-02-29 00:00:00-08
17498	77	250	1740	1361	2024-02-29 00:00:00-08
17499	35	250	1741	1362	2024-02-29 00:00:00-08
17500	153	250	1742	1363	2024-02-29 00:00:00-08
17501	24	250	1744	1364	2024-02-29 00:00:00-08
17502	53	250	1745	1365	2024-02-29 00:00:00-08
17503	88	285	1746	1366	2024-02-29 00:00:00-08
17504	264	250	1747	1367	2024-02-29 00:00:00-08
17505	29	250	1748	1368	2024-02-29 00:00:00-08
17506	88	228	1749	1369	2024-02-29 00:00:00-08
17507	88	256	1750	1370	2024-02-29 00:00:00-08
17508	261	139	1751	1371	2024-02-29 00:00:00-08
17509	13	250	1752	1372	2024-02-29 00:00:00-08
17510	11	250	1753	1373	2024-02-29 00:00:00-08
17511	23	250	1754	1374	2024-02-29 00:00:00-08
17512	88	127	1755	1375	2024-02-29 00:00:00-08
17513	33	250	1756	1376	2024-02-29 00:00:00-08
17514	41	250	1757	1377	2024-02-29 00:00:00-08
17515	33	250	1758	1378	2024-02-29 00:00:00-08
17516	69	250	1760	1380	2024-02-29 00:00:00-08
17517	88	237	1761	1381	2024-02-29 00:00:00-08
17518	27	250	1762	1382	2024-02-29 00:00:00-08
17519	11	350	1764	1383	2024-02-29 00:00:00-08
17520	16	250	1765	1384	2024-02-29 00:00:00-08
17521	26	250	1767	1386	2024-02-29 00:00:00-08
17522	28	250	1768	1387	2024-02-29 00:00:00-08
17523	\N	\N	4600	1232	2024-02-29 00:00:00-08
17524	57	250	1769	1388	2024-02-29 00:00:00-08
17525	17	350	1770	1389	2024-02-29 00:00:00-08
17526	88	252	1771	1390	2024-02-29 00:00:00-08
17527	58	250	1772	1391	2024-02-29 00:00:00-08
17528	57	119	1773	1392	2024-02-29 00:00:00-08
17529	22	250	1774	1393	2024-02-29 00:00:00-08
17530	17	250	1775	1397	2024-02-29 00:00:00-08
17531	7	350	1776	1398	2024-02-29 00:00:00-08
17532	23	250	1778	1399	2024-02-29 00:00:00-08
17533	52	250	1779	1401	2024-02-29 00:00:00-08
17534	0	\N	1781	1416	2024-02-29 00:00:00-08
17535	0	\N	1782	1417	2024-02-29 00:00:00-08
17536	0	\N	1783	1418	2024-02-29 00:00:00-08
17537	0	\N	1784	1419	2024-02-29 00:00:00-08
17538	0	\N	1785	1420	2024-02-29 00:00:00-08
17539	0	\N	1786	1421	2024-02-29 00:00:00-08
17540	0	\N	1787	1422	2024-02-29 00:00:00-08
17541	0	\N	1788	1423	2024-02-29 00:00:00-08
17542	0	\N	1789	1424	2024-02-29 00:00:00-08
17543	0	\N	1790	1425	2024-02-29 00:00:00-08
17544	0	\N	1791	1426	2024-02-29 00:00:00-08
17545	0	\N	1792	1427	2024-02-29 00:00:00-08
17546	0	\N	1793	1428	2024-02-29 00:00:00-08
17547	0	\N	1794	1429	2024-02-29 00:00:00-08
17548	0	\N	1795	1430	2024-02-29 00:00:00-08
17549	0	\N	1796	1431	2024-02-29 00:00:00-08
17550	0	\N	1797	1432	2024-02-29 00:00:00-08
17551	0	\N	1798	1433	2024-02-29 00:00:00-08
17552	0	\N	1799	1434	2024-02-29 00:00:00-08
17553	0	\N	1800	1435	2024-02-29 00:00:00-08
17554	0	\N	1801	1436	2024-02-29 00:00:00-08
17555	0	\N	1802	1437	2024-02-29 00:00:00-08
17556	0	\N	1803	1443	2024-02-29 00:00:00-08
17557	0	\N	1804	1444	2024-02-29 00:00:00-08
17558	0	\N	1805	1445	2024-02-29 00:00:00-08
17559	0	\N	1806	2828	2024-02-29 00:00:00-08
17560	0	\N	1807	2829	2024-02-29 00:00:00-08
17561	0	\N	1808	2830	2024-02-29 00:00:00-08
17562	0	\N	1809	2831	2024-02-29 00:00:00-08
17563	0	\N	1810	2832	2024-02-29 00:00:00-08
17564	0	\N	1811	2833	2024-02-29 00:00:00-08
17565	Infinity	100	1815	899	2024-02-29 00:00:00-08
17566	Infinity	76.7	1816	1115	2024-02-29 00:00:00-08
17567	Infinity	77.6	1817	1116	2024-02-29 00:00:00-08
17568	Infinity	99.7	1818	1117	2024-02-29 00:00:00-08
17569	1	10.5	1819	304	2024-02-29 00:00:00-08
17570	Infinity	62.6	1820	1118	2024-02-29 00:00:00-08
17571	Infinity	51	1821	1119	2024-02-29 00:00:00-08
17572	746	76.1	1822	1120	2024-02-29 00:00:00-08
17573	Infinity	67	1823	305	2024-02-29 00:00:00-08
17574	Infinity	77.4	1824	1121	2024-02-29 00:00:00-08
17575	Infinity	22.6	1825	306	2024-02-29 00:00:00-08
17576	Infinity	100	1826	1122	2024-02-29 00:00:00-08
17577	Infinity	53.2	1827	1123	2024-02-29 00:00:00-08
17578	Infinity	76	1828	1124	2024-02-29 00:00:00-08
17579	Infinity	96.6	1829	1125	2024-02-29 00:00:00-08
17580	Infinity	75.1	1830	1143	2024-02-29 00:00:00-08
17581	Infinity	82.4	1831	1144	2024-02-29 00:00:00-08
17582	Infinity	74.2	1832	1145	2024-02-29 00:00:00-08
17583	Infinity	10.1	1833	307	2024-02-29 00:00:00-08
17584	Infinity	86.1	1834	1146	2024-02-29 00:00:00-08
17585	Infinity	75.3	1835	1147	2024-02-29 00:00:00-08
17586	Infinity	100	1836	308	2024-02-29 00:00:00-08
17587	Infinity	100	1837	309	2024-02-29 00:00:00-08
17588	Infinity	93.5	1838	310	2024-02-29 00:00:00-08
17589	Infinity	100	1839	311	2024-02-29 00:00:00-08
17590	Infinity	74.2	1840	312	2024-02-29 00:00:00-08
17591	Infinity	100	1841	313	2024-02-29 00:00:00-08
17592	Infinity	100	1842	314	2024-02-29 00:00:00-08
17593	Infinity	100	1843	317	2024-02-29 00:00:00-08
17594	0	\N	1848	2157	2024-02-29 00:00:00-08
17595	0	\N	1848	2149	2024-02-29 00:00:00-08
17596	0	\N	1849	2158	2024-02-29 00:00:00-08
17597	0	\N	1849	2150	2024-02-29 00:00:00-08
17598	0	\N	1850	2159	2024-02-29 00:00:00-08
17599	0	\N	1850	2151	2024-02-29 00:00:00-08
17600	0	\N	1851	2160	2024-02-29 00:00:00-08
17601	0	\N	1851	2152	2024-02-29 00:00:00-08
17602	0	\N	1852	2161	2024-02-29 00:00:00-08
17603	0	\N	1852	2153	2024-02-29 00:00:00-08
17604	0	\N	1853	2162	2024-02-29 00:00:00-08
17605	0	\N	1853	2154	2024-02-29 00:00:00-08
17606	Infinity	77.5	1967	397	2024-02-29 00:00:00-08
17607	\N	\N	4601	296	2024-02-29 00:00:00-08
17608	0	\N	1854	2163	2024-02-29 00:00:00-08
17609	0	\N	1854	2155	2024-02-29 00:00:00-08
17610	0	\N	1855	2164	2024-02-29 00:00:00-08
17611	0	\N	1855	2156	2024-02-29 00:00:00-08
17612	Infinity	20.5	1856	338	2024-02-29 00:00:00-08
17613	Infinity	14	1857	339	2024-02-29 00:00:00-08
17614	Infinity	76.3	1858	340	2024-02-29 00:00:00-08
17615	Infinity	78.5	1859	341	2024-02-29 00:00:00-08
17616	Infinity	11	1860	342	2024-02-29 00:00:00-08
17617	\N	\N	1861	343	2024-02-29 00:00:00-08
17618	Infinity	100	1862	344	2024-02-29 00:00:00-08
17619	Infinity	34.3	1863	900	2024-02-29 00:00:00-08
17620	Infinity	100	1864	901	2024-02-29 00:00:00-08
17621	Infinity	95.8	1865	902	2024-02-29 00:00:00-08
17622	Infinity	100	1866	903	2024-02-29 00:00:00-08
17623	Infinity	67	1867	904	2024-02-29 00:00:00-08
17624	Infinity	100	1868	905	2024-02-29 00:00:00-08
17625	Infinity	84.4	1869	906	2024-02-29 00:00:00-08
17626	Infinity	100	1870	907	2024-02-29 00:00:00-08
17627	Infinity	82.6	1871	924	2024-02-29 00:00:00-08
17628	Infinity	100	1872	925	2024-02-29 00:00:00-08
17629	Infinity	68.3	1873	926	2024-02-29 00:00:00-08
17630	Infinity	100	1874	927	2024-02-29 00:00:00-08
17631	Infinity	100	1875	928	2024-02-29 00:00:00-08
17632	Infinity	86.5	1876	929	2024-02-29 00:00:00-08
17633	Infinity	100	1877	930	2024-02-29 00:00:00-08
17634	Infinity	100	1878	931	2024-02-29 00:00:00-08
17635	Infinity	100	1879	932	2024-02-29 00:00:00-08
17636	Infinity	100	1880	933	2024-02-29 00:00:00-08
17637	Infinity	97.4	1881	934	2024-02-29 00:00:00-08
17638	Infinity	100	1882	935	2024-02-29 00:00:00-08
17639	\N	\N	1883	345	2024-02-29 00:00:00-08
17640	Infinity	21.6	1884	346	2024-02-29 00:00:00-08
17641	Infinity	65.1	1885	347	2024-02-29 00:00:00-08
17642	Infinity	80.6	1886	348	2024-02-29 00:00:00-08
17643	Infinity	93.6	1887	349	2024-02-29 00:00:00-08
17644	Infinity	42.8	1888	350	2024-02-29 00:00:00-08
17645	Infinity	100	1889	1148	2024-02-29 00:00:00-08
17646	Infinity	100	1890	1149	2024-02-29 00:00:00-08
17647	Infinity	48.1	1891	1150	2024-02-29 00:00:00-08
17648	Infinity	61.5	1892	1151	2024-02-29 00:00:00-08
17649	Infinity	11.3	1893	1152	2024-02-29 00:00:00-08
17650	Infinity	38.3	1894	351	2024-02-29 00:00:00-08
17651	Infinity	49	1895	352	2024-02-29 00:00:00-08
17652	Infinity	100	1896	353	2024-02-29 00:00:00-08
17653	Infinity	11	1897	354	2024-02-29 00:00:00-08
17654	Infinity	21.4	1898	355	2024-02-29 00:00:00-08
17655	Infinity	100	1899	1153	2024-02-29 00:00:00-08
17656	Infinity	100	1900	1154	2024-02-29 00:00:00-08
17657	Infinity	65.1	1901	1155	2024-02-29 00:00:00-08
17658	Infinity	77.1	1902	1156	2024-02-29 00:00:00-08
17659	Infinity	17.6	1903	1157	2024-02-29 00:00:00-08
17660	Infinity	34.8	1904	1158	2024-02-29 00:00:00-08
17661	Infinity	39.6	1905	1159	2024-02-29 00:00:00-08
17662	Infinity	11.4	1906	1160	2024-02-29 00:00:00-08
17663	Infinity	19.1	1907	1161	2024-02-29 00:00:00-08
17664	Infinity	20.7	1908	1162	2024-02-29 00:00:00-08
17665	Infinity	100	1909	1169	2024-02-29 00:00:00-08
17666	Infinity	100	1910	1170	2024-02-29 00:00:00-08
17667	Infinity	41.5	1911	1171	2024-02-29 00:00:00-08
17668	Infinity	61.2	1912	1172	2024-02-29 00:00:00-08
17669	Infinity	10.2	1913	1173	2024-02-29 00:00:00-08
17670	Infinity	94.9	1914	1163	2024-02-29 00:00:00-08
17671	Infinity	100	1915	1164	2024-02-29 00:00:00-08
17672	Infinity	82.4	1916	1165	2024-02-29 00:00:00-08
17673	Infinity	20.2	1917	1166	2024-02-29 00:00:00-08
17674	Infinity	10.8	1918	1167	2024-02-29 00:00:00-08
17675	Infinity	22.9	1919	1174	2024-02-29 00:00:00-08
17676	Infinity	57.2	1920	1175	2024-02-29 00:00:00-08
17677	Infinity	11	1921	1176	2024-02-29 00:00:00-08
17678	Infinity	24.2	1922	1177	2024-02-29 00:00:00-08
17679	Infinity	10.1	1923	1178	2024-02-29 00:00:00-08
17680	146	250	1924	1211	2024-02-29 00:00:00-08
17681	5	250	1925	1209	2024-02-29 00:00:00-08
17682	5	250	1926	1210	2024-02-29 00:00:00-08
17683	7	250	1927	1215	2024-02-29 00:00:00-08
17684	6	250	1928	1214	2024-02-29 00:00:00-08
17685	11	250	1929	1213	2024-02-29 00:00:00-08
17686	6	250	1930	1218	2024-02-29 00:00:00-08
17687	18	250	1931	1217	2024-02-29 00:00:00-08
17688	6	250	1932	1216	2024-02-29 00:00:00-08
17689	6	250	1933	1219	2024-02-29 00:00:00-08
17690	5	250	1934	1226	2024-02-29 00:00:00-08
17691	38	250	1935	1225	2024-02-29 00:00:00-08
17692	Infinity	250	1936	1224	2024-02-29 00:00:00-08
17693	40	250	1937	1220	2024-02-29 00:00:00-08
17694	22	250	1938	1221	2024-02-29 00:00:00-08
17695	317	250	1939	1222	2024-02-29 00:00:00-08
17696	6	250	1940	1223	2024-02-29 00:00:00-08
17697	198	250	1941	1208	2024-02-29 00:00:00-08
17698	5	250	1942	1207	2024-02-29 00:00:00-08
17699	4	250	1943	1205	2024-02-29 00:00:00-08
17700	5	250	1944	1206	2024-02-29 00:00:00-08
17701	Infinity	100	1945	827	2024-02-29 00:00:00-08
17702	\N	\N	1946	1000	2024-02-29 00:00:00-08
17703	\N	\N	1947	1001	2024-02-29 00:00:00-08
17704	Infinity	100	1948	802	2024-02-29 00:00:00-08
17705	Infinity	100	1949	847	2024-02-29 00:00:00-08
17706	\N	\N	1950	1002	2024-02-29 00:00:00-08
17707	Infinity	50	1951	803	2024-02-29 00:00:00-08
17708	\N	\N	1952	1003	2024-02-29 00:00:00-08
17709	Infinity	100	1953	804	2024-02-29 00:00:00-08
17710	Infinity	96.9	1954	388	2024-02-29 00:00:00-08
17711	\N	\N	1955	389	2024-02-29 00:00:00-08
17712	Infinity	100	1956	805	2024-02-29 00:00:00-08
17713	Infinity	100	1957	390	2024-02-29 00:00:00-08
17714	\N	\N	1958	1018	2024-02-29 00:00:00-08
17715	\N	\N	1959	1019	2024-02-29 00:00:00-08
17716	Infinity	68.8	1960	391	2024-02-29 00:00:00-08
17717	Infinity	100	1961	392	2024-02-29 00:00:00-08
17718	Infinity	65.2	1962	393	2024-02-29 00:00:00-08
17719	Infinity	100	1963	394	2024-02-29 00:00:00-08
17720	Infinity	100	1964	395	2024-02-29 00:00:00-08
17721	1	100	1965	806	2024-02-29 00:00:00-08
17722	Infinity	10.3	1966	396	2024-02-29 00:00:00-08
17723	Infinity	89.4	1968	398	2024-02-29 00:00:00-08
17724	Infinity	100	1969	399	2024-02-29 00:00:00-08
17725	Infinity	100	1970	807	2024-02-29 00:00:00-08
17726	Infinity	39.7	1971	400	2024-02-29 00:00:00-08
17727	Infinity	100	1972	401	2024-02-29 00:00:00-08
17728	Infinity	100	1973	402	2024-02-29 00:00:00-08
17729	Infinity	100	1974	849	2024-02-29 00:00:00-08
17730	Infinity	100	1975	403	2024-02-29 00:00:00-08
17731	90	19	1976	2179	2024-02-29 00:00:00-08
17732	89	65	1977	2695	2024-02-29 00:00:00-08
17733	90	98.1	1978	2696	2024-02-29 00:00:00-08
17734	90	124.2	1979	2697	2024-02-29 00:00:00-08
17735	90	72.8	1980	2698	2024-02-29 00:00:00-08
17736	90	43.3	1981	2699	2024-02-29 00:00:00-08
17737	30	59.1	1982	2700	2024-02-29 00:00:00-08
17738	30	19.6	1983	2701	2024-02-29 00:00:00-08
17739	30	40.8	1984	2702	2024-02-29 00:00:00-08
17740	30	97.8	1985	2703	2024-02-29 00:00:00-08
17741	15	57.9	1986	2704	2024-02-29 00:00:00-08
17742	25	62	1987	2180	2024-02-29 00:00:00-08
17743	50	85	1988	2181	2024-02-29 00:00:00-08
17744	50	199	1989	2182	2024-02-29 00:00:00-08
17745	50	93	1990	2183	2024-02-29 00:00:00-08
17746	50	129	1991	2184	2024-02-29 00:00:00-08
17747	50	199	1992	2185	2024-02-29 00:00:00-08
17748	50	223	1993	2186	2024-02-29 00:00:00-08
17749	\N	\N	1994	1022	2024-02-29 00:00:00-08
17750	\N	\N	1995	1023	2024-02-29 00:00:00-08
17751	\N	\N	1996	1024	2024-02-29 00:00:00-08
17752	\N	\N	1997	1025	2024-02-29 00:00:00-08
17753	\N	\N	1998	1026	2024-02-29 00:00:00-08
17754	\N	\N	1999	1027	2024-02-29 00:00:00-08
17755	\N	\N	2000	1028	2024-02-29 00:00:00-08
17756	\N	\N	2001	1029	2024-02-29 00:00:00-08
17757	\N	\N	2002	1030	2024-02-29 00:00:00-08
17758	\N	\N	2003	1031	2024-02-29 00:00:00-08
17759	\N	\N	2004	1032	2024-02-29 00:00:00-08
17760	\N	\N	2005	1033	2024-02-29 00:00:00-08
17761	\N	\N	2006	1034	2024-02-29 00:00:00-08
17762	\N	\N	2007	1035	2024-02-29 00:00:00-08
17763	Infinity	96.4	2008	404	2024-02-29 00:00:00-08
17764	Infinity	85.2	2009	405	2024-02-29 00:00:00-08
17765	Infinity	70	2010	406	2024-02-29 00:00:00-08
17766	Infinity	40	2011	407	2024-02-29 00:00:00-08
17767	Infinity	100	2012	914	2024-02-29 00:00:00-08
17768	0	\N	2016	1451	2024-02-29 00:00:00-08
17769	0	\N	2017	1452	2024-02-29 00:00:00-08
17770	0	\N	2018	1453	2024-02-29 00:00:00-08
17771	0	\N	2019	1454	2024-02-29 00:00:00-08
17772	0	\N	2020	1455	2024-02-29 00:00:00-08
17773	0	\N	2021	1456	2024-02-29 00:00:00-08
17774	0	\N	2022	1457	2024-02-29 00:00:00-08
17775	0	\N	2023	1458	2024-02-29 00:00:00-08
17776	0	\N	2024	1459	2024-02-29 00:00:00-08
17777	0	\N	2025	1460	2024-02-29 00:00:00-08
17778	0	\N	2026	1461	2024-02-29 00:00:00-08
17779	0	\N	2027	1462	2024-02-29 00:00:00-08
17780	0	\N	2028	1438	2024-02-29 00:00:00-08
17781	0	\N	2029	1439	2024-02-29 00:00:00-08
17782	0	\N	2030	1440	2024-02-29 00:00:00-08
17783	\N	\N	4591	1243	2024-02-29 00:00:00-08
17784	5	100	2061	408	2024-02-29 00:00:00-08
17785	13	100	2062	409	2024-02-29 00:00:00-08
17786	38	100	2064	410	2024-02-29 00:00:00-08
17787	43	100	2065	411	2024-02-29 00:00:00-08
17788	38	100	2067	412	2024-02-29 00:00:00-08
17789	42	100	2068	413	2024-02-29 00:00:00-08
17790	5	100	2070	414	2024-02-29 00:00:00-08
17791	39	100	2071	415	2024-02-29 00:00:00-08
17792	32	100	2074	416	2024-02-29 00:00:00-08
17793	25	100	2075	417	2024-02-29 00:00:00-08
17794	0	\N	2096	2940	2024-02-29 00:00:00-08
17795	0	\N	2096	2240	2024-02-29 00:00:00-08
17796	4	250	2097	2941	2024-02-29 00:00:00-08
17797	4	250	2097	2268	2024-02-29 00:00:00-08
17798	2	250	2098	2942	2024-02-29 00:00:00-08
17799	2	250	2098	2269	2024-02-29 00:00:00-08
17800	5	250	2099	2943	2024-02-29 00:00:00-08
17801	5	250	2099	2270	2024-02-29 00:00:00-08
17802	17	250	2100	2944	2024-02-29 00:00:00-08
17803	17	250	2100	2271	2024-02-29 00:00:00-08
17804	11	250	2101	2945	2024-02-29 00:00:00-08
17805	11	250	2101	2272	2024-02-29 00:00:00-08
17806	3	250	2102	2946	2024-02-29 00:00:00-08
17807	3	250	2102	2273	2024-02-29 00:00:00-08
17808	4	250	2103	2947	2024-02-29 00:00:00-08
17809	4	250	2103	2274	2024-02-29 00:00:00-08
17810	8	250	2104	2948	2024-02-29 00:00:00-08
17811	8	250	2104	2275	2024-02-29 00:00:00-08
17812	0	\N	2105	2949	2024-02-29 00:00:00-08
17813	0	\N	2105	2241	2024-02-29 00:00:00-08
17814	0	\N	2106	2950	2024-02-29 00:00:00-08
17815	0	\N	2106	2242	2024-02-29 00:00:00-08
17816	0	\N	2107	2951	2024-02-29 00:00:00-08
17817	0	\N	2107	2243	2024-02-29 00:00:00-08
17818	0	\N	2108	2952	2024-02-29 00:00:00-08
17819	0	\N	2108	2244	2024-02-29 00:00:00-08
17820	10	250	2109	2953	2024-02-29 00:00:00-08
17821	10	250	2109	2276	2024-02-29 00:00:00-08
17822	0	\N	2110	2954	2024-02-29 00:00:00-08
17823	0	\N	2110	2245	2024-02-29 00:00:00-08
17824	0	\N	2111	2955	2024-02-29 00:00:00-08
17825	0	\N	2111	2246	2024-02-29 00:00:00-08
17826	0	\N	2112	2956	2024-02-29 00:00:00-08
17827	0	\N	2112	2247	2024-02-29 00:00:00-08
17828	3	250	2113	2957	2024-02-29 00:00:00-08
17829	3	250	2113	2277	2024-02-29 00:00:00-08
17830	0	\N	2114	2958	2024-02-29 00:00:00-08
17831	0	\N	2114	2248	2024-02-29 00:00:00-08
17832	2	250	2115	2959	2024-02-29 00:00:00-08
17833	2	250	2115	2278	2024-02-29 00:00:00-08
17834	0	\N	2116	2960	2024-02-29 00:00:00-08
17835	0	\N	2116	2249	2024-02-29 00:00:00-08
17836	172	67.2	2117	2434	2024-02-29 00:00:00-08
17837	125	61.4	2118	2435	2024-02-29 00:00:00-08
17838	197	130.1	2119	2436	2024-02-29 00:00:00-08
17839	224	176.6	2120	2437	2024-02-29 00:00:00-08
17840	249	129.6	2121	2438	2024-02-29 00:00:00-08
17841	199	65.8	2122	2439	2024-02-29 00:00:00-08
17842	181	25.4	2123	491	2024-02-29 00:00:00-08
17843	161	46.6	2124	2440	2024-02-29 00:00:00-08
17844	162	61.4	2125	2441	2024-02-29 00:00:00-08
17845	218	39.2	2126	2442	2024-02-29 00:00:00-08
17846	323	142.1	2127	2443	2024-02-29 00:00:00-08
17847	48	61	2128	2444	2024-02-29 00:00:00-08
17848	825	132	2129	2445	2024-02-29 00:00:00-08
17849	388	104.6	2130	2446	2024-02-29 00:00:00-08
17850	406	61	2131	2447	2024-02-29 00:00:00-08
17851	859	77.3	2133	2448	2024-02-29 00:00:00-08
17852	475	95	2134	2449	2024-02-29 00:00:00-08
17853	153	85	2135	2450	2024-02-29 00:00:00-08
17854	176	250	2136	2451	2024-02-29 00:00:00-08
17855	680	81.6	2137	2452	2024-02-29 00:00:00-08
17856	428	250	2138	2453	2024-02-29 00:00:00-08
17857	48	30.4	2139	492	2024-02-29 00:00:00-08
17858	164	250	2140	2454	2024-02-29 00:00:00-08
17859	640	159.4	2141	2455	2024-02-29 00:00:00-08
17860	436	117.6	2142	2456	2024-02-29 00:00:00-08
17861	48	100.3	2145	2457	2024-02-29 00:00:00-08
17862	48	132	2152	2458	2024-02-29 00:00:00-08
17863	48	57.6	2153	2459	2024-02-29 00:00:00-08
17864	48	46.9	2154	2460	2024-02-29 00:00:00-08
17865	48	127.2	2155	2461	2024-02-29 00:00:00-08
17866	48	107.5	2157	2462	2024-02-29 00:00:00-08
17867	48	71.5	2158	2463	2024-02-29 00:00:00-08
17868	48	110.9	2159	2464	2024-02-29 00:00:00-08
17869	48	65.3	2160	2465	2024-02-29 00:00:00-08
17870	48	47	2161	2466	2024-02-29 00:00:00-08
17871	48	80.6	2162	2467	2024-02-29 00:00:00-08
17872	0	\N	2216	2978	2024-02-29 00:00:00-08
17873	\N	\N	4592	1244	2024-02-29 00:00:00-08
17874	Infinity	55	2352	418	2024-02-29 00:00:00-08
17875	0	\N	2353	1449	2024-02-29 00:00:00-08
17876	0	\N	2354	1450	2024-02-29 00:00:00-08
17877	16	250	2355	2417	2024-02-29 00:00:00-08
17878	6	250	2356	2827	2024-02-29 00:00:00-08
17879	15	250	2357	2418	2024-02-29 00:00:00-08
17880	12	250	2358	2419	2024-02-29 00:00:00-08
17881	15	250	2359	2420	2024-02-29 00:00:00-08
17882	18	250	2360	2421	2024-02-29 00:00:00-08
17883	27	250	2361	2412	2024-02-29 00:00:00-08
17884	25	250	2362	2423	2024-02-29 00:00:00-08
17885	17	250	2363	2411	2024-02-29 00:00:00-08
17886	Infinity	100	2364	850	2024-02-29 00:00:00-08
17887	Infinity	100	2365	851	2024-02-29 00:00:00-08
17888	Infinity	100	2366	852	2024-02-29 00:00:00-08
17889	Infinity	100	2367	853	2024-02-29 00:00:00-08
17890	Infinity	100	2368	854	2024-02-29 00:00:00-08
17891	Infinity	100	2369	855	2024-02-29 00:00:00-08
17892	Infinity	100	2370	856	2024-02-29 00:00:00-08
17893	Infinity	100	2371	857	2024-02-29 00:00:00-08
17894	Infinity	100	2372	858	2024-02-29 00:00:00-08
17895	Infinity	100	2373	859	2024-02-29 00:00:00-08
17896	Infinity	32.1	2374	936	2024-02-29 00:00:00-08
17897	Infinity	100	2375	915	2024-02-29 00:00:00-08
17898	Infinity	100	2376	916	2024-02-29 00:00:00-08
17899	Infinity	100	2377	917	2024-02-29 00:00:00-08
17900	Infinity	100	2378	918	2024-02-29 00:00:00-08
17901	Infinity	100	2379	919	2024-02-29 00:00:00-08
17902	Infinity	100	2380	920	2024-02-29 00:00:00-08
17903	Infinity	100	2381	921	2024-02-29 00:00:00-08
17904	Infinity	100	2382	922	2024-02-29 00:00:00-08
17905	Infinity	100	2383	937	2024-02-29 00:00:00-08
17906	10	250	2384	2187	2024-02-29 00:00:00-08
17907	8	250	2385	2188	2024-02-29 00:00:00-08
17908	13	250	2386	2189	2024-02-29 00:00:00-08
17909	50	123	2387	2705	2024-02-29 00:00:00-08
17910	7	250	2388	2706	2024-02-29 00:00:00-08
17911	10	250	2389	2190	2024-02-29 00:00:00-08
17912	9	250	2390	2707	2024-02-29 00:00:00-08
17913	3	250	2391	2708	2024-02-29 00:00:00-08
17914	4	250	2392	2191	2024-02-29 00:00:00-08
17915	3	250	2393	2192	2024-02-29 00:00:00-08
17916	16	250	2394	2193	2024-02-29 00:00:00-08
17917	8	250	2395	2194	2024-02-29 00:00:00-08
17918	3	250	2396	2195	2024-02-29 00:00:00-08
17919	1	250	2397	2709	2024-02-29 00:00:00-08
17920	7	250	2398	2196	2024-02-29 00:00:00-08
17921	6	250	2399	2710	2024-02-29 00:00:00-08
17922	11	250	2400	2197	2024-02-29 00:00:00-08
17923	11	250	2401	2198	2024-02-29 00:00:00-08
17924	47	250	2402	2711	2024-02-29 00:00:00-08
17925	25	250	2403	2199	2024-02-29 00:00:00-08
17926	50	223	2404	2200	2024-02-29 00:00:00-08
17927	27	250	2405	2201	2024-02-29 00:00:00-08
17928	16	250	2406	2202	2024-02-29 00:00:00-08
17929	32	250	2407	2712	2024-02-29 00:00:00-08
17930	20	250	2408	2713	2024-02-29 00:00:00-08
17931	3	250	2409	2714	2024-02-29 00:00:00-08
17932	13	250	2410	2715	2024-02-29 00:00:00-08
17933	14	250	2411	2716	2024-02-29 00:00:00-08
17934	11	250	2412	2717	2024-02-29 00:00:00-08
17935	8	250	2413	2718	2024-02-29 00:00:00-08
17936	50	193	2414	2203	2024-02-29 00:00:00-08
17937	3	250	2415	2719	2024-02-29 00:00:00-08
17938	16	250	2416	2720	2024-02-29 00:00:00-08
17939	50	231	2417	2204	2024-02-29 00:00:00-08
17940	7	250	2418	2205	2024-02-29 00:00:00-08
17941	9	250	2419	2538	2024-02-29 00:00:00-08
17942	2	250	2420	2539	2024-02-29 00:00:00-08
17943	9	250	2421	2533	2024-02-29 00:00:00-08
17944	4	250	2422	2540	2024-02-29 00:00:00-08
17945	50	72.5	2423	2541	2024-02-29 00:00:00-08
17946	20	250	2424	2542	2024-02-29 00:00:00-08
17947	11	250	2425	2559	2024-02-29 00:00:00-08
17948	96	170	2426	2560	2024-02-29 00:00:00-08
17949	9	250	2427	2561	2024-02-29 00:00:00-08
17950	10	250	2428	2562	2024-02-29 00:00:00-08
17951	36	250	2429	2563	2024-02-29 00:00:00-08
17952	12	250	2430	2564	2024-02-29 00:00:00-08
17953	12	250	2431	2565	2024-02-29 00:00:00-08
17954	96	229	2432	2566	2024-02-29 00:00:00-08
17955	96	230	2433	2567	2024-02-29 00:00:00-08
17956	38	250	2434	2568	2024-02-29 00:00:00-08
17957	26	250	2435	2569	2024-02-29 00:00:00-08
17958	22	250	2436	2570	2024-02-29 00:00:00-08
17959	11	250	2437	2571	2024-02-29 00:00:00-08
17960	45	250	2438	2572	2024-02-29 00:00:00-08
17961	96	172	2439	2573	2024-02-29 00:00:00-08
17962	95	46	2440	2574	2024-02-29 00:00:00-08
17963	21	250	2441	2575	2024-02-29 00:00:00-08
17964	72	250	2442	2576	2024-02-29 00:00:00-08
17965	85	250	2443	2577	2024-02-29 00:00:00-08
17966	7	250	2444	2578	2024-02-29 00:00:00-08
17967	9	250	2445	2579	2024-02-29 00:00:00-08
17968	11	250	2446	2580	2024-02-29 00:00:00-08
17969	17	250	2447	2581	2024-02-29 00:00:00-08
17970	96	248	2448	2582	2024-02-29 00:00:00-08
17971	23	250	2449	2583	2024-02-29 00:00:00-08
17972	65	250	2450	2584	2024-02-29 00:00:00-08
17973	17	250	2451	2585	2024-02-29 00:00:00-08
17974	23	250	2452	2586	2024-02-29 00:00:00-08
17975	6	250	2453	2587	2024-02-29 00:00:00-08
17976	15	250	2454	2588	2024-02-29 00:00:00-08
17977	9	250	2455	2589	2024-02-29 00:00:00-08
17978	96	132	2456	2590	2024-02-29 00:00:00-08
17979	46	250	2457	2591	2024-02-29 00:00:00-08
17980	4	250	2458	2592	2024-02-29 00:00:00-08
17981	8	250	2459	2593	2024-02-29 00:00:00-08
17982	6	250	2460	2594	2024-02-29 00:00:00-08
17983	74	250	2461	497	2024-02-29 00:00:00-08
17984	16	250	2462	2595	2024-02-29 00:00:00-08
17985	96	129	2463	2596	2024-02-29 00:00:00-08
17986	96	169	2464	2597	2024-02-29 00:00:00-08
17987	5	250	2465	2598	2024-02-29 00:00:00-08
17988	5	250	2466	2599	2024-02-29 00:00:00-08
17989	26	250	2467	2600	2024-02-29 00:00:00-08
17990	5	250	2468	2601	2024-02-29 00:00:00-08
17991	6	250	2469	2503	2024-02-29 00:00:00-08
17992	15	250	2470	2504	2024-02-29 00:00:00-08
17993	4	250	2471	2505	2024-02-29 00:00:00-08
17994	7	250	2472	2506	2024-02-29 00:00:00-08
17995	48	231	2473	2507	2024-02-29 00:00:00-08
17996	45	250	2474	2508	2024-02-29 00:00:00-08
17997	6	250	2475	2509	2024-02-29 00:00:00-08
17998	2	250	2476	2624	2024-02-29 00:00:00-08
17999	9	250	2477	2625	2024-02-29 00:00:00-08
18000	16	250	2478	2626	2024-02-29 00:00:00-08
18001	10	250	2479	2627	2024-02-29 00:00:00-08
18002	95	53	2480	2628	2024-02-29 00:00:00-08
18003	47	250	2481	2629	2024-02-29 00:00:00-08
18004	21	250	2482	2630	2024-02-29 00:00:00-08
18005	25	250	2483	2631	2024-02-29 00:00:00-08
18006	72	250	2484	2632	2024-02-29 00:00:00-08
18007	13	250	2485	2633	2024-02-29 00:00:00-08
18008	53	250	2486	2634	2024-02-29 00:00:00-08
18009	13	250	2487	2635	2024-02-29 00:00:00-08
18010	24	250	2488	2636	2024-02-29 00:00:00-08
18011	96	109	2489	2637	2024-02-29 00:00:00-08
18012	60	250	2490	2638	2024-02-29 00:00:00-08
18013	7	250	2491	2639	2024-02-29 00:00:00-08
18014	20	250	2492	2640	2024-02-29 00:00:00-08
18015	96	201	2493	2671	2024-02-29 00:00:00-08
18016	96	231	2494	2672	2024-02-29 00:00:00-08
18017	91	500	2495	2673	2024-02-29 00:00:00-08
18018	58	2900	2496	2669	2024-02-29 00:00:00-08
18019	58	2900	2496	2665	2024-02-29 00:00:00-08
18020	58	2900	2496	2660	2024-02-29 00:00:00-08
18021	58	2900	2496	2659	2024-02-29 00:00:00-08
18022	96	292	2497	2674	2024-02-29 00:00:00-08
18023	96	307	2498	2675	2024-02-29 00:00:00-08
18024	96	262	2499	2676	2024-02-29 00:00:00-08
18025	96	145	2500	2677	2024-02-29 00:00:00-08
18026	96	153	2501	2678	2024-02-29 00:00:00-08
18027	80	500	2502	2679	2024-02-29 00:00:00-08
18028	47	500	2503	2680	2024-02-29 00:00:00-08
18029	96	253	2504	2681	2024-02-29 00:00:00-08
18030	74	500	2505	2682	2024-02-29 00:00:00-08
18031	63	2000	2506	2670	2024-02-29 00:00:00-08
18032	63	2000	2506	2666	2024-02-29 00:00:00-08
18033	63	2000	2506	2662	2024-02-29 00:00:00-08
18034	63	2000	2506	2661	2024-02-29 00:00:00-08
18035	96	268	2507	2683	2024-02-29 00:00:00-08
18036	96	156	2508	2684	2024-02-29 00:00:00-08
18037	45	500	2509	2685	2024-02-29 00:00:00-08
18038	96	100	2510	2686	2024-02-29 00:00:00-08
18039	81	500	2511	2687	2024-02-29 00:00:00-08
18040	73	500	2512	2688	2024-02-29 00:00:00-08
18041	96	262	2513	2689	2024-02-29 00:00:00-08
18042	61	500	2514	2690	2024-02-29 00:00:00-08
18043	0	\N	2515	2664	2024-02-29 00:00:00-08
18044	0	\N	2515	2663	2024-02-29 00:00:00-08
18045	97	83	2516	2691	2024-02-29 00:00:00-08
18046	91	500	2517	2692	2024-02-29 00:00:00-08
18047	96	252	2518	2693	2024-02-29 00:00:00-08
18048	61	500	2519	2694	2024-02-29 00:00:00-08
18049	96	77	2520	2722	2024-02-29 00:00:00-08
18050	55	500	2521	2723	2024-02-29 00:00:00-08
18051	96	404	2522	2724	2024-02-29 00:00:00-08
18052	96	366	2523	2725	2024-02-29 00:00:00-08
18053	96	176	2524	2726	2024-02-29 00:00:00-08
18054	96	221	2525	2727	2024-02-29 00:00:00-08
18055	96	491	2526	2728	2024-02-29 00:00:00-08
18056	96	124	2527	2729	2024-02-29 00:00:00-08
18057	14	500	2528	2668	2024-02-29 00:00:00-08
18058	14	500	2528	2667	2024-02-29 00:00:00-08
18059	96	172	2529	2730	2024-02-29 00:00:00-08
18060	96	434	2530	2731	2024-02-29 00:00:00-08
18061	96	372	2531	2732	2024-02-29 00:00:00-08
18062	47	500	2532	2733	2024-02-29 00:00:00-08
18063	96	251	2533	2734	2024-02-29 00:00:00-08
18064	71	500	2534	2735	2024-02-29 00:00:00-08
18065	96	94	2535	2736	2024-02-29 00:00:00-08
18066	96	225	2536	2737	2024-02-29 00:00:00-08
18067	96	132	2537	2738	2024-02-29 00:00:00-08
18068	96	141	2538	2739	2024-02-29 00:00:00-08
18069	96	268	2539	2740	2024-02-29 00:00:00-08
18070	96	136	2540	2741	2024-02-29 00:00:00-08
18071	96	303	2541	2742	2024-02-29 00:00:00-08
18072	96	159	2542	2743	2024-02-29 00:00:00-08
18073	96	156	2543	2744	2024-02-29 00:00:00-08
18074	96	153	2544	2745	2024-02-29 00:00:00-08
18075	96	320	2545	2746	2024-02-29 00:00:00-08
18076	68	500	2546	2747	2024-02-29 00:00:00-08
18077	\N	\N	4593	1245	2024-02-29 00:00:00-08
18078	78	500	2549	2748	2024-02-29 00:00:00-08
18079	96	270	2550	2749	2024-02-29 00:00:00-08
18080	97	49	2551	2750	2024-02-29 00:00:00-08
18081	96	343	2552	2751	2024-02-29 00:00:00-08
18082	96	159	2553	2752	2024-02-29 00:00:00-08
18083	96	253	2554	2753	2024-02-29 00:00:00-08
18084	96	106	2556	2754	2024-02-29 00:00:00-08
18085	96	453	2557	2755	2024-02-29 00:00:00-08
18086	96	292	2558	2756	2024-02-29 00:00:00-08
18087	96	74	2559	2757	2024-02-29 00:00:00-08
18088	96	197	2560	2758	2024-02-29 00:00:00-08
18089	96	415	2561	2759	2024-02-29 00:00:00-08
18090	96	120	2562	2760	2024-02-29 00:00:00-08
18091	58	500	2563	2761	2024-02-29 00:00:00-08
18092	96	226	2564	2762	2024-02-29 00:00:00-08
18093	96	243	2565	2763	2024-02-29 00:00:00-08
18094	96	269	2566	2764	2024-02-29 00:00:00-08
18095	96	448	2567	2765	2024-02-29 00:00:00-08
18096	16	500	2568	2766	2024-02-29 00:00:00-08
18097	73	500	2569	2767	2024-02-29 00:00:00-08
18098	96	151	2570	2768	2024-02-29 00:00:00-08
18099	96	255	2571	2769	2024-02-29 00:00:00-08
18100	80	66	2572	2770	2024-02-29 00:00:00-08
18101	80	206	2573	2771	2024-02-29 00:00:00-08
18102	29	500	2574	2772	2024-02-29 00:00:00-08
18103	80	60	2575	2773	2024-02-29 00:00:00-08
18104	80	106	2577	2774	2024-02-29 00:00:00-08
18105	80	184	2578	2775	2024-02-29 00:00:00-08
18106	80	326	2579	2776	2024-02-29 00:00:00-08
18107	80	55	2580	2777	2024-02-29 00:00:00-08
18108	15	500	2581	2778	2024-02-29 00:00:00-08
18109	80	460	2582	2779	2024-02-29 00:00:00-08
18110	80	118	2583	2780	2024-02-29 00:00:00-08
18111	80	406	2584	2781	2024-02-29 00:00:00-08
18112	55	500	2585	2782	2024-02-29 00:00:00-08
18113	80	162	2586	2783	2024-02-29 00:00:00-08
18114	38	500	2587	2784	2024-02-29 00:00:00-08
18115	36	500	2588	2785	2024-02-29 00:00:00-08
18116	77	500	2589	2786	2024-02-29 00:00:00-08
19100	0	\N	4497	1322	2024-02-29 00:00:00-08
18117	80	189	2590	2787	2024-02-29 00:00:00-08
18118	80	214	2591	2788	2024-02-29 00:00:00-08
18119	80	346	2592	2789	2024-02-29 00:00:00-08
18120	80	182	2593	2790	2024-02-29 00:00:00-08
18121	23	500	2594	2791	2024-02-29 00:00:00-08
18122	80	150	2596	2792	2024-02-29 00:00:00-08
18123	80	498	2597	2793	2024-02-29 00:00:00-08
18124	80	147	2598	2794	2024-02-29 00:00:00-08
18125	80	158	2599	2795	2024-02-29 00:00:00-08
18126	80	230	2600	2796	2024-02-29 00:00:00-08
18127	37	500	2601	2797	2024-02-29 00:00:00-08
18128	80	238	2602	2798	2024-02-29 00:00:00-08
18129	80	74	2603	2799	2024-02-29 00:00:00-08
18130	45	500	2604	2800	2024-02-29 00:00:00-08
18131	61	250	2605	2427	2024-02-29 00:00:00-08
18132	Infinity	46.7	2606	419	2024-02-29 00:00:00-08
18133	Infinity	14.3	2607	420	2024-02-29 00:00:00-08
18134	Infinity	19	2608	421	2024-02-29 00:00:00-08
18135	Infinity	100	2609	422	2024-02-29 00:00:00-08
18136	Infinity	30.9	2610	423	2024-02-29 00:00:00-08
18137	Infinity	100	2611	424	2024-02-29 00:00:00-08
18138	0	\N	2612	3138	2024-02-29 00:00:00-08
18139	0	\N	2613	3139	2024-02-29 00:00:00-08
18140	0	\N	2614	3149	2024-02-29 00:00:00-08
18141	0	\N	2615	3141	2024-02-29 00:00:00-08
18142	10	250	2616	2413	2024-02-29 00:00:00-08
18143	38	250	2617	2414	2024-02-29 00:00:00-08
18144	16	250	2618	2415	2024-02-29 00:00:00-08
18145	14	250	2619	2416	2024-02-29 00:00:00-08
18146	20	250	2620	2422	2024-02-29 00:00:00-08
18147	10	250	2621	3092	2024-02-29 00:00:00-08
18148	10	250	2622	3100	2024-02-29 00:00:00-08
18149	10	250	2622	3097	2024-02-29 00:00:00-08
18150	10	250	2622	212	2024-02-29 00:00:00-08
18151	10	250	2622	208	2024-02-29 00:00:00-08
18152	21	250	2623	3091	2024-02-29 00:00:00-08
18153	32	250	2624	3085	2024-02-29 00:00:00-08
18154	47	250	2626	3088	2024-02-29 00:00:00-08
18155	88	178	2627	3078	2024-02-29 00:00:00-08
18156	88	167	2628	3071	2024-02-29 00:00:00-08
18157	88	234	2630	3066	2024-02-29 00:00:00-08
18158	176	232	2632	3072	2024-02-29 00:00:00-08
18159	88	68	2635	3076	2024-02-29 00:00:00-08
18160	88	65	2640	3057	2024-02-29 00:00:00-08
18161	88	202	2650	3074	2024-02-29 00:00:00-08
18162	46	250	2655	3079	2024-02-29 00:00:00-08
18163	43	250	2657	3070	2024-02-29 00:00:00-08
18164	88	79	2658	3087	2024-02-29 00:00:00-08
18165	0	\N	2661	3086	2024-02-29 00:00:00-08
18166	68	250	2678	3059	2024-02-29 00:00:00-08
18167	88	82	2690	3065	2024-02-29 00:00:00-08
18168	0	\N	2694	3064	2024-02-29 00:00:00-08
18169	68	250	2699	3063	2024-02-29 00:00:00-08
18170	88	58	2709	3062	2024-02-29 00:00:00-08
18171	88	218	2714	3080	2024-02-29 00:00:00-08
18172	6	250	2715	3094	2024-02-29 00:00:00-08
18173	6	250	2715	211	2024-02-29 00:00:00-08
18174	174	250	2736	3084	2024-02-29 00:00:00-08
18175	76	250	2777	3069	2024-02-29 00:00:00-08
18176	25	250	2778	3090	2024-02-29 00:00:00-08
18177	14	250	2780	3098	2024-02-29 00:00:00-08
18178	14	250	2780	3095	2024-02-29 00:00:00-08
18179	14	250	2780	213	2024-02-29 00:00:00-08
18180	14	250	2780	209	2024-02-29 00:00:00-08
18181	88	185	2787	3055	2024-02-29 00:00:00-08
18182	8	250	2792	3093	2024-02-29 00:00:00-08
18183	8	250	2792	210	2024-02-29 00:00:00-08
18184	17	250	2796	3099	2024-02-29 00:00:00-08
18185	17	250	2796	3096	2024-02-29 00:00:00-08
18186	17	250	2796	207	2024-02-29 00:00:00-08
18187	\N	\N	4594	1246	2024-02-29 00:00:00-08
18188	\N	\N	4595	1227	2024-02-29 00:00:00-08
18189	65	250	3178	2409	2024-02-29 00:00:00-08
18190	42	250	3179	2410	2024-02-29 00:00:00-08
18191	4	250	3180	2381	2024-02-29 00:00:00-08
18192	6	250	3181	2382	2024-02-29 00:00:00-08
18193	12	250	3182	2383	2024-02-29 00:00:00-08
18194	8	250	3183	2384	2024-02-29 00:00:00-08
18195	15	250	3184	2385	2024-02-29 00:00:00-08
18196	25	250	3185	2386	2024-02-29 00:00:00-08
18197	21	250	3186	2387	2024-02-29 00:00:00-08
18198	29	250	3187	2388	2024-02-29 00:00:00-08
18199	28	250	3188	2389	2024-02-29 00:00:00-08
18200	4	250	3189	2390	2024-02-29 00:00:00-08
18201	8	250	3190	2391	2024-02-29 00:00:00-08
18202	48	53.3	3191	2392	2024-02-29 00:00:00-08
18203	5	250	3192	2393	2024-02-29 00:00:00-08
18204	1	250	3193	2394	2024-02-29 00:00:00-08
18205	22	250	3194	2395	2024-02-29 00:00:00-08
18206	21	250	3195	2396	2024-02-29 00:00:00-08
18207	39	250	3196	2397	2024-02-29 00:00:00-08
18208	2	250	3197	2428	2024-02-29 00:00:00-08
18209	48	48.5	3198	2429	2024-02-29 00:00:00-08
18210	8	250	3199	2398	2024-02-29 00:00:00-08
18211	18	250	3200	2430	2024-02-29 00:00:00-08
18212	14	250	3201	2431	2024-02-29 00:00:00-08
18213	22	250	3202	2399	2024-02-29 00:00:00-08
18214	10	250	3203	2400	2024-02-29 00:00:00-08
18215	5	250	3204	2401	2024-02-29 00:00:00-08
18216	6	250	3205	2402	2024-02-29 00:00:00-08
18217	46	250	3206	2403	2024-02-29 00:00:00-08
18218	26	250	3207	2432	2024-02-29 00:00:00-08
18219	17	250	3208	2404	2024-02-29 00:00:00-08
18220	13	250	3209	2405	2024-02-29 00:00:00-08
18221	7	250	3210	2433	2024-02-29 00:00:00-08
18222	7	250	3211	2343	2024-02-29 00:00:00-08
18223	38	250	3212	2344	2024-02-29 00:00:00-08
18224	15	250	3213	2345	2024-02-29 00:00:00-08
18225	14	250	3214	2346	2024-02-29 00:00:00-08
18226	48	46.6	3215	2347	2024-02-29 00:00:00-08
18227	13	250	3216	2348	2024-02-29 00:00:00-08
18228	48	97.9	3217	2349	2024-02-29 00:00:00-08
18229	7	250	3218	2350	2024-02-29 00:00:00-08
18230	11	250	3219	2351	2024-02-29 00:00:00-08
18231	12	250	3220	2352	2024-02-29 00:00:00-08
18232	48	101.8	3221	2406	2024-02-29 00:00:00-08
18233	Infinity	27.1	3222	425	2024-02-29 00:00:00-08
18234	0	\N	3223	3145	2024-02-29 00:00:00-08
18235	0	\N	3224	3146	2024-02-29 00:00:00-08
18236	0	\N	3225	3147	2024-02-29 00:00:00-08
18237	0	\N	3226	3148	2024-02-29 00:00:00-08
18238	\N	\N	3227	828	2024-02-29 00:00:00-08
18239	\N	\N	3228	829	2024-02-29 00:00:00-08
18240	\N	\N	3229	830	2024-02-29 00:00:00-08
18241	\N	\N	3230	831	2024-02-29 00:00:00-08
18242	\N	\N	3231	832	2024-02-29 00:00:00-08
18243	\N	\N	3232	833	2024-02-29 00:00:00-08
18244	\N	\N	3233	834	2024-02-29 00:00:00-08
18245	\N	\N	3234	835	2024-02-29 00:00:00-08
18246	\N	\N	3235	836	2024-02-29 00:00:00-08
18247	\N	\N	3236	837	2024-02-29 00:00:00-08
18248	\N	\N	3237	838	2024-02-29 00:00:00-08
18249	\N	\N	3238	839	2024-02-29 00:00:00-08
18250	\N	\N	3239	840	2024-02-29 00:00:00-08
18251	\N	\N	3240	841	2024-02-29 00:00:00-08
18252	\N	\N	3241	842	2024-02-29 00:00:00-08
18253	\N	\N	3242	843	2024-02-29 00:00:00-08
18254	20	250	3244	2361	2024-02-29 00:00:00-08
18255	7	250	3245	2362	2024-02-29 00:00:00-08
18256	41	250	3246	2363	2024-02-29 00:00:00-08
18257	49	59	3247	2364	2024-02-29 00:00:00-08
18258	45	36.1	3248	2365	2024-02-29 00:00:00-08
18259	48	72.5	3249	2366	2024-02-29 00:00:00-08
18260	50	44.6	3250	2367	2024-02-29 00:00:00-08
18261	9	250	3251	2368	2024-02-29 00:00:00-08
18262	47	79.2	3252	2369	2024-02-29 00:00:00-08
18263	48	115.7	3253	2370	2024-02-29 00:00:00-08
18264	49	83.5	3254	2371	2024-02-29 00:00:00-08
18265	47	65.8	3255	2372	2024-02-29 00:00:00-08
18266	12	250	3256	2493	2024-02-29 00:00:00-08
18267	13	250	3258	2279	2024-02-29 00:00:00-08
18268	48	83	3259	2494	2024-02-29 00:00:00-08
18269	8	250	3260	426	2024-02-29 00:00:00-08
18270	9	250	3261	427	2024-02-29 00:00:00-08
18271	7	250	3262	2280	2024-02-29 00:00:00-08
18272	7	250	3263	2281	2024-02-29 00:00:00-08
18273	9	250	3264	2536	2024-02-29 00:00:00-08
18274	11	250	3265	2495	2024-02-29 00:00:00-08
18275	7	250	3266	2496	2024-02-29 00:00:00-08
18276	8	250	3267	2282	2024-02-29 00:00:00-08
18277	25	250	3268	2283	2024-02-29 00:00:00-08
18278	16	250	3269	2303	2024-02-29 00:00:00-08
18279	45	250	3270	2284	2024-02-29 00:00:00-08
18280	9	250	3271	2518	2024-02-29 00:00:00-08
18281	10	250	3272	2519	2024-02-29 00:00:00-08
18282	8	250	3273	2534	2024-02-29 00:00:00-08
18283	6	250	3274	2285	2024-02-29 00:00:00-08
18284	48	237.1	3275	2520	2024-02-29 00:00:00-08
18285	48	88.3	3276	2521	2024-02-29 00:00:00-08
18286	6	250	3277	2286	2024-02-29 00:00:00-08
18287	6	250	3278	2522	2024-02-29 00:00:00-08
18288	5	250	3279	2523	2024-02-29 00:00:00-08
18289	5	250	3280	2287	2024-02-29 00:00:00-08
18290	5	250	3281	2288	2024-02-29 00:00:00-08
18291	10	250	3282	2524	2024-02-29 00:00:00-08
18292	5	250	3283	2289	2024-02-29 00:00:00-08
18293	7	250	3284	2290	2024-02-29 00:00:00-08
18294	48	70.6	3285	2291	2024-02-29 00:00:00-08
18295	14	250	3286	2292	2024-02-29 00:00:00-08
18296	29	250	3287	2293	2024-02-29 00:00:00-08
18297	48	39.4	3288	2304	2024-02-29 00:00:00-08
18298	8	250	3289	2537	2024-02-29 00:00:00-08
18299	22	250	3290	2525	2024-02-29 00:00:00-08
18300	48	43.1	3291	2305	2024-02-29 00:00:00-08
18301	14	250	3292	2526	2024-02-29 00:00:00-08
18302	19	250	3293	2527	2024-02-29 00:00:00-08
18303	16	250	3294	2294	2024-02-29 00:00:00-08
18304	44	250	3295	2528	2024-02-29 00:00:00-08
18305	48	93.1	3296	2529	2024-02-29 00:00:00-08
18306	48	28.9	3297	2306	2024-02-29 00:00:00-08
18307	48	128.2	3298	428	2024-02-29 00:00:00-08
18308	35	250	3299	429	2024-02-29 00:00:00-08
18309	9	250	3300	2530	2024-02-29 00:00:00-08
18310	48	94.1	3301	2531	2024-02-29 00:00:00-08
18311	16	250	3302	430	2024-02-29 00:00:00-08
18312	6	250	3303	2532	2024-02-29 00:00:00-08
18313	48	26.5	3304	2497	2024-02-29 00:00:00-08
18314	6	250	3305	2295	2024-02-29 00:00:00-08
18315	6	250	3306	2296	2024-02-29 00:00:00-08
18316	5	250	3307	2297	2024-02-29 00:00:00-08
18317	5	250	3308	2641	2024-02-29 00:00:00-08
18318	5	250	3309	2642	2024-02-29 00:00:00-08
18319	12	250	3310	2878	2024-02-29 00:00:00-08
18320	12	250	3310	2643	2024-02-29 00:00:00-08
18321	52	250	3311	2644	2024-02-29 00:00:00-08
18322	16	250	3312	2645	2024-02-29 00:00:00-08
18323	8	250	3313	2646	2024-02-29 00:00:00-08
18324	19	250	3314	2647	2024-02-29 00:00:00-08
18325	64	250	3315	2648	2024-02-29 00:00:00-08
18326	6	250	3316	2649	2024-02-29 00:00:00-08
18327	8	250	3317	2650	2024-02-29 00:00:00-08
18328	7	250	3318	2651	2024-02-29 00:00:00-08
18329	17	250	3319	2652	2024-02-29 00:00:00-08
18330	51	250	3320	2653	2024-02-29 00:00:00-08
18331	90	250	3321	2654	2024-02-29 00:00:00-08
18332	68	250	3322	2655	2024-02-29 00:00:00-08
18333	30	250	3323	2656	2024-02-29 00:00:00-08
18334	15	250	3324	2657	2024-02-29 00:00:00-08
18335	38	250	3325	2658	2024-02-29 00:00:00-08
18336	10	150	3326	1492	2024-02-29 00:00:00-08
18337	10	150	3327	1493	2024-02-29 00:00:00-08
18338	8	150	3328	1494	2024-02-29 00:00:00-08
18339	109	150	3329	1495	2024-02-29 00:00:00-08
18340	0	\N	3330	1402	2024-02-29 00:00:00-08
18341	0	\N	3331	1403	2024-02-29 00:00:00-08
18342	0	\N	3332	1404	2024-02-29 00:00:00-08
18343	0	\N	3333	1405	2024-02-29 00:00:00-08
18344	0	\N	3334	1406	2024-02-29 00:00:00-08
18345	0	\N	3335	1407	2024-02-29 00:00:00-08
18346	0	\N	3336	1408	2024-02-29 00:00:00-08
18347	0	\N	3337	1409	2024-02-29 00:00:00-08
18348	0	\N	3338	1410	2024-02-29 00:00:00-08
18349	0	\N	3339	1411	2024-02-29 00:00:00-08
18350	0	\N	3340	1412	2024-02-29 00:00:00-08
18351	0	\N	3341	1413	2024-02-29 00:00:00-08
18352	0	\N	3342	1414	2024-02-29 00:00:00-08
18353	0	\N	3343	1415	2024-02-29 00:00:00-08
18354	0	\N	3346	3027	2024-02-29 00:00:00-08
18355	0	\N	3347	3013	2024-02-29 00:00:00-08
18356	0	\N	3348	3014	2024-02-29 00:00:00-08
18357	0	\N	3349	3015	2024-02-29 00:00:00-08
18358	0	\N	3351	3016	2024-02-29 00:00:00-08
18359	0	\N	3353	3017	2024-02-29 00:00:00-08
18360	0	\N	3354	3018	2024-02-29 00:00:00-08
18361	0	\N	3355	3019	2024-02-29 00:00:00-08
18362	0	\N	3356	3020	2024-02-29 00:00:00-08
18363	0	\N	3359	3021	2024-02-29 00:00:00-08
18364	0	\N	3360	3022	2024-02-29 00:00:00-08
18365	0	\N	3361	3023	2024-02-29 00:00:00-08
18366	0	\N	3362	3029	2024-02-29 00:00:00-08
18367	0	\N	3363	3030	2024-02-29 00:00:00-08
18368	0	\N	3364	3031	2024-02-29 00:00:00-08
18369	0	\N	3365	3024	2024-02-29 00:00:00-08
18370	0	\N	3366	3025	2024-02-29 00:00:00-08
18371	0	\N	3367	3026	2024-02-29 00:00:00-08
18372	0	\N	3371	3032	2024-02-29 00:00:00-08
18373	0	\N	3373	3033	2024-02-29 00:00:00-08
18374	0	\N	3374	3034	2024-02-29 00:00:00-08
18375	0	\N	3375	3035	2024-02-29 00:00:00-08
18376	0	\N	3377	3036	2024-02-29 00:00:00-08
18377	0	\N	3378	3037	2024-02-29 00:00:00-08
18378	0	\N	3379	3038	2024-02-29 00:00:00-08
18379	0	\N	3381	3039	2024-02-29 00:00:00-08
18380	0	\N	3382	3040	2024-02-29 00:00:00-08
18381	0	\N	3383	3041	2024-02-29 00:00:00-08
18382	0	\N	3384	3042	2024-02-29 00:00:00-08
18383	0	\N	3385	3043	2024-02-29 00:00:00-08
18384	0	\N	3386	3044	2024-02-29 00:00:00-08
18385	0	\N	3387	3045	2024-02-29 00:00:00-08
18386	0	\N	3389	3046	2024-02-29 00:00:00-08
18387	0	\N	3390	3047	2024-02-29 00:00:00-08
18388	0	\N	3391	3048	2024-02-29 00:00:00-08
18389	0	\N	3393	3049	2024-02-29 00:00:00-08
18390	0	\N	3396	3050	2024-02-29 00:00:00-08
18391	0	\N	3397	3051	2024-02-29 00:00:00-08
18392	0	\N	3398	3052	2024-02-29 00:00:00-08
18393	0	\N	3414	2881	2024-02-29 00:00:00-08
18394	0	\N	3418	2882	2024-02-29 00:00:00-08
18395	0	\N	3420	2883	2024-02-29 00:00:00-08
18396	0	\N	3424	2884	2024-02-29 00:00:00-08
18397	0	\N	3428	2888	2024-02-29 00:00:00-08
18398	0	\N	3431	2885	2024-02-29 00:00:00-08
18399	0	\N	3433	2889	2024-02-29 00:00:00-08
18400	0	\N	3434	2886	2024-02-29 00:00:00-08
18401	0	\N	3438	2887	2024-02-29 00:00:00-08
18402	0	\N	3440	2890	2024-02-29 00:00:00-08
18403	0	\N	3441	2891	2024-02-29 00:00:00-08
18404	0	\N	3442	2892	2024-02-29 00:00:00-08
18405	23	250	3443	2880	2024-02-29 00:00:00-08
18406	23	250	3443	2879	2024-02-29 00:00:00-08
18407	23	250	3443	431	2024-02-29 00:00:00-08
18408	9	250	3444	3004	2024-02-29 00:00:00-08
18409	0	\N	3446	2893	2024-02-29 00:00:00-08
18410	0	\N	3447	2894	2024-02-29 00:00:00-08
18411	0	\N	3448	2895	2024-02-29 00:00:00-08
18412	0	\N	3449	2896	2024-02-29 00:00:00-08
18413	0	\N	3450	2897	2024-02-29 00:00:00-08
18414	0	\N	3451	2898	2024-02-29 00:00:00-08
18415	Infinity	100	3474	808	2024-02-29 00:00:00-08
18416	0	\N	3475	3142	2024-02-29 00:00:00-08
18417	0	\N	3476	3143	2024-02-29 00:00:00-08
18418	0	\N	3477	3140	2024-02-29 00:00:00-08
18419	0	\N	3478	3144	2024-02-29 00:00:00-08
18420	100	83	3479	3183	2024-02-29 00:00:00-08
18421	100	32	3480	318	2024-02-29 00:00:00-08
18422	99	16	3481	319	2024-02-29 00:00:00-08
18423	39	333	3482	3184	2024-02-29 00:00:00-08
18424	57	333	3483	3185	2024-02-29 00:00:00-08
18425	99	7	3484	320	2024-02-29 00:00:00-08
18426	99	9	3486	321	2024-02-29 00:00:00-08
18427	105	10	3489	322	2024-02-29 00:00:00-08
18428	100	202	3490	3186	2024-02-29 00:00:00-08
18429	100	94	3491	3187	2024-02-29 00:00:00-08
18430	99	71	3492	3188	2024-02-29 00:00:00-08
18431	140	250	3493	3191	2024-02-29 00:00:00-08
18432	199	143	3494	3196	2024-02-29 00:00:00-08
18433	15	250	3495	3193	2024-02-29 00:00:00-08
18434	15	250	3495	3192	2024-02-29 00:00:00-08
18435	16	250	3496	3189	2024-02-29 00:00:00-08
18436	184	193	3497	3194	2024-02-29 00:00:00-08
18437	23	250	3498	3190	2024-02-29 00:00:00-08
18438	73	250	3500	3197	2024-02-29 00:00:00-08
18439	73	250	3500	334	2024-02-29 00:00:00-08
18440	36	250	3501	3195	2024-02-29 00:00:00-08
18441	43	250	3502	331	2024-02-29 00:00:00-08
18442	76	250	3503	335	2024-02-29 00:00:00-08
18443	76	250	3503	332	2024-02-29 00:00:00-08
18444	76	250	3504	3199	2024-02-29 00:00:00-08
18445	76	250	3504	3198	2024-02-29 00:00:00-08
18446	0	100	3508	323	2024-02-29 00:00:00-08
18447	0	100	3509	324	2024-02-29 00:00:00-08
18448	19	100	3510	325	2024-02-29 00:00:00-08
18449	4	100	3512	326	2024-02-29 00:00:00-08
18450	7	100	3513	327	2024-02-29 00:00:00-08
18451	7	100	3514	328	2024-02-29 00:00:00-08
18452	2	100	3516	329	2024-02-29 00:00:00-08
18453	9	100	3517	330	2024-02-29 00:00:00-08
18454	39	300	3520	1810	2024-02-29 00:00:00-08
18455	39	300	3520	1802	2024-02-29 00:00:00-08
18456	2	300	3521	1811	2024-02-29 00:00:00-08
18457	2	300	3521	1803	2024-02-29 00:00:00-08
18458	6	200	3522	1804	2024-02-29 00:00:00-08
18459	6	200	3522	336	2024-02-29 00:00:00-08
18460	4	200	3524	1812	2024-02-29 00:00:00-08
18461	4	200	3524	1805	2024-02-29 00:00:00-08
18462	12	500	3526	1817	2024-02-29 00:00:00-08
18463	12	500	3526	1813	2024-02-29 00:00:00-08
18464	12	500	3526	1806	2024-02-29 00:00:00-08
18465	6	300	3527	1814	2024-02-29 00:00:00-08
18466	6	300	3527	1807	2024-02-29 00:00:00-08
18467	8	300	3528	337	2024-02-29 00:00:00-08
18468	8	300	3528	333	2024-02-29 00:00:00-08
18469	8	300	3529	1815	2024-02-29 00:00:00-08
18470	8	300	3529	1808	2024-02-29 00:00:00-08
18471	23	500	3530	1818	2024-02-29 00:00:00-08
18472	23	500	3530	1816	2024-02-29 00:00:00-08
18473	23	500	3530	1809	2024-02-29 00:00:00-08
18474	2	400	3531	3159	2024-02-29 00:00:00-08
18475	5	400	3532	3160	2024-02-29 00:00:00-08
18476	1	400	3533	3150	2024-02-29 00:00:00-08
18477	20	192	3534	3151	2024-02-29 00:00:00-08
18478	20	214	3535	3152	2024-02-29 00:00:00-08
18479	6	400	3536	3161	2024-02-29 00:00:00-08
18480	12	400	3537	3153	2024-02-29 00:00:00-08
18481	20	312	3538	3162	2024-02-29 00:00:00-08
18482	9	400	3539	3163	2024-02-29 00:00:00-08
18483	11	400	3540	483	2024-02-29 00:00:00-08
18484	20	200	3541	3154	2024-02-29 00:00:00-08
18485	12	400	3542	3155	2024-02-29 00:00:00-08
18486	5	400	3543	3156	2024-02-29 00:00:00-08
18487	0	400	3544	3157	2024-02-29 00:00:00-08
18488	17	400	3545	3164	2024-02-29 00:00:00-08
18489	7	400	3546	3165	2024-02-29 00:00:00-08
18490	15	400	3547	1691	2024-02-29 00:00:00-08
18491	7	400	3548	3166	2024-02-29 00:00:00-08
18492	17	400	3549	484	2024-02-29 00:00:00-08
18493	20	280	3550	485	2024-02-29 00:00:00-08
18494	5	400	3551	3167	2024-02-29 00:00:00-08
18495	3	400	3552	3158	2024-02-29 00:00:00-08
18496	4	400	3553	486	2024-02-29 00:00:00-08
18497	6	400	3554	1685	2024-02-29 00:00:00-08
18498	20	86	3555	1692	2024-02-29 00:00:00-08
18499	5	400	3556	3168	2024-02-29 00:00:00-08
18500	8	400	3557	3169	2024-02-29 00:00:00-08
18501	2	400	3558	3170	2024-02-29 00:00:00-08
18502	11	400	3559	3171	2024-02-29 00:00:00-08
18503	2	400	3560	3172	2024-02-29 00:00:00-08
18504	2	400	3561	3173	2024-02-29 00:00:00-08
18505	20	310	3562	3174	2024-02-29 00:00:00-08
18506	15	400	3563	3175	2024-02-29 00:00:00-08
18507	18	400	3564	3176	2024-02-29 00:00:00-08
18508	2	400	3565	3177	2024-02-29 00:00:00-08
18509	8	400	3566	3178	2024-02-29 00:00:00-08
18510	12	400	3567	3179	2024-02-29 00:00:00-08
18511	8	400	3568	3180	2024-02-29 00:00:00-08
18512	3	400	3569	3181	2024-02-29 00:00:00-08
18513	2	400	3570	3182	2024-02-29 00:00:00-08
18514	17	400	3571	1496	2024-02-29 00:00:00-08
18515	20	106	3572	1497	2024-02-29 00:00:00-08
18516	20	232	3573	1498	2024-02-29 00:00:00-08
18517	7	400	3574	1499	2024-02-29 00:00:00-08
18518	20	192	3575	1500	2024-02-29 00:00:00-08
18519	20	70	3576	1501	2024-02-29 00:00:00-08
18520	20	86	3577	1502	2024-02-29 00:00:00-08
18521	17	400	3578	1503	2024-02-29 00:00:00-08
18522	3	400	3579	1504	2024-02-29 00:00:00-08
18523	7	400	3580	1505	2024-02-29 00:00:00-08
18524	20	280	3581	1506	2024-02-29 00:00:00-08
18525	20	300	3582	1507	2024-02-29 00:00:00-08
18526	4	400	3583	1508	2024-02-29 00:00:00-08
18527	20	200	3584	1509	2024-02-29 00:00:00-08
18528	4	400	3585	1510	2024-02-29 00:00:00-08
18529	2	400	3586	1511	2024-02-29 00:00:00-08
18530	17	400	3587	432	2024-02-29 00:00:00-08
18531	20	30	3588	433	2024-02-29 00:00:00-08
18532	20	94	3589	1512	2024-02-29 00:00:00-08
18533	20	32	3590	1513	2024-02-29 00:00:00-08
18534	7	400	3591	1514	2024-02-29 00:00:00-08
18535	8	400	3592	1515	2024-02-29 00:00:00-08
18536	10	400	3593	1516	2024-02-29 00:00:00-08
18537	20	200	3594	2863	2024-02-29 00:00:00-08
18538	2	400	3595	1517	2024-02-29 00:00:00-08
18539	2	400	3596	1518	2024-02-29 00:00:00-08
18540	19	400	3597	1673	2024-02-29 00:00:00-08
18541	30	126	3598	1674	2024-02-29 00:00:00-08
18542	30	221	3599	1675	2024-02-29 00:00:00-08
18543	30	196	3600	1676	2024-02-29 00:00:00-08
18544	30	120	3601	1679	2024-02-29 00:00:00-08
18545	20	46	3602	1680	2024-02-29 00:00:00-08
18546	10	400	3603	1677	2024-02-29 00:00:00-08
18547	20	105	3604	1678	2024-02-29 00:00:00-08
18548	20	50	3605	1681	2024-02-29 00:00:00-08
18549	11	400	3606	1682	2024-02-29 00:00:00-08
18550	1	400	3607	1648	2024-02-29 00:00:00-08
18551	1	400	3608	1649	2024-02-29 00:00:00-08
18552	1	400	3609	1650	2024-02-29 00:00:00-08
18553	1	400	3610	1651	2024-02-29 00:00:00-08
18554	1	400	3611	1652	2024-02-29 00:00:00-08
18555	1	400	3612	1653	2024-02-29 00:00:00-08
18556	20	378	3613	1693	2024-02-29 00:00:00-08
18557	20	220	3619	1686	2024-02-29 00:00:00-08
18558	20	176.6	3620	1687	2024-02-29 00:00:00-08
18559	20	167.8	3622	1688	2024-02-29 00:00:00-08
18560	20	112.4	3630	1694	2024-02-29 00:00:00-08
18561	20	216	3631	1695	2024-02-29 00:00:00-08
18562	20	230	3635	434	2024-02-29 00:00:00-08
18563	20	366	3636	435	2024-02-29 00:00:00-08
18564	20	42	3637	1696	2024-02-29 00:00:00-08
18565	20	304	3638	1697	2024-02-29 00:00:00-08
18566	7	400	3639	1698	2024-02-29 00:00:00-08
18567	7	400	3639	447	2024-02-29 00:00:00-08
18568	20	348	3652	1683	2024-02-29 00:00:00-08
18569	20	116.6	3657	1700	2024-02-29 00:00:00-08
18570	32	200	3697	1858	2024-02-29 00:00:00-08
18571	32	200	3697	445	2024-02-29 00:00:00-08
18572	12	100	3701	1822	2024-02-29 00:00:00-08
18573	4	50	3704	1870	2024-02-29 00:00:00-08
18574	5	150	3706	1843	2024-02-29 00:00:00-08
18575	9	150	3707	1852	2024-02-29 00:00:00-08
18576	9	150	3708	1868	2024-02-29 00:00:00-08
18577	18	150	3710	1853	2024-02-29 00:00:00-08
18578	20	150	3713	1854	2024-02-29 00:00:00-08
18579	12	150	3714	1855	2024-02-29 00:00:00-08
18580	30	150	3715	1856	2024-02-29 00:00:00-08
18581	3	50	3717	1869	2024-02-29 00:00:00-08
18582	45	150	3718	1896	2024-02-29 00:00:00-08
18583	19	150	3728	1857	2024-02-29 00:00:00-08
18584	6	150	3735	1844	2024-02-29 00:00:00-08
18585	1	100	3742	1823	2024-02-29 00:00:00-08
18586	0	100	3743	1821	2024-02-29 00:00:00-08
18587	22	200	3747	1940	2024-02-29 00:00:00-08
18588	40	174	3749	1941	2024-02-29 00:00:00-08
18589	30	200	3750	1942	2024-02-29 00:00:00-08
18590	30	200	3774	1943	2024-02-29 00:00:00-08
18591	40	190	3775	1944	2024-02-29 00:00:00-08
18592	38	79.8	3776	1945	2024-02-29 00:00:00-08
18593	39	100	3778	1842	2024-02-29 00:00:00-08
18594	2	100	3779	1878	2024-02-29 00:00:00-08
18595	2	100	3780	1879	2024-02-29 00:00:00-08
18596	4	100	3781	1880	2024-02-29 00:00:00-08
18597	16	200	3782	1859	2024-02-29 00:00:00-08
18598	16	200	3782	449	2024-02-29 00:00:00-08
18599	10	200	3783	1871	2024-02-29 00:00:00-08
18600	10	200	3783	450	2024-02-29 00:00:00-08
18601	0	\N	3784	1881	2024-02-29 00:00:00-08
18602	0	\N	3785	1890	2024-02-29 00:00:00-08
18603	9	200	3787	1829	2024-02-29 00:00:00-08
18604	9	200	3787	451	2024-02-29 00:00:00-08
18605	8	200	3788	1898	2024-02-29 00:00:00-08
18606	8	200	3788	452	2024-02-29 00:00:00-08
18607	34	200	3789	1946	2024-02-29 00:00:00-08
18608	45	95	3790	1947	2024-02-29 00:00:00-08
18609	2	100	3792	1891	2024-02-29 00:00:00-08
18610	6	100	3793	1892	2024-02-29 00:00:00-08
18611	19	100	3794	1882	2024-02-29 00:00:00-08
18612	8	100	3795	1893	2024-02-29 00:00:00-08
18613	2	100	3796	1883	2024-02-29 00:00:00-08
18614	20	100	3797	1894	2024-02-29 00:00:00-08
18615	6	200	3798	1845	2024-02-29 00:00:00-08
18616	6	200	3798	453	2024-02-29 00:00:00-08
18617	22	200	3799	1872	2024-02-29 00:00:00-08
18618	22	200	3799	454	2024-02-29 00:00:00-08
18619	5	100	3800	1884	2024-02-29 00:00:00-08
18620	27	100	3801	1885	2024-02-29 00:00:00-08
18621	48	156	3802	1899	2024-02-29 00:00:00-08
18622	48	156	3802	455	2024-02-29 00:00:00-08
18623	11	200	3803	1830	2024-02-29 00:00:00-08
18624	11	200	3803	456	2024-02-29 00:00:00-08
18625	13	200	3804	1831	2024-02-29 00:00:00-08
18626	13	200	3804	457	2024-02-29 00:00:00-08
18627	22	200	3805	1832	2024-02-29 00:00:00-08
18628	22	200	3805	458	2024-02-29 00:00:00-08
18629	11	200	3806	1860	2024-02-29 00:00:00-08
18630	11	200	3806	459	2024-02-29 00:00:00-08
18631	9	200	3807	1846	2024-02-29 00:00:00-08
18632	9	200	3807	461	2024-02-29 00:00:00-08
18633	24	200	3808	1873	2024-02-29 00:00:00-08
18634	24	200	3808	462	2024-02-29 00:00:00-08
18635	40	200	3809	1847	2024-02-29 00:00:00-08
18636	40	200	3809	463	2024-02-29 00:00:00-08
18637	26	200	3810	1874	2024-02-29 00:00:00-08
18638	26	200	3810	464	2024-02-29 00:00:00-08
18639	38	200	3811	1848	2024-02-29 00:00:00-08
18640	38	200	3811	465	2024-02-29 00:00:00-08
18641	48	148.8	3812	1849	2024-02-29 00:00:00-08
18642	48	148.8	3812	466	2024-02-29 00:00:00-08
18643	45	200	3813	1862	2024-02-29 00:00:00-08
18644	45	200	3813	467	2024-02-29 00:00:00-08
18645	13	200	3814	1875	2024-02-29 00:00:00-08
18646	13	200	3814	468	2024-02-29 00:00:00-08
18647	5	200	3815	1900	2024-02-29 00:00:00-08
18648	5	200	3815	469	2024-02-29 00:00:00-08
18649	17	200	3816	1876	2024-02-29 00:00:00-08
18650	17	200	3816	470	2024-02-29 00:00:00-08
18651	30	100	3817	1895	2024-02-29 00:00:00-08
18652	43	200	3818	1833	2024-02-29 00:00:00-08
18653	43	200	3818	471	2024-02-29 00:00:00-08
18654	45	100	3819	1834	2024-02-29 00:00:00-08
18655	45	100	3819	472	2024-02-29 00:00:00-08
18656	28	100	3821	1863	2024-02-29 00:00:00-08
18657	28	100	3821	473	2024-02-29 00:00:00-08
18658	58	200	3822	1864	2024-02-29 00:00:00-08
18659	58	200	3822	474	2024-02-29 00:00:00-08
18660	15	200	3823	1861	2024-02-29 00:00:00-08
18661	15	200	3823	460	2024-02-29 00:00:00-08
18662	96	341	3827	1897	2024-02-29 00:00:00-08
18663	96	341	3827	448	2024-02-29 00:00:00-08
18664	42	100	3830	1835	2024-02-29 00:00:00-08
18665	23	100	3831	1836	2024-02-29 00:00:00-08
18666	61	100	3833	1837	2024-02-29 00:00:00-08
18667	40	57	3834	1838	2024-02-29 00:00:00-08
18668	40	100	3835	1886	2024-02-29 00:00:00-08
18669	45	135	3837	1866	2024-02-29 00:00:00-08
18670	45	135	3837	475	2024-02-29 00:00:00-08
18671	45	199	3838	1865	2024-02-29 00:00:00-08
18672	45	199	3838	476	2024-02-29 00:00:00-08
18673	35	14	3839	1824	2024-02-29 00:00:00-08
18674	31	100	3840	1877	2024-02-29 00:00:00-08
18675	31	100	3840	477	2024-02-29 00:00:00-08
18676	5	100	3842	1825	2024-02-29 00:00:00-08
18677	7	100	3843	1826	2024-02-29 00:00:00-08
18678	5	200	3845	1887	2024-02-29 00:00:00-08
18679	5	200	3845	478	2024-02-29 00:00:00-08
18680	21	188	3846	1888	2024-02-29 00:00:00-08
18681	21	188	3846	479	2024-02-29 00:00:00-08
18682	21	175	3847	1850	2024-02-29 00:00:00-08
18683	21	175	3847	480	2024-02-29 00:00:00-08
18684	20	200	3849	1901	2024-02-29 00:00:00-08
18685	20	200	3849	481	2024-02-29 00:00:00-08
18686	14	200	3850	1851	2024-02-29 00:00:00-08
18687	14	200	3850	482	2024-02-29 00:00:00-08
18688	\N	\N	4596	1228	2024-02-29 00:00:00-08
18689	0	\N	3852	1827	2024-02-29 00:00:00-08
18690	0	\N	3853	1828	2024-02-29 00:00:00-08
18691	Infinity	100	3855	487	2024-02-29 00:00:00-08
18692	Infinity	100	3856	923	2024-02-29 00:00:00-08
18693	20	250	3857	2858	2024-02-29 00:00:00-08
18694	1	400	3858	2859	2024-02-29 00:00:00-08
18695	Infinity	35.4	3859	488	2024-02-29 00:00:00-08
18696	Infinity	44.3	3860	489	2024-02-29 00:00:00-08
18697	2	250	3865	2424	2024-02-29 00:00:00-08
18698	2	250	3866	2425	2024-02-29 00:00:00-08
18699	5	250	3867	2825	2024-02-29 00:00:00-08
18700	2	250	3868	2426	2024-02-29 00:00:00-08
18701	9	250	3869	2826	2024-02-29 00:00:00-08
18702	48	65.3	3870	2298	2024-02-29 00:00:00-08
18703	48	100.8	3871	2299	2024-02-29 00:00:00-08
18704	29	250	3872	2300	2024-02-29 00:00:00-08
18705	48	145	3873	2301	2024-02-29 00:00:00-08
18706	48	124.8	3874	2302	2024-02-29 00:00:00-08
18707	48	17.6	3875	490	2024-02-29 00:00:00-08
18708	48	99.8	3876	2315	2024-02-29 00:00:00-08
18709	48	198.7	3877	2316	2024-02-29 00:00:00-08
18710	48	44	3878	2317	2024-02-29 00:00:00-08
18711	48	209.3	3879	2318	2024-02-29 00:00:00-08
18712	48	67.2	3880	2319	2024-02-29 00:00:00-08
18713	17	250	3881	2320	2024-02-29 00:00:00-08
18714	26	250	3882	2321	2024-02-29 00:00:00-08
18715	48	159.8	3883	2322	2024-02-29 00:00:00-08
18716	29	250	3884	2323	2024-02-29 00:00:00-08
18717	48	109	3885	2324	2024-02-29 00:00:00-08
18718	37	250	3886	2325	2024-02-29 00:00:00-08
18719	37	250	3887	2326	2024-02-29 00:00:00-08
18720	48	58.6	3888	2327	2024-02-29 00:00:00-08
18721	42	250	3889	2328	2024-02-29 00:00:00-08
18722	48	36.9	3890	2329	2024-02-29 00:00:00-08
18723	48	89.8	3891	2330	2024-02-29 00:00:00-08
18724	48	39.7	3892	2331	2024-02-29 00:00:00-08
18725	48	73.9	3893	2332	2024-02-29 00:00:00-08
18726	48	113.3	3894	2721	2024-02-29 00:00:00-08
18727	Infinity	100	3895	1056	2024-02-29 00:00:00-08
18728	Infinity	10.2	3896	1094	2024-02-29 00:00:00-08
18729	Infinity	57.6	3897	1095	2024-02-29 00:00:00-08
18730	Infinity	76.2	3898	1057	2024-02-29 00:00:00-08
18731	Infinity	23.3	3899	1058	2024-02-29 00:00:00-08
18732	Infinity	95.2	3900	1059	2024-02-29 00:00:00-08
18733	Infinity	100	3901	1060	2024-02-29 00:00:00-08
18734	Infinity	100	3902	1061	2024-02-29 00:00:00-08
18735	Infinity	69.8	3903	1096	2024-02-29 00:00:00-08
18736	Infinity	39	3904	1097	2024-02-29 00:00:00-08
18737	Infinity	62.5	3905	1098	2024-02-29 00:00:00-08
18738	Infinity	35.5	3906	1099	2024-02-29 00:00:00-08
18739	Infinity	98.4	3907	1062	2024-02-29 00:00:00-08
18740	Infinity	34.4	3908	1100	2024-02-29 00:00:00-08
18741	Infinity	68.9	3909	1101	2024-02-29 00:00:00-08
18742	Infinity	71.7	3910	1102	2024-02-29 00:00:00-08
18743	Infinity	100	3911	1063	2024-02-29 00:00:00-08
18744	Infinity	39.6	3912	1064	2024-02-29 00:00:00-08
18745	Infinity	100	3913	1065	2024-02-29 00:00:00-08
18746	Infinity	85.8	3914	1066	2024-02-29 00:00:00-08
18747	Infinity	100	3915	1067	2024-02-29 00:00:00-08
18748	Infinity	100	3916	1068	2024-02-29 00:00:00-08
18749	20	176	3917	1957	2024-02-29 00:00:00-08
18750	10	400	3918	1958	2024-02-29 00:00:00-08
18751	2	400	3919	1961	2024-02-29 00:00:00-08
18752	12	400	3920	1962	2024-02-29 00:00:00-08
18753	16	400	3921	1963	2024-02-29 00:00:00-08
18754	20	298	3922	1959	2024-02-29 00:00:00-08
18755	5	400	3923	1960	2024-02-29 00:00:00-08
18756	17	400	3924	1964	2024-02-29 00:00:00-08
18757	20	172	3925	1965	2024-02-29 00:00:00-08
18758	11	400	3926	1966	2024-02-29 00:00:00-08
18759	89	47	3927	2834	2024-02-29 00:00:00-08
18760	88	44	3928	2835	2024-02-29 00:00:00-08
18761	88	60	3930	2836	2024-02-29 00:00:00-08
18762	88	51	3931	2837	2024-02-29 00:00:00-08
18763	88	50	3932	2838	2024-02-29 00:00:00-08
18764	78	250	3933	2839	2024-02-29 00:00:00-08
18765	88	58	3935	2840	2024-02-29 00:00:00-08
18766	88	61	3936	2841	2024-02-29 00:00:00-08
18767	88	81	3939	2842	2024-02-29 00:00:00-08
18768	88	180	3940	2843	2024-02-29 00:00:00-08
18769	88	114	3941	2844	2024-02-29 00:00:00-08
18770	88	192	3943	2845	2024-02-29 00:00:00-08
18771	88	77	3945	2846	2024-02-29 00:00:00-08
19101	0	\N	4498	1324	2024-02-29 00:00:00-08
18772	88	95	3946	2847	2024-02-29 00:00:00-08
18773	88	184	3947	2848	2024-02-29 00:00:00-08
18774	88	102	3948	2849	2024-02-29 00:00:00-08
18775	88	135	3949	2850	2024-02-29 00:00:00-08
18776	87	48	3950	2851	2024-02-29 00:00:00-08
18777	88	56	3951	2852	2024-02-29 00:00:00-08
18778	65	250	3953	2853	2024-02-29 00:00:00-08
18779	69	250	3954	2854	2024-02-29 00:00:00-08
18780	48	35.6	3966	2899	2024-02-29 00:00:00-08
18781	48	72	3967	2900	2024-02-29 00:00:00-08
18782	48	103	3968	2901	2024-02-29 00:00:00-08
18783	Infinity	45.7	4004	505	2024-02-29 00:00:00-08
18784	100	135	4005	1968	2024-02-29 00:00:00-08
18785	100	85.6	4006	1969	2024-02-29 00:00:00-08
18786	100	159	4007	1970	2024-02-29 00:00:00-08
18787	100	90.3	4008	1971	2024-02-29 00:00:00-08
18788	100	56.1	4009	1972	2024-02-29 00:00:00-08
18789	100	48.1	4010	1967	2024-02-29 00:00:00-08
18790	100	379	4011	2062	2024-02-29 00:00:00-08
18791	100	108	4012	1973	2024-02-29 00:00:00-08
18792	100	94.1	4013	1974	2024-02-29 00:00:00-08
18793	100	82.6	4014	2060	2024-02-29 00:00:00-08
18794	100	61.4	4015	1975	2024-02-29 00:00:00-08
18795	100	167	4016	1976	2024-02-29 00:00:00-08
18796	100	340	4017	1977	2024-02-29 00:00:00-08
18797	100	463	4018	1978	2024-02-29 00:00:00-08
18798	100	101	4019	1979	2024-02-29 00:00:00-08
18799	100	420	4020	1980	2024-02-29 00:00:00-08
18800	100	230	4021	1981	2024-02-29 00:00:00-08
18801	100	394	4022	2061	2024-02-29 00:00:00-08
18802	100	3240	4023	1982	2024-02-29 00:00:00-08
18803	100	1050	4024	1983	2024-02-29 00:00:00-08
18804	100	358	4025	1984	2024-02-29 00:00:00-08
18805	100	888	4026	1985	2024-02-29 00:00:00-08
18806	100	462	4027	1986	2024-02-29 00:00:00-08
18807	100	1500	4028	1987	2024-02-29 00:00:00-08
18808	100	614	4029	1988	2024-02-29 00:00:00-08
18809	100	1420	4030	1989	2024-02-29 00:00:00-08
18810	100	1430	4031	1990	2024-02-29 00:00:00-08
18811	100	97.8	4032	2063	2024-02-29 00:00:00-08
18812	16	250	4033	2064	2024-02-29 00:00:00-08
18813	96	250	4034	2065	2024-02-29 00:00:00-08
18814	95	250	4035	2145	2024-02-29 00:00:00-08
18815	24	250	4036	2066	2024-02-29 00:00:00-08
18816	37	250	4037	2067	2024-02-29 00:00:00-08
18817	61	250	4038	2129	2024-02-29 00:00:00-08
18818	45	250	4039	2068	2024-02-29 00:00:00-08
18819	38	250	4040	2146	2024-02-29 00:00:00-08
18820	33	250	4041	2069	2024-02-29 00:00:00-08
18821	48	250	4042	2070	2024-02-29 00:00:00-08
18822	25	250	4043	2071	2024-02-29 00:00:00-08
18823	18	250	4044	2072	2024-02-29 00:00:00-08
18824	54	250	4045	2073	2024-02-29 00:00:00-08
18825	100	37.5	4046	2074	2024-02-29 00:00:00-08
18826	10	250	4047	2075	2024-02-29 00:00:00-08
18827	27	250	4048	2076	2024-02-29 00:00:00-08
18828	28	250	4049	2077	2024-02-29 00:00:00-08
18829	23	250	4050	2078	2024-02-29 00:00:00-08
18830	20	250	4052	2079	2024-02-29 00:00:00-08
18831	26	250	4054	2080	2024-02-29 00:00:00-08
18832	36	250	4055	2130	2024-02-29 00:00:00-08
18833	23	250	4056	2081	2024-02-29 00:00:00-08
18834	23	250	4057	2082	2024-02-29 00:00:00-08
18835	100	131	4058	2083	2024-02-29 00:00:00-08
18836	80	250	4059	2084	2024-02-29 00:00:00-08
18837	21	250	4060	2147	2024-02-29 00:00:00-08
18838	100	192	4061	2085	2024-02-29 00:00:00-08
18839	38	250	4062	2086	2024-02-29 00:00:00-08
18840	61	250	4063	2131	2024-02-29 00:00:00-08
18841	55	250	4064	2087	2024-02-29 00:00:00-08
18842	96	250	4065	2132	2024-02-29 00:00:00-08
18843	17	250	4066	2088	2024-02-29 00:00:00-08
18844	5	250	4067	2089	2024-02-29 00:00:00-08
18845	19	250	4068	2090	2024-02-29 00:00:00-08
18846	100	189	4069	2148	2024-02-29 00:00:00-08
18847	100	220	4070	2091	2024-02-29 00:00:00-08
18848	13	250	4071	2092	2024-02-29 00:00:00-08
18849	40	250	4072	2133	2024-02-29 00:00:00-08
18850	100	156	4073	2093	2024-02-29 00:00:00-08
18851	66	250	4074	2094	2024-02-29 00:00:00-08
18852	49	250	4075	2095	2024-02-29 00:00:00-08
18853	60	250	4076	2096	2024-02-29 00:00:00-08
18854	45	250	4077	2097	2024-02-29 00:00:00-08
18855	61	250	4078	2134	2024-02-29 00:00:00-08
18856	18	250	4079	2098	2024-02-29 00:00:00-08
18857	100	108	4080	2099	2024-02-29 00:00:00-08
18858	100	83.6	4081	2100	2024-02-29 00:00:00-08
18859	100	71.8	4082	2101	2024-02-29 00:00:00-08
18860	37	250	4083	2102	2024-02-29 00:00:00-08
18861	43	250	4084	2135	2024-02-29 00:00:00-08
18862	25	250	4085	2103	2024-02-29 00:00:00-08
18863	14	250	4086	2104	2024-02-29 00:00:00-08
18864	58	250	4087	2105	2024-02-29 00:00:00-08
18865	17	250	4088	2106	2024-02-29 00:00:00-08
18866	100	192	4089	2107	2024-02-29 00:00:00-08
18867	100	179	4090	2136	2024-02-29 00:00:00-08
18868	38	250	4091	2108	2024-02-29 00:00:00-08
18869	100	23	4092	2109	2024-02-29 00:00:00-08
18870	14	250	4093	2137	2024-02-29 00:00:00-08
18871	91	250	4094	2110	2024-02-29 00:00:00-08
18872	93	250	4095	2111	2024-02-29 00:00:00-08
18873	96	250	4096	2112	2024-02-29 00:00:00-08
18874	100	51.8	4097	2138	2024-02-29 00:00:00-08
18875	22	250	4098	2113	2024-02-29 00:00:00-08
18876	24	250	4099	2114	2024-02-29 00:00:00-08
18877	66	250	4100	2115	2024-02-29 00:00:00-08
18878	56	250	4101	2139	2024-02-29 00:00:00-08
18879	100	184	4102	2140	2024-02-29 00:00:00-08
18880	21	250	4103	2116	2024-02-29 00:00:00-08
18881	25	250	4104	2117	2024-02-29 00:00:00-08
18882	34	250	4105	2118	2024-02-29 00:00:00-08
18883	10	250	4106	2119	2024-02-29 00:00:00-08
18884	22	250	4107	2120	2024-02-29 00:00:00-08
18885	17	250	4108	2121	2024-02-29 00:00:00-08
18886	98	250	4109	2141	2024-02-29 00:00:00-08
18887	24	250	4110	2122	2024-02-29 00:00:00-08
18888	12	250	4111	2123	2024-02-29 00:00:00-08
18889	26	250	4112	2124	2024-02-29 00:00:00-08
18890	35	250	4113	2125	2024-02-29 00:00:00-08
18891	17	250	4114	2126	2024-02-29 00:00:00-08
18892	100	71	4115	2127	2024-02-29 00:00:00-08
18893	20	250	4116	2142	2024-02-29 00:00:00-08
18894	39	250	4117	2128	2024-02-29 00:00:00-08
18895	100	230	4118	2143	2024-02-29 00:00:00-08
18896	18	250	4119	2144	2024-02-29 00:00:00-08
18897	9	250	4120	2206	2024-02-29 00:00:00-08
18898	30	250	4121	2207	2024-02-29 00:00:00-08
18899	13	250	4122	2208	2024-02-29 00:00:00-08
18900	11	250	4123	2619	2024-02-29 00:00:00-08
18901	15	250	4124	2250	2024-02-29 00:00:00-08
18902	22	250	4125	2251	2024-02-29 00:00:00-08
18903	4	250	4126	2209	2024-02-29 00:00:00-08
18904	5	250	4127	2210	2024-02-29 00:00:00-08
18905	10	250	4128	2620	2024-02-29 00:00:00-08
18906	48	130	4129	2252	2024-02-29 00:00:00-08
18907	22	250	4130	2211	2024-02-29 00:00:00-08
18908	9	250	4131	2212	2024-02-29 00:00:00-08
18909	14	250	4132	2213	2024-02-29 00:00:00-08
18910	6	250	4133	2214	2024-02-29 00:00:00-08
18911	6	250	4134	2253	2024-02-29 00:00:00-08
18912	39	250	4135	2215	2024-02-29 00:00:00-08
18913	29	250	4136	2216	2024-02-29 00:00:00-08
18914	25	250	4137	2254	2024-02-29 00:00:00-08
18915	3	250	4138	2217	2024-02-29 00:00:00-08
18916	7	250	4139	2218	2024-02-29 00:00:00-08
18917	14	250	4140	2219	2024-02-29 00:00:00-08
18918	9	250	4141	2220	2024-02-29 00:00:00-08
18919	11	250	4142	2255	2024-02-29 00:00:00-08
18920	11	250	4143	2221	2024-02-29 00:00:00-08
18921	11	250	4144	2222	2024-02-29 00:00:00-08
18922	48	226	4145	2223	2024-02-29 00:00:00-08
18923	18	250	4146	2224	2024-02-29 00:00:00-08
18924	6	250	4147	2256	2024-02-29 00:00:00-08
18925	7	250	4148	2225	2024-02-29 00:00:00-08
18926	17	250	4149	2226	2024-02-29 00:00:00-08
18927	10	250	4150	2257	2024-02-29 00:00:00-08
18928	12	250	4151	2621	2024-02-29 00:00:00-08
18929	22	250	4152	2227	2024-02-29 00:00:00-08
18930	10	250	4153	2228	2024-02-29 00:00:00-08
18931	13	250	4154	2258	2024-02-29 00:00:00-08
18932	16	250	4155	2229	2024-02-29 00:00:00-08
18933	12	250	4156	2259	2024-02-29 00:00:00-08
18934	38	250	4157	2260	2024-02-29 00:00:00-08
18935	6	250	4158	2230	2024-02-29 00:00:00-08
18936	14	250	4159	2231	2024-02-29 00:00:00-08
18937	15	250	4160	2261	2024-02-29 00:00:00-08
18938	5	250	4161	2232	2024-02-29 00:00:00-08
18939	3	250	4162	2233	2024-02-29 00:00:00-08
18940	4	250	4163	2234	2024-02-29 00:00:00-08
18941	10	250	4164	2262	2024-02-29 00:00:00-08
18942	3	250	4165	2263	2024-02-29 00:00:00-08
18943	4	250	4166	2264	2024-02-29 00:00:00-08
18944	9	250	4167	2265	2024-02-29 00:00:00-08
18945	11	250	4168	2235	2024-02-29 00:00:00-08
18946	8	250	4169	2236	2024-02-29 00:00:00-08
18947	6	250	4170	2237	2024-02-29 00:00:00-08
18948	7	250	4171	2266	2024-02-29 00:00:00-08
18949	7	250	4172	2238	2024-02-29 00:00:00-08
18950	13	250	4173	2267	2024-02-29 00:00:00-08
18951	5	250	4174	2239	2024-02-29 00:00:00-08
18952	0	\N	4175	968	2024-02-29 00:00:00-08
18953	1	100	4176	938	2024-02-29 00:00:00-08
18954	3	100	4177	969	2024-02-29 00:00:00-08
18955	6	100	4178	970	2024-02-29 00:00:00-08
18956	0	\N	4179	971	2024-02-29 00:00:00-08
18957	2	100	4180	939	2024-02-29 00:00:00-08
18958	0	100	4181	809	2024-02-29 00:00:00-08
18959	1	100	4182	810	2024-02-29 00:00:00-08
18960	0	100	4183	811	2024-02-29 00:00:00-08
18961	14	100	4184	1197	2024-02-29 00:00:00-08
18962	24	100	4185	1198	2024-02-29 00:00:00-08
18963	5	100	4186	1199	2024-02-29 00:00:00-08
18964	2	100	4187	1200	2024-02-29 00:00:00-08
18965	35	100	4188	1201	2024-02-29 00:00:00-08
18966	38	100	4189	1202	2024-02-29 00:00:00-08
18967	13	100	4190	1203	2024-02-29 00:00:00-08
18968	10	100	4191	1204	2024-02-29 00:00:00-08
18969	2	400	4192	3200	2024-02-29 00:00:00-08
18970	2	400	4193	3201	2024-02-29 00:00:00-08
18971	2	400	4194	3202	2024-02-29 00:00:00-08
18972	2	400	4195	3203	2024-02-29 00:00:00-08
18973	2	400	4196	3204	2024-02-29 00:00:00-08
18974	2	400	4197	3205	2024-02-29 00:00:00-08
18975	2	400	4198	3206	2024-02-29 00:00:00-08
18976	2	400	4199	3207	2024-02-29 00:00:00-08
18977	2	400	4200	3208	2024-02-29 00:00:00-08
18978	2	400	4201	3209	2024-02-29 00:00:00-08
18979	2	400	4202	3210	2024-02-29 00:00:00-08
18980	2	400	4203	3211	2024-02-29 00:00:00-08
18981	2	400	4204	3212	2024-02-29 00:00:00-08
18982	2	400	4205	3213	2024-02-29 00:00:00-08
18983	2	400	4206	3214	2024-02-29 00:00:00-08
18984	2	400	4207	3215	2024-02-29 00:00:00-08
18985	2	400	4208	3216	2024-02-29 00:00:00-08
18986	2	400	4209	3217	2024-02-29 00:00:00-08
18987	2	400	4210	3218	2024-02-29 00:00:00-08
18988	2	400	4211	3219	2024-02-29 00:00:00-08
18989	2	400	4212	3220	2024-02-29 00:00:00-08
18990	2	400	4213	3221	2024-02-29 00:00:00-08
18991	2	400	4214	3222	2024-02-29 00:00:00-08
18992	2	400	4215	3223	2024-02-29 00:00:00-08
18993	2	400	4216	3224	2024-02-29 00:00:00-08
18994	2	400	4217	3225	2024-02-29 00:00:00-08
18995	2	400	4218	3226	2024-02-29 00:00:00-08
18996	2	400	4219	3227	2024-02-29 00:00:00-08
18997	2	400	4220	3228	2024-02-29 00:00:00-08
18998	2	400	4221	3229	2024-02-29 00:00:00-08
18999	2	400	4222	3230	2024-02-29 00:00:00-08
19000	3	400	4223	3231	2024-02-29 00:00:00-08
19001	2	400	4224	3232	2024-02-29 00:00:00-08
19002	2	400	4225	3233	2024-02-29 00:00:00-08
19003	2	400	4226	3234	2024-02-29 00:00:00-08
19004	2	400	4227	3235	2024-02-29 00:00:00-08
19005	2	400	4228	3236	2024-02-29 00:00:00-08
19006	2	400	4229	3237	2024-02-29 00:00:00-08
19007	2	400	4230	3238	2024-02-29 00:00:00-08
19008	2	400	4231	3239	2024-02-29 00:00:00-08
19009	2	400	4232	3240	2024-02-29 00:00:00-08
19010	2	400	4233	3241	2024-02-29 00:00:00-08
19011	2	400	4234	3242	2024-02-29 00:00:00-08
19012	2	400	4235	3243	2024-02-29 00:00:00-08
19013	2	400	4236	3244	2024-02-29 00:00:00-08
19014	2	400	4237	3245	2024-02-29 00:00:00-08
19015	2	400	4238	3246	2024-02-29 00:00:00-08
19016	2	400	4239	3247	2024-02-29 00:00:00-08
19017	2	400	4240	3248	2024-02-29 00:00:00-08
19018	2	400	4241	3249	2024-02-29 00:00:00-08
19019	2	400	4242	3250	2024-02-29 00:00:00-08
19020	2	400	4243	3251	2024-02-29 00:00:00-08
19021	2	400	4244	3252	2024-02-29 00:00:00-08
19022	2	400	4245	3253	2024-02-29 00:00:00-08
19023	2	400	4246	3254	2024-02-29 00:00:00-08
19024	4	400	4247	3255	2024-02-29 00:00:00-08
19025	4	400	4248	3256	2024-02-29 00:00:00-08
19026	3	400	4249	3257	2024-02-29 00:00:00-08
19027	2	400	4250	3258	2024-02-29 00:00:00-08
19028	3	400	4251	3259	2024-02-29 00:00:00-08
19029	2	400	4252	3260	2024-02-29 00:00:00-08
19030	5	400	4253	3261	2024-02-29 00:00:00-08
19031	3	400	4254	3262	2024-02-29 00:00:00-08
19032	10	212	4255	3263	2024-02-29 00:00:00-08
19033	\N	\N	4597	1229	2024-02-29 00:00:00-08
19034	63	250	4373	1910	2024-02-29 00:00:00-08
19035	63	250	4373	1902	2024-02-29 00:00:00-08
19036	42	250	4374	1903	2024-02-29 00:00:00-08
19037	94	250	4377	1919	2024-02-29 00:00:00-08
19038	94	250	4377	1913	2024-02-29 00:00:00-08
19039	71	250	4378	1914	2024-02-29 00:00:00-08
19040	175	250	4381	1915	2024-02-29 00:00:00-08
19041	29	250	4382	1916	2024-02-29 00:00:00-08
19042	96	250	4385	1904	2024-02-29 00:00:00-08
19043	11	250	4386	1905	2024-02-29 00:00:00-08
19044	73	250	4389	1911	2024-02-29 00:00:00-08
19045	73	250	4389	1906	2024-02-29 00:00:00-08
19046	14	250	4390	1907	2024-02-29 00:00:00-08
19047	46	250	4396	1908	2024-02-29 00:00:00-08
19048	8	250	4398	1912	2024-02-29 00:00:00-08
19049	8	250	4398	1909	2024-02-29 00:00:00-08
19050	78	250	4401	361	2024-02-29 00:00:00-08
19051	100	250	4403	1922	2024-02-29 00:00:00-08
19052	100	250	4403	1921	2024-02-29 00:00:00-08
19053	100	250	4403	1920	2024-02-29 00:00:00-08
19054	100	250	4403	1917	2024-02-29 00:00:00-08
19055	15	250	4404	1918	2024-02-29 00:00:00-08
19056	15	250	4404	365	2024-02-29 00:00:00-08
19057	15	250	4404	362	2024-02-29 00:00:00-08
19058	\N	\N	4598	1230	2024-02-29 00:00:00-08
19059	13	250	4407	1924	2024-02-29 00:00:00-08
19060	13	250	4407	1923	2024-02-29 00:00:00-08
19061	13	250	4407	363	2024-02-29 00:00:00-08
19062	35	250	4408	1925	2024-02-29 00:00:00-08
19063	35	250	4408	364	2024-02-29 00:00:00-08
19064	0	\N	4463	1328	2024-02-29 00:00:00-08
19065	0	\N	4463	1274	2024-02-29 00:00:00-08
19066	0	\N	4464	1286	2024-02-29 00:00:00-08
19067	0	\N	4465	1288	2024-02-29 00:00:00-08
19068	0	\N	4466	1290	2024-02-29 00:00:00-08
19069	0	\N	4467	1292	2024-02-29 00:00:00-08
19070	0	\N	4468	1294	2024-02-29 00:00:00-08
19071	0	\N	4469	1296	2024-02-29 00:00:00-08
19072	0	\N	4470	1298	2024-02-29 00:00:00-08
19073	0	\N	4471	1300	2024-02-29 00:00:00-08
19074	0	\N	4472	1302	2024-02-29 00:00:00-08
19075	0	\N	4473	1304	2024-02-29 00:00:00-08
19076	0	\N	4474	1306	2024-02-29 00:00:00-08
19077	0	\N	4475	1308	2024-02-29 00:00:00-08
19078	0	\N	4476	1316	2024-02-29 00:00:00-08
19079	0	\N	4477	1318	2024-02-29 00:00:00-08
19080	0	\N	4478	1320	2024-02-29 00:00:00-08
19081	0	\N	4479	1322	2024-02-29 00:00:00-08
19082	0	\N	4480	1324	2024-02-29 00:00:00-08
19083	0	\N	4481	1326	2024-02-29 00:00:00-08
19084	0	\N	4482	1286	2024-02-29 00:00:00-08
19085	0	\N	4483	1288	2024-02-29 00:00:00-08
19086	0	\N	4484	1290	2024-02-29 00:00:00-08
19087	0	\N	4485	1292	2024-02-29 00:00:00-08
19088	0	\N	4486	1294	2024-02-29 00:00:00-08
19089	0	\N	4487	1296	2024-02-29 00:00:00-08
19090	0	\N	4488	1298	2024-02-29 00:00:00-08
19091	0	\N	4489	1300	2024-02-29 00:00:00-08
19092	0	\N	4490	1302	2024-02-29 00:00:00-08
19093	0	\N	4491	1304	2024-02-29 00:00:00-08
19094	0	\N	4492	1306	2024-02-29 00:00:00-08
19095	0	\N	4493	1308	2024-02-29 00:00:00-08
19096	\N	\N	4599	1231	2024-02-29 00:00:00-08
19102	0	\N	4499	1326	2024-02-29 00:00:00-08
19103	45	197.6	4500	367	2024-02-29 00:00:00-08
19104	45	197.6	4500	366	2024-02-29 00:00:00-08
19105	7	250	4501	1250	2024-02-29 00:00:00-08
19106	7	250	4501	368	2024-02-29 00:00:00-08
19107	34	250	4502	378	2024-02-29 00:00:00-08
19108	34	250	4502	377	2024-02-29 00:00:00-08
19109	18	250	4503	1252	2024-02-29 00:00:00-08
19110	18	250	4503	379	2024-02-29 00:00:00-08
19111	0	\N	4504	380	2024-02-29 00:00:00-08
19112	106	250	4505	382	2024-02-29 00:00:00-08
19113	106	250	4505	381	2024-02-29 00:00:00-08
19114	0	\N	4508	384	2024-02-29 00:00:00-08
19115	0	\N	4509	385	2024-02-29 00:00:00-08
19116	0	\N	4510	369	2024-02-29 00:00:00-08
19117	0	\N	4511	386	2024-02-29 00:00:00-08
19118	0	\N	4512	387	2024-02-29 00:00:00-08
19119	0	\N	4513	1310	2024-02-29 00:00:00-08
19120	0	\N	4514	1311	2024-02-29 00:00:00-08
19121	0	\N	4515	1312	2024-02-29 00:00:00-08
19122	0	\N	4516	1313	2024-02-29 00:00:00-08
19123	0	\N	4517	1314	2024-02-29 00:00:00-08
19124	0	\N	4518	1315	2024-02-29 00:00:00-08
19125	0	\N	4519	1253	2024-02-29 00:00:00-08
19126	0	\N	4520	1254	2024-02-29 00:00:00-08
19127	0	\N	4521	1247	2024-02-29 00:00:00-08
19128	0	\N	4522	1255	2024-02-29 00:00:00-08
19129	0	\N	4523	1256	2024-02-29 00:00:00-08
19130	0	\N	4524	1257	2024-02-29 00:00:00-08
19131	0	\N	4525	1258	2024-02-29 00:00:00-08
19132	0	\N	4526	1259	2024-02-29 00:00:00-08
19133	0	\N	4527	1260	2024-02-29 00:00:00-08
19134	0	\N	4528	1261	2024-02-29 00:00:00-08
19135	0	\N	4529	370	2024-02-29 00:00:00-08
19136	0	\N	4530	1262	2024-02-29 00:00:00-08
19137	46	250	4531	372	2024-02-29 00:00:00-08
19138	46	250	4531	371	2024-02-29 00:00:00-08
19139	18	250	4532	1248	2024-02-29 00:00:00-08
19140	18	250	4532	373	2024-02-29 00:00:00-08
19141	0	\N	4533	1263	2024-02-29 00:00:00-08
19142	89	250	4534	375	2024-02-29 00:00:00-08
19143	89	250	4534	374	2024-02-29 00:00:00-08
19144	9	250	4535	1249	2024-02-29 00:00:00-08
19145	9	250	4535	376	2024-02-29 00:00:00-08
19146	0	\N	4536	1269	2024-02-29 00:00:00-08
19147	0	\N	4537	1268	2024-02-29 00:00:00-08
19148	0	\N	4538	1270	2024-02-29 00:00:00-08
19149	0	\N	4539	1271	2024-02-29 00:00:00-08
19150	0	\N	4540	1265	2024-02-29 00:00:00-08
19151	0	\N	4541	1264	2024-02-29 00:00:00-08
19152	0	\N	4542	1267	2024-02-29 00:00:00-08
19153	0	\N	4543	1266	2024-02-29 00:00:00-08
19154	0	\N	4544	498	2024-02-29 00:00:00-08
19155	0	\N	4545	1272	2024-02-29 00:00:00-08
19156	0	\N	4546	1273	2024-02-29 00:00:00-08
19157	0	\N	4547	506	2024-02-29 00:00:00-08
19158	0	\N	4548	507	2024-02-29 00:00:00-08
19159	0	\N	4549	1196	2024-02-29 00:00:00-08
19160	\N	\N	4550	221	2024-02-29 00:00:00-08
19161	0	\N	4551	1183	2024-02-29 00:00:00-08
19162	\N	\N	4552	502	2024-02-29 00:00:00-08
19163	\N	\N	4553	503	2024-02-29 00:00:00-08
19164	\N	\N	4554	504	2024-02-29 00:00:00-08
19165	\N	\N	4555	499	2024-02-29 00:00:00-08
19166	\N	\N	4556	500	2024-02-29 00:00:00-08
19167	\N	\N	4557	501	2024-02-29 00:00:00-08
19168	\N	\N	4558	1126	2024-02-29 00:00:00-08
19169	\N	\N	4559	1127	2024-02-29 00:00:00-08
19170	\N	\N	4560	1128	2024-02-29 00:00:00-08
19171	\N	\N	4561	1129	2024-02-29 00:00:00-08
19172	\N	\N	4562	1130	2024-02-29 00:00:00-08
19173	\N	\N	4563	1131	2024-02-29 00:00:00-08
19174	\N	\N	4564	1132	2024-02-29 00:00:00-08
19175	\N	\N	4565	1133	2024-02-29 00:00:00-08
19176	\N	\N	4566	1134	2024-02-29 00:00:00-08
19177	\N	\N	4567	1135	2024-02-29 00:00:00-08
19178	\N	\N	4568	1136	2024-02-29 00:00:00-08
19179	0	\N	4569	1184	2024-02-29 00:00:00-08
19180	0	\N	4570	1185	2024-02-29 00:00:00-08
19181	0	\N	4571	1186	2024-02-29 00:00:00-08
19182	0	\N	4572	1187	2024-02-29 00:00:00-08
19183	0	\N	4573	1188	2024-02-29 00:00:00-08
19184	0	\N	4574	1189	2024-02-29 00:00:00-08
19185	0	\N	4575	1190	2024-02-29 00:00:00-08
19186	0	\N	4576	1191	2024-02-29 00:00:00-08
19187	0	\N	4577	1192	2024-02-29 00:00:00-08
19188	0	\N	4578	1193	2024-02-29 00:00:00-08
19189	0	\N	4579	1194	2024-02-29 00:00:00-08
19190	0	\N	4580	1195	2024-02-29 00:00:00-08
19191	0	\N	4581	1233	2024-02-29 00:00:00-08
19192	0	\N	4582	1237	2024-02-29 00:00:00-08
19193	0	\N	4582	1234	2024-02-29 00:00:00-08
19194	0	\N	4583	1235	2024-02-29 00:00:00-08
19195	0	\N	4585	1236	2024-02-29 00:00:00-08
19196	0	\N	4586	1238	2024-02-29 00:00:00-08
19197	0	\N	4587	1239	2024-02-29 00:00:00-08
19198	0	\N	4588	1240	2024-02-29 00:00:00-08
19199	\N	\N	4589	1241	2024-02-29 00:00:00-08
19200	\N	\N	4590	1242	2024-02-29 00:00:00-08
19201	\N	\N	4602	300	2024-02-29 00:00:00-08
19202	\N	\N	4603	302	2024-02-29 00:00:00-08
19203	\N	\N	4604	303	2024-02-29 00:00:00-08
19204	\N	\N	4605	508	2024-02-29 00:00:00-08
19205	\N	\N	4606	509	2024-02-29 00:00:00-08
19206	\N	\N	4607	510	2024-02-29 00:00:00-08
19207	\N	\N	4608	511	2024-02-29 00:00:00-08
19208	\N	\N	4609	512	2024-02-29 00:00:00-08
19209	\N	\N	4610	513	2024-02-29 00:00:00-08
19210	\N	\N	4611	514	2024-02-29 00:00:00-08
19211	\N	\N	4612	515	2024-02-29 00:00:00-08
19212	\N	\N	4613	1275	2024-02-29 00:00:00-08
19213	\N	\N	4614	1276	2024-02-29 00:00:00-08
19214	\N	\N	4615	1277	2024-02-29 00:00:00-08
19215	\N	\N	4616	1278	2024-02-29 00:00:00-08
19216	\N	\N	4617	315	2024-02-29 00:00:00-08
19217	\N	\N	4618	1279	2024-02-29 00:00:00-08
19218	\N	\N	4619	1280	2024-02-29 00:00:00-08
19219	\N	\N	4620	1281	2024-02-29 00:00:00-08
19220	\N	\N	4621	1282	2024-02-29 00:00:00-08
19221	\N	\N	4622	316	2024-02-29 00:00:00-08
19222	\N	\N	4623	1283	2024-02-29 00:00:00-08
19223	\N	\N	4624	1284	2024-02-29 00:00:00-08
19224	\N	\N	4625	1285	2024-02-29 00:00:00-08
19225	\N	\N	4626	9	2024-02-29 00:00:00-08
19226	\N	\N	4627	10	2024-02-29 00:00:00-08
19227	\N	\N	4628	11	2024-02-29 00:00:00-08
19228	\N	\N	4629	1329	2024-02-29 00:00:00-08
19229	\N	\N	4630	1330	2024-02-29 00:00:00-08
19230	\N	\N	4631	1331	2024-02-29 00:00:00-08
19231	\N	\N	4632	1332	2024-02-29 00:00:00-08
19232	\N	\N	4633	1333	2024-02-29 00:00:00-08
19233	\N	\N	4634	1334	2024-02-29 00:00:00-08
19234	\N	\N	4635	1335	2024-02-29 00:00:00-08
19235	\N	\N	4636	1336	2024-02-29 00:00:00-08
19236	\N	\N	4637	1337	2024-02-29 00:00:00-08
19237	\N	\N	4638	1338	2024-02-29 00:00:00-08
19238	\N	\N	4639	1339	2024-02-29 00:00:00-08
19239	\N	\N	4640	1340	2024-02-29 00:00:00-08
19240	\N	\N	4641	289	2024-02-29 00:00:00-08
19241	\N	\N	4642	1568	2024-02-29 00:00:00-08
19242	\N	\N	4643	1569	2024-02-29 00:00:00-08
19243	\N	\N	4644	1570	2024-02-29 00:00:00-08
19244	\N	\N	4645	1571	2024-02-29 00:00:00-08
19245	\N	\N	4646	1572	2024-02-29 00:00:00-08
19246	\N	\N	4647	1573	2024-02-29 00:00:00-08
19247	\N	\N	4648	1574	2024-02-29 00:00:00-08
19248	\N	\N	4649	1575	2024-02-29 00:00:00-08
19249	\N	\N	4650	1576	2024-02-29 00:00:00-08
19250	\N	\N	4651	1577	2024-02-29 00:00:00-08
19251	\N	\N	4652	1578	2024-02-29 00:00:00-08
19252	\N	\N	4653	1579	2024-02-29 00:00:00-08
19253	\N	\N	4654	1580	2024-02-29 00:00:00-08
19254	\N	\N	4655	1581	2024-02-29 00:00:00-08
19255	\N	\N	4656	1582	2024-02-29 00:00:00-08
19256	\N	\N	4657	1583	2024-02-29 00:00:00-08
19257	\N	\N	4658	1584	2024-02-29 00:00:00-08
19258	\N	\N	4659	1585	2024-02-29 00:00:00-08
19259	\N	\N	4660	1586	2024-02-29 00:00:00-08
19260	\N	\N	4661	1587	2024-02-29 00:00:00-08
19261	\N	\N	4662	1588	2024-02-29 00:00:00-08
19262	\N	\N	4663	1589	2024-02-29 00:00:00-08
19263	\N	\N	4664	1590	2024-02-29 00:00:00-08
19264	\N	\N	4665	1591	2024-02-29 00:00:00-08
19265	\N	\N	10000	10000	2024-02-29 00:00:00-08
19266	\N	\N	10001	10001	2024-02-29 00:00:00-08
19267	\N	\N	10002	10002	2024-02-29 00:00:00-08
19268	\N	\N	10003	10003	2024-02-29 00:00:00-08
19269	\N	\N	10004	10004	2024-02-29 00:00:00-08
19270	\N	\N	10005	10005	2024-02-29 00:00:00-08
19271	\N	\N	10006	10006	2024-02-29 00:00:00-08
19272	\N	\N	10007	10007	2024-02-29 00:00:00-08
19273	\N	\N	10008	10008	2024-02-29 00:00:00-08
19274	\N	\N	10009	10009	2024-02-29 00:00:00-08
19275	\N	\N	10010	10010	2024-02-29 00:00:00-08
19276	\N	\N	10011	10011	2024-02-29 00:00:00-08
19277	\N	\N	10012	10012	2024-02-29 00:00:00-08
19278	\N	\N	10013	10013	2024-02-29 00:00:00-08
19279	\N	\N	10014	10014	2024-02-29 00:00:00-08
19280	\N	\N	10015	10015	2024-02-29 00:00:00-08
19281	\N	\N	10016	10016	2024-02-29 00:00:00-08
19282	\N	\N	10017	10017	2024-02-29 00:00:00-08
19283	\N	\N	10018	10018	2024-02-29 00:00:00-08
19284	\N	\N	10019	10019	2024-02-29 00:00:00-08
19285	\N	\N	10020	10020	2024-02-29 00:00:00-08
19286	\N	\N	10021	10023	2024-02-29 00:00:00-08
19287	\N	\N	10021	10022	2024-02-29 00:00:00-08
19288	\N	\N	10021	10021	2024-02-29 00:00:00-08
19289	\N	\N	10022	10023	2024-02-29 00:00:00-08
19290	\N	\N	10022	10022	2024-02-29 00:00:00-08
19291	\N	\N	10022	10021	2024-02-29 00:00:00-08
19292	\N	\N	10023	10023	2024-02-29 00:00:00-08
19293	\N	\N	10023	10022	2024-02-29 00:00:00-08
19294	\N	\N	10023	10021	2024-02-29 00:00:00-08
19295	\N	\N	10024	10024	2024-02-29 00:00:00-08
19296	\N	\N	10025	10025	2024-02-29 00:00:00-08
19297	\N	\N	10026	10026	2024-02-29 00:00:00-08
19298	\N	\N	10027	10027	2024-02-29 00:00:00-08
19299	\N	\N	10028	10028	2024-02-29 00:00:00-08
19300	\N	\N	10029	10029	2024-02-29 00:00:00-08
19301	\N	\N	10030	10030	2024-02-29 00:00:00-08
19302	\N	\N	10031	10047	2024-02-29 00:00:00-08
19303	\N	\N	10031	10046	2024-02-29 00:00:00-08
19304	\N	\N	10031	10045	2024-02-29 00:00:00-08
19305	\N	\N	10031	10044	2024-02-29 00:00:00-08
19306	\N	\N	10031	10031	2024-02-29 00:00:00-08
19307	\N	\N	10032	10032	2024-02-29 00:00:00-08
19308	\N	\N	10033	10033	2024-02-29 00:00:00-08
19309	\N	\N	10034	10034	2024-02-29 00:00:00-08
19310	\N	\N	10035	10035	2024-02-29 00:00:00-08
19311	\N	\N	10036	10036	2024-02-29 00:00:00-08
19312	\N	\N	10037	10037	2024-02-29 00:00:00-08
19313	\N	\N	10038	10038	2024-02-29 00:00:00-08
19314	\N	\N	10039	10039	2024-02-29 00:00:00-08
19315	\N	\N	10040	10040	2024-02-29 00:00:00-08
19316	\N	\N	10041	10041	2024-02-29 00:00:00-08
19317	\N	\N	10042	10042	2024-02-29 00:00:00-08
19318	\N	\N	10043	10043	2024-02-29 00:00:00-08
19319	\N	\N	10044	10047	2024-02-29 00:00:00-08
19320	\N	\N	10044	10046	2024-02-29 00:00:00-08
19321	\N	\N	10044	10045	2024-02-29 00:00:00-08
19322	\N	\N	10044	10044	2024-02-29 00:00:00-08
19323	\N	\N	10044	10031	2024-02-29 00:00:00-08
19324	\N	\N	10045	10047	2024-02-29 00:00:00-08
19325	\N	\N	10045	10046	2024-02-29 00:00:00-08
19326	\N	\N	10045	10045	2024-02-29 00:00:00-08
19327	\N	\N	10045	10044	2024-02-29 00:00:00-08
19328	\N	\N	10045	10031	2024-02-29 00:00:00-08
19329	\N	\N	10046	10047	2024-02-29 00:00:00-08
19330	\N	\N	10046	10046	2024-02-29 00:00:00-08
19331	\N	\N	10046	10045	2024-02-29 00:00:00-08
19332	\N	\N	10046	10044	2024-02-29 00:00:00-08
19333	\N	\N	10046	10031	2024-02-29 00:00:00-08
19334	\N	\N	10047	10047	2024-02-29 00:00:00-08
19335	\N	\N	10047	10046	2024-02-29 00:00:00-08
19336	\N	\N	10047	10045	2024-02-29 00:00:00-08
19337	\N	\N	10047	10044	2024-02-29 00:00:00-08
19338	\N	\N	10047	10031	2024-02-29 00:00:00-08
19339	\N	\N	10068	10068	2024-02-29 00:00:00-08
19340	\N	\N	10069	10070	2024-02-29 00:00:00-08
19341	\N	\N	10069	10069	2024-02-29 00:00:00-08
19342	\N	\N	10070	10070	2024-02-29 00:00:00-08
19343	\N	\N	10070	10069	2024-02-29 00:00:00-08
19344	\N	\N	10073	10073	2024-02-29 00:00:00-08
19345	\N	\N	10074	10075	2024-02-29 00:00:00-08
19346	\N	\N	10074	10074	2024-02-29 00:00:00-08
19347	\N	\N	10075	10075	2024-02-29 00:00:00-08
19348	\N	\N	10075	10074	2024-02-29 00:00:00-08
19349	\N	\N	10076	10077	2024-02-29 00:00:00-08
19350	\N	\N	10076	10076	2024-02-29 00:00:00-08
19351	\N	\N	10077	10077	2024-02-29 00:00:00-08
19352	\N	\N	10077	10076	2024-02-29 00:00:00-08
19353	\N	\N	10078	10078	2024-02-29 00:00:00-08
19354	\N	\N	10119	10708	2024-02-29 00:00:00-08
19355	\N	\N	10120	10709	2024-02-29 00:00:00-08
19356	\N	\N	10121	10710	2024-02-29 00:00:00-08
19357	\N	\N	10122	10711	2024-02-29 00:00:00-08
19358	\N	\N	10126	10872	2024-02-29 00:00:00-08
19359	\N	\N	10126	10871	2024-02-29 00:00:00-08
19360	\N	\N	10126	10870	2024-02-29 00:00:00-08
19361	\N	\N	10193	10698	2024-02-29 00:00:00-08
19362	\N	\N	10195	10699	2024-02-29 00:00:00-08
19363	\N	\N	10224	10617	2024-02-29 00:00:00-08
19364	\N	\N	10226	10618	2024-02-29 00:00:00-08
19365	\N	\N	10248	10633	2024-02-29 00:00:00-08
19366	\N	\N	10286	10068	2024-02-29 00:00:00-08
19367	\N	\N	10292	10596	2024-02-29 00:00:00-08
19368	\N	\N	10374	10374	2024-02-29 00:00:00-08
19369	\N	\N	10375	10375	2024-02-29 00:00:00-08
19370	\N	\N	10376	10376	2024-02-29 00:00:00-08
19371	\N	\N	10377	10378	2024-02-29 00:00:00-08
19372	\N	\N	10377	10377	2024-02-29 00:00:00-08
19373	\N	\N	10378	10378	2024-02-29 00:00:00-08
19374	\N	\N	10378	10377	2024-02-29 00:00:00-08
19375	\N	\N	10379	10379	2024-02-29 00:00:00-08
19376	\N	\N	10380	11022	2024-02-29 00:00:00-08
19377	\N	\N	10380	11021	2024-02-29 00:00:00-08
19378	\N	\N	10380	10380	2024-02-29 00:00:00-08
19379	\N	\N	10381	10971	2024-02-29 00:00:00-08
19380	\N	\N	10381	10970	2024-02-29 00:00:00-08
19381	\N	\N	10381	10381	2024-02-29 00:00:00-08
19382	\N	\N	10382	10382	2024-02-29 00:00:00-08
19383	\N	\N	10383	10383	2024-02-29 00:00:00-08
19384	\N	\N	10384	10384	2024-02-29 00:00:00-08
19385	\N	\N	10385	10385	2024-02-29 00:00:00-08
19386	\N	\N	10386	10386	2024-02-29 00:00:00-08
19387	\N	\N	10387	10387	2024-02-29 00:00:00-08
19388	\N	\N	10388	10388	2024-02-29 00:00:00-08
19389	\N	\N	10389	10389	2024-02-29 00:00:00-08
19390	\N	\N	10390	10390	2024-02-29 00:00:00-08
19391	\N	\N	10391	10391	2024-02-29 00:00:00-08
19392	\N	\N	10392	10392	2024-02-29 00:00:00-08
19393	\N	\N	10393	10393	2024-02-29 00:00:00-08
19394	\N	\N	10405	10653	2024-02-29 00:00:00-08
19395	\N	\N	10406	10653	2024-02-29 00:00:00-08
19396	\N	\N	10420	10637	2024-02-29 00:00:00-08
19397	\N	\N	10421	10637	2024-02-29 00:00:00-08
19398	\N	\N	10422	10634	2024-02-29 00:00:00-08
19399	\N	\N	10423	10634	2024-02-29 00:00:00-08
19400	\N	\N	10424	10636	2024-02-29 00:00:00-08
19401	\N	\N	10430	10696	2024-02-29 00:00:00-08
19402	\N	\N	10450	10697	2024-02-29 00:00:00-08
19403	\N	\N	10456	10596	2024-02-29 00:00:00-08
19404	\N	\N	10460	10652	2024-02-29 00:00:00-08
19405	\N	\N	10461	10652	2024-02-29 00:00:00-08
19406	\N	\N	10478	10741	2024-02-29 00:00:00-08
19407	\N	\N	10482	10699	2024-02-29 00:00:00-08
19408	\N	\N	10485	10619	2024-02-29 00:00:00-08
19409	\N	\N	10487	10620	2024-02-29 00:00:00-08
19410	\N	\N	10490	10621	2024-02-29 00:00:00-08
19411	\N	\N	10657	10657	2024-02-29 00:00:00-08
19412	\N	\N	10551	10551	2024-02-29 00:00:00-08
19413	\N	\N	10552	10552	2024-02-29 00:00:00-08
19414	\N	\N	10553	10553	2024-02-29 00:00:00-08
19415	\N	\N	10554	10554	2024-02-29 00:00:00-08
19416	\N	\N	10555	10555	2024-02-29 00:00:00-08
19417	\N	\N	10556	10556	2024-02-29 00:00:00-08
19418	\N	\N	10557	10557	2024-02-29 00:00:00-08
19419	\N	\N	10558	10558	2024-02-29 00:00:00-08
19420	\N	\N	10559	10559	2024-02-29 00:00:00-08
19421	\N	\N	10560	10560	2024-02-29 00:00:00-08
19422	\N	\N	10561	10561	2024-02-29 00:00:00-08
19423	\N	\N	10563	10634	2024-02-29 00:00:00-08
19424	\N	\N	10565	10636	2024-02-29 00:00:00-08
19425	\N	\N	10596	10596	2024-02-29 00:00:00-08
19426	\N	\N	10598	10598	2024-02-29 00:00:00-08
19427	\N	\N	10599	10599	2024-02-29 00:00:00-08
19428	\N	\N	10600	10600	2024-02-29 00:00:00-08
19429	\N	\N	10601	10601	2024-02-29 00:00:00-08
19430	\N	\N	10602	10602	2024-02-29 00:00:00-08
19431	\N	\N	10603	10603	2024-02-29 00:00:00-08
19432	\N	\N	10604	10604	2024-02-29 00:00:00-08
19433	\N	\N	10606	10606	2024-02-29 00:00:00-08
19434	\N	\N	10607	10607	2024-02-29 00:00:00-08
19435	\N	\N	10608	10608	2024-02-29 00:00:00-08
19436	\N	\N	10609	10609	2024-02-29 00:00:00-08
19437	\N	\N	10610	10691	2024-02-29 00:00:00-08
19438	\N	\N	10610	10690	2024-02-29 00:00:00-08
19439	\N	\N	10610	10611	2024-02-29 00:00:00-08
19440	\N	\N	10610	10610	2024-02-29 00:00:00-08
19441	\N	\N	10611	10691	2024-02-29 00:00:00-08
19442	\N	\N	10611	10690	2024-02-29 00:00:00-08
19443	\N	\N	10611	10611	2024-02-29 00:00:00-08
19444	\N	\N	10611	10610	2024-02-29 00:00:00-08
19445	\N	\N	10612	10612	2024-02-29 00:00:00-08
19446	\N	\N	10613	10692	2024-02-29 00:00:00-08
19447	\N	\N	10613	10614	2024-02-29 00:00:00-08
19448	\N	\N	10613	10613	2024-02-29 00:00:00-08
19449	\N	\N	10614	10692	2024-02-29 00:00:00-08
19450	\N	\N	10614	10614	2024-02-29 00:00:00-08
19451	\N	\N	10614	10613	2024-02-29 00:00:00-08
19452	\N	\N	10615	10616	2024-02-29 00:00:00-08
19453	\N	\N	10615	10615	2024-02-29 00:00:00-08
19454	\N	\N	10616	10616	2024-02-29 00:00:00-08
19455	\N	\N	10616	10615	2024-02-29 00:00:00-08
19456	\N	\N	10617	10617	2024-02-29 00:00:00-08
19457	\N	\N	10618	10618	2024-02-29 00:00:00-08
19458	\N	\N	10619	10619	2024-02-29 00:00:00-08
19459	\N	\N	10620	10620	2024-02-29 00:00:00-08
19460	\N	\N	10621	10621	2024-02-29 00:00:00-08
19461	\N	\N	10622	10687	2024-02-29 00:00:00-08
19462	\N	\N	10622	10622	2024-02-29 00:00:00-08
19463	\N	\N	10623	10688	2024-02-29 00:00:00-08
19464	\N	\N	10623	10623	2024-02-29 00:00:00-08
19465	\N	\N	10624	10624	2024-02-29 00:00:00-08
19466	\N	\N	10625	10625	2024-02-29 00:00:00-08
19467	\N	\N	10626	10629	2024-02-29 00:00:00-08
19468	\N	\N	10626	10627	2024-02-29 00:00:00-08
19469	\N	\N	10626	10626	2024-02-29 00:00:00-08
19470	\N	\N	10627	10629	2024-02-29 00:00:00-08
19471	\N	\N	10627	10627	2024-02-29 00:00:00-08
19472	\N	\N	10627	10626	2024-02-29 00:00:00-08
19473	\N	\N	10628	10628	2024-02-29 00:00:00-08
19474	\N	\N	10629	10629	2024-02-29 00:00:00-08
19475	\N	\N	10629	10627	2024-02-29 00:00:00-08
19476	\N	\N	10629	10626	2024-02-29 00:00:00-08
19477	\N	\N	10630	10630	2024-02-29 00:00:00-08
19478	\N	\N	10631	10631	2024-02-29 00:00:00-08
19479	\N	\N	10632	10632	2024-02-29 00:00:00-08
19480	\N	\N	10633	10633	2024-02-29 00:00:00-08
19481	\N	\N	10634	10634	2024-02-29 00:00:00-08
19482	\N	\N	10635	10635	2024-02-29 00:00:00-08
19483	\N	\N	10636	10636	2024-02-29 00:00:00-08
19484	\N	\N	10637	10637	2024-02-29 00:00:00-08
19485	\N	\N	10638	10638	2024-02-29 00:00:00-08
19486	\N	\N	10639	10639	2024-02-29 00:00:00-08
19487	\N	\N	10640	10640	2024-02-29 00:00:00-08
19488	\N	\N	10641	10641	2024-02-29 00:00:00-08
19489	\N	\N	10642	10642	2024-02-29 00:00:00-08
19490	\N	\N	10643	10643	2024-02-29 00:00:00-08
19491	\N	\N	10644	10644	2024-02-29 00:00:00-08
19492	\N	\N	10645	10645	2024-02-29 00:00:00-08
19493	\N	\N	10646	10646	2024-02-29 00:00:00-08
19494	\N	\N	10647	10647	2024-02-29 00:00:00-08
19495	\N	\N	10648	10648	2024-02-29 00:00:00-08
19496	\N	\N	10649	10649	2024-02-29 00:00:00-08
19497	\N	\N	10650	10650	2024-02-29 00:00:00-08
19498	\N	\N	10651	10651	2024-02-29 00:00:00-08
19499	\N	\N	10652	10652	2024-02-29 00:00:00-08
19500	\N	\N	10653	10653	2024-02-29 00:00:00-08
19501	\N	\N	10654	10654	2024-02-29 00:00:00-08
19502	\N	\N	10655	10655	2024-02-29 00:00:00-08
19503	\N	\N	10656	10656	2024-02-29 00:00:00-08
19504	\N	\N	10658	10658	2024-02-29 00:00:00-08
19505	\N	\N	10659	10659	2024-02-29 00:00:00-08
19506	\N	\N	10660	10660	2024-02-29 00:00:00-08
19507	\N	\N	10661	10661	2024-02-29 00:00:00-08
19508	\N	\N	10662	10662	2024-02-29 00:00:00-08
19509	\N	\N	10663	10663	2024-02-29 00:00:00-08
19510	\N	\N	10664	10664	2024-02-29 00:00:00-08
19511	\N	\N	10665	10666	2024-02-29 00:00:00-08
19512	\N	\N	10665	10665	2024-02-29 00:00:00-08
19513	\N	\N	10666	10666	2024-02-29 00:00:00-08
19514	\N	\N	10666	10665	2024-02-29 00:00:00-08
19515	\N	\N	10667	10667	2024-02-29 00:00:00-08
19516	\N	\N	10668	10668	2024-02-29 00:00:00-08
19517	\N	\N	10669	10670	2024-02-29 00:00:00-08
19518	\N	\N	10669	10669	2024-02-29 00:00:00-08
19519	\N	\N	10670	10670	2024-02-29 00:00:00-08
19520	\N	\N	10670	10669	2024-02-29 00:00:00-08
19521	\N	\N	10671	10672	2024-02-29 00:00:00-08
19522	\N	\N	10671	10671	2024-02-29 00:00:00-08
19523	\N	\N	10672	10672	2024-02-29 00:00:00-08
19524	\N	\N	10672	10671	2024-02-29 00:00:00-08
19525	\N	\N	10673	10673	2024-02-29 00:00:00-08
19526	\N	\N	10674	10674	2024-02-29 00:00:00-08
19527	\N	\N	10675	10675	2024-02-29 00:00:00-08
19528	\N	\N	10676	10676	2024-02-29 00:00:00-08
19529	\N	\N	10677	10677	2024-02-29 00:00:00-08
19530	\N	\N	10678	10678	2024-02-29 00:00:00-08
19531	\N	\N	10679	10679	2024-02-29 00:00:00-08
19532	\N	\N	10680	10680	2024-02-29 00:00:00-08
19533	\N	\N	10681	10681	2024-02-29 00:00:00-08
19534	\N	\N	10682	10682	2024-02-29 00:00:00-08
19535	\N	\N	10683	10683	2024-02-29 00:00:00-08
19536	\N	\N	10684	10684	2024-02-29 00:00:00-08
19537	\N	\N	10685	10685	2024-02-29 00:00:00-08
19538	\N	\N	10686	10686	2024-02-29 00:00:00-08
19539	\N	\N	10687	10687	2024-02-29 00:00:00-08
19540	\N	\N	10687	10622	2024-02-29 00:00:00-08
19541	\N	\N	10688	10688	2024-02-29 00:00:00-08
19542	\N	\N	10688	10623	2024-02-29 00:00:00-08
19543	\N	\N	10690	10691	2024-02-29 00:00:00-08
19544	\N	\N	10690	10690	2024-02-29 00:00:00-08
19545	\N	\N	10690	10611	2024-02-29 00:00:00-08
19546	\N	\N	10690	10610	2024-02-29 00:00:00-08
19547	\N	\N	10691	10691	2024-02-29 00:00:00-08
19548	\N	\N	10691	10690	2024-02-29 00:00:00-08
19549	\N	\N	10691	10611	2024-02-29 00:00:00-08
19550	\N	\N	10691	10610	2024-02-29 00:00:00-08
19551	\N	\N	10692	10692	2024-02-29 00:00:00-08
19552	\N	\N	10692	10614	2024-02-29 00:00:00-08
19553	\N	\N	10692	10613	2024-02-29 00:00:00-08
19554	\N	\N	10693	10692	2024-02-29 00:00:00-08
19555	\N	\N	10693	10614	2024-02-29 00:00:00-08
19556	\N	\N	10693	10613	2024-02-29 00:00:00-08
19557	\N	\N	10694	10616	2024-02-29 00:00:00-08
19558	\N	\N	10694	10615	2024-02-29 00:00:00-08
19559	\N	\N	10695	10616	2024-02-29 00:00:00-08
19560	\N	\N	10695	10615	2024-02-29 00:00:00-08
19561	\N	\N	10696	10696	2024-02-29 00:00:00-08
19562	\N	\N	10697	10697	2024-02-29 00:00:00-08
19563	\N	\N	10698	10698	2024-02-29 00:00:00-08
19564	\N	\N	10699	10699	2024-02-29 00:00:00-08
19565	\N	\N	10700	10696	2024-02-29 00:00:00-08
19566	\N	\N	10705	10656	2024-02-29 00:00:00-08
19567	\N	\N	10706	10660	2024-02-29 00:00:00-08
19568	\N	\N	10707	10662	2024-02-29 00:00:00-08
19569	\N	\N	10708	10708	2024-02-29 00:00:00-08
19570	\N	\N	10709	10709	2024-02-29 00:00:00-08
19571	\N	\N	10710	10710	2024-02-29 00:00:00-08
19572	\N	\N	10711	10711	2024-02-29 00:00:00-08
19573	\N	\N	10713	10713	2024-02-29 00:00:00-08
19574	\N	\N	10714	10714	2024-02-29 00:00:00-08
19575	\N	\N	10715	10715	2024-02-29 00:00:00-08
19576	\N	\N	10716	10716	2024-02-29 00:00:00-08
19577	\N	\N	10717	10717	2024-02-29 00:00:00-08
19578	\N	\N	10718	10718	2024-02-29 00:00:00-08
19579	\N	\N	10719	10719	2024-02-29 00:00:00-08
19580	\N	\N	10720	10720	2024-02-29 00:00:00-08
19581	\N	\N	10721	10721	2024-02-29 00:00:00-08
19582	\N	\N	10722	10722	2024-02-29 00:00:00-08
19583	\N	\N	10723	10723	2024-02-29 00:00:00-08
19584	\N	\N	10724	10724	2024-02-29 00:00:00-08
19585	\N	\N	10725	10725	2024-02-29 00:00:00-08
19586	\N	\N	10726	10727	2024-02-29 00:00:00-08
19587	\N	\N	10726	10726	2024-02-29 00:00:00-08
19588	\N	\N	10727	10727	2024-02-29 00:00:00-08
19589	\N	\N	10727	10726	2024-02-29 00:00:00-08
19590	\N	\N	10728	10728	2024-02-29 00:00:00-08
19591	\N	\N	10729	10729	2024-02-29 00:00:00-08
19592	\N	\N	10730	10730	2024-02-29 00:00:00-08
19593	\N	\N	10731	10731	2024-02-29 00:00:00-08
19594	\N	\N	10732	10732	2024-02-29 00:00:00-08
19595	\N	\N	10733	10733	2024-02-29 00:00:00-08
19596	\N	\N	10734	10734	2024-02-29 00:00:00-08
19597	\N	\N	10735	10735	2024-02-29 00:00:00-08
19598	\N	\N	10736	10736	2024-02-29 00:00:00-08
19599	\N	\N	10737	10737	2024-02-29 00:00:00-08
19600	\N	\N	10738	10738	2024-02-29 00:00:00-08
19601	\N	\N	10739	10739	2024-02-29 00:00:00-08
19602	\N	\N	10740	10740	2024-02-29 00:00:00-08
19603	\N	\N	10741	10741	2024-02-29 00:00:00-08
19604	\N	\N	10742	10743	2024-02-29 00:00:00-08
19605	\N	\N	10742	10742	2024-02-29 00:00:00-08
19606	\N	\N	10743	10743	2024-02-29 00:00:00-08
19607	\N	\N	10743	10742	2024-02-29 00:00:00-08
19608	\N	\N	10744	10745	2024-02-29 00:00:00-08
19609	\N	\N	10744	10744	2024-02-29 00:00:00-08
19610	\N	\N	10745	10745	2024-02-29 00:00:00-08
19611	\N	\N	10745	10744	2024-02-29 00:00:00-08
19612	\N	\N	10746	10747	2024-02-29 00:00:00-08
19613	\N	\N	10746	10746	2024-02-29 00:00:00-08
19614	\N	\N	10747	10747	2024-02-29 00:00:00-08
19615	\N	\N	10747	10746	2024-02-29 00:00:00-08
19616	\N	\N	10748	10749	2024-02-29 00:00:00-08
19617	\N	\N	10748	10748	2024-02-29 00:00:00-08
19618	\N	\N	10749	10749	2024-02-29 00:00:00-08
19619	\N	\N	10749	10748	2024-02-29 00:00:00-08
19620	\N	\N	10750	10750	2024-02-29 00:00:00-08
19621	\N	\N	10751	10751	2024-02-29 00:00:00-08
19622	\N	\N	10752	10752	2024-02-29 00:00:00-08
19623	\N	\N	10753	10753	2024-02-29 00:00:00-08
19624	\N	\N	10754	10754	2024-02-29 00:00:00-08
19625	\N	\N	10755	10755	2024-02-29 00:00:00-08
19626	\N	\N	10756	10756	2024-02-29 00:00:00-08
19627	\N	\N	10757	10758	2024-02-29 00:00:00-08
19628	\N	\N	10757	10757	2024-02-29 00:00:00-08
19629	\N	\N	10758	10758	2024-02-29 00:00:00-08
19630	\N	\N	10758	10757	2024-02-29 00:00:00-08
19631	\N	\N	10759	10925	2024-02-29 00:00:00-08
19632	\N	\N	10759	10760	2024-02-29 00:00:00-08
19633	\N	\N	10759	10759	2024-02-29 00:00:00-08
19634	\N	\N	10760	10925	2024-02-29 00:00:00-08
19635	\N	\N	10760	10760	2024-02-29 00:00:00-08
19636	\N	\N	10760	10759	2024-02-29 00:00:00-08
19637	\N	\N	10762	10762	2024-02-29 00:00:00-08
19638	\N	\N	10763	10763	2024-02-29 00:00:00-08
19639	\N	\N	10764	10764	2024-02-29 00:00:00-08
19640	\N	\N	10765	10765	2024-02-29 00:00:00-08
19641	\N	\N	10766	10766	2024-02-29 00:00:00-08
19642	\N	\N	10767	10767	2024-02-29 00:00:00-08
19643	\N	\N	10768	10768	2024-02-29 00:00:00-08
19644	\N	\N	10769	10769	2024-02-29 00:00:00-08
19645	\N	\N	10770	10770	2024-02-29 00:00:00-08
19646	\N	\N	10771	10771	2024-02-29 00:00:00-08
19647	\N	\N	10772	10772	2024-02-29 00:00:00-08
19648	\N	\N	10773	10773	2024-02-29 00:00:00-08
19649	\N	\N	10774	10774	2024-02-29 00:00:00-08
19650	\N	\N	10775	10775	2024-02-29 00:00:00-08
19651	\N	\N	10776	10776	2024-02-29 00:00:00-08
19652	\N	\N	10777	10777	2024-02-29 00:00:00-08
19653	\N	\N	10778	10778	2024-02-29 00:00:00-08
19654	\N	\N	10779	10779	2024-02-29 00:00:00-08
19655	\N	\N	10780	10780	2024-02-29 00:00:00-08
19656	\N	\N	10781	10781	2024-02-29 00:00:00-08
19657	\N	\N	10782	10782	2024-02-29 00:00:00-08
19658	\N	\N	10783	10783	2024-02-29 00:00:00-08
19659	\N	\N	10784	10784	2024-02-29 00:00:00-08
19660	\N	\N	10785	10785	2024-02-29 00:00:00-08
19661	\N	\N	10786	10786	2024-02-29 00:00:00-08
19662	\N	\N	10787	10787	2024-02-29 00:00:00-08
19663	\N	\N	10788	10788	2024-02-29 00:00:00-08
19664	\N	\N	10789	10789	2024-02-29 00:00:00-08
19665	\N	\N	10790	10790	2024-02-29 00:00:00-08
19666	\N	\N	10791	10657	2024-02-29 00:00:00-08
19667	\N	\N	10792	10659	2024-02-29 00:00:00-08
19668	\N	\N	10793	10661	2024-02-29 00:00:00-08
19669	\N	\N	10794	10794	2024-02-29 00:00:00-08
19670	\N	\N	10795	10795	2024-02-29 00:00:00-08
19671	\N	\N	10796	10796	2024-02-29 00:00:00-08
19672	\N	\N	10797	10797	2024-02-29 00:00:00-08
19673	\N	\N	10798	10798	2024-02-29 00:00:00-08
19674	\N	\N	10799	10799	2024-02-29 00:00:00-08
19675	\N	\N	10800	10800	2024-02-29 00:00:00-08
19676	\N	\N	10801	10070	2024-02-29 00:00:00-08
19677	\N	\N	10801	10069	2024-02-29 00:00:00-08
19678	\N	\N	10802	10070	2024-02-29 00:00:00-08
19679	\N	\N	10802	10069	2024-02-29 00:00:00-08
19680	\N	\N	10803	10803	2024-02-29 00:00:00-08
19681	\N	\N	10804	10804	2024-02-29 00:00:00-08
19682	\N	\N	10805	10805	2024-02-29 00:00:00-08
19683	\N	\N	10806	10806	2024-02-29 00:00:00-08
19684	\N	\N	10807	10807	2024-02-29 00:00:00-08
19685	\N	\N	10808	10808	2024-02-29 00:00:00-08
19686	\N	\N	10809	10809	2024-02-29 00:00:00-08
19687	\N	\N	10810	10810	2024-02-29 00:00:00-08
19688	\N	\N	10811	10811	2024-02-29 00:00:00-08
19689	\N	\N	10812	10812	2024-02-29 00:00:00-08
19690	\N	\N	10813	10813	2024-02-29 00:00:00-08
19691	\N	\N	10814	10814	2024-02-29 00:00:00-08
19692	\N	\N	10815	10815	2024-02-29 00:00:00-08
19693	\N	\N	10816	10816	2024-02-29 00:00:00-08
19694	\N	\N	10817	10817	2024-02-29 00:00:00-08
19695	\N	\N	10818	10819	2024-02-29 00:00:00-08
19696	\N	\N	10818	10818	2024-02-29 00:00:00-08
19697	\N	\N	10819	10819	2024-02-29 00:00:00-08
19698	\N	\N	10819	10818	2024-02-29 00:00:00-08
19699	\N	\N	10820	10821	2024-02-29 00:00:00-08
19700	\N	\N	10820	10820	2024-02-29 00:00:00-08
19701	\N	\N	10821	10821	2024-02-29 00:00:00-08
19702	\N	\N	10821	10820	2024-02-29 00:00:00-08
19703	\N	\N	10822	10822	2024-02-29 00:00:00-08
19704	\N	\N	10823	10823	2024-02-29 00:00:00-08
19705	\N	\N	10824	10824	2024-02-29 00:00:00-08
19706	\N	\N	10825	10825	2024-02-29 00:00:00-08
19707	\N	\N	10826	10826	2024-02-29 00:00:00-08
19708	\N	\N	10827	10827	2024-02-29 00:00:00-08
19709	\N	\N	10828	10828	2024-02-29 00:00:00-08
19710	\N	\N	10829	10829	2024-02-29 00:00:00-08
19711	\N	\N	10830	10830	2024-02-29 00:00:00-08
19712	\N	\N	10831	10831	2024-02-29 00:00:00-08
19713	\N	\N	10832	10832	2024-02-29 00:00:00-08
19714	\N	\N	10833	10833	2024-02-29 00:00:00-08
19715	\N	\N	10834	10834	2024-02-29 00:00:00-08
19716	\N	\N	10835	10835	2024-02-29 00:00:00-08
19717	\N	\N	10836	10836	2024-02-29 00:00:00-08
19718	\N	\N	10837	10837	2024-02-29 00:00:00-08
19719	\N	\N	10838	10838	2024-02-29 00:00:00-08
19720	\N	\N	10839	10839	2024-02-29 00:00:00-08
19721	\N	\N	10840	10840	2024-02-29 00:00:00-08
19722	\N	\N	10841	10841	2024-02-29 00:00:00-08
19723	\N	\N	10842	10842	2024-02-29 00:00:00-08
19724	\N	\N	10843	10843	2024-02-29 00:00:00-08
19725	\N	\N	10844	10844	2024-02-29 00:00:00-08
19726	\N	\N	10845	10845	2024-02-29 00:00:00-08
19727	\N	\N	10846	10846	2024-02-29 00:00:00-08
19728	\N	\N	10847	10847	2024-02-29 00:00:00-08
19729	\N	\N	10848	10848	2024-02-29 00:00:00-08
19730	\N	\N	10849	10849	2024-02-29 00:00:00-08
19731	\N	\N	10850	10850	2024-02-29 00:00:00-08
19732	\N	\N	10851	10851	2024-02-29 00:00:00-08
19733	\N	\N	10852	10852	2024-02-29 00:00:00-08
19734	\N	\N	10853	10853	2024-02-29 00:00:00-08
19735	\N	\N	10854	10854	2024-02-29 00:00:00-08
19736	\N	\N	10855	10855	2024-02-29 00:00:00-08
19737	\N	\N	10856	10856	2024-02-29 00:00:00-08
19738	\N	\N	10857	10857	2024-02-29 00:00:00-08
19739	\N	\N	10858	10858	2024-02-29 00:00:00-08
19740	\N	\N	10859	10859	2024-02-29 00:00:00-08
19741	\N	\N	10860	10860	2024-02-29 00:00:00-08
19742	\N	\N	10861	10861	2024-02-29 00:00:00-08
19743	\N	\N	10862	10862	2024-02-29 00:00:00-08
19744	\N	\N	10863	10863	2024-02-29 00:00:00-08
19745	\N	\N	10864	10864	2024-02-29 00:00:00-08
19746	\N	\N	10865	10865	2024-02-29 00:00:00-08
19747	\N	\N	10866	10866	2024-02-29 00:00:00-08
19748	\N	\N	10867	10780	2024-02-29 00:00:00-08
19749	\N	\N	10868	10781	2024-02-29 00:00:00-08
19750	\N	\N	10869	10869	2024-02-29 00:00:00-08
19751	\N	\N	10870	10872	2024-02-29 00:00:00-08
19752	\N	\N	10870	10871	2024-02-29 00:00:00-08
19753	\N	\N	10870	10870	2024-02-29 00:00:00-08
19754	\N	\N	10871	10872	2024-02-29 00:00:00-08
19755	\N	\N	10871	10871	2024-02-29 00:00:00-08
19756	\N	\N	10871	10870	2024-02-29 00:00:00-08
19757	\N	\N	10872	10872	2024-02-29 00:00:00-08
19758	\N	\N	10872	10871	2024-02-29 00:00:00-08
19759	\N	\N	10872	10870	2024-02-29 00:00:00-08
19760	\N	\N	10873	10873	2024-02-29 00:00:00-08
19761	\N	\N	10874	10875	2024-02-29 00:00:00-08
19762	\N	\N	10874	10874	2024-02-29 00:00:00-08
19763	\N	\N	10875	10875	2024-02-29 00:00:00-08
19764	\N	\N	10875	10874	2024-02-29 00:00:00-08
19765	\N	\N	10876	10878	2024-02-29 00:00:00-08
19766	\N	\N	10876	10877	2024-02-29 00:00:00-08
19767	\N	\N	10876	10876	2024-02-29 00:00:00-08
19768	\N	\N	10877	10878	2024-02-29 00:00:00-08
19769	\N	\N	10877	10877	2024-02-29 00:00:00-08
19770	\N	\N	10877	10876	2024-02-29 00:00:00-08
19771	\N	\N	10878	10878	2024-02-29 00:00:00-08
19772	\N	\N	10878	10877	2024-02-29 00:00:00-08
19773	\N	\N	10878	10876	2024-02-29 00:00:00-08
19774	\N	\N	10879	10879	2024-02-29 00:00:00-08
19775	\N	\N	10880	10880	2024-02-29 00:00:00-08
19776	\N	\N	10881	10882	2024-02-29 00:00:00-08
19777	\N	\N	10881	10881	2024-02-29 00:00:00-08
19778	\N	\N	10882	10882	2024-02-29 00:00:00-08
19779	\N	\N	10882	10881	2024-02-29 00:00:00-08
19780	\N	\N	10883	10883	2024-02-29 00:00:00-08
19781	\N	\N	10884	10884	2024-02-29 00:00:00-08
19782	\N	\N	10885	10886	2024-02-29 00:00:00-08
19783	\N	\N	10885	10885	2024-02-29 00:00:00-08
19784	\N	\N	10886	10886	2024-02-29 00:00:00-08
19785	\N	\N	10886	10885	2024-02-29 00:00:00-08
19786	\N	\N	10887	10887	2024-02-29 00:00:00-08
19787	\N	\N	10888	10888	2024-02-29 00:00:00-08
19788	\N	\N	10889	10889	2024-02-29 00:00:00-08
19789	\N	\N	10890	10890	2024-02-29 00:00:00-08
19790	\N	\N	10891	10891	2024-02-29 00:00:00-08
19791	\N	\N	10892	10892	2024-02-29 00:00:00-08
19792	\N	\N	10893	10893	2024-02-29 00:00:00-08
19793	\N	\N	10894	10894	2024-02-29 00:00:00-08
19794	\N	\N	10895	10897	2024-02-29 00:00:00-08
19795	\N	\N	10895	10896	2024-02-29 00:00:00-08
19796	\N	\N	10895	10895	2024-02-29 00:00:00-08
19797	\N	\N	10896	10897	2024-02-29 00:00:00-08
19798	\N	\N	10896	10896	2024-02-29 00:00:00-08
19799	\N	\N	10896	10895	2024-02-29 00:00:00-08
19800	\N	\N	10897	10897	2024-02-29 00:00:00-08
19801	\N	\N	10897	10896	2024-02-29 00:00:00-08
19802	\N	\N	10897	10895	2024-02-29 00:00:00-08
19803	\N	\N	10898	10898	2024-02-29 00:00:00-08
19804	\N	\N	10899	10899	2024-02-29 00:00:00-08
19805	\N	\N	10900	10900	2024-02-29 00:00:00-08
19806	\N	\N	10901	10901	2024-02-29 00:00:00-08
19807	\N	\N	10902	10902	2024-02-29 00:00:00-08
19808	\N	\N	10903	10903	2024-02-29 00:00:00-08
19809	\N	\N	10904	10904	2024-02-29 00:00:00-08
19810	\N	\N	10905	10905	2024-02-29 00:00:00-08
19811	\N	\N	10906	10908	2024-02-29 00:00:00-08
19812	\N	\N	10906	10907	2024-02-29 00:00:00-08
19813	\N	\N	10906	10906	2024-02-29 00:00:00-08
19814	\N	\N	10907	10908	2024-02-29 00:00:00-08
19815	\N	\N	10907	10907	2024-02-29 00:00:00-08
19816	\N	\N	10907	10906	2024-02-29 00:00:00-08
19817	\N	\N	10908	10908	2024-02-29 00:00:00-08
19818	\N	\N	10908	10907	2024-02-29 00:00:00-08
19819	\N	\N	10908	10906	2024-02-29 00:00:00-08
19820	\N	\N	10909	10909	2024-02-29 00:00:00-08
19821	\N	\N	10910	10911	2024-02-29 00:00:00-08
19822	\N	\N	10910	10910	2024-02-29 00:00:00-08
19823	\N	\N	10911	10911	2024-02-29 00:00:00-08
19824	\N	\N	10911	10910	2024-02-29 00:00:00-08
19825	\N	\N	10912	10912	2024-02-29 00:00:00-08
19826	\N	\N	10913	10913	2024-02-29 00:00:00-08
19827	\N	\N	10914	10914	2024-02-29 00:00:00-08
19828	\N	\N	10915	10915	2024-02-29 00:00:00-08
19829	\N	\N	10916	10916	2024-02-29 00:00:00-08
19830	\N	\N	10917	10917	2024-02-29 00:00:00-08
19831	\N	\N	10918	10918	2024-02-29 00:00:00-08
19832	\N	\N	10919	10920	2024-02-29 00:00:00-08
19833	\N	\N	10919	10919	2024-02-29 00:00:00-08
19834	\N	\N	10920	10920	2024-02-29 00:00:00-08
19835	\N	\N	10920	10919	2024-02-29 00:00:00-08
19836	\N	\N	10921	10922	2024-02-29 00:00:00-08
19837	\N	\N	10921	10921	2024-02-29 00:00:00-08
19838	\N	\N	10922	10922	2024-02-29 00:00:00-08
19839	\N	\N	10922	10921	2024-02-29 00:00:00-08
19840	\N	\N	10923	10923	2024-02-29 00:00:00-08
19841	\N	\N	10924	10924	2024-02-29 00:00:00-08
19842	\N	\N	10925	10925	2024-02-29 00:00:00-08
19843	\N	\N	10925	10760	2024-02-29 00:00:00-08
19844	\N	\N	10925	10759	2024-02-29 00:00:00-08
19845	\N	\N	10926	10926	2024-02-29 00:00:00-08
19846	\N	\N	10927	10927	2024-02-29 00:00:00-08
19847	\N	\N	10928	10928	2024-02-29 00:00:00-08
19848	\N	\N	10929	10929	2024-02-29 00:00:00-08
19849	\N	\N	10930	10931	2024-02-29 00:00:00-08
19850	\N	\N	10930	10930	2024-02-29 00:00:00-08
19851	\N	\N	10931	10931	2024-02-29 00:00:00-08
19852	\N	\N	10931	10930	2024-02-29 00:00:00-08
19853	\N	\N	10932	10934	2024-02-29 00:00:00-08
19854	\N	\N	10932	10933	2024-02-29 00:00:00-08
19855	\N	\N	10932	10932	2024-02-29 00:00:00-08
19856	\N	\N	10933	10934	2024-02-29 00:00:00-08
19857	\N	\N	10933	10933	2024-02-29 00:00:00-08
19858	\N	\N	10933	10932	2024-02-29 00:00:00-08
19859	\N	\N	10934	10934	2024-02-29 00:00:00-08
19860	\N	\N	10934	10933	2024-02-29 00:00:00-08
19861	\N	\N	10934	10932	2024-02-29 00:00:00-08
19862	\N	\N	10956	11217	2024-02-29 00:00:00-08
19863	\N	\N	10956	11216	2024-02-29 00:00:00-08
19864	\N	\N	10956	11215	2024-02-29 00:00:00-08
19865	\N	\N	10956	11214	2024-02-29 00:00:00-08
19866	\N	\N	10956	11212	2024-02-29 00:00:00-08
19867	\N	\N	10957	10957	2024-02-29 00:00:00-08
19868	\N	\N	10958	10958	2024-02-29 00:00:00-08
19869	\N	\N	10959	10959	2024-02-29 00:00:00-08
19870	\N	\N	10960	10960	2024-02-29 00:00:00-08
19871	\N	\N	10961	10961	2024-02-29 00:00:00-08
19872	\N	\N	10962	10962	2024-02-29 00:00:00-08
19873	\N	\N	10963	10965	2024-02-29 00:00:00-08
19874	\N	\N	10963	10963	2024-02-29 00:00:00-08
19875	\N	\N	10964	10964	2024-02-29 00:00:00-08
19876	\N	\N	10965	10965	2024-02-29 00:00:00-08
19877	\N	\N	10965	10963	2024-02-29 00:00:00-08
19878	\N	\N	10966	10968	2024-02-29 00:00:00-08
19879	\N	\N	10966	10967	2024-02-29 00:00:00-08
19880	\N	\N	10966	10966	2024-02-29 00:00:00-08
19881	\N	\N	10967	10968	2024-02-29 00:00:00-08
19882	\N	\N	10967	10967	2024-02-29 00:00:00-08
19883	\N	\N	10967	10966	2024-02-29 00:00:00-08
19884	\N	\N	10968	10968	2024-02-29 00:00:00-08
19885	\N	\N	10968	10967	2024-02-29 00:00:00-08
19886	\N	\N	10968	10966	2024-02-29 00:00:00-08
19887	\N	\N	10969	10969	2024-02-29 00:00:00-08
19888	\N	\N	10970	10971	2024-02-29 00:00:00-08
19889	\N	\N	10970	10970	2024-02-29 00:00:00-08
19890	\N	\N	10970	10381	2024-02-29 00:00:00-08
19891	\N	\N	10971	10971	2024-02-29 00:00:00-08
19892	\N	\N	10971	10970	2024-02-29 00:00:00-08
19893	\N	\N	10971	10381	2024-02-29 00:00:00-08
19894	\N	\N	10972	10973	2024-02-29 00:00:00-08
19895	\N	\N	10972	10972	2024-02-29 00:00:00-08
19896	\N	\N	10973	10973	2024-02-29 00:00:00-08
19897	\N	\N	10973	10972	2024-02-29 00:00:00-08
19898	\N	\N	10974	10974	2024-02-29 00:00:00-08
19899	\N	\N	10975	10976	2024-02-29 00:00:00-08
19900	\N	\N	10975	10975	2024-02-29 00:00:00-08
19901	\N	\N	10976	10976	2024-02-29 00:00:00-08
19902	\N	\N	10976	10975	2024-02-29 00:00:00-08
19903	\N	\N	10977	10977	2024-02-29 00:00:00-08
19904	\N	\N	10978	10978	2024-02-29 00:00:00-08
19905	\N	\N	10979	10979	2024-02-29 00:00:00-08
19906	\N	\N	10980	10980	2024-02-29 00:00:00-08
19907	\N	\N	10981	10981	2024-02-29 00:00:00-08
19908	\N	\N	10982	10982	2024-02-29 00:00:00-08
19909	\N	\N	10983	10983	2024-02-29 00:00:00-08
19910	\N	\N	10984	10984	2024-02-29 00:00:00-08
19911	\N	\N	10985	10985	2024-02-29 00:00:00-08
19912	\N	\N	10986	10986	2024-02-29 00:00:00-08
19913	\N	\N	10991	10991	2024-02-29 00:00:00-08
19914	\N	\N	10992	10992	2024-02-29 00:00:00-08
19915	\N	\N	10993	10993	2024-02-29 00:00:00-08
19916	\N	\N	10994	10994	2024-02-29 00:00:00-08
19917	\N	\N	10995	10995	2024-02-29 00:00:00-08
19918	\N	\N	10996	10996	2024-02-29 00:00:00-08
19919	\N	\N	10997	10997	2024-02-29 00:00:00-08
19920	\N	\N	10998	10998	2024-02-29 00:00:00-08
19921	\N	\N	10999	10999	2024-02-29 00:00:00-08
19922	\N	\N	11000	11000	2024-02-29 00:00:00-08
19923	\N	\N	11001	11001	2024-02-29 00:00:00-08
19924	\N	\N	11002	11002	2024-02-29 00:00:00-08
19925	\N	\N	11003	11003	2024-02-29 00:00:00-08
19926	\N	\N	11004	11004	2024-02-29 00:00:00-08
19927	\N	\N	11005	11005	2024-02-29 00:00:00-08
19928	\N	\N	11006	11006	2024-02-29 00:00:00-08
19929	\N	\N	11007	11007	2024-02-29 00:00:00-08
19930	\N	\N	11008	11008	2024-02-29 00:00:00-08
19931	\N	\N	11009	11009	2024-02-29 00:00:00-08
19932	\N	\N	11010	11010	2024-02-29 00:00:00-08
19933	\N	\N	11011	11011	2024-02-29 00:00:00-08
19934	\N	\N	11012	11012	2024-02-29 00:00:00-08
19935	\N	\N	11013	11013	2024-02-29 00:00:00-08
19936	\N	\N	11014	11014	2024-02-29 00:00:00-08
19937	\N	\N	11015	11015	2024-02-29 00:00:00-08
19938	\N	\N	11016	11016	2024-02-29 00:00:00-08
19939	\N	\N	11017	11017	2024-02-29 00:00:00-08
19940	\N	\N	11018	11018	2024-02-29 00:00:00-08
19941	\N	\N	11019	11227	2024-02-29 00:00:00-08
19942	\N	\N	11019	11219	2024-02-29 00:00:00-08
19943	\N	\N	11019	11218	2024-02-29 00:00:00-08
19944	\N	\N	11019	11213	2024-02-29 00:00:00-08
19945	\N	\N	11019	11020	2024-02-29 00:00:00-08
19946	\N	\N	11019	11019	2024-02-29 00:00:00-08
19947	\N	\N	11020	11227	2024-02-29 00:00:00-08
19948	\N	\N	11020	11219	2024-02-29 00:00:00-08
19949	\N	\N	11020	11218	2024-02-29 00:00:00-08
19950	\N	\N	11020	11213	2024-02-29 00:00:00-08
19951	\N	\N	11020	11020	2024-02-29 00:00:00-08
19952	\N	\N	11020	11019	2024-02-29 00:00:00-08
19953	\N	\N	11021	11022	2024-02-29 00:00:00-08
19954	\N	\N	11021	11021	2024-02-29 00:00:00-08
19955	\N	\N	11021	10380	2024-02-29 00:00:00-08
19956	\N	\N	11022	11022	2024-02-29 00:00:00-08
19957	\N	\N	11022	11021	2024-02-29 00:00:00-08
19958	\N	\N	11022	10380	2024-02-29 00:00:00-08
19959	\N	\N	11023	11023	2024-02-29 00:00:00-08
19960	\N	\N	11024	11024	2024-02-29 00:00:00-08
19961	\N	\N	11025	11025	2024-02-29 00:00:00-08
19962	\N	\N	11026	11026	2024-02-29 00:00:00-08
19963	\N	\N	11027	10751	2024-02-29 00:00:00-08
19964	\N	\N	11028	10753	2024-02-29 00:00:00-08
19965	\N	\N	11029	10755	2024-02-29 00:00:00-08
19966	\N	\N	11030	10768	2024-02-29 00:00:00-08
19967	\N	\N	11031	10773	2024-02-29 00:00:00-08
19968	\N	\N	11032	11032	2024-02-29 00:00:00-08
19969	\N	\N	11033	11033	2024-02-29 00:00:00-08
19970	\N	\N	11034	11034	2024-02-29 00:00:00-08
19971	\N	\N	11035	11035	2024-02-29 00:00:00-08
19972	\N	\N	11036	11036	2024-02-29 00:00:00-08
19973	\N	\N	11037	11037	2024-02-29 00:00:00-08
19974	\N	\N	11038	11038	2024-02-29 00:00:00-08
19975	\N	\N	11039	11039	2024-02-29 00:00:00-08
19976	\N	\N	11040	11040	2024-02-29 00:00:00-08
19977	\N	\N	11041	11041	2024-02-29 00:00:00-08
19978	\N	\N	11042	11042	2024-02-29 00:00:00-08
19979	\N	\N	11043	11043	2024-02-29 00:00:00-08
19980	\N	\N	11047	10378	2024-02-29 00:00:00-08
19981	\N	\N	11047	10377	2024-02-29 00:00:00-08
19982	\N	\N	11048	10378	2024-02-29 00:00:00-08
19983	\N	\N	11048	10377	2024-02-29 00:00:00-08
19984	\N	\N	11049	10379	2024-02-29 00:00:00-08
19985	\N	\N	11050	11022	2024-02-29 00:00:00-08
19986	\N	\N	11050	11021	2024-02-29 00:00:00-08
19987	\N	\N	11050	10380	2024-02-29 00:00:00-08
19988	\N	\N	11051	10971	2024-02-29 00:00:00-08
19989	\N	\N	11051	10970	2024-02-29 00:00:00-08
19990	\N	\N	11051	10381	2024-02-29 00:00:00-08
19991	\N	\N	11065	11065	2024-02-29 00:00:00-08
19992	\N	\N	11100	1231	2024-02-29 00:00:00-08
19993	\N	\N	11101	1230	2024-02-29 00:00:00-08
19994	\N	\N	11102	1229	2024-02-29 00:00:00-08
19995	\N	\N	11103	1228	2024-02-29 00:00:00-08
19996	\N	\N	11104	1227	2024-02-29 00:00:00-08
19997	\N	\N	11105	1232	2024-02-29 00:00:00-08
19998	\N	\N	11106	11106	2024-02-29 00:00:00-08
19999	\N	\N	11107	11107	2024-02-29 00:00:00-08
20000	\N	\N	11108	11108	2024-02-29 00:00:00-08
20001	\N	\N	11109	11109	2024-02-29 00:00:00-08
20002	\N	\N	11110	11110	2024-02-29 00:00:00-08
20003	\N	\N	11111	11111	2024-02-29 00:00:00-08
20004	\N	\N	11112	11112	2024-02-29 00:00:00-08
20005	\N	\N	11113	11113	2024-02-29 00:00:00-08
20006	\N	\N	11114	11114	2024-02-29 00:00:00-08
20007	\N	\N	11115	11115	2024-02-29 00:00:00-08
20008	\N	\N	11116	11116	2024-02-29 00:00:00-08
20009	\N	\N	11117	11117	2024-02-29 00:00:00-08
20010	\N	\N	11118	11118	2024-02-29 00:00:00-08
20011	\N	\N	11119	11119	2024-02-29 00:00:00-08
20012	\N	\N	11120	11120	2024-02-29 00:00:00-08
20013	\N	\N	11121	11121	2024-02-29 00:00:00-08
20014	\N	\N	11122	11122	2024-02-29 00:00:00-08
20015	\N	\N	11123	11123	2024-02-29 00:00:00-08
20016	\N	\N	11124	11124	2024-02-29 00:00:00-08
20017	\N	\N	11125	11125	2024-02-29 00:00:00-08
20018	\N	\N	11126	11126	2024-02-29 00:00:00-08
20019	\N	\N	11127	11127	2024-02-29 00:00:00-08
20020	\N	\N	11128	11128	2024-02-29 00:00:00-08
20021	\N	\N	11129	11129	2024-02-29 00:00:00-08
20022	\N	\N	11130	11130	2024-02-29 00:00:00-08
20023	\N	\N	11131	11131	2024-02-29 00:00:00-08
20024	\N	\N	11132	11132	2024-02-29 00:00:00-08
20025	\N	\N	11133	11133	2024-02-29 00:00:00-08
20026	\N	\N	11134	11134	2024-02-29 00:00:00-08
20027	\N	\N	11135	11135	2024-02-29 00:00:00-08
20028	\N	\N	11136	11136	2024-02-29 00:00:00-08
20029	\N	\N	11137	11137	2024-02-29 00:00:00-08
20030	\N	\N	11138	11138	2024-02-29 00:00:00-08
20031	\N	\N	11139	11139	2024-02-29 00:00:00-08
20032	\N	\N	11140	11140	2024-02-29 00:00:00-08
20033	\N	\N	11141	11141	2024-02-29 00:00:00-08
20034	\N	\N	11142	11142	2024-02-29 00:00:00-08
20035	\N	\N	11143	11143	2024-02-29 00:00:00-08
20036	\N	\N	11144	11144	2024-02-29 00:00:00-08
20037	\N	\N	11145	11145	2024-02-29 00:00:00-08
20038	\N	\N	11146	11146	2024-02-29 00:00:00-08
20039	\N	\N	11147	11147	2024-02-29 00:00:00-08
20040	\N	\N	11148	11148	2024-02-29 00:00:00-08
20041	\N	\N	11149	11149	2024-02-29 00:00:00-08
20042	\N	\N	11150	11150	2024-02-29 00:00:00-08
20043	\N	\N	11151	11151	2024-02-29 00:00:00-08
20044	\N	\N	11152	11152	2024-02-29 00:00:00-08
20045	\N	\N	11153	11153	2024-02-29 00:00:00-08
20046	\N	\N	11154	11154	2024-02-29 00:00:00-08
20047	\N	\N	11155	11155	2024-02-29 00:00:00-08
20048	\N	\N	11156	11156	2024-02-29 00:00:00-08
20049	\N	\N	11157	11157	2024-02-29 00:00:00-08
20050	\N	\N	11158	11158	2024-02-29 00:00:00-08
20051	\N	\N	11159	11159	2024-02-29 00:00:00-08
20052	\N	\N	11160	11160	2024-02-29 00:00:00-08
20053	\N	\N	11161	11161	2024-02-29 00:00:00-08
20054	\N	\N	11162	11162	2024-02-29 00:00:00-08
20055	\N	\N	11163	11163	2024-02-29 00:00:00-08
20056	\N	\N	11164	11164	2024-02-29 00:00:00-08
20057	\N	\N	11165	11165	2024-02-29 00:00:00-08
20058	\N	\N	11166	11166	2024-02-29 00:00:00-08
20059	\N	\N	11167	11167	2024-02-29 00:00:00-08
20060	\N	\N	11168	11168	2024-02-29 00:00:00-08
20061	\N	\N	11169	11169	2024-02-29 00:00:00-08
20062	\N	\N	11170	11170	2024-02-29 00:00:00-08
20063	\N	\N	11171	11171	2024-02-29 00:00:00-08
20064	\N	\N	11172	11172	2024-02-29 00:00:00-08
20065	\N	\N	11173	11173	2024-02-29 00:00:00-08
20066	\N	\N	11174	11174	2024-02-29 00:00:00-08
20067	\N	\N	11175	11175	2024-02-29 00:00:00-08
20068	\N	\N	11176	11176	2024-02-29 00:00:00-08
20069	\N	\N	11177	11177	2024-02-29 00:00:00-08
20070	\N	\N	11178	11178	2024-02-29 00:00:00-08
20071	\N	\N	11179	11179	2024-02-29 00:00:00-08
20072	\N	\N	11180	11180	2024-02-29 00:00:00-08
20073	\N	\N	11181	11181	2024-02-29 00:00:00-08
20074	\N	\N	11182	11182	2024-02-29 00:00:00-08
20075	\N	\N	11183	11183	2024-02-29 00:00:00-08
20076	\N	\N	11184	11184	2024-02-29 00:00:00-08
20077	\N	\N	11185	11185	2024-02-29 00:00:00-08
20078	\N	\N	11186	11186	2024-02-29 00:00:00-08
20079	\N	\N	11187	11187	2024-02-29 00:00:00-08
20080	\N	\N	11188	11188	2024-02-29 00:00:00-08
20081	\N	\N	11189	11189	2024-02-29 00:00:00-08
20082	\N	\N	11190	11190	2024-02-29 00:00:00-08
20083	\N	\N	11191	11191	2024-02-29 00:00:00-08
20084	\N	\N	11192	11192	2024-02-29 00:00:00-08
20085	\N	\N	11193	11193	2024-02-29 00:00:00-08
20086	\N	\N	11194	11194	2024-02-29 00:00:00-08
20087	\N	\N	11195	11195	2024-02-29 00:00:00-08
20088	\N	\N	11196	11196	2024-02-29 00:00:00-08
20089	\N	\N	11197	11197	2024-02-29 00:00:00-08
20090	\N	\N	11198	11198	2024-02-29 00:00:00-08
20091	\N	\N	11199	11199	2024-02-29 00:00:00-08
20092	\N	\N	11200	11200	2024-02-29 00:00:00-08
20093	\N	\N	11201	11201	2024-02-29 00:00:00-08
20094	\N	\N	11202	11202	2024-02-29 00:00:00-08
20095	\N	\N	11203	11203	2024-02-29 00:00:00-08
20096	\N	\N	11204	11204	2024-02-29 00:00:00-08
20097	\N	\N	11205	11205	2024-02-29 00:00:00-08
20098	\N	\N	11206	11206	2024-02-29 00:00:00-08
20099	\N	\N	11207	11207	2024-02-29 00:00:00-08
20100	\N	\N	11208	11208	2024-02-29 00:00:00-08
20101	\N	\N	11209	11209	2024-02-29 00:00:00-08
20102	\N	\N	11210	11210	2024-02-29 00:00:00-08
20103	\N	\N	11211	11211	2024-02-29 00:00:00-08
20104	\N	\N	11212	11217	2024-02-29 00:00:00-08
20105	\N	\N	11212	11216	2024-02-29 00:00:00-08
20106	\N	\N	11212	11215	2024-02-29 00:00:00-08
20107	\N	\N	11212	11214	2024-02-29 00:00:00-08
20108	\N	\N	11212	11212	2024-02-29 00:00:00-08
20109	\N	\N	11213	11227	2024-02-29 00:00:00-08
20110	\N	\N	11213	11219	2024-02-29 00:00:00-08
20111	\N	\N	11213	11218	2024-02-29 00:00:00-08
20112	\N	\N	11213	11213	2024-02-29 00:00:00-08
20113	\N	\N	11213	11020	2024-02-29 00:00:00-08
20114	\N	\N	11213	11019	2024-02-29 00:00:00-08
20115	\N	\N	11214	11217	2024-02-29 00:00:00-08
20116	\N	\N	11214	11216	2024-02-29 00:00:00-08
20117	\N	\N	11214	11215	2024-02-29 00:00:00-08
20118	\N	\N	11214	11214	2024-02-29 00:00:00-08
20119	\N	\N	11214	11212	2024-02-29 00:00:00-08
20120	\N	\N	11215	11217	2024-02-29 00:00:00-08
20121	\N	\N	11215	11216	2024-02-29 00:00:00-08
20122	\N	\N	11215	11215	2024-02-29 00:00:00-08
20123	\N	\N	11215	11214	2024-02-29 00:00:00-08
20124	\N	\N	11215	11212	2024-02-29 00:00:00-08
20125	\N	\N	11216	11217	2024-02-29 00:00:00-08
20126	\N	\N	11216	11216	2024-02-29 00:00:00-08
20127	\N	\N	11216	11215	2024-02-29 00:00:00-08
20128	\N	\N	11216	11214	2024-02-29 00:00:00-08
20129	\N	\N	11216	11212	2024-02-29 00:00:00-08
20130	\N	\N	11217	11217	2024-02-29 00:00:00-08
20131	\N	\N	11217	11216	2024-02-29 00:00:00-08
20132	\N	\N	11217	11215	2024-02-29 00:00:00-08
20133	\N	\N	11217	11214	2024-02-29 00:00:00-08
20134	\N	\N	11217	11212	2024-02-29 00:00:00-08
20135	\N	\N	11218	11227	2024-02-29 00:00:00-08
20136	\N	\N	11218	11219	2024-02-29 00:00:00-08
20137	\N	\N	11218	11218	2024-02-29 00:00:00-08
20138	\N	\N	11218	11213	2024-02-29 00:00:00-08
20139	\N	\N	11218	11020	2024-02-29 00:00:00-08
20140	\N	\N	11218	11019	2024-02-29 00:00:00-08
20141	\N	\N	11219	11227	2024-02-29 00:00:00-08
20142	\N	\N	11219	11219	2024-02-29 00:00:00-08
20143	\N	\N	11219	11218	2024-02-29 00:00:00-08
20144	\N	\N	11219	11213	2024-02-29 00:00:00-08
20145	\N	\N	11219	11020	2024-02-29 00:00:00-08
20146	\N	\N	11219	11019	2024-02-29 00:00:00-08
20147	\N	\N	11220	11220	2024-02-29 00:00:00-08
20148	\N	\N	11221	11221	2024-02-29 00:00:00-08
20149	\N	\N	11222	11222	2024-02-29 00:00:00-08
20150	\N	\N	11223	11223	2024-02-29 00:00:00-08
20151	\N	\N	11224	11224	2024-02-29 00:00:00-08
20152	\N	\N	11225	11225	2024-02-29 00:00:00-08
20153	\N	\N	11226	11226	2024-02-29 00:00:00-08
20154	\N	\N	11227	11227	2024-02-29 00:00:00-08
20155	\N	\N	11227	11219	2024-02-29 00:00:00-08
20156	\N	\N	11227	11218	2024-02-29 00:00:00-08
20157	\N	\N	11227	11213	2024-02-29 00:00:00-08
20158	\N	\N	11227	11020	2024-02-29 00:00:00-08
20159	\N	\N	11227	11019	2024-02-29 00:00:00-08
20160	\N	\N	11228	11229	2024-02-29 00:00:00-08
20161	\N	\N	11228	11228	2024-02-29 00:00:00-08
20162	\N	\N	11229	11229	2024-02-29 00:00:00-08
20163	\N	\N	11229	11228	2024-02-29 00:00:00-08
20164	\N	\N	11230	11230	2024-02-29 00:00:00-08
20165	\N	\N	11231	11231	2024-02-29 00:00:00-08
20166	\N	\N	11232	11232	2024-02-29 00:00:00-08
20167	\N	\N	11233	11233	2024-02-29 00:00:00-08
20168	\N	\N	11234	11234	2024-02-29 00:00:00-08
20169	\N	\N	11235	11235	2024-02-29 00:00:00-08
20170	\N	\N	11236	11236	2024-02-29 00:00:00-08
20171	\N	\N	11237	11237	2024-02-29 00:00:00-08
20172	\N	\N	11238	11238	2024-02-29 00:00:00-08
20173	\N	\N	11239	11239	2024-02-29 00:00:00-08
20174	\N	\N	11240	11240	2024-02-29 00:00:00-08
20175	\N	\N	11241	11241	2024-02-29 00:00:00-08
20176	\N	\N	11242	11242	2024-02-29 00:00:00-08
20177	\N	\N	11243	11243	2024-02-29 00:00:00-08
20178	\N	\N	11244	11244	2024-02-29 00:00:00-08
20179	\N	\N	11245	11245	2024-02-29 00:00:00-08
20180	\N	\N	11246	11246	2024-02-29 00:00:00-08
20181	\N	\N	11247	11247	2024-02-29 00:00:00-08
20182	\N	\N	11248	11248	2024-02-29 00:00:00-08
20183	\N	\N	11249	11249	2024-02-29 00:00:00-08
20184	\N	\N	11250	11250	2024-02-29 00:00:00-08
20185	\N	\N	11251	11251	2024-02-29 00:00:00-08
\.


--
-- Data for Name: nuc_acids; Type: TABLE DATA; Schema: public; Owner: borisbastian
--

COPY public.nuc_acids (nu_id, name, date, na_type, conc, vol_init, vol_remain, notes, method_id) FROM stdin;
1	D1_NA	2012-04-11 00:00:00-07	DNA	10.24	50	50	\N	\N
2	D2_NA	2012-04-11 00:00:00-07	DNA	4.2	50	50	\N	\N
3	D6_NA	2012-04-11 00:00:00-07	DNA	20	50	50	\N	\N
4	D7_NA	2012-04-11 00:00:00-07	DNA	20	50	50	\N	\N
5	D11_NA	2012-04-11 00:00:00-07	DNA	9.6	50	50	\N	\N
6	D12_M_NA	\N	DNA	\N	\N	\N	\N	\N
7	D13_NA	2012-04-11 00:00:00-07	DNA	20	50	50	\N	\N
8	D15_NA	2012-04-11 00:00:00-07	DNA	6.6	50	50	\N	\N
9	D20_NA	2012-04-24 00:00:00-07	DNA	20	50	50	\N	\N
10	D21-1_NA	2012-08-23 00:00:00-07	DNA	1.38	100	100	\N	\N
11	21-2_NA	2012-08-23 00:00:00-07	DNA	0.94	100	100	\N	\N
12	21-3_NA	2012-08-23 00:00:00-07	DNA	1.35	100	100	\N	\N
13	21-4_NA	2012-08-23 00:00:00-07	DNA	1.02	100	100	\N	\N
14	21-5_NA	2013-03-18 00:00:00-07	DNA	1.19	200	200	\N	5
15	22_IS_NA	\N	DNA	\N	\N	\N	\N	\N
16	22_Melanoma_NA	\N	DNA	\N	\N	\N	\N	\N
17	22_Nevus_NA	\N	DNA	\N	\N	\N	\N	\N
18	22_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
19	22-44183B-DNA	2023-07-24 00:00:00-07	DNA	0.71	190	190	\N	2
20	22-44183B-RNA	2023-07-24 00:00:00-07	RNA	17.5	91	91	\N	1
21	22-104389A2-DNA	2023-05-19 00:00:00-07	DNA	6.2	160	160	\N	6
22	22-104389A2-RNA	2023-05-19 00:00:00-07	RNA	4.28	40	40	-80 BOX3	6
23	22-104389A4-DNA	2023-06-05 00:00:00-07	DNA	0	200	200	\N	6
24	22-104389A4-RNA	2023-06-05 00:00:00-07	RNA	0	46	46	\N	6
25	22-104389C-DNA	2023-05-19 00:00:00-07	DNA	0.74	160	160	\N	6
26	22-104389C-RNA	2023-05-19 00:00:00-07	RNA	2.53	40	40	-80 BOX3	6
27	22-125373-DNA	2023-02-08 00:00:00-08	DNA	12.2	352	352	\N	2
28	22-125373-RNA	2023-02-08 00:00:00-08	RNA	34.8	160	160	-80 BOX3	1
29	23_NA	2012-04-24 00:00:00-07	DNA	20	50	50	\N	\N
30	24_NA	2012-04-24 00:00:00-07	DNA	8	50	50	\N	\N
31	24-1_NA	2012-08-23 00:00:00-07	DNA	38.33	100	100	\N	\N
32	24-2_NA	2012-08-23 00:00:00-07	DNA	11.27	100	100	\N	\N
33	24-3_NA	2012-08-23 00:00:00-07	DNA	1.89	100	100	\N	\N
34	24-4_NA	2012-08-23 00:00:00-07	DNA	2.47	100	100	\N	\N
35	24-5_NA	2013-03-21 00:00:00-07	DNA	0.84	200	200	\N	5
36	26_NA	2012-04-24 00:00:00-07	DNA	2.58	50	50	\N	5
37	27_NA	2012-04-24 00:00:00-07	DNA	11.08	50	50	\N	\N
38	28_NA	2012-04-24 00:00:00-07	DNA	20	50	50	\N	\N
39	D28-1_NA	2012-08-23 00:00:00-07	DNA	3.55	100	100	\N	\N
40	D28-2_NA	2012-08-23 00:00:00-07	DNA	5.98	100	100	\N	\N
41	D28-3_NA	2012-08-23 00:00:00-07	DNA	0.31	100	100	\N	\N
42	28-4_NA	2012-08-23 00:00:00-07	DNA	1.17	100	100	\N	\N
43	28-5_NA	2012-08-23 00:00:00-07	DNA	1.03	100	100	\N	\N
44	D29_NA	2012-04-24 00:00:00-07	DNA	20	50	50	\N	\N
45	D31_NA	2012-04-24 00:00:00-07	DNA	20	50	50	\N	\N
46	35_M_NA	\N	DNA	\N	\N	\N	\N	\N
47	D35_NA	2012-04-25 00:00:00-07	DNA	7.42	50	50	\N	\N
48	D36_NA	2012-04-25 00:00:00-07	DNA	20	50	50	\N	\N
49	38_NA	2012-04-25 00:00:00-07	DNA	3.14	50	50	\N	\N
50	D39_NA	2012-04-25 00:00:00-07	DNA	9.94	50	50	\N	\N
51	D40_NA	2012-04-25 00:00:00-07	DNA	20	50	50	\N	\N
52	D41_NA	2012-04-25 00:00:00-07	DNA	20	50	50	\N	\N
53	D43_NA_BC	\N	DNA	20	50	50	\N	\N
54	D43_NA_SCC	\N	DNA	20	50	50	\N	\N
55	D44_NA	\N	DNA	15	50	50	\N	\N
56	D45_NA	\N	DNA	10	50	50	\N	\N
57	D46_NA	\N	DNA	5	50	50	\N	\N
58	D47_NA	\N	DNA	38.3	65	65	\N	\N
59	D48_NA	\N	DNA	20.1	65	65	\N	\N
60	49_M_NA	\N	DNA	\N	\N	\N	\N	\N
61	D49_NA	2015-07-31 00:00:00-07	DNA	35.8	65	65	\N	\N
62	D51_NA	2015-07-31 00:00:00-07	DNA	6.83	65	65	\N	\N
63	D55_NA	2015-07-31 00:00:00-07	DNA	11.9	65	65	\N	\N
64	D56_NA	2015-07-31 00:00:00-07	DNA	10.3	65	65	\N	\N
65	D58_NA	2015-07-31 00:00:00-07	DNA	48.7	65	65	\N	\N
66	D59_NA	2015-07-31 00:00:00-07	DNA	39	65	65	\N	\N
67	D60_NA	2015-07-31 00:00:00-07	DNA	85.2	65	65	\N	\N
68	D61_NA	2015-07-31 00:00:00-07	DNA	41.6	65	65	\N	\N
69	D62_NA	2015-07-31 00:00:00-07	DNA	4.28	65	65	\N	\N
70	D64_NA	2015-07-31 00:00:00-07	DNA	5.68	65	65	\N	\N
71	D65_NA	2015-07-31 00:00:00-07	DNA	44.5	65	65	\N	\N
72	D66_NA	2015-07-31 00:00:00-07	DNA	20.4	65	65	\N	\N
73	D67_NA	2015-07-31 00:00:00-07	DNA	3.21	65	65	\N	\N
74	D68_NA	2015-07-31 00:00:00-07	DNA	36.5	65	65	\N	\N
75	D70_NA	2015-07-31 00:00:00-07	DNA	4.66	65	65	\N	\N
76	D71_NA	2015-07-31 00:00:00-07	DNA	15.1	65	65	\N	\N
77	D72_NA	2015-07-31 00:00:00-07	DNA	9.29	65	65	\N	\N
78	D73_NA	2015-07-31 00:00:00-07	DNA	10	50	50	\N	\N
79	D74_NA	2015-07-31 00:00:00-07	DNA	5	50	50	\N	\N
80	D75_NA	2015-07-31 00:00:00-07	DNA	2	50	50	\N	\N
81	D76_NA	2014-07-22 00:00:00-07	DNA	4.83	50	50	\N	\N
82	DNA-144 Imat B15	\N	DNA	59	230	230	MISC -20oC BOX; MK Cells for the Broad Institute	\N
83	144 Imat B15-2	\N	DNA	18.8	100	100	MISC -20oC BOX; MK Cells for the Broad Institute	\N
84	144aI WT	\N	DNA	206	15	15	\N	\N
85	230 WT	\N	DNA	536	15	15	\N	\N
86	ACL01	2023-02-22 00:00:00-08	DNA	17.2	140	140	3mm punch biopsy	3
87	ACL03	2023-02-22 00:00:00-08	DNA	16.1	140	140	3mm punch biopsy	3
88	ACL05	2023-02-22 00:00:00-08	DNA	12.1	140	140	3mm punch biopsy	3
89	ACL06	2023-02-22 00:00:00-08	DNA	20.3	140	140	3mm punch biopsy	3
90	AF13_212_NA	2012-07-30 00:00:00-07	DNA	\N	\N	\N	\N	\N
91	Algazi_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
92	ALK_Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
93	AM_7_Tumor_NA	2013-08-15 00:00:00-07	DNA	\N	\N	\N	\N	\N
94	AM_9_Tumor_NA	2013-08-15 00:00:00-07	DNA	\N	\N	\N	\N	\N
95	AM_11_Tumor_NA	2013-08-15 00:00:00-07	DNA	\N	\N	\N	\N	\N
96	AM_13_Tumor_NA	2013-08-15 00:00:00-07	DNA	\N	\N	\N	\N	\N
97	AM_14_Tumor_NA	2013-08-15 00:00:00-07	DNA	\N	\N	\N	\N	\N
98	AM2 D-01	\N	DNA	0.39	90	90	\N	\N
99	AM2 D-02	\N	DNA	0.12	90	90	\N	\N
100	AM2 D-03	\N	DNA	0.76	90	90	\N	\N
101	AM2 D-04	\N	DNA	0	0	0	\N	\N
102	AM2 D-05	\N	DNA	0	0	0	\N	\N
103	AM2 D-06	\N	DNA	0	0	0	\N	\N
104	AM2 D-07	\N	DNA	0	0	0	\N	\N
105	AM2 D-08	\N	DNA	0	0	0	\N	\N
106	AM2 D-09	\N	DNA	0	0	0	\N	\N
107	AM2 D-10	\N	DNA	0	0	0	\N	\N
108	AM2 D-11	\N	DNA	0	0	0	\N	\N
109	AM2 D-12	\N	DNA	0	0	0	\N	\N
110	AM2 D-13	\N	DNA	0	0	0	\N	\N
111	AM2 D-14	\N	DNA	0.09	90	90	\N	\N
112	AM2 D-15	\N	DNA	0.11	90	90	\N	\N
113	AM2 D-16	\N	DNA	0.54	90	90	\N	\N
114	AM2 D-17	\N	DNA	0.09	90	90	\N	\N
115	AM2 D-18	\N	DNA	0.05	90	90	\N	\N
116	AM2 D-19	\N	DNA	1.58	90	90	\N	\N
117	AM2 D-20	\N	DNA	0.17	90	90	\N	\N
118	AM2 D-21	\N	DNA	0.48	90	90	\N	\N
119	AM2 D-22	\N	DNA	0.31	90	90	\N	\N
120	AM2 D-23	\N	DNA	0.68	90	90	\N	\N
121	AM2 D-24	\N	DNA	2.4	50	50	\N	\N
122	AM2 D-25	\N	DNA	0.1	90	90	\N	\N
123	AM2 D-26	\N	DNA	1.11	90	90	\N	\N
124	AM2 D-27	\N	DNA	2.85	90	90	\N	\N
125	AM2 D-28	\N	DNA	3.01	90	90	\N	\N
126	AM2 D-29	\N	DNA	4.63	90	90	\N	\N
127	AM2 D-30	\N	DNA	35.3	90	90	\N	\N
128	AM2 D-31	\N	DNA	7.78	90	90	\N	\N
129	AM2 D-32	\N	DNA	4	90	90	\N	\N
130	AM2 D-33	\N	DNA	48.1	90	90	\N	\N
131	AM2 D-34	\N	DNA	116	90	90	\N	\N
132	AM2 D-35	\N	DNA	6.11	90	90	\N	\N
133	AM2 D-36	\N	DNA	95.2	90	90	\N	\N
134	AM2 D-37	2017-12-20 00:00:00-08	DNA	29	50	50	\N	\N
135	AM2 D-38	2017-12-20 00:00:00-08	DNA	110	50	50	\N	\N
136	AM2 D-39	2017-12-20 00:00:00-08	DNA	175.6	50	50	\N	\N
137	AM2 D-40	2017-12-20 00:00:00-08	DNA	54.4	50	50	\N	\N
138	AM2 D-41	2017-12-20 00:00:00-08	DNA	108	50	50	\N	\N
139	AM2 D-42	2017-12-20 00:00:00-08	DNA	50.2	50	50	\N	\N
140	AM2 D-43	2017-12-20 00:00:00-08	DNA	25.6	50	50	\N	\N
141	AM2 D-44	2017-12-20 00:00:00-08	DNA	37.8	50	50	\N	\N
142	AM2 D-45	\N	DNA	1.57	50	50	\N	\N
143	AM2 D-46	\N	DNA	50.6	50	50	\N	\N
144	AM2 D-47	\N	DNA	7.12	50	50	\N	\N
145	AM2 D-48	\N	DNA	55.8	50	50	\N	\N
146	AM2 D-49	\N	DNA	8.48	50	50	\N	\N
147	AM2 D-50	\N	DNA	62.2	50	50	\N	\N
148	AM2 D-51	\N	DNA	15.1	50	50	\N	\N
149	AM2 D-52	\N	DNA	2.84	50	50	\N	\N
150	AM2 D-53	\N	DNA	28.4	50	50	\N	\N
151	AM2 D-54	\N	DNA	20	50	50	\N	\N
152	AM2 D-55	\N	DNA	2.56	50	50	\N	\N
153	AM2 D-56	\N	DNA	58	50	50	\N	\N
154	AM2 D-57	\N	DNA	43.6	50	50	\N	\N
155	AM2 D-58	\N	DNA	58	50	50	\N	\N
156	AM2 D-59	\N	DNA	10.1	50	50	\N	\N
157	AM2 D-60	\N	DNA	75.6	50	50	\N	\N
158	AM2 D-61	\N	DNA	102	50	50	\N	\N
159	AM2 D-62	\N	DNA	6.14	50	50	\N	\N
160	AM2 D-63	\N	DNA	48.8	50	50	\N	\N
161	AM2 D-64	\N	DNA	13.7	50	50	\N	\N
162	AM2 D-65	\N	DNA	60.6	50	50	\N	\N
163	AM2 D-66	\N	DNA	5.56	50	50	\N	\N
164	AM2 D-67	\N	DNA	5.06	50	50	\N	\N
165	AM2 D-68	\N	DNA	12.5	50	50	\N	\N
166	AM2 D-69	\N	DNA	52.4	50	50	\N	\N
167	AM2 D-70	\N	DNA	7.52	50	50	\N	\N
168	AM2 D-71	\N	DNA	23.4	50	50	\N	\N
169	AM2 D-72	\N	DNA	0	0	0	not circled on the slide image	\N
170	AM2 D-73	\N	DNA	35.2	50	50	\N	\N
171	AM2 D-74	\N	DNA	14.7	50	50	\N	\N
172	AM2 D-75	\N	DNA	58.8	50	50	\N	\N
173	AM2 D-76	\N	DNA	49.6	50	50	\N	\N
174	AM2 D-77	\N	DNA	74.4	50	50	\N	\N
175	AM2 D-78	\N	DNA	114	50	50	\N	\N
176	AM2 D-79	\N	DNA	22.6	50	50	\N	\N
177	AM2 D-80	\N	DNA	37.8	50	50	\N	\N
178	AM2 D-81	\N	DNA	17.6	50	50	\N	\N
179	AM2 D-82	\N	DNA	8.68	50	50	\N	\N
180	AM2 D-83	\N	DNA	15.4	50	50	\N	\N
181	AM2 D-84	\N	DNA	41.6	50	50	\N	\N
182	AM2 D-85	\N	DNA	32.6	50	50	\N	\N
183	AM2 D-86	\N	DNA	90	50	50	\N	\N
184	AM2 D-87	\N	DNA	116	50	50	\N	\N
1337	DM-62-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
185	AM2 D-88	\N	DNA	164.4	50	50	\N	\N
186	AM2 D-89	\N	DNA	5.92	50	50	\N	\N
187	AM2 D-90	\N	DNA	30.4	50	50	No DNA left over	\N
188	AM2 D-91	\N	DNA	69.4	50	50	\N	\N
189	AM2 D-92	\N	DNA	15.6	50	50	\N	\N
190	AM2 D-93	\N	DNA	33.4	50	50	\N	\N
191	AM2 D-94	\N	DNA	8.78	50	50	\N	\N
192	AM2 D-95	\N	DNA	15.4	50	50	\N	\N
193	AM2 D-96	\N	DNA	62.8	50	50	\N	\N
194	AM2 D-97	\N	DNA	63.4	50	50	\N	\N
195	AM2 D-98	\N	DNA	91.2	50	50	\N	\N
196	AM2 D-99	\N	DNA	32.2	50	50	\N	\N
197	AM2 D-100	2018-07-30 00:00:00-07	DNA	0.5	50	50	Qubit conc. <0.50 ng/ul	4
198	AM2 D-101	2018-07-30 00:00:00-07	DNA	5.72	50	50	\N	4
199	AM2 D-102	2018-07-30 00:00:00-07	DNA	20	50	50	\N	4
200	AM2 D-103	2018-07-30 00:00:00-07	DNA	43	50	50	\N	4
201	AM2 D-104	2018-07-30 00:00:00-07	DNA	49.8	50	50	\N	4
202	AM2 D-104-1	2020-03-07 00:00:00-08	DNA	8.47	96	96	\N	5
203	AM2 D-105	2018-07-30 00:00:00-07	DNA	4.84	50	50	\N	4
204	AM2 D-106	2018-07-30 00:00:00-07	DNA	0.11	50	50	\N	4
205	AM2 D-107	2018-07-30 00:00:00-07	DNA	108	50	50	\N	4
206	AM2 D-108	2018-07-30 00:00:00-07	DNA	0.83	50	50	\N	4
207	AM2 D-109	2018-07-30 00:00:00-07	DNA	83	50	50	\N	4
208	AM2 D-110	2018-07-30 00:00:00-07	DNA	30.4	50	50	\N	4
209	AM2 D-111	2018-10-30 00:00:00-07	DNA	5.97	48	48	\N	5
210	AM2 D-112	2018-10-30 00:00:00-07	DNA	24.3	48	48	\N	5
211	AM2 D-113	2018-10-30 00:00:00-07	DNA	7.7	48	48	\N	5
212	AM2 D-114	2018-10-30 00:00:00-07	DNA	4.07	48	48	\N	5
213	AM2 D-115	2018-10-30 00:00:00-07	DNA	9.7	48	48	DNA sample missing	5
214	AM2 D-116	2018-11-13 00:00:00-08	DNA	5.07	48	48	\N	5
215	AM2 D-117	2018-11-13 00:00:00-08	DNA	11.4	48	48	\N	5
216	AM2 D-118	2018-10-30 00:00:00-07	DNA	2.86	48	48	\N	5
217	AM2 D-119	2018-11-13 00:00:00-08	DNA	6.84	48	48	\N	5
218	AM2 D-120	2018-10-30 00:00:00-07	DNA	6.22	48	48	\N	5
219	AM2 D-121	2018-10-30 00:00:00-07	DNA	3.04	48	48	\N	5
220	AM2 D-122	2018-10-30 00:00:00-07	DNA	9.58	48	48	\N	5
221	AM2 D-123	2018-10-30 00:00:00-07	DNA	6.74	48	48	\N	5
222	AM2 D-124	2018-11-15 00:00:00-08	DNA	1.54	48	48	\N	5
223	AM2 D-125	2018-10-30 00:00:00-07	DNA	4.03	48	48	\N	5
224	AM2 D-126	2018-11-15 00:00:00-08	DNA	3.58	48	48	AMLP-172 sheared 268 ng	5
225	AM2 D-127	2018-10-30 00:00:00-07	DNA	6.79	48	48	\N	5
226	AM2 D-128	2018-10-30 00:00:00-07	DNA	5.69	48	48	\N	5
227	AM2 D-129	2018-10-30 00:00:00-07	DNA	36.1	48	48	\N	5
228	AM2 D-130	2018-10-30 00:00:00-07	DNA	48.4	48	48	\N	5
229	AM2 D-131	2018-10-30 00:00:00-07	DNA	1.41	48	48	\N	5
230	AM2 D-132	2018-10-30 00:00:00-07	DNA	3.86	48	48	\N	5
231	AM2 D-133	2018-10-30 00:00:00-07	DNA	5.68	48	48	\N	5
232	AM2 D-134	2018-10-30 00:00:00-07	DNA	1	48	48	\N	5
233	AM2 D-135	2018-10-30 00:00:00-07	DNA	47.8	48	48	\N	5
234	AM2 D-136	2018-10-30 00:00:00-07	DNA	3.88	48	48	AMLP-190 sheared 94 ng	5
235	AM2 D-137	2018-10-30 00:00:00-07	DNA	2.6	48	48	\N	5
236	AM2 D-138	2018-10-30 00:00:00-07	DNA	5.77	48	48	\N	5
237	AM2 D-139	2018-10-30 00:00:00-07	DNA	2.24	48	48	\N	5
238	AM2 D-140	2018-10-30 00:00:00-07	DNA	12.4	48	48	\N	5
239	AM2 D-141	2018-10-30 00:00:00-07	DNA	45.1	48	48	\N	5
240	AM2 D-142	2018-10-30 00:00:00-07	DNA	7.7	48	48	\N	5
241	AM2 D-143	2018-10-30 00:00:00-07	DNA	38.7	48	48	\N	5
242	AM2 D-144	2018-11-15 00:00:00-08	DNA	25.5	48	48	\N	5
243	AM2 D-145	2018-11-13 00:00:00-08	DNA	13.2	48	48	\N	5
244	AM2 D-146	2018-11-13 00:00:00-08	DNA	23.3	48	48	\N	5
245	AM2 D-147	2018-11-13 00:00:00-08	DNA	49.5	48	48	\N	5
246	AM2 D-148	2018-11-13 00:00:00-08	DNA	0	48	48	extracted DNA < 0.5 ng/ul	5
247	AM2 D-149	2018-11-13 00:00:00-08	DNA	0	48	48	extracted DNA < 0.5 ng/ul	5
248	AM2 D-150	2018-11-15 00:00:00-08	DNA	39.9	48	48	\N	5
249	AM2 D-151	2018-11-13 00:00:00-08	DNA	1.13	48	48	AMLP-182 sheared 344 ng	5
250	AM2 D-152	2018-11-13 00:00:00-08	DNA	0.32	48	48	\N	5
251	AM2 D-153	2018-11-13 00:00:00-08	DNA	10.8	48	48	AMLP-184 sheared 333ng	5
252	AM2 D-154	2018-11-13 00:00:00-08	DNA	1.91	48	48	AMLP-185 sheared sheared 325 ng	5
253	AM2 D-155	2018-11-15 00:00:00-08	DNA	47.8	48	48	\N	5
254	AM2 D-156	2018-11-15 00:00:00-08	DNA	22.2	48	48	\N	5
255	AM2 D-157	2018-11-15 00:00:00-08	DNA	2.13	48	48	\N	5
256	AM2 D-158	2018-11-15 00:00:00-08	DNA	21.1	48	48	\N	5
257	AM2 D-159	2018-11-15 00:00:00-08	DNA	10.8	48	48	\N	5
258	AM2 D-160	2018-11-15 00:00:00-08	DNA	2.11	48	48	\N	5
259	AM2 D-161	2018-11-15 00:00:00-08	DNA	4.46	48	48	\N	5
260	AM2 D-162	2018-11-15 00:00:00-08	DNA	29.6	48	48	\N	5
261	AM2 D-163	2018-11-13 00:00:00-08	DNA	8.16	48	48	\N	5
262	AM2 D-164	2018-11-13 00:00:00-08	DNA	4.67	48	48	\N	5
263	AM2 D-165	2018-11-13 00:00:00-08	DNA	12.9	48	48	\N	5
264	AM2 D-166	2018-11-13 00:00:00-08	DNA	38.6	48	48	\N	5
265	AM2 D-167	2018-11-13 00:00:00-08	DNA	0.53	48	48	\N	5
1338	DM-63-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
266	AM2 D-168	2018-11-13 00:00:00-08	DNA	0.45	48	48	\N	5
267	AM2 D-169	2018-11-13 00:00:00-08	DNA	1.41	48	48	\N	5
268	AM2 D-170	2018-11-13 00:00:00-08	DNA	0.68	48	48	\N	5
269	AM2 D-171	2018-11-13 00:00:00-08	DNA	1.43	48	48	\N	5
270	AM2 D-172	2018-11-13 00:00:00-08	DNA	2.88	48	48	\N	5
271	AM2 D-173	2018-11-13 00:00:00-08	DNA	1.61	48	48	\N	5
272	AM2 D-174	2018-11-13 00:00:00-08	DNA	33.6	48	48	\N	5
273	AM2 D-175	2018-11-15 00:00:00-08	DNA	14	48	48	\N	5
274	AM2 D-176	2019-11-18 00:00:00-08	DNA	0.3	96	96	\N	5
275	AM2 D-177	2019-11-18 00:00:00-08	DNA	0.09	96	96	\N	5
276	AM2 D-178	2019-11-18 00:00:00-08	DNA	0	96	96	\N	5
277	AM2 D-179	2019-11-18 00:00:00-08	DNA	31.5	96	96	\N	5
278	AM2 D-180	2019-11-18 00:00:00-08	DNA	0.58	96	96	\N	5
279	AM2 D-181	2019-11-18 00:00:00-08	DNA	0.15	96	96	\N	5
280	AM2 D-182	2019-11-18 00:00:00-08	DNA	2.65	96	96	\N	5
281	AM2 D-183	2019-11-18 00:00:00-08	DNA	44	96	96	Has Melanin	5
282	AM2 D-184	2019-11-18 00:00:00-08	DNA	21.9	96	96	\N	5
283	AM2 D-185	2019-11-18 00:00:00-08	DNA	40.1	96	96	\N	5
284	AM2 D-186	2020-01-19 00:00:00-08	DNA	52	96	96	\N	5
285	AM2 D-187	2020-01-19 00:00:00-08	DNA	40.4	96	96	\N	5
286	AM2 D-188	2020-01-23 00:00:00-08	DNA	0.56	96	96	\N	5
287	AM2 D-189	2020-01-23 00:00:00-08	DNA	2.34	96	96	\N	5
288	AM2 D-190	2020-01-23 00:00:00-08	DNA	2.78	96	96	\N	5
289	AM2 D-191	2020-01-23 00:00:00-08	DNA	9.22	96	96	\N	5
290	AM2 D-192	2020-01-23 00:00:00-08	DNA	8.09	96	96	\N	5
291	AM2 D-193	2020-01-23 00:00:00-08	DNA	2.7	192	192	Combined Normal 1 and Normal 2	5
292	AM2 D-194	2020-01-23 00:00:00-08	DNA	3.42	96	96	\N	5
293	AM2 D-195	2020-01-23 00:00:00-08	DNA	2.37	96	96	\N	5
294	AM2 D-196	2020-03-07 00:00:00-08	DNA	2.95	96	96	\N	5
295	AM2 D-199	2020-03-07 00:00:00-08	DNA	1.56	96	96	\N	5
296	AM2 D-200	2020-03-07 00:00:00-08	DNA	0.25	96	96	\N	5
297	AM2 D-201	2020-03-07 00:00:00-08	DNA	0.06	96	96	\N	5
298	AM2 D-202	2020-03-07 00:00:00-08	DNA	16.9	96	96	\N	5
299	AM2 D-203	2020-03-07 00:00:00-08	DNA	12.19	192	192	\N	5
300	AM2 D-205	2020-03-07 00:00:00-08	DNA	4.97	96	96	\N	5
301	AM2 D-206	2020-03-07 00:00:00-08	DNA	0.57	96	96	\N	5
302	AM2 D-207	2020-03-07 00:00:00-08	DNA	11.5	96	96	\N	5
303	AM2 D-208	2020-03-07 00:00:00-08	DNA	4.76	96	96	\N	5
304	AM2 D-210	2020-03-07 00:00:00-08	DNA	0.07	96	96	\N	5
305	AM2 D-211	2020-03-07 00:00:00-08	DNA	1.28	96	96	\N	5
306	AM2 D-212	2020-03-07 00:00:00-08	DNA	0.18	96	96	\N	5
307	AM2 D-213	2020-03-07 00:00:00-08	DNA	1.11	96	96	\N	5
308	AM2 D-214	2020-03-07 00:00:00-08	DNA	0.63	96	96	\N	5
309	AM2 D-215	2020-03-07 00:00:00-08	DNA	40.1	96	96	\N	5
310	AM2 D-216	2020-03-07 00:00:00-08	DNA	0.71	96	96	\N	5
311	AM2 D-217	2020-03-07 00:00:00-08	DNA	0.7	96	96	\N	5
312	AM2 D-218	2020-03-07 00:00:00-08	DNA	20.3	96	96	AMLP-222 (sheared 250 ng)	5
313	AM2 D-219	2020-03-07 00:00:00-08	DNA	22	96	96	\N	5
314	AM2 D-220	2020-03-07 00:00:00-08	DNA	0.62	96	96	\N	5
315	AM2 D-221	2020-03-07 00:00:00-08	DNA	2.37	96	96	\N	5
316	AM2 D-222	2020-03-07 00:00:00-08	DNA	6.75	96	96	\N	5
317	AM2 D-223	2020-03-07 00:00:00-08	DNA	4.16	96	96	\N	5
318	AM2 D-224	2020-03-07 00:00:00-08	DNA	11.9	96	96	\N	5
319	AM2 D-225	2020-07-22 00:00:00-07	DNA	3.25	100	100	\N	6
320	AM2 D-226	2020-07-22 00:00:00-07	DNA	0.68	100	100	\N	6
321	AM2 D-227	2020-07-22 00:00:00-07	DNA	2.06	100	100	\N	6
322	AM2 D-228	2020-07-22 00:00:00-07	DNA	1.63	100	100	\N	6
323	AM2 D-229	2020-07-22 00:00:00-07	DNA	5.12	100	100	\N	6
324	AM2 D-232	2020-07-22 00:00:00-07	DNA	5.25	100	100	\N	6
325	AM2 D-233	2020-07-22 00:00:00-07	DNA	0.85	100	100	\N	6
326	AM2 D-236	2020-07-22 00:00:00-07	DNA	0.72	100	100	\N	6
327	AM2 D-237	2020-07-22 00:00:00-07	DNA	33	100	100	\N	6
328	AM2 D-238	2020-07-22 00:00:00-07	DNA	2.89	100	100	\N	6
329	AM2 D-239	2020-07-22 00:00:00-07	DNA	0.17	100	100	\N	6
330	AM2 D-240	2020-07-22 00:00:00-07	DNA	0.2	100	100	\N	6
331	AM2 D-241	2020-07-22 00:00:00-07	DNA	1.12	100	100	\N	6
332	AM2 D-242	2020-07-22 00:00:00-07	DNA	32	100	100	\N	6
333	AM2 D-243	2020-07-22 00:00:00-07	DNA	0.25	100	100	\N	6
334	AM2 D-244	2020-07-22 00:00:00-07	DNA	1.47	100	100	\N	6
335	AM2 D-245	2020-07-22 00:00:00-07	DNA	0.69	100	100	\N	6
336	AM2 D-246	2020-07-22 00:00:00-07	DNA	0.37	100	100	\N	6
337	AM2 D-247	2020-07-22 00:00:00-07	DNA	0.46	100	100	\N	6
338	AM2 D-248	2020-07-22 00:00:00-07	DNA	0	100	100	\N	6
339	AM2 D-249	2020-07-22 00:00:00-07	DNA	0.3	100	100	\N	6
340	AM2 D-250	2020-07-22 00:00:00-07	DNA	0.38	100	100	\N	6
341	AM2 D-251	2020-07-22 00:00:00-07	DNA	3.23	100	100	\N	6
342	AM2 D-252	2020-07-22 00:00:00-07	DNA	0.64	100	100	\N	6
343	AM2 D-253	2020-07-22 00:00:00-07	DNA	2.1	100	100	\N	6
344	AM2 D-254	2020-07-22 00:00:00-07	DNA	0.62	100	100	\N	6
345	AM2 D-255	2020-07-22 00:00:00-07	DNA	0.19	100	100	\N	6
346	AM2 D-256	2020-11-10 00:00:00-08	DNA	0.1	96	96	\N	6
347	AM2 D-257	2020-11-10 00:00:00-08	DNA	0.29	96	96	\N	6
348	AM2 D-258	2020-11-10 00:00:00-08	DNA	0.21	96	96	\N	6
349	AM2 D-259	2020-11-10 00:00:00-08	DNA	1.86	96	96	\N	6
350	AM2 D-260	2020-11-10 00:00:00-08	DNA	5.11	96	96	\N	6
351	AM2 D-261	2020-11-10 00:00:00-08	DNA	1.25	96	96	\N	6
352	AM2 D-262	2020-11-10 00:00:00-08	DNA	0.44	96	96	\N	6
353	AM2 D-263	2020-11-10 00:00:00-08	DNA	0.28	96	96	\N	6
354	AM2 D-264	2020-11-10 00:00:00-08	DNA	4.07	96	96	\N	6
355	AM2 D-265	2020-11-10 00:00:00-08	DNA	2.55	96	96	\N	6
356	AM2 D-266	2020-11-10 00:00:00-08	DNA	0.62	96	96	\N	6
357	AM2 D-268	2020-11-10 00:00:00-08	DNA	0.13	96	96	\N	6
358	AM2 D-269	2020-11-10 00:00:00-08	DNA	12.6	96	96	\N	6
359	AM2 D-270	2020-11-10 00:00:00-08	DNA	3.26	96	96	\N	6
360	AM2 D-271	2020-11-10 00:00:00-08	DNA	0.37	96	96	\N	6
361	AM2 D-272	2020-11-10 00:00:00-08	DNA	0.75	96	96	\N	6
362	AM2 D-273	2020-11-10 00:00:00-08	DNA	0.67	96	96	\N	6
363	AM2 D-274	2020-11-10 00:00:00-08	DNA	2.36	96	96	\N	6
364	AM2 D-275	2020-11-10 00:00:00-08	DNA	0.38	96	96	\N	6
365	AM2 D-276	2020-11-10 00:00:00-08	DNA	0.2	96	96	\N	6
366	AM2 D-277	2020-11-10 00:00:00-08	DNA	0.13	96	96	\N	6
367	AM2 D-278	2020-11-10 00:00:00-08	DNA	0	96	96	\N	6
368	AM2 D-279	2020-11-10 00:00:00-08	DNA	0	96	96	\N	6
369	AM2 D-280	2020-11-10 00:00:00-08	DNA	0	96	96	\N	6
370	AM2 D-281	2020-12-28 00:00:00-08	DNA	0.59	96	96	\N	6
371	AM2 D-282	2020-12-28 00:00:00-08	DNA	0	96	96	\N	6
372	AM2 D-283	2020-12-28 00:00:00-08	DNA	0.26	96	96	\N	6
373	AM2 D-284	2020-12-28 00:00:00-08	DNA	0.18	96	96	\N	6
374	AM2 D-286	2020-12-28 00:00:00-08	DNA	0	96	96	\N	6
375	AM2 D-287	2020-12-28 00:00:00-08	DNA	1.57	96	96	\N	6
376	AM2 D-288	2020-12-28 00:00:00-08	DNA	0.2	96	96	\N	6
377	AM2 D-289	2020-12-28 00:00:00-08	DNA	0.4	96	96	\N	6
378	AM2 D-291	2020-12-28 00:00:00-08	DNA	0.57	96	96	\N	6
379	AM2 D-293	2021-02-22 00:00:00-08	DNA	1.23	95	95	\N	2
380	AM2 D-294	2020-12-28 00:00:00-08	DNA	11	96	96	\N	6
381	AM2 D-295	2020-12-28 00:00:00-08	DNA	11.4	96	96	\N	6
382	AM2 D-296	2020-12-28 00:00:00-08	DNA	0.81	96	96	\N	6
383	AM2 D-297	2020-12-28 00:00:00-08	DNA	0.18	96	96	\N	6
384	AM2 D-298	2020-12-28 00:00:00-08	DNA	0.83	96	96	\N	6
385	AM2 D-299	2020-12-28 00:00:00-08	DNA	0.3	96	96	\N	6
386	AM2 D-300	2020-12-28 00:00:00-08	DNA	0.13	96	96	\N	6
387	AM2 D-303	2020-12-28 00:00:00-08	DNA	0.05	96	96	\N	6
388	AM2 D-304	2020-12-28 00:00:00-08	DNA	0.26	96	96	\N	6
389	AM2 D-308	2020-12-28 00:00:00-08	DNA	4	96	96	\N	6
390	AM2 D-309	2020-12-28 00:00:00-08	DNA	4.23	96	96	\N	6
391	AM2 D-310	2020-12-28 00:00:00-08	DNA	1.51	96	96	\N	6
392	AM2 D-311	2020-12-28 00:00:00-08	DNA	2.17	96	96	\N	6
393	AM2 D-312	2020-12-28 00:00:00-08	DNA	0.88	96	96	\N	6
394	AM2 D-313	2020-12-28 00:00:00-08	DNA	1.09	96	96	\N	6
395	AM2 D-314	2021-01-05 00:00:00-08	DNA	0	96	96	\N	6
396	AM2 D-316	2021-01-05 00:00:00-08	DNA	9.53	96	96	\N	6
397	AM2 D-317	2021-01-05 00:00:00-08	DNA	2.13	96	96	\N	6
398	AM2 D-318	2021-01-05 00:00:00-08	DNA	10.7	96	96	\N	6
399	AM2 D-319	2021-01-05 00:00:00-08	DNA	0.14	96	96	\N	6
400	AM2 D-320	2021-01-05 00:00:00-08	DNA	0.52	96	96	\N	6
401	AM2 D-321	\N	DNA	0	0	0	\N	\N
402	AM2 D-322	2021-01-05 00:00:00-08	DNA	1.47	96	96	\N	6
403	AM2 D-323	2021-01-05 00:00:00-08	DNA	33.3	96	96	\N	6
404	AM2 D-324	2021-01-05 00:00:00-08	DNA	0.09	96	96	\N	6
405	AM2 D-325	2021-01-05 00:00:00-08	DNA	0.09	96	96	\N	6
406	AM2 D-326	2021-01-05 00:00:00-08	DNA	0	96	96	\N	6
407	AM2 D-327	2021-01-05 00:00:00-08	DNA	0.11	96	96	\N	6
408	AM2 D-328	2021-01-05 00:00:00-08	DNA	5.45	96	96	\N	6
409	AM2 D-329	2021-01-05 00:00:00-08	DNA	2.64	96	96	\N	6
410	AM2 D-330	2021-01-05 00:00:00-08	DNA	0	96	96	\N	6
411	AM2 D-331	2021-01-05 00:00:00-08	DNA	42	96	96	\N	6
412	AM2 D-332	2021-02-21 00:00:00-08	DNA	4.51	95	95	\N	2
413	AM2 D-333	2021-01-05 00:00:00-08	DNA	2.76	96	96	\N	6
414	AM2 D-334	2021-01-05 00:00:00-08	DNA	1.4	96	96	\N	6
415	AM2 D-335	2021-01-05 00:00:00-08	DNA	0.75	96	96	\N	6
416	AM2 D-336	2021-01-05 00:00:00-08	DNA	1.31	96	96	\N	6
417	AM2 D-337	2021-01-05 00:00:00-08	DNA	0.28	96	96	\N	6
418	AM2 D-338	2021-01-05 00:00:00-08	DNA	0.71	96	96	\N	6
419	AM2 D-339	2021-01-05 00:00:00-08	DNA	0.58	96	96	\N	6
420	AM2 D-340	2021-01-05 00:00:00-08	DNA	1.97	96	96	\N	6
421	AM2 D-341	2021-02-22 00:00:00-08	DNA	1.57	95	95	\N	2
422	AM2 D-342	2021-02-22 00:00:00-08	DNA	0.84	95	95	\N	2
423	AM2 D-343	2021-02-22 00:00:00-08	DNA	1.13	95	95	\N	2
424	AM2 D-345	2021-02-22 00:00:00-08	DNA	1	95	95	\N	2
425	AM2 D-347	2021-02-22 00:00:00-08	DNA	5.87	95	95	AMLP-301 sheared 200 ng	2
426	AM2 D-348	2021-02-22 00:00:00-08	DNA	3.24	95	95	\N	2
427	AM2 D-349	2021-03-08 00:00:00-08	DNA	1.68	95	95	\N	2
1339	DM-66-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
428	AM2 D-350	2021-03-08 00:00:00-08	DNA	0.46	95	95	\N	2
429	AM2 D-351	2021-03-08 00:00:00-08	DNA	0.77	95	95	\N	2
430	AM2 D-352	2021-03-08 00:00:00-08	DNA	0.3	95	95	\N	2
431	AM2 D-353	2021-03-08 00:00:00-08	DNA	0.19	95	95	\N	2
432	AM2 D-354	2021-03-08 00:00:00-08	DNA	0.74	95	95	\N	2
433	AM2 D-355	2021-02-22 00:00:00-08	DNA	0.23	95	95	\N	2
434	AM2 D-356	2021-02-22 00:00:00-08	DNA	0.26	95	95	\N	2
435	AM2 D-357	2021-02-22 00:00:00-08	DNA	0.41	95	95	\N	2
436	AM2 D-358	2021-02-22 00:00:00-08	DNA	1.21	95	95	DO NOT USE	2
437	AM2 D-360	2021-03-09 00:00:00-08	DNA	1.2	95	95	45 min incubation at 72oC	2
438	AM2 D-361	2021-03-09 00:00:00-08	DNA	0.77	95	95	45 min incubation at 72oC	2
439	AM2 D-362	2021-03-09 00:00:00-08	DNA	1.22	95	95	45 min incubation at 72oC	2
440	AM2 D-363	2021-03-09 00:00:00-08	DNA	0.65	95	95	45 min incubation at 72oC	2
441	AM2 D-365	2021-03-09 00:00:00-08	DNA	35.3	95	95	45 min incubation at 72oC	2
442	AM2 D-366	2021-03-09 00:00:00-08	DNA	1.44	95	95	45 min incubation at 72oC	2
443	AM2 D-367	2021-03-09 00:00:00-08	DNA	15.4	95	95	45 min incubation at 72oC	2
444	AM2 D-368	2021-03-09 00:00:00-08	DNA	1.65	95	95	45 min incubation at 72oC	2
445	AM2 D-369	2021-02-27 00:00:00-08	DNA	3.07	95	95	45 min incubation at 72oC	2
446	AM2 D-370	2021-02-27 00:00:00-08	DNA	2.83	95	95	45 min incubation at 72oC	2
447	AM2 D-371	2021-02-27 00:00:00-08	DNA	7.46	95	95	45 min incubation at 72oC	2
448	AM2 D-372	2021-02-11 00:00:00-08	DNA	10.5	95	95	30 min incubation at 72oC	2
449	AM2 D-373	2021-02-14 00:00:00-08	DNA	18.6	95	95	45 min incubation at 72oC	2
450	AM2 D-374	2021-02-11 00:00:00-08	DNA	14.8	95	95	60 min incubation at 72oC	2
451	AM2 D-375	2021-02-14 00:00:00-08	DNA	25.5	95	95	75 min incubation at 72oC	2
452	AM2 D-376	2020-02-17 00:00:00-08	DNA	38.1	88	88	\N	6
453	AM2 D-378	2021-02-27 00:00:00-08	DNA	7.53	190	190	45 min incubation at 72oC	2
454	AM2 D-379	2021-02-27 00:00:00-08	DNA	19.5	190	190	45 min incubation at 72oC	2
455	AM2 D-380	2021-02-27 00:00:00-08	DNA	51	190	190	45 min incubation at 72oC	2
456	AM2 D-381	2021-09-06 00:00:00-07	DNA	15.4	88	88	\N	2
457	AM2 D-382	2021-09-06 00:00:00-07	DNA	5.31	88	88	\N	2
458	AM2 D-383	2021-02-11 00:00:00-08	DNA	11.7	95	95	30 min incubation at 72oC	2
459	AM2 D-384	2021-02-14 00:00:00-08	DNA	14.8	95	95	45 min incubation at 72oC	2
460	AM2 D-385	2021-02-11 00:00:00-08	DNA	8.54	95	95	60 min incubation at 72oC	2
461	AM2 D-386	2021-02-14 00:00:00-08	DNA	14.4	95	95	75 min incubation at 72oC	2
462	AM2 D-387	2020-02-17 00:00:00-08	DNA	12.6	88	88	\N	6
463	AM2 D-393	2021-03-01 00:00:00-08	DNA	0	95	95	45 min incubation at 72oC	2
464	AM2 D-394	2021-03-01 00:00:00-08	DNA	0	95	95	45 min incubation at 72oC	2
465	AM2 D-395	2021-03-01 00:00:00-08	DNA	0	95	95	45 min incubation at 72oC	2
466	AM2 D-399	2021-02-27 00:00:00-08	DNA	1.67	190	190	45 min incubation at 72oC	2
467	AM2 D-400	2021-02-27 00:00:00-08	DNA	3.84	95	95	45 min incubation at 72oC	2
468	AM2 D-401	2021-03-01 00:00:00-08	DNA	36.3	190	190	45 min incubation at 72oC	2
469	AM2 D-402	2021-02-27 00:00:00-08	DNA	40.2	95	95	45 min incubation at 72oC	2
470	AM2 D-403	2021-03-01 00:00:00-08	DNA	0.56	95	95	45 min incubation at 72oC	2
471	AM2 D-404	2021-03-01 00:00:00-08	DNA	0.89	95	95	45 min incubation at 72oC	2
472	AM2 D-405	2021-03-01 00:00:00-08	DNA	4.46	95	95	45 min incubation at 72oC	2
473	AM2 D-406	2021-03-01 00:00:00-08	DNA	1.03	95	95	45 min incubation at 72oC	2
474	AM2 D-407	2021-03-01 00:00:00-08	DNA	0.78	95	95	45 min incubation at 72oC	2
475	AM2 D-408	2021-03-01 00:00:00-08	DNA	0.96	95	95	45 min incubation at 72oC	2
476	AM2 D-410	2021-02-04 00:00:00-08	DNA	0.84	95	95	\N	2
477	AM2 D-411	2021-02-03 00:00:00-08	DNA	0.11	88	88	\N	6
478	AM2 D-412	2021-02-04 00:00:00-08	DNA	51	95	95	\N	2
479	AM2 D-413	2021-02-03 00:00:00-08	DNA	38.4	88	88	\N	6
480	AM2 D-414	2021-02-04 00:00:00-08	DNA	7.3	88	88	\N	2
481	AM2 D-415	2021-02-03 00:00:00-08	DNA	2.04	88	88	\N	6
482	AM2 D-419	2021-03-01 00:00:00-08	DNA	3.96	95	95	45 min incubation at 72oC	2
483	AM2 D-420	2021-03-01 00:00:00-08	DNA	2.25	95	95	45 min incubation at 72oC	2
484	AM2 D-421	2021-03-01 00:00:00-08	DNA	1.86	95	95	45 min incubation at 72oC	2
485	AM2 D-422	2021-03-01 00:00:00-08	DNA	35.9	190	190	45 min incubation at 72oC	2
486	AM2 D-423	2021-03-01 00:00:00-08	DNA	11.1	190	190	45 min incubation at 72oC	2
487	AM2 D-425	2021-02-11 00:00:00-08	DNA	1.19	95	95	30 min incubation at 72oC	2
488	AM2 D-426	2021-02-14 00:00:00-08	DNA	2.19	95	95	45 min incubation at 72oC	2
489	AM2 D-427	2021-02-11 00:00:00-08	DNA	1.18	95	95	60 min incubation at 72oC	2
490	AM2 D-428	2021-02-14 00:00:00-08	DNA	1.8	95	95	75 min incubation at 72oC	2
491	AM2 D-429	2020-02-17 00:00:00-08	DNA	1.1	88	88	\N	6
492	AM2 D-430	2021-03-01 00:00:00-08	DNA	2.45	190	190	45 min incubation at 72oC	2
493	AM2 D-431	2021-09-06 00:00:00-07	DNA	23.4	88	88	\N	2
494	AM2 D-433	2021-02-27 00:00:00-08	DNA	6.74	95	95	45 min incubation at 72oC	2
495	AM2 D-434	2021-02-27 00:00:00-08	DNA	1.08	95	95	45 min incubation at 72oC	2
496	AM2 D-435	2021-02-27 00:00:00-08	DNA	2.51	95	95	45 min incubation at 72oC	2
566	AM2 D-509	2022-05-16 00:00:00-07	DNA	2.39	88	88	\N	2
497	AM2 D-436	2021-02-27 00:00:00-08	DNA	1.74	95	95	45 min incubation at 72oC	2
498	AM2 D-437	2021-02-27 00:00:00-08	DNA	1.08	190	190	45 min incubation at 72oC	2
499	AM2 D-438	2021-02-27 00:00:00-08	DNA	12.8	95	95	45 min incubation at 72oC	2
500	AM2 D-439	2021-03-09 00:00:00-08	DNA	0.16	95	95	45 min incubation at 72oC	2
501	AM2 D-440	2021-03-09 00:00:00-08	DNA	0.18	95	95	45 min incubation at 72oC	2
502	AM2 D-441	2021-03-09 00:00:00-08	DNA	7.43	95	95	45 min incubation at 72oC	2
503	AM2 D-443	2021-03-09 00:00:00-08	DNA	1.22	95	95	45 min incubation at 72oC	2
504	AM2 D-444	2021-03-09 00:00:00-08	DNA	0	95	95	45 min incubation at 72oC	2
505	AM2 D-445	2021-03-22 00:00:00-07	DNA	3.59	95	95	45 min incubation at 72oC	2
506	AM2 D-446	2021-03-22 00:00:00-07	DNA	6.14	95	95	45 min incubation at 72oC	2
507	AM2 D-447	2021-03-22 00:00:00-07	DNA	0.61	95	95	45 min incubation at 72oC	2
508	AM2 D-448	2021-03-22 00:00:00-07	DNA	2.62	95	95	45 min incubation at 72oC	2
509	AM2 D-450	2021-03-22 00:00:00-07	DNA	1.44	95	95	45 min incubation at 72oC	2
510	AM2 D-451	2021-03-22 00:00:00-07	DNA	1.06	95	95	45 min incubation at 72oC	2
511	AM2 D-452	2021-03-22 00:00:00-07	DNA	1.89	95	95	45 min incubation at 72oC	2
512	AM2 D-453	2021-04-15 00:00:00-07	DNA	0.73	380	380	45 min incubation at 72oC	2
513	AM2 D-454	2021-05-06 00:00:00-07	DNA	2.4	95	95	45 min incubation at 72oC	2
514	AM2 D-455	2021-05-18 00:00:00-07	DNA	1.68	95	95	45 min incubation at 72oC	2
515	AM2 D-456	2021-05-18 00:00:00-07	DNA	2.95	95	95	45 min incubation at 72oC	2
516	AM2 D-457	2021-05-18 00:00:00-07	DNA	10.2	95	95	45 min incubation at 72oC	2
517	AM2 D-458	2021-05-18 00:00:00-07	DNA	6.65	95	95	45 min incubation at 72oC	2
518	AM2 D-459	2021-05-18 00:00:00-07	DNA	19	95	95	45 min incubation at 72oC	2
519	AM2 D-460	2021-05-18 00:00:00-07	DNA	9.94	95	95	45 min incubation at 72oC	2
520	AM2 D-461	2021-05-18 00:00:00-07	DNA	7.76	95	95	45 min incubation at 72oC	2
521	AM2 D-462	2021-05-18 00:00:00-07	DNA	1.73	95	95	45 min incubation at 72oC	2
522	AM2 D-463	2021-05-18 00:00:00-07	DNA	2.6	95	95	45 min incubation at 72oC	2
523	AM2 D-464	2021-05-18 00:00:00-07	DNA	5.47	95	95	45 min incubation at 72oC	2
524	AM2 D-465	2021-05-18 00:00:00-07	DNA	6.25	95	95	45 min incubation at 72oC	2
525	AM2 D-466	2021-05-18 00:00:00-07	DNA	1.25	95	95	45 min incubation at 72oC	2
526	AM2 D-467	2021-05-25 00:00:00-07	DNA	0.55	190	190	45 min incubation at 72oC	2
527	AM2 D-468	2021-05-25 00:00:00-07	DNA	7.74	95	95	45 min incubation at 72oC	2
528	AM2 D-470	2021-05-25 00:00:00-07	DNA	1.85	190	190	45 min incubation at 72oC	2
529	AM2 D-471	2021-05-25 00:00:00-07	DNA	1.05	95	95	45 min incubation at 72oC	2
530	AM2 D-472	2021-05-25 00:00:00-07	DNA	1.58	95	95	45 min incubation at 72oC	2
531	AM2 D-473	2021-05-25 00:00:00-07	DNA	0	0	0	45 min incubation at 72oC	2
532	AM2 D-474	2021-05-25 00:00:00-07	DNA	1.37	95	95	45 min incubation at 72oC	2
533	AM2 D-475	2021-05-25 00:00:00-07	DNA	2.78	95	95	45 min incubation at 72oC	2
534	AM2 D-476	2021-05-25 00:00:00-07	DNA	1.27	95	95	45 min incubation at 72oC	2
535	AM2 D-477	2021-05-25 00:00:00-07	DNA	0.27	95	95	45 min incubation at 72oC	2
536	AM2 D-478	2021-05-25 00:00:00-07	DNA	5.19	95	95	45 min incubation at 72oC	2
537	AM2 D-479	2021-05-25 00:00:00-07	DNA	0.48	95	95	45 min incubation at 72oC	2
538	AM2 D-480	2021-05-25 00:00:00-07	DNA	0.64	95	95	45 min incubation at 72oC	2
539	AM2 D-481 (P041_03B)	2021-07-29 00:00:00-07	DNA	1.09	48	48	DIN:2.4, 10 x (1-48 mm^2; 15 um)\n16 ng input	7
540	AM2 D-482 (P041_03C)	2021-07-29 00:00:00-07	DNA	4.85	48	48	DIN:1.9, 10 x (1-48 mm^2; 15 um)\n90 ng input	7
541	AM2 D-483 (P041_03D)	2021-07-29 00:00:00-07	DNA	2.21	48	48	DIN: 2.2, 10 x (1-48 mm^2; 15 um)\n40.0 ng input	7
542	AM2 D-484	2021-09-06 00:00:00-07	DNA	0.44	88	88	\N	2
543	AM2 D-485	2021-09-06 00:00:00-07	DNA	8.12	176	176	Has Melanin	2
544	AM2 D-486-1	2021-09-06 00:00:00-07	DNA	9.07	88	88	Use this sample for LP	2
545	AM2 D-486-2	2021-09-06 00:00:00-07	DNA	0.23	88	88	\N	2
546	AM2 D-487	2021-09-10 00:00:00-07	DNA	1.61	88	88	\N	2
547	AM2 D-488	2021-09-21 00:00:00-07	DNA	3.6	88	88	No DNA left over	2
548	AM2 D-489	2021-09-21 00:00:00-07	DNA	22.4	88	88	\N	2
549	AM2 D-490	2022-01-17 00:00:00-08	DNA	4.84	88	88	\N	2
550	AM2 D-491	2022-01-17 00:00:00-08	DNA	11	88	88	\N	2
551	AM2 D-492	2022-01-17 00:00:00-08	DNA	1.61	88	88	\N	2
552	AM2 D-493	2022-01-17 00:00:00-08	DNA	1.31	88	88	\N	2
553	AM2 D-494	2022-01-17 00:00:00-08	DNA	2.14	88	88	\N	2
554	AM2 D-495	2022-01-17 00:00:00-08	DNA	1.36	88	88	\N	2
555	AM2 D-496	2022-01-17 00:00:00-08	DNA	4.8	88	88	\N	2
556	AM2 D-498	2022-05-16 00:00:00-07	DNA	0.14	88	88	\N	2
557	AM2 D-499	2022-05-16 00:00:00-07	DNA	0.16	88	88	\N	2
558	AM2 D-500	2022-05-16 00:00:00-07	DNA	4.65	88	88	\N	2
559	AM2 D-501	2022-05-16 00:00:00-07	DNA	2.17	88	88	\N	2
560	AM2 D-503	2022-05-16 00:00:00-07	DNA	10.2	88	88	\N	2
561	AM2 D-504	2022-05-16 00:00:00-07	DNA	2.28	88	88	\N	2
562	AM2 D-505	2022-05-16 00:00:00-07	DNA	3.25	88	88	\N	2
563	AM2 D-506	2022-05-16 00:00:00-07	DNA	0.57	88	88	\N	2
564	AM2 D-507	2022-05-16 00:00:00-07	DNA	2.24	88	88	\N	2
565	AM2 D-508	2022-05-16 00:00:00-07	DNA	4.85	88	88	\N	2
567	AM2 D-510	2022-05-16 00:00:00-07	DNA	5.74	88	88	\N	2
568	AM2 D-511	2022-05-16 00:00:00-07	DNA	1.73	88	88	\N	2
569	AM2 D-512	2022-05-16 00:00:00-07	DNA	4.34	88	88	\N	2
570	AM2 D-513	2023-02-08 00:00:00-08	DNA	6.47	180	180	\N	2
571	AM2 D-514	2023-02-08 00:00:00-08	DNA	9.46	180	180	\N	2
572	AM2 D-516	2023-02-08 00:00:00-08	DNA	5.72	180	180	\N	2
573	AM2 D-517	2023-02-08 00:00:00-08	DNA	0.98	180	180	\N	2
574	AM2 D-518	2023-02-08 00:00:00-08	DNA	2.56	80	80	\N	2
575	AM2 D-519	2023-02-08 00:00:00-08	DNA	0.56	80	80	\N	2
576	AM2 D-520	\N	DNA	0	0	0	\N	2
577	AM2 D-521	2023-02-08 00:00:00-08	DNA	2.54	180	180	\N	2
578	AM2 D-522	2023-02-08 00:00:00-08	DNA	0.87	80	80	\N	2
579	AM2 D-523	2023-02-08 00:00:00-08	DNA	8.63	180	180	\N	2
580	AM2 D-524	2023-02-08 00:00:00-08	DNA	4.1	180	180	\N	2
581	AM2 D-525	2023-02-08 00:00:00-08	DNA	1.51	180	180	\N	2
582	AM2 D-526	2023-02-08 00:00:00-08	DNA	1.58	80	80	\N	2
583	AM2 D-527	\N	DNA	0	0	0	\N	2
584	AM2 D-528	2023-02-14 00:00:00-08	DNA	0.34	176	176	\N	2
585	AM2 D-531	2023-02-14 00:00:00-08	DNA	3.76	88	88	\N	2
586	AM2 D-532	2023-02-14 00:00:00-08	DNA	13.4	176	176	\N	2
587	AM2 D-533	\N	DNA	0	0	0	\N	2
588	AM2 D-534	\N	DNA	0	0	0	\N	2
589	AM2 D-535	\N	DNA	0	0	0	\N	2
590	AM2 D-536	2023-03-29 00:00:00-07	DNA	2.52	80	80	\N	2
591	AM2 D-537	2023-03-29 00:00:00-07	DNA	6.92	80	80	\N	2
592	AM2 D-538	2023-06-07 00:00:00-07	DNA	51	88	88	\N	6
593	AM2 D-539	2023-06-07 00:00:00-07	DNA	12.5	88	88	\N	6
594	AM2 D-540	2023-06-07 00:00:00-07	DNA	6.37	88	88	\N	6
595	AM2 D-541	2023-06-07 00:00:00-07	DNA	33.6	88	88	\N	6
596	AM2 D-544	2023-10-10 00:00:00-07	DNA	53	182	182	\N	2
597	AM2 D-547	2023-10-10 00:00:00-07	DNA	0.35	182	182	\N	2
598	AM2 D-550	2023-10-10 00:00:00-07	DNA	1.7	88	88	\N	2
599	AM2 D-554	2023-10-10 00:00:00-07	DNA	1.94	200	200	\N	2
600	AM2 D-557	2023-10-10 00:00:00-07	DNA	2.39	88	88	\N	2
601	AM2 D-560	2023-10-10 00:00:00-07	DNA	0.63	88	88	\N	2
602	AM2 D-563	2023-10-10 00:00:00-07	DNA	0.85	88	88	\N	2
603	AM2 R-225	2020-07-25 00:00:00-07	RNA	11.8	20	20	\N	6
604	AM2 R-226	2020-07-25 00:00:00-07	RNA	30.1	20	20	\N	6
605	AM2 R-227	2020-07-25 00:00:00-07	RNA	74	20	20	DV200: 30-50	6
606	AM2 R-228	2020-07-25 00:00:00-07	RNA	61	20	20	DV200: 50-70	6
607	AM2 R-229	2020-07-25 00:00:00-07	RNA	91	20	20	\N	6
608	AM2 R-232	2020-07-25 00:00:00-07	RNA	446	20	20	\N	6
609	AM2 R-233	2020-07-25 00:00:00-07	RNA	33	20	20	\N	6
610	AM2 R-236	2020-07-25 00:00:00-07	RNA	47.4	20	20	\N	6
611	AM2 R-237	2020-07-25 00:00:00-07	RNA	956	20	20	\N	6
612	AM2 R-238	2020-07-25 00:00:00-07	RNA	27.1	20	20	\N	6
613	AM2 R-239	2020-07-25 00:00:00-07	RNA	5.22	20	20	\N	6
614	AM2 R-240	2020-07-25 00:00:00-07	RNA	13.4	20	20	\N	6
615	AM2 R-241	2020-07-25 00:00:00-07	RNA	23	20	20	\N	6
616	AM2 R-242	2020-07-25 00:00:00-07	RNA	476	20	20	\N	6
617	AM2 R-243	2020-07-25 00:00:00-07	RNA	5.58	20	20	\N	6
618	AM2 R-244	2020-07-25 00:00:00-07	RNA	35.3	20	20	\N	6
619	AM2 R-245	2020-07-25 00:00:00-07	RNA	55	20	20	\N	6
620	AM2 R-246	2020-07-25 00:00:00-07	RNA	13.3	20	20	\N	6
621	AM2 R-247	2020-07-25 00:00:00-07	RNA	5.67	20	20	\N	6
622	AM2 R-248	2020-07-25 00:00:00-07	RNA	0	20	20	\N	6
623	AM2 R-249	2020-07-25 00:00:00-07	RNA	14.8	20	20	\N	6
624	AM2 R-250	2020-07-25 00:00:00-07	RNA	44.5	20	20	\N	6
625	AM2 R-251	2020-07-25 00:00:00-07	RNA	29.8	20	20	\N	6
626	AM2 R-252	2020-07-25 00:00:00-07	RNA	22.7	20	20	\N	6
627	AM2 R-253	2020-07-25 00:00:00-07	RNA	24.8	20	20	\N	6
628	AM2 R-254	2020-07-25 00:00:00-07	RNA	15.9	20	20	\N	6
629	AM2 R-255	2020-07-25 00:00:00-07	RNA	0	20	20	\N	6
630	AM2 R-256	2020-11-11 00:00:00-08	RNA	9.61	20	20	\N	6
631	AM2 R-257	2020-11-11 00:00:00-08	RNA	69	20	20	\N	6
632	AM2 R-258	2020-11-11 00:00:00-08	RNA	11.7	20	20	\N	6
633	AM2 R-259	2020-11-11 00:00:00-08	RNA	32.9	20	20	\N	6
634	AM2 R-260	2020-11-11 00:00:00-08	RNA	28.7	20	20	\N	6
635	AM2 R-261	2020-11-11 00:00:00-08	RNA	0	20	20	\N	6
636	AM2 R-262	2020-11-11 00:00:00-08	RNA	3.62	20	20	\N	6
637	AM2 R-263	2020-11-11 00:00:00-08	RNA	5.68	20	20	\N	6
638	AM2 R-264	2020-11-11 00:00:00-08	RNA	79	20	20	\N	6
639	AM2 R-265	2020-11-11 00:00:00-08	RNA	7.29	20	20	\N	6
640	AM2 R-266	2020-11-11 00:00:00-08	RNA	6.55	20	20	\N	6
641	AM2 R-268	2020-11-11 00:00:00-08	RNA	10.3	20	20	\N	6
642	AM2 R-269	2020-11-11 00:00:00-08	RNA	46.6	20	20	\N	6
643	AM2 R-270	2020-11-11 00:00:00-08	RNA	69	20	20	\N	6
644	AM2 R-271	2020-11-11 00:00:00-08	RNA	34.1	20	20	\N	6
645	AM2 R-272	2020-11-11 00:00:00-08	RNA	28	20	20	\N	6
646	AM2 R-273	2020-11-11 00:00:00-08	RNA	30.9	20	20	DV200: 50-70	6
647	AM2 R-274	2020-11-11 00:00:00-08	RNA	31.3	20	20	\N	6
1340	DM-67-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
648	AM2 R-275	2020-11-11 00:00:00-08	RNA	20.3	20	20	\N	6
649	AM2 R-276	2020-11-11 00:00:00-08	RNA	10.4	20	20	\N	6
650	AM2 R-277	2020-11-11 00:00:00-08	RNA	2.84	20	20	\N	6
651	AM2 R-278	2020-11-11 00:00:00-08	RNA	0	20	20	\N	6
652	AM2 R-279	2020-11-11 00:00:00-08	RNA	0	20	20	\N	6
653	AM2 R-280	2020-11-11 00:00:00-08	RNA	5.35	20	20	\N	6
654	AM2 R-281	2021-01-02 00:00:00-08	RNA	7.06	20	20	\N	6
655	AM2 R-282	2021-01-02 00:00:00-08	RNA	2.4	20	20	\N	6
656	AM2 R-283	2021-01-02 00:00:00-08	RNA	7.7	20	20	\N	6
657	AM2 R-284	2021-01-02 00:00:00-08	RNA	2.99	20	20	\N	6
658	AM2 R-286	2021-01-02 00:00:00-08	RNA	6.99	20	20	\N	6
659	AM2 R-287	2021-01-02 00:00:00-08	RNA	51	20	20	\N	6
660	AM2 R-288	2021-01-02 00:00:00-08	RNA	21.3	20	20	\N	6
661	AM2 R-289	2021-01-02 00:00:00-08	RNA	10.5	20	20	\N	6
662	AM2 R-291	2021-01-02 00:00:00-08	RNA	55	20	20	\N	6
663	AM2 R-293	2021-02-22 00:00:00-08	RNA	9.76	48	48	\N	1
664	AM2 R-294	2021-01-02 00:00:00-08	RNA	0	20	20	\N	6
665	AM2 R-295	2021-01-02 00:00:00-08	RNA	0	20	20	\N	6
666	AM2 R-296	2021-01-02 00:00:00-08	RNA	28.7	20	20	\N	6
667	AM2 R-297	2021-01-02 00:00:00-08	RNA	5.36	20	20	\N	6
668	AM2 R-298	2021-01-02 00:00:00-08	RNA	38.7	20	20	\N	6
669	AM2 R-299	2021-01-02 00:00:00-08	RNA	17.6	20	20	\N	6
670	AM2 R-300	2021-01-02 00:00:00-08	RNA	9.51	20	20	\N	6
671	AM2 R-303	2021-01-02 00:00:00-08	RNA	0	20	20	\N	6
672	AM2 R-304	2021-01-02 00:00:00-08	RNA	2.51	20	20	\N	6
673	AM2 R-308	2021-01-02 00:00:00-08	RNA	22.5	20	20	\N	6
674	AM2 R-309	2021-01-02 00:00:00-08	RNA	58	20	20	\N	6
675	AM2 R-310	2021-01-02 00:00:00-08	RNA	48.9	20	20	\N	6
676	AM2 R-311	2021-01-02 00:00:00-08	RNA	52	20	20	\N	6
677	AM2 R-312	2021-01-02 00:00:00-08	RNA	41.7	20	20	\N	6
678	AM2 R-313	2021-01-02 00:00:00-08	RNA	17.4	20	20	\N	6
679	AM2 R-314	2021-01-09 00:00:00-08	RNA	6.84	20	20	\N	6
680	AM2 R-316	2021-01-09 00:00:00-08	RNA	28	20	20	\N	6
681	AM2 R-317	2021-01-09 00:00:00-08	RNA	56	20	20	\N	6
682	AM2 R-318	2021-01-09 00:00:00-08	RNA	25.7	20	20	\N	6
683	AM2 R-319	2021-01-09 00:00:00-08	RNA	6.46	20	20	\N	6
684	AM2 R-320	2021-01-09 00:00:00-08	RNA	22	20	20	\N	6
685	AM2 R-321	\N	RNA	0	0	0	\N	\N
686	AM2 R-322	2021-01-09 00:00:00-08	RNA	3.98	20	20	\N	6
687	AM2 R-323	2021-01-09 00:00:00-08	RNA	17.8	20	20	\N	6
688	AM2 R-324	2021-01-09 00:00:00-08	RNA	0	20	20	\N	6
689	AM2 R-325	2021-01-09 00:00:00-08	RNA	0	20	20	\N	6
690	AM2 R-326	2021-01-09 00:00:00-08	RNA	0	20	20	\N	6
691	AM2 R-327	2021-01-09 00:00:00-08	RNA	5.03	20	20	\N	6
692	AM2 R-328	2021-01-09 00:00:00-08	RNA	23.9	20	20	\N	6
693	AM2 R-329	2021-01-09 00:00:00-08	RNA	14.9	20	20	\N	6
694	AM2 R-330	2021-01-09 00:00:00-08	RNA	4.06	20	20	\N	6
695	AM2 R-331	2021-01-09 00:00:00-08	RNA	93	20	20	\N	6
696	AM2 R-333	2021-01-09 00:00:00-08	RNA	43.2	20	20	\N	6
697	AM2 R-334	2021-01-09 00:00:00-08	RNA	31	20	20	\N	6
698	AM2 R-335	2021-01-09 00:00:00-08	RNA	12.8	20	20	\N	6
699	AM2 R-336	2021-01-09 00:00:00-08	RNA	20.1	20	20	\N	6
700	AM2 R-337	2021-01-09 00:00:00-08	RNA	9.15	20	20	\N	6
701	AM2 R-338	2021-01-09 00:00:00-08	RNA	8.8	20	20	\N	6
702	AM2 R-339	2021-01-09 00:00:00-08	RNA	8.9	20	20	\N	6
703	AM2 R-340	2021-01-09 00:00:00-08	RNA	19.7	20	20	\N	6
704	AM2 R-341	2021-02-22 00:00:00-08	RNA	6.66	48	48	\N	1
705	AM2 R-342	2021-02-22 00:00:00-08	RNA	2.3	48	48	\N	1
706	AM2 R-343	2021-02-22 00:00:00-08	RNA	0	48	48	\N	1
707	AM2 R-345	2021-02-22 00:00:00-08	RNA	4.45	48	48	\N	1
708	AM2 R-347	2021-02-22 00:00:00-08	RNA	22.9	48	48	\N	1
709	AM2 R-348	2021-02-22 00:00:00-08	RNA	18.6	48	48	\N	1
710	AM2 R-350	2021-03-09 00:00:00-08	RNA	0	48	48	\N	1
711	AM2 R-351	2021-03-09 00:00:00-08	RNA	0	48	48	\N	1
712	AM2 R-352	2021-03-09 00:00:00-08	RNA	2	48	48	\N	1
713	AM2 R-353	2021-03-09 00:00:00-08	RNA	2.1	48	48	\N	1
714	AM2 R-354	2021-03-09 00:00:00-08	RNA	9.56	48	48	\N	1
715	AM2 R-355	2021-02-22 00:00:00-08	RNA	5.83	48	48	\N	1
716	AM2 R-356	2021-02-22 00:00:00-08	RNA	3.52	48	48	\N	1
717	AM2 R-357	2021-02-22 00:00:00-08	RNA	7.59	48	48	\N	1
718	AM2 R-358	2021-02-22 00:00:00-08	RNA	4.29	48	48	DO NOT USE	1
719	AM2 R-361	2021-03-09 00:00:00-08	RNA	7.28	48	48	45 min incubation at 72oC	1
720	AM2 R-363	2021-03-09 00:00:00-08	RNA	9.31	48	48	45 min incubation at 72oC	1
721	AM2 R-370	2021-02-27 00:00:00-08	RNA	18.5	48	48	45 min incubation at 72oC	1
722	AM2 R-371	2021-02-27 00:00:00-08	RNA	38.1	48	48	45 min incubation at 72oC	1
723	AM2 R-372	2021-02-11 00:00:00-08	RNA	37.4	48	48	30 min incubation at 72oC	1
724	AM2 R-373	2021-02-14 00:00:00-08	RNA	35.9	48	48	45 min incubation at 72oC	1
725	AM2 R-374	2021-02-11 00:00:00-08	RNA	45.4	48	48	60 min incubation at 72oC	1
726	AM2 R-375	2021-02-14 00:00:00-08	RNA	54	48	48	75 min incubation at 72oC	1
1341	DM-69-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
727	AM2 R-376	2020-02-17 00:00:00-08	RNA	219	20	20	\N	6
728	AM2 R-379	2021-02-27 00:00:00-08	RNA	20.5	144	144	45 min incubation at 72oC	1
729	AM2 R-380	2021-02-27 00:00:00-08	RNA	46.9	96	96	45 min incubation at 72oC	1
730	AM2 R-381	2021-09-06 00:00:00-07	RNA	27.4	48	48	\N	1
731	AM2 R-382	2021-09-06 00:00:00-07	RNA	5.31	48	48	\N	1
732	AM2 R-383	2021-02-11 00:00:00-08	RNA	46.7	48	48	30 min incubation at 72oC	1
733	AM2 R-384	2021-02-14 00:00:00-08	RNA	45.1	48	48	45 min incubation at 72oC	1
734	AM2 R-385	2021-02-11 00:00:00-08	RNA	44	48	48	60 min incubation at 72oC	1
735	AM2 R-386	2021-02-14 00:00:00-08	RNA	46.3	48	48	75 min incubation at 72oC	1
736	AM2 R-387	2020-02-17 00:00:00-08	RNA	81	20	20	\N	6
737	AM2 R-393	2021-03-01 00:00:00-08	RNA	0	48	48	45 min incubation at 72oC	1
738	AM2 R-394	2021-03-01 00:00:00-08	RNA	0	48	48	45 min incubation at 72oC	1
739	AM2 R-395	2021-03-01 00:00:00-08	RNA	0	48	48	45 min incubation at 72oC	1
740	AM2 R-400	2021-02-27 00:00:00-08	RNA	21.1	48	48	45 min incubation at 72oC	1
741	AM2 R-401	2021-03-01 00:00:00-08	RNA	72	96	96	45 min incubation at 72oC	1
742	AM2 R-402	2021-02-27 00:00:00-08	RNA	38.1	48	48	45 min incubation at 72oC	1
743	AM2 R-403	2021-03-01 00:00:00-08	RNA	20	48	48	45 min incubation at 72oC	1
744	AM2 R-404	2021-03-01 00:00:00-08	RNA	4.68	48	48	45 min incubation at 72oC	1
745	AM2 R-405	2021-03-01 00:00:00-08	RNA	12.2	48	48	45 min incubation at 72oC	1
746	AM2 R-408	2021-03-01 00:00:00-08	RNA	0	48	48	45 min incubation at 72oC	1
747	AM2 R-410	2021-02-04 00:00:00-08	RNA	0	48	48	120 min incubation at 72oC	1
748	AM2 R-411	2021-02-03 00:00:00-08	RNA	3.12	20	20	120 min incubation at 72oC	6
749	AM2 R-412	2021-02-04 00:00:00-08	RNA	25	48	48	120 min incubation at 72oC	1
750	AM2 R-413	2021-02-03 00:00:00-08	RNA	544	20	20	120 min incubation at 72oC	6
751	AM2 R-414	2021-02-04 00:00:00-08	RNA	0	48	48	120 min incubation at 72oC	1
752	AM2 R-415	2021-02-03 00:00:00-08	RNA	6.97	20	20	120 min incubation at 72oC	6
753	AM2 R-419	2021-03-01 00:00:00-08	RNA	25.2	48	48	45 min incubation at 72oC	1
754	AM2 R-420	2021-03-01 00:00:00-08	RNA	16.5	48	48	45 min incubation at 72oC	1
755	AM2 R-422	2021-03-01 00:00:00-08	RNA	81	96	96	45 min incubation at 72oC	1
756	AM2 R-423	2021-03-01 00:00:00-08	RNA	42.2	96	96	45 min incubation at 72oC	1
757	AM2 R-425	2021-02-11 00:00:00-08	RNA	4.57	48	48	30 min incubation at 72oC	1
758	AM2 R-426	2021-02-14 00:00:00-08	RNA	6.22	48	48	45 min incubation at 72oC	1
759	AM2 R-427	2021-02-11 00:00:00-08	RNA	5.14	48	48	60 min incubation at 72oC	1
760	AM2 R-428	2021-02-14 00:00:00-08	RNA	6.84	48	48	75 min incubation at 72oC	1
761	AM2 R-429	2020-02-17 00:00:00-08	RNA	3.81	20	20	\N	6
762	AM2 R-431	2021-09-06 00:00:00-07	RNA	15.9	48	48	\N	1
763	AM2 R-433	2021-02-27 00:00:00-08	RNA	16.4	48	48	45 min incubation at 72oC	1
764	AM2 R-434	2021-02-27 00:00:00-08	RNA	8.82	48	48	45 min incubation at 72oC	1
765	AM2 R-435	2021-02-27 00:00:00-08	RNA	7.53	48	48	45 min incubation at 72oC	1
766	AM2 R-436	2021-02-27 00:00:00-08	RNA	11.5	48	48	45 min incubation at 72oC	1
767	AM2 R-438	2021-02-27 00:00:00-08	RNA	14.8	48	48	45 min incubation at 72oC	1
768	AM2 R-445	2021-03-22 00:00:00-07	RNA	22.2	48	48	45 min incubation at 72oC	1
769	AM2 R-446	2021-03-22 00:00:00-07	RNA	25.8	48	48	45 min incubation at 72oC	1
770	AM2 R-447	2021-03-22 00:00:00-07	RNA	10.1	48	48	45 min incubation at 72oC	1
771	AM2 R-448	2021-03-22 00:00:00-07	RNA	24.5	48	48	45 min incubation at 72oC	1
772	AM2 R-450	2021-03-22 00:00:00-07	RNA	7.08	48	48	45 min incubation at 72oC	1
773	AM2 R-451	2021-03-22 00:00:00-07	RNA	10.2	48	48	45 min incubation at 72oC	1
774	AM2 R-452	2021-03-22 00:00:00-07	RNA	19.1	48	48	45 min incubation at 72oC	1
775	AM2 R-453	2021-04-15 00:00:00-07	RNA	17.3	96	96	45 min incubation at 72oC	1
776	AM2 R-454	2021-05-06 00:00:00-07	RNA	14.7	48	48	45 min incubation at 72oC	1
777	AM2 R-455	2021-05-18 00:00:00-07	RNA	13.3	45	45	45 min incubation at 72oC	1
778	AM2 R-456	2021-05-18 00:00:00-07	RNA	9.99	45	45	45 min incubation at 72oC	1
779	AM2 R-457	2021-05-18 00:00:00-07	RNA	42.8	45	45	45 min incubation at 72oC	1
780	AM2 R-458	2021-05-18 00:00:00-07	RNA	11.7	45	45	45 min incubation at 72oC	1
781	AM2 R-459	2021-05-18 00:00:00-07	RNA	47.5	45	45	45 min incubation at 72oC	1
782	AM2 R-460	2021-05-18 00:00:00-07	RNA	9.94	45	45	45 min incubation at 72oC	1
783	AM2 R-461	2021-05-18 00:00:00-07	RNA	10.7	45	45	45 min incubation at 72oC	1
784	AM2 R-462	2021-05-18 00:00:00-07	RNA	3.37	45	45	45 min incubation at 72oC	1
785	AM2 R-463	2021-05-18 00:00:00-07	RNA	2.69	45	45	45 min incubation at 72oC	1
786	AM2 R-464	2021-05-18 00:00:00-07	RNA	11.2	45	45	45 min incubation at 72oC	1
787	AM2 R-465	2021-05-18 00:00:00-07	RNA	8.88	45	45	45 min incubation at 72oC	1
788	AM2 R-466	2021-05-18 00:00:00-07	RNA	2.58	45	45	45 min incubation at 72oC	1
789	AM2 R-467	2021-05-25 00:00:00-07	RNA	2.5	90	90	45 min incubation at 72oC	1
790	AM2 R-468	2021-05-25 00:00:00-07	RNA	11.7	45	45	45 min incubation at 72oC	1
791	AM2 R-470	2021-05-25 00:00:00-07	RNA	8.52	90	90	45 min incubation at 72oC	1
792	AM2 R-471	2021-05-25 00:00:00-07	RNA	4.56	45	45	45 min incubation at 72oC	1
793	AM2 R-472	2021-05-25 00:00:00-07	RNA	6.14	45	45	45 min incubation at 72oC	1
794	AM2 R-473	2021-05-25 00:00:00-07	RNA	0	0	0	45 min incubation at 72oC	1
795	AM2 R-474	2021-05-25 00:00:00-07	RNA	3.91	45	45	45 min incubation at 72oC	1
796	AM2 R-475	2021-05-25 00:00:00-07	RNA	2.59	45	45	45 min incubation at 72oC	1
797	AM2 R-476	2021-05-25 00:00:00-07	RNA	0	45	45	45 min incubation at 72oC	1
798	AM2 R-477	2021-05-25 00:00:00-07	RNA	0	45	45	45 min incubation at 72oC	1
799	AM2 R-478	2021-05-25 00:00:00-07	RNA	7.94	45	45	45 min incubation at 72oC	1
800	AM2 R-479	2021-05-25 00:00:00-07	RNA	6.85	45	45	45 min incubation at 72oC	1
801	AM2 R-480	2021-05-25 00:00:00-07	RNA	8.17	45	45	45 min incubation at 72oC	1
802	AM2 R-484	2021-09-06 00:00:00-07	RNA	3.31	48	48	\N	1
803	AM2 R-485	2021-09-06 00:00:00-07	RNA	0	48	48	\N	1
804	AM2 R-486-1	2021-09-06 00:00:00-07	RNA	9.7	48	48	\N	1
805	AM2 R-486-2	2021-09-06 00:00:00-07	RNA	4.66	48	48	\N	1
806	AM2 R-487	2021-09-10 00:00:00-07	RNA	11.3	48	48	\N	1
807	AM2 R-488	2021-09-21 00:00:00-07	RNA	19.6	48	48	\N	1
808	AM2 R-489	2021-09-21 00:00:00-07	RNA	27.5	48	48	\N	1
809	AM2 R-490	2022-01-17 00:00:00-08	RNA	10.9	48	48	\N	1
810	AM2 R-491	2022-01-17 00:00:00-08	RNA	25.6	48	48	\N	1
811	AM2 R-492	2022-01-17 00:00:00-08	RNA	3.13	48	48	\N	1
812	AM2 R-493	2022-01-17 00:00:00-08	RNA	5.34	48	48	\N	1
813	AM2 R-494	2022-01-17 00:00:00-08	RNA	4.21	48	48	\N	1
814	AM2 R-495	2022-01-17 00:00:00-08	RNA	7	48	48	\N	1
815	AM2 R-496	2022-01-17 00:00:00-08	RNA	7.75	48	48	\N	1
816	AM2 R-498	2022-05-16 00:00:00-07	RNA	2.2	48	48	\N	1
817	AM2 R-499	2022-05-16 00:00:00-07	RNA	2.4	48	48	\N	1
818	AM2 R-500	2022-05-16 00:00:00-07	RNA	24.6	48	48	\N	1
819	AM2 R-501	2022-05-16 00:00:00-07	RNA	9.23	48	48	\N	1
820	AM2 R-503	2022-05-16 00:00:00-07	RNA	15.8	48	48	\N	1
821	AM2 R-504	2022-05-16 00:00:00-07	RNA	8.31	48	48	\N	1
822	AM2 R-505	2022-05-16 00:00:00-07	RNA	6.4	48	48	\N	1
823	AM2 R-506	2022-05-16 00:00:00-07	RNA	5.41	48	48	\N	1
824	AM2 R-507	2022-05-16 00:00:00-07	RNA	8.4	48	48	\N	1
825	AM2 R-508	2022-05-16 00:00:00-07	RNA	10	48	48	\N	1
826	AM2 R-509	2022-05-16 00:00:00-07	RNA	4.88	48	48	\N	1
827	AM2 R-510	2022-05-16 00:00:00-07	RNA	11.5	48	48	\N	1
828	AM2 R-511	2022-05-16 00:00:00-07	RNA	8.79	48	48	\N	1
829	AM2 R-512	2022-05-16 00:00:00-07	RNA	12.4	48	48	\N	1
830	AM2 R-513	2023-02-08 00:00:00-08	RNA	6.47	80	80	\N	1
831	AM2 R-514	2023-02-08 00:00:00-08	RNA	9.46	80	80	\N	1
832	AM2 R-516	2023-02-08 00:00:00-08	RNA	16.1	80	80	\N	1
833	AM2 R-517	2023-02-08 00:00:00-08	RNA	8.66	80	80	\N	1
834	AM2 R-518	2023-02-08 00:00:00-08	RNA	18.2	40	40	\N	1
835	AM2 R-519	2023-02-08 00:00:00-08	RNA	6.52	40	40	\N	1
836	AM2 R-520	\N	RNA	0	0	0	\N	1
837	AM2 R-521	2023-02-08 00:00:00-08	RNA	21.7	80	80	\N	1
838	AM2 R-522	2023-02-08 00:00:00-08	RNA	9.99	40	40	\N	1
839	AM2 R-523	2023-02-08 00:00:00-08	RNA	0	80	80	\N	1
840	AM2 R-524	2023-02-08 00:00:00-08	RNA	0	80	80	\N	1
841	AM2 R-525	2023-02-08 00:00:00-08	RNA	13.3	80	80	\N	1
842	AM2 R-526	2023-02-08 00:00:00-08	RNA	21.9	40	40	\N	1
843	AM2 R-527	\N	RNA	0	0	0	\N	1
844	AM2 R-528	2023-02-14 00:00:00-08	RNA	0.99	70	70	\N	1
845	AM2 R-531	2023-02-14 00:00:00-08	RNA	15.8	40	40	\N	1
846	AM2 R-532	2023-02-14 00:00:00-08	RNA	11.8	80	80	\N	1
847	AM2 R-536	2023-03-29 00:00:00-07	RNA	5.64	40	40	\N	1
848	AM2 R-537	2023-03-29 00:00:00-07	RNA	6.78	40	40	\N	1
849	AM2 R-538	2023-06-07 00:00:00-07	RNA	83	18	18	\N	6
850	AM2 R-539	2023-06-07 00:00:00-07	RNA	24.5	18	18	\N	6
851	AM2 R-540	2023-06-07 00:00:00-07	RNA	8.41	18	18	\N	6
852	AM2 R-541	2023-06-07 00:00:00-07	RNA	52	18	18	\N	6
853	BB008_CGH10-013_NA	\N	DNA	\N	\N	\N	FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	\N
854	BB008_CGH11-036_NA	\N	DNA	\N	\N	\N	FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	\N
855	BB008_CGH11-153_NA	\N	DNA	\N	\N	\N	FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	\N
856	BB008_CGH11-386_NA	\N	DNA	\N	\N	\N	FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	\N
857	BB008_CGH12-047_NA	\N	DNA	\N	\N	\N	FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	\N
858	BB008_HW2NC_NA	2012-09-20 00:00:00-07	DNA	\N	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	5
859	BB008_HW2TC_NA	\N	DNA	\N	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
860	BB008_HW8NC_NA	\N	DNA	\N	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
861	BB008_HW8TC_NA	\N	DNA	\N	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
862	BB008_HW9-NB_NA	\N	DNA	\N	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
863	BB008_HW9TC_NA	\N	DNA	\N	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
864	BB008_Kit 227 Acral WT_NA	\N	DNA	\N	\N	\N	Alyssa Kit mutations.  Same template was used to go into BB007, BB004. Understanding run to run variation.  Influence of LM-PCR cycle reduction 	\N
1059	CGH16-062	2017-07-10 00:00:00-07	DNA	4.9	50	50	\N	\N
865	BB008_LAL-L1_NA	\N	DNA	\N	\N	\N	N5_15 and N5_16 are the exact same template done in duplicate with two different barcodes	\N
866	BB008_LAL-L2_NA	\N	DNA	\N	\N	\N	N5_15 and N5_16 are the exact same template done in duplicate with two different barcodes	\N
867	BB008_NB2107_NA	\N	DNA	\N	\N	\N	Cell Line DNA received from Patricia Brafford, Wistar Institute	\N
868	BB008_WM3211_NA	\N	DNA	\N	\N	\N	Cell Line DNA received from Patricia Brafford, Wistar Institute	\N
869	BB09_Bivona_L7_NA	2012-12-03 00:00:00-08	DNA	106	100	100	\N	\N
870	BB09_Bivona_L8_NA	2012-12-03 00:00:00-08	DNA	44.8	100	100	\N	\N
871	BB09_Bivona_L9_NA	2012-12-03 00:00:00-08	DNA	22.8	100	100	\N	\N
872	BB09_Bivona_L10_NA	2012-12-03 00:00:00-08	DNA	42.3	100	100	\N	\N
873	BB09_Bivona_L11_NA	2012-12-03 00:00:00-08	DNA	56.6	100	100	\N	\N
874	BB09_CGH11_029_NA	2012-09-21 00:00:00-07	DNA	244	100	100	\N	5
875	BB09_CGH11_045_NA	2012-09-21 00:00:00-07	DNA	254	100	100	\N	5
876	BB09_CGH11_092_NA	2012-09-21 00:00:00-07	DNA	734	100	100	\N	5
877	BB09_CGH11_125_NA	2012-09-21 00:00:00-07	DNA	136	100	100	\N	5
878	BB09_CGH11_194_NA	2012-09-21 00:00:00-07	DNA	74	100	100	\N	5
879	BB09_HW3_N_NA	\N	DNA	\N	\N	\N	\N	\N
880	BB09_HW3_T_NA	\N	DNA	\N	\N	\N	\N	\N
881	BB09_HW4_N_NA	\N	DNA	\N	\N	\N	\N	\N
882	BB09_HW4_T_NA	\N	DNA	\N	\N	\N	\N	\N
883	BB09_HW6_ND_NA	\N	DNA	\N	\N	\N	\N	\N
884	BB09_HW6_TD_NA	\N	DNA	\N	\N	\N	\N	\N
885	Bivona_L_17_NA	\N	DNA	\N	\N	\N	 Patient Treated with EGFR TK1	\N
886	Bivona_L_1_NA	\N	DNA	\N	\N	\N	\N	\N
887	Bivona_L_18_NA	\N	DNA	\N	\N	\N	 Patient Treated with EGFR TK1	\N
888	Bivona_L_19_NA	\N	DNA	\N	\N	\N	 Patient Treated with EGFR TK1	\N
889	Bivona_L2_NA	\N	DNA	\N	\N	\N	\N	\N
890	Bivona_L3_NA	\N	DNA	\N	\N	\N	\N	\N
891	Bivona_L4_NA	\N	DNA	\N	\N	\N	\N	\N
892	Bivona_L5_NA	\N	DNA	\N	\N	\N	\N	\N
893	Bivona_L6_NA	\N	DNA	\N	\N	\N	\N	\N
894	bMV_10_0206_NA	\N	DNA	\N	\N	\N	\N	\N
895	BN_M1_NA	\N	DNA	\N	\N	\N	\N	\N
896	BN_M2_NA	\N	DNA	\N	\N	\N	\N	\N
897	BN_N1_NA	\N	DNA	\N	\N	\N	\N	\N
898	BN_N2_NA	\N	DNA	\N	\N	\N	\N	\N
899	BND-001	2019-02-20 00:00:00-08	DNA	2.2	48	48	\N	5
900	BND-002	2019-02-20 00:00:00-08	DNA	2.8	48	48	\N	5
901	BND-003	2019-02-20 00:00:00-08	DNA	3.9	48	48	\N	5
902	BND-004	2019-02-20 00:00:00-08	DNA	1.1	48	48	\N	5
903	BND-005	2019-02-20 00:00:00-08	DNA	0.6	48	48	\N	5
904	BND-006	2019-02-20 00:00:00-08	DNA	1.1	48	48	\N	5
905	BND-007	2019-02-20 00:00:00-08	DNA	1.1	48	48	\N	5
906	BND-008	2019-02-20 00:00:00-08	DNA	0.8	48	48	\N	5
907	BND-009	2019-02-20 00:00:00-08	DNA	2	48	48	\N	5
908	BND-010	2019-02-20 00:00:00-08	DNA	0.2	48	48	\N	5
909	BND-011	2019-02-20 00:00:00-08	DNA	13.2	48	48	\N	5
910	BND-012	2019-02-20 00:00:00-08	DNA	1.6	48	48	\N	5
911	BTK01	2023-02-22 00:00:00-08	DNA	0.41	140	140	3mm punch biopsy	3
912	BTK03	2023-02-22 00:00:00-08	DNA	17.2	140	140	3mm punch biopsy	3
913	BTK05	2023-02-22 00:00:00-08	DNA	16.4	140	140	3mm punch biopsy	3
914	BTK06	2023-02-22 00:00:00-08	DNA	0.55	140	140	3mm punch biopsy	3
915	CGH_11_361_NA	\N	DNA	\N	\N	\N	NTRK1	\N
916	CGH_11_366_NA	\N	DNA	\N	\N	\N	NTRK1	\N
917	CGH_11_376_NA	\N	DNA	\N	\N	\N	BRAF	\N
918	CGH_11_388_NA	\N	DNA	\N	\N	\N	NTRK1	\N
919	CGH_11_422_NA	\N	DNA	\N	\N	\N	BRAF	\N
920	CGH_12_016_NA	\N	DNA	\N	\N	\N	BRAF	\N
921	CGH10_16_NA	\N	DNA	\N	\N	\N	\N	\N
922	CGH10_17_NA	\N	DNA	\N	\N	\N	\N	\N
923	CGH10_020_NA	\N	DNA	\N	\N	\N	NTRK1	\N
924	CGH10_049_NA	\N	DNA	\N	\N	\N	NTRK1	\N
925	CGH10_058_NA	\N	DNA	\N	\N	\N	NTRK3	\N
926	CGH10-028_NA	\N	DNA	\N	\N	\N	\N	\N
927	CGH10-045_NA	\N	DNA	\N	\N	\N	\N	\N
928	CGH10-058_NA	\N	DNA	\N	\N	\N	\N	\N
929	CGH10-062_NA	\N	DNA	\N	\N	\N	\N	\N
930	CGH11_020_NA	\N	DNA	\N	\N	\N	NTRK1	\N
931	CGH11_035_NA	\N	DNA	\N	\N	\N	\N	\N
932	CGH11_60_NA	\N	DNA	\N	\N	\N	\N	\N
933	CGH11_078_NA	\N	DNA	\N	\N	\N	NTRK1	\N
934	CGH11_080_NA	\N	DNA	\N	\N	\N	NTRK1	\N
935	CGH11_091_NA	\N	DNA	\N	\N	\N	\N	\N
936	CGH11_109_NA	\N	DNA	\N	\N	\N	\N	\N
937	CGH11_252_NA	\N	DNA	\N	\N	\N	\N	\N
938	CGH11_281_NA	\N	DNA	\N	\N	\N	BRAF	\N
939	CGH11_283_NA	\N	DNA	\N	\N	\N	NTRK3	\N
940	CGH11_292_NA	\N	DNA	\N	\N	\N	\N	\N
941	CGH11_305_NA	\N	DNA	\N	\N	\N	\N	\N
942	CGH11_310_NA	\N	DNA	\N	\N	\N	\N	\N
943	CGH11_319_NA	\N	DNA	\N	\N	\N	\N	\N
944	CGH11_343_NA	\N	DNA	\N	\N	\N	\N	\N
945	CGH11_348_NA	\N	DNA	\N	\N	\N	\N	\N
946	CGH11_410_NA	\N	DNA	\N	\N	\N	\N	\N
947	CGH11_424_NA	\N	DNA	\N	\N	\N	\N	\N
948	CGH11-011_NA	\N	DNA	\N	\N	\N	\N	\N
949	CGH11-035_NA	\N	DNA	\N	\N	\N	\N	\N
950	CGH11-045_NA	2017-06-27 00:00:00-07	DNA	4.2	50	50	\N	\N
951	CGH11-072_NA	\N	DNA	\N	\N	\N	\N	\N
952	CGH11-087_NA	\N	DNA	\N	\N	\N	\N	\N
953	CGH11-089_NA	\N	DNA	\N	\N	\N	\N	\N
954	CGH11-092	2017-06-27 00:00:00-07	DNA	6.85	50	50	\N	\N
955	CGH11-098-D	\N	DNA	10.3	50	50	DNA from Dermpath/Swapna	\N
956	CGH11-115_NA	\N	DNA	\N	\N	\N	\N	\N
957	CGH11-147_NA	\N	DNA	\N	\N	\N	\N	\N
958	CGH11-158_NA	\N	DNA	\N	\N	\N	\N	\N
959	CGH11-166_NA	\N	DNA	\N	\N	\N	\N	\N
960	CGH11-172_NA	\N	DNA	\N	\N	\N	\N	\N
961	CGH11-184_NA	\N	DNA	\N	\N	\N	\N	\N
962	CGH11-194_NA	\N	DNA	\N	\N	\N	\N	\N
963	CGH11-224_NA	\N	DNA	\N	\N	\N	\N	\N
964	CGH11-229_NA	2013-07-10 00:00:00-07	DNA	204	100	100	\N	5
965	CGH11-231_NA	2013-07-10 00:00:00-07	DNA	710	100	100	\N	5
966	CGH11-232_NA	2013-07-10 00:00:00-07	DNA	139	100	100	\N	5
1060	CGH16-071	2017-07-10 00:00:00-07	DNA	4.7	50	50	\N	\N
967	CGH11-237_NA	2013-07-10 00:00:00-07	DNA	93.1	100	100	\N	5
968	CGH11-252_NA	\N	DNA	\N	\N	\N	\N	\N
969	CGH11-259_NA	2013-07-10 00:00:00-07	DNA	471	100	100	\N	5
970	CGH11-268	2017-06-27 00:00:00-07	DNA	6.21	50	50	\N	5
971	CGH11-282	2017-06-27 00:00:00-07	DNA	6.95	50	50	\N	5
972	CGH11-294	2017-06-27 00:00:00-07	DNA	7.22	50	50	\N	5
973	CGH11-315_NA	\N	DNA	\N	\N	\N	\N	\N
974	CGH11-339_NA	\N	DNA	\N	\N	\N	\N	\N
975	CGH11-386_DNA	2017-06-27 00:00:00-07	DNA	4.24	50	50	\N	\N
976	CGH11-399	2017-06-27 00:00:00-07	DNA	2.59	50	50	\N	\N
977	CGH11-402	2017-06-27 00:00:00-07	DNA	5.75	50	50	\N	\N
978	CGH11-404_NA	\N	DNA	\N	\N	\N	\N	\N
979	CGH11-409_NA	\N	DNA	\N	\N	\N	\N	\N
980	CGH12_026_NA	\N	DNA	\N	\N	\N	\N	\N
981	CGH12_039_NA	2012-07-24 00:00:00-07	DNA	145	100	100	\N	\N
982	CGH12_040_NA	2012-07-24 00:00:00-07	DNA	920	100	100	\N	\N
983	CGH12_053_NA	2012-07-24 00:00:00-07	DNA	120	100	100	\N	\N
984	CGH12_056_NA	2012-07-24 00:00:00-07	DNA	236	100	100	\N	\N
985	CGH12_058_NA	\N	DNA	\N	\N	\N	\N	\N
986	CGH12_135_NA	\N	DNA	\N	\N	\N	NTRK1	\N
987	CGH12_161_NA	\N	DNA	\N	\N	\N	NTRK1	\N
988	CGH12_224_NA	\N	DNA	\N	\N	\N	\N	\N
989	CGH12_317_NA	\N	DNA	\N	\N	\N	NTRK3 | Barcode mismatch comment in note	\N
990	CGH12_343_NA	\N	DNA	\N	\N	\N	NTRK3	\N
991	CGH12-039-D	\N	DNA	7.34	50	50	DNA from Dermpath/Swapna	\N
992	CGH12-043_NA	\N	DNA	\N	\N	\N	\N	\N
993	CGH12-055	2017-06-27 00:00:00-07	DNA	4.39	50	50	\N	\N
994	CGH12-056-D	\N	DNA	6.14	50	50	DNA from Dermpath/Swapna	\N
995	CGH12-058	\N	DNA	41.6	10	10	DNA from Dermpath/Swapna	\N
996	CGH12-067	\N	DNA	29.52	10	10	DNA from Dermpath/Swapna	\N
997	CGH12-092-D	\N	DNA	8.42	50	50	DNA from Dermpath/Swapna	\N
998	CGH12-104_NA	\N	DNA	\N	\N	\N	\N	\N
999	CGH12-109	\N	DNA	25	10	10	From Swapna	5
1000	CGH12-124_NA	\N	DNA	\N	\N	\N	\N	\N
1001	CGH12-191	2017-06-27 00:00:00-07	DNA	18.3	50	50	\N	\N
1002	CGH12-273	2017-06-27 00:00:00-07	DNA	6.43	50	50	\N	\N
1003	CGH12-280	\N	DNA	25	10	10	\N	5
1004	CGH12-301	\N	DNA	41.6	10	10	DNA from Dermpath/Swapna	\N
1005	CGH12-345_NA	\N	DNA	\N	\N	\N	NTRK1	\N
1006	CGH12-347_NA	\N	DNA	\N	\N	\N	NTRK2	\N
1007	CGH13-003_NA	\N	DNA	\N	\N	\N	BRAF	\N
1008	CGH13-009_NA	\N	DNA	\N	\N	\N	NTRK1	\N
1009	CGH13-011_NA	\N	DNA	\N	\N	\N	BRAF	\N
1010	CGH13-033_NA	\N	DNA	\N	\N	\N	NTRK1	\N
1011	CGH13-034_NA	\N	DNA	\N	\N	\N	NTRK1?	\N
1012	CGH13-041_NA	\N	DNA	\N	\N	\N	NTRK3	\N
1013	CGH13-044_NA	\N	DNA	\N	\N	\N	NTRK3	\N
1014	CGH13-046_NA	\N	DNA	\N	\N	\N	BRAF	\N
1015	CGH13-058_NA	\N	DNA	\N	\N	\N	NTRK3	\N
1016	CGH13-159	2017-06-27 00:00:00-07	DNA	5.16	50	50	\N	\N
1017	CGH13-321	2017-06-27 00:00:00-07	DNA	4.24	50	50	\N	\N
1018	CGH13-340	2017-06-27 00:00:00-07	DNA	8.27	50	50	\N	\N
1019	CGH14-032	2017-06-27 00:00:00-07	DNA	7.55	50	50	\N	\N
1020	CGH14-050	\N	DNA	31.6	10	10	DNA from Dermpath/Swapna	\N
1021	CGH14-059_NA	\N	DNA	\N	\N	\N	\N	\N
1022	CGH14-083-D	\N	DNA	5.02	50	50	DNA from Dermpath/Swapna	\N
1023	CGH14-119	2017-06-27 00:00:00-07	DNA	6.09	50	50	\N	\N
1024	CGH14-144	2017-06-27 00:00:00-07	DNA	5.86	50	50	\N	\N
1025	CGH14-145	\N	DNA	25	10	10	\N	5
1026	CGH14-147	\N	DNA	31.44	10	10	DNA from Dermpath/Swapna	\N
1027	CGH14-181	2017-06-27 00:00:00-07	DNA	10.8	50	50	\N	\N
1028	CGH14-286	2017-06-27 00:00:00-07	DNA	8.64	50	50	\N	\N
1029	CGH14-293	2017-06-27 00:00:00-07	DNA	9.5	50	50	\N	\N
1030	CGH14-328	2017-06-27 00:00:00-07	DNA	5.65	50	50	\N	\N
1031	CGH14-341-D	\N	DNA	1.89	50	50	DNA from Dermpath/Swapna	\N
1032	CGH14-348	\N	DNA	25	10	10	\N	5
1033	CGH15-043	2017-07-10 00:00:00-07	DNA	4.8	50	50	\N	\N
1034	CGH15-064	2017-07-10 00:00:00-07	DNA	6.8	50	50	\N	\N
1035	CGH15-081	2017-07-10 00:00:00-07	DNA	5.5	50	50	\N	\N
1036	CGH15-082	2017-07-10 00:00:00-07	DNA	4.8	50	50	\N	\N
1037	CGH15-090	2017-07-10 00:00:00-07	DNA	6.4	50	50	\N	\N
1038	CGH15-109-D	\N	DNA	7.88	50	50	DNA from Dermpath/Swapna	\N
1039	CGH15-115	2017-07-10 00:00:00-07	DNA	7.6	50	50	\N	\N
1040	CGH15-139	2017-07-10 00:00:00-07	DNA	3.7	50	50	\N	\N
1041	CGH15-151	2017-07-10 00:00:00-07	DNA	3.7	50	50	\N	\N
1042	CGH15-163	2017-07-10 00:00:00-07	DNA	6.1	50	50	\N	\N
1043	CGH15-176	2017-07-10 00:00:00-07	DNA	10.8	50	50	\N	\N
1044	CGH15-206	2017-07-10 00:00:00-07	DNA	5	50	50	\N	\N
1045	CGH15-210	2017-07-10 00:00:00-07	DNA	5.7	50	50	\N	\N
1046	CGH15-211	2017-07-10 00:00:00-07	DNA	17.6	50	50	\N	\N
1047	CGH15-246	2017-07-10 00:00:00-07	DNA	4.3	50	50	\N	\N
1048	CGH15-249	\N	DNA	28.96	10	10	DNA from Dermpath/Swapna	\N
1049	CGH15-253	2017-07-10 00:00:00-07	DNA	4.6	50	50	\N	\N
1050	CGH15-263	2017-07-10 00:00:00-07	DNA	5.9	50	50	\N	\N
1051	CGH16-002	2017-07-10 00:00:00-07	DNA	29.2	50	50	\N	\N
1052	CGH16-023	2017-07-10 00:00:00-07	DNA	7.5	50	50	\N	\N
1053	CGH16-025	2017-07-10 00:00:00-07	DNA	8.4	50	50	\N	\N
1054	CGH16-032	2017-07-10 00:00:00-07	DNA	12.8	50	50	\N	\N
1055	CGH16-035	2017-07-10 00:00:00-07	DNA	4.2	50	50	\N	\N
1056	CGH16-038	2017-07-10 00:00:00-07	DNA	26.6	50	50	\N	\N
1057	CGH16-053	2017-07-10 00:00:00-07	DNA	5.6	50	50	\N	\N
1058	CGH16-054	2017-07-10 00:00:00-07	DNA	6.1	50	50	\N	\N
1061	CGH16-087	2017-07-10 00:00:00-07	DNA	8.6	50	50	\N	\N
1062	CGH16-089	2017-07-10 00:00:00-07	DNA	3.9	50	50	\N	\N
1063	CGH16-093	2017-07-10 00:00:00-07	DNA	6.2	50	50	\N	\N
1064	CGH16-097	2017-07-10 00:00:00-07	DNA	8.1	50	50	\N	\N
1065	CGH16-105	2017-07-10 00:00:00-07	DNA	12.1	50	50	\N	\N
1066	CGH16-117	2017-07-10 00:00:00-07	DNA	24.4	50	50	\N	\N
1067	CGH16-123	2017-07-10 00:00:00-07	DNA	15.2	50	50	\N	\N
1068	CGH16-130	2017-07-10 00:00:00-07	DNA	6.2	50	50	\N	\N
1069	CGH16-136	2017-07-10 00:00:00-07	DNA	5.9	50	50	\N	\N
1070	CGH16-172-2	2017-07-10 00:00:00-07	DNA	6.1	50	50	\N	\N
1071	CGH16-179	2017-07-10 00:00:00-07	DNA	4	50	50	\N	\N
1072	CGH16-198	2017-07-10 00:00:00-07	DNA	6.5	50	50	\N	\N
1073	CGH16-200	\N	DNA	25	10	10	\N	5
1074	CGH16-209	2017-07-10 00:00:00-07	DNA	5	50	50	\N	\N
1075	CGH16-215	2017-07-10 00:00:00-07	DNA	6.6	50	50	\N	\N
1076	CGH16-222	2017-07-10 00:00:00-07	DNA	7.4	50	50	\N	\N
1077	CGH16-250	2017-07-10 00:00:00-07	DNA	3	50	50	\N	\N
1078	CGH16-254	2017-07-10 00:00:00-07	DNA	3.2	50	50	\N	\N
1079	CGH17-001	2017-07-10 00:00:00-07	DNA	3.9	50	50	\N	\N
1080	CGH17-003	2017-07-10 00:00:00-07	DNA	7.1	50	50	\N	\N
1081	CGH17-008	2017-07-10 00:00:00-07	DNA	6.6	50	50	\N	\N
1082	CGH17-015	2017-07-10 00:00:00-07	DNA	2.1	50	50	\N	\N
1083	CGH17-017	2017-07-10 00:00:00-07	DNA	2.4	50	50	\N	\N
1084	CGH17-021	2017-07-10 00:00:00-07	DNA	4	50	50	\N	\N
1085	CGH17-024	2017-07-10 00:00:00-07	DNA	4.2	50	50	\N	\N
1086	CGH17-026	2017-07-10 00:00:00-07	DNA	3.8	50	50	\N	\N
1087	CGH17-031	2017-07-10 00:00:00-07	DNA	5	50	50	\N	\N
1088	CGH17-033	2017-07-10 00:00:00-07	DNA	3.2	50	50	\N	\N
1089	CGH17-039	2017-07-10 00:00:00-07	DNA	3	50	50	\N	\N
1090	CGH17-052	2017-07-10 00:00:00-07	DNA	2.6	50	50	\N	\N
1091	CGH17-058	2017-07-10 00:00:00-07	DNA	4.3	50	50	\N	\N
1092	CGH17-076	2017-07-10 00:00:00-07	DNA	4.7	50	50	\N	\N
1093	CGH17-083	2017-07-10 00:00:00-07	DNA	4	50	50	\N	\N
1094	CGH17-095	2017-07-10 00:00:00-07	DNA	2.9	50	50	\N	\N
1095	CGH17-097	2017-07-10 00:00:00-07	DNA	2.1	50	50	\N	\N
1096	CGH17-104	2017-07-10 00:00:00-07	DNA	4.4	50	50	\N	\N
1097	CGH17-135	\N	DNA	25	10	10	\N	5
1098	CGH17-240	\N	DNA	25	10	10	\N	5
1099	CGH18-012-D	\N	DNA	6.78	50	50	DNA from Dermpath/Swapna	\N
1100	CGH18-137	\N	DNA	25	10	10	\N	5
1101	CGH18-139	\N	DNA	25	10	10	\N	5
1102	CGH19-097_1.00	\N	DNA	31.92	10	10	Atypical Spitz tumor-nodule	\N
1103	CGH19-097_2	2019-08-17 00:00:00-07	DNA	22.2	96	96	Atypical Spitz tumor-nodule	\N
1104	CHG11-402_NA	\N	DNA	\N	\N	\N	\N	\N
1105	CHG12-335_NA	\N	DNA	\N	\N	\N	BRAF	\N
1106	CMD-01	2019-05-17 00:00:00-07	DNA	11.5	48	48	\N	5
1107	CMD-02	2019-05-17 00:00:00-07	DNA	0.89	48	48	\N	5
1108	CM D-03	2019-05-17 00:00:00-07	DNA	2.6	48	48	\N	5
1109	CM D-04	2019-05-17 00:00:00-07	DNA	13.8	48	48	\N	5
1110	CM D-05	2019-05-17 00:00:00-07	DNA	7.47	48	48	\N	5
1111	CM D-06	2019-05-17 00:00:00-07	DNA	29	48	48	\N	5
1112	CM D-07	2019-05-17 00:00:00-07	DNA	9.2	48	48	\N	5
1113	CM D-08	2019-05-17 00:00:00-07	DNA	45.2	48	48	\N	5
1114	CM D-09	2019-05-17 00:00:00-07	DNA	3.74	48	48	\N	5
1115	CM D-10	2019-05-17 00:00:00-07	DNA	8.84	48	48	\N	5
1116	CM D-11	2019-05-17 00:00:00-07	DNA	2.94	48	48	\N	5
1117	CM D-12	2019-05-17 00:00:00-07	DNA	1	48	48	\N	5
1118	CM D-13	2019-05-17 00:00:00-07	DNA	14.9	48	48	\N	5
1119	CM D-14	2019-05-17 00:00:00-07	DNA	10.6	48	48	\N	5
1120	CM D-15	2019-05-17 00:00:00-07	DNA	2.74	48	48	\N	5
1121	CM D-16	2019-05-17 00:00:00-07	DNA	15.8	48	48	\N	5
1122	CM D-17	2019-05-17 00:00:00-07	DNA	9.32	48	48	\N	5
1123	CM D-18	2019-05-17 00:00:00-07	DNA	0.47	48	48	Not sufficient for LP	5
1124	CM D-19	2019-05-17 00:00:00-07	DNA	25.6	48	48	\N	5
1125	CM D-20	2019-05-17 00:00:00-07	DNA	0.06	48	48	Not sufficient for LP	5
1126	CM D-21	2019-05-17 00:00:00-07	DNA	1.15	48	48	\N	5
1127	CM D-22	2019-05-17 00:00:00-07	DNA	6.22	48	48	\N	5
1128	CM D-23	2019-05-17 00:00:00-07	DNA	9.66	48	48	\N	5
1129	CM D-24	2019-05-17 00:00:00-07	DNA	18.9	48	48	\N	5
1130	CM D-25	2019-05-19 00:00:00-07	DNA	48.2	48	48	\N	5
1131	CM D-26	2019-05-19 00:00:00-07	DNA	5.45	48	48	\N	5
1132	CM D-27	2019-05-19 00:00:00-07	DNA	15.9	48	48	\N	5
1133	CM D-28	2019-05-19 00:00:00-07	DNA	0.39	48	48	Not sufficient for LP	5
1134	CM D-29	2019-05-19 00:00:00-07	DNA	7.23	48	48	\N	5
1135	CM D-30	2019-05-19 00:00:00-07	DNA	17.3	48	48	\N	5
1136	CM D-31	2019-05-19 00:00:00-07	DNA	14.8	48	48	\N	5
1137	CM D-32	2019-05-19 00:00:00-07	DNA	38.8	48	48	\N	5
1138	CM D-33	2019-05-19 00:00:00-07	DNA	20.8	48	48	\N	5
1139	CM D-34	2019-05-19 00:00:00-07	DNA	26	48	48	\N	5
1140	CM D-35	2019-05-19 00:00:00-07	DNA	58	48	48	\N	5
1141	CM D-36	2019-05-19 00:00:00-07	DNA	4.58	48	48	\N	5
1142	CM D-37	2019-05-19 00:00:00-07	DNA	54	48	48	\N	5
1143	CM D-38	2019-05-19 00:00:00-07	DNA	36.6	48	48	\N	5
1144	CM D-39	2019-05-19 00:00:00-07	DNA	3.19	48	48	\N	5
1145	CM D-40	2019-05-19 00:00:00-07	DNA	15.1	48	48	\N	5
1146	CM D-41	2019-05-19 00:00:00-07	DNA	5.44	48	48	\N	5
1147	CM D-42	2019-05-19 00:00:00-07	DNA	5.84	48	48	\N	5
1148	CM D-43	2019-05-19 00:00:00-07	DNA	18.7	48	48	\N	5
1149	CM D-44	2019-05-19 00:00:00-07	DNA	0.88	48	48	\N	5
1150	CM D-45	2019-05-19 00:00:00-07	DNA	3.42	48	48	\N	5
1151	CM D-46	2019-05-19 00:00:00-07	DNA	2.81	48	48	\N	5
1152	CM D-47	2019-05-19 00:00:00-07	DNA	2.64	48	48	\N	5
1153	CM D-48	2019-05-19 00:00:00-07	DNA	4.91	48	48	\N	5
1154	CM D-49	2019-06-05 00:00:00-07	DNA	2.31	48	48	\N	5
1155	CM D-50	2019-06-05 00:00:00-07	DNA	3	48	48	\N	5
1156	CM D-51	2019-06-05 00:00:00-07	DNA	21.3	48	48	\N	5
1157	CM D-52	2019-06-05 00:00:00-07	DNA	9.89	48	48	\N	5
1158	CM D-53	2019-06-05 00:00:00-07	DNA	25.1	48	48	\N	5
1159	CM D-54	2019-06-05 00:00:00-07	DNA	2.41	48	48	\N	5
1160	CM D-55	2019-06-05 00:00:00-07	DNA	1.62	48	48	\N	5
1161	CM D-56	2019-06-05 00:00:00-07	DNA	41	48	48	\N	5
1162	CM D-57	2019-06-05 00:00:00-07	DNA	13.5	48	48	\N	5
1163	CM D-58	2019-06-05 00:00:00-07	DNA	0.68	48	48	Not sufficient for LP	5
1164	CM D-59	2019-06-05 00:00:00-07	DNA	0.33	48	48	Not sufficient for LP	5
1165	CM D-60	2019-06-05 00:00:00-07	DNA	2.33	48	48	\N	5
1166	CM D-61	2019-06-05 00:00:00-07	DNA	0.55	48	48	Not sufficient for LP	5
1167	CM D-62	2019-06-05 00:00:00-07	DNA	0.6	48	48	Not sufficient for LP	5
1168	CM D-63	2019-06-05 00:00:00-07	DNA	18	48	48	\N	5
1169	CM D-64	2019-06-05 00:00:00-07	DNA	4.63	48	48	\N	5
1170	CM D-65	2019-06-05 00:00:00-07	DNA	2.22	48	48	\N	5
1171	CM D-66	2019-06-05 00:00:00-07	DNA	2.4	48	48	\N	5
1172	CM D-67	2019-06-05 00:00:00-07	DNA	0.52	48	48	Not sufficient for LP	5
1173	CM D-68	2019-06-07 00:00:00-07	DNA	0	96	96	Not sufficient for LP	5
1174	CM D-69	2019-07-26 00:00:00-07	DNA	2.35	96	96	\N	5
1175	CM D-70	2019-07-26 00:00:00-07	DNA	4.52	96	96	\N	5
1176	CM D-71	2019-07-26 00:00:00-07	DNA	18	96	96	\N	5
1177	CM D-72	2019-07-26 00:00:00-07	DNA	0.5	96	96	\N	5
1178	CM D-73	2019-07-26 00:00:00-07	DNA	0.44	96	96	\N	5
1179	CM D-74	2019-07-26 00:00:00-07	DNA	0.19	96	96	\N	5
1180	CM D-75	2019-07-26 00:00:00-07	DNA	2.93	96	96	\N	5
1181	CM D-76	2019-07-26 00:00:00-07	DNA	1.12	96	96	\N	5
1182	CM D-77	2019-07-26 00:00:00-07	DNA	167	96	96	\N	5
1183	CM D-78	2019-07-26 00:00:00-07	DNA	51	96	96	\N	5
1184	CM D-79	2019-07-26 00:00:00-07	DNA	45	96	96	\N	5
1185	CM D-80	2019-07-26 00:00:00-07	DNA	5.07	96	96	\N	5
1186	CM D-81	2019-07-26 00:00:00-07	DNA	47.3	96	96	\N	5
1187	CM D-82	2019-07-26 00:00:00-07	DNA	1.2	96	96	\N	5
1188	CM D-83	2019-07-26 00:00:00-07	DNA	47.5	96	96	\N	5
1189	CM D-84	2019-07-26 00:00:00-07	DNA	0.38	96	96	\N	5
1190	CM D-85	2019-07-26 00:00:00-07	DNA	5.08	96	96	\N	5
1191	CNS_29_Normal_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1192	CNS_29_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1193	CNS_30_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1194	CNS_31_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1195	CNS_33_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1196	CNS_34_Normal_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1197	CNS_34_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1198	CNS_35_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1199	CNS_36_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1200	CNS_37_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1201	CNS_38_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1202	CNS_39_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1203	CNS_40_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1204	CNS_41_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1205	CNS_42_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1206	CNS_43_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1207	CNS_44_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1208	CNS_48_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1209	CNS_49_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1210	CNS_50_Tumor_NA	\N	DNA	\N	\N	\N	Jantima CNS	\N
1211	D-NA-536	\N	DNA	0	50	50	\N	5
1212	D-NA-537	\N	DNA	13.6	50	50	\N	5
1213	D-NA-538	\N	DNA	106	50	50	\N	5
1214	D-NA-539	\N	DNA	5.41	50	50	\N	5
1215	D-NA-540	\N	DNA	4.34	50	50	\N	5
1216	D-NA-541	\N	DNA	35.3	50	50	\N	5
1217	D-NA-542	\N	DNA	0.76	50	50	\N	5
1218	D-NA-543	\N	DNA	1.14	50	50	\N	5
1219	D-NA-544	\N	DNA	1.62	50	50	\N	5
1220	D-NA-545	\N	DNA	0	50	50	\N	5
1221	D-NA-546	\N	DNA	0	50	50	\N	5
1222	D-NA-547	\N	DNA	0.18	50	50	\N	5
1223	D-NA-548	\N	DNA	0.45	50	50	\N	5
1224	D-NA-549	\N	DNA	0.1	50	50	\N	5
1225	D-NA-550	\N	DNA	0.24	50	50	\N	5
1226	D-NA-551	2015-02-26 00:00:00-08	DNA	0.57	45	45	\N	5
1227	D-NA-552	2015-02-26 00:00:00-08	DNA	9.9	45	45	\N	5
1228	D-NA-553	2015-02-26 00:00:00-08	DNA	29.4	45	45	\N	5
1229	D-NA-554	2015-02-26 00:00:00-08	DNA	1.21	45	45	\N	5
1230	D-NA-555	2015-02-26 00:00:00-08	DNA	1.03	45	45	\N	5
1336	DM-61-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1231	D-NA-556	2015-02-26 00:00:00-08	DNA	4.92	45	45	\N	5
1232	D-NA-557	2015-02-26 00:00:00-08	DNA	0.12	45	45	\N	5
1233	D-NA-558	2015-02-26 00:00:00-08	DNA	0.81	45	45	\N	5
1234	D-NA-559	2015-02-26 00:00:00-08	DNA	1.75	45	45	\N	5
1235	D-NA-560	2015-02-26 00:00:00-08	DNA	6.76	45	45	\N	5
1236	D-NA-561	2015-02-26 00:00:00-08	DNA	3.46	45	45	\N	5
1237	D-NA-562	2015-02-26 00:00:00-08	DNA	21.2	45	45	\N	5
1238	D-NA-563	2015-02-26 00:00:00-08	DNA	0.88	45	45	\N	5
1239	D-NA-564	2015-02-26 00:00:00-08	DNA	6.22	45	45	\N	5
1240	D-NA-565	2015-02-26 00:00:00-08	DNA	18.9	45	45	\N	5
1241	D-NA-585	2015-03-04 00:00:00-08	DNA	0.24	45	45	\N	5
1242	D-NA-586	2015-03-04 00:00:00-08	DNA	0.32	45	45	\N	5
1243	D-NA-587	2015-03-04 00:00:00-08	DNA	1.16	45	45	\N	5
1244	D-NA-588	2015-03-04 00:00:00-08	DNA	0.54	45	45	\N	5
1245	D-NA-589	2015-03-04 00:00:00-08	DNA	0.18	45	45	\N	5
1246	D-NA-590	2015-03-04 00:00:00-08	DNA	0.29	45	45	\N	5
1247	D-NA-620	2015-03-05 00:00:00-08	DNA	0.55	45	45	\N	5
1248	D-NA-621	2015-03-05 00:00:00-08	DNA	0.27	45	45	\N	5
1249	D-NA-622	2015-03-05 00:00:00-08	DNA	0.67	45	45	\N	5
1250	D-NA-623	2015-03-05 00:00:00-08	DNA	0.93	45	45	\N	5
1251	D-NA-624	2015-03-05 00:00:00-08	DNA	0.62	45	45	\N	5
1252	D-NA-625	2015-03-05 00:00:00-08	DNA	0.29	45	45	\N	5
1253	D-NA-626	2015-03-05 00:00:00-08	DNA	0.2	45	45	\N	5
1254	D-NA-627	2015-03-05 00:00:00-08	DNA	0.9	45	45	\N	5
1255	D-NA-628	2015-03-05 00:00:00-08	DNA	0.38	45	45	\N	5
1256	D-NA-629	2015-03-05 00:00:00-08	DNA	0.2	45	45	\N	5
1257	D-NA-630	2015-03-05 00:00:00-08	DNA	0.61	45	45	\N	5
1258	D-NA-631	2015-03-05 00:00:00-08	DNA	0.51	45	45	\N	5
1259	D-NA-645	2015-03-04 00:00:00-08	DNA	0.5	45	45	\N	5
1260	D-NA-646	2015-03-04 00:00:00-08	DNA	2.4	45	45	\N	5
1261	D-NA-647	2015-03-04 00:00:00-08	DNA	0.41	45	45	\N	5
1262	D-NA-8691	\N	DNA	5.32	100	100	\N	5
1263	D-NA-8692	\N	DNA	10.4	100	100	\N	5
1264	D12_54296_Norm_NA	\N	DNA	\N	\N	\N	Melanoma, Rt Inguinal Lymph node & Rt. Vulva	\N
1265	D12_54296_Tumor_NA	\N	DNA	\N	\N	\N	Melanoma, Rt Inguinal Lymph node & Rt. Vulva	\N
1266	D12_54992_Norm_NA	\N	DNA	\N	\N	\N	Melanoma, Lt groin sentinel lymph nodes	\N
1267	D12_54992_Tumor_NA	\N	DNA	\N	\N	\N	Melanoma, Lt groin sentinel lymph nodes	\N
1268	D12_67298_Norm_NA	\N	DNA	\N	\N	\N	lft, Lateral Ankle, Malignant S-100 positive spindle cell Neloplasm, Braf15 V600E mutation	\N
1269	D12_67298_Tumor_NA	\N	DNA	\N	\N	\N	lft, Lateral Ankle, Malignant S-100 positive spindle cell Neloplasm, Braf15 V600E mutation	\N
1270	DM_1_Normal_NA	\N	DNA	1.27	45	45	\N	\N
1271	DM_1_Tumor_NA	\N	DNA	60.8	10	10	\N	\N
1272	DM_2_NA	\N	DNA	\N	\N	\N	\N	\N
1273	DM_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1274	DM_4_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1275	DM_4_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1276	DM_6_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1277	DM_6_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1278	DM_8_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1279	DM_10_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1280	DM_10_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1281	DM_11_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1282	DM_13_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1283	DM_13_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1284	DM_14_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1285	DM_17_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1286	DM_17_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1287	DM_18_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1288	DM_18_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1289	DM_22_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1290	DM_22_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1291	DM_23_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1292	DM_23_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1293	DM_25_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1294	DM_25_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1295	DM_31_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1296	DM_31_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1297	DM_36_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1298	DM_36_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1299	DM_37_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1300	DM_42_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1301	DM_42_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1302	DM_43_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1303	DM_43_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1304	DM_48_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1305	DM_49_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1306	DM_49_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1307	DM_51_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1308	DM_58_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1309	DM_58_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1310	DM_59_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1311	DM_64_1_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1312	DM_64_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1313	DM_65_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1314	DM_68_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1315	DM_74_1_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1316	DM_74_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1317	DM_93_3_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1318	DM_93_cgn_NA	\N	DNA	\N	\N	\N	\N	\N
1319	DM_93_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1320	DM_94_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1321	DM_94_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1322	DM_95_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1323	DM_95_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1324	DM_96_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1325	DM_96_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1326	DM_98_2_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1327	DM_98_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1328	DM_99_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1329	DM_99_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1330	DM_100_Tumor_Pool_NA	\N	DNA	\N	\N	\N	\N	\N
1331	DM_101_IS_NA	\N	DNA	\N	\N	\N	\N	\N
1332	DM_101_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1333	DM_101_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1334	DM_102_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1335	DM-60-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1342	DM-70-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1343	DM-81-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1344	DM1_Normal_NA	2013-01-29 00:00:00-08	DNA	2.54	100	100	\N	5
1345	DM1_Tumor_NA	2013-01-29 00:00:00-08	DNA	121.6	100	100	\N	5
1346	DM2_Normal_NA	2013-01-29 00:00:00-08	DNA	10.56	100	100	\N	5
1347	DM2_Tumor_NA	2013-01-29 00:00:00-08	DNA	175	100	100	\N	5
1348	DM5 _Tumor_NA	2013-01-29 00:00:00-08	DNA	90.2	100	100	\N	5
1349	DM5_Normal_NA	2013-01-29 00:00:00-08	DNA	2.8	100	100	\N	5
1350	DM7_Normal_NA	2013-01-29 00:00:00-08	DNA	3.76	100	100	\N	5
1351	DM7_Tumor_NA	2013-01-29 00:00:00-08	DNA	34.2	100	100	\N	5
1352	DM11_Normal_NA	2013-01-29 00:00:00-08	DNA	2.88	100	100	\N	5
1353	DM11_Tumor_NA	2013-01-29 00:00:00-08	DNA	104	100	100	\N	5
1354	DM12_Normal_NA	2013-01-29 00:00:00-08	DNA	13.28	100	100	\N	5
1355	DM12_Tumor_NA	2013-01-29 00:00:00-08	DNA	30.2	100	100	\N	5
1356	DM13_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1357	DM13_Tumor_NA	2013-01-29 00:00:00-08	DNA	83.2	100	100	\N	5
1358	DM14_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1359	DM14_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1360	DM16_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1361	DM16_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1362	DM21_Normal_NA	2013-01-29 00:00:00-08	DNA	2.16	100	100	\N	5
1363	DM21_Tumor_NA	2013-01-29 00:00:00-08	DNA	15.66	100	100	\N	5
1364	DM26_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1365	DM26_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1366	DM28_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1367	DM28_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1368	DM29_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1369	DM29_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1370	DM34_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1371	DM34_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1372	DM37_1_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1373	DM45_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1374	DM45_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1375	DM55 Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1376	DM55_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1377	DM77_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1378	DM77_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1379	DM79_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1380	DM79_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1381	DM93_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1382	DM93_CGN_NA	2013-01-29 00:00:00-08	DNA	28	100	100	\N	5
1383	DM93_Normal_NA	2013-01-29 00:00:00-08	DNA	14.64	100	100	\N	5
1384	DN-052	\N	DNA	0	0	0	\N	\N
1385	DN-053	\N	DNA	0.23	80	80	\N	5
1386	DN-054	\N	DNA	0.1	80	80	\N	5
1387	DN-055	\N	DNA	1.01	80	80	\N	5
1388	DN-056	\N	DNA	0.26	80	80	\N	5
1389	DN-057	\N	DNA	1.23	80	80	\N	5
1390	DN-058	\N	DNA	0.4	80	80	\N	5
1391	DN-059	\N	DNA	1.19	80	80	\N	5
1392	DN-060	\N	DNA	2.87	80	80	\N	5
1393	DN-061	\N	DNA	1.36	80	80	\N	5
1394	DN-062	\N	DNA	4.58	80	80	\N	5
1395	DN-063	\N	DNA	1.52	80	80	\N	5
1396	DN-064	\N	DNA	1.85	80	80	\N	5
1397	DN-065	\N	DNA	1.23	80	80	\N	5
1398	DN-066	\N	DNA	2.36	80	80	\N	5
1399	DN-067	\N	DNA	14.2	80	80	\N	5
1400	DN-068	\N	DNA	0.25	80	80	\N	5
1401	DN-069	\N	DNA	3.29	80	80	\N	5
1402	DN-070	\N	DNA	1.47	80	80	\N	5
1403	DN-071	\N	DNA	4.06	80	80	\N	5
1404	DN-072	\N	DNA	1.59	80	80	\N	5
1405	DN-073	\N	DNA	3.73	80	80	\N	5
1406	DN-074	\N	DNA	0	80	80	\N	5
1407	DN-075	\N	DNA	0	0	0	\N	\N
1408	DN-076	\N	DNA	1.02	80	80	\N	5
1409	DN-077	\N	DNA	0.09	80	80	\N	5
1410	DN-078	\N	DNA	0.52	80	80	\N	5
1411	DN-079	\N	DNA	0.07	80	80	\N	5
1412	DN-080	\N	DNA	0.1	80	80	\N	5
1413	DN-081	\N	DNA	0	0	0	\N	\N
1414	DN-082	\N	DNA	1.05	80	80	\N	5
1415	DN-083	\N	DNA	2.17	80	80	\N	5
1416	DN-084	\N	DNA	1.9	80	80	\N	5
1417	DN-085	\N	DNA	3.95	80	80	\N	5
1418	DN-086	\N	DNA	5.35	80	80	\N	5
1419	DN-087	\N	DNA	2.21	80	80	\N	5
1420	DNA-01	2019-04-05 00:00:00-07	DNA	2.88	18	18	\N	6
1421	DNA-01_REPEAT	\N	DNA	3.01	96	96	\N	6
1422	DNA-02	2019-05-22 00:00:00-07	DNA	3.9	96	96	\N	5
1423	DNA-03	2019-05-22 00:00:00-07	DNA	9.24	96	96	\N	5
1424	DNA-04	2019-05-22 00:00:00-07	DNA	0.39	48	48	\N	5
1425	DNA-05	2019-05-22 00:00:00-07	DNA	0.62	96	96	\N	5
1426	DNA-06	2019-05-22 00:00:00-07	DNA	3.5	96	96	\N	5
1427	DNA-07	2019-05-22 00:00:00-07	DNA	0.17	90	90	\N	5
1428	DNA-08	2019-05-22 00:00:00-07	DNA	0.48	48	48	\N	5
1429	DNA-09	2019-05-22 00:00:00-07	DNA	0.45	48	48	\N	5
1430	DNA-10	\N	DNA	0	48	48	\N	5
1431	DNA-11	\N	DNA	1.92	48	48	\N	6
1432	DNA-12	\N	DNA	6.54	48	48	\N	6
1433	DNA-15	2019-05-22 00:00:00-07	DNA	0.46	57	57	\N	5
1434	DNA-16	2019-05-22 00:00:00-07	DNA	0.55	57	57	\N	5
1435	DNA-17	\N	DNA	4.45	48	48	\N	6
1436	DNA-18	\N	DNA	19.1	48	48	\N	6
1437	DNA-19	2019-05-22 00:00:00-07	DNA	0.92	96	96	\N	5
1438	DNA-20	\N	DNA	0	0	0	\N	5
1439	DNA-21	\N	DNA	1.97	48	48	\N	6
1440	DNA-22	\N	DNA	11.1	48	48	\N	6
1441	DNA-23	2019-05-22 00:00:00-07	DNA	0.43	96	96	\N	5
1442	DNA-24	2019-05-22 00:00:00-07	DNA	1.42	48	48	\N	5
1443	DNA-25	\N	DNA	0.88	75	75	\N	6
1444	DNA-26	\N	DNA	2.14	91	91	\N	6
1445	DNA-27	\N	DNA	3.82	60	60	\N	6
1446	DNA-28	\N	DNA	23.5	85	85	\N	6
1447	DNA-29	\N	DNA	3.35	91	91	\N	6
1448	DNA-30	\N	DNA	2.55	48	48	\N	6
1449	DNA-31	\N	DNA	12.3	48	48	\N	6
1450	DNA-38	\N	DNA	0.35	48	48	\N	5
1451	DNA-41	\N	DNA	6.03	61	61	\N	6
1452	DNA-43	\N	DNA	1.92	48	48	\N	6
1453	DNA-44	\N	DNA	2.08	48	48	\N	6
1454	DNA-45	\N	DNA	5.39	48	48	\N	6
1455	DNA-46	\N	DNA	2.57	48	48	\N	6
1456	DNA-47	\N	DNA	4.14	48	48	\N	6
1457	DNA-48	2019-05-22 00:00:00-07	DNA	0.18	96	96	\N	5
1458	DNA-49	\N	DNA	14.5	48	48	\N	6
1459	DNA-50	\N	DNA	2.4	48	48	\N	6
1460	DNA-52	\N	DNA	2.01	48	48	\N	6
1461	DNA-53	\N	DNA	9.13	48	48	\N	6
1462	DNA-53_REPEAT	2019-05-22 00:00:00-07	DNA	5.45	96	96	\N	5
1463	DNA-54	\N	DNA	1.64	48	48	\N	6
1464	DNA-54_REPEAT	2019-05-22 00:00:00-07	DNA	1.08	96	96	\N	5
1465	DNA-55	\N	DNA	14.3	48	48	\N	6
1466	DNA-56	\N	DNA	19.7	48	48	\N	6
1467	DNA-59	2019-04-09 00:00:00-07	DNA	2.29	48	48	\N	6
1468	DNA-59_REPEAT	2019-05-22 00:00:00-07	DNA	1.08	96	96	\N	5
1469	DNA-61	\N	DNA	3.84	48	48	\N	6
1470	DNA-62	\N	DNA	1.56	48	48	\N	6
1471	DNA-65	\N	DNA	4.98	48	48	\N	6
1472	DNA-68	2019-05-22 00:00:00-07	DNA	0	48	48	\N	5
1473	DNA-69	\N	DNA	1.65	97	97	\N	6
1474	DNA-70	\N	DNA	0.55	91	91	\N	6
1475	DNA-71	2019-05-22 00:00:00-07	DNA	0.75	99	99	\N	6
1476	DNA-72	2019-05-22 00:00:00-07	DNA	0.35	96	96	\N	5
1477	DNA-73	\N	DNA	0.52	95	95	\N	6
1478	DNA-74	2019-05-22 00:00:00-07	DNA	0.28	48	48	\N	5
1479	DNA-75	2019-05-22 00:00:00-07	DNA	0.76	48	48	\N	5
1480	DNA-76	2019-05-22 00:00:00-07	DNA	0.79	48	48	\N	5
1481	DNA-77	\N	DNA	0.24	48	48	\N	5
1482	DNA-78	\N	DNA	0.18	48	48	\N	5
1483	DNA-79	2019-05-22 00:00:00-07	DNA	0.96	48	48	\N	5
1484	DNA-80	2019-05-22 00:00:00-07	DNA	1.57	48	48	\N	5
1485	DNA-81	2019-05-22 00:00:00-07	DNA	0.76	48	48	\N	5
1486	DNA-82	2019-05-22 00:00:00-07	DNA	0.52	48	48	\N	5
1487	DNA-83	2019-05-22 00:00:00-07	DNA	0.28	48	48	\N	5
1488	DNA-85	2019-05-22 00:00:00-07	DNA	1.22	96	96	\N	5
1489	DNA-86	2019-05-22 00:00:00-07	DNA	1.91	96	96	\N	5
1490	DNA-87	2019-05-22 00:00:00-07	DNA	0.16	96	96	\N	5
1491	DNA-88	\N	DNA	16.3	48	48	\N	5
1492	DNA-89	\N	DNA	9.25	48	48	\N	5
1493	DNA-90	\N	DNA	12	48	48	\N	5
1494	DNA-91	\N	DNA	2.25	48	48	\N	5
1495	DNA-92	\N	DNA	1.47	48	48	\N	5
1496	DNA-93	\N	DNA	1.45	48	48	\N	5
1497	DNA-94	2019-06-19 00:00:00-07	DNA	263	48	48	\N	5
1498	DNA-95	2019-06-19 00:00:00-07	DNA	20.6	48	48	\N	5
1499	DNA-96	2019-06-19 00:00:00-07	DNA	41.6	48	48	\N	5
1500	DNA-97	2020-07-29 00:00:00-07	DNA	0.08	96	96	\N	6
1501	DNA-98	2020-07-29 00:00:00-07	DNA	2.44	96	96	\N	6
1502	DNA-99	2020-07-29 00:00:00-07	DNA	0.87	96	96	\N	6
1503	DNA-100	2020-07-29 00:00:00-07	DNA	0	96	96	\N	6
1504	DNA-101	2020-07-29 00:00:00-07	DNA	2.28	96	96	\N	6
1505	DNA-107	2020-08-23 00:00:00-07	DNA	1.28	90	90	\N	6
1506	DNA-108	2020-08-23 00:00:00-07	DNA	14.6	90	90	\N	6
1507	DNA-109	2020-08-23 00:00:00-07	DNA	0.87	90	90	\N	6
1508	DNA-110	2020-08-23 00:00:00-07	DNA	0	90	90	\N	6
1509	DNA-111	2020-08-23 00:00:00-07	DNA	0.23	90	90	\N	6
1510	DNA-112	2020-08-23 00:00:00-07	DNA	0.27	90	90	\N	6
1511	DNA-113	2020-08-23 00:00:00-07	DNA	0.24	90	90	\N	6
1512	DNA-114	2020-08-23 00:00:00-07	DNA	0.22	90	90	\N	6
1513	DNA-115	2020-08-23 00:00:00-07	DNA	0	90	90	\N	6
1514	DNA-116	2020-08-23 00:00:00-07	DNA	0.2	90	90	\N	6
1515	DNA-117	2020-08-23 00:00:00-07	DNA	0	0	0	\N	6
1516	DNA-118	2020-08-23 00:00:00-07	DNA	1.16	90	90	\N	6
1517	DNA-119	2020-08-23 00:00:00-07	DNA	0.11	90	90	\N	6
1518	DNA-120	2020-08-23 00:00:00-07	DNA	10.3	90	90	\N	6
1519	DNA-121	2020-08-23 00:00:00-07	DNA	1.25	90	90	\N	6
1520	DNA-122	2020-08-23 00:00:00-07	DNA	4.71	90	90	\N	6
1521	DNA-123	2020-08-23 00:00:00-07	DNA	0.51	90	90	\N	6
1522	DNA-124	2020-08-23 00:00:00-07	DNA	0.47	90	90	\N	6
1523	DNA-125	2020-08-23 00:00:00-07	DNA	0.8	90	90	\N	6
1524	DNA-126	2020-08-23 00:00:00-07	DNA	0.33	90	90	\N	6
1525	DNA-127	2020-08-23 00:00:00-07	DNA	1.51	90	90	\N	6
1526	DNA-128	2020-08-23 00:00:00-07	DNA	0	90	90	DO NOT USE; WRONG TISSUE WAS MICRODISSECTED: 17-43707	6
1527	DNA-129	2020-08-23 00:00:00-07	DNA	0.41	90	90	\N	6
1528	DNA-130	2020-08-23 00:00:00-07	DNA	1.46	90	90	\N	6
1529	DNA-131	2020-08-23 00:00:00-07	DNA	0.06	90	90	\N	6
1530	DNA-132	2020-08-23 00:00:00-07	DNA	1.3	90	90	\N	6
1531	DNA-133	2020-08-23 00:00:00-07	DNA	7.04	90	90	\N	6
1532	DNA-134	2020-09-12 00:00:00-07	DNA	0.14	90	90	\N	6
1533	DNA-135	2020-09-12 00:00:00-07	DNA	1.23	90	90	\N	6
1534	DNA-136	2020-09-12 00:00:00-07	DNA	0.82	90	90	\N	6
1535	DNA-137	2020-09-12 00:00:00-07	DNA	3.58	90	90	\N	6
1536	DNA-138	2020-09-12 00:00:00-07	DNA	2.49	90	90	\N	6
1537	DNA-139	2020-09-12 00:00:00-07	DNA	0.62	90	90	\N	6
1538	DNA-140	2020-09-12 00:00:00-07	DNA	0.19	90	90	\N	6
1539	DNA-141	2020-09-12 00:00:00-07	DNA	1.07	90	90	\N	6
1540	DNA-142	2020-09-18 00:00:00-07	DNA	0	90	90	\N	6
1541	DNA-143	2020-09-18 00:00:00-07	DNA	0	90	90	\N	6
1542	DNA-144	2020-09-18 00:00:00-07	DNA	4.12	90	90	\N	6
1543	DNA-145	2020-09-18 00:00:00-07	DNA	0	90	90	\N	6
1544	DNA-146	2020-10-03 00:00:00-07	DNA	10.6	96	96	\N	6
1545	DNA-147	2020-10-03 00:00:00-07	DNA	0.41	96	96	\N	6
1546	DNA-148	2020-10-03 00:00:00-07	DNA	0.77	96	96	\N	6
1547	DNA-149	2020-10-03 00:00:00-07	DNA	0.28	96	96	\N	6
1548	DNA-150	2020-10-03 00:00:00-07	DNA	1.02	96	96	\N	6
1549	DNA-151	2020-10-03 00:00:00-07	DNA	1.08	96	96	\N	6
1550	DNA-152	2020-10-05 00:00:00-07	DNA	0.61	96	96	\N	6
1551	DNA-153	2020-10-05 00:00:00-07	DNA	1.07	96	96	\N	6
1552	DNA-154	2020-10-05 00:00:00-07	DNA	0.09	96	96	\N	6
1553	DNA-155	2020-10-05 00:00:00-07	DNA	1.31	96	96	\N	6
1554	DNA-156	2020-10-05 00:00:00-07	DNA	0.19	96	96	\N	6
1555	DNA-157	2020-10-07 00:00:00-07	DNA	0.25	96	96	\N	6
1556	DNA-158	2020-10-07 00:00:00-07	DNA	0.13	96	96	\N	6
1557	DNA-159	2020-10-07 00:00:00-07	DNA	0.85	96	96	\N	6
1558	DNA-160	2022-03-14 00:00:00-07	DNA	2.09	88	88	\N	2
1559	DNA-161	2022-03-14 00:00:00-07	DNA	1.16	88	88	\N	2
1560	DNA-162	2022-03-14 00:00:00-07	DNA	1.3	88	88	\N	2
1561	DNA-163	2022-03-14 00:00:00-07	DNA	0.12	88	88	\N	2
1562	DNA-164	2022-03-14 00:00:00-07	DNA	11.8	88	88	\N	2
1563	DNA-165	2022-03-14 00:00:00-07	DNA	0.85	88	88	\N	2
1564	DNA-166	2022-03-14 00:00:00-07	DNA	1.99	88	88	\N	2
1565	DNA-167	2022-03-14 00:00:00-07	DNA	0.36	88	88	\N	2
1566	DNA-168	2022-03-14 00:00:00-07	DNA	0.11	88	88	\N	2
1567	DNA-169	2022-03-14 00:00:00-07	DNA	1.51	88	88	\N	2
1568	DNA-170	2022-03-14 00:00:00-07	DNA	0.91	88	88	\N	2
1569	DNA-171	2022-03-14 00:00:00-07	DNA	0.43	88	88	\N	2
1570	DNA-172	2022-03-14 00:00:00-07	DNA	0.18	88	88	\N	2
1571	DNA-173	2022-03-14 00:00:00-07	DNA	0.72	88	88	\N	2
1572	DNA-174	2022-03-14 00:00:00-07	DNA	1.07	88	88	\N	2
1573	DNA-175	2022-03-14 00:00:00-07	DNA	2.12	88	88	\N	2
1574	DNA-176	2022-03-14 00:00:00-07	DNA	0.34	88	88	\N	2
1575	DNA-177	2022-03-14 00:00:00-07	DNA	0.32	88	88	\N	2
1576	DNA-178	2022-03-14 00:00:00-07	DNA	1.33	88	88	\N	2
1577	DNA-179	2022-03-14 00:00:00-07	DNA	0.15	88	88	\N	2
1578	DNA-180	2022-03-15 00:00:00-07	DNA	0.15	88	88	\N	2
1579	DNA-181	2022-03-15 00:00:00-07	DNA	0.91	88	88	\N	2
1580	DNA-182	2022-03-15 00:00:00-07	DNA	0.35	88	88	\N	2
1581	DNA-183	2022-03-15 00:00:00-07	DNA	0.38	88	88	\N	2
1582	DNA-184	2022-03-15 00:00:00-07	DNA	6.56	88	88	\N	2
1583	DNA-185	2022-03-15 00:00:00-07	DNA	0.2	88	88	\N	2
1584	DNA-186	2022-03-15 00:00:00-07	DNA	0.46	88	88	\N	2
1585	DNA-187	2022-03-15 00:00:00-07	DNA	13.5	88	88	\N	2
1586	DNA-188	2022-03-15 00:00:00-07	DNA	2.09	88	88	\N	2
1587	DNA-189	2022-03-15 00:00:00-07	DNA	2.44	88	88	\N	2
1588	DNA-190	2022-03-15 00:00:00-07	DNA	1.71	88	88	\N	2
1589	DNA-191	2022-03-15 00:00:00-07	DNA	1.71	88	88	\N	2
1590	DNA-192	2022-03-15 00:00:00-07	DNA	0.13	88	88	\N	2
1591	DNA-193	2022-03-15 00:00:00-07	DNA	0.2	88	88	\N	2
1592	DNA-194	2022-03-15 00:00:00-07	DNA	1	88	88	\N	2
1593	DNA-195	2022-03-15 00:00:00-07	DNA	6.47	88	88	\N	2
1594	DNA-196	2022-03-15 00:00:00-07	DNA	2.35	88	88	\N	2
1595	DNA-197	2022-03-15 00:00:00-07	DNA	0.75	88	88	\N	2
1596	DNA-198	2022-04-14 00:00:00-07	DNA	0.74	88	88	\N	2
1597	DNA-199	2022-04-21 00:00:00-07	DNA	2.5	88	88	\N	2
1598	DNA-200	2022-04-21 00:00:00-07	DNA	0.38	88	88	\N	2
1599	DNA-201	2022-04-14 00:00:00-07	DNA	0.56	88	88	\N	2
1600	DNA-202	2022-04-14 00:00:00-07	DNA	1.55	88	88	\N	2
1601	DNA-203	2022-04-18 00:00:00-07	DNA	3.69	88	88	\N	2
1602	DNA-204	2022-04-18 00:00:00-07	DNA	2.12	88	88	\N	2
1603	DNA-205	2022-04-18 00:00:00-07	DNA	1.97	88	88	\N	2
1604	DNA-206	2022-04-14 00:00:00-07	DNA	0.41	88	88	\N	2
1605	DNA-207	2022-04-18 00:00:00-07	DNA	14.1	88	88	\N	2
1606	DNA-208	2022-04-18 00:00:00-07	DNA	1.55	88	88	\N	2
1607	DNA-209	2022-04-18 00:00:00-07	DNA	1.91	88	88	\N	2
1608	DNA-210	2022-04-18 00:00:00-07	DNA	0.61	88	88	\N	2
1609	DNA-211	2022-04-14 00:00:00-07	DNA	0.22	88	88	\N	2
1610	DNA-212	2022-04-18 00:00:00-07	DNA	4.93	88	88	\N	2
1611	DNA-213	2022-04-18 00:00:00-07	DNA	2.12	88	88	\N	2
1612	DNA-214	2022-04-18 00:00:00-07	DNA	1.03	88	88	\N	2
1613	DNA-215	2022-04-14 00:00:00-07	DNA	0.34	88	88	\N	2
1614	DNA-216	2022-04-14 00:00:00-07	DNA	0.99	88	88	\N	2
1615	DNA-217	2022-04-18 00:00:00-07	DNA	0.75	88	88	\N	2
1616	DNA-218	2022-04-18 00:00:00-07	DNA	3.08	88	88	\N	2
1617	DNA-219	2022-04-18 00:00:00-07	DNA	0.64	88	88	\N	2
1618	DNA-220	2022-04-14 00:00:00-07	DNA	0.15	88	88	\N	2
1619	DNA-221	2022-04-18 00:00:00-07	DNA	1.76	88	88	\N	2
1620	DNA-222	2022-04-18 00:00:00-07	DNA	0.25	88	88	\N	2
1621	DNA-223	2022-04-14 00:00:00-07	DNA	0.29	88	88	\N	2
1622	DNA-224	2022-04-18 00:00:00-07	DNA	1.69	88	88	\N	2
1623	DNA-225	2022-04-18 00:00:00-07	DNA	0.48	88	88	\N	2
1624	DNA-226	2022-04-14 00:00:00-07	DNA	0.52	88	88	\N	2
1625	DNA-227	\N	DNA	0	0	0	\N	\N
1626	DNA-228	\N	DNA	0	0	0	\N	\N
1627	DNA-229	\N	DNA	0	0	0	\N	\N
1628	DNA-230	2022-04-18 00:00:00-07	DNA	10.1	88	88	\N	2
1629	DNA-231	2022-04-18 00:00:00-07	DNA	1.06	88	88	\N	2
1630	DNA-232	2022-04-14 00:00:00-07	DNA	1.54	88	88	\N	2
1631	DNA-233	2022-04-18 00:00:00-07	DNA	1.17	88	88	\N	2
1632	DNA-234	2022-04-18 00:00:00-07	DNA	2.95	88	88	5 sections/tube	2
1633	DNA-235	2022-04-21 00:00:00-07	DNA	4.97	88	88	\N	2
1634	DNA-236	2022-04-14 00:00:00-07	DNA	0.44	88	88	\N	2
1635	DNA-237	2022-04-14 00:00:00-07	DNA	0.65	88	88	10 sections/tube	2
1636	DNA-238	2022-04-21 00:00:00-07	DNA	1.4	88	88	\N	2
1637	DNA-239	\N	DNA	0	0	0	\N	\N
1638	DNA-240	2022-04-14 00:00:00-07	DNA	3.79	88	88	\N	2
1639	DNA-241	2022-04-14 00:00:00-07	DNA	0.73	88	88	\N	2
1640	DNA-242	2022-04-21 00:00:00-07	DNA	2.97	88	88	\N	2
1641	DNA-243	2022-04-21 00:00:00-07	DNA	0.52	88	88	\N	2
1642	DNA-244	2022-04-21 00:00:00-07	DNA	0.24	88	88	\N	2
1643	DNA-245	2022-04-18 00:00:00-07	DNA	13	88	88	6 sections/tube	2
1644	DNA-246	2022-04-18 00:00:00-07	DNA	1.11	88	88	6 sections/tube	2
1645	DNA-247	2022-04-18 00:00:00-07	DNA	3.7	88	88	5 sections/tube	2
1646	DNA-248	2022-04-14 00:00:00-07	DNA	0.48	88	88	10 sections/tube	2
1647	DNA-251	2022-05-13 00:00:00-07	DNA	0.65	88	88	\N	2
1648	DNA-252	2022-05-13 00:00:00-07	DNA	0.34	88	88	\N	2
1649	DNA-253	2022-05-13 00:00:00-07	DNA	0.16	88	88	\N	2
1650	DNA-254	2022-05-13 00:00:00-07	DNA	0.75	88	88	\N	2
1651	DNA-255	2022-05-13 00:00:00-07	DNA	0.28	88	88	\N	2
1652	DNA-256	2022-05-13 00:00:00-07	DNA	1.19	88	88	4 tissue sections/tube	2
1653	DNA-257	2022-05-13 00:00:00-07	DNA	0.47	88	88	2 tissue sections	2
1654	DNA-258	2022-05-13 00:00:00-07	DNA	0.93	88	88	6.5 tissue sections/tube	2
1655	DNA-259	2022-05-13 00:00:00-07	DNA	8.14	88	88	2.5 tissue sections/tube	2
1656	DNA-260	2022-05-13 00:00:00-07	DNA	1.29	88	88	\N	2
1657	DNA-261	2022-05-13 00:00:00-07	DNA	1.34	88	88	2.5 tissue sections/tube	2
1658	DNA-262	2022-05-13 00:00:00-07	DNA	1.28	88	88	2.5 tissue sections/tube	2
1659	DNA-263	2022-05-13 00:00:00-07	DNA	0.86	88	88	6.5 tissue sections/tube	2
1660	DNA-264	2022-05-13 00:00:00-07	DNA	7.36	88	88	2.5 tissue sections/tube	2
1661	DNA-265	2022-05-13 00:00:00-07	DNA	1.39	88	88	\N	2
1662	DNA-266	2022-05-25 00:00:00-07	DNA	16.2	88	88	\N	2
1663	DNA-267	2022-05-25 00:00:00-07	DNA	0.58	88	88	\N	2
1664	DNA-268	\N	DNA	0	0	0	NOT MICRODISSECTED NOR EXTRACTED	\N
1665	DNA-269	\N	DNA	0	0	0	NOT MICRODISSECTED NOR EXTRACTED	\N
1666	DNA-270	2022-06-06 00:00:00-07	DNA	0.03	90	90	\N	2
1667	DNA-271	2022-06-06 00:00:00-07	DNA	0.37	100	100	\N	2
1668	DNA-272	\N	DNA	0	0	0	\N	\N
1669	DNA-273	2022-08-25 00:00:00-07	DNA	0.15	88	88	\N	2
1670	DNA-274	2022-08-17 00:00:00-07	DNA	0	88	88	\N	2
1671	DNA-275	2022-08-25 00:00:00-07	DNA	3.04	88	88	\N	2
1672	DNA-276	2022-08-25 00:00:00-07	DNA	0.26	88	88	\N	2
1673	DNA-277	2022-08-17 00:00:00-07	DNA	0.47	88	88	\N	2
1674	DNA-278	2022-08-25 00:00:00-07	DNA	1.24	88	88	\N	2
1675	DNA-279	2022-08-25 00:00:00-07	DNA	2.33	88	88	\N	2
1676	DNA-280	2022-08-17 00:00:00-07	DNA	0.5	88	88	\N	2
1677	DNA-281	\N	DNA	0	0	0	\N	\N
1678	DNA-282	\N	DNA	0	0	0	\N	\N
1679	DNA-283	\N	DNA	0	0	0	\N	\N
1680	DNA-284	\N	DNA	0	0	0	\N	\N
1681	DNA-285	2022-08-25 00:00:00-07	DNA	0.49	88	88	\N	2
1682	DNA-286	2022-08-25 00:00:00-07	DNA	11.3	88	88	\N	2
1683	DNA-287	2022-08-17 00:00:00-07	DNA	0.64	88	88	\N	2
1684	DNA-288	2022-08-25 00:00:00-07	DNA	0.97	88	88	\N	2
1685	DNA-289	2022-08-25 00:00:00-07	DNA	0.19	88	88	\N	2
1686	DNA-290	2022-08-17 00:00:00-07	DNA	0.1	88	88	\N	2
1687	DNA-291	2022-08-17 00:00:00-07	DNA	0.41	88	88	\N	2
1688	DNA-292	2022-08-17 00:00:00-07	DNA	6.05	88	88	\N	2
1689	DNA-293	\N	DNA	0	0	0	\N	\N
1690	DNA-294	2022-08-25 00:00:00-07	DNA	3.58	88	88	\N	2
1691	DNA-295	2022-08-25 00:00:00-07	DNA	0.47	88	88	\N	2
1692	DNA-296	\N	DNA	0	0	0	\N	\N
1693	DNA-297	2022-08-17 00:00:00-07	DNA	0.24	88	88	5 sections/tube	2
1694	DNA-298	2022-08-26 00:00:00-07	DNA	7.91	88	88	5 sections/tube	2
1695	DNA-299	2022-08-26 00:00:00-07	DNA	26.7	88	88	5 sections/tube	2
1696	DNA-300	2022-08-26 00:00:00-07	DNA	0.1	88	88	\N	2
1697	DNA-301	2022-08-26 00:00:00-07	DNA	1.5	88	88	\N	2
1698	DNA-302	2022-08-17 00:00:00-07	DNA	3.89	88	88	\N	2
1699	DNA-303	2022-08-26 00:00:00-07	DNA	1.75	88	88	\N	2
1700	DNA-304	2022-08-26 00:00:00-07	DNA	0.76	88	88	\N	2
1701	DNA-305	2022-08-26 00:00:00-07	DNA	7.89	88	88	\N	2
1702	DNA-306	2022-08-26 00:00:00-07	DNA	3.77	88	88	\N	2
1703	DNA-307	2022-08-26 00:00:00-07	DNA	0.81	88	88	\N	2
1704	DNA-308	2022-08-17 00:00:00-07	DNA	0.43	88	88	5 sections/tube	2
1705	DNA-309	2022-08-26 00:00:00-07	DNA	7.3	88	88	5 sections/tube	2
1706	DNA-310	2022-08-26 00:00:00-07	DNA	26.4	88	88	5 sections/tube	2
1707	DNA-311	2022-08-25 00:00:00-07	DNA	0.05	88	88	\N	2
1708	DNA-312	\N	DNA	0	0	0	\N	\N
1709	DNA-313	2022-08-25 00:00:00-07	DNA	2.12	88	88	\N	2
1710	DNA-314	2022-08-26 00:00:00-07	DNA	0.97	88	88	\N	2
1711	DNA-315	2022-08-26 00:00:00-07	DNA	0.98	88	88	\N	2
1712	DNA-316	2022-08-17 00:00:00-07	DNA	0.3	88	88	5 sections/tube	2
1713	DNA-317	2022-08-17 00:00:00-07	DNA	0.56	88	88	5 sections/tube	2
1714	DNA-318	2022-11-22 00:00:00-08	DNA	0.3	88	88	\N	2
1715	DNA-319	2022-11-28 00:00:00-08	DNA	0.41	88	88	\N	2
1716	DNA-320	2022-12-09 00:00:00-08	DNA	1.6	88	88	\N	2
1717	DNA-330	2022-10-28 00:00:00-07	DNA	38.1	176	176	\N	2
1718	DNA-331	2022-10-28 00:00:00-07	DNA	36.6	176	176	\N	2
1719	DNA-332	2022-10-28 00:00:00-07	DNA	39.4	88	88	\N	2
1720	DNA-333	2022-11-03 00:00:00-07	DNA	8.2	176	176	\N	2
1721	DNA-334	2022-10-28 00:00:00-07	DNA	2.77	176	176	\N	2
1722	DNA-335	2022-10-28 00:00:00-07	DNA	6.31	88	88	\N	2
1723	DNA-336	2022-11-03 00:00:00-07	DNA	0.66	200	200	\N	2
1724	DNA-337	2022-10-28 00:00:00-07	DNA	20.9	88	88	\N	2
1725	DNA-338	2022-10-28 00:00:00-07	DNA	4.81	88	88	\N	2
1726	DNA-339	2022-10-28 00:00:00-07	DNA	1.74	88	88	\N	2
1727	DNA-340	2022-10-28 00:00:00-07	DNA	21.2	88	88	\N	2
1728	DNA-341	2022-10-31 00:00:00-07	DNA	7.44	88	88	\N	2
1729	DNA-342	2022-11-03 00:00:00-07	DNA	0.72	264	264	\N	2
1730	DNA-344	2022-12-09 00:00:00-08	DNA	21.7	176	176	\N	2
1731	DNA-346	2022-12-09 00:00:00-08	DNA	3.56	88	88	\N	2
1732	DNA-347	2022-12-09 00:00:00-08	DNA	5.46	88	88	\N	2
1733	DNA-348	2022-10-31 00:00:00-07	DNA	20.6	352	352	\N	2
1734	DNA-350	2022-10-31 00:00:00-07	DNA	4.79	176	176	\N	2
1735	DNA-351	2022-10-31 00:00:00-07	DNA	5.43	352	352	\N	2
1736	DNA-353	2022-11-03 00:00:00-07	DNA	2	176	176	\N	2
1737	DNA-355	2022-10-31 00:00:00-07	DNA	7.79	88	88	\N	2
1738	DNA-356	2022-11-10 00:00:00-08	DNA	16	88	88	\N	2
1739	DNA-357	2022-11-10 00:00:00-08	DNA	1.49	88	88	\N	2
1740	DNA-358	2022-11-03 00:00:00-07	DNA	3.23	100	100	\N	2
1741	DNA-359	2022-11-10 00:00:00-08	DNA	7.23	176	176	\N	2
1742	DNA-361	2022-11-10 00:00:00-08	DNA	1.63	176	176	\N	2
1743	DNA-363	2022-11-28 00:00:00-08	DNA	0.14	88	88	\N	2
1744	DNA-364	2022-11-10 00:00:00-08	DNA	10.5	176	176	\N	2
1745	DNA-365	2022-11-10 00:00:00-08	DNA	4.74	88	88	\N	2
1746	DNA-366	2022-11-10 00:00:00-08	DNA	3.24	88	88	\N	2
1747	DNA-367	2022-11-28 00:00:00-08	DNA	0.95	352	352	\N	2
1748	DNA-369	2022-11-14 00:00:00-08	DNA	8.74	264	264	\N	2
1749	DNA-372	2022-11-10 00:00:00-08	DNA	2.6	88	88	\N	2
1750	DNA-373	2022-11-10 00:00:00-08	DNA	2.91	88	88	\N	2
1751	DNA-374	2022-11-28 00:00:00-08	DNA	0.53	264	264	\N	2
1752	DNA-377	2022-11-14 00:00:00-08	DNA	19	264	264	\N	2
1753	DNA-379	2022-11-14 00:00:00-08	DNA	23.3	176	176	\N	2
1754	DNA-381	2022-11-14 00:00:00-08	DNA	10.8	88	88	\N	2
1755	DNA-382	2022-11-28 00:00:00-08	DNA	1.45	88	88	\N	2
1756	DNA-383	2022-11-14 00:00:00-08	DNA	7.58	176	176	\N	2
1757	DNA-385	2022-11-22 00:00:00-08	DNA	6.09	88	88	\N	2
1758	DNA-387	2022-11-22 00:00:00-08	DNA	7.53	88	88	\N	2
1759	DNA-388	2022-11-28 00:00:00-08	DNA	0.41	176	176	\N	2
1760	DNA-390	2022-11-22 00:00:00-08	DNA	3.61	88	88	\N	2
1761	DNA-391	2022-11-22 00:00:00-08	DNA	2.7	88	88	\N	2
1762	DNA-392	2022-11-22 00:00:00-08	DNA	9.28	88	88	\N	2
1763	DNA-393	2022-11-28 00:00:00-08	DNA	0.99	88	88	\N	2
1764	DNA-394	2022-11-22 00:00:00-08	DNA	32.6	176	176	\N	2
1765	DNA-396	2022-11-22 00:00:00-08	DNA	15.5	88	88	\N	2
1766	DNA-397	2022-11-28 00:00:00-08	DNA	0.17	352	352	\N	2
1767	DNA-399	2022-12-09 00:00:00-08	DNA	9.68	88	88	\N	2
1768	DNA-401	2022-12-09 00:00:00-08	DNA	8.78	88	88	\N	2
4600	NA_CP1_Normal	\N	DNA	\N	\N	\N	\N	\N
1769	DNA-402	2022-12-09 00:00:00-08	DNA	4.41	88	88	\N	2
1770	DNA-403	2022-12-09 00:00:00-08	DNA	20.4	176	176	\N	2
1771	DNA-404	2022-11-22 00:00:00-08	DNA	2.87	88	88	\N	2
1772	DNA-405	2022-11-22 00:00:00-08	DNA	4.33	176	176	\N	2
1773	DNA-407	2022-11-28 00:00:00-08	DNA	2.09	176	176	\N	2
1774	DNA-417	2022-11-14 00:00:00-08	DNA	11.2	88	88	\N	2
1775	DNA-418	2022-12-09 00:00:00-08	DNA	14.8	88	88	\N	2
1776	DNA-419	2022-12-09 00:00:00-08	DNA	50	176	176	\N	2
1777	DNA-420	2022-12-09 00:00:00-08	DNA	0.82	176	176	\N	2
1778	DNA-421	2022-12-09 00:00:00-08	DNA	11	88	88	\N	2
1779	DNA-422	2022-12-09 00:00:00-08	DNA	4.81	88	88	\N	2
1780	DNA-423	2022-12-09 00:00:00-08	DNA	1.11	88	88	\N	2
1781	DNA-424	2023-04-18 00:00:00-07	DNA	6.6	160	160	\N	2
1782	DNA-425	2023-04-18 00:00:00-07	DNA	25.2	160	160	\N	2
1783	DNA-426	2023-04-18 00:00:00-07	DNA	141	160	160	\N	2
1784	DNA-427	2023-04-20 00:00:00-07	DNA	11.3	160	160	\N	2
1785	DNA-428	2023-04-18 00:00:00-07	DNA	8.52	80	80	\N	2
1786	DNA-429	2023-04-20 00:00:00-07	DNA	24.5	160	160	\N	2
1787	DNA-430	2023-04-20 00:00:00-07	DNA	49.4	80	80	\N	2
1788	DNA-431	2023-04-20 00:00:00-07	DNA	8.54	80	80	\N	2
1789	DNA-432	2023-04-20 00:00:00-07	DNA	22.4	80	80	\N	2
1790	DNA-433	2023-04-20 00:00:00-07	DNA	2.55	80	80	\N	2
1791	DNA-434	2023-04-20 00:00:00-07	DNA	8.22	80	80	\N	2
1792	DNA-435	2023-04-20 00:00:00-07	DNA	3.57	80	80	\N	2
1793	DNA-436	2023-04-25 00:00:00-07	DNA	21.3	160	160	\N	2
1794	DNA-437	2023-04-25 00:00:00-07	DNA	19.3	80	80	\N	2
1795	DNA-438	2023-04-25 00:00:00-07	DNA	3.85	160	160	\N	2
1796	DNA-439	2023-06-05 00:00:00-07	DNA	20.7	198	198	\N	6
1797	DNA-440	2023-06-05 00:00:00-07	DNA	3.79	96	96	\N	6
1798	DNA-441	2023-06-05 00:00:00-07	DNA	3.06	96	96	\N	6
1799	DNA-442	2023-06-05 00:00:00-07	DNA	1.42	198	198	\N	6
1800	DNA-443	2023-06-06 00:00:00-07	DNA	2.39	200	200	\N	6
1801	DNA-444	2023-06-06 00:00:00-07	DNA	5.48	200	200	\N	6
1802	DNA-445	2023-06-06 00:00:00-07	DNA	0.09	200	200	\N	6
1803	DNA-446	2023-06-06 00:00:00-07	DNA	7.96	200	200	\N	6
1804	DNA-447	2023-06-06 00:00:00-07	DNA	2.41	100	100	\N	6
1805	DNA-448	2023-06-06 00:00:00-07	DNA	1.81	100	100	\N	6
1806	DNPD-01	2020-06-01 00:00:00-07	DNA	0.95	80	80	\N	5
1807	DNPD-02	2020-06-01 00:00:00-07	DNA	2.13	80	80	\N	5
1808	DNPD-03	2020-06-01 00:00:00-07	DNA	0.83	80	80	\N	5
1809	DNPD-04	2020-06-01 00:00:00-07	DNA	1.88	80	80	\N	5
1810	DNPD-05	2020-06-01 00:00:00-07	DNA	2.27	80	80	\N	5
1811	DNPD-06	2020-06-01 00:00:00-07	DNA	2.3	80	80	\N	5
1812	DNPD-07	2020-06-01 00:00:00-07	DNA	0	80	80	\N	5
1813	DNPD-08	2020-06-01 00:00:00-07	DNA	0.09	80	80	\N	5
1814	DNPD-09	2020-06-01 00:00:00-07	DNA	0.19	80	80	\N	5
1815	DP12_200_NA	\N	DNA	\N	\N	\N	\N	\N
1816	DPN_1_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1817	DPN_3_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1818	DPN_4_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1819	DPN_5_Normal_NA	2013-08-06 00:00:00-07	DNA	9.28	100	100	\N	5
1820	DPN_5_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1821	DPN_6_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1822	DPN_7_Tumor_NA	2013-08-06 00:00:00-07	DNA	0.1	100	100	\N	5
1823	DPN_8_Normal_NA	2013-07-30 00:00:00-07	DNA	\N	\N	\N	\N	\N
1824	DPN_8_Tumor_NA	2013-07-30 00:00:00-07	DNA	\N	\N	\N	\N	\N
1825	DPN_9_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1826	DPN_9_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1827	DPN_10_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1828	DPN_11_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1829	DPN_12_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1830	DPN_14_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1831	DPN_16_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1832	DPN_17_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1833	DPN_18_Normal_NA	2013-07-30 00:00:00-07	DNA	\N	\N	\N	\N	\N
1834	DPN_18_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1835	DPN_19_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1836	DPN_35_NA	\N	DNA	\N	\N	\N	\N	\N
1837	DPN_CNN 30_NA	\N	DNA	\N	\N	\N	\N	\N
1838	DPN_CNN 32_NA	\N	DNA	\N	\N	\N	\N	\N
1839	DPN_Conv_35_NA	\N	DNA	\N	\N	\N	\N	\N
1840	DPN_MM 20_NA	\N	DNA	\N	\N	\N	\N	\N
1841	DPN_MM 21_NA	\N	DNA	\N	\N	\N	\N	\N
1842	DPN_MM 22_NA	\N	DNA	\N	\N	\N	\N	\N
1843	DT10_63051C_NA	\N	DNA	\N	\N	\N	Ivanka Normal (for #9)	\N
1844	FAC01	2023-02-22 00:00:00-08	DNA	0.64	140	140	3mm punch biopsy	3
1845	FAC03	2023-02-22 00:00:00-08	DNA	24.8	140	140	3mm punch biopsy	3
1846	FAC05	2023-02-22 00:00:00-08	DNA	30.7	140	140	3mm punch biopsy	3
1847	FAC06	2023-02-22 00:00:00-08	DNA	23.8	140	140	3mm punch biopsy	3
1848	Fusion-01	\N	RNA	26.9	20	20	Fusion Gene: MET; Fusion Verified DNA: EPS15-MET; **Nanodrop was used to quantify	\N
1849	Fusion-02	\N	RNA	7.8	15	15	Fusion Gene: BRAF; Fusion Verified DNA: MAD1L-BRAF; **Nanodrop was used to quantify	\N
1850	Fusion-05	\N	RNA	161.6	20	20	Fusion Gene: MET; Fusion Verified DNA: ZKSCAN1-MET; **Nanodrop was used to quantify	\N
1851	Fusion-06	\N	RNA	13.8	20	20	Fusion Gene: PRKCA; Fusion Verified RNA: ATP2B4-PRKCA; **Nanodrop was used to quantify	\N
1852	Fusion-08	\N	RNA	17.2	20	20	Fusion Gene: NTRK3; Fusion Verified RNA: Myo5A-NTRK3; **Nanodrop was used to quantify	\N
1853	Fusion-09	\N	RNA	64.5	20	20	Fusion Gene: ROS1; Fusion Verified RNA: PWWP2A-ROS1; **Nanodrop was used to quantify	\N
1967	KIT_244_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
4601	DM45_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1854	Fusion-10	\N	RNA	43.9	100	100	Fusion Gene: BRAF; Fusion Verified DNA: Cell line MA9254; **Nanodrop was used to quantify	\N
1855	Fusion-11	\N	RNA	536.5	20	20	Fusion Gene: ALK; Fusion Verified DNA: Lung cancer with ALK fusion; ; **Nanodrop was used to quantify	\N
1856	G3 DP08-21965C Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1857	G3 DP08-21965C Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1858	G5 DP08-4205A Normal_NA	\N	DNA	\N	\N	\N	\N	\N
1859	G5 DP08-4205A Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1860	HW_2_Tumor Dissect_NA	\N	DNA	\N	\N	\N	\N	\N
1861	HW_3_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1862	HW_8_Mucosal_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1863	HW_A1_Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
1864	HW_A1_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1865	HW_A2_Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
1866	HW_A2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1867	HW_A3_Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
1868	HW_A3_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1869	HW_A4_Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
1870	HW_A4_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1871	HW_A5_Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
1872	HW_A5_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1873	HW_A6_Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
1874	HW_A6_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1875	HW_A7 Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
1876	HW_A7_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1877	HW_A8_Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
1878	HW_A8_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1879	HW_A9_Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
1880	HW_A9_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1881	HW_A10_Cntl_NA	\N	DNA	\N	\N	\N	\N	\N
1882	HW_A10_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1883	HW_Acral_#8_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
1884	Ivanka_5_1_NA	\N	DNA	\N	\N	\N	\N	\N
1885	Ivanka_5_2_NA	\N	DNA	\N	\N	\N	\N	\N
1886	Ivanka_5_3_NA	\N	DNA	\N	\N	\N	\N	\N
1887	Ivanka_5_4_NA	\N	DNA	\N	\N	\N	\N	\N
1888	Ivanka_5_5_NA	\N	DNA	\N	\N	\N	\N	\N
1889	Ivanka_9_1_NA	\N	DNA	\N	\N	\N	\N	\N
1890	Ivanka_9_2_NA	\N	DNA	\N	\N	\N	\N	\N
1891	Ivanka_9_3_NA	\N	DNA	\N	\N	\N	\N	\N
1892	Ivanka_9_4_NA	\N	DNA	\N	\N	\N	\N	\N
1893	Ivanka_9_5_NA	\N	DNA	\N	\N	\N	\N	\N
1894	Ivanka_10_1_NA	\N	DNA	\N	\N	\N	\N	\N
1895	Ivanka_10_2_NA	\N	DNA	\N	\N	\N	\N	\N
1896	Ivanka_10_3_NA	\N	DNA	\N	\N	\N	\N	\N
1897	Ivanka_10_4_NA	\N	DNA	\N	\N	\N	\N	\N
1898	Ivanka_10_5_NA	\N	DNA	\N	\N	\N	\N	\N
1899	Ivanka_12_1_NA	\N	DNA	\N	\N	\N	\N	\N
1900	Ivanka_12_2_NA	\N	DNA	\N	\N	\N	\N	\N
1901	Ivanka_12_3_NA	\N	DNA	\N	\N	\N	\N	\N
1902	Ivanka_12_4_NA	\N	DNA	\N	\N	\N	\N	\N
1903	Ivanka_12_5_NA	\N	DNA	\N	\N	\N	\N	\N
1904	Ivanka_16_1_NA	\N	DNA	\N	\N	\N	\N	\N
1905	Ivanka_16_2_NA	\N	DNA	\N	\N	\N	\N	\N
1906	Ivanka_16_3_NA	\N	DNA	\N	\N	\N	\N	\N
1907	Ivanka_16_4_NA	\N	DNA	\N	\N	\N	\N	\N
1908	Ivanka_16_5_NA	\N	DNA	\N	\N	\N	\N	\N
1909	Ivanka_20_1_NA	\N	DNA	\N	\N	\N	\N	\N
1910	Ivanka_20_2_NA	\N	DNA	\N	\N	\N	\N	\N
1911	Ivanka_20_3_NA	\N	DNA	\N	\N	\N	\N	\N
1912	Ivanka_20_4_NA	\N	DNA	\N	\N	\N	\N	\N
1913	Ivanka_20_5_NA	\N	DNA	\N	\N	\N	\N	\N
1914	Ivanka_22_1_NA	\N	DNA	\N	\N	\N	\N	\N
1915	Ivanka_22_2_NA	\N	DNA	\N	\N	\N	\N	\N
1916	Ivanka_22_3_NA	\N	DNA	\N	\N	\N	\N	\N
1917	Ivanka_22_4_NA	\N	DNA	\N	\N	\N	\N	\N
1918	Ivanka_22_5_NA	\N	DNA	\N	\N	\N	\N	\N
1919	Ivanka_23_1_NA	\N	DNA	\N	\N	\N	\N	\N
1920	Ivanka_23_2_NA	\N	DNA	\N	\N	\N	\N	\N
1921	Ivanka_23_3_NA	\N	DNA	\N	\N	\N	\N	\N
1922	Ivanka_23_4_NA	\N	DNA	\N	\N	\N	\N	\N
1923	Ivanka_23_5_NA	\N	DNA	\N	\N	\N	\N	\N
1924	K1_13	2014-07-22 00:00:00-07	DNA	1.71	50	50	\N	\N
1925	K1_14	2014-07-22 00:00:00-07	DNA	46.4	50	50	\N	\N
1926	K1_15	2014-07-22 00:00:00-07	DNA	47.5	50	50	\N	\N
1927	K1_16	2014-07-22 00:00:00-07	DNA	36.2	50	50	\N	\N
1928	K1_17	2014-07-22 00:00:00-07	DNA	39.3	50	50	\N	\N
1929	K1_18	2014-07-22 00:00:00-07	DNA	23.3	50	50	\N	\N
1930	K1_19	2014-07-22 00:00:00-07	DNA	43.2	50	50	\N	\N
1931	K1_20	2014-07-22 00:00:00-07	DNA	14.1	50	50	\N	\N
1932	K1_21	2014-07-22 00:00:00-07	DNA	38.9	50	50	\N	\N
1933	K1_22	2014-07-22 00:00:00-07	DNA	44.7	50	50	\N	\N
1934	K2_1_NA	2014-07-22 00:00:00-07	DNA	51	50	50	\N	\N
1935	K2_2_NA	2014-07-22 00:00:00-07	DNA	6.56	50	50	\N	\N
1936	K2_3_NA	2014-07-22 00:00:00-07	DNA	\N	50	50	\N	\N
1937	K2_4	2014-07-22 00:00:00-07	DNA	6.26	50	50	\N	\N
1938	K2_5	2014-07-22 00:00:00-07	DNA	11.2	50	50	\N	\N
1939	K2_6	2014-07-22 00:00:00-07	DNA	0.79	50	50	\N	\N
1940	K2_7	2014-07-22 00:00:00-07	DNA	41.8	50	50	\N	\N
1941	K2_8	2014-07-22 00:00:00-07	DNA	1.26	50	50	\N	\N
1942	K2_9	2014-07-22 00:00:00-07	DNA	54	50	50	\N	\N
1943	K2_10	2014-07-22 00:00:00-07	DNA	56	50	50	\N	\N
1944	K2_11_NA	2014-07-22 00:00:00-07	DNA	49.7	50	50	\N	\N
1945	Kit 262_NA	\N	DNA	\N	\N	\N	\N	\N
1946	Kit_8_NA	\N	DNA	\N	\N	\N	WT/Mucosal Oral	\N
1947	Kit_21_NA	\N	DNA	\N	\N	\N	BRAF/Mucosal Anal	\N
1948	Kit_37_Acral_NRAS_NA	\N	DNA	\N	\N	\N	\N	\N
1949	Kit_53_Acral_NRAS_NA	\N	DNA	\N	\N	\N	Melanoma, Heel	\N
1950	Kit_55_NA	\N	DNA	\N	\N	\N	WT/Mucosal Anal	\N
1951	Kit_62__Acral_NRAS_NA	\N	DNA	\N	\N	\N	\N	\N
1952	Kit_76_NA	\N	DNA	\N	\N	\N	WT/Mucosal Sinus	\N
1953	Kit_118_Muc_NRAS_NA	\N	DNA	\N	\N	\N	\N	\N
1954	KIT_134_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
1955	Kit_181_Muc BRAF_NA	\N	DNA	\N	\N	\N	\N	\N
1956	Kit_181_Muc_BRAF_NA	\N	DNA	\N	\N	\N	\N	\N
1957	KIT_191_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
1958	Kit_192_NA	\N	DNA	\N	\N	\N	Acral Mucosal	\N
1959	Kit_203_NA	\N	DNA	\N	\N	\N	Acral Mucosal	\N
1960	KIT_205_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
1961	KIT_206_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
1962	KIT_210_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
1963	KIT_217_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
1964	KIT_225_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
1965	Kit_227_Acral_WT_NA	2012-07-31 00:00:00-07	DNA	70.5	45	45	Melanoma, vulva	\N
1966	KIT_230_NA	\N	DNA	\N	\N	\N	\N	\N
1968	KIT_260_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
1969	KIT_273_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
1970	Kit_275_Muc_BRAF_NA	\N	DNA	\N	\N	\N	\N	\N
1971	KIT_295_NA	\N	DNA	\N	\N	\N	Alyssa Acral Mucosal DNA	\N
1972	KIT_297_NA	\N	DNA	\N	\N	\N	\N	\N
1973	KIT_302_NA	\N	DNA	\N	\N	\N	\N	\N
1974	Kit_313_Mucosal_NA	\N	DNA	\N	\N	\N	Melanoma, Rectum	\N
1975	KIT_316_NA	\N	DNA	\N	\N	\N	\N	\N
1976	KIT-01	2017-11-07 00:00:00-08	DNA	0.21	90	90	\N	5
1977	KIT-02	2017-11-07 00:00:00-08	DNA	0.73	90	90	\N	5
1978	KIT-03	2017-11-07 00:00:00-08	DNA	1.09	90	90	\N	5
1979	KIT-04	2017-11-07 00:00:00-08	DNA	1.38	90	90	\N	5
1980	KIT-05	2017-11-07 00:00:00-08	DNA	0.81	90	90	\N	5
1981	KIT-06	2017-11-07 00:00:00-08	DNA	0.48	90	90	\N	5
1982	KIT-07	2017-11-15 00:00:00-08	DNA	1.97	30	30	\N	4
1983	KIT-08	2017-11-15 00:00:00-08	DNA	0.65	30	30	\N	4
1984	KIT-09	2017-11-15 00:00:00-08	DNA	1.36	30	30	\N	4
1985	KIT-10	2017-11-15 00:00:00-08	DNA	3.26	30	30	\N	4
1986	KIT-11	2017-11-07 00:00:00-08	DNA	3.86	15	15	\N	5
1987	KIT-12	2017-11-07 00:00:00-08	DNA	2.46	25	25	\N	5
1988	KIT-13	2018-01-26 00:00:00-08	DNA	1.69	50	50	\N	4
1989	KIT-14	2018-01-26 00:00:00-08	DNA	3.98	50	50	\N	4
1990	KIT-15	2018-01-26 00:00:00-08	DNA	1.85	50	50	\N	4
1991	KIT-16	2018-01-26 00:00:00-08	DNA	2.58	50	50	\N	4
1992	KIT-17	2018-01-26 00:00:00-08	DNA	3.98	50	50	\N	4
1993	KIT-18	2018-01-26 00:00:00-08	DNA	4.46	50	50	\N	4
1994	KR_8_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
1995	KR_150_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
1996	KR_166_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
1997	KR_177_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
1998	KR_203_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
1999	KR_229_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
2000	KR_2030_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
2001	KR_2064_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
2002	KR_5233_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
2003	KR_RMK0091B_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
2004	KR_RMK0137C_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
2005	KR_RMK0162C_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
2006	KR_RMK0168C_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
2007	KR_RMK0194C_NA	\N	DNA	\N	\N	\N	Kate Rauen RASopathy cases	\N
2008	L2-HGD_NA	\N	DNA	\N	\N	\N	\N	\N
2009	L2-Normal_NA	\N	DNA	\N	\N	\N	\N	\N
2010	L3-HGD_NA	\N	DNA	\N	\N	\N	\N	\N
2011	L3-Normal_NA	\N	DNA	\N	\N	\N	\N	\N
2012	L11_96096_A2_Norm_NA	\N	DNA	\N	\N	\N	Metastatic Melanoma, Lymph Node, sentinel. Capsular nevus is present	\N
2013	LMM D-001	2023-04-18 00:00:00-07	DNA	1.46	80	80	\N	2
2014	LMM D-002	2023-04-18 00:00:00-07	DNA	0.72	80	80	\N	2
2015	LMM D-003	2023-04-18 00:00:00-07	DNA	0.32	80	80	\N	2
2016	LMM D-004	2023-04-18 00:00:00-07	DNA	20.4	80	80	\N	2
2017	LMM D-005	2023-04-18 00:00:00-07	DNA	4.6	80	80	\N	2
2018	LMM D-006	2023-04-18 00:00:00-07	DNA	6.68	80	80	\N	2
2019	LMM D-007	2023-04-20 00:00:00-07	DNA	6.99	80	80	\N	2
2020	LMM D-008	2023-04-20 00:00:00-07	DNA	7.3	80	80	\N	2
2021	LMM D-009	2023-04-20 00:00:00-07	DNA	4.12	80	80	\N	2
2022	LMM D-010	2023-04-20 00:00:00-07	DNA	24.5	80	80	\N	2
2023	LMM D-011	2023-04-20 00:00:00-07	DNA	26.3	80	80	\N	2
2024	LMM D-012	2023-04-20 00:00:00-07	DNA	13.5	80	80	\N	2
2025	LMM D-013	2023-04-18 00:00:00-07	DNA	27.7	80	80	\N	2
2026	LMM D-014	2023-04-18 00:00:00-07	DNA	8.56	80	80	\N	2
2027	LMM D-015	2023-04-18 00:00:00-07	DNA	5.34	80	80	\N	2
2028	LMM D-016	2023-05-19 00:00:00-07	DNA	0.93	170	170	\N	6
2029	LMM D-017	2023-05-19 00:00:00-07	DNA	2.08	80	80	\N	6
2030	LMM D-018	2023-05-19 00:00:00-07	DNA	2.26	80	80	\N	6
2031	LMM D-019	2023-05-19 00:00:00-07	DNA	2.24	80	80	\N	6
2032	LMM D-020	2023-05-19 00:00:00-07	DNA	0.18	80	80	\N	6
2033	LMM D-021	2023-05-19 00:00:00-07	DNA	0.2	80	80	\N	6
2034	LMM D-022	2023-06-07 00:00:00-07	DNA	0.74	88	88	\N	6
2035	LMM D-023	2023-06-07 00:00:00-07	DNA	0.08	88	88	\N	6
2036	LMM D-024	2023-06-07 00:00:00-07	DNA	1.03	88	88	\N	6
2037	LMM D-025	2023-08-25 00:00:00-07	DNA	3.12	88	88	\N	2
2038	LMM D-026	2023-08-25 00:00:00-07	DNA	1.01	88	88	\N	2
2039	LMM D-027	2023-08-28 00:00:00-07	DNA	0.13	88	88	\N	2
2040	LMM D-028	2023-08-25 00:00:00-07	DNA	0.7	88	88	\N	2
2041	LMM D-029	2023-08-25 00:00:00-07	DNA	2.07	88	88	\N	2
2042	LMM D-030	2023-08-28 00:00:00-07	DNA	0.14	88	88	\N	2
2043	LMM D-031	2023-08-25 00:00:00-07	DNA	31.6	88	88	\N	2
2044	LMM D-032	2023-08-25 00:00:00-07	DNA	3.08	88	88	\N	2
2045	LMM D-033	2023-08-28 00:00:00-07	DNA	5.48	88	88	\N	2
2046	LMM D-034	2023-08-25 00:00:00-07	DNA	3.61	88	88	\N	2
2047	LMM D-035	2023-08-25 00:00:00-07	DNA	3.71	88	88	\N	2
2048	LMM D-036	2023-08-28 00:00:00-07	DNA	0.26	88	88	\N	2
2049	LMM D-037	2023-08-25 00:00:00-07	DNA	0.32	88	88	\N	2
2050	LMM D-038	2023-08-25 00:00:00-07	DNA	0.87	88	88	\N	2
2051	LMM D-039	2023-08-28 00:00:00-07	DNA	0.11	88	88	\N	2
2052	LMM D-040	2023-08-25 00:00:00-07	DNA	1.39	88	88	\N	2
2053	LMM D-041	2023-08-25 00:00:00-07	DNA	1.9	88	88	\N	2
4591	UM23_NA	\N	DNA	\N	\N	\N	\N	\N
2054	LMM D-042	2023-08-28 00:00:00-07	DNA	0.36	88	88	\N	2
2055	LMM D-043	2023-08-25 00:00:00-07	DNA	12.7	88	88	\N	2
2056	LMM D-044	2023-08-25 00:00:00-07	DNA	8.03	88	88	\N	2
2057	LMM D-045	2023-08-28 00:00:00-07	DNA	5.15	88	88	\N	2
2058	LMM R-001	2023-04-18 00:00:00-07	RNA	3.28	45	45	\N	1
2059	LMM R-002	2023-04-18 00:00:00-07	RNA	1.16	40	40	\N	1
2060	LMM R-003	2023-04-18 00:00:00-07	RNA	0	45	45	\N	1
2061	LMM R-004	2023-04-18 00:00:00-07	RNA	18.7	45	45	\N	1
2062	LMM R-005	2023-04-18 00:00:00-07	RNA	7.57	45	45	\N	1
2063	LMM R-006	2023-04-18 00:00:00-07	RNA	7.36	45	45	\N	1
2064	LMM R-007	2023-04-20 00:00:00-07	RNA	2.65	45	45	\N	1
2065	LMM R-008	2023-04-20 00:00:00-07	RNA	2.3	45	45	\N	1
2066	LMM R-009	2023-04-20 00:00:00-07	RNA	5.21	45	45	\N	1
2067	LMM R-010	2023-04-20 00:00:00-07	RNA	2.65	45	45	\N	1
2068	LMM R-011	2023-04-20 00:00:00-07	RNA	2.4	45	45	\N	1
2069	LMM R-012	2023-04-20 00:00:00-07	RNA	2.1	45	45	\N	1
2070	LMM R-013	2023-04-18 00:00:00-07	RNA	19.2	45	45	\N	1
2071	LMM R-014	2023-04-18 00:00:00-07	RNA	2.58	45	45	\N	1
2072	LMM R-015	2023-04-18 00:00:00-07	RNA	2.3	45	45	\N	1
2073	LMM R-016	2023-05-19 00:00:00-07	RNA	3.03	18	18	\N	6
2074	LMM R-017	2023-05-19 00:00:00-07	RNA	3.12	18	18	\N	6
2075	LMM R-018	2023-05-19 00:00:00-07	RNA	3.93	18	18	\N	6
2076	LMM R-019	2023-05-19 00:00:00-07	RNA	53	18	18	\N	6
2077	LMM R-020	2023-05-19 00:00:00-07	RNA	4.44	18	18	\N	6
2078	LMM R-021	2023-05-19 00:00:00-07	RNA	3.35	18	18	\N	6
2079	LMM R-022	2023-06-07 00:00:00-07	RNA	5.44	18	18	\N	6
2080	LMM R-023	2023-06-07 00:00:00-07	RNA	1.44	18	18	\N	6
2081	LMM R-024	2023-06-07 00:00:00-07	RNA	23.1	18	18	\N	6
2082	LMM R-025	2023-08-25 00:00:00-07	RNA	12	45	45	\N	1
2083	LMM R-026	2023-08-25 00:00:00-07	RNA	4.2	45	45	\N	1
2084	LMM R-028	2023-08-25 00:00:00-07	RNA	1.75	35	35	\N	1
2085	LMM R-029	2023-08-25 00:00:00-07	RNA	3.91	45	45	\N	1
2086	LMM R-031	2023-08-25 00:00:00-07	RNA	36	45	45	\N	1
2087	LMM R-032	2023-08-25 00:00:00-07	RNA	4.84	45	45	\N	1
2088	LMM R-034	2023-08-25 00:00:00-07	RNA	3.84	45	45	\N	1
2089	LMM R-035	2023-08-25 00:00:00-07	RNA	5.53	45	45	\N	1
2090	LMM R-037	2023-08-25 00:00:00-07	RNA	1.06	35	35	\N	1
2091	LMM R-038	2023-08-25 00:00:00-07	RNA	3.92	45	45	\N	1
2092	LMM R-040	2023-08-25 00:00:00-07	RNA	2.3	45	45	\N	1
2093	LMM R-041	2023-08-25 00:00:00-07	RNA	7.67	45	45	\N	1
2094	LMM R-043	2023-08-25 00:00:00-07	RNA	19.8	45	45	\N	1
2095	LMM R-044	2023-08-25 00:00:00-07	RNA	17.6	45	45	\N	1
2096	LN D-01 (LN-01)	\N	DNA	98	50	50	\N	\N
2097	LN D-02 (LN-02)	\N	DNA	59.6	50	50	\N	\N
2098	LN D-03 (LN-03)	\N	DNA	106	50	50	\N	\N
2099	LN D-04 (LN-04)	\N	DNA	47.4	50	50	\N	\N
2100	LN D-05 (LN-05)	\N	DNA	15	50	50	\N	\N
2101	LN D-06 (LN-06)	\N	DNA	22.8	50	50	\N	\N
2102	LN D-07 (LN-07)	\N	DNA	85.8	50	50	\N	\N
2103	LN D-08 (LN-08)	\N	DNA	65.8	50	50	\N	\N
2104	LN D-09 (LN-09)	\N	DNA	29.8	50	50	\N	\N
2105	LN D-10 (LN-10)	\N	DNA	59	50	50	\N	\N
2106	LN D-11 (LN-11)	\N	DNA	23	50	50	\N	\N
2107	LN D-12 (LN-12)	\N	DNA	91.6	50	50	\N	\N
2108	LN D-13 (LN-13)	\N	DNA	100	50	50	\N	\N
2109	LN D-14 (LN-14)	\N	DNA	25.8	50	50	\N	\N
2110	LN D-15 (LN-15)	\N	DNA	36.6	50	50	\N	\N
2111	LN D-16 (LN-16)	\N	DNA	92.4	50	50	\N	\N
2112	LN D-17 (LN-17)	\N	DNA	49.8	50	50	\N	\N
2113	LN D-18 (LN-18)	\N	DNA	73.6	50	50	\N	\N
2114	LN D-19 (LN-19)	\N	DNA	17.6	50	50	\N	\N
2115	LN D-20 (LN-20)	\N	DNA	120	50	50	\N	\N
2116	LN D-21 (LN-21)	\N	DNA	35.2	50	50	\N	\N
2117	LN D-022 (LN-022)	2019-03-15 00:00:00-07	DNA	0.39	48	48	\N	5
2118	LN D-023 (LN-023)	2019-03-15 00:00:00-07	DNA	0.49	48	48	\N	5
2119	LN D-024 (LN-024)	2019-03-15 00:00:00-07	DNA	0.66	48	48	\N	5
2120	LN D-025 (LN-025)	2019-03-15 00:00:00-07	DNA	0.79	48	48	\N	5
2121	LN D-026 (LN-026)	2019-03-15 00:00:00-07	DNA	0.52	48	48	\N	5
2122	LN D-027 (LN-027)	2019-03-15 00:00:00-07	DNA	0.33	48	48	\N	5
2123	LN D-028 (LN-028)	2019-03-15 00:00:00-07	DNA	0.14	48	48	\N	5
2124	LN D-029 (LN-029)	2019-03-15 00:00:00-07	DNA	0.29	48	48	\N	5
2125	LN D-030 (LN-030)	2019-03-15 00:00:00-07	DNA	0.38	48	48	\N	5
2126	LN D-031 (LN-031)	2019-03-15 00:00:00-07	DNA	0.18	48	48	\N	5
2127	LN D-032 (LN-032)	2019-03-15 00:00:00-07	DNA	0.44	48	48	\N	5
2128	LN D-033 (LN-033)	2019-03-15 00:00:00-07	DNA	1.27	48	48	\N	5
2129	LN D-034 (LN-034)	2019-03-15 00:00:00-07	DNA	0.16	48	48	\N	5
2130	LN D-035 (LN-035)	2019-03-15 00:00:00-07	DNA	0.27	48	48	\N	5
2131	LN D-036 (LN-036)	2019-03-15 00:00:00-07	DNA	0.15	48	48	\N	5
2132	LN D-037 (LN-037)	2019-03-15 00:00:00-07	DNA	0.05	48	48	\N	5
2133	LN D-038 (LN-038)	2019-03-15 00:00:00-07	DNA	0.09	48	48	\N	5
2134	LN D-039 (LN-039)	2019-03-15 00:00:00-07	DNA	0.2	48	48	\N	5
2135	LN D-040 (LN-040)	2019-03-15 00:00:00-07	DNA	0.55	48	48	\N	5
2136	LN D-041 (LN-041)	2019-03-15 00:00:00-07	DNA	1.42	48	48	\N	5
2137	LN D-042 LN-042)	2019-03-15 00:00:00-07	DNA	0.12	48	48	\N	5
2138	LN D-043 (LN-043)	2019-03-15 00:00:00-07	DNA	0.58	48	48	\N	5
2139	LN D-044 (LN-044)	2019-03-15 00:00:00-07	DNA	0.63	48	48	\N	5
2140	LN D-045 (LN-045)	2019-03-15 00:00:00-07	DNA	1.52	48	48	\N	5
2141	LN D-046 (LN-046)	2019-03-15 00:00:00-07	DNA	0.25	48	48	\N	5
2142	LN D-047 (LN-047)	2019-03-15 00:00:00-07	DNA	0.27	48	48	\N	5
2143	LN D-048 (LN-048)	2019-03-29 00:00:00-07	DNA	1.3	48	48	\N	5
2144	LN D-049 (LN-049)	2019-03-29 00:00:00-07	DNA	0.63	48	48	\N	5
2145	LN D-050 (LN-050)	2019-03-29 00:00:00-07	DNA	2.09	48	48	\N	5
2146	LN D-051 (LN-051)	2019-03-29 00:00:00-07	DNA	0.46	48	48	\N	5
2147	LN D-052 (LN-052)	2019-03-29 00:00:00-07	DNA	0.18	48	48	\N	5
2148	LN D-053 (LN-053)	2019-03-29 00:00:00-07	DNA	0.78	48	48	\N	5
2149	LN D-054 (LN-054)	2019-04-24 00:00:00-07	DNA	0.09	48	48	\N	5
2150	LN D-055 (LN-055)	2019-04-24 00:00:00-07	DNA	0.44	48	48	\N	5
2151	LN D-056 (LN-056)	2019-04-24 00:00:00-07	DNA	0.62	48	48	\N	5
2152	LN D-057 (LN-057)	2019-04-24 00:00:00-07	DNA	2.75	48	48	\N	5
2153	LN D-058 (LN-058)	2019-04-24 00:00:00-07	DNA	1.2	48	48	\N	5
2154	LN D-059 (LN-059)	2019-04-24 00:00:00-07	DNA	0.98	48	48	\N	5
2155	LN D-060 (LN-060)	2019-04-24 00:00:00-07	DNA	2.65	48	48	\N	5
2156	LN D-061 (LN-061)	2019-04-24 00:00:00-07	DNA	0.51	48	48	\N	5
2157	LN D-062 (LN-062)	2019-04-24 00:00:00-07	DNA	2.24	48	48	\N	5
2158	LN D-063 (LN-063)	2019-04-24 00:00:00-07	DNA	1.49	48	48	\N	5
2159	LN D-064 (LN-064)	2019-04-24 00:00:00-07	DNA	2.31	48	48	\N	5
2160	LN D-065 (LN-065)	2019-04-24 00:00:00-07	DNA	1.36	48	48	\N	5
2161	LN D-066 (LN-066)	2019-04-24 00:00:00-07	DNA	0.98	48	48	\N	5
2162	LN D-067 (LN-067)	2019-04-24 00:00:00-07	DNA	1.68	48	48	\N	5
2163	LN D-068 (LN-068)	2019-04-24 00:00:00-07	DNA	0.4	48	48	\N	5
2164	LN D-069	2022-01-10 00:00:00-08	DNA	0.23	88	88	\N	2
2165	LN D-070	2022-01-10 00:00:00-08	DNA	0.16	88	88	\N	2
2166	LN D-071	2021-12-10 00:00:00-08	DNA	0.95	95	95	\N	2
2167	LN D-072	2021-12-10 00:00:00-08	DNA	1.62	95	95	\N	2
2168	LN D-073	2021-12-10 00:00:00-08	DNA	1.02	95	95	\N	2
2169	LN D-074	2021-12-10 00:00:00-08	DNA	1.16	95	95	\N	2
2170	LN D-075	2021-12-10 00:00:00-08	DNA	1.24	95	95	\N	2
2171	LN D-076	2022-01-13 00:00:00-08	DNA	0.94	88	88	\N	2
2172	LN D-077	2022-01-13 00:00:00-08	DNA	1.97	88	88	\N	2
2173	LN D-078	2022-01-13 00:00:00-08	DNA	0.84	88	88	\N	2
2174	LN D-079	2021-12-10 00:00:00-08	DNA	2.23	95	95	\N	2
2175	LN D-080	2022-01-10 00:00:00-08	DNA	1.37	88	88	\N	2
2176	LN D-082	2021-12-10 00:00:00-08	DNA	0.12	95	95	\N	2
2177	LN D-083	2021-12-10 00:00:00-08	DNA	0.74	95	95	\N	2
2178	LN D-084	2021-12-10 00:00:00-08	DNA	1.59	95	95	\N	2
2179	LN D-085	2021-12-10 00:00:00-08	DNA	0.71	95	95	\N	2
2180	LN D-086	2022-01-10 00:00:00-08	DNA	1.47	88	88	\N	2
2181	LN D-087	2022-01-13 00:00:00-08	DNA	1.83	88	88	\N	2
2182	LN D-089	2022-01-13 00:00:00-08	DNA	0.45	88	88	\N	2
2183	LN D-090	2022-01-13 00:00:00-08	DNA	0.62	88	88	\N	2
2184	LN D-091	2022-01-13 00:00:00-08	DNA	0.62	88	88	\N	2
2185	LN D-092	2022-01-10 00:00:00-08	DNA	0.16	88	88	\N	2
2186	LN D-093	2022-01-10 00:00:00-08	DNA	0.47	88	88	\N	2
2187	LN D-094	2022-01-13 00:00:00-08	DNA	2.07	88	88	\N	2
2188	LN D-095	2022-01-10 00:00:00-08	DNA	0.43	88	88	\N	2
2189	LN D-096	2022-01-10 00:00:00-08	DNA	0.8	88	88	\N	2
2190	LN D-097	2022-01-10 00:00:00-08	DNA	0.77	88	88	\N	2
2191	LN D-098	2022-01-10 00:00:00-08	DNA	0.65	88	88	\N	2
2192	LN D-099	2022-01-10 00:00:00-08	DNA	0.56	88	88	\N	2
2193	LN D-100	2022-01-10 00:00:00-08	DNA	0.99	88	88	\N	2
2194	LN D-101	2022-01-10 00:00:00-08	DNA	0.05	88	88	\N	2
2195	LN D-102	2022-01-10 00:00:00-08	DNA	0.47	88	88	\N	2
2196	LN D-103	2022-01-10 00:00:00-08	DNA	1.08	88	88	\N	2
2197	LN D-104	2022-01-10 00:00:00-08	DNA	0.42	88	88	\N	2
2198	LN D-105	2022-01-10 00:00:00-08	DNA	1.45	88	88	\N	2
2199	LN D-106	2022-01-10 00:00:00-08	DNA	0.93	88	88	\N	2
2200	LN D-107	2022-01-17 00:00:00-08	DNA	0.46	88	88	\N	2
2201	LN D-108	2022-01-10 00:00:00-08	DNA	0.43	88	88	\N	2
2202	LN D-109	2022-01-10 00:00:00-08	DNA	1.67	88	88	\N	2
2203	LN D-110	2022-01-17 00:00:00-08	DNA	1.64	88	88	\N	2
2204	LN D-111	2022-01-17 00:00:00-08	DNA	1.79	88	88	\N	2
2205	LN D-112	2022-01-10 00:00:00-08	DNA	0.84	88	88	\N	2
2206	LN D-113	2022-01-10 00:00:00-08	DNA	1.26	88	88	\N	2
2207	LN D-114	2022-01-10 00:00:00-08	DNA	1.58	88	88	\N	2
2208	LN D-115	2022-01-10 00:00:00-08	DNA	1.32	88	88	\N	2
2209	LN D-116	2022-01-13 00:00:00-08	DNA	0.27	88	88	\N	2
2210	LN D-117	2022-01-13 00:00:00-08	DNA	0.28	88	88	\N	2
2211	LN D-118	2022-01-20 00:00:00-08	DNA	0.41	88	88	\N	2
2212	LN D-119	2022-01-20 00:00:00-08	DNA	1.26	88	88	\N	2
2213	LN D-120	2022-01-20 00:00:00-08	DNA	0.72	88	88	\N	2
2214	LN D-121	2022-01-20 00:00:00-08	DNA	1.56	88	88	\N	2
2215	LN D-122	2022-01-24 00:00:00-08	DNA	2.3	88	88	\N	2
2216	LN D-123	2022-01-24 00:00:00-08	DNA	3.37	88	88	\N	2
2217	LN D-124	2022-01-20 00:00:00-08	DNA	0.67	88	88	\N	2
2218	LN D-125	2022-01-20 00:00:00-08	DNA	1.56	88	88	\N	2
2219	LN D-126	2022-01-20 00:00:00-08	DNA	0.27	88	88	\N	2
2220	LN D-127	2022-01-13 00:00:00-08	DNA	0.39	88	88	\N	2
2221	LN D-128	2022-01-13 00:00:00-08	DNA	1.05	88	88	\N	2
2222	LN D-129	2022-01-17 00:00:00-08	DNA	1.14	88	88	\N	2
2223	LN D-130	2022-01-24 00:00:00-08	DNA	2.77	88	88	\N	2
2224	LN D-131	2022-01-24 00:00:00-08	DNA	2.43	88	88	\N	2
2225	LN D-132	2022-01-17 00:00:00-08	DNA	0.82	88	88	\N	2
2226	LN D-133	2022-01-17 00:00:00-08	DNA	0.51	88	88	\N	2
2227	LN D-134	2022-01-17 00:00:00-08	DNA	0.61	88	88	\N	2
2228	LN D-135	2022-01-24 00:00:00-08	DNA	0.46	88	88	\N	2
2229	LN D-136	2022-01-24 00:00:00-08	DNA	2.79	88	88	\N	2
2230	LN D-137	2022-02-04 00:00:00-08	DNA	0.1	88	88	\N	2
2231	LN D-138	2022-02-04 00:00:00-08	DNA	0.93	88	88	\N	2
2232	LN D-139	2022-01-13 00:00:00-08	DNA	1.69	88	88	\N	2
2233	LN D-140	2022-01-13 00:00:00-08	DNA	4.63	88	88	\N	2
2234	LN D-141	2022-01-17 00:00:00-08	DNA	4.37	88	88	\N	2
2235	LN D-142	2022-01-17 00:00:00-08	DNA	5.9	88	88	\N	2
2236	LN D-143	2022-01-24 00:00:00-08	DNA	1.23	88	88	\N	2
2237	LN D-144	2022-01-24 00:00:00-08	DNA	1.02	88	88	\N	2
2238	LN D-145	2022-01-24 00:00:00-08	DNA	2.43	88	88	\N	2
2239	LN D-146	2022-01-24 00:00:00-08	DNA	2.25	88	88	\N	2
2240	LN D-147	2022-02-02 00:00:00-08	DNA	0.79	88	88	\N	2
2241	LN D-148	2022-02-02 00:00:00-08	DNA	1.43	88	88	\N	2
2242	LN D-149	2022-02-02 00:00:00-08	DNA	0.88	88	88	\N	2
2243	LN D-150	2022-02-02 00:00:00-08	DNA	0.81	88	88	\N	2
2244	LN D-151	2022-02-02 00:00:00-08	DNA	0.98	88	88	\N	2
2245	LN D-152	2022-02-02 00:00:00-08	DNA	1.22	88	88	\N	2
2246	LN D-153	2022-02-02 00:00:00-08	DNA	1.44	88	88	\N	2
2247	LN D-154	2022-02-02 00:00:00-08	DNA	0.26	88	88	\N	2
2248	LN D-155	2022-02-02 00:00:00-08	DNA	1.27	88	88	\N	2
2249	LN D-156	2022-02-02 00:00:00-08	DNA	1.61	88	88	\N	2
2250	LN D-157	2022-02-04 00:00:00-08	DNA	0.39	88	88	\N	2
2251	LN D-158	2022-02-04 00:00:00-08	DNA	1.38	88	88	\N	2
2252	LN D-159	2022-02-04 00:00:00-08	DNA	0.21	88	88	\N	2
2253	LN D-160	2022-02-04 00:00:00-08	DNA	0.42	88	88	\N	2
2254	LN D-161	2022-02-04 00:00:00-08	DNA	0.85	88	88	\N	2
2255	LN D-162	2022-02-04 00:00:00-08	DNA	0.85	88	88	\N	2
2256	LN D-163	2022-02-04 00:00:00-08	DNA	1.13	88	88	\N	2
2257	LN D-164	2022-02-22 00:00:00-08	DNA	0.56	88	88	\N	2
2258	LN R-069	2022-01-10 00:00:00-08	RNA	4.4	48	48	\N	1
2259	LN R-070	2022-01-10 00:00:00-08	RNA	2.4	48	48	\N	1
2260	LN R-071	2021-12-10 00:00:00-08	RNA	0	48	48	\N	1
2261	LN R-072	2021-12-10 00:00:00-08	RNA	2.3	48	48	\N	1
2262	LN R-073	2021-12-10 00:00:00-08	RNA	0	48	48	\N	1
2263	LN R-074	2021-12-10 00:00:00-08	RNA	2	48	48	\N	1
2264	LN R-075	2021-12-10 00:00:00-08	RNA	2.2	48	48	\N	1
2265	LN R-076	2022-01-13 00:00:00-08	RNA	2	48	48	\N	1
2266	LN R-077	2022-01-13 00:00:00-08	RNA	0	48	48	\N	1
2267	LN R-078	2022-01-13 00:00:00-08	RNA	2.1	48	48	\N	1
2268	LN R-079	2021-12-10 00:00:00-08	RNA	2.2	48	48	\N	1
2269	LN R-080	2022-01-10 00:00:00-08	RNA	3.3	48	48	\N	1
2270	LN R-082	2021-12-10 00:00:00-08	RNA	0	48	48	\N	1
2271	LN R-083	2021-12-10 00:00:00-08	RNA	2.4	48	48	\N	1
2272	LN R-084	2021-12-10 00:00:00-08	RNA	2.85	48	48	\N	1
2273	LN R-085	2021-12-10 00:00:00-08	RNA	0	48	48	\N	1
2274	LN R-086	2022-01-10 00:00:00-08	RNA	2.87	48	48	\N	1
2275	LN R-087	2022-01-13 00:00:00-08	RNA	3.41	48	48	\N	1
2276	LN R-089	2022-01-13 00:00:00-08	RNA	0	48	48	\N	1
2277	LN R-090	2022-01-13 00:00:00-08	RNA	0	48	48	\N	1
2278	LN R-091	2022-01-13 00:00:00-08	RNA	0	48	48	\N	1
2279	LN R-092	2022-01-10 00:00:00-08	RNA	0	48	48	\N	1
2280	LN R-093	2022-01-10 00:00:00-08	RNA	0	48	48	\N	1
2281	LN R-094	2022-01-13 00:00:00-08	RNA	2.74	48	48	\N	1
2282	LN R-095	2022-01-10 00:00:00-08	RNA	0	48	48	\N	1
2283	LN R-096	2022-01-10 00:00:00-08	RNA	2.5	48	48	\N	1
2284	LN R-097	2022-01-10 00:00:00-08	RNA	2	48	48	\N	1
2285	LN R-098	2022-01-10 00:00:00-08	RNA	2.1	48	48	\N	1
2286	LN R-099	2022-01-10 00:00:00-08	RNA	2	48	48	\N	1
2287	LN R-100	2022-01-10 00:00:00-08	RNA	2.64	48	48	\N	1
2288	LN R-101	2022-01-10 00:00:00-08	RNA	0	48	48	\N	1
2289	LN R-102	2022-01-10 00:00:00-08	RNA	3.17	48	48	\N	1
2290	LN R-103	2022-01-10 00:00:00-08	RNA	3.76	48	48	\N	1
2291	LN R-104	2022-01-10 00:00:00-08	RNA	0	48	48	\N	1
2292	LN R-105	2022-01-10 00:00:00-08	RNA	2.78	48	48	\N	1
2293	LN R-106	2022-01-10 00:00:00-08	RNA	2.51	48	48	\N	1
2294	LN R-107	2022-01-17 00:00:00-08	RNA	0	48	48	\N	1
2295	LN R-108	2022-01-10 00:00:00-08	RNA	0	48	48	\N	1
2296	LN R-109	2022-01-10 00:00:00-08	RNA	2.88	48	48	\N	1
4592	UM24_NA	\N	DNA	\N	\N	\N	\N	\N
2297	LN R-110	2022-01-17 00:00:00-08	RNA	3.13	48	48	\N	1
2298	LN R-111	2022-01-17 00:00:00-08	RNA	3.01	48	48	\N	1
2299	LN R-112	2022-01-10 00:00:00-08	RNA	2.2	48	48	\N	1
2300	LN R-113	2022-01-10 00:00:00-08	RNA	2.61	48	48	\N	1
2301	LN R-114	2022-01-10 00:00:00-08	RNA	5.66	48	48	\N	1
2302	LN R-115	2022-01-10 00:00:00-08	RNA	4.12	48	48	\N	1
2303	LN R-116	2022-01-13 00:00:00-08	RNA	4.7	48	48	\N	1
2304	LN R-117	2022-01-13 00:00:00-08	RNA	6.55	48	48	\N	1
2305	LN R-118	2022-01-20 00:00:00-08	RNA	0	48	48	\N	1
2306	LN R-119	2022-01-20 00:00:00-08	RNA	0	48	48	\N	1
2307	LN R-120	2022-01-20 00:00:00-08	RNA	0	48	48	\N	1
2308	LN R-121	2022-01-20 00:00:00-08	RNA	3.07	48	48	\N	1
2309	LN R-122	2022-01-20 00:00:00-08	RNA	3.27	48	48	\N	1
2310	LN R-123	2022-01-20 00:00:00-08	RNA	4.59	48	48	\N	1
2311	LN R-124	2022-01-20 00:00:00-08	RNA	0	48	48	\N	1
2312	LN R-125	2022-01-20 00:00:00-08	RNA	0	48	48	\N	1
2313	LN R-126	2022-01-20 00:00:00-08	RNA	0	48	48	\N	1
2314	LN R-127	2022-01-13 00:00:00-08	RNA	0	48	48	\N	1
2315	LN R-128	2022-01-13 00:00:00-08	RNA	0	48	48	\N	1
2316	LN R-129	2022-01-17 00:00:00-08	RNA	2.99	48	48	\N	1
2317	LN R-130	2022-01-24 00:00:00-08	RNA	0	48	48	\N	1
2318	LN R-131	2022-01-24 00:00:00-08	RNA	4.39	48	48	\N	1
2319	LN R-132	2022-01-17 00:00:00-08	RNA	0	48	48	\N	1
2320	LN R-133	2022-01-17 00:00:00-08	RNA	0	48	48	\N	1
2321	LN R-134	2022-01-17 00:00:00-08	RNA	0	48	48	\N	1
2322	LN R-135	2022-01-24 00:00:00-08	RNA	0	48	48	\N	1
2323	LN R-136	2022-01-24 00:00:00-08	RNA	2.5	48	48	\N	1
2324	LN R-137	2022-02-04 00:00:00-08	RNA	0	48	48	\N	1
2325	LN R-138	2022-02-04 00:00:00-08	RNA	0	48	48	\N	1
2326	LN R-139	2022-01-13 00:00:00-08	RNA	2	48	48	\N	1
2327	LN R-140	2022-01-13 00:00:00-08	RNA	5.93	48	48	\N	1
2328	LN R-141	2022-01-17 00:00:00-08	RNA	3.18	48	48	\N	1
2329	LN R-142	2022-01-17 00:00:00-08	RNA	3.32	48	48	\N	1
2330	LN R-143	2022-01-24 00:00:00-08	RNA	0	48	48	\N	1
2331	LN R-144	2022-01-24 00:00:00-08	RNA	2.4	48	48	\N	1
2332	LN R-145	2022-01-24 00:00:00-08	RNA	3.68	48	48	\N	1
2333	LN R-146	2022-01-24 00:00:00-08	RNA	2.61	48	48	\N	1
2334	LN R-147	2022-02-02 00:00:00-08	RNA	2.55	48	48	\N	1
2335	LN R-148	2022-02-02 00:00:00-08	RNA	4.26	48	48	\N	1
2336	LN R-149	2022-02-02 00:00:00-08	RNA	2.3	48	48	\N	1
2337	LN R-150	2022-02-02 00:00:00-08	RNA	2.59	48	48	\N	1
2338	LN R-151	2022-02-02 00:00:00-08	RNA	3.14	48	48	\N	1
2339	LN R-152	2022-02-02 00:00:00-08	RNA	3.73	48	48	\N	1
2340	LN R-153	2022-02-02 00:00:00-08	RNA	5.02	48	48	\N	1
2341	LN R-154	2022-02-02 00:00:00-08	RNA	0	48	48	\N	1
2342	LN R-155	2022-02-02 00:00:00-08	RNA	3.6	48	48	\N	1
2343	LN R-156	2022-02-02 00:00:00-08	RNA	4.73	48	48	\N	1
2344	LN R-157	2022-02-04 00:00:00-08	RNA	2	48	48	\N	1
2345	LN R-158	2022-02-04 00:00:00-08	RNA	3.51	48	48	\N	1
2346	LN R-159	2022-02-04 00:00:00-08	RNA	0	48	48	\N	1
2347	LN R-160	2022-02-04 00:00:00-08	RNA	0	48	48	\N	1
2348	LN R-161	2022-02-04 00:00:00-08	RNA	4.9	48	48	\N	1
2349	LN R-162	2022-02-04 00:00:00-08	RNA	3.15	48	48	\N	1
2350	LN R-163	2022-02-04 00:00:00-08	RNA	2.98	48	48	\N	1
2351	LN R-164	\N	RNA	0	0	0	\N	\N
2352	Luping_ROS 1_NA	\N	DNA	\N	\N	\N	\N	\N
2353	M230 Imat A2	\N	DNA	10.5	200	200	MISC -20oC BOX; MK Cells for the Broad Institute	\N
2354	M230 Imat A3	\N	DNA	18	200	200	MISC -20oC BOX; MK Cells for the Broad Institute	\N
2355	M040204 (AMC-07)	\N	DNA	15.2	50	50	\N	\N
2356	M040204 Dec2019 (AMC-07)	\N	DNA	40	10	10	\N	\N
2357	M040415 (AMC-08)	\N	DNA	16.5	50	50	\N	\N
2358	M040416 (AMC-08)	\N	DNA	21	50	50	\N	\N
2359	M040418 (AMC-08)	\N	DNA	16.2	50	50	\N	\N
2360	M040419A (AMC-08)	\N	DNA	14.1	50	50	\N	\N
2361	M100118 (AMC-02)	\N	DNA	9.3	50	50	\N	\N
2362	M180322 (AMC-13)	\N	DNA	9.88	50	50	\N	\N
2363	MaMel  152aI (AMC-01)	\N	DNA	15.1	50	50	\N	\N
2364	MB_161_Normal_NA	\N	DNA	\N	\N	\N	UC Denver, FFPE	\N
2365	MB_161_Tumor_NA	\N	DNA	\N	\N	\N	UC Denver, Frozen Tissue	\N
2366	MB_327_Tumor_NA	\N	DNA	\N	\N	\N	UC Denver, Frozen Tissue	\N
2367	MB_760_Tumor_NA	\N	DNA	\N	\N	\N	UC Denver, Frozen Tissue	\N
2368	MB_1028_Normal_NA	\N	DNA	\N	\N	\N	UC Denver, Frozen Tissue	\N
2369	MB_1029_Tumor_NA	\N	DNA	\N	\N	\N	UC Denver, Frozen Tissue	\N
2370	MB_1036_Normal_NA	\N	DNA	\N	\N	\N	UC Denver, Frozen Tissue	\N
2371	MB_1046_Tumor_NA	\N	DNA	\N	\N	\N	UC Denver,Frozen Tissue	\N
2372	MB_1418_Normal_NA	\N	DNA	\N	\N	\N	UC Denver, Frozen Tissue	\N
2373	MB_1454_Normal_NA	\N	DNA	\N	\N	\N	UC Denver, Frozen Tissue	\N
2374	MB_1609_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
2375	MB1241_Norm_NA	\N	DNA	\N	\N	\N	Acral Normal, Frozen Tissue DNA  Extracted by Denver	\N
2376	MB1242_Tumor_NA	\N	DNA	\N	\N	\N	Acral Tumor, Frozen Tissue DNA Extracted by Denver	\N
2377	MB1421_Norm_NA	\N	DNA	\N	\N	\N	Acral Normal, Thumb, Frozen Tissue DNA extracted by Denver	\N
2378	MB1423_Norm_NA	\N	DNA	\N	\N	\N	Acral Normal Heel, FFPE Extracted DNA by Denver	\N
2379	MB1423_Tumor_NA	\N	DNA	\N	\N	\N	Acral Tumor, Heel, Frozen Tissue DNA Extracted by Denver	\N
2380	MB1424 _Tumor_NA	\N	DNA	\N	\N	\N	Acral Tumor, Thumb, Frozen Tissue DNA extracted by Denver	\N
2381	MB1428_Norm_NA	\N	DNA	\N	\N	\N	Acral Normal, Heel Frozen Tissue DNA Extracted by Denver | Barcode mismatch comment in note	\N
2382	MB1429_Tumor_NA	\N	DNA	\N	\N	\N	Acral Tumor, Heel, Frozen Tissue DNA Extracted by Denver	\N
2383	MB1617_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
2384	MDD-01	\N	DNA	24.4	50	50	\N	5
2385	MDD-02	\N	DNA	31.2	50	50	\N	5
2386	MDD-03	\N	DNA	19.8	50	50	\N	5
2387	MDD-04	\N	DNA	2.46	50	50	\N	5
2388	MDD-05	\N	DNA	36.6	50	50	\N	5
2389	MDD-06	\N	DNA	25.6	50	50	\N	5
2390	MDD-07	\N	DNA	28.6	50	50	\N	5
2391	MDD-08	\N	DNA	86.6	50	50	\N	5
2392	MDD-09	\N	DNA	61	50	50	\N	5
2393	MDD-10	\N	DNA	77.6	50	50	\N	5
2394	MDD-11	\N	DNA	15.4	50	50	\N	5
2395	MDD-12	\N	DNA	32.4	50	50	\N	5
2396	MDD-13	\N	DNA	79.4	50	50	\N	5
2397	MDD-14	\N	DNA	346	50	50	\N	5
2398	MDD-15	\N	DNA	38.2	50	50	\N	5
2399	MDD-16	\N	DNA	39	50	50	\N	5
2400	MDD-17	\N	DNA	21.8	50	50	\N	5
2401	MDD-18	\N	DNA	23.4	50	50	\N	5
2402	MDD-19	\N	DNA	5.32	50	50	\N	5
2403	MDD-20	\N	DNA	9.9	50	50	\N	5
2404	MDD-21	\N	DNA	4.46	50	50	\N	5
2405	MDD-22	\N	DNA	9.38	50	50	\N	5
2406	MDD-23	\N	DNA	15.4	50	50	\N	5
2407	MDD-24	\N	DNA	7.84	50	50	\N	5
2408	MDD-25	\N	DNA	12.6	50	50	\N	5
2409	MDD-26	\N	DNA	73	50	50	\N	5
2410	MDD-27	\N	DNA	19.3	50	50	\N	5
2411	MDD-28	\N	DNA	17.7	50	50	\N	5
2412	MDD-29	\N	DNA	23.6	50	50	\N	5
2413	MDD-30	\N	DNA	32.6	50	50	\N	5
2414	MDD-31	\N	DNA	3.86	50	50	\N	5
2415	MDD-32	\N	DNA	78.4	50	50	\N	5
2416	MDD-33	\N	DNA	15.2	50	50	\N	5
2417	MDD-34	\N	DNA	4.62	50	50	\N	5
2418	MDD-35	\N	DNA	33.4	50	50	\N	5
2419	MDD-36	\N	DNA	29.2	50	50	\N	5
2420	MDD-37	\N	DNA	104	50	50	\N	5
2421	MDD-38	\N	DNA	28.8	50	50	\N	5
2422	MDD-39	\N	DNA	70	50	50	\N	5
2423	MDD-40	\N	DNA	1.45	50	50	\N	5
2424	MDD-41	\N	DNA	12.4	50	50	\N	5
2425	MDD-42	2019-07-08 00:00:00-07	DNA	22.7	96	96	\N	5
2426	MDD-43	2019-07-08 00:00:00-07	DNA	1.77	96	96	\N	5
2427	MDD-44	2019-07-08 00:00:00-07	DNA	27.1	96	96	\N	5
2428	MDD-45	2019-07-08 00:00:00-07	DNA	25.8	96	96	\N	5
2429	MDD-46	2019-07-08 00:00:00-07	DNA	6.88	96	96	\N	5
2430	MDD-47	2019-07-08 00:00:00-07	DNA	21.3	96	96	\N	5
2431	MDD-48	2019-07-08 00:00:00-07	DNA	21.7	96	96	\N	5
2432	MDD-49	2019-07-08 00:00:00-07	DNA	2.39	96	96	\N	5
2433	MDD-50	2019-07-08 00:00:00-07	DNA	2.4	96	96	\N	5
2434	MDD-51	2019-07-08 00:00:00-07	DNA	6.52	96	96	\N	5
2435	MDD-52	2019-07-08 00:00:00-07	DNA	9.74	96	96	\N	5
2436	MDD-53	2019-07-08 00:00:00-07	DNA	11.6	96	96	\N	5
2437	MDD-54	2019-07-08 00:00:00-07	DNA	22.2	96	96	\N	5
2438	MDD-55	2019-07-08 00:00:00-07	DNA	5.54	96	96	\N	5
2439	MDD-56	2019-07-08 00:00:00-07	DNA	1.79	96	96	\N	5
2440	MDD-57	2019-07-08 00:00:00-07	DNA	0.48	96	96	\N	5
2441	MDD-58	2019-07-08 00:00:00-07	DNA	11.7	96	96	\N	5
2442	MDD-59	2019-07-08 00:00:00-07	DNA	3.46	96	96	\N	5
2443	MDD-60	2019-07-08 00:00:00-07	DNA	2.94	96	96	\N	5
2444	MDD-61	2019-07-08 00:00:00-07	DNA	37.5	96	96	\N	5
2445	MDD-62	2019-07-08 00:00:00-07	DNA	28	96	96	\N	5
2446	MDD-63	2019-07-08 00:00:00-07	DNA	23.6	96	96	\N	5
2447	MDD-64	2019-07-16 00:00:00-07	DNA	14.5	96	96	\N	5
2448	MDD-65	2019-07-16 00:00:00-07	DNA	2.58	96	96	\N	5
2449	MDD-66	2019-07-16 00:00:00-07	DNA	11.1	96	96	\N	5
2450	MDD-67	2019-07-16 00:00:00-07	DNA	3.87	96	96	\N	5
2451	MDD-68	2019-07-16 00:00:00-07	DNA	15	96	96	\N	5
2452	MDD-69	2019-07-16 00:00:00-07	DNA	10.7	96	96	\N	5
2453	MDD-70	2019-07-16 00:00:00-07	DNA	38.8	96	96	\N	5
2454	MDD-71	2019-07-16 00:00:00-07	DNA	16.6	96	96	\N	5
2455	MDD-72	2019-07-16 00:00:00-07	DNA	28.4	96	96	\N	5
2456	MDD-73	2019-07-16 00:00:00-07	DNA	1.37	96	96	\N	5
2457	MDD-74	2019-07-16 00:00:00-07	DNA	5.4	96	96	\N	5
2458	MDD-75	2019-07-16 00:00:00-07	DNA	56	96	96	\N	5
2459	MDD-76	2019-07-16 00:00:00-07	DNA	32.7	96	96	\N	5
2460	MDD-77	2019-07-16 00:00:00-07	DNA	39.4	96	96	\N	5
2461	MDD-78	2019-07-16 00:00:00-07	DNA	3.36	96	96	\N	5
2462	MDD-79	2019-07-16 00:00:00-07	DNA	16.1	96	96	\N	5
2463	MDD-80	2019-07-16 00:00:00-07	DNA	1.34	96	96	\N	5
2464	MDD-81	2019-07-16 00:00:00-07	DNA	1.76	96	96	\N	5
2465	MDD-82	2019-07-16 00:00:00-07	DNA	53	96	96	\N	5
2466	MDD-83	2019-07-16 00:00:00-07	DNA	53	96	96	\N	5
2467	MDD-84	2019-07-16 00:00:00-07	DNA	9.55	96	96	\N	5
2468	MDD-85	2019-07-16 00:00:00-07	DNA	47.4	96	96	\N	5
2469	MDD-86	2019-07-16 00:00:00-07	DNA	41.1	96	96	\N	5
2470	MDD-87	2019-07-16 00:00:00-07	DNA	17	96	96	\N	5
2471	MDD-88	2019-07-23 00:00:00-07	DNA	59	96	96	\N	5
2472	MDD-89	2019-07-23 00:00:00-07	DNA	35.2	96	96	\N	5
2473	MDD-90	2019-07-23 00:00:00-07	DNA	4.81	96	96	\N	5
2474	MDD-91	2019-07-23 00:00:00-07	DNA	5.57	96	96	\N	5
2475	MDD-92	2019-07-23 00:00:00-07	DNA	44.5	96	96	\N	5
2476	MDD-93	2019-07-23 00:00:00-07	DNA	127	96	96	\N	5
2477	MDD-94	2019-07-23 00:00:00-07	DNA	26.5	96	96	\N	5
2478	MDD-95	2019-07-23 00:00:00-07	DNA	15.2	96	96	\N	5
2479	MDD-96	2019-07-23 00:00:00-07	DNA	25.1	96	96	\N	5
2480	MDD-97	2019-07-23 00:00:00-07	DNA	0.56	96	96	\N	5
2481	MDD-98	2019-07-23 00:00:00-07	DNA	5.37	96	96	\N	5
2482	MDD-99	2019-07-23 00:00:00-07	DNA	11.8	96	96	\N	5
2483	MDD-100	2019-07-23 00:00:00-07	DNA	10.2	96	96	\N	5
2484	MDD-101	2019-07-23 00:00:00-07	DNA	3.47	96	96	\N	5
2485	MDD-102	2019-07-23 00:00:00-07	DNA	18.6	96	96	\N	5
2486	MDD-103	2019-07-23 00:00:00-07	DNA	4.73	96	96	\N	5
2487	MDD-104	2019-07-23 00:00:00-07	DNA	19.9	96	96	\N	5
2488	MDD-105	2019-07-23 00:00:00-07	DNA	10.6	96	96	\N	5
2489	MDD-106	2019-07-23 00:00:00-07	DNA	1.14	96	96	\N	5
2490	MDD-107	2019-07-23 00:00:00-07	DNA	4.15	96	96	\N	5
2491	MDD-108	2019-07-23 00:00:00-07	DNA	37.5	96	96	\N	5
2492	MDD-109	2019-07-23 00:00:00-07	DNA	12.5	96	96	\N	5
2493	MDD-110	2019-10-05 00:00:00-07	DNA	2.09	96	96	\N	5
2494	MDD-111	2019-10-05 00:00:00-07	DNA	2.41	96	96	\N	5
2495	MDD-112	2019-10-05 00:00:00-07	DNA	5.47	96	96	\N	5
2496	MDD-113	2019-10-05 00:00:00-07	DNA	50	96	96	\N	5
2497	MDD-114	2019-10-05 00:00:00-07	DNA	3.04	96	96	\N	5
2498	MDD-115	2019-10-05 00:00:00-07	DNA	3.2	96	96	\N	5
2499	MDD-116	2019-10-05 00:00:00-07	DNA	2.73	96	96	\N	5
2500	MDD-117	2019-10-05 00:00:00-07	DNA	1.51	96	96	\N	5
2501	MDD-118	2019-10-05 00:00:00-07	DNA	1.59	96	96	\N	5
2502	MDD-119	2019-10-05 00:00:00-07	DNA	6.27	96	96	\N	5
2503	MDD-120	2019-10-05 00:00:00-07	DNA	10.6	96	96	\N	5
2504	MDD-121	2019-10-05 00:00:00-07	DNA	2.64	96	96	\N	5
2505	MDD-122	2019-10-05 00:00:00-07	DNA	6.77	96	96	\N	5
2506	MDD-123	2019-10-05 00:00:00-07	DNA	31.8	96	96	\N	5
2507	MDD-124	2019-10-05 00:00:00-07	DNA	2.79	96	96	\N	5
2508	MDD-125	2019-10-05 00:00:00-07	DNA	1.62	96	96	\N	5
2509	MDD-126	2019-10-05 00:00:00-07	DNA	11.1	96	96	\N	5
2510	MDD-127	2019-10-05 00:00:00-07	DNA	1.04	96	96	\N	5
2511	MDD-128	2019-10-05 00:00:00-07	DNA	6.15	96	96	\N	5
2512	MDD-129	2019-10-05 00:00:00-07	DNA	6.86	96	96	\N	5
2513	MDD-130	2019-10-05 00:00:00-07	DNA	2.73	96	96	\N	5
2514	MDD-131	2019-10-05 00:00:00-07	DNA	8.16	96	96	\N	5
2515	MDD-132	2019-10-05 00:00:00-07	DNA	15.9	96	96	\N	5
2516	MDD-133	2019-10-05 00:00:00-07	DNA	0.86	96	96	\N	5
2517	MDD-134	2019-10-08 00:00:00-07	DNA	5.51	96	96	\N	5
2518	MDD-135	2019-10-08 00:00:00-07	DNA	2.62	96	96	\N	5
2519	MDD-136	2019-10-08 00:00:00-07	DNA	8.14	96	96	\N	5
2520	MDD-137	2019-10-08 00:00:00-07	DNA	0.8	96	96	\N	5
2521	MDD-138	2019-10-08 00:00:00-07	DNA	9.05	96	96	\N	5
2522	MDD-139	2019-10-08 00:00:00-07	DNA	4.21	96	96	\N	5
2523	MDD-140	2019-10-08 00:00:00-07	DNA	3.81	96	96	\N	5
2524	MDD-141	2019-10-08 00:00:00-07	DNA	1.83	96	96	\N	5
2525	MDD-142	2019-10-08 00:00:00-07	DNA	2.3	96	96	\N	5
2526	MDD-143	2019-10-08 00:00:00-07	DNA	5.11	96	96	\N	5
2527	MDD-144	2019-10-08 00:00:00-07	DNA	1.29	96	96	\N	5
2528	MDD-145	2019-10-08 00:00:00-07	DNA	35.7	96	96	\N	5
2529	MDD-146	2019-10-08 00:00:00-07	DNA	1.79	96	96	\N	5
2530	MDD-147	2019-10-08 00:00:00-07	DNA	4.52	96	96	\N	5
2531	MDD-148	2019-10-08 00:00:00-07	DNA	3.87	96	96	\N	5
2532	MDD-149	2019-10-08 00:00:00-07	DNA	10.7	96	96	\N	5
2533	MDD-150	2019-10-12 00:00:00-07	DNA	2.61	96	96	\N	5
2534	MDD-151	2019-10-12 00:00:00-07	DNA	7.07	96	96	\N	5
2535	MDD-152	2019-10-12 00:00:00-07	DNA	0.98	96	96	\N	5
2536	MDD-153	2019-10-12 00:00:00-07	DNA	2.34	96	96	\N	5
2537	MDD-154	2019-10-12 00:00:00-07	DNA	1.37	96	96	\N	5
2538	MDD-155	2019-10-12 00:00:00-07	DNA	1.47	96	96	\N	5
2539	MDD-156	2019-10-12 00:00:00-07	DNA	2.79	96	96	\N	5
2540	MDD-157	2019-10-12 00:00:00-07	DNA	1.42	96	96	\N	5
2541	MDD-158	2019-10-12 00:00:00-07	DNA	3.16	96	96	\N	5
2542	MDD-159	2019-10-12 00:00:00-07	DNA	1.66	96	96	\N	5
2543	MDD-160	2019-10-12 00:00:00-07	DNA	1.63	96	96	\N	5
2544	MDD-161	2019-10-12 00:00:00-07	DNA	1.59	96	96	\N	5
2545	MDD-162	2019-10-12 00:00:00-07	DNA	3.33	96	96	\N	5
2546	MDD-163	2019-10-12 00:00:00-07	DNA	7.32	96	96	\N	5
4593	UM25_NA	\N	DNA	\N	\N	\N	\N	\N
2547	MDD-164	2019-10-12 00:00:00-07	DNA	0.24	96	96	\N	5
2548	MDD-165	2019-10-12 00:00:00-07	DNA	0	96	96	\N	5
2549	MDD-166	2019-10-12 00:00:00-07	DNA	6.45	96	96	\N	5
2550	MDD-167	2019-10-12 00:00:00-07	DNA	2.81	96	96	\N	5
2551	MDD-168	2019-10-12 00:00:00-07	DNA	0.51	96	96	\N	5
2552	MDD-169	2019-10-12 00:00:00-07	DNA	3.57	96	96	\N	5
2553	MDD-170	2019-10-12 00:00:00-07	DNA	1.66	96	96	\N	5
2554	MDD-171	2019-10-12 00:00:00-07	DNA	2.64	96	96	\N	5
2555	MDD-172	2019-10-12 00:00:00-07	DNA	0.38	96	96	\N	5
2556	MDD-173	2019-10-12 00:00:00-07	DNA	1.1	96	96	\N	5
2557	MDD-174	2019-10-26 00:00:00-07	DNA	4.72	96	96	\N	5
2558	MDD-175	2019-10-26 00:00:00-07	DNA	3.04	96	96	\N	5
2559	MDD-176	2019-10-26 00:00:00-07	DNA	0.77	96	96	\N	5
2560	MDD-177	2019-10-26 00:00:00-07	DNA	2.05	96	96	\N	5
2561	MDD-178	2019-10-26 00:00:00-07	DNA	4.32	96	96	\N	5
2562	MDD-179	2019-10-26 00:00:00-07	DNA	1.25	96	96	\N	5
2563	MDD-180	2019-10-26 00:00:00-07	DNA	8.58	96	96	\N	5
2564	MDD-181	2019-10-26 00:00:00-07	DNA	2.35	96	96	\N	5
2565	MDD-182	2019-10-26 00:00:00-07	DNA	2.53	96	96	\N	5
2566	MDD-183	2019-10-26 00:00:00-07	DNA	2.8	96	96	\N	5
2567	MDD-184	2019-10-26 00:00:00-07	DNA	4.67	96	96	\N	5
2568	MDD-185	2019-10-26 00:00:00-07	DNA	31.7	96	96	\N	5
2569	MDD-186	2019-10-26 00:00:00-07	DNA	6.81	96	96	\N	5
2570	MDD-187	2019-10-26 00:00:00-07	DNA	1.57	96	96	\N	5
2571	MDD-188	2019-10-26 00:00:00-07	DNA	2.66	96	96	\N	5
2572	MDD-189	2019-10-26 00:00:00-07	DNA	0.83	80	80	\N	5
2573	MDD-190	2019-10-26 00:00:00-07	DNA	2.57	80	80	\N	5
2574	MDD-191	2019-10-26 00:00:00-07	DNA	17	80	80	\N	5
2575	MDD-192	2019-10-26 00:00:00-07	DNA	0.75	80	80	\N	5
2576	MDD-193	2019-10-26 00:00:00-07	DNA	0.13	80	80	\N	5
2577	MDD-194	2019-10-26 00:00:00-07	DNA	1.33	80	80	\N	5
2578	MDD-195	2019-10-26 00:00:00-07	DNA	2.3	80	80	\N	5
2579	MDD-196	2019-10-26 00:00:00-07	DNA	4.07	80	80	\N	5
2580	MDD-197	2019-10-26 00:00:00-07	DNA	0.69	80	80	\N	5
2581	MDD-198	2019-10-30 00:00:00-07	DNA	34.3	80	80	\N	5
2582	MDD-199	2019-10-30 00:00:00-07	DNA	5.75	80	80	\N	5
2583	MDD-200	2019-10-30 00:00:00-07	DNA	1.47	80	80	\N	5
2584	MDD-201	2019-10-30 00:00:00-07	DNA	5.08	80	80	\N	5
2585	MDD-202	2019-10-30 00:00:00-07	DNA	9.08	80	80	\N	5
2586	MDD-203	2019-10-30 00:00:00-07	DNA	2.02	80	80	\N	5
2587	MDD-204	2019-10-30 00:00:00-07	DNA	13.3	80	80	\N	5
2588	MDD-205	2019-10-30 00:00:00-07	DNA	13.7	80	80	\N	5
2589	MDD-206	2019-10-30 00:00:00-07	DNA	6.52	80	80	\N	5
2590	MDD-207	2019-10-30 00:00:00-07	DNA	2.36	80	80	\N	5
2591	MDD-208	2019-10-30 00:00:00-07	DNA	2.68	80	80	\N	5
2592	MDD-209	2019-10-30 00:00:00-07	DNA	4.33	80	80	\N	5
2593	MDD-210	2019-10-30 00:00:00-07	DNA	2.28	80	80	\N	5
2594	MDD-211	2019-10-30 00:00:00-07	DNA	21.6	80	80	\N	5
2595	MDD-212	2019-10-30 00:00:00-07	DNA	0.12	80	80	\N	5
2596	MDD-213	2019-10-30 00:00:00-07	DNA	1.88	80	80	\N	5
2597	MDD-214	2019-10-30 00:00:00-07	DNA	6.22	80	80	\N	5
2598	MDD-215	2019-10-30 00:00:00-07	DNA	1.84	80	80	\N	5
2599	MDD-216	2019-10-30 00:00:00-07	DNA	1.97	80	80	\N	5
2600	MDD-217	2019-10-30 00:00:00-07	DNA	2.87	80	80	\N	5
2601	MDD-218	2019-10-30 00:00:00-07	DNA	13.4	80	80	\N	5
2602	MDD-219	2019-10-30 00:00:00-07	DNA	2.97	80	80	\N	5
2603	MDD-220	2019-10-30 00:00:00-07	DNA	0.93	80	80	\N	5
2604	MDD-221	2019-10-30 00:00:00-07	DNA	11.2	80	80	\N	5
2605	Mel290	\N	DNA	4.08	50	50	\N	\N
2606	MIN_1_NA	\N	DNA	\N	\N	\N	\N	\N
2607	MIN_2_NA	\N	DNA	\N	\N	\N	\N	\N
2608	MIN_3_NA	\N	DNA	\N	\N	\N	\N	\N
2609	MIN_4_NA	\N	DNA	\N	\N	\N	\N	\N
2610	MIN_5_NA	\N	DNA	\N	\N	\N	\N	\N
2611	MIN_6_NA	\N	DNA	\N	\N	\N	\N	\N
2612	MM-1	2019-04-01 00:00:00-07	DNA	8.83	20	20	\N	5
2613	MM-2	2019-04-01 00:00:00-07	DNA	42.6	42	42	\N	5
2614	MM-3	2019-04-01 00:00:00-07	DNA	1.17	48	48	\N	5
2615	MM-4	2019-04-01 00:00:00-07	DNA	31.5	80	80	\N	5
2616	MM100511 (AMC-03)	\N	DNA	24.8	50	50	\N	\N
2617	MM100512 (AMC-03)	\N	DNA	6.52	50	50	\N	\N
2618	MM100513 (AMC-03)	\N	DNA	15.8	50	50	\N	\N
2619	MM100916 (AMC-03)	\N	DNA	18.3	50	50	\N	\N
2620	MM160113 (AMC-12)	\N	DNA	12.8	50	50	\N	\N
2621	MMD-01	\N	DNA	25.3	88	88	\N	6
2622	MMD-02	\N	DNA	26.2	88	88	\N	6
2623	MMD-03	\N	DNA	11.7	88	88	\N	6
2624	MMD-04	\N	DNA	7.92	88	88	\N	6
2625	MMD-05	\N	DNA	0.27	88	88	\N	6
2626	MMD-06	\N	DNA	5.37	88	88	\N	6
2627	MMD-07	\N	DNA	2.02	88	88	\N	6
2628	MMD-08	\N	DNA	1.9	88	88	\N	6
2629	MMD-09	\N	DNA	0.18	88	88	\N	6
2630	MMD-10	\N	DNA	2.66	88	88	\N	6
2631	MMD-11	\N	DNA	1.45	88	88	\N	6
2632	MMD-12	\N	DNA	1.32	88	88	\N	6
2633	MMD-13	\N	DNA	1.31	88	88	\N	6
2634	MMD-14	\N	DNA	0.44	88	88	\N	6
2635	MMD-15	\N	DNA	0.77	88	88	\N	6
2636	MMD-16	\N	DNA	0.34	88	88	\N	6
2637	MMD-17	\N	DNA	0	88	88	\N	6
2638	MMD-18	\N	DNA	1.96	88	88	\N	6
2639	MMD-19	\N	DNA	0.45	88	88	\N	6
2640	MMD-20	\N	DNA	0.74	88	88	\N	6
2641	MMD-21	\N	DNA	0.24	88	88	\N	6
2642	MMD-22	\N	DNA	0.29	88	88	\N	6
2643	MMD-23	\N	DNA	1.72	88	88	\N	5
2644	MMD-24	\N	DNA	0.9	88	88	\N	5
2645	MMD-25	\N	DNA	1.79	88	88	\N	5
2646	MMD-26	\N	DNA	0.68	88	88	\N	5
2647	MMD-27	\N	DNA	0.74	88	88	\N	5
2648	MMD-28	\N	DNA	0.17	88	88	\N	6
2649	MMD-29	\N	DNA	0.15	88	88	\N	5
2650	MMD-30	\N	DNA	2.29	88	88	\N	6
2651	MMD-31	\N	DNA	0.12	88	88	\N	6
2652	MMD-32	\N	DNA	0.43	88	88	\N	6
2653	MMD-33	\N	DNA	0.14	88	88	\N	6
2654	MMD-34	\N	DNA	0.41	88	88	\N	5
2655	MMD-35	\N	DNA	5.41	88	88	\N	6
2656	MMD-36	\N	DNA	0.7	88	88	\N	5
2657	MMD-37	\N	DNA	5.84	88	88	\N	6
2658	MMD-38	\N	DNA	0.89	88	88	\N	6
2659	MMD-39	\N	DNA	0.86	88	88	\N	5
2660	MMD-40	\N	DNA	0.79	88	88	\N	6
2661	MMD-41	\N	DNA	5.24	88	88	\N	6
2662	MMD-42	\N	DNA	1.12	88	88	\N	6
2663	MMD-43	\N	DNA	0.17	88	88	\N	5
2664	MMD-44	\N	DNA	0.24	88	88	\N	6
2665	MMD-45	\N	DNA	0.84	88	88	\N	2
2666	MMD-46	\N	DNA	0.1	88	88	\N	6
2667	MMD-47	\N	DNA	0.08	88	88	\N	5
2668	MMD-48	\N	DNA	0.57	88	88	\N	6
2669	MMD-49	\N	DNA	4.66	88	88	\N	5
2670	MMD-50	\N	DNA	0.08	88	88	\N	6
2671	MMD-51	\N	DNA	0.42	88	88	\N	6
2672	MMD-52	\N	DNA	0.65	88	88	\N	5
2673	MMD-53	\N	DNA	0.51	88	88	\N	6
2674	MMD-54	\N	DNA	0.22	88	88	\N	6
2675	MMD-55	\N	DNA	0.23	88	88	\N	6
2676	MMD-56	\N	DNA	0.5	88	88	\N	6
2677	MMD-59	\N	DNA	0.52	88	88	\N	5
2678	MMD-60	\N	DNA	3.65	88	88	\N	5
2679	MMD-61	\N	DNA	2.45	88	88	\N	5
2680	MMD-62	\N	DNA	0.97	88	88	\N	5
2681	MMD-63	\N	DNA	0.89	88	88	\N	5
2682	MMD-64	\N	DNA	0.64	88	88	\N	5
2683	MMD-65	\N	DNA	7.28	88	88	\N	5
2684	MMD-66	\N	DNA	0.87	88	88	\N	5
2685	MMD-67	\N	DNA	1.01	88	88	\N	5
2686	MMD-68	\N	DNA	0.66	88	88	\N	5
2687	MMD-69	\N	DNA	0.66	88	88	\N	5
2688	MMD-70	\N	DNA	0.01	88	88	\N	6
2689	MMD-71	\N	DNA	0.08	88	88	\N	5
2690	MMD-72	\N	DNA	0.93	88	88	\N	6
2691	MMD-73	\N	DNA	21.9	88	88	\N	6
2692	MMD-74	\N	DNA	44	88	88	\N	2
2693	MMD-75	\N	DNA	35.8	88	88	\N	5
2694	MMD-76	\N	DNA	8.55	88	88	\N	6
2695	MMD-77	\N	DNA	1.2	88	88	\N	5
2696	MMD-78	\N	DNA	10.3	88	88	\N	6
2697	MMD-79	\N	DNA	13.6	88	88	\N	2
2698	MMD-80	\N	DNA	12.9	88	88	\N	5
2699	MMD-81	\N	DNA	3.68	88	88	\N	6
2700	MMD-82	\N	DNA	2.86	88	88	\N	5
2701	MMD-83	\N	DNA	11.3	88	88	\N	6
2702	MMD-84	\N	DNA	32.8	88	88	\N	2
2703	MMD-85	\N	DNA	21.9	88	88	\N	5
2704	MMD-86	\N	DNA	3.2	88	88	\N	6
2705	MMD-87	\N	DNA	1.08	88	88	\N	5
2706	MMD-88	\N	DNA	0.12	88	88	\N	6
2707	MMD-89	\N	DNA	2.69	88	88	\N	6
2708	MMD-90	\N	DNA	0.55	88	88	\N	6
2709	MMD-91	\N	DNA	0.66	88	88	\N	6
2710	MMD-92	\N	DNA	0.94	88	88	\N	5
2711	MMD-93	\N	DNA	16.6	88	88	\N	6
2712	MMD-94	\N	DNA	8.07	88	88	\N	6
2713	MMD-95	\N	DNA	11.6	88	88	\N	6
2714	MMD-96	\N	DNA	2.48	88	88	\N	6
2715	MMD-97	\N	DNA	42.6	88	88	\N	6
2716	MMD-98	\N	DNA	1.24	88	88	\N	6
2717	MMD-99	\N	DNA	0.88	88	88	\N	5
2718	MMD-100	\N	DNA	1.87	88	88	\N	6
2719	MMD-101	\N	DNA	1.2	88	88	\N	6
2720	MMD-102	\N	DNA	2.36	88	88	\N	5
2721	MMD-103	\N	DNA	2.33	88	88	\N	5
2722	MMD-104	\N	DNA	1.81	88	88	\N	5
2723	MMD-105	\N	DNA	0.13	88	88	\N	5
2724	MMD-106	\N	DNA	0.41	88	88	\N	5
2725	MMD-107	\N	DNA	0.14	88	88	\N	5
2726	MMD-108	\N	DNA	3.69	88	88	\N	5
2727	MMD-109	\N	DNA	0.14	88	88	\N	5
2728	MMD-111	\N	DNA	0.13	88	88	\N	5
2729	MMD-112	\N	DNA	0.21	88	88	\N	2
2730	MMD-113	\N	DNA	0.2	88	88	\N	5
2731	MMD-114	\N	DNA	0	88	88	\N	2
2732	MMD-115	\N	DNA	19.2	88	88	\N	2
2733	MMD-116	\N	DNA	1.2	88	88	\N	2
2734	MMD-117	\N	DNA	0.5	88	88	\N	5
2735	MMD-118	\N	DNA	0	88	88	\N	2
2736	MMD-119	\N	DNA	1.44	88	88	\N	2
2737	MMD-120	\N	DNA	17.4	88	88	\N	2
2738	MMD-121	\N	DNA	8.55	88	88	\N	2
2739	MMD-122	\N	DNA	0.19	88	88	\N	5
2740	MMD-123	\N	DNA	0.44	88	88	\N	2
2741	MMD-124	\N	DNA	1.9	88	88	\N	2
2742	MMD-125	\N	DNA	0.4	88	88	\N	5
2743	MMD-126	\N	DNA	2.16	88	88	\N	2
2744	MMD-127	\N	DNA	0.15	88	88	\N	5
2745	MMD-128	\N	DNA	0.09	88	88	\N	2
2746	MMD-129	\N	DNA	0.49	88	88	\N	2
2747	MMD-130	\N	DNA	1.88	88	88	\N	5
2748	MMD-131	\N	DNA	0.16	88	88	\N	2
2749	MMD-132	\N	DNA	0.56	88	88	\N	2
2750	MMD-133	\N	DNA	0.06	88	88	\N	5
2751	MMD-134	\N	DNA	2.03	88	88	\N	2
2752	MMD-135	\N	DNA	0.85	88	88	\N	5
2753	MMD-136	\N	DNA	0	88	88	\N	2
2754	MMD-137	\N	DNA	0.06	88	88	\N	5
2755	MMD-140	\N	DNA	0	88	88	\N	2
2756	MMD-141	\N	DNA	0.17	88	88	\N	2
2757	MMD-142	\N	DNA	0.05	88	88	\N	5
2758	MMD-143	\N	DNA	0.48	88	88	\N	2
2759	MMD-144	\N	DNA	0.14	88	88	\N	2
2760	MMD-145	\N	DNA	0.2	88	88	DNA ONLY	2
2761	MMD-146	\N	DNA	0.44	88	88	\N	5
2762	MMD-147	\N	DNA	0.09	88	88	DNA ONLY	2
2763	MMD-148	\N	DNA	0.14	88	88	\N	5
2764	MMD-149	\N	DNA	0.71	88	88	\N	2
2765	MMD-150	\N	DNA	0.44	88	88	\N	5
2766	MMD-151	\N	DNA	1.37	88	88	\N	2
2767	MMD-152	\N	DNA	0.11	88	88	DNA ONLY	2
2768	MMD-153	\N	DNA	0.13	88	88	\N	2
2769	MMD-154	\N	DNA	0.18	88	88	\N	5
2770	MMD-155	\N	DNA	0.07	88	88	\N	2
2771	MMD-156	\N	DNA	0.09	88	88	\N	5
2772	MMD-157	\N	DNA	9.52	88	88	\N	2
2773	MMD-158	\N	DNA	2.19	88	88	\N	2
2774	MMD-159	\N	DNA	0.07	88	88	\N	2
2775	MMD-160	\N	DNA	15.9	88	88	\N	2
2776	MMD-161	\N	DNA	0.52	88	88	\N	5
2777	MMD-162	\N	DNA	3.3	88	88	\N	2
2778	MMD-163	\N	DNA	9.84	88	88	\N	2
2779	MMD-164	\N	DNA	1.01	88	88	\N	5
2780	MMD-165	\N	DNA	17.4	88	88	\N	2
2781	MMD-166	\N	DNA	1.93	88	88	\N	5
2782	MMD-167	\N	DNA	0.6	88	88	\N	2
2783	MMD-168	\N	DNA	0.57	88	88	\N	5
2784	MMD-169	\N	DNA	0.23	88	88	\N	2
2785	MMD-170	\N	DNA	0.17	88	88	\N	2
2786	MMD-171	\N	DNA	0.11	88	88	\N	5
2787	MMD-172	\N	DNA	2.1	88	88	\N	2
2788	MMD-173	\N	DNA	0.59	88	88	\N	2
2789	MMD-174	\N	DNA	0.05	88	88	\N	5
2790	MMD-175	\N	DNA	5.42	88	88	\N	2
2791	MMD-176	\N	DNA	0.9	88	88	\N	5
2792	MMD-177	\N	DNA	30.5	88	88	\N	2
2793	MMD-178	\N	DNA	2.49	88	88	\N	2
2794	MMD-179	\N	DNA	0.74	88	88	\N	2
2795	MMD-180	\N	DNA	1.42	88	88	\N	5
2796	MMD-181	\N	DNA	14.7	88	88	\N	2
2797	MMD-182	\N	DNA	3.52	88	88	\N	2
2798	MMD-183	\N	DNA	0.64	88	88	\N	5
2799	MMD-184	\N	DNA	3.79	88	88	\N	2
2800	MMD-185	\N	DNA	0.29	88	88	\N	5
2801	MMD-186	\N	DNA	0.08	88	88	\N	2
2802	MMD-187	\N	DNA	0.26	88	88	\N	2
2803	MMD-188	\N	DNA	0	88	88	\N	5
2804	MMD-189	\N	DNA	0.23	88	88	DNA ONLY	2
2805	MMD-190	\N	DNA	0	88	88	DNA ONLY	2
2806	MMD-191	\N	DNA	0.93	88	88	\N	2
2807	MMD-192	\N	DNA	0.14	88	88	\N	2
2808	MMD-193	\N	DNA	0.14	88	88	DNA ONLY	2
2809	MMD-194	\N	DNA	0.14	88	88	DNA ONLY	2
2810	MMD-195	\N	DNA	0.13	88	88	\N	2
2811	MMD-196	\N	DNA	0.47	88	88	\N	2
2812	MMD-197	\N	DNA	0.28	88	88	\N	2
2813	MMD-198	\N	DNA	0.44	88	88	DNA ONLY	2
2814	MMD-199	\N	DNA	0.47	88	88	\N	5
2815	MMD-200	\N	DNA	1.35	88	88	\N	2
2816	MMD-201	\N	DNA	0.72	88	88	\N	2
2817	MMD-202	\N	DNA	0	88	88	DNA ONLY	2
2818	MMD-203	\N	DNA	0	88	88	\N	5
2819	MMD-204	\N	DNA	1.61	88	88	\N	2
2820	MMD-205	\N	DNA	0.06	88	88	\N	5
2821	MMD-206	\N	DNA	0.24	88	88	\N	2
2822	MMD-207	\N	DNA	0.25	88	88	DNA ONLY	2
2823	MMD-208	\N	DNA	0.18	88	88	\N	\N
2824	MMD-209	\N	DNA	0.34	88	88	DNA ONLY	2
2825	MMD-210	\N	DNA	0.13	88	88	\N	5
2826	MMD-211	\N	DNA	1.87	88	88	DNA ONLY	2
2827	MMD-212	\N	DNA	0.22	88	88	DNA ONLY	2
2828	MMD-213	\N	DNA	0.07	88	88	\N	2
2829	MMD-214	\N	DNA	0.15	88	88	\N	2
2830	MMD-215	\N	DNA	0.18	88	88	DNA ONLY	2
2831	MMD-216	\N	DNA	0.06	88	88	\N	2
2832	MMD-217	\N	DNA	3.21	88	88	DNA ONLY	2
2833	MMD-218	\N	DNA	0.45	88	88	DNA ONLY	2
2834	MMD-219	\N	DNA	0.3	88	88	DNA ONLY	2
2835	MMD-220	\N	DNA	0	88	88	DNA ONLY	2
2836	MMD-221	\N	DNA	0.16	88	88	\N	2
2837	MMD-222	\N	DNA	0	88	88	\N	2
2838	MMD-223	\N	DNA	1.79	88	88	\N	2
2839	MMD-224	\N	DNA	0.8	88	88	DNA ONLY	2
2840	MMD-225	\N	DNA	0.54	88	88	\N	2
2841	MMD-226	\N	DNA	0.34	88	88	DNA ONLY	2
2842	MMD-227	\N	DNA	0.13	88	88	\N	2
2843	MMD-228	\N	DNA	1.74	88	88	\N	2
2844	MMD-229	\N	DNA	0.05	88	88	DNA ONLY	2
2845	MMD-230	\N	DNA	0.63	88	88	\N	2
2846	MMD-231	\N	DNA	0.19	88	88	DNA ONLY	2
2847	MMD-232	\N	DNA	0.18	88	88	\N	2
2848	MMD-233	\N	DNA	0.18	88	88	DNA ONLY	2
2849	MMD-234	\N	DNA	0.51	88	88	\N	2
2850	MMD-235	\N	DNA	0.36	88	88	DNA ONLY	2
2851	MMD-236	\N	DNA	0.99	88	88	\N	2
2852	MMD-237	\N	DNA	0.28	88	88	\N	2
2853	MMD-238	\N	DNA	2.41	88	88	\N	2
2854	MMD-239	\N	DNA	1.34	88	88	DNA ONLY	2
2855	MMD-240	\N	DNA	0.68	88	88	\N	2
2856	MMD-241	\N	DNA	0.18	88	88	DNA ONLY	2
2857	MMD-242	\N	DNA	2.13	88	88	\N	2
2858	MMD-243	\N	DNA	0.89	88	88	DNA ONLY	2
2859	MMD-244	\N	DNA	1.26	88	88	\N	2
2860	MMD-245	\N	DNA	0	88	88	DNA ONLY	2
2861	MMD-246	\N	DNA	1.25	88	88	\N	2
2862	MMD-247	\N	DNA	0.24	88	88	DNA ONLY	2
2863	MMD-248	\N	DNA	0.12	88	88	\N	2
2864	MMD-249	\N	DNA	0.4	88	88	\N	2
2865	MMD-250	\N	DNA	0.07	88	88	DNA ONLY	2
2866	MMD-251	\N	DNA	1.99	88	88	\N	2
2867	MMD-252	\N	DNA	0.09	88	88	DNA ONLY	2
2868	MMD-253	\N	DNA	0	88	88	\N	2
2869	MMD-254	\N	DNA	0.07	88	88	DNA ONLY	2
2870	MMD-255	\N	DNA	0	88	88	\N	2
2871	MMD-256	\N	DNA	0.09	88	88	DNA ONLY	2
2872	MMD-257	\N	DNA	0	88	88	DNA ONLY	2
2873	MMD-258	\N	DNA	0.16	88	88	DNA ONLY	2
2874	MMD-259	\N	DNA	0.08	88	88	DNA ONLY	2
2875	MMD-260	\N	DNA	0.37	88	88	DNA ONLY	2
2876	MMD-261	\N	DNA	0.24	88	88	DNA ONLY	2
2877	MMD-262	\N	DNA	0.14	88	88	\N	2
2878	MMD-263	\N	DNA	0.23	88	88	DNA ONLY	2
2879	MMD-264	\N	DNA	0.1	88	88	DNA ONLY	2
2880	MMD-265	\N	DNA	0.07	88	88	DNA ONLY	2
2881	MMD-266	\N	DNA	0.11	88	88	DNA ONLY	2
2882	MMD-267	\N	DNA	0	88	88	\N	2
2883	MMD-268	\N	DNA	0.07	88	88	DNA ONLY	2
2884	MMD-269	\N	DNA	2.5	88	88	DNA ONLY	2
2885	MMD-270	\N	DNA	0.99	88	88	DNA ONLY	2
2886	MMD-271	\N	DNA	0.09	88	88	DNA ONLY	2
2887	MMD-272	\N	DNA	0.1	88	88	DNA ONLY	2
2888	MMD-273	\N	DNA	0.29	88	88	DNA ONLY	2
2889	MMD-274	\N	DNA	0	88	88	DNA ONLY	2
2890	MMD-275	\N	DNA	0	88	88	\N	2
2891	MMD-276	\N	DNA	0.85	88	88	DNA ONLY	2
2892	MMD-277	\N	DNA	0.89	88	88	DNA ONLY	2
2893	MMD-278	\N	DNA	0.24	88	88	DNA ONLY	2
2894	MMD-279	\N	DNA	0.19	88	88	\N	2
2895	MMD-280	\N	DNA	0.12	88	88	DNA ONLY	2
2896	MMD-281	\N	DNA	0.58	88	88	\N	2
2897	MMD-282	\N	DNA	0.06	88	88	\N	2
2898	MMD-283	\N	DNA	0.47	88	88	DNA ONLY	2
2899	MMD-284	\N	DNA	0.17	88	88	DNA ONLY	2
2900	MMD-285	\N	DNA	1.48	88	88	DNA ONLY	2
2901	MMD-286	\N	DNA	0.41	88	88	DNA ONLY	2
2902	MMD-287	\N	DNA	0.52	88	88	DNA ONLY	2
2903	MMD-288	\N	DNA	0.18	88	88	\N	2
2904	MMD-289	\N	DNA	0.2	88	88	DNA ONLY	2
2905	MMD-290	\N	DNA	0.08	88	88	DNA ONLY	2
2906	MMD-291	\N	DNA	0.15	88	88	DNA ONLY	2
2907	MMD-292	\N	DNA	1.57	88	88	DNA ONLY	2
2908	MMD-293	\N	DNA	0.07	88	88	\N	2
2909	MMD-294	\N	DNA	1.03	88	88	DNA ONLY	2
2910	MMD-295	\N	DNA	0.07	88	88	DNA ONLY	2
4594	UM26_NA	\N	DNA	\N	\N	\N	\N	\N
2911	MMD-296	\N	DNA	0.16	88	88	DNA ONLY	2
2912	MMD-297	\N	DNA	0.25	88	88	DNA ONLY	2
2913	MMD-298	\N	DNA	0.54	88	88	DNA ONLY	2
2914	MMD-299	\N	DNA	0	88	88	DNA ONLY	2
2915	MMD-300	\N	DNA	0.29	88	88	DNA ONLY	2
2916	MMD-301	\N	DNA	0	88	88	\N	2
2917	MMD-302	\N	DNA	1.46	88	88	\N	2
2918	MMD-303	\N	DNA	0.23	88	88	DNA ONLY	2
2919	MMD-304	\N	DNA	0.21	88	88	\N	2
2920	MMD-305	\N	DNA	4.36	88	88	\N	2
2921	MMD-306	\N	DNA	0.34	88	88	DNA ONLY	2
2922	MMD-307	\N	DNA	0.16	88	88	DNA ONLY	2
2923	MMD-308	\N	DNA	0.13	88	88	\N	2
2924	MMD-309	\N	DNA	0.35	88	88	DNA ONLY	2
2925	MMD-310	\N	DNA	0	88	88	DNA ONLY	2
2926	MMD-311	\N	DNA	0.39	88	88	DNA ONLY	2
2927	MMD-312	\N	DNA	0.31	88	88	DNA ONLY	2
2928	MMD-313	\N	DNA	0.1	88	88	\N	2
2929	MMD-314	\N	DNA	0	88	88	DNA ONLY	2
2930	MMD-315	\N	DNA	0.76	88	88	DNA ONLY	2
2931	MMD-316	\N	DNA	0.14	88	88	DNA ONLY	2
2932	MMD-317	\N	DNA	0.29	88	88	DNA ONLY	2
2933	MMD-318	\N	DNA	0.56	88	88	DNA ONLY	2
2934	MMD-319	\N	DNA	0.57	88	88	DNA ONLY	2
2935	MMD-320	\N	DNA	0	88	88	DNA ONLY	2
2936	MMD-321	\N	DNA	0.25	88	88	\N	2
2937	MMD-322	\N	DNA	0.25	88	88	DNA ONLY	2
2938	MMD-323	\N	DNA	0.21	88	88	\N	2
2939	MMD-324	\N	DNA	1.79	88	88	\N	2
2940	MMD-325	2021-09-23 00:00:00-07	DNA	0	88	88	DNA ONLY	2
2941	MMD-326	\N	DNA	0.2	88	88	\N	2
2942	MMD-327	2021-09-23 00:00:00-07	DNA	0.37	88	88	DNA ONLY	2
2943	MMD-328	\N	DNA	2.58	88	88	\N	2
2944	MMD-329	2021-09-23 00:00:00-07	DNA	0.98	88	88	DNA ONLY	2
2945	MMD-330	\N	DNA	1.01	88	88	\N	2
2946	MMD-331	2021-09-23 00:00:00-07	DNA	2.48	88	88	DNA ONLY	2
2947	MMD-332	\N	DNA	0.21	88	88	\N	2
2948	MMD-333	2021-09-23 00:00:00-07	DNA	1.29	88	88	DNA ONLY	2
2949	MMD-334	\N	DNA	1.4	88	88	\N	2
2950	MMD-335	\N	DNA	9.02	88	88	\N	2
2951	MMD-336	\N	DNA	0.41	88	88	\N	2
2952	MMD-337	2021-09-23 00:00:00-07	DNA	0.12	88	88	DNA ONLY	2
2953	MMD-338	\N	DNA	7.66	88	88	\N	2
2954	MMD-339	\N	DNA	0	88	88	DNA ONLY	2
2955	MMD-340	2021-09-23 00:00:00-07	DNA	11.8	88	88	\N	2
2956	MMD-341	2021-09-23 00:00:00-07	DNA	3.35	88	88	DNA ONLY	2
2957	MMD-342	2021-09-23 00:00:00-07	DNA	4.38	88	88	\N	2
2958	MMD-343	2021-09-23 00:00:00-07	DNA	2.22	88	88	DNA ONLY	2
2959	MMD-344	2021-09-23 00:00:00-07	DNA	6.94	88	88	\N	2
2960	MMD-345	2021-09-23 00:00:00-07	DNA	2.76	88	88	DNA ONLY	2
2961	MMD-346	2021-09-23 00:00:00-07	DNA	1.47	88	88	\N	2
2962	MMD-347	2021-09-23 00:00:00-07	DNA	1.85	88	88	\N	2
2963	MMD-348	2021-09-23 00:00:00-07	DNA	1.18	88	88	DNA ONLY	2
2964	MMD-349	2021-09-23 00:00:00-07	DNA	1.02	88	88	\N	2
2965	MMD-350	2021-09-23 00:00:00-07	DNA	1.57	88	88	\N	2
2966	MMD-351	2021-09-23 00:00:00-07	DNA	0.34	88	88	DNA ONLY	2
2967	MMD-352	2021-09-23 00:00:00-07	DNA	9.99	88	88	\N	2
2968	MMD-353	2021-09-23 00:00:00-07	DNA	0.65	88	88	DNA ONLY	2
2969	MMD-354	2021-09-23 00:00:00-07	DNA	0.68	88	88	\N	2
2970	MMD-355 (P041_01A)	2021-07-29 00:00:00-07	DNA	0.39	50	50	DIN:4.2, 5 x (1-48 mm^2; 10 um)\n	7
2971	MMD-356 (P041_01B)	2021-07-29 00:00:00-07	DNA	0	50	50	DIN:5.2, 5 x (1-48 mm^2; 10 um)\n	7
2972	MMD-357 (P041_01C)	2021-07-29 00:00:00-07	DNA	0.48	50	50	DIN:5.6, 5 x (1-48 mm^2; 10 um)\n	7
2973	MMD-358	2021-09-23 00:00:00-07	DNA	0.47	88	88	\N	2
2974	MMD-359 (P041_01D)	2021-07-29 00:00:00-07	DNA	0.97	50	50	DIN:UND, 5 x (1-48 mm^2; 10 um)\n	7
2975	MMD-360	2021-09-23 00:00:00-07	DNA	0.88	88	88	\N	2
2976	MMD-361 (P041_03A)	2021-07-29 00:00:00-07	DNA	1	50	50	DIN:4.8, 5 x (1-48 mm^2; 10 um)\n	7
2977	MMR-01	\N	RNA	570	25	25	\N	6
2978	MMR-02	\N	RNA	381	25	25	\N	6
2979	MMR-03	\N	RNA	0	25	25	\N	6
2980	MMR-04	\N	RNA	100	25	25	\N	6
2981	MMR-05	\N	RNA	7.86	25	25	\N	6
2982	MMR-06	\N	RNA	76	25	25	\N	6
2983	MMR-07	\N	RNA	63	25	25	\N	6
2984	MMR-08	\N	RNA	100	25	25	\N	6
2985	MMR-09	\N	RNA	4	25	25	\N	6
2986	MMR-10	\N	RNA	0	25	25	\N	6
2987	MMR-11	\N	RNA	52	25	25	\N	6
2988	MMR-12	\N	RNA	20.3	25	25	\N	6
2989	MMR-13	\N	RNA	20.5	25	25	\N	6
2990	MMR-14	\N	RNA	22.6	25	25	\N	6
2991	MMR-15	\N	RNA	16.1	25	25	\N	6
2992	MMR-16	\N	RNA	18	25	25	\N	6
2993	MMR-17	\N	RNA	0	25	25	\N	6
2994	MMR-18	\N	RNA	24.3	25	25	\N	6
2995	MMR-19	\N	RNA	30.7	25	25	\N	6
2996	MMR-20	\N	RNA	32.2	25	25	\N	6
2997	MMR-21	\N	RNA	17.6	25	25	\N	6
2998	MMR-22	\N	RNA	15.7	25	25	\N	6
2999	MMR-23	\N	RNA	0	0	0	\N	\N
3000	MMR-24	\N	RNA	0	0	0	\N	\N
3001	MMR-25	\N	RNA	0	0	0	\N	\N
3002	MMR-26	\N	RNA	0	0	0	\N	\N
3003	MMR-27	\N	RNA	0	0	0	\N	\N
3004	MMR-28	\N	RNA	14.3	25	25	\N	6
3005	MMR-29	\N	RNA	0	0	0	\N	\N
3006	MMR-30	\N	RNA	81	25	25	\N	6
3007	MMR-31	\N	RNA	5.46	25	25	\N	6
3008	MMR-32	\N	RNA	14.4	25	25	\N	6
3009	MMR-33	\N	RNA	14.2	25	25	\N	6
3010	MMR-34	\N	RNA	0	0	0	\N	\N
3011	MMR-35	\N	RNA	166	25	25	\N	6
3012	MMR-37	\N	RNA	265	25	25	\N	6
3013	MMR-38	\N	RNA	95	25	25	\N	6
3014	MMR-40	\N	RNA	0	25	25	\N	6
3015	MMR-41	\N	RNA	14.6	25	25	\N	6
3016	MMR-42	\N	RNA	54	25	25	\N	6
3017	MMR-44	\N	RNA	13.6	25	25	\N	6
3018	MMR-45	\N	RNA	7.7	50	50	\N	1
3019	MMR-46	\N	RNA	9.6	25	25	\N	6
3020	MMR-48	\N	RNA	21.8	25	25	\N	6
3021	MMR-50	\N	RNA	4.32	25	25	\N	6
3022	MMR-51	\N	RNA	15.6	25	25	\N	6
3023	MMR-53	\N	RNA	9.87	25	25	\N	6
3024	MMR-54	\N	RNA	6.22	25	25	\N	6
3025	MMR-55	\N	RNA	4.3	25	25	\N	6
3026	MMR-56	\N	RNA	0	25	25	\N	6
3027	MMR-70	\N	RNA	13.6	25	25	\N	6
3028	MMR-73	\N	RNA	346	25	25	\N	6
3029	MMR-74	\N	RNA	316	25	25	\N	6
3030	MMR-76	\N	RNA	0	25	25	\N	6
3031	MMR-78	\N	RNA	0	25	25	\N	6
3032	MMR-79	\N	RNA	0	50	50	\N	1
3033	MMR-81	\N	RNA	29.3	25	25	\N	6
3034	MMR-83	\N	RNA	0	25	25	\N	6
3035	MMR-84	\N	RNA	0	50	50	\N	1
3036	MMR-86	\N	RNA	64	25	25	\N	6
3037	MMR-88	\N	RNA	2.63	25	25	\N	6
3038	MMR-89	\N	RNA	36	25	25	\N	6
3039	MMR-90	\N	RNA	7.11	25	25	\N	6
3040	MMR-91	\N	RNA	44	25	25	\N	6
3041	MMR-93	\N	RNA	710	25	25	\N	6
3042	MMR-94	\N	RNA	0	25	25	\N	6
3043	MMR-95	\N	RNA	0	25	25	\N	6
3044	MMR-96	\N	RNA	183	25	25	\N	6
3045	MMR-97	\N	RNA	183	25	25	\N	6
3046	MMR-98	\N	RNA	42.5	25	25	\N	6
3047	MMR-100	\N	RNA	26.1	25	25	\N	6
3048	MMR-101	\N	RNA	27.2	25	25	\N	6
3049	MMR-112	\N	RNA	6.25	50	50	\N	1
3050	MMR-114	\N	RNA	0	50	50	\N	1
3051	MMR-115	\N	RNA	38.7	50	50	\N	1
3052	MMR-116	\N	RNA	64	50	50	\N	1
3053	MMR-118	\N	RNA	2	50	50	\N	1
3054	MMR-119	\N	RNA	13.9	50	50	\N	1
3055	MMR-120	\N	RNA	56	50	50	\N	1
3056	MMR-121	\N	RNA	37.3	50	50	\N	1
3057	MMR-123	\N	RNA	3.03	50	50	\N	1
3058	MMR-124	\N	RNA	15	50	50	\N	1
3059	MMR-126	\N	RNA	14	50	50	\N	1
3060	MMR-128	\N	RNA	0	50	50	\N	1
3061	MMR-129	\N	RNA	18.4	50	50	\N	1
3062	MMR-131	\N	RNA	3.45	50	50	\N	1
3063	MMR-132	\N	RNA	6.63	50	50	\N	1
3064	MMR-134	\N	RNA	12.4	50	50	\N	1
3065	MMR-136	\N	RNA	0	50	50	\N	1
3066	MMR-140	\N	RNA	0	50	50	\N	1
3067	MMR-141	\N	RNA	2.1	50	50	\N	1
3068	MMR-143	\N	RNA	5.32	50	50	\N	1
3069	MMR-144	\N	RNA	2.44	50	50	\N	1
3070	MMR-149	\N	RNA	6.94	50	50	\N	1
3071	MMR-151	\N	RNA	9.66	50	50	\N	1
3072	MMR-153	\N	RNA	2.2	50	50	\N	1
3073	MMR-155	\N	RNA	0	50	50	\N	1
3074	MMR-157	\N	RNA	45.5	50	50	\N	1
3075	MMR-158	\N	RNA	29.8	50	50	\N	1
3076	MMR-159	\N	RNA	2.2	50	50	\N	1
3077	MMR-160	\N	RNA	50	50	50	\N	1
3078	MMR-162	\N	RNA	43.6	50	50	\N	1
3079	MMR-163	\N	RNA	44.9	50	50	\N	1
3080	MMR-165	\N	RNA	38.6	50	50	\N	1
3081	MMR-167	\N	RNA	13.6	50	50	\N	1
3082	MMR-169	\N	RNA	13.6	50	50	\N	1
3083	MMR-170	\N	RNA	4.34	50	50	\N	1
3084	MMR-172	\N	RNA	8.18	50	50	\N	1
3085	MMR-173	\N	RNA	9.34	50	50	\N	1
3086	MMR-175	\N	RNA	2.52	50	50	\N	1
3087	MMR-177	\N	RNA	254	50	50	\N	1
3088	MMR-178	\N	RNA	13.6	50	50	\N	1
3089	MMR-179	\N	RNA	3.33	50	50	\N	1
3090	MMR-181	\N	RNA	60	50	50	\N	1
3091	MMR-182	\N	RNA	54	50	50	\N	1
4595	NA_CP1-5_Tumor	\N	DNA	\N	\N	\N	\N	\N
3092	MMR-184	\N	RNA	18.3	50	50	\N	1
3093	MMR-186	\N	RNA	0	50	50	\N	1
3094	MMR-187	\N	RNA	5.61	50	50	\N	1
3095	MMR-191	\N	RNA	33.4	50	50	\N	1
3096	MMR-192	\N	RNA	5.55	50	50	\N	1
3097	MMR-195	\N	RNA	0	0	0	\N	1
3098	MMR-196	\N	RNA	5.5	50	50	\N	1
3099	MMR-197	\N	RNA	0.28	50	50	\N	1
3100	MMR-200	\N	RNA	25.9	50	50	\N	1
3101	MMR-201	\N	RNA	10.1	50	50	\N	1
3102	MMR-204	\N	RNA	12.3	50	50	\N	1
3103	MMR-206	\N	RNA	2.4	50	50	\N	1
3104	MMR-208	\N	RNA	2.4	50	50	\N	\N
3105	MMR-213	\N	RNA	0	50	50	\N	1
3106	MMR-214	\N	RNA	4.61	50	50	\N	1
3107	MMR-216	\N	RNA	0	50	50	\N	1
3108	MMR-221	\N	RNA	2.86	50	50	\N	1
3109	MMR-223	\N	RNA	11.7	50	50	\N	1
3110	MMR-225	\N	RNA	3.11	50	50	\N	1
3111	MMR-227	\N	RNA	0	50	50	\N	1
3112	MMR-228	\N	RNA	0	50	50	\N	1
3113	MMR-230	\N	RNA	4.88	50	50	\N	1
3114	MMR-232	\N	RNA	0	50	50	\N	1
3115	MMR-234	\N	RNA	6.72	50	50	\N	1
3116	MMR-236	\N	RNA	10.8	50	50	\N	1
3117	MMR-237	\N	RNA	0	50	50	\N	1
3118	MMR-240	\N	RNA	7.67	50	50	\N	1
3119	MMR-242	\N	RNA	16.1	50	50	\N	1
3120	MMR-244	\N	RNA	4.6	50	50	\N	1
3121	MMR-246	\N	RNA	5.46	50	50	\N	1
3122	MMR-248	\N	RNA	0	50	50	\N	1
3123	MMR-249	\N	RNA	19.4	50	50	\N	1
3124	MMR-251	\N	RNA	5.39	50	50	\N	1
3125	MMR-253	\N	RNA	0	50	50	\N	1
3126	MMR-255	\N	RNA	2.55	50	50	\N	1
3127	MMR-262	\N	RNA	2.3	50	50	\N	1
3128	MMR-267	\N	RNA	0	25	25	\N	1
3129	MMR-275	\N	RNA	0	50	50	\N	1
3130	MMR-279	\N	RNA	2.95	50	50	\N	1
3131	MMR-288	\N	RNA	2	50	50	\N	1
3132	MMR-293	\N	RNA	0	50	50	\N	1
3133	MMR-301	\N	RNA	0	50	50	\N	1
3134	MMR-302	\N	RNA	18.3	50	50	\N	1
3135	MMR-304	\N	RNA	5.45	50	50	\N	1
3136	MMR-305	\N	RNA	2.2	50	50	\N	1
3137	MMR-308	\N	RNA	0.13	50	50	\N	1
3138	MMR-313	\N	RNA	0	50	50	\N	1
3139	MMR-321	\N	RNA	0	50	50	\N	1
3140	MMR-323	\N	RNA	2.6	50	50	\N	1
3141	MMR-324	\N	RNA	0	50	50	\N	1
3142	MMR-325	2021-09-23 00:00:00-07	RNA	0	50	50	\N	1
3143	MMR-326	\N	RNA	2.94	50	50	\N	1
3144	MMR-327	2021-09-23 00:00:00-07	RNA	2.51	50	50	\N	1
3145	MMR-328	\N	RNA	0	50	50	\N	1
3146	MMR-329	2021-09-23 00:00:00-07	RNA	0	50	50	\N	1
3147	MMR-330	\N	RNA	8.7	50	50	\N	1
3148	MMR-331	2021-09-23 00:00:00-07	RNA	7.04	50	50	\N	1
3149	MMR-332	\N	RNA	2	50	50	\N	1
3150	MMR-333	2021-09-23 00:00:00-07	RNA	5.6	50	50	\N	1
3151	MMR-334	\N	RNA	8.72	50	50	\N	1
3152	MMR-335	\N	RNA	68	50	50	\N	1
3153	MMR-336	\N	RNA	3.35	50	50	\N	1
3154	MMR-337	2021-09-23 00:00:00-07	RNA	0	50	50	\N	1
3155	MMR-338	\N	RNA	42.1	50	50	\N	1
3156	MMR-340	2021-09-23 00:00:00-07	RNA	27.4	50	50	\N	1
3157	MMR-341	2021-09-23 00:00:00-07	RNA	9.46	50	50	\N	1
3158	MMR-342	2021-09-23 00:00:00-07	RNA	5.69	50	50	\N	1
3159	MMR-343	2021-09-23 00:00:00-07	RNA	2.3	50	50	\N	1
3160	MMR-344	2021-09-23 00:00:00-07	RNA	11.3	50	50	\N	1
3161	MMR-345	2021-09-23 00:00:00-07	RNA	6.56	50	50	\N	1
3162	MMR-346	2021-09-23 00:00:00-07	RNA	2.5	50	50	\N	1
3163	MMR-347	2021-09-23 00:00:00-07	RNA	0	50	50	\N	1
3164	MMR-348	2021-09-23 00:00:00-07	RNA	0	50	50	\N	1
3165	MMR-349	2021-09-23 00:00:00-07	RNA	0	50	50	\N	1
3166	MMR-350	2021-09-23 00:00:00-07	RNA	2.4	50	50	\N	1
3167	MMR-351	2021-09-23 00:00:00-07	RNA	0	50	50	\N	1
3168	MMR-352	2021-09-23 00:00:00-07	RNA	5.8	50	50	\N	1
3169	MMR-353	2021-09-23 00:00:00-07	RNA	0	50	50	\N	1
3170	MMR-354	2021-09-23 00:00:00-07	RNA	2.5	50	50	\N	1
3171	MMR-355	\N	RNA	0	0	0	\N	\N
3172	MMR-356	\N	RNA	0	0	0	\N	\N
3173	MMR-357	\N	RNA	0	0	0	\N	\N
3174	MMR-358	2021-09-23 00:00:00-07	RNA	2	50	50	\N	1
3175	MMR-359	\N	RNA	0	0	0	\N	\N
3176	MMR-360	2021-09-23 00:00:00-07	RNA	0	50	50	\N	1
3177	MMR-361	\N	RNA	0	0	0	\N	\N
3178	MP41-D	\N	DNA	3.82	0	0	from human uveal melanoma cell line	\N
3179	MP41-YM-R1-D	\N	DNA	5.89	0	0	\N	\N
3180	MR-001	\N	DNA	58	48	48	\N	\N
3181	MR-002	\N	DNA	41.6	48	48	\N	\N
3182	MR-003	\N	DNA	21.7	48	48	\N	\N
3183	MR-004	\N	DNA	29.6	48	48	\N	\N
3184	MR-005	\N	DNA	16.8	48	48	\N	\N
3185	MR-006	\N	DNA	9.84	48	48	\N	\N
3186	MR-008	\N	DNA	12	48	48	\N	\N
3187	MR-009	\N	DNA	8.6	48	48	\N	\N
3188	MR-010	\N	DNA	8.87	48	48	\N	\N
3189	MR-011	\N	DNA	59	48	48	\N	\N
3190	MR-012	\N	DNA	31.1	48	48	\N	\N
3191	MR-015	\N	DNA	1.11	48	48	\N	\N
3192	MR-017	\N	DNA	53	48	48	\N	\N
3193	MR-020	\N	DNA	207	48	48	\N	\N
3194	MR-021	\N	DNA	11.5	48	48	\N	\N
3195	MR-024	\N	DNA	11.8	48	48	\N	\N
3196	MR-025	\N	DNA	6.4	48	48	\N	\N
3197	MR-026	\N	DNA	121	48	48	\N	\N
3198	MR-027	\N	DNA	1.01	48	48	\N	\N
3199	MR-029	\N	DNA	29.5	48	48	\N	\N
3200	MR-030	\N	DNA	13.7	48	48	\N	\N
3201	MR-031	\N	DNA	18.1	48	48	\N	\N
3202	MR-032	\N	DNA	11.5	48	48	\N	\N
3203	MR-033	\N	DNA	24.5	48	48	\N	\N
3204	MR-034	\N	DNA	46.2	48	48	\N	\N
3205	MR-035	\N	DNA	44.6	48	48	\N	\N
3206	MR-036	\N	DNA	5.41	48	48	\N	\N
3207	MR-037	\N	DNA	9.44	48	48	\N	\N
3208	MR-038	\N	DNA	14.4	48	48	\N	\N
3209	MR-039	\N	DNA	19.9	48	48	\N	\N
3210	MR-040	\N	DNA	34.6	48	48	\N	\N
3211	MR-041	\N	DNA	34.9	48	48	\N	\N
3212	MR-042	\N	DNA	6.61	48	48	\N	\N
3213	MR-043	\N	DNA	17.2	48	48	\N	\N
3214	MR-044	\N	DNA	18.1	48	48	\N	\N
3215	MR-045	\N	DNA	0.97	48	48	\N	\N
3216	MR-046	\N	DNA	19.2	48	48	\N	\N
3217	MR-047	\N	DNA	2.04	48	48	\N	\N
3218	MR-048	\N	DNA	37.8	48	48	\N	\N
3219	MR-049	\N	DNA	23.7	48	48	\N	\N
3220	MR-050	\N	DNA	20.2	48	48	\N	\N
3221	MR-051	\N	DNA	2.12	48	48	\N	\N
3222	MS_1_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3223	N-1	2019-06-21 00:00:00-07	DNA	9.13	21	21	\N	5
3224	N-2	2019-07-01 00:00:00-07	DNA	2.32	48	48	\N	5
3225	N-3	2019-07-01 00:00:00-07	DNA	3.75	48	48	\N	5
3226	N-4	2019-07-01 00:00:00-07	DNA	16.3	33	33	\N	5
3227	N3_1_NA	\N	DNA	\N	\N	\N	\N	\N
3228	N3_2_NA	\N	DNA	\N	\N	\N	\N	\N
3229	N3_3_NA	\N	DNA	\N	\N	\N	\N	\N
3230	N3_4_NA	\N	DNA	\N	\N	\N	\N	\N
3231	N3_5_NA	\N	DNA	\N	\N	\N	\N	\N
3232	N3_6_NA	\N	DNA	\N	\N	\N	\N	\N
3233	N3_7_NA	\N	DNA	\N	\N	\N	\N	\N
3234	N3_8_NA	\N	DNA	\N	\N	\N	\N	\N
3235	N3_9_NA	\N	DNA	\N	\N	\N	\N	\N
3236	N3_10_NA	\N	DNA	\N	\N	\N	\N	\N
3237	N3_11_NA	\N	DNA	\N	\N	\N	\N	\N
3238	N3_12_NA	\N	DNA	\N	\N	\N	\N	\N
3239	N3_13_NA	\N	DNA	\N	\N	\N	\N	\N
3240	N3_14_NA	\N	DNA	\N	\N	\N	\N	\N
3241	N3_15_NA	\N	DNA	\N	\N	\N	\N	\N
3242	N3_16_NA	\N	DNA	\N	\N	\N	\N	\N
3243	NLD-013	2019-02-20 00:00:00-08	DNA	0.09	48	48	Not enough for LP	5
3244	NLD-014	2019-02-20 00:00:00-08	DNA	12.6	48	48	\N	5
3245	NLD-015	2019-02-20 00:00:00-08	DNA	34.2	48	48	\N	5
3246	NLD-016	2019-02-20 00:00:00-08	DNA	6.1	48	48	\N	5
3247	NLD-017	2019-02-20 00:00:00-08	DNA	1.2	48	48	\N	5
3248	NLD-018	2019-02-20 00:00:00-08	DNA	0.8	48	48	\N	5
3249	NLD-019	2019-02-20 00:00:00-08	DNA	1.5	48	48	\N	5
3250	NLD-020	2019-02-20 00:00:00-08	DNA	0.9	48	48	\N	5
3251	NLD-021	2019-02-20 00:00:00-08	DNA	26.5	48	48	\N	5
3252	NLD-022	2019-02-20 00:00:00-08	DNA	1.7	48	48	\N	5
3253	NLD-023	2019-02-20 00:00:00-08	DNA	2.4	48	48	\N	5
3254	NLD-024	2019-02-20 00:00:00-08	DNA	1.7	48	48	\N	5
3255	NLD-025	2019-02-20 00:00:00-08	DNA	1.4	48	48	\N	5
3256	NM D-01	2018-11-15 00:00:00-08	DNA	21.7	48	48	\N	5
3257	NM D-02	2018-11-15 00:00:00-08	DNA	0.26	48	48	\N	5
3258	NM D-03	2018-11-15 00:00:00-08	DNA	19.2	48	48	\N	5
3259	NM D-04	2018-11-15 00:00:00-08	DNA	1.73	48	48	\N	5
3260	NM D-05	2018-11-15 00:00:00-08	DNA	30.6	48	48	\N	5
3261	NM D-06	2018-11-15 00:00:00-08	DNA	28.4	48	48	\N	5
3262	NM D-07	2018-11-15 00:00:00-08	DNA	37.9	48	48	\N	5
3263	NM D-08	2018-11-15 00:00:00-08	DNA	35	48	48	\N	5
3264	NM D-09	2018-11-15 00:00:00-08	DNA	26.9	48	48	\N	5
3265	NM D-10	2018-11-15 00:00:00-08	DNA	23.4	48	48	\N	5
3266	NM D-11	2018-11-15 00:00:00-08	DNA	36.8	48	48	\N	5
3267	NM D-12	2018-11-17 00:00:00-08	DNA	32.5	48	48	\N	5
3268	NM D-13	2018-11-17 00:00:00-08	DNA	9.95	48	48	\N	5
3269	NM D-14	2018-11-17 00:00:00-08	DNA	15.8	48	48	\N	5
3270	NM D-15	2018-11-17 00:00:00-08	DNA	5.52	48	48	\N	5
3271	NM D-16	2018-11-17 00:00:00-08	DNA	27.3	48	48	\N	5
3272	NM D-17	2018-11-17 00:00:00-08	DNA	25	48	48	\N	5
3273	NM D-18	2018-11-17 00:00:00-08	DNA	31.3	48	48	\N	5
3274	NM D-19	2018-11-17 00:00:00-08	DNA	43.7	48	48	\N	5
3275	NM D-27	2018-11-17 00:00:00-08	DNA	4.94	48	48	\N	5
3276	NM D-29	2018-11-17 00:00:00-08	DNA	1.84	48	48	\N	5
3277	NM D-31	2018-11-17 00:00:00-08	DNA	45	48	48	\N	5
3278	NM D-32	2018-11-17 00:00:00-08	DNA	45	48	48	\N	5
3279	NM D-033	2018-11-17 00:00:00-08	DNA	46.2	48	48	\N	5
3280	NM D-034	2018-11-17 00:00:00-08	DNA	49	48	48	\N	5
3281	NM D-035	2018-11-17 00:00:00-08	DNA	50	48	48	\N	5
3282	NM D-036	2018-11-17 00:00:00-08	DNA	26.2	48	48	\N	5
3283	NM D-037	2018-11-17 00:00:00-08	DNA	50	48	48	\N	5
3284	NM D-038	2018-11-17 00:00:00-08	DNA	38.2	48	48	\N	5
3285	NM D-039	2018-11-17 00:00:00-08	DNA	1.47	48	48	\N	5
3286	NM D-040	2018-11-17 00:00:00-08	DNA	17.9	48	48	\N	5
3287	NM D-041	2018-11-17 00:00:00-08	DNA	8.55	48	48	\N	5
3288	NM D-043	2018-11-17 00:00:00-08	DNA	0.82	48	48	\N	5
3289	NM D-044	2018-11-17 00:00:00-08	DNA	30.2	48	48	\N	5
3290	NM D-045	2018-11-17 00:00:00-08	DNA	11.6	48	48	\N	5
3291	NM D-046	2018-11-17 00:00:00-08	DNA	0.9	48	48	\N	5
3292	NM D-047	2018-11-17 00:00:00-08	DNA	17.4	48	48	\N	5
3293	NM D-048	2018-11-24 00:00:00-08	DNA	13.4	48	48	\N	5
3294	NM D-049	2018-11-24 00:00:00-08	DNA	15.4	48	48	\N	5
3295	NM D-050	2018-11-24 00:00:00-08	DNA	5.7	48	48	\N	5
3296	NM D-051	2018-11-24 00:00:00-08	DNA	1.94	48	48	\N	5
3297	NM D-052	2018-11-24 00:00:00-08	DNA	0.6	48	48	\N	5
3298	NM D-053	2018-11-24 00:00:00-08	DNA	2.67	48	48	\N	5
3299	NM D-054	2018-11-24 00:00:00-08	DNA	7.1	48	48	\N	5
3300	NM D-055	2018-11-24 00:00:00-08	DNA	27.8	48	48	\N	5
3301	NM D-058	2018-11-24 00:00:00-08	DNA	1.96	48	48	\N	5
3302	NM D-059	2018-11-24 00:00:00-08	DNA	16.1	48	48	\N	5
3303	NM D-060	2018-11-24 00:00:00-08	DNA	40.3	48	48	\N	5
3304	NM D-061	2018-11-24 00:00:00-08	DNA	0.55	48	48	\N	5
3305	NM D-063	2018-11-24 00:00:00-08	DNA	40	48	48	\N	5
3306	NM D-064	2018-11-24 00:00:00-08	DNA	43.4	48	48	\N	5
3307	NM D-065	2018-11-24 00:00:00-08	DNA	48.4	48	48	\N	5
3308	NM D-066	2019-09-23 00:00:00-07	DNA	52	96	96	\N	5
3309	NM D-067	2019-09-23 00:00:00-07	DNA	49.1	96	96	\N	5
3310	NM D-068	2019-09-23 00:00:00-07	DNA	21.2	96	96	250 ng of DNA per library prep.	5
3311	NM D-069	2019-09-23 00:00:00-07	DNA	4.77	96	96	\N	5
3312	NM D-070	2019-09-23 00:00:00-07	DNA	15.2	96	96	\N	5
3313	NM D-071	2019-09-23 00:00:00-07	DNA	29.9	96	96	\N	5
3314	NM D-072	2019-09-23 00:00:00-07	DNA	13.5	96	96	\N	5
3315	NM D-073	2019-09-23 00:00:00-07	DNA	3.92	96	96	\N	5
3316	NM D-074	2019-09-23 00:00:00-07	DNA	42.3	96	96	\N	5
3317	NM D-075	2019-09-23 00:00:00-07	DNA	33.3	96	96	\N	5
3318	NM D-076	2019-09-23 00:00:00-07	DNA	35.9	96	96	\N	5
3319	NM D-077	2019-09-23 00:00:00-07	DNA	14.3	96	96	\N	5
3320	NM D-078	2019-09-23 00:00:00-07	DNA	4.88	96	96	\N	5
3321	NM D-079	2019-09-23 00:00:00-07	DNA	2.78	96	96	\N	5
3322	NM D-080	2019-09-23 00:00:00-07	DNA	3.69	96	96	\N	5
3323	NM D-081	2019-09-23 00:00:00-07	DNA	8.23	96	96	\N	5
3324	NM D-082	2019-09-23 00:00:00-07	DNA	17.1	96	96	\N	5
3325	NM D-083	2019-09-23 00:00:00-07	DNA	6.51	96	96	\N	5
3326	NM D-084	2022-06-15 00:00:00-07	DNA	15.4	90	90	(NM_01-A), Region A below C.  GREEN = Normal, BLUE = Melanoma. Image in Nod Mel	2
3327	NM D-085	2022-06-15 00:00:00-07	DNA	14.5	90	90	(NM_01-B), Region B upper side of C. GREEN = Normal, BLUE = Melanoma	2
3328	NM D-086	2022-06-15 00:00:00-07	DNA	17.9	90	90	(NM_01-C), Center Region. GREEN = Normal, BLUE = Melanoma	2
3329	NM D-087	2022-06-15 00:00:00-07	DNA	1.37	90	90	(NM_01-N), Normal Region. GREEN = Normal, BLUE = Melanoma	2
3330	NM D-088	2022-06-15 00:00:00-07	DNA	2.39	90	90	(NM_02-A), Region A below C.  GREEN = Normal, BLUE = Melanoma. Image in Nod Mel	2
3331	NM D-089	2022-06-15 00:00:00-07	DNA	1.65	90	90	(NM_02-B), Region B upper side of C. GREEN = Normal, BLUE = Melanoma	2
3332	NM D-090	2022-06-15 00:00:00-07	DNA	2.62	90	90	(NM_02-C), Center Region. GREEN = Normal, BLUE = Melanoma	2
3333	NM D-091	2022-06-15 00:00:00-07	DNA	1.13	90	90	(NM_02-N), Normal Region. GREEN = Normal, BLUE = Melanoma	2
3334	NM D-092	2022-06-15 00:00:00-07	DNA	4.4	90	90	(NM_03-A), Region A below C.  GREEN = Normal, BLUE = Melanoma. Image in Nod Mel	2
3335	NM D-093	2022-06-15 00:00:00-07	DNA	4.6	90	90	(NM_03-B), Region B upper side of C. GREEN = Normal, BLUE = Melanoma	2
3336	NM D-094	2022-06-15 00:00:00-07	DNA	6.6	90	90	(NM_03-C), Center Region. GREEN = Normal, BLUE = Melanoma	2
3337	NM D-095	2022-06-15 00:00:00-07	DNA	11.2	90	90	(NM_03-N), Normal Region. GREEN = Normal, BLUE = Melanoma	2
3338	NM D-096	2022-06-15 00:00:00-07	DNA	2.16	90	90	(NM_04-A), Region A below C.  GREEN = Normal, BLUE = Melanoma. Image in Nod Mel	2
3339	NM D-097	2022-06-15 00:00:00-07	DNA	1.53	90	90	(NM_04-B), Region B upper side of C. GREEN = Normal, BLUE = Melanoma	2
3340	NM D-098	2022-06-15 00:00:00-07	DNA	2.68	90	90	(NM_04-C), Center Region. GREEN = Normal, BLUE = Melanoma	2
3341	NM D-099	2022-06-15 00:00:00-07	DNA	0.82	90	90	(NM_04-N), Normal Region. GREEN = Normal, BLUE = Melanoma	2
3342	NM D-100	2023-03-29 00:00:00-07	DNA	11	180	180	\N	2
3343	NM D-101	2023-03-29 00:00:00-07	DNA	11.7	180	180	\N	2
3344	NM R-100	2023-03-29 00:00:00-07	RNA	11	90	90	\N	1
3345	NM R-101	2023-03-29 00:00:00-07	RNA	11.8	90	90	\N	1
3346	OM D-30	2022-02-22 00:00:00-08	DNA	0.25	88	88	\N	2
3347	OM D-31	2022-02-04 00:00:00-08	DNA	2.52	88	88	\N	2
3348	OM D-32	2022-02-04 00:00:00-08	DNA	4.55	88	88	\N	2
3349	OM D-33	2022-02-04 00:00:00-08	DNA	1.6	88	88	\N	2
3350	OM D-33A	2022-03-16 00:00:00-07	DNA	0.99	88	88	\N	2
3351	OM D-34	2022-02-04 00:00:00-08	DNA	5.17	88	88	\N	2
3352	OM D-35	2022-02-04 00:00:00-08	DNA	0.12	88	88	\N	2
3353	OM D-36	2022-02-04 00:00:00-08	DNA	10.2	88	88	\N	2
3354	OM D-37	2022-02-04 00:00:00-08	DNA	1.78	88	88	\N	2
3355	OM D-38	2022-02-04 00:00:00-08	DNA	0.89	88	88	\N	2
3356	OM D-39	2022-02-04 00:00:00-08	DNA	0.5	88	88	\N	2
3357	OM D-40.1	2022-02-22 00:00:00-08	DNA	1.69	88	88	\N	2
3358	OM D-40.2	2022-02-22 00:00:00-08	DNA	0.47	88	88	\N	2
3359	OM D-41	2022-02-04 00:00:00-08	DNA	8	88	88	\N	2
3360	OM D-42	2022-02-04 00:00:00-08	DNA	1.54	88	88	\N	2
3361	OM D-43	2022-02-04 00:00:00-08	DNA	1.14	88	88	\N	2
3362	OM D-44.1	2022-02-22 00:00:00-08	DNA	1.49	88	88	\N	2
3363	OM D-44.2	2022-02-22 00:00:00-08	DNA	1.44	88	88	\N	2
3364	OM D-44.3	2022-02-22 00:00:00-08	DNA	0.81	88	88	\N	2
3365	OM D-45	2022-02-04 00:00:00-08	DNA	46	88	88	\N	2
3366	OM D-46	2022-02-04 00:00:00-08	DNA	5.71	88	88	\N	2
3367	OM D-47	2022-02-04 00:00:00-08	DNA	7.1	88	88	\N	2
3368	OM D-48	2022-03-16 00:00:00-07	DNA	0.15	88	88	\N	2
3369	OM D-49	2022-03-16 00:00:00-07	DNA	0.1	88	88	\N	2
3370	OM D-50	2022-03-16 00:00:00-07	DNA	0.22	88	88	\N	2
3371	OM D-51	2022-03-16 00:00:00-07	DNA	1	88	88	\N	2
3372	OM D-52	2022-03-16 00:00:00-07	DNA	0.21	88	88	\N	2
3373	OM D-53	2022-03-16 00:00:00-07	DNA	1.77	88	88	\N	2
3374	OM D-54	2022-03-16 00:00:00-07	DNA	1.04	88	88	\N	2
3375	OM D-55	2022-03-16 00:00:00-07	DNA	0.84	88	88	\N	2
3376	OM D-56	2022-03-16 00:00:00-07	DNA	0.41	88	88	\N	2
3377	OM D-57	2022-03-16 00:00:00-07	DNA	2.4	88	88	\N	2
3378	OM D-58.1	2022-03-16 00:00:00-07	DNA	1.03	88	88	\N	2
3379	OM D-58.2	2022-03-16 00:00:00-07	DNA	0.66	88	88	\N	2
3380	OM D-58.3	2022-03-16 00:00:00-07	DNA	0.25	88	88	\N	2
3381	OM D-59	2022-03-16 00:00:00-07	DNA	2.11	88	88	\N	2
3382	OM D-60	2022-03-16 00:00:00-07	DNA	1.5	88	88	\N	2
3383	OM D-61	2022-03-17 00:00:00-07	DNA	0.81	88	88	\N	2
3384	OM D-62A	2022-03-17 00:00:00-07	DNA	1.23	88	88	\N	2
3385	OM D-62B	2022-03-17 00:00:00-07	DNA	3.1	88	88	\N	2
3386	OM D-63	2022-03-17 00:00:00-07	DNA	1.04	88	88	\N	2
3387	OM D-64	2022-03-17 00:00:00-07	DNA	0.5	88	88	\N	2
3388	OM D-65	2022-03-17 00:00:00-07	DNA	0.13	88	88	\N	2
3389	OM D-66.1	2022-03-17 00:00:00-07	DNA	4.08	88	88	\N	2
3390	OM D-66.2	2022-03-17 00:00:00-07	DNA	1.64	88	88	\N	2
3391	OM D-66.3	2022-03-17 00:00:00-07	DNA	3.71	88	88	\N	2
3392	OM D-67	2022-03-17 00:00:00-07	DNA	0.2	88	88	\N	2
3393	OM D-68.1	2022-03-17 00:00:00-07	DNA	0.48	88	88	\N	2
3394	OM D-68.2	2022-03-17 00:00:00-07	DNA	0.28	88	88	\N	2
3395	OM D-68.3	2022-03-17 00:00:00-07	DNA	0.31	88	88	\N	2
3396	OM D-69	2022-03-17 00:00:00-07	DNA	0.74	88	88	\N	2
3397	OM D-70	2022-03-17 00:00:00-07	DNA	1.12	88	88	\N	2
3398	OM D-71	2022-03-17 00:00:00-07	DNA	0.49	88	88	\N	2
3399	OM R-31	2022-02-04 00:00:00-08	RNA	14.3	46	46	\N	1
3400	OM R-32	2022-02-04 00:00:00-08	RNA	27.7	46	46	\N	1
3401	OM R-33	2022-02-04 00:00:00-08	RNA	22	46	46	\N	1
3402	OM R-34	2022-02-04 00:00:00-08	RNA	20.3	46	46	\N	1
3403	OM R-35	2022-02-04 00:00:00-08	RNA	3.77	46	46	\N	1
3404	OM R-36	2022-02-04 00:00:00-08	RNA	50	46	46	\N	1
3405	OM R-37	2022-02-04 00:00:00-08	RNA	17.6	46	46	\N	1
3406	OM R-38	2022-02-04 00:00:00-08	RNA	10.4	46	46	\N	1
3407	OM R-39	2022-02-04 00:00:00-08	RNA	14.7	46	46	\N	1
3408	OM R-41	2022-02-04 00:00:00-08	RNA	44.8	46	46	\N	1
3409	OM R-42	2022-02-04 00:00:00-08	RNA	33.11	46	46	\N	1
3410	OM R-43	2022-02-04 00:00:00-08	RNA	11.2	46	46	\N	1
3411	OM R-45	2022-02-04 00:00:00-08	RNA	62	46	46	\N	1
3412	OM R-46	2022-02-04 00:00:00-08	RNA	67	46	46	\N	1
3413	OM R-47	2022-02-04 00:00:00-08	RNA	0	46	46	\N	1
3414	OM-1D (P040_09A)	2021-06-07 00:00:00-07	DNA	1.8	52	52	DIN 4.1	7
3415	OM-1D-2	2022-01-05 00:00:00-08	DNA	1.49	88	88	\N	2
3416	OM-1D-3	2022-01-20 00:00:00-08	DNA	1.03	88	88	\N	2
3417	OM-1R (P040_05A)	2021-06-07 00:00:00-07	RNA	7.6	50	50	DV200 17%	7
3418	OM-3D (P040_09B)	2021-06-07 00:00:00-07	DNA	1.9	53	53	DIN 3.9	7
3419	OM-3R (P040_05B)	2021-06-07 00:00:00-07	RNA	8.4	50	50	DV200 14%	7
3420	OM-4D (P040_09C)	2021-06-07 00:00:00-07	DNA	0.4	51	51	DIN UND	7
3421	OM-4D-2	2022-01-05 00:00:00-08	DNA	0.43	88	88	\N	2
3422	OM-4D-3	2022-01-20 00:00:00-08	DNA	1.08	88	88	\N	2
3423	OM-4R (P040_05C)	2021-06-07 00:00:00-07	RNA	3	50	50	DV200 38%	7
3424	OM-5D (P040_09D)	2021-06-07 00:00:00-07	DNA	0.4	52	52	DIN 3.6	7
3425	OM-5D-2	2022-01-05 00:00:00-08	DNA	0.15	88	88	\N	2
3426	OM-5D-3	2022-01-20 00:00:00-08	DNA	0.36	88	88	\N	2
3427	OM-5R (P040_05D)	2021-06-07 00:00:00-07	RNA	1.7	50	50	DV200 26%	7
3428	OM-6D	2021-08-30 00:00:00-07	DNA	0.83	48	48	\N	7
3429	OM-6D-2	2022-01-05 00:00:00-08	DNA	0.64	88	88	\N	2
3430	OM-6D-3	2022-01-20 00:00:00-08	DNA	1.16	88	88	\N	2
3431	OM-8D (P040_11A)	2021-06-07 00:00:00-07	DNA	0.1	52	52	DIN 5.9	7
3432	OM-8R (P040_07A)	2021-06-07 00:00:00-07	RNA	0.7	51	51	DV200 46%	7
3433	OM-9D	2021-08-30 00:00:00-07	DNA	0.85	48	48	DO NOT use sequencing data.	7
3434	OM-10D (P040_11B)	2021-06-07 00:00:00-07	DNA	2	51	51	DIN 3.3	7
3435	OM-10D-2	2022-01-05 00:00:00-08	DNA	2.21	88	88	\N	2
3436	OM-10D-3	2022-01-20 00:00:00-08	DNA	1.65	88	88	\N	2
3437	OM-10R (P040_07B)	2021-06-07 00:00:00-07	RNA	11.6	50	50	DV200 22%	7
3438	OM-11D (P040_11C)	2021-06-07 00:00:00-07	DNA	0.1	51	51	DIN 3.6	7
3439	OM-11R (P040_07C)	2021-06-07 00:00:00-07	RNA	1.2	49	49	DV200 13%	7
3440	OM-12D	2021-08-30 00:00:00-07	DNA	0.56	48	48	\N	7
3441	OM-13D	2021-08-30 00:00:00-07	DNA	0.32	48	48	\N	7
3442	OM-14D	2021-08-30 00:00:00-07	DNA	0.07	48	48	\N	7
3443	OM-15D (P040_11D)	2021-06-07 00:00:00-07	DNA	10.9	51	51	DIN 2.4	7
3444	OM-15D-2	2022-01-05 00:00:00-08	DNA	27.2	88	88	\N	2
3445	OM-15R (P040_07D)	2021-06-07 00:00:00-07	RNA	21.7	50	50	DV200 58%	7
3446	OM-16D	2021-08-30 00:00:00-07	DNA	0.73	48	48	\N	7
3447	OM-17D	2021-08-30 00:00:00-07	DNA	2.53	48	48	\N	7
3448	OM-18D	2021-08-30 00:00:00-07	DNA	0.39	48	48	\N	7
3449	OM-18D2	2021-08-30 00:00:00-07	DNA	1.39	48	48	\N	7
3450	OM-18D3	2021-08-30 00:00:00-07	DNA	1.29	48	48	\N	7
3451	OM-18D4	2021-08-30 00:00:00-07	DNA	0.56	48	48	\N	7
3452	OM-22D	2022-01-05 00:00:00-08	DNA	1.04	88	88	\N	2
3453	OM-22D-2	2022-01-20 00:00:00-08	DNA	1.64	88	88	\N	2
3454	OM-23D	2022-01-05 00:00:00-08	DNA	0.74	88	88	\N	2
3455	OM-23D-2	2022-01-20 00:00:00-08	DNA	4.3	88	88	\N	2
3456	OM-24D	2022-01-05 00:00:00-08	DNA	0.61	88	88	\N	2
3457	OM-24D-2	2022-01-20 00:00:00-08	DNA	2.49	88	88	\N	2
3458	OM-25D	2022-01-05 00:00:00-08	DNA	1.12	88	88	\N	2
3459	OM-25D-2	2022-01-20 00:00:00-08	DNA	3.59	88	88	\N	2
3460	OM-26D	2022-01-05 00:00:00-08	DNA	0.34	88	88	\N	2
3461	OM-26D-2	2022-01-20 00:00:00-08	DNA	2.13	88	88	\N	2
3462	OM-27D	2022-01-05 00:00:00-08	DNA	1.17	88	88	\N	2
3463	OM-27D-2	2022-01-20 00:00:00-08	DNA	2.35	88	88	\N	2
3464	OM-28D	2022-01-05 00:00:00-08	DNA	1.76	88	88	\N	2
3465	OM-28D-2	2022-01-20 00:00:00-08	DNA	0.91	88	88	\N	2
3466	OM-29D	2022-01-05 00:00:00-08	DNA	1.03	88	88	\N	2
3467	OM-29D-2	2022-01-20 00:00:00-08	DNA	2.91	88	88	\N	2
3468	P57-A-1.0mm_NA	2023-06-07 00:00:00-07	DNA	0.78	48	48	1mm punch biopsy, Epidermis Only	3
3469	P57-A-2.0mm_NA	2023-06-07 00:00:00-07	DNA	23.7	48	48	1mm punch biopsy, possible dermis contamination	3
3470	P57-B-1.0mm_NA	2023-06-07 00:00:00-07	DNA	3.01	48	48	1mm punch biopsy, possible dermis contamination	3
3471	P57-B-2.0mm_NA	2023-06-07 00:00:00-07	DNA	2.93	48	48	2mm punch biopsy, Epidermis Only	3
3472	P57-Normal_NA	2023-06-07 00:00:00-07	DNA	57	138	138	~20 ug tissue for Bulk LP	3
3473	P57-Normal_NA	2023-06-07 00:00:00-07	DNA	34.1	138	138	~20 ug tissue for Bulk LP	3
3474	PG_8_NA	\N	DNA	\N	\N	\N	\N	\N
3475	PM-1	2019-04-01 00:00:00-07	DNA	19	35	35	\N	5
3476	PM-2	2019-04-01 00:00:00-07	DNA	18.8	35	35	\N	5
3477	PM-3	2019-04-01 00:00:00-07	DNA	20.4	36	36	\N	5
3478	PM-4	2019-04-01 00:00:00-07	DNA	38	41	41	\N	5
3479	PROG D-01	2020-07-28 00:00:00-07	DNA	0.83	100	100	\N	6
3480	PROG D-02	2020-07-28 00:00:00-07	DNA	0.32	100	100	\N	6
3481	PROG D-03	2020-07-28 00:00:00-07	DNA	0.16	100	100	\N	6
3482	PROG D-04	2020-07-28 00:00:00-07	DNA	8.55	100	100	\N	6
3483	PROG D-05	2020-07-28 00:00:00-07	DNA	5.84	100	100	\N	6
3484	PROG D-06	2020-07-28 00:00:00-07	DNA	0.07	100	100	\N	6
3485	PROG D-07	2020-07-28 00:00:00-07	DNA	0	100	100	\N	6
3486	PROG D-08	2020-07-28 00:00:00-07	DNA	0.09	100	100	\N	6
3487	PROG D-09	2020-07-28 00:00:00-07	DNA	0	100	100	\N	6
3488	PROG D-10	2020-07-28 00:00:00-07	DNA	0	100	100	\N	6
3489	PROG D-11	2020-07-28 00:00:00-07	DNA	0.1	100	100	\N	6
3490	PROG D-12	2020-07-28 00:00:00-07	DNA	2.02	100	100	\N	6
3491	PROG D-13	2020-07-28 00:00:00-07	DNA	0.94	100	100	\N	6
3492	PROG D-14	2020-08-23 00:00:00-07	DNA	0.71	100	100	\N	6
3493	PROG D-15	2023-05-19 00:00:00-07	DNA	1.78	308	308	\N	6
3494	PROG D-16	2023-05-19 00:00:00-07	DNA	0.72	198	198	\N	6
3495	PROG D-17	2023-05-12 00:00:00-07	DNA	16.6	200	200	\N	6
3496	PROG D-18	2023-05-19 00:00:00-07	DNA	15.2	88	88	\N	6
3497	PROG D-19	2023-05-18 00:00:00-07	DNA	1.05	184	184	\N	6
3498	PROG D-20	2023-05-18 00:00:00-07	DNA	10.7	308	308	\N	6
3499	PROG D-21	2023-05-12 00:00:00-07	DNA	0.36	200	200	\N	6
3500	PROG D-22	2023-05-12 00:00:00-07	DNA	3.43	400	400	\N	6
3501	PROG D-23	2023-05-12 00:00:00-07	DNA	7.02	400	400	\N	6
3502	PROG D-24	2023-05-18 00:00:00-07	DNA	5.78	408	408	\N	6
3503	PROG D-25	2023-05-18 00:00:00-07	DNA	3.3	438	438	\N	6
3504	PROG D-26	2023-05-18 00:00:00-07	DNA	3.28	428	428	\N	6
3505	PROG R-01	2020-08-03 00:00:00-07	RNA	12.5	20	20	\N	6
3506	PROG R-02	2020-08-03 00:00:00-07	RNA	9.48	20	20	\N	6
3507	PROG R-03	2020-08-03 00:00:00-07	RNA	5.78	20	20	\N	6
3508	PROG R-04	2020-08-03 00:00:00-07	RNA	321	20	20	\N	6
3509	PROG R-05	2020-08-03 00:00:00-07	RNA	309	20	20	\N	6
3510	PROG R-06	2020-08-03 00:00:00-07	RNA	5.32	20	20	\N	6
3511	PROG R-07	2020-08-03 00:00:00-07	RNA	7.92	20	20	\N	6
3512	PROG R-08	2020-08-03 00:00:00-07	RNA	23.7	20	20	\N	6
3513	PROG R-09	2020-08-03 00:00:00-07	RNA	13.5	20	20	\N	6
3514	PROG R-10	2020-08-03 00:00:00-07	RNA	15.2	20	20	\N	6
3515	PROG R-11	2020-08-03 00:00:00-07	RNA	3.17	20	20	\N	6
3516	PROG R-12	2020-08-03 00:00:00-07	RNA	40.8	20	20	\N	6
3517	PROG R-13	2020-08-03 00:00:00-07	RNA	11.5	20	20	\N	6
3518	PROG R-14	2020-08-18 00:00:00-07	RNA	5.49	20	20	\N	6
3519	PROG R-15	2023-05-19 00:00:00-07	RNA	7.92	55	55	\N	6
3520	PROG R-16	2023-05-19 00:00:00-07	RNA	7.64	40	40	\N	6
3521	PROG R-17	2023-05-12 00:00:00-07	RNA	172.8	40	40	\N	6
3522	PROG R-18	2023-05-19 00:00:00-07	RNA	30.8	18	18	\N	6
3523	PROG R-19	2023-05-18 00:00:00-07	RNA	3.27	16	16	\N	6
3524	PROG R-20	2023-05-18 00:00:00-07	RNA	45.5	53	53	\N	6
3525	PROG R-21	2023-05-12 00:00:00-07	RNA	3.78	41	41	\N	6
3526	PROG R-22	2023-05-12 00:00:00-07	RNA	41.1	81	81	\N	6
3527	PROG R-23	2023-05-12 00:00:00-07	RNA	54	81	81	\N	6
3528	PROG R-24	2023-05-18 00:00:00-07	RNA	39.7	77	77	\N	6
3529	PROG R-25	2023-05-18 00:00:00-07	RNA	39.8	77	77	\N	6
3530	PROG R-26	2023-05-18 00:00:00-07	RNA	22.1	78	78	\N	6
3531	RNA-01	\N	RNA	208	20	20	\N	6
3532	RNA-02	\N	RNA	86.4	20	20	\N	6
3533	RNA-03	\N	RNA	299	20	20	\N	6
3534	RNA-04	\N	RNA	9.6	20	20	\N	6
3535	RNA-05	\N	RNA	10.7	20	20	\N	6
3536	RNA-06	\N	RNA	64.4	20	20	\N	6
3537	RNA-07	\N	RNA	33.5	20	20	\N	6
3538	RNA-08	\N	RNA	15.6	20	20	\N	6
3539	RNA-09	\N	RNA	47	20	20	\N	6
3540	RNA-10	\N	RNA	38	20	20	\N	6
3541	RNA-11	\N	RNA	10	20	20	\N	6
3542	RNA-12	\N	RNA	33	20	20	\N	6
3543	RNA-13	\N	RNA	73.2	20	20	\N	6
3544	RNA-14	\N	RNA	834	20	20	\N	6
3545	RNA-15	\N	RNA	24.2	20	20	\N	6
3546	RNA-16	\N	RNA	54	20	20	\N	6
3547	RNA-17	\N	RNA	27	20	20	\N	6
3548	RNA-18	\N	RNA	61	20	20	\N	6
3549	RNA-19	\N	RNA	23	20	20	\N	6
3550	RNA-20	\N	RNA	14	20	20	\N	6
3551	RNA-21	\N	RNA	83	20	20	\N	6
3552	RNA-22	\N	RNA	135	20	20	\N	6
3553	RNA-23	\N	RNA	100	20	20	\N	6
3554	RNA-24	\N	RNA	63.5	20	20	\N	6
3555	RNA-25	\N	RNA	4.3	20	20	\N	6
3556	RNA-26	\N	RNA	81	20	20	\N	6
3557	RNA-27	\N	RNA	52	20	20	\N	6
3558	RNA-28	\N	RNA	223	20	20	\N	6
3559	RNA-29	\N	RNA	36	20	20	\N	6
3560	RNA-30	\N	RNA	163	20	20	\N	6
3561	RNA-31	\N	RNA	206	20	20	\N	6
3562	RNA-32	\N	RNA	15.5	20	20	\N	6
3563	RNA-33	\N	RNA	26	20	20	\N	6
3564	RNA-34	\N	RNA	22.4	20	20	\N	6
3565	RNA-35	\N	RNA	209	20	20	\N	6
3566	RNA-36	\N	RNA	50	20	20	\N	6
3567	RNA-37	\N	RNA	33.7	20	20	\N	6
3568	RNA-38	\N	RNA	48	20	20	\N	6
3569	RNA-39	\N	RNA	150	20	20	\N	6
3570	RNA-40	\N	RNA	228	20	20	\N	6
3571	RNA-41	\N	RNA	23.7	20	20	\N	6
3572	RNA-42	\N	RNA	5.3	20	20	\N	6
3573	RNA-43	\N	RNA	11.6	20	20	\N	6
3574	RNA-44	\N	RNA	57.3	20	20	\N	6
3575	RNA-45	\N	RNA	9.6	20	20	\N	6
3576	RNA-46	\N	RNA	3.5	20	20	\N	6
3577	RNA-47	\N	RNA	4.3	20	20	\N	6
3578	RNA-48	\N	RNA	23.5	20	20	\N	6
3579	RNA-49	\N	RNA	140	20	20	\N	6
3580	RNA-50	\N	RNA	61	20	20	\N	6
3581	RNA-51	\N	RNA	14	20	20	\N	6
3582	RNA-52	\N	RNA	15	20	20	\N	6
3583	RNA-53	\N	RNA	112	20	20	\N	6
3584	RNA-54	\N	RNA	10	20	20	\N	6
3585	RNA-55	\N	RNA	91	20	20	\N	6
3586	RNA-56	\N	RNA	167	20	20	\N	6
3587	RNA-57	\N	RNA	23.4	20	20	\N	6
3588	RNA-58	\N	RNA	1.5	20	20	\N	6
3589	RNA-59	\N	RNA	4.7	20	20	\N	6
3590	RNA-60	\N	RNA	1.6	20	20	\N	6
3591	RNA-61	\N	RNA	59	20	20	\N	6
3592	RNA-62	\N	RNA	52	20	20	\N	6
3593	RNA-63	\N	RNA	39	20	20	\N	6
3594	RNA-64	\N	RNA	10	20	20	\N	6
3595	RNA-65	\N	RNA	170	20	20	\N	6
3596	RNA-66	\N	RNA	171	20	20	\N	6
3597	RNA-72	\N	RNA	20.6	30	30	\N	6
3598	RNA-73	\N	RNA	4.2	30	30	\N	6
3599	RNA-74	\N	RNA	7.4	30	30	\N	6
3600	RNA-75	\N	RNA	6.6	30	30	\N	6
3601	RNA-76	\N	RNA	4	30	30	\N	6
3602	RNA-97	2020-08-03 00:00:00-07	RNA	2.3	20	20	\N	6
3603	RNA-98	2020-08-03 00:00:00-07	RNA	38.1	20	20	\N	6
3604	RNA-99	2020-08-03 00:00:00-07	RNA	5.27	20	20	\N	6
3605	RNA-100	2020-08-03 00:00:00-07	RNA	2.51	20	20	\N	6
3606	RNA-101	2020-08-03 00:00:00-07	RNA	37.8	20	20	\N	6
3607	RNA-101 (Mel_1)	\N	RNA	405	47	47	\N	6
3608	RNA-102 (Mel_2)	\N	RNA	485	47	47	\N	6
3609	RNA-103 (Mel_3)	\N	RNA	365	47	47	\N	6
3610	RNA-104 (Mel_4)	\N	RNA	380	47	47	\N	6
3611	RNA-105 (Mel_5)	\N	RNA	450	47	47	\N	6
3612	RNA-106 (Mel_6)	\N	RNA	410	47	47	\N	6
3613	RNA-107	2020-08-28 00:00:00-07	RNA	18.9	20	20	\N	6
3614	RNA-108	2020-08-28 00:00:00-07	RNA	124	20	20	\N	6
3615	RNA-109	2020-08-28 00:00:00-07	RNA	18.1	20	20	\N	6
3616	RNA-110	2020-08-28 00:00:00-07	RNA	0	20	20	\N	6
3617	RNA-111	2020-08-28 00:00:00-07	RNA	5.06	20	20	\N	6
3618	RNA-112	2020-08-28 00:00:00-07	RNA	10.3	20	20	\N	6
3619	RNA-113	2020-08-28 00:00:00-07	RNA	11	20	20	\N	6
3620	RNA-114	2020-08-28 00:00:00-07	RNA	8.83	20	20	\N	6
3621	RNA-115	2020-08-28 00:00:00-07	RNA	0	20	20	\N	6
3622	RNA-116	2020-08-28 00:00:00-07	RNA	8.39	20	20	\N	6
3623	RNA-117	2020-08-28 00:00:00-07	RNA	0	20	20	\N	6
3624	RNA-118	2020-08-28 00:00:00-07	RNA	8.74	20	20	\N	6
3625	RNA-119	2020-08-28 00:00:00-07	RNA	0	20	20	\N	6
3626	RNA-120	2020-08-28 00:00:00-07	RNA	25.1	20	20	\N	6
3627	RNA-121	2020-08-28 00:00:00-07	RNA	10.4	20	20	\N	6
3628	RNA-122	2020-08-28 00:00:00-07	RNA	32.4	20	20	\N	6
3629	RNA-123	2020-08-28 00:00:00-07	RNA	4.75	20	20	\N	6
3630	RNA-124	2020-08-28 00:00:00-07	RNA	5.62	20	20	\N	6
3631	RNA-125	2020-08-28 00:00:00-07	RNA	10.8	20	20	\N	6
3632	RNA-126	2020-08-28 00:00:00-07	RNA	3.26	20	20	\N	6
3633	RNA-127	2020-08-28 00:00:00-07	RNA	8.72	20	20	\N	6
3634	RNA-128	2020-08-28 00:00:00-07	RNA	2.2	20	20	DO NOT USE: DO NOT USE; WRONG TISSUE WAS MICRODISSECTED: 17-43707	6
3635	RNA-129	2020-08-28 00:00:00-07	RNA	11.5	20	20	\N	6
3636	RNA-130	2020-08-28 00:00:00-07	RNA	18.3	20	20	\N	6
3637	RNA-131	2020-08-28 00:00:00-07	RNA	2.1	20	20	\N	6
3638	RNA-132	2020-08-28 00:00:00-07	RNA	15.2	20	20	\N	6
3639	RNA-133	2020-08-28 00:00:00-07	RNA	57	20	20	\N	6
3640	RNA-134	2020-09-11 00:00:00-07	RNA	0	20	20	Third try, tissue failed to produce RNA	6
3641	RNA-135	2020-09-11 00:00:00-07	RNA	4.32	20	20	\N	6
3642	RNA-136	2020-09-11 00:00:00-07	RNA	4.19	20	20	\N	6
3643	RNA-137	2020-09-11 00:00:00-07	RNA	3.48	20	20	\N	6
3644	RNA-138	2020-09-11 00:00:00-07	RNA	0	20	20	\N	6
3645	RNA-139	2020-09-11 00:00:00-07	RNA	0	20	20	\N	6
3646	RNA-140	2020-09-11 00:00:00-07	RNA	0	20	20	\N	6
3647	RNA-141	2020-09-11 00:00:00-07	RNA	2.55	20	20	\N	6
3648	RNA-142	2020-09-22 00:00:00-07	RNA	0	20	20	\N	6
3649	RNA-143	2020-09-22 00:00:00-07	RNA	0	20	20	\N	6
3650	RNA-144	2020-09-22 00:00:00-07	RNA	4.18	20	20	\N	6
3651	RNA-145	2020-09-22 00:00:00-07	RNA	0	20	20	\N	6
3652	RNA-146	2020-10-03 00:00:00-07	RNA	17.4	20	20	\N	6
3653	RNA-147	2020-10-03 00:00:00-07	RNA	3.54	20	20	\N	6
3654	RNA-148	2020-10-03 00:00:00-07	RNA	6.11	20	20	\N	6
3655	RNA-149	2020-10-03 00:00:00-07	RNA	7.5	20	20	\N	6
3656	RNA-150	2020-10-03 00:00:00-07	RNA	8.6	20	20	\N	6
3657	RNA-151	2020-10-03 00:00:00-07	RNA	5.83	20	20	\N	6
3658	RNA-152	2020-10-05 00:00:00-07	RNA	3.44	20	20	\N	6
3659	RNA-153	2020-10-05 00:00:00-07	RNA	4.51	20	20	\N	6
3660	RNA-154	2020-10-05 00:00:00-07	RNA	2.57	20	20	\N	6
3661	RNA-155	2020-10-05 00:00:00-07	RNA	5.26	20	20	\N	6
3662	RNA-156	2020-10-05 00:00:00-07	RNA	0	20	20	\N	6
3663	RNA-157	2020-10-09 00:00:00-07	RNA	0	20	20	\N	6
3664	RNA-158	2020-10-09 00:00:00-07	RNA	0	20	20	\N	6
3665	RNA-159	2020-10-09 00:00:00-07	RNA	0	20	20	\N	6
3666	RNA-160	2022-03-14 00:00:00-07	RNA	16.1	48	48	\N	1
3667	RNA-161	2022-03-14 00:00:00-07	RNA	8.28	48	48	\N	1
3668	RNA-162	2022-03-14 00:00:00-07	RNA	5.33	48	48	\N	1
3669	RNA-163	2022-03-14 00:00:00-07	RNA	0	48	48	\N	1
3670	RNA-164	2022-03-14 00:00:00-07	RNA	35	48	48	\N	1
3671	RNA-165	2022-03-14 00:00:00-07	RNA	2.83	48	48	\N	1
3672	RNA-166	2022-03-14 00:00:00-07	RNA	23.6	48	48	\N	1
3673	RNA-167	2022-03-14 00:00:00-07	RNA	2.4	48	48	\N	1
3674	RNA-168	2022-03-14 00:00:00-07	RNA	0	48	48	\N	1
3675	RNA-169	2022-03-14 00:00:00-07	RNA	9.24	48	48	\N	1
3676	RNA-170	2022-03-14 00:00:00-07	RNA	7.32	48	48	\N	1
3677	RNA-171	2022-03-14 00:00:00-07	RNA	2	48	48	\N	1
3678	RNA-172	2022-03-14 00:00:00-07	RNA	0	48	48	\N	1
3679	RNA-173	2022-03-14 00:00:00-07	RNA	2.3	48	48	\N	1
3680	RNA-174	2022-03-14 00:00:00-07	RNA	10.3	48	48	\N	1
3681	RNA-175	2022-03-14 00:00:00-07	RNA	15.1	48	48	\N	1
3682	RNA-176	2022-03-14 00:00:00-07	RNA	2.93	48	48	\N	1
3683	RNA-177	2022-03-14 00:00:00-07	RNA	2	48	48	\N	1
3684	RNA-178	2022-03-14 00:00:00-07	RNA	10.3	48	48	\N	1
3685	RNA-179	2022-03-14 00:00:00-07	RNA	0	48	48	\N	1
3686	RNA-180	2022-03-15 00:00:00-07	RNA	0	48	48	\N	1
3687	RNA-181	2022-03-15 00:00:00-07	RNA	5.22	48	48	\N	1
3688	RNA-182	2022-03-15 00:00:00-07	RNA	0	48	48	\N	1
3689	RNA-183	2022-03-15 00:00:00-07	RNA	0	48	48	\N	1
3690	RNA-184	2022-03-15 00:00:00-07	RNA	20.2	48	48	\N	1
3691	RNA-185	2022-03-15 00:00:00-07	RNA	0	48	48	\N	1
3692	RNA-186	2022-03-15 00:00:00-07	RNA	2.2	48	48	\N	1
3693	RNA-187	2022-03-15 00:00:00-07	RNA	23	48	48	\N	1
3694	RNA-188	2022-03-15 00:00:00-07	RNA	7.06	48	48	\N	1
3695	RNA-189	2022-03-15 00:00:00-07	RNA	6.79	48	48	\N	1
3696	RNA-190	2022-03-15 00:00:00-07	RNA	5.22	48	48	\N	1
3697	RNA-191	2022-03-15 00:00:00-07	RNA	6.32	48	48	\N	1
3698	RNA-192	2022-03-15 00:00:00-07	RNA	0	48	48	\N	1
3699	RNA-193	2022-03-15 00:00:00-07	RNA	3.85	48	48	\N	1
3700	RNA-194	2022-03-15 00:00:00-07	RNA	0	48	48	\N	1
3701	RNA-195	2022-03-15 00:00:00-07	RNA	8.06	48	48	\N	1
3702	RNA-196	2022-03-15 00:00:00-07	RNA	6.99	48	48	\N	1
3703	RNA-197	2022-03-15 00:00:00-07	RNA	4.92	48	48	\N	1
3704	RNA-199	2022-04-21 00:00:00-07	RNA	12.4	48	48	\N	1
3705	RNA-200	2022-04-21 00:00:00-07	RNA	0	48	48	\N	1
3706	RNA-203	2022-04-18 00:00:00-07	RNA	32.7	48	48	\N	1
3707	RNA-204	2022-04-18 00:00:00-07	RNA	16	48	48	\N	1
3708	RNA-205	2022-04-18 00:00:00-07	RNA	16.6	48	48	\N	1
3709	RNA-207	2022-04-18 00:00:00-07	RNA	28.9	48	48	\N	1
3710	RNA-208	2022-04-18 00:00:00-07	RNA	8.15	48	48	\N	1
3711	RNA-209	2022-04-18 00:00:00-07	RNA	25.5	48	48	\N	1
3712	RNA-210	2022-04-18 00:00:00-07	RNA	4.44	48	48	\N	1
3713	RNA-212	2022-04-18 00:00:00-07	RNA	7.6	48	48	\N	1
3714	RNA-213	2022-04-18 00:00:00-07	RNA	12.4	48	48	\N	1
3715	RNA-214	2022-04-18 00:00:00-07	RNA	4.95	48	48	\N	1
3716	RNA-217	2022-04-18 00:00:00-07	RNA	9.21	48	48	\N	1
3717	RNA-218	2022-04-18 00:00:00-07	RNA	18.1	48	48	\N	1
3718	RNA-219	2022-04-18 00:00:00-07	RNA	3.35	48	48	\N	1
3719	RNA-221	2022-04-18 00:00:00-07	RNA	14.8	48	48	\N	1
3720	RNA-222	2022-04-18 00:00:00-07	RNA	2	48	48	\N	1
3721	RNA-224	2022-04-18 00:00:00-07	RNA	8.04	48	48	\N	1
3722	RNA-225	2022-04-18 00:00:00-07	RNA	0	48	48	\N	1
3723	RNA-227	\N	RNA	0	0	0	\N	\N
3724	RNA-228	\N	RNA	0	0	0	\N	\N
3725	RNA-230	2022-04-18 00:00:00-07	RNA	16.7	48	48	\N	1
3726	RNA-231	2022-04-18 00:00:00-07	RNA	4.25	48	48	\N	1
3727	RNA-233	2022-04-18 00:00:00-07	RNA	6.33	48	48	\N	1
3728	RNA-234	2022-04-18 00:00:00-07	RNA	7.7	48	48	5 sections/tube	1
3729	RNA-235	2022-04-21 00:00:00-07	RNA	6.27	48	48	\N	1
3730	RNA-238	2022-04-21 00:00:00-07	RNA	0	48	48	\N	1
3731	RNA-239	\N	RNA	0	0	0	\N	\N
3732	RNA-242	2022-04-21 00:00:00-07	RNA	8.98	48	48	\N	1
3733	RNA-243	2022-04-21 00:00:00-07	RNA	0	48	48	\N	1
3734	RNA-244	2022-04-21 00:00:00-07	RNA	0	48	48	\N	1
3735	RNA-245	2022-04-18 00:00:00-07	RNA	24.4	48	48	6 sections/tube	1
3736	RNA-246	2022-04-18 00:00:00-07	RNA	15.4	48	48	6 sections/tube	1
3737	RNA-247	2022-04-18 00:00:00-07	RNA	6.87	48	48	5 sections/tube	1
3738	RNA-251	2022-05-13 00:00:00-07	RNA	3.2	48	48	\N	1
3739	RNA-252	2022-05-13 00:00:00-07	RNA	2.61	48	48	\N	1
3740	RNA-253	2022-05-13 00:00:00-07	RNA	0	38	38	\N	1
3741	RNA-254	2022-05-13 00:00:00-07	RNA	1.14	38	38	\N	1
3742	RNA-266	2022-05-25 00:00:00-07	RNA	200	48	48	\N	1
3743	RNA-268	2022-05-25 00:00:00-07	RNA	268	36	36	\N	1
3744	RNA-269	2022-06-06 00:00:00-07	RNA	0	48	48	\N	1
3745	RNA-272	\N	RNA	0	0	0	\N	\N
3746	RNA-273	2022-08-25 00:00:00-07	RNA	7	45	45	\N	1
3747	RNA-275	2022-08-25 00:00:00-07	RNA	9.06	45	45	\N	1
3748	RNA-276	2022-08-25 00:00:00-07	RNA	1.02	38	38	\N	1
3749	RNA-278	2022-08-25 00:00:00-07	RNA	4.36	45	45	\N	1
3750	RNA-279	2022-08-25 00:00:00-07	RNA	6.77	45	45	\N	1
3751	RNA-281	\N	RNA	0	0	0	\N	\N
3752	RNA-282	\N	RNA	0	0	0	\N	\N
3753	RNA-283	\N	RNA	0	0	0	\N	\N
3754	RNA-284	\N	RNA	0	0	0	\N	\N
3755	RNA-285	2022-08-25 00:00:00-07	RNA	0	38	38	\N	1
3756	RNA-286	2022-08-25 00:00:00-07	RNA	25	45	45	\N	1
3757	RNA-288	2022-08-25 00:00:00-07	RNA	3.83	45	45	\N	1
3758	RNA-289	2022-08-25 00:00:00-07	RNA	0.52	38	38	\N	1
3759	RNA-294	2022-08-25 00:00:00-07	RNA	12.8	45	45	\N	1
3760	RNA-295	2022-08-25 00:00:00-07	RNA	2	45	45	\N	1
3761	RNA-298	2022-08-26 00:00:00-07	RNA	15.3	45	45	\N	1
3762	RNA-299	2022-08-26 00:00:00-07	RNA	30.5	45	45	\N	1
3763	RNA-300	2022-08-26 00:00:00-07	RNA	0	38	38	\N	1
3764	RNA-301	2022-08-26 00:00:00-07	RNA	0.55	38	38	\N	1
3765	RNA-303	2022-08-26 00:00:00-07	RNA	0.9	38	38	\N	1
3766	RNA-304	2022-08-26 00:00:00-07	RNA	0	38	38	\N	1
3767	RNA-305	2022-08-26 00:00:00-07	RNA	10.4	45	45	\N	1
3768	RNA-306	2022-08-26 00:00:00-07	RNA	5.7	45	45	\N	1
3769	RNA-307	2022-08-26 00:00:00-07	RNA	0.95	38	38	\N	1
3770	RNA-309	2022-08-26 00:00:00-07	RNA	12.9	45	45	\N	1
3771	RNA-310	2022-08-26 00:00:00-07	RNA	25	45	45	\N	1
3772	RNA-311	2022-08-25 00:00:00-07	RNA	1.22	38	38	\N	1
3773	RNA-312	\N	RNA	0	0	0	\N	\N
3774	RNA-313	2022-08-25 00:00:00-07	RNA	6.71	45	45	\N	1
3775	RNA-314	2022-08-26 00:00:00-07	RNA	4.73	45	45	\N	1
3776	RNA-315	2022-08-26 00:00:00-07	RNA	2.1	38	38	\N	1
3777	RNA-318	2022-11-22 00:00:00-08	RNA	0	0	0	\N	1
3778	RNA-320	2022-12-09 00:00:00-08	RNA	2.56	48	48	\N	1
3779	RNA-330	2022-10-28 00:00:00-07	RNA	46	80	80	\N	1
3780	RNA-331	2022-10-28 00:00:00-07	RNA	40.3	80	80	\N	1
3781	RNA-332	2022-10-28 00:00:00-07	RNA	25.4	45	45	\N	1
3782	RNA-334	2022-10-28 00:00:00-07	RNA	12.5	90	90	\N	1
3783	RNA-335	2022-10-28 00:00:00-07	RNA	20	45	45	\N	1
3784	RNA-337	2022-10-28 00:00:00-07	RNA	36.5	45	45	\N	1
3785	RNA-338	2022-10-28 00:00:00-07	RNA	8.11	45	45	\N	1
3786	RNA-339	2022-10-28 00:00:00-07	RNA	4.65	45	45	\N	1
3787	RNA-340	2022-10-28 00:00:00-07	RNA	22.3	45	45	\N	1
3788	RNA-341	2022-10-31 00:00:00-07	RNA	23.9	40	40	\N	1
3789	RNA-344	2022-12-09 00:00:00-08	RNA	5.92	96	96	\N	1
3790	RNA-346	2022-12-09 00:00:00-08	RNA	2.1	48	48	\N	1
3791	RNA-347	2022-12-09 00:00:00-08	RNA	4.91	48	48	\N	1
3792	RNA-348	2022-10-31 00:00:00-07	RNA	41.5	183	183	\N	1
3793	RNA-350	2022-10-31 00:00:00-07	RNA	16.7	95	95	\N	1
3794	RNA-351	2022-10-31 00:00:00-07	RNA	5.19	190	190	\N	1
3795	RNA-355	2022-10-31 00:00:00-07	RNA	12.4	52	52	\N	1
3796	RNA-356	2022-11-10 00:00:00-08	RNA	65	48	48	\N	1
3797	RNA-357	2022-11-10 00:00:00-08	RNA	5.12	48	48	\N	1
3798	RNA-359	2022-11-10 00:00:00-08	RNA	33.5	90	90	\N	1
3799	RNA-361	2022-11-10 00:00:00-08	RNA	9.09	90	90	\N	1
3800	RNA-364	2022-11-10 00:00:00-08	RNA	19	90	90	\N	1
3801	RNA-365	2022-11-10 00:00:00-08	RNA	3.71	48	48	\N	1
3802	RNA-366	2022-11-10 00:00:00-08	RNA	3.25	48	48	\N	1
3803	RNA-369	2022-11-14 00:00:00-08	RNA	18.5	135	135	\N	1
3804	RNA-372	2022-11-10 00:00:00-08	RNA	15	48	48	\N	1
3805	RNA-373	2022-11-10 00:00:00-08	RNA	9.27	48	48	\N	1
3806	RNA-377	2022-11-14 00:00:00-08	RNA	18.5	135	135	\N	1
3807	RNA-379	2022-11-14 00:00:00-08	RNA	22.7	84	84	\N	1
3808	RNA-381	2022-11-14 00:00:00-08	RNA	8.28	48	48	\N	1
3809	RNA-383	2022-11-14 00:00:00-08	RNA	5.05	84	84	\N	1
3810	RNA-385	2022-11-22 00:00:00-08	RNA	7.67	48	48	\N	1
3811	RNA-387	2022-11-22 00:00:00-08	RNA	5.24	48	48	\N	1
3812	RNA-390	2022-11-22 00:00:00-08	RNA	3.1	48	48	\N	1
3813	RNA-391	2022-11-22 00:00:00-08	RNA	4.45	48	48	\N	1
3814	RNA-392	2022-11-22 00:00:00-08	RNA	15.3	48	48	\N	1
3815	RNA-394	2022-11-22 00:00:00-08	RNA	37.9	96	96	\N	1
3816	RNA-396	2022-11-22 00:00:00-08	RNA	11.6	48	48	\N	1
3817	RNA-399	2022-12-09 00:00:00-08	RNA	3.32	48	48	\N	1
3818	RNA-401	2022-12-09 00:00:00-08	RNA	4.67	48	48	\N	1
3819	RNA-402	2022-12-09 00:00:00-08	RNA	2.2	48	48	\N	1
3820	RNA-403	2022-12-09 00:00:00-08	RNA	7.71	96	96	\N	1
3821	RNA-404	2022-11-22 00:00:00-08	RNA	3.57	48	48	\N	1
3822	RNA-405	2022-11-22 00:00:00-08	RNA	3.45	96	96	\N	1
3823	RNA-417	2022-11-14 00:00:00-08	RNA	13.4	48	48	\N	1
3824	RNA-418	2022-12-09 00:00:00-08	RNA	4.88	48	48	\N	1
3825	RNA-419	2022-12-09 00:00:00-08	RNA	16.3	96	96	\N	1
3826	RNA-420	2022-12-09 00:00:00-08	RNA	0.7	86	86	\N	1
3827	RNA-421	2022-12-09 00:00:00-08	RNA	3.56	96	96	\N	1
3828	RNA-422	2022-12-09 00:00:00-08	RNA	1.08	48	48	\N	1
3829	RNA-423	2022-12-09 00:00:00-08	RNA	0	48	48	\N	1
3830	RNA-424	2023-04-18 00:00:00-07	RNA	2.4	45	45	\N	1
3831	RNA-425	2023-04-18 00:00:00-07	RNA	4.36	45	45	\N	1
3832	RNA-426	2023-04-18 00:00:00-07	RNA	7.6	45	45	\N	1
3833	RNA-427	2023-04-20 00:00:00-07	RNA	1.64	80	80	\N	1
3834	RNA-428	2023-04-18 00:00:00-07	RNA	1.43	40	40	\N	1
3835	RNA-429	2023-04-20 00:00:00-07	RNA	2.5	80	80	\N	1
3836	RNA-430	2023-04-20 00:00:00-07	RNA	2.82	40	40	\N	1
3837	RNA-431	2023-04-20 00:00:00-07	RNA	3.02	45	45	\N	1
3838	RNA-432	2023-04-20 00:00:00-07	RNA	4.42	45	45	\N	1
3839	RNA-433	2023-04-20 00:00:00-07	RNA	0.4	35	35	\N	1
3840	RNA-434	2023-04-20 00:00:00-07	RNA	3.22	45	45	\N	1
3841	RNA-435	2023-04-20 00:00:00-07	RNA	1.47	40	40	\N	1
3842	RNA-436	2023-04-25 00:00:00-07	RNA	19.5	80	80	\N	1
3843	RNA-437	2023-04-25 00:00:00-07	RNA	13.6	40	40	\N	1
3844	RNA-438	2023-04-25 00:00:00-07	RNA	2.5	80	80	\N	1
3845	RNA-439	2023-06-05 00:00:00-07	RNA	38.1	51	51	\N	6
3846	RNA-440	2023-06-05 00:00:00-07	RNA	8.81	21	21	\N	6
3847	RNA-441	2023-06-05 00:00:00-07	RNA	8.3	21	21	\N	6
3848	RNA-442	2023-06-05 00:00:00-07	RNA	7.97	48	48	\N	6
3849	RNA-443	2023-06-06 00:00:00-07	RNA	10.1	41	41	\N	6
3850	RNA-444	2023-06-06 00:00:00-07	RNA	14.3	41	41	\N	6
4596	NA_CP1-10_Tumor	\N	DNA	\N	\N	\N	\N	\N
3851	RNA-445	2023-06-06 00:00:00-07	RNA	48.2	36	36	\N	6
3852	RNA-446	2023-06-06 00:00:00-07	RNA	70	43	43	\N	6
3853	RNA-447	2023-06-06 00:00:00-07	RNA	13.5	20	20	\N	6
3854	RNA-448	2023-06-06 00:00:00-07	RNA	18.2	20	20	\N	6
3855	RPA_09_0209_NA	\N	DNA	\N	\N	\N	\N	\N
3856	S12_20321_A2_Tumor_NA	\N	DNA	\N	\N	\N	Brain, right frontal, biopsy: Glioblastoma, WHO Grade IV 	\N
3857	SCH D-01	2020-11-23 00:00:00-08	DNA	12.2	88	88	SP13-6852-B2	6
3858	SCH R-01	2020-11-28 00:00:00-08	RNA	540	20	20	\N	6
3859	Seider_Roe_NA	\N	DNA	\N	\N	\N	\N	\N
3860	Seider_Uveal Melanoma_NA	\N	DNA	\N	\N	\N	\N	\N
3861	SHR01	2023-02-22 00:00:00-08	DNA	12.6	140	140	3mm punch biopsy	3
3862	SHR03	2023-02-22 00:00:00-08	DNA	10.6	140	140	3mm punch biopsy	3
3863	SHR05	2023-02-22 00:00:00-08	DNA	11.1	140	140	3mm punch biopsy	3
3864	SHR06	2023-02-22 00:00:00-08	DNA	0.38	140	140	3mm punch biopsy	3
3865	SKMEL 1023A	\N	DNA	116	10	10	\N	\N
3866	SKMEL 1107B	\N	DNA	118	10	10	\N	\N
3867	SKMel 1107B Dec2019 (MC-02)	\N	DNA	47.8	13	13	\N	\N
3868	SKMEL 1121B	\N	DNA	114	10	10	\N	\N
3869	SKMel 1121B Dec2019 (MC-03)	\N	DNA	26.4	33	33	\N	\N
3870	SM D-01	2018-12-12 00:00:00-08	DNA	1.36	48	48	\N	5
3871	SM D-02	2018-12-12 00:00:00-08	DNA	2.1	48	48	\N	5
3872	SM D-03	2018-12-12 00:00:00-08	DNA	8.67	48	48	\N	5
3873	SM D-04	2018-12-12 00:00:00-08	DNA	3.02	48	48	\N	5
3874	SM D-05	2018-12-12 00:00:00-08	DNA	2.6	48	48	\N	5
3875	SM D-06	2018-12-12 00:00:00-08	DNA	0.37	48	48	\N	5
3876	SM D-07	2018-12-12 00:00:00-08	DNA	2.08	48	48	\N	5
3877	SM D-08	2018-12-12 00:00:00-08	DNA	4.14	48	48	\N	5
3878	SM D-09	2018-12-12 00:00:00-08	DNA	0.92	48	48	\N	5
3879	SM D-10	2018-12-12 00:00:00-08	DNA	4.36	48	48	\N	5
3880	SM D-11	2018-12-12 00:00:00-08	DNA	1.4	48	48	\N	5
3881	SM D-12	2018-12-12 00:00:00-08	DNA	14.4	48	48	\N	5
3882	SM D-13	2018-12-12 00:00:00-08	DNA	9.44	48	48	\N	5
3883	SM D-14	2018-12-12 00:00:00-08	DNA	3.3	48	48	\N	5
3884	SM D-15	2018-12-12 00:00:00-08	DNA	8.61	48	48	\N	5
3885	SM D-16	2018-12-12 00:00:00-08	DNA	2.27	48	48	\N	5
3886	SM D-17	2018-12-12 00:00:00-08	DNA	6.84	48	48	\N	5
3887	SM D-18	2018-12-12 00:00:00-08	DNA	6.75	48	48	\N	5
3888	SM D-19	2018-12-12 00:00:00-08	DNA	1.22	48	48	\N	5
3889	SM D-20	2018-12-12 00:00:00-08	DNA	5.97	48	48	\N	5
3890	SM D-21	2018-12-12 00:00:00-08	DNA	0.77	48	48	\N	5
3891	SM D-22	2018-12-12 00:00:00-08	DNA	1.87	48	48	\N	5
3892	SM D-23	2018-12-12 00:00:00-08	DNA	0.83	48	48	\N	5
3893	SM D-24	2018-12-12 00:00:00-08	DNA	1.54	48	48	\N	5
3894	SM D-25	2018-12-12 00:00:00-08	DNA	2.36	48	48	\N	5
3895	SM_1_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3896	SM_2_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
3897	SM_2_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3898	SM_3_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3899	SM_4_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
3900	SM_4_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3901	SM_5_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
3902	SM_5_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3903	SM_6_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3904	SM_7_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
3905	SM_7_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3906	SM_8_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
3907	SM_8_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3908	SM_9_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
3909	SM_9_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3910	SM_10_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3911	SM_11_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3912	SM_12_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3913	SM_16_Normal_NA	\N	DNA	\N	\N	\N	\N	\N
3914	SM_16_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3915	SM_18_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3916	SM7_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
3917	SMPR2	\N	RNA	8.8	20	20	\N	6
3918	SMPR4	\N	RNA	41.1	20	20	\N	6
3919	SMPR11	\N	RNA	205.8	20	20	\N	6
3920	SMPR12	\N	RNA	34.1	20	20	\N	6
3921	SMPR20	\N	RNA	24.7	20	20	\N	6
3922	SMPR48	\N	RNA	14.9	20	20	\N	6
3923	SMPR55	\N	RNA	77.2	20	20	\N	6
3924	SMPR56	\N	RNA	23.8	20	20	\N	6
3925	SMPR58A	\N	RNA	8.6	20	20	\N	6
3926	SMPR58B	\N	RNA	35.5	20	20	\N	6
3927	SND-01	2020-07-12 00:00:00-07	DNA	0.53	88	88	MAP2K1	6
3928	SND-02	2020-07-12 00:00:00-07	DNA	0.5	88	88	MAP2K1	6
3929	SND-03	2020-07-12 00:00:00-07	DNA	0.09	88	88	GNAQ	6
3930	SND-04	2020-07-12 00:00:00-07	DNA	0.68	88	88	GNAQ	6
3931	SND-05	2020-07-12 00:00:00-07	DNA	0.58	88	88	MAP2K1	6
3932	SND-06	2020-07-12 00:00:00-07	DNA	0.57	88	88	GNAQ	6
3933	SND-07	2020-07-12 00:00:00-07	DNA	3.19	88	88	MAP2K1	6
3934	SND-08	2020-07-12 00:00:00-07	DNA	0.22	88	88	GNAQ	6
3935	SND-09	2020-07-12 00:00:00-07	DNA	0.66	88	88	MAP2K1	6
3936	SND-10	2020-07-12 00:00:00-07	DNA	0.69	88	88	GNAQ	6
3937	SND-11	2020-07-12 00:00:00-07	DNA	0.37	88	88	MAP2K1	6
3938	SND-12	2020-07-12 00:00:00-07	DNA	0.44	88	88	MAP2K1	6
3939	SND-13	2020-07-12 00:00:00-07	DNA	0.92	88	88	GNAQ	6
3940	SND-14	2020-07-12 00:00:00-07	DNA	2.04	88	88	MAP2K1	6
3941	SND-15	2020-07-12 00:00:00-07	DNA	1.3	88	88	MAP2K1	6
3942	SND-16	2020-07-12 00:00:00-07	DNA	0.26	88	88	GNAQ	6
3943	SND-17	2020-07-12 00:00:00-07	DNA	2.18	88	88	MAP2K1	6
3944	SND-18	2020-07-12 00:00:00-07	DNA	0.24	88	88	MAP2K1	6
3945	SND-19	2020-07-12 00:00:00-07	DNA	0.88	88	88	MAP2K1	6
3946	SND-20	2020-11-23 00:00:00-08	DNA	1.08	88	88	\N	6
3947	SND-21	2020-11-23 00:00:00-08	DNA	2.09	88	88	\N	6
3948	SND-22	2020-11-23 00:00:00-08	DNA	1.16	88	88	\N	6
3949	SND-23	2020-11-23 00:00:00-08	DNA	1.53	88	88	\N	6
3950	SND-24	2020-11-23 00:00:00-08	DNA	0.55	88	88	\N	6
3951	SND-25	2020-11-23 00:00:00-08	DNA	0.64	88	88	\N	6
3952	SND-26	2020-11-23 00:00:00-08	DNA	0.18	88	88	\N	6
3953	SND-27	2020-11-23 00:00:00-08	DNA	3.84	88	88	\N	6
3954	SND-28	2020-11-23 00:00:00-08	DNA	3.63	88	88	\N	6
3955	SND-29	2020-11-23 00:00:00-08	DNA	0	88	88	\N	6
3956	SND-30	2020-11-23 00:00:00-08	DNA	0.11	88	88	\N	6
3957	SND-31	2020-11-23 00:00:00-08	DNA	0.15	88	88	\N	6
3958	SND-32	2020-11-23 00:00:00-08	DNA	0.05	88	88	\N	6
3959	SND-33	2020-11-23 00:00:00-08	DNA	0.26	88	88	\N	6
3960	SND-34	2020-11-23 00:00:00-08	DNA	0	88	88	\N	6
3961	SND-35	2020-12-03 00:00:00-08	DNA	0	88	88	\N	6
3962	SND-36	2020-12-03 00:00:00-08	DNA	0.15	88	88	\N	6
3963	SND-37	2020-12-03 00:00:00-08	DNA	0	88	88	\N	6
3964	SND-38	2020-12-03 00:00:00-08	DNA	0.32	88	88	\N	6
3965	SND-39	2021-08-30 00:00:00-07	DNA	0.57	48	48	\N	7
3966	SND-40	2021-08-30 00:00:00-07	DNA	0.74	48	48	\N	7
3967	SND-41	2021-08-30 00:00:00-07	DNA	1.5	48	48	\N	7
3968	SND-42	2021-08-30 00:00:00-07	DNA	2.14	48	48	\N	7
3969	SND-43	2021-08-30 00:00:00-07	DNA	0.17	48	48	\N	7
3970	SNR-01	2020-07-12 00:00:00-07	RNA	9.89	20	20	MAP2K1	6
3971	SNR-02	2020-07-12 00:00:00-07	RNA	8.04	20	20	MAP2K1	6
3972	SNR-03	2020-07-12 00:00:00-07	RNA	0	20	20	GNAQ	6
3973	SNR-04	2020-07-12 00:00:00-07	RNA	3.2	20	20	GNAQ	6
3974	SNR-05	2020-07-12 00:00:00-07	RNA	7.62	20	20	MAP2K1	6
3975	SNR-06	2020-07-12 00:00:00-07	RNA	3.17	20	20	GNAQ	6
3976	SNR-07	2020-07-12 00:00:00-07	RNA	19.8	20	20	MAP2K1	6
3977	SNR-08	2020-07-12 00:00:00-07	RNA	0	20	20	GNAQ	6
3978	SNR-09	2020-07-12 00:00:00-07	RNA	2.5	20	20	MAP2K1	6
3979	SNR-10	2020-07-12 00:00:00-07	RNA	5.79	20	20	GNAQ	6
3980	SNR-11	2020-07-12 00:00:00-07	RNA	3.09	20	20	MAP2K1	6
3981	SNR-12	2020-07-12 00:00:00-07	RNA	7.67	20	20	MAP2K1	6
3982	SNR-13	2020-07-12 00:00:00-07	RNA	7.3	20	20	GNAQ	6
3983	SNR-14	2020-07-12 00:00:00-07	RNA	20.5	20	20	MAP2K1	6
3984	SNR-15	2020-07-12 00:00:00-07	RNA	8.59	20	20	MAP2K1	6
3985	SNR-16	2020-07-12 00:00:00-07	RNA	0	20	20	GNAQ	6
3986	SNR-17	2020-07-12 00:00:00-07	RNA	20.2	20	20	MAP2K1	6
3987	SNR-18	2020-07-12 00:00:00-07	RNA	2.52	20	20	MAP2K1	6
3988	SNR-19	2020-07-12 00:00:00-07	RNA	0	20	20	MAP2K1	6
3989	SNR-20	2020-11-28 00:00:00-08	RNA	2.76	20	20	\N	6
3990	SNR-21	2020-11-28 00:00:00-08	RNA	2.9	20	20	\N	6
3991	SNR-22	2020-11-28 00:00:00-08	RNA	8.9	20	20	\N	6
3992	SNR-23	2020-11-28 00:00:00-08	RNA	11.3	20	20	\N	6
3993	SNR-24	2020-11-28 00:00:00-08	RNA	2.2	20	20	\N	6
3994	SNR-25	2020-11-28 00:00:00-08	RNA	6.75	20	20	\N	6
3995	SNR-26	2020-11-28 00:00:00-08	RNA	0	20	20	\N	6
3996	SNR-27	2020-11-28 00:00:00-08	RNA	14.3	20	20	\N	6
3997	SNR-28	2020-11-28 00:00:00-08	RNA	69	20	20	\N	6
3998	SNR-29	2020-11-28 00:00:00-08	RNA	0	20	20	\N	6
3999	SNR-30	2020-11-28 00:00:00-08	RNA	0	20	20	\N	6
4000	SNR-31	2020-11-28 00:00:00-08	RNA	2.3	20	20	\N	6
4001	SNR-32	2020-11-28 00:00:00-08	RNA	5.94	20	20	\N	6
4002	SNR-33	2020-11-28 00:00:00-08	RNA	2.59	20	20	\N	6
4003	SNR-34	2020-11-28 00:00:00-08	RNA	0	20	20	\N	6
4004	Thomas_SK_MEL_23_NA	\N	DNA	\N	\N	\N	\N	\N
4005	TPP 1_1	\N	DNA	1.35	90	90	\N	\N
4006	TPP 1_2	\N	DNA	0.86	90	90	\N	\N
4007	TPP 1_3	\N	DNA	1.59	90	90	\N	\N
4008	TPP 1_4	\N	DNA	0.9	90	90	\N	\N
4009	TPP 1_5	\N	DNA	0.56	90	90	\N	\N
4010	TPP 1_6	\N	DNA	0.48	90	90	\N	\N
4011	TPP 1_7	\N	DNA	3.79	90	90	\N	\N
4012	TPP 1_8	\N	DNA	1.08	90	90	\N	\N
4013	TPP 1_9	\N	DNA	0.94	90	90	\N	\N
4014	TPP 1_10	\N	DNA	0.83	90	90	\N	\N
4015	TPP 1_11	\N	DNA	0.61	90	90	\N	\N
4016	TPP 1_12	\N	DNA	1.67	90	90	\N	\N
4017	TPP 1_13	\N	DNA	3.4	90	90	\N	\N
4018	TPP 1_14	\N	DNA	4.63	90	90	\N	\N
4019	TPP 1_15	\N	DNA	1.01	90	90	\N	\N
4020	TPP 1_16	\N	DNA	4.2	90	90	\N	\N
4021	TPP 1_17	\N	DNA	2.3	90	90	\N	\N
4022	TPP 1_18	\N	DNA	3.94	90	90	\N	\N
4023	TPP 1_19	\N	DNA	32.4	90	90	\N	\N
4024	TPP 1_20	\N	DNA	10.5	90	90	\N	\N
4025	TPP 1_21	\N	DNA	3.58	90	90	\N	\N
4026	TPP 1_22	\N	DNA	8.88	90	90	\N	\N
4027	TPP 1_23	\N	DNA	4.62	90	90	\N	\N
4028	TPP 1_24	\N	DNA	15	90	90	\N	\N
4029	TPP 1_25	\N	DNA	6.14	90	90	\N	\N
4030	TPP 1_26	\N	DNA	14.2	90	90	\N	\N
4031	TPP 1_27	\N	DNA	14.3	90	90	\N	\N
4032	TPP 2_1	2017-08-02 00:00:00-07	DNA	0.98	100	100	\N	\N
4033	TPP 2_2	2017-08-02 00:00:00-07	DNA	15.6	100	100	\N	\N
4034	TPP 2_3	2017-08-02 00:00:00-07	DNA	2.61	100	100	\N	\N
4035	TPP 2_4	2017-08-02 00:00:00-07	DNA	2.63	100	100	\N	\N
4036	TPP 2_5	2017-08-02 00:00:00-07	DNA	10.3	100	100	\N	\N
4037	TPP 2_6	2017-08-02 00:00:00-07	DNA	6.8	100	100	\N	\N
4038	TPP 2_7	2017-08-02 00:00:00-07	DNA	4.07	100	100	\N	\N
4039	TPP 2_8	2017-08-02 00:00:00-07	DNA	5.6	100	100	\N	\N
4040	TPP 2_9	2017-08-02 00:00:00-07	DNA	6.5	100	100	\N	\N
4041	TPP 2_10	2017-08-02 00:00:00-07	DNA	7.53	100	100	\N	\N
4042	TPP 2_11	2017-08-02 00:00:00-07	DNA	5.23	100	100	\N	\N
4043	TPP 2_12	2017-08-02 00:00:00-07	DNA	10.2	100	100	\N	\N
4044	TPP 2_13	2017-08-02 00:00:00-07	DNA	14.1	100	100	\N	\N
4045	TPP 2_14	2017-08-02 00:00:00-07	DNA	4.64	100	100	\N	\N
4046	TPP 2_15	2017-08-02 00:00:00-07	DNA	0.38	100	100	\N	\N
4047	TPP 2_16	2017-08-02 00:00:00-07	DNA	24.3	100	100	\N	\N
4048	TPP 2_17	2017-08-02 00:00:00-07	DNA	9.26	100	100	\N	\N
4049	TPP 2_18	2017-08-02 00:00:00-07	DNA	9.09	100	100	\N	\N
4050	TPP 2_19	2017-08-02 00:00:00-07	DNA	10.8	100	100	\N	\N
4051	TPP 2_20	2017-08-02 00:00:00-07	DNA	2.3	100	100	\N	\N
4052	TPP 2_21	2017-08-02 00:00:00-07	DNA	12.2	100	100	\N	\N
4053	TPP 2_22	2017-08-02 00:00:00-07	DNA	1.13	100	100	\N	\N
4054	TPP 2_23	2017-08-02 00:00:00-07	DNA	9.74	100	100	\N	\N
4055	TPP 2_24	2017-08-02 00:00:00-07	DNA	6.96	100	100	\N	\N
4056	TPP 2_25	2017-08-09 00:00:00-07	DNA	11	100	100	\N	\N
4057	TPP 2_26	2017-08-09 00:00:00-07	DNA	11	100	100	\N	\N
4058	TPP 2_27	2017-08-09 00:00:00-07	DNA	1.31	100	100	\N	\N
4059	TPP 2_28	2017-08-09 00:00:00-07	DNA	3.12	100	100	\N	\N
4060	TPP 2_29	2017-08-09 00:00:00-07	DNA	12	100	100	\N	\N
4061	TPP 2_30	2017-08-09 00:00:00-07	DNA	1.92	100	100	\N	\N
4062	TPP 2_31	2017-08-09 00:00:00-07	DNA	6.58	100	100	\N	\N
4063	TPP 2_32	2017-08-09 00:00:00-07	DNA	4.1	100	100	\N	\N
4064	TPP 2_33	2017-08-09 00:00:00-07	DNA	4.54	100	100	\N	\N
4065	TPP 2_34	2017-08-09 00:00:00-07	DNA	2.6	100	100	\N	\N
4066	TPP 2_35	2017-08-09 00:00:00-07	DNA	14.9	100	100	\N	\N
4067	TPP 2_36	2017-08-09 00:00:00-07	DNA	48.2	100	100	\N	\N
4068	TPP 2_37	2017-08-09 00:00:00-07	DNA	12.9	100	100	\N	\N
4069	TPP 2_38	2017-08-09 00:00:00-07	DNA	1.89	100	100	\N	\N
4070	TPP 2_39	2017-08-09 00:00:00-07	DNA	2.2	100	100	\N	\N
4071	TPP 2_40	2017-08-09 00:00:00-07	DNA	19.1	100	100	\N	\N
4072	TPP 2_41	2017-08-09 00:00:00-07	DNA	6.2	100	100	\N	\N
4073	TPP 2_42	2017-08-09 00:00:00-07	DNA	1.56	100	100	\N	\N
4074	TPP 2_43	2017-08-09 00:00:00-07	DNA	3.76	100	100	\N	\N
4075	TPP 2_44	2017-08-09 00:00:00-07	DNA	5.12	100	100	\N	\N
4076	TPP 2_45	2017-08-09 00:00:00-07	DNA	4.14	100	100	\N	\N
4077	TPP 2_46	2017-08-09 00:00:00-07	DNA	5.56	100	100	\N	\N
4078	TPP 2_47	2017-08-09 00:00:00-07	DNA	4.08	100	100	\N	\N
4079	TPP 2_48	2017-08-09 00:00:00-07	DNA	14	100	100	\N	\N
4080	TPP 2_49	2017-08-09 00:00:00-07	DNA	1.08	100	100	\N	\N
4081	TPP 2_50	2017-08-09 00:00:00-07	DNA	0.84	100	100	\N	\N
4082	TPP 2_51	2017-08-09 00:00:00-07	DNA	0.72	100	100	\N	\N
4083	TPP 2_52	2017-08-09 00:00:00-07	DNA	6.74	100	100	\N	\N
4084	TPP 2_53	2017-08-09 00:00:00-07	DNA	5.8	100	100	\N	\N
4085	TPP 2_54	2017-08-09 00:00:00-07	DNA	10	100	100	\N	\N
4086	TPP 2_55	\N	DNA	18.1	100	100	\N	\N
4087	TPP 2_56	\N	DNA	4.3	100	100	\N	\N
4088	TPP 2_57	\N	DNA	15	100	100	\N	\N
4089	TPP 2_58	\N	DNA	1.92	100	100	\N	\N
4090	TPP 2_59	\N	DNA	1.79	100	100	\N	\N
4091	TPP 2_60	\N	DNA	6.6	100	100	\N	\N
4092	TPP 2_61	\N	DNA	0.23	100	100	\N	\N
4093	TPP 2_62	\N	DNA	17.6	100	100	\N	\N
4094	TPP 2_63	\N	DNA	2.76	100	100	\N	\N
4095	TPP 2_64	\N	DNA	2.7	100	100	\N	\N
4096	TPP 2_65	\N	DNA	2.6	100	100	\N	\N
4097	TPP 2_66	\N	DNA	0.52	100	100	\N	\N
4098	TPP 2_67	\N	DNA	11.4	100	100	\N	\N
4099	TPP 2_68	\N	DNA	10.3	100	100	\N	\N
4100	TPP 2_69	\N	DNA	3.76	100	100	\N	\N
4101	TPP 2_70	\N	DNA	4.46	100	100	\N	\N
4102	TPP 2_71	\N	DNA	1.84	100	100	\N	\N
4103	TPP 2_72	\N	DNA	12.1	100	100	\N	\N
4104	TPP 2_73	\N	DNA	10	100	100	\N	\N
4105	TPP 2_74	\N	DNA	7.32	100	100	\N	\N
4106	TPP 2_75	\N	DNA	24.8	100	100	\N	\N
4107	TPP 2_76	\N	DNA	11.5	100	100	\N	\N
4108	TPP 2_77	\N	DNA	14.9	100	100	\N	\N
4109	TPP 2_78	\N	DNA	2.56	100	100	\N	\N
4110	TPP 2_79	\N	DNA	10.4	100	100	\N	\N
4111	TPP 2_80	\N	DNA	20.2	100	100	\N	\N
4112	TPP 2_81	\N	DNA	9.68	100	100	\N	\N
4113	TPP 2_82	\N	DNA	7.2	100	100	\N	\N
4114	TPP 2_83	\N	DNA	14.9	100	100	\N	\N
4115	TPP 2_84	\N	DNA	0.71	100	100	\N	\N
4116	TPP 2_85	\N	DNA	12.2	100	100	\N	\N
4117	TPP 2_86	\N	DNA	6.34	100	100	\N	\N
4118	TPP 2_87	\N	DNA	2.3	100	100	\N	\N
4119	TPP 2_88	\N	DNA	14	100	100	\N	\N
4120	TPP_3-01	\N	DNA	28.6	48	48	\N	\N
4121	TPP_3-02	\N	DNA	8.34	48	48	\N	\N
4122	TPP_3-03	\N	DNA	19	48	48	\N	\N
4123	TPP_3-04	\N	DNA	23.2	48	48	\N	\N
4124	TPP_3-05	\N	DNA	16.3	48	48	\N	\N
4125	TPP_3-06	\N	DNA	11.5	48	48	\N	\N
4126	TPP_3-07	\N	DNA	67.2	48	48	\N	\N
4127	TPP_3-08	\N	DNA	47.4	48	48	\N	\N
4128	TPP_3-09	\N	DNA	25.4	48	48	\N	\N
4129	TPP_3-10	\N	DNA	2.7	48	48	\N	\N
4130	TPP_3-11	\N	DNA	11.5	48	48	\N	\N
4131	TPP_3-12	\N	DNA	28.6	48	48	\N	\N
4132	TPP_3-13	\N	DNA	18.3	48	48	\N	\N
4133	TPP_3-14	\N	DNA	39.4	48	48	\N	\N
4134	TPP_3-15	\N	DNA	43.4	48	48	\N	\N
4135	TPP_3-16	\N	DNA	6.34	48	48	\N	\N
4136	TPP_3-17	\N	DNA	8.52	48	48	\N	\N
4137	TPP_3-18	\N	DNA	10.2	48	48	\N	\N
4138	TPP_3-19	\N	DNA	99.8	48	48	\N	\N
4139	TPP_3-20	\N	DNA	33.4	48	48	\N	\N
4140	TPP_3-21	\N	DNA	18.1	48	48	\N	\N
4141	TPP_3-22	\N	DNA	27.4	48	48	\N	\N
4142	TPP_3-23	\N	DNA	22.6	48	48	\N	\N
4143	TPP_3-24	\N	DNA	22.4	48	48	\N	\N
4144	TPP_3-25	\N	DNA	23.4	48	48	\N	\N
4145	TPP_3-26	\N	DNA	4.7	48	48	\N	\N
4146	TPP_3-27	\N	DNA	13.7	48	48	\N	\N
4147	TPP_3-28	\N	DNA	39.2	48	48	\N	\N
4148	TPP_3-29	\N	DNA	33.4	48	48	\N	\N
4149	TPP_3-30	\N	DNA	14.3	48	48	\N	\N
4150	TPP_3-31	\N	DNA	26.2	48	48	\N	\N
4151	TPP_3-32	\N	DNA	20.4	48	48	\N	\N
4152	TPP_3-33	\N	DNA	11.3	48	48	\N	\N
4153	TPP_3-34	\N	DNA	25.6	48	48	\N	\N
4154	TPP_3-35	\N	DNA	20	48	48	\N	\N
4155	TPP_3-36	\N	DNA	16.1	48	48	\N	\N
4156	TPP_3-37	\N	DNA	20.4	48	48	\N	\N
4157	TPP_3-38	\N	DNA	6.6	48	48	\N	\N
4158	TPP_3-39	\N	DNA	42.2	48	48	\N	\N
4159	TPP_3-40	\N	DNA	17.9	48	48	\N	\N
4160	TPP_3-41	\N	DNA	16.6	48	48	\N	\N
4161	TPP_3-42	\N	DNA	48.8	48	48	\N	\N
4162	TPP_3-43	\N	DNA	89.6	48	48	\N	\N
4163	TPP_3-44	\N	DNA	58.6	48	48	\N	\N
4164	TPP_3-45	\N	DNA	24	48	48	\N	\N
4165	TPP_3-46	\N	DNA	85.8	48	48	\N	\N
4166	TPP_3-47	\N	DNA	70.6	48	48	\N	\N
4167	TPP_3-48	\N	DNA	29.4	48	48	\N	\N
4168	TPP_3-49	\N	DNA	23.6	48	48	\N	\N
4169	TPP_3-50	\N	DNA	33.2	48	48	\N	\N
4170	TPP_3-51	\N	DNA	41.2	48	48	\N	\N
4171	TPP_3-52	\N	DNA	36.8	48	48	\N	\N
4172	TPP_3-53	\N	DNA	34.2	48	48	\N	\N
4173	TPP_3-54	\N	DNA	18.9	48	48	\N	\N
4174	TPP_3-55	\N	DNA	46.2	48	48	\N	\N
4175	WM8_NA	2012-11-01 00:00:00-07	DNA	38.4	30	30	wt/wt	\N
4176	WM51_NA	2012-11-01 00:00:00-07	DNA	98.1	30	30	\N	\N
4177	WM1963_NA	2012-11-01 00:00:00-07	DNA	28.7	30	30	wt/wt	\N
4178	WM3622_NA	2012-11-01 00:00:00-07	DNA	17	30	30	wt/wt	\N
4179	WM3912_NA	\N	DNA	16.5	100	100	wt/wt	\N
4180	WM3918_NA	2012-11-01 00:00:00-07	DNA	52.7	30	30	\N	\N
4181	WP_11_NA	2012-06-01 00:00:00-07	DNA	454	50	50	\N	\N
4182	WP_23_NA	2012-06-01 00:00:00-07	DNA	179	50	50	\N	\N
4183	WP_29_NA	2012-06-01 00:00:00-07	DNA	394	50	50	\N	\N
4184	WTMM-17-Tumor_NA	2015-07-27 00:00:00-07	DNA	7.13	100	100	\N	\N
4185	WTMM-18-Tumor_NA	2015-07-27 00:00:00-07	DNA	4.16	100	100	\N	\N
4186	WTMM-19-Tumor_NA	2015-07-27 00:00:00-07	DNA	19.9	100	100	\N	\N
4187	WTMM-20-Tumor_NA	2015-07-27 00:00:00-07	DNA	40.4	100	100	\N	\N
4188	WTMM-21-Tumor_NA	2015-07-27 00:00:00-07	DNA	2.89	100	100	\N	\N
4189	WTMM-22-Tumor_NA	2015-07-27 00:00:00-07	DNA	2.63	100	100	\N	\N
4190	WTMM-23-Tumor_NA	2015-07-27 00:00:00-07	DNA	7.96	100	100	\N	\N
4191	WTMM-24-Tumor_NA	2015-07-27 00:00:00-07	DNA	9.93	100	100	\N	\N
4192	Xu-1	\N	RNA	200	10	10	\N	\N
4193	Xu-2	\N	RNA	200	10	10	\N	\N
4194	Xu-3	\N	RNA	200	10	10	\N	\N
4195	Xu-4	\N	RNA	200	10	10	\N	\N
4196	Xu-5	\N	RNA	200	10	10	\N	\N
4197	Xu-6	\N	RNA	200	10	10	\N	\N
4198	Xu-7	\N	RNA	200	10	10	\N	\N
4199	Xu-8	\N	RNA	200	10	10	\N	\N
4200	Xu-9	\N	RNA	200	10	10	\N	\N
4201	Xu-10	\N	RNA	200	10	10	\N	\N
4202	Xu-11	\N	RNA	200	10	10	\N	\N
4203	Xu-12	\N	RNA	200	10	10	\N	\N
4204	Xu-13	\N	RNA	200	10	10	\N	\N
4205	Xu-14	\N	RNA	200	10	10	\N	\N
4206	Xu-015	\N	RNA	200	10	10	\N	\N
4207	Xu-016	\N	RNA	200	10	10	\N	\N
4208	Xu-017	\N	RNA	200	10	10	\N	\N
4209	Xu-018	\N	RNA	200	10	10	\N	\N
4210	Xu-019	\N	RNA	200	10	10	\N	\N
4211	Xu-020	\N	RNA	200	10	10	\N	\N
4212	Xu-021	\N	RNA	200	10	10	\N	\N
4213	Xu-022	\N	RNA	200	10	10	\N	\N
4214	Xu-023	\N	RNA	200	10	10	\N	\N
4215	Xu-024	\N	RNA	200	10	10	\N	\N
4216	Xu-025	\N	RNA	200	10	10	\N	\N
4217	Xu-026	\N	RNA	200	10	10	\N	\N
4218	Xu-027	\N	RNA	200	10	10	\N	\N
4219	Xu-028	\N	RNA	200	10	10	\N	\N
4220	Xu-029	\N	RNA	200	10	10	\N	\N
4221	Xu-030	\N	RNA	200	10	10	\N	\N
4222	Xu-031	\N	RNA	200	10	10	\N	\N
4223	Xu-032	\N	RNA	130	10	10	\N	\N
4224	Xu-033	\N	RNA	200	10	10	\N	\N
4225	Xu-034	\N	RNA	200	10	10	\N	\N
4226	Xu-035	\N	RNA	200	10	10	\N	\N
4227	Xu-036	\N	RNA	200	10	10	\N	\N
4228	Xu-037	\N	RNA	200	10	10	\N	\N
4229	Xu-038	\N	RNA	200	10	10	\N	\N
4230	Xu-039	\N	RNA	200	10	10	\N	\N
4231	Xu-040	\N	RNA	200	10	10	\N	\N
4232	Xu-041	\N	RNA	200	10	10	\N	\N
4233	Xu-042	\N	RNA	200	10	10	\N	\N
4234	Xu-043	\N	RNA	200	10	10	\N	\N
4235	Xu-044	\N	RNA	200	10	10	\N	\N
4236	Xu-045	\N	RNA	200	10	10	\N	\N
4237	Xu-046	\N	RNA	200	10	10	\N	\N
4238	Xu-047	\N	RNA	200	10	10	\N	\N
4239	Xu-048	\N	RNA	200	10	10	\N	\N
4240	Xu-049	\N	RNA	200	10	10	\N	\N
4241	Xu-050	\N	RNA	200	10	10	\N	\N
4242	Xu-051	\N	RNA	200	10	10	\N	\N
4243	Xu-052	\N	RNA	200	10	10	\N	\N
4244	Xu-053	\N	RNA	200	10	10	\N	\N
4245	Xu-054	\N	RNA	200	10	10	\N	\N
4246	Xu-055	\N	RNA	165	10	10	\N	\N
4247	Xu-056	\N	RNA	113	10	10	\N	\N
4248	Xu-057	\N	RNA	94.3	10	10	\N	\N
4249	Xu-058	\N	RNA	119.1	10	10	\N	\N
4250	Xu-059	\N	RNA	201.9	10	10	\N	\N
4251	Xu-060	\N	RNA	150.5	10	10	\N	\N
4252	Xu-061	\N	RNA	179.2	10	10	\N	\N
4253	Xu-062	\N	RNA	76.7	10	10	\N	\N
4254	Xu-063	\N	RNA	129.5	10	10	\N	\N
4255	Xu-064	\N	RNA	21.2	25	25	\N	\N
4256	DMS-001A	\N	DNA	19.9	48	48	\N	2
4257	DMS-001B	\N	DNA	21.4	48	48	\N	2
4258	DMS-001C	\N	DNA	16.3	48	48	\N	2
4259	DMS-002	\N	DNA	11.7	48	48	\N	2
4260	DMS-003	\N	DNA	14.7	48	48	\N	2
4261	DMS-004	\N	DNA	1.05	48	48	\N	2
4262	DMS-005	\N	DNA	2.88	48	48	\N	2
4263	DMS-006	\N	DNA	7.4	48	48	\N	2
4264	DMS-007	\N	DNA	19.5	48	48	\N	2
4265	DMS-008	\N	DNA	7.23	48	48	\N	2
4266	DMS-009	\N	DNA	1.21	48	48	\N	2
4267	DMS-010	\N	DNA	10.7	48	48	\N	2
4268	DMS-011	\N	DNA	0.12	48	48	\N	2
4269	DMS-012	\N	DNA	0.28	48	48	\N	2
4270	DMS-013	\N	DNA	6.83	48	48	\N	2
4271	DMS-014	\N	DNA	1.17	48	48	\N	2
4272	DMS-015	\N	DNA	1.8	48	48	\N	2
4273	DMS-016	\N	DNA	5.67	48	48	\N	2
4274	DMS-017	\N	DNA	4.13	48	48	\N	2
4275	DMS-018	\N	DNA	1.72	48	48	\N	2
4276	DMS-019	\N	DNA	12.5	48	48	\N	2
4277	DMS-020	\N	DNA	1.08	48	48	\N	2
4278	DMS-021	\N	DNA	2.13	48	48	\N	2
4279	DMS-022	\N	DNA	15.5	48	48	\N	2
4280	DMS-023	\N	DNA	8.09	48	48	\N	2
4281	DMS-024	\N	DNA	2.94	48	48	\N	2
4282	DMS-025	\N	DNA	9.7	48	48	\N	2
4283	DMS-026	\N	DNA	15.9	48	48	\N	2
4284	DMS-027	\N	DNA	0.38	48	48	\N	2
4285	DMS-028	\N	DNA	1.02	48	48	\N	2
4286	DMS-029	\N	DNA	0.24	48	48	\N	2
4287	DMS-030	\N	DNA	7.47	48	48	\N	2
4288	DMS-031	\N	DNA	0.16	48	48	\N	2
4289	DMS-032	\N	DNA	16.3	48	48	\N	2
4290	DMS-033	\N	DNA	16.4	48	48	\N	2
4291	DMS-034	\N	DNA	8.38	48	48	\N	2
4292	DMS-035	\N	DNA	0.6	48	48	\N	2
4293	DMS-035N	\N	DNA	0.1	48	48	\N	2
4294	DMS-036	\N	DNA	13.1	48	48	\N	2
4295	DMS-037	\N	DNA	0.74	48	48	\N	2
4296	DMS-037N	\N	DNA	0	48	48	\N	2
4297	DMS-038	\N	DNA	1.85	48	48	\N	2
4298	DMS-038N	\N	DNA	0.62	48	48	\N	2
4299	DMS-039	\N	DNA	5.25	48	48	\N	2
4300	DMS-039N	\N	DNA	0.34	48	48	\N	2
4301	DMS-040	\N	DNA	1.87	48	48	\N	2
4302	DMS-040N	\N	DNA	0.16	48	48	\N	2
4303	DMS-041	\N	DNA	4.57	48	48	\N	2
4304	DMS-042	\N	DNA	7.82	48	48	\N	2
4305	DMS-043	\N	DNA	7.2	48	48	\N	2
4306	DMS-044	\N	DNA	12.1	48	48	\N	2
4307	DMS-045	\N	DNA	20	48	48	\N	2
4308	DMS-046	\N	DNA	1.59	48	48	\N	2
4309	DMS-047	\N	DNA	6.88	48	48	\N	2
4310	DMS-048	\N	DNA	6.78	48	48	\N	2
4311	DMS-049	\N	DNA	16	48	48	\N	2
4312	DMS-050	\N	DNA	5.94	48	48	\N	2
4313	DMS-051	\N	DNA	0.56	48	48	\N	2
4314	DMS-052 A	\N	DNA	0.18	48	48	\N	2
4315	DMS-052 B	\N	DNA	0.53	48	48	\N	2
4316	DMS-053	\N	DNA	8.01	48	48	\N	2
4597	NA_CP1-20_Tumor	\N	DNA	\N	\N	\N	\N	\N
4317	DMS-054	\N	DNA	4.32	48	48	\N	2
4318	DMS-055	\N	DNA	1.19	48	48	\N	2
4319	DMS-056	\N	DNA	5.67	48	48	\N	2
4320	DMS-057	\N	DNA	7.21	48	48	\N	2
4321	DMS-058	\N	DNA	15.8	48	48	\N	2
4322	DMS-059A	\N	DNA	1.99	48	48	\N	2
4323	DMS-059B	\N	DNA	3.06	48	48	\N	2
4324	DMS-060	\N	DNA	9.82	48	48	\N	2
4325	DMS-061	\N	DNA	1.42	48	48	\N	2
4326	DMS-062	\N	DNA	6.94	48	48	\N	2
4327	DMS-062N	\N	DNA	1.45	48	48	\N	2
4328	DMS-063	\N	DNA	0.99	48	48	\N	2
4329	RMS-001A	\N	RNA	8.92	48	48	\N	1
4330	RMS-001B	\N	RNA	12.8	48	48	\N	1
4331	RMS-001C	\N	RNA	16	48	48	\N	1
4332	RMS-018	\N	RNA	5.12	48	48	\N	1
4333	RMS-019	\N	RNA	16	48	48	\N	1
4334	RMS-020	\N	RNA	2.82	48	48	\N	1
4335	RMS-021	\N	RNA	7.67	48	48	\N	1
4336	RMS-032	\N	RNA	4.82	48	48	\N	1
4337	RMS-033	\N	RNA	21.7	48	48	\N	1
4338	RMS-034	\N	RNA	12	48	48	\N	1
4339	RMS-035	\N	RNA	31.6	48	48	\N	1
4340	RMS-036	\N	RNA	29.4	48	48	\N	1
4341	RMS-037	\N	RNA	40	48	48	\N	1
4342	RMS-038	\N	RNA	8.59	48	48	\N	1
4343	RMS-038N	\N	RNA	20.9	48	48	\N	1
4344	RMS-039	\N	RNA	9.55	48	48	\N	1
4345	RMS-039N	\N	RNA	8.2	48	48	\N	1
4346	RMS-040	\N	RNA	32	48	48	\N	1
4347	RMS-040N	\N	RNA	5.35	48	48	\N	1
4348	RMS-041	\N	RNA	4.53	48	48	\N	1
4349	RMS-043	\N	RNA	4.48	48	48	\N	1
4350	RMS-044	\N	RNA	7.96	48	48	\N	1
4351	RMS-045	\N	RNA	15.8	48	48	\N	1
4352	RMS-046	\N	RNA	10	48	48	\N	1
4353	RMS-047	\N	RNA	6.03	48	48	\N	1
4354	RMS-048	\N	RNA	6.06	48	48	\N	1
4355	RMS-049	\N	RNA	12.8	48	48	\N	1
4356	RMS-050	\N	RNA	9.98	48	48	\N	1
4357	RMS-051	\N	RNA	23.2	48	48	\N	1
4358	RMS-052A	\N	RNA	8.1	48	48	\N	1
4359	RMS-052B	\N	RNA	10.3	48	48	\N	1
4360	RMS-053	\N	RNA	9.75	48	48	\N	1
4361	RMS-054	\N	RNA	24.9	48	48	\N	1
4362	RMS-055	\N	RNA	11.4	48	48	\N	1
4363	RMS-056	\N	RNA	6.1	48	48	\N	1
4364	RMS-057	\N	RNA	22.5	48	48	\N	1
4365	RMS-058	\N	RNA	8.67	48	48	\N	1
4366	RMS-059A	\N	RNA	7.94	48	48	\N	1
4367	RMS-059B	\N	RNA	12.9	48	48	\N	1
4368	RMS-060	\N	RNA	58	48	48	\N	1
4369	RMS-061	\N	RNA	16.9	48	48	\N	1
4370	RMS-062	\N	RNA	26.7	48	48	\N	1
4371	RMS-062N	\N	RNA	9.95	48	48	\N	1
4372	RMS-063	\N	RNA	8.38	48	48	\N	1
4373	KA D-01	2023-08-22 00:00:00-07	DNA	4	88	88	\N	2
4374	KA D-02	2023-08-17 00:00:00-07	DNA	5.98	88	88	\N	2
4375	KA D-03	2023-08-22 00:00:00-07	DNA	1.55	88	88	\N	2
4376	KA D-04	2023-08-17 00:00:00-07	DNA	1.6	88	88	\N	2
4377	KA D-05	2023-08-22 00:00:00-07	DNA	2.66	176	176	\N	2
4378	KA D-06	2023-08-17 00:00:00-07	DNA	3.51	352	352	\N	2
4379	KA D-07	2023-08-22 00:00:00-07	DNA	4.55	176	176	\N	2
4380	KA D-08	2023-08-17 00:00:00-07	DNA	\N	0	0	\N	2
4381	KA D-09	2023-08-22 00:00:00-07	DNA	1.43	176	176	\N	2
4382	KA D-10	2023-08-17 00:00:00-07	DNA	8.53	88	88	\N	2
4383	KA D-11	2023-08-22 00:00:00-07	DNA	1.38	176	176	\N	2
4384	KA D-12	2023-08-17 00:00:00-07	DNA	7.26	88	88	\N	2
4385	KA D-13	2023-08-22 00:00:00-07	DNA	2.6	176	176	\N	2
4386	KA D-14	2023-08-17 00:00:00-07	DNA	22.1	88	88	\N	2
4387	KA D-15	2023-08-22 00:00:00-07	DNA	2.23	88	88	\N	2
4388	KA D-16	2023-08-17 00:00:00-07	DNA	17.2	176	176	\N	2
4389	KA D-17	2023-08-22 00:00:00-07	DNA	3.44	176	176	\N	2
4390	KA D-18	2023-08-17 00:00:00-07	DNA	17.9	88	88	\N	2
4391	KA D-19	2023-08-17 00:00:00-07	DNA	17.4	88	88	\N	2
4392	KA D-20	2023-08-17 00:00:00-07	DNA	30.3	88	88	\N	2
4393	KA D-21	2023-08-17 00:00:00-07	DNA	11.2	88	88	\N	2
4394	KA D-22	2023-08-22 00:00:00-07	DNA	1.25	176	176	\N	2
4395	KA D-23	2023-08-17 00:00:00-07	DNA	7.79	88	88	\N	2
4396	KA D-24	2023-08-22 00:00:00-07	DNA	5.39	176	176	\N	2
4397	KA D-25	2023-08-17 00:00:00-07	DNA	\N	0	0	\N	2
4398	KA D-26	2023-08-21 00:00:00-07	DNA	32.4	176	176	\N	2
4399	KA D-27	2023-08-22 00:00:00-07	DNA	1.87	88	88	\N	2
4400	KA D-28	2023-08-21 00:00:00-07	DNA	4.89	88	88	\N	2
4401	KA D-29	2023-08-22 00:00:00-07	DNA	3.21	88	88	\N	2
4402	KA D-30	2023-08-21 00:00:00-07	DNA	20.7	88	88	\N	2
4403	KA D-31	2023-08-22 00:00:00-07	DNA	2.49	176	176	\N	2
4404	KA D-32	2023-08-21 00:00:00-07	DNA	17.2	176	176	\N	2
4405	KA D-33	2023-08-22 00:00:00-07	DNA	2.74	88	88	\N	2
4598	NA_CP1-40_Tumor	\N	DNA	\N	\N	\N	\N	\N
4406	KA D-34	2023-08-21 00:00:00-07	DNA	9.52	88	88	\N	2
4407	KA D-35	2023-08-21 00:00:00-07	DNA	18.7	88	88	\N	2
4408	KA D-36	2023-08-22 00:00:00-07	DNA	7.18	176	176	\N	2
4409	KA R-02	2023-08-17 00:00:00-07	RNA	42.8	45	45	\N	1
4410	KA R-04	2023-08-17 00:00:00-07	RNA	6.22	45	45	\N	1
4411	KA R-06	2023-08-17 00:00:00-07	RNA	17.2	180	180	\N	1
4412	KA R-08	2023-08-17 00:00:00-07	RNA	0	45	45	\N	1
4413	KA R-10	2023-08-17 00:00:00-07	RNA	10.4	45	45	\N	1
4414	KA R-12	2023-08-17 00:00:00-07	RNA	20	45	45	\N	1
4415	KA R-14	2023-08-17 00:00:00-07	RNA	38.8	45	45	\N	1
4416	KA R-16	2023-08-17 00:00:00-07	RNA	30.5	90	90	\N	1
4417	KA R-18	2023-08-17 00:00:00-07	RNA	28.8	45	45	\N	1
4418	KA R-19	2023-08-17 00:00:00-07	RNA	45.4	45	45	\N	1
4419	KA R-20	2023-08-17 00:00:00-07	RNA	37.6	45	45	\N	1
4420	KA R-21	2023-08-17 00:00:00-07	RNA	45.8	45	45	\N	1
4421	KA R-23	2023-08-17 00:00:00-07	RNA	35.5	45	45	\N	1
4422	KA R-25	2023-08-17 00:00:00-07	RNA	49.7	45	45	\N	1
4423	KA R-26	2023-08-21 00:00:00-07	RNA	83	90	90	\N	1
4424	KA R-28	2023-08-21 00:00:00-07	RNA	37	45	45	\N	1
4425	KA R-30	2023-08-21 00:00:00-07	RNA	56	45	45	\N	1
4426	KA R-32	2023-08-21 00:00:00-07	RNA	48	45	45	\N	1
4427	KA R-34	2023-08-21 00:00:00-07	RNA	70	45	45	\N	1
4428	KA R-35	2023-08-21 00:00:00-07	RNA	128	45	45	\N	1
4429	LMM D-046	\N	DNA	\N	\N	\N	\N	2
4430	LMM D-047	\N	DNA	\N	\N	\N	\N	2
4431	LMM D-048	\N	DNA	\N	\N	\N	\N	2
4432	LMM D-049	\N	DNA	\N	\N	\N	\N	2
4433	LMM D-050	\N	DNA	\N	\N	\N	\N	2
4434	LMM D-051	\N	DNA	\N	\N	\N	\N	2
4435	LMM D-052	\N	DNA	\N	\N	\N	\N	2
4436	LMM D-053	\N	DNA	\N	\N	\N	\N	2
4437	LMM D-054	2023-10-10 00:00:00-07	DNA	0.82	210	210	\N	2
4438	LMM D-055	\N	DNA	\N	\N	\N	\N	2
4439	LMM D-056	\N	DNA	\N	\N	\N	\N	2
4440	LMM D-057	2023-10-10 00:00:00-07	DNA	1.61	88	88	\N	2
4441	LMM D-060	2023-10-10 00:00:00-07	DNA	2.95	88	88	\N	2
4442	LMM D-061	\N	DNA	\N	\N	\N	\N	\N
4443	LMM D-062	\N	DNA	\N	\N	\N	\N	\N
4444	LMM D-063	2023-10-10 00:00:00-07	DNA	5.69	88	88	\N	2
4445	LMM R-046	\N	RNA	8.8	45	45	\N	1
4446	LMM R-047	\N	RNA	10.7	45	45	\N	1
4447	LMM R-048	\N	RNA	0	45	45	\N	1
4448	LMM R-049	\N	RNA	11	45	45	\N	1
4449	LMM R-050	\N	RNA	7.19	45	45	\N	1
4450	LMM R-051	\N	RNA	0	45	45	\N	1
4451	LMM R-052	\N	RNA	13.8	45	45	\N	1
4452	LMM R-053	\N	RNA	4.6	45	45	\N	1
4453	LMM R-054	\N	RNA	0	45	45	\N	1
4454	LMM R-055	\N	RNA	5.46	45	45	\N	1
4455	LMM R-056	\N	RNA	2.1	45	45	\N	1
4456	LMM R-057	\N	RNA	0	45	45	\N	1
4457	MucM D-006	2023-10-10 00:00:00-07	DNA	45.5	88	88	\N	2
4458	MucM D-009	2023-10-10 00:00:00-07	DNA	12.3	200	200	\N	2
4459	MucM D-012	2023-10-10 00:00:00-07	DNA	37.3	88	88	\N	2
4460	MucM D-015	2023-10-10 00:00:00-07	DNA	10.6	88	88	\N	2
4461	MucM D-019	2023-10-10 00:00:00-07	DNA	0.7	116	116	\N	2
4462	MucM D-020	2023-10-10 00:00:00-07	DNA	1.06	430	430	\N	2
4463	DPN 49	\N	DNA	6.89	48	48	Sent from Dr. Helmut Kerl, University of Graz, 'Cerebral meta'	\N
4464	AM-15-Tumor	2015-02-25 00:00:00-08	DNA	4.31	48	48	\N	\N
4465	AM-16-Tumor	2015-02-25 00:00:00-08	DNA	45.3	48	48	\N	\N
4466	AM-17-Tumor	2015-02-25 00:00:00-08	DNA	43.6	48	48	\N	\N
4467	AM-18-Tumor	2015-02-25 00:00:00-08	DNA	1.09	48	48	\N	\N
4468	AM-19-Tumor	2015-02-25 00:00:00-08	DNA	12.9	48	48	\N	\N
4469	AM-20-Tumor	2015-02-25 00:00:00-08	DNA	1.82	48	48	\N	\N
4470	AM-21-Tumor	2015-02-25 00:00:00-08	DNA	1.08	48	48	\N	\N
4471	AM-22-Tumor	2015-02-25 00:00:00-08	DNA	2.5	48	48	\N	\N
4472	AM-23-Tumor	2015-02-25 00:00:00-08	DNA	4.39	48	48	\N	\N
4473	AM-24-Tumor	2015-02-25 00:00:00-08	DNA	1.47	48	48	\N	\N
4474	AM-25-Tumor	2015-02-25 00:00:00-08	DNA	1.77	48	48	\N	\N
4475	AM-26-Tumor	2015-02-25 00:00:00-08	DNA	2.81	48	48	\N	\N
4476	AM-27-Tumor	2015-02-25 00:00:00-08	DNA	48.6	48	48	\N	\N
4477	AM-28-Tumor	2015-02-25 00:00:00-08	DNA	1.47	48	48	\N	\N
4478	AM-29-Tumor	2015-02-25 00:00:00-08	DNA	28	48	48	\N	\N
4479	AM-30-Tumor	2015-02-25 00:00:00-08	DNA	5.06	48	48	\N	\N
4480	AM-31-Tumor	2015-02-25 00:00:00-08	DNA	1.52	48	48	\N	\N
4481	AM-32-Tumor	2015-02-25 00:00:00-08	DNA	2.6	48	48	\N	\N
4482	AM-15-Tumor	2015-02-25 00:00:00-08	RNA	35.1	16	16	\N	\N
4483	AM-16-Tumor	2015-02-25 00:00:00-08	RNA	22.6	16	16	\N	\N
4484	AM-17-Tumor	2015-02-25 00:00:00-08	RNA	\N	16	16	\N	\N
4485	AM-18-Tumor	2015-02-25 00:00:00-08	RNA	29.7	16	16	\N	\N
4486	AM-19-Tumor	2015-02-25 00:00:00-08	RNA	77	16	16	\N	\N
4487	AM-20-Tumor	2015-02-25 00:00:00-08	RNA	49.7	16	16	\N	\N
4488	AM-21-Tumor	2015-02-25 00:00:00-08	RNA	39.3	16	16	\N	\N
4489	AM-22-Tumor	2015-02-25 00:00:00-08	RNA	67	16	16	\N	\N
4490	AM-23-Tumor	2015-02-25 00:00:00-08	RNA	73	16	16	\N	\N
4491	AM-24-Tumor	2015-02-25 00:00:00-08	RNA	33.8	16	16	\N	\N
4492	AM-25-Tumor	2015-02-25 00:00:00-08	RNA	42	16	16	\N	\N
4493	AM-26-Tumor	2015-02-25 00:00:00-08	RNA	55	16	16	\N	\N
4599	NA_CP1-80_Tumor	\N	DNA	\N	\N	\N	\N	\N
4494	AM-27-Tumor	2015-02-25 00:00:00-08	RNA	\N	16	16	\N	\N
4495	AM-28-Tumor	2015-02-25 00:00:00-08	RNA	37	16	16	\N	\N
4496	AM-29-Tumor	2015-02-25 00:00:00-08	RNA	69	16	16	\N	\N
4497	AM-30-Tumor	2015-02-25 00:00:00-08	RNA	39.6	16	16	\N	\N
4498	AM-31-Tumor	2015-02-25 00:00:00-08	RNA	75	16	16	\N	\N
4499	AM-32-Tumor	2015-02-25 00:00:00-08	RNA	43.5	16	16	\N	\N
4500	KAM10-N-B7	2014-10-21 00:00:00-07	DNA	4.39	50	50	\N	\N
4501	KAM10-T	2014-08-26 00:00:00-07	DNA	34.9	50	50	\N	\N
4502	KAM100-N	2014-10-15 00:00:00-07	DNA	7.38	50	50	\N	\N
4503	KAM100-T-11	2014-10-15 00:00:00-07	DNA	13.7	50	50	\N	\N
4504	KAM102-T-B	2014-10-15 00:00:00-07	DNA	8.12	50	50	\N	\N
4505	KAM111-N-A4	2014-10-23 00:00:00-07	DNA	2.36	50	50	\N	\N
4506	KAM111-T-A1	2014-11-06 00:00:00-08	DNA	10.1	50	50	\N	\N
4507	KAM111-T-A2	2014-10-15 00:00:00-07	DNA	33.3	50	50	\N	\N
4508	KAM113-T-H	2014-10-15 00:00:00-07	DNA	2.87	50	50	\N	\N
4509	KAM116-T	2014-10-15 00:00:00-07	DNA	1.59	50	50	\N	\N
4510	KAM12-T	2014-08-13 00:00:00-07	DNA	1.03	50	50	\N	\N
4511	KAM122-T-A	2014-10-21 00:00:00-07	DNA	1.64	50	50	\N	\N
4512	KAM123-T	2014-10-21 00:00:00-07	DNA	4.82	50	50	\N	\N
4513	KAM127-N	2015-07-06 00:00:00-07	DNA	43.9	48	48	\N	\N
4514	KAM127-T	2015-07-06 00:00:00-07	DNA	9.45	48	48	\N	\N
4515	KAM128-T	2015-07-06 00:00:00-07	DNA	0.59	48	48	\N	\N
4516	KAM130-T	2015-07-06 00:00:00-07	DNA	0.47	48	48	\N	\N
4517	KAM131-N	2015-07-06 00:00:00-07	DNA	0.88	48	48	\N	\N
4518	KAM131-T	2015-07-06 00:00:00-07	DNA	24	48	48	\N	\N
4519	KAM14-T	2014-08-13 00:00:00-07	DNA	6.21	50	50	\N	\N
4520	KAM26-T	2014-08-22 00:00:00-07	DNA	3.02	50	50	\N	\N
4521	KAM3-T-A	2014-08-13 00:00:00-07	DNA	0.07	50	50	\N	\N
4522	KAM34-T	2014-08-22 00:00:00-07	DNA	1.63	50	50	\N	\N
4523	KAM37-T	2014-08-26 00:00:00-07	DNA	3.27	50	50	\N	\N
4524	KAM43-T	2014-08-26 00:00:00-07	DNA	1.78	50	50	\N	\N
4525	KAM48-T	2014-08-27 00:00:00-07	DNA	15.7	50	50	\N	\N
4526	KAM62-T	2014-08-27 00:00:00-07	DNA	7.79	50	50	\N	\N
4527	KAM65-T	2014-08-27 00:00:00-07	DNA	7.01	50	50	\N	\N
4528	KAM71-T	2014-08-28 00:00:00-07	DNA	7.39	50	50	\N	\N
4529	KAM75-T	2014-09-02 00:00:00-07	DNA	24.9	50	50	\N	\N
4530	KAM79-T	2014-09-02 00:00:00-07	DNA	5.84	50	50	\N	\N
4531	KAM93-N-B10	2014-10-23 00:00:00-07	DNA	5.38	50	50	\N	\N
4532	KAM93-T	2014-09-10 00:00:00-07	DNA	14	55	55	\N	\N
4533	KAM95-T-B1	2014-11-06 00:00:00-08	DNA	5.2	50	50	\N	\N
4534	KAM99-N	2014-09-10 00:00:00-07	DNA	2.8	55	55	\N	\N
4535	KAM99-T	2014-09-10 00:00:00-07	DNA	27.6	50	50	\N	\N
4536	JBU10-Norm	\N	DNA	53	50	50	\N	\N
4537	JBU10-MVP	\N	DNA	31.2	50	50	\N	\N
4538	JBU11-MVP	\N	DNA	35.4	50	50	\N	\N
4539	JBU11-Norm	\N	DNA	13.9	50	50	\N	\N
4540	JBU7-Norm	\N	DNA	27	50	50	\N	\N
4541	JBU7-MVP	\N	DNA	41.5	50	50	\N	\N
4542	JBU8-Norm	\N	DNA	0.48	50	50	\N	\N
4543	JBU8-MVP	\N	DNA	33.4	50	50	\N	\N
4544	Thomas_SK_Mel23	2013-07-02 00:00:00-07	DNA	147	50	50	\N	\N
4545	UM38-Normal_NA	2014-12-10 00:00:00-08	DNA	14.3	45	45	\N	\N
4546	UM38-Tumor_NA	2014-12-10 00:00:00-08	DNA	68	45	45	\N	\N
4547	UM1_NA	2013-08-30 00:00:00-07	DNA	0.99	45	45	Uveal Melanoma, Dr. Seider	\N
4548	UM2_NA	2013-09-03 00:00:00-07	DNA	0.34	45	45	Uveal Melanoma, Dr. Seider	\N
4549	CGH11-051	2013-07-30 00:00:00-07	DNA	133	100	100	\N	5
4550	CGH11-275	\N	DNA	\N	\N	\N	\N	\N
4551	CHG11-409_NA	2013-07-10 00:00:00-07	DNA	86.7	100	100	\N	\N
4552	SKMEL28-1_NA	\N	DNA	\N	\N	\N	\N	\N
4553	SKMEL28-2_NA	\N	DNA	\N	\N	\N	\N	\N
4554	SKMEL28-3_NA	\N	DNA	\N	\N	\N	\N	\N
4555	SKMEL5-1_NA	\N	DNA	\N	\N	\N	\N	\N
4556	SKMEL5-2_NA	\N	DNA	\N	\N	\N	\N	\N
4557	SKMEL5-3_NA	\N	DNA	\N	\N	\N	\N	\N
4558	NGS 1-1_NA	\N	DNA	\N	\N	\N	\N	\N
4559	NGS 1-3_NA	\N	DNA	\N	\N	\N	\N	\N
4560	NGS 1-4_NA	\N	DNA	\N	\N	\N	\N	\N
4561	NGS 1-5_NA	\N	DNA	\N	\N	\N	\N	\N
4562	NGS 1-6_NA	\N	DNA	\N	\N	\N	\N	\N
4563	NGS 1-7_NA	\N	DNA	\N	\N	\N	\N	\N
4564	NGS 1-8_NA	\N	DNA	\N	\N	\N	\N	\N
4565	NGS 1-9_NA	\N	DNA	\N	\N	\N	\N	\N
4566	NGS 1-10_NA	\N	DNA	\N	\N	\N	\N	\N
4567	NGS 1-13_NA	\N	DNA	\N	\N	\N	\N	\N
4568	NGS 1-14_NA	\N	DNA	\N	\N	\N	\N	\N
4569	ChIP1_1_NA	\N	DNA	5.33	25	25	\N	\N
4570	ChIP1_2_NA	\N	DNA	0.31	25	25	\N	\N
4571	ChIP1_3_NA	\N	DNA	0.15	25	25	\N	\N
4572	ChIP1_4_NA	\N	DNA	7.72	25	25	\N	\N
4573	ChIP1_5_NA	\N	DNA	0.39	25	25	\N	\N
4574	ChIP1_6_NA	\N	DNA	0.21	25	25	\N	\N
4575	ChIP1_7_NA	\N	DNA	4.21	25	25	\N	\N
4576	ChIP1_8_NA	\N	DNA	0.33	25	25	\N	\N
4577	ChIP1_9_NA	\N	DNA	0.07	25	25	\N	\N
4578	ChIP1_10_NA	\N	DNA	6.39	25	25	\N	\N
4579	ChIP1_11_NA	\N	DNA	0.35	25	25	\N	\N
4580	ChIP1_12_NA	\N	DNA	0.14	25	25	\N	\N
4581	JBP-6-Met_NA	\N	DNA	22.6	50	50	\N	\N
4582	JBP-6-MM_NA	\N	DNA	29.1	50	50	\N	\N
4583	JBP-6-Norm_NA	\N	DNA	10.2	50	50	\N	\N
4584	JBP-9MM_NA	\N	DNA	1.9	50	50	\N	\N
4585	JBP-9Met_NA	\N	DNA	31.5	50	50	\N	\N
4586	JBP-11Met	\N	DNA	29.4	50	50	\N	\N
4587	JBP-11MM	\N	DNA	25.1	50	50	\N	\N
4588	JBP-11Norm	\N	DNA	38.2	50	50	\N	\N
4589	TCR-Beta-1_NA	\N	DNA	\N	\N	\N	\N	\N
4590	TCR-Beta-2_NA	\N	DNA	\N	\N	\N	\N	\N
4602	DM79_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4603	DM93_NFKBIE_NA	\N	DNA	\N	\N	\N	\N	\N
4604	DM93_Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4605	VS-01_NA	\N	RNA	\N	\N	\N	\N	\N
4606	VS-02_NA	\N	RNA	\N	\N	\N	\N	\N
4607	VS-03_NA	\N	RNA	\N	\N	\N	\N	\N
4608	VS-04_NA	\N	RNA	\N	\N	\N	\N	\N
4609	VS-05_NA	\N	RNA	\N	\N	\N	\N	\N
4610	VS-06_NA	\N	RNA	\N	\N	\N	\N	\N
4611	VS-07_NA	\N	RNA	\N	\N	\N	\N	\N
4612	VS-08_NA	\N	RNA	\N	\N	\N	\N	\N
4613	DPN50-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4614	DPN51-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4615	DPN52-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4616	DPN53-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4617	DPN54-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4618	DPN55-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4619	DPN56-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4620	DPN57-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4621	DPN58-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4622	DPN59-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4623	DPN60-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4624	DPN61-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4625	DPN62-Tumor_NA	\N	DNA	\N	\N	\N	\N	\N
4626	1205lu-1_NA	\N	DNA	\N	\N	\N	\N	\N
4627	1205lu-2_NA	\N	DNA	\N	\N	\N	\N	\N
4628	1205LU-3_NA	\N	DNA	\N	\N	\N	\N	\N
4629	Rob-T001-Mel_NA	\N	DNA	\N	\N	\N	\N	\N
4630	Rob-T001-Normal_NA	\N	DNA	\N	\N	\N	\N	\N
4631	Rob-T003-Mel_NA	\N	DNA	\N	\N	\N	\N	\N
4632	Rob-T003-Normal_NA	\N	DNA	\N	\N	\N	\N	\N
4633	Rob-T005-Nev_NA	\N	DNA	\N	\N	\N	\N	\N
4634	Rob-T005-Normal_NA	\N	DNA	\N	\N	\N	\N	\N
4635	Rob-T008-Nev_NA	\N	DNA	\N	\N	\N	\N	\N
4636	Rob-T008-Normal_NA	\N	DNA	\N	\N	\N	\N	\N
4637	Rob-T009-Nev_NA	\N	DNA	\N	\N	\N	\N	\N
4638	Rob-T009-Normal_NA	\N	DNA	\N	\N	\N	\N	\N
4639	Rob-T010-Nev_NA	\N	DNA	\N	\N	\N	\N	\N
4640	Rob-T010-Normal_NA	\N	DNA	\N	\N	\N	\N	\N
4641	DM8TumorCrest_NA	\N	DNA	\N	\N	\N	\N	\N
4642	CGP-1481_NA	\N	DNA	\N	\N	\N	\N	\N
4643	CGP-1482_NA	\N	DNA	\N	\N	\N	\N	\N
4644	CGP-1483_NA	\N	DNA	\N	\N	\N	\N	\N
4645	CGP-1550_NA	\N	DNA	\N	\N	\N	\N	\N
4646	CGP-1551_NA	\N	DNA	\N	\N	\N	\N	\N
4647	CGP-1552_NA	\N	DNA	\N	\N	\N	\N	\N
4648	CGP-1544_NA	\N	DNA	\N	\N	\N	\N	\N
4649	CGP-1545_NA	\N	DNA	\N	\N	\N	\N	\N
4650	CGP-1546_NA	\N	DNA	\N	\N	\N	\N	\N
4651	CGP-1547_NA	\N	DNA	\N	\N	\N	\N	\N
4652	CGP-1548_NA	\N	DNA	\N	\N	\N	\N	\N
4653	CGP-1549_NA	\N	DNA	\N	\N	\N	\N	\N
4654	CGP-1553_NA	\N	DNA	\N	\N	\N	\N	\N
4655	CGP-1554_NA	\N	DNA	\N	\N	\N	\N	\N
4656	CGP-1555_NA	\N	DNA	\N	\N	\N	\N	\N
4657	CGP-1556_NA	\N	DNA	\N	\N	\N	\N	\N
4658	CGP-1557_NA	\N	DNA	\N	\N	\N	\N	\N
4659	CGP-1558_NA	\N	DNA	\N	\N	\N	\N	\N
4660	CGP-1559_NA	\N	DNA	\N	\N	\N	\N	\N
4661	CGP-1560_NA	\N	DNA	\N	\N	\N	\N	\N
4662	CGP-1561_NA	\N	DNA	\N	\N	\N	\N	\N
4663	CGP-1575_NA	\N	DNA	\N	\N	\N	\N	\N
4664	CGP-1576_NA	\N	DNA	\N	\N	\N	\N	\N
4665	CGP-1577_NA	\N	DNA	\N	\N	\N	\N	\N
4666	PG8_NA	\N	DNA	\N	\N	\N	\N	\N
10000	NA_12-6261A_Tumor	\N	DNA	512	\N	\N	Cheek	\N
10001	NA_12-6261B_Tumor	\N	DNA	210	\N	\N	Neck	\N
10002	NA_12-12366_Tumor	\N	DNA	1000	\N	\N	\N	\N
10003	NA_12-12467_Tumor	\N	DNA	1000	\N	\N	\N	\N
10004	NA_12-12470D_Tumor	\N	DNA	480	\N	\N	\N	\N
10005	NA_12-562_Tumor	\N	DNA	1000	\N	\N	\N	\N
10006	NA_12-12647_Tumor	\N	DNA	330	\N	\N	\N	\N
10007	NA_12-12626_Tumor	\N	DNA	1000	\N	\N	Right Arm	\N
10008	NA_12-13587_Tumor	\N	DNA	1000	\N	\N	\N	\N
10009	NA_12-18438A_Tumor	\N	DNA	400	\N	\N	\N	\N
10010	NA_12-13152_Tumor	\N	DNA	554	\N	\N	\N	\N
10011	NA_12-12750B_Tumor	\N	DNA	1000	\N	\N	Forehead	\N
10012	NA_12-19596_Tumor	\N	DNA	1000	\N	\N	\N	\N
10013	NA_12-19187A_Tumor	\N	DNA	1000	\N	\N	Shin	\N
10014	NA_12-22172_Normal	\N	DNA	371	\N	\N	\N	\N
10015	NA_12-22172_Tumor	\N	DNA	1000	\N	\N	\N	\N
10016	NA_12-21726A_Tumor	\N	DNA	157	\N	\N	\N	\N
10017	NA_12-22901A_Normal	\N	DNA	497	\N	\N	\N	\N
10018	NA_12-22901A_Tumor	\N	DNA	1000	\N	\N	\N	\N
10019	NA_12-22776_Normal	\N	DNA	1000	\N	\N	\N	\N
10020	NA_BuffyCoat_Tumor	\N	DNA	1000	\N	\N	\N	\N
10021	NA_12-13587B2_Tumor	\N	DNA	750	\N	\N	\N	\N
10022	NA_12-13587B2_Tumor	\N	DNA	500	\N	\N	\N	\N
10023	NA_12-13587B2_Tumor	\N	DNA	250	\N	\N	\N	\N
10024	NA_BuffyCoa_Tumor	\N	DNA	1000	\N	\N	Collaborated with Robert Nussbaum to get this blood	\N
10025	NA_12-22775_Tumor	\N	DNA	1000	\N	\N	\N	\N
10026	NA_12-22794A_Tumor	\N	DNA	1000	\N	\N	\N	\N
10027	NA_12-22573_Tumor	\N	DNA	1000	\N	\N	\N	\N
10028	NA_12-22582A_Tumor	\N	DNA	444	\N	\N	\N	\N
10029	NA_12-22587_Tumor	\N	DNA	773	\N	\N	\N	\N
10030	NA_12-22592_Tumor	\N	DNA	670	\N	\N	Scalp	\N
10031	NA_12-22597_Tumor	\N	DNA	1000	\N	\N	\N	\N
10032	NA_12-22602A_Tumor	\N	DNA	1000	\N	\N	\N	\N
10033	NA_12-22602B_Tumor	\N	DNA	1000	\N	\N	\N	\N
10034	NA_12-22603_Tumor	\N	DNA	1000	\N	\N	Forehead	\N
10035	NA_12-22604_Tumor	\N	DNA	278	\N	\N	\N	\N
10036	NA_12-22720A_Tumor	\N	DNA	370	\N	\N	Upper back	\N
10037	NA_12-22868_Tumor	\N	DNA	1000	\N	\N	\N	\N
10038	NA_12-22884C_Tumor	\N	DNA	1000	\N	\N	\N	\N
10039	NA_12-22884D_Tumor	\N	DNA	208	\N	\N	\N	\N
10040	NA_12-22886_Tumor	\N	DNA	1000	\N	\N	\N	\N
10041	NA_12-22894B_Tumor	\N	DNA	303	\N	\N	\N	\N
10042	NA_12-22898_Tumor	\N	DNA	981	\N	\N	\N	\N
10043	NA_12-22900_Tumor	\N	DNA	604	\N	\N	Eybrow	\N
10044	NA_12-22597_Tumor	\N	DNA	700	\N	\N	\N	\N
10045	NA_12-22597_Tumor	\N	DNA	500	\N	\N	\N	\N
10046	NA_12-22597_Tumor	\N	DNA	250	\N	\N	\N	\N
10047	NA_12-22597_Tumor	\N	DNA	100	\N	\N	\N	\N
10048	NA_WP11_Tumor	\N	DNA	100	\N	\N	\N	\N
10049	NA_WP23_Tumor	\N	DNA	100	\N	\N	\N	\N
10050	NA_WP29_Tumor	\N	DNA	100	\N	\N	\N	\N
10051	NA_PG8_Tumor	\N	DNA	100	\N	\N	\N	\N
10052	NA_KIT37_Tumor	\N	DNA	100	\N	\N	_Acral_NRAS	\N
10053	NA_KIT62_Tumor	\N	DNA	50	\N	\N	__Acral_NRAS	\N
10054	NA_KIT118_Tumor	\N	DNA	100	\N	\N	_Muc_NRAS	\N
10055	NA_KIT181_Tumor	\N	DNA	100	\N	\N	_Muc_BRAF	\N
10056	NA_KIT227_Tumor	\N	DNA	100	\N	\N	_Acral_WT	\N
10057	NA_KIT275_Tumor	\N	DNA	100	\N	\N	_Muc_BRAF	\N
10058	NA_Bivona-L1_Tumor	\N	DNA	100	\N	\N	\N	\N
10059	NA_Bivona-L2_Tumor	\N	DNA	100	\N	\N	\N	\N
10060	NA_Bivona-L3_Tumor	\N	DNA	100	\N	\N	\N	\N
10061	NA_Bivona-L4_Tumor	\N	DNA	100	\N	\N	\N	\N
10062	NA_Bivona-L5_Tumor	\N	DNA	100	\N	\N	\N	\N
10063	NA_Bivona-L6_Tumor	\N	DNA	100	\N	\N	\N	\N
10064	NA_10-41439_Melanoma	\N	DNA	62.5	\N	\N	\N	\N
10065	NA_10-41439_Melanoma	\N	DNA	62.5	\N	\N	\N	\N
10066	NA_10-41439_Nevus	\N	DNA	62.5	\N	\N	\N	\N
10067	NA_10-41439_Nevus	\N	DNA	62.5	\N	\N	\N	\N
10068	NA_10-41439_Normal	\N	DNA	44.8	\N	\N	\N	\N
10069	NA_11-23681_Melanoma	\N	DNA	62.5	\N	\N	\N	\N
10070	NA_11-23681_Melanoma	\N	DNA	62.5	\N	\N	\N	\N
10071	NA_11-23681_Nevus	\N	DNA	62.5	\N	\N	\N	\N
10072	NA_11-23681_Nevus	\N	DNA	62.5	\N	\N	\N	\N
10073	NA_11-23681_Normal	\N	DNA	33.04	\N	\N	\N	\N
10074	NA_11-37533_Melanoma	\N	DNA	33.88	\N	\N	\N	\N
10075	NA_11-37533_Melanoma	\N	DNA	62.5	\N	\N	\N	\N
10076	NA_11-37533_Nevus	\N	DNA	62.5	\N	\N	\N	\N
10077	NA_11-37533_Nevus	\N	DNA	62.5	\N	\N	\N	\N
10078	NA_11-37533_Normal	\N	DNA	62.5	\N	\N	\N	\N
10079	NA_KIT262_Tumor	\N	DNA	62.5	\N	\N	\N	\N
10080	NA_Dog12_Tumor	\N	DNA	45	\N	\N	sp-12-3436|mucosal melanoma +EIN	\N
10081	NA_Dog24_Tumor	\N	DNA	62.5	\N	\N	sp-07-8373|mucosal melanomas-non-pigmented	\N
10082	NA_Dog43_Tumor	\N	DNA	62.5	\N	\N	2990543-1|melanocytoma	\N
10083	NA_Dog55_Tumor	\N	DNA	62.5	\N	\N	3146318-1|acral melanoma	\N
10084	NA_HW3_Tumor	\N	DNA	62.5	\N	\N	\N	\N
10085	NA_HW3_Normal	\N	DNA	62.5	\N	\N	\N	\N
10086	NA_HW4_Tumor	\N	DNA	62.5	\N	\N	\N	\N
10087	NA_HW4_Normal	\N	DNA	62.50000000000001	\N	\N	\N	\N
10088	NA_HW6_Tumor	\N	DNA	62.5	\N	\N	\N	\N
10089	NA_HW6_Normal	\N	DNA	62.5	\N	\N	\N	\N
10090	NA_10-86469_Tumor	\N	DNA	62.50000000000001	\N	\N	CGH11-029 Need to Get diagnosis from Iwei|NTRK3 Translocation case	\N
10091	NA_11-12273_Tumor	\N	DNA	62.5	\N	\N	CGH11-045 Need to Get diagnosis from Iwei|ROS1 Translocation case	\N
10092	NA_11-23710_Tumor	\N	DNA	62.5	\N	\N	CGH11-092 Need to Get diagnosis from Iwei|ROS1 Translocation case	\N
10093	NA_11-30426_Tumor	\N	DNA	62.5	\N	\N	CGH11-125 Need to Get diagnosis from Iwei|NTRK3 Translocation case	\N
10094	NA_11-31904_Tumor	\N	DNA	62.5	\N	\N	CGH11-194 Need to Get diagnosis from Iwei|BRAF Translocation case	\N
10095	NA_11-47644_Tumor	\N	DNA	60	\N	\N	CGH11-201 Need to Get diagnosis from Iwei|BRAF Translocation case	\N
10096	NA_MB_161_Tumor	\N	DNA	100	\N	\N	\N	\N
10097	NA_MB_161_Normal	\N	DNA	100	\N	\N	\N	\N
10098	NA_MB_327_Tumor	\N	DNA	100	\N	\N	\N	\N
10099	NA_MB_1454_Normal	\N	DNA	100	\N	\N	\N	\N
10100	NA_MB_760_Tumor	\N	DNA	100	\N	\N	\N	\N
10101	NA_MB_1418_Normal	\N	DNA	100	\N	\N	\N	\N
10102	NA_MB_1029_Tumor	\N	DNA	100	\N	\N	\N	\N
10103	NA_MB_1028_Normal	\N	DNA	100	\N	\N	\N	\N
10104	NA_MB_1046_Tumor	\N	DNA	100	\N	\N	\N	\N
10105	NA_MB_1036_Normal	\N	DNA	100	\N	\N	\N	\N
10106	NA_Bivona-L17_Tumor	\N	DNA	100	\N	\N	\N	\N
10107	NA_Bivona-L18_Tumor	\N	DNA	62.72	\N	\N	\N	\N
10108	NA_Bivona-L19_Tumor	\N	DNA	9.12	\N	\N	\N	\N
10109	NA_KIT227_Tumor	\N	DNA	100	\N	\N	_Acral_WT	\N
10110	NA_KIT53_Tumor	\N	DNA	100	\N	\N	_Acral_NRAS	\N
10111	NA_KIT313_Tumor	\N	DNA	100	\N	\N	_Mucosal	\N
10112	NA_HW2_Normal	\N	DNA	100	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
10113	NA_HW2_Tumor	\N	DNA	100	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
10114	NA_HW8_Normal	\N	DNA	100	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
10115	NA_HW8_Tumor	\N	DNA	100	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
10116	NA_HW9_Normal	\N	DNA	100	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
10117	NA_HW9_Tumor	\N	DNA	100	\N	\N	 FFPE extracted DNA sample received from Hong Wu at the FCCC (Boris has diagnosis)	\N
10118	NA_12-6981_Tumor	\N	DNA	100	\N	\N	CGH12-047 FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	\N
10119	NA_10-55707_Tumor	\N	DNA	100	\N	\N	CGH10-013 FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	\N
10120	NA_11-34950_Tumor	\N	DNA	100	\N	\N	CGH11-153 FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	\N
10121	NA_11-8228_Tumor	\N	DNA	100	\N	\N	CGH11-036 FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	\N
10122	NA_11-84681_Tumor	\N	DNA	100	\N	\N	CGH11-386 FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	\N
10123	NA_KIT227_Tumor	\N	DNA	100	\N	\N	\N	\N
10124	NA_WM3211_Tumor	\N	DNA	100	\N	\N	\N	\N
10125	NA_NB2107_Tumor	\N	DNA	100	\N	\N	\N	\N
10126	NA_London-L1_Tumor	\N	DNA	100	\N	\N	N5_15 and N5_16 are the exact same template done in duplicate with two different barcodes	\N
10127	NA_London-L2_Tumor	\N	DNA	100	\N	\N	N5_15 and N5_16 are the exact same template done in duplicate with two different barcodes	\N
10128	NA_Bivona-L7_Tumor	\N	DNA	\N	\N	\N	N/A|Bivona Lung Cell Line	\N
10129	NA_Bivona-L8_Tumor	\N	DNA	\N	\N	\N	N/A|Bivona Lung Cell Line	\N
10130	NA_Bivona-L9_Tumor	\N	DNA	\N	\N	\N	N/A|Bivona Lung Cell Line	\N
10131	NA_Bivona-L10_Tumor	\N	DNA	\N	\N	\N	N/A|Bivona Lung Cell Line	\N
10132	NA_HW3_Tumor	\N	DNA	\N	\N	\N	\N	\N
10133	NA_HW3_Normal	\N	DNA	\N	\N	\N	\N	\N
10134	NA_HW4_Tumor	\N	DNA	\N	\N	\N	\N	\N
10135	NA_HW4_Normal	\N	DNA	\N	\N	\N	\N	\N
10136	NA_HW6_Tumor	\N	DNA	\N	\N	\N	\N	\N
10137	NA_HW6_Normal	\N	DNA	\N	\N	\N	\N	\N
10138	NA_10-86469_Tumor	\N	DNA	\N	\N	\N	CGH11-029 N/A|Iwei, CGH Array run	\N
10139	NA_11-12273_Tumor	\N	DNA	\N	\N	\N	CGH11-045 N/A|Iwei, CGH Array run	\N
10140	NA_11-23710_Tumor	\N	DNA	\N	\N	\N	CGH11-092 N/A|Iwei, CGH Array run	\N
10141	NA_11-30426_Tumor	\N	DNA	\N	\N	\N	CGH11-125 N/A|Iwei, CGH Array run	\N
10142	NA_11-31904_Tumor	\N	DNA	\N	\N	\N	CGH11-194 N/A|Iwei, CGH Array run	\N
10143	NA_Bivona-L11_Tumor	\N	DNA	\N	\N	\N	N/A|Bivona Lung Cell Line	\N
10144	NA_HWA1_Tumor	\N	DNA	100	\N	\N	Hong Wu	\N
10145	NA_HWA1_Normal	\N	DNA	34.3	\N	\N	Hong Wu	\N
10146	NA_HWA2_Tumor	\N	DNA	100	\N	\N	Hong Wu	\N
10147	NA_HWA2_Normal	\N	DNA	95.8	\N	\N	Hong Wu	\N
10148	NA_HWA3_Tumor	\N	DNA	100	\N	\N	Hong Wu	\N
10149	NA_HWA3_Normal	\N	DNA	67	\N	\N	Hong Wu	\N
10150	NA_HWA4_Tumor	\N	DNA	100	\N	\N	Hong Wu	\N
10151	NA_HWA4_Normal	\N	DNA	84.39999999999999	\N	\N	Hong Wu	\N
10152	NA_11-5482_Tumor	\N	DNA	100	\N	\N	CGH11-035 Iwei Translocation Case	\N
10153	NA_11-79158_Tumor	\N	DNA	100	\N	\N	CGH11-343 Iwei Translocation Case	\N
10154	NA_DP12-200_Tumor	\N	DNA	100	\N	\N	Dr. Lutzky's Case	\N
10155	NA_TissueCoreALKControl_Normal	\N	DNA	100	\N	\N	Tissue Core ALK | Barcode mismatch comment in note	\N
10156	NA_10-59344_Tumor	\N	DNA	74.30000000000001	\N	\N	CGH10-016 Iwei Translocation Case | Barcode mismatch comment in note	\N
10157	NA_11-16253_Tumor	\N	DNA	34	\N	\N	CGH11-060 Iwei Translocation Case	\N
10158	NA_11-61046_Tumor	\N	DNA	100	\N	\N	CGH11-252 Iwei Translocation Case	\N
10159	NA_10-56047_Tumor	\N	DNA	100	\N	\N	CGH10-017 Iwei Translocation Case	\N
10160	NA_12-67298_Tumor	\N	DNA	100	\N	\N	\N	\N
10161	NA_12-67298_Normal	\N	DNA	78.19999999999999	\N	\N	Less than 100 ng input for End Repair	\N
10162	NA_12-20321_Tumor	\N	DNA	100	\N	\N	\N	\N
10163	NA_11-96096_Normal	\N	DNA	100	\N	\N	\N	\N
10164	NA_MB1242_Tumor	\N	DNA	100	\N	\N	\N	\N
10165	NA_MB1241_Normal	\N	DNA	100	\N	\N	\N	\N
10166	NA_MB1423_Tumor	\N	DNA	100	\N	\N	\N	\N
10167	NA_MB1423_Normal	\N	DNA	100	\N	\N	\N	\N
10168	NA_MB1424__Tumor	\N	DNA	100	\N	\N	\N	\N
10169	NA_MB1421_Normal	\N	DNA	100	\N	\N	\N	\N
10170	NA_MB1429_Tumor	\N	DNA	100	\N	\N	\N	\N
10171	NA_MB1428_Normal	\N	DNA	100	\N	\N	\N	\N
10172	NA_12-71679_Tumor	\N	DNA	100	\N	\N	CGH12-317 	\N
10173	NA_12-80985B_Tumor	\N	DNA	74.55	\N	\N	CGH12-343 Less than 100 ng input for End Repair	\N
10174	NA_12-31996_Tumor	\N	DNA	100	\N	\N	CGH12-135 	\N
10175	NA_12-39632_Tumor	\N	DNA	30.3	\N	\N	CGH12-161 Less than 100 ng input for End Repair	\N
10176	NA_HWA5_Tumor	\N	DNA	100	\N	\N	\N	\N
10177	NA_HWA5_Normal	\N	DNA	82.60000000000002	\N	\N	\N	\N
10178	NA_HWA6_Tumor	\N	DNA	100	\N	\N	\N	\N
10179	NA_HWA6_Normal	\N	DNA	68.3	\N	\N	\N	\N
10180	NA_HWA7_Tumor	\N	DNA	86.49999999999999	\N	\N	\N	\N
10181	NA_HWA7_Normal	\N	DNA	100	\N	\N	\N	\N
10182	NA_HWA8_Tumor	\N	DNA	100	\N	\N	\N	\N
10183	NA_HWA8_Normal	\N	DNA	100	\N	\N	\N	\N
10184	NA_HWA9_Tumor	\N	DNA	100	\N	\N	\N	\N
10185	NA_HWA9_Normal	\N	DNA	100	\N	\N	\N	\N
10186	NA_HWA10_Tumor	\N	DNA	100	\N	\N	\N	\N
10187	NA_HWA10_Normal	\N	DNA	97.4	\N	\N	\N	\N
10188	NA_MB1617_Tumor	\N	DNA	100	\N	\N	\N	\N
10189	NA_MB1609_Normal	\N	DNA	32.09999999999999	\N	\N	\N	\N
10190	NA_WM51_Tumor	\N	DNA	100	\N	\N	Wistar	\N
10191	NA_wm3918_Tumor	\N	DNA	100	\N	\N	Wistar	\N
10192	NA_DM1_Normal	\N	DNA	34.3	\N	\N	\N	\N
10193	NA_DM1_Tumor	\N	DNA	100	\N	\N	\N	\N
10194	NA_DM2_Normal	\N	DNA	89.9	\N	\N	\N	\N
10195	NA_DM2_Tumor	\N	DNA	100	\N	\N	\N	\N
10196	NA_DM5_Normal	\N	DNA	32.59999999999999	\N	\N	\N	\N
10197	NA_DM5_Tumor	\N	DNA	38.3	\N	\N	\N	\N
10198	NA_DM7_Normal	\N	DNA	51.49999999999999	\N	\N	\N	\N
10199	NA_DM7_Tumor	\N	DNA	100	\N	\N	\N	\N
10200	NA_DM12_Normal	\N	DNA	100	\N	\N	\N	\N
10201	NA_DM12_Tumor	\N	DNA	100	\N	\N	\N	\N
10202	NA_DM13_Normal	\N	DNA	67.5	\N	\N	\N	\N
10203	NA_DM13_Tumor	\N	DNA	100	\N	\N	\N	\N
10204	NA_DM21_Normal	\N	DNA	39.6	\N	\N	\N	\N
10205	NA_DM21_Tumor	\N	DNA	16.4	\N	\N	\N	\N
10206	NA_DM93_Normal	\N	DNA	100	\N	\N	\N	\N
10207	NA_DM93_Tumor	\N	DNA	45.7	\N	\N	\N	\N
10208	NA_11-20375_Tumor	\N	DNA	\N	\N	\N	CGH11-078 Iwei Translocation Cases	\N
10209	NA_11-21491_Tumor	\N	DNA	\N	\N	\N	CGH11-080 Iwei Translocation Cases	\N
10210	NA_11-65778_Tumor	\N	DNA	\N	\N	\N	CGH11-281 Iwei Translocation Cases	\N
10211	NA_10-88482_Tumor	\N	DNA	\N	\N	\N	CGH10-058 Iwei Translocation Cases	\N
10212	NA_11-63178_Tumor	\N	DNA	\N	\N	\N	CGH11-283 Iwei Translocation Cases	\N
10213	NA_10-71761_Tumor	\N	DNA	\N	\N	\N	CGH10-020 Iwei Translocation Cases	\N
10214	NA_10-84478_Tumor	\N	DNA	\N	\N	\N	CGH10-049 Iwei Translocation Cases	\N
10215	NA_10-88475_Tumor	\N	DNA	\N	\N	\N	CGH11-020 Iwei Translocation Cases	\N
10216	NA_12-54296_Normal	\N	DNA	\N	\N	\N	\N	\N
10217	NA_12-54296_Tumor	\N	DNA	\N	\N	\N	\N	\N
10218	NA_12-54992_Normal	\N	DNA	\N	\N	\N	\N	\N
10219	NA_12-54992_Tumor	\N	DNA	\N	\N	\N	\N	\N
10220	NA_WM3622_Tumor	\N	DNA	\N	\N	\N	\N	\N
10221	NA_WM1963_Tumor	\N	DNA	\N	\N	\N	\N	\N
10222	NA_WM8_Tumor	\N	DNA	\N	\N	\N	\N	\N
10223	NA_WM3912_Tumor	\N	DNA	\N	\N	\N	\N	\N
10224	NA_DM11_Tumor	\N	DNA	\N	\N	\N	\N	\N
10225	NA_DM11_Normal	\N	DNA	\N	\N	\N	Less than the optimal 100 ng input conc. For End Repair	\N
10226	NA_DM14_Tumor	\N	DNA	\N	\N	\N	\N	\N
10227	NA_DM14_Normal	\N	DNA	\N	\N	\N	\N	\N
10228	NA_DM26_Tumor	\N	DNA	\N	\N	\N	\N	\N
10229	NA_DM26_Normal	\N	DNA	\N	\N	\N	\N	\N
10230	NA_DM28_Tumor	\N	DNA	\N	\N	\N	\N	\N
10231	NA_DM28_Normal	\N	DNA	\N	\N	\N	\N	\N
10232	NA_DM29_Tumor	\N	DNA	\N	\N	\N	Less than the optimal 100 ng input conc. For End Repair	\N
10233	NA_DM29_Normal	\N	DNA	\N	\N	\N	\N	\N
10234	NA_DM34_Tumor	\N	DNA	\N	\N	\N	\N	\N
10235	NA_DM34_Normal	\N	DNA	\N	\N	\N	Less than the optimal 100 ng input conc. For End Repair	\N
10236	NA_DM55_Tumor	\N	DNA	\N	\N	\N	\N	\N
10237	NA_DM55_Normal	\N	DNA	\N	\N	\N	\N	\N
10238	NA_DM79_Tumor	\N	DNA	\N	\N	\N	Less than the optimal 100 ng input conc. For End Repair	\N
10239	NA_DM79_Normal	\N	DNA	\N	\N	\N	\N	\N
10240	NA_11-78845_Tumor	\N	DNA	100	\N	\N	CGH11-361 Iwei Translocation Project	\N
10241	NA_11-81405_Tumor	\N	DNA	12.4	\N	\N	CGH11-366 Iwei Translocation Project	\N
10242	NA_11-85075_Tumor	\N	DNA	84.3	\N	\N	CGH11-376 Iwei Translocation Project	\N
10243	NA_11-83908_Tumor	\N	DNA	69.4	\N	\N	CGH11-388 Iwei Translocation Project	\N
10244	NA_11-85859_Tumor	\N	DNA	100	\N	\N	CGH11-422 Iwei Translocation Project	\N
10245	NA_11-95663_Tumor	\N	DNA	94.6	\N	\N	CGH12-016 Iwei Translocation Project	\N
10246	NA_DM4_Tumor	\N	DNA	33.5	\N	\N	Hunter Dermoplastic Melanoma	\N
10247	NA_DM4_Normal	\N	DNA	97.8	\N	\N	Hunter Dermoplastic Melanoma	\N
10248	NA_DM95_Tumor	\N	DNA	73.6	\N	\N	Hunter Dermoplastic Melanoma	\N
10249	NA_DM95_Normal	\N	DNA	100	\N	\N	Hunter Dermoplastic Melanoma	\N
10250	NA_DM96_Tumor	\N	DNA	100	\N	\N	Hunter Dermoplastic Melanoma	\N
10251	NA_DM96_Normal	\N	DNA	29.5	\N	\N	Hunter Dermoplastic Melanoma	\N
10252	NA_KIT8_Tumor	\N	DNA	100	\N	\N	Alyssa Kit Mutations	\N
10253	NA_KIT21_Tumor	\N	DNA	100	\N	\N	Alyssa Kit Mutations	\N
10254	NA_KIT55_Tumor	\N	DNA	87	\N	\N	Alyssa Kit Mutations	\N
10255	NA_KIT76_Tumor	\N	DNA	100	\N	\N	Alyssa Kit Mutations	\N
10256	NA_W09-1121_Tumor	\N	DNA	85.9	\N	\N	N14_1	\N
10257	NA_W09-1121_Normal	\N	DNA	91.7	\N	\N	N14_2	\N
10258	NA_W10-143_Tumor	\N	DNA	100	\N	\N	N14_3	\N
10259	NA_S94-31062_Tumor	\N	DNA	100	\N	\N	N14_4	\N
10260	NA_S02-23636A02_Tumor	\N	DNA	100	\N	\N	N14_5	\N
10261	NA_S02-33818A03_Tumor	\N	DNA	100	\N	\N	N14_6	\N
10262	NA_S02-33818A03_Normal	\N	DNA	80.8	\N	\N	N14_7	\N
10263	NA_S05-7439A12_Tumor	\N	DNA	100	\N	\N	N14_8	\N
10264	NA_S05-41924_Tumor	\N	DNA	100	\N	\N	N14_9	\N
10265	NA_S06-47079A02_Tumor	\N	DNA	70.4	\N	\N	N14_10	\N
10266	NA_S08-4544A03_Tumor	\N	DNA	100	\N	\N	N14_11	\N
10267	NA_S10-26316A2_Tumor	\N	DNA	100	\N	\N	N14_12	\N
10268	NA_S10-44069A4_Tumor	\N	DNA	100	\N	\N	N14_13	\N
10269	NA_S11-38910A2_Tumor	\N	DNA	100	\N	\N	N14_14	\N
10270	NA_KIT192_Tumor	\N	DNA	100	\N	\N	N14_15	\N
10271	NA_KIT203_Tumor	\N	DNA	100	\N	\N	N14_16	\N
10272	NA_KR_166_Tumor	\N	DNA	53.90000000000001	\N	\N	blood derived.	\N
10273	NA_KR_2064_Tumor	\N	DNA	74.2	\N	\N	blood derived	\N
10274	NA_KR_2030_Tumor	\N	DNA	85.8	\N	\N	blood derived	\N
10275	NA_KR_177_Tumor	\N	DNA	100	\N	\N	blood derived	\N
10276	NA_KR_150_Tumor	\N	DNA	100	\N	\N	blood derived	\N
10277	NA_KR_229_Tumor	\N	DNA	54.1	\N	\N	blood derived	\N
10278	NA_KR_203_Tumor	\N	DNA	47.5	\N	\N	blood derived	\N
10279	NA_KR_8_Tumor	\N	DNA	88.6	\N	\N	blood derived	\N
10280	NA_KR_5233_Tumor	\N	DNA	100	\N	\N	blood	\N
10281	NA_KR_RMK0091B_Tumor	\N	DNA	100	\N	\N	skin	\N
10282	NA_KR_RMK0194C_Tumor	\N	DNA	100	\N	\N	Saliva-tube	\N
10283	NA_KR_RMK0137C_Tumor	\N	DNA	25	\N	\N	saliva | Barcode mismatch comment in note	\N
10284	NA_KR_RMK0162C_Tumor	\N	DNA	100	\N	\N	saliva | Barcode mismatch comment in note	\N
10285	NA_KR_RMK0168C_Tumor	\N	DNA	67.10000000000001	\N	\N	saliva	\N
10286	NA_10-41439_Normal	\N	DNA	100	\N	\N	\N	\N
10287	NA_11-23681A+C_Normal	\N	DNA	74.6	\N	\N	\N	\N
10288	NA_DM10_Tumor	\N	DNA	80.60000000000001	\N	\N	\N	\N
10289	NA_DM10_Normal	\N	DNA	97.8	\N	\N	\N	\N
10290	NA_DM17_Tumor	\N	DNA	100	\N	\N	\N	\N
10291	NA_DM17_Normal	\N	DNA	31.3	\N	\N	\N	\N
10292	NA_DM18_Tumor	\N	DNA	100	\N	\N	\N	\N
10293	NA_DM18_Normal	\N	DNA	100	\N	\N	\N	\N
10294	NA_DM22_Tumor	\N	DNA	100	\N	\N	\N	\N
10295	NA_DM22_Normal	\N	DNA	12	\N	\N	\N	\N
10296	NA_DM23_Tumor	\N	DNA	10.3	\N	\N	\N	\N
10297	NA_DM23_Normal	\N	DNA	30.8	\N	\N	\N	\N
10298	NA_DM25_Tumor	\N	DNA	24.5	\N	\N	\N	\N
10299	NA_DM25_Normal	\N	DNA	76.5	\N	\N	| Barcode mismatch comment in note	\N
10300	NA_DM6_Tumor	\N	DNA	90.1	\N	\N	| Barcode mismatch comment in note	\N
10301	NA_DM37_Tumor	\N	DNA	100	\N	\N	\N	\N
10302	NA_DM93_Normal	\N	DNA	100	\N	\N	\N	\N
10303	NA_DM93_Tumor	\N	DNA	45.7	\N	\N	\N	\N
10304	NA_SM_1_Tumor	\N	DNA	100	\N	\N	\N	\N
10305	NA_SM_3_Tumor	\N	DNA	76.2	\N	\N	\N	\N
10306	NA_SM_4_Tumor	\N	DNA	95.20000000000002	\N	\N	\N	\N
10307	NA_SM_4_Normal	\N	DNA	23.3	\N	\N	\N	\N
10308	NA_SM_5_Tumor	\N	DNA	100	\N	\N	\N	\N
10309	NA_SM_5_Normal	\N	DNA	100	\N	\N	\N	\N
10310	NA_SM7_Tumor	\N	DNA	100	\N	\N	\N	\N
10311	NA_SM_8_Tumor	\N	DNA	98.4	\N	\N	\N	\N
10312	NA_SM_11_Tumor	\N	DNA	100	\N	\N	\N	\N
10313	NA_SM_12_Tumor	\N	DNA	39.6	\N	\N	\N	\N
10314	NA_SM_16_Tumor	\N	DNA	85.8	\N	\N	\N	\N
10315	NA_SM_16_Normal	\N	DNA	100	\N	\N	| Barcode mismatch comment in note	\N
10316	NA_SM_18_Tumor	\N	DNA	100	\N	\N	| Barcode mismatch comment in note	\N
10317	NA_DM42_Tumor	\N	DNA	100	\N	\N	\N	\N
10318	NA_DM43_Tumor	\N	DNA	91.8	\N	\N	\N	\N
10319	NA_DM48_Tumor	\N	DNA	44.79999999999998	\N	\N	\N	\N
10320	NA_11-64496_Tumor	\N	DNA	100	\N	\N	CGH11-292 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10321	NA_11-71491_Tumor	\N	DNA	54.3	\N	\N	CGH11-305 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10353	NA_12-81749_Tumor	\N	DNA	88.5	\N	\N	CGH12-347 Iwei, Translocation CGH NTRK2	\N
10354	NA_12-97031_Tumor	\N	DNA	13.6	\N	\N	CGH13-003 Iwei, Translocation CGH BRAF	\N
10322	NA_11-65756_Tumor	\N	DNA	54	\N	\N	CGH11-310 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10323	NA_11-74100_Tumor	\N	DNA	100	\N	\N	CGH11-319 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10324	NA_11-74517_Tumor	\N	DNA	60.2	\N	\N	CGH11-348 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10325	NA_10-74513_Tumor	\N	DNA	100	\N	\N	CGH10-028 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10326	NA_10-80009_Tumor	\N	DNA	100	\N	\N	CGH10-045 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10327	NA_10-91484_Tumor	\N	DNA	100	\N	\N	CGH10-062 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10328	NA_11-699_Tumor	\N	DNA	100	\N	\N	CGH11-011 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10329	NA_11-18560_Tumor	\N	DNA	100	\N	\N	CGH11-072 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10330	NA_11-20772_Tumor	\N	DNA	100	\N	\N	CGH11-087 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10331	NA_11-19877_Tumor	\N	DNA	100	\N	\N	CGH11-089 | Barcode mismatch comment in note| Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10332	NA_11-35616_Tumor	\N	DNA	100	\N	\N	CGH11-147 | Barcode mismatch comment in note| Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10333	NA_11-33856_Tumor	\N	DNA	100	\N	\N	CGH11-158 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10334	NA_11-38771_Tumor	\N	DNA	100	\N	\N	CGH11-166 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10335	NA_11-39639_Tumor	\N	DNA	100	\N	\N	CGH11-172 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	\N
10336	NA_10-88482_Tumor	\N	DNA	\N	\N	\N	CGH10-058 NTRK3	\N
10337	NA_11-5482_Tumor	\N	DNA	\N	\N	\N	CGH11-035 MET	\N
10338	NA_11-31904_Tumor	\N	DNA	\N	\N	\N	CGH11-194 BRAF	\N
10339	NA_11-61046_Tumor	\N	DNA	\N	\N	\N	CGH11-252 NTRK3	\N
10340	NA_08-27590_Tumor	\N	DNA	57.59999999999999	\N	\N	\N	\N
10341	NA_08-27590_Normal	\N	DNA	10.2	\N	\N	\N	\N
10342	NA_06-32942_Tumor	\N	DNA	69.80000000000001	\N	\N	\N	\N
10343	NA_06-52508_Tumor	\N	DNA	62.5	\N	\N	\N	\N
10344	NA_06-52508_Normal	\N	DNA	39	\N	\N	\N	\N
10345	NA_07-04365_Tumor	\N	DNA	60.4	\N	\N	\N	\N
10346	NA_07-04365_Normal	\N	DNA	35.5	\N	\N	\N	\N
10347	NA_07-14044A_Tumor	\N	DNA	68.9	\N	\N	\N	\N
10348	NA_07-14044A_Normal	\N	DNA	34.4	\N	\N	\N	\N
10349	NA_07-26247_Tumor	\N	DNA	71.7	\N	\N	\N	\N
10350	NA_09-37302_Tumor	\N	DNA	62.3	\N	\N	\N	\N
10351	NA_12-79358_Tumor	\N	DNA	100	\N	\N	Iwei, Translocation CGH BRAF	\N
10352	NA_12-81302_Tumor	\N	DNA	100	\N	\N	CGH12-345 Iwei, Translocation CGH NTRK1	\N
10355	NA_12-98736_Tumor	\N	DNA	96.2	\N	\N	CGH13-009 Iwei, Translocation CGH NTRK1	\N
10356	NA_13-3874_Tumor	\N	DNA	100	\N	\N	CGH13-033 Iwei, Translocation CGH NTRK1	\N
10357	NA_13-3732_Tumor	\N	DNA	68.6	\N	\N	CGH13-034 Iwei, Translocation CGH NTRK1?	\N
10358	NA_13-3889_Tumor	\N	DNA	29.1	\N	\N	CGH13-041 Iwei, Translocation CGH NTRK3	\N
10359	NA_13-4090B_Tumor	\N	DNA	100	\N	\N	CGH13-044 Iwei, Translocation CGH NTRK3	\N
10360	NA_13-4136_Tumor	\N	DNA	71.1	\N	\N	CGH13-046 Iwei, Translocation CGH BRAF	\N
10361	NA_13-7186_Tumor	\N	DNA	100	\N	\N	CGH13-058 Iwei, Translocation CGH NTRK3	\N
10362	NA_13-25A_Tumor	\N	DNA	100	\N	\N	CGH13-011 Iwei, Translocation CGH BRAF	\N
10363	NA_11-71241_Tumor	\N	DNA	76.7	\N	\N	\N	\N
10364	NA_11-26903_Tumor	\N	DNA	77.6	\N	\N	\N	\N
10365	NA_11-28912B_Tumor	\N	DNA	99.7	\N	\N	\N	\N
10366	NA_11-5210D_Tumor	\N	DNA	62.60000000000001	\N	\N	\N	\N
10367	NA_10-83193_Tumor	\N	DNA	51	\N	\N	\N	\N
10368	NA_11-95856_Tumor	\N	DNA	76.10000000000001	\N	\N	\N	\N
10369	NA_10-23569A_Tumor	\N	DNA	77.39999999999999	\N	\N	\N	\N
10370	NA_09-92749_Tumor	\N	DNA	100	\N	\N	\N	\N
10371	NA_09-72944_Tumor	\N	DNA	53.2	\N	\N	\N	\N
10372	NA_10-46536_Tumor	\N	DNA	76	\N	\N	\N	\N
10373	NA_10-83613A_Tumor	\N	DNA	96.6	\N	\N	\N	\N
10374	NA_K1_1_Tumor	\N	DNA	1000	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10375	NA_K1_2_Tumor	\N	DNA	1000	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10376	NA_K1_3_Tumor	\N	DNA	1000	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10377	NA_London-L20_Melanoma	\N	DNA	84.39999999999999	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10378	NA_London-L20_Normal	\N	DNA	39.52	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10379	NA_London-L20_Nevus	\N	DNA	17.172	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10380	NA_London-L15_Normal	\N	DNA	12.441	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10381	NA_London-L23C_Nevus	\N	DNA	4.968	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10382	NA_K1_9_Tumor	\N	DNA	5.236	\N	\N	\N	\N
10383	NA_K1_10_Tumor	\N	DNA	7.4	\N	\N	\N	\N
10384	NA_K1_11_Tumor	\N	DNA	1000	\N	\N	\N	\N
10385	NA_K1_12_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10386	NA_K1_13_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10387	NA_K1_14_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10388	NA_K1_15_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10389	NA_K1_16_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10390	NA_K1_17_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10391	NA_K1_18_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10392	NA_K1_19_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10393	NA_K1_20_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10394	NA_10-32987_Tumor	\N	DNA	75.1	\N	\N	\N	\N
10395	NA_06-08042_Tumor	\N	DNA	82.4	\N	\N	\N	\N
10396	NA_06-00911_Tumor	\N	DNA	74.2	\N	\N	\N	\N
10397	NA_06-21363_Tumor	\N	DNA	86.1	\N	\N	\N	\N
10398	NA_06-47334_Tumor	\N	DNA	75.3	\N	\N	\N	\N
10399	NA_S12-6332A5_Tumor	\N	DNA	100	\N	\N	\N	\N
10400	NA_S11-032523A1_Tumor	\N	DNA	97	\N	\N	\N	\N
10401	NA_S08-1463A2_Tumor	\N	DNA	100	\N	\N	\N	\N
10402	NA_S12-7093NG176-1_Tumor	\N	DNA	100	\N	\N	\N	\N
10403	NA_S10-7937B2_Tumor	\N	DNA	95.9	\N	\N	\N	\N
10404	NA_S11-21025B1_Tumor	\N	DNA	100	\N	\N	\N	\N
10405	NA_10-58663_Melanoma	\N	DNA	100	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10406	NA_10-58663_Melanoma	\N	DNA	100	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10407	NA_10-58663_Nevus	\N	DNA	48.09999999999999	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10408	NA_10-58663_Nevus	\N	DNA	61.5	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10409	NA_10-58663_Normal	\N	DNA	11.3	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10410	NA_08-52519_Melanoma	\N	DNA	100	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10411	NA_08-52519_Melanoma	\N	DNA	100	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10412	NA_08-52519_Nevus	\N	DNA	65.10000000000001	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10413	NA_08-52519_Nevus	\N	DNA	77.1	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10414	NA_08-52519_Normal	\N	DNA	17.6	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10415	NA_09-8165_Melanoma	\N	DNA	34.8	\N	\N	\N	\N
10416	NA_09-8165_Melanoma	\N	DNA	39.6	\N	\N	\N	\N
10417	NA_09-8165_Nevus	\N	DNA	11.4	\N	\N	\N	\N
10418	NA_09-8165_Nevus	\N	DNA	19.1	\N	\N	\N	\N
10419	NA_09-8165_Normal	\N	DNA	20.7	\N	\N	\N	\N
10420	NA_08-46462_Melanoma	\N	DNA	94.9	\N	\N	\N	\N
10421	NA_08-46462_Melanoma	\N	DNA	100	\N	\N	\N	\N
10422	NA_08-46462_Nevus	\N	DNA	82.4	\N	\N	\N	\N
10423	NA_08-46462_Nevus	\N	DNA	20.2	\N	\N	\N	\N
10424	NA_08-46462_Normal	\N	DNA	10.8	\N	\N	\N	\N
10425	NA_11-25808_Tumor	\N	DNA	45.09999999999999	\N	\N	CGH11-115 	\N
10426	NA_11-42027_Tumor	\N	DNA	100	\N	\N	CGH11-184 	\N
10427	NA_12-7775_Tumor	\N	DNA	100	\N	\N	CGH12-043 	\N
10428	NA_DM93_Tumor	\N	DNA	10	\N	\N	\N	\N
10429	NA_DM37_Normal	\N	DNA	62	\N	\N	\N	\N
10430	NA_DM45_Tumor	\N	DNA	31.6	\N	\N	\N	\N
10431	NA_DM45_Normal	\N	DNA	22	\N	\N	\N	\N
10432	NA_DM16_Tumor	\N	DNA	31.3	\N	\N	\N	\N
10433	NA_DM16_Normal	\N	DNA	100	\N	\N	\N	\N
10434	NA_DM77_Tumor	\N	DNA	57.2	\N	\N	\N	\N
10435	NA_DM77_Normal	\N	DNA	100	\N	\N	\N	\N
10436	NA_HW3_Tumor	\N	DNA	\N	\N	\N	\N	\N
10437	NA_HW2_Tumor	\N	DNA	11	\N	\N	\N	\N
10438	NA_HWAcr_Tumor	\N	DNA	\N	\N	\N	\N	\N
10439	NA_KIT181_Tumor	\N	DNA	\N	\N	\N	_Muc BRAF	\N
10440	NA_DM13_Tumor	\N	DNA	100	\N	\N	\N	\N
10441	NA_DM94_Tumor	\N	DNA	69.6	\N	\N	\N	\N
10442	NA_DM94_Normal	\N	DNA	10.1	\N	\N	\N	\N
10443	NA_DM98_Tumor	\N	DNA	100	\N	\N	\N	\N
10444	NA_DM98_Normal	\N	DNA	89.59999999999997	\N	\N	\N	\N
10445	NA_DM99_Tumor	\N	DNA	12.6	\N	\N	\N	\N
10446	NA_DM99_Normal	\N	DNA	77.8	\N	\N	\N	\N
10447	NA_DM64_Tumor	\N	DNA	100	\N	\N	\N	\N
10448	NA_DM64_Normal	\N	DNA	35.8	\N	\N	\N	\N
10449	NA_DM51_Tumor	\N	DNA	100	\N	\N	\N	\N
10450	NA_DM58_Tumor	\N	DNA	100	\N	\N	\N	\N
10451	NA_DM59_Tumor	\N	DNA	100	\N	\N	\N	\N
10452	NA_DM31_Tumor	\N	DNA	16.2	\N	\N	\N	\N
10453	NA_DM36_Tumor	\N	DNA	28.6	\N	\N	\N	\N
10454	NA_DM74_Tumor	\N	DNA	12.2	\N	\N	\N	\N
10455	NA_DM10_Tumor	\N	DNA	\N	\N	\N	\N	\N
10456	NA_DM18_Tumor	\N	DNA	\N	\N	\N	\N	\N
10457	NA_HW8_Tumor	\N	DNA	100	\N	\N	\N	\N
10458	NA_08-43264_Melanoma	\N	DNA	21.6	\N	\N	\N	\N
10459	NA_08-43264_Melanoma	\N	DNA	65.10000000000001	\N	\N	\N	\N
10460	NA_08-43264_Nevus	\N	DNA	80.60000000000001	\N	\N	\N	\N
10461	NA_08-43264_Nevus	\N	DNA	93.6	\N	\N	\N	\N
10462	NA_08-43264_Normal	\N	DNA	42.8	\N	\N	\N	\N
10463	NA_08-51219_Melanoma	\N	DNA	38.3	\N	\N	\N	\N
10464	NA_08-51219_Melanoma	\N	DNA	49	\N	\N	\N	\N
10465	NA_08-51219_Nevus	\N	DNA	100	\N	\N	\N	\N
10466	NA_08-51219_Nevus	\N	DNA	11	\N	\N	\N	\N
10467	NA_08-51219_Normal	\N	DNA	21.4	\N	\N	\N	\N
10468	NA_S12-18826_Tumor	\N	DNA	40.7	\N	\N	\N	\N
10469	NA_11-81851_Melanoma	\N	DNA	100	\N	\N	\N	\N
10470	NA_11-81851_Melanoma	\N	DNA	100	\N	\N	\N	\N
10471	NA_11-81851_Nevus	\N	DNA	41.5	\N	\N	\N	\N
10472	NA_11-81851_Nevus	\N	DNA	61.2	\N	\N	\N	\N
10473	NA_11-81851_Normal	\N	DNA	10.2	\N	\N	\N	\N
10474	NA_10-73024_Melanoma	\N	DNA	22.9	\N	\N	\N	\N
10475	NA_10-73024_Melanoma	\N	DNA	57.2	\N	\N	\N	\N
10476	NA_10-73024_Nevus	\N	DNA	11	\N	\N	\N	\N
10477	NA_10-73024_Nevus	\N	DNA	24.2	\N	\N	\N	\N
10478	NA_10-73024_Normal	\N	DNA	10.1	\N	\N	\N	\N
10479	NA_12_M_Tumor	\N	DNA	75.7	\N	\N	\N	\N
10480	NA_35_M_Tumor	\N	DNA	100	\N	\N	\N	\N
10481	NA_49_M_Tumor	\N	DNA	100	\N	\N	\N	\N
10482	NA_DM2_Tumor	\N	DNA	100	\N	\N	\N	\N
10483	NA_10-0206_Tumor	\N	DNA	100	\N	\N	\N	\N
10484	NA_09-0209_Tumor	\N	DNA	100	\N	\N	\N	\N
10485	NA_13-25110A1_Melanoma	\N	DNA	46.7	\N	\N	\N	\N
10486	NA_13-25110A1_Nevus	\N	DNA	14.3	\N	\N	\N	\N
10487	NA_13-25110A1_Normal	\N	DNA	19	\N	\N	\N	\N
10488	NA_13-45163_Melanoma	\N	DNA	100	\N	\N	\N	\N
10489	NA_13-45163_Nevus	\N	DNA	30.9	\N	\N	\N	\N
10490	NA_13-45163_Normal	\N	DNA	100	\N	\N	\N	\N
10491	NA_DM49_Tumor	\N	DNA	26.9	\N	\N	\N	\N
10492	NA_DP08-21965C_Tumor	\N	DNA	14	\N	\N	\N	\N
10493	NA_DP08-21965C_Normal	\N	DNA	20.5	\N	\N	\N	\N
10494	NA_DP08-4205A_Tumor	\N	DNA	78.5	\N	\N	\N	\N
10495	NA_DP08-4205A_Normal	\N	DNA	76.30000000000001	\N	\N	\N	\N
10496	NA_11-50182_Tumor	\N	DNA	51.40000000000001	\N	\N	CGH11-229 	\N
10497	NA_11-51553_Tumor	\N	DNA	100	\N	\N	CGH11-231 	\N
10498	NA_11-52339_Tumor	\N	DNA	67.8	\N	\N	CGH11-232 	\N
10499	NA_11-55993_Tumor	\N	DNA	70.9	\N	\N	CGH11-237 	\N
10500	NA_11-57051_Tumor	\N	DNA	93.5	\N	\N	CGH11-259 	\N
10501	NA_11-71006_Tumor	\N	DNA	31.1	\N	\N	CGH11-315 	\N
10502	NA_11-76464_Tumor	\N	DNA	100	\N	\N	CGH11-339 	\N
10503	NA_11-88431_Tumor	\N	DNA	22	\N	\N	\N	\N
10504	NA_11-88432_Tumor	\N	DNA	65.5	\N	\N	CGH11-404 	\N
10505	NA_11-88209_Tumor	\N	DNA	100	\N	\N	CGH11-409 	\N
10506	NA_Thomas_SK_MEL_23_Tumor	\N	DNA	45.7	\N	\N	\N	\N
10507	NA_KIT134_Tumor	\N	DNA	96.9	\N	\N	Alyssa Acral Mucosal DNA	\N
10508	NA_KIT191_Tumor	\N	DNA	100	\N	\N	Alyssa Acral Mucosal DNA	\N
10509	NA_KIT205_Tumor	\N	DNA	68.8	\N	\N	Alyssa Acral Mucosal DNA	\N
10510	NA_KIT206_Tumor	\N	DNA	100	\N	\N	Alyssa Acral Mucosal DNA	\N
10511	NA_KIT210_Tumor	\N	DNA	65.19999999999999	\N	\N	Alyssa Acral Mucosal DNA	\N
10512	NA_KIT217_Tumor	\N	DNA	100	\N	\N	Alyssa Acral Mucosal DNA	\N
10513	NA_KIT225_Tumor	\N	DNA	100	\N	\N	Alyssa Acral Mucosal DNA	\N
10514	NA_KIT244_Tumor	\N	DNA	77.5	\N	\N	Alyssa Acral Mucosal DNA	\N
10515	NA_KIT260_Tumor	\N	DNA	89.39999999999999	\N	\N	Alyssa Acral Mucosal DNA	\N
10516	NA_KIT273_Tumor	\N	DNA	100	\N	\N	Alyssa Acral Mucosal DNA	\N
10517	NA_KIT295_Tumor	\N	DNA	39.7	\N	\N	Alyssa Acral Mucosal DNA	\N
10518	NA_11-23878_Tumor	\N	DNA	100	\N	\N	CGH11-109 	\N
10519	NA_12-11041_Tumor	\N	DNA	100	\N	\N	CGH12-058 	\N
10520	NA_12-55584_Tumor	\N	DNA	100	\N	\N	CGH12-224 	\N
10521	NA_11-85416_Tumor	\N	DNA	93.2	\N	\N	CGH11-410 	\N
10522	NA_11-94134_Tumor	\N	DNA	100	\N	\N	CGH11-424 	\N
10523	NA_12-2898_Tumor	\N	DNA	89.5	\N	\N	CGH12-026 	\N
10524	NA_12-1782_Tumor	\N	DNA	82.90000000000003	\N	\N	CGH12-039 	\N
10525	NA_12-4251_Tumor	\N	DNA	100	\N	\N	CGH12-040 	\N
10526	NA_12-8171_Tumor	\N	DNA	100	\N	\N	CGH12-053 	\N
10527	NA_12-10777_Tumor	\N	DNA	78.3	\N	\N	CGH12-056 	\N
10528	NA_10_63051C_Normal	\N	DNA	100	\N	\N	\N	\N
10529	NA_DPN8_Normal	\N	DNA	67	\N	\N	\N	\N
10530	NA_DPN9_Normal	\N	DNA	22.6	\N	\N	\N	\N
10531	NA_DPN18_Normal	\N	DNA	10.1	\N	\N	\N	\N
10532	NA_11-21178_Tumor	\N	DNA	100	\N	\N	CGH11-091 	\N
10533	NA_13-212_Tumor	\N	DNA	71.4	\N	\N	\N	\N
10534	NA_DM74_Tumor	\N	DNA	\N	\N	\N	\N	\N
10535	NA_DM99_Tumor	\N	DNA	\N	\N	\N	\N	\N
10536	NA_KIT230_Tumor	\N	DNA	10.3	\N	\N	\N	\N
10537	NA_KIT297_Tumor	\N	DNA	100	\N	\N	\N	\N
10538	NA_KIT302_Tumor	\N	DNA	100	\N	\N	\N	\N
10539	NA_KIT316_Tumor	\N	DNA	100	\N	\N	\N	\N
10540	NA_DM6_Normal	\N	DNA	72	\N	\N	\N	\N
10541	NA_DM31_Normal	\N	DNA	40.3	\N	\N	\N	\N
10542	NA_DM36_Normal	\N	DNA	47.40000000000001	\N	\N	\N	\N
10543	NA_DM42_Normal	\N	DNA	35.2	\N	\N	\N	\N
10544	NA_DM68_Tumor	\N	DNA	10	\N	\N	\N	\N
10545	NA_DM10_Tumor	\N	DNA	100	\N	\N	\N	\N
10546	NA_DM10_Normal	\N	DNA	30.7	\N	\N	\N	\N
10547	NA_DM10_Tumor	\N	DNA	38	\N	\N	\N	\N
10548	NA_11-50270_Tumor	\N	DNA	25.6	\N	\N	CGH11-224 	\N
10549	NA_12-23578_Tumor	\N	DNA	71.2	\N	\N	CGH12-104 	\N
10657	NA_99-15313_Tumor	\N	DNA	\N	\N	\N	\N	\N
10550	NA_12-31421_Tumor	\N	DNA	71.6	\N	\N	CGH12-124 	\N
10551	NA_11-13661_Tumor	\N	DNA	\N	\N	\N	CGH11-051 	\N
10552	NA_RC11-001_Tumor	\N	DNA	\N	\N	\N	\N	\N
10553	NA_RC11-002_Tumor	\N	DNA	\N	\N	\N	\N	\N
10554	NA_RC11-003_Tumor	\N	DNA	\N	\N	\N	\N	\N
10555	NA_RC11-004_Tumor	\N	DNA	\N	\N	\N	\N	\N
10556	NA_RC11-005_Tumor	\N	DNA	\N	\N	\N	\N	\N
10557	NA_RC11-021_Tumor	\N	DNA	\N	\N	\N	\N	\N
10558	NA_RC11-022_Tumor	\N	DNA	\N	\N	\N	\N	\N
10559	NA_RC11-023_Tumor	\N	DNA	\N	\N	\N	\N	\N
10560	NA_RC11-024_Tumor	\N	DNA	\N	\N	\N	\N	\N
10561	NA_Kit298_Tumor	\N	DNA	\N	\N	\N	\N	\N
10562	NA_08-46462_Tumor	\N	DNA	11.4	\N	\N	\N	\N
10563	NA_08-46462_Nevus	\N	DNA	42.70000000000002	\N	\N	\N	\N
10564	NA_08-46462_Tumor	\N	DNA	39.6	\N	\N	\N	\N
10565	NA_08-46462_Normal	\N	DNA	100	\N	\N	\N	\N
10566	NA_BN_N1_Tumor	\N	DNA	100	\N	\N	\N	\N
10567	NA_BN_N2_Tumor	\N	DNA	100	\N	\N	\N	\N
10568	NA_BN_M1_Tumor	\N	DNA	100	\N	\N	\N	\N
10569	NA_BN_M2_Tumor	\N	DNA	100	\N	\N	\N	\N
10570	NA_DM74_Tumor	\N	DNA	36.2	\N	\N	\N	\N
10571	NA_DM10_Tumor	\N	DNA	100	\N	\N	\N	\N
10572	NA_SQ13-8208B_Tumor	\N	DNA	27.1	\N	\N	\N	\N
10573	NA_98-18400a_Tumor	\N	DNA	100	\N	\N	\N	\N
10574	NA_12-11406A_Tumor	\N	DNA	67.4	\N	\N	\N	\N
10575	NA_08-70283a_Tumor	\N	DNA	100	\N	\N	\N	\N
10576	NA_03-34051A1_Tumor	\N	DNA	100	\N	\N	\N	\N
10577	NA_02-42436_Tumor	\N	DNA	100	\N	\N	\N	\N
10578	NA_11-38149_Normal	\N	DNA	10.5	\N	\N	\N	\N
10579	NA_13-2939B_Tumor	\N	DNA	74.2	\N	\N	\N	\N
10580	NA_L13-48798_Tumor	\N	DNA	100	\N	\N	\N	\N
10581	NA_13-51115A_Tumor	\N	DNA	100	\N	\N	\N	\N
10582	NA_11-73238A_Normal	\N	DNA	100	\N	\N	\N	\N
10583	NA_11-73999_Normal	\N	DNA	93.5	\N	\N	\N	\N
10584	NA_DM43_Normal	\N	DNA	100	\N	\N	\N	\N
10585	NA_DM49_Normal	\N	DNA	100	\N	\N	\N	\N
10586	NA_DM58_Normal	\N	DNA	100	\N	\N	\N	\N
10587	NA_DM65_Tumor	\N	DNA	60.09999999999999	\N	\N	\N	\N
10588	NA_DM93_Tumor	\N	DNA	100	\N	\N	\N	\N
10589	NA_DM10_Tumor	\N	DNA	10	\N	\N	\N	\N
10590	NA_13-59840_Tumor	\N	DNA	100	\N	\N	\N	\N
10591	NA_13-59840_Tumor	\N	DNA	100	\N	\N	\N	\N
10592	NA_Seider_Uveal_Tumor	\N	DNA	44.3	\N	\N	\N	\N
10593	NA_Luping_ROS_1_Tumor	\N	DNA	55	\N	\N	\N	\N
10594	NA_Seider_Roe_Tumor	\N	DNA	35.4	\N	\N	\N	\N
10595	NA_DP08-21965C_Tumor	\N	DNA	54.39999999999999	\N	\N	\N	\N
10596	NA_DM18_Tumor	\N	DNA	67.69999999999999	\N	\N	\N	\N
10597	NA_11-50182_Tumor	\N	DNA	100	\N	\N	CGH11-229 	\N
10598	NA_11-41004_Tumor	\N	DNA	100	\N	\N	CGH11-202 	\N
10599	NA_11-51223_Tumor	\N	DNA	84	\N	\N	CGH11-215 	\N
10600	NA_12-22542_Tumor	\N	DNA	100	\N	\N	CGH12-088 	\N
10601	NA_12-42406_Tumor	\N	DNA	100	\N	\N	CGH12-188 	\N
10602	NA_12-55875_Tumor	\N	DNA	100	\N	\N	CGH12-227 	\N
10603	NA_12-88454_Tumor	\N	DNA	100	\N	\N	CGH12-376 	\N
10604	NA_12-98328_Tumor	\N	DNA	100	\N	\N	CGH13-007 	\N
10605	NA_13-25A_Tumor	\N	DNA	45.09999999999999	\N	\N	CGH13-011 	\N
10606	NA_12-762B_Normal	\N	DNA	2.35	\N	\N	\N	\N
10607	NA_12-168B_Normal	\N	DNA	2.86	\N	\N	\N	\N
10608	NA_11-75173_Normal	\N	DNA	3.46	\N	\N	\N	\N
10609	NA_12-167B_Normal	\N	DNA	5.04	\N	\N	\N	\N
10610	NA_13-47668_Tumor	\N	DNA	8.57	\N	\N	\N	\N
10611	NA_13-47668_Tumor	\N	DNA	1.97	\N	\N	\N	\N
10612	NA_12-66661_Tumor	\N	DNA	3.75	\N	\N	\N	\N
10613	NA_13-47621_Tumor	\N	DNA	2.53	\N	\N	\N	\N
10614	NA_13-47621_Tumor	\N	DNA	3	\N	\N	\N	\N
10615	NA_13-37371_Tumor	\N	DNA	4.49	\N	\N	\N	\N
10616	NA_13-37371_Tumor	\N	DNA	4.73	\N	\N	\N	\N
10617	NA_DM11_Tumor	\N	DNA	3.66	\N	\N	\N	\N
10618	NA_DM14_Tumor	\N	DNA	2.37	\N	\N	\N	\N
10619	NA_13-25110A1_Melanoma	\N	DNA	2.64	\N	\N	\N	\N
10620	NA_13-25110A1_Normal	\N	DNA	4.66	\N	\N	\N	\N
10621	NA_13-45163_Normal	\N	DNA	2.83	\N	\N	\N	\N
10622	NA_Acral-11_Tumor	\N	DNA	\N	\N	\N	_Tumor	\N
10623	NA_Acral-11_Normal	\N	DNA	\N	\N	\N	_Cntl	\N
10624	NA_Acral-12_Tumor	\N	DNA	\N	\N	\N	_Tumor	\N
10625	NA_Acral-12_Normal	\N	DNA	\N	\N	\N	_Cntl	\N
10626	NA_02-2599_Tumor	\N	DNA	\N	\N	\N	\N	\N
10627	NA_02-2599_Tumor	\N	DNA	\N	\N	\N	\N	\N
10628	NA_02-2599C_Tumor	\N	DNA	\N	\N	\N	\N	\N
10629	NA_02-2599_Tumor	\N	DNA	\N	\N	\N	\N	\N
10630	NA_DM48_Normal	\N	DNA	\N	\N	\N	\N	\N
10631	NA_DM59_Normal	\N	DNA	\N	\N	\N	\N	\N
10632	NA_DM68_Normal	\N	DNA	\N	\N	\N	\N	\N
10633	NA_DM95_Tumor	\N	DNA	\N	\N	\N	\N	\N
10634	NA_08-46462_Nevus	\N	DNA	\N	\N	\N	\N	\N
10635	NA_08-46462_MIS	\N	DNA	\N	\N	\N	\N	\N
10636	NA_08-46462_Normal	\N	DNA	\N	\N	\N	\N	\N
10637	NA_08-46462_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10638	NA_T07-1120_Tumor	\N	DNA	5.1792	\N	\N	\N	\N
10639	NA_T09-8069_Tumor	\N	DNA	7.8214	\N	\N	\N	\N
10640	NA_T02-16195_Tumor	\N	DNA	15.959	\N	\N	\N	\N
10641	NA_T00-12011_Tumor	\N	DNA	8.9639	\N	\N	\N	\N
10642	NA_T06-6855_Tumor	\N	DNA	1.0365	\N	\N	\N	\N
10643	NA_12-18832AA_Tumor	\N	DNA	16.6144	\N	\N	\N	\N
10644	NA_CNS52_Tumor	\N	DNA	0.2966	\N	\N	\N	\N
10645	NA_CNS53_Tumor	\N	DNA	9.2806	\N	\N	\N	\N
10646	NA_CNS54_Tumor	\N	DNA	6.3439	\N	\N	\N	\N
10647	NA_CNS57_Tumor	\N	DNA	13.1388	\N	\N	\N	\N
10648	NA_CNS57_Normal	\N	DNA	13.2164	\N	\N	\N	\N
10649	NA_BN-N1-Tert_Tumor	\N	DNA	0.1454	\N	\N	Amplicon Seq: Hunter Melanoma In Nevus (Blue Nevus)	\N
10650	NA_BN-N2-Tert_Tumor	\N	DNA	0.1761	\N	\N	Amplicon Seq: Hunter Melanoma In Nevus (Blue Nevus)	\N
10651	NA_BN-M1-Tert_Tumor	\N	DNA	0.179	\N	\N	Amplicon Seq: Hunter Melanoma In Nevus (Blue Nevus)	\N
10652	NA_08-43264_Nevus	\N	DNA	0.0728	\N	\N	Amplicon Seq: Ivanka Patient Melanoma  	\N
10653	NA_10-58663_Melanoma	\N	DNA	0.2129	\N	\N	Amplicon Seq: Ivanka Patient Melanoma  	\N
10654	NA_12-12039B_Tumor	\N	DNA	\N	\N	\N	\N	\N
10655	NA_12-22776B3_Tumor	\N	DNA	\N	\N	\N	\N	\N
10656	NA_99-29482_Tumor	\N	DNA	\N	\N	\N	\N	\N
10658	NA_99-885_Tumor	\N	DNA	\N	\N	\N	\N	\N
10659	NA_98-37643_Tumor	\N	DNA	\N	\N	\N	\N	\N
10660	NA_13-25288_Tumor	\N	DNA	\N	\N	\N	\N	\N
10661	NA_09-29997_Tumor	\N	DNA	\N	\N	\N	\N	\N
10662	NA_04-11158_Tumor	\N	DNA	\N	\N	\N	\N	\N
10663	NA_UM4_Tumor	\N	DNA	\N	\N	\N	\N	\N
10664	NA_UM5_Tumor	\N	DNA	\N	\N	\N	\N	\N
10665	NA_08-84352_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10666	NA_08-84352_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10667	NA_08-84352_Nevus	\N	DNA	\N	\N	\N	\N	\N
10668	NA_08-84352_Normal	\N	DNA	\N	\N	\N	\N	\N
10669	NA_11-88792_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10670	NA_11-88792_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10671	NA_11-88792_Nevus	\N	DNA	\N	\N	\N	\N	\N
10672	NA_11-88792_Nevus	\N	DNA	\N	\N	\N	\N	\N
10673	NA_11-88792_Normal	\N	DNA	\N	\N	\N	\N	\N
10674	NA_13-74952_Tumor	\N	DNA	\N	\N	\N	CGH13-324 	\N
10675	NA_13-75067_Tumor	\N	DNA	\N	\N	\N	CGH13-331 ETV6 Fusion	\N
10676	NA_Spitz_M1_Tumor	\N	DNA	\N	\N	\N	\N	\N
10677	NA_Spitz_M2_(?)_Tumor	\N	DNA	\N	\N	\N	\N	\N
10678	NA_Spitz_N1_Tumor	\N	DNA	\N	\N	\N	\N	\N
10679	NA_Spitz_N2_Tumor	\N	DNA	\N	\N	\N	\N	\N
10680	NA_Spitz_N3_Tumor	\N	DNA	\N	\N	\N	\N	\N
10681	NA_BN_Normal	\N	DNA	\N	\N	\N	\N	\N
10682	NA_13-159_Tumor	\N	DNA	\N	\N	\N	CGH13-016 	\N
10683	NA_12-43016_Tumor	\N	DNA	\N	\N	\N	CGH12-163 	\N
10684	NA_13-34291_Tumor	\N	DNA	\N	\N	\N	CGH13-166 	\N
10685	NA_GAK_DNA_Tumor	\N	DNA	\N	\N	\N	\N	\N
10686	NA_Yurif_DNA_Tumor	\N	DNA	\N	\N	\N	\N	\N
10687	NA_Acral-11_Tumor	\N	DNA	\N	\N	\N	Tumor	\N
10688	NA_Acral-11_Normal	\N	DNA	\N	\N	\N	Cntl	\N
10689	NA_DPN26_Tumor	\N	DNA	\N	\N	\N	\N	\N
10690	NA_13-47668_Tumor	\N	DNA	\N	\N	\N	\N	\N
10691	NA_13-47668_Tumor	\N	DNA	\N	\N	\N	\N	\N
10692	NA_13-47621_Tumor	\N	DNA	\N	\N	\N	\N	\N
10693	NA_13-47621_Tumor	\N	DNA	\N	\N	\N	\N	\N
10694	NA_13-37371_Tumor	\N	DNA	\N	\N	\N	\N	\N
10695	NA_13-37371_Tumor	\N	DNA	\N	\N	\N	\N	\N
10696	NA_DM45_Tumor	\N	DNA	\N	\N	\N	\N	\N
10697	NA_DM58_Tumor	\N	DNA	\N	\N	\N	\N	\N
10698	NA_DM1_Tumor	\N	DNA	\N	\N	\N	Hunter Amplicon Sequencing	\N
10699	NA_DM2_Tumor	\N	DNA	\N	\N	\N	Hunter Amplicon Sequencing	\N
10700	NA_DM45_Tumor	\N	DNA	\N	\N	\N	Hunter Amplicon Sequencing	\N
10701	NA_DM79_Tumor	\N	DNA	\N	\N	\N	Hunter Amplicon Sequencing	\N
10702	NA_DM93_Tumor	\N	DNA	\N	\N	\N	Hunter Amplicon Sequencing	\N
10703	NA_13-2939B_Tumor	\N	DNA	100	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10704	NA_11-73238A_Tumor	\N	DNA	100	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10705	NA_99-29482_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10706	NA_13-25288_Tumor	\N	DNA	11	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10707	NA_04-11158_Tumor	\N	DNA	10.7	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
10708	NA_10-55707_Tumor	\N	DNA	\N	\N	\N	CGH10-013 13 Cycle Post Hybridization LM-PCR	\N
10709	NA_11-34950_Tumor	\N	DNA	\N	\N	\N	CGH11-153 13 Cycle Post Hybridization LM-PCR	\N
10710	NA_11-8228_Tumor	\N	DNA	\N	\N	\N	CGH11-036 13 Cycle Post Hybridization LM-PCR	\N
10711	NA_11-84681_Tumor	\N	DNA	\N	\N	\N	CGH11-386 13 Cycle Post Hybridization LM-PCR	\N
10712	NA_11-50182_Tumor	\N	DNA	100	\N	\N	CGH11-229 13 Cycle Post Hybridization LM-PCR	\N
10713	NA_MIN_7_Normal	\N	DNA	\N	\N	\N	\N	\N
10714	NA_MIN_7_Nevus	\N	DNA	\N	\N	\N	\N	\N
10715	NA_MIN_7_Tumor	\N	DNA	\N	\N	\N	\N	\N
10716	NA_MIN_8_Normal	\N	DNA	\N	\N	\N	\N	\N
10717	NA_MIN_8_Nevus	\N	DNA	\N	\N	\N	\N	\N
10718	NA_MIN_8_Tumor	\N	DNA	\N	\N	\N	\N	\N
10719	NA_501_Mel_Tumor	\N	DNA	\N	\N	\N	\N	\N
10720	NA_Sk_Mel_1_Tumor	\N	DNA	\N	\N	\N	\N	\N
10721	NA_DPN24_Tumor	\N	DNA	\N	\N	\N	\N	\N
10722	NA_DPN28_Tumor	\N	DNA	\N	\N	\N	\N	\N
10723	NA_DPN29_Tumor	\N	DNA	\N	\N	\N	\N	\N
10724	NA_DPN31_Tumor	\N	DNA	\N	\N	\N	\N	\N
10725	NA_DPN33_Tumor	\N	DNA	\N	\N	\N	\N	\N
10726	NA_DPN40_Tumor	\N	DNA	\N	\N	\N	\N	\N
10727	NA_DPN40_Tumor	\N	DNA	\N	\N	\N	\N	\N
10728	NA_DPN41_Tumor	\N	DNA	\N	\N	\N	\N	\N
10729	NA_DPN42_Tumor	\N	DNA	\N	\N	\N	\N	\N
10730	NA_DPN44_Tumor	\N	DNA	\N	\N	\N	\N	\N
10731	NA_DPN45_Tumor	\N	DNA	\N	\N	\N	\N	\N
10732	NA_DPN46_Tumor	\N	DNA	\N	\N	\N	\N	\N
10733	NA_UM_6_Tumor	\N	DNA	\N	\N	\N	\N	\N
10734	NA_Birt_Hogg_Dube_Tumor	\N	DNA	\N	\N	\N	\N	\N
10735	NA_13-1939_Tumor	\N	DNA	\N	\N	\N	CGH13-027 NTRK3	\N
10736	NA_13-51657_Tumor	\N	DNA	\N	\N	\N	CGH13-268 MET	\N
10737	NA_13-89069_Tumor	\N	DNA	\N	\N	\N	CGH13-365 DPN-like Melanoma	\N
10738	NA_11-1051A_Tumor	\N	DNA	\N	\N	\N	CGH11-018 	\N
10739	NA_11-5480_Tumor	\N	DNA	\N	\N	\N	CGH11-027 	\N
10740	NA_10-73024_Tumor	\N	DNA	\N	\N	\N	\N	\N
10741	NA_10-73024_Normal	\N	DNA	\N	\N	\N	\N	\N
10742	NA_09-33283_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10743	NA_09-33283_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10744	NA_09-33283_Nevus	\N	DNA	\N	\N	\N	\N	\N
10745	NA_09-33283_Nevus	\N	DNA	\N	\N	\N	\N	\N
10746	NA_09-31895_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10747	NA_09-31895_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10748	NA_09-31895_Nevus	\N	DNA	\N	\N	\N	\N	\N
10749	NA_09-31895_Nevus	\N	DNA	\N	\N	\N	\N	\N
10750	NA_09-31895_Normal	\N	DNA	\N	\N	\N	\N	\N
10751	NA_R29032-05_Tumor	\N	DNA	\N	\N	\N	\N	\N
10752	NA_R29032-05_Normal	\N	DNA	\N	\N	\N	\N	\N
10753	NA_01-8297_Tumor	\N	DNA	\N	\N	\N	\N	\N
10754	NA_01-8297_Normal	\N	DNA	\N	\N	\N	\N	\N
10755	NA_8298-01_Tumor	\N	DNA	\N	\N	\N	\N	\N
10756	NA_8298-01_Normal	\N	DNA	\N	\N	\N	\N	\N
10757	NA_08-53951_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10758	NA_08-53951_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10759	NA_08-53951_Nevus	\N	DNA	\N	\N	\N	\N	\N
10760	NA_08-53951_Nevus	\N	DNA	\N	\N	\N	\N	\N
10761	NA_13000212_Tumor	\N	DNA	\N	\N	\N	\N	\N
10762	NA_8528-05_Tumor	\N	DNA	\N	\N	\N	\N	\N
10763	NA_1286184b_Tumor	\N	DNA	\N	\N	\N	\N	\N
10764	NA_1286184b_Normal	\N	DNA	\N	\N	\N	\N	\N
10765	NA_206436_Tumor	\N	DNA	\N	\N	\N	\N	\N
10766	NA_35942-04_Tumor	\N	DNA	\N	\N	\N	\N	\N
10767	NA_15329-03_Normal	\N	DNA	\N	\N	\N	\N	\N
10768	NA_Z1188-03_Tumor	\N	DNA	\N	\N	\N	\N	\N
10769	NA_1185-03_Normal	\N	DNA	\N	\N	\N	\N	\N
10770	NA_14514-02_Tumor	\N	DNA	\N	\N	\N	\N	\N
10771	NA_15102-02_Normal	\N	DNA	\N	\N	\N	\N	\N
10772	NA_9116-05_Tumor	\N	DNA	\N	\N	\N	\N	\N
10773	NA_24516-06_Tumor	\N	DNA	\N	\N	\N	\N	\N
10774	NA_24516-06_Normal	\N	DNA	\N	\N	\N	\N	\N
10775	NA_07-3078_Tumor	\N	DNA	\N	\N	\N	\N	\N
10776	NA_B06-37358_Tumor	\N	DNA	\N	\N	\N	\N	\N
10777	NA_21590_Tumor	\N	DNA	\N	\N	\N	\N	\N
10778	NA_21590_Normal	\N	DNA	\N	\N	\N	\N	\N
10779	NA_A2A79@_Tumor	\N	DNA	\N	\N	\N	\N	\N
10780	NA_356A3-075_Tumor	\N	DNA	\N	\N	\N	\N	\N
10781	NA_20847-09_Normal	\N	DNA	\N	\N	\N	\N	\N
10782	NA_525_Tumor	\N	DNA	\N	\N	\N	\N	\N
10783	NA_PMM_23_Tumor	\N	DNA	\N	\N	\N	\N	\N
10784	NA_PMM_23_Normal	\N	DNA	\N	\N	\N	\N	\N
10785	NA_UM7_Tumor	\N	DNA	\N	\N	\N	\N	\N
10786	NA_UM8_Tumor	\N	DNA	\N	\N	\N	\N	\N
10787	NA_UM9_Tumor	\N	DNA	\N	\N	\N	\N	\N
10788	NA_UM10_Tumor	\N	DNA	\N	\N	\N	\N	\N
10789	NA_UM11_Tumor	\N	DNA	\N	\N	\N	\N	\N
10790	NA_Xanthoma_Disseminatum_Tumor	\N	DNA	\N	\N	\N	\N	\N
10791	NA_99-15313_Tumor	\N	DNA	\N	\N	\N	Nimblegen43 (BB50)	\N
10792	NA_98-37643_Tumor	\N	DNA	\N	\N	\N	Nimblegen43 (BB50)	\N
10793	NA_09-29997_Tumor	\N	DNA	\N	\N	\N	Nimblegen43 (BB50)	\N
10794	NA_13-94981_Tumor	\N	DNA	\N	\N	\N	CGH13-392 	\N
10795	NA_13-99411A_Tumor	\N	DNA	\N	\N	\N	CGH13-399 	\N
10796	NA_13-94484_Tumor	\N	DNA	\N	\N	\N	CGH13-394 	\N
10797	NA_DM27_Tumor	\N	DNA	\N	\N	\N	\N	\N
10798	NA_DM32_Tumor	\N	DNA	\N	\N	\N	\N	\N
10799	NA_DM35_Tumor	\N	DNA	\N	\N	\N	\N	\N
10800	NA_DM40_Tumor	\N	DNA	\N	\N	\N	\N	\N
10801	NA_11-23681_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10802	NA_11-23681_Melanoma	\N	DNA	\N	\N	\N	\N	\N
10803	NA_H01.10457/II_Primary	\N	DNA	\N	\N	\N	\N	\N
10804	NA_H01.10457/II_Normal	\N	DNA	\N	\N	\N	\N	\N
10805	NA_14.20/II_Met1	\N	DNA	\N	\N	\N	\N	\N
10806	NA_HS14.18/I_Met2	\N	DNA	\N	\N	\N	\N	\N
10807	NA_HS14.19/D_Primary	\N	DNA	\N	\N	\N	\N	\N
10808	NA_HS14.19/D_Nevus	\N	DNA	\N	\N	\N	\N	\N
10809	NA_HS2014.15/7_Met1	\N	DNA	\N	\N	\N	\N	\N
10810	NA_HS2014.15/7_Normal	\N	DNA	\N	\N	\N	\N	\N
10811	NA_HS14.16_Primary	\N	DNA	\N	\N	\N	\N	\N
10812	NA_HS14.16_Normal	\N	DNA	\N	\N	\N	\N	\N
10813	NA_HS14.17/I_Met1	\N	DNA	\N	\N	\N	\N	\N
10814	NA_Long-TN1_Normal	\N	DNA	\N	\N	\N	\N	\N
10815	NA_Long-TN1_Tumor	\N	DNA	\N	\N	\N	\N	\N
10816	NA_Long-TN2_Normal	\N	DNA	\N	\N	\N	\N	\N
10817	NA_Long-TN2_Tumor	\N	DNA	\N	\N	\N	\N	\N
10818	NA_D326_Tumor	\N	DNA	\N	\N	\N	\N	\N
10819	NA_D326_Tumor	\N	DNA	\N	\N	\N	\N	\N
10820	NA_D366_Tumor	\N	DNA	\N	\N	\N	\N	\N
10821	NA_D366_Tumor	\N	DNA	\N	\N	\N	\N	\N
10822	NA_DPN48_Tumor	\N	DNA	\N	\N	\N	\N	\N
10823	NA_11-2532_Tumor	\N	DNA	\N	\N	\N	CGH11-023 	\N
10824	NA_AST-1_Tumor	\N	DNA	\N	\N	\N	\N	\N
10825	NA_08-18595B_Tumor	\N	DNA	\N	\N	\N	\N	\N
10826	NA_13-60273_Tumor	\N	DNA	\N	\N	\N	\N	\N
10827	NA_12-52454_Tumor	\N	DNA	\N	\N	\N	\N	\N
10828	NA_12-75125_Tumor	\N	DNA	\N	\N	\N	\N	\N
10829	NA_12-98235A_Tumor	\N	DNA	\N	\N	\N	\N	\N
10830	NA_13-3619B_Tumor	\N	DNA	\N	\N	\N	\N	\N
10831	NA_13-67500AL_Normal	\N	DNA	\N	\N	\N	\N	\N
10832	NA_13-19205_Tumor	\N	DNA	\N	\N	\N	\N	\N
10833	NA_13-48330_Tumor	\N	DNA	\N	\N	\N	\N	\N
10834	NA_13-11086_Tumor	\N	DNA	\N	\N	\N	\N	\N
10835	NA_13-15966_Tumor	\N	DNA	\N	\N	\N	\N	\N
10836	NA_13-39228_Tumor	\N	DNA	\N	\N	\N	\N	\N
10837	NA_13-45942_Tumor	\N	DNA	\N	\N	\N	\N	\N
10838	NA_13-49600_Tumor	\N	DNA	\N	\N	\N	\N	\N
10839	NA_13-59640_Tumor	\N	DNA	\N	\N	\N	\N	\N
10840	NA_13-67817_Tumor	\N	DNA	\N	\N	\N	\N	\N
10841	NA_SP-12-5612(1K)_Normal	\N	DNA	\N	\N	\N	\N	\N
10842	NA_SP-13-14992(1A)_Tumor	\N	DNA	\N	\N	\N	\N	\N
10843	NA_SP-12-2294-2(2A)_Normal	\N	DNA	\N	\N	\N	\N	\N
10844	NA_SP-13-17075(1B)_Tumor	\N	DNA	\N	\N	\N	\N	\N
10845	NA_SP-42-10361(1A)_Normal	\N	DNA	\N	\N	\N	\N	\N
10846	NA_SP-13-1038(1A)_Tumor	\N	DNA	\N	\N	\N	\N	\N
10847	NA_S13-13286A6_Tumor	\N	DNA	98.55999999999996	\N	\N	NTRK3	\N
10848	NA_S13-13286A6_Normal	\N	DNA	99.22	\N	\N	MET	\N
10849	NA_S11-20884A-A1_Tumor	\N	DNA	102	\N	\N	DPN-like Melanoma	\N
10850	NA_S11-20884A-A1_Normal	\N	DNA	101.06	\N	\N	\N	\N
10851	NA_S12-6218A-D3_Tumor	\N	DNA	101.66	\N	\N	\N	\N
10852	NA_S12-6218A-D3_Normal	\N	DNA	100.8	\N	\N	\N	\N
10853	NA_ZS06-11249A-C2_Tumor	\N	DNA	99.45	\N	\N	\N	\N
10854	NA_S12-26125A2_Tumor	\N	DNA	100.54	\N	\N	\N	\N
10855	NA_S12-28585A6_Tumor	\N	DNA	99.12	\N	\N	\N	\N
10856	NA_S11-2018B5_Tumor	\N	DNA	100.25	\N	\N	\N	\N
10857	NA_S13-11748F5_Tumor	\N	DNA	101.8	\N	\N	\N	\N
10858	NA_S12-7250E3_Tumor	\N	DNA	98.7	\N	\N	\N	\N
10859	NA_S13-3401B3_Tumor	\N	DNA	102.3	\N	\N	\N	\N
10860	NA_S13-12947A2_Tumor	\N	DNA	97.8	\N	\N	\N	\N
10861	NA_S13-18444A16_Tumor	\N	DNA	98.56	\N	\N	\N	\N
10862	NA_ZS07-1210F6_Tumor	\N	DNA	100.75	\N	\N	\N	\N
10863	NA_ZS10-11930B12_Tumor	\N	DNA	99.6	\N	\N	\N	\N
10864	NA_S12-28988_Tumor	\N	DNA	100.38	\N	\N	\N	\N
10865	NA_SSS13-1652B2_Tumor	\N	DNA	102.06	\N	\N	\N	\N
10866	NA_S13-5249_Tumor	\N	DNA	99.75	\N	\N	\N	\N
10867	NA_356A3-075_Tumor	\N	DNA	52.8	\N	\N	\N	\N
10868	NA_20847-09_Normal	\N	DNA	71.2	\N	\N	\N	\N
10869	NA_London-L1_Normal	\N	DNA	46	\N	\N	\N	\N
10870	NA_London-L1_Nevus	\N	DNA	68.4	\N	\N	\N	\N
10871	NA_London-L1_MIS	\N	DNA	40	\N	\N	\N	\N
10872	NA_London-L1_Melanoma	\N	DNA	68.4	\N	\N	\N	\N
10873	NA_London-L14_Normal	\N	DNA	40	\N	\N	\N	\N
10874	NA_London-L14_Nevus	\N	DNA	59.6	\N	\N	\N	\N
10875	NA_London-L14_Nevus	\N	DNA	73.6	\N	\N	\N	\N
10876	NA_London-L14_Melanoma	\N	DNA	52.40000000000001	\N	\N	\N	\N
10877	NA_London-L14_Melanoma	\N	DNA	50.4	\N	\N	\N	\N
10878	NA_London-L14_Melanoma	\N	DNA	70.8	\N	\N	\N	\N
10879	NA_London-L14C_Normal	\N	DNA	40	\N	\N	\N	\N
10880	NA_London-L14C_Intermediate	\N	DNA	49.6	\N	\N	\N	\N
10881	NA_08-79358_Melanoma	\N	DNA	70.4	\N	\N	\N	\N
10882	NA_08-79358_Melanoma	\N	DNA	89.59999999999997	\N	\N	\N	\N
10883	NA_08-79358_Nevus	\N	DNA	81.19999999999999	\N	\N	\N	\N
10884	NA_08-79358_Normal	\N	DNA	100.86	\N	\N	\N	\N
10885	NA_09-45509_Melanoma	\N	DNA	100.62	\N	\N	\N	\N
10886	NA_09-45509_Melanoma	\N	DNA	98.5	\N	\N	\N	\N
10887	NA_09-45509_Nevus	\N	DNA	76.8	\N	\N	\N	\N
10888	NA_09-45509_Normal	\N	DNA	47.2	\N	\N	\N	\N
10889	NA_DM50_Tumor	\N	DNA	98.81	\N	\N	\N	\N
10890	NA_DM56_Tumor	\N	DNA	60	\N	\N	\N	\N
10891	NA_11-94204_Melanoma	\N	DNA	98.91	\N	\N	\N	\N
10892	NA_11-94204_Nevus	\N	DNA	76	\N	\N	\N	\N
10893	NA_11-94204_Normal	\N	DNA	41.2	\N	\N	\N	\N
10894	NA_London-L10_Normal	\N	DNA	46.8	\N	\N	\N	\N
10895	NA_London-L10_MIS	\N	DNA	99.62	\N	\N	\N	\N
10896	NA_London-L10_Melanoma	\N	DNA	98.56	\N	\N	\N	\N
10897	NA_London-L10_Intermediate	\N	DNA	40	\N	\N	\N	\N
10898	NA_London-L12_Normal	\N	DNA	100.8	\N	\N	\N	\N
10899	NA_London-L12_Nevus	\N	DNA	98.28	\N	\N	\N	\N
10900	NA_London-L12_Intermediate	\N	DNA	99.28	\N	\N	\N	\N
10901	NA_London-L16_Nevus	\N	DNA	40	\N	\N	\N	\N
10902	NA_London-L16_Melanoma	\N	DNA	99.33	\N	\N	\N	\N
10903	NA_London-L16A_Normal	\N	DNA	71.2	\N	\N	\N	\N
10904	NA_London-L16A_Nevus	\N	DNA	40.4	\N	\N	\N	\N
10905	NA_London-L16A_Melanoma	\N	DNA	100	\N	\N	\N	\N
10906	NA_London-L16B_Intermediate	\N	DNA	97.2	\N	\N	\N	\N
10907	NA_London-L16B_Intermediate	\N	DNA	93.6	\N	\N	\N	\N
10908	NA_London-L16B_Normal	\N	DNA	101.06	\N	\N	\N	\N
10909	NA_DM15_Tumor	\N	DNA	40	\N	\N	\N	\N
10910	NA_DM19_Tumor	\N	DNA	48	\N	\N	\N	\N
10911	NA_DM19_Tumor	\N	DNA	45.60000000000001	\N	\N	\N	\N
10912	NA_DM46_Tumor	\N	DNA	43.6	\N	\N	\N	\N
10913	NA_140038340_Tumor	\N	DNA	100.1	\N	\N	\N	\N
10914	NA_140092090_Normal	\N	DNA	50.4	\N	\N	\N	\N
10915	NA_UM13_Tumor	\N	DNA	50	\N	\N	\N	\N
10916	NA_UM14_Tumor	\N	DNA	62.39999999999999	\N	\N	\N	\N
10917	NA_UM16_Tumor	\N	DNA	48	\N	\N	\N	\N
10918	NA_London-L17_Normal	\N	DNA	42	\N	\N	\N	\N
10919	NA_London-L17_Nevus	\N	DNA	101.32	\N	\N	\N	\N
10920	NA_London-L17_Nevus	\N	DNA	99.82	\N	\N	\N	\N
10921	NA_London-L17_Melanoma	\N	DNA	98.75	\N	\N	\N	\N
10922	NA_London-L17_Melanoma	\N	DNA	98.4	\N	\N	\N	\N
10923	NA_GAK_Tumor	\N	DNA	60.4	\N	\N	\N	\N
10924	NA_Yurif_Tumor	\N	DNA	69.6	\N	\N	\N	\N
10925	NA_08-53951_Nevus	\N	DNA	46.8	\N	\N	\N	\N
10926	NA_08-53951_M1	\N	DNA	40.4	\N	\N	\N	\N
10927	NA_08-53951_M2	\N	DNA	40.8	\N	\N	\N	\N
10928	NA_London-L18_Normal	\N	DNA	43.99999999999999	\N	\N	\N	\N
10929	NA_London-L18_Nevus	\N	DNA	40	\N	\N	\N	\N
10930	NA_London-L18_Melanoma	\N	DNA	65.60000000000001	\N	\N	\N	\N
10931	NA_London-L18_Melanoma	\N	DNA	101.01	\N	\N	\N	\N
10932	NA_London-L21_MIS	\N	DNA	101.36	\N	\N	\N	\N
10933	NA_London-L21_Intermediate	\N	DNA	98.79	\N	\N	\N	\N
10934	NA_London-L21_Normal	\N	DNA	40.4	\N	\N	\N	\N
10935	NA_14-16247_Tumor	\N	DNA	100	\N	\N	CGH14-059 	\N
10936	NA_13-35959_Tumor	\N	DNA	100	\N	\N	\N	\N
10937	NA_13-102610_Tumor	\N	DNA	100	\N	\N	\N	\N
10938	NA_13-99417_Tumor	\N	DNA	100	\N	\N	\N	\N
10939	NA_13-98534_Tumor	\N	DNA	100	\N	\N	\N	\N
10940	NA_13-32982A_Tumor	\N	DNA	100	\N	\N	\N	\N
10941	NA_13-9916_Tumor	\N	DNA	100	\N	\N	\N	\N
10942	NA_11-44609F_Tumor	\N	DNA	100	\N	\N	\N	\N
10943	NA_12-98575A1_Tumor	\N	DNA	100	\N	\N	\N	\N
10944	NA_DM60_Tumor	\N	DNA	49.6	\N	\N	\N	\N
10945	NA_DM61_Tumor	\N	DNA	54	\N	\N	\N	\N
10946	NA_DM62_Tumor	\N	DNA	90	\N	\N	\N	\N
10947	NA_DM63_Tumor	\N	DNA	86.8	\N	\N	\N	\N
10948	NA_DM66_Tumor	\N	DNA	40	\N	\N	\N	\N
10949	NA_DM67_Tumor	\N	DNA	45.2	\N	\N	\N	\N
10950	NA_DM69_Tumor	\N	DNA	60	\N	\N	\N	\N
10951	NA_DM70_Tumor	\N	DNA	100	\N	\N	\N	\N
10952	NA_DM81_Tumor	\N	DNA	100	\N	\N	\N	\N
10953	NA_London-L2_Normal	\N	DNA	85.19999999999999	\N	\N	\N	\N
10954	NA_London-L2_Intermediate	\N	DNA	96.4	\N	\N	\N	\N
10955	NA_London-L3_Normal	\N	DNA	40	\N	\N	\N	\N
10956	NA_London-L3_Intermediate	\N	DNA	70	\N	\N	\N	\N
10957	NA_S12-27617B9_Normal	\N	DNA	100	\N	\N	\N	\N
10958	NA_S12-25164A_Tumor	\N	DNA	100	\N	\N	\N	\N
10959	NA_S12-25164C1_Tumor	\N	DNA	100	\N	\N	\N	\N
10960	NA_London-L19_Normal	\N	DNA	76.8	\N	\N	\N	\N
10961	NA_London-L19_Nevus	\N	DNA	47.59999999999999	\N	\N	\N	\N
10962	NA_London-L19_Melanoma	\N	DNA	100	\N	\N	\N	\N
10963	NA_London-L19E_Normal	\N	DNA	57.59999999999999	\N	\N	\N	\N
10964	NA_London-L19E_Nevus	\N	DNA	94	\N	\N	\N	\N
10965	NA_London-L19E_Melanoma	\N	DNA	100	\N	\N	\N	\N
10966	NA_London-L22_MIS	\N	DNA	68.4	\N	\N	\N	\N
10967	NA_London-L22_Melanoma	\N	DNA	92.4	\N	\N	\N	\N
10968	NA_London-L22_Normal	\N	DNA	89.60000000000001	\N	\N	\N	\N
10969	NA_London-L23_Melanoma	\N	DNA	100	\N	\N	\N	\N
10970	NA_London-L23C_Normal	\N	DNA	68	\N	\N	\N	\N
10971	NA_London-L23C_Melanoma	\N	DNA	100	\N	\N	\N	\N
10972	NA_London-L23D_Normal	\N	DNA	41.6	\N	\N	\N	\N
10973	NA_London-L23D_Intermediate	\N	DNA	47.2	\N	\N	\N	\N
10974	NA_London-L6_Normal	\N	DNA	100	\N	\N	\N	\N
10975	NA_London-L6_Nevus	\N	DNA	100	\N	\N	\N	\N
10976	NA_London-L6_Nevus	\N	DNA	40.4	\N	\N	\N	\N
10977	NA_XD-2_Tumor	\N	DNA	100	\N	\N	\N	\N
10978	NA_XD-2_Normal	\N	DNA	100	\N	\N	\N	\N
10979	NA_SP-13-006364_Normal	\N	DNA	100	\N	\N	\N	\N
10980	NA_SP-14-001249_Tumor	\N	DNA	100	\N	\N	\N	\N
10981	NA_SP-13-0185993A_Normal	\N	DNA	100	\N	\N	\N	\N
10982	NA_SP-13-0185992B_Tumor	\N	DNA	100	\N	\N	\N	\N
10983	NA_SP-12-003309B_Normal	\N	DNA	100	\N	\N	\N	\N
10984	NA_SP-13-0212981A_Tumor	\N	DNA	100	\N	\N	\N	\N
10985	NA_SP-13-0068754A_Normal	\N	DNA	100	\N	\N	\N	\N
10986	NA_SP-13-0068751C_Tumor	\N	DNA	100	\N	\N	\N	\N
10987	NA_SP-07-0116602_Normal	\N	DNA	100	\N	\N	\N	\N
10988	NA_12GS-2466_Tumor	\N	DNA	100	\N	\N	\N	\N
10989	NA_SP-09-0150202A_Normal	\N	DNA	54	\N	\N	\N	\N
10990	NA_SP-13-006535C_Tumor	\N	DNA	100	\N	\N	\N	\N
10991	NA_SP-10-003167A_Normal	\N	DNA	67.6	\N	\N	\N	\N
10992	NA_SP-13-009897_Tumor	\N	DNA	100	\N	\N	\N	\N
10993	NA_SP-12-0087723B_Normal	\N	DNA	100	\N	\N	\N	\N
10994	NA_SP-12-020017C_Tumor	\N	DNA	100	\N	\N	\N	\N
10995	NA_SP-12-0032671A_Normal	\N	DNA	100	\N	\N	\N	\N
10996	NA_SP-13-006337A_Tumor	\N	DNA	100	\N	\N	\N	\N
10997	NA_SP-12-0228802A_Normal	\N	DNA	100	\N	\N	\N	\N
10998	NA_SP-12-0228801A_Tumor	\N	DNA	100	\N	\N	\N	\N
10999	NA_SP-12-0146612A_Normal	\N	DNA	100	\N	\N	\N	\N
11000	NA_SP-12-01466111A_Tumor	\N	DNA	100	\N	\N	\N	\N
11001	NA_SP-10-004335_Normal	\N	DNA	100	\N	\N	\N	\N
11002	NA_SP-13-000848_Tumor	\N	DNA	100	\N	\N	\N	\N
11003	NA_M230_Tumor	\N	DNA	100	\N	\N	\N	\N
11004	NA_M257_Tumor	\N	DNA	100	\N	\N	\N	\N
11005	NA_M285_Tumor	\N	DNA	100	\N	\N	\N	\N
11006	NA_M368_Tumor	\N	DNA	100	\N	\N	\N	\N
11007	NA_M375_Tumor	\N	DNA	100	\N	\N	\N	\N
11008	NA_M418_Tumor	\N	DNA	100	\N	\N	\N	\N
11009	NA_C8161_Tumor	\N	DNA	100	\N	\N	\N	\N
11010	NA_London-L4_Normal	\N	DNA	42.40000000000001	\N	\N	\N	\N
11011	NA_London-L4_Nevus	\N	DNA	53.6	\N	\N	\N	\N
11012	NA_London-L5_Normal	\N	DNA	40.4	\N	\N	\N	\N
11013	NA_London-L5_Nevus	\N	DNA	41.2	\N	\N	\N	\N
11014	NA_London-L8_Normal	\N	DNA	51.6	\N	\N	\N	\N
11015	NA_London-L8_Nevus	\N	DNA	40.4	\N	\N	\N	\N
11016	NA_London-L9_Normal	\N	DNA	40	\N	\N	\N	\N
11017	NA_London-L9_Intermediate	\N	DNA	94.8	\N	\N	\N	\N
11018	NA_London-L13_Normal	\N	DNA	64.80000000000001	\N	\N	\N	\N
11019	NA_London-L13_Intermediate	\N	DNA	64.4	\N	\N	\N	\N
11020	NA_London-L13_Intermediate	\N	DNA	100	\N	\N	\N	\N
11021	NA_London-L15_Nevus	\N	DNA	70.4	\N	\N	\N	\N
11022	NA_London-L15_Melanoma	\N	DNA	100	\N	\N	\N	\N
11023	NA_1212_Tumor	\N	DNA	\N	\N	\N	\N	\N
11024	NA_1213_Tumor	\N	DNA	\N	\N	\N	\N	\N
11025	NA_1214_Tumor	\N	DNA	\N	\N	\N	\N	\N
11026	NA_3860_Tumor	\N	DNA	\N	\N	\N	\N	\N
11027	NA_R29032-05_Tumor	\N	DNA	94.4	\N	\N	\N	\N
11028	NA_01-8297_Tumor	\N	DNA	\N	\N	\N	\N	\N
11029	NA_8298-01_Tumor	\N	DNA	\N	\N	\N	\N	\N
11030	NA_Z1188-03_Tumor	\N	DNA	\N	\N	\N	\N	\N
11031	NA_24516-06_Tumor	\N	DNA	86.4	\N	\N	\N	\N
11032	NA_UM17_Tumor	\N	DNA	101.44	\N	\N	\N	\N
11033	NA_S12-23475A6_Normal	\N	DNA	99.36	\N	\N	\N	\N
11034	NA_S12-23475A4_Tumor	\N	DNA	101.06	\N	\N	\N	\N
11035	NA_S12-23475C1_Tumor	\N	DNA	99	\N	\N	\N	\N
11036	NA_13-21725_Normal	\N	DNA	99.12	\N	\N	\N	\N
11037	NA_SP-14-68521D_Tumor	\N	DNA	97.92	\N	\N	\N	\N
11038	NA_SP-13-208365A_Normal	\N	DNA	98.4	\N	\N	\N	\N
11039	NA_SP-14-36134A_Tumor	\N	DNA	102.27	\N	\N	\N	\N
11040	NA_SP-14-73676A_Normal	\N	DNA	97.2	\N	\N	\N	\N
11041	NA_SP-14-73671M_Tumor	\N	DNA	100.59	\N	\N	\N	\N
11042	NA_SP-14-7691A_Normal	\N	DNA	101.14	\N	\N	\N	\N
11043	NA_SP-14-7691A_Tumor	\N	DNA	102.17	\N	\N	\N	\N
11044	NA_WM3928F_Tumor	\N	DNA	1000	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11045	NA_C037_Tumor	\N	DNA	1000	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11046	NA_C022_Tumor	\N	DNA	1000	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11047	NA_London-L20_Melanoma	\N	DNA	84.39999999999999	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11048	NA_London-L20_Normal	\N	DNA	39.52	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11049	NA_London-L20_Nevus	\N	DNA	17.172	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11050	NA_London-L15_Normal	\N	DNA	12.441	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11051	NA_London-L23C_Nevus	\N	DNA	4.968	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11052	NA_UM15_Tumor	\N	DNA	5.236	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11053	NA_UM19_Tumor	\N	DNA	7.4	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11054	NA_UM20_Tumor	\N	DNA	1000	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11055	NA_CP-1_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11056	NA_CP-2_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11057	NA_CP-3_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11058	NA_CP-4_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11059	NA_CP-5_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11060	NA_CP-6_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11061	NA_14-18_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11062	NA_14-19_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11063	NA_14-21_Tumor	\N	DNA	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	\N
11064	NA_XD-1_Tumor	\N	DNA	250	\N	\N	\N	\N
11065	NA_XD-1.1_Tumor	\N	DNA	250	\N	\N	\N	\N
11066	NA_PMM-8_Tumor	\N	DNA	\N	\N	\N	\N	\N
11067	NA_Long-TN10_Normal	\N	DNA	250	\N	\N	\N	\N
11068	NA_Long-TN10_Tumor	\N	DNA	250	\N	\N	\N	\N
11069	NA_Long-TN11_Normal	\N	DNA	39.4	\N	\N	\N	\N
11070	NA_Long-TN11_Tumor	\N	DNA	250	\N	\N	\N	\N
11071	NA_JBP-3_Normal	\N	DNA	63	\N	\N	\N	\N
11072	NA_JBP-3-MM_Tumor	\N	DNA	250	\N	\N	\N	\N
11073	NA_JBP-3-Met1_Tumor	\N	DNA	250	\N	\N	\N	\N
11074	NA_S12-15765B3_Tumor	\N	DNA	250	\N	\N	\N	\N
11075	NA_S12-4365A8_Normal	\N	DNA	241.5	\N	\N	\N	\N
11076	NA_S12-4365A7_Tumor	\N	DNA	85.5	\N	\N	\N	\N
11077	NA_S12-4365B1_Tumor	\N	DNA	250	\N	\N	\N	\N
11078	NA_S12-4365C1_Tumor	\N	DNA	250	\N	\N	\N	\N
11079	NA_S12-9606C4_Normal	\N	DNA	250	\N	\N	\N	\N
11080	NA_S12-9606EE_Tumor	\N	DNA	250	\N	\N	\N	\N
11081	NA_S12-9606A2_Tumor	\N	DNA	250	\N	\N	\N	\N
11082	NA_ZS10-972C2_Normal	\N	DNA	250	\N	\N	\N	\N
11083	NA_ZS10-972A9_Tumor	\N	DNA	250	\N	\N	\N	\N
11084	NA_JBP-7-Met_Tumor	\N	DNA	250	\N	\N	\N	\N
11085	NA_ZS10-1843A5_Normal	\N	DNA	250	\N	\N	\N	\N
11086	NA_ZS10-8439A4_Tumor	\N	DNA	89.3	\N	\N	\N	\N
11087	NA_ZS10-1843A4_Tumor	\N	DNA	250	\N	\N	\N	\N
11088	NA_ZS10-10558B1_Normal	\N	DNA	250	\N	\N	\N	\N
11089	NA_ZS10-10558A10_Tumor	\N	DNA	250	\N	\N	\N	\N
11090	NA_ZS10-10558C1_Tumor	\N	DNA	250	\N	\N	\N	\N
11091	NA_ZS10-3560F1_Normal	\N	DNA	250	\N	\N	\N	\N
11092	NA_ZS10-3560A3_Tumor	\N	DNA	250	\N	\N	\N	\N
11093	NA_ZS10-3560C1_Tumor	\N	DNA	250	\N	\N	\N	\N
11094	NA_UM23_Tumor	\N	DNA	250	\N	\N	\N	\N
11095	NA_UM24_Tumor	\N	DNA	13.536	\N	\N	\N	\N
11096	NA_UM25_Tumor	\N	DNA	31.396	\N	\N	\N	\N
11097	NA_UM26_Tumor	\N	DNA	2.35	\N	\N	\N	\N
11098	NA_TCR-Beta-1_Tumor	\N	DNA	250	\N	\N	\N	\N
11099	NA_TCR-Beta-2_Tumor	\N	DNA	250	\N	\N	\N	\N
11100	NA_CP1-80_Tumor	\N	DNA	250	\N	\N	\N	\N
11101	NA_CP1-40_Tumor	\N	DNA	250	\N	\N	\N	\N
11102	NA_CP1-20_Tumor	\N	DNA	250	\N	\N	\N	\N
11103	NA_CP1-10_Tumor	\N	DNA	250	\N	\N	\N	\N
11104	NA_CP1-5_Tumor	\N	DNA	250	\N	\N	\N	\N
11105	NA_CP1_Normal	\N	DNA	250	\N	\N	\N	\N
11106	NA_SMU10-0457_Tumor	\N	DNA	\N	\N	\N	\N	\N
11107	NA_SMU10-0206_Tumor	\N	DNA	\N	\N	\N	\N	\N
11108	NA_SMU10-0240_Tumor	\N	DNA	\N	\N	\N	\N	\N
11109	NA_SCC10-0092_Tumor	\N	DNA	\N	\N	\N	\N	\N
11110	NA_MASCRI-432_Tumor	\N	DNA	\N	\N	\N	\N	\N
11111	NA_RPA08-0209_Tumor	\N	DNA	\N	\N	\N	\N	\N
11112	NA_RPA08-0315_Tumor	\N	DNA	\N	\N	\N	\N	\N
11113	NA_NZM52_Tumor	\N	DNA	\N	\N	\N	\N	\N
11114	NA_NZM40_Tumor	\N	DNA	\N	\N	\N	\N	\N
11115	NA_NZM91_Tumor	\N	DNA	\N	\N	\N	\N	\N
11116	NA_SP-13-198211A_Tumor	\N	DNA	\N	\N	\N	DH	\N
11117	NA_RNS11P15316B1_Normal	\N	DNA	\N	\N	\N	DH	\N
11118	NA_9246581-A3_Tumor	\N	DNA	\N	\N	\N	JG	\N
11119	NA_9246581-A6_Normal	\N	DNA	\N	\N	\N	JG	\N
11120	NA_DHM4855-14MP_Tumor	\N	DNA	\N	\N	\N	MLH	\N
11121	NA_SNPN08289D_Normal	\N	DNA	\N	\N	\N	MLH	\N
11122	NA_SP-10-143551E_Tumor	\N	DNA	\N	\N	\N	JM	\N
11123	NA_SP-10-143552A_Normal	\N	DNA	\N	\N	\N	JM	\N
11124	NA_04-SW-12-31366B1_Tumor	\N	DNA	\N	\N	\N	AH	\N
11125	NA_04-SW-12-31366B6_Normal	\N	DNA	\N	\N	\N	AH	\N
11126	NA_SP-13-63011A_Tumor	\N	DNA	\N	\N	\N	FN	\N
11127	NA_SP-11-160493A_Normal	\N	DNA	\N	\N	\N	FN	\N
11128	NA_SP-13-87981B_Tumor	\N	DNA	\N	\N	\N	GJ	\N
11129	NA_SP-11-40641B_Normal	\N	DNA	\N	\N	\N	GJ	\N
11130	NA_SP-14-125801B_Tumor	\N	DNA	\N	\N	\N	CG	\N
11131	NA_SP-14-125802A_Normal	\N	DNA	\N	\N	\N	CG	\N
11132	NA_WCRS97-025628_Tumor	\N	DNA	184.5	\N	\N	17	\N
11133	NA_SCHS10-026422_Tumor	\N	DNA	190.35	\N	\N	41	\N
11134	NA_SROS12-001198_Tumor	\N	DNA	250	\N	\N	90	\N
11135	NA_SROS09-001574_Tumor	\N	DNA	250	\N	\N	92	\N
11136	NA_SCHS09-005840-B5_Tumor	\N	DNA	250	\N	\N	93	\N
11137	NA_SACS05-011507_Tumor	\N	DNA	250	\N	\N	99	\N
11138	NA_FRSS09-009402-A1_Tumor	\N	DNA	250	\N	\N	105	\N
11139	NA_RCHS07-000380-B1_Tumor	\N	DNA	250	\N	\N	28	\N
11140	NA_SROS11-005030_Tumor	\N	DNA	250	\N	\N	30	\N
11141	NA_VALS09-000266_Tumor	\N	DNA	250	\N	\N	72	\N
11142	NA_SFOS09-007093_Tumor	\N	DNA	250	\N	\N	18	\N
11143	NA_FRSS09-008805_Tumor	\N	DNA	250	\N	\N	63	\N
11144	NA_RCHS06-004567_Tumor	\N	DNA	250	\N	\N	70	\N
11145	NA_VALS05-014946-E_Tumor	\N	DNA	250	\N	\N	54	\N
11146	NA_SCHS08-007754_Tumor	\N	DNA	250	\N	\N	2	\N
11147	NA_SFOS12-018173_Tumor	\N	DNA	250	\N	\N	5	\N
11148	NA_SROS00-001103_Tumor	\N	DNA	250	\N	\N	10	\N
11149	NA_MTZS94-007340_Tumor	\N	DNA	250	\N	\N	45	\N
11150	NA_SFOS94-003116_Tumor	\N	DNA	250	\N	\N	49	\N
11151	NA_SACS93-027850_Tumor	\N	DNA	250	\N	\N	27	\N
11152	NA_SCLS91-006557_Tumor	\N	DNA	250	\N	\N	68	\N
11153	NA_OAKS90-012369_Tumor	\N	DNA	250	\N	\N	9	\N
11154	NA_HAYS02-005731_Tumor	\N	DNA	250	\N	\N	98	\N
11155	NA_SRFS97-002805_Tumor	\N	DNA	250	\N	\N	67	\N
11156	NA_VALS03-019832_Tumor	\N	DNA	250	\N	\N	124	\N
11157	NA_SSCS03-014369_Tumor	\N	DNA	250	\N	\N	58	\N
11158	NA_RCHS01-003684_Tumor	\N	DNA	250	\N	\N	86	\N
11159	NA_WCRS99-012800_Tumor	\N	DNA	250	\N	\N	111	\N
11160	NA_HAYS90-005154_Tumor	\N	DNA	250	\N	\N	77	\N
11161	NA_SFOS00-016989_Tumor	\N	DNA	250	\N	\N	69	\N
11162	NA_VALS03-007457_Tumor	\N	DNA	250	\N	\N	117	\N
11163	NA_SFO93-005184_Tumor	\N	DNA	250	\N	\N	103	\N
11164	NA_DHM50691-14MP5C_Tumor	\N	DNA	250	\N	\N	\N	\N
11165	NA_DHM50691-14MP3_Normal	\N	DNA	250	\N	\N	\N	\N
11166	NA_RNS14P13907B1_Tumor	\N	DNA	250	\N	\N	\N	\N
11167	NA_SP-10-197431A_Normal	\N	DNA	122.8	\N	\N	\N	\N
11168	NA_DHM57444-14MP_Tumor	\N	DNA	250	\N	\N	\N	\N
11169	NA_SP-12-177322A_Normal	\N	DNA	250	\N	\N	\N	\N
11170	NA_DHM94457-13SK_Tumor	\N	DNA	250	\N	\N	\N	\N
11171	NA_DHM48742-12MPE_Normal	\N	DNA	250	\N	\N	\N	\N
11172	NA_Laverty13-88354_Tumor	\N	DNA	250	\N	\N	\N	\N
11173	NA_ICPMR19684.13A11_Normal	\N	DNA	250	\N	\N	\N	\N
11174	NA_SP-13-15691B_Tumor	\N	DNA	250	\N	\N	\N	\N
11175	NA_SP-13-15691D_Normal	\N	DNA	250	\N	\N	\N	\N
11176	NA_57059699_Tumor	\N	DNA	250	\N	\N	\N	\N
11177	NA_57269600_Tumor	\N	DNA	250	\N	\N	\N	\N
11178	NA_57213442_Tumor	\N	DNA	174.8	\N	\N	\N	\N
11179	NA_57346060_Tumor	\N	DNA	250	\N	\N	\N	\N
11180	NA_SROS10-009251_Tumor	\N	DNA	110	\N	\N	19	\N
11181	NA_FRSS99-007026_Tumor	\N	DNA	100	\N	\N	32	\N
11182	NA_SCLS04-001045_Tumor	\N	DNA	84.80000000000001	\N	\N	60	\N
11183	NA_OAKS96-014392-G_Tumor	\N	DNA	108	\N	\N	74	\N
11184	NA_OAKS96-022398_Tumor	\N	DNA	80.39999999999999	\N	\N	109	\N
11185	NA_OAK84-008979-B_Tumor	\N	DNA	100.4	\N	\N	112	\N
11186	NA_ROSS09-022626-A1_Tumor	\N	DNA	105.2	\N	\N	115	\N
11187	NA_SCHS11-018842-A1_Tumor	\N	DNA	101.6	\N	\N	119	\N
11188	NA_SSCS03-004945_Tumor	\N	DNA	\N	\N	\N	46	\N
11189	NA_WCRS02-022688_Tumor	\N	DNA	\N	\N	\N	47	\N
11190	NA_SACS02-020334_Tumor	\N	DNA	\N	\N	\N	100	\N
11191	NA_HAYS98-001046_Tumor	\N	DNA	\N	\N	\N	75	\N
11192	NA_SACS88-019073_Tumor	\N	DNA	\N	\N	\N	64	\N
11193	NA_SACS87-010145_Tumor	\N	DNA	\N	\N	\N	50	\N
11194	NA_STRS91-006237_Tumor	\N	DNA	\N	\N	\N	39	\N
11195	NA_SSCS92-009981_Tumor	\N	DNA	\N	\N	\N	22	\N
11196	NA_14-59304A_Normal	\N	DNA	44.325	\N	\N	\N	\N
11197	NA_14-59304A_Nevus	\N	DNA	102.15	\N	\N	\N	\N
11198	NA_13-48020_Normal	\N	DNA	32.04	\N	\N	\N	\N
11199	NA_13-48020_Nevus	\N	DNA	110.4	\N	\N	\N	\N
11200	NA_14-13499_Normal	\N	DNA	31.59	\N	\N	\N	\N
11201	NA_14-13499_Nevus	\N	DNA	110.7	\N	\N	\N	\N
11202	NA_13-64515B_Normal	\N	DNA	66.15	\N	\N	\N	\N
11203	NA_13-64515B_Nevus	\N	DNA	16.875	\N	\N	\N	\N
11204	NA_13-64515B_Tumor	\N	DNA	40.095	\N	\N	\N	\N
11205	NA_14-22939_Nevus	\N	DNA	37.62	\N	\N	\N	\N
11206	NA_14-22939_Tumor	\N	DNA	13.59	\N	\N	\N	\N
11207	NA_13-61146_Normal	\N	DNA	23.895	\N	\N	\N	\N
11208	NA_13-61146_Nevus	\N	DNA	105.25	\N	\N	\N	\N
11209	NA_13-61146_Tumor	\N	DNA	118.35	\N	\N	\N	\N
11210	NA_57001550_Tumor	\N	DNA	15.525	\N	\N	\N	\N
11211	NA_57291680_Tumor	\N	DNA	17.1	\N	\N	\N	\N
11212	NA_London-L3_Tumor	\N	DNA	\N	\N	\N	\N	\N
11213	NA_London-L13_Tumor	\N	DNA	\N	\N	\N	\N	\N
11214	NA_London-L3_Tumor	\N	DNA	\N	\N	\N	\N	\N
11215	NA_London-L3_Tumor	\N	DNA	\N	\N	\N	\N	\N
11216	NA_London-L3_Tumor	\N	DNA	\N	\N	\N	\N	\N
11217	NA_London-L3_Tumor	\N	DNA	\N	\N	\N	\N	\N
11218	NA_London-L13_Tumor	\N	DNA	\N	\N	\N	\N	\N
11219	NA_London-L13_Tumor	\N	DNA	\N	\N	\N	\N	\N
11220	NA_UM33_Tumor	\N	DNA	\N	\N	\N	\N	\N
11221	NA_UM35_A_Tumor	\N	DNA	\N	\N	\N	\N	\N
11222	NA_UM39_Tumor	\N	DNA	\N	\N	\N	\N	\N
11223	NA_UM40_Tumor	\N	DNA	\N	\N	\N	\N	\N
11224	NA_UM41_Tumor	\N	DNA	\N	\N	\N	\N	\N
11225	NA_UM36_Tumor	\N	DNA	\N	\N	\N	\N	\N
11226	NA_UM37_Tumor	\N	DNA	\N	\N	\N	\N	\N
11227	NA_London-L13_Tumor	\N	DNA	\N	\N	\N	\N	\N
11228	NA_57715138_Tumor	\N	DNA	742.5	\N	\N	\N	\N
11229	NA_57715138_Tumor	\N	DNA	418.05	\N	\N	\N	\N
11230	NA_332771_Tumor	\N	DNA	688.5	\N	\N	\N	\N
11231	NA_57723220_Tumor	\N	DNA	2.79	\N	\N	\N	\N
11232	NA_55875588_Tumor	\N	DNA	3.15	\N	\N	\N	\N
11233	NA_57714581_Tumor	\N	DNA	7.92	\N	\N	\N	\N
11234	NA_UM47_Tumor	\N	DNA	1.11	\N	\N	\N	\N
11235	NA_UM47_Normal	\N	DNA	59	\N	\N	\N	\N
11236	NA_Sample_KAM1-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
11237	NA_Sample_KAM106-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
11238	NA_Sample_KAM12-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
11239	NA_Sample_KAM121-T-B_Tumor	\N	DNA	\N	\N	\N	\N	\N
11240	NA_Sample_KAM20-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
11241	NA_Sample_KAM3-T-A_Tumor	\N	DNA	\N	\N	\N	\N	\N
11242	NA_Sample_KAM35-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
11243	NA_Sample_KAM38-T-B_Tumor	\N	DNA	\N	\N	\N	\N	\N
11244	NA_Sample_KAM53-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
11245	NA_Sample_KAM61-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
11246	NA_Sample_KAM7-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
11247	NA_Sample_KAM78-T-III_Tumor	\N	DNA	\N	\N	\N	\N	\N
11248	NA_Sample_KAM82-T-B8_Tumor	\N	DNA	\N	\N	\N	\N	\N
11249	NA_Sample_KAM84-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
11250	NA_Sample_KAM94-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
11251	NA_Sample_KAM96-T_Tumor	\N	DNA	\N	\N	\N	\N	\N
\.


--
-- Data for Name: patients; Type: TABLE DATA; Schema: public; Owner: borisbastian
--

COPY public.patients (pat_id, sex, dob, race, source, blocks_temp, notes, pa_id, date_added, pat_ip_id) FROM stdin;
AM2-127	\N	\N	Unknown	UCSF	\N	\N	97	\N	\N
SYNAT1	\N	\N	\N	\N	00-001103, 00-001103B7	\N	1767	\N	\N
SYNAT58	\N	\N	\N	\N	10-1843A4, 10-1843A5	\N	2129	\N	IP896413
SYNAT60	\N	\N	\N	\N	10-4769A	\N	2046	\N	IP852443
SYNAT61	\N	\N	\N	\N	10-006275	\N	1851	\N	\N
SYNAT112	\N	\N	\N	\N	14-53894B	\N	2137	\N	IP1403832
SYNAT2	\N	\N	\N	\N	01-003845	\N	1761	\N	\N
SYNAT115	\N	\N	\N	\N	14-58586	\N	2193	\N	IP1408527
SYNAT116	\N	\N	\N	\N	14-58667	\N	2095	\N	IP1304478
SYNAT117	\N	\N	\N	\N	14-59332	\N	1847	\N	IP988413
SYNAT118	\N	\N	\N	\N	14-59956	\N	2339	\N	IP1409897
SYNAT119	\N	\N	\N	\N	14-61297	\N	2331	\N	IP1411239
SYNAT120	\N	\N	\N	\N	14-61299	\N	2251	\N	IP1411241
SYNAT121	\N	\N	\N	\N	14-61835	\N	1798	\N	IP1411777
SYNAT127	\N	\N	\N	\N	14-88685	\N	1870	\N	\N
SYNAT128	\N	\N	\N	\N	14-94217A	\N	2127	\N	IP1444208
SYNAT3	\N	\N	\N	\N	02-000540	\N	1771	\N	\N
SYNAT4	\N	\N	\N	\N	02-5203B2, 02-5203G2	\N	2341	\N	\N
SYNAT179	\N	\N	\N	\N	23-97273	\N	2148	\N	IP2626851
SYNAT180	\N	\N	\N	\N	23-107334C2	\N	2090	\N	IP2626851
SYNAT182	\N	\N	\N	\N	91-017419	\N	2050	\N	\N
SYNAT183	\N	\N	\N	\N	96-6536	\N	2056	\N	IP77652
SYNAT228	\N	\N	\N	\N	Cell-Line_Xu-22	\N	2126	\N	\N
SYNAT229	\N	\N	\N	\N	Cell-Line_Xu-23	\N	1664	\N	\N
SYNAT230	\N	\N	\N	\N	Cell-Line_Xu-24	\N	2326	\N	\N
SYNAT231	\N	\N	\N	\N	Cell-Line_Xu-25	\N	2140	\N	\N
SYNAT232	\N	\N	\N	\N	Cell-Line_Xu-26	\N	2336	\N	\N
SYNAT233	\N	\N	\N	\N	Cell-Line_Xu-27	\N	1885	\N	\N
SYNAT234	\N	\N	\N	\N	Cell-Line_Xu-28	\N	1934	\N	\N
SYNAT235	\N	\N	\N	\N	Cell-Line_Xu-29	\N	1948	\N	\N
SYNAT236	\N	\N	\N	\N	Cell-Line_Xu-30	\N	1857	\N	\N
SYNAT237	\N	\N	\N	\N	Cell-Line_Xu-31	\N	2189	\N	\N
SYNAT238	\N	\N	\N	\N	Cell-Line_Xu-32	\N	2012	\N	\N
SYNAT239	\N	\N	\N	\N	Cell-Line_Xu-33	\N	1936	\N	\N
SYNAT240	\N	\N	\N	\N	Cell-Line_Xu-34	\N	1797	\N	\N
SYNAT6	\N	\N	\N	\N	02-008514	\N	2217	\N	\N
SYNAT7	\N	\N	\N	\N	02-012396A	\N	1884	\N	\N
SYNAT8	\N	\N	\N	\N	02-020334-11	\N	2161	\N	\N
SYNAT241	\N	\N	\N	\N	Cell-Line_Xu-35	\N	1893	\N	\N
SYNAT242	\N	\N	\N	\N	Cell-Line_Xu-36	\N	2333	\N	\N
SYNAT243	\N	\N	\N	\N	Cell-Line_Xu-37	\N	2216	\N	\N
SYNAT244	\N	\N	\N	\N	Cell-Line_Xu-38	\N	2315	\N	\N
SYNAT245	\N	\N	\N	\N	Cell-Line_Xu-39	\N	2027	\N	\N
SYNAT246	\N	\N	\N	\N	Cell-Line_Xu-40	\N	2303	\N	\N
SYNAT247	\N	\N	\N	\N	Cell-Line_Xu-41	\N	2053	\N	\N
SYNAT248	\N	\N	\N	\N	Cell-Line_Xu-42	\N	1958	\N	\N
SYNAT249	\N	\N	\N	\N	Cell-Line_Xu-43	\N	2194	\N	\N
SYNAT250	\N	\N	\N	\N	Cell-Line_Xu-44	\N	1722	\N	\N
SYNAT251	\N	\N	\N	\N	Cell-Line_Xu-45	\N	2128	\N	\N
SYNAT252	\N	\N	\N	\N	Cell-Line_Xu-46	\N	2163	\N	\N
SYNAT253	\N	\N	\N	\N	Cell-Line_Xu-47	\N	1849	\N	\N
SYNAT254	\N	\N	\N	\N	Cell-Line_Xu-48	\N	1710	\N	\N
SYNAT255	\N	\N	\N	\N	Cell-Line_Xu-49	\N	2240	\N	\N
SYNAT256	\N	\N	\N	\N	Cell-Line_Xu-50	\N	1814	\N	\N
SYNAT257	\N	\N	\N	\N	Cell-Line_Xu-51	\N	1765	\N	\N
SYNAT258	\N	\N	\N	\N	Cell-Line_Xu-52	\N	1965	\N	\N
SYNAT259	\N	\N	\N	\N	Cell-Line_Xu-53	\N	2118	\N	\N
SYNAT260	\N	\N	\N	\N	Cell-Line_Xu-54	\N	2073	\N	\N
SYNAT261	\N	\N	\N	\N	Cell-Line_Xu-55	\N	1900	\N	\N
SYNAT262	\N	\N	\N	\N	Cell-Line_Xu-56	\N	1779	\N	\N
SYNAT263	\N	\N	\N	\N	Cell-Line_Xu-57	\N	2022	\N	\N
SYNAT264	\N	\N	\N	\N	Cell-Line_Xu-58	\N	2178	\N	\N
SYNAT265	\N	\N	\N	\N	Cell-Line_Xu-59	\N	2009	\N	\N
SYNAT266	\N	\N	\N	\N	Cell-Line_Xu-60	\N	2172	\N	\N
SYNAT267	\N	\N	\N	\N	Cell-Line_Xu-61	\N	1770	\N	\N
SYNAT268	\N	\N	\N	\N	Cell-Line_Xu-62	\N	1850	\N	\N
SYNAT269	\N	\N	\N	\N	Cell-Line_Xu-63	\N	1824	\N	\N
SYNAT270	\N	\N	\N	\N	Cell-Line_Xu-64	\N	2350	\N	\N
SYNAT271	\N	\N	\N	\N	CGH12-067	\N	2025	\N	IP963226
SYNAT272	\N	\N	\N	\N	CGH12-146	\N	1970	\N	IP1121579
SYNAT9	\N	\N	\N	\N	02-20629	\N	1931	\N	IP325354
SYNAT10	\N	\N	\N	\N	02-23636A-02	\N	1865	\N	\N
SYNAT11	\N	\N	\N	\N	02-33818A-03	\N	1714	\N	\N
SYNAT12	\N	\N	\N	\N	03-197B2	\N	2026	\N	IP358509
SYNAT13	\N	\N	\N	\N	03-1978B3	\N	2239	\N	\N
SYNAT274	\N	\N	\N	\N	CGH13-010	\N	1878	\N	IP300725
SYNAT275	\N	\N	\N	\N	CGH13-014	\N	2231	\N	IP1185530
SYNAT14	\N	\N	\N	\N	03-007239	\N	1942	\N	\N
SYNAT276	\N	\N	\N	\N	CGH13-026	\N	2156	\N	IP1185221
SYNAT277	\N	\N	\N	\N	CGH13-034	\N	2002	\N	IP1188475
SYNAT278	\N	\N	\N	\N	DM8	\N	2244	\N	\N
SYNAT279	\N	\N	\N	\N	CGH13-094	\N	2328	\N	IP1202986
SYNAT280	\N	\N	\N	\N	CGH14-050	\N	1883	\N	IP1365348
SYNAT281	\N	\N	\N	\N	CGH14-147	\N	1921	\N	IP1393739
SYNAT282	\N	\N	\N	\N	CGH15-249	\N	1793	\N	IP1573327
SYNAT283	\N	\N	\N	\N	CGH19-097	\N	1941	\N	IP2049186
SYNAT313	\N	\N	\N	\N	HW4-Tumor	\N	2144	\N	\N
SYNAT314	\N	\N	\N	\N	HW6-NormalDissect	\N	2252	\N	\N
SYNAT315	\N	\N	\N	\N	HW6-TumorDissect	\N	1831	\N	\N
SYNAT316	\N	\N	\N	\N	HW8- Normal Curls	\N	1784	\N	\N
SYNAT317	\N	\N	\N	\N	HW8- Tumor Curls	\N	1662	\N	\N
SYNAT318	\N	\N	\N	\N	HW9- Normal gDNA from Blood (129920)	\N	2089	\N	\N
SYNAT319	\N	\N	\N	\N	HW9- Tumor Curls	\N	1991	\N	\N
ME-09	M	\N	Unknown	UCSF	16-110683	\N	1104	\N	IP1710779
SYNAT16	\N	\N	\N	\N	04-003736A	\N	2230	\N	\N
SYNAT17	\N	\N	\N	\N	04-9498	\N	2181	\N	IP425897
SYNAT18	\N	\N	\N	\N	06-6624A7, 06-6624D1	\N	2158	\N	\N
SYNAT18	\N	\N	\N	\N	06-6624A7, 06-6624D1	\N	2300	\N	IP227601
ME-06	M	\N	Unknown	UCSF	17-95052A,17-88262, 17-95052A, 17-88262	\N	1101	\N	IP1818404
ME-20	M	\N	Unknown	UCSF	17-61310	\N	1115	\N	IP1791101
ME-04	F	\N	Unknown	UCSF	16-106975	\N	1099	\N	IP822002
ME-08	M	\N	Unknown	UCSF	16-88453A	\N	1103	\N	IP1688270
ME-12	M	\N	Unknown	UCSF	17-33401C	\N	1107	\N	IP1762801
ME-21	M	\N	Unknown	UCSF	17-56506	\N	1116	\N	IP1786249
SYNAT19	\N	\N	\N	\N	04-37400	\N	1733	\N	IP453803
SYNAT5	\N	\N	\N	\N	08-65412A, 08-65412B	\N	2111	\N	IP504172
ME-16	M	\N	Unknown	UCSF	17-83378D,17-83378C,17-83378B, 17-83378D, 17-83378C, 17-83378B	\N	1111	\N	IP1813443
SYNAT20	\N	\N	\N	\N	09-1121	\N	2312	\N	\N
SYNAT21	\N	\N	\N	\N	09-005840	\N	2299	\N	\N
ME-13	F	\N	Unknown	UCSF	17-130286	\N	1108	\N	IP1860925
ME-22	M	\N	Unknown	UCSF	17-43703	\N	1117	\N	IP1773263
SYNAT22	\N	\N	\N	\N	05-006815	\N	1819	\N	\N
SYNAT23	\N	\N	\N	\N	05-7439A12	\N	1684	\N	IP484151
SYNAT24	\N	\N	\N	\N	05-011507	\N	1960	\N	\N
SYNAT25	\N	\N	\N	\N	05-015408	\N	1777	\N	\N
ME-17	M	\N	Unknown	UCSF	16-101803B	\N	1112	\N	IP1701781
MD-30	\N	\N	Unknown	Madrid, Spain	12-12352 T3	\N	936	\N	\N
ME-30	F	\N	Unknown	UCSF	19-4879	\N	1125	\N	IP935967
NM-33	\N	\N	Unknown	Greece	4136/16	\N	1211	\N	\N
ME-37	M	\N	Unknown	UCSF	22-17043	\N	1132	\N	IP1179175
SYNAT15	\N	\N	\N	\N	05-29484F, 05-29484E, 05-29484A, 05-29484B, 05-29484C, 05-29484D	\N	1713	\N	IP504172
SYNAT26	\N	\N	\N	\N	05-41924	\N	2184	\N	\N
MD-31	\N	\N	Unknown	Madrid, Spain	13-24372B CONSULTA,13-24372B T1,13-24372A T1, 13-24372B CONSULTA, 13-24372B T1, 13-24372A T1	\N	937	\N	\N
ME-24	M	\N	Unknown	UCSF	17-13334,17-27224, 17-13334, 17-27224	\N	1119	\N	IP1732209
MucM-05	\N	\N	Unknown	UCSF	13-17186A21,13-17186A16,13-17186A14,13-17186A20, 13-17186A21, 13-17186A16, 13-17186A14, 13-17186A20	\N	1173	\N	\N
ME-38	F	\N	Unknown	UCSF	18-97419C	\N	1133	\N	IP1934546
ME-40	M	\N	Unknown	UCSF	17-100072A	\N	1135	\N	IP1830366
ME-41	M	\N	Unknown	UCSF	17-23681	\N	1136	\N	IP802036
ME-28	M	\N	Unknown	UCSF	17-43712,17-62026B, 17-43712, 17-62026B	\N	1123	\N	IP741233
ME-42	M	\N	Unknown	UCSF	16-109052C	\N	1137	\N	IP1709134
ME-43	M	\N	Unknown	UCSF	17-38404A2	\N	1138	\N	IP1767896
ME-23	F	\N	Unknown	UCSF	17-32863B	\N	1118	\N	IP1762252
LN-024	M	\N	Unknown	UCSF	17-111571	\N	844	\N	IP1767762
ME-46	M	\N	Unknown	UCSF	17-89239A	\N	1141	\N	IP850037
SYNAT28	\N	\N	\N	\N	06-018998	\N	2078	\N	\N
ME-55	M	\N	Unknown	UCSF	20-53075B	\N	1150	\N	IP1769161
ME-57	M	\N	Unknown	UCSF	21-118604	\N	1152	\N	IP2381778
ME-58	M	\N	Unknown	UCSF	21-131828	\N	1153	\N	IP2395063
SYNAT29	\N	\N	\N	\N	07-011660-2	\N	1782	\N	\N
SYNAT30	\N	\N	\N	\N	07-012236B1	\N	2191	\N	\N
SYNAT31	\N	\N	\N	\N	12-004374B	\N	1815	\N	IP222047
ME-25	F	\N	Unknown	UCSF	17-31440	\N	1120	\N	IP266136
SYNAT32	\N	\N	\N	\N	06-47079A02	\N	2155	\N	IP586773
ME-26	F	\N	Unknown	UCSF	17-36409	\N	1121	\N	IP1765868
ME-44	M	\N	Unknown	UCSF	17-68780A,17-68780B,17-68780C, 17-68780A, 17-68780B, 17-68780C	EXCLUDE CASE	1139	\N	IP543552
SYNAT33	\N	\N	\N	\N	07-13061	\N	2293	\N	IP504172
MD-32	\N	\N	Unknown	Madrid, Spain	13-26846A1 N1,13-26846 T4, 13-26846A1 N1, 13-26846 T4	\N	938	\N	\N
ME-49	M	\N	Unknown	UCSF	18-139329	\N	1144	\N	IP2003493
NM-49	\N	\N	Unknown	Greece	B236709/ 1B	\N	1226	\N	\N
NM-50	\N	\N	Unknown	Greece	B206739	\N	1227	\N	\N
NM-51	\N	\N	Unknown	Greece	B215962	\N	1228	\N	\N
NM-52	\N	\N	Unknown	Greece	B167003/1B  I	\N	1229	\N	\N
NM-53	\N	\N	Unknown	Greece	351/10 2 (HBD)	\N	1230	\N	\N
NM-54	\N	\N	Unknown	Greece	351/10 4 (HBD)	\N	1231	\N	\N
NM-55	\N	\N	Unknown	Greece	467/10  1	\N	1232	\N	\N
NM-58	\N	\N	Unknown	Greece	N-ID 2225	\N	1233	\N	\N
NM-60	\N	\N	Unknown	Greece	3188/18	\N	1235	\N	\N
NM-65	\N	\N	Unknown	Greece	17-1741I	\N	1239	\N	\N
SYNAT34	\N	\N	\N	\N	07-1210F6	\N	1699	\N	IP614870
ME-27	M	\N	Unknown	UCSF	17-61108	\N	1122	\N	IP983876
OM-04	F	\N	Unknown	UCSF	13-68674	RIGHT LABIA MINORA	1265	\N	IP475265
OM-05	M	\N	Unknown	UCSF	13-107061	LEFT INFERIOR VERMILLION LIP	1266	\N	IP1349079
SYNAT35	\N	\N	\N	\N	07-20501	\N	1930	\N	\N
DN-089	M	\N	Unknown	\N	18-96989	\N	564	\N	IP1960988
OM-06	F	\N	Unknown	UCSF	15-1495	LEFT LABIA MAJORA	1267	\N	IP1472484
OM-07	F	\N	Unknown	UCSF	18-103965B	LEFT LOWER LIP	1268	\N	IP1386790
OM-08	M	\N	Unknown	UCSF	18-91716	GLANS PENIS	1269	\N	IP1955698
OM-12	F	\N	Unknown	Mexico	19-126110	\N	1273	\N	IP1847018
SYNAT36	\N	\N	\N	\N	07-41091A, 07-41091B	\N	1769	\N	IP659911
SYNAT37	\N	\N	\N	\N	08-1463A2	\N	1837	\N	IP475429
ME-29	M	\N	Unknown	UCSF	17-125030	\N	1124	\N	IP1855625
ME-31	M	\N	Unknown	UCSF	19-2118	\N	1126	\N	IP2001940
ME-35	M	\N	Unknown	UCSF	19-2710	\N	1130	\N	IP2006742
ME-61	F	\N	Unknown	UCSF	21-1134A,21-44171, 21-1134A, 21-44171	\N	1156	\N	IP426984
SYNAT38	\N	\N	\N	\N	08-4205A	\N	1939	\N	IP700910
SYNAT39	\N	\N	\N	\N	08-4544A03	\N	1967	\N	IP424543
SYNAT40	\N	\N	\N	\N	08-018003	\N	1763	\N	\N
SYNAT41	\N	\N	\N	\N	08-21965C	\N	1899	\N	IP730606
ME-36	M	\N	Unknown	UCSF	17-88895	\N	1131	\N	IP979333
MD-39	\N	\N	Unknown	Madrid, Spain	06-08092 T3	\N	945	\N	\N
OM-38	F	\N	Unknown	UCSF	15-102731B	\N	1296	\N	IP1567130
OM-40	F	\N	Unknown	UCSF	16-2833	\N	1298	\N	\N
OM-41	M	\N	Unknown	UCSF	16-77557	\N	1299	\N	\N
OM-42	F	\N	Unknown	UCSF	17-70204	\N	1300	\N	\N
OM-43	M	\N	Unknown	UCSF	17-24139	\N	1301	\N	\N
OM-44	M	\N	Unknown	UCSF	17-116120	\N	1302	\N	\N
SYNAT42	\N	\N	\N	\N	08-43265	\N	2054	\N	\N
SYNAT43	\N	\N	\N	\N	08-43266	\N	1736	\N	IP751907
SYNAT44	\N	\N	\N	\N	08-43267	\N	1774	\N	IP751908
SYNAT45	\N	\N	\N	\N	08-43268	\N	1719	\N	\N
ME-45	M	\N	Unknown	UCSF	14-50051	\N	1140	\N	IP988468
SYNAT46	\N	\N	\N	\N	08-51220	\N	2224	\N	IP759861
SYNAT47	\N	\N	\N	\N	08-51221	\N	1840	\N	\N
SYNAT48	\N	\N	\N	\N	08-51222	\N	2243	\N	IP759863
SYNAT49	\N	\N	\N	\N	08-51223	\N	2311	\N	IP692531
MD-40	\N	\N	Unknown	Madrid, Spain	05-12693C M1	\N	946	\N	\N
MD-41	\N	\N	Unknown	Madrid, Spain	05-27343A M1	\N	947	\N	\N
SYNAT50	\N	\N	\N	\N	09-008704	\N	2206	\N	\N
SYNAT51	\N	\N	\N	\N	09-015020-2A	\N	1743	\N	\N
SYNAT52	\N	\N	\N	\N	09-22513A	\N	2329	\N	IP823276
ME-39	F	\N	Unknown	UCSF	17-51847B	\N	1134	\N	IP524148
SYNAT53	\N	\N	\N	\N	09-36483	\N	2314	\N	IP757083
SYNAT54	\N	\N	\N	\N	09-80101A-2	\N	1859	\N	\N
SYNAT55	\N	\N	\N	\N	10-44069A4	\N	1775	\N	IP929046
NL-018	M	\N	Unknown	UCSF	18-121971A	\N	1180	\N	IP599761
NL-019	F	\N	Unknown	UCSF	18-121973	\N	1181	\N	IP828094
NL-020	M	\N	Unknown	UCSF	18-121986	\N	1182	\N	IP1986075
OM-45	M	\N	Unknown	UCSF	18-44728A	\N	1303	\N	IP1510187
OM-49	F	\N	Unknown	UCSF	13-55769	\N	1307	\N	\N
SYNAT56	\N	\N	\N	\N	10-143	\N	1708	\N	\N
OM-50	F	\N	Unknown	UCSF	15-86891	\N	1308	\N	\N
OM-51	M	\N	Unknown	UCSF	15-43382	\N	1309	\N	\N
OM-52	F	\N	Unknown	UCSF	15-74487	\N	1310	\N	\N
OM-53	M	\N	Unknown	UCSF	15-96473	\N	1311	\N	\N
OM-54	F	\N	Unknown	UCSF	16-53528	\N	1312	\N	\N
OM-55	M	\N	Unknown	UCSF	16-55930	\N	1313	\N	\N
SYNAT57	\N	\N	\N	\N	10-972C2, 10-972A9, 10-972A17	\N	2289	\N	IP895542
SYNAT59	\N	\N	\N	\N	10-3560A3, 10-3560A4, 10-3560A10, 10-3560F1, 10-3560C1\n	\N	1880	\N	\N
SYNAT59	\N	\N	\N	\N	10-3560A3, 10-3560A4, 10-3560A10, 10-3560F1, 10-3560C1\n	\N	2263	\N	IP773046
SYNAT62	\N	\N	\N	\N	10-7937B2	\N	2061	\N	IP164592
SYNAT63	\N	\N	\N	\N	10-008371A1	\N	2215	\N	\N
SYNAT64	\N	\N	\N	\N	10-8439A4	\N	2276	\N	IP903012
SYNAT65	\N	\N	\N	\N	10-10558A10, 10-10558B1\n, 10-10558C1	\N	1806	\N	IP644642
SYNAT65	\N	\N	\N	\N	10-10558A10, 10-10558B1\n, 10-10558C1	\N	2330	\N	\N
SYNAT66	\N	\N	\N	\N	10-11930B12	\N	2221	\N	IP906503
OM-56	F	\N	Unknown	UCSF	16-8674	\N	1314	\N	\N
SYNAT67	\N	\N	\N	\N	10-26316A2	\N	1983	\N	IP666578
SYNAT68	\N	\N	\N	\N	10-42241	\N	2145	\N	\N
NL-022	F	\N	Unknown	UCSF	11-91034,19-135490,14-113821,19-28178, 11-91034, 19-135490, 14-113821, 19-28178	\N	1184	\N	IP1080482
NL-023	F	\N	Unknown	UCSF	18-34960	\N	1185	\N	IP1898705
KF-11	\N	\N	Unknown	\N	12-11041	\N	781	\N	\N
OM-57	F	\N	Unknown	UCSF	16-37928A	\N	1315	\N	IP1630601
OM-61	F	\N	Unknown	UCSF	16-118278	\N	1319	\N	\N
OM-63	M	\N	Unknown	UCSF	19-94975	\N	1321	\N	IP2099586
OM-64	M	\N	Unknown	UCSF	16-24795	\N	1322	\N	\N
OM-65	F	\N	Unknown	UCSF	20-026598	\N	1323	\N	\N
ME-47	M	\N	Unknown	UCSF	16-17132B	\N	1142	\N	IP1616233
SYNAT69	\N	\N	\N	\N	10-63051C	\N	2088	\N	IP953239
MD-47	\N	\N	Unknown	Madrid, Spain	94-00669 N1	\N	953	\N	\N
NM-013	\N	\N	Unknown	Greece	10B7952 (eppendorf)	\N	1200	\N	\N
NM-014	\N	\N	Unknown	Greece	16B8849 (eppendorf)	\N	1201	\N	\N
NM-015	\N	\N	Unknown	Greece	14B1910 (eppendorf)	\N	1202	\N	\N
NM-016	\N	\N	Unknown	Greece	13B10486 (eppendorf)	\N	1203	\N	\N
NM-017	\N	\N	Unknown	Greece	11B9724 (eppendorf)	\N	1204	\N	\N
NM-018	\N	\N	Unknown	Greece	11B2562 (eppendorf)	\N	1205	\N	\N
NM-019	\N	\N	Unknown	Greece	11522/18	\N	1206	\N	\N
NM-027	\N	\N	Unknown	Greece	2065/12 (2065/117 slide)	\N	1207	\N	\N
OM-67	F	\N	Unknown	UCSF	14-01007	\N	1324	\N	\N
OM-68	F	\N	Unknown	UCSF	14-4953	\N	1325	\N	\N
OM-69	M	\N	Unknown	UCSF	15-122795	\N	1326	\N	\N
OM-70	F	\N	Unknown	UCSF	16-85059	\N	1327	\N	\N
OM-71	F	\N	Unknown	UCSF	17-91629	\N	1328	\N	\N
SM-005	F	\N	Unknown	UCSF	17-120984	\N	1335	\N	IP1851544
SM-006	M	\N	Unknown	UCSF	12-51532	\N	1336	\N	IP368502
LN-037	M	\N	Unknown	UCSF	17-111038B	\N	856	\N	IP1772327
MD-48	\N	\N	Unknown	Madrid, Spain	94-00143-2 N1	\N	954	\N	\N
MD-49	\N	\N	Unknown	Madrid, Spain	93-06269-4 N1	\N	955	\N	\N
NM-61	\N	\N	Unknown	Greece	15356/1 (H08.15356/1 slide)	\N	1236	\N	\N
NM-63	\N	\N	Unknown	Greece	176323	\N	1237	\N	\N
NM-64	\N	\N	Unknown	Greece	17-1468II-2	\N	1238	\N	\N
DP-56	M	\N	Unknown	UCSF	16-19895	\N	693	\N	IP1619022
SM-012	M	\N	Unknown	UCSF	17-115105	\N	1341	\N	IP1271461
SM-013	F	\N	Unknown	UCSF	15-16261	\N	1342	\N	IP1487321
NM-84	F	\N	Unknown	UCSF	22-81852A,22-81852B,22-51092, 22-81852A, 22-81852B, 22-51092	\N	1258	\N	\N
OM-01	M	\N	Unknown	UCSF	07-74058B,07-74058A, 07-74058B, 07-74058A	RIGHT LOWER LIP, LATERAL	1262	\N	IP696592
SN-06	M	\N	Unknown	UCSF	19-115700A	\N	1369	\N	IP2120444
SYNAT349	\N	\N	\N	\N	13-25110A1	\N	1988	\N	IP1209855
CCR-015	F	\N	White	\N	08-51663	\N	129	\N	IP760304
CCR-020	M	\N	White	\N	08-44748	\N	130	\N	IP753389
CCR-031	M	\N	White	\N	09-16836	\N	134	\N	IP371067
CCR-032	F	\N	White	\N	07-28805	\N	135	\N	IP651337
DP-85	F	\N	Unknown	UCSF	17-6351	\N	722	\N	IP1735471
MD-50	\N	\N	Unknown	Madrid, Spain	95-05959 M1	\N	956	\N	\N
OM-11	F	\N	Unknown	Mexico	BB21-21334	BB21-21334	1272	\N	\N
OM-15	M	\N	Unknown	Mexico	BB21-21351	\N	1276	\N	\N
CCR-034	F	\N	White	\N	12-85105A	\N	136	\N	IP1170922
CCR-035	F	\N	White	\N	09-48136A	\N	137	\N	IP848899
CCR-040	\N	\N	Unknown	\N	07-37378	\N	138	\N	IP659911
CCR-042	F	\N	White	\N	95-5908	\N	140	\N	IP60334
ME-48	M	\N	Unknown	UCSF	16-35900	\N	1143	\N	IP1635170
CCR-046	M	\N	White	\N	05-58791	\N	141	\N	IP535505
CCR-055	M	\N	White	\N	13-14077	\N	146	\N	IP1198820
SYNAT71	\N	\N	\N	\N	11-21025B1	\N	1963	\N	\N
OM-59	M	\N	Unknown	UCSF	16-76143	\N	1317	\N	\N
CCR-057	M	\N	White	\N	04-6689B	\N	147	\N	IP423088
CCR-066	F	\N	White	\N	09-31608	\N	149	\N	IP832371
CCR-067	F	\N	White	\N	08-25654	\N	150	\N	IP734295
OM-62	F	\N	Unknown	UCSF	17-3165B,17-3165A, 17-3165B, 17-3165A	\N	1320	\N	IP1729294
AM2-094	\N	\N	Asian	Taiwan	10-39146A1,10-18253B,10-39146A2,10-15411B,10-17734, 10-39146A1, 10-18253B, 10-39146A2, 10-15411B, 10-17734	\N	64	\N	\N
MD-23	\N	\N	Unknown	Madrid, Spain	07-25593 T2,07-25593-2 T2, 07-25593 T2, 07-25593-2 T2	\N	929	\N	\N
ME-50	M	\N	Unknown	UCSF	18-75585B	\N	1145	\N	IP844686
MD-33	\N	\N	Unknown	Madrid, Spain	14-03473 T3	\N	939	\N	\N
SYNAT72	\N	\N	\N	\N	11-032523A1	\N	2324	\N	IP939446
MD-34	\N	\N	Unknown	Madrid, Spain	15-02416 T2	\N	940	\N	\N
MD-51	\N	\N	Unknown	Madrid, Spain	89-10432A M1	\N	957	\N	\N
SM-010	M	\N	Unknown	UCSF	17-106118C,17-106118B, 17-106118C, 17-106118B	\N	1340	\N	IP1836502
DN-088	F	\N	Unknown	\N	16-12574	can't find patient age for tnis one, will look into intellipath later, double check this is not T16-125754	563	\N	\N
CCR-086	M	\N	White	\N	01-16263	\N	153	\N	IP272666
CCR-099	M	\N	White	\N	11-37100B	\N	156	\N	IP1026539
LN-089	M	\N	Unknown	UCSF	\N	\N	902	\N	\N
CCR-109	M	\N	White	\N	07-77608	\N	159	\N	IP31137
CCR-112	M	\N	White	\N	07-42908	\N	160	\N	IP665441
CCR-124	F	\N	White	\N	98-13466	\N	163	\N	IP151039
SYNAT73	\N	\N	\N	\N	11-38910A2	\N	2021	\N	IP1028349
ME-51	F	\N	Unknown	UCSF	19-36210A	\N	1146	\N	IP2040437
SYNAT74	\N	\N	\N	\N	11-62022	\N	1953	\N	IP948784
DP-70	M	\N	Unknown	UCSF	16-42198	\N	707	\N	IP1641515
SMP20	M	\N	Unknown	UCSF	12-91942	\N	1359	\N	\N
CCR-125	M	\N	White	\N	98-6161B	\N	164	\N	IP136586
SMP58	M	\N	Unknown	UCSF	14-115431C,14-115431A, 14-115431C, 14-115431A	\N	1363	\N	\N
MD-52	\N	\N	Unknown	Madrid, Spain	85-01186	\N	958	\N	\N
CCR-130	M	\N	White	\N	07-76799A	\N	165	\N	IP641150
CCR-142	F	\N	White	\N	05-27460	\N	168	\N	IP504172
CCR-144	M	\N	White	\N	00-5989A2	\N	169	\N	IP221092
SYNAT141	\N	\N	\N	\N	12-6981	\N	2348	\N	IP1092797
CCR-146	F	\N	White	\N	98-10389	\N	170	\N	IP147962
CCR-147	M	\N	White	\N	97-13166G	\N	171	\N	IP115935
SYNAT142	\N	\N	\N	\N	10-59344	\N	1933	\N	IP953920
CCR-154	M	\N	White	\N	92-5109	\N	174	\N	IP14859
SYNAT143	\N	\N	\N	\N	11-96096	\N	2220	\N	IP1085544
CCR-157	F	\N	White	\N	10-43330	\N	176	\N	IP937906
SYNAT144	\N	\N	\N	\N	10-71761	\N	1868	\N	IP966340
CCR-272	Unknown	\N	Unknown	\N	98-21806	\N	222	\N	IP159379
SN-26	F	\N	Unknown	UCSF	20-48331	\N	1389	\N	IP2196043
CCR-213	M	\N	White	\N	05-66206A	\N	192	\N	IP542950
SYNAT75	\N	\N	\N	\N	Cell-Line_Xu-14	\N	1718	\N	\N
ME-52	M	\N	Unknown	UCSF	19-5916	\N	1147	\N	IP1359612
CCR-214	F	\N	White	\N	06-47809B	\N	193	\N	IP592878
MD-53	\N	\N	Unknown	Madrid, Spain	95-01141-1 M1	\N	959	\N	\N
DPN-01	\N	\N	Unknown	UCSF	19-88385	\N	735	\N	\N
CCR-219	F	\N	White	\N	06-4069	\N	196	\N	IP549135
CCR-220	F	\N	White	\N	06-64692B	\N	197	\N	IP609761
SYNAT147	\N	\N	\N	\N	12-81302	\N	2153	\N	IP1167119
JJS4	F	\N	Unknown	UCSF	11-49127	BAD SAMPLE	743	\N	\N
AM2-096	\N	\N	Asian	Taiwan	15-18463,15-3736C5,15-3736A1,15-3736C1, 15-18463, 15-3736C5, 15-3736A1, 15-3736C1	\N	66	\N	\N
SYNAT27	\N	\N	\N	\N	12-4365C2, 12-4365B1, 12-4365C1, 12-4365A8	\N	1971	\N	IP39574
AM2-097	\N	\N	Asian	Taiwan	15-4505A1,22-25497A1,15-4505B,22-44747A1,22-25497A2,23-6349A3,23-6349A1,22-44747A2,23-6349A2,15-4505C, 15-4505A1, 22-25497A1, 15-4505B, 22-44747A1, 22-25497A2, 23-6349A3, 23-6349A1, 22-44747A2, 23-6349A2, 15-4505C	\N	67	\N	\N
CCGL-2973	M	\N	Unknown	UCSF	18-28169,18-68921A, 18-28169, 18-68921A	DermPath patient with multiple BCC	117	\N	\N
BN-011	F	\N	Unknown	UCSF	11-19048	blue nevus, cellular	115	\N	\N
BN-012	F	\N	Unknown	UCSF	11-43354	blue nevus, cellular	116	\N	\N
CM-70	\N	\N	Unknown	Denmark	19Rig750007.05.14.03	\N	298	\N	\N
AM2-098	\N	\N	Asian	Taiwan	18-15332A3,18-15332A6,18-15332A1,18-15332A5,19-20141,18-15332A4,18-15332A2,19-23613C4, 18-15332A3, 18-15332A6, 18-15332A1, 18-15332A5, 19-20141, 18-15332A4, 18-15332A2, 19-23613C4	\N	68	\N	\N
AM2-101	\N	\N	Asian	Taiwan	19-6410A1,19-6410A2,18-12734,15-26253A1,18-28886, 19-6410A1, 19-6410A2, 18-12734, 15-26253A1, 18-28886	\N	71	\N	\N
AM2-102	\N	\N	Asian	Taiwan	17-9337A2,17-14203A1,16-552A7,19-19590,17-9337A1,17-14203A2, 17-9337A2, 17-14203A1, 16-552A7, 19-19590, 17-9337A1, 17-14203A2	\N	72	\N	\N
AM2-103	\N	\N	Asian	Taiwan	16-10035A3,17-21588,16-10035C, 16-10035A3, 17-21588, 16-10035C	\N	73	\N	\N
AM2-104	\N	\N	Asian	Taiwan	20-09338A1,18-22781A1, 20-09338A1, 18-22781A1	\N	74	\N	\N
AM2-105	\N	\N	Asian	Taiwan	18-35014B2,20-21458A2,18-35014A1,20-21458A1, 18-35014B2, 20-21458A2, 18-35014A1, 20-21458A1	\N	75	\N	\N
AM2-106	\N	\N	Asian	Taiwan	19-34937A2,19-34937S1, 19-34937A2, 19-34937S1	\N	76	\N	\N
AM2-107	\N	\N	Asian	Taiwan	19-43366A1,19-43366F,19-43366G, 19-43366A1, 19-43366F, 19-43366G	\N	77	\N	\N
AM2-108	\N	\N	Asian	Taiwan	20-59076A1,19-44348A4,19-44348A1, 20-59076A1, 19-44348A4, 19-44348A1	\N	78	\N	\N
AM2-109	\N	\N	Asian	Taiwan	20-33334A1,19-44987C1,19-44987A1, 20-33334A1, 19-44987C1, 19-44987A1	\N	79	\N	\N
AM2-110	\N	\N	Asian	Taiwan	19-52004A1,19-52004B1, 19-52004A1, 19-52004B1	\N	80	\N	\N
SYNAT76	\N	\N	\N	\N	12_20321A2	\N	2040	\N	\N
SYNAT77	\N	\N	\N	\N	12_54296	\N	1688	\N	\N
ME-53	F	\N	Unknown	UCSF	20-31447	\N	1148	\N	IP2179033
MD-55	\N	\N	Unknown	Madrid, Spain	96-06832D M1	\N	961	\N	\N
AM2-111	\N	\N	Asian	Taiwan	21-961A,21-26009A1,19-51759,20-28721A1,21-13227A,08-35719A1, 21-961A, 21-26009A1, 19-51759, 20-28721A1, 21-13227A, 08-35719A1	\N	81	\N	\N
AM2-112	\N	\N	Asian	Taiwan	20-12501E1,20-12501A1, 20-12501E1, 20-12501A1	\N	82	\N	\N
AM2-113	\N	\N	Asian	Taiwan	16-32182,16-35844B2, 16-32182, 16-35844B2	\N	83	\N	\N
AM2-114	\N	\N	Asian	Taiwan	15-24753A1,20-26269A1, 15-24753A1, 20-26269A1	\N	84	\N	\N
SYNAT78	\N	\N	\N	\N	12-6332A5	\N	2228	\N	IP1092148
SYNAT79	\N	\N	\N	\N	12-7093NG176-1	\N	2283	\N	\N
SYNAT70	\N	\N	\N	\N	12-9606E4, 12-9606E9, 12-9606A2, 12-9606C4	\N	1879	\N	IP1095422
SYNAT70	\N	\N	\N	\N	12-9606E4, 12-9606E9, 12-9606A2, 12-9606C4	\N	2284	\N	\N
AM2-115	\N	\N	Asian	Taiwan	21-108508B,21-108508A, 21-108508B, 21-108508A	\N	85	\N	\N
AM2-116	\N	\N	Asian	Taiwan	21-108509D,21-108509C,21-108509A,21-108509E,21-108509B, 21-108509D, 21-108509C, 21-108509A, 21-108509E, 21-108509B	\N	86	\N	\N
AM2-117	\N	\N	Asian	Taiwan	21-108510C,21-108510A,21-108510B, 21-108510C, 21-108510A, 21-108510B	\N	87	\N	\N
ME-56	F	\N	Unknown	UCSF	20-79197A	\N	1151	\N	IP264110
AM2-120	\N	\N	Unknown	UCSF	18-51740B2,18-51740C7,18-51740C6, 18-51740B2, 18-51740C7, 18-51740C6	\N	90	\N	\N
AM2-121	\N	\N	Unknown	UCSF	21-4449A5,21-4449B2,21-4449A3, 21-4449A5, 21-4449B2, 21-4449A3	\N	91	\N	\N
AM2-122	\N	\N	Unknown	UCSF	19-360A2,19-360A1, 19-360A2, 19-360A1	\N	92	\N	\N
AM2-123	\N	\N	Unknown	UCSF	20-113547A2,20-113547A3,20-113547C2, 20-113547A2, 20-113547A3, 20-113547C2	\N	93	\N	\N
AM2-124	\N	\N	Unknown	UCSF	20-37211I,20-37211A, 20-37211I, 20-37211A	\N	94	\N	\N
AM2-125	\N	\N	Unknown	UCSF	20-83082A3,20-83082B, 20-83082A3, 20-83082B	\N	95	\N	\N
AM2-126	\N	\N	Unknown	UCSF	20-8536E,20-8536D, 20-8536E, 20-8536D	\N	96	\N	\N
AMC-03	\N	\N	Unknown	\N	MM100512,MM100916,MM100513,MM100511, MM100512, MM100916, MM100513, MM100511	\N	100	\N	\N
AMC-07	\N	\N	Unknown	\N	M040204 Dec2019,M040204, M040204 Dec2019, M040204	\N	101	\N	\N
SYNAT80	\N	\N	\N	\N	12-15765B3	\N	1799	\N	IP1101581
SYNAT81	\N	\N	\N	\N	12-18826	\N	2192	\N	IP535712
SYNAT82	\N	\N	\N	\N	12-19018B	\N	2157	\N	IP1104835
SYNAT83	\N	\N	\N	\N	12-21933I	\N	1727	\N	\N
MD-56	\N	\N	Unknown	Madrid, Spain	91-16318 M1	\N	962	\N	\N
BN-003	F	\N	Unknown	UCSF	12-97918	blue nevus, cellular	107	\N	\N
DN-102	F	\N	Unknown	\N	17-72563	\N	577	\N	IP1350209
SYNAT85	\N	\N	\N	\N	12-22720A1	\N	1773	\N	IP118827
SYNAT351	\N	\N	\N	\N	11-85416	\N	1669	\N	IP1074864
BN-004	F	\N	Unknown	UCSF	12-6550	blue nevus, cellular	108	\N	\N
CCR-221	F	\N	White	\N	06-5249	\N	198	\N	IP550315
SYNAT86	\N	\N	\N	\N	12-22776B5	\N	2146	\N	IP1096148
ME-60	M	\N	Unknown	UCSF	21-41149	\N	1155	\N	IP2303774
CCR-005	M	\N	White	\N	99-14477	\N	122	\N	IP190010
CCR-222	M	\N	White	\N	02-17626	\N	199	\N	IP322353
CCR-008	M	\N	White	\N	01-10896,02-7356, 01-10896, 02-7356	\N	124	\N	IP267299
CCR-224	F	\N	White	\N	05-28152B	\N	200	\N	IP504864
CCR-225	F	\N	White	\N	06-70035C	\N	201	\N	IP615104
MD-44	\N	\N	Unknown	Madrid, Spain	06-16008-1	\N	950	\N	\N
MD-45	\N	\N	Unknown	Madrid, Spain	10-10942A2 M1	\N	951	\N	\N
CGH17-135	F	\N	Unknown	UCSF	17-61001	cases with MAP3K8 fusions	245	\N	IP1790788
CCR-228	M	\N	White	\N	04-31313A	\N	202	\N	IP446906
CCR-021	M	\N	White	\N	07-85201,04-34117, 07-85201, 04-34117	\N	131	\N	\N
CCR-231	M	\N	White	\N	04-28340	\N	203	\N	IP444742
CCR-233	F	\N	White	\N	06-68314	\N	204	\N	IP613383
MD-27	\N	\N	Unknown	Madrid, Spain	11-03286-4 M1,11-03286 T3, 11-03286-4 M1, 11-03286 T3	\N	933	\N	\N
CCR-234	M	\N	White	\N	03-44586	\N	205	\N	IP402900
SYNAT87	\N	\N	\N	\N	13-2054	\N	2042	\N	IP1186796
NL-015	M	\N	Unknown	UCSF	19-1978C	\N	1177	\N	IP2006010
NL-016	F	\N	Unknown	UCSF	19-2264A	\N	1178	\N	IP1955064
NL-017	F	\N	Unknown	UCSF	18-121943A	\N	1179	\N	IP1986032
SYNAT148	\N	\N	\N	\N	09-72944	\N	1697	\N	IP563362
SYNAT88	\N	\N	\N	\N	13-006535C	\N	2285	\N	IP1191278
SYNAT89	\N	\N	\N	\N	13-8208B	\N	2237	\N	IP1192951
SYNAT90	\N	\N	\N	\N	13-9682	\N	2175	\N	\N
SYNAT91	\N	\N	\N	\N	13-10776A1	\N	2198	\N	\N
NM-001	\N	\N	Unknown	Greece	5890/08	\N	1188	\N	\N
SYNAT92	\N	\N	\N	\N	13-12947A2	\N	1907	\N	IP1197690
SYNAT93	\N	\N	\N	\N	13-61266A	\N	2250	\N	\N
AM2-050	\N	\N	Asian	Japan	K2-B,K2-C,K2-A,K2-D, K2-B, K2-C, K2-A, K2-D	Case K2	24	\N	\N
AM2-055	\N	\N	Unknown	Bolivia	38637-16.3,38637-16.1,38637-16.2, 38637-16.3, 38637-16.1, 38637-16.2	Sites of cancer are not sure, diagnosis are in Spanish.  See scanned file:  "AM2_051 to AM2_056" in "Materials came with the speciment" folder. 	27	\N	\N
SYNAT94	\N	\N	\N	\N	13-17202A11, 13-17202C4	\N	1972	\N	\N
SYNAT95	\N	\N	\N	\N	13-18444A16	\N	2295	\N	IP1203187
NM-010	\N	\N	Unknown	Greece	08B9531 (eppendorf)	\N	1197	\N	\N
SYNAT96	\N	\N	\N	\N	13-62943	\N	2004	\N	\N
NM-011	\N	\N	Unknown	Greece	08B8345 (eppendorf)	\N	1198	\N	\N
NM-012	\N	\N	Unknown	Greece	10B339 (eppendorf)	\N	1199	\N	\N
CCR-041	M	\N	White	\N	02-28807	\N	139	\N	IP333561
CCR-235	M	\N	White	\N	06-65105	\N	206	\N	IP592825
CGH12-109	F	\N	Unknown	UCSF	12-26470	cases with MAP3K8 fusions	240	\N	IP1112288
SYNAT97	\N	\N	\N	\N	13-46194	\N	2060	\N	\N
SYNAT98	\N	\N	\N	\N	13-48798	\N	2245	\N	IP1290801
CCR-048	M	\N	White	\N	09-23922A,09-23922B, 09-23922A, 09-23922B	\N	142	\N	IP824685
SYNAT99	\N	\N	\N	\N	13-69386B	\N	2261	\N	\N
SYNAT100	\N	\N	\N	\N	13-90988	\N	1823	\N	\N
NM-66	\N	\N	Unknown	Greece	1135/19	\N	1240	\N	\N
SYNAT101	\N	\N	\N	\N	14-159A2	\N	2008	\N	\N
NM-67	\N	\N	Unknown	Greece	59/15	\N	1241	\N	\N
NM-68	\N	\N	Unknown	Greece	718/12a	\N	1242	\N	\N
NM-69	\N	\N	Unknown	Greece	115016	\N	1243	\N	\N
SYNAT102	\N	\N	\N	\N	14-3598	\N	2069	\N	\N
NM-70	\N	\N	Unknown	Greece	46976B	\N	1244	\N	\N
NM-71	\N	\N	Unknown	Greece	6258/2015	\N	1245	\N	\N
NM-72	\N	\N	Unknown	Greece	21831/14	\N	1246	\N	\N
NM-73	\N	\N	Unknown	Greece	156/13	\N	1247	\N	\N
NM-74	\N	\N	Unknown	Greece	2017-19575	\N	1248	\N	\N
NM-75	\N	\N	Unknown	Greece	K3920/19 A1	\N	1249	\N	\N
NM-76	\N	\N	Unknown	Greece	10226 2	\N	1250	\N	\N
NM-77	\N	\N	Unknown	Greece	M32727/18 A1	\N	1251	\N	\N
NM-78	\N	\N	Unknown	Greece	M21326/18 A1	\N	1252	\N	\N
NM-79	\N	\N	Unknown	Greece	14531/14	\N	1253	\N	\N
SYNAT103	\N	\N	\N	\N	14-4989D3	\N	1690	\N	\N
NM-80	\N	\N	Unknown	Greece	8716/2016	\N	1254	\N	\N
NM-81	\N	\N	Unknown	Greece	M31513/18	\N	1255	\N	\N
NM-82	\N	\N	Unknown	Greece	2017-07184	\N	1256	\N	\N
CM-21	\N	\N	Unknown	Denmark	19Rig750007.02.02.03,19Rig750007.02.02.04, 19Rig750007.02.02.03, 19Rig750007.02.02.04	\N	263	\N	\N
CM-22	\N	\N	Unknown	Denmark	19Rig750007.02.03.02,19Rig750007.02.03.03, 19Rig750007.02.03.02, 19Rig750007.02.03.03	\N	264	\N	\N
NM-83	\N	\N	Unknown	Greece	15864 3	\N	1257	\N	\N
NM-85	M	\N	Unknown	UCSF	20-106642A	\N	1259	\N	\N
SYNAT104	\N	\N	\N	\N	14-5893	\N	2325	\N	IP370740
SYNAT105	\N	\N	\N	\N	14-13830	\N	2190	\N	\N
SYNAT106	\N	\N	\N	\N	14-32353	\N	2030	\N	\N
SYNAT107	\N	\N	\N	\N	14-37911A	\N	1906	\N	\N
CCR-054	M	\N	White	\N	13-32289A,13-32289B, 13-32289A, 13-32289B	\N	145	\N	IP1217034
NM-86	M	\N	Unknown	UCSF	20-91914A	\N	1260	\N	\N
NM-87	M	\N	Unknown	UCSF	20-60974B	\N	1261	\N	\N
OM-02	F	\N	Unknown	UCSF	08-16770	LEFT LABIA MINORA	1263	\N	IP725411
SYNAT108	\N	\N	\N	\N	14-40331B	\N	1762	\N	IP1380659
OM-09	F	\N	Unknown	UCSF	\N	LEFT LABIUM MAJUS	1270	\N	\N
SYNAT109	\N	\N	\N	\N	14-44611	\N	1788	\N	IP1394545
OM-03	F	\N	Unknown	UCSF	09-88536	LEFT LABIA	1264	\N	IP840903
SYNAT110	\N	\N	\N	\N	14-53094\t	\N	2219	\N	IP1403032
SYNAT111	\N	\N	\N	\N	14-53375	\N	2207	\N	IP1403313
SYNAT113	\N	\N	\N	\N	14-58566	\N	2135	\N	\N
OM-16	F	\N	Unknown	Mexico	BB21-21341	\N	1277	\N	\N
SYNAT114	\N	\N	\N	\N	14-58579	\N	1739	\N	IP1408520
OM-18	F	\N	Unknown	Mexico	BB21-21315C	\N	1279	\N	IP2283796
OM-22	M	\N	Unknown	UCSF	18-00192	\N	1280	\N	\N
SYNAT122	\N	\N	\N	\N	14-62335	\N	1982	\N	IP1412277
SYNAT123	\N	\N	\N	\N	14-66686B	\N	1712	\N	\N
SYNAT124	\N	\N	\N	\N	14-74770	\N	2343	\N	IP1424729
SYNAT125	\N	\N	\N	\N	14-80165	\N	2075	\N	IP1430130
SYNAT126	\N	\N	\N	\N	14-83646	\N	2133	\N	\N
SYNAT129	\N	\N	\N	\N	14-96795	\N	2226	\N	IP1069336
SYNAT130	\N	\N	\N	\N	14-99831	\N	1673	\N	\N
SYNAT131	\N	\N	\N	\N	14-102015A	\N	2204	\N	\N
SYNAT132	\N	\N	\N	\N	14-106005	\N	2236	\N	IP1456016
SYNAT133	\N	\N	\N	\N	14-113574	\N	2167	\N	IP1463605
SYNAT134	\N	\N	\N	\N	14-118975	\N	1803	\N	\N
OM-60	M	\N	Unknown	UCSF	16-108474	\N	1318	\N	\N
SYNAT135	\N	\N	\N	\N	15-3641	\N	2079	\N	\N
SYNAT136	\N	\N	\N	\N	15-6952	\N	2112	\N	IP1477972
SYNAT137	\N	\N	\N	\N	15-8321	\N	2124	\N	IP1448202
SM-007	F	\N	Unknown	UCSF	15-72350	\N	1337	\N	IP495959
SM-008	F	\N	Unknown	UCSF	17-82364B	\N	1338	\N	IP650361
SM-009	M	\N	Unknown	UCSF	17-90774B	\N	1339	\N	IP1314381
SYNAT138	\N	\N	\N	\N	15-16543B	\N	1666	\N	\N
MD-108	\N	\N	Unknown	Madrid, Spain	03-19132B T1	Two tubes, one extracted on 10/12/2019	1003	\N	\N
CCR-074	M	\N	White	\N	08-1851C,08-1851A,08-1851B, 08-1851C, 08-1851A, 08-1851B	\N	151	\N	IP710492
SYNAT139	\N	\N	\N	\N	15-45455F	\N	1846	\N	\N
SYNAT140	\N	\N	\N	\N	49_M	\N	2275	\N	\N
CCR-090	F	\N	White	\N	03-57585C,03-57585E,03-57585A, 03-57585C, 03-57585E, 03-57585A	\N	154	\N	IP415901
CCR-083	M	\N	White	\N	07-67657A,07-67657B, 07-67657A, 07-67657B	\N	152	\N	IP690191
CCR-240	F	\N	White	\N	03-39293	\N	209	\N	IP397607
SM-014	F	\N	Unknown	UCSF	15-118245A	\N	1343	\N	IP1590062
CCR-102	M	\N	White	\N	10-25517A,10-25517E,10-23548, 10-25517A, 10-25517E, 10-23548	\N	157	\N	IP918121
CCR-107	F	\N	White	\N	08-8920B,08-8920A, 08-8920B, 08-8920A	\N	158	\N	IP717561
CCR-241	F	\N	White	\N	02-20619B	\N	210	\N	IP325344
CCR-248	F	\N	White	\N	00-26584A1	\N	212	\N	IP241687
CCR-250	M	\N	White	\N	00-7684A2	\N	213	\N	IP222787
CGH12-280	F	\N	Unknown	UCSF	12-67286	cases with MAP3K8 fusions	241	\N	IP1153102
SM-015	F	\N	Unknown	UCSF	17-10753	\N	1344	\N	IP1739922
CCR-134	F	\N	White	\N	99-19410B,99-19410A, 99-19410B, 99-19410A	\N	166	\N	IP194943
CCR-141	F	\N	White	\N	05-37586A1,05-37586A3, 05-37586A1, 05-37586A3	\N	167	\N	IP514299
CCR-257	M	\N	White	\N	94-7602A	\N	215	\N	IP43096
SYNAT152	\N	\N	\N	\N	10-32987	\N	1811	\N	IP927561
SM-016	M	\N	Unknown	UCSF	17-21788B	\N	1345	\N	IP1747915
CGH14-145	F	\N	Unknown	UCSF	14-48102	cases with MAP3K8 fusions	242	\N	IP1398038
SM-017	M	\N	Unknown	UCSF	17-52720	\N	1346	\N	IP1782404
CCR-148	F	\N	White	\N	05-5976C,05-5976A,05-5976B, 05-5976C, 05-5976A, 05-5976B	\N	172	\N	IP476117
CCR-268	F	\N	White	\N	07-37090	\N	220	\N	IP659623
SM-018	F	\N	Unknown	UCSF	17-120487A	\N	1347	\N	IP349912
CCR-269	M	\N	White	\N	98-9595B	\N	221	\N	IP146596
CCR-155	M	\N	White	\N	92-1608A,92-1608B, 92-1608A, 92-1608B	\N	175	\N	IP11358
CCR-158	M	\N	White	\N	04-12137A,04-12137E,04-12137D, 04-12137A, 04-12137E, 04-12137D	\N	177	\N	IP426119
CCR-159	F	\N	White	\N	03-29330A,03-29330B, 03-29330A, 03-29330B	\N	178	\N	IP387643
SM-019	F	\N	Unknown	UCSF	18-24908	\N	1348	\N	IP1888575
SYNAT145	\N	\N	\N	\N	Cell-Line_Xu-15	\N	2101	\N	\N
CCR-162	M	\N	White	\N	03-30961A,03-30961B, 03-30961A, 03-30961B	\N	179	\N	IP389274
CCR-163	F	\N	White	\N	99-23502A,99-23502C, 99-23502A, 99-23502C	\N	180	\N	IP199035
SM-020	F	\N	Unknown	UCSF	18-59376	\N	1349	\N	IP1491105
SYNAT155	\N	\N	\N	\N	10-73024	\N	1890	\N	IP967603
CCR-274	F	\N	White	\N	95-21392	\N	224	\N	IP51560
CCR-282	M	\N	White	\N	01-11378A2	\N	226	\N	IP129632
CCR-287	M	\N	White	\N	98-1556	\N	227	\N	IP17286
AM2-019	\N	\N	Unknown	Bolivia	385/14	\N	10	\N	\N
P_MEL202	\N	\N	Unknown	UCSF	MEL202_DMSO,MEL202_Vemu, MEL202_DMSO, MEL202_Vemu	melanoma cell line	1329	\N	\N
SCH-01	M	\N	Unknown	UCSF	20-30367	\N	1330	\N	IP2177946
SM-001	F	\N	Unknown	UCSF	15-21302	SM-skin mole	1331	\N	IP488197
SM-002	M	\N	Unknown	UCSF	11-53065	\N	1332	\N	IP1042505
SM-004	F	\N	Unknown	UCSF	16-33907	\N	1334	\N	IP1633163
CCR-290	F	\N	Unknown	\N	06-22923	\N	228	\N	IP334006
SM-022	M	\N	Unknown	UCSF	18-113402B	\N	1351	\N	IP1977457
CCR-296	F	\N	White	\N	04-57347A	\N	229	\N	IP473755
CCR-298	M	\N	White	\N	03-24651	\N	230	\N	IP382964
SM-025	F	\N	Unknown	UCSF	18-85718	\N	1354	\N	IP1949687
SMP55	M	\N	Unknown	UCSF	11-1044	\N	1361	\N	\N
SMP56	F	\N	Unknown	UCSF	11-7028	\N	1362	\N	\N
CM-45	\N	\N	Unknown	Denmark	19Rig750007.04.04.03	\N	282	\N	\N
CM-46	\N	\N	Unknown	Denmark	19Rig750007.04.05.03	\N	283	\N	\N
SYNAT157	\N	\N	\N	\N	11-20375	\N	2152	\N	IP1009813
SN-01	M	\N	Unknown	UCSF	19-53945B	\N	1364	\N	IP2058294
CM-50	\N	\N	Unknown	Denmark	19Rig750007.04.09.03	\N	286	\N	\N
CM-51	\N	\N	Unknown	Denmark	19Rig750007.04.10.03	\N	287	\N	\N
CCR-311	F	\N	White	\N	00-4845	\N	236	\N	IP219948
CCR-316	F	\N	White	\N	97-23367	\N	239	\N	IP126136
CM-48	\N	\N	Unknown	Denmark	19Rig750007.04.07.03,19Rig750007.04.07.09, 19Rig750007.04.07.03, 19Rig750007.04.07.09	\N	285	\N	\N
CGH17-240	M	\N	Unknown	UCSF	17-112474	\N	246	\N	IP1806028
CM-53	\N	\N	Unknown	Denmark	19Rig750007.04.12.08,19Rig750007.04.12.03, 19Rig750007.04.12.08, 19Rig750007.04.12.03	\N	288	\N	\N
CGH18-137	\N	\N	Unknown	UCSF	18-95536	already sequenced (BCB004, SGLP-0412 Mean target cov-140, leftover library 176ng)	247	\N	IP1959535
CGH18-139	F	\N	Unknown	UCSF	18-95537	\N	248	\N	IP1959536
CME-007	\N	\N	Asian	Taiwan	13-33924	\N	309	\N	\N
CME-008	\N	\N	Asian	Taiwan	13-50059	\N	310	\N	\N
CME-009	\N	\N	Asian	Taiwan	14-31325	\N	311	\N	\N
CCR-113	F	\N	White	\N	07-40241A	\N	161	\N	IP662774
CCR-114	F	\N	White	\N	07-7626	\N	162	\N	IP630157
SN-02	M	\N	Unknown	UCSF	19-69103	\N	1365	\N	IP316729
SN-03	M	\N	Unknown	UCSF	19-104449D	\N	1366	\N	IP2109117
CCR-237	M	\N	White	\N	03-16497A,03-16497B, 03-16497A, 03-16497B	\N	207	\N	IP374810
DN-070	M	\N	Unknown	\N	16-98735	\N	545	\N	IP1698660
SYNAT149	\N	\N	\N	\N	11-28912B	\N	1909	\N	IP1018350
SYNAT150	\N	\N	\N	\N	17-8769A	\N	2196	\N	IP1576568
CCR-238	F	\N	White	\N	04-25639A,04-25639B, 04-25639A, 04-25639B	\N	208	\N	IP441707
SN-04	M	\N	Unknown	UCSF	19-103058B	\N	1367	\N	IP2107719
SN-05	M	\N	Unknown	UCSF	15-102927	\N	1368	\N	IP1374483
SN-07	F	\N	Unknown	UCSF	19-117270	\N	1370	\N	IP2115907
DN-071	M	\N	Unknown	\N	17-20501C	\N	546	\N	IP183716
DN-072	M	\N	Unknown	\N	17-63163	\N	547	\N	IP1572575
DN-073	F	\N	Unknown	\N	17-27380	\N	548	\N	IP1756705
DN-074	M	\N	Unknown	\N	17-62251	\N	549	\N	IP1792072
DN-075	M	\N	Unknown	\N	16-98130	\N	550	\N	IP166471
SN-08	M	\N	Unknown	UCSF	19-97163	\N	1371	\N	IP679852
DP-04	F	\N	Unknown	UCSF	12-24226	\N	641	\N	IP1110044
CCR-256	M	\N	White	\N	05-27756A,05-27756B, 05-27756A, 05-27756B	\N	214	\N	IP504468
DP-06	F	\N	Unknown	UCSF	14-90528	\N	643	\N	IP1440512
DP-07	M	\N	Unknown	UCSF	17-132120	\N	644	\N	IP1862784
DP-08	M	\N	Unknown	UCSF	15-42060	\N	645	\N	IP1513334
SN-09	F	\N	Unknown	UCSF	19-59869A	\N	1372	\N	IP2064255
SYNAT153	\N	\N	\N	\N	Cell-Line_Xu-16	\N	1813	\N	\N
CCR-261	M	\N	White	\N	03-3075B,03-3075A, 03-3075B, 03-3075A	\N	217	\N	IP361387
LN-10	M	\N	Unknown	UCSF	17-119451	\N	830	\N	IP1849990
SN-11	F	\N	Unknown	UCSF	19-79825	\N	1374	\N	IP1933035
CCR-264	M	\N	White	\N	04-14908,04-14908A, 04-14908, 04-14908A	\N	219	\N	IP431307
CCR-273	F	\N	White	\N	06-17933B,06-17933A, 06-17933B, 06-17933A	\N	223	\N	IP562999
SN-12	M	\N	Unknown	UCSF	19-80535A	\N	1375	\N	IP2085042
SN-14	F	\N	Unknown	UCSF	19-78038	\N	1377	\N	IP144115
SN-15	F	\N	Unknown	UCSF	19-89855A	\N	1378	\N	IP2094427
CCR-281	F	\N	White	\N	93-13675A,93-13675B, 93-13675A, 93-13675B	\N	225	\N	IP35049
CM-58	\N	\N	Unknown	Denmark	19Rig750007.05.02.03,19Rig750007.05.02.04, 19Rig750007.05.02.03, 19Rig750007.05.02.04	\N	292	\N	\N
CM-60	\N	\N	Unknown	Denmark	19Rig750007.05.04.03	\N	293	\N	\N
DMS-046	\N	\N	Unknown	UCSF	23-42323	\N	458	\N	\N
DP-16	M	\N	Unknown	UCSF	11-12273	\N	653	\N	IP1001710
DP-10	F	\N	Unknown	UCSF	12-70514	Diagnosis on IntelliPath: Spitzoid Melanoma	647	\N	IP1156331
DP-11	F	\N	Unknown	UCSF	14-15427	Consultation; Diagnosis on IntelliPath: Atypical Melanocytic Proliferation	648	\N	IP1365348
LN-05	F	\N	Unknown	UCSF	17-119013	\N	825	\N	IP1849540
LN-06	F	\N	Unknown	UCSF	17-119445	\N	826	\N	IP1849984
LN-07	M	\N	Unknown	UCSF	17-119302B	\N	827	\N	IP1849840
CM-61	\N	\N	Unknown	Denmark	19Rig750007.05.05.03,19Rig750007.05.05.08, 19Rig750007.05.05.03, 19Rig750007.05.05.08	\N	294	\N	\N
SYNAT156	\N	\N	\N	\N	Cell-Line_Xu-17	\N	1758	\N	\N
CCR-302	F	\N	White	\N	03-57215A,03-57215B, 03-57215A, 03-57215B	\N	233	\N	IP415531
SN-17	F	\N	Unknown	UCSF	19-21355B	\N	1380	\N	IP90936
CCR-303	F	\N	Unknown	\N	06-21115A,06-21115B, 06-21115A, 06-21115B	\N	234	\N	IP566181
SN-18	F	\N	Unknown	UCSF	19-9438B	\N	1381	\N	IP182592
SN-19	F	\N	Unknown	UCSF	20-25263A	\N	1382	\N	IP1865438
SYNAT158	\N	\N	\N	\N	Cell-Line_Xu-18	\N	2041	\N	\N
MD-205	\N	\N	Unknown	Madrid, Spain	92-14752-1 T2	\N	1082	\N	\N
CCR-310	M	\N	Unknown	\N	06-11151D,06-11151F,06-11151C, 06-11151D, 06-11151F, 06-11151C	\N	235	\N	IP551533
LN-08	F	\N	Unknown	UCSF	17-118980	\N	828	\N	IP1629847
LN-09	F	\N	Unknown	UCSF	17-120790	\N	829	\N	IP1851350
LN-13	M	\N	Unknown	UCSF	17-120276	\N	833	\N	IP1850825
SYNAT159	\N	\N	\N	\N	17-43707	\N	1998	\N	\N
MD-206	\N	\N	Unknown	Madrid, Spain	94-19725B T3	\N	1083	\N	\N
MD-207	\N	\N	Unknown	Madrid, Spain	92-06469A T2	\N	1084	\N	\N
MD-208	\N	\N	Unknown	Madrid, Spain	94-01469-2 T3	\N	1085	\N	\N
CCR-312	M	\N	White	\N	01-34127A,01-34127B, 01-34127A, 01-34127B	\N	237	\N	IP290530
CCR-313	F	\N	White	\N	00-556B,00-556A, 00-556B, 00-556A	\N	238	\N	IP215659
LN-14	M	\N	Unknown	UCSF	17-110828C	\N	834	\N	IP1614923
LN-15	F	\N	Unknown	UCSF	17-118904B	\N	835	\N	IP1849428
LN-16	M	\N	Unknown	UCSF	17-119079A	\N	836	\N	IP1692384
LN-17	M	\N	Unknown	UCSF	17-99294B	\N	837	\N	IP1154787
MD-209	\N	\N	Unknown	Madrid, Spain	86-04906-2 T2	\N	1086	\N	\N
MD-210	\N	\N	Unknown	Madrid, Spain	93-12428-1 T2	\N	1087	\N	\N
MD-211	\N	\N	Unknown	Madrid, Spain	91-09968E T3	\N	1088	\N	\N
SYNAT355	\N	\N	\N	\N	12-12467	\N	1834	\N	IP1098283
SYNAT358	\N	\N	\N	\N	12-12647	\N	2246	\N	IP858006
CM-01	\N	\N	Unknown	Denmark	19Rig750007.01.01.03,19Rig750007.01.01.02, 19Rig750007.01.01.03, 19Rig750007.01.01.02	\N	249	\N	\N
SYNAT359	\N	\N	\N	\N	12-12626	\N	1678	\N	IP1098442
CM-05	\N	\N	Unknown	Denmark	19Rig750007.01.05.03,19Rig750007.01.05.02, 19Rig750007.01.05.03, 19Rig750007.01.05.02	\N	251	\N	\N
CM-07	\N	\N	Unknown	Denmark	19Rig750007.01.07.03,19Rig750007.01.07.02, 19Rig750007.01.07.03, 19Rig750007.01.07.02	\N	252	\N	\N
CM-08	\N	\N	Unknown	Denmark	19Rig750007.01.08.03,19Rig750007.01.08.05, 19Rig750007.01.08.03, 19Rig750007.01.08.05	\N	253	\N	\N
SYNAT360	\N	\N	\N	\N	12-18438A	\N	2083	\N	IP1104255
SYNAT361	\N	\N	\N	\N	12-13152	\N	2340	\N	IP1098968
SYNAT362	\N	\N	\N	\N	12-12750B	\N	1812	\N	IP114451
CM-13	\N	\N	Unknown	Denmark	19Rig750007.05.11.03,19Rig750007.01.13.04,19Rig750007.01.13.03, 19Rig750007.05.11.03, 19Rig750007.01.13.04, 19Rig750007.01.13.03	\N	257	\N	\N
CME-001	\N	\N	Asian	Taiwan	21-13595A1,21-13595C1,21-20305A1,21-09097A1, 21-13595A1, 21-13595C1, 21-20305A1, 21-09097A1	\N	303	\N	\N
MD-212	\N	\N	Unknown	Madrid, Spain	89-13569-1 T2	\N	1089	\N	\N
MD-213	\N	\N	Unknown	Madrid, Spain	94-18018-2 T3	\N	1090	\N	\N
MD-214	\N	\N	Unknown	Madrid, Spain	94-12246 T3	\N	1091	\N	\N
CME-002	\N	\N	Asian	Taiwan	21-20002A1,21-20368A1,21-20368A3, 21-20002A1, 21-20368A1, 21-20368A3	\N	304	\N	\N
CME-003	\N	\N	Asian	Taiwan	20-52125A1,22-42722B1,20-54923B1, 20-52125A1, 22-42722B1, 20-54923B1	\N	305	\N	\N
AM2-001	\N	\N	Unknown	Bolivia	86502f,86502d,86502c,86502b, 86502f, 86502d, 86502c, 86502b	\N	1	\N	\N
AM2-004	\N	\N	Unknown	Bolivia	534-1-11.2,534-1-11.3,534-1-11.1, 534-1-11.2, 534-1-11.3, 534-1-11.1	\N	3	\N	\N
MD-215	\N	\N	Unknown	Madrid, Spain	94-23180 T4	\N	1092	\N	\N
MD-216	\N	\N	Unknown	Madrid, Spain	94-08318-1 T2	\N	1093	\N	\N
SYNAT364	\N	\N	\N	\N	12-19187A	\N	2113	\N	IP1105004
SYNAT365	\N	\N	\N	\N	12-22172	\N	1892	\N	IP1107990
SYNAT366	\N	\N	\N	\N	12-21726A	\N	1856	\N	IP1107544
SYNAT367	\N	\N	\N	\N	12-22901A	\N	1677	\N	IP1108719
SYNAT369	\N	\N	\N	\N	12-22775	\N	1919	\N	IP249102
SYNAT370	\N	\N	\N	\N	12-22794A	\N	1873	\N	IP454633
AM2-012	\N	\N	Unknown	Bolivia	352-1-15.1,352-1-15.2,352-1-15.3, 352-1-15.1, 352-1-15.2, 352-1-15.3	\N	7	\N	\N
AM2-014	\N	\N	Unknown	Bolivia	2686-1-13.1,2686-1-13.2, 2686-1-13.1, 2686-1-13.2	\N	8	\N	\N
AM2-018	\N	\N	Unknown	Bolivia	1586-2-13-B,1586-2-13-A,1586-2-13-C, 1586-2-13-B, 1586-2-13-A, 1586-2-13-C	\N	9	\N	\N
AM2-022	\N	\N	Unknown	Bolivia	4070/2/13.3,4070/3/13.3,4070/2/13.1,4070/2/13.2,4070/3/13.2,4070/3/13.1, 4070/2/13.3, 4070/3/13.3, 4070/2/13.1, 4070/2/13.2, 4070/3/13.2, 4070/3/13.1	\N	11	\N	\N
MD-217	\N	\N	Unknown	Madrid, Spain	93-13951 T2	\N	1094	\N	\N
SYNAT371	\N	\N	\N	\N	12-22573	\N	2103	\N	IP1108391
SYNAT84	\N	\N	\N	\N	12-22582C, 12-22582A	\N	2248	\N	IP1108400
SYNAT377	\N	\N	\N	\N	12-22604	\N	1980	\N	IP1108422
SYNX29	F	\N	\N	\N	12-22720A	Upper back	1432	\N	IP118827
SYNAT378	\N	\N	\N	\N	12-22868	\N	1829	\N	IP1108686
SYNAT380	\N	\N	\N	\N	12-22886	\N	1969	\N	IP337537
SYNAT382	\N	\N	\N	\N	12-22898	\N	2182	\N	IP445158
SYNAT383	\N	\N	\N	\N	12-22900	\N	2255	\N	IP2427054
SYNAT384	\N	\N	\N	\N	10-55707	\N	1968	\N	IP950283
MD-218	\N	\N	Unknown	Madrid, Spain	89-10450-1 T2	\N	1095	\N	\N
SYNAT385	\N	\N	\N	\N	11-34950	\N	2059	\N	IP1024388
SYNAT160	\N	\N	\N	\N	13-99417	\N	1711	\N	IP2344638
SYNAT161	\N	\N	\N	\N	13-98534	\N	2055	\N	IP1340550
SYNAT387	\N	\N	\N	\N	10-86469	\N	2203	\N	IP981048
SYNAT388	\N	\N	\N	\N	11-30426	\N	2029	\N	IP1019864
MD-181	\N	\N	Unknown	Madrid, Spain	01-17200 T3	\N	1058	\N	\N
SYNAT390	\N	\N	\N	\N	11-79158	\N	1764	\N	IP1068606
SYNAT391	\N	\N	\N	\N	11-16253	\N	2280	\N	IP1005690
SYNAT392	\N	\N	\N	\N	10-41439	\N	2123	\N	IP936014
SYNAT354	\N	\N	\N	\N	12-12366	\N	2036	\N	\N
SYNAT357	\N	\N	\N	\N	12-562	\N	1698	\N	\N
SYNAT393	\N	\N	\N	\N	10-56047	\N	1693	\N	IP950623
SYNAT394	\N	\N	\N	\N	11-38771	\N	2232	\N	IP1028210
SYNAT353	\N	\N	\N	\N	12-6261B, 12-6261A	\N	1895	\N	IP1092077
SYNAT395	\N	\N	\N	\N	11-21491	\N	1691	\N	IP1010929
SYNAT363	\N	\N	\N	\N	12-19596	\N	2006	\N	\N
SYNAT396	\N	\N	\N	\N	11-65778	\N	2085	\N	IP1055221
SYNAT397	\N	\N	\N	\N	10-88482	\N	2034	\N	IP983061
SYNAT368	\N	\N	\N	\N	12-13587B2	\N	2082	\N	IP502329
SYNX8	F	\N	\N	\N	12-13587B2,12-13587, 12-13587	NaN	1411	\N	IP502329
SYNAT398	\N	\N	\N	\N	11-63178	\N	2302	\N	IP1052621
SYNAT399	\N	\N	\N	\N	12-71679	\N	1679	\N	IP1157496
SYNAT400	\N	\N	\N	\N	12-80985B	\N	1672	\N	IP1166802
SYNAT375	\N	\N	\N	\N	12-22602A, 12-22602B	\N	2316	\N	IP1081809
SYNAT381	\N	\N	\N	\N	12-22894B	\N	1694	\N	IP1108712
SYNAT402	\N	\N	\N	\N	12-39632	\N	1732	\N	IP1125450
SYNAT403	\N	\N	\N	\N	10-84478	\N	2142	\N	IP979057
SYNAT405	\N	\N	\N	\N	11-39639	\N	1861	\N	IP1029078
SYNAT407	\N	\N	\N	\N	08-27590	\N	1726	\N	IP736231
SYNX37	F	\N	\N	\N	11-23681A+C,11-23681, 11-23681A+C	NaN	1440	\N	IP1013119
SN-20	F	\N	Unknown	UCSF	20-36120	\N	1383	\N	IP2183737
SYNAT408	\N	\N	\N	\N	06-32942	\N	2003	\N	IP578011
SYNAT410	\N	\N	\N	\N	11-78845	\N	1910	\N	IP1068293
SYNAT411	\N	\N	\N	\N	11-81405	\N	1853	\N	IP1070853
SN-22	M	\N	Unknown	UCSF	20-43801	\N	1385	\N	IP2191480
SYNAT412	\N	\N	\N	\N	11-85075	\N	1747	\N	IP1074523
SYNAT413	\N	\N	\N	\N	11-83908	\N	1889	\N	IP1073356
SYNAT414	\N	\N	\N	\N	11-85859	\N	1721	\N	IP1075307
SN-24	F	\N	Unknown	UCSF	20-36500A	\N	1387	\N	IP2184119
SN-25	F	\N	Unknown	UCSF	20-48338A	\N	1388	\N	IP515987
SYNAT415	\N	\N	\N	\N	11-95663	\N	2139	\N	IP1085111
SYNAT416	\N	\N	\N	\N	07-14044A	\N	2214	\N	IP636575
SYNAT417	\N	\N	\N	\N	07-26247	\N	2294	\N	IP208441
SYNAT162	\N	\N	\N	\N	Cell-Line_Xu-19	\N	2063	\N	\N
ME-01	F	\N	Unknown	UCSF	16-109659A4	\N	1096	\N	IP1687145
SYNAT418	\N	\N	\N	\N	09-37302	\N	2200	\N	IP838065
SYNAT419	\N	\N	\N	\N	12-79358	\N	1932	\N	IP1165175
SYNAT420	\N	\N	\N	\N	12-81749	\N	2066	\N	IP1167566
SYNAT422	\N	\N	\N	\N	12-98736	\N	2279	\N	IP1184553
SYNAT423	\N	\N	\N	\N	13-3874	\N	2032	\N	IP1188617
SN-27	F	\N	Unknown	UCSF	20-57308	\N	1390	\N	IP2205057
SN-28	F	\N	Unknown	UCSF	20-34915	\N	1391	\N	IP2182521
SYNAT424	\N	\N	\N	\N	13-3732	\N	1810	\N	IP1188475
SYNAT425	\N	\N	\N	\N	13-3889	\N	1783	\N	IP1188632
SYNAT426	\N	\N	\N	\N	13-4090B	\N	2310	\N	IP1188833
SYNAT163	\N	\N	\N	\N	Cell-Line_Xu-20	\N	2233	\N	\N
SYNAT427	\N	\N	\N	\N	13-4136	\N	2229	\N	IP1179510
SYNAT428	\N	\N	\N	\N	13-7186	\N	2033	\N	IP1191929
SYNAT429	\N	\N	\N	\N	13-25A	\N	1757	\N	IP1184767
SYNAT432	\N	\N	\N	\N	11-5210D	\N	2121	\N	IP873475
SYNAT433	\N	\N	\N	\N	11-95856	\N	1954	\N	IP1085304
SYNAT434	\N	\N	\N	\N	10-23569A	\N	2201	\N	IP918142
SYNAT435	\N	\N	\N	\N	09-92749	\N	1717	\N	IP893515
SYNAT436	\N	\N	\N	\N	10-46536	\N	1675	\N	IP941112
SYNAT437	\N	\N	\N	\N	10-83613A	\N	2169	\N	IP978192
SYNAT439	\N	\N	\N	\N	11-18560	\N	1914	\N	IP1007998
SYNAT440	\N	\N	\N	\N	11-64496	\N	1935	\N	IP1053939
SYNAT441	\N	\N	\N	\N	11-71491	\N	1957	\N	IP1060934
VS-01	\N	\N	Unknown	UCSF	11-14908C	\N	1394	\N	IP1004345
SYNAT442	\N	\N	\N	\N	11-65756	\N	2130	\N	IP1055199
SYNAT443	\N	\N	\N	\N	11-74100	\N	1749	\N	IP1063547
SYNAT444	\N	\N	\N	\N	11-74517	\N	1729	\N	IP1063964
SYNAT445	\N	\N	\N	\N	10-74513	\N	1842	\N	IP969092
SYNAT446	\N	\N	\N	\N	10-80009	\N	2259	\N	IP974588
NM-029	\N	\N	Unknown	Greece	16053/12 wy (16053/12 slide)	\N	1208	\N	\N
NM-031	\N	\N	Unknown	Greece	2227/14 4	\N	1209	\N	\N
SYNAT447	\N	\N	\N	\N	10-91484	\N	2117	\N	IP986063
SYNAT448	\N	\N	\N	\N	11-699	\N	2096	\N	IP990136
MucM-02	\N	\N	Unknown	UCSF	20-10245F1,20-10245D1,20-10245H3, 20-10245F1, 20-10245D1, 20-10245H3	\N	1170	\N	\N
SYNAT379	\N	\N	\N	\N	12-22884C, 12-22884D	\N	1676	\N	IP1108702
MucM-03	\N	\N	Unknown	UCSF	17-33973C4,17-33973D3,17-33973A1, 17-33973C4, 17-33973D3, 17-33973A1	\N	1171	\N	\N
SYNAT430	\N	\N	\N	\N	11-71241	\N	2051	\N	IP1060684
SYNAT450	\N	\N	\N	\N	11-35616	\N	1707	\N	IP1025054
SYNAT451	\N	\N	\N	\N	11-33856	\N	2125	\N	IP1023294
SYNAT452	\N	\N	\N	\N	10-58663	\N	2173	\N	IP953239
SYNAT453	\N	\N	\N	\N	08-52519	\N	2072	\N	IP761160
ME-18	M	\N	Unknown	UCSF	16-103071,16-105218C, 16-103071, 16-105218C	\N	1113	\N	IP1174641
VS-04_JJS22	F	\N	Unknown	UCSF	15-22411	PMID: 29990500 case 76; RPA-566	1397	\N	IP1199550
SYNAT454	\N	\N	\N	\N	09-8165	\N	1730	\N	IP458841
MucM-04	\N	\N	Unknown	UCSF	20-16903A2,20-16903C4,20-16903C1, 20-16903A2, 20-16903C4, 20-16903C1	\N	1172	\N	\N
SYNAT438	\N	\N	\N	\N	11-38149	\N	1751	\N	IP1018350
SYNAT164	\N	\N	\N	\N	Cell-Line_Xu-21	\N	2020	\N	\N
VS-05	\N	\N	Unknown	UCSF	22-75050A2	\N	1398	\N	IP2476934
VS-07	\N	\N	Unknown	UCSF	22-119466	\N	1400	\N	\N
SYNAT456	\N	\N	\N	\N	06-21363	\N	1670	\N	IP566429
SYNAT457	\N	\N	\N	\N	06-47334	\N	2238	\N	IP454219
MucM-06	\N	\N	Unknown	UCSF	14-12190A1,14-12190L4, 14-12190A1, 14-12190L4	\N	1174	\N	\N
SYNAT458	\N	\N	\N	\N	11-25808	\N	1792	\N	IP1015246
SYNAT459	\N	\N	\N	\N	12-7775	\N	2272	\N	IP1093591
ME-02	M	\N	Unknown	UCSF	16-84820	\N	1097	\N	IP1684607
SYNAT460	\N	\N	\N	\N	08-43264	\N	2086	\N	IP179649
SYNAT461	\N	\N	\N	\N	08-51219	\N	1744	\N	IP754897
SM-003	F	\N	Unknown	UCSF	06-2345	\N	1333	\N	IP395583
CCR-205	M	\N	White	\N	05-46869B	\N	185	\N	IP523582
ME-19	M	\N	Unknown	UCSF	17-82793A,19-135629A, 17-82793A, 19-135629A	\N	1114	\N	IP1812855
VS-08	\N	\N	Unknown	UCSF	22-73345B	\N	1401	\N	IP2475216
MD-112	\N	\N	Unknown	Madrid, Spain	95-14690F T1	\N	1004	\N	\N
MD-113	\N	\N	Unknown	Madrid, Spain	00-16651B T1	\N	1005	\N	\N
ME-64	F	\N	Unknown	UCSF	23-11588A,23-2718 (block 1),23-2718 (block 2), 23-11588A, 23-2718 (block 1), 23-2718 (block 2)	\N	1159	\N	IP347366
MD-114	\N	\N	Unknown	Madrid, Spain	99-13402-3 T1	\N	1006	\N	\N
MD-118	\N	\N	Unknown	Madrid, Spain	06-24998B T2	\N	1007	\N	\N
MD-119	\N	\N	Unknown	Madrid, Spain	00-23160D T1	\N	1008	\N	\N
MD-121	\N	\N	Unknown	Madrid, Spain	06-21073E T3	\N	1009	\N	\N
MD-122	\N	\N	Unknown	Madrid, Spain	06-20661-2 T1	\N	1010	\N	\N
MD-125	\N	\N	Unknown	Madrid, Spain	06-17562-2 T1	\N	1011	\N	\N
MD-127	\N	\N	Unknown	Madrid, Spain	06-15453C T1	\N	1012	\N	\N
MD-128	\N	\N	Unknown	Madrid, Spain	06-10522-2B T1	\N	1013	\N	\N
AMC-02	\N	\N	Unknown	\N	M100118	\N	99	\N	\N
AMC-13	\N	\N	Unknown	\N	M180322	\N	104	\N	\N
BN-001	F	\N	Unknown	UCSF	12-37217	blue nevus, cellular	105	\N	\N
BN-002	F	\N	Unknown	UCSF	12-52736	blue nevus, cellular	106	\N	\N
SYNAT462	\N	\N	\N	\N	11-81851	\N	2045	\N	IP1071299
SYNAT463	\N	\N	\N	\N	13-45163	\N	1966	\N	IP468757
SYNAT464	\N	\N	\N	\N	11-50182	\N	1827	\N	IP1039621
SYNAT465	\N	\N	\N	\N	11-51553	\N	2150	\N	IP1040993
SYNAT467	\N	\N	\N	\N	11-55993	\N	1801	\N	IP1045436
SYNAT468	\N	\N	\N	\N	11-57051	\N	1973	\N	IP1046494
SYNAT470	\N	\N	\N	\N	11-76464	\N	1753	\N	IP1065911
SYNX150	F	\N	\N	\N	11-23878	CGH11-109 	1553	\N	IP1013316
SYNAT350	\N	\N	\N	\N	12-55584	\N	2052	\N	IP1141397
SYNAT471	\N	\N	\N	\N	11-88432	\N	2147	\N	IP1077880
MD-59	\N	\N	Unknown	Madrid, Spain	98-02267-5 M1	\N	965	\N	\N
BN-005	F	\N	Unknown	UCSF	12-20144	blue nevus, cellular	109	\N	\N
SYNAT472	\N	\N	\N	\N	11-88209	\N	1920	\N	IP1071369
SYNAT473	\N	\N	\N	\N	11-94134	\N	1866	\N	IP1083582
SYNAT474	\N	\N	\N	\N	12-2898	\N	2308	\N	IP1088714
ME-54	M	\N	Unknown	UCSF	20-43011,18-67239, 20-43011, 18-67239	\N	1149	\N	IP1919209
CCR-	M	\N	White	\N	04-15284	\N	118	\N	IP431683
SYNAT476	\N	\N	\N	\N	11-21178	\N	1854	\N	IP1010616
SYNAT478	\N	\N	\N	\N	11-50270	\N	1995	\N	IP1039709
SYNAT479	\N	\N	\N	\N	12-23578	\N	2010	\N	IP1101847
ME-59	M	\N	Unknown	UCSF	21-2141,21-16708A, 21-2141, 21-16708A	\N	1154	\N	IP2267514
CCR-001	F	\N	White	\N	99-3122A	\N	119	\N	IP178655
CCR-003	M	\N	White	\N	14-34758	\N	120	\N	IP1384692
NM-35	\N	\N	Unknown	Greece	1283/14	\N	1213	\N	\N
NM-36	\N	\N	Unknown	Greece	1205/17	\N	1214	\N	\N
SYNAT480	\N	\N	\N	\N	12-31421	\N	1740	\N	IP1117239
SYNAT481	\N	\N	\N	\N	11-13661	\N	2070	\N	IP1003098
SYNAT482	\N	\N	\N	\N	13-2939B	\N	1913	\N	IP1187682
SYNAT488	\N	\N	\N	\N	13-51115A	\N	2287	\N	IP380899
SYNAT489	\N	\N	\N	\N	11-73238A	\N	2353	\N	IP987085
SYNAT490	\N	\N	\N	\N	11-73999	\N	2049	\N	IP1063446
SYNAT491	\N	\N	\N	\N	13-59840	\N	2171	\N	IP352453
SYNAT484	\N	\N	\N	\N	12-11406A	\N	1979	\N	\N
SYNAT485	\N	\N	\N	\N	08-70283a	\N	2320	\N	\N
SYNAT486	\N	\N	\N	\N	03-34051A1	\N	1817	\N	\N
SYNAT487	\N	\N	\N	\N	02-42436	\N	2168	\N	\N
SYNAT165	\N	\N	\N	\N	19-94061	\N	2115	\N	IP370740
CCR-004	F	\N	White	\N	07-55149	\N	121	\N	IP677682
CCR-007	M	\N	White	\N	00-14127B	\N	123	\N	IP229230
SYNAT492	\N	\N	\N	\N	13-32982A	\N	2110	\N	IP1210033
NM-59	\N	\N	Unknown	Greece	N-ID 1941	\N	1234	\N	\N
CCR-049	M	\N	White	\N	98-11545	\N	143	\N	IP149118
CGH16-200	M	\N	Unknown	UCSF	16-83056	cases with MAP3K8 fusions	244	\N	IP1682818
CCR-009	F	\N	White	\N	06-18321	\N	125	\N	IP563387
OM-13	F	\N	Unknown	Mexico	BB21-21338	\N	1274	\N	\N
LMM-01	\N	\N	Unknown	UCSF	20-81257B,"20-81257A\n", 20-81257B, 20-81257A\n	\N	800	\N	IP1127057
CCR-010	M	\N	White	\N	05-19406	\N	126	\N	IP496118
CCR-014	M	\N	White	\N	09-90221	\N	128	\N	IP890987
OM-46	M	\N	Unknown	UCSF	18-88579	\N	1304	\N	\N
OM-47	M	\N	Unknown	UCSF	18-90413	\N	1305	\N	\N
OM-48	F	\N	Unknown	UCSF	10-86269	\N	1306	\N	\N
SYNX239	F	\N	\N	\N	09-45509	NaN	1642	\N	IP846272
SYNAT493	\N	\N	\N	\N	14-16247	\N	1776	\N	IP1366169
SYNAT496	\N	\N	\N	\N	13-9916	\N	1795	\N	IP1194427
SYNAT497	\N	\N	\N	\N	11-44609F	\N	1752	\N	IP1029070
SM-023	\N	\N	\N	\N	12-16974C	\N	1949	\N	IP1102790
NL-013	M	\N	Unknown	UCSF	12-16974C,12-16974B, 12-16974B	\N	1175	\N	IP1102790
DN-132	M	\N	Unknown	\N	18-136800A,18-136800B, 18-136800A	\N	607	\N	IP1417678
DN-136	\N	\N	\N	\N	18-136800B	\N	2080	\N	IP1417678
SYNAT166	\N	\N	\N	\N	21-3841E1	\N	2225	\N	IP1199808
SMP2	F	\N	Unknown	UCSF	14-39393	\N	1355	\N	\N
SMP4	F	\N	Unknown	UCSF	14-59414	\N	1356	\N	\N
LN-023	M	\N	Unknown	UCSF	17-112365B,17-112365A, 17-112365B	\N	843	\N	IP1842838
LN-040	\N	\N	\N	\N	17-112365A	\N	2292	\N	IP1842838
SN-10	M	\N	Unknown	UCSF	19-43600A,19-43600B, 19-43600A	\N	1373	\N	IP1927911
SN-13	\N	\N	\N	\N	19-43600B	\N	1731	\N	IP1927911
DN-144	\N	\N	\N	\N	19-7357B	\N	2298	\N	IP2011413
DN-143	M	\N	Unknown	\N	19-7357B,19-7357A, 19-7357A	\N	618	\N	IP2011413
DN-154	M	\N	Unknown	\N	19-37607E,19-37607D,19-37607F, 19-37607E	\N	629	\N	IP2041843
DN-162	\N	\N	\N	\N	19-37607D	\N	2011	\N	IP2041843
SYNAT167	\N	\N	\N	\N	ct-H3K4	\N	2038	\N	\N
DN-157	\N	\N	\N	\N	19-37607F	\N	2120	\N	IP2041843
LN-087	\N	\N	\N	\N	21-112195D	\N	2352	\N	IP2375313
LN-086	M	\N	Unknown	UCSF	21-112195D,21-112195B, 21-112195B	Jessica assigned different Pat_ID to same sample. LN-086 = LN-087	899	\N	IP2375313
LN-045	\N	\N	\N	\N	17-111004C, 17-111004A	\N	1929	\N	IP366882
LN-022	M	\N	Unknown	UCSF	17-111004C,17-111004A,17-111004B, 17-111004B	Jessica assigned different Pat_ID to same sample. LN-022 = LN-045	842	\N	IP366882
LN-050	\N	\N	\N	\N	18-27178A	\N	2211	\N	IP401538
LN-043	M	\N	Unknown	UCSF	18-27178A,18-27178B, 18-27178B	Jessica assigned different Pat_ID to same sample. LN-043 = LN-050	861	\N	IP401538
DP-38	F	\N	Unknown	UCSF	15-16907A,07-55184, 15-16907A	\N	675	\N	IP677717
SYNAT168	\N	\N	\N	\N	21-21324	\N	2015	\N	\N
DP-40	\N	\N	\N	\N	07-55184	\N	2242	\N	IP677717
LN-032	M	\N	Unknown	UCSF	18-18111A,18-18111B,18-18111C, 18-18111A	Jessica assigned different Pat_ID to same sample. LN-032 = LN-056	851	\N	IP683601
LN-056	\N	\N	\N	\N	18-18111B, 18-18111C	\N	2001	\N	IP683601
CCR-208	F	\N	White	\N	02-5600A,06-23240A,06-10811, 02-5600A	\N	188	\N	IP76569
SYNAT169	\N	\N	\N	\N	ct-H3K27	\N	2247	\N	\N
CCR-209	\N	\N	\N	\N	06-23240A, 06-10811	\N	2165	\N	IP443105
CCR-209	\N	\N	\N	\N	06-23240A, 06-10811	\N	2222	\N	IP76569
SYNAT495	\N	\N	\N	\N	13-102610	\N	2323	\N	\N
SYNX254	F	\N	\N	\N	13-48020	NaN	1657	\N	IP1289322
SYNX255	F	\N	\N	\N	14-13499	NaN	1658	\N	IP1363420
SYNX257	M	\N	\N	\N	14-22939	NaN	1660	\N	IP1372863
SYNX258	F	\N	\N	\N	13-61146	NaN	1661	\N	IP1303150
SYNAT170	\N	\N	\N	\N	ct-Input	\N	2208	\N	\N
UV-02	\N	\N	Unknown	UCSF	MP41-YM-R1	Cell culture DNA from Xu	1393	\N	\N
VS-02	\N	\N	Unknown	UCSF	20-30233-2,20-30233, 20-30233, 20-30233-2	\N	1395	\N	\N
VS-03	\N	\N	Unknown	UCSF	19-10031-2,19-10031, 19-10031, 19-10031-2	\N	1396	\N	\N
SYNX256	M	\N	\N	\N	13-64515B	NaN	1659	\N	IP1292049
SYNX250	F	\N	\N	\N	14-18	13 Cycle Post Hybridization LM-PCR	1653	\N	IP703498
SYNX251	F	\N	\N	\N	14-19	13 Cycle Post Hybridization LM-PCR	1654	\N	IP1349938
SYNX252	M	\N	\N	\N	14-21	13 Cycle Post Hybridization LM-PCR	1655	\N	IP1349940
MD-24	\N	\N	Unknown	Madrid, Spain	08-21729 T2,08-21729-2 M1, 08-21729-2 M1, 08-21729 T2	\N	930	\N	\N
CME-034	\N	\N	Asian	Taiwan	22-25709C1	\N	336	\N	\N
CME-035	\N	\N	Asian	Taiwan	23-09618	\N	337	\N	\N
CME-036	F	\N	Asian	Japan	23-02692-3	\N	338	\N	\N
CME-037	M	\N	Asian	Japan	23-03529-3	\N	339	\N	\N
CME-038	F	\N	Asian	Japan	23-04707-7	\N	340	\N	\N
CME-039	F	\N	Asian	Japan	23-05091-4	\N	341	\N	\N
CME-040	F	\N	Asian	Japan	23-04628-5	\N	342	\N	\N
CME-041	F	\N	Asian	Japan	23-05782-2	\N	343	\N	\N
CME-042	M	\N	Asian	Japan	23-06001-12	\N	344	\N	\N
CME-043	M	\N	Asian	Japan	23-07186-13	\N	345	\N	\N
CME-045	M	\N	Asian	Japan	18-02303-1	\N	347	\N	\N
CME-046	F	\N	Asian	Japan	18-08429-4	\N	348	\N	\N
CME-053	F	\N	Asian	Japan	19-05094-9	\N	355	\N	\N
CME-054	M	\N	Asian	Japan	19-05307-8	\N	356	\N	\N
CME-056	M	\N	Asian	Japan	19-09700-4	\N	358	\N	\N
CME-057	F	\N	Asian	Japan	20-01244-2	\N	359	\N	\N
CME-058	M	\N	Asian	Japan	20-00548-10	\N	360	\N	\N
CME-059	M	\N	Asian	Japan	20-01665-3	\N	361	\N	\N
CME-044	F	\N	Asian	Japan	18-00447-2,18-00447N1, 18-00447-2, 18-00447N1	\N	346	\N	\N
CME-061	M	\N	Asian	Japan	20-04152-8	\N	363	\N	\N
CME-063	F	\N	Asian	Japan	20-08679-5	\N	365	\N	\N
CME-047	F	\N	Asian	Japan	18-09671N1,18-09671-4,20-00782N3, 18-09671N1, 18-09671-4, 20-00782N3	\N	349	\N	\N
CME-048	M	\N	Asian	Japan	19-01043-1,19-01043N2,19-03736, 19-01043-1, 19-01043N2, 19-03736	\N	350	\N	\N
CME-051	M	\N	Asian	Japan	20-02956-5,20-00698,19-03361-3, 20-02956-5, 20-00698, 19-03361-3	\N	353	\N	\N
CME-052	F	\N	Asian	Japan	19-05268-9,19-05268N1, 19-05268-9, 19-05268N1	\N	354	\N	\N
CME-064	M	\N	Asian	Japan	20-06242	\N	366	\N	\N
CME-067	M	\N	Asian	Japan	21-06796-5	\N	369	\N	\N
CME-068	M	\N	Asian	Japan	21-08944-3	\N	370	\N	\N
BN-009	M	\N	Unknown	UCSF	11-85008	blue nevus, cellular	113	\N	\N
CME-055	M	\N	Asian	Japan	19-08527-2,19-08527N1, 19-08527-2, 19-08527N1	\N	357	\N	\N
CME-072	M	\N	Asian	Japan	22-00892-16	\N	374	\N	\N
CME-077	F	\N	Asian	Japan	23-01133	\N	379	\N	\N
CME-078	F	\N	Asian	Japan	23-01329-1	\N	380	\N	\N
CME-079	F	\N	Asian	Japan	15-05771-4	\N	381	\N	\N
CME-060	M	\N	Asian	Japan	20-03009-7,20-03009N1, 20-03009-7, 20-03009N1	\N	362	\N	\N
CME-080	M	\N	Asian	Japan	15-06395-3	\N	382	\N	\N
CME-062	M	\N	Asian	Japan	21-03240,22-07164-1,20-04546-3, 21-03240, 22-07164-1, 20-04546-3	\N	364	\N	\N
CME-081	F	\N	Asian	Japan	15-07035-1	\N	383	\N	\N
CME-082	F	\N	Asian	Japan	15-08075-5	\N	384	\N	\N
CME-065	M	\N	Asian	Japan	21-04018,22-03790,20-05671-2, 21-04018, 22-03790, 20-05671-2	\N	367	\N	\N
CME-066	M	\N	Asian	Japan	23-03515-1,21-04690-3, 23-03515-1, 21-04690-3	\N	368	\N	\N
CME-083	M	\N	Asian	Japan	15-08126-3	\N	385	\N	\N
CME-084	M	\N	Asian	Japan	15-08727-2	\N	386	\N	\N
CME-069	F	\N	Asian	Japan	21-09119N2,21-09119-2,21-09119-4, 21-09119N2, 21-09119-2, 21-09119-4	\N	371	\N	\N
CME-070	M	\N	Asian	Japan	21-09543-1,21-09543-2, 21-09543-1, 21-09543-2	\N	372	\N	\N
CME-071	M	\N	Asian	Japan	22-00847N5,21-09545-2, 22-00847N5, 21-09545-2	\N	373	\N	\N
CME-085	F	\N	Asian	Japan	15-10294-1	\N	387	\N	\N
AM2-118	\N	\N	Asian	Taiwan	22-510407A1,22-9055C1,22-9055A1, 22-510407A1, 22-9055C1, 22-9055A1	\N	88	\N	\N
AM2-119	\N	\N	Unknown	UCSF	23-51956B17,23-51956B14,23-51956B16,23-51956A3, 23-51956B14, 23-51956B16, 23-51956A3, 23-51956B17	\N	89	\N	\N
CME-074	M	\N	Asian	Japan	22-04201N2,22-04201-6, 22-04201N2, 22-04201-6	\N	376	\N	\N
CME-075	M	\N	Asian	Japan	22-05287-15,22-05287N2, 22-05287-15, 22-05287N2	\N	377	\N	\N
CME-073	M	\N	Asian	Japan	22-01164-2	\N	375	\N	\N
CME-076	F	\N	Asian	Japan	22-06500-1	\N	378	\N	\N
CME-090	F	\N	Asian	Japan	16-05265-2	\N	392	\N	\N
CME-091	M	\N	Asian	Japan	16-05548-2	\N	393	\N	\N
CME-093	F	\N	Asian	Japan	16-06126-2	\N	395	\N	\N
CME-094	M	\N	Asian	Japan	16-06348-2	\N	396	\N	\N
CME-095	F	\N	Asian	Japan	16-06590-2	\N	397	\N	\N
CME-096	F	\N	Asian	Japan	16-06994-1	\N	398	\N	\N
CME-108	F	\N	Asian	Japan	17-10231-5	\N	410	\N	\N
CME-089	M	\N	Asian	Japan	17-00792,16-04805-2, 17-00792, 16-04805-2	\N	391	\N	\N
DMS-003	\N	\N	Unknown	UCSF	23-4595	\N	415	\N	\N
DMS-004	\N	\N	Unknown	UCSF	23-5236	\N	416	\N	\N
CME-092	M	\N	Asian	Japan	21-10478-2,16-05958-2, 21-10478-2, 16-05958-2	\N	394	\N	\N
DMS-005	\N	\N	Unknown	UCSF	22-35051	\N	417	\N	\N
DMS-006	\N	\N	Unknown	UCSF	23-4742	\N	418	\N	\N
DMS-007	\N	\N	Unknown	UCSF	23-4604	\N	419	\N	\N
DMS-008	\N	\N	Unknown	UCSF	22-122015	\N	420	\N	\N
DMS-009	\N	\N	Unknown	UCSF	22-115763	\N	421	\N	\N
DMS-010	\N	\N	Unknown	UCSF	22-59468	\N	422	\N	\N
DMS-011	\N	\N	Unknown	UCSF	23-5230	\N	423	\N	\N
DMS-012	\N	\N	Unknown	UCSF	22-114644	\N	424	\N	\N
DMS-013	\N	\N	Unknown	UCSF	22-127365	\N	425	\N	\N
DMS-014	\N	\N	Unknown	UCSF	22-127490	\N	426	\N	\N
DMS-015	\N	\N	Unknown	UCSF	22-128532	\N	427	\N	\N
DMS-016	\N	\N	Unknown	UCSF	22-128941	\N	428	\N	\N
DMS-017	\N	\N	Unknown	UCSF	22-83883	\N	429	\N	\N
DMS-020	\N	\N	Unknown	UCSF	22-115140	\N	432	\N	\N
DMS-021	\N	\N	Unknown	UCSF	23-3020	\N	433	\N	\N
DMS-022	\N	\N	Unknown	UCSF	22-8115	\N	434	\N	\N
SYNAT171	\N	\N	\N	\N	22-83923A	\N	1748	\N	IP2060770
CME-103	F	\N	Asian	Japan	17-09063-N1,17-09063-1, 17-09063-N1, 17-09063-1	\N	405	\N	\N
CME-098	F	\N	Asian	Japan	16-10561-3	\N	400	\N	\N
CME-106	M	\N	Asian	Japan	17-10987-6,17-10987-N2, 17-10987-6, 17-10987-N2	\N	408	\N	\N
CME-099	M	\N	Asian	Japan	16-10560-1	\N	401	\N	\N
CME-100	M	\N	Asian	Japan	17-00730-3	\N	402	\N	\N
MD-130	\N	\N	Unknown	Madrid, Spain	06-01846D T1	\N	1014	\N	\N
MD-131	\N	\N	Unknown	Madrid, Spain	06-06053B T1	\N	1015	\N	\N
AM2-053	\N	\N	Unknown	Bolivia	21159 A6,21159 G5,21159 A5,21159 G2, 21159 A6, 21159 G5, 21159 A5, 21159 G2	Sites of cancer are not sure, diagnosis are in Spanish.  See scanned file:  "AM2_051 to AM2_056" in "Materials came with the speciment" folder. 	26	\N	\N
AM2-027	\N	\N	Unknown	Chile	501950A3,501950C, 501950A3, 501950C	\N	12	\N	\N
AM2-030	\N	\N	Unknown	Chile	604076	\N	14	\N	\N
AM2-039	\N	\N	Unknown	Chile	488836A	\N	15	\N	\N
AM2-040	\N	\N	Unknown	Zurich	H13.10897/11,H13.10897/2,B13.26332/1, H13.10897/11, H13.10897/2, B13.26332/1	\N	16	\N	\N
AM2-041	\N	\N	Unknown	Zurich	B06.41962/5,H13.21587/1,B14.2561/12,B06.41962/3, B06.41962/5, H13.21587/1, B14.2561/12, B06.41962/3	\N	17	\N	\N
AM2-042	\N	\N	Unknown	Zurich	B15.28523/11,H16.660,B 62056/15, B15.28523/11, H16.660, B 62056/15	Patient 3	18	\N	\N
AM2-043	\N	\N	Unknown	Zurich	H15.2058/1,H12.27716/7, H15.2058/1, H12.27716/7	\N	19	\N	\N
AM2-045	\N	\N	Unknown	Zurich	H 2008.8956/1,B2008.3067/5,H2007.215/5, H 2008.8956/1, B2008.3067/5, H2007.215/5	Patient 6	20	\N	\N
AM2-046	\N	\N	Unknown	Zurich	B2007.15494/1,B2008.24393/1,H2007.4636/9, B2007.15494/1, B2008.24393/1, H2007.4636/9	\N	21	\N	\N
AM2-048	\N	\N	Unknown	Zurich	H2007.358/1,H2007.358/3,B2007.998/2, H2007.358/1, H2007.358/3, B2007.998/2	Patient 9	22	\N	\N
AM2-049	\N	\N	Asian	Japan	K1-A,K1-D,K1-A.2,K1-C,K1-B, K1-A, K1-D, K1-A.2, K1-C, K1-B	Case K1	23	\N	\N
CME-101	F	\N	Asian	Japan	17-00731-3	\N	403	\N	\N
CME-102	M	\N	Asian	Japan	17-03472-1	\N	404	\N	\N
CME-104	M	\N	Asian	Japan	17-08581-5	\N	406	\N	\N
DMS-023	\N	\N	Unknown	UCSF	22-81230	\N	435	\N	\N
DMS-024	\N	\N	Unknown	UCSF	22-83760	\N	436	\N	\N
DMS-026	\N	\N	Unknown	UCSF	22-85528	\N	438	\N	\N
DMS-027	\N	\N	Unknown	UCSF	22-88969	\N	439	\N	\N
SYNAT172	\N	\N	\N	\N	22-80980	\N	2223	\N	IP2482899
CCR-011	M	\N	White	\N	11-89154A6,11-89154A7,08-48442, 11-89154A7, 08-48442, 11-89154A6	\N	127	\N	IP757083
CS-01	M	\N	Unknown	UCSF	22-104389A4,22-104389A2,22-104389C,22-44813B, 22-104389A4, 22-104389A2, 22-104389C, 22-44813B	CS = Clinical Sample	411	\N	IP2435904
CS-02	F	\N	Unknown	UCSF	22-125373	\N	412	\N	\N
DMS-028	\N	\N	Unknown	UCSF	22-90430	\N	440	\N	\N
CM-72	\N	\N	Unknown	Denmark	19Rig750007.05.16.01	\N	300	\N	\N
DMS-001	\N	\N	Unknown	UCSF	23-7246A ,23-7246C,23-7246B, 23-7246A , 23-7246C, 23-7246B	\N	413	\N	\N
DMS-029	\N	\N	Unknown	UCSF	22-91591	\N	441	\N	\N
DMS-030	\N	\N	Unknown	UCSF	22-94507	\N	442	\N	\N
DMS-031	\N	\N	Unknown	UCSF	22-95858	\N	443	\N	\N
DMS-032	\N	\N	Unknown	UCSF	22-99877	\N	444	\N	\N
DMS-033	\N	\N	Unknown	UCSF	19-111428	\N	445	\N	\N
DMS-034	\N	\N	Unknown	UCSF	20-103041	\N	446	\N	\N
DMS-035	\N	\N	Unknown	UCSF	20-14475	\N	447	\N	\N
DMS-036	\N	\N	Unknown	UCSF	20-23650	\N	448	\N	\N
DMS-037	\N	\N	Unknown	UCSF	20-31361	\N	449	\N	\N
DMS-038	\N	\N	Unknown	UCSF	20-35177	\N	450	\N	\N
DMS-039	\N	\N	Unknown	UCSF	20-43970	\N	451	\N	\N
DMS-040	\N	\N	Unknown	UCSF	20-5264	\N	452	\N	\N
DMS-041	\N	\N	Unknown	UCSF	20-57917	\N	453	\N	\N
DMS-042	\N	\N	Unknown	UCSF	20-64178	\N	454	\N	\N
DMS-043	\N	\N	Unknown	UCSF	23-7509	\N	455	\N	\N
DMS-044	\N	\N	Unknown	UCSF	23-14412	\N	456	\N	\N
DMS-048	\N	\N	Unknown	UCSF	17-113038	\N	460	\N	\N
DMS-049	\N	\N	Unknown	UCSF	17-130985	\N	461	\N	\N
DMS-050	\N	\N	Unknown	UCSF	17-48914	\N	462	\N	\N
DMS-051	\N	\N	Unknown	UCSF	17-75346	\N	463	\N	\N
DMS-055	\N	\N	Unknown	UCSF	22-47776	\N	467	\N	\N
DMS-056	\N	\N	Unknown	UCSF	22-51687	\N	468	\N	\N
DMS-057	\N	\N	Unknown	UCSF	22-53879	\N	469	\N	\N
DMS-058	\N	\N	Unknown	UCSF	22-61674	\N	470	\N	\N
DMS-059	\N	\N	Unknown	UCSF	22-67443	\N	471	\N	\N
DMS-060	\N	\N	Unknown	UCSF	22-84696	\N	472	\N	\N
DMS-061	\N	\N	Unknown	UCSF	22-88291	\N	473	\N	\N
DMS-062	\N	\N	Unknown	UCSF	22-93578	\N	474	\N	\N
DN-001	F	\N	Unknown	\N	16-119468	\N	476	\N	IP1458214
DN-002	M	\N	Unknown	\N	17-20901	\N	477	\N	IP1750156
DN-004	M	\N	Unknown	\N	17-21285	\N	479	\N	IP1750551
DMS-052	\N	\N	Unknown	UCSF	17-91856A,17-91856B, 17-91856A, 17-91856B	\N	464	\N	\N
SYNAT173	\N	\N	\N	\N	D12_M	\N	2346	\N	\N
CM-15	\N	\N	Unknown	Denmark	19Rig750007.01.15.01,19Rig750007.01.15.03, 19Rig750007.01.15.01, 19Rig750007.01.15.03	\N	259	\N	\N
CCR-024	M	\N	White	\N	06-8729	\N	132	\N	IP553795
DN-005	M	\N	Unknown	\N	16-125611	\N	480	\N	IP1713848
DMS-063	\N	\N	Unknown	UCSF	22-95643B,22-95643, 22-95643B, 22-95643	\N	475	\N	\N
DN-041	F	\N	Unknown	\N	17-65000	\N	516	\N	IP1794850
DN-006	M	\N	Unknown	\N	16-126284A	\N	481	\N	IP1726527
SYNAT174	\N	\N	\N	\N	22-107614	\N	1772	\N	IP2509746
SYNAT175	\N	\N	\N	\N	22-115635C4	\N	1860	\N	IP908318
CM-18	\N	\N	Unknown	Denmark	19rig75000701.18.01,19rig75000701.18.02, 19rig75000701.18.02, 19rig75000701.18.01	\N	262	\N	\N
SYNAT176	\N	\N	\N	\N	22-152373	\N	2177	\N	\N
CM-17	\N	\N	Unknown	Denmark	19rig750007.01.17.01	\N	261	\N	\N
DN-008	M	\N	Unknown	\N	16-125177	\N	483	\N	IP1660916
DN-007	F	\N	Unknown	\N	17-21066B	\N	482	\N	IP711299
DN-009	M	\N	Unknown	\N	17-35916B	\N	484	\N	IP1765367
DN-010	M	\N	Unknown	\N	17-62447B,17-62447A, 17-62447B, 17-62447A	\N	485	\N	IP1792269
DN-011	M	\N	Unknown	\N	17-21476B	\N	486	\N	IP1745878
SYNAT177	\N	\N	\N	\N	23-18865	\N	1702	\N	IP2557030
DN-013	M	\N	Unknown	\N	17-62828B,17-62828A, 17-62828B, 17-62828A	\N	488	\N	IP1792659
DN-012	M	\N	Unknown	\N	16-125754	\N	487	\N	IP1725994
DN-015	F	\N	Unknown	\N	17-34432D,17-34432C,17-34432B, 17-34432D, 17-34432C, 17-34432B	\N	490	\N	IP1697427
DN-014	M	\N	Unknown	\N	16-98123	\N	489	\N	IP1698042
SYNAT178	\N	\N	\N	\N	23-83099	\N	2100	\N	IP2621535
SYNAT181	\N	\N	\N	\N	90-012097B	\N	1994	\N	\N
SYNAT184	\N	\N	\N	\N	92-003527H	\N	2286	\N	\N
DN-018	M	\N	Unknown	\N	17-35917B,17-35917A, 17-35917B, 17-35917A	\N	493	\N	IP1765368
DN-017	M	\N	Unknown	\N	17-65201A	\N	492	\N	IP1795054
DN-022	M	\N	Unknown	\N	17-35859C,17-35859A,17-35859B, 17-35859C, 17-35859A, 17-35859B	\N	497	\N	IP1082132
DN-020	F	\N	Unknown	\N	17-62534	\N	495	\N	IP1792363
SYNAT185	\N	\N	\N	\N	94-016368	\N	2268	\N	\N
SYNAT186	\N	\N	\N	\N	94-31062  	\N	2313	\N	\N
SYNAT187	\N	\N	\N	\N	95-007992	\N	2183	\N	\N
SYNAT188	\N	\N	\N	\N	98-019394	\N	2291	\N	\N
DN-021	M	\N	Unknown	\N	16-126258A	\N	496	\N	IP1726501
DN-023	F	\N	Unknown	\N	16-119063	\N	498	\N	IP1719254
DN-024	M	\N	Unknown	\N	16-125609	\N	499	\N	IP1408533
DN-030	M	\N	Unknown	\N	16-98055B,16-98055A, 16-98055B, 16-98055A	\N	505	\N	IP834471
DN-025	F	\N	Unknown	\N	16-98528A	\N	500	\N	IP1698449
DN-026	M	\N	Unknown	\N	16-97347	\N	501	\N	IP438654
DN-027	M	\N	Unknown	\N	16-117695A	\N	502	\N	IP1717875
CM-30	\N	\N	Unknown	Denmark	19Rig750007.03.01.03	\N	270	\N	\N
SYNAT189	\N	\N	\N	\N	98-001046	\N	2151	\N	\N
SYNAT190	\N	\N	\N	\N	98-1056, 98-1056A9	\N	1874	\N	\N
SYNAT190	\N	\N	\N	\N	98-1056, 98-1056A9	\N	1876	\N	IP138629
DN-031	M	\N	Unknown	\N	17-64032	\N	506	\N	IP1793874
DN-028	F	\N	Unknown	\N	17-63837	\N	503	\N	IP342191
DN-029	F	\N	Unknown	\N	17-27830B	\N	504	\N	IP709271
DN-032	M	\N	Unknown	\N	17-27833	\N	507	\N	IP1757164
DN-033	F	\N	Unknown	\N	16-98733	\N	508	\N	IP1494176
DN-034	M	\N	Unknown	\N	17-26455B	\N	509	\N	IP1755773
CM-31	\N	\N	Unknown	Denmark	19Rig750007.03.02.05,19Rig750007.03.02.03, 19Rig750007.03.02.05, 19Rig750007.03.02.03	\N	271	\N	\N
DN-038	M	\N	Unknown	\N	17-2270A	\N	513	\N	IP1731355
DN-036	F	\N	Unknown	\N	17-34979	\N	511	\N	IP1689367
DN-037	M	\N	Unknown	\N	17-63503	\N	512	\N	IP1793343
DN-039	M	\N	Unknown	\N	16-119311	\N	514	\N	IP1719503
DN-044	M	\N	Unknown	\N	17-62502A,17-62502B, 17-62502A, 17-62502B	\N	519	\N	IP1792328
DN-040	M	\N	Unknown	\N	17-65020B	\N	515	\N	IP87016
DN-042	F	\N	Unknown	\N	17-28040A	\N	517	\N	IP884112
SYNAT191	\N	\N	\N	\N	99-005681	\N	1950	\N	\N
SYNAT192	\N	\N	\N	\N	99-012800, 99-012800-2	\N	2199	\N	\N
CM-33	\N	\N	Unknown	Denmark	19Rig750007.03.04.02,19Rig750007.03.04.03, 19Rig750007.03.04.02, 19Rig750007.03.04.03	\N	273	\N	\N
DN-046	M	\N	Unknown	\N	16-98043	\N	521	\N	IP1697959
DN-048	M	\N	Unknown	\N	16-119467C,16-119467B,16-119467D, 16-119467C, 16-119467B, 16-119467D	\N	523	\N	IP1719660
DN-043	F	\N	Unknown	\N	17-3739	\N	518	\N	IP891221
DN-045	F	\N	Unknown	\N	17-27410	\N	520	\N	IP465995
SYNAT193	\N	\N	\N	\N	144 Imat B15	\N	2007	\N	\N
SYNAT194	\N	\N	\N	\N	144 Imat B15-2	\N	1808	\N	\N
SYNAT195	\N	\N	\N	\N	144aI WT	\N	1668	\N	\N
SYNAT196	\N	\N	\N	\N	230 WT	\N	2109	\N	\N
SYNAT197	\N	\N	\N	\N	1205lu-1	\N	1830	\N	\N
SYNAT198	\N	\N	\N	\N	1205lu-2	\N	1974	\N	\N
SYNAT199	\N	\N	\N	\N	1205LU-3	\N	2081	\N	\N
DN-049	F	\N	Unknown	\N	16-98328A	\N	524	\N	IP1698249
DN-047	M	\N	Unknown	\N	17-3829B	\N	522	\N	IP1732930
DN-086	M	\N	Unknown	\N	16-118014	\N	561	\N	IP1647593
DN-050	M	\N	Unknown	\N	17-26447	\N	525	\N	IP1755765
DN-051	M	\N	Unknown	\N	17-26969	\N	526	\N	IP313644
DN-052	M	\N	Unknown	\N	17-34448	\N	527	\N	IP1572932
DN-053	F	\N	Unknown	\N	17-34977	\N	528	\N	IP1764420
AM2-051	\N	\N	Unknown	Bolivia	"19111/14.1\n",19111/14.4,19111/14.5,19111/14.2,19111/14.3, 19111/14.4, 19111/14.5, 19111/14.2, 19111/14.3, 19111/14.1\n	\N	25	\N	\N
CM-37	\N	\N	Unknown	Denmark	19Rig750007.03.08.03,19Rig750007.03.08.05, 19Rig750007.03.08.03, 19Rig750007.03.08.05	\N	276	\N	\N
SYNAT200	\N	\N	\N	\N	61000/00 (LN)	\N	1816	\N	\N
AM2-007	\N	\N	Unknown	Bolivia	"79447-a\n",79447-b,79447-d,79447-c, 79447-b, 79447-d, 79447-c, 79447-a\n	\N	5	\N	\N
AM2-029	\N	\N	Unknown	Chile	610186A,"610186B\n",610186C,610186D, 610186A, 610186C, 610186D, 610186B\n	\N	13	\N	\N
SYNAT201	\N	\N	\N	\N	AM2_D-72	\N	1716	\N	\N
DN-055	M	\N	Unknown	\N	17-26432B,17-26432A, 17-26432B, 17-26432A	\N	530	\N	IP99195
CCR-051	M	\N	White	\N	15-43069A	\N	144	\N	IP116836
DN-054	M	\N	Unknown	\N	17-65263C	\N	529	\N	IP1662759
SYNAT202	\N	\N	\N	\N	BB21-21314	\N	2057	\N	\N
SYNAT203	\N	\N	\N	\N	Bivona L1	\N	1674	\N	\N
SYNAT204	\N	\N	\N	\N	Bivona L2	\N	2065	\N	\N
SYNAT205	\N	\N	\N	\N	Bivona L3	\N	1780	\N	\N
SYNAT206	\N	\N	\N	\N	Bivona L4	\N	2258	\N	\N
SYNAT207	\N	\N	\N	\N	Bivona L5	\N	2349	\N	\N
SYNAT208	\N	\N	\N	\N	Bivona L6	\N	2271	\N	\N
SYNAT209	\N	\N	\N	\N	Bivona L7	\N	1992	\N	\N
SYNAT210	\N	\N	\N	\N	Bivona L8	\N	2067	\N	\N
SYNAT211	\N	\N	\N	\N	Bivona L9	\N	1940	\N	\N
SYNAT212	\N	\N	\N	\N	Bivona L10	\N	2241	\N	\N
SYNAT213	\N	\N	\N	\N	Bivona L11	\N	1756	\N	\N
SYNAT214	\N	\N	\N	\N	Buffy Coat	\N	2266	\N	\N
SYNAT215	\N	\N	\N	\N	Cell-Line_Xu-1	\N	2297	\N	\N
SYNAT216	\N	\N	\N	\N	Cell-Line_Xu-2	\N	2098	\N	\N
SYNAT217	\N	\N	\N	\N	Cell-Line_Xu-3	\N	1683	\N	\N
SYNAT218	\N	\N	\N	\N	Cell-Line_Xu-4	\N	1845	\N	\N
SYNAT219	\N	\N	\N	\N	Cell-Line_Xu-5	\N	2234	\N	\N
SYNAT220	\N	\N	\N	\N	Cell-Line_Xu-6	\N	2274	\N	\N
SYNAT221	\N	\N	\N	\N	Cell-Line_Xu-7	\N	1725	\N	\N
SYNAT222	\N	\N	\N	\N	Cell-Line_Xu-8	\N	2106	\N	\N
SYNAT223	\N	\N	\N	\N	Cell-Line_Xu-9	\N	1875	\N	\N
SYNAT224	\N	\N	\N	\N	Cell-Line_Xu-10	\N	1952	\N	\N
SYNAT225	\N	\N	\N	\N	Cell-Line_Xu-11	\N	1986	\N	\N
SYNAT226	\N	\N	\N	\N	Cell-Line_Xu-12	\N	2305	\N	\N
SYNAT227	\N	\N	\N	\N	Cell-Line_Xu-13	\N	1918	\N	\N
DN-103	M	\N	Unknown	\N	17-92405	\N	578	\N	IP1822602
SYNAT352	\N	\N	\N	\N	12-67298	\N	1945	\N	IP960004
SYNAT273	\N	\N	\N	\N	CGH13-008	\N	2309	\N	IP1175438
CM-40	\N	\N	Unknown	Denmark	19Rig750007.03.11.03,19Rig750007.03.11.02, 19Rig750007.03.11.02, 19Rig750007.03.11.03	\N	277	\N	\N
SYNAT284	\N	\N	\N	\N	DM100	\N	1709	\N	\N
SYNAT285	\N	\N	\N	\N	DM101	\N	2094	\N	\N
SYNAT286	\N	\N	\N	\N	DM102	\N	1981	\N	\N
SYNAT287	\N	\N	\N	\N	DP12-200 	\N	2131	\N	\N
DN-061	F	\N	Unknown	\N	17-34464A,17-34464B, 17-34464A, 17-34464B	\N	536	\N	IP1725842
DN-062	F	\N	Unknown	\N	17-65218B	\N	537	\N	IP464470
DN-056	F	\N	Unknown	\N	17-3731	\N	531	\N	IP28684
DN-057	M	\N	Unknown	\N	17-21049	\N	532	\N	IP899509
DN-058	M	\N	Unknown	\N	17-26289G	\N	533	\N	IP1691692
DN-059	F	\N	Unknown	\N	17-62813A	\N	534	\N	IP1275465
SYNAT288	\N	\N	\N	\N	HW Acral #1 Cntl	\N	2185	\N	\N
SYNAT289	\N	\N	\N	\N	HW Acral #1 Tumor	\N	1947	\N	\N
SYNAT290	\N	\N	\N	\N	HW Acral #2 Cntl	\N	2047	\N	\N
SYNAT291	\N	\N	\N	\N	HW Acral #2 Tumor	\N	2154	\N	\N
SYNAT292	\N	\N	\N	\N	HW Acral #3 Cntl	\N	1852	\N	\N
SYNAT293	\N	\N	\N	\N	HW Acral #3 Tumor	\N	2321	\N	\N
SYNAT294	\N	\N	\N	\N	HW Acral #4 Cntl	\N	2288	\N	\N
SYNAT295	\N	\N	\N	\N	HW Acral #4 Tumor	\N	1789	\N	\N
SYNAT296	\N	\N	\N	\N	HW Acral #5 Cntl	\N	2064	\N	\N
SYNAT297	\N	\N	\N	\N	HW Acral #5 Tumor	\N	1768	\N	\N
SYNAT298	\N	\N	\N	\N	HW Acral #6 Cntl	\N	1700	\N	\N
SYNAT299	\N	\N	\N	\N	HW Acral #6 Tumor	\N	2014	\N	\N
SYNAT300	\N	\N	\N	\N	HW Acral #7 Cntl	\N	1912	\N	\N
SYNAT301	\N	\N	\N	\N	HW Acral #7 Tumor	\N	1881	\N	\N
SYNAT302	\N	\N	\N	\N	HW Acral #8 Cntl	\N	1898	\N	\N
SYNAT303	\N	\N	\N	\N	HW Acral #8 Tumor	\N	1839	\N	\N
SYNAT304	\N	\N	\N	\N	HW Acral #9 Cntl	\N	1822	\N	\N
SYNAT305	\N	\N	\N	\N	HW Acral #9 Tumor	\N	2254	\N	\N
SYNAT306	\N	\N	\N	\N	HW Acral #10 Cntl	\N	1671	\N	\N
SYNAT307	\N	\N	\N	\N	HW Acral #10 Tumor	\N	1877	\N	\N
SYNAT308	\N	\N	\N	\N	HW2- Normal Curls	\N	2062	\N	\N
SYNAT309	\N	\N	\N	\N	HW2- Tumor Dissect	\N	2024	\N	\N
SYNAT310	\N	\N	\N	\N	HW3-Normal	\N	1962	\N	\N
SYNAT311	\N	\N	\N	\N	HW3-Tumor	\N	2188	\N	\N
SYNAT312	\N	\N	\N	\N	HW4-Normal	\N	2071	\N	\N
CM-41	\N	\N	Unknown	Denmark	19Rig750007.03.12.03,19Rig750007.03.12.05,19Rig750007.03.12.02, 19Rig750007.03.12.03, 19Rig750007.03.12.05, 19Rig750007.03.12.02	\N	278	\N	\N
CCR-217	M	\N	White	\N	98-16285A2	\N	195	\N	IP153858
DN-063	M	\N	Unknown	\N	17-20908	\N	538	\N	IP1750163
DN-066	M	\N	Unknown	\N	17-36682	\N	541	\N	IP1766150
DN-067	F	\N	Unknown	\N	16-126879A	\N	542	\N	IP1705946
DN-068	M	\N	Unknown	\N	16-125621	\N	543	\N	IP1725860
DN-076	M	\N	Unknown	\N	17-65315B	\N	551	\N	IP1795170
DN-077	M	\N	Unknown	\N	17-65160B	\N	552	\N	IP1795010
SYNAT320	\N	\N	\N	\N	LAL-L Cells	\N	1685	\N	\N
SYNAT321	\N	\N	\N	\N	M230 Imat A2	\N	2162	\N	\N
SYNAT322	\N	\N	\N	\N	M230 Imat A3	\N	1862	\N	\N
SYNAT323	\N	\N	\N	\N	MB1424	\N	2282	\N	\N
DN-084	M	\N	Unknown	\N	17-36614	\N	559	\N	IP1766078
DN-078	M	\N	Unknown	\N	16-48776B	\N	553	\N	IP546
DN-079	F	\N	Unknown	\N	17-63890C	\N	554	\N	IP1793730
DN-080	M	\N	Unknown	\N	17-2241	\N	555	\N	IP1731326
SYNAT324	\N	\N	\N	\N	P57	\N	2277	\N	\N
SYNAT325	\N	\N	\N	\N	P57-A-1.0mm	\N	2176	\N	\N
SYNAT326	\N	\N	\N	\N	P57-A-2.0mm	\N	2170	\N	\N
SYNAT327	\N	\N	\N	\N	P57-B-1.0mm	\N	2028	\N	\N
SYNAT328	\N	\N	\N	\N	P57-B-2.0mm	\N	2107	\N	\N
SYNAT329	\N	\N	\N	\N	PG_8	\N	1706	\N	\N
SYNAT330	\N	\N	\N	\N	sh-H3K4	\N	1926	\N	\N
SYNAT331	\N	\N	\N	\N	sh-H3K27	\N	1728	\N	\N
SYNAT332	\N	\N	\N	\N	sh-Input	\N	1790	\N	\N
SYNAT333	\N	\N	\N	\N	SKMEL5-1	\N	2195	\N	\N
SYNAT334	\N	\N	\N	\N	SKMEL5-2	\N	2202	\N	\N
SYNAT335	\N	\N	\N	\N	SKMEL5-3	\N	2174	\N	\N
SYNAT336	\N	\N	\N	\N	SKMEL28-1	\N	1802	\N	\N
SYNAT337	\N	\N	\N	\N	SKMEL28-2	\N	1886	\N	\N
SYNAT338	\N	\N	\N	\N	SKMEL28-3	\N	1848	\N	\N
SYNAT339	\N	\N	\N	\N	SM_2_Tumor	\N	1917	\N	\N
SYNAT340	\N	\N	\N	\N	SM_10_Tumor	\N	1786	\N	\N
SYNAT341	\N	\N	\N	\N	Thomas_SK_Mel23	\N	2260	\N	\N
SYNAT342	\N	\N	\N	\N	UCSF-23-041_Biopsy	\N	1858	\N	\N
SYNAT343	\N	\N	\N	\N	UM1_UvealMel	\N	1990	\N	\N
SYNAT344	\N	\N	\N	\N	UM2_UvealMel	\N	2334	\N	\N
SYNAT345	\N	\N	\N	\N	WM3918	\N	1891	\N	\N
SYNAT346	\N	\N	\N	\N	WP 11	\N	2345	\N	\N
SYNAT347	\N	\N	\N	\N	WP 23	\N	2281	\N	\N
SYNAT348	\N	\N	\N	\N	WP 29	\N	1800	\N	\N
DN-090	F	\N	Unknown	\N	17-72585A,17-72585B,17-72585C, 17-72585A, 17-72585B, 17-72585C	\N	565	\N	IP1177975
SYNAT146	\N	\N	\N	\N	10-88475	\N	1734	\N	IP983054
CCR-202	M	\N	White	\N	96-3842	\N	182	\N	IP80606
CM-42	\N	\N	Unknown	Denmark	19Rig750007.04.01.03	\N	279	\N	\N
DN-081	M	\N	Unknown	\N	17-20497A	\N	556	\N	IP898098
DN-082	F	\N	Unknown	\N	17-27403	\N	557	\N	IP111660
DN-083	M	\N	Unknown	\N	17-48595B	\N	558	\N	IP1567816
DN-085	F	\N	Unknown	\N	17-20244B	\N	560	\N	IP1164464
DN-087	M	\N	Unknown	\N	16-126714	\N	562	\N	IP1683560
CM-44	\N	\N	Unknown	Denmark	19Rig750007.04.03.03	\N	281	\N	\N
MD-35	\N	\N	Unknown	Madrid, Spain	15-22166 T4	\N	941	\N	\N
MD-36	\N	\N	Unknown	Madrid, Spain	15-32174 T2	\N	942	\N	\N
DN-091	M	\N	Unknown	\N	17-93945C	\N	566	\N	IP1824168
DN-092	F	\N	Unknown	\N	17-82365B	\N	567	\N	IP1812422
MD-38	\N	\N	Unknown	Madrid, Spain	05-01411C N1,05-01411 T4, 05-01411C N1, 05-01411 T4	\N	944	\N	\N
DN-093	M	\N	Unknown	\N	17-72429A	\N	568	\N	IP1802357
DN-094	F	\N	Unknown	\N	18-119366A	\N	569	\N	IP1908323
DN-106	M	\N	Unknown	\N	17-74882B,17-74882A, 17-74882B, 17-74882A	\N	581	\N	IP1804838
DN-095	F	\N	Unknown	\N	17-91889	\N	570	\N	IP1822073
DN-096	F	\N	Unknown	\N	18-96108	\N	571	\N	IP720723
DN-108	F	\N	Unknown	\N	17-125335	\N	583	\N	IP1855930
DN-097	M	\N	Unknown	\N	18-121403A	\N	572	\N	IP1312981
DN-098	F	\N	Unknown	\N	18-119369B	\N	573	\N	IP1983455
DN-099	M	\N	Unknown	\N	18-120593B	\N	574	\N	IP1984680
DN-100	F	\N	Unknown	\N	18-90550	\N	575	\N	IP605933
CM-47	\N	\N	Unknown	Denmark	19Rig750007.04.06.03	\N	284	\N	\N
DN-101	F	\N	Unknown	\N	17-72580	\N	576	\N	IP698516
DN-104	F	\N	Unknown	\N	17-85037	\N	579	\N	IP373264
DN-105	F	\N	Unknown	\N	17-74152D	\N	580	\N	IP255809
DN-107	F	\N	Unknown	\N	17-74282	\N	582	\N	IP1804228
DN-119	M	\N	Unknown	\N	17-81767C,17-81767B, 17-81767C, 17-81767B	\N	594	\N	IP339970
DN-109	M	\N	Unknown	\N	17-93961A	\N	584	\N	IP1805672
DN-110	F	\N	Unknown	\N	18-54612	\N	585	\N	IP650724
DN-111	M	\N	Unknown	\N	18-121415	\N	586	\N	IP1985504
CM-54	\N	\N	Unknown	Denmark	19Rig750007.04.13.03,19Rig750007.04.13.08, 19Rig750007.04.13.03, 19Rig750007.04.13.08	\N	289	\N	\N
DN-124	M	\N	Unknown	\N	17-112631B	\N	599	\N	IP1843109
MD-43	\N	\N	Unknown	Madrid, Spain	06-06325 M1	\N	949	\N	\N
DN-112	F	\N	Unknown	\N	17-112277	\N	587	\N	IP781920
DN-113	M	\N	Unknown	\N	18-121006	\N	588	\N	IP556850
DN-114	M	\N	Unknown	\N	18-52908	\N	589	\N	IP1916757
DN-115	F	\N	Unknown	\N	17-92850	\N	590	\N	IP1596350
DN-116	M	\N	Unknown	\N	18-120470	\N	591	\N	IP1984557
DN-117	M	\N	Unknown	\N	18-120587	\N	592	\N	IP1779775
DN-118	M	\N	Unknown	\N	17-82806	\N	593	\N	IP877561
DN-120	M	\N	Unknown	\N	17-117666	\N	595	\N	IP1588836
DN-121	F	\N	Unknown	\N	17-117775B	\N	596	\N	IP1499470
DN-122	F	\N	Unknown	\N	17-49739B	\N	597	\N	IP302644
DN-123	M	\N	Unknown	\N	17-81609B	\N	598	\N	IP1811650
DN-125	M	\N	Unknown	\N	18-65038B	\N	600	\N	IP439323
DN-126	M	\N	Unknown	\N	17-93920	\N	601	\N	IP749893
DN-127	M	\N	Unknown	\N	18-135600	\N	602	\N	IP777076
DN-128	M	\N	Unknown	\N	18-135492	\N	603	\N	IP1697627
DN-129	F	\N	Unknown	\N	18-135488	\N	604	\N	IP681488
DN-130	M	\N	Unknown	\N	18-136721	\N	605	\N	IP2000868
DN-131	M	\N	Unknown	\N	18-136716B	\N	606	\N	IP126817
DN-133	F	\N	Unknown	\N	19-7686A	\N	608	\N	IP881926
DN-134	F	\N	Unknown	\N	18-135485	\N	609	\N	IP1658571
DN-135	M	\N	Unknown	\N	18-136484	\N	610	\N	IP2000624
DN-137	M	\N	Unknown	\N	18-137340A	\N	612	\N	IP1431131
DN-139	M	\N	Unknown	\N	18-137857	\N	614	\N	IP2002013
DN-140	M	\N	Unknown	\N	18-137809B	\N	615	\N	IP171892
DN-141	M	\N	Unknown	\N	19-7126B	\N	616	\N	IP2011182
CCR-258	F	\N	White	\N	96-12193	\N	216	\N	IP88957
DN-142	M	\N	Unknown	\N	19-7344	\N	617	\N	IP266145
DN-145	F	\N	Unknown	\N	19-7596C	\N	620	\N	IP2011652
DN-146	F	\N	Unknown	\N	19-7600	\N	621	\N	IP2011656
DN-147	M	\N	Unknown	\N	19-7601	\N	622	\N	IP2011657
DN-149	M	\N	Unknown	\N	19-29433C	\N	624	\N	IP630209
DN-150	F	\N	Unknown	\N	19-15130	\N	625	\N	IP2019231
CCR-203	M	\N	White	\N	04-38345	\N	183	\N	IP454748
DN-151	F	\N	Unknown	\N	19-37609	\N	626	\N	IP2041845
DN-152	M	\N	Unknown	\N	19-29129	\N	627	\N	IP1663236
DN-153	M	\N	Unknown	\N	19-30025B	\N	628	\N	IP143268
DN-155	M	\N	Unknown	\N	19-38447	\N	630	\N	IP2042685
DN-156	M	\N	Unknown	\N	19-15378	\N	631	\N	IP2019479
DN-158	M	\N	Unknown	\N	19-37409B	\N	633	\N	IP2041641
DN-159	F	\N	Unknown	\N	19-30079A	\N	634	\N	IP1858202
DN-160	M	\N	Unknown	\N	19-38090	\N	635	\N	IP2042328
DN-161	M	\N	Unknown	\N	19-15442	\N	636	\N	IP2019543
DP-01	F	\N	Unknown	UCSF	11-13665	\N	638	\N	IP249076
DP-12	F	\N	Unknown	UCSF	15-101612	IntelliPath says its an "atypical Spitz tumor"	649	\N	IP1573327
LN-036	F	\N	Unknown	UCSF	17-115149A	\N	855	\N	IP1845642
CCR-263	M	\N	White	\N	04-50387	\N	218	\N	IP466795
DP-13	M	\N	Unknown	UCSF	14-43805	Consultation. IntelliPath says its a "Spitzoid melanoma"	650	\N	IP1393739
DP-15	M	\N	Unknown	UCSF	19-44904	\N	652	\N	IP2049186
CGH14-348	M	\N	Unknown	UCSF	14-96361	cases with MAP3K8 fusions	243	\N	IP1446353
DP-19	F	\N	Unknown	UCSF	11-65284	\N	656	\N	IP1054727
DP-20	F	\N	Unknown	UCSF	11-66564	\N	657	\N	IP1056007
CM-62	\N	\N	Unknown	Denmark	19Rig750007.05.06.04,19Rig750007.05.06.03,19Rig750007.05.06.10, 19Rig750007.05.06.04, 19Rig750007.05.06.03, 19Rig750007.05.06.10	\N	295	\N	\N
DP-31	F	\N	Unknown	UCSF	14-42631	\N	668	\N	IP1392565
DP-22	F	\N	Unknown	UCSF	11-87412	\N	659	\N	IP1076860
DP-24	F	\N	Unknown	UCSF	12-9397B	\N	661	\N	IP1095213
DMS-047	\N	\N	Unknown	UCSF	17-102266	\N	459	\N	\N
DP-26	M	\N	Unknown	UCSF	12-64897	\N	663	\N	IP1150713
DP-27	F	\N	Unknown	UCSF	13-32039	\N	664	\N	IP1216784
DP-28	F	\N	Unknown	UCSF	13-73582	\N	665	\N	IP1315587
DP-29	M	\N	Unknown	UCSF	13-75788B	\N	666	\N	IP1317793
DP-30	M	\N	Unknown	UCSF	14-11769	\N	667	\N	IP1361690
DP-32	F	\N	Unknown	UCSF	14-46549	\N	669	\N	IP1396485
CCR-204	F	\N	Unknown	\N	06-28087	\N	184	\N	IP573155
JJS20	M	\N	Unknown	UCSF	14-78242	PMID: 29990500 case 60; RPA-303	759	\N	\N
DP-71	F	\N	Unknown	UCSF	16-63804	\N	708	\N	IP1663322
DP-33	M	\N	Unknown	UCSF	14-57552	\N	670	\N	IP1407492
DP-34	M	\N	Unknown	UCSF	14-83928	\N	671	\N	IP1433898
DP-35	M	\N	Unknown	UCSF	14-82758	\N	672	\N	IP1432726
CM-63	\N	\N	Unknown	Denmark	19Rig750007.05.07.03	\N	296	\N	\N
DP-36	F	\N	Unknown	UCSF	14-95595	\N	673	\N	IP1445586
DP-37	M	\N	Unknown	UCSF	15-10108	\N	674	\N	IP1481138
DP-39	M	\N	Unknown	UCSF	15-25818	\N	676	\N	IP1496980
DP-41	F	\N	Unknown	UCSF	15-33496	\N	678	\N	IP1030082
DP-42	F	\N	Unknown	UCSF	15-41815	\N	679	\N	IP1513088
DP-43	F	\N	Unknown	UCSF	15-52489	\N	680	\N	IP1523838
DP-44	F	\N	Unknown	UCSF	15-60391	\N	681	\N	IP1531774
DP-45	F	\N	Unknown	UCSF	15-61456	\N	682	\N	IP1532843
DP-46	F	\N	Unknown	UCSF	15-71393	\N	683	\N	IP1542843
DP-54	F	\N	Unknown	UCSF	16-13909	\N	691	\N	IP1563705
DP-48	M	\N	Unknown	UCSF	15-92618	\N	685	\N	IP1564268
DP-50	F	\N	Unknown	UCSF	15-110181	\N	687	\N	IP1581959
AM2-006	\N	\N	Unknown	Bolivia	86541-1g,86541-1f,86541-1E,86541-2a,86541-2c,86541-2b, 86541-2b, 86541-1g, 86541-1f, 86541-1E, 86541-2a, 86541-2c	\N	4	\N	\N
CCR-207	F	\N	White	\N	04-59140B	\N	187	\N	IP475548
ME-05	M	\N	Unknown	UCSF	17-99365,17-12444, 17-12444, 17-99365	\N	1100	\N	\N
AM2-002	\N	\N	Unknown	Bolivia	78821-1b,78821-2a,78821-1c,78821-2b,"78821-1a\n", 78821-2a, 78821-1c, 78821-2b, 78821-1a\n, 78821-1b	\N	2	\N	\N
CCR-211	M	\N	White	\N	03-47623B	\N	190	\N	IP405938
ME-10	F	\N	Unknown	UCSF	06-72820A,17-68446, 17-68446, 06-72820A	17-68446: 63 yrs old; T06-72820-A: 52 yrs old	1105	\N	IP524944
ME-11	M	\N	Unknown	UCSF	17-55182D,17-55182C, 17-55182D, 17-55182C	\N	1106	\N	IP1784912
ME-14	F	\N	Unknown	UCSF	16-103438,16-108259C, 16-103438, 16-108259C	DROPPED CASE	1109	\N	IP1703438
ME-15	M	\N	Unknown	UCSF	16-104614H,16-99265, 16-99265, 16-104614H	16-99265 = Male, whereas T16-104614-H = Female	1110	\N	IP1699195
SYNAT151	\N	\N	\N	\N	11-20772	\N	1944	\N	IP1010210
NM-006	\N	\N	Unknown	Greece	07B2313 (eppendorf)	\N	1193	\N	\N
CCR-247	M	\N	White	\N	01-6748	\N	211	\N	IP263151
SYNAT154	\N	\N	\N	\N	11-42027	\N	2104	\N	\N
NM-43	\N	\N	Unknown	Greece	12410/09	\N	1220	\N	\N
CCR-300	F	\N	White	\N	99-4387	\N	231	\N	IP179920
ME-34	M	\N	Unknown	UCSF	19-596B	\N	1129	\N	IP2004620
NM-032	\N	\N	Unknown	Greece	150/17	\N	1210	\N	\N
CM-04	\N	\N	Unknown	Denmark	19Rig750007.01.04.02	\N	250	\N	\N
CM-10	\N	\N	Unknown	Denmark	19Rig750007.01.10.03	\N	254	\N	\N
CM-11	\N	\N	Unknown	Denmark	19Rig750007.01.11.02	\N	255	\N	\N
CM-12	\N	\N	Unknown	Denmark	19Rig750007.01.12.02	\N	256	\N	\N
MD-22	\N	\N	Unknown	Madrid, Spain	06-16759 T1,06-16759A T1, 06-16759 T1, 06-16759A T1	\N	928	\N	\N
CME-010	\N	\N	Asian	Taiwan	16-32627A1	\N	312	\N	\N
CME-011	\N	\N	Asian	Taiwan	15-13150A1	\N	313	\N	\N
LN-04	M	\N	Unknown	UCSF	17-120049C	\N	824	\N	IP932194
LN-12	F	\N	Unknown	UCSF	17-120280	\N	832	\N	IP1850829
SYNAT372	\N	\N	\N	\N	12-22587	\N	1871	\N	IP1108405
SYNAT374	\N	\N	\N	\N	12-22597	\N	1794	\N	IP575947
SYNAT386	\N	\N	\N	\N	11-8228	\N	1916	\N	IP997665
DP-03	M	\N	Unknown	UCSF	12-1782	\N	640	\N	IP1087598
MD-203	\N	\N	Unknown	Madrid, Spain	87-14087B T2	\N	1080	\N	\N
MD-204	\N	\N	Unknown	Madrid, Spain	88-6851-2 T3	\N	1081	\N	\N
OM-10	M	\N	Unknown	Mexico	BB21-21342	BB21-21342	1271	\N	\N
SYNAT409	\N	\N	\N	\N	06-52508	\N	1807	\N	IP597577
WS-01	\N	\N	Unknown	Japan	11-1969-F,11-1973,12-3277,12-1450, 11-1973, 12-3277, 12-1450, 11-1969-F	\nChanged Pat_ID to WS-01; moved 11-1969 to WS-01 (04/06/23)\n	1402	\N	\N
SM-021	F	\N	Unknown	UCSF	18-76281	\N	1350	\N	IP1940225
SYNAT431	\N	\N	\N	\N	11-26903	\N	2253	\N	IP1016341
SMP11	F	\N	Unknown	UCSF	12-24027C	\N	1357	\N	\N
SMP12	F	\N	Unknown	UCSF	13-105024A	\N	1358	\N	\N
ME-32	M	\N	Unknown	UCSF	19-488	\N	1127	\N	IP2004512
ME-33	M	\N	Unknown	UCSF	16-1675	\N	1128	\N	\N
UV-01	\N	\N	Unknown	UCSF	MP41	Cell culture DNA from Xu	1392	\N	\N
WS-02	\N	\N	Unknown	Japan	07-2889-1 ,07-1841,07-2479-1 ,07-3001,07-2479-2,07-1791,07-2889-2,07-2104, 07-2889-1 , 07-1841, 07-2479-1 , 07-3001, 07-2479-2, 07-1791, 07-2889-2, 07-2104	Changed Pat_ID to WS-02 (04/06/23)	1403	\N	\N
SYNAT455	\N	\N	\N	\N	08-46462	\N	2186	\N	IP755103
VS-06	\N	\N	Unknown	UCSF	22-124532-2	\N	1399	\N	\N
NM-34	\N	\N	Unknown	Greece	4449/16 (4449/16 3 slide)	\N	1212	\N	\N
SYNAT469	\N	\N	\N	\N	11-71006	\N	2265	\N	IP1060449
AMC-08	\N	\N	Unknown	\N	M040416,M040419A,M040415,M040418, M040416, M040419A, M040415, M040418	\N	102	\N	\N
CM-73	\N	\N	Unknown	Denmark	19Rig750007.06.01	\N	301	\N	\N
CM-16	\N	\N	Unknown	Denmark	19Rig750007.01.16.03,19Rig750007.01.16.02, 19Rig750007.01.16.03, 19Rig750007.01.16.02	\N	260	\N	\N
OM-39	M	\N	Unknown	UCSF	15-122774	\N	1297	\N	\N
CM-28	\N	\N	Unknown	Denmark	19Rig750007.02.09.02,19Rig750007.02.09.03, 19Rig750007.02.09.02, 19Rig750007.02.09.03	\N	268	\N	\N
CM-29	\N	\N	Unknown	Denmark	19Rig750007.02.10.01,19Rig750007.02.10.02, 19Rig750007.02.10.01, 19Rig750007.02.10.02	\N	269	\N	\N
OM-14	F	\N	Unknown	Mexico	BB21-21336	\N	1275	\N	\N
OM-17	F	\N	Unknown	Mexico	BB21-21316	\N	1278	\N	\N
SYNX213	M	\N	\N	\N	09-33283	NaN	1616	\N	IP834046
AM2-095	\N	\N	Asian	Taiwan	10-14100,10-13619,10-14390,10-15514A2, 10-14100, 10-13619, 10-14390, 10-15514A2	\N	65	\N	\N
SYNX232	F	\N	\N	\N	13-15966	NaN	1635	\N	IP1200709
SYNX233	M	\N	\N	\N	13-39228	NaN	1636	\N	IP1104118
SYNX234	M	\N	\N	\N	13-45942	NaN	1637	\N	IP1005877
CM-32	\N	\N	Unknown	Denmark	19Rig750007.03.03.05,19Rig750007.03.03.03,19Rig750007.03.03.04, 19Rig750007.03.03.05, 19Rig750007.03.03.03, 19Rig750007.03.03.04	\N	272	\N	\N
CM-34	\N	\N	Unknown	Denmark	19Rig750007.03.05.02	\N	274	\N	\N
DMS-045	\N	\N	Unknown	UCSF	23-37594	\N	457	\N	\N
CM-36	\N	\N	Unknown	Denmark	19Rig750007.03.07.05,19Rig750007.03.07.03, 19Rig750007.03.07.05, 19Rig750007.03.07.03	\N	275	\N	\N
CME-097	F	\N	Asian	Japan	16-09944-2	\N	399	\N	\N
CME-105	F	\N	Asian	Japan	17-11446-5	\N	407	\N	\N
CME-107	M	\N	Asian	Japan	17-11087-5	\N	409	\N	\N
DMS-002	\N	\N	Unknown	UCSF	23-4594	\N	414	\N	\N
DMS-053	\N	\N	Unknown	UCSF	17-94254	\N	465	\N	\N
DMS-054	\N	\N	Unknown	UCSF	22-46448	\N	466	\N	\N
CM-23	\N	\N	Unknown	Denmark	19Rig750007.02.04.02	\N	265	\N	\N
CM-24	\N	\N	Unknown	Denmark	19Rig750007.02.05.03	\N	266	\N	\N
CCR-206	M	\N	White	\N	02-8746B,02-8746A, 02-8746A, 02-8746B	\N	186	\N	IP172758
CCR-215	M	\N	White	\N	96-18458A,96-18458F,96-18458E,96-18458C, 96-18458F, 96-18458E, 96-18458C, 96-18458A	\N	194	\N	IP95222
DN-064	M	\N	Unknown	\N	16-118019	\N	539	\N	IP1034557
CM-43	\N	\N	Unknown	Denmark	19Rig750007.04.02.03	\N	280	\N	\N
MD-28	\N	\N	Unknown	Madrid, Spain	11-27846-2 N1,11-27846 T3, 11-27846-2 N1, 11-27846 T3	\N	934	\N	\N
CM-57	\N	\N	Unknown	Denmark	19Rig750007.05.01.04,19Rig750007.05.01.03, 19Rig750007.05.01.03, 19Rig750007.05.01.04	\N	291	\N	\N
CCR-301	M	\N	White	\N	06-73878A,06-73878D,06-73878C, 06-73878A, 06-73878D, 06-73878C	\N	232	\N	IP89612
DP-14	M	\N	Unknown	UCSF	10-75211	IntelliPath says its a "melanocytic nevus"	651	\N	IP963226
MD-25	\N	\N	Unknown	Madrid, Spain	09-21320A3 N1-M1,09-21320 T2, 09-21320A3 N1-M1, 09-21320 T2	\N	931	\N	\N
DP-18	F	\N	Unknown	UCSF	11-63724	\N	655	\N	IP835595
CM-69	\N	\N	Unknown	Denmark	19Rig750007.05.13.03,19Rig750007.05.13.09, 19Rig750007.05.13.03, 19Rig750007.05.13.09	\N	297	\N	\N
CME-005	\N	\N	Asian	Taiwan	22-21012A4,21-32669B1,22-21012A1,21-30633A1,22-21012A3,22-21012A5,22-21012A2, 22-21012A4, 21-32669B1, 22-21012A1, 21-30633A1, 22-21012A3, 22-21012A5, 22-21012A2	\N	307	\N	\N
CME-049	F	\N	Asian	Japan	19-03114N1,19-03114-6, 19-03114-6, 19-03114N1	\N	351	\N	\N
DP-47	F	\N	Unknown	UCSF	15-88900	\N	684	\N	IP1528823
DP-51	M	\N	Unknown	UCSF	15-116253	\N	688	\N	IP1588055
AMC-12	\N	\N	Unknown	\N	MM160113	\N	103	\N	\N
DP-52	F	\N	Unknown	UCSF	15-117186	\N	689	\N	IP1588995
CM-56	\N	\N	Unknown	Denmark	19Rig750007.04.15.03	\N	290	\N	\N
MD-180	\N	\N	Unknown	Madrid, Spain	01-1112 T2	\N	1057	\N	\N
DP-53	M	\N	Unknown	UCSF	15-123058	\N	690	\N	IP1594906
DP-55	F	\N	Unknown	UCSF	16-10466	\N	692	\N	IP1609493
SYNAT373	\N	\N	\N	\N	12-22592	\N	1821	\N	\N
SYNAT376	\N	\N	\N	\N	12-22603	\N	2351	\N	IP1108421
KF-02	F	\N	Unknown	\N	11-31904	\N	777	\N	\N
JJS28	M	\N	Unknown	UCSF	15-21741	PMID: 29990500 case 82; RPA-572	766	\N	\N
DP-93	F	\N	Unknown	UCSF	17-13205	\N	730	\N	IP1742388
SYNAT389	\N	\N	\N	\N	11-47644	\N	1805	\N	IP1037083
JJS6	M	\N	Unknown	UCSF	12-79097B	\N	745	\N	\N
SYNX17	M	\N	\N	\N	12-22776B3,12-22776, 12-22776B3, 12-22776	NaN	1420	\N	IP1096148
LN-042	M	\N	Unknown	UCSF	17-111040A	\N	860	\N	IP1841501
SYNAT401	\N	\N	\N	\N	12-31996	\N	1894	\N	IP1148421
SYNAT404	\N	\N	\N	\N	12-54296	\N	1689	\N	\N
SYNAT406	\N	\N	\N	\N	12-54992	\N	1855	\N	\N
SYNAT421	\N	\N	\N	\N	12-97031	\N	1838	\N	IP1182848
DP-58	M	\N	Unknown	UCSF	16-18320A	\N	695	\N	IP1617429
DP-61	F	\N	Unknown	UCSF	16-26672	\N	698	\N	IP1625850
DP-62	F	\N	Unknown	UCSF	16-31382	\N	699	\N	IP1630595
DP-63	M	\N	Unknown	UCSF	16-41709	\N	700	\N	IP1641025
DP-64	F	\N	Unknown	UCSF	16-42657	\N	701	\N	IP1641978
DP-65	F	\N	Unknown	UCSF	16-27084	\N	702	\N	IP1626264
ME-03	M	\N	Unknown	UCSF	17-26457	\N	1098	\N	IP1755775
DP-67	M	\N	Unknown	UCSF	16-42062	\N	704	\N	IP1641378
NM-41	\N	\N	Unknown	Greece	5698.3 (14.5698.3 slide)	\N	1219	\N	\N
OM-58	F	\N	Unknown	UCSF	16-44627	\N	1316	\N	\N
SM-024	F	\N	Unknown	UCSF	17-128346A	\N	1353	\N	IP1787557
CCR-029	F	\N	White	\N	01-18107A	\N	133	\N	IP129670
CCR-097	M	\N	White	\N	11-80898	\N	155	\N	IP61385
CCR-212	F	\N	White	\N	04-18467	\N	191	\N	IP434866
CCR-151	M	\N	White	\N	99-32835	\N	173	\N	IP208368
DP-05	F	\N	Unknown	UCSF	14-29390	\N	642	\N	IP1379315
LN-11	F	\N	Unknown	UCSF	17-120839	\N	831	\N	IP1562416
DP-69	F	\N	Unknown	UCSF	16-56300	\N	706	\N	IP1655740
SYNAT356	\N	\N	\N	\N	12-12470D	\N	2197	\N	IP192328
DP-73	M	\N	Unknown	UCSF	16-80354	\N	710	\N	IP1680083
DP-74	M	\N	Unknown	UCSF	16-89926	\N	711	\N	IP1689756
DP-75	F	\N	Unknown	UCSF	16-90917	\N	712	\N	IP1690755
DP-76	M	\N	Unknown	UCSF	16-94655	\N	713	\N	IP1694537
DP-77	M	\N	Unknown	UCSF	16-96276	\N	714	\N	IP1696172
DP-78	M	\N	Unknown	UCSF	16-105648	\N	715	\N	IP1705676
DP-79	M	\N	Unknown	UCSF	16-97391	\N	716	\N	IP1697302
MD-152	\N	\N	Unknown	Madrid, Spain	04-11144C T1	\N	1031	\N	\N
MD-151	\N	\N	Unknown	Madrid, Spain	04-00122C T1	\N	1030	\N	\N
MD-153	\N	\N	Unknown	Madrid, Spain	04-14508C T1	\N	1032	\N	\N
MD-154	\N	\N	Unknown	Madrid, Spain	04-15616C T2	\N	1033	\N	\N
DP-80	M	\N	Unknown	UCSF	16-127388	\N	717	\N	IP1727647
DP-81	F	\N	Unknown	UCSF	16-92011	\N	718	\N	IP1691865
DP-82	M	\N	Unknown	UCSF	16-125975	\N	719	\N	IP1726217
DP-83	F	\N	Unknown	UCSF	17-2869	\N	720	\N	IP1731960
DP-84	F	\N	Unknown	UCSF	17-2120	\N	721	\N	IP1731205
DP-87	F	\N	Unknown	UCSF	17-8968	\N	724	\N	IP1738128
DP-88	M	\N	Unknown	UCSF	17-9550	\N	725	\N	IP1738711
DP-89	M	\N	Unknown	UCSF	17-10585	\N	726	\N	IP1739754
DP-90	F	\N	Unknown	UCSF	17-14313	\N	727	\N	IP1743507
DP-91	F	\N	Unknown	UCSF	17-26078	\N	728	\N	IP1755396
DP-92	F	\N	Unknown	UCSF	17-29457B	\N	729	\N	IP80460
SYNAT466	\N	\N	\N	\N	11-52339	\N	2249	\N	IP1041779
DP-94	F	\N	Unknown	UCSF	17-42757	\N	731	\N	IP1772311
DP-95	F	\N	Unknown	UCSF	17-48219	\N	732	\N	IP1777827
DP-96	F	\N	Unknown	UCSF	17-49361	\N	733	\N	IP655827
DP-97	F	\N	Unknown	UCSF	17-50829	\N	734	\N	IP1780487
JJS7	F	\N	Unknown	UCSF	12-12684	PMID: 29990500 case XX; RPA-297	746	\N	\N
JJS9	M	\N	Unknown	UCSF	12-57797	\N	748	\N	\N
JJS12	F	\N	Unknown	UCSF	12-93589A	PMID: 29990500 case 42; RPA-316	751	\N	\N
JJS13	M	\N	Unknown	UCSF	13-2138C	PMID: 29990500 case 64; RPA-331	752	\N	\N
JJS14	M	\N	Unknown	UCSF	13-98648	PMID: 29990500 case 54; RPA-299	753	\N	\N
JJS15	M	\N	Unknown	UCSF	14-2508	BAD SAMPLE	754	\N	\N
JJS16	F	\N	Unknown	UCSF	14-64047	PMID: 29990500 case 68; RPA-300	755	\N	\N
JJS18	M	\N	Unknown	UCSF	14-47962	PMID: 29990500 case 48; RPA-341	757	\N	\N
JJS19	F	\N	Unknown	UCSF	14-73175B	PMID: 29990500 case 51; RPA-302	758	\N	\N
KIT-04	\N	\N	Unknown	\N	13-129	\N	785	\N	\N
KIT-05	\N	\N	Unknown	\N	13-122	\N	786	\N	\N
KIT-06	\N	\N	Unknown	\N	13-074	\N	787	\N	\N
KIT-07	\N	\N	Unknown	\N	13-028	\N	788	\N	\N
KIT-08	\N	\N	Unknown	\N	12-073	\N	789	\N	\N
KIT-09	\N	\N	Unknown	\N	12-095	\N	790	\N	\N
KIT-10	\N	\N	Unknown	\N	12-122	\N	791	\N	\N
KIT-11	\N	\N	Unknown	\N	12-169	\N	792	\N	\N
KIT-12	\N	\N	Unknown	\N	12-200	\N	793	\N	\N
KIT-13	\N	\N	Unknown	\N	11-072	\N	794	\N	\N
KIT-14	\N	\N	Unknown	\N	11-091	\N	795	\N	\N
KIT-15	\N	\N	Unknown	\N	11-133	\N	796	\N	\N
KIT-16	\N	\N	Unknown	\N	11-154	\N	797	\N	\N
KIT-17	\N	\N	Unknown	\N	11-172	\N	798	\N	\N
KIT-18	\N	\N	Unknown	\N	11-256	\N	799	\N	\N
LN-075	F	\N	Unknown	UCSF	21-98013A	\N	888	\N	IP2361035
LMM-06	\N	\N	Unknown	UCSF	23-37003	\N	805	\N	IP2569388
MD-01	\N	\N	Unknown	Madrid, Spain	00-21551 T3	\N	907	\N	\N
MD-02	\N	\N	Unknown	Madrid, Spain	01-00027 T1	\N	908	\N	\N
MD-03	\N	\N	Unknown	Madrid, Spain	01-07957 T4	\N	909	\N	\N
MD-04	\N	\N	Unknown	Madrid, Spain	01-20248 T3	\N	910	\N	\N
LMM-13	\N	\N	Unknown	UCSF	21-62764	\N	812	\N	IP2325554
MD-179	\N	\N	Unknown	Madrid, Spain	01-26615B T2	\N	1056	\N	\N
LN-21	M	\N	Unknown	UCSF	18-15487B	\N	841	\N	IP1078920
LN-01	M	\N	Unknown	\N	17-119570C	\N	821	\N	IP1817562
LN-02	M	\N	Unknown	UCSF	17-118831C	\N	822	\N	IP842282
LN-03	M	\N	Unknown	UCSF	17-109907D	\N	823	\N	IP1840351
LN-20	M	\N	Unknown	UCSF	18-15803	\N	840	\N	IP1879395
LN-025	F	\N	Unknown	UCSF	17-115572A	\N	845	\N	IP1846067
LN-026	M	\N	Unknown	UCSF	17-115588	\N	846	\N	IP1846085
LN-027	F	\N	Unknown	UCSF	17-115635	\N	847	\N	IP1463681
LN-030	M	\N	Unknown	UCSF	17-111279	\N	849	\N	IP1841740
LN-031	F	\N	Unknown	UCSF	18-61924A	\N	850	\N	IP1791157
LN-033	M	\N	Unknown	UCSF	17-112653	\N	852	\N	IP512135
LN-034	M	\N	Unknown	UCSF	17-115568B	\N	853	\N	IP185229
LN-035	F	\N	Unknown	UCSF	17-114505	\N	854	\N	IP1812345
LN-044	M	\N	Unknown	UCSF	18-35802B	\N	862	\N	IP1899554
LN-047	F	\N	Unknown	UCSF	18-81165B	\N	864	\N	IP1945117
LN-048	F	\N	Unknown	UCSF	18-136508B	\N	865	\N	IP1911688
LN-049	F	\N	Unknown	UCSF	17-114552	\N	866	\N	IP630078
LN-051	M	\N	Unknown	UCSF	17-111324	\N	868	\N	IP403180
LN-058	F	\N	Unknown	UCSF	18-57977B	\N	873	\N	IP1921853
SYNAT483	\N	\N	\N	\N	98-18400a	\N	1985	\N	\N
LN-076	M	\N	Unknown	UCSF	21-62140A	\N	889	\N	IP225884
LN-059	F	\N	Unknown	UCSF	18-65460	\N	874	\N	IP1929354
LN-060	M	\N	Unknown	UCSF	18-65957A	\N	875	\N	IP1929851
LN-061	F	\N	Unknown	UCSF	18-19195A	\N	876	\N	IP1487591
LN-064	M	\N	Unknown	UCSF	18-44464	\N	878	\N	IP1908258
LN-070	F	\N	Unknown	UCSF	20-60575	\N	883	\N	IP1156616
LN-071	M	\N	Unknown	UCSF	21-61821	\N	884	\N	IP1860574
LN-072	F	\N	Unknown	UCSF	21-63579A	\N	885	\N	IP2326379
LN-073	F	\N	Unknown	UCSF	21-59993A	\N	886	\N	IP1020374
LN-074	F	\N	Unknown	UCSF	21-98047	\N	887	\N	IP558857
LN-077	M	\N	Unknown	UCSF	21-63575B	\N	890	\N	IP2326375
LN-078	M	\N	Unknown	UCSF	21-61319	\N	891	\N	IP278814
LN-079	M	\N	Unknown	UCSF	21-96630	\N	892	\N	IP968238
LN-080	M	\N	Unknown	UCSF	21-110504	\N	893	\N	IP2373605
LN-081	M	\N	Unknown	UCSF	21-110027B	\N	894	\N	IP981802
LN-082	M	\N	Unknown	UCSF	21-110012A	\N	895	\N	IP2281905
LN-083	M	\N	Unknown	UCSF	21-110009A	\N	896	\N	IP2373107
LN-084	M	\N	Unknown	UCSF	21-112103B	\N	897	\N	IP1386399
LN-085	F	\N	Unknown	UCSF	21-112298	\N	898	\N	IP1358879
MD-60	\N	\N	Unknown	Madrid, Spain	98-03336-8 M1	\N	966	\N	\N
MD-169	\N	\N	Unknown	Madrid, Spain	03-19080C T1	\N	1046	\N	\N
MD-170	\N	\N	Unknown	Madrid, Spain	03-15183D T1	\N	1047	\N	\N
MD-166	\N	\N	Unknown	Madrid, Spain	03-23238B T2	\N	1043	\N	\N
MD-167	\N	\N	Unknown	Madrid, Spain	99-19998 T2	\N	1044	\N	\N
MD-168	\N	\N	Unknown	Madrid, Spain	03-21273-1G T1	\N	1045	\N	\N
MD-155	\N	\N	Unknown	Madrid, Spain	04-17745B T1	\N	1034	\N	\N
MD-156	\N	\N	Unknown	Madrid, Spain	04-15689C T1	\N	1035	\N	\N
MD-157	\N	\N	Unknown	Madrid, Spain	04-13607 T1	\N	1036	\N	\N
MD-158	\N	\N	Unknown	Madrid, Spain	04-13171C T1	\N	1037	\N	\N
MD-159	\N	\N	Unknown	Madrid, Spain	04-03547G T1	\N	1038	\N	\N
MD-161	\N	\N	Unknown	Madrid, Spain	04-03311H T2	\N	1039	\N	\N
MD-162	\N	\N	Unknown	Madrid, Spain	01-10208A T1	\N	1040	\N	\N
MD-163	\N	\N	Unknown	Madrid, Spain	04-02031D T1	\N	1041	\N	\N
MD-165	\N	\N	Unknown	Madrid, Spain	03-22623A T1	\N	1042	\N	\N
MD-61	\N	\N	Unknown	Madrid, Spain	98-05054 N1	\N	967	\N	\N
MD-63	\N	\N	Unknown	Madrid, Spain	99-27534 M1	\N	969	\N	\N
MD-64	\N	\N	Unknown	Madrid, Spain	00-09653C M1	\N	970	\N	\N
MD-65	\N	\N	Unknown	Madrid, Spain	00-11793E M1	\N	971	\N	\N
MD-66	\N	\N	Unknown	Madrid, Spain	00-15034-1B M1	\N	972	\N	\N
MD-67	\N	\N	Unknown	Madrid, Spain	02-11468D M1	\N	973	\N	\N
MD-68	\N	\N	Unknown	Madrid, Spain	02-22843 M1	\N	974	\N	\N
MD-69	\N	\N	Unknown	Madrid, Spain	02-22662B M1	\N	975	\N	\N
MD-70	\N	\N	Unknown	Madrid, Spain	02-16325B M1	\N	976	\N	\N
MD-71	\N	\N	Unknown	Madrid, Spain	03-04925E M1	\N	977	\N	\N
MD-72	\N	\N	Unknown	Madrid, Spain	03-16198-1C M1	\N	978	\N	\N
SMP48	M	\N	Unknown	UCSF	15-52921B	\N	1360	\N	\N
MD-73	\N	\N	Unknown	Madrid, Spain	04-00065-6 M1	\N	979	\N	\N
MD-74	\N	\N	Unknown	Madrid, Spain	04-01241G M1	\N	980	\N	\N
MD-75	\N	\N	Unknown	Madrid, Spain	04-21305-4 M1	\N	981	\N	\N
MD-77	\N	\N	Unknown	Madrid, Spain	05-21257 M1	\N	982	\N	\N
MD-79	\N	\N	Unknown	Madrid, Spain	09-15598 M1	\N	983	\N	\N
MD-84	\N	\N	Unknown	Madrid, Spain	10-20397-3 M1	\N	985	\N	\N
MD-85	\N	\N	Unknown	Madrid, Spain	10-30890-5 N1	\N	986	\N	\N
MD-86	\N	\N	Unknown	Madrid, Spain	10-30525-4 M1	\N	987	\N	\N
MD-92	\N	\N	Unknown	Madrid, Spain	14-04359A2 N1	\N	988	\N	\N
MD-93	\N	\N	Unknown	Madrid, Spain	14-17085A2 M1	\N	989	\N	\N
MD-95	\N	\N	Unknown	Madrid, Spain	96-07395C M1	\N	991	\N	\N
MD-96	\N	\N	Unknown	Madrid, Spain	96-13701 M1	\N	992	\N	\N
MD-97	\N	\N	Unknown	Madrid, Spain	96-23601-4 M1	\N	993	\N	\N
MD-98	\N	\N	Unknown	Madrid, Spain	98-23221F M1	\N	994	\N	\N
MD-99	\N	\N	Unknown	Madrid, Spain	01-00467B N1	\N	995	\N	\N
LN-18	M	\N	Unknown	UCSF	18-15165	\N	838	\N	IP1878752
LN-19	F	\N	Unknown	UCSF	18-15028	\N	839	\N	IP260019
ME-07	F	\N	Unknown	UCSF	16-107007	\N	1102	\N	IP1707061
OM-35	F	\N	Unknown	UCSF	14-14773	\N	1293	\N	\N
MD-135	\N	\N	Unknown	Madrid, Spain	05-26408 T1	\N	1017	\N	\N
MD-137	\N	\N	Unknown	Madrid, Spain	05-24184C T1	\N	1018	\N	\N
MD-138	\N	\N	Unknown	Madrid, Spain	05-26627-1B T1	\N	1019	\N	\N
MD-139	\N	\N	Unknown	Madrid, Spain	01-15780R T1	\N	1020	\N	\N
MD-140	\N	\N	Unknown	Madrid, Spain	05-20065-4 T1	\N	1021	\N	\N
MD-141	\N	\N	Unknown	Madrid, Spain	05-13894C T2	\N	1022	\N	\N
MD-142	\N	\N	Unknown	Madrid, Spain	05-17080 T2	\N	1023	\N	\N
MD-144	\N	\N	Unknown	Madrid, Spain	05-04841C T2	\N	1024	\N	\N
MD-146	\N	\N	Unknown	Madrid, Spain	04-08148D T1	\N	1025	\N	\N
MD-147	\N	\N	Unknown	Madrid, Spain	04-22191D T1	\N	1026	\N	\N
MD-148	\N	\N	Unknown	Madrid, Spain	05-04949-1C T1	\N	1027	\N	\N
MD-149	\N	\N	Unknown	Madrid, Spain	04-18775B T1	\N	1028	\N	\N
MD-150	\N	\N	Unknown	Madrid, Spain	04-14677 T1	\N	1029	\N	\N
SYNAT449	\N	\N	\N	\N	11-19877	\N	2270	\N	IP1009315
SYNAT475	\N	\N	\N	\N	12-8171	\N	2044	\N	IP1093987
SYNAT477	\N	\N	\N	\N	13-212	\N	1766	\N	\N
SYNAT494	\N	\N	\N	\N	13-35959	\N	1896	\N	IP1217226
SYNAT498	\N	\N	\N	\N	12-98575A1	\N	2235	\N	IP824297
SYNAT499	\N	\N	\N	\N	14-59304A	\N	1809	\N	IP1409245
SYNX249	F	\N	\N	\N	13-21725	NaN	1652	\N	IP1175186
CME-086	M	\N	Asian	Japan	15-11029-1	\N	388	\N	\N
CME-087	M	\N	Asian	Japan	16-00657-2	\N	389	\N	\N
CME-088	M	\N	Asian	Japan	16-03460-1	\N	390	\N	\N
MD-29	\N	\N	Unknown	Madrid, Spain	12-05858 T3,12-05858A3 M1, 12-05858A3 M1, 12-05858 T3	\N	935	\N	\N
DMS-018	\N	\N	Unknown	UCSF	23-293	\N	430	\N	\N
DMS-019	\N	\N	Unknown	UCSF	23-4720	\N	431	\N	\N
DN-003	F	\N	Unknown	\N	17-35589	\N	478	\N	IP1765035
DN-016	M	\N	Unknown	\N	17-35486B,17-35486A, 17-35486A, 17-35486B	\N	491	\N	IP1764932
DN-019	M	\N	Unknown	\N	17-26400	\N	494	\N	IP1755718
DN-035	F	\N	Unknown	\N	17-35502A,17-35502B, 17-35502A, 17-35502B	\N	510	\N	IP1764948
DN-065	M	\N	Unknown	\N	16-119333	\N	540	\N	IP529433
MD-42	\N	\N	Unknown	Madrid, Spain	06-03046F N1	\N	948	\N	\N
DN-138	M	\N	Unknown	\N	18-137854C	\N	613	\N	IP477134
MD-46	\N	\N	Unknown	Madrid, Spain	12-05089-3	\N	952	\N	\N
DP-25	M	\N	Unknown	UCSF	12-48249	\N	662	\N	IP1134062
DP-49	F	\N	Unknown	UCSF	15-87833	\N	686	\N	IP1559454
DP-57	F	\N	Unknown	UCSF	16-20360	\N	694	\N	IP1619491
DP-59	F	\N	Unknown	UCSF	16-25723	\N	696	\N	IP1624894
MD-174	\N	\N	Unknown	Madrid, Spain	02-26442 T4	\N	1051	\N	\N
MD-175	\N	\N	Unknown	Madrid, Spain	02-20732 T2	\N	1052	\N	\N
MD-176	\N	\N	Unknown	Madrid, Spain	02-17209C T2	\N	1053	\N	\N
MD-177	\N	\N	Unknown	Madrid, Spain	02-28682 T4	\N	1054	\N	\N
MD-178	\N	\N	Unknown	Madrid, Spain	02-20495B T2	\N	1055	\N	\N
MD-183	\N	\N	Unknown	Madrid, Spain	00-06521B T3	\N	1060	\N	\N
MD-184	\N	\N	Unknown	Madrid, Spain	00-12952-3 T2	\N	1061	\N	\N
MD-185	\N	\N	Unknown	Madrid, Spain	00-15364 T2	\N	1062	\N	\N
MD-186	\N	\N	Unknown	Madrid, Spain	99-15953D T2	\N	1063	\N	\N
MD-187	\N	\N	Unknown	Madrid, Spain	99-24969F T4	\N	1064	\N	\N
MD-188	\N	\N	Unknown	Madrid, Spain	99-09753 T2	\N	1065	\N	\N
MD-189	\N	\N	Unknown	Madrid, Spain	99-16706 T2	\N	1066	\N	\N
MD-190	\N	\N	Unknown	Madrid, Spain	98-21389A T2	\N	1067	\N	\N
MD-191	\N	\N	Unknown	Madrid, Spain	98-06203-3 T2	\N	1068	\N	\N
MD-192	\N	\N	Unknown	Madrid, Spain	97-8417 T2	\N	1069	\N	\N
MD-193	\N	\N	Unknown	Madrid, Spain	95-02325-1 T3	\N	1070	\N	\N
MD-194	\N	\N	Unknown	Madrid, Spain	90-07958-1 T2	\N	1071	\N	\N
MD-196	\N	\N	Unknown	Madrid, Spain	93-21060-4 T2	\N	1073	\N	\N
MD-197	\N	\N	Unknown	Madrid, Spain	92-03953C T2	\N	1074	\N	\N
MD-198	\N	\N	Unknown	Madrid, Spain	91-08026A T2	\N	1075	\N	\N
MD-199	\N	\N	Unknown	Madrid, Spain	95-14297-5 T2	\N	1076	\N	\N
MD-200	\N	\N	Unknown	Madrid, Spain	96-02480 T3	\N	1077	\N	\N
MD-195	\N	\N	Unknown	Madrid, Spain	96-20650-1A T3	\N	1072	\N	\N
MD-171	\N	\N	Unknown	Madrid, Spain	03-17395J T2	\N	1048	\N	\N
MD-172	\N	\N	Unknown	Madrid, Spain	03-24659-2 T2	\N	1049	\N	\N
MD-173	\N	\N	Unknown	Madrid, Spain	03-08311E T2	\N	1050	\N	\N
MD-201	\N	\N	Unknown	Madrid, Spain	95-16013B T3	\N	1078	\N	\N
MD-202	\N	\N	Unknown	Madrid, Spain	92-18572E T3	\N	1079	\N	\N
DP-60	M	\N	Unknown	UCSF	16-30292	\N	697	\N	IP1629500
DP-66	M	\N	Unknown	UCSF	16-19890	\N	703	\N	IP1619017
JJS26	M	\N	Unknown	UCSF	15-14665B,15-14665C, 15-14665B, 15-14665C	PMID: 29990500 case 80; RPA-570	764	\N	\N
JJS17	M	\N	Unknown	UCSF	14-33100	PMID: 29990500 case 71; RPA-301	756	\N	\N
MD-54	\N	\N	Unknown	Madrid, Spain	95-05724-1 M1	\N	960	\N	\N
KF-10	\N	\N	Unknown	\N	Lung cancer with ALK fusion	\N	780	\N	\N
KIT-01	\N	\N	Unknown	\N	14-077	\N	782	\N	\N
KIT-02	\N	\N	Unknown	\N	13-207	\N	783	\N	\N
KIT-03	\N	\N	Unknown	\N	13-140	\N	784	\N	\N
MD-57	\N	\N	Unknown	Madrid, Spain	96-18967-1 M1	\N	963	\N	\N
MD-58	\N	\N	Unknown	Madrid, Spain	97-01837E M1	\N	964	\N	\N
LN-088	M	\N	Unknown	UCSF	21-112321A	\N	901	\N	IP847876
DP-68	M	\N	Unknown	UCSF	16-55411	\N	705	\N	IP1654849
MD-10	\N	\N	Unknown	Madrid, Spain	05-23001E T4,05-23001 T4, 05-23001E T4, 05-23001 T4	\N	916	\N	\N
MD-15	\N	\N	Unknown	Madrid, Spain	06-04915 T2	\N	921	\N	\N
MD-14	\N	\N	Unknown	Madrid, Spain	06-01845E T4,06-01845 T4, 06-01845E T4, 06-01845 T4	\N	920	\N	\N
MD-16	\N	\N	Unknown	Madrid, Spain	06-14812E T2,06-14812D T2, 06-14812E T2, 06-14812D T2	\N	922	\N	\N
MD-17	\N	\N	Unknown	Madrid, Spain	06-17441-2 T2,06-17441 T2, 06-17441-2 T2, 06-17441 T2	\N	923	\N	\N
SYNX63	F	\N	\N	\N	11-20375	CGH11-078 Iwei Translocation Cases	1466	\N	IP1009813
MD-18	\N	\N	Unknown	Madrid, Spain	06-25697 T1,06-25697-1 T1, 06-25697 T1, 06-25697-1 T1	\N	924	\N	\N
DP-72	M	\N	Unknown	UCSF	16-77392	\N	709	\N	IP1677083
CME-004	\N	\N	Asian	Taiwan	20-56832A1,21-37814A1,19-25808,20-50565B1,20-50565A1, 20-56832A1, 21-37814A1, 19-25808, 20-50565B1, 20-50565A1	\N	306	\N	\N
AM2-075	\N	\N	Asian	Japan	K16-A-B,K16-D, K16-A-B, K16-D	\N	45	\N	\N
ME-62	M	\N	Unknown	UCSF	22-102809	\N	1157	\N	IP642510
ME-63	M	\N	Unknown	UCSF	22-114059B,22-101809, 22-114059B, 22-101809	\N	1158	\N	IP2503898
ME-65	M	\N	Unknown	UCSF	22-80319A1,22-80319A2, 22-80319A1, 22-80319A2	\N	1160	\N	IP2482233
MP-02	\N	\N	Unknown	\N	06-521B2,04-35102A, 06-521B2, 04-35102A	08/11/22: Blocks do NOT match patient. Why is this?	1166	\N	IP545586
MP-03	\N	\N	Unknown	\N	08-6790A,11-19653B2,08-6790B, 08-6790A, 11-19653B2, 08-6790B	08/11/22: Blocks do NOT match patient. Why is this?	1167	\N	IP715431
ME-66	F	\N	Unknown	UCSF	22-104652	\N	1161	\N	IP2506763
ME-67	F	\N	Unknown	UCSF	23-47967	\N	1162	\N	IP2586261
ME-69	\N	\N	Unknown	UCSF	23-49347	\N	1164	\N	IP434922
NM-37	\N	\N	Unknown	Greece	1813/15 3	\N	1215	\N	\N
NM-39	\N	\N	Unknown	Greece	6172.3 (14.6172.3 slide)	\N	1217	\N	\N
NL-014	M	\N	Unknown	UCSF	18-129422	\N	1176	\N	IP1993538
NM-38	\N	\N	Unknown	Greece	4890/15 8	\N	1216	\N	\N
ME-68	M	\N	Unknown	UCSF	23-47727,23-34755, 23-34755, 23-47727	\N	1163	\N	\N
MP-01	\N	\N	Unknown	\N	02-49261,05-605A2, 02-49261, 05-605A2	08/11/22: Blocks do NOT match patient. Why is this?	1165	\N	IP353896
NM-40	\N	\N	Unknown	Greece	11649.2 (15.11649.2 slide)	\N	1218	\N	\N
JJS21	F	\N	Unknown	UCSF	15-98263	PMID: 29990500 case 75; RPA-565	760	\N	\N
JJS23	M	\N	Unknown	UCSF	15-50051	PMID: 29990500 case 77; RPA-567	761	\N	\N
JJS24	M	\N	Unknown	UCSF	15-48134	PMID: 29990500 case 78; RPA-568	762	\N	\N
JJS25	M	\N	Unknown	UCSF	15-12964B	PMID: 29990500 case 79; RPA-569	763	\N	\N
SYNAT671	\N	\N	\N	\N	35_M	\N	1760	\N	\N
JJS27	M	\N	Unknown	UCSF	15-85517	PMID: 29990500 case 81; RPA-571	765	\N	\N
LN-038	F	\N	Unknown	UCSF	17-115571C,17-115571D, 17-115571C, 17-115571D	\N	857	\N	IP1840629
KA-01	M	\N	Unknown	UCSF	21-89776A,21-89776B, 21-89776A, 21-89776B	\N	767	\N	IP2352756
DPN-02	\N	\N	Unknown	UCSF	19-109646	\N	736	\N	\N
DPN-03	\N	\N	Unknown	UCSF	12-051311	\N	737	\N	\N
DPN-05	\N	\N	Unknown	UCSF	18-31431	\N	738	\N	\N
DPN-06	\N	\N	Unknown	UCSF	10-57426	\N	739	\N	\N
JJS2	F	\N	Unknown	UCSF	11-29719	BAD SAMPLE	741	\N	\N
JJS1	F	\N	Unknown	UCSF	11-23681C,11-23681B,11-23681,11-23681A, 11-23681C, 11-23681B, 11-23681, 11-23681A	PMID: 29990500 case 33 OR 33_2; RPA-294	740	\N	\N
JJS3	F	\N	Unknown	UCSF	11-37533B,11-37533, 11-37533, 11-37533B	PMID: 29990500 case 22-2; RPA-329	742	\N	\N
JJS8	M	\N	Unknown	UCSF	12-21993I,12-21993C, 12-21993I, 12-21993C	PMID: 29990500 case XX; RPA-298	747	\N	\N
JJS10	M	\N	Unknown	UCSF	12-67568B,12-67568A, 12-67568B, 12-67568A	PMID: 29990500 case 74; RPA-295	749	\N	\N
JJS11	F	\N	Unknown	UCSF	12-57349C,12-57349E, 12-57349C, 12-57349E	PMID: 29990500 case 57; RPA-330	750	\N	\N
KA-02	F	\N	Unknown	UCSF	20-91483A,20-91483B, 20-91483A, 20-91483B	\N	768	\N	IP2239395
KA-03	F	\N	Unknown	UCSF	22-52528-1,22-52528-2, 22-52528-1, 22-52528-2	\N	769	\N	\N
KA-04	F	\N	Unknown	UCSF	22-105120-1,22-105120-2, 22-105120-1, 22-105120-2	\N	770	\N	\N
NL-021	M	\N	Unknown	UCSF	15-101715	\N	1183	\N	IP1573430
NL-024	F	\N	Unknown	UCSF	18-122476	\N	1186	\N	IP594622
NL-025	M	\N	Unknown	UCSF	18-122972	\N	1187	\N	IP1987073
NM-002	\N	\N	Unknown	Greece	1485/15 (1485/15 slide)	\N	1189	\N	\N
NM-003	\N	\N	Unknown	Greece	2997/11	\N	1190	\N	\N
NM-004	\N	\N	Unknown	Greece	5696/15	\N	1191	\N	\N
NM-005	\N	\N	Unknown	Greece	03B12175 (eppendorf)	\N	1192	\N	\N
NM-007	\N	\N	Unknown	Greece	16B10343 (eppendorf)	\N	1194	\N	\N
NM-008	\N	\N	Unknown	Greece	14B13985 (eppendorf)	\N	1195	\N	\N
NM-009	\N	\N	Unknown	Greece	10B18943 (eppendorf)	\N	1196	\N	\N
NM-44	\N	\N	Unknown	Greece	17890/18 (HBD)	\N	1221	\N	\N
NM-45	\N	\N	Unknown	Greece	B246205/ 1BI	\N	1222	\N	\N
NM-46	\N	\N	Unknown	Greece	B247206/ 1Bl	\N	1223	\N	\N
NM-47	\N	\N	Unknown	Greece	B224228/2	\N	1224	\N	\N
NM-48	\N	\N	Unknown	Greece	B205907 III	\N	1225	\N	\N
OM-23	M	\N	Unknown	UCSF	19-72316	\N	1281	\N	\N
OM-24	M	\N	Unknown	UCSF	19-122139	\N	1282	\N	\N
OM-25	F	\N	Unknown	UCSF	20-16705	\N	1283	\N	\N
OM-26	M	\N	Unknown	UCSF	20-28273	\N	1284	\N	\N
OM-27	F	\N	Unknown	UCSF	21-59477	\N	1285	\N	\N
OM-28	M	\N	Unknown	UCSF	21-59483	\N	1286	\N	\N
OM-29	F	\N	Unknown	UCSF	21-93208	\N	1287	\N	\N
OM-30	M	\N	Unknown	UCSF	11-48013	\N	1288	\N	\N
OM-31	F	\N	Unknown	UCSF	13-48	LEFT LATERAL PLANTAR FOOT	1289	\N	\N
OM-32	F	\N	Unknown	UCSF	13-11936	\N	1290	\N	\N
OM-36	M	\N	Unknown	UCSF	15-30226	\N	1294	\N	\N
OM-37	F	\N	Unknown	UCSF	15-99261C	\N	1295	\N	IP1570965
SYNX138	F	\N	\N	\N	13-25110A1	NaN	1541	\N	IP1209855
SN-16	F	\N	Unknown	UCSF	19-105255	\N	1379	\N	IP162083
SN-21	M	\N	Unknown	UCSF	20-92494	\N	1384	\N	IP2240410
SN-23	M	\N	Unknown	UCSF	19-117072A,19-117072A2, 19-117072A, 19-117072A2	\N	1386	\N	IP2121822
SYNX152	F	\N	\N	\N	12-55584	CGH12-224 	1555	\N	IP1141397
SYNX153	F	\N	\N	\N	11-85416	CGH11-410 	1556	\N	IP1074864
CCR-058	M	\N	White	\N	99-18307	\N	148	\N	IP193840
CM-27	\N	\N	Unknown	Denmark	19Rig750007.02.08.02	\N	267	\N	\N
CCR-201	F	\N	White	\N	99-30301	\N	181	\N	IP58570
CM-14	\N	\N	Unknown	Denmark	19Rig750007.01.14.04	replacement for 19rig750007.02.02.04	258	\N	\N
CM-76	\N	\N	Unknown	Denmark	19rig750007.02.11.01	\N	302	\N	\N
CME-006	\N	\N	Asian	Taiwan	13-32637	\N	308	\N	\N
SYNX1	M	\N	\N	\N	12-6261B,12-6261A	Cheek	1404	\N	IP1092077
SYNX2	M	\N	\N	\N	12-12366	NaN	1405	\N	IP1098182
SYNX3	F	\N	\N	\N	12-12467	NaN	1406	\N	IP1098283
SYNX4	M	\N	\N	\N	12-12470D	NaN	1407	\N	IP192328
SYNX5	M	\N	\N	\N	12-562	NaN	1408	\N	IP1042076
SYNX6	M	\N	\N	\N	12-12647	NaN	1409	\N	IP858006
SYNX7	F	\N	\N	\N	12-12626	Right Arm	1410	\N	IP1098442
SYNX9	M	\N	\N	\N	12-18438A	NaN	1412	\N	IP1104255
SYNX10	M	\N	\N	\N	12-13152	NaN	1413	\N	IP1098968
SYNX11	M	\N	\N	\N	12-12750B	Forehead	1414	\N	IP114451
SYNX12	F	\N	\N	\N	12-19596	NaN	1415	\N	IP1105413
SYNX13	F	\N	\N	\N	12-19187A	Shin	1416	\N	IP1105004
SYNX14	F	\N	\N	\N	12-22172	NaN	1417	\N	IP1107990
SYNX15	F	\N	\N	\N	12-21726A	NaN	1418	\N	IP1107544
SYNX16	M	\N	\N	\N	12-22901A	NaN	1419	\N	IP1108719
SYNX45	F	\N	\N	\N	12-6981	CGH12-047 FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	1448	\N	IP1092797
SYNX19	M	\N	\N	\N	12-22775	NaN	1422	\N	IP249102
SYNX20	M	\N	\N	\N	12-22794A	NaN	1423	\N	IP454633
SYNX21	F	\N	\N	\N	12-22573	NaN	1424	\N	IP1108391
SYNX57	M	\N	\N	\N	12-20321	NaN	1460	\N	IP1102231
SYNX22	F	\N	\N	\N	12-22582A	NaN	1425	\N	IP1108400
SYNX23	F	\N	\N	\N	12-22587	NaN	1426	\N	IP1108405
SYNX24	M	\N	\N	\N	12-22592	Scalp	1427	\N	IP559886
SYNX25	M	\N	\N	\N	12-22597	NaN	1428	\N	IP575947
SYNX26	F	\N	\N	\N	12-22602A,12-22602B	NaN	1429	\N	IP1081809
SYNX27	F	\N	\N	\N	12-22603	Forehead	1430	\N	IP1108421
SYNX28	M	\N	\N	\N	12-22604	NaN	1431	\N	IP1108422
SYNX30	F	\N	\N	\N	12-22868	NaN	1433	\N	IP1108686
SYNX31	F	\N	\N	\N	12-22884C,12-22884D	NaN	1434	\N	IP1108702
SYNX32	F	\N	\N	\N	12-22886	NaN	1435	\N	IP337537
SYNX33	M	\N	\N	\N	12-22894B	NaN	1436	\N	IP1108712
SYNX34	F	\N	\N	\N	12-22898	NaN	1437	\N	IP445158
SYNX35	M	\N	\N	\N	12-22900	Eybrow	1438	\N	IP2427054
SYNX46	F	\N	\N	\N	10-55707	CGH10-013 FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	1449	\N	IP950283
SYNX47	F	\N	\N	\N	11-34950	CGH11-153 FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	1450	\N	IP1024388
SYNX48	M	\N	\N	\N	11-8228	CGH11-036 FFPE extracted DNA from Swapna in the Clinical Diagnostic lab that has already been tested on the CGH array	1451	\N	IP997665
SYNX50	F	\N	\N	\N	11-5482	CGH11-035 Iwei Translocation Case	1453	\N	IP994919
SYNX39	M	\N	\N	\N	10-86469	CGH11-029 Need to Get diagnosis from Iwei|NTRK3 Translocation case	1442	\N	IP981048
SYNX42	F	\N	\N	\N	11-30426	CGH11-125 Need to Get diagnosis from Iwei|NTRK3 Translocation case	1445	\N	IP1019864
SYNX43	F	\N	\N	\N	11-31904	CGH11-194 Need to Get diagnosis from Iwei|BRAF Translocation case	1446	\N	IP1021342
SYNX44	F	\N	\N	\N	11-47644	CGH11-201 Need to Get diagnosis from Iwei|BRAF Translocation case	1447	\N	IP1037083
SYNX51	M	\N	\N	\N	11-79158	CGH11-343 Iwei Translocation Case	1454	\N	IP1068606
SYNX52	F	\N	\N	\N	10-59344	CGH10-016 Iwei Translocation Case | Barcode mismatch comment in note	1455	\N	IP953920
SYNX53	F	\N	\N	\N	11-16253	CGH11-060 Iwei Translocation Case	1456	\N	IP1005690
SYNX54	F	\N	\N	\N	11-61046	CGH11-252 Iwei Translocation Case	1457	\N	IP1050489
SYNX36	M	\N	\N	\N	10-41439	NaN	1439	\N	IP936014
SYNX38	F	\N	\N	\N	11-37533	NaN	1441	\N	IP1021763
SYNX55	F	\N	\N	\N	10-56047	CGH10-017 Iwei Translocation Case	1458	\N	IP950623
SYNX56	F	\N	\N	\N	12-67298	NaN	1459	\N	IP960004
SYNX58	F	\N	\N	\N	11-96096	NaN	1461	\N	IP1085544
SYNX93	F	\N	\N	\N	11-38771	CGH11-166 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1496	\N	IP1028210
SYNX64	M	\N	\N	\N	11-21491	CGH11-080 Iwei Translocation Cases	1467	\N	IP1010929
SYNX65	F	\N	\N	\N	11-65778	CGH11-281 Iwei Translocation Cases	1468	\N	IP1055221
SYNX66	M	\N	\N	\N	10-88482	CGH10-058 Iwei Translocation Cases	1469	\N	IP983061
SYNX67	F	\N	\N	\N	11-63178	CGH11-283 Iwei Translocation Cases	1470	\N	IP1052621
SYNX59	F	\N	\N	\N	12-71679	CGH12-317 	1462	\N	IP1157496
SYNX60	M	\N	\N	\N	12-80985B	CGH12-343 Less than 100 ng input for End Repair	1463	\N	IP1166802
SYNX61	F	\N	\N	\N	12-31996	CGH12-135 	1464	\N	IP1148421
SYNX62	F	\N	\N	\N	12-39632	CGH12-161 Less than 100 ng input for End Repair	1465	\N	IP1125450
SYNX68	F	\N	\N	\N	10-71761	CGH10-020 Iwei Translocation Cases	1471	\N	IP966340
SYNX69	F	\N	\N	\N	10-84478	CGH10-049 Iwei Translocation Cases	1472	\N	IP979057
SYNX70	F	\N	\N	\N	10-88475	CGH11-020 Iwei Translocation Cases	1473	\N	IP983054
SYNX71	F	\N	\N	\N	12-54296	NaN	1474	\N	IP1140109
SYNX94	M	\N	\N	\N	11-39639	CGH11-172 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1497	\N	IP1029078
SYNX72	F	\N	\N	\N	12-54992	NaN	1475	\N	IP1140805
SYNX95	F	\N	\N	\N	08-27590	NaN	1498	\N	IP736231
SYNX96	F	\N	\N	\N	06-32942	NaN	1499	\N	IP578011
SYNX97	M	\N	\N	\N	06-52508	NaN	1500	\N	IP597577
SYNX73	F	\N	\N	\N	11-78845	CGH11-361 Iwei Translocation Project	1476	\N	IP1068293
SYNX74	F	\N	\N	\N	11-81405	CGH11-366 Iwei Translocation Project	1477	\N	IP1070853
SYNX75	F	\N	\N	\N	11-85075	CGH11-376 Iwei Translocation Project	1478	\N	IP1074523
SYNX76	F	\N	\N	\N	11-83908	CGH11-388 Iwei Translocation Project	1479	\N	IP1073356
SYNX77	F	\N	\N	\N	11-85859	CGH11-422 Iwei Translocation Project	1480	\N	IP1075307
SYNX78	F	\N	\N	\N	11-95663	CGH12-016 Iwei Translocation Project	1481	\N	IP1085111
SYNX98	M	\N	\N	\N	07-14044A	NaN	1501	\N	IP636575
SYNX99	F	\N	\N	\N	07-26247	NaN	1502	\N	IP208441
SYNX100	M	\N	\N	\N	09-37302	NaN	1503	\N	IP838065
SYNX101	M	\N	\N	\N	12-79358	Iwei, Translocation CGH BRAF	1504	\N	IP1165175
SYNX102	F	\N	\N	\N	12-81302	CGH12-345 Iwei, Translocation CGH NTRK1	1505	\N	IP1167119
SYNX103	M	\N	\N	\N	12-81749	CGH12-347 Iwei, Translocation CGH NTRK2	1506	\N	IP1167566
SYNX104	F	\N	\N	\N	12-97031	CGH13-003 Iwei, Translocation CGH BRAF	1507	\N	IP1182848
SYNX105	M	\N	\N	\N	12-98736	CGH13-009 Iwei, Translocation CGH NTRK1	1508	\N	IP1184553
SYNX106	M	\N	\N	\N	13-3874	CGH13-033 Iwei, Translocation CGH NTRK1	1509	\N	IP1188617
SYNX107	F	\N	\N	\N	13-3732	CGH13-034 Iwei, Translocation CGH NTRK1?	1510	\N	IP1188475
SYNX108	F	\N	\N	\N	13-3889	CGH13-041 Iwei, Translocation CGH NTRK3	1511	\N	IP1188632
SYNX109	M	\N	\N	\N	13-4090B	CGH13-044 Iwei, Translocation CGH NTRK3	1512	\N	IP1188833
SYNX110	M	\N	\N	\N	13-4136	CGH13-046 Iwei, Translocation CGH BRAF	1513	\N	IP1179510
SYNX111	M	\N	\N	\N	13-7186	CGH13-058 Iwei, Translocation CGH NTRK3	1514	\N	IP1191929
SYNX112	F	\N	\N	\N	13-25A	CGH13-011 Iwei, Translocation CGH BRAF	1515	\N	IP1184767
SYNX113	F	\N	\N	\N	11-71241	NaN	1516	\N	IP1060684
SYNX114	M	\N	\N	\N	11-26903	NaN	1517	\N	IP1016341
SYNX116	M	\N	\N	\N	11-5210D	NaN	1519	\N	IP873475
SYNX117	F	\N	\N	\N	10-83193	NaN	1520	\N	IP977772
SYNX118	M	\N	\N	\N	11-95856	NaN	1521	\N	IP1085304
SYNX119	F	\N	\N	\N	10-23569A	NaN	1522	\N	IP918142
SYNX120	M	\N	\N	\N	09-92749	NaN	1523	\N	IP893515
SYNX121	F	\N	\N	\N	09-72944	NaN	1524	\N	IP563362
SYNX122	F	\N	\N	\N	10-46536	NaN	1525	\N	IP941112
SYNX123	M	\N	\N	\N	10-83613A	NaN	1526	\N	IP978192
SYNX115	M	\N	\N	\N	11-38149,11-28912B	NaN	1518	\N	IP1018350
SYNX88	M	\N	\N	\N	11-18560	CGH11-072 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1491	\N	IP1007998
SYNX79	F	\N	\N	\N	11-64496	CGH11-292 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1482	\N	IP1053939
SYNX80	F	\N	\N	\N	11-71491	CGH11-305 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1483	\N	IP1060934
SYNX81	M	\N	\N	\N	11-65756	CGH11-310 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1484	\N	IP1055199
SYNX82	M	\N	\N	\N	11-74100	CGH11-319 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1485	\N	IP1063547
SYNX89	F	\N	\N	\N	11-20772	CGH11-087 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1492	\N	IP1010210
SYNX83	M	\N	\N	\N	11-74517	CGH11-348 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1486	\N	IP1063964
SYNX84	F	\N	\N	\N	10-74513	CGH10-028 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1487	\N	IP969092
SYNX85	M	\N	\N	\N	10-80009	CGH10-045 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1488	\N	IP974588
SYNX86	F	\N	\N	\N	10-91484	CGH10-062 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1489	\N	IP986063
SYNX87	F	\N	\N	\N	11-699	CGH11-011 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1490	\N	IP990136
SYNX90	F	\N	\N	\N	11-19877	CGH11-089 | Barcode mismatch comment in note| Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1493	\N	IP1009315
SYNX91	F	\N	\N	\N	11-35616	CGH11-147 | Barcode mismatch comment in note| Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1494	\N	IP1025054
SYNX92	M	\N	\N	\N	11-33856	CGH11-158 Increased Tert 1 and 2 spike-in to 10pg/ul|Decreased SF3B 1 and 2 spike-in to 4pg/ul | New dilutions based on data analysis of BB013 Library. SF3B was successful, so we will decrease the spike-in concentration until ideal input is found | Tert promoter had poor results, will increase the concentration to obtain better results. Refer to Hunter's email (Subject: Spike-in, 4/1/2013)	1495	\N	IP1023294
SYNX127	F	\N	\N	\N	10-58663	13 Cycle Post Hybridization LM-PCR	1530	\N	IP953239
SYNX128	F	\N	\N	\N	08-52519	13 Cycle Post Hybridization LM-PCR	1531	\N	IP761160
SYNX124	M	\N	\N	\N	10-32987	NaN	1527	\N	IP927561
SYNX129	M	\N	\N	\N	09-8165	NaN	1532	\N	IP458841
SYNX130	M	\N	\N	\N	08-46462	NaN	1533	\N	IP755103
SYNX216	F	\N	\N	\N	08-53951	NaN	1619	\N	IP596372
SYNX176	M	\N	\N	\N	11-41004	CGH11-202 	1579	\N	IP1030443
SYNX125	F	\N	\N	\N	06-21363	NaN	1528	\N	IP566429
SYNX126	F	\N	\N	\N	06-47334	NaN	1529	\N	IP454219
SYNX131	F	\N	\N	\N	11-25808	CGH11-115 	1534	\N	IP1015246
SYNX132	M	\N	\N	\N	11-42027	CGH11-184 	1535	\N	IP940410
SYNX133	F	\N	\N	\N	12-7775	CGH12-043 	1536	\N	IP1093591
SYNX134	F	\N	\N	\N	08-43264	NaN	1537	\N	IP179649
SYNX135	M	\N	\N	\N	08-51219	NaN	1538	\N	IP754897
SYNX136	F	\N	\N	\N	11-81851	NaN	1539	\N	IP1071299
SYNX137	M	\N	\N	\N	10-73024	NaN	1540	\N	IP967603
SYNX139	F	\N	\N	\N	13-45163	NaN	1542	\N	IP468757
SYNX140	M	\N	\N	\N	11-50182	CGH11-229 	1543	\N	IP1039621
SYNX141	F	\N	\N	\N	11-51553	CGH11-231 	1544	\N	IP1040993
SYNX142	F	\N	\N	\N	11-52339	CGH11-232 	1545	\N	IP1041779
SYNX143	F	\N	\N	\N	11-55993	CGH11-237 	1546	\N	IP1045436
SYNX144	M	\N	\N	\N	11-57051	CGH11-259 	1547	\N	IP1046494
SYNX145	F	\N	\N	\N	11-71006	CGH11-315 	1548	\N	IP1060449
SYNX146	M	\N	\N	\N	11-76464	CGH11-339 	1549	\N	IP1065911
SYNX148	F	\N	\N	\N	11-88432	CGH11-404 	1551	\N	IP1077880
SYNX149	M	\N	\N	\N	11-88209	CGH11-409 	1552	\N	IP1071369
SYNX154	F	\N	\N	\N	11-94134	CGH11-424 	1557	\N	IP1083582
SYNX155	F	\N	\N	\N	12-2898	CGH12-026 	1558	\N	IP1088714
SYNX157	F	\N	\N	\N	12-4251	CGH12-040 	1560	\N	IP1090067
SYNX158	M	\N	\N	\N	12-8171	CGH12-053 	1561	\N	IP1093987
SYNX160	F	\N	\N	\N	11-21178	CGH11-091 	1563	\N	IP1010616
SYNX161	M	\N	\N	\N	13-212	NaN	1564	\N	IP1184954
SYNX162	F	\N	\N	\N	11-50270	CGH11-224 	1565	\N	IP1039709
SYNX163	F	\N	\N	\N	12-23578	CGH12-104 	1566	\N	IP1101847
SYNX164	M	\N	\N	\N	12-31421	CGH12-124 	1567	\N	IP1117239
SYNX165	M	\N	\N	\N	11-13661	CGH11-051 	1568	\N	IP1003098
SYNX171	M	\N	\N	\N	13-2939B	NaN	1574	\N	IP1187682
SYNX166	F	\N	\N	\N	98-18400a	NaN	1569	\N	IP155973
SYNX167	F	\N	\N	\N	12-11406A	NaN	1570	\N	IP1097222
SYNX168	F	\N	\N	\N	08-70283a	NaN	1571	\N	IP778923
SYNX169	M	\N	\N	\N	03-34051A1	NaN	1572	\N	IP392364
SYNX170	F	\N	\N	\N	02-42436	NaN	1573	\N	IP347170
SYNX172	M	\N	\N	\N	13-51115A	NaN	1575	\N	IP380899
SYNX173	F	\N	\N	\N	11-73238A	NaN	1576	\N	IP987085
SYNX174	F	\N	\N	\N	11-73999	NaN	1577	\N	IP1063446
SYNX175	M	\N	\N	\N	13-59840	NaN	1578	\N	IP352453
SYNX193	M	\N	\N	\N	12-12039B	NaN	1596	\N	IP1097855
SYNX177	F	\N	\N	\N	11-51223	CGH11-215 	1580	\N	IP1040663
SYNX178	M	\N	\N	\N	12-22542	CGH12-088 	1581	\N	IP1108360
SYNX180	M	\N	\N	\N	12-55875	CGH12-227 	1583	\N	IP1141688
SYNX181	M	\N	\N	\N	12-88454	CGH12-376 	1584	\N	IP1174271
SYNX182	M	\N	\N	\N	12-98328	CGH13-007 	1585	\N	IP1176562
SYNX183	M	\N	\N	\N	12-762B	NaN	1586	\N	IP1086578
SYNX184	M	\N	\N	\N	12-168B	NaN	1587	\N	IP1080712
SYNX185	F	\N	\N	\N	11-75173	NaN	1588	\N	IP1064620
SYNX186	F	\N	\N	\N	12-167B	NaN	1589	\N	IP671051
SYNX188	F	\N	\N	\N	12-66661	NaN	1591	\N	IP1152477
SYNX189	F	\N	\N	\N	13-47621	NaN	1592	\N	IP1288923
SYNX190	F	\N	\N	\N	13-37371	NaN	1593	\N	IP1278673
SYNX194	?	\N	\N	\N	99-29482	NaN	1597	\N	IP205015
SYNX195	F	\N	\N	\N	99-15313	NaN	1598	\N	IP190846
SYNX196	M	\N	\N	\N	99-885	NaN	1599	\N	IP176418
SYNX197	M	\N	\N	\N	98-37643	NaN	1600	\N	IP175216
SYNX199	M	\N	\N	\N	09-29997	NaN	1602	\N	IP310907
SYNX208	F	\N	\N	\N	13-1939	CGH13-027 NTRK3	1611	\N	IP1186681
SYNX209	F	\N	\N	\N	13-51657	CGH13-268 MET	1612	\N	IP1293660
SYNX198	M	\N	\N	\N	13-32982A,13-25288, 13-25288	NaN	1601	\N	IP1210033
SYNX179	M	\N	\N	\N	12-42406	CGH12-188 	1582	\N	IP1128224
SYNX187	F	\N	\N	\N	13-47668	NaN	1590	\N	IP298118
SYNX192	F	\N	\N	\N	12-18832AA	NaN	1595	\N	IP1104649
SYNX200	F	\N	\N	\N	04-11158	NaN	1603	\N	IP427557
SYNX191	M	\N	\N	\N	02-2599,02-2599C, 02-2599, 02-2599C	NaN	1594	\N	IP307333
SYNX222	M	\N	\N	\N	08-18595B	NaN	1625	\N	IP711218
SYNX236	F	\N	\N	\N	13-59640	NaN	1639	\N	IP1276884
SYNX240	M	\N	\N	\N	11-94204	NaN	1643	\N	IP1083652
SYNX241	F	\N	\N	\N	14-16247	CGH14-059 	1644	\N	IP1366169
SYNX242	F	\N	\N	\N	13-35959	NaN	1645	\N	IP1217226
SYNX243	F	\N	\N	\N	13-102610	NaN	1646	\N	IP1138765
SYNX244	F	\N	\N	\N	13-99417	NaN	1647	\N	IP2344638
SYNX245	M	\N	\N	\N	13-98534	NaN	1648	\N	IP1340550
SYNX246	M	\N	\N	\N	13-9916	NaN	1649	\N	IP1194427
SYNX247	M	\N	\N	\N	11-44609F	NaN	1650	\N	IP1029070
SYNX248	F	\N	\N	\N	12-98575A1	NaN	1651	\N	IP824297
SYNX253	M	\N	\N	\N	14-59304A	NaN	1656	\N	IP1409245
SYNX201	M	\N	\N	\N	08-84352	NaN	1604	\N	IP792993
SYNX202	M	\N	\N	\N	11-88792	NaN	1605	\N	IP787073
SYNX203	M	\N	\N	\N	13-74952	CGH13-324 	1606	\N	IP1316957
SYNX204	M	\N	\N	\N	13-75067	CGH13-331 ETV6 Fusion	1607	\N	IP1317072
SYNX217	F	\N	\N	\N	07-3078	NaN	1620	\N	IP625607
SYNX210	F	\N	\N	\N	13-89069	CGH13-365 DPN-like Melanoma	1613	\N	IP1331074
SYNX211	M	\N	\N	\N	11-1051A	CGH11-018 	1614	\N	IP990488
SYNX212	F	\N	\N	\N	11-5480	CGH11-027 	1615	\N	IP994917
SYNX214	M	\N	\N	\N	09-31895	NaN	1617	\N	IP79298
SYNX215	F	\N	\N	\N	01-8297	NaN	1618	\N	IP264700
SYNX218	M	\N	\N	\N	13-94981	CGH13-392 	1621	\N	IP1336996
SYNX219	F	\N	\N	\N	13-99411A	CGH13-399 	1622	\N	IP1341428
SYNX220	F	\N	\N	\N	13-94484	CGH13-394 	1623	\N	IP1336499
SYNX221	F	\N	\N	\N	11-2532	CGH11-023 	1624	\N	IP991969
SYNX223	M	\N	\N	\N	13-60273	NaN	1626	\N	IP841587
SYNX224	M	\N	\N	\N	12-52454	NaN	1627	\N	IP1032345
SYNX225	F	\N	\N	\N	12-75125	NaN	1628	\N	IP1160942
SYNX226	M	\N	\N	\N	12-98235A	NaN	1629	\N	IP1184052
SYNX227	M	\N	\N	\N	13-3619B	NaN	1630	\N	IP1188362
SYNX228	M	\N	\N	\N	13-67500AL	NaN	1631	\N	IP1309505
SYNX229	F	\N	\N	\N	13-19205	NaN	1632	\N	IP1203948
SYNX230	F	\N	\N	\N	13-48330	NaN	1633	\N	IP467959
SYNX231	F	\N	\N	\N	13-11086	NaN	1634	\N	IP1158926
SYNX235	M	\N	\N	\N	13-49600	NaN	1638	\N	IP61201
SYNX237	M	\N	\N	\N	13-67817	NaN	1640	\N	IP1199676
DP-09	F	\N	Unknown	UCSF	12-11041	Consultation; Diagnosis on IntelliPath: Melanoma	646	\N	IP1096857
SYNX238	M	\N	\N	\N	08-79358	NaN	1641	\N	IP172751
SYNX205	F	\N	\N	\N	13-159	CGH13-016 	1608	\N	IP1183551
SYNX206	F	\N	\N	\N	12-43016	CGH12-163 	1609	\N	IP1128829
SYNX207	M	\N	\N	\N	13-34291	CGH13-166 	1610	\N	IP1275593
KA-05	F	\N	Unknown	UCSF	20-82651B,20-82651E,20-82651A,20-82651D,20-82651C, 20-82651B, 20-82651E, 20-82651A, 20-82651D, 20-82651C	\N	771	\N	IP2230518
KA-06	M	\N	Unknown	UCSF	21-96446A1,21-96446A2, 21-96446A1, 21-96446A2	\N	772	\N	IP2359460
KA-07	M	\N	Unknown	UCSF	20-104213B,20-104213A, 20-104213B, 20-104213A	\N	773	\N	IP2252203
SYNAT672	\N	\N	\N	\N	09-0209	\N	1905	\N	\N
LN-041	M	\N	Unknown	UCSF	17-112588B	\N	859	\N	IP1843066
KA-08	M	\N	Unknown	UCSF	20-18514B,20-18514A, 20-18514B, 20-18514A	\N	774	\N	IP2166036
KA-09	F	\N	Unknown	UCSF	20-98774D,20-98774A,20-98774B, 20-98774D, 20-98774A, 20-98774B	\N	775	\N	IP2246722
LMM-02	\N	\N	Unknown	UCSF	21-7055B6,21-7055B1,21-7055B4, 21-7055B6, 21-7055B1, 21-7055B4	\N	801	\N	IP554241
KF-05	F	\N	Unknown	\N	11-5482	\N	778	\N	\N
KF-01	F	\N	Unknown	\N	12-4251	\N	776	\N	\N
LMM-03	\N	\N	Unknown	UCSF	21-35943A,21-457B,21-457C, 21-35943A, 21-457B, 21-457C	\N	802	\N	IP2011798
LMM-04	\N	\N	Unknown	UCSF	21-21304A1,21-25546B2,21-21304A10, 21-21304A1, 21-25546B2, 21-21304A10	\N	803	\N	IP2283785
LMM-09	\N	\N	Unknown	UCSF	20-11796D,20-6751, 20-11796D, 20-6751	\N	808	\N	IP2097439
AM2-008	\N	\N	Unknown	Bolivia	79049-1b,79049-1c,79049-2a,79049-1a,79049-2b,79049-1d, 79049-1c, 79049-2a, 79049-1a, 79049-2b, 79049-1d, 79049-1b	\N	6	\N	\N
LMM-05	\N	\N	Unknown	UCSF	22-91699A1,22-91699A7,22-91699A4, 22-91699A1, 22-91699A7, 22-91699A4	\N	804	\N	IP1692985
DN-069	F	\N	Unknown	\N	17-20900B	\N	544	\N	IP83591
LMM-07	\N	\N	Unknown	UCSF	22-29280,21-135927, 22-29280, 21-135927	\N	806	\N	IP2399198
LMM-08	\N	\N	Unknown	UCSF	20-102366B1,17-77365,20-102366B2, 20-102366B1, 17-77365, 20-102366B2	\N	807	\N	IP115267
MC-02	\N	\N	Unknown	\N	SKMEL 1107B,SKMel 1107B Dec2019, SKMEL 1107B, SKMel 1107B Dec2019	\N	904	\N	\N
MC-03	\N	\N	Unknown	\N	SKMel 1121B Dec2019,SKMEL 1121B, SKMel 1121B Dec2019, SKMEL 1121B	\N	905	\N	\N
LMM-10	\N	\N	Unknown	UCSF	18-83370A,18-83370B,19-75051, 18-83370A, 18-83370B, 19-75051	\N	809	\N	IP1469433
MP-04	\N	\N	Unknown	\N	96-4039,96-4039A5,96-4039A7,02-1274B1,96-14850, 96-4039, 96-4039A5, 96-4039A7, 02-1274B1, 96-14850	08/11/22: Blocks do NOT match patient. Why is this?	1168	\N	\N
LMM-11	\N	\N	Unknown	UCSF	18-12160D,18-12160F,18-12160E, 18-12160D, 18-12160F, 18-12160E	\N	810	\N	IP1875716
MC-04	\N	\N	Unknown	\N	Mel290	\N	906	\N	\N
LMM-12	\N	\N	Unknown	UCSF	21-83029A,22-94741,21-83029B, 21-83029A, 22-94741, 21-83029B	\N	811	\N	IP1380659
MD-05	\N	\N	Unknown	Madrid, Spain	02-05776 T1,02-05776D T1, 02-05776 T1, 02-05776D T1	\N	911	\N	\N
LMM-14	\N	\N	Unknown	UCSF	20-18383A1,20-18383B2, 20-18383A1, 20-18383B2	\N	813	\N	IP2165905
LMM-15	\N	\N	Unknown	UCSF	21-79845,22-76519A, 21-79845, 22-76519A	\N	814	\N	IP49555
LMM-16	\N	\N	Unknown	UCSF	22-102807-4,22-102807-2, 22-102807-4, 22-102807-2	\N	815	\N	\N
LMM-17	\N	\N	Unknown	UCSF	22-7578,22-15594-4, 22-7578, 22-15594-4	\N	816	\N	IP150179
MD-06	\N	\N	Unknown	Madrid, Spain	03-26518 T1,03-26518B M1, 03-26518 T1, 03-26518B M1	\N	912	\N	\N
MD-08	\N	\N	Unknown	Madrid, Spain	04-01809 T4,04-01809E T4, 04-01809 T4, 04-01809E T4	\N	914	\N	\N
CME-050	F	\N	Asian	Japan	19-03800-4	\N	352	\N	\N
CME-026	\N	\N	Asian	Taiwan	21-15959	\N	328	\N	\N
CME-027	\N	\N	Asian	Taiwan	21-17351	\N	329	\N	\N
CME-028	\N	\N	Asian	Taiwan	20-24373A1	\N	330	\N	\N
CME-029	\N	\N	Asian	Taiwan	16-37564A1	\N	331	\N	\N
CME-030	\N	\N	Asian	Taiwan	18-31426A	\N	332	\N	\N
CME-031	\N	\N	Asian	Taiwan	21-21081	\N	333	\N	\N
CME-032	\N	\N	Asian	Taiwan	22-34951	\N	334	\N	\N
CME-033	\N	\N	Asian	Taiwan	22-21031A1	\N	335	\N	\N
DMS-025	\N	\N	Unknown	UCSF	22-854	\N	437	\N	\N
DN-060	M	\N	Unknown	\N	17-27000	\N	535	\N	IP1756322
MD-37	\N	\N	Unknown	Madrid, Spain	16-31317 T4	\N	943	\N	\N
KF-08	F	\N	Unknown	\N	11-61046	\N	779	\N	\N
BN-010	F	\N	Unknown	UCSF	10-83193	blue nevus, cellular	114	\N	\N
JJS5	M	\N	Unknown	UCSF	11-94204	PMID: 29990500 case 27_2; RPA-315	744	\N	\N
MC-01	\N	\N	Unknown	\N	SKMEL 1023A	\N	903	\N	\N
MD-100	\N	\N	Unknown	Madrid, Spain	00-27758D M1	\N	996	\N	\N
MD-101	\N	\N	Unknown	Madrid, Spain	02-16797C M1	\N	997	\N	\N
MD-102	\N	\N	Unknown	Madrid, Spain	02-00594E M1	\N	998	\N	\N
MD-103	\N	\N	Unknown	Madrid, Spain	06-11147 N1	\N	999	\N	\N
MD-105	\N	\N	Unknown	Madrid, Spain	04-20471E M1	\N	1000	\N	\N
MD-106	\N	\N	Unknown	Madrid, Spain	05-14728C M1	\N	1001	\N	\N
MD-107	\N	\N	Unknown	Madrid, Spain	06-12646D M1	\N	1002	\N	\N
MD-182	\N	\N	Unknown	Madrid, Spain	00-24216D T4	\N	1059	\N	\N
OM-34	F	\N	Unknown	UCSF	14-70636	\N	1292	\N	\N
MD-132	\N	\N	Unknown	Madrid, Spain	96-24948 T1	\N	1016	\N	\N
MD-62	\N	\N	Unknown	Madrid, Spain	99-16633E N1	\N	968	\N	\N
DP-17	F	\N	Unknown	UCSF	11-23710	\N	654	\N	IP1013148
DP-21	F	\N	Unknown	UCSF	11-84681	\N	658	\N	IP1074129
DP-23	F	\N	Unknown	UCSF	11-88431	\N	660	\N	IP1077879
CM-71	\N	\N	Unknown	Denmark	19Rig750007.05.15.03	\N	299	\N	\N
BN-006	F	\N	Unknown	UCSF	12-32138	blue nevus, cellular	110	\N	\N
BN-007	F	\N	Unknown	UCSF	11-47908	blue nevus, cellular	111	\N	\N
BN-008	F	\N	Unknown	UCSF	11-59209	blue nevus, cellular	112	\N	\N
AM2-077	\N	\N	Asian	Japan	K18-A-B	no area circled, confirmed with Iwei\n	47	\N	\N
AM2-078	\N	\N	Asian	Japan	K19-A-B	no area circled, confirmed with Iwei\n	48	\N	\N
AM2-079	\N	\N	Asian	Japan	K20-A-B	\N	49	\N	\N
AM2-080	\N	\N	Asian	Japan	K21-A-B	\N	50	\N	\N
AM2-083	\N	\N	Asian	Japan	K24-A-B	\N	53	\N	\N
AMC-01	\N	\N	Unknown	\N	MaMel 152aI	\N	98	\N	\N
DN-148	M	\N	Unknown	\N	19-7669	\N	623	\N	IP11027
LN-067	F	\N	Unknown	UCSF	18-76615	\N	880	\N	IP109853
LN-068	M	\N	Unknown	UCSF	18-44465	\N	881	\N	IP1908259
LN-069	F	\N	Unknown	UCSF	20-52881	\N	882	\N	\N
CME-012	\N	\N	Asian	Taiwan	15-36675	\N	314	\N	\N
CME-013	\N	\N	Asian	Taiwan	15-36291	\N	315	\N	\N
CME-016	\N	\N	Asian	Taiwan	17-37055	\N	318	\N	\N
CME-020	\N	\N	Asian	Taiwan	19-33672A1	\N	322	\N	\N
CME-021	\N	\N	Asian	Taiwan	19-44938	\N	323	\N	\N
MD-09	\N	\N	Unknown	Madrid, Spain	04-05355 T4,04-05355B T4, 04-05355 T4, 04-05355B T4	\N	915	\N	\N
LMM-18	\N	\N	Unknown	UCSF	16-74494,17-81380B, 16-74494, 17-81380B	\N	817	\N	IP1674137
LMM-19	\N	\N	Unknown	UCSF	23-1012A2,22-38234B, 23-1012A2, 22-38234B	\N	818	\N	IP2376091
MD-07	\N	\N	Unknown	Madrid, Spain	04-28824 T2	\N	913	\N	\N
LMM-20	\N	\N	Unknown	UCSF	17-111862B,17-122697A,17-111862A, 17-111862B, 17-122697A, 17-111862A	\N	819	\N	IP1814097
LMM-21	\N	\N	Unknown	UCSF	23-12491,23-3314, 23-12491, 23-3314	\N	820	\N	IP746083
MD-11	\N	\N	Unknown	Madrid, Spain	05-14988B T3,05-14988 T3, 05-14988B T3, 05-14988 T3	\N	917	\N	\N
LN-028	F	\N	Unknown	UCSF	17-111657B,17-111657A, 17-111657B, 17-111657A	\N	848	\N	IP531322
LN-052	F	\N	Unknown	UCSF	17-113511	\N	869	\N	\N
MD-12	\N	\N	Unknown	Madrid, Spain	05-29322B T3,05-29322 T3, 05-29322B T3, 05-29322 T3	\N	918	\N	\N
LN-054	F	\N	Unknown	UCSF	17-111704B,17-111704A, 17-111704B, 17-111704A	\N	871	\N	IP327995
LN-053	F	\N	Unknown	UCSF	18-17957	\N	870	\N	IP825795
MD-13	\N	\N	Unknown	Madrid, Spain	06-05518B T4,06-05518 T4, 06-05518B T4, 06-05518 T4	\N	919	\N	\N
LN-062	M	\N	Unknown	UCSF	18-44463B,18-44463C, 18-44463B, 18-44463C	\N	877	\N	IP1908257
LN-065	F	\N	Unknown	UCSF	18-69862B,18-69862A, 18-69862B, 18-69862A	\N	879	\N	IP128042
MD-94	\N	\N	Unknown	Madrid, Spain	94-21132 M1	\N	990	\N	\N
MD-19	\N	\N	Unknown	Madrid, Spain	06-23345 T1	\N	925	\N	\N
MD-20	\N	\N	Unknown	Madrid, Spain	06-27633 T1	\N	926	\N	\N
MD-21	\N	\N	Unknown	Madrid, Spain	06-23587B T1,06-23587 T1, 06-23587B T1, 06-23587 T1	\N	927	\N	\N
MD-80	\N	\N	Unknown	Madrid, Spain	09-13370-2G N1,09-13370-1M N1, 09-13370-2G N1, 09-13370-1M N1	\N	984	\N	\N
OM-33	F	\N	Unknown	UCSF	13-51506A,13-51506B, 13-51506A, 13-51506B	\N	1291	\N	IP1293509
AM2-057	\N	\N	Unknown	Zurich	H13.5620/1,H09.22183/1, H13.5620/1, H09.22183/1	Patient 10	28	\N	\N
AM2-058	\N	\N	Unknown	Zurich	H18.7977,H15.5120/1,H16.5818/2, H18.7977, H15.5120/1, H16.5818/2	Patient 11	29	\N	\N
AM2-059	\N	\N	Unknown	Zurich	H14.26934/2,HS17.35/2, H14.26934/2, HS17.35/2	Patient 12	30	\N	\N
AM2-060	\N	\N	Unknown	Zurich	H15.19121/7,H16.872/2, H15.19121/7, H16.872/2	Patient 13	31	\N	\N
AM2-061	\N	\N	Asian	Japan	K3-C,K3-D,K3-A-B, K3-C, K3-D, K3-A-B	Case K3 (Sole)	32	\N	\N
AM2-062	\N	\N	Asian	Japan	K4-B,K4-C-2,K4-D,K4-C,K4-A, K4-B, K4-C-2, K4-D, K4-C, K4-A	Case K4 (Sole)	33	\N	\N
AM2-063	\N	\N	Asian	Japan	K5-D,K5-A-B, K5-D, K5-A-B	\N	34	\N	\N
AM2-065	\N	\N	Asian	Japan	K6-B,K6-A-D, K6-B, K6-A-D	\N	35	\N	\N
AM2-066	\N	\N	Asian	Japan	K7-A,K7-B,K7-D,K7-B-2, K7-A, K7-B, K7-D, K7-B-2	\N	36	\N	\N
AM2-067	\N	\N	Asian	Japan	K8-B,K8-A, K8-B, K8-A	\N	37	\N	\N
AM2-068	\N	\N	Asian	Japan	K9-D,K9-C,K9-A-B, K9-D, K9-C, K9-A-B	\N	38	\N	\N
AM2-069	\N	\N	Asian	Japan	K10-A,K10-B,K10-C,K10-D, K10-A, K10-B, K10-C, K10-D	\N	39	\N	\N
AM2-070	\N	\N	Asian	Japan	K11-B,K11-D,K11-A, K11-B, K11-D, K11-A	\N	40	\N	\N
AM2-071	\N	\N	Asian	Japan	K12-A,K12-D,K12-B, K12-A, K12-D, K12-B	\N	41	\N	\N
AM2-072	\N	\N	Asian	Japan	K13-A,K13-B,K13-D, K13-A, K13-B, K13-D	\N	42	\N	\N
AM2-073	\N	\N	Asian	Japan	K14-A,K14-B,K14-D, K14-A, K14-B, K14-D	\N	43	\N	\N
AM2-074	\N	\N	Asian	Japan	K15-D,K15-A-B, K15-D, K15-A-B	\N	44	\N	\N
DP-86	F	\N	Unknown	UCSF	17-6368	\N	723	\N	\N
MucM-01	\N	\N	Unknown	UCSF	22-34510B1,22-34510A3, 22-34510B1, 22-34510A3	\N	1169	\N	\N
SYNAT500	\N	\N	\N	\N	DM37	\N	2327	\N	\N
SYNAT501	\N	\N	\N	\N	Bivona-L17	\N	2077	\N	\N
SYNAT502	\N	\N	\N	\N	MB_161	\N	2102	\N	\N
SYNAT503	\N	\N	\N	\N	MB1429	\N	2087	\N	\N
SYNAT504	\N	\N	\N	\N	DM93	\N	2037	\N	\N
SYNAT505	\N	\N	\N	\N	DM58	\N	1745	\N	\N
SYNAT506	\N	\N	\N	\N	SM7	\N	1682	\N	\N
SYNAT507	\N	\N	\N	\N	London-L3	\N	2016	\N	\N
SYNAT508	\N	\N	\N	\N	KIT227	\N	2318	\N	\N
SYNAT509	\N	\N	\N	\N	DM11	\N	2160	\N	\N
SYNAT510	\N	\N	\N	\N	MB1609	\N	2018	\N	\N
SYNAT511	\N	\N	\N	\N	DM29	\N	1925	\N	\N
SYNAT512	\N	\N	\N	\N	KR_8	\N	2210	\N	\N
SYNAT513	\N	\N	\N	\N	KIT191	\N	2043	\N	\N
SYNAT514	\N	\N	\N	\N	MB_760	\N	2093	\N	\N
SYNAT515	\N	\N	\N	\N	DM74	\N	1663	\N	\N
SYNAT516	\N	\N	\N	\N	JBP-3	\N	1687	\N	\N
SYNAT517	\N	\N	\N	\N	DM34	\N	2344	\N	\N
SYNAT518	\N	\N	\N	\N	DM4	\N	2019	\N	\N
SYNAT519	\N	\N	\N	\N	WM8	\N	2337	\N	\N
SYNAT520	\N	\N	\N	\N	DM28	\N	2074	\N	\N
SYNAT521	\N	\N	\N	\N	DM14	\N	2000	\N	\N
SYNAT522	\N	\N	\N	\N	JBP-3-MM	\N	2091	\N	\N
SYNAT523	\N	\N	\N	\N	BN_M2	\N	2116	\N	\N
SYNAT524	\N	\N	\N	\N	Dog43	\N	1869	\N	\N
SYNAT525	\N	\N	\N	\N	DM96	\N	1836	\N	\N
SYNAT526	\N	\N	\N	\N	DM7	\N	1882	\N	\N
SYNAT527	\N	\N	\N	\N	MB1423	\N	1978	\N	\N
SYNAT528	\N	\N	\N	\N	MB1428	\N	1904	\N	\N
SYNAT529	\N	\N	\N	\N	DM61	\N	2227	\N	\N
SYNAT530	\N	\N	\N	\N	DM1	\N	2307	\N	\N
SYNAT531	\N	\N	\N	\N	Seider_Uveal	\N	2166	\N	\N
SYNAT532	\N	\N	\N	\N	DM81	\N	1864	\N	\N
SYNAT533	\N	\N	\N	\N	KIT260	\N	2256	\N	\N
SYNAT534	\N	\N	\N	\N	MB1242	\N	1746	\N	\N
SYNAT535	\N	\N	\N	\N	XD-1	\N	2317	\N	\N
SYNAT536	\N	\N	\N	\N	MB_1046	\N	1977	\N	\N
SYNAT537	\N	\N	\N	\N	JBP-3-Met1	\N	1928	\N	\N
SYNAT538	\N	\N	\N	\N	KR_177	\N	1750	\N	\N
SYNAT539	\N	\N	\N	\N	CP1-40	\N	1701	\N	\N
SYNAT540	\N	\N	\N	\N	CP1-10	\N	1997	\N	\N
SYNAT541	\N	\N	\N	\N	KIT55	\N	2048	\N	\N
SYNAT542	\N	\N	\N	\N	CP1	\N	1835	\N	\N
SYNAT543	\N	\N	\N	\N	SM_11	\N	1843	\N	\N
SYNAT544	\N	\N	\N	\N	DM60	\N	1754	\N	\N
SYNAT545	\N	\N	\N	\N	DM49	\N	2205	\N	\N
SYNAT546	\N	\N	\N	\N	KIT275	\N	1723	\N	\N
SYNAT547	\N	\N	\N	\N	KIT244	\N	1818	\N	\N
SYNAT548	\N	\N	\N	\N	CP1-5	\N	2084	\N	\N
SYNAT549	\N	\N	\N	\N	06-00911	\N	2347	\N	IP545976
SYNAT550	\N	\N	\N	\N	KR_RMK0091B	\N	1832	\N	\N
SYNAT551	\N	\N	\N	\N	DM12	\N	1705	\N	\N
SYNAT552	\N	\N	\N	\N	DM43	\N	2136	\N	\N
SYNAT553	\N	\N	\N	\N	DM45	\N	1888	\N	\N
SYNAT554	\N	\N	\N	\N	DM59	\N	2179	\N	\N
SYNAT555	\N	\N	\N	\N	WM51	\N	1720	\N	\N
SYNAT556	\N	\N	\N	\N	SM_4	\N	2023	\N	\N
SYNAT557	\N	\N	\N	\N	KIT225	\N	2301	\N	\N
SYNAT558	\N	\N	\N	\N	SM_12	\N	2076	\N	\N
SYNAT559	\N	\N	\N	\N	KIT210	\N	1951	\N	\N
SYNAT560	\N	\N	\N	\N	MB1617	\N	1692	\N	\N
SYNAT561	\N	\N	\N	\N	DM18	\N	1844	\N	\N
SYNAT562	\N	\N	\N	\N	KIT313	\N	1897	\N	\N
SYNAT563	\N	\N	\N	\N	MB1421	\N	1781	\N	\N
SYNAT564	\N	\N	\N	\N	PMM-8	\N	1943	\N	\N
SYNAT565	\N	\N	\N	\N	KR_5233	\N	2097	\N	\N
SYNAT566	\N	\N	\N	\N	DM42	\N	1923	\N	\N
SYNAT567	\N	\N	\N	\N	KIT37	\N	2134	\N	\N
SYNAT568	\N	\N	\N	\N	DM94	\N	1984	\N	\N
SYNAT569	\N	\N	\N	\N	Bivona-L19	\N	2338	\N	\N
SYNAT570	\N	\N	\N	\N	KIT134	\N	2335	\N	\N
SYNAT571	\N	\N	\N	\N	DM64	\N	2273	\N	\N
SYNAT572	\N	\N	\N	\N	KR_RMK0168C	\N	2264	\N	\N
SYNAT573	\N	\N	\N	\N	DM10	\N	2141	\N	\N
SYNAT574	\N	\N	\N	\N	UM26	\N	1975	\N	\N
SYNAT575	\N	\N	\N	\N	Dog12	\N	2296	\N	\N
SYNAT576	\N	\N	\N	\N	BN_N2	\N	2304	\N	\N
SYNAT577	\N	\N	\N	\N	MB_1418	\N	1742	\N	\N
SYNAT578	\N	\N	\N	\N	Seider_Roe	\N	2122	\N	\N
SYNAT579	\N	\N	\N	\N	DM99	\N	2105	\N	\N
SYNAT580	\N	\N	\N	\N	DM23	\N	2290	\N	\N
SYNAT581	\N	\N	\N	\N	KR_166	\N	1759	\N	\N
SYNAT582	\N	\N	\N	\N	DM13	\N	2212	\N	\N
SYNAT583	\N	\N	\N	\N	DM51	\N	1987	\N	\N
SYNAT584	\N	\N	\N	\N	PG8	\N	1863	\N	\N
SYNAT585	\N	\N	\N	\N	DM21	\N	1681	\N	\N
SYNAT586	\N	\N	\N	\N	Dog55	\N	1778	\N	\N
SYNAT587	\N	\N	\N	\N	KIT316	\N	1804	\N	\N
SYNAT588	\N	\N	\N	\N	KIT21	\N	2013	\N	\N
SYNAT589	\N	\N	\N	\N	KR_229	\N	1964	\N	\N
SYNAT590	\N	\N	\N	\N	07-04365	\N	2149	\N	IP617346
SYNAT591	\N	\N	\N	\N	MB_1029	\N	1696	\N	\N
SYNAT592	\N	\N	\N	\N	DM5	\N	1927	\N	\N
SYNAT593	\N	\N	\N	\N	KIT295	\N	1946	\N	\N
SYNAT594	\N	\N	\N	\N	KR_RMK0162C	\N	2108	\N	\N
SYNAT595	\N	\N	\N	\N	KR_203	\N	1704	\N	\N
SYNAT596	\N	\N	\N	\N	KR_2030	\N	2267	\N	\N
SYNAT597	\N	\N	\N	\N	NB2107	\N	1787	\N	\N
SYNAT598	\N	\N	\N	\N	DM36	\N	1715	\N	\N
SYNAT599	\N	\N	\N	\N	DM69	\N	1828	\N	\N
SYNAT600	\N	\N	\N	\N	KIT297	\N	1755	\N	\N
SYNAT601	\N	\N	\N	\N	KIT181	\N	2269	\N	\N
SYNAT602	\N	\N	\N	\N	KIT302	\N	2218	\N	\N
SYNAT603	\N	\N	\N	\N	KR_RMK0194C	\N	1976	\N	\N
SYNAT604	\N	\N	\N	\N	DM65	\N	2209	\N	\N
SYNAT605	\N	\N	\N	\N	UM25	\N	2332	\N	\N
SYNAT606	\N	\N	\N	\N	06-08042	\N	1791	\N	IP553108
SYNAT607	\N	\N	\N	\N	TCR-Beta-1	\N	2092	\N	\N
SYNAT608	\N	\N	\N	\N	UM24	\N	2159	\N	\N
SYNAT609	\N	\N	\N	\N	DM25	\N	1956	\N	\N
SYNAT610	\N	\N	\N	\N	KIT206	\N	2213	\N	\N
SYNAT611	\N	\N	\N	\N	Thomas_SK_MEL_23	\N	2068	\N	\N
SYNAT612	\N	\N	\N	\N	DM68	\N	1955	\N	\N
SYNAT613	\N	\N	\N	\N	Luping_ROS_1	\N	1989	\N	\N
SYNAT614	\N	\N	\N	\N	10-0206	\N	1695	\N	IP894776
SYNAT615	\N	\N	\N	\N	DM22	\N	1667	\N	\N
SYNAT616	\N	\N	\N	\N	SM_5	\N	1841	\N	\N
SYNAT617	\N	\N	\N	\N	DM31	\N	2262	\N	\N
SYNAT618	\N	\N	\N	\N	MB_1036	\N	1996	\N	\N
SYNAT619	\N	\N	\N	\N	DM17	\N	2017	\N	\N
SYNAT620	\N	\N	\N	\N	KIT203	\N	1993	\N	\N
SYNAT621	\N	\N	\N	\N	MB1241	\N	1902	\N	\N
SYNAT622	\N	\N	\N	\N	TCR-Beta-2	\N	1911	\N	\N
SYNAT623	\N	\N	\N	\N	KIT76	\N	1938	\N	\N
SYNAT624	\N	\N	\N	\N	DPN9	\N	2257	\N	\N
SYNAT625	\N	\N	\N	\N	DM95	\N	1785	\N	\N
SYNAT626	\N	\N	\N	\N	BN_N1	\N	1908	\N	\N
SYNAT627	\N	\N	\N	\N	DM6	\N	1999	\N	\N
SYNAT628	\N	\N	\N	\N	DM79	\N	1959	\N	\N
SYNAT629	\N	\N	\N	\N	JBP-7-Met	\N	2342	\N	\N
SYNAT630	\N	\N	\N	\N	UM23	\N	2039	\N	\N
SYNAT631	\N	\N	\N	\N	KIT262	\N	2099	\N	\N
SYNAT632	\N	\N	\N	\N	KIT192	\N	1903	\N	\N
SYNAT633	\N	\N	\N	\N	DM48	\N	1703	\N	\N
SYNAT634	\N	\N	\N	\N	WM3912	\N	2180	\N	\N
SYNAT635	\N	\N	\N	\N	KIT217	\N	1867	\N	\N
SYNAT636	\N	\N	\N	\N	DM62	\N	2114	\N	\N
SYNAT637	\N	\N	\N	\N	SM_3	\N	1741	\N	\N
SYNAT638	\N	\N	\N	\N	KIT62	\N	2031	\N	\N
SYNAT639	\N	\N	\N	\N	KR_RMK0137C	\N	1961	\N	\N
SYNAT640	\N	\N	\N	\N	DM98	\N	1825	\N	\N
SYNAT641	\N	\N	\N	\N	KR_150	\N	2005	\N	\N
SYNAT642	\N	\N	\N	\N	DM66	\N	2306	\N	\N
SYNAT643	\N	\N	\N	\N	WM3211	\N	1738	\N	\N
SYNAT644	\N	\N	\N	\N	CP1-80	\N	1796	\N	\N
SYNAT645	\N	\N	\N	\N	DM16	\N	2187	\N	\N
SYNAT646	\N	\N	\N	\N	KIT205	\N	2143	\N	\N
SYNAT647	\N	\N	\N	\N	DM67	\N	1665	\N	\N
SYNAT648	\N	\N	\N	\N	Bivona-L18	\N	1737	\N	\N
SYNAT649	\N	\N	\N	\N	KIT8	\N	2164	\N	\N
SYNAT650	\N	\N	\N	\N	WM1963	\N	1826	\N	\N
SYNAT651	\N	\N	\N	\N	XD-1.1	\N	1686	\N	\N
SYNAT652	\N	\N	\N	\N	BN_M1	\N	1915	\N	\N
SYNAT653	\N	\N	\N	\N	CP1-20	\N	2058	\N	\N
SYNAT654	\N	\N	\N	\N	DM77	\N	2119	\N	\N
SYNAT655	\N	\N	\N	\N	KIT273	\N	1724	\N	\N
SYNAT656	\N	\N	\N	\N	MB_327	\N	1833	\N	\N
SYNAT657	\N	\N	\N	\N	London-L2	\N	1937	\N	\N
SYNAT658	\N	\N	\N	\N	KIT118	\N	2035	\N	\N
SYNAT659	\N	\N	\N	\N	Dog24	\N	1872	\N	\N
SYNAT660	\N	\N	\N	\N	MB_1454	\N	1735	\N	\N
SYNAT661	\N	\N	\N	\N	SM_16	\N	2138	\N	\N
SYNAT662	\N	\N	\N	\N	DM55	\N	1922	\N	\N
SYNAT663	\N	\N	\N	\N	DM70	\N	2278	\N	\N
SYNAT664	\N	\N	\N	\N	DM2	\N	1680	\N	\N
SYNAT665	\N	\N	\N	\N	KIT230	\N	2132	\N	\N
SYNAT666	\N	\N	\N	\N	MB_1028	\N	1901	\N	\N
SYNAT667	\N	\N	\N	\N	KR_2064	\N	1924	\N	\N
SYNAT668	\N	\N	\N	\N	DM63	\N	2319	\N	\N
SYNAT669	\N	\N	\N	\N	WM3622	\N	1887	\N	\N
SYNAT670	\N	\N	\N	\N	DM26	\N	1820	\N	\N
MD-26	\N	\N	Unknown	Madrid, Spain	10-10275 T2,10-10275D13 M1, 10-10275 T2, 10-10275D13 M1	\N	932	\N	\N
AM2-091	\N	\N	Asian	Taiwan	11-35367,11-36301A1,11-36301A5,11-36301C1, 11-35367, 11-36301A1, 11-36301A5, 11-36301C1	\N	61	\N	\N
AM2-092	\N	\N	Asian	Taiwan	10-38178A1,12-41833E1, 10-38178A1, 12-41833E1	\N	62	\N	\N
AM2-093	\N	\N	Asian	Taiwan	10-22013,13-37513, 10-22013, 13-37513	\N	63	\N	\N
AM2-076	\N	\N	Asian	Japan	K17-B,K17-A,K17-D, K17-B, K17-A, K17-D	\N	46	\N	\N
AM2-081	\N	\N	Asian	Japan	K22-D,K22-A-B, K22-D, K22-A-B	\N	51	\N	\N
AM2-082	\N	\N	Asian	Japan	K23-D,K23-A-B, K23-D, K23-A-B	\N	52	\N	\N
AM2-084	\N	\N	Unknown	Zurich	B17.80125 ,H 2015.1871,B 2015.54040, B17.80125 , H 2015.1871, B 2015.54040	\N	54	\N	\N
AM2-085	\N	\N	Unknown	Zurich	B14. 951 ,H13.3143 , B14. 951 , H13.3143 	\N	55	\N	\N
AM2-086	\N	\N	Asian	Taiwan	14-31886,15-29364A1,13-30315A3, 14-31886, 15-29364A1, 13-30315A3	\N	56	\N	\N
AM2-087	\N	\N	Asian	Taiwan	10-22319,15-14674, 10-22319, 15-14674	\N	57	\N	\N
AM2-088	\N	\N	Asian	Taiwan	15-17010A2,15-17010A1,15-17010C1, 15-17010A2, 15-17010A1, 15-17010C1	\N	58	\N	\N
AM2-089	\N	\N	Asian	Taiwan	12-24502B,12-24502A1, 12-24502B, 12-24502A1	\N	59	\N	\N
AM2-090	\N	\N	Asian	Taiwan	12-24189A1,12-24455, 12-24189A1, 12-24455	\N	60	\N	\N
AM2-099	\N	\N	Asian	Taiwan	16-21256,14-37577A5,14-35086A,16-9204,13-23696A5, 16-21256, 14-37577A5, 14-35086A, 16-9204, 13-23696A5	\N	69	\N	\N
AM2-100	\N	\N	Asian	Taiwan	17-21835A3,17-34742,15-0176A1,15-48543A1,14-51352,15-00176S2, 15-0176A1, 17-21835A3, 17-34742, 15-48543A1, 14-51352, 15-00176S2	\N	70	\N	\N
CME-014	\N	\N	Asian	Taiwan	15-49595A1,15-49595, 15-49595A1, 15-49595	\N	316	\N	\N
CME-015	\N	\N	Asian	Taiwan	16-53749A1,16-53749A2, 16-53749A1, 16-53749A2	\N	317	\N	\N
CME-017	\N	\N	Asian	Taiwan	17-55712A2,17-55712A1, 17-55712A2, 17-55712A1	\N	319	\N	\N
SYNAT673	\N	\N	\N	\N	TissueCoreALKControl	\N	2322	\N	\N
SYNX18	NaN	\N	\N	\N	57269600,SP-13-006535C,Sample_KAM53-T,AST-1,K1_13,Bivona-L10,WCRS97-025628,35_M,SP-13-208365A,Sample_KAM3-T-A,DM37,FRSS99-007026,S12-25164A,Bivona-L17,MB_161,Bivona-L9,1214,MB1429,SP-10-004335,SP-13-198211A,S08-1463A2,DM93,RC11-023,HWA1,UM37,UM39,DM58,London-L20,London-L5,57291680,SCLS04-001045,UM33,ZS07-1210F6,501_Mel,356A3-075,DM56,DPN29,SROS12-001198,HWA4,SM7,Bivona-L6,London-L3,KIT227,M368,HWA5,DM11,Dummer-KF3-Primary,SP-10-143551E,RC11-024,MB1609,DM29,DPN18,KR_8,KIT191,BN-M1-Tert,K1_9,S12-15765B3,MB_760,S12-23475C1,DPN45,DM40,S11-20884A-A1,Dummer-KF1-Met2,UM7,57346060,Dummer-KF2-Met1,DM74,London-L10,JBP-3,DM34,DM4,SP-14-68521D,WCRS99-012800,WM8,Sample_KAM35-T,S13-13286A6,STRS91-006237,NZM52,DM28,T02-16195,DPN44,SP-14-73676A,C022,DM14,W09-1121,8528-05,London-L19E,NZM40,JBP-3-MM,BN_M2,Dog43,Sample_KAM94-T,HWA3,BuffyCoat,Laverty13-88354,S11-032523A1,HAYS98-001046,RC11-004,K1_12,DM15,DM96,CNS54,DM7,SACS87-010145,MB1423,S02-33818A03,C8161,S12-4365C1,MB1428,DM61,DPN46,525,Spitz_M1,Sk_Mel_1,UM14,SP-13-87981B,S12-28988,Birt_Hogg_Dube,SP-07-0116602,ZS10-1843A5,DM1,13000212,Long-TN11,UM10,Seider_Uveal,ZS10-11930B12,DM81,KIT260,10_63051C,London-L23D,DPN33,ZS06-11249A-C2,S12-4365A7,MB1242,HAYS90-005154,XD-1,Sample_KAM61-T,SSCS03-004945,SP-11-160493A,SROS10-009251,S12-9606EE,332771,MB_1046,S12-7093NG176-1,K1_16,JBP-3-Met1,S12-7250E3,3860,S13-11748F5,VALS05-014946-E,KR_177,CP1-40,ICPMR19684.13A11,UM35_A,London-L23,S05-41924,London-L21,MIN_7,S10-44069A4,CP1-10,9116-05,UM41,UM9,KIT55,SSCS03-014369,SP-14-36134A,S05-7439A12,DP08-21965C,DPN24,CP1,SM_11,S12-25164C1,SP-13-1038(1A),ZS10-972C2,57723220,DM60,HW6,S12-9606C4,DM49,SROS09-001574,London-L16,HAYS02-005731,KIT275,KIT244,CP1-5,London-L12,06-00911,RC11-022,S10-7937B2,Kit298,HW8,KR_RMK0091B,K1_19,Sample_KAM84-T,DM12,UM19,CNS53,SP-12-020017C,SMU10-0206,SM_1,UM20,DM43,DHM50691-14MP5C,DM45,15102-02,SM_18,DHM4855-14MP,D326,OAK84-008979-B,S12-23475A6,DM59,K1_15,CP-5,Sample_KAM106-T,SP-12-0087723B,WM51,SM_4,DHM48742-12MPE,S12-26125A2,KIT225,L13-48798,57001550,London-L22,SM_12,KIT210,SP-14-125802A,WP11,K1_17,CP-2,KIT53,Z1188-03,Yurif,MB1617,WCRS02-022688,HWA2,M285,Sample_KAM96-T,DM18,KIT313,Dummer-KF2-Primary,MB1421,SP-12-2294-2(2A),SP-13-009897,HWA7,SSS13-1652B2,PMM-8,SFO93-005184,35942-04,KR_5233,Sample_KAM78-T-III,DM42,KIT37,DM94,ZS10-10558C1,21590,SROS11-005030,SFOS00-016989,BN,Bivona-L19,KIT134,ZS10-8439A4,DPN31,SP-09-0150202A,DM64,KR_RMK0168C,DM10,S12-4365B1,UM26,Dog12,SMU10-0240,CP-6,Sample_KAM82-T-B8,T00-12011,BN_N2,S08-4544A03,S12-28585A6,DHM50691-14MP3,MB_1418,1212,Xanthoma_Disseminatum,SQ13-8208B,A2A79@,8298-01,Bivona-L7,SP-12-177322A,HW4,ZS10-3560A3,London-L23C,Seider_Roe,SCC10-0092,S13-5249,DM32,Yurif_DNA,DM99,140092090,ZS10-972A9,9246581-A3,DM23,Long-TN2,KR_166,London-L18,DM13,SP-13-000848,DM51,55875588,Spitz_M2_(?),SP-13-17075(1B),WP29,PG8,04-SW-12-31366B1,HWA6,London-L1,SP-13-0185992B,London-L14,SP-14-7691A,DM21,Dog55,RC11-005,Acral-11,ROSS09-022626-A1,Bivona-L1,KIT316,KIT21,S11-2018B5,UM15,KR_229,07-04365,S13-3401B3,Sample_KAM7-T,Sample_KAM38-T-B,M257,MB_1029,Dummer-KF1,SCHS11-018842-A1,SP-13-14992(1A),DM5,London-L13,KIT295,14514-02,CP-3,57715138,DPN28,UM17,KR_RMK0162C,S12-27617B9,SACS93-027850,London-L14C,KR_203,KR_2030,M230,S02-23636A02,DM27,SP-13-63011A,20847-09,K1_3,12GS-2466,NB2107,S11-21025B1,UM13,DM36,UM16,DM69,SP-13-15691D,SP-13-006337A,SP-13-0068754A,KIT297,UM4,HW2,Spitz_N2,KIT181,SM_8,Long-TN10,DPN48,04-SW-12-31366B6,UM11,S13-12947A2,09-0209,T06-6855,9246581-A6,KIT302,KR_RMK0194C,London-L19,DM65,SSCS92-009981,SP-12-0146612A,DM19,ZS10-3560F1,GAK,SP-14-125801B,UM25,London-L9,RPA08-0315,SP-13-0212981A,S12-23475A4,06-08042,SACS05-011507,W10-143,TCR-Beta-1,UM24,CP-4,RNS11P15316B1,UM_6,C037,DM25,WM3928F,24516-06,SP-12-01466111A,DPN26,SP-12-5612(1K),RC11-001,S12-18826,S12-6332A5,RCHS07-000380-B1,KIT206,London-L16A,Dummer-KF3,GAK_DNA,S12-9606A2,XD-2,VALS03-019832,SFOS94-003116,Thomas_SK_MEL_23,SP-11-40641B,London-L16B,SP-12-003309B,DM68,RCHS06-004567,SP-14-001249,K1_2,Luping_ROS_1,10-0206,DM22,DPN41,1286184b,HWA8,140038340,SM_5,DM31,DP08-4205A,RC11-021,M418,Sample_KAM1-T,MB_1036,SP-13-15691B,DM17,RNS14P13907B1,SCHS08-007754,KIT203,Long-TN1,Bivona-L5,OAKS96-022398,BN-N2-Tert,M375,CNS57,MB1241,49_M,HWAcr,K1_20,TCR-Beta-2,VALS09-000266,MTZS94-007340,1213,SP-13-0185993A,KIT76,DPN9,SFOS12-018173,BuffyCoa,London-L15,WP23,ZS10-3560C1,DM95,BN_N1,DM6,MB1424_,DM50,HW9,DHM57444-14MP,SP-10-197431A,S94-31062,S12-6218A-D3,London-L17,DM46,RC11-003,wm3918,SRFS97-002805,T09-8069,SACS88-019073,RPA08-0209,FRSS09-009402-A1,DM79,57714581,Bivona-L11,12_M,JBP-7-Met,Dummer-KF2,UM23,KIT262,57059699,Spitz_N1,ZS10-10558A10,RC11-002,SP-10-143552A,SACS02-020334,KIT192,K1_1,VALS03-007457,DM48,SP-10-003167A,K1_14,WM3912,KIT217,DM62,SP-12-0228801A,Bivona-L2,Sample_KAM12-T,Acral-12,DPN42,SM_3,B06-37358,KIT62,KR_RMK0137C,SP-42-10361(1A),HWA10,DM98,DP12-200,CNS52,UM36,SCHS09-005840-B5,206436,57213442,Dummer-KF3-Met1,Dummer-KF1-Met1,Bivona-L8,PMM_23,KR_150,R29032-05,DPN40,DM66,WM3211,UM40,HWA9,CP1-80,Dummer-KF1-Primary,DM16,KIT205,MIN_8,UM5,DM67,Bivona-L18,KIT8,S10-26316A2,WM1963,DM35,XD-1.1,OAKS96-014392-G,S11-38910A2,SP-13-006364,SCLS91-006557,TissueCoreALKControl,BN-N1-Tert,BN_M1,CP-1,CP1-20,DM77,T07-1120,London-L4,KIT273,UM47,MB_327,SP-13-0068751C,DHM94457-13SK,London-L2,KIT118,K1_18,SNPN08289D,Bivona-L4,Dog24,MB_1454,SM_16,SP-12-0032671A,S06-47079A02,D366,SCHS10-026422,Sample_KAM20-T,K1_10,K1_11,15329-03,S13-18444A16,DM55,DPN8,SMU10-0457,Bivona-L3,DM70,London-L8,SROS00-001103,DM2,Sample_KAM121-T-B,S12-4365A8,HW3,NZM91,RCHS01-003684,KIT230,ZS10-10558B1,London-L6,FRSS09-008805,MB_1028,KR_2064,SFOS09-007093,UM8,OAKS90-012369,ZS10-1843A4,DM63,WM3622,SP-14-73671M,Spitz_N3,DM26,SP-12-0228802A,MASCRI-432,1185-03, Sample_KAM53-T, Sample_KAM3-T-A, STRS91-006237, K1_10, Sample_KAM84-T, S13-12947A2, T06-6855, 12_M, SP-13-006364, 57269600, SP-13-006535C, AST-1, K1_13, Bivona-L10, WCRS97-025628, SP-13-208365A, FRSS99-007026, S12-25164A, Bivona-L9, 1214, SP-10-004335, SP-13-198211A, S08-1463A2, RC11-023, HWA1, UM37, UM39, London-L20, London-L5, 57291680, SCLS04-001045, UM33, ZS07-1210F6, 501_Mel, 356A3-075, DM56, DPN29, SROS12-001198, HWA4, Bivona-L6, M368, HWA5, Dummer-KF3-Primary, SP-10-143551E, RC11-024, DPN18, BN-M1-Tert, K1_9, S12-15765B3, S12-23475C1, DPN45, DM40, S11-20884A-A1, Dummer-KF1-Met2, UM7, 57346060, Dummer-KF2-Met1, London-L10, SP-14-68521D, WCRS99-012800, Sample_KAM35-T, S13-13286A6, NZM52, T02-16195, DPN44, SP-14-73676A, C022, W09-1121, 8528-05, London-L19E, NZM40, Sample_KAM94-T, HWA3, BuffyCoat, Laverty13-88354, S11-032523A1, HAYS98-001046, RC11-004, K1_12, DM15, CNS54, SACS87-010145, S02-33818A03, C8161, S12-4365C1, DPN46, 525, Spitz_M1, Sk_Mel_1, UM14, SP-13-87981B, S12-28988, Birt_Hogg_Dube, SP-07-0116602, ZS10-1843A5, 13000212, Long-TN11, UM10, ZS10-11930B12, 10_63051C, London-L23D, DPN33, ZS06-11249A-C2, S12-4365A7, HAYS90-005154, Sample_KAM61-T, SSCS03-004945, SP-11-160493A, SROS10-009251, S12-9606EE, 332771, S12-7093NG176-1, K1_16, S12-7250E3, 3860, S13-11748F5, VALS05-014946-E, ICPMR19684.13A11, UM35_A, London-L23, S05-41924, London-L21, MIN_7, S10-44069A4, 9116-05, UM41, UM9, SSCS03-014369, SP-14-36134A, S05-7439A12, DP08-21965C, DPN24, S12-25164C1, SP-13-1038(1A), ZS10-972C2, 57723220, HW6, S12-9606C4, SROS09-001574, London-L16, HAYS02-005731, London-L12, RC11-022, S10-7937B2, Kit298, HW8, K1_19, UM19, CNS53, SP-12-020017C, SMU10-0206, SM_1, UM20, DHM50691-14MP5C, 15102-02, SM_18, DHM4855-14MP, D326, OAK84-008979-B, S12-23475A6, K1_15, CP-5, Sample_KAM106-T, SP-12-0087723B, DHM48742-12MPE, S12-26125A2, L13-48798, 57001550, London-L22, SP-14-125802A, WP11, K1_17, CP-2, KIT53, Z1188-03, Yurif, WCRS02-022688, HWA2, M285, Sample_KAM96-T, Dummer-KF2-Primary, SP-12-2294-2(2A), SP-13-009897, HWA7, SSS13-1652B2, SFO93-005184, 35942-04, Sample_KAM78-T-III, ZS10-10558C1, 21590, SROS11-005030, SFOS00-016989, BN, ZS10-8439A4, DPN31, SP-09-0150202A, S12-4365B1, SMU10-0240, CP-6, Sample_KAM82-T-B8, T00-12011, S08-4544A03, S12-28585A6, DHM50691-14MP3, 1212, Xanthoma_Disseminatum, SQ13-8208B, A2A79@, 8298-01, Bivona-L7, SP-12-177322A, HW4, ZS10-3560A3, London-L23C, SCC10-0092, S13-5249, DM32, Yurif_DNA, 140092090, ZS10-972A9, 9246581-A3, Long-TN2, London-L18, SP-13-000848, 55875588, Spitz_M2_(?), SP-13-17075(1B), WP29, 04-SW-12-31366B1, HWA6, London-L1, SP-13-0185992B, London-L14, SP-14-7691A, RC11-005, Acral-11, ROSS09-022626-A1, Bivona-L1, S11-2018B5, UM15, S13-3401B3, Sample_KAM7-T, Sample_KAM38-T-B, M257, Dummer-KF1, SCHS11-018842-A1, SP-13-14992(1A), London-L13, 14514-02, CP-3, 57715138, DPN28, UM17, S12-27617B9, SACS93-027850, London-L14C, M230, S02-23636A02, DM27, SP-13-63011A, 20847-09, K1_3, 12GS-2466, S11-21025B1, UM13, UM16, SP-13-15691D, SP-13-006337A, SP-13-0068754A, UM4, HW2, Spitz_N2, SM_8, Long-TN10, DPN48, 04-SW-12-31366B6, UM11, 9246581-A6, London-L19, SSCS92-009981, SP-12-0146612A, DM19, ZS10-3560F1, GAK, SP-14-125801B, London-L9, RPA08-0315, SP-13-0212981A, S12-23475A4, SACS05-011507, W10-143, CP-4, RNS11P15316B1, UM_6, C037, WM3928F, 24516-06, SP-12-01466111A, DPN26, SP-12-5612(1K), RC11-001, S12-18826, S12-6332A5, RCHS07-000380-B1, London-L16A, Dummer-KF3, GAK_DNA, S12-9606A2, XD-2, VALS03-019832, SFOS94-003116, SP-11-40641B, London-L16B, SP-12-003309B, RCHS06-004567, SP-14-001249, K1_2, DPN41, 1286184b, HWA8, 140038340, DP08-4205A, RC11-021, M418, Sample_KAM1-T, SP-13-15691B, RNS14P13907B1, SCHS08-007754, Long-TN1, Bivona-L5, OAKS96-022398, BN-N2-Tert, M375, CNS57, HWAcr, K1_20, VALS09-000266, MTZS94-007340, 1213, SP-13-0185993A, SFOS12-018173, BuffyCoa, London-L15, WP23, ZS10-3560C1, MB1424_, DM50, HW9, DHM57444-14MP, SP-10-197431A, S94-31062, S12-6218A-D3, London-L17, DM46, RC11-003, wm3918, SRFS97-002805, T09-8069, SACS88-019073, RPA08-0209, FRSS09-009402-A1, 57714581, Bivona-L11, Dummer-KF2, 57059699, Spitz_N1, ZS10-10558A10, RC11-002, SP-10-143552A, SACS02-020334, K1_1, VALS03-007457, SP-10-003167A, K1_14, SP-12-0228801A, Bivona-L2, Sample_KAM12-T, Acral-12, DPN42, B06-37358, SP-42-10361(1A), HWA10, DP12-200, CNS52, UM36, SCHS09-005840-B5, 206436, 57213442, Dummer-KF3-Met1, Dummer-KF1-Met1, Bivona-L8, PMM_23, R29032-05, DPN40, UM40, HWA9, Dummer-KF1-Primary, MIN_8, UM5, S10-26316A2, DM35, OAKS96-014392-G, S11-38910A2, CP-1, T07-1120, London-L4, UM47, SP-13-0068751C, DHM94457-13SK, K1_18, SNPN08289D, Bivona-L4, SP-12-0032671A, S06-47079A02, D366, SCHS10-026422, Sample_KAM20-T, K1_11, 15329-03, S13-18444A16, DPN8, SMU10-0457, Bivona-L3, London-L8, SROS00-001103, Sample_KAM121-T-B, S12-4365A8, HW3, NZM91, RCHS01-003684, ZS10-10558B1, London-L6, FRSS09-008805, SFOS09-007093, UM8, OAKS90-012369, ZS10-1843A4, SP-14-73671M, Spitz_N3, SP-12-0228802A, MASCRI-432, 1185-03, SCLS91-006557, BN-N1-Tert	NaN	1421	\N	\N
CME-018	\N	\N	Asian	Taiwan	18-05067	\N	320	\N	\N
CME-019	\N	\N	Asian	Taiwan	19-17484	\N	321	\N	\N
CME-022	\N	\N	Asian	Taiwan	20-7562\t	\N	324	\N	\N
CME-023	\N	\N	Asian	Taiwan	20-13577A1	\N	325	\N	\N
CME-024	\N	\N	Asian	Taiwan	20-56532	\N	326	\N	\N
CME-025	\N	\N	Asian	Taiwan	21-20367A1	\N	327	\N	\N
DP-02	F	\N	Unknown	UCSF	12-10777	\N	639	\N	IP1096593
\.


--
-- Data for Name: sample_lib; Type: TABLE DATA; Schema: public; Owner: borisbastian
--

COPY public.sample_lib (id, name, date, qubit, shear_volume, qpcr_conc, pcr_cycles, amount_in, amount_final, vol_init, vol_remain, notes, barcode_id, method_id, na_name) FROM stdin;
1	12_M	\N	\N	Infinity	\N	\N	75.7	\N	\N	\N	Hunter, Desmoplastic Melanoma Amplicon Sequence	L2DR11	\N	D12_M_NA
2	22_IS	\N	\N	Infinity	\N	\N	11.4	\N	\N	\N	Ivanka Patient Melanoma (Hunter Extraction Rcvd 8-13-13)	L2DR09	\N	22_IS_NA
3	22_Melanoma	\N	\N	Infinity	\N	\N	39.6	\N	\N	\N	Ivanka Patient Melanoma (Hunter Extraction Rcvd 8-13-13)	L2DR11	\N	22_Melanoma_NA
4	22_Nevus	\N	\N	Infinity	\N	\N	42.7	\N	\N	\N	Ivanka Patient Melanoma (Hunter Extraction Rcvd 8-13-13)	L2DR10	\N	22_Nevus_NA
5	22_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Ivanka Patient Melanoma (Hunter Extraction Rcvd 8-13-13)	L2DR12	\N	22_Normal_NA
6	26	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	26_NA
7	35_M	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hunter, Desmoplastic Melanoma Amplicon Sequence	L2DR12	\N	35_M_NA
8	49_M	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hunter, Desmoplastic Melanoma Amplicon Sequence	L2DR13	\N	49_M_NA
9	1205lu-1_Unknown	\N	\N	\N	\N	\N	\N	\N	\N	\N	cell line: 1205Lu (RRID:CVCL_5239)	\N	\N	1205lu-1_NA
10	1205lu-2_Unknown	\N	\N	\N	\N	\N	\N	\N	\N	\N	cell line: 1205Lu (RRID:CVCL_5239)	\N	\N	1205lu-2_NA
11	1205LU-3_Unknown	\N	\N	\N	\N	\N	\N	\N	\N	\N	cell line: 1205Lu (RRID:CVCL_5239)	\N	\N	1205LU-3_NA
12	AF13_212	\N	\N	Infinity	\N	\N	71.4	\N	\N	\N	 A. Fouchardiere Project	L2DR13	\N	AF13_212_NA
13	AGLP-03	2018-04-26 00:00:00-07	96.6	5	257.7	\N	250	\N	\N	\N	SureSelect Library Prep	\N	\N	AM2 D-40
14	AGLP-04	2018-04-26 00:00:00-07	1	5	0	\N	250	\N	\N	\N	SureSelect Library Prep	\N	\N	AM2 D-42
15	AM_7_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Acral Melanoma	L2DR03	\N	AM_7_Tumor_NA
16	AM_9_Tumor	\N	\N	Infinity	\N	\N	67.4	\N	\N	\N	Iwei Acral Melanoma	L2DR04	\N	AM_9_Tumor_NA
17	AM_11_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Acral Melanoma	L2DR05	\N	AM_11_Tumor_NA
18	AM_13_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Acral Melanoma	L2DR06	\N	AM_13_Tumor_NA
19	AM_14_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Acral Melanoma	L2DR07	\N	AM_14_Tumor_NA
20	AMLP-20_1	2018-05-08 00:00:00-07	5.5	5	1.2	\N	250	\N	\N	\N	\N	H8	\N	AM2 D-33
21	AMLP-20_2	2018-07-23 00:00:00-07	3.7	5	0.4	\N	250	\N	\N	\N	\N	A5	\N	AM2 D-33
22	AMLP-23_1	2018-05-08 00:00:00-07	2.9	17	1.3	\N	250	\N	\N	\N	\N	H11	\N	AM2 D-74
23	AMLP-23_2	2018-07-23 00:00:00-07	1.5	17	0.42	\N	250	\N	\N	\N	\N	A7	\N	AM2 D-74
24	AMLP-24_1	2018-05-08 00:00:00-07	1.9	3	0.6	\N	250	\N	\N	\N	\N	H12	\N	AM2 D-77
25	AMLP-24_2	2018-07-23 00:00:00-07	1.4	3	0.25	\N	250	\N	\N	\N	\N	A8	\N	AM2 D-77
26	AMLP-25	2018-05-08 00:00:00-07	2.9	2	1.1	\N	250	\N	\N	\N	\N	A1	\N	AM2 D-78
27	AMLP-26	2018-05-08 00:00:00-07	6.9	7	0.1	\N	250	\N	\N	\N	\N	A2	\N	AM2 D-80
28	AMLP-27	2018-05-08 00:00:00-07	3.2	14	1.1	\N	250	\N	\N	\N	\N	A3	\N	AM2 D-81
29	AMLP-28	2018-05-07 00:00:00-07	1	6	0.4	\N	250	\N	\N	\N	\N	A4	\N	AM2 D-84
30	AMLP-31	2018-06-21 00:00:00-07	1.8	215	0.8	\N	338	\N	\N	\N	\N	H9	\N	AM2 D-45
31	AMLP-32	2018-06-21 00:00:00-07	2.7	14	0.7	\N	350	\N	\N	\N	\N	H10	\N	AM2 D-43
32	AMLP-33	2018-06-21 00:00:00-07	3.1	9	0.9	\N	350	\N	\N	\N	\N	H11	\N	AM2 D-44
33	AMLP-34	2018-06-21 00:00:00-07	2	7	1.5	\N	350	\N	\N	\N	\N	H12	\N	AM2 D-46
34	AMLP-35	2018-06-21 00:00:00-07	4.3	6	0.2	\N	350	\N	\N	\N	\N	A9	\N	AM2 D-50
35	AMLP-36	2018-06-21 00:00:00-07	7.7	12	0.4	\N	350	\N	\N	\N	\N	A10	\N	AM2 D-53
36	AMLP-37	2018-06-21 00:00:00-07	2.5	6	0.6	\N	350	\N	\N	\N	\N	A11	\N	AM2 D-56
37	AMLP-38	2018-06-21 00:00:00-07	4	8	0.6	\N	350	\N	\N	\N	\N	A12	\N	AM2 D-57
38	AMLP-39	2018-06-21 00:00:00-07	3.3	6	1.1	\N	350	\N	\N	\N	\N	B1	\N	AM2 D-58
39	AMLP-40	2018-06-21 00:00:00-07	5.7	5	1.7	\N	350	\N	\N	\N	\N	B2	\N	AM2 D-60
40	AMLP-42	2018-07-23 00:00:00-07	1.2	0	0.1	\N	\N	\N	\N	\N	\N	B5	\N	AM2 D-85
41	AMLP-43	2018-07-23 00:00:00-07	6.1	0	1.38	\N	\N	\N	\N	\N	\N	B6	\N	AM2 D-87
42	AMLP-56	\N	\N	44	1.1	\N	250	\N	\N	\N	\N	C9	\N	AM2 D-101
43	AMLP-57	\N	\N	13	0.5	\N	250	\N	\N	\N	\N	C10	\N	AM2 D-102
44	AMLP-59	\N	\N	5	0.4	\N	250	\N	\N	\N	\N	C12	\N	AM2 D-104
45	AMLP-60	\N	\N	52	0.4	\N	250	\N	\N	\N	\N	D1	\N	AM2 D-105
46	AMLP-62	\N	\N	302	0.5	\N	250	\N	\N	\N	\N	D3	\N	AM2 D-108
47	AMLP-63	\N	\N	3	1.1	\N	250	\N	\N	\N	\N	D4	\N	AM2 D-109
48	AMLP-65	2018-11-27 00:00:00-08	5.33	48	1.95	4	286.6	\N	\N	\N	\N	39	\N	AM2 D-111
49	AMLP-67	2018-11-27 00:00:00-08	4.47	39	1.52	4	300	\N	\N	\N	\N	41	\N	AM2 D-113
50	AMLP-70	2018-11-27 00:00:00-08	5.98	23	2.71	4	300	\N	\N	\N	\N	44	\N	AM2 D-145
51	AMLP-71	2018-11-27 00:00:00-08	3.88	48	0.99	4	243.4	\N	\N	\N	\N	45	\N	AM2 D-116
52	AMLP-72	2018-11-27 00:00:00-08	4.06	26	0.91	4	300	\N	\N	\N	\N	46	\N	AM2 D-117
53	AMLP-73	2018-11-27 00:00:00-08	2.17	48	0.49	4	137.3	\N	\N	\N	\N	47	\N	AM2 D-118
54	AMLP-74	2018-11-27 00:00:00-08	5.06	44	1.49	4	300	\N	\N	\N	\N	48	\N	AM2 D-119
55	AMLP-79	2018-11-27 00:00:00-08	2.79	48	1.08	4	73.9	\N	\N	\N	\N	53	\N	AM2 D-124
56	AMLP-86	2018-11-27 00:00:00-08	1.48	48	0.91	4	67.7	\N	\N	\N	\N	60	\N	AM2 D-131
57	AMLP-94	2018-11-30 00:00:00-08	2.59	48	1.81	4	107.5	\N	\N	\N	\N	20	\N	AM2 D-139
58	AMLP-98	2018-11-30 00:00:00-08	18.5	39	8.4	4	300	\N	\N	\N	\N	24	\N	AM2 D-142
59	AMLP-100	2018-11-30 00:00:00-08	8.03	13	6.99	4	300	\N	\N	\N	\N	26	\N	AM2 D-146
60	AMLP-101	2018-11-30 00:00:00-08	26.4	6	4.03	4	300	\N	\N	\N	\N	27	\N	AM2 D-147
61	AMLP-106	2018-11-30 00:00:00-08	23.7	6	9.76	4	300	\N	\N	\N	\N	32	\N	AM2 D-155
62	AMLP-115	2018-12-07 00:00:00-08	6.67	48	0.63	4	224.2	\N	\N	\N	\N	93	\N	AM2 D-164
63	AMLP-116	2018-12-07 00:00:00-08	\N	23	0.52	4	300	\N	\N	\N	\N	94	\N	AM2 D-165
64	AMLP-118	2018-12-07 00:00:00-08	\N	48	0.11	4	67.7	\N	\N	\N	\N	96	\N	AM2 D-169
65	AMLP-119	2018-12-07 00:00:00-08	\N	48	0.31	4	32.7	\N	\N	\N	\N	1	\N	AM2 D-170
66	AMLP-120	2018-12-07 00:00:00-08	\N	48	0.43	4	68.6	\N	\N	\N	\N	2	\N	AM2 D-171
67	AMLP-122	2018-12-07 00:00:00-08	\N	48	0.46	4	77.3	\N	\N	\N	\N	4	\N	AM2 D-173
68	AMLP-124	2018-12-07 00:00:00-08	\N	21	0.63	4	300	\N	\N	\N	\N	6	\N	AM2 D-175
69	AMLP-144	2019-12-03 00:00:00-08	1.74	0	0.59	4	\N	\N	\N	\N	120s shear time; DNA repaired, combined with AM2 D-176 (area 1145 Mel1)	78	\N	AM2 D-03
227	CGH12_053	\N	\N	1	\N	\N	100	\N	\N	\N	Iwei CGH, 7Q Gain 	L2DR05	\N	CGH12_053_NA
70	AMLP-154	2020-01-31 00:00:00-08	13.1	5	2.3	3	250	\N	\N	\N	120s shear time; DNA repaired	14	\N	AM2 D-33
71	AMLP-155	2020-01-31 00:00:00-08	11.6	25	2.36	3	999	\N	\N	\N	120s shear time; DNA repaired	15	\N	AM2 D-185
72	AMLP-157	2020-01-31 00:00:00-08	22.5	23	2.09	3	999	\N	\N	\N	120s shear time; DNA repaired	21	\N	AM2 D-183
73	AMLP-158	2020-01-31 00:00:00-08	10.8	0	5.92	3	\N	\N	\N	\N	120s shear time; DNA repaired	22	\N	AM2 D-96
74	AMLP-159	2020-01-31 00:00:00-08	12.4	0	1.24	3	\N	\N	\N	\N	120s shear time; DNA repaired	23	\N	AM2 D-187
75	AMLP-187	2020-02-07 00:00:00-08	0.84	157	0.18	4	71	\N	\N	\N	\N	109	\N	AM2 D-168
76	AMLP-188	2020-02-07 00:00:00-08	0.98	48	0.17	4	67.7	\N	\N	\N	\N	110	\N	AM2 D-169
77	AMLP-189	2020-02-07 00:00:00-08	4.27	72	1.23	4	666	\N	\N	\N	\N	111	\N	AM2 D-191
78	AMLP-190	2020-02-07 00:00:00-08	0.47	48	0.11	4	32.7	\N	\N	\N	\N	112	\N	AM2 D-170
79	AMLP-212	2020-08-06 00:00:00-07	1.89	\N	0.79	4	\N	\N	\N	\N	\N	147	\N	AM2 D-59,AM2 D-205
80	AMLP-213	2020-08-06 00:00:00-07	1.45	5	1.41	4	350	\N	\N	\N	\N	148	\N	AM2 D-60
81	AMLP-228	2020-08-06 00:00:00-07	1.65	\N	0.7	4	\N	\N	\N	\N	\N	163	\N	AM2 D-206,AM2 D-252
82	AMLP-229	2020-08-06 00:00:00-07	4.03	29	1.7	4	333	\N	\N	\N	\N	164	\N	AM2 D-207
83	AMLP-230	2020-08-06 00:00:00-07	2.28	70	0.2	4	333	\N	\N	\N	\N	165	\N	AM2 D-208
84	AMLP-232	2020-08-06 00:00:00-07	4.46	72	2.8	4	666	\N	\N	\N	\N	167	\N	AM2 D-191
85	AMLP-233	2020-12-05 00:00:00-08	3.19	96	1.23	4	490	\N	\N	\N	\N	168	\N	AM2 D-260
86	AMLP-234	2021-03-17 00:00:00-07	3.68	\N	0.24	4	\N	\N	\N	\N	\N	97	\N	AM2 D-261,AM2 D-363
87	AMLP-235	2021-03-17 00:00:00-07	5.36	96	0.25	4	390.7	\N	\N	\N	\N	98	\N	AM2 D-264
88	AMLP-236	2021-03-17 00:00:00-07	4.07	96	0.41	4	244.8	\N	\N	\N	\N	99	\N	AM2 D-265
89	AMLP-242	2021-03-17 00:00:00-07	5.68	79	0.4	4	333	\N	\N	\N	\N	106	\N	AM2 D-309
90	AMLP-243	2021-03-17 00:00:00-07	3.74	96	0.18	4	145	\N	\N	\N	\N	107	\N	AM2 D-310
91	AMLP-246	2021-03-17 00:00:00-07	5.02	35	0.2	4	333	\N	\N	\N	\N	110	\N	AM2 D-316
92	AMLP-251	2021-03-17 00:00:00-07	6.37	10	0.43	4	333	\N	\N	\N	\N	117	\N	AM2 D-323
93	AMLP-253	2021-03-17 00:00:00-07	5	96	0.22	4	253.4	\N	\N	\N	\N	119	\N	AM2 D-329
94	AMLP-258	2021-03-17 00:00:00-07	3.35	96	0.74	4	134.4	\N	\N	\N	\N	124	\N	AM2 D-334
95	AMLP-260	2021-03-17 00:00:00-07	3.17	95	0.49	4	149	\N	\N	\N	\N	126	\N	AM2 D-341
96	AMLP-294	2021-03-17 00:00:00-07	3.09	95	0.26	4	115	\N	\N	\N	DISCARD. DO NOT USE THIS LIBRARY. THE SAMPLE WAS POOLED WITH MEL1.	178	\N	AM2 D-358
97	AMLP-309	2021-05-13 00:00:00-07	3.53	35	0.9	4	333	\N	\N	\N	\N	147	\N	AM2 D-316
98	AMLP-328	2021-05-27 00:00:00-07	5.06	95	3.42	4	307	\N	\N	\N	\N	158	\N	AM2 D-348
99	AMLP-329	2021-05-27 00:00:00-07	5.41	95	4.61	4	264	\N	\N	\N	\N	167	\N	AM2 D-475
100	AMLP-333	2021-08-04 00:00:00-07	1.01	96	0.37	4	20	\N	\N	\N	DO NOT USE! Adapter Ligation: O/N (15 hrs) at 20oC	179	\N	AM2 D-258
101	AMLP-334	2021-08-04 00:00:00-07	1	96	0.26	4	42	\N	\N	\N	DO NOT USE! Adapter Ligation: O/N (15 hrs) at 20oC	180	\N	AM2 D-262
102	AMLP-335	2021-08-04 00:00:00-07	0.92	96	0.53	4	22	\N	\N	\N	DO NOT USE! Adapter Ligation: O/N (15 hrs) at 20oC	181	\N	AM2 D-355
103	AMLP-336	2021-08-04 00:00:00-07	0.67	18	0.24	4	20	\N	\N	\N	DO NOT USE! Adapter Ligation: O/N (15 hrs) at 20oC	182	\N	AM2 D-481 (P041_03B)
104	AMLP-337	2021-08-04 00:00:00-07	0.84	9	0.28	4	42	\N	\N	\N	DO NOT USE! Adapter Ligation: O/N (15 hrs) at 20oC	183	\N	AM2 D-482 (P041_03C)
105	AMLP-338	2021-08-04 00:00:00-07	1.22	10	0.58	4	22	\N	\N	\N	DO NOT USE! Adapter Ligation: O/N (15 hrs) at 20oC	184	\N	AM2 D-483 (P041_03D)
106	AMLP-351	2021-09-15 00:00:00-07	5.91	51	6.11	4	1200	\N	\N	\N	HyperPREP; Ligation: 60 min at 20 oC	98	\N	AM2 D-431
107	AMLP-356	2021-09-15 00:00:00-07	11.9	78	12.03	4	1200	\N	\N	\N	HyperPLUS, Ligation: 15 min at 20 oC	116	\N	AM2 D-381
108	AMLP-357	2021-09-15 00:00:00-07	9.93	51	10.03	4	1200	\N	\N	\N	HyperPLUS, Ligation: 15 min at 20 oC	117	\N	AM2 D-431
109	AMLP-358	2021-09-15 00:00:00-07	1.29	148	0.4	4	1200	\N	\N	\N	HyperPLUS, Ligation: 15 min at 20 oC	118	\N	AM2 D-485
110	AMLP-359	2021-09-15 00:00:00-07	12.5	78	12.03	4	1200	\N	\N	\N	HyperPLUS, Ligation: 60 min at 20 oC	116	\N	AM2 D-381
111	AMLP-360	2021-09-15 00:00:00-07	10.3	51	10.97	4	1200	\N	\N	\N	HyperPLUS, Ligation: 60 min at 20 oC	117	\N	AM2 D-431
112	AMLP-361	2021-09-15 00:00:00-07	1.54	148	0.56	4	1200	\N	\N	\N	HyperPLUS, Ligation: 60 min at 20 oC	118	\N	AM2 D-485
113	AMLP-365	2021-09-18 00:00:00-07	0.75	88	0.36	4	38.7	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	102	\N	AM2 D-484
114	AMLP-368	2021-09-18 00:00:00-07	3.22	37	1.31	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	105	\N	AM2 D-486-1
115	AMLP-370	2021-09-18 00:00:00-07	1.94	27	0.34	4	583	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	107	\N	AM2 D-219
116	AMLP-370-1	2021-09-27 00:00:00-07	5.16	27	2.66	4	583	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	107	\N	AM2 D-219
117	AMLP-370-2	2021-09-27 00:00:00-07	5.74	27	2.66	4	583	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	107	\N	AM2 D-219
118	AMLP-371	2021-09-18 00:00:00-07	1.44	96	0.54	4	390.7	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	108	\N	AM2 D-264
119	AMLP-374	2021-09-27 00:00:00-07	4.93	15	2.32	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	108	\N	AM2 D-489
120	AMLP-375	2021-09-27 00:00:00-07	4.97	37	2.74	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	105	\N	AM2 D-486-1
121	AMLP-380	2022-01-26 00:00:00-08	0	31	0	4	300	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	129	\N	AM2 D-122
122	AMLP-382	2022-01-26 00:00:00-08	7.99	10	6.74	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	131	\N	AM2 D-323
123	AMLP-385	2022-01-26 00:00:00-08	0	95	0	4	307	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	134	\N	AM2 D-348
124	AMLP-393	2022-01-26 00:00:00-08	1.45	88	0.93	4	115	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	144	\N	AM2 D-493
125	AMLP-394	2022-01-26 00:00:00-08	2.85	88	1.2	4	188	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	145	\N	AM2 D-494
126	AMLP-425	2023-01-10 00:00:00-08	0.65	5	0.98	8	400	\N	\N	\N	65oC X 1 min; 1.5 uM adapter; 8 cycles	100	\N	AM2 R-227
127	AMLP-426	2023-01-10 00:00:00-08	1.05	7	1.5	8	400	\N	\N	\N	65oC X 1 min; 1.5 uM adapter; 8 cycles	101	\N	AM2 R-228
128	AMLP-427	2023-01-10 00:00:00-08	0.16	13	0.13	8	400	\N	\N	\N	65oC X 1 min; 1.5 uM adapter; 8 cycles	102	\N	AM2 R-273
129	AMLP-428	2023-01-10 00:00:00-08	0.58	5	0.71	8	400	\N	\N	\N	85oC X 3 min; 1.5 uM adapter; 8 cycles	103	\N	AM2 R-227
130	AMLP-429	2023-01-10 00:00:00-08	0.62	7	0.92	8	400	\N	\N	\N	85oC X 3 min; 1.5 uM adapter; 8 cycles	106	\N	AM2 R-228
131	AMLP-430	2023-01-10 00:00:00-08	0.16	13	0.14	8	400	\N	\N	\N	85oC X 3 min; 1.5 uM adapter; 8 cycles	112	\N	AM2 R-273
132	AMLP-431	2023-01-10 00:00:00-08	0.62	5	0.94	8	400	\N	\N	\N	85oC x 6 min; 1.5 uM adapter; 8 cycles	113	\N	AM2 R-227
133	AMLP-432	2023-01-10 00:00:00-08	0.59	7	0.89	8	400	\N	\N	\N	85oC x 6 min; 1.5 uM adapter; 8 cycles	114	\N	AM2 R-228
134	AMLP-433	2023-01-10 00:00:00-08	0.17	13	0.22	8	400	\N	\N	\N	85oC x 6 min; 1.5 uM adapter; 8 cycles	115	\N	AM2 R-273
135	AMLP-436	2023-01-13 00:00:00-08	0.28	13	0.36	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	121	\N	AM2 R-273
136	AMLP-441	2023-01-20 00:00:00-08	1.63	0	2.43	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	126	\N	AM2 R-237
137	AMLP-442	2023-01-20 00:00:00-08	0.33	11	0.41	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	127	\N	AM2 R-238
138	AMLP-446	2023-01-20 00:00:00-08	0.17	9	0.18	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	131	\N	AM2 R-271
139	AMLP-447	2023-01-20 00:00:00-08	0.32	11	0.43	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	132	\N	AM2 R-272
140	AMLP-448	2023-01-20 00:00:00-08	0.41	10	0.57	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	133	\N	AM2 R-274
141	AMLP-449	2023-01-20 00:00:00-08	0.29	5	0.29	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	134	\N	AM2 R-291
142	AMLP-452	2023-01-20 00:00:00-08	1.32	2	1.96	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	137	\N	AM2 R-310
143	AMLP-459	2023-01-20 00:00:00-08	0.91	20	1.27	8	298	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	146	\N	AM2 R-329
144	AMLP-467	2023-01-24 00:00:00-08	0.06	32	0.14	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	156	\N	AM2 R-363
145	AMLP-485	2023-01-26 00:00:00-08	0.14	0	0.13	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	184	\N	AM2 R-342
146	AMLP-489	2023-01-26 00:00:00-08	0.19	33	0.23	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	188	\N	AM2 R-472
147	AMLP-490	2023-01-26 00:00:00-08	0.14	21	0.14	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	189	\N	AM2 R-486-1
148	AMLP-494	2023-01-26 00:00:00-08	0.9	33	1.67	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	87	\N	AM2 R-501
149	AMLP-495	2023-01-26 00:00:00-08	0.9	24	1.72	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	88	\N	AM2 R-504
150	AMLP-496	2023-01-26 00:00:00-08	0.84	47	1.6	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	89	\N	AM2 R-505
151	AMLP-497	2023-03-02 00:00:00-08	0.55	1	0.66	8	600	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	167	\N	AM2 R-232
152	AMLP-498	2023-03-02 00:00:00-08	0.56	1	0.5	8	600	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	168	\N	AM2 R-232
153	AMLP-499	2023-03-02 00:00:00-08	0.25	11	0.19	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	169	\N	AM2 R-238
154	AMLP-500	2023-03-02 00:00:00-08	0.22	11	0.15	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	170	\N	AM2 R-238
155	AMLP-501	2023-03-02 00:00:00-08	0.62	14	0.59	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	171	\N	AM2 R-260
156	AMLP-502	2023-03-02 00:00:00-08	0.13	9	0.09	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	172	\N	AM2 R-271
157	AMLP-503	2023-03-02 00:00:00-08	0.16	9	0.1	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	173	\N	AM2 R-271
158	AMLP-504	2023-03-02 00:00:00-08	0.25	11	0.18	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	174	\N	AM2 R-272
159	AMLP-505	2023-03-02 00:00:00-08	0.44	11	0.36	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	175	\N	AM2 R-272
160	AMLP-506	2023-03-02 00:00:00-08	0.5	10	0.42	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	176	\N	AM2 R-274
161	AMLP-507	2023-03-02 00:00:00-08	0.39	10	0.3	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	177	\N	AM2 R-274
162	AMLP-508	2023-03-02 00:00:00-08	0.19	5	0.12	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	178	\N	AM2 R-291
163	AMLP-509	2023-03-02 00:00:00-08	0.23	5	0.18	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	179	\N	AM2 R-291
164	AMLP-510	2023-03-02 00:00:00-08	0.55	17	0.46	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	180	\N	AM2 R-328
165	AMLP-511	2023-03-02 00:00:00-08	0.76	20	0.68	8	298	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	181	\N	AM2 R-329
166	AMLP-512	2023-03-02 00:00:00-08	0.09	32	0.04	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	182	\N	AM2 R-363
167	AMLP-513	2023-03-02 00:00:00-08	0.11	32	0.06	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	183	\N	AM2 R-363
168	AMLP-514	2023-03-02 00:00:00-08	0.84	47	0.74	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	184	\N	AM2 R-470
169	AMLP-515	2023-03-02 00:00:00-08	0.25	33	0.19	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	185	\N	AM2 R-472
170	AMLP-516	2023-03-02 00:00:00-08	0.18	21	0.11	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	186	\N	AM2 R-486-1
171	AMLP-517	2023-03-02 00:00:00-08	1.45	46	1.26	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	190	\N	AM2 R-513
172	AMLP-518	2023-03-02 00:00:00-08	1.83	21	1.87	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	191	\N	AM2 R-514
173	AMLP-519	2023-03-02 00:00:00-08	0.67	25	0.62	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	192	\N	AM2 R-516
228	CGH12_056	\N	\N	0	\N	\N	78.3	\N	\N	\N	Iwei CGH, 7Q Gain 	L2DR06	\N	CGH12_056_NA
174	AMLP-520	2023-03-02 00:00:00-08	0.74	46	0.84	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	92	\N	AM2 R-517
175	AMLP-522	2023-03-02 00:00:00-08	0.43	5	0.4	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	96	\N	AM2 R-521
176	AMLP-523	2023-03-02 00:00:00-08	0.53	10	0.53	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	159	\N	AM2 R-522
177	AMLP-524	2023-03-02 00:00:00-08	0.44	38	0.4	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	100	\N	AM2 R-525
178	AMLP-525	2023-03-02 00:00:00-08	0.93	18	0.98	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	101	\N	AM2 R-526
179	AMLP-526	2023-03-31 00:00:00-07	8.63	0	4.28	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	109	\N	AM2 D-517
180	AMLP-536	2023-03-31 00:00:00-07	7.92	0	4.84	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	133	\N	AM2 D-531
181	AMLP-538	2023-04-05 00:00:00-07	0.64	0	0.82	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	117	\N	AM2 R-462
182	AMLP-539	2023-04-05 00:00:00-07	0.25	0	0.22	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	134	\N	AM2 R-463
183	AMLP-543	2023-04-05 00:00:00-07	1.1	46	1.77	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	141	\N	AM2 R-513
184	AMLP-545	2023-04-05 00:00:00-07	0.56	25	0.77	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	143	\N	AM2 R-516
185	AMLP-546	2023-04-05 00:00:00-07	0.93	46	1.29	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	144	\N	AM2 R-517
186	AMLP-547	2023-04-05 00:00:00-07	0.39	38	0.51	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	145	\N	AM2 R-525
187	AMLP-548	2023-04-05 00:00:00-07	0.81	18	1.32	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	146	\N	AM2 R-526
188	AMLP-550	2023-04-05 00:00:00-07	0.22	8	0.22	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	148	\N	AM2 R-532
189	AMLP-551	2023-04-05 00:00:00-07	1.04	40	1.46	8	225	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	149	\N	AM2 R-536
190	AMLP-555	2023-04-21 00:00:00-07	0.47	1	0.49	8	600	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	124	\N	AM2 R-232
191	AMLP-557	2023-04-21 00:00:00-07	0.83	14	0.88	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	130	\N	AM2 R-260
192	AMLP-561	2023-04-21 00:00:00-07	0.74	47	0.97	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	187	\N	AM2 R-470
193	AMLP-564	2023-04-21 00:00:00-07	0.44	8	0.52	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	127	\N	AM2 R-500
194	AMLP-565	2023-04-21 00:00:00-07	0.44	8	0.53	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	127	\N	AM2 R-500
195	AMLP-568	2023-04-21 00:00:00-07	0.5	38	0.59	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	145	\N	AM2 R-525
196	AMLP-569	2023-04-21 00:00:00-07	0.51	38	0.6	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	145	\N	AM2 R-525
197	AMLP-570	2023-04-21 00:00:00-07	0.51	38	0.61	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	145	\N	AM2 R-525
198	AMLP-571	2023-04-21 00:00:00-07	1.1	18	1.06	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	146	\N	AM2 R-526
199	AMLP-572	2023-04-21 00:00:00-07	0.92	18	0.96	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	146	\N	AM2 R-526
200	AMLP-581	2023-04-28 00:00:00-07	0.34	20	0.58	8	298	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	146	\N	AM2 R-329
201	AMLP-582	2023-04-28 00:00:00-07	1.65	19	2.33	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	146	\N	AM2 R-461
202	bMV_10_0206	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hunter, Desmoplastic Melanoma Amplicon Sequence	L2DR15	\N	bMV_10_0206_NA
203	BN_M1	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hunter Blue Nevus (Melanoma in Nevus Project)	L2DR15	\N	BN_M1_NA
204	BN_M2	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hunter Blue Nevus (Melanoma in Nevus Project)	L2DR16	\N	BN_M2_NA
205	BN_N1	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hunter Blue Nevus (Melanoma in Nevus Project)	L2DR13	\N	BN_N1_NA
206	BN_N2	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hunter Blue Nevus (Melanoma in Nevus Project)	L2DR14	\N	BN_N2_NA
207	CCRLP-0032	2021-08-04 00:00:00-07	2.03	17	1.12	4	250	\N	\N	\N	DO NOT USE! Adapter Ligation: O/N (15 hrs) at 20oC	186	\N	MMD-181
208	CCRLP-0040	2021-08-04 00:00:00-07	1.06	10	0.55	4	250	\N	\N	\N	DO NOT USE! Adapter Ligation: O/N (15 hrs) at 20oC	187	\N	MMD-02
209	CCRLP-0042	2021-08-04 00:00:00-07	1.59	14	0.96	4	250	\N	\N	\N	DO NOT USE! Adapter Ligation: O/N (15 hrs) at 20oC	185	\N	MMD-165
210	CCRLP-0055 (DO NOT USE)	2021-07-06 00:00:00-07	0	8	0	4	250	\N	\N	\N	Jessica practice LP	103	\N	MMD-177
211	CCRLP-0056 (DO NOT USE)	2021-07-06 00:00:00-07	0	6	0	4	250	\N	\N	\N	Jessica practice LP	104	\N	MMD-97
212	CCRLP-0057 (DO NOT USE)	2021-07-06 00:00:00-07	0	10	0	4	250	\N	\N	\N	Jessica practice LP	105	\N	MMD-02
213	CCRLP-0058 (DO NOT USE)	2021-07-06 00:00:00-07	0	14	0	4	250	\N	\N	\N	Jessica practice LP	106	\N	MMD-165
214	CGH11_091	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei CGH, Translocation	L2DR12	\N	CGH11_091_NA
215	CGH11_109	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei CGH, Translocation 	L2DR13	\N	CGH11_109_NA
216	CGH11_410	\N	\N	Infinity	\N	\N	93.2	\N	\N	\N	Iwei CGH, 7Q Gain 	L2DR16	\N	CGH11_410_NA
217	CGH11_424	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei CGH, 7Q Gain 	L2DR01	\N	CGH11_424_NA
218	CGH11-115	\N	\N	Infinity	\N	\N	45.1	\N	\N	\N	Iwei, Translocation CGH, PDGFRB	L2DR02	\N	CGH11-115_NA
219	CGH11-184	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei, Translocation CGH, PDGFRB	L2DR03	\N	CGH11-184_NA
220	CGH11-224	\N	\N	Infinity	\N	\N	25.6	\N	\N	\N	Iwei CGH, 7Q Gain	L2DR11	\N	CGH11-224_NA
221	CGH11-275	2013-07-09 00:00:00-07	\N	\N	\N	\N	\N	\N	\N	\N	Iwei 7Q gain\n, Swapna CGH screened, FFPE derived; Not sequenced, <2 ul volume remaining\n\n	L2DR12	\N	CGH11-275
222	CGH11-399	2013-07-09 00:00:00-07	\N	50	\N	\N	129.5	\N	\N	\N	Iwei 7Q gain\n, Swapna CGH screened, FFPE derived; Not sequenced, <2 ul volume remaining\n	L2DR15	\N	CGH11-399
223	CGH11-402	2013-07-09 00:00:00-07	18.5	43	\N	\N	250	\N	\N	\N	Iwei 7Q gain, Swapna CGH screened, FFPE derived	L2DR14	\N	CGH11-402
224	CGH12_026	\N	\N	Infinity	\N	\N	89.5	\N	\N	\N	Iwei CGH, 7Q Gain 	L2DR02	\N	CGH12_026_NA
225	CGH12_039	\N	\N	1	\N	\N	82.9	\N	\N	\N	Iwei CGH, 7Q Gain 	L2DR03	\N	CGH12_039_NA
226	CGH12_040	\N	\N	0	\N	\N	100	\N	\N	\N	Iwei CGH, 7Q Gain 	L2DR04	\N	CGH12_040_NA
229	CGH12_058	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei CGH, Translocation FLT4	L2DR14	\N	CGH12_058_NA
230	CGH12_224	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei CGH, Translocation 	L2DR15	\N	CGH12_224_NA
231	CGH12-043	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei, Translocation CGH, MET	L2DR04	\N	CGH12-043_NA
232	CGH12-104	\N	\N	Infinity	\N	\N	71.2	\N	\N	\N	Iwei CGH, 7Q Gain	L2DR12	\N	CGH12-104_NA
233	CGH12-124	\N	\N	Infinity	\N	\N	71.6	\N	\N	\N	Iwei CGH, 7Q Gain	L2DR13	\N	CGH12-124_NA
234	CGH14-059	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Translocation	NextFlex 9	\N	CGH14-059_NA
235	CHG11-402	\N	\N	Infinity	\N	\N	22	\N	\N	\N	Iwei 7Q Gain	L2DR14	\N	CHG11-402_NA
236	DLP-01_RE	2019-05-23 00:00:00-07	5.79	0	1.26	4	\N	\N	\N	\N	\N	1	\N	DNA-01_REPEAT
237	DLP-053_RE	2019-05-23 00:00:00-07	3.95	0	1.19	4	\N	\N	\N	\N	\N	75	\N	DNA-53_REPEAT
238	DLP-054_RE	2019-05-23 00:00:00-07	2.66	0	0.98	4	\N	\N	\N	\N	\N	76	\N	DNA-54_REPEAT
239	DLP-100	2020-08-02 00:00:00-07	0.28	\N	0.19	4	\N	\N	\N	\N	\N	133	\N	DNA-100
240	DLP-112	2020-09-03 00:00:00-07	0.69	91	0.33	4	30	\N	\N	\N	Sample removed from study	190	\N	DNA-126
241	DLP-113	2020-09-03 00:00:00-07	3.16	90	1.52	4	136	\N	\N	\N	Sample removed from study	191	\N	DNA-127
242	DM_2	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hunter, Desmoplastic Melanoma Amplicon Sequence	L2DR14	\N	DM_2_NA
243	DM_6_Normal	\N	\N	Infinity	\N	\N	72	\N	\N	\N	\N	L2DR03	\N	DM_6_Normal_NA
244	DM_13_2_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR09	\N	DM_13_2_Tumor_NA
245	DM_31_2_Tumor	\N	\N	Infinity	\N	\N	16.2	\N	\N	\N	\N	L2DR08	\N	DM_31_2_Tumor_NA
246	DM_31_Normal	\N	\N	Infinity	\N	\N	40.3	\N	\N	\N	\N	L2DR04	\N	DM_31_Normal_NA
247	DM_36_2_Tumor	\N	\N	Infinity	\N	\N	28.6	\N	\N	\N	\N	L2DR09	\N	DM_36_2_Tumor_NA
248	DM_36_Normal	\N	\N	Infinity	\N	\N	47.4	\N	\N	\N	\N	L2DR05	\N	DM_36_Normal_NA
249	DM_42_Normal	\N	\N	Infinity	\N	\N	35.2	\N	\N	\N	\N	L2DR06	\N	DM_42_Normal_NA
250	DM_43_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR14	\N	DM_43_Normal_NA
251	DM_49_2_Tumor	\N	\N	Infinity	\N	\N	26.9	\N	\N	\N	\N	L2DR02	\N	DM_49_2_Tumor_NA
252	DM_49_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR15	\N	DM_49_Normal_NA
253	DM_51_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR04	\N	DM_51_Tumor_NA
254	DM_58_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR16	\N	DM_58_Normal_NA
255	DM_58_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR06	\N	DM_58_Tumor_NA
256	DM_59_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR07	\N	DM_59_Tumor_NA
257	DM_64_1_Normal	\N	\N	Infinity	\N	\N	35.8	\N	\N	\N	\N	L2DR03	\N	DM_64_1_Normal_NA
258	DM_64_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR02	\N	DM_64_Tumor_NA
259	DM_65_2_Tumor	\N	\N	Infinity	\N	\N	60.1	\N	\N	\N	\N	L2DR01	\N	DM_65_2_Tumor_NA
260	DM_68_Tumor	\N	\N	Infinity	\N	\N	10	\N	\N	\N	\N	L2DR07	\N	DM_68_Tumor_NA
261	DM_74_1_Tumor	\N	\N	Infinity	\N	\N	36.2	\N	\N	\N	\N	L2DR01	\N	DM_74_1_Tumor_NA
262	DM_74_2_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR10	\N	DM_74_2_Tumor_NA
264	DM_93_3_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR02	\N	DM_93_3_Tumor_NA
265	DM_94_Normal	\N	\N	Infinity	\N	\N	10.1	\N	\N	\N	\N	L2DR11	\N	DM_94_Normal_NA
266	DM_94_Tumor	\N	\N	Infinity	\N	\N	69.6	\N	\N	\N	\N	L2DR10	\N	DM_94_Tumor_NA
267	DM_98_2_Normal	\N	\N	Infinity	\N	\N	89.6	\N	\N	\N	\N	L2DR13	\N	DM_98_2_Normal_NA
268	DM_98_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR12	\N	DM_98_Tumor_NA
269	DM_99_Normal	\N	\N	Infinity	\N	\N	77.8	\N	\N	\N	\N	L2DR15	\N	DM_99_Normal_NA
270	DM_99_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR14	\N	DM_99_Tumor_NA
272	DM_100_Tumor_Pool	\N	\N	Infinity	\N	\N	10	\N	\N	\N	\N	L2DR03	\N	DM_100_Tumor_Pool_NA
273	DM_101_IS	\N	\N	Infinity	\N	\N	38	\N	\N	\N	\N	L2DR10	\N	DM_101_IS_NA
274	DM_101_Normal	\N	\N	Infinity	\N	\N	30.7	\N	\N	\N	\N	L2DR09	\N	DM_101_Normal_NA
275	DM_101_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR08	\N	DM_101_Tumor_NA
276	DM_102_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR02	\N	DM_102_Tumor_NA
277	DM-60-Tumor	\N	\N	Infinity	\N	\N	49.6	\N	\N	\N	\N	NextFlex 18	\N	DM-60-Tumor_NA
278	DM-61-Tumor	\N	\N	Infinity	\N	\N	54	\N	\N	\N	\N	NextFlex 19	\N	DM-61-Tumor_NA
279	DM-62-Tumor	\N	\N	Infinity	\N	\N	90	\N	\N	\N	\N	NextFlex 20	\N	DM-62-Tumor_NA
280	DM-63-Tumor	\N	\N	Infinity	\N	\N	86.8	\N	\N	\N	\N	NextFlex 21	\N	DM-63-Tumor_NA
281	DM-66-Tumor	\N	\N	Infinity	\N	\N	40	\N	\N	\N	\N	NextFlex 22	\N	DM-66-Tumor_NA
282	DM-67-Tumor	\N	\N	Infinity	\N	\N	45.2	\N	\N	\N	\N	NextFlex 23	\N	DM-67-Tumor_NA
283	DM-69-Tumor	\N	\N	Infinity	\N	\N	60	\N	\N	\N	\N	NextFlex 24	\N	DM-69-Tumor_NA
284	DM-70-Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	NextFlex 1	\N	DM-70-Tumor_NA
285	DM-81-Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	NextFlex 2	\N	DM-81-Tumor_NA
286	DM1-Tert-Amplicon	\N	\N	0	\N	\N	\N	\N	\N	\N	Hunter Amplicon Sequencing\n; Tert 1, Tert 2, and Tert 3 spike-in at 10pg/ul; SF3B1 1 and SF3B1 2 spike-in at 4pg/ul; NFKBIE spike-in at 10pg/ul\n	\N	\N	DM_1_Tumor_NA
287	DM2-Tert-Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Amplicon Sequencing\n; Tert 1, Tert 2, and Tert 3 spike-in at 10pg/ul; SF3B1 1 and SF3B1 2 spike-in at 4pg/ul; NFKBIE spike-in at 10pg/ul	\N	\N	DM_2_Tumor_NA
288	DM8Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DM_8_Tumor_NA
289	DM8TumorCrest	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DM8TumorCrest_NA
290	DM11-Tert-Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter DM Amplicon Sequencing; Tert 1, Tert 2, and Tert 3 spike-in at 10pg/ul\n; SF3B1 1 and SF3B1 2 spike-in at 4pg/ul; NFKBIE spike-in at 10pg/ul\n\n	\N	\N	DM_11_Tumor_NA
291	DM14-Tert-Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter DM Amplicon Sequencing; Tert 1, Tert 2, and Tert 3 spike-in at 10pg/ul\n; SF3B1 1 and SF3B1 2 spike-in at 4pg/ul; NFKBIE spike-in at 10pg/ul\n\n"	\N	\N	DM_14_Tumor_NA
292	DM16_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR10	\N	DM16_Normal_NA
293	DM16_Tumor	\N	\N	Infinity	\N	\N	31.3	\N	\N	\N	\N	L2DR09	\N	DM16_Tumor_NA
294	DM37_1_Normal	\N	\N	Infinity	\N	\N	62	\N	\N	\N	\N	L2DR06	\N	DM37_1_Normal_NA
295	DM45_2_Tumor	\N	\N	Infinity	\N	\N	31.6	\N	\N	\N	\N	L2DR07	\N	DM45_2_Tumor_NA
296	DM45_NFKBIE_Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Amplicon Sequencing\n; Tert 1, Tert 2, and Tert 3 spike-in at 10pg/ul; SF3B1 1 and SF3B1 2 spike-in at 4pg/ul; NFKBIE spike-in at 10pg/ul	\N	\N	DM45_Tumor_NA
297	DM45_Normal	\N	\N	Infinity	\N	\N	22	\N	\N	\N	\N	L2DR08	\N	DM45_Normal_NA
298	DM77_2_Tumor	\N	\N	Infinity	\N	\N	57.2	\N	\N	\N	\N	L2DR11	\N	DM77_2_Tumor_NA
299	DM77_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR12	\N	DM77_Normal_NA
300	DM79_NFKBIE_Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Amplicon Sequencing\n; Tert 1, Tert 2, and Tert 3 spike-in at 10pg/ul; SF3B1 1 and SF3B1 2 spike-in at 4pg/ul; NFKBIE spike-in at 10pg/ul	\N	\N	DM79_Tumor_NA
301	DM93_2_Tumor	\N	\N	Infinity	\N	\N	10	\N	\N	\N	\N	L2DR05	\N	DM93_2_Tumor_NA
302	DM93_NFKBIE_Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Amplicon Sequencing\n; Tert 1, Tert 2, and Tert 3 spike-in at 10pg/ul; SF3B1 1 and SF3B1 2 spike-in at 4pg/ul; NFKBIE spike-in at 10pg/ul	\N	\N	DM93_NFKBIE_NA
303	DM93_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DM93_Tumor_NA
304	DPN_5_Normal	\N	\N	1	\N	\N	10.5	\N	\N	\N	Iwei DPN	L2DR08	\N	DPN_5_Normal_NA
305	DPN_8_Normal	\N	\N	Infinity	\N	\N	67	\N	\N	\N	Iwei DPN	L2DR08	\N	DPN_8_Normal_NA
306	DPN_9_Normal	\N	\N	Infinity	\N	\N	22.6	\N	\N	\N	Iwei DPN	L2DR09	\N	DPN_9_Normal_NA
307	DPN_18_Normal	\N	\N	Infinity	\N	\N	10.1	\N	\N	\N	Iwei DPN	L2DR11	\N	DPN_18_Normal_NA
308	DPN_35	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei DPN	L2DR04	\N	DPN_35_NA
309	DPN_CNN 30	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei DPN (Control Normal Nevus)	L2DR12	\N	DPN_CNN 30_NA
310	DPN_CNN 32	\N	\N	Infinity	\N	\N	93.5	\N	\N	\N	Iwei DPN (Control Normal Nevus)	L2DR13	\N	DPN_CNN 32_NA
311	DPN_Conv_35	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei DPN	L2DR05	\N	DPN_Conv_35_NA
312	DPN_MM 20	\N	\N	Infinity	\N	\N	74.2	\N	\N	\N	Iwei DPN (DPN like Melanoma)	L2DR09	\N	DPN_MM 20_NA
313	DPN_MM 21	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei DPN (DPN like Melanoma)	L2DR10	\N	DPN_MM 21_NA
314	DPN_MM 22	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei DPN (DPN like Melanoma)	L2DR11	\N	DPN_MM 22_NA
315	DPN54-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN54-Tumor_NA
316	DPN59-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN59-Tumor_NA
317	DT10_63051C	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Ivanka Normal (for #9) 	L2DR07	\N	DT10_63051C_NA
318	EXLP-02	2020-08-05 00:00:00-07	1.63	100	1.14	4	32	\N	\N	\N	\N	122	\N	PROG D-02
319	EXLP-03	2020-08-05 00:00:00-07	0.65	99	0.35	4	16	\N	\N	\N	\N	123	\N	PROG D-03
320	EXLP-06	2020-08-05 00:00:00-07	0.16	99	0.06	4	7	\N	\N	\N	\N	126	\N	PROG D-06
321	EXLP-07	2020-08-05 00:00:00-07	0.2	99	0.07	4	9	\N	\N	\N	\N	127	\N	PROG D-08
322	EXLP-08	2020-08-05 00:00:00-07	0.55	105	0.43	4	10	\N	\N	\N	\N	128	\N	PROG D-11
323	EXLP-12	2023-01-26 00:00:00-08	0.86	0	1.64	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	90	\N	PROG R-04
324	EXLP-13	2023-01-26 00:00:00-08	1.16	0	2.18	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	91	\N	PROG R-05
325	EXLP-14	2023-01-26 00:00:00-08	0.07	19	0.04	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	92	\N	PROG R-06
326	EXLP-15	2023-01-26 00:00:00-08	0.11	4	0.06	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	95	\N	PROG R-08
327	EXLP-16	2023-01-26 00:00:00-08	0.09	7	0.05	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	96	\N	PROG R-09
328	EXLP-17	2023-01-26 00:00:00-08	0.11	7	0.06	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	97	\N	PROG R-10
329	EXLP-18	2023-01-26 00:00:00-08	3.14	2	5.22	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	98	\N	PROG R-12
330	EXLP-19	2023-01-26 00:00:00-08	4.76	9	7.43	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	99	\N	PROG R-13
331	EXLP-28	2023-05-25 00:00:00-07	7.78	43	3.26	4	250	\N	\N	\N	1 hr adapter ligation at 20oC	159	\N	PROG D-24
332	EXLP-29	2023-05-25 00:00:00-07	3.88	76	0.55	4	250	\N	\N	\N	1 hr adapter ligation at 20oC	160	\N	PROG D-25
333	EXLP-37	2023-05-29 00:00:00-07	0.65	8	0.58	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	168	\N	PROG R-24
334	EXLP-41	2023-06-13 00:00:00-07	3.63	73	1	4	250	\N	\N	\N	1 hr adapter ligation at 20oC	157	\N	PROG D-22
335	EXLP-42	2023-06-13 00:00:00-07	3.06	76	0.33	4	250	\N	\N	\N	1 hr adapter ligation at 20oC	160	\N	PROG D-25
336	EXLP-46	2023-06-20 00:00:00-07	1.75	6	2.34	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	164	\N	PROG R-18
337	EXLP-50	2023-06-20 00:00:00-07	0.6	8	0.69	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	168	\N	PROG R-24
338	G3 DP08-21965C Normal	\N	\N	Infinity	\N	\N	20.5	\N	\N	\N	Normal	L2DR04	\N	G3 DP08-21965C Normal_NA
339	G3 DP08-21965C Tumor	\N	\N	Infinity	\N	\N	14	\N	\N	\N	Tumor	L2DR03	\N	G3 DP08-21965C Tumor_NA
340	G5 DP08-4205A Normal	\N	\N	Infinity	\N	\N	76.3	\N	\N	\N	Normal	L2DR06	\N	G5 DP08-4205A Normal_NA
341	G5 DP08-4205A Tumor	\N	\N	Infinity	\N	\N	78.5	\N	\N	\N	Tumor	L2DR05	\N	G5 DP08-4205A Tumor_NA
342	HW_2_Tumor Dissect	\N	\N	Infinity	\N	\N	11	\N	\N	\N	Hong Wu, Melanoma, Mucosal Melanoma, vulva	L2DR06	\N	HW_2_Tumor Dissect_NA
343	HW_3_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, Melanoma, Tumor Melanoma, nasal sinus	L2DR05	\N	HW_3_Tumor_NA
344	HW_8_Mucosal_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hong Wu	L2DR11	\N	HW_8_Mucosal_Tumor_NA
345	HW_Acral_#8_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hong Wu, FCCC, Dissect, Acral Melanoma, Dissect	L2DR07	\N	HW_Acral_#8_Tumor_NA
346	Ivanka_5_1	\N	2.24	Infinity	\N	\N	21.6	\N	\N	\N	Ivanka Patient Melanoma	L2DR12	\N	Ivanka_5_1_NA
347	Ivanka_5_2	\N	8.85	Infinity	\N	\N	65.1	\N	\N	\N	Ivanka Patient Melanoma	L2DR13	\N	Ivanka_5_2_NA
348	Ivanka_5_3	\N	7.88	Infinity	\N	\N	80.6	\N	\N	\N	Ivanka Patient Melanoma	L2DR14	\N	Ivanka_5_3_NA
349	Ivanka_5_4	\N	7.29	Infinity	\N	\N	93.6	\N	\N	\N	Ivanka Patient Melanoma	L2DR15	\N	Ivanka_5_4_NA
350	Ivanka_5_5	\N	8.04	Infinity	\N	\N	42.8	\N	\N	\N	Ivanka Patient Melanoma	L2DR16	\N	Ivanka_5_5_NA
351	Ivanka_10_1	\N	6.68	Infinity	\N	\N	38.3	\N	\N	\N	Ivanka Patient Melanoma	L2DR01	\N	Ivanka_10_1_NA
352	Ivanka_10_2	\N	13.4	Infinity	\N	\N	49	\N	\N	\N	Ivanka Patient Melanoma	L2DR02	\N	Ivanka_10_2_NA
353	Ivanka_10_3	\N	14.7	Infinity	\N	\N	100	\N	\N	\N	Ivanka Patient Melanoma	L2DR03	\N	Ivanka_10_3_NA
354	Ivanka_10_4	\N	2.62	Infinity	\N	\N	11	\N	\N	\N	Ivanka Patient Melanoma	L2DR04	\N	Ivanka_10_4_NA
355	Ivanka_10_5	\N	2.86	Infinity	\N	\N	21.4	\N	\N	\N	Ivanka Patient Melanoma	L2DR05	\N	Ivanka_10_5_NA
356	IYEH-01	2023-05-29 00:00:00-07	0.36	47	0.25	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	171	\N	22-104389A2-RNA
357	IYEH-02	2023-05-29 00:00:00-07	0.41	79	0.39	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	172	\N	22-104389C-RNA
358	IYEH-03	2023-05-29 00:00:00-07	5.01	3	4.68	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	173	\N	22-125373-RNA
359	IYEH-07	2023-06-19 00:00:00-07	0.36	47	0.52	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	171	\N	22-104389A2-RNA
360	IYEH-08	2023-06-19 00:00:00-07	0.28	79	0.32	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	172	\N	22-104389C-RNA
361	KALP-013	2023-09-06 00:00:00-07	6.28	78	2.47	4	250	\N	\N	\N	\N	187	\N	KA D-29
362	KALP-016	2023-09-06 00:00:00-07	4.39	15	1.51	4	250	\N	\N	\N	\N	190	\N	KA D-32
363	KALP-017	2023-09-06 00:00:00-07	2.31	13	0.84	4	250	\N	\N	\N	\N	191	\N	KA D-35
364	KALP-018	2023-09-06 00:00:00-07	2.11	35	1.49	4	250	\N	\N	\N	\N	192	\N	KA D-36
365	KALP-026	2023-09-15 00:00:00-07	11	15	3.22	4	250	\N	\N	\N	\N	190	\N	KA D-32
366	KAM10-normal	2015-11-19 00:00:00-08	7.09	45	\N	\N	197.6	\N	\N	\N	\N	E1	\N	KAM10-N-B7
367	KAM10-normal_kapa-NGv3-PE100-NGv3-ready	\N	\N	45	\N	\N	197.6	\N	\N	\N	\N	\N	\N	KAM10-N-B7
368	KAM10-Tumor_kapa-NGv3-PE100-NGv3-ready	\N	\N	7	\N	\N	250	\N	\N	\N	\N	\N	\N	KAM10-T
369	KAM12-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM12-T
370	KAM75-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM75-T
371	KAM93-normal	2015-11-19 00:00:00-08	3.32	46	\N	\N	250	\N	\N	\N	\N	D5	\N	KAM93-N-B10
372	KAM93-normal_kapa-NGv3-PE100-NGv3-ready	\N	\N	46	\N	\N	250	\N	\N	\N	\N	\N	\N	KAM93-N-B10
373	KAM93-tumor_kapa-NGv3-PE100-NGv3-ready	\N	\N	18	\N	\N	250	\N	\N	\N	\N	\N	\N	KAM93-T
374	KAM99-normal	2015-11-19 00:00:00-08	2.15	89	\N	\N	250	\N	\N	\N	\N	D7	\N	KAM99-N
375	KAM99-normal_kapa-NGv3-PE100-NGv3-ready	\N	\N	89	\N	\N	250	\N	\N	\N	\N	\N	\N	KAM99-N
376	KAM99-tumor_kapa-NGv3-PE100-NGv3-ready	\N	\N	9	\N	\N	250	\N	\N	\N	\N	\N	\N	KAM99-T
377	KAM100-normal	2015-11-19 00:00:00-08	5.09	34	\N	\N	250	\N	\N	\N	\N	D9	\N	KAM100-N
378	KAM100-normal_kapa-NGv3-PE100-NGv3-ready	\N	\N	34	\N	\N	250	\N	\N	\N	\N	\N	\N	KAM100-N
379	KAM100-tumor_kapa-NGv3-PE100-NGv3-ready	\N	\N	18	\N	\N	250	\N	\N	\N	\N	\N	\N	KAM100-T-11
380	KAM102-T-B	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM102-T-B
381	KAM111-normal	2015-11-19 00:00:00-08	5.03	106	\N	\N	250	\N	\N	\N	\N	E6	\N	KAM111-N-A4
382	KAM111-normal_kapa-NGv3-PE100-NGv3-ready	\N	\N	106	\N	\N	250	\N	\N	\N	\N	\N	\N	KAM111-N-A4
383	KAM111-tumor_kapa-NGv3-PE100-NGv3-ready	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM111-T-A1,KAM111-T-A2
384	KAM113-T-H	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM113-T-H
385	KAM116-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM116-T
386	KAM122-T-A	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM122-T-A
387	KAM123-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM123-T
388	KIT_134	\N	\N	Infinity	\N	\N	96.9	\N	\N	\N	Mucosal melanoma, rectal, WT	L2DR02	\N	KIT_134_NA
389	Kit_181_Muc BRAF	\N	\N	\N	\N	\N	\N	\N	\N	\N	Alyssa Acral Mucosal, Mucosal, BRAF, glans penis	L2DR08	\N	Kit_181_Muc BRAF_NA
390	KIT_191	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Acral melanoma, heel, WT	L2DR03	\N	KIT_191_NA
391	KIT_205	\N	\N	Infinity	\N	\N	68.8	\N	\N	\N	Acral melanoma, toe, WT	L2DR04	\N	KIT_205_NA
392	KIT_206	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Mucosal melanoma, ?, WT	L2DR05	\N	KIT_206_NA
393	KIT_210	\N	\N	Infinity	\N	\N	65.2	\N	\N	\N	Mucosal melanoma, rectal, WT	L2DR06	\N	KIT_210_NA
394	KIT_217	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Mucosal melanoma, vaginal, WT	L2DR07	\N	KIT_217_NA
395	KIT_225	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Mucosal melanoma, anal, 	L2DR08	\N	KIT_225_NA
396	KIT_230	\N	\N	Infinity	\N	\N	10.3	\N	\N	\N	Alyssa Acral Mucosal DNA	L2DR15	\N	KIT_230_NA
397	KIT_244	\N	\N	Infinity	\N	\N	77.5	\N	\N	\N	Mucosal melanoma, urethra, WT	L2DR09	\N	KIT_244_NA
398	KIT_260	\N	\N	Infinity	\N	\N	89.4	\N	\N	\N	Mucosal melanoma, perirectal, 	L2DR10	\N	KIT_260_NA
399	KIT_273	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Mucosal melanoma, duodenal, NRAS	L2DR11	\N	KIT_273_NA
400	KIT_295	\N	\N	Infinity	\N	\N	39.7	\N	\N	\N	Mucosal melanoma, oral, WT	L2DR12	\N	KIT_295_NA
401	KIT_297	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Alyssa Acral Mucosal DNA	L2DR16	\N	KIT_297_NA
402	KIT_302	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Alyssa Acral Mucosal DNA	L2DR01	\N	KIT_302_NA
403	KIT_316	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Alyssa Acral Mucosal DNA	L2DR02	\N	KIT_316_NA
404	L2-HGD	\N	\N	Infinity	\N	\N	96.4	\N	\N	\N	Hunter Dysplastic Nevus	NextFlex 4	\N	L2-HGD_NA
405	L2-Normal	\N	\N	Infinity	\N	\N	85.2	\N	\N	\N	Hunter Dysplastic Nevus	NextFlex 3	\N	L2-Normal_NA
406	L3-HGD	\N	\N	Infinity	\N	\N	70	\N	\N	\N	Hunter Dysplastic Nevus	NextFlex 6	\N	L3-HGD_NA
407	L3-Normal	\N	\N	Infinity	\N	\N	40	\N	\N	\N	Hunter Dysplastic Nevus	NextFlex 5	\N	L3-Normal_NA
408	LMM-04	2023-05-29 00:00:00-07	0.67	5	0.66	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	174	\N	LMM R-004
409	LMM-05	2023-05-29 00:00:00-07	0.99	13	0.94	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	175	\N	LMM R-005
410	LMM-07	2023-05-29 00:00:00-07	2.38	38	2.26	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	176	\N	LMM R-007
411	LMM-08	2023-05-29 00:00:00-07	3.29	43	3.46	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	177	\N	LMM R-008
412	LMM-10	2023-05-29 00:00:00-07	4.53	38	4.6	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	178	\N	LMM R-010
413	LMM-11	2023-05-29 00:00:00-07	3.66	42	4.98	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	179	\N	LMM R-011
414	LMM-13	2023-05-29 00:00:00-07	10.5	5	10	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	180	\N	LMM R-013
415	LMM-14	2023-05-29 00:00:00-07	4.24	39	5.34	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	181	\N	LMM R-014
416	LMM-17	2023-05-29 00:00:00-07	0.39	32	0.38	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	183	\N	LMM R-017
417	LMM-18	2023-05-29 00:00:00-07	0.39	25	0.3	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	182	\N	LMM R-018
418	Luping_ROS 1	\N	\N	Infinity	\N	\N	55	\N	\N	\N	Bivona Lab, ROS 1	L2DR07	\N	Luping_ROS 1_NA
419	MIN_1	\N	\N	Infinity	\N	\N	46.7	\N	\N	\N	\N	L2DR12	\N	MIN_1_NA
420	MIN_2	\N	\N	Infinity	\N	\N	14.3	\N	\N	\N	\N	L2DR13	\N	MIN_2_NA
421	MIN_3	\N	\N	Infinity	\N	\N	19	\N	\N	\N	\N	L2DR14	\N	MIN_3_NA
422	MIN_4	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR15	\N	MIN_4_NA
423	MIN_5	\N	\N	Infinity	\N	\N	30.9	\N	\N	\N	\N	L2DR16	\N	MIN_5_NA
424	MIN_6	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR01	\N	MIN_6_NA
425	MS_1_Tumor	\N	\N	Infinity	\N	\N	27.1	\N	\N	\N	Dr. Perry, Melanocytic Shwannoma	L2DR08	\N	MS_1_Tumor_NA
426	NMLP-005	2018-12-07 00:00:00-08	3.64	8	0.03	4	250	\N	\N	\N	\N	4	\N	NM D-05
427	NMLP-006	2018-12-07 00:00:00-08	3.66	9	0.04	4	250	\N	\N	\N	\N	5	\N	NM D-06
428	NMLP-043	\N	\N	48	0	4	128.2	\N	\N	\N	Sample had high melanin	63	\N	NM D-053
429	NMLP-044	\N	\N	35	0.01	4	250	\N	\N	\N	Sample had high melanin	64	\N	NM D-054
430	NMLP-047	\N	\N	16	0.03	4	250	\N	\N	\N	not enough LP\n	67	\N	NM D-059
431	OMLP-001	2021-08-04 00:00:00-07	4.53	23	2.27	4	250	\N	\N	\N	DO NOT USE SEQUENCED DATA! Adapter Ligation: O/N (15 hrs) at 20oC	188	\N	OM-15D (P040_11D)
432	RLP-57	2018-11-05 00:00:00-08	1.24	17	2.72	11	400	\N	\N	\N	RLP-57, Sample removed from study	81	\N	RNA-57
433	RLP-58	2018-11-05 00:00:00-08	1.95	20	3.99	11	30	\N	\N	\N	RLP-58, Sample removed from study	82	\N	RNA-58
434	RLP-83	2020-09-05 00:00:00-07	8.82	20	15.93	11	230	\N	\N	\N	Sample removed from study	174	\N	RNA-129
435	RLP-84	2020-09-05 00:00:00-07	16.2	20	26.83	11	366	\N	\N	\N	Sample removed from study	175	\N	RNA-130
436	RLP-108	2023-03-03 00:00:00-08	0.66	\N	0.67	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles, KAPAEX-31; Sequenced with RLP-171, BCB063	98	\N	RNA-161,RNA-204
437	RLP-110	2023-03-03 00:00:00-08	1.13	\N	1.25	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles, KAPAEX-30; Sequenced with RLP-173, BCB062	100	\N	RNA-207,RNA-245
438	RLP-111	2023-03-03 00:00:00-08	0.52	\N	0.54	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles, KAPAEX-31; Sequenced with RLP-174, BCB063	101	\N	RNA-165,RNA-208
439	RLP-112	2023-03-03 00:00:00-08	0.39	\N	0.43	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles, KAPAEX-31; Sequenced with RLP-175, BCB063	102	\N	RNA-169,RNA-212
440	RLP-113	2023-03-03 00:00:00-08	0.51	\N	0.46	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles, KAPAEX-31; Sequenced with RLP-176, BCB063	103	\N	RNA-170,RNA-213
441	RLP-114	2023-03-03 00:00:00-08	0.57	\N	0.59	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles, KAPAEX-31; Sequenced with RLP-177, BCB063	104	\N	RNA-171,RNA-214
442	RLP-116	2023-03-03 00:00:00-08	0.81	\N	0.93	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-32; Sequenced with RLP-179, BCB059	109	\N	RNA-175,RNA-218
443	RLP-117	2023-03-03 00:00:00-08	0.92	\N	1.38	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-34; Sequenced with RLP-180, BCB064	110	\N	RNA-176,RNA-219
444	RLP-121	2023-03-03 00:00:00-08	0.33	\N	0.28	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-31; Sequenced with RLP-184, BCB063	114	\N	RNA-234,RNA-247
445	RLP-122	2023-03-03 00:00:00-08	0.33	32	0.31	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-31; Sequenced with RLP-185, BCB063	115	\N	RNA-191
446	RLP-123	2023-03-03 00:00:00-08	0.92	\N	0.89	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-32; Sequenced with RLP-186, BCB059	119	\N	RNA-199,RNA-242
447	RLP-127	2023-03-03 00:00:00-08	0	7	0.01	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	123	\N	RNA-133
448	RLP-128	2023-03-08 00:00:00-08	1.39	96	1.52	8	341	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-34; Sequenced with RLP-190, BCB064	124	\N	RNA-421
449	RLP-133	2023-03-08 00:00:00-08	0.41	16	0.42	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-31; Sequenced with RLP-195, BCB063	129	\N	RNA-334
450	RLP-134	2023-03-08 00:00:00-08	0.63	10	0.72	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-32; Sequenced with RLP-196, BCB059	130	\N	RNA-335
451	RLP-137	2023-03-08 00:00:00-08	1.53	9	1.77	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles. KAPAEX-29; Sequenced with RLP-199, BCB059	133	\N	RNA-340
452	RLP-138	2023-03-08 00:00:00-08	1.33	8	1.15	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-34; Sequenced with RLP-200, BCB064	134	\N	RNA-341
453	RLP-145	2023-03-08 00:00:00-08	0.86	6	0.93	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles, KAPAEX-30; Sequenced with RLP-207, BCB062	142	\N	RNA-359
454	RLP-146	2023-03-08 00:00:00-08	0.77	22	0.76	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-32; Sequenced with RLP-208, BCB059	143	\N	RNA-361
455	RLP-149	2023-03-10 00:00:00-08	3.55	48	0.64	8	156	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	146	\N	RNA-366
456	RLP-150	2023-03-10 00:00:00-08	3.02	11	0.5	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	147	\N	RNA-369
457	RLP-151	2023-03-10 00:00:00-08	2.01	13	0.73	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles;  KAPAEX-29; Sequenced with RLP-213, BCB059	148	\N	RNA-372
458	RLP-152	2023-03-10 00:00:00-08	2.83	22	0.37	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-29; Sequenced with RLP-214, BCB059	149	\N	RNA-373
459	RLP-153	2023-03-10 00:00:00-08	0.58	11	0.48	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-31; Sequenced with RLP-215, BCB063	150	\N	RNA-377
460	RLP-154	2023-03-10 00:00:00-08	0.62	15	0.58	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-31; Sequenced with RLP-216, BCB063	151	\N	RNA-417
461	RLP-155	2023-03-10 00:00:00-08	0.8	9	0.96	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-30; Sequenced with RLP-217, BCB062	152	\N	RNA-379
462	RLP-156	2023-03-10 00:00:00-08	0.59	24	0.68	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-32; Sequenced with RLP-218, BCB059	153	\N	RNA-381
463	RLP-157	2023-03-10 00:00:00-08	0.51	40	0.56	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-30; Sequenced with RLP-219, BCB062	154	\N	RNA-383
464	RLP-158	2023-03-10 00:00:00-08	0.51	26	0.5	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-32; Sequenced with RLP-220, BCB059	155	\N	RNA-385
465	RLP-159	2023-03-10 00:00:00-08	0.68	38	0.71	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-30; Sequenced with RLP-221, BCB062	156	\N	RNA-387
466	RLP-160	2023-03-10 00:00:00-08	0.42	48	0.39	8	148.8	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-30; Sequenced with RLP-222, BCB062	157	\N	RNA-390
467	RLP-161	2023-03-10 00:00:00-08	0.42	45	0.43	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-31; Sequenced with RLP-223, BCB063	158	\N	RNA-391
468	RLP-162	2023-03-10 00:00:00-08	0.55	13	0.58	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-32; Sequenced with RLP-224, BCB059	159	\N	RNA-392
469	RLP-163	2023-03-10 00:00:00-08	0.83	5	0.93	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-34; Sequenced with RLP-225, BCB064	160	\N	RNA-394
530	AMLP-13	2018-05-08 00:00:00-07	4.8	41	2	\N	250	\N	\N	\N	\N	H1	\N	AM2 D-62
470	RLP-164	2023-03-10 00:00:00-08	0.56	17	0.51	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-32; Sequenced with RLP-226, BCB059	161	\N	RNA-396
471	RLP-166	2023-03-10 00:00:00-08	1.26	43	1.5	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-29; Sequenced with RLP-228, BCB059	163	\N	RNA-401
472	RLP-167	2023-03-10 00:00:00-08	0.99	45	0.95	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-29; Sequenced with RLP-229, BCB059	164	\N	RNA-402
473	RLP-168	2023-03-10 00:00:00-08	0.34	28	0.36	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; ; KAPAEX-31; Sequenced with RLP-230, BCB063	165	\N	RNA-404
474	RLP-169	2023-03-10 00:00:00-08	0.47	58	0.61	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-31; Sequenced with RLP-231, BCB063	166	\N	RNA-405
475	RLP-237	2023-07-18 00:00:00-07	0.57	45	0.62	8	135	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-31; Sequenced with RLP-256, BCB063	172	\N	RNA-431
476	RLP-238	2023-07-18 00:00:00-07	0.75	45	0.76	8	199	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-31; Sequenced with RLP-250, BCB063	173	\N	RNA-432
477	RLP-240	2023-07-18 00:00:00-07	0.58	31	0.6	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-32; Sequenced with RLP-257, BCB059	175	\N	RNA-434
478	RLP-243	2023-07-18 00:00:00-07	1.53	5	1.94	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-33; Sequenced with RLP-251, BCB061	178	\N	RNA-439
479	RLP-244	2023-07-18 00:00:00-07	1.26	21	1.55	8	188	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-33; Sequenced with RLP-252, BCB061	179	\N	RNA-440
480	RLP-245	2023-07-18 00:00:00-07	1.4	21	1.78	8	175	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-30; Sequenced with RLP-253, BCB062	180	\N	RNA-441
481	RLP-246	2023-07-18 00:00:00-07	1.39	20	1.73	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; KAPAEX-34; Sequenced with RLP-254, BCB064	181	\N	RNA-443
482	RLP-247	2023-07-18 00:00:00-07	1.02	14	1.14	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; ; KAPAEX-30; Sequenced with RLP-255, BCB062	182	\N	RNA-444
483	RNA-10	2018-08-20 00:00:00-07	1.9	11	1.2	11	400	\N	\N	\N	RLP-10	E11	\N	RNA-10
484	RNA-19	2018-08-20 00:00:00-07	1.6	17	1.1	11	400	\N	\N	\N	RLP-19, Sample removed from study	D10	\N	RNA-19
485	RNA-20	2018-08-20 00:00:00-07	2.8	20	1.4	11	280	\N	\N	\N	RLP-20, Sample removed from study	D12	\N	RNA-20
486	RNA-23	2018-08-20 00:00:00-07	0.6	4	0.4	11	400	\N	\N	\N	RLP-23	E10	\N	RNA-23
487	RPA_09_0209	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hunter, Desmoplastic Melanoma Amplicon Sequence	L2DR16	\N	RPA_09_0209_NA
488	Seider_Roe	\N	\N	Infinity	\N	\N	35.4	\N	\N	\N	Seider Uveal Melanoma	L2DR08	\N	Seider_Roe_NA
489	Seider_Uveal Melanoma	\N	\N	Infinity	\N	\N	44.3	\N	\N	\N	Seider Uveal Melanoma	L2DR06	\N	Seider_Uveal Melanoma_NA
490	SGLP-0361	2018-12-20 00:00:00-08	0	48	0	4	17.6	\N	\N	\N	\N	78	\N	SM D-06
491	SGLP-0419	2019-05-07 00:00:00-07	0.4	181	0.09	\N	25.4	\N	\N	\N	Not enough LP	24	\N	LN D-028 (LN-028)
492	SGLP-0435	2019-05-07 00:00:00-07	0.43	48	0.05	\N	30.4	\N	\N	\N	Not enough LP	39	\N	LN D-044 (LN-044)
493	SGLP-0472	2019-06-04 00:00:00-07	0.32	49	0.04	4	23	\N	\N	\N	Not enough LP	65	\N	CM D-18
494	SGLP-0476	2019-06-04 00:00:00-07	9.94	26	0	4	250	\N	\N	\N	Not enough LP; High Melanin	69	\N	CM D-23
495	SGLP-0483	2019-06-06 00:00:00-07	3.35	17	0.01	4	250	\N	\N	\N	Not enough LP; High Melanin	76	\N	CM D-31
496	SGLP-0494	2019-06-06 00:00:00-07	1	43	0	4	250	\N	\N	\N	Not enough LP	87	\N	CM D-42
497	SGLP-0551	2019-07-24 00:00:00-07	2.37	74	0	4	250	\N	\N	\N	Madrid Melanoma	68	\N	MDD-78
498	Sk-Mel-23	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR01	\N	Thomas_SK_Mel23
499	SKMEL5-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	SKMEL5-1_NA
500	SKMEL5-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	SKMEL5-2_NA
501	SKMEL5-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	SKMEL5-3_NA
502	SKMEL28-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	SKMEL28-1_NA
503	SKMEL28-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	SKMEL28-2_NA
504	SKMEL28-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	SKMEL28-3_NA
505	Thomas_SK_MEL_23	\N	\N	Infinity	\N	\N	45.7	\N	\N	\N	SKMEL23(Cell Line)	L2DR01	\N	Thomas_SK_MEL_23_NA
506	UM_1	\N	\N	0	\N	\N	\N	\N	\N	\N	Tert 1, Tert 2, and Tert 3 spike-in at 10pg/ul; SF3B1 1 and SF3B1 2 spike-in at 4pg/ul; NFKBIE spike-in at 10pg/ul\n	\N	\N	UM1_NA
507	UM_2	\N	\N	0	\N	\N	\N	\N	\N	\N	Tert 1, Tert 2, and Tert 3 spike-in at 10pg/ul; SF3B1 1 and SF3B1 2 spike-in at 4pg/ul; NFKBIE spike-in at 10pg/ul\n	\N	\N	UM2_NA
508	VS-01	2022-07-21 00:00:00-07	3.18	\N	2.37	18	\N	\N	\N	\N	SI-TS-A1	SI-TS-A1	\N	VS-01_NA
509	VS-02	2022-07-21 00:00:00-07	2.4	\N	1.98	16	\N	\N	\N	\N	SI-TS-A2	SI-TS-A2	\N	VS-02_NA
510	VS-03	2022-07-21 00:00:00-07	2.72	\N	2.67	18	\N	\N	\N	\N	SI-TS-A3	SI-TS-A3	\N	VS-03_NA
511	VS-04	2022-07-21 00:00:00-07	2.82	\N	2.54	18	\N	\N	\N	\N	SI-TS-A4	SI-TS-A4	\N	VS-04_NA
512	VS-05	2023-10-06 00:00:00-07	1.07	\N	0.72	16	\N	\N	\N	\N	LOT #: 164486	SI-TS-A5	\N	VS-05_NA
513	VS-06	2023-10-06 00:00:00-07	1.8	\N	1.23	14	\N	\N	\N	\N	LOT #: 164486	SI-TS-A6	\N	VS-06_NA
514	VS-07	2023-10-06 00:00:00-07	1.02	\N	0.57	15	\N	\N	\N	\N	LOT #: 164486	SI-TS-A7	\N	VS-07_NA
515	VS-08	2023-10-06 00:00:00-07	1.95	\N	0.69	14	\N	\N	\N	\N	LOT #: 164486	SI-TS-A8	\N	VS-08_NA
516	AGLP-01	2018-04-26 00:00:00-07	90.4	9	167.2	\N	250	\N	\N	\N	SureSelect Library Prep	AGXTHS-01	\N	AM2 D-37
517	AGLP-02	2018-04-26 00:00:00-07	118	1	231.5	\N	250	\N	\N	\N	SureSelect Library Prep	AGXTHS-02	\N	AM2 D-39
518	AMLP-01	2018-05-08 00:00:00-07	5.6	9	2.1	\N	250	\N	\N	\N	\N	G1	\N	AM2 D-37
519	AMLP-02	2018-05-08 00:00:00-07	6.7	1	3	\N	250	\N	\N	\N	\N	G2	\N	AM2 D-39
520	AMLP-03	2018-05-08 00:00:00-07	11	5	6.3	\N	250	\N	\N	\N	\N	G3	\N	AM2 D-40
521	AMLP-04	2018-05-08 00:00:00-07	3.6	5	1.3	\N	250	\N	\N	\N	\N	G4	\N	AM2 D-42
522	AMLP-05	2018-05-08 00:00:00-07	7.4	35	1.7	\N	250	\N	\N	\N	\N	G5	\N	AM2 D-47
523	AMLP-06	2018-05-08 00:00:00-07	5	4	2	\N	250	\N	\N	\N	\N	G6	\N	AM2 D-48
524	AMLP-07	2018-05-08 00:00:00-07	9.8	29	3.3	\N	250	\N	\N	\N	\N	G7	\N	AM2 D-49
525	AMLP-08	2018-05-08 00:00:00-07	10.7	17	4.3	\N	250	\N	\N	\N	\N	G8	\N	AM2 D-51
526	AMLP-09	2018-05-08 00:00:00-07	3.7	50	0.8	\N	142	\N	\N	\N	\N	G9	\N	AM2 D-52
527	AMLP-10	2018-05-08 00:00:00-07	9.4	13	1.9	\N	250	\N	\N	\N	\N	G10	\N	AM2 D-54
528	AMLP-11	2018-05-08 00:00:00-07	4.1	25	1.3	\N	250	\N	\N	\N	\N	G11	\N	AM2 D-59
529	AMLP-12	2018-05-08 00:00:00-07	5	2	1	\N	250	\N	\N	\N	\N	G12	\N	AM2 D-61
531	AMLP-14	2018-05-08 00:00:00-07	3	4	1.7	\N	250	\N	\N	\N	\N	H2	\N	AM2 D-65
532	AMLP-15	2018-05-08 00:00:00-07	8.3	45	3	\N	250	\N	\N	\N	\N	H3	\N	AM2 D-66
533	AMLP-16	2018-05-08 00:00:00-07	6.1	5	2.3	\N	250	\N	\N	\N	\N	H4	\N	AM2 D-69
534	AMLP-17	2018-05-08 00:00:00-07	5.3	33	1.1	\N	250	\N	\N	\N	\N	H5	\N	AM2 D-70
535	AMLP-18	2018-05-08 00:00:00-07	1.6	7	0.2	\N	250	\N	\N	\N	\N	H6	\N	AM2 D-73
536	AMLP-21	2018-05-08 00:00:00-07	6.4	2	1.9	\N	250	\N	\N	\N	\N	H9	\N	AM2 D-34
537	AMLP-22_1	2018-05-08 00:00:00-07	5.3	3	1.3	\N	250	\N	\N	\N	\N	H10	\N	AM2 D-36
538	AMLP-22_2	2018-07-23 00:00:00-07	3.2	3	0.35	\N	250	\N	\N	\N	\N	A6	\N	AM2 D-36
539	AMLP-44	2018-07-23 00:00:00-07	4.6	0	0.98	\N	\N	\N	\N	\N	\N	B7	\N	AM2 D-88
540	AMLP-46	2018-07-23 00:00:00-07	4.2	50	1.85	\N	1520	\N	\N	\N	\N	B9	\N	AM2 D-90
541	AMLP-49	2018-07-23 00:00:00-07	2.9	0	0.8	\N	\N	\N	\N	\N	\N	B12	\N	AM2 D-93
542	AMLP-66	2018-11-27 00:00:00-08	6.3	12	2.26	4	300	\N	\N	\N	\N	40	\N	AM2 D-112
543	AMLP-69	2019-02-27 00:00:00-08	4.83	31	2.26	4	300	\N	\N	\N	repeated sequencing	43	\N	AM2 D-115
544	AMLP-75	2018-11-27 00:00:00-08	4.85	48	2.14	4	298.6	\N	\N	\N	\N	49	\N	AM2 D-120
545	AMLP-77	2019-02-27 00:00:00-08	5.89	31	2.06	4	300	\N	\N	\N	repeated sequencing	51	\N	AM2 D-122
546	AMLP-87	2018-11-27 00:00:00-08	3.79	48	1.74	4	185.3	\N	\N	\N	\N	61	\N	AM2 D-132
547	AMLP-95	2018-11-30 00:00:00-08	6.33	24	4.36	4	300	\N	\N	\N	\N	21	\N	AM2 D-140
548	AMLP-96	2018-11-30 00:00:00-08	7.55	12	6.63	4	300	\N	\N	\N	\N	22	\N	AM2 D-144
549	AMLP-99	2018-11-30 00:00:00-08	7.06	8	5.59	4	300	\N	\N	\N	\N	25	\N	AM2 D-143
550	AMLP-97	2018-11-30 00:00:00-08	1.44	7	1.08	4	300	\N	\N	\N	re-LP on 2/27/19; repeated sequencing	23	\N	AM2 D-141
551	AMLP-102	2018-11-30 00:00:00-08	8.73	8	4.65	4	300	\N	\N	\N	\N	28	\N	AM2 D-150
552	AMLP-107	2018-11-30 00:00:00-08	6.33	14	3.78	4	300	\N	\N	\N	\N	33	\N	AM2 D-156
553	AMLP-109	2018-11-30 00:00:00-08	6.63	14	3.92	4	300	\N	\N	\N	\N	35	\N	AM2 D-158
554	AMLP-110	2018-11-30 00:00:00-08	7.85	28	5.7	4	300	\N	\N	\N	re-LP on 2/27/19; repeated sequencing	36	\N	AM2 D-159
555	AMLP-113	2018-11-30 00:00:00-08	7.14	10	5.46	4	300	\N	\N	\N	\N	91	\N	AM2 D-162
556	AMLP-114	2018-11-30 00:00:00-08	7.91	37	5.7	4	300	\N	\N	\N	\N	92	\N	AM2 D-163
557	AMLP-117	2018-12-07 00:00:00-08	\N	8	1.07	4	300	\N	\N	\N	repeated sequencing	95	\N	AM2 D-166
558	AMLP-30	\N	\N	3	9.3	\N	350	\N	\N	\N	\N	H8	\N	AM2 D-41
559	AMLP-41	\N	\N	4	3.2	\N	350	\N	\N	\N	\N	B3	\N	AM2 D-86
560	AMLP-45	2018-07-23 00:00:00-07	4.4	0	2.17	\N	\N	\N	\N	\N	\N	B8	\N	AM2 D-89
561	AMLP-125	2019-06-04 00:00:00-07	5.62	41	1.91	4	250	\N	\N	\N	\N	71	\N	AM2 D-35
562	AMLP-126	2019-12-03 00:00:00-08	13.7	5	2.45	3	250	\N	\N	\N	120s shear time; DNA repaired	40	\N	AM2 D-33
563	AMLP-127	2019-12-03 00:00:00-08	14.3	25	1.63	3	999	\N	\N	\N	120s shear time; DNA repaired	41	\N	AM2 D-185
564	AMLP-128	2019-12-03 00:00:00-08	11.3	46	2.09	3	999	\N	\N	\N	120s shear time; DNA repaired	48	\N	AM2 D-184
565	AMLP-130	2019-12-03 00:00:00-08	9.21	3	1.73	3	250	\N	\N	\N	120s shear time; DNA repaired	51	\N	AM2 D-36
566	AMLP-131	2019-12-03 00:00:00-08	20.6	23	1.3	3	999	\N	\N	\N	120s shear time; DNA repaired	52	\N	AM2 D-183
567	AMLP-132	2019-12-03 00:00:00-08	10.3	50	4.28	3	1520	\N	\N	\N	120s shear time; DNA repaired	53	\N	AM2 D-90
568	AMLP-133	2019-12-03 00:00:00-08	7.94	0	2.97	3	\N	\N	\N	\N	120s shear time; DNA repaired	54	\N	AM2 D-98
569	AMLP-135	2019-12-03 00:00:00-08	18.8	6	2.42	3	300	\N	\N	\N	120s shear time; DNA repaired	56	\N	AM2 D-135
570	AMLP-137	2019-12-03 00:00:00-08	14.8	8	4.8	3	300	\N	\N	\N	120s shear time; DNA repaired	67	\N	AM2 D-143
571	AMLP-140	2019-12-03 00:00:00-08	11.8	10	4.02	3	300	\N	\N	\N	120s shear time; DNA repaired	74	\N	AM2 D-162
572	AMLP-142	2019-12-03 00:00:00-08	13.5	8	3.52	3	300	\N	\N	\N	120s shear time; DNA repaired	76	\N	AM2 D-166
573	AMLP-147	2019-12-03 00:00:00-08	9.9	32	2.49	3	999	\N	\N	\N	120s shear time; DNA repaired	81	\N	AM2 D-179
574	AMLP-149	2019-12-03 00:00:00-08	9	6	2.34	3	350	\N	\N	\N	120s shear time; DNA repaired	83	\N	AM2 D-58
575	AMLP-150	2019-12-03 00:00:00-08	24.4	2	1.63	3	250	\N	\N	\N	120s shear time; DNA repaired	84	\N	AM2 D-61
576	AMLP-151	2019-12-03 00:00:00-08	17.6	5	4.89	3	250	\N	\N	\N	120s shear time; DNA repaired	85	\N	AM2 D-69
577	AMLP-19_1	2018-05-08 00:00:00-07	5.4	7	1.1	\N	250	\N	\N	\N	\N	H7	\N	AM2 D-30
578	AMLP-19_2	2018-07-23 00:00:00-07	5.2	7	0.9	\N	250	\N	\N	\N	\N	B4	\N	AM2 D-30
579	AMLP-48	2018-07-23 00:00:00-07	4.8	0	2.13	\N	\N	\N	\N	\N	\N	B11	\N	AM2 D-92
580	AMLP-51	2018-07-23 00:00:00-07	5.1	0	3.09	\N	\N	\N	\N	\N	\N	C2	\N	AM2 D-95
581	AMLP-53	2018-07-23 00:00:00-07	4.6	11	1.91	\N	666	\N	\N	\N	\N	C4	\N	AM2 D-97
582	AMLP-55	2018-07-23 00:00:00-07	8.3	0	2.82	\N	\N	\N	\N	\N	\N	C6	\N	AM2 D-99
583	AMLP-84	2019-02-27 00:00:00-08	6.99	8	2.3	4	300	\N	\N	\N	\N	58	\N	AM2 D-129
584	AMLP-90	2018-11-27 00:00:00-08	3.81	48	1.97	4	186.2	\N	\N	\N	\N	64	\N	AM2 D-136
585	AMLP-129	2019-12-03 00:00:00-08	5.28	41	1.77	4	250	\N	\N	\N	120s shear time; DNA repaired	50	\N	AM2 D-35
586	AMLP-136	2019-12-03 00:00:00-08	5.79	24	3.14	4	300	\N	\N	\N	120s shear time; DNA repaired	66	\N	AM2 D-140
587	AMLP-138	2019-12-03 00:00:00-08	11.5	14	5.48	4	300	\N	\N	\N	120s shear time; DNA repaired	70	\N	AM2 D-156
588	AMLP-139	2019-12-03 00:00:00-08	11.4	14	5.82	4	300	\N	\N	\N	120s shear time; DNA repaired	73	\N	AM2 D-158
589	AMLP-143	2019-12-03 00:00:00-08	2.87	37	1.9	4	300	\N	\N	\N	120s shear time; DNA repaired	77	\N	AM2 D-163
590	AMLP-146	2019-12-03 00:00:00-08	7.33	0	3.66	4	\N	\N	\N	\N	120s shear time; DNA repaired. SGPC-20: 12 Cycles post Hyb, 43ng captured	80	\N	AM2 D-29
591	AMLP-148	2019-12-03 00:00:00-08	6.3	0	3.79	4	\N	\N	\N	\N	120s shear time; DNA repaired	82	\N	AM2 D-55
592	AMLP-78	2018-11-27 00:00:00-08	4.56	45	1.32	4	300	\N	\N	\N	\N	52	\N	AM2 D-123
593	AMLP-82	2018-11-27 00:00:00-08	4.67	44	0.92	4	300	\N	\N	\N	\N	56	\N	AM2 D-127
594	AMLP-156	2020-01-31 00:00:00-08	11.7	46	1.75	3	999	\N	\N	\N	120s shear time; DNA repaired	16	\N	AM2 D-184
595	AMLP-160	2020-01-31 00:00:00-08	15.6	19	2.21	3	999	\N	\N	\N	120s shear time; DNA repaired	24	\N	AM2 D-186
596	AMLP-163	2020-01-31 00:00:00-08	4.91	31	1.87	4	300	\N	\N	\N	120s shear time; DNA repaired	27	\N	AM2 D-115
597	AMLP-168	2020-01-31 00:00:00-08	6.4	31	1.16	4	300	\N	\N	\N	120s shear time; DNA repaired	79	\N	AM2 D-122
598	AMLP-169	2020-01-31 00:00:00-08	8	45	1.76	4	300	\N	\N	\N	120s shear time; DNA repaired	80	\N	AM2 D-123
599	AMLP-172-81	2020-01-31 00:00:00-08	6.29	48	1.57	4	171.8	\N	\N	\N	120s shear time; DNA repaired. Sequenced as: AMLP-172 (AMLP-172 captured 79 ng in AGEX-9; AMLP-81 captured 69 ng in AGEX-9). Same adapter #55	55	\N	AM2 D-126
600	AMLP-175	2020-02-07 00:00:00-08	5.94	46	1.41	4	999	\N	\N	\N	\N	97	\N	AM2 D-184
601	AMLP-176	2020-02-07 00:00:00-08	7.13	19	1.45	4	999	\N	\N	\N	\N	98	\N	AM2 D-186
602	AMLP-186	2020-02-07 00:00:00-08	4.78	32	1.46	4	258	\N	\N	\N	\N	108	\N	AM2 D-192
603	AMLP-195	2020-02-07 00:00:00-08	5.94	5	2	4	250	\N	\N	\N	\N	117	\N	AM2 D-33
604	AMLP-196	2020-02-07 00:00:00-08	5.17	25	1.88	4	999	\N	\N	\N	\N	118	\N	AM2 D-185
605	AMLP-197	2020-02-07 00:00:00-08	8.05	23	2.65	4	999	\N	\N	\N	\N	119	\N	AM2 D-183
606	AMLP-198	2020-02-07 00:00:00-08	4.9	0	4.2	4	\N	\N	\N	\N	\N	120	\N	AM2 D-96
607	AMLP-58	\N	\N	6	4.3	\N	250	\N	\N	\N	\N	C11	\N	AM2 D-103
608	AMLP-61	\N	2.8	2	4	\N	250	\N	\N	\N	\N	D2	\N	AM2 D-107
609	AMLP-64	\N	\N	8	1.7	\N	250	\N	\N	\N	\N	F4	\N	AM2 D-110
610	AMLP-105	2018-11-30 00:00:00-08	2.03	48	0.82	4	91.7	\N	\N	\N	\N	31	\N	AM2 D-154
611	AMLP-123	2018-12-07 00:00:00-08	\N	9	0.67	4	300	\N	\N	\N	\N	5	\N	AM2 D-174
612	AMLP-174	2020-01-31 00:00:00-08	6.3	23	4.58	4	300	\N	\N	\N	120s shear time; DNA repaired	94	\N	AM2 D-165
613	AMLP-178	2020-02-07 00:00:00-08	7.15	8	2.6	4	300	\N	\N	\N	\N	100	\N	AM2 D-129
614	AMLP-179	2020-02-07 00:00:00-08	15.8	6	2.97	4	300	\N	\N	\N	\N	101	\N	AM2 D-130
615	AMLP-180	2020-02-07 00:00:00-08	2.91	48	0.77	4	186.2	\N	\N	\N	\N	102	\N	AM2 D-136
616	AMLP-181	2020-02-07 00:00:00-08	7.91	8	2.38	4	300	\N	\N	\N	\N	103	\N	AM2 D-150
617	AMLP-184	2020-02-07 00:00:00-08	5.88	28	1.31	4	300	\N	\N	\N	\N	106	\N	AM2 D-153
618	AMLP-185	2020-02-07 00:00:00-08	4.72	48	1.38	4	91.7	\N	\N	\N	\N	107	\N	AM2 D-154
619	AMLP-191	2020-02-07 00:00:00-08	7.57	96	1.71	4	259	\N	\N	\N	\N	113	\N	AM2 D-193
620	AMLP-194	2020-02-07 00:00:00-08	6.12	9	1.12	4	300	\N	\N	\N	\N	116	\N	AM2 D-174
621	AMLP-104	2018-11-30 00:00:00-08	5.85	28	2.78	4	300	\N	\N	\N	re-LP on 2/27/19; repeated sequencing	30	\N	AM2 D-153
622	AMLP-85	2018-11-27 00:00:00-08	16.5	6	3.63	4	300	\N	\N	\N	\N	59	\N	AM2 D-130
623	AMLP-68	2018-11-27 00:00:00-08	2.64	48	1.09	4	195.4	\N	\N	\N	\N	42	\N	AM2 D-114
624	AMLP-83	2018-11-27 00:00:00-08	4.08	48	1.52	4	273.1	\N	\N	\N	\N	57	\N	AM2 D-128
625	AMLP-88	2018-11-27 00:00:00-08	5.16	48	2	4	272.6	\N	\N	\N	\N	62	\N	AM2 D-133
626	AMLP-93	2018-11-30 00:00:00-08	6.06	48	2.55	4	277	\N	\N	\N	\N	19	\N	AM2 D-138
627	AMLP-112	2018-11-30 00:00:00-08	5.07	48	5.07	4	214.1	\N	\N	\N	\N	38	\N	AM2 D-161
628	AMLP-121	2018-12-07 00:00:00-08	\N	48	0.54	4	138.2	\N	\N	\N	\N	3	\N	AM2 D-172
629	AMLP-153	2020-01-31 00:00:00-08	6.98	0	2.3	4	\N	\N	\N	\N	120s shear time; DNA repaired	11	\N	AM2 D-32
630	AMLP-162	2020-01-31 00:00:00-08	2.98	48	1.14	4	195.4	\N	\N	\N	120s shear time; DNA repaired	26	\N	AM2 D-114
631	AMLP-170	2020-01-31 00:00:00-08	9.06	48	2.38	4	73.9	\N	\N	\N	120s shear time; DNA repaired	81	\N	AM2 D-124
632	AMLP-173	2020-01-31 00:00:00-08	6.56	48	3.4	4	224.2	\N	\N	\N	120s shear time; DNA repaired. Accidentally added an excess of 71 ng in the capture.	93	\N	AM2 D-164
633	AMLP-177	2020-02-07 00:00:00-08	2.93	48	0.85	4	273.1	\N	\N	\N	\N	99	\N	AM2 D-128
634	AMLP-192	2020-02-07 00:00:00-08	7.27	96	1.98	4	328	\N	\N	\N	\N	114	\N	AM2 D-194
635	AMLP-199	2020-08-02 00:00:00-07	7.1	\N	4.68	4	\N	\N	\N	\N	Accidentally added an excess of 154 ng in the capture.	134	\N	AM2 D-24,AM2 D-225
636	AMLP-76-164	2018-11-27 00:00:00-08	3.19	48	1.22	4	145.9	\N	\N	\N	Sequenced as: AMLP-76. 120s shear time; DNA repaired (AMLP-164 captured 10ng, AGEX-12). (AMLP-76 captured 61.0 ng in AGEX-12). Same adapter #50. AMLP-164: 1/31/2020	50	\N	AM2 D-121
637	AMLP-80	2018-11-27 00:00:00-08	2.6	48	0.45	4	193.4	\N	\N	\N	\N	54	\N	AM2 D-125
638	AMLP-91	2018-11-30 00:00:00-08	1.44	48	0.8	4	48	\N	\N	\N	\N	17	\N	AM2 D-134
639	AMLP-92	2018-11-30 00:00:00-08	2.68	48	1.34	4	124.8	\N	\N	\N	\N	18	\N	AM2 D-137
640	AMLP-103	2018-11-30 00:00:00-08	1.28	48	0.51	4	54.2	\N	\N	\N	\N	29	\N	AM2 D-151
641	AMLP-108	2018-11-30 00:00:00-08	2.81	48	1.72	4	102.2	\N	\N	\N	\N	34	\N	AM2 D-157
642	AMLP-165	2020-01-31 00:00:00-08	5.76	0	1.77	4	\N	\N	\N	\N	120s shear time; DNA repaired	73	\N	AM2 D-190
643	AMLP-171	2020-01-31 00:00:00-08	4.54	48	0.81	4	193.4	\N	\N	\N	120s shear time; DNA repaired	86	\N	AM2 D-125
644	AMLP-182	2020-02-07 00:00:00-08	5.98	48	1.2	4	54.2	\N	\N	\N	\N	104	\N	AM2 D-151
645	AMLP-204	2020-08-02 00:00:00-07	6.83	32	4.17	4	999	\N	\N	\N	\N	139	\N	AM2 D-179
646	AMLP-210	2020-08-06 00:00:00-07	3.2	20	1.54	4	333	\N	\N	\N	\N	145	\N	AM2 D-202
647	AMLP-231	2020-08-06 00:00:00-07	4.53	9	2.1	4	300	\N	\N	\N	\N	166	\N	AM2 D-174
648	AMLP-29	\N	\N	3	2.6	\N	350	\N	\N	\N	\N	H7	\N	AM2 D-38
649	AMLP-211	2020-08-06 00:00:00-07	6.01	27	3.98	4	333	\N	\N	\N	\N	146	\N	AM2 D-203
650	AMLP-214	2020-08-06 00:00:00-07	3.99	88	1.44	4	254	\N	\N	\N	\N	149	\N	AM2 D-238
651	AMLP-218	2020-08-06 00:00:00-07	3.54	\N	2.3	4	\N	\N	\N	\N	\N	153	\N	AM2 D-22,AM2 D-245
652	AMLP-219	2020-08-06 00:00:00-07	4	\N	2.6	4	\N	\N	\N	\N	\N	154	\N	AM2 D-23,AM2 D-246,AM2 D-254
836	N3_9	\N	\N	\N	\N	\N	\N	\N	\N	\N	73010|Tumor Melanoma, Mucosal vulva	L2DR09	\N	N3_9_NA
653	AMLP-267	2021-03-17 00:00:00-07	9.81	32	2.72	4	333	\N	\N	\N	\N	133	\N	AM2 D-372
654	AMLP-269	2021-03-17 00:00:00-07	5.79	17	1.66	4	333	\N	\N	\N	\N	135	\N	AM2 D-379
655	AMLP-289	2021-03-17 00:00:00-07	6.57	30	2.49	4	333	\N	\N	\N	\N	173	\N	AM2 D-423
656	AMLP-290	2021-03-17 00:00:00-07	5.77	\N	1.37	4	\N	\N	\N	\N	\N	174	\N	AM2 D-426,AM2 D-428
657	AMLP-291	2021-03-17 00:00:00-07	5.17	136	1.63	4	333	\N	\N	\N	\N	175	\N	AM2 D-430
658	AMLP-240	2021-03-17 00:00:00-07	11.1	29	2.26	4	333	\N	\N	\N	\N	103	\N	AM2 D-295
659	AMLP-247	2021-03-17 00:00:00-07	6.8	31	1.59	4	333	\N	\N	\N	\N	112	\N	AM2 D-318
660	AMLP-263	2021-03-17 00:00:00-07	23.9	7	11.26	4	333	\N	\N	\N	\N	129	\N	AM2 D-412
661	AMLP-264	2021-03-17 00:00:00-07	6.56	95	1.57	4	291.7	\N	\N	\N	\N	130	\N	AM2 D-369
662	AMLP-265	2021-03-17 00:00:00-07	6.77	95	2.26	4	268.9	\N	\N	\N	\N	131	\N	AM2 D-370
663	AMLP-266	2021-03-17 00:00:00-07	7.95	45	3.52	4	333	\N	\N	\N	\N	132	\N	AM2 D-371
664	AMLP-268	2021-03-17 00:00:00-07	6.09	44	1.68	4	333	\N	\N	\N	\N	134	\N	AM2 D-378
665	AMLP-238	2021-03-17 00:00:00-07	6.64	22	1.28	4	333	\N	\N	\N	\N	101	\N	AM2 D-367
666	AMLP-241	2021-03-17 00:00:00-07	5.71	83	0.86	4	333	\N	\N	\N	\N	104	\N	AM2 D-308
667	AMLP-245	2021-03-17 00:00:00-07	4.36	\N	0.33	4	\N	\N	\N	\N	\N	109	\N	AM2 D-410,AM2 D-411,AM2 D-360
668	AMLP-252	2021-03-17 00:00:00-07	5.82	61	0.16	4	333	\N	\N	\N	\N	118	\N	AM2 D-328
669	AMLP-256	2021-03-17 00:00:00-07	5.49	74	1.05	4	333	\N	\N	\N	\N	122	\N	AM2 D-332
670	AMLP-257	2021-03-17 00:00:00-07	6.36	96	1.07	4	265	\N	\N	\N	\N	123	\N	AM2 D-333
671	AMLP-259	2021-03-17 00:00:00-07	5.4	96	1.26	4	189	\N	\N	\N	\N	125	\N	AM2 D-340
672	AMLP-261	2021-03-17 00:00:00-07	6.23	\N	0.91	4	\N	\N	\N	\N	\N	127	\N	AM2 D-342,AM2 D-343
673	AMLP-237	2021-03-17 00:00:00-07	3.2	95	0.39	4	116.9	\N	\N	\N	\N	100	\N	AM2 D-293
674	AMLP-272	2021-03-17 00:00:00-07	4.09	95	1.18	4	103	\N	\N	\N	\N	145	\N	AM2 D-434
675	AMLP-295	2021-04-07 00:00:00-07	5.38	35	1.25	4	333	\N	\N	\N	\N	179	\N	AM2 D-316
676	AMLP-296	2021-04-07 00:00:00-07	4.58	0	2.38	4	\N	\N	\N	\N	\N	180	\N	AM2 D-317
677	AMLP-298	2021-04-07 00:00:00-07	3.96	61	0.97	4	333	\N	\N	\N	\N	182	\N	AM2 D-328
678	AMLP-299	2021-04-07 00:00:00-07	7.25	9	5.22	4	333	\N	\N	\N	\N	183	\N	AM2 D-365
679	AMLP-273	2021-03-17 00:00:00-07	6.15	95	1.78	4	238.5	\N	\N	\N	\N	147	\N	AM2 D-435
680	AMLP-274	2021-03-17 00:00:00-07	5.19	95	1.66	4	165.3	\N	\N	\N	\N	148	\N	AM2 D-436
681	AMLP-275	2021-03-17 00:00:00-07	8.54	190	1.77	4	205.2	\N	\N	\N	\N	152	\N	AM2 D-437
682	AMLP-277	2021-03-17 00:00:00-07	8.08	190	3.16	4	317	\N	\N	\N	\N	160	\N	AM2 D-399
683	AMLP-279	2021-03-17 00:00:00-07	7.03	9	2.43	4	333	\N	\N	\N	\N	162	\N	AM2 D-401
684	AMLP-200	2020-08-02 00:00:00-07	3.91	\N	1.86	4	\N	\N	\N	\N	\N	135	\N	AM2 D-26,AM2 D-226
685	AMLP-221	2020-08-06 00:00:00-07	1.28	96	0.8	4	67	\N	\N	\N	\N	156	\N	AM2 D-217
686	AMLP-222	2020-08-06 00:00:00-07	3.52	29	1.8	4	583	\N	\N	\N	\N	157	\N	AM2 D-218
687	AMLP-224	2020-08-06 00:00:00-07	4.28	\N	1.6	4	\N	\N	\N	\N	\N	159	\N	AM2 D-220,AM2 D-253
688	AMLP-225	2020-08-06 00:00:00-07	2.36	96	0.8	4	227	\N	\N	\N	\N	160	\N	AM2 D-221
689	AMLP-226	2020-08-06 00:00:00-07	3.31	49	1.2	4	333	\N	\N	\N	\N	161	\N	AM2 D-222
690	AMLP-227	2020-08-06 00:00:00-07	7.32	80	5.1	4	333	\N	\N	\N	\N	162	\N	AM2 D-223
691	AMLP-217	2020-08-06 00:00:00-07	3.99	\N	2.8	4	\N	\N	\N	\N	\N	152	\N	AM2 D-21,AM2 D-244
692	AMLP-206	2020-08-02 00:00:00-07	5.29	\N	3.3	4	\N	\N	\N	\N	RE-CAPTURED 6/4/21, 10 cycles, XT HS baits, 45 ng library	141	\N	AM2 D-199,AM2 D-233
693	AMLP-208	2020-08-02 00:00:00-07	3.27	88	2.75	4	63	\N	\N	\N	RE-CAPTURED 6/4/21, 10 cycles, XT HS baits, 50 ng library	143	\N	AM2 D-236
694	AMLP-220	2020-08-06 00:00:00-07	6.96	\N	3.9	4	\N	\N	\N	\N	RE-CAPTURED 6/4/21, 10 cycles, XT HS baits, 65 ng library	155	\N	AM2 D-247,AM2 D-251
695	AMLP-254	2021-03-17 00:00:00-07	8.95	9	0.82	4	333	\N	\N	\N	\N	120	\N	AM2 D-365
696	AMLP-255	2021-03-17 00:00:00-07	9.19	8	1.19	4	333	\N	\N	\N	\N	121	\N	AM2 D-331
697	AMLP-262	2021-03-17 00:00:00-07	6.32	57	0.96	4	333	\N	\N	\N	\N	128	\N	AM2 D-347
698	AMLP-280	2021-03-17 00:00:00-07	7.14	8	3.23	4	333	\N	\N	\N	\N	163	\N	AM2 D-402
699	AMLP-282	2021-03-17 00:00:00-07	4.32	75	1.43	4	333	\N	\N	\N	\N	165	\N	AM2 D-405
700	AMLP-292	2021-03-17 00:00:00-07	11.3	45	2.81	4	333	\N	\N	\N	\N	176	\N	AM2 D-441
701	AMLP-293	2021-03-17 00:00:00-07	3.25	95	1.19	4	115.9	\N	\N	\N	\N	177	\N	AM2 D-443
702	AMLP-312	2021-05-20 00:00:00-07	10.2	33	3.17	4	333	\N	\N	\N	\N	115	\N	AM2 D-457
703	AMLP-318	2021-05-20 00:00:00-07	5.47	61	2.44	4	333	\N	\N	\N	\N	145	\N	AM2 D-464
704	AMLP-320	2021-05-20 00:00:00-07	1.25	95	2.28	4	118.8	\N	\N	\N	\N	150	\N	AM2 D-466
705	AMLP-300	2021-04-07 00:00:00-07	9.25	8	5.1	4	333	\N	\N	\N	70 ng in AGEX-22	184	\N	AM2 D-331
706	AMLP-278	2021-03-17 00:00:00-07	5.44	87	1.64	4	333	\N	\N	\N	\N	161	\N	AM2 D-400
707	AMLP-281	2021-03-17 00:00:00-07	1.23	95	0.19	4	84.6	\N	\N	\N	\N	164	\N	AM2 D-404
708	AMLP-283	2021-03-17 00:00:00-07	2.49	\N	0.68	4	\N	\N	\N	\N	\N	166	\N	AM2 D-406,AM2 D-407
709	AMLP-285	2021-03-17 00:00:00-07	4.38	84	1.34	4	333	\N	\N	\N	\N	169	\N	AM2 D-419
710	AMLP-286	2021-03-17 00:00:00-07	3.53	95	1.06	4	214	\N	\N	\N	\N	170	\N	AM2 D-420
711	AMLP-287	2021-03-17 00:00:00-07	2.91	95	0.75	4	177	\N	\N	\N	\N	171	\N	AM2 D-421
712	AMLP-288	2021-03-17 00:00:00-07	5	9	1.39	4	333	\N	\N	\N	\N	172	\N	AM2 D-422
713	AMLP-250	2021-03-17 00:00:00-07	3.44	96	0.22	4	141.1	\N	\N	\N	\N	116	\N	AM2 D-322
714	AMLP-310	2021-05-20 00:00:00-07	1.68	95	1.68	4	159	\N	\N	\N	\N	110	\N	AM2 D-455
715	AMLP-314	2021-05-20 00:00:00-07	19	18	3.52	4	333	\N	\N	\N	\N	135	\N	AM2 D-459
716	AMLP-315	2021-05-20 00:00:00-07	9.94	34	2.89	4	333	\N	\N	\N	\N	141	\N	AM2 D-460
717	AMLP-316	2021-05-20 00:00:00-07	7.76	43	2.66	4	333	\N	\N	\N	\N	142	\N	AM2 D-461
718	AMLP-321	2021-05-27 00:00:00-07	1.79	191	0.93	4	105	\N	\N	\N	\N	105	\N	AM2 D-467
719	AMLP-322	2021-05-27 00:00:00-07	4.3	43	2.46	4	333	\N	\N	\N	\N	151	\N	AM2 D-468
720	AMLP-323	2021-05-27 00:00:00-07	4.36	180	1.87	4	333	\N	\N	\N	\N	153	\N	AM2 D-470
721	AMLP-331	2021-05-27 00:00:00-07	6.33	64	5.7	4	333	\N	\N	\N	\N	180	\N	AM2 D-478
722	AMLP-301	2021-04-07 00:00:00-07	4.59	57	3.03	4	333	\N	\N	\N	42 ng in AGEX-25	185	\N	AM2 D-347
723	AMLP-324	2021-05-27 00:00:00-07	2.99	96	0.94	4	490	\N	\N	\N	\N	154	\N	AM2 D-260
724	AMLP-325	2021-05-27 00:00:00-07	1.76	95	0.88	4	100	\N	\N	\N	\N	155	\N	AM2 D-471
725	AMLP-326	2021-05-27 00:00:00-07	2.83	95	1.36	4	150	\N	\N	\N	\N	156	\N	AM2 D-472
726	AMLP-327	2021-05-27 00:00:00-07	2.55	95	1.42	4	130	\N	\N	\N	\N	157	\N	AM2 D-474
727	AMLP-330	2021-05-27 00:00:00-07	3.15	95	2.69	4	121	\N	\N	\N	\N	179	\N	AM2 D-476
728	AMLP-332	2021-05-27 00:00:00-07	0.98	95	0.38	4	61	\N	\N	\N	\N	183	\N	AM2 D-480
729	AMLP-248	2021-03-17 00:00:00-07	4.13	\N	0.37	4	\N	\N	\N	\N	\N	113	\N	AM2 D-320,AM2 D-361
730	AMLP-249	2021-03-17 00:00:00-07	2.95	95	0.27	4	115.9	\N	\N	\N	\N	114	\N	AM2 D-362
731	AMLP-302	2021-04-07 00:00:00-07	5.08	54	1.9	4	333	\N	\N	\N	\N	186	\N	AM2 D-446
732	AMLP-303	2021-05-13 00:00:00-07	4.97	95	1.67	4	249	\N	\N	\N	\N	136	\N	AM2 D-448
733	AMLP-304	2021-05-13 00:00:00-07	2.25	95	0.58	4	180	\N	\N	\N	\N	137	\N	AM2 D-452
734	AMLP-307	2021-05-13 00:00:00-07	2.93	95	0.73	4	228	\N	\N	\N	\N	144	\N	AM2 D-454
735	AMLP-111	2018-11-30 00:00:00-08	4.33	48	3.42	4	101.3	\N	\N	\N	\N	37	\N	AM2 D-160
736	AMLP-161	2020-01-31 00:00:00-08	5.58	39	2.26	4	300	\N	\N	\N	120s shear time; DNA repaired	25	\N	AM2 D-113
737	AMLP-193	2020-02-07 00:00:00-08	4.5	96	1.4	4	228	\N	\N	\N	\N	115	\N	AM2 D-195
738	AMLP-284	2021-03-17 00:00:00-07	2.47	95	0.89	4	91.4	\N	\N	\N	\N	168	\N	AM2 D-408
739	AMLP-305-306	2021-05-13 00:00:00-07	3.2	380	1.75	4	278	\N	\N	\N	Merged AMLP-305 (91.7ng captured in AGEX-27), and AMLP-306 (83.4ng captured in AGEX-28; 302bp size) and submitted as AMLP-305 in BCB031. Same adapter #138.	138	\N	AM2 D-453
740	AMLP-347	2021-09-15 00:00:00-07	6.51	78	5.79	4	1200	\N	\N	\N	HyperPREP; Ligation: 15 min at 20 oC	97	\N	AM2 D-381
741	AMLP-348	2021-09-15 00:00:00-07	5.09	51	4.7	4	1200	\N	\N	\N	HyperPREP; Ligation: 15 min at 20 oC	98	\N	AM2 D-431
742	AMLP-367	2021-09-18 00:00:00-07	6.8	63	5.32	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	104	\N	AM2 D-382
743	AMLP-375-1	2021-09-27 00:00:00-07	2.2	37	4.52	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	105	\N	AM2 D-486-1
744	AMLP-202	2020-08-02 00:00:00-07	5.73	\N	3.36	4	\N	\N	\N	\N	\N	137	\N	AM2 D-28,AM2 D-228
745	AMLP-203	2020-08-02 00:00:00-07	9.32	\N	6.67	4	\N	\N	\N	\N	\N	138	\N	AM2 D-29,AM2 D-229
746	AMLP-373	2021-09-27 00:00:00-07	3.79	50	2.46	4	180	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	108	\N	AM2 D-488
747	AMLP-201	2020-08-02 00:00:00-07	9.49	\N	5.61	4	\N	\N	\N	\N	AGEX-30: 150ng, SSXTHS Hu All Exon V7	136	\N	AM2 D-27,AM2 D-227
748	AMLP-349-352	2021-09-15 00:00:00-07	3.34	148	1.75	4	1200	\N	\N	\N	Sequenced as: AMLP-349; HyperPREP; Ligation: 60 min at 20 oC., HyperPREP; Ligation: 15 min at 20 oC. AMLP-349: capture 87.5 ng in AGEX-29. AMLP-352: capture 81.0 ng in AGEX-30.	99	\N	AM2 D-485
749	Buffy_Coat	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	Buffy Coat Derived DNA	NF-96-28	\N	D43_NA_BC
750	H12_22776_B5_Norm	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	Melanoma, Acral; Biopsy site w/residual Acral,Toe web	NF-96-27	\N	D41_NA
751	T12_562	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	None	NF-96-10	\N	D13_NA
752	T12_6261A	2012-05-14 00:00:00-07	\N	50	10.24	\N	512	\N	\N	\N	None	NF-96-1	\N	D1_NA
753	T12_6261B	2012-05-14 00:00:00-07	\N	50	4.2	\N	210	\N	\N	\N	None	NF-96-2	\N	D2_NA
754	T12_12366	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	None	NF-96-3	\N	D6_NA
755	T12_12467	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	Hybridization Input DNA Manipulation	NF-96-4	\N	D7_NA
756	T12_12470D	2012-05-14 00:00:00-07	\N	50	9.6	\N	480	\N	\N	\N	None	NF-96-8	\N	D11_NA
757	T12_12626	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	Hybridization Input DNA Manipulation	NF-96-13	\N	D20_NA
758	T12_12647	2012-05-14 00:00:00-07	\N	50	6.6	\N	330	\N	\N	\N	None	NF-96-12	\N	D15_NA
759	T12_12750B	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	None	NF-96-18	\N	28_NA
760	T12_13152_Tumor	2012-05-14 00:00:00-07	\N	50	11.08	\N	554	\N	\N	\N	Hybridization Input DNA Manipulation	NF-96-17	\N	27_NA
761	T12_13587_B2	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	None	NF-96-14	\N	23_NA
762	T12_13587_B2_0_5ug	2012-05-14 00:00:00-07	\N	50	10	\N	500	\N	\N	\N	Diluted Input Library DNA, Samples 44-46 were dilutions made from sample 23 to test how the same template with varying input concentrations under the required 1 ug input effects sequencing. 	NF-96-30	\N	D45_NA
763	T12_13587_B2_0_25ug	2012-05-14 00:00:00-07	\N	50	5	\N	250	\N	\N	\N	Diluted Input Library DNA, Samples 44-46 were dilutions made from sample 23 to test how the same template with varying input concentrations under the required 1 ug input effects sequencing. 	NF-96-31	\N	D46_NA
764	T12_13587_B2_0_75ug	2012-05-14 00:00:00-07	\N	50	15	\N	750	\N	\N	\N	Diluted Input Library DNA, Samples 44-46 were dilutions made from sample 23 to test how the same template with varying input concentrations under the required 1 ug input effects sequencing. 	NF-96-29	\N	D44_NA
765	T12_18438A	2012-05-14 00:00:00-07	\N	50	8	\N	400	\N	\N	\N	None	NF-96-15	\N	24_NA
766	T12_19596	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	None	NF-96-19	\N	D29_NA
767	T12_21726A_Tumor	2012-05-14 00:00:00-07	\N	50	3.14	\N	157	\N	\N	\N	None; Dermatofibroma	NF-96-24	\N	38_NA
768	T12_22172_Norm	\N	\N	50	7.42	\N	371	\N	\N	\N	 Normal Tumor Pair; Bowen's Disease,Left lateral back; SCC, in situ	NF-96-22	\N	D35_NA
769	T12_22172_Tumor	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	Normal Tumor Pair; Bowen's Disease,Left lateral back; SCC, in situ	NF-96-23	\N	D36_NA
837	N3_10	\N	\N	\N	\N	\N	\N	\N	\N	\N	73010|Normal Melanoma, Mucosal vulva	L2DR10	\N	N3_10_NA
838	N3_11	\N	\N	\N	\N	\N	\N	\N	\N	\N	Need to Get diagnosis from Iwei|NTRK3 Translocation case	L2DR11	\N	N3_11_NA
770	T12_22901A_Norm	2012-05-14 00:00:00-07	\N	50	9.94	\N	497	\N	\N	\N	Normal Tumor Pair; Melanocytic Nevus; Intradermal, forehead; PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)	NF-96-25	\N	D39_NA
771	T12_22901A_Tumor	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	Normal Tumor Pair; Melanocytic Nevus; Intradermal, forehead; PREDOMINANTLY INTRADERMAL MELANOCYTIC NEVUS, COMPLETELY EXCISED (MARGINS ARE FREE OF NEOPLASM)\n	NF-96-26	\N	D40_NA
772	T12-19187A	2012-05-14 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	None	NF-96-20	\N	D31_NA
773	H12_22775	2012-06-08 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	\N	NF-96-32	\N	D43_NA_SCC
774	H12_22794A	2012-06-08 00:00:00-07	\N	26	20	\N	1000	\N	\N	\N	\N	NF-96-33	\N	D47_NA
775	T12_22573	2012-06-08 00:00:00-07	\N	50	20	\N	1000	\N	\N	\N	\N	NF-96-34	\N	D48_NA
776	T12_22582A	2012-06-08 00:00:00-07	\N	12	8.88	\N	444	\N	\N	\N	\N	NF-96-36	\N	D49_NA
777	T12_22587	2012-06-08 00:00:00-07	\N	113	15.46	\N	773	\N	\N	\N	\N	NF-96-40	\N	D51_NA
778	T12_22592	2012-06-08 00:00:00-07	\N	56	13.4	\N	670	\N	\N	\N	\N	NF-96-41	\N	D55_NA
779	T12_22597_100ng	2012-06-08 00:00:00-07	\N	50	2	\N	100	\N	\N	\N	Samples 73-76 were dilutions made from sample 58 to test how the same template with varying input concentrations ( under the required 1 ug input) effects sequencing. 	NF-96-61	\N	D75_NA
780	T12_22597_250ng	2012-06-08 00:00:00-07	\N	50	5	\N	250	\N	\N	\N	Samples 73-76 were dilutions made from sample 58 to test how the same template with varying input concentrations ( under the required 1 ug input) effects sequencing. 	NF-96-60	\N	D74_NA
781	T12_22597_500ng	2012-06-08 00:00:00-07	\N	50	10	\N	500	\N	\N	\N	Samples 73-76 were dilutions made from sample 58 to test how the same template with varying input concentrations ( under the required 1 ug input) effects sequencing. 	NF-96-59	\N	D73_NA
782	T12_22597_700ng	2012-06-08 00:00:00-07	\N	75	14	\N	700	\N	\N	\N	Samples 73-76 were dilutions made from sample 58 to test how the same template with varying input concentrations ( under the required 1 ug input) effects sequencing. \n	NF-96-58	\N	D72_NA
783	T12_22597_1000ng	2012-06-08 00:00:00-07	\N	97	20	\N	1000	\N	\N	\N	\N	NF-96-43	\N	D56_NA
784	T12_22602A	2012-06-08 00:00:00-07	\N	21	20	\N	1000	\N	\N	\N	\N	NF-96-44	\N	D58_NA
785	T12_22602B	2012-06-08 00:00:00-07	\N	26	20	\N	1000	\N	\N	\N	\N	NF-96-45	\N	D59_NA
786	T12_22603	2012-06-08 00:00:00-07	\N	12	20	\N	1000	\N	\N	\N	\N	NF-96-46	\N	D60_NA
787	T12_22604	2012-06-08 00:00:00-07	\N	7	5.56	\N	278	\N	\N	\N	\N	NF-96-47	\N	D61_NA
788	T12_22720A1	2012-06-08 00:00:00-07	\N	86	7.4	\N	370	\N	\N	\N	\N	NF-96-49	\N	D62_NA
789	T12_22868	2012-06-08 00:00:00-07	\N	176	20	\N	1000	\N	\N	\N	\N	NF-96-50	\N	D64_NA
790	T12_22884C	2012-06-08 00:00:00-07	\N	22	20	\N	1000	\N	\N	\N	\N	NF-96-51	\N	D65_NA
791	T12_22884D	2012-06-08 00:00:00-07	\N	10	4.16	\N	208	\N	\N	\N	\N	NF-96-52	\N	D66_NA
792	T12_22886	2012-06-08 00:00:00-07	\N	312	20	\N	1000	\N	\N	\N	\N	NF-96-53	\N	D67_NA
793	T12_22894B	2012-06-08 00:00:00-07	\N	8	6.06	\N	303	\N	\N	\N	\N	NF-96-55	\N	D68_NA
794	T12_22898	2012-06-08 00:00:00-07	\N	211	19.62	\N	981	\N	\N	\N	\N	NF-96-56	\N	D70_NA
795	T12_22900	2012-06-08 00:00:00-07	\N	40	12.08	\N	604	\N	\N	\N	\N	NF-96-57	\N	D71_NA
796	Bivona_L_1	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR11	\N	Bivona_L_1_NA
797	Bivona_L2	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR12	\N	Bivona_L2_NA
798	Bivona_L3	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR13	\N	Bivona_L3_NA
799	Bivona_L4	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR14	\N	Bivona_L4_NA
800	Bivona_L5	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR15	\N	Bivona_L5_NA
801	Bivona_L6	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR16	\N	Bivona_L6_NA
802	Kit_37_Acral_NRAS	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR05	\N	Kit_37_Acral_NRAS_NA
803	Kit_62__Acral_NRAS	\N	\N	Infinity	\N	\N	50	\N	\N	\N	\N	L2DR06	\N	Kit_62__Acral_NRAS_NA
804	Kit_118_Muc_NRAS	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR07	\N	Kit_118_Muc_NRAS_NA
805	Kit_181_Muc_BRAF	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR08	\N	Kit_181_Muc_BRAF_NA
806	Kit_227_Acral_WT	\N	\N	1	\N	\N	100	\N	\N	\N	\N	L2DR09	\N	Kit_227_Acral_WT_NA
807	Kit_275_Muc_BRAF	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR10	\N	Kit_275_Muc_BRAF_NA
808	PG_8	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR04	\N	PG_8_NA
809	WP_11	\N	\N	0	\N	\N	100	\N	\N	\N	Iwei Autopsy	L2DR01	\N	WP_11_NA
810	WP_23	\N	\N	1	\N	\N	100	\N	\N	\N	Iwei Autopsy	L2DR02	\N	WP_23_NA
811	WP_29	\N	\N	0	\N	\N	100	\N	\N	\N	Iwei Autopsy	L2DR03	\N	WP_29_NA
812	21_5	\N	\N	13	\N	\N	15.6	\N	\N	\N	Ivanka_21_5_Norm, RIGHT MID UPPER BACK	L2DR05	\N	21-5_NA
813	21-1	\N	\N	72	\N	\N	100	\N	\N	\N	RIGHT MID UPPER BACK	L2DR01	\N	D21-1_NA
814	21-2	\N	\N	106	\N	\N	100	\N	\N	\N	RIGHT MID UPPER BACK	L2DR02	\N	21-2_NA
815	21-3	\N	\N	74	\N	\N	100	\N	\N	\N	RIGHT MID UPPER BACK	L2DR03	\N	21-3_NA
816	21-4	\N	\N	98	\N	\N	100	\N	\N	\N	RIGHT MID UPPER BACK	L2DR04	\N	21-4_NA
817	24_5_Norm	\N	\N	14	\N	\N	12	\N	\N	\N	Ivanka_24_5_Norm, RIGHT GLUTEUS	L2DR10	\N	24-5_NA
818	24-3	\N	\N	53	\N	\N	100	\N	\N	\N	RIGHT GLUTEUS	L2DR08	\N	24-3_NA
819	24-4	\N	\N	40	\N	\N	100	\N	\N	\N	RIGHT GLUTEUS	L2DR09	\N	24-4_NA
820	28_1	\N	\N	28	\N	\N	100	\N	\N	\N	LEFT POPLITEAL FOSSA	L2DR11	\N	D28-1_NA
821	28_2	\N	\N	17	\N	\N	100	\N	\N	\N	LEFT POPLITEAL FOSSA	L2DR12	\N	D28-2_NA
822	28_3	\N	\N	120	\N	\N	37	\N	\N	\N	LEFT POPLITEAL FOSSA	L2DR13	\N	D28-3_NA
823	28_4	\N	\N	85	\N	\N	100	\N	\N	\N	LEFT POPLITEAL FOSSA	L2DR14	\N	28-4_NA
824	28_5	\N	\N	97	\N	\N	100	\N	\N	\N	LEFT POPLITEAL FOSSA	L2DR15	\N	28-5_NA
825	Ivanka_24-1_Tert	\N	\N	3	\N	\N	100	\N	\N	\N	RIGHT GLUTEUS	L2DR06	\N	24-1_NA
826	Ivanka_24-2_Tert	\N	\N	9	\N	\N	100	\N	\N	\N	RIGHT GLUTEUS	L2DR07	\N	24-2_NA
827	Kit 262	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Rectal	L2DR16	\N	Kit 262_NA
828	N3_1	\N	\N	\N	\N	\N	\N	\N	\N	\N	sp-12-3436|mucosal melanoma +EIN	L2DR01	\N	N3_1_NA
829	N3_2	\N	\N	\N	\N	\N	\N	\N	\N	\N	sp-07-8373|mucosal melanomas-non-pigmented	L2DR02	\N	N3_2_NA
830	N3_3	\N	\N	\N	\N	\N	\N	\N	\N	\N	2990543-1|melanocytoma	L2DR03	\N	N3_3_NA
831	N3_4	\N	\N	\N	\N	\N	\N	\N	\N	\N	3146318-1|acral melanoma	L2DR04	\N	N3_4_NA
832	N3_5	\N	\N	\N	\N	\N	\N	\N	\N	\N	73001, 73002|TUMOR Mucosal Melanoma, nasal sinus	L2DR05	\N	N3_5_NA
833	N3_6	\N	\N	\N	\N	\N	\N	\N	\N	\N	73003|Normal Melanoma, Mucosal nasal sinus	L2DR06	\N	N3_6_NA
834	N3_7	\N	\N	\N	\N	\N	\N	\N	\N	\N	73004|TUMOR Melanoma, Mucosal nasal sinus	L2DR07	\N	N3_7_NA
835	N3_8	\N	\N	\N	\N	\N	\N	\N	\N	\N	73005|Normal Melanoma, Mucosal nasal sinus	L2DR08	\N	N3_8_NA
839	N3_12	\N	\N	\N	\N	\N	\N	\N	\N	\N	Need to Get diagnosis from Iwei|ROS1 Translocation case	L2DR12	\N	N3_12_NA
840	N3_13	\N	\N	\N	\N	\N	\N	\N	\N	\N	Need to Get diagnosis from Iwei|ROS1 Translocation case	L2DR13	\N	N3_13_NA
841	N3_14	\N	\N	\N	\N	\N	\N	\N	\N	\N	Need to Get diagnosis from Iwei|NTRK3 Translocation case	L2DR14	\N	N3_14_NA
842	N3_15	\N	\N	\N	\N	\N	\N	\N	\N	\N	Need to Get diagnosis from Iwei|BRAF Translocation case	L2DR15	\N	N3_15_NA
843	N3_16	\N	\N	\N	\N	\N	\N	\N	\N	\N	Need to Get diagnosis from Iwei|BRAF Translocation case	L2DR16	\N	N3_16_NA
844	Bivona__L_17	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR11	\N	Bivona_L_17_NA
845	Bivona_L_18	\N	\N	Infinity	\N	\N	62.7	\N	\N	\N	\N	L2DR12	\N	Bivona_L_18_NA
846	Bivona_L_19	\N	\N	Infinity	\N	\N	9.1	\N	\N	\N	\N	L2DR13	\N	Bivona_L_19_NA
847	Kit_53_Acral_NRAS	\N	63.4	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR15	\N	Kit_53_Acral_NRAS_NA
849	Kit_313_Mucosal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR16	\N	Kit_313_Mucosal_NA
850	MB_161_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR02	\N	MB_161_Normal_NA
851	MB_161_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR01	\N	MB_161_Tumor_NA
852	MB_327_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR03	\N	MB_327_Tumor_NA
853	MB_760_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR05	\N	MB_760_Tumor_NA
854	MB_1028_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR08	\N	MB_1028_Normal_NA
855	MB_1029_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR07	\N	MB_1029_Tumor_NA
856	MB_1036_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR10	\N	MB_1036_Normal_NA
857	MB_1046_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR09	\N	MB_1046_Tumor_NA
858	MB_1418_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR06	\N	MB_1418_Normal_NA
859	MB_1454_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR04	\N	MB_1454_Normal_NA
860	BB008_CGH10-013	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR08	\N	BB008_CGH10-013_NA
861	BB008_CGH11-036	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR10	\N	BB008_CGH11-036_NA
862	BB008_CGH11-153	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR09	\N	BB008_CGH11-153_NA
863	BB008_CGH11-386	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR11	\N	BB008_CGH11-386_NA
864	BB008_CGH12-047	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR07	\N	BB008_CGH12-047_NA
865	BB008_HW2NC	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Mucosal Melanoma, vulva, Hong Wu	L2DR01	\N	BB008_HW2NC_NA
866	BB008_HW2TC	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Mucosal Melanoma, vulva, Hong Wu	L2DR02	\N	BB008_HW2TC_NA
867	BB008_HW8NC	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Mucosal Melanoma, Urethra, Hong Wu	L2DR03	\N	BB008_HW8NC_NA
868	BB008_HW8TC	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Mucosal Melanoma, Urethra, Hong Wu	L2DR04	\N	BB008_HW8TC_NA
869	BB008_HW9-NB	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Mucosal Melanoma, Blood, Hong Wu	L2DR05	\N	BB008_HW9-NB_NA
870	BB008_HW9TC	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Mucosla Melanoma, vulva, Hong Wu	L2DR06	\N	BB008_HW9TC_NA
871	BB008_Kit 227 Acral WT	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR12	\N	BB008_Kit 227 Acral WT_NA
872	BB008_LAL-L1	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR15	\N	BB008_LAL-L1_NA
873	BB008_LAL-L2	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR16	\N	BB008_LAL-L2_NA
874	BB008_NB2107	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR14	\N	BB008_NB2107_NA
875	BB008_WM3211	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR13	\N	BB008_WM3211_NA
876	BB09_Bivona_L7	\N	\N	0	\N	\N	\N	\N	\N	\N	Unknown	L2DR01	\N	BB09_Bivona_L7_NA
877	BB09_Bivona_L8	\N	\N	0	\N	\N	\N	\N	\N	\N	Unknown	L2DR02	\N	BB09_Bivona_L8_NA
878	BB09_Bivona_L9	\N	\N	0	\N	\N	\N	\N	\N	\N	Unknown	L2DR03	\N	BB09_Bivona_L9_NA
879	BB09_Bivona_L10	\N	\N	0	\N	\N	\N	\N	\N	\N	Unknown	L2DR04	\N	BB09_Bivona_L10_NA
880	BB09_Bivona_L11	\N	\N	0	\N	\N	\N	\N	\N	\N	Unknown	L2DR16	\N	BB09_Bivona_L11_NA
881	BB09_CGH11_029	\N	\N	0	\N	\N	\N	\N	\N	\N	NTRK3 Translocation case	L2DR11	\N	BB09_CGH11_029_NA
882	BB09_CGH11_045	\N	\N	0	\N	\N	\N	\N	\N	\N	ROS1 Translocation case	L2DR12	\N	BB09_CGH11_045_NA
883	BB09_CGH11_092	\N	\N	0	\N	\N	\N	\N	\N	\N	ROS1 Translocation case	L2DR13	\N	BB09_CGH11_092_NA
884	BB09_CGH11_125	\N	\N	0	\N	\N	\N	\N	\N	\N	NTRK3 Translocation case	L2DR14	\N	BB09_CGH11_125_NA
885	BB09_CGH11_194	\N	\N	0	\N	\N	\N	\N	\N	\N	BRAF Translocation case	L2DR15	\N	BB09_CGH11_194_NA
886	BB09_HW3_N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Normal Melanoma, Mucosal nasal sinus	L2DR06	\N	BB09_HW3_N_NA
887	BB09_HW3_T	\N	\N	\N	\N	\N	\N	\N	\N	\N	TUMOR Mucosal Melanoma, nasal sinus	L2DR05	\N	BB09_HW3_T_NA
888	BB09_HW4_N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Normal Melanoma, Mucosal nasal sinus	L2DR08	\N	BB09_HW4_N_NA
889	BB09_HW4_T	\N	\N	\N	\N	\N	\N	\N	\N	\N	TUMOR Melanoma, Mucosal nasal sinus	L2DR07	\N	BB09_HW4_T_NA
890	BB09_HW6_ND	\N	\N	\N	\N	\N	\N	\N	\N	\N	Normal Melanoma, Mucosal vulva	L2DR10	\N	BB09_HW6_ND_NA
891	BB09_HW6_TD	\N	\N	\N	\N	\N	\N	\N	\N	\N	Tumor Melanoma, Mucosal vulva	L2DR09	\N	BB09_HW6_TD_NA
892	ALK_Cntl	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Tissue Core ALK | Barcode mismatch comment in note	L2DR12	\N	ALK_Cntl_NA
893	CGH10_16	\N	\N	Infinity	\N	\N	74.3	\N	\N	\N	Iwei Translocation Case | Barcode mismatch comment in note	L2DR13	\N	CGH10_16_NA
894	CGH10_17	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Translocation Case	L2DR16	\N	CGH10_17_NA
895	CGH11_035	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Translocation Case	L2DR09	\N	CGH11_035_NA
896	CGH11_60	\N	\N	Infinity	\N	\N	34	\N	\N	\N	Iwei Translocation Case	L2DR14	\N	CGH11_60_NA
897	CGH11_252	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Translocation Case	L2DR15	\N	CGH11_252_NA
898	CGH11_343	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Translocation Case	L2DR10	\N	CGH11_343_NA
899	DP12_200	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Dr. Lutzky's Case	L2DR11	\N	DP12_200_NA
900	HW_A1_Cntl	\N	\N	Infinity	\N	\N	34.3	\N	\N	\N	Hong Wu	L2DR02	\N	HW_A1_Cntl_NA
901	HW_A1_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hong Wu	L2DR01	\N	HW_A1_Tumor_NA
902	HW_A2_Cntl	\N	\N	Infinity	\N	\N	95.8	\N	\N	\N	Hong Wu	L2DR04	\N	HW_A2_Cntl_NA
903	HW_A2_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hong Wu	L2DR03	\N	HW_A2_Tumor_NA
904	HW_A3_Cntl	\N	\N	Infinity	\N	\N	67	\N	\N	\N	Hong Wu	L2DR06	\N	HW_A3_Cntl_NA
905	HW_A3_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hong Wu	L2DR05	\N	HW_A3_Tumor_NA
906	HW_A4_Cntl	\N	\N	Infinity	\N	\N	84.4	\N	\N	\N	Hong Wu	L2DR08	\N	HW_A4_Cntl_NA
907	HW_A4_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Hong Wu	L2DR07	\N	HW_A4_Tumor_NA
908	CGH12_135	\N	\N	Infinity	\N	\N	100	\N	\N	\N	NTRK1	L2DR15	\N	CGH12_135_NA
909	CGH12_161	\N	\N	Infinity	\N	\N	30.3	\N	\N	\N	NTRK1	L2DR16	\N	CGH12_161_NA
910	CGH12_317	\N	\N	Infinity	\N	\N	100	\N	\N	\N	NTRK3 | Barcode mismatch comment in note	L2DR13	\N	CGH12_317_NA
911	CGH12_343	\N	\N	Infinity	\N	\N	74.6	\N	\N	\N	NTRK3	L2DR14	\N	CGH12_343_NA
912	D12_67298_Norm	\N	\N	Infinity	\N	\N	78.2	\N	\N	\N	lft, Lateral Ankle, Malignant S-100 positive spindle cell Neloplasm, Braf15 V600E mutation	L2DR02	\N	D12_67298_Norm_NA
913	D12_67298_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	lft, Lateral Ankle, Malignant S-100 positive spindle cell Neloplasm, Braf15 V600E mutation	L2DR01	\N	D12_67298_Tumor_NA
914	L11_96096_A2_Norm	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Metastatic Melanoma, Lymph Node, sentinel. Capsular nevus is present	L2DR04	\N	L11_96096_A2_Norm_NA
915	MB1241_Norm	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Acral Normal, Frozen Tissue DNA  Extracted by Denver	L2DR06	\N	MB1241_Norm_NA
916	MB1242_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Acral Tumor, Frozen Tissue DNA Extracted by Denver	L2DR05	\N	MB1242_Tumor_NA
917	MB1421_Norm	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Acral Normal, Thumb, Frozen Tissue DNA extracted by Denver	L2DR10	\N	MB1421_Norm_NA
918	MB1423_Norm	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Acral Normal Heel, FFPE Extracted DNA by Denver	L2DR08	\N	MB1423_Norm_NA
919	MB1423_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Acral Tumor, Heel, Frozen Tissue DNA Extracted by Denver	L2DR07	\N	MB1423_Tumor_NA
920	MB1424 _Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Acral Tumor, Thumb, Frozen Tissue DNA extracted by Denver	L2DR09	\N	MB1424 _Tumor_NA
921	MB1428_Norm	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Acral Normal, Heel Frozen Tissue DNA Extracted by Denver | Barcode mismatch comment in note	L2DR13	\N	MB1428_Norm_NA
922	MB1429_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Acral Tumor, Heel, Frozen Tissue DNA Extracted by Denver	L2DR11	\N	MB1429_Tumor_NA
923	S12_20321_A2_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Brain, right frontal, biopsy: Glioblastoma, WHO Grade IV 	L2DR03	\N	S12_20321_A2_Tumor_NA
924	HW_A5_Cntl	\N	\N	Infinity	\N	\N	82.6	\N	\N	\N	\N	L2DR02	\N	HW_A5_Cntl_NA
925	HW_A5_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR01	\N	HW_A5_Tumor_NA
926	HW_A6_Cntl	\N	\N	Infinity	\N	\N	68.3	\N	\N	\N	\N	L2DR04	\N	HW_A6_Cntl_NA
927	HW_A6_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR03	\N	HW_A6_Tumor_NA
928	HW_A7 Cntl	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR06	\N	HW_A7 Cntl_NA
929	HW_A7_Tumor	\N	\N	Infinity	\N	\N	86.5	\N	\N	\N	\N	L2DR05	\N	HW_A7_Tumor_NA
930	HW_A8_Cntl	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR08	\N	HW_A8_Cntl_NA
931	HW_A8_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR07	\N	HW_A8_Tumor_NA
932	HW_A9_Cntl	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR10	\N	HW_A9_Cntl_NA
933	HW_A9_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR09	\N	HW_A9_Tumor_NA
934	HW_A10_Cntl	\N	\N	Infinity	\N	\N	97.4	\N	\N	\N	\N	L2DR12	\N	HW_A10_Cntl_NA
935	HW_A10_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR11	\N	HW_A10_Tumor_NA
936	MB_1609_Normal	\N	\N	Infinity	\N	\N	32.1	\N	\N	\N	\N	L2DR14	\N	MB_1609_Normal_NA
937	MB1617_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR13	\N	MB1617_Tumor_NA
938	WM51	2013-03-25 00:00:00-07	\N	1	\N	\N	100	\N	\N	\N	\N	L2DR15	\N	WM51_NA
939	WM3918	2013-03-25 00:00:00-07	\N	2	\N	\N	100	\N	\N	\N	\N	L2DR16	\N	WM3918_NA
940	DM1_Normal	\N	\N	14	\N	\N	34.3	\N	\N	\N	\N	L2DR01	\N	DM1_Normal_NA
941	DM1_Tumor	\N	\N	1	\N	\N	100	\N	\N	\N	\N	L2DR02	\N	DM1_Tumor_NA
942	DM2_Normal	\N	\N	9	\N	\N	89.9	\N	\N	\N	\N	L2DR03	\N	DM2_Normal_NA
943	DM2_Tumor	\N	\N	1	\N	\N	100	\N	\N	\N	\N	L2DR04	\N	DM2_Tumor_NA
944	DM5 _Tumor	\N	\N	0	\N	\N	38.3	\N	\N	\N	\N	L2DR06	\N	DM5 _Tumor_NA
945	DM5_Normal	\N	\N	12	\N	\N	32.6	\N	\N	\N	\N	L2DR05	\N	DM5_Normal_NA
946	DM7_Normal	\N	\N	14	\N	\N	51.5	\N	\N	\N	\N	L2DR07	\N	DM7_Normal_NA
947	DM7_Tumor	\N	\N	3	\N	\N	100	\N	\N	\N	\N	L2DR08	\N	DM7_Tumor_NA
948	DM12_Normal	\N	\N	8	\N	\N	100	\N	\N	\N	\N	L2DR09	\N	DM12_Normal_NA
949	DM12_Tumor	\N	\N	3	\N	\N	100	\N	\N	\N	\N	L2DR10	\N	DM12_Tumor_NA
950	DM13_Normal	\N	\N	Infinity	\N	\N	67.5	\N	\N	\N	\N	L2DR11	\N	DM13_Normal_NA
951	DM13_Tumor	\N	\N	1	\N	\N	100	\N	\N	\N	\N	L2DR12	\N	DM13_Tumor_NA
952	DM21_Normal	\N	\N	18	\N	\N	39.6	\N	\N	\N	\N	L2DR13	\N	DM21_Normal_NA
953	DM21_Tumor	\N	\N	1	\N	\N	16.4	\N	\N	\N	\N	L2DR14	\N	DM21_Tumor_NA
954	DM93_CGN	\N	\N	2	\N	\N	45.7	\N	\N	\N	\N	L2DR16	\N	DM93_CGN_NA
955	DM93_Normal	\N	\N	7	\N	\N	100	\N	\N	\N	\N	L2DR15	\N	DM93_Normal_NA
956	CGH10_020	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Translocation Cases	L2DR06	\N	CGH10_020_NA
957	CGH10_049	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Translocation Cases	L2DR07	\N	CGH10_049_NA
958	CGH10_058	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Translocation Cases	L2DR04	\N	CGH10_058_NA
959	CGH11_020	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Translocation Cases	L2DR08	\N	CGH11_020_NA
960	CGH11_078	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Translocation Cases	L2DR01	\N	CGH11_078_NA
961	CGH11_080	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Translocation Cases	L2DR02	\N	CGH11_080_NA
962	CGH11_281	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Translocation Cases	L2DR03	\N	CGH11_281_NA
963	CGH11_283	\N	\N	\N	\N	\N	\N	\N	\N	\N	Iwei Translocation Cases	L2DR05	\N	CGH11_283_NA
964	D12_54296_Norm	\N	\N	\N	\N	\N	\N	\N	\N	\N	Swapna DNA, screened	L2DR09	\N	D12_54296_Norm_NA
965	D12_54296_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	Swapna DNA, screened	L2DR10	\N	D12_54296_Tumor_NA
966	D12_54992_Norm	\N	\N	\N	\N	\N	\N	\N	\N	\N	Swapna DNA, screened	L2DR11	\N	D12_54992_Norm_NA
967	D12_54992_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	Swapna DNA, screened	L2DR13	\N	D12_54992_Tumor_NA
968	WM8	2013-03-25 00:00:00-07	\N	0	\N	\N	\N	\N	\N	\N	Wistar, Fusion Project, Cell Line DNA	L2DR15	\N	WM8_NA
969	WM1963	2013-03-25 00:00:00-07	\N	3	\N	\N	100	\N	\N	\N	Wistar, Fusion Project, Cell Line DNA	L2DR14	\N	WM1963_NA
970	WM3622	2013-03-25 00:00:00-07	\N	6	\N	\N	100	\N	\N	\N	Wistar, Fusion Project, Cell Line DNA	L2DR12	\N	WM3622_NA
971	WM3912	2013-03-25 00:00:00-07	\N	0	\N	\N	\N	\N	\N	\N	Wistar, Fusion Project, Cell Line DNA	L2DR16	\N	WM3912_NA
972	DM11_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	Less than the optimal 100 ng input conc. For End Repair	L2DR02	\N	DM11_Normal_NA
973	DM11_Tumor	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR01	\N	DM11_Tumor_NA
974	DM14_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR04	\N	DM14_Normal_NA
975	DM14_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR03	\N	DM14_Tumor_NA
976	DM26_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR06	\N	DM26_Normal_NA
977	DM26_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR05	\N	DM26_Tumor_NA
978	DM28_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR08	\N	DM28_Normal_NA
979	DM28_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR07	\N	DM28_Tumor_NA
980	DM29_2_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	Less than the optimal 100 ng input conc. For End Repair	L2DR09	\N	DM29_2_Tumor_NA
981	DM29_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR10	\N	DM29_Normal_NA
982	DM34_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	Less than the optimal 100 ng input conc. For End Repair	L2DR12	\N	DM34_Normal_NA
983	DM34_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR11	\N	DM34_Tumor_NA
984	DM55 Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR14	\N	DM55 Normal_NA
985	DM55_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR13	\N	DM55_Tumor_NA
986	DM79_2_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	Less than the optimal 100 ng input conc. For End Repair	L2DR15	\N	DM79_2_Tumor_NA
987	DM79_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR16	\N	DM79_Normal_NA
988	CGH_11_361	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Translocation Project	L2DR01	\N	CGH_11_361_NA
989	CGH_11_366	\N	\N	Infinity	\N	\N	12.4	\N	\N	\N	Iwei Translocation Project	L2DR02	\N	CGH_11_366_NA
990	CGH_11_376	\N	\N	Infinity	\N	\N	84.3	\N	\N	\N	Iwei Translocation Project	L2DR03	\N	CGH_11_376_NA
991	CGH_11_388	\N	\N	Infinity	\N	\N	69.4	\N	\N	\N	Iwei Translocation Project	L2DR04	\N	CGH_11_388_NA
992	CGH_11_422	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei Translocation Project	L2DR05	\N	CGH_11_422_NA
993	CGH_12_016	\N	\N	Infinity	\N	\N	94.6	\N	\N	\N	Iwei Translocation Project	L2DR06	\N	CGH_12_016_NA
994	DM_4_Normal	\N	\N	Infinity	\N	\N	97.8	\N	\N	\N	\N	L2DR08	\N	DM_4_Normal_NA
995	DM_4_Tumor	\N	\N	Infinity	\N	\N	33.5	\N	\N	\N	\N	L2DR07	\N	DM_4_Tumor_NA
996	DM_95_2_Tumor	\N	\N	Infinity	\N	\N	73.6	\N	\N	\N	\N	L2DR09	\N	DM_95_2_Tumor_NA
997	DM_95_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR10	\N	DM_95_Normal_NA
998	DM_96_2_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR11	\N	DM_96_2_Tumor_NA
999	DM_96_Normal	\N	\N	Infinity	\N	\N	29.5	\N	\N	\N	\N	L2DR13	\N	DM_96_Normal_NA
1000	Kit_8	\N	\N	\N	\N	\N	\N	\N	\N	\N	Alyssa Kit Mutations	L2DR12	\N	Kit_8_NA
1001	Kit_21	\N	\N	\N	\N	\N	\N	\N	\N	\N	Alyssa Kit Mutations	L2DR14	\N	Kit_21_NA
1002	Kit_55	\N	\N	\N	\N	\N	\N	\N	\N	\N	Alyssa Kit Mutations	L2DR15	\N	Kit_55_NA
1003	Kit_76	\N	\N	\N	\N	\N	\N	\N	\N	\N	Alyssa Kit Mutations	L2DR16	\N	Kit_76_NA
1004	CNS_29_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_2	L2DR02	\N	CNS_29_Normal_NA
1005	CNS_29_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_1	L2DR01	\N	CNS_29_Tumor_NA
1006	CNS_30_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_3	L2DR03	\N	CNS_30_Tumor_NA
1007	CNS_31_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_4	L2DR04	\N	CNS_31_Tumor_NA
1008	CNS_33_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_5	L2DR05	\N	CNS_33_Tumor_NA
1009	CNS_34_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_7	L2DR07	\N	CNS_34_Normal_NA
1010	CNS_34_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_6	L2DR06	\N	CNS_34_Tumor_NA
1011	CNS_35_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_8	L2DR08	\N	CNS_35_Tumor_NA
1012	CNS_36_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_9	L2DR09	\N	CNS_36_Tumor_NA
1013	CNS_37_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_10	L2DR10	\N	CNS_37_Tumor_NA
1014	CNS_38_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_11	L2DR11	\N	CNS_38_Tumor_NA
1015	CNS_39_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_12	L2DR12	\N	CNS_39_Tumor_NA
1016	CNS_40_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_13	L2DR13	\N	CNS_40_Tumor_NA
1017	CNS_41_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_14	L2DR14	\N	CNS_41_Tumor_NA
1018	Kit_192	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_15	L2DR15	\N	Kit_192_NA
1019	Kit_203	\N	\N	\N	\N	\N	\N	\N	\N	\N	N14_16	L2DR16	\N	Kit_203_NA
1020	Ivanka_21_5_Norm	\N	\N	13	\N	\N	15.6	\N	\N	\N	Ivanka Normal Resequencing	L2DR15	\N	21-5_NA
1021	Ivanka_24_5_Norm	\N	\N	14	\N	\N	12	\N	\N	\N	Ivanka Normal Resequencing	L2DR16	\N	24-5_NA
1022	KR_8	\N	\N	\N	\N	\N	\N	\N	\N	\N	blood derived	L2DR08	\N	KR_8_NA
1023	KR_150	\N	\N	\N	\N	\N	\N	\N	\N	\N	blood derived	L2DR05	\N	KR_150_NA
1024	KR_166	\N	\N	\N	\N	\N	\N	\N	\N	\N	blood derived.	L2DR01	\N	KR_166_NA
1025	KR_177	\N	\N	\N	\N	\N	\N	\N	\N	\N	blood derived	L2DR04	\N	KR_177_NA
1026	KR_203	\N	\N	\N	\N	\N	\N	\N	\N	\N	blood derived	L2DR07	\N	KR_203_NA
1027	KR_229	\N	\N	\N	\N	\N	\N	\N	\N	\N	blood derived	L2DR06	\N	KR_229_NA
1028	KR_2030	\N	\N	\N	\N	\N	\N	\N	\N	\N	blood derived	L2DR03	\N	KR_2030_NA
1029	KR_2064	\N	\N	\N	\N	\N	\N	\N	\N	\N	blood derived	L2DR02	\N	KR_2064_NA
1030	KR_5233	\N	\N	\N	\N	\N	\N	\N	\N	\N	blood	L2DR09	\N	KR_5233_NA
1031	KR_RMK0091B	\N	\N	\N	\N	\N	\N	\N	\N	\N	skin	L2DR10	\N	KR_RMK0091B_NA
1032	KR_RMK0137C	\N	\N	\N	\N	\N	\N	\N	\N	\N	saliva | Barcode mismatch comment in note	L2DR13	\N	KR_RMK0137C_NA
1033	KR_RMK0162C	\N	\N	\N	\N	\N	\N	\N	\N	\N	saliva | Barcode mismatch comment in note	L2DR12	\N	KR_RMK0162C_NA
1034	KR_RMK0168C	\N	\N	\N	\N	\N	\N	\N	\N	\N	saliva	L2DR14	\N	KR_RMK0168C_NA
1035	KR_RMK0194C	\N	\N	\N	\N	\N	\N	\N	\N	\N	Saliva-tube	L2DR11	\N	KR_RMK0194C_NA
1036	DM_6_Tumor	\N	\N	Infinity	\N	\N	90.1	\N	\N	\N	\N	L2DR12	\N	DM_6_Tumor_NA
1037	DM_10_Normal	\N	\N	Infinity	\N	\N	97.8	\N	\N	\N	\N	L2DR02	\N	DM_10_Normal_NA
1038	DM_10_Tumor	\N	\N	Infinity	\N	\N	80.6	\N	\N	\N	\N	L2DR01	\N	DM_10_Tumor_NA
1039	DM_17_Normal	\N	\N	Infinity	\N	\N	31.3	\N	\N	\N	\N	L2DR04	\N	DM_17_Normal_NA
1040	DM_17_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR03	\N	DM_17_Tumor_NA
1041	DM_18_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR06	\N	DM_18_Normal_NA
1042	DM_18_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR05	\N	DM_18_Tumor_NA
1044	DM_22_Normal	\N	\N	Infinity	\N	\N	12	\N	\N	\N	\N	L2DR08	\N	DM_22_Normal_NA
1045	DM_22_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR07	\N	DM_22_Tumor_NA
1046	DM_23_Normal	\N	\N	Infinity	\N	\N	30.8	\N	\N	\N	\N	L2DR10	\N	DM_23_Normal_NA
1047	DM_23_Tumor	\N	\N	Infinity	\N	\N	10.3	\N	\N	\N	\N	L2DR09	\N	DM_23_Tumor_NA
1048	DM_25_Normal	\N	\N	Infinity	\N	\N	76.5	\N	\N	\N	\N	L2DR13	\N	DM_25_Normal_NA
1049	DM_25_Tumor	\N	\N	Infinity	\N	\N	24.5	\N	\N	\N	\N	L2DR11	\N	DM_25_Tumor_NA
1050	DM_37_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR14	\N	DM_37_Tumor_NA
1051	DM_93_cgn	\N	\N	Infinity	\N	\N	45.7	\N	\N	\N	\N	L2DR16	\N	DM_93_cgn_NA
1052	DM_93_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR15	\N	DM_93_Normal_NA
1053	DM_42_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR14	\N	DM_42_Tumor_NA
1054	DM_43_Tumor	\N	\N	Infinity	\N	\N	91.8	\N	\N	\N	\N	L2DR15	\N	DM_43_Tumor_NA
1055	DM_48_Tumor	\N	\N	Infinity	\N	\N	44.8	\N	\N	\N	\N	L2DR16	\N	DM_48_Tumor_NA
1056	SM_1_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Spitzoid Melanoma Maria	L2DR01	\N	SM_1_Tumor_NA
1057	SM_3_Tumor	\N	\N	Infinity	\N	\N	76.2	\N	\N	\N	Spitzoid Melanoma Maria	L2DR02	\N	SM_3_Tumor_NA
1058	SM_4_Normal	\N	\N	Infinity	\N	\N	23.3	\N	\N	\N	Spitzoid Melanoma Maria	L2DR04	\N	SM_4_Normal_NA
1059	SM_4_Tumor	\N	\N	Infinity	\N	\N	95.2	\N	\N	\N	Spitzoid Melanoma Maria	L2DR03	\N	SM_4_Tumor_NA
1060	SM_5_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Spitzoid Melanoma Maria	L2DR06	\N	SM_5_Normal_NA
1061	SM_5_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Spitzoid Melanoma Maria	L2DR05	\N	SM_5_Tumor_NA
1062	SM_8_Tumor	\N	\N	Infinity	\N	\N	98.4	\N	\N	\N	Spitzoid Melanoma Maria	L2DR08	\N	SM_8_Tumor_NA
1063	SM_11_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Spitzoid Melanoma Maria	L2DR09	\N	SM_11_Tumor_NA
1064	SM_12_Tumor	\N	\N	Infinity	\N	\N	39.6	\N	\N	\N	Spitzoid Melanoma Maria	L2DR10	\N	SM_12_Tumor_NA
1065	SM_16_Normal	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Spitzoid Melanoma Maria	L2DR13	\N	SM_16_Normal_NA
1066	SM_16_Tumor	\N	\N	Infinity	\N	\N	85.8	\N	\N	\N	Spitzoid Melanoma Maria	L2DR11	\N	SM_16_Tumor_NA
1067	SM_18_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Spitzoid Melanoma Maria	L2DR12	\N	SM_18_Tumor_NA
1068	SM7_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Spitzoid Melanoma Maria	L2DR07	\N	SM7_Tumor_NA
1069	CGH10-028	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR06	\N	CGH10-028_NA
1070	CGH10-045	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR07	\N	CGH10-045_NA
1071	CGH10-062	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR08	\N	CGH10-062_NA
1072	CGH11_292	\N	\N	Infinity	\N	\N	100	\N	\N	\N	ALK Iwei, Translocation	L2DR01	\N	CGH11_292_NA
1073	CGH11_305	\N	\N	Infinity	\N	\N	54.3	\N	\N	\N	NTRK1 Iwei, Translocation	L2DR02	\N	CGH11_305_NA
1074	CGH11_310	\N	\N	Infinity	\N	\N	54	\N	\N	\N	ALK Iwei, Translocation	L2DR03	\N	CGH11_310_NA
1075	CGH11_319	\N	\N	Infinity	\N	\N	100	\N	\N	\N	NTRK1 Iwei, Translocation	L2DR04	\N	CGH11_319_NA
1076	CGH11_348	\N	\N	Infinity	\N	\N	60.2	\N	\N	\N	NTRK1 Iwei, Translocation	L2DR05	\N	CGH11_348_NA
1077	CGH11-011	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR09	\N	CGH11-011_NA
1078	CGH11-072	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR10	\N	CGH11-072_NA
1079	CGH11-087	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR11	\N	CGH11-087_NA
1080	CGH11-089	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR13	\N	CGH11-089_NA
1081	CGH11-147	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR12	\N	CGH11-147_NA
1082	CGH11-158	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR14	\N	CGH11-158_NA
1083	CGH11-166	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR15	\N	CGH11-166_NA
1084	CGH11-172	\N	\N	Infinity	\N	\N	100	\N	\N	\N	 Iwei, 7QGain	L2DR16	\N	CGH11-172_NA
1085	CGH10-058	\N	\N	Infinity	\N	\N	120	\N	\N	\N	\N	L2DR04	\N	CGH10-058_NA
1086	CGH11-035	\N	\N	Infinity	\N	\N	120	\N	\N	\N	\N	L2DR09	\N	CGH11-035_NA
1087	CGH11-194	\N	\N	Infinity	\N	\N	120	\N	\N	\N	\N	L2DR15	\N	CGH11-194_NA
1088	CGH11-252	\N	\N	Infinity	\N	\N	120	\N	\N	\N	\N	L2DR01	\N	CGH11-252_NA
1089	CGH11-259	\N	20.3	0	\N	\N	93.5	\N	\N	\N	Iwei 7Q Gain	L2DR11	\N	CGH11-259_NA
1090	CGH11-315	\N	15.8	Infinity	\N	\N	31.1	\N	\N	\N	Iwei 7Q Gain	L2DR12	\N	CGH11-315_NA
1091	CGH11-339	\N	20.8	Infinity	\N	\N	100	\N	\N	\N	Iwei 7Q Gain	L2DR13	\N	CGH11-339_NA
1092	CGH11-404	\N	21.7	Infinity	\N	\N	65.5	\N	\N	\N	Iwei 7Q Gain	L2DR15	\N	CGH11-404_NA
1093	CGH11-409	\N	16	Infinity	\N	\N	100	\N	\N	\N	Iwei 7Q Gain	L2DR16	\N	CGH11-409_NA
1094	SM_2_Normal	\N	\N	Infinity	\N	\N	10.2	\N	\N	\N	Spitzoid Melanoma	L2DR02	\N	SM_2_Normal_NA
1095	SM_2_Tumor	\N	\N	Infinity	\N	\N	57.6	\N	\N	\N	Spitzoid Melanoma	L2DR01	\N	SM_2_Tumor_NA
1096	SM_6_Tumor	\N	\N	Infinity	\N	\N	69.8	\N	\N	\N	Spitzoid Melanoma	L2DR03	\N	SM_6_Tumor_NA
1097	SM_7_Normal	\N	\N	Infinity	\N	\N	39	\N	\N	\N	Spitzoid Melanoma	L2DR05	\N	SM_7_Normal_NA
1098	SM_7_Tumor	\N	\N	Infinity	\N	\N	62.5	\N	\N	\N	Spitzoid Melanoma	L2DR04	\N	SM_7_Tumor_NA
1099	SM_8_Normal	\N	\N	Infinity	\N	\N	35.5	\N	\N	\N	Spitzoid Melanoma	L2DR07	\N	SM_8_Normal_NA
1100	SM_9_Normal	\N	\N	Infinity	\N	\N	34.4	\N	\N	\N	Spitzoid Melanoma	L2DR09	\N	SM_9_Normal_NA
1101	SM_9_Tumor	\N	\N	Infinity	\N	\N	68.9	\N	\N	\N	Spitzoid Melanoma	L2DR08	\N	SM_9_Tumor_NA
1102	SM_10_Tumor	\N	\N	Infinity	\N	\N	71.7	\N	\N	\N	Spitzoid Melanoma	L2DR10	\N	SM_10_Tumor_NA
1103	CGH12-345	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei, Translocation CGH NTRK1	L2DR13	\N	CGH12-345_NA
1104	CGH12-347	\N	\N	Infinity	\N	\N	88.5	\N	\N	\N	Iwei, Translocation CGH NTRK2	L2DR14	\N	CGH12-347_NA
1105	CGH13-003	\N	\N	Infinity	\N	\N	13.6	\N	\N	\N	Iwei, Translocation CGH BRAF	L2DR15	\N	CGH13-003_NA
1106	CGH13-009	\N	\N	Infinity	\N	\N	96.2	\N	\N	\N	Iwei, Translocation CGH NTRK1	L2DR16	\N	CGH13-009_NA
1107	CGH13-011	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei, Translocation CGH BRAF	L2DR07	\N	CGH13-011_NA
1108	CGH13-033	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei, Translocation CGH NTRK1	L2DR01	\N	CGH13-033_NA
1109	CGH13-034	\N	\N	Infinity	\N	\N	68.6	\N	\N	\N	Iwei, Translocation CGH NTRK1?	L2DR02	\N	CGH13-034_NA
1110	CGH13-041	\N	\N	Infinity	\N	\N	29.1	\N	\N	\N	Iwei, Translocation CGH NTRK3	L2DR03	\N	CGH13-041_NA
1111	CGH13-044	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei, Translocation CGH NTRK3	L2DR04	\N	CGH13-044_NA
1112	CGH13-046	\N	\N	Infinity	\N	\N	71.1	\N	\N	\N	Iwei, Translocation CGH BRAF	L2DR05	\N	CGH13-046_NA
1113	CGH13-058	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei, Translocation CGH NTRK3	L2DR06	\N	CGH13-058_NA
1114	CHG12-335	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei, Translocation CGH BRAF	L2DR12	\N	CHG12-335_NA
1115	DPN_1_Tumor	\N	\N	Infinity	\N	\N	76.7	\N	\N	\N	Iwei DPN	L2DR08	\N	DPN_1_Tumor_NA
1116	DPN_3_Tumor	\N	\N	Infinity	\N	\N	77.6	\N	\N	\N	Iwei DPN	L2DR09	\N	DPN_3_Tumor_NA
1117	DPN_4_Tumor	\N	\N	Infinity	\N	\N	99.7	\N	\N	\N	Iwei DPN	L2DR10	\N	DPN_4_Tumor_NA
1118	DPN_5_Tumor	\N	\N	Infinity	\N	\N	62.6	\N	\N	\N	Iwei DPN	L2DR11	\N	DPN_5_Tumor_NA
1119	DPN_6_Tumor	\N	\N	Infinity	\N	\N	51	\N	\N	\N	Iwei DPN	L2DR12	\N	DPN_6_Tumor_NA
1120	DPN_7_Tumor	\N	\N	746	\N	\N	76.1	\N	\N	\N	Iwei DPN	L2DR13	\N	DPN_7_Tumor_NA
1121	DPN_8_Tumor	\N	\N	Infinity	\N	\N	77.4	\N	\N	\N	Iwei DPN	L2DR14	\N	DPN_8_Tumor_NA
1122	DPN_9_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Iwei DPN	L2DR15	\N	DPN_9_Tumor_NA
1123	DPN_10_Tumor	\N	\N	Infinity	\N	\N	53.2	\N	\N	\N	Iwei DPN	L2DR16	\N	DPN_10_Tumor_NA
1124	DPN_11_Tumor	\N	\N	Infinity	\N	\N	76	\N	\N	\N	Iwei DPN	L2DR01	\N	DPN_11_Tumor_NA
1125	DPN_12_Tumor	\N	\N	Infinity	\N	\N	96.6	\N	\N	\N	Iwei DPN	L2DR02	\N	DPN_12_Tumor_NA
1126	NGS 1-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR01	\N	NGS 1-1_NA
1127	NGS 1-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR02	\N	NGS 1-3_NA
1128	NGS 1-4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR03	\N	NGS 1-4_NA
1129	NGS 1-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR04	\N	NGS 1-5_NA
1130	NGS 1-6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR05	\N	NGS 1-6_NA
1131	NGS 1-7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR06	\N	NGS 1-7_NA
1132	NGS 1-8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR07	\N	NGS 1-8_NA
1133	NGS 1-9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR08	\N	NGS 1-9_NA
1134	NGS 1-10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR09	\N	NGS 1-10_NA
1135	NGS 1-13	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR10	\N	NGS 1-13_NA
1136	NGS 1-14	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR11	\N	NGS 1-14_NA
1137	CNS_42_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR08	\N	CNS_42_Tumor_NA
1138	CNS_43_Tumor	\N	\N	Infinity	\N	\N	97	\N	\N	\N	\N	L2DR09	\N	CNS_43_Tumor_NA
1139	CNS_44_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR10	\N	CNS_44_Tumor_NA
1140	CNS_48_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR11	\N	CNS_48_Tumor_NA
1141	CNS_49_Tumor	\N	\N	Infinity	\N	\N	95.9	\N	\N	\N	\N	L2DR12	\N	CNS_49_Tumor_NA
1142	CNS_50_Tumor	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR13	\N	CNS_50_Tumor_NA
1143	DPN_14_Tumor	\N	\N	Infinity	\N	\N	75.1	\N	\N	\N	Iwei DPN	L2DR03	\N	DPN_14_Tumor_NA
1144	DPN_16_Tumor	\N	\N	Infinity	\N	\N	82.4	\N	\N	\N	Iwei DPN	L2DR04	\N	DPN_16_Tumor_NA
1145	DPN_17_Tumor	\N	\N	Infinity	\N	\N	74.2	\N	\N	\N	Iwei DPN	L2DR05	\N	DPN_17_Tumor_NA
1146	DPN_18_Tumor	\N	\N	Infinity	\N	\N	86.1	\N	\N	\N	Iwei DPN	L2DR06	\N	DPN_18_Tumor_NA
1147	DPN_19_Tumor	\N	\N	Infinity	\N	\N	75.3	\N	\N	\N	Iwei DPN	L2DR07	\N	DPN_19_Tumor_NA
1148	Ivanka_9_1	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR14	\N	Ivanka_9_1_NA
1149	Ivanka_9_2	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR15	\N	Ivanka_9_2_NA
1150	Ivanka_9_3	\N	\N	Infinity	\N	\N	48.1	\N	\N	\N	\N	L2DR16	\N	Ivanka_9_3_NA
1151	Ivanka_9_4	\N	\N	Infinity	\N	\N	61.5	\N	\N	\N	\N	L2DR01	\N	Ivanka_9_4_NA
1152	Ivanka_9_5	\N	\N	Infinity	\N	\N	11.3	\N	\N	\N	\N	L2DR02	\N	Ivanka_9_5_NA
1153	Ivanka_12_1	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR03	\N	Ivanka_12_1_NA
1154	Ivanka_12_2	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR04	\N	Ivanka_12_2_NA
1155	Ivanka_12_3	\N	\N	Infinity	\N	\N	65.1	\N	\N	\N	\N	L2DR05	\N	Ivanka_12_3_NA
1156	Ivanka_12_4	\N	\N	Infinity	\N	\N	77.1	\N	\N	\N	\N	L2DR06	\N	Ivanka_12_4_NA
1157	Ivanka_12_5	\N	\N	Infinity	\N	\N	17.6	\N	\N	\N	\N	L2DR07	\N	Ivanka_12_5_NA
1158	Ivanka_16_1	\N	\N	Infinity	\N	\N	34.8	\N	\N	\N	\N	L2DR08	\N	Ivanka_16_1_NA
1159	Ivanka_16_2	\N	\N	Infinity	\N	\N	39.6	\N	\N	\N	\N	L2DR09	\N	Ivanka_16_2_NA
1160	Ivanka_16_3	\N	\N	Infinity	\N	\N	11.4	\N	\N	\N	\N	L2DR10	\N	Ivanka_16_3_NA
1161	Ivanka_16_4	\N	\N	Infinity	\N	\N	19.1	\N	\N	\N	\N	L2DR11	\N	Ivanka_16_4_NA
1162	Ivanka_16_5	\N	\N	Infinity	\N	\N	20.7	\N	\N	\N	\N	L2DR12	\N	Ivanka_16_5_NA
1163	Ivanka_22_1	\N	\N	Infinity	\N	\N	94.9	\N	\N	\N	\N	L2DR13	\N	Ivanka_22_1_NA
1164	Ivanka_22_2	\N	\N	Infinity	\N	\N	100	\N	\N	\N	\N	L2DR14	\N	Ivanka_22_2_NA
1165	Ivanka_22_3	\N	\N	Infinity	\N	\N	82.4	\N	\N	\N	\N	L2DR15	\N	Ivanka_22_3_NA
1166	Ivanka_22_4	\N	\N	Infinity	\N	\N	20.2	\N	\N	\N	\N	L2DR16	\N	Ivanka_22_4_NA
1167	Ivanka_22_5	\N	\N	Infinity	\N	\N	10.8	\N	\N	\N	\N	L2DR01	\N	Ivanka_22_5_NA
1168	Algazi_Tumor	\N	\N	Infinity	\N	\N	40.7	\N	\N	\N	Alain Algazi	L2DR06	\N	Algazi_Tumor_NA
1169	Ivanka_20_1	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Ivanka Patient Melanoma	L2DR01	\N	Ivanka_20_1_NA
1170	Ivanka_20_2	\N	\N	Infinity	\N	\N	100	\N	\N	\N	Ivanka Patient Melanoma	L2DR02	\N	Ivanka_20_2_NA
1171	Ivanka_20_3	\N	\N	Infinity	\N	\N	41.5	\N	\N	\N	Ivanka Patient Melanoma	L2DR03	\N	Ivanka_20_3_NA
1172	Ivanka_20_4	\N	\N	Infinity	\N	\N	61.2	\N	\N	\N	Ivanka Patient Melanoma	L2DR04	\N	Ivanka_20_4_NA
1173	Ivanka_20_5	\N	\N	Infinity	\N	\N	10.2	\N	\N	\N	Ivanka Patient Melanoma	L2DR05	\N	Ivanka_20_5_NA
1174	Ivanka_23_1	\N	\N	Infinity	\N	\N	22.9	\N	\N	\N	Ivanka Patient Melanoma	L2DR06	\N	Ivanka_23_1_NA
1175	Ivanka_23_2	\N	\N	Infinity	\N	\N	57.2	\N	\N	\N	Ivanka Patient Melanoma	L2DR07	\N	Ivanka_23_2_NA
1176	Ivanka_23_3	\N	\N	Infinity	\N	\N	11	\N	\N	\N	Ivanka Patient Melanoma	L2DR08	\N	Ivanka_23_3_NA
1177	Ivanka_23_4	\N	\N	Infinity	\N	\N	24.2	\N	\N	\N	Ivanka Patient Melanoma	L2DR09	\N	Ivanka_23_4_NA
1178	Ivanka_23_5	\N	\N	Infinity	\N	\N	10.1	\N	\N	\N	Ivanka Patient Melanoma	L2DR10	\N	Ivanka_23_5_NA
1179	CGH11-229	\N	1.64	0	\N	\N	51.4	\N	\N	\N	Iwei 7Q Gain	L2DR07	\N	CGH11-229_NA
1180	CGH11-231	\N	40.3	0	\N	\N	100	\N	\N	\N	Iwei 7Q Gain	L2DR08	\N	CGH11-231_NA
1181	CGH11-232	\N	15.2	0	\N	\N	67.8	\N	\N	\N	Iwei 7Q Gain	L2DR09	\N	CGH11-232_NA
1182	CGH11-237	\N	28.5	1	\N	\N	70.9	\N	\N	\N	Iwei 7Q Gain	L2DR10	\N	CGH11-237_NA
1183	CHG11-409	2013-07-09 00:00:00-07	16	0	\N	\N	\N	\N	\N	\N	Iwei 7Q gain, Swapna CGH screened, FFPE derived\n	L2DR16	\N	CHG11-409_NA
1184	ChIP1_1	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR01	\N	ChIP1_1_NA
1185	ChIP1_2	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR02	\N	ChIP1_2_NA
1186	ChIP1_3	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR03	\N	ChIP1_3_NA
1187	ChIP1_4	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR04	\N	ChIP1_4_NA
1188	ChIP1_5	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR05	\N	ChIP1_5_NA
1189	ChIP1_6	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR06	\N	ChIP1_6_NA
1190	ChIP1_7	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR07	\N	ChIP1_7_NA
1191	ChIP1_8	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR08	\N	ChIP1_8_NA
1192	ChIP1_9	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR09	\N	ChIP1_9_NA
1193	ChIP1_10	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR10	\N	ChIP1_10_NA
1194	ChIP1_11	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR11	\N	ChIP1_11_NA
1195	ChIP1_12	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	L2DR12	\N	ChIP1_12_NA
1196	CGH11-051	2013-07-31 00:00:00-07	39.4	0	\N	\N	\N	\N	\N	\N	Iwei Translocation	NextFlex 1	\N	CGH11-051
1197	WTMM-17-Tumor	\N	\N	14	\N	\N	100	\N	\N	\N	UCSF Wild Type Melanoma	NextFlex 10	\N	WTMM-17-Tumor_NA
1198	WTMM-18-Tumor	\N	\N	24	\N	\N	100	\N	\N	\N	UCSF Wild Type Melanoma	NextFlex 11	\N	WTMM-18-Tumor_NA
1199	WTMM-19-Tumor	\N	\N	5	\N	\N	100	\N	\N	\N	UCSF Wild Type Melanoma	NextFlex 12	\N	WTMM-19-Tumor_NA
1200	WTMM-20-Tumor	\N	\N	2	\N	\N	100	\N	\N	\N	UCSF Wild Type Melanoma	NextFlex 13	\N	WTMM-20-Tumor_NA
1201	WTMM-21-Tumor	\N	\N	35	\N	\N	100	\N	\N	\N	UCSF Wild Type Melanoma	NextFlex 14	\N	WTMM-21-Tumor_NA
1202	WTMM-22-Tumor	\N	\N	38	\N	\N	100	\N	\N	\N	UCSF Wild Type Melanoma	NextFlex 15	\N	WTMM-22-Tumor_NA
1203	WTMM-23-Tumor	\N	\N	13	\N	\N	100	\N	\N	\N	UCSF Wild Type Melanoma	NextFlex 16	\N	WTMM-23-Tumor_NA
1204	WTMM-24-Tumor	\N	\N	10	\N	\N	100	\N	\N	\N	UCSF Wild Type Melanoma	NextFlex 17	\N	WTMM-24-Tumor_NA
1205	JBP-3-Met1	2014-08-14 00:00:00-07	10	4	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 19	\N	K2_10
1206	JBP-3-Met2	2014-08-14 00:00:00-07	9.29	5	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 20	\N	K2_11_NA
1280	DPN56-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN56-Tumor_NA
1207	JBP-3-MM	2014-08-14 00:00:00-07	9.99	5	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 18	\N	K2_9
1208	JBP-3-Norm	2014-08-14 00:00:00-07	2.98	198	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 17	\N	K2_8
1209	JBP-4-Met1	2014-08-14 00:00:00-07	15.1	5	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 23	\N	K1_14
1210	JBP-4-Met2	2014-08-14 00:00:00-07	14.6	5	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 24	\N	K1_15
1211	JBP-4-MM	2014-08-14 00:00:00-07	8.29	146	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 22	\N	K1_13
1212	JBP-4-Norm	2014-08-14 00:00:00-07	20.3	52	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 21	\N	D76_NA
1213	JBP-5-Met	2014-08-14 00:00:00-07	13.9	11	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 3	\N	K1_18
1214	JBP-5-MM	2014-08-14 00:00:00-07	18.9	6	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 2	\N	K1_17
1215	JBP-5-Norm	2014-08-14 00:00:00-07	19.3	7	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 1	\N	K1_16
1216	JBP-7-Met	2014-08-14 00:00:00-07	18.1	6	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 6	\N	K1_21
1217	JBP-7-MM	2014-08-14 00:00:00-07	17.2	18	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 5	\N	K1_20
1218	JBP-7-Norm	2014-08-14 00:00:00-07	19.1	6	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 4	\N	K1_19
1219	JBP-9-Norm	2014-08-14 00:00:00-07	9.94	6	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 7	\N	K1_22
1220	Long-TN10-Normal	2014-08-14 00:00:00-07	1.73	40	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 13	\N	K2_4
1221	Long-TN10-Tumor	2014-08-14 00:00:00-07	1.39	22	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 14	\N	K2_5
1222	Long-TN11-Normal	2014-08-14 00:00:00-07	1.12	317	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 15	\N	K2_6
1223	Long-TN11-Tumor	2014-08-14 00:00:00-07	4.82	6	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 16	\N	K2_7
1224	PMM-8-Tumor	2014-08-14 00:00:00-07	1.02	Infinity	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 12	\N	K2_3_NA
1225	XD-1-1-Tumor	2014-08-14 00:00:00-07	8.79	38	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 11	\N	K2_2_NA
1226	XD-1-Tumor	2014-08-14 00:00:00-07	15.7	5	\N	6	250	\N	\N	\N	Spike-in Bait Mix 3: TERT1, TERT2, TERT3, SF3B1,SF3B2, NFKBIE	NextFlex 10	\N	K2_1_NA
1227	CP1-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 5	\N	NA_CP1-5_Tumor
1228	CP1-10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 4	\N	NA_CP1-10_Tumor
1229	CP1-20	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 3	\N	NA_CP1-20_Tumor
1230	CP1-40	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 2	\N	NA_CP1-40_Tumor
1231	CP1-80	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 1	\N	NA_CP1-80_Tumor
1232	CP1-Norm	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 6	\N	NA_CP1_Normal
1233	JBP-6-Met	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	JBP-6-Met_NA
1234	JBP-6-MM	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	JBP-6-MM_NA
1235	JBP-6-Norm	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	JBP-6-Norm_NA
1236	JBP-9-Met	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	JBP-9Met_NA
1237	JBP-9-MM	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	JBP-6-MM_NA
1238	JBP-11-Met	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	JBP-11Met
1239	JBP-11-MM	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	JBP-11MM
1240	JBP-11-Norm	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	JBP-11Norm
1241	TCR-Beta-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	TCR-Beta-1_NA
1242	TCR-Beta-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	TCR-Beta-2_NA
1243	UM23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	UM23_NA
1244	UM24	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	UM24_NA
1245	UM25	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	UM25_NA
1246	UM26	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	UM26_NA
1247	KAM3-T-A	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM3-T-A
1248	KAM93-tumor	2015-11-19 00:00:00-08	5.01	18	\N	4	250	\N	\N	\N	\N	D6	\N	KAM93-T
1249	KAM99-tumor	2015-11-19 00:00:00-08	4.41	9	\N	4	250	\N	\N	\N	\N	D8	\N	KAM99-T
1250	KAM10-Tumor	2015-11-19 00:00:00-08	3.74	7	\N	4	250	\N	\N	\N	\N	D4	\N	KAM10-T
1251	KAM111-tumor	2015-11-19 00:00:00-08	7.64	\N	\N	4	\N	\N	\N	\N	\N	E7	\N	KAM111-T-A1,KAM111-T-A2
1252	KAM100-tumor	2015-11-19 00:00:00-08	6.58	18	\N	4	250	\N	\N	\N	\N	D3	\N	KAM100-T-11
1253	KAM14-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM14-T
1254	KAM26-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM26-T
1255	KAM34-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM34-T
1256	KAM37-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM37-T
1257	KAM43-T	\N	\N	0	\N	4	\N	\N	\N	\N	\N	\N	\N	KAM43-T
1258	KAM48-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM48-T
1259	KAM62-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM62-T
1260	KAM65-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM65-T
1261	KAM71-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM71-T
1262	KAM79-T	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM79-T
1263	KAM95-T-B1	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	KAM95-T-B1
1264	JBU7-MVP	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	JBU7-MVP
1265	JBU7-Norm	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	JBU7-Norm
1266	JBU8-MVP	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	JBU8-MVP
1267	JBU8-Norm	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	JBU8-Norm
1268	JBU10-MVP	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	JBU10-MVP
1269	JBU10-Norm	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	JBU10-Norm
1270	JBU11-MVP	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	JBU11-MVP
1271	JBU11-Norm	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	JBU11-Norm
1272	UM38-Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	UM38-Normal_NA
1273	UM38-Tumor	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	UM38-Tumor_NA
1274	DPN49-Tumor	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN 49
1275	DPN50-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN50-Tumor_NA
1276	DPN51-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN51-Tumor_NA
1277	DPN52-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN52-Tumor_NA
1278	DPN53-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN53-Tumor_NA
1279	DPN55-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN55-Tumor_NA
1281	DPN57-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN57-Tumor_NA
1282	DPN58-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN58-Tumor_NA
1283	DPN60-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN60-Tumor_NA
1284	DPN61-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN61-Tumor_NA
1285	DPN62-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN62-Tumor_NA
1286	AM-15-Tumor	\N	6.43	0	5.57	6	\N	\N	\N	\N	\N	A7	\N	AM-15-Tumor
1288	AM-16-Tumor	\N	29.8	0	36.16	6	\N	\N	\N	\N	\N	A8	\N	AM-16-Tumor
1290	AM-17-Tumor	\N	15.5	0	18.11	6	\N	\N	\N	\N	\N	A9	\N	AM-17-Tumor
1292	AM-18-Tumor	\N	1.54	0	1.29	6	\N	\N	\N	\N	\N	A10	\N	AM-18-Tumor
1294	AM-19-Tumor	\N	14.5	0	15.91	6	\N	\N	\N	\N	\N	A11	\N	AM-19-Tumor
1296	AM-20-Tumor	\N	6.1	0	7.22	6	\N	\N	\N	\N	\N	A12	\N	AM-20-Tumor
1298	AM-21-Tumor	\N	3.67	0	3.89	6	\N	\N	\N	\N	\N	B1	\N	AM-21-Tumor
1300	AM-22-Tumor	\N	8.99	0	10.38	6	\N	\N	\N	\N	\N	B2	\N	AM-22-Tumor
1302	AM-23-Tumor	\N	7.2	0	9	6	\N	\N	\N	\N	\N	B3	\N	AM-23-Tumor
1304	AM-24-Tumor	\N	7.53	0	8.46	6	\N	\N	\N	\N	\N	B4	\N	AM-24-Tumor
1306	AM-25-Tumor	\N	11.1	0	13.01	6	\N	\N	\N	\N	\N	B5	\N	AM-25-Tumor
1308	AM-26-Tumor	\N	12.6	0	12.95	6	\N	\N	\N	\N	\N	B6	\N	AM-26-Tumor
1310	KAM127-N	\N	23.6	0	26.13	6	\N	\N	\N	\N	\N	A2	\N	KAM127-N
1311	KAM127-T	\N	20	0	21.73	6	\N	\N	\N	\N	\N	A1	\N	KAM127-T
1312	KAM128-T	\N	1.93	0	1.5	6	\N	\N	\N	\N	\N	A3	\N	KAM128-T
1313	KAM130-T	\N	1.2	0	1.04	6	\N	\N	\N	\N	\N	A4	\N	KAM130-T
1314	KAM131-N	\N	4.27	0	4.54	6	\N	\N	\N	\N	\N	A6	\N	KAM131-N
1315	KAM131-T	\N	17.7	0	19.72	6	\N	\N	\N	\N	\N	A5	\N	KAM131-T
1316	AM-27-Tumor	\N	29.2	0	39.06	6	\N	\N	\N	\N	\N	B7	\N	AM-27-Tumor
1318	AM-28-Tumor	\N	3.49	0	3.37	6	\N	\N	\N	\N	\N	B8	\N	AM-28-Tumor
1320	AM-29-Tumor	\N	10.4	0	11.23	6	\N	\N	\N	\N	\N	B9	\N	AM-29-Tumor
1322	AM-30-Tumor	\N	15.6	0	16.64	6	\N	\N	\N	\N	\N	B10	\N	AM-30-Tumor
1324	AM-31-Tumor	\N	6.03	0	6.12	6	\N	\N	\N	\N	\N	B11	\N	AM-31-Tumor
1326	AM-32-Tumor	\N	10.4	0	10.5	6	\N	\N	\N	\N	\N	B12	\N	AM-32-Tumor
1328	DPN-49-Graz	\N	5.27	0	2.86	6	\N	\N	\N	\N	\N	C1	\N	DPN 49
1329	Rob-T001-Mel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C3	\N	Rob-T001-Mel_NA
1330	Rob-T001-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C2	\N	Rob-T001-Normal_NA
1331	Rob-T003-Mel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C5	\N	Rob-T003-Mel_NA
1332	Rob-T003-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C4	\N	Rob-T003-Normal_NA
1333	Rob-T005-Nev	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C7	\N	Rob-T005-Nev_NA
1334	Rob-T005-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C6	\N	Rob-T005-Normal_NA
1335	Rob-T008-Nev	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C9	\N	Rob-T008-Nev_NA
1336	Rob-T008-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C8	\N	Rob-T008-Normal_NA
1337	Rob-T009-Nev	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C11	\N	Rob-T009-Nev_NA
1338	Rob-T009-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C10	\N	Rob-T009-Normal_NA
1339	Rob-T010-Nev	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	D1	\N	Rob-T010-Nev_NA
1340	Rob-T010-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	C12	\N	Rob-T010-Normal_NA
1341	2180_Mel1	2023-04-06 00:00:00-07	\N	9	\N	\N	350	\N	\N	\N	SM-MQTSC; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-330
1342	2181_Mel2	2023-04-06 00:00:00-07	\N	10	\N	\N	350	\N	\N	\N	SM-MQTSD; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-331
1343	2182_Nevus	2023-04-06 00:00:00-07	\N	9	\N	\N	350	\N	\N	\N	SM-MQTSE; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-332
1344	2183_Normal	2023-04-06 00:00:00-07	\N	30	\N	\N	250	\N	\N	\N	SM-MQTSF; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-333
1345	2184_Mel	2023-04-06 00:00:00-07	\N	90	\N	\N	250	\N	\N	\N	SM-MQTSG; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-334
1346	2185_Nevus	2023-04-06 00:00:00-07	\N	32	\N	\N	200	\N	\N	\N	SM-MQTSH; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-335
1347	2186_Normal	2023-04-06 00:00:00-07	\N	176	\N	\N	116	\N	\N	\N	SM-MTN3L; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-336
1348	2187_Mel	2023-04-06 00:00:00-07	\N	12	\N	\N	250	\N	\N	\N	SM-MTHZS; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-337
1349	2188_Nevus	2023-04-06 00:00:00-07	\N	52	\N	\N	250	\N	\N	\N	SM-MQTUV; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-338
1350	2189_Normal	2023-04-06 00:00:00-07	\N	88	\N	\N	153	\N	\N	\N	SM-MQTSL; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-339
1351	2190_Mel	2023-04-06 00:00:00-07	\N	12	\N	\N	250	\N	\N	\N	SM-MQTSM; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-340
1352	2191_Nevus	2023-04-06 00:00:00-07	\N	34	\N	\N	250	\N	\N	\N	SM-MQTSN; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-341
1353	2192_Normal	2023-04-06 00:00:00-07	\N	264	\N	\N	190	\N	\N	\N	SM-MQTSO; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-342
1354	2196_Mel	2023-04-06 00:00:00-07	\N	12	\N	\N	250	\N	\N	\N	SM-MQTSS; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-348
1355	2197_MIS	2023-04-06 00:00:00-07	\N	52	\N	\N	250	\N	\N	\N	SM-MQTST; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-350
1356	2198_Nevus	2023-04-06 00:00:00-07	\N	46	\N	\N	250	\N	\N	\N	SM-MQTSU; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-351
1357	2199_Normal	2023-04-06 00:00:00-07	\N	125	\N	\N	250	\N	\N	\N	SM-MTLID; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-353
1358	2200_Mel	2023-04-06 00:00:00-07	\N	32	\N	\N	250	\N	\N	\N	SM-MQTUU; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-355
1359	2201_MIS	2023-04-06 00:00:00-07	\N	16	\N	\N	250	\N	\N	\N	SM-MQTSX; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-356
1360	2202_Nevus	2023-04-06 00:00:00-07	\N	88	\N	\N	131	\N	\N	\N	SM-MQTSY; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-357
1361	2203_Normal	2023-04-06 00:00:00-07	\N	77	\N	\N	250	\N	\N	\N	SM-MQTSZ; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-358
1362	2204_Mel	2023-04-06 00:00:00-07	\N	35	\N	\N	250	\N	\N	\N	SM-MQTT1; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-359
1363	2205_Nevus	2023-04-06 00:00:00-07	\N	153	\N	\N	250	\N	\N	\N	SM-MQTT2; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-361
1364	2207_MIS	2023-04-06 00:00:00-07	\N	24	\N	\N	250	\N	\N	\N	SM-MQTT4; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-364
1365	2208_Nevus	2023-04-06 00:00:00-07	\N	53	\N	\N	250	\N	\N	\N	SM-MQTT5; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-365
1366	2209_PRAME-positive_Nevus	2023-04-06 00:00:00-07	\N	88	\N	\N	285	\N	\N	\N	SM-MQTT6; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-366
1367	2210_Normal	2023-04-06 00:00:00-07	\N	264	\N	\N	250	\N	\N	\N	SM-MQTT7; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-367
1368	2211_Mel	2023-04-06 00:00:00-07	\N	29	\N	\N	250	\N	\N	\N	SM-MTKPX; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-369
1369	2212_MIS	2023-04-06 00:00:00-07	\N	88	\N	\N	228	\N	\N	\N	SM-MQTUT; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-372
1370	2213_Nevus	2023-04-06 00:00:00-07	\N	88	\N	\N	256	\N	\N	\N	SM-MQTTA; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-373
1371	2214_Normal	2023-04-06 00:00:00-07	\N	261	\N	\N	139	\N	\N	\N	SM-MQTTB; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-374
1372	2215_Mel	2023-04-06 00:00:00-07	\N	13	\N	\N	250	\N	\N	\N	SM-MQTTC; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-377
1373	2216_Nevus	2023-04-06 00:00:00-07	\N	11	\N	\N	250	\N	\N	\N	SM-MQTTE; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-379
1374	2217_Regressed-Area	2023-04-06 00:00:00-07	\N	23	\N	\N	250	\N	\N	\N	SM-MQTTF; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-381
1375	2218_Normal	2023-04-06 00:00:00-07	\N	88	\N	\N	127	\N	\N	\N	SM-MQTTG; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-382
1376	2219_Mel	2023-04-06 00:00:00-07	\N	33	\N	\N	250	\N	\N	\N	SM-MQTTH; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-383
1377	2220_MIS	2023-04-06 00:00:00-07	\N	41	\N	\N	250	\N	\N	\N	SM-MQTTI; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-385
1378	2221_Nevus	2023-04-06 00:00:00-07	\N	33	\N	\N	250	\N	\N	\N	SM-MQTTJ; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-387
1379	2222_Normal	2023-04-06 00:00:00-07	\N	\N	\N	\N	\N	\N	\N	\N	SM-MTL7E; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-388,DNA-423
1380	2223_Mel1	2023-04-06 00:00:00-07	\N	69	\N	\N	250	\N	\N	\N	SM-MTMX4; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-390
1381	2224_Mel2	2023-04-06 00:00:00-07	\N	88	\N	\N	237	\N	\N	\N	SM-MQTTM; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-391
1382	2225_Nevus	2023-04-06 00:00:00-07	\N	27	\N	\N	250	\N	\N	\N	SM-MQTTN; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-392
1383	2227_Mel	2023-04-06 00:00:00-07	\N	11	\N	\N	350	\N	\N	\N	SM-MQTTP; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-394
1384	2228_Nevus	2023-04-06 00:00:00-07	\N	16	\N	\N	250	\N	\N	\N	SM-MQTTQ; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-396
1385	2229_Normal	2023-04-06 00:00:00-07	\N	\N	\N	\N	\N	\N	\N	\N	SM-MQTTR; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-397,DNA-420
1386	2230_Mel	2023-04-06 00:00:00-07	\N	26	\N	\N	250	\N	\N	\N	SM-MQTTS; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-399
1387	2231_MIS	2023-04-06 00:00:00-07	\N	28	\N	\N	250	\N	\N	\N	SM-MQTTT; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-401
1388	2232_Nevus	2023-04-06 00:00:00-07	\N	57	\N	\N	250	\N	\N	\N	SM-MQTTU; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-402
1389	2233_Normal	2023-04-06 00:00:00-07	\N	17	\N	\N	350	\N	\N	\N	SM-MQTTV; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-403
1390	2234_Mel	2023-04-06 00:00:00-07	\N	88	\N	\N	252	\N	\N	\N	SM-MVZGV; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-404
1391	2235_Nevus	2023-04-06 00:00:00-07	\N	58	\N	\N	250	\N	\N	\N	SM-MW1V9; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-405
1392	2236_Normal	2023-04-06 00:00:00-07	\N	57	\N	\N	119	\N	\N	\N	SM-MW3G4; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-407
1393	2237_MIS	2023-04-06 00:00:00-07	\N	22	\N	\N	250	\N	\N	\N	SM-MQTTD; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-417
1394	2238_Mel	2023-04-06 00:00:00-07	\N	12	\N	\N	250	\N	\N	\N	SM-MQTSP; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-344
1395	2239_Nevus	2023-04-06 00:00:00-07	\N	70	\N	\N	250	\N	\N	\N	SM-MQTSQ; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-346
1396	2240_Normal	2023-04-06 00:00:00-07	\N	46	\N	\N	250	\N	\N	\N	SM-MQTSR; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-347
1397	2241_Normal	2023-04-06 00:00:00-07	\N	17	\N	\N	250	\N	\N	\N	SM-MQTT3; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-418
1398	2242_Normal	2023-04-06 00:00:00-07	\N	7	\N	\N	350	\N	\N	\N	SM-MQTTO; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-419
1399	2243_MIS	2023-04-06 00:00:00-07	\N	23	\N	\N	250	\N	\N	\N	SM-MQTS9; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-421
1400	2244_Nevus	2023-04-06 00:00:00-07	\N	156	\N	\N	250	\N	\N	\N	SM-MQTSA; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-320
1401	2245_Normal	2023-04-06 00:00:00-07	\N	52	\N	\N	250	\N	\N	\N	SM-MQTSB; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-422
1402	2043_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-088
1403	2044_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-089
1404	2045_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-090
1405	2046_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-091
1406	2047_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-092
1407	2048_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-093
1408	2049_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-094
1409	2050_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-095
1410	2051_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-096
1411	2052_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-097
1412	2053_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-098
1413	2054_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-099
1414	2268_Met1-2269_Met2	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-100
1415	2270_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	NM D-101
1416	2287_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-424
1417	2288_Melanocytoma	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-425
1418	2289_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-426
1419	2290_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-427
1420	2291_Nevus	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-428
1421	2292_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-429
1422	2293_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-430
1423	2294_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-431
1424	2295_MIS	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-432
1425	2296_Nevus	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-433
1426	2297_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-434
1427	2298_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-435
1428	2299_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-436
1429	2300_Nevus	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-437
1430	2301_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-438
1431	2443_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-439
1432	2444_MIS	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-440
1433	2445_Nevus	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-441
1434	2446_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-442
1435	2447_Mel	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-443
1436	2448_Nevus	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-444
1437	2449_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-445
1438	2450_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-016
1439	2451_MIS	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-017
1440	2452_Invasive	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-018
1441	2456_Tumor	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	22-104389A2-DNA
1442	2457_Tumor	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	22-104389C-DNA
1443	2459_MIS	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-446
1444	2460_Nevus	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-447
1445	2461_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-448
1446	2463_Melanoma-Cell-Line	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	DNA-144 Imat B15
1447	2465_Cell-Line	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	144aI WT
1448	2466_Cell-Line	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	230 WT
1449	2467_Melanoma-Cell-Line	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	M230 Imat A2
1450	2468_Melanoma-Cell-Line	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	M230 Imat A3
1451	2494_Invasive	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-004
1452	2495_MIS	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-005
1453	2496_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-006
1454	2497_Invasive	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-007
1455	2498_MIS	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-008
1456	2499_Normal_flag	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-009
1457	2500_Invasive	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-010
1458	2501_MIS	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-011
1459	2502_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-012
1460	2503_Invasive	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-013
1461	2504_MIS	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-014
1462	2505_Normal	\N	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	\N	LMM D-015
1463	892_Mel	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ8I; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-132,DNA-266
1464	893_Nevus	2022-11-15 00:00:00-08	\N	21	\N	\N	150	\N	\N	\N	SM-MQT6A; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-133
1465	894_Normal	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ5L; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-131,DNA-267,DNA-270,DNA-271
1466	1641_Mel	2022-11-15 00:00:00-08	\N	60	\N	\N	150	\N	\N	\N	SM-MRJ8C; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-199
1467	1917_Mel	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ7Q; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-160,DNA-203
1468	1918_MIS	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ7S; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-161,DNA-204
1469	1919_Nevus	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ7T; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-162,DNA-205
1470	1921_Mel	2022-11-15 00:00:00-08	\N	13	\N	\N	150	\N	\N	\N	SM-MRJ7V; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-164
1471	1922_Nevus	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ87; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-165,DNA-208
1472	1926_Mel	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ7W; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-169,DNA-212
1473	1927_MIS	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ7X; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-170,DNA-213
1474	1928_Nevus	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ7Y; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-171,DNA-214
1475	1930_Normal	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ89; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-216,DNA-173
1476	1931_Mel	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ8G; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-174,DNA-217
1477	1932_MIS	2022-11-15 00:00:00-08	\N	71	\N	\N	150	\N	\N	\N	SM-MRJ85; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-175
1478	1933_Nevus	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ8A; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-176,DNA-219,DNA-252
1479	1944_Mel	2022-11-15 00:00:00-08	\N	11	\N	\N	150	\N	\N	\N	SM-MRJ8E; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-187
1480	1945_Nevus	2022-11-15 00:00:00-08	\N	72	\N	\N	150	\N	\N	\N	SM-MRJ83; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-188
1481	1946_Normal	2022-11-15 00:00:00-08	\N	61	\N	\N	150	\N	\N	\N	SM-MRJ84; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-189
1482	1947_Melanocytoma	2022-11-15 00:00:00-08	\N	88	\N	\N	150	\N	\N	\N	SM-MRJ81; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-190
1483	1948_Nevus	2022-11-15 00:00:00-08	\N	88	\N	\N	150	\N	\N	\N	SM-MRJ82; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-191
1484	1949_1956_Normal	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ8B; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-236,DNA-192,DNA-201,DNA-244,DNA-255
1485	1951_Mel	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ8D; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-194,DNA-238
1486	1952_Nevus	2022-11-15 00:00:00-08	\N	23	\N	\N	150	\N	\N	\N	SM-MRJ86; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-195
1487	1953_Normal	2022-11-15 00:00:00-08	\N	40	\N	\N	150	\N	\N	\N	SM-MRJ8H; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-240
1488	1954_MIS	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ8F; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-197,DNA-233
1489	1955_Normal	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ88; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-198,DNA-241,DNA-256
1490	1958_Normal	2022-11-15 00:00:00-08	\N	\N	\N	\N	\N	\N	\N	\N	SM-MRJ7Z; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-258,DNA-263
1491	2036_Normal	2022-11-15 00:00:00-08	\N	18	\N	\N	150	\N	\N	\N	SM-MRJ7U; GATK4-Mutect2/CNV pipeline	\N	\N	DNA-259
1492	2038_Mel	2022-11-15 00:00:00-08	\N	10	\N	\N	150	\N	\N	\N	SM-MRJ5K; GATK4-Mutect2/CNV pipeline	\N	\N	NM D-084
1493	2039_Mel	2022-11-15 00:00:00-08	\N	10	\N	\N	150	\N	\N	\N	SM-MRJ5J; GATK4-Mutect2/CNV pipeline	\N	\N	NM D-085
1494	2040_Mel	2022-11-15 00:00:00-08	\N	8	\N	\N	150	\N	\N	\N	SM-MRJ5I; GATK4-Mutect2/CNV pipeline	\N	\N	NM D-086
1495	2041_Normal	2022-11-15 00:00:00-08	\N	109	\N	\N	150	\N	\N	\N	SM-MRJ5H; GATK4-Mutect2/CNV pipeline	\N	\N	NM D-087
1496	VMRLP-41	2018-11-05 00:00:00-08	14.6	17	32.89	11	400	\N	\N	\N	RLP-41	65	\N	RNA-41
1497	VMRLP-42	2018-11-05 00:00:00-08	8.93	20	18.31	11	106	\N	\N	\N	RLP-42	66	\N	RNA-42
1498	VMRLP-43	2018-11-05 00:00:00-08	13.1	20	26.38	11	232	\N	\N	\N	RLP-43	67	\N	RNA-43
1499	VMRLP-44	2018-11-05 00:00:00-08	10.7	7	21.58	11	400	\N	\N	\N	RLP-44	68	\N	RNA-44
1500	VMRLP-45	2018-11-05 00:00:00-08	8.67	20	18.61	11	192	\N	\N	\N	RLP-45	69	\N	RNA-45
1501	VMRLP-46	2018-11-05 00:00:00-08	7.79	20	16.53	11	70	\N	\N	\N	RLP-46	70	\N	RNA-46
1502	VMRLP-47	2018-11-05 00:00:00-08	4.98	20	11.48	11	86	\N	\N	\N	RLP-47	71	\N	RNA-47
1503	VMRLP-48	2018-11-05 00:00:00-08	8.29	17	18.01	11	400	\N	\N	\N	RLP-48	72	\N	RNA-48
1504	VMRLP-49	2018-11-05 00:00:00-08	23.7	3	47.7	11	400	\N	\N	\N	RLP-49	73	\N	RNA-49
1505	VMRLP-50	2018-11-05 00:00:00-08	4.55	7	9.05	11	400	\N	\N	\N	RLP-50	74	\N	RNA-50
1506	VMRLP-51	2018-11-05 00:00:00-08	15	20	30.39	11	280	\N	\N	\N	RLP-51	75	\N	RNA-51
1507	VMRLP-52	2018-11-05 00:00:00-08	18	20	39.94	11	300	\N	\N	\N	RLP-52	76	\N	RNA-52
1508	VMRLP-53	2018-11-05 00:00:00-08	22.7	4	54.77	11	400	\N	\N	\N	RLP-53	77	\N	RNA-53
1509	VMRLP-54	2018-11-05 00:00:00-08	14.7	20	33.88	11	200	\N	\N	\N	RLP-54	78	\N	RNA-54
1510	VMRLP-55	2018-11-05 00:00:00-08	17.3	4	39.67	11	400	\N	\N	\N	RLP-55, Sample removed from study	79	\N	RNA-55
1511	VMRLP-56	2018-11-05 00:00:00-08	14.8	2	32.57	11	400	\N	\N	\N	RLP-56, Sample removed from study	80	\N	RNA-56
1512	VMRLP-59	2018-11-05 00:00:00-08	7.13	20	14.45	11	94	\N	\N	\N	RLP-59	83	\N	RNA-59
1513	VMRLP-60	2018-11-05 00:00:00-08	5.39	20	10.64	11	32	\N	\N	\N	RLP-60	84	\N	RNA-60
1514	VMRLP-61	2018-11-05 00:00:00-08	23.6	7	51.79	11	400	\N	\N	\N	RLP-61	85	\N	RNA-61
1515	VMRLP-62	2018-11-05 00:00:00-08	12.8	8	28.64	11	400	\N	\N	\N	RLP-62	86	\N	RNA-62
1516	VMRLP-63	2018-11-05 00:00:00-08	14	10	32.35	11	400	\N	\N	\N	RLP-63	87	\N	RNA-63
1517	RLP-65	2018-11-05 00:00:00-08	10.2	2	21.66	11	400	\N	\N	\N	RLP-65, Sample removed from study	89	\N	RNA-65
1518	RLP-66	2018-11-05 00:00:00-08	1.57	2	3.28	11	400	\N	\N	\N	RLP-66, Sample removed from study	90	\N	RNA-66
1519	CGP-600	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-545
1520	CGP-601	\N	2.61	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-546
1521	CGP-602	\N	11.4	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-547
1522	CGP-603	\N	4.72	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-548
1523	CGP-604	\N	4.89	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-549
1524	CGP-605	\N	11.5	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-550
1525	CGP-606	\N	3.53	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 143	\N	\N	D-NA-551
1526	CGP-607	\N	19.2	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 390	\N	\N	D-NA-552
1527	CGP-608	\N	27.7	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 393	\N	\N	D-NA-553
1528	CGP-609	\N	0	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 412	\N	\N	D-NA-554
1529	CGP-610	\N	0	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 385	\N	\N	D-NA-555
1530	CGP-611	\N	2.71	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 450	\N	\N	D-NA-556
1531	CGP-612	\N	0	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 28	\N	\N	D-NA-557
1532	CGP-613	\N	0	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 227	\N	\N	D-NA-558
1533	CGP-614	\N	2.71	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 346	\N	\N	D-NA-559
1534	CGP-615	\N	0	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 519	\N	\N	D-NA-560
1535	CGP-616	\N	0	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 396	\N	\N	D-NA-561
1536	CGP-617	\N	3.34	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 473	\N	\N	D-NA-562
1537	CGP-618	\N	0	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 272	\N	\N	D-NA-563
1538	CGP-619	\N	0	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 370	\N	\N	D-NA-564
1539	CGP-620	\N	3.79	0	0	4	\N	\N	\N	\N	Mean Target Coverage: 401	\N	\N	D-NA-565
1540	CGP-664	\N	0	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 99	\N	\N	D-NA-585
1541	CGP-665	\N	0	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 126	\N	\N	D-NA-586
1542	CGP-666	\N	0	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 274	\N	\N	D-NA-587
1543	CGP-667	\N	4.62	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 151	\N	\N	D-NA-588
1544	CGP-668	\N	3.35	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 47	\N	\N	D-NA-589
1545	CGP-669	\N	5.55	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 67	\N	\N	D-NA-590
1546	CGP-672	\N	0	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 18	\N	\N	D-NA-645
1547	CGP-673	\N	6.04	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 320	\N	\N	D-NA-646
1548	CGP-674	\N	4.32	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 164	\N	\N	D-NA-647
1549	CGP-675	\N	11.8	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 228	\N	\N	D-NA-620
1550	CGP-676	\N	2.59	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 161	\N	\N	D-NA-621
1551	CGP-677	\N	17.1	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 279	\N	\N	D-NA-622
1552	CGP-678	\N	7.54	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 337	\N	\N	D-NA-623
1553	CGP-683	\N	3.2	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 311	\N	\N	D-NA-628
1554	CGP-684	\N	2	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 169	\N	\N	D-NA-629
1555	CGP-685	\N	8.13	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 358	\N	\N	D-NA-630
1556	CGP-686	\N	4.98	0	0	5	\N	\N	\N	\N	Mean Target Coverage: 351	\N	\N	D-NA-631
1557	CGP-679	\N	4.21	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-624
1558	CGP-680	\N	0	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-625
1559	CGP-681	\N	4.58	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-626
1560	CGP-682	\N	7.79	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-627
1561	CGP-583	\N	0	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-537
1562	CGP-584	\N	19.5	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-538
1563	CGP-998	\N	0	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-537
1564	CGP-999	\N	0	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-538
1565	CGP-585	\N	66	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-539
1566	CGP-586	\N	6.17	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-540
1567	CGP-587	\N	29.5	0	0	\N	\N	\N	\N	\N	\N	\N	\N	D-NA-541
1568	CGP-1481	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1481_NA
1569	CGP-1482	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1482_NA
1570	CGP-1483	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1483_NA
1571	CGP-1550	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1550_NA
1572	CGP-1551	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1551_NA
1573	CGP-1552	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1552_NA
1574	CGP-1544	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1544_NA
1575	CGP-1545	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1545_NA
1576	CGP-1546	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1546_NA
1577	CGP-1547	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1547_NA
1578	CGP-1548	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1548_NA
1579	CGP-1549	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1549_NA
1580	CGP-1553	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1553_NA
1581	CGP-1554	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1554_NA
1582	CGP-1555	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1555_NA
1583	CGP-1556	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1556_NA
1584	CGP-1557	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1557_NA
1585	CGP-1558	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1558_NA
1586	CGP-1559	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1559_NA
1587	CGP-1560	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1560_NA
1588	CGP-1561	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1561_NA
1589	CGP-1575	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1575_NA
1590	CGP-1576	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1576_NA
1591	CGP-1577	\N	0	\N	0	\N	\N	\N	\N	\N	\N	\N	\N	CGP-1577_NA
1592	DLP-011	2019-01-02 00:00:00-08	3.15	48	1.52	4	92.2	\N	\N	\N	\N	7	\N	DNA-11
1593	DLP-012	2019-01-02 00:00:00-08	6.3	38	3.21	4	250	\N	\N	\N	\N	8	\N	DNA-12
1594	DLP-021	2019-01-02 00:00:00-08	4.7	48	1.83	4	94.6	\N	\N	\N	Sample removed from study	13	\N	DNA-21
1595	DLP-022	2019-01-02 00:00:00-08	2.75	23	2.85	4	250	\N	\N	\N	Sample removed from study	14	\N	DNA-22
1596	DLP-043	2019-01-02 00:00:00-08	2.65	48	1.56	4	92.2	\N	\N	\N	\N	65	\N	DNA-43
1597	DLP-044	2019-01-02 00:00:00-08	2.59	48	1.63	4	99.8	\N	\N	\N	\N	66	\N	DNA-44
1598	DLP-045	2019-01-02 00:00:00-08	4.26	46	2.38	4	250	\N	\N	\N	\N	67	\N	DNA-45
1599	DLP-046	2019-01-02 00:00:00-08	2.32	48	1.34	4	123.4	\N	\N	\N	\N	68	\N	DNA-46
1600	DLP-049	2019-01-02 00:00:00-08	4.33	17	2.62	4	250	\N	\N	\N	\N	71	\N	DNA-49
1601	DLP-050	2019-01-02 00:00:00-08	3.2	48	2.21	4	115.2	\N	\N	\N	\N	72	\N	DNA-50
1602	DLP-061	2019-01-02 00:00:00-08	5.55	48	3.19	4	184.3	\N	\N	\N	\N	79	\N	DNA-61
1603	DLP-062	2019-01-02 00:00:00-08	2.16	48	1.43	4	74.9	\N	\N	\N	\N	80	\N	DNA-62
1604	DLP-017	2019-01-02 00:00:00-08	5.83	48	2.79	4	213.6	\N	\N	\N	\N	9	\N	DNA-17
1605	DLP-018	2019-01-02 00:00:00-08	5.59	13	3.01	4	250	\N	\N	\N	\N	10	\N	DNA-18
1606	DLP-055	2019-01-02 00:00:00-08	4.97	17	2.73	4	250	\N	\N	\N	Sample removed from study	73	\N	DNA-55
1607	DLP-056	2019-01-02 00:00:00-08	5.04	13	2.92	4	250	\N	\N	\N	Sample removed from study	74	\N	DNA-56
1608	CGP-9008	\N	\N	0	9.89	\N	\N	\N	\N	\N	\N	87	\N	D-NA-8692
1609	CGP-9023	\N	\N	0	13.23	\N	\N	\N	\N	\N	\N	6	\N	D-NA-8691
1610	DLP-026	2019-04-08 00:00:00-07	4.77	91	2.75	4	194.7	\N	\N	\N	\N	14	\N	DNA-26
1611	DLP-027	2019-04-08 00:00:00-07	4.96	60	3.55	4	229	\N	\N	\N	\N	15	\N	DNA-27
1612	DLP-029	2019-04-08 00:00:00-07	5.58	75	4.01	4	250	\N	\N	\N	\N	63	\N	DNA-29
1613	DLP-031	2019-01-02 00:00:00-08	6.27	20	4.9	4	250	\N	\N	\N	\N	10	\N	DNA-31
1614	DLP-065	2019-04-08 00:00:00-07	5.44	48	3.48	4	239	\N	\N	\N	Sample removed from study	67	\N	DNA-65
1615	DLP-069	2019-04-08 00:00:00-07	2.93	97	2.23	4	160.1	\N	\N	\N	\N	71	\N	DNA-69
1616	DLP-001	2019-04-08 00:00:00-07	1.66	18	0.8	4	52	\N	\N	\N	\N	7	\N	DNA-01
1617	DLP-025	2019-04-08 00:00:00-07	1.88	75	0.85	4	65.6	\N	\N	\N	\N	13	\N	DNA-25
1618	DLP-028	2019-04-08 00:00:00-07	4.56	11	2.26	4	250	\N	\N	\N	\N	16	\N	DNA-28
1619	DLP-030	2019-01-02 00:00:00-08	3.85	48	2.5	4	122.4	\N	\N	\N	\N	9	\N	DNA-30
1620	DLP-041	2019-04-08 00:00:00-07	4.34	41	2.49	4	250	\N	\N	\N	\N	64	\N	DNA-41
1621	DLP-047	2019-01-02 00:00:00-08	3.49	48	1.9	4	198.7	\N	\N	\N	\N	69	\N	DNA-47
1622	DLP-052	2019-04-08 00:00:00-07	2.41	48	2	4	96.5	\N	\N	\N	\N	65	\N	DNA-52
1623	DLP-053	2019-01-02 00:00:00-08	4.9	27	2.3	4	250	\N	\N	\N	\N	75	\N	DNA-53
1624	DLP-054	2019-04-08 00:00:00-07	1.97	48	1.2	4	78.7	\N	\N	\N	\N	76	\N	DNA-54
1625	DLP-59	2019-05-23 00:00:00-07	2.11	48	1.18	4	110	\N	\N	\N	\N	66	\N	DNA-59
1626	DLP-070	2019-04-08 00:00:00-07	1.4	91	1.11	4	50.1	\N	\N	\N	\N	72	\N	DNA-70
1627	DLP-071	2019-04-08 00:00:00-07	1.76	99	1.23	4	73.8	\N	\N	\N	\N	73	\N	DNA-71
1628	DLP-073	2019-04-08 00:00:00-07	1.23	95	0.8	4	49.4	\N	\N	\N	\N	77	\N	DNA-73
1629	DLP-02	2019-05-23 00:00:00-07	\N	64	1.17	4	250	\N	\N	\N	\N	1	\N	DNA-02
1630	DLP-03	2019-05-23 00:00:00-07	\N	27	1.12	4	250	\N	\N	\N	\N	3	\N	DNA-03
1631	DLP-06	2019-05-23 00:00:00-07	\N	0	1.19	4	\N	\N	\N	\N	\N	5	\N	DNA-06
1632	DLP-08	2019-05-23 00:00:00-07	\N	512	1.51	4	247.7	\N	\N	\N	\N	59	\N	DNA-08
1633	DLP-09	2019-05-23 00:00:00-07	\N	553	1.72	4	250	\N	\N	\N	\N	60	\N	DNA-09
1634	DLP-19	2019-05-23 00:00:00-07	\N	66	0.71	4	60.5	\N	\N	\N	Sample removed from study	11	\N	DNA-19
1635	DLP-72	2019-05-23 00:00:00-07	\N	149	0.67	4	51.7	\N	\N	\N	Sample removed from study	74	\N	DNA-72
1636	DLP-75	2019-05-23 00:00:00-07	\N	145	0.88	4	110.6	\N	\N	\N	\N	84	\N	DNA-75
1637	DLP-79	2019-05-23 00:00:00-07	\N	161	0.83	4	154.1	\N	\N	\N	\N	86	\N	DNA-79
1638	DLP-85	2019-05-23 00:00:00-07	\N	96	0.83	4	117.1	\N	\N	\N	Sample removed from study	94	\N	DNA-85
1639	DLP-86	2019-05-23 00:00:00-07	\N	96	2.72	4	183.4	\N	\N	\N	\N	96	\N	DNA-86
1640	DLP-89	2019-06-20 00:00:00-07	5.3	27	3.9	4	250	\N	\N	\N	\N	33	\N	DNA-89
1641	DLP-90	2019-06-20 00:00:00-07	6.6	21	4.63	4	250	\N	\N	\N	\N	34	\N	DNA-90
1642	DLP-91	2019-06-20 00:00:00-07	4.04	48	2.11	4	108	\N	\N	\N	\N	35	\N	DNA-91
1643	DLP-92	2019-06-20 00:00:00-07	2.1	48	1.16	4	71	\N	\N	\N	\N	36	\N	DNA-92
1644	DLP-93	2019-06-20 00:00:00-07	1.86	48	1.12	4	70	\N	\N	\N	\N	37	\N	DNA-93
1645	DLP-94	2019-06-20 00:00:00-07	3.32	1	1.99	4	250	\N	\N	\N	\N	38	\N	DNA-94
1646	DLP-95	2019-06-20 00:00:00-07	5.24	12	3.3	4	250	\N	\N	\N	\N	39	\N	DNA-95
1647	DLP-96	2019-06-20 00:00:00-07	5.09	6	2.99	4	250	\N	\N	\N	\N	40	\N	DNA-96
1648	VMRLP-101	2019-08-07 00:00:00-07	35.5	1	72.27	9	400	\N	\N	\N	cell culture	9	\N	RNA-101 (Mel_1)
1649	VMRLP-102	2019-08-07 00:00:00-07	32.9	1	74.49	9	400	\N	\N	\N	cell culture	10	\N	RNA-102 (Mel_2)
1650	VMRLP-103	2019-08-07 00:00:00-07	29.7	1	67.36	9	400	\N	\N	\N	cell culture	11	\N	RNA-103 (Mel_3)
1651	VMRLP-104	2019-08-07 00:00:00-07	29.8	1	63.85	9	400	\N	\N	\N	cell culture	12	\N	RNA-104 (Mel_4)
1652	VMRLP-105	2019-08-07 00:00:00-07	33.1	1	64.93	9	400	\N	\N	\N	cell culture	13	\N	RNA-105 (Mel_5)
1653	VMRLP-106	2019-08-07 00:00:00-07	36.5	1	66.91	9	400	\N	\N	\N	cell culture	14	\N	RNA-106 (Mel_6)
1654	DLP-04	2019-08-23 00:00:00-07	1.54	0	0.31	4	\N	\N	\N	\N	\N	3	\N	DNA-04
1655	DLP-05	2019-05-23 00:00:00-07	1.31	96	0.29	4	59.8	\N	\N	\N	\N	4	\N	DNA-05
1656	DLP-07	2019-05-23 00:00:00-07	0.89	350	0.42	4	60.5	\N	\N	\N	\N	6	\N	DNA-07
1657	DLP-10	2019-04-08 00:00:00-07	0.82	Infinity	0.58	4	48	\N	\N	\N	\N	8	\N	DNA-10
1658	DLP-15	2019-05-23 00:00:00-07	1.05	154	0.43	4	70.6	\N	\N	\N	\N	61	\N	DNA-15
1659	DLP-16	2019-05-23 00:00:00-07	1.92	231	0.73	4	126.7	\N	\N	\N	\N	62	\N	DNA-16
1660	DLP-20	2019-08-23 00:00:00-07	2.24	Infinity	0.54	4	66.2	\N	\N	\N	Sample removed from study	12	\N	DNA-20
1661	DLP-23	2019-08-23 00:00:00-07	4.63	0	1.12	4	\N	\N	\N	\N	\N	13	\N	DNA-23
1662	DLP-24	2019-05-23 00:00:00-07	0.42	67	0.24	4	94.5	\N	\N	\N	\N	69	\N	DNA-24
1663	DLP-48	2019-01-02 00:00:00-08	0.63	0	0.46	4	\N	\N	\N	\N	\N	70	\N	DNA-48
1664	DLP-059_RE2	2019-05-24 00:00:00-07	1.95	0	0.6	4	\N	\N	\N	\N	\N	83	\N	DNA-59_REPEAT
1665	DLP-059_RE3	2019-08-23 00:00:00-07	1.16	0	0.19	4	\N	\N	\N	\N	\N	83	\N	DNA-59_REPEAT
1666	DLP-68	2019-04-08 00:00:00-07	2.01	Infinity	0.6	4	72.1	\N	\N	\N	\N	68	\N	DNA-68
1667	DLP-76	2019-05-23 00:00:00-07	1.37	117	0.67	4	92.2	\N	\N	\N	\N	85	\N	DNA-76
1668	DLP-80	2019-05-23 00:00:00-07	0.64	71	0.6	4	110.7	\N	\N	\N	\N	87	\N	DNA-80
1669	DLP-81	2019-05-23 00:00:00-07	1.31	105	0.55	4	79.6	\N	\N	\N	Sample removed from study	92	\N	DNA-81
1670	DLP-83	2019-05-23 00:00:00-07	2.56	201	0.3	4	57.2	\N	\N	\N	Sample removed from study	93	\N	DNA-83
1671	DLP-87	2019-08-23 00:00:00-07	4.46	0	1.02	4	\N	\N	\N	\N	\N	95	\N	DNA-87
1672	DLP-88	2019-06-20 00:00:00-07	6.86	15	5.28	4	250	\N	\N	\N	\N	32	\N	DNA-88
1673	RLP-67	2020-08-15 00:00:00-07	17.1	19	28.6	11	400	\N	\N	\N	\N	17	\N	RNA-72
1674	RLP-68	2020-08-15 00:00:00-07	7.47	30	13.02	11	126	\N	\N	\N	\N	18	\N	RNA-73
1675	RLP-69	2020-08-15 00:00:00-07	8	30	13.11	11	221	\N	\N	\N	\N	19	\N	RNA-74
1676	RLP-70	2020-08-15 00:00:00-07	9.38	30	15.04	11	196	\N	\N	\N	\N	20	\N	RNA-75
1677	RLP-73	2020-08-15 00:00:00-07	8.29	10	14.11	11	400	\N	\N	\N	\N	26	\N	RNA-98
1678	RLP-74	2020-08-15 00:00:00-07	8.18	20	12.54	11	105	\N	\N	\N	\N	28	\N	RNA-99
1679	RLP-71	2020-08-15 00:00:00-07	4.18	30	6.01	11	120	\N	\N	\N	\N	24	\N	RNA-76
1680	RLP-72	2020-08-15 00:00:00-07	2.47	20	3.75	11	46	\N	\N	\N	\N	25	\N	RNA-97
1681	RLP-75	2020-08-15 00:00:00-07	2.31	20	3.85	11	50	\N	\N	\N	\N	29	\N	RNA-100
1682	RLP-76	2020-08-15 00:00:00-07	10	11	18.59	11	400	\N	\N	\N	\N	30	\N	RNA-101
1683	RLP-88	2020-10-13 00:00:00-07	9.19	20	21.22	11	348	\N	\N	\N	\N	110	\N	RNA-146
1684	RLP-92	2020-10-13 00:00:00-07	1.96	\N	3.21	11	\N	\N	\N	\N	\N	114	\N	RNA-155,RNA-150
1685	RLP-24	2018-08-20 00:00:00-07	1.2	6	0.8	11	400	\N	\N	\N	RLP-24	E11	\N	RNA-24
1686	RLP-78	2020-09-05 00:00:00-07	4.24	20	6.89	11	220	\N	\N	\N	\N	169	\N	RNA-113
1687	RLP-79	2020-09-05 00:00:00-07	4.68	20	6.25	11	176.6	\N	\N	\N	\N	170	\N	RNA-114
1688	RLP-80	2020-09-05 00:00:00-07	3.04	20	4.88	11	167.8	\N	\N	\N	\N	171	\N	RNA-116
1689	RLP-89	2020-10-13 00:00:00-07	1.87	\N	3.18	11	\N	\N	\N	\N	\N	111	\N	RNA-152,RNA-147
1690	RLP-90	2020-10-13 00:00:00-07	1.58	\N	2.78	11	\N	\N	\N	\N	\N	112	\N	RNA-153,RNA-148
1691	RLP-17	2018-08-20 00:00:00-07	11.7	15	3.3	11	400	\N	\N	\N	RLP-17	B6	\N	RNA-17
1692	RLP-25	2018-09-27 00:00:00-07	4.8	20	7.9	11	86	\N	\N	\N	RLP-25	1	\N	RNA-25
1693	RLP-77	2020-09-05 00:00:00-07	12.9	20	19.04	11	378	\N	\N	\N	\N	168	\N	RNA-107
1694	RLP-81	2020-09-05 00:00:00-07	4.49	20	6.82	11	112.4	\N	\N	\N	\N	172	\N	RNA-124
1695	RLP-82	2020-09-05 00:00:00-07	8.39	20	15.82	11	216	\N	\N	\N	\N	173	\N	RNA-125
1696	RLP-85	2020-09-05 00:00:00-07	11.7	20	20.36	11	42	\N	\N	\N	\N	176	\N	RNA-131
1697	RLP-86	2020-09-05 00:00:00-07	15.3	20	25.94	11	304	\N	\N	\N	\N	177	\N	RNA-132
1698	RLP-87	2020-09-05 00:00:00-07	18.1	7	32.5	11	400	\N	\N	\N	\N	178	\N	RNA-133
1699	RLP-91	2020-10-13 00:00:00-07	3.63	\N	7.1	11	\N	\N	\N	\N	\N	113	\N	RNA-154,RNA-149
1700	RLP-93	2020-10-13 00:00:00-07	3.49	20	6.97	11	116.6	\N	\N	\N	\N	115	\N	RNA-151
1701	DLP-98	2020-08-02 00:00:00-07	6.84	0	5.61	4	\N	\N	\N	\N	\N	131	\N	DNA-98
1702	DLP-99	2020-08-02 00:00:00-07	2.57	0	2.53	4	\N	\N	\N	\N	\N	132	\N	DNA-99
1703	DLP-105	2020-09-03 00:00:00-07	3.48	90	1.57	4	104	\N	\N	\N	\N	183	\N	DNA-118
1704	DLP-108	2020-09-03 00:00:00-07	4.73	71	1.82	4	333	\N	\N	\N	\N	186	\N	DNA-122
1705	DLP-115	2020-09-28 00:00:00-07	2.47	90	0.72	4	111	\N	\N	\N	\N	2	\N	DNA-135
1706	DLP-116	2020-09-28 00:00:00-07	1.91	89	0.7	4	73	\N	\N	\N	\N	31	\N	DNA-136
1707	DLP-117	2020-09-28 00:00:00-07	5.71	70	2.42	4	250	\N	\N	\N	\N	55	\N	DNA-137
1708	DLP-118	2020-09-28 00:00:00-07	6.06	90	2.99	4	224	\N	\N	\N	\N	56	\N	DNA-138
1709	DLP-119	2020-09-28 00:00:00-07	1.58	90	0.62	4	96	\N	\N	\N	\N	73	\N	DNA-141
1710	DLP-120	2020-09-28 00:00:00-07	3.75	61	1.97	4	250	\N	\N	\N	\N	75	\N	DNA-144
1711	DLP-123	2020-10-10 00:00:00-07	3.38	\N	1.52	4	\N	\N	\N	\N	\N	85	\N	DNA-153,DNA-148
1712	DLP-124	2020-10-10 00:00:00-07	1.42	\N	0.7	4	\N	\N	\N	\N	\N	86	\N	DNA-158,DNA-154,DNA-149
1713	DLP-126	2020-10-10 00:00:00-07	3.83	\N	3	4	\N	\N	\N	\N	\N	101	\N	DNA-159,DNA-156,DNA-151
1714	DLP-101	2020-09-03 00:00:00-07	5.17	23	1.78	4	333	\N	\N	\N	\N	179	\N	DNA-108
1715	DLP-102	2020-09-03 00:00:00-07	2.93	90	1.25	4	78	\N	\N	\N	\N	180	\N	DNA-109
1716	DLP-103	2020-09-03 00:00:00-07	0.83	90	0.35	4	21.6	\N	\N	\N	\N	181	\N	DNA-113
1717	DLP-104	2020-09-03 00:00:00-07	0.7	90	0.3	4	19.8	\N	\N	\N	\N	182	\N	DNA-114
1718	DLP-106	2020-09-03 00:00:00-07	5.29	32	2.56	4	333	\N	\N	\N	\N	184	\N	DNA-120
1719	DLP-107	2020-09-03 00:00:00-07	2.44	90	1.48	4	112.5	\N	\N	\N	\N	185	\N	DNA-121
1720	DLP-109	2020-09-03 00:00:00-07	0.99	90	0.41	4	46	\N	\N	\N	\N	187	\N	DNA-123
1721	DLP-110	2020-09-03 00:00:00-07	1	90	0.47	4	42	\N	\N	\N	\N	188	\N	DNA-124
1722	DLP-111	2020-09-03 00:00:00-07	2.08	90	0.85	4	72	\N	\N	\N	\N	189	\N	DNA-125
1723	DLP-114	2020-09-03 00:00:00-07	6.01	90	3.22	4	205	\N	\N	\N	\N	192	\N	DNA-101
1724	DLP-121	2020-10-10 00:00:00-07	4.05	24	2.82	4	250	\N	\N	\N	\N	109	\N	DNA-146
1725	DLP-122	2020-10-10 00:00:00-07	2.77	\N	1.52	4	\N	\N	\N	\N	\N	82	\N	DNA-157,DNA-152,DNA-147
1726	DLP-125	2020-10-10 00:00:00-07	5.78	\N	5.17	4	\N	\N	\N	\N	\N	100	\N	DNA-155,DNA-150
1727	AMLP-468	2023-01-24 00:00:00-08	8.83	5	17.94	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	157	\N	AM2 R-370
1728	AMLP-469	2023-01-24 00:00:00-08	5.22	3	9.24	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	158	\N	AM2 R-371
1729	AMLP-470	2023-01-24 00:00:00-08	8.95	2	15.88	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	169	\N	AM2 R-375
1730	AMLP-471	2023-01-24 00:00:00-08	9.74	5	18.73	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	170	\N	AM2 R-379
1731	AMLP-472	2023-01-24 00:00:00-08	9.24	2	16.14	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	171	\N	AM2 R-380
1732	AMLP-473	2023-01-24 00:00:00-08	7.46	4	13.33	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	172	\N	AM2 R-381
1733	AMLP-474	2023-01-24 00:00:00-08	15.1	19	29.15	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	173	\N	AM2 R-382
1734	AMLP-478	2023-01-24 00:00:00-08	10.2	4	17.53	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	177	\N	AM2 R-412
1735	AMLP-461	2023-01-24 00:00:00-08	5.7	2	11.76	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	149	\N	AM2 R-333
1736	AMLP-462	2023-01-24 00:00:00-08	4.12	3	8.85	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	150	\N	AM2 R-334
1737	AMLP-463	2023-01-24 00:00:00-08	4.43	5	9.15	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	152	\N	AM2 R-336
1738	AMLP-464	2023-01-24 00:00:00-08	5.33	5	11.04	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	153	\N	AM2 R-340
1739	AMLP-465	2023-01-24 00:00:00-08	5.37	4	11.15	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	154	\N	AM2 R-347
1740	AMLP-475	2023-01-24 00:00:00-08	4.93	5	9.71	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	174	\N	AM2 R-400
1741	AMLP-476	2023-01-24 00:00:00-08	6.33	1	11.23	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	175	\N	AM2 R-401
1742	AMLP-477	2023-01-24 00:00:00-08	4.74	3	7.5	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	176	\N	AM2 R-402
1743	AMLP-541	2023-04-05 00:00:00-07	1.19	24	1.94	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	139	\N	AM2 R-504
1744	AMLP-542	2023-04-05 00:00:00-07	0.98	47	1.57	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-550 in BCB057	140	\N	AM2 R-505
1745	AMLP-552	2023-04-05 00:00:00-07	0.62	40	0.92	8	271	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	150	\N	AM2 R-537
1746	AMLP-575	2023-04-21 00:00:00-07	0.6	40	0.55	8	271	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-552 in BCB057	150	\N	AM2 R-537
1747	AMLP-576	2023-04-21 00:00:00-07	0.48	40	0.47	8	271	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-552 in BCB057	150	\N	AM2 R-537
1748	AMLP-580	2023-04-28 00:00:00-07	1.02	47	1.58	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	140	\N	AM2 R-505
1749	AMLP-434	2023-01-13 00:00:00-08	3.03	5	4.26	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	119	\N	AM2 R-227
1750	AMLP-435	2023-01-13 00:00:00-08	3.13	7	4.89	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	120	\N	AM2 R-228
1751	AMLP-437	2023-01-20 00:00:00-08	3.98	3	6.8	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	122	\N	AM2 R-226
1752	AMLP-438	2023-01-20 00:00:00-08	2.49	1	4.25	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	123	\N	AM2 R-229
1753	AMLP-486	2023-01-26 00:00:00-08	3.83	16	6.58	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	185	\N	AM2 R-426
1754	AMLP-537	2023-04-05 00:00:00-07	4.08	0	5.82	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	110	\N	AM2 R-423
1755	AMLP-439	2023-01-20 00:00:00-08	0.54	1	0.78	8	600	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	124	\N	AM2 R-232
1756	AMLP-440	2023-01-20 00:00:00-08	1.38	3	2.04	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	125	\N	AM2 R-233
1757	AMLP-521	2023-03-02 00:00:00-08	2.82	5	3.34	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	160	\N	AM2 R-518
1758	AMLP-553	2023-04-21 00:00:00-07	0.95	1	1.07	8	600	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles. Sequenced as AMLP-439	124	\N	AM2 R-232
1759	AMLP-554	2023-04-21 00:00:00-07	1.03	1	1.23	8	600	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles. Sequenced as AMLP-439	124	\N	AM2 R-232
1760	AMLP-443	2023-01-20 00:00:00-08	2.14	4	3.08	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; PENDING SEQUENCING	128	\N	AM2 R-241
1761	AMLP-444	2023-01-20 00:00:00-08	3.33	0	5.24	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; PENDING SEQUENCING	129	\N	AM2 R-242
1762	AMLP-482	2023-01-24 00:00:00-08	3.67	6	6.55	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; PENDING SEQUENCING	181	\N	AM2 R-453
1763	AMLP-491	2023-01-26 00:00:00-08	1.89	9	3.39	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; PENDING SEQUENCING	190	\N	AM2 R-487
1764	AMLP-492	2023-01-26 00:00:00-08	3.32	9	6.01	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; PENDING SEQUENCING	191	\N	AM2 R-490
1765	AMLP-493	2023-01-26 00:00:00-08	3.05	4	6.03	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; PENDING SEQUENCING	192	\N	AM2 R-491
1766	AMLP-540	2023-04-05 00:00:00-07	0.93	33	1.35	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-577 in BCB055	135	\N	AM2 R-501
1767	AMLP-566	2023-04-21 00:00:00-07	0.84	25	1.33	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	192	\N	AM2 R-516
1768	AMLP-567	2023-04-21 00:00:00-07	1.03	25	1.42	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-566 in BCB055	192	\N	AM2 R-516
1769	AMLP-573	2023-04-21 00:00:00-07	1.1	40	1.25	8	225	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	149	\N	AM2 R-536
1770	AMLP-574	2023-04-21 00:00:00-07	1.03	40	1.31	8	225	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-573 in BCB055	149	\N	AM2 R-536
1771	AMLP-577	2023-04-28 00:00:00-07	1.01	33	1.35	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	135	\N	AM2 R-501
1772	AMLP-578	2023-04-28 00:00:00-07	1.09	46	1.56	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	144	\N	AM2 R-517
1773	AMLP-579	2023-04-28 00:00:00-07	1.01	46	1.58	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-578 in BCB055	144	\N	AM2 R-517
1774	AMLP-445	2023-01-20 00:00:00-08	0.78	14	1.21	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	130	\N	AM2 R-260
1775	AMLP-466	2023-01-24 00:00:00-08	3.2	20	6.68	8	70.4	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	155	\N	AM2 R-356
1776	AMLP-483	2023-01-24 00:00:00-08	1.17	8	1.89	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	182	\N	AM2 R-455
1777	AMLP-484	2023-01-24 00:00:00-08	1.64	10	3.17	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	183	\N	AM2 R-456
1778	AMLP-487	2023-01-26 00:00:00-08	1.63	9	2.59	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	186	\N	AM2 R-468
1779	AMLP-488	2023-01-26 00:00:00-08	0.72	47	1.04	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	187	\N	AM2 R-470
1780	AMLP-556	2023-04-21 00:00:00-07	0.87	14	1.14	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-445 in BCB055	130	\N	AM2 R-260
1781	AMLP-560	2023-04-21 00:00:00-07	0.89	47	1.23	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-488 in BCB055	187	\N	AM2 R-470
1782	AMLP-457	2023-01-20 00:00:00-08	1.76	5	3	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	143	\N	AM2 R-320
1783	AMLP-458	2023-01-20 00:00:00-08	0.61	17	0.93	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	144	\N	AM2 R-328
1784	AMLP-460	2023-01-20 00:00:00-08	4.93	1	8.65	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	151	\N	AM2 R-331
1785	AMLP-558	2023-04-21 00:00:00-07	0.59	17	0.74	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-458 in BCB056	144	\N	AM2 R-328
1786	AMLP-559	2023-04-21 00:00:00-07	0.66	17	0.85	8	400	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-458 in BCB056	144	\N	AM2 R-328
1787	AMLP-562	2023-04-21 00:00:00-07	0.9	26	1.15	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	188	\N	AM2 R-496
1788	AMLP-563	2023-04-21 00:00:00-07	0.93	26	1.15	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; Sequenced as AMLP-562 in BCB056	188	\N	AM2 R-496
1789	AMLP-584	2023-04-28 00:00:00-07	1.91	19	2.9	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	146	\N	AM2 R-461
1790	AMLP-479	2023-01-24 00:00:00-08	1.22	4	1.94	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	178	\N	AM2 R-419
1791	AMLP-480	2023-01-24 00:00:00-08	1.16	6	1.74	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	179	\N	AM2 R-420
1792	AMLP-481	2023-01-24 00:00:00-08	1.52	1	2.57	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	180	\N	AM2 R-422
1793	AMLP-544	2023-04-05 00:00:00-07	1.49	21	2.55	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	142	\N	AM2 R-514
1794	AMLP-583	2023-04-28 00:00:00-07	1.64	46	2.33	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	141	\N	AM2 R-513
1795	AMLP-450	2023-01-20 00:00:00-08	2.64	4	4.71	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	135	\N	AM2 R-308
1796	AMLP-451	2023-01-20 00:00:00-08	1.16	2	1.81	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	136	\N	AM2 R-309
1797	AMLP-453	2023-01-20 00:00:00-08	1.33	2	2.5	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	138	\N	AM2 R-311
1798	AMLP-454	2023-01-20 00:00:00-08	1.37	2	2.71	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	139	\N	AM2 R-312
1799	AMLP-455	2023-01-20 00:00:00-08	3.15	6	5.86	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	140	\N	AM2 R-313
1800	AMLP-456	2023-01-20 00:00:00-08	2.24	4	4.06	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	141	\N	AM2 R-318
1801	AMLP-549	2023-04-05 00:00:00-07	1.31	6	2.03	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	147	\N	AM2 R-531
1802	EXLP-31	2023-05-29 00:00:00-07	0.66	39	0.52	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	162	\N	PROG R-16
1803	EXLP-32	2023-05-29 00:00:00-07	0.63	2	0.66	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	163	\N	PROG R-17
1804	EXLP-33	2023-05-29 00:00:00-07	2.4	6	2.86	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	164	\N	PROG R-18
1805	EXLP-34	2023-05-29 00:00:00-07	1.41	4	1.23	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	165	\N	PROG R-20
1806	EXLP-35	2023-05-29 00:00:00-07	0.38	12	0.26	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	166	\N	PROG R-22
1807	EXLP-36	2023-05-29 00:00:00-07	0.74	6	0.78	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	167	\N	PROG R-23
1808	EXLP-38	2023-05-29 00:00:00-07	0.63	8	0.53	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	169	\N	PROG R-25
1809	EXLP-39	2023-05-29 00:00:00-07	0.21	23	0.13	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	170	\N	PROG R-26
1810	EXLP-44	2023-06-19 00:00:00-07	0.67	39	0.81	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC; Sequenced as EXLP-44 in BCB058	162	\N	PROG R-16
1811	EXLP-45	2023-06-20 00:00:00-07	0.54	2	0.71	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC; Sequenced as EXLP-32 in BCB058	163	\N	PROG R-17
1812	EXLP-47	2023-06-20 00:00:00-07	1.15	4	1.43	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC; Sequenced as EXLP-34 in BCB058	165	\N	PROG R-20
1813	EXLP-48	2023-06-20 00:00:00-07	0.36	12	0.35	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC; Sequenced as EXLP-35 in BCB058	166	\N	PROG R-22
1814	EXLP-49	2023-06-20 00:00:00-07	0.76	6	0.88	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC; Sequenced as EXLP-36 in BCB058	167	\N	PROG R-23
1815	EXLP-51	2023-06-19 00:00:00-07	0.63	8	0.77	8	300	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC; Sequenced as EXLP-38 in BCB058	169	\N	PROG R-25
1816	EXLP-52	2023-06-19 00:00:00-07	0.24	23	0.27	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC; Sequenced as EXLP-39 in BCB058	170	\N	PROG R-26
1817	EXLP-53	2023-06-30 00:00:00-07	0.36	12	0.31	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC; Sequenced as EXLP-35 in BCB058	166	\N	PROG R-22
1818	EXLP-54	2023-06-30 00:00:00-07	0.25	23	0.16	8	500	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC; Sequenced as EXLP-39 in BCB058	170	\N	PROG R-26
1819	IYEH-09	2023-07-25 00:00:00-07	1.27	0	1.56	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	185	\N	22-44183B-RNA
1820	RLP-118	2023-03-03 00:00:00-08	2.71	\N	2.9	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	111	\N	RNA-187,RNA-230
1821	RLP-124	2023-03-03 00:00:00-08	5.79	0	6.28	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	168	\N	RNA-268
1822	RLP-125	2023-03-03 00:00:00-08	10.3	12	15.15	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	121	\N	RNA-195
1823	RLP-126	2023-03-03 00:00:00-08	4.12	1	5.5	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	122	\N	RNA-266
1824	RLP-239	2023-07-18 00:00:00-07	2.38	35	2.89	12	14	\N	\N	\N	65oC X 1 min, 15 uM adapter; 12 cycles	174	\N	RNA-433
1825	RLP-241	2023-07-18 00:00:00-07	6.44	5	7.35	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	176	\N	RNA-436
1826	RLP-242	2023-07-18 00:00:00-07	6.45	7	8.54	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	177	\N	RNA-437
1827	RLP-248	2023-07-25 00:00:00-07	4.19	0	5.67	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	183	\N	RNA-446
1828	RLP-249	2023-07-25 00:00:00-07	3.27	0	4.78	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	184	\N	RNA-447
1829	RLP-199	2023-07-05 00:00:00-07	1.33	9	1.26	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	133	\N	RNA-340
1830	RLP-212	2023-07-05 00:00:00-07	3.57	11	3.16	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	147	\N	RNA-369
1831	RLP-213	2023-07-05 00:00:00-07	2.28	13	2.16	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	148	\N	RNA-372
1832	RLP-214	2023-07-05 00:00:00-07	2.85	22	2.6	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	149	\N	RNA-373
1833	RLP-228	2023-07-11 00:00:00-07	2.33	43	2.52	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	163	\N	RNA-401
1834	RLP-229	2023-07-11 00:00:00-07	1.96	45	2.29	10	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 10 cycles	164	\N	RNA-402
1835	RLP-232	2023-07-11 00:00:00-07	5.77	42	5.45	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	167	\N	RNA-424
1836	RLP-233	2023-07-11 00:00:00-07	5.77	23	6.21	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	168	\N	RNA-425
1837	RLP-234	2023-07-11 00:00:00-07	5.67	61	5.76	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	169	\N	RNA-427
1838	RLP-235	2023-07-11 00:00:00-07	2.77	40	2.99	8	57	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	170	\N	RNA-428
1839	RLP-107	2023-03-03 00:00:00-08	1.11	\N	1.18	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	169	\N	RNA-160,RNA-203
1840	RLP-115	2023-03-03 00:00:00-08	1.47	\N	1.8	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	167	\N	RNA-174,RNA-217
1841	RLP-119	2023-03-03 00:00:00-08	2.32	\N	1.87	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	112	\N	RNA-188,RNA-231
1842	RLP-129	2023-03-08 00:00:00-08	1.86	39	1.76	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	125	\N	RNA-320
1843	RLP-170	2023-06-30 00:00:00-07	0.64	5	0.62	8	150	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	97	\N	RNA-203
1844	RLP-173	2023-06-30 00:00:00-07	0.48	6	0.37	8	150	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	100	\N	RNA-245
1845	RLP-207	2023-07-05 00:00:00-07	0.83	6	0.83	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	142	\N	RNA-359
1846	RLP-217	2023-07-05 00:00:00-07	0.88	9	0.7	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	152	\N	RNA-379
1847	RLP-219	2023-07-11 00:00:00-07	1.1	40	1.15	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	154	\N	RNA-383
1848	RLP-221	2023-07-11 00:00:00-07	1.18	38	1.16	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	156	\N	RNA-387
1849	RLP-222	2023-07-11 00:00:00-07	1.35	48	1.29	10	148.8	\N	\N	\N	65oC X 1 min, 15 uM adapter; 10 cycles	157	\N	RNA-390
1850	RLP-253	2023-08-04 00:00:00-07	1.18	21	0.68	8	175	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	180	\N	RNA-441
1851	RLP-255	2023-08-04 00:00:00-07	1.06	14	0.72	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	182	\N	RNA-444
1852	RLP-171	2023-06-30 00:00:00-07	0.45	9	0.37	8	150	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	98	\N	RNA-204
1853	RLP-174	2023-06-30 00:00:00-07	0.44	18	0.39	8	150	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	101	\N	RNA-208
1854	RLP-175	2023-06-30 00:00:00-07	0.09	20	0.02	8	150	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	102	\N	RNA-212
1855	RLP-176	2023-06-30 00:00:00-07	0.37	12	0.3	8	150	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	103	\N	RNA-213
1856	RLP-177	2023-06-30 00:00:00-07	0.52	30	0.49	8	150	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	104	\N	RNA-214
1857	RLP-184	2023-06-30 00:00:00-07	0.16	19	0.09	8	150	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	114	\N	RNA-234
1858	RLP-185	2023-06-30 00:00:00-07	0.24	32	0.15	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	115	\N	RNA-191
1859	RLP-195	2023-07-05 00:00:00-07	0.48	16	0.39	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	129	\N	RNA-334
1860	RLP-215	2023-07-05 00:00:00-07	0.59	11	0.45	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	150	\N	RNA-377
1861	RLP-216	2023-07-05 00:00:00-07	0.67	15	0.59	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	151	\N	RNA-417
1862	RLP-223	2023-07-11 00:00:00-07	0.67	45	0.55	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	158	\N	RNA-391
1863	RLP-230	2023-07-11 00:00:00-07	0.57	28	0.5	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	165	\N	RNA-404
1864	RLP-231	2023-07-11 00:00:00-07	0.67	58	0.5	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	166	\N	RNA-405
1865	RLP-250	2023-08-04 00:00:00-07	0.61	45	0.38	8	199	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	173	\N	RNA-432
1866	RLP-256	2023-08-04 00:00:00-07	0.28	45	0.18	8	135	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	172	\N	RNA-431
1867	RLP-109	2023-03-03 00:00:00-08	0.77	\N	0.9	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	170	\N	RNA-162,RNA-205
1868	RLP-172	2023-06-30 00:00:00-07	0.77	9	0.64	8	150	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	99	\N	RNA-205
1869	RLP-179	2023-06-30 00:00:00-07	0.47	3	0.42	8	50	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	109	\N	RNA-218
1870	RLP-186	2023-07-05 00:00:00-07	0.68	4	0.59	8	50	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	119	\N	RNA-199
1871	RLP-196	2023-07-05 00:00:00-07	0.61	10	0.56	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	130	\N	RNA-335
1872	RLP-208	2023-07-05 00:00:00-07	0.76	22	0.79	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	143	\N	RNA-361
1873	RLP-218	2023-07-05 00:00:00-07	0.72	24	0.59	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	153	\N	RNA-381
1874	RLP-220	2023-07-11 00:00:00-07	0.92	26	0.87	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	155	\N	RNA-385
1875	RLP-224	2023-07-11 00:00:00-07	0.87	13	0.67	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	159	\N	RNA-392
1876	RLP-226	2023-07-11 00:00:00-07	0.95	17	0.84	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	161	\N	RNA-396
1877	RLP-257	2023-08-04 00:00:00-07	1.02	31	0.81	10	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 10 cycles; 1 hr adapter ligation at 20oC	175	\N	RNA-434
1878	RLP-130	2023-03-08 00:00:00-08	5.31	2	5.99	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	126	\N	RNA-330
1879	RLP-131	2023-03-08 00:00:00-08	5.98	2	6.4	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	127	\N	RNA-331
1880	RLP-132	2023-03-08 00:00:00-08	4.02	4	4.49	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	128	\N	RNA-332
1881	RLP-135	2023-03-08 00:00:00-08	2.93	0	3.54	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	131	\N	RNA-337
1882	RLP-141	2023-03-08 00:00:00-08	2.6	19	3.28	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	137	\N	RNA-351
1883	RLP-143	2023-03-08 00:00:00-08	2.83	2	3.11	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	140	\N	RNA-356
1884	RLP-147	2023-03-08 00:00:00-08	4.5	5	4.99	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	144	\N	RNA-364
1885	RLP-148	2023-03-08 00:00:00-08	3.21	27	3.21	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	145	\N	RNA-365
1886	RLP-236	2023-07-18 00:00:00-07	6.59	40	9.37	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	171	\N	RNA-429
1887	RLP-251	2023-08-04 00:00:00-07	1.72	5	1.17	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	178	\N	RNA-439
1888	RLP-252	2023-08-04 00:00:00-07	1.27	21	0.98	8	188	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	179	\N	RNA-440
1889	RLP-120	2023-03-03 00:00:00-08	2.16	\N	2.26	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	113	\N	RNA-197,RNA-233
1890	RLP-136	2023-03-08 00:00:00-08	2.59	0	2.74	8	\N	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	132	\N	RNA-338
1891	RLP-139	2023-03-08 00:00:00-08	2.41	2	2.76	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	135	\N	RNA-348
1892	RLP-140	2023-03-08 00:00:00-08	2.1	6	2.19	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	136	\N	RNA-350
1893	RLP-142	2023-03-08 00:00:00-08	2.01	8	2.03	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	139	\N	RNA-355
1894	RLP-144	2023-03-08 00:00:00-08	2.6	20	2.38	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	141	\N	RNA-357
1895	RLP-165	2023-03-10 00:00:00-08	1.76	30	2.4	8	100	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	162	\N	RNA-399
1896	RLP-180	2023-06-30 00:00:00-07	0.73	45	0.72	8	150	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	110	\N	RNA-219
1897	RLP-190	2023-07-05 00:00:00-07	0.96	96	0.98	8	341	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	124	\N	RNA-421
1898	RLP-200	2023-07-05 00:00:00-07	1.04	8	1.06	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	134	\N	RNA-341
1899	RLP-211	2023-07-05 00:00:00-07	2.24	48	2.17	8	156	\N	\N	\N	\N	146	\N	RNA-366
1900	RLP-225	2023-07-11 00:00:00-07	1.38	5	1.25	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles	160	\N	RNA-394
1901	RLP-254	2023-08-04 00:00:00-07	1.23	20	0.69	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	181	\N	RNA-443
1902	KALP-001	2023-09-06 00:00:00-07	0.98	63	1.77	4	250	\N	\N	\N	\N	126	\N	KA D-01
1903	KALP-002	2023-09-06 00:00:00-07	6.79	42	3.57	4	250	\N	\N	\N	\N	128	\N	KA D-02
1904	KALP-007	2023-09-06 00:00:00-07	6.34	96	3.25	4	250	\N	\N	\N	\N	138	\N	KA D-13
1905	KALP-008	2023-09-06 00:00:00-07	8.19	11	4.97	4	250	\N	\N	\N	\N	139	\N	KA D-14
1906	KALP-009	2023-09-06 00:00:00-07	4.09	73	1.82	4	250	\N	\N	\N	\N	140	\N	KA D-17
1907	KALP-010	2023-09-06 00:00:00-07	6.22	14	3.52	4	250	\N	\N	\N	\N	141	\N	KA D-18
1908	KALP-011	2023-09-06 00:00:00-07	5.19	46	3.14	4	250	\N	\N	\N	\N	142	\N	KA D-24
1909	KALP-012	2023-09-06 00:00:00-07	3.96	8	1.81	4	250	\N	\N	\N	\N	186	\N	KA D-26
1910	KALP-019	2023-09-15 00:00:00-07	4.9	63	2.36	4	250	\N	\N	\N	Captured as KALP-001 in KAPAEX-35 and sequenced in BCB065.	126	\N	KA D-01
1911	KALP-021	2023-09-15 00:00:00-07	10.6	73	4	4	250	\N	\N	\N	Captured as KALP-009 in KAPAEX-35 and sequenced in BCB065.	140	\N	KA D-17
1912	KALP-022	2023-09-15 00:00:00-07	12.1	8	6.18	4	250	\N	\N	\N	Captured as KALP-012 in KAPAEX-35 and sequenced in BCB065.	186	\N	KA D-26
1913	KALP-003	2023-09-06 00:00:00-07	5.27	94	2.12	4	250	\N	\N	\N	\N	131	\N	KA D-05
1914	KALP-004	2023-09-06 00:00:00-07	7.33	71	2.69	4	250	\N	\N	\N	\N	132	\N	KA D-06
1915	KALP-005	2023-09-06 00:00:00-07	6.43	175	2.49	4	250	\N	\N	\N	\N	136	\N	KA D-09
1916	KALP-006	2023-09-06 00:00:00-07	7.26	29	3.72	4	250	\N	\N	\N	\N	137	\N	KA D-10
1917	KALP-014	2023-09-06 00:00:00-07	0.75	100	0.33	4	250	\N	\N	\N	\N	188	\N	KA D-31
1918	KALP-015	2023-09-06 00:00:00-07	18.1	15	5.18	4	250	\N	\N	\N	\N	189	\N	KA D-32
1919	KALP-020	2023-09-15 00:00:00-07	7.3	94	3.59	4	250	\N	\N	\N	Captured as KALP-003 in KAPAEX-36 and sequenced in BCB066.	131	\N	KA D-05
1920	KALP-023	2023-09-15 00:00:00-07	1.36	100	0.27	4	250	\N	\N	\N	Captured as KALP-014 in KAPAEX-36 and sequenced in BCB066.	188	\N	KA D-31
1921	KALP-024	2023-09-15 00:00:00-07	1.53	100	0.27	4	250	\N	\N	\N	Captured as KALP-014 in KAPAEX-36 and sequenced in BCB066.	188	\N	KA D-31
1922	KALP-025	2023-09-15 00:00:00-07	1.37	100	0.27	4	250	\N	\N	\N	Captured as KALP-014 in KAPAEX-36 and sequenced in BCB066.	188	\N	KA D-31
1923	KALP-027	2023-09-15 00:00:00-07	14.1	13	3.55	4	250	\N	\N	\N	\N	191	\N	KA D-35
1924	KALP-028	2023-09-15 00:00:00-07	12	13	3.55	4	250	\N	\N	\N	Captured as KALP-027 in KAPAEX-36 and sequenced in BCB066.	191	\N	KA D-35
1925	KALP-029	2023-09-15 00:00:00-07	12.2	35	5.85	4	250	\N	\N	\N	\N	192	\N	KA D-36
1926	DLP-127	2022-10-04 00:00:00-07	3.45	0	1.75	4	\N	\N	\N	\N	\N	153	\N	DNA-275
1927	DLP-128	2022-10-04 00:00:00-07	1.42	\N	0.97	4	\N	\N	\N	\N	\N	154	\N	DNA-277,DNA-291
1928	DLP-129	2022-10-04 00:00:00-07	2.86	\N	1.59	4	\N	\N	\N	\N	\N	155	\N	DNA-276,DNA-313
1929	DLP-130	2022-10-04 00:00:00-07	1.98	0	1.42	4	\N	\N	\N	\N	\N	156	\N	DNA-278
1930	DLP-132	2022-10-04 00:00:00-07	0.78	0	0.63	4	\N	\N	\N	\N	\N	158	\N	DNA-292
1931	DLP-133	2022-10-04 00:00:00-07	2.18	0	1.26	4	\N	\N	\N	\N	\N	159	\N	DNA-314
1932	DLP-134	2022-10-04 00:00:00-07	2.4	0	1.22	4	\N	\N	\N	\N	\N	160	\N	DNA-315
1933	DLP-135	2022-10-04 00:00:00-07	0.95	\N	0.53	4	\N	\N	\N	\N	\N	161	\N	DNA-316,DNA-317
1934	DLP-136	2022-10-04 00:00:00-07	4.61	0	1.97	4	\N	\N	\N	\N	\N	162	\N	DNA-298
1935	DLP-138	2022-10-04 00:00:00-07	1.76	0	1.05	4	\N	\N	\N	\N	\N	164	\N	DNA-304
1936	DLP-131	2022-10-04 00:00:00-07	3.69	0	2.48	4	\N	\N	\N	\N	\N	157	\N	DNA-279
1937	DLP-137	2022-10-04 00:00:00-07	4.01	0	2.7	4	\N	\N	\N	\N	\N	163	\N	DNA-303
1938	DLP-139	2022-10-04 00:00:00-07	5.18	0	3.44	4	\N	\N	\N	\N	\N	165	\N	DNA-305
1939	DLP-140	2022-10-04 00:00:00-07	4.46	0	2.76	4	\N	\N	\N	\N	\N	166	\N	DNA-306
1940	RLP-258	2023-08-29 00:00:00-07	0.71	22	0.8	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	173	\N	RNA-275
1941	RLP-259	2023-08-29 00:00:00-07	1.18	40	1.4	8	174	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	174	\N	RNA-278
1942	RLP-260	2023-08-29 00:00:00-07	1.61	30	2.05	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	175	\N	RNA-279
1943	RLP-261	2023-08-29 00:00:00-07	0.92	30	0.98	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	176	\N	RNA-313
1944	RLP-262	2023-08-29 00:00:00-07	0.72	40	0.76	8	190	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	177	\N	RNA-314
1945	RLP-263	2023-08-29 00:00:00-07	0.38	38	0.36	8	79.8	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	178	\N	RNA-315
1946	RLP-264	2023-08-29 00:00:00-07	2.34	34	2.72	8	200	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	179	\N	RNA-344
1947	RLP-265	2023-08-29 00:00:00-07	2.21	45	2.62	8	95	\N	\N	\N	65oC X 1 min, 15 uM adapter; 8 cycles; 1 hr adapter ligation at 20oC	180	\N	RNA-346
1948	AMLP-527	2023-03-31 00:00:00-07	9.04	\N	7.77	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	102	\N	AM2 D-268,AM2 D-368
1949	AMLP-528	2023-03-31 00:00:00-07	7.53	0	6.49	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	111	\N	AM2 D-513
1950	AMLP-529	2023-03-31 00:00:00-07	4.41	0	3.27	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	115	\N	AM2 D-514
1951	AMLP-530	2023-03-31 00:00:00-07	1.61	0	0.86	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	126	\N	AM2 D-519
1952	AMLP-531	2023-03-31 00:00:00-07	7.38	0	3.88	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	128	\N	AM2 D-521
1953	AMLP-532	2023-03-31 00:00:00-07	2.5	0	1.57	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	129	\N	AM2 D-522
1954	AMLP-533	2023-03-31 00:00:00-07	2	0	1.15	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	130	\N	AM2 D-528
1955	AMLP-534	2023-03-31 00:00:00-07	4.8	0	2.5	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	131	\N	AM2 D-525
1956	AMLP-535	2023-03-31 00:00:00-07	4.48	0	2.34	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	132	\N	AM2 D-526
1957	IRLP-001	2019-01-08 00:00:00-08	8.61	20	15.84	11	176	\N	\N	\N	\N	32	\N	SMPR2
1958	IRLP-002	2019-01-08 00:00:00-08	9.64	10	16.1	11	400	\N	\N	\N	\N	33	\N	SMPR4
1959	IRLP-006	2019-01-08 00:00:00-08	5.42	20	8.93	11	298	\N	\N	\N	\N	37	\N	SMPR48
1960	IRLP-007	2019-01-08 00:00:00-08	7.32	5	13.74	11	400	\N	\N	\N	\N	39	\N	SMPR55
1961	IRLP-003	2019-01-08 00:00:00-08	1.36	2	2.36	11	400	\N	\N	\N	\N	34	\N	SMPR11
1962	IRLP-004	2019-01-08 00:00:00-08	1.47	12	2.51	11	400	\N	\N	\N	\N	35	\N	SMPR12
1963	IRLP-005	2019-01-08 00:00:00-08	1.74	16	2.85	11	400	\N	\N	\N	\N	36	\N	SMPR20
1964	IRLP-008	2019-01-08 00:00:00-08	3.24	17	4.88	11	400	\N	\N	\N	\N	40	\N	SMPR56
1965	IRLP-009	2019-01-08 00:00:00-08	1.74	20	3.42	11	172	\N	\N	\N	\N	41	\N	SMPR58A
1966	IRLP-010	2019-01-08 00:00:00-08	3.15	11	5.26	11	400	\N	\N	\N	\N	42	\N	SMPR58B
1967	SGLP-0028	2017-07-11 00:00:00-07	0.9	100	0.3	\N	48.1	\N	\N	\N	\N	C4	\N	TPP 1_6
1968	SGLP-0023	2017-07-11 00:00:00-07	4.1	100	1.8	\N	135	\N	\N	\N	\N	B11	\N	TPP 1_1
1969	SGLP-0024	2017-07-11 00:00:00-07	3.3	100	1.8	\N	85.6	\N	\N	\N	\N	B12	\N	TPP 1_2
1970	SGLP-0025	2017-07-11 00:00:00-07	4.3	100	2.1	\N	159	\N	\N	\N	\N	C1	\N	TPP 1_3
1971	SGLP-0026	2017-07-11 00:00:00-07	2.1	100	0.9	\N	90.3	\N	\N	\N	\N	C2	\N	TPP 1_4
1972	SGLP-0027	2017-07-11 00:00:00-07	2.3	100	1.3	\N	56.1	\N	\N	\N	\N	C3	\N	TPP 1_5
1973	SGLP-0030	2017-07-11 00:00:00-07	3.4	100	1.77	\N	108	\N	\N	\N	\N	C6	\N	TPP 1_8
1974	SGLP-0031	2017-07-11 00:00:00-07	3.16	100	1.58	\N	94.1	\N	\N	\N	\N	C7	\N	TPP 1_9
1975	SGLP-0033	2017-07-11 00:00:00-07	2.1	100	0.99	\N	61.4	\N	\N	\N	\N	C9	\N	TPP 1_11
1976	SGLP-0034	2017-07-11 00:00:00-07	5.44	100	3.08	\N	167	\N	\N	\N	\N	C10	\N	TPP 1_12
1977	SGLP-0035	2017-07-11 00:00:00-07	6.3	100	3.08	\N	340	\N	\N	\N	\N	C11	\N	TPP 1_13
1978	SGLP-0036	2017-07-11 00:00:00-07	8.46	100	5.1	\N	463	\N	\N	\N	\N	C12	\N	TPP 1_14
1979	SGLP-0037	2017-07-11 00:00:00-07	1.14	100	0.35	\N	101	\N	\N	\N	\N	D1	\N	TPP 1_15
1980	SGLP-0038	2017-07-11 00:00:00-07	8.2	100	4.58	\N	420	\N	\N	\N	\N	D2	\N	TPP 1_16
1981	SGLP-0039	2017-07-11 00:00:00-07	5.36	100	2.88	\N	230	\N	\N	\N	\N	D3	\N	TPP 1_17
1982	SGLP-0041	2017-07-11 00:00:00-07	11	100	7.05	\N	3240	\N	\N	\N	\N	D5	\N	TPP 1_19
1983	SGLP-0042	2017-07-11 00:00:00-07	11.5	100	8.12	\N	1050	\N	\N	\N	\N	D6	\N	TPP 1_20
1984	SGLP-0043	2017-07-11 00:00:00-07	6.94	100	4.08	\N	358	\N	\N	\N	\N	D7	\N	TPP 1_21
1985	SGLP-0044	2017-07-11 00:00:00-07	8.68	100	7.58	\N	888	\N	\N	\N	\N	D8	\N	TPP 1_22
1986	SGLP-0045	2017-07-11 00:00:00-07	9.76	100	7.68	\N	462	\N	\N	\N	\N	D9	\N	TPP 1_23
1987	SGLP-0046	2017-07-11 00:00:00-07	9.82	100	7.63	\N	1500	\N	\N	\N	\N	D10	\N	TPP 1_24
1988	SGLP-0047	2017-07-11 00:00:00-07	8.96	100	6.09	\N	614	\N	\N	\N	\N	D11	\N	TPP 1_25
1989	SGLP-0048	2017-07-11 00:00:00-07	10.8	100	7.81	\N	1420	\N	\N	\N	\N	D12	\N	TPP 1_26
1990	SGLP-0049	2017-07-11 00:00:00-07	11.1	100	9.91	\N	1430	\N	\N	\N	\N	E1	\N	TPP 1_27
1991	SGLP-0001	2017-07-06 00:00:00-07	3.3	50	6.91	\N	210	\N	\N	\N	\N	A1	\N	CGH11-045_NA
1992	SGLP-0002	2017-07-06 00:00:00-07	4.07	36	8.3	\N	250	\N	\N	\N	\N	A2	\N	CGH11-092
1993	SGLP-0003	2017-07-06 00:00:00-07	4.13	40	7.26	\N	250	\N	\N	\N	\N	A3	\N	CGH11-268
1994	SGLP-0004	2017-07-06 00:00:00-07	4.75	36	10.87	\N	250	\N	\N	\N	\N	A4	\N	CGH11-282
1995	SGLP-0005	2017-07-06 00:00:00-07	4.73	35	9.63	\N	250	\N	\N	\N	\N	A5	\N	CGH11-294
1996	SGLP-0006	2017-07-06 00:00:00-07	3.94	50	7.18	\N	212	\N	\N	\N	\N	A6	\N	CGH11-386_DNA
1997	SGLP-0007	2017-07-06 00:00:00-07	2.32	50	3.92	\N	129.5	\N	\N	\N	\N	A7	\N	CGH11-399
1998	SGLP-0008	2017-07-06 00:00:00-07	4.1	43	7.68	\N	250	\N	\N	\N	\N	A8	\N	CGH11-402
1999	SGLP-0009	2017-07-06 00:00:00-07	1.9	50	2.85	\N	219.5	\N	\N	\N	\N	A9	\N	CGH12-055
2000	SGLP-0010	2017-07-06 00:00:00-07	2.99	14	6.3	\N	250	\N	\N	\N	\N	A10	\N	CGH12-191
2001	SGLP-0011	2017-07-06 00:00:00-07	4.81	39	10.64	\N	250	\N	\N	\N	\N	A11	\N	CGH12-273
2002	SGLP-0012	2017-07-06 00:00:00-07	3.56	6	7.85	\N	250	\N	\N	\N	\N	A12	\N	CGH12-301
2003	SGLP-0013	2017-07-06 00:00:00-07	3.26	48	6.13	\N	250	\N	\N	\N	\N	B1	\N	CGH13-159
2004	SGLP-0014	2017-07-06 00:00:00-07	2.95	50	5.53	\N	212	\N	\N	\N	\N	B2	\N	CGH13-321
2005	SGLP-0015	2017-07-06 00:00:00-07	1.7	30	2.46	\N	250	\N	\N	\N	\N	B3	\N	CGH13-340
2006	SGLP-0016	2017-07-06 00:00:00-07	2.49	33	4.15	\N	250	\N	\N	\N	\N	B4	\N	CGH14-032
2007	SGLP-0017	2017-07-06 00:00:00-07	3.77	41	9.6	\N	250	\N	\N	\N	\N	B5	\N	CGH14-119
2008	SGLP-0018	2017-07-06 00:00:00-07	3.11	43	7.29	\N	250	\N	\N	\N	\N	B6	\N	CGH14-144
2009	SGLP-0019	2017-07-06 00:00:00-07	3.71	23	9.17	\N	250	\N	\N	\N	\N	B7	\N	CGH14-181
2010	SGLP-0020	2017-07-06 00:00:00-07	2.85	29	5.96	\N	250	\N	\N	\N	\N	B8	\N	CGH14-286
2011	SGLP-0021	2017-07-06 00:00:00-07	2.49	26	4.97	\N	250	\N	\N	\N	\N	B9	\N	CGH14-293
2012	SGLP-0022	2017-07-06 00:00:00-07	3.75	44	7.88	\N	250	\N	\N	\N	\N	B10	\N	CGH14-328
2013	SGLP-0050	2017-07-17 00:00:00-07	7.36	50	4.53	\N	238	\N	\N	\N	\N	E5	\N	CGH15-043
2014	SGLP-0051	2017-07-17 00:00:00-07	9.5	37	7.18	\N	250	\N	\N	\N	\N	E6	\N	CGH15-064
2015	SGLP-0052	2017-07-17 00:00:00-07	6.46	45	4.58	\N	250	\N	\N	\N	\N	E7	\N	CGH15-081
2016	SGLP-0053	2017-07-17 00:00:00-07	2.84	50	1.05	\N	242	\N	\N	\N	\N	E8	\N	CGH15-082
2017	SGLP-0054	2017-07-17 00:00:00-07	8.52	39	5.74	\N	250	\N	\N	\N	\N	E9	\N	CGH15-090
2018	SGLP-0055	2017-07-17 00:00:00-07	9.48	33	9.62	\N	250	\N	\N	\N	\N	E10	\N	CGH15-115
2019	SGLP-0056	2017-07-17 00:00:00-07	5.18	50	2.97	\N	185	\N	\N	\N	\N	E11	\N	CGH15-139
2020	SGLP-0057	2017-07-17 00:00:00-07	10.2	50	7.16	\N	185.5	\N	\N	\N	\N	E12	\N	CGH15-151
2021	SGLP-0058	2017-07-17 00:00:00-07	8.68	41	6.55	\N	250	\N	\N	\N	\N	F1	\N	CGH15-163
2022	SGLP-0059	2017-07-17 00:00:00-07	6.2	23	5.25	\N	250	\N	\N	\N	\N	F2	\N	CGH15-176
2023	SGLP-0060	2017-07-17 00:00:00-07	6.46	50	3.01	\N	248	\N	\N	\N	\N	F3	\N	CGH15-206
2024	SGLP-0061	2017-07-17 00:00:00-07	6.18	44	4.89	\N	250	\N	\N	\N	\N	F4	\N	CGH15-210
2025	SGLP-0062	2017-07-17 00:00:00-07	5.34	14	4.63	\N	250	\N	\N	\N	\N	F5	\N	CGH15-211
2026	SGLP-0063	2017-07-17 00:00:00-07	8.34	50	5.2	\N	213	\N	\N	\N	\N	F6	\N	CGH15-246
2027	SGLP-0064	2017-07-17 00:00:00-07	7.46	50	7.11	\N	232	\N	\N	\N	\N	F7	\N	CGH15-253
2028	SGLP-0065	2017-07-17 00:00:00-07	8.46	42	7.28	\N	250	\N	\N	\N	\N	F8	\N	CGH15-263
2029	SGLP-0066	2017-07-17 00:00:00-07	7.86	9	6.22	\N	250	\N	\N	\N	\N	F9	\N	CGH16-002
2030	SGLP-0067	2017-07-17 00:00:00-07	9.2	33	8.13	\N	250	\N	\N	\N	\N	F10	\N	CGH16-023
2031	SGLP-0068	2017-07-17 00:00:00-07	7.96	30	5.97	\N	250	\N	\N	\N	\N	F11	\N	CGH16-025
2032	SGLP-0069	2017-07-17 00:00:00-07	9.52	20	8.59	\N	250	\N	\N	\N	\N	F12	\N	CGH16-032
2033	SGLP-0070	2017-07-17 00:00:00-07	4.46	50	2.87	\N	208	\N	\N	\N	\N	G1	\N	CGH16-035
2034	SGLP-0071	2017-07-17 00:00:00-07	15.1	9	13.66	\N	250	\N	\N	\N	\N	G2	\N	CGH16-038
2035	SGLP-0072	2017-07-17 00:00:00-07	10.5	45	9.29	\N	250	\N	\N	\N	\N	G3	\N	CGH16-053
2036	SGLP-0073	2017-07-17 00:00:00-07	11.7	41	10.2	\N	250	\N	\N	\N	\N	G4	\N	CGH16-054
2037	SGLP-0074	2017-07-17 00:00:00-07	7	50	4.52	\N	245	\N	\N	\N	\N	G5	\N	CGH16-062
2038	SGLP-0075	2017-07-17 00:00:00-07	7.26	50	5.23	\N	233	\N	\N	\N	\N	G6	\N	CGH16-071
2039	SGLP-0076	2017-07-17 00:00:00-07	6.94	29	5.13	\N	250	\N	\N	\N	\N	G7	\N	CGH16-087
2040	SGLP-0077	2017-07-17 00:00:00-07	7.22	50	4.53	\N	195.5	\N	\N	\N	\N	G8	\N	CGH16-089
2041	SGLP-0078	2017-07-17 00:00:00-07	5.22	40	3.79	\N	250	\N	\N	\N	\N	G9	\N	CGH16-093
2042	SGLP-0079	2017-07-17 00:00:00-07	5.9	31	2.32	\N	250	\N	\N	\N	\N	G10	\N	CGH16-097
2043	SGLP-0080	2017-07-24 00:00:00-07	5.54	21	5.2	\N	250	\N	\N	\N	\N	G11	\N	CGH16-105
2044	SGLP-0081	2017-07-24 00:00:00-07	8.82	10	9.98	\N	250	\N	\N	\N	\N	G12	\N	CGH16-117
2045	SGLP-0082	2017-07-24 00:00:00-07	5.82	16	6.08	\N	250	\N	\N	\N	\N	H1	\N	CGH16-123
2046	SGLP-0083	2017-07-24 00:00:00-07	4.2	40	3.72	\N	250	\N	\N	\N	\N	H2	\N	CGH16-130
2047	SGLP-0084	2017-07-24 00:00:00-07	6.54	42	5.79	\N	250	\N	\N	\N	\N	H3	\N	CGH16-136
2048	SGLP-0085	2017-07-24 00:00:00-07	4.78	41	5.13	\N	250	\N	\N	\N	\N	H4	\N	CGH16-172-2
2049	SGLP-0086	2017-07-24 00:00:00-07	6.22	51	5.46	\N	202	\N	\N	\N	\N	H5	\N	CGH16-179
2050	SGLP-0087	2017-07-24 00:00:00-07	6.02	38	6.94	\N	250	\N	\N	\N	\N	H6	\N	CGH16-198
2051	SGLP-0088	2017-07-24 00:00:00-07	4.42	50	4.07	\N	250	\N	\N	\N	\N	H7	\N	CGH16-209
2052	SGLP-0089	2017-07-24 00:00:00-07	8.5	38	8.66	\N	250	\N	\N	\N	\N	H8	\N	CGH16-215
2053	SGLP-0090	2017-07-24 00:00:00-07	7.14	34	6.47	\N	250	\N	\N	\N	\N	H9	\N	CGH16-222
2054	SGLP-0091	2017-07-24 00:00:00-07	7.82	50	6.73	\N	149	\N	\N	\N	\N	H10	\N	CGH16-250
2055	SGLP-0092	2017-07-24 00:00:00-07	5.8	51	4.29	\N	162	\N	\N	\N	\N	H11	\N	CGH16-254
2056	SGLP-0093	2017-07-24 00:00:00-07	5.36	51	4.94	\N	197	\N	\N	\N	\N	H12	\N	CGH17-001
2057	SGLP-0094	2017-07-24 00:00:00-07	3.56	35	3.92	\N	250	\N	\N	\N	\N	E4	\N	CGH17-003
2058	SGLP-0095	2017-07-24 00:00:00-07	8.9	38	10.37	\N	250	\N	\N	\N	\N	E2	\N	CGH17-008
2059	SGLP-0096	2017-07-24 00:00:00-07	4.22	50	1.94	\N	106	\N	\N	\N	\N	E3	\N	CGH17-015
2060	SGLP-0032	2017-07-11 00:00:00-07	2.94	100	1.34	4	82.6	\N	\N	\N	\N	C8	\N	TPP 1_10
2061	SGLP-0040	2017-07-11 00:00:00-07	3.36	100	1.08	4	394	\N	\N	\N	\N	D4	\N	TPP 1_18
2062	SGLP-0029	2017-07-11 00:00:00-07	9.26	100	5	4	379	\N	\N	\N	\N	C5	\N	TPP 1_7
2063	SGLP-0097	2017-08-15 00:00:00-07	2.4	100	0.8	\N	97.8	\N	\N	\N	\N	A1	\N	TPP 2_1
2064	SGLP-0098	2017-08-15 00:00:00-07	6.3	16	2.6	\N	250	\N	\N	\N	\N	A2	\N	TPP 2_2
2065	SGLP-0099	2017-08-15 00:00:00-07	4.2	96	1.7	\N	250	\N	\N	\N	\N	A3	\N	TPP 2_3
2066	SGLP-0101	2017-08-15 00:00:00-07	8.5	24	4.4	\N	250	\N	\N	\N	\N	A5	\N	TPP 2_5
2067	SGLP-0102	2017-08-15 00:00:00-07	9.9	37	5.3	\N	250	\N	\N	\N	\N	A6	\N	TPP 2_6
2068	SGLP-0104	2017-08-15 00:00:00-07	6.5	45	3	\N	250	\N	\N	\N	\N	A8	\N	TPP 2_8
2069	SGLP-0106	2017-08-15 00:00:00-07	6.2	33	3.7	\N	250	\N	\N	\N	\N	A10	\N	TPP 2_10
2070	SGLP-0107	2017-08-15 00:00:00-07	6.7	48	3	\N	250	\N	\N	\N	\N	A11	\N	TPP 2_11
2071	SGLP-0108	2017-08-15 00:00:00-07	6	25	2.5	\N	250	\N	\N	\N	\N	A12	\N	TPP 2_12
2072	SGLP-0109	2017-08-15 00:00:00-07	4.9	18	2.5	\N	250	\N	\N	\N	\N	B1	\N	TPP 2_13
2073	SGLP-0110	2017-08-15 00:00:00-07	4.2	54	1.9	\N	250	\N	\N	\N	\N	B2	\N	TPP 2_14
2074	SGLP-0111	2017-08-15 00:00:00-07	0.6	100	0.2	\N	37.5	\N	\N	\N	\N	B3	\N	TPP 2_15
2075	SGLP-0112	2017-08-15 00:00:00-07	3.9	10	1.6	\N	250	\N	\N	\N	\N	B4	\N	TPP 2_16
2076	SGLP-0113	2017-08-15 00:00:00-07	6.6	27	2.9	\N	250	\N	\N	\N	\N	B5	\N	TPP 2_17
2077	SGLP-0114	2017-08-15 00:00:00-07	4.8	28	2.1	\N	250	\N	\N	\N	\N	B6	\N	TPP 2_18
2078	SGLP-0115	2017-08-15 00:00:00-07	4.7	23	1.5	\N	250	\N	\N	\N	\N	B7	\N	TPP 2_19
2079	SGLP-0117	2017-08-15 00:00:00-07	4.6	20	2.6	\N	250	\N	\N	\N	\N	B9	\N	TPP 2_21
2080	SGLP-0119	2017-08-15 00:00:00-07	5.5	26	2.8	\N	250	\N	\N	\N	\N	B11	\N	TPP 2_23
2081	SGLP-0121	2017-08-15 00:00:00-07	5.5	23	3.2	\N	250	\N	\N	\N	\N	C1	\N	TPP 2_25
2082	SGLP-0122	2017-08-15 00:00:00-07	5.6	23	3.2	\N	250	\N	\N	\N	\N	C2	\N	TPP 2_26
2083	SGLP-0123	2017-08-15 00:00:00-07	0.9	100	0.2	\N	131	\N	\N	\N	\N	C3	\N	TPP 2_27
2084	SGLP-0124	2017-08-15 00:00:00-07	5	80	2.8	\N	250	\N	\N	\N	\N	C4	\N	TPP 2_28
2085	SGLP-0126	2017-08-15 00:00:00-07	1.3	100	0.3	\N	192	\N	\N	\N	\N	C6	\N	TPP 2_30
2086	SGLP-0127	2017-08-22 00:00:00-07	8.5	38	4	\N	250	\N	\N	\N	\N	C9	\N	TPP 2_31
2087	SGLP-0129	2017-08-22 00:00:00-07	6.3	55	2.6	\N	250	\N	\N	\N	\N	C11	\N	TPP 2_33
2088	SGLP-0131	2017-08-22 00:00:00-07	10.4	17	7.9	\N	250	\N	\N	\N	\N	D1	\N	TPP 2_35
2089	SGLP-0132	2017-08-22 00:00:00-07	7.5	5	4.6	\N	250	\N	\N	\N	\N	D2	\N	TPP 2_36
2090	SGLP-0133	2017-08-22 00:00:00-07	7.4	19	4.8	\N	250	\N	\N	\N	\N	D3	\N	TPP 2_37
2091	SGLP-0135	2017-08-22 00:00:00-07	4.6	100	1.7	\N	220	\N	\N	\N	\N	D5	\N	TPP 2_39
2092	SGLP-0136	2017-08-22 00:00:00-07	8.3	13	4.9	\N	250	\N	\N	\N	\N	D6	\N	TPP 2_40
2093	SGLP-0138	2017-08-22 00:00:00-07	8.3	100	5	\N	156	\N	\N	\N	\N	D8	\N	TPP 2_42
2094	SGLP-0139	2017-08-22 00:00:00-07	6	66	4.3	\N	250	\N	\N	\N	\N	D9	\N	TPP 2_43
2095	SGLP-0140	2017-08-22 00:00:00-07	8.3	49	5.5	\N	250	\N	\N	\N	\N	D10	\N	TPP 2_44
2096	SGLP-0141	2017-08-22 00:00:00-07	6	60	3.7	\N	250	\N	\N	\N	\N	D11	\N	TPP 2_45
2097	SGLP-0142	2017-08-22 00:00:00-07	8.6	45	6.5	\N	250	\N	\N	\N	\N	D12	\N	TPP 2_46
2098	SGLP-0144	2017-08-22 00:00:00-07	6.4	18	2.9	\N	250	\N	\N	\N	\N	E2	\N	TPP 2_48
2099	SGLP-0145	2017-08-22 00:00:00-07	1.2	100	0.3	\N	108	\N	\N	\N	\N	E3	\N	TPP 2_49
2100	SGLP-0146	2017-08-22 00:00:00-07	1.3	100	0.4	\N	83.6	\N	\N	\N	\N	E4	\N	TPP 2_50
2101	SGLP-0147	2017-08-22 00:00:00-07	0.7	100	0.3	\N	71.8	\N	\N	\N	\N	E5	\N	TPP 2_51
2102	SGLP-0148	2017-08-22 00:00:00-07	7.1	37	5.2	\N	250	\N	\N	\N	\N	E6	\N	TPP 2_52
2103	SGLP-0150	2017-08-22 00:00:00-07	10.4	25	4.9	\N	250	\N	\N	\N	\N	E8	\N	TPP 2_54
2104	SGLP-0151	2017-08-22 00:00:00-07	10.7	14	5.8	\N	250	\N	\N	\N	\N	E9	\N	TPP 2_55
2105	SGLP-0152	2017-08-22 00:00:00-07	8.3	58	5.2	\N	250	\N	\N	\N	\N	E10	\N	TPP 2_56
2106	SGLP-0153	2017-08-22 00:00:00-07	6.9	17	4.4	\N	250	\N	\N	\N	\N	E11	\N	TPP 2_57
2107	SGLP-0154	2017-08-28 00:00:00-07	3.4	100	1.3	\N	192	\N	\N	\N	\N	F5	\N	TPP 2_58
2108	SGLP-0156	2017-08-28 00:00:00-07	5.5	38	3.6	\N	250	\N	\N	\N	\N	F7	\N	TPP 2_60
2109	SGLP-0157	2017-08-28 00:00:00-07	0.4	100	0.1	\N	23	\N	\N	\N	\N	F8	\N	TPP 2_61
2110	SGLP-0159	2017-08-28 00:00:00-07	2.7	91	0.7	\N	250	\N	\N	\N	\N	F10	\N	TPP 2_63
2111	SGLP-0160	2017-08-28 00:00:00-07	2.2	93	0.5	\N	250	\N	\N	\N	\N	F11	\N	TPP 2_64
2112	SGLP-0161	2017-08-28 00:00:00-07	3.6	96	1.3	\N	250	\N	\N	\N	\N	F12	\N	TPP 2_65
2113	SGLP-0163	2017-08-28 00:00:00-07	6.6	22	4.1	\N	250	\N	\N	\N	\N	G2	\N	TPP 2_67
2114	SGLP-0164	2017-08-28 00:00:00-07	6.4	24	4.1	\N	250	\N	\N	\N	\N	G3	\N	TPP 2_68
2115	SGLP-0165	2017-08-28 00:00:00-07	4.2	66	2.4	\N	250	\N	\N	\N	\N	G4	\N	TPP 2_69
2116	SGLP-0168	2017-08-28 00:00:00-07	6	21	3.4	\N	250	\N	\N	\N	\N	G7	\N	TPP 2_72
2117	SGLP-0169	2017-08-28 00:00:00-07	5	25	2.7	\N	250	\N	\N	\N	\N	G8	\N	TPP 2_73
2118	SGLP-0170	2017-08-28 00:00:00-07	3.9	34	2.8	\N	250	\N	\N	\N	\N	G9	\N	TPP 2_74
2119	SGLP-0171	2017-08-28 00:00:00-07	7.5	10	5	\N	250	\N	\N	\N	\N	G10	\N	TPP 2_75
2120	SGLP-0172	2017-08-28 00:00:00-07	5	22	2.6	\N	250	\N	\N	\N	\N	G11	\N	TPP 2_76
2121	SGLP-0173	2017-08-28 00:00:00-07	6	17	3.3	\N	250	\N	\N	\N	\N	G12	\N	TPP 2_77
2122	SGLP-0175	2017-08-28 00:00:00-07	5.1	24	3	\N	250	\N	\N	\N	\N	H2	\N	TPP 2_79
2123	SGLP-0176	2017-08-28 00:00:00-07	5.2	12	2.7	\N	250	\N	\N	\N	\N	H3	\N	TPP 2_80
2124	SGLP-0177	2017-08-28 00:00:00-07	6.4	26	4.3	\N	250	\N	\N	\N	\N	H4	\N	TPP 2_81
2125	SGLP-0178	2017-08-28 00:00:00-07	3.5	35	1.4	\N	250	\N	\N	\N	\N	H5	\N	TPP 2_82
2126	SGLP-0179	2017-08-28 00:00:00-07	7.1	17	4.9	\N	250	\N	\N	\N	\N	H6	\N	TPP 2_83
2127	SGLP-0180	2017-08-28 00:00:00-07	0.6	100	0.2	\N	71	\N	\N	\N	\N	H7	\N	TPP 2_84
2128	SGLP-0182	2017-08-28 00:00:00-07	5.8	39	5.5	\N	250	\N	\N	\N	\N	H9	\N	TPP 2_86
2129	SGLP-0103	2017-08-15 00:00:00-07	5.5	61	2.17	4	250	\N	\N	\N	\N	A7	\N	TPP 2_7
2130	SGLP-0120	2017-08-15 00:00:00-07	5.3	36	3.06	4	250	\N	\N	\N	\N	B12	\N	TPP 2_24
2131	SGLP-0128	2017-08-22 00:00:00-07	5.8	61	3.2	4	250	\N	\N	\N	\N	C10	\N	TPP 2_32
2132	SGLP-0130	2017-08-22 00:00:00-07	4.5	96	2.8	4	250	\N	\N	\N	\N	C12	\N	TPP 2_34
2133	SGLP-0137	2017-08-22 00:00:00-07	2.6	40	1.3	4	250	\N	\N	\N	\N	D7	\N	TPP 2_41
2134	SGLP-0143	2017-08-22 00:00:00-07	4.9	61	1.3	4	250	\N	\N	\N	\N	E1	\N	TPP 2_47
2135	SGLP-0149	2017-08-22 00:00:00-07	5.3	43	2.7	4	250	\N	\N	\N	\N	E7	\N	TPP 2_53
2136	SGLP-0155	2017-08-28 00:00:00-07	3.1	100	1.5	4	179	\N	\N	\N	\N	F6	\N	TPP 2_59
2137	SGLP-0158	2017-08-28 00:00:00-07	4.5	14	2.2	4	250	\N	\N	\N	\N	F9	\N	TPP 2_62
2138	SGLP-0162	2017-08-28 00:00:00-07	1	100	0.6	4	51.8	\N	\N	\N	\N	G1	\N	TPP 2_66
2139	SGLP-0166	2017-08-28 00:00:00-07	2.8	56	0.9	4	250	\N	\N	\N	\N	G5	\N	TPP 2_70
2140	SGLP-0167	2017-08-28 00:00:00-07	1.3	100	0.3	4	184	\N	\N	\N	\N	G6	\N	TPP 2_71
2141	SGLP-0174	2017-08-28 00:00:00-07	3.4	98	2.3	4	250	\N	\N	\N	\N	H1	\N	TPP 2_78
2142	SGLP-0181	2017-08-28 00:00:00-07	5.5	20	2.3	4	250	\N	\N	\N	\N	H8	\N	TPP 2_85
2143	SGLP-0183	2017-08-28 00:00:00-07	2.8	100	1.7	4	230	\N	\N	\N	\N	H10	\N	TPP 2_87
2144	SGLP-0184	2017-08-28 00:00:00-07	5.7	18	3.6	4	250	\N	\N	\N	\N	H11	\N	TPP 2_88
2145	SGLP-0100	2017-08-15 00:00:00-07	4.9	95	2.1	4	250	\N	\N	\N	\N	A4	\N	TPP 2_4
2146	SGLP-0105	2017-08-15 00:00:00-07	5.1	38	1.84	4	250	\N	\N	\N	\N	A9	\N	TPP 2_9
2147	SGLP-0125	2017-08-15 00:00:00-07	5.9	21	3.88	4	250	\N	\N	\N	Barcode overlap	C5	\N	TPP 2_29
2148	SGLP-0134	2017-08-22 00:00:00-07	4.2	100	2.3	4	189	\N	\N	\N	Barcode overlap	D4	\N	TPP 2_38
2149	FKP-01	2018-03-05 00:00:00-08	\N	0	112.22	4	\N	\N	\N	\N	KAPA RNA LP Kit, Capture hyb at 65c for 4 hours. \n	B5	\N	Fusion-01
2150	FKP-02	2018-03-05 00:00:00-08	\N	0	28.73	4	\N	\N	\N	\N	KAPA RNA LP Kit, Capture hyb at 65c for 4 hours. \n	B6	\N	Fusion-02
2151	FKP-05	2018-03-05 00:00:00-08	\N	0	413.29	4	\N	\N	\N	\N	KAPA RNA LP Kit, Capture hyb at 65c for 4 hours. \n	B7	\N	Fusion-05
2152	FKP-06	2018-03-05 00:00:00-08	\N	0	1033.36	4	\N	\N	\N	\N	KAPA RNA LP Kit, Capture hyb at 65c for 4 hours. \n	B8	\N	Fusion-06
2153	FKP-08	2018-03-05 00:00:00-08	\N	0	491.3	4	\N	\N	\N	\N	KAPA RNA LP Kit, Capture hyb at 65c for 4 hours. \n	B9	\N	Fusion-08
2154	FKP-09	2018-03-05 00:00:00-08	\N	0	1062.35	4	\N	\N	\N	\N	KAPA RNA LP Kit, Capture hyb at 65c for 4 hours. \n	B10	\N	Fusion-09
2155	FKP-10	2018-03-05 00:00:00-08	\N	0	3337.2	4	\N	\N	\N	\N	KAPA RNA LP Kit, Capture hyb at 65c for 4 hours. \n	B11	\N	Fusion-10
2156	FKP-11	2018-03-05 00:00:00-08	\N	0	863.29	4	\N	\N	\N	\N	KAPA RNA LP Kit, Capture hyb at 65c for 4 hours. \n	B12	\N	Fusion-11
2157	Nu-01	\N	\N	0	0.9	\N	\N	\N	\N	\N	NuGen LP Kit, Spiked after capture clean up, NuGen A01 adapter, CACGTCTA\n\n	A01	\N	Fusion-01
2158	Nu-02	\N	\N	0	3.1	\N	\N	\N	\N	\N	NuGen LP Kit, Spiked after capture clean up, NuGen B01, AGCTAGTG\n\n	B01	\N	Fusion-02
2159	Nu-05	\N	\N	0	1.6	\N	\N	\N	\N	\N	NuGen LP Kit, Spiked after capture clean up, NuGen C01, ACTATCGC\n\n	C01	\N	Fusion-05
2160	Nu-06	\N	\N	0	2.8	\N	\N	\N	\N	\N	NuGen LP Kit, Spiked after capture clean up, NuGen D01, GCGTATCA\n\n	D01	\N	Fusion-06
2161	Nu-08	\N	\N	0	3.7	\N	\N	\N	\N	\N	NuGen LP Kit, Spiked after capture clean up, NuGen E01, ACTCTCCA\n\n	E01	\N	Fusion-08
2162	Nu-09	\N	\N	0	3.8	\N	\N	\N	\N	\N	NuGen LP Kit, Spiked after capture clean up, NuGen F01, CGTCCATT\n\n	F01	\N	Fusion-09
2163	Nu-10	\N	\N	0	11.2	\N	\N	\N	\N	\N	NuGen LP Kit, Spiked after capture clean up, NuGen G01, AGCCGTAA\n\n	G01	\N	Fusion-10
2164	Nu-11	\N	\N	0	2.1	\N	\N	\N	\N	\N	NuGen LP Kit, Spiked after capture clean up, NuGen H01, GAGTAGAG. Lung cancer with ALK fusion\n\n	H01	\N	Fusion-11
2165	SGLP-0185	2018-03-20 00:00:00-07	4.2	50	1.3	\N	119	\N	\N	\N	Capture hyb at 65c for 4 hours. 	F5	\N	CGH17-017
2166	SGLP-0186	2018-03-20 00:00:00-07	2.7	50	1	\N	199	\N	\N	\N	Capture hyb at 65c for 4 hours. 	F6	\N	CGH17-021
2167	SGLP-0187	2018-03-20 00:00:00-07	3	50	1.1	\N	208	\N	\N	\N	Capture hyb at 65c for 4 hours. 	F7	\N	CGH17-024
2168	SGLP-0188	2018-03-20 00:00:00-07	2.6	50	0.9	\N	189	\N	\N	\N	Capture hyb at 65c for 4 hours. 	F8	\N	CGH17-026
2169	SGLP-0189	2018-03-20 00:00:00-07	3.8	50	2.3	\N	249	\N	\N	\N	Capture hyb at 65c for 4 hours. 	F9	\N	CGH17-031
2170	SGLP-0190	2018-03-20 00:00:00-07	2.3	50	0.6	\N	159	\N	\N	\N	Capture hyb at 65c for 4 hours. 	F10	\N	CGH17-033
2171	SGLP-0191	2018-03-20 00:00:00-07	2	50	0.8	\N	150	\N	\N	\N	Capture hyb at 65c for 4 hours. 	F11	\N	CGH17-039
2172	SGLP-0192	2018-03-20 00:00:00-07	5.5	50	2.4	\N	129	\N	\N	\N	Capture hyb at 65c for 4 hours. 	F12	\N	CGH17-052
2173	SGLP-0193	2018-03-20 00:00:00-07	3.4	50	1.1	\N	215	\N	\N	\N	Capture hyb at 65c for 4 hours. 	G1	\N	CGH17-058
2174	SGLP-0194	2018-03-20 00:00:00-07	2	50	0.5	\N	235	\N	\N	\N	Capture hyb at 65c for 4 hours. 	G2	\N	CGH17-076
2175	SGLP-0195	2018-03-20 00:00:00-07	2.6	50	1.3	\N	201	\N	\N	\N	Capture hyb at 65c for 4 hours. 	G3	\N	CGH17-083
2176	SGLP-0196	2018-03-20 00:00:00-07	1.5	49	0.4	\N	143	\N	\N	\N	Capture hyb at 65c for 4 hours. 	G4	\N	CGH17-095
2177	SGLP-0197	2018-03-20 00:00:00-07	3.3	50	1.2	\N	106	\N	\N	\N	Capture hyb at 65c for 4 hours. 	G5	\N	CGH17-097
2178	SGLP-0198	2018-03-20 00:00:00-07	3	50	1.4	\N	220	\N	\N	\N	Capture hyb at 65c for 4 hours. 	G6	\N	CGH17-104
2179	SGLP-0199	2018-03-20 00:00:00-07	1.2	90	0.3	4	19	\N	\N	\N	KIT mutant DNA samples, Capture hyb at 65c for 4 hours. 	G7	\N	KIT-01
2180	SGLP-0210	2018-03-20 00:00:00-07	1.3	25	0.1	4	62	\N	\N	\N	KIT mutant DNA samples, Capture hyb at 65c for 4 hours. 	H6	\N	KIT-12
2181	SGLP-0211	2018-03-20 00:00:00-07	4.9	50	1	4	85	\N	\N	\N	KIT mutant DNA samples, Capture hyb at 65c for 4 hours. 	H7	\N	KIT-13
2182	SGLP-0212	2018-03-20 00:00:00-07	10.5	50	2.4	4	199	\N	\N	\N	KIT mutant DNA samples, Capture hyb at 65c for 4 hours. 	H8	\N	KIT-14
2183	SGLP-0213	2018-03-20 00:00:00-07	3.7	50	0.7	4	93	\N	\N	\N	KIT mutant DNA samples, Capture hyb at 65c for 4 hours. 	H9	\N	KIT-15
2184	SGLP-0214	2018-03-20 00:00:00-07	4.7	50	1.4	4	129	\N	\N	\N	KIT mutant DNA samples, Capture hyb at 65c for 4 hours. 	H10	\N	KIT-16
2185	SGLP-0215	2018-03-20 00:00:00-07	5.8	50	2.2	4	199	\N	\N	\N	KIT mutant DNA samples, Capture hyb at 65c for 4 hours. 	H11	\N	KIT-17
2186	SGLP-0216	2018-03-20 00:00:00-07	4.6	50	1.6	4	223	\N	\N	\N	KIT mutant DNA samples, Capture hyb at 65c for 4 hours. 	H12	\N	KIT-18
2187	SGLP-0217	\N	2.7	10	0.9	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A1	\N	MDD-01
2188	SGLP-0218	\N	2.5	8	0.5	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A2	\N	MDD-02
2189	SGLP-0219	\N	3.7	13	0.8	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A3	\N	MDD-03
2190	SGLP-0222	\N	3.4	10	0.9	4	250	\N	\N	\N	Madrid Melanoma, Capture hyb at 65c for 4 hours. 	A6	\N	MDD-06
2191	SGLP-0225	\N	3.1	4	0.4	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A9	\N	MDD-09
2192	SGLP-0226	\N	3.4	3	0.6	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A10	\N	MDD-10
2193	SGLP-0227	\N	3	16	0.6	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A11	\N	MDD-11
2194	SGLP-0228	\N	4	8	0.9	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A12	\N	MDD-12
2195	SGLP-0229	\N	5	3	1.2	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	B1	\N	MDD-13
2196	SGLP-0231	\N	3.4	7	0.7	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	B3	\N	MDD-15
2197	SGLP-0233	\N	3.1	11	0.6	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C1	\N	MDD-17
2198	SGLP-0234	\N	3.8	11	1.4	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C2	\N	MDD-18
2199	SGLP-0236	\N	3.7	25	1.4	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C4	\N	MDD-20
2200	SGLP-0237	\N	6	50	1.8	4	223	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C5	\N	MDD-21
2201	SGLP-0238	\N	2	27	0.6	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C6	\N	MDD-22
2202	SGLP-0239	\N	4.2	16	1.5	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C7	\N	MDD-23
2203	SGLP-0247	\N	4.2	50	2.1	4	193	\N	\N	\N	Capture hyb at 65c for 4 hours. 	D3	\N	MDD-31
2204	SGLP-0250	\N	5	50	1.3	4	231	\N	\N	\N	Capture hyb at 65c for 4 hours. 	D6	\N	MDD-34
2205	SGLP-0251	\N	6.6	7	1.7	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	D7	\N	MDD-35
2206	SGLP-0258	\N	\N	9	1.5	4	250	\N	\N	\N	\N	A1	\N	TPP_3-01
2207	SGLP-0259	\N	\N	30	2.2	4	250	\N	\N	\N	\N	A2	\N	TPP_3-02
2208	SGLP-0260	\N	\N	13	2.8	4	250	\N	\N	\N	\N	A3	\N	TPP_3-03
2209	SGLP-0264	\N	\N	4	0.6	4	250	\N	\N	\N	\N	A7	\N	TPP_3-07
2210	SGLP-0265	\N	\N	5	2.8	4	250	\N	\N	\N	\N	A8	\N	TPP_3-08
2211	SGLP-0268	\N	\N	22	3.3	4	250	\N	\N	\N	\N	A11	\N	TPP_3-11
2212	SGLP-0269	\N	\N	9	2.4	4	250	\N	\N	\N	\N	A12	\N	TPP_3-12
2213	SGLP-0270	\N	\N	14	2.9	4	250	\N	\N	\N	\N	B1	\N	TPP_3-13
2214	SGLP-0271	\N	\N	6	2.7	4	250	\N	\N	\N	\N	B2	\N	TPP_3-14
2215	SGLP-0273	\N	\N	39	2.4	4	250	\N	\N	\N	\N	B4	\N	TPP_3-16
2216	SGLP-0274	\N	\N	29	2	4	250	\N	\N	\N	\N	B5	\N	TPP_3-17
2217	SGLP-0276	\N	\N	3	2.3	4	250	\N	\N	\N	\N	B7	\N	TPP_3-19
2218	SGLP-0277	\N	\N	7	2.5	4	250	\N	\N	\N	\N	B8	\N	TPP_3-20
2219	SGLP-0278	\N	\N	14	3.2	4	250	\N	\N	\N	\N	B9	\N	TPP_3-21
2220	SGLP-0279	\N	\N	9	3.5	4	250	\N	\N	\N	\N	B10	\N	TPP_3-22
2221	SGLP-0281	\N	\N	11	2	4	250	\N	\N	\N	\N	B12	\N	TPP_3-24
2222	SGLP-0282	\N	\N	11	3.3	4	250	\N	\N	\N	\N	C1	\N	TPP_3-25
2223	SGLP-0283	\N	\N	48	4.5	4	226	\N	\N	\N	\N	C2	\N	TPP_3-26
2224	SGLP-0284	\N	\N	18	2.4	4	250	\N	\N	\N	\N	C3	\N	TPP_3-27
2225	SGLP-0286	\N	\N	7	2.1	4	250	\N	\N	\N	\N	C5	\N	TPP_3-29
2226	SGLP-0287	\N	\N	17	2.1	4	250	\N	\N	\N	\N	C6	\N	TPP_3-30
2227	SGLP-0290	\N	\N	22	1.6	4	250	\N	\N	\N	\N	C9	\N	TPP_3-33
2228	SGLP-0291	\N	\N	10	2	4	250	\N	\N	\N	\N	C10	\N	TPP_3-34
2229	SGLP-0293	\N	\N	16	1.7	4	250	\N	\N	\N	\N	C12	\N	TPP_3-36
2230	SGLP-0296	\N	\N	6	0.3	4	250	\N	\N	\N	\N	D3	\N	TPP_3-39
2231	SGLP-0297	\N	\N	14	1	4	250	\N	\N	\N	\N	D4	\N	TPP_3-40
2232	SGLP-0299	\N	\N	5	1	4	250	\N	\N	\N	\N	D6	\N	TPP_3-42
2233	SGLP-0300	\N	\N	3	1.1	4	250	\N	\N	\N	\N	D7	\N	TPP_3-43
2234	SGLP-0301	\N	\N	4	0.8	4	250	\N	\N	\N	\N	D8	\N	TPP_3-44
2235	SGLP-0306	\N	\N	11	1.5	4	250	\N	\N	\N	\N	E1	\N	TPP_3-49
2236	SGLP-0307	\N	\N	8	1.4	4	250	\N	\N	\N	\N	E2	\N	TPP_3-50
2237	SGLP-0308	\N	\N	6	1.3	4	250	\N	\N	\N	\N	E3	\N	TPP_3-51
2238	SGLP-0310	\N	\N	7	0.2	4	250	\N	\N	\N	\N	E5	\N	TPP_3-53
2239	SGLP-0312	\N	\N	5	1.2	4	250	\N	\N	\N	\N	E7	\N	TPP_3-55
2240	SGLP-0313	\N	6.3	0	3.5	4	\N	\N	\N	\N	\N	\N	\N	LN D-01 (LN-01)
2241	SGLP-0322	\N	4.1	0	2	4	\N	\N	\N	\N	\N	\N	\N	LN D-10 (LN-10)
2242	SGLP-0323	\N	3.9	0	2.2	4	\N	\N	\N	\N	\N	\N	\N	LN D-11 (LN-11)
2243	SGLP-0324	\N	4.2	0	2.3	4	\N	\N	\N	\N	\N	\N	\N	LN D-12 (LN-12)
2244	SGLP-0325	\N	5.6	0	2.4	4	\N	\N	\N	\N	\N	\N	\N	LN D-13 (LN-13)
2245	SGLP-0327	\N	4.8	0	2.7	4	\N	\N	\N	\N	\N	\N	\N	LN D-15 (LN-15)
2246	SGLP-0328	\N	5	0	2.7	4	\N	\N	\N	\N	\N	\N	\N	LN D-16 (LN-16)
2247	SGLP-0329	\N	4.1	0	2.7	4	\N	\N	\N	\N	\N	\N	\N	LN D-17 (LN-17)
2248	SGLP-0331	\N	6.3	0	4.7	4	\N	\N	\N	\N	\N	\N	\N	LN D-19 (LN-19)
2249	SGLP-0333	\N	9.2	0	7.3	4	\N	\N	\N	\N	\N	\N	\N	LN D-21 (LN-21)
2250	SGLP-0262	\N	4	15	1.55	4	250	\N	\N	\N	\N	A5	\N	TPP_3-05
2251	SGLP-0263	\N	3.5	22	1.35	4	250	\N	\N	\N	\N	A6	\N	TPP_3-06
2252	SGLP-0267	\N	3.1	48	1.26	4	130	\N	\N	\N	\N	A10	\N	TPP_3-10
2253	SGLP-0272	\N	4.8	6	2.09	4	250	\N	\N	\N	\N	B3	\N	TPP_3-15
2254	SGLP-0275	\N	5.9	25	2.85	4	250	\N	\N	\N	\N	B6	\N	TPP_3-18
2255	SGLP-0280	\N	4	11	1.76	4	250	\N	\N	\N	\N	B11	\N	TPP_3-23
2256	SGLP-0285	\N	3.3	6	2.48	4	250	\N	\N	\N	\N	C4	\N	TPP_3-28
2257	SGLP-0288	\N	5.4	10	1.48	4	250	\N	\N	\N	\N	C7	\N	TPP_3-31
2258	SGLP-0292	\N	5.3	13	1.55	4	250	\N	\N	\N	\N	C11	\N	TPP_3-35
2259	SGLP-0294	\N	3.3	12	0.61	4	250	\N	\N	\N	\N	D1	\N	TPP_3-37
2260	SGLP-0295	\N	2.9	38	0.6	4	250	\N	\N	\N	\N	D2	\N	TPP_3-38
2261	SGLP-0298	\N	5	15	2.02	4	250	\N	\N	\N	\N	D5	\N	TPP_3-41
2262	SGLP-0302	\N	3.8	10	0.65	4	250	\N	\N	\N	\N	D9	\N	TPP_3-45
2263	SGLP-0303	\N	3.9	3	1.05	4	250	\N	\N	\N	\N	D10	\N	TPP_3-46
2264	SGLP-0304	\N	4	4	1.12	4	250	\N	\N	\N	\N	D11	\N	TPP_3-47
2265	SGLP-0305	\N	4.8	9	1.43	4	250	\N	\N	\N	\N	D12	\N	TPP_3-48
2266	SGLP-0309	\N	2.1	7	0.4	4	250	\N	\N	\N	\N	E4	\N	TPP_3-52
2267	SGLP-0311	\N	3.6	13	1.18	4	250	\N	\N	\N	\N	E6	\N	TPP_3-54
2268	SGLP-0314	\N	4.7	4	2.31	4	250	\N	\N	\N	Reseqencing of Previous LN	E10	\N	LN D-02 (LN-02)
2269	SGLP-0315	\N	6	2	3.54	4	250	\N	\N	\N	Reseqencing of Previous LN	E11	\N	LN D-03 (LN-03)
2270	SGLP-0316	\N	4.3	5	2.09	4	250	\N	\N	\N	Reseqencing of Previous LN	E12	\N	LN D-04 (LN-04)
2271	SGLP-0317	\N	5	17	2.28	4	250	\N	\N	\N	Reseqencing of Previous LN	F1	\N	LN D-05 (LN-05)
2272	SGLP-0318	\N	5.5	11	3	4	250	\N	\N	\N	Reseqencing of Previous LN	F2	\N	LN D-06 (LN-06)
2273	SGLP-0319	\N	4.4	3	2.29	4	250	\N	\N	\N	Reseqencing of Previous LN	F3	\N	LN D-07 (LN-07)
2274	SGLP-0320	\N	5.6	4	2.68	4	250	\N	\N	\N	Reseqencing of Previous LN	F4	\N	LN D-08 (LN-08)
2275	SGLP-0321	\N	5.4	8	2.61	4	250	\N	\N	\N	Reseqencing of Previous LN	F5	\N	LN D-09 (LN-09)
2276	SGLP-0326	\N	1.7	10	2.21	4	250	\N	\N	\N	Reseqencing of Previous LN	F10	\N	LN D-14 (LN-14)
2277	SGLP-0330	\N	6.2	3	4.53	4	250	\N	\N	\N	Reseqencing of Previous LN	G2	\N	LN D-18 (LN-18)
2278	SGLP-0332	\N	7	2	5.22	4	250	\N	\N	\N	Reseqencing of Previous LN	G4	\N	LN D-20 (LN-20)
2279	NMLP-003	2018-12-07 00:00:00-08	4.43	13	1.94	4	250	\N	\N	\N	\N	2	\N	NM D-03
2280	NMLP-007	2018-12-07 00:00:00-08	4.48	7	0.42	4	250	\N	\N	\N	\N	6	\N	NM D-07
2281	NMLP-008	2018-12-07 00:00:00-08	5.7	7	0.75	4	250	\N	\N	\N	\N	7	\N	NM D-08
2282	NMLP-012	2018-12-07 00:00:00-08	3.09	8	0.38	4	250	\N	\N	\N	\N	11	\N	NM D-12
2283	NMLP-013	2018-12-07 00:00:00-08	3.65	25	1.45	4	250	\N	\N	\N	\N	12	\N	NM D-13
2284	NMLP-015	2018-12-07 00:00:00-08	3.58	45	0.35	4	250	\N	\N	\N	\N	14	\N	NM D-15
2285	NMLP-019	2018-12-11 00:00:00-08	10.2	6	0.58	4	250	\N	\N	\N	\N	39	\N	NM D-19
2286	NMLP-022	2018-12-11 00:00:00-08	9.17	6	3.33	4	250	\N	\N	\N	\N	52	\N	NM D-31
2287	NMLP-025	2018-12-11 00:00:00-08	13.6	5	5.29	4	250	\N	\N	\N	\N	45	\N	NM D-034
2288	NMLP-026	2018-12-11 00:00:00-08	9.14	5	2.89	4	250	\N	\N	\N	\N	46	\N	NM D-035
2289	NMLP-028	2018-12-11 00:00:00-08	11.6	5	4.98	4	250	\N	\N	\N	\N	48	\N	NM D-037
2290	NMLP-029	2018-12-11 00:00:00-08	2.33	7	0.64	4	250	\N	\N	\N	\N	49	\N	NM D-038
2291	NMLP-030	2018-12-11 00:00:00-08	1.25	48	0.28	4	70.6	\N	\N	\N	\N	50	\N	NM D-039
2292	NMLP-031	2018-12-11 00:00:00-08	6.62	14	3.63	4	250	\N	\N	\N	\N	51	\N	NM D-040
2293	NMLP-032	2018-12-11 00:00:00-08	3.89	29	0.94	4	250	\N	\N	\N	\N	52	\N	NM D-041
2294	NMLP-039	2018-12-11 00:00:00-08	3.92	16	1.48	4	250	\N	\N	\N	\N	59	\N	NM D-049
2295	NMLP-050	\N	8.63	6	0.46	4	250	\N	\N	\N	\N	70	\N	NM D-063
2296	NMLP-051	\N	5.67	6	0.47	4	250	\N	\N	\N	\N	71	\N	NM D-064
2297	NMLP-052	\N	8.63	5	2.79	4	250	\N	\N	\N	\N	72	\N	NM D-065
2298	SGLP-0356	2018-12-20 00:00:00-08	1.36	48	0.77	4	65.3	\N	\N	\N	Nevus from Iwei	73	\N	SM D-01
2299	SGLP-0357	2018-12-20 00:00:00-08	2.1	48	0.63	4	100.8	\N	\N	\N	Nevus from Iwei	74	\N	SM D-02
2300	SGLP-0358	2018-12-20 00:00:00-08	8.67	29	1.96	4	250	\N	\N	\N	Nevus from Iwei	75	\N	SM D-03
2301	SGLP-0359	2018-12-20 00:00:00-08	3.02	48	1.54	4	145	\N	\N	\N	Nevus from Iwei	76	\N	SM D-04
2302	SGLP-0360	2018-12-20 00:00:00-08	2.6	48	0.73	4	124.8	\N	\N	\N	Nevus from Iwei	77	\N	SM D-05
2303	NMLP-014	2018-12-07 00:00:00-08	3.25	16	0.12	4	250	\N	\N	\N	\N	13	\N	NM D-14
2304	NMLP-033	2018-12-11 00:00:00-08	0.94	48	0.19	4	39.4	\N	\N	\N	\N	53	\N	NM D-043
2305	NMLP-036	2018-12-11 00:00:00-08	0.63	48	0.11	4	43.1	\N	\N	\N	\N	56	\N	NM D-046
2306	NMLP-042	\N	0.3	48	0.15	4	28.9	\N	\N	\N	\N	62	\N	NM D-052
2307	SGLP-0347	2018-10-13 00:00:00-07	1.92	24	4.17	4	250	\N	\N	\N	DNA from Dermpath/Swapna	30	\N	CGH11-098-D
2308	SGLP-0348	2018-10-13 00:00:00-07	1.97	41	2.07	4	250	\N	\N	\N	DNA from Dermpath/Swapna	31	\N	CGH12-056-D
2309	SGLP-0349	2018-10-13 00:00:00-07	2.71	34	1.62	4	250	\N	\N	\N	DNA from Dermpath/Swapna	32	\N	CGH12-039-D
2310	SGLP-0350	2018-10-13 00:00:00-07	2.06	30	4.26	4	250	\N	\N	\N	DNA from Dermpath/Swapna	33	\N	CGH12-092-D
2311	SGLP-0351	2018-10-13 00:00:00-07	1.53	50	2.89	4	250	\N	\N	\N	DNA from Dermpath/Swapna	34	\N	CGH14-083-D
2312	SGLP-0352	2018-10-13 00:00:00-07	0.59	50	0.94	4	94.5	\N	\N	\N	DNA from Dermpath/Swapna	35	\N	CGH14-341-D
2313	SGLP-0353	2018-10-13 00:00:00-07	1.34	37	2.58	4	250	\N	\N	\N	DNA from Dermpath/Swapna	36	\N	CGH18-012-D
2314	SGLP-0354	2018-10-13 00:00:00-07	1.89	32	3.43	4	250	\N	\N	\N	DNA from Dermpath/Swapna	37	\N	CGH15-109-D
2315	SGLP-0362	2018-12-20 00:00:00-08	2.08	48	0.99	4	99.8	\N	\N	\N	Nevus from Iwei	79	\N	SM D-07
2316	SGLP-0363	2018-12-20 00:00:00-08	4.14	48	4.28	4	198.7	\N	\N	\N	Nevus from Iwei; NEED TO RE-SEQUENCE	80	\N	SM D-08
2317	SGLP-0364	2018-12-20 00:00:00-08	0.92	48	0.85	4	44	\N	\N	\N	Nevus from Iwei	81	\N	SM D-09
2318	SGLP-0365	2018-12-20 00:00:00-08	4.36	48	2.89	4	209.3	\N	\N	\N	Nevus from Iwei	82	\N	SM D-10
2319	SGLP-0366	2018-12-20 00:00:00-08	1.4	48	1.3	4	67.2	\N	\N	\N	Nevus from Iwei	83	\N	SM D-11
2320	SGLP-0367	2018-12-20 00:00:00-08	14.4	17	3.56	4	250	\N	\N	\N	Nevus from Iwei	84	\N	SM D-12
2321	SGLP-0368	2018-12-20 00:00:00-08	9.44	26	3.29	4	250	\N	\N	\N	Nevus from Iwei	85	\N	SM D-13
2322	SGLP-0369	2018-12-20 00:00:00-08	3.3	48	2.69	4	159.8	\N	\N	\N	Nevus from Iwei	86	\N	SM D-14
2323	SGLP-0370	2018-12-20 00:00:00-08	8.61	29	4.22	4	250	\N	\N	\N	Nevus from Iwei; NEED TO RE-SEQUENCE	87	\N	SM D-15
2324	SGLP-0371	2018-12-20 00:00:00-08	2.27	48	0.46	4	109	\N	\N	\N	Nevus from Iwei	88	\N	SM D-16
2325	SGLP-0372	2018-12-20 00:00:00-08	6.84	37	1.9	4	250	\N	\N	\N	Nevus from Iwei	89	\N	SM D-17
2326	SGLP-0373	2018-12-20 00:00:00-08	6.75	37	1.63	4	250	\N	\N	\N	Nevus from Iwei	90	\N	SM D-18
2327	SGLP-0374	2018-12-20 00:00:00-08	1.22	48	0.91	4	58.6	\N	\N	\N	Nevus from Iwei	91	\N	SM D-19
2328	SGLP-0375	2018-12-20 00:00:00-08	5.97	42	3.95	4	250	\N	\N	\N	Nevus from Iwei	92	\N	SM D-20
2329	SGLP-0376	2018-12-20 00:00:00-08	0.77	48	0.28	4	36.9	\N	\N	\N	Nevus from Iwei	93	\N	SM D-21
2330	SGLP-0377	2018-12-20 00:00:00-08	1.87	48	2.02	4	89.8	\N	\N	\N	Nevus from Iwei	94	\N	SM D-22
2331	SGLP-0378	2018-12-20 00:00:00-08	0.83	48	0.29	4	39.7	\N	\N	\N	Nevus from Iwei	95	\N	SM D-23
2332	SGLP-0379	2018-12-20 00:00:00-08	1.54	48	0.7	4	73.9	\N	\N	\N	Nevus from Iwei	96	\N	SM D-24
2333	AMLP-141	2019-12-03 00:00:00-08	3.68	28	2.1	4	300	\N	\N	\N	120s shear time; DNA repaired	75	\N	AM2 D-159
2334	SGLP-0404	2019-02-27 00:00:00-08	25	10	9.77	4	250	\N	\N	\N	cases with MAP3K8 fusions	15	\N	CGH12-109
2335	SGLP-0405	2019-02-27 00:00:00-08	25	10	5.39	4	250	\N	\N	\N	cases with MAP3K8 fusions	16	\N	CGH12-280
2336	SGLP-0406	2019-02-27 00:00:00-08	25	10	4.55	4	250	\N	\N	\N	cases with MAP3K8 fusions	18	\N	CGH14-145
2337	SGLP-0407	2019-02-27 00:00:00-08	25	10	2.59	4	250	\N	\N	\N	cases with MAP3K8 fusions	19	\N	CGH14-348
2338	SGLP-0408	2019-02-27 00:00:00-08	25	10	4.59	4	250	\N	\N	\N	cases with MAP3K8 fusions	20	\N	CGH16-200
2339	SGLP-0409	2019-02-27 00:00:00-08	25	10	7.49	4	250	\N	\N	\N	cases with MAP3K8 fusions	21	\N	CGH17-135
2340	SGLP-0410	2019-02-27 00:00:00-08	25	10	12.08	4	250	\N	\N	\N	\N	22	\N	CGH18-139
2341	SGLP-0411	2019-02-27 00:00:00-08	25	10	6.03	4	250	\N	\N	\N	\N	23	\N	CGH17-240
2342	SGLP-0412	2019-02-27 00:00:00-08	25	10	3.68	4	250	\N	\N	\N	\N	24	\N	CGH18-137
2343	MRLP-041	2019-02-13 00:00:00-08	34.9	7	3.29	4	250	\N	\N	\N	\N	58	\N	MR-041
2344	MRLP-042	2019-02-13 00:00:00-08	6.61	38	0.83	4	250	\N	\N	\N	\N	59	\N	MR-042
2345	MRLP-043	2019-02-13 00:00:00-08	17.2	15	2.68	4	250	\N	\N	\N	\N	60	\N	MR-043
2346	MRLP-044	2019-02-13 00:00:00-08	18.1	14	2.15	4	250	\N	\N	\N	\N	61	\N	MR-044
2347	MRLP-045	2019-02-13 00:00:00-08	0.97	48	0.28	4	46.6	\N	\N	\N	\N	62	\N	MR-045
2348	MRLP-046	2019-02-13 00:00:00-08	19.2	13	0.91	4	250	\N	\N	\N	\N	63	\N	MR-046
2349	MRLP-047	2019-02-13 00:00:00-08	2.04	48	0.67	4	97.9	\N	\N	\N	\N	64	\N	MR-047
2350	MRLP-048	2019-02-13 00:00:00-08	37.8	7	2	4	250	\N	\N	\N	\N	65	\N	MR-048
2351	MRLP-049	2019-02-13 00:00:00-08	23.7	11	1.55	4	250	\N	\N	\N	\N	66	\N	MR-049
2352	MRLP-050	2019-02-13 00:00:00-08	20.2	12	3.11	4	250	\N	\N	\N	\N	67	\N	MR-050
2353	SGLP-0381	2019-02-21 00:00:00-08	2.2	48	1.05	4	105.6	\N	\N	\N	\N	69	\N	BND-001
2354	SGLP-0382	2019-02-21 00:00:00-08	2.81	48	1.56	4	134.9	\N	\N	\N	\N	70	\N	BND-002
2355	SGLP-0384	2019-02-21 00:00:00-08	1.14	50	0.81	4	54.7	\N	\N	\N	\N	72	\N	BND-004
2356	SGLP-0386	2019-02-21 00:00:00-08	1.13	49	0.38	4	54.2	\N	\N	\N	\N	74	\N	BND-006
2357	SGLP-0388	2019-02-21 00:00:00-08	0.78	47	0.38	4	37.6	\N	\N	\N	\N	76	\N	BND-008
2358	SGLP-0389	2019-02-21 00:00:00-08	1.96	47	0.47	4	94.1	\N	\N	\N	\N	73	\N	BND-009
2359	SGLP-0390	2019-02-21 00:00:00-08	13.2	19	1.42	4	250	\N	\N	\N	\N	74	\N	BND-011
2360	SGLP-0391	2019-02-21 00:00:00-08	1.59	48	0.55	4	76.3	\N	\N	\N	\N	79	\N	BND-012
2361	SGLP-0392	2019-02-21 00:00:00-08	12.6	20	3.08	4	250	\N	\N	\N	\N	80	\N	NLD-014
2362	SGLP-0393	2019-02-21 00:00:00-08	34.2	7	5.74	4	250	\N	\N	\N	\N	81	\N	NLD-015
2363	SGLP-0394	2019-02-21 00:00:00-08	6.1	41	7.83	4	250	\N	\N	\N	\N	82	\N	NLD-016
2364	SGLP-0395	2019-02-21 00:00:00-08	1.23	49	0.42	4	59	\N	\N	\N	\N	83	\N	NLD-017
2365	SGLP-0396	2019-02-21 00:00:00-08	0.75	45	0.18	4	36.1	\N	\N	\N	\N	84	\N	NLD-018
2366	SGLP-0397	2019-02-21 00:00:00-08	1.51	48	0.39	4	72.5	\N	\N	\N	\N	85	\N	NLD-019
2367	SGLP-0398	2019-02-21 00:00:00-08	0.93	50	0.34	4	44.6	\N	\N	\N	\N	86	\N	NLD-020
2368	SGLP-0399	2019-02-21 00:00:00-08	26.5	9	0.95	4	250	\N	\N	\N	\N	87	\N	NLD-021
2369	SGLP-0400	2019-02-21 00:00:00-08	1.65	47	1.31	4	79.2	\N	\N	\N	\N	88	\N	NLD-022
2370	SGLP-0401	2019-02-21 00:00:00-08	2.41	48	1.74	4	115.7	\N	\N	\N	\N	89	\N	NLD-023
2371	SGLP-0402	2019-02-21 00:00:00-08	1.74	49	2.91	4	83.5	\N	\N	\N	\N	90	\N	NLD-024
2372	SGLP-0403	2019-02-21 00:00:00-08	1.37	47	2.1	4	65.8	\N	\N	\N	\N	91	\N	NLD-025
2373	SGLP-0458	2019-06-04 00:00:00-07	8.29	18	2.3	4	250	\N	\N	\N	\N	15	\N	CM D-04
2374	SGLP-0459	2019-06-04 00:00:00-07	10.2	33	3.56	4	250	\N	\N	\N	\N	16	\N	CM D-05
2375	SGLP-0471	2019-06-04 00:00:00-07	4.74	27	3.03	4	250	\N	\N	\N	\N	64	\N	CM D-17
2376	SGLP-0474	2019-06-04 00:00:00-07	0.77	48	0.13	4	55	\N	\N	\N	\N	67	\N	CM D-21
2377	SGLP-0478	2019-06-06 00:00:00-07	7.49	5	4.4	4	250	\N	\N	\N	\N	71	\N	CM D-25
2378	SGLP-0492	2019-06-06 00:00:00-07	2.99	17	1.47	4	250	\N	\N	\N	\N	85	\N	CM D-40
2379	SGLP-0493	2019-06-06 00:00:00-07	3.6	46	2.08	4	250	\N	\N	\N	\N	86	\N	CM D-41
2380	SGLP-0495	2019-06-06 00:00:00-07	5.74	13	2.84	4	250	\N	\N	\N	\N	88	\N	CM D-43
2381	MRLP-001	2019-02-08 00:00:00-08	58	4	3.87	4	250	\N	\N	\N	\N	25	\N	MR-001
2382	MRLP-002	2019-02-08 00:00:00-08	41.6	6	2.09	4	250	\N	\N	\N	\N	26	\N	MR-002
2383	MRLP-003	2019-02-08 00:00:00-08	21.7	12	0.53	4	250	\N	\N	\N	\N	27	\N	MR-003
2384	MRLP-004	2019-02-08 00:00:00-08	29.6	8	0.68	4	250	\N	\N	\N	\N	28	\N	MR-004
2385	MRLP-005	2019-02-08 00:00:00-08	16.8	15	0.96	4	250	\N	\N	\N	\N	29	\N	MR-005
2386	MRLP-006	2019-02-08 00:00:00-08	9.84	25	1.16	4	250	\N	\N	\N	\N	30	\N	MR-006
2387	MRLP-008	2019-02-08 00:00:00-08	12	21	0.55	4	250	\N	\N	\N	\N	31	\N	MR-008
2388	MRLP-009	2019-02-08 00:00:00-08	8.6	29	4.48	4	250	\N	\N	\N	\N	32	\N	MR-009
2389	MRLP-010	2019-02-08 00:00:00-08	8.87	28	0.62	4	250	\N	\N	\N	\N	33	\N	MR-010
2390	MRLP-011	2019-02-08 00:00:00-08	59	4	1.76	4	250	\N	\N	\N	\N	34	\N	MR-011
2391	MRLP-012	2019-02-08 00:00:00-08	31.1	8	0.27	4	250	\N	\N	\N	\N	35	\N	MR-012
2392	MRLP-015	2019-02-08 00:00:00-08	1.11	48	1.34	4	53.3	\N	\N	\N	\N	36	\N	MR-015
2393	MRLP-017	2019-02-08 00:00:00-08	53	5	1.04	4	250	\N	\N	\N	\N	37	\N	MR-017
2394	MRLP-020	2019-02-08 00:00:00-08	207	1	1.39	4	250	\N	\N	\N	\N	38	\N	MR-020
2395	MRLP-021	2019-02-08 00:00:00-08	11.5	22	2.17	4	250	\N	\N	\N	\N	39	\N	MR-021
2396	MRLP-024	2019-02-08 00:00:00-08	11.8	21	1.26	4	250	\N	\N	\N	\N	40	\N	MR-024
2397	MRLP-025	2019-02-08 00:00:00-08	6.4	39	0.36	4	250	\N	\N	\N	\N	41	\N	MR-025
2398	MRLP-029	2019-02-08 00:00:00-08	29.5	8	1.18	4	250	\N	\N	\N	\N	44	\N	MR-029
2399	MRLP-032	2019-02-13 00:00:00-08	11.5	22	2.53	4	250	\N	\N	\N	\N	49	\N	MR-032
2400	MRLP-033	2019-02-13 00:00:00-08	24.5	10	1.47	4	250	\N	\N	\N	\N	50	\N	MR-033
2401	MRLP-034	2019-02-13 00:00:00-08	46.2	5	2.88	4	250	\N	\N	\N	\N	51	\N	MR-034
2402	MRLP-035	2019-02-13 00:00:00-08	44.6	6	4.17	4	250	\N	\N	\N	\N	52	\N	MR-035
2403	MRLP-036	2019-02-13 00:00:00-08	5.41	46	0.76	4	250	\N	\N	\N	\N	53	\N	MR-036
2404	MRLP-038	2019-02-13 00:00:00-08	14.4	17	0.82	4	250	\N	\N	\N	\N	55	\N	MR-038
2405	MRLP-039	2019-02-13 00:00:00-08	19.9	13	0.65	4	250	\N	\N	\N	\N	56	\N	MR-039
2406	MRLP-051	2019-02-13 00:00:00-08	2.12	48	0.4	4	101.8	\N	\N	\N	\N	68	\N	MR-051
2407	SGLP-0383	2019-02-21 00:00:00-08	3.85	47	0.43	4	184.8	\N	\N	\N	\N	71	\N	BND-003
2408	SGLP-0480	2019-06-06 00:00:00-07	7.98	16	6.5	4	250	\N	\N	\N	\N	73	\N	CM D-27
2409	MP41	2019-01-03 00:00:00-08	13	65	10.89	\N	250	\N	\N	\N	4/25/23: deleted -LP from the LP_ID	73	\N	MP41-D
2410	MP41-YMR1	2019-01-03 00:00:00-08	9.14	42	6.03	\N	250	\N	\N	\N	4/25/23: deleted -LP from the LP_ID	74	\N	MP41-YM-R1-D
2411	SGLP-0334	2018-10-13 00:00:00-07	3.02	17	6.16	4	250	\N	\N	\N	Acral Melanoma Cell Line	17	\N	MaMel  152aI (AMC-01)
2412	SGLP-0335	2018-10-13 00:00:00-07	2.31	27	3.96	4	250	\N	\N	\N	Acral Melanoma Cell Line; NEED TO RE SEQUENCE	18	\N	M100118 (AMC-02)
2413	SGLP-0336	2018-10-13 00:00:00-07	2.41	10	4.37	4	250	\N	\N	\N	Acral Melanoma Cell Line	19	\N	MM100511 (AMC-03)
2414	SGLP-0337	2018-10-13 00:00:00-07	2.87	38	7.24	4	250	\N	\N	\N	Acral Melanoma Cell Line	20	\N	MM100512 (AMC-03)
2415	SGLP-0338	2018-10-13 00:00:00-07	2.71	16	7.5	4	250	\N	\N	\N	Acral Melanoma Cell Line	21	\N	MM100513 (AMC-03)
2416	SGLP-0339	2018-10-13 00:00:00-07	3.2	14	8.25	4	250	\N	\N	\N	Acral Melanoma Cell Line	22	\N	MM100916 (AMC-03)
2417	SGLP-0340	2018-10-13 00:00:00-07	2.69	16	0.37	4	250	\N	\N	\N	Acral Melanoma Cell Line	23	\N	M040204 (AMC-07)
2418	SGLP-0341	2018-10-13 00:00:00-07	2.14	15	1.6	4	250	\N	\N	\N	Acral Melanoma Cell Line	24	\N	M040415 (AMC-08)
2419	SGLP-0342	2018-10-13 00:00:00-07	3.21	12	9.75	4	250	\N	\N	\N	Acral Melanoma Cell Line	25	\N	M040416 (AMC-08)
2420	SGLP-0343	2018-10-13 00:00:00-07	3.28	15	9.66	4	250	\N	\N	\N	Acral Melanoma Cell Line	26	\N	M040418 (AMC-08)
2421	SGLP-0344	2018-10-13 00:00:00-07	4.06	18	8.58	4	250	\N	\N	\N	Acral Melanoma Cell Line	27	\N	M040419A (AMC-08)
2422	SGLP-0345	2018-10-13 00:00:00-07	1.79	20	4.31	4	250	\N	\N	\N	Acral Melanoma Cell Line	28	\N	MM160113 (AMC-12)
2423	SGLP-0346	2018-10-13 00:00:00-07	2.56	25	4.73	4	250	\N	\N	\N	Acral Melanoma Cell Line	29	\N	M180322 (AMC-13)
2424	SGLP-0450	2019-05-14 00:00:00-07	10.4	2	8.91	4	250	\N	\N	\N	Acral Melanoma Cell Line	52	\N	SKMEL 1023A
2425	SGLP-0451	2019-05-14 00:00:00-07	17.7	2	13.59	4	250	\N	\N	\N	Acral Melanoma Cell Line	53	\N	SKMEL 1107B
2426	SGLP-0453	2019-05-14 00:00:00-07	20.3	2	17.72	4	250	\N	\N	\N	Acral Melanoma Cell Line	55	\N	SKMEL 1121B
2427	SGLP-0454	2019-05-14 00:00:00-07	7.9	61	7.93	4	250	\N	\N	\N	Acral Melanoma Cell Line	56	\N	Mel290
2428	MRLP-026	2019-02-08 00:00:00-08	121	2	4.35	4	250	\N	\N	\N	\N	52	\N	MR-026
2429	MRLP-027	2019-02-08 00:00:00-08	1.01	48	3.29	4	48.5	\N	\N	\N	\N	43	\N	MR-027
2430	MRLP-030	2019-02-08 00:00:00-08	13.7	18	4.91	4	250	\N	\N	\N	\N	45	\N	MR-030
2431	MRLP-031	2019-02-08 00:00:00-08	18.1	14	4.1	4	250	\N	\N	\N	\N	46	\N	MR-031
2432	MRLP-037	2019-02-13 00:00:00-08	9.44	26	3.56	4	250	\N	\N	\N	\N	54	\N	MR-037
2433	MRLP-040	2019-02-13 00:00:00-08	34.6	7	3.13	4	250	\N	\N	\N	\N	57	\N	MR-040
2434	SGLP-0413	2019-05-07 00:00:00-07	1.09	172	0.2	4	67.2	\N	\N	\N	\N	17	\N	LN D-022 (LN-022)
2435	SGLP-0414	2019-05-07 00:00:00-07	1.04	125	0.17	4	61.4	\N	\N	\N	\N	18	\N	LN D-023 (LN-023)
2436	SGLP-0415	2019-05-07 00:00:00-07	1.67	197	0.32	4	130.1	\N	\N	\N	\N	19	\N	LN D-024 (LN-024)
2437	SGLP-0416	2019-05-07 00:00:00-07	2.51	224	0.91	4	176.6	\N	\N	\N	\N	20	\N	LN D-025 (LN-025)
2438	SGLP-0417	2019-05-07 00:00:00-07	2.41	249	0.8	4	129.6	\N	\N	\N	\N	21	\N	LN D-026 (LN-026)
2439	SGLP-0418	2019-05-07 00:00:00-07	0.96	199	0.27	4	65.8	\N	\N	\N	\N	22	\N	LN D-027 (LN-027)
2440	SGLP-0420	2019-05-07 00:00:00-07	0.85	161	0.24	4	46.6	\N	\N	\N	\N	25	\N	LN D-029 (LN-029)
2441	SGLP-0421	2019-05-07 00:00:00-07	1.15	162	0.29	4	61.4	\N	\N	\N	\N	26	\N	LN D-030 (LN-030)
2442	SGLP-0422	2019-05-07 00:00:00-07	0.73	218	0.15	4	39.2	\N	\N	\N	\N	27	\N	LN D-031 (LN-031)
2443	SGLP-0423	2019-05-07 00:00:00-07	2.72	323	0.6	4	142.1	\N	\N	\N	\N	28	\N	LN D-032 (LN-032)
2444	SGLP-0424	2019-05-07 00:00:00-07	2.71	48	0.61	4	61	\N	\N	\N	\N	29	\N	LN D-033 (LN-033)
2445	SGLP-0425	2019-05-07 00:00:00-07	2.32	825	0.72	4	132	\N	\N	\N	\N	30	\N	LN D-034 (LN-034)
2446	SGLP-0426	2019-05-07 00:00:00-07	1.59	388	0.35	4	104.6	\N	\N	\N	\N	31	\N	LN D-035 (LN-035)
2447	SGLP-0427	2019-05-07 00:00:00-07	1.5	406	0.39	4	61	\N	\N	\N	\N	32	\N	LN D-036 (LN-036)
2448	SGLP-0429	2019-05-07 00:00:00-07	1.38	859	0.34	4	77.3	\N	\N	\N	\N	33	\N	LN D-038 (LN-038)
2449	SGLP-0430	2019-05-07 00:00:00-07	1.94	475	0.55	4	95	\N	\N	\N	\N	34	\N	LN D-039 (LN-039)
2450	SGLP-0431	2019-05-07 00:00:00-07	1.68	153	0.38	4	85	\N	\N	\N	\N	35	\N	LN D-040 (LN-040)
2451	SGLP-0432	2019-05-07 00:00:00-07	5.65	176	2.11	4	250	\N	\N	\N	\N	36	\N	LN D-041 (LN-041)
2452	SGLP-0433	2019-05-07 00:00:00-07	2.2	680	0.57	4	81.6	\N	\N	\N	\N	37	\N	LN D-042 LN-042)
2453	SGLP-0434	2019-05-07 00:00:00-07	5.01	428	2	4	250	\N	\N	\N	\N	38	\N	LN D-043 (LN-043)
2454	SGLP-0436	2019-05-07 00:00:00-07	5.53	164	1.29	4	250	\N	\N	\N	\N	40	\N	LN D-045 (LN-045)
2455	SGLP-0437	2019-05-07 00:00:00-07	3.36	640	0.59	4	159.4	\N	\N	\N	\N	41	\N	LN D-046 (LN-046)
2456	SGLP-0438	2019-05-14 00:00:00-07	2.13	436	0.9	4	117.6	\N	\N	\N	\N	2	\N	LN D-047 (LN-047)
2457	SGLP-0439	2019-05-14 00:00:00-07	3.28	48	2	4	100.3	\N	\N	\N	\N	4	\N	LN D-050 (LN-050)
2458	SGLP-0440	2019-05-14 00:00:00-07	3.07	48	1.8	4	132	\N	\N	\N	\N	5	\N	LN D-057 (LN-057)
2459	SGLP-0441	2019-05-14 00:00:00-07	1.46	48	0.93	4	57.6	\N	\N	\N	repeat qPCR	6	\N	LN D-058 (LN-058)
2460	SGLP-0442	2019-05-14 00:00:00-07	1	48	0.4	4	46.9	\N	\N	\N	\N	11	\N	LN D-059 (LN-059)
2461	SGLP-0443	2019-05-14 00:00:00-07	2.49	48	1	4	127.2	\N	\N	\N	\N	12	\N	LN D-060 (LN-060)
2462	SGLP-0444	2019-05-14 00:00:00-07	2.23	48	1.2	4	107.5	\N	\N	\N	\N	52	\N	LN D-062 (LN-062)
2463	SGLP-0445	2019-05-14 00:00:00-07	1.97	48	1.1	4	71.5	\N	\N	\N	\N	44	\N	LN D-063 (LN-063)
2464	SGLP-0446	2019-05-14 00:00:00-07	2.39	48	1.2	4	110.9	\N	\N	\N	\N	45	\N	LN D-064 (LN-064)
2465	SGLP-0447	2019-05-14 00:00:00-07	1.52	48	1	4	65.3	\N	\N	\N	\N	46	\N	LN D-065 (LN-065)
2466	SGLP-0448	2019-05-14 00:00:00-07	1.21	48	0.7	4	47	\N	\N	\N	\N	49	\N	LN D-066 (LN-066)
2467	SGLP-0449	2019-05-14 00:00:00-07	2.61	48	1.5	4	80.6	\N	\N	\N	\N	50	\N	LN D-067 (LN-067)
2468	SGLP-0455	2019-06-04 00:00:00-07	4.26	22	0.69	4	250	\N	\N	\N	\N	7	\N	CMD-01
2469	SGLP-0456	2019-06-04 00:00:00-07	0.94	48	0.15	4	43	\N	\N	\N	\N	13	\N	CMD-02
2470	SGLP-0457	2019-06-04 00:00:00-07	4	48	1.51	4	125	\N	\N	\N	\N	14	\N	CM D-03
2471	SGLP-0460	2019-06-04 00:00:00-07	3.21	9	0.38	4	250	\N	\N	\N	\N	43	\N	CM D-06
2472	SGLP-0461	2019-06-04 00:00:00-07	27	27	0.58	4	250	\N	\N	\N	\N	47	\N	CM D-07
2473	SGLP-0462	2019-06-04 00:00:00-07	4.79	6	2.23	4	250	\N	\N	\N	\N	48	\N	CM D-08
2474	SGLP-0463	2019-06-04 00:00:00-07	3.03	48	0.66	4	180	\N	\N	\N	\N	51	\N	CM D-09
2475	SGLP-0464	2019-06-04 00:00:00-07	5.91	28	1.69	4	250	\N	\N	\N	\N	57	\N	CM D-10
2476	SGLP-0465	2019-06-04 00:00:00-07	2.89	48	1.36	4	141	\N	\N	\N	\N	58	\N	CM D-11
2477	SGLP-0466	2019-06-04 00:00:00-07	1.31	48	0.5	4	48	\N	\N	\N	\N	59	\N	CM D-12
2478	SGLP-0467	2019-06-04 00:00:00-07	4.76	17	3.02	4	250	\N	\N	\N	\N	60	\N	CM D-13
2479	SGLP-0468	2019-06-04 00:00:00-07	3.46	24	1.17	4	250	\N	\N	\N	\N	61	\N	CM D-14
2480	SGLP-0469	2019-06-04 00:00:00-07	1.73	48	0.63	4	132	\N	\N	\N	\N	62	\N	CM D-15
2481	SGLP-0470	2019-06-04 00:00:00-07	4.91	16	1.65	4	250	\N	\N	\N	\N	63	\N	CM D-16
2482	SGLP-0473	2019-06-04 00:00:00-07	3.48	10	1.23	4	250	\N	\N	\N	\N	66	\N	CM D-19
2483	SGLP-0475	2019-06-04 00:00:00-07	5.66	40	1.85	4	250	\N	\N	\N	\N	68	\N	CM D-22
2484	SGLP-0477	2019-06-04 00:00:00-07	5.29	13	1.55	4	250	\N	\N	\N	\N	70	\N	CM D-24
2485	SGLP-0486	2019-06-06 00:00:00-07	6.61	10	3.36	4	250	\N	\N	\N	\N	79	\N	CM D-34
2486	SGLP-0487	2019-06-06 00:00:00-07	4.55	4	1.51	4	250	\N	\N	\N	\N	80	\N	CM D-35
2487	SGLP-0488	2019-06-06 00:00:00-07	2.84	48	0.49	4	220	\N	\N	\N	\N	81	\N	CM D-36
2488	SGLP-0491	2019-06-06 00:00:00-07	2.52	48	0.71	4	153	\N	\N	\N	\N	84	\N	CM D-39
2489	SGLP-0496	2019-06-06 00:00:00-07	1	48	0.34	4	42	\N	\N	\N	\N	89	\N	CM D-44
2490	SGLP-0497	2019-06-06 00:00:00-07	2.89	48	0.76	4	164	\N	\N	\N	\N	90	\N	CM D-45
2491	SGLP-0498	2019-06-06 00:00:00-07	3.59	48	1.58	4	135	\N	\N	\N	\N	91	\N	CM D-46
2492	SGLP-0499	2019-06-06 00:00:00-07	4.28	48	2.1	4	127	\N	\N	\N	\N	92	\N	CM D-47
2493	NMLP-001	2018-12-07 00:00:00-08	3.43	12	2.15	4	250	\N	\N	\N	NM from Greece	1	\N	NM D-01
2494	NMLP-004	2018-12-07 00:00:00-08	1.2	48	1.36	4	83	\N	\N	\N	\N	3	\N	NM D-04
2495	NMLP-010	2018-12-07 00:00:00-08	2.65	11	1.21	4	250	\N	\N	\N	\N	9	\N	NM D-10
2496	NMLP-011	2018-12-07 00:00:00-08	5.32	7	1.8	4	250	\N	\N	\N	\N	10	\N	NM D-11
2497	NMLP-049	\N	0.53	48	0.88	4	26.5	\N	\N	\N	\N	69	\N	NM D-061
2498	SGLP-0479	2019-06-06 00:00:00-07	8.35	46	5.09	4	250	\N	\N	\N	\N	72	\N	CM D-26
2499	SGLP-0481	2019-06-06 00:00:00-07	7.03	35	4.52	4	250	\N	\N	\N	\N	74	\N	CM D-29
2500	SGLP-0482	2019-06-06 00:00:00-07	5.05	14	2.38	4	250	\N	\N	\N	\N	75	\N	CM D-30
2501	SGLP-0484	2019-06-06 00:00:00-07	6.55	6	3.22	4	250	\N	\N	\N	\N	77	\N	CM D-32
2502	SGLP-0485	2019-06-06 00:00:00-07	8.44	12	5.65	4	250	\N	\N	\N	\N	78	\N	CM D-33
2503	SGLP-0576	2019-08-05 00:00:00-07	\N	6	0.37	4	250	\N	\N	\N	Madrid Melanoma	89	\N	MDD-86
2504	SGLP-0577	2019-08-05 00:00:00-07	\N	15	0.98	4	250	\N	\N	\N	Madrid Melanoma	90	\N	MDD-87
2505	SGLP-0578	2019-08-05 00:00:00-07	\N	4	1.76	4	250	\N	\N	\N	Madrid Melanoma	91	\N	MDD-88
2506	SGLP-0579	2019-08-05 00:00:00-07	\N	7	0.8	4	250	\N	\N	\N	Madrid Melanoma	92	\N	MDD-89
2507	SGLP-0580	2019-08-05 00:00:00-07	\N	48	1.4	4	231	\N	\N	\N	Madrid Melanoma	94	\N	MDD-90
2508	SGLP-0581	2019-08-05 00:00:00-07	\N	45	0.6	4	250	\N	\N	\N	Madrid Melanoma	95	\N	MDD-91
2509	SGLP-0582	2019-08-05 00:00:00-07	\N	6	1.6	4	250	\N	\N	\N	Madrid Melanoma	96	\N	MDD-92
2510	SGLP-0600	2019-08-13 00:00:00-07	\N	6	5.49	4	250	\N	\N	\N	PRKC fused cases	32	\N	CGH12-058
2511	SGLP-0601	2019-08-13 00:00:00-07	\N	6	3.51	4	250	\N	\N	\N	PRKC fused cases	33	\N	CGH12-301
2512	SGLP-0602	2019-08-13 00:00:00-07	\N	8	2.71	4	250	\N	\N	\N	PRKC fused cases	34	\N	CGH14-050
2513	SGLP-0603	2019-08-13 00:00:00-07	\N	9	4.82	4	250	\N	\N	\N	NRAS sequencing	35	\N	CGH15-249
2514	SGLP-0604	2019-08-13 00:00:00-07	\N	8	5.07	4	250	\N	\N	\N	NRAS sequencing	36	\N	CGH14-147
2515	SGLP-0605	2019-08-13 00:00:00-07	\N	8	3.84	4	250	\N	\N	\N	NRAS sequencing	37	\N	CGH12-067
2516	SGLP-0606	2019-08-13 00:00:00-07	\N	\N	3.27	4	\N	\N	\N	\N	Atypical Spitz tumor-nodule	38	\N	"CGH19-097_1\n.00"
2517	SGLP-0607	2019-08-13 00:00:00-07	4.76	11	1.54	4	250	\N	\N	\N	Atypical Spitz tumor-nevus	39	\N	CGH19-097_2
2518	NMLP-016	2018-12-11 00:00:00-08	4.42	9	1.83	4	250	\N	\N	\N	\N	15	\N	NM D-16
2519	NMLP-017	2018-12-11 00:00:00-08	5.35	10	1.93	4	250	\N	\N	\N	\N	16	\N	NM D-17
2520	NMLP-020	2018-12-11 00:00:00-08	6.73	48	5.01	4	237.1	\N	\N	\N	\N	40	\N	NM D-27
2521	NMLP-021	2018-12-11 00:00:00-08	2.49	48	1.23	4	88.3	\N	\N	\N	\N	41	\N	NM D-29
2522	NMLP-023	2018-12-11 00:00:00-08	6.69	6	4.1	4	250	\N	\N	\N	\N	43	\N	NM D-32
2523	NMLP-024	2018-12-11 00:00:00-08	25.3	5	4.34	4	250	\N	\N	\N	\N	44	\N	NM D-033
2524	NMLP-027	2018-12-11 00:00:00-08	4.1	10	0.34	4	250	\N	\N	\N	\N	47	\N	NM D-036
2525	NMLP-035	2018-12-11 00:00:00-08	4.06	22	0.94	4	250	\N	\N	\N	\N	55	\N	NM D-045
2526	NMLP-037	2018-12-11 00:00:00-08	1.98	14	0.42	4	250	\N	\N	\N	\N	57	\N	NM D-047
2527	NMLP-038	2018-12-11 00:00:00-08	2.44	19	0.44	4	250	\N	\N	\N	\N	58	\N	NM D-048
2528	NMLP-040	\N	2.56	44	0.47	4	250	\N	\N	\N	NEED TO RE SEQUENCE	60	\N	NM D-050
2529	NMLP-041	\N	1.57	48	0.32	4	93.1	\N	\N	\N	\N	61	\N	NM D-051
2530	NMLP-045	\N	2.65	9	0.56	4	250	\N	\N	\N	\N	65	\N	NM D-055
2531	NMLP-046	\N	1.37	48	0.33	4	94.1	\N	\N	\N	\N	66	\N	NM D-058
2532	NMLP-048	\N	3.88	6	0.86	4	250	\N	\N	\N	\N	68	\N	NM D-060
2533	SGLP-0254	\N	1.4	9	0.2	4	250	\N	\N	\N	Madrid Melanoma	D10	\N	MDD-38
2534	NMLP-018	2018-12-11 00:00:00-08	6.21	8	2.56	4	250	\N	\N	\N	\N	17	\N	NM D-18
2535	SGLP-0489	2019-06-06 00:00:00-07	3.88	5	0.14	4	250	\N	\N	\N	\N	82	\N	CM D-37
2536	NMLP-009	2018-12-07 00:00:00-08	1.71	9	0.38	4	250	\N	\N	\N	\N	8	\N	NM D-09
2537	NMLP-034	2018-12-11 00:00:00-08	2.74	8	0.25	4	250	\N	\N	\N	\N	54	\N	NM D-044
2538	SGLP-0252	\N	4.2	9	1.7	4	250	\N	\N	\N	Madrid Melanoma	D8	\N	MDD-36
2539	SGLP-0253	\N	5.7	2	2.2	4	250	\N	\N	\N	Madrid Melanoma	D9	\N	MDD-37
2540	SGLP-0255	\N	3.3	4	1.4	4	250	\N	\N	\N	Madrid Melanoma	D11	\N	MDD-39
2541	SGLP-0256	\N	4.4	50	1.9	4	72.5	\N	\N	\N	Madrid Melanoma	D12	\N	MDD-40
2542	SGLP-0257	\N	5.3	20	2.9	4	250	\N	\N	\N	Madrid Melanoma	E1	\N	MDD-41
2543	SGLP-0490	2019-06-06 00:00:00-07	2.5	7	0.4	4	250	\N	\N	\N	\N	83	\N	CM D-38
2544	SGLP-0500	2019-06-06 00:00:00-07	10.4	48	5.73	4	236	\N	\N	\N	\N	93	\N	CM D-48
2545	SGLP-0501	2019-06-20 00:00:00-07	3.65	48	1.64	4	110.9	\N	\N	\N	\N	17	\N	CM D-49
2546	SGLP-0502	2019-06-20 00:00:00-07	3.47	48	1.03	4	144	\N	\N	\N	\N	18	\N	CM D-50
2547	SGLP-0503	2019-06-20 00:00:00-07	4.8	12	1.49	4	250	\N	\N	\N	\N	19	\N	CM D-51
2548	SGLP-0504	2019-06-20 00:00:00-07	6.33	25	3.58	4	250	\N	\N	\N	\N	20	\N	CM D-52
2549	SGLP-0505	2019-06-20 00:00:00-07	4.79	10	1.56	4	250	\N	\N	\N	\N	21	\N	CM D-53
2550	SGLP-0506	2019-06-20 00:00:00-07	3.04	48	1.06	4	115.7	\N	\N	\N	\N	22	\N	CM D-54
2551	SGLP-0507	2019-06-20 00:00:00-07	2.05	48	0.66	4	77.8	\N	\N	\N	\N	23	\N	CM D-55
2552	SGLP-0508	2019-06-20 00:00:00-07	9.08	6	5.73	4	250	\N	\N	\N	\N	24	\N	CM D-56
2553	SGLP-0509	2019-06-20 00:00:00-07	11	19	10.3	4	250	\N	\N	\N	\N	25	\N	CM D-57
2554	SGLP-0510	2019-06-20 00:00:00-07	2.7	48	1.36	4	111.8	\N	\N	\N	\N	26	\N	CM D-60
2555	SGLP-0511	2019-06-20 00:00:00-07	6.62	14	4.15	4	250	\N	\N	\N	\N	27	\N	CM D-63
2556	SGLP-0512	2019-06-20 00:00:00-07	5.77	48	2.18	4	222.2	\N	\N	\N	\N	28	\N	CM D-64
2557	SGLP-0513	2019-06-20 00:00:00-07	2.23	48	0.97	4	106.6	\N	\N	\N	\N	29	\N	CM D-65
2558	SGLP-0514	2019-06-20 00:00:00-07	2.37	48	1.22	4	115.2	\N	\N	\N	\N	31	\N	CM D-66
2559	SGLP-0515	2019-07-15 00:00:00-07	2.12	11	0.24	4	250	\N	\N	\N	Madrid Melanoma; 05-12693-C M1	32	\N	MDD-42
2560	SGLP-0516	2019-07-15 00:00:00-07	3.52	96	0.88	4	170	\N	\N	\N	Madrid Melanoma; 05-27343-A M1	33	\N	MDD-43
2561	SGLP-0517	2019-07-15 00:00:00-07	3.1	9	0.66	4	250	\N	\N	\N	Madrid Melanoma; 06-03046-F N1	34	\N	MDD-44
2562	SGLP-0518	2019-07-15 00:00:00-07	2.86	10	0.49	4	250	\N	\N	\N	Madrid Melanoma; 06-06325 M1	35	\N	MDD-45
2563	SGLP-0519	2019-07-15 00:00:00-07	4.87	36	1.28	4	250	\N	\N	\N	Madrid Melanoma	36	\N	MDD-46
2564	SGLP-0520	2019-07-15 00:00:00-07	5.11	12	0.01	4	250	\N	\N	\N	Madrid Melanoma; 10-10942-A2 M1	37	\N	MDD-47
2565	SGLP-0521	2019-07-15 00:00:00-07	1.89	12	0.43	4	250	\N	\N	\N	Madrid Melanoma	38	\N	MDD-48
2566	SGLP-0522	2019-07-15 00:00:00-07	3.17	96	0.27	4	229	\N	\N	\N	Madrid Melanoma	39	\N	MDD-49
2567	SGLP-0523	2019-07-15 00:00:00-07	3.03	96	0.18	4	230	\N	\N	\N	Madrid Melanoma	40	\N	MDD-50
2568	SGLP-0524	2019-07-15 00:00:00-07	3.28	38	0.32	4	250	\N	\N	\N	Madrid Melanoma	41	\N	MDD-51
2569	SGLP-0525	2019-07-15 00:00:00-07	3.87	26	0.62	4	250	\N	\N	\N	Madrid Melanoma; Need to resequence due to barcode error	52	\N	MDD-52
2570	SGLP-0526	2019-07-15 00:00:00-07	2.57	22	0.24	4	250	\N	\N	\N	Madrid Melanoma	43	\N	MDD-53
2571	SGLP-0527	2019-07-15 00:00:00-07	2.37	11	0.29	4	250	\N	\N	\N	Madrid Melanoma	44	\N	MDD-54
2572	SGLP-0528	2019-07-15 00:00:00-07	4.14	45	0.74	4	250	\N	\N	\N	Madrid Melanoma	45	\N	MDD-55
2573	SGLP-0529	2019-07-15 00:00:00-07	2.54	96	0.43	4	172	\N	\N	\N	Madrid Melanoma	46	\N	MDD-56
2574	SGLP-0530	2019-07-15 00:00:00-07	1.05	95	0.28	4	46	\N	\N	\N	Madrid Melanoma	47	\N	MDD-57
2575	SGLP-0531	2019-07-15 00:00:00-07	3.78	21	0.8	4	250	\N	\N	\N	Madrid Melanoma	48	\N	MDD-58
2576	SGLP-0532	2019-07-15 00:00:00-07	3.84	72	0.8	4	250	\N	\N	\N	Madrid Melanoma	49	\N	MDD-59
2577	SGLP-0533	2019-07-15 00:00:00-07	3.56	85	0.56	4	250	\N	\N	\N	Madrid Melanoma	50	\N	MDD-60
2578	SGLP-0534	2019-07-15 00:00:00-07	2.61	7	0.4	4	250	\N	\N	\N	Madrid Melanoma	51	\N	MDD-61
2579	SGLP-0535	2019-07-24 00:00:00-07	0.14	9	0.16	4	250	\N	\N	\N	Madrid Melanoma; Need to resequence due to barcode error	52	\N	MDD-62
2580	SGLP-0536	2019-07-24 00:00:00-07	4.11	11	0.56	4	250	\N	\N	\N	Madrid Melanoma	53	\N	MDD-63
2581	SGLP-0537	2019-07-24 00:00:00-07	2.8	17	0.43	4	250	\N	\N	\N	Madrid Melanoma	54	\N	MDD-64
2582	SGLP-0538	2019-07-24 00:00:00-07	2.23	96	0.31	4	248	\N	\N	\N	Madrid Melanoma	55	\N	MDD-65
2583	SGLP-0539	2019-07-24 00:00:00-07	2.12	23	0.67	4	250	\N	\N	\N	Madrid Melanoma	56	\N	MDD-66
2584	SGLP-0540	2019-07-24 00:00:00-07	3.52	65	0.77	4	250	\N	\N	\N	Madrid Melanoma	57	\N	MDD-67
2585	SGLP-0541	2019-07-24 00:00:00-07	3.1	17	0.83	4	250	\N	\N	\N	Madrid Melanoma	58	\N	MDD-68
2586	SGLP-0542	2019-07-24 00:00:00-07	2.86	23	0.82	4	250	\N	\N	\N	Madrid Melanoma	59	\N	MDD-69
2587	SGLP-0543	2019-07-24 00:00:00-07	4.87	6	0.2	4	250	\N	\N	\N	Madrid Melanoma	60	\N	MDD-70
2588	SGLP-0544	2019-07-24 00:00:00-07	5.11	15	0.9	4	250	\N	\N	\N	Madrid Melanoma	61	\N	MDD-71
2589	SGLP-0545	2019-07-24 00:00:00-07	1.89	9	0.83	4	250	\N	\N	\N	Madrid Melanoma	62	\N	MDD-72
2590	SGLP-0546	2019-07-24 00:00:00-07	3.17	96	0.72	4	132	\N	\N	\N	Madrid Melanoma	63	\N	MDD-73
2591	SGLP-0547	2019-07-24 00:00:00-07	3.03	46	0.67	4	250	\N	\N	\N	Madrid Melanoma	64	\N	MDD-74
2592	SGLP-0548	2019-07-24 00:00:00-07	3.28	4	0.51	4	250	\N	\N	\N	Madrid Melanoma	65	\N	MDD-75
2593	SGLP-0549	2019-07-24 00:00:00-07	3.87	8	0.72	4	250	\N	\N	\N	Madrid Melanoma	66	\N	MDD-76
2594	SGLP-0550	2019-07-24 00:00:00-07	2.57	6	0.29	4	250	\N	\N	\N	Madrid Melanoma	67	\N	MDD-77
2595	SGLP-0552	2019-07-24 00:00:00-07	4.14	16	0.79	4	250	\N	\N	\N	Madrid Melanoma	69	\N	MDD-79
2596	SGLP-0553	2019-07-24 00:00:00-07	2.54	96	0.2	4	129	\N	\N	\N	Madrid Melanoma	70	\N	MDD-80
2597	SGLP-0554	2019-07-24 00:00:00-07	1.05	96	1.16	4	169	\N	\N	\N	Madrid Melanoma	71	\N	MDD-81
2598	SGLP-0555	2019-07-24 00:00:00-07	3.78	5	0.43	4	250	\N	\N	\N	Madrid Melanoma	72	\N	MDD-82
2599	SGLP-0556	2019-07-24 00:00:00-07	3.84	5	0.89	4	250	\N	\N	\N	Madrid Melanoma	76	\N	MDD-83
2600	SGLP-0557	2019-07-24 00:00:00-07	3.56	26	0.29	4	250	\N	\N	\N	Madrid Melanoma	77	\N	MDD-84
2601	SGLP-0558	2019-07-24 00:00:00-07	2.61	5	0.39	4	250	\N	\N	\N	Madrid Melanoma	78	\N	MDD-85
2602	SGLP-0559	2019-08-05 00:00:00-07	\N	96	0.79	4	226	\N	\N	\N	\N	1	\N	CM D-69
2603	SGLP-0560	2019-08-05 00:00:00-07	\N	55	0.79	4	250	\N	\N	\N	\N	3	\N	CM D-70
2604	SGLP-0561	2019-08-05 00:00:00-07	\N	14	0.76	4	250	\N	\N	\N	\N	4	\N	CM D-71
2605	SGLP-0562	2019-08-05 00:00:00-07	\N	97	0.29	4	48	\N	\N	\N	\N	5	\N	CM D-72
2606	SGLP-0563	2019-08-05 00:00:00-07	\N	95	0.15	4	42	\N	\N	\N	\N	6	\N	CM D-73
2607	SGLP-0564	2019-08-05 00:00:00-07	\N	93	0.09	4	18	\N	\N	\N	\N	7	\N	CM D-74
2608	SGLP-0565	2019-08-05 00:00:00-07	\N	85	1.26	4	250	\N	\N	\N	\N	8	\N	CM D-75
2609	SGLP-0566	2019-08-05 00:00:00-07	\N	96	0.88	4	108	\N	\N	\N	\N	79	\N	CM D-76
2610	SGLP-0567	2019-08-05 00:00:00-07	\N	1	1.59	4	250	\N	\N	\N	\N	80	\N	CM D-77
2611	SGLP-0568	2019-08-05 00:00:00-07	\N	5	0.62	4	250	\N	\N	\N	\N	81	\N	CM D-78
2612	SGLP-0569	2019-08-05 00:00:00-07	\N	6	2.45	4	250	\N	\N	\N	\N	82	\N	CM D-79
2613	SGLP-0570	2019-08-05 00:00:00-07	\N	49	2.59	4	250	\N	\N	\N	\N	83	\N	CM D-80
2614	SGLP-0571	2019-08-05 00:00:00-07	\N	5	2.98	4	250	\N	\N	\N	\N	84	\N	CM D-81
2615	SGLP-0572	2019-08-05 00:00:00-07	\N	96	1.1	4	115	\N	\N	\N	\N	85	\N	CM D-82
2616	SGLP-0573	2019-08-05 00:00:00-07	\N	5	0.87	4	250	\N	\N	\N	\N	86	\N	CM D-83
2617	SGLP-0574	2019-08-05 00:00:00-07	\N	47	0.37	4	18	\N	\N	\N	\N	87	\N	CM D-84
2618	SGLP-0575	2019-08-05 00:00:00-07	\N	48	1.09	4	244	\N	\N	\N	\N	88	\N	CM D-85
2619	SGLP-0261	\N	5	11	2.61	4	250	\N	\N	\N	Barcode overlap	A4	\N	TPP_3-04
2620	SGLP-0266	\N	4.4	10	1.47	4	250	\N	\N	\N	Barcode overlap	A9	\N	TPP_3-09
2621	SGLP-0289	\N	5.6	12	1.45	4	250	\N	\N	\N	Barcode overlap	C8	\N	TPP_3-32
2622	SGLP-0385	2019-02-21 00:00:00-08	0.66	45	0.17	4	26.7	\N	\N	\N	Blue Nevus	73	\N	BND-005
2623	SGLP-0387	2019-02-21 00:00:00-08	0.84	49	0.15	4	53.8	\N	\N	\N	Blue Nevus	75	\N	BND-007
2624	SGLP-0583	2019-08-13 00:00:00-07	\N	2	2.31	4	250	\N	\N	\N	Madrid Melanoma	15	\N	MDD-93
2625	SGLP-0584	2019-08-13 00:00:00-07	\N	9	2.04	4	250	\N	\N	\N	Madrid Melanoma	16	\N	MDD-94
2626	SGLP-0585	2019-08-13 00:00:00-07	\N	16	2.35	4	250	\N	\N	\N	Madrid Melanoma	17	\N	MDD-95
2627	SGLP-0586	2019-08-13 00:00:00-07	\N	10	0.1	4	250	\N	\N	\N	Madrid Melanoma	18	\N	MDD-96
2628	SGLP-0587	2019-08-13 00:00:00-07	\N	95	0.21	4	53	\N	\N	\N	Madrid Melanoma	19	\N	MDD-97
2629	SGLP-0588	2019-08-13 00:00:00-07	\N	47	0.35	4	250	\N	\N	\N	Madrid Melanoma	20	\N	MDD-98
2630	SGLP-0589	2019-08-13 00:00:00-07	\N	21	0.8	4	250	\N	\N	\N	Madrid Melanoma	21	\N	MDD-99
2631	SGLP-0590	2019-08-13 00:00:00-07	\N	25	0.41	4	250	\N	\N	\N	Madrid Melanoma	22	\N	MDD-100
2632	SGLP-0591	2019-08-13 00:00:00-07	\N	72	0.4	4	250	\N	\N	\N	Madrid Melanoma	23	\N	MDD-101
2633	SGLP-0592	2019-08-13 00:00:00-07	\N	13	0.72	4	250	\N	\N	\N	Madrid Melanoma	24	\N	MDD-102
2634	SGLP-0593	2019-08-13 00:00:00-07	\N	53	1.38	4	250	\N	\N	\N	Madrid Melanoma	25	\N	MDD-103
2635	SGLP-0594	2019-08-13 00:00:00-07	\N	13	1.2	4	250	\N	\N	\N	Madrid Melanoma	26	\N	MDD-104
2636	SGLP-0595	2019-08-13 00:00:00-07	\N	24	1.66	4	250	\N	\N	\N	Madrid Melanoma	27	\N	MDD-105
2637	SGLP-0596	2019-08-13 00:00:00-07	\N	96	0.79	4	109	\N	\N	\N	Madrid Melanoma	28	\N	MDD-106
2638	SGLP-0597	2019-08-13 00:00:00-07	\N	60	0.55	4	250	\N	\N	\N	Madrid Melanoma	29	\N	MDD-107
2639	SGLP-0598	2019-08-13 00:00:00-07	\N	7	1.04	4	250	\N	\N	\N	Madrid Melanoma	30	\N	MDD-108
2640	SGLP-0599	2019-08-13 00:00:00-07	\N	20	1.75	4	250	\N	\N	\N	Madrid Melanoma	31	\N	MDD-109
2641	SGLP-0608	2019-09-24 00:00:00-07	6.47	5	3.8	4	250	\N	\N	\N	\N	32	\N	NM D-066
2642	SGLP-0609	2019-09-24 00:00:00-07	4.48	5	1.5	4	250	\N	\N	\N	\N	33	\N	NM D-067
2643	SGLP-0610	2019-09-24 00:00:00-07	3.9	12	1.4	4	250	\N	\N	\N	\N	34	\N	NM D-068
2644	SGLP-0611	2019-09-24 00:00:00-07	5.18	52	1.3	4	250	\N	\N	\N	\N	35	\N	NM D-069
2645	SGLP-0612	2019-09-24 00:00:00-07	2.16	16	0.5	4	250	\N	\N	\N	\N	36	\N	NM D-070
2646	SGLP-0613	2019-09-24 00:00:00-07	3.69	8	1.3	4	250	\N	\N	\N	\N	37	\N	NM D-071
2647	SGLP-0614	2019-09-24 00:00:00-07	3.04	19	1.2	4	250	\N	\N	\N	\N	39	\N	NM D-072
2648	SGLP-0615	2019-09-24 00:00:00-07	5.61	64	1.9	4	250	\N	\N	\N	\N	40	\N	NM D-073
2649	SGLP-0616	2019-09-24 00:00:00-07	3.01	6	0.6	4	250	\N	\N	\N	\N	41	\N	NM D-074
2650	SGLP-0617	2019-09-24 00:00:00-07	7.58	8	4.9	4	250	\N	\N	\N	\N	43	\N	NM D-075
2651	SGLP-0618	2019-09-24 00:00:00-07	3.5	7	1	4	250	\N	\N	\N	\N	44	\N	NM D-076
2652	SGLP-0619	2019-09-24 00:00:00-07	5.31	17	2.2	4	250	\N	\N	\N	\N	45	\N	NM D-077
2653	SGLP-0620	2019-09-24 00:00:00-07	3.7	51	1.2	4	250	\N	\N	\N	\N	46	\N	NM D-078
2654	SGLP-0621	2019-09-24 00:00:00-07	5.41	90	1.6	4	250	\N	\N	\N	\N	47	\N	NM D-079
2655	SGLP-0622	2019-09-24 00:00:00-07	5.47	68	2.9	4	250	\N	\N	\N	\N	48	\N	NM D-080
2656	SGLP-0623	2019-09-24 00:00:00-07	4.98	30	1.4	4	250	\N	\N	\N	\N	50	\N	NM D-081
2657	SGLP-0624	2019-09-24 00:00:00-07	3.05	15	0.5	4	250	\N	\N	\N	\N	51	\N	NM D-082
2658	SGLP-0625	2019-09-24 00:00:00-07	4.35	38	0.7	4	250	\N	\N	\N	\N	52	\N	NM D-083
2659	SGLP-0626	2019-10-16 00:00:00-07	3.73	58	1.46	4	2900	\N	\N	\N	Madrid Melanoma; 200ng; No repair	79	\N	MDD-113
2660	SGLP-0627	2019-10-16 00:00:00-07	4.38	58	2.19	4	2900	\N	\N	\N	Madrid Melanoma; 200ng; repair	80	\N	MDD-113
2661	SGLP-0628	2019-10-16 00:00:00-07	2.8	63	1.04	4	2000	\N	\N	\N	Madrid Melanoma; 250ng; No repair	81	\N	MDD-123
2662	SGLP-0629	2019-10-16 00:00:00-07	2.84	63	1.31	4	2000	\N	\N	\N	Madrid Melanoma; 250 ng; repair	86	\N	MDD-123
2663	SGLP-0630	2019-10-16 00:00:00-07	5.35	0	1.73	4	\N	\N	\N	\N	Madrid Melanoma; 500ng; No repair	88	\N	MDD-132
2664	SGLP-0631	2019-10-16 00:00:00-07	5.62	0	2.53	4	\N	\N	\N	\N	Madrid Melanoma; 500ng; repair	89	\N	MDD-132
2665	SGLP-0632	2019-10-16 00:00:00-07	9.07	58	2.73	4	2900	\N	\N	\N	Madrid Melanoma; 500ng; No repair; 4 Cycles\n	90	\N	MDD-113
2666	SGLP-0633	2019-10-16 00:00:00-07	5.88	63	1.68	4	2000	\N	\N	\N	Madrid Melanoma; 500ng; No repair; 4 Cycles	93	\N	MDD-123
2667	SGLP-0634	2019-10-16 00:00:00-07	13.7	14	0.79	4	500	\N	\N	\N	Madrid Melanoma; 500ng; No repair; 4 Cycles	95	\N	MDD-145
2668	SGLP-0635	2019-10-16 00:00:00-07	28.7	14	0.51	4	500	\N	\N	\N	Madrid Melanoma; 1000ng; No repair; 4 Cycles	96	\N	MDD-145
2669	SGLP-0636	2019-10-16 00:00:00-07	16.1	58	2.09	3	2900	\N	\N	\N	Madrid Melanoma; 1000ng; No repair; 3 Cycles	91	\N	MDD-113
2670	SGLP-0637	2019-10-16 00:00:00-07	10.2	63	1.27	3	2000	\N	\N	\N	Madrid Melanoma; 1000ng; No repair; 3 Cycles	94	\N	MDD-123
2671	SGLP-0638	2019-11-07 00:00:00-08	3.94	96	1	4	201	\N	\N	\N	Madrid Melanoma; 100s shear time	53	\N	MDD-110
2672	SGLP-0639	2019-11-07 00:00:00-08	3.22	96	0.32	4	231	\N	\N	\N	Madrid Melanoma; 100s shear time	54	\N	MDD-111
2673	SGLP-0640	2019-11-07 00:00:00-08	7.75	91	1.44	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	55	\N	MDD-112
2674	SGLP-0641	2019-11-07 00:00:00-08	4.32	96	0.76	4	292	\N	\N	\N	Madrid Melanoma; 100s shear time	56	\N	MDD-114
2675	SGLP-0642	2019-11-07 00:00:00-08	4.65	96	0.83	4	307	\N	\N	\N	Madrid Melanoma; 100s shear time	57	\N	MDD-115
2676	SGLP-0643	2019-11-07 00:00:00-08	3.51	96	0.98	4	262	\N	\N	\N	Madrid Melanoma; 100s shear time	11	\N	MDD-116
2677	SGLP-0644	2019-11-07 00:00:00-08	1.85	96	0.19	4	145	\N	\N	\N	Madrid Melanoma; 100s shear time	59	\N	MDD-117
2678	SGLP-0645	2019-11-07 00:00:00-08	2.73	96	0.88	4	153	\N	\N	\N	Madrid Melanoma; 100s shear time	60	\N	MDD-118
2679	SGLP-0646	2019-11-07 00:00:00-08	7.14	80	1.12	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	13	\N	MDD-119
2680	SGLP-0647	2019-11-07 00:00:00-08	7.04	47	1.21	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	14	\N	MDD-120
2681	SGLP-0648	2019-11-07 00:00:00-08	2.78	96	0.45	4	253	\N	\N	\N	Madrid Melanoma; 100s shear time	64	\N	MDD-121
2682	SGLP-0649	2019-11-07 00:00:00-08	4.66	74	0.56	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	65	\N	MDD-122
2683	SGLP-0650	2019-11-07 00:00:00-08	3.46	96	0.8	4	268	\N	\N	\N	Madrid Melanoma; 100s shear time	66	\N	MDD-124
2684	SGLP-0651	2019-11-07 00:00:00-08	0.99	96	0.04	4	156	\N	\N	\N	Madrid Melanoma; 100s shear time	67	\N	MDD-125
2685	SGLP-0652	2019-11-07 00:00:00-08	5.42	45	1.5	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	68	\N	MDD-126
2686	SGLP-0653	2019-11-07 00:00:00-08	1.42	96	0.33	4	100	\N	\N	\N	Madrid Melanoma; 100s shear time	69	\N	MDD-127
2687	SGLP-0654	2019-11-07 00:00:00-08	5.46	81	0.7	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	70	\N	MDD-128
2688	SGLP-0655	2019-11-07 00:00:00-08	7.14	73	1.46	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	72	\N	MDD-129
2689	SGLP-0656	2019-11-07 00:00:00-08	2.39	96	0.23	4	262	\N	\N	\N	Madrid Melanoma; 100s shear time	74	\N	MDD-130
2690	SGLP-0657	2019-11-07 00:00:00-08	6.66	61	1.32	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	76	\N	MDD-131
2691	SGLP-0658	2019-11-07 00:00:00-08	1.39	97	0.42	4	83	\N	\N	\N	Madrid Melanoma; 100s shear time	77	\N	MDD-133
2692	SGLP-0659	2019-11-07 00:00:00-08	6.51	91	1.04	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	78	\N	MDD-134
2693	SGLP-0660	2019-11-07 00:00:00-08	4.12	96	0.64	4	252	\N	\N	\N	Madrid Melanoma; 100s shear time	5	\N	MDD-135
2694	SGLP-0661	2019-11-07 00:00:00-08	8.24	61	2	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	7	\N	MDD-136
2695	SGLP-0200	2018-03-20 00:00:00-07	3.2	89	1.1	4	65	\N	\N	\N	KIT mutant DNA samples	G8	\N	KIT-02
2696	SGLP-0201	2018-03-20 00:00:00-07	5	90	1.3	4	98.1	\N	\N	\N	KIT mutant DNA samples	G9	\N	KIT-03
2697	SGLP-0202	2018-03-20 00:00:00-07	7.3	90	2	4	124.2	\N	\N	\N	KIT mutant DNA samples	G10	\N	KIT-04
2698	SGLP-0203	2018-03-20 00:00:00-07	3.8	90	0.8	4	72.8	\N	\N	\N	KIT mutant DNA samples	G11	\N	KIT-05
2699	SGLP-0204	2018-03-20 00:00:00-07	1.7	90	0.4	4	43.3	\N	\N	\N	KIT mutant DNA samples	G12	\N	KIT-06
2700	SGLP-0205	2018-03-20 00:00:00-07	4.6	30	1.1	4	59.1	\N	\N	\N	KIT mutant DNA samples	H1	\N	KIT-07
2701	SGLP-0206	2018-03-20 00:00:00-07	1.3	30	0.4	4	19.6	\N	\N	\N	KIT mutant DNA samples	H2	\N	KIT-08
2702	SGLP-0207	2018-03-20 00:00:00-07	2.3	30	0.8	4	40.8	\N	\N	\N	KIT mutant DNA samples	H3	\N	KIT-09
2703	SGLP-0208	2018-03-20 00:00:00-07	3.3	30	1	4	97.8	\N	\N	\N	KIT mutant DNA samples	H4	\N	KIT-10
2704	SGLP-0209	2018-03-20 00:00:00-07	1.6	15	0.3	4	57.9	\N	\N	\N	KIT mutant DNA samples	H5	\N	KIT-11
2705	SGLP-0220	\N	2.9	50	0.9	4	123	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A4	\N	MDD-04
2706	SGLP-0221	\N	2	7	0.4	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A5	\N	MDD-05
2707	SGLP-0223	\N	2.1	9	0.4	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A7	\N	MDD-07
2708	SGLP-0224	\N	3.2	3	1.3	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	A8	\N	MDD-08
2709	SGLP-0230	\N	3.4	1	1.4	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	B2	\N	MDD-14
2710	SGLP-0232	\N	3.3	6	1.2	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	B4	\N	MDD-16
2711	SGLP-0235	\N	2.2	47	0.7	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C3	\N	MDD-19
2712	SGLP-0240	\N	4	32	1.3	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C8	\N	MDD-24
2713	SGLP-0241	\N	3.5	20	1.7	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C9	\N	MDD-25
2714	SGLP-0242	\N	4.5	3	1.6	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C10	\N	MDD-26
2715	SGLP-0243	\N	5.5	13	3	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C11	\N	MDD-27
2716	SGLP-0244	\N	4.5	14	1.7	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	C12	\N	MDD-28
2717	SGLP-0245	\N	5.8	11	3.3	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	D1	\N	MDD-29
2718	SGLP-0246	\N	5.3	8	2.5	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	D2	\N	MDD-30
2719	SGLP-0248	\N	4.5	3	2.6	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	D4	\N	MDD-32
2720	SGLP-0249	\N	4.1	16	1.2	4	250	\N	\N	\N	Capture hyb at 65c for 4 hours. 	D5	\N	MDD-33
2721	SGLP-0380	2018-12-20 00:00:00-08	2.36	48	4.8	4	113.3	\N	\N	\N	Nevus from Iwei	38	\N	SM D-25
2722	SGLP-0662	2020-05-30 00:00:00-07	1.64	96	0.41	4	77	\N	\N	\N	Madrid Melanoma; 100s shear time	121	\N	MDD-137
10002	12-12366	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	3	\N	NA_12-12366_Tumor
2723	SGLP-0663	2020-05-30 00:00:00-07	7.04	55	1.91	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	122	\N	MDD-138
2724	SGLP-0664	2020-05-30 00:00:00-07	6.4	96	0.88	4	404	\N	\N	\N	Madrid Melanoma; 100s shear time	123	\N	MDD-139
2725	SGLP-0665	2020-05-30 00:00:00-07	7.05	96	1.28	4	366	\N	\N	\N	Madrid Melanoma; 100s shear time	124	\N	MDD-140
2726	SGLP-0666	2020-05-30 00:00:00-07	3	96	0.71	4	176	\N	\N	\N	Madrid Melanoma; 100s shear time	125	\N	MDD-141
2727	SGLP-0667	2020-05-30 00:00:00-07	3.52	96	0.65	4	221	\N	\N	\N	Madrid Melanoma; 100s shear time	126	\N	MDD-142
2728	SGLP-0668	2020-05-30 00:00:00-07	6.74	96	0.78	4	491	\N	\N	\N	Madrid Melanoma; 100s shear time	127	\N	MDD-143
2729	SGLP-0669	2020-05-30 00:00:00-07	2.05	96	0.5	4	124	\N	\N	\N	Madrid Melanoma; 100s shear time	128	\N	MDD-144
2730	SGLP-0670	2020-05-30 00:00:00-07	2.2	96	0.39	4	172	\N	\N	\N	Madrid Melanoma; 100s shear time	129	\N	MDD-146
2731	SGLP-0671	2020-05-30 00:00:00-07	4.7	96	1.32	4	434	\N	\N	\N	Madrid Melanoma; 100s shear time	130	\N	MDD-147
2732	SGLP-0672	2020-05-30 00:00:00-07	6.03	96	1.62	4	372	\N	\N	\N	Madrid Melanoma; 100s shear time	131	\N	MDD-148
2733	SGLP-0673	2020-05-30 00:00:00-07	4.27	47	0.41	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	132	\N	MDD-149
2734	SGLP-0674	2020-05-30 00:00:00-07	1.83	96	0.24	4	251	\N	\N	\N	Madrid Melanoma; 100s shear time	133	\N	MDD-150
2735	SGLP-0675	2020-05-30 00:00:00-07	5.88	71	1.16	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	134	\N	MDD-151
2736	SGLP-0676	2020-05-30 00:00:00-07	1.37	96	0.38	4	94	\N	\N	\N	Madrid Melanoma; 100s shear time	135	\N	MDD-152
2737	SGLP-0677	2020-05-30 00:00:00-07	3.9	96	0.82	4	225	\N	\N	\N	Madrid Melanoma; 100s shear time	136	\N	MDD-153
2738	SGLP-0678	2020-05-30 00:00:00-07	1.57	96	0.35	4	132	\N	\N	\N	Madrid Melanoma; 100s shear time	137	\N	MDD-154
2739	SGLP-0679	2020-05-30 00:00:00-07	3.13	96	0.77	4	141	\N	\N	\N	Madrid Melanoma; 100s shear time	138	\N	MDD-155
2740	SGLP-0680	2020-05-30 00:00:00-07	4.3	96	0.94	4	268	\N	\N	\N	Madrid Melanoma; 100s shear time	139	\N	MDD-156
2741	SGLP-0681	2020-05-30 00:00:00-07	3.59	96	0.8	4	136	\N	\N	\N	Madrid Melanoma; 100s shear time	140	\N	MDD-157
2742	SGLP-0682	2020-05-30 00:00:00-07	4.9	96	0.83	4	303	\N	\N	\N	Madrid Melanoma; 100s shear time	141	\N	MDD-158
2743	SGLP-0683	2020-05-30 00:00:00-07	2.85	96	0.82	4	159	\N	\N	\N	Madrid Melanoma; 100s shear time	142	\N	MDD-159
2744	SGLP-0684	2020-05-30 00:00:00-07	1.7	96	0.18	4	156	\N	\N	\N	Madrid Melanoma; 100s shear time	143	\N	MDD-160
2745	SGLP-0685	2020-05-30 00:00:00-07	2.44	96	0.41	4	153	\N	\N	\N	Madrid Melanoma; 100s shear time	144	\N	MDD-161
2746	SGLP-0686	2020-05-31 00:00:00-07	6.29	96	1.55	4	320	\N	\N	\N	Madrid Melanoma; 100s shear time	145	\N	MDD-162
2747	SGLP-0687	2020-05-31 00:00:00-07	6.08	68	1.51	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	146	\N	MDD-163
2748	SGLP-0688	2020-05-31 00:00:00-07	5.53	78	2.55	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	147	\N	MDD-166
2749	SGLP-0689	2020-05-31 00:00:00-07	5.67	96	1.92	4	270	\N	\N	\N	Madrid Melanoma; 100s shear time	148	\N	MDD-167
2750	SGLP-0690	2020-05-31 00:00:00-07	1.7	97	0.42	4	49	\N	\N	\N	Madrid Melanoma; 100s shear time	149	\N	MDD-168
2751	SGLP-0691	2020-05-31 00:00:00-07	3.73	96	0.25	4	343	\N	\N	\N	Madrid Melanoma; 100s shear time	150	\N	MDD-169
2752	SGLP-0692	2020-05-31 00:00:00-07	2.07	96	0.53	4	159	\N	\N	\N	Madrid Melanoma; 100s shear time	151	\N	MDD-170
2753	SGLP-0693	2020-05-31 00:00:00-07	4.79	96	1.11	4	253	\N	\N	\N	Madrid Melanoma; 100s shear time	152	\N	MDD-171
2754	SGLP-0694	2020-05-31 00:00:00-07	1.07	96	0.4	4	106	\N	\N	\N	Madrid Melanoma; 100s shear time	153	\N	MDD-173
2755	SGLP-0695	2020-05-31 00:00:00-07	3.49	96	0.4	4	453	\N	\N	\N	Madrid Melanoma; 100s shear time	154	\N	MDD-174
2756	SGLP-0696	2020-05-31 00:00:00-07	2.81	96	0.8	4	292	\N	\N	\N	Madrid Melanoma; 100s shear time	155	\N	MDD-175
2757	SGLP-0697	2020-05-31 00:00:00-07	0.52	96	0.1	4	74	\N	\N	\N	Madrid Melanoma; 100s shear time	156	\N	MDD-176
2758	SGLP-0698	2020-05-31 00:00:00-07	0.65	96	0.09	4	197	\N	\N	\N	Madrid Melanoma; 100s shear time	157	\N	MDD-177
2759	SGLP-0699	2020-05-31 00:00:00-07	6.78	96	1.49	4	415	\N	\N	\N	Madrid Melanoma; 100s shear time	158	\N	MDD-178
2760	SGLP-0700	2020-05-31 00:00:00-07	2.14	96	0.62	4	120	\N	\N	\N	Madrid Melanoma; 100s shear time	159	\N	MDD-179
2761	SGLP-0701	2020-05-31 00:00:00-07	8.3	58	2.48	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	160	\N	MDD-180
2762	SGLP-0702	2020-05-31 00:00:00-07	2.62	96	2.13	4	226	\N	\N	\N	Madrid Melanoma; 100s shear time	161	\N	MDD-181
2763	SGLP-0703	2020-05-31 00:00:00-07	3.51	96	0.49	4	243	\N	\N	\N	Madrid Melanoma; 100s shear time	162	\N	MDD-182
2764	SGLP-0704	2020-05-31 00:00:00-07	2.17	96	0.6	4	269	\N	\N	\N	Madrid Melanoma; 100s shear time	163	\N	MDD-183
2765	SGLP-0705	2020-05-31 00:00:00-07	4.19	96	1.64	4	448	\N	\N	\N	Madrid Melanoma; 100s shear time	164	\N	MDD-184
2766	SGLP-0706	2020-05-31 00:00:00-07	3.92	16	1.02	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	165	\N	MDD-185
2767	SGLP-0707	2020-05-31 00:00:00-07	3.28	73	0.47	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	166	\N	MDD-186
2768	SGLP-0708	2020-05-31 00:00:00-07	1.71	96	0.53	4	151	\N	\N	\N	Madrid Melanoma; 100s shear time	167	\N	MDD-187
2769	SGLP-0709	2020-05-31 00:00:00-07	2.4	96	0.63	4	255	\N	\N	\N	Madrid Melanoma; 100s shear time	168	\N	MDD-188
2770	SGLP-0710	2020-06-06 00:00:00-07	1.66	80	0.74	4	66	\N	\N	\N	Madrid Melanoma; 100s shear time	169	\N	MDD-189
2771	SGLP-0711	2020-06-06 00:00:00-07	3.56	80	1.12	4	206	\N	\N	\N	Madrid Melanoma; 100s shear time	170	\N	MDD-190
2772	SGLP-0712	2020-06-06 00:00:00-07	4.97	29	2.1	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	171	\N	MDD-191
2773	SGLP-0713	2020-06-06 00:00:00-07	0.12	80	0.02	4	60	\N	\N	\N	Madrid Melanoma; 100s shear time	172	\N	MDD-192
2774	SGLP-0714	2020-06-06 00:00:00-07	2.01	80	0.71	4	106	\N	\N	\N	Madrid Melanoma; 100s shear time	173	\N	MDD-194
2775	SGLP-0715	2020-06-06 00:00:00-07	1.43	80	0.1	4	184	\N	\N	\N	Madrid Melanoma; 100s shear time	174	\N	MDD-195
2776	SGLP-0716	2020-06-06 00:00:00-07	3.4	80	0.75	4	326	\N	\N	\N	Madrid Melanoma; 100s shear time	175	\N	MDD-196
2777	SGLP-0717	2020-06-06 00:00:00-07	0.82	80	0.16	4	55	\N	\N	\N	Madrid Melanoma; 100s shear time	176	\N	MDD-197
2778	SGLP-0718	2020-06-06 00:00:00-07	5.45	15	2.44	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	177	\N	MDD-198
2779	SGLP-0719	2020-06-06 00:00:00-07	4.13	80	0.71	4	460	\N	\N	\N	Madrid Melanoma; 100s shear time	178	\N	MDD-199
2780	SGLP-0720	2020-06-06 00:00:00-07	2.58	80	0.95	4	118	\N	\N	\N	Madrid Melanoma; 100s shear time	179	\N	MDD-200
2781	SGLP-0721	2020-06-06 00:00:00-07	4.68	80	0.7	4	406	\N	\N	\N	Madrid Melanoma; 100s shear time	180	\N	MDD-201
2782	SGLP-0722	2020-06-06 00:00:00-07	4.84	55	0.82	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	181	\N	MDD-202
2783	SGLP-0723	2020-06-06 00:00:00-07	1.67	80	0.36	4	162	\N	\N	\N	Madrid Melanoma; 100s shear time	182	\N	MDD-203
2784	SGLP-0724	2020-06-06 00:00:00-07	5.76	38	1.62	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	183	\N	MDD-204
2785	SGLP-0725	2020-06-06 00:00:00-07	3.56	36	0.51	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	184	\N	MDD-205
2786	SGLP-0726	2020-06-06 00:00:00-07	5.12	77	0.56	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	185	\N	MDD-206
2787	SGLP-0727	2020-06-06 00:00:00-07	3.19	80	0.84	4	189	\N	\N	\N	Madrid Melanoma; 100s shear time	186	\N	MDD-207
2788	SGLP-0728	2020-06-06 00:00:00-07	2.55	80	0.72	4	214	\N	\N	\N	Madrid Melanoma; 100s shear time	187	\N	MDD-208
2789	SGLP-0729	2020-06-06 00:00:00-07	4.02	80	0.66	4	346	\N	\N	\N	Madrid Melanoma; 100s shear time	188	\N	MDD-209
2790	SGLP-0730	2020-06-06 00:00:00-07	2.57	80	0.5	4	182	\N	\N	\N	Madrid Melanoma; 100s shear time	189	\N	MDD-210
2791	SGLP-0731	2020-06-06 00:00:00-07	4.45	23	1.1	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	190	\N	MDD-211
2792	SGLP-0732	2020-06-06 00:00:00-07	1.13	80	0.1	4	150	\N	\N	\N	Madrid Melanoma; 100s shear time	191	\N	MDD-213
2793	SGLP-0733	2020-06-06 00:00:00-07	6.75	80	1.1	4	498	\N	\N	\N	Madrid Melanoma; 100s shear time	192	\N	MDD-214
2794	SGLP-0734	2020-06-11 00:00:00-07	1.62	80	0.32	4	147	\N	\N	\N	Madrid Melanoma; 100s shear time	97	\N	MDD-215
2795	SGLP-0735	2020-06-11 00:00:00-07	2.52	80	0.48	4	158	\N	\N	\N	Madrid Melanoma; 100s shear time	98	\N	MDD-216
2796	SGLP-0736	2020-06-11 00:00:00-07	2.31	80	0.48	4	230	\N	\N	\N	Madrid Melanoma; 100s shear time	99	\N	MDD-217
2797	SGLP-0737	2020-06-11 00:00:00-07	4.61	37	0.03	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	100	\N	MDD-218
2798	SGLP-0738	2020-06-11 00:00:00-07	3.24	80	0.68	4	238	\N	\N	\N	Madrid Melanoma; 100s shear time	101	\N	MDD-219
2799	SGLP-0739	2020-06-11 00:00:00-07	1.19	80	0.38	4	74	\N	\N	\N	Madrid Melanoma; 100s shear time	102	\N	MDD-220
2800	SGLP-0740	2020-06-11 00:00:00-07	3.27	45	0.95	4	500	\N	\N	\N	Madrid Melanoma; 100s shear time	103	\N	MDD-221
2801	SGLP-0741	2020-06-11 00:00:00-07	2.96	0	2.15	4	\N	\N	\N	\N	\N	104	\N	DN-055
2802	SGLP-0742	2020-06-11 00:00:00-07	2.7	0	1.57	4	\N	\N	\N	\N	\N	105	\N	DN-057
2803	SGLP-0743	2020-06-11 00:00:00-07	1.64	0	0.73	4	\N	\N	\N	\N	\N	106	\N	DN-059
2804	SGLP-0744	2020-06-11 00:00:00-07	6.15	0	3.95	4	\N	\N	\N	\N	\N	107	\N	DN-060
2805	SGLP-0745	2020-06-11 00:00:00-07	3.09	0	0.2	4	\N	\N	\N	\N	\N	108	\N	DN-061
2806	SGLP-0746	2020-06-11 00:00:00-07	7.29	0	4.53	4	\N	\N	\N	\N	\N	109	\N	DN-062
2807	SGLP-0747	2020-06-11 00:00:00-07	4.37	0	2.92	4	\N	\N	\N	\N	\N	110	\N	DN-063
2808	SGLP-0748	2020-06-11 00:00:00-07	4.04	0	2.42	4	\N	\N	\N	\N	\N	111	\N	DN-064
2809	SGLP-0749	2020-06-11 00:00:00-07	2.65	0	1.8	4	\N	\N	\N	\N	\N	112	\N	DN-065
2810	SGLP-0750	2020-06-11 00:00:00-07	4.74	0	2.82	4	\N	\N	\N	\N	\N	113	\N	DN-066
2811	SGLP-0751	2020-06-11 00:00:00-07	4.96	0	2.46	4	\N	\N	\N	\N	\N	114	\N	DN-067
2812	SGLP-0752	2020-06-11 00:00:00-07	5.5	0	2.11	4	\N	\N	\N	\N	\N	115	\N	DN-069
2813	SGLP-0753	2020-06-11 00:00:00-07	4.68	0	2.91	4	\N	\N	\N	\N	\N	116	\N	DN-070
2814	SGLP-0754	2020-06-11 00:00:00-07	8.64	0	4.33	4	\N	\N	\N	\N	\N	117	\N	DN-071
2815	SGLP-0755	2020-06-11 00:00:00-07	3.66	0	2.24	4	\N	\N	\N	\N	\N	118	\N	DN-072
2816	SGLP-0756	2020-06-11 00:00:00-07	8.06	0	4.91	4	\N	\N	\N	\N	\N	119	\N	DN-073
2817	SGLP-0757	2020-06-11 00:00:00-07	0.28	0	0.13	4	\N	\N	\N	\N	\N	120	\N	DN-076
2818	SGLP-0758	\N	1.45	0	0.8	4	\N	\N	\N	\N	\N	5	\N	DN-078
2819	SGLP-0759	\N	1.1	0	0.35	4	\N	\N	\N	\N	\N	6	\N	DN-082
2820	SGLP-0760	\N	1.91	0	0.82	4	\N	\N	\N	\N	\N	15	\N	DN-083
2821	SGLP-0761	\N	4.18	0	1.74	4	\N	\N	\N	\N	\N	16	\N	DN-084
2822	SGLP-0762	\N	6.41	0	2.58	4	\N	\N	\N	\N	\N	17	\N	DN-085
2823	SGLP-0763	\N	5.17	0	0.9	4	\N	\N	\N	\N	\N	18	\N	DN-086
2824	SGLP-0764	\N	2.18	0	0.39	4	\N	\N	\N	\N	\N	19	\N	DN-087
2825	SGLP-0765	2020-06-18 00:00:00-07	12.5	5	12.23	4	250	\N	\N	\N	MK cell culture: 12.2019 batch	20	\N	SKMel 1107B Dec2019 (MC-02)
2826	SGLP-0766	2020-06-18 00:00:00-07	8	9	8.2	4	250	\N	\N	\N	MK cell culture: 12.2019 batch	21	\N	SKMel 1121B Dec2019 (MC-03)
2827	SGLP-0767	2020-06-18 00:00:00-07	11.2	6	12.4	4	250	\N	\N	\N	\N	22	\N	M040204 Dec2019 (AMC-07)
2828	SGLP-0768	2020-06-18 00:00:00-07	2.05	0	1.1	4	\N	\N	\N	\N	\N	23	\N	DNPD-01
2829	SGLP-0769	2020-06-18 00:00:00-07	7.12	0	5	4	\N	\N	\N	\N	\N	27	\N	DNPD-02
2830	SGLP-0770	2020-06-18 00:00:00-07	1.85	0	1.1	4	\N	\N	\N	\N	\N	28	\N	DNPD-03
2831	SGLP-0771	2020-06-18 00:00:00-07	2.54	0	0.8	4	\N	\N	\N	\N	\N	29	\N	DNPD-04
2832	SGLP-0772	2020-06-18 00:00:00-07	6.83	0	6.1	4	\N	\N	\N	\N	\N	30	\N	DNPD-05
2833	SGLP-0773	2020-06-18 00:00:00-07	3.81	0	2.2	4	\N	\N	\N	\N	\N	31	\N	DNPD-06
2834	SGLP-0774	2020-11-18 00:00:00-08	1.54	89	0.81	4	47	\N	\N	\N	\N	97	\N	SND-01
2835	SGLP-0775	2020-11-18 00:00:00-08	1.85	88	1.02	4	44	\N	\N	\N	\N	98	\N	SND-02
2836	SGLP-0776	2020-11-18 00:00:00-08	2.42	88	1.72	4	60	\N	\N	\N	\N	99	\N	SND-04
2837	SGLP-0777	2020-11-18 00:00:00-08	1.91	88	1.12	4	51	\N	\N	\N	\N	100	\N	SND-05
2838	SGLP-0778	2020-11-18 00:00:00-08	3.15	88	2.29	4	50	\N	\N	\N	\N	101	\N	SND-06
2839	SGLP-0779	2020-11-18 00:00:00-08	9.19	78	6.45	4	250	\N	\N	\N	\N	102	\N	SND-07
2840	SGLP-0780	2020-11-18 00:00:00-08	1.16	88	0.53	4	58	\N	\N	\N	\N	103	\N	SND-09
2841	SGLP-0781	2020-11-18 00:00:00-08	2.83	88	2.02	4	61	\N	\N	\N	\N	104	\N	SND-10
2842	SGLP-0782	2020-11-18 00:00:00-08	3.59	88	2.5	4	81	\N	\N	\N	\N	105	\N	SND-13
2843	SGLP-0783	2020-11-18 00:00:00-08	7.38	88	5.15	4	180	\N	\N	\N	\N	106	\N	SND-14
2844	SGLP-0784	2020-11-18 00:00:00-08	5.01	88	3.53	4	114	\N	\N	\N	\N	107	\N	SND-15
2845	SGLP-0785	2020-11-18 00:00:00-08	6.62	88	4.59	4	192	\N	\N	\N	\N	108	\N	SND-17
2846	SGLP-0786	2020-11-18 00:00:00-08	2.59	88	1.18	4	77	\N	\N	\N	\N	109	\N	SND-19
2847	SGLP-0787	2020-11-25 00:00:00-08	2.39	88	1.68	4	95	\N	\N	\N	\N	110	\N	SND-20
2848	SGLP-0788	2020-11-25 00:00:00-08	7.08	88	5.7	4	184	\N	\N	\N	\N	111	\N	SND-21
2849	SGLP-0789	2020-11-25 00:00:00-08	3.83	88	3.02	4	102	\N	\N	\N	\N	112	\N	SND-22
2850	SGLP-0790	2020-11-25 00:00:00-08	4.99	88	3.44	4	135	\N	\N	\N	\N	113	\N	SND-23
2851	SGLP-0791	2020-11-25 00:00:00-08	1.79	87	1.45	4	48	\N	\N	\N	\N	114	\N	SND-24
2852	SGLP-0792	2020-11-25 00:00:00-08	1.25	88	0.85	4	56	\N	\N	\N	\N	115	\N	SND-25
2853	SGLP-0793	2020-11-25 00:00:00-08	8.9	65	7.52	4	250	\N	\N	\N	\N	116	\N	SND-27
2854	SGLP-0794	2020-11-25 00:00:00-08	7.36	69	4.85	4	250	\N	\N	\N	\N	117	\N	SND-28
2855	SGLP-0795	2020-11-25 00:00:00-08	2.24	\N	1.76	4	\N	\N	\N	\N	\N	118	\N	SND-11,SND-31
2856	SGLP-0796	2020-11-25 00:00:00-08	2.22	\N	1.85	4	\N	\N	\N	\N	\N	119	\N	SND-12,SND-32
2857	SGLP-0797	2020-11-25 00:00:00-08	1.58	\N	1.11	4	\N	\N	\N	\N	\N	120	\N	SND-16,SND-33
2858	SGLP-0798	2020-11-25 00:00:00-08	12.5	20	9.19	4	250	\N	\N	\N	Seattle Children's Hospital	121	\N	SCH D-01
2859	SGLP-0799	2020-12-02 00:00:00-08	31.7	1	57.03	11	400	\N	\N	\N	Seattle Children's Hospital	122	\N	SCH R-01
2860	SGLP-0800	2020-12-05 00:00:00-08	1.5	\N	1.14	4	\N	\N	\N	\N	\N	123	\N	SND-08,SND-30,SND-36
2861	SGLP-0801	2020-12-05 00:00:00-08	0.66	\N	0.36	4	\N	\N	\N	\N	\N	124	\N	SND-18,SND-37
2862	SGLP-0802	2020-12-05 00:00:00-08	1.49	\N	1.3	4	\N	\N	\N	\N	\N	125	\N	SND-26,SND-38
2863	RLP-64	2018-11-05 00:00:00-08	13.9	20	30.9	11	200	\N	\N	\N	RLP-64	88	\N	RNA-64
2864	AMLP-339	2021-08-06 00:00:00-07	0.41	18	0.13	4	20	\N	\N	\N	HyperPREP, Ligation: 17 hrs,16oC.	136	\N	AM2 D-481 (P041_03B)
2865	AMLP-340	2021-08-06 00:00:00-07	1.11	9	0.22	4	42	\N	\N	\N	HyperPREP, Ligation: 17 hrs,16oC.	137	\N	AM2 D-482 (P041_03C)
2866	AMLP-341	2021-08-06 00:00:00-07	1.51	10	0.71	4	22	\N	\N	\N	HyperPREP, Ligation: 17 hrs,16oC.	138	\N	AM2 D-483 (P041_03D)
2867	AMLP-342	2021-08-06 00:00:00-07	0.42	18	0.08	4	20	\N	\N	\N	HyperPlus; Frag: 12min,37oC; Ligation: 17 hrs,16oC. Used 16 ng DNA.	189	\N	AM2 D-481 (P041_03B)
2868	AMLP-343	2021-08-06 00:00:00-07	1.58	9	0.28	4	42	\N	\N	\N	HyperPlus; Frag: 12min,37oC; Ligation: 17 hrs,16oC. Used 90 ng of DNA.	190	\N	AM2 D-482 (P041_03C)
2869	AMLP-344	2021-08-06 00:00:00-07	1.62	10	0.88	4	22	\N	\N	\N	HyperPlus; Frag: 12min,37oC; Ligation: 17 hrs,16oC. Used 40 ng of DNA.	191	\N	AM2 D-483 (P041_03D)
2870	AMLP-353	2021-09-16 00:00:00-07	7.18	78	6.73	4	1200	\N	\N	\N	HyperPREP; Ligation: O/N (23hrs) at 4 oC	97	\N	AM2 D-381
2871	AMLP-354	2021-09-16 00:00:00-07	6.04	51	6.25	4	1200	\N	\N	\N	HyperPREP; Ligation: O/N (23hrs) at 4 oC	98	\N	AM2 D-431
2872	AMLP-355	2021-09-16 00:00:00-07	1.31	148	0.56	4	1200	\N	\N	\N	HyperPREP; Ligation: O/N (23hrs) at 4 oC	99	\N	AM2 D-485
2873	AMLP-362	2021-09-16 00:00:00-07	9.63	78	9.69	4	1200	\N	\N	\N	HyperPLUS, Ligation: O/N at 4 oC	116	\N	AM2 D-381
2874	AMLP-363	2021-09-16 00:00:00-07	9.82	51	10.56	4	1200	\N	\N	\N	HyperPLUS, Ligation: O/N at 4 oC	117	\N	AM2 D-431
2875	AMLP-364	2021-09-16 00:00:00-07	1.36	148	0.68	4	1200	\N	\N	\N	HyperPLUS, Ligation: O/N at 4 oC	118	\N	AM2 D-485
2876	AMLP-370-3	2021-09-27 00:00:00-07	5.69	27	3.99	4	583	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	107	\N	AM2 D-219
2877	AMLP-372	2021-09-18 00:00:00-07	1.25	95	0.54	4	100.7	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC	109	\N	AM2 D-451
2878	NMLP-053	2021-09-08 00:00:00-07	1.83	12	0.31	4	250	\N	\N	\N	KAPA HyperPLUS, 10 min Frag at 37oC, 30 min ligation at 20oC	154	\N	NM D-068
2879	OMLP-002	2021-08-06 00:00:00-07	3.93	23	1.91	4	250	\N	\N	\N	DO NOT USE SEQUENCED DATA! Purigen, HyperPlus; Frag: 12min,37oC; Ligation: 17 hrs,16oC. SGPC-21: xx Cycles post Hyb, XXng captured	167	\N	OM-15D (P040_11D)
2880	OMLP-003	2021-08-06 00:00:00-07	2.88	23	0.89	4	250	\N	\N	\N	DO NOT USE SEQUENCED DATA! HyperPrep, NEBRepair, Ligation: 17 hrs,16oC.	153	\N	OM-15D (P040_11D)
2881	OMLP-004	2021-09-22 00:00:00-07	0.24	0	0.1	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	119	\N	OM-1D (P040_09A)
2882	OMLP-005	2021-09-22 00:00:00-07	0.27	0	0.12	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	120	\N	OM-3D (P040_09B)
2883	OMLP-006	2021-09-22 00:00:00-07	0.07	0	0.01	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	121	\N	OM-4D (P040_09C)
2884	OMLP-007	2021-09-22 00:00:00-07	0.07	0	0.01	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	122	\N	OM-5D (P040_09D)
2885	OMLP-008	2021-09-22 00:00:00-07	0	0	0	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	123	\N	OM-8D (P040_11A)
2886	OMLP-009	2021-09-22 00:00:00-07	0.13	0	0.04	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	124	\N	OM-10D (P040_11B)
2887	OMLP-010	2021-09-22 00:00:00-07	0	0	0	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	125	\N	OM-11D (P040_11C)
10003	12-12467	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	4	\N	NA_12-12467_Tumor
10004	12-12470D	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	8	\N	NA_12-12470D_Tumor
2888	OMLP-011	2021-09-22 00:00:00-07	0.09	0	0.02	4	\N	\N	\N	\N	DO NOT USE SEQUENCED DATA! HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	126	\N	OM-6D
2889	OMLP-012	2021-09-22 00:00:00-07	0.28	0	0.17	4	\N	\N	\N	\N	DO NOT USE SEQUENCED DATA! HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	127	\N	OM-9D
2890	OMLP-013	2021-09-22 00:00:00-07	0	0	0	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	128	\N	OM-12D
2891	OMLP-014	2021-09-22 00:00:00-07	0.13	0	0.03	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	129	\N	OM-13D
2892	OMLP-015	2021-09-22 00:00:00-07	0.06	0	0	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	130	\N	OM-14D
2893	OMLP-016	2021-09-22 00:00:00-07	0.09	0	0.02	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	131	\N	OM-16D
2894	OMLP-017	2021-09-22 00:00:00-07	0.26	0	0.04	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	132	\N	OM-17D
2895	OMLP-018	2021-09-22 00:00:00-07	0	0	0	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	133	\N	OM-18D
2896	OMLP-019	2021-09-22 00:00:00-07	0	0	0.01	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	134	\N	OM-18D2
2897	OMLP-020	2021-09-22 00:00:00-07	0.06	0	0	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	135	\N	OM-18D3
2898	OMLP-021	2021-09-22 00:00:00-07	0.06	0	0	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	139	\N	OM-18D4
2899	SGLP-0803	2021-09-22 00:00:00-07	0.11	48	0.04	4	35.6	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	140	\N	SND-40
2900	SGLP-0804	2021-09-22 00:00:00-07	0.24	48	0.12	4	72	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	141	\N	SND-41
2901	SGLP-0805	2021-09-22 00:00:00-07	0.34	48	0.22	4	103	\N	\N	\N	HyperPlus; Frag: 10min,37oC; NEBRepair, Ligation: 30min, 20oC.	142	\N	SND-42
2902	AMLP-166	2020-01-31 00:00:00-08	2.35	0	0.52	4	\N	\N	\N	\N	120s shear time; DNA repaired	75	\N	AM2 D-189
2903	AMLP-167	2020-01-31 00:00:00-08	0.76	0	0.29	4	\N	\N	\N	\N	120s shear time; DNA repaired	78	\N	AM2 D-188
2904	AMLP-308	2021-05-13 00:00:00-07	5.26	3	3.52	4	350	\N	\N	\N	Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	146	\N	AM2 D-38
2905	AMLP-345	2021-09-08 00:00:00-07	4.45	19	1.34	4	999	\N	\N	\N	KAPA HyperPLUS, 10 min Frag at 37oC, 60 min ligation at 20oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	155	\N	AM2 D-186
2906	AMLP-346	2021-09-08 00:00:00-07	2.47	32	0.91	4	999	\N	\N	\N	KAPA HyperPLUS, 10 min Frag at 37oC, 120 min ligation at 20oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	156	\N	AM2 D-179
2907	AMLP-350	2021-09-15 00:00:00-07	6.24	78	5.56	4	1200	\N	\N	\N	HyperPREP; Ligation: 60 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	97	\N	AM2 D-381
2908	AMLP-376	2022-01-26 00:00:00-08	5.87	1	6.09	4	250	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	100	\N	AM2 D-39
2909	AMLP-377	2022-01-26 00:00:00-08	6.12	50	8.15	4	1520	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	101	\N	AM2 D-90
2910	AMLP-378	2022-01-26 00:00:00-08	7.33	11	8.7	4	666	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	127	\N	AM2 D-97
2911	AMLP-379	2022-01-26 00:00:00-08	6.02	0	7.44	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	128	\N	AM2 D-99
2912	AMLP-381	2022-01-26 00:00:00-08	6.35	28	3.63	4	300	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	130	\N	AM2 D-153
2913	AMLP-383	2022-01-26 00:00:00-08	2.58	88	2.5	4	115	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	132	\N	AM2 D-336
2914	AMLP-384	2022-01-26 00:00:00-08	3.83	61	5.31	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	133	\N	AM2 D-464
2915	AMLP-386	2022-01-26 00:00:00-08	3.61	\N	2.58	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	135	\N	AM2 D-338,AM2 D-339
2916	AMLP-387	2022-01-26 00:00:00-08	5.54	17	7.72	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	136	\N	AM2 D-379
2917	AMLP-388	2022-01-26 00:00:00-08	7.73	32	8.82	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	137	\N	AM2 D-372
2918	AMLP-389	2022-01-26 00:00:00-08	5.32	63	6.19	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	138	\N	AM2 D-382
2919	AMLP-390	2022-01-26 00:00:00-08	5.12	69	3.79	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	140	\N	AM2 D-490
2920	AMLP-391	2022-01-26 00:00:00-08	8.39	30	9.31	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	141	\N	AM2 D-491
2921	AMLP-392	2022-01-26 00:00:00-08	1.99	88	1.12	4	142	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	142	\N	AM2 D-492
2922	AMLP-395	2022-01-26 00:00:00-08	2.35	88	1.2	4	120	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	147	\N	AM2 D-495
2923	AMLP-396	2022-01-26 00:00:00-08	5.49	69	4.67	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	148	\N	AM2 D-496
2924	AMLP-52	2018-07-23 00:00:00-07	4.1	0	2.28	\N	\N	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 30ng captured	C3	\N	AM2 D-96
2925	AMLP-89	2019-02-27 00:00:00-08	8.57	6	2.61	4	300	\N	\N	\N	repeated sequencing. SGPC-20: 12 Cycles post Hyb, 50ng captured	63	\N	AM2 D-135
2926	AMLP-47	2018-07-23 00:00:00-07	5.4	0	1.7	\N	\N	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 35ng captured	B10	\N	AM2 D-91
2927	AMLP-50	2018-07-23 00:00:00-07	5.8	0	4.3	\N	\N	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 50ng captured	C1	\N	AM2 D-94
2928	AMLP-54	2018-07-23 00:00:00-07	8.4	0	3.68	\N	\N	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 50ng captured	C5	\N	AM2 D-98
10005	12-562	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	10	\N	NA_12-562_Tumor
2929	AMLP-145	2019-12-03 00:00:00-08	4.87	90	1.81	4	271	\N	\N	\N	120s shear time; DNA repaired	79	\N	AM2 D-28
2930	AMLP-270	2021-03-17 00:00:00-07	7	7	2.87	4	333	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 40ng captured	139	\N	AM2 D-380
2931	AMLP-276	2021-03-17 00:00:00-07	8.28	26	4.72	4	333	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 40ng captured	159	\N	AM2 D-438
2932	AMLP-223	2020-08-06 00:00:00-07	5.31	27	3.5	4	583	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 50ng captured	158	\N	AM2 D-219
2933	AMLP-215	2020-08-06 00:00:00-07	2.82	88	2.93	4	99	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 43ng captured	150	\N	AM2 D-241
2934	AMLP-216	2020-08-06 00:00:00-07	15.4	10	13.54	4	333	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 50ng captured	151	\N	AM2 D-242
2935	AMLP-317	2021-05-20 00:00:00-07	2.6	95	3.98	4	247	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 44ng captured. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	143	\N	AM2 D-463
2936	AMLP-319	2021-05-20 00:00:00-07	6.25	53	3.09	4	333	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 31ng captured. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	149	\N	AM2 D-465
2937	AMLP-297	2021-04-07 00:00:00-07	7.51	10	4.22	4	333	\N	\N	\N	SGPC-20: 12 Cycles post Hyb, 50ng captured. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	181	\N	AM2 D-323
2938	AMLP-366	2021-09-18 00:00:00-07	2.76	88	1.51	4	141.7	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. SGPC-20: 12 Cycles post Hyb, 25ng captured. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	103	\N	AM2 D-487
2939	AMLP-369	2021-09-18 00:00:00-07	5.59	29	2.88	4	583	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. SGPC-20: 12 Cycles post Hyb, 50ng captured. Cat.#: 1080577, xGen Hyb Capture of DNA Libraries, v5.	106	\N	AM2 D-218
2940	SGLP-0806	2021-11-02 00:00:00-07	7.39	0	5.89	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	105	\N	LN D-01 (LN-01)
2941	SGLP-0807	2021-11-02 00:00:00-07	6.28	4	4.62	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	106	\N	LN D-02 (LN-02)
2942	SGLP-0808	2021-11-02 00:00:00-07	7.63	2	5.91	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	108	\N	LN D-03 (LN-03)
2943	SGLP-0809	2021-11-02 00:00:00-07	6.7	5	4.86	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	109	\N	LN D-04 (LN-04)
2944	SGLP-0810	2021-11-02 00:00:00-07	5.69	17	3.73	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	110	\N	LN D-05 (LN-05)
2945	SGLP-0811	2021-11-02 00:00:00-07	6.37	11	5.24	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	111	\N	LN D-06 (LN-06)
2946	SGLP-0812	2021-11-02 00:00:00-07	6.05	3	4.98	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	112	\N	LN D-07 (LN-07)
2947	SGLP-0813	2021-11-02 00:00:00-07	7.55	4	5.78	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	113	\N	LN D-08 (LN-08)
2948	SGLP-0814	2021-11-02 00:00:00-07	8.76	8	8.72	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	114	\N	LN D-09 (LN-09)
2949	SGLP-0815	2021-11-02 00:00:00-07	6.93	0	4.55	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	115	\N	LN D-10 (LN-10)
2950	SGLP-0816	2021-11-02 00:00:00-07	7.61	0	6.06	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	116	\N	LN D-11 (LN-11)
2951	SGLP-0817	2021-11-02 00:00:00-07	6.5	0	4.55	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	117	\N	LN D-12 (LN-12)
2952	SGLP-0818	2021-11-02 00:00:00-07	6.26	0	3.44	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	118	\N	LN D-13 (LN-13)
2953	SGLP-0819	2021-11-02 00:00:00-07	8.89	10	5.42	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	119	\N	LN D-14 (LN-14)
2954	SGLP-0820	2021-11-02 00:00:00-07	6.31	0	4.72	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	120	\N	LN D-15 (LN-15)
2955	SGLP-0821	2021-11-02 00:00:00-07	6.23	0	5.8	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	121	\N	LN D-16 (LN-16)
2956	SGLP-0822	2021-11-02 00:00:00-07	6.8	0	11.23	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	122	\N	LN D-17 (LN-17)
2957	SGLP-0823	2021-11-02 00:00:00-07	7.5	3	6.54	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	123	\N	LN D-18 (LN-18)
2958	SGLP-0824	2021-11-02 00:00:00-07	7.41	0	7.93	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	124	\N	LN D-19 (LN-19)
2959	SGLP-0825	2021-11-02 00:00:00-07	10.9	2	10.67	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	125	\N	LN D-20 (LN-20)
2960	SGLP-0826	2021-11-02 00:00:00-07	8.44	0	10.01	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	126	\N	LN D-21 (LN-21)
2961	SGLP-0827	2022-02-08 00:00:00-08	1.14	\N	0.38	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	173	\N	LN D-069,LN D-116
2962	SGLP-0828	2022-02-08 00:00:00-08	0.9	\N	0.12	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	174	\N	LN D-070,LN D-117
2963	SGLP-0829	2022-02-08 00:00:00-08	3.7	\N	0.59	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	175	\N	LN D-071,LN D-095,LN D-147
2964	SGLP-0830	2022-02-08 00:00:00-08	3.61	\N	0.44	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	176	\N	LN D-072,LN D-096,LN D-148
2965	SGLP-0831	2022-02-08 00:00:00-08	4.19	\N	0.55	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	177	\N	LN D-073,LN D-097,LN D-149
2966	SGLP-0832	2022-02-08 00:00:00-08	4.67	\N	0.86	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	178	\N	LN D-074,LN D-098,LN D-150
2967	SGLP-0833	2022-02-08 00:00:00-08	4.22	\N	0.65	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	179	\N	LN D-075,LN D-099,LN D-151
2968	SGLP-0834	2022-02-08 00:00:00-08	2.41	\N	0.54	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	180	\N	LN D-076,LN D-118
2969	SGLP-0835	2022-02-24 00:00:00-08	6.44	\N	4.15	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	127	\N	LN D-077,LN D-119
2970	SGLP-0836	2022-02-24 00:00:00-08	5.21	\N	3	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	128	\N	LN D-078,LN D-120
2971	SGLP-0837	2022-02-24 00:00:00-08	5.75	\N	5.43	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	129	\N	LN D-079,LN D-100
2972	SGLP-0838	2022-02-24 00:00:00-08	13.4	\N	9.52	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	130	\N	LN D-080,LN D-121
2973	SGLP-0839	2022-02-24 00:00:00-08	1.18	\N	0.85	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	131	\N	LN D-082,LN D-101,LN D-154
2974	SGLP-0840	2022-02-24 00:00:00-08	6.58	\N	5.13	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	132	\N	LN D-083,LN D-102,LN D-155
2975	SGLP-0841	2022-02-24 00:00:00-08	4.98	\N	4.11	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	133	\N	LN D-084,LN D-103,LN D-156
2976	SGLP-0842	2022-02-24 00:00:00-08	3.25	\N	2.38	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	134	\N	LN D-085,LN D-104,LN D-157
2977	SGLP-0843	2022-02-24 00:00:00-08	5.86	\N	3.41	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	135	\N	LN D-086,LN D-122
2978	SGLP-0844	2022-02-24 00:00:00-08	5.39	0	2.63	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	136	\N	LN D-123
2979	SGLP-0845	2022-02-24 00:00:00-08	2.2	\N	0.74	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	137	\N	LN D-089,LN D-124
2980	SGLP-0846	2022-02-24 00:00:00-08	3.95	\N	1.68	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	138	\N	LN D-090,LN D-125
2981	SGLP-0847	2022-02-24 00:00:00-08	1.91	\N	0.65	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	139	\N	LN D-091,LN D-126
2982	SGLP-0848	2022-02-24 00:00:00-08	0.91	\N	0.35	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	140	\N	LN D-092,LN D-127,LN D-159
2983	SGLP-0849	2022-02-24 00:00:00-08	2.32	\N	0.75	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	141	\N	LN D-093,LN D-128,LN D-160
2984	SGLP-0850	2022-03-07 00:00:00-08	5.73	\N	4.11	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	142	\N	LN D-094,LN D-129
2985	SGLP-0851	2022-03-07 00:00:00-08	6.64	\N	6.78	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	143	\N	LN D-105,LN D-130,LN D-161
2986	SGLP-0852	2022-03-07 00:00:00-08	9.55	\N	11.47	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	144	\N	LN D-106,LN D-131,LN D-162
2987	SGLP-0853	2022-03-07 00:00:00-08	2.95	\N	2.64	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	145	\N	LN D-107,LN D-135
2988	SGLP-0854	2022-03-07 00:00:00-08	7.99	\N	7.68	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	146	\N	LN D-132,LN D-136
2989	SGLP-0855	2022-03-07 00:00:00-08	2.38	\N	2.87	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	147	\N	LN D-133,LN D-137
2990	SGLP-0856	2022-03-07 00:00:00-08	5.37	\N	6.35	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	148	\N	LN D-134,LN D-138
2991	SGLP-0857	2022-03-07 00:00:00-08	6.16	\N	7.71	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	149	\N	LN D-108,LN D-139
2992	SGLP-0858	2022-03-07 00:00:00-08	6.18	\N	7.51	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	150	\N	LN D-109,LN D-140
2993	SGLP-0859	2022-03-07 00:00:00-08	8.21	\N	8.9	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	151	\N	LN D-110,LN D-141
2994	SGLP-0860	2022-03-07 00:00:00-08	7.72	\N	7.66	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	152	\N	LN D-111,LN D-142
2995	SGLP-0861	2022-03-07 00:00:00-08	8.47	\N	9.32	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	153	\N	LN D-112,LN D-143
2996	SGLP-0862	2022-03-07 00:00:00-08	6.6	\N	7.89	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	154	\N	LN D-113,LN D-144,LN D-164
2997	SGLP-0863	2022-03-07 00:00:00-08	6.86	\N	7.24	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	155	\N	LN D-114,LN D-145
2998	SGLP-0864	2022-03-07 00:00:00-08	6.7	\N	7.86	4	\N	\N	\N	\N	HyperPREP; Ligation: 30min, 20oC.	156	\N	LN D-115,LN D-146
2999	OMLP-022	2022-01-28 00:00:00-08	5.65	\N	4.96	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	159	\N	OM-1D-2,OM-1D-3
3000	OMLP-023	2022-01-28 00:00:00-08	4.35	\N	3.61	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	160	\N	OM-4D-2,OM-4D-3
3001	OMLP-024	2022-01-28 00:00:00-08	1.4	\N	3.46	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	161	\N	OM-5D-2,OM-5D-3
3002	OMLP-025	2022-01-28 00:00:00-08	7.69	\N	6.93	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	162	\N	OM-6D-2,OM-6D-3
3003	OMLP-026	2022-01-28 00:00:00-08	5.8	\N	4.8	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	163	\N	OM-10D-2,OM-10D-3
3004	OMLP-027	2022-01-28 00:00:00-08	6.74	9	5.71	4	250	\N	\N	\N	Ligation: 30min, 20oC.	164	\N	OM-15D-2
3005	OMLP-028	2022-01-28 00:00:00-08	5.8	\N	3.52	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	165	\N	OM-22D,OM-22D-2
3006	OMLP-029	2022-01-28 00:00:00-08	8.08	\N	5.1	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	166	\N	OM-23D,OM-23D-2
3007	OMLP-030	2022-01-28 00:00:00-08	10.5	\N	8.41	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	167	\N	OM-24D,OM-24D-2
3008	OMLP-031	2022-01-28 00:00:00-08	7.63	\N	5.74	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	168	\N	OM-25D,OM-25D-2
3009	OMLP-032	2022-01-28 00:00:00-08	2.84	\N	1.37	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	169	\N	OM-26D,OM-26D-2
3010	OMLP-033	2022-01-28 00:00:00-08	8.95	\N	6.17	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	170	\N	OM-27D,OM-27D-2
3011	OMLP-034	2022-01-28 00:00:00-08	14.8	\N	10	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	171	\N	OM-28D,OM-28D-2
3012	OMLP-035	2022-01-28 00:00:00-08	5.44	\N	4.41	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	172	\N	OM-29D,OM-29D-2
3013	OMLP-036	2022-02-21 00:00:00-08	4.34	0	2.14	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	182	\N	OM D-31
3014	OMLP-037	2022-02-21 00:00:00-08	4.73	0	2.17	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	183	\N	OM D-32
3015	OMLP-038	2022-02-21 00:00:00-08	3.14	0	0.98	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	184	\N	OM D-33
3016	OMLP-039	2022-02-21 00:00:00-08	6.88	0	3.65	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	185	\N	OM D-34
3017	OMLP-040	2022-02-21 00:00:00-08	4.48	0	1.77	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	186	\N	OM D-36
3018	OMLP-041	2022-02-21 00:00:00-08	3.72	0	1.45	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	187	\N	OM D-37
3019	OMLP-042	2022-02-21 00:00:00-08	1.68	0	0.79	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	188	\N	OM D-38
3020	OMLP-043	2022-02-21 00:00:00-08	1.14	0	0.44	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	189	\N	OM D-39
3021	OMLP-044	2022-02-21 00:00:00-08	5.42	0	3.2	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	190	\N	OM D-41
3022	OMLP-045	2022-02-21 00:00:00-08	2.89	0	1.16	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	191	\N	OM D-42
3023	OMLP-046	2022-02-21 00:00:00-08	2.65	0	0.88	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	192	\N	OM D-43
3024	OMLP-047	2022-02-21 00:00:00-08	6.99	0	4.26	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	104	\N	OM D-45
3025	OMLP-048	2022-02-21 00:00:00-08	5.28	0	3.03	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	105	\N	OM D-46
3026	OMLP-049	2022-02-21 00:00:00-08	4.35	0	2.98	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	111	\N	OM D-47
3027	OMLP-050	2022-03-07 00:00:00-08	0.22	0	0.12	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	88	\N	OM D-30
3028	OMLP-051	2022-03-07 00:00:00-08	2.73	\N	1.65	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	89	\N	OM D-40.1,OM D-40.2
3029	OMLP-052	2022-03-07 00:00:00-08	2.38	0	1.41	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	90	\N	OM D-44.1
3030	OMLP-053	2022-03-07 00:00:00-08	2.14	0	1.31	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	91	\N	OM D-44.2
3031	OMLP-054	2022-03-07 00:00:00-08	1.49	0	0.86	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	93	\N	OM D-44.3
3032	OMLP-055	2022-03-24 00:00:00-07	1.82	0	0.52	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	1	\N	OM D-51
3033	OMLP-056	2022-03-24 00:00:00-07	3.22	0	1.66	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	38	\N	OM D-53
3034	OMLP-057	2022-03-24 00:00:00-07	1.93	0	1.18	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	84	\N	OM D-54
3035	OMLP-058	2022-03-24 00:00:00-07	1.88	0	1.01	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	87	\N	OM D-55
3036	OMLP-059	2022-03-24 00:00:00-07	5.12	0	3.4	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	94	\N	OM D-57
3037	OMLP-060	2022-03-24 00:00:00-07	2.2	0	0.97	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	95	\N	OM D-58.1
3038	OMLP-061	2022-03-24 00:00:00-07	1	0	0.47	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	96	\N	OM D-58.2
3039	OMLP-062	2022-03-24 00:00:00-07	4.34	0	2.85	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	100	\N	OM D-59
3040	OMLP-063	2022-03-24 00:00:00-07	3	0	2.95	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	101	\N	OM D-60
3041	OMLP-064	2022-03-24 00:00:00-07	1.73	0	1.19	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	102	\N	OM D-61
3042	OMLP-065	2022-03-24 00:00:00-07	2.03	0	1.12	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	103	\N	OM D-62A
3043	OMLP-066	2022-03-24 00:00:00-07	4.84	0	3.29	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	106	\N	OM D-62B
3044	OMLP-067	2022-03-24 00:00:00-07	2.38	0	1.67	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	112	\N	OM D-63
3045	OMLP-068	2022-03-24 00:00:00-07	1.17	0	0.65	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	113	\N	OM D-64
3046	OMLP-069	2022-03-24 00:00:00-07	3.64	0	3	4	\N	\N	\N	\N	Ligation: 30min, 20oC. 3/31/22 CHANGED PAT ID TO OM-01	114	\N	OM D-66.1
3047	OMLP-070	2022-03-24 00:00:00-07	3.31	0	1.78	4	\N	\N	\N	\N	Ligation: 30min, 20oC. 3/31/22 CHANGED PAT ID TO OM-01	115	\N	OM D-66.2
3048	OMLP-071	2022-03-24 00:00:00-07	4.82	0	2.62	4	\N	\N	\N	\N	Ligation: 30min, 20oC. 3/31/22 CHANGED PAT ID TO OM-01	119	\N	OM D-66.3
3049	OMLP-072	2022-03-24 00:00:00-07	0.79	0	0.27	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	120	\N	OM D-68.1
3050	OMLP-073	2022-03-24 00:00:00-07	1.51	0	0.96	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	157	\N	OM D-69
3051	OMLP-074	2022-03-24 00:00:00-07	1.84	0	1.01	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	158	\N	OM D-70
3052	OMLP-075	2022-03-24 00:00:00-07	1.39	0	0.69	4	\N	\N	\N	\N	Ligation: 30min, 20oC.	181	\N	OM D-71
3053	AMLP-271	2021-03-17 00:00:00-07	9.16	49	3.21	4	333	\N	\N	\N	SGPC-22: 12 Cycles post Hyb, 49ng captured	140	\N	AM2 D-433
3054	CCRLP-0001	2021-10-16 00:00:00-07	1.23	\N	0.41	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; Ligation: 20min, 20oC. 	107	\N	MMD-09,MMD-55,MMD-69
3055	CCRLP-0002	2021-10-16 00:00:00-07	1.87	88	1.32	4	185	\N	\N	\N	HyperPlus; Frag: 10min,37oC; Ligation: 20min, 20oC. 	108	\N	MMD-172
3056	CCRLP-0003	2021-10-16 00:00:00-07	0.76	\N	0.19	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; Ligation: 20min, 20oC. 	116	\N	MMD-28,MMD-59
3057	CCRLP-0004	2021-10-16 00:00:00-07	0.97	88	0.31	4	65	\N	\N	\N	HyperPlus; Frag: 10min,37oC; Ligation: 20min, 20oC. 	117	\N	MMD-20
3058	CCRLP-0005	2021-10-16 00:00:00-07	2.15	\N	1.04	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; Ligation: 20min, 20oC. 	118	\N	MMD-16,MMD-24
3059	CCRLP-0006	2021-10-16 00:00:00-07	5.3	68	3.77	4	250	\N	\N	\N	HyperPlus; Frag: 10min,37oC; Ligation: 20min, 20oC. 	119	\N	MMD-60
3060	CCRLP-0007	2021-10-16 00:00:00-07	2.12	\N	3.85	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; Ligation: 20min, 20oC. 	120	\N	MMD-19,MMD-25
3061	CCRLP-0008	2021-10-16 00:00:00-07	1.89	\N	1.56	4	\N	\N	\N	\N	HyperPlus; Frag: 10min,37oC; Ligation: 20min, 20oC. 	121	\N	MMD-33,MMD-62,MMD-106
3062	CCRLP-0009	2021-10-22 00:00:00-07	1.11	88	1.23	4	58	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	122	\N	MMD-91
3063	CCRLP-0010	2021-10-22 00:00:00-07	4.98	68	1.99	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	123	\N	MMD-81
3064	CCRLP-0011	2021-10-22 00:00:00-07	1.34	0	0.08	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	124	\N	MMD-76
3065	CCRLP-0012	2021-10-22 00:00:00-07	2.95	88	1.78	4	82	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	125	\N	MMD-72
3066	CCRLP-0013	2021-10-22 00:00:00-07	2.39	88	0.74	4	234	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	126	\N	MMD-10
3067	CCRLP-0015	2021-10-22 00:00:00-07	4.94	\N	1.48	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	127	\N	MMD-51,MMD-102
3068	CCRLP-0019	2021-10-22 00:00:00-07	1.68	\N	0.34	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	129	\N	MMD-40,MMD-56
3069	CCRLP-0020	2021-10-22 00:00:00-07	2.77	76	1.51	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	130	\N	MMD-162
3070	CCRLP-0021	2021-11-02 00:00:00-07	7.48	43	5.2	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	131	\N	MMD-37
3071	CCRLP-0022	2021-11-02 00:00:00-07	5.08	88	2.7	4	167	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	132	\N	MMD-08
3072	CCRLP-0023	2021-11-02 00:00:00-07	3.19	176	2.19	4	232	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	134	\N	MMD-12
3073	CCRLP-0024	2021-11-02 00:00:00-07	2.25	\N	1.08	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	136	\N	MMD-05,MMD-54,MMD-68
3074	CCRLP-0025	2021-11-02 00:00:00-07	4.24	88	1.66	4	202	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	137	\N	MMD-30
3075	CCRLP-0026	2021-11-02 00:00:00-07	4	\N	1.58	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	138	\N	MMD-21,MMD-26,MMD-22,MMD-27
3076	CCRLP-0027	2021-11-02 00:00:00-07	2.33	88	1.36	4	68	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	139	\N	MMD-15
3077	CCRLP-0028	2021-11-02 00:00:00-07	3.82	\N	1.22	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	140	\N	MMD-32,MMD-61
3078	CCRLP-0029	2021-11-02 00:00:00-07	4.28	88	1.96	4	178	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	141	\N	MMD-07
3079	CCRLP-0030	2021-11-02 00:00:00-07	6.09	46	4.11	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	142	\N	MMD-35
3080	CCRLP-0031	2021-11-02 00:00:00-07	4.99	88	1.79	4	218	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	143	\N	MMD-96
3081	CCRLP-0034	2021-11-02 00:00:00-07	2.87	\N	1.15	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	186	\N	MMD-173,MMD-315
3082	CCRLP-0035	2021-11-02 00:00:00-07	3.77	\N	1.06	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	147	\N	MMD-217,MMD-129
3083	CCRLP-0037	2021-11-02 00:00:00-07	3.94	\N	2.41	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	148	\N	MMD-53,MMD-67
3084	CCRLP-0038	2021-11-02 00:00:00-07	2.26	174	1.22	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	149	\N	MMD-119
3085	CCRLP-0039	2021-11-02 00:00:00-07	6.48	32	4.25	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	150	\N	MMD-04
3086	CCRLP-0041	2021-11-02 00:00:00-07	6.57	0	2.92	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	187	\N	MMD-41
3087	CCRLP-0043	2021-11-02 00:00:00-07	2.22	88	0.92	4	79	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	152	\N	MMD-38
3088	CCRLP-0044	2021-11-02 00:00:00-07	5.68	47	1.97	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	153	\N	MMD-06
3089	CCRLP-0051	2021-11-02 00:00:00-07	5.26	\N	1.29	4	\N	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	97	\N	MMD-73,MMD-74,MMD-75,MMD-93
3090	CCRLP-0052	2021-11-02 00:00:00-07	4.04	25	1.38	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	98	\N	MMD-163
3091	CCRLP-0053	2021-11-02 00:00:00-07	3.89	21	1.44	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	99	\N	MMD-03
3092	CCRLP-0054	2021-11-02 00:00:00-07	3.14	10	0.68	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	102	\N	MMD-01
3093	CCRLP-0059	2021-11-02 00:00:00-07	2.27	8	0.69	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	103	\N	MMD-177
3094	CCRLP-0060	2021-11-02 00:00:00-07	3.95	6	1.89	4	250	\N	\N	\N	HyperPREP; Ligation: 20min, 20oC.	104	\N	MMD-97
3095	CCRLP-0045	2021-08-06 00:00:00-07	2.87	14	1.78	4	250	\N	\N	\N	HyperPlus; Frag: 12min,37oC; Ligation: 17 hrs,16oC. SGPC-23: xx Cycles post Hyb, 66ng captured	192	\N	MMD-165
3096	CCRLP-0046	2021-08-06 00:00:00-07	3.16	17	1.85	4	250	\N	\N	\N	HyperPlus; Frag: 12min,37oC; Ligation: 17 hrs,16oC. SGPC-23: xx Cycles post Hyb, 67ng captured	157	\N	MMD-181
3097	CCRLP-0047	2021-08-06 00:00:00-07	1.81	10	1.02	4	250	\N	\N	\N	HyperPlus; Frag: 12min,37oC; Ligation: 17 hrs,16oC. SGPC-23: xx Cycles post Hyb, 36ng captured	158	\N	MMD-02
3098	CCRLP-0048	2021-08-06 00:00:00-07	1.54	14	0.79	4	250	\N	\N	\N	HyperPrep, Ligation: 17 hrs,16oC. SGPC-23: xx Cycles post Hyb, 20ng captured	144	\N	MMD-165
3099	CCRLP-0049	2021-08-06 00:00:00-07	1.58	17	0.82	4	250	\N	\N	\N	HyperPrep, Ligation: 17 hrs,16oC. SGPC-23: xx Cycles post Hyb, 21ng captured	146	\N	MMD-181
3100	CCRLP-0050	2021-08-06 00:00:00-07	1.04	10	0.39	4	250	\N	\N	\N	HyperPrep, Ligation: 17 hrs,16oC. SGPC-23: xx Cycles post Hyb, 7ng captured	151	\N	MMD-02
3101	AMLP-183	2020-02-07 00:00:00-08	1.83	263	0.53	4	84	\N	\N	\N	\N	105	\N	AM2 D-152
3102	AMLP-244	2021-03-17 00:00:00-07	5.5	96	0.41	4	208	\N	\N	\N	SGPC-24: 12 Cycles post Hyb, 20.5ng captured	108	\N	AM2 D-311
3103	AMLP-397	2022-04-27 00:00:00-07	3.73	54	2.9	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC. 	106	\N	AM2 D-446
3104	AMLP-398	2022-04-27 00:00:00-07	5.72	3	4.06	4	250	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	112	\N	AM2 D-36
3105	AMLP-399	2022-04-27 00:00:00-07	10.9	8	5.93	4	300	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	113	\N	AM2 D-129
3106	AMLP-400	2022-04-27 00:00:00-07	19.6	6	7.44	4	300	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	114	\N	AM2 D-130
3107	AMLP-401	2022-04-27 00:00:00-07	6.49	9	2.9	4	300	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	120	\N	AM2 D-174
3108	AMLP-402	2022-04-27 00:00:00-07	7.88	33	6.6	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	121	\N	AM2 D-457
3109	AMLP-403	2022-04-27 00:00:00-07	6.56	18	5.95	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	122	\N	AM2 D-459
3110	AMLP-404	2022-04-27 00:00:00-07	8.81	31	6.34	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	123	\N	AM2 D-318
3111	AMLP-405	2022-04-27 00:00:00-07	3.16	0	3.93	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	124	\N	AM2 D-345
3112	AMLP-406	2022-04-27 00:00:00-07	8.58	9	7.32	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	125	\N	AM2 D-422
3113	AMLP-407	2022-04-27 00:00:00-07	8.81	30	8.93	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	126	\N	AM2 D-423
3114	AMLP-408	2022-04-27 00:00:00-07	9.75	0	10.55	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	127	\N	AM2 D-414
3115	AMLP-409	2022-05-20 00:00:00-07	13.4	29	10.92	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	129	\N	AM2 D-295
3116	AMLP-410	2022-05-20 00:00:00-07	0.43	90	0.21	4	14	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	134	\N	AM2 D-499
3117	AMLP-411	2022-05-20 00:00:00-07	5.48	72	2.64	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	136	\N	AM2 D-500
3118	AMLP-412	2022-05-20 00:00:00-07	4.31	88	2.34	4	191	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	137	\N	AM2 D-501
3119	AMLP-413	2022-05-20 00:00:00-07	6.16	33	4.56	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	138	\N	AM2 D-503
3120	AMLP-414	2022-05-20 00:00:00-07	3.7	88	1.7	4	201	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	139	\N	AM2 D-504
3121	AMLP-415	2022-05-20 00:00:00-07	5.73	88	3.2	4	286	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	146	\N	AM2 D-505
3122	AMLP-416	2022-05-20 00:00:00-07	2.77	\N	2.91	4	\N	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	151	\N	AM2 D-356,AM2 D-506
3123	AMLP-417	2022-05-20 00:00:00-07	4.12	88	3.2	4	197	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	154	\N	AM2 D-507
3124	AMLP-418	2022-05-20 00:00:00-07	6.1	69	4.92	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	155	\N	AM2 D-508
3125	AMLP-419	2022-05-20 00:00:00-07	6.08	88	5.49	4	210	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	156	\N	AM2 D-509
3126	AMLP-420	2022-05-20 00:00:00-07	5.15	58	3.67	4	333	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	157	\N	AM2 D-510
3127	AMLP-421	2022-05-20 00:00:00-07	2.4	88	1.27	4	152	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	158	\N	AM2 D-511
3128	AMLP-422	2022-05-31 00:00:00-07	6.67	5	4.77	4	250	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	167	\N	AM2 D-33
3129	AMLP-423	2022-05-31 00:00:00-07	6.77	25	4.74	4	999	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	181	\N	AM2 D-185
3130	AMLP-424	2022-05-31 00:00:00-07	7.84	23	3.02	4	999	\N	\N	\N	HyperPREP, Ligation: 30 min at 20 oC.	189	\N	AM2 D-183
3131	AMLP-152	2020-01-31 00:00:00-08	13.6	0	3.47	4	\N	\N	\N	\N	120s shear time; DNA repaired. SGPC-24: 12 Cycles post Hyb, 60ng captured	7	\N	AM2 D-31
3132	AMLP-239	2021-03-17 00:00:00-07	8.39	30	2.83	4	333	\N	\N	\N	SGPC-24: 12 Cycles post Hyb, 45ng captured	102	\N	AM2 D-294
3133	AMLP-207	2020-08-02 00:00:00-07	8.63	39	6.76	4	333	\N	\N	\N	RE-CAPTURED 6/4/21, 10 cycles, XT HS baits, 100 ng library. SGPC-24: 12 Cycles post Hyb, 50ng captured	142	\N	AM2 D-104-1
3134	AMLP-209	2020-08-02 00:00:00-07	7.1	10	5.9	4	333	\N	\N	\N	RE-CAPTURED 6/4/21, 10 cycles, XT HS baits, 100 ng library. SGPC-24: 12 Cycles post Hyb, 50ng captured	144	\N	AM2 D-237
3135	AMLP-311	2021-05-20 00:00:00-07	2.95	95	3.61	4	280	\N	\N	\N	SGPC-24: 12 Cycles post Hyb, 25ng captured	111	\N	AM2 D-456
3136	AMLP-313	2021-05-20 00:00:00-07	6.65	50	3.64	4	333	\N	\N	\N	SGPC-24: 12 Cycles post Hyb, 32ng captured	133	\N	AM2 D-458
3137	AMLP-205	2020-08-02 00:00:00-07	8.06	63	4.19	4	333	\N	\N	\N	SGPC-24: 12 Cycles post Hyb, 50ng captured	140	\N	AM2 D-232
3138	U5LP-01	2019-07-02 00:00:00-07	4.05	0	1.02	4	\N	\N	\N	\N	\N	1	\N	MM-1
3139	U5LP-02	2019-07-02 00:00:00-07	5.61	0	2.7	4	\N	\N	\N	\N	\N	3	\N	MM-2
3140	U5LP-03	2019-07-02 00:00:00-07	5.3	0	2.17	4	\N	\N	\N	\N	\N	8	\N	PM-3
3141	U5LP-04	2019-07-11 00:00:00-07	1.03	0	1.21	4	\N	\N	\N	\N	\N	9	\N	MM-4
3142	U5LP-05	2019-07-11 00:00:00-07	3.17	0	0.6	4	\N	\N	\N	\N	\N	10	\N	PM-1
3143	U5LP-06	2019-07-02 00:00:00-07	3.7	0	1.05	4	\N	\N	\N	\N	\N	12	\N	PM-2
3144	U5LP-08	2019-07-16 00:00:00-07	2.37	0	0.46	4	\N	\N	\N	\N	\N	42	\N	PM-4
3145	U5LP-09	2019-07-02 00:00:00-07	5.54	0	1.66	4	\N	\N	\N	\N	\N	43	\N	N-1
3146	U5LP-10	2019-07-02 00:00:00-07	2.91	0	1.66	4	\N	\N	\N	\N	\N	44	\N	N-2
3147	U5LP-11	2019-07-02 00:00:00-07	3.01	0	1.27	4	\N	\N	\N	\N	\N	45	\N	N-3
3148	U5LP-12	2019-07-02 00:00:00-07	3.16	0	1.33	4	\N	\N	\N	\N	\N	46	\N	N-4
3149	U5LP-13	2019-07-02 00:00:00-07	0.48	0	0.05	4	\N	\N	\N	\N	\N	49	\N	MM-3
3150	RNA-03	2018-08-20 00:00:00-07	21.6	1	16.4	11	400	\N	\N	\N	RLP-03	D9	\N	RNA-03
3151	RNA-04	2018-08-20 00:00:00-07	2.8	20	2.6	11	192	\N	\N	\N	RLP-04	D10	\N	RNA-04
3152	RNA-05	2018-08-20 00:00:00-07	3.2	20	2.2	11	214	\N	\N	\N	RLP-05	D11	\N	RNA-05
3153	RNA-07	2018-08-20 00:00:00-07	4.8	12	2.1	11	400	\N	\N	\N	RLP-07	UN	\N	RNA-07
3154	RNA-11	2018-08-20 00:00:00-07	13.3	20	11.5	11	200	\N	\N	\N	RLP-11	H8	\N	RNA-11
3155	RNA-12	2018-08-20 00:00:00-07	12.3	12	11.7	11	400	\N	\N	\N	RLP-12	H9	\N	RNA-12
3156	RNA-13	2018-08-20 00:00:00-07	18.2	5	17.9	11	400	\N	\N	\N	RLP-13	A3	\N	RNA-13
3157	RNA-14	2018-08-20 00:00:00-07	27	0	23.4	11	400	\N	\N	\N	RLP-14	A5	\N	RNA-14
3158	RNA-22	2018-08-20 00:00:00-07	19.7	3	24.2	11	400	\N	\N	\N	RLP-22, Sample removed from study	E9	\N	RNA-22
3159	RNA-01	2018-08-20 00:00:00-07	13.6	2	8.9	11	400	\N	\N	\N	RLP-01	B7	\N	RNA-01
3160	RNA-02	2018-08-20 00:00:00-07	13.1	5	7.8	11	400	\N	\N	\N	RLP-02	D8	\N	RNA-02
3161	RNA-06	2018-08-20 00:00:00-07	9.1	6	4.4	11	400	\N	\N	\N	RLP-06	D12	\N	RNA-06
3162	RNA-08	2018-08-20 00:00:00-07	6.5	20	4.2	11	312	\N	\N	\N	RLP-08	E9	\N	RNA-08
3163	RNA-09	2018-08-20 00:00:00-07	12.1	9	7.4	11	400	\N	\N	\N	RLP-09	E10	\N	RNA-09
3164	RNA-15	2018-08-20 00:00:00-07	10.2	17	7.3	11	400	\N	\N	\N	RLP-15	B4	\N	RNA-15
3165	RNA-16	2018-08-20 00:00:00-07	11	7	7.3	11	400	\N	\N	\N	RLP-16	B5	\N	RNA-16
3166	RNA-18	2018-08-20 00:00:00-07	20.4	7	13	11	400	\N	\N	\N	RLP-18	D9	\N	RNA-18
3167	RNA-21	2018-08-20 00:00:00-07	8.1	5	5.3	11	400	\N	\N	\N	RLP-21, Sample removed from study	UN	\N	RNA-21
3168	RNA-26	2018-09-27 00:00:00-07	6.6	5	11	11	400	\N	\N	\N	RLP-26	2	\N	RNA-26
3169	RNA-27	2018-09-27 00:00:00-07	10.2	8	19.1	11	400	\N	\N	\N	RLP-27	3	\N	RNA-27
3170	RNA-28	2018-09-27 00:00:00-07	17.3	2	33.8	11	400	\N	\N	\N	RLP-28	4	\N	RNA-28
3171	RNA-29	2018-09-27 00:00:00-07	17.8	11	37.8	11	400	\N	\N	\N	RLP-29	5	\N	RNA-29
3172	RNA-30	2018-09-27 00:00:00-07	5.2	2	10.5	11	400	\N	\N	\N	RLP-30	6	\N	RNA-30
3173	RNA-31	2018-09-27 00:00:00-07	14.3	2	31.3	11	400	\N	\N	\N	RLP-31	7	\N	RNA-31
3174	RNA-32	2018-09-27 00:00:00-07	4.8	20	10.7	11	310	\N	\N	\N	RLP-32	8	\N	RNA-32
3175	RNA-33	2018-09-27 00:00:00-07	5.7	15	9.7	11	400	\N	\N	\N	RLP-33	9	\N	RNA-33
3176	RNA-34	2018-09-27 00:00:00-07	7.4	18	11.8	11	400	\N	\N	\N	RLP-34	10	\N	RNA-34
3177	RNA-35	2018-09-27 00:00:00-07	4.8	2	8.8	11	400	\N	\N	\N	RLP-35	11	\N	RNA-35
3178	RNA-36	2018-09-27 00:00:00-07	9.1	8	18.5	11	400	\N	\N	\N	RLP-36	12	\N	RNA-36
3179	RNA-37	2018-09-27 00:00:00-07	7.4	12	19	11	400	\N	\N	\N	RLP-37	13	\N	RNA-37
3180	RNA-38	2018-09-27 00:00:00-07	9.8	8	18.3	11	400	\N	\N	\N	RLP-38, Sample removed from study	14	\N	RNA-38
3181	RNA-39	2018-09-27 00:00:00-07	8.5	3	17.6	11	400	\N	\N	\N	RLP-39, Sample removed from study	15	\N	RNA-39
3182	RNA-40	2018-09-27 00:00:00-07	9.1	2	16.9	11	400	\N	\N	\N	RLP-40, Sample removed from study	16	\N	RNA-40
3183	EXLP-01	2020-08-05 00:00:00-07	3.84	100	3.07	4	83	\N	\N	\N	Whole Genome Sequencing (WGS)	121	\N	PROG D-01
3184	EXLP-04	2020-08-05 00:00:00-07	9.71	39	7.06	4	333	\N	\N	\N	Whole Genome Sequencing (WGS)	124	\N	PROG D-04
3185	EXLP-05	2020-08-05 00:00:00-07	7.84	57	4.29	4	333	\N	\N	\N	Whole Genome Sequencing (WGS)	125	\N	PROG D-05
3186	EXLP-09	2020-08-05 00:00:00-07	9.04	100	7.58	4	202	\N	\N	\N	Whole Genome Sequencing (WGS)	129	\N	PROG D-12
3187	EXLP-10	2020-08-05 00:00:00-07	3.31	100	2.92	4	94	\N	\N	\N	Whole Genome Sequencing (WGS)	130	\N	PROG D-13
3188	EXLP-11	2020-09-03 00:00:00-07	2.65	99	1.53	4	71	\N	\N	\N	Whole Genome Sequencing (WGS)	128	\N	PROG D-14
3189	EXLP-23	2023-05-25 00:00:00-07	8.15	16	4.7	4	250	\N	\N	\N	1 hr adapter ligation at 20oC	154	\N	PROG D-18
3190	EXLP-25	2023-05-25 00:00:00-07	7.12	23	3.79	4	250	\N	\N	\N	1 hr adapter ligation at 20oC	156	\N	PROG D-20
3191	EXLP-20	2023-05-25 00:00:00-07	5.53	140	2	4	250	\N	\N	\N	1 hr adapter ligation at 20oC	151	\N	PROG D-15
3192	EXLP-22	2023-05-25 00:00:00-07	5.41	15	2.31	4	250	\N	\N	\N	1 hr adapter ligation at 20oC. Merged with EXLP-40 for sequencing (17.5 ng each)	153	\N	PROG D-17
3193	EXLP-40	2023-06-13 00:00:00-07	4.28	15	1.45	4	250	\N	\N	\N	1 hr adapter ligation at 20oC. Merged with EXLP-22 for sequencing (17.5 ng each)	153	\N	PROG D-17
3194	EXLP-24	2023-05-25 00:00:00-07	5.02	184	2.76	4	193	\N	\N	\N	1 hr adapter ligation at 20oC	155	\N	PROG D-19
3195	EXLP-27	2023-05-25 00:00:00-07	8.22	36	6.85	4	250	\N	\N	\N	1 hr adapter ligation at 20oC	158	\N	PROG D-23
3196	EXLP-21	2023-05-25 00:00:00-07	3.69	199	1.52	4	143	\N	\N	\N	1 hr adapter ligation at 20oC	152	\N	PROG D-16
3197	EXLP-26	2023-05-25 00:00:00-07	4.76	73	1.59	4	250	\N	\N	\N	1 hr adapter ligation at 20oC	157	\N	PROG D-22
3198	EXLP-30	2023-05-25 00:00:00-07	4.73	76	1.17	4	250	\N	\N	\N	1 hr adapter ligation at 20oC	161	\N	PROG D-26
3199	EXLP-43	2023-06-13 00:00:00-07	3.51	76	1.03	4	250	\N	\N	\N	1 hr adapter ligation at 20oC. Sequenced as EXLP-30	161	\N	PROG D-26
3200	XuRLP-001	2019-01-07 00:00:00-08	89.03	2	46.2	\N	400	\N	\N	\N	\N	18	\N	Xu-1
3201	XuRLP-002	2019-01-07 00:00:00-08	82.66	2	42.7	\N	400	\N	\N	\N	\N	19	\N	Xu-2
3202	XuRLP-003	2019-01-07 00:00:00-08	90.55	2	40.5	\N	400	\N	\N	\N	\N	20	\N	Xu-3
3203	XuRLP-004	2019-01-07 00:00:00-08	105.74	2	40	\N	400	\N	\N	\N	\N	21	\N	Xu-4
3204	XuRLP-005	2019-01-07 00:00:00-08	106.46	2	43.8	\N	400	\N	\N	\N	\N	22	\N	Xu-5
3205	XuRLP-006	2019-01-07 00:00:00-08	114.27	2	44	\N	400	\N	\N	\N	\N	23	\N	Xu-6
3206	XuRLP-007	2019-01-07 00:00:00-08	99.85	2	43.8	\N	400	\N	\N	\N	\N	24	\N	Xu-7
3207	XuRLP-008	2019-01-07 00:00:00-08	71.75	2	31.2	\N	400	\N	\N	\N	\N	25	\N	Xu-8
3208	XuRLP-009	2019-01-07 00:00:00-08	107.18	2	45.5	\N	400	\N	\N	\N	\N	26	\N	Xu-9
3209	XuRLP-010	2019-01-07 00:00:00-08	98.51	2	48.9	\N	400	\N	\N	\N	\N	27	\N	Xu-10
3210	XuRLP-011	2019-01-07 00:00:00-08	91.47	2	46.9	\N	400	\N	\N	\N	\N	28	\N	Xu-11
3211	XuRLP-012	2019-01-07 00:00:00-08	96.54	2	43.9	\N	400	\N	\N	\N	\N	29	\N	Xu-12
3212	XuRLP-013	2019-01-07 00:00:00-08	111.98	2	44.4	\N	400	\N	\N	\N	\N	30	\N	Xu-13
3213	XuRLP-014	2019-01-07 00:00:00-08	74.71	2	32.9	\N	400	\N	\N	\N	\N	31	\N	Xu-14
3214	XuRLP-015	2019-01-10 00:00:00-08	106.46	2	42.8	\N	400	\N	\N	\N	\N	43	\N	Xu-015
3215	XuRLP-016	2019-01-10 00:00:00-08	118.99	2	42.3	\N	400	\N	\N	\N	\N	44	\N	Xu-016
3216	XuRLP-017	2019-01-10 00:00:00-08	92.08	2	37	\N	400	\N	\N	\N	\N	45	\N	Xu-017
3217	XuRLP-018	2019-01-10 00:00:00-08	111.23	2	40.7	\N	400	\N	\N	\N	\N	46	\N	Xu-018
3218	XuRLP-019	2019-01-10 00:00:00-08	118.59	2	43.9	\N	400	\N	\N	\N	\N	47	\N	Xu-019
3219	XuRLP-020	2019-01-10 00:00:00-08	124.74	2	43.2	\N	400	\N	\N	\N	\N	48	\N	Xu-020
3220	XuRLP-021	2019-01-10 00:00:00-08	117	2	42.6	\N	400	\N	\N	\N	\N	49	\N	Xu-021
3221	XuRLP-022	2019-01-10 00:00:00-08	109.74	2	43.7	\N	400	\N	\N	\N	\N	50	\N	Xu-022
3222	XuRLP-023	2019-01-10 00:00:00-08	104.68	2	40.3	\N	400	\N	\N	\N	\N	51	\N	Xu-023
3223	XuRLP-024	2019-01-10 00:00:00-08	103.97	2	43.4	\N	400	\N	\N	\N	\N	52	\N	Xu-024
3224	XuRLP-025	2019-01-10 00:00:00-08	105.38	2	47.6	\N	400	\N	\N	\N	\N	53	\N	Xu-025
3225	XuRLP-026	2019-01-10 00:00:00-08	117.79	2	47.2	\N	400	\N	\N	\N	\N	54	\N	Xu-026
3226	XuRLP-027	2019-01-10 00:00:00-08	113.5	2	44.5	\N	400	\N	\N	\N	\N	55	\N	Xu-027
3227	XuRLP-028	2019-01-10 00:00:00-08	110.85	2	43.6	\N	400	\N	\N	\N	\N	56	\N	Xu-028
3228	XuRLP-029	2019-01-10 00:00:00-08	121.83	2	46.1	\N	400	\N	\N	\N	\N	57	\N	Xu-029
3229	XuRLP-030	2019-01-10 00:00:00-08	107.54	2	46.2	\N	400	\N	\N	\N	\N	58	\N	Xu-030
3230	XuRLP-031	2019-01-10 00:00:00-08	113.12	2	45.2	\N	400	\N	\N	\N	\N	59	\N	Xu-031
3231	XuRLP-032	2019-01-10 00:00:00-08	123.9	3	43.6	\N	400	\N	\N	\N	\N	60	\N	Xu-032
3232	XuRLP-033	2019-01-10 00:00:00-08	106.82	2	41.9	\N	400	\N	\N	\N	\N	61	\N	Xu-033
3233	XuRLP-034	2019-01-10 00:00:00-08	108.27	2	42.3	\N	400	\N	\N	\N	\N	62	\N	Xu-034
3234	XuRLP-035	2019-01-10 00:00:00-08	105.03	2	45	\N	400	\N	\N	\N	\N	63	\N	Xu-035
3235	XuRLP-036	2019-01-10 00:00:00-08	118.99	2	43.6	\N	400	\N	\N	\N	\N	64	\N	Xu-036
3236	XuRLP-037	2019-01-10 00:00:00-08	109.37	2	44.3	\N	400	\N	\N	\N	\N	91	\N	Xu-037
3237	XuRLP-038	2019-01-10 00:00:00-08	111.98	2	46.5	\N	400	\N	\N	\N	\N	92	\N	Xu-038
3238	XuRLP-039	2019-01-10 00:00:00-08	126.01	2	47.4	\N	400	\N	\N	\N	\N	93	\N	Xu-039
3239	XuRLP-040	2019-01-10 00:00:00-08	123.07	2	40.4	\N	400	\N	\N	\N	\N	94	\N	Xu-040
3240	XuRLP-041	2019-01-24 00:00:00-08	86.37	2	48.3	\N	400	\N	\N	\N	\N	95	\N	Xu-041
3241	XuRLP-042	2019-01-24 00:00:00-08	75.72	2	45.7	\N	400	\N	\N	\N	\N	96	\N	Xu-042
3242	XuRLP-043	2019-01-24 00:00:00-08	63.97	2	43.4	\N	400	\N	\N	\N	\N	1	\N	Xu-043
3243	XuRLP-044	2019-01-24 00:00:00-08	78.32	2	46.3	\N	400	\N	\N	\N	\N	2	\N	Xu-044
3244	XuRLP-045	2019-01-24 00:00:00-08	72.48	2	42.1	\N	400	\N	\N	\N	\N	3	\N	Xu-045
3245	XuRLP-046	2019-01-24 00:00:00-08	73.96	2	44.4	\N	400	\N	\N	\N	\N	4	\N	Xu-046
3246	XuRLP-047	2019-01-24 00:00:00-08	65.72	2	45.8	\N	400	\N	\N	\N	\N	5	\N	Xu-047
3247	XuRLP-048	2019-01-24 00:00:00-08	77.53	2	43.5	\N	400	\N	\N	\N	\N	6	\N	Xu-048
3248	XuRLP-049	2019-01-24 00:00:00-08	59.2	2	45	\N	400	\N	\N	\N	\N	7	\N	Xu-049
3249	XuRLP-050	2019-01-24 00:00:00-08	46.12	2	32.7	\N	400	\N	\N	\N	\N	8	\N	Xu-050
3250	XuRLP-051	2019-01-24 00:00:00-08	59	2	37.6	\N	400	\N	\N	\N	\N	9	\N	Xu-051
3251	XuRLP-052	2019-01-24 00:00:00-08	62.48	2	40.8	\N	400	\N	\N	\N	\N	10	\N	Xu-052
3252	XuRLP-053	2019-01-24 00:00:00-08	66.39	2	44.8	\N	400	\N	\N	\N	\N	11	\N	Xu-053
3253	XuRLP-054	2019-01-24 00:00:00-08	76.24	2	44.5	\N	400	\N	\N	\N	\N	12	\N	Xu-054
3254	XuRLP-055	2019-01-24 00:00:00-08	78.59	2	47.4	\N	400	\N	\N	\N	\N	13	\N	Xu-055
3255	XuRLP-056	2019-01-24 00:00:00-08	64.19	4	37.2	\N	400	\N	\N	\N	\N	14	\N	Xu-056
3256	XuRLP-057	2019-01-24 00:00:00-08	41.55	4	25.5	\N	400	\N	\N	\N	\N	15	\N	Xu-057
3257	XuRLP-058	2019-01-24 00:00:00-08	32.26	3	24.5	\N	400	\N	\N	\N	\N	16	\N	Xu-058
3258	XuRLP-059	2019-01-24 00:00:00-08	30.26	2	22.5	\N	400	\N	\N	\N	\N	17	\N	Xu-059
3259	XuRLP-060	2019-01-24 00:00:00-08	38.7	3	19.3	\N	400	\N	\N	\N	\N	81	\N	Xu-060
3260	XuRLP-061	2019-01-24 00:00:00-08	62.27	2	42.8	\N	400	\N	\N	\N	\N	82	\N	Xu-061
3261	XuRLP-062	2019-01-24 00:00:00-08	69.37	5	38.8	\N	400	\N	\N	\N	\N	88	\N	Xu-062
3262	XuRLP-063	2019-01-24 00:00:00-08	63.76	3	41.5	\N	400	\N	\N	\N	\N	89	\N	Xu-063
3263	XuRLP-064	2019-01-24 00:00:00-08	44	10	33.5	\N	212	\N	\N	\N	\N	90	\N	Xu-064
10000	12-6261A	\N	\N	\N	\N	\N	\N	\N	\N	\N	Cheek	1	\N	NA_12-6261A_Tumor
10001	12-6261B	\N	\N	\N	\N	\N	\N	\N	\N	\N	Neck	2	\N	NA_12-6261B_Tumor
10006	12-12647	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	12	\N	NA_12-12647_Tumor
10007	12-12626	\N	\N	\N	\N	\N	\N	\N	\N	\N	Right Arm	13	\N	NA_12-12626_Tumor
10008	12-13587 B2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	14	\N	NA_12-13587_Tumor
10009	12-18438A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	15	\N	NA_12-18438A_Tumor
10010	12-13152 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	17	\N	NA_12-13152_Tumor
10011	12-12750B	\N	\N	\N	\N	\N	\N	\N	\N	\N	Forehead	18	\N	NA_12-12750B_Tumor
10012	12-19596	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	19	\N	NA_12-19596_Tumor
10013	12-19187A	\N	\N	\N	\N	\N	\N	\N	\N	\N	Shin	20	\N	NA_12-19187A_Tumor
10014	12-22172 Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	22	\N	NA_12-22172_Normal
10015	12-22172 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	23	\N	NA_12-22172_Tumor
10016	12-21726A Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	24	\N	NA_12-21726A_Tumor
10017	12-22901A Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	25	\N	NA_12-22901A_Normal
10018	12-22901A Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	26	\N	NA_12-22901A_Tumor
10019	12-22776 B5 Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	27	\N	NA_12-22776_Normal
10020	Buffy Coat	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	28	\N	NA_BuffyCoat_Tumor
10021	12-13587 B2_0_75ug	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	29	\N	NA_12-13587B2_Tumor
10022	12-13587_B2_0_5ug	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	30	\N	NA_12-13587B2_Tumor
10023	12-13587 B2_0_25ug	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	31	\N	NA_12-13587B2_Tumor
10024	Buffy Coa	\N	\N	\N	\N	\N	\N	\N	\N	\N	Collaborated with Robert Nussbaum to get this blood	28	\N	NA_BuffyCoa_Tumor
10025	12-22775	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	32	\N	NA_12-22775_Tumor
10026	12-22794A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	33	\N	NA_12-22794A_Tumor
10027	12-22573	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	34	\N	NA_12-22573_Tumor
10028	12-22582A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	36	\N	NA_12-22582A_Tumor
10029	12-22587	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	40	\N	NA_12-22587_Tumor
10030	12-22592	\N	\N	\N	\N	\N	\N	\N	\N	\N	Scalp	41	\N	NA_12-22592_Tumor
10031	12-22597	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	43	\N	NA_12-22597_Tumor
10032	12-22602A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	44	\N	NA_12-22602A_Tumor
10033	12-22602B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	45	\N	NA_12-22602B_Tumor
10034	12-22603	\N	\N	\N	\N	\N	\N	\N	\N	\N	Forehead	46	\N	NA_12-22603_Tumor
10035	12-22604	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	47	\N	NA_12-22604_Tumor
10036	12-22720A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	Upper back	49	\N	NA_12-22720A_Tumor
10037	12-22868	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	50	\N	NA_12-22868_Tumor
10038	12-22884C	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	51	\N	NA_12-22884C_Tumor
10039	12-22884D	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	52	\N	NA_12-22884D_Tumor
10040	12-22886	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	53	\N	NA_12-22886_Tumor
10041	12-22894B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	55	\N	NA_12-22894B_Tumor
10042	12-22898	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	56	\N	NA_12-22898_Tumor
10043	12-22900	\N	\N	\N	\N	\N	\N	\N	\N	\N	Eybrow	57	\N	NA_12-22900_Tumor
10044	12-22597_700ng	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	58	\N	NA_12-22597_Tumor
10045	12-22597_500ng	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	59	\N	NA_12-22597_Tumor
10046	12-22597_250ng	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	60	\N	NA_12-22597_Tumor
10047	12-22597_100ng	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	61	\N	NA_12-22597_Tumor
10068	21-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR05	\N	NA_10-41439_Normal
10069	24-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR06	\N	NA_11-23681_Melanoma
10070	24-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR07	\N	NA_11-23681_Melanoma
10073	24-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR10	\N	NA_11-23681_Normal
10074	28-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR11	\N	NA_11-37533_Melanoma
10075	28-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR12	\N	NA_11-37533_Melanoma
10076	28-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR13	\N	NA_11-37533_Nevus
10077	28-4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR14	\N	NA_11-37533_Nevus
10078	28-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR15	\N	NA_11-37533_Normal
10374	WM3928 F	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 14	\N	NA_K1_1_Tumor
10375	C037	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 15	\N	NA_K1_2_Tumor
10376	C022	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 16	\N	NA_K1_3_Tumor
10377	L20-Mel	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 17	\N	NA_London-L20_Tumor
10378	L20-NL	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 18	\N	NA_London-L20_Tumor
10379	L20-Nevus-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 19	\N	NA_London-L20_Nevus
10380	L15-NL	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 20	\N	NA_London-L15_Tumor
10381	L23C-Dysplastic	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 21	\N	NA_London-L23C_Tumor
10382	UM15	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_K1_9_Tumor
10383	UM19	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_K1_10_Tumor
10384	UM20	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_K1_11_Tumor
10385	CP-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 1	\N	NA_K1_12_Tumor
10386	CP-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 2	\N	NA_K1_13_Tumor
10387	CP-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 3	\N	NA_K1_14_Tumor
10388	CP-4	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 4	\N	NA_K1_15_Tumor
10389	CP-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 5	\N	NA_K1_16_Tumor
10390	CP-6	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 6	\N	NA_K1_17_Tumor
10391	14-18	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 7	\N	NA_K1_18_Tumor
10392	14-19	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 8	\N	NA_K1_19_Tumor
10393	14-21	\N	\N	\N	\N	\N	\N	\N	\N	\N	13 Cycle Post Hybridization LM-PCR	NextFlex 9	\N	NA_K1_20_Tumor
10551	BS1	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH11-051 	 NextFlex 1	\N	NA_11-13661_Tumor
10552	BS2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 2	\N	NA_RC11-001_Tumor
10553	BS3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_RC11-002_Tumor
10554	BS4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_RC11-003_Tumor
10555	BS5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_RC11-004_Tumor
10556	BS6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_RC11-005_Tumor
10557	BS7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_RC11-021_Tumor
10558	BS8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_RC11-022_Tumor
10559	BS9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_RC11-023_Tumor
10560	BS10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 10	\N	NA_RC11-024_Tumor
10561	BS11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 11	\N	NA_Kit298_Tumor
10596	DM_18_2_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR02	\N	NA_DM18_Tumor
10598	CGH11-202	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH11-202 	L2DR04	\N	NA_11-41004_Tumor
10599	CGH11-215	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH11-215 	L2DR05	\N	NA_11-51223_Tumor
10600	CGH12-088	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH12-088 	L2DR06	\N	NA_12-22542_Tumor
10601	CGH12-188	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH12-188 	L2DR07	\N	NA_12-42406_Tumor
10602	CGH12-227	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH12-227 	L2DR08	\N	NA_12-55875_Tumor
10603	CGH12-376	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH12-376 	L2DR09	\N	NA_12-88454_Tumor
10604	CGH13-007	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-007 	L2DR10	\N	NA_12-98328_Tumor
10606	DPN_CNN 23	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR01	\N	NA_12-762B_Normal
10607	DPN_CNN 25	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR02	\N	NA_12-168B_Normal
10608	DPN_CNN 26	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR03	\N	NA_11-75173_Normal
10609	DPN_CNN 27	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR04	\N	NA_12-167B_Normal
10610	DPN 34 pool	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR05	\N	NA_13-47668_Tumor
10611	DPN 34 Conv pool	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR06	\N	NA_13-47668_Tumor
10612	DPN 36 pool	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR07	\N	NA_12-66661_Tumor
10613	DPN 37 pool	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR08	\N	NA_13-47621_Tumor
10614	DPN Conv 37	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR09	\N	NA_13-47621_Tumor
10615	DPN 38	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR10	\N	NA_13-37371_Tumor
10616	DPN Conv 38	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR11	\N	NA_13-37371_Tumor
10617	DM11_Tert_Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR12	\N	NA_DM11_Tumor
10618	DM14_Tert_Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR13	\N	NA_DM14_Tumor
10619	MIN_1_Tert_Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR14	\N	NA_13-25110A1_Melanoma
10620	MIN_3_Tert_Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR15	\N	NA_13-25110A1_Normal
10621	MIN_6_Tert_Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR16	\N	NA_13-45163_Normal
10622	Acral_11_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	_Tumor	L2DR01	\N	NA_Acral-11_Tumor
10623	Acral_11_Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	_Cntl	L2DR02	\N	NA_Acral-11_Normal
10624	Acral_12_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	_Tumor	L2DR03	\N	NA_Acral-12_Tumor
10625	Acral_12_Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	_Cntl	L2DR04	\N	NA_Acral-12_Normal
10626	Mucosal_02-2599_Primary A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR05	\N	NA_02-2599_Tumor
10627	Mucosal_02-2599_Primary B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR06	\N	NA_02-2599_Tumor
10628	Mucosal_02-2599_Control	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR07	\N	NA_02-2599C_Tumor
10629	Mucosal_02-2599_Met	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR08	\N	NA_02-2599_Tumor
10630	DM_48_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR09	\N	NA_DM48_Normal
10631	DM_59_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR10	\N	NA_DM59_Normal
10632	DM_68_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR11	\N	NA_DM68_Normal
10633	DM_95_Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR12	\N	NA_DM95_Tumor
10634	Ivanka_22_Nevus_Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR13	\N	NA_08-46462_Nevus
10635	Ivanka_22_IS_Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR14	\N	NA_08-46462_MIS
10636	Ivanka_22_Normal_Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR15	\N	NA_08-46462_Normal
10637	Ivanka_22_Mel_Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR16	\N	NA_08-46462_Melanoma
10638	CNS20-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR01	\N	NA_T07-1120_Tumor
10639	CNS21-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR02	\N	NA_T09-8069_Tumor
10640	CNS22-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR03	\N	NA_T02-16195_Tumor
10641	CNS23-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR04	\N	NA_T00-12011_Tumor
10642	CNS24-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR05	\N	NA_T06-6855_Tumor
10643	CNS51-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR06	\N	NA_12-18832AA_Tumor
10644	CNS52-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR07	\N	NA_CNS52_Tumor
10645	CNS53-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR08	\N	NA_CNS53_Tumor
10646	CNS54-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR09	\N	NA_CNS54_Tumor
10647	CNS57-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR10	\N	NA_CNS57_Tumor
10648	CNS57-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR11	\N	NA_CNS57_Normal
10649	BN-N1-Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	Amplicon Seq: Hunter Melanoma In Nevus (Blue Nevus)	L2DR12	\N	NA_BN-N1-Tert_Tumor
10650	BN-N2-Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	Amplicon Seq: Hunter Melanoma In Nevus (Blue Nevus)	L2DR13	\N	NA_BN-N2-Tert_Tumor
10651	BN-M1-Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	Amplicon Seq: Hunter Melanoma In Nevus (Blue Nevus)	L2DR14	\N	NA_BN-M1-Tert_Tumor
10652	Ivanka-5-4-Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	Amplicon Seq: Ivanka Patient Melanoma  	L2DR15	\N	NA_08-43264_Nevus
10653	Ivanka-9-1-Tert	\N	\N	\N	\N	\N	\N	\N	\N	\N	Amplicon Seq: Ivanka Patient Melanoma  	L2DR16	\N	NA_10-58663_Melanoma
10654	AM_1_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR01	\N	NA_12-12039B_Tumor
10655	AM_2_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR02	\N	NA_12-22776B3_Tumor
10656	AM_3_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR03	\N	NA_99-29482_Tumor
10657	AM_4_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR04	\N	NA_99-15313_Tumor
10658	AM_5_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR05	\N	NA_99-885_Tumor
10659	AM_6_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR06	\N	NA_98-37643_Tumor
10660	AM_8_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR07	\N	NA_13-25288_Tumor
10661	AM_10_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR08	\N	NA_09-29997_Tumor
10662	AM_12_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR09	\N	NA_04-11158_Tumor
10663	UM4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR10	\N	NA_UM4_Tumor
10664	UM5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR11	\N	NA_UM5_Tumor
10665	Ivanka_13_1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 1	\N	NA_08-84352_Melanoma
10666	Ivanka_13_2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 2	\N	NA_08-84352_Melanoma
10667	Ivanka_13_3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_08-84352_Nevus
10668	Ivanka_13_5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_08-84352_Normal
10669	Ivanka_25_1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_11-88792_Melanoma
10670	Ivanka_25_2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_11-88792_Melanoma
10671	Ivanka_25_3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_11-88792_Nevus
10672	Ivanka_25_4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_11-88792_Nevus
10673	Ivanka_25_5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_11-88792_Normal
10674	CGH13_324	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-324 	 NextFlex 10	\N	NA_13-74952_Tumor
10675	CGH13_331	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-331 ETV6 Fusion	 NextFlex 11	\N	NA_13-75067_Tumor
10676	Spitz_M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 2	\N	NA_Spitz_M1_Tumor
10677	Spitz_M2 (?)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_Spitz_M2_(?)_Tumor
10678	Spitz_N1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_Spitz_N1_Tumor
10679	Spitz_N2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_Spitz_N2_Tumor
10680	Spitz_N3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_Spitz_N3_Tumor
10681	BN_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_BN_Normal
10682	CGH13-016	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-016 	 NextFlex 8	\N	NA_13-159_Tumor
10683	CGH12_163	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH12-163 	 NextFlex 9	\N	NA_12-43016_Tumor
10684	CGH13_166	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-166 	 NextFlex 10	\N	NA_13-34291_Tumor
10685	GAK_DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 11	\N	NA_GAK_DNA_Tumor
10686	Yurif_DNA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 12	\N	NA_Yurif_DNA_Tumor
10687	Acral 11 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	Tumor	L2DR01	\N	NA_Acral-11_Tumor
10688	Acral 11 Cntl	\N	\N	\N	\N	\N	\N	\N	\N	\N	Cntl	L2DR02	\N	NA_Acral-11_Normal
10690	DPN 34	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR05	\N	NA_13-47668_Tumor
10691	DPN Conv 34	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR06	\N	NA_13-47668_Tumor
10692	DPN 37	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR08	\N	NA_13-47621_Tumor
10696	DM45 2 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR07	\N	NA_DM45_Tumor
10697	DM58 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	L2DR04	\N	NA_DM58_Tumor
10698	DM1_Tert_Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Amplicon Sequencing	L2DR12	\N	NA_DM1_Tumor
10699	DM2_Tert_Amplicon	\N	\N	\N	\N	\N	\N	\N	\N	\N	Hunter Amplicon Sequencing	L2DR13	\N	NA_DM2_Tumor
10708	CGH10-013	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH10-013 13 Cycle Post Hybridization LM-PCR	N5_8 (BB008)	\N	NA_10-55707_Tumor
10709	CGH11-153	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH11-153 13 Cycle Post Hybridization LM-PCR	N5_9 (BB008)	\N	NA_11-34950_Tumor
10710	CGH11-036	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH11-036 13 Cycle Post Hybridization LM-PCR	N5_10 (BB008)	\N	NA_11-8228_Tumor
10711	CGH11-386	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH11-386 13 Cycle Post Hybridization LM-PCR	N5_11 (BB008)	\N	NA_11-84681_Tumor
10713	MIN_7_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_MIN_7_Normal
10714	MIN_7_Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_MIN_7_Nevus
10715	MIN_7_Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_MIN_7_Tumor
10716	MIN_8_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_MIN_8_Normal
10717	MIN_8_Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_MIN_8_Nevus
10718	MIN_8_Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_MIN_8_Tumor
10719	501_Mel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_501_Mel_Tumor
10720	Sk_Mel_1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 10	\N	NA_Sk_Mel_1_Tumor
10721	DPN_CNN 24	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_DPN24_Tumor
10722	DPN_CNN 28	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_DPN28_Tumor
10723	DPN_CNN 29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_DPN29_Tumor
10724	DPN_CNN 31	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_DPN31_Tumor
10725	DPN_CNN 33	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_DPN33_Tumor
10726	DPN 40 A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_DPN40_Tumor
10727	DPN 40 B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_DPN40_Tumor
10728	DPN 41	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_DPN41_Tumor
10729	DPN42	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_DPN42_Tumor
10730	DPN44	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_DPN44_Tumor
10731	DPN 45	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_DPN45_Tumor
10732	DPN 46	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_DPN46_Tumor
10733	UM_6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_UM_6_Tumor
10734	Birt_Hogg_Dube	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_Birt_Hogg_Dube_Tumor
10735	CGH13-027	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-027 NTRK3	 NextFlex 1	\N	NA_13-1939_Tumor
10736	CGH13-268	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-268 MET	 NextFlex 2	\N	NA_13-51657_Tumor
10737	CGH13-365	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-365 DPN-like Melanoma	 NextFlex 3	\N	NA_13-89069_Tumor
10738	CGH11-018	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH11-018 	 NextFlex 4	\N	NA_11-1051A_Tumor
10739	CGH11-027	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH11-027 	 NextFlex 5	\N	NA_11-5480_Tumor
10740	Ivanka_23_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_10-73024_Tumor
10741	Ivanka_23_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_10-73024_Normal
10742	Ivanka_2-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NexFlex 8	\N	NA_09-33283_Melanoma
10743	Ivanka_2-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_09-33283_Melanoma
10744	Ivanka_2-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 10	\N	NA_09-33283_Nevus
10745	Ivanka_2-4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_09-33283_Nevus
10746	Ivanka_3-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_09-31895_Melanoma
10747	Ivanka_3-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_09-31895_Melanoma
10748	Ivanka_3-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_09-31895_Nevus
10749	Ivanka_3-4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_09-31895_Nevus
10750	Ivanka_3-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_09-31895_Normal
10751	PMM_1_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_R29032-05_Tumor
10752	PMM_1_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_R29032-05_Normal
10753	PMM_3_A_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_01-8297_Tumor
10754	PMM_3_A_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_01-8297_Normal
10755	PMM_3_B_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_8298-01_Tumor
10756	PMM_3_B_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_8298-01_Normal
10757	Ivanka_11-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_08-53951_Melanoma
10758	Ivanka_11-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_08-53951_Melanoma
10759	Ivanka_11-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_08-53951_Nevus
10760	Ivanka_11-4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_08-53951_Nevus
10762	PMM_5_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_8528-05_Tumor
10763	PMM_6_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_1286184b_Tumor
10764	PMM_6_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 10	\N	NA_1286184b_Normal
10765	PMM_7_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_206436_Tumor
10766	PMM_8_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_35942-04_Tumor
10767	PMM_8_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_15329-03_Normal
10768	PMM_10_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_Z1188-03_Tumor
10769	PMM_10_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_1185-03_Normal
10770	PMM_12_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_14514-02_Tumor
10771	PMM_12_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_15102-02_Normal
10772	PMM_13_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_9116-05_Tumor
10773	PMM_14_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_24516-06_Tumor
10774	PMM_14_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_24516-06_Normal
10775	PMM_15_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_07-3078_Tumor
10776	PMM_17_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_B06-37358_Tumor
10777	PMM_18_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_21590_Tumor
10778	PMM_18_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_21590_Normal
10779	PMM_19_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 1	\N	NA_A2A79@_Tumor
10780	PMM_20_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 2	\N	NA_356A3-075_Tumor
10781	PMM_20_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_20847-09_Normal
10782	PMM_22_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_525_Tumor
10783	PMM_23_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_PMM_23_Tumor
10784	PMM_23_Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_PMM_23_Normal
10785	UM7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_UM7_Tumor
10786	UM8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_UM8_Tumor
10787	UM9	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_UM9_Tumor
10788	UM10	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_UM10_Tumor
10789	UM11	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_UM11_Tumor
10790	Xanthoma_Disseminatum	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_Xanthoma_Disseminatum_Tumor
10794	CGH13-392	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-392 	 NextFlex 10	\N	NA_13-94981_Tumor
10795	CGH13-399	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-399 	NextFlex 11	\N	NA_13-99411A_Tumor
10796	CGH13-394	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH13-394 	NextFlex 12	\N	NA_13-94484_Tumor
10797	DM_27_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_DM27_Tumor
10798	DM_32_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_DM32_Tumor
10799	DM_35_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_DM35_Tumor
10800	DM_40_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_DM40_Tumor
10803	Dummer-KF1-Primary	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_H01.10457/II_Primary
10804	Dummer-KF1-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_H01.10457/II_Normal
10805	Dummer-KF1-Met1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_14.20/II_Met1
10806	Dummer-KF1-Met2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_HS14.18/I_Met2
10807	Dummer-KF2-Primary	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_HS14.19/D_Primary
10808	Dummer-KF2-Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_HS14.19/D_Nevus
10809	Dummer-KF2-Met1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_HS2014.15/7_Met1
10810	Dummer-KF2-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 10	\N	NA_HS2014.15/7_Normal
10811	Dummer-KF3-Primary	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_HS14.16_Primary
10812	Dummer-KF3-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_HS14.16_Normal
10813	Dummer-KF3-Met1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_HS14.17/I_Met1
10814	Long-TN1-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_Long-TN1_Normal
10815	Long-TN1-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_Long-TN1_Tumor
10816	Long-TN2-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_Long-TN2_Normal
10817	Long-TN2-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_Long-TN2_Tumor
10818	D326-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_D326_Tumor
10819	D326-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_D326_Tumor
10820	D366 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_D366_Tumor
10821	D366-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_D366_Tumor
10822	DPN 48	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_DPN48_Tumor
10823	CGH11-023	\N	\N	\N	\N	\N	\N	\N	\N	\N	CGH11-023 	NextFlex 23	\N	NA_11-2532_Tumor
10824	AST-1-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_AST-1_Tumor
10825	WTMM-1-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_08-18595B_Tumor
10826	WTMM-2-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_13-60273_Tumor
10827	WTMM-3-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_12-52454_Tumor
10828	WTMM-4-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_12-75125_Tumor
10829	WTMM-5-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_12-98235A_Tumor
10830	WTMM-6-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_13-3619B_Tumor
10831	XD-1-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 10	\N	NA_13-67500AL_Normal
10832	WTMM-8-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_13-19205_Tumor
10833	WTMM-9-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_13-48330_Tumor
10834	WTMM-10-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_13-11086_Tumor
10835	WTMM-11-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_13-15966_Tumor
10836	WTMM-12-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_13-39228_Tumor
10837	WTMM-13-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_13-45942_Tumor
10838	WTMM-14-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_13-49600_Tumor
10839	WTMM-15-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_13-59640_Tumor
10840	WTMM-16-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_13-67817_Tumor
10841	Long-TN3-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_Russel,SP-12-5612(1K)_Normal
10842	Long-TN3-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_Russel,SP-13-14992(1A)_Tumor
10843	Long-TN4-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_Larcombe,SP-12-2294-2(2A)_Normal
10844	Long-TN4-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_Larcombe,SP-13-17075(1B)_Tumor
10845	Long-TN5-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_Thomas,SP-42-10361(1A)_Normal
10846	Long-TN5-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 1	\N	NA_Thomas,SP-13-1038(1A)_Tumor
10847	AGL14-89-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	NTRK3	 NextFlex 5	\N	NA_S13-13286A6_Tumor
10848	AGL14-89-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	MET	 NextFlex 6	\N	NA_S13-13286A6_Normal
10849	AGL14-92-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	DPN-like Melanoma	 NextFlex 7	\N	NA_S11-20884A-A1_Tumor
10850	AGL14-92-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_S11-20884A-A1_Normal
10851	AGL14-91-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_S12-6218A-D3_Tumor
10852	AGL14-91-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 10	\N	NA_S12-6218A-D3_Normal
10853	AGL4-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_ZS06-11249A-C2_Tumor
10854	AGL14-96-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_S12-26125A2_Tumor
10855	AGL14-94-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_S12-28585A6_Tumor
10856	AGL14-97-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_S11-2018B5_Tumor
10857	AGL14-93-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_S13-11748F5_Tumor
10858	AGL9-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_S12-7250E3_Tumor
10859	AGL14-95-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_S13-3401B3_Tumor
10860	AGL11-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_S13-12947A2_Tumor
10861	AGL12-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_S13-18444A16_Tumor
10862	AGL13-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_ZS07-1210F6_Tumor
10863	AGL14-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_ZS10-11930B12_Tumor
10864	AGL15-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_S12-28988_Tumor
10865	AGL16-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_SSS13-1652B2_Tumor
10866	AGL17-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_S13-5249_Tumor
10869	L1-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_London-L1_Normal
10870	L1-DN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_London-L1_Tumor
10871	L1-MIS	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_London-L1_Tumor
10872	L1-INV	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_London-L1_Tumor
10873	L14-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 10	\N	NA_London-L14_Normal
10874	L14-Nevus-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_London-L14_Nevus
10875	L14-Nevus-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_London-L14_Nevus
10876	L14-Mel-Comb	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_London-L14_Tumor
10877	L14-Mel-S	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_London-L14_Tumor
10878	L14-Mel-Deep	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_London-L14_Tumor
10879	L14C-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_London-L14C_Normal
10880	L14C-HGD	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_London-L14C_Tumor
10881	Ivanka-6-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_08-79358_Melanoma
10882	Ivanka-6-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_08-79358_Melanoma
10883	Ivanka-6-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_08-79358_Nevus
10884	Ivanka-6-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_08-79358_Normal
10885	Ivanka-27-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_09-45509_Melanoma
10886	Ivanka-27-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_09-45509_Melanoma
10887	Ivanka-27-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_09-45509_Nevus
10888	Ivanka-27-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 1	\N	NA_09-45509_Normal
10889	DM_50_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 2	\N	NA_DM50_Tumor
10890	DM_56_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_DM56_Tumor
10891	Ivanka-26-1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_11-94204_Melanoma
10892	Ivanka-26-3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_11-94204_Nevus
10893	Ivanka-26-5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_11-94204_Normal
10894	L10-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 10	\N	NA_London-L10_Normal
10895	L10-MIS	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_London-L10_Tumor
10896	L10-INV	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_London-L10_Tumor
10897	L10-HGD	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_London-L10_Tumor
10898	L12-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_London-L12_Normal
10899	L12-Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_London-L12_Nevus
10900	L12-HGD	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_London-L12_Tumor
10901	L16-Nevus-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_London-L16_Nevus
10902	L16-Mel-Deep	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_London-L16_Tumor
10903	L16A-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_London-L16A_Normal
10904	L16A-Nevus-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_London-L16A_Nevus
10905	L16A-Mel-Sup	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_London-L16A_Tumor
10906	L16B-Lesion-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_London-L16B_Tumor
10907	L16B-Lesion-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_London-L16B_Tumor
10908	L16B-NL	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_London-L16B_Tumor
10909	DM15 Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 1	\N	NA_DM15_Tumor
10910	DM19	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 2	\N	NA_DM19_Tumor
10911	DM19-2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_DM19_Tumor
10912	DM_46_Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_DM46_Tumor
10913	Heinzerling-1-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	TTAGGC	\N	NA_140038340_Tumor
10914	Heinzerling-1-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	ACTTGA	\N	NA_140092090_Normal
10915	UM13	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	GATCAG	\N	NA_UM13_Tumor
10916	UM14	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	TAGCTT	\N	NA_UM14_Tumor
10917	UM16	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	GGCTAC	\N	NA_UM16_Tumor
10918	L17-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_London-L17_Normal
10919	L17-Nevus-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_London-L17_Nevus
10920	L17-Nevus-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_London-L17_Nevus
10921	L17-Mel-S	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_London-L17_Tumor
10922	L17-Mel-Deep	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_London-L17_Tumor
10923	GAK	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_GAK_Tumor
10924	Yurif	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_Yurif_Tumor
10925	Ivanka-11-Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_08-53951_Nevus
10926	Ivanka-11-M1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_08-53951_M1
10927	Ivanka-11-M2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_08-53951_M2
10928	L18-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_London-L18_Normal
10929	L18-Nevus-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_London-L18_Nevus
10930	L18-Mel-S	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 1	\N	NA_London-L18_Tumor
10931	L18-Mel-D	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 2	\N	NA_London-L18_Tumor
10932	L21-MIS-Lesion-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_London-L21_Tumor
10933	L21-LesionB	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_London-L21_Tumor
10934	L21-NL	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_London-L21_Tumor
10957	JBP-1-Norm	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 10	\N	NA_S12-27617B9_Normal
10958	JBP-1-MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_S12-25164A3,A4,A5_Tumor
10959	JBP-1-Met	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_S12-25164C1_Tumor
10960	L19-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_London-L19_Normal
10961	L19-Nevus-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_London-L19_Nevus
10962	L19-Mel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_London-L19_Tumor
10963	L19E-NL	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_London-L19E_Tumor
10964	L19E-Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_London-L19E_Nevus
10965	L19E-MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_London-L19E_Tumor
10966	L22-MIS	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_London-L22_Tumor
10967	L22-Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_London-L22_Tumor
10968	L22-NL	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_London-L22_Tumor
10969	L23-MM-Deep	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_London-L23_Tumor
10970	L23C-NL	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_London-L23C_Tumor
10971	L23C-Mel-Sup	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_London-L23C_Tumor
10972	L23D-NL	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 1	\N	NA_London-L23D_Tumor
10973	L23D-HGD	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 2	\N	NA_London-L23D_Tumor
10974	L6-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_London-L6_Normal
10975	L6-LGD-Super	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_London-L6_Tumor
10976	L6-LGD-Deep	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_London-L6_Tumor
10977	XD-2-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_XD-2_Tumor
10978	XD-2-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_XD-2_Normal
10979	Long-TN6-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_SP-13-006364_Normal
10980	Long-TN6-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_SP-14-001249_Tumor
10981	Long-TN7-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_SP-13-0185993A_Normal
10982	Long-TN7-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_SP-13-0185992B_Tumor
10983	Long-TN8-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_SP-12-003309B_Normal
10984	Long-TN8-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_SP-13-0212981A_Tumor
10985	Long-TN9-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_SP-13-0068754A_Normal
10986	Long-TN9-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_SP-13-0068751C_Tumor
10991	Long-TN12-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_SP-10-003167A_Normal
10992	Long-TN12-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_SP-13-009897_Tumor
10993	Long-TN13-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 1	\N	NA_SP-12-0087723B_Normal
10994	Long-TN13-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 2	\N	NA_SP-12-020017C_Tumor
10995	Long-TN14-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_SP-12-0032671A_Normal
10996	Long-TN14-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_SP-13-006337A_Tumor
10997	Long-TN15-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_SP-12-0228802A_Normal
10998	Long-TN15-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_SP-12-0228801A_Tumor
10999	Long-TN16-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_SP-12-0146612A_Normal
11000	Long-TN16-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_SP-12-01466111A_Tumor
11001	Long-TN17-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_West,D.SP-10-004335_Normal
11002	Long-TN17-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_West,D.SP-13-000848_Tumor
11003	M230	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 14	\N	NA_M230_Tumor
11004	M257	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_M257_Tumor
11005	M285	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_M285_Tumor
11006	M368	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_M368_Tumor
11007	M375	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_M375_Tumor
11008	M418	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 19	\N	NA_M418_Tumor
11009	C8161	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_C8161_Tumor
11010	L4-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 21	\N	NA_London-L4_Normal
11011	L4-LGD	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_London-L4_Tumor
11012	L5-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 23	\N	NA_London-L5_Normal
11013	L5-LGD	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 24	\N	NA_London-L5_Tumor
11014	L8-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 1	\N	NA_London-L8_Normal
11015	L8-LGD	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 2	\N	NA_London-L8_Tumor
11016	L9-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 3	\N	NA_London-L9_Normal
11017	L9-HGD	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 4	\N	NA_London-L9_Tumor
11018	L13-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 5	\N	NA_London-L13_Normal
11019	L13-Lesion-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 6	\N	NA_London-L13_Tumor
11020	L13-Lesion-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 7	\N	NA_London-L13_Tumor
11021	L15-DysPN	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_London-L15_Tumor
11022	L15-MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_London-L15_Tumor
11023	1212	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 1	\N	NA_1212_Tumor
11024	1213	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 2	\N	NA_1213_Tumor
11025	1214	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 3	\N	NA_1214_Tumor
11026	3860	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 4	\N	NA_3860_Tumor
11032	UM17	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 8	\N	NA_UM17_Tumor
11033	JBP-2-Norm	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 9	\N	NA_S12-23475A6_Normal
11034	JBP-2-MM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	 NextFlex 10	\N	NA_S12-23475A4,A5_Tumor
11035	JBP-2-Met	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_S12-23475C1_Tumor
11036	Long-TN18-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 12	\N	NA_13-21725_Normal
11037	Long-TN18-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 13	\N	NA_SP-14-68521D_Tumor
11038	Long-TN19-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 15	\N	NA_SP-13-208365A_Normal
11039	Long-TN19-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 16	\N	NA_SP-14-36134A_Tumor
11040	Long-TN20-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 17	\N	NA_SP-14-73676A_Normal
11041	Long-TN20-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 18	\N	NA_SP-14-73671M_Tumor
11042	Long-TN21-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 20	\N	NA_SP-14-7691A_Normal
11043	Long-TN21-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 22	\N	NA_SP-14-7691A_Tumor
11065	XD-1.1-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NextFlex 11	\N	NA_XD-1.1_Tumor
11106	ADM_1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	807	\N	NA_SMU10-0457_Tumor
11107	ADM_2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	808	\N	NA_SMU10-0206_Tumor
11108	ADM_3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	809	\N	NA_SMU10-0240_Tumor
11109	ADM_4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	812	\N	NA_SCC10-0092_Tumor
11110	ADM_5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	813	\N	NA_MASCRI-432_Tumor
11111	ADM_6	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	814	\N	NA_RPA08-0209_Tumor
11112	ADM_7	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	815	\N	NA_RPA08-0315_Tumor
11113	NZM52	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	816	\N	NA_NZM52_Tumor
11114	NZM40	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	817	\N	NA_NZM40_Tumor
11115	NZM91	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	818	\N	NA_NZM91_Tumor
11116	Long-TN22-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	DH	\N	\N	NA_SP-13-198211A_Tumor
11117	Long-TN22-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	DH	\N	\N	NA_RNS11P15316B1_Normal
11118	Long-TN23-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	JG	\N	\N	NA_9246581-A3_Tumor
11119	Long-TN23-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	JG	\N	\N	NA_9246581-A6_Normal
11120	Long-TN24-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	MLH	\N	\N	NA_DHM4855-14MP_Tumor
11121	Long-TN24-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	MLH	\N	\N	NA_SNPN08289D_Normal
11122	Long-TN25-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	JM	\N	\N	NA_SP-10-143551E_Tumor
11123	Long-TN25-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	JM	\N	\N	NA_SP-10-143552A_Normal
11124	Long-TN26-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	AH	\N	\N	NA_04-SW-12-31366B1_Tumor
11125	Long-TN26-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	AH	\N	\N	NA_04-SW-12-31366B6_Normal
11126	Long-TN27-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	FN	\N	\N	NA_SP-13-63011A_Tumor
11127	Long-TN27-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	FN	\N	\N	NA_SP-11-160493A_Normal
11128	Long-TN28-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	GJ	\N	\N	NA_SP-13-87981B_Tumor
11129	Long-TN28-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	GJ	\N	\N	NA_SP-11-40641B_Normal
11130	Long-TN29-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	CG	\N	\N	NA_SP-14-125801B_Tumor
11131	Long-TN29-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	CG	\N	\N	NA_SP-14-125802A_Normal
11132	KAM17-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	17	Dual_AD707 Duplex	\N	NA_WCRS97-025628_Tumor
11133	KAM41-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	41	Dual_AD708 Duplex	\N	NA_SCHS10-026422_Tumor
11134	KAM90-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	90	Dual_AD709 Duplex	\N	NA_SROS12-001198_Tumor
11135	KAM92-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	92	Dual_AD710 Duplex	\N	NA_SROS09-001574_Tumor
11136	KAM93-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	93	Dual_AD711 Duplex	\N	NA_SCHS09-005840-B5_Tumor
11137	KAM99-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	99	Dual_AD712 Duplex	\N	NA_SACS05-011507_Tumor
11138	KAM105-T-A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	105	Dual_AD801 Duplex	\N	NA_FRSS09-009402-A1_Tumor
11139	KAM28-T-B1	\N	\N	\N	\N	\N	\N	\N	\N	\N	28	Dual_AD802 Duplex	\N	NA_RCHS07-000380-B1_Tumor
11140	KAM30-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	30	Dual_AD803 Duplex	\N	NA_SROS11-005030_Tumor
11141	KAM72-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	72	Dual_AD804 Duplex	\N	NA_VALS09-000266_Tumor
11142	KAM18-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	18	Dual_AD805 Duplex	\N	NA_SFOS09-007093_Tumor
11143	KAM63-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	63	Dual_AD806 Duplex	\N	NA_FRSS09-008805_Tumor
11144	KAM70-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	70	Dual_AD807 Duplex	\N	NA_RCHS06-004567_Tumor
11145	KAM54-T-E	\N	\N	\N	\N	\N	\N	\N	\N	\N	54	Dual_AD808 Duplex	\N	NA_VALS05-014946-E_Tumor
11146	KAM2-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	2	Dual_AD809 Duplex	\N	NA_SCHS08-007754_Tumor
11147	KAM5-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	5	Dual_AD812 Duplex	\N	NA_SFOS12-018173_Tumor
11148	KAM10-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	10	Dual_AD824 Duplex	\N	NA_SROS00-001103_Tumor
11149	KAM45-T-D	\N	\N	\N	\N	\N	\N	\N	\N	\N	45	Dual_AD826 Duplex	\N	NA_MTZS94-007340_Tumor
11150	KAM49-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	49	Dual_AD827 Duplex	\N	NA_SFOS94-003116_Tumor
11151	KAM27-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	27	Dual_AD828 Duplex	\N	NA_SACS93-027850_Tumor
11152	KAM68-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	68	Dual_AD829 Duplex	\N	NA_SCLS91-006557_Tumor
11153	KAM9-T-H	\N	\N	\N	\N	\N	\N	\N	\N	\N	9	Dual_AD830 Duplex	\N	NA_OAKS90-012369_Tumor
11154	KAM98-T-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	98	Dual_AD832 Duplex	\N	NA_HAYS02-005731_Tumor
11155	KAM67-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	67	Dual_AD833 Duplex	\N	NA_SRFS97-002805_Tumor
11156	KAM124-T-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	124	Dual_AD887 Duplex	\N	NA_VALS03-019832_Tumor
11157	KAM58-T-GIV	\N	\N	\N	\N	\N	\N	\N	\N	\N	58	Dual_AD836 Duplex	\N	NA_SSCS03-014369_Tumor
11158	KAM86-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	86	Dual_AD837 Duplex	\N	NA_RCHS01-003684_Tumor
11159	KAM111-T-A2	\N	\N	\N	\N	\N	\N	\N	\N	\N	111	Dual_AD838 Duplex	\N	NA_WCRS99-012800_Tumor
11160	KAM77-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	77	Dual_AD840 Duplex	\N	NA_HAYS90-005154_Tumor
11161	KAM69-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	69	Dual_AD841 Duplex	\N	NA_SFOS00-016989_Tumor
11162	KAM117-T-D	\N	\N	\N	\N	\N	\N	\N	\N	\N	117	Dual_AD882 Duplex	\N	NA_VALS03-007457_Tumor
11163	KAM103-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	103	Dual_AD843 Duplex	\N	NA_SFO93-005184_Tumor
11164	Long-TN30-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD810 Duplex	\N	NA_DHM50691-14MP5C_Tumor
11165	Long-TN30-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD504 Duplex	\N	NA_DHM50691-14MP3_Normal
11166	Long-TN31-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD856 Duplex	\N	NA_RNS14P13907B1_Tumor
11167	Long-TN31-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD857 Duplex	\N	NA_SP-10-197431A_Normal
11168	Long-TN32-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD858 Duplex	\N	NA_DHM57444-14MP_Tumor
11169	Long-TN32-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD859 Duplex	\N	NA_SP-12-177322A_Normal
11170	Long-TN33-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD860 Duplex	\N	NA_DHM94457-13SK_Tumor
11171	Long-TN33-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD861 Duplex	\N	NA_DHM48742-12MPE_Normal
11172	Long-TN34-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD862 Duplex	\N	NA_Laverty13-88354_Tumor
11173	Long-TN34-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD863 Duplex	\N	NA_ICPMR19684.13A11_Normal
11174	Long-TN35-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD864 Duplex	\N	NA_SP-13-15691B_Tumor
11175	Long-TN35-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD865 Duplex	\N	NA_SP-13-15691D_Normal
11176	UM29	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD868 Duplex	\N	NA_57059699_Tumor
11177	UM30	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD869 Duplex	\N	NA_57269600_Tumor
11178	UM31	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD870 Duplex	\N	NA_57213442_Tumor
11179	UM34	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	Dual_AD871 Duplex	\N	NA_57346060_Tumor
11180	KAM19-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	19	AD501	\N	NA_SROS10-009251_Tumor
11181	KAM32-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	32	AD503	\N	NA_FRSS99-007026_Tumor
11182	KAM60-T-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	60	AD505	\N	NA_SCLS04-001045_Tumor
11183	KAM74-T-G	\N	\N	\N	\N	\N	\N	\N	\N	\N	74	AD506	\N	NA_OAKS96-014392-G_Tumor
11184	KAM109-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	109	AD507	\N	NA_OAKS96-022398_Tumor
11185	KAM112-T-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	112	AD508	\N	NA_OAK84-008979-B_Tumor
11186	KAM115-T-A1	\N	\N	\N	\N	\N	\N	\N	\N	\N	115	AD703	\N	NA_ROSS09-022626-A1_Tumor
11187	KAM119-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	119	AD704	\N	NA_SCHS11-018842-A1_Tumor
11188	KAM46-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	46	AD819	\N	NA_SSCS03-004945_Tumor
11189	KAM47-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	47	AD821	\N	NA_WCRS02-022688_Tumor
11190	KAM100-T-II	\N	\N	\N	\N	\N	\N	\N	\N	\N	100	AD822 	\N	NA_SACS02-020334_Tumor
11191	KAM75	\N	\N	\N	\N	\N	\N	\N	\N	\N	75	AD825 	\N	NA_HAYS98-001046_Tumor
11192	KAM64-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	64	AD831 	\N	NA_SACS88-019073_Tumor
11193	KAM50-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	50	AD834 	\N	NA_SACS87-010145_Tumor
11194	KAM39-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	39	AD820 	\N	NA_STRS91-006237_Tumor
11195	KAM22-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	22	AD853 	\N	NA_SSCS92-009981_Tumor
11196	T015-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD816	\N	NA_14-59304A_Normal
11197	T015-Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD817	\N	NA_14-59304A_Nevus
11198	T016-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD818	\N	NA_13-48020_Normal
11199	T016-Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD866	\N	NA_13-48020_Nevus
11200	T017-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD819	\N	NA_14-13499_Normal
11201	T017-Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD821	\N	NA_14-13499_Nevus
11202	T020-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD822	\N	NA_13-64515B_Normal
11203	T020-Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD824	\N	NA_13-64515B_Nevus
11204	T020-Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD825	\N	NA_13-64515B_Tumor
11205	T021-Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD826	\N	NA_14-22939_Nevus
11206	T021-Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD827	\N	NA_14-22939_Tumor
11207	T023-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD828	\N	NA_13-61146_Normal
11208	T023-Nevus	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD829	\N	NA_13-61146_Nevus
11209	T023-Melanoma	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD830 	\N	NA_13-61146_Tumor
11210	UM27	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD831	\N	NA_57001550_Tumor
11211	UM28	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD834	\N	NA_57291680_Tumor
11212	736TP-FFPE-L3	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD861 	\N	NA_London-L3_Tumor
11213	736TP-FFPE-L13	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD862 	\N	NA_London-L13_Tumor
11214	736TP-MB-L3-L2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD863 	\N	NA_London-L3_Tumor
11215	736TP-MB-L3-L4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD864 	\N	NA_London-L3_Tumor
11216	736TP-MB-L3-P1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD865 	\N	NA_London-L3_Tumor
11217	736TP-MB-L3-P2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD868 	\N	NA_London-L3_Tumor
11218	736TP-MB-L13-L1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD869 	\N	NA_London-L13_Tumor
11219	736TP-MB-L13-P2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD870 	\N	NA_London-L13_Tumor
11220	UM33	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD871 	\N	NA_UM33_Tumor
11221	UM35_A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD872 	\N	NA_UM35_A_Tumor
11222	UM39	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD873 	\N	NA_UM39_Tumor
11223	UM40	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD874 	\N	NA_UM40_Tumor
11224	UM41	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD875 	\N	NA_UM41_Tumor
11225	UM36	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD847 	\N	NA_UM36_Tumor
11226	UM37	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD848 	\N	NA_UM37_Tumor
11227	736TP-F-L13	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	AD878 	\N	NA_London-L13_Tumor
11228	UM41-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_57715138_Tumor
11229	UM41-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_57715138_Tumor
11230	UM42	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_332771_Tumor
11231	UM43	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_57723220_Tumor
11232	UM44	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_55875588_Tumor
11233	UM45	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_57714581_Tumor
11234	UM47-Tumor	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_UM47_Tumor
11235	UM47-Normal	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_UM47_Normal
11236	Sample_KAM1-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM1-T_Tumor
11237	Sample_KAM106-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM106-T_Tumor
11238	Sample_KAM12-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM12-T_Tumor
11239	Sample_KAM121-T-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM121-T-B_Tumor
11240	Sample_KAM20-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM20-T_Tumor
11241	Sample_KAM3-T-A	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM3-T-A_Tumor
11242	Sample_KAM35-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM35-T_Tumor
11243	Sample_KAM38-T-B	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM38-T-B_Tumor
11244	Sample_KAM53-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM53-T_Tumor
11245	Sample_KAM61-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM61-T_Tumor
11246	Sample_KAM7-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM7-T_Tumor
11247	Sample_KAM78-T-III	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM78-T-III_Tumor
11248	Sample_KAM82-T-B8	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM82-T-B8_Tumor
11249	Sample_KAM84-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM84-T_Tumor
11250	Sample_KAM94-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM94-T_Tumor
11251	Sample_KAM96-T	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	NA_Sample_KAM96-T_Tumor
\.


--
-- Name: area_na_link_id_seq; Type: SEQUENCE SET; Schema: public; Owner: borisbastian
--

SELECT pg_catalog.setval('public.area_na_link_id_seq', 96720, true);


--
-- Name: block_area_link_id_seq; Type: SEQUENCE SET; Schema: public; Owner: borisbastian
--

SELECT pg_catalog.setval('public.block_area_link_id_seq', 35782, true);


--
-- Name: na_sl_link_id_seq; Type: SEQUENCE SET; Schema: public; Owner: borisbastian
--

SELECT pg_catalog.setval('public.na_sl_link_id_seq', 20185, true);


--
-- Name: nuc_acids_nu_id_seq; Type: SEQUENCE SET; Schema: public; Owner: borisbastian
--

SELECT pg_catalog.setval('public.nuc_acids_nu_id_seq', 1, false);


--
-- Name: patients_pa_id_seq; Type: SEQUENCE SET; Schema: public; Owner: borisbastian
--

SELECT pg_catalog.setval('public.patients_pa_id_seq', 2353, true);


--
-- Name: sample_lib_id_seq; Type: SEQUENCE SET; Schema: public; Owner: borisbastian
--

SELECT pg_catalog.setval('public.sample_lib_id_seq', 1, false);


--
-- Name: area_na_link area_na_link_pkey; Type: CONSTRAINT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.area_na_link
    ADD CONSTRAINT area_na_link_pkey PRIMARY KEY (id);


--
-- Name: block_area_link block_area_link_pkey; Type: CONSTRAINT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.block_area_link
    ADD CONSTRAINT block_area_link_pkey PRIMARY KEY (id);


--
-- Name: na_sl_link na_sl_link_pkey; Type: CONSTRAINT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.na_sl_link
    ADD CONSTRAINT na_sl_link_pkey PRIMARY KEY (id);


--
-- Name: nuc_acids nuc_acids_pkey; Type: CONSTRAINT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.nuc_acids
    ADD CONSTRAINT nuc_acids_pkey PRIMARY KEY (nu_id);


--
-- Name: patients patients_pkey; Type: CONSTRAINT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.patients
    ADD CONSTRAINT patients_pkey PRIMARY KEY (pa_id);


--
-- Name: sample_lib sample_lib_name_key; Type: CONSTRAINT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.sample_lib
    ADD CONSTRAINT sample_lib_name_key UNIQUE (name);


--
-- Name: sample_lib sample_lib_pkey; Type: CONSTRAINT; Schema: public; Owner: borisbastian
--

ALTER TABLE ONLY public.sample_lib
    ADD CONSTRAINT sample_lib_pkey PRIMARY KEY (id);


--
-- PostgreSQL database dump complete
--

